FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Howe, GW
   Pantin, H
   Perrino, T
AF Howe, George W.
   Pantin, Hilda
   Perrino, Tatiana
TI Programs for Preventing Depression in Adolescence: Who Benefits and Who
   Does Not? An Introduction to the Supplemental Issue
SO PREVENTION SCIENCE
LA English
DT Editorial Material
DE Integrative data analysis; Adolescent depression; Randomized trials;
   Moderation
ID LIFETIME PREVALENCE; METAANALYSIS; DISORDERS; CHILDREN
AB We introduce this supplemental issue of Prevention Science, which brings together a set of papers from leading investigators who have conducted trials testing whether intervention programs prevent adolescent depression. Using data from these trials, these papers explore a series of factors that might account for variation in intervention benefit, employing several novel methods for assessing effect heterogeneity. These studies follow two general paradigms: three papers report findings from single randomized preventive intervention trials, while the remaining papers develop and apply new methods for combining data from multiple studies to evaluate effect heterogeneity more broadly. Colleagues from NIMH and SAMHSA also provide commentaries on these studies. They conclude that synthesis of findings from multiple trials holds great promise for advancing the field, and progress will be accelerated if collaborative data sharing becomes the norm rather than the exception.
C1 [Howe, George W.] George Washington Univ, Dept Psychol, 2125 G St NW, Washington, DC 20052 USA.
   [Pantin, Hilda; Perrino, Tatiana] Univ Miami, Miller Sch Med, Div Prevent Sci & Community Hlth, Dept Publ Hlth Sci, Miami, FL 33136 USA.
RP Howe, GW (corresponding author), George Washington Univ, Dept Psychol, 2125 G St NW, Washington, DC 20052 USA.
EM ghowe@gwu.edu
FU NIMHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH) [R01-MH040859]; NCATSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [UL1-TR000460]; NATIONAL CENTER
   FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000460]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Mental Health (NIMH)
   [R01MH040859] Funding Source: NIH RePORTER
FX Funding for this project was provided by NIMH R01-MH040859
   (Collaborative Data Synthesis for Adolescent Depression Trials, Brown
   PI), and NCATS UL1-TR000460 (Miami Clinical and Translational Science
   Institute, Szapocznik PI).
CR Brincks A., 2017, PREVENTION SCI
   Brincks A., 2016, PREVENTION SCI
   Brown C. H., 2016, PREVENTION SCI
   Brunwasser S. M., 2015, PREVENTION SCI
   Brunwasser SM, 2009, J CONSULT CLIN PSYCH, V77, P1042, DOI 10.1037/a0017671
   Connell A. M., 2015, PREVENTION SCI
   Curran PJ, 2009, PSYCHOL METHODS, V14, P81, DOI 10.1037/a0015914
   Dagne GA, 2016, STAT MED, V35, P2485, DOI 10.1002/sim.6883
   del Vecchio P., 2017, PREVENTION SCI
   Garber J., 2015, PREVENTION SCI
   Goldstein A., 2017, PREVENTION SCI
   Hardeveld F, 2010, ACTA PSYCHIAT SCAND, V122, P184, DOI 10.1111/j.1600-0447.2009.01519.x
   Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593
   Mauricio A. M., 2017, PREVENTION SCI
   Merry SN, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003380.pub3
   Moffitt TE, 2010, PSYCHOL MED, V40, P899, DOI 10.1017/S0033291709991036
   Sandler I, 2015, CHILD DEV PERSPECT, V9, P164, DOI 10.1111/cdep.12126
   Siddique J., 2017, PREVENTION SCI
   STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K
   Stice E, 2009, J CONSULT CLIN PSYCH, V77, P486, DOI 10.1037/a0015168
NR 20
TC 1
Z9 1
U1 0
U2 1
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1389-4986
EI 1573-6695
J9 PREV SCI
JI Prev. Sci.
PD FEB
PY 2018
VL 19
IS 1
SU S
BP S1
EP S5
DI 10.1007/s11121-018-0870-0
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA GB0DP
UT WOS:000428714300001
PM 29368296
DA 2021-10-30
ER

PT J
AU Bailey, Z
   Balise, R
   Bouzoubaa, L
   Kobetz, E
AF Bailey, Zinzi
   Balise, Raymond
   Bouzoubaa, Layla
   Kobetz, Erin
TI SCAN360: A Resource for a 360-Degree View of Cancer Prevention, Risk,
   and Survival
SO PREVENTING CHRONIC DISEASE
LA English
DT Article
AB SCAN360, an interactive web platform aiming to provide a "360 degree view" of factors that drive cancer, calculates and integrates several measures of cancer burden from the Florida Cancer Data System, the state's cancer registry, from 2012 to 2016 with cancer risk factors, clinical factors, and social determinants of health on multiple levels of geography - ranging from the entire state to the neighborhood. Integrating various sources of data, the web platform visualizes numerous indicators, including sociodemographic characteristics, cancer histology and staging, risk behaviors, screening behavior, environmental factors, hazardous sites, health insurance access, prevalence of potential comorbidities, housing characteristics, and levels of residential segregation, through maps and easy-to-interpret graphs. By walking through an example of a practical use, we show that SCAN360 provides data that are easily accessible to public health professionals, decision makers, and researchers and can assist them with identifying potential drivers of cancer burden on a localized level.
C1 [Bailey, Zinzi; Balise, Raymond; Bouzoubaa, Layla; Kobetz, Erin] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA.
   [Bailey, Zinzi; Kobetz, Erin] Univ Miami, Miller Sch Med, Dept Med, Div Med Oncol, Miami, FL 33136 USA.
   [Balise, Raymond] Univ Miami, Dept Publ Hlth Sci, Div Biostat, Miami, FL USA.
RP Kobetz, E (corresponding author), Univ Miami, Miller Sch Med, 1120 NW 14 St, Miami, FL 33136 USA.
EM EKobetz@med.miami.edu
OI Bouzoubaa, Layla/0000-0002-6616-0950; Balise,
   Raymond/0000-0002-9856-5901
FU University of Miami's Sylvester Comprehensive Cancer Center; National
   Center for Advancing Translational Sciences, National Institutes of
   Health, through the Miami Clinical and Translational Science Institute
   [UL1 TR002736]
FX The development of SCAN360 was funded by the University of Miami's
   Sylvester Comprehensive Cancer Center, as well as by the National Center
   for Advancing Translational Sciences, National Institutes of Health,
   through the Miami Clinical and Translational Science Institute Grant
   Number UL1 TR002736. Its contents are solely the responsibility of the
   authors and do not necessarily represent the official views of the NIH.
   SCAN360 is protected by US Provisional Patent Application No.
   62/751,299. The authors have no conflicts of interest to disclose.
CR [Anonymous], 2019, **NON-TRADITIONAL**, V4, P1, DOI DOI 10.21105/JOSS.01686
   Centers for Disease Control and Prevention National Center for Chronic Disease Prevention and Health Promotion Division of Population Health, 500 CITIES PROJECT 2
   Correll M, 2018, PROCEEDINGS OF THE 2018 CHI CONFERENCE ON HUMAN FACTORS IN COMPUTING SYSTEMS (CHI 2018), DOI 10.1145/3173574.3174216
   Gomez SL, 2015, CANCER-AM CANCER SOC, V121, P2314, DOI 10.1002/cncr.29345
   Johns MME, 2019, GUIDING CANC CONTROL
   Lynch SM, 2013, CANCER EPIDEM BIOMAR, V22, P485, DOI 10.1158/1055-9965.EPI-13-0010
   Missouri Census Data Center University of Missouri Center for Health Policy, 2016, GEOCORR 2014 GEOGRAP
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Singh G, 2011, J INEQUAL APPL, P1, DOI [10.1186/1029-242X-2011-35, 10.1155/2011/107497]
   Sylvester Comprehensive Cancer Center, 2018, SCAN 360
   US Census Bureau, AM COMMUNITY SURVEY
   US Department of Health and Human Services Centers for Disease Control and Prevention, 2006, LESSON THREE MEASURE
   Westrick A, 2020, CANCER CAUSE CONTROL, V31, P333, DOI 10.1007/s10552-020-01276-2
   Westrick AC, 2020, CANCER-AM CANCER SOC, V126, P3698, DOI 10.1002/cncr.32989
   Zahnd WE, 2018, CANCER EPIDEM BIOMAR, V27, P1265, DOI 10.1158/1055-9965.EPI-17-0430
NR 15
TC 0
Z9 0
U1 0
U2 0
PU CENTERS  DISEASE CONTROL & PREVENTION
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1545-1151
J9 PREV CHRONIC DIS
JI Prev. Chronic Dis.
PD NOV
PY 2020
VL 17
AR 200263
DI 10.5888/pcd17.200263
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA PE4EG
UT WOS:000598317600003
PM 33241989
OA gold, Green Published
DA 2021-10-30
ER

PT J
AU Diaz-Pachon, DA
   Rao, JS
AF Diaz-Pachon, Daniel Andres
   Rao, J. Sunil
TI A simple correction for COVID-19 sampling bias
SO JOURNAL OF THEORETICAL BIOLOGY
LA English
DT Article
DE Estimation of prevalence; Symptoms; Outbreak; Epidemic; Entropy
ID INFORMATION
AB COVID-19 testing has become a standard approach for estimating prevalence which then assist in public health decision making to contain and mitigate the spread of the disease. The sampling designs used are often biased in that they do not reflect the true underlying populations. For instance, individuals with strong symptoms are more likely to be tested than those with no symptoms. This results in biased estimates of prevalence (too high). Typical post-sampling corrections are not always possible. Here we present a simple bias correction methodology derived and adapted from a correction for publication bias in meta analysis studies. The methodology is general enough to allow a wide variety of customization making it more useful in practice. Implementation is easily done using already collected information. Via a simulation and two real datasets, we show that the bias corrections can provide dramatic reductions in estimation error. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Diaz-Pachon, Daniel Andres; Rao, J. Sunil] Univ Miami, Don Soffer Clin Res Ctr, Div Biostat, 1120 NW 14th St, Miami, FL 33136 USA.
RP Rao, JS (corresponding author), Univ Miami, Don Soffer Clin Res Ctr, Div Biostat, 1120 NW 14th St, Miami, FL 33136 USA.
EM Ddiaz3@miami.edu; JRao@biostat.med.miami.edu
OI Diaz-Pachon, Daniel Andres/0000-0001-6281-1720
FU NSFNational Science Foundation (NSF) [DMS-1915976]; NIHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [U54 MD010722, UL1 TR000460]
FX JSR was partially supported by NSF grant DMS-1915976 and NIH grants U54
   MD010722 and UL1 TR000460. We would like to thank the two referees for
   their helpful input which improved the final version of the paper.
CR Alleva G., 2020, TECHNICAL REPORT
   Andrews I, 2019, AM ECON REV, V109, P2766, DOI 10.1257/aer.20180310
   Dembski WA, 2009, IEEE SYS MAN CYBERN, P2647, DOI 10.1109/ICSMC.2009.5346119
   Diaz-Pachon D.A., 2020, BIOCOMPLEXITY, V2020, P1
   Diggle P.J., 2011, EPIDEMIOL RES INT
   Greenland S, 1996, INT J EPIDEMIOL, V25, P1107, DOI 10.1093/ije/25.6.1107-a
   JAYNES ET, 1957, PHYS REV, V106, P620, DOI 10.1103/PhysRev.106.620
   Mizumoto K, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.10.2000180
   Poletti P., 2020, PREPRINT
   Sudre C.H., 2020, SYMPTOM CLUSTERS COV, DOI [10.1101/2020.06.12, DOI 10.1101/2020.06.12]
NR 10
TC 1
Z9 1
U1 0
U2 0
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-5193
EI 1095-8541
J9 J THEOR BIOL
JI J. Theor. Biol.
PD MAR 7
PY 2021
VL 512
AR 110556
DI 10.1016/j.jtbi.2020.110556
PG 6
WC Biology; Mathematical & Computational Biology
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
   Biology
GA PY6WT
UT WOS:000612183900007
PM 33385402
OA Green Published, Green Submitted
DA 2021-10-30
ER

PT J
AU Govindarajan, V
   Burks, JD
   Luther, EM
   Thompson, JW
   Starke, RM
AF Govindarajan, Vaidya
   Burks, Joshua D.
   Luther, Evan M.
   Thompson, John W.
   Starke, Robert M.
TI Medical Adjuvants in the Treatment of Surgically Refractory
   Arteriovenous Malformations of the Head and Face: Case Report and Review
   of Literature
SO CEREBROVASCULAR DISEASES
LA English
DT Review
DE Surgery; Bleeding; Inoperable; Molecular target of rapamycin;
   Arteriovenous malformation; Rapamycin; Embolization; Adjuvant; Medical
   therapy; Vascular malformation
ID PULSED DYE-LASER; MANAGEMENT; SIROLIMUS
AB Background: Arteriovenous malformations (AVMs) of the brain and face present unique challenges for clinicians. Cerebral AVMs may induce hemorrhage or form aneurysms, while facial AVMs can cause significant disfigurement and pain. Moreover, facial AVMs often draw blood supply from arteries providing critical blood flow to other important structures of the head which may make them impossible to treat curatively. Medical adjuvants may be an important consideration in the management of these patients. Summary: We conducted a systematic review of the literature to identify other instances of molecular target of rapamycin (mTOR) inhibitors used as medical adjuvants for the treatment of cranial and facial AVMs. We also present 2 cases from our own institution where patients were treated with partial embolization, followed by adjuvant therapy with rapamycin. After screening a total of 75 articles, 7 were identified which described use of rapamycin in the treatment of inoperable cranial or facial AVM. In total, 21 cases were reviewed. The median treatment duration was 12 months (3-24.5 months), and the highest recorded dose was 3.5 mg/m(2). 76.2% of patients demonstrated at least a partial response to rapamycin therapy. In 2 patients treated at our institution, symptomatic and radiographic improvement were noted 6 months after initiation of therapy. Key Messages: Early results have been encouraging in a small number of patients with inoperable AVM of the head and face treated with mTOR inhibitors. Further study of medical adjuvants such as rapamycin may be worthwhile.
C1 [Govindarajan, Vaidya; Burks, Joshua D.; Luther, Evan M.; Thompson, John W.; Starke, Robert M.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA.
RP Burks, JD (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA.
EM joshua.burks@jhsmiami.org
OI Govindarajan, Vaidya/0000-0002-0248-346X
FU NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [KL2 TR002737, UL1 TR002736] Funding
   Source: Medline; NINDS NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Neurological Disorders & Stroke (NINDS) [R01 NS111119] Funding
   Source: Medline
CR Adams DM, 2019, HEMATOL ONCOL CLIN N, V33, P455, DOI 10.1016/j.hoc.2019.01.011
   Bendok BR, 2014, NEUROSURGERY, V74, pS60, DOI 10.1227/NEU.0000000000000230
   Blauwblomme T, 2014, STROKE, V45, P1664, DOI 10.1161/STROKEAHA.113.004292
   Chelliah MP, 2018, JAMA DERMATOL, V154, P1316, DOI 10.1001/jamadermatol.2018.3039
   Chen CJ, 2018, NEUROSURG FOCUS, V45, DOI 10.3171/2018.3.FOCUS18113
   Dodds M, 2020, PEDIATR DERMATOL, V37, P272, DOI 10.1111/pde.14104
   Freixo C, 2020, J VASC SURG, V71, P318, DOI 10.1016/j.jvs.2019.06.217
   Gabeff R, 2019, ACTA DERM-VENEREOL, V99, P1105, DOI 10.2340/00015555-3273
   Goncharova EA, 2013, FASEB J, V27, P1796, DOI 10.1096/fj.12-222224
   Greveling K, 2017, LASER SURG MED, V49, P104, DOI 10.1002/lsm.22548
   Hammer J, 2018, ORPHANET J RARE DIS, V13, DOI 10.1186/s13023-018-0934-z
   Mack JM., 2019, PEDIATR BLOOD CANCER, V66, P27896, DOI [10.1002/pbc.27896, DOI 10.1002/pbc.27896]
   Marques L, 2015, J AM ACAD DERMATOL, V72, P151, DOI 10.1016/j.jaad.2014.10.011
   Maynard K., 2019, J NEUROSURG-PEDIATR, P1, DOI [10.3171/2019.7.PEDS1976, DOI 10.3171/2019.7.PEDS1976]
   Nikolaev SI, 2018, NEW ENGL J MED, V378, P250, DOI 10.1056/NEJMoa1709449
   Peschillo Simone, 2014, ScientificWorldJournal, V2014, P834931, DOI 10.1155/2014/834931
   Sandbank S, 2019, ACTA DERM-VENEREOL, V99, P990, DOI 10.2340/00015555-3262
   Sehgal SN., 2003, TRANSPLANT P S, V35, p7S, DOI DOI 10.1016/S0041-1345(03)00211-2
   Soblet J, 2013, MOL SYNDROMOL, V4, P179, DOI 10.1159/000348327
   Suazo L, 2012, INTERV NEURORADIOL, V18, P42, DOI 10.1177/159101991201800106
   Switon K, 2017, NEUROSCIENCE, V341, P112, DOI 10.1016/j.neuroscience.2016.11.017
   Thomas JM, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0248-8
   Triana P, 2017, EUR J PEDIATR SURG, V27, P86, DOI 10.1055/s-0036-1593383
   Waner M, 2018, OTOLARYNG CLIN N AM, V51, P159, DOI 10.1016/j.otc.2017.09.012
   Yang J, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0954-x
NR 25
TC 0
Z9 0
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-9770
EI 1421-9786
J9 CEREBROVASC DIS
JI Cerebrovasc. Dis.
PD SEP
PY 2021
VL 50
IS 5
BP 493
EP 499
DI 10.1159/000515168
PG 7
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA UQ8IX
UT WOS:000696303400003
PM 34198289
OA Green Accepted, Bronze
DA 2021-10-30
ER

PT J
AU Lanzoni, G
   Linetsky, E
   Correa, D
   Cayetano, SM
   Alvarez, RA
   Kouroupis, D
   Gil, AA
   Poggioli, R
   Ruiz, P
   Marttos, AC
   Hirani, K
   Bell, CA
   Kusack, H
   Rafkin, L
   Baidal, D
   Pastewski, A
   Gawri, K
   Lenero, C
   Mantero, AMA
   Metalonis, SW
   Wang, XJ
   Roque, L
   Masters, B
   Kenyon, NS
   Ginzburg, E
   Xu, XM
   Tan, JM
   Caplan, AI
   Glassberg, MK
   Alejandro, R
   Ricordi, C
AF Lanzoni, Giacomo
   Linetsky, Elina
   Correa, Diego
   Cayetano, Shari Messinger
   Alvarez, Roger A.
   Kouroupis, Dimitrios
   Gil, Ana Alvarez
   Poggioli, Raffaella
   Ruiz, Phillip
   Marttos, Antonio C.
   Hirani, Khemraj
   Bell, Crystal A.
   Kusack, Halina
   Rafkin, Lisa
   Baidal, David
   Pastewski, Andrew
   Gawri, Kunal
   Lenero, Clarissa
   Mantero, Alejandro M. A.
   Metalonis, Sarah W.
   Wang, Xiaojing
   Roque, Luis
   Masters, Burlett
   Kenyon, Norma S.
   Ginzburg, Enrique
   Xu, Xiumin
   Tan, Jianming
   Caplan, Arnold, I
   Glassberg, Marilyn K.
   Alejandro, Rodolfo
   Ricordi, Camillo
TI Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory
   distress syndrome: A double-blind, phase 1/2a, randomized controlled
   trial
SO STEM CELLS TRANSLATIONAL MEDICINE
LA English
DT Article
DE cell transplantation; cellular therapy; clinical trials; mesenchymal
   stem cells; respiratory tract; transplantation; umbilical cord
ID CLINICAL-TRIAL; STROMAL CELL; TRANSPLANTATION; SAFETY
AB Acute respiratory distress syndrome (ARDS) in COVID-19 is associated with high mortality. Mesenchymal stem cells are known to exert immunomodulatory and anti-inflammatory effects and could yield beneficial effects in COVID-19 ARDS. The objective of this study was to determine safety and explore efficacy of umbilical cord mesenchymal stem cell (UC-MSC) infusions in subjects with COVID-19 ARDS. A double-blind, phase 1/2a, randomized, controlled trial was performed. Randomization and stratification by ARDS severity was used to foster balance among groups. All subjects were analyzed under intention to treat design. Twenty-four subjects were randomized 1:1 to either UC-MSC treatment (n = 12) or the control group (n = 12). Subjects in the UC-MSC treatment group received two intravenous infusions (at day 0 and 3) of 100 +/- 20 x 10(6) UC-MSCs; controls received two infusions of vehicle solution. Both groups received best standard of care. Primary endpoint was safety (adverse events [AEs]) within 6 hours; cardiac arrest or death within 24 hours postinfusion). Secondary endpoints included patient survival at 31 days after the first infusion and time to recovery. No difference was observed between groups in infusion-associated AEs. No serious adverse events (SAEs) were observed related to UC-MSC infusions. UC-MSC infusions in COVID-19 ARDS were found to be safe. Inflammatory cytokines were significantly decreased in UC-MSC-treated subjects at day 6. Treatment was associated with significantly improved patient survival (91% vs 42%, P = .015), SAE-free survival (P = .008), and time to recovery (P = .03). UC-MSC infusions are safe and could be beneficial in treating subjects with COVID-19 ARDS.
C1 [Lanzoni, Giacomo; Linetsky, Elina; Correa, Diego; Kouroupis, Dimitrios; Gil, Ana Alvarez; Poggioli, Raffaella; Hirani, Khemraj; Rafkin, Lisa; Baidal, David; Lenero, Clarissa; Wang, Xiaojing; Roque, Luis; Masters, Burlett; Kenyon, Norma S.; Xu, Xiumin; Alejandro, Rodolfo; Ricordi, Camillo] Univ Miami, Cell Transplant Ctr, Diabet Res Inst, Miller Sch Med, 1450 NW 10th Ave, Miami, FL 33137 USA.
   [Lanzoni, Giacomo] Univ Miami, Dept Biochem & Mol Biol, Miller Sch Med, Miami, FL 33137 USA.
   [Linetsky, Elina; Ruiz, Phillip; Ginzburg, Enrique; Ricordi, Camillo] Univ Miami, Dept Surg, Miller Sch Med, Miami, FL 33137 USA.
   [Correa, Diego] Univ Miami, UHlth Sports Med Inst, Dept Orthoped, Miller Sch Med, Miami, FL 33137 USA.
   [Cayetano, Shari Messinger; Mantero, Alejandro M. A.; Metalonis, Sarah W.] Univ Miami, Dept Publ Hlth Sci, Div Biostat, Miller Sch Med, Miami, FL 33137 USA.
   [Alvarez, Roger A.; Marttos, Antonio C.; Hirani, Khemraj; Bell, Crystal A.; Kusack, Halina; Baidal, David; Gawri, Kunal; Alejandro, Rodolfo] Univ Miami, Dept Med, Miller Sch Med, Miami, FL 33137 USA.
   [Alvarez, Roger A.; Marttos, Antonio C.; Baidal, David; Gawri, Kunal; Ginzburg, Enrique; Alejandro, Rodolfo] Univ Miami Hlth Syst, Miami, FL USA.
   [Marttos, Antonio C.; Pastewski, Andrew; Ginzburg, Enrique] Jackson Hlth Syst, Miami, FL USA.
   [Tan, Jianming] Hainan Med Univ, Affiliated Hosp 2, Haikou, Hainan, Peoples R China.
   [Caplan, Arnold, I] Case Western Reserve Univ, Skeletal Res Ctr, Cleveland, OH USA.
   [Glassberg, Marilyn K.] Univ Arizona, Coll Med, Tucson, AZ USA.
RP Ricordi, C (corresponding author), Univ Miami, Cell Transplant Ctr, Diabet Res Inst, Miller Sch Med, 1450 NW 10th Ave, Miami, FL 33137 USA.
EM glanzoni@med.miami.edu; cricordi@med.miami.edu
RI Alvarez, Roger A./AAZ-3730-2020; Mantero, Alejandro/AAS-6415-2021;
   KOUROUPIS, DIMITRIOS/AAE-4192-2020
OI Alvarez, Roger A./0000-0001-7819-6486; KOUROUPIS,
   DIMITRIOS/0000-0002-3892-9013; Roque, Luis/0000-0003-1969-0315
FU National Center for Advancing Translational SciencesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1TR002736, UL1TR000460]; Simkins Family Foundation; Fondazione Silvio
   Tronchetti Provera; Diabetes Research Institute Foundation (DRIF); Cure
   Alliance; North America's Building Trades Unions (NABTU); Ugo Colombo;
   Barilla Group and Family
FX National Center for Advancing Translational Sciences, Grant/Award
   Numbers: UL1TR002736, UL1TR000460; Ugo Colombo; Simkins Family
   Foundation; Fondazione Silvio Tronchetti Provera; Barilla Group and
   Family; Diabetes Research Institute Foundation (DRIF); The Cure
   Alliance; North America's Building Trades Unions (NABTU)
CR Atala A, 2021, STEM CELL TRANSL MED, V10, P5, DOI 10.1002/sctm.20-0245
   Barkai O, 2019, PAIN, V160, P1281, DOI 10.1097/j.pain.0000000000001523
   Bartolucci J, 2017, CIRC RES, V121, P1192, DOI 10.1161/CIRCRESAHA.117.310712
   Berlin DA, 2020, NEW ENGL J MED, V383, P2451, DOI 10.1056/NEJMcp2009575
   Cai JQ, 2016, DIABETES CARE, V39, P149, DOI 10.2337/dc15-0171
   Can A, 2020, STEM CELL TRANSL MED, V9, P1287, DOI 10.1002/sctm.20-0164
   Can A, 2017, CYTOTHERAPY, V19, P1351, DOI 10.1016/j.jcyt.2017.08.004
   Caplan AI, 2017, STEM CELL TRANSL MED, V6, P1445, DOI 10.1002/sctm.17-0051
   Caplan AI, 2011, CELL STEM CELL, V9, P11, DOI 10.1016/j.stem.2011.06.008
   Carlsson PO, 2015, DIABETES, V64, P587, DOI 10.2337/db14-0656
   Castro-Dopico T, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107857
   Centers for Disease Control and Prevention, INT CLIN GUID MAN PA
   Chen JJ, 2020, ENGINEERING-PRC, V6, P1153, DOI 10.1016/j.eng.2020.02.006
   Del Valle DM, 2020, NAT MED, V26, P1636, DOI 10.1038/s41591-020-1051-9
   Demoule A, 2020, AM J RESP CRIT CARE, V202, P1039, DOI 10.1164/rccm.202005-2007LE
   Deng DQ, 2017, ANN RHEUM DIS, V76, P1436, DOI 10.1136/annrheumdis-2017-211073
   Garcia-Olmo D, 2005, DIS COLON RECTUM, V48, P1416, DOI 10.1007/s10350-005-0052-6
   Guo ZN, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03142-8
   Harrell CR, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/4236973
   Kang ZY, 2020, INT J OBESITY, V44, P2479, DOI 10.1038/s41366-020-00677-2
   Kardas G, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00047
   Kox M, 2020, JAMA-J AM MED ASSOC, V324, P1565, DOI 10.1001/jama.2020.17052
   Lanzoni G, 2020, CellR4 Repair Replace Regen Reprogram, V8, DOI 10.32113/cellr4_20204_2839
   Laroye C, 2020, STEM CELL TRANSL MED, V9, P1488, DOI 10.1002/sctm.20-0239
   LeBlanc K, 2008, LANCET, V371, P1579, DOI 10.1016/S0140-6736(08)60690-X
   Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228
   Li J, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00892-2020
   Liang B, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000021429
   Liu STH, 2020, NAT MED, V26, P1708, DOI 10.1038/s41591-020-1088-9
   Lucas C, 2020, NATURE, V584, P463, DOI 10.1038/s41586-020-2588-y
   Matthay MA, 2020, AM J RESP CRIT CARE, V202, P1489, DOI 10.1164/rccm.202009-3629ED
   Matthay MA, 2019, LANCET RESP MED, V7, P154, DOI 10.1016/S2213-2600(18)30418-1
   McElvaney OJ, 2020, AM J RESP CRIT CARE, V202, P812, DOI 10.1164/rccm.202005-1583OC
   McGonagle D, 2020, LANCET RHEUMATOL, V2, pE437, DOI 10.1016/S2665-9913(20)30121-1
   Meng FP, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00286-5
   Moodley Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069299
   Patel A, 2017, US patent, Patent No. [9,803,176 B2, 9803176]
   Patel AN, 2013, CELL TRANSPLANT, V22, P513, DOI 10.3727/096368912X655064
   Patel BV, 2020, AM J RESP CRIT CARE, V202, P690, DOI 10.1164/rccm.202004-1412OC
   Qu WC, 2020, STEM CELL TRANSL MED, V9, P1007, DOI 10.1002/sctm.20-0146
   Soeroto AY, 2020, DIABETES METAB SYND, V14, P1897, DOI 10.1016/j.dsx.2020.09.029
   Sterne JAC, 2020, JAMA-J AM MED ASSOC, V324, P1330, DOI 10.1001/jama.2020.17023
   Tang YJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01708
   Thompson M, 2020, ECLINICALMEDICINE, V19, DOI 10.1016/j.eclinm.2019.100249
   Tuma J, 2016, CELL TRANSPLANT, V25, P1713, DOI 10.3727/096368915X690314
   van Steensel L, 2010, INVEST OPHTH VIS SCI, V51, P1002, DOI 10.1167/iovs.09-4338
   Wen LH, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/7061408
   Wiersinga WJ, 2020, JAMA-J AM MED ASSOC, V324, P782, DOI 10.1001/jama.2020.12839
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu JT, 2020, NAT MED, V26, P506, DOI 10.1038/s41591-020-0822-7
   Yip HK, 2020, CRIT CARE MED, V48, pE391, DOI 10.1097/CCM.0000000000004285
   Zhao RZ, 2017, ONCOTARGET, V8, P30511, DOI 10.18632/oncotarget.15426
   Zheng GP, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-39
   Zhou P, 2020, NATURE, V588, pE6, DOI [10.1038/s41586-020-2951-z, 10.1038/s41586-020-2012-7]
NR 54
TC 35
Z9 35
U1 5
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2157-6564
EI 2157-6580
J9 STEM CELL TRANSL MED
JI Stem Cells Transl. Med.
PD MAY
PY 2021
VL 10
IS 5
BP 660
EP 673
DI 10.1002/sctm.20-0472
EA JAN 2021
PG 14
WC Cell & Tissue Engineering
SC Cell Biology
GA RN3BR
UT WOS:000604705500001
PM 33400390
OA gold, Green Published
HC Y
HP N
DA 2021-10-30
ER

PT J
AU Li, YC
   Chen, SH
   Spiotta, AM
   Jabbour, P
   Levitt, MR
   Kan, PT
   Griessenauer, CJ
   Arthur, AS
   Osbun, JW
   Park, MS
   Chalouhi, N
   Sweid, A
   Wolfe, SQ
   Fargen, KM
   Dumont, AS
   Dumont, TM
   Brunet, MC
   Sur, S
   Luther, E
   Strickland, A
   Yavagal, DR
   Peterson, EC
   Schirmer, CM
   Goren, O
   Dalal, S
   Weiner, G
   Rosengart, A
   Raper, D
   Chen, CJ
   Amenta, P
   Scullen, T
   Kelly, CM
   Young, C
   Nahhas, M
   Almallouhi, E
   Gunasekaran, A
   Pai, SH
   Lanzino, G
   Brinjikji, W
   Abbasi, M
   Iii, DD
   Goyal, N
   Peterson, J
   El-Ghanem, MH
   Starke, RM
AF Li, Yangchun
   Chen, Stephanie H.
   Spiotta, Alejandro M.
   Jabbour, Pascal
   Levitt, Michael R.
   Kan, Peter
   Griessenauer, Christoph J.
   Arthur, Adam S.
   Osbun, Joshua W.
   Park, Min S.
   Chalouhi, Nohra
   Sweid, Ahmad
   Wolfe, Stacey Q.
   Fargen, Kyle M.
   Dumont, Aaron S.
   Dumont, Travis M.
   Brunet, Marie-Christine
   Sur, Samir
   Luther, Evan
   Strickland, Allison
   Yavagal, Dileep R.
   Peterson, Eric C.
   Schirmer, Clemens M.
   Goren, Oded
   Dalal, Shamsher
   Weiner, Gregory
   Rosengart, Axel
   Raper, Daniel
   Chen, Ching-Jen
   Amenta, Peter
   Scullen, Tyler
   Kelly, Cory Michael
   Young, Christopher
   Nahhas, Michael
   Almallouhi, Eyad
   Gunasekaran, Arunprasad
   Pai, Suhas
   Lanzino, Giuseppe
   Brinjikji, Waleed
   Abbasi, Mehdi
   Dornbos III, David
   Goyal, Nitin
   Peterson, Jeremy
   El-Ghanem, Mohammad H.
   Starke, Robert M.
TI Lower complication rates associated with transradial versus transfemoral
   flow diverting stent placement
SO JOURNAL OF NEUROINTERVENTIONAL SURGERY
LA English
DT Article
DE aneurysm; intervention; flow diverter; complication; artery
ID RADIAL ARTERY-OCCLUSION; CORONARY INTERVENTION; GUIDE CATHETER; ACCESS;
   METAANALYSIS; ANGIOPLASTY; ANGIOGRAPHY
AB Background Currently, there are no large-scale studies in the neurointerventional literature comparing safety between transradial (TRA) and transfemoral (TFA) approaches for flow diversion procedures. This study aims to assess complication rates in a large multicenter registry for TRA versus TFA flow diversion.
   Methods We retrospectively analyzed flow diversion cases for cerebral aneurysms from 14 institutions from 2010 to 2019. Pooled analysis of proportions was calculated using weighted analysis with 95% CI to account for results from multiple centers. Access site complication rate and overall complication rate were compared between the two approaches.
   Results A total of 2,285 patients who underwent flow diversion were analyzed, with 134 (5.86%) treated with TRA and 2151 (94.14%) via TFA. The two groups shared similar patient and aneurysm characteristics. Crossover from TRA to TFA was documented in 12 (8.63%) patients. There were no access site complications in the TRA group. There was a significantly higher access site complication rate in the TFA cohort as compared with TRA (2.48%, 95% CI 2.40% to 2.57%, vs 0%; p=0.039). One death resulted from a femoral access site complication. The overall complications rate was also higher in the TFA group (9.02%, 95% CI 8.15% to 9.89%) compared with the TRA group (3.73%, 95% CI 3.13% to 4.28%; p=0.035).
   Conclusion TRA may be a safer approach for flow diversion to treat cerebral aneurysms at a wide range of locations. Both access site complication rate and overall complication rate were lower for TRA flow diversion compared with TFA in this large series.
C1 [Li, Yangchun; Sur, Samir; Starke, Robert M.] Univ Miami, Miller Sch Med, Neurol Surg, Miami, FL 33136 USA.
   [Chen, Stephanie H.; Brunet, Marie-Christine; Luther, Evan; Strickland, Allison] Univ Miami, Dept Neurol Surg, Med Sch Miami, Miami, FL 33136 USA.
   [Spiotta, Alejandro M.; Gunasekaran, Arunprasad; Pai, Suhas] Med Univ South Carolina, Neurosurg, Charleston, SC 29425 USA.
   [Jabbour, Pascal; Chalouhi, Nohra; Sweid, Ahmad] Thomas Jefferson Univ Hosp, Neurol Surg, Philadelphia, PA 19107 USA.
   [Levitt, Michael R.] Univ Washington, Neurol Surg Radiol & Mech Engn & Stroke & Appl Ne, Seattle, WA USA.
   [Kan, Peter] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA.
   [Griessenauer, Christoph J.; Schirmer, Clemens M.; Dalal, Shamsher; Rosengart, Axel] Geisinger Hlth Syst, Neurosurg, Danville, PA USA.
   [Griessenauer, Christoph J.] Paracelsus Med Univ Salzburg, Res Inst Neurointervent, Salzburg, Austria.
   [Arthur, Adam S.] Semmes Murphey Neurol & Spine Inst, Dept Neurol Surg, Memphis, TN USA.
   [Arthur, Adam S.; Peterson, Jeremy] Univ Tennessee, Neurosurg, Hlth Sci Ctr, Memphis, TN USA.
   [Osbun, Joshua W.] Washington Univ, Neurosurg, Sch Med, St Louis, MO USA.
   [Park, Min S.] Univ Virginia, Neurol Surg, Charlottesville, VA USA.
   [Wolfe, Stacey Q.] Wake Forest Sch Med, Neurosurg, Salem, NC USA.
   [Fargen, Kyle M.] Wake Forest Univ, Neurosurg, Winston Salem, NC 27101 USA.
   [Dumont, Aaron S.] Tulane Univ, Dept Neurol Surg, New Orleans, LA 70118 USA.
   [Dumont, Travis M.] Univ Arizona, Arizona Hlth Sci Ctr, Neurosurg Neurol & Med Imaging, Tucson, AZ USA.
   [Yavagal, Dileep R.] Univ Miami, Neurol & Neurosurg, Miami, FL USA.
   [Peterson, Eric C.] Univ Miami, Neurol Surg, Miami, FL USA.
   [Schirmer, Clemens M.] Paracelsus Med Univ Salzburg, Res Inst Neurointervent, Salzburg, Austria.
   [Goren, Oded] Geisinger, Neurosurg, Danville, PA USA.
   [Weiner, Gregory] Geisinger Hlth Syst, Neurosurg, Wilkes Barre, PA USA.
   [Raper, Daniel] Univ Virginia, Dept Neurol Surg, Charlottesville, VA USA.
   [Chen, Ching-Jen] Univ Virginia Hlth Syst, Neurol Surg, Charlottesville, VA USA.
   [Amenta, Peter] Tulane Med Ctr Downtown, Neurol Surg, New Orleans, LA USA.
   [Scullen, Tyler] Tulane Univ, Neurosurggery, New Orleans, LA USA.
   [Kelly, Cory Michael; Young, Christopher] Univ Washington, Neurol Surg, Seattle, WA USA.
   [Nahhas, Michael; Almallouhi, Eyad] Med Univ South Carolina, Neurol, Charleston, SC 29425 USA.
   [Lanzino, Giuseppe; Abbasi, Mehdi] Mayo Clin, Neurosurg, Rochester, MN USA.
   [Brinjikji, Waleed] Mayo Clin Minnesota, Neurosurg, Rochester, MN USA.
   [Dornbos III, David] Semmes Murphey Clin, Neurosurg, Memphis, TN USA.
   [Dornbos III, David] Univ Tennessee, Ctr Hlth Sci, Neurosurg, Memphis, TN 38163 USA.
   [Goyal, Nitin] Univ Tennessee, Ctr Hlth Sci, Neurol, Memphis, TN 38163 USA.
   [Peterson, Jeremy] Semmes Murphey Neurol & Spine Inst, Neurosurg, Memphis, TN USA.
   [El-Ghanem, Mohammad H.] Univ Arizona, Neurosurg Neurol & Med Imaging, Hlth Sci Ctr, Tucson, AZ USA.
   [Starke, Robert M.] Univ Miami, Miller Sch Med, Radiol, Miami, FL 33136 USA.
RP Starke, RM (corresponding author), Univ Miami, Miller Sch Med, Neurol Surg, Miami, FL 33136 USA.; Starke, RM (corresponding author), Univ Miami, Miller Sch Med, Radiol, Miami, FL 33136 USA.
EM RStarke@med.miami.edu
OI Wolfe, Stacey/0000-0001-7603-2728; Schirmer, Clemens/0000-0003-1743-8781
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01NS111119-01A1,
   UL1TR002736, KL2TR002737]; Miami Clinical and Translational Science
   Institute
FX This research is in part supported by National Institutes of Health
   (R01NS111119-01A1) and (UL1TR002736, KL2TR002737) through the Miami
   Clinical and Translational Science Institute.
CR Agostoni P, 2004, J AM COLL CARDIOL, V44, P349, DOI 10.1016/j.jacc.2004.04.034
   Andreu G, 2018, TRANSFUS MED REV, V32, P16, DOI 10.1016/j.tmrv.2017.07.001
   Brunet MC, 2020, J NEUROINTERV SURG, V12, P82, DOI 10.1136/neurintsurg-2019-015145
   Catapano JS, 2020, J NEUROINTERV SURG, V12, P611, DOI 10.1136/neurintsurg-2019-015569
   Cauley R, 2019, ANN VASC SURG, V56, P87, DOI 10.1016/j.avsg.2018.07.064
   Chen SH, 2019, J NEUROINTERV SURG, V11, P796, DOI 10.1136/neurintsurg-2018-014620
   Chen SH, 2019, J NEUROINTERV SURG, V11, P874, DOI 10.1136/neurintsurg-2018-014485
   Dahm JB, 2002, CATHETER CARDIO INTE, V57, P172, DOI 10.1002/ccd.10321
   Daou B, 2016, CLIN NEUROL NEUROSUR, V145, P89, DOI 10.1016/j.clineuro.2016.04.015
   Dietrich C, 2013, NEUROSURGERY, V73, P111, DOI 10.1227/NEU.0b013e31827e0d67
   Horie K, 2018, EUROINTERVENTION, V13, P2018, DOI 10.4244/EIJ-D-17-00239
   Jaroenngarmsamer T, 2020, J NEUROINTERV SURG, V12, P87, DOI 10.1136/neurintsurg-2019-014994
   Jolly SS, 2009, AM HEART J, V157, P132, DOI 10.1016/j.ahj.2008.08.023
   Kiemeneij F, 1997, J AM COLL CARDIOL, V29, P1269, DOI 10.1016/S0735-1097(97)00064-8
   Kinoshita N, 2011, AM J CARDIOL, V107, p45A, DOI 10.1016/j.amjcard.2011.02.102
   Kok MM, 2018, CATHETER CARDIO INTE, V91, P17, DOI 10.1002/ccd.27039
   Mamas MA, 2018, CIRC-CARDIOVASC QUAL, V11, DOI 10.1161/CIRCOUTCOMES.117.004482
   Mann JT, 1996, J INVASIVE CARDIOL, V8, pD40
   Mitchell MD, 2012, CIRC-CARDIOVASC QUAL, V5, P454, DOI 10.1161/CIRCOUTCOMES.112.965269
   Patel AS, 2016, INTERV NEURORADIOL, V22, P402, DOI 10.1177/1591019916632490
   Peitz Geoffrey W, 2017, J Vasc Interv Neurol, V9, P42
   Plaeke P, 2020, SURG TODAY, V50, P427, DOI 10.1007/s00595-019-01827-4
   Rashid M, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.002686
   Raz E, 2019, OPER NEUROSURG, V17, P340, DOI 10.1093/ons/opy378
   Sciahbasi A, 2009, AM J CARDIOL, V103, P796, DOI 10.1016/j.amjcard.2008.11.049
   Starke RM, 2020, J NEUROINTERV SURG, V12, P733, DOI 10.1136/neurintsurg-2019-015573
   Sweid A, 2019, J NEUROSURG SCI, V63, P509, DOI 10.23736/S0390-5616.19.04761-1
   Takeshita S, 2014, AM J CARDIOL, V113, P1986, DOI 10.1016/j.amjcard.2014.03.040
   Valgimigli M, 2018, LANCET, V392, P835, DOI 10.1016/S0140-6736(18)31714-8
   Valgimigli M, 2015, LANCET, V385, P2465, DOI 10.1016/S0140-6736(15)60292-6
NR 30
TC 16
Z9 16
U1 1
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1759-8478
EI 1759-8486
J9 J NEUROINTERV SURG
JI J. NeuroInterventional Surg.
PD JAN
PY 2021
VL 13
IS 1
BP 91
EP +
DI 10.1136/neurintsurg-2020-015992
PG 6
WC Neuroimaging; Surgery
SC Neurosciences & Neurology; Surgery
GA PT1QN
UT WOS:000608393900019
PM 32487766
OA Green Accepted
HC Y
HP N
DA 2021-10-30
ER

PT J
AU Kumar, N
   Ramirez-Ortiz, D
   Solo-Gabriele, HM
   Treaster, JB
   Carrasquillo, O
   Toborek, M
   Deo, S
   Klaus, J
   Bachas, LG
   Whitall, D
   Daunert, S
   Szapocznik, J
AF Kumar, Naresh
   Ramirez-Ortiz, Daisy
   Solo-Gabriele, Helena M.
   Treaster, Joseph B.
   Carrasquillo, Olveen
   Toborek, Michal
   Deo, Sapna
   Klaus, Jim
   Bachas, Leonidas G.
   Whitall, David
   Daunert, Sylvia
   Szapocznik, Jose
TI Environmental PCBs in Guanica Bay, Puerto Rico: implications for
   community health
SO ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH
LA English
DT Article
DE PCB; Fish; Sediment; Guanica; Community-based participatory approach;
   Health risks; PCB exposure
ID HARTWELL SUPERFUND SITE; LONG-TERM RECOVERY; POLYCHLORINATED-BIPHENYLS;
   CHEMICAL CONCENTRATIONS; CONTAMINATED SEDIMENTS; RIVER; DECHLORINATION;
   ACCUMULATION; POPULATION; CONGENERS
AB Guanica Bay, located in southwestern Puerto Rico, has suffered oil spills and other pollution discharges since the 1960s. Previous research showed elevated concentrations of polychlorinated biphenyls (PCBs) in coral reef and sediment. This research examined PCB concentrations in sediment and fish. Sediment and fish sampling in the bay was facilitated by community members. This study identified the second highest reported PCB level (129,300 ng/g) in sediment in the USA. Fish samples also showed elevated concentrations (1623 to 3768 ng/g), which were higher than the thresholds of safe levels of PCBs in fish for human consumption. The alarmingly high concentration of PCBs calls for proactive community engagement to bring awareness about contamination of the bay and more extensive sampling to test for the concentration of PCBs in seafood and the people of Guanica. This study also underscores the value of the involvement of local communities during sampling design aimed at identifying hot spots of contaminants.
C1 [Kumar, Naresh; Ramirez-Ortiz, Daisy; Carrasquillo, Olveen; Szapocznik, Jose] Univ Miami, Dept Publ Hlth Sci, Miami, FL 33136 USA.
   [Carrasquillo, Olveen] Univ Miami, Gen Med, Miami, FL 33136 USA.
   [Toborek, Michal; Deo, Sapna; Daunert, Sylvia] Univ Miami, Dept Biochem & Mol Biol, Miami, FL 33136 USA.
   [Solo-Gabriele, Helena M.] Univ Miami, Dept Civil Environm & Architectural Engn, Miami, FL 33146 USA.
   [Klaus, Jim; Bachas, Leonidas G.] Univ Miami, Dept Chem, Miami, FL 33146 USA.
   [Whitall, David] NOAA, Natl Ctr Coastal Ocean Sci, Silver Spring, MD 20910 USA.
   [Treaster, Joseph B.] Univ Miami, Sch Commun, Coral Gables, FL 33146 USA.
RP Kumar, N (corresponding author), Univ Miami, Dept Publ Hlth Sci, 1120 NW 14th St Suite 1063, Miami, FL 33136 USA.
EM nkumar@med.miami.edu
OI Kumar, Naresh/0000-0001-6200-9172; Bachas, Leonidas/0000-0002-3308-6264;
   Ramirez Ortiz, Daisy/0000-0002-5374-3348
FU Miami Clinical and Translational Science Institute (CTSI) (NCATS)
   [TR000461]; Public Health Sciences Department, University of Miami;
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000460, KL2TR000461] Funding Source: NIH RePORTER
FX This work was partly supported by the Miami Clinical and Translational
   Science Institute (CTSI) (NCATS Grant # TR000461) and Public Health
   Sciences Department, University of Miami. We are greatly thankful to
   both reviewers' thoughtful, constructive, and meticulous comments, which
   helped us improve the quality of this paper.
CR Abraham WR, 2002, CURR OPIN MICROBIOL, V5, P246, DOI 10.1016/S1369-5274(02)00323-5
   Agency for Toxic Substances and Disease Registry (ATSDR), 2000, TOX PROF POL BIPH PC
   Agency for Toxic Substances and Disease Registry (ATSDR), 1995, EXP PCBS HAZ WAST MO
   [Anonymous], 1994, ORLANDO SENTINEL
   Axelrad D, 2009, ENVIRON RES, P368
   Azaroff LS, 2011, J COMMUN HEALTH, V36, P658, DOI 10.1007/s10900-011-9357-7
   Baker JE, 2006, PCBS UPPER TIDAL FRE
   Bjerregaard P, 2013, SCI TOTAL ENVIRON, V454, P283, DOI 10.1016/j.scitotenv.2013.03.031
   Bopp RF, 1998, ENVIRON HEALTH PERSP, V106, P1075, DOI 10.2307/3434155
   Carro T, 2013, ENVIRON TOXICOL CHEM, V32, P1325, DOI 10.1002/etc.2178
   CDC (Centers for Disease Control and Prevention), 2014, 4 CDCP
   CSA Group, 2001, PHAS 1 ENV SIT ASS O
   Dallaire R, 2014, ENVIRON RES, V134, P17, DOI 10.1016/j.envres.2014.06.023
   Diaz-Piferrer M, 1962, P 4 M ASS ISL MAR LA
   Echols KR, 2000, ENVIRON SCI TECHNOL, V34, P4095, DOI 10.1021/es001169f
   Echols KR, 1999, EVALUATION POLYCHLOR
   Environmental Protection Agency (EPA), 2013, HLTH EFF PCBS
   EPA, 2000, GUID ASS CHEM CONT D
   EPA, 2013, WAST HAZ WAST TEST M
   EPA, 2007, 8082A EPA
   EPA, 2013, PUBL HLTH IMPL EXP P
   EPA, 2013, AR OTH PCB MIXT
   ESRI, 2014, ARCGIS
   Everett CJ, 2011, J ENVIRON MONITOR, V13, P241, DOI 10.1039/c0em00400f
   Field JA, 2008, ENVIRON POLLUT, V155, P1, DOI 10.1016/j.envpol.2007.10.016
   Fieldler H, 1997, POLYCHLORINATED BIPH
   Golob R, 1994, VANDALISM SUSPECTED
   Grimm FA, 2015, CRIT REV TOXICOL, V45, P245, DOI 10.3109/10408444.2014.999365
   Hennig B, 2002, INT J HYG ENVIR HEAL, V205, P95, DOI 10.1078/1438-4639-00134
   Holloman EL, 2010, ENVIRON RES, V110, P213, DOI 10.1016/j.envres.2010.01.002
   Hu DF, 2010, ATMOS ENVIRON, V44, P1550, DOI 10.1016/j.atmosenv.2010.01.006
   Kannan K, 1997, ENVIRON SCI TECHNOL, V31, P1483, DOI 10.1021/es960721r
   Kondo MC, 2014, PROG COMM HLTH PARTN, V8, P291, DOI 10.1353/cpr.2014.0047
   Lauby-Secretan B, 2013, LANCET ONCOL, V14, P287, DOI 10.1016/S1470-2045(13)70104-9
   Levinton J. S., 2006, HUDSON RIVER ESTUARY
   Long E.R., 1990, POTENTIAL BIOL EFFEC
   LONG ER, 1992, MAR POLLUT BULL, V24, P38, DOI 10.1016/0025-326X(92)90315-W
   LONG ER, 1995, ENVIRON MANAGE, V19, P81, DOI 10.1007/BF02472006
   Magar VS, 2005, ENVIRON SCI TECHNOL, V39, P3538, DOI 10.1021/es048622y
   Magar VS, 2005, ENVIRON SCI TECHNOL, V39, P3548, DOI 10.1021/es0486216
   Maruya KA, 1998, ENVIRON TOXICOL CHEM, V17, P2463, DOI 10.1002/etc.5620171212
   Meador JP, 2002, AQUAT CONSERV, V12, P493, DOI 10.1002/aqc.523
   Michigan Department of Natural Resources (MDNR), 1988, REM ACT PLAN SAG RIV
   Morales MV, 2009, NOTICE INTENT NOI MU
   Narquis CT, 2007, DEAC0696RL13200 ASS
   National Research Council, 2001, RISK MAN PCB CONT SE
   NCCOS, 2014, NAT STAT TRENDS DAT
   NRCS, 2009, WORK TOG REST FOR CO
   Ohtsubo Y, 2004, APPL MICROBIOL BIOT, V65, P250, DOI 10.1007/s00253-004-1654-y
   Robertson A, 1988, MONITORING COASTAL W
   Robles F, 2007, THE SPOKESMAN REV
   Rodrigueq M, 2015, GUANICA BAY WATERSHE
   Santschi PH, 2001, MAR ENVIRON RES, V52, P51, DOI 10.1016/S0141-1136(00)00260-9
   Steinbacher J.C., 2002, FINAL REPORTS TIBOR
   Straub CP, 1983, ENV LEVELS PCB GREAT
   Sturm P, 2012, 12 INT COR REEF S CA
   Totten LA, 2006, MAR CHEM, DOI [10.1016/S0304-4203(98)90086-X, DOI 10.1016/S0304-4203(98)90086-X]
   *US FDA, 1998, ACT LEV POIS DEL SUB
   WENNING RJ, 1994, ARCH ENVIRON CON TOX, V27, P64, DOI 10.1007/BF00203890
   Whitall D., 2013, BASELINE ASSESSMENT
   Xue J, 2014, J EXPO SCI ENV EPID, V24, P615, DOI 10.1038/jes.2013.91
   Zhao HX, 2010, ENVIRON INT, V36, P819, DOI 10.1016/j.envint.2009.03.003
NR 62
TC 8
Z9 8
U1 1
U2 62
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0944-1344
EI 1614-7499
J9 ENVIRON SCI POLLUT R
JI Environ. Sci. Pollut. Res.
PD FEB
PY 2016
VL 23
IS 3
BP 2003
EP 2013
DI 10.1007/s11356-015-4913-9
PG 11
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA DB2YO
UT WOS:000368376800005
PM 26122576
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Badell, ML
   Sheth, AN
   Momplaisir, F
   Rahangdale, L
   Potter, J
   Woodham, PC
   Lazenby, GB
   Short, WR
   Gillespie, SE
   Baldreldin, N
   Miller, ES
   Alleyne, G
   Duthely, LM
   Allen, SM
   Levison, J
   Chakraborty, R
AF Badell, Martina L.
   Sheth, Anandi N.
   Momplaisir, Florence
   Rahangdale, Lisa
   Potter, JoNell
   Woodham, Padmashree C.
   Lazenby, Gweneth B.
   Short, William R.
   Gillespie, Scott E.
   Baldreldin, Nevert
   Miller, Emily S.
   Alleyne, Gregg
   Duthely, Lunthita M.
   Allen, Stephanie M.
   Levison, Judy
   Chakraborty, Rana
CA HOPES HIV OB Pregnancy Educ Study
TI A Multicenter Analysis of Elvitegravir Use During Pregnancy on HIV Viral
   Suppression and Perinatal Outcomes
SO OPEN FORUM INFECTIOUS DISEASES
LA English
DT Article
DE HIV viral suppression; obstetrics and gynecology; perinatal outcomes;
   prevention of mother-to-child transmission
ID ACTIVE ANTIRETROVIRAL THERAPY; ADVERSE BIRTH OUTCOMES; INFANT OUTCOMES;
   INFECTED WOMEN; DELIVERY; EXPOSURE; RISK; INHIBITORS
AB Background. There is a knowledge gap on the clinical use of elvitegravir (EVG) during pregnancy and maternal viral suppression. Our objective was to evaluate the effects of EVG use in pregnancy on rates of HIV virologic suppression and perinatal outcomes.
   Methods. We conducted a retrospective, multicenter study of pregnant women living with HIV (WLHIV) who used EVG-containing antiretroviral therapy (ART) between January 2014 and March 2017 at 9 tertiary care centers in the United States. WLHIV were included if they took EVG at any time during pregnancy. We described the characteristics of the WLHIV using EVG during the study period and evaluated the rates of HIV suppression and perinatal outcomes.
   Results. Among 134 pregnant WLHIV who received EVG at any time during pregnancy, viral suppression at delivery (HIV-1 RNA < 40 copies/mL) occurred in 81.3%. In WLHIV who initiated EVG before pregnancy and continued through delivery (n = 68), the rate of viral suppression at delivery was 88.2%. The average gestational age at the time of delivery was 37 weeks 6 days, and the overall rate of preterm birth was 20%. No cases of open neural tube defects were noted in women on EVG at the time of conception (n = 82). The perinatal HIV transmission rate was 0.8%.
   Conclusions. EVG use was associated with high sustained levels of HIV suppression during pregnancy and a low rate of perinatal HIV transmission.
C1 [Badell, Martina L.] Emory Univ, Sch Med, Dept Gynecol & Obstet, Div Maternal Fetal Med, Atlanta, GA 30308 USA.
   [Sheth, Anandi N.] Emory Univ, Sch Med, Dept Med, Div Infect Dis, Atlanta, GA 30308 USA.
   [Momplaisir, Florence; Alleyne, Gregg] Drexel Univ, Sch Med, Div Infect Dis & HIV Med, Philadelphia, PA 19104 USA.
   [Rahangdale, Lisa] Univ N Carolina, Dept Obstet & Gynecol, Chapel Hill, NC 27515 USA.
   [Potter, JoNell; Duthely, Lunthita M.] Univ Miami, Miller Sch Med, Dept Obstet & Gynecol, Miami, FL 33136 USA.
   [Woodham, Padmashree C.] Mercer Univ, Sch Med, Dept Obstet & Gynecol, Div Maternal Fetal Med,Med Ctr Navicent Hlth, Macon, GA 31207 USA.
   [Lazenby, Gweneth B.] Med Univ South Carolina, Dept Obstet & Gynecol, Charleston, SC 29425 USA.
   [Lazenby, Gweneth B.] Med Univ South Carolina, Dept Med, Charleston, SC 29425 USA.
   [Short, William R.] Univ Penn, Perelman Sch Med, Div Infect Dis, Philadelphia, PA 19104 USA.
   [Gillespie, Scott E.] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA 30308 USA.
   [Baldreldin, Nevert; Miller, Emily S.] Northwestern Univ, Feinberg Sch Med, Div Maternal Fetal Med, Dept Obstet & Gynecol, Chicago, IL 60611 USA.
   [Allen, Stephanie M.; Levison, Judy] Baylor Coll Med, Dept Obstet & Gynecol, Houston, TX 77030 USA.
   [Chakraborty, Rana] Mayo Clin, Dept Pediat & Adolescent Med, Coll Med, Rochester, MN USA.
RP Badell, ML (corresponding author), Emory Univ, Hosp Midtown, Perinatal Ctr, 8th Floor,550 Peachtree St, Atlanta, GA 30308 USA.
EM rnbadell@emory.edu
OI Duthely, Lunthita/0000-0002-9003-3257; Allen,
   Stephanie/0000-0002-8835-8431
FU NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [KL2 TR002737] Funding Source: Medline;
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [KL2TR002737] Funding Source: NIH RePORTER
CR American College of Obstetricians and Gynecologists Committee on Practice BulletinsObstetrics, 2016, Obstet Gynecol, V128, pe155, DOI 10.1097/AOG.0000000000001711
   Bisio F, 2015, NEW MICROBIOL, V38, P185
   Chen JY, 2012, J INFECT DIS, V206, P1695, DOI 10.1093/infdis/jis553
   Grayhack C, 2018, AIDS, V32, P2017, DOI 10.1097/QAD.0000000000001931
   HOCHBERG Y, 1990, STAT MED, V9, P811, DOI 10.1002/sim.4780090710
   Katz IT, 2015, ANN INTERN MED, V162, P90, DOI 10.7326/M13-2005
   Katz IT, 2010, JAIDS-J ACQ IMM DEF, V54, P27, DOI 10.1097/QAI.0b013e3181caea89
   Kreitchmann R, 2014, BJOG-INT J OBSTET GY, V121, P1501, DOI 10.1111/1471-0528.12680
   Mesfin YM, 2016, REPROD HEALTH, V13, DOI 10.1186/s12978-016-0149-5
   Momper JD, 2018, AIDS, V32, P2507, DOI [10.1097/QAD.0000000000001992, 10.1097/qad.0000000000001992]
   Moodley T, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0821-3
   Mounce ML, 2017, INFECT DIS THER, V6, P531, DOI 10.1007/s40121-017-0170-1
   Patel M, 2018, J INT ASS PROVID AID, V17
   Perry MEO, 2016, HIV MED, V17, P28, DOI 10.1111/hiv.12277
   Rahangdale L, 2016, AM J OBSTET GYNECOL, V214, DOI 10.1016/j.ajog.2015.12.052
   Rimawi BH, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/aac.02213-16, 10.1128/AAC.02213-16]
   Rudin C, 2011, HIV MED, V12, P228, DOI 10.1111/j.1468-1293.2010.00876.x
   Rynn L., 2008, Morbidity and Mortality Weekly Report, V57, P1
   Schalkwijk S, 2016, AIDS, V30, P807, DOI 10.1097/QAD.0000000000000976
   Townsend CL, 2007, AIDS, V21, P1019, DOI 10.1097/QAD.0b013e328133884b
   US Department of Health and Human Services, REC US ANT DRUGS PRE
   van der Merwe K, 2011, J INT AIDS SOC, V14, DOI 10.1186/1758-2652-14-42
   Vannappagari V, 2016, BJOG-INT J OBSTET GY, V123, P910, DOI 10.1111/1471-0528.13542
   Watts DH, 2004, AM J OBSTET GYNECOL, V191, P985, DOI [10.1016/j.ajog.2004.05.06, 10.1016/j.ajog.2004.05.061]
   World Health Organization, 2018, POT SAF ISS AFF WOM
   Zash R, 2018, NEW ENGL J MED, V379, P979, DOI 10.1056/NEJMc1807653
NR 26
TC 3
Z9 3
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 2328-8957
J9 OPEN FORUM INFECT DI
JI Open Forum Infect. Dis.
PD APR
PY 2019
VL 6
IS 4
AR ofz129
DI 10.1093/ofid/ofz129
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA IH9RN
UT WOS:000474844200040
PM 31037241
OA Green Published, gold, Green Submitted
DA 2021-10-30
ER

PT J
AU Goldberg, JM
   Gavcovich, T
   Saigal, G
   Goldman, JW
   Rosen, LS
AF Goldberg, John M.
   Gavcovich, Tara
   Saigal, Gaurav
   Goldman, Jonathan W.
   Rosen, Lee S.
TI Extended Progression-Free Survival in Two Patients With Alveolar Soft
   Part Sarcoma Exposed to Tivantinib
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID C-MET RECEPTOR; SELECTIVE INHIBITOR; VEGF EXPRESSION; ANGIOGENESIS;
   TUMORS
C1 [Goldberg, John M.; Gavcovich, Tara; Saigal, Gaurav] Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
   [Goldman, Jonathan W.; Rosen, Lee S.] Univ Calif Los Angeles, Los Angeles, CA USA.
RP Goldberg, JM (corresponding author), Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
FU NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [KL2 TR000461] Funding Source: Medline;
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [KL2TR000461] Funding Source: NIH RePORTER
CR Azizi AA, 2006, LANCET ONCOL, V7, P521, DOI 10.1016/S1470-2045(06)70729-X
   Balasubramanian L, 2006, CURR OPIN ONCOL, V18, P354, DOI 10.1097/01.cco.0000228741.64541.ca
   Jun HJ, 2010, MED ONCOL, V27, P459, DOI 10.1007/s12032-009-9234-8
   Kummar AS, 2011, J CLIN ONCOL S, V29, p605s
   Ladanyi M, 2001, ONCOGENE, V20, P48, DOI 10.1038/sj.onc.1204074
   Matsumura A, 2013, INT J ONCOL, V42, P535, DOI 10.3892/ijo.2012.1728
   Ogose A, 2003, ONCOLOGY-BASEL, V65, P7, DOI 10.1159/000071199
   Reichardt P, 2003, EUR J CANCER, V39, P1511, DOI 10.1016/S0959-8049(03)00264-8
   Rosen L, 2006, EJC SUPPL, V4, P196, DOI 10.1016/S1359-6349(06)70656-5
   Tsuda M, 2007, CANCER RES, V67, P919, DOI 10.1158/0008-5472.CAN-06-2855
   Wagner AJ, 2012, CANCER-AM CANCER SOC, V118, P5894, DOI 10.1002/cncr.27582
   Zhang YW, 2003, P NATL ACAD SCI USA, V100, P12718, DOI 10.1073/pnas.2135113100
NR 12
TC 17
Z9 17
U1 0
U2 5
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD DEC 1
PY 2014
VL 32
IS 34
BP E114
EP E116
DI 10.1200/JCO.2013.48.7462
PG 3
WC Oncology
SC Oncology
GA AU9ID
UT WOS:000345904300001
PM 24550414
OA Green Published
DA 2021-10-30
ER

PT J
AU Singer, RH
   Stoutenberg, M
   Gellman, MD
   Archer, E
   Davis, SM
   Gotman, N
   Marquez, DX
   Buelna, C
   Deng, Y
   Hosgood, HD
   Zambrana, RE
AF Singer, Richard H.
   Stoutenberg, Mark
   Gellman, Marc D.
   Archer, Edward
   Davis, Sonia M.
   Gotman, Nathan
   Marquez, David X.
   Buelna, Christina
   Deng, Yu
   Hosgood, H. Dean
   Zambrana, Ruth E.
TI Occupational Physical Activity and Body Mass Index: Results from the
   Hispanic Community Health Study/Study of Latinos
SO PLOS ONE
LA English
DT Article
ID CANADIAN ADULTS; UNITED-STATES; SOCIAL-CLASS; US ADULTS; OBESITY;
   OVERWEIGHT; PREVALENCE; TIME; ASSOCIATIONS; TRENDS
AB Purpose
   To examine the associations between overweight/obesity and occupation among Hispanics/Latinos, the largest minority population in the U.S.
   Methods
   This study included 7,409 employed individuals in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL), a prospective study of Hispanic/Latino individuals aged 18-74 in four communities in the U.S. We independently examined the relationships between BMI, Occupational Activity (OA), and Total Hours Worked, quantified via self-reported hours worked per week and occupation-assigned Metabolic Equivalents (METs).
   Results
   More than three quarters of the participants were either overweight (39.3%) or obese (37.8%). Individuals with a primary occupation and those employed in a secondary occupation worked an average of 36.8 and 14.6 hrs/wk, respectively. The overall adjusted odds for being obese compared to normal weight were 3.2% (AOR = 1.03, 95% CI 1.01, 1.05) and 14.4% (AOR = 1.14 95% Cl 1.07, 1.23) greater for each 10 MET.hrs/wk unit of increased OA, and each 10-hrs/wk unit of Total Hours Worked, respectively.
   Conclusion
   This study presents the first findings on the association between OA with overweight/obesity among Hispanic/Latino individuals in the U.S. Increasing OA and Total Hours Worked per week were independently associated with increasing odds of overweight/obesity suggesting that the workplace is only one part of the overall energy expenditure dynamic. Our findings point to the need to emphasize engaging employed individuals in greater levels of PA outside of the work environment to impact overweight/obesity.
C1 [Singer, Richard H.; Stoutenberg, Mark] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA.
   [Singer, Richard H.] Nova SE Univ, Coll Dent Med, Ft Lauderdale, FL 33314 USA.
   [Gellman, Marc D.] Univ Miami, Dept Psychol, Miami, FL USA.
   [Archer, Edward] Univ Alabama Birmingham, Nutr Obes Res Ctr, Off Energet, Birmingham, AL USA.
   [Davis, Sonia M.; Gotman, Nathan; Deng, Yu] Univ N Carolina, Dept Biostat, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA.
   [Marquez, David X.] Univ Illinois, Dept Kinesiol & Nutr, Chicago, IL USA.
   [Buelna, Christina] San Diego State Univ, Grad Sch Publ Hlth, Inst Behav & Community Hlth, San Diego, CA 92182 USA.
   [Hosgood, H. Dean] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA.
   [Zambrana, Ruth E.] Univ Maryland, Dept Womens Studies, Consortium Race Gender & Ethn, College Pk, MD 20742 USA.
RP Singer, RH (corresponding author), Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA.; Singer, RH (corresponding author), Nova SE Univ, Coll Dent Med, Ft Lauderdale, FL 33314 USA.
EM rsinger@med.miami.edu
RI Archer, Edward/J-9567-2017; Zambrana, Ruth/ABD-5509-2020
OI Archer, Edward/0000-0002-9339-6918; Thomas, Sonia/0000-0003-1362-5627
FU NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [KL2TR000461] Funding Source: NIH RePORTER; NCATS NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [KL2 TR000461] Funding Source: Medline
CR Ali SM, 2006, EUR J PUBLIC HEALTH, V16, P324, DOI 10.1093/eurpub/cki187
   Allman-Farinelli MA, 2010, J OCCUP MED TOXICOL, V5, DOI 10.1186/1745-6673-5-14
   Archer E, 2013, MAYO CLIN PROC, V88, P1398, DOI 10.1016/j.mayocp.2013.08.019
   Archer E, 2013, MAYO CLIN PROC, V88, P1368, DOI 10.1016/j.mayocp.2013.09.009
   Archer E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076632
   Archer E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056620
   Barberio A, 2011, CAN J PUBLIC HEALTH, V102, P169, DOI 10.1007/BF03404888
   Bonauto DK, 2014, PREV CHRONIC DIS, V11, DOI 10.5888/pcd11.130219
   Caban-Martinez AJ, 2007, PREV MED, V44, P432, DOI 10.1016/j.ypmed.2006.12.017
   Centers for Disease Control and Prevention, 2010, 1988 2008 NO LEISURE
   Centers for Disease Control and Prevention (CDC), 2009, DIFFERENCES IN PREVA
   Chau JY, 2012, PREV MED, V54, P195, DOI 10.1016/j.ypmed.2011.12.020
   Church TS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019657
   Duffey KJ, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001050
   Finkelstein EA, 2003, HLTH AFF MILLWOOD S
   Flegal KM, 2010, JAMA-J AM MED ASSOC, V303, P235, DOI 10.1001/jama.2009.2014
   Flegal KM, 2005, JAMA-J AM MED ASSOC, V293, P1861, DOI 10.1001/jama.293.15.1861
   Hall KD, 2011, LANCET, V378, P826, DOI 10.1016/S0140-6736(11)60812-X
   Ham S. A., 2004, Morbidity and Mortality Weekly Report, V53, P82
   Hasselbalch AL, 2010, INT J OBESITY, V34, P892, DOI 10.1038/ijo.2010.1
   Healthy People 2020, 2020, HLTH PEOPL 2020
   Hill JO, 2006, ENDOCR REV, V27, P750, DOI 10.1210/er.2006-0032
   Imai K, 2008, OBESITY, V16, P402, DOI 10.1038/oby.2007.70
   Ioannidis JPA, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6698
   Jang TW, 2013, J OCCUP HEALTH, V55, P359, DOI 10.1539/joh.13-0043-OA
   Jitnarin N, 2010, NUTRIENTS, V2, P60, DOI [10.3390/nu2010060, 10.3390/nu20100060]
   Kaleta Dorota, 2007, International Journal of Occupational Medicine and Environmental Health, V20, P9, DOI 10.2478/v10001-007-0009-1
   King GA, 2001, INT J OBESITY, V25, P606, DOI 10.1038/sj.ijo.0801583
   Lavange LM, 2010, ANN EPIDEMIOL, V20, P642, DOI 10.1016/j.annepidem.2010.05.006
   Luckhaupt SE, 2014, AM J PREV MED, V46, P237, DOI 10.1016/j.amepre.2013.11.002
   McLaren L, 2007, EPIDEMIOL REV, V29, P29, DOI 10.1093/epirev/mxm001
   McLaren L, 2009, OBESITY, V17, P290, DOI 10.1038/oby.2008.539
   National Cancer Institute U.S. NIH, 2013, USUAL DIETARY INTAKE
   National Cancer Institute U.S. NIH, 2014, METABOLIC EQUIVALENT
   National Heart Lung and Blood Institute, 2012, AIM FOR A HEALTHY WE
   Ogden CL, 2014, JAMA-J AM MED ASSOC, V311, P806, DOI 10.1001/jama.2014.732
   Panasiuk L, 2008, ANN AGR ENV MED, V15, P149
   Patterson E., 2010, GUIDELINES FOR DATA
   Physical Activity Guidelines Advisory Committee, 2008, PHYSICAL ACTIVITY GU
   Proper KI, 2010, INT ARCH OCC ENV HEA, V83, P61, DOI 10.1007/s00420-009-0438-1
   Martin AR, 2008, APPETITE, V51, P266, DOI 10.1016/j.appet.2008.02.021
   Schoeller DA, 2013, AM J CLIN NUTR, V97, P1413, DOI 10.3945/ajcn.113.062125
   Shao Q, 2011, NUTR RES PRACT, V5, P253, DOI 10.4162/nrp.2011.5.3.253
   Singh GK, 2011, J COMMUN HEALTH, V36, P94, DOI 10.1007/s10900-010-9287-9
   Sorlie PD, 2010, ANN EPIDEMIOL, V20, P629, DOI 10.1016/j.annepidem.2010.03.015
   Steeves JA, 2012, INT J OBESITY, V36, P100, DOI 10.1038/ijo.2011.50
   Thomas DM, 2009, MATH BIOSCI ENG, V6, P873, DOI 10.3934/mbe.2009.6.873
   Tooze JA, 2010, STAT MED, V29, P2857, DOI 10.1002/sim.4063
   Trivedi T, 2015, RURAL REMOTE HEALTH, V15
   Tudor-Locke C, 2011, J PHYS ACT HEALTH, V8, P581, DOI 10.1123/jpah.8.4.581
   U.S. Bureau of Labor Statistics, 2014, LABOR FORCE STATISTI
   Whitlock G, 2009, LANCET, V373, P1083, DOI 10.1016/S0140-6736(09)60318-4
NR 52
TC 9
Z9 10
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 31
PY 2016
VL 11
IS 3
AR e0152339
DI 10.1371/journal.pone.0152339
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DH9NC
UT WOS:000373121800060
PM 27031996
OA Green Published, gold, Green Submitted
DA 2021-10-30
ER

PT J
AU Schlumbrecht, M
   Bussies, P
   Huang, M
   Kobetz, E
   George, S
AF Schlumbrecht, Matthew
   Bussies, Parker
   Huang, Marilyn
   Kobetz, Erin
   George, Sophia
TI Endometrial cancer among a cohort of urban Haitian immigrants
SO WORLD JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
DE Endometrial cancer; Nativity; Haitian; Black; Survival
ID HEALTH-INSURANCE; RISK; DISPARITIES; SURVIVAL; RACE
AB BACKGROUND
   Black women are known to have a higher risk of aggressive endometrial cancers. Little data exist about the role of nativity as a determinant of survival outcomes in women with this disease.
   AIM
   Our objective was to evaluate a population of Haitian immigrants with endometrial cancer in an urban setting using the Florida Cancer Data System (FCDS).
   METHODS
   A search of FCDS identified 107 women born in Haiti and who received treatment for invasive endometrial cancer in Miami-Dade County between 1989 and 2013. Clinicopathologic data were extracted to describe the cohort and assess associations with overall survival. Statistical analyses were performed using Cox proportional hazards models, the log-rank test, and the Kaplan-Meier method, with significance set at P = 0.05.
   RESULTS
   Median age at diagnosis was 65 years. 63.9% of the patients had a type II, highgrade, histology, and 52.6% presented with extrauterine metastatic disease. Nearly three quarters had health insurance. Within the entire cohort, only presence of extrauterine disease was associated with worse overall survival [Hazard ratio (HR) = 2.70, 95% confidence interval (CI): 1.31-5.57, P = 0.007].
   However, after stratification by histologic grade, both age (HR = 0.88, 95%CI: 0.81-0.96, P = 0.002) and extrauterine disease (HR = 2.49, 95%CI: 1.01-6.21, P = 0.049) were independently associated with worse survival, but only in women with type II malignancies.
   CONCLUSION
   Urban Haitian women with endometrial cancer have a high burden of aggressive histologies. Additional investigation to explain the etiology of these findings is needed.
C1 [Schlumbrecht, Matthew; Huang, Marilyn; George, Sophia] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Div Gynecol Oncol, 1121 Northwest 14th St,Suite 345C, Miami, FL 33139 USA.
   [Schlumbrecht, Matthew; Bussies, Parker; Huang, Marilyn; George, Sophia] Univ Miami, Miller Sch Med, Dept Obstet Gynecol & Reprod Sci, Miami, FL 33139 USA.
   [Kobetz, Erin] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33139 USA.
RP Schlumbrecht, M (corresponding author), Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Div Gynecol Oncol, 1121 Northwest 14th St,Suite 345C, Miami, FL 33139 USA.
EM mschlumbrecht@miami.edu
RI GEORGE, SOPHIA/AAZ-7443-2020
OI GEORGE, SOPHIA/0000-0003-1013-1883
FU NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1TR002736] Funding Source: NIH RePORTER; NCATS NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1 TR002736] Funding Source: Medline
CR Anderson M., 2018, KEY FACTS BLACK IMMI
   BOKHMAN JV, 1983, GYNECOL ONCOL, V15, P10, DOI 10.1016/0090-8258(83)90111-7
   Cavazos-Rehg PA, 2007, J NATL MED ASSOC, V99, P1126
   Cote ML, 2015, CANCER EPIDEM BIOMAR, V24, P1407, DOI 10.1158/1055-9965.EPI-15-0316
   Creque A, 2010, FUTURE ONCOL, V6, P319, DOI 10.2217/FON.09.169
   Dubil EA, 2018, GYNECOL ONCOL, V149, P106, DOI 10.1016/j.ygyno.2017.12.009
   Echeverria SE, 2006, MED CARE, V44, P788, DOI 10.1097/01.mlr.0000215863.24214.41
   Flores G, 2005, AMBUL PEDIATR, V5, P332, DOI 10.1367/A04-067R2.1
   Guttery David S, 2018, Oncotarget, V9, P17093, DOI 10.18632/oncotarget.24907
   Hearst AA, 2010, J IMMIGR MINOR HEALT, V12, P580, DOI 10.1007/s10903-009-9308-x
   Jamison PM, 2013, CANCER EPIDEM BIOMAR, V22, P233, DOI 10.1158/1055-9965.EPI-12-0996
   Olson SH, 2012, CANCER EPIDEM BIOMAR, V21, P753, DOI 10.1158/1055-9965.EPI-11-0735
   PERRY M, 2000, MEDICAID CHILDREN OV
   Schlumbrecht M, 2019, INT J GYNECOL CANC, DOI 10.1136/ijgc-2019-000347
   Schlumbrecht M, 2017, GYNECOL ONCOL, V147, P329, DOI 10.1016/j.ygyno.2017.09.002
   Schulz J., 2017, HAITIAN IMMIGRANTS U
   Seay JS, 2017, ETHNIC HEALTH, V22, P257, DOI 10.1080/13557858.2016.1246423
   Seay JS, 2015, PROG COMM HLTH PARTN, V9, P11, DOI 10.1353/cpr.2015.0029
   Setiawan VW, 2007, AM J EPIDEMIOL, V165, P262, DOI 10.1093/aje/kwk010
   Siddiqi A, 2009, SOC SCI MED, V69, P1452, DOI 10.1016/j.socscimed.2009.08.030
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Sohmer Rebecca, 2005, HAITIAN COMMUNITY MI, P1
   Xie R, 2009, LAB INVEST, V89, P937, DOI 10.1038/labinvest.2009.52
   Zong J., 2019, CARIBBEAN IMMIGRANTS
NR 24
TC 2
Z9 2
U1 0
U2 1
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES
SN 2218-4333
J9 WORLD J CLIN ONCOL
JI World J. Clin. Oncol.
PD OCT 24
PY 2019
VL 10
IS 10
BP 340
EP 349
DI 10.5306/wjco.v10.i10.340
PG 10
WC Oncology
SC Oncology
GA JS5JG
UT WOS:000500341000002
PM 31799149
OA Green Published, gold
DA 2021-10-30
ER

PT J
AU Chen, SH
   McCarthy, D
   Saini, V
   Brunet, MC
   Peterson, EC
   Yavagal, D
   Starke, RM
AF Chen, Stephanie H.
   McCarthy, David
   Saini, Vasu
   Brunet, Marie-Christine
   Peterson, Eric C.
   Yavagal, Dileep
   Starke, Robert M.
TI Effect of Body Mass Index on Outcomes of Mechanical Thrombectomy in
   Acute Ischemic Stroke
SO WORLD NEUROSURGERY
LA English
DT Article
DE Body mass index; Cerebral ischemia; Large vessel occlusion; Obesity;
   Stroke; Thrombectomy
ID MYOCARDIAL-INFARCTION; OBESITY PARADOX; TOTAL MORTALITY; HEART-DISEASE;
   RISK; ASSOCIATION; HEMORRHAGE; UPDATE; IMPACT
AB BACKGROUND: Obesity is an established risk factor for the development of acute ischemic stroke. However, its effect on clinical outcomes after acute ischemic stroke has remained controversial. In the present study, we evaluated the association of body mass index (BMI) on outcomes after mechanical thrombectomy (MT) for large vessel oc-clusion acute ischemic stroke (LVOS).
   METHODS: We reviewed our prospective endovascular database for patients who had undergone MT for LVOS from 2015 to 2018. The BMI was analyzed as a continuous and categorical variable, with the latter defined as BMI, 18.5 kg/m(2) (underweight); BMI, 18.5-24.9 kg/m(2) (normal); BMI, 25-29.9 kg/m(2) (overweight), and BMI, 30 kg/m(2) (obese). Multivariate analysis was used to determine the outcome predictors.
   RESULTS: A total of 335 patients had undergone MT, with 7 (2.1%) classified as underweight, 107 (31.9%) normal, 141 (42.1%) overweight, and 80 (23.9%) obese. The procedural times, techniques, and reperfusion success (treatment in cerebral infarction score 2b) were not significantly different among the BMI categories. A significant inverse linear correlation was found between the BMI and symptomatic hemorrhagic. For patients with successful reperfusion (treatment in cerebral infarction score >2b), we also found a significant bell-shaped relationship between the BMI and functional independence (modified Rankin scale score <3), with high and low BMIs associated with worse outcomes. For patients without post-MT symptomatic hemorrhage, a significant linear correlation was found between BMI and inpatient mortality.
   CONCLUSION: For LVOS patients treated with MT, a high BMI will not affect procedural success. However, it was independently associated with lower rates of functional independence in recanalized patients. Thus, the obesity paradox does not appear to pertain to MT, although larger prospective studies are necessary.
C1 [Chen, Stephanie H.; McCarthy, David; Brunet, Marie-Christine; Peterson, Eric C.; Starke, Robert M.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA.
   [Saini, Vasu; Yavagal, Dileep] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA.
   [Yavagal, Dileep; Starke, Robert M.] Univ Miami, Miller Sch Med, Dept Radiol, Miami, FL 33136 USA.
RP Chen, SH (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA.
EM stephanie.chen@jhsmiami.org
RI Saini, Vasu/AAA-9360-2019
OI Saini, Vasu/0000-0002-6796-5881; Chen, Stephanie/0000-0002-5396-5813
FU Neurosurgery Research and Education Foundation, Joe Niekro Foundation;
   Brain Aneurysm Foundation, Bee Foundation; National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [UL1TR002736, KL2TR002737]; Miami
   Clinical and Translational Science Institute; National Center for
   Advancing Translational SciencesUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS); National Institute
   on Minority Health and Health DisparitiesUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Minority Health & Health Disparities (NIMHD);
   AbbottAbbott Laboratories; InNeuroCo
FX The Robert M. Starke research is supported by the Neurosurgery Research
   and Education Foundation, Joe Niekro Foundation, Brain Aneurysm
   Foundation, Bee Foundation, and National Institutes of Health (grants
   UL1TR002736 and KL2TR002737) through the Miami Clinical and
   Translational Science Institute, from the National Center for Advancing
   Translational Sciences and the National Institute on Minority Health and
   Health Disparities. Its contents are solely the responsibility of the
   authors and do not necessarily represent the official views of the
   National Institutes of Health. Robert M. Starke has consulting and
   teaching agreements with Penumbra, Abbott, Medtronic, InNeuroCo, and
   Cerenovus.
CR Andersen KK, 2013, J STROKE CEREBROVASC, V22, pE576, DOI 10.1016/j.jstrokecerebrovasdis.2013.06.031
   Benjamin EJ, 2019, CIRCULATION, V139, pE56, DOI 10.1161/CIR.0000000000000659
   Bouslama M, 2020, INTERV NEUROL, V8, P144, DOI 10.1159/000496703
   Diedler J, 2011, STROKE, V42, P1615, DOI 10.1161/STROKEAHA.110.603514
   Elagizi A, 2018, PROG CARDIOVASC DIS, V61, P142, DOI 10.1016/j.pcad.2018.07.003
   Gensicke H, 2016, EUR J NEUROL, V23, P1705, DOI 10.1111/ene.13071
   Hassan AE, 2013, J STROKE CEREBROVASC, V22, P545, DOI 10.1016/j.jstrokecerebrovasdis.2013.01.022
   Hong NS, 2012, INT J OBESITY, V36, P1170, DOI 10.1038/ijo.2011.187
   Katsnelson M, 2011, STROKE, V42, P3331, DOI 10.1161/STROKEAHA.111.632471
   Kim BJ, 2012, NEUROLOGY, V79, P856, DOI 10.1212/WNL.0b013e318266fad1
   Kim CK, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-123
   Kurth T, 2002, ARCH INTERN MED, V162, P2557, DOI 10.1001/archinte.162.22.2557
   Lavie CJ, 2018, NAT REV CARDIOL, V15, P45, DOI 10.1038/nrcardio.2017.108
   Lavie CJ, 2017, J AM COLL CARDIOL, V70, P2750, DOI 10.1016/j.jacc.2017.10.017
   Lavie CJ, 2014, J AM COLL CARDIOL, V63, P1345, DOI 10.1016/j.jacc.2014.01.022
   Maier B, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.006484
   May Susanne, 2005, Dose-Response, V3, P474, DOI 10.2203/dose-response.003.04.004
   Oesch L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171334
   Ogden Cynthia L, 2015, NCHS Data Brief, P1
   Ovbiagele B, 2011, STROKE, V42, P3397, DOI 10.1161/STROKEAHA.111.624957
   Ozeke O, 2011, MED HYPOTHESES, V76, P61, DOI 10.1016/j.mehy.2010.08.030
   Poirier P, 2006, CIRCULATION, V113, P898, DOI 10.1161/01.ATV.0000216787.85457.f3
   Rao NM, 2014, STROKE, V45, P2728, DOI 10.1161/STROKEAHA.114.005135
   Romero-Corral A, 2006, LANCET, V368, P666, DOI 10.1016/S0140-6736(06)69251-9
   Ryu WS, 2011, CEREBROVASC DIS, V32, P170, DOI 10.1159/000328250
   Sarikaya H, 2011, STROKE, V42, P2330, DOI 10.1161/STROKEAHA.110.599613
   Sharma A, 2014, MAYO CLIN PROC, V89, P1080, DOI 10.1016/j.mayocp.2014.04.020
   Spall JC, 2005, J COMPUT GRAPH STAT, V14, P889, DOI 10.1198/106186005X78800
   Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9
NR 29
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2020
VL 143
BP E503
EP E515
DI 10.1016/j.wneu.2020.07.220
PG 13
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA OS1VO
UT WOS:000589953600012
PM 32777391
DA 2021-10-30
ER

PT J
AU Masterson, JM
   Kava, B
   Ramasamy, R
AF Masterson, John M.
   Kava, Bruce
   Ramasamy, Ranjith
TI Commercial Insurance Coverage for Inflatable Penile Prosthesis at a
   Tertiary Care Center
SO UROLOGY PRACTICE
LA English
DT Article
DE insurance; penile prosthesis; erectile dysfunction
AB Introduction: Inflatable penile prosthesis has become an important treatment modality for men with erectile dysfunction that is refractory to medication. Despite high levels of patient satisfaction following inflatable penile prosthesis placement and inflatable penile prosthesis coverage by Medicare, coverage by commercial insurance providers is unknown. The purpose of this study was to determine the coverage of inflatable penile prosthesis by commercial insurance providers.
   Methods: Following institutional review board approval all men with erectile dysfunction interested in obtaining inflatable penile prosthesis at our tertiary care center between January 2016 and December 2017 were evaluated. We reviewed billing records for CPT code 54405 during the study period to evaluate the insurance provider for all men who received an inflatable penile prosthesis. We also reviewed a manually maintained record of excluded or denied inflatable penile prosthesis claims for men who desired inflatable penile prosthesis but could not obtain it. Through medical record review we recorded the etiology of erectile dysfunction and the specific type of insurance policy for each man.
   Results: Medicare is the most common insurer for inflatable penile prosthesis, insuring 87 of 220 (39.5%) men seeking inflatable penile prosthesis between 2016 and 2017. Among the remaining 127 men seeking inflatable penile prosthesis with commercial insurance coverage 61 (48.0%) were unable to obtain the device due to exclusions in their coverage or denials. Among commercially insured men seeking inflatable penile prosthesis 77 (62.6%) and 37 (30.0%) had health maintenance organization and preferred provider organization plans, respectively. The most prevalent indications for inflatable penile prosthesis among the entire study population were radical prostatectomy (30.9%), organic erectile dysfunction (30.5%) and diabetes mellitus (20.9%).
   Conclusions: The largest insurer for inflatable penile prosthesis in the Miami region is Medicare. While some patients seeking inflatable penile prostheses can receive insurance coverage, a large percentage (48.0%) are not able to receive coverage despite having a medical necessity for the treatment of erectile dysfunction.
C1 [Masterson, John M.; Kava, Bruce; Ramasamy, Ranjith] Univ Miami, Miller Sch Med, Dept Urol, Miami, FL 33136 USA.
RP Masterson, JM (corresponding author), 1150 NW 14th St, Miami, FL 33136 USA.
EM Jmm557@med.miami.edu
RI Ramasamy, Ranjith/ABD-7373-2020
OI Ramasamy, Ranjith/0000-0003-1387-7904
FU NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1 TR002736] Funding Source: Medline;
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1TR002736] Funding Source: NIH RePORTER
CR Le B, 2017, UROLOGY, V102, P126, DOI 10.1016/j.urology.2016.12.031
   Le B, 2015, KOREAN J UROL, V56, P179, DOI 10.4111/kju.2015.56.3.179
   Lee DJ, 2015, J SEX MED, V12, P1638, DOI 10.1111/jsm.12921
   MORALES PA, 1973, J UROLOGY, V109, P641, DOI 10.1016/S0022-5347(17)60503-2
   Rodriguez KM, 2017, TRANSL ANDROL UROL, V6, pS860, DOI 10.21037/tau.2017.05.28
   Segal RL, 2014, INT J IMPOT RES, V26, P167, DOI 10.1038/ijir.2014.11
   Tefilli MV, 1998, UROLOGY, V52, P1106, DOI 10.1016/S0090-4295(98)00362-8
NR 7
TC 6
Z9 6
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 2352-0779
EI 2352-0787
J9 UROL PRACT
JI Urol. Pract.
PD MAY
PY 2019
VL 6
IS 3
BP 155
EP 158
DI 10.1016/j.urpr.2018.07.002
PG 4
WC Urology & Nephrology
SC Urology & Nephrology
GA IJ2VL
UT WOS:000475762900002
PM 31372371
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Jones, PD
   Scheinberg, AR
   Muenyi, V
   Gonzalez-Diaz, J
   Martin, PM
   Kobetz, E
AF Jones, Patricia D.
   Scheinberg, Andrew R.
   Muenyi, Valery
   Gonzalez-Diaz, Joselin
   Martin, Paul M.
   Kobetz, Erin
TI Socioeconomic And Survival Differences Among Minorities With
   Hepatocellular Carcinoma In Florida
SO JOURNAL OF HEPATOCELLULAR CARCINOMA
LA English
DT Article
DE racial disparities; hepatocellular carcinoma; geographic disparities
ID UNITED-STATES; GEOGRAPHIC-VARIATION; CANCER INCIDENCE; DISPARITIES;
   DISEASE; ACCESS; STAGE; AREAS; CARE; RACE
AB Background: Disparities in hepatocellular carcinoma (HCC) have been partly attributed to low socioeconomic status among minorities. We investigated associations between race, socioeconomic characteristics, geographic characteristics and survival in HCC patients in Florida.
   Methods: Using the Florida Cancer Data System (FCDS), we analyzed HCC cases diagnosed between 1/1/2004 and 12/31/2013. To ascertain population-level socioeconomic characteristics, we linked FCDS to the 2010-2014 US Census American Community Survey and the 2013 Florida Behavioral Risk Factor Surveillance System. We also estimated patient distance to liver transplant and academic cancer centers. Using Cox proportional hazards, we modeled the association between race and survival.
   Results: Of 10,852 patients, 13.1% were Black, 67.1% White, 15.7% Hispanic, and 3.2% Asian. At diagnosis, Blacks were younger with more extensive disease, p <0.001. Transplants were performed in 9.3% of Hispanics, 7.5% of Whites, 5.8% of Asians and 4.2% of Blacks, p <0.001. Median survival was longest in Hispanics and shortest in Blacks, p<0.001 When adjusted for gender, age, payer, SEER stage, surgery type, and receipt of treatment, Blacks had a 17% increased risk of death [hazard ratio (HR) 1.17, 95% confidence interval (CI) 1.07-1.29] and Whites a 9% increased risk of death [HR 1.09, 95% CI 1.02-1.17] compared to Hispanics. As a group, Hispanics lived closest to any transplant or academic cancer center, p <0.001. Neighborhood poverty level was highest where Hispanic patients lived, p <0.001.
   Conclusion: Though socioeconomic differences may contribute to disparities, Hispanics survived longer than Blacks and Whites in Florida despite living in the most socioeconomically depressed neighborhoods. Increased access to transplant likely contributed to improved survival. Additional research is needed to identify which individual socioeconomic and geographic determinants contribute most to disparities.
C1 [Jones, Patricia D.; Gonzalez-Diaz, Joselin; Martin, Paul M.] Univ Miami, Dept Med, Div Gastroenterol & Hepatol, Miller Sch Med, 1120 NW 14th St, Miami, FL 33136 USA.
   [Jones, Patricia D.; Martin, Paul M.; Kobetz, Erin] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA.
   [Scheinberg, Andrew R.; Muenyi, Valery] Univ Miami, Dept Med, Miller Sch Med, Miami, FL 33136 USA.
   [Kobetz, Erin] Univ Miami, Miller Sch Med, Dept Med, Div Computat Med & Populat Hlth, Miami, FL 33136 USA.
RP Jones, PD (corresponding author), Univ Miami, Dept Med, Div Gastroenterol & Hepatol, Miller Sch Med, 1120 NW 14th St, Miami, FL 33136 USA.
EM pdjones@med.miami.edu
OI Muenyi, Valery/0000-0001-9990-7259
FU NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1TR002736] Funding Source: NIH RePORTER; NCATS NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1 TR002736] Funding Source: Medline
CR Altekruse Sean F, 2011, J Registry Manag, V38, P201
   Apparicio P, 2017, INT J HEALTH GEOGR, V16, DOI 10.1186/s12942-017-0105-9
   Artinyan A, 2010, CANCER-AM CANCER SOC, V116, P1367, DOI 10.1002/cncr.24817
   Boscoe FP, 2012, PROF GEOGR, V64, P188, DOI 10.1080/00330124.2011.583586
   Davila JA, 2003, J CLIN EPIDEMIOL, V56, P487, DOI 10.1016/S0895-4356(02)00605-4
   Di Poto C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192748
   Dillon ST, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-239
   El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061
   Estevez J, 2018, AM J GASTROENTEROL
   Ha J, 2016, CANCER-AM CANCER SOC, V122, P2512, DOI 10.1002/cncr.30103
   Jones PD, 2018, DIGEST DIS SCI, V63, P515, DOI 10.1007/s10620-017-4869-3
   Kim D, 2019, HEPATOLOGY, V69, P1064, DOI 10.1002/hep.30161
   Krieger N, 2002, AM J PUBLIC HEALTH, V92, P1100, DOI 10.2105/AJPH.92.7.1100
   Krieger N, 2002, AM J EPIDEMIOL, V156, P471, DOI 10.1093/aje/kwf068
   Li Chaoyang, 2011, Morbidity and Mortality Weekly Report, V60, P1
   Major JM, 2014, ANN EPIDEMIOL, V24, P104, DOI 10.1016/j.annepidem.2013.11.006
   Mathur AK, 2010, ARCH SURG-CHICAGO, V145, P1158, DOI 10.1001/archsurg.2010.272
   Njei B, 2015, HEPATOLOGY, V61, P191, DOI 10.1002/hep.27388
   Pierannunzi C, 2016, PREV CHRONIC DIS, V13, DOI 10.5888/pcd13.150480
   Pinheiro PS, 2011, CANCER CAUSE CONTROL, V22, P553, DOI 10.1007/s10552-011-9727-6
   Pruitt SL, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13121238
   Rich NE, 2018, CLIN GASTROENTEROL H
   Roberts LR, 2018, HEPATOLOGY, V67, P401, DOI 10.1002/hep.29487
   Sanoff HK, 2015, J NATL COMPR CANC NE, V13, P1102, DOI 10.6004/jnccn.2015.0135
   Setiawan VW, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju326
   Sherman CB, 2016, J CLIN GASTROENTEROL, V2, P26, DOI [10.23937/2469-584X/1510026, DOI 10.23937/2469-584X/1510026]
   Singal AG, 2015, AM J MED, V128, P90, DOI 10.1016/j.amjmed.2014.07.027
   Sloane D, 2006, J NATL MED ASSOC, V98, P1934
   Sonnenday CJ, 2007, J GASTROINTEST SURG, V11, P1636, DOI 10.1007/s11605-007-0315-8
   Spielman SE, 2014, APPL GEOGR, V46, P147, DOI 10.1016/j.apgeog.2013.11.002
   White DL, 2017, GASTROENTEROLOGY, V152, P812, DOI 10.1053/j.gastro.2016.11.020
   Wong MS, 2017, MED CARE, V55, P817, DOI 10.1097/MLR.0000000000000774
   Yu JC, 2010, CANCER-AM CANCER SOC, V116, P1801, DOI 10.1002/cncr.24936
NR 33
TC 7
Z9 7
U1 0
U2 0
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
EI 2253-5969
J9 J HEPATOCELL CARCINO
JI J. HEPATOCELL. CARCINOMA
PY 2019
VL 6
BP 167
EP 181
DI 10.2147/JHC.S212401
PG 15
WC Oncology
SC Oncology
GA JN2US
UT WOS:000496756600001
PM 31815112
OA Green Published, gold
DA 2021-10-30
ER

PT J
AU Chang, A
   Patberg, E
   Cueto, V
   Li, H
   Singh, B
   Kenya, S
   Alonzo, Y
   Carrasquillo, O
AF Chang, Aileen
   Patberg, Elizabeth
   Cueto, Victor
   Li, Hua
   Singh, Bhavana
   Kenya, Sonjia
   Alonzo, Yisel
   Carrasquillo, Olveen
TI Community Health Workers, Access to Care, and Service Utilization Among
   Florida Latinos: A Randomized Controlled Trial
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID INTERVENTIONS
AB Objectives. To determine whether a 1-year community health worker intervention improves access to care and service utilization among Latinos with diabetes.
   Methods. We conducted a single-blind randomized trial of 300 adults with poorly controlled diabetes treated in 2 public hospital clinics in Miami, Florida. We began enrollment in 2010 and completed follow-up in 2015. We examined access and utilization using self-reported measures and data from electronic medical records.
   Results. Participants randomized to the community health worker intervention self-reported fewer problems accessing needed care and prescriptions than did those in the usual care group (30% vs 43% and 28% vs 41%, respectively; P < .05 for both). Adjusting for age, gender, education, depression, and comorbidities showed similar results (odds ratio [OR] = 0.52; 95% confidence interval [CI] = 0.29, 0.93 and OR= 0.45; CI = 0.24, 0.82, respectively). We found no significant utilization differences in primary care visits, emergency department utilization, or hospitalization between the 2 groups.
   Conclusions. Among Latinos with poorly controlled diabetes, a 1-year community health worker intervention was associated with improvements in self-reported access to care but not service utilization.
C1 [Chang, Aileen; Patberg, Elizabeth; Cueto, Victor; Li, Hua; Singh, Bhavana; Kenya, Sonjia; Alonzo, Yisel; Carrasquillo, Olveen] Univ Miami, Miami, FL USA.
RP Chang, A (corresponding author), 2150 Pennsylvania Ave,NW 5-416, Washington, DC USA.
EM chang@e-mail.gwu.edu
RI Patberg, Elizabeth/K-1240-2019
OI Chang, Aileen/0000-0001-7410-9867
FU NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000460] Funding Source: NIH RePORTER; NCATS NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1 TR000460] Funding Source: Medline
CR Carrasquillo O, 2017, JAMA INTERN MED, V177, P948, DOI 10.1001/jamainternmed.2017.0926
   Carrasquillo O, 2014, INT J GEN MED, V7, P115, DOI 10.2147/IJGM.S56250
   Centers for Disease Control and Prevention, 2017, NAT DIAB STAT REP 20
   Cohen J., 1997, DESIGN METHODS MED E
   Kangovi S, 2017, AM J PUBLIC HEALTH, V107, P1660, DOI [10.2105/ajph.2017.303985, 10.2105/AJPH.2017.303985]
   Kim K, 2016, AM J PUBLIC HEALTH, V106, pE3, DOI 10.2105/AJPH.2015.302987
   Lebron CN, 2015, J HEALTH CARE POOR U, V26, P453, DOI 10.1353/hpu.2015.0033
   Norris SL, 2006, DIABETIC MED, V23, P544, DOI 10.1111/j.1464-5491.2006.01845.x
   Palmas W, 2015, J GEN INTERN MED, V30, P1004, DOI 10.1007/s11606-015-3247-0
   Perez LM, 2010, AM J PUBLIC HEALTH, V100, P1826, DOI 10.2105/AJPH.2006.100842e
   Perez LM, 2008, AM J PUBLIC HEALTH, V98, P11, DOI 10.2105/AJPH.2006.100842
   Shah MK, 2014, J HEALTH CARE POOR U, V25, P17, DOI 10.1353/hpu.2014.0019
   Verhagen L, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/s12913-014-0497-1
NR 13
TC 4
Z9 4
U1 0
U2 3
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD SEP
PY 2018
VL 108
IS 9
BP 1249
EP 1251
DI 10.2105/AJPH.2018.304542
PG 3
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA GP7DZ
UT WOS:000441054400053
PM 30024805
OA Green Published
DA 2021-10-30
ER

PT J
AU Bhattacharya, P
   Pandey, AK
   Paul, S
   Patnaik, R
   Yavagal, DR
AF Bhattacharya, Pallab
   Pandey, Anand Kumar
   Paul, Sudip
   Patnaik, Ranjana
   Yavagal, Dileep R.
TI Aquaporin-4 Inhibition Mediates Piroxicam-Induced Neuroprotection
   against Focal Cerebral Ischemia/Reperfusion Injury in Rodents
SO PLOS ONE
LA English
DT Article
ID DELAYED NEURONAL DEATH; ARTERY OCCLUSION; BRAIN EDEMA;
   LIPID-PEROXIDATION; GERBIL HIPPOCAMPUS; ISCHEMIC-STROKE; KNOCKOUT MICE;
   RAT-BRAIN; DAMAGE; CYCLOOXYGENASE
AB Background and Purpose: Aquaporin-4(AQP4) is an abundant water channel protein in brain that regulates water transport to maintain homeostasis. Cerebral edema resulting from AQP4 over expression is considered to be one of the major determinants for progressive neuronal insult during cerebral ischemia. Although, both upregulation and downregulation of AQP4 expression is associated with brain pathology, over expression of AQP4 is one of the chief contributors of water imbalance in brain during ischemic pathology. We have found that Piroxicam binds to AQP4 with optimal binding energy value. Thus, we hypothesized that Piroxicam is neuroprotective in the rodent cerebral ischemic model by mitigating cerebral edema via AQP4 regulation.
   Methods: Rats were treated with Piroxicam OR placebo at 30 min prior, 2 h post and 4 h post 60 minutes of MCAO followed by 24 hour reperfusion. Rats were evaluated for neurological deficits and motor function just before sacrifice. Brains were harvested for infarct size estimation, water content measurement, biochemical analysis, RT-PCR and western blot experiments.
   Results: Piroxicam pretreatment thirty minutes prior to ischemia and four hour post reperfusion afforded neuroprotection as evident through significant reduction in cerebral infarct volume, improvement in motor behavior, neurological deficit and reduction in brain edema. Furthermore, ischemia induced surge in levels of nitrite and malondialdehyde were also found to be significantly reduced in ischemic brain regions in treated animals. This neuroprotection was found to be associated with inhibition of acid mediated rise in intracellular calcium levels and also downregulated AQP4 expression.
   Conclusions: Findings of the present study provide significant evidence that Piroxicam acts as a potent AQP4 regulator and renders neuroprotection in focal cerebral ischemia. Piroxicam could be clinically exploited for the treatment of brain stroke along with other anti-stroke therapeutics in future.
C1 [Bhattacharya, Pallab; Pandey, Anand Kumar; Paul, Sudip; Patnaik, Ranjana] Banaras Hindu Univ, Indian Inst Technol, Sch Biomed Engn, Varanasi 221005, Uttar Pradesh, India.
   [Paul, Sudip] NE Hill Univ, Dept Biomed Engn, Shillong 793014, Meghalaya, India.
   [Bhattacharya, Pallab; Yavagal, Dileep R.] Univ Miami, Leonard M Miller Sch Med, Dept Neurol, Miami, FL USA.
RP Bhattacharya, P (corresponding author), Banaras Hindu Univ, Indian Inst Technol, Sch Biomed Engn, Varanasi 221005, Uttar Pradesh, India.
EM pallab.bhu@gmail.com; drranjanapatnaik@gmail.com
RI Patnaik, Ranjana/AAZ-4440-2020; Paul, Sudip/AAE-8890-2020; Patnaik,
   Ranjana/D-1469-2017
OI Patnaik, Ranjana/0000-0002-8131-177X; Patnaik,
   Ranjana/0000-0002-8131-177X
FU NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000460] Funding Source: NIH RePORTER; NCATS NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1 TR000460] Funding Source: Medline
CR Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P2106, DOI 10.1073/pnas.0437946100
   Antezana DF, 2003, J NEUROSURG, V98, P860, DOI 10.3171/jns.2003.98.4.0860
   Bendel O, 2005, MOL BRAIN RES, V137, P119, DOI 10.1016/j.molbrainres.2005.02.023
   Bhattacharya P, 2013, MED CHEM RES, V22, P5112, DOI 10.1007/s00044-013-0514-7
   Bhattacharya P, 2012, MED HYPOTHESES, V79, P393, DOI 10.1016/j.mehy.2012.06.003
   Bhattacharya P, 2012, MED HYPOTHESES, V79, P352, DOI 10.1016/j.mehy.2012.05.033
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Burgos-Ramos E, 2008, NEUROSCIENCE, V154, P1458, DOI 10.1016/j.neuroscience.2008.04.036
   Callaway JK, 1999, STROKE, V30, P2704, DOI 10.1161/01.STR.30.12.2704
   Casper D, 2000, NEUROSCI LETT, V289, P201, DOI 10.1016/S0304-3940(00)01294-5
   Cendelin J, 2008, BEHAV BRAIN RES, V189, P65, DOI 10.1016/j.bbr.2007.12.013
   Chan PH, 1996, STROKE, V27, P1124, DOI 10.1161/01.STR.27.6.1124
   CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527
   Chu XP, 2002, J NEUROPHYSIOL, V87, P2555, DOI 10.1152/jn.00741.2001
   DESAI ID, 1984, METHOD ENZYMOL, V105, P138, DOI 10.1016/S0076-6879(84)05019-9
   Dorofeeva NA, 2008, J NEUROCHEM, V106, P429, DOI 10.1111/j.1471-4159.2008.05412.x
   DUNHAM NW, 1957, J AM PHARM ASSOC, V46, P208, DOI 10.1002/jps.3030460322
   Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100
   Fan Y, 2005, J NEUROSCI RES, V82, P458, DOI 10.1002/jnr.20664
   Fisher M, 2007, STROKE, V38, P245, DOI 10.1161/01.STR.0000255951.37434.aa
   Friedman B, 2009, STROKE, V40, P2182, DOI 10.1161/STROKEAHA.108.523720
   Fryclenlund DS, 2006, P NATL ACAD SCI USA, V103, P13532, DOI 10.1073/pnas.0605796103
   Galvao RIM, 2005, NEUROCHEM RES, V30, P39, DOI 10.1007/s11064-004-9684-5
   Green AR, 2006, DRUG DISCOV TODAY, V11, P681, DOI 10.1016/j.drudis.2006.06.001
   Guevara I, 1998, CLIN CHIM ACTA, V274, P177, DOI 10.1016/S0009-8981(98)00060-6
   Gunnarson E, 2004, NEUROSCIENCE, V129, P947, DOI 10.1016/j.neuroscience.2004.08.022
   Gupta RK, 2011, AGE, P9330
   HALLIWELL B, 1987, FASEB J, V1, P358, DOI 10.1096/fasebj.1.5.2824268
   Han BC, 2004, LIFE SCI, V76, P573, DOI 10.1016/j.lfs.2004.07.016
   Hara H, 1996, J CEREBR BLOOD F MET, V16, P605, DOI 10.1097/00004647-199607000-00010
   JAGOTA SK, 1982, ANAL BIOCHEM, V127, P178, DOI 10.1016/0003-2697(82)90162-2
   KADER A, 1993, STROKE, V24, P1709, DOI 10.1161/01.STR.24.11.1709
   Katsuta K, 2003, EUR J PHARMACOL, V467, P103, DOI 10.1016/S0014-2999(03)01573-5
   KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2
   Kovalenko T, 2006, HIPPOCAMPUS, V16, P814, DOI 10.1002/hipo.20211
   Lennon AM, 2002, BIOCHEM PHARMACOL, V63, P163, DOI 10.1016/S0006-2952(01)00826-7
   LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84
   Ma B, 1997, ACTA PHARM SIN, V25, P90
   Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256
   Manley GT, 2004, NEUROSCIENCE, V129, P983, DOI 10.1016/j.neuroscience.2004.06.088
   Mathew LK, 2011, NEUROSCI LETT, V488, P60
   NAKAGOMI T, 1989, STROKE, V20, P925, DOI 10.1161/01.STR.20.7.925
   NELSON SK, 1994, FREE RADICAL BIO MED, V16, P195, DOI 10.1016/0891-5849(94)90143-0
   Papadopoulos MC, 2002, MT SINAI J MED, V69, P242
   POKORSKI M, 1993, ADV EXP MED BIOL, V337, P191
   Popp A, 2009, PLOS ONE, V4, P47
   PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509
   Rash JE, 1998, P NATL ACAD SCI USA, V95, P11981, DOI 10.1073/pnas.95.20.11981
   Ribeiro MD, 2006, J NEUROSCI RES, V83, P1231, DOI 10.1002/jnr.20819
   Serteser M, 2002, PROG NEURO-PSYCHOPH, V26, P871, DOI 10.1016/S0278-5846(01)00332-3
   SUZUKI J, 1990, JPN J VET SCI, V52, P1281
   Tegeder I, 2001, FASEB J, V15, P2, DOI 10.1096/fasebj.15.1.2
   van der Worp HB, 2002, NEUROLOGY, V58, P133, DOI 10.1212/WNL.58.1.133
   VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0
   Vartiainen N, 2001, J NEUROCHEM, V76, P480, DOI 10.1046/j.1471-4159.2001.00065.x
   Verkman AS, 2006, BBA-BIOMEMBRANES, V1758, P1085, DOI 10.1016/j.bbamem.2006.02.018
   Wang C, 2008, CHINESE MED J-PEKING, V121, P2572, DOI 10.1097/00029330-200812020-00019
   Wang CX, 2007, DRUG AGING, V24, P537, DOI 10.2165/00002512-200724070-00002
NR 58
TC 40
Z9 43
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 4
PY 2013
VL 8
IS 9
AR e73481
DI 10.1371/journal.pone.0073481
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 219OE
UT WOS:000324515600104
PM 24023878
OA gold, Green Published, Green Submitted
DA 2021-10-30
ER

PT J
AU Villarreal, R
   Mitrofanova, A
   Maiguel, D
   Morales, X
   Jeon, J
   Grahammer, F
   Leibiger, IB
   Guzman, J
   Fachado, A
   Yoo, TH
   Katin, AB
   Gellermann, J
   Merscher, S
   Burke, GW
   Berggren, PO
   Oh, J
   Huber, TB
   Fornoni, A
AF Villarreal, Rodrigo
   Mitrofanova, Alla
   Maiguel, Dony
   Morales, Ximena
   Jeon, Jongmin
   Grahammer, Florian
   Leibiger, Ingo B.
   Guzman, Johanna
   Fachado, Alberto
   Yoo, Tae H.
   Katin, Anja Busher
   Gellermann, Jutta
   Merscher, Sandra
   Burke, George W.
   Berggren, Per-Olof
   Oh, Jun
   Huber, Tobias B.
   Fornoni, Alessia
TI Nephrin Contributes to Insulin Secretion and Affects Mammalian Target of
   Rapamycin Signaling Independently of Insulin Receptor
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID SLIT DIAPHRAGM; KINASE; KIDNEY; PHOSPHORYLATION; PROTEIN; ACTIN; GENE;
   AKT; SENSITIVITY; EXPRESSION
AB Nephrin belongs to a family of highly conserved proteins with a well characterized function as modulators of cell adhesion and guidance, and nephrin may have a role in metabolic pathways linked to podocyte and pancreatic beta-cell survival. However, this role is incompletely characterized. In this study, we developed floxed nephrin mice for pancreatic beta-cell-specific deletion of nephrin, which had no effect on islet size and glycemia. Nephrin deficiency, however, resulted in glucose intolerance in vivo and impaired glucose-stimulated insulin release ex vivo. Glucose intolerance was also observed in eight patients with nephrin mutations compared with three patients with other genetic forms of nephrotic syndrome or nine healthy controls. In vitro experiments were conducted to investigate if nephrin affects autocrine signaling through insulin receptor A (IRA) and B (IRB), which are both expressed in human podocytes and pancreatic islets. Coimmunoprecipitation of nephrin and IRB but not IRA was observed and required IR phosphorylation. Nephrin per se was sufficient to induce phosphorylation of p70S6K in an phosphatidylinositol 3-kinase-dependent but IR/Src-independent manner, which was not augmented by exogenous insulin. These results suggest a role for nephrin as an independent modulator of podocyte and pancreatic P-cell nutrient sensing in the fasting state and the potential of nephrin as a drug target in diabetes.
C1 [Villarreal, Rodrigo; Mitrofanova, Alla; Maiguel, Dony; Morales, Ximena; Jeon, Jongmin; Guzman, Johanna; Yoo, Tae H.; Merscher, Sandra; Fornoni, Alessia] Univ Miami, Miller Sch Med, Katz Family Drug Discovery Ctr, Div Nephrol & Hypertens, Miami, FL 33136 USA.
   [Villarreal, Rodrigo; Maiguel, Dony; Jeon, Jongmin; Guzman, Johanna; Fachado, Alberto; Merscher, Sandra; Berggren, Per-Olof; Fornoni, Alessia] Univ Miami, Diabet Res Inst, Miller Sch Med, Miami, FL 33136 USA.
   [Grahammer, Florian; Huber, Tobias B.] Univ Hosp Freiburg, Div Renal, Freiburg, Germany.
   [Leibiger, Ingo B.; Berggren, Per-Olof] Karolinska Inst, Rolf Luft Res Ctr Diabet & Endocrinol, Stockholm, Sweden.
   [Yoo, Tae H.] Yonsei Univ, Coll Med, Dept Internal Med, Div Nephrol, Seoul, South Korea.
   [Katin, Anja Busher] Univ Childrens Hosp Essen, Pediat Nephrol, Pediat 2, Essen, Germany.
   [Gellermann, Jutta] Charite Childrens Hosp, Dept Pediat Nephrol, Berlin, Germany.
   [Burke, George W.] Univ Miami, Dept Surg, Miami, FL 33136 USA.
   [Oh, Jun] Univ Med Ctr Hamburg Eppendorf, Pediat Nephrol, Hamburg, Germany.
RP Fornoni, A (corresponding author), Univ Miami, Miller Sch Med, Katz Family Drug Discovery Ctr, Div Nephrol & Hypertens, Miami, FL 33136 USA.; Fornoni, A (corresponding author), Univ Miami, Katz Family Drug Discovery Ctr, Div Nephrol & Hypertens, 1580 NW 10th Ave, Miami, FL 33136 USA.; Fornoni, A (corresponding author), Univ Miami, Diabet Res Inst, 1580 NW 10th Ave, Miami, FL 33136 USA.
EM afornoni@med.miami.edu
RI Oh, Jun/K-4039-2013; Grahammer, Florian/ABB-7775-2021; Mitrofanova,
   Alla/L-1590-2019
OI Mitrofanova, Alla/0000-0001-5065-9522; fornoni,
   Alessia/0000-0002-1313-7773; Berggren, Per-Olof/0000-0001-8991-413X;
   Huber, Tobias B./0000-0001-7175-5062; Merscher,
   Sandra/0000-0002-4757-7494
FU American Heart AssociationAmerican Heart Association [12POST11640007];
   National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA; National Institute of
   Diabetes and Digestive and Kidney DiseasesUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)
   [DK090316, DK104753, U24-DK076169, U54-DK083912, UL1-TR000460,
   UM1-DK100846]; National Center for Advancing Translational
   SciencesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [1UL1-TR000460]; Diabetes Research
   Institute Foundation; Peggy and Harold Katz Family Foundation; NATIONAL
   CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000460] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)
   [UM1DK100846, K08DK082636, R01DK104753, R01DK090316, U54DK083912,
   U24DK076169] Funding Source: NIH RePORTER
FX We thank Dr. Damaris Molano, Dr. Antonello Pileggi, Yalena Gadea, Elsie
   Zahr-Akrawi, and Maite Lopez from the Preclinical Cell Processing and
   Translational Models Program at the Diabetes Research Institute for
   their excellent technical assistance.; R.V. is supported by American
   Heart Association Grant 12POST11640007. S.M. and A.F. are supported by
   National Institutes of Health and National Institute of Diabetes and
   Digestive and Kidney Diseases Grants DK090316, DK104753, and
   U24-DK076169. A.F. is also supported by National Institutes of Health
   and National Institute of Diabetes and Digestive and Kidney Diseases
   Grants U54-DK083912, UL1-TR000460, and UM1-DK100846; National Center for
   Advancing Translational Sciences Grant 1UL1-TR000460; the Diabetes
   Research Institute Foundation, and the Peggy and Harold Katz Family
   Foundation.
CR Agarwal R, 2006, AM J CARDIOL, V97, P748, DOI 10.1016/j.amjcard.2005.09.110
   Aikin R, 2000, BIOCHEM BIOPH RES CO, V277, P455, DOI 10.1006/bbrc.2000.3664
   Barletta GM, 2003, J BIOL CHEM, V278, P19266, DOI 10.1074/jbc.M301279200
   Bernal-Mizrachi E, 2001, J CLIN INVEST, V108, P1631, DOI 10.1172/JCI200113785
   Bouche C, 2010, P NATL ACAD SCI USA, V107, P4770, DOI 10.1073/pnas.1000002107
   Canaud G, 2013, NAT MED, V19, P1288, DOI 10.1038/nm.3313
   Coward RJM, 2007, DIABETES, V56, P1127, DOI 10.2337/db06-0693
   Donoviel DB, 2001, MOL CELL BIOL, V21, P4829, DOI 10.1128/MCB.21.14.4829-4836.2001
   Dor Y, 2004, NATURE, V429, P41, DOI 10.1038/nature02520
   Faul C, 2007, TRENDS CELL BIOL, V17, P428, DOI 10.1016/j.tcb.2007.06.006
   Fornoni A, 2010, DIABETES, V59, P190, DOI 10.2337/db09-0655
   Garg P, 2007, MOL CELL BIOL, V27, P8698, DOI 10.1128/MCB.00948-07
   Gerke P, 2003, J AM SOC NEPHROL, V14, P918, DOI 10.1097/01.ASN.0000057853.05686.89
   Grahammer F, 2013, NAT REV NEPHROL, V9, P587, DOI 10.1038/nrneph.2013.169
   Harita Y, 2009, J BIOL CHEM, V284, P8951, DOI 10.1074/jbc.M806851200
   Heikkila E, 2011, BIOCHEM J, V435, P619, DOI 10.1042/BJ20101599
   Huber TB, 2003, MOL CELL BIOL, V23, P4917, DOI 10.1128/MCB.23.14.4917-4928.2003
   Ijaz A, 2009, KIDNEY INT, V75, P381, DOI 10.1038/ki.2008.559
   Jacob KK, 2002, MOL CELL ENDOCRINOL, V186, P7, DOI 10.1016/S0303-7207(01)00674-8
   Jeon J, 2012, J BIOL CHEM, V287, P28932, DOI 10.1074/jbc.M112.389452
   Jones N, 2006, NATURE, V440, P818, DOI 10.1038/nature04662
   Katz A, 2000, J CLIN ENDOCR METAB, V85, P2402, DOI 10.1210/jc.85.7.2402
   Kestila M, 1998, MOL CELL, V1, P575, DOI 10.1016/S1097-2765(00)80057-X
   Khoshnoodi J, 2003, AM J PATHOL, V163, P2337, DOI 10.1016/S0002-9440(10)63590-0
   Lee JY, 2006, J BIOL CHEM, V281, P2649, DOI 10.1074/jbc.M512373200
   Leibiger B, 2001, MOL CELL, V7, P559, DOI 10.1016/S1097-2765(01)00203-9
   Leibiger IB, 2002, FEBS LETT, V532, P1, DOI 10.1016/S0014-5793(02)03627-X
   Li H, 2004, J AM SOC NEPHROL, V15, P3006, DOI 10.1097/01.ASN.0000146689.88078.80
   Nakatsu Y, 2011, J BIOL CHEM, V286, P20812, DOI 10.1074/jbc.M110.206904
   New LA, 2013, J BIOL CHEM, V288, P1500, DOI 10.1074/jbc.M112.439463
   Palmen T, 2001, DIABETOLOGIA, V44, P1274, DOI 10.1007/s001250100641
   Patrakka J, 2007, TRENDS MOL MED, V13, P396, DOI 10.1016/j.molmed.2007.06.006
   Pavenstadt H, 2003, PHYSIOL REV, V83, P253, DOI 10.1152/physrev.00020.2002
   Pezze PD, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002469
   Putaala H, 2001, HUM MOL GENET, V10, P1, DOI 10.1093/hmg/10.1.1
   Qin XS, 2009, J AM SOC NEPHROL, V20, P2534, DOI 10.1681/ASN.2009010011
   Quack I, 2006, P NATL ACAD SCI USA, V103, P14110, DOI 10.1073/pnas.0602587103
   RAPOLA J, 1987, PEDIATR NEPHROL, V1, P441, DOI 10.1007/BF00849252
   Rinta-Valkama J, 2007, MOL CELL BIOCHEM, V294, P117, DOI 10.1007/s11010-006-9251-2
   Ruotsalainen V, 1999, P NATL ACAD SCI USA, V96, P7962, DOI 10.1073/pnas.96.14.7962
   SEINO S, 1989, BIOCHEM BIOPH RES CO, V159, P312, DOI 10.1016/0006-291X(89)92439-X
   SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114
   Sellin L, 2002, FASEB J, V16, P115, DOI 10.1096/fj.02-0242fje
   SIEGEL TW, 1981, J BIOL CHEM, V256, P9266
   Tejada T, 2008, KIDNEY INT, V73, P1385, DOI 10.1038/ki.2008.109
   Tuttle RL, 2001, NAT MED, V7, P1133, DOI 10.1038/nm1001-1133
   Uhles S, 2003, J CELL BIOL, V163, P1327, DOI 10.1083/jcb.200306093
   Verma R, 2006, J CLIN INVEST, V116, P1346, DOI 10.1172/JCI27414
   Verma R, 2003, J BIOL CHEM, V278, P20716, DOI 10.1074/jbc.M301689200
   Wartiovaara J, 2004, J CLIN INVEST, V114, P1475, DOI 10.1172/JCI200422562
   Xu G, 1999, DIABETES, V48, P2270, DOI 10.2337/diabetes.48.12.2270
   Yoo TH, 2015, J AM SOC NEPHROL, V26, P133, DOI 10.1681/ASN.2013111213
NR 52
TC 13
Z9 13
U1 0
U2 1
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1046-6673
EI 1533-3450
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD APR
PY 2016
VL 27
IS 4
BP 1029
EP 1041
DI 10.1681/ASN.2015020210
PG 13
WC Urology & Nephrology
SC Urology & Nephrology
GA DH8GW
UT WOS:000373032500011
PM 26400569
OA Green Published, Bronze
DA 2021-10-30
ER

PT J
AU Eichberg, DG
   Di, L
   Shah, AH
   Luther, EM
   Jackson, C
   Marenco-Hillembrand, L
   Chaichana, KL
   Ivan, ME
   Starke, RM
   Komotar, RJ
AF Eichberg, Daniel G.
   Di, Long
   Shah, Ashish H.
   Luther, Evan M.
   Jackson, Christina
   Marenco-Hillembrand, Lina
   Chaichana, Kaisorn L.
   Ivan, Michael E.
   Starke, Robert M.
   Komotar, Ricardo J.
TI Minimally invasive resection of intracranial lesions using tubular
   retractors: a large, multi-surgeon, multi-institutional series
SO JOURNAL OF NEURO-ONCOLOGY
LA English
DT Article
DE Tubular retractor; Minimally invasive surgery; Brain tumor; Exoscope;
   Microsurgery; Neurosurgery
ID BRAIN RETRACTION; MICROSURGICAL RESECTION; RECURRENT GLIOBLASTOMA;
   EXTENT; PRESSURE; COMPLICATIONS; REMOVAL; RISK
AB Purpose Lesions located in subcortical areas are difficult to safely access. Tubular retractors have been increasingly used successfully with low complication profile to access lesions by minimizing brain retraction trauma and distributing pressure radially. Both binocular operative microscope and monocular exoscope are utilized for lesion visualization through tubular retractors. We present the largest multi-surgeon, multi-institutional series to determine the efficacy and safety profile of a transcortical-transtubular approach for intracranial lesion resections with both microscopic and exoscopic visualization. Methods We reviewed a multi-surgeon, multi-institutional case series including transcortical-transtubular resection of intracranial lesions using either BrainPath (NICO, Indianapolis, Indiana) or ViewSite Brain Access System (VBAS, Vycor Medical, Boca Raton, Florida) tubular retractors (n = 113). Results One hundred thirteen transtubular resections for intracranial lesions were performed. Patients presented with a diverse number of pathologies including 25 cavernous hemangiomas (21.2%), 15 colloid cysts (13.3%), 26 GBM (23.0%), two meningiomas (1.8%), 27 metastases (23.9%), 9 gliomas (7.9%) and 9 other lesions (7.9%). Mean lesion depth below the cortical surface was 4.4 cm, and mean lesion size was 2.7 cm. A gross total resection was achieved in 81 (71.7%) cases. Permanent complication rate was 4.4%. One patient (0.8%) experienced one early postoperative seizure (< 1 week postop). No patients experienced late seizures (> 1 week follow-up). Mean post-operative hospitalization length was 4.1 days. Conclusion Tubular retractors provide a minimally invasive operative corridor for resection of intracranial lesions. They provide an effective tool in the neurosurgical armamentarium to resect subcortical lesions with a low complication profile.
C1 [Eichberg, Daniel G.; Di, Long; Shah, Ashish H.; Luther, Evan M.; Ivan, Michael E.; Starke, Robert M.; Komotar, Ricardo J.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA.
   [Jackson, Christina] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA.
   [Marenco-Hillembrand, Lina; Chaichana, Kaisorn L.] Mayo Clin, Dept Neurosurg, Jacksonville, FL 32224 USA.
   [Ivan, Michael E.; Komotar, Ricardo J.] Sylvester Comprehens Canc Ctr, Miami, FL USA.
   [Eichberg, Daniel G.] Univ Miami Hosp, 1321 NW 14th St,West Bldg,Suite 306, Miami, FL 33125 USA.
RP Eichberg, DG (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA.; Eichberg, DG (corresponding author), Univ Miami Hosp, 1321 NW 14th St,West Bldg,Suite 306, Miami, FL 33125 USA.
EM dge18@med.miami.edu
OI Eichberg, Daniel/0000-0002-7654-2944
FU National Institute of Health through the Miami Clinical and
   Translational Science Institute [UL1TR002736, KL2TR002737]
FX Robert M. Starke has the following disclosures: RMS research is
   supported by the NREF, Joe Niekro Foundation, Brain Aneurysm Foundation,
   Bee Foundation, and by National Institute of Health (UL1TR002736,
   KL2TR002737) through the Miami Clinical and Translational Science
   Institute, from the National Center for Advancing Translational Sciences
   and the National Institute on Minority Health and Health Disparities.
   Its contents are solely the responsibility of the authors and do not
   necessarily represent the official views of the NIH. RMS has consulting
   and teaching agreements with Penumbra, Abbott, Medtronic, InNeuroCo and
   Cerenovus. Michael E. Ivan: Consultant to and receiving research funding
   from Medtronic and the NX Development Corporation. No other authors have
   any disclosures or conflicts of interest to declare.
CR Ajlan AM, 2014, NEUROSCIENCES, V19, P43
   ANDREWS RJ, 1993, NEUROSURGERY, V33, P1052
   Bander ED, 2016, J NEUROSURG, V124, P1053, DOI 10.3171/2015.4.JNS142576
   BATES A, 2018, BMJ-BRIT MED J, V362, DOI DOI 10.1136/BMJ.K2924
   Bloch O, 2012, J NEUROSURG, V117, P1032, DOI 10.3171/2012.9.JNS12504
   Cabbell KL, 1996, NEUROSURGERY, V38, P301, DOI 10.1097/00006123-199602000-00013
   Chaichana KL, 2013, J NEUROSURG, V118, P812, DOI 10.3171/2012.9.JNS1277
   Chen CJ, 2016, CASE REP NEUROL MED, V2016, DOI 10.1155/2016/8654262
   Childers CP, 2018, JAMA SURG, V153, DOI 10.1001/jamasurg.2017.6233
   Cohen-Gadol AA, 2013, WORLD NEUROSURG, V79, DOI 10.1016/j.wneu.2011.03.045
   CRUSE PJE, 1973, ARCH SURG-CHICAGO, V107, P206, DOI 10.1001/archsurg.1973.01350200078018
   Ding DL, 2015, J CLIN NEUROSCI, V22, P1025, DOI 10.1016/j.jocn.2015.01.004
   DONAGHY RMP, 1972, AM J SURG, V123, P429, DOI 10.1016/0002-9610(72)90195-X
   Eichberg DG, 2020, OPER NEUROSURG, V18, P629, DOI 10.1093/ons/opz184
   Eichberg DG, 2019, OPER NEUROSURG, V16, P571, DOI 10.1093/ons/opy249
   Eichberg DG, 2018, WORLD NEUROSURG, V112, pE50, DOI 10.1016/j.wneu.2017.12.023
   Gassie K, 2018, J NEUROSURG SCI, V62, P682, DOI 10.23736/S0390-5616.18.04466-1
   Greenfield JP, 2008, NEUROSURGERY, V63, P334, DOI [10.1227/01.neu.0000334741.61745.72, 10.1227/01.NEU.0000334741.61745.72]
   Harris Anthony E, 2005, Neurosurgery, V56, P125
   Herrera Sebastian R, 2010, Surg Technol Int, V19, P47
   Hervey-Jumper SL, 2014, NEUROSURGERY, V75, P491, DOI 10.1227/NEU.0000000000000486
   Hong CS, 2016, J NEUROSURG, V124, P799, DOI 10.3171/2015.1.JNS141113
   Jo KI, 2011, CHILD NERV SYST, V27, P1989, DOI 10.1007/s00381-011-1529-3
   KELLY PJ, 1988, J NEUROSURG, V69, P301, DOI 10.3171/jns.1988.69.2.0301
   Kim JYS, 2015, JAMA SURG, V150, P110, DOI 10.1001/jamasurg.2014.1841
   Labib MA, 2017, NEUROSURGERY, V80, P515, DOI 10.1227/NEU.0000000000001316
   Lacroix M, 2001, J NEUROSURG, V95, P190, DOI 10.3171/jns.2001.95.2.0190
   Malone H, 2015, WORLD NEUROSURG, V84, P1084, DOI 10.1016/j.wneu.2015.05.025
   Marko NF, 2014, J CLIN ONCOL, V32, P774, DOI 10.1200/JCO.2013.51.8886
   Moosa S, 2018, J CLIN NEUROSCI, V53, P269, DOI 10.1016/j.jocn.2018.04.028
   Nagatani Kimihiro, 2015, No Shinkei Geka, V43, P611, DOI 10.11477/mf.1436203086
   NUMOTO M, 1970, J NEUROSURG, V33, P381, DOI 10.3171/jns.1970.33.4.0381
   Oppenlander ME, 2014, J NEUROSURG, V120, P846, DOI 10.3171/2013.12.JNS13184
   Ratre S, 2016, J NEUROL SURG PART A, V77, P312, DOI 10.1055/s-0036-1580595
   Ricciardi L, 2019, WORLD NEUROSURG, V124, P136, DOI 10.1016/j.wneu.2018.12.202
   ROSENORN J, 1982, J NEUROSURG, V56, P826, DOI 10.3171/jns.1982.56.6.0826
   Sanai N, 2011, J NEUROSURG, V115, P3, DOI 10.3171/2011.2.JNS10998
   Savardekar AR, 2018, WORLD NEUROSURG, V119, P294, DOI 10.1016/j.wneu.2018.06.231
   Zhong J, 2003, NEUROL RES, V25, P831, DOI 10.1179/016164103771953925
NR 39
TC 5
Z9 5
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0167-594X
EI 1573-7373
J9 J NEURO-ONCOL
JI J. Neuro-Oncol.
PD AUG
PY 2020
VL 149
IS 1
BP 35
EP 44
DI 10.1007/s11060-020-03500-0
EA JUN 2020
PG 10
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA NF3CC
UT WOS:000543627900001
PM 32556805
DA 2021-10-30
ER

PT J
AU Bassi, R
   Fornoni, A
   Doria, A
   Fiorina, P
AF Bassi, Roberto
   Fornoni, Alessia
   Doria, Alessandro
   Fiorina, Paolo
TI CTLA4-Ig in B7-1-positive diabetic and non-diabetic kidney disease
SO DIABETOLOGIA
LA English
DT Review
DE B7-1; CD80; CTLA4-Ig; Diabetic kidney disease; Podocytes; Review
ID LONG-TERM SAFETY; DOUBLE-BLIND; RENAL-INSUFFICIENCY; URINARY CD80;
   ABATACEPT; PODOCYTES; PROTEINURIA; ARTHRITIS; CELLS; NEPHROPATHY
AB Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease in the Western world. Standard treatments have ultimately proven ineffective in blocking DKD progression, thus necessitating the design of new therapies to complement glycaemic and blood pressure control. High glucose levels upregulate the immune-related molecule B7-1 in podocytes, and such an event may play a relevant role in DKD onset, suggesting that B7-1 is a suitable therapeutic target for DKD. CTLA4-Ig is a clinically available fusion protein, approved for the treatment of some autoimmune diseases, which binds B7-1 and blocks its signalling. We have previously demonstrated that CTLA4-Ig restores the physiological structure and cellular motility of podocytes challenged with high glucose in vitro and abrogates the onset of proteinuria in murine models of DKD in vivo. Notably, these beneficial effects occurred independently of any systemic immunological effects of CTLA4-Ig. While the expression of B7-1 on podocytes raises questions regarding the very nature of the podocyte as we know it, the preliminary positive effect of CTLA4-Ig on proteinuria in preclinical models and the evidence of B7-1 expression in kidney biopsies of diabetic individuals suggest a potential novel indication for CTLA4-Ig in DKD. Nonetheless, recent reports of problems with detecting podocyte B7-1 and of inconsistent therapeutic efficacy of CTLA4-Ig in proteinuric patients highlight the necessity to establish uniformly accepted protocols for the detection of B7-1 and underline the need for randomised trials with CTLA4-Ig in kidney diseases.
C1 [Bassi, Roberto; Fiorina, Paolo] Harvard Univ, Sch Med, Boston Childrens Hosp, Div Nephrol, Boston, MA 02115 USA.
   [Bassi, Roberto; Fiorina, Paolo] Univ Milan, Osped San Raffaele, IRCCS, Dept Transplant Med, I-20127 Milan, Italy.
   [Fornoni, Alessia] Univ Miami, Miller Sch Med, Div Nephrol & Hypertens, Peggy & Harold Katz Family Drug Discovery Ctr, Miami, FL 33136 USA.
   [Doria, Alessandro] Joslin Diabet Ctr, Sect Genet & Epidemiol, Boston, MA 02215 USA.
RP Fiorina, P (corresponding author), Harvard Univ, Sch Med, Boston Childrens Hosp, Div Nephrol, 300 Longwood Ave,Enders Bldg, Boston, MA 02115 USA.
EM paolo.fiorina@childrens.harvard.edu
RI Doria, Alessandro/H-9157-2018; Fiorina, Paolo/B-4532-2019
OI Doria, Alessandro/0000-0002-3830-4304; Fiorina,
   Paolo/0000-0002-1093-7724; fornoni, Alessia/0000-0002-1313-7773
FU AST Genentech/Novartis Clinical Science Fellowship grant; JDRF
   Post-Doctoral Fellowship grant; 'AMD-SID Pasquale di Coste' Award;
   American Heart AssociationAmerican Heart Association; Italian Ministry
   of HealthMinistry of Health, Italy [RF-2010-2303119, RF-2010-2314794];
   NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01-DK090316, U24-DK076169,
   UL1-TR000460, U54-DK083912]; Katz Drug Discovery Center; NATIONAL CENTER
   FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000460]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND
   DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Diabetes & Digestive & Kidney Diseases (NIDDK) [U54DK083912,
   R01DK090316, R01DK104753, U24DK076169] Funding Source: NIH RePORTER
FX RB is the recipient of an AST Genentech/Novartis Clinical Science
   Fellowship grant, a JDRF Post-Doctoral Fellowship grant and an 'AMD-SID
   Pasquale di Coste' Award. PF is the recipient of an American Heart
   Association Grant-In-Aid; Italian Ministry of Health grant
   RF-2010-2303119 and RF-2010-2314794. AF is supported by NIH grants
   R01-DK090316, U24-DK076169, UL1-TR000460, U54-DK083912 and by the Katz
   Drug Discovery Center.
CR Abbate M, 2006, J AM SOC NEPHROL, V17, P2974, DOI 10.1681/ASN.2006040377
   Abe K, 2001, KIDNEY INT, V60, P137, DOI 10.1046/j.1523-1755.2001.00780.x
   Afkarian M, 2013, J AM SOC NEPHROL, V24, P302, DOI 10.1681/ASN.2012070718
   Agrawal S, 2014, KIDNEY INT, V86, P1150, DOI 10.1038/ki.2014.196
   Alachkar N, 2014, NEW ENGL J MED, V370, P1263, DOI 10.1056/NEJMc1400502
   Alten R, 2014, ARTHRITIS RHEUMATOL, V66, P1987, DOI 10.1002/art.38687
   Atzeni F, 2013, AUTOIMMUN REV, V12, P1115, DOI 10.1016/j.autrev.2013.06.011
   Banas MC, 2008, J AM SOC NEPHROL, V19, P704, DOI 10.1681/ASN.2007040395
   Bassi R, 2012, EXP DIABETES RES, DOI 10.1155/2012/916560
   Benigni A, 2014, NEW ENGL J MED, V370, P1261, DOI 10.1056/NEJMc1400502
   Caramori ML, 2000, DIABETES, V49, P1399, DOI 10.2337/diabetes.49.9.1399
   Chandraker A, 1998, J CLIN INVEST, V101, P2309, DOI 10.1172/JCI2299
   Chang JM, 2013, AM J PHYSIOL-RENAL, V304, pF127, DOI 10.1152/ajprenal.00108.2012
   Chow FY, 2006, KIDNEY INT, V69, P73, DOI 10.1038/sj.ki.5000014
   D'Addio F, 2014, ACTA DIABETOL, V51, P897, DOI 10.1007/s00592-014-0603-1
   de Boer IH, 2011, NEW ENGL J MED, V365, P2366, DOI 10.1056/NEJMoa1111732
   Delville M, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008538
   Diez-Sampedro A, 2011, AM J KIDNEY DIS, V58, P637, DOI 10.1053/j.ajkd.2011.03.035
   Doria A, 2012, SEMIN NEPHROL, V32, P437, DOI 10.1016/j.semnephrol.2012.07.006
   Fiorina P, 2014, J AM SOC NEPHROL, V25, P1415, DOI 10.1681/ASN.2013050518
   Fornoni A, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002231
   Fornoni A, 2010, NEW ENGL J MED, V363, P2068, DOI 10.1056/NEJMcibr1008395
   Fullerton B, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009122.pub2
   Furie R, 2014, ARTHRITIS RHEUMATOL, V66, P379, DOI 10.1002/art.38260
   Garin EH, 2015, PEDIATR NEPHROL, V30, P469, DOI 10.1007/s00467-014-2957-6
   Garin EH, 2009, J AM SOC NEPHROL, V20, P260, DOI 10.1681/ASN.2007080836
   Genovese MC, 2005, NEW ENGL J MED, V353, P1114, DOI 10.1056/NEJMoa050524
   Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031
   Goldwich A, 2013, J AM SOC NEPHROL, V24, P906, DOI 10.1681/ASN.2012020133
   Grellier J, 2015, TRANSPL INT, V28, P1109, DOI 10.1111/tri.12574
   Gross JL, 2005, DIABETES CARE, V28, P164, DOI 10.2337/diacare.28.1.164
   Huber TB, 2002, J IMMUNOL, V168, P6244, DOI 10.4049/jimmunol.168.12.6244
   Ishimoto T, 2013, NEPHROL DIAL TRANSPL, V28, P1439, DOI 10.1093/ndt/gfs543
   Jerums G, 2009, NAT REV NEPHROL, V5, P397, DOI 10.1038/nrneph.2009.91
   Krolewski AS, 2014, DIABETES CARE, V37, P226, DOI 10.2337/dc13-0985
   Kuravi SJ, 2014, J IMMUNOL, V193, P234, DOI 10.4049/jimmunol.1300229
   Larsen CP, 2014, AM J KIDNEY DIS, V64, P1001, DOI 10.1053/j.ajkd.2014.07.023
   LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004
   Ma Y, 2009, ACTA PHARMACOL SIN, V30, P364, DOI 10.1038/aps.2009.13
   MacIsaac R, 2004, DIABETES CARE, V27, P195, DOI 10.2337/diacare.27.1.195
   Martin ST, 2011, PHARMACOTHERAPY, V31, P394, DOI 10.1592/phco.31.4.394
   Molitch ME, 2010, DIABETES CARE, V33, P1536, DOI 10.2337/dc09-1098
   Mundel P, 2002, J AM SOC NEPHROL, V13, P3005, DOI 10.1097/01.ASN.0000039661.06947.FD
   Nash P, 2013, ARTHRIT CARE RES, V65, P718, DOI 10.1002/acr.21876
   Nathan D, 2009, DIABETOLOGIA, V52, P17, DOI 10.1007/s00125-008-1157-y
   Niemir ZI, 1997, KIDNEY INT, V52, P393, DOI 10.1038/ki.1997.346
   Niewczas MA, 2012, J AM SOC NEPHROL, V23, P507, DOI 10.1681/ASN.2011060627
   Nolasco F E, 1987, Nephrol Dial Transplant, V2, P304
   Orabona C, 2004, NAT IMMUNOL, V5, P1134, DOI 10.1038/ni1124
   Orban T, 2011, LANCET, V378, P412, DOI 10.1016/S0140-6736(11)60886-6
   Reiser J, 2004, J CLIN INVEST, V113, P1390, DOI 10.1172/JCI200420402
   Reynolds J, 2007, PHARMACOTHERAPY, V27, P1693, DOI 10.1592/phco.27.12.1693
   Rocco MV, 2012, AM J KIDNEY DIS, V60, P857, DOI 10.1053/j.ajkd.2012.07.005
   Ruperto N, 2008, LANCET, V372, P383, DOI 10.1016/S0140-6736(08)60998-8
   Sayegh MH, 1998, NEW ENGL J MED, V338, P1813, DOI 10.1056/NEJM199806183382506
   Scarsi M, 2011, J RHEUMATOL, V38, P2105, DOI 10.3899/jrheum.110386
   Taal MW, 2000, KIDNEY INT, V57, P1803, DOI 10.1046/j.1523-1755.2000.00031.x
   Tian X, 2014, J CLIN INVEST, V124, P1098, DOI 10.1172/JCI69778
   Valmadrid CT, 2000, ARCH INTERN MED, V160, P1093, DOI 10.1001/archinte.160.8.1093
   Weinblatt ME, 2013, J RHEUMATOL, V40, P787, DOI 10.3899/jrheum.120906
   Yu CC, 2013, NEW ENGL J MED, V369, P2416, DOI 10.1056/NEJMoa1304572
   Zhang JD, 2014, EXP PHYSIOL, V99, P802, DOI 10.1113/expphysiol.2013.077610
NR 62
TC 16
Z9 18
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0012-186X
EI 1432-0428
J9 DIABETOLOGIA
JI Diabetologia
PD JAN
PY 2016
VL 59
IS 1
BP 21
EP 29
DI 10.1007/s00125-015-3766-6
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CX6IN
UT WOS:000365804500005
PM 26409459
OA Green Accepted, Bronze
DA 2021-10-30
ER

PT J
AU Rodriguez-Blanco, YF
   Gologorsky, A
   Salerno, TA
   Lo, K
   Gologorsky, E
AF Rodriguez-Blanco, Yiliam F.
   Gologorsky, Angela
   Salerno, Tomas Antonio
   Lo, Kaming
   Gologorsky, Edward
TI Pulmonary Perfusion and Ventilation during Cardiopulmonary Bypass Are
   Not Associated with Improved Postoperative Outcomes after Cardiac
   Surgery
SO FRONTIERS IN CARDIOVASCULAR MEDICINE
LA English
DT Article
DE cardiopulmonary bypass; postoperative complications; pulmonary
   perfusion; pulmonary ventilation; cardiac surgery outcome
ID LUNG-PROTECTIVE VENTILATION; BEATING HEART; MECHANICAL VENTILATION;
   INFLAMMATORY RESPONSE; OXYGENATED BLOOD; RIGHT VENTRICLE; GRAFT-SURGERY;
   LOW-FLOW; COMPLICATIONS; INJURY
AB Objectives: Clinical trials of either pulmonary perfusion or ventilation during cardiopulmonary bypass (CBP) are equivocal. We hypothesized that to achieve significant improvement in outcomes both interventions had to be concurrent.
   Design: Retrospective case-control study.
   Settings: Major academic tertiary referral medical center.
   Participants: Two hundred seventy-four consecutive patients who underwent open heart surgery with CBP 2009-2013. Interventions: The outcomes of 86 patients who received pulmonary perfusion and ventilation during CBP were retrospectively compared to the control group of 188 patients.
   Measurements and main results: Respiratory complications rates were similar in both groups (33.7 vs. 33.5%), as were the rates of postoperative pneumonia (4.7 vs. 4.3%), pleural effusions (13.9 vs. 12.2%), and re-intubations (9.3 vs. 9.1%). Rates of adverse postoperative cardiac events including ventricular tachycardia (9.3 vs. 8.5%) and atrial fibrillation (33.7 vs. 28.2%) were equivalent in both groups. Incidence of sepsis (8.1 vs. 5.3%), postoperative stroke (2.3 vs. 2.1%), acute kidney injury (2.3 vs. 3.7%), and renal failure (5.8 vs. 3.7%) was likewise comparable. Despite similar transfusion requirements, coagulopathy (12.8 vs. 5.3%, p = 0.031) and the need for mediastinal re exploration (17.4 vs. 9.6%, p = 0.0633) were observed more frequently in the pulmonary perfusion and ventilation group, but the difference did not reach the statistical significance. Intensive care unit (ICU) and hospital stays, and the ICU readmission rates (7.0 vs. 8.0%) were similar in both groups.
   Conclusion: Simultaneous pulmonary perfusion and ventilation during CBP were not associated with improved clinical outcomes.
C1 [Rodriguez-Blanco, Yiliam F.] Univ Miami, Miller Sch Med, Anesthesiol, Miami, FL 33136 USA.
   [Salerno, Tomas Antonio] Univ Miami, Miller Sch Med, Cardiovasc Surg, Miami, FL 33136 USA.
   [Lo, Kaming] Univ Miami, Dept Publ Hlth Sci, Div Biostat, Miami, FL USA.
   [Gologorsky, Edward] Allegheny Gen Hosp, Anesthesiol, Pittsburgh, PA 15212 USA.
RP Gologorsky, E (corresponding author), Allegheny Gen Hosp, Anesthesiol, Pittsburgh, PA 15212 USA.
EM doctorsg@bellsouth.net
FU NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000460] Funding Source: NIH RePORTER; NCATS NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1 TR000460] Funding Source: Medline
CR Al Jaaly E, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/416235
   Apostolakis E, 2010, J CARDIOTHORAC SURG, V5, DOI 10.1186/1749-8090-5-114
   Cavalcante JL, 2016, J AM SOC ECHOCARDIOG, V29, P325, DOI 10.1016/j.echo.2015.12.001
   Cislaghi F, 2009, EUR J ANAESTH, V26, P396, DOI 10.1097/EJA.0b013e3283232c69
   Freitas CRD, 2016, ANESTH ANALG, V122, P943, DOI 10.1213/ANE.0000000000001118
   Gabriel Edmo Atique, 2008, Interact Cardiovasc Thorac Surg, V7, P1089, DOI 10.1510/icvts.2008.184275
   Gagnon J, 2010, PERFUSION-UK, V25, P205, DOI 10.1177/0267659110373839
   Glance LG, 2015, ANESTH ANALG, V120, P526, DOI 10.1213/ANE.0000000000000522
   Guldner A, 2015, ANESTHESIOLOGY, V123, P692, DOI 10.1097/ALN.0000000000000754
   Imura H, 2009, J THORAC CARDIOV SUR, V137, P1530, DOI 10.1016/j.jtcvs.2008.11.014
   Ioannidis JPA, 2005, PLOS MED, V2, P696, DOI 10.1371/journal.pmed.0020124
   Ji Q, 2013, INT J MED SCI, V10, P1578, DOI 10.7150/ijms.6904
   Kerendi F, 2011, ANN THORAC SURG, V91, P8, DOI 10.1016/j.athoracsur.2010.08.003
   Khandelwal N, 2015, J CARDIOTHOR VASC AN, V29, P551, DOI 10.1053/j.jvca.2014.11.009
   Kiessling AH, 2014, INTERACT CARDIOV TH, V18, P732, DOI 10.1093/icvts/ivu062
   Lachapelle Kevin, 2011, Ann Thorac Surg, V91, P15, DOI 10.1016/j.athoracsur.2010.08.057
   Macedo FIB, 2012, SEMIN THORAC CARDIOV, V24, P308, DOI 10.1053/j.semtcvs.2012.08.002
   Macedo FIB, 2010, J THORAC CARDIOV SUR, V139, P234, DOI 10.1016/j.jtcvs.2009.08.062
   Marik PE, 2008, CRIT CARE MED, V36, P3080, DOI 10.1097/CCM.0b013e31818c3801
   Neto AS, 2015, CRIT CARE MED, V43, P2155, DOI 10.1097/CCM.0000000000001189
   Parissis H, 2015, J CARDIOTHORAC SURG, V10, DOI 10.1186/s13019-015-0362-2
   Quader N, 2016, J AM SOC ECHOCARDIOG, V29, P334, DOI 10.1016/j.echo.2016.02.006
   Reddy SLC, 2007, ANN THORAC SURG, V84, P528, DOI 10.1016/j.athoracsur.2007.04.002
   Ricci M, 2009, ANN THORAC SURG, V87, P527, DOI 10.1016/j.athoracsur.2008.10.030
   Richter JA, 2000, ANN THORAC SURG, V69, P77, DOI 10.1016/S0003-4975(99)01131-5
   Romagnoli S, 2015, HEART LUNG VESSEL, V7, P5
   Salerno TA, 2007, J CARDIAC SURG, V22, P459, DOI 10.1111/j.1540-8191.2007.00448.x
   Salerno Tomas A, 2012, J Cardiothorac Vasc Anesth, V26, pe60, DOI 10.1053/j.jvca.2012.04.014
   Santini F, 2012, EUR J CARDIO-THORAC, V42, P942, DOI 10.1093/ejcts/ezs199
   Santini F, 2011, EUR J CARDIO-THORAC, V40, P794, DOI 10.1016/j.ejcts.2011.01.065
   Schreiber JU, 2012, J CARDIOTHOR VASC AN, V26, P448, DOI 10.1053/j.jvca.2012.01.034
   Siepe M, 2008, ANN THORAC SURG, V86, P115, DOI 10.1016/j.athoracsur.2008.03.062
   Sutherasan Y, 2014, CRIT CARE, V18, DOI 10.1186/cc13778
   Suzuki T, 2000, ANN THORAC SURG, V69, P602, DOI 10.1016/S0003-4975(99)01332-6
   Thell R, 2015, OXFORD TXB CARDIOTHO, P339
   Voelkel NF, 2015, PULM CIRC, V5, P81, DOI 10.1086/679702
   Weissman Charles, 2004, Semin Cardiothorac Vasc Anesth, V8, P185
NR 37
TC 1
Z9 1
U1 0
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2297-055X
J9 FRONT CARDIOVASC MED
JI Front. Cardiovasc. Med.
PD NOV 28
PY 2016
VL 3
BP 1
EP 8
AR 47
DI 10.3389/fcvm.2016.00047
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA FC7OB
UT WOS:000407029800001
PM 27965964
OA gold, Green Published
DA 2021-10-30
ER

PT J
AU Luther, E
   Chen, SH
   McCarthy, DJ
   Nada, A
   Heath, R
   Berry, K
   Strickland, A
   Burks, J
   Silva, M
   Sur, S
   Yavagal, DR
   Starke, RM
   Peterson, EC
AF Luther, Evan
   Chen, Stephanie H.
   McCarthy, David J.
   Nada, Ahmed
   Heath, Rainya
   Berry, Katherine
   Strickland, Allison
   Burks, Joshua
   Silva, Michael
   Sur, Samir
   Yavagal, Dileep R.
   Starke, Robert M.
   Peterson, Eric C.
TI Implementation of a radial long sheath protocol for radial artery spasm
   reduces access site conversions in neurointerventions
SO JOURNAL OF NEUROINTERVENTIONAL SURGERY
LA English
DT Article
DE angiography; technique; intervention; artery; device
ID TRANSRADIAL CORONARY INTERVENTION; CARDIAC-CATHETERIZATION; FEASIBILITY;
   ANTERIOR
AB Background
   Many neurointerventionalists have transitioned to transradial access (TRA) as the preferred approach for neurointerventions as studies continue to demonstrate fewer access site complications than transfemoral access. However, radial artery spasm (RAS) remains one of the most commonly cited reasons for access site conversions. We discuss the benefits, techniques, and indications for using the long radial sheath in RAS and present our experience after implementing a protocol for routine use.
   Methods
   A retrospective review of all patients undergoing neurointerventions via TRA at our institution from July 2018 to April 2020 was performed. In November 2019, we implemented a long radial sheath protocol to address RAS. Patient demographics, RAS rates, radial artery diameter, and access site conversions were compared before and after the introduction of the protocol.
   Results
   747 diagnostic cerebral angiograms and neurointerventional procedures in which TRA was attempted as the primary access site were identified; 247 were performed after the introduction of the long radial sheath protocol. No significant differences in age, gender, procedure type, sheath sizes, and radial artery diameter were seen between the two cohorts. Radial anomalies and small radial diameters were more frequently seen in patients with RAS. Patients with clinically significant RAS more often required access site conversion (p<0.0001), and in our multivariable model use of the long sheath was the only covariate protective against radial failure (OR 0.061, 95% CI 0.007 to 0.517; p=0.0103).
   Conclusion
   In our experience, we have found that the use of long radial sheaths significantly reduces the need for access site conversions in patients with RAS during cerebral angiography and neurointerventions.
C1 [Luther, Evan; Chen, Stephanie H.; Nada, Ahmed; Heath, Rainya; Berry, Katherine; Strickland, Allison; Burks, Joshua; Silva, Michael; Sur, Samir; Starke, Robert M.; Peterson, Eric C.] Univ Miami, Dept Neurol Surg, Sch Med, Miami, FL 33127 USA.
   [McCarthy, David J.] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15260 USA.
   [Yavagal, Dileep R.] Univ Miami, Neurol & Neurosurg, Miami, FL USA.
RP Luther, E (corresponding author), Univ Miami, Dept Neurol Surg, Sch Med, Miami, FL 33127 USA.
EM evan.luther@jhsmiami.org
OI Luther, Evan/0000-0001-9164-4984
FU NREF; Joe Niekro Foundation; Brain Aneurysm Foundation; Bee Foundation;
   National Institute of Health through the Miami Clinical and
   Translational Science Institute, from the National Center for Advancing
   Translational Sciences [R01NS111119-01A1, UL1TR002736, KL2TR002737];
   National Institute of Health through the Miami Clinical and
   Translational Science Institute, from the National Institute on Minority
   Health and Health Disparities [R01NS111119-01A1, UL1TR002736,
   KL2TR002737]; MedtronicMedtronic
FX RMS's research is supported by the NREF, Joe Niekro Foundation, Brain
   Aneurysm Foundation, Bee Foundation, and by National Institute of Health
   (R01NS111119--01A1) and (UL1TR002736, KL2TR002737) through the Miami
   Clinical and Translational Science Institute, from the National Center
   for Advancing Translational Sciences and the National Institute on
   Minority Health and Health Disparities. He also has an unrestricted
   research grant from Medtronic and has consulting and teaching agreements
   with Penumbra, Abbott, Medtronic, InNeuroCo and Cerenovus. The contents
   of this publication are solely the responsibility of the authors and do
   not necessarily represent the official views of the NIH.
CR Aminian A, 2017, CATHETER CARDIO INTE, V89, P1014, DOI 10.1002/ccd.26773
   Barros G, 2020, J NEUROINTERV SURG, V12, P427, DOI 10.1136/neurintsurg-2019-015386
   Bernat I, 2013, AM HEART J, V165, P338, DOI 10.1016/j.ahj.2013.01.012
   Brunet MC, 2020, J NEUROINTERV SURG, V12, P82, DOI 10.1136/neurintsurg-2019-015145
   Brunet MC, 2019, J NEUROINTERV SURG, V11, P710, DOI 10.1136/neurintsurg-2019-014718
   Caussin C, 2010, CATHETER CARDIO INTE, V76, P668, DOI 10.1002/ccd.22552
   Chen SH., 2019, ENDOVASCULAR TODAY
   Chen SH., 2019, J NEUROINTERV SURG
   Chen SH, 2019, WORLD NEUROSURG, V127, pE86, DOI 10.1016/j.wneu.2019.02.135
   Chen SH, 2019, J NEUROINTERV SURG, V11, P796, DOI 10.1136/neurintsurg-2018-014620
   Chen SH, 2019, J NEUROINTERV SURG, V11, P874, DOI 10.1136/neurintsurg-2018-014485
   Coghill EM, 2020, WORLD J CARDIOL, V12, P26, DOI 10.4330/wjc.v12.i1.26
   Kiemeneij F, 2003, CATHETER CARDIO INTE, V59, P161, DOI 10.1002/ccd.10444
   Kim SH, 2007, INT J CARDIOL, V120, P325, DOI 10.1016/j.ijcard.2006.10.008
   Koga S, 2004, INT J CARDIOL, V96, P255, DOI 10.1016/j.ijcard.2003.07.016
   Kristic I, 2011, J INVASIVE CARDIOL, V23, P527
   Li YC, 2021, J NEUROINTERV SURG, V13, P91, DOI 10.1136/neurintsurg-2020-015992
   Lo TS, 2009, HEART, V95, P410, DOI 10.1136/hrt.2008.150474
   Luther E, 2020, WORLD NEUROSURG, V139, P101, DOI 10.1016/j.wneu.2020.03.221
   McCarthy DJ, 2019, WORLD NEUROSURG, V122, P355, DOI 10.1016/j.wneu.2018.11.030
   Rathore S, 2010, JACC-CARDIOVASC INTE, V3, P475, DOI 10.1016/j.jcin.2010.03.009
   Ruiz-Salmeron RJ, 2005, CATHETER CARDIO INTE, V66, P192, DOI 10.1002/ccd.20434
   Seto AH, 2015, JACC-CARDIOVASC INTE, V8, P283, DOI 10.1016/j.jcin.2014.05.036
   Shah SS, 2018, WORLD NEUROSURG, V120, P415, DOI 10.1016/j.wneu.2018.09.095
   Snelling BM, 2019, OPER NEUROSURG, V17, P293, DOI 10.1093/ons/opy352
   Snelling BM, 2018, J NEUROINTERV SURG, V10, P874, DOI 10.1136/neurintsurg-2017-013584
   Snelling BM, 2018, J NEUROINTERV SURG, V10, P493, DOI 10.1136/neurintsurg-2017-013295
   Spaulding C, 1996, CATHETER CARDIO DIAG, V39, P365, DOI 10.1002/(SICI)1097-0304(199612)39:4<365::AID-CCD8>3.0.CO;2-B
   Sur S, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.1.FOCUS16525
   Sweid A, 2019, J NEUROSURG SCI, V63, P509, DOI 10.23736/S0390-5616.19.04761-1
NR 30
TC 2
Z9 2
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1759-8478
EI 1759-8486
J9 J NEUROINTERV SURG
JI J. NeuroInterventional Surg.
PD JUN
PY 2021
VL 13
IS 6
BP 547
EP +
DI 10.1136/neurintsurg-2020-016564
PG 6
WC Neuroimaging; Surgery
SC Neurosciences & Neurology; Surgery
GA SH6JY
UT WOS:000654242700015
PM 32843358
DA 2021-10-30
ER

PT J
AU Gurol, ME
   Sacco, RL
   McCullough, LD
AF Gurol, M. Edip
   Sacco, Ralph L.
   McCullough, Louise D.
TI Multiple Faces of Cerebral Small Vessel Diseases
SO STROKE
LA English
DT Article
DE arteriolosclerosis; atrial fibrillation; cerebral amyloid angiopathy;
   cerebral small vessel diseases; neuroimaging
ID INTRACRANIAL HEMORRHAGE; ATRIAL-FIBRILLATION; STROKE
C1 [Gurol, M. Edip] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02115 USA.
   [Sacco, Ralph L.] Univ Miami, Miller Sch Med, Dept Neurol, Coral Gables, FL 33124 USA.
   [McCullough, Louise D.] Univ Texas Hlth Sci Ctr Houston UTHlth, Dept Neurol, McGovern Med Sch, Houston, TX USA.
RP Gurol, ME (corresponding author), MGH Stroke Res Ctr, 175 Cambridge St,300, Boston, MA 02114 USA.
EM edip@mail.harvard.edu
FU National Institutes of Health [NIH]United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [NS083711,
   5R01NS09673004, 5R01AG026484]; NIHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [NS29993,
   NS40807, NS 086528, MD012467]; UM CTSA [UL1 TR002736]; Evelyn McKnight
   Brain Institute; Florida Department of Health; NIA-RFI [AG05843];
   National Institute of Neurological Disorders and Stroke [NINDS]United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Neurological Disorders &
   Stroke (NINDS) [R01 NS094543, NINDS-R01 NS103592]
FX We are supported by the following funding agencies/grants: Dr Gurol
   (National Institutes of Health [NIH] NS083711, 5R01NS09673004, and
   5R01AG026484); Dr Sacco (NIH NS29993, NS40807, NS 086528, MD012467, UM
   CTSA UL1 TR002736, Evelyn McKnight Brain Institute, Florida Department
   of Health); and Dr McCullough (NIA-RFI AG05843, National Institute of
   Neurological Disorders and Stroke [NINDS]-R01 NS094543, and NINDS-R01
   NS103592).
CR Banerjee G, 2019, J NEUROL, V266, P1250, DOI 10.1007/s00415-019-09256-6
   Corriveau RA, 2016, CELL MOL NEUROBIOL, V36, P281, DOI 10.1007/s10571-016-0334-7
   Eikelboom JW, 2017, NEW ENGL J MED, V377, P1319, DOI 10.1056/NEJMoa1709118
   Feigin VL, 2003, LANCET NEUROL, V2, P43, DOI 10.1016/S1474-4422(03)00266-7
   Gurol ME, 2020, STROKE, V51, P29, DOI 10.1161/STROKEAHA.119.024149
   Gurol ME, 2018, STROKE, V49, P247, DOI 10.1161/STROKEAHA.117.017081
   January CT, 2019, CIRCULATION, V140, pE125, DOI 10.1161/CIR.0000000000000665
   Jouvent E, 2020, STROKE, V51, P21, DOI 10.1161/STROKEAHA.119.024152
   Marini S, 2020, STROKE, V51, P12, DOI 10.1161/STROKEAHA.119.024151
   Marti-Fabregas J, 2019, NEUROLOGY, V92, pE2432, DOI 10.1212/WNL.0000000000007532
   Osmancik P, EUR SOC CARD SEPT 2
   Pasi M, 2020, STROKE, V51, P47, DOI 10.1161/STROKEAHA.119.024148
   Smith EE, 2020, STROKE, V51, P38, DOI 10.1161/STROKEAHA.119.024150
   Vickrey BG, 2013, STROKE, V44, P2338, DOI 10.1161/STROKEAHA.113.001196
   Wilson D, 2018, LANCET NEUROL, V17, P539, DOI 10.1016/S1474-4422(18)30145-5
NR 15
TC 1
Z9 4
U1 2
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0039-2499
EI 1524-4628
J9 STROKE
JI Stroke
PD JAN
PY 2020
VL 51
IS 1
BP 9
EP 11
DI 10.1161/STROKEAHA.119.027969
PG 3
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA JY2BK
UT WOS:000504225600009
PM 31752615
OA Green Accepted, Bronze
DA 2021-10-30
ER

PT J
AU Abecassis, IJ
   Saini, V
   Phillips, TJ
   Osbun, JW
   Martinez-Galdamez, M
   Nada, A
   Levitt, MR
   Crowley, RW
   Sattur, MG
   Spiotta, AM
   Luther, E
   Chen, SH
   Burks, J
   Jabbour, P
   Sweid, A
   Psychogios, MN
   Park, MS
   Yavagal, DR
   Peterson, EC
   Waqas, M
   Dossani, RH
   Davies, JM
   Brehm, A
   Selkirk, GD
   Fox, WC
   Abud, DG
   Fernandez, JG
   Arteaga, MS
   Starke, RM
AF Abecassis, Isaac Josh
   Saini, Vasu
   Phillips, Timothy John
   Osbun, Joshua W.
   Martinez-Galdamez, Mario
   Nada, Ahmed
   Levitt, Michael R.
   Crowley, R. Webster
   Sattur, Mithun G.
   Spiotta, Alejandro M.
   Luther, Evan
   Chen, Stephanie H.
   Burks, Joshua
   Jabbour, Pascal
   Sweid, Ahmad
   Psychogios, Marios N.
   Park, Min S.
   Yavagal, Dileep R.
   Peterson, Eric C.
   Waqas, Muhammad
   Dossani, Rimal Hanif
   Davies, Jason M.
   Brehm, Alex
   Selkirk, Gregory D.
   Fox, W. Christopher
   Abud, Daniel Giansante
   Fernandez, Jorge Galvan
   Arteaga, Miguel Schueller
   Starke, Robert M.
TI Upper extremity transvenous access for neuroendovascular procedures: an
   international multicenter case series
SO JOURNAL OF NEUROINTERVENTIONAL SURGERY
LA English
DT Article
DE angiography; intervention; technique
AB Background
   Radial artery access for transarterial procedures has gained recent traction in neurointerventional due to decreased patient morbidity, technical feasibility, and improved patient satisfaction. Upper extremity transvenous access (UETV) has recently emerged as an alternative strategy for the neurointerventionalist, but data are limited. Our objective was to quantify the use of UETV access in neurointerventions and to measure failure and complication rates.
   Methods
   An international multicenter retrospective review of medical records for patients undergoing UETV neurointerventions or diagnostic procedures was performed. We also present our institutional protocol for obtaining UETV and review the existing literature.
   Results
   One hundred and thirteen patients underwent a total of 147 attempted UETV procedures at 13 centers. The most common site of entry was the right basilic vein. There were 21 repeat puncture events into the same vein following the primary diagnostic procedure for secondary interventional procedures without difficulty. There were two minor complications (1.4%) and five failures (ie, conversion to femoral vein access) (3.4%).
   Conclusions
   UETV is safe and technically feasible for diagnostic and neurointerventional procedures. Further studies are needed to determine the benefit over alternative venous access sites and the effect on patient satisfaction.
C1 [Abecassis, Isaac Josh; Saini, Vasu; Nada, Ahmed; Luther, Evan; Chen, Stephanie H.; Burks, Joshua; Yavagal, Dileep R.; Peterson, Eric C.; Starke, Robert M.] Univ Miami, Miller Sch Med, Neurol Surg, Miami, FL 33136 USA.
   [Saini, Vasu; Yavagal, Dileep R.] Univ Miami, Neurol, Miami, FL USA.
   [Phillips, Timothy John; Selkirk, Gregory D.] Sir Charles Gairdner Hosp, Neurol Intervent & Imaging Serv Western Australia, Nedlands, WA, Australia.
   [Osbun, Joshua W.] Washington Univ, Sch Med, Neurosurg, St Louis, MO 63110 USA.
   [Martinez-Galdamez, Mario] Hosp Clin Univ Valladolid, Intervent Neuroradiol Endovasc Neurosurg, Valladolid, Spain.
   [Nada, Ahmed] Port Said Univ, Neurol Surg, Port Said, Egypt.
   [Levitt, Michael R.] Univ Washington, Sch Med, Neurol Surg, Seattle, WA 98195 USA.
   [Crowley, R. Webster] Rush Univ, Med Ctr, Dept Neurosurg, Chicago, IL 60612 USA.
   [Sattur, Mithun G.; Spiotta, Alejandro M.] Med Univ South Carolina, Neurosurg, Charleston, SC 29425 USA.
   [Jabbour, Pascal; Sweid, Ahmad] Thomas Jefferson Univ, Neurol Surg, Philadelphia, PA 19107 USA.
   [Psychogios, Marios N.; Brehm, Alex] Univ Hosp Basel, Dept Neuroradiol, Clin Radiol & Nucl Med, Basel, Switzerland.
   [Park, Min S.] Univ Virginia, Neurosurg, Charlottesville, VA USA.
   [Waqas, Muhammad; Dossani, Rimal Hanif; Davies, Jason M.] Univ Buffalo, Neurosurg, Buffalo, NY USA.
   [Fox, W. Christopher] Mayo Clin Hosp Jacksonville, Neurosurg, Jacksonville, FL USA.
   [Abud, Daniel Giansante] Med Sch Ribeirao Preto, Intervent Neuroradiol, Ribeirao Preto, SP, Brazil.
   [Fernandez, Jorge Galvan; Arteaga, Miguel Schueller] Hosp Clin Univ Valladolid, Intervent Neuroradiol & Endovasc Neurosurg, Valladolid, Castilla & Leon, Spain.
RP Abecassis, IJ (corresponding author), Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
EM jabecassis@mac.com
RI Saini, Vasu/AAA-9360-2019
OI Saini, Vasu/0000-0002-6796-5881; Martinez-Galdamez,
   Mario/0000-0002-8024-4712; Phillips, Timothy/0000-0001-9023-5986; Fox, W
   Christopher/0000-0002-7762-9902; Levitt, Michael/0000-0003-3612-3347
FU NREF; Joe Niekro Foundation; Brain Aneurysm Foundation; Bee Foundation;
   National Institute of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01NS111119-01A1];
   Miami Clinical and Translational Science Institute [UL1TR002736,
   KL2TR002737]; National Center for Advancing Translational SciencesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Advancing Translational
   Sciences (NCATS); National Institute on Minority Health and Health
   DisparitiesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Minority
   Health & Health Disparities (NIMHD)
FX RMS: research is supported by the NREF, Joe Niekro Foundation, Brain
   Aneurysm Foundation, Bee Foundation, and by the National Institute of
   Health (R01NS111119-01A1) and (UL1TR002736, KL2TR002737) through the
   Miami Clinical and Translational Science Institute, from the National
   Center for Advancing Translational Sciences and the National Institute
   on Minority Health and Health Disparities. Its contents are solely the
   responsibility of the authors and do not necessarily represent the
   official views of the NIH. RMS has an unrestricted research grant from
   Medtronic and has consulting and teaching agreements with Penumbra,
   Abbott, Medtronic, InNeuroCo, and Cerenovus.
CR Brunet MC, 2019, J NEUROINTERV SURG, V11, P710, DOI 10.1136/neurintsurg-2019-014718
   Chen SH, 2019, J NEUROINTERV SURG, V11, P796, DOI 10.1136/neurintsurg-2018-014620
   Forssmann W., 1929, KLIN WOCHENSCHR, V8, P2085, DOI DOI 10.1007/BF01875120
   Fernandez JG, 2021, J NEUROINTERV SURG, V13, P39, DOI 10.1136/neurintsurg-2020-016540
   Gilchrist IC, 2006, CATHETER CARDIO INTE, V67, P585, DOI 10.1002/ccd.20678
   Gilchrist IC, 2002, CATHETER CARDIO INTE, V55, P20, DOI 10.1002/ccd.10069
   Lo Ted S N, 2006, J Interv Cardiol, V19, P258, DOI 10.1111/j.1540-8183.2006.00139.x
   McCarthy DJ, 2019, WORLD NEUROSURG, V122, P355, DOI 10.1016/j.wneu.2018.11.030
   Ramos AD, 2020, INTERV NEURORADIOL, V26, P501, DOI 10.1177/1591019920920992
   Roule V, 2015, CAN J CARDIOL, V31, P1497, DOI 10.1016/j.cjca.2015.04.026
   Shah S, 2014, CATHETER CARDIO INTE, V84, P70, DOI 10.1002/ccd.25249
   Speiser B, 2017, CATHETER CARDIO INTE, V89, P658, DOI 10.1002/ccd.26573
   Stone JG, 2020, J NEUROINTERV SURG, V12, P993, DOI 10.1136/neurintsurg-2019-015642
   Valgimigli M, 2018, LANCET, V392, P835, DOI 10.1016/S0140-6736(18)31714-8
NR 14
TC 2
Z9 2
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1759-8478
EI 1759-8486
J9 J NEUROINTERV SURG
JI J. NeuroInterventional Surg.
PD APR
PY 2021
VL 13
IS 4
BP 357
EP 362
DI 10.1136/neurintsurg-2020-017102
PG 6
WC Neuroimaging; Surgery
SC Neurosciences & Neurology; Surgery
GA RB1NN
UT WOS:000631883200019
PM 33593801
DA 2021-10-30
ER

PT J
AU Lu, VM
   Chen, SH
   Young, CC
   Starke, RM
AF Lu, Victor M.
   Chen, Stephanie H.
   Young, Christopher C.
   Starke, Robert M.
TI Nature, content and shifts over time of the most impactful unruptured
   intracranial aneurysms articles: a bibliometric analysis
SO JOURNAL OF NEUROINTERVENTIONAL SURGERY
LA English
DT Article
DE aneurysm
ID HISTORY; MANAGEMENT; SURGERY; ERA
AB Background
   The management of unruptured intracranial aneurysms (UIAs) has evolved significantly over the last few decades. Our objective was to evaluate the 100 most cited UIA articles by bibliometric analysis to identify nature, content and shifts over time.
   Methods
   Elsevier's Scopus database was interrogated for the 100 most cited articles that focused on UIA. Older versus newer articles were compared, with categorical data analyzed using Pearson's Chi-square, and continuous data analyzed using Wilcoxon's rank-sum test.
   Results
   The 100 most cited articles were published between 1975 and 2015, with the majority of these reporting patient clinical outcomes (n=69). There were 47/69 (68%) articles that described surgical intervention, with 38/47 (81%) and 18/47 (38%) including endovascular and open approaches, respectively . Publications peaked in 2004 (n=8), and the most common country of correspondence was the United States (n=59). Compared to older articles, newer articles had statistically higher citation rates (P<0.01), higher number of authors (P<0.01) with more multiple institution collaborations (P=0.01), greater disclosures of funding (P<0.01), more focus on endovascular treatments (P=0.04), in more journals with a clinical, non-surgical focus (P<0.01) published under open access policies (P<0.01).
   Conclusions
   In the 100 most cited articles about UIAs to date, there is a distinct shift towards more co-authored efforts utilizing multi-institutional efforts focused on endovascular approaches supported by funding. The emergence of endovascular techniques has refreshed the need for more contemporary rupture risk prediction models and natural history data to validate current attitudes towards clinical management after these minimally invasive procedures for UIAs.
C1 [Lu, Victor M.] Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA.
   [Lu, Victor M.; Chen, Stephanie H.; Starke, Robert M.] Univ Miami, Dept Neurol Surg, Miami, FL USA.
   [Young, Christopher C.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA.
RP Lu, VM (corresponding author), Mayo Clin, Neurosurg, Rochester, MN 55905 USA.
EM lu.victor@mayo.edu
OI Young, Christopher/0000-0002-3679-3212
FU NREP; Brain Aneurysm Foundation; Bee Foundation; National Institute of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01NS111119--01A1]; Miami Clinical and
   Translational Science Institute, from the National Center for Advancing
   Translational Sciences [UL1TR002736, KL2TR002737]; National Institute on
   Minority Health and Health DisparitiesUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute on Minority Health & Health Disparities (NIMHD)
FX RMS research is supported by the NREF, Joe Niekro Foundation, Brain
   Aneurysm Foundation, Bee Foundation, and by National Institute of Health
   (R01NS111119--01A1) and (UL1TR002736, KL2TR002737) through the Miami
   Clinical and Translational Science Institute, from the National Center
   for Advancing Translational Sciences and the National Institute on
   Minority Health and Health Disparities. Its contents are solely the
   responsibility of the authors and do not necessarily represent the
   official views of the NIH. RMS has consulting and teaching agreements
   with Penumbra, Abbott, Medtronic, InNeuroCo and Cerenovus.
CR Asamoto S, 2017, WORLD NEUROSURG, V99, P145, DOI 10.1016/j.wneu.2016.11.079
   Bender MT, 2017, WORLD NEUROSURG, V106, P919, DOI [10.1016/j.wneu.2017.07.074, 10.1016/J.WNEU.2017.07.074]
   Brown RD, 2014, LANCET NEUROL, V13, P393, DOI 10.1016/S1474-4422(14)70015-8
   Cebral JR, 2011, AM J NEURORADIOL, V32, P145, DOI 10.3174/ajnr.A2419
   Cebral JR, 2011, AM J NEURORADIOL, V32, P264, DOI 10.3174/ajnr.A2274
   Cebral JR, 2005, IEEE T MED IMAGING, V24, P457, DOI 10.1109/TMI.2005.844159
   Cebral JR, 2005, AM J NEURORADIOL, V26, P2550
   Engele T, 2019, WORLD NEUROSURG, V125, P461, DOI 10.1016/j.wneu.2019.01.195
   Falagas ME, 2008, FASEB J, V22, P338, DOI 10.1096/fj.07-9492LSF
   Greving JP, 2014, LANCET NEUROL, V13, P59, DOI 10.1016/S1474-4422(13)70263-1
   JUVELA S, 1993, J NEUROSURG, V79, P174, DOI 10.3171/jns.1993.79.2.0174
   Juvela S, 2001, STROKE, V32, P485, DOI 10.1161/01.STR.32.2.485
   Juvela S, 2013, STROKE, V44, P2414, DOI 10.1161/STROKEAHA.113.001838
   Juvela S, 2008, J NEUROSURG, V108, P1052, DOI 10.3171/JNS/2008/108/5/1052
   Kassell NF, 2001, STROKE, V32, P603
   KASSELL NF, 1990, J NEUROSURG, V73, P37, DOI 10.3171/jns.1990.73.1.0037
   Khan Nickalus R, 2013, World Neurosurg, V80, P766, DOI 10.1016/j.wneu.2013.07.011
   Luther E, 2020, J NEUROINTERV SURG, V12, P682, DOI 10.1136/neurintsurg-2019-015418
   Mazur MD, 2018, J NEUROL NEUROSUR PS, V89, P277, DOI 10.1136/jnnp-2016-314477
   Millan RD, 2007, IEEE T MED IMAGING, V26, P1270, DOI 10.1109/TMI.2007.901008
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Mukhopadhyay S, 2019, J NEUROSURG, P1, DOI [10.3171/2018.10.JNS171723, DOI 10.3171/2018.10.JNS171723]
   Silva MA, 2019, WORLD NEUROSURG, V131, pE46, DOI 10.1016/j.wneu.2019.06.231
   Thompson BG, 2015, STROKE, V46, P2368, DOI 10.1161/STR.0000000000000070
   Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3
   Wiebers D, 1998, NEW ENGL J MED, V339, P1725, DOI 10.1056/nejm199812103392401
   Yasargil M G, 1975, Surg Neurol, V3, P7
   Yasuno K, 2010, NAT GENET, V42, P420, DOI 10.1038/ng.563
NR 28
TC 0
Z9 0
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1759-8478
EI 1759-8486
J9 J NEUROINTERV SURG
JI J. NeuroInterventional Surg.
PD FEB
PY 2021
VL 13
IS 2
DI 10.1136/neurintsurg-2020-016238
PG 6
WC Neuroimaging; Surgery
SC Neurosciences & Neurology; Surgery
GA QB6GZ
UT WOS:000614238000017
PM 32606102
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Ramos, AR
   Gangwisch, JE
AF Ramos, Alberto R.
   Gangwisch, James E.
TI Is sleep duration a risk factor for stroke?
SO NEUROLOGY
LA English
DT Editorial Material
ID LONG-SLEEP; HEALTH
AB A total of 50 to 70 million Americans have a sleep or circadian disorder, with widespread consequences for health and safety.(1) Sleep health has become a national priority and a goal of the Healthy People 2020 program.(2) Observational and experimental studies demonstrate that poor sleep can lead to adverse health consequences.(2,3) In particular, epidemiologic studies demonstrate associations between short sleep (5-6 hours) and long sleep (8-9 hours) durations with increased cardiovascular morbidity and mortality, compared to 7-8 hours of sleep.(3</SUP)
C1 [Ramos, Alberto R.] Univ Miami, Miller Sch Med, Dept Neurol, Coral Gables, FL 33124 USA.
   [Gangwisch, James E.] Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY USA.
RP Ramos, AR (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol, Coral Gables, FL 33124 USA.
EM aramos@med.miami.edu
RI Ramos, Alberto/X-4249-2019
OI Gangwisch, James/0000-0001-7042-3381
FU NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [KL2TR000461] Funding Source: NIH RePORTER; NCATS NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [KL2 TR000461] Funding Source: Medline; NIMHD NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Minority Health & Health Disparities
   (NIMHD) [L60 MD005231] Funding Source: Medline
CR Abe T, 2011, ATHEROSCLEROSIS, V217, P509, DOI 10.1016/j.atherosclerosis.2011.02.029
   Altevogt B.M., 2006, SLEEP DISORDERS SLEE
   Buysse DJ, 2014, SLEEP, V37, P9, DOI 10.5665/sleep.3298
   Cappuccio FP, 2011, EUR HEART J, V32, P1484, DOI 10.1093/eurheartj/ehr007
   Gangwisch JE, 2009, OBES REV, V10, P37, DOI 10.1111/j.1467-789X.2009.00663.x
   Knutson KL, 2006, SLEEP, V29, P878, DOI 10.1093/sleep/29.7.878
   Leng Y, 2015, NEUROLOGY, V84, P1072, DOI 10.1212/WNL.0000000000001371
   Patel SR, 2009, SLEEP, V32, P200, DOI 10.1093/sleep/32.2.200
   Ramos AR, 2013, AM J CARDIOL, V112, P599, DOI 10.1016/j.amjcard.2013.04.029
NR 9
TC 3
Z9 4
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD MAR 17
PY 2015
VL 84
IS 11
BP 1066
EP 1067
DI 10.1212/WNL.0000000000001374
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA CD9YU
UT WOS:000351458600004
PM 25716359
DA 2021-10-30
ER

PT J
AU Margolesky, J
   Saporta, M
AF Margolesky, Jason
   Saporta, Mario
TI Twenty-year-old African American woman with prion disease associated
   with the G114V PRNP variant
SO NEUROLOGY-GENETICS
LA English
DT Editorial Material
AB The c. 341G>T (p.G114V) variant of the prion protein gene (PRNP) has been reported in a Uruguayan and a Chinese family to cause an inheritable prion disease, albeit with incomplete penetrance. The condition is characterized by early-onset, relatively prolonged course, early neuropsychiatric symptoms, followed by pyramidal and extrapyramidal symptoms. We present a 20-year-old African American woman, with no family history of neurodegenerative disease, who presented with rapidly progressive cognitive decline and subsequent movement disorders who was found to have the PRNP variant.
C1 [Margolesky, Jason; Saporta, Mario] Univ Miami, Miller Sch Med, Coral Gables, FL 33124 USA.
RP Margolesky, J (corresponding author), Univ Miami, Miller Sch Med, Coral Gables, FL 33124 USA.
EM jhmargolesky@med.miami.edu
OI Margolesky, Jason/0000-0001-8976-2500
FU NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [KL2 TR002737] Funding Source: Medline
CR Liberski PP, 2012, J NEUROPATH EXP NEUR, V71, P92, DOI 10.1097/NEN.0b013e3182444efd
   Liu Z, 2010, ACTA NEUROL SCAND, V121, P377, DOI 10.1111/j.1600-0404.2009.01236.x
   Rodriguez MM, 2005, NEUROLOGY, V64, P1455, DOI 10.1212/01.WNL.0000158618.39527.93
   Ye Jing, 2008, J Med Case Rep, V2, P331, DOI 10.1186/1752-1947-2-331
NR 4
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 2376-7839
J9 NEUROL-GENET
JI Neurol.-Genet.
PD APR
PY 2018
VL 4
IS 2
AR e229
DI 10.1212/NXG.0000000000000229
PG 2
WC Genetics & Heredity; Clinical Neurology
SC Genetics & Heredity; Neurosciences & Neurology
GA GD4WK
UT WOS:000430503200008
PM 29577079
OA Green Published, gold
DA 2021-10-30
ER

PT J
AU Hadley, C
   Srinivasan, V
   Burkhardt, JK
   Johnson, J
   Luther, E
   Strickland, A
   Starke, RM
   Kan, P
AF Hadley, Caroline
   Srinivasan, Visish
   Burkhardt, Jan-Karl
   Johnson, Jeremiah
   Luther, Evan
   Strickland, Allison
   Starke, Robert M.
   Kan, Peter
TI Forming the Simmons Catheter for Cerebral Angiography and
   Neurointerventions via the Transradial Approach-Techniques and Operative
   Videos
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral angiography; Neurointerventions; Radial access; Simmons
   catheter
AB OBJECTIVE: Transradial access has been used increasingly for diagnostic cerebral angiography and neurointerventions. This requires development of a new skillset. Forming the Simmons catheter to catheterize the cerebral vessels is the most fundamental. Patient anatomy can complicate the formation of the Simmons catheter and the success of the procedure. The aim of this paper is to identify and describe the techniques that can be used transradially to facilitate the formation of the Simmons catheter for catheterization of the cerebral vessels.
   METHODS: We reviewed our series of 85 cerebral angiograms performed via a transradial approach at our institution between 2018 and 2019. We identified the techniques employed to form the Simmons catheter and compiled operative videos demonstrating each technique and its nuances.
   RESULTS: We have identified 7 techniques used to form the Simmons catheter from a right radial approach: in the ascending aorta, in the descending aorta, in the aortic arch, by deflecting the catheter off of the aortic valve with the glidewire in the common carotid artery, by deflecting the catheter off of the aortic valve with the glidewire in the descending aorta, and directly in the right or left common carotid arteries. We have identified that formation of the Simmons catheter from a left radial approach is most easily done in the descending aorta.
   CONCLUSIONS: Transradial artery access has become increasingly common in cerebral angiography and neurointerventions. We describe techniques used for the formation of the Simmons catheter, a fundamental skill necessary for transradial cerebral angiogram or neurointervention.
C1 [Hadley, Caroline; Srinivasan, Visish; Burkhardt, Jan-Karl; Johnson, Jeremiah] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA.
   [Luther, Evan; Strickland, Allison; Starke, Robert M.] Univ Miami, Miller Sch Med, Dept Neurosurg & Radiol, Miami, FL 33136 USA.
   [Kan, Peter] Univ Texas Med Branch, Dept Neurosurg, Galveston, TX 77555 USA.
RP Kan, P (corresponding author), Univ Texas Med Branch, Dept Neurosurg, Galveston, TX 77555 USA.
EM ptkan@utmb.edu
FU NREF; Joe Niekro Foundation; Brain Aneurysm Foundation; Bee Foundation;
   National Institutes of Health (NIH)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA
   [R01NS111119-01A1]; Miami Clinical and Translational Science Institute,
   from the National Center for Advancing Translational Sciences
   [UL1TR002736, KL2TR002737]; National Institute on Minority Health and
   Health DisparitiesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Minority Health & Health Disparities (NIMHD)
FX R. M. Starke's research is supported by the NREF, Joe Niekro Foundation,
   Brain Aneurysm Foundation, Bee Foundation, and the National Institutes
   of Health (NIH) (R01NS111119-01A1) and (UL1TR002736, KL2TR002737)
   through the Miami Clinical and Translational Science Institute, from the
   National Center for Advancing Translational Sciences and the National
   Institute on Minority Health and Health Disparities. Its contents are
   solely the responsibility of the authors and do not necessarily
   represent the official views of the NIH. R. M. Starke has consulting and
   teaching agreements with Penumbra, Abbott, Medtronic, InNeuroCo, and
   Cerenovus. The rest of the authors have no potential conflicts of
   interest to disclose.
CR Barros G, 2020, J NEUROINTERV SURG, V12, P427, DOI 10.1136/neurintsurg-2019-015386
   Brunet MC, 2020, J NEUROINTERV SURG, V12, P82, DOI 10.1136/neurintsurg-2019-015145
   Chase AJ, 2008, HEART, V94, P1019, DOI 10.1136/hrt.2007.136390
   Chivot C, 2019, AM J NEURORADIOL, V40, P1947, DOI 10.3174/ajnr.A6234
   Hung MJ, 2002, INT J CLIN PRACT, V56, P718
   Jolly SS, 2011, LANCET, V377, P1409, DOI 10.1016/S0140-6736(11)60404-2
   Patel T, 2010, CATHETER CARDIO INTE, V75, P268, DOI 10.1002/ccd.22159
   Satti SR, 2016, INTERV NEURORADIOL, V22, P227, DOI 10.1177/1591019915617314
   Snelling BM, 2018, J NEUROINTERV SURG, V10, P874, DOI 10.1136/neurintsurg-2017-013584
   Srinivasan VM, 2020, J NEUROINTERV SURG, V12, P893, DOI 10.1136/neurintsurg-2020-015835
   Stone JG, 2020, J NEUROINTERV SURG, V12, P993, DOI 10.1136/neurintsurg-2019-015642
   Wang Z., 2019, J INTERV MED, DOI [10.1016/j.jimed.2019.05.008, DOI 10.1016/J.JIMED.2019.05.008]
   Zussman BM, 2019, J NEUROINTERV SURG, V11, P1235, DOI 10.1136/neurintsurg-2019-014920
   Zussman BM, 2019, J NEUROINTERV SURG, V11, P1045, DOI 10.1136/neurintsurg-2018-014686
NR 14
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2021
VL 147
BP E351
EP E353
DI 10.1016/j.wneu.2020.12.054
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA QT7BH
UT WOS:000626743400041
PM 33346049
DA 2021-10-30
ER

PT J
AU Morris, TP
   Gomes-Osman, J
   Pascual-Leone, A
AF Morris, Timothy P.
   Gomes-Osman, Joyce
   Pascual-Leone, Alvaro
TI Author Response: Exercise for cognitive brain health in aging: A
   systematic review for an evaluation of dose
SO NEUROLOGY-CLINICAL PRACTICE
LA English
DT Editorial Material
RI Pascual-Leone, Alvaro/AAC-5101-2019
OI Pascual-Leone, Alvaro/0000-0001-8975-0382
FU NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [KL2 TR002737] Funding Source: Medline
CR Colcombe S, 2003, PSYCHOL SCI, V14, P125, DOI 10.1111/1467-9280.t01-1-01430
   Gomes-Osman J, 2018, NEUROL-CLIN PRACT, V8, P257, DOI 10.1212/CPJ.0000000000000460
   Smith PJ, 2010, PSYCHOSOM MED, V72, P239, DOI 10.1097/PSY.0b013e3181d14633
NR 3
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 2163-0402
EI 2163-0933
J9 NEUROL-CLIN PRACT
JI Neurol.-Clin. Pract.
PD OCT
PY 2018
VL 8
IS 5
BP 366
EP 368
DI 10.1212/CPJ.0000000000000532
PG 3
WC Clinical Neurology
SC Neurosciences & Neurology
GA HI8ZJ
UT WOS:000456744200027
PM 30564482
OA Green Published, Bronze
DA 2021-10-30
ER

PT J
AU Fisher, JS
   Rezk, A
   Nwefo, E
   Masterson, J
   Ramasamy, R
AF Fisher, John S.
   Rezk, Andrew
   Nwefo, Elie
   Masterson, John
   Ramasamy, Ranjith
TI Sexual Health in the Elderly Population
SO CURRENT SEXUAL HEALTH REPORTS
LA English
DT Article
DE Hypogonadism; Erectile dysfunction; Vulvovaginal atrophy; Sexual health
ID ERECTILE DYSFUNCTION; ANDROGEN DEFICIENCY; DESIRE DISORDER; OLDER MEN;
   RISK-FACTORS; DOUBLE-BLIND; TESTOSTERONE; THERAPY; PREVALENCE; MENOPAUSE
AB Purpose of ReviewAmong the growing elderly population, sexual health remains an important concern for individuals and couples. An understanding of the expected changes with aging and taking care of aging men and women is important for treating sexual dysfunction. Sexual health issues related to aging can be both linked between men and women and independent. The aim of this study is to determine the most important considerations that contribute to sexual satisfaction in men and women in this population.Recent FindingsMany factors contribute to the overall sexual health of men and women. Hypogonadism and erectile dysfunction both warrant thorough evaluation and consideration of treatment to improve sexual satisfaction. Underlying cardiovascular issues may be present in men presenting with these concerns. In addition to hormone replacement and traditional therapy for erectile dysfunction, therapeutic stem cell injection has shown some promise. Menopause, vaginal dryness, and dyspareunia play important roles in sexual satisfaction in women. Vaginal moisturizers, topical estrogen, and MonaLisa Touch laser therapy all may aid in improving these symptoms and ultimately sex lives. Studies have also demonstrated some benefit in populations with arousal disorders, which can be present in the elderly.SummaryMale patients often describe issues related to erectile dysfunction and hypogonadism, and issues with sexual drive. The pathophysiology is linked between these conditions and treatment of one component can provide symptom relief on a larger scale. A combination of testosterone therapy, lifestyle modifications, and therapy for erectile dysfunction relates to sexual satisfaction in men. In women, an understanding of the physiological process of menopause and offering therapy when indicated can improve the quality of sexual health and provide satisfaction to both patient and partner. While aging can diminish drive and desire, proper counseling and treatment may significantly benefit some patients. A multimodal approach involving the physician, patient, and partner will optimize care and may improve the quality of life in the elderly. This review outlines some normal changes due to aging and identifies some current treatment options for a population in which sexual health can be often ignored or dismissed. By understanding the available tools, a more comprehensive approach can be taken to achieve satisfaction in couples and individuals alike.
C1 [Fisher, John S.] Univ Tennessee, Dept Urol, Knoxville, TN 37996 USA.
   [Rezk, Andrew; Nwefo, Elie; Ramasamy, Ranjith] Univ Miami, Dept Urol, Miami, FL USA.
   [Masterson, John] Cedars Sinai Dept Urol, Beverly Hills, CA USA.
RP Fisher, JS (corresponding author), Univ Tennessee, Dept Urol, Knoxville, TN 37996 USA.
EM John.sam.fisher@gmail.com
FU NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [KL2 TR000461] Funding Source: Medline
CR American College of Obstetricians and Gynecologists, 2020, MEN RES OV AC
   American Psychiatric Association, DIAGN STAT MAN MENT, VFourth, DOI [10.1016/j.juro.2015.10.083, DOI 10.1016/J.JURO.2015.10.083]
   Amin S, 2001, RHEUM DIS CLIN N AM, V27, P19, DOI 10.1016/S0889-857X(05)70186-1
   [Anonymous], 2005, MENOPAUSE, V12, P497, DOI 10.1097/01.gme.0000177709.65944.b0
   Araujo AB, 2007, J CLIN ENDOCR METAB, V92, P4241, DOI 10.1210/jc.2007-1245
   Bahk JY, 2010, EXP CLIN TRANSPLANT
   Berg AO, 2003, AM FAM PHYSICIAN, V67, P358
   Berman JR, 2003, J UROLOGY, V170, P2333, DOI 10.1097/01.ju.0000090966.74607.34
   Bhasin S, 2006, J CLIN ENDOCR METAB, V91, P1995, DOI 10.1210/jc.2005-2847
   Bitzer J, 2008, J SEX MED, V5, P2027, DOI 10.1111/j.1743-6109.2008.00926.x
   Brock G, 2016, J UROLOGY, V195, P699, DOI 10.1016/j.juro.2015.10.083
   Cagnacci A, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/medicina55090602
   DAVIDSON JM, 1983, J CLIN ENDOCR METAB, V57, P71, DOI 10.1210/jcem-57-1-71
   Dusing R, 2005, DRUGS, V65, P773
   Edwards D, 2016, CLIMACTERIC, V19, P151, DOI 10.3109/13697137.2015.1124259
   Esposito K, 2004, JAMA-J AM MED ASSOC, V291, P2978, DOI 10.1001/jama.291.24.2978
   FELDMAN HA, 1994, J UROLOGY, V151, P54, DOI 10.1016/S0022-5347(17)34871-1
   Gott CM, 2001, HEALTH SOC CARE COMM, V9, P72, DOI 10.1046/j.1365-2524.2001.00285.x
   Gruenewald DA, 2003, J AM GERIATR SOC, V51, P101, DOI 10.1034/j.1601-5215.2002.51018.x
   Gruenwald I, 2013, THER ADV UROL, V5, P95, DOI 10.1177/1756287212470696
   Gunes S, 2016, J ASSIST REPROD GEN, V33, P441, DOI 10.1007/s10815-016-0663-y
   Ito TY, 2006, J SEX MARITAL THER, V32, P369, DOI 10.1080/00926230600834901
   Kingsberg S, 2007, J SEX MED, V4, P227, DOI 10.1111/j.1743-6109.2007.00449.x
   Kohler TS., 2008, UROLOGY
   Laumann EO, 1999, JAMA-J AM MED ASSOC, V281, P537, DOI 10.1001/jama.281.6.537
   Lee DM, 2016, J GERONTOL B-PSYCHOL, V71, P698, DOI 10.1093/geronb/gbw018
   Lee DM, 2016, ARCH SEX BEHAV, V45, P133, DOI 10.1007/s10508-014-0465-1
   Lin CS, 2012, STEM CELLS DEV, V21, P343, DOI 10.1089/scd.2011.0303
   Lindau ST, 2007, NEW ENGL J MED, V357, P762, DOI 10.1056/NEJMoa067423
   Mac Bride MB, 2010, MAYO CLIN PROC, V85, P87, DOI 10.4065/mcp.2009.0413
   Meuleman EJH, 2005, BJU INT, V95, P291, DOI 10.1111/j.1464-410X.2005.05285.x
   Meystre-Agustoni G, 2011, SWISS MED WKLY, V141, DOI 10.4414/smw.2011.13178
   Min JK, 2006, ARCH INTERN MED, V166, P201, DOI 10.1001/archinte.166.2.201
   Mitchell CM, 2018, OBSTET GYN CLIN N AM, V45, P737, DOI 10.1016/j.ogc.2018.07.010
   Montgomery Keith A, 2008, Psychiatry (Edgmont), V5, P50
   Nappi RE, 2012, CLIMACTERIC, V15, P36, DOI 10.3109/13697137.2011.647840
   Nastri CO, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009672.pub2
   North American Menopause Society, 2007, MEN PRACT CLIN GUID
   North American Menopause Society, 2007, MENOPAUSE, DOI [10.1097/gme.0b013-3180533b2a, DOI 10.1097/GME.0B013-3180533B2A]
   Parish Sharon J, 2016, Sex Med Rev, V4, P103, DOI 10.1016/j.sxmr.2015.11.009
   Portman DJ, 2013, MENOPAUSE, V20, P623, DOI 10.1097/gme.0b013e318279ba64
   Raheem OA, 2017, AM J MENS HEALTH, V11, P552, DOI 10.1177/1557988316630305
   Ramasamy R., 2014, REV UROL
   Rogers JH, 2010, CATHETER CARDIO INTE, V76, P882, DOI 10.1002/ccd.22646
   Roy S, 2004, AM J OBSTET GYNECOL, V190, P1272, DOI 10.1016/j.ajog.2003.12.015
   Salvatore S, 2014, CLIMACTERIC, V17, P363, DOI 10.3109/13697137.2014.899347
   Sarrel PM, 2002, FERTIL STERIL, V77, pS63
   Selvin E, 2007, AM J MED, V120, P151, DOI 10.1016/j.amjmed.2006.06.010
   SHERWIN BB, 1985, PSYCHOSOM MED, V47, P339, DOI 10.1097/00006842-198507000-00004
   Simon JA, 2014, MENOPAUSE, V21, P633, DOI [10.1097/gme.0000000000000134, 10.1097/GME.0000000000000134]
   Srinivas-Shankar U, 2010, J CLIN ENDOCR METAB, V95, P639, DOI 10.1210/jc.2009-1251
   Stock H, 2004, CLIN ORTHOP RELAT R, P143, DOI 10.1097/01.blo.0000136842.75487.e2
   Suckling J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001500.pub2
   SULTANA CJ, 1994, MATURITAS, V20, P129, DOI 10.1016/0378-5122(94)90008-6
   Travison TG, 2006, J CLIN ENDOCR METAB, V91, P2509, DOI 10.1210/jc.2005-2508
   Wu FCW, 2008, J CLIN ENDOCR METAB, V93, P2737, DOI 10.1210/jc.2007-1972
NR 56
TC 1
Z9 1
U1 0
U2 0
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1548-3584
EI 1548-3592
J9 CURR SEX HEALTH REP
JI Curr. Sex. Health Rep.
PD DEC
PY 2020
VL 12
IS 4
BP 381
EP 388
DI 10.1007/s11930-020-00278-0
PG 8
WC Urology & Nephrology
SC Urology & Nephrology
GA WA6XH
UT WOS:000703028000020
PM 33437223
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Sacco, RL
AF Sacco, Ralph L.
TI Stroke Vision 2020 Creating a Roadmap for the Next Decade
SO STROKE
LA English
DT Article
DE American Heart Association; interdisciplinary research; multimedia;
   patient care; social media
C1 [Sacco, Ralph L.] Univ Miami, Miller Sch Med, Dept Neurol, 1120 NW 14th St,Suite 1352, Miami, FL 33136 USA.
RP Sacco, RL (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol, 1120 NW 14th St,Suite 1352, Miami, FL 33136 USA.
EM rsacco@med.miami.edu
OI Sacco, Ralph/0000-0003-4629-684X
FU NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1 TR000460, UL1 TR002736] Funding
   Source: Medline; NIMHD NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Minority Health & Health Disparities (NIMHD) [R01 MD012467] Funding
   Source: Medline; NINDS NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Neurological Disorders & Stroke (NINDS) [U24 NS107267, R01 NS029993]
   Funding Source: Medline
CR Cordonnier Charlotte, 2019, Stroke, V50, pe149, DOI 10.1161/STROKEAHA.118.024788
NR 1
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0039-2499
EI 1524-4628
J9 STROKE
JI Stroke
PD MAR
PY 2020
VL 51
IS 3
BP 1040
EP 1046
DI 10.1161/STROKEAHA.120.028423
PG 7
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA LE8VP
UT WOS:000527004700062
PM 32073364
OA Bronze, Green Accepted
DA 2021-10-30
ER

PT J
AU Pinheiro, PS
   Callahan, KE
   Jones, PD
   Morris, C
   Ransdell, JM
   Kwon, D
   Brown, CP
   Kobetz, EN
AF Pinheiro, Paulo S.
   Callahan, Karen E.
   Jones, Patricia D.
   Morris, Cyllene
   Ransdell, Justine M.
   Kwon, Deukwoo
   Brown, Clyde Perry
   Kobetz, Erin N.
TI Liver cancer: A leading cause of cancer death in the United States and
   the role of the 1945-1965 birth cohort by ethnicity
SO JHEP REPORTS
LA English
DT Article
DE hepatocellular carcinoma; mortality; etiology; race; ethnicity; liver
   cancer; Hispanic; Asian; Caucasian; epidemiology
AB Background & Aims: Liver cancer is highly fatal and the most rapidly increasing cancer in the US, where chronic hepatitis C (HCV) infection is the leading etiology. HCV is particularly prevalent among the 1945-1965 birth cohort, the so-called "baby boomers". Focusing on this cohort-etiology link, we aim to characterize liver cancer patterns for 15 unique US populations: White, African American, Mexican Immigrant, Mexican American, Cuban and Chinese, among others.
   Methods: Individual-level mortality data from 2012-2016 from the health departments of 3 large states - California, Florida, New York - were pooled to compute liver cancer mortality rates for each racial/ethnic group and for 2 birth cohorts of interest: "1945-1965 cohort" and "older cohort".
   Results: Liver cancer is a major cause of cancer death among all US male groups and the leading cause in Mexican American men. Over 50% of the age-adjusted liver cancer mortality of White, African American, Mexican American, and Puerto Rican males came from the 1945-1965 birth cohort. In contrast, foreign-born male and all female populations had higher liver cancer mortality originating from the older cohort. Internationally, US White male baby boomers had a 49% higher liver cancer mortality rate than their counterparts in Europe (mortality rate ratio 1.49; 95% CI 1.43-1.56).
   Conclusions: Populations burdened disproportionately by liver cancer in the 1945-1965 cohort include US-born males who were all present in the US during the 1960s-1990s when significant HCV transmission took place; these individuals will benefit most from HCV screening and treatment. For the others, including all women, Asian subgroups, and especially burgeoning Hispanic immigrant populations, comprehensive liver cancer prevention efforts will require detailed study of the distribution of etiologies. (C) 2019 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).
C1 [Pinheiro, Paulo S.] Univ Miami, Dept Publ Hlth Sci, Div Epidemiol & Populat Hlth Sci, Sch Med, Miami, FL 33136 USA.
   [Callahan, Karen E.] Univ Nevada, Sch Publ Hlth, Las Vegas, NV 89154 USA.
   [Jones, Patricia D.] Univ Miami, Dept Med, Div Hepatol, Sch Med, Miami, FL 33136 USA.
   [Morris, Cyllene] Univ Calif Davis Hlth Syst, Inst Populat Hlth Improvement, CalCARES Program, Davis, CA USA.
   [Ransdell, Justine M.] Univ Miami, Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA.
   [Kwon, Deukwoo] Univ Miami, Dept Publ Hlth Sci, Biostat, Sch Med, Miami, FL 33136 USA.
   [Brown, Clyde Perry] Florida A&M Univ, Coll Pharm & Pharmaceut Sci, Tallahassee, FL 32307 USA.
   [Kobetz, Erin N.] Univ Miami, Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL USA.
RP Pinheiro, PS (corresponding author), Univ Miami, Sch Med, Div Epidemiol & Populat Hlth Sci, Sylvester Comprehens Canc Ctr,Dept Publ Hlth Sci, Clin Res Bldg,1120 NW 14th St, Miami, FL 33136 USA.
EM ppinheiro@med.miami.edu
FU NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1 TR002736] Funding Source: Medline
CR Altekruse SF, 2014, AM J GASTROENTEROL, V109, P542, DOI 10.1038/ajg.2014.11
   Alter MJ, 1999, J HEPATOL, V31, P88, DOI 10.1016/S0168-8278(99)80381-X
   Beste LA, 2015, GASTROENTEROLOGY, V149, P1471, DOI 10.1053/j.gastro.2015.07.056
   Borie F, 2009, EUR J GASTROEN HEPAT, V21, P984, DOI 10.1097/MEG.0b013e3283293783
   Chang ET, 2010, CANCER EPIDEM BIOMAR, V19, P3106, DOI 10.1158/1055-9965.EPI-10-0863
   Control ECfDPa, SYST REV HEP B C PRE
   Cronin KA, 2018, CANCER-AM CANCER SOC, V124, P2785, DOI 10.1002/cncr.31551
   Denniston MM, 2014, ANN INTERN MED, V160, P293, DOI 10.7326/M13-1133
   Edlin BR, 2015, HEPATOLOGY, V62, P1353, DOI 10.1002/hep.27978
   El-Serag HB, 2007, ARCH INTERN MED, V167, P1983, DOI 10.1001/archinte.167.18.1983
   El-Serag HB, 2012, GASTROENTEROLOGY, V142, P1264, DOI 10.1053/j.gastro.2011.12.061
   German RR, 2011, CANCER EPIDEMIOL, V35, P126, DOI 10.1016/j.canep.2010.09.005
   Goetze T, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.e12010
   Gomez SL, 2004, ETHNIC DIS, V14, P292
   Hall EW, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3133-6
   Howlader N, SURVEILLANCE EPIDEMI
   Jones PD, 2018, DIGEST DIS SCI, V63, P515, DOI 10.1007/s10620-017-4869-3
   Joy JB, 2016, LANCET INFECT DIS, V16, P698, DOI 10.1016/S1473-3099(16)00124-9
   Kanwal F, 2018, GASTROENTEROLOGY, V155, P1828, DOI 10.1053/j.gastro.2018.08.024
   Kanwal F, 2017, GASTROENTEROLOGY, V153, P996, DOI 10.1053/j.gastro.2017.06.012
   Kasting ML, 2018, CANCER EPIDEM BIOMAR, V27, P503, DOI 10.1158/1055-9965.EPI-17-0855
   Kershenobich D, 2011, LIVER INT, V31, P18, DOI 10.1111/j.1478-3231.2011.02538.x
   Kowdley KV, 2012, HEPATOLOGY, V56, P422, DOI 10.1002/hep.24804
   Kruszon-Moran Deanna, 2015, NCHS Data Brief, P1
   Kuniholm MH, 2014, J INFECT DIS, V209, P1585, DOI 10.1093/infdis/jit672
   Lazo M, 2015, CURR DIABETES REP, V15, DOI 10.1007/s11892-015-0674-6
   Makarova-Rusher OV, 2016, CANCER-AM CANCER SOC, V122, P1757, DOI 10.1002/cncr.29971
   Miller BA, 2008, CANCER CAUSE CONTROL, V19, P227, DOI 10.1007/s10552-007-9088-3
   Miller KD, 2018, CA-CANCER J CLIN, V68, P425, DOI 10.3322/caac.21494
   Momin BR, 2017, CANCER-AM CANCER SOC, V123, P5059, DOI 10.1002/cncr.30820
   Petrick JL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186643
   Pinheiro PS, 2018, CANCER EPIDEM BIOMAR, V27, P917, DOI 10.1158/1055-9965.EPI-18-0194
   Pinheiro PS, 2018, INT J CANCER, V142, P477, DOI 10.1002/ijc.31068
   Pinheiro PS, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3469-0
   Pinheiro PS, 2017, CANCER EPIDEM BIOMAR, V26, P376, DOI 10.1158/1055-9965.EPI-16-0684
   Pinheiro PS, 2016, CANCER CONTROL, V23, P347, DOI 10.1177/107327481602300406
   Pinheiro PS, 2009, CANCER EPIDEM BIOMAR, V18, P2162, DOI 10.1158/1055-9965.EPI-09-0329
   Pinheiro PS, 2019, DISAGGREGATED HISPAN
   Plummer M, 2016, LANCET GLOB HEALTH, V4, pE609, DOI 10.1016/S2214-109X(16)30143-7
   Rich NE, 2018, CLIN GASTROENTEROL H, V7
   Ruggles S, INTEGRATED PUBLIC US
   Ryerson AB, 2016, CANCER-AM CANCER SOC, V122, P1312, DOI 10.1002/cncr.29936
   Saab S, 2016, CLIN GASTROENTEROL H, V14, P5, DOI 10.1016/j.cgh.2015.05.001
   Schutte K, 2014, BMC GASTROENTEROL, V14, DOI 10.1186/1471-230X-14-117
   Smith Bryce D., 2012, Morbidity and Mortality Weekly Report, V61, P1
   United Nations Statistical Division, STAND COUNTR AR COD
   Vaeth PAC, 2012, ADDICT BEHAV, V37, P1029, DOI 10.1016/j.addbeh.2012.04.015
   Welzel TM, 2013, AM J GASTROENTEROL, V108, P1314, DOI 10.1038/ajg.2013.160
   World Health Organization (WHO), WHO MORT DAT
NR 49
TC 17
Z9 17
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2589-5559
J9 JHEP REP
JI JHEP Rep.
PD SEP
PY 2019
VL 1
IS 3
BP 162
EP 169
DI 10.1016/j.jhepr.2019.05.008
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA VJ9TI
UT WOS:000648541600005
PM 32039366
OA Green Published, gold
DA 2021-10-30
ER

PT J
AU Cayetano, SM
   Crandall, L
AF Cayetano, Shari Messinger
   Crandall, Lee
TI Paradox of success and public perspective: COVID-19 and the perennial
   problem of prevention
SO JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH
LA English
DT Letter
C1 [Cayetano, Shari Messinger] Univ Miami, Miller Sch Med, Publ Hlth Sci, Miami, FL 33136 USA.
   [Cayetano, Shari Messinger] Univ Miami, Miami, FL USA.
   [Crandall, Lee] Clemson Univ, Publ Hlth Sci, Clemson, SC USA.
RP Cayetano, SM (corresponding author), Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA.
EM smessinger@biostat.med.miami.edu
FU NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1 TR002736] Funding Source: Medline
NR 0
TC 3
Z9 3
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0143-005X
EI 1470-2738
J9 J EPIDEMIOL COMMUN H
JI J. Epidemiol. Community Health
PD AUG
PY 2020
VL 74
IS 8
BP 679
EP 679
DI 10.1136/jech-2020-214518
PG 1
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA NM6MQ
UT WOS:000568210100011
PM 32503891
OA Green Published, hybrid
DA 2021-10-30
ER

PT J
AU Drexler, Y
   Molina, J
   Mitrofanova, A
   Fornoni, A
   Merscher, S
AF Drexler, Yelena
   Molina, Judith
   Mitrofanova, Alla
   Fornoni, Alessia
   Merscher, Sandra
TI Sphingosine-1-Phosphate Metabolism and Signaling in Kidney Diseases
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Review
DE kidney disease; sphingosine-1-phosphate; ceramide; sphingolipid
   metabolism; sphingolipids
ID SPHINGOSINE 1-PHOSPHATE RECEPTOR; PROTEIN-COUPLED RECEPTOR;
   ISCHEMIA-REPERFUSION INJURY; RANDOMIZED CONTROLLED-TRIAL;
   HIGH-DENSITY-LIPOPROTEIN; 1ST PHASE 2A; CELL-MIGRATION; GROWTH-FACTOR;
   APOLIPOPROTEIN-M; ENDOPLASMIC-RETICULUM
AB In the past few decades, sphingolipids and sphingolipid metabolites have gained attention because of their essential role in the pathogenesis and progression of kidney diseases. Studies in models of experimental and clinical nephropathies have described accumulation of sphingolipids and sphingolipid metabolites, and it has become clear that the intracellular sphingolipid composition of renal cells is an important determinant of renal function. Proper function of the glomerular filtration barrier depends heavily on the integrity of lipid rafts, which include sphingolipids as key components. In addition to contributing to the structural integrity of membranes, sphingolipid metabolites, such as sphingosine-1-phosphate (S1P), play important roles as second messengers regulating biologic processes, such as cell growth, differentiation, migration, and apoptosis. This review will focus on the role of S1P in renal cells and how aberrant extracellular and intracellular S1P signaling contributes to the pathogenesis and progression of kidney diseases.
C1 [Drexler, Yelena; Molina, Judith; Mitrofanova, Alla; Fornoni, Alessia; Merscher, Sandra] Univ Miami, Peggy & Harold Katz Family Drug Discovery Ctr, Miller Sch Med, Katz Family Div Nephrol & Hypertens,Dept Med, Miami, FL USA.
RP Drexler, Y (corresponding author), Univ Miami, Katz Family Div Nephrol & Hypertens, Peggy & Harold Katz Family Drug Discovery Ctr, 1120 NW 14th St,8th Floor, Miami, FL 33136 USA.; Merscher, S (corresponding author), Univ Miami, Katz Family Div Nephrol & Hypertens, Peggy & Harold Katz Family Drug Discovery Ctr, 1580 NW 10th Ave, Miami, FL 33136 USA.
EM yrd6@med.miami.edu; smerscher@med.miami.edu
OI Merscher, Sandra/0000-0002-4757-7494
FU National Center for Advancing Translational Sciences (Miami Clinical
   Translational Science Institute) [UL1TR002736]; National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01DK117599, R01DK104753, R01CA227493,
   U54DK083912, UM1DK100846, U01DK116101]; Boehringer Ingelheim
   grantBoehringer Ingelheim [GR014854]; National Institute on Minority
   Health and Health Disparities grant [UL1TR000460]
FX Y. Drexler is supported by National Center for Advancing Translational
   Sciences grant UL1TR002736 (Miami Clinical Translational Science
   Institute). A. Fornoni and S. Merscher are supported by National
   Institutes of Health grants R01DK117599, R01DK104753, and R01CA227493,
   and by Boehringer Ingelheim grant GR014854. A. Fornoni is supported by
   National Institutes of Health grants U54DK083912, UM1DK100846,
   U01DK116101 and by National Institute on Minority Health and Health
   Disparities grant UL1TR000460.
CR Ahmad A, 2017, FASEB J, V31, P771, DOI 10.1096/fj.201600618R
   Airola Michael V, 2013, Handb Exp Pharmacol, P57, DOI 10.1007/978-3-7091-1368-4_3
   Alderton F, 2001, J BIOL CHEM, V276, P28578, DOI 10.1074/jbc.M102771200
   Allende ML, 2011, J BIOL CHEM, V286, P7348, DOI 10.1074/jbc.M110.171819
   Allende ML, 2010, J EXP MED, V207, P1113, DOI 10.1084/jem.20092210
   Allende ML, 2004, J BIOL CHEM, V279, P52487, DOI 10.1074/jbc.M406512200
   Alperovich G, 2007, LUPUS, V16, P18, DOI 10.1177/0961203306073136
   Alvarez SE, 2010, NATURE, V465, P1084, DOI 10.1038/nature09128
   Atkinson D, 2017, NEUROLOGY, V88, P533, DOI 10.1212/WNL.0000000000003595
   Awad AS, 2011, KIDNEY INT, V79, P1090, DOI 10.1038/ki.2010.544
   Awad AS, 2006, AM J PHYSIOL-RENAL, V290, pF1516, DOI 10.1152/ajprenal.00311.2005
   Bajwa A, 2015, J AM SOC NEPHROL, V26, P908, DOI 10.1681/ASN.2013121351
   Bajwa A, 2010, J AM SOC NEPHROL, V21, P955, DOI 10.1681/ASN.2009060662
   Begagne E, 2014, J CLIN INVEST, V124, P5368, DOI 10.1172/JCI74188
   Bekpinar S, 2015, CLIN BIOCHEM, V48, P1264, DOI 10.1016/j.clinbiochem.2015.08.001
   Berger JR, 2018, NEUROLOGY, V90, pE1815, DOI 10.1212/WNL.0000000000005529
   BERNARDO K, 1995, J BIOL CHEM, V270, P11098, DOI 10.1074/jbc.270.19.11098
   Billich A, 2005, CELL SIGNAL, V17, P1203, DOI 10.1016/j.cellsig.2004.12.005
   Billich A, 2003, J BIOL CHEM, V278, P47408, DOI 10.1074/jbc.M307687200
   Bjorklund S, 2005, MOL CELL ENDOCRINOL, V231, P65, DOI 10.1016/j.mce.2004.12.001
   Blaho VA, 2015, NATURE, V523, P342, DOI 10.1038/nature14462
   Bomback AS, 2016, CLIN J AM SOC NEPHRO, V11, P547, DOI 10.2215/CJN.01880216
   Breitz H, 2004, CANCER BIOTHER RADIO, V19, P359, DOI 10.1089/1084978041425106
   Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200
   Brunskill EW, 2012, BMC NEPHROL, V13, DOI 10.1186/1471-2369-13-70
   Buehrer BM, 1996, BBA-LIPID LIPID MET, V1303, P233, DOI 10.1016/0005-2760(96)00092-6
   Camerer E, 2009, J CLIN INVEST, V119, P1871, DOI 10.1172/JCI38575
   Cartier A, 2019, SCIENCE, V366, P323, DOI 10.1126/science.aar5551
   CASSADY JR, 1995, INT J RADIAT ONCOL, V31, P1249, DOI 10.1016/0360-3016(94)00428-N
   Checa A, 2017, LUPUS, V26, P1023, DOI 10.1177/0961203316686707
   Chen PF, 1998, KIDNEY INT, V54, P1470, DOI 10.1046/j.1523-1755.1998.00162.x
   Chiba K, 2006, CELL MOL IMMUNOL, V3, P11
   Chipuk JE, 2012, CELL, V148, P988, DOI 10.1016/j.cell.2012.01.038
   Christoffersen C, 2011, P NATL ACAD SCI USA, V108, P9613, DOI 10.1073/pnas.1103187108
   Coelho RP, 2007, J PHARMACOL EXP THER, V323, P626, DOI 10.1124/jpet.107.123927
   Cohen JA, 2010, NEW ENGL J MED, V362, P402, DOI 10.1056/NEJMoa0907839
   Coppo R, 2017, J NEPHROL, V30, P339, DOI 10.1007/s40620-016-0360-z
   Daehn IS, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00076
   Dai L, 2014, MOL ENDOCRINOL, V28, P197, DOI 10.1210/me.2013-1237
   Ding G, 2007, J BIOL CHEM, V282, P27493, DOI 10.1074/jbc.M701641200
   Drouillard A, 2018, J ALLERGY CLIN IMMUN, V141, P2265, DOI 10.1016/j.jaci.2017.11.022
   Edsall LC, 2001, J NEUROCHEM, V76, P1573, DOI 10.1046/j.1471-4159.2001.00164.x
   Edsall LC, 1997, J NEUROSCI, V17, P6952
   Engelmann B, 1996, BIOCHEM J, V315, P781, DOI 10.1042/bj3150781
   Faber K, 2004, J LIPID RES, V45, P1272, DOI 10.1194/jlr.M300451-JLR200
   Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363
   Fornoni A, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002231
   Forrest M, 2004, J PHARMACOL EXP THER, V309, P758, DOI 10.1124/jpet.103.062828
   Frej C, 2015, ANAL BIOANAL CHEM, V407, P8533, DOI 10.1007/s00216-015-9008-4
   Fryer RM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052985
   Fu J, 2019, J AM SOC NEPHROL, V30, P533, DOI 10.1681/ASN.2018090896
   Galvani S, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa2581
   Geoffroy K, 2005, FEBS LETT, V579, P1249, DOI 10.1016/j.febslet.2004.12.094
   Gergely P, 2012, BRIT J PHARMACOL, V167, P1035, DOI 10.1111/j.1476-5381.2012.02061.x
   GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543
   GOODEMOTE KA, 1995, J BIOL CHEM, V270, P10272, DOI 10.1074/jbc.270.17.10272
   Graler MH, 1998, GENOMICS, V53, P164, DOI 10.1006/geno.1998.5491
   Graler MH, 2003, J CELL BIOCHEM, V89, P507, DOI 10.1002/jcb.10537
   Hanel P, 2007, FASEB J, V21, P1202, DOI 10.1096/fj.06-7433com
   Hait NC, 2007, J BIOL CHEM, V282, P12058, DOI 10.1074/jbc.M609559200
   Hait NC, 2006, BBA-BIOMEMBRANES, V1758, P2016, DOI 10.1016/j.bbamem.2006.08.007
   Hait NC, 2009, SCIENCE, V325, P1254, DOI 10.1126/science.1176709
   Ham A, 2014, KIDNEY INT, V85, P807, DOI 10.1038/ki.2013.345
   Hanada K, 2003, NATURE, V426, P803, DOI 10.1038/nature02188
   Hanafusa N, 2002, NEPHROL DIAL TRANSPL, V17, P580, DOI 10.1093/ndt/17.4.580
   Hao JA, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4604
   Hemdan NYA, 2016, EUR J IMMUNOL, V46, P2767, DOI 10.1002/eji.201646417
   Hengst JA, 2009, ARCH BIOCHEM BIOPHYS, V492, P62, DOI 10.1016/j.abb.2009.09.013
   Heringdorf DM, 1999, FEBS LETT, V461, P217, DOI 10.1016/S0014-5793(99)01463-5
   Hill RZ, 2018, J NEUROSCI, V38, P7833, DOI 10.1523/JNEUROSCI.1266-18.2018
   HIRSCHBERG K, 1993, BIOCHEM J, V290, P751, DOI 10.1042/bj2900751
   Hisano Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038941
   Hla T, 2008, BBA-MOL CELL BIOL L, V1781, P477, DOI 10.1016/j.bbalip.2008.07.003
   Hofmann LP, 2008, BIOL CHEM, V389, P1399, DOI 10.1515/BC.2008.160
   Hou JC, 2017, AM J RESP CRIT CARE, V196, P1559, DOI [10.1164/rccm.201701-0241OC, 10.1164/rccm.201701-0241oc]
   Huang KP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043874
   Huitema K, 2004, EMBO J, V23, P33, DOI 10.1038/sj.emboj.7600034
   Huwiler A, 2006, BBA-MOL CELL BIOL L, V1761, P367, DOI 10.1016/j.bbalip.2006.02.007
   Igarashi N, 2003, J BIOL CHEM, V278, P46832, DOI 10.1074/jbc.M306577200
   Im DS, 2004, J PHARMACOL SCI, V95, P284, DOI 10.1254/jphs.FPJ04007X
   Im DS, 2000, J BIOL CHEM, V275, P14281, DOI 10.1074/jbc.275.19.14281
   Im DS, 1997, AM J PHYSIOL-GASTR L, V272, pG1091, DOI 10.1152/ajpgi.1997.272.5.G1091
   Imasawa T, 2010, EXP TOXICOL PATHOL, V62, P53, DOI 10.1016/j.etp.2009.02.068
   Ishii M, 2009, NATURE, V458, P524, DOI 10.1038/nature07713
   Jaillard C, 2005, J NEUROSCI, V25, P1459, DOI 10.1523/JNEUROSCI.4645-04.2005
   Jain A, 2017, J CELL SCI, V130, P360, DOI 10.1242/jcs.194191
   Jain N, 2012, NEUROLOGY, V78, P672, DOI 10.1212/WNL.0b013e318248deea
   Janecke AR, 2017, HUM MUTAT, V38, P365, DOI 10.1002/humu.23192
   Jenne CN, 2009, J EXP MED, V206, P2469, DOI 10.1084/jem.20090525
   Jiang LI, 2007, J BIOL CHEM, V282, P10576, DOI 10.1074/jbc.M609695200
   Jo EJ, 2005, CHEM BIOL, V12, P703, DOI 10.1016/j.chembiol.2005.04.019
   Jo SK, 2008, KIDNEY INT, V73, P1220, DOI 10.1038/ki.2008.34
   Jo SK, 2009, KIDNEY INT, V75, P167, DOI 10.1038/ki.2008.400
   Jolly PS, 2004, J EXP MED, V199, P959, DOI 10.1084/jem.20030680
   Kahan BD, 2003, TRANSPLANTATION, V76, P1079, DOI 10.1097/01.TP.0000084822.01372.AC
   Kajimoto T, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aat6662
   Kappos L, 2006, NEW ENGL J MED, V355, P1124, DOI 10.1056/NEJMoa052643
   Kappos L, 2014, MULT SCLER RELAT DIS, V3, P494, DOI 10.1016/j.msard.2014.03.002
   Kappos L, 2010, NEW ENGL J MED, V362, P387, DOI 10.1056/NEJMoa0909494
   Katsuma S, 2002, GENES CELLS, V7, P1217, DOI 10.1046/j.1365-2443.2002.00594.x
   Katsuma S., 2001, Pharmacogenomics Journal, V1, P211
   Kawahara A, 2009, SCIENCE, V323, P524, DOI 10.1126/science.1167449
   Keul P, 2011, CIRC RES, V108, P314, DOI 10.1161/CIRCRESAHA.110.235028
   Kihara A, 2006, J BIOL CHEM, V281, P4532, DOI 10.1074/jbc.M510308200
   Kihara A, 2004, J BIOL CHEM, V279, P49243, DOI 10.1074/jbc.M405915200
   Kim M, 2010, AM J NEPHROL, V31, P353, DOI 10.1159/000298339
   Kim M, 2007, AM J PHYSIOL-RENAL, V293, pF1827, DOI 10.1152/ajprenal.00290.2007
   Klawitter S, 2007, BRIT J PHARMACOL, V150, P271, DOI 10.1038/sj.bjp.0706983
   Kleinwort A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020391
   Kleuser B, 1998, CANCER RES, V58, P1817
   Kleuser B, 2001, FEBS LETT, V503, P85, DOI 10.1016/S0014-5793(01)02697-7
   Kobayashi N, 2006, J LIPID RES, V47, P614, DOI 10.1194/jlr.M500468-JLR200
   Kobayashi N, 2009, J BIOL CHEM, V284, P21192, DOI 10.1074/jbc.M109.006163
   Koch A, 2015, BIOL CHEM, V396, P803, DOI 10.1515/hsz-2014-0288
   Koch A, 2013, BBA-MOL CELL BIOL L, V1831, P1634, DOI 10.1016/j.bbalip.2013.07.011
   Koch M, 2016, TRANSPL IMMUNOL, V35, P12, DOI 10.1016/j.trim.2016.01.003
   Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722
   Kono M, 2004, J BIOL CHEM, V279, P29367, DOI 10.1074/jbc.M403937200
   Kupperman E, 2000, NATURE, V406, P192, DOI 10.1038/35018092
   Kurano M, 2020, DIABETES, V69, P867, DOI 10.2337/db19-0811
   Kurano M, 2019, FASEB J, V33, P5181, DOI 10.1096/fj.201801748R
   Kurano M, 2018, THROMB HAEMOSTASIS, V118, P1021, DOI 10.1055/s-0038-1641750
   Lai LW, 2007, KIDNEY INT, V71, P1223, DOI 10.1038/sj.ki.5002203
   Lamour NF, 2007, J LIPID RES, V48, P1293, DOI 10.1194/jlr.M700083-JLR200
   Lan T, 2011, MOL ENDOCRINOL, V25, P2094, DOI 10.1210/me.2011-0095
   Lan TA, 2010, ARCH BIOCHEM BIOPHYS, V502, P112, DOI 10.1016/j.abb.2010.07.012
   Laychock SG, 2006, ENDOCRINOLOGY, V147, P4705, DOI 10.1210/en.2006-0456
   Le Stunff H, 2002, J BIOL CHEM, V277, P8920, DOI 10.1074/jbc.M109968200
   Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552
   Lee MJ, 1996, J BIOL CHEM, V271, P11272, DOI 10.1074/jbc.271.19.11272
   Lee MJ, 2001, MOL CELL, V8, P693, DOI 10.1016/S1097-2765(01)00324-0
   Lee SY, 2011, NEPHROLOGY, V16, P163, DOI 10.1111/j.1440-1797.2010.01386.x
   Lee YM, 2007, PROSTAG OTH LIPID M, V84, P154, DOI 10.1016/j.prostaglandins.2007.08.001
   Li Q, 2015, EXP PHYSIOL, V100, P95, DOI 10.1113/expphysiol.2014.082149
   Li X, 2020, AM J NEPHROL, V51, P1, DOI 10.1159/000502855
   Liao JL, 2020, SCI DATA, V7, DOI 10.1038/s41597-019-0351-8
   Lien YHH, 2006, KIDNEY INT, V69, P1601, DOI 10.1038/sj.ki.5000360
   Liu CH, 1999, MOL BIOL CELL, V10, P1179, DOI 10.1091/mbc.10.4.1179
   Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200
   Liu H, 2003, J BIOL CHEM, V278, P40330, DOI 10.1074/jbc.M304455200
   Liu XJ, 2016, EXP BIOL MED, V241, P265, DOI 10.1177/1535370215605586
   Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905
   Lovric S, 2017, J CLIN INVEST, V127, P912, DOI 10.1172/JCI89626
   Maceyka M, 2005, J BIOL CHEM, V280, P37118, DOI 10.1074/jbc.M502207200
   Maceyka M, 2002, BBA-MOL CELL BIOL L, V1585, P193, DOI 10.1016/S1388-1981(02)00341-4
   Maceyka M, 2012, TRENDS CELL BIOL, V22, P50, DOI 10.1016/j.tcb.2011.09.003
   Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238
   Mandala SM, 2000, P NATL ACAD SCI USA, V97, P7859, DOI 10.1073/pnas.120146897
   MANDON EC, 1992, J BIOL CHEM, V267, P11144
   Mao CG, 2001, J BIOL CHEM, V276, P26577, DOI 10.1074/jbc.M102818200
   Mao CG, 2003, J BIOL CHEM, V278, P31184, DOI 10.1074/jbc.M303875200
   Martini S, 2007, AM J PHYSIOL-RENAL, V292, pF1761, DOI 10.1152/ajprenal.00253.2006
   Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284
   Meadows KRT, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193236
   Mechtcheriakova D, 2007, CELL SIGNAL, V19, P748, DOI 10.1016/j.cellsig.2006.09.004
   Memon AA, 2014, NUTR METAB CARDIOVAS, V24, P1174, DOI 10.1016/j.numecd.2014.05.007
   Miller AV, 2008, MOL CELL BIOL, V28, P4142, DOI 10.1128/MCB.01465-07
   Mitra P, 2006, P NATL ACAD SCI USA, V103, P16394, DOI 10.1073/pnas.0603734103
   Mitrofanova A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10584-4
   Mitroi DN, 2017, AUTOPHAGY, V13, P885, DOI 10.1080/15548627.2017.1291471
   Miyawaki S, 1997, NEPHRON, V76, P201, DOI 10.1159/000190169
   Mizugishi K, 2005, MOL CELL BIOL, V25, P11113, DOI 10.1128/MCB.25.24.11113-11121.2005
   Morizane R, 2015, NAT BIOTECHNOL, V33, P1193, DOI 10.1038/nbt.3392
   Mousseau Y, 2012, BIOCHIMIE, V94, P2523, DOI 10.1016/j.biochi.2012.07.002
   Mundel P, 1997, EXP CELL RES, V236, P248, DOI 10.1006/excr.1997.3739
   Nagahashi M, 2013, FASEB J, V27, P1001, DOI 10.1096/fj.12-219618
   Nava VE, 2002, EXP CELL RES, V281, P115, DOI 10.1006/excr.2002.5658
   Neubauer HA, 2013, FEBS J, V280, P5317, DOI 10.1111/febs.12314
   Nijnik A, 2012, J IMMUNOL, V189, P102, DOI 10.4049/jimmunol.1200282
   Novgorodov AS, 2007, FASEB J, V21, P1503, DOI 10.1096/fj.06-7420com
   Okamoto H, 1999, BIOCHEM BIOPH RES CO, V260, P203, DOI 10.1006/bbrc.1999.0886
   Okamoto H, 2000, MOL CELL BIOL, V20, P9247, DOI 10.1128/MCB.20.24.9247-9261.2000
   Okazaki H, 2002, J RHEUMATOL, V29, P707
   OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0
   Olivera A, 2006, J BIOL CHEM, V281, P2515, DOI 10.1074/jbc.M508931200
   Osawa Y, 2001, J IMMUNOL, V167, P173, DOI 10.4049/jimmunol.167.1.173
   Osborne N, 2008, CURR BIOL, V18, P1882, DOI 10.1016/j.cub.2008.10.061
   Oskouian B, 2006, P NATL ACAD SCI USA, V103, P17384, DOI 10.1073/pnas.0600050103
   Paik JH, 2001, J BIOL CHEM, V276, P11830, DOI 10.1074/jbc.M009422200
   Pankratz N, 2016, NAT GENET, V48, P867, DOI 10.1038/ng.3607
   Pappu R, 2007, SCIENCE, V316, P295, DOI 10.1126/science.1139221
   Park J, 2018, SCIENCE, V360, P758, DOI 10.1126/science.aar2131
   Park SW, 2012, J AM SOC NEPHROL, V23, P266, DOI 10.1681/ASN.2011050503
   Park SW, 2011, KIDNEY INT, V80, P1315, DOI 10.1038/ki.2011.281
   Patmanathan SN, 2015, J CELL MOL MED, V19, P2329, DOI 10.1111/jcmm.12635
   Patyna S, 2019, PROSTAG OTH LIPID M, V144, DOI 10.1016/j.prostaglandins.2019.106348
   Perry HM, 2016, J AM SOC NEPHROL, V27, P3383, DOI 10.1681/ASN.2015080922
   Peters H, 2004, KIDNEY INT, V66, P1434, DOI 10.1111/j.1523-1755.2004.00906.x
   Pitson SM, 2003, EMBO J, V22, P5491, DOI 10.1093/emboj/cdg540
   Pitson SM, 2005, J EXP MED, V201, P49, DOI 10.1084/jem.20040559
   Prasad R, 2017, J CLIN INVEST, V127, P942, DOI 10.1172/JCI90171
   Pyne S, 2016, PROG LIPID RES, V62, P93, DOI 10.1016/j.plipres.2016.03.001
   Reiss U, 2004, J BIOL CHEM, V279, P1281, DOI 10.1074/jbc.M309646200
   Ren SY, 2009, KIDNEY INT, V76, P857, DOI 10.1038/ki.2009.297
   Ryu Y, 2002, CIRC RES, V90, P325, DOI 10.1161/hh0302.104455
   Saleem MA, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133630
   Salvadori M, 2006, AM J TRANSPLANT, V6, P2912, DOI 10.1111/j.1600-6143.2006.01552.x
   Sanna MG, 2004, J BIOL CHEM, V279, P13839, DOI 10.1074/jbc.M311743200
   Saxena V, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36921-z
   Schulze T, 2011, FASEB J, V25, P4024, DOI 10.1096/fj.10-179028
   Schwab SR, 2005, SCIENCE, V309, P1735, DOI 10.1126/science.1113640
   Selvam SP, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa4998
   Shimeno H, 1998, LIPIDS, V33, P601, DOI 10.1007/s11745-998-0246-2
   SHIMENO H, 1995, BIOL PHARM BULL, V18, P1335
   Shu XD, 2002, MOL CELL BIOL, V22, P7758, DOI 10.1128/MCB.22.22.7758-7768.2002
   Siddiqi FS, 2013, DIABETES, V62, P3647, DOI 10.2337/db13-0795
   Snider AJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053521
   Sorensen IMH, 2018, ATHEROSCLEROSIS, V275, P304, DOI 10.1016/j.atherosclerosis.2018.06.815
   Spiegel S, 2000, ANN NY ACAD SCI, V905, P54
   STOFFEL W, 1969, H-S Z PHYSIOL CHEM, V350, P1233, DOI 10.1515/bchm2.1969.350.2.1233
   Strub GM, 2011, FASEB J, V25, P600, DOI 10.1096/fj.10-167502
   Su K, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/3701385
   Sugahara K, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/5821589
   Sugimoto N, 2003, MOL CELL BIOL, V23, P1534, DOI 10.1128/MCB.23.5.1534-1545.2003
   Sukocheva O, 2006, J CELL BIOL, V173, P301, DOI 10.1083/jcb.200506033
   Sun XJ, 2018, J CELL MOL MED, V22, P1769, DOI 10.1111/jcmm.13458
   Sun XJ, 2017, NEPHROL DIAL TRANSPL, V32, P1313, DOI 10.1093/ndt/gfw427
   SUTHANTHIRAN M, 1994, NEW ENGL J MED, V331, P365, DOI 10.1056/NEJM199408113310606
   Sutherland CM, 2006, J BIOL CHEM, V281, P11693, DOI 10.1074/jbc.M601042200
   Suzuki S, 1998, TRANSPLANT INT, V11, P95, DOI 10.1007/s001470050111
   Swendeman SL, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aal2722
   Takasato M, 2015, NATURE, V526, P564, DOI 10.1038/nature15695
   Tanfin Z, 2011, CELL SIGNAL, V23, P1997, DOI 10.1016/j.cellsig.2011.07.010
   Tani M, 2005, J LIPID RES, V46, P2458, DOI 10.1194/jlr.M500268-JLR200
   Tani M, 2000, J BIOL CHEM, V275, P3462, DOI 10.1074/jbc.275.5.3462
   Tedesco-Silva H, 2005, TRANSPLANTATION, V79, P1553, DOI 10.1097/01.TP.0000121761.02129.A6
   Tedesco-Silva H, 2004, TRANSPLANTATION, V77, P1826, DOI 10.1097/01.tp.0000121761.02129.a6
   Tedesco-Silva H, 2006, TRANSPLANTATION, V82, P1689, DOI 10.1097/01.tp.0000251718.95622.b3
   Ueda H, 2005, TRANSPL IMMUNOL, V14, P1, DOI 10.1016/j.trim.2005.01.002
   Ueda H, 2000, EUR SURG RES, V32, P279, DOI 10.1159/000008776
   Van Brocklyn JR, 2000, BLOOD, V95, P2624
   Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229
   VANCE JE, 1990, J BIOL CHEM, V265, P7248
   vanKoppen CJ, 1996, J BIOL CHEM, V271, P2082, DOI 10.1074/jbc.271.4.2082
   Venkataraman K, 2008, CIRC RES, V102, P669, DOI 10.1161/CIRCRESAHA.107.165845
   Volzke A, 2014, BBA-MOL CELL BIOL L, V1841, P11, DOI 10.1016/j.bbalip.2013.09.009
   Vu TM, 2017, NATURE, V550, P524, DOI 10.1038/nature24053
   WALTER VP, 1983, BIOCHIM BIOPHYS ACTA, V750, P346, DOI 10.1016/0005-2760(83)90039-5
   Walzer T, 2007, NAT IMMUNOL, V8, P1337, DOI 10.1038/ni1523
   Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343
   Wang L, 2008, HISTOCHEM CELL BIOL, V129, P579, DOI 10.1007/s00418-008-0389-8
   Wang LY, 2020, CLIN SCI, V134, P1475, DOI 10.1042/CS20200497
   Wang WG, 2005, FASEB J, V19, P1731, DOI 10.1096/fj.05-3730fje
   Waters CM, 2005, CELL SIGNAL, V17, P263, DOI 10.1016/j.cellsig.2004.07.011
   Watson L, 2012, J CLIN IMMUNOL, V32, P1019, DOI 10.1007/s10875-012-9710-3
   Wenderfer SE, 2008, KIDNEY INT, V74, P1319, DOI 10.1038/ki.2008.396
   Wilkerson BA, 2012, J BIOL CHEM, V287, P44645, DOI 10.1074/jbc.M112.423426
   Wilson PC, 2019, P NATL ACAD SCI USA, V116, P19619, DOI 10.1073/pnas.1908706116
   Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351
   Wu BX, 2010, J BIOL CHEM, V285, P17993, DOI 10.1074/jbc.M110.102988
   Wu JL, 2019, DIS MARKERS, V2019, DOI 10.1155/2019/1825849
   Xia P, 2002, J BIOL CHEM, V277, P7996, DOI 10.1074/jbc.M111423200
   Xu CB, 2002, ATHEROSCLEROSIS, V164, P237, DOI 10.1016/S0021-9150(02)00100-4
   Xu N, 1999, J BIOL CHEM, V274, P31286, DOI 10.1074/jbc.274.44.31286
   Xu RJ, 2006, FASEB J, V20, P1813, DOI 10.1096/fj.05-5689com
   Yamazaki Y, 2000, BIOCHEM BIOPH RES CO, V268, P583, DOI 10.1006/bbrc.2000.2162
   Yatomi Y, 2004, J BIOCHEM, V136, P495, DOI 10.1093/jb/mvh143
   Ye D, 2013, DEVELOPMENT, V140, P789, DOI 10.1242/dev.085340
   Yoo TH, 2015, J AM SOC NEPHROL, V26, P133, DOI 10.1681/ASN.2013111213
   Zhang L, 2013, BLOOD, V122, P791, DOI 10.1182/blood-2012-12-473884
   Zhang XY, 2003, ACTA HISTOCHEM, V105, P67, DOI 10.1078/0065-1281-00687
NR 261
TC 2
Z9 2
U1 4
U2 8
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1046-6673
EI 1533-3450
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD JAN
PY 2021
VL 32
IS 1
BP 9
EP 31
DI 10.1681/ASN.2020050697
PG 23
WC Urology & Nephrology
SC Urology & Nephrology
GA PP1KS
UT WOS:000605628100005
PM 33376112
DA 2021-10-30
ER

PT J
AU Al Hazzouri, AZ
   Elfassy, T
   Glymour, MM
AF Al Hazzouri, Adina Zeki
   Elfassy, Tali
   Glymour, M. Maria
TI Response by Zeki Al Hazzouri et al to Letter Regarding Article,
   "Associations of Income Volatility With Incident Cardiovascular Disease
   and All-Cause Mortality in a US Cohort: 1990 to 2015"
SO CIRCULATION
LA English
DT Letter
C1 [Al Hazzouri, Adina Zeki] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10027 USA.
   [Elfassy, Tali] Univ Miami, Dept Publ Hlth Sci, Div Epidemiol, Coral Gables, FL 33124 USA.
   [Glymour, M. Maria] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA USA.
RP Al Hazzouri, AZ (corresponding author), Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10027 USA.
FU NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [KL2TR002737] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON
   AGINGUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)
   [K01AG047273] Funding Source: NIH RePORTER; NCATS NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [KL2 TR002737] Funding Source: Medline; NIA NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Aging (NIA) [K01 AG047273] Funding
   Source: Medline
CR Elfassy T, 2019, CIRCULATION, V139, P850, DOI 10.1161/CIRCULATIONAHA.118.035521
NR 1
TC 0
Z9 0
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009-7322
EI 1524-4539
J9 CIRCULATION
JI Circulation
PD AUG 20
PY 2019
VL 140
IS 8
BP E327
EP E328
DI 10.1161/CIRCULATIONAHA.119.041482
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA IV5UW
UT WOS:000484336700002
PM 31424982
OA Green Accepted, Bronze
DA 2021-10-30
ER

PT J
AU Leong, JY
   Patel, AS
   Ramasamy, R
AF Leong, Joon Yau
   Patel, Amir S.
   Ramasamy, Ranjith
TI Minimizing Sexual Dysfunction in BPH Surgery
SO CURRENT SEXUAL HEALTH REPORTS
LA English
DT Article
DE Benign prostatic hyperplasia; Lower urinary tract symptoms; Sexual
   dysfunction; Erectile dysfunction; Ejaculatory dysfunction
AB Purpose of ReviewTo review the prevalence and risks of sexual dysfunction associated with current treatment options for benign prostatic hyperplasia and to characterize techniques and methods to manage postoperative sexual dysfunction-related side effects.Recent FindingsCurrent surgical therapies available for the treatment of benign prostatic hyperplasia are associated with a substantial risk of both ejaculatory and erectile function. However, many of the novel minimally invasive treatment alternatives have demonstrated the ability to preserve postoperative sexual function to a better degree, all while providing significant relief of lower urinary tract symptoms in an equally safe and efficacious manner.SummaryBenign prostatic hyperplasia remains a highly prevalent disease among the aging population. While surgical treatments are often necessary to relieve bothersome urinary symptoms, these procedures are associated with an increased risk of sexual dysfunction. As such, there has been an increased interest in the development of minimally invasive therapies, such as the UroLift (R), Rezum (R), and Aquablation (R), with the hopes of achieving similar symptomatic relief while maintaining sexual function. Aside from reporting lower rates of sexual dysfunction, these procedures have also demonstrated comparable safety, durability, and efficacy to current gold standard therapies. Some procedures can even be performed in an outpatient setting, avoiding the need for general anesthesia altogether. Overall, an individualized, shared decision-making approach is necessary to determine the ideal treatment option for each patient.
C1 [Leong, Joon Yau] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Dept Urol, 1025 Walnut St,Coll Bldg,Suite 1112, Philadelphia, PA 19107 USA.
   [Patel, Amir S.] Oregon Hlth & Sci Univ, Dept Urol, Portland, OR USA.
   [Ramasamy, Ranjith] Univ Miami, Miller Sch Med, Dept Urol, Miami, FL 33136 USA.
RP Leong, JY (corresponding author), Thomas Jefferson Univ, Sidney Kimmel Med Coll, Dept Urol, 1025 Walnut St,Coll Bldg,Suite 1112, Philadelphia, PA 19107 USA.
EM joonyau.leong@jefferson.edu
OI Leong, Joon Yau/0000-0002-1698-8442
FU NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1 TR002736] Funding Source: Medline
CR Ahmed M, 1997, BRIT J UROL, V79, P181, DOI 10.1046/j.1464-410X.1997.02667.x
   Albaugh JA, 2017, BMC UROL, V17, DOI 10.1186/s12894-017-0231-5
   Alloussi SH, 2014, J ENDOUROL, V28, P84, DOI 10.1089/end.2013.0093
   Bachmann A, 2014, EUR UROL, V65, P931, DOI 10.1016/j.eururo.2013.10.040
   Bagla S, 2015, J VASC INTERV RADIOL, V26, P1832, DOI 10.1016/j.jvir.2015.08.018
   Becher Edgardo F, 2014, Sex Med Rev, V2, P47, DOI 10.1002/smrj.20
   Borchert A, 2018, CURR UROL REP, V19, DOI 10.1007/s11934-018-0813-0
   Bowen DK, 2015, CAN J UROL, V22, P8063
   Briganti A, 2006, J UROLOGY, V175, P1817, DOI 10.1016/S0022-5347(05)00983-3
   Bruskewitz R, 1998, J UROLOGY, V159, P1588, DOI 10.1097/00005392-199805000-00048
   Bruyere Franck, 2011, Curr Urol Rep, V12, P261, DOI 10.1007/s11934-011-0199-8
   Bruyere F, 2010, EUR UROL, V58, P207, DOI 10.1016/j.eururo.2010.04.027
   Cantwell AL, 2014, BJU INT, V113, P615, DOI 10.1111/bju.12540
   Catania JA, 2013, J SEX RES, V50, P524, DOI 10.1080/00224499.2012.666815
   Chen Q, 2010, BJU INT, V106, P1339, DOI 10.1111/j.1464-410X.2010.09401.x
   Chin PT, 2012, UROLOGY, V79, P5, DOI 10.1016/j.urology.2011.10.021
   Chung A, 2016, CURR OPIN UROL, V26, P42, DOI 10.1097/MOU.0000000000000247
   Cimentepe E, 2003, J ENDOUROL, V17, P103, DOI 10.1089/08927790360587432
   Cornell LF, 2017, ANN SURG ONCOL, V24, P2526, DOI 10.1245/s10434-017-5894-3
   Coursey JW, 2001, J UROLOGY, V166, P2273, DOI 10.1016/S0022-5347(05)65549-8
   Darson MF, 2017, RES REP UROL, V9, P159, DOI 10.2147/RRU.S143679
   DaSilva FC, 1997, EUR UROL, V31, P272
   Delay KJ, 2016, TRANSL ANDROL UROL, V5, P450, DOI 10.21037/tau.2016.06.06
   Dixon C, 2015, UROLOGY, V86, P1042, DOI 10.1016/j.urology.2015.05.046
   Dixon CM, 2016, RES REP UROL, V8, P207, DOI 10.2147/RRU.S119596
   Donovan JL, 2000, J UROLOGY, V164, P65, DOI 10.1016/S0022-5347(05)67450-2
   El-Assmy A, 2018, INT UROL NEPHROL, V50, P1569, DOI 10.1007/s11255-018-1950-6
   Elhilali MM, 2013, J UROLOGY, V189, P1421, DOI 10.1016/j.juro.2012.11.003
   Elshal AM, 2012, UROLOGY, V80, P1098, DOI 10.1016/j.urology.2012.08.001
   Fan YH, 2017, UROL SCI, V28, P169, DOI 10.1016/j.urols.2016.12.003
   Foster HE, 2018, J UROLOGY, V200, P612, DOI 10.1016/j.juro.2018.05.048
   Frieben RW, 2010, ASIAN J ANDROL, V12, P500, DOI 10.1038/aja.2010.33
   Gilling P, 2018, J UROLOGY, V199, P1252, DOI 10.1016/j.juro.2017.12.065
   Gilling P, 2017, J UROLOGY, V197, P1565, DOI 10.1016/j.juro.2017.01.056
   Gilling P, 2016, BJU INT, V117, P923, DOI 10.1111/bju.13358
   Gilling PJ, 2019, UROLOGY, V125, P169, DOI 10.1016/j.urology.2018.12.002
   Gilling PJ, 1998, J ENDOUROL, V12, P457, DOI 10.1089/end.1998.12.457
   GILVERNET JM, 1994, BRIT J UROL, V73, P442, DOI 10.1111/j.1464-410X.1994.tb07612.x
   Herberts M, 2016, CURR UROL REP, V17, DOI 10.1007/s11934-016-0604-4
   Hill B, 2004, J UROLOGY, V171, P2336, DOI 10.1097/01.ju.0000127761.87421.a0
   Isaacson AJ, 2016, J VASC INTERV RADIOL, V27, P709, DOI 10.1016/j.jvir.2016.01.146
   Kasivisvanathan V, 2018, CAN J UROL, V25, P9317
   Kavoussi PK, 2008, J SEX MED, V5, P2669, DOI 10.1111/j.1743-6109.2008.00978.x
   Keehn A, 2017, UROLOGY, V104, P230, DOI 10.1016/j.urology.2016.11.029
   Kim M, 2015, INT J IMPOT RES, V27, P20, DOI 10.1038/ijir.2014.22
   Kuntz RM, 2008, EUR UROL, V53, P160, DOI 10.1016/j.eururo.2007.08.036
   Kurbatov D, 2014, UROLOGY, V84, P400, DOI 10.1016/j.urology.2014.04.028
   Li Q, 2015, CHINESE MED J-PEKING, V128, P2072, DOI 10.4103/0366-6999.161370
   Li Z, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003862
   MacRae C, 2016, CAN J UROL, V23, P8590
   Malaeb BS, 2012, UROLOGY, V79, P1111, DOI 10.1016/j.urology.2011.11.084
   Mamoulakis C, 2013, BJU INT, V112, P109, DOI 10.1111/j.1464-410X.2012.11662.x
   Marra G, 2016, INT J UROL, V23, P22, DOI 10.1111/iju.12866
   McVary KT, 2019, UROLOGY, V126, P171, DOI 10.1016/j.urology.2018.12.041
   McVary KT, 2018, UROLOGY, V111, P1, DOI 10.1016/j.urology.2017.10.023
   McVary KT, 2016, J SEX MED, V13, P924, DOI 10.1016/j.jsxm.2016.03.372
   McVary KT, 2016, J UROLOGY, V195, P1529, DOI 10.1016/j.juro.2015.10.181
   McVary KT, 2014, J SEX MED, V11, P279, DOI 10.1111/jsm.12333
   Mebust WK, 2002, J UROLOGY, V167, P999, DOI 10.1016/S0022-5347(02)80323-8
   Meng FW, 2007, J ANDROL, V28, P259, DOI 10.2164/jandrol.106.000372
   Mock S, 2013, J UROLOGY, V190, P1805, DOI 10.1016/j.juro.2013.05.010
   Mollengarden D, 2018, PROSTATE CANCER P D, V21, P379, DOI 10.1038/s41391-017-0022-9
   MOLLERNIELSEN C, 1985, UROL INT, V40, P3, DOI 10.1159/000281022
   Muntener M, 2007, EUR UROL, V52, P510, DOI 10.1016/j.eururo.2007.01.088
   Patel RM, 2019, ANZ J SURG, V89, P345, DOI 10.1111/ans.15016
   Pavone C, 2015, ARCH ITAL UROL ANDRO, V87, P8, DOI 10.4081/aiua.2015.1.8
   Pham H, 2018, CAN J UROL, V25, P9228
   Pisco J, 2016, J VASC INTERV RADIOL, V27, P700, DOI 10.1016/j.jvir.2016.01.138
   Pisco JM, 2016, J VASC INTERV RADIOL, V27, P1115, DOI 10.1016/j.jvir.2016.04.001
   Ponholzer A, 2007, INT J IMPOT RES, V19, P544, DOI 10.1038/sj.ijir.3901578
   Porpiglia F, 2018, BJU INT, V122, P106, DOI 10.1111/bju.14141
   Ray AF, 2018, BJU INT, V122, P270, DOI 10.1111/bju.14249
   Roehrborn Claus G, 2005, Rev Urol, V7 Suppl 9, pS3
   Roehrborn CG, 2017, CAN J UROL, V24, P8802
   Roehrborn CG, 2017, J UROLOGY, V197, P1507, DOI 10.1016/j.juro.2016.12.045
   Roehrborn CG, 2016, UROL CLIN N AM, V43, P357, DOI 10.1016/j.ucl.2016.04.008
   Roehrborn CG, 2015, CAN J UROL, V22, P7772
   Roehrborn CG, 2013, J UROLOGY, V190, P2161, DOI 10.1016/j.juro.2013.05.116
   Rosen R, 2003, EUR UROL, V44, P637, DOI 10.1016/j.eururo.2003.08.015
   Shore N, 2014, CAN J UROL, V21, P7094
   Sonksen J, 2015, EUR UROL, V68, P643, DOI 10.1016/j.eururo.2015.04.024
   Spaliviero M, 2010, J ENDOUROL, V24, P2051, DOI 10.1089/end.2010.0296
   Taher A, 2004, WORLD J UROL, V22, P457, DOI 10.1007/s00345-004-0449-1
   Talab SS, 2013, J UROLOGY, V189, pE164, DOI 10.1016/j.juro.2013.02.1792
   Thomas JA, 2016, EUR UROL, V69, P94, DOI 10.1016/j.eururo.2015.07.054
   Wang MQ, 2015, BMC UROL, V15, DOI 10.1186/s12894-015-0026-5
   Wang MQ, 2016, BJU INT, V117, P155, DOI 10.1111/bju.13147
   Wang MQ, 2015, INT J UROL, V22, P766, DOI 10.1111/iju.12797
   Wang P, 2018, UROLOGY, V119, P85, DOI 10.1016/j.urology.2018.06.005
   Wang XY, 2016, CLIN INTERV AGING, V11, P1609, DOI 10.2147/CIA.S119241
   Woo HH, 2012, J SEX MED, V9, P568, DOI 10.1111/j.1743-6109.2011.02568.x
   Zong HT, 2012, J ANDROL, V33, P427, DOI 10.2164/jandrol.111.013490
NR 92
TC 11
Z9 12
U1 1
U2 2
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1548-3584
EI 1548-3592
J9 CURR SEX HEALTH REP
JI Curr. Sex. Health Rep.
PD SEP
PY 2019
VL 11
IS 3
BP 190
EP 200
DI 10.1007/s11930-019-00210-1
PG 11
WC Urology & Nephrology
SC Urology & Nephrology
GA VK4QN
UT WOS:000703024800008
PM 31467497
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Parikh, NS
   Dueker, N
   Varela, D
   Del Brutto, VJ
   Rundek, T
   Wright, CB
   Sacco, RL
   Elkind, MSV
   Gutierrez, J
AF Parikh, Neal S.
   Dueker, Nicole
   Varela, Dalila
   Del Brutto, Victor J.
   Rundek, Tatjana
   Wright, Clinton B.
   Sacco, Ralph L.
   Elkind, Mitchell S. V.
   Gutierrez, Jose
TI Association between PNPLA3 rs738409 G variant and MRI cerebrovascular
   disease biomarkers
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE Cerebrovascular disease/stroke; Epidemiology; Association studies in
   genetics; Metabolic disease; Nonalcoholic fatty liver disease
ID FATTY LIVER-DISEASE; MATTER HYPERINTENSITY VOLUME; SMALL VESSEL DISEASE;
   SUBCLINICAL ATHEROSCLEROSIS; CARDIOVASCULAR-DISEASE; SYSTEMIC
   INFLAMMATION; RISK; ADULTS; SUSCEPTIBILITY; PREVALENCE
AB Introduction: Nonalcoholic fatty liver disease (NAFLD) has been associated with greater cerebral white matter hyperintensity (WMH) volume and microbleeds. The adiponutrin (PNPLA3) rs738409 G variant, a robust NAFLD susceptibility variant, has been variably associated with carotid atherosclerosis. We hypothesized that this variant is associated with WMH volume, microbleeds, covert brain infarction (CBI), and small perivascular spaces.
   Methods: We performed a cross-sectional analysis of the Northern Manhattan Study-MRI Substudy. The associations between the rs738409 G variant allele and outcomes were assessed using linear regression for WMH volume, logistic regression for microbleeds and CBI, and Poisson regression for small perivascular spaces. Models were adjusted for age, sex, principal components, diabetes, and body mass index.
   Results: We included 1063 Northern Manhattan Study participants who had brain MRI and genotype data available (mean age 70 +/- 9 years, 61% women). The G allele frequency was 24%. The prevalence of any microbleeds and CBI were 8% and 18%, respectively. The median WMH volume and small perivascular space count score were 7.7 mL and 6, respectively. GG homozygosity, but not heterozygosity, was associated with WMH volume (beta = 0.27; 95% CI, 0.03, 0.51) compared to non-carriers. Having at least one G allele was associated with the presence of microbleeds (Odds ratio, 1.78; 95% CI, 1.02, 3.12); the association was attenuated in other models. No associations were observed for CBI and small perivascular spaces.
   Conclusion: The PNPLA3 rs738409 G allele was associated with greater WMH volume, and inconsistent associations with microbleeds were seen.
C1 [Parikh, Neal S.; Varela, Dalila; Elkind, Mitchell S. V.; Gutierrez, Jose] Columbia Univ, Dept Neurol, Vagelos Coll Phys & Surg, New York, NY USA.
   [Dueker, Nicole; Sacco, Ralph L.] Univ Miami, John P Hussman Inst Human Genom, Miami, FL USA.
   [Del Brutto, Victor J.; Rundek, Tatjana; Sacco, Ralph L.] Univ Miami, Miller Sch Med, Dept Neurol Epidemiol & Publ Hlth, Miami, FL 33136 USA.
   [Rundek, Tatjana; Sacco, Ralph L.] Univ Miami, Evelyn F McKnight Brain Inst, Miami, FL USA.
   [Wright, Clinton B.] NINDS, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.
   [Elkind, Mitchell S. V.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA.
RP Parikh, NS (corresponding author), 420 E 70th St,4th Floor, New York, NY 10021 USA.
EM nsp2001@med.cornell.edu
OI Parikh, Neal/0000-0002-8802-2380
FU National Institute of Neurological Disorders and Stroke (NINDS)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Neurological Disorders &
   Stroke (NINDS) [T32NS07153]; National Institutes of Health (NIH)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA [R01NS040807]; NIHUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS029993,
   NS040807, UL1TR002736, KL2TR002737, R01 AG05770903]
FX Dr. Parikh was supported by National Institute of Neurological Disorders
   and Stroke (NINDS)T32NS07153 (PI: Elkind). Dr. Dueker is funded by the
   National Institutes of Health (NIH) (R01NS040807). The Northern
   Manhattan Study is funded by the NIH (R01 NS029993; Elkind/Sacco). Dr.
   Rundek is funded by the grants from NIH (R01 NS029993, NS040807,
   UL1TR002736 and KL2TR002737). Dr. Gutierrez is funded by the NIH (R01
   AG05770903).
CR Al Rifai M, 2015, ATHEROSCLEROSIS, V239, P629, DOI 10.1016/j.atherosclerosis.2015.02.011
   Alexander KS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194153
   Brouwers MCGJ, 2019, HEPATOL COMMUN, V3, P587, DOI 10.1002/hep4.1319
   Caunca MR, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.116.003477
   Di Costanzo A, 2017, ATHEROSCLEROSIS, V257, P232, DOI 10.1016/j.atherosclerosis.2016.12.018
   Dongiovanni P, 2016, METABOLISM, V65, P1026, DOI 10.1016/j.metabol.2015.08.018
   Ekstedt M, 2015, HEPATOLOGY, V61, P1547, DOI 10.1002/hep.27368
   Elkind MSV, 2005, NEUROLOGY, V64, P2121, DOI 10.1212/01.WNL.0000165989.12122.49
   Fanning JP, 2014, STROKE, V45, P3461, DOI 10.1161/STROKEAHA.114.005919
   Gu Y, 2019, NEUROL-NEUROIMMUNOL, V6, DOI 10.1212/NXI.0000000000000521
   Gutierrez J, 2017, AM J NEURORADIOL, V38, P862, DOI 10.3174/ajnr.A5129
   Gutierrez J, 2015, J HYPERTENS, V33, P2115, DOI 10.1097/HJH.0000000000000686
   Jang H, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-38357-x
   Jimenez-Conde J, 2010, STROKE, V41, P437, DOI 10.1161/STROKEAHA.109.563502
   Judge C, 2019, J STROKE CEREBROVASC, V28, P1703, DOI 10.1016/j.jstrokecerebrovasdis.2019.02.018
   Kim D, 2013, HEPATOLOGY, V57, P1357, DOI 10.1002/hep.26156
   Kim YD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139227
   Lampe L, 2019, ANN NEUROL, V85, P194, DOI 10.1002/ana.25396
   Lauridsen BK, 2018, EUR HEART J, V39, P385, DOI 10.1093/eurheartj/ehx662
   Le MH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173499
   Lee HJ, 2017, METABOLISM, V67, P72, DOI 10.1016/j.metabol.2016.11.004
   Liu DJ, 2017, NAT GENET, V49, P1758, DOI 10.1038/ng.3977
   Long MT, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.116.005227
   Madan SA, 2015, EUR J GASTROEN HEPAT, V27, P1237, DOI 10.1097/MEG.0000000000000429
   Mellinger JL, 2015, J HEPATOL, V63, P470, DOI 10.1016/j.jhep.2015.02.045
   Novembre J, 2008, NAT GENET, V40, P646, DOI 10.1038/ng.139
   Petta S, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003446
   Petta S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074089
   Posadas-Sanchez R, 2017, IMMUNOBIOLOGY, V222, P960, DOI 10.1016/j.imbio.2016.08.008
   Prabhakaran S, 2008, NEUROLOGY, V70, P425, DOI 10.1212/01.wnl.0000277521.66947.e5
   Romeo S, 2008, NAT GENET, V40, P1461, DOI 10.1038/ng.257
   Ruschenbaum S, 2018, HEPATOL COMMUN, V2, P798, DOI 10.1002/hep4.1183
   Shoamanesh A, 2015, NEUROLOGY, V84, P825, DOI 10.1212/WNL.0000000000001279
   Simons N, 2017, GASTROENTEROLOGY, V152, P912, DOI 10.1053/j.gastro.2016.12.020
   Sinn DH, 2017, GUT, V66, P323, DOI 10.1136/gutjnl-2016-311854
   Stefan N, 2019, LANCET DIABETES ENDO, V7, P313, DOI 10.1016/S2213-8587(18)30154-2
   Stender S, 2017, NAT GENET, V49, P842, DOI 10.1038/ng.3855
   Sun LL, 2019, NAT MED, V25, P569, DOI 10.1038/s41591-019-0366-x
   Targher G, 2016, J HEPATOL, V65, P589, DOI 10.1016/j.jhep.2016.05.013
   VanWagner LB, 2014, ATHEROSCLEROSIS, V235, P599, DOI 10.1016/j.atherosclerosis.2014.05.962
   Walker KA, 2017, STROKE, V48, P3196, DOI 10.1161/STROKEAHA.117.018675
   Wang LY, 2010, CIRC-CARDIOVASC GENE, V3, P386, DOI 10.1161/CIRCGENETICS.110.938381
   Wardlaw JM, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.114.001140
   Willey JZ, 2011, NEUROLOGY, V76, P2112, DOI 10.1212/WNL.0b013e31821f4472
   Willey JZ, 2014, CEREBROVASC DIS, V37, P423, DOI 10.1159/000362920
   Wright CB, 2005, STROKE, V36, P1207, DOI 10.1161/01.STR.0000165923.02318.22
   Ying I, 2011, EPIDEMIOLOGY, V22, P129, DOI 10.1097/EDE.0b013e3181feb50a
   Zampino R, 2014, INT J CARDIOL, V172, P291, DOI 10.1016/j.ijcard.2013.12.231
NR 48
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 1878-5883
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD SEP 15
PY 2020
VL 416
AR 116981
DI 10.1016/j.jns.2020.116981
PG 6
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA PB7DD
UT WOS:000596476500016
PM 32592869
DA 2021-10-30
ER

PT J
AU Lu, M
   Ishwaran, H
AF Lu, Min
   Ishwaran, Hemant
TI A prediction-based alternative to P values in regression models
SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
LA English
DT Editorial Material
C1 [Lu, Min; Ishwaran, Hemant] Univ Miami, Div Biostat, Miami, FL 33136 USA.
RP Ishwaran, H (corresponding author), Univ Miami, Room 1058,Clin Res Bldg,1120 NW 14th St, Miami, FL 33136 USA.
EM hemant.ishwaran@gmail.com
RI Lu, Min/AAX-1605-2021
OI Lu, Min/0000-0002-1386-1315
FU NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1 TR000460] Funding Source: Medline;
   NIGMS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [R01 GM125072] Funding Source: Medline;
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000460] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   GENERAL MEDICAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of General Medical Sciences (NIGMS) [R01GM125072] Funding Source: NIH
   RePORTER
CR Breiman L, 2001, STAT SCI, V16, P199, DOI 10.1214/ss/1009213726
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Breiman L., 1984, CLASSIFICATION REGRE
   Breiman L., 1996, OUT OF BAG ESTIMATIO
   Efron B, 1997, J AM STAT ASSOC, V92, P548, DOI 10.2307/2965703
   EFRON B, 1983, J AM STAT ASSOC, V78, P316, DOI 10.2307/2288636
   Eilers PHC, 1996, STAT SCI, V11, P89, DOI 10.1214/ss/1038425655
   Hsich E, 2011, CIRC-CARDIOVASC QUAL, V4, P39, DOI 10.1161/CIRCOUTCOMES.110.939371
   Ishwaran H, 2008, ANN APPL STAT, V2, P841, DOI 10.1214/08-AOAS169
   Nuzzo R, 2014, NATURE, V506, P150, DOI 10.1038/506150a
   Trafimow D, 2015, BASIC APPL SOC PSYCH, V37, P197, DOI 10.1080/01973533.2015.1064290
   Wasserstein RL, 2016, AM STAT, V70, P129, DOI 10.1080/00031305.2016.1154108
NR 12
TC 8
Z9 8
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5223
EI 1097-685X
J9 J THORAC CARDIOV SUR
JI J. Thorac. Cardiovasc. Surg.
PD MAR
PY 2018
VL 155
IS 3
BP 1130
EP +
DI 10.1016/j.jtcvs.2017.08.056
PG 11
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA FX2TT
UT WOS:000425915100082
PM 29306487
OA Green Accepted, Bronze
DA 2021-10-30
ER

PT J
AU Carrasquillo, O
AF Carrasquillo, Olveen
TI Making America Great
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Editorial Material
C1 [Carrasquillo, Olveen] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA.
   [Carrasquillo, Olveen] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA.
RP Carrasquillo, O (corresponding author), Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA.; Carrasquillo, O (corresponding author), Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA.
EM oc6@med.miami.edu
FU NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1 TR002736] Funding Source: Medline
CR Adler NE, 2016, VITAL DIRECTIONS HLT
   Bor J, 2017, AM J PUBLIC HEALTH, V107, P1560, DOI [10.2105/AJPH.2017.303945, 10.2105/ajph.2017.303945]
   Carrasquillo O, 2018, ANNU REV MED, V69, P29, DOI 10.1146/annurev-med-090916-120540
   Goldman L, 2019, J GEN INTERN MED, V34, P363, DOI 10.1007/s11606-018-4568-6
   Goodwin JS, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.0450
   Himmelstein DU, 2018, LANCET, V392, P993, DOI 10.1016/S0140-6736(18)32171-8
   Kindig D, 2018, AM J PUBLIC HEALTH, V108, P87, DOI 10.2105/AJPH.2017.304099
   Schaffner BF, 2018, POLIT SCI QUART, V133, P9, DOI 10.1002/polq.12737
   Stein Letitia, 2018, REUTERS INVESTIGATES
NR 9
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD MAR
PY 2019
VL 34
IS 3
BP 331
EP 332
DI 10.1007/s11606-018-4821-z
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA HP0OM
UT WOS:000461365400002
PM 30652273
OA Green Published, Bronze
DA 2021-10-30
ER

PT J
AU Rice, TW
   Chen, L-Q
   Hofstetter, WL
   Smithers, BM
   Rusch, VW
   Wijnhoven, BPL
   Chen, KL
   Davies, AR
   D'Journo, XB
   Kesler, KA
   Luketich, JD
   Ferguson, MK
   Rasanen, JV
   van Hillegersberg, R
   Fang, W
   Durand, L
   Cecconello, I
   Allum, WH
   Cerfolio, RJ
   Pera, M
   Griffin, SM
   Burger, R
   Liu, J-F
   Allen, MS
   Law, S
   Watson, TJ
   Darling, GE
   Scott, WJ
   Duranceau, A
   Denlinger, CE
   Schipper, PH
   Lerut, TEMR
   Orringer, MB
   Ishwaran, H
   Apperson-Hansen, C
   DiPaola, LM
   Semple, ME
   Blackstone, EH
AF Rice, T. W.
   Chen, L. -Q.
   Hofstetter, W. L.
   Smithers, B. M.
   Rusch, V. W.
   Wijnhoven, B. P. L.
   Chen, K. L.
   Davies, A. R.
   D'Journo, X. B.
   Kesler, K. A.
   Luketich, J. D.
   Ferguson, M. K.
   Raesaenen, J. V.
   van Hillegersberg, R.
   Fang, W.
   Durand, L.
   Cecconello, I.
   Allum, W. H.
   Cerfolio, R. J.
   Pera, M.
   Griffin, S. M.
   Burger, R.
   Liu, J. -F.
   Allen, M. S.
   Law, S.
   Watson, T. J.
   Darling, G. E.
   Scott, W. J.
   Duranceau, A.
   Denlinger, C. E.
   Schipper, P. H.
   Lerut, T. E. M. R.
   Orringer, M. B.
   Ishwaran, H.
   Apperson-Hansen, C.
   DiPaola, L. M.
   Semple, M. E.
   Blackstone, E. H.
TI Worldwide Esophageal Cancer Collaboration: pathologic staging data
SO DISEASES OF THE ESOPHAGUS
LA English
DT Article
DE survival; cancer staging; esophagectomy; decision-making;
   prognostication
ID TIME
AB We report datasimple descriptions of patient characteristics, cancer categories, and non-risk-adjusted survivalfor patients with pathologically staged cancer of the esophagus and esophagogastric junction after resection or ablation with no preoperative therapy from the Worldwide Esophageal Cancer Collaboration (WECC). Thirty-three institutions from six continents submitted de-identified data using standard definitions: demographics, comorbidities, clinical cancer categories, and all-cause mortality from first management decision. Of 13,300 patients, 5,631 had squamous cell carcinoma, 7,558 adenocarcinoma, 85 adenosquamous carcinoma, and 26 undifferentiated carcinoma. Patients were older (62 years) men (80%) with normal body mass index (51%), little weight loss (1.8 kg), 0-2 ECOG performance status (83%), and a history of smoking (70%). Cancers were pT1 (24%), pT2 (15%), pT3 (50%), pN0 (52%), pM0 (93%), and pG2-G3 (78%); most involved distal esophagus (71%). Non-risk-adjusted survival for both squamous cell carcinoma and adenocarcinoma was monotonic and distinctive across pTNM. Survival was more distinctive for adenocarcinoma than squamous cell carcinoma when pT was ordered by pN. Survival for pTis-1 adenocarcinoma was better than for squamous cell carcinoma, although monotonic and distinctive for both. WECC pathologic staging data is improved over that of the 7th edition, with more patients studied and patient and cancer variables collected. These data will be the basis for the 8th edition cancer staging manuals following risk adjustment for patient, cancer, and treatment characteristics, and should direct 9th edition data collection. However, the role of pure pathologic staging as the principal point of reference for esophageal cancer staging is waning.
C1 [Rice, T. W.; DiPaola, L. M.; Semple, M. E.; Blackstone, E. H.] Cleveland Clin, Cleveland, OH 44106 USA.
   [Chen, L. -Q.] Sichuan Univ, West China Hosp, Chengdu, Sichuan, Peoples R China.
   [Hofstetter, W. L.] Univ Texas MD Anderson Hosp, Houston, TX USA.
   [Smithers, B. M.] Univ Queensland, Princess Alexandra Hosp, Brisbane, Qld, Australia.
   [Rusch, V. W.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
   [Wijnhoven, B. P. L.] Erasmus MC, Rotterdam, Netherlands.
   [Chen, K. L.] Beijing Canc Hosp, Beijing, Peoples R China.
   [Davies, A. R.] Guys & St Thomas Hosp, London, England.
   [D'Journo, X. B.] Hop Nord Marseille, Marseille, France.
   [Kesler, K. A.] Indiana Univ, Med Ctr, Indianapolis, IN USA.
   [Luketich, J. D.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
   [Ferguson, M. K.] Univ Chicago, Dept Surg, 5841 S Maryland Ave, Chicago, IL 60637 USA.
   [Raesaenen, J. V.] Helsinki Univ Hosp, Helsinki, Finland.
   [van Hillegersberg, R.] Univ Med Ctr Utrecht, Utrecht, Netherlands.
   [Fang, W.] Shanghai Chest Hosp, Shanghai, Peoples R China.
   [Durand, L.] Univ Buenos Aires, Hosp Clin, Buenos Aires, DF, Argentina.
   [Cecconello, I.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Allum, W. H.] Royal Marsden NHS Fdn Trust, London, England.
   [Cerfolio, R. J.] Univ Alabama Birmingham, Sect Thorac Surg, Birmingham, AL USA.
   [Pera, M.] Hosp Univ Mar, Barcelona, Spain.
   [Griffin, S. M.] Newcastle Univ, Newcastle Upon Tyne, Tyne & Wear, England.
   [Burger, R.] Univ Cape Town, Groote Schuur Hosp, Cape Town, South Africa.
   [Liu, J. -F.] Hebei Med Univ, Hosp 4, Shijiazhuang, Hebei, Peoples R China.
   [Allen, M. S.] Mayo Clin, Rochester, MN USA.
   [Law, S.] Univ Hong Kong, Med Ctr, Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China.
   [Watson, T. J.] Univ Rochester, Rochester, NY USA.
   [Darling, G. E.] Toronto Gen Hosp, Toronto, ON, Canada.
   [Scott, W. J.] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA.
   [Duranceau, A.] Univ Montreal, Montreal, PQ, Canada.
   [Denlinger, C. E.] Med Univ South Carolina, Charleston, SC USA.
   [Schipper, P. H.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
   [Lerut, T. E. M. R.] Univ Ziekenhuizen Leuven, Leuven, Belgium.
   [Orringer, M. B.] Univ Michigan, Ann Arbor, MI 48109 USA.
   [Ishwaran, H.] Univ Miami, Miami, FL USA.
   [Apperson-Hansen, C.] Case Western Reserve Univ, Cleveland, OH 44106 USA.
RP Rice, TW (corresponding author), Cleveland Clin, Dept Thorac & Cardiovasc Surg, 9500 Euclid Ave Desk JJ 40, Cleveland, OH 44195 USA.
EM ricet@ccf.org
RI Cecconello, Ivan/A-3918-2013; Rasanen, Jari/AAV-1231-2020; D'journo,
   Xavier Benoit/AAJ-4457-2021; luketich, james/AAY-6230-2020; Law,
   Simon/C-4324-2009; Smithers, Bernard M/F-2060-2010; Wijnhoven,
   Bas/AAF-4838-2020
OI Cecconello, Ivan/0000-0002-3535-4170; Rasanen, Jari/0000-0002-7826-532X;
   D'journo, Xavier Benoit/0000-0001-6747-4583; Law,
   Simon/0000-0002-6518-5806; Smithers, Bernard M/0000-0002-8333-8685;
   Griffin, Selwyn Michael/0000-0003-1583-7009; Rusch,
   Valerie/0000-0003-2345-6900; Cerfolio, Robert/0000-0002-5598-599X; Pera,
   Manuel/0000-0002-9449-1810
FU NATIONAL CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [R01CA163739] Funding Source: NIH RePORTER; NATIONAL
   CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000460] Funding Source: NIH RePORTER; NCATS NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1 TR000460] Funding Source: Medline; NCI NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI) [R01 CA163739] Funding Source:
   Medline
CR Black WC, 2002, JNCI-J NATL CANCER I, V94, P167, DOI 10.1093/jnci/94.3.167
   BLACKSTONE EH, 1986, J AM STAT ASSOC, V81, P615, DOI 10.2307/2288989
   Edge SB, 2010, AM JOINT COMMITTEE C
   GOLDMAN AI, 1992, AM STAT, V46, P13, DOI 10.2307/2684402
   Lauer MS, 1999, J AM COLL CARDIOL, V34, P618, DOI 10.1016/S0735-1097(99)00250-8
   Rice T, 2016, DIS ESOPHAGUS, V22, P1
   Rice T, 2016, ESOPHAGUS IN PRESS
   Rice TW, 2009, DIS ESOPHAGUS, V22, P1, DOI 10.1111/j.1442-2050.2008.00901.x
   Rice TW, 2010, CANCER-AM CANCER SOC, V116, P3763, DOI 10.1002/cncr.25146
   Sobin L, 2009, TNM CLASSIFICATION M
   van Leeuwen PJ, 2010, J MED SCREEN, V17, P204, DOI 10.1258/jms.2010.010074
NR 11
TC 37
Z9 44
U1 0
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
EI 1442-2050
J9 DIS ESOPHAGUS
JI Dis. Esophagus
PD OCT
PY 2016
VL 29
IS 7
BP 724
EP 733
DI 10.1111/dote.12520
PG 10
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DZ3AX
UT WOS:000385716800002
PM 27731547
OA Green Published, Green Accepted
DA 2021-10-30
ER

PT J
AU Chen, SH
   Scott, XO
   Marcelo, YF
   Almeida, VW
   Blackwelder, PL
   Yavagal, DR
   Peterson, EC
   Starke, RM
   Dietrich, WD
   Keane, RW
   Vaccari, JPD
AF Chen, Stephanie H.
   Scott, Xavier O.
   Ferrer Marcelo, Yoandy
   Almeida, Vania W.
   Blackwelder, Patricia L.
   Yavagal, Dileep R.
   Peterson, Eric C.
   Starke, Robert M.
   Dietrich, W. Dalton
   Keane, Robert W.
   de Rivero Vaccari, Juan Pablo
TI Netosis and Inflammasomes in Large Vessel Occlusion Thrombi
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE inflammation; stroke; inflammasome; thrombus; caspase-1; ASC; neutrophil
   extracellular traps; NETs
AB The inflammatory response appears to play a critical role in clotting in which neutrophil extracellular traps (NETs) are the major drivers of thrombosis in acute ischemic stroke (AIS). The inflammasome is an innate immune complex involved in the activation of interleukin (IL)-18 and IL-1 beta through caspase-1, but whether the inflammasome plays a role in NETosis in AIS remains poorly understood. Here we assessed the levels of inflammasome signaling proteins in NETs and their association with clinical and procedural outcomes of mechanical thrombectomy for AIS. Electron microscopy and immunofluorescence indicate the presence of NETs in thrombi of patients with AIS. Moreover, the inflammasome signaling proteins caspase-1 and apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) were also present in clots associated with the marker of NETosis citrullinated histone H-3 (CitH3). Analysis of protein levels by a simple plex assay show that caspase-1, ASC and interleukin (IL)-1 beta were significantly elevated in clots when compared to plasma of AIS patients and healthy controls, while IL-18 levels were lower. Moreover, multivariate analyses show that IL-1 beta levels in clots contribute to the number of passes to achieve complete recanalization, and that ASC, caspase-1 and IL-18 are significant contributors to time to recanalization. Thus, inflammasome proteins are elevated in NETs present in thrombi of patients with AIS that contribute to poor outcomes following stroke.
C1 [Chen, Stephanie H.; Ferrer Marcelo, Yoandy; Almeida, Vania W.; Peterson, Eric C.; Starke, Robert M.; Dietrich, W. Dalton; Keane, Robert W.; de Rivero Vaccari, Juan Pablo] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA.
   [Chen, Stephanie H.; Ferrer Marcelo, Yoandy; Almeida, Vania W.; Peterson, Eric C.; Starke, Robert M.; Dietrich, W. Dalton; Keane, Robert W.; de Rivero Vaccari, Juan Pablo] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA.
   [Scott, Xavier O.; Keane, Robert W.] Univ Miami, Miller Sch Med, Dept Physiol & Biophys, Miami, FL 33136 USA.
   [de Rivero Vaccari, Juan Pablo] Univ Miami, Miller Sch Med, Ctr Cognit Neurosci & Aging, Miami, FL 33136 USA.
   [Blackwelder, Patricia L.] Univ Miami, Ctr Adv Microscopy UMCAM, Coral Gables, FL 33124 USA.
   [Blackwelder, Patricia L.] Univ Miami, Dept Chem, Coral Gables, FL 33124 USA.
   [Yavagal, Dileep R.] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA.
RP Vaccari, JPD (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA.; Vaccari, JPD (corresponding author), Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA.; Vaccari, JPD (corresponding author), Univ Miami, Miller Sch Med, Ctr Cognit Neurosci & Aging, Miami, FL 33136 USA.
EM JdeRivero@med.miami.edu
FU Robert J. Dempsey Cerebrovascular Research Award; R01 grant from the
   NIH/NINDS [R01NS113969-01]; James and Ester King Biomedical Research
   Program grant from the State of Florida [7JK03]; NREF; Joe Niekro
   Foundation; Brain Aneurysm Foundation; Bee Foundation; NIHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [R01NS111119-01A1]; Miami Clinical and Translational Science
   Institute [UL1TR002736, KL2TR002737]; National Center for Advancing
   Translational SciencesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS); National Institute on Minority
   Health and Health DisparitiesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Minority Health & Health Disparities (NIMHD)
FX This research received grant funding from the Robert J. Dempsey
   Cerebrovascular Research Award to SC and JdR, an R01 grant from the
   NIH/NINDS to RK and JdR (R01NS113969-01) and a James and Ester King
   Biomedical Research Program grant from the State of Florida (7JK03) to
   WD. RS research is supported by the NREF, Joe Niekro Foundation, Brain
   Aneurysm Foundation, Bee Foundation, and by the NIH (R01NS111119-01A1)
   and (UL1TR002736, KL2TR002737) through the Miami Clinical and
   Translational Science Institute, from the National Center for Advancing
   Translational Sciences and the National Institute on Minority Health and
   Health Disparities. Its contents are solely the responsibility of the
   authors and do not necessarily represent the official views of the NIH.
CR Abulafia DP, 2009, J CEREBR BLOOD F MET, V29, P534, DOI 10.1038/jcbfm.2008.143
   Adamczak S, 2012, J NEUROSURG, V117, P1119, DOI 10.3171/2012.9.JNS12815
   Adamczak SE, 2014, J CEREBR BLOOD F MET, V34, P621, DOI 10.1038/jcbfm.2013.236
   Bester J, 2016, SCI REP-UK, V6, DOI 10.1038/srep32188
   Brand FJ, 2016, J INFLAMM-LOND, V13, DOI 10.1186/s12950-016-0137-0
   Brand FJ, 2015, J INFLAMM-LOND, V12, DOI 10.1186/s12950-015-0101-4
   Brill A, 2011, BLOOD, V117, P1400, DOI 10.1182/blood-2010-05-287623
   Brinjikji W, 2017, J NEUROINTERV SURG, V9, P529, DOI 10.1136/neurintsurg-2016-012391
   Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385
   Caparosa EM, 2019, NEUROSURGERY, V85, pE284, DOI 10.1093/neuros/nyy470
   Chen KW, 2020, EMBO J, V39, DOI 10.15252/embj.2019103397
   Chen KW, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aar6676
   Danton GH, 2003, J NEUROPATH EXP NEUR, V62, P127, DOI 10.1093/jnen/62.2.127
   Dinarello CA, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00289
   Ducroux C, 2018, STROKE, V49, P754, DOI 10.1161/STROKEAHA.117.019896
   Duewell P, 2010, NATURE, V464, P1357, DOI 10.1038/nature08938
   Etulain J, 2015, BLOOD, V126, P242, DOI 10.1182/blood-2015-01-624023
   Fann DYW, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.326
   Forouzandeh M, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01238
   Fransen PSS, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-343
   Fuchs TA, 2007, J CELL BIOL, V176, P231, DOI 10.1083/jcb.200606027
   Gabay C, 2010, NAT REV RHEUMATOL, V6, P232, DOI 10.1038/nrrheum.2010.4
   Gao L, 2017, INFLAMM RES, V66, P17, DOI 10.1007/s00011-016-0981-7
   Govindarajan V, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-01944-9
   Goyal M, 2016, LANCET, V387, P1723, DOI 10.1016/S0140-6736(16)00163-X
   Goyal M, 2016, STROKE, V47, P548, DOI 10.1161/STROKEAHA.115.011426
   Gupta AK, 2010, FEBS LETT, V584, P3193, DOI 10.1016/j.febslet.2010.06.006
   Hankey GJ, 2017, LANCET, V389, P641, DOI 10.1016/S0140-6736(16)30962-X
   Hirose T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111755
   Ismael S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24350-x
   Jadhav AP, 2018, STROKE, V49, P1015, DOI 10.1161/STROKEAHA.117.020273
   Jagani M, 2017, INTERV NEURORADIOL, V23, P274, DOI 10.1177/1591019917694478
   Kahlenberg JM, 2013, J IMMUNOL, V190, P1217, DOI 10.4049/jimmunol.1202388
   Kastbom A, 2015, J RHEUMATOL, V42, P1740, DOI 10.3899/jrheum.141529
   Kawasaki J, 2004, ANESTH ANALG, V99, P1440, DOI 10.1213/01.ANE.0000134805.30532.59
   Keane RW, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00135
   Kerr N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0210128
   Kerr N, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00309
   Kessenbrock K, 2009, NAT MED, V15, P623, DOI 10.1038/nm.1959
   Kim H, 2020, BRAIN BEHAV IMMUN, V87, P765, DOI 10.1016/j.bbi.2020.03.011
   Kim SK, 2015, AM J NEURORADIOL, V36, P1756, DOI 10.3174/ajnr.A4402
   Kimball AS, 2016, FRONT IMMUNOL, V7, P1, DOI 10.3389/fimmu.2016.00236
   Laridan E, 2019, SEMIN THROMB HEMOST, V45, P86, DOI 10.1055/s-0038-1677040
   Laridan E, 2017, ANN NEUROL, V82, P223, DOI 10.1002/ana.24993
   Levi M, 2004, CIRCULATION, V109, P2698, DOI 10.1161/01.CIR.0000131660.51520.9A
   Levinsohn JL, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002638
   Niesten JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088882
   Papayannopoulos V, 2018, NAT REV IMMUNOL, V18, P134, DOI 10.1038/nri.2017.105
   Perez-Barcena J, 2021, J NEUROSURG, V134, P1644, DOI 10.3171/2020.2.JNS193079
   Powers WJ, 2019, STROKE, V50, pE344, DOI 10.1161/STR.0000000000000211
   Rennert RC, 2019, NEUROSURGERY, V85, pS4, DOI 10.1093/neuros/nyz042
   Scott XO, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134674
   Sollberger G, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aar6689
   Tong YQ, 2015, INT J CLIN EXP MED, V8, P4787
   Vaccari JPD, 2016, TRANSL RES, V167, P35, DOI 10.1016/j.trsl.2015.05.003
   Vaccari JPD, 2014, J CEREBR BLOOD F MET, V34, P369, DOI 10.1038/jcbfm.2013.227
   Vaccari JPD, 2009, J CEREBR BLOOD F MET, V29, P1251, DOI 10.1038/jcbfm.2009.46
   WADA H, 1991, THROMB HAEMOSTASIS, V65, P364
   Warnatsch A, 2015, SCIENCE, V349, P316, DOI 10.1126/science.aaa8064
   Westerterp M, 2018, CIRCULATION, V138, P898, DOI 10.1161/CIRCULATIONAHA.117.032636
   Yang F, 2014, J CEREBR BLOOD F MET, V34, P660, DOI 10.1038/jcbfm.2013.242
   Yang SJ, 2018, CELL MOL NEUROBIOL, V38, P595, DOI 10.1007/s10571-017-0526-9
   Yeo LLL, 2013, JAMA NEUROL, V70, P353, DOI 10.1001/2013.jamaneurol.547
   Zaidat OO, 2018, STROKE, V49, P660, DOI 10.1161/STROKEAHA.117.020315
NR 64
TC 2
Z9 2
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JAN 22
PY 2021
VL 11
AR 607287
DI 10.3389/fphar.2020.607287
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA QD9GG
UT WOS:000615817700001
PM 33569001
OA gold, Green Published
DA 2021-10-30
ER

PT J
AU Gloppen, KM
   Brown, EC
   Wagenaar, BH
   Hawkins, JD
   Rhew, IC
   Oesterle, S
AF Gloppen, Kari M.
   Brown, Eric C.
   Wagenaar, Bradley H.
   Hawkins, J. David
   Rhew, Isaac C.
   Oesterle, Sabrina
TI SUSTAINING ADOPTION OF SCIENCE-BASED PREVENTION THROUGH COMMUNITIES THAT
   CARE
SO JOURNAL OF COMMUNITY PSYCHOLOGY
LA English
DT Article
ID TRANSLATIONAL RESEARCH; PROBLEM BEHAVIORS; SYSTEM; IMPLEMENTATION;
   DELINQUENCY
AB Communities That Care (CTC) has been shown to increase the use of science-based prevention, resulting in community-wide improvements in youth development. Using data from a community-randomized trial of CTC in 24 communities, this study examined the extent to which community leaders endorsed the use of science-based prevention in CTC communities compared to control communities 3 years after study support for implementation ended, and whether participation in CTC training affected leader endorsement of science-based prevention. This study found that CTC community leaders reported significantly higher stages of adoption of science-based prevention than did leaders in control communities 3 years after study funding ended. However, use of science-based prevention in CTC communities declined. At follow-up, leaders who participated in CTC training reported significantly higher use of science-based prevention than did leaders in CTC communities who did not receive training. Providing continued CTC training could support sustained community adoption of science-based prevention.
C1 [Gloppen, Kari M.; Hawkins, J. David; Oesterle, Sabrina] Univ Washington, Sch Social Work, Seattle, WA 98115 USA.
   [Brown, Eric C.] Univ Miami, Miller Sch Med, Coral Gables, FL 33124 USA.
   [Wagenaar, Bradley H.] Univ Washington, Sch Publ Hlth, Seattle, WA 98115 USA.
   [Rhew, Isaac C.] Univ Washington, Sch Med, Seattle, WA 98115 USA.
RP Gloppen, KM (corresponding author), Univ Washington, Sch Social Work, Social Dev Res Grp, 9725 3rd Ave NE,Suite 401, Seattle, WA 98115 USA.
EM kgloppen@uw.edu
RI Oesterle, Sabrina/AAD-8393-2019; Hawkins, J. David/B-8159-2017
OI Oesterle, Sabrina/0000-0002-2898-6145; 
FU NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1 TR000460] Funding Source: Medline;
   NIDA NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Drug Abuse
   (NIDA) [R01 DA015183] Funding Source: Medline; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000460]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European
   Commission [R01DA015183] Funding Source: NIH RePORTER
CR Arthur MW, 2005, RESILIENCE IN CHILDREN, FAMILIES, AND COMMUNITIES: LINKING CONTEXT TO PRACTICE AND POLICY, P177, DOI 10.1007/0-387-23824-7_11
   Arthur MW, 2002, EVALUATION REV, V26, P575, DOI 10.1177/019384102237850
   Brown EC, 2008, AM J COMMUN PSYCHOL, V41, P115, DOI 10.1007/s10464-007-9154-8
   Brown EC, 2007, PREV SCI, V8, P180, DOI 10.1007/s11121-007-0068-3
   Brown EC, 2014, PREV SCI, V15, P623, DOI 10.1007/s11121-013-0413-7
   Brown EC, 2011, J COMMUNITY PSYCHOL, V39, P183, DOI 10.1002/jcop.20426
   Fagan AA, 2012, AM J COMMUN PSYCHOL, V49, P365, DOI 10.1007/s10464-011-9463-9
   Fagan AA, 2011, PREV SCI, V12, P223, DOI 10.1007/s11121-011-0226-5
   Fagan AA, 2009, J COMMUNITY PSYCHOL, V37, P809, DOI 10.1002/jcop.20332
   Gloppen KM, 2012, J ADOLESCENT HEALTH, V51, P259, DOI 10.1016/j.jadohealth.2011.12.018
   Hallfors D, 2002, AM J PREV MED, V23, P237, DOI 10.1016/S0749-3797(02)00511-1
   Hawkins J. D., 1992, COMMUNITIES CARE ACT
   Hawkins JD, 2008, PREV SCI, V9, P178, DOI 10.1007/s11121-008-0092-y
   Hawkins JD, 2008, J ADOLESCENT HEALTH, V43, P15, DOI 10.1016/j.jadohealth.2008.01.022
   Hawkins JD, 2014, JAMA PEDIATR, V168, P122, DOI 10.1001/jamapediatrics.2013.4009
   Hawkins JD, 2009, ARCH PEDIAT ADOL MED, V163, P789, DOI 10.1001/archpediatrics.2009.141
   Hawkins JD, 2002, ADDICT BEHAV, V27, P951, DOI 10.1016/S0306-4603(02)00298-8
   Kerner J., 2005, HEALTH PSYCHOL, V24, P4
   Mihalic S., 2004, BLUEPRINTS VIOLENCE
   Raudenbush S. W., 2004, 6 HLM SCI SOFTW INT
   Raudenbush S. W., 2002, HIERARCHICAL LINEAR
   Rhew IC, 2013, AM J PUBLIC HEALTH, V103, P529, DOI 10.2105/AJPH.2011.300567
   Shapiro VB, 2013, SOC WORK RES, V37, P349, DOI 10.1093/swr/svt028
   Substance Abuse and Mental Health Services Administration, 2013, NAT REG EV BAS PROGR
   U. S. Department of Health and Human Services, 2013, HLTH PEOPL 2020 AD H
NR 25
TC 8
Z9 8
U1 2
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0090-4392
EI 1520-6629
J9 J COMMUNITY PSYCHOL
JI J. Community Psychol.
PD JAN
PY 2016
VL 44
IS 1
BP 78
EP 89
DI 10.1002/jcop.21743
PG 12
WC Public, Environmental & Occupational Health; Psychology,
   Multidisciplinary; Social Work
SC Public, Environmental & Occupational Health; Psychology; Social Work
GA CZ0YL
UT WOS:000366832400005
PM 27397946
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Perrino, T
   Howe, G
   Sperling, A
   Beardslee, W
   Sandler, I
   Shern, D
   Pantin, H
   Kaupert, S
   Cano, N
   Cruden, G
   Bandiera, F
   Brown, CH
AF Perrino, Tatiana
   Howe, George
   Sperling, Anne
   Beardslee, William
   Sandler, Irwin
   Shern, David
   Pantin, Hilda
   Kaupert, Sheila
   Cano, Nicole
   Cruden, Gracelyn
   Bandiera, Frank
   Brown, C. Hendricks
TI Advancing Science Through Collaborative Data Sharing and Synthesis
SO PERSPECTIVES ON PSYCHOLOGICAL SCIENCE
LA English
DT Article
DE collaborative research; data sharing; data synthesis; scientific equity;
   integrative data analysis
ID RANDOMIZED CONTROLLED-TRIAL; INTEGRATIVE DATA-ANALYSIS; DEPRESSIVE
   SYMPTOMS; PREVENTIVE INTERVENTION; SUBSTANCE USE; CHILDREN; ADOLESCENTS;
   FAMILY; EFFICACY; RISK
AB The demand for researchers to share their data has increased dramatically in recent years. There is a need to replicate and confirm scientific findings to bolster confidence in many research areas. Data sharing also serves the critical function of allowing synthesis of findings across trials. As innovative statistical methods have helped resolve barriers to synthesis analyses, data sharing and synthesis can help answer research questions that cannot be answered by individual trials alone. However, the sharing of data among researchers remains challenging and infrequent. This article aims to (a) increase support for data sharing and synthesis collaborations among researchers to advance scientific knowledge and (b) provide a model for establishing these collaborations using the example of the ongoing National Institute of Mental Health's Collaborative Data Synthesis on Adolescent Depression Trials. This study brings together datasets from existing prevention and treatment trials in adolescent depression, as well as researchers and stakeholders, to answer questions about for whom interventions work and by what pathways interventions have their effects. This is critical to improving interventions, including increasing knowledge about intervention efficacy among minority populations, or what we call scientific equity. The collaborative model described is relevant to fields with research questions that can only be addressed by synthesizing individual-level data.
C1 [Perrino, Tatiana; Pantin, Hilda; Kaupert, Sheila; Cano, Nicole; Cruden, Gracelyn; Brown, C. Hendricks] Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
   [Howe, George] George Washington Univ, Washington, DC 20052 USA.
   [Sperling, Anne] NIMH, Bethesda, MD 20892 USA.
   [Beardslee, William] Childrens Hosp, Boston, MA 02115 USA.
   [Beardslee, William] Harvard Univ, Cambridge, MA 02138 USA.
   [Sandler, Irwin] Arizona State Univ, Tempe, AZ 85287 USA.
   [Shern, David] Mental Hlth Amer, Alexandria, VA USA.
   [Bandiera, Frank] Univ Calif San Francisco, San Francisco, CA 94143 USA.
RP Perrino, T (corresponding author), Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, 1425 NW 10th Ave,307F R-669, Miami, FL 33136 USA.
EM tperrino@med.miami.edu
OI Brown, C Hendricks/0000-0002-0294-2419
FU NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1 TR000460] Funding Source: Medline;
   NIMH NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH) [R01 MH040859] Funding Source: Medline; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000460]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Mental Health (NIMH)
   [R01MH040859] Funding Source: NIH RePORTER
CR Bauer DJ, 2009, PSYCHOL METHODS, V14, P101, DOI 10.1037/a0015583
   Beardslee WR, 2003, PEDIATRICS, V112, pE119, DOI 10.1542/peds.112.2.e119
   Berlin JA, 2002, STAT MED, V21, P371, DOI 10.1002/sim.1023
   Brent DA, 1997, ARCH GEN PSYCHIAT, V54, P877
   Brown C. H., 2011, PREVENTION SCI OFFIC
   Brown CH, 2008, CHILD DEV PERSPECT, V2, P198
   CARDEMIL EV, 2002, PREVENTION TREATMENT, V5
   Chan ME, 2012, PERSPECT PSYCHOL SCI, V7, P79, DOI 10.1177/1745691611429355
   Clarke GN, 2001, ARCH GEN PSYCHIAT, V58, P1127, DOI 10.1001/archpsyc.58.12.1127
   Compas BE, 2009, J CONSULT CLIN PSYCH, V77, P1007, DOI 10.1037/a0016930
   Cooper H., 2012, AM PSYCHOL
   Curran PJ, 2009, PSYCHOL METHODS, V14, P81, DOI 10.1037/a0015914
   Dagne G., 2013, MODERATED NETW UNPUB
   Dishion Thomas J, 2002, Prev Sci, V3, P191, DOI 10.1023/A:1019994500301
   Garber J, 2009, JAMA-J AM MED ASSOC, V301, P2215, DOI 10.1001/jama.2009.788
   Gibbons RD, 2012, ARCH GEN PSYCHIAT
   Gillham JE, 2007, J CONSULT CLIN PSYCH, V75, P9, DOI 10.1037/0022-006x.75.1.9
   Guttmacher AE, 2009, P NATL ACAD SCI USA, V106, P16894, DOI 10.1073/pnas.0910378106
   Hernan MA, 2009, EPIDEMIOLOGY, V20, P167, DOI 10.1097/EDE.0b013e318196784a
   Higgins JPT, 2001, STAT MED, V20, P2219, DOI 10.1002/sim.918
   Hofer SM, 2009, PSYCHOL METHODS, V14, P150, DOI 10.1037/a0015566
   Horowitz JL, 2006, J CONSULT CLIN PSYCH, V74, P401, DOI 10.1037/0022-006X.74.3.401
   Howe G. H., 2012, S 2012 SOC PREV RES
   Israel B. A, 2005, METHODS COMMUNITY BA
   Kell DB, 2008, NATURE, V456, P29, DOI 10.1038/456029c
   MacKinnon D. P., 2008, INTRO STAT MEDIATION, DOI 10.4324/9780203809556
   MacKinnon D. P., 2012, NEW APPROACH I UNPUB
   MacKinnon DP, 2008, HEALTH PSYCHOL, V27, pS99, DOI 10.1037/0278-6133.27.2(Suppl.).S99
   March J, 2004, JAMA-J AM MED ASSOC, V292, P807
   Merry SN, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003380.pub3
   National Research Council and Institute of Medicine, 2009, PREVENTING MENTAL EM
   National Research Council and Institute of Medicine, 2009, DEPR PAR PAR CHILDR
   Nosek BA, 2012, PERSPECT PSYCHOL SCI, V7, P615, DOI 10.1177/1745691612459058
   Pashler H, 2012, PERSPECT PSYCHOL SCI, V7, P528, DOI 10.1177/1745691612465253
   Perrino T., 2012, PREVENTING INT UNPUB
   Piwowar HA, 2008, PLOS MED, V5, P1315, DOI 10.1371/journal.pmed.0050183
   Prado G, 2007, J CONSULT CLIN PSYCH, V75, P914, DOI 10.1037/0022-006X.75.6.914
   Rose BM, 2004, J DEV BEHAV PEDIATR, V25, P58, DOI 10.1097/00004703-200402000-00013
   Rossello J, 1999, J CONSULT CLIN PSYCH, V67, P734, DOI 10.1037/0022-006X.67.5.734
   Sandler IN, 2003, J CONSULT CLIN PSYCH, V71, P587, DOI 10.1037/0022-006X.71.3.587
   Savage CJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007078
   Spoth R, 2009, J CONSULT CLIN PSYCH, V77, P620, DOI 10.1037/a0016029
   Stice E, 2009, J CONSULT CLIN PSYCH, V77, P486, DOI 10.1037/a0015168
   Wicherts JM, 2006, AM PSYCHOL, V61, P726, DOI 10.1037/0003-066X.61.7.726
   Young JF, 2006, J CHILD PSYCHOL PSYC, V47, P1254, DOI 10.1111/j.1469-7610.2006.01667.x
NR 45
TC 35
Z9 35
U1 2
U2 23
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1745-6916
EI 1745-6924
J9 PERSPECT PSYCHOL SCI
JI Perspect. Psychol. Sci.
PD JUL
PY 2013
VL 8
IS 4
BP 433
EP 444
DI 10.1177/1745691613491579
PG 12
WC Psychology, Multidisciplinary
SC Psychology
GA 179BU
UT WOS:000321493400007
PM 24244216
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Gomes-Osman, J
   Kloos, A
AF Gomes-Osman, Joyce
   Kloos, Anne
TI Lateropulsion An Overlooked Driver of Balance and Gait Deficits in
   Stroke?
SO NEUROLOGY
LA English
DT Editorial Material
ID PUSHER SYNDROME; POSTSTROKE
C1 [Gomes-Osman, Joyce] Univ Miami, Miller Sch Med, Dept Phys Therapy, Miami, FL 33136 USA.
   [Gomes-Osman, Joyce] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA.
   [Kloos, Anne] Ohio State Univ, Sch Hlth & Rehabil Sci, Div Phys Therapy, Columbus, OH 43210 USA.
RP Gomes-Osman, J (corresponding author), Univ Miami, Miller Sch Med, Dept Phys Therapy, Miami, FL 33136 USA.; Gomes-Osman, J (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA.
EM j.gomes@miami.edu
FU National Center for Advancing Translational Sciences of the NIHUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Advancing Translational
   Sciences (NCATS) [KL2TR002737]
FX J. Gomes-Osman was supported by the National Center for Advancing
   Translational Sciences of the NIH under award KL2TR002737.
CR Abe H, 2012, STROKE, V43, P1654, DOI 10.1161/STROKEAHA.111.638379
   Babyar SR, 2019, STROKE, V50, P1067, DOI 10.1161/STROKEAHA.118.023445
   Babyar SR, 2015, NEUROREHAB NEURAL RE, V29, P207, DOI 10.1177/1545968314541330
   Dai SH, 2021, NEUROLOGY, V96, pE2147, DOI 10.1212/WNL.0000000000011152
   Koter R, 2017, J NEUROL PHYS THER, V41, P145, DOI 10.1097/NPT.0000000000000194
   Pardo V, 2019, NEUROREHABILITATION, V44, P131, DOI 10.3233/NRE-182549
   Tyson SF, 2006, PHYS THER, V86, P30, DOI 10.1093/ptj/86.1.30
   Veerbeek JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087987
   Yang YR, 2015, CLIN REHABIL, V29, P987, DOI 10.1177/0269215514564898
   Yun N, 2018, EUR J PHYS REHAB MED, V54, P827, DOI 10.23736/S1973-9087.18.05077-3
NR 10
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD APR 27
PY 2021
VL 96
IS 17
BP 779
EP 780
DI 10.1212/WNL.0000000000011156
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA SO2RB
UT WOS:000658823300001
PM 33177225
DA 2021-10-30
ER

PT J
AU Kishtagari, A
   Watts, J
AF Kishtagari, Ashwin
   Watts, Justin
TI Biological and clinical implications of telomere dysfunction in myeloid
   malignancies
SO THERAPEUTIC ADVANCES IN HEMATOLOGY
LA English
DT Review
DE acute myeloid leukemia; myeloid malignancies; telomerase; telomerase
   inhibitors; telomeres; telomere length
ID INHIBITOR IMETELSTAT; GENOME INSTABILITY; ACUTE-LEUKEMIA; LENGTH; CELL;
   CANCER; ASSOCIATION; MUTATIONS; SURVIVAL; CHROMOSOMES
AB Telomeres at the ends of linear chromosomes protect the genome. Telomeres shorten with each round of cell division, placing a finite limit on cell growth. Telomere attrition is associated with cell senescence and apoptosis. Telomerase, a specialized ribonucleoprotein complex, maintains telomeres homeostasis through repeat addition of telomere sequences to the 3 telomeric overhang. Telomere biology is closely related to cancer and normal aging. Upregulation of telomerase or activation of the alternative pathway of telomere lengthening is a hallmark of cancer cells, making telomerase an attractive target for cancer therapeutics. In this review, we will discuss telomere biology and the prognostic implications of telomere length in acute myeloid leukemia, and review exciting new investigational approaches using telomerase inhibitors in acute myeloid leukemia and other myeloid malignancies.
C1 [Watts, Justin] Univ Miami, Miller Sch Med, Dept Med, Div Hematol,Sylvester Comprehens Canc Ctr, 1475 NW 12th Ave, Miami, FL 33136 USA.
   [Kishtagari, Ashwin] Taussig Canc Inst, Dept Translat Hematol & Oncol Res, Cleveland, OH USA.
RP Watts, J (corresponding author), Univ Miami, Miller Sch Med, Dept Med, Div Hematol,Sylvester Comprehens Canc Ctr, 1475 NW 12th Ave, Miami, FL 33136 USA.
EM jwatts@med.miami.edu
RI Kishtagari, Ashwin/AAU-9417-2020
FU American Society of Hematology HONORS award; University of Miami
   Clinical and Translational Science Institute (CTSI) KL2 award
   [KL2TR000461]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [KL2TR000461] Funding Source: NIH
   RePORTER
FX This work was supported by American Society of Hematology HONORS award
   (AK) and University of Miami Clinical and Translational Science
   Institute (CTSI) KL2 award (KL2TR000461) (JW).
CR Aalbers AM, 2013, LEUKEMIA, V27, P1786, DOI 10.1038/leu.2013.57
   Armanios M, 2015, NEW ENGL J MED, V373, P965, DOI 10.1056/NEJMe1508740
   Aubert G, 2012, MUTAT RES-FUND MOL M, V730, P59, DOI 10.1016/j.mrfmmm.2011.04.003
   Baerlocher GM, 2006, NAT PROTOC, V1, P2365, DOI 10.1038/nprot.2006.263
   Baerlocher GM, 2015, NEW ENGL J MED, V373, P920, DOI 10.1056/NEJMoa1503479
   Baljevic M, 2016, ACTA HAEMATOL-BASEL, V136, P210, DOI 10.1159/000448160
   Blackburn EH, 2015, SCIENCE, V350, P1193, DOI 10.1126/science.aab3389
   Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730
   Bruedigam C, 2014, CELL STEM CELL, V15, P775, DOI 10.1016/j.stem.2014.11.010
   Brummendorf TH, 2006, LEUKEMIA, V20, P1706, DOI 10.1038/sj.leu.2404339
   Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271
   Calado RT, 2009, P NATL ACAD SCI USA, V106, P1187, DOI 10.1073/pnas.0807057106
   Capraro V, 2011, EXP HEMATOL, V39, P195, DOI 10.1016/j.exphem.2010.10.008
   Cawthon RM, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkn1027
   Cawthon RM, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e47
   Colla S, 2015, CANCER CELL, V27, P644, DOI 10.1016/j.ccell.2015.04.007
   COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4
   de Lange T, 2009, SCIENCE, V326, P948, DOI 10.1126/science.1170633
   di Fagagna FD, 2003, NATURE, V426, P194, DOI 10.1038/nature02118
   Gerbing RB, 2016, J CLIN ONCOL, V34, P3766, DOI 10.1200/JCO.2016.66.9622
   Gessner A, 2010, LEUKEMIA, V24, P1751, DOI 10.1038/leu.2010.155
   Hartmann U, 2005, HAEMATOLOGICA, V90, P307
   Khoury HJ, 2017, CANCER-AM CANCER SOC, V123, P3061, DOI 10.1002/cncr.30696
   KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428
   LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0
   LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3
   Maciejowski J, 2017, NAT REV MOL CELL BIO, V18, P175, DOI 10.1038/nrm.2016.171
   Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063
   Mosrati MA, 2015, ONCOTARGET, V6, P25109, DOI 10.18632/oncotarget.4668
   Mrozek K, 2004, BLOOD REV, V18, P115, DOI 10.1016/S0268-960X(03)00040-7
   O'Sullivan RJ, 2010, NAT REV MOL CELL BIO, V11, P171, DOI 10.1038/nrm2848
   OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7
   Parker M, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-12-r113
   Scheinberg P, 2010, JAMA-J AM MED ASSOC, V304, P1358, DOI 10.1001/jama.2010.1376
   Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2
   Swiggers SJJ, 2006, GENE CHROMOSOME CANC, V45, P247, DOI 10.1002/gcc.20286
   Tefferi A., 2016, BLOOD CANC J, V126, P55
   Tefferi A, 2015, NEW ENGL J MED, V373, P908, DOI 10.1056/NEJMoa1310523
   Townsley DM, 2014, BLOOD, V124, P2775, DOI 10.1182/blood-2014-05-526285
   Wang Y, 2010, INT J LAB HEMATOL, V32, P230, DOI 10.1111/j.1751-553X.2009.01178.x
   WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0
   Watts JM, 2016, LEUKEMIA RES, V49, P62, DOI 10.1016/j.leukres.2016.07.013
NR 42
TC 5
Z9 5
U1 0
U2 5
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 2040-6207
EI 2040-6215
J9 THER ADV HEMATOL
JI Ther. Adv. Hematol.
PD NOV
PY 2017
VL 8
IS 11
BP 317
EP 326
DI 10.1177/2040620717731549
PG 10
WC Hematology
SC Hematology
GA FK4YV
UT WOS:000413504900001
PM 29093807
OA Green Published, Bronze
DA 2021-10-30
ER

PT C
AU Sadiq, S
   Yan, YL
   Shyu, ML
   Chen, SC
   Ishwaran, H
AF Sadiq, Saad
   Yan, Yilin
   Shyu, Mei-Ling
   Chen, Shu-Ching
   Ishwaran, Hemant
GP IEEE
TI Enhancing Multimedia Imbalanced Concept Detection Using VIMP in Random
   Forests
SO PROCEEDINGS OF 2016 IEEE 17TH INTERNATIONAL CONFERENCE ON INFORMATION
   REUSE AND INTEGRATION (IEEE IRI)
LA English
DT Proceedings Paper
CT 17th IEEE International Conference on Information Reuse and Integration
CY JUL 28-30, 2016
CL Pittsburgh, PA
SP IEEE, IEEE Comp Soc, Univ Pittsburgh, Sch Informat Sci, IBM, Almaden Inst
DE Multimedia imbalanced concept detection; Multivariate regression;
   Variable importance (VIMP); Random forests
ID LEARNING FRAMEWORK; VIDEO; RETRIEVAL; RECOGNITION
AB Recent developments in social media and cloud storage lead to an exponential growth in the amount of multimedia data, which increases the complexity of managing, storing, indexing, and retrieving information from such big data. Many current content-based concept detection approaches lag from successfully bridging the semantic gap. To solve this problem, a multi-stage random forest framework is proposed to generate predictor variables based on multivariate regressions using variable importance (VIMP). By fine tuning the forests and significantly reducing the predictor variables, the concept detection scores are evaluated when the concept of interest is rare and imbalanced, i.e., having little collaboration with other high level concepts. Using classical multivariate statistics, estimating the value of one coordinate using other coordinates standardizes the covariates and it depends upon the variance of the correlations instead of the mean. Thus, conditional dependence on the data being normally distributed is eliminated. Experimental results demonstrate that the proposed framework outperforms those approaches in the comparison in terms of the Mean Average Precision (MAP) values.
C1 [Sadiq, Saad; Yan, Yilin; Shyu, Mei-Ling] Univ Miami, Dept Elect & Comp Engn, Coral Gables, FL 33124 USA.
   [Chen, Shu-Ching] Florida Int Univ, Sch Comp & Informat Sci, Miami, FL 33199 USA.
   [Ishwaran, Hemant] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Div Biostat, Miami, FL 33136 USA.
RP Sadiq, S (corresponding author), Univ Miami, Dept Elect & Comp Engn, Coral Gables, FL 33124 USA.
EM saadsadiq@miami.edu; y.yan4@umiami.edu; shyu@miami.edu; chens@csfiu.edu;
   hishwaran@biostat.med.miami.edu
FU NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1 TR000460] Funding Source: Medline;
   NCI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01
   CA163739] Funding Source: Medline; Division Of Human Resource
   DevelopmentNational Science Foundation (NSF)NSF- Directorate for
   Education & Human Resources (EHR) [1547798] Funding Source: National
   Science Foundation; NATIONAL CANCER INSTITUTEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Cancer Institute (NCI) [R01CA163739] Funding Source: NIH
   RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Advancing Translational
   Sciences (NCATS) [UL1TR000460] Funding Source: NIH RePORTER
CR Aytar Y, 2007, 2007 IEEE INTERNATIONAL CONFERENCE ON MULTIMEDIA AND EXPO, VOLS 1-5, P536
   Bai L., 2011, P INT C INT MULT COM, P158
   Ballan L, 2010, IEEE MULTIMEDIA, V17, P80, DOI 10.1109/MMUL.2010.4
   Benmokhtar R, 2014, MULTIMED TOOLS APPL, V73, P663, DOI 10.1007/s11042-011-0936-5
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Chen LC, 2015, PATTERN RECOGN, V48, P1979, DOI 10.1016/j.patcog.2014.12.018
   Chen S.-C., 2000, INT J NETWORKING INF, V3, P9
   Chen S.-C., 2000, SEMANTIC MODELS MULT
   Chen S. -C., 1997, P INT S MULT INF PRO, P441
   Chen SC, 2001, 2001 IEEE INTELLIGENT TRANSPORTATION SYSTEMS - PROCEEDINGS, P213, DOI 10.1109/ITSC.2001.948658
   Chen SC, 2006, IEEE T SYST MAN CY C, V36, P772, DOI 10.1109/TSMCC.2005.855507
   Chen Shu-Ching, 2005, VIDEO DATA MANAGEMEN, P217
   Chen X, 2005, IEEE INT SYM MULTIM, P37
   Chen X, 2009, IEEE T SYST MAN CY C, V39, P228, DOI 10.1109/TSMCC.2008.2007257
   Choi MJ, 2012, IEEE T PATTERN ANAL, V34, P240, DOI 10.1109/TPAMI.2011.119
   Elleuch N., 2011, P INT WORKSH MULT DA
   Fan JP, 2004, IEEE T IMAGE PROCESS, V13, P974, DOI 10.1109/TIP.2004.827232
   Feng H., 2004, P 12 ANN ACM INT C M, P960, DOI [10.1145/1027527.1027748, DOI 10.1145/1027527.1027748]
   Huang X., 2002, P 3 INT WORKSH MULT, P100
   Ishwaran Hemant, 2011, Statistical Analysis and Data Mining, V4, P115, DOI 10.1002/sam.10103
   Jiang Y.-G., 2010, PREDICTION SCORES TR
   Jiang YG, 2009, IEEE I CONF COMP VIS, P1420, DOI 10.1109/ICCV.2009.5459295
   Li XQ, 2002, P INT COMP SOFTW APP, P914, DOI 10.1109/CMPSAC.2002.1045122
   Li XX, 2002, PROCEEDINGS OF THE SECOND INTERNATIONAL SYMPOSIUM ON INSTRUMENTATION SCIENCE AND TECHNOLOGY, VOL 1, P152
   Lin L, 2007, 2007 IEEE INTERNATIONAL CONFERENCE ON MULTIMEDIA AND EXPO, VOLS 1-5, P859
   Lin L, 2011, IEEE MULTIMEDIA, V18, P32, DOI 10.1109/MMUL.2011.35
   Lin L, 2010, INT J MULTIMED DATA, V1, P37, DOI 10.4018/jmdem.2010111203
   Lin Lin, 2008, 2008 IEEE International Conference on Sensor Networks, Ubiquitous, and Trustworthy Computing (SUTC '08), P262, DOI 10.1109/SUTC.2008.66
   Lin L, 2009, IEEE INT CON MULTI, P418, DOI 10.1109/ICME.2009.5202523
   Liu DT, 2015, INT J MULTIMED DATA, V6, P1, DOI 10.4018/ijmdem.2015010101
   MARSZALEK M, 2007, P VIS REC CHALL WORK
   Mei-Ling Shyu, 2001, 2001 IEEE International Conference on Systems, Man and Cybernetics. e-Systems and e-Man for Cybernetics in Cyberspace (Cat.No.01CH37236), P1717, DOI 10.1109/ICSMC.2001.973533
   Merler M, 2012, IEEE T MULTIMEDIA, V14, P88, DOI 10.1109/TMM.2011.2168948
   Moosmann F., 2007, ADV NEURAL INF PROCE, P985
   Philbin J., 2008, P IEEE C COMP VIS PA, P1, DOI DOI 10.1109/CVPR.2008.4587635
   Rabinovich A, 2007, IEEE I CONF COMP VIS, P1237, DOI 10.1109/iccv.2007.4408986
   Segal M.R., 2004, MACHINE LEARNING BEN
   Shotton J., 2008, IEEE C COMP VIS PATT, V2008, P1, DOI DOI 10.1109/CVPR.2008.4587503
   Shu-Ching Chen, 1999, Proceedings 11th International Conference on Tools with Artificial Intelligence, P175, DOI 10.1109/TAI.1999.809783
   Shu-Ching Chen, 2001, International Journal on Artificial Intelligence Tools (Architectures, Languages, Algorithms), V10, P715
   Shyu M.-L., 2001, Knowledge and Information Systems, V3, P319, DOI 10.1007/PL00011671
   Shyu M.-L., 2003, P 1 ACM INT WORKSH M, P78
   Shyu ML, 2007, ACM T AUTON ADAP SYS, V2, DOI 10.1145/1278460.1278463
   Shyu ML, 2008, IEEE T MULTIMEDIA, V10, P252, DOI 10.1109/TMM.2007.911830
   Shyu ML, 2005, INTERNATIONAL WORKSHOP ON CHALLENGES IN WEB INFORMATION RETRIEVAL AND INTEGRATION, PROCEEDINGS, P128
   Shyu ML, 2005, 15th International Workshop on Research Issues in Data Engineering: Stream Data Mining and Applications, Proceedings, P55, DOI 10.1109/RIDE.2005.10
   Shyu ML, 2003, INFORM SCIENCES, V155, P181, DOI 10.1016/S0020-0255(03)00169-5
   SHYU ML, 2004, P 2 ACM INT WORKSH M, P19
   Smeaton A.F., 2006, MIR 2006, P321, DOI DOI 10.1145/1178677.1178722
   Strobl C, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-307
   Uijlings JRR, 2010, IEEE T MULTIMEDIA, V12, P665, DOI 10.1109/TMM.2010.2052027
   Van de Sande K. E., 2008, P 2008 INT C CONT BA, P141, DOI DOI 10.1145/1386352.1386376
   van Gemert JC, 2010, IEEE T PATTERN ANAL, V32, P1271, DOI 10.1109/TPAMI.2009.132
   Yan YL, 2014, 2014 IEEE 15TH INTERNATIONAL CONFERENCE ON INFORMATION REUSE AND INTEGRATION (IRI), P561, DOI 10.1109/IRI.2014.7051939
   Yan YL, 2015, IEEE INT SYM MULTIM, P483, DOI 10.1109/ISM.2015.126
   Zhang J, 2007, INT J COMPUT VISION, V73, P213, DOI 10.1007/s11263-006-9794-4
   Zhu QS, 2015, IEEE T EMERG TOP COM, V3, P152, DOI 10.1109/TETC.2014.2384992
   Zhu QS, 2011, INT J MULTIMED DATA, V2, P34, DOI 10.4018/jmdem.2011070103
   Zhu QS, 2010, IEEE INT C SEMANT CO, P462, DOI 10.1109/ICSC.2010.65
NR 59
TC 9
Z9 9
U1 0
U2 2
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
BN 978-1-5090-3207-5
PY 2016
BP 601
EP 608
DI 10.1109/IRI.2016.87
PG 8
WC Computer Science, Theory & Methods; Engineering, Electrical & Electronic
SC Computer Science; Engineering
GA BG7KA
UT WOS:000391397100078
PM 28929141
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Schwartz, SJ
   Unger, JB
   Lorenzo-Blanco, EI
   Des Rosiers, SE
   Villamar, JA
   Soto, DW
   Pattarroyo, M
   Baezconde-Garbanati, L
   Szapocznik, J
AF Schwartz, Seth J.
   Unger, Jennifer B.
   Lorenzo-Blanco, Elma I.
   Des Rosiers, Sabrina E.
   Villamar, Juan A.
   Soto, Daniel W.
   Pattarroyo, Monica
   Baezconde-Garbanati, Lourdes
   Szapocznik, Jose
TI Perceived Context of Reception Among Recent Hispanic Immigrants:
   Conceptualization, Instrument Development, and Preliminary Validation
SO CULTURAL DIVERSITY & ETHNIC MINORITY PSYCHOLOGY
LA English
DT Article
DE context of reception; discrimination; Hispanic; immigrants;
   acculturation
ID ETHNIC DISCRIMINATION; IDENTITY; ACCULTURATION; INVARIANCE;
   COMMUNICATION; ASSIMILATION; PSYCHOLOGY; MINORITY; SYMPTOMS; VIOLENCE
AB Context of reception has been discussed widely in the sociological and anthropological literature, but no measures of this construct exist. We designed a measure of perceived context of reception and provide initial support for the factorial validity, internal consistency reliability, and incremental and discriminant validity of scores generated by this measure. A sample of 302 recent-immigrant Hispanic parent-adolescent dyads from Miami and Los Angeles completed the new perceived context of reception measure, as well as measures of perceived discrimination; Hispanic/American cultural practices, values, and identifications; and depressive symptoms. In Phase 1, exploratory and confirmatory factor analyses extracted a factor for negative perceived context of reception. A subscale corresponding to this factor was used in Phase 2; for parents and adolescents, negative perceived context of reception and perceived discrimination were differentially associated with acculturation-related variables-suggesting discriminant validity between perceived discrimination and negative perceived context of reception. For adolescents at both sites and for parents in Los Angeles only, the negative perceived context of reception dimensions were significantly associated with depressive symptoms 6 months later, over and above the contribution made by perceived discrimination-suggesting incremental validity. Results are discussed in terms of perceived context of reception as a new and emerging construct.
C1 [Schwartz, Seth J.; Szapocznik, Jose] Univ Miami, Dept Publ Hlth Sci, Leonard M Miller Sch Med, Miami, FL 33136 USA.
   [Unger, Jennifer B.; Soto, Daniel W.; Pattarroyo, Monica; Baezconde-Garbanati, Lourdes] Univ So Calif, Keck Sch Med, Dept Prevent Med, Inst Prevent Res, Los Angeles, CA 90033 USA.
   [Lorenzo-Blanco, Elma I.] Univ So Calif, Dept Psychol, Los Angeles, CA 90089 USA.
   [Des Rosiers, Sabrina E.] Barry Univ, Dept Psychol, Miami Shores, FL USA.
   [Villamar, Juan A.] Northwestern Univ, Dept Prevent Med, Feinberg Sch Med, Evanston, IL 60208 USA.
RP Schwartz, SJ (corresponding author), Univ Miami, Dept Publ Hlth Sci, Leonard M Miller Sch Med, 1425 NW 10th Ave,Suite 321, Miami, FL 33136 USA.
EM sschwartz@med.miami.edu
OI Unger, Jennifer/0000-0001-9064-6603
FU NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000460] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG
   ABUSEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Drug Abuse
   (NIDA)European Commission [R01DA025694] Funding Source: NIH RePORTER;
   NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [1UL1TR000460, UL1 TR000460] Funding
   Source: Medline; NIDA NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Drug Abuse (NIDA) [DA025694, R01 DA025694] Funding Source: Medline
CR Alba R, 2006, REMAKING AM MAINSTRE
   Arnett JJ, 2002, AM PSYCHOL, V57, P774, DOI 10.1037//0003-066X.57.10.774
   Barker V, 2001, J COMMUN, V51, P3, DOI 10.1111/j.1460-2466.2001.tb02870.x
   BARNES HL, 1985, CHILD DEV, V56, P438, DOI 10.1111/j.1467-8624.1985.tb00118.x
   Buchanan P.J., 2006, STATE EMERGENCY 3 WO
   Byrne B., 2011, STRUCTURAL EQUATION
   CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016
   Castillo LG, 2009, REHABIL PSYCHOL, V54, P351, DOI 10.1037/a0017801
   CERVANTES RC, 1989, HOSP COMMUNITY PSYCH, V40, P615
   Cohen J., 2013, STAT POWER ANAL BEHA
   Conway JM, 2003, ORGAN RES METHODS, V6, P147, DOI 10.1177/1094428103251541
   Cooley PC, 2001, COMPUT HUM BEHAV, V17, P285, DOI 10.1016/S0747-5632(01)00005-X
   Cordova D, 2010, HISPANIC J BEHAV SCI, V32, P259, DOI 10.1177/0739986310362371
   Cornelius Wayne, 2002, LATINOS REMAKING AM, P165
   Dimitrov DM, 2010, MEAS EVAL COUNS DEV, V43, P121, DOI 10.1177/0748175610373459
   Erwin D. O., 2003, Southern Rural Sociology, V19, P46
   Fernandez-Kelly Patricia, 2001, ETHNICITIES CHILDREN, P127
   Finch Brian Karl, 2003, J Immigr Health, V5, P109, DOI 10.1023/A:1023987717921
   Fox C, 2004, AM J SOCIOL, V110, P580, DOI 10.1086/422587
   Galenson DW, 1997, AM J EDUC, V105, P261, DOI 10.1086/444157
   GormanSmith D, 1996, J FAM PSYCHOL, V10, P115, DOI 10.1037/0893-3200.10.2.115
   Guo XH, 2009, PSYCHOL ASSESSMENT, V21, P22, DOI 10.1037/a0014495
   HayesBautista DE, 2004, NUEVA CALIFORNIA: LATINOS IN THE GOLDEN STATE, P1
   Hirschman C, 2001, DEMOGRAPHY, V38, P317, DOI 10.2307/3088348
   Huntington S.P., 2004, WHO ARE WE CHALLENGE
   Jensen LA, 2011, HANDBOOK OF IDENTITY THEORY AND RESEARCH, VOLS 1 AND 2, P285, DOI 10.1007/978-1-4419-7988-9_13
   KAISER HF, 1958, PSYCHOMETRIKA, V23, P187, DOI 10.1007/BF02289233
   Kasinitz Philip., 2008, INHERITING CITY CHIL
   Kauermann G, 2001, J AM STAT ASSOC, V96, P1387, DOI 10.1198/016214501753382309
   Kim SY, 2011, DEV PSYCHOL, V47, P289, DOI 10.1037/a0020712
   King EB, 2011, PSYCHOL PUBLIC POL L, V17, P54, DOI 10.1037/a0021673
   Kline RB., 2006, PRINCIPLES PRACTICES, V2nd ed
   LARSEN L, 2004, P20551 US CENS BUR
   Light I., 2006, DEFLECTING IMMIGRATI
   Logan JR, 2002, AM SOCIOL REV, V67, P299, DOI 10.2307/3088897
   Marsh HW, 2004, STRUCT EQU MODELING, V11, P320, DOI 10.1207/s15328007sem1103_2
   Massey DS, 2010, MEX STUD, V26, P129, DOI 10.1525/msem.2010.26.1.129
   Murry K., 2011, J HISPANIC HIGHER ED, V10, P266, DOI [10.1177/1538192708330232, DOI 10.1177/1538192708330232]
   Passel J. S, 2006, SIZE CHARACTERISTICS
   Perez W., 2009, WE ARE AM UNDOCUMENT WE ARE AM UNDOCUMENT
   Phinney J., 2003, ACCULTURATION ADV TH, P63, DOI DOI 10.1037/10472-006
   Phinney JS, 1998, J APPL SOC PSYCHOL, V28, P937, DOI 10.1111/j.1559-1816.1998.tb01661.x
   Pieterse AL, 2010, J COUNS PSYCHOL, V57, P255, DOI 10.1037/a0020040
   Portes A., 2001, LEGACIES STORY IMMIG
   Portes A, 2006, IMMIGRANT AM PORTRAI, V3
   RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306
   Raudenbush S. W., 2002, HIERARCHICAL LINEAR
   Roberts RE, 1999, J EARLY ADOLESCENCE, V19, P301, DOI 10.1177/0272431699019003001
   Rumbaut R., 2001, ETHNICITIES CHILDREN
   Sabogal E, 2005, LAT STUD, V3, P113, DOI 10.1057/palgrave.lst.8600128
   Saenz R., 2003, Southern Rural Sociology, V19, P1
   Scheepers D, 2002, J EXP SOC PSYCHOL, V38, P611, DOI 10.1016/S0022-1031(02)00506-1
   Schwartz S. J., OXFORD HDB IN PRESS
   Schwartz SJ, 2007, BASIC APPL SOC PSYCH, V29, P159, DOI 10.1080/01973530701332229
   Schwartz SJ, 2012, IDENTITY, V12, P93, DOI 10.1080/15283488.2012.668730
   Schwartz SJ, 2011, J COUNS PSYCHOL, V58, P27, DOI 10.1037/a0021356
   Schwartz SJ, 2010, CULT DIVERS ETHN MIN, V16, P548, DOI 10.1037/a0021370
   Schwartz SJ, 2010, AM PSYCHOL, V65, P237, DOI 10.1037/a0019330
   Schwartz SJ, 2006, J CROSS CULT PSYCHOL, V37, P345, DOI 10.1177/0022022106286928
   Sireci SG, 2006, J CROSS CULT PSYCHOL, V37, P557, DOI 10.1177/0022022106290478
   Steele CM, 1997, AM PSYCHOL, V52, P613, DOI 10.1037/0003-066X.52.6.613
   Steiner N., 2009, INT MIGRATION CITIZE
   Stepick A, 2003, THIS LAND IS OUR LAND: IMMIGRANTS AND POWER IN MIAMI, P1
   Stepick A., 2002, LATINOS REMAKING AM, P75
   Stepick A, 2011, HANDBOOK OF IDENTITY THEORY AND RESEARCH, VOLS 1 AND 2, P867, DOI 10.1007/978-1-4419-7988-9_37
   Stepick A, 2010, ETHNIC RACIAL STUD, V33, P1149, DOI 10.1080/01419871003599518
   Stepick Alex., 1994, CITY EDGE TRANSFORMA
   STERBA CM, 2003, GOOD AM ITALIAN JEWI
   Stoll MA, 2002, REG STUD, V36, P97, DOI 10.1080/00343400220121891
   Suarez-Orozco C., 2008, LEARNING NEW LAND IM
   Suarez-Orozco C., 2001, CHILDREN IMMIGRATION
   SZAPOCZNIK J, 1978, J CONSULT CLIN PSYCH, V46, P961, DOI 10.1037/0022-006X.46.5.961
   Szapocznik J., 1980, INT J INTERCULT REL, V4, P353, DOI [10.1016/0147-1767(80)90010-3, DOI 10.1016/0147-1767(80)90010-3]
   Thompson B, 1996, EDUC PSYCHOL MEAS, V56, P197, DOI 10.1177/0013164496056002001
   Thompson B., 2004, EXPLORATORY CONFIRMA, DOI DOI 10.1037/10694-000
   Todorova ILG, 2010, SOCIOL HEALTH ILL, V32, P843, DOI 10.1111/j.1467-9566.2010.01257.x
   Torres L, 2010, CULT DIVERS ETHN MIN, V16, P561, DOI 10.1037/a0020652
   Triandis H.C., 2018, INDIVIDUALISM COLLEC
   Turner CF, 1998, SCIENCE, V280, P867, DOI 10.1126/science.280.5365.867
   U. S. Census Bureau, 2010, NAT SEX AG HISP OR
   Ullman J.B., 2007, USING MULTIVARIATE S, V5
   van de Vijver FJR, 2004, APPL PSYCHOL-INT REV, V53, P215, DOI 10.1111/j.1464-0597.2004.00169.x
   Vandenberg RJ, 2000, ORGAN RES METHODS, V3, P4, DOI 10.1177/109442810031002
   Waters MC, 2005, ANNU REV SOCIOL, V31, P105, DOI 10.1146/annurev.soc.29.010202.100026
NR 84
TC 71
Z9 71
U1 3
U2 26
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 1099-9809
EI 1939-0106
J9 CULT DIVERS ETHN MIN
JI Cult. Divers. Ethn. Minor. Psychol.
PD JAN
PY 2014
VL 20
IS 1
BP 1
EP 15
DI 10.1037/a0033391
PG 15
WC Ethnic Studies; Psychology, Social
SC Ethnic Studies; Psychology
GA AA1SN
UT WOS:000330876100001
PM 24099485
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Kornfeld, J
   Byrne, MM
   Vanderpool, R
   Shin, S
   Kobetz, E
AF Kornfeld, Julie
   Byrne, Margaret M.
   Vanderpool, Robin
   Shin, Sarah
   Kobetz, Erin
TI HPV Knowledge and Vaccine Acceptability Among Hispanic Fathers
SO JOURNAL OF PRIMARY PREVENTION
LA English
DT Article
DE Human papillomavirus (HPV); HPV vaccine acceptability; Hispanic men; HPV
   knowledge
ID HUMAN-PAPILLOMAVIRUS INFECTION; RACIAL-DIFFERENCES; NATIONAL SAMPLE;
   RISK-FACTORS; MEN; PREVALENCE; ACCULTURATION; ACCEPTANCE; PREVENTION;
   INTERVENTION
AB The purpose of this study was to examine human papillomavirus (HPV) knowledge and vaccine acceptability in a convenience sample of immigrant Hispanic men, many of whom are parents of adolescents. Data on 189 male callers were collected from the National Cancer Institute's Cancer Information Service Spanish-language call center. Most participants were willing to vaccinate their adolescent son (87.5 %) or daughter (78.8 %) against HPV. However, among this sample, awareness of HPV was low and knowledge of key risk factors varied. These findings can help guide the development of culturally informed educational efforts aimed at increasing informed decision-making about HPV vaccination among Hispanic fathers.
C1 [Kornfeld, Julie; Byrne, Margaret M.; Kobetz, Erin] Univ Miami, Miller Sch Med, Dept Epidemiol & Publ Hlth, Miami, FL 33136 USA.
   [Vanderpool, Robin] Univ Kentucky, Coll Publ Hlth, Dept Hlth Behav, Lexington, KY USA.
   [Shin, Sarah] Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
RP Kornfeld, J (corresponding author), Univ Miami, Miller Sch Med, Dept Epidemiol & Publ Hlth, Clin Res Bldg,Room 910 Locator Code R669,1120 NW, Miami, FL 33136 USA.
EM jkornfel@med.miami.edu
FU NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1 TR000460] Funding Source: Medline;
   NCI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [N02
   CO051106, U54 CA153705] Funding Source: Medline; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [U54CA153705] Funding Source: NIH RePORTER; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000460]
   Funding Source: NIH RePORTER
CR Anonymous, 2010, Morbidity and Mortality Weekly Report, V59, P630
   [Anonymous], 1974, Health Education Monograph, V2, P324
   Armitage CJ, 2001, BRIT J SOC PSYCHOL, V40, P471, DOI 10.1348/014466601164939
   Bair RM, 2008, AMBUL PEDIATR, V8, P98, DOI 10.1016/j.ambp.2007.11.002
   Benard VB, 2008, CANCER-AM CANCER SOC, V113, P2910, DOI 10.1002/cncr.23742
   Boehner CW, 2003, SEX TRANSM DIS, V30, P774, DOI 10.1097/01.OLQ.0000078823.05041.9E
   Bosch FX, 1996, JNCI-J NATL CANCER I, V88, P1060, DOI 10.1093/jnci/88.15.1060
   Bosch FX, 2002, J CLIN PATHOL, V55, P244, DOI 10.1136/jcp.55.4.244
   Brewer NT, 2007, PREV MED, V45, P107, DOI 10.1016/j.ypmed.2007.05.013
   Cates JR, 2009, J RURAL HEALTH, V25, P93, DOI 10.1111/j.1748-0361.2009.00204.x
   Centers for Disease Control and Prevention, 2008, HIV AIDS HISP LAT
   Chin-Hong PV, 2004, J INFECT DIS, V190, P2070, DOI 10.1086/425906
   Colon-Lopez V, 2010, P R HEALTH SCI J, V29, P232
   Daley EM, 2011, VACCINE, V29, P4013, DOI 10.1016/j.vaccine.2011.03.060
   Dempsey AF, 2006, PEDIATRICS, V117, P1486, DOI 10.1542/peds.2005-1381
   DiClemente RJ, 2004, JAMA-J AM MED ASSOC, V292, P171, DOI 10.1001/jama.292.2.171
   Dunne EF, 2006, J INFECT DIS, V194, P1044, DOI 10.1086/507432
   Ferris DG, 2009, J AM BOARD FAM MED, V22, P34, DOI 10.3122/jabfm.2009.01.080008
   Ferris DG, 2008, J LOW GENIT TRACT DI, V12, P276, DOI 10.1097/LGT.0b013e318167913e
   Fishbein M., 1975, BELIEF ATTITUDE INTE
   Gerend MA, 2009, SEX TRANSM DIS, V36, P58, DOI 10.1097/OLQ.0b013e31818606fc
   Gillison ML, 2008, CANCER-AM CANCER SOC, V113, P3036, DOI 10.1002/cncr.23764
   Giuliano AR, 2010, GYNECOL ONCOL, V117, pS15, DOI 10.1016/j.ygyno.2010.01.026
   Hildesheim A, 2007, J INFECT DIS, V196, P1431, DOI 10.1086/522869
   Jones M, 2008, J AM COLL HEALTH, V57, P23, DOI 10.3200/JACH.57.1.23-32
   Lenselink CH, 2008, PUBLIC HEALTH, V122, P1295, DOI 10.1016/j.puhe.2008.02.010
   Liddon N, 2010, J ADOLESCENT HEALTH, V46, P113, DOI 10.1016/j.jadohealth.2009.11.199
   MARIN G, 1987, HISPANIC J BEHAV SCI, V9, P183, DOI 10.1177/07399863870092005
   National Cancer Institute, 2009, HLTH INF NAT TRENDS
   NEGY C, 1992, HISPANIC J BEHAV SCI, V14, P248, DOI 10.1177/07399863920142004
   Nielson CM, 2009, CANCER EPIDEM BIOMAR, V18, P1077, DOI 10.1158/1055-9965.EPI-08-0447
   Palefsky JM, 1998, J INFECT DIS, V177, P361, DOI 10.1086/514194
   Reiter PL, 2010, SEX TRANSM INFECT, V86, P241, DOI 10.1136/sti.2009.039065
   Reiter PL, 2010, SEX TRANSM DIS, V37, P197, DOI 10.1097/OLQ.0b013e3181bf542c
   Rosenthal SL, 2008, J ADOLESCENT HEALTH, V43, P239, DOI 10.1016/j.jadohealth.2008.06.009
   SABOGAL F, 1987, HISPANIC J BEHAV SCI, V9, P397, DOI 10.1177/07399863870094003
   Santos JI, 2004, J INFECT DIS, V189, pS243, DOI 10.1086/378520
   Schillinger D, 2002, JAMA-J AM MED ASSOC, V288, P475, DOI 10.1001/jama.288.4.475
   Viswanath K., 1996, ANN INT COMMUN ASS, V19, P187, DOI [10.1080/23808985.1996.11678931, DOI 10.1080/23808985.1996.11678931]
   Watson M, 2008, CANCER-AM CANCER SOC, V113, P2841, DOI 10.1002/cncr.23758
   Watts LA, 2009, GYNECOL ONCOL, V112, P577, DOI 10.1016/j.ygyno.2008.12.010
   Weinstock H, 2004, PERSPECT SEX REPRO H, V36, P6, DOI 10.1363/3600604
NR 42
TC 19
Z9 19
U1 1
U2 11
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0278-095X
EI 1573-6547
J9 J PRIM PREV
JI J. Prim. Prev.
PD APR
PY 2013
VL 34
IS 1-2
SI SI
BP 59
EP 69
DI 10.1007/s10935-013-0297-0
PG 11
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 143OY
UT WOS:000318878200007
PM 23377881
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Schwartz, SJ
   Benet-Martinez, V
   Knight, GP
   Unger, JB
   Zamboanga, BL
   Rosiers, SED
   Stephens, DP
   Huang, S
   Szapocznik, J
AF Schwartz, Seth J.
   Benet-Martinez, Veronica
   Knight, George P.
   Unger, Jennifer B.
   Zamboanga, Byron L.
   Rosiers, Sabrina E. Des
   Stephens, Dionne P.
   Huang, Shi
   Szapocznik, Jose
TI Effects of Language of Assessment on the Measurement of Acculturation:
   Measurement Equivalence and Cultural Frame Switching
SO PSYCHOLOGICAL ASSESSMENT
LA English
DT Article
DE acculturation; measurement equivalence; Hispanics; construct validity;
   cultural frame switching
ID BICULTURAL IDENTITY INTEGRATION; OF-FIT INDEXES; ETHNIC-IDENTITY;
   ADOLESCENTS; INVARIANCE; SCALE; VALIDATION; LATINO; ASSIMILATION;
   IMMIGRATION
AB The present study used a randomized design, with fully bilingual Hispanic participants from the Miami area, to investigate 2 sets of research questions. First, we sought to ascertain the extent to which measures of acculturation (Hispanic and U.S. practices, values, and identifications) satisfied criteria for linguistic measurement equivalence. Second, we sought to examine whether cultural frame switching would emerge-that is, whether latent acculturation mean scores for U.S. acculturation would be higher among participants randomized to complete measures in English and whether latent acculturation mean scores for Hispanic acculturation would be higher among participants randomized to complete measures in Spanish. A sample of 722 Hispanic students from a Hispanic-serving university participated in the study. Participants were first asked to complete translation tasks to verify that they were fully bilingual. Based on ratings from 2 independent coders, 574 participants (79.5% of the sample) qualified as fully bilingual and were randomized to complete the acculturation measures in either English or Spanish. Theoretically relevant criterion measures-self-esteem, depressive symptoms, and personal identity-were also administered in the randomized language. Measurement equivalence analyses indicated that all of the acculturation measures-Hispanic and U. S. practices, values, and identifications-met criteria for configural, weak/metric, strong/scalar, and convergent validity equivalence. These findings indicate that data generated using acculturation measures can, at least under some conditions, be combined or compared across languages of administration. Few latent mean differences emerged. These results are discussed in terms of the measurement of acculturation in linguistically diverse populations.
C1 [Schwartz, Seth J.; Huang, Shi; Szapocznik, Jose] Univ Miami, Leonard M Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA.
   [Benet-Martinez, Veronica] Univ Pompeu Fabra, Inst Catalana Recerca & Estudis Avancats, Barcelona, Spain.
   [Benet-Martinez, Veronica] Univ Pompeu Fabra, Dept Polit & Social Sci, Barcelona, Spain.
   [Knight, George P.] Arizona State Univ, Dept Psychol, Tempe, AZ 85287 USA.
   [Unger, Jennifer B.] Univ So Calif, Keck Sch Med, Inst Prevent Res, Los Angeles, CA 90089 USA.
   [Zamboanga, Byron L.] Smith Coll, Dept Psychol, Northampton, MA 01063 USA.
   [Rosiers, Sabrina E. Des] Barry Univ, Dept Psychol, Miami Shores, FL USA.
   [Stephens, Dionne P.] Florida Int Univ, Dept Psychol, Miami, FL 33199 USA.
RP Schwartz, SJ (corresponding author), Univ Miami, Leonard M Miller Sch Med, Dept Publ Hlth Sci, 1425 NW 10th Ave,Suite 321, Miami, FL 33136 USA.
EM SSchwartz@med.miami.edu
RI Benet-Martinez, Veronica/AAS-8624-2020; Benet-Martinez,
   Veronica/B-5398-2011
OI Benet-Martinez, Veronica/0000-0002-3352-9731; Benet-Martinez,
   Veronica/0000-0002-3352-9731; Stephens, Dionne/0000-0002-6636-6625;
   Unger, Jennifer/0000-0001-9064-6603
FU ICREAICREA Funding Source: Custom; NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [UL1TR000460] Funding Source:
   NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Drug Abuse (NIDA)European Commission [R01DA025694]
   Funding Source: NIH RePORTER; NCATS NIH HHSUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Advancing Translational Sciences (NCATS) [UL1
   TR000460, 1UL1TR000460] Funding Source: Medline; NIDA NIH HHSUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA026594,
   R01 DA025694] Funding Source: Medline
CR Acosta-Belen E., 2006, PUERTO RICANS US CON
   Barker V, 2001, J COMMUN, V51, P3, DOI 10.1111/j.1460-2466.2001.tb02870.x
   Benet-Martinez V, 2005, J PERS, V73, P1015, DOI 10.1111/j.1467-6494.2005.00337.x
   Benet-Martinez V, 2002, J CROSS CULT PSYCHOL, V33, P492, DOI 10.1177/0022022102033005005
   BERRY J. W., 1980, ACCULTURATION THEORY, P9, DOI DOI 10.1525/AE.1981.8.4.02A00200
   Berry J. W., 2006, IMMIGRANT YOUTH CULT
   Berry JW, 1997, APPL PSYCHOL-INT REV, V46, P5, DOI 10.1080/026999497378467
   Branch CW, 2000, INT J INTERCULT REL, V24, P777, DOI 10.1016/S0147-1767(00)00031-6
   Buhrmester M, 2011, PERSPECT PSYCHOL SCI, V6, P3, DOI 10.1177/1745691610393980
   Caetano R, 2012, HISPANIC J BEHAV SCI, V34, P95, DOI 10.1177/0739986311424040
   Chen FF, 2007, STRUCT EQU MODELING, V14, P464, DOI 10.1080/10705510701301834
   Cheng CY, 2006, J CROSS CULT PSYCHOL, V37, P742, DOI 10.1177/0022022106292081
   Cheung GW, 2002, STRUCT EQU MODELING, V9, P233, DOI 10.1207/S15328007SEM0902_5
   CUELLAR I, 1995, HISPANIC J BEHAV SCI, V17, P275, DOI 10.1177/07399863950173001
   Dimitrov DM, 2010, MEAS EVAL COUNS DEV, V43, P121, DOI 10.1177/0748175610373459
   Erikson E., 1950, CHILDHOOD SOC
   FELIXORTIZ M, 1994, HISPANIC J BEHAV SCI, V16, P99, DOI 10.1177/07399863940162001
   Galanti Geri-Ann, 2003, J Transcult Nurs, V14, P180, DOI 10.1177/1043659603014003004
   Gonzales NA, 2002, PRAEG S APPL PSYCHOL, P45
   Guo XH, 2009, PSYCHOL ASSESSMENT, V21, P22, DOI 10.1037/a0014495
   Hancock G. R., 2004, HDB QUANTITATIVE MET, P318, DOI [10.4135/9781412986311.n17, DOI 10.4135/9781412986311]
   Hancock GR, 2000, STRUCT EQU MODELING, V7, P534, DOI 10.1207/S15328007SEM0704_2
   Henderson T. J., 2011, BORDERS HIST MEXICAN, DOI [10.1002/9781444394962, DOI 10.1002/9781444394962]
   Hirschman EC, 2003, J ADVERTISING, V32, P9, DOI 10.1080/00913367.2003.10601001
   Hofstede G., 2001, CULTURES CONSEQUENCE, V2nd
   Hong S, 2003, EDUC PSYCHOL MEAS, V63, P636, DOI 10.1177/0013164403251332
   Hong YY, 2000, AM PSYCHOL, V55, P709, DOI 10.1037//0003-066X.55.7.709
   Huntington S.P., 2004, WHO ARE WE CHALLENGE
   Ji LJ, 2004, J PERS SOC PSYCHOL, V87, P57, DOI 10.1037/0022-3514.87.1.57
   Kang SM, 2006, J CROSS CULT PSYCHOL, V37, P669, DOI 10.1177/0022022106292077
   Keith TZ., 2006, MULTIPLE REGRESSION
   Kline R. B., 2010, PRINCIPLES PRACTICES, V3rd
   Knight G. P., 2009, STUDYING ETHNIC MINO, DOI [10.1037/11887-000, DOI 10.1037/11887-000, 10.1037/11887-002]
   Lance CE, 2006, ORGAN RES METHODS, V9, P202, DOI 10.1177/1094428105284919
   Lechuga J, 2008, HISPANIC J BEHAV SCI, V30, P324, DOI 10.1177/0739986308319570
   Little T., 2013, LONGITUDINAL STRUCTU
   Little TD, 1997, MULTIVAR BEHAV RES, V32, P53, DOI 10.1207/s15327906mbr3201_3
   Lonner W. J., 1996, ADV METHODOLOGICAL I, P79
   Luna D, 2008, J CONSUM RES, V35, P279, DOI 10.1086/586914
   Luyckx K., 2011, DIMENSIONS IDE UNPUB
   Luyckx K, 2008, J RES PERS, V42, P58, DOI 10.1016/j.jrp.2007.04.004
   Luyckx K, 2006, J ADOLESCENCE, V29, P361, DOI 10.1016/j.adolescence.2005.03.008
   Mar?n G.E., 2003, ACCULTURATION ADV TH, P95, DOI DOI 10.1037/10472-008
   Marcia J. E., 1980, HDB ADOLESCENT PSYCH, V9, P159, DOI [10.4324/9780203346860, DOI 10.1002/9780470479193]
   MARCIA JE, 1966, J PERS SOC PSYCHOL, V3, P551, DOI 10.1037/h0023281
   Marklein M. B., 2010, US TODAY
   Marsiglia FF, 2004, SUBST USE MISUSE, V39, P1061, DOI 10.1081/JA-120038030
   Martinez CR, 2011, HISPANIC J BEHAV SCI, V33, P323, DOI 10.1177/0739986311411281
   Maxwell SE., 2004, DESIGNING EXPT ANAL, V2nd ed.
   Nguyen AMD, 2013, J CROSS CULT PSYCHOL, V44, P122, DOI 10.1177/0022022111435097
   Nguyen HHD, 2008, J APPL PSYCHOL, V93, P1314, DOI 10.1037/a0012702
   Phinney J. S., 1992, J ADOLESCENT RES, V7, P156, DOI [DOI 10.1177/074355489272003, 10.1177/074355489272003]
   Phinney JS, 2007, J COUNS PSYCHOL, V54, P271, DOI 10.1037/0022-0167.54.3.271
   Pouliasi K, 2007, J EXP SOC PSYCHOL, V43, P955, DOI 10.1016/j.jesp.2006.10.005
   Quilty LC, 2006, STRUCT EQU MODELING, V13, P99, DOI 10.1207/s15328007sem1301_5
   RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306
   Ramirez-Esparza N, 2006, J RES PERS, V40, P99, DOI 10.1016/j.jrp.2004.09.001
   Raykov T., ED PSYCHOL IN PRESS
   Reips UD, 2002, EXP PSYCHOL, V49, P243, DOI 10.1027//1618-3169.49.4.243
   Roberts RE, 1999, J EARLY ADOLESCENCE, V19, P301, DOI 10.1177/0272431699019003001
   Rodriguez N, 2002, PSYCHOL ASSESSMENT, V14, P451, DOI 10.1037//1040-3590.14.4.451
   Romero Andrea J, 2003, Cultur Divers Ethnic Minor Psychol, V9, P171, DOI 10.1037/1099-9809.9.2.171
   Rosenberg M., 1968, SOC ADOLESCENT SELF
   ROSENTHAL DA, 1981, J YOUTH ADOLESCENCE, V10, P525, DOI 10.1007/BF02087944
   Rudmin FW, 2003, REV GEN PSYCHOL, V7, P3, DOI 10.1037/1089-2680.7.1.3
   Ryder AG, 2000, J PERS SOC PSYCHOL, V79, P49, DOI 10.1037//0022-3514.79.1.49
   Sabogal E, 2005, LAT STUD, V3, P113, DOI 10.1057/palgrave.lst.8600128
   Sam D. L., 2006, CAMBRIDGE HDB ACCULT, P11, DOI [10.1017/CBO9780511489891.005, DOI 10.1017/CBO9780511489891.005]
   Sanchez DT, 2012, J CROSS CULT PSYCHOL, V43, P1019, DOI 10.1177/0022022111416979
   Schwartz S. J., 2001, IDENTITY INT J THEOR, V1, P87, DOI DOI 10.1207/S1532706XSCHWARTZ2
   Schwartz SJ, 2013, EMERG ADULTHOOD, V1, P96, DOI 10.1177/2167696813479781
   Schwartz SJ, 2013, CHILD DEV, V84, P1355, DOI 10.1111/cdev.12047
   Schwartz SJ, 2013, CULT DIVERS ETHN MIN, V19, P155, DOI 10.1037/a0030753
   Schwartz SJ, 2012, IDENTITY, V12, P93, DOI 10.1080/15283488.2012.668730
   Schwartz SJ, 2012, DRUG ALCOHOL DEPEN, V125, pS26, DOI 10.1016/j.drugalcdep.2012.05.020
   Schwartz SJ, 2011, J COUNS PSYCHOL, V58, P27, DOI 10.1037/a0021356
   Schwartz SJ, 2010, AM PSYCHOL, V65, P237, DOI 10.1037/a0019330
   Schwartz SJ, 2010, HUM DEV, V53, P26, DOI 10.1159/000268137
   Schwartz SJ, 2009, J PERS ASSESS, V91, P143, DOI 10.1080/00223890802634266
   Sireci SG, 2006, J CROSS CULT PSYCHOL, V37, P557, DOI 10.1177/0022022106290478
   Smith TB, 2011, J COUNS PSYCHOL, V58, P42, DOI 10.1037/a0021528
   Steele CM, 1997, AM PSYCHOL, V52, P613, DOI 10.1037/0003-066X.52.6.613
   Steiner N., 2009, INT MIGRATION CITIZE
   Stepick A., 2002, LATINOS REMAKING AM, P75
   Suarez-Orozco Marcelo M., 2002, LATINOS REMAKING AM
   Szapocznik J., 1980, INT J INTERCULT REL, V4, P353, DOI [10.1016/0147-1767(80)90010-3, DOI 10.1016/0147-1767(80)90010-3]
   Tajfel Henri., 1986, PSYCHOL INTERGROUP R, P7
   Triandis HC, 1998, J PERS SOC PSYCHOL, V74, P118, DOI 10.1037/0022-3514.74.1.118
   U. S. Department of Education, 2013, DEV HISP SERV I PROG
   Umana- ~Taylor A. J., 2004, IDENTITY, V4, P9, DOI [10.1207/S1532706XID0401_2, DOI 10.1207/S1532706XID0401_2]
   Vandenberg RJ, 2000, ORGAN RES METHODS, V3, P4, DOI 10.1177/109442810031002
   Verkuyten M, 2006, J CROSS CULT PSYCHOL, V37, P312, DOI 10.1177/0022022106286926
   West S. G., 2012, HDB STRUCTURAL EQUAT, P209, DOI DOI 10.1016/J.SURFCOAT.2015.05.023
   White RMB, 2011, J EARLY ADOLESCENCE, V31, P817, DOI 10.1177/0272431610376246
   Widaman KF., 1997, SCI PREV METHODOL AD, P281, DOI [10.1037/10222-009, DOI 10.1037/10222-009]
   Yoon E, 2011, J COUNS PSYCHOL, V58, P83, DOI 10.1037/a0021128
NR 96
TC 33
Z9 33
U1 2
U2 49
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 1040-3590
EI 1939-134X
J9 PSYCHOL ASSESSMENT
JI Psychol. Assess.
PD MAR
PY 2014
VL 26
IS 1
BP 100
EP 114
DI 10.1037/a0034717
PG 15
WC Psychology, Clinical
SC Psychology
GA AB5ZJ
UT WOS:000331866900011
PM 24188146
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Mao, BJ
   Morgan, SE
   Peng, W
   McFarlane, SJ
   Occa, A
   Grinfeder, G
   Byrne, MM
AF Mao, Bingjing
   Morgan, Susan E.
   Peng, Wei
   McFarlane, Soroya Julian
   Occa, Aurora
   Grinfeder, Gilles
   Byrne, Margaret M.
TI What Motivates You to Share? The Effect of Interactive Tailored
   Information Aids on Information Sharing about Clinical Trials
SO HEALTH COMMUNICATION
LA English
DT Article
ID WORD-OF-MOUTH; TREATMENT DECISION-MAKING; TECHNOLOGY ACCEPTANCE;
   PERCEIVED EASE; COGNITIVE ABSORPTION; COMMUNICATION; KNOWLEDGE; IMPACT;
   MODEL; ENJOYMENT
AB Cancer patients learn about research studies outside of the clinical environment, including websites, print and online advertisements, and interpersonal interactions. When cancer patients share credible information about clinical trials, they also frequently help clarify misunderstandings that may exist in their social networks. The present study investigated how an interactive tailored information aid on clinical trial participation motivated patients' information sharing behaviors. In this study of 312 cancer patients and survivors, an interactive tailored information aid improved patients' likelihood of sharing online and offline information more than a non-interactive tool. Information sharing was directly predicted by cognitive absorption and perceived visual informativeness. In addition, perceived utility and ease of use indirectly impact information sharing positively through the antecedent factors of user engagement and design esthetics. Education level further moderated this effect; information sharing was higher among patients with more education. The implications of these findings are discussed and recommendations for future research are provided.
C1 [Mao, Bingjing; Morgan, Susan E.; Grinfeder, Gilles] Univ Miami, Sch Commun, 5100 Brunson Dr, Coral Gables, FL 33146 USA.
   [McFarlane, Soroya Julian] Univ Georgia, Dept Commun Studies, Athens, GA 30602 USA.
   [Occa, Aurora] Univ Kentucky, Dept Commun, Lexington, KY 40506 USA.
   [Byrne, Margaret M.] H Lee Moffitt Canc Ctr & Res Inst, Dept Hlth Outcomes & Behav, Tampa, FL USA.
RP Mao, BJ (corresponding author), Univ Miami, Sch Commun, 5100 Brunson Dr, Coral Gables, FL 33146 USA.
EM bxm644@miami.edu
RI Peng, Wei/AAB-2526-2021
OI Peng, Wei/0000-0002-2229-4682
FU Miami Clinical and Translational Science Institute [UL1TR000460]
FX This work was supported by the Miami Clinical and Translational Science
   Institute [UL1TR000460].
CR Agarwal R, 2000, MIS QUART, V24, P665, DOI 10.2307/3250951
   Antal H, 2017, J BIOMED INFORM, V66, P248, DOI 10.1016/j.jbi.2017.01.011
   Argan M, 2012, HEALTHMED, V6, P216
   Bailenson JN, 2008, J LEARN SCI, V17, P102, DOI 10.1080/10508400701793141
   Berger J, 2014, J CONSUM PSYCHOL, V24, P586, DOI 10.1016/j.jcps.2014.05.002
   Berkowsky RW, 2017, INNOV AGING, V1, DOI 10.1093/geroni/igy002
   Cameron P, 2013, CURR ONCOL, V20, pE193, DOI 10.3747/co.20.1323
   Carpenter JS, 2011, MATURITAS, V69, P11, DOI 10.1016/j.maturitas.2011.02.005
   Choi J, 2010, INT J MED INFORM, V79, P565, DOI 10.1016/j.ijmedinf.2010.05.001
   Davenport T.H., 1998, WORKING KNOWLEDGE OR
   DAVIS FD, 1989, MIS QUART, V13, P319, DOI 10.2307/249008
   De Bruyn A, 2008, INT J RES MARK, V25, P151, DOI 10.1016/j.ijresmar.2008.03.004
   Elwyn G, 2001, PATIENT EDUC COUNS, V43, P5, DOI 10.1016/S0738-3991(00)00149-X
   Elwyn G, 2012, J GEN INTERN MED, V27, P1361, DOI 10.1007/s11606-012-2077-6
   Foster AD, 2010, ANNU REV ECON, V2, P395, DOI 10.1146/annurev.economics.102308.124433
   Foster C, 2013, EUR J DEV RES, V25, P333, DOI 10.1057/ejdr.2013.7
   Gao Q, 2010, BEHAV INFORM TECHNOL, V29, P35, DOI 10.1080/01449290802666770
   Gillies K, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009736.pub2
   Gui M, 2011, NEW MEDIA SOC, V13, P963, DOI 10.1177/1461444810389751
   Hargittai E, 2008, COMMUN RES, V35, P602, DOI 10.1177/0093650208321782
   Hsu CL, 2008, INFORM MANAGE-AMSTER, V45, P65, DOI 10.1016/j.im.2007.11.001
   Hunsaker A, 2018, NEW MEDIA SOC, V20, P3937, DOI 10.1177/1461444818787348
   Kim Y, 2012, COMPUT HUM BEHAV, V28, P1356, DOI 10.1016/j.chb.2012.02.021
   King AJ, 2014, J HEALTH COMMUN, V19, P1099, DOI 10.1080/10810730.2013.878004
   Kraft SA, 2017, CLIN TRIALS, V14, P94, DOI 10.1177/1740774516669352
   Krieger JL, 2017, QUAL HEALTH RES, V27, P1146, DOI 10.1177/1049732316645321
   Krieger JL, 2015, J CANCER EDUC, V30, P743, DOI 10.1007/s13187-015-0789-0
   Krieger JL, 2014, COMM YEARB, V38, P279
   Krieger JL, 2014, J HEALTH COMMUN, V19, P1161, DOI 10.1080/10810730.2013.801537
   Lazard A, 2014, INT J MED INFORM, V83, P726, DOI 10.1016/j.ijmedinf.2014.06.010
   Legare F, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006732.pub3
   Liu YP, 2009, J ADVERTISING, V38, P53, DOI 10.2753/JOA0091-3367380204
   Lu HP, 2010, J INF SCI, V36, P401, DOI 10.1177/0165551510363631
   McEachan RRC, 2011, HEALTH PSYCHOL REV, V5, P97, DOI 10.1080/17437199.2010.521684
   Moorhead SA, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.1933
   Morgan C, 2017, NONPROFIT CIV SOC ST, P199, DOI 10.1007/978-1-4939-6915-9_9
   Morgan SE, 2017, J HEALTH COMMUN, V22, P95, DOI 10.1080/10810730.2016.1256356
   Morgan SE, 2017, HEALTH COMMUN, V32, P461, DOI 10.1080/10410236.2016.1140266
   Morgan SE, 2016, J HEALTH COMMUN, V21, P765, DOI 10.1080/10810730.2016.1157654
   Neter E, 2012, J MED INTERNET RES, V14, DOI 10.2196/jmir.1619
   Occa A., 2018, CLIN TRIALS VULNERAB, P177
   Occa A., 2018, THESIS
   Occa A, 2018, J RACIAL ETHN HEALTH, V5, P322, DOI 10.1007/s40615-017-0373-x
   Oh J, 2015, J COMMUN, V65, P213, DOI 10.1111/jcom.12147
   Peng W., 2018, 104 ANN CONV NAT COM
   Politi MC, 2016, ONCOLOGIST, V21, P1461, DOI 10.1634/theoncologist.2016-0068
   Rafaeli S., 2007, OXFORD HDB INTERNET, P71, DOI DOI 10.1093/0XF0RDHB/9780199561803.013.0006
   Ruiz JG, 2009, MED EDUC, V43, P838, DOI 10.1111/j.1365-2923.2009.03429.x
   Saade R, 2005, INFORM MANAGE-AMSTER, V42, P317, DOI 10.1016/j.im.2003.12.013
   Shneerson C, 2013, PATIENT EDUC COUNS, V90, P111, DOI 10.1016/j.pec.2012.06.031
   Song JH, 2008, J MARKETING, V72, P99, DOI 10.1509/jmkg.72.2.99
   Stacey D, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001431.pub5
   Sun HS, 2006, J ASSOC INF SYST, V7, P618, DOI 10.17705/1jais.00100
   Tate T., 2017, LANGUAGE ED TECHNOLO, P45
   Teo TSH, 1999, OMEGA-INT J MANAGE S, V27, P25, DOI 10.1016/S0305-0483(98)00028-0
   Wang S, 2010, HUM RESOUR MANAGE R, V20, P115, DOI 10.1016/j.hrmr.2009.10.001
   Wicks P, 2010, J MED INTERNET RES, V12, DOI 10.2196/jmir.1549
   Yan ZJ, 2016, INFORM MANAGE-AMSTER, V53, P643, DOI 10.1016/j.im.2016.02.001
   Yi MY, 2003, INT J HUM-COMPUT ST, V59, P431, DOI 10.1016/S1071-5819(03)00114-9
NR 59
TC 1
Z9 1
U1 2
U2 4
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1041-0236
EI 1532-7027
J9 HEALTH COMMUN
JI Health Commun.
PD SEP 19
PY 2021
VL 36
IS 11
BP 1388
EP 1396
DI 10.1080/10410236.2020.1754588
EA APR 2020
PG 9
WC Communication; Health Policy & Services
SC Communication; Health Care Sciences & Services
GA UI6ZY
UT WOS:000532054500001
PM 32345059
DA 2021-10-30
ER

PT J
AU Strbo, N
   Garcia-Soto, A
   Schreiber, TH
   Podack, ER
AF Strbo, Natasa
   Garcia-Soto, Arlene
   Schreiber, Taylor H.
   Podack, Eckhard R.
TI Secreted heat shock protein gp96-Ig: next-generation vaccines for cancer
   and infectious diseases
SO IMMUNOLOGIC RESEARCH
LA English
DT Article
DE Heat shock proteins; Gp96; Vaccine; Cancer; HIV; Immunotherapy
ID REGULATORY T-CELLS; PEPTIDE-BINDING-SITE; N-TERMINAL FRAGMENT; MINOR
   H-ANTIGENS; ENDOPLASMIC-RETICULUM; DENDRITIC CELLS; CUTTING EDGE;
   CROSS-PRESENTATION; CLASS-I; TUMOR MICROENVIRONMENT
AB Over the past decade, our laboratory has developed a secreted heat shock protein (HSP), chaperone gp96, cell-based vaccine that generates effective anti-tumor and anti-infectious immunity in vivo. Gp96-peptide complexes were identified as an extremely efficient stimulator of MHC I-mediated antigen cross-presentation, generating CD8 cytotoxic T-lymphocyte responses detectable in blood, spleen, gut and reproductive tract to femto-molar concentrations of antigen. These studies provided the first evidence that cell-based gp96-Ig-secreting vaccines may serve as a potent modality to induce both systemic and mucosal immunity. This approach takes advantage of the combined adjuvant and antigen delivery capacity of gp96 for the generation of cytotoxic immunity against a wide range of antigens in both anti-vial and anti-cancer vaccination. Here, we review the vaccine design that utilizes the unique property/ability of endoplasmic HSP gp96 to bind antigenic peptides and deliver them to antigen-presenting cells.
C1 [Strbo, Natasa; Garcia-Soto, Arlene; Schreiber, Taylor H.; Podack, Eckhard R.] Univ Miami Miller Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA.
   [Garcia-Soto, Arlene] Univ Miami Miller Sch Med, Dept Obstet & Gynecol, Miami, FL 33136 USA.
RP Strbo, N (corresponding author), Univ Miami Miller Sch Med, Dept Microbiol & Immunol, RMSB 3008,1600 NW 10th Ave, Miami, FL 33136 USA.
EM nstrbo@med.miami.edu
OI Schreiber, Taylor/0000-0002-8070-1303
FU NIAIDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R33 AI 073234]; NIH, NCATS NIH
   [UL1TR000460, 1KL2TR000461]; Miami-CFAR; NIHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA
   [P30A1073961]; National Cancer Institute, Center for Cancer
   ResearchUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI);
   Alliance for Cancer Gene Therapy (ACGT), New York; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000460,
   KL2TR000461] Funding Source: NIH RePORTER
FX The work is supported by the NIAID R33 AI 073234, Intramural Research
   Program of the NIH, NCATS NIH UL1TR000460 and 1KL2TR000461, Miami-CFAR
   and NIH P30A1073961, National Cancer Institute, Center for Cancer
   Research and support from the Alliance for Cancer Gene Therapy (ACGT),
   New York.
CR Aguilera R, 2011, CLIN CANCER RES, V17, P2474, DOI 10.1158/1078-0432.CCR-10-2384
   Ahmed R, 2009, NAT REV IMMUNOL, V9, P662, DOI 10.1038/nri2619
   Akondy RS, 2009, J IMMUNOL, V183, P7919, DOI 10.4049/jimmunol.0803903
   Arnold-Schild D, 1999, J IMMUNOL, V162, P3757
   Asea A, 2002, J BIOL CHEM, V277, P15028, DOI 10.1074/jbc.M200497200
   Banerjee PP, 2002, J IMMUNOL, V169, P3507, DOI 10.4049/jimmunol.169.7.3507
   Basu S, 2000, INT IMMUNOL, V12, P1539, DOI 10.1093/intimm/12.11.1539
   Basu S, 2001, IMMUNITY, V14, P303, DOI 10.1016/S1074-7613(01)00111-X
   Belli F, 2002, J CLIN ONCOL, V20, P4169, DOI 10.1200/JCO.2002.09.134
   Berwin B, 2004, J BIOL CHEM, V279, P51250, DOI 10.1074/jbc.M406202200
   BEVAN MJ, 1976, EUR J IMMUNOL, V6, P150, DOI 10.1002/eji.1830060303
   BEVAN MJ, 1976, J IMMUNOL, V117, P2233
   BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283
   Beyer M, 2006, BLOOD, V108, P804, DOI 10.1182/blood-2006-02-002774
   Binder RJ, 2000, J IMMUNOL, V165, P6029, DOI 10.4049/jimmunol.165.11.6029
   Binder RJ, 2004, P NATL ACAD SCI USA, V101, P6128, DOI 10.1073/pnas.0308180101
   Binder RJ, 2000, NAT IMMUNOL, V1, P151, DOI 10.1038/77835
   Binder RJ, 2001, J BIOL CHEM, V276, P17163, DOI 10.1074/jbc.M011547200
   Binder RJ, 2000, J IMMUNOL, V165, P2582, DOI 10.4049/jimmunol.165.5.2582
   Biswas C, 2006, INT IMMUNOL, V18, P1147, DOI 10.1093/intimm/dxl049
   Calderwood SK, 2007, ANN NY ACAD SCI, V1113, P28, DOI 10.1196/annals.1391.019
   Calderwood SK, 2012, AUTOIMMUN DIS, V2012, DOI 10.1155/2012/486069
   Cavallo F, 2011, CANCER IMMUNOL IMMUN, V60, P319, DOI 10.1007/s00262-010-0968-0
   Chen W, 1999, J IMMUNOL, V162, P3212
   Coombes JL, 2005, IMMUNOL REV, V204, P184, DOI 10.1111/j.0105-2896.2005.00250.x
   Crane CA, 2009, ONCOGENE, V28, P306, DOI 10.1038/onc.2008.384
   Crane CA, 2013, CLIN CANCER RES, V19, P205, DOI 10.1158/1078-0432.CCR-11-3358
   Daemi A, 2012, IMMUNOL LETT, V148, P117, DOI 10.1016/j.imlet.2012.10.003
   DeSmet C, 1997, EYE, V11, P243, DOI 10.1038/eye.1997.59
   Dollins DE, 2005, J BIOL CHEM, V280, P30438, DOI 10.1074/jbc.M503761200
   Doody ADH, 2004, J IMMUNOL, V172, P6087, DOI 10.4049/jimmunol.172.10.6087
   Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991
   Eton O, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-9
   Genesca M, 2008, MUCOSAL IMMUNOL, V1, P219, DOI 10.1038/mi.2008.6
   Genesca M, 2008, J VIROL, V82, P11181, DOI 10.1128/JVI.01433-08
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0
   Gidalevitz T, 2004, J BIOL CHEM, V279, P16543, DOI 10.1074/jbc.M313060200
   Gordon NF, 2004, METHODS, V32, P63, DOI 10.1016/S1046-2023(03)00188-9
   Habich C, 2002, J IMMUNOL, V168, P569, DOI 10.4049/jimmunol.168.2.569
   HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2
   Immormino RM, 2004, J BIOL CHEM, V279, P46162, DOI 10.1074/jbc.M405253200
   Ishii T, 1999, J IMMUNOL, V162, P1303
   Janetzki S, 2000, INT J CANCER, V88, P232, DOI 10.1002/1097-0215(20001015)88:2<232::AID-IJC14>3.0.CO;2-8
   Johansson-Lindbom B, 2005, J EXP MED, V202, P1063, DOI 10.1084/jem.20051100
   Jonasch E, 2008, BRIT J CANCER, V98, P1336, DOI 10.1038/sj.bjc.6604266
   Kato Y, 2012, AUTOIMMUN DIS, V2012, DOI 10.1155/2012/745962
   Kim R, 2006, CANCER RES, V66, P5527, DOI 10.1158/0008-5472.CAN-05-4128
   KOCH G, 1986, J CELL SCI, V86, P217
   Kovalchin J T, 2001, Cancer Immun, V1, P7
   Kurotaki T, 2007, J IMMUNOL, V179, P1803, DOI 10.4049/jimmunol.179.3.1803
   LEE AS, 1981, J CELL PHYSIOL, V106, P119, DOI 10.1002/jcp.1041060113
   Lefrancois L, 2006, IMMUNOL REV, V211, P93, DOI 10.1111/j.0105-2896.2006.00393.x
   Lehner T, 2000, EUR J IMMUNOL, V30, P594, DOI 10.1002/1521-4141(200002)30:2<594::AID-IMMU594>3.3.CO;2-T
   LEWIS MJ, 1985, J BIOL CHEM, V260, P6926
   Li CY, 2012, P NATL ACAD SCI USA, V109, P17543, DOI 10.1073/pnas.1205867109
   Li HT, 2005, J IMMUNOL, V174, P195, DOI 10.4049/jimmunol.174.1.195
   Li QS, 2009, SCIENCE, V323, P1726, DOI 10.1126/science.1168676
   LI ZH, 1993, EMBO J, V12, P3143, DOI 10.1002/j.1460-2075.1993.tb05983.x
   Linderoth NA, 2001, J BIOL CHEM, V276, P11049, DOI 10.1074/jbc.M010059200
   Linderoth NA, 2001, BIOCHEMISTRY-US, V40, P1483, DOI 10.1021/bi0016218
   Linderoth NA, 2000, J BIOL CHEM, V275, P5472, DOI 10.1074/jbc.275.8.5472
   Liyanage UK, 2006, J IMMUNOTHER, V29, P416, DOI 10.1097/01.cji.0000205644.43735.4e
   Liyanage UK, 2002, J IMMUNOL, V169, P2756, DOI 10.4049/jimmunol.169.5.2756
   Lv LH, 2012, J BIOL CHEM, V287, P15874, DOI 10.1074/jbc.M112.340588
   Maki RG, 2007, DIGEST DIS SCI, V52, P1964, DOI 10.1007/s10620-006-9205-2
   Masopust D, 2006, J IMMUNOL, V176, P2079, DOI 10.4049/jimmunol.176.4.2079
   Masopust D, 2009, J INTERN MED, V265, P125, DOI 10.1111/j.1365-2796.2008.02054.x
   Matsutake Toyoshi, 2010, Cancer Immun, V10, P7
   Mazzaferro V, 2003, CLIN CANCER RES, V9, P3235
   MELNICK J, 1994, NATURE, V370, P373, DOI 10.1038/370373a0
   Mohit E, 2012, SCAND J IMMUNOL, V75, P27, DOI 10.1111/j.1365-3083.2011.02620.x
   Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788
   Nover L, 1991, Results Probl Cell Differ, V17, P1
   Oizumi S, 2008, J IMMUNOTHER, V31, P394, DOI 10.1097/CJI.0b013e31816bc74d
   Oizumi S, 2007, J IMMUNOL, V179, P2310, DOI 10.4049/jimmunol.179.4.2310
   Oki Y, 2007, CANCER-AM CANCER SOC, V109, P77, DOI 10.1002/cncr.22389
   Pakravan N, 2011, CELL STRESS CHAPERON, V16, P449, DOI 10.1007/s12192-011-0258-6
   Pakravan N, 2010, J GENE MED, V12, P345, DOI 10.1002/jgm.1445
   PALLADINO MA, 1987, CANCER RES, V47, P5074
   Panjwani NN, 2002, J IMMUNOL, V168, P2997, DOI 10.4049/jimmunol.168.6.2997
   Parsa AT, 2007, NAT MED, V13, P84, DOI 10.1038/nm1517
   PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253
   Peng P, 1997, J IMMUNOL METHODS, V204, P13, DOI 10.1016/S0022-1759(97)00017-3
   Picker LJ, 2006, J CLIN INVEST, V116, P1514, DOI 10.1172/JCI27564
   Pilla L, 2006, CANCER IMMUNOL IMMUN, V55, P958, DOI 10.1007/s00262-005-0084-8
   Precopio ML, 2007, J EXP MED, V204, P1405, DOI 10.1084/jem.20062363
   Ramirez SR, 2005, CELL STRESS CHAPERON, V10, P221, DOI 10.1379/CSC-117R.1
   Randow F, 2001, NAT CELL BIOL, V3, P891, DOI 10.1038/ncb1001-891
   Rapp UK, 2004, INT IMMUNOL, V16, P597, DOI 10.1093/intimm/dxh064
   Riley JP, 2001, J IMMUNOTHER, V24, P212, DOI 10.1097/00002371-200105000-00004
   Rivoltini L, 2003, J IMMUNOL, V171, P3467, DOI 10.4049/jimmunol.171.7.3467
   Robert J, 2008, J IMMUNOL, V180, P3176, DOI 10.4049/jimmunol.180.5.3176
   Rock KL, 2005, IMMUNOL REV, V207, P166, DOI 10.1111/j.0105-2896.2005.00301.x
   Russnes HG, 2011, J CLIN INVEST, V121, P3810, DOI 10.1172/JCI57088
   Sastry S, 1999, J BIOL CHEM, V274, P12023, DOI 10.1074/jbc.274.17.12023
   Schreiber TH, 2012, ONCOIMMUNOLOGY, V1, P642, DOI 10.4161/onci.20298
   Schreiber TH, 2012, J IMMUNOL, V189, P3311, DOI 10.4049/jimmunol.1200597
   Schreiber TH, 2010, SEMIN IMMUNOL, V22, P105, DOI 10.1016/j.smim.2010.02.001
   Schreiber TH, 2009, CANCER RES, V69, P2026, DOI 10.1158/0008-5472.CAN-08-3706
   Singh-Jasuja H, 2000, J EXP MED, V191, P1965, DOI 10.1084/jem.191.11.1965
   Singh-Jasuja H, 2000, CELL STRESS CHAPERON, V5, P462, DOI 10.1379/1466-1268(2000)005<0462:THSPGA>2.0.CO;2
   Singh-Jasuja H, 2000, EUR J IMMUNOL, V30, P2211, DOI 10.1002/1521-4141(2000)30:8<2211::AID-IMMU2211>3.0.CO;2-0
   Singhal S, 2008, LUNG CANCER, V60, P313, DOI 10.1016/j.lungcan.2008.03.007
   Srivastava P, 2002, ANNU REV IMMUNOL, V20, P395, DOI 10.1146/annurev.immunol.20.100301.064801
   Srivastava PK, 2000, METH MOL B, V156, P175
   SRIVASTAVA PK, 1986, P NATL ACAD SCI USA, V83, P3407, DOI 10.1073/pnas.83.10.3407
   SRIVASTAVA PK, 1994, IMMUNOGENETICS, V39, P93
   Strbo N, 2003, IMMUNITY, V18, P381, DOI 10.1016/S1074-7613(03)00056-6
   Strbo N, 2010, MUCOSAL IMMUNOL, V3, P182, DOI 10.1038/mi.2009.127
   Strbo N, 2008, AM J REPROD IMMUNOL, V59, P407, DOI 10.1111/j.1600-0897.2008.00594.x
   Strbo N, 2013, J IMMUNOL, V190, P2495, DOI 10.4049/jimmunol.1202655
   Strbo N, 2011, VACCINE, V29, P2619, DOI 10.1016/j.vaccine.2011.01.044
   SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313
   Tamura Y, 1997, SCIENCE, V278, P117, DOI 10.1126/science.278.5335.117
   Testori A, 2008, J CLIN ONCOL, V26, P955, DOI 10.1200/JCO.2007.11.9941
   Todryk SM, 2000, IMMUNOLOGY, V99, P334, DOI 10.1046/j.1365-2567.2000.00002.x
   UDONO H, 1994, J IMMUNOL, V152, P5398
   UDONO H, 1993, J EXP MED, V178, P1391, DOI 10.1084/jem.178.4.1391
   Vabulas RM, 2002, J BIOL CHEM, V277, P20847, DOI 10.1074/jbc.M200425200
   Wakim LM, 2008, SCIENCE, V319, P198, DOI 10.1126/science.1151869
   Watts C, 1997, ANNU REV IMMUNOL, V15, P821, DOI 10.1146/annurev.immunol.15.1.821
   Wearsch PA, 1997, J BIOL CHEM, V272, P5152, DOI 10.1074/jbc.272.8.5152
   WELCH WJ, 1993, SCI AM, V268, P56, DOI 10.1038/scientificamerican0593-56
   Wood C, 2008, LANCET, V372, P145, DOI 10.1016/S0140-6736(08)60697-2
   Yamazaki K, 1999, J IMMUNOL, V163, P5178
   Yan JB, 2007, J GENE MED, V9, P107, DOI 10.1002/jgm.998
   Yang Y, 2007, IMMUNITY, V26, P215, DOI 10.1016/j.immuni.2006.12.005
   Ying M, 2006, FEBS J, V273, P513, DOI 10.1111/j.1742-4658.2005.05084.x
   Younes A, 2003, CLIN LYMPHOMA, V4, P183, DOI 10.3816/CLM.2003.n.029
NR 130
TC 19
Z9 20
U1 1
U2 16
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0257-277X
EI 1559-0755
J9 IMMUNOL RES
JI Immunol. Res.
PD DEC
PY 2013
VL 57
IS 1-3
SI SI
BP 311
EP 325
DI 10.1007/s12026-013-8468-x
PG 15
WC Immunology
SC Immunology
GA 269RK
UT WOS:000328259400032
PM 24254084
DA 2021-10-30
ER

PT J
AU Montes-Chinea, NI
   Guan, Z
   Coutts, M
   Vidal, C
   Courel, S
   Rebelo, AP
   Abreu, L
   Zuchner, S
   Littleton, JT
   Saporta, MA
AF Montes-Chinea, Nataly, I
   Guan, Zhuo
   Coutts, Marcella
   Vidal, Cecilia
   Courel, Steve
   Rebelo, Adriana P.
   Abreu, Lisa
   Zuchner, Stephan
   Littleton, J. Troy
   Saporta, Mario A.
TI Identification of a new SYT2 variant validates an unusual distal motor
   neuropathy phenotype
SO NEUROLOGY-GENETICS
LA English
DT Article
ID NEUROTRANSMITTER RELEASE; NEUROMUSCULAR-JUNCTION; ASYNCHRONOUS RELEASE;
   SYNAPTOTAGMIN; MUTATIONS; TRANSMISSION; DOMINANT
AB Objective
   To report a new SYT2 missense mutation causing distal hereditary motor neuropathy and presynaptic neuromuscular junction (NMJ) transmission dysfunction.
   Methods
   We report a multigenerational family with a new missense mutation, c. 1112T>A (p. Ile371- Lys), in the C2B domain of SYT2, describe the clinical and electrophysiologic phenotype associated with this variant, and validate its pathogenicity in a Drosophila model.
   Results
   Both proband and her mother present a similar clinical phenotype characterized by a slowly progressive, predominantly motor neuropathy and clear evidence of presynaptic NMJ dysfunction on nerve conduction studies. Validation of this new variant was accomplished by characterization of the mutation homologous to the human c. 1112T>A variant in Drosophila, confirming its dominant-negative effect on neurotransmitter release.
   Conclusions
   This report provides further confirmation of the role of SYT2 in human disease and corroborates the resultant unique clinical phenotype consistent with heriditary distal motor neuropathy. SYT2-related motor neuropathy is a rare disease but should be suspected in patients presenting with a combination of presynaptic NMJ dysfunction (resembling Lambert-Eaton myasthenic syndrome) and a predominantly motor neuropathy, especially in the context of a positive family history.
C1 [Montes-Chinea, Nataly, I; Coutts, Marcella; Vidal, Cecilia; Saporta, Mario A.] Univ Miami, Miller Sch Med, Dept Neurol, Coral Gables, FL 33124 USA.
   [Guan, Zhuo; Littleton, J. Troy] MIT, Picower Inst Learning & Memory, Dept Biol, Cambridge, MA 02139 USA.
   [Guan, Zhuo; Littleton, J. Troy] MIT, Picower Inst Learning & Memory, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA.
   [Courel, Steve; Rebelo, Adriana P.; Abreu, Lisa; Zuchner, Stephan; Saporta, Mario A.] Univ Miami, Miller Sch Med, Dept Human Genet, Miami, FL 33136 USA.
RP Saporta, MA (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol, Coral Gables, FL 33124 USA.; Saporta, MA (corresponding author), Univ Miami, Miller Sch Med, Dept Human Genet, Miami, FL 33136 USA.
EM mas638@med.miami.edu
FU NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [KL2 TR002737] Funding Source: Medline;
   NINDS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Neurological
   Disorders & Stroke (NINDS) [R01 NS040296] Funding Source: Medline;
   NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Neurological Disorders & Stroke (NINDS)
   [R01NS040296] Funding Source: NIH RePORTER
CR Bansagi B, 2017, NEUROLOGY, V88, P1226, DOI 10.1212/WNL.0000000000003772
   Barwick KES, 2012, AM J HUM GENET, V91, P1103, DOI 10.1016/j.ajhg.2012.09.019
   DIANTONIO A, 1994, NEURON, V12, P909, DOI 10.1016/0896-6273(94)90342-5
   Grice SJ, 2015, HUM MOL GENET, V24, P4397, DOI 10.1093/hmg/ddv176
   Guan Z, 2017, ELIFE, V6, DOI 10.7554/eLife.28409
   Herrmann DN, 2014, AM J HUM GENET, V95, P332, DOI 10.1016/j.ajhg.2014.08.007
   Huntwork S, 2007, NAT NEUROSCI, V10, P1235, DOI 10.1038/nn1980
   Jorquera RA, 2012, J NEUROSCI, V32, P18234, DOI 10.1523/JNEUROSCI.3212-12.2012
   LITTLETON JT, 1993, CELL, V74, P1125, DOI 10.1016/0092-8674(93)90733-7
   LITTLETON JT, 1994, P NATL ACAD SCI USA, V91, P10888, DOI 10.1073/pnas.91.23.10888
   Luo FJ, 2017, NEURON, V94, P826, DOI 10.1016/j.neuron.2017.04.020
   Mackler JM, 2002, NATURE, V418, P340, DOI 10.1038/nature00846
   Murphy SM, 2011, J PERIPHER NERV SYST, V16, P191, DOI 10.1111/j.1529-8027.2011.00350.x
   Pang ZPP, 2006, J NEUROSCI, V26, P13493, DOI 10.1523/JNEUROSCI.3519-06.2006
   Patzko A, 2012, BRAIN, V135, P3551, DOI 10.1093/brain/aws299
   Rossor AM, 2012, J NEUROL NEUROSUR PS, V83, P6, DOI 10.1136/jnnp-2011-300952
   Sabblah TT, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20081-1
   Scurry AN, 2016, J NEUROPATH EXP NEUR, V75, P334, DOI 10.1093/jnen/nlw004
   Sleigh JN, 2014, HUM MOL GENET, V23, P2639, DOI 10.1093/hmg/ddt659
   Spaulding EL, 2016, J NEUROSCI, V36, P3254, DOI 10.1523/JNEUROSCI.1762-15.2016
   Turecek J, 2018, J NEUROSCI, V38, P3240, DOI 10.1523/JNEUROSCI.3207-17.2018
   Whittaker RG, 2015, NEUROLOGY, V85, P1964, DOI 10.1212/WNL.0000000000002185
NR 22
TC 13
Z9 14
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 2376-7839
J9 NEUROL-GENET
JI Neurol.-Genet.
PD DEC
PY 2018
VL 4
IS 6
AR e282
DI 10.1212/NXG.0000000000000282
PG 9
WC Genetics & Heredity; Clinical Neurology
SC Genetics & Heredity; Neurosciences & Neurology
GA HG6NS
UT WOS:000455099800006
PM 30533528
OA gold, Green Published
DA 2021-10-30
ER

PT J
AU Di, L
   Wang, CP
   Shah, AH
   Eichberg, DG
   Semonche, AM
   Sanjurjo, AD
   Luther, EM
   Jermakowicz, WJ
   Komotar, RJ
   Ivan, ME
AF Di, Long
   Wang, Christopher P.
   Shah, Ashish H.
   Eichberg, Daniel G.
   Semonche, Alexa M.
   Sanjurjo, Alexander D.
   Luther, Evan M.
   Jermakowicz, Walter J.
   Komotar, Ricardo J.
   Ivan, Michael E.
TI A Cohort Study on Prognostic Factors for Laser Interstitial Thermal
   Therapy Success in Newly Diagnosed Glioblastoma
SO NEUROSURGERY
LA English
DT Article
DE Glioblastoma; Laser; Outcomes; Brain tumor; Extent of ablation;
   Chemotherapy
ID PROGRESSION-FREE SURVIVAL; BLOOD-BRAIN-BARRIER; RESECTION; ABLATION;
   LESIONS; EXTENT; TEMOZOLOMIDE; METAANALYSIS; COAGULATION; DISRUPTION
AB BACKGROUND: Laser interstitial thermal therapy (LITT) is a promising approach for cytoreduction of deep-seated gliomas. However, parameters contributing to treatment success remain unclear.
   OBJECTIVE: To identify extent of ablation (EOA) and time to chemotherapy (TTC) as predictors of improved overall and progression-free survival (OS, PFS) and suggest laser parameters to achieve optimal EOA.
   METHODS: Demographic, clinical, and survival data were collected retrospectively from 20 patients undergoing LITT for newly diagnosed glioblastoma (nGBM). EOA was calculated through magnetic resonance imaging-based volumetric analysis. Kaplan-Meier and multivariate Cox regression were used to examine the relationship between EOA with OS and PFS accounting for covariates (age, isocitrate dehydrogenase-1 (IDH1) mutation, O6-methylguanine-DNA methyltransferase hypermethylation). The effect of laser thermodynamic parameters (power, energy, time) on EOA was identified through linear regression.
   RESULTS: Median OS and PFS for the entire cohort were 36.2 and 3.5 mo respectively. Patient's with >70% EOA had significantly improved PFS compared to =70% EOA (5.2 vs 2.3 mo, P =.01) and trended toward improved OS (36.2 vs 11 mo, P =.07) on univariate and multivariate analysis. Total laser power was a significant predictor for increased EOA when accounting for preoperative lesion volume (P=.001). Chemotherapywithin 16 d of surgery significantly predicted improved PFS compared to delaying chemotherapy (9.4 vs 3.1 mo, P =.009).
   CONCLUSION: Increased EOA was a predictor of improved PFS with evidence of a trend toward improved OS in LITT treatment of nGBM. A strategy favoring higher laser power during tumor ablation may achieve optimal EOA. Early transition to chemotherapy after LITT improves PFS.
C1 [Di, Long; Wang, Christopher P.; Shah, Ashish H.; Eichberg, Daniel G.; Semonche, Alexa M.; Sanjurjo, Alexander D.; Luther, Evan M.; Jermakowicz, Walter J.; Komotar, Ricardo J.; Ivan, Michael E.] Univ Miami, Dept Neurosurg, Sch Med, Miami, FL 33136 USA.
   [Komotar, Ricardo J.; Ivan, Michael E.] Sylvestor Comprehens Canc Ctr, Miami, FL USA.
RP Di, L (corresponding author), Univ Miami, Dept Neurosurg, 1095 NW 14th Terrace, Miami, FL 33136 USA.
EM Longdi1996@gmail.com
OI Eichberg, Daniel/0000-0002-7654-2944
FU National Center for Advancing Translational Sciences of the National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [UL1TR002736]
FX This project was supported by the National Center for Advancing
   Translational Sciences of the National Institutes of Health under Award
   Number UL1TR002736.
CR Almenawer SA, 2015, NEURO-ONCOLOGY, V17, P868, DOI 10.1093/neuonc/nou349
   Awad A, 2017, J NEURO-ONCOL, V135, P161, DOI 10.1007/s11060-017-2562-1
   Ballman KV, 2007, NEURO-ONCOLOGY, V9, P29, DOI 10.1215/15228517-2006-025
   Banerjee C, 2015, BRIT J NEUROSURG, V29, P192, DOI 10.3109/02688697.2014.996527
   Barnett GH, 2016, STEREOT FUNCT NEUROS, V94, P164, DOI 10.1159/000446247
   Chaichana KL, 2013, J NEUROSURG, V118, P812, DOI 10.3171/2012.9.JNS1277
   Darefsky AS, 2012, CANCER-AM CANCER SOC, V118, P2163, DOI 10.1002/cncr.26494
   Di L, 2020, J NEURO-ONCOL, V148, P155, DOI 10.1007/s11060-020-03508-6
   Diaz R, 2016, NEUROSURGERY, V79, pS3
   Han KL, 2014, NEURO-ONCOLOGY, V16, P696, DOI 10.1093/neuonc/not236
   Hawasli AH, 2013, NEUROSURGERY, V73, P1007, DOI 10.1227/NEU.0000000000000144
   Heisterkamp J, 2001, LASER SURG MED, V28, P80, DOI 10.1002/1096-9101(2001)28:1<80::AID-LSM1020>3.0.CO;2-1
   ISHIHARA Y, 1995, MAGNET RESON MED, V34, P814, DOI 10.1002/mrm.1910340606
   Ivan ME, 2017, WORLD NEUROSURG, V98, P162, DOI 10.1016/j.wneu.2016.10.037
   Ivan ME, 2016, NEUROSURGERY, V79, pS17, DOI 10.1227/NEU.0000000000001446
   Jermakowicz WJ, 2019, J NEURO-ONCOL, V144, P193, DOI 10.1007/s11060-019-03220-0
   Jermakowicz WJ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199190
   Jethwa PR, 2012, NEUROSURGERY, V71, P133, DOI 10.1227/NEU.0b013e31826101d4
   Juweid M, 2017, GLIOBLASTOMA, P143, DOI DOI 10.15586/codon.glioblastoma.2017.ch8
   Kamath AA, 2019, NEUROSURGERY, V84, P836, DOI 10.1093/neuros/nyy375
   Lacroix M, 2001, J NEUROSURG, V95, P190, DOI 10.3171/jns.2001.95.2.0190
   Marko NF, 2014, J CLIN ONCOL, V32, P774, DOI 10.1200/JCO.2013.51.8886
   Medvid R, 2015, AM J NEURORADIOL, V36, P1998, DOI 10.3174/ajnr.A4362
   Mohammadi AM, 2019, NEUROSURGERY, V85, P762, DOI 10.1093/neuros/nyy449
   Mohammadi AM, 2014, CANCER MED-US, V3, P971, DOI 10.1002/cam4.266
   Nakagawa Minoru, 1994, Neurologia Medico-Chirurgica, V34, P668, DOI 10.2176/nmc.34.668
   Patel NV, 2013, LASER SURG MED, V45, P362, DOI 10.1002/lsm.22151
   Rennert RC, 2020, NEUROSURGERY, V86, P538, DOI 10.1093/neuros/nyz141
   Rodriguez A, 2015, PHARMACEUTICS, V7, P175, DOI 10.3390/pharmaceutics7030175
   ROSOMOFF HL, 1966, ARCH NEUROL-CHICAGO, V14, P143, DOI 10.1001/archneur.1966.00470080027004
   Salem U, 2019, CANCER IMAGING, V19, DOI 10.1186/s40644-019-0250-4
   Sanai N., 2011, J NEUROSURG, P1, DOI DOI 10.3171/2011.2.JNS10998
   SCHOBER R, 1993, LASER SURG MED, V13, P234, DOI 10.1002/lsm.1900130212
   Schwabe B, 1997, J COMPUT ASSIST TOMO, V21, P818, DOI 10.1097/00004728-199709000-00031
   Shah AH, 2020, NEUROSURGERY, V87, P266, DOI 10.1093/neuros/nyz424
   Shah AH, 2019, NEUROSURGERY, V84, P768, DOI 10.1093/neuros/nyy238
   Sloan AE, 2013, J NEUROSURG, V118, P1202, DOI 10.3171/2013.1.JNS1291
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Sun XNR, 2015, NEUROSURGERY, V77, P51, DOI 10.1227/NEU.0000000000000732
   Thakkar JP, 2014, CANCER EPIDEM BIOMAR, V23, P1985, DOI 10.1158/1055-9965.EPI-14-0275
   Thomas JG, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.7.FOCUS16234
   Tran D, 2017, NEURO-ONCOLOGY, V19, P18
   Voigt JD, 2016, COST EFFECT RESOUR A, V14, DOI 10.1186/s12962-016-0055-2
   von Elm E, 2007, ANN INTERN MED, V147, P573, DOI 10.1016/j.jclinepi.2007.11.008
   Wen PY, 2017, J CLIN ONCOL, V35, P2439, DOI 10.1200/JCO.2017.72.7511
   Zhu D, 2002, LASER SURG MED, V31, P313, DOI 10.1002/lsm.10108
NR 46
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0148-396X
EI 1524-4040
J9 NEUROSURGERY
JI Neurosurgery
PD SEP
PY 2021
VL 89
IS 3
BP 496
EP 503
DI 10.1093/neuros/nyab193
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA UL4BM
UT WOS:000692598400053
PM 34156076
DA 2021-10-30
ER

PT J
AU Soni, Y
   Arora, H
   Ramasamy, R
AF Soni, Yash
   Arora, Himanshu
   Ramasamy, Ranjith
TI THERAPEUTIC POTENTIAL OF NITRIC OXIDE SIGNALING PATHWAY AGONISTS AGAINST
   CASTRATION RESISTANT PROSTATE CANCER
SO JOURNAL OF UROLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Urological-Association (AUA)
CY MAY 15-18, 2020
CL Washington, DC
SP Amer Urol Assoc
RI Ramasamy, Ranjith/ABD-7373-2020
OI Ramasamy, Ranjith/0000-0003-1387-7904
FU Clinician Scientist Development Grant from American Cancer Society;
   Pilot Award from the Clinical and Translational Science Institute -
   NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [UL1TR002736]
FX Supported by Clinician Scientist Development Grant from American Cancer
   Society (RR), Pilot Award from the Clinical and Translational Science
   Institute supported by NIH (UL1TR002736)
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0022-5347
EI 1527-3792
J9 J UROLOGY
JI J. Urol.
PD APR
PY 2020
VL 203
SU 4
MA MP16-03
BP E215
EP E215
PG 1
WC Urology & Nephrology
SC Urology & Nephrology
GA LE8XO
UT WOS:000527010301398
DA 2021-10-30
ER

PT J
AU Dazard, JE
   Choe, M
   LeBlanc, M
   Rao, JS
AF Dazard, Jean-Eudes
   Choe, Michael
   LeBlanc, Michael
   Rao, J. Sunil
TI Cross-validation and Peeling Strategies for Survival Bump Hunting using
   Recursive Peeling Methods
SO STATISTICAL ANALYSIS AND DATA MINING
LA English
DT Article
DE exploratory survival/risk analysis; survival/risk estimation and
   prediction; non-parametric method; cross-validation; bump hunting;
   patient rule induction method
ID VARIABLE SELECTION; ERROR ESTIMATION; CANCER; MICROARRAY; PREDICTION;
   REGRESSION; TREES; MODELS; BIAS
AB We introduce a framework to build a survival/risk bump hunting model with a censored time-to-event response. Our survival bump hunting (SBH) method is based on a recursive peeling procedure that uses a specific survival peeling criterion derived from non-/semi-parametric statistics such as the hazard ratio, the log-rank test or the Nelson-Aalen estimator. To optimize the tuning parameter of the model and validate it, we introduce an objective function based on survival-or prediction-error statistics, such as the log-rank test and the concordance error rate. We also describe two alternative cross-validation techniques adapted for the joint task of decision-rule making by recursive peeling and survival estimation. Numerical analyses show the importance of replicated cross-validation and the differences between criteria and techniques in both low-and high-dimensional settings. Although several non-parametric survival models exist, none address the problem of directly identifying local extrema. We show how SBH efficiently estimates extreme survival/risk subgroups, unlike other models. This provides an insight into the behavior of commonly used models and suggests alternatives to be adopted in practice. Finally, our SBH framework was applied to a clinical dataset. In it, we identified subsets of patients characterized by clinical and demographic covariates with a distinct extreme survival outcome for which tailored medical interventions could be made. An R package Patient Rule Induction Method in Survival, Regression and Classification settings (PRIMsrc) is available on Comprehensive R Archive Network (CRAN) and GitHub. (C) 2016 The Authors. Statistical Analysis and Data Mining: The ASA Data Science Journal published by Wiley Periodicals, Inc. Statistical Analysis and Data Mining: The ASA Data Science Journal 9: 12-42, 2016
C1 [Dazard, Jean-Eudes; Choe, Michael] Case Western Reserve Univ, Ctr Prote & Bioinformat, Cleveland, OH 44106 USA.
   [LeBlanc, Michael] Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA.
   [LeBlanc, Michael] Fred Hutchinson Canc Res Ctr, Publ Hlth Sci, Seattle, WA 98109 USA.
   [Rao, J. Sunil] Univ Miami, Dept Epidemiol & Publ Hlth, Div Biostat, Miami, FL 33136 USA.
RP Dazard, JE (corresponding author), Case Western Reserve Univ, Ctr Prote & Bioinformat, Cleveland, OH 44106 USA.
EM jxd101@case.edu
OI Dazard, Jean-Eudes/0000-0003-4720-3684
FU NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1 TR000460] Funding Source: Medline;
   NCI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30
   CA043703, R01 CA160593] Funding Source: Medline; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [P30CA043703, R01CA160593] Funding Source: NIH RePORTER; NATIONAL CENTER
   FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000460]
   Funding Source: NIH RePORTER
CR AHN HS, 1994, BIOMETRICS, V50, P471, DOI 10.2307/2533389
   Ambroise C, 2002, P NATL ACAD SCI USA, V99, P6562, DOI 10.1073/pnas.102102699
   Bacon MC, 2005, CLIN DIAGN LAB IMMUN, V12, P1013, DOI 10.1128/CDLI.12.9.1013-1019.2005
   Bair E, 2006, J AM STAT ASSOC, V101, P119, DOI 10.1198/016214505000000628
   Bair E, 2004, PLOS BIOL, V2, P511, DOI 10.1371/journal.pbio.0020108
   Baker Stuart G, 2002, BMC Med Res Methodol, V2, P4, DOI 10.1186/1471-2288-2-4
   Bohning D, 2003, COMPUT STAT DATA AN, V41, P349, DOI 10.1016/S0167-9473(02)00161-5
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Breiman L., 1984, CLASSIFICATION REGRE
   Burman P, 2009, J MULTIVARIATE ANAL, V100, P1198, DOI 10.1016/j.jmva.2008.10.015
   Chong IG, 2008, EXPERT SYST APPL, V34, P3014, DOI 10.1016/j.eswa.2007.05.047
   CIAMPI A, 1986, COMPUT STAT DATA AN, V4, P185, DOI 10.1016/0167-9473(86)90033-2
   COX DR, 1972, J R STAT SOC B, V34, P187
   DAVIS RB, 1989, STAT MED, V8, P947, DOI 10.1002/sim.4780080806
   Dazard J.-E., 2014, JSM P SECT SURV METH, P3366
   Dazard J.-E., 2016, PRIMSRC IDENTI UNPUB
   Dazard Jean-Eudes, 2015, Proc Am Stat Assoc, V2015, P650
   Dazard JE, 2012, STAT MED, V31, P1203, DOI 10.1002/sim.4389
   Dazard JE, 2010, J COMPUT GRAPH STAT, V19, P900, DOI 10.1198/jcgs.2010.09029
   Diaz-Pachon D., 2015, ARXIV14098630
   Diaz-Pachon D., 2015, ARXIV14044917
   Dobbin KK, 2007, BIOSTATISTICS, V8, P101, DOI 10.1093/biostatistics/kxj036
   Dobbin KK, 2005, CLIN CANCER RES, V11, P565
   Dupuy A, 2007, JNCI-J NATL CANCER I, V99, P147, DOI 10.1093/jnci/djk018
   Efron B, 1997, J AM STAT ASSOC, V92, P548, DOI 10.2307/2965703
   Efron B, 2004, ANN STAT, V32, P407, DOI 10.1214/009053604000000067
   EFRON B, 1983, J AM STAT ASSOC, V78, P316, DOI 10.2307/2288636
   Efron B., 1993, INTRO BOOTSTRAP CRC
   Ein-Dor L, 2005, BIOINFORMATICS, V21, P171, DOI 10.1093/bioinformatics/bth469
   Fan JQ, 2008, J R STAT SOC B, V70, P849, DOI 10.1111/j.1467-9868.2008.00674.x
   Fan JQ, 2014, NATL SCI REV, V1, P293, DOI 10.1093/nsr/nwt032
   Friedman JH, 1999, STAT COMPUT, V9, P123, DOI 10.1023/A:1008894516817
   GORDON L, 1985, CANCER TREAT REP, V69, P1065
   Haibe-Kains B, 2013, NATURE, V504, P389, DOI 10.1038/nature12831
   HARRELL FE, 1982, JAMA-J AM MED ASSOC, V247, P2543, DOI 10.1001/jama.247.18.2543
   HARTIGAN JA, 1992, J CLASSIF, V9, P63, DOI 10.1007/BF02618468
   Hastie T., 2009, ELEMENTS STAT LEARNI, V2
   Huang J, 2006, BIOMETRICS, V62, P813, DOI 10.1111/j.1541-0420.2006.00562.x
   Ishwaran H, 2005, ANN STAT, V33, P730, DOI 10.1214/009053604000001147
   Ishwaran H, 2008, ANN APPL STAT, V2, P841, DOI 10.1214/08-AOAS169
   Klement W., 2008, P 3 INT WORKSH EV ME
   LEBLANC M, 1993, J AM STAT ASSOC, V88, P457, DOI 10.2307/2290325
   LeBlanc M, 2005, BIOMETRICS, V61, P370, DOI 10.1111/j.1541-0420.2005.020738.x
   LeBlanc M, 2002, STAT METHODS MED RES, V11, P247, DOI 10.1191/0962280202sm286ra
   LEBLANC M, 1992, BIOMETRICS, V48, P411, DOI 10.2307/2532300
   Leek JT, 2010, NAT REV GENET, V11, P733, DOI 10.1038/nrg2825
   Markatou M, 2005, J MACH LEARN RES, V6, P1127
   McShane LM, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-220
   McShane LM, 2013, NATURE, V502, P317, DOI 10.1038/nature12564
   Michiels S, 2005, LANCET, V365, P488, DOI 10.1016/S0140-6736(05)17866-0
   Molinaro AM, 2005, BIOINFORMATICS, V21, P3301, DOI 10.1093/bioinformatics/bti499
   Naftel D., 1985, RES REPORT
   Ntzani EE, 2003, LANCET, V362, P1439, DOI 10.1016/S0140-6736(03)14686-7
   POLONIK W, 1995, ANN STAT, V23, P855, DOI 10.1214/aos/1176324626
   Polonik W, 2010, J MULTIVARIATE ANAL, V101, P525, DOI 10.1016/j.jmva.2009.08.010
   Ransohoff DF, 2004, NAT REV CANCER, V4, P309, DOI 10.1038/nrc1322
   ROZAL GPM, 1994, J CLASSIF, V11, P5, DOI 10.1007/BF01201021
   SEGAL MR, 1988, BIOMETRICS, V44, P35, DOI 10.2307/2531894
   Shi LM, 2006, NAT BIOTECHNOL, V24, P1151, DOI 10.1038/nbt1239
   Simon R, 2003, J NATL CANCER I, V95, P14, DOI 10.1093/jnci/95.1.14
   Simon RM, 2011, BRIEF BIOINFORM, V12, P203, DOI 10.1093/bib/bbr001
   Subramanian J, 2013, CONTEMP CLIN TRIALS, V36, P636, DOI 10.1016/j.cct.2013.06.011
   Subramanian J, 2011, STAT MED, V30, P642, DOI 10.1002/sim.4106
   Subramanian J, 2010, JNCI-J NATL CANCER I, V102, P464, DOI 10.1093/jnci/djq025
   THERNEAU TM, 1990, BIOMETRIKA, V77, P147, DOI 10.2307/2336057
   Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x
   Varma S, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-91
   Wang P, 2004, 2004 IEEE COMPUTATIONAL SYSTEMS BIOINFORMATICS CONFERENCE, PROCEEDINGS, P604
   Wu L., 2003, TECHNICAL REPORT
   Zou H, 2005, J R STAT SOC B, V67, P301, DOI 10.1111/j.1467-9868.2005.00503.x
NR 70
TC 3
Z9 3
U1 2
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1932-1864
EI 1932-1872
J9 STAT ANAL DATA MIN
JI Stat. Anal. Data Min.
PD FEB
PY 2016
VL 9
IS 1
BP 12
EP 42
DI 10.1002/sam.11301
PG 31
WC Computer Science, Artificial Intelligence; Computer Science,
   Interdisciplinary Applications; Statistics & Probability
SC Computer Science; Mathematics
GA DD5LI
UT WOS:000369964800002
PM 27034730
OA Green Submitted, Green Accepted, hybrid
DA 2021-10-30
ER

PT J
AU Duthely, LM
   Sanchez-Covarrubias, AP
   Brown, MR
   Thomas, TE
   Montgomerie, EK
   Dale, S
   Safren, SA
   Potter, JE
AF Duthely, Lunthita M.
   Sanchez-Covarrubias, Alex P.
   Brown, Megan R.
   Thomas, Tanya E.
   Montgomerie, Emily K.
   Dale, Sannisha
   Safren, Steven A.
   Potter, JoNell E.
TI Pills, PrEP, and Pals: Adherence, Stigma, Resilience, Faith and the Need
   to Connect Among Minority Women With HIV/AIDS in a US HIV Epicenter
SO FRONTIERS IN PUBLIC HEALTH
LA English
DT Article
DE women and HIV; adherence; minority health and mental health; mobile
   health; mixed methods
ID MOBILE HEALTH INTERVENTION; VIRAL LOAD; CARE; RETENTION; PEOPLE;
   EXPERIENCES; CONTINUUM; OUTCOMES; SUPPORT
AB Background: Ending HIV/AIDS in the United States requires tailored interventions. This study is part of a larger investigation to design mCARES, a mobile technology-based, adherence intervention for ethnic minority women with HIV (MWH). Objective: To understand barriers and facilitators of care adherence (treatment and appointment) for ethnic MWH; examine the relationship between these factors across three ethnic groups; and, explore the role of mobile technologies in care adherence. Methods: Cross-sectional, mixed-methods data were collected from a cohort of African-American, Hispanic-American and Haitian-American participants. Qualitative data were collected through a focus group (n = 8) to assess barriers and facilitators to care adherence. Quantitative data (n = 48) surveyed women on depressive symptomology (PHQ-9), HIV-related stigma (HSS) and resiliency (CD-RISC25). We examined the relationships between these factors and adherence to treatment and care and across groups. Findings: Qualitative analyses revealed that barriers to treatment and appointment adherence were caregiver-related stressors (25%) and structural issues (25%); routinization (30%) and religion/spirituality (30%) promoted adherence to treatment and care. Caregiver role was both a hindrance (25%) and promoter (20%) of adherence to treatment and appointments. Quantitatively, HIV-related stigma differed by ethnic group; Haitian-Americans endorsed the highest levels while African-Americans endorsed the lowest. Depression correlated to stigma (R = 0.534; p < 0.001) and resiliency (R = -0.486; p < 0.001). Across ethnic groups, higher depressive symptomology and stigma were related to viral non-suppression (p < 0.05)-a treatment adherence marker; higher resiliency was related to viral suppression. Among Hispanic-Americans, viral non-suppression was related to depression (p < 0.05), and among African-Americans, viral suppression was related to increased resiliency (p < 0.04). Conclusion: Multiple interrelated barriers to adherence were identified. These findings on ethnic group-specific differences underscore the importance of implementing culturally-competent interventions. While privacy and confidentiality were of concern, participants suggested additional intervention features and endorsed the use of mCARES as a strategy to improve adherence to treatment and appointments.
C1 [Duthely, Lunthita M.; Potter, JoNell E.] Univ Miami, Miller Sch Med, Obstet Gynecol & Reprod Sci, Div Res & Special Projects, Miami, FL 33136 USA.
   [Sanchez-Covarrubias, Alex P.] Univ Miami, Miller Sch Med, Div Gynecol Oncol, Obstet Gynecol & Reprod Sci, Miami, FL 33136 USA.
   [Brown, Megan R.; Thomas, Tanya E.] Univ Miami, Miller Sch Med, Med Educ, Miami, FL 33136 USA.
   [Montgomerie, Emily K.] Univ Miami, Miller Sch Med, Miami Ctr AIDS Res, Miami, FL 33136 USA.
   [Dale, Sannisha; Safren, Steven A.] Univ Miami, Dept Psychol, POB 248185, Coral Gables, FL 33124 USA.
RP Duthely, LM (corresponding author), Univ Miami, Miller Sch Med, Obstet Gynecol & Reprod Sci, Div Res & Special Projects, Miami, FL 33136 USA.
EM lduthely@med.miami.edu
OI Sanchez-Covarrubias, Alex P/0000-0002-0474-992X
FU Miami Clinical and Translational Science Institute, from the National
   Center for Advancing Translational Sciences [KL2TR002737]; National
   Center for Advancing Translational SciencesUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Advancing Translational Sciences (NCATS); National
   Institute on Minority Health and Health DisparitiesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Minority Health & Health Disparities
   (NIMHD)
FX The project described was supported by grant number KL2TR002737, Miami
   Clinical and Translational Science Institute, from the National Center
   for Advancing Translational Sciences and the National Institute on
   Minority Health and Health Disparities. Its contents are solely the
   responsibility of the authors and do not necessarily represent the
   official views of the National Institutes of Health.
CR Algarin AB, 2020, AIDS PATIENT CARE ST, V34, P316, DOI 10.1089/apc.2020.0031
   Algarin AB, 2021, AIDS BEHAV, V25, P93, DOI 10.1007/s10461-020-02948-5
   [Anonymous], 2019, DEDOOSE VERSION 8 3
   Berger BE, 2001, RES NURS HEALTH, V24, P518, DOI 10.1002/nur.10011
   Bruck-Segal D, 2020, SEX ROLES, V82, P716, DOI 10.1007/s11199-019-01086-0
   Centers for Disease Control and Prevention, 2020, HIV US DEP AR NOV
   Centers for Disease Control and Prevention, 2018, HIV SURV REP
   Cheng C, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.604401
   Connor KM, 2003, DEPRESS ANXIETY, V18, P76, DOI 10.1002/da.10113
   Dale S, 2014, AIDS PATIENT CARE ST, V28, P136, DOI 10.1089/apc.2013.0329
   Dale SK, 2018, AIDS CARE, V30, pS18, DOI 10.1080/09540121.2018.1503225
   Dillingham R, 2018, AIDS PATIENT CARE ST, V32, P241, DOI 10.1089/apc.2017.0303
   Duthely LM, 2020, FRONT COMMUN, V5, DOI 10.3389/fcomm.2020.530164
   Duthely LM, 2020, JMIR RES PROTOC, V9, DOI 10.2196/17656
   Earnshaw VA, 2013, AM PSYCHOL, V68, P225, DOI 10.1037/a0032705
   Fauci AS, 2019, JAMA-J AM MED ASSOC, V321, P844, DOI 10.1001/jama.2019.1343
   Fletcher F, 2016, AIDS PATIENT CARE ST, V30, P349, DOI 10.1089/apc.2016.0026
   Fletcher FE, 2020, AIDS PATIENT CARE ST, V34, P356, DOI 10.1089/apc.2019.0309
   Garett R, 2016, CURR OPIN PSYCHOL, V9, P56, DOI 10.1016/j.copsyc.2015.10.024
   Henny KD, 2018, AIDS BEHAV, V22, P43, DOI 10.1007/s10461-017-1923-2
   Ingram L, 2019, J ASSOC NURSE AIDS C, V30, P330, DOI 10.1097/JNC.0000000000000076
   Jones Deborah L, 2020, Res Sq, DOI 10.21203/rs.3.rs-109131/v1
   Kemp CG, 2019, AIDS, V33, P1511, DOI 10.1097/QAD.0000000000002212
   Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x
   Kurth AE, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.5830
   Levison JH, 2017, AIDS PATIENT CARE ST, V31, P394, DOI 10.1089/apc.2017.0084
   Lipira L, 2019, JAIDS-J ACQ IMM DEF, V81, P175, DOI 10.1097/QAI.0000000000002006
   Mayer JE, 2017, AIDS CARE, V29, P409, DOI 10.1080/09540121.2016.1214674
   Mbuagbaw L, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-034793
   Muessig KE, 2015, CURR HIV-AIDS REP, V12, P173, DOI 10.1007/s11904-014-0239-3
   Pantalone DW., 2020, J SEX RES, V57, P681, DOI [10.1080/00224499.2020.1728514, DOI 10.1080/00224499.2020.1728514]
   Rana AI, 2016, AIDS PATIENT CARE ST, V30, P178, DOI 10.1089/apc.2016.0025
   Simoni JM, 2015, CURR HIV-AIDS REP, V12, P437, DOI 10.1007/s11904-015-0289-1
   Spies G, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004200
   Taylor D, 2019, SYST REV-LONDON, V8, DOI 10.1186/s13643-018-0921-4
   Trint, 2021, TRINT SPEECH TEXT PL
   Wilson IB, 2016, AIDS BEHAV, V20, P2700, DOI 10.1007/s10461-016-1406-x
   Yam EA, 2020, AIDS, V34, pS43, DOI 10.1097/QAD.0000000000002642
   Ye M, 2018, J PUBLIC HEALTH-UK, V40, P42, DOI 10.1093/pubmed/fdy196
NR 39
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-2565
J9 FRONT PUBLIC HEALTH
JI Front. Public Health
PD JUN 21
PY 2021
VL 9
AR 667331
DI 10.3389/fpubh.2021.667331
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA TD6UG
UT WOS:000669458800001
PM 34235129
OA gold, Green Published
DA 2021-10-30
ER

PT J
AU Duthely, LM
   Sanchez-Covarrubias, AP
AF Duthely, Lunthita M.
   Sanchez-Covarrubias, Alex P.
TI Digitized HIV/AIDS Treatment Adherence Interventions: A Review of Recent
   SMS/Texting Mobile Health Applications and Implications for Theory and
   Practice
SO FRONTIERS IN COMMUNICATION
LA English
DT Review
DE access to healthcare; mHealth ethics; minorities; health disparities in
   HIV/AIDS; intervention - behavioral; HIV/AIDS; mHealth
ID HIV TREATMENT ADHERENCE; TEXT MESSAGE REMINDERS; ANTIRETROVIRAL THERAPY;
   CARE; INFORMATION; TECHNOLOGY; WOMEN; DISPARITIES; ENGAGEMENT; RETENTION
AB Background: Mobile health technologies (mHealth) are efficacious along the continuum of HIV/AIDS-from prevention of HIV transmission to those at the highest risk of acquiring infection, to adherence to HIV medical care, for those living with the disease-decreasing the public health burden of the disease. HIV/AIDS is a complex condition, as certain population subgroups are disproportionately affected. Furthermore, barriers experienced at the individual level (e.g., HIV stigma) and at the systems level (i.e., access to care) contribute to these disparities. Low cost, high penetration rates and ease of use mean mHealth SMS/texting solutions hold the biggest promise for curbing the global HIV/AIDS epidemic; yet these technologies have their own challenges. Our primary objective was to assess interventions that promote adherence, which are delivered via SMS/texting, and important design and ethical considerations of these technologies. Specifically, we evaluated the underlying frameworks underpinning intervention design, strategies to safeguard privacy and confidentiality, and measures taken to ensure equity and equitable access across different subgroups of persons living with HIV (PLWH). We also synthesized study outcomes, barriers/facilitators to adherence, and barriers/facilitators of technology to support HIV adherence.
   Methods: A scoping review methodology was utilized, searching the Medline database for recently published articles (January 2017 to June 2019). Two reviewers independently screened titles and abstracts for relevancy using the following eligibility criteria: (a) original research or protocol; (b) inclusion of persons living with HIV; (c) intervention delivery via SMS/text messaging; and, (d) intervention included HIV care adherence.
   Results: Seven (7) of the 134 articles met full criteria. The great majority (n = 6) did not report whether the interventions were developed under established behavioral change models or frameworks. Strategies to address privacy, confidentiality and equity/equitable access were taken in four (n = 4) studies.
   Conclusion: Our mixed methods review determined that privacy and confidentiality remain a concern for PLWH. Provisions to accommodate literacy, infrastructure, technology and other challenges (e.g., access to smartphones and Wifi) are important ethical considerations that guarantee equity and equitable access. Further investigation will determine the contexts within which theoretical models and frameworks remain relevant in the rapidly evolving field of digitized interventions that support adherence.
C1 [Duthely, Lunthita M.] Univ Miami, Miller Sch Med, Div Res & Special Projects, Obstet Gynecol & Reprod Sci, Miami, FL 33136 USA.
   [Sanchez-Covarrubias, Alex P.] Univ Miami, Miller Sch Med, Div Gynecol Oncol, Obstet Gynecol & Reprod Sci, Miami, FL 33136 USA.
RP Duthely, LM (corresponding author), Univ Miami, Miller Sch Med, Div Res & Special Projects, Obstet Gynecol & Reprod Sci, Miami, FL 33136 USA.
EM lduthely@med.miami.edu
OI Sanchez-Covarrubias, Alex P/0000-0002-0474-992X; Duthely,
   Lunthita/0000-0002-9003-3257
FU Miami Clinical and Translational Science Institute (CTSI), from the
   National Institute of Health (NIH) National Center for Advancing
   Translational Sciences (NCATS) [KL2TR002737]; National Institute on
   Minority Health and Health Disparities (NIMHHD)
FX The writing of this manuscript was supported by Grant Number
   KL2TR002737, Miami Clinical and Translational Science Institute (CTSI),
   from the National Institute of Health (NIH) National Center for
   Advancing Translational Sciences (NCATS) and the National Institute on
   Minority Health and Health Disparities (NIMHHD). Its contents are solely
   the responsibility of the authors and do not necessarily represent the
   official views of the NIH.
CR Alaei A., 2018, INT J STD AIDS, V29, P1183, DOI [10.1177/0956462418779658, DOI 10.1177/0956462418779658]
   Amankwaa I, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204091
   Amico KR, 2005, AIDS CARE, V17, P661, DOI 10.1080/09540120500038058
   Arksey H, 2005, INT J SOC RES METHOD, V8, P19, DOI [10.1080/1364557032000119616, DOI 10.1080/1364557032000119616]
   Avert, 2018, HIV AIDS S AFRICA
   Bandura A, 2001, ANNU REV PSYCHOL, V52, P1, DOI 10.1146/annurev.psych.52.1.1
   Bauermeister JA, 2017, CURR OPIN HIV AIDS, V12, P442, DOI 10.1097/COH.0000000000000396
   Blas E, 2010, EQUITY, SOCIAL DETERMINANTS AND PUBLIC HEALTH PROGRAMMES, P1
   Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]
   Burrus O, 2018, MED CARE, V56, P756, DOI 10.1097/MLR.0000000000000957
   Catalani Caricia, 2013, Open AIDS J, V7, P17, DOI 10.2174/1874613620130812003
   Centers for Disease Control, 2018, HIV SURV REP
   Chan CV, 2011, J MED INTERNET RES, V13, DOI 10.2196/jmir.1750
   Cole-Lewis H, 2010, EPIDEMIOL REV, V32, P56, DOI 10.1093/epirev/mxq004
   Crepaz N, 2020, JAIDS-J ACQ IMM DEF, V83, P334, DOI 10.1097/QAI.0000000000002277
   Daher J, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017604
   Dahlgren G.W., 2006, LEVELING DISCUSSIO 2 LEVELING DISCUSSIO 2
   Dale SK, 2019, AIDS PATIENT CARE ST, V33, P175, DOI 10.1089/apc.2018.0258
   DAVIS FD, 1989, MIS QUART, V13, P319, DOI 10.2307/249008
   Deci E. L., 1995, EFFICACY AGENCY SELF, P31
   Dillingham R, 2018, AIDS PATIENT CARE ST, V32, P241, DOI 10.1089/apc.2017.0303
   Drysdale K., 2020, QUAL HEALTH RES, V30, P793, DOI [10.1177/1049732319890304, DOI 10.1177/1049732319890304]
   Duggal M, 2018, AIDS PATIENT CARE ST, V32, P349, DOI 10.1089/apc.2017.0315
   Earnshaw VA, 2013, AM PSYCHOL, V68, P225, DOI 10.1037/a0032705
   Essuon AD, 2020, MMWR-MORBID MORTAL W, V69, P97, DOI 10.15585/mmwr.mm6904a2
   Evans JM, 2016, INT J INTEGR CARE, V16, DOI 10.5334/ijic.2416
   Evans T.W.M., 2001, CHALLENGING INEQUITI, P13, DOI [10.1093/acprof:oso/9780195137408.001.0001, DOI 10.1093/ACPROF:OSO/9780195137408.001.0001]
   Fisher W.A., 2009, BLACKW SER HLTH PSYC, P82
   Flickinger TE, 2018, AIDS BEHAV, V22, P3395, DOI 10.1007/s10461-018-2174-6
   Glanz K., 2004, EDUC HEALTH, V17, P399, DOI [10.1249/00005768-199112000-00016, DOI 10.1249/00005768-199112000-00016]
   Godin G, 1996, AM J HEALTH PROMOT, V11, P87, DOI 10.4278/0890-1171-11.2.87
   Guo Y, 2020, J MED INTERNET RES, V22, DOI 10.2196/16715
   Henny KD, 2018, AIDS BEHAV, V22, P43, DOI 10.1007/s10461-017-1923-2
   Hightow-Weidman LB, 2018, JMIR RES PROTOC, V7, DOI 10.2196/10365
   Hightow-Weidman LB, 2015, CURR HIV-AIDS REP, V12, P500, DOI 10.1007/s11904-015-0280-x
   Horvath KJ, 2019, JMIR RES PROTOC, V8, DOI 10.2196/11502
   Huotari K., 2012, P 16 INT AC MINDTREK
   Ingersoll KS, 2015, HEALTH PSYCHOL, V34, P1305, DOI 10.1037/hea0000295
   Jack C.L., 2014, AFR J PRIM HLTH CARE, V6, pE1, DOI [10.4102/phcfm.v6i1.607, DOI 10.4102/PHCFM.V6I1.607]
   Jessor R., 1977, PROBLEM BEHAV PSYCHO
   Kempf MC, 2015, CURR HIV-AIDS REP, V12, P472, DOI 10.1007/s11904-015-0292-6
   Labrique AB, 2013, AIDS RES TREAT, V2013, DOI 10.1155/2013/189645
   Levac D, 2010, IMPLEMENT SCI, V5, DOI 10.1186/1748-5908-5-69
   Li N, 2013, PSYCHIAT SERV, V64, P638, DOI 10.1176/appi.ps.001232012
   Madiba S, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/9623159
   Marent B, 2018, JMIR MHEALTH UHEALTH, V6, DOI 10.2196/mhealth.9856
   Marent B, 2018, SOC SCI MED, V215, P133, DOI 10.1016/j.socscimed.2018.09.003
   Marhefka SL, 2020, AIDS BEHAV, V24, P1463, DOI 10.1007/s10461-019-02723-1
   Perez GM, 2015, PAN AFR MED J, V21, DOI 10.11604/pamj.2015.21.201.6844
   Mayer JE, 2017, AIDS CARE, V29, P409, DOI 10.1080/09540121.2016.1214674
   Miller CWT, 2013, AIDS RES TREAT, V2013, DOI 10.1155/2013/670525
   Moher D, 2009, PLOS MED, V6, DOI DOI 10.1371/JOURNAL.PMED.1000097
   Mohr DC, 2013, AM J PREV MED, V45, P517, DOI 10.1016/j.amepre.2013.06.006
   Muessig KE, 2017, CURR OPIN HIV AIDS, V12, P432, DOI 10.1097/COH.0000000000000401
   Muessig KE, 2015, CURR HIV-AIDS REP, V12, P173, DOI 10.1007/s11904-014-0239-3
   National Institute of Allergy Infectious Diseases, 2018, SCI VAL UND UNTR HIV SCI VAL UND UNTR HIV
   Okano JT, 2016, LANCET INFECT DIS, V16, P789, DOI 10.1016/S1473-3099(16)30022-6
   Okawa S, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0697-7
   Purnomo J, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-2972-5
   Rana AI, 2016, AIDS PATIENT CARE ST, V30, P178, DOI 10.1089/apc.2016.0025
   RHODES F, 1996, DRUGS SOC, V9, P109
   Riley WT, 2011, TRANSL BEHAV MED, V1, P53, DOI 10.1007/s13142-011-0021-7
   Sabin Lora L, 2018, Open AIDS J, V12, P20, DOI 10.2174/1874613601812010020
   Sabin LL, 2015, JAIDS-J ACQ IMM DEF, V69, P551, DOI 10.1097/QAI.0000000000000651
   Sanou B., 2016, ICT FACTS FIG
   Schnall R, 2015, AIDS BEHAV, V19, pS81, DOI 10.1007/s10461-014-0984-8
   Shah M, 2016, LANCET HIV, V3, pE140, DOI 10.1016/S2352-3018(16)00007-2
   Shah R, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-6899-6
   Solar O., 2007, CONCEPTUAL FRAMEWORK
   Staunton C, 2019, SAMJ S AFR MED J, V109, P468, DOI [10.7196/SAMJ.2019.v109i7.14148, 10.7196/samj.2019.v109i7.14148]
   Sullivan MC, 2020, ARCH SEX BEHAV, V49, P2005, DOI 10.1007/s10508-019-01531-x
   Taylor D, 2019, SYST REV-LONDON, V8, DOI 10.1186/s13643-018-0921-4
   Taylor K, 2020, JAIDS-J ACQ IMM DEF, V84, P242, DOI 10.1097/QAI.0000000000002334
   The Joint United Nations Programme on HIV AIDS [UNAIDS], 2015, UNAIDS 2016 2021 STR
   The White House Office of National AIDS Policy, 2016, NAT HIV AIDS STRAT U
   U.S. Department of Health Human Services, 2009, REC PRIV CONF REC PRIV CONF
   United Nations, 2015, UN TRANSF OUR WORLD UN TRANSF OUR WORLD
   Venter WDF, 2019, JMIR MHEALTH UHEALTH, V7, DOI 10.2196/12652
   Watts DH, 2013, JAIDS-J ACQ IMM DEF, V64, P299, DOI 10.1097/QAI.0b013e3182a2123a
   Whiteley L, 2018, JMIR MHEALTH UHEALTH, V6, DOI 10.2196/mhealth.8155
   World Health Organization, 2015, MAPS TOOLK MHEALTH A MAPS TOOLK MHEALTH A
   Ye M, 2018, J PUBLIC HEALTH-UK, V40, P42, DOI 10.1093/pubmed/fdy196
NR 82
TC 1
Z9 1
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2297-900X
J9 FRONT COMMUN
JI Front. Commun.
PD NOV 10
PY 2020
VL 5
AR 530164
DI 10.3389/fcomm.2020.530164
PG 19
WC Communication
SC Communication
GA TP5WF
UT WOS:000677669000001
PM 33644162
OA Green Accepted, gold
DA 2021-10-30
ER

PT J
AU Rice, TW
   Lerut, TEMR
   Orringer, MB
   Chen, LQ
   Hofstetter, WL
   Smithers, BM
   Rusch, VW
   van Lanschot, J
   Chen, KN
   Davies, AR
   D'Journo, XB
   Kesler, KA
   Luketich, JD
   Ferguson, MK
   Rasanen, JV
   van Hillegersberg, R
   Fang, W
   Durand, L
   Allum, WH
   Cecconello, I
   Cerfolio, RJ
   Pera, M
   Griffin, SM
   Burger, R
   Liu, JF
   Allen, MS
   Law, S
   Watson, TJ
   Darling, GE
   Scott, WJ
   Duranceau, A
   Denlinger, CE
   Schipper, PH
   Ishwaran, H
   Apperson-Hansen, C
   DiPaola, LM
   Semple, ME
   Blackstone, EH
AF Rice, T. W.
   Lerut, T. E. M. R.
   Orringer, M. B.
   Chen, L. -Q.
   Hofstetter, W. L.
   Smithers, B. M.
   Rusch, V. W.
   van Lanschot, J.
   Chen, K. N.
   Davies, A. R.
   D'Journo, X. B.
   Kesler, K. A.
   Luketich, J. D.
   Ferguson, M. K.
   Rasanen, J. V.
   van Hillegersberg, R.
   Fang, W.
   Durand, L.
   Allum, W. H.
   Cecconello, I.
   Cerfolio, R. J.
   Pera, M.
   Griffin, S. M.
   Burger, R.
   Liu, J. -F.
   Allen, M. S.
   Law, S.
   Watson, T. J.
   Darling, G. E.
   Scott, W. J.
   Duranceau, A.
   Denlinger, C. E.
   Schipper, P. H.
   Ishwaran, H.
   Apperson-Hansen, C.
   DiPaola, L. M.
   Semple, M. E.
   Blackstone, E. H.
TI Worldwide Esophageal Cancer Collaboration: neoadjuvant pathologic
   staging data
SO DISEASES OF THE ESOPHAGUS
LA English
DT Article
DE cancer staging; chemotherapy; prognostication; radiotherapy; survival
ID TIME
AB To address uncertainty of whether pathologic stage groupings after neoadjuvant therapy (ypTNM) for esophageal cancer share prognostic implications with pathologic groupings after esophagectomy alone (pTNM), we report datasimple descriptions of patient characteristics, cancer categories, and non-risk-adjusted survivalfor pathologically staged cancers after neoadjuvant therapy from the Worldwide Esophageal Cancer Collaboration (WECC). Thirty-three institutions from six continents submitted data using variables with standard definitions: demographics, comorbidities, clinical cancer categories, and all-cause mortality from first management decision. Of 7,773 pathologically staged neoadjuvant patients, 2,045 had squamous cell carcinoma, 5,686 adenocarcinoma, 31 adenosquamous carcinoma, and 11 undifferentiated carcinoma. Patients were older (61 years) men (83%) with normal (40%) or overweight (35%) body mass index, 0-1 Eastern Cooperative Oncology Group performance status (96%), and a history of smoking (69%). Cancers were ypT0 (20%), ypT1 (13%), ypT2 (18%), ypT3 (44%), ypN0 (55%), ypM0 (94%), and G2-G3 (72%); most involved the distal esophagus (80%). Non-risk-adjusted survival for yp categories was unequally depressed, more for earlier categories than later, compared with equivalent categories from prior WECC data for esophagectomy-alone patients. Thus, survival of patients with ypT0-2N0M0 cancers was intermediate and similar regardless of ypT; survival for ypN+ cancers was poor. Because prognoses for ypTNM and pTNM categories are dissimilar, prognostication should be based on separate ypTNM categories and groupings. These data will be the basis for the 8th edition cancer staging manuals following risk adjustment for patient, cancer, and treatment characteristics and should direct 9th edition data collection.
C1 [Rice, T. W.; DiPaola, L. M.; Semple, M. E.; Blackstone, E. H.] Cleveland Clin, Cleveland, OH 44106 USA.
   [Lerut, T. E. M. R.] Univ Ziekenhuizen Leuven, Leuven, Belgium.
   [Orringer, M. B.] Univ Michigan, Ann Arbor, MI 48109 USA.
   [Chen, L. -Q.] Sichuan Univ, West China Hosp, Chengdu, Sichuan, Peoples R China.
   [Hofstetter, W. L.] Univ Texas MD Anderson Hosp, Houston, TX USA.
   [Smithers, B. M.] Univ Queensland, Princess Alexandra Hosp, Brisbane, Qld, Australia.
   [Rusch, V. W.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
   [van Lanschot, J.] Erasmus MC, Rotterdam, Netherlands.
   [Chen, K. N.] Beijing Canc Hosp, Beijing, Peoples R China.
   [Davies, A. R.] Guys & St Thomas Hosp, London, England.
   [D'Journo, X. B.] Hop Nord Marseille, Marseille, France.
   [Kesler, K. A.] Indiana Univ, Med Ctr, Indianapolis, IN USA.
   [Luketich, J. D.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
   [Ferguson, M. K.] Univ Chicago, Dept Surg, 5841 S Maryland Ave, Chicago, IL 60637 USA.
   [Rasanen, J. V.] Helsinki Univ Hosp, Helsinki, Finland.
   [van Hillegersberg, R.] Univ Med Ctr Utrecht, Utrecht, Netherlands.
   [Fang, W.] Shanghai Chest Hosp, Shanghai, Peoples R China.
   [Durand, L.] Univ Buenos Aires, Hosp Clin, Buenos Aires, DF, Argentina.
   [Allum, W. H.] Royal Marsden NHS Fdn Trust, London, England.
   [Cecconello, I.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Cerfolio, R. J.] Univ Alabama Birmingham, Birmingham, AL USA.
   [Pera, M.] Hosp Univ del Mar, Barcelona, Spain.
   [Griffin, S. M.] Newcastle Univ, Newcastle Upon Tyne, Tyne & Wear, England.
   [Burger, R.] Univ Cape Town, Groote Schuur Hosp, Cape Town, South Africa.
   [Liu, J. -F.] Hebei Med Univ, Hosp 4, Shijiazhuang, Hebei, Peoples R China.
   [Allen, M. S.] Mayo Clin, Rochester, MN USA.
   [Law, S.] Univ Hong Kong, Queen Mary Hosp, Med Ctr, Hong Kong, Hong Kong, Peoples R China.
   [Watson, T. J.] Univ Rochester, Rochester, NY USA.
   [Darling, G. E.] Toronto Gen Hosp, Toronto, ON, Canada.
   [Scott, W. J.] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA.
   [Duranceau, A.] Univ Montreal, Montreal, PQ, Canada.
   [Denlinger, C. E.] Med Univ South Carolina, Charleston, SC USA.
   [Schipper, P. H.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
   [Ishwaran, H.] Univ Miami, Miami, FL USA.
   [Apperson-Hansen, C.] Case Western Reserve Univ, Cleveland, OH 44106 USA.
RP Rice, TW (corresponding author), Cleveland Clin, Dept Thorac & Cardiovasc Surg, 9500 Euclid Ave Desk JJ 40, Cleveland, OH 44195 USA.
EM ricet@ccf.org
RI Smithers, Bernard M/F-2060-2010; Rasanen, Jari/AAV-1231-2020; Law,
   Simon/C-4324-2009; Cecconello, Ivan/A-3918-2013; D'journo, Xavier
   Benoit/AAJ-4457-2021; luketich, james/AAY-6230-2020
OI Smithers, Bernard M/0000-0002-8333-8685; Rasanen,
   Jari/0000-0002-7826-532X; Law, Simon/0000-0002-6518-5806; Cecconello,
   Ivan/0000-0002-3535-4170; D'journo, Xavier Benoit/0000-0001-6747-4583;
   Griffin, Selwyn Michael/0000-0003-1583-7009; Pera,
   Manuel/0000-0002-9449-1810; Cerfolio, Robert/0000-0002-5598-599X; Rusch,
   Valerie/0000-0003-2345-6900
FU NATIONAL CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [R01CA163739] Funding Source: NIH RePORTER; NATIONAL
   CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000460, UL1TR000439] Funding Source: NIH RePORTER; NCATS NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1 TR000439, UL1 TR000460] Funding
   Source: Medline; NCI NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [R01 CA163739] Funding Source: Medline
CR Black WC, 2002, JNCI-J NATL CANCER I, V94, P167, DOI 10.1093/jnci/94.3.167
   BLACKSTONE EH, 1986, J AM STAT ASSOC, V81, P615, DOI 10.2307/2288989
   Edge SB, 2010, AM JOINT COMMITTEE C, V253
   GOLDMAN AI, 1992, AM STAT, V46, P13, DOI 10.2307/2684402
   Lauer MS, 1999, J AM COLL CARDIOL, V34, P618, DOI 10.1016/S0735-1097(99)00250-8
   Rice TW, 2009, DIS ESOPHAGUS, V22, P1, DOI 10.1111/j.1442-2050.2008.00901.x
   Rice T W, 2016, ESOPHAGUS IN PRESS
   Rice TW, 2010, CANCER-AM CANCER SOC, V116, P3763, DOI 10.1002/cncr.25146
   Sobin L, 2009, TNM CLASSIFICATION M
   van Leeuwen PJ, 2010, J MED SCREEN, V17, P204, DOI 10.1258/jms.2010.010074
NR 10
TC 36
Z9 38
U1 0
U2 9
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
EI 1442-2050
J9 DIS ESOPHAGUS
JI Dis. Esophagus
PD OCT
PY 2016
VL 29
IS 7
BP 715
EP 723
DI 10.1111/dote.12513
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DZ3AX
UT WOS:000385716800001
PM 27731548
OA Green Accepted, Green Published
DA 2021-10-30
ER

PT J
AU Kenya, S
   Jones, J
   Arheart, K
   Kobetz, E
   Chida, N
   Baer, S
   Powell, A
   Symes, S
   Hunte, T
   Monroe, A
   Carrasquillo, O
AF Kenya, Sonjia
   Jones, Jamal
   Arheart, Kristopher
   Kobetz, Erin
   Chida, Natasha
   Baer, Shelly
   Powell, Alexis
   Symes, Stephen
   Hunte, Tai
   Monroe, Anne
   Carrasquillo, Olveen
TI Using Community Health Workers to Improve Clinical Outcomes Among People
   Living with HIV: A Randomized Controlled Trial
SO AIDS AND BEHAVIOR
LA English
DT Article
DE Community health workers; HIV viral load; African-Americans; HIV
   disparities
ID DIRECTLY OBSERVED THERAPY; ACTIVE ANTIRETROVIRAL THERAPY; ADHERENCE;
   HAART; CARE; INTERVENTION; MORTALITY; SERVICES; IMPACT; WOMEN
AB AIDS-related mortality remains a leading cause of preventable death among African-Americans. We sought to determine if community health workers could improve clinical outcomes among vulnerable African-Americans living with HIV in Miami, Florida. We recruited 91 medically indigent persons with HIV viral loads a parts per thousand yen1,000 and/or a CD4 cell count a parts per thousand currency sign350. Patients were randomized to a community health worker (CHW) intervention or control group. Viral load and CD4 cell count data were abstracted from electronic medical records. At 12 months, the mean VL in the intervention group was log 0.9 copies/mu L lower than the control group. The CD4 counts were not significantly different among the groups. Compared to the control group, patients randomized to CHWs experienced statistically significant improvements in HIV viral load. Larger multi-site studies of longer duration are needed to determine whether CHWs should be incorporated into standard treatment models for vulnerable populations living with HIV.
C1 [Kenya, Sonjia; Carrasquillo, Olveen] Univ Miami, Miller Sch Med, Div Gen Med, Jay Weiss Ctr Social Med & Hlth Equ, Miami, FL 33136 USA.
   [Jones, Jamal; Chida, Natasha; Hunte, Tai; Monroe, Anne] Univ Miami, Miller Sch Med, Jay Weiss Ctr Social Med & Hlth Equ, Miami, FL 33136 USA.
   [Arheart, Kristopher] Univ Miami, Miller Sch Med, Dept Epidemiol & Publ Hlth, Miami, FL 33136 USA.
   [Kobetz, Erin] Univ Miami, Miller Sch Med, Dept Epidemiol & Publ Hlth, Jay Weiss Ctr Social Med & Hlth Equ, Miami, FL 33136 USA.
   [Baer, Shelly] Univ Miami, Miller Sch Med, Dept Pediat, Mailman Ctr Child Dev, Miami, FL 33136 USA.
   [Powell, Alexis] Univ Miami, Miller Sch Med, Div Infect Dis, Miami, FL 33136 USA.
   [Symes, Stephen] Univ Miami, Miller Sch Med, Div Infect Dis, Jay Weiss Ctr Social Med & Hlth Equ, Miami, FL 33136 USA.
RP Kenya, S (corresponding author), Univ Miami, Miller Sch Med, Div Gen Med, Jay Weiss Ctr Social Med & Hlth Equ, 1400 NW 10th Ave,Suite 801, Miami, FL 33136 USA.
EM skenya@med.miami.edu; jjones3@med.miami.edu
FU NATIONAL CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [U54CA153705] Funding Source: NIH RePORTER; NATIONAL
   CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000460] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [P30AI073961] Funding
   Source: NIH RePORTER; NCATS NIH HHSUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1 TR000460]
   Funding Source: Medline; NCI NIH HHSUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Cancer Institute (NCI) [U54 CA153705] Funding Source: Medline; NIAID NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [P30 AI073961] Funding Source: Medline
CR Babamoto KS, 2009, HEALTH EDUC BEHAV, V36, P113, DOI 10.1177/1090198108325911
   Behforouz HL, 2004, CLIN INFECT DIS, V38, pS429, DOI 10.1086/421408
   Behforouz HL, 2004, JAIDS-J ACQ IMM DEF, V36, P642, DOI 10.1097/00126334-200405010-00016
   Brownstein JN, 2007, AM J PREV MED, V32, P435, DOI 10.1016/j.amepre.2007.01.011
   CDC, 2008, HIV AIDS AFR AM FACT
   CDC, 2011, HIV LAT FACT SHEET
   CDC (Centers for Disease Control and Prevention), 2008, CAS HIV INF AIDS US
   Centers for Disease Control, 2009, DIAGN HIV INF AIDS U
   Centers for Disease Control and Prevention, 2008, HIV AIDS US
   Crum NF, 2006, JAIDS-J ACQ IMM DEF, V41, P194, DOI 10.1097/01.qai.0000179459.31562.16
   Deeks SG, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.a3172
   Farmer P, 2001, LANCET, V358, P404, DOI 10.1016/S0140-6736(01)05550-7
   Farmer P, 2001, B WORLD HEALTH ORGAN, V79, P1145
   Fawzi MCS, 2006, AIDS CARE, V18, P764, DOI 10.1080/09540120500373844
   Florida Department of Health, 2007, AIDS HIV BLACKS MIAM
   Health Council of South Florida, 2011, 2011 DISTR 11 HLTH P
   Ickovics JR, 2001, JAMA-J AM MED ASSOC, V285, P1466, DOI 10.1001/jama.285.11.1466
   Kenya S, 2011, HIV MED, V12, P525, DOI 10.1111/j.1468-1293.2011.00921.x
   Khanlou H, 2003, JAIDS-J ACQ IMM DEF, V33, P651, DOI 10.1097/00126334-200308150-00017
   Macalino GE, 2007, AIDS, V21, P1473, DOI 10.1097/QAD.0b013e32811ebf68
   Massachusetts General Hospital Disparities Solutions Center using multi-disciplinary teams to address disparities, 2006, US MULT TEAMS ADDR D
   Parker EA, 2008, HEALTH EDUC BEHAV, V35, P376, DOI 10.1177/1090198106290622
   Rahman SM, 2010, HUM RESOUR HEALTH, V8, DOI 10.1186/1478-4491-8-12
   Sledjeski EM, 2005, AIDS PATIENT CARE ST, V19, P728, DOI 10.1089/apc.2005.19.728
   Smith-Rohrberg D, 2006, JAIDS-J ACQ IMM DEF, V43, pS48, DOI 10.1097/01.qai.0000248338.74943.85
   STENZEL MS, 2001, AIDS READ, V11, P324
   *UNAIDS, 2008, AIDS EP UPD REG SUMM
   Visnegarwala F, 2006, AIDS CARE, V18, P332, DOI 10.1080/09540120500162155
   WHO, 2003, ADHERENCE LONG TERM
NR 29
TC 17
Z9 17
U1 0
U2 12
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-7165
EI 1573-3254
J9 AIDS BEHAV
JI AIDS Behav.
PD NOV
PY 2013
VL 17
IS 9
BP 2927
EP 2934
DI 10.1007/s10461-013-0440-1
PG 8
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA 240QW
UT WOS:000326113100008
PM 23515640
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Occa, A
   Morgan, SE
   Peng, W
   Mao, BJ
   McFarlane, SJ
   Grinfeder, K
   Byrne, M
AF Occa, Aurora
   Morgan, Susan E.
   Peng, Wei
   Mao, Bingjing
   McFarlane, Soroya Julian
   Grinfeder, Kim
   Byrne, Margaret
TI Untangling interactivity's effects: The role of cognitive absorption,
   perceived visual informativeness, and cancer information overload
SO PATIENT EDUCATION AND COUNSELING
LA English
DT Article
DE Information aid; Clinical trial communication; Interactivity perceived
   visual; informativeness; Cognitive absorption; Cancer information
   overload
ID CLINICAL-TRIALS; DECISION-MAKING; PARTICIPATION; COMMUNICATION;
   COMPREHENSION; KNOWLEDGE; AIDS
AB Objective: Learning about clinical trials is as stressful and challenging for cancer patients as it is for the clinical staff who provide education to patients. Information aids (IAs) can support both discussions and patients' decision-making, especially when IAs offer interactive features that provide information based on individuals' needs and experiences. However, it is not clear which factors contribute to interactive IAs' effectiveness.
   Methods: An experiment with cancer patients and survivors (n = 313) compared the effects of two IAs about clinical trial participation: one with modality (i.e. website/technological) interactivity only and one with both modality and message interactivity (i.e. provides information contingent on individual users' information needs).
   Results: The IA with both modality and message interactivity features elicited the higher perceived visual informativeness (PVI) and cognitive absorption (CA) scores. The model supports the moderating role of PVI and cancer information overload (CIO), and the mediating role of CA.
   Conclusion: The IA with both modality and message interactivity better supported individuals' decision-making and improved attitudes and knowledge scores. CIO was experienced more by participants using the modality interactivity-only IA. Practice implications: Message interactivity may simplify individuals' cognitive processes. IAs about clinical trial participation should include both message and modality interactivity. (C) 2020 Elsevier B.V. All rights reserved.
C1 [Occa, Aurora] Univ Kentucky, Dept Commun, Lexington, KY 40506 USA.
   [Morgan, Susan E.; Mao, Bingjing] Univ Miami, Dept Commun Studies, Coral Gables, FL 33146 USA.
   [Peng, Wei] Washington State Univ, Edward R Murrow Coll Commun, Pullman, WA 99164 USA.
   [McFarlane, Soroya Julian] Univ Georgia, Dept Commun Studies, Athens, GA 30602 USA.
   [Grinfeder, Kim] Univ Miami, Dept Interact Media, Coral Gables, FL 33146 USA.
   [Byrne, Margaret] Moffit Canc Ctr, Dept Hlth Outcomes & Behav, Tampa, FL 33612 USA.
RP Occa, A (corresponding author), 343 S Martin Luther,King Blvd,Room 272, Lexington, KY 40526 USA.
EM aurora.occa@uky.edu
OI Julian McFarlane, Soroya/0000-0002-2826-0926; Byrne, Margaret
   M/0000-0002-8143-4702; Mao, Bingjing/0000-0003-3956-9045
FU Miami Clinical and Translational Science Institute, from the National
   Center for Advancing Translational Sciences [UL1TR000460]; National
   Institute on Minority Health and Health DisparitiesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Minority Health & Health Disparities
   (NIMHD)
FX This research was supported by Grant Number UL1TR000460, Miami Clinical
   and Translational Science Institute, from the National Center for
   Advancing Translational Sciences and the National Institute on Minority
   Health and Health Disparities. Its contents are solely the
   responsibility of the authors and do not necessarily represent the
   official views of the NIH.
CR Agarwal R, 2000, MIS QUART, V24, P665, DOI 10.2307/3250951
   Albrecht TL, 2008, J CLIN ONCOL, V26, P2666, DOI 10.1200/JCO.2007.14.8114
   Byrne MM, 2014, MED DECIS MAKING, V34, P116, DOI 10.1177/0272989X13497264
   Cameron P, 2013, CURR ONCOL, V20, pE193, DOI 10.3747/co.20.1323
   Carpenter JS, 2011, MATURITAS, V69, P11, DOI 10.1016/j.maturitas.2011.02.005
   Elwyn G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004705
   Flood-Grady E., 2019, J CANCER EDUC, P1
   Friedman DB, 2014, CONTEMP CLIN TRIALS, V38, P275, DOI 10.1016/j.cct.2014.05.004
   Gillies K, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009736.pub2
   Gillies K, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005734
   Hayes A.F, 2013, J EDUC MEAS
   Houts PS, 2006, PATIENT EDUC COUNS, V61, P173, DOI 10.1016/j.pec.2005.05.004
   Jenkins V, 2000, BRIT J CANCER, V82, P1783, DOI 10.1054/bjoc.2000.1142
   Jensen JD, 2014, PATIENT EDUC COUNS, V94, P90, DOI 10.1016/j.pec.2013.09.016
   Jones Q, 2004, INFORM SYST RES, V15, P194, DOI 10.1287/isre.1040.0023
   King AJ, 2015, HEALTH EDUC J, V74, P732, DOI 10.1177/0017896914558645
   King AJ, 2014, J HEALTH COMMUN, V19, P1099, DOI 10.1080/10810730.2013.878004
   Kraft SA, 2017, CLIN TRIALS, V14, P94, DOI 10.1177/1740774516669352
   Krieger JL, 2015, J CANCER EDUC, V30, P743, DOI 10.1007/s13187-015-0789-0
   Lazard A, 2014, INT J MED INFORM, V83, P726, DOI 10.1016/j.ijmedinf.2014.06.010
   Lazard AJ, 2016, J HEALTH COMMUN, V21, P1260, DOI 10.1080/10810730.2016.1245374
   Lehmann V, 2020, PATIENT EDUC COUNS, V103, P514, DOI 10.1016/j.pec.2019.09.024
   Luebbert R, 2016, J TRANSCULT NURS, V27, P456, DOI 10.1177/1043659615575578
   Mao BJ, 2021, HEALTH COMMUN, V36, P1388, DOI 10.1080/10410236.2020.1754588
   Miller SM, 2013, PSYCHO-ONCOLOGY, V22, P481, DOI 10.1002/pon.3043
   Neil JM, 2019, J CANCER EDUC, V34, P725, DOI 10.1007/s13187-018-1364-2
   O'Connor AM, 1998, PATIENT EDUC COUNS, V33, P267, DOI 10.1016/S0738-3991(98)00026-3
   Occa A, 2019, J HEALTH COMMUN, V24, P749, DOI 10.1080/10810730.2019.1668089
   Oh J, 2019, J MASS COMMUN Q, V96, P1099, DOI 10.1177/1077699019835911
   Oh J, 2015, J COMMUN, V65, P213, DOI 10.1111/jcom.12147
   Peng W, 2019, J HEALTH COMMUN, V24, P865, DOI 10.1080/10810730.2019.1680773
   Politi MC, 2016, ONCOLOGIST, V21, P1461, DOI 10.1634/theoncologist.2016-0068
   Shneerson C, 2013, PATIENT EDUC COUNS, V90, P111, DOI 10.1016/j.pec.2012.06.031
   Shrivastav H., 2013, INFORM OVERLOAD TECH
   Stacey D, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001431.pub5
   Sundar S S., 2008, DIGITAL MEDIA YOUTH, P73, DOI [10.1162/dmal.9780262562324.073, DOI 10.1162/DMAL.9780262562324.073]
   Sundar SS, 2015, HBK COMMUN MEDIA, P47
   Sundar SS, 2003, COMMUN RES, V30, P30, DOI 10.1177/0093650202239025
   Windle RJ, 2011, BRIT J EDUC TECHNOL, V42, P811, DOI 10.1111/j.1467-8535.2010.01108.x
NR 39
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0738-3991
EI 1873-5134
J9 PATIENT EDUC COUNS
JI Patient Educ. Couns.
PD MAY
PY 2021
VL 104
IS 5
BP 1059
EP 1065
DI 10.1016/j.pec.2020.10.007
PG 7
WC Public, Environmental & Occupational Health; Social Sciences,
   Interdisciplinary
SC Public, Environmental & Occupational Health; Social Sciences - Other
   Topics
GA RY1QH
UT WOS:000647691300016
PM 33969824
DA 2021-10-30
ER

PT J
AU Starke, RM
   McCarthy, DJ
   Chen, CJ
   Kano, H
   McShane, BJ
   Lee, J
   Patibandla, MR
   Mathieu, D
   Vasas, LT
   Kaufmann, AM
   Wang, WG
   Grills, IS
   Cifarelli, CP
   Paisan, G
   Vargo, J
   Chytka, T
   Janouskova, L
   Feliciano, CE
   Sujijantarat, N
   Matouk, C
   Chiang, V
   Hess, J
   Rodriguez-Mercado, R
   Tonetti, DA
   Lunsford, LD
   Sheehan, JP
AF Starke, Robert M.
   McCarthy, David J.
   Chen, Ching-Jen
   Kano, Hideyuki
   McShane, Brendan J.
   Lee, John
   Patibandla, Mohana Rao
   Mathieu, David
   Vasas, Lucas T.
   Kaufmann, Anthony M.
   Wang, Wei Gang
   Grills, Inga S.
   Cifarelli, Christopher P.
   Paisan, Gabriella
   Vargo, John
   Chytka, Tomas
   Janouskova, Ladislava
   Feliciano, Caleb E.
   Sujijantarat, Nanthiya
   Matouk, Charles
   Chiang, Veronica
   Hess, Judith
   Rodriguez-Mercado, Rafael
   Tonetti, Daniel A.
   Lunsford, L. Dade
   Sheehan, Jason P.
TI Hemorrhage risk of cerebral dural arteriovenous fistulas following Gamma
   Knife radiosurgery in a multicenter international consortium
SO JOURNAL OF NEUROSURGERY
LA English
DT Article
DE Gamma Knife; arteriovenous; fistula; dural; hemorrhage; embolization;
   surgery; radiation; grading; scale; complication; outcome; vascular
   disorders; stereotactic radiosurgery
ID STEREOTACTIC RADIOSURGERY; NATURAL-HISTORY; TRANSARTERIAL EMBOLIZATION;
   PARTICULATE EMBOLIZATION; CLINICAL PRESENTATION; MALFORMATIONS; SURGERY;
   CLASSIFICATION; SHUNTS; MODEL
AB OBJECTIVE The authors performed a study to evaluate the hemorrhagic rates of cerebral dural arteriovenous fistulas (dAVFs) and the risk factors of hemorrhage following Gamma Knife radiosurgery (GKRS).
   METHODS Data from a cohort of patients undergoing GKRS for cerebral dAVFs were compiled from the International Radiosurgery Research Foundation. The annual posttreatment hemorrhage rate was calculated as the number of hemorrhages divided by the patient-years at risk. Risk factors for dAVF hemorrhage prior to GKRS and during the latency period after radiosurgery were evaluated in a multivariate analysis.
   RESULTS A total of 147 patients with dAVFs were treated with GKRS. Thirty-six patients (24.5%) presented with hemorrhage. dAVFs that had any cortical venous drainage (CVD) (OR = 3.8, p = 0.003) or convexity or torcula location (OR = 3.3, p = 0.017) were more likely to present with hemorrhage in multivariate analysis. Half of the patients had prior treatment (49.7%). Post-GRKS hemorrhage occurred in 4 patients, with an overall annual risk of 0.84% during the latency period. The annual risks of post-GKRS hemorrhage for Borden type 2-3 dAVFs and Borden type 2-3 hemorrhagic dAVFs were 1.45% and 0.93%, respectively. No hemorrhage occurred after radiological confirmation of obliteration. Independent predictors of hemorrhage following GKRS included nonhemorrhagic neural deficit presentation (HR = 21.6, p = 0.027) and increasing number of past endovascular treatments (HR = 1.81, p = 0.036).
   CONCLUSIONS Patients have similar rates of hemorrhage before and after radiosurgery until obliteration is achieved. dAVFs that have any CVD or are located in the convexity or torcula were more likely to present with hemorrhage. Patients presenting with nonhemorrhagic neural deficits and a history of endovascular treatments had higher risks of post-GKRS hemorrhage.
C1 [Starke, Robert M.; McCarthy, David J.] Univ Miami, Dept Neurol Surg, Miami, FL USA.
   [Chen, Ching-Jen; Patibandla, Mohana Rao; Paisan, Gabriella; Sheehan, Jason P.] Univ Virginia, Dept Neurol Surg, Charlottesville, VA USA.
   [Kano, Hideyuki; Tonetti, Daniel A.; Lunsford, L. Dade] Univ Pittsburgh, Dept Neurol Surg, Philadelphia, PA USA.
   [McShane, Brendan J.; Lee, John] Univ Penn, Dept Neurol Surg, Philadelphia, PA 19104 USA.
   [Mathieu, David] Univ Sherbrooke, Dept Neurol Surg, Sherbrooke, PQ, Canada.
   [Vasas, Lucas T.; Kaufmann, Anthony M.] Univ Manitoba, Dept Neurol Surg, Winnipeg, MB, Canada.
   [Wang, Wei Gang; Grills, Inga S.] Beaumont Hlth Syst, Dept Radiat Oncol, Royal Oak, MI USA.
   [Cifarelli, Christopher P.] West Virginia Univ, Dept Neurol Surg, Morgantown, WV 26506 USA.
   [Vargo, John] West Virginia Univ, Dept Radiat Oncol, Morgantown, WV 26506 USA.
   [Chytka, Tomas; Janouskova, Ladislava] Na Homolce Hosp, Dept Neurol Surg, Prague, Czech Republic.
   [Feliciano, Caleb E.; Rodriguez-Mercado, Rafael] Univ Puerto Rico, Dept Neurol Surg, San Juan, PR 00936 USA.
   [Sujijantarat, Nanthiya; Matouk, Charles; Chiang, Veronica; Hess, Judith] Yale Univ, Dept Neurol Surg, Sch Med, New Haven, CT USA.
RP McCarthy, DJ (corresponding author), Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
EM djm77@med.miami.edu
RI Chen, Ching-Jen/F-5976-2013
OI Chen, Ching-Jen/0000-0002-7830-9273
FU NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1 TR002736] Funding Source: Medline;
   NIGMS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [U54 GM104942] Funding Source: Medline;
   NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of General Medical Sciences (NIGMS) [U54GM104942]
   Funding Source: NIH RePORTER
CR Altman D. G., 1990, PRACTICAL STAT MED R
   AWAD IA, 1990, J NEUROSURG, V72, P839, DOI 10.3171/jns.1990.72.6.0839
   BARCIASALORIO JL, 1994, STEREOT FUNCT NEUROS, V63, P266, DOI 10.1159/000100330
   BORDEN JA, 1995, J NEUROSURG, V82, P166, DOI 10.3171/jns.1995.82.2.0166
   BROWN RD, 1994, J NEUROSURG, V81, P531, DOI 10.3171/jns.1994.81.4.0531
   Bulters DO, 2012, NEUROSURGERY, V70, P312, DOI 10.1227/NEU.0b013e318230966f
   Chen CJ, 2018, WORLD NEUROSURG, V116, pE640, DOI 10.1016/j.wneu.2018.05.062
   Cifarelli CP, 2010, NEUROSURGERY, V67, P1230, DOI 10.1227/NEU.0b013e3181eff6f7
   COGNARD C, 1995, RADIOLOGY, V194, P671, DOI 10.1148/radiology.194.3.7862961
   Cohen-Inbar O, 2017, J NEUROSURG, V127, P512, DOI 10.3171/2016.7.JNS161208
   Cohen-Inbar O, 2017, J NEUROSURG, V127, P503, DOI 10.3171/2016.7.JNS161194
   Daniels DJ, 2013, NEUROSURG FOCUS, V34, DOI 10.3171/2013.4.FOCUS1335
   Della Pepa GM, 2017, NEUROSURGERY, V81, P315, DOI 10.1093/neuros/nyw175
   Dmytriw AA, 2017, INTERV NEURORADIOL, V23, P211, DOI 10.1177/1591019916683689
   Elhammady MS, 2017, HAND CLINIC, V143, P99, DOI 10.1016/B978-0-444-63640-9.00009-6
   Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170
   Friedman JA, 2001, J NEUROSURG, V94, P886, DOI 10.3171/jns.2001.94.6.0886
   GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951
   Gross BA, 2018, J NEUROSURG, V129, P1114, DOI 10.3171/2017.6.JNS171090
   Gross BA, 2013, J NEUROSURG, V118, P437, DOI 10.3171/2012.10.JNS121280
   Gross BA, 2012, NEUROSURGERY, V71, P594, DOI 10.1227/NEU.0b013e31825eabdb
   Gross BA, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2012.1.FOCUS11354
   Hai J, 2002, J NEUROSURG, V97, P1198, DOI 10.3171/jns.2002.97.5.1198
   Hanakita S, 2012, J NEUROSURG, V117, P158, DOI 10.3171/2012.7.GKS12967
   Jung HH, 2010, J NEUROSURG, V113, P21, DOI 10.3171/2010.8.GKS10977
   Koebbe CJ, 2005, SURG NEUROL, V64, P392, DOI 10.1016/j.surneu.2004.12.026
   LEWIS AI, 1994, J NEUROSURG, V81, P851, DOI 10.3171/jns.1994.81.6.0851
   Li CH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131235
   Link MJ, 1996, J NEUROSURG, V84, P804, DOI 10.3171/jns.1996.84.5.0804
   O'Leary S, 2002, CLIN ONCOL-UK, V14, P97, DOI 10.1053/clon.2002.0072
   Pan DHC, 2013, PROG NEUROL SURG, V27, P176, DOI 10.1159/000341793
   Park KS, 2016, ACTA NEUROCHIR, V158, P821, DOI 10.1007/s00701-016-2720-9
   Peng TM, 2014, J CLIN NEUROSCI, V21, P769, DOI 10.1016/j.jocn.2013.07.024
   Piippo A, 2013, J NEUROSURG, V119, P164, DOI 10.3171/2013.3.JNS121547
   Pollock BE, 1999, NEUROSURGERY, V45, P459, DOI 10.1097/00006123-199909000-00008
   Schneider BF, 1997, J NEUROSURG, V87, P352, DOI 10.3171/jns.1997.87.3.0352
   Shah MN, 2012, J NEUROSURG, V117, P539, DOI 10.3171/2012.5.JNS111257
   Sheehan JP, 2015, J NEUROSURG, V122, P1479, DOI 10.3171/2014.10.JNS14139
   Soderman M, 2006, J NEUROSURG, V104, P867, DOI 10.3171/jns.2006.104.6.867
   Soderman M, 2008, STROKE, V39, P1735, DOI 10.1161/STROKEAHA.107.506485
   Starke RM, 2017, J NEUROSURG, V126, P36, DOI 10.3171/2015.9.JNS151311
   Strom RG, 2009, NEUROSURGERY, V64, P241, DOI 10.1227/01.NEU.0000338066.30665.B2
   Tonetti DA, 2019, J NEUROSURG, V130, P972, DOI 10.3171/2017.10.JNS171802
   Tonetti DA, 2017, WORLD NEUROSURG, V107, P371, DOI 10.1016/j.wneu.2017.07.170
   van Dijk JMC, 2009, STROKE, V40, pE412, DOI 10.1161/STROKEAHA.108.545327
   van Dijk JMC, 2002, STROKE, V33, P1233, DOI 10.1161/01.STR.0000014772.02908.44
   Willinsky R, 1999, AM J NEURORADIOL, V20, P1031
   Zipfel GJ, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.2.FOCUS0928
NR 48
TC 1
Z9 1
U1 0
U2 1
PU AMER ASSOC NEUROLOGICAL SURGEONS
PI ROLLING MEADOWS
PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA
SN 0022-3085
EI 1933-0693
J9 J NEUROSURG
JI J. Neurosurg.
PD APR
PY 2020
VL 132
IS 4
BP 1209
EP 1217
DI 10.3171/2018.12.JNS182208
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KZ3SM
UT WOS:000523185100280
PM 30875690
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Horigian, VE
   Anderson, AR
   Szapocznik, J
AF Horigian, Viviana E.
   Anderson, Austen R.
   Szapocznik, Jose
TI Taking Brief Strategic Family Therapy from Bench to Trench: Evidence
   Generation Across Translational Phases
SO FAMILY PROCESS
LA English
DT Article
DE Brief Strategic Family Therapy; Adolescent Substance Use; Translational
   Research
ID ADOLESCENT SUBSTANCE USE; DRUG-ABUSERS; ONE-PERSON; FOLLOW-UP;
   ACCULTURATION; PARENT; INTERVENTION; CONJOINT; EFFICACY; BEHAVIOR
AB In this article, we review the research evidence generated over 40years on Brief Strategic Family Therapy illustrating the NIH stages of intervention development and highlighting the translational process. Basic research (Stage 0) led to the discovery of the characteristics of the population and the nature of the problems that needed to be addressed. This step informed the selection of an intervention model that addressed the problems presented by the population, but in a fashion that was congruent with the population's culture, defined in terms of its value orientations. From this basic research, an intervention that integrated structural and strategic elements was selected and refined through testing (Stage I). The second stage of translation (Stage II) included efficacy trials of a specialized engagement module that responded to challenges to the provision of services. It also included several other efficacy trials that documented the effects of the intervention, mostly in research settings or with research therapists. Stages III/IV in the translational process led to the testing of the effectiveness of the intervention in real-world settings with community therapists and some oversight from the developer. This work revealed that an implementation/organizational intervention was required to achieve fidelity and sustainability of the intervention in real-world settings. The work is currently in Stage V in which new model development led to an implementation intervention that can ensure fidelity and sustainability. Future research will evaluate the effectiveness of the current implementation model in increasing adoption, fidelity, and long-term sustainability in real-world settings.
C1 [Horigian, Viviana E.; Anderson, Austen R.; Szapocznik, Jose] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, 1120 NW 14th St,CRB Room 1040, Miami, FL 33136 USA.
RP Horigian, VE (corresponding author), Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, 1120 NW 14th St,CRB Room 1040, Miami, FL 33136 USA.
EM vhorigian@med.miami.edu
FU National Institute on Drug AbuseUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute on Drug Abuse (NIDA)European Commission [UG1DA013720];
   Clinical and Translational Science Institute [UL1TR000460]; NATIONAL
   CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000460] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG
   ABUSEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Drug Abuse
   (NIDA)European Commission [UG1DA013720] Funding Source: NIH RePORTER
FX This work was supported by grant UG1DA013720 awarded by the National
   Institute on Drug Abuse, and UL1TR000460 awarded by the Clinical and
   Translational Science Institute.
CR Coatsworth JD, 2001, FAM PROCESS, V40, P313, DOI 10.1111/j.1545-5300.2001.4030100313.x
   Fernandez MA, 2009, J ABNORM CHILD PSYCH, V37, P431, DOI 10.1007/s10802-008-9281-1
   Foote F H, 1985, NIDA Res Monogr, V58, P51
   Haley J., 1976, PROBLEM SOLVING THER
   Hogue A, 2014, J CLIN CHILD ADOLESC, V43, P695, DOI 10.1080/15374416.2014.915550
   Horigian V. E., CHILD ADOLE IN PRESS
   Horigian VE, 2015, AM J ADDICTION, V24, P637, DOI 10.1111/ajad.12278
   Horigian VE, 2015, ADDICT BEHAV, V42, P44, DOI 10.1016/j.addbeh.2014.10.024
   Madanes C., 1981, STRATEGIC FAMILY THE
   Minuchin S., 1974, FAMILIES FAMILY THER
   Minuchin S., 1981, FAMILY THERAPY TECHN
   Nickel M, 2006, PSYCHOTHER PSYCHOSOM, V75, P47, DOI 10.1159/000089226
   Nickel MK, 2006, CAN J PSYCHIAT, V51, P355, DOI 10.1177/070674370605100604
   Onken LS, 2014, CLIN PSYCHOL SCI, V2, P22, DOI 10.1177/2167702613497932
   Robbins MS, 2011, J CONSULT CLIN PSYCH, V79, P713, DOI 10.1037/a0025477
   Robbins MS, 2011, J CONSULT CLIN PSYCH, V79, P43, DOI 10.1037/a0022146
   Robbins MS, 2006, J FAM PSYCHOL, V20, P108, DOI 10.1037/0893-3200.20.1.108
   Robbins MS, 2000, J FAM PSYCHOL, V14, P688, DOI 10.1037//0893-3200.14.4.688
   Rubio DM, 2010, ACAD MED, V85, P470, DOI 10.1097/ACM.0b013e3181ccd618
   SABOGAL F, 1987, HISPANIC J BEHAV SCI, V9, P397, DOI 10.1177/07399863870094003
   Santisteban DA, 1996, J FAM PSYCHOL, V10, P35, DOI 10.1037/0893-3200.10.1.35
   Santisteban DA, 2003, J FAM PSYCHOL, V17, P121, DOI 10.1037/0893-3200.17.1.121
   Schwartz SJ, 2006, J CROSS CULT PSYCHOL, V37, P345, DOI 10.1177/0022022106286928
   SZAPOCZNIK J, 1988, J CONSULT CLIN PSYCH, V56, P552, DOI 10.1037/0022-006X.56.4.552
   SZAPOCZNIK J, 1978, J CONSULT CLIN PSYCH, V46, P961, DOI 10.1037/0022-006X.46.5.961
   SZAPOCZNIK J, 1989, HISPANIC J BEHAV SCI, V11, P4, DOI 10.1177/07399863890111002
   SZAPOCZNIK J, 1989, J CONSULT CLIN PSYCH, V57, P571, DOI 10.1037/0022-006X.57.5.571
   SZAPOCZNIK J, 1978, REV INTERAM PSICOL, V12, P113
   Szapocznik J, 1978, J Community Psychol, V6, P112, DOI 10.1002/1520-6629(197804)6:2<112::AID-JCOP2290060203>3.0.CO;2-R
   SZAPOCZNIK J, 1986, J CONSULT CLIN PSYCH, V54, P395, DOI 10.1037/0022-006X.54.3.395
   SZAPOCZNIK J, 1983, J CONSULT CLIN PSYCH, V51, P889, DOI 10.1037/0022-006X.51.6.889
   Szapocznik J., 1999, DRUG ABUSE ORIGINS I, P331, DOI [10.1037/10341-014, DOI 10.1037/10341-014]
   Szapocznik J., 2003, BRIEF STRATEGIC FAMI
   SZAPOCZNIK J, 1989, BREAKTHROUGHS FAMILY
   Szapocznik J, 2015, PSYCHOTHER RES, V25, P121, DOI 10.1080/10503307.2013.856044
   Tanner-Smith EE, 2013, J SUBST ABUSE TREAT, V44, P145, DOI 10.1016/j.jsat.2012.05.006
   Woolf SH, 2008, JAMA-J AM MED ASSOC, V299, P211, DOI 10.1001/jama.2007.26
NR 37
TC 13
Z9 13
U1 1
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-7370
EI 1545-5300
J9 FAM PROCESS
JI Fam. Process
PD SEP
PY 2016
VL 55
IS 3
SI SI
BP 529
EP 542
DI 10.1111/famp.12233
PG 14
WC Psychology, Clinical; Family Studies
SC Psychology; Family Studies
GA DW5FP
UT WOS:000383669000010
PM 27412949
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Cabral, DF
   Rice, J
   Morris, TP
   Rundek, T
   Pascual-Leone, A
   Gomes-Osman, J
AF Cabral, Danylo F.
   Rice, Jordyn
   Morris, Timothy P.
   Rundek, Tatjana
   Pascual-Leone, Alvaro
   Gomes-Osman, Joyce
TI Exercise for Brain Health: An Investigation into the Underlying
   Mechanisms Guided by Dose
SO NEUROTHERAPEUTICS
LA English
DT Review
DE Physical exercise; cognitive brain health; exercise dose; aging brain;
   older adults; physiological mechanisms
ID NEUROTROPHIC FACTOR BDNF; CEREBRAL-BLOOD-FLOW; GROWTH-FACTOR-I; SYNAPTIC
   PLASTICITY; PHYSICAL-ACTIVITY; AEROBIC EXERCISE; OLDER-ADULTS;
   HIPPOCAMPAL NEUROGENESIS; RESISTANCE EXERCISE; IMPROVES COGNITION
AB There is a strong link between the practice of regular physical exercise and maintenance of cognitive brain health. Animal and human studies have shown that exercise exerts positive effects on cognition through a variety of mechanisms, such as changes in brain volume and connectivity, cerebral perfusion, synaptic plasticity, neurogenesis, and regulation of trophic factors. However, much of this data has been conducted in young humans and animals, raising questions regarding the generalizability of these findings to aging adults. Furthermore, it is not clear at which doses these effects might take place, and if effects would differ with varying exercise modes (such as aerobic, resistance training, combinations, or other). The purpose of this review is to summarize the evidence on the effects of exercise interventions on various mechanisms believed to support cognitive improvements: cerebral perfusion, synaptic neuroplasticity, brain volume and connectivity, neurogenesis, and regulation of trophic factors. We synthesized the findings according to exposure to exercise (short- [1 day-16 weeks], medium- [24-40 weeks], and long-term exercise [52 weeks and beyond]) and have limited our discussion of dose effects to studies in aging adults and aged animals (when human data was not available).
C1 [Cabral, Danylo F.; Rice, Jordyn; Gomes-Osman, Joyce] Univ Miami, Miller Sch Med, Dept Phys Therapy, 5915 Ponce de Leon Blvd,5th Floor, Coral Gables, FL 33146 USA.
   [Cabral, Danylo F.; Rice, Jordyn; Rundek, Tatjana; Gomes-Osman, Joyce] Univ Miami, Miller Sch Med, Evelyn McKnight Brain Inst, 1150 Northwest 14th St,Suite 309, Miami, FL 33136 USA.
   [Morris, Timothy P.; Pascual-Leone, Alvaro; Gomes-Osman, Joyce] Harvard Med Sch, Berenson Allen Ctr Noninvas Brain Stimulat, 330 Brookline Ave, Boston, MA 02215 USA.
   [Morris, Timothy P.; Pascual-Leone, Alvaro; Gomes-Osman, Joyce] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Neurol, Div Cognit Neurol, 330 Brookline Ave, Boston, MA 02215 USA.
   [Rundek, Tatjana; Gomes-Osman, Joyce] Univ Miami, Miller Sch Med, Dept Neurol, 1150 Northwest 14th St,Suite 309, Miami, FL 33136 USA.
RP Gomes-Osman, J (corresponding author), Univ Miami, Miller Sch Med, Dept Phys Therapy, 5915 Ponce de Leon Blvd,5th Floor, Coral Gables, FL 33146 USA.; Gomes-Osman, J (corresponding author), Univ Miami, Miller Sch Med, Evelyn McKnight Brain Inst, 1150 Northwest 14th St,Suite 309, Miami, FL 33136 USA.; Gomes-Osman, J (corresponding author), Harvard Med Sch, Berenson Allen Ctr Noninvas Brain Stimulat, 330 Brookline Ave, Boston, MA 02215 USA.; Gomes-Osman, J (corresponding author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Neurol, Div Cognit Neurol, 330 Brookline Ave, Boston, MA 02215 USA.; Gomes-Osman, J (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol, 1150 Northwest 14th St,Suite 309, Miami, FL 33136 USA.
EM j.gomes@miami.edu
RI Cabral, Danylo/T-8855-2019; Pascual-Leone, Alvaro/AAC-5101-2019
OI Pascual-Leone, Alvaro/0000-0001-8975-0382; Rice,
   Jordyn/0000-0002-6250-5974; Gomes-Osman, Joyce R/0000-0001-6510-0780;
   Cabral, Danylo/0000-0003-0162-1039
FU Evelyn F. McKnight Pilot Grant; National Center for Advancing
   Translational Sciences of the National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [KL2TR002737]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [KL2TR002737] Funding Source: NIH
   RePORTER
FX Dr. Gomes-Osman was supported by an Evelyn F. McKnight Pilot Grant. The
   project described was supported by the National Center for Advancing
   Translational Sciences of the National Institutes of Health under Award
   Number KL2TR002737. The content is solely the responsibility of the
   authors and does not necessarily represent the official views of the
   National Institutes of Health.
CR Baker LD, 2010, J ALZHEIMERS DIS, V22, P569, DOI 10.3233/JAD-2010-100768
   Banitalebi E, 2018, HORM MOL BIOL CLIN I, V35, DOI 10.1515/hmbci-2018-0020
   Best JR, 2015, J INT NEUROPSYCH SOC, V21, P745, DOI 10.1017/S1355617715000673
   BLACK JE, 1990, P NATL ACAD SCI USA, V87, P5568, DOI 10.1073/pnas.87.14.5568
   Blackmore DG, 2009, STEM CELLS, V27, P2044, DOI 10.1002/stem.120
   Blazer DG, 2015, JAMA-J AM MED ASSOC, V313, P2121, DOI 10.1001/jama.2015.4380
   Bliss TVP, 1973, J PHYSL, P232
   Bliss TVP, 1993, SYNAPTIC MODEL MEMOR
   Boldrini M, 2018, CELL STEM CELL, V22, P589, DOI 10.1016/j.stem.2018.03.015
   Bouchard C, 1999, J APPL PHYSIOL, V87, P1003, DOI 10.1152/jappl.1999.87.3.1003
   Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011
   Bugg JM, 2011, NEUROBIOL AGING, V32, P506, DOI 10.1016/j.neurobiolaging.2009.03.008
   Buijs PC, 1998, RADIOLOGY, V209, P667, DOI 10.1148/radiology.209.3.9844657
   Burdette JH, 2010, FRONT AGING NEUROSCI, V2, DOI 10.3389/fnagi.2010.00023
   Bureau UC, AG NAT PROJ NUMB CHI
   Burgess N, 2002, NEURON, V35, P625, DOI 10.1016/S0896-6273(02)00830-9
   Canas PM, 2009, NEUROBIOL AGING, V30, P1877, DOI 10.1016/j.neurobiolaging.2008.01.003
   Carlson MC, 2009, J GERONTOL A-BIOL, V64, P110, DOI 10.1093/gerona/gln008
   Cassilhas RC, 2007, MED SCI SPORT EXER, V39, P1401, DOI 10.1249/mss.0b013e318060111f
   Centers for Disease Control (CDC), 2017, NAT DIAB STAT REP 20
   Chapman SB, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00338
   Chapman SB, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00075
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00357
   Christie BR, 2005, EUR J NEUROSCI, V21, P1719, DOI 10.1111/j.1460-9568.2005.04004.x
   Christie BR, 2008, NEUROMOL MED, V10, P47, DOI 10.1007/s12017-008-8033-2
   Coelho FM, 2012, ARCH GERONTOL GERIAT, V54, P415, DOI 10.1016/j.archger.2011.05.014
   Colcombe SJ, 2004, P NATL ACAD SCI USA, V101, P3316, DOI 10.1073/pnas.0400266101
   Colcombe SJ, 2003, J GERONTOL A-BIOL, V58, P176
   Colcombe SJ, 2006, J GERONTOL A-BIOL, V61, P1166, DOI 10.1093/gerona/61.11.1166
   Cotman CW, 2007, TRENDS NEUROSCI, V30, P464, DOI 10.1016/j.tins.2007.06.011
   Creer DJ, 2010, P NATL ACAD SCI USA, V107, P2367, DOI 10.1073/pnas.0911725107
   Dao AT, 2014, INT J NEUROPSYCHOPH, V17, P593, DOI 10.1017/S1461145713001351
   Vale RGD, 2009, ARCH GERONTOL GERIAT, V49, P343, DOI 10.1016/j.archger.2008.11.011
   DeCarli C, 2005, NEUROBIOL AGING, V26, P491, DOI 10.1016/j.neurobiolaging.2004.05.004
   Dennis NA, 2008, J EXP PSYCHOL LEARN, V34, P791, DOI 10.1037/0278-7393.34.4.791
   Ding Q, 2006, NEUROSCIENCE, V140, P823, DOI 10.1016/j.neuroscience.2006.02.084
   Ding YH, 2006, CURR NEUROVASC RES, V3, P15, DOI 10.2174/156720206775541787
   Dong C, 2015, NEUROLOGY, V85, P441, DOI 10.1212/WNL.0000000000001716
   Dosenbach NUF, 2006, NEURON, V50, P799, DOI 10.1016/j.neuron.2006.04.031
   Enzinger C, 2005, NEUROLOGY, V64, P1704, DOI 10.1212/01.WNL.0000161871.83614.BB
   Erickson KI, 2015, CURR OPIN BEHAV SCI, V4, P27, DOI 10.1016/j.cobeha.2015.01.005
   Erickson KI, 2011, P NATL ACAD SCI USA, V108, P3017, DOI 10.1073/pnas.1015950108
   Fabel K, 2003, EUR J NEUROSCI, V18, P2803, DOI 10.1111/j.1460-9568.2003.03041.x
   Fisher JP, 2013, J PHYSIOL-LONDON, V591, P1859, DOI 10.1113/jphysiol.2012.244905
   Fluck D, 2014, AM J PHYSIOL-HEART C, V307, pH515, DOI 10.1152/ajpheart.00177.2014
   Forti LN, 2015, EXP GERONTOL, V70, P144, DOI 10.1016/j.exger.2015.08.004
   Forti LN, 2014, AGE, V36, DOI 10.1007/s11357-014-9704-6
   Fotenos AF, 2005, NEUROLOGY, V64, P1032, DOI 10.1212/01.WNL.0000154530.72969.11
   Gibbons TE, 2014, BEHAV BRAIN RES, V272, P131, DOI 10.1016/j.bbr.2014.05.049
   Gomes-Osman J, 2018, NEUROL CLIN PRACT, P1
   Gorelick PB, 2017, STROKE, V48, pE284, DOI 10.1161/STR.0000000000000148
   Grady CL, 2003, HIPPOCAMPUS, V13, P572, DOI 10.1002/hipo.10114
   Hofmann M, 2016, EUR J APPL PHYSIOL, V116, P885, DOI 10.1007/s00421-016-3344-8
   Holscher C, 1999, J NEUROSCI RES, V58, P62
   Hsieh H, 2006, NEURON, V52, P831, DOI 10.1016/j.neuron.2006.10.035
   Huang YQ, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00177
   Hvid LG, 2017, EXP GERONTOL, V93, P29, DOI 10.1016/j.exger.2017.03.019
   Itou Y, 2011, HIPPOCAMPUS, V21, P446, DOI 10.1002/hipo.20761
   Jessop P, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00045
   Jonasson LS, 2017, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00336
   Kannangara TS, 2011, NEUROBIOL AGING, V32, P2279, DOI 10.1016/j.neurobiolaging.2009.12.025
   Kim H, 2015, PLOS ONE, V10, DOI [10.1371/journal.pone.0125020, 10.1371/journal.pone.0116256]
   Kleemeyer MM, 2016, NEUROIMAGE, V131, P155, DOI 10.1016/j.neuroimage.2015.11.026
   Knaepen K, 2010, SPORTS MED, V40, P765, DOI 10.2165/11534530-000000000-00000
   Kohman RA, 2012, BRAIN BEHAV IMMUN, V26, P803, DOI 10.1016/j.bbi.2011.10.006
   Kronenberg G, 2006, NEUROBIOL AGING, V27, P1505, DOI 10.1016/j.neurobiolaging.2005.09.016
   Kumar A, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.06.023
   Leckie RL, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00985
   Levinger I, 2008, MED SCI SPORT EXER, V40, P535, DOI [10.1249/mss.0b013e31815dd057, 10.1249/MSS.0b013e31815dd057]
   Littlefield AM, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0362-0
   Liu HL, 2011, BEHAV BRAIN RES, V218, P308, DOI 10.1016/j.bbr.2010.12.030
   Liu-Ambrose T, 2010, ARCH INTERN MED, V170, P170, DOI 10.1001/archinternmed.2009.494
   Lobelo F, 2014, BRIT J SPORT MED, V48, P1627, DOI 10.1136/bjsports-2013-093080
   Lommatzsch M, 2005, NEUROBIOL AGING, V26, P115, DOI 10.1016/j.neurobiolaging.2004.03.002
   Maass A, 2015, MOL PSYCHIATR, V20, P585, DOI 10.1038/mp.2014.114
   Maass A, 2016, NEUROIMAGE, V131, P142, DOI 10.1016/j.neuroimage.2015.10.084
   Mason C, 2013, CANCER EPIDEM BIOMAR, V22, P1457, DOI 10.1158/1055-9965.EPI-13-0337
   Mattson MP, 2004, TRENDS NEUROSCI, V27, P589, DOI 10.1016/j.tins.2004.08.001
   Matura S, 2017, TRANSL PSYCHIAT, V7, DOI 10.1038/tp.2017.135
   MORAINE JJ, 1993, EUR J APPL PHYSIOL O, V67, P35, DOI 10.1007/BF00377701
   Mortimer JA, 2012, J ALZHEIMERS DIS, V30, P757, DOI 10.3233/JAD-2012-120079
   Mukherjee J, 2002, SYNAPSE, V46, P170, DOI 10.1002/syn.10128
   Murrell CJ, 2013, AGE, V35, P905, DOI 10.1007/s11357-012-9414-x
   Nichol K, 2009, ALZHEIMERS DEMENT, V5, P287, DOI 10.1016/j.jalz.2009.02.006
   Niemann C, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00170
   Nwankwo T, 2011, DATA NATL HLTH NUTR
   Nyberg L, 2004, NEURON, V42, P701, DOI 10.1016/j.neuron.2004.05.016
   O'Callaghan RM, 2009, HIPPOCAMPUS, V19, P1019, DOI 10.1002/hipo.20591
   Ogawa K, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/171023
   Pereira AC, 2007, PNAS, P104
   Piercy KL, 2018, JAMA-J AM MED ASSOC, V320, P2020, DOI 10.1001/jama.2018.14854
   Prestes J, 2015, AGE, V37, DOI 10.1007/s11357-015-9793-x
   Pudas S, 2018, CEREB CORTEX, V28, P936, DOI 10.1093/cercor/bhw418
   Rasmussen P, 2009, EXP PHYSIOL, V94, P1062, DOI 10.1113/expphysiol.2009.048512
   Raz N, 2004, NEUROBIOL AGING, V25, P377, DOI 10.1016/S0197-4580(03)00118-0
   Raz N, 2005, CEREB CORTEX, V15, P1676, DOI 10.1093/cercor/bhi044
   Rehfeld K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196636
   Rosano C, 2017, AM J GERIAT PSYCHIAT, V25, P209, DOI 10.1016/j.jagp.2016.11.007
   Ruiz JR, 2015, INT J SPORTS MED, V36, P54, DOI 10.1055/s-0034-1375693
   Ruscheweyh R, 2011, NEUROBIOL AGING, V32, P1304, DOI 10.1016/j.neurobiolaging.2009.08.001
   Schneider WJ., 2012, CONT INTELLECTUAL AS, V3, P99
   Seo DI, 2010, INT J SPORT NUTR EXE, V20, P21, DOI 10.1123/ijsnem.20.1.21
   Smith JC, 2013, BRAIN SCI, V3, P54, DOI 10.3390/brainsci3010054
   Stevens FL, 2011, J NEUROPSYCH CLIN N, V23, P120, DOI 10.1176/appi.neuropsych.23.2.121
   Stimpson NJ, 2018, NEUROSCI BIOBEHAV R, V88, P177, DOI 10.1016/j.neubiorev.2018.03.018
   Tarumi T, 2014, J CEREBR BLOOD F MET, V34, P971, DOI 10.1038/jcbfm.2014.44
   Thomas C, 2008, J COGNITIVE NEUROSCI, V20, P268, DOI 10.1162/jocn.2008.20025
   Trigiani LJ, 2017, J CEREBR BLOOD F MET, V37, P2649, DOI 10.1177/0271678X17714655
   Tsai CL, 2015, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00023
   van Praag H, 2005, J NEUROSCI, V25, P8680, DOI 10.1523/JNEUROSCI.1731-05.2005
   van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368
   van Praag H, 2008, NEUROMOL MED, V10, P128, DOI 10.1007/s12017-008-8028-z
   Vanzella C, 2017, BEHAV BRAIN RES, V334, P78, DOI 10.1016/j.bbr.2017.07.034
   Vaughan S, 2014, AGE AGEING, V43, P623, DOI 10.1093/ageing/afu010
   Vaynman S, 2004, EUR J NEUROSCI, V20, P2580, DOI 10.1111/j.1460-9568.2004.03720.x
   Vedovelli K, 2017, GEROSCIENCE, V39, P407, DOI 10.1007/s11357-017-9987-5
   Vilela TC, 2017, MOL NEUROBIOL, V54, P7928, DOI 10.1007/s12035-016-0272-x
   Voelcker-Rehage C, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00026
   Voss MW, 2013, HUM BRAIN MAPP, V34, P2972, DOI 10.1002/hbm.22119
   Voss MW, 2013, BRAIN BEHAV IMMUN, V28, P90, DOI 10.1016/j.bbi.2012.10.021
   Voss MW, 2010, FRONT AGING NEUROSCI, V2, DOI 10.3389/fnagi.2010.00032
   Weinstein AM, 2012, BRAIN BEHAV IMMUN, V26, P811, DOI 10.1016/j.bbi.2011.11.008
   Ylikoski R, 2000, ARCH GERONTOL GERIAT, V30, P115, DOI 10.1016/S0167-4943(00)00045-5
   Zhao G, 2015, NEUROSCIENCE, V298, P357, DOI 10.1016/j.neuroscience.2015.04.038
NR 124
TC 23
Z9 24
U1 6
U2 19
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1933-7213
EI 1878-7479
J9 NEUROTHERAPEUTICS
JI Neurotherapeutics
PD JUL
PY 2019
VL 16
IS 3
SI SI
BP 580
EP 599
DI 10.1007/s13311-019-00749-w
PG 20
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA IR4WL
UT WOS:000481434900005
PM 31197642
OA Bronze, Green Published
DA 2021-10-30
ER

PT J
AU Peng, W
   Morgan, SE
   Mao, BJ
   Mcfarlane, SJ
   Occa, A
   Grinfeder, G
   Byrne, MM
AF Peng, Wei
   Morgan, Susan E.
   Mao, Bingjing
   Mcfarlane, Soroya Julian
   Occa, Aurora
   Grinfeder, Gilles
   Byrne, Margaret M.
TI Ready to Make A Decision: A Model of Informational Aids to Improve
   Informed Participation in Clinical Trial Research
SO JOURNAL OF HEALTH COMMUNICATION
LA English
DT Article
ID HEALTH BELIEF MODEL; BREAST-CANCER SURGERY; SELF-EFFICACY;
   INTERVENTIONS; COMMUNICATION; KNOWLEDGE; ATTITUDES; METAANALYSIS;
   PERCEPTIONS; BARRIERS
AB Enrollment rates for cancer clinical trials remain low, affecting the generalizability of new treatments. Research shows that many patients face significant challenges in understanding basic clinical trial vocabulary and making informed decisions about participation. Informational aids (IA) are developed to address these challenges and support decision making of cancer clinical trial participation. The present study proposed and tested a structural path model to explain the efficacy of three (i.e., interactive, non-interactive, non-cancer control) IAs. The results revealed that clinical trial participation intention was associated with attitudes and social constructs (i.e., social norm, social sharing, and cues to action). Ease of use, rather than knowledge, was the primary communication feature of IA that influenced the outcome variables. The path relations linking messages features, mediators, and outcome variables were different across all three IAs. The results therefore provide theoretical and practical implications for the use and development of IAs to support clinical trial accrual.
C1 [Peng, Wei; Morgan, Susan E.; Mao, Bingjing; Grinfeder, Gilles] Univ Miami, Sch Commun, 5100 Brunson Dr, Coral Gables, FL 33146 USA.
   [Mcfarlane, Soroya Julian] Univ Georgia, Dept Commun Studies, Athens, GA 30602 USA.
   [Occa, Aurora] Univ Kentucky, Dept Commun, Lexington, KY USA.
   [Byrne, Margaret M.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
RP Peng, W (corresponding author), Univ Miami, Sch Commun, 5100 Brunson Dr, Coral Gables, FL 33146 USA.
EM wxp124@miami.edu
RI Peng, Wei/AAB-2526-2021
OI Peng, Wei/0000-0002-2229-4682; Morgan, Susan/0000-0002-8403-9484
FU Miami Clinical and Translational Science Institute, from the National
   Center for Advancing Translational Sciences [UL1TR000460]; National
   Institute on Minority Health and Health DisparitiesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Minority Health & Health Disparities
   (NIMHD)
FX This research was supported by Grant Number UL1TR000460, Miami Clinical
   and Translational Science Institute, from the National Center for
   Advancing Translational Sciences and the National Institute on Minority
   Health and Health Disparities. Its contents are solely the
   responsibility of the authors and do not necessarily represent the
   official views of the NIH.
CR Agoritsas T, 2011, J CLIN EPIDEMIOL, V64, P107, DOI 10.1016/j.jclinepi.2010.02.007
   AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T
   Albrecht TL, 2008, J CLIN ONCOL, V26, P2666, DOI 10.1200/JCO.2007.14.8114
   Bailey RA, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1262-4
   Boas TC, 2020, POLIT SCI RES METH, V8, P232, DOI 10.1017/psrm.2018.28
   Byrne MM, 2014, MED DECIS MAKING, V34, P116, DOI 10.1177/0272989X13497264
   Caldon LJM, 2011, HEALTH EXPECT, V14, P133, DOI 10.1111/j.1369-7625.2010.00633.x
   Cameron P, 2013, CURR ONCOL, V20, pE193, DOI 10.3747/co.20.1323
   Carpenter CJ, 2010, HEALTH COMMUN, V25, P661, DOI 10.1080/10410236.2010.521906
   Carpenter JS, 2011, MATURITAS, V69, P11, DOI 10.1016/j.maturitas.2011.02.005
   Charles C, 1999, SOC SCI MED, V49, P651, DOI 10.1016/S0277-9536(99)00145-8
   Comis RL, 2003, J CLIN ONCOL, V21, P830, DOI 10.1200/JCO.2003.02.105
   Conner M, 2005, PREDICTING HLTH BEHA, V2, P170, DOI DOI 10.1348/014466699164121
   Duncan O. D., 1975, INTRO STRUCTURAL EQU
   Ellis PM, 1998, AUST NZ J PUBL HEAL, V22, P528, DOI 10.1111/j.1467-842X.1998.tb01432.x
   Elwyn G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004705
   Flory J, 2004, JAMA-J AM MED ASSOC, V292, P1593, DOI 10.1001/jama.292.13.1593
   Ford JG, 2008, CANCER, V112, P228, DOI 10.1002/cncr.23157
   Frew PM, 2010, J CLIN EPIDEMIOL, V63, P1110, DOI 10.1016/j.jclinepi.2009.12.002
   Gillies K, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009736.pub2
   Haynes-Maslow L, 2014, CANCER MED-US, V3, P1430, DOI 10.1002/cam4.284
   Healthwise, 2017, FLU VACC SHOULD I GE
   Hersch J, 2015, LANCET, V385, P1642, DOI 10.1016/S0140-6736(15)60123-4
   Hopp T, 2016, J PUBLIC RELAT RES, V28, P127, DOI 10.1080/1062726X.2016.1204303
   Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118
   JANZ NK, 1984, HEALTH EDUC QUART, V11, P1, DOI 10.1177/109019818401100101
   Jenkins V, 2000, BRIT J CANCER, V82, P1783, DOI 10.1054/bjoc.2000.1142
   Jones T, 2000, AM J HEALTH PROMOT, V14, P170, DOI 10.4278/0890-1171-14.3.170
   Kim MS., 2000, COMMUN MONOGR, V67, P262, DOI [10.1080/03637750009376510, DOI 10.1080/03637750009376510]
   Kline R.B., 2010, PRINCIPLES PRACTICE, V3rd ed.
   Kraft SA, 2017, CLIN TRIALS, V14, P94, DOI 10.1177/1740774516669352
   Krieger JL, 2015, J CANCER EDUC, V30, P743, DOI 10.1007/s13187-015-0789-0
   Lipstein EA, 2013, PEDIATR RHEUMATOL, V11, DOI 10.1186/1546-0096-11-34
   Manne S, 2010, HEALTH PSYCHOL, V29, P583, DOI 10.1037/a0021387
   Melton Genevieve B, 2010, Adv Surg, V44, P117
   Meropol NJ, 2003, J CLIN ONCOL, V21, P2589, DOI 10.1200/JCO.2003.10.072
   Michaels M, 2012, J CANCER EDUC, V27, P67, DOI 10.1007/s13187-011-0271-6
   Miller SM, 2013, PSYCHO-ONCOLOGY, V22, P481, DOI 10.1002/pon.3043
   Mills EJ, 2006, LANCET ONCOL, V7, P141, DOI 10.1016/S1470-2045(06)70576-9
   Morgan SE, 2017, HEALTH COMMUN, V32, P461, DOI 10.1080/10410236.2016.1140266
   Morgan SE, 2016, J HEALTH COMMUN, V21, P765, DOI 10.1080/10810730.2016.1157654
   Murthy VH, 2004, JAMA-J AM MED ASSOC, V291, P2720, DOI 10.1001/jama.291.22.2720
   National Institutes of Health, 2015, NIH CLIN TRIALS YOU
   Tam NT, 2015, B WORLD HEALTH ORGAN, V93, P186, DOI 10.2471/BLT.14.141390
   Nishimura A, 2013, BMC MED ETHICS, V14, DOI 10.1186/1472-6939-14-28
   O'Connor AM, 1999, BRIT MED J, V319, P731, DOI 10.1136/bmj.319.7212.731
   O'Connor AM, 2007, HEALTH AFFAIR, V26, P716, DOI 10.1377/hlthaff.26.3.716
   Obeidat R, 2011, PATIENT EDUC COUNS, V85, pE311, DOI 10.1016/j.pec.2011.03.019
   Occa A, 2018, J RACIAL ETHN HEALTH, V5, P322, DOI 10.1007/s40615-017-0373-x
   Oh SS, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001918
   Paterniti DA, 2005, CANCER-AM CANCER SOC, V104, P3015, DOI 10.1002/cncr.21522
   Politi MC, 2016, ONCOLOGIST, V21, P1461, DOI 10.1634/theoncologist.2016-0068
   Robertson EG, 2018, PATIENT EDUC COUNS, V101, P1157, DOI 10.1016/j.pec.2018.02.001
   ROSENSTOCK IM, 1974, HEALTH EDUC QUART, V2, P354, DOI 10.1177/109019817400200405
   Sepucha KR, 2013, BMC MED INFORM DECIS, V13, DOI 10.1186/1472-6947-13-S2-S12
   Shneerson C, 2013, PATIENT EDUC COUNS, V90, P111, DOI 10.1016/j.pec.2012.06.031
   Simon C, 2003, J CLIN ONCOL, V21, P2173, DOI 10.1200/JCO.2003.03.003
   Stacey Dawn, 2003, Health Expect, V6, P3, DOI 10.1046/j.1369-6513.2003.00195.x
   Stacey D, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001431.pub5
   Stephenson MT, 2006, HEALTH COMMUN, V20, P159, DOI 10.1207/s15327027hc2002_7
   Sundar SS, 2003, COMMUN RES, V30, P30, DOI 10.1177/0093650202239025
   Sutherland HJ, 1998, MED DECIS MAKING, V18, P61, DOI 10.1177/0272989X9801800113
   Thomson RG, 2007, QUAL SAF HEALTH CARE, V16, P216, DOI 10.1136/qshc.2006.018481
   Umphrey L.R., 2004, COMMUN RES REP, V21, P329, DOI [10.1080/08824090409359997, DOI 10.1080/08824090409359997]
   Whelan T, 2004, JAMA-J AM MED ASSOC, V292, P435, DOI 10.1001/jama.292.4.435
   Windle RJ, 2011, BRIT J EDUC TECHNOL, V42, P811, DOI 10.1111/j.1467-8535.2010.01108.x
   Wright JR, 2002, CANCER-AM CANCER SOC, V95, P1584, DOI 10.1002/cncr.10864
   Yang ZJ, 2012, J HEALTH COMMUN, V17, P477, DOI 10.1080/10810730.2011.635774
   Yang ZJ, 2010, HEALTH COMMUN, V25, P423, DOI 10.1080/10410236.2010.483338
   Yi MY, 2003, INT J HUM-COMPUT ST, V59, P431, DOI 10.1016/S1071-5819(03)00114-9
NR 70
TC 3
Z9 3
U1 0
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1081-0730
EI 1087-0415
J9 J HEALTH COMMUN
JI J. Health Commun.
PY 2019
VL 24
IS 12
BP 865
EP 877
DI 10.1080/10810730.2019.1680773
EA OCT 2019
PG 13
WC Communication; Information Science & Library Science
SC Communication; Information Science & Library Science
GA LY3WT
UT WOS:000493244400001
PM 31663824
DA 2021-10-30
ER

PT J
AU Rodriguez, NM
   Casanova, F
   Pages, G
   Claure, L
   Pedreira, M
   Touchton, M
   Knaul, F
AF Rodriguez, Natalia M.
   Casanova, Felicia
   Pages, Gabriela
   Claure, Layla
   Pedreira, Marian
   Touchton, Michael
   Knaul, Felicia
TI Community-based participatory design of a community health worker breast
   cancer training intervention for South Florida Latinx farmworkers
SO PLOS ONE
LA English
DT Article
ID PERSONAL PROTECTIVE EQUIPMENT; HISPANIC WOMEN; PESTICIDE EXPOSURE;
   ORANGE-COUNTY; IMMIGRANT; KNOWLEDGE; RISK; BEHAVIORS; DIAGNOSIS; CARE
AB Objective Community health worker (CHW)-led education is an important strategy to increase awareness and access to breast cancer screening in medically-underserved communities. This study aimed to develop a context-specific, culturally-appropriate training intervention for South Florida CHWs to educate Latinx immigrant farmworkers on breast cancer and early detection. Methods A community-based participatory research (CBPR) study, conducted 2017-2019, informed the design of a training curriculum for CHWs and educational dissemination materials. Twenty-two CHWs were trained and knowledge gains were measuring using a one-group pre-and post-test design. Triangulated evaluation consisted of field observations of CHW-client interactions, CHW self-reports, and rapid assessment surveys of community members. Results A community stakeholder-informed breast cancer training curriculum resulted in significant, sustained breast cancer knowledge gains among CHWs when comparing pre-, post-, and 4-6 month post-training follow-up test scores. Field observations of educational material dissemination, CHW self-reported evaluations, and community rapid assessment surveys at three health fairs demonstrated this was an effective strategy to engage female Latinx farmworkers in breast cancer education. Conclusions Community and key stakeholder participation in the development of a breast cancer educational intervention allowed for tailored design priorities around knowledge-based content, comprehensiveness, relevance, appropriateness, and ease of dissemination to community members. This model of participatory CHW training intervention design can enable future train-the-trainer approaches to disseminate and scale-up evidence-based health education interventions.
C1 [Rodriguez, Natalia M.] Purdue Univ, Dept Publ Hlth, Coll Hlth & Human Sci, W Lafayette, IN 47907 USA.
   [Casanova, Felicia] Univ Miami, Coll Arts & Sci, Dept Sociol, Miami, FL USA.
   [Casanova, Felicia; Pages, Gabriela; Claure, Layla; Pedreira, Marian; Touchton, Michael; Knaul, Felicia] Univ Miami, Inst Adv Study Amer, Miami, FL USA.
RP Rodriguez, NM (corresponding author), Purdue Univ, Dept Publ Hlth, Coll Hlth & Human Sci, W Lafayette, IN 47907 USA.
EM natalia@purdue.edu
RI Rodriguez, Natalia/AAP-8861-2021
OI Rodriguez, Natalia/0000-0002-2633-4397
FU Florida Breast Cancer Foundation; Miami Clinical and Translational
   Science Institute, from the National Center for Advancing Translational
   Sciences [UL1TR002736]; Miami Clinical and Translational Science
   Institute, from National Institute on Minority Health and Health
   Disparities [UL1TR002736]
FX This study was generously supported by the Florida Breast Cancer
   Foundation and by Grant Number UL1TR002736, Miami Clinical and
   Translational Science Institute, from the National Center for Advancing
   Translational Sciences and the National Institute on Minority Health and
   Health Disparities. Its contents are solely the responsibility of the
   authors and do not necessarily represent the official views of the NIH.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Schwartz NA, 2015, HEALTH PLACE, V32, P83, DOI 10.1016/j.healthplace.2014.12.016
   [Anonymous], 2013, COMMUNITY HLTH WORKE
   Arcury TA, 2001, ENVIRON HEALTH PERSP, V109, P429, DOI 10.2307/3434791
   Arcury TA, 2016, ALCOHOL CLIN EXP RES, V40, P377, DOI 10.1111/acer.12969
   Arnold TJ, 2019, PROG COMM HLTH PARTN, V13, P191, DOI 10.1353/cpr.2019.0019
   Campbell K, 2017, WORKPLACE HEALTH SAF, V65, P313, DOI 10.1177/2165079916671955
   Charmaz Kathy, 2008, HDB CONSTRUCTIONIST, P397, DOI DOI 10.1016/J.DESTUD.2004.08.003
   Chavez LR, 2012, SOC SCI MED, V74, P887, DOI 10.1016/j.socscimed.2011.05.023
   Chavez LR, 1997, INT MIGR REV, V31, P88, DOI 10.2307/2547259
   Cosgrove S, 2014, HEALTH PROMOT PRACT, V15, P795, DOI 10.1177/1524839914541442
   De Alba I, 2005, J GEN INTERN MED, V20, P290, DOI 10.1111/j.1525-1497.2005.40158.x
   Earle-Richardson G, 2014, AM J IND MED, V57, P1053, DOI 10.1002/ajim.22352
   Echeverria SE, 2006, MED CARE, V44, P788, DOI 10.1097/01.mlr.0000215863.24214.41
   Engel LS, 2017, ENVIRON HEALTH PERSP, V125, DOI 10.1289/EHP1295
   Engel LS, 2005, AM J EPIDEMIOL, V161, P121, DOI 10.1093/aje/kwi022
   European Food Safety Authority (EFSA), 2005, EFSA J, V3, P235
   Furgurson KF, 2019, J IMMIGR MINOR HEALT, V21, P515, DOI 10.1007/s10903-018-0771-0
   Furgurson KF, 2019, HEALTH PROMOT PRACT, V20, P445, DOI 10.1177/1524839918764671
   Guerrero N, 2016, PREV CHRONIC DIS, V13, DOI 10.5888/pcd13.160036
   Hugo G., 2013, MIGRATION FACTOR DEV, V7, P1
   Ingram M, 2015, HEALTH EXPECT, V18, P3007, DOI 10.1111/hex.12284
   Israel B A, 2001, Educ Health (Abingdon), V14, P182
   Joint Commitee For Guides In Metrology(JCGM), 2012, VIM3 INT VOCAB METRO, V3, P104
   Keating NL, 2014, ONCOLOGIST, V19, P1091, DOI 10.1634/theoncologist.2014-0104
   Kim K, 2016, AM J PUBLIC HEALTH, V106, pE3, DOI 10.2105/AJPH.2015.302987
   Kim NJE, 2016, J AGROMEDICINE, V21, P154, DOI 10.1080/1059924X.2016.1143903
   Knaul FM, 2010, DETECCION TEMPRANA C
   Magana-Valladares L, 2018, J CANCER EDUC, V33, P160, DOI 10.1007/s13187-016-1065-7
   Meade C D, 2001, Oncol Nurs Forum, V28, P1577
   Mobley LR, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14050484
   Montealegre JR, 2013, CANCER CAUSE CONTROL, V24, P1985, DOI 10.1007/s10552-013-0274-1
   Palmer RC, 2005, HEALTH EDUC BEHAV, V32, P488, DOI 10.1177/1090198105276213
   Payne J, 2017, J COMMUN HEALTH, V42, P983, DOI 10.1007/s10900-017-0345-4
   Polat P, 2017, SOC WORK PUBLIC HLTH, V32, P166, DOI 10.1080/19371918.2015.1137525
   Quandt SA, 2004, ENVIRON HEALTH PERSP, V112, P636, DOI 10.1289/ehp.6754
   Quandt SA, 2013, HEALTH PROMOT PRACT, V14, P425, DOI 10.1177/1524839912459652
   Remennick L, 2006, BREAST J, V12, pS103, DOI 10.1111/j.1075-122X.2006.00204.x
   Salvatore Alicia L, 2009, Am J Public Health, V99 Suppl 3, pS578, DOI 10.2105/AJPH.2008.149146
   Scan 360, CANC DAT
   Schlehofer MM, 2015, J COMMUN HEALTH NURS, V32, P71, DOI 10.1080/07370016.2015.1024541
   Seay JS, 2015, PROG COMM HLTH PARTN, V9, P11, DOI 10.1353/cpr.2015.0029
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI [10.1001/jamaoto.2014.2530, 10.3322/caac.21254, 10.1136/bmj.g1502, 10.3322/caac.21208]
   Silver K, 2014, PROG COMM HLTH PARTN, V8, P501, DOI 10.1353/cpr.2014.0056
   The Lancet, 2020, LANCET PLANET HLTH, V4, pe168
   Tovar-Aguilar JA, 2014, J AGROMEDICINE, V19, P107, DOI 10.1080/1059924X.2014.884397
   Wadler BM, 2011, J ONCOL, V2011, DOI 10.1155/2011/150423
   Widger K, 2016, BMC PALLIAT CARE, V15, DOI 10.1186/s12904-016-0085-8
   Yarber L, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-1224-2
   Zambrana RE, 1999, PREV MED, V29, P466, DOI 10.1006/pmed.1999.0566
NR 49
TC 1
Z9 1
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 19
PY 2020
VL 15
IS 10
AR e0240827
DI 10.1371/journal.pone.0240827
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OM3IS
UT WOS:000585920200013
PM 33075111
OA Green Published, gold
DA 2021-10-30
ER

PT J
AU Duthely, LM
   Sanchez-Covarrubias, AP
   Mohamed, AB
   Potter, JE
AF Duthely, Lunthita M.
   Sanchez-Covarrubias, Alex P.
   Mohamed, Adhar B.
   Potter, JoNell E.
TI A Multilingual, Culturally Competent Mobile Health Intervention to
   Improve Treatment Adherence Among Women Living With HIV: Protocol for a
   Randomized Controlled Trial
SO JMIR RESEARCH PROTOCOLS
LA English
DT Article
DE telemedicine; HIV; acquired immunodeficiency syndrome; women; adherence;
   clinical trial protocol; barriers; facilitators; text; messaging;
   mHealth; SMS/texting
ID DAVIDSON RESILIENCE SCALE; PSYCHOMETRIC PROPERTIES; MEDICATION
   ADHERENCE; CARE; STIGMA; DEPRESSION; VALIDITY; MISTRUST
AB Background: Adherence to HIV care is complex, as barriers to care are multidimensional, particularly for ethnic minority women. Mobile health (mHealth) solutions are supportive in improving HIV health care outcomes. In the United States, however, mHealth interventions are not widely implemented in public HIV clinics and have not been customized for women. There is an unmet need for culturally and linguistically appropriate mHealth interventions that address the health care needs of minority women living with HIV.
   Objective: This study aims to describe a protocol investigating the feasibility of an mHealth intervention for treatment adherence among women living with HIV. This is a two-phase, mixed methods, pilot randomized controlled trial that begins with qualitative patient interviews to inform the system design. Participants will be block randomized by language (English, Spanish, and Haitian Creole) to 1 of 2 study arms.
   Methods: Women (age >= 18 years) who were followed up at the women's HIV clinic of an academic medical center, with a recent history of nonadherence to HIV care (missed appointments, unsuppressed viral load, or not taking medications as prescribed), will be enrolled. The experimental arm will receive the intervention, which includes health reminders and psychoeducational messaging, plus clinical standard of care reminders. The psychoeducational messaging will target patient-level barriers of HIV stigma and medical mistrust and resilience as a patient-level strength. The control arm will receive standard of care reminders only (ie, mailed appointments and automated telephone calls). All aspects of the study and intervention will be offered in the participants' preferred language. The primary outcome is the feasibility and acceptability of the study. The secondary outcomes are changes in self-reported medication adherence, depression symptoms, HIV stigma, medical mistrust, resilience, and clinic attendance and viral suppression extracted from the participants' medical records. Data will be assessed at baseline (T0) and 2 subsequent clinic visits-approximately 3 to 4 months from the baseline (time 1; T1) and 6 to 9 months from the baseline (time 2; T2). Qualitative data will be transcribed and analyzed iteratively. Bivariate analyses will compare data by the study group (chi-square, odds ratios, and t tests). Exploratory analyses will be conducted for each outcome variable-T1 and T2 values will be compared with values at T0 by the study group.
   Results: As of March 2020, baseline quantitative data were collected on 54 participants (28 English speakers, 14 Spanish speakers, and 12 Haitian Creole speakers). The first 3 focus groups (1 in each of the 3 languages) were completed, with a total of 20 participants. The findings are currently being integrated into the beta version of the mHealth texting system.
   Conclusions: The findings of this novel HIV adherence intervention may shed light on the barriers and facilitators of HIV health care and the mechanisms of an mHealth intervention that is customized for ethnic minority women living with HIV.
C1 [Duthely, Lunthita M.; Mohamed, Adhar B.; Potter, JoNell E.] Univ Miami, Miller Sch Med, Obstet Gynecol & Reprod Serv, POB 016960 D-53, Miami, FL 33101 USA.
   [Sanchez-Covarrubias, Alex P.] Univ Miami, Miller Sch Med, Miami Clin & Translat Sci Inst, Miami, FL 33101 USA.
RP Duthely, LM (corresponding author), Univ Miami, Miller Sch Med, Obstet Gynecol & Reprod Serv, POB 016960 D-53, Miami, FL 33101 USA.
EM lduthely@med.miami.edu
OI Sanchez-Covarrubias, Alex P/0000-0002-0474-992X; Duthely,
   Lunthita/0000-0002-9003-3257; Mohamed, Adhar/0000-0002-0137-2469;
   Potter, JoNell/0000-0002-4620-2316
FU Miami Clinical and Translational Science Institute [KL2TR002737];
   National Center for Advancing Translational SciencesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS);
   National Institute on Minority Health and Health DisparitiesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute on Minority Health & Health
   Disparities (NIMHD)
FX The project described was supported by grant number KL2TR002737, Miami
   Clinical and Translational Science Institute, from the National Center
   for Advancing Translational Sciences and the National Institute on
   Minority Health and Health Disparities. Its contents are solely the
   responsibility of the authors and do not necessarily represent the
   official views of the National Institutes of Health.
CR Berger BE, 2001, RES NURS HEALTH, V24, P518, DOI 10.1002/nur.10011
   Blanc J, 2016, J AFFECT DISORDERS, V190, P697, DOI 10.1016/j.jad.2015.10.046
   Centers for Disease Control and Prevention, 2016, HIV HISP LAT
   Centers for Disease Control and Prevention, 2017, HIV AFR AM
   Centers for Disease Control and Prevention, 2018, EST HIV INC PREV US
   Centers for Disease Control and Prevention, 2017, HIV SURV REP
   Connor KM, 2003, DEPRESS ANXIETY, V18, P76, DOI 10.1002/da.10113
   Dale S, 2014, AIDS PATIENT CARE ST, V28, P136, DOI 10.1089/apc.2013.0329
   Dale SK, 2018, COGN BEHAV PRACT, V25, P361, DOI 10.1016/j.cbpra.2017.10.004
   Earnshaw VA, 2013, AM PSYCHOL, V68, P225, DOI 10.1037/a0032705
   Familiar I, 2015, INT J METH PSYCH RES, V24, P74, DOI 10.1002/mpr.1461
   Glanz K, 2008, HLTH BEHAV HLTH ED T
   Henny KD, 2018, AIDS BEHAV, V22, P43, DOI 10.1007/s10461-017-1923-2
   Jimenez JC, 2010, AIDS CARE, V22, P1314, DOI 10.1080/09540121003758481
   Kalichman SC, 2017, J HEALTH PSYCHOL, V22, P269, DOI 10.1177/1359105315600239
   Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x
   Lopez-Cevallos DF, 2014, J RURAL HEALTH, V30, P344, DOI 10.1111/jrh.12063
   Manzano-Garcia G, 2013, PSICOTHEMA, V25, P245, DOI 10.7334/psicothema2012.183
   Marc LG, 2014, J GEN INTERN MED, V29, P1679, DOI 10.1007/s11606-014-2951-5
   Miami-Dade Beacon Council, 2018, POP DIV STRENGTH COM
   Momplaisir FM, 2018, AIDS, V32, P133, DOI 10.1097/QAD.0000000000001707
   ROSENSTOCK IM, 1974, HEALTH EDUC QUART, V2, P328, DOI 10.1177/109019817400200403
   Shah M, 2016, LANCET HIV, V3, pE140, DOI 10.1016/S2352-3018(16)00007-2
   Thompson HS, 2004, PREV MED, V38, P209, DOI 10.1016/j.ypmed.2003.09.041
   Wawrzyniak AJ, 2015, JAIDS-J ACQ IMM DEF, V69, pS63, DOI 10.1097/QAI.0000000000000572
   Wilson IB, 2016, AIDS BEHAV, V20, P2700, DOI 10.1007/s10461-016-1406-x
   Wulsin Lawson, 2002, Prim Care Companion J Clin Psychiatry, V4, P191
NR 27
TC 2
Z9 2
U1 0
U2 1
PU JMIR PUBLICATIONS, INC
PI TORONTO
PA 130 QUEENS QUAY E, STE 1102, TORONTO, ON M5A 0P6, CANADA
SN 1929-0748
J9 JMIR RES PROTOC
JI JMIR RES. Protoc.
PD JUN
PY 2020
VL 9
IS 6
AR e17656
DI 10.2196/17656
PG 11
WC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
GA MJ7FQ
UT WOS:000548253000027
PM 32438338
OA Green Published, gold
DA 2021-10-30
ER

PT J
AU Myers, ND
AF Myers, Nicholas D.
TI Coaching competency and (exploratory) structural equation modeling: A
   substantive-methodological synergy
SO PSYCHOLOGY OF SPORT AND EXERCISE
LA English
DT Article
DE athlete's evaluations; Coaching effectiveness; Geomin; Target;
   Categorical data
ID COVARIANCE STRUCTURE-ANALYSIS; FIT INDEXES; EFFICACY; ROTATION; SPORT;
   NUMBER
AB Objectives: The purpose of this manuscript was to provide a substantive-methodological synergy of potential importance to future research in the psychology of sport and exercise.
   Design: The substantive focus was the emerging role for, and particularly the measurement of, athletes' evaluations of their coach's competency within conceptual models of effective coaching. The methodological focus was exploratory structural equation modeling (ESEM), a methodology that integrates the advantages of exploratory factor analysis and confirmatory factor analysis (CFA) within the general structural equation model.
   Methods: The synergy was a demonstration of when a new and flexible methodological framework, ESEM, may be preferred as compared to a more familiar and restrictive methodological framework, CFA, by reanalyzing existing data.
   Results: ESEM analysis on extant datasets suggested that for responses to the Athletes' Perceptions of Coaching Competency Scale II - High School Teams (APCCS II-HST), a CFA model based on the relevant literature plus one post hoc modification, offered a viable alternative to a more complex ESEM model. For responses to the Coaching Competency Scale (CCS), a CFA model based on the relevant literature did not offer a viable alternative to a more complex ESEM model.
   Conclusions: The ESEM framework should be strongly considered in subsequent studies validity studies for new and/or existing instruments in the psychology of sport and exercise. A key consideration for deciding between ESEM and the accompanying rotation criterion and CFA in future validity studies should be level of a priori measurement theory. (C) 2013 Elsevier Ltd. All rights reserved.
C1 Univ Miami, Dept Educ & Psychol Studies, Coral Gables, FL 33124 USA.
RP Myers, ND (corresponding author), Univ Miami, Dept Educ & Psychol Studies, Merrick Bldg 311E, Coral Gables, FL 33124 USA.
EM nmyers@miami.edu
OI Myers, Nicholas/0000-0001-9069-9940
FU National Center for Advancing Translational Sciences of the National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [UL1TR000460]; NATIONAL CENTER
   FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000460]
   Funding Source: NIH RePORTER
FX Research reported in this publication was supported, in part, by the
   National Center for Advancing Translational Sciences of the National
   Institutes of Health under Award Number UL1TR000460. The content is
   solely the responsibility of the authors and does not necessarily
   represent the official views of the National Institutes of Health.
CR American Educational Research Association, 1999, STAND ED PSYCH TEST
   Asparouhov T, 2009, STRUCT EQU MODELING, V16, P397, DOI 10.1080/10705510903008204
   Bandura A, 1997, SELF EFFICACY THE EX
   Bollen K.A., 1989, STRUCTURAL EQUATIONS, DOI 10.1002/9781118619179
   Bosselut G, 2012, J SPORT EXERCISE PSY, V34, P345, DOI 10.1123/jsep.34.3.345
   Browne MW, 2001, MULTIVAR BEHAV RES, V36, P111, DOI 10.1207/S15327906MBR3601_05
   Feltz DL, 1999, J EDUC PSYCHOL, V91, P765, DOI 10.1037/0022-0663.91.4.765
   Finney SJ, 2006, QUANT METH EDUC BEHA, P269
   Garrido LE, 2012, PSYCHOL METHODS
   Hayashi K, 2007, STRUCT EQU MODELING, V14, P505, DOI 10.1080/10705510701301891
   HORN JL, 1965, PSYCHOMETRIKA, V30, P179, DOI 10.1007/BF02289447
   HORN TS, 2002, ADV SPORT PSYCHOL, P309
   Hox JJ, 2001, STRUCT EQU MODELING, V8, P157, DOI 10.1207/S15328007SEM0802_1
   Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118
   JORESKOG KG, 1969, PSYCHOMETRIKA, V34, P183, DOI 10.1007/BF02289343
   Julian MW, 2001, STRUCT EQU MODELING, V8, P325, DOI 10.1207/S15328007SEM0803_1
   KAPLAN D, 1988, MULTIVAR BEHAV RES, V23, P69, DOI 10.1207/s15327906mbr2301_4
   MACCALLUM RC, 1992, PSYCHOL BULL, V111, P490, DOI 10.1037/0033-2909.111.3.490
   Marsh HW, 2007, CONTEMP EDUC PSYCHOL, V32, P151, DOI 10.1016/j.cedpsych.2006.10.008
   Marsh HW, 2012, EDUC PSYCHOL-US, V47, P106, DOI 10.1080/00461520.2012.670488
   Marsh HW, 2009, STRUCT EQU MODELING, V16, P439, DOI 10.1080/10705510903008220
   Marsh HW, 2004, STRUCT EQU MODELING, V11, P320, DOI 10.1207/s15328007sem1103_2
   Millsap R.E, 2011, STAT APPROACHES MEAS
   Millsap RE, 2004, MULTIVAR BEHAV RES, V39, P479, DOI 10.1207/S15327906MBR3903_4
   Morin AJS, 2013, QUANT METH EDUC BEHA, P395
   Morin AJS, 2011, PSYCHOL SPORT EXERC, V12, P540, DOI 10.1016/j.psychsport.2011.04.003
   Muth?n B. O., 2010, SIMPLE 2 ORDER CHI S
   MUTHEN B, 1984, PSYCHOMETRIKA, V49, P115, DOI 10.1007/BF02294210
   MUTHEN BO, 1994, SOCIOL METHOD RES, V22, P376, DOI 10.1177/0049124194022003006
   Muthen L.K., 1998, MPLUS USERS GUIDE, V8th ed.
   Myers N. D., 2011, MOD MOD METH C STORR
   Myers N. D., ROTATION PARTI UNPUB
   Myers N. D., 2013, ROUTLEDGE HDB SPORTS, P81
   Myers ND, 2006, RES Q EXERCISE SPORT, V77, P111, DOI 10.5641/027013606X13080769704082
   Myers N, 2011, RES Q EXERCISE SPORT, V82, P79, DOI 10.1080/02701367.2011.10599724
   Myers ND, 2008, EDUC PSYCHOL MEAS, V68, P1059, DOI 10.1177/0013164408318773
   Myers ND, 2008, RES Q EXERCISE SPORT, V79, P300, DOI 10.5641/193250308X13086832905752
   Myers ND, 2006, RES Q EXERCISE SPORT, V77, P451
   Myers ND, 2013, STRUCT EQU MODELING, V20, P131, DOI 10.1080/10705511.2013.742399
   Myers ND, 2011, J SPORT EXERCISE PSY, V33, P779, DOI 10.1123/jsep.33.6.779
   Myers ND, 2011, J SPORT SCI, V29, P411, DOI 10.1080/02640414.2010.538710
   Myers ND, 2010, EDUC PSYCHOL MEAS, V70, P477, DOI 10.1177/0013164409344520
   National Association for Sport and Physical Education, 2006, QUAL COACH QUAL SPOR
   Nunnally J., 1978, PSYCHOMETRIC THEORY
   ROZEBOOM WW, 1992, MULTIVAR BEHAV RES, V27, P585, DOI 10.1207/s15327906mbr2704_5
   Ryu E, 2009, STRUCT EQU MODELING, V16, P583, DOI 10.1080/10705510903203466
   SMOLL FL, 1989, J APPL SOC PSYCHOL, V19, P1522, DOI 10.1111/j.1559-1816.1989.tb01462.x
   Spearman C, 1904, AM J PSYCHOL, V15, P201, DOI 10.2307/1412107
   Thurstone L.L., 1947, MULTIPLE FACTOR ANAL
   Vernon T., 2007, PERSONALITY INDIVIDU, V42, P5
   Yates A., 1987, MULTIVARIATE EXPLORA
   Yuan KH, 2004, EDUC PSYCHOL MEAS, V64, P737, DOI 10.1177/0013164404264853
NR 52
TC 24
Z9 24
U1 1
U2 42
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1469-0292
EI 1878-5476
J9 PSYCHOL SPORT EXERC
JI Psychol. Sport Exerc.
PD SEP
PY 2013
VL 14
IS 5
BP 709
EP 718
DI 10.1016/j.psychsport.2013.04.008
PG 10
WC Hospitality, Leisure, Sport & Tourism; Psychology, Applied; Psychology;
   Sport Sciences
SC Social Sciences - Other Topics; Psychology; Sport Sciences
GA 218TD
UT WOS:000324454500014
PM 23794951
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Morgan, SE
   Peng, W
   Occa, A
   Mao, BJ
   McFarlane, S
   Grinfeder, G
   Millet, B
   Byrne, MM
AF Morgan, Susan E.
   Peng, Wei
   Occa, Aurora
   Mao, Bingjing
   McFarlane, Soroya
   Grinfeder, Gilles
   Millet, Barbara
   Byrne, Margaret M.
TI Tailored Messages About Research Participation: Using an Interactive
   Information Aid to Improve Study Recruitment
SO JOURNAL OF CANCER EDUCATION
LA English
DT Article; Early Access
DE Information aids; Cancer communication; Clinical trials
ID RANDOMIZED CLINICAL-TRIALS; BREAST-CANCER PATIENTS; DECISION-MAKING;
   COMMUNICATION; KNOWLEDGE
AB After a diagnosis of cancer (or other serious disease), patients may be asked to consider joining a clinical trial. Because most people are unfamiliar with the scientific concepts that are necessary to the provision of meaningful informed consent, patient education is necessary. Increasing knowledge alone is not sufficient; understanding how clinical trial participation aligns with personal circumstances and knowledge is central to the decision-making process. In this study, 302 cancer patients and survivors evaluated an interactive information aid (IA) designed to inform their decision to join a research study or clinical trial by providing tailored information to patients' responses to questions pertaining to seven key barriers or facilitators of clinical trial participation. The development of the IA was done with input from the authors' Clinical Translational Science Institute; linked components of the IA were vetted by members and leaders of the institution's NCI-designated comprehensive cancer center. Results of the study indicated that the information aid was successful in significantly reducing fears and increasing knowledge, attitudes, perceived behavioral control, and behavioral intentions about research participation relative to a control condition. Thus, an interactive information aid that provides information that is responsive to patients' values, knowledge, and personal circumstances can help patients to be better prepared to consider a decision about research participation.
C1 [Morgan, Susan E.; Peng, Wei; Mao, Bingjing] Univ Miami, Dept Commun Studies, Coral Gables, FL 33146 USA.
   [Occa, Aurora] Univ Kentucky, Dept Commun Studies, Lexington, KY USA.
   [McFarlane, Soroya] Univ Georgia, Dept Commun Studies, Athens, GA 30602 USA.
   [Grinfeder, Gilles; Millet, Barbara] Univ Miami, Dept Interact Media, Coral Gables, FL 33124 USA.
   [Byrne, Margaret M.] H Lee Moffitt Canc Ctr & Res Inst, Dept Hlth Outcomes & Behav, Tampa, FL USA.
RP Morgan, SE (corresponding author), Univ Miami, Dept Commun Studies, Coral Gables, FL 33146 USA.
EM semorgan@miami.edu
RI Peng, Wei/AAB-2526-2021
OI Peng, Wei/0000-0002-2229-4682; Morgan, Susan/0000-0002-8403-9484
FU Miami Clinical and Translational Science Institute, from the National
   Center for Advancing Translational Sciences [UL1TR000460]; National
   Institute on Minority Health and Health DisparitiesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Minority Health & Health Disparities
   (NIMHD)
FX This research was supported by Grant Number UL1TR000460, Miami Clinical
   and Translational Science Institute, from the National Center for
   Advancing Translational Sciences and the National Institute on Minority
   Health and Health Disparities. Its contents are solely the
   responsibility of the authors and do not necessarily represent the
   official views of the NIH.
CR Albrecht TL, 2008, J CLIN ONCOL, V26, P2666, DOI 10.1200/JCO.2007.14.8114
   Albrecht TL, 1999, J CLIN ONCOL, V17, P3324, DOI 10.1200/JCO.1999.17.10.3324
   Cameron P, 2013, CURR ONCOL, V20, pE193, DOI 10.3747/co.20.1323
   Eggly S, 2008, PATIENT EDUC COUNS, V70, P143, DOI 10.1016/j.pec.2007.09.019
   Elwyn G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004705
   Gillies K, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009736.pub2
   Hutchison C, 2007, BRIT J CANCER, V97, P705, DOI 10.1038/sj.bjc.6603943
   Jenkins V, 2005, BMJ-BRIT MED J, V330, P400, DOI 10.1136/bmj.38366.562685.8F
   Jenkins V, 2000, BRIT J CANCER, V82, P1783, DOI 10.1054/bjoc.2000.1142
   Kraft SA, 2017, CLIN TRIALS, V14, P94, DOI 10.1177/1740774516669352
   Manne S, 2015, EUR J CANCER CARE, V24, P28, DOI 10.1111/ecc.12180
   McSweeney JC, 2009, RES GERONTOL NURS, V2, P256, DOI 10.3928/19404921-20090803-01
   Miller SM, 2013, PSYCHO-ONCOLOGY, V22, P481, DOI 10.1002/pon.3043
   Morgan S.E., 2018, CLIN TRIALS VULNERAB, P199
   Morgan S. E., 2015, ORG COMMUNICATION HL, P82
   Morgan S.E., HDB APPL COMMUNICATI
   Morgan SE, 2017, J HEALTH COMMUN, V22, P95, DOI 10.1080/10810730.2016.1256356
   Morgan SE, 2017, HEALTH COMMUN, V32, P461, DOI 10.1080/10410236.2016.1140266
   Morgan SE, 2016, J HEALTH COMMUN, V21, P765, DOI 10.1080/10810730.2016.1157654
   Shneerson C, 2013, PATIENT EDUC COUNS, V90, P111, DOI 10.1016/j.pec.2012.06.031
   Siminoff LA, 2005, HEALTH PSYCHOL, V24, pS99, DOI 10.1037/0278-6133.24.4.S99
   Siminoff LA, 2000, J CLIN ONCOL, V18, P1203, DOI 10.1200/JCO.2000.18.6.1203
   Stacey D, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001431.pub5
   Stevens T, 2004, PATIENT EDUC COUNS, V52, P341, DOI 10.1016/S0738-3991(03)00041-7
   Umphrey L.R., 2004, COMMUN RES REP, V21, P329, DOI [10.1080/08824090409359997, DOI 10.1080/08824090409359997]
   Woolfall K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067352
NR 26
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0885-8195
EI 1543-0154
J9 J CANCER EDUC
JI J. Cancer Educ.
DI 10.1007/s13187-020-01775-5
EA JUN 2020
PG 7
WC Oncology; Education, Scientific Disciplines; Public, Environmental &
   Occupational Health
SC Oncology; Education & Educational Research; Public, Environmental &
   Occupational Health
GA MO3FI
UT WOS:000551415800001
PM 32533538
DA 2021-10-30
ER

PT J
AU Achua, JK
   Chu, KY
   Ibrahim, E
   Khodamoradi, K
   Delma, KS
   Iakymenko, OA
   Kryvenko, ON
   Arora, H
   Ramasamy, R
AF Achua, Justin K.
   Chu, Kevin Y.
   Ibrahim, Emad
   Khodamoradi, Kajal
   Delma, Katiana S.
   Iakymenko, Oleksii A.
   Kryvenko, Oleksandr N.
   Arora, Himanshu
   Ramasamy, Ranjith
TI Histopathology and Ultrastructural Findings of Fatal COVID-19 Infections
   on Testis
SO WORLD JOURNAL OF MENS HEALTH
LA English
DT Article
DE Autopsy; Coronavirus; COVID-19; Infertility; Testis
AB Purpose: Ta evaluate the presence and analyze the pathological changes within the testes of patients who died or recovered from severe acute respiratory syndrome coronavirus 2 (COVID-19) complications.
   Materials and Methods: Testis tissue was collected from autopsies of COVID-19 positive (n=6) and negative men (n-3). Formalin-fixed paraffin-embedded tissues were stained with hematoxylin and eosin (H&E) and subjected to immunofluorescence for angiotensin-converting enzyme 2 (ACE-2) expression. Fluorescent-labeled tissue slides were imaged on a quantitative pathology scope with various zoom levels allowing for qualitative and quantitative interpretation. Tissue from four COVID-19 positive autopsy cases and a live seroconverted patient was imaged with transmission electron microscopy (TEM).
   Results: H&E histomorphology showed three of the six COVID-19 biopsies had normal spermatogenesis while the remaining three had impaired spermatogenesis. TEM showed the COVID-19 virus in testis tissue of one COVID-19 positive autopsy case and the live biopsy, H&E stain on the same autopsy case demonstrated interstitial macrophage and leukocyte infiltration. Immunofluorescent stained slides from six COVID-19 positive men demonstrated a direct association between increased quantitative ACE-2 levels and impairment of spermatogenesis.
   Conclusions: The novel COVID-19 has an affinity for ACE-2 receptors. Since ACE-2 receptor expression is high in the testes, we hypothesized that COVID-19 is prevalent in testes tissue of infected patients. This study suggests the male reproductive tract, specifically the testes, may be targets of COVID-19 infection. We found an inverse association between ACE-2 receptor levels and spennatogenesis, suggesting a possible mechanism of how COVID-19 can cause infertility.
C1 [Achua, Justin K.; Chu, Kevin Y.; Ibrahim, Emad; Khodamoradi, Kajal; Kryvenko, Oleksandr N.; Arora, Himanshu; Ramasamy, Ranjith] Univ Miami, Miller Sch Med, Dept Urol, 1120 NW 14th St,1551, Miami, FL 33136 USA.
   [Delma, Katiana S.; Iakymenko, Oleksii A.; Kryvenko, Oleksandr N.] Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL 33136 USA.
   [Arora, Himanshu; Ramasamy, Ranjith] Univ Miami, Miller Sch Med, Interdisciplinary Stem Cell Inst, Miami, FL 33136 USA.
   [Arora, Himanshu] Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, Miami, FL 33136 USA.
RP Ramasamy, R (corresponding author), Univ Miami, Miller Sch Med, Dept Urol, 1120 NW 14th St,1551, Miami, FL 33136 USA.
EM Ramasamy@miami.edu
RI Ramasamy, Ranjith/ABD-7373-2020; khodamoradi, kajal/ABF-6551-2020
OI Ramasamy, Ranjith/0000-0003-1387-7904; khodamoradi,
   kajal/0000-0003-2951-4382; Achua, Justin/0000-0002-4159-439X
FU Miami CTSI -Clinical and Translational Science Institute [UL1TR002736]
FX This research was supported by the Miami CTSI -Clinical and
   Translational Science Institute (UL1TR002736). The authors would like to
   acknowledge Dr. Emma Lee as well as the rest of the Miami-Dade County
   Medical Examiner Department for their assistance with the procurement of
   autopsy testes biopsies. The authors would like to acknowledge Vania
   Almeida and the University of Miami Transmission Electron Microscopy
   Core for assistance with the generation of EM images.
CR Bian XW, 2020, NATL SCI REV, V7, P1414, DOI 10.1093/nsr/nwaa123
   Corona G, 2020, J ENDOCRINOL INVEST, V43, P1153, DOI 10.1007/s40618-020-01290-w
   Cui HM, 2020, MED CLIN-BARCELONA, V155, P295, DOI 10.1016/j.medcli.2020.06.007
   De Paoli P, 2005, FEMS MICROBIOL REV, V29, P897, DOI 10.1016/j.femsre.2005.01.005
   Dejucq N, 2001, MICROBIOL MOL BIOL R, V65, P208, DOI 10.1128/MMBR.65.2.208-231.2001
   Esteves SC, 2021, ANDROLOGY-US, V9, P10, DOI 10.1111/andr.12809
   Farkash EA, 2020, J AM SOC NEPHROL, V31, P1683, DOI 10.1681/ASN.2020040432
   Georges J-L, 2020, Ann Cardiol Angeiol (Paris), V69, P247, DOI 10.1016/j.ancard.2020.09.030
   Goren A, 2020, J COSMET DERMATOL-US, V19, P1545, DOI 10.1111/jocd.13443
   Hasoksuz M, 2020, TURK J MED SCI, V50, P549, DOI 10.3906/sag-2004-127
   He YX, 2004, BIOCHEM BIOPH RES CO, V324, P773, DOI 10.1016/j.bbrc.2004.09.106
   Hoffmann M, 2020, CAMOSTAT MESYLATE IN, DOI [10.1101/2020.01.31.929042, DOI 10.1101/2020.01.31.929042]
   Huang CZ, 2020, LIMIT ANALYSIS THEORY OF THE SOIL MASS AND ITS APPLICATION, P1, DOI [10.1007/978-981-15-1572-9_1, 10.1016/S0140-6736(20)30183-5]
   Leung JM, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00688-2020
   Li DG, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8292
   McLachlan RI, 2007, HUM REPROD, V22, P2, DOI 10.1093/humrep/del279
   Muus C., 2020, BIORXIV, DOI [DOI 10.1101/2020.04.19.049254, 10.1101/2020.04.19.049254, 10.1101/2020.04.19.049254(2020]
   Pan F, 2020, FERTIL STERIL, V113, P1135, DOI 10.1016/j.fertnstert.2020.04.024
   Paoli D, 2021, J ENDOCRINOL INVEST, V44, P1091, DOI 10.1007/s40618-020-01438-8
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Prasad S, 2020, INDIAN J MED RES, V151, P241, DOI 10.4103/ijmr.IJMR_577_20
   Puelles VG, 2020, NEW ENGL J MED, V383, P590, DOI [10.1056/NEJMc2013400, 10.1056/NEJMc2011400]
   Wambier CG, 2020, J AM ACAD DERMATOL, V83, P308, DOI 10.1016/j.jaad.2020.04.032
   Wang W, 2014, J INFECT DEV COUNTR, V8, P208, DOI 10.3855/jidc.3557
   Xu J, 2006, BIOL REPROD, V74, P410, DOI 10.1095/biolreprod.105.044776
   Yang M, 2020, EUR UROL FOCUS, V6, P1124, DOI 10.1016/j.euf.2020.05.009
   Yokoyama Y, 2021, J MED VIROL, V93, P2084, DOI 10.1002/jmv.26588
   Zheng JQ, 2019, IEEE T SERV COMPUT, V12, P800, DOI 10.1109/TSC.2016.2631519
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
NR 29
TC 18
Z9 20
U1 5
U2 6
PU KOREAN SOC SEXUAL MEDICINE & ANDROLOGY
PI BUSAN
PA PUSAN NATL UNIV MEDICAL SCH, DEPT UROLOGY, 179 GUDEOK-RO, SEO-GU, BUSAN,
   SOUTH KOREA
SN 2287-4208
EI 2287-4690
J9 WORLD J MENS HEALTH
JI World J. Mens Health
PD JAN
PY 2021
VL 39
IS 1
BP 65
EP 74
DI 10.5534/wjmh.200170
PG 10
WC Andrology; Health Care Sciences & Services; Urology & Nephrology
SC Endocrinology & Metabolism; Health Care Sciences & Services; Urology &
   Nephrology
GA PH0QT
UT WOS:000600129300007
PM 33151050
OA gold, Green Published
HC Y
HP N
DA 2021-10-30
ER

PT J
AU Lu, M
   Sadiq, S
   Feaster, DJ
   Ishwaran, H
AF Lu, Min
   Sadiq, Saad
   Feaster, Daniel J.
   Ishwaran, Hemant
TI Estimating Individual Treatment Effect in Observational Data Using
   Random Forest Methods
SO JOURNAL OF COMPUTATIONAL AND GRAPHICAL STATISTICS
LA English
DT Article
DE Counterfactual model; Individual treatment effect (ITE); Propensity
   score; Synthetic forests; Treatment heterogeneity
ID PROPENSITY SCORE; HIV
AB Estimation of individual treatment effect in observational data is complicated due to the challenges of confounding and selection bias. A useful inferential framework to address this is the counterfactual (potential outcomes) model, which takes the hypothetical stance of asking what if an individual had received both treatments. Making use of random forests (RF) within the counterfactual framework we estimate individual treatment effects by directly modeling the response. We find that accurate estimation of individual treatment effects is possible even in complex heterogenous settings but that the type of RF approach plays an important role in accuracy. Methods designed to be adaptive to confounding, when used in parallel with out-of-sample estimation, do best. One method found to be especially promising is counterfactual synthetic forests. We illustrate this new methodology by applying it to a large comparative effectiveness trial, Project Aware, to explore the role drug use plays in sexual risk. The analysis reveals important connections between risky behavior, drug usage, and sexual risk. Supplementary material for this article is available online.
C1 [Lu, Min; Feaster, Daniel J.; Ishwaran, Hemant] Univ Miami, Div Biostat, Coral Gables, FL 33146 USA.
   [Sadiq, Saad] Univ Miami, Dept Elect & Comp Engn, Coral Gables, FL 33146 USA.
RP Ishwaran, H (corresponding author), Univ Miami, Div Biostat, Coral Gables, FL 33146 USA.
EM hemant.ishwaran@gmail.com
RI Lu, Min/AAX-1605-2021
OI Lu, Min/0000-0002-1386-1315
FU NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000460] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   GENERAL MEDICAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of General Medical Sciences (NIGMS) [R01GM125072] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Drug Abuse (NIDA)European Commission [UG1DA013720,
   R21DA038641] Funding Source: NIH RePORTER; NCATS NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1 TR000460] Funding Source: Medline; NIDA NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Drug Abuse (NIDA) [R21 DA038641] Funding
   Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of General Medical Sciences (NIGMS) [R01 GM125072] Funding Source:
   Medline
CR Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Breiman L., 1996, OUT OF BAG ESTIMATIO
   Chipman HA, 2010, ANN APPL STAT, V4, P266, DOI 10.1214/09-AOAS285
   Dasgupta A, 2014, BIODATA MIN, V7, DOI 10.1186/1756-0381-7-2
   Foster JC, 2011, STAT MED, V30, P2867, DOI 10.1002/sim.4322
   Ghosh D, 2015, STAT MED, V34, P1645, DOI 10.1002/sim.6433
   Hernandez D, 2016, AIDS BEHAV, V20, P204, DOI 10.1007/s10461-015-1074-2
   Hill JL, 2011, J COMPUT GRAPH STAT, V20, P217, DOI 10.1198/jcgs.2010.08162
   Hirano K, 2003, ECONOMETRICA, V71, P1161, DOI 10.1111/1468-0262.00442
   Ishwaran H., 2016, RANDOM FORESTS SURVI
   Ishwaran H, 2008, ANN APPL STAT, V2, P841, DOI 10.1214/08-AOAS169
   Ishwaran H, 2014, BIODATA MIN, V7, DOI 10.1186/s13040-014-0028-y
   Lamont A, 2018, STAT METHODS MED RES, V27, P142, DOI 10.1177/0962280215623981
   Lee BK, 2010, STAT MED, V29, P337, DOI 10.1002/sim.3782
   Lunceford JK, 2004, STAT MED, V23, P2937, DOI 10.1002/SIM.1903
   Metsch LR, 2013, JAMA-J AM MED ASSOC, V310, P1701, DOI 10.1001/jama.2013.280034
   Neyman J., 1990, STAT SCI, V5, P465, DOI DOI 10.1214/ss/1177012031
   Politis D., 1999, SUBSAMPLING SPRINGER
   Robins JM, 1999, J AM STAT ASSOC, V94, P687, DOI 10.2307/2669978
   ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41
   RUBIN DB, 1974, J EDUC PSYCHOL, V66, P688, DOI 10.1037/h0037350
   Rubin DB, 2007, STAT MED, V26, P20, DOI 10.1002/sim.2739
   Su XG, 2011, J R STAT SOC C-APPL, V60, P457, DOI 10.1111/j.1467-9876.2010.00754.x
   Su XG, 2009, J MACH LEARN RES, V10, P141
   Tang F., 2017, STAT ANAL DATA MININ
   Tricoci P, 2009, JAMA-J AM MED ASSOC, V301, P831, DOI 10.1001/jama.2009.205
   Wager S, 2017, J AM STAT ASSOC, DOI [10.1080/01621459.2017.1319839?journalCode=uasa20, DOI 10.1080/01621459.2017.1319839?JOURNALCODE=UASA20]
NR 27
TC 34
Z9 36
U1 4
U2 14
PU AMER STATISTICAL ASSOC
PI ALEXANDRIA
PA 732 N WASHINGTON ST, ALEXANDRIA, VA 22314-1943 USA
SN 1061-8600
EI 1537-2715
J9 J COMPUT GRAPH STAT
JI J. Comput. Graph. Stat.
PY 2018
VL 27
IS 1
BP 209
EP 219
DI 10.1080/10618600.2017.1356325
PG 11
WC Statistics & Probability
SC Mathematics
GA GD4PE
UT WOS:000430484300018
PM 29706752
OA Green Submitted, Green Accepted
DA 2021-10-30
ER

PT J
AU Horigian, VE
   Anderson, AR
   Szapocznik, J
AF Horigian, Viviana E.
   Anderson, Austen R.
   Szapocznik, Jose
TI Family-Based Treatments for Adolescent Substance Use
SO CHILD AND ADOLESCENT PSYCHIATRIC CLINICS OF NORTH AMERICA
LA English
DT Article
DE Substance use; Family therapy; Externalizing problems; Behavioral
   interventions; Evidence-based treatment
ID ILLICIT DRUG-USE; RANDOMIZED CONTROLLED-TRIAL; CANNABIS USE;
   MULTISYSTEMIC THERAPY; BEHAVIOR THERAPIES; EARLY-INTERVENTION;
   PROTECTIVE FACTORS; CLINICAL-TRIAL; MAIN FINDINGS; FOLLOW-UP
AB Adolescent substance use is a major risk factor for negative outcomes, including substance dependence later in life, criminal behavior, school problems, mental health disorders, injury, and death. This article provides a user-friendly, clinically focused, and pragmatic review of current and evidence-based family treatments, including multisystemic therapy, multidimensional family therapy, functional family therapy, brief strategic family therapy, ecologically based family therapy, family behavior therapy, culturally informed flexible family treatment for adolescents, and strengths oriented family therapy. Outcomes, treatment parameters, adolescent characteristics, and implementation factors are reviewed.
C1 [Horigian, Viviana E.] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, 1120 Northwest 14th St,CRB Room 910, Miami, FL 33136 USA.
   [Anderson, Austen R.] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, 1120 Northwest 14th St,CRB Room 1069A, Miami, FL 33136 USA.
   [Szapocznik, Jose] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, 1120 Northwest 14th St,CRB Room 1020, Miami, FL 33136 USA.
RP Horigian, VE (corresponding author), Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, 1120 Northwest 14th St,CRB Room 910, Miami, FL 33136 USA.
EM vhorigian@med.miami.edu
FU National Institute on Drug AbuseUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute on Drug Abuse (NIDA)European Commission [UG1DA013720];
   Clinical and Translational Science Institute [UL1TR000460]; NATIONAL
   CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000460] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG
   ABUSEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Drug Abuse
   (NIDA)European Commission [UG1DA013720] Funding Source: NIH RePORTER
FX J. Szapocznik is the developer of the BSFT model and has copyrighted the
   intervention. He is also the director for the BSFT training institute.
   This work was supported by grant UG1DA013720 awarded by the National
   Institute on Drug Abuse, and UL1TR000460 awarded by the Clinical and
   Translational Science Institute.
CR AACAP, 2005, J AM ACAD CHILD PSY, V44, P609, DOI 10.1097/01.chi.0000159135.33706.37
   ALEXANDER JF, 1973, J ABNORM PSYCHOL, V81, P219, DOI 10.1037/h0034537
   AZRIN NH, 1994, BEHAV RES THER, V32, P857, DOI 10.1016/0005-7967(94)90166-X
   Azrin NH, 2001, J CHILD ADOLES SUBST, V11, P1, DOI 10.1300/J029v11n01_01
   Baldwin SA, 2012, J MARITAL FAM THER, V38, P281, DOI 10.1111/j.1752-0606.2011.00248.x
   Barnes GM, 2006, J MARRIAGE FAM, V68, P1084, DOI 10.1111/j.1741-3737.2006.00315.x
   Becker SJ, 2008, J CONSULT CLIN PSYCH, V76, P531, DOI 10.1037/0022-006X.76.4.531
   Belendiuk Katherine A, 2014, Curr Treat Options Psychiatry, V1, P175
   Beyers JM, 2004, J ADOLESCENT HEALTH, V35, P3, DOI 10.1016/j.jadohealth.2003.08.015
   Biederman J, 2000, PEDIATRICS, V106, P792, DOI 10.1542/peds.106.4.792
   Brook JS, 1998, J AM ACAD CHILD PSY, V37, P322, DOI 10.1097/00004583-199803000-00018
   Brown T. L., 1999, CHILDRENS SERVICES S, V2, P81, DOI DOI 10.1207/S15326918CS0202_
   Burnette ML, 2012, DEV PSYCHOPATHOL, V24, P857, DOI 10.1017/S0954579412000417
   Calabria B, 2011, ADDICTION, V106, P1406, DOI 10.1111/j.1360-0443.2011.03418.x
   Capaldi DM, 2009, DRUG ALCOHOL DEPEN, V105, P109, DOI 10.1016/j.drugalcdep.2009.06.013
   Caughlin JP, 2004, J SOC PERS RELAT, V21, P125, DOI 10.1177/0265407504039843
   Coatsworth JD, 2001, FAM PROCESS, V40, P313, DOI 10.1111/j.1545-5300.2001.4030100313.x
   Dakof GA, 2015, J FAM PSYCHOL, V29, P232, DOI 10.1037/fam0000053
   Degenhardt L, 2012, LANCET, V379, P55, DOI 10.1016/S0140-6736(11)61138-0
   Degenhardt L, 2010, BRIT J PSYCHIAT, V196, P290, DOI 10.1192/bjp.bp.108.056952
   Dennis M, 2004, J SUBST ABUSE TREAT, V27, P197, DOI 10.1016/j.jsat.2003.09.005
   Donohue B, 2009, BEHAV MODIF, V33, P495, DOI 10.1177/0145445509340019
   Fergusson DM, 2002, ADDICTION, V97, P1123, DOI 10.1046/j.1360-0443.2002.00103.x
   FRIEDMAN AS, 1989, AM J FAM THER, V17, P335, DOI 10.1080/01926188908250780
   Hall J. A., 2008, HDB EVIDENCE BASED T, P491
   Hartnett D, 2016, FAM PROCESS, V55, P287, DOI 10.1111/famp.12195
   HAWKINS JD, 1992, PSYCHOL BULL, V112, P64, DOI 10.1037/0033-2909.112.1.64
   Henderson CE, 2009, AM J DRUG ALCOHOL AB, V35, P220, DOI 10.1080/00952990903005890
   Hendriks V, 2011, DRUG ALCOHOL DEPEN, V119, P64, DOI 10.1016/j.drugalcdep.2011.05.021
   Henggeler S W, 1999, Ment Health Serv Res, V1, P171, DOI 10.1023/A:1022373813261
   Henggeler S. W., 2009, MULTISYSTEMIC THERAP
   Henggeler SW, 2006, J CONSULT CLIN PSYCH, V74, P42, DOI 10.1037/0022-006X.74.1.42
   Henggeler SW, 2002, J AM ACAD CHILD PSY, V41, DOI 10.1097/00004583-200207000-00021
   Hogue A, 2014, J CLIN CHILD ADOLESC, V43, P695, DOI 10.1080/15374416.2014.915550
   Hops H, 2011, AIDS BEHAV, V15, P1664, DOI 10.1007/s10461-011-0019-7
   Horigian VE, 2015, HDB ADOLESCENT DRUG, P249
   Horigian VE, 2015, AM J ADDICTION, V24, P637, DOI 10.1111/ajad.12278
   Horigian VE, 2013, AM J ADDICTION, V22, P329, DOI 10.1111/j.1521-0391.2013.12031.x
   Kaplow JB, 2002, J ABNORM CHILD PSYCH, V30, P199
   KLEIN NC, 1977, J CONSULT CLIN PSYCH, V45, P469, DOI 10.1037/0022-006X.45.3.469
   Liddle H. A., 2005, HDB CLIN FAMILY THER, P128
   Liddle H. A., 2010, EVIDENCE BASED PSYCH, P416
   Liddle HA, 2004, J PSYCHOACTIVE DRUGS, V36, P49, DOI 10.1080/02791072.2004.10399723
   Liddle HA, 2001, AM J DRUG ALCOHOL AB, V27, P651, DOI 10.1081/ADA-100107661
   LIDDLE HA, 2001, CANNABIS YOUTH TREAT, V5
   Liddle HA, 2008, ADDICTION, V103, P1660, DOI 10.1111/j.1360-0443.2008.02274.x
   Liddle HA, 2009, J CONSULT CLIN PSYCH, V77, P12, DOI 10.1037/a0014160
   Macgowan MJ, 2010, CHILD ADOL PSYCH CL, V19, P527, DOI 10.1016/j.chc.2010.03.006
   McCambridge J, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000413
   Miller JW, 2007, PEDIATRICS, V119, P76, DOI 10.1542/peds.2006-1517
   Montgomery C, 2008, DRUG ALCOHOL REV, V27, P640, DOI 10.1080/09595230802392790
   Moore THM, 2007, LANCET, V370, P319, DOI 10.1016/S0140-6736(07)61162-3
   Nickel M, 2006, PSYCHOTHER PSYCHOSOM, V75, P47, DOI 10.1159/000089226
   Nickel MK, 2006, CAN J PSYCHIAT, V51, P355, DOI 10.1177/070674370605100604
   Oshri A, 2011, PSYCHOL ADDICT BEHAV, V25, P634, DOI 10.1037/a0023151
   Pantin H, 2003, HISPANIC J BEHAV SCI, V25, P469, DOI 10.1177/0739986303259355
   PARSONS BV, 1973, J CONSULT CLIN PSYCH, V41, P195, DOI 10.1037/h0035181
   Rigter H, 2013, DRUG ALCOHOL DEPEN, V130, P85, DOI 10.1016/j.drugalcdep.2012.10.013
   Robbins MS, 2011, J CONSULT CLIN PSYCH, V79, P713, DOI 10.1037/a0025477
   Robbins MS, 2011, J CONSULT CLIN PSYCH, V79, P43, DOI 10.1037/a0022146
   Rohde P, 2014, J CONSULT CLIN PSYCH, V82, P342, DOI 10.1037/a0035808
   Rowe C, 2013, J SUBST ABUSE TREAT, V44, P391, DOI 10.1016/j.jsat.2012.08.225
   Rowe CL, 2010, CHILD ADOL PSYCH CL, V19, P563, DOI 10.1016/j.chc.2010.03.008
   Rowland MD, 2008, J CHILD ADOLES SUBST, V17, P11, DOI 10.1080/15470650802071622
   Santisteban DA, 1996, J FAM PSYCHOL, V10, P35, DOI 10.1037/0893-3200.10.1.35
   Santisteban DA, 2003, J FAM PSYCHOL, V17, P121, DOI 10.1037/0893-3200.17.1.121
   Santisteban DA, 2011, J FAM PSYCHOL, V25, P610, DOI 10.1037/a0024016
   Santisteban DA, 2009, FAM PROCESS, V48, P253, DOI 10.1111/j.1545-5300.2009.01280.x
   Schaub MP, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/1471-244X-14-26
   Schinke SP, 2008, J ADOLESCENT HEALTH, V43, P191, DOI 10.1016/j.jadohealth.2007.12.014
   Sexton T, 2010, J FAM PSYCHOL, V24, P339, DOI 10.1037/a0019406
   Sexton TL, 2004, FUNCTIONAL FAMILY TH
   Skeer M, 2009, DRUG ALCOHOL DEPEN, V104, P65, DOI 10.1016/j.drugalcdep.2009.03.017
   Slesnick N, 2005, J ADOLESCENCE, V28, P277, DOI 10.1016/j.adolescence.2005.02.008
   Slesnick N, 2013, J CONSULT CLIN PSYCH, V81, P600, DOI 10.1037/a0033463
   Slesnick N, 2009, J MARITAL FAM THER, V35, P255, DOI 10.1111/j.1752-0606.2009.00121.x
   Smith DC, 2008, SOC WORK, V53, P185, DOI 10.1093/sw/53.2.185
   Smith DC, 2006, AM J ADDICTION, V15, P131, DOI 10.1080/10550490601006253
   Soloski KL, 2016, J MARITAL FAM THER, V42, P76, DOI 10.1111/jmft.12111
   Squeglia LM, 2009, CLIN EEG NEUROSCI, V40, P31, DOI 10.1177/155005940904000110
   SZAPOCZNIK J, 1988, J CONSULT CLIN PSYCH, V56, P552, DOI 10.1037/0022-006X.56.4.552
   SZAPOCZNIK J, 1989, J CONSULT CLIN PSYCH, V57, P571, DOI 10.1037/0022-006X.57.5.571
   Szapocznik J, 2003, NIH PUBLICATION
   Szapocznik J., 1999, DRUG ABUSE ORIGINS I, P331, DOI [10.1037/10341-014, DOI 10.1037/10341-014]
   SZAPOCZNIK J, 1989, BREAKTHROUGHS FAMILY
   Tanner-Smith EE, 2013, J SUBST ABUSE TREAT, V44, P145, DOI 10.1016/j.jsat.2012.05.006
   Valdez A, 2013, RES SOCIAL WORK PRAC, V23, P383, DOI 10.1177/1049731513481389
   van der Stouwe T, 2014, CLIN PSYCHOL REV, V34, P468, DOI 10.1016/j.cpr.2014.06.006
   Vermeulen-Smit E, 2015, CLIN CHILD FAM PSYCH, V18, P218, DOI 10.1007/s10567-015-0185-7
   Waldron HB, 2001, J CONSULT CLIN PSYCH, V69, P802, DOI 10.1037//0022-006X.69.5.802
   Waldron HB, 2008, J CLIN CHILD ADOLESC, V37, P238, DOI 10.1080/15374410701820133
   Zajac K, 2015, CHILD ADOL PSYCH CL, V24, P601, DOI 10.1016/j.chc.2015.02.007
NR 92
TC 9
Z9 9
U1 1
U2 50
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1056-4993
EI 1558-0490
J9 CHILD ADOL PSYCH CL
JI Child Adolesc. Psychiatr. N. Am.
PD OCT
PY 2016
VL 25
IS 4
BP 603
EP +
DI 10.1016/j.chc.2016.06.001
PG 27
WC Psychiatry
SC Psychiatry
GA EB9SU
UT WOS:000387738200004
PM 27613341
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Watts, JM
   Wang, XV
   Swords, RT
   Paietta, E
   Douer, D
   Lugar, SM
   Fernandez, HF
   Rowe, JM
   Lazarus, HM
   Tallman, MS
   Litzow, MR
AF Watts, J. M.
   Wang, X. V.
   Swords, R. T.
   Paietta, E.
   Douer, D.
   Lugar, S. M.
   Fernandez, H. F.
   Rowe, J. M.
   Lazarus, H. M.
   Tallman, M. S.
   Litzow, M. R.
TI Very late relapse of AML after allogeneic hematopoietic cell
   transplantation is often extramedullary
SO BONE MARROW TRANSPLANTATION
LA English
DT Letter
ID ACUTE MYELOID-LEUKEMIA; BONE-MARROW
C1 [Watts, J. M.; Swords, R. T.] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA.
   [Wang, X. V.] Dana Farber Canc Inst, Boston, MA 02115 USA.
   [Wang, X. V.] Harvard Sch Publ Hlth, Boston, MA USA.
   [Paietta, E.] Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA.
   [Douer, D.; Tallman, M. S.] Weill Cornell Med Coll, Mem Sloan Kettering Canc Ctr, Leukemia Serv, New York, NY USA.
   [Lugar, S. M.] Univ Penn, Philadelphia, PA 19104 USA.
   [Fernandez, H. F.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
   [Rowe, J. M.] Shaare Zedek Med Ctr, Jerusalem, Israel.
   [Lazarus, H. M.] Case Western Reserve Univ, Cleveland, OH 44106 USA.
   [Litzow, M. R.] Mayo Clin, Rochester, MN USA.
RP Watts, JM (corresponding author), Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA.
EM jwatts@med.miami.edu
FU NATIONAL CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [U10CA180820, U10CA180791, U10CA180794] Funding Source:
   NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Advancing Translational
   Sciences (NCATS) [KL2TR000461] Funding Source: NIH RePORTER; NCATS NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [KL2 TR000461] Funding Source: Medline;
   NCI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [U10
   CA180794, U10 CA180791, U10 CA180820] Funding Source: Medline
CR Buchner T, 2009, J CLIN ONCOL, V27, P61, DOI 10.1200/JCO.2007.15.4245
   Chakraverty R, 2006, J EXP MED, V203, P2021, DOI 10.1084/jem.20060376
   Clark WB, 2010, HAEMATOL-HEMATOL J, V95, P860, DOI 10.3324/haematol.2010.025890
   Cunningham I, 2006, LEUKEMIA LYMPHOMA, V47, P1754, DOI 10.1080/10428190600632857
   Estey EH, 2000, LEUKEMIA, V14, P476, DOI 10.1038/sj.leu.2401568
   Klco JM, 2014, CANCER CELL, V25, P379, DOI 10.1016/j.ccr.2014.01.031
   Lee KH, 2003, BONE MARROW TRANSPL, V32, P835, DOI 10.1038/sj.bmt.1704223
   Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689
   Reichard KK, 2006, AM J HEMATOL, V81, P178, DOI 10.1002/ajh.20389
   Simpson DR, 1998, BONE MARROW TRANSPL, V22, P259, DOI 10.1038/sj.bmt.1701319
   Tallman MS, 2005, BLOOD, V106, P1154, DOI 10.1182/blood-2005-01-0178
   Verma D, 2010, LEUKEMIA LYMPHOMA, V51, P778, DOI 10.3109/10428191003661852
   Watts JM, 2014, LEUKEMIA RES, V38, P901, DOI 10.1016/j.leukres.2014.05.018
NR 13
TC 3
Z9 3
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
EI 1476-5365
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD JUL
PY 2016
VL 51
IS 7
BP 1013
EP 1015
DI 10.1038/bmt.2016.44
PG 3
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA DQ9OW
UT WOS:000379540200028
PM 26974275
OA Green Accepted, Bronze
DA 2021-10-30
ER

PT J
AU Besser, RR
   Bowles, AC
   Alassaf, A
   Carbonero, D
   Claure, I
   Jones, E
   Reda, J
   Wubker, L
   Batchelor, W
   Ziebarth, N
   Silvera, R
   Khan, A
   Maciel, R
   Saporta, M
   Agarwal, A
AF Besser, Rachel R.
   Bowles, Annie C.
   Alassaf, Ahmad
   Carbonero, Daniel
   Claure, Isabella
   Jones, Ellery
   Reda, Joseph
   Wubker, Laura
   Batchelor, Wyndham
   Ziebarth, Noel
   Silvera, Risset
   Khan, Aisha
   Maciel, Renata
   Saporta, Mario
   Agarwal, Ashutosh
TI Enzymatically crosslinked gelatin-laminin hydrogels for applications in
   neuromuscular tissue engineering
SO BIOMATERIALS SCIENCE
LA English
DT Article
ID ATOMIC-FORCE MICROSCOPY; HYALURONIC-ACID; EXTRACELLULAR-MATRIX;
   FUNCTIONAL MATURATION; MECHANICAL-PROPERTIES; SCHWANN-CELLS; MOUSE
   MODEL; MUSCLE; DIFFERENTIATION; GROWTH
AB We report a water-soluble and non-toxic method to incorporate additional extracellular matrix proteins into gelatin hydrogels, while obviating the use of chemical crosslinkers such as glutaraldehyde. Gelatin hydrogels were fabricated using a range of gelatin concentrations (4%-10%) that corresponded to elastic moduli of approximately 1 kPa-25 kPa, respectively, a substrate stiffness relevant for multiple cell types. Microbial transglutaminase was then used to enzymatically crosslink a layer of laminin on top of gelatin hydrogels, resulting in 2-component gelatin-laminin hydrogels. Human induced pluripotent stem cell derived spinal spheroids readily adhered and rapidly extended axons on GEL-LN hydrogels. Axons displayed a more mature morphology and superior electrophysiological properties on GEL-LN hydrogels compared to the controls. Schwann cells on GEL-LN hydrogels adhered and proliferated normally, displayed a healthy morphology, and maintained the expression of Schwann cell specific markers. Lastly, skeletal muscle cells on GEL-LN hydrogels achieved long-term culture for up to 28 days without delamination, while expressing higher levels of terminal genes including myosin heavy chain, MyoD, MuSK, and M-cadherin suggesting enhanced maturation potential and myotube formation compared to the controls. Future studies will employ the superior culture outcomes of this hybrid substrate for engineering functional neuromuscular junctions and related organ on a chip applications.
C1 [Besser, Rachel R.; Bowles, Annie C.; Alassaf, Ahmad; Carbonero, Daniel; Claure, Isabella; Jones, Ellery; Reda, Joseph; Wubker, Laura; Batchelor, Wyndham; Ziebarth, Noel; Agarwal, Ashutosh] Univ Miami, Dept Biomed Engn, 1251 Mem Dr,MEA 203, Coral Gables, FL 33146 USA.
   [Alassaf, Ahmad] Majmaah Univ, Dept Med Equipment Technol, Al Majmaah 11952, Saudi Arabia.
   [Silvera, Risset; Khan, Aisha] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, 1095 NW 14th Terrace 48, Miami, FL 33136 USA.
   [Khan, Aisha] Univ Miami, Miller Sch Med, Interdisciplinary Stem Cell Inst, 1600 NW 10th Ave 1140, Miami, FL 33136 USA.
   [Maciel, Renata; Saporta, Mario] Univ Miami, Miller Sch Med, Dept Neurol, 1120 NW 14th St,Suite 1310, Miami, FL 33136 USA.
RP Agarwal, A (corresponding author), Univ Miami, Dept Biomed Engn, 1251 Mem Dr,MEA 203, Coral Gables, FL 33146 USA.
EM A.agarwal2@miami.edu
RI Jones, Ellery/AAM-7286-2021
OI Jones, Ellery/0000-0002-5898-6699
FU Wallace H. Coulter Center Translational Research Commercialization
   Grant; NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [1UC4DK104208, 1U01CA233363]; Mentored
   Translational Research Scholars Program Award by Miami CTSI
   [KL2TR002737]; Charcot-Marie-Tooth Association
FX This work was supported by the Wallace H. Coulter Center Translational
   Research Commercialization Grant (AA), the NIH (1UC4DK104208 and
   1U01CA233363 to AA), the Mentored Translational Research Scholars
   Program Award (KL2TR002737) by Miami CTSI (MS), and a
   Charcot-Marie-Tooth Association research grant (MS).
CR Addington CP, 2017, MATRIX BIOL, V60-61, P206, DOI 10.1016/j.matbio.2016.09.007
   Addington CP, 2015, BIOMATERIALS, V72, P11, DOI 10.1016/j.biomaterials.2015.08.041
   Agarwal A, 2013, ADV FUNCT MATER, V23, P3738, DOI 10.1002/adfm.201203319
   Ahearne M, 2005, J R SOC INTERFACE, V2, P455, DOI 10.1098/rsif.2005.0065
   Alarake NZ, 2017, INT J ARTIF ORGANS, V40, P159, DOI 10.5301/ijao.5000553
   Bahrami H, 2016, ARTIF CELL NANOMED B, V44, P1556, DOI 10.3109/21691401.2015.1062390
   Bakkum DJ, 2014, FRONT COMPUT NEUROSC, V7, DOI 10.3389/fncom.2013.00193
   Bakshi A, 2004, J NEUROSURG-SPINE, V1, P322, DOI 10.3171/spi.2004.1.3.0322
   Banerjee A, 2009, BIOMATERIALS, V30, P4695, DOI 10.1016/j.biomaterials.2009.05.050
   Bastidas J, 2017, GLIA, V65, P1278, DOI 10.1002/glia.23161
   Bettadapur A, 2016, SCI REP-UK, V6, DOI 10.1038/srep28855
   Biffi E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083899
   Bosman FT, 2003, J PATHOL, V200, P423, DOI 10.1002/path.1437
   Burkin DJ, 1999, CELL TISSUE RES, V296, P183, DOI 10.1007/s004410051279
   Cameron K, 2015, STEM CELL REP, V5, P1250, DOI 10.1016/j.stemcr.2015.10.016
   Chernousov MA, 2000, HISTOL HISTOPATHOL, V15, P593, DOI 10.14670/HH-15.593
   Choi YS, 2012, BIOMATERIALS, V33, P2482, DOI 10.1016/j.biomaterials.2011.12.004
   Colognato H, 1999, J CELL BIOL, V145, P619, DOI 10.1083/jcb.145.3.619
   Cotterill E, 2016, J NEUROPHYSIOL, V116, P306, DOI 10.1152/jn.00093.2016
   Crescenzi V, 2002, BIOMACROMOLECULES, V3, P1384, DOI 10.1021/bm025657m
   Damodaran G, 2009, J BIOMED MATER RES A, V89A, P1001, DOI 10.1002/jbm.a.32045
   De Colli M, 2012, BIOMED MATER, V7, DOI 10.1088/1748-6041/7/5/055005
   Denes LT, 2019, SKELET MUSCLE, V9, DOI 10.1186/s13395-019-0203-4
   Dias J, 2015, EXP EYE RES, V138, P1, DOI 10.1016/j.exer.2015.06.015
   Dias J, 2013, EXP EYE RES, V116, P58, DOI 10.1016/j.exer.2013.07.028
   Dixon TA, 2018, TISSUE ENG PART C-ME, V24, P346, DOI [10.1089/ten.TEC.2018.0062, 10.1089/ten.tec.2018.0062]
   Doe JA, 2011, J CELL SCI, V124, P2287, DOI 10.1242/jcs.083311
   DONALIES M, 1991, P NATL ACAD SCI USA, V88, P8024, DOI 10.1073/pnas.88.18.8024
   Dowell-Mesfin NM, 2004, J NEURAL ENG, V1, P78, DOI 10.1088/1741-2560/1/2/003
   EFTIMIE R, 1991, P NATL ACAD SCI USA, V88, P1349, DOI 10.1073/pnas.88.4.1349
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Farrukh A, 2017, STEM CELL REP, V9, P1432, DOI 10.1016/j.stemcr.2017.09.002
   Feinberg AW, 2012, BIOMATERIALS, V33, P5732, DOI 10.1016/j.biomaterials.2012.04.043
   Flanagan LA, 2002, NEUROREPORT, V13, P2411, DOI 10.1097/00001756-200212200-00007
   Fleckenstein B, 2004, J BIOL CHEM, V279, P17607, DOI 10.1074/jbc.M310198200
   Francisco AT, 2014, ACTA BIOMATER, V10, P1102, DOI 10.1016/j.actbio.2013.11.013
   Francisco AT, 2013, BIOMATERIALS, V34, P7381, DOI 10.1016/j.biomaterials.2013.06.038
   Gauvin R, 2012, BIOMATERIALS, V33, P3824, DOI 10.1016/j.biomaterials.2012.01.048
   Geissler SA, 2018, J NEURAL ENG, V15, DOI 10.1088/1741-2552/aaa55c
   Georges PC, 2006, BIOPHYS J, V90, P3012, DOI 10.1529/biophysj.105.073114
   Gu Y, 2012, BIOMATERIALS, V33, P6672, DOI 10.1016/j.biomaterials.2012.06.006
   Guilak F, 2009, CELL STEM CELL, V5, P17, DOI 10.1016/j.stem.2009.06.016
   Guvendiren M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1792
   Habibey R, 2015, LAB CHIP, V15, P4578, DOI 10.1039/c5lc01027f
   Hanson JN, 2009, LAB CHIP, V9, P122, DOI 10.1039/b803595d
   Happe CL, 2017, MOL BIOL CELL, V28, P1950, DOI 10.1091/mbc.E17-01-0046
   Hennink WE, 2012, ADV DRUG DELIVER REV, V64, P223, DOI 10.1016/j.addr.2012.09.009
   Hertz H., 1896, MISCELLANEOUS PAPERS, P146
   Hiemstra C, 2007, MACROMOLECULES, V40, P1165, DOI 10.1021/ma062468d
   Hinds S, 2011, BIOMATERIALS, V32, P3575, DOI 10.1016/j.biomaterials.2011.01.062
   Holmberg J, 2013, CELL ADHES MIGR, V7, P111, DOI 10.4161/cam.22618
   Horn MA, 2016, J MOL CELL CARDIOL, V93, P175, DOI 10.1016/j.yjmcc.2015.11.005
   Hou SP, 2005, J NEUROSCI METH, V148, P60, DOI 10.1016/j.jneumeth.2005.04.016
   Hu MF, 2017, SCI REP-UK, V7, DOI 10.1038/srep43934
   Juhas M, 2014, P NATL ACAD SCI USA, V111, P5508, DOI 10.1073/pnas.1402723111
   Kloxin AM, 2010, ADV MATER, V22, P3484, DOI 10.1002/adma.200904179
   Kuo PL, 2012, AM J PATHOL, V181, P2030, DOI 10.1016/j.ajpath.2012.08.045
   Last JA, 2010, INVEST OPHTH VIS SCI, V51, P6083, DOI 10.1167/iovs.10-5470
   Levett PA, 2014, ACTA BIOMATER, V10, P214, DOI 10.1016/j.actbio.2013.10.005
   Li SJ, 2005, P NATL ACAD SCI USA, V102, P1082, DOI 10.1073/pnas.0409103102
   Liang HF, 2004, BIOMACROMOLECULES, V5, P1917, DOI 10.1021/bm049813w
   Long HY, 2017, PEERJ, V5, DOI 10.7717/peerj.3665
   Lukaszczyk J, 2005, MACROMOL BIOSCI, V5, P64, DOI 10.1002/mabi.200400135
   MacGregor-Ramiasa M, 2017, ACTA BIOMATER, V56, P171, DOI 10.1016/j.actbio.2017.02.036
   Maciel R, 2018, EXP NEUROL, V307, P155, DOI 10.1016/j.expneurol.2018.06.008
   Marcinczyk M, 2017, BIOMATERIALS, V141, P233, DOI 10.1016/j.biomaterials.2017.07.003
   Martin A., 2011, INT J ALZHEIMERS DIS, V2011
   Mayer M, 2018, BIOSENS BIOELECTRON, V100, P462, DOI 10.1016/j.bios.2017.09.034
   McCain ML, 2014, BIOMATERIALS, V35, P5462, DOI 10.1016/j.biomaterials.2014.03.052
   Morimoto Y, 2013, BIOMATERIALS, V34, P9413, DOI 10.1016/j.biomaterials.2013.08.062
   Noel E. P. W., 2007, MOL VIS, V13, P504
   Obien MEJ, 2015, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00423
   Paavilainen T, 2018, STEM CELL RES, V27, P151, DOI 10.1016/j.scr.2018.01.018
   Pan LB, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/4/046031
   Pasquale V, 2010, J COMPUT NEUROSCI, V29, P213, DOI 10.1007/s10827-009-0175-1
   Rajnicek AM, 1997, J CELL SCI, V110, P2905
   Rao Shreyas S, 2009, Front Neuroeng, V2, P6, DOI 10.3389/neuro.16.006.2009
   Rooney JE, 2009, P NATL ACAD SCI USA, V106, P7991, DOI 10.1073/pnas.0811599106
   Sahebalzamani M. A, 2017, NANOBIOMED ENG, V9, P191, DOI DOI 10.5101/nbe.v9i3.p191-198
   Saporta MA, 2015, EXP NEUROL, V263, P190, DOI 10.1016/j.expneurol.2014.10.005
   Seidlits SK, 2010, BIOMATERIALS, V31, P3930, DOI 10.1016/j.biomaterials.2010.01.125
   Shim WS, 2007, INT J PHARM, V331, P11, DOI 10.1016/j.ijpharm.2006.09.027
   SOROKIN L, 1990, J CELL BIOL, V111, P1265, DOI 10.1083/jcb.111.3.1265
   Sugiyama JE, 1997, J CELL BIOL, V139, P181, DOI 10.1083/jcb.139.1.181
   Teixeira AI, 2009, BIOMATERIALS, V30, P4567, DOI 10.1016/j.biomaterials.2009.05.013
   Teixeira LSM, 2012, BIOMATERIALS, V33, P1281, DOI 10.1016/j.biomaterials.2011.10.067
   Tsai CC, 2019, J MATER CHEM B, V7, P1064, DOI 10.1039/c8tb02835d
   VOGEL Z, 1983, J NEUROSCI, V3, P1058
   Xing Q, 2014, SCI REP-UK, V4, DOI 10.1038/srep04706
   Yang W, 2018, BIOMATERIALS, V177, P52, DOI 10.1016/j.biomaterials.2018.05.026
   Young JL, 2011, BIOMATERIALS, V32, P1002, DOI 10.1016/j.biomaterials.2010.10.020
   Yu WM, 2009, J CELL SCI, V122, P929, DOI 10.1242/jcs.033928
   Yu XJ, 1999, TISSUE ENG, V5, P291, DOI 10.1089/ten.1999.5.291
NR 93
TC 11
Z9 12
U1 2
U2 32
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2047-4830
EI 2047-4849
J9 BIOMATER SCI-UK
JI Biomater. Sci.
PD JAN 21
PY 2020
VL 8
IS 2
BP 591
EP 606
DI 10.1039/c9bm01430f
PG 16
WC Materials Science, Biomaterials
SC Materials Science
GA KF9HJ
UT WOS:000509549500018
PM 31859298
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Meltzer, RS
   Kooby, DA
   Switchenko, JM
   Datta, J
   Carpizo, DR
   Maithel, SK
   Shah, MM
AF Meltzer, Rebecca S.
   Kooby, David A.
   Switchenko, Jeffrey M.
   Datta, Jashodeep
   Carpizo, Darren R.
   Maithel, Shishir K.
   Shah, Mihir M.
TI Does Major Pancreatic Surgery Have Utility in Nonagenarians with
   Pancreas Cancer?
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Article
ID LONG-TERM OUTCOMES; ELDERLY-PATIENTS; DUCTAL ADENOCARCINOMA; OLDER
   PATIENTS; PANCREATICODUODENECTOMY; CHEMOTHERAPY; OCTOGENARIANS;
   MORTALITY; RESECTION; CHEMORADIOTHERAPY
AB Objective This study aims to define the role of surgery and assess different therapies for nonagenarians with localized, nonmetastatic pancreatic adenocarcinoma (PDAC). Methods The National Cancer Database (NCDB) was queried for patients >= 90 years of age with nonmetastatic, localized PDAC from 2004-2016. Postoperative mortality was assessed at 30 and 90 days in patients receiving pancreatoduodenectomy or total pancreatectomy. Overall survival (OS) was compared between three treatment groups: surgery alone, chemotherapy alone, and chemoradiation (chemoRT) alone. Results Of 380,524 patients with PDAC, 98 patients >= 90 years of age underwent curative-intent resection; 55% were female and 75% had a Charlson-Deyo comorbidity score of 0. A total of 17% received postoperative chemotherapy, 51.1% had poorly differentiated tumors with a median tumor size of 3 cm, 55.1% had positive lymph nodes, and 19.4% had positive resection margins. Postoperative median length of stay was 11 days. Postoperative 30- and 90-day mortality was 10.0% and 18.9%, respectively. Median OS for the surgery alone group was 11.6 months compared with 20.4 months in those receiving adjuvant therapy (p = 0.01). Among nonoperative PDAC patients, median OS in patients receiving chemotherapy only (n = 207) was 7.2 months, while chemoRT only (n = 100) was similar to surgery only (11 versus 11.6 months, p = 0.97). Conclusions Even in well-selected nonagenarians, pancreatoduodenectomy or total pancreatectomy carries a high mortality rate. While adjuvant therapy after resection provides the best survival, it is seldom achieved, and chemoRT alone affords identical survival statistics as surgery alone. These data suggest it is reasonable to consider chemoRT as initial therapy, then reassess candidacy for resection if performance status allows.
C1 [Meltzer, Rebecca S.] Emory Univ, Sch Med, Atlanta, GA 30322 USA.
   [Kooby, David A.; Maithel, Shishir K.; Shah, Mihir M.] Emory Univ, Div Surg Oncol, Dept Surg, Winship Canc Inst, Atlanta, GA 30322 USA.
   [Switchenko, Jeffrey M.] Emory Univ, Rollins Sch Publ Hlth, Dept Biostat & Bioinformat, Atlanta, GA 30322 USA.
   [Datta, Jashodeep] Univ Miami, Miller Sch Med, Div Surg Oncol, Miami, FL 33136 USA.
   [Carpizo, Darren R.] Univ Rochester, Div Surg Oncol, Wilmot Canc Inst, Rochester, NY USA.
RP Shah, MM (corresponding author), Emory Univ, Div Surg Oncol, Dept Surg, Winship Canc Inst, Atlanta, GA 30322 USA.
EM mihir.m.shah@emory.edu
RI Shah, Mihir/AAY-1489-2021
OI Shah, Mihir/0000-0002-4665-5534
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01 CA20080]; KL2 career development
   grant from the Miami Clinical and Translational Science Institute (CTSI)
   under NIH [UL1TR002736]
FX Dr. Carpizo is funded by the grant NIH R01 CA20080; Dr. Datta is funded
   by a KL2 career development grant from the Miami Clinical and
   Translational Science Institute (CTSI) under NIH UL1TR002736.
CR American Cancer Society, 2020, CANC FACTS FIG 2020
   Beltrame V, 2015, J VISC SURG, V152, P279, DOI 10.1016/j.jviscsurg.2015.06.004
   Belyaev O, 2013, WORLD J SURG, V37, P1013, DOI 10.1007/s00268-013-1944-6
   Bonnetain F, 2010, EUR J CANCER, V46, P2753, DOI 10.1016/j.ejca.2010.07.023
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Cheng KKF, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-018101
   Collard RM, 2012, J AM GERIATR SOC, V60, P1487, DOI 10.1111/j.1532-5415.2012.04054.x
   Extermann M, 2015, CANCER-AM CANCER SOC, V121, P2984, DOI 10.1002/cncr.29423
   Gangl O, 2014, WIEN KLIN WOCHENSCHR, V126, P757, DOI 10.1007/s00508-014-0603-8
   Gerstenhaber F, 2013, J AM GERIATR SOC, V61, P1351, DOI 10.1111/jgs.12360
   Hammel P, 2016, JAMA-J AM MED ASSOC, V315, P1844, DOI 10.1001/jama.2016.4324
   Hatzaras I, 2011, J AM COLL SURGEONS, V212, P373, DOI 10.1016/j.jamcollsurg.2010.10.015
   He W, 2011, AM COMMUNITY SURVEY
   Hurria A, 2011, J CLIN ONCOL, V29, P3457, DOI 10.1200/JCO.2011.34.7625
   Janssen QP, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00041
   Kang JS, 2020, ANN SURG TREAT RES, V98, P7, DOI 10.4174/astr.2020.98.1.7
   Katz M, 2019, CURR PROB SURG, V56, P260, DOI 10.1067/j.cpsurg.2019.03.003
   Khalaf N, 2021, CLIN GASTROENTEROL H, V19, P876, DOI 10.1016/j.cgh.2020.02.054
   Khan S, 2010, J GASTROINTEST SURG, V14, P1826, DOI 10.1007/s11605-010-1294-8
   Kim SY, 2018, ANZ J SURG, V88, pE445, DOI 10.1111/ans.14039
   Kim SY, 2017, HPB, V19, P475, DOI 10.1016/j.hpb.2017.01.018
   Kinoshita S, 2015, PANCREATOLOGY, V15, P240, DOI 10.1016/j.pan.2015.03.015
   Li R, 2020, J GERIATR ONCOL, V11, P652, DOI 10.1016/j.jgo.2019.12.006
   Liu Yuan, 2018, F1000Res, V7, P1955, DOI 10.12688/f1000research.16866.1
   Makary MA, 2006, J GASTROINTEST SURG, V10, P347, DOI 10.1016/j.gassur.2005.12.014
   Melis M, 2012, HPB, V14, P583, DOI 10.1111/j.1477-2574.2012.00484.x
   Motoi F, 2020, JPN J CLIN ONCOL, V50, P483, DOI 10.1093/jjco/hyaa018
   Neoptolemos JP, 2004, NEW ENGL J MED, V350, P1200, DOI 10.1056/NEJMoa032295
   Oettle H, 2013, JAMA-J AM MED ASSOC, V310, P1473, DOI 10.1001/jama.2013.279201
   Pedziwiatr M, 2018, SURG ONCOL, V27, P346, DOI 10.1016/j.suronc.2018.05.021
   Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155
   Raimondi S, 2009, NAT REV GASTRO HEPAT, V6, P699, DOI 10.1038/nrgastro.2009.177
   Satoi S, 2020, PANCREAS, V49, P837, DOI 10.1097/MPA.0000000000001579
   Shaib WL, 2020, J GERIATR ONCOL, V11, P660, DOI 10.1016/j.jgo.2019.10.012
   Sho M, 2016, J HEPATO-BIL-PAN SCI, V23, P188, DOI 10.1002/jhbp.320
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Sperti C, 2017, WORLD J GASTRO ONCOL, V9, P30, DOI 10.4251/wjgo.v9.i1.30
   St-Louis E, 2016, EUR J TRAUMA EMERG S, V42, P107, DOI 10.1007/s00068-015-0517-9
   Sudlow A, 2018, ANN ROY COLL SURG, V100, P172, DOI 10.1308/rcsann.2017.0203
   Versteijne E, 2020, J CLIN ONCOL, V38, P1763, DOI 10.1200/JCO.19.02274
   Watters JM, 2002, CAN J SURG, V45, P104
   Wedding U, 2007, EUR J CANCER, V43, P2203, DOI 10.1016/j.ejca.2007.06.001
   Wu WR, 2018, CLIN EPIDEMIOL, V10, P789, DOI 10.2147/CLEP.S160018
NR 43
TC 1
Z9 1
U1 1
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1068-9265
EI 1534-4681
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD APR
PY 2021
VL 28
IS 4
BP 2265
EP 2272
DI 10.1245/s10434-020-09279-8
EA NOV 2020
PG 8
WC Oncology; Surgery
SC Oncology; Surgery
GA QT7LC
UT WOS:000586309300004
PM 33141373
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Watts, JM
   Perez, A
   Pereira, L
   Fan, YS
   Brown, G
   Vega, F
   Petrie, K
   Swords, RT
   Zelent, A
AF Watts, Justin M.
   Perez, Aymee
   Pereira, Lutecia
   Fan, Yao-Shan
   Brown, Geoffrey
   Vega, Francisco
   Petrie, Kevin
   Swords, Ronan T.
   Zelent, Arthur
TI A Case of AML Characterized by a Novel t(4;15)(q31;q22) Translocation
   That Confers a Growth-Stimulatory Response to Retinoid-Based Therapy
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE acute myeloid leukemia; t(4;15)(q31; q22); TMEM154-RASGRF1; ATRA;
   retinoid
ID ACUTE MYELOID-LEUKEMIA; STEM-CELLS; FUTURE; GENE
AB Here we report the case of a 30-year-old woman with relapsed acute myeloid leukemia (AML) who was treated with all-trans retinoic acid (ATRA) as part of investigational therapy (NCT02273102). The patient died from rapid disease progression following eight days of continuous treatment with ATRA. Karyotype analysis and RNA-Seq revealed the presence of a novel t(4; 15)(q31;q22) reciprocal translocation involving the TMEM154 and RASGRF1 genes. Analysis of primary cells from the patient revealed the expression of TMEM154-RASGRF1 mRNA and the resulting fusion protein, but no expression of the reciprocal RASGRF1-TMEM154 fusion. Consistent with the response of the patient to ATRA therapy, we observed a rapid proliferation of t(4; 15) primary cells following ATRA treatment ex vivo. Preliminary characterization of the retinoid response of t(4; 15) AML revealed that in stark contrast to non-t(4; 15) AML, these cells proliferate in response to specific agonists of RAR alpha and RAR gamma. Furthermore, we observed an increase in the levels of nuclear RAR gamma upon ATRA treatment. In summary, the identification of the novel t(4; 15)(q31; q22) reciprocal translocation opens new avenues in the study of retinoid resistance and provides potential for a new biomarker for therapy of AML.
C1 [Watts, Justin M.; Perez, Aymee; Pereira, Lutecia; Swords, Ronan T.; Zelent, Arthur] Univ Miami, Miller Sch Med, Dept Med, Div Hematol Oncol, Miami, FL 33136 USA.
   [Fan, Yao-Shan; Vega, Francisco] Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL 33136 USA.
   [Brown, Geoffrey] Univ Birmingham, Inst Immunol & Immunotherapy, Birmingham B15 2TT, W Midlands, England.
   [Brown, Geoffrey] Univ Birmingham, Inst Clin Sci, Birmingham B15 2TT, W Midlands, England.
   [Petrie, Kevin] Univ Stirling, Fac Nat Sci, Stirling FK9 4LA, Scotland.
RP Zelent, A (corresponding author), Univ Miami, Miller Sch Med, Dept Med, Div Hematol Oncol, Miami, FL 33136 USA.; Petrie, K (corresponding author), Univ Stirling, Fac Nat Sci, Stirling FK9 4LA, Scotland.
EM jxw401@miami.edu; aperez10@med.miami.edu; lpereira@med.miami.edu;
   yfan@med.miami.edu; g.brown@bham.ac.uk; fvega@med.miami.edu;
   kevin.petrie@stir.ac.uk; rswords@med.miami.edu; a.zelent@med.miami.edu
RI Petrie, Kevin/I-7115-2015
OI Petrie, Kevin/0000-0002-9805-9152; Vega, Francisco/0000-0001-5956-452X;
   Zelent, Arthur/0000-0002-7968-9888
FU Miami Clinical and Translational Science Institute [KL2TR000461];
   National Center for Advancing Translational SciencesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS);
   National Institute on Minority Health and Health DisparitiesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute on Minority Health & Health
   Disparities (NIMHD); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [KL2TR000461] Funding Source: NIH
   RePORTER
FX We thank Omar Lopez, Ana Rodrigues, Veronica Gil, Terrence Bradley,
   Fernando Vargas, Sandra Algaze and Jennifer Chapman for helpful advice
   and comments. This study was supported by Grant Number KL2TR000461,
   Miami Clinical and Translational Science Institute, from the National
   Center for Advancing Translational Sciences and the National Institute
   on Minority Health and Health Disparities. Its contents are solely the
   responsibility of the authors and do not necessarily represent the
   official views of the NIH.
CR American Cancer Society, 2017, CANC FACTS FIG 2015
   Bacher U, 2006, BLOOD, V107, P3847, DOI 10.1182/blood-2005-08-3522
   Chen XY, 2016, BIOINFORMATICS, V32, P1220, DOI 10.1093/bioinformatics/btv710
   Coombs CC, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.25
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Fernandez-Medarde A, 2011, BBA-REV CANCER, V1815, P170, DOI 10.1016/j.bbcan.2010.11.001
   Forghieri F, 2016, CLIN CASE REP, V4, P1138, DOI 10.1002/ccr3.723
   Glasow A, 2008, BLOOD, V111, P2374, DOI 10.1182/blood-2007-05-088344
   Gores GJ, 2012, GENE DEV, V26, P305, DOI 10.1101/gad.186189.111
   Klco JM, 2015, JAMA-J AM MED ASSOC, V314, P811, DOI 10.1001/jama.2015.9643
   Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j
   Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689
   Petrie K, 2009, CURR OPIN HEMATOL, V16, P84, DOI 10.1097/MOH.0b013e3283257aee
   Schenk T, 2012, NAT MED, V18, P605, DOI 10.1038/nm.2661
   Scholl C, 2008, SEMIN ONCOL, V35, P336, DOI 10.1053/j.seminoncol.2008.04.004
   Shibata H, 1998, GENOMICS, V49, P30, DOI 10.1006/geno.1998.5218
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   Simandi Z, 2010, FEBS LETT, V584, P3123, DOI 10.1016/j.febslet.2010.05.052
   Takeishi S, 2014, BRIT J CANCER, V111, P1054, DOI 10.1038/bjc.2014.259
NR 19
TC 3
Z9 3
U1 0
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUL
PY 2017
VL 18
IS 7
AR 1492
DI 10.3390/ijms18071492
PG 8
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA FF2SJ
UT WOS:000408746800161
PM 28696354
OA Green Published, Green Submitted, gold, Green Accepted
DA 2021-10-30
ER

PT J
AU Rao, JS
   Zhang, H
   Kobetz, E
   Aldrich, MC
   Conway, D
AF Rao, J. Sunil
   Zhang, Hang
   Kobetz, Erin
   Aldrich, Melinda C.
   Conway, Douglas
TI Predicting DNA methylation from genetic data lacking racial diversity
   using shared classified random effects
SO GENOMICS
LA English
DT Article
DE DNA methylation; Prediction; Mixed effects models; Racial diversity
AB Public genomic repositories are notoriously lacking in racially and ethnically diverse samples. This limits the reaches of exploration and has in fact been one of the driving factors for the initiation of the All of Us project. Our particular focus here is to provide a model-based framework for accurately predicting DNA methylation from genetic data using racially sparse public repository data. Epigenetic alterations are of great interest in cancer research but public repository data is limited in the information it provides. However, genetic data is more plentiful. Our phenotype of interest is cervical cancer in The Cancer Genome Atlas (TCGA) repository. Being able to generate such predictions would nicely complement other work that has generated gene-level predictions of gene expression for normal samples.
   We develop a new prediction approach which uses shared random effects from a nested error mixed effects regression model. The sharing of random effects allows borrowing of strength across racial groups greatly improving predictive accuracy. Additionally, we show how to further borrow strength by combining data from different cancers in TCGA even though the focus of our predictions is DNA methylation in cervical cancer. We compare our methodology against other popular approaches including the elastic net shrinkage estimator and random forest prediction. Results are very encouraging with the shared classified random effects approach uniformly producing more accurate predictions - overall and for each racial group.
C1 [Rao, J. Sunil; Zhang, Hang; Kobetz, Erin] Univ Miami, Coral Gables, FL 33124 USA.
   [Aldrich, Melinda C.; Conway, Douglas] Vanderbilt Univ, Med Ctr, Nashville, TN USA.
RP Rao, JS (corresponding author), Univ Miami, Coral Gables, FL 33124 USA.
EM jrao@miami.edu
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [U54 MD010722, UL1TR000460]
FX JSR, EK, MCA and DC were all partially supported by NIH grant U54
   MD010722. JSR and EK were also partially supported by NIH grant
   UL1TR000460.
CR Barnholtz-Sloan Jill S., 2011, Frontiers in Genetics, V2, P37, DOI 10.3389/fgene.2011.00037
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Du JM, 2015, NAT REV MOL CELL BIO, V16, P519, DOI 10.1038/nrm4043
   Du P, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-587
   Duenas-Gonzalez A, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-38
   Edge SB., 2010, AJCC CANC STAGING HD, V7th
   Gamazon ER, 2015, NAT GENET, V47, P1091, DOI 10.1038/ng.3367
   Gel B, 2017, BIOINFORMATICS, V33, P3088, DOI 10.1093/bioinformatics/btx346
   Genovese C, 2002, J ROY STAT SOC B, V64, P499, DOI 10.1111/1467-9868.00347
   GHOSH M, 1994, STAT SCI, V9, P55, DOI 10.1214/ss/1177010647
   Gini C., 1921, ECON J, V31, P124, DOI 10.2307/2223319
   Jiang J. Jiming, 2018, J AM STAT ASS, P1
   Jiang JM, 2006, TEST-SPAIN, V15, P1, DOI 10.1007/BF02595419
   Jiang JM, 2011, J AM STAT ASSOC, V106, P732, DOI 10.1198/jasa.2011.tm10221
   Jiang RW, 2015, SCI REP-UK, V5, DOI 10.1038/srep08257
   Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653
   Martin Maechler, 2019, CLUSTER CLUSTER ANAL
   McCulloch CE, 2011, STAT SCI, V26, P388, DOI 10.1214/11-STS361
   NIH, ALL US RES PROGRAM
   Schwartz AG, 2009, J THORAC ONCOL, V4, P1195, DOI 10.1097/JTO.0b013e3181b244ef
   Sherbecoe RL, 2004, INT J AUDIOL, V43, P442, DOI 10.1080/14992020400050056
   Siegmund KD, 2011, HUM GENET, V129, P585, DOI 10.1007/s00439-011-0993-x
   Sinha SK, 2009, CAN J STAT, V37, P381, DOI 10.1002/cjs.10029
   Tibshirani R, 2001, J ROY STAT SOC B, V63, P411, DOI 10.1111/1467-9868.00293
   Triche TJ, 2016, BIORXIV
   Wan YW, 2016, BIOINFORMATICS, V32, P952, DOI 10.1093/bioinformatics/btv677
   Weinhold L, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-016-1347-4
   Xu W, 2019, STRUCT CHEM, V30, P1459, DOI 10.1007/s11224-019-01306-z
   Zou H, 2005, J R STAT SOC B, V67, P301, DOI 10.1111/j.1467-9868.2005.00503.x
NR 29
TC 0
Z9 0
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0888-7543
EI 1089-8646
J9 GENOMICS
JI Genomics
PD JAN
PY 2021
VL 113
IS 1
BP 1018
EP 1028
DI 10.1016/j.ygeno.2020.10.036
PN 2
PG 11
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA QB1JH
UT WOS:000613897500002
PM 33161089
DA 2021-10-30
ER

PT J
AU Maziero, D
   Straza, MW
   Ford, JC
   Bovi, JA
   Diwanji, T
   Stoyanova, R
   Paulson, ES
   Mellon, EA
AF Maziero, Danilo
   Straza, Michael W.
   Ford, John C.
   Bovi, Joseph A.
   Diwanji, Tejan
   Stoyanova, Radka
   Paulson, Eric S.
   Mellon, Eric A.
TI MR-Guided Radiotherapy for Brain and Spine Tumors
SO FRONTIERS IN ONCOLOGY
LA English
DT Review
DE glioblastoma; brain and spine tumors; MRI; MRgRT; radiotherapy;
   pseudoprogression
AB MRI is the standard modality to assess anatomy and response to treatment in brain and spine tumors given its superb anatomic soft tissue contrast (e.g., T1 and T2) and numerous additional intrinsic contrast mechanisms that can be used to investigate physiology (e.g., diffusion, perfusion, spectroscopy). As such, hybrid MRI and radiotherapy (RT) devices hold unique promise for Magnetic Resonance guided Radiation Therapy (MRgRT). In the brain, MRgRT provides daily visualizations of evolving tumors that are not seen with cone beam CT guidance and cannot be fully characterized with occasional standalone MRI scans. Significant evolving anatomic changes during radiotherapy can be observed in patients with glioblastoma during the 6-week fractionated MRIgRT course. In this review, a case of rapidly changing symptomatic tumor is demonstrated for possible therapy adaptation. For stereotactic body RT of the spine, MRgRT acquires clear isotropic images of tumor in relation to spinal cord, cerebral spinal fluid, and nearby moving organs at risk such as bowel. This visualization allows for setup reassurance and the possibility of adaptive radiotherapy based on anatomy in difficult cases. A review of the literature for MR relaxometry, diffusion, perfusion, and spectroscopy during RT is also presented. These techniques are known to correlate with physiologic changes in the tumor such as cellularity, necrosis, and metabolism, and serve as early biomarkers of chemotherapy and RT response correlating with patient survival. While physiologic tumor investigations during RT have been limited by the feasibility and cost of obtaining frequent standalone MRIs, MRIgRT systems have enabled daily and widespread physiologic measurements. We demonstrate an example case of a poorly responding tumor on the 0.35 T MRIgRT system with relaxometry and diffusion measured several times per week. Future studies must elucidate which changes in MR-based physiologic metrics and at which timepoints best predict patient outcomes. This will lead to early treatment intensification for tumors identified to have the worst physiologic responses during RT in efforts to improve glioblastoma survival.
C1 [Maziero, Danilo; Ford, John C.; Diwanji, Tejan; Stoyanova, Radka; Mellon, Eric A.] Univ Miami, Miller Sch Med, Dept Radiat Oncol, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA.
   [Straza, Michael W.; Bovi, Joseph A.; Paulson, Eric S.] Med Coll Wisconsin, Dept Radiat Oncol, Milwaukee, WI 53226 USA.
RP Mellon, EA (corresponding author), Univ Miami, Miller Sch Med, Dept Radiat Oncol, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA.
EM eric.mellon@med.miami.edu
FU National Cancer InstituteUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI); National Center For Advancing Translational Sciences of
   the National Institutes of HealthUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [K12CA226330,
   UL1TR002736]
FX The project described was supported by the National Cancer Institute and
   National Center For Advancing Translational Sciences of the National
   Institutes of Health under Award Numbers K12CA226330 and UL1TR002736.
   These funders provided salary support for some of the authors and for
   study coordination, but did not contribute to study design, collection,
   analysis, or interpretation of data.
CR Acharya S, 2016, INT J RADIAT ONCOL, V96, P785, DOI 10.1016/j.ijrobp.2016.08.006
   Aerts HJWL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5006
   Asher D, 2018, CUREUS, V10, DOI 10.7759/cureus.2577
   Atalar B, 2013, NEUROSURGERY, V72, P180, DOI 10.1227/NEU.0b013e31827b99f3
   Barajas RF, 2009, RADIOLOGY, V253, P486, DOI 10.1148/radiol.2532090007
   Batchelor TT, 2013, P NATL ACAD SCI USA, V110, P19059, DOI 10.1073/pnas.1318022110
   BELLIVEAU JW, 1990, MAGNET RESON MED, V14, P538, DOI 10.1002/mrm.1910140311
   Bisdas S, 2011, ACAD RADIOL, V18, P575, DOI 10.1016/j.acra.2011.01.018
   Blystad I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177135
   Booth TC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176528
   Brandes AA, 2008, NEURO-ONCOLOGY, V10, P361, DOI 10.1215/15228517-2008-008
   Brandes AA, 2008, J CLIN ONCOL, V26, P2192, DOI 10.1200/JCO.2007.14.8163
   Breto AL, 2018, CUREUS, V10, DOI 10.7759/cureus.2385
   Bruijnen T, 2020, PHYS MED BIOL, V65, DOI 10.1088/1361-6560/abbb9d
   Chang PD, 2017, AM J ROENTGENOL, V208, P57, DOI 10.2214/AJR.16.16234
   Chaskis C, 2009, SURG NEUROL, V72, P423, DOI 10.1016/j.surneu.2008.09.023
   Chen YS, 2018, MAGN RESON IMAGING, V46, P130, DOI 10.1016/j.mri.2017.10.005
   Chenevert TL, 2019, TOMOGRAPHY, V5, P7, DOI 10.18383/j.tom.2018.00049
   Chin S, 2020, J MED IMAG RADIAT ON, V64, P163, DOI 10.1111/1754-9485.12968
   Choi YJ, 2013, ACTA RADIOL, V54, P448, DOI 10.1177/0284185112474916
   Cordova JS, 2016, NEURO-ONCOLOGY, V18, P1180, DOI 10.1093/neuonc/now036
   Crawford FW, 2009, J NEURO-ONCOL, V91, P337, DOI 10.1007/s11060-008-9719-x
   Croteau D, 2001, NEUROSURGERY, V49, P823, DOI 10.1097/00006123-200110000-00008
   de Koste JRV, 2018, INT J RADIAT ONCOL, V102, P858, DOI 10.1016/j.ijrobp.2018.05.048
   Di Costanzo A, 2006, J EXP CLIN CANC RES, V25, P383
   Di Costanzo A, 2006, NEURORADIOLOGY, V48, P622, DOI 10.1007/s00234-006-0102-3
   El-Bared N, 2019, PRACT RADIAT ONCOL, V9, pE46, DOI 10.1016/j.prro.2018.08.010
   Ellingson BM, 2010, J MAGN RESON IMAGING, V31, P538, DOI 10.1002/jmri.22068
   Elson A, 2015, J NEURO-ONCOL, V122, P549, DOI 10.1007/s11060-015-1743-z
   Fabi A, 2009, ANTICANCER RES, V29, P2607
   Federau C, 2017, CLIN NEURORADIOL, V27, P485, DOI 10.1007/s00062-016-0510-7
   Galban CJ, 2009, NAT MED, V15, P572, DOI 10.1038/nm.1919
   Garcia J, 2017, PHILOS T R SOC A, V375, DOI 10.1098/rsta.2017.0180
   Gurbani S, 2019, TOMOGRAPHY, V5, P184, DOI 10.18383/j.tom.2018.00028
   Hal WA, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0236570
   Hamstra DA, 2005, P NATL ACAD SCI USA, V102, P16759, DOI 10.1073/pnas.0508347102
   Hamstra DA, 2008, J CLIN ONCOL, V26, P3387, DOI 10.1200/JCO.2007.15.2363
   Hamstra DA, 2007, J CLIN ONCOL, V25, P4104, DOI 10.1200/JCO.2007.11.9610
   Hattingen E, 2017, ONCOTARGET, V8, P53542, DOI 10.18632/oncotarget.18612
   Hein PA, 2004, AM J NEURORADIOL, V25, P201
   Henke L, 2018, RADIOTHER ONCOL, V126, P519, DOI 10.1016/j.radonc.2017.11.032
   Herminghaus S, 2002, NMR BIOMED, V15, P385, DOI 10.1002/nbm.793
   Hu LS, 2009, AM J NEURORADIOL, V30, P552, DOI 10.3174/ajnr.A1377
   Jakubovic R, 2014, CLIN ONCOL-UK, V26, P704, DOI 10.1016/j.clon.2014.06.010
   Jones KK., 2020, RES SQUARE, DOI [10.21203/rs.3.rs-42434/v1, DOI 10.21203/RS.3.RS-42434/V1]
   Kupelian P, 2014, SEMIN RADIAT ONCOL, V24, P227, DOI 10.1016/j.semradonc.2014.02.013
   Larsson C, 2020, MAGN RESON IMAGING, V68, P106, DOI 10.1016/j.mri.2020.01.012
   LEBIHAN D, 1986, RADIOLOGY, V161, P401, DOI 10.1148/radiology.161.2.3763909
   Lescher S, 2015, NEURORADIOLOGY, V57, P11, DOI 10.1007/s00234-014-1445-9
   Li J, 2011, INT J RADIAT ONCOL, V81, P623, DOI 10.1016/j.ijrobp.2010.06.012
   Lin HX, 2019, LECT NOTES COMPUT SC, V11905, P58, DOI 10.1007/978-3-030-33843-5_6
   Llorente R, 2020, BRIT J RADIOL, V93, DOI 10.1259/bjr.20190655
   Mangla R, 2010, RADIOLOGY, V256, P575, DOI 10.1148/radiol.10091440
   McGarry SD, 2016, TOMOGRAPHY, V2, P223, DOI 10.18383/j.tom.2016.00250
   Mehranian A, 2020, MAGN RESON MED, V84, P1306, DOI 10.1002/mrm.28205
   Mehta S, 2018, CUREUS, V10, DOI 10.7759/cureus.2346
   Mellon E, 2019, NEURO-ONCOLOGY, V21, P29
   Moffat BA, 2005, P NATL ACAD SCI USA, V102, P5524, DOI 10.1073/pnas.0501532102
   Moffat BA, 2006, NEOPLASIA, V8, P259, DOI 10.1593/neo.05844
   Moller S, 2015, ACTA ONCOL, V54, P1521, DOI 10.3109/0284186X.2015.1063777
   Mori S, 1999, ANAT REC, V257, P102
   Muruganandham M, 2014, INT J RADIAT ONCOL, V90, P181, DOI 10.1016/j.ijrobp.2014.05.014
   Nakamura H, 2013, ACTA RADIOL, V54, P214, DOI 10.1258/ar.2012.120525
   Natarajan SK, 2019, CANCERS, V11, DOI 10.3390/cancers11111628
   Nejad-Davarani SP, 2020, MED PHYS, V47, P4064, DOI 10.1002/mp.14251
   O'Connor JPB, 2011, BRIT J RADIOL, V84, pS112, DOI 10.1259/bjr/55166688
   Ostergaard L, 2005, J MAGN RESON IMAGING, V22, P710, DOI 10.1002/jmri.20460
   Ostrom QT, 2019, NEURO-ONCOLOGY, V21, pV1, DOI 10.1093/neuonc/noz150
   OTT D, 1993, RADIOLOGY, V186, P745, DOI 10.1148/radiology.186.3.8430183
   Paldino MJ, 2009, MAGN RESON IMAGING C, V17, P277, DOI 10.1016/j.mric.2009.01.007
   Park JE, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61178-w
   Parra NA, 2014, INT J RADIAT ONCOL, V90, P376, DOI 10.1016/j.ijrobp.2014.03.049
   Patel P, 2017, NEURO-ONCOLOGY, V19, P118, DOI 10.1093/neuonc/now148
   Paulson ES, 2020, CLIN TRANSL RAD ONCO, V23, P72, DOI 10.1016/j.ctro.2020.05.002
   Petrella JR, 2000, AM J ROENTGENOL, V175, P207, DOI 10.2214/ajr.175.1.1750207
   Pirzkall A, 2001, INT J RADIAT ONCOL, V50, P915, DOI 10.1016/S0360-3016(01)01548-6
   Prost RW, 1997, MAGN RESON MED, V37, P615, DOI 10.1002/mrm.1910370422
   Quon H, 2011, ANTICANCER RES, V31, P3559
   Ramesh K, 2020, TOMOGRAPHY, V6, P93, DOI 10.18383/j.tom.2020.00001
   Ramey SJ, 2018, PRACT RADIAT ONCOL, V8, pE312, DOI 10.1016/j.prro.2018.02.010
   Reddy K, 2013, J MED IMAG RADIAT ON, V57, P349, DOI 10.1111/j.1754-9485.2012.02472.x
   Reimer C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174620
   Rettenmeier C, 2019, MAGN RESON MED, V81, P1685, DOI 10.1002/mrm.27522
   Rudra S, 2019, CANCER MED-US, V8, P2123, DOI 10.1002/cam4.2100
   Salkeld AL, 2018, INT J RADIAT ONCOL, V102, P727, DOI 10.1016/j.ijrobp.2018.06.021
   Saraswathy S, 2009, J NEURO-ONCOL, V91, P69, DOI 10.1007/s11060-008-9685-3
   Schmid RK, 2019, PRACT RADIAT ONCOL, V9, pE549, DOI 10.1016/j.prro.2019.05.014
   Shimizu H, 2000, AM J NEURORADIOL, V21, P659
   Simonetto C, 2019, RADIOTHER ONCOL, V131, P202, DOI 10.1016/j.radonc.2018.07.024
   Simpson G, 2020, MED PHYS, V47, P3682, DOI 10.1002/mp.14200
   Spieler B, 2020, PRACT RADIAT ONCOL, V10, P339, DOI 10.1016/j.prro.2019.10.018
   Stewart J, 2021, INT J RADIAT ONCOL, V109, P736, DOI 10.1016/j.ijrobp.2020.10.002
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Stupp R, 2017, JAMA-J AM MED ASSOC, V318, P2306, DOI 10.1001/jama.2017.18718
   Sugahara T, 1998, AM J ROENTGENOL, V171, P1479, DOI 10.2214/ajr.171.6.9843274
   Sun JH, 2013, NEURAL REGEN RES, V8, P2775, DOI 10.3969/j.issn.1673-5374.2013.29.009
   Taal W, 2008, CANCER, V113, P405, DOI 10.1002/cncr.23562
   Tetar SU, 2019, PHYS IMAG RADIAT ONC, V9, P69, DOI 10.1016/j.phro.2019.02.002
   Cao-Pham TT, 2016, INT J RADIAT ONCOL, V96, P149, DOI 10.1016/j.ijrobp.2016.04.029
   Thomas AA, 2015, J NEURO-ONCOL, V125, P183, DOI 10.1007/s11060-015-1893-z
   Thomas DH, 2018, BRIT J RADIOL, V91, DOI 10.1259/bjr.20170522
   Tsien C, 2010, J CLIN ONCOL, V28, P2293, DOI 10.1200/JCO.2009.25.3971
   Wang S, 2016, AM J NEURORADIOL, V37, P28, DOI 10.3174/ajnr.A4474
   Weiskopf N, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00095
   Welker K, 2015, AM J NEURORADIOL, V36, pE41, DOI 10.3174/ajnr.A4341
   Wen PY, 2010, J CLIN ONCOL, V28, P1963, DOI 10.1200/JCO.2009.26.3541
   WILLIAMS DS, 1992, P NATL ACAD SCI USA, V89, P212, DOI 10.1073/pnas.89.1.212
   Winkel D, 2019, CLIN TRANSL RAD ONCO, V18, P54, DOI 10.1016/j.ctro.2019.04.001
   Winkfield KM, 2009, INT J RADIAT ONCOL, V73, P716, DOI 10.1016/j.ijrobp.2008.05.010
   Yang YL, 2016, MED PHYS, V43, P1369, DOI 10.1118/1.4942381
   Yankeelov TE, 2007, CURR MED IMAGING REV, V3, P91, DOI 10.2174/157340507780619179
   Young RJ, 2011, NEUROLOGY, V76, P1918, DOI 10.1212/WNL.0b013e31821d74e7
   Yun TJ, 2015, RADIOLOGY, V274, P830, DOI 10.1148/radiol.14132632
   Zhou HL, 2017, ONCOTARGET, V8, P37464, DOI 10.18632/oncotarget.16395
NR 114
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD MAR 8
PY 2021
VL 11
AR 626100
DI 10.3389/fonc.2021.626100
PG 11
WC Oncology
SC Oncology
GA QZ9TP
UT WOS:000631062400001
PM 33763361
OA Green Published, gold
DA 2021-10-30
ER

PT J
AU Casanova, F
   Knaul, FM
   Rodriguez, NM
AF Casanova, Felicia
   Knaul, Felicia M.
   Rodriguez, Natalia M.
TI Harvesting Health Knowledge: Breast Cancer Perceptions in the South
   Florida Latinx Farmworker Community
SO QUALITATIVE HEALTH RESEARCH
LA English
DT Article
DE breast cancer; Latinx farmworkers; community health workers;
   community-based participatory research; health disparities; qualitative;
   women&#8217; s health; focus groups; in-depth interviews; Grounded
   Theory; South Florida
AB South Florida agricultural regions, home to Latinx immigrant farmworkers, report higher rates of late-stage breast cancer diagnosis than national, state, and county-level averages. We conducted a community-based qualitative study on the needs, health knowledge gaps, barriers to breast cancer screening, and the role of community health workers (CHWs) in supporting the community's access to early detection services. We conducted three CHW focus groups (FGs) (n = 25) and in-depth interviews (n = 15), two FGs (n = 18) and in-depth interviews (n = 3) with farmworker community members, and informal interviews with cancer clinicians (n = 7). Using a grounded theory approach, five core themes regarding the community's barriers to accessing health care services emerged: (a) lack of information; (b) social and economic barriers; (c) cultural factors; (d) fears and mistrust; and (e) psychosocial concerns. Findings yield implications for community health practice, the potential impact of CHWs, and the production of breast cancer education to improve health equity along with the care continuum.
C1 [Casanova, Felicia] Univ Miami, Dept Sociol, Coral Gables, FL 33124 USA.
   [Knaul, Felicia M.] Univ Miami, Inst Adv Study Amer, Coral Gables, FL 33124 USA.
   [Knaul, Felicia M.] Univ Miami, Leonard M Miller Sch Med, Coral Gables, FL 33124 USA.
   [Knaul, Felicia M.] Univ Miami, Sylvester Comprehens Canc Ctr, Coral Gables, FL 33124 USA.
   [Rodriguez, Natalia M.] Purdue Univ, Dept Publ Hlth, W Lafayette, IN USA.
   [Rodriguez, Natalia M.] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN USA.
RP Rodriguez, NM (corresponding author), Purdue Univ, Dept Publ Hlth, Coll Hlth & Human Sci, 812 West State St, W Lafayette, IN 47907 USA.
EM natalia@purdue.edu
RI Rodriguez, Natalia/AAP-8861-2021
OI Rodriguez, Natalia/0000-0002-2633-4397
FU Florida Breast Cancer Foundation; Miami Clinical and Translational
   Science Institute, from the National Center for Advancing Translational
   Sciences [UL1TR002736]; National Institute on Minority Health and Health
   DisparitiesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Minority
   Health & Health Disparities (NIMHD)
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: This study was
   funded by the Florida Breast Cancer Foundation and by Grant Number
   UL1TR002736, Miami Clinical and Translational Science Institute, from
   the National Center for Advancing Translational Sciences and the
   National Institute on Minority Health and Health Disparities. Its
   contents are solely the responsibility of the authors and do not
   necessarily represent the official views of the NIH.
CR ADAY LA, 1994, ANNU REV PUBL HEALTH, V15, P487, DOI 10.1146/annurev.pu.15.050194.002415
   American Cancer Society, 2018, CANC FACTS FIG HISP
   Angier H, 2013, J HEALTH CARE POOR U, V24, P840, DOI 10.1353/hpu.2013.0086
   Arcury TA, 2003, LANCET, V362, P2021, DOI 10.1016/S0140-6736(03)15027-1
   Arcury TA, 2007, ANNU REV PUBL HEALTH, V28, P345, DOI 10.1146/annurev.publhealth.27.021405.102106
   Asad AL, 2018, SOC SCI MED, V199, P19, DOI 10.1016/j.socscimed.2017.03.010
   Baena-Canada JM, 2014, BREAST, V23, P883, DOI 10.1016/j.breast.2014.09.010
   Bailey ZD, 2017, LANCET, V389, P1453, DOI 10.1016/S0140-6736(17)30569-X
   Banegas M.P., 2017, ONCOLOGY TIMES, V39, P13
   BONACICH E, 1973, AM SOCIOL REV, V38, P583, DOI 10.2307/2094409
   Brown P, 2004, SOCIOL HEALTH ILL, V26, P50, DOI 10.1111/j.1467-9566.2004.00378.x
   Bryant A., 2019, SAGE HDB CURRENT DEV
   Castaneda H, 2015, ANNU REV PUBL HEALTH, V36, P375, DOI 10.1146/annurev-publhealth-032013-182419
   Castaneda H, 2010, SOC SCI MED, V71, P2028, DOI 10.1016/j.socscimed.2010.09.024
   Castaneda H, 2009, SOC SCI MED, V68, P1552, DOI 10.1016/j.socscimed.2009.01.024
   Charmaz K., 2014, CONSTRUCTING GROUNDE, V2nd
   Charmaz Kathy, 2008, HDB CONSTRUCTIONIST, P397, DOI DOI 10.1016/J.DESTUD.2004.08.003
   Chavez LR, 2012, SOC SCI MED, V74, P887, DOI 10.1016/j.socscimed.2011.05.023
   Cockerham W.C., 2015, MED SOCIOLOGY MOVE
   Conrad, 2008, SOCIOLOGY HLTH ILLNE, P239
   Conrad P, 2010, J HEALTH SOC BEHAV, V51, pS67, DOI 10.1177/0022146510383495
   Coughlin SS, 2002, CANCER DETECT PREV, V26, P203, DOI 10.1016/S0361-090X(02)00058-2
   Cuervo I, 2021, QUAL HEALTH RES, V31, P3, DOI 10.1177/1049732320964262
   De Zapien J., 2016, OPEN J SOCIAL SCI, V4, P140
   Dean L, 2014, SOC SCI MED, V104, P148, DOI 10.1016/j.socscimed.2013.11.057
   Donaldson EA, 2012, CANCER-AM CANCER SOC, V118, P4851, DOI 10.1002/cncr.27487
   Dondero M, 2020, SSM-POPUL HLTH, V10, DOI 10.1016/j.ssmph.2020.100559
   Fernandez ME, 2009, AM J PUBLIC HEALTH, V99, P936, DOI 10.2105/AJPH.2008.136713
   Findling MG, 2019, HEALTH SERV RES, V54, P1409, DOI 10.1111/1475-6773.13216
   Fixsen A, 2020, QUAL HEALTH RES, V30, P1101, DOI 10.1177/1049732320911364
   Franco-Marina F, 2015, CANCER EPIDEMIOL, V39, P831, DOI 10.1016/j.canep.2015.10.004
   Freidson E, 1988, PROFESSION MED STUDY
   Gee GC, 2011, DU BOIS REV, V8, P115, DOI 10.1017/S1742058X11000130
   Gelberg L, 2000, HEALTH SERV RES, V34, P1273
   Hansen E, 2003, J HEALTH CARE POOR U, V14, P153, DOI 10.1177/1049208903014002001
   Holmes SM, 2011, MED ANTHROPOL, V30, P425, DOI 10.1080/01459740.2011.576728
   Joseph TD, 2017, J ETHN MIGR STUD, V43, P1965, DOI 10.1080/1369183X.2017.1323446
   Keating NL, 2018, JAMA-J AM MED ASSOC, V319, P1814, DOI 10.1001/jama.2018.3388
   Krieger N., 2011, EPIDEMIOLOGY PEOPLES
   Lehmann u, 2007, COMMUNITY HLTH WORKE
   Link BG, 1998, MILBANK Q, V76, P375, DOI 10.1111/1468-0009.00096
   Love MB, 1997, HEALTH EDUC BEHAV, V24, P510, DOI 10.1177/109019819702400409
   Magana-Valladares L, 2018, J CANCER EDUC, V33, P160, DOI 10.1007/s13187-016-1065-7
   Marrow HB, 2012, SOC SCI MED, V74, P846, DOI 10.1016/j.socscimed.2011.08.001
   McClure ES, 2020, AM J EPIDEMIOL, V189, P1244, DOI 10.1093/aje/kwaa126
   Montealegre JR, 2013, CANCER CAUSE CONTROL, V24, P1985, DOI 10.1007/s10552-013-0274-1
   Murphy J.W., 2018, DIMENSIONS COMMUNITY, P15
   Murphy J.W., 2017, NARRATIVE MED COMMUN
   National Center for Farmworker Health, 2020, PROF MIGR HLTH 2018
   National Comprehensive Cancer Network, 2020, NCCN GUIDELINES VERS
   Nelson A, 2002, J NATL MED ASSOC, V94, P666
   Oluwole SF, 2003, J AM COLL SURGEONS, V196, P180, DOI 10.1016/S1072-7515(02)01765-9
   Palmer RC, 2005, HEALTH EDUC BEHAV, V32, P488, DOI 10.1177/1090198105276213
   Palmer-Wackerly AL, 2020, QUAL HEALTH RES, V30, P423, DOI 10.1177/1049732319855963
   Pattillo, 2010, BLACK BLOCK POLITICS
   Perez LM, 2008, AM J PUBLIC HEALTH, V98, P11, DOI 10.2105/AJPH.2006.100842
   Pinheiro PS, 2020, ADVANCING THE SCIENCE OF CANCER IN LATINOS, P17, DOI 10.1007/978-3-030-29286-7_2
   Portes A., 1985, LATIN JOURNEY CUBAN
   Quesada J, 2011, MED ANTHROPOL, V30, P339, DOI 10.1080/01459740.2011.576725
   Rapport F, 2018, QUAL HEALTH RES, V28, P30, DOI 10.1177/1049732317730569
   Rashidi E, 2021, QUAL HEALTH RES, V31, P349, DOI 10.1177/1049732320968069
   Rodriguez NM, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0240827
   Roland KB, 2017, HEALTH EQUITY, V1, P61, DOI 10.1089/heq.2017.0001
   Schwingel A, 2017, HEALTH PROMOT PRACT, V18, P444, DOI 10.1177/1524839916670576
   Sewell AA, 2015, SOC SCI RES, V54, P1, DOI 10.1016/j.ssresearch.2015.06.020
   Shelton RC, 2016, J HEALTH CARE POOR U, V27, P1794, DOI 10.1353/hpu.2016.0163
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI [10.1001/jamaoto.2014.2530, 10.3322/caac.21254, 10.1136/bmj.g1502, 10.3322/caac.21208]
   Stokols D, 1996, AM J HEALTH PROMOT, V10, P282, DOI 10.4278/0890-1171-10.4.282
   Sylvester Comprehensive Cancer Center, 2020, SCAN CANC DAT
   Thorne S E, 2000, Health Care Women Int, V21, P141
   Tucker CM, 2018, J COMMUN HEALTH, V43, P552, DOI 10.1007/s10900-017-0451-3
   Tuohy B, 2020, SOC FORCES, V98, P1052, DOI 10.1093/sf/soz048
   Viladrich A, 2019, QUAL HEALTH RES, V29, P1447, DOI 10.1177/1049732319830426
   Zambrana RE, 1999, PREV MED, V29, P466, DOI 10.1006/pmed.1999.0566
NR 74
TC 0
Z9 0
U1 4
U2 4
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1049-7323
EI 1552-7557
J9 QUAL HEALTH RES
JI Qual. Health Res.
PD JUL
PY 2021
VL 31
IS 8
BP 1423
EP 1436
AR 10497323211003542
DI 10.1177/10497323211003542
EA APR 2021
PG 14
WC Public, Environmental & Occupational Health; Information Science &
   Library Science; Social Sciences, Interdisciplinary; Social Sciences,
   Biomedical
SC Public, Environmental & Occupational Health; Information Science &
   Library Science; Social Sciences - Other Topics; Biomedical Social
   Sciences
GA TJ2FX
UT WOS:000639899900001
PM 33834911
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Besser, RR
   Bowles, AC
   Alassaf, A
   Carbonero, D
   Maciel, R
   Saporta, M
   Agarwal, A
AF Besser, Rachel R.
   Bowles, Annie C.
   Alassaf, Ahmad
   Carbonero, Daniel
   Maciel, Renata
   Saporta, Mario
   Agarwal, Ashutosh
TI A Chemically Defined Common Medium for Culture of C2C12 Skeletal Muscle
   and Human Induced Pluripotent Stem Cell Derived Spinal Spheroids
SO CELLULAR AND MOLECULAR BIOENGINEERING
LA English
DT Article
DE Skeletal muscle; Organs on chips; Co-culture motor neurons;
   Neuromuscular junction; Chemically defined media
ID CILIARY NEUROTROPHIC FACTOR; NEUROMUSCULAR-JUNCTION FORMATION;
   MOTOR-NEURONS; SATELLITE CELLS; ACTIVATION; GDNF; CNTF; DIFFERENTIATION;
   PROLIFERATION; DORSOMORPHIN
AB Introduction Multicellular platforms and linked multi organ on chip devices are powerful tools for drug discovery, and basic mechanistic studies. Often, a critical constraint is defining a culture medium optimal for all cells present in the system. In this study, we focused on the key cells of the neuromuscular junction i.e., skeletal muscle and motor neurons. Methods Formulation of a chemically defined medium for the co-culture of C2C12 skeletal muscle cells and human induced pluripotent stem cell (hiPSC) derived spinal spheroids (SpS) was optimized. C2C12 cells in 10 experimental media conditions and 2 topographies were evaluated over a 14-day maturation period to determine the ideal medium formulation for skeletal muscle tissue development. Results During early maturation, overexpression of genes for myogenesis and myopathy was observed for several media conditions, corresponding to muscle delamination and death. Together, we identified 3 media formulations that allowed for more controlled differentiation, healthier muscle tissue, and long-term culture duration. This evidence was then used to select media formulations to culture SpS and subsequently assessed axonal growth. As axonal growth in SpS cultures was comparable in all selected media conditions, our data suggest that the neuronal basal medium with no added supplements is the ideal medium formulation for both cell types. Conclusions Optimization using both topographical cues and culture media formulations provides a comprehensive analyses of culture conditions that are vital to future applications forin vitroNMJ models.
C1 [Besser, Rachel R.; Bowles, Annie C.; Alassaf, Ahmad; Carbonero, Daniel; Agarwal, Ashutosh] Univ Miami, DJTMF Biomed Nanotechnol Inst, Dept Biomed Engn, 1251 Mem Dr,MEA 203, Coral Gables, FL 33146 USA.
   [Maciel, Renata; Saporta, Mario] Univ Miami, Miller Sch Med, Dept Neurol, 1120 NW 14th St,Suite 1310, Miami, FL 33136 USA.
RP Agarwal, A (corresponding author), Univ Miami, DJTMF Biomed Nanotechnol Inst, Dept Biomed Engn, 1251 Mem Dr,MEA 203, Coral Gables, FL 33146 USA.; Saporta, M (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol, 1120 NW 14th St,Suite 1310, Miami, FL 33136 USA.
EM mas638@miami.edu; A.agarwal2@miami.edu
FU Wallace H. Coulter Center Translational Research Commercialization
   Grant; NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [1UC4DK104208, 1U01CA233363,
   UG3DK122638]; Mentored Translational Research Scholars Program Award by
   Miami CTSI [KL2TR002737]; Charcot-Marie-Tooth Association research grant
FX This work was supported by the Wallace H. Coulter Center Translational
   Research Commercialization Grant (AA), the NIH (1UC4DK104208,
   1U01CA233363, UG3DK122638 to AA), the Mentored Translational Research
   Scholars Program Award (KL2TR002737) by Miami CTSI (MS), and a
   Charcot-Marie-Tooth Association research grant (MS).
CR Amoroso MW, 2013, J NEUROSCI, V33, P574, DOI 10.1523/JNEUROSCI.0906-12.2013
   Aubry EM, 2009, ENDOCRINOLOGY, V150, P2700, DOI 10.1210/en.2008-1618
   Besser RR, 2020, BIOMATER SCI-UK, V8, P591, DOI 10.1039/c9bm01430f
   Bettadapur A, 2016, SCI REP-UK, V6, DOI 10.1038/srep28855
   Boergermann JH, 2010, INT J BIOCHEM CELL B, V42, P1802, DOI 10.1016/j.biocel.2010.07.018
   Chambers SM, 2009, NAT BIOTECHNOL, V27, P275, DOI 10.1038/nbt.1529
   Chen W, 2012, BIOCHEM BIOPH RES CO, V418, P571, DOI 10.1016/j.bbrc.2012.01.078
   Chen XP, 2005, MOL BIOL CELL, V16, P3140, DOI 10.1091/mbc.E05-03-0218
   Chevrel G, 2006, MUSCLE NERVE, V33, P462, DOI 10.1002/mus.20444
   D'Amico A, 2006, NEUROMUSCULAR DISORD, V16, P548, DOI 10.1016/j.nmd.2006.07.005
   Das M, 2010, BIOMATERIALS, V31, P4880, DOI 10.1016/j.biomaterials.2010.02.055
   DECHIARA TM, 1995, CELL, V83, P313, DOI 10.1016/0092-8674(95)90172-8
   Demestre M, 2015, STEM CELL RES, V15, P328, DOI 10.1016/j.scr.2015.07.005
   DOWNES M, 1994, ENDOCRINOLOGY, V134, P2658, DOI 10.1210/en.134.6.2658
   Duester G, 2008, CELL, V134, P921, DOI 10.1016/j.cell.2008.09.002
   Duffy RM, 2016, ANN BIOMED ENG, V44, P2076, DOI 10.1007/s10439-016-1592-8
   Faravelli I, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt476
   Feng JJ, 2009, NEUROMUSCULAR DISORD, V19, P6, DOI 10.1016/j.nmd.2008.09.005
   Fu X, 2015, J BIOL CHEM, V290, P26445, DOI 10.1074/jbc.M115.665232
   Furutani Y, 2011, J CELL BIOCHEM, V112, P614, DOI 10.1002/jcb.22953
   Guo XF, 2010, TISSUE ENG PART C-ME, V16, P1347, DOI [10.1089/ten.tec.2010.0040, 10.1089/ten.TEC.2010.0040]
   Guo XF, 2011, BIOMATERIALS, V32, P9602, DOI 10.1016/j.biomaterials.2011.09.014
   Happe CL, 2017, MOL BIOL CELL, V28, P1950, DOI 10.1091/mbc.E17-01-0046
   Horbelt D, 2015, J BIOL CHEM, V290, P3390, DOI 10.1074/jbc.M114.604397
   Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65
   Janesick A, 2015, CELL MOL LIFE SCI, V72, P1559, DOI 10.1007/s00018-014-1815-9
   Johnson RW, 2014, BONE, V64, P47, DOI 10.1016/j.bone.2014.03.053
   Kishino A, 1997, EXP NEUROL, V144, P273, DOI 10.1006/exnr.1996.6367
   Kong LL, 2009, J NEUROSCI, V29, P842, DOI 10.1523/JNEUROSCI.4434-08.2009
   Kudo T, 2011, GENES CELLS, V16, P1121, DOI 10.1111/j.1365-2443.2011.01556.x
   Kumar A, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-502
   Kuo PL, 2012, AM J PATHOL, V181, P2030, DOI 10.1016/j.ajpath.2012.08.045
   Lam MT, 2006, BIOMATERIALS, V27, P4340, DOI 10.1016/j.biomaterials.2006.04.012
   Lee YM, 2008, J BIOL CHEM, V283, P33969, DOI 10.1074/jbc.M804469200
   Maciel R, 2020, CLIN PHARMACOL THER, V107, P1231, DOI 10.1002/cpt.1718
   Maciel R, 2018, EXP NEUROL, V307, P155, DOI 10.1016/j.expneurol.2018.06.008
   Maeda S, 2004, EMBO J, V23, P552, DOI 10.1038/sj.emboj.7600067
   MASELLI RA, 1991, NEUROLOGY, V41, P1497, DOI 10.1212/WNL.41.9.1497
   MASELLI RA, 1993, MUSCLE NERVE, V16, P1193, DOI 10.1002/mus.880161109
   MASU Y, 1993, NATURE, V365, P27, DOI 10.1038/365027a0
   Matthews VB, 2009, DIABETOLOGIA, V52, P1409, DOI 10.1007/s00125-009-1364-1
   MITSUMOTO H, 1994, SCIENCE, V265, P1107, DOI 10.1126/science.8066451
   Mousavi K, 2006, J NEUROSCI, V26, P5739, DOI 10.1523/JNEUROSCI.5398-05.2006
   Nagano M, 2003, NEUROSCI RES, V45, P391, DOI 10.1016/S0168-0102(03)00010-5
   Novitch BG, 2003, NEURON, V40, P81, DOI 10.1016/j.neuron.2003.08.006
   OPPENHEIM RW, 1995, NATURE, V373, P344, DOI 10.1038/373344a0
   Patani R, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1216
   Sances S, 2016, NAT NEUROSCI, V19, P542, DOI 10.1038/nn.4273
   Saporta Mario A, 2014, Continuum (Minneap Minn), V20, P1208, DOI 10.1212/01.CON.0000455885.37169.4c
   Saporta MA, 2015, EXP NEUROL, V263, P190, DOI 10.1016/j.expneurol.2014.10.005
   SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0
   Smith LR, 2013, WIRES SYST BIOL MED, V5, P55, DOI 10.1002/wsbm.1197
   Sockanathan S, 1998, CELL, V94, P503, DOI 10.1016/S0092-8674(00)81591-3
   Southam KA, 2013, J NEUROSCI METH, V218, P164, DOI 10.1016/j.jneumeth.2013.06.002
   Sun Y, 2013, ACTA BIOMATER, V9, P7885, DOI 10.1016/j.actbio.2013.04.036
   Teperino R, 2012, CELL, V151, P414, DOI 10.1016/j.cell.2012.09.021
   Umbach JA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036049
   Vianney JM, 2014, BRAIN RES, V1588, P47, DOI 10.1016/j.brainres.2014.09.024
   Wang H, 2017, INT J BIOL SCI, V13, P413, DOI 10.7150/ijbs.17508
   Wang L, 2016, MOL MED REP, V14, P1309, DOI 10.3892/mmr.2016.5346
   Wang RN, 2014, GENES DIS, V1, P87, DOI 10.1016/j.gendis.2014.07.005
   Wang X, 2008, CELL MOL NEUROBIOL, V28, P113, DOI 10.1007/s10571-007-9247-9
   Watt KI, 2010, MUSCLE NERVE, V41, P624, DOI 10.1002/mus.21573
   Wehrwein EA, 2002, MUSCLE NERVE, V26, P206, DOI 10.1002/mus.10179
   WONG V, 1993, EUR J NEUROSCI, V5, P466, DOI 10.1111/j.1460-9568.1993.tb00513.x
   YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0
   YAN Q, 1995, NATURE, V373, P341, DOI 10.1038/373341a0
   Yang LX, 2004, NEUROSCIENCE, V128, P497, DOI 10.1016/j.neuroscience.2004.06.067
   Yoshida M, 2015, STEM CELL REP, V4, P561, DOI 10.1016/j.stemcr.2015.02.010
   Yoshimura K, 2012, DIFFERENTIATION, V83, pS78, DOI 10.1016/j.diff.2011.10.006
   Yui PB, 2008, NAT CHEM BIOL, V4, P33, DOI 10.1038/nchembio.2007.54
   Zammit PS, 2017, SEMIN CELL DEV BIOL, V72, P19, DOI 10.1016/j.semcdb.2017.11.011
   Zhu GH, 2009, DIFFERENTIATION, V78, P195, DOI 10.1016/j.diff.2009.06.001
   Zwick M, 2001, EXP NEUROL, V171, P342, DOI 10.1006/exnr.2001.7753
NR 74
TC 1
Z9 1
U1 1
U2 11
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1865-5025
EI 1865-5033
J9 CELL MOL BIOENG
JI Cell. Mol. Bioeng.
PD DEC
PY 2020
VL 13
IS 6
BP 605
EP 619
DI 10.1007/s12195-020-00624-1
EA JUN 2020
PG 15
WC Cell & Tissue Engineering; Biophysics; Cell Biology; Engineering,
   Biomedical
SC Cell Biology; Biophysics; Engineering
GA PE2XM
UT WOS:000539535500001
PM 33281990
OA Green Published
DA 2021-10-30
ER

PT J
AU Yang, D
   Rundek, T
   Patel, SR
   Cabral, D
   Redline, S
   Testai, FD
   Cai, J
   Wallace, DM
   Zee, PC
   Ramos, AR
AF Yang, Dixon
   Rundek, Tatjana
   Patel, Sanjay R.
   Cabral, Digna
   Redline, Susan
   Testai, Fernando D.
   Cai, Jianwen
   Wallace, Douglas M.
   Zee, Phyllis C.
   Ramos, Alberto R.
TI Cerebral Hemodynamics in Sleep Apnea and Actigraphy-Determined Sleep
   Duration in a Sample of the Hispanic Community Health Study/Study of
   Latinos
SO JOURNAL OF CLINICAL SLEEP MEDICINE
LA English
DT Article
DE cerebral hemodynamics; Hispanic/Latinos; sleep apnea; sleep duration;
   stroke risk
ID TRANSCRANIAL DOPPLER; BLOOD-FLOW; STROKE; ARTERY; RISK; AUTOREGULATION;
   METAANALYSIS; SEVERITY; DISEASE; QUALITY
AB Study Objectives: We sought to evaluate cerebral hemodynamics in obstructive sleep apnea (OSA) and actigraphy-defined short sleep duration using transcranial Doppler ultrasound (TCD) blood flow velocity in a subsample of Hispanics/Latinos without stroke and cardiovascular disease.
   Methods: The sample consisted of consecutive participants at the Miami site of the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) with overnight home sleep testing and 7 days of wrist actigraphy in the Sueno sleep ancillary study. Ninety-five participants had sleep data and TCD determined cerebral hemodynamics. We evaluated the association between OSA (apnea-hypopnea index [AHI] >= 5 events/h) and short sleep duration (< 6.8 hours; sample median) with cerebral blood flow velocities (CBFV) and pulsatility index (PI) for the middle cerebral (MCA) and basilar arteries (BA).
   Results: Median age was 48 years (range 20-64) with 71% females. Twenty-eight percent of the sample had OSA (AHI >= 5 events/h) with median AHI of 10.0 (range 5.0-51.7) events/h. In unadjusted analyses, participants with OSA had lower median CBFV in the BA (30.5 cm/s [interquartile range: 10.2] versus 39.4 cm/s [13.3] P < .05), but not the MCA, whereas short sleepers had higher median vascular resistance in the MCA (PI = 0.92 [0.18] versus 0.86 [0.14] P < .05) and BA (PI = 1.0 [0.17] versus 0.93 [0.24] P < .05). After full adjustment, OSA was associated with decreased CBFV (beta [SE] = -5.1 [2.5] P < .05) in the BA. Short sleep was associated with increased PI (beta [SE] = 0.05 [0.02] P < .05) in the MCA.
   Conclusions: In this sample of Hispanic/Latinos, OSA was associated with decreased daytime blood flow velocity in the BA, whereas actigraphy-defined short sleep duration was associated with increased cerebrovascular pulsatility in the MCA.
C1 [Yang, Dixon; Rundek, Tatjana; Cabral, Digna; Wallace, Douglas M.; Ramos, Alberto R.] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA.
   [Patel, Sanjay R.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.
   [Redline, Susan] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
   [Redline, Susan] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA.
   [Testai, Fernando D.] Univ Illinois, Chicago Med Ctr, Dept Neurol & Rehabil, Chicago, IL USA.
   [Cai, Jianwen] Univ N Carolina, Collaborat Studies Coordinating Ctr, Chapel Hill, NC 27515 USA.
   [Zee, Phyllis C.] Northwestern Univ, Feinberg Sch Med, Dept Neurol, Chicago, IL 60611 USA.
   [Zee, Phyllis C.] Northwestern Univ, Feinberg Sch Med, Ctr Circadian & Sleep Med, Chicago, IL 60611 USA.
RP Ramos, AR (corresponding author), Univ Miami, Miller Sch Med, Neurol, Miami, FL 33136 USA.
RI Wallace, Douglas/AAL-3719-2020; Ramos, Alberto/X-4249-2019
OI Wallace, Douglas/0000-0002-8982-1088; Patel, Sanjay/0000-0002-9142-5172
FU NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [KL2TR000461] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND
   BLOOD INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [K24HL127307] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Aging (NIA) [R21AG056952] Funding Source: NIH RePORTER; NCATS NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [KL2 TR000461] Funding Source: Medline;
   NHLBI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [R01 HL098297, K24 HL127307] Funding Source: Medline;
   NIA NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)
   [R21 AG056952] Funding Source: Medline; NIMHD NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Minority Health & Health Disparities
   (NIMHD) [L60 MD005231] Funding Source: Medline
CR AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769
   American College of Radiology (ACR), 2012, J ULTRAS MED, V31, P1489
   Baguet JP, 2005, CHEST, V128, P3407, DOI 10.1378/chest.128.5.3407
   Cappuccio FP, 2011, EUR HEART J, V32, P1484, DOI 10.1093/eurheartj/ehr007
   Cespedes EM, 2016, AM J EPIDEMIOL, V183, P561, DOI 10.1093/aje/kwv251
   Demirkaya S, 2008, TOHOKU J EXP MED, V214, P145, DOI 10.1620/tjem.214.145
   Drager LF, 2007, HYPERTENSION, V49, pE38, DOI 10.1161/HYPERTENSIONAHA.107.090274
   Dudley KA, 2017, SLEEP, V40
   Dudley KA, 2016, SLEEP MED, V18, P96, DOI 10.1016/j.sleep.2015.01.015
   Durgan DJ, 2012, J AM HEART ASSOC, V1, DOI 10.1161/JAHA.111.000091
   Faraci FM, 2011, AM J PHYSIOL-HEART C, V300, pH1566, DOI 10.1152/ajpheart.01310.2010
   Fernando MS, 2004, J NEUROL SCI, V226, P13, DOI 10.1016/j.jns.2004.09.004
   Fu CH, 2006, NEUROL RES, V28, P871, DOI 10.1179/016164106X110463
   He Q, 2017, SLEEP MED, V32, P66, DOI 10.1016/j.sleep.2016.12.012
   Caballero PEJ, 2014, ACTA NEUROL SCAND, V129, P80, DOI 10.1111/ane.12156
   Kaynak D, 2003, EUR J NEUROL, V10, P487, DOI 10.1046/j.1468-1331.2003.00658.x
   Keage HAD, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-3
   Kim BK, 2011, KOREAN CIRC J, V41, P191, DOI 10.4070/kcj.2011.41.4.191
   Kim BK, 2013, J KOREAN MED SCI, V28, P1334, DOI 10.3346/jkms.2013.28.9.1334
   Kim CW, 2017, DIABETIC MED, V34, P1591, DOI 10.1111/dme.13432
   Leng Y, 2015, NEUROLOGY, V84, P1072, DOI 10.1212/WNL.0000000000001371
   Marshall RS, 2011, STROKE, V42, P221, DOI 10.1161/STROKEAHA.110.595645
   MEYER JS, 1987, BRAIN COGNITION, V6, P266, DOI 10.1016/0278-2626(87)90127-8
   MEYER JS, 1980, ANN NEUROL, V7, P479, DOI 10.1002/ana.410070515
   Mossavar-Rahmani Y, 2017, J SLEEP RES, V26, P739, DOI 10.1111/jsr.12513
   Nasr N, 2009, EUR J NEUROL, V16, P386, DOI 10.1111/j.1468-1331.2008.02505.x
   Patel SR, 2015, SLEEP, V38, P1497, DOI 10.5665/sleep.4998
   Ramos AR, 2018, CHEST, V153, P87, DOI 10.1016/j.chest.2017.09.028
   Ramos AR, 2013, SLEEP BREATH, V17, P723, DOI 10.1007/s11325-012-0748-5
   Rasche K, 2010, EUR J MED RES, V15, P152
   Redline S, 2014, AM J RESP CRIT CARE, V189, P335, DOI 10.1164/rccm.201309-1735OC
   Redline S, 2010, AM J RESP CRIT CARE, V182, P269, DOI 10.1164/rccm.200911-1746OC
   Sabayan B, 2012, AGEING RES REV, V11, P271, DOI 10.1016/j.arr.2011.12.009
   Sacco RL, 1998, AM J EPIDEMIOL, V147, P259, DOI 10.1093/oxfordjournals.aje.a009445
   Silvestrini M, 2002, STROKE, V33, P1782, DOI 10.1161/01.STR.0000019123.47840.2D
   Sorlie PD, 2010, ANN EPIDEMIOL, V20, P629, DOI 10.1016/j.annepidem.2010.03.015
   Sorond FA, 2008, CORTEX, V44, P179, DOI 10.1016/j.cortex.2006.01.003
   Spacek M, 2016, PHYSIOL RES, V65, P71, DOI 10.33549/physiolres.933077
   St-Onge MP, 2016, CIRCULATION, V134, pE367, DOI 10.1161/CIR.0000000000000444
   Urbano F, 2008, J APPL PHYSIOL, V105, P1852, DOI 10.1152/japplphysiol.90900.2008
   Wallace DM, 2012, INT J STROKE, V7, P231, DOI 10.1111/j.1747-4949.2011.00760.x
   Wright Clinton B, 2006, Sci Aging Knowledge Environ, V2006, pdn1, DOI 10.1126/sageke.2006.10.dn1
   Yang DX, 2016, J ULTRAS MED, V35, P1907, DOI 10.7863/ultra.15.10040
NR 43
TC 2
Z9 3
U1 0
U2 2
PU AMER ACAD SLEEP MEDICINE
PI DARIEN
PA 2510 N FRONTAGE RD, DARIEN, IL 60561 USA
SN 1550-9389
EI 1550-9397
J9 J CLIN SLEEP MED
JI J. Clin. Sleep Med.
PY 2019
VL 15
IS 1
BP 15
EP 21
DI 10.5664/jcsm.7560
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA HP1GZ
UT WOS:000461415800004
PM 30621830
OA Green Published, Bronze
DA 2021-10-30
ER

PT J
AU Alkhachroum, A
   Der-Nigoghossian, CA
   Rubinos, C
   Claassen, J
AF Alkhachroum, Ayham
   Der-Nigoghossian, Caroline A.
   Rubinos, Clio
   Claassen, Jan
TI Markers in Status Epilepticus Prognosis
SO JOURNAL OF CLINICAL NEUROPHYSIOLOGY
LA English
DT Review
DE Status epilepticus; Markers; Prognosis; Electroencephalogram;
   Biochemical
ID REFRACTORY STATUS EPILEPTICUS; CONVULSIVE STATUS EPILEPTICUS;
   NEURON-SPECIFIC ENOLASE; GENERALIZED PERIODIC DISCHARGES; INDEPENDENT
   EXTERNAL VALIDATION; CLONIC STATUS EPILEPTICUS; CARDIAC-ARREST;
   INTENSIVE-CARE; 1ST EPISODE; THERAPEUTIC HYPOTHERMIA
AB Status epilepticus (SE) is a neurologic emergency with high morbidity and mortality. The assessment of a patient's prognosis is crucial in making treatment decisions. In this review, we discuss various markers that have been used to prognosticate SE in terms of recurrence, mortality, and functional outcome. These markers include demographic, clinical, electrophysiological, biochemical, and structural data. The heterogeneity of SE etiology and semiology renders development of prognostic markers challenging. Currently, prognostication in SE is limited to a few clinical scores. Future research should integrate clinical, genetic and epigenetic, metabolic, inflammatory, and structural biomarkers into prognostication models to approach "personalized medicine" in prognostication of outcomes after SE.
C1 [Alkhachroum, Ayham; Der-Nigoghossian, Caroline A.; Rubinos, Clio; Claassen, Jan] Columbia Univ, Dept Neurol, New York, NY USA.
   [Alkhachroum, Ayham] Univ Miami, Dept Neurol, Miami, FL USA.
RP Claassen, J (corresponding author), Columbia Univ, Neurol Inst, New York Presbyterian Hosp, 177 Ft Washington Ave,MHB 8 Ctr,Room 300, New York, NY 10032 USA.
EM jc1439@columbia.edu
RI Rubinos, Clio/ABA-9937-2021; Alkhachroum, Ayham/V-6050-2019
OI Rubinos, Clio/0000-0002-1680-2302; Alkhachroum,
   Ayham/0000-0003-0352-5913; Der-Nigoghossian,
   Caroline/0000-0001-5445-9421
FU NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1 TR002736] Funding Source: Medline;
   NINDS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Neurological
   Disorders & Stroke (NINDS) [R03 NS112760, R01 NS106014] Funding Source:
   Medline
CR Alkhachroum AM, 2018, J CLIN NEUROPHYSIOL, V35, P144, DOI 10.1097/WNP.0000000000000441
   Alvarez V, 2012, EPILEPSIA, V53, pe89, DOI 10.1111/j.1528-1167.2012.03451.x
   AMINOFF MJ, 1980, AM J MED, V69, P657, DOI 10.1016/0002-9343(80)90415-5
   Anney RJL, 2014, LANCET NEUROL, V13, P893, DOI 10.1016/S1474-4422(14)70171-1
   Bar-Klein G, 2017, BRAIN, V140, P1692, DOI 10.1093/brain/awx073
   Barnard C, 1999, J CHILD NEUROL, V14, P787, DOI 10.1177/088307389901401204
   Bauer S, 2008, EXP NEUROL, V211, P370, DOI 10.1016/j.expneurol.2008.01.017
   Bauer S, 2009, EPILEPSY RES, V86, P82, DOI 10.1016/j.eplepsyres.2009.05.009
   Bausell R, 2011, NEUROLOGY, V77, P1494, DOI 10.1212/WNL.0b013e318232abc0
   Becker KL, 2010, BRIT J PHARMACOL, V159, P253, DOI 10.1111/j.1476-5381.2009.00433.x
   Belluzzo M, 2017, CLIN NEUROL NEUROSUR, V154, P13, DOI 10.1016/j.clineuro.2016.12.017
   Brindley E, 2019, EPILEPSY BEHAV, V101, DOI 10.1016/j.yebeh.2019.04.025
   Brophy GM, 2012, NEUROCRIT CARE, V17, P3, DOI 10.1007/s12028-012-9695-z
   Brunkhorst FM, 1999, CRIT CARE MED, V27, P2172, DOI 10.1097/00003246-199910000-00016
   CELESIA GG, 1988, ARCH NEUROL-CHICAGO, V45, P781, DOI 10.1001/archneur.1988.00520310099023
   Chen JWY, 2006, LANCET NEUROL, V5, P246, DOI 10.1016/S1474-4422(06)70374-X
   Chin RFM, 2004, EUR J NEUROL, V11, P800, DOI 10.1111/j.1468-1331.2004.00943.x
   Chin RFM, 2006, LANCET, V368, P222, DOI 10.1016/S0140-6736(06)69043-0
   Choi JY, 2019, CLIN NEUROL NEUROSUR, V184, DOI 10.1016/j.clineuro.2019.105454
   Ciurans J, 2018, SEIZURE-EUR J EPILEP, V56, P98, DOI 10.1016/j.seizure.2018.02.007
   Claassen J, 2002, EPILEPSIA, V43, P146, DOI 10.1046/j.1528-1157.2002.28501.x
   Claassen J, 2014, ANN NEUROL, V75, P771, DOI 10.1002/ana.24166
   Coeytaux A, 2000, NEUROLOGY, V55, P693, DOI 10.1212/WNL.55.5.693
   Correale J, 1998, NEUROLOGY, V50, P1388, DOI 10.1212/WNL.50.5.1388
   Crepeau AZ, 2013, NEUROLOGY, V80, P339, DOI 10.1212/WNL.0b013e31827f089d
   Datta S, 2009, CRIT CARE RESUSC, V11, P39
   DEGIORGIO CM, 1995, NEUROLOGY, V45, P1134, DOI 10.1212/WNL.45.6.1134
   DeGiorgio CM, 1996, EPILEPSIA, V37, P606, DOI 10.1111/j.1528-1157.1996.tb00623.x
   DeGiorgio CM, 1999, NEUROLOGY, V52, P746, DOI 10.1212/WNL.52.4.746
   DeLorenzo RJ, 1996, NEUROLOGY, V46, P1029, DOI 10.1212/WNL.46.4.1029
   Devinsky O, 2013, TRENDS NEUROSCI, V36, P174, DOI 10.1016/j.tins.2012.11.008
   Dham BS, 2014, NEUROCRIT CARE, V20, P476, DOI 10.1007/s12028-013-9935-x
   Diamond ML, 2014, EPILEPSIA, V55, P1109, DOI 10.1111/epi.12628
   Drislane FW, 2009, EPILEPSIA, V50, P1566, DOI 10.1111/j.1528-1167.2008.01993.x
   English WA, 2009, ANAESTHESIA, V64, P908, DOI 10.1111/j.1365-2044.2009.05939.x
   Fabene PF, 2008, NAT MED, V14, P1377, DOI 10.1038/nm.1878
   Fernandez-Torre JL, 2012, EPILEPTIC DISORD, V14, P41, DOI 10.1684/epd.2012.0488
   Foreman B, 2016, CLIN NEUROPHYSIOL, V127, P1073, DOI 10.1016/j.clinph.2015.07.018
   Foreman B, 2012, NEUROLOGY, V79, P1951, DOI 10.1212/WNL.0b013e3182735cd7
   Fugate JE, 2010, ANN NEUROL, V68, P907, DOI 10.1002/ana.22133
   Fukuda M, 2008, BRAIN DEV-JPN, V30, P131, DOI 10.1016/j.braindev.2007.07.005
   Gallentine WB, 2017, EPILEPSIA, V58, P1102, DOI 10.1111/epi.13750
   Gao Q, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1221-9
   Giovannini G, 2018, EPILEPSIA, V59, P120, DOI 10.1111/epi.14493
   Giovannini G, 2017, SEIZURE-EUR J EPILEP, V46, P31, DOI 10.1016/j.seizure.2017.01.004
   Giovannini G, 2015, EPILEPSY BEHAV, V49, P141, DOI 10.1016/j.yebeh.2015.05.022
   Glaser CA, 2008, NEUROCRIT CARE, V9, P74, DOI 10.1007/s12028-007-9042-y
   Gonzalez-Cuevas M, 2016, EUR J NEUROL, V23, P1534, DOI 10.1111/ene.13073
   Govoni V, 2008, EUR NEUROL, V59, P120, DOI 10.1159/000111873
   Henshall DC, 2018, EPILEPSIA, V59, P82, DOI 10.1111/epi.14502
   Hesdorffer DC, 2007, NEUROLOGY, V69, P73, DOI 10.1212/01.wnl.0000265056.31752.ff
   Hesdorffer DC, 1998, NEUROLOGY, V50, P735, DOI 10.1212/WNL.50.3.735
   Holtkamp M, 2005, ARCH NEUROL-CHICAGO, V62, P1428, DOI 10.1001/archneur.62.9.1428
   Holtkamp M, 2005, J NEUROL NEUROSUR PS, V76, P534, DOI 10.1136/jnnp.2004.041947
   Hui ACF, 2005, EUR NEUROL, V54, P10, DOI 10.1159/000086755
   Hussain N, 2007, SEIZURE-EUR J EPILEP, V16, P305, DOI 10.1016/j.seizure.2007.01.007
   Ishikawa N, 2014, NEUROPEDIATRICS, V45, P36, DOI 10.1055/s-0033-1357479
   Jaitly R, 1997, J CLIN NEUROPHYSIOL, V14, P326, DOI 10.1097/00004691-199707000-00005
   Jallon P, 1999, LANCET, V353, P1496, DOI 10.1016/S0140-6736(99)00583-8
   Janigro D, 2012, EPILEPSIA, V53, P26, DOI 10.1111/j.1528-1167.2012.03472.x
   Jayalakshmi S, 2014, EPILEPSY RES, V108, P1609, DOI 10.1016/j.eplepsyres.2014.08.010
   JOYCE CD, 1990, SURGERY, V108, P1097
   Kalita J, 2006, Electromyogr Clin Neurophysiol, V46, P139
   Kang BS, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1190-z
   Kilbride RD, 2013, NEUROCRIT CARE, V18, P374, DOI 10.1007/s12028-013-9823-4
   Knake S, 2001, EPILEPSIA, V42, P714, DOI 10.1046/j.1528-1157.2001.01101.x
   Knake S, 2006, EPILEPSIA, V47, P2020, DOI 10.1111/j.1528-1167.2006.00845.x
   Koubeissi M, 2007, NEUROLOGY, V69, P886, DOI 10.1212/01.wnl.0000269791.96189.70
   Legriel S, 2008, INTENS CARE MED, V34, P476, DOI 10.1007/s00134-007-0915-5
   Legriel S, 2013, RESUSCITATION, V84, P343, DOI 10.1016/j.resuscitation.2012.11.001
   Legriel S, 2010, CRIT CARE MED, V38, P2295, DOI 10.1097/CCM.0b013e3181f859a6
   Leitinger M, 2015, EPILEPSY BEHAV, V49, P126, DOI 10.1016/j.yebeh.2015.04.066
   Leitinger M, 2015, NEUROCRIT CARE, V22, P273, DOI 10.1007/s12028-014-0080-y
   Leitinger M, 2019, EPILEPSIA, V60, P53, DOI 10.1111/epi.14607
   Li G, 2011, SEIZURE-EUR J EPILEP, V20, P249, DOI 10.1016/j.seizure.2010.12.005
   Li YH, 2014, SEIZURE-EUR J EPILEP, V23, P722, DOI 10.1016/j.seizure.2014.05.014
   Logroscino G, 2005, EPILEPSIA, V46, P46, DOI 10.1111/j.1528-1167.2005.00409.x
   Logroscino G, 2002, NEUROLOGY, V58, P537, DOI 10.1212/WNL.58.4.537
   Logroscino G, 1997, EPILEPSIA, V38, P1344, DOI 10.1111/j.1528-1157.1997.tb00073.x
   Logroscino G, 2001, EPILEPSIA, V42, P1031, DOI 10.1046/j.1528-1157.2001.0420081031.x
   Logroscino G, 2008, ARCH NEUROL-CHICAGO, V65, P221, DOI 10.1001/archneurol.2007.43
   Madzar D, 2016, J NEUROL, V263, P485, DOI 10.1007/s00415-015-7992-0
   Maegaki Y, 2005, NEUROPEDIATRICS, V36, P186, DOI 10.1055/s-2005-865611
   Marchi NA, 2015, CRIT CARE MED, V43, P1003, DOI 10.1097/CCM.0000000000000881
   Mendiratta P, 2019, GERIATRICS-BASEL, V4, DOI 10.3390/geriatrics4030045
   Monti G, 2015, EPILEPSY BEHAV, V49, P150, DOI 10.1016/j.yebeh.2015.04.030
   Morris HR, 1998, J NEUROL NEUROSUR PS, V64, P267, DOI 10.1136/jnnp.64.2.267
   Mortberg E, 2011, RESUSCITATION, V82, P26, DOI 10.1016/j.resuscitation.2010.10.011
   Murgia F, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00459
   Nei M, 1999, EPILEPSIA, V40, P157, DOI 10.1111/j.1528-1157.1999.tb02069.x
   Neligan A, 2011, EPILEPSY RES, V93, P1, DOI 10.1016/j.eplepsyres.2010.09.003
   Neligan A, 2010, ARCH NEUROL-CHICAGO, V67, P931, DOI 10.1001/archneurol.2010.169
   Oksanen T, 2009, RESUSCITATION, V80, P165, DOI 10.1016/j.resuscitation.2008.08.017
   PACIFICI R, 1995, EPILEPSIA, V36, P384, DOI 10.1111/j.1528-1157.1995.tb01013.x
   Peltola J, 2002, SEIZURE-EUR J EPILEP, V11, P44, DOI 10.1053/seiz.2001.0575
   Pitkanen A, 2002, LANCET NEUROL, V1, P173, DOI 10.1016/S1474-4422(02)00073-X
   Pitkanen A, 2016, LANCET NEUROL, V15, P843, DOI 10.1016/S1474-4422(16)00112-5
   RABINOWICZ AL, 1995, EPILEPSIA, V36, P475, DOI 10.1111/j.1528-1157.1995.tb00489.x
   Reisinger J, 2007, EUR HEART J, V28, P52, DOI 10.1093/eurheartj/ehl316
   Rosen H, 2001, RESUSCITATION, V49, P183, DOI 10.1016/S0300-9572(00)00348-8
   Rossetti AO, 2007, NEUROLOGY, V69, P255, DOI 10.1212/01.wnl.0000265819.36639.e0
   Rossetti AO, 2012, NEUROLOGY, V78, P796, DOI 10.1212/WNL.0b013e318249f6bb
   Rossetti AO, 2008, J NEUROL, V255, P1561, DOI 10.1007/s00415-008-0989-1
   Rossetti AO, 2006, J NEUROL NEUROSUR PS, V77, P611, DOI 10.1136/jnnp.2005.080887
   ROYDS JA, 1981, J NEUROL NEUROSUR PS, V44, P1129, DOI 10.1136/jnnp.44.12.1129
   Rubenstein R, 2017, JAMA NEUROL, V74, P1063, DOI 10.1001/jamaneurol.2017.0655
   Rudin D, 2011, EPILEPSY RES, V96, P140, DOI 10.1016/j.eplepsyres.2011.05.018
   Rundgren M, 2010, CRIT CARE MED, V38, P1838, DOI 10.1097/CCM.0b013e3181eaa1e7
   Sagduyu A, 1998, J NEUROL, V245, P640, DOI 10.1007/s004150050260
   Salmenpera T, 2000, EPILEPSY RES, V40, P155, DOI 10.1016/S0920-1211(00)00121-2
   Samaniego EA, 2011, NEUROCRIT CARE, V15, P113, DOI 10.1007/s12028-010-9412-8
   Sandroni C, 2013, RESUSCITATION, V84, P1324, DOI 10.1016/j.resuscitation.2013.06.020
   Sculier C, 2018, EPILEPSIA, V59, P155, DOI 10.1111/epi.14515
   Shneker BF, 2003, NEUROLOGY, V61, P1066, DOI 10.1212/01.WNL.0000082653.40257.0B
   Steffen IG, 2010, CRIT CARE, V14, DOI 10.1186/cc8975
   Storm C, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-6
   Sutter R, 2015, EUR J NEUROL, V22, P79, DOI 10.1111/ene.12531
   Sutter R, 2019, EPILEPSIA, V60, P42, DOI 10.1111/epi.14603
   Sutter R, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1072-9
   Sutter R, 2013, CRIT CARE MED, V41, pE475, DOI 10.1097/CCM.0b013e31829eca06
   Sutter R, 2013, EPILEPSIA, V54, P23, DOI 10.1111/epi.12269
   Sutter R, 2013, NAT REV NEUROL, V9, P525, DOI 10.1038/nrneurol.2013.154
   Sutter R, 2013, CRIT CARE MED, V41, P1526, DOI 10.1097/CCM.0b013e318287f2ac
   Sutter R, 2013, EPILEPSIA, V54, P502, DOI 10.1111/epi.12064
   Sutter R, 2011, CRIT CARE, V15, DOI 10.1186/cc10555
   Temkin NR, 2009, EPILEPSIA, V50, P10, DOI 10.1111/j.1528-1167.2008.02005.x
   Terrone G, 2019, EPILEPSY BEHAV, V101, DOI 10.1016/j.yebeh.2019.04.028
   Thomke F, 2005, BMC NEUROL, V5, DOI 10.1186/1471-2377-5-14
   Tiainen M, 2003, STROKE, V34, P2881, DOI 10.1161/01.STR.0000103320.90706.35
   Tian F, 2013, EPILEPSY RES, V105, P174, DOI 10.1016/j.eplepsyres.2013.02.007
   TOWNE AR, 1994, EPILEPSIA, V35, P27, DOI 10.1111/j.1528-1157.1994.tb02908.x
   Trinka E, 2015, EPILEPSIA, V56, P1515, DOI 10.1111/epi.13121
   Vezzani A, 2015, NEUROPHARMACOLOGY, V96, P70, DOI 10.1016/j.neuropharm.2014.10.027
   Vezzani A, 2011, BIOMARK MED, V5, P607, DOI [10.2217/BMM.11.61, 10.2217/bmm.11.61]
   Vezzani A, 2011, BRAIN BEHAV IMMUN, V25, P1281, DOI 10.1016/j.bbi.2011.03.018
   Vignatelli L, 2005, EUR J NEUROL, V12, P897, DOI 10.1111/j.1468-1331.2005.01073.x
   Vignatelli L, 2003, EPILEPSIA, V44, P964, DOI 10.1046/j.1528-1157.2003.63702.x
   WASTERLAIN CG, 1993, EPILEPSIA, V34, pS37, DOI 10.1111/j.1528-1157.1993.tb05905.x
   Waterhouse EJ, 1998, EPILEPSY RES, V29, P175, DOI 10.1016/S0920-1211(97)00071-5
   Waterhouse EJ, 1999, EPILEPSIA, V40, P752, DOI 10.1111/j.1528-1157.1999.tb00774.x
   WIJDICKS EFM, 1994, LANCET, V343, P1642, DOI 10.1016/S0140-6736(94)93100-3
   Wu YW, 2002, NEUROLOGY, V58, P1070, DOI 10.1212/WNL.58.7.1070
   Young GB, 2005, NEUROCRIT CARE, V2, P159, DOI 10.1385/NCC:2:2:159
   Zandbergen EGJ, 2006, NEUROLOGY, V66, P62, DOI 10.1212/01.wnl.0000191308.22233.88
   Zoons E, 2008, NEUROLOGY, V70, P2109, DOI 10.1212/01.wnl.0000288178.91614.5d
NR 145
TC 2
Z9 2
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0736-0258
EI 1537-1603
J9 J CLIN NEUROPHYSIOL
JI J. Clin. Neurophysiol.
PD SEP
PY 2020
VL 37
IS 5
BP 422
EP 428
DI 10.1097/WNP.0000000000000761
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA NQ8OB
UT WOS:000571126200009
PM 32890064
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Vu, DM
   Stoler, J
   Rothman, AL
   Chang, TC
AF Vu, Daniel M.
   Stoler, Justin
   Rothman, Adam L.
   Chang, Ta Chen
TI A Service Coverage Analysis of Primary Congenital Glaucoma Care Across
   the United
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID HEALTH-PROFESSIONAL SHORTAGE; FOLLOW-UP; EYE CARE; RETINOPATHY;
   OUTCOMES; STATES; INFANTILE; ADHERENCE; ACCESS; TIME
AB PURPOSE: To assess the number of infants at risk of delayed primary congenital glaucoma (PCG) evaluation due to long travel times to specialists.
   DESIGN: Cross-sectional geospatial service coverage analysis.
   METHODS: All American Glaucoma Society (AGS) and American Association for Pediatric Ophthalmology and Strabismus (AAPOS) provider locations were geocoded using each organization's member directory. Sixty-minute drive time regions to providers were generated using ArcGIS Pro (Esri). The geographic intersection of AGS and AAPOS service areas was computed because patients typically require visits to both types of specialists. American Community Survey data were then overlaid to estimate the number of infants within and beyond the AGS/AAPOS service areas.
   RESULTS: One thousand twenty-nine AGS and 1,040 AAPOS provider locations were geocoded. The analysis yielded 944,047 infants age 0-1 year (23.6%) who live beyond the AGS/AAPOS service areas. Therefore, approximately 14-94 new PCG cases/year may be at risk of delayed diagnosis as a result of living in a potential service desert. Compared with children living within the AGS/AAPOS service areas, children aged <6 years in these potential service deserts were more likely to live in households earning below the US federal poverty level, lack health insurance, and live in a single-parent home. These communities are disproportionately likely to experience other rural health disparities and are more prevalent across the Great Plains.
   CONCLUSION: Service coverage analysis is a useful tool for identifying underserved regions for PCG referrals and evaluation. These data may assist in targeting screening programs in low access areas for pediatric glaucoma care.
   (Am J Ophthalmol 2021;224:112-119. (c) 2020 Elsevier Inc. All rights reserved.)
C1 [Vu, Daniel M.; Rothman, Adam L.; Chang, Ta Chen] Univ Miami Hlth Syst, Bascom Palmer Eye Inst, Miami, FL USA.
   [Stoler, Justin] Univ Miami, Dept Geog & Reg Studies, Coral Gables, FL 33124 USA.
   [Stoler, Justin] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA.
RP Vu, DM (corresponding author), Massachusetts Eye & Ear, 243 Charles St, Boston, MA 02114 USA.
EM daniel_vu@meei.harvard.edu
RI Stoler, Justin/AAY-8224-2021
OI Stoler, Justin/0000-0001-8435-7012; Vu, Daniel/0000-0003-0592-2648;
   Chang, Ta Chen/0000-0003-4827-5014; Rothman, Adam/0000-0002-9189-6548
FU NIH CENTER CORE GRANTUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [P30EY014801];
   RESEARCH TO PREvent BlindnessResearch to Prevent Blindness (RPB);
   University of Miami Institute for Advanced Study of the Americas 2019
   Pilot Grant; Miami Clinical and Translational Science Institute, from
   the National Center for Advancing Translational Sciences; National
   Institute on Minority Health and Health DisparitiesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Minority Health & Health Disparities
   (NIMHD) [UL1TR002736]
FX THIS STUDY WAS SUPPORTED IN PART BY THE NIH CENTER CORE GRANT
   (P30EY014801), RESEARCH TO PREvent Blindness Unrestricted Grant, the
   University of Miami Institute for Advanced Study of the Americas 2019
   Pilot Grant (T.C.C.), and by the Miami Clinical and Translational
   Science Institute, from the National Center for Advancing Translational
   Sciences and the National Institute on Minority Health and Health
   Disparities (T.C.C.; grant UL1TR002736).
CR Alanazi FF, 2013, AM J OPHTHALMOL, V155, P882, DOI 10.1016/j.ajo.2012.12.006
   Aponte EP, 2010, ARCH OPHTHALMOL-CHIC, V128, P478, DOI 10.1001/archophthalmol.2010.41
   Bermejo E, 1998, AM J MED GENET, V75, P497, DOI 10.1002/(SICI)1096-8628(19980217)75:5<497::AID-AJMG8>3.3.CO;2-S
   Bureau of Health Workforce, 2016, SHORT DES SCOR CRIT
   Chiang MF, 2007, ARCH OPHTHALMOL-CHIC, V125, P1531, DOI 10.1001/archopht.125.11.1531
   Daniel MC, 2019, J GLAUCOMA, V28, P878, DOI 10.1097/IJG.0000000000001336
   Fathy C, 2016, SEMIN OPHTHALMOL, V31, P364, DOI 10.3109/08820538.2016.1154170
   Fierson WM, 2015, PEDIATRICS, V135, pE238, DOI 10.1542/peds.2014-0978
   Gencik A, 1989, Dev Ophthalmol, V16, P76
   Gilbert C, 2003, EPIDEMIOLOGY EYE DIS
   Hoguet A, 2016, INDIAN J OPHTHALMOL, V64, P118, DOI 10.4103/0301-4738.179716
   Jayaram H, 2015, OPHTHALMOLOGY, V122, P2216, DOI 10.1016/j.ophtha.2015.07.028
   Johnson K, 2012, CARSEY SCH PUBLIC PO
   Johnson TJ, 2020, PEDIATRICS, V146, DOI 10.1542/peds.2020-003657
   Kantipuly A, 2019, AM J OPHTHALMOL, V205, P106, DOI 10.1016/j.ajo.2019.05.003
   Khitri MR, 2012, J AAPOS, V16, P376, DOI 10.1016/j.jaapos.2012.05.007
   Knapp KK, 2000, J PUBLIC HEALTH DENT, V60, P43, DOI 10.1111/j.1752-7325.2000.tb03291.x
   Lee CS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182598
   Lee CS, 2016, OPHTHALMOLOGY, V123, P2456, DOI 10.1016/j.ophtha.2016.08.015
   Lichter DT, 2012, RURAL SOCIOL, V77, P3, DOI 10.1111/j.1549-0831.2012.00070.x
   Liu D, 2016, J GLAUCOMA, V25, P790, DOI 10.1097/IJG.0000000000000412
   Liu J, 2007, J HEALTH CARE POOR U, V18, P590, DOI 10.1353/hpu.2007.0062
   Maa AY, 2017, RURAL REMOTE HEALTH, V17, DOI 10.22605/rrh4045
   Marmot M, 2008, LANCET, V372, P1661, DOI 10.1016/S0140-6736(08)61690-6
   Miller S J, 1966, Trans Ophthalmol Soc U K, V86, P425
   Neustein RF, 2017, AM J OPHTHALMOL, V183, P17, DOI 10.1016/j.ajo.2017.08.008
   Papadopoulos M, 2007, INVEST OPHTH VIS SCI, V48, P4100, DOI 10.1167/iovs.06-1350
   Papadopoulos M, 2020, OPHTHALMOL GLAUCOMA, V3, P145, DOI 10.1016/j.ogla.2019.12.007
   Parker DM, 2018, AM J OPHTHALMOL, V191, pXVI, DOI 10.1016/j.ajo.2018.03.028
   Pedersen KB, 2020, ACTA OPHTHALMOL, V98, P182, DOI 10.1111/aos.14207
   Rothman AL, 2020, J GLAUCOMA, V29, P1147, DOI 10.1097/IJG.0000000000001648
   Segel JE, 2020, J RURAL HEALTH, V36, P476, DOI 10.1111/jrh.12498
   SEIDMAN DJ, 1986, PEDIATRICS, V77, P399
   Stein JD, 2018, JAMA OPHTHALMOL, V136, P39, DOI 10.1001/jamaophthalmol.2017.5081
   Streeter RA, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231443
   Thompson AC, 2015, INVEST OPHTH VIS SCI, V56, P4324, DOI 10.1167/iovs.15-16444
   Ung C, 2013, AM J OPHTHALMOL, V156, P362, DOI 10.1016/j.ajo.2013.03.005
   Walton DS, 2013, J PEDIAT OPHTH STRAB, V50, P234, DOI 10.3928/01913913-20130423-02
   Zlotnick C, 2007, J URBAN HEALTH, V84, P45, DOI 10.1007/s11524-006-9123-9
NR 39
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD APR
PY 2021
VL 224
BP 112
EP 119
DI 10.1016/j.ajo.2020.12.009
PG 8
WC Ophthalmology
SC Ophthalmology
GA RN7UW
UT WOS:000640559300012
PM 33340505
DA 2021-10-30
ER

PT J
AU Rothman, AL
   Townsend, JH
   Chang, TC
AF Rothman, Adam L.
   Townsend, Justin H.
   Chang, Ta C.
TI Pediatric intraoperative ciliary block
SO JOURNAL OF AAPOS
LA English
DT Article
ID MALIGNANT GLAUCOMA
AB Pediatric patients who undergo intraocular surgery are at risk for many of the same perioperative complications as adults. The same methodical approach to assessing perioperative shallowing of the anterior chamber that presents in the adult population should be followed for children. We present a rare case of intraoperative ciliary block in a 3-year-old boy undergoing a second glaucoma drainage device implantation that was successfully treated with pars plana vitrectomy and hyaloid-zonulo-iridectomy.
C1 [Rothman, Adam L.; Townsend, Justin H.; Chang, Ta C.] Univ Miami Hlth Syst, Bascom Palmer Eye Inst, Miami, FL USA.
RP Rothman, AL (corresponding author), Bascom Palmer Eye Inst, 8100 SW 10th St,Suite 3000, Plantation, FL 33324 USA.
EM alr235@med.miami.edu
FU NIH Center Core GrantUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [P30EY014801];
   Research to Prevent BlindnessResearch to Prevent Blindness (RPB)
   [GR004596]; Heed Ophthalmic Foundation; 2019 University of Miami
   Institute for Advanced Study of the Americas Pilot Grant [UL1TR002736];
   Miami Clinical and Translational Science Institute
FX Supported in part by NIH Center Core Grant P30EY014801, an unrestricted
   grant from Research to Prevent Blindness (GR004596), the Heed Ophthalmic
   Foundation (ALR), the 2019 University of Miami Institute for Advanced
   Study of the Americas Pilot Grant (TCC), and Grant Number UL1TR002736,
   Miami Clinical and Translational Science Institute (TCC).
CR Budenz DL, 2004, OPHTHALMOLOGY, V111, P2204, DOI 10.1016/j.ophtha.2004.05.017
   EPSTEIN DL, 1984, AM J OPHTHALMOL, V98, P137, DOI 10.1016/0002-9394(87)90347-3
   HERSCHLER J, 1980, OPHTHALMOLOGY, V87, P1155
   Kaplowitz K, 2015, SURV OPHTHALMOL, V60, P229, DOI 10.1016/j.survophthal.2014.12.004
   LYNCH MG, 1986, AM J OPHTHALMOL, V102, P149, DOI 10.1016/0002-9394(86)90135-2
   Maki JL, 2007, J AAPOS, V11, P395, DOI 10.1016/j.jaapos.2006.12.057
   Quigley HA, 2003, J GLAUCOMA, V12, P167, DOI 10.1097/00061198-200304000-00013
   Ruben S, 1997, BRIT J OPHTHALMOL, V81, P163, DOI 10.1136/bjo.81.2.163
   Thompson AC, 2020, AM J OPHTHALMOL, V209, P141, DOI 10.1016/j.ajo.2019.07.023
   VAJPAYEE RB, 1991, OPHTHALMIC SURG LAS, V22, P266
NR 10
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1091-8531
EI 1528-3933
J9 J AAPOS
JI J. AAPOS
PD AUG
PY 2021
VL 25
IS 4
BP 242
EP 245
DI 10.1016/j.jaapos.2021.02.007
PG 5
WC Ophthalmology; Pediatrics
SC Ophthalmology; Pediatrics
GA WH5XX
UT WOS:000707751300032
PM 33989795
DA 2021-10-30
ER

PT J
AU Lu, VM
   O'Connor, KP
   Shah, AH
   Eichberg, DG
   Luther, EM
   Komotar, RJ
   Ivan, ME
AF Lu, Victor M.
   O'Connor, Kyle P.
   Shah, Ashish H.
   Eichberg, Daniel G.
   Luther, Evan M.
   Komotar, Ricardo J.
   Ivan, Michael E.
TI The prognostic significance of CDKN2A homozygous deletion in IDH-mutant
   lower-grade glioma and glioblastoma: a systematic review of the
   contemporary literature
SO JOURNAL OF NEURO-ONCOLOGY
LA English
DT Review
DE CDKN2A; Deletion; Glioma; Glioblastoma; Cyclin; Prognosis; Survival
ID SURVIVAL
AB Background The most recent cIMPACT-NOW update highlighted the homozygous deletion of the Cyclin Dependent Kinase Inhibitor 2A (CDKN2A) gene as a clinically important molecular alteration in IDH-mutant glioma. Correspondingly, we systematically reviewed the contemporary literature to affirm the contemporary stance of the literature on the prognostic significance of this alteration in this setting based on the current World Health Organization (WHO) Grade classification. Methods A systematic search of seven electronic databases from inception to February 2020 was conducted following PRISMA guidelines. Articles were screened against pre-specified criteria to include lower-grade glioma (LGG, WHO Grade II/III) and glioblastoma (GBM, WHO Grade IV) separately. Progression free survival (PFS) and overall survival (OS) from Kaplan-Meier and multivariable analyses were outcomes of interest. Results Nine institutional studies describing 2193 IDH-mutant gliomas satisfied criteria for evaluation, with 1756 (80%) LGG and 437 (20%) GBM. When reported, the proportion of CDKN2A homozygous deleted gliomas ranged from 9 to 43%, with a median incidence of 22%. For LGG, Kaplan-Meier analyses demonstrated shorter PFS in the presence of CDKN2A homozygous deletion in three studies (median values, 31 versus 91 months), and shorter OS in five studies (median values, 61 versus 154 months). For GBM, Kaplan-Meier analyses demonstrated shorter PFS in the presence of CDKN2A homozygous deletion in two studies (median values, 16 versus 30 months), and shorter OS in four studies (median values, 38 versus 86 months). By multivariable analyses, CDKN2A homozygous deletion was a predictor of significantly shorter PFS and OS in both LGG and GBM across all included studies. Conclusions The CDKN2A homozygous deletion is an important prognostic factor for survival outcomes of IDH-mutant glioma patients across multiple histologic WHO grades with specific molecular features likely dependent on IDH-mutant status. Greater understanding of how identifying this deletion can assist in the stratification of management for these tumors to optimize clinical course is required.
C1 [Lu, Victor M.; Shah, Ashish H.; Eichberg, Daniel G.; Luther, Evan M.; Komotar, Ricardo J.; Ivan, Michael E.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Lois Pope Life Ctr,Jackson Hlth Syst, 1095 NW 14th Terrace, Miami, FL 33136 USA.
   [Lu, Victor M.] Mayo Clin, Dept Neurol Surg, 200 First St SW, Rochester, MN 55905 USA.
   [O'Connor, Kyle P.] Univ Texas Hlth Sci Ctr Houston, Vivian L Smith Dept Neurosurg, McGovern Med Sch, Houston, TX 77030 USA.
RP Lu, VM; Ivan, ME (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Surg, Lois Pope Life Ctr,Jackson Hlth Syst, 1095 NW 14th Terrace, Miami, FL 33136 USA.; Lu, VM (corresponding author), Mayo Clin, Dept Neurol Surg, 200 First St SW, Rochester, MN 55905 USA.
EM lu.victor@mayo.edu; MIvan@med.miami.edu
FU National Center For Advancing Translational Sciences of the National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [UL1TR002736]
FX The project described was supported by the National Center For Advancing
   Translational Sciences of the National Institutes of Health under Award
   Number UL1TR002736 (M.E.I.). The content is solely the responsibility of
   the authors and does not necessarily represent the official views of the
   National Institutes of Health. All other authors report no funding
   sources or conflict of interest concerning the materials or methods used
   in this study or the findings specified in this paper.
CR Aoki K, 2018, NEURO-ONCOLOGY, V20, P66, DOI 10.1093/neuonc/nox132
   Appay R, 2019, NEURO-ONCOLOGY, V21, P1519, DOI 10.1093/neuonc/noz124
   Arita H, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0351-2
   Brat DJ, 2020, ACTA NEUROPATHOL, V139, P603, DOI 10.1007/s00401-020-02127-9
   Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034
   Bui NQ, 2019, CLIN SARCOMA RES, V9, DOI 10.1186/s13569-019-0122-5
   Chai RC, 2019, CARCINOGENESIS, V40, P1229, DOI 10.1093/carcin/bgz102
   Cimino PJ, 2019, NEURO-ONCOLOGY, V21, P819, DOI 10.1093/neuonc/noz052
   Eckel-Passow JE, 2015, NEW ENGL J MED, V372, P2499, DOI 10.1056/NEJMoa1407279
   Fontana R, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9030087
   Guo Y, 2019, J CELL PHYSIOL, V234, P7356, DOI 10.1002/jcp.27495
   Korshunov A, 2019, NEUROPATH APPL NEURO, V45, P108, DOI 10.1111/nan.12523
   Larjavaara S, 2007, NEURO-ONCOLOGY, V9, P319, DOI 10.1215/15228517-2007-016
   LI KW, 2019, OPT ENG, V58
   Louis DN, 2020, BRAIN PATHOL, V30, P844, DOI 10.1111/bpa.12832
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Lu VM, 2018, J NEURO-ONCOL, V139, P231, DOI 10.1007/s11060-018-2897-2
   Mirchia K, 2019, ACTA NEUROPATHOL COM, V7, DOI 10.1186/s40478-019-0746-y
   Moher D, 2010, INT J SURG, V8, P336, DOI [10.1016/j.ijsu.2010.02.007, 10.1371/journal.pmed.1000217, 10.1371/journal.pmed.1000097, 10.1136/bmj.c869]
   Olar A, 2015, ACTA NEUROPATHOL, V129, P585, DOI 10.1007/s00401-015-1398-z
   Ostrom QT, 2018, NEURO-ONCOLOGY, V20, P1, DOI 10.1093/neuonc/noy131
   Ostrom QT, 2014, NEURO-ONCOLOGY, V16, P896, DOI 10.1093/neuonc/nou087
   Reis GF, 2015, J NEUROPATH EXP NEUR, V74, P442, DOI 10.1097/NEN.0000000000000188
   SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0
   Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501
   Shirahata M, 2018, ACTA NEUROPATHOL, V136, P153, DOI 10.1007/s00401-018-1849-4
   Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001
   Tachon G, 2019, CANCER MED-US, V8, P7556, DOI 10.1002/cam4.2599
   Vuong HG, 2019, EUR J NEUROL, V26, P379, DOI 10.1111/ene.13826
   Wells G.A., 2014, NEWCASTLE OTTAWA SCA
   Worst TS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32569-x
   Xia L, 2019, BIOMARKERS, V24, P700, DOI 10.1080/1354750X.2019.1652685
   Yang RR, 2020, BRAIN PATHOL, V30, P541, DOI 10.1111/bpa.12801
   Yoda RA, 2019, J NEUROPATH EXP NEUR, V78, P1002, DOI 10.1093/jnen/nlz082
   Zhang L, 2017, J MOL CELL BIOL, V9, P477, DOI 10.1093/jmcb/mjx056
NR 35
TC 9
Z9 9
U1 1
U2 9
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0167-594X
EI 1573-7373
J9 J NEURO-ONCOL
JI J. Neuro-Oncol.
PD JUN
PY 2020
VL 148
IS 2
BP 221
EP 229
DI 10.1007/s11060-020-03528-2
EA MAY 2020
PG 9
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA MC2GN
UT WOS:000531123000001
PM 32385699
DA 2021-10-30
ER

PT J
AU Lu, VTM
   Shah, AHH
   Eichberg, DG
   Quinones-Hinojosa, A
   Esquenazi, Y
   Komotar, RJ
   Ivan, ME
AF Lu, Victor M.
   Shah, Ashish H.
   Eichberg, Daniel G.
   Quinones-Hinojosa, Alfredo
   Esquenazi, Yoshua
   Komotar, Ricardo J.
   Ivan, Michael E.
TI Geographic disparities in access to glioblastoma treatment based on
   Hispanic ethnicity in the United States: Insights from a national
   database
SO JOURNAL OF NEURO-ONCOLOGY
LA English
DT Article
DE Hispanic; Glioblastoma; Surgery; Radiation; Chemotherapy; Access; United
   States
ID CANCER DATA-BASE; DETERMINANTS; SURVIVAL; HISPANICS/LATINOS; SAFETY;
   CARE
AB Background Access to treatment for glioblastoma (GBM) can be impacted by multiple demographic parameters. Barriers specific to the Hispanic population of the United States (US) are not fully understood. Therefore, the aim of this study was to elucidate geographic disparities for access to GBM treatment in the US Hispanic population. Methods All GBM patients with known Hispanic ethnicity status (and Caucasian race) in the US National Cancer Database (NCDB) between the years 2005-2016 were retrospectively reviewed. Treatment statuses of surgical resection, chemotherapy, radiation therapy and triple therapy (resection, chemotherapy and radiation) were summarized, and analyzed by comparison and regression analyses over US Census regions. Results A total cohort size of 40,232 Caucasian GBM patients were included, with 3,111 (8%) identifying as Hispanic. The odds of treatment by chemotherapy (OR 0.78, P < 0.01), radiation therapy (OR 0.82, P < 0.01) and triple therapy (OR 0.84, P < 0.01) were all significantly lower in the Hispanic group versus non-Hispanic group. The odds of being treated in the Hispanic group were significantly lower in multiple Census regions with respect to surgical resection (New England, OR 0.51; Mountain, OR 0.68), chemotherapy (East North Central, OR 0.77; Middle Atlantic, OR 0.71; Pacific, OR 0.77), radiation therapy (Middle Atlantic, OR 0.77) and triple therapy (New England, OR 0.49; Middle Atlantic, OR 0.87; Pacific, OR 0.84). Significant barriers to triple therapy in the Hispanic group within these regions were older age (OR 0.97; P < 0.01), treatment in a community facility (OR 0.85, P = 0.03), lack of insurance (OR 0.71, P = 0.03), yearly income < $40,227 (OR 0.69, P < 0.01), low education levels (OR 0.75, P = 0.03) and presence of co-morbidity (OR 0.82; P < 0.01). Conclusions Currently in the US, there exists heterogenous geographic disparities for Hispanic GBM patients to access different treatments compared to non-Hispanic patients. Multiple circumstances can influence access to treatment within the Hispanic community of these regions, and greater investigation with more granularity required to reveal mechanisms in which these disparities may be addressed in the future.
C1 [Lu, Victor M.; Shah, Ashish H.; Eichberg, Daniel G.; Komotar, Ricardo J.; Ivan, Michael E.] Univ Miami, Miller Sch Med, Jackson Hlth Syst, Dept Neurol Surg,Lois Pope Life Ctr, Miami, FL 33136 USA.
   [Lu, Victor M.] Dept Neurol Surg, 200 First St SW, Rochester, MN 55905 USA.
   [Quinones-Hinojosa, Alfredo] Mayo Clin, Dept Neurol Surg, Jacksonville, FL 32224 USA.
   [Esquenazi, Yoshua] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Vivian L Smith Dept Neurosurg, Houston, TX 77030 USA.
RP Lu, VM (corresponding author), Univ Miami, Miller Sch Med, Jackson Hlth Syst, Dept Neurol Surg,Lois Pope Life Ctr, Miami, FL 33136 USA.
EM lu.victor@mayo.edu
RI Esquenazi, Yoshua/AAG-6576-2021
FU National Center For Advancing Translational Sciences of the National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [UL1TR002736]
FX The project described was supported by the National Center For Advancing
   Translational Sciences of the National Institutes of Health under Award
   Number UL1TR002736 (M.E.I.). The content is solely the responsibility of
   the authors and does not necessarily represent the official views of the
   National Institutes of Health. All other authors report no funding
   sources or conflict of interest concerning the materials or methods used
   in this study or the findings specified in this paper.
CR Akee R, 2019, DEMOGRAPHY, V56, P999, DOI 10.1007/s13524-019-00773-7
   Alvarez E, 2017, CANCER-AM CANCER SOC, V123, P2516, DOI 10.1002/cncr.30562
   Bakk L, 2018, SOC WORK PUBLIC HLTH, V33, P250, DOI 10.1080/19371918.2018.1462285
   Brown DA, 2018, NEURO-ONCOLOGY, V20, P1374, DOI 10.1093/neuonc/noy102
   Cadet TJ, 2017, HEALTH CARE WOMEN IN, V38, P1289, DOI 10.1080/07399332.2017.1364740
   Caram MEV, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.2589
   Cardona AF, 2018, J NEURO-ONCOL, V136, P363, DOI 10.1007/s11060-017-2660-0
   Chandra A, 2018, NEUROSURG FOCUS, V44, DOI 10.3171/2018.3.FOCUS1852
   Dickmann LJ, 2018, ONCOLOGIST, V23, P243, DOI 10.1634/theoncologist.2017-0237
   Dressler EV, 2019, NEURO-ONCOL PRACT, V6, P37, DOI 10.1093/nop/npy014
   Duong Courtney, 2017, Brain Tumor Res Treat, V5, P64, DOI 10.14791/btrt.2017.5.2.64
   Edward J, 2018, PUBLIC HEALTH NURS, V35, P176, DOI 10.1111/phn.12385
   Ghaddar S, 2018, PATIENT EDUC COUNS, V101, P2233, DOI 10.1016/j.pec.2018.08.033
   Ikoma N, 2018, CANCER-AM CANCER SOC, V124, P998, DOI 10.1002/cncr.31155
   Ilowite MF, 2017, CANCER-AM CANCER SOC, V123, P3995, DOI 10.1002/cncr.30960
   Jaiswal K, 2018, J NATL COMPR CANC NE, V16, P1451, DOI 10.6004/jnccn.2018.7067
   Kamara D, 2018, J GENET COUNS, V27, P155, DOI 10.1007/s10897-017-0132-5
   Lerro CC, 2013, ANN SURG ONCOL, V20, P1759, DOI 10.1245/s10434-013-2901-1
   Liederbach E, 2015, ANN SURG ONCOL, V22, P4422, DOI 10.1245/s10434-015-4560-x
   Manuel JI, 2018, HEALTH SERV RES, V53, P1407, DOI 10.1111/1475-6773.12705
   Miller KD, 2018, CA-CANCER J CLIN, V68, P425, DOI 10.3322/caac.21494
   Mojica Cynthia M, 2017, Hisp Health Care Int, V15, P160, DOI 10.1177/1540415317735343
   Mukherjee D, 2010, ARCH SURG-CHICAGO, V145, P247, DOI 10.1001/archsurg.2009.288
   Mukherjee D, 2009, EUR J ENDOCRINOL, V161, P259, DOI 10.1530/EJE-09-0043
   Mukherjee D, 2009, PEDIATRICS, V124, pE688, DOI 10.1542/peds.2009-0377
   O'Connor JM, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.3146
   Ostrom QT, 2018, JAMA ONCOL, V4, P1254, DOI 10.1001/jamaoncol.2018.1789
   Pan IW, 2015, J CLIN NEUROSCI, V22, P1575, DOI 10.1016/j.jocn.2015.03.032
   Rhome R, 2016, J NEURO-ONCOL, V128, P241, DOI 10.1007/s11060-016-2101-5
   Shabihkhani M, 2017, J NEURO-ONCOL, V132, P351, DOI 10.1007/s11060-017-2377-0
   Shergalis A, 2018, PHARMACOL REV, V70, P412, DOI 10.1124/pr.117.014944
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P457, DOI 10.3322/caac.21314
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Tang JM, 2005, CANCER EPIDEM BIOMAR, V14, P2040, DOI 10.1158/1055-9965.EPI-05-0136
   Tyson DM, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/fpubh.2018.00219
   van der Goes DN, 2018, J MED ECON, V21, P1139, DOI 10.1080/13696998.2018.1515083
   Villanueva C, 2019, J NATL COMPR CANC NE, V17, P1318, DOI 10.6004/jnccn.2019.7325
   Weller M, 2018, EUR J CANCER, V96, P1, DOI 10.1016/j.ejca.2018.03.016
   Wu CC, 2016, WORLD NEUROSURG, V88, P260, DOI 10.1016/j.wneu.2015.12.081
   Yanez B, 2016, J LAT O PSYCHOL, V4, P114, DOI 10.1037/lat0000055
NR 40
TC 6
Z9 6
U1 1
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0167-594X
EI 1573-7373
J9 J NEURO-ONCOL
JI J. Neuro-Oncol.
PD MAY
PY 2020
VL 147
IS 3
BP 711
EP 720
DI 10.1007/s11060-020-03480-1
EA MAR 2020
PG 10
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA LS8GZ
UT WOS:000522722000001
PM 32236779
DA 2021-10-30
ER

PT J
AU Ryon, EL
   Kronenfeld, JP
   Lee, RM
   Yopp, A
   Wang, A
   Lee, AY
   Luu, S
   Hsu, C
   Silberfein, E
   Russell, MC
   Goel, N
   Merchant, NB
   Datta, J
AF Ryon, Emily L.
   Kronenfeld, Joshua P.
   Lee, Rachel M.
   Yopp, Adam
   Wang, Annie
   Lee, Ann Y.
   Luu, Sommer
   Hsu, Cary
   Silberfein, Eric
   Russell, Maria C.
   Goel, Neha
   Merchant, Nipun B.
   Datta, Jashodeep
TI Surgical management of hepatocellular carcinoma patients with portal
   vein thrombosis: The United States Safety Net and Academic Center
   Collaborative Analysis
SO JOURNAL OF SURGICAL ONCOLOGY
LA English
DT Article
DE cancer; hepatobiliary; outcomes
ID PRIMARY LIVER-CANCER; SORAFENIB; RESECTION; THERAPY
AB Background Although consensus guidelines generally discourage any surgical management (ASM; i.e., resection and/or transplantation) in patients with hepatocellular carcinoma (HCC) and portal vein thrombosis (PVT), recent series from Asia have challenged this paradigm.
   Methods Patients from the US Safety Net Collaborative database (2012-2014) with localized HCC and radiographically confirmed PVT were propensity-score matched based on demographic and clinicopathologic factors associated with receipt of ASM and overall survival (OS). OS was compared between patients undergoing ASM and those not selected for surgery.
   Results Of 1910 HCC patients, 207 (14.5%) had localized disease and PVT. The majority received either liver-directed therapies (LDTs; 34%) and/or targeted systemic therapies (36%). Twenty-one patients (10.1%) underwent ASM (resection [n = 11], transplantation [n = 10]); a third experienced any complication with no 30-day mortalities. Independent predictors of undergoing ASM were younger age, recent hepatology consultation, and lower model of end-stage liver disease (MELD) score. After matching for age, comorbidities, MELD, tumor size, receipt of LDT, or systemic therapy, OS was significantly longer for patients selected for ASM versus non-ASM patients (median not reached vs. 5.8 months, p < .001).
   Conclusion In a large North American multi-institutional cohort, a minority of HCC patients with PVT were selected for ASM. Resection or transplantation was associated with improved survival and may have a role in the multimodality management in selected patients.
C1 [Ryon, Emily L.; Kronenfeld, Joshua P.; Goel, Neha; Merchant, Nipun B.; Datta, Jashodeep] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Div Surg Oncol,Dept Surg, 1120 NW 14th St,Suite 410, Miami, FL 33136 USA.
   [Lee, Rachel M.; Russell, Maria C.] Emory Univ, Dept Surg, Div Surg Oncol, Winship Canc Inst, Atlanta, GA USA.
   [Yopp, Adam] Univ Texas Southwestern Med Sch, Dept Surg, Div Surg Oncol, Dallas, TX USA.
   [Wang, Annie; Lee, Ann Y.] NYU, Dept Surg, Div Surg Oncol, Langone Hlth, New York, NY 10016 USA.
   [Luu, Sommer; Hsu, Cary; Silberfein, Eric] Baylor Coll Med, Dept Surg, Div Surg Oncol, Houston, TX 77030 USA.
RP Datta, J (corresponding author), Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Div Surg Oncol,Dept Surg, 1120 NW 14th St,Suite 410, Miami, FL 33136 USA.
EM jash.datta@med.miami.edu
RI Lee, Ann Yeelin/H-9538-2019
OI Lee, Ann Yeelin/0000-0002-8143-2635; Kronenfeld,
   Joshua/0000-0003-4540-3658; Russell, Maria/0000-0003-1584-6992
FU National Cancer InstituteUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [2R01CA161976-06, P30 CA240139, T32CA211034]; National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [UL1TR002736]
FX National Cancer Institute, Grant/Award Numbers: 2R01CA161976-06, P30
   CA240139, T32CA211034; National Institutes of Health, Grant/Award
   Number: UL1TR002736
CR Chan SL, 2016, WORLD J GASTROENTERO, V22, P7289, DOI 10.3748/wjg.v22.i32.7289
   Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7
   Choo SP, 2016, CANCER-AM CANCER SOC, V122, P3430, DOI 10.1002/cncr.30237
   Connolly GC, 2008, THROMB RES, V122, P299, DOI 10.1016/j.thromres.2007.10.009
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Howlader NR, 2020, BREAST CANCER RES TR, V182, P739, DOI 10.1007/s10549-020-05738-8
   Ikai I, 2010, HEPATOL RES, V40, P1043, DOI 10.1111/j.1872-034X.2010.00731.x
   Jiang JF, 2017, ONCOTARGET, V8, P33911, DOI 10.18632/oncotarget.15411
   Kamarajah SK, 2018, J SURG ONCOL, V117, P644, DOI 10.1002/jso.24908
   Klein JP, 2003, SURVIVAL ANAL TECHNI, P21
   Kokudo T, 2016, J HEPATOL, V65, P938, DOI 10.1016/j.jhep.2016.05.044
   Kulik L, 2019, GASTROENTEROLOGY, V156, P477, DOI 10.1053/j.gastro.2018.08.065
   Lee JM, 2016, CLIN MOL HEPATOL, V22, P160, DOI 10.3350/cmh.2016.22.1.160
   Liang L, 2018, HPB, V20, P1119, DOI 10.1016/j.hpb.2018.06.1804
   Llovet JM, 1999, HEPATOLOGY, V29, P62, DOI 10.1002/hep.510290145
   Llovet JM, 1999, SEMIN LIVER DIS, V19, P329, DOI 10.1055/s-2007-1007122
   Minagawa M, 2006, WORLD J GASTROENTERO, V12, P7561, DOI 10.3748/wjg.v12.i47.7561
   Nathan H, 2013, ANN SURG, V258, P1022, DOI 10.1097/SLA.0b013e31827da749
   Njei B, 2015, HEPATOLOGY, V61, P191, DOI 10.1002/hep.27388
   Pawlik TM, 2005, SURGERY, V137, P403, DOI 10.1016/j.surg.2004.12.012
   Perz JF, 2006, J HEPATOL, V45, P529, DOI 10.1016/j.jhep.2006.05.013
   Randolph J. J., 2014, PRACTICAL ASSESSMENT, V19, P1, DOI DOI 10.7275/N3PV-TX27
   Shah C, 2017, J GASTROINTEST ONCOL, V8, P789, DOI 10.21037/jgo.2017.06.16
   Yau T, 2014, GASTROENTEROLOGY, V146, P1691, DOI 10.1053/j.gastro.2014.02.032
NR 24
TC 2
Z9 2
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-4790
EI 1096-9098
J9 J SURG ONCOL
JI J. Surg. Oncol.
PD FEB
PY 2021
VL 123
IS 2
BP 407
EP 415
DI 10.1002/jso.26282
EA OCT 2020
PG 9
WC Oncology; Surgery
SC Oncology; Surgery
GA TR1DH
UT WOS:000583507900001
PM 33125746
DA 2021-10-30
ER

PT J
AU Thompson, JW
   Elwardany, O
   McCarthy, DJ
   Sheinberg, DL
   Alvarez, CM
   Nada, A
   Snelling, BM
   Chen, SH
   Sur, S
   Starke, RM
AF Thompson, John W.
   Elwardany, Omar
   McCarthy, David J.
   Sheinberg, Dallas L.
   Alvarez, Carlos M.
   Nada, Ahmed
   Snelling, Brian M.
   Chen, Stephanie H.
   Sur, Samir
   Starke, Robert M.
TI In vivo cerebral aneurysm models aneurysm models
SO NEUROSURGICAL FOCUS
LA English
DT Article
DE aneurysm; animal; model; in vivo; mice; rabbit; porcine; canine
ID UNRUPTURED INTRACRANIAL ANEURYSMS; EXPERIMENTAL SACCULAR ANEURYSMS;
   BIFURCATION ANEURYSM; WALL DEGENERATION; THROMBUS ORGANIZATION; RUPTURE;
   GROWTH; ELASTASE; HYPERTENSION; CREATION
AB Cerebral aneurysm rupture is a devastating event resulting in subarachnoid hemorrhage and is associated with significant morbidity and death. Up to 50% of individuals do not survive aneurysm rupture, with the majority of survivors suffering some degree of neurological deficit. Therefore, prior to aneurysm rupture, a large number of diagnosed patients are treated either microsurgically via dipping or endovascularly to prevent aneurysm filling. With the advancement of endovascular surgical techniques and devices, endovascular treatment of cerebral aneurysms is becoming the first-line therapy at many hospitals. Despite this fact, a large number of endovascularly treated patients will have aneurysm recanalization and progression and will require retreatment. The lack of approved pharmacological interventions for cerebral aneurysms and the need for retreatment have led to a growing interest in understanding the molecular, cellular, and physiological determinants of cerebral aneurysm pathogenesis, maturation, and rupture. To this end, the use of animal cerebral aneurysm models has contributed significantly to our current understanding of cerebral aneurysm biology and to the development of and training in endovascular devices. This review summarizes the small and large animal models of cerebral aneurysm that are being used to explore the pathophysiology of cerebral aneurysms, as well as the development of novel endovascular devices for aneurysm treatment.
C1 [Thompson, John W.; Elwardany, Omar; McCarthy, David J.; Sheinberg, Dallas L.; Alvarez, Carlos M.; Nada, Ahmed; Snelling, Brian M.; Chen, Stephanie H.; Sur, Samir; Starke, Robert M.] Univ Miami, Dept Neurol Surg, Boca Raton, FL USA.
   [Starke, Robert M.] Univ Miami, Dept Radiol, Boca Raton, FL USA.
   [Thompson, John W.; Elwardany, Omar; McCarthy, David J.; Sheinberg, Dallas L.; Alvarez, Carlos M.; Nada, Ahmed; Snelling, Brian M.; Chen, Stephanie H.; Sur, Samir; Starke, Robert M.] Univ Miami, Cerebrovasc Initiat, Boca Raton, FL USA.
   [Snelling, Brian M.] Boca Raton Reg Hosp, Marcus Neurosci Inst, Boca Raton, FL USA.
RP Starke, RM (corresponding author), Miami Univ, Lois Pope & & Ctr, Miami, FL 33136 USA.
EM rstarke@med.miami.edu
RI Alvarez, Carlos/Z-3852-2019; Elwardany, Omar/AAO-9429-2020; Elwardany,
   Omar/T-6994-2018
OI Alvarez, Carlos/0000-0002-2965-090X; Elwardany,
   Omar/0000-0001-8897-0551; Elwardany, Omar/0000-0001-8897-0551;
   Sheinberg, Dallas/0000-0002-1480-9500
FU National Research and Education Foundation (NREF) Young Clinician
   Investigator Award; Joe Niekro Research Grant; Bee Foundation Award;
   Brain Aneurysm Foundation Award; Miami Clinical and Translational
   Science Institute Award; Miami Clinical and Translational Science
   Institute [UL1TR002736]; National Center for Advancing Translational
   SciencesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS); National Institute on Minority Health
   and Health DisparitiesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Minority Health & Health Disparities (NIMHD); NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR002736]
   Funding Source: NIH RePORTER
FX This work was supported by a National Research and Education Foundation
   (NREF) Young Clinician Investigator Award, Joe Niekro Research Grant,
   Bee Foundation Award, Brain Aneurysm Foundation Award, and Miami
   Clinical and Translational Science Institute Award (R.M.S.). The project
   described was supported by grant no. UL1TR002736, Miami Clinical and
   Translational Science Institute, from the National Center for Advancing
   Translational Sciences and the National Institute on Minority Health and
   Health Disparities. Its contents are solely the responsibility of the
   authors and do not necessarily represent the official views of the NIH.
CR Altes TA, 2000, AM J ROENTGENOL, V174, P349, DOI 10.2214/ajr.174.2.1740349
   Amili O, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0188323
   Aoki T, 2011, BRIT J PHARMACOL, V163, P1237, DOI 10.1111/j.1476-5381.2011.01358.x
   Aoki T, 2008, STROKE, V39, P2603, DOI 10.1161/STROKEAHA.107.513648
   Aoki T, 2007, CIRCULATION, V116, P2830, DOI 10.1161/CIRCULATIONAHA.107.728303
   Aoki T, 2007, STROKE, V38, P2337, DOI 10.1161/STROKEAHA.107.481838
   Aoki T, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-34
   Aoki T, 2011, LAB INVEST, V91, P619, DOI 10.1038/labinvest.2010.204
   Aoki T, 2009, LAB INVEST, V89, P730, DOI 10.1038/labinvest.2009.36
   Aoki T, 2009, STROKE, V40, P942, DOI 10.1161/STROKEAHA.108.532556
   Aquarius R, 2018, J NEUROINTERV SURG, V10, P88, DOI 10.1136/neurintsurg-2016-012878
   Avery MB, 2019, J NEUROSURG, V131, P88, DOI 10.3171/2018.2.JNS173168
   Bavinzski G, 1998, MINIM INVAS NEUROSUR, V41, P129, DOI 10.1055/s-2008-1052027
   Benet A, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/939387
   Bouzeghrane F, 2010, AM J NEURORADIOL, V31, P418, DOI 10.3174/ajnr.A1853
   Brinjikji W, 2016, AM J NEURORADIOL, V37, P615, DOI 10.3174/ajnr.A4575
   Chalouhi N, 2013, STROKE, V44, P3613, DOI 10.1161/STROKEAHA.113.002390
   Cloft HJ, 1999, RADIOLOGY, V213, P223, DOI 10.1148/radiology.213.1.r99oc15223
   D'Urso PS, 1999, SURG NEUROL, V52, P490, DOI 10.1016/S0090-3019(99)00143-3
   FORREST MD, 1989, AM J NEURORADIOL, V10, P400
   Frosen J, 2006, NEUROSURGERY, V58, P936, DOI 10.1227/01.NEU.0000210260.55124.A4
   Frosen J, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-71
   Gao L, 2008, STROKE, V39, P2085, DOI 10.1161/STROKEAHA.107.509422
   GERMAN WJ, 1954, NEW ENGL J MED, V250, P104, DOI 10.1056/NEJM195401212500303
   Goericke SL, 2009, INTERV NEURORADIOL, V15, P413, DOI 10.1177/159101990901500406
   GRAVES VB, 1993, AM J NEURORADIOL, V14, P801
   Gruter BE, 2019, J NEUROINTERV SURG
   GUGLIELMI G, 1994, NEURORADIOLOGY, V36, P547, DOI 10.1007/BF00593518
   Guo SW, 2018, INT ANGIOL, V37, P32, DOI 10.23736/S0392-9590.17.03869-X
   HASHIMOTO N, 1978, SURG NEUROL, V10, P3
   HASSLER O, 1963, J NEUROSURG, V20, P1, DOI 10.3171/jns.1963.20.1.0001
   HELPERN VJ, 1994, J VASC SURG, V20, P51, DOI 10.1016/0741-5214(94)90175-9
   Hosaka K, 2014, J NEUROINTERV SURG, V6, P474, DOI 10.1136/neurintsurg-2013-010788
   Jiang YZ, 2015, EUR REV MED PHARMACO, V19, P4241
   Kang W, 2010, NEURORADIOL J, V23, P616, DOI 10.1177/197140091002300512
   Kimura T, 2009, NEUROSURGERY, V65, P719, DOI 10.1227/01.NEU.0000354350.88899.07
   Krings T, 2003, NEURORADIOLOGY, V45, P423, DOI 10.1007/s00234-003-0976-2
   Lee D, 2007, J NEUROSURG, V107, P94, DOI 10.3171/JNS-07/07/0094
   Lee S, 2015, CIRCULATION, V131, P995, DOI 10.1161/CIRCULATIONAHA.114.012568
   Makino H, 2012, STROKE, V43, P2450, DOI 10.1161/STROKEAHA.112.659821
   Marbacher S, 2011, AM J NEURORADIOL, V32, P772, DOI 10.3174/ajnr.A2374
   Marbacher S, 2014, STROKE, V45, P3684, DOI 10.1161/STROKEAHA.114.006600
   Marbacher S, 2014, STROKE, V45, P248, DOI 10.1161/STROKEAHA.113.002745
   Marjamaa J, 2009, SURG NEUROL, V71, P458, DOI 10.1016/j.surneu.2007.12.026
   Mashiko T, 2015, WORLD NEUROSURG, V83, P351, DOI 10.1016/j.wneu.2013.10.032
   MASSOUD TF, 1994, NEURORADIOLOGY, V36, P537, DOI 10.1007/BF00593517
   Meadowcroft MD, 2018, J NEUROSURG, V129, P1530, DOI 10.3171/2017.6.JNS17722
   Meng H, 2007, STROKE, V38, P1924, DOI 10.1161/STROKEAHA.106.481234
   Merei F T, 1980, Neurol Res, V2, P283
   Morimoto M, 2002, STROKE, V33, P1911, DOI 10.1161/01.STR.0000021000.19637.3D
   Murayama Y, 1999, AM J NEURORADIOL, V20, P1992
   Namba K, 2013, INTERV NEURORADIOL, V19, P153, DOI 10.1177/159101991301900202
   Nuki Y, 2009, HYPERTENSION, V54, P1337, DOI 10.1161/HYPERTENSIONAHA.109.138297
   Ollikainen E, 2016, J NEUROPATH EXP NEUR, V75, P689, DOI 10.1093/jnen/nlw041
   Raymond J, 2013, AM J NEURORADIOL, V34, P346, DOI 10.3174/ajnr.A3407
   Raymond J, 2002, AM J NEURORADIOL, V23, P1710
   Raymond J, 1999, J NEURORADIOLOGY, V26, P7
   Sherif C, 2016, J NEUROSCI METH, V268, P7, DOI 10.1016/j.jneumeth.2016.04.020
   Sorteberg A, 2002, AM J NEURORADIOL, V23, P288
   Starke RM, 2018, ARTERIOSCL THROM VAS, V38, P610, DOI 10.1161/ATVBAHA.117.310478
   Starke RM, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-77
   Tada Y, 2014, HYPERTENSION, V63, P1339, DOI 10.1161/HYPERTENSIONAHA.114.03300
   Tada Y, 2014, STROKE, V45, P579, DOI 10.1161/STROKEAHA.113.003072
   Tulamo R, 2006, NEUROSURGERY, V59, P1069, DOI 10.1227/01.NEU.0000245598.84698.26
   Tutino VM, 2015, ANAT REC, V298, P1903, DOI 10.1002/ar.23205
   Wang J, 2014, AM J NEURORADIOL, V35, P1805, DOI 10.3174/ajnr.A3926
   Weir B, 2002, J NEUROSURG, V96, P3, DOI 10.3171/jns.2002.96.1.0003
   Wiebers D, 1998, NEW ENGL J MED, V339, P1725, DOI 10.1056/nejm199812103392401
   Yan L, 2013, STROKE, V44, P2926, DOI 10.1161/STROKEAHA.113.002290
   Yang Xin-jian, 2007, Journal of Zhejiang University-Science B, V8, P697, DOI 10.1631/jzus.2007.B0697
   YAPOR W, 1991, SURG NEUROL, V36, P426, DOI 10.1016/0090-3019(91)90155-3
   Ysuda R, 2012, AM J NEURORADIOL, V33, P507, DOI 10.3174/ajnr.A2789
NR 72
TC 9
Z9 9
U1 3
U2 7
PU AMER ASSOC NEUROLOGICAL SURGEONS
PI ROLLING MEADOWS
PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA
SN 1092-0684
J9 NEUROSURG FOCUS
JI Neurosurg. Focus
PD JUL
PY 2019
VL 47
IS 1
AR E20
DI 10.3171/2019.4.FOCUS19219
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF8HZ
UT WOS:000473332200020
PM 31261125
OA gold
DA 2021-10-30
ER

PT J
AU Javitt, MJ
   Vanner, EA
   Grajewski, AL
   Chang, TC
AF Javitt, Matthew J.
   Vanner, Elizabeth A.
   Grajewski, Alana L.
   Chang, Ta C.
TI Evaluation of a computer-based facial dysmorphology analysis algorithm
   (Face2Gene) using standardized textbook photos
SO EYE
LA English
DT Article; Early Access
ID DIABETIC-RETINOPATHY; IDX-DR
AB Background Genetic syndromes often have ocular involvement. Ophthalmologists may have difficulty identifying dysmorphic features in genetic syndrome evaluations. We investigated the sensitivity and specificity of Face2Gene (F2G), a digital image analysis software trained on integrating dysmorphic features, by analysing patient photos from genetics textbooks. Methods We analysed all clear facial photos contained within the textbooks Smith's Recognizable Patterns of Human Malformation and Genetic Diseases of the Eye using F2G under standard lighting conditions. Variables captured include colour versus grey scale photo, the gender of the patient (if known), age of the patient (if known), disease categories, diagnosis as listed in the textbook, and whether the disease has ophthalmic involvement (as described in the textbook entries). Any photos rejected by F2G were excluded. We analysed the data for accuracy, sensitivity, and specificity based on disease categories as outlined in Smith's Recognizable Patterns of Malformation. Results We analysed 353 photos found within two textbooks. The exact book diagnosis was identified by F2G in 150 (42.5%) entries, and was included in the top three differential diagnoses in 191 (54.1%) entries. F2G is highly sensitive for craniosynostosis syndromes (point estimate [PE] 80.0%, 95% confidence interval [CI] 56.3-94.3%, P = 0.0118) and syndromes with facial defects as a major feature (PE 77.8%, 95% CI 52.4-93.6%, P = 0.0309). F2G was highly specific (PE > 83percentage with P < 0.001) for all disease categories. Conclusions F2G is a useful tool for paediatric ophthalmologists to help build a differential diagnosis when evaluating children with dysmorphic facial features.
C1 [Javitt, Matthew J.; Vanner, Elizabeth A.; Grajewski, Alana L.; Chang, Ta C.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
RP Chang, TC (corresponding author), Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
EM t.chang@med.miami.edu
OI Chang, Ta Chen/0000-0003-4827-5014; Vanner,
   Elizabeth/0000-0003-1875-4524
FU National Institute of Health (NIH) Center Core GrantUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [P30EY014801]; Research to Prevent BlindnessResearch to Prevent
   Blindness (RPB); University of Miami Institute for Advanced Study of the
   Americas; 2018 IRIS-RegistryAGS Research Initiative Grant; Miami
   Clinical and Translational Science Institute, from the National Center
   for Advancing Translational Sciences [UL1TR002736]; National Institute
   on Minority Health and Health DisparitiesUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Minority Health & Health Disparities (NIMHD)
FX The project was supported by the National Institute of Health (NIH)
   Center Core Grant P30EY014801, Research to Prevent Blindness
   Unrestricted Grant, The 2019 University of Miami Institute for Advanced
   Study of the Americas Pilot Grant, 2018 IRIS-RegistryAGS Research
   Initiative Grant, and Grant Number UL1TR002736, Miami Clinical and
   Translational Science Institute, from the National Center for Advancing
   Translational Sciences and the National Institute on Minority Health and
   Health Disparities. Its contents are solely the responsibility of the
   authors and do not necessarily represent the official views of the NIH.
CR Danyel M, 2019, EUR J HUM GENET, V27, P1827, DOI 10.1038/s41431-019-0469-3
   Elmas M, 2020, MOL SYNDROMOL, V11, P4, DOI 10.1159/000505800
   Hoguet A, 2016, INDIAN J OPHTHALMOL, V64, P118, DOI 10.4103/0301-4738.179716
   Jones K.L., 2013, SMITHS RECOGNIZABLE
   Liehr T, 2018, CLIN GENET, V93, P378, DOI 10.1111/cge.13087
   Pantel JT, 2018, J INHERIT METAB DIS, V41, P533, DOI 10.1007/s10545-018-0174-3
   Pillai GS, 2018, INDIAN J PEDIATR, V85, P217, DOI 10.1007/s12098-018-2623-2
   Savoy M, 2020, AM FAM PHYSICIAN, V101, P307
   Smith AC, 2020, J TELEMED TELECARE, V26, P309, DOI 10.1177/1357633X20916567
   van der Heijden AA, 2018, ACTA OPHTHALMOL, V96, P63, DOI 10.1111/aos.13613
   Vorravanpreecha N, 2018, AM J MED GENET A, V176, P1935, DOI 10.1002/ajmg.a.40483
NR 11
TC 0
Z9 0
U1 3
U2 3
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
DI 10.1038/s41433-021-01563-5
EA APR 2021
PG 3
WC Ophthalmology
SC Ophthalmology
GA RV5OP
UT WOS:000645882300001
PM 33931761
OA Green Published, Bronze
DA 2021-10-30
ER

PT J
AU Gonzalez, L
   Strbo, N
   Podack, ER
AF Gonzalez, Louis
   Strbo, Natasa
   Podack, Eckhard R.
TI Humanized mice: novel model for studying mechanisms of human
   immune-based therapies
SO IMMUNOLOGIC RESEARCH
LA English
DT Article
DE Humanized immunity; NOD/SCID-gamma(-/-)(c) mice; Vaccine; gp96 chaperone
ID IMMUNODEFICIENCY-VIRUS INFECTION; HEMATOPOIETIC STEM-CELLS; GAMMA-CHAIN
   GENE; SCID-HU MOUSE; T-CELLS; DENDRITIC CELLS; TRANSGENIC MICE; CUTTING
   EDGE; IN-VIVO; BLOOD
AB The lack of relevant animal models is the major bottleneck for understanding human immunology and immunopathology. In the last few years, a novel model of humanized mouse has been successfully employed to investigate some of the most critical questions in human immunology. We have set up and tested in our laboratory the latest technology for generating mice with a human immune system by reconstituting newborn immunodeficient NOD/SCID-gamma (c) (-/-) mice with human fetal liver-derived hematopoietic stem cells. These humanized mice have been deemed most competent as human models in a thorough comparative study with other humanized mouse technologies. Lymphocytes in these mice are of human origin while other hematopoietic cells are chimeric, partly of mouse and partly of human origin. We demonstrate that human CD8 T lymphocytes in humanized mice are fully responsive to our novel cell-based secreted heat shock protein gp96(HIV)-Ig vaccine. We also show that the gp96(HIV)-Ig vaccine induces powerful mucosal immune responses in the rectum and the vagina, which are thought to be required for protection from HIV infection. We posit the hypothesis that vaccine approaches tested in humanized mouse models can generate data rapidly, economically and with great flexibility (genetic manipulations are possible), to be subsequently tested in larger nonhuman primate models and humans.
C1 [Gonzalez, Louis; Strbo, Natasa; Podack, Eckhard R.] Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA.
RP Podack, ER (corresponding author), Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA.
EM EPodack@med.miami.edu
FU NIAIDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R33 AI 073234]; NCATS NIHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000460, 1KL2TR000461]; Miami-CFAR; NIHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA
   [P30A1073961]; Biopsychosocial Research Training In Immunology and AIDS
   [5T32MH018917-22]; National Cancer Institute, Center for Cancer
   ResearchUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI);
   Alliance for Cancer Gene Therapy (ACGT), New York; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [P01CA109094] Funding Source: NIH RePORTER; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [KL2TR000461,
   UL1TR000460] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY
   AND INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R21AI073234, P01AI096396,
   R33AI073234] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL
   HEALTHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH) [T32MH018917] Funding Source: NIH RePORTER
FX The work is supported by the NIAID R33 AI 073234, NCATS NIH UL1TR000460
   and 1KL2TR000461, Miami-CFAR and NIH P30A1073961, Biopsychosocial
   Research Training In Immunology and AIDS 5T32MH018917-22, National
   Cancer Institute, Center for Cancer Research and support from the
   Alliance for Cancer Gene Therapy (ACGT), New York.
CR Berges BK, 2010, VIROLOGY, V397, P100, DOI 10.1016/j.virol.2009.10.034
   Brehm MA, 2010, CURR OPIN ENDOCRINOL, V17, P120, DOI 10.1097/MED.0b013e328337282f
   Brehm MA, 2010, CLIN IMMUNOL, V135, P84, DOI 10.1016/j.clim.2009.12.008
   Browning J, 1997, P NATL ACAD SCI USA, V94, P14637, DOI 10.1073/pnas.94.26.14637
   Carballido JM, 2000, NAT MED, V6, P103, DOI 10.1038/71434
   Covassin L, 2013, CLIN EXP IMMUNOL, V174, P372, DOI 10.1111/cei.12180
   Czechowicz A, 2007, SCIENCE, V318, P1296, DOI 10.1126/science.1149726
   Giannelli S, 2008, CYTOM PART B-CLIN CY, V74B, P349, DOI 10.1002/cyto.b.20434
   Gimeno R, 2004, BLOOD, V104, P3886, DOI 10.1182/blood-2004-02-0656
   Gorantla S, 2005, J VIROL, V79, P2124, DOI 10.1128/JVI.79.4.2124-2132.2005
   HESSELTON RM, 1995, J INFECT DIS, V172, P974, DOI 10.1093/infdis/172.4.974
   Ishikawa F, 2005, BLOOD, V106, P1565, DOI 10.1182/blood-2005-02-0516
   Ito M, 2002, BLOOD, V100, P3175, DOI 10.1182/blood-2001-12-0207
   Jiang Q, 2008, BLOOD, V112, P2858, DOI 10.1182/blood-2008-03-145946
   Joo SY, 2012, TRANSPLANTATION, V94, P1095, DOI 10.1097/TP.0b013e318270f392
   King MA, 2009, CLIN EXP IMMUNOL, V157, P104, DOI 10.1111/j.1365-2249.2009.03933.x
   King M, 2008, CLIN IMMUNOL, V126, P303, DOI 10.1016/j.clim.2007.11.001
   Kropp LE, 2010, J IMMUNOL, V184, P5619, DOI 10.4049/jimmunol.0902368
   Legrand N, 2006, J IMMUNOL, V176, P2053, DOI 10.4049/jimmunol.176.4.2053
   LORES P, 1992, AIDS RES HUM RETROV, V8, P2063, DOI 10.1089/aid.1992.8.2063
   MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269
   McDermott SP, 2010, BLOOD, V116, P193, DOI 10.1182/blood-2010-02-271841
   McKinney DM, 1999, J IMMUNOL, V163, P861
   MOSIER DE, 1988, NATURE, V335, P256, DOI 10.1038/335256a0
   MOSIER DE, 1991, SCIENCE, V251, P791, DOI 10.1126/science.1990441
   Nakata H, 2005, J VIROL, V79, P2087, DOI 10.1128/JVI.79.4.2087-2096.2005
   NAMIKAWA R, 1988, SCIENCE, V242, P1684, DOI 10.1126/science.3201256
   Notta F, 2010, BLOOD, V115, P3704, DOI 10.1182/blood-2009-10-249326
   Oizumi S, 2008, J IMMUNOTHER, V31, P394, DOI 10.1097/CJI.0b013e31816bc74d
   Oizumi S, 2007, J IMMUNOL, V179, P2310, DOI 10.4049/jimmunol.179.4.2310
   Podack ER, 2007, EXPERT OPIN BIOL TH, V7, P1679, DOI 10.1517/14712598.7.11.1679
   Rochman Y, 2009, NAT REV IMMUNOL, V9, P480, DOI 10.1038/nri2580
   SAWADA S, 1998, J EXP MED, V187, P1439
   Schreiber TH, 2009, CANCER RES, V69, P2026, DOI 10.1158/0008-5472.CAN-08-3706
   Shultz LD, 2005, J IMMUNOL, V174, P6477, DOI 10.4049/jimmunol.174.10.6477
   SHULTZ LD, 1995, J IMMUNOL, V154, P180
   Shultz LD, 2007, NAT REV IMMUNOL, V7, P118, DOI 10.1038/nri2017
   Shultz LD, 2012, NAT REV IMMUNOL, V12, P786, DOI 10.1038/nri3311
   Staron M, 2010, BLOOD, V115, P2380, DOI 10.1182/blood-2009-07-233031
   Stoddart CA, 2011, VIROLOGY, V417, P154, DOI 10.1016/j.virol.2011.05.013
   Strbo N, 2003, IMMUNITY, V18, P381, DOI 10.1016/S1074-7613(03)00056-6
   Strbo N, 2010, MUCOSAL IMMUNOL, V3, P182, DOI 10.1038/mi.2009.127
   Strbo N, 2013, J IMMUNOL, V190, P2495, DOI 10.4049/jimmunol.1202655
   Strbo N, 2011, VACCINE, V29, P2619, DOI 10.1016/j.vaccine.2011.01.044
   Traggiai E, 2004, SCIENCE, V304, P104, DOI 10.1126/science.1093933
   van Rijn RS, 2003, BLOOD, V102, P2522, DOI 10.1182/blood-2002-10-3241
   Wege AK, 2008, CURR TOP MICROBIOL, V324, P149
   Yamazaki K, 1999, J IMMUNOL, V163, P5178
   Zhang LG, 2012, CELL MOL IMMUNOL, V9, P237, DOI 10.1038/cmi.2012.7
NR 49
TC 28
Z9 30
U1 0
U2 16
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0257-277X
EI 1559-0755
J9 IMMUNOL RES
JI Immunol. Res.
PD DEC
PY 2013
VL 57
IS 1-3
SI SI
BP 326
EP 334
DI 10.1007/s12026-013-8471-2
PG 9
WC Immunology
SC Immunology
GA 269RK
UT WOS:000328259400033
PM 24248605
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Perez, E
   Viziano, A
   Al-Zaghal, Z
   Telischi, FF
   Sangaletti, R
   Jiang, WT
   Dietrich, WD
   King, C
   Hoffer, ME
   Rajguru, SM
AF Perez, Enrique
   Viziano, Andrea
   Al-Zaghal, Zaid
   Telischi, Fred F.
   Sangaletti, Rachele
   Jiang, Weitao
   Dietrich, William Dalton
   King, Curtis
   Hoffer, Michael E.
   Rajguru, Suhrud M.
TI Anatomical Correlates and Surgical Considerations for Localized
   Therapeutic Hypothermia Application in Cochlear Implantation Surgery
SO OTOLOGY & NEUROTOLOGY
LA English
DT Article
DE Cochlea; Cochlear implant; Electrode insertion; Hearing; Hearing loss;
   Neuroprosthetics; Residual hearing; Therapeutic hypothermia
ID POSTISCHEMIC MILD HYPOTHERMIA; GUINEA-PIG MODEL; HEARING-LOSS; RESIDUAL
   HEARING; COMPUTED-TOMOGRAPHY; INSERTION TRAUMA; ELECTRODE ARRAY; FACIAL
   RECESS; BRAIN; DEXAMETHASONE
AB Hypothesis: Application of localized, mild therapeutic hypothermia during cochlear implantation (CI) surgery is feasible for residual hearing preservation.
   Background: CI surgery often results in a loss of residual hearing. In preclinical studies, local application of controlled, mild therapeutic hypothermia has shown promising results as a hearing preservation strategy. This study investigated a suitable surgical approach to deliver local hypothermia in patients utilizing anatomical and radiologic measurements and experimental measurements from cadaveric human temporal bones.
   Methods: Ten human cadaveric temporal bones were scanned with micro-computed tomography and anatomical features and measurements predicting round window (RW) visibility were characterized. For each bone, the standard facial recess and myringotomy approaches for delivery of hypothermia were developed. The St. Thomas Hospital (STH) classification was used to record degree of RW visibility with and without placement of custom hypothermia probe. Therapeutic hypothermia was delivered through both approaches and temperatures recorded at the RW, RW niche, over the lateral semicircular canal and the supero-lateral mastoid edge.
   Results: The average facial recess area was 13.87 +/- 5.52 mm(2). The introduction of the cooling probe through either approach did not impede visualization of the RW or cochleostomy as determined by STH grading. The average temperatures at RW using the FR approach reduced by 4.57 +/- 1.68 degrees C for RW, while using the myringotomy approach reduced by 4.11 +/- 0.98 degrees C for RW.
   Conclusion: Local application of therapeutic hypothermia is clinically feasible both through the facial recess and myringotomy approaches without limiting optimal surgical visualization.
C1 [Perez, Enrique; Viziano, Andrea; Al-Zaghal, Zaid; Telischi, Fred F.; Sangaletti, Rachele; Hoffer, Michael E.; Rajguru, Suhrud M.] Univ Miami, Dept Otolaryngol, Miami, FL 33134 USA.
   [Jiang, Weitao; Rajguru, Suhrud M.] Univ Miami, Dept Biomed Engn, Miami, FL 33134 USA.
   [Viziano, Andrea] Univ Roma Tor Vergata, Dept Clin Sci & Translat Med, Rome, Italy.
   [Dietrich, William Dalton] Univ Miami, Dept Neurol Surg, Miami Project Cure Paralysis, Miami, FL 33134 USA.
   [King, Curtis] Lucent Med Syst, Seattle, WA USA.
RP Rajguru, SM (corresponding author), Univ Miami, Ear Inst, Lois Pope Life Ctr, 1095 NW 14 Terrance,Room 4-25, Miami, FL 33134 USA.
EM s.rajguru@miami.edu
FU Cochlear [R01 DC01379801A1]; National Center For Advancing Translational
   Sciences of the National Institutes of Health under Miami Clinical and
   Translational Science Institute [UL1TR002736]; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR002736]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER
   COMMUNICATION DISORDERSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Deafness & Other Communication Disorders (NIDCD) [R01DC013798]
   Funding Source: NIH RePORTER
FX This work was supported by a Research Grant from Cochlear, R01
   DC01379801A1 and a pilot award from National Center For Advancing
   Translational Sciences of the National Institutes of Health under Award
   Number UL1TR002736, Miami Clinical and Translational Science Institute.
CR Ahmed AI, 2016, NEUROSURG CLIN N AM, V27, P489, DOI 10.1016/j.nec.2016.05.004
   Astolfi L, 2014, J BIOMED MATER RES B, V102, P267, DOI 10.1002/jbm.b.33004
   Atkins CM, 2010, EUR J NEUROSCI, V32, P1912, DOI 10.1111/j.1460-9568.2010.07467.x
   Balkany TJ, 2005, LARYNGOSCOPE, V115, P1543, DOI 10.1097/01.mlg.0000173169.45262.ae
   Bas E, 2012, ANAT REC, V295, P1909, DOI 10.1002/ar.22574
   Cappuccino A, 2010, SPINE, V35, pE57, DOI 10.1097/BRS.0b013e3181b9dc28
   CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13
   Cochlear, 2016, COCHL ANN REP 2016
   Darwazeh R, 2013, NEURAL REGEN RES, V8, P2677, DOI 10.3969/j.issn.1673-5374.2013.28.010
   Dietrich WD, 2007, PROG BRAIN RES, V162, P201, DOI 10.1016/S0079-6123(06)62011-6
   Dietrich WD, 2011, NEUROTHERAPEUTICS, V8, P229, DOI 10.1007/s13311-011-0035-3
   Dietrich WD, 2010, NEUROTHERAPEUTICS, V7, P43, DOI 10.1016/j.nurt.2009.10.015
   Dorman MF, 2008, AUDIOL NEURO-OTOL, V13, P105, DOI 10.1159/000111782
   DRESCHER DG, 1976, J ACOUST SOC AM, V59, P401, DOI 10.1121/1.380877
   Eshraghi AA, 2005, OTOL NEUROTOL, V26, P442, DOI 10.1097/01.mao.0000169791.53201.e1
   Eshraghi AA, 2007, OTOL NEUROTOL, V28, P842, DOI 10.1097/MAO.0b013e31805778fc
   FDA, 2015, FDA EX SUMM PREM POS
   FDA, 2013, EX SUMM COCHL CORP N
   Gantz BJ, 2009, AUDIOL NEURO-OTOL, V14, P32, DOI 10.1159/000206493
   Gebauer CM, 2006, PEDIATRICS, V117, P843, DOI 10.1542/peds.2004-1587
   Gfeller Kate E, 2006, Audiol Neurootol, V11 Suppl 1, P12, DOI 10.1159/000095608
   Gifford RH, 2013, EAR HEARING, V34, P413, DOI 10.1097/AUD.0b013e31827e8163
   Hassepass F, 2014, OTOL NEUROTOL, V35, P1415, DOI 10.1097/MAO.0000000000000412
   Henry KR, 2003, HEARING RES, V179, P88, DOI 10.1016/S0378-5955(03)00097-2
   James DP, 2008, AUDIOL NEURO-OTOL, V13, P86, DOI 10.1159/000111780
   Kang SY, 2010, JARO-J ASSOC RES OTO, V11, P245, DOI 10.1007/s10162-009-0194-7
   Kashio A, 2015, OTOL NEUROTOL, V36, pE18, DOI 10.1097/MAO.0000000000000644
   Koka K, 2017, FRONT NEUROSCI-SWITZ, V11, P1, DOI 10.3389/fnins.2017.00337
   Kontorinis G, 2011, OTOL NEUROTOL, V32, P565, DOI 10.1097/MAO.0b013e318219f6ac
   Kopelovich JC, 2015, OTOL NEUROTOL, V36, P1035, DOI 10.1097/MAO.0000000000000754
   Kurz M, 2018, THER HYPOTHERMIA TEM, V8, P4, DOI 10.1089/ther.2018.29041.mjk
   Lee DH, 2012, J CRANIOFAC SURG, V23, P817, DOI 10.1097/SCS.0b013e31824e6ca7
   Leong AC, 2013, EUR ARCH OTO-RHINO-L, V270, P1237, DOI 10.1007/s00405-012-2106-4
   Levi AD, 2010, NEUROSURGERY, V66, P670, DOI 10.1227/01.NEU.0000367557.77973.5F
   Lotocki G, 2006, EUR J NEUROSCI, V24, P2283, DOI 10.1111/j.1460-9568.2006.05123.x
   Maria PLS, 2013, OTOL NEUROTOL, V34, P526, DOI 10.1097/MAO.0b013e318281e0c9
   Matsui T, 2006, J NEUROSURG ANESTH, V18, P189, DOI 10.1097/01.ana.0000188639.39844.f6
   Meshik X, 2010, OTOL NEUROTOL, V31, P58, DOI 10.1097/MAO.0b013e3181b76bb8
   Ni YS, 2017, CLIN ANAT, V30, P39, DOI 10.1002/ca.22770
   Nikolopoulos TP, 1999, LARYNGOSCOPE, V109, P595, DOI 10.1097/00005537-199904000-00014
   O'Connell BP, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00291
   Ohta H, 2007, NEUROSCI RES, V57, P424, DOI 10.1016/j.neures.2006.12.002
   Polderman KH, 2009, CRIT CARE MED, V37, pS186, DOI 10.1097/CCM.0b013e3181aa5241
   Povlishock JT, 2009, J NEUROTRAUM, V26, P333, DOI 10.1089/neu.2008.0604
   Prentiss S, 2010, J AM ACAD AUDIOL, V21, P197, DOI 10.3766/jaaa.21.3.8
   Purdy PD, 2013, AM J NEURORADIOL, V34, P252, DOI 10.3174/ajnr.A3175
   Rajan GP, 2013, AUDIOL NEURO-OTOL, V18, P17, DOI 10.1159/000342821
   Ramos BF, 2015, ACTA OTO-LARYNGOL, V135, P473, DOI 10.3109/00016489.2014.995831
   Rebscher SJ, 2008, J REHABIL RES DEV, V45, P731, DOI 10.1682/JRRD.2007.08.0119
   Scheper V, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183820
   Shintani Y, 2011, STROKE RES TREAT, V2011, DOI 10.4061/2011/809874
   Stathopoulos Dimitra, 2014, Cochlear Implants Int, V15, P254, DOI 10.1179/1754762813Y.0000000054
   Takeda S, 2008, NEUROREPORT, V19, P1325, DOI 10.1097/WNR.0b013e32830b5f73
   Tamames I, 2018, EAR HEARING, V39, P712, DOI 10.1097/AUD.0000000000000529
   Tamames I, 2016, HEARING RES, V339, P32, DOI 10.1016/j.heares.2016.05.015
   Tanaka C, 2014, HEARING RES, V316, P82, DOI 10.1016/j.heares.2014.07.011
   Teszler CB, 2005, OTOL NEUROTOL, V26, P782, DOI 10.1097/01.mao.0000178141.04601.dc
   Thompson Hilaire J, 2010, J Trauma Nurs, V17, P173, DOI 10.1097/JTN.0b013e3181ff272e
   Tobey EA, 2013, INT J AUDIOL, V52, P219, DOI 10.3109/14992027.2012.759666
   Turner CW, 2004, J ACOUST SOC AM, V115, P1729, DOI 10.1121/1.1687425
   Tzen YT, 2013, J SPINAL CORD MED, V36, P357, DOI 10.1179/2045772312Y.0000000085
   Van De Water Thomas R, 2010, Cochlear Implants Int, V11 Suppl 1, P42, DOI 10.1179/146701010X12671178390834
   Wanna GB, 2014, LARYNGOSCOPE, V124, pS1, DOI 10.1002/lary.24728
   Wardrop P, 2005, HEARING RES, V203, P54, DOI 10.1016/j.heares.2004.11.006
   Watanabe F, 2001, NEUROSCIENCE, V102, P639, DOI 10.1016/S0306-4522(00)00510-8
   Wright CG, 2013, OTOL NEUROTOL, V34, P402, DOI 10.1097/MAO.0b013e318278509a
   Yanamoto H, 1999, STROKE, V30, P2720, DOI 10.1161/01.STR.30.12.2720
   Yokobori Shoji, 2013, Acta Neurochir Suppl, V118, P77, DOI 10.1007/978-3-7091-1434-6_13
   Yokobori S, 2011, THER HYPOTHERMIA TEM, V1, P185, DOI 10.1089/ther.2011.0012
   Zhang H, 2010, NEUROL RES, V32, P384, DOI 10.1179/016164110X12670144526228
NR 70
TC 4
Z9 4
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1531-7129
EI 1537-4505
J9 OTOL NEUROTOL
JI Otol. Neurotol.
PD OCT
PY 2019
VL 40
IS 9
BP 1167
EP 1177
DI 10.1097/MAO.0000000000002373
PG 11
WC Clinical Neurology; Otorhinolaryngology
SC Neurosciences & Neurology; Otorhinolaryngology
GA KG1CG
UT WOS:000509678200020
PM 31318786
OA hybrid, Green Published
DA 2021-10-30
ER

PT J
AU Alkhachroum, A
   Eliseyev, A
   Der-Nigoghossian, CA
   Rubinos, C
   Kromm, JA
   Mathews, E
   Bauerschmidt, A
   Doyle, K
   Velasquez, A
   Egbebike, JA
   Calderon, AR
   Roh, DJ
   Park, S
   Agarwal, S
   Connolly, ES
   Claassen, J
AF Alkhachroum, Ayham
   Eliseyev, Andrey
   Der-Nigoghossian, Caroline A.
   Rubinos, Clio
   Kromm, Julie Anne
   Mathews, Elizabeth
   Bauerschmidt, Andrew
   Doyle, Kevin
   Velasquez, Angela
   Egbebike, Jennifer A.
   Calderon, Anna R.
   Roh, David J.
   Park, Soojin
   Agarwal, Sachin
   Connolly, Edward Sander
   Claassen, Jan
TI EEG to detect early recovery of consciousness in amantadine-treated
   acute brain injury patients
SO JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
LA English
DT Letter
DE consciousness; EEG; COMA
C1 [Alkhachroum, Ayham; Eliseyev, Andrey; Mathews, Elizabeth; Doyle, Kevin; Velasquez, Angela; Egbebike, Jennifer A.; Calderon, Anna R.; Roh, David J.; Claassen, Jan] Columbia Univ, Neurorol, New York, NY 10032 USA.
   [Alkhachroum, Ayham] Univ Miami, Neurorol, Miami, FL USA.
   [Alkhachroum, Ayham] Jackson Mem Hlth Syst, Neurorol, Miami, FL USA.
   [Der-Nigoghossian, Caroline A.] Columbia Univ, Pharm, New York, NY USA.
   [Rubinos, Clio] Univ North Carolina Syst, Neurol, Chapel Hill, NC USA.
   [Kromm, Julie Anne] Univ Alberta, Neurol, Edmonton, AB, Canada.
   [Bauerschmidt, Andrew; Park, Soojin; Agarwal, Sachin] Columbia Univ, Neurocrit Care, New York, NY USA.
   [Connolly, Edward Sander] Columbia Univ, Neurosurg, New York, NY USA.
RP Claassen, J (corresponding author), Columbia Univ, Neurorol, New York, NY 10032 USA.
EM jc1439@cumc.columbia.edu
RI Rubinos, Clio/ABA-9937-2021; Alkhachroum, Ayham/V-6050-2019
OI Rubinos, Clio/0000-0002-1680-2302; Alkhachroum,
   Ayham/0000-0003-0352-5913; Egbebike, Jennifer/0000-0002-1255-5893;
   Eliseyev, Andrey/0000-0002-0312-889X; Bauerschmidt,
   Andrew/0000-0001-8535-127X; Der-Nigoghossian,
   Caroline/0000-0001-5445-9421
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01 NS106014, R03 NS112760]; DANA
   Foundation; Miami Clinical and Translation Science Institute (CTSI), KL2
   Career Development Award [UL1TR002736]
FX JC is supported by grant funding from the NIH R01 NS106014 and R03
   NS112760, and the DANA Foundation. AA is supported by grant funding from
   the Miami Clinical and Translation Science Institute (CTSI), KL2 Career
   Development Award UL1TR002736. JC is a minority shareholder at iCE
   Neurosystems.
CR Claassen J, 2019, NEW ENGL J MED, V380, P2497, DOI 10.1056/NEJMoa1812757
   Forgacs PB, 2017, ANN CLIN TRANSL NEUR, V4, P119, DOI 10.1002/acn3.385
   Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609
   Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004
   Schiff ND, 2010, TRENDS NEUROSCI, V33, P1, DOI 10.1016/j.tins.2009.11.002
NR 5
TC 2
Z9 2
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-3050
EI 1468-330X
J9 J NEUROL NEUROSUR PS
JI J. Neurol. Neurosurg. Psychiatry
PD JUN
PY 2020
VL 91
IS 6
BP 675
EP 676
DI 10.1136/jnnp-2019-322645
PG 2
WC Clinical Neurology; Psychiatry; Surgery
SC Neurosciences & Neurology; Psychiatry; Surgery
GA LW3RG
UT WOS:000539061900019
PM 32241920
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Gardener, H
   Sacco, RL
   Rundek, T
   Battistella, V
   Cheung, YK
   Elkind, MSV
AF Gardener, Hannah
   Sacco, Ralph L.
   Rundek, Tatjana
   Battistella, Valeria
   Cheung, Ying Kuen
   Elkind, Mitchell S. V.
TI Race and Ethnic Disparities in Stroke Incidence in the Northern
   Manhattan Study
SO STROKE
LA English
DT Article
DE cardiovascular disease; cohort studies; incidence; prevalence; risk
   factors
ID ISCHEMIC-STROKE; RISK; HISPANICS; WHITES; BLACKS; ADULTS
AB Background and Purpose-An excess incidence of strokes among blacks versus whites has been shown, but data on disparities related to Hispanic ethnicity remain limited. This study examines race/ethnic differences in stroke incidence in the multiethnic, largely Caribbean Hispanic, NOMAS (Northern Manhattan Study), and whether disparities vary by age.
   Methods-The study population included participants in the prospective population-based NOMAS, followed for a mean of 14 +/- 7 years. Multivariable-adjusted Cox proportional hazards models were constructed to estimate the association between race/ethnicity and incident stroke of any subtype and ischemic stroke, stratified by age.
   Results-Among 3298 participants (mean baseline age 69 +/- 10 years, 37% men, 24% black, 21% white, 52% Hispanic), 460 incident strokes accrued (400 ischemic, 43 intracerebral hemorrhage, 9 subarachnoid hemorrhage). The most common ischemic subtype was cardioembolic, followed by lacunar infarcts, then cryptogenic. The greatest incidence rate was observed in blacks (13/1000 person-years), followed by Hispanics (10/1000 person-years), and lowest in whites (9/1000 person-years), and this order was observed for crude incidence rates until age 75. By age 85, the greatest incidence rate was in Hispanics. Blacks had an increased risk of stroke versus whites overall in multivariable models that included sociodemographics (hazard ratio, 1.51 [95% CI, 1.13-2.02]), and stratified analyses showed that this disparity was driven by women of age >= 70. The increased rate of stroke among Hispanics (age/sex-adjusted hazard ratio, 1.48 [95% CI, 1.13-1.93]) was largely explained by education and insurance status (a proxy for socieoeconomic status; hazard ratio after further adjusting for these variables, 1.17 [95% CI, 0.85-1.62]) but remained significant for women age >= 70.
   Conclusions-This study provides novel data regarding the increased stroke risk among Caribbean Hispanics in this elderly population. Results highlight the need to create culturally tailored campaigns to reach black and Hispanic populations to reduce race/ethnic stroke disparities and support the important role of low socioeconomic status in driving an elevated risk among Caribbean Hispanics.
C1 [Gardener, Hannah; Sacco, Ralph L.; Rundek, Tatjana] Univ Miami, Miller Sch Med, Dept Neurol, Clin Res Bldg,1120 NW 14th St, Miami, FL 33136 USA.
   [Battistella, Valeria] Vila Nova de Gaia & Espinho Hosp Ctr, Stroke Unit, Vila Nova De Gaia, Portugal.
   [Cheung, Ying Kuen] Columbia Univ, Dept Biostat, Mailman Publ Sch Hlth, New York, NY USA.
   [Elkind, Mitchell S. V.] Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY USA.
RP Gardener, H (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol, Clin Res Bldg,1120 NW 14th St, Miami, FL 33136 USA.
EM hgardener@med.miami.edu
FU National Institutes of Health/National Institute of Neurological
   Disorders and StrokeUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Neurological Disorders & Stroke (NINDS) [R01 NS 29993]; National
   Center for Advancing Translational Sciences, Clinical Translational
   Science Institute [UL1TR000460]
FX This study was supported by National Institutes of Health/National
   Institute of Neurological Disorders and Stroke (R01 NS 29993). Support
   was also provided from the National Center for Advancing Translational
   Sciences, Clinical Translational Science Institute (UL1TR000460).
CR Appelros P, 2009, STROKE, V40, P1082, DOI 10.1161/STROKEAHA.108.540781
   Boden-Albala B, 2008, DIABETES CARE, V31, P1132, DOI 10.2337/dc07-0797
   Daviglus ML, 2012, JAMA-J AM MED ASSOC, V308, P1775, DOI 10.1001/jama.2012.14517
   Dong CH, 2012, CIRCULATION, V125, P2975, DOI 10.1161/CIRCULATIONAHA.111.081083
   Howard VJ, 2011, ANN NEUROL, V69, P619, DOI 10.1002/ana.22385
   Kissela B, 2004, STROKE, V35, P426, DOI 10.1161/01.STR.0000110982.74967.39
   Monteith TS, 2015, NEUROLOGY, V85, P715, DOI 10.1212/WNL.0000000000001854
   Moon JR, 2012, STROKE, V43, P1224, DOI 10.1161/STROKEAHA.111.643700
   Morgenstern LB, 2004, AM J EPIDEMIOL, V160, P376, DOI 10.1093/aje/kwh225
   Morgenstern LB, 2013, ANN NEUROL, V74, P778, DOI 10.1002/ana.23972
   Roger VL, 2012, CIRCULATION, V125, pE2, DOI 10.1161/CIR.0b013e31823ac046
   Rosamond WD, 1999, STROKE, V30, P736, DOI 10.1161/01.STR.30.4.736
   Sacco RL, 2004, STROKE, V35, P2263, DOI 10.1161/01.STR.0000142374.33919.92
   Sacco RL, 1998, AM J EPIDEMIOL, V147, P259, DOI 10.1093/oxfordjournals.aje.a009445
   White H, 2005, CIRCULATION, V111, P1327, DOI 10.1161/01.CIR.0000157736.19739.D0
   Willey JZ, 2010, J COMMUN HEALTH, V35, P602, DOI 10.1007/s10900-010-9249-2
NR 16
TC 18
Z9 18
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0039-2499
EI 1524-4628
J9 STROKE
JI Stroke
PD APR
PY 2020
VL 51
IS 4
BP 1064
EP 1069
DI 10.1161/STROKEAHA.119.028806
PG 6
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA LE8WP
UT WOS:000527007500020
PM 32078475
OA Green Accepted, Bronze
DA 2021-10-30
ER

PT J
AU Dugan, EA
   Bennett, C
   Tamames, I
   Dietrich, WD
   King, CS
   Prasad, A
   Rajguru, SM
AF Dugan, Elizabeth A.
   Bennett, Cassie
   Tamames, Ilmar
   Dietrich, W. Dalton
   King, Curtis S.
   Prasad, Abhishek
   Rajguru, Suhrud M.
TI Therapeutic hypothermia reduces cortical inflammation associated with
   utah array implants
SO JOURNAL OF NEURAL ENGINEERING
LA English
DT Article
DE therapeutic hypothermia; Utah arrays; microelectrodes; neuroprotection;
   brain computer interface; neuroprosthesis; inflammation
ID TRAUMATIC BRAIN-INJURY; TRANSIENT CEREBRAL-ISCHEMIA; SPINAL-CORD-INJURY;
   NF-KAPPA-B; MILD HYPOTHERMIA; MATRIX METALLOPROTEINASES; NEUTROPHIL
   INFILTRATION; SYSTEMIC HYPOTHERMIA; POSTISCHEMIC HYPOTHERMIA;
   EXPERIMENTAL STROKE
AB Objective. Neuroprosthetics hold tremendous promise to restore function through brain-computer interfaced devices. However, clinical applications of implantable microelectrodes remain limited given the challenges of maintaining neuronal signals for extended periods of time and with multiple biological mechanisms negatively affecting electrode performance. Acute and chronic inflammation, oxidative stress, and blood brain barrier disruption contribute to inconsistent electrode performance. We hypothesized that therapeutic hypothermia (TH) applied at the microelectrode insertion site will positively modulate both inflammatory and apoptotic pathways, promoting neuroprotection and improved performance in the long-term. Approach. A custom device and thermoelectric system were designed to deliver controlled TH locally to the cortical implant site at the time of microelectrode array insertion and immediately following surgery. The TH paradigm was derived from in vivo cortical temperature measurements and finite element modeling of temperature distribution profiles in the cortex. Male Sprague-Dawley rats were implanted with non-functional Utah microelectrodes arrays (UMEA) consisting of 4 x 4 grid of 1.5 mm long parylene-coated silicon shanks. In one group, TH was applied to the implant site for two hours following the UMEA implantation, while the other group was implanted under normothermic conditions without treatment. At 48 h, 72 h, 7 d and 14 d post-implantation, mRNA expression levels for genes associated with inflammation and apoptosis were compared between normothermic and hypothermia-treated groups. Main results. The custom system delivered controlled TH to the cortical implant site and the numerical models confirmed that the temperature decrease was confined locally. Furthermore, a one-time application of TH post UMEA insertion significantly reduced the acute inflammatory response with a reduction in the expression of inflammatory regulating cytokines and chemokines. Significance. This work provides evidence that acutely applied hypothermia is effective in significantly reducing acute inflammation post intracortical electrode implantation.
C1 [Dugan, Elizabeth A.; Bennett, Cassie; Tamames, Ilmar; Prasad, Abhishek; Rajguru, Suhrud M.] Univ Miami, Dept Biomed Engn, Coral Gables, FL 33124 USA.
   [Dietrich, W. Dalton] Univ Miami, Miami Project Cure Paralysis, Coral Gables, FL 33124 USA.
   [King, Curtis S.] Lucent Med Syst, Kirkland, WA USA.
   [Rajguru, Suhrud M.] Univ Miami, Dept Otolaryngol, Coral Gables, FL 33124 USA.
RP Prasad, A (corresponding author), Univ Miami, Dept Biomed Engn, Coral Gables, FL 33124 USA.
EM a.prasad@miami.edu; s.rajguru@miami.edu
OI Rajguru, Suhrud/0000-0001-5953-8516
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [1DP2EB022357, R01DC01379801A1];
   National Center for Advancing Translational Sciences of the National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [UL1TR002736]; Miami Clinical
   and Translational Science Institute; Wallace H Coulter Center for
   Translational Research Neural Engineering SEED Grants
FX This work was supported by NIH R01DC01379801A1, NIH 1DP2EB022357, a
   pilot award from National Center for Advancing Translational Sciences of
   the National Institutes of Health under Award Number UL1TR002736, Miami
   Clinical and Translational Science Institute, and the Wallace H Coulter
   Center for Translational Research Neural Engineering SEED Grants. The
   authors sincerely thank Drs Florian Solzbacher and Rohit Sharma at the
   University of Utah for providing the non-functional Utah microelectrode
   arrays for this study.
CR Agrawal Y, 2008, ARCH INTERN MED, V168, P1522, DOI 10.1001/archinte.168.14.1522
   Alva N, 2004, J THERM BIOL, V29, P259, DOI 10.1016/j.jtherbio.2004.04.001
   Alva N, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/957054
   Barrese JC, 2013, J NEURAL ENG, V10, DOI 10.1088/1741-2560/10/6/066014
   BELCH JJF, 1992, SCOT MED J, V37, P67, DOI 10.1177/003693309203700301
   Bennett C, 2019, BIOMATERIALS, V188, P144, DOI 10.1016/j.biomaterials.2018.09.040
   Bennett C, 2018, BIOMATERIALS, V164, P1, DOI 10.1016/j.biomaterials.2018.02.036
   BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401
   Brandman DM, 2017, IEEE T NEUR SYS REH, V25, P1687, DOI 10.1109/TNSRE.2017.2677443
   Butte A J, 2001, Pac Symp Biocomput, P6
   Cappuccino A, 2010, SPINE, V35, pE57, DOI 10.1097/BRS.0b013e3181b9dc28
   Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012
   Choi CH, 2012, INT J PEDIATR OTORHI, V76, P544, DOI 10.1016/j.ijporl.2012.01.013
   Choi JS, 2011, STROKE RES TREAT, V2011, DOI 10.4061/2011/846716
   CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13
   Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001
   Cooper D J, 2017, PROPHYLACTIC HYPOTHE
   Deng H, 2003, STROKE, V34, P2495, DOI 10.1161/01.STR.0000091269.67384.E7
   DEXTER F, 1994, ANN THORAC SURG, V57, P1171, DOI 10.1016/0003-4975(94)91350-1
   Diao CG, 2003, ANN BIOMED ENG, V31, P346, DOI 10.1114/1.1554924
   Dietrich W Dalton, 2017, Brain Circ, V3, P186, DOI 10.4103/bc.bc_28_17
   Dietrich WD, 2011, NEUROTHERAPEUTICS, V8, P229, DOI 10.1007/s13311-011-0035-3
   Dietrich WD, 2010, NEUROTHERAPEUTICS, V7, P43, DOI 10.1016/j.nurt.2009.10.015
   Fairchild KD, 2005, AM J PHYSIOL-CELL PH, V289, pC1114, DOI 10.1152/ajpcell.00152.2005
   Gamen S, 1998, CELL DEATH DIFFER, V5, P241, DOI 10.1038/sj.cdd.4400344
   Gidday JM, 2005, AM J PHYSIOL-HEART C, V289, pH558, DOI 10.1152/ajpheart.01275.2004
   Gilja V, 2015, NAT MED, V21, P1142, DOI 10.1038/nm.3953
   Hall ED, 1997, NEUROSURG CLIN N AM, V8, P195
   Han HS, 2002, J NEUROSCI, V22, P3921, DOI 10.1523/JNEUROSCI.22-10-03921.2002
   Hang CH, 2005, J SURG RES, V123, P188, DOI 10.1016/j.jss.2004.08.002
   Hata R, 1999, METAB BRAIN DIS, V14, P117, DOI 10.1023/A:1020709814456
   Hermann John K., 2018, Critical Reviews in Biomedical Engineering, V46, P341, DOI 10.1615/CritRevBiomedEng.2018027166
   Hochberg LR, 2012, NATURE, V485, P372, DOI 10.1038/nature11076
   Homer ML, 2013, ANNU REV BIOMED ENG, V15, P383, DOI 10.1146/annurev-bioeng-071910-124640
   Huggins CE, 2008, J MOL CELL CARDIOL, V44, P270, DOI 10.1016/j.yjmcc.2007.11.020
   Inamasu J, 2003, J NEUROL SCI, V209, P55, DOI 10.1016/S0022-510X(02)00463-X
   Inamasu J, 2002, ANN EMERG MED, V40, P220, DOI 10.1067/mem.2002.123697
   Inamasu J, 2000, ACT NEUR S, V76, P525
   Jiang J, 2017, RANDOMIZED CONTROLLE
   Justicia C, 2003, J CEREBR BLOOD F MET, V23, P1430, DOI 10.1097/01.WCB.0000090680.07515.C8
   Kawai N, 2000, STROKE, V31, P1982, DOI 10.1161/01.STR.31.8.1982
   Keller E, 2009, J NEUROSCI METH, V178, P345, DOI 10.1016/j.jneumeth.2008.12.030
   Kim S, 2007, IEEE T NEUR SYS REH, V15, P493, DOI 10.1109/TNSRE.2007.908429
   Lawrence MS, 1996, J NEUROSCI, V16, P486
   Lee JE, 2005, J NEUROSURG, V103, P289, DOI 10.3171/jns.2005.103.2.0289
   Lee SM, 2009, J CEREBR BLOOD F MET, V29, P1589, DOI 10.1038/jcbfm.2009.81
   Levi AD, 2010, NEUROSURGERY, V66, P670, DOI 10.1227/01.NEU.0000367557.77973.5F
   Liu YC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170682
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lo TP, 2009, J COMP NEUROL, V514, P433, DOI 10.1002/cne.22014
   Maekawa T, 2012, THERAPEUTIC HYPOTHER
   Maier CM, 1998, STROKE, V29, P2171, DOI 10.1161/01.STR.29.10.2171
   MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6
   McManus T, 2004, J NEUROCHEM, V91, P327, DOI 10.1111/j.1471-4159.2004.02711.x
   Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245
   Mirzaie M, 2018, INT J MOL CELL MED, V7, P8, DOI 10.22088/IJMCM.BUMS.7.1.8
   Nagel S, 2008, BRAIN RES, V1188, P198, DOI 10.1016/j.brainres.2007.10.052
   Nakashima K, 1996, STROKE, V27, P913, DOI 10.1161/01.STR.27.5.913
   Oh SH, 2000, ACTA OTO-LARYNGOL, V120, P146
   Peart MJ, 2005, P NATL ACAD SCI USA, V102, P3697, DOI 10.1073/pnas.0500369102
   Perez E, 2019, OTOL NEUROTOL, V40, P1167, DOI 10.1097/MAO.0000000000002373
   Polderman KH, 2006, CRIT CARE, V10, DOI 10.1186/cc5023
   Polderman KH, 2009, CRIT CARE MED, V37, pS186, DOI 10.1097/CCM.0b013e3181aa5241
   Polderman KH, 2009, CRIT CARE MED, V37, P1101, DOI 10.1097/CCM.0b013e3181962ad5
   Polderman KH, 2004, INTENS CARE MED, V30, P556, DOI 10.1007/s00134-003-2152-x
   Prasad Abhishek, 2014, Front Neuroeng, V7, P2, DOI 10.3389/fneng.2014.00002
   Prasad A, 2012, J NEURAL ENG, V9, DOI 10.1088/1741-2560/9/5/056015
   Purdy PD, 2013, AM J NEURORADIOL, V34, P252, DOI 10.3174/ajnr.A3175
   Raouf A, 2008, CELL STEM CELL, V3, P109, DOI 10.1016/j.stem.2008.05.018
   ROKKAS CK, 1995, J THORAC CARDIOV SUR, V110, P27, DOI 10.1016/S0022-5223(05)80006-6
   Rosenberg GA, 2002, NEUROSCIENTIST, V8, P586, DOI 10.1177/1073858402238517
   Shih RH, 2015, FRONT MOL NEUROSCI, V8, DOI 10.3389/fnmol.2015.00077
   Smith KD, 2011, P I MECH ENG H, V225, P533, DOI 10.1177/0954411911400156
   Tamames I, 2018, EAR HEARING, V39, P712, DOI 10.1097/AUD.0000000000000529
   Tamames I, 2016, HEARING RES, V339, P32, DOI 10.1016/j.heares.2016.05.015
   Toyoda T, 1996, NEUROSURGERY, V39, P1200, DOI 10.1097/00006123-199612000-00024
   Truettner JS, 2005, J CEREBR BLOOD F MET, V25, P1505, DOI 10.1038/sj.jcbfm.9600150
   Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006
   Tzen YT, 2013, J SPINAL CORD MED, V36, P357, DOI 10.1179/2045772312Y.0000000085
   Wagner S, 2003, BRAIN RES, V984, P63, DOI 10.1016/S0006-8993(03)03088-9
   Wang GJ, 2002, NEUROSCIENCE, V114, P1081, DOI 10.1016/S0306-4522(02)00350-0
   Wang YJ, 2007, EUR J APPL PHYSIOL, V101, P31, DOI 10.1007/s00421-007-0451-6
   Yin L, 2019, MED BIOL ENG COMPUT, V57, P1313, DOI 10.1007/s11517-019-01962-7
   Zhang H, 2010, NEUROL RES, V32, P384, DOI 10.1179/016164110X12670144526228
   Zhang HZ, 2015, OTOL NEUROTOL, V36, P1157, DOI 10.1097/MAO.0000000000000787
   Zhang ZJ, 2001, MOL BRAIN RES, V95, P75, DOI 10.1016/S0169-328X(01)00247-9
NR 86
TC 2
Z9 2
U1 0
U2 8
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 1741-2560
EI 1741-2552
J9 J NEURAL ENG
JI J. Neural Eng.
PD APR
PY 2020
VL 17
IS 2
AR 026035
DI 10.1088/1741-2552/ab85d2
PG 12
WC Engineering, Biomedical; Neurosciences
SC Engineering; Neurosciences & Neurology
GA LL1MC
UT WOS:000531318200001
PM 32240985
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Rice, D
   Martinelli, GP
   Jiang, WT
   Holstein, GR
   Rajguru, SM
AF Rice, Darrian
   Martinelli, Giorgio P.
   Jiang, Weitao
   Holstein, Gay R.
   Rajguru, Suhrud M.
TI Pulsed Infrared Stimulation of Vertical Semicircular Canals Evokes
   Cardiovascular Changes in the Rat
SO FRONTIERS IN NEUROLOGY
LA English
DT Article
DE optical stimulation; vestibulo-sympathetic reflex; vestibular system;
   autonomic; heart rate; blood pressure; infrared stimulation
ID SYMPATHETIC-NERVE ACTIVITY; GALVANIC VESTIBULAR STIMULATION; FREQUENCY
   PHYSIOLOGICAL ACTIVATION; ARTERIAL-BLOOD PRESSURE; VESTIBULOSYMPATHETIC
   REFLEX; LINEAR ACCELERATION; SURGICAL APPROACH; POSTURAL CHANGES;
   RESPONSES; NEURONS
AB A variety of stimuli activating vestibular end organs, including sinusoidal galvanic vestibular stimulation, whole body rotation and tilt, and head flexion have been shown to evoke significant changes in blood pressure (BP) and heart rate (HR). While a role for the vertical semicircular canals in altering autonomic activity has been hypothesized, studies to-date attribute the evoked BP and HR responses to the otolith organs. The present study determined whether unilateral activation of the posterior (PC) or anterior (AC) semicircular canal is sufficient to elicit changes in BP and/or HR. The study employed frequency-modulated pulsed infrared radiation (IR: 1,863 nm) directed via optical fibers to PC or AC of adult male Long-Evans rats. BP and HR changes were detected using a small-animal single pressure telemetry device implanted in the femoral artery. Eye movements evoked during IR of the vestibular endorgans were used to confirm the stimulation site. We found that sinusoidal IR delivered to either PC or AC elicited a rapid decrease in BP and HR followed by a stimulation frequency-matched modulation. The magnitude of the initial decrements in HR and BP did not correlate with the energy of the suprathreshold stimulus. This response pattern was consistent across multiple trials within an experimental session, replicable, and in most animals showed no evidence of habituation or an additive effect. Frequency modulated electrical current delivered to the PC and IR stimulation of the AC, caused decrements in HR and BP that resembled those evoked by IR of the PC. Frequency domain heart rate variability assessment revealed that, in most subjects, IR stimulation increased the low frequency (LF) component and decreased the high frequency (HF) component, resulting in an increase in the LF/HF ratio. This ratio estimates the relative contributions of sympathetic nervous system (SNS) and parasympathetic nervous system (PNS) activities. An injection of atropine, a muscarinic cholinergic receptor antagonist, diminished the IR evoked changes in HR, while the non-selective beta blocker propranolol eliminated changes in both HR and BP. This study provides direct evidence that activation of a single vertical semicircular canal is sufficient to activate and modulate central pathways that control HR and BP.
C1 [Rice, Darrian; Jiang, Weitao; Rajguru, Suhrud M.] Univ Miami, Dept Biomed Engn, Miami, FL 33146 USA.
   [Martinelli, Giorgio P.; Holstein, Gay R.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA.
   [Holstein, Gay R.] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY USA.
   [Rajguru, Suhrud M.] Univ Miami, Dept Otolaryngol, Miami, FL 33136 USA.
RP Rajguru, SM (corresponding author), Univ Miami, Dept Biomed Engn, Miami, FL 33146 USA.; Rajguru, SM (corresponding author), Univ Miami, Dept Otolaryngol, Miami, FL 33136 USA.
EM s.rajguru@miami.edu
FU NIH NIDCDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Deafness &
   Other Communication Disorders (NIDCD) [1R01DC008846, 1R01DC013798];
   National Center for Advancing Translational Sciences of the National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [UL1TR002736]; Miami Clinical
   and Translational Science Institute; Wallace H. Coulter Center for
   Translational Research Neural Engineering SEED Grants
FX This work was supported by NIH NIDCD 1R01DC008846 (GH) and 1R01DC013798
   (SR), a pilot award from National Center for Advancing Translational
   Sciences of the National Institutes of Health under Award Number
   UL1TR002736, Miami Clinical and Translational Science Institute, and the
   Wallace H. Coulter Center for Translational Research Neural Engineering
   SEED Grants (SR).
CR Abe C, 2008, J APPL PHYSIOL, V104, P34, DOI 10.1152/japplphysiol.00454.2007
   Abe C, 2009, J APPL PHYSIOL, V107, P1089, DOI 10.1152/japplphysiol.00400.2009
   BALABAN CD, 1994, EXP BRAIN RES, V98, P200
   Barman SM, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00730
   Barrett JN, 2018, J NEUROPHYSIOL, V120, P509, DOI 10.1152/jn.00740.2017
   Bent LR, 2006, EXP BRAIN RES, V174, P701, DOI 10.1007/s00221-006-0515-6
   BLESSING WW, 1988, AM J PHYSIOL, V254, pH686
   Camm A. J., 1996, CIRCULATION
   Cathers I, 2005, J PHYSIOL-LONDON, V563, P229, DOI 10.1113/jphysiol.2004.079525
   Cohen B, 2013, FASEB J, V27, P2564, DOI 10.1096/fj.12-226381
   Cohen B, 2011, EXP BRAIN RES, V210, P45, DOI 10.1007/s00221-011-2604-4
   COSTA F, 1995, CLIN AUTON RES, V5, P289, DOI 10.1007/BF01818894
   Cui J, 1997, J AUTONOM NERV SYST, V66, P154, DOI 10.1016/S0165-1838(97)00077-5
   Cui J, 1999, AM J PHYSIOL-REG I, V276, pR738
   Cui J, 2001, AM J PHYSIOL-REG I, V281, pR625
   Curthoys Ian S, 2012, Front Neurol, V3, P117, DOI 10.3389/fneur.2012.00117
   DOBA N, 1974, CIRC RES, V34, P9, DOI 10.1161/01.RES.34.1.9
   Fazan R, 2011, EPILEPSY BEHAV, V22, P666, DOI 10.1016/j.yebeh.2011.09.010
   Fitzpatrick RC, 2004, J APPL PHYSIOL, V96, P2301, DOI 10.1152/japplphysiol.00008.2004
   Gagliuso AH, 2019, J NEUROPHYSIOL, V122, P512, DOI 10.1152/jn.00082.2019
   Gotoh TM, 2004, AM J PHYSIOL-REG I, V286, pR25, DOI 10.1152/ajpregu.00458.2003
   Grewal T, 2012, EXP BRAIN RES, V220, P101, DOI 10.1007/s00221-012-3118-4
   Grewal T, 2009, EXP BRAIN RES, V197, P379, DOI 10.1007/s00221-009-1926-y
   Gulli G, 2005, CLIN AUTON RES, V15, P207, DOI 10.1007/s10286-005-0273-8
   Guyenet PG, 2006, NAT REV NEUROSCI, V7, P335, DOI 10.1038/nrn1902
   HALE GM, 1973, APPL OPTICS, V12, P555, DOI 10.1364/AO.12.000555
   Hammam E, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00334
   Hammam E, 2013, EXP BRAIN RES, V230, P137, DOI 10.1007/s00221-013-3637-7
   Hitier M, 2016, J NEUROSCI METH, V270, P1, DOI 10.1016/j.jneumeth.2016.05.013
   Holstein GR, 2011, NEUROSCIENCE, V175, P104, DOI 10.1016/j.neuroscience.2010.12.011
   Holstein GP, 2016, FRONT NEUROANAT, V10, DOI 10.3389/fnana.2016.00007
   Holstein GR, 2014, J COMP NEUROL, V522, P2053, DOI 10.1002/cne.23517
   Holstein Gay R, 2012, Front Neurol, V3, P4, DOI 10.3389/fneur.2012.00004
   Holstein GR., 2020, SENSES COMPREHENSIVE, V2, P432
   Holstein GR., 2012, HUMAN NERVOUS SYSTEM, V3rd Edition ed, P1239
   Izzo AD, 2006, LASER SURG MED, V38, P745, DOI 10.1002/lsm.20358
   James C, 2010, EXP BRAIN RES, V202, P291, DOI 10.1007/s00221-009-2131-8
   Jauregui-Renaud K, 2005, OTOL NEUROTOL, V26, P484
   JESKE I, 1993, AM J PHYSIOL, V264, pR169
   Jian BJ, 1999, J APPL PHYSIOL, V86, P1552, DOI 10.1152/jappl.1999.86.5.1552
   Jiang WT, 2018, ANN BIOMED ENG, V46, P1406, DOI 10.1007/s10439-018-2059-x
   Kasumacic N, 2012, J PHYSIOL-LONDON, V590, P5809, DOI 10.1113/jphysiol.2012.234609
   Kaufmann H, 2002, EXP BRAIN RES, V143, P463, DOI 10.1007/s00221-002-1002-3
   Kuipers NT, 2003, J PHYSIOL-LONDON, V548, P955, DOI 10.1113/jphysiol.2002.033357
   Liu Q, 2014, BIOPHYS J, V106, P1570, DOI 10.1016/j.bpj.2014.03.008
   Mandel DA, 2006, J PHYSIOL-LONDON, V572, P881, DOI 10.1113/jphysiol.2005.103622
   McCraty Rollin, 2015, Glob Adv Health Med, V4, P46, DOI 10.7453/gahmj.2014.073
   Moreno LE, 2011, HEARING RES, V282, P289, DOI 10.1016/j.heares.2011.06.006
   Nakamura Y, 2009, EXP BRAIN RES, V194, P563, DOI 10.1007/s00221-009-1732-6
   Natarajan M, 2000, AM J PHYSIOL-REG I, V279, pR364, DOI 10.1152/ajpregu.2000.279.2.R364
   Rabbitt RD, 2016, J NEUROPHYSIOL, V116, P825, DOI 10.1152/jn.00110.2016
   Rajguru SM, 2011, J PHYSIOL-LONDON, V589, P1283, DOI 10.1113/jphysiol.2010.198333
   Rajguru SM, 2010, HEARING RES, V269, P102, DOI 10.1016/j.heares.2010.06.021
   Ray CA, 2003, ACTA PHYSIOL SCAND, V177, P313, DOI 10.1046/j.1365-201X.2003.01084.x
   Ray CA, 1998, AM J PHYSIOL-REG I, V275, pR1274
   Reynolds Raymond Francis, 2012, Front Neurol, V3, P104
   Sauder CL, 2008, AM J PHYSIOL-RENAL, V295, pF1166, DOI 10.1152/ajprenal.90408.2008
   Serrador JM, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-119
   Shortt TL, 1997, AM J PHYSIOL-HEART C, V272, pH1780
   Spyer K M, 1981, Rev Physiol Biochem Pharmacol, V88, P24, DOI 10.1007/BFb0034536
   Stahl JS, 2000, J NEUROSCI METH, V99, P101, DOI 10.1016/S0165-0270(00)00218-1
   Tanaka K, 2014, AUTON NEUROSCI-BASIC, V185, P100, DOI 10.1016/j.autneu.2014.04.001
   TANG PC, 1969, EXP NEUROL, V24, P558, DOI 10.1016/0014-4886(69)90158-7
   Thurrell A, 2003, EXP BRAIN RES, V150, P325, DOI 10.1007/s00221-003-1422-8
   Vidal P.P., 2015, RAT NERVOUS SYSTEM, P805, DOI [10.1016/B978-0-12-374245-2.00028-0, DOI 10.1016/B978-0-12-374245-2.00028-0]
   Voustianiouk A, 2006, EXP BRAIN RES, V171, P251, DOI 10.1007/s00221-005-0266-9
   Watson SRD, 1998, EXP BRAIN RES, V122, P453, DOI 10.1007/s002210050533
   Wells J, 2005, OPT LETT, V30, P504, DOI 10.1364/OL.30.000504
   Wilson TD, 2006, J PHYSIOL-LONDON, V575, P671, DOI 10.1113/jphysiol.2006.112904
   Wilson TD, 2006, J APPL PHYSIOL, V100, P1475, DOI 10.1152/japplphysiol.01585.2005
   Woodring SF, 1997, EXP BRAIN RES, V113, P165
   Yates BJ, 2014, COMPR PHYSIOL, V4, P851, DOI 10.1002/cphy.c130041
   Yates BJ, 1996, ANN NY ACAD SCI, V781, P458, DOI 10.1111/j.1749-6632.1996.tb15720.x
   YATES BJ, 1994, J NEUROPHYSIOL, V71, P2087, DOI 10.1152/jn.1994.71.6.2087
   Yates BJ., 1996, NEURAL CONTROL RESP, P271
   Yates BJ., 2019, NEURAL CONTROL RESP, V1
   Yavorcik KJ, 2009, AM J PHYSIOL-REG I, V297, pR1777, DOI 10.1152/ajpregu.00551.2009
   Zhu H, 2007, J APPL PHYSIOL, V103, P646, DOI 10.1152/japplphysiol.00328.2007
   Zygmunt A, 2010, ARCH MED SCI, V6, P11, DOI 10.5114/aoms.2010.13500
NR 79
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2295
J9 FRONT NEUROL
JI Front. Neurol.
PD MAY 28
PY 2021
VL 12
AR 680044
DI 10.3389/fneur.2021.680044
PG 16
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA SQ0JA
UT WOS:000660046500001
PM 34122320
OA gold, Green Published
DA 2021-10-30
ER

PT J
AU Strbo, N
   Romero, L
   Alcaide, M
   Fischl, M
AF Strbo, Natasa
   Romero, Laura
   Alcaide, Maria
   Fischl, Margaret
TI Isolation and Flow Cytometric Analysis of Human Endocervical Gamma Delta
   T Cells
SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
DE Immunology; Issue 120; Mucosa; Female reproductive tract; endocervix;
   intraepithelial lymphocytes; gamma delta T cells; HIV
ID INFECTION
AB The female reproductive tract (FRT) mucosal immune system serves as the first line of defense. Better knowledge of the genital mucosa is therefore essential for understanding pathogenicity of different pathogens including HIV. Gamma delta (GD) T cells are the prototype of 'unconventional' T cells and represent a relatively small subset of T cells defined by their expression of heterodimeric T-cell receptors (TCRs) composed of gamma and delta chains. This sets them apart from the classical and much better known CD4(+) helper T cells and CD8(+) cytotoxic T cells that are defined by alpha-beta TCRs. GD T cells often show tissue-specific localization and are enriched in epithelium. GD T cells orchestrate immune responses in inflammation, tumor surveillance, infectious disease, and autoimmunity.
   Here, we present a method to reproducibly isolate and analyze human endocervical intraepithelial GD T lymphocytes. We have used endocervical cytobrush samples from women participating in the Women's Interagency HIV Infection Study (WIHS). Knowledge about GD T cells interactions during conditions in which there is an insult to the vaginal mucosal could be applied to any clinical study in which mucosal vulnerability is addressed, including the development of vaginal microbicides. In addition, knowledge about mucosal GD T cell responses has potential for application of GD T cell-based immune therapy in treating infectious diseases.
C1 [Strbo, Natasa; Romero, Laura] Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Coral Gables, FL 33124 USA.
   [Alcaide, Maria; Fischl, Margaret] Univ Miami, Miller Sch Med, Div Infect Dis, Coral Gables, FL 33124 USA.
RP Strbo, N (corresponding author), Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Coral Gables, FL 33124 USA.
EM NStrbo@med.miami.edu
OI Alcaide, Maria/0000-0003-4648-0145
FU National Institute of Allergy and Infectious Diseases and Women's
   Interagency HIV Infection Study (WIHS) [U01 AI103397]; National
   Institute of Allergy and Infectious Diseases, National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [P30AI073961]; National Center for Advancing
   Translational Sciences and the National Institute on Minority Health and
   Health Disparities, National Institute of Health [UL1TR000460,
   1KL2TR000461]; National Institute of Child Health and Human Development,
   National Institute of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD)
   [K23HD074489]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH
   & HUMAN DEVELOPMENTUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD)
   [K23HD074489] Funding Source: NIH RePORTER; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000460,
   KL2TR000461] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY
   AND INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [P30AI073961, U01AI103397]
   Funding Source: NIH RePORTER
FX We thank the Miami WIHS study participants for their willingness to
   participate in this work. Data in this manuscript were collected by the
   Miami Women's Interagency HIV Study (WIHS). The contents of this
   publication are solely the responsibility of the authors and do not
   represent the official views of the National Institutes of Health (NIH).
   This work was supported by National Institute of Allergy and Infectious
   Diseases and Women's Interagency HIV Infection Study (WIHS) [grant
   number U01 AI103397], National Institute of Allergy and Infectious
   Diseases, National Institutes of Health [grant number P30AI073961],
   National Center for Advancing Translational Sciences and the National
   Institute on Minority Health and Health Disparities, National Institute
   of Health [grant number UL1TR000460 and 1KL2TR000461], and National
   Institute of Child Health and Human Development, National Institute of
   Health [grant number K23HD074489].
CR Alcaide ML, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153045
   AUTRAN B, 1989, CLIN EXP IMMUNOL, V75, P206
   Cheroutre H, 2011, NAT REV IMMUNOL, V11, P445, DOI 10.1038/nri3007
   Dominguez MH, 2013, J IMMUNOL METHODS, V391, P133, DOI 10.1016/j.jim.2013.03.002
   Fichorova RN, 2004, BIOL REPROD, V71, P761, DOI 10.1095/biolreprod.104.029603
   Haase AT, 2010, NATURE, V464, P217, DOI 10.1038/nature08757
   Hayday AC, 2000, ANNU REV IMMUNOL, V18, P975, DOI 10.1146/annurev.immunol.18.1.975
   Hayday AC, 2009, SEMIN IMMUNOL, V21, P99, DOI 10.1016/j.smim.2009.04.003
   Juno J. A., 2014, JOVE
   Kaul R, 2008, J REPROD IMMUNOL, V77, P32, DOI 10.1016/j.jri.2007.02.002
   Masson L, 2014, SEX TRANSM INFECT, V90, P580, DOI 10.1136/sextrans-2014-051601
   McKinnon LR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085675
   Nakasone C, 2007, MICROBES INFECT, V9, P251, DOI 10.1016/j.micinf.2006.11.015
   Pauza CD, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00687
   Strbo N, 2016, AM J REPROD IMMUNOL, V75, P134, DOI 10.1111/aji.12458
   Szabo S E, 2004, Lab Hematol, V10, P109, DOI 10.1532/LH96.04020
NR 16
TC 2
Z9 2
U1 0
U2 4
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940-087X
J9 JOVE-J VIS EXP
JI J. Vis. Exp.
PD FEB
PY 2017
IS 120
AR e55038
DI 10.3791/55038
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EQ1RQ
UT WOS:000397847700038
PM 28287518
OA Green Published
DA 2021-10-30
ER

PT J
AU Ducasa, GM
   Mitrofanova, A
   Fornoni, A
AF Ducasa, G. Michelle
   Mitrofanova, Alla
   Fornoni, Alessia
TI Crosstalk Between Lipids and Mitochondria in Diabetic Kidney Disease
SO CURRENT DIABETES REPORTS
LA English
DT Review
DE Diabetic kidney disease; Podocyte; Mitochondria; Cardiolipin; ABCA1;
   Lipid metabolism
ID TUBULAR EPITHELIAL-CELLS; B SCAVENGER RECEPTOR; SPHINGOSINE KINASE 2;
   INSULIN-RESISTANCE; TANGIER-DISEASE; FATTY-ACID; ADRENAL INSUFFICIENCY;
   SUPEROXIDE-PRODUCTION; MOLECULAR-MECHANISMS; CARDIOLIPIN PROVIDES
AB Purpose of Review The goal of this review is to review the role that renal parenchymal lipid accumulation plays in contributing to diabetic kidney disease (DKD), specifically contributing to the mitochondrial dysfunction observed in glomerular renal cells in the context of DKD development and progression.
   Recent Findings Mitochondrial dysfunction has been observed in experimental and clinical DKD. Recently, Ayanga et al. demonstrate that podocyte-specific deletion of a protein involved in mitochondrial dynamics protects from DKD progression. Furthermore, our group has recently shown that ATP-binding cassette A1 (a protein involved in cholesterol and phospholipid efflux) is significantly reduced in clinical and experimental DKD and that genetic or pharmacological induction of ABCA1 is sufficient to protect from DKD. ABCA1 deficiency in podocytes leads to mitochondrial dysfunction observed with alterations of mitochondrial lipids, in particular, cardiolipin (a mitochondrial-specific phospholipid). However, through pharmacological reduction of cardiolipin peroxidation DKD progression is reverted.
   Summary Lipid metabolism is significantly altered in the diabetic kidney and renders cellular components, such as the podocyte, susceptible to injury leading to worsened DKD progression. Dysfunction of the lipid metabolism pathway can also lead to mitochondrial dysfunction and mitochondrial lipid alteration. Future research aimed at targeting mitochondrial lipids content and function could prove to be beneficial for the treatment of DKD.
C1 [Ducasa, G. Michelle; Mitrofanova, Alla; Fornoni, Alessia] Univ Miami, Miller Sch Med, Katz Family Div Nephrol & Hypertens, Dept Med, 1580 NW 10th Ave, Miami, FL 33136 USA.
   [Ducasa, G. Michelle; Mitrofanova, Alla; Fornoni, Alessia] Univ Miami, Miller Sch Med, Peggy & Harold Katz Family Drug Discovery Ctr, Miami, FL 33136 USA.
   [Mitrofanova, Alla] Univ Miami, Miller Sch Med, Dept Surg, Miami, FL 33136 USA.
RP Fornoni, A (corresponding author), Univ Miami, Miller Sch Med, Katz Family Div Nephrol & Hypertens, Dept Med, 1580 NW 10th Ave, Miami, FL 33136 USA.; Fornoni, A (corresponding author), Univ Miami, Miller Sch Med, Peggy & Harold Katz Family Drug Discovery Ctr, Miami, FL 33136 USA.
EM gducasa@ucsd.edu; a.mitrofanova@miami.edu; afornoni@miami.edu
OI fornoni, Alessia/0000-0002-1313-7773
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01DK117599, R01DK104753, R01CA227493,
   U54DK083912, UM1DK100846, U01DK116101, UL1TR000460]
FX Research in Dr. Alessia Fornoni's laboratory is supported by the NIH
   grants R01DK117599, R01DK104753, R01CA227493, U54DK083912, UM1DK100846,
   U01DK116101, and UL1TR000460 (Miami Clinical Translational Science
   Institute).
CR Ahmad A, 2017, FASEB J, V31, P771, DOI 10.1096/fj.201600618R
   Alvarez SE, 2010, NATURE, V465, P1084, DOI 10.1038/nature09128
   ARNAREZ C, 2013, SCI REP UK, V3
   Arnarez C, 2013, J AM CHEM SOC, V135, P3112, DOI 10.1021/ja310577u
   Awad AS, 2011, KIDNEY INT, V79, P1090, DOI 10.1038/ki.2010.544
   Ayanga BA, 2016, J AM SOC NEPHROL, V27, P2733, DOI 10.1681/ASN.2015101096
   Bajwa A, 2017, J AM SOC NEPHROL, V28, P1145, DOI 10.1681/ASN.2016030306
   Bakris G, 2008, AM J KIDNEY DIS, V51, pS1, DOI 10.1053/j.ajkd.2008.01.015
   Bayir H, 2006, BBA-BIOENERGETICS, V1757, P648, DOI 10.1016/j.bbabio.2006.03.002
   Bhat VK, 2019, J INVEST DERMATOL, V139, P807, DOI 10.1016/j.jid.2018.10.024
   Birk AV, 2014, BRIT J PHARMACOL, V171, P2017, DOI 10.1111/bph.12468
   Bischof J, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2017.16
   Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914
   Bottinger L, 2012, J MOL BIOL, V423, P677, DOI 10.1016/j.jmb.2012.09.001
   Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905
   Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a
   Bruce CR, 2013, ENDOCRINOLOGY, V154, P65, DOI 10.1210/en.2012-1847
   Bruce CR, 2012, DIABETES, V61, P3148, DOI 10.2337/db12-0029
   Chalfant CE, 2005, J CELL SCI, V118, P4605, DOI 10.1242/jcs.02637
   Choi HJ, 2011, PEDIATR NEPHROL, V26, P1981, DOI 10.1007/s00467-011-1903-0
   Choi HS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e39
   Claypool SM, 2012, TRENDS BIOCHEM SCI, V37, P32, DOI 10.1016/j.tibs.2011.09.003
   Cusick M, 2004, KIDNEY INT, V66, P1173, DOI 10.1111/j.1523-1755.2004.00869.x
   deKroon AIPM, 1997, BBA-BIOMEMBRANES, V1325, P108, DOI 10.1016/S0005-2736(96)00240-4
   Di Pardo A, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00698
   Ding W, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.94818
   Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222
   Ducasa GM, 2019, J CLIN INVEST, V129, P3387, DOI 10.1172/JCI125316
   Dudkina NV, 2010, BBA-BIOENERGETICS, V1797, P664, DOI 10.1016/j.bbabio.2009.12.013
   El Buri Ashref, 2018, Oncotarget, V9, P29453, DOI 10.18632/oncotarget.25658
   Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI14006
   Feng L, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/1414070
   FERRANS VJ, 1975, AM J PATHOL, V78, P101
   Fobker M, 2001, FEBS LETT, V500, P157, DOI 10.1016/S0014-5793(01)02578-9
   Forbes JM, 2008, DIABETES, V57, P1446, DOI 10.2337/db08-0057
   Forbes JM, 2018, NAT REV NEPHROL, V14, P291, DOI 10.1038/nrneph.2018.9
   Fornoni A, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002231
   Fox TE, 2011, J LIPID RES, V52, P509, DOI 10.1194/jlr.M010595
   Ganda A, 2017, J MOL CELL CARDIOL, V112, P114, DOI 10.1016/j.yjmcc.2017.05.001
   Gomez-Munoz A, 2000, SHINGOLIPIDS SIGNALI
   Gomez-Munoz A, 2006, BBA-BIOMEMBRANES, V1758, P2049, DOI 10.1016/j.bbamem.2006.05.011
   Gonzalvez F, 2008, J CELL BIOL, V183, P681, DOI 10.1083/jcb.200803129
   Gredilla R, 2004, ANN NY ACAD SCI, V1019, P333, DOI 10.1196/annals.1297.057
   Hait NC, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/4806541
   Han D, 2001, BIOCHEM J, V353, P411, DOI 10.1042/0264-6021:3530411
   Han JH, 1997, J BIOL CHEM, V272, P21654, DOI 10.1074/jbc.272.34.21654
   Hasan SS, 2011, J MOL BIOL, V414, P145, DOI 10.1016/j.jmb.2011.09.023
   Heinz LX, 2015, CELL REP, V11, P1919, DOI 10.1016/j.celrep.2015.05.006
   Herman-Edelstein M, 2014, J LIPID RES, V55, P561, DOI 10.1194/jlr.P040501
   Horvath SE, 2013, PROG LIPID RES, V52, P590, DOI 10.1016/j.plipres.2013.07.002
   Hou YJ, 2015, BIOCHEM BIOPH RES CO, V468, P281, DOI 10.1016/j.bbrc.2015.10.112
   Hu JJ, 2019, J CELL PHYSIOL, V234, P23559, DOI 10.1002/jcp.28924
   Hua W, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127507
   Huls M, 2008, KIDNEY INT, V73, P220, DOI 10.1038/sj.ki.5002645
   Huls M, 2006, KIDNEY INT, V69, P2186, DOI 10.1038/sj.ki.5000407
   Ibold B, 2019, LIPIDS HEALTH DIS, V18, DOI 10.1186/s12944-018-0943-x
   Jiang T, 2005, J BIOL CHEM, V280, P32317, DOI 10.1074/jbc.M500801200
   Joly S, 2017, NEURAL PLAST, V2017, DOI 10.1155/2017/6818970
   Joshi AS, 2009, BBA-MOL CELL RES, V1793, P212, DOI 10.1016/j.bbamcr.2008.07.024
   Jun DJ, 2006, ENDOCRINOLOGY, V147, P5835, DOI 10.1210/en.2006-0579
   Jun JY, 2011, AM J PHYSIOL-ENDOC M, V301, pE145, DOI 10.1152/ajpendo.00034.2011
   Kampe K, 2014, AM J PHYSIOL-RENAL, V306, pF401, DOI 10.1152/ajprenal.00454.2013
   Kang HM, 2015, NAT MED, V21, P37, DOI 10.1038/nm.3762
   Kim CH, 2012, LEUKEMIA, V26, P106, DOI 10.1038/leu.2011.185
   Kolavennu V, 2008, DIABETES, V57, P714, DOI 10.2337/db07-1241
   Kowalski GM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072449
   Kutik S, 2008, J CELL BIOL, V183, P1213, DOI 10.1083/jcb.200806048
   Lara-Castro C, 2008, ENDOCRIN METAB CLIN, V37, P841, DOI 10.1016/j.ecl.2008.09.002
   Lee SY, 2015, HEPATOLOGY, V62, P135, DOI 10.1002/hep.27804
   Lee WC, 2016, DNA CELL BIOL, V35, P657, DOI 10.1089/dna.2016.3261
   Linhares ND, 2018, CLIN KIDNEY J, V11, P462, DOI 10.1093/ckj/sfx130
   Liu Y, 2013, J PATHOL, V230, P365, DOI 10.1002/path.4194
   Lovric S, 2017, J CLIN INVEST, V127, P912, DOI 10.1172/JCI89626
   Lu L, 2011, J ZHEJIANG UNIV-SC B, V12, P652, DOI 10.1631/jzus.B1101004
   Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395
   Mahringer A, 2019, BIOL CHEM, V400, P1335, DOI 10.1515/hsz-2018-0425
   Masereeuw R, 2012, AAPS J, V14, P883, DOI 10.1208/s12248-012-9404-z
   McKenzie M, 2006, J MOL BIOL, V361, P462, DOI 10.1016/j.jmb.2006.06.057
   Merscher S, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00127
   Merscher-Gomez S, 2013, DIABETES, V62, P3817, DOI 10.2337/db13-0399
   Meyer TW, 1999, DIABETOLOGIA, V42, P1341, DOI 10.1007/s001250051447
   Mileykovskaya E, 2012, J BIOL CHEM, V287, P23095, DOI 10.1074/jbc.M112.367888
   Mitrofanova A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10584-4
   Mitrofanova A, 2018, KIDNEY INT, V94, P1151, DOI 10.1016/j.kint.2018.06.031
   Motyl J, 2018, NEUROPHARMACOLOGY, V135, P139, DOI 10.1016/j.neuropharm.2018.02.023
   Nagahashi M, 2018, CANCER SCI, V109, P3671, DOI 10.1111/cas.13802
   Nassir F, 2007, J BIOL CHEM, V282, P19493, DOI 10.1074/jbc.M703330200
   Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121
   Nojiri T, 2014, J DIABETES INVEST, V5, P639, DOI 10.1111/jdi.12232
   Osawa Y, 2005, J BIOL CHEM, V280, P27879, DOI 10.1074/jbc.M503002200
   Osellame LD, 2012, BEST PRACT RES CL EN, V26, P711, DOI 10.1016/j.beem.2012.05.003
   Osman C, 2011, J CELL BIOL, V192, P7, DOI 10.1083/jcb.201006159
   Pagtalunan ME, 1997, J CLIN INVEST, V99, P342, DOI 10.1172/JCI119163
   Paradies G, 2014, BBA-BIOENERGETICS, V1837, P408, DOI 10.1016/j.bbabio.2013.10.006
   Pastukhov O, 2014, CELL PHYSIOL BIOCHEM, V34, P119, DOI 10.1159/000362989
   Pedigo CE, 2016, J CLIN INVEST, V126, P3336, DOI 10.1172/JCI85939
   Perry HM, 2016, J AM SOC NEPHROL, V27, P3383, DOI 10.1681/ASN.2015080922
   Perry RJ, 2014, NATURE, V510, P84, DOI 10.1038/nature13478
   Prasad R, 2017, J CLIN INVEST, V127, P942, DOI 10.1172/JCI90171
   Proctor G, 2006, DIABETES, V55, P2502, DOI 10.2337/db05-0603
   Qi HY, 2017, DIABETES, V66, P763, DOI 10.2337/db16-0695
   Qin X, 2019, THERANOSTICS, V9, P1698, DOI 10.7150/thno.30640
   Raichur S, 2014, CELL METAB, V20, P687, DOI 10.1016/j.cmet.2014.09.015
   Rapizzi E, 2009, CELL MOL LIFE SCI, V66, P3207, DOI 10.1007/s00018-009-0106-3
   Ravid M, 1998, ARCH INTERN MED, V158, P998, DOI 10.1001/archinte.158.9.998
   Ribas V, 2016, CLIN TRANSL MED, V5, DOI 10.1186/s40169-016-0106-5
   Rosca MG, 2005, AM J PHYSIOL-RENAL, V289, pF420, DOI 10.1152/ajprenal.00415.2004
   Ruan XZ, 2009, NAT REV NEPHROL, V5, P713, DOI 10.1038/nrneph.2009.184
   Russo GT, 2016, DIABETES CARE, V39, P2278, DOI 10.2337/dc16-1246
   Samad F, 2006, DIABETES, V55, P2579, DOI 10.2337/db06-0330
   Schofield JD, 2016, DIABETES THER, V7, P203, DOI 10.1007/s13300-016-0167-x
   Schug ZT, 2009, BBA-BIOMEMBRANES, V1788, P2022, DOI 10.1016/j.bbamem.2009.05.004
   Sharma K, 2013, J AM SOC NEPHROL, V24, P1901, DOI 10.1681/ASN.2013020126
   Sieber J, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00186
   Sieber J, 2013, AM J PATHOL, V183, P735, DOI 10.1016/j.ajpath.2013.05.023
   Simon N, 2015, FRONT MED, V2, DOI 10.3389/fmed.2015.00052
   Sivitz WI, 2010, ANTIOXID REDOX SIGN, V12, P537, DOI 10.1089/ars.2009.2531
   Small DM, 2012, NEPHRON EXP NEPHROL, V122, P123, DOI 10.1159/000350726
   St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200
   Su W, 2017, KIDNEY DIS-BASEL, V3, P171, DOI 10.1159/000479874
   Sun H, 2013, INT J ENDOCRINOL, V2013, DOI 10.1155/2013/592576
   Susztak K, 2006, DIABETES, V55, P225, DOI 10.2337/diabetes.55.1.225
   Szeto HH, 2016, KIDNEY INT, V90, P997, DOI 10.1016/j.kint.2016.06.013
   Szeto HH, 2014, BRIT J PHARMACOL, V171, P2029, DOI 10.1111/bph.12461
   Tang CR, 2010, J LIPID RES, V51, P1719, DOI 10.1194/jlr.M003525
   Toyoda M, 2007, DIABETES, V56, P2155, DOI 10.2337/db07-0019
   Unsay JD, 2013, LANGMUIR, V29, P15878, DOI 10.1021/la402669z
   van der Bliek AM, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a011072
   Van Krieken R, 2018, ENDOCRINOLOGY, V159, P1479, DOI 10.1210/en.2018-00093
   Wang L, 2018, J INVEST SURG, V31, P69, DOI 10.1080/08941939.2016.1278057
   Wang XXX, 2010, DIABETES, V59, P2916, DOI 10.2337/db10-0019
   Wang XX, 2009, AM J PHYSIOL-RENAL, V297, pF1587, DOI 10.1152/ajprenal.00404.2009
   Wang ZW, 2005, DIABETES, V54, P2328, DOI 10.2337/diabetes.54.8.2328
   Wei P, 2009, RENAL FAILURE, V31, P503, DOI 10.1080/08860220902963848
   Westermann B, 2010, NAT REV MOL CELL BIO, V11, P872, DOI 10.1038/nrm3013
   White KE, 2002, DIABETES, V51, P3083, DOI 10.2337/diabetes.51.10.3083
   Yang XJ, 2018, MED SCI MONITOR, V24, P6832, DOI 10.12659/MSM.909810
   Yang Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02937-0
   Yoo TH, 2015, J AM SOC NEPHROL, V26, P133, DOI 10.1681/ASN.2013111213
   Youle RJ, 2005, NAT REV MOL CELL BIO, V6, P657, DOI 10.1038/nrm1697
   Yu TZ, 2006, P NATL ACAD SCI USA, V103, P2653, DOI 10.1073/pnas.0511154103
   Zhang M, 2005, J BIOL CHEM, V280, P29403, DOI 10.1074/jbc.M504955200
   Zhang Y, 2015, ACTA DIABETOL, V52, P1045, DOI 10.1007/s00592-015-0753-9
   Zhang Y, 2015, AM J PHYSIOL-ENDOC M, V308, pE1140, DOI 10.1152/ajpendo.00591.2014
   Zhao J, 2019, MEDIAT INFLAMM, V2019, DOI 10.1155/2019/3172647
   Zheng XJ, 2019, PHARMACOL THERAPEUT, V195, P85, DOI 10.1016/j.pharmthera.2018.10.011
   Zhou CC, 2011, J LIPID RES, V52, P1483, DOI 10.1194/jlr.M014092
   ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602
NR 148
TC 14
Z9 14
U1 0
U2 3
PU CURRENT MEDICINE GROUP
PI PHILADELPHIA
PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA
SN 1534-4827
EI 1539-0829
J9 CURR DIABETES REP
JI Curr. Diabetes Rep.
PD DEC
PY 2019
VL 19
IS 12
AR 144
DI 10.1007/s11892-019-1263-x
PG 12
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA KH2MC
UT WOS:000510480500006
PM 31754839
DA 2021-10-30
ER

PT J
AU Comai, G
   Malvi, D
   Angeletti, A
   Vasuri, F
   Valente, S
   Ambrosi, F
   Capelli, I
   Ravaioli, M
   Pasquinelli, G
   D'Errico, A
   Fornoni, A
   La Manna, G
AF Comai, Giorgia
   Malvi, Deborah
   Angeletti, Andrea
   Vasuri, Francesco
   Valente, Sabrina
   Ambrosi, Francesca
   Capelli, Irene
   Ravaioli, Matteo
   Pasquinelli, Gianandrea
   D'Errico, Antonietta
   Fornoni, Alessia
   La Manna, Gaetano
TI Histological Evidence of Diabetic Kidney Disease Precede Clinical
   Diagnosis
SO AMERICAN JOURNAL OF NEPHROLOGY
LA English
DT Article
DE Albuminuria diabetes mellitus; Diabetic nephropathy; Diabetic kidney
   disease; Kidney biopsy
ID NONDIABETIC RENAL-DISEASE; ALBUMIN EXCRETION; PODOCYTE NUMBER;
   RISK-FACTORS; NEPHROPATHY; BIOPSY; ADULTS; COMPLICATIONS; PROGRESSION;
   PREVALENCE
AB Background: In the absence of a histological diagnosis, persistent albuminuria is globally accepted as the main diagnostic criteria for diabetic kidney disease (DKD). Methods: In the present retrospective study, we evaluated data from an Italian cohort of 42 deceased diabetic donors (mainly with type 2 diabetes). Using the kidney biopsies obtained at the time of donation to evaluate single or double allocation based on Karpinski score, we determined the prevalence of histological lesions attributable to diabetes. Results: All 42 donors presented with proteinuria in the normal range and an estimated glomerular filtration rate (eGFR) (chronic kidney disease [CKD]-EPI) >60 mL/min/1.73 m(2). A kidney biopsy was available for 36 patients; of these, one was not interpretable and 32 showed histopathological lesions consistent with DKD and encompassing all histological classes. Thus, we found a relatively high proportion of histologically proven DKD that had been clinically undiagnosed, as none of the patient had significant proteinuria and eGFR <60 mL/min/1.73 m(2). Conclusions: The data we present here support the need to implement routine kidney biopsies in normoalbuminuric diabetic subjects in the early stages of CKD. Such strategy may help to improve risk stratification in diabetic patients and guide therapeutic decisions during the early stages of the disease.
C1 [Comai, Giorgia; Angeletti, Andrea; Capelli, Irene; La Manna, Gaetano] Univ Bologna, S Orsola Malpighi Hosp, Dept Expt Diagnost & Specialty Med, Nephrol Dialysis & Renal Transplant Unit, Via G Massarenti 9,Pad 15, IT-40138 Bologna, Italy.
   [Malvi, Deborah; Vasuri, Francesco; Ambrosi, Francesca; D'Errico, Antonietta] Univ Bologna, S Orsola Malpighi Hosp, Pathol Unit, Dept Expt Diagnost & Specialty Med, Bologna, Italy.
   [Valente, Sabrina; Pasquinelli, Gianandrea] Univ Bologna, Clin Pathol S Orsola Malpighi Hosp, Dept Expt Diagnost & Specialty Med, Bologna, Italy.
   [Ravaioli, Matteo] Univ Bologna, S Orsola Malpighi Hosp Bologna, Dept Med & Surg Sci, Unit Gen & Transplant Surg, Bologna, Italy.
   [Fornoni, Alessia] Univ Miami, Dept Med, Katz Family Drug Discovery Ctr, Miami, FL USA.
RP La Manna, G (corresponding author), Univ Bologna, S Orsola Malpighi Hosp, Dept Expt Diagnost & Specialty Med, Nephrol Dialysis & Renal Transplant Unit, Via G Massarenti 9,Pad 15, IT-40138 Bologna, Italy.
EM gaetano.lamanna@unibo.it
RI Pasquinelli, Gianandrea/I-7088-2012; Angeletti, Andrea/AAB-3826-2020;
   Valente, Sabrina/ABI-1022-2020; Angeletti, Andrea/AAE-7944-2020
OI Pasquinelli, Gianandrea/0000-0003-1506-1829; Angeletti,
   Andrea/0000-0002-6121-5326; VALENTE, SABRINA/0000-0002-4090-291X;
   fornoni, Alessia/0000-0002-1313-7773; La Manna,
   Gaetano/0000-0001-5473-8551; D'ERRICO, ANTONIETTA/0000-0003-2747-3732;
   Ravaioli, Matteo/0000-0001-5862-6151; Comai, Giorgia/0000-0003-4160-8840
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01DK117599, R01DK104753, R01CA227493,
   U54DK083912, UM1DK100846, U01DK116101, UL1TR000460]; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [R01CA227493] Funding Source: NIH RePORTER; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000460]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND
   DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK104753,
   U54DK083912, R01DK117599, U01DK116101, UM1DK100846] Funding Source: NIH
   RePORTER
FX A.F. is supported by the NIH grants R01DK117599, R01DK104753,
   R01CA227493, U54DK083912, UM1DK100846, U01DK116101, and UL1TR000460
   (Miami Clinical Translational Science Institute).
CR Adler AI, 2003, KIDNEY INT, V63, P225, DOI 10.1046/j.1523-1755.2003.00712.x
   Afkarian M, 2016, JAMA-J AM MED ASSOC, V316, P602, DOI 10.1001/jama.2016.10924
   Amer Diabet Assoc, 2018, DIABETES CARE, V41, pS13, DOI 10.2337/dc18-S002
   Angeletti A, 2019, NEPHRON, V142, P34, DOI 10.1159/000499452
   Bolignano D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178699
   Campbell KN, 2011, CURR DIABETES REV, V7, P3, DOI 10.2174/157339911794273973
   Caramori ML, 2013, J AM SOC NEPHROL, V24, P1175, DOI 10.1681/ASN.2012070739
   Cassis P, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98720
   Danaei G, 2011, LANCET, V378, P31, DOI 10.1016/S0140-6736(11)60679-X
   de Boer IH, 2011, JAMA-J AM MED ASSOC, V305, P2532, DOI 10.1001/jama.2011.861
   DONOVAN KL, 1991, NEPHROL DIAL TRANSPL, V6, P731, DOI 10.1093/ndt/6.10.731
   Doshi SM, 2017, CLIN J AM SOC NEPHRO, V12, P1366, DOI 10.2215/CJN.11111016
   Dwyer JP, 2012, CARDIORENAL MED, V2, P1, DOI 10.1159/000333249
   Fiorentino M, 2017, NEPHROL DIAL TRANSPL, V32, P97, DOI 10.1093/ndt/gfw070
   FIORETTO P, 1995, KIDNEY INT, V48, P1929, DOI 10.1038/ki.1995.493
   FIORETTO P, 1994, DIABETES, V43, P1358, DOI 10.2337/diabetes.43.11.1358
   Gansevoort RT, 2013, LANCET, V382, P339, DOI 10.1016/S0140-6736(13)60595-4
   Gekle M, 2005, ANNU REV PHYSIOL, V67, P573, DOI 10.1146/annurev.physiol.67.031103.154845
   Gesualdo L, 2015, NEPHROL DIAL TRANSPL, V30, P155, DOI 10.1093/ndt/gfu372
   Haas M, 2009, ARCH PATHOL LAB MED, V133, P224, DOI 10.1043/1543-2165-133.2.224
   He F, 2013, DIABETOLOGIA, V56, P457, DOI 10.1007/s00125-012-2796-6
   Karpinski J, 1999, TRANSPLANTATION, V67, P1162, DOI 10.1097/00007890-199904270-00013
   Klessens CQF, 2016, KIDNEY INT, V90, P149, DOI 10.1016/j.kint.2016.01.023
   Kramer HJ, 2003, JAMA-J AM MED ASSOC, V289, P3273, DOI 10.1001/jama.289.24.3273
   Maclsaac RJ, 2014, KIDNEY INT, V86, P50, DOI 10.1038/ki.2014.98
   Maggiore U, 2014, CURR OPIN ORGAN TRAN, V19, P372, DOI 10.1097/MOT.0000000000000081
   Mak SK, 1997, NEPHROL DIAL TRANSPL, V12, P2588, DOI 10.1093/ndt/12.12.2588
   Manno C, 2004, KIDNEY INT, V66, P1570, DOI 10.1111/j.1523-1755.2004.00922.x
   Markowitz GS, 2002, HUM PATHOL, V33, P826, DOI 10.1053/hupa.2002.126189
   Meyer TW, 1999, DIABETOLOGIA, V42, P1341, DOI 10.1007/s001250051447
   Mise K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183190
   Molitch ME, 2010, DIABETES CARE, V33, P1536, DOI 10.2337/dc09-1098
   Mulder S, 2018, DIABETES OBES METAB, V20, P6, DOI 10.1111/dom.13416
   Najafian B, 2015, AM J KIDNEY DIS, V66, pE37, DOI 10.1053/j.ajkd.2015.08.010
   Nosadini R, 2000, DIABETES, V49, P476, DOI 10.2337/diabetes.49.3.476
   Pagtalunan ME, 1997, J CLIN INVEST, V99, P342, DOI 10.1172/JCI119163
   Papale M, 2010, DIABETES CARE, V33, P2409, DOI 10.2337/dc10-0345
   Parving HH, 2006, KIDNEY INT, V69, P2057, DOI 10.1038/sj.ki.5000377
   Penno G, 2011, J HYPERTENS, V29, P1802, DOI 10.1097/HJH.0b013e3283495cd6
   Retnakaran R, 2006, DIABETES, V55, P1832, DOI 10.2337/db05-1620
   Rodriguez-Poncelas A, 2018, J NEPHROL, V31, P743, DOI 10.1007/s40620-018-0524-0
   Ruggenenti P, 2011, J HYPERTENS, V29, P207, DOI 10.1097/HJH.0b013e32834069bd
   Said SM, 2016, KIDNEY INT, V90, P24, DOI 10.1016/j.kint.2016.02.042
   Sharma SG, 2013, CLIN J AM SOC NEPHRO, V8, P1718, DOI 10.2215/CJN.02510213
   Soni SS, 2006, NEPHROLOGY, V11, P533, DOI 10.1111/j.1440-1797.2006.00681.x
   Suarez MLG, 2013, WORLD J DIABETES, V4, P245, DOI 10.4239/wjd.v4.i6.245
   Tervaert TWC, 2010, J AM SOC NEPHROL, V21, P556, DOI 10.1681/ASN.2010010010
   Thomas MC, 2009, DIABETES CARE, V32, P1497, DOI 10.2337/dc08-2186
   Tondel C, 2012, CLIN J AM SOC NEPHRO, V7, P1591, DOI 10.2215/CJN.02150212
   Tone A, 2005, DIABETES RES CLIN PR, V69, P237, DOI 10.1016/j.diabres.2005.02.009
   Vallon V, 2011, COMPR PHYSIOL, V1, P1175, DOI 10.1002/cphy.c100049
   Whaley-Connell AT, 2012, AM J KIDNEY DIS, V59, pS1, DOI 10.1053/j.ajkd.2011.11.018
   White KE, 2002, DIABETES, V51, P3083, DOI 10.2337/diabetes.51.10.3083
   WISEMAN DA, 1990, KIDNEY INT, V38, P347, DOI 10.1038/ki.1990.208
   Zhuo L, 2017, FRONT MED-PRC, V11, P386, DOI 10.1007/s11684-017-0574-z
NR 55
TC 5
Z9 5
U1 0
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0250-8095
EI 1421-9670
J9 AM J NEPHROL
JI Am. J. Nephrol.
PY 2019
VL 50
IS 1
BP 29
EP 36
DI 10.1159/000500353
PG 8
WC Urology & Nephrology
SC Urology & Nephrology
GA II6LK
UT WOS:000475305200005
PM 31167184
OA Green Accepted, Green Submitted
DA 2021-10-30
ER

PT J
AU Faigle, R
   Chen, BJ
   Krieger, R
   Marsh, EB
   Alkhachroum, A
   Xiong, W
   Urrutia, VC
   Gottesman, RF
AF Faigle, Roland
   Chen, Bridget J.
   Krieger, Rachel
   Marsh, Elisabeth B.
   Alkhachroum, Ayham
   Xiong, Wei
   Urrutia, Victor C.
   Gottesman, Rebecca F.
TI Novel Score for Stratifying Risk of Critical Care Needs in Patients With
   Intracerebral Hemorrhage
SO NEUROLOGY
LA English
DT Article
ID UNIT ADMISSION; INTRACRANIAL HEMORRHAGE; COMPLICATIONS; EPIDEMIOLOGY;
   STAY
AB Objective To develop a risk prediction score identifying patients with intracerebral hemorrhage (ICH) at low risk for critical care. Methods We retrospectively analyzed data of 451 patients with ICH between 2010 and 2018. The sample was randomly divided into a development and a validation cohort. Logistic regression was used to develop a risk score by weighting independent predictors of intensive care unit (ICU) needs according to strength of association. The risk score was tested in the validation cohort and externally validated in a dataset from another institution. Results The rate of ICU interventions was 80.3%. Systolic blood pressure (SBP), Glasgow Coma Scale (GCS) score, intraventricular hemorrhage (IVH), and ICH volume were independent predictors of critical care, resulting in the following point assignments for the Intensive Care Triaging in Spontaneous Intracerebral Hemorrhage (INTRINSIC) score: SBP 160 to 190 mm Hg (1 point), SBP >190 mm Hg (3 points); GCS 8 to 13 (1 point), GCS <8 (3 points); ICH volume 16 to 40 cm(3) (1 point), ICH volume >40 cm(3) (2 points); and presence of IVH (1 point), with values ranging between 0 and 9. Among patients with a score of 0 and no ICU needs during their emergency department stay, 93.6% remained without critical care needs. In an external validation cohort of patients with ICH, the INTRINSIC score achieved an area under the receiver operating characteristic curve of 0.823 (95% confidence interval 0.782-0.863). A score <2 predicted the absence of critical care needs with 48.5% sensitivity and 88.5% specificity, and a score Conclusion The INTRINSIC score identifies patients with ICH who are at low risk for critical care interventions. Classification of Evidence This study provides Class II evidence that the INTRINSIC score identifies patients with ICH at low risk for critical care interventions.
C1 [Faigle, Roland; Chen, Bridget J.; Krieger, Rachel; Marsh, Elisabeth B.; Urrutia, Victor C.; Gottesman, Rebecca F.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA.
   [Alkhachroum, Ayham] Univ Miami, Dept Neurol, Miller Sch Med, Jackson Mem Hlth Syst, Coral Gables, FL 33124 USA.
   [Xiong, Wei] Case Western Reserve Univ, Dept Neurol, Sch Med, Univ Hosp Cleveland,Med Ctr, Cleveland, OH 44106 USA.
RP Faigle, R (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA.
EM rfaigle1@jhmi.edu
RI Gottesman, Rebecca/ABA-8468-2020
OI Faigle, Roland/0000-0002-9074-1915; Chen, Bridget/0000-0001-6167-8315
FU National Institute of Neurologic Disorders and StrokeUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Neurological Disorders & Stroke (NINDS)
   [K23NS101124]; Morningstar Foundation; National Center for Advancing
   Translational Sciences of the NIH under the Miami CTSI KL2 Career
   Development Award [UL1TR002736]; National Institute on AgingUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute on Aging (NIA) [K24AG052573]
FX R.F. is supported by a career development grant from the National
   Institute of Neurologic Disorders and Stroke (K23NS101124) and The
   Morningstar Foundation. A.A. is supported by the National Center for
   Advancing Translational Sciences of the NIH under the Miami CTSI KL2
   Career Development Award (UL1TR002736). R.F.G. is supported by a grant
   from the National Institute on Aging (K24AG052573).
CR Alberti C, 2002, INTENS CARE MED, V28, P108, DOI 10.1007/s00134-001-1143-z
   Alkhachroum AM, 2017, CLIN NEUROL NEUROSUR, V162, P12, DOI 10.1016/j.clineuro.2017.09.002
   Balami JS, 2012, LANCET NEUROL, V11, P101, DOI 10.1016/S1474-4422(11)70264-2
   Brott T, 1997, STROKE, V28, P1, DOI 10.1161/01.STR.28.1.1
   Bui JQH, 2011, J NEUROSURG, V115, P1236, DOI 10.3171/2011.8.JNS11105
   Coughlin DG, 2018, NEUROCRIT CARE, V28, P175, DOI 10.1007/s12028-017-0446-z
   Desai SV, 2011, CRIT CARE MED, V39, P371, DOI DOI 10.1097/CCM.0b013e3181fd66e5
   Elliott M, 2014, INTENS CRIT CARE NUR, V30, P121, DOI 10.1016/j.iccn.2013.10.005
   Faigle R, 2020, NEUROCRIT CARE, V33, P333, DOI 10.1007/s12028-020-00998-0
   Faigle R, 2020, NEUROHOSPITALIST, V10, P11, DOI 10.1177/1941874419845229
   Faigle R, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.116.003540
   Faigle R, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1195-7
   Faigle R, 2015, NEURORADIOLOGY, V57, P171, DOI 10.1007/s00234-014-1453-9
   Faigle R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088652
   Hemphill JC, 2015, STROKE, V46, P2032, DOI 10.1161/STR.0000000000000069
   Hemphill JC, 2001, STROKE, V32, P891, DOI 10.1161/01.STR.32.4.891
   Junttila EK, 2011, ACTA ANAESTH SCAND, V55, P1052, DOI 10.1111/j.1399-6576.2011.02512.x
   KRAISS LW, 1995, AM J SURG, V169, P512, DOI 10.1016/S0002-9610(99)80207-4
   Kramer AA, 2012, CRIT CARE MED, V40, P3, DOI 10.1097/CCM.0b013e31822d751e
   KWAK R, 1983, STROKE, V14, P493, DOI 10.1161/01.STR.14.4.493
   Laws L, 2020, NEUROHOSPITALIST, V10, P272, DOI 10.1177/1941874420926760
   Lyden P, 2020, STROKE, V51, P1910, DOI 10.1161/STROKEAHA.120.030023
   Naidech AM, 2009, NEUROCRIT CARE, V10, P11, DOI 10.1007/s12028-008-9148-x
   Nair Dilip, 2013, W V Med J, V109, P44
   Nishijima DK, 2012, INJURY, V43, P1827, DOI 10.1016/j.injury.2011.07.020
   Rincon F, 2013, NEUROCRIT CARE, V19, P95, DOI 10.1007/s12028-012-9793-y
   Rosa RG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143127
   Salluh JI, 2010, CRIT CARE, V14, DOI 10.1186/cc9333
   Salluh JIF, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2538
   van Asch CJJ, 2010, LANCET NEUROL, V9, P167, DOI 10.1016/S1474-4422(09)70340-0
   Washington CW, 2012, J NEUROSURG, V116, P549, DOI 10.3171/2011.11.JNS111092
NR 31
TC 5
Z9 5
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD MAY 18
PY 2021
VL 96
IS 20
BP E2458
EP E2468
DI 10.1212/WNL.0000000000011927
PG 11
WC Clinical Neurology
SC Neurosciences & Neurology
GA UZ7MV
UT WOS:000702386800019
PM 33790039
DA 2021-10-30
ER

PT J
AU Carrasquillo, O
   Lebron, C
   Alonzo, Y
   Li, H
   Chang, A
   Kenya, S
AF Carrasquillo, Olveen
   Lebron, Cynthia
   Alonzo, Yisel
   Li, Hua
   Chang, Aileen
   Kenya, Sonjia
TI Effect of a Community Health Worker Intervention Among Latinos With
   Poorly Controlled Type 2 Diabetes The Miami Healthy Heart Initiative
   Randomized Clinical Trial
SO JAMA INTERNAL MEDICINE
LA English
DT Article
ID BLOOD-GLUCOSE CONTROL; PEOPLE; SCALE
AB IMPORTANCE Community health worker (CHW) intervention is a promising approach to address type 2 diabetes among Latinos. However, evidence from randomized clinical studies is limited.
   OBJECTIVE To compare a CHW intervention with enhanced usual care.
   DESIGN, SETTING, AND PARTICIPANTS This 52-week, single-blind, randomized clinical trial included 300 Latino adults aged 18 to 65 years who were treated in 2 public hospital outpatient clinics in Miami-Dade County, Florida, from July 1, 2010, through October 31, 2013. Eligible participants had a hemoglobin A(1c) (HbA(1c)) level of 8.0 or greater. Follow-up was completed January 31, 2015, and data were analyzed from March 10, 2015, to June 6, 2016.
   INTERVENTIONS A 1-year CHW intervention consisted of home visits, telephone calls, and group-level activities.
   MAIN OUTCOMES AND MEASURES Primary outcomes included systolic blood pressure (SBP), low-density lipoprotein cholesterol (LDLC) levels, and HbA(1c) levels. Secondary outcomes included body mass index, medication regimen intensification, and self-reported measures of diet, physical activity, and medication regimen adherence.
   RESULTS Of the 300 participants randomized (135 men [45%] and 165 women [55%]; mean [SD] age, 55.2 [7.0] years), we obtained follow-up data on 215 (71.7%). Participants in the CHW group received a median of 4 home visits and 20 telephone calls. After adjusting for baseline values and covariates, participants in the CHW group had an HbA(1c) level that was 0.51% lower (95% CI, -0.94% to -0.08%) than that of participants in the enhanced usual care group. The reduction in SBP of 4.62 mmHg (95% CI, -9.01 to -0.24 mmHg) did not meet the preplanned target of 8 mmHg and was not statistically significant in unadjusted models. No significant differences in LDLC levels (mean difference, -8.2 mg/dL; 95% CI, -18.8 to 2.3 mg/dL) or any of the preplanned secondary outcomes were observed. Post hoc analyses suggest that the intervention may be more beneficial among those with worse control of their type 2 diabetes at baseline.
   CONCLUSIONS AND RELEVANCE Among Latinos with poorly controlled type 2 diabetes, a 12-month CHW intervention lowered HbA(1c) levels by 0.51%. The intervention did not lead to improvements in LDLC levels, and the findings with respect to SBP were variable and half of what was targeted. Future studies should examine whether CHW interventions affect other measures, such as access to health care or social determinants of health.
C1 [Carrasquillo, Olveen; Lebron, Cynthia; Alonzo, Yisel; Chang, Aileen; Kenya, Sonjia] Univ Miami, Miller Sch Med, Dept Med, Clin Res Bldg,Room 962,Locator Code C223, Miami, FL 33136 USA.
   [Carrasquillo, Olveen; Lebron, Cynthia; Li, Hua; Chang, Aileen; Kenya, Sonjia] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA.
   [Chang, Aileen] George Washington Univ, Sch Med, Dept Med, Washington, DC USA.
RP Carrasquillo, O (corresponding author), Univ Miami, Miller Sch Med, Dept Med, Clin Res Bldg,Room 962,Locator Code C223, Miami, FL 33136 USA.
EM oc6@med.miami.edu
OI Chang, Aileen/0000-0001-7410-9867
FU National Heart, Blood, and Lung InstituteUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [R01 HL083857]; National
   Center for Advancing Translational SciencesUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000460]; National Institute on Minority Health and Health
   DisparitiesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Minority
   Health & Health Disparities (NIMHD); NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [UL1TR000460] Funding Source:
   NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL083857]
   Funding Source: NIH RePORTER
FX This study was supported by grant R01 HL083857 from the National Heart,
   Blood, and Lung Institute. Use of the Clinical Translation Research
   Center was supported by grant UL1TR000460 from the National Center for
   Advancing Translational Sciences and the National Institute on Minority
   Health and Health Disparities.
CR Adler NE, 2006, ADDRESSING SOCIAL DE
   Amer Diabet Assoc, 2013, DIABETES CARE, V36, P1033, DOI 10.2337/dc12-2625
   [Anonymous], 2012, DIABETES CARE, V35, pS11, DOI [10.2337/dc12-s011, 10.2337/dc35-S011, 10.2337/dc12-s004]
   Baig AA, 2015, J GEN INTERN MED, V30, P1481, DOI 10.1007/s11606-015-3339-x
   Carrasquillo O, 2014, INT J GEN MED, V7, P115, DOI 10.2147/IJGM.S56250
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   De Waal Ton, 2011, HDB STAT DATA EDITIN
   Duckworth W, 2007, J DIABETES COMPLICAT, V21, P196, DOI 10.1016/j.jdiacomp.2007.01.001
   Emdin CA, 2015, JAMA-J AM MED ASSOC, V313, P603, DOI 10.1001/jama.2014.18574
   Grimm K. A., 2010, Morbidity and Mortality Weekly Report, V59, P1125
   Holman RR, 2008, NEW ENGL J MED, V359, P1577, DOI 10.1056/NEJMoa0806470
   Kearney PM, 2008, LANCET, V371, P117, DOI 10.1016/S0140-6736(08)60104-X
   Kenya S, 2015, J COMMUNITY HOSP INT, V5, DOI 10.3402/jchimp.v5.26586
   Lebron C, 2015, ONE CHW ANOTHER COMM
   Lebron CN, 2015, J HEALTH CARE POOR U, V26, P453, DOI 10.1353/hpu.2015.0033
   Lee SYD, 2010, HEALTH SERV RES, V45, P1105, DOI 10.1111/j.1475-6773.2010.01119.x
   MARIN G, 1987, HISPANIC J BEHAV SCI, V9, P183, DOI 10.1177/07399863870092005
   Morisky DE, 2008, J CLIN HYPERTENS, V10, P348, DOI 10.1111/j.1751-7176.2008.07572.x
   Mutamba BB, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-412
   National Heart Lung and Blood Institute., 2013, HISP COMM HLTH STUD, P13
   National Research Council, 2010, PREV TREATM MISS DAT
   Palmas W, 2015, J GEN INTERN MED, V30, P1004, DOI 10.1007/s11606-015-3247-0
   Palmas W, 2014, DIABETES CARE, V37, P963, DOI 10.2337/dc13-2142
   Patel A, 2008, NEW ENGL J MED, V358, P2560, DOI 10.1056/NEJMoa0802987
   Peek ME, 2007, MED CARE RES REV, V64, p101S, DOI 10.1177/1077558707305409
   Perez-Escamilla R, 2015, DIABETES CARE, V38, P197, DOI 10.2337/dc14-0327
   PERLOFF D, 1993, CIRCULATION, V88, P2460, DOI 10.1161/01.CIR.88.5.2460
   Prince MJ, 1999, BRIT J PSYCHIAT, V174, P330, DOI 10.1192/bjp.174.4.330
   Rothschild SK, 2014, AM J PUBLIC HEALTH, V104, P1540, DOI 10.2105/AJPH.2013.301439
   Stratton IM, 2000, BMJ-BRIT MED J, V321, P405, DOI 10.1136/bmj.321.7258.405
NR 30
TC 23
Z9 23
U1 1
U2 13
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD JUL
PY 2017
VL 177
IS 7
BP 948
EP 954
DI 10.1001/jamainternmed.2017.0926
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA EZ3GL
UT WOS:000404599100014
PM 28459925
OA Green Published
DA 2021-10-30
ER

PT J
AU Swaminathan, SS
   Kunkler, AL
   Quan, AV
   Medert, CM
   Vanner, EA
   Feuer, W
   Chang, TC
AF Swaminathan, Swarup S.
   Kunkler, Anne L.
   Quan, Ann, V
   Medert, Charles M.
   Vanner, Elizabeth A.
   Feuer, William
   Chang, Ta Chen
TI Rates of RNFL Thinning in Patients with Suspected or Confirmed Glaucoma
   Receiving Unilateral Intravitreal Injections for Exudative AMD
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID NERVE-FIBER LAYER; ENDOTHELIAL GROWTH-FACTOR; GANGLION-CELL COMPLEX;
   ANTERIOR-CHAMBER PARACENTESIS; INNER PLEXIFORM LAYER; MACULAR
   DEGENERATION; INTRAOCULAR-PRESSURE; ANTI-VEGF; OCULAR HYPERTENSION;
   THICKNESS CHANGES
AB PURPOSE: This study evaluated whether the rate of retinal nerve fiber layer (RNFL) thinning is faster in eyes receiving intravitreal injections than in fellow uninjected eyes among patients suspected of having or confirmed to have glaucoma and exudative age-related macular degeneration (AMD).
   DESIGN: Retrospective comparative cohort study.
   METHODS: Patients with a diagnosis of unilateral exudative AMD and confirmed to have or suspected of having glaucoma in both eyes receiving unilateral intravitreal injections were identified. Those with >= 3 RNFL optical coherence tomography scans and >= 6 injections were included in the study. Rates of RNFL thinning in the injected eye versus the uninjected eye were estimated using linear mixed models. The main outcome measurement was the differences in rates of RNFL thinning in the injected versus the fellow uninjected eye. The effects of postinjection elevation of intraocular pressure (IOP), injection frequency, and number of injections were also evaluated.
   RESULTS: A total of 53 patients met the inclusion criteria, receiving 26.4 +/- 15.9 intravitreal injections. The average rate of RNFL thinning in uninjected eyes was -0.620 mu m/year (P = .029). Injected eyes had an additional incremental loss of -0.385 mm/year, but this value was not statistically significant (95% confidence interval [CI]:-1.147 to 0.379 mm/year; P = .324). Subgroup analysis with only glaucoma patients (n = 33) also demonstrated a nonsignificant effect of injections (-0.568 mm/year; 95% CI:-1.454 to 0.319 mm/year; P = .212). Postinjection IOP elevation, injection frequency, and total number of injections were not associated with faster RNFL loss.
   CONCLUSIONS: Among exudative AMD patients with glaucoma or suspected of having glaucoma, the rate of RNFL thinning in eyes receiving intravitreal injections did not significantly differ from that of fellow uninjected eyes. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Swaminathan, Swarup S.; Kunkler, Anne L.; Quan, Ann, V; Medert, Charles M.; Vanner, Elizabeth A.; Feuer, William; Chang, Ta Chen] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
RP Swaminathan, SS (corresponding author), Bascom Palmer Eye Inst, 900 NW 17th St, Miami, FL 33136 USA.
EM sswaminathan@miami.edu
OI Chang, Ta Chen/0000-0003-4827-5014; Vanner,
   Elizabeth/0000-0003-1875-4524
FU US National Institutes of Health Center Core grantUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [P30EY014801]; Research to Prevent BlindnessResearch to Prevent
   Blindness (RPB); University of Miami Institute for Advanced Study of the
   Americas Pilot grant; Intelligent Research in Sight (IRIS)
   Registry-American Glaucoma Society (AGS) Research Initiative grant;
   Miami Clinical and Translational Science Institute [UL1TR002736];
   National Center for Advancing Translational SciencesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS);
   National Institute on Minority Health and Health DisparitiesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute on Minority Health & Health
   Disparities (NIMHD)
FX Publication of this article was supported by US National Institutes of
   Health Center Core grant P30EY014801; an unrestricted grant from
   Research to Prevent Blindness; a 2019 University of Miami Institute for
   Advanced Study of the Americas Pilot grant; a 2018 Intelligent Research
   in Sight (IRIS) Registry-American Glaucoma Society (AGS) Research
   Initiative grant; Miami Clinical and Translational Science Institute
   grant UL1TR002736; and support from the National Center for Advancing
   Translational Sciences and the National Institute on Minority Health and
   Health Disparities. The funding organizations had no role in the design
   or conduct of this research.
CR Adelman RA, 2010, J OCUL PHARMACOL TH, V26, P105, DOI 10.1089/jop.2009.0076
   Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   Beck M, 2016, AM J OPHTHALMOL, V167, P10, DOI 10.1016/j.ajo.2016.04.003
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Chauhan BC, 2020, OPHTHALMOLOGY, V127, P177, DOI 10.1016/j.ophtha.2019.09.013
   Crowther MJ, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-146
   Demirel S, 2015, CURR EYE RES, V40, P87, DOI 10.3109/02713683.2014.917190
   Du J, 2019, J GLAUCOMA, V28, P1035, DOI 10.1097/IJG.0000000000001382
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gabrielle PH, 2020, OPHTHALMOL RETINA, V4, P861, DOI 10.1016/j.oret.2020.06.020
   Gomez-Mariscal M, 2019, GRAEF ARCH CLIN EXP, V257, P2221, DOI 10.1007/s00417-019-04354-7
   Hodapp E, 1993, CLIN DECISIONS GLAUC, V1st
   Hoguet A, 2019, OPHTHALMOLOGY, V126, P611, DOI 10.1016/j.ophtha.2018.11.019
   Horsley MB, 2010, AM J OPHTHALMOL, V150, P558, DOI 10.1016/j.ajo.2010.04.029
   Hwang DJ, 2014, INVEST OPHTH VIS SCI, V55, P4213, DOI 10.1167/iovs.13-13776
   Jo Young-Joon, 2016, Korean J Ophthalmol, V30, P114, DOI 10.3341/kjo.2016.30.2.114
   Kitsu K, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.9.10
   Kopic A, 2017, ACTA CLIN CROAT, V56, P406, DOI 10.20471/acc.2017.56.03.07
   Lee EK, 2015, INVEST OPHTH VIS SCI, V56, P3976, DOI 10.1167/iovs.15-17013
   Lee HJ, 2016, AM J OPHTHALMOL, V161, P214, DOI 10.1016/j.ajo.2015.09.020
   Lee JW, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0255-8
   Lee WJ, 2017, J GLAUCOMA, V26, P980, DOI 10.1097/IJG.0000000000000776
   Martinez-de-la-Casa JM, 2012, INVEST OPHTH VIS SCI, V53, P6214, DOI 10.1167/iovs.12-9875
   Medeiros FA, 2011, INVEST OPHTH VIS SCI, V52, P5794, DOI 10.1167/iovs.10-7111
   Medeiros FA, 2010, AM J OPHTHALMOL, V149, P908, DOI 10.1016/j.ajo.2010.01.010
   Michalska-Malecka K, 2016, CLIN INTERV AGING, V11, P357, DOI 10.2147/CIA.S93820
   Mwanza JC, 2015, INVEST OPHTH VIS SCI, V56, P6344, DOI 10.1167/iovs.15-17248
   Nuesi R, 2020, CURR OPHTHALMOL REP, V8, P111, DOI 10.1007/s40135-020-00235-z
   Parlak M, 2015, INT OPHTHALMOL, V35, P473, DOI 10.1007/s10792-014-9972-2
   Quigley HA, 2011, LANCET, V377, P1367, DOI 10.1016/S0140-6736(10)61423-7
   Rouvas A, 2009, OPHTHALMOLOGICA, V223, P383, DOI 10.1159/000228590
   Rufai SR, 2017, EYE, V31, P1337, DOI 10.1038/eye.2017.67
   Saleh R, 2017, GRAEF ARCH CLIN EXP, V255, P817, DOI 10.1007/s00417-017-3590-4
   Saxena Sandeep, 2019, Int J Retina Vitreous, V5, P8, DOI 10.1186/s40942-019-0157-z
   Sengul EA, 2016, J OCUL PHARMACOL TH, V32, P665, DOI 10.1089/jop.2016.0014
   Shin HJ, 2016, INVEST OPHTH VIS SCI, V57, P1798, DOI 10.1167/iovs.15-18404
   Shin HJ, 2014, INVEST OPHTH VIS SCI, V55, P2403, DOI 10.1167/iovs.13-13769
   Sobaci G, 2013, INT J OPHTHALMOL-CHI, V6, P211, DOI 10.3980/j.issn.2222-3959.2013.02.20
   Soheilian M, 2017, GRAEF ARCH CLIN EXP, V255, P1705, DOI 10.1007/s00417-017-3702-1
   Song S, 2016, INDIAN J OPHTHALMOL, V64, P762, DOI 10.4103/0301-4738.195006
   Tah V, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/627674
   Tseng JJ, 2012, J GLAUCOMA, V21, P241, DOI 10.1097/IJG.0b013e31820d7d19
   Valverde-Megias A, 2019, GRAEF ARCH CLIN EXP, V257, P1459, DOI 10.1007/s00417-019-04325-y
   Wingard JB, 2019, CLIN OPHTHALMOL, V13, P2563, DOI 10.2147/OPTH.S232548
   Wu ZC, 2017, AM J OPHTHALMOL, V181, P106, DOI 10.1016/j.ajo.2017.06.017
   Yang J., 2020, OPHTHALMOL RETINA
   Zhang ZH, 2016, SCI REP-UK, V6, DOI 10.1038/srep38326
   Zucchiatti I, 2017, RETINA-J RET VIT DIS, V37, P1314, DOI 10.1097/IAE.0000000000001360
   Zucchiatti I, 2015, AM J OPHTHALMOL, V160, P602, DOI 10.1016/j.ajo.2015.05.030
NR 49
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUN
PY 2021
VL 226
BP 206
EP 216
DI 10.1016/j.ajo.2020.12.016
PG 11
WC Ophthalmology
SC Ophthalmology
GA TL1CP
UT WOS:000674592100023
PM 33359714
DA 2021-10-30
ER

PT J
AU Chang, TC
   Parrish, RK
   Fujino, D
   Kelly, SP
   Vanner, EA
AF Chang, Ta C.
   Parrish, Richard K.
   Fujino, Danielle
   Kelly, Scott P.
   Vanner, Elizabeth A.
TI Factors Associated With Favorable Laser Trabeculoplasty Response: IRIS
   Registry Analysis
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
AB PURPOSE: We examined patients in a large clinical registry to assess factors associated with laser trabeculoplasty (LTP) responses.
   DESIGN: Retrospective cohort study.
   METHODS: STUDY POPULATION: LTP patients in the Intelligent Research in Sight (IRIS) Registry, 2013-2018. OBSERVATION: IRIS Registry data were extracted if the eye had a procedural code for LTP and a glaucoma diagnosis. Eyes were excluded if LTP laterality or baseline intraocular pressure (IOP) could not be determined. Following LTP, ``nonresponders'' were those with <20% IOP reduction after 8 weeks, while "responders'' were those with >= 20% IOP reduction.MAIN OUTCOME MEASURES: Proportion of responders, odds ratios (OR) of pre-LTP factors associated with being a nonresponder.
   RESULTS: A total of 263,480 eyes were included, with mean age 71.4 +/- 11.7 years. Mean baseline IOP was 19.1 +/- 5.0 mm Hg, mean number of pre-LTP medications was 2.1 +/- 1.5. Response rate was 36.9% overall and 68.8% for those with baseline IOP >24 mm Hg. Higher baseline IOP was associated with reduced odds of nonresponse (OR = 0.60, P < .0001 for a 3 mm Hg increase). Angle recession, uveitis, and aphakia increased the odds of a nonresponse (ORs 2.46, 1.50 (both P < .0001), and 1.55 (P = .0259), respectively). In nonresponders with at least 1 medication at baseline, 76.3% of eyes had fewer medications postoperatively.
   CONCLUSIONS: Lower baseline IOP, angle recession, uveitis, and aphakia were associated with increased odds of nonresponse. Future studies that analyze LTP responder survival and implementation lag would facilitate resource optimization in glaucoma therapy. ((C) 2020 Elsevier Inc. All rights reserved.)
C1 [Chang, Ta C.; Parrish, Richard K.; Vanner, Elizabeth A.] Bascom Palmer Eye Inst, 900 NW 17th St,450N, Miami, FL 33136 USA.
   [Fujino, Danielle; Kelly, Scott P.] Amer Acad Ophthalmol, San Francisco, CA USA.
RP Chang, TC (corresponding author), Bascom Palmer Eye Inst, 900 NW 17th St,450N, Miami, FL 33136 USA.
EM t.chang@med.miami.edu
OI Vanner, Elizabeth/0000-0003-1875-4524; Chang, Ta
   Chen/0000-0003-4827-5014; Fujino, Danielle/0000-0002-4116-8657
FU NIH CENTER CORE GRANTUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [P30EY014801];
   RESEARCH TO PREVENT BLINDness Unrestricted GrantResearch to Prevent
   Blindness (RPB); 2019 University of Miami Institute for Advanced Study
   of the Americas Pilot Grant; 2018 IRIS-Registry-AGS Research Initiative
   Grant; Miami Clinical and Translational Science Institute, from the
   National Center for Advancing Translational Sciences [UL1TR002736];
   National Institute on Minority Health and Health DisparitiesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute on Minority Health & Health
   Disparities (NIMHD)
FX THE PROJECT WAS SUPPORTED BY NIH CENTER CORE GRANT P30EY014801, RESEARCH
   TO PREVENT BLINDness Unrestricted Grant, The 2019 University of Miami
   Institute for Advanced Study of the Americas Pilot Grant, 2018
   IRIS-Registry-AGS Research Initiative Grant, and Grant Number
   UL1TR002736, Miami Clinical and Translational Science Institute, from
   the National Center for Advancing Translational Sciences and the
   National Institute on Minority Health and Health Disparities. Its
   contents are solely the responsibility of the authors and do not
   necessarily represent the official views of the NIH. Financial
   Disclosures: There are no financial disclosures for any of the authors.
   All authors attest that they meet the current ICMJE criteria for
   authorship. Other Acknowledgments: The authors wish to acknowledge Mr.
   and Mrs. Bruce and Cynthia Sherman for their generous support of the
   Samuel & Ethel Balkan International Pediatric Glaucoma Center, and their
   tremendous foresight in the value of integrated informatics clinical
   research.
CR Abe RY, 2017, J GLAUCOMA, V26, P1019, DOI 10.1097/IJG.0000000000000775
   Abelson MB, 2001, ADV THER, V18, P282, DOI 10.1007/BF02850198
   Alaghband P, 2020, BRIT J OPHTHALMOL, V104, P1390, DOI 10.1136/bjophthalmol-2019-315489
   [Anonymous], 1995, Am J Ophthalmol, V120, P718
   Arora KS, 2015, OPHTHALMOLOGY, V122, P1615, DOI 10.1016/j.ophtha.2015.04.015
   Atchison EA, 2018, OPHTHALMOLOGY, V125, P676, DOI 10.1016/j.ophtha.2017.11.027
   Ayala M, 2011, CLIN OPHTHALMOL, V5, P573, DOI 10.2147/OPTH.S19873
   Bruen R, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/642869
   Cantor LB, 2008, CURR MED RES OPIN, V24, P2905, DOI [10.1185/03007990802379996, 10.1185/03007990802379996 ]
   Chang TC, 2019, EYE, V33, P1577, DOI 10.1038/s41433-019-0452-9
   Chiang MF, 2018, OPHTHALMOLOGY, V125, P1143, DOI 10.1016/j.ophtha.2017.12.001
   Chun M, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0385-z
   Connor MA, 2010, OPHTHAL SURG LAS IM, V41, P523, DOI 10.3928/15428877-20100625-01
   Cvenkel B, 2004, OPHTHALMOLOGICA, V218, P20, DOI 10.1159/000074562
   Damji KF, 1999, BRIT J OPHTHALMOL, V83, P718, DOI 10.1136/bjo.83.6.718
   Garg A, 2019, OPHTHALMOLOGY, V126, P1238, DOI 10.1016/j.ophtha.2019.04.012
   Gazzard G, 2019, HEALTH TECHNOL ASSES, V23, P1, DOI 10.3310/hta23310
   Gazzard G, 2019, LANCET, V393, P1505, DOI 10.1016/S0140-6736(18)32213-X
   GOLDBERG I, 1985, AUST NZ J OPHTHALMOL, V13, P243, DOI 10.1111/j.1442-9071.1985.tb00430.x
   Hirn C, 2014, KLIN MONATSBL AUGENH, V231, P351, DOI 10.1055/s-0034-1368218
   Hodge WG, 2005, BRIT J OPHTHALMOL, V89, P1157, DOI 10.1136/bjo.2004.062414
   Jampel HD, 2014, JAMA OPHTHALMOL, V132, P685, DOI 10.1001/jamaophthalmol.2014.369
   Khawaja AP, 2020, OPHTHALMOLOGY, V127, P748, DOI 10.1016/j.ophtha.2019.11.017
   Lai JS, 2004, CLIN EXP OPHTHALMOL, V32, P368, DOI 10.1111/j.1442-9071.2004.00839.x
   Latina MA, 1998, OPHTHALMOLOGY, V105, P2082, DOI 10.1016/S0161-6420(98)91129-0
   Lee JWY, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/1471-2415-15-1
   Mao AJ, 2008, J GLAUCOMA, V17, P449, DOI 10.1097/IJG.0b013e31815f52cb
   Martow E, 2011, J GLAUCOMA, V20, P266, DOI 10.1097/IJG.0b013e3181e3d2c1
   McIlraith I, 2006, J GLAUCOMA, V15, P124, DOI 10.1097/00061198-200604000-00009
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Melamed S, 2003, ARCH OPHTHALMOL-CHIC, V121, P957, DOI 10.1001/archopht.121.7.957
   Nathan H, 2008, ANN SURG ONCOL, V15, P415, DOI 10.1245/s10434-007-9658-3
   Newman-Casey PA, 2020, OPHTHALMOLOGY, V127, P477, DOI 10.1016/j.ophtha.2019.10.022
   Odberg T, 1999, ACTA OPHTHALMOL SCAN, V77, P176, DOI 10.1034/j.1600-0420.1999.770212.x
   Parke DW, 2018, OPHTHALMOLOGY, V125, P1273, DOI 10.1016/j.ophtha.2018.01.009
   Pershing S, 2020, OPHTHALMOLOGY, V127, P151, DOI 10.1016/j.ophtha.2019.08.026
   Pillunat KR, 2016, ACTA OPHTHALMOL, V94, P692, DOI 10.1111/aos.13094
   Rao P, 2018, OPHTHALMOLOGY, V125, P522, DOI 10.1016/j.ophtha.2017.10.010
   Realini T, 2019, J GLAUCOMA, V28, P622, DOI 10.1097/IJG.0000000000001250
   Realini T, 2017, AM J OPHTHALMOL, V184, P28, DOI 10.1016/j.ajo.2017.09.022
   Realini T, 2013, JAMA OPHTHALMOL, V131, P321, DOI 10.1001/jamaophthalmol.2013.1706
   Repka MX, 2018, OPHTHALMOLOGY, V125, P1646, DOI 10.1016/j.ophtha.2018.04.024
   ROBIN AL, 1983, ARCH OPHTHALMOL-CHIC, V101, P382
   Rossi GCM, 2011, EUR J OPHTHALMOL, V21, P410, DOI 10.5301/EJO.2010.6112
   Rouland JF, 2005, EUR J OPHTHALMOL, V15, P562, DOI 10.1177/112067210501500507
   Rouland JF, 2003, EUR J OPHTHALMOL, V13, pS5
   Rozsival P, 2004, Cesk Slov Oftalmol, V60, P267
   Samples JR, 2011, OPHTHALMOLOGY, V118, P2296, DOI 10.1016/j.ophtha.2011.04.037
   Schmier JK, 2007, PHARMACOECONOMICS, V25, P287, DOI 10.2165/00019053-200725040-00003
   Schwartz AL, 1997, OPHTHALMIC SURG LAS, V28, P215
   Sleath B, 2006, OPHTHALMOLOGY, V113, P431, DOI 10.1016/j.ophtha.2005.10.034
   Sleath B, 2011, OPHTHALMOLOGY, V118, P2398, DOI 10.1016/j.ophtha.2011.05.013
   Song J, 2005, J GLAUCOMA, V14, P400, DOI 10.1097/01.ijg.0000176939.43681.c2
   Stein JD, 2016, JAMA OPHTHALMOL, V134, P1095, DOI 10.1001/jamaophthalmol.2016.2495
   Stein JD, 2012, ARCH OPHTHALMOL-CHIC, V130, P497, DOI 10.1001/archophthalmol.2011.2727
   Tai V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110403
   Tsai JC, 2009, OPHTHALMOLOGY, V116, pS30, DOI 10.1016/j.ophtha.2009.06.024
   Walkden A, 2018, EYE, V32, P1253, DOI 10.1038/s41433-018-0059-6
   Willis J, 2017, OPHTHALMOLOGY, V124, P935, DOI 10.1016/j.ophtha.2017.02.018
NR 59
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2021
VL 223
BP 149
EP 158
DI 10.1016/j.ajo.2020.10.004
PG 10
WC Ophthalmology
SC Ophthalmology
GA RC2MF
UT WOS:000632638100017
PM 33049242
DA 2021-10-30
ER

PT J
AU Strbo, N
   Alcaide, ML
   Romero, L
   Bolivar, H
   Jones, D
   Podack, ER
   Fischl, MA
AF Strbo, Natasa
   Alcaide, Maria L.
   Romero, Laura
   Bolivar, Hector
   Jones, Deborah
   Podack, Eckhard R.
   Fischl, Margaret A.
TI Loss of Intra-Epithelial Endocervical Gamma Delta (GD) 1 T Cells in
   HIV-Infected Women
SO AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY
LA English
DT Article
DE Biomarker; female reproductive tract; gamma delta T cells; HIV
ID HUMAN-IMMUNODEFICIENCY-VIRUS; REPRODUCTIVE-TRACT; GENITAL-TRACT;
   B-CELLS; LYMPHOCYTES; EXPRESSION; MUCOSAL; RESPONSES; CD4(+);
   SUSCEPTIBILITY
AB Problem
   Human gamma delta (GD) T cells play a well-documented role in epithelial barrier surveillance and protection. Two subsets of GD T cells, defined by the use of either the Vdelta2 (GD2) or Vdelta1 (GD1) TCR, predominate. We hypothesized that endocervical GD T cells play important role in lower genital tract anti-HIV immune responses.
   Method of study
   HIV-infected (n = 18) and HIV-uninfected (n = 19) pre-menopausal women participating in the WIHS cohort were recruited. Frequency and phenotype of GD T cells were determined in endocervical cytobrush samples and peripheral blood by multicolor flow cytometry.
   Results
   We found depletion of GD2 cells in the blood of HIV-infected women as well as significant decrease in the frequency of endocervical GD1 cells compared to uninfected women.
   Conclusion
   We report for the first time, the GD1 cells are a predominant endocervical T-cell subset that is significantly decreased in HIV-infected women.
C1 [Strbo, Natasa; Romero, Laura; Podack, Eckhard R.] Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA.
   [Alcaide, Maria L.; Bolivar, Hector; Fischl, Margaret A.] Univ Miami, Miller Sch Med, Div Infect Dis, Miami, FL 33136 USA.
   [Jones, Deborah] Univ Miami, Miller Sch Med, Dept Psychiat & Behav Sci, Miami, FL 33136 USA.
RP Strbo, N (corresponding author), 1600 NW 10th Ave,RMSB 3014, Miami, FL 33136 USA.
EM nstrbo@med.miami.edu
OI Alcaide, Maria/0000-0003-4648-0145
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID);
   Women's Interagency HIV Infection Study (WIHS) [U01 AI103397]; National
   Institute of Allergy and Infectious Diseases, National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [P30AI073961]; National Center for Advancing
   Translational SciencesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS); National Institute on Minority
   Health and Health Disparities, National Institute of Health
   [UL1TR000460, 1KL2TR000461]; National Institute of Child Health and
   Human Development, National Institute of HealthUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   Eunice Kennedy Shriver National Institute of Child Health & Human
   Development (NICHD) [K23HD074489]; EUNICE KENNEDY SHRIVER NATIONAL
   INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   Eunice Kennedy Shriver National Institute of Child Health & Human
   Development (NICHD) [K23HD074489] Funding Source: NIH RePORTER; NATIONAL
   CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000460, KL2TR000461] Funding Source: NIH RePORTER; NATIONAL HEART,
   LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [U01HL146203] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [U01AI103397, P30AI073961] Funding Source: NIH RePORTER
FX We thank the Miami WIHS study participants for their willingness to
   participate in this work. Data in this manuscript were collected by the
   Miami Women's Interagency HIV Study (WIHS). The contents of this
   publication are solely the responsibility of the authors and do not
   represent the official views of the National Institutes of Health (NIH).
   This work was supported by National Institute of Allergy and Infectious
   Diseases and Women's Interagency HIV Infection Study (WIHS) [grant
   number U01 AI103397], National Institute of Allergy and Infectious
   Diseases, National Institutes of Health [grant number P30AI073961],
   National Center for Advancing Translational Sciences and the National
   Institute on Minority Health and Health Disparities, National Institute
   of Health [grant number UL1TR000460 and 1KL2TR000461], and National
   Institute of Child Health and Human Development, National Institute of
   Health [grant number K23HD074489].
CR Ashour HM, 2007, J LEUKOCYTE BIOL, V82, P1033, DOI 10.1189/jlb.0507310
   AUTRAN B, 1989, CLIN EXP IMMUNOL, V75, P206
   Carding SR, 2002, NAT REV IMMUNOL, V2, P336, DOI 10.1038/nri797
   Chen Zheng W., 2002, Science Progress, V85, P347, DOI 10.3184/003685002783238762
   Cheroutre H, 2011, NAT REV IMMUNOL, V11, P445, DOI 10.1038/nri3007
   De Rosa SC, 2001, J LEUKOCYTE BIOL, V70, P518
   Douek DC, 2002, NATURE, V417, P95, DOI 10.1038/417095a
   Exley MA, 2011, CLIN IMMUNOL, V141, P236, DOI 10.1016/j.clim.2011.09.004
   Fettke F, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00285
   Haase AT, 2010, NATURE, V464, P217, DOI 10.1038/nature08757
   Harris LD, 2010, BLOOD, V116, P4148, DOI 10.1182/blood-2010-05-283549
   Hasselrot K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047570
   Hayday A, 2008, MUCOSAL IMMUNOL, V1, P172, DOI 10.1038/mi.2008.8
   Hayday A, 2003, NAT REV IMMUNOL, V3, P233, DOI 10.1038/nri1030
   Hayday A, 2001, NAT IMMUNOL, V2, P997, DOI 10.1038/ni1101-997
   Hayday AC, 2000, ANNU REV IMMUNOL, V18, P975, DOI 10.1146/annurev.immunol.18.1.975
   Hayday AC, 2009, IMMUNITY, V31, P184, DOI 10.1016/j.immuni.2009.08.006
   Hayday AC, 2009, SEMIN IMMUNOL, V21, P99, DOI 10.1016/j.smim.2009.04.003
   Hirbod T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025551
   Hladik F, 2007, IMMUNITY, V26, P257, DOI 10.1016/j.immuni.2007.01.007
   Hodara VL, 2014, J MED PRIMATOL, V43, P258, DOI 10.1111/jmp.12115
   Imlach S, 2003, VIROLOGY, V305, P415, DOI 10.1006/viro.2002.1759
   Juno JA, 2014, JOVE-J VIS EXP, V6, P89
   Kabelitz D, 2003, CRIT REV IMMUNOL, V23, P339, DOI 10.1615/CritRevImmunol.v23.i56.10
   Kader M, 2009, MUCOSAL IMMUNOL, V2, P439, DOI 10.1038/mi.2009.90
   Kaul R, 2008, J REPROD IMMUNOL, V77, P32, DOI 10.1016/j.jri.2007.02.002
   Kosub DA, 2008, J VIROL, V82, P1155, DOI 10.1128/JVI.01275-07
   Liebenberg LJ, 2011, J IMMUNOL METHODS, V367, P47, DOI 10.1016/j.jim.2011.01.013
   McKinnon LR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085675
   Meditz AL, 2012, JAIDS-J ACQ IMM DEF, V59, P221, DOI 10.1097/QAI.0b013e31823fd215
   Mincheva-Nilsson Lucia, 2003, Reprod Biol Endocrinol, V1, P120, DOI 10.1186/1477-7827-1-120
   MINCHEVANILSSON L, 1992, J IMMUNOL, V149, P2203
   Nagaeva O, 2002, AM J REPROD IMMUNOL, V48, P9, DOI 10.1034/j.1600-0897.2002.01131.x
   Nakasone C, 2007, MICROBES INFECT, V9, P251, DOI 10.1016/j.micinf.2006.11.015
   Patterson BK, 1998, AM J PATHOL, V153, P481, DOI 10.1016/S0002-9440(10)65591-5
   Pauza CD, 2015, CELL IMMUNOL, V296, P22, DOI 10.1016/j.cellimm.2015.02.010
   Pauza CD, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00687
   Poccia F, 2005, IMMUNOL LETT, V100, P14, DOI 10.1016/j.imlet.2005.06.025
   Poccia F, 2005, MICROBES INFECT, V7, P518, DOI 10.1016/j.micinf.2004.12.009
   Poles MA, 2003, J VIROL, V77, P10456, DOI 10.1128/JVI.77.19.10456-10467.2003
   Rodriguez-Garcia M, 2014, MUCOSAL IMMUNOL, V7, P1375, DOI 10.1038/mi.2014.26
   Rodriguez-Garcia M, 2013, J REPROD IMMUNOL, V97, P74, DOI 10.1016/j.jri.2012.10.010
   Saba E, 2010, MUCOSAL IMMUNOL, V3, P280, DOI 10.1038/mi.2010.2
   Shanmugasundaram U, 2014, AM J REPROD IMMUNOL, V71, P95, DOI 10.1111/aji.12182
   Shires J, 2001, IMMUNITY, V15, P419, DOI 10.1016/S1074-7613(01)00192-3
   Szekeres-Bartho J, 2001, SEMIN IMMUNOL, V13, P229, DOI 10.1006/smim.2000.0318
   Wallace M, 1997, MOL MED, V3, P60, DOI 10.1007/BF03401668
   Wira CR, 2008, AIDS, V22, P1909, DOI 10.1097/QAD.0b013e3283060ea4
   Wira CR, 2014, AM J REPROD IMMUNOL, V72, P236, DOI 10.1111/aji.12252
   Wira CR, 2014, AM J REPROD IMMUNOL, V71, P487, DOI 10.1111/aji.12269
   Zheng NN, 2011, JAIDS-J ACQ IMM DEF, V57, P92, DOI 10.1097/QAI.0b013e318215a877
   Ziegler H, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00645
NR 52
TC 16
Z9 16
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1046-7408
EI 1600-0897
J9 AM J REPROD IMMUNOL
JI Am. J. Reprod. Immunol.
PD FEB
PY 2016
VL 75
IS 2
BP 134
EP 145
DI 10.1111/aji.12458
PG 12
WC Immunology; Reproductive Biology
SC Immunology; Reproductive Biology
GA DD8EL
UT WOS:000370157900007
PM 26666220
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Cano, MA
   Schwartz, SJ
   Castillo, LG
   Unger, JB
   Huang, S
   Zamboanga, BL
   Romero, AJ
   Lorenzo-Blanco, EI
   Cordova, D
   Des Rosiers, SE
   Lizzi, KM
   Baezconde-Garbanati, L
   Soto, DW
   Villamar, JA
   Pattarroyo, M
   Szapocznik, J
AF Cano, Miguel Angel
   Schwartz, Seth J.
   Castillo, Linda G.
   Unger, Jennifer B.
   Huang, Shi
   Zamboanga, Byron L.
   Romero, Andrea J.
   Lorenzo-Blanco, Elma I.
   Cordova, David
   Des Rosiers, Sabrina E.
   Lizzi, Karina M.
   Baezconde-Garbanati, Lourdes
   Soto, Daniel W.
   Villamar, Juan Andres
   Pattarroyo, Monica
   Szapocznik, Jose
TI Health Risk Behaviors and Depressive Symptoms Among Hispanic
   Adolescents: Examining Acculturation Discrepancies and Family
   Functioning
SO JOURNAL OF FAMILY PSYCHOLOGY
LA English
DT Article
DE acculturation; family functioning; substance use; sexual behavior;
   depressive symptoms
ID ETHNIC-IDENTITY; SEXUAL-BEHAVIOR; UNITED-STATES; SUBSTANCE USE; LATINO
   YOUTH; ALCOHOL-USE; BICULTURALISM; INTERVENTION; INVOLVEMENT; VIOLENCE
AB Drawing from a theory of bicultural family functioning 2 models were tested to examine the longitudinal effects of acculturation-related variables on adolescent health risk behaviors and depressive symptoms (HRB/DS) mediated by caregiver and adolescent reports of family functioning. One model examined the effects of caregiver-adolescent acculturation discrepancies in relation to family functioning and HRB/DS. A second model examined the individual effects of caregiver and adolescent acculturation components in relation to family functioning and HRB/DS. A sample of 302 recently immigrated Hispanic caregiver-child dyads completed measures of Hispanic and U.S. cultural practices, values, and identities at baseline (predictors); measures of family cohesion, family communications, and family involvement 6 months postbaseline (mediators); and only adolescents completed measures of smoking, binge drinking, incon sistent condom use, and depressive symptoms 1 year postbaseline (outcomes). Measures of family cohesion, family communications, and family involvement were used to conduct a confirmatory factor analysis to estimate the fit of a latent construct for family functioning. Key findings indicate that (a) adolescent acculturation components drove the effect of caregiver-adolescent acculturation discrepancies in relation to family functioning; (b) higher levels of adolescent family functioning were associated with less HRB/DS, whereas higher levels of caregiver family functioning were associated with more adolescent HRB/DS; (c) and only adolescent reports of family functioning mediated the effects of acculturation components and caregiver-adolescent acculturation discrepancies on HRB/DS.
C1 [Cano, Miguel Angel] Florida Int Univ, Dept Epidemiol, 11200 SW 8th St,AHC 5-488, Miami, FL 33199 USA.
   [Schwartz, Seth J.; Huang, Shi; Lizzi, Karina M.; Szapocznik, Jose] Univ Miami, Dept Epidemiol & Publ Hlth, Coral Gables, FL 33124 USA.
   [Castillo, Linda G.] Texas A&M Univ, Dept Educ Psychol, College Stn, TX 77843 USA.
   [Unger, Jennifer B.] Univ So Calif, Inst Prevent Res, Los Angeles, CA 90089 USA.
   [Zamboanga, Byron L.] Smith Coll, Dept Psychol, Northampton, MA 01063 USA.
   [Romero, Andrea J.] Univ Arizona, Dept Family Studies & Human Dev, Tucson, AZ 85721 USA.
   [Lorenzo-Blanco, Elma I.] Univ S Carolina, Dept Psychol, Columbia, SC 29208 USA.
   [Cordova, David] Univ Michigan, Sch Social Work, Ann Arbor, MI 48109 USA.
   [Des Rosiers, Sabrina E.] Barry Univ, Dept Psychol, Miami, FL USA.
   [Baezconde-Garbanati, Lourdes] Univ So Calif, Dept Prevent Med, Los Angeles, CA 90089 USA.
   [Soto, Daniel W.; Pattarroyo, Monica] Univ So Calif, Inst Hlth Promot & Dis Prevent Res, Los Angeles, CA 90089 USA.
   [Villamar, Juan Andres] Northwestern Univ, Dept Psychiat & Behav Sci, Evanston, IL 60208 USA.
RP Cano, MA (corresponding author), Florida Int Univ, Dept Epidemiol, 11200 SW 8th St,AHC 5-488, Miami, FL 33199 USA.
EM mcanojr@fiu.edu
RI Cano, Miguel Angel/V-8215-2017
OI Cano, Miguel Angel/0000-0002-9847-1358; Unger,
   Jennifer/0000-0001-9064-6603
FU NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1 TR000460] Funding Source: Medline;
   NICHD NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD) [R25 HD045810]
   Funding Source: Medline; NIDA NIH HHSUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute on Drug Abuse (NIDA) [R01 DA025694, R25 DA026401] Funding
   Source: Medline; NIMH NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Mental Health (NIMH) [R25 MH067127] Funding Source: Medline; EUNICE
   KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN
   DEVELOPMENTUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD) [R25HD045810]
   Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [UL1TR000460] Funding Source:
   NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Mental Health (NIMH) [R25MH067127]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European
   Commission [R01DA025694, R25DA026401] Funding Source: NIH RePORTER
CR Abraido-Lanza AF, 2005, SOC SCI MED, V61, P1243, DOI 10.1016/j.socscimed.2005.01.016
   Abraido-Lanza AF, 2006, AM J PUBLIC HEALTH, V96, P1342, DOI 10.2105/AJPH.2005.064980
   Afable-Munsuz A, 2006, PERSPECT SEX REPRO H, V38, P208, DOI 10.1111/j.1931-2393.2006.tb00281.x
   Agresti A., 2007, INTRO CATEGORICAL DA, V2nd
   Azen R, 2011, CATEGORICAL DATA ANALYSIS FOR THE BEHAVIORAL AND SOCIAL SCIENCES, P1
   Bacallao Martica L, 2005, J Prim Prev, V26, P485, DOI 10.1007/s10935-005-0008-6
   Brown T.A., 2015, CONFIRMATORY FACTOR, V2nd
   Cano M.A., 2010, J HISPANIC HIGHER ED, V9, P221, DOI [10.1177/1538192710370899, DOI 10.1177/1538192710370899]
   Castro FG, 2007, AM J PUBLIC HEALTH, V97, P1162, DOI 10.2105/AJPH.2007.116145
   Castro FG, 2009, J PRIM PREV, V30, P265, DOI 10.1007/s10935-009-0174-z
   Cheung BY, 2011, PSYCHOL SCI, V22, P147, DOI 10.1177/0956797610394661
   Coatsworth JD, 2002, CLIN CHILD FAM PSYCH, V5, P113, DOI 10.1023/A:1015420503275
   Cordova D, 2014, FAM PROCESS, V53, P348, DOI 10.1111/famp.12067
   Cordova D, 2012, PSYCHOL ADDICT BEHAV, V26, P655, DOI 10.1037/a0026438
   Cox RB, 2011, J FAM THEOR REV, V3, P96, DOI DOI 10.1111/J.1756-2589.2011.00086.X
   French SE, 2006, DEV PSYCHOL, V42, P1, DOI 10.1037/0012-1649.42.1.1
   Gil AG, 2000, J COMMUNITY PSYCHOL, V28, P443, DOI 10.1002/1520-6629(200007)28:4<443::AID-JCOP6>3.3.CO;2-1
   Glymour MM, 2005, AM J EPIDEMIOL, V162, P267, DOI 10.1093/aje/kwi187
   Gonzales NA, 2006, FAM RELAT, V55, P318, DOI 10.1111/j.1741-3729.2006.00405.x
   GormanSmith D, 1996, J FAM PSYCHOL, V10, P115, DOI 10.1037/0893-3200.10.2.115
   Guilamo-Ramos V, 2004, PSYCHOL ADDICT BEHAV, V18, P135, DOI 10.1037/0893-164X.18.2.135
   Guilamo-Ramos V, 2006, J MARRIAGE FAM, V68, P1229, DOI 10.1111/j.1741-3737.2006.00325.x
   Guo XH, 2009, PSYCHOL ASSESSMENT, V21, P22, DOI 10.1037/a0014495
   Hofstede G., 2001, CULTURES CONSEQUENCE, V2nd
   Holcomb-McCoy C., 2005, PROFESSIONAL SCH COU, V9, P120, DOI DOI 10.5330/PRSC.9.2.21Q8M2724R545414
   Johnston LD, 2012, Monitoring the Future National Survey Results on Drug Use. ,1975-2001 Volume I: Secondary School Students, VI
   Kann L, 2014, MMWR SURVEILL SUMM, V63, P1
   Kauermann G, 2001, J AM STAT ASSOC, V96, P1387, DOI 10.1198/016214501753382309
   Kim SY, 2013, DEV PSYCHOL, V49, P900, DOI 10.1037/a0029169
   Kline R.B., 2015, PRINCIPLES PRACTICE, V4
   Lorenzo-Blanco EI, 2011, J YOUTH ADOLESCENCE, V40, P1519, DOI 10.1007/s10964-011-9633-y
   Perrino T., 2015, FAMILY PROCESS
   Portes A, 2006, IMMIGRANT AM PORTRAI, V3
   Prado Guillermo, 2011, Psychosocial Intervention, V20, P63, DOI 10.5093/in2011v20n1a6
   RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306
   Ram N, 2005, PSYCHOMETRIKA, V70, P773, DOI 10.1007/s11336-001-1270-5
   Raudenbush S. W., 2002, HIERARCHICAL LINEAR
   Roberts RE, 1999, J EARLY ADOLESCENCE, V19, P301, DOI 10.1177/0272431699019003001
   Rumbaut RG, 2008, APPL DEV SCI, V12, P108, DOI 10.1080/10888690801997341
   Schildkraut DJ, 2011, HANDBOOK OF IDENTITY THEORY AND RESEARCH, VOLS 1 AND 2, P845, DOI 10.1007/978-1-4419-7988-9_36
   Schwartz SJ, 2014, PREV SCI, V15, P385, DOI 10.1007/s11121-013-0419-1
   Schwartz SJ, 2013, CHILD DEV, V84, P1355, DOI 10.1111/cdev.12047
   Schwartz SJ, 2012, IDENTITY, V12, P93, DOI 10.1080/15283488.2012.668730
   Schwartz SJ, 2010, CULT DIVERS ETHN MIN, V16, P548, DOI 10.1037/a0021370
   Schwartz SJ, 2010, AM PSYCHOL, V65, P237, DOI 10.1037/a0019330
   Schwartz SJ, 2007, CULT DIVERS ETHN MIN, V13, P364, DOI 10.1037/1099-9809.13.4.364
   Schwartz SJ, 2006, J CROSS CULT PSYCHOL, V37, P345, DOI 10.1177/0022022106286928
   Schwartz SJ, 2005, J EARLY ADOLESCENCE, V25, P392, DOI 10.1177/0272431605279843
   Smokowski PR, 2008, FAM RELAT, V57, P295, DOI 10.1111/j.1741-3729.2008.00501.x
   SZAPOCZNIK J, 1993, AM PSYCHOL, V48, P400, DOI 10.1037/0003-066X.48.4.400
   SZAPOCZNIK J, 1986, HISPANIC J BEHAV SCI, V8, P303, DOI 10.1177/07399863860084001
   SZAPOCZNIK J, 1997, PSYCHOL INTERVENTION, P156
   Tolan PH, 1997, PSYCHOL ASSESSMENT, V9, P212, DOI 10.1037/1040-3590.9.3.212
   Triandis HC, 1998, J PERS SOC PSYCHOL, V74, P118, DOI 10.1037/0022-3514.74.1.118
   Turner CF, 1998, SCIENCE, V280, P867, DOI 10.1126/science.280.5365.867
   Unger JB, 2009, J IMMIGR MINOR HEALT, V11, P149, DOI 10.1007/s10903-007-9083-5
   Yu C. Y., 2002, EVALUATING CUTOFF CR
NR 57
TC 23
Z9 24
U1 7
U2 24
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0893-3200
EI 1939-1293
J9 J FAM PSYCHOL
JI J. Fam. Psychol.
PD MAR
PY 2016
VL 30
IS 2
BP 254
EP 265
DI 10.1037/fam0000142
PG 12
WC Psychology, Clinical; Family Studies
SC Psychology; Family Studies
GA DF1EW
UT WOS:000371082900009
PM 26301514
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Senior, PA
   Bellin, MD
   Alejandro, R
   Yankey, JW
   Clarke, WR
   Qidwai, JC
   Schwieger, TR
   Eggerman, TL
   Robien, MA
   Rickels, MR
AF Senior, Peter A.
   Bellin, Melena D.
   Alejandro, Rodolfo
   Yankey, Jon W.
   Clarke, William R.
   Qidwai, Julie C.
   Schwieger, Traci R.
   Eggerman, Thomas L.
   Robien, Mark A.
   Rickels, Michael R.
CA Clinical Islet Transplantation
TI Consistency of Quantitative Scores of Hypoglycemia Severity and Glycemic
   Lability and Comparison with Continuous Glucose Monitoring System
   Measures in Long-Standing Type 1 Diabetes
SO DIABETES TECHNOLOGY & THERAPEUTICS
LA English
DT Article
ID ISLET TRANSPLANTATION; AUTONOMIC FAILURE; BLOOD-GLUCOSE; FREQUENCY;
   AWARENESS; ADULTS; RISK; MECHANISMS; RESPONSES; MELLITUS
AB Background: In long-standing type 1 diabetes (T1D), loss of endogenous insulin secretion and glucose dysregulation can lead to severe hypoglycemia and associated complications. Here, we report the serial consistency and the correlation between different scores that characterize glucose dysregulation using self-monitoring of blood glucose (SMBG), in a cohort of T1D individuals being evaluated for transplant eligibility in Clinical Islet Transplantation Consortium trials.
   Subjects and Methods: In total, 152 C-peptide-negative T1D subjects with at least one severe hypoglycemia episode in the prior year documented SMBG at enrollment and every 6 months until deemed ineligible or transplanted. SMBG was used to calculate the HYPO score, Lability Index (LI), and mean amplitude of glycemic excursion (MAGE). Additionally, a blinded continuous glucose monitoring system (CGMS) was worn for 72 h at enrollment and every 12 months.
   Results: In this cohort, LI was the most consistent (intraclass correlation coefficient=0.70) over time, followed by the HYPO score (0.51), with MAGE being the least consistent (0.36). Although MAGE and LI were highly correlated with each other, neither correlated with CGMS SD or glucose coefficient of variation (CV). Subjects spent a median of 97 min/day at Conclusions: The HYPO score and LI are more consistent than MAGE in patients with established T1D experiencing severe hypoglycemic events and may be especially useful both for identifying subjects experiencing the greatest difficulty in maintaining glycemic control and for longitudinal assessment of novel interventions.
C1 [Senior, Peter A.] Univ Alberta, Div Endocrinol, Clin Islet Transplant Program, Edmonton, AB T6G2C8, Canada.
   [Bellin, Melena D.] Univ Minnesota, Dept Pediat, Minneapolis, MN 55455 USA.
   [Alejandro, Rodolfo] Univ Miami, Miller Sch Med, Div Endocrinol Diabet & Metab, Diabet Res Inst,Dept Med, Miami, FL 33136 USA.
   [Yankey, Jon W.; Clarke, William R.; Qidwai, Julie C.; Schwieger, Traci R.] Univ Iowa, Clin Trials Stat & Data Management Ctr, Dept Biostat, Iowa City, IA USA.
   [Eggerman, Thomas L.] NIDDK, Div Diabet Endocrinol & Metab Dis, Bethesda, MD 20892 USA.
   [Robien, Mark A.] NIAID, Transplantat Branch, Bethesda, MD 20892 USA.
   [Rickels, Michael R.] Univ Penn, Dept Med, Div Endocrinol Diabet & Metab, Perelman Sch Med, Philadelphia, PA 19104 USA.
RP Senior, PA (corresponding author), Univ Alberta, 2000 Coll Plaza,8215 112 St, Edmonton, AB T6G2C8, Canada.
EM peters@islet.ca; rickels@mail.med.upenn.edu
RI Senior, Peter/O-4934-2019; Robien, Mark/AAA-9260-2021; Rickels,
   Michael/D-1380-2009; Senior, Peter A/E-3031-2013
OI Senior, Peter/0000-0003-1033-8673; Robien, Mark/0000-0003-0403-0955;
   Rickels, Michael/0000-0002-9253-838X; Senior, Peter
   A/0000-0003-1033-8673
FU U.S. Public Health ServicesUnited States Department of Health & Human
   ServicesUnited States Public Health Service [U01 DK070430, U01 DK070431,
   U01 DK070460, U01DK085531, U01 AI065191, U01 AI065193, U01AI089316, U01
   AI089317, U01 5U01DK070431-10]; Clinical & Translational Science Awards
   [UL1 TR000003, UL1 TR000004, UL1 TR000050, UL1 TR000114, UL1 TR000150,
   UL1 TR000454, UL1 TR000460];  [RO1 DK091331]; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000454,
   UL1TR000003, UL1TR000004, UL1TR000460, UL1TR000114, UL1TR000050,
   UL1TR000150] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY
   AND INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [U01AI065193, U01AI065191,
   U01AI089316, U01AI089317] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Diabetes & Digestive & Kidney Diseases
   (NIDDK) [U01DK070431, U01DK070460, U01DK070430, P30DK063720,
   U01DK085531] Funding Source: NIH RePORTER; Alberta Innovates [201201154]
   Funding Source: researchfish
FX This work was performed as a project of the CIT Consortium, a
   collaborative clinical research program head-quartered at the National
   Institute of Diabetes and Digestive and Kidney Diseases and the National
   Institute of Allergy and Infectious Diseases and supported by U.S.
   Public Health Services research grants U01 DK070430 (to the University
   of Pennsylvania), U01 DK070431 (to the University of Iowa), U01 DK070460
   (to the University of Miami), U01DK085531 (to the University of
   California San Francisco), U01 AI065191 (to the University of Alberta),
   U01 AI065193 (to the University of Minnesota), U01AI089316 (to
   Northwestern University), U01 AI089317 (to Emory University), and U01
   5U01DK070431-10 (to the University of Illinois at Chicago), as well as
   by Clinical & Translational Science Awards UL1 TR000003 (to the
   University of Pennsylvania), UL1 TR000004 (to the University of
   California San Francisco), UL1 TR000050 (to the University of Illinois
   at Chicago), UL1 TR000114 (to the University of Minnesota), UL1 TR000150
   (to Northwestern University), UL1 TR000454 (to Emory University), and
   UL1 TR000460 (to the University of Miami) and also by grant RO1 DK091331
   (to M. R. R.). We would like to thank the referring endocrinologists and
   diabetologists and the industry sponsor, LifeScan Inc./Johnson & Johnson
   Co., for contributing their products to the CIT trials.
CR Barton FB, 2012, DIABETES CARE, V35, P1436, DOI 10.2337/dc12-0063
   Bergenstal RM, 2013, DIABETES TECHNOL THE, V15, P198, DOI 10.1089/dia.2013.0051
   Choudhary P, 2010, DIABETIC MED, V27, P666, DOI 10.1111/j.1464-5491.2010.03006.x
   CLARKE WL, 1995, DIABETES CARE, V18, P517, DOI 10.2337/diacare.18.4.517
   COX DJ, 1994, J CLIN ENDOCR METAB, V79, P1659, DOI 10.1210/jc.79.6.1659
   Cryer PE, 2005, DIABETES, V54, P3592, DOI 10.2337/diabetes.54.12.3592
   Cryer PE, 2013, NEW ENGL J MED, V369, P362, DOI 10.1056/NEJMra1215228
   DCCT Res Grp, 1991, AM J MED, V90, P450, DOI 10.1016/0002-9343(91)80085-Z
   Feltbower RG, 2008, DIABETES CARE, V31, P922, DOI 10.2337/dc07-2029
   GOLD AE, 1995, PHYSIOL BEHAV, V58, P501, DOI 10.1016/0031-9384(95)00085-W
   Heller SR, 2007, DIABETOLOGIA, V50, P1140, DOI 10.1007/s00125-007-0599-y
   Janssen MMJ, 2000, DIABETES CARE, V23, P529, DOI 10.2337/diacare.23.4.529
   Kilpatrick ES, 2007, DIABETOLOGIA, V50, P2553, DOI 10.1007/s00125-007-0820-z
   Kovatchev Boris P, 2005, Diabetes Technol Ther, V7, P849, DOI 10.1089/dia.2005.7.849
   McDonnell C M, 2005, Diabetes Technol Ther, V7, P253, DOI 10.1089/dia.2005.7.253
   Pedersen-Bjergaard U, 2004, DIABETES-METAB RES, V20, P479, DOI 10.1002/dmrr.482
   Rickels MR, 2007, J CLIN ENDOCR METAB, V92, P873, DOI 10.1210/jc.2006-2426
   Rickels MR, 2005, DIABETES, V54, P3205, DOI 10.2337/diabetes.54.11.3205
   Rodbard D, 2012, DIABETES TECHNOL THE, V14, P868, DOI 10.1089/dia.2012.0062
   Ryan EA, 2004, DIABETES, V53, P955, DOI 10.2337/diabetes.53.4.955
   SERVICE FJ, 1970, DIABETES, V19, P644, DOI 10.2337/diab.19.9.644
   Skrivarhaug T, 2006, DIABETOLOGIA, V49, P298, DOI 10.1007/s00125-005-0082-6
NR 22
TC 19
Z9 20
U1 1
U2 3
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1520-9156
EI 1557-8593
J9 DIABETES TECHNOL THE
JI Diabetes Technol. Ther.
PD APR 1
PY 2015
VL 17
IS 4
BP 235
EP 242
DI 10.1089/dia.2014.0289
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CD4MO
UT WOS:000351057300003
PM 25629445
OA Green Published
DA 2021-10-30
ER

PT J
AU Rojas, MJ
   Felix, E
   Small, L
   Goldhardt, R
   Galor, A
AF Rojas, Mario Joseph
   Felix, Elizabeth
   Small, Leslie
   Goldhardt, Raquel
   Galor, Anat
TI Autonomic Function Testing and After-sensations as Predictors for
   Postoperative Dry Eye Symptoms after Laser-Assisted in Situ
   Keratomileusis
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Meeting Abstract
CT Annual Meeting of the
   Association-for-Research-in-Vision-and-Ophthalmology (ARVO)
CY APR 28-MAY 02, 2019
CL Vancouver, CANADA
SP Assoc Res Vis & Ophthalmol
C1 [Rojas, Mario Joseph; Felix, Elizabeth; Small, Leslie; Goldhardt, Raquel; Galor, Anat] Bascom Palmer, Ophthalmol, Miami, FL USA.
RI Felix, Elizabeth/AAD-6356-2021
FU Department of Veterans Affairs, Veterans Health Administration, Office
   of Research and Development, Clinical Sciences ResearchUS Department of
   Veterans Affairs [EPID-006-15S, R01EY026174]; Miami CTSI Pilot Program
   FY16 (NIH)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [UL1TR000460]; NIH Center Core
   GrantUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [P30EY014801]; Research to Prevent
   Blindness Unrestricted GrantResearch to Prevent Blindness (RPB)
FX Supported by the Department of Veterans Affairs, Veterans Health
   Administration, Office of Research and Development, Clinical Sciences
   Research EPID-006-15S (Dr. Galor), R01EY026174 (Dr. Galor), Miami CTSI
   Pilot Program FY16 (NIH UL1TR000460, Miami CTSI), NIH Center Core Grant
   P30EY014801 and Research to Prevent Blindness Unrestricted Grant.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2019
VL 60
IS 9
MA 5202
PG 3
WC Ophthalmology
SC Ophthalmology
GA JB8EY
UT WOS:000488800704153
DA 2021-10-30
ER

PT J
AU Mitrofanova, A
   Fontanella, AM
   Merscher, S
   Fornoni, A
AF Mitrofanova, Alla
   Fontanella, Antonio M.
   Merscher, Sandra
   Fornoni, Alessia
TI Lipid deposition and metaflammation in diabetic kidney disease
SO CURRENT OPINION IN PHARMACOLOGY
LA English
DT Review
ID C-REACTIVE PROTEIN; TUMOR-NECROSIS-FACTOR; TNF RECEPTORS 1; MONOCYTE
   CHEMOATTRACTANT PROTEIN-1; INTERCELLULAR-ADHESION MOLECULE-1;
   NF-KAPPA-B; OXIDATIVE STRESS; SIGNALING PATHWAYS; ALBUMIN EXCRETION;
   RENAL-FUNCTION
AB A critical link between metabolic disorders and a form of low-grade systemic and chronic inflammation has been recently established and named 'Metaflammation'. Metaflammation has been recognized as a key mediator of both microvascular and macrovascular complications of diabetes and as a significant contributor to the development of diabetic kidney disease (DKD). The goal of this review is to summarize the contribution of diabetes-induced inflammation and the related signaling pathways to diabetic complications, with a particular focus on how innate immunity and lipid metabolism influence each other.
C1 [Mitrofanova, Alla; Fontanella, Antonio M.; Merscher, Sandra; Fornoni, Alessia] Univ Miami, Miller Sch Med, Dept Med, Katz Family Div Nephrol & Hypertens, Miami, FL 33136 USA.
   [Mitrofanova, Alla; Fontanella, Antonio M.; Merscher, Sandra; Fornoni, Alessia] Univ Miami, Miller Sch Med, Peggy & Harold Katz Family Drug Discovery Ctr, Miami, FL 33136 USA.
   [Mitrofanova, Alla] Univ Miami, Miller Sch Med, Dept Surg, Miami, FL 33136 USA.
RP Fornoni, A (corresponding author), Univ Miami, Miller Sch Med, Dept Med, Katz Family Div Nephrol & Hypertens, Miami, FL 33136 USA.; Fornoni, A (corresponding author), Univ Miami, Miller Sch Med, Peggy & Harold Katz Family Drug Discovery Ctr, Miami, FL 33136 USA.
EM afornoni@miami.edu
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01DK117599,
   R01DK104753, R01CA227493, U54DK083912, UM1DK100846, U01DK116101]; Miami
   Clinical Translational Science Institute [UL1TR000460]
FX Research in Dr Alessia Fornoni's laboratory is supported by the National
   Institutes of Health [grant numbers R01DK117599, R01DK104753,
   R01CA227493, U54DK083912, UM1DK100846, U01DK116101] and by the Miami
   Clinical Translational Science Institute [grant number UL1TR000460]. We
   give a special thanks to the Katz family for continuous support.
CR Ablamunits V, 2012, DIABETES, V61, P145, DOI 10.2337/db11-1033
   Ahluwalia TS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005168
   Akash MSH, 2018, J CELL BIOCHEM, V119, P105, DOI 10.1002/jcb.26174
   Al-Lamki RS, 2015, KIDNEY INT, V87, P281, DOI 10.1038/ki.2014.285
   Alkhatatbeh MJ, 2013, NUTR DIABETES, V3, DOI 10.1038/nutd.2013.1
   Amior L, 2019, FASEB J, V33, P4975, DOI 10.1096/fj.201801823R
   An ZM, 2015, J HUAZHONG U SCI-MED, V35, P356, DOI 10.1007/s11596-015-1437-y
   Aroune D, 2017, SAUDI J BIOL SCI, V24, P843, DOI 10.1016/j.sjbs.2016.05.009
   Assmann TS, 2015, ARCH ENDOCRIN METAB, V59, P4, DOI 10.1590/2359-3997000000003
   Avci E, 2016, BIOMED RES-INDIA, V27, pS343
   Awad AS, 2011, KIDNEY INT, V79, P1090, DOI 10.1038/ki.2010.544
   Ballak DB, 2018, J BIOL CHEM, V293, P14224, DOI 10.1074/jbc.RA118.003698
   Barr ELM, 2018, DIABETES CARE, V41, P739, DOI 10.2337/dc17-1919
   Behl T, 2016, PROSTAG OTH LIPID M, V122, P1, DOI 10.1016/j.prostaglandins.2015.12.001
   Bhattacharjee CK, 2019, J DIABETES, V11, P90, DOI 10.1111/1753-0407.12845
   Blaha V, 2006, PHARMACOL RES, V54, P421, DOI 10.1016/j.phrs.2006.08.005
   Boni-Schnetzler M, 2009, ENDOCRINOLOGY, V150, P5218, DOI 10.1210/en.2009-0543
   Boulbou MS, 2005, INT J CARDIOL, V98, P39, DOI 10.1016/j.ijcard.2003.07.037
   Brennan EP, 2018, DIABETES, V67, P2657, DOI 10.2337/db17-1317
   Brennan EP, 2017, MOL ASPECTS MED, V58, P102, DOI 10.1016/j.mam.2017.05.001
   Cavalot F, 2002, DIABETES CARE, V25, P2354, DOI 10.2337/diacare.25.12.2354-a
   Cha DR, 2005, NEPHROLOGY, V10, pS37, DOI 10.1111/j.1440-1797.2005.00455.x
   Chavarria-Smith J, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1006052
   Chawla A, 2011, NAT REV IMMUNOL, V11, P738, DOI 10.1038/nri3071
   Chen FQ, 2018, BMC COMPLEM ALTERN M, V18, DOI 10.1186/s12906-018-2257-y
   Cherney DZI, 2008, DIABETES, V57, P688, DOI 10.2337/db07-1230
   Chertow GM, 2019, J AM SOC NEPHROL, V30, P1980, DOI 10.1681/ASN.2018121231
   Chin MP, 2018, AM J NEPHROL, V47, P40, DOI 10.1159/000486398
   Chow FY, 2005, J AM SOC NEPHROL, V16, P1711, DOI 10.1681/ASN.2004070612
   Chung FM, 2005, DIABETES CARE, V28, P1710, DOI 10.2337/diacare.28.7.1710
   Chung KW, 2019, CELL METAB, V30, P784, DOI 10.1016/j.cmet.2019.08.003
   Dasu MR, 2008, DIABETES, V57, P3090, DOI 10.2337/db08-0564
   de la Maza MP, 2015, J NUTR HEALTH AGING, V19, P389, DOI 10.1007/s12603-014-0548-7
   Garcia FAD, 2015, J INFLAMM-LOND, V12, DOI 10.1186/s12950-015-0080-5
   Devaraj S, 2008, J CLIN ENDOCR METAB, V93, P578, DOI 10.1210/jc.2007-2185
   Dong BJ, 2012, AM J PHYSIOL-HEART C, V303, pH732, DOI 10.1152/ajpheart.00948.2011
   Ducasa GM, 2019, CURR DIABETES REP, V19, DOI 10.1007/s11892-019-1263-x
   Ducasa GM, 2019, J CLIN INVEST, V129, P3387, DOI 10.1172/JCI125316
   Fang ZJ, 2019, PROG LIPID RES, V74, P145, DOI 10.1016/j.plipres.2019.04.001
   Feng H, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/6973175
   Freeman DJ, 2002, DIABETES, V51, P1596, DOI 10.2337/diabetes.51.5.1596
   Freire MO, 2017, J IMMUNOL, V198, P718, DOI 10.4049/jimmunol.1601543
   Gohda T, 2018, DIABETES RES CLIN PR, V141, P62, DOI 10.1016/j.diabres.2018.04.026
   Gohda T, 2012, J AM SOC NEPHROL, V23, P516, DOI 10.1681/ASN.2011060628
   Grandemange S, 2017, ANN RHEUM DIS, V76, P1191, DOI 10.1136/annrheumdis-2016-210021
   Gulden E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075385
   Hammad SM, 2020, GENES-BASEL, V11, DOI 10.3390/genes11020178
   Han KH, 2010, INFLAMMATION, V33, P137, DOI 10.1007/s10753-009-9167-6
   Hardy G, 2005, PROSTAG OTH LIPID M, V78, P291, DOI 10.1016/j.prostaglandins.2005.10.001
   HASEGAWA G, 1991, KIDNEY INT, V40, P1007, DOI 10.1038/ki.1991.308
   Hegazy GA, 2019, J INT MED RES, DOI 10.1177/0300060519893858
   Heinz LX, 2015, CELL REP, V11, P1919, DOI 10.1016/j.celrep.2015.05.006
   Hellmann J, 2011, FASEB J, V25, P2399, DOI 10.1096/fj.10-178657
   Hojs R, 2016, NEPHRON, V133, P159, DOI 10.1159/000447434
   Hu FB, 2004, DIABETES, V53, P693, DOI 10.2337/diabetes.53.3.693
   Ishizawa S, 2014, CLIN EXP NEPHROL, V18, P844, DOI 10.1007/s10157-014-0933-x
   Jia ZJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093182
   Jing YL, 2011, CLIN CHIM ACTA, V412, P466, DOI 10.1016/j.cca.2010.11.030
   Karadeniz M, 2010, ENDOCRINE, V37, P513, DOI 10.1007/s12020-010-9342-4
   Karimi Z, 2018, DIABETES METAB SYND, V12, P365, DOI 10.1016/j.dsx.2017.12.028
   Khedr S, 2020, FASEB J, V34, P1
   Kochetova OV, 2019, MOL BIOL REP, V46, P887, DOI 10.1007/s11033-018-4544-6
   Kouyama Kunichi, 2008, Kobe J Med Sci, V53, P345
   Kowalski GM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072449
   Kulkarni H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151177
   Kuriya G, 2013, DIABETOLOGIA, V56, P1773, DOI 10.1007/s00125-013-2935-8
   Laaksonen DE, 2004, DIABETOLOGIA, V47, P1403, DOI 10.1007/s00125-004-1472-x
   Larsen CM, 2007, NEW ENGL J MED, V356, P1517, DOI 10.1056/NEJMoa065213
   Lee AS, 2011, DIABETOLOGIA, V54, P1407, DOI 10.1007/s00125-011-2083-y
   Lee CC, 2009, DIABETOLOGIA, V52, P1040, DOI 10.1007/s00125-009-1338-3
   Lee CP, 2019, J CELL MOL MED, V23, P7699, DOI 10.1111/jcmm.14643
   Lee Y, 2019, NEPHROL DIAL TRANSPL, V34
   Li CR, 2014, J IMMUNOL, V192, P1425, DOI 10.4049/jimmunol.1301742
   Lin JL, 2008, DIABETES CARE, V31, P2338, DOI 10.2337/dc08-0277
   Liu HW, 2017, BIOMED PHARMACOTHER, V94, P619, DOI 10.1016/j.biopha.2017.07.102
   Liu LY, 2018, LIPIDS HEALTH DIS, V17, DOI 10.1186/s12944-018-0922-2
   Liu ZH, 2012, J ENDOCRINOL INVEST, V35, P585, DOI 10.3275/7981
   Lopes-Virella MF, 2013, DIABETES CARE, V36, P2317, DOI 10.2337/dc12-2521
   Lopez-Vicario C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15951-z
   Lovric S, 2017, J CLIN INVEST, V127, P912, DOI 10.1172/JCI89626
   Maceyka M, 2014, NATURE, V510, P58, DOI 10.1038/nature13475
   Majumdar I, 2012, ENDOCRINE, V41, P442, DOI 10.1007/s12020-011-9589-4
   Makino H, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000019782.37851.BF
   Mallela SK, 2019, BBA-MOL CELL BIOL L, V1864, DOI 10.1016/j.bbalip.2019.158517
   Meng XM, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00082
   Merscher-Gomez S, 2013, DIABETES, V62, P3817, DOI 10.2337/db13-0399
   Milas O, 2020, J DIABETES COMPLICAT, V34, DOI 10.1016/j.jdiacomp.2019.107479
   Mitrofanova A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10584-4
   Mohammad MK, 2006, INT IMMUNOL, V18, P1101, DOI 10.1093/intimm/dxl045
   Moon JY, 2007, J KOREAN MED SCI, V22, P810, DOI 10.3346/jkms.2007.22.5.810
   Mueller PW, 2006, J AM SOC NEPHROL, V17, P1782, DOI 10.1681/ASN.2005080822
   Muller S, 2002, DIABETOLOGIA, V45, P805, DOI 10.1007/s00125-002-0829-2
   Murphy AJ, 2016, CELL METAB, V23, P155, DOI 10.1016/j.cmet.2015.09.024
   Nadkarni GN, 2016, CLIN J AM SOC NEPHRO, V11, P1343, DOI 10.2215/CJN.12051115
   Nasrallah R, 2007, AM J PHYSIOL-RENAL, V292, pF278, DOI 10.1152/ajprenal.00089.2006
   Nasrallah R, 2009, AM J NEPHROL, V30, P346, DOI 10.1159/000229304
   Nassar M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01374
   Navarro-Gonzalez JF, 2015, J AM SOC NEPHROL, V26, P220, DOI 10.1681/ASN.2014010012
   Nawaz SS, 2019, MOL BIOL REP, V46, P1239, DOI 10.1007/s11033-019-04592-2
   Niewczas MA, 2019, NAT MED, V25, P805, DOI 10.1038/s41591-019-0415-5
   Niewczas MA, 2012, J AM SOC NEPHROL, V23, P507, DOI 10.1681/ASN.2011060627
   Okada S, 2003, DIABETES, V52, P2586, DOI 10.2337/diabetes.52.10.2586
   Paykov ME, 2015, KIDNEY INT, V87, P812, DOI 10.1038/ki.2014.330
   Pedigo CE, 2016, J CLIN INVEST, V126, P3336, DOI 10.1172/JCI85939
   Piemonti L, 2009, DIABETES CARE, V32, P2105, DOI 10.2337/dc09-0763
   Pitsavos Christos, 2007, Rev Diabet Stud, V4, P98, DOI 10.1900/RDS.2007.4.98
   Pradhan AD, 2001, JAMA-J AM MED ASSOC, V286, P327, DOI 10.1001/jama.286.3.327
   Proctor MJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116206
   Radhakrishnan Preethi, 2014, Indian J Endocrinol Metab, V18, P505, DOI 10.4103/2230-8210.137498
   Rafnsson A, 2013, DIS MARKERS, V2013, P475, DOI 10.1155/2013/370461
   Rodgers K, 2005, AM J PATHOL, V167, P683, DOI 10.1016/S0002-9440(10)62043-3
   Ruiz S, 2013, KIDNEY INT, V83, P1029, DOI 10.1038/ki.2012.439
   Salazar-Leon J, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49546-7
   Samad F, 2006, DIABETES, V55, P2579, DOI 10.2337/db06-0330
   Samra YA, 2016, LIFE SCI, V157, P187, DOI 10.1016/j.lfs.2016.06.002
   Satirapoj B, 2018, BMC NEPHROL, V19, DOI 10.1186/s12882-018-1043-x
   Shahzad K, 2016, SCI REP-UK, V6, DOI 10.1038/srep34228
   Sima C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13185-7
   Sindhu S, 2017, J DIABETES METAB DIS, V16, DOI 10.1186/s40200-017-0297-3
   Stanford JC, 2012, J BIOL CHEM, V287, P13457, DOI 10.1074/jbc.M111.268185
   Su N, 2018, MEDICINE, V97, DOI [10.1097/MD.0000000000011232, 10.1097/md.0000000000011232]
   Sun XX, 2019, J DIABETES RES, V2019, DOI 10.1155/2019/7405120
   Thibodeau JF, 2013, AM J PATHOL, V183, P1789, DOI 10.1016/j.ajpath.2013.08.022
   Tong X, 2020, DIABETES, V69, P342, DOI 10.2337/db19-0281
   Vallois D, 2007, J IMMUNOL, V179, P3896, DOI 10.4049/jimmunol.179.6.3896
   Wada T, 2004, J AM SOC NEPHROL, V15, P940, DOI 10.1097/01.ASN.0000120371.09769.80
   Wan RJ, 2018, MOL MED REP, V17, P4759, DOI 10.3892/mmr.2018.8407
   Wang C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038285
   Wei XC, 2016, NATURE, V539, P294, DOI 10.1038/nature20117
   Wu C, 2015, MOL CELL ENDOCRINOL, V417, P84, DOI 10.1016/j.mce.2015.09.024
   Wu L, 2020, NEPHROL DIAL TRANSPL, V35, P291, DOI 10.1093/ndt/gfy314
   Xiao J, 2015, MOL IMMUNOL, V66, P310, DOI 10.1016/j.molimm.2015.03.250
   Yahya Mohd Jokha, 2019, Int J Chronic Dis, V2019, P2053015, DOI 10.1155/2019/2053015
   Yoo TH, 2015, J AM SOC NEPHROL, V26, P133, DOI 10.1681/ASN.2013111213
   ZADOR IZ, 1993, J CLIN INVEST, V91, P797, DOI 10.1172/JCI116299
NR 135
TC 3
Z9 3
U1 4
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1471-4892
EI 1471-4973
J9 CURR OPIN PHARMACOL
JI Curr. Opin. Pharmacol.
PD DEC
PY 2020
VL 55
SI SI
BP 60
EP 72
DI 10.1016/j.coph.2020.09.004
PG 13
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA PH7KS
UT WOS:000600587300010
PM 33137677
DA 2021-10-30
ER

PT J
AU Peixoto, E
   Vendrame, F
   Arnau, A
   Padilla, N
   Baidal, D
   Alvarez, A
   Delmonte, V
   Fornoni, A
   Ricordi, C
   Alejandro, R
AF Peixoto, Eduardo
   Vendrame, Francesco
   Arnau, Alvaro
   Padilla, Nathalia
   Baidal, David
   Alvarez, Ana
   Delmonte, Valentina
   Fornoni, Alessia
   Ricordi, Camillo
   Alejandro, Rodolfo
TI Ten Years of Preserved Kidney Function After Islet Transplant Graft
   Failure
SO DIABETES CARE
LA English
DT Letter
ID IMPROVEMENT; IMPACT
C1 [Peixoto, Eduardo; Vendrame, Francesco; Arnau, Alvaro; Padilla, Nathalia; Baidal, David; Alvarez, Ana; Delmonte, Valentina; Ricordi, Camillo; Alejandro, Rodolfo] Univ Miami, Miller Sch Med, Diabet Res Inst, Miami, FL 33136 USA.
   [Peixoto, Eduardo] Framingham Union Hosp, MetroWest Med Ctr, Dept Internal Med, Boston, MA USA.
   [Vendrame, Francesco; Baidal, David; Alejandro, Rodolfo] Univ Miami, Miller Sch Med, Dept Med, Div Endocrinol Metab & Diabet, Miami, FL 33136 USA.
   [Arnau, Alvaro] Univ Cantabria, Fdn Marques Valdecilla IFIMAV, Hosp Univ Marques Valdecilla, Serv Nefrol, Cantabria, Spain.
   [Delmonte, Valentina] Univ Milan, Dept Biomed Sci Hlth, Milan, Italy.
   [Fornoni, Alessia] Univ Miami, Miller Sch Med, Dept Med, Div Nephrol, Miami, FL 33136 USA.
RP Alejandro, R (corresponding author), Univ Miami, Miller Sch Med, Diabet Res Inst, Miami, FL 33136 USA.; Alejandro, R (corresponding author), Univ Miami, Miller Sch Med, Dept Med, Div Endocrinol Metab & Diabet, Miami, FL 33136 USA.
EM ralejand@med.miami.edu
RI RICORDI, CAMILLO/AAA-4740-2019; Padilla, Nathalia/AAQ-9596-2020
OI Padilla, Nathalia/0000-0002-7177-1107; fornoni,
   Alessia/0000-0002-1313-7773
FU NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1 TR000460] Funding Source: Medline;
   NCRR NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Research
   Resources (NCRR) [M01 RR016587, U42 RR016603] Funding Source: Medline;
   NIDDK NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Diabetes &
   Digestive & Kidney Diseases (NIDDK) [R01 DK055347, K08 DK082636] Funding
   Source: Medline; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1TR000460] Funding Source: NIH
   RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Research Resources (NCRR) [M01RR016587, U42RR016603]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND
   DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Diabetes & Digestive & Kidney Diseases (NIDDK) [K08DK082636,
   R01DK055347] Funding Source: NIH RePORTER
CR Barton FB, 2012, DIABETES CARE, V35, P1436, DOI 10.2337/dc12-0063
   Fiorina P, 2003, J AM SOC NEPHROL, V14, P2150, DOI 10.1097/01.ASN.0000077339.20759.A3
   Maffi P, 2007, DIABETES CARE, V30, P1150, DOI 10.2337/dc06-1794
   Shapiro AMJ, 2003, J AM SOC NEPHROL, V14, P2214, DOI 10.1097/01.ASN.0000082923.60142.72
   Thompson DM, 2011, TRANSPLANTATION, V91, P373, DOI 10.1097/TP.0b013e31820437f3
NR 5
TC 3
Z9 3
U1 0
U2 1
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
EI 1935-5548
J9 DIABETES CARE
JI Diabetes Care
PD DEC
PY 2016
VL 39
IS 12
BP E209
EP E211
DI 10.2337/dc16-1093
PG 3
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA EG1IF
UT WOS:000390785000001
PM 27650978
OA Green Published, Bronze
DA 2021-10-30
ER

PT J
AU Ge, MY
   Merscher, S
   Fornoni, A
AF Ge, Mengyuan
   Merscher, Sandra
   Fornoni, Alessia
TI Use of Lipid-Modifying Agents for the Treatment of Glomerular Diseases
SO JOURNAL OF PERSONALIZED MEDICINE
LA English
DT Review
DE lipids; podocytes; glomerular diseases; therapies; proteinuria;
   nephrotic syndrome
ID ACTIVATED RECEPTOR-ALPHA; NONALCOHOLIC FATTY LIVER; CASSETTE TRANSPORTER
   A1; LOW-DENSITY-LIPOPROTEIN; GLUCAGON-LIKE PEPTIDE-1; ESTER TRANSFER
   PROTEIN; KIDNEY-DISEASE; NEPHROTIC SYNDROME; DIABETIC-NEPHROPATHY;
   GENE-EXPRESSION
AB Although dyslipidemia is associated with chronic kidney disease (CKD), it is more common in nephrotic syndrome (NS), and guidelines for the management of hyperlipidemia in NS are largely opinion-based. In addition to the role of circulating lipids, an increasing number of studies suggest that intrarenal lipids contribute to the progression of glomerular diseases, indicating that proteinuric kidney diseases may be a form of "fatty kidney disease" and that reducing intracellular lipids could represent a new therapeutic approach to slow the progression of CKD. In this review, we summarize recent progress made in the utilization of lipid-modifying agents to lower renal parenchymal lipid accumulation and to prevent or reduce kidney injury. The agents mentioned in this review are categorized according to their specific targets, but they may also regulate other lipid-relevant pathways.
C1 [Ge, Mengyuan; Merscher, Sandra; Fornoni, Alessia] Univ Miami, Miller Sch Med, Katz Family Div Nephrol & Hypertens, Dept Med,Peggy & Harold Katz Family Drug Discover, Miami, FL 33136 USA.
RP Fornoni, A (corresponding author), Univ Miami, Miller Sch Med, Katz Family Div Nephrol & Hypertens, Dept Med,Peggy & Harold Katz Family Drug Discover, Miami, FL 33136 USA.
EM mengyuange@med.miami.edu; smerscher@med.miami.edu;
   afornoni@med.miami.edu
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01DK117599,
   R01DK104753, R01CA227493]; American Heart AssociationAmerican Heart
   Association [18PRE34030042]; Miami Clinical Translational Science
   Institute [U54DK083912, UM1DK100846, U01DK116101, UL1TR000460]
FX A.F. and S.M. are supported by National Institutes of Health grants
   R01DK117599, R01DK104753 and R01CA227493. A.F. is also supported
   byU54DK083912, UM1DK100846, U01DK116101 and UL1TR000460 (Miami Clinical
   Translational Science Institute). M.G. was supported by a predoctoral
   fellowship from the American Heart Association (18PRE34030042).
CR Aghajan M, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.126124
   Aragon-Herrera A, 2019, BIOCHEM PHARMACOL, V170, DOI 10.1016/j.bcp.2019.113677
   Basu D, 2018, ARTERIOSCL THROM VAS, V38, P2207, DOI 10.1161/ATVBAHA.118.311339
   Bjorkegren J, 2001, J BIOL CHEM, V276, P38511, DOI 10.1074/jbc.M106839200
   Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905
   Bruggeman LA, 2019, AM J PHYSIOL-RENAL, V316, pF1, DOI 10.1152/ajprenal.00426.2018
   Calkin AC, 2012, NAT REV MOL CELL BIO, V13, P213, DOI 10.1038/nrm3312
   Casaschi A, 2004, J NUTR, V134, P1340, DOI 10.1093/jn/134.6.1340
   Cases S, 2001, J BIOL CHEM, V276, P38870, DOI 10.1074/jbc.M106219200
   Chang TY, 2008, CELL METAB, V7, P469, DOI 10.1016/j.cmet.2008.05.001
   Chang TY, 2006, ANNU REV CELL DEV BI, V22, P129, DOI 10.1146/annurev.cellbio.22.010305.104656
   Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336
   Chehade JM, 2013, METABOLISM, V62, P265, DOI 10.1016/j.metabol.2012.07.005
   Cheng JL, 2009, HISTOCHEM CELL BIOL, V132, P281, DOI 10.1007/s00418-009-0615-z
   Cheng X, 2018, CURR TOP MED CHEM, V18, P484, DOI 10.2174/1568026618666180523104541
   Chun J, 2019, P NATL ACAD SCI USA, V116, P3712, DOI 10.1073/pnas.1820414116
   Costa R, 2017, J NUTR BIOCHEM, V45, P39, DOI 10.1016/j.jnutbio.2017.03.006
   Czabany T, 2008, J BIOL CHEM, V283, P17065, DOI 10.1074/jbc.M800401200
   DeFronzo RA, 2012, DIABETES OBES METAB, V14, P5, DOI 10.1111/j.1463-1326.2011.01511.x
   Drexler Y, 2021, J AM SOC NEPHROL, V32, P9, DOI 10.1681/ASN.2020050697
   DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7
   DRUILHET RE, 1975, INT J BIOCHEM, V6, P893, DOI 10.1016/0020-711X(75)90010-5
   Ducasa GM, 2019, J CLIN INVEST, V129, P3387, DOI 10.1172/JCI125316
   Duchateau PN, 1997, J BIOL CHEM, V272, P25576, DOI 10.1074/jbc.272.41.25576
   Edwards PA, 2000, BBA-MOL CELL BIOL L, V1529, P103, DOI 10.1016/S1388-1981(00)00140-2
   Farquhar MG, 2006, J CLIN INVEST, V116, P2090, DOI 10.1172/JCI29488
   Fessler MB, 2018, PHARMACOL THERAPEUT, V181, P1, DOI 10.1016/j.pharmthera.2017.07.010
   Fornoni A, 2014, NAT REV NEPHROL, V10, P379, DOI 10.1038/nrneph.2014.87
   Frasca GM, 2004, NEPHROL DIAL TRANSPL, V19, P1622, DOI 10.1093/ndt/gfh179
   Friedman DJ, 2020, ANNU REV PHYSIOL, V82, P323, DOI 10.1146/annurev-physiol-021119-034345
   Friesen JA, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-11-248
   Fujimoto T, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004838
   Gai ZB, 2016, J BIOL CHEM, V291, P2397, DOI 10.1074/jbc.M115.694323
   Ge MY, 2021, HUM MOL GENET, V30, P182, DOI 10.1093/hmg/ddab022
   Genovese G, 2010, SCIENCE, V329, P841, DOI 10.1126/science.1193032
   Germain DP, 2010, ORPHANET J RARE DIS, V5, DOI 10.1186/1750-1172-5-30
   Glastras SJ, 2015, NUTR METAB, V12, DOI 10.1186/s12986-015-0032-3
   GOLDSTEIN JL, 1973, P NATL ACAD SCI USA, V70, P2804, DOI 10.1073/pnas.70.10.2804
   Guan YF, 2001, KIDNEY INT, V60, P14, DOI 10.1046/j.1523-1755.2001.00766.x
   Gui YZ, 2016, ACTA PHARMACOL SIN, V37, P1337, DOI 10.1038/aps.2016.46
   Guo W, 2016, NUTR METAB, V13, DOI 10.1186/s12986-016-0082-1
   Haas ME, 2016, CIRCULATION, V134, P61, DOI 10.1161/CIRCULATIONAHA.115.020912
   HARMON CM, 1993, J MEMBRANE BIOL, V133, P43
   Herman-Edelstein M, 2014, J LIPID RES, V55, P561, DOI 10.1194/jlr.P040501
   Hong YA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096147
   Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593
   Hou YJ, 2018, NEPHROL DIAL TRANSPL, V33, P1908, DOI 10.1093/ndt/gfy021
   Hua W, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127507
   Ishigaki N, 2007, BIOCHEM BIOPH RES CO, V364, P502, DOI 10.1016/j.bbrc.2007.10.038
   Isshiki K, 2000, DIABETES, V49, P1022, DOI 10.2337/diabetes.49.6.1022
   Jiang T, 2007, DIABETES, V56, P2485, DOI 10.2337/db06-1642
   Jonas A, 2000, BBA-MOL CELL BIOL L, V1529, P245, DOI 10.1016/S1388-1981(00)00153-0
   Kalaany NY, 2006, ANNU REV PHYSIOL, V68, P159, DOI 10.1146/annurev.physiol.68.033104.152158
   Kamisuki S, 2009, CHEM BIOL, V16, P882, DOI 10.1016/j.chembiol.2009.07.007
   Kim JJ, 2021, EBIOMEDICINE, V63, DOI 10.1016/j.ebiom.2020.103162
   Kiss E, 2013, AM J PATHOL, V182, P727, DOI 10.1016/j.ajpath.2012.11.033
   Kopp JB, 2020, CLIN J AM SOC NEPHRO, V15, P126, DOI 10.2215/CJN.01810219
   Kretzler M, 2002, MICROSC RES TECHNIQ, V57, P247, DOI 10.1002/jemt.10083
   Kuchay MS, 2018, DIABETES CARE, V41, P1801, DOI 10.2337/dc18-0165
   Li LC, 2018, AM J PHYSIOL-RENAL, V315, pF1720, DOI 10.1152/ajprenal.00536.2017
   Li SY, 2004, AM J PHYSIOL-RENAL, V286, pF572, DOI 10.1152/ajprenal.00190.2003
   Liu XC, 2020, KIDNEY INT, V98, P1275, DOI 10.1016/j.kint.2020.06.040
   Lovric S, 2017, J CLIN INVEST, V127, P912, DOI 10.1172/JCI89626
   Luo YH, 2014, FASEB J, V28
   LUPIEN PJ, 1976, LANCET, V1, P1261
   Mahli A, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8040359
   Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362
   Marchesini G, 2003, HEPATOLOGY, V37, P917, DOI 10.1053/jhep.2003.50161
   Merscher S, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00169
   Merscher S, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00127
   Merscher-Gomez S, 2013, DIABETES, V62, P3817, DOI 10.2337/db13-0399
   Metzinger MP, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.018136
   Mitrofanova A, 2018, KIDNEY INT, V94, P1151, DOI 10.1016/j.kint.2018.06.031
   Miyai Y, 2011, J ENDOCRINOL INVEST, V34, pE268, DOI 10.3275/7683
   Miyata S, 2015, J BIOL CHEM, V290, P20565, DOI 10.1074/jbc.M115.656975
   MOORHEAD JF, 1982, LANCET, V2, P1309
   Mostafa AM, 2015, BIOCHEM BIOPH RES CO, V468, P900, DOI 10.1016/j.bbrc.2015.11.054
   Motojima K, 1998, J BIOL CHEM, V273, P16710, DOI 10.1074/jbc.273.27.16710
   MOULIN P, 1992, J LIPID RES, V33, P1817
   Mustafa M, 2016, AM J PHYSIOL-RENAL, V311, pF614, DOI 10.1152/ajprenal.00140.2016
   Nishi H, 2019, NUTRIENTS, V11, DOI 10.3390/nu11071664
   Okada T, 2006, DIABETES, V55, P1666, DOI 10.2337/db05-1285
   Park CW, 2006, KIDNEY INT, V69, P1511, DOI 10.1038/sj.ki.5000209
   Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365
   Patel M, 2014, DIABETOLOGIA, V57, P435, DOI 10.1007/s00125-013-3095-6
   Pedigo CE, 2016, J CLIN INVEST, V126, P3336, DOI 10.1172/JCI85939
   PRITCHARD PH, 1985, CLIN BIOCHEM, V18, P98, DOI 10.1016/S0009-9120(85)80089-8
   Raina R, 2019, PEDIATR NEPHROL, V34, P1655, DOI 10.1007/s00467-018-4061-9
   Rakhshandehroo M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006796
   Reiser J., 2016, F1000 RES, V5, P114
   Rickards E, 1883, Br Med J, V2, P2
   Rosenson R.S., 2021, FAMILIAL HYPERCHOLES
   Ruan XZ, 2008, AM J PHYSIOL-RENAL, V294, pF1032, DOI 10.1152/ajprenal.00152.2007
   Ruan XZ, 2003, J AM SOC NEPHROL, V14, P593, DOI 10.1097/01.ASN.0000050414.52908.DA
   Ryu JH, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211559
   Sabnis Ram W, 2020, ACS Med Chem Lett, V11, P2352, DOI 10.1021/acsmedchemlett.0c00531
   Schmit D, 2019, NEPHROL DIAL TRANSPL, V34, P1266, DOI 10.1093/ndt/gfz122
   Schulz Rainer, 2017, Clin Res Cardiol Suppl, V12, P2, DOI 10.1007/s11789-017-0085-0
   Seiler S, 2008, NEPHROL DIAL TRANSPL, V23, P3599, DOI 10.1093/ndt/gfn296
   Shati AA, 2017, J TAIBAH UNIV SCI, V11, P458, DOI 10.1016/j.jtusci.2016.09.009
   Shibuya T, 2018, DIABETES OBES METAB, V20, P438, DOI 10.1111/dom.13061
   Shrestha P, 2019, CELL SIGNAL, V55, P53, DOI 10.1016/j.cellsig.2018.12.001
   Simons M, 2001, AM J PATHOL, V159, P1069, DOI 10.1016/S0002-9440(10)61782-8
   Simons M, 1999, J AM SOC NEPHROL, V10, P1633
   Souza ACP, 2016, KIDNEY INT, V89, P809, DOI 10.1016/j.kint.2015.12.043
   Spurney R.F, 2019, NEPHROL DIAL TRANSPL, V34, DOI [10.1093/ndt/gfz096.FO068, DOI 10.1093/NDT/GFZ096.FO068]
   Stanifer JW, 2017, J AM SOC NEPHROL, V28, P3034, DOI 10.1681/ASN.2016090957
   Su XL, 2016, AM J KIDNEY DIS, V67, P881, DOI 10.1053/j.ajkd.2016.01.016
   Sun LJ, 2002, J BIOL CHEM, V277, P18919, DOI 10.1074/jbc.M110650200
   Szeto HH, 2014, CLIN PHARMACOL THER, V96, P672, DOI 10.1038/clpt.2014.174
   Tachibana H, 2012, J AM SOC NEPHROL, V23, P1835, DOI 10.1681/ASN.2012010022
   Takahashi S, 2013, J AM SOC NEPHROL, V24, P1305, DOI 10.1681/ASN.2012090913
   Tanaka Y, 2011, KIDNEY INT, V79, P871, DOI 10.1038/ki.2010.530
   Tesch GH, 2008, AM J PHYSIOL-RENAL, V294, pF697, DOI 10.1152/ajprenal.00016.2008
   Torra IP, 2003, MOL ENDOCRINOL, V17, P259, DOI 10.1210/me.2002-0120
   Unger RH, 2002, ANNU REV MED, V53, P319, DOI 10.1146/annurev.med.53.082901.104057
   van Herpen NA, 2008, PHYSIOL BEHAV, V94, P231, DOI 10.1016/j.physbeh.2007.11.049
   Van Krieken R, 2018, ENDOCRINOLOGY, V159, P1479, DOI 10.1210/en.2018-00093
   Vaziri ND, 2001, AM J PHYSIOL-RENAL, V280, pF823, DOI 10.1152/ajprenal.2001.280.5.F823
   Vaziri ND, 2016, KIDNEY INT, V90, P41, DOI 10.1016/j.kint.2016.02.026
   Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9
   Walther TC, 2009, BBA-MOL CELL BIOL L, V1791, P459, DOI 10.1016/j.bbalip.2008.10.009
   Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200
   Wang TN, 2015, J AM SOC NEPHROL, V26, P1839, DOI 10.1681/ASN.2013121332
   Wang XXX, 2018, J AM SOC NEPHROL, V29, P118, DOI 10.1681/ASN.2017020222
   Wang XXX, 2017, J BIOL CHEM, V292, P12018, DOI 10.1074/jbc.C117.794982
   Wang XXX, 2010, DIABETES, V59, P2916, DOI 10.2337/db10-0019
   Wang XX, 2009, AM J PHYSIOL-RENAL, V297, pF1587, DOI 10.1152/ajprenal.00404.2009
   Wright MB, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24890-3
   Xu S, 2013, BIOCHEMISTRY-US, V52, P7254, DOI 10.1021/bi400914c
   Yang JC, 2009, CLIN SCI, V116, P17, DOI 10.1042/CS20070462
   Yen CLE, 2008, J LIPID RES, V49, P2283, DOI 10.1194/jlr.R800018-JLR200
   Yin QH, 2016, J BIOL CHEM, V291, P26487, DOI 10.1074/jbc.M116.730564
   Zaid A, 2008, HEPATOLOGY, V48, P646, DOI 10.1002/hep.22354
   Zhao J, 2019, MEDIAT INFLAMM, V2019, DOI 10.1155/2019/3172647
   Zheng F, 2002, AM J PHYSIOL-RENAL, V282, pF639, DOI 10.1152/ajprenal.00189.2001
   Zhou YT, 2000, P NATL ACAD SCI USA, V97, P1784, DOI 10.1073/pnas.97.4.1784
   Zhou YF, 2011, KIDNEY INT, V79, P1302, DOI 10.1038/ki.2011.17
NR 138
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2075-4426
J9 J PERS MED
JI J. Pers. Med.
PD AUG
PY 2021
VL 11
IS 8
AR 820
DI 10.3390/jpm11080820
PG 16
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA UH0HE
UT WOS:000689621300001
PM 34442464
OA Green Published, gold
DA 2021-10-30
ER

PT J
AU Mitrofanova, A
   Burke, G
   Merscher, S
   Fornoni, A
AF Mitrofanova, Alla
   Burke, George
   Merscher, Sandra
   Fornoni, Alessia
TI New insights into renal lipid dysmetabolism in diabetic kidney disease
SO WORLD JOURNAL OF DIABETES
LA English
DT Review
DE Diabetes; Lipids; Free fatty acids; ATP-binding cassette transporters
   sub-class A; Sterol-O-acyltransferase 1; CD36; Sphingolipids;
   Sphingomyelin phosphodiesterase acid-like 3b; Diabetic kidney disease
ID TUBULAR EPITHELIAL-CELLS; FATTY-ACID OXIDATION; SOLUBLE CD36; ADRENAL
   INSUFFICIENCY; GLUCOSE-METABOLISM; NLRP3 INFLAMMASOME; NEPHROTIC
   SYNDROME; MESANGIAL CELLS; RISK-FACTORS; RECEPTOR 4
AB Lipid dysmetabolism is one of the main features of diabetes mellitus and manifests by dyslipidemia as well as the ectopic accumulation of lipids in various tissues and organs, including the kidney. Research suggests that impaired cholesterol metabolism, increased lipid uptake or synthesis, increased fatty acid oxidation, lipid droplet accumulation and an imbalance in biologically active sphingolipids (such as ceramide, ceramide-1-phosphate and sphingosine-1-phosphate) contribute to the development of diabetic kidney disease (DKD). Currently, the literature suggests that both quality and quantity of lipids are associated with DKD and contribute to increased reactive oxygen species production, oxidative stress, inflammation, or cell death. Therefore, control of renal lipid dysmetabolism is a very important therapeutic goal, which needs to be archived. This article will review some of the recent advances leading to a better understanding of the mechanisms of dyslipidemia and the role of particular lipids and sphingolipids in DKD.
C1 [Mitrofanova, Alla; Merscher, Sandra; Fornoni, Alessia] Univ Miami, Miller Sch Med, Peggy & Harold Katz Family Drug Discovery Ctr, 1580 NW 10th Ave,Batchelor Bldg,6th Floor, Miami, FL 33136 USA.
   [Mitrofanova, Alla; Merscher, Sandra; Fornoni, Alessia] Univ Miami, Miller Sch Med, Dept Med, Katz Family Div Nephrol & Hypertens, Miami, FL 33136 USA.
   [Mitrofanova, Alla; Burke, George] Univ Miami, Miller Sch Med, Dept Surg, Miami, FL 33136 USA.
   [Burke, George] Univ Miami, Miller Sch Med, Diabet Res Inst, Miami, FL 33136 USA.
RP Mitrofanova, A (corresponding author), Univ Miami, Miller Sch Med, Peggy & Harold Katz Family Drug Discovery Ctr, 1580 NW 10th Ave,Batchelor Bldg,6th Floor, Miami, FL 33136 USA.
EM a.mitrofanova@miami.edu
FU National Institute of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01DK117599,
   R01DK104753, R01CA227493, U54DK083912, UM1DK100846, U01DK116101]; Miami
   Clinical Translational Science Institute [UL1TR000460]; Chernowitz
   Medical Research Foundation [GR016291]
FX Supported by the National Institute of Health (Research in Dr. Alessia
   Fornoni's laboratory), No. R01DK117599, No. R01DK104753, No.
   R01CA227493, No. U54DK083912, No. UM1DK100846, and No. U01DK116101; the
   Miami Clinical Translational Science Institute, No. UL1TR000460; and the
   Chernowitz Medical Research Foundation (Mitrofanova A and Burke G), No.
   GR016291.
CR Afshinnia F, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.130317
   Agarwal R, 2005, KIDNEY INT, V68, P285, DOI 10.1111/j.1523-1755.2005.00416.x
   Ahmad A, 2017, FASEB J, V31, P771, DOI 10.1096/fj.201600618R
   Artunc F, 2020, KIDNEY INT, V98, P1393, DOI 10.1016/j.kint.2020.07.027
   Askari B, 2014, LAB INVEST, V94, P851, DOI 10.1038/labinvest.2014.80
   Awad AS, 2011, KIDNEY INT, V79, P1090, DOI 10.1038/ki.2010.544
   Awad AS, 2006, AM J PHYSIOL-RENAL, V290, pF1516, DOI 10.1152/ajprenal.00311.2005
   Bekpinar S, 2015, CLIN BIOCHEM, V48, P1264, DOI 10.1016/j.clinbiochem.2015.08.001
   Brown PM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125126
   Cansby E, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.140483
   Castelblanco E., 2019, J CLIN MED, V8
   Cha DR, 2007, DIABETES, V56, P2036, DOI 10.2337/db06-1134
   Chen RX, 2018, BMC NEPHROL, V19, DOI 10.1186/s12882-018-0913-6
   Cusick M, 2004, KIDNEY INT, V66, P1173, DOI 10.1111/j.1523-1755.2004.00869.x
   Drexler Y, 2021, J AM SOC NEPHROL, V32, P9, DOI 10.1681/ASN.2020050697
   Ducasa GM, 2019, CURR DIABETES REP, V19, DOI 10.1007/s11892-019-1263-x
   Ducasa GM, 2019, J CLIN INVEST, V129, P3387, DOI 10.1172/JCI125316
   Ngan DTT, 2020, J MED BIOCHEM, V39, P224, DOI 10.2478/jomb-2019-0037
   Ekici M, 2018, BRIT J NUTR, V119, P153, DOI [10.1017/S0007114517003269, 10.1017/s0007114517003269]
   Ene Corina Daniela, 2016, J Immunoassay Immunochem, V37, P68, DOI 10.1080/15321819.2015.1050107
   Ergen HA, 2012, BIOCHEM MEDICA, V22, P114
   Falkevall A, 2017, CELL METAB, V25, P713, DOI 10.1016/j.cmet.2017.01.004
   Feng L, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/1414070
   Fornoni A., 2021, EBIOMEDICINE, V63
   Fornoni A, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002231
   Fox TE, 2011, J LIPID RES, V52, P509, DOI 10.1194/jlr.M010595
   Fu J, 2019, J AM SOC NEPHROL, V30, P533, DOI 10.1681/ASN.2018090896
   Fujita A, 2008, DIABETES RES CLIN PR, V79, P11, DOI 10.1016/j.diabres.2007.08.009
   Fukuda A, 2012, KIDNEY INT, V81, P40, DOI 10.1038/ki.2011.306
   Gai ZB, 2019, NUTRIENTS, V11, DOI 10.3390/nu11040722
   Geoffroy K, 2005, FEBS LETT, V579, P1249, DOI 10.1016/j.febslet.2004.12.094
   Handberg A, 2009, DIABETES VASC DIS RE, V6, P15, DOI 10.3132/dvdr.2009.003
   Hao J, 2009, HISTOCHEM CELL BIOL, V131, P327, DOI 10.1007/s00418-008-0528-2
   Hashani M, 2018, CELL TISSUE RES, V374, P121, DOI 10.1007/s00441-018-2845-7
   Heinz LX, 2015, CELL REP, V11, P1919, DOI 10.1016/j.celrep.2015.05.006
   Herman-Edelstein M, 2014, J LIPID RES, V55, P561, DOI 10.1194/jlr.P040501
   Hou BY, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00359
   Hua W, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127507
   Huang WX, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029092
   Ishigaki N, 2007, BIOCHEM BIOPH RES CO, V364, P502, DOI 10.1016/j.bbrc.2007.10.038
   Ito Hiroyuki, 2017, J Clin Med Res, V9, P366, DOI 10.14740/jocmr2934w
   Jatem E, 2021, KIDNEY INT REP, V6, P101, DOI 10.1016/j.ekir.2020.09.046
   Jiang T, 2005, KIDNEY INT, V68, P2608, DOI 10.1111/j.1523-1755.2005.00733.x
   Jiang T, 2005, J BIOL CHEM, V280, P32317, DOI 10.1074/jbc.M500801200
   Ju WJ, 2013, GENOME RES, V23, P1862, DOI 10.1101/gr.155697.113
   Kang HM, 2015, NAT MED, V21, P37, DOI 10.1038/nm.3762
   Kennedy DJ, 2013, HYPERTENSION, V61, P216, DOI 10.1161/HYPERTENSIONAHA.112.198770
   Khan S, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.136845
   Kim CH, 2012, LEUKEMIA, V26, P106, DOI 10.1038/leu.2011.185
   Kim HJ, 2017, ENDOCRINOL METAB, V32, P375, DOI 10.3803/EnM.2017.32.3.375
   Kiss E, 2013, AM J PATHOL, V182, P727, DOI 10.1016/j.ajpath.2012.11.033
   Kowalski GM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072449
   Lan TA, 2010, ARCH BIOCHEM BIOPHYS, V502, P112, DOI 10.1016/j.abb.2010.07.012
   Lara-Riegos JC, 2015, GENE, V565, P68, DOI 10.1016/j.gene.2015.03.065
   Li C, 2018, BIOSCIENCE REP, V38
   Li GB, 2020, AM J PATHOL, V190, P1211, DOI 10.1016/j.ajpath.2020.02.008
   Li YZ, 2013, CELL MOL IMMUNOL, V10, P506, DOI 10.1038/cmi.2013.32
   Linhares ND, 2018, CLIN KIDNEY J, V11, P462, DOI 10.1093/ckj/sfx130
   Liu JJ, 2017, KIDNEY INT REP, V2, P470, DOI 10.1016/j.ekir.2016.12.003
   Liu P, 2020, J DIABETES RES, V2020, DOI 10.1155/2020/8721536
   Liu XC, 2020, KIDNEY INT, V98, P1275, DOI 10.1016/j.kint.2020.06.040
   Lopes-Virella MF, 2019, J CLIN LIPIDOL, V13, P481, DOI 10.1016/j.jacl.2019.03.005
   Lovric S, 2017, J CLIN INVEST, V127, P912, DOI 10.1172/JCI89626
   Mallela SK, 2019, BBA-MOL CELL BIOL L, V1864, DOI 10.1016/j.bbalip.2019.158517
   Matsushita Y, 2011, DIABETES, V60, P960, DOI 10.2337/db10-1361
   Melo RCN, 2011, J HISTOCHEM CYTOCHEM, V59, P540, DOI 10.1369/0022155411404073
   Merscher-Gomez S, 2013, DIABETES, V62, P3817, DOI 10.2337/db13-0399
   Mitrofanova A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10584-4
   Mitrofanova A, 2020, CURR OPIN PHARMACOL, V55, P60, DOI 10.1016/j.coph.2020.09.004
   Mitrofanova A, 2019, AM J PHYSIOL-RENAL, V317, pF1241, DOI 10.1152/ajprenal.00379.2019
   MOORHEAD JF, 1982, LANCET, V2, P1309
   Morita Y, 2020, J DIABETES INVEST, V11, P441, DOI 10.1111/jdi.13154
   Nerstedt A, 2012, DIABETOLOGIA, V55, P1797, DOI 10.1007/s00125-012-2511-7
   Ni XQ, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/4578140
   Nojiri T, 2014, J DIABETES INVEST, V5, P639, DOI 10.1111/jdi.12232
   Ohgami N, 2001, J BIOL CHEM, V276, P3195, DOI 10.1074/jbc.M006545200
   Panduru NM, 2013, DIABETES CARE, V36, P2077, DOI 10.2337/dc12-1868
   Park CW, 2006, DIABETES, V55, P885, DOI 10.2337/diabetes.55.04.06.db05-1329
   Pastukhov O, 2014, CELL PHYSIOL BIOCHEM, V34, P119, DOI 10.1159/000362989
   Pedigo CE, 2016, J CLIN INVEST, V126, P3336, DOI 10.1172/JCI85939
   Pistrosch F, 2005, DIABETES, V54, P2206, DOI 10.2337/diabetes.54.7.2206
   Prasad R, 2017, J CLIN INVEST, V127, P942, DOI 10.1172/JCI90171
   Proctor G, 2006, DIABETES, V55, P2502, DOI 10.2337/db05-0603
   Ravid M, 1998, ARCH INTERN MED, V158, P998, DOI 10.1001/archinte.158.9.998
   Ren SY, 2009, KIDNEY INT, V76, P857, DOI 10.1038/ki.2009.297
   Ruan XZ, 2009, NAT REV NEPHROL, V5, P713, DOI 10.1038/nrneph.2009.184
   Ruan XZ, 2003, J AM SOC NEPHROL, V14, P593, DOI 10.1097/01.ASN.0000050414.52908.DA
   Russo GT, 2016, DIABETES CARE, V39, P2278, DOI 10.2337/dc16-1246
   Saravani R, 2017, IRAN RED CRESCENT ME, V19, DOI 10.5812/ircmj.55100
   Sas KM., 2015, J PROTEOM BIOINFORM, V14
   Schermer B, 2009, J AM SOC NEPHROL, V20, P473, DOI 10.1681/ASN.2008070694
   Schumann J, 2015, TOXICOL PATHOL, V43, P694, DOI 10.1177/0192623314565650
   Sheedy FJ, 2013, NAT IMMUNOL, V14, P812, DOI 10.1038/ni.2639
   Shiffman D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106631
   Shiju TM, 2015, J DIABETES COMPLICAT, V29, P400, DOI 10.1016/j.jdiacomp.2014.12.012
   Sieber J, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00186
   Simon N, 2015, FRONT MED, V2, DOI 10.3389/fmed.2015.00052
   Singh R, 2009, NATURE, V458, P1131, DOI 10.1038/nature07976
   Sohn JH, 2018, J BIOL CHEM, V293, P13974, DOI 10.1074/jbc.RA118.003541
   Sorensson J, 2002, J AM SOC NEPHROL, V13, P2639, DOI 10.1097/01.ASN.0000033277.32822.23
   Stewart CR, 2010, NAT IMMUNOL, V11, P155, DOI 10.1038/ni.1836
   Su Y, 2019, PHARMACOL REP, V71, P319, DOI 10.1016/j.pharep.2018.12.008
   Suleiman HY, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.94137
   Sun H, 2013, INT J ENDOCRINOL, V2013, DOI 10.1155/2013/592576
   Sun XD, 2013, INT UROL NEPHROL, V45, P1197, DOI 10.1007/s11255-013-0428-9
   Susztak K, 2005, PLOS MED, V2, P152, DOI 10.1371/journal.pmed.0020045
   Takagi A, 2016, SCI REP-UK, V6, DOI 10.1038/srep18944
   Tang CR, 2010, J LIPID RES, V51, P1719, DOI 10.1194/jlr.M003525
   Trevino MB, 2015, DIABETES, V64, P1299, DOI 10.2337/db14-0559
   Tsai IT, 2020, INT J MED SCI, V17, P2338, DOI 10.7150/ijms.49078
   Tsun JGS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105787
   Van Krieken R, 2018, ENDOCRINOLOGY, V159, P1479, DOI 10.1210/en.2018-00093
   Viswanathan V, 2015, Indian J Nephrol, V25, P269, DOI 10.4103/0971-4065.145097
   Vukovic I, 2015, KIDNEY BLOOD PRESS R, V40, P306, DOI 10.1159/000368506
   Wang ZW, 2005, DIABETES, V54, P2328, DOI 10.2337/diabetes.54.8.2328
   Woo CY, 2020, DIABETES METAB J, V44, P581, DOI 10.4093/dmj.2019.0063
   Woroniecka KI, 2011, DIABETES, V60, P2354, DOI 10.2337/db10-1181
   Yakubenko VP, 2011, CIRC RES, V108, P544, DOI 10.1161/CIRCRESAHA.110.231803
   Yamada S, 2021, CLIN EXP NEPHROL, V25, P365, DOI 10.1007/s10157-020-02007-2
   Yan HL, 2019, LIPIDS HEALTH DIS, V18, DOI 10.1186/s12944-019-0998-3
   Yan Q, 2018, CELL DEATH DISCOV, V4, DOI 10.1038/s41420-018-0065-2
   Yang WX, 2018, CLIN SCI, V132, P2407, DOI 10.1042/CS20180702
   Yang XJ, 2018, MED SCI MONITOR, V24, P6832, DOI 10.12659/MSM.909810
   Yin QH, 2016, J BIOL CHEM, V291, P26487, DOI 10.1074/jbc.M116.730564
   Yoo TH, 2015, J AM SOC NEPHROL, V26, P133, DOI 10.1681/ASN.2013111213
   Yuan Y, 2017, LIPIDS HEALTH DIS, V16, DOI 10.1186/s12944-017-0522-6
   ZADOR IZ, 1993, J CLIN INVEST, V91, P797, DOI 10.1172/JCI116299
   Zhao J, 2019, MEDIAT INFLAMM, V2019, DOI 10.1155/2019/3172647
   Zhou CC, 2011, J LIPID RES, V52, P1483, DOI 10.1194/jlr.M014092
   Zhou ZM, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.74
NR 130
TC 1
Z9 1
U1 1
U2 1
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES
EI 1948-9358
J9 WORLD J DIABETES
JI World J. Diabetes
PD MAY 15
PY 2021
VL 12
IS 5
BP 524
EP 540
DI 10.4239/wjd.v12.i5.524
PG 17
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA SA3JZ
UT WOS:000649196000002
PM 33995842
OA gold, Green Published
DA 2021-10-30
ER

PT J
AU Datta, J
   Wilson, GC
   D'Angelica, MI
   Katz, MHG
   Maithel, SK
   Merchant, NB
   Ahmad, SA
AF Datta, Jashodeep
   Wilson, Gregory C.
   D'Angelica, Michael I.
   Katz, Matthew H. G.
   Maithel, Shishir K.
   Merchant, Nipun B.
   Ahmad, Syed A.
TI A Call for Caution in Overinterpreting Exceptional Outcomes After
   Radical Surgery for Pancreatic Cancer Let the Data Speak
SO ANNALS OF SURGERY
LA English
DT Editorial Material
DE arterial resection; biology; biomarkers; borderline resectable;
   chemotherapy; denominator; intention to treat; locally advanced;
   metastasectomy; pancreatic cancer; radical surgery
ID ADJUVANT CHEMOTHERAPY; GEMCITABINE; ADENOCARCINOMA; FOLFIRINOX;
   RESECTION; SURVIVAL; THERAPY
C1 [Datta, Jashodeep; Merchant, Nipun B.] Univ Miami, Miller Sch Med, Dept Surg, Div Surg Oncol,Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA.
   [Wilson, Gregory C.; Ahmad, Syed A.] Univ Cincinnati Coll Med, Dept Surg, Div Surg Oncol, Cincinnati, OH USA.
   [D'Angelica, Michael I.] Mem Sloan Kettering Canc Ctr, Dept Surg, Hepatopancreatobiliary Serv, 1275 York Ave, New York, NY 10021 USA.
   [Katz, Matthew H. G.] Univ Texas MD Anderson Canc Ctr, Dept Surg, Houston, TX 77030 USA.
   [Maithel, Shishir K.] Emory Univ, Sch Med, Dept Surg, Div Surg Oncol,Winship Canc Inst, Atlanta, GA 30322 USA.
RP Merchant, NB (corresponding author), Univ Miami, Miller Sch Med, Dept Surg, Div Surg Oncol,Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA.; Ahmad, SA (corresponding author), Univ Cincinnati Coll Med, Dept Surg, Div Surg Oncol, Cincinnati, OH USA.
EM nmerchant@med.miami.edu; ahmadsy@ucmail.uc.edu
FU National Cancer Institute (NCI) of the National Institutes of Health
   (NIH)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30
   CA240139]; Miami Clinical and Translational Science Institute (CTSI)
   under NIH [UL1TR002736]; American College of Surgeon Frankin H. Martin
   Faculty Research Award; Stanley Glaser Foundation Award; NCI/NIHUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Cancer Institute (NCI) [2R01CA161976-06]
FX The authors acknowledge support from the National Cancer Institute (NCI)
   of the National Institutes of Health (NIH) Award-P30 CA240139 (J.D and
   N.B.M); KL2 career development grant by the Miami Clinical and
   Translational Science Institute (CTSI) under NIH Award-UL1TR002736
   (J.D); American College of Surgeon Frankin H. Martin Faculty Research
   Award (J.D.); Stanley Glaser Foundation Award (J.D.); NCI/NIH Award
   2R01CA161976-06 (N.B.M).
CR Aung KL, 2018, CLIN CANCER RES, V24, P1344, DOI 10.1158/1078-0432.CCR-17-2994
   Bachellier P, 2020, ANN SURG, V271, P932, DOI 10.1097/SLA.0000000000003010
   Cady B, 1997, ARCH SURG-CHICAGO, V132, P338
   Chunara R, 2017, AM J PREV MED, V52, P549, DOI 10.1016/j.amepre.2016.10.038
   Collisson EA, 2011, NAT MED, V17, P500, DOI 10.1038/nm.2344
   Conroy T, 2018, NEW ENGL J MED, V379, P2395, DOI 10.1056/NEJMoa1809775
   Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923
   D'Angelica M, 2016, HPB, V18, P631, DOI 10.1016/j.hpb.2016.07.003
   Di Maio M, 2020, JAMA ONCOL
   Hackert T, 2017, EJSO-EUR J SURG ONC, V43, P358, DOI 10.1016/j.ejso.2016.10.023
   Iacobuzio-Donahue CA, 2009, J CLIN ONCOL, V27, P1806, DOI 10.1200/JCO.2008.17.7188
   Klaiber U, 2021, ANN SURG, V273, P154, DOI 10.1097/SLA.0000000000003270
   Loveday BPT, 2019, HPB, V21, P643, DOI 10.1016/j.hpb.2018.10.004
   Neoptolemos JP, 2017, LANCET, V389, P1011, DOI 10.1016/S0140-6736(16)32409-6
   Neoptolemos JP, 2012, JAMA-J AM MED ASSOC, V308, P147, DOI 10.1001/jama.2012.7352
   Neoptolemos JP, 2001, LANCET, V358, P1576, DOI 10.1016/S0140-6736(01)06651-X
   Oettle H, 2007, JAMA-J AM MED ASSOC, V297, P267, DOI 10.1001/jama.297.3.267
   Sadot E, 2015, ANN SURG ONCOL, V22, P3512, DOI 10.1245/s10434-015-4647-4
   Tee MC, 2018, J AM COLL SURGEONS, V227, P255, DOI 10.1016/j.jamcollsurg.2018.05.001
   Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369
   Winter JM, 2012, ANN SURG ONCOL, V19, P169, DOI 10.1245/s10434-011-1900-3
NR 21
TC 3
Z9 3
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-4932
EI 1528-1140
J9 ANN SURG
JI Ann. Surg.
PD JUL
PY 2021
VL 274
IS 1
BP E82
EP E84
DI 10.1097/SLA.0000000000004471
PG 3
WC Surgery
SC Surgery
GA ST2GJ
UT WOS:000662268000029
PM 33086320
OA Bronze
DA 2021-10-30
ER

PT J
AU Levine, CG
   Casiano, RR
   Lee, DJ
   Mantero, A
   Liu, XZ
   Palacio, AM
AF Levine, Corinna G.
   Casiano, Roy R.
   Lee, David J.
   Mantero, Alejandro
   Liu, Xue Zhong
   Palacio, Ana M.
TI Chronic Rhinosinusitis Disease Disparity in the South Florida Hispanic
   Population
SO LARYNGOSCOPE
LA English
DT Article; Early Access
DE Chronic rhinosinusitis; health disparities; quality of life; care delay;
   social determinants of health
ID ENDOSCOPIC SINUS SURGERY; OF-LIFE OUTCOMES; SOCIOECONOMIC-FACTORS;
   SOCIAL DETERMINANTS; HEALTH; IMPACT; SEVERITY
AB Objectives/Hypothesis The role of social determinants of health in chronic rhinosinusitis (CRS) is poorly characterized. Limited research examining CRS health disparities indicates that minority status is associated with worse CRS. However, many of these studies are retrospective or performed in populations without substantial ethnic minorities. Rhinologists need to characterize existing CRS disease disparities to develop targeted strategies for improving care in these populations. This prospective study assesses preoperative CRS disease burden in South Florida (SFL) Hispanic and non-Hispanic patients and examines potential factors contributing CRS disease disparities. Study Design Prospective cohort study. Methods The prospective cohort study included consecutive patients having primary endoscopic sinus surgery (ESS) for CRS between September 2019 and February 2020 with complete preoperative data. Data were collected in clinic and surgery. Descriptive statistics compare Hispanic and non-Hispanic cohorts. Linear regression adjusts for confounders. Relative risk (RR) compared CRS severity markers. Results Thirty-eight Hispanic and 56 non-Hispanic patients met inclusion criteria. Age, sex, CT scores, insurance payer, and comorbidities were similar between cohorts. Hispanics presented with worse 22-item Sinonasal Outcome Test (SNOT-22) (55; SD = 18) compared to non-Hispanics (37; SD = 22) (P < .001). Hispanics tended to have a higher risk of severe CRS markers, including nasal polyps RR = 2.5 (95% CI: 1.0-5.9), neo-osteogenesis RR = 1.6 (95% CI: 0.5-4.7), extended procedures (i.e., draft III) RR = 2.97 (95% CI: 1.0-9.1), and tissue eosinophilia RR = 1.46 (95% CI: 0.6-3.5). Hispanics reported longer sinonasal symptom duration. Conclusions SFL hispanic patients presenting for primary ESS have worse sinonasal disease burden. SFL Hispanics have markers of greater CRS severity and report longer delays before receiving CRS care. These factors may contribute to increased sinonasal disease burden in Hispanic patients. Level of Evidence 3 Laryngoscope, 2021
C1 [Levine, Corinna G.; Casiano, Roy R.; Liu, Xue Zhong] Univ Miami, Miller Sch Med, Dept Otolaryngol Head & Neck Surg, Miami, FL 33136 USA.
   [Lee, David J.; Mantero, Alejandro; Palacio, Ana M.] Univ Miami, Dept Publ Hlth Sci, Miller Sch Med, Miami, FL 33136 USA.
RP Levine, CG (corresponding author), Univ Miami, Rhinol & Skull Base Surg, Dept Otolaryngol, Miller Sch Med, 1120 NW 14th St,5th Floor, Miami, FL 33136 USA.
EM cxl861@maimi.edu
FU Triological Society Research Career Development Award; Miami Clinical
   and Translational Science Institute, from the National Center for
   Advancing Translational Sciences and the National Institute on Minority
   Health and Health Disparities [UL1TR002736];  [CTSI-Pilot-FY2020-04]
FX The project described was supported by: 1) Triological Society Research
   Career Development Award PI: Corinna G Levine MD, MPH. 2) Grant Number
   UL1TR002736, Miami Clinical and Translational Science Institute, from
   the National Center for Advancing Translational Sciences and the
   National Institute on Minority Health and Health Disparities. Its
   contents are solely the responsibility of the authors and do not
   necessarily represent the official views of the NIH. Subgrant number:
   CTSI-Pilot-FY2020-04.
CR Benninger MS, 2015, OTOLARYNG HEAD NECK, V152, P546, DOI 10.1177/0194599814565606
   Beswick DM, 2019, INT FORUM ALLERGY RH, V9, P231, DOI 10.1002/alr.22256
   Bhandarkar ND, 2011, INT FORUM ALLERGY RH, V1, P372, DOI 10.1002/alr.20068
   Brooks SG, 2018, INT FORUM ALLERGY RH, V8, P668, DOI 10.1002/alr.22109
   Bureau USC, 2010, 2010 CENS U S CENS B 2010 CENS U S CENS B
   Chew LD, 2004, FAM MED, V36, P588
   Chowdhury NI, 2017, INT FORUM ALLERGY RH, V7, P1149, DOI 10.1002/alr.22028
   Chung SD, 2014, LARYNGOSCOPE, V124, P1285, DOI 10.1002/lary.24500
   Czerny MS, 2014, INT FORUM ALLERGY RH, V4, P463, DOI 10.1002/alr.21304
   Dover DC, 2019, INT J EQUITY HEALTH, V18, DOI 10.1186/s12939-019-0935-0
   Draf W., 1991, OPER TECH OTOLARYNGO, V2, P234
   Ferguson BJ, 2000, OTOLARYNG CLIN N AM, V33, P441, DOI 10.1016/S0030-6665(00)80018-3
   Hopkins C, 2015, RHINOLOGY, V53, P18, DOI [10.4193/Rhino14.077, 10.4193/Rhin14.077]
   Huang ZX, 2015, INT FORUM ALLERGY RH, V5, P303, DOI 10.1002/alr.21485
   Kountakis SE, 2004, LARYNGOSCOPE, V114, P1895, DOI 10.1097/01.mlg.0000147917.43615.c0
   Kuhar HN, 2017, INT FORUM ALLERGY RH, V7, P679, DOI 10.1002/alr.21943
   Leigh JA, 2016, CURR ATHEROSCLER REP, V18, DOI 10.1007/s11883-016-0559-4
   Levine CG, 2016, INT FORUM ALLERGY RH, V6, P52, DOI 10.1002/alr.21620
   Li SS, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.008088
   Lu-Myers Y, 2015, OTOLARYNG HEAD NECK, V153, P137, DOI 10.1177/0194599815580978
   Mensah GA, 2005, CIRCULATION, V111, P1233, DOI 10.1161/01.CIR.0000158136.76824.04
   Rudmik L, 2017, CURR ALLERGY ASTHM R, V17, DOI 10.1007/s11882-017-0690-5
   Samuelson MB, 2017, AM J RHINOL ALLERGY, V31, P376, DOI 10.2500/ajra.2017.31.4476
   Siddiqui J, 2013, J LARYNGOL OTOL, V127, P755, DOI 10.1017/S0022215113001461
   Soler ZM, 2012, AM J RHINOL ALLERGY, V26, P110, DOI 10.2500/ajra.2012.26.3741
   Walker RJ, 2014, ENDOCRINE, V47, P29, DOI 10.1007/s12020-014-0195-0
   Wise SK, 2008, OTOLARYNG HEAD NECK, V138, P38, DOI 10.1016/j.otohns.2007.10.020
NR 27
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0023-852X
EI 1531-4995
J9 LARYNGOSCOPE
JI Laryngoscope
DI 10.1002/lary.29664
EA JUL 2021
PG 7
WC Medicine, Research & Experimental; Otorhinolaryngology
SC Research & Experimental Medicine; Otorhinolaryngology
GA TI0TV
UT WOS:000672496200001
PM 34254684
DA 2021-10-30
ER

PT J
AU Matory, AL
   Alkhachroum, A
   Chiu, WT
   Eliseyev, A
   Doyle, K
   Rohaut, B
   Egbebike, JA
   Velazquez, AG
   Der-Nigoghossian, C
   Paniker, L
   Prager, KM
   Agarwal, S
   Roh, D
   Park, S
   Claassen, J
AF Matory, Adu L.
   Alkhachroum, Ayham
   Chiu, Wei-Ting
   Eliseyev, Andrey
   Doyle, Kevin
   Rohaut, Benjamin
   Egbebike, Jennifer A.
   Velazquez, Angela G.
   Der-Nigoghossian, Caroline
   Paniker, Lucy
   Prager, Kenneth M.
   Agarwal, Sachin
   Roh, David
   Park, Soojin
   Claassen, Jan
TI Electrocerebral Signature of Cardiac Death
SO NEUROCRITICAL CARE
LA English
DT Article; Early Access
DE Death; Encephalography; Consciousness; Cardiac arrest; Brain hypoxia;
   Hypotension
ID LIFE-SUSTAINING THERAPY; CARDIOPULMONARY-RESUSCITATION; PERMUTATION
   ENTROPY; BRAIN-DEATH; ARREST; EEG; CONSCIOUSNESS; WITHDRAWAL; SILENCE;
   ELECTROENCEPHALOGRAPHY
AB Background Electroencephalography (EEG) findings following cardiovascular collapse in death are uncertain. We aimed to characterize EEG changes immediately preceding and following cardiac death. Methods We retrospectively analyzed EEGs of patients who died from cardiac arrest while undergoing standard EEG monitoring in an intensive care unit. Patients with brain death preceding cardiac death were excluded. Three events during fatal cardiovascular failure were investigated: (1) last recorded QRS complex on electrocardiogram (QRS(0)), (2) cessation of cerebral blood flow (CBF0) estimated as the time that blood pressure and heart rate dropped below set thresholds, and (3) electrocerebral silence on EEG (EEG(0)). We evaluated EEG spectral power, coherence, and permutation entropy at these time points. Results Among 19 patients who died while undergoing EEG monitoring, seven (37%) had a comfort-measures-only status and 18 (95%) had a do-not-resuscitate status in place at the time of death. EEG(0) occurred at the time of QRS(0) in five patients and after QRS(0) in two patients (cohort median - 2.0, interquartile range - 8.0 to 0.0), whereas EEG(0) was seen at the time of CBF0 in six patients and following CBF0 in 11 patients (cohort median 2.0 min, interquartile range - 1.5 to 6.0). After CBF0, full-spectrum log power (p < 0.001) and coherence (p < 0.001) decreased on EEG, whereas delta (p = 0.007) and theta (p < 0.001) permutation entropy increased. Conclusions Rarely may patients have transient electrocerebral activity following the last recorded QRS (less than 5 min) and estimated cessation of cerebral blood flow. These results may have implications for discussions around cardiopulmonary resuscitation and organ donation.
C1 [Matory, Adu L.; Alkhachroum, Ayham; Chiu, Wei-Ting; Eliseyev, Andrey; Doyle, Kevin; Rohaut, Benjamin; Egbebike, Jennifer A.; Velazquez, Angela G.; Paniker, Lucy; Agarwal, Sachin; Roh, David; Park, Soojin; Claassen, Jan] Columbia Univ, Med Ctr, MHB Ctr 8, Neurol Inst,Dept Neurol, 177 Ft Washington Ave,Room 300, New York, NY 10032 USA.
   [Matory, Adu L.] Bernstein Ctr Computat Neurosci, Berlin, Germany.
   [Alkhachroum, Ayham] Univ Miami, Dept Neurol, Miami, FL USA.
   [Chiu, Wei-Ting] Taipei Med Univ, Dept Neurol, Shuang Ho Hosp, Taipei, Taiwan.
   [Chiu, Wei-Ting] Taipei Med Univ, Coll Med, Dept Neurol, Sch Med, Taipei, Taiwan.
   [Chiu, Wei-Ting] Taipei Med Univ, Taipei Neurosci Inst, Taipei, Taiwan.
   [Chiu, Wei-Ting] Taipei Med Univ, Shuang Ho Hosp, Dept Emergency & Crit Care Med, Div Crit Care Med, Taipei, Taiwan.
   [Rohaut, Benjamin] Sorbonne Univ, Brain Inst ICM, CNRS, UMR 7225,INSERM U1127, Paris, France.
   [Rohaut, Benjamin] Sorbonne Univ, Grp Hosp Univ, AP HP, Dept Neurol,NeuroICU,Pitie Sal Petriere, Paris, France.
   [Rohaut, Benjamin] Sorbonne Univ, Paris, France.
   [Der-Nigoghossian, Caroline] Columbia Univ, Irving Med Ctr, Pharm, New York, NY USA.
   [Prager, Kenneth M.] Columbia Univ, Irving Med Ctr, Dept Med, Clin Eth, New York, NY USA.
RP Claassen, J (corresponding author), Columbia Univ, Med Ctr, MHB Ctr 8, Neurol Inst,Dept Neurol, 177 Ft Washington Ave,Room 300, New York, NY 10032 USA.
EM jc1439@columbia.edu
RI Alkhachroum, Ayham/V-6050-2019; Rohaut, Benjamin/O-9250-2017
OI Alkhachroum, Ayham/0000-0003-0352-5913; Rohaut,
   Benjamin/0000-0001-6752-8756; Der-Nigoghossian,
   Caroline/0000-0001-5445-9421
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [K01 ES026833, R01
   NS106014, R03 NS112760]; James McDonnell Foundation; Dana Foundation;
   National Center for Advancing Translational Sciences of the National
   Institutes of Health under the Miami Clinical and Translational Science
   Institute KL2 Career Development Award [UL1TR002736]
FX JC is supported by grant funding from the National Institutes of Health
   (R01 NS106014 and R03 NS112760), the James McDonnell Foundation, and the
   Dana Foundation. AA is supported by the National Center for Advancing
   Translational Sciences of the National Institutes of Health under the
   Miami Clinical and Translational Science Institute KL2 Career
   Development Award (UL1TR002736). SP is supported by the National
   Institutes of Health (K01 ES026833).
CR Altwegg-Boussac T, 2017, BRAIN, V140, P2381, DOI 10.1093/brain/awx175
   Auyong DB, 2010, ANESTH ANALG, V110, P1428, DOI 10.1213/ANE.0b013e3181d27067
   Azevedo MA, 2020, MORTALITY-UK, V25, P490, DOI 10.1080/13576275.2020.1756765
   Bandt C, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.174102
   Blundon EG, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67234-9
   Bokil H, 2010, J NEUROSCI METH, V192, P146, DOI 10.1016/j.jneumeth.2010.06.020
   Bonenfant RJ., 2001, JNDS, V20, P87, DOI [10.1023/A:1013058221999, DOI 10.1023/A:1013058221999]
   Borjigin J, 2013, P NATL ACAD SCI USA, V110, P14432, DOI 10.1073/pnas.1308285110
   Chawla LS, 2017, DEATH STUD, V41, P385, DOI 10.1080/07481187.2017.1287138
   Chawla LS, 2009, J PALLIAT MED, V12, P1095, DOI 10.1089/jpm.2009.0159
   Claassen J, 2019, NEW ENGL J MED, V380, P2497, DOI 10.1056/NEJMoa1812757
   CLARKE HB, 1989, J COMPUT ASSIST TOMO, V13, P889, DOI 10.1097/00004728-198909000-00026
   CLUTE HL, 1990, ANESTHESIOLOGY, V73, P821, DOI 10.1097/00000542-199011000-00004
   Das MK, 2009, HEART RHYTHM, V6, pS8, DOI 10.1016/j.hrthm.2008.10.019
   de Vries JW, 1998, ANESTH ANALG, V87, P16, DOI 10.1097/00000539-199807000-00005
   Dhanani S, 2021, NEW ENGL J MED, V384, P345, DOI 10.1056/NEJMoa2022713
   Dhanani S, 2014, CRIT CARE MED, V42, P2358, DOI 10.1097/CCM.0000000000000417
   Dreier JP, 2018, ANN NEUROL, V83, P295, DOI 10.1002/ana.25147
   Edlow BL, 2018, J HEAD TRAUMA REHAB, V33, P424, DOI 10.1097/HTR.0000000000000448
   Ferlazzo E, 2005, BRAIN, V128, P700, DOI 10.1093/brain/awh446
   Fernandez-Torre JL, 2013, CLIN NEUROPHYSIOL, V124, P2362, DOI 10.1016/j.clinph.2013.05.028
   Ferreira PG, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02772-x
   French CC, 2001, LANCET, V358, P2010, DOI 10.1016/S0140-6736(01)07133-1
   Greer DM, 2020, JAMA-J AM MED ASSOC, V324, P1078, DOI 10.1001/jama.2020.11586
   GREYSON B, 1992, PSYCHIATRY, V55, P95
   Haut SR, 2007, NEUROLOGY, V69, P1905, DOI 10.1212/01.wnl.0000278112.48285.84
   HOSSMANN KA, 1974, BRAIN RES, V81, P59, DOI 10.1016/0006-8993(74)90478-8
   Jacobs J, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0304
   KeshavarzShirazi T., 2020, CIRCULATION, V142, P314
   Kreuzer M, 2014, J CLIN MONIT COMPUT, V28, P573, DOI 10.1007/s10877-014-9553-y
   Lee DE, 2017, BRAIN CONNECT, V7, P172, DOI 10.1089/brain.2016.0471
   LEVIN P, 1966, ARCH INTERN MED, V117, P557, DOI 10.1001/archinte.117.4.557
   Loscher Wolfgang, 2020, Handb Exp Pharmacol, DOI 10.1007/164_2020_406
   Morley PT, 2015, CIRCULATION, V132, pS40, DOI 10.1161/CIR.0000000000000271
   MOSS J, 1980, JAMA-J AM MED ASSOC, V244, P2750, DOI 10.1001/jama.244.24.2750
   MUELLER AL, 1983, EPILEPSIA, V24, P57, DOI 10.1111/j.1528-1157.1983.tb04866.x
   Nagao K, 2016, CIRCULATION, V133, P1386, DOI 10.1161/CIRCULATIONAHA.115.018788
   Nakagawa TA, 2012, ANN NEUROL, V71, P573, DOI 10.1002/ana.23552
   Nichols GS, 2012, J CLIN NEUROPHYSIOL, V29, P109, DOI 10.1097/WNP.0b013e31824ceee5
   NITSCH C, 1983, J NEUROL SCI, V59, P305, DOI 10.1016/0022-510X(83)90016-3
   Norton L, 2017, CAN J NEUROL SCI, V44, P139, DOI 10.1017/cjn.2016.309
   Olofsen E, 2008, BRIT J ANAESTH, V101, P810, DOI 10.1093/bja/aen290
   Oostenveld R, 2011, COMPUT INTEL NEUROSC, V2011, DOI 10.1155/2011/156869
   Palmieri A, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00429
   Pana R, 2016, J CRIT CARE, V34, P77, DOI 10.1016/j.jcrc.2016.04.001
   Pozhitkov AE, 2017, OPEN BIOL, V7, DOI 10.1098/rsob.160267
   Reagan EM, 2018, CRIT CARE MED, V46, P757, DOI 10.1097/CCM.0000000000003014
   Salehi S, 2018, YALE J BIOL MED, V91, P301
   Schramm AE, 2020, PROG NEUROBIOL, V185, DOI 10.1016/j.pneurobio.2019.101733
   Seiffert E, 2004, J NEUROSCI, V24, P7829, DOI 10.1523/JNEUROSCI.1751-04.2004
   Sitt JD, 2014, BRAIN, V137, P2258, DOI 10.1093/brain/awu141
   Stiegler P, 2012, TRANSPL INT, V25, P481, DOI 10.1111/j.1432-2277.2012.01437.x
   Suffczynski P, 2004, NEUROSCIENCE, V126, P467, DOI 10.1016/j.neuroscience.2004.03.014
   Takeshita D, 2007, PHYS REV E, V75, DOI 10.1103/PhysRevE.75.051925
   TROJABOR.W, 1973, ELECTROEN CLIN NEURO, V34, P61, DOI 10.1016/0013-4694(73)90151-X
   Truog RD, 2018, JAMA-J AM MED ASSOC, V319, P1859, DOI 10.1001/jama.2018.3441
   van Vliet EA, 2014, NEUROBIOL DIS, V63, P74, DOI 10.1016/j.nbd.2013.11.019
   Vrselja Z, 2019, NATURE, V568, P336, DOI 10.1038/s41586-019-1099-1
   Wang J, 2011, NEUROSCI LETT, V499, P84, DOI 10.1016/j.neulet.2011.05.037
   Watrous AJ, 2013, HIPPOCAMPUS, V23, P656, DOI 10.1002/hipo.22124
   Wortsman J, 2002, ENDOCRIN METAB CLIN, V31, P79, DOI 10.1016/S0889-8529(01)00024-X
NR 61
TC 0
Z9 0
U1 1
U2 1
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1541-6933
EI 1556-0961
J9 NEUROCRIT CARE
JI Neurocrit. Care
DI 10.1007/s12028-021-01233-0
EA JUN 2021
PG 9
WC Critical Care Medicine; Clinical Neurology
SC General & Internal Medicine; Neurosciences & Neurology
GA TB0KK
UT WOS:000667631900004
PM 34184175
DA 2021-10-30
ER

PT J
AU Megjhani, M
   Kaffashi, F
   Terilli, K
   Alkhachroum, A
   Esmaeili, B
   Doyle, KW
   Murthy, S
   Velazquez, AG
   Connolly, ES
   Roh, DJ
   Agarwal, S
   Loparo, KA
   Claassen, J
   Boehme, A
   Park, S
AF Megjhani, Murad
   Kaffashi, Farhad
   Terilli, Kalijah
   Alkhachroum, Ayham
   Esmaeili, Behnaz
   Doyle, Kevin William
   Murthy, Santosh
   Velazquez, Angela G.
   Connolly, E. Sander, Jr.
   Roh, David Jinou
   Agarwal, Sachin
   Loparo, Ken A.
   Claassen, Jan
   Boehme, Amelia
   Park, Soojin
TI Heart Rate Variability as a Biomarker of Neurocardiogenic Injury After
   Subarachnoid Hemorrhage
SO NEUROCRITICAL CARE
LA English
DT Article
DE Data mining; Neurocardiogenic; Heart rate variability; Subarachnoid
   hemorrhage; Myocardial stunning; Machine learning
ID LEFT-VENTRICULAR DYSFUNCTION; WALL-MOTION ABNORMALITIES; NEUROGENIC
   STRESS CARDIOMYOPATHY; ACUTE MYOCARDIAL-INFARCTION; TAKOTSUBO
   CARDIOMYOPATHY; PERIOD VARIABILITY; DECISION-SUPPORT; SYSTOLIC
   DYSFUNCTION; DOBUTAMINE INFUSION; CLINICAL-OUTCOMES
AB Background The objective of this study was to examine whether heart rate variability (HRV) measures can be used to detect neurocardiogenic injury (NCI). Methods Three hundred and twenty-six consecutive admissions with aneurysmal subarachnoid hemorrhage (SAH) met criteria for the study. Of 326 subjects, 56 (17.2%) developed NCI which we defined by wall motion abnormality with ventricular dysfunction on transthoracic echocardiogram or cardiac troponin-I > 0.3 ng/mL without electrocardiogram evidence of coronary artery insufficiency. HRV measures (in time and frequency domains, as well as nonlinear technique of detrended fluctuation analysis) were calculated over the first 48 h. We applied longitudinal multilevel linear regression to characterize the relationship of HRV measures with NCI and examine between-group differences at baseline and over time. Results There was decreased vagal activity in NCI subjects with a between-group difference in low/high frequency ratio (beta 3.42, SE 0.92, p = 0.0002), with sympathovagal balance in favor of sympathetic nervous activity. All time-domain measures were decreased in SAH subjects with NCI. An ensemble machine learning approach translated these measures into a classification tool that demonstrated good discrimination using the area under the receiver operating characteristic curve (AUROC 0.82), the area under precision recall curve (AUPRC 0.75), and a correct classification rate of 0.81. Conclusions HRV measures are significantly associated with our label of NCI and a machine learning approach using features derived from HRV measures can classify SAH patients that develop NCI.
C1 [Megjhani, Murad; Terilli, Kalijah; Alkhachroum, Ayham; Esmaeili, Behnaz; Doyle, Kevin William; Velazquez, Angela G.; Roh, David Jinou; Agarwal, Sachin; Claassen, Jan; Boehme, Amelia; Park, Soojin] Columbia Univ, Irving Med Ctr, Dept Neurol, 177 Ft Washington Ave,8 Milstein 300 Ctr, New York, NY 10032 USA.
   [Kaffashi, Farhad; Loparo, Ken A.] Case Western Reserve Univ, Case Sch Engn, Cleveland, OH 44106 USA.
   [Murthy, Santosh] Weill Cornell Med Coll, Dept Neurol, New York, NY USA.
   [Connolly, E. Sander, Jr.] Columbia Univ, Irving Med Ctr, Dept Neurosurg, New York, NY 10032 USA.
RP Park, S (corresponding author), Columbia Univ, Irving Med Ctr, Dept Neurol, 177 Ft Washington Ave,8 Milstein 300 Ctr, New York, NY 10032 USA.
EM spark@columbia.edu
RI Alkhachroum, Ayham/V-6050-2019
OI Alkhachroum, Ayham/0000-0003-0352-5913; Esmaeili,
   Behnaz/0000-0003-2547-0853; Terilli, Kalijah/0000-0003-2198-5147
FU NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1 TR002736] Funding Source: Medline;
   NIEHS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Environmental
   Health Sciences (NIEHS) [K01 ES026833] Funding Source: Medline; NIMHD
   NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Minority
   Health & Health Disparities (NIMHD) [R21 MD012451] Funding Source:
   Medline; NINDS NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Neurological Disorders & Stroke (NINDS) [R03 NS101417, K23 NS105948]
   Funding Source: Medline
CR Banki N, 2006, J NEUROSURG, V105, P15, DOI 10.3171/jns.2006.105.1.15
   Binici Z, 2011, STROKE, V42, P3196, DOI 10.1161/STROKEAHA.110.607697
   Bulsara KR, 2003, J NEUROSURG, V98, P524, DOI 10.3171/jns.2003.98.3.0524
   Bzdok D, 2017, NAT METHODS, V14, P1119, DOI 10.1038/nmeth.4526
   Calvert JS, 2016, COMPUT BIOL MED, V74, P69, DOI 10.1016/j.compbiomed.2016.05.003
   Camm AJ, 1996, EUR HEART J, V17, P354
   Claesen M, 2015, NEUROCOMPUTING, V160, P73, DOI 10.1016/j.neucom.2014.10.081
   Davis Jesse, 2006, P 23 INT C MACH LEAR, V148, P233
   DeGiorgio CM, 2010, EPILEPSY BEHAV, V19, P78, DOI 10.1016/j.yebeh.2010.06.011
   Deibert E, 2003, J NEUROSURG, V98, P741, DOI 10.3171/jns.2003.98.4.0741
   Gail MH, 2018, JNCI-J NATL CANCER I, V110, P994, DOI 10.1093/jnci/djy013
   Goadrich M, 2006, MACH LEARN, V64, P231, DOI 10.1007/s10994-006-8958-3
   Gultepe E, 2014, J AM MED INFORM ASSN, V21, P315, DOI 10.1136/amiajnl-2013-001815
   Henry KE, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab3719
   Hillebrand S, 2013, EUROPACE, V15, P742, DOI 10.1093/europace/eus341
   Hinojosa-Laborde C, 2011, FRONT PHYSIOL, V2, DOI 10.3389/fphys.2011.00085
   Johnson AEW, 2016, P IEEE, V104, P444, DOI 10.1109/JPROC.2015.2501978
   JULIAN DG, 1964, AM J MED, V37, P915, DOI 10.1016/0002-9343(64)90133-0
   Kawahara E, 2003, CIRC J, V67, P753
   Kawai S, 2000, JPN CIRC J, V64, P156, DOI 10.1253/jcj.64.156
   Kilbourn KJ, 2015, CLIN NEUROL NEUROSUR, V128, P4, DOI 10.1016/j.clineuro.2014.10.017
   Kilbourn KJ, 2013, CLIN NEUROL NEUROSUR, V115, P909, DOI 10.1016/j.clineuro.2012.09.006
   KONO T, 1994, J AM COLL CARDIOL, V24, P636, DOI 10.1016/0735-1097(94)90008-6
   Kothavale A, 2006, NEUROCRIT CARE, V4, P199, DOI 10.1385/NCC:4:3:199
   Lee VH, 2006, NEUROCRIT CARE, V5, P243, DOI 10.1385/NCC:5:3:243
   Lee VH, 2006, J NEUROSURG, V105, P264, DOI 10.3171/jns.2006.105.2.264
   Leisman DE, 2018, CRIT CARE MED, V46, P418, DOI 10.1097/CCM.0000000000002943
   Malik AN, 2015, WORLD NEUROSURG, V83, P880, DOI 10.1016/j.wneu.2015.01.013
   Mani S, 2014, J AM MED INFORM ASSN, V21, P326, DOI 10.1136/amiajnl-2013-001854
   Mayer SA, 1999, STROKE, V30, P780, DOI 10.1161/01.STR.30.4.780
   MAYER SA, 1995, J NEUROSURG, V83, P889, DOI 10.3171/jns.1995.83.5.0889
   MAYER SA, 1994, NEUROLOGY, V44, P815, DOI 10.1212/WNL.44.5.815
   Mazzeo AT, 2011, ACTA ANAESTH SCAND, V55, P797, DOI 10.1111/j.1399-6576.2011.02466.x
   Moorman JR, 2011, PHYSIOL MEAS, V32, P1821, DOI 10.1088/0967-3334/32/11/S08
   Mosley WJ, 2010, ECHOCARDIOGR-J CARD, V27, pE30, DOI 10.1111/j.1540-8175.2009.01089.x
   Murthy SB, 2015, J INTENSIVE CARE MED, V30, P318, DOI 10.1177/0885066613511054
   Nachimuthu Senthil K, 2012, AMIA Annu Symp Proc, V2012, P653
   Naidech AM, 2005, CIRCULATION, V112, P2851, DOI 10.1161/CIRCULATIONAHA.105.533620
   Ong MEH, 2012, CRIT CARE, V16, DOI 10.1186/cc11396
   Parekh N, 2000, J AM COLL CARDIOL, V36, P1328, DOI 10.1016/S0735-1097(00)00857-3
   Park S, 2013, J CLIN MONIT COMPUT, V27, P385, DOI 10.1007/s10877-013-9467-0
   PENG CK, 1994, PHYS REV E, V49, P1685, DOI 10.1103/PhysRevE.49.1685
   Peng HC, 2005, IEEE T PATTERN ANAL, V27, P1226, DOI 10.1109/TPAMI.2005.159
   POLLICK C, 1988, J AM COLL CARDIOL, V12, P600, DOI 10.1016/S0735-1097(88)80044-5
   Rickards CA, 2010, CRIT CARE MED, V38, P1666, DOI 10.1097/CCM.0b013e3181e74cab
   Rickards CA, 2010, J CLIN MONIT COMPUT, V24, P61, DOI 10.1007/s10877-009-9210-z
   Roederer A, 2014, NEUROCRIT CARE, V21, P444, DOI 10.1007/s12028-014-9976-9
   Ryan KL, 2010, SHOCK, V33, P583, DOI 10.1097/SHK.0b013e3181cd8cbe
   Ryan ML, 2011, J TRAUMA, V70, P1371, DOI 10.1097/TA.0b013e31821858e6
   Ryan ML, 2011, ANESTHESIOL RES PRAC, V2011, DOI 10.1155/2011/416590
   Sacha J, 2008, INT J CARDIOL, V128, P444, DOI 10.1016/j.ijcard.2007.06.047
   Saito R, 2010, NEUROL MED-CHIR, V50, P393, DOI 10.2176/nmc.50.393
   Salomao E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134387
   Santoro F, 2013, CARDIOVASC THER, V31, pE133, DOI 10.1111/1755-5922.12047
   Saria S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001304
   Sato K, 1990, J Cardiol, V20, P359
   Sethuraman G, 2010, AVIAT SPACE ENVIR MD, V81, P125, DOI 10.3357/ASEM.2597.2010
   SPANN JF, 1964, NEW ENGL J MED, V271, P427, DOI 10.1056/NEJM196408272710901
   Stanculescu I, 2014, IEEE J BIOMED HEALTH, V18, P1560, DOI 10.1109/JBHI.2013.2294692
   STOCK E, 1967, BRIT MED J, V2, P719, DOI 10.1136/bmj.2.5554.719
   Syed TU, 2014, SYSTEM APPARATUS MET
   Taccone FS, 2013, INTENS CARE MED, V39, P1497, DOI 10.1007/s00134-013-2945-5
   Tang CHH, 2010, PHYSIOL MEAS, V31, P775, DOI 10.1088/0967-3334/31/6/004
   Taylor RA, 2016, ACAD EMERG MED, V23, P269, DOI 10.1111/acem.12876
   Temes RE, 2010, NEUROCRIT CARE, V13, P359, DOI 10.1007/s12028-010-9447-x
   Tung P, 2004, STROKE, V35, P548, DOI 10.1161/01.STR.0000114874.96688.54
   Waldenborg M, 2011, BMC CARDIOVASC DISOR, V11, DOI 10.1186/1471-2261-11-14
   Wybraniec M, 2014, CARDIOL J, V21, P220, DOI 10.5603/CJ.a2014.0019
   YAMAGUCHI T, 1991, JPN J MED, V30, P142
   Yaman M, 2016, CARDIOL J, V23, P610, DOI 10.5603/CJ.a2016.0100
   Zaroff JG, 2000, J AM SOC ECHOCARDIOG, V13, P774, DOI 10.1067/mje.2000.105763
NR 71
TC 5
Z9 5
U1 1
U2 2
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1541-6933
EI 1556-0961
J9 NEUROCRIT CARE
JI Neurocrit. Care
PD FEB
PY 2020
VL 32
IS 1
BP 162
EP 171
DI 10.1007/s12028-019-00734-3
PG 10
WC Critical Care Medicine; Clinical Neurology
SC General & Internal Medicine; Neurosciences & Neurology
GA KK6PD
UT WOS:000512861100012
PM 31093884
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Kim, JJ
   Fornoni, A
AF Kim, Jin-Ju
   Fornoni, Alessia
TI Bedside to benchAlport syndromeresearch: are human urine-derived
   podocytes the answer?
SO JOURNAL OF PATHOLOGY
LA English
DT Editorial Material
DE Alport syndrome; collagen IV mutation; glomerular basement membrane;
   glomerular filtration barrier; urinary podocytes
ID RESISTANT NEPHROTIC SYNDROME; BASEMENT-MEMBRANE; IV COLLAGEN; MUTATIONS;
   DISEASE; IDENTIFICATION; PROTEINURIA; BARRIER; COL4A5; GENES
AB In a recent issue ofThe Journal of Pathology, Iampietroet alisolated and characterized several clones of urine-derived podocytes from three patients with Alport syndrome (AS) and proteinuria and one age-matched non-proteinuric control. They reported differential expression of genes involved in cell motility, adhesion, survival, and angiogenesis. The authors found AS podocytes to be less motile and to have significantly higher permeability to albumin compared to control podocytes, highlighting that AS podocytes may retain their phenotype even when losing contact with the glomerular basement membrane. The establishment of urine-derived podocyte cell lines from patients with different genetic forms of AS may represent a valuable and minimally invasive tool to investigate the cellular mechanisms contributing to kidney disease progression in AS and may allow for the establishment of patient-specific drug screening opportunities. (c) 2020 The Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
C1 Univ Miami, Miller Sch Med, Katz Family Div Nephrol & Hypertens, Miami, FL 33136 USA.
   Univ Miami, Miller Sch Med, Peggy & Harold Katz Drug Discovery Ctr, Dept Med, Miami, FL 33136 USA.
RP Fornoni, A (corresponding author), Univ Miami, Katz Family Div Nephrol & Hypertens, 1580 NW 10th Ave, Miami, FL 33136 USA.; Fornoni, A (corresponding author), Univ Miami, Peggy & Harold Katz Family Drug Discovery Ctr, 1580 NW 10th Ave, Miami, FL 33136 USA.
EM afornoni@med.miami.edu
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01DK117599, R01DK104753, R01CA227493,
   U54KD083912, UM1DK100846, U01DK116101, UL1TR000460]; Hoffmann-La
   RocheHoffmann-La Roche; Alport Syndrome Foundation; NIH/NIDDKUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Diabetes & Digestive &
   Kidney Diseases (NIDDK) [F32DK115109]
FX AF is supported by the NIH grants R01DK117599, R01DK104753, R01CA227493,
   U54KD083912, UM1DK100846, U01DK116101, and UL1TR000460 (Miami Clinical
   Translational Science Institute); Hoffmann-La Roche; and the Alport
   Syndrome Foundation. JJK is supported by a postdoctoral fellowship of
   the NIH/NIDDK (F32DK115109). We give special thanks to the Katz family
   for continuous support.
CR Abrahamson DR, 2009, J AM SOC NEPHROL, V20, P1471, DOI 10.1681/ASN.2008101086
   Bullich G, 2015, EUR J HUM GENET, V23, P1192, DOI 10.1038/ejhg.2014.252
   Faul C, 2007, TRENDS CELL BIOL, V17, P428, DOI 10.1016/j.tcb.2007.06.006
   Gast C, 2016, NEPHROL DIAL TRANSPL, V31, P961, DOI 10.1093/ndt/gfv325
   Gribouval O, 2018, KIDNEY INT, V94, P1013, DOI 10.1016/j.kint.2018.07.024
   Groopman E, 2019, NEW ENGL J MED, V380, P2080, DOI 10.1056/NEJMc1903250
   Gunwar S, 1998, J BIOL CHEM, V273, P8767, DOI 10.1074/jbc.273.15.8767
   Hudson BG, 2003, NEW ENGL J MED, V348, P2543, DOI 10.1056/NEJMra022296
   Iampietro C, 2020, J PATHOL, V252, P88, DOI 10.1002/path.5496
   Ivanova EA, 2016, KIDNEY INT, V89, P1037, DOI 10.1016/j.kint.2016.01.013
   Lausecker F, 2018, KIDNEY INT, V93, P643, DOI 10.1016/j.kint.2017.09.021
   Lennon R, 2015, PEDIATR NEPHROL, V30, P1459, DOI 10.1007/s00467-015-3067-9
   Mundel P, 2010, KIDNEY INT, V77, P571, DOI 10.1038/ki.2009.424
   NINOMIYA Y, 1995, J CELL BIOL, V130, P1219, DOI 10.1083/jcb.130.5.1219
   Richter H, 2019, ACS CHEM BIOL, V14, P37, DOI 10.1021/acschembio.8b00866
   Savige J, 2014, J PHYSIOL-LONDON, V592, P4013, DOI 10.1113/jphysiol.2014.274449
   Tonna S, 2008, PEDIATR NEPHROL, V23, P2201, DOI 10.1007/s00467-008-0934-7
NR 17
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3417
EI 1096-9896
J9 J PATHOL
JI J. Pathol.
PD JAN
PY 2021
VL 253
IS 1
BP 11
EP 13
DI 10.1002/path.5564
EA OCT 2020
PG 3
WC Oncology; Pathology
SC Oncology; Pathology
GA PD5XZ
UT WOS:000581073300001
PM 33009821
OA Green Accepted, Bronze
DA 2021-10-30
ER

PT J
AU Alkhachroum, A
   Der-Nigoghossian, CA
   Mathews, E
   Massad, N
   Letchinger, R
   Doyle, K
   Chiu, WT
   Kromm, J
   Rubinos, C
   Velazquez, A
   Roh, D
   Agarwal, S
   Park, S
   Connolly, ES
   Claassen, J
AF Alkhachroum, Ayham
   Der-Nigoghossian, Caroline A.
   Mathews, Elizabeth
   Massad, Nina
   Letchinger, Riva
   Doyle, Kevin
   Chiu, Wei-Ting
   Kromm, Julie
   Rubinos, Clio
   Velazquez, Angela
   Roh, David
   Agarwal, Sachin
   Park, Soojin
   Connolly, E. Sander
   Claassen, Jan
TI Ketamine to treat super-refractory status epilepticus
SO NEUROLOGY
LA English
DT Article
ID CONVULSIVE STATUS EPILEPTICUS; ELECTROENCEPHALOGRAPHY; GUIDELINES;
   MANAGEMENT; INJURY; UK
AB Objective
   To test ketamine infusion efficacy in the treatment of super-refractory status epilepticus (SRSE), we studied patients with SRSE who were treated with ketamine retrospectively. We also studied the effect of high doses of ketamine on brain physiology as reflected by invasive multimodality monitoring (MMM).
   Methods
   We studied a consecutive series of 68 patients with SRSE who were admitted between 2009 and 2018, treated with ketamine, and monitored with scalp EEG. Eleven of these patients underwent MMM at the time of ketamine administration. We compared patients who had seizure cessation after ketamine initiation to those who did not.
   Results
   Mean age was 53 +/- 18 years and 46% of patients were female. Seizure burden decreased by at least 50% within 24 hours of starting ketamine in 55 (81%) patients, with complete cessation in 43 (63%). Average dose of ketamine infusion was 2.2 +/- 1.8 mg/kg/h, with median duration of 2 (1-4) days. Average dose of midazolam was 1.0 +/- 0.8 mg/kg/h at the time of ketamine initiation and was started at a median of 0.4 (0.1-1.0) days before ketamine. Using a generalized linear mixed effect model, ketamine was associated with stable mean arterial pressure (odds ratio 1.39, 95% confidence interval 1.38-1.40) and with decreased vasopressor requirements over time. We found no effect on intracranial pressure, cerebral blood flow, or cerebral perfusion pressure.
   Conclusion
   Ketamine treatment was associated with a decrease in seizure burden in patients with SRSE. Our data support the notion that high-dose ketamine infusions are associated with decreased vasopressor requirements without increased intracranial pressure.
   Classification of evidence
   This study provides Class IV evidence that ketamine decreases seizures in patients with SRSE.
C1 [Alkhachroum, Ayham; Der-Nigoghossian, Caroline A.; Mathews, Elizabeth; Massad, Nina; Letchinger, Riva; Doyle, Kevin; Chiu, Wei-Ting; Rubinos, Clio; Velazquez, Angela; Roh, David; Agarwal, Sachin; Park, Soojin; Claassen, Jan] Columbia Univ, Dept Neurol, New York, NY 10032 USA.
   [Connolly, E. Sander] Columbia Univ, Dept Neurosurg, New York, NY USA.
   [Kromm, Julie] Univ Calgary, Dept Crit Care Med, Calgary, AB, Canada.
   [Kromm, Julie] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada.
RP Claassen, J (corresponding author), Columbia Univ, Dept Neurol, New York, NY 10032 USA.
EM jc1439@columbia.edu
RI Rubinos, Clio/ABA-9937-2021; Alkhachroum, Ayham/V-6050-2019
OI Rubinos, Clio/0000-0002-1680-2302; Alkhachroum,
   Ayham/0000-0003-0352-5913; Der-Nigoghossian,
   Caroline/0000-0001-5445-9421
FU National Center for Advancing Translational Sciences of the NIH under
   the Miami CTSI KL2 Career Development Award [UL1TR002736]; NIHUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA [R01 NS106014, R03 NS112760]; DANA Foundation
FX A. Alkhachroum is supported by the National Center for Advancing
   Translational Sciences of the NIH under the Miami CTSI KL2 Career
   Development Award UL1TR002736. C. Der-Nigoghossian, E. Mathews, N.
   Massad, R. Letchinger, K. Doyle, W-T. Chiu, J. Kromm, C. Rubinos, A.
   Velazquez, D. Roh, S. Agarwal, S. Park, and E. Connolly report no
   disclosures relevant to the manuscript. J. Claassen is supported by
   grant funding from the NIH R01 NS106014 and R03 NS112760 and the DANA
   Foundation. Go to Neurology. org/N for full disclosures.
CR Alkhachroum A, 2020, J CEREBR BLOOD F MET, V40, P1290, DOI 10.1177/0271678X19863028
   Aroni F, 2009, J CLIN PHARMACOL, V49, P957, DOI 10.1177/0091270009337941
   Borris DJ, 2000, EPILEPSY RES, V42, P117, DOI 10.1016/S0920-1211(00)00175-3
   Brophy GM, 2012, NEUROCRIT CARE, V17, P3, DOI 10.1007/s12028-012-9695-z
   Chen JWY, 2006, LANCET NEUROL, V5, P246, DOI 10.1016/S1474-4422(06)70374-X
   Claassen J, 2016, ANN NEUROL, V80, P541, DOI 10.1002/ana.24752
   Fang Y, 2015, SEIZURE-EUR J EPILEP, V30, P14, DOI 10.1016/j.seizure.2015.05.010
   FARRELL B, 1991, J NEUROL NEUROSUR PS, V54, P1044, DOI 10.1136/jnnp.54.12.1044
   Gaspard N, 2013, EPILEPSIA, V54, P1498, DOI 10.1111/epi.12247
   Glauser T, 2016, EPILEPSY CURR, V16, P48, DOI 10.5698/1535-7597-16.1.48
   Golub D, 2018, ANAESTH INTENS CARE, V46, P516, DOI 10.1177/0310057X1804600514
   Himmelseher S, 2005, ANESTH ANALG, V101, P524, DOI 10.1213/01.ANE.0000160585.43587.5B
   Hsieh CY, 2010, CLIN NEUROPHARMACOL, V33, P165, DOI 10.1097/WNF.0b013e3181d1e3cd
   JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285
   Kofke WA, 1997, J NEUROSURG ANESTH, V9, P269, DOI 10.1097/00008506-199707000-00012
   Kramer AH, 2012, NEUROCRIT CARE, V16, P299, DOI 10.1007/s12028-011-9668-7
   Mikell CB, 2016, SEIZURE-EUR J EPILEP, V41, P201, DOI 10.1016/j.seizure.2016.05.017
   Pruss H, 2008, EPILEPSY RES, V82, P219, DOI 10.1016/j.eplepsyres.2008.08.005
   Rosati A, 2012, NEUROLOGY, V79, P2355, DOI 10.1212/WNL.0b013e318278b685
   Sabharwal V, 2015, EPILEPSY BEHAV, V52, P264, DOI 10.1016/j.yebeh.2015.07.040
   Sheth RD, 1998, NEUROLOGY, V51, P1765, DOI 10.1212/WNL.51.6.1765
   Synowiec AS, 2013, EPILEPSY RES, V105, P183, DOI 10.1016/j.eplepsyres.2013.01.007
   Trinka E, 2015, EPILEPSIA, V56, P1515, DOI 10.1111/epi.13121
   Ubogu EE, 2003, EPILEPSY BEHAV, V4, P70, DOI 10.1016/S1525-5050(02)00643-1
   WALKER MC, 1995, ANAESTHESIA, V50, P130, DOI 10.1111/j.1365-2044.1995.tb15095.x
   Waziri A, 2009, ANN NEUROL, V66, P366, DOI 10.1002/ana.21721
   Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573
   Zeiler FA, 2014, NEUROCRIT CARE, V21, P163, DOI 10.1007/s12028-013-9950-y
   Zeiler FA, 2014, J CRIT CARE, V29, P1096, DOI 10.1016/j.jcrc.2014.05.024
NR 29
TC 6
Z9 6
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD OCT 20
PY 2020
VL 95
IS 16
BP E2286
EP E2294
DI 10.1212/WNL.0000000000010611
PG 9
WC Clinical Neurology
SC Neurosciences & Neurology
GA OP1CO
UT WOS:000587818900025
PM 32873691
OA Green Published
DA 2021-10-30
ER

PT J
AU Brincks, A
   Montag, S
   Howe, GW
   Huang, S
   Siddique, J
   Ahn, S
   Sandler, IN
   Pantin, H
   Brown, CH
AF Brincks, Ahnalee
   Montag, Samantha
   Howe, George W.
   Huang, Shi
   Siddique, Juned
   Ahn, Soyeon
   Sandler, Irwin N.
   Pantin, Hilda
   Brown, C. Hendricks
TI Addressing Methodologic Challenges and Minimizing Threats to Validity in
   Synthesizing Findings from Individual-Level Data Across Longitudinal
   Randomized Trials
SO PREVENTION SCIENCE
LA English
DT Article
DE Integrative data analysis; Synthesis methodology; Participant-level
   meta-analysis; Harmonization
ID INTEGRATIVE DATA-ANALYSIS; MISSING DATA; MENTAL-HEALTH; PREVENTION;
   INTERVENTION; SCIENCE; MODELS; IMPACT; PART
AB Integrative Data Analysis (IDA) encompasses a collection of methods for data synthesis that pools participant-level data across multiple studies. Compared with single-study analyses, IDA provides larger sample sizes, better representation of participant characteristics, and often increased statistical power. Many of the methods currently available for IDA have focused on examining developmental changes using longitudinal observational studies employing different measures across time and study. However, IDA can also be useful in synthesizing across multiple randomized clinical trials to improve our understanding of the comprehensive effectiveness of interventions, as well as mediators and moderators of those effects. The pooling of data from randomized clinical trials presents a number of methodological challenges, and we discuss ways to examine potential threats to internal and external validity. Using as an illustration a synthesis of 19 randomized clinical trials on the prevention of adolescent depression, we articulate IDA methods that can be used to minimize threats to internal validity, including (1) heterogeneity in the outcome measures across trials, (2) heterogeneity in the follow-up assessments across trials, (3) heterogeneity in the sample characteristics across trials, (4) heterogeneity in the comparison conditions across trials, and (5) heterogeneity in the impact trajectories. We also demonstrate a technique for minimizing threats to external validity in synthesis analysis that may result from non-availability of some trial datasets. The proposed methods rely heavily on latent variable modeling extensions of the latent growth curve model, as well as missing data procedures. The goal is to provide strategies for researchers considering IDA.
C1 [Brincks, Ahnalee] Michigan State Univ, Dept Epidemiol & Biostat, Coll Human Med, E Lansing, MI 48824 USA.
   [Montag, Samantha; Siddique, Juned; Brown, C. Hendricks] Northwestern Univ, Dept Psychiat & Behav Sci, Feinberg Sch Med, 750 N Lake Shore Dr,10th Floor, Chicago, IL 60611 USA.
   [Montag, Samantha; Siddique, Juned; Brown, C. Hendricks] Northwestern Univ, Dept Prevent Med, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Howe, George W.] George Washington Univ, Dept Psychol, Washington, DC 20052 USA.
   [Huang, Shi] Vanderbilt Univ, Dept Biostat, 221 Kirkland Hall, Nashville, TN 37235 USA.
   [Ahn, Soyeon] Univ Miami, Sch Educ & Human Dev, Miami, FL USA.
   [Sandler, Irwin N.] Arizona State Univ, Dept Psychol, Tempe, AZ 85287 USA.
   [Pantin, Hilda] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA.
RP Brown, CH (corresponding author), Northwestern Univ, Dept Psychiat & Behav Sci, Feinberg Sch Med, 750 N Lake Shore Dr,10th Floor, Chicago, IL 60611 USA.; Brown, CH (corresponding author), Northwestern Univ, Dept Prevent Med, Feinberg Sch Med, Chicago, IL 60611 USA.
EM hendricks.brown@northwestern.edu
OI Brown, C Hendricks/0000-0002-0294-2419; Ahn, Soyeon/0000-0003-2581-306X
FU NIMHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH) [R01-MH040859, R01-MH048696, R01-MH064717, R01-MH064503,
   R03-MH048118, R01-MH064735, R01-MH064707, P30-MH068685, R01MH049155,
   R01-MH052270, MH063042, K08-MH072918, K23-MH071320]; NCATSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1-TR000460]; NIDAUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Drug Abuse (NIDA) [R01-DA07031, R01-DA13773, R01-DA017462,
   R01-DA025894, R01-DA007029, R01-DA018374]; WT Grant Foundation [961730];
   CDCUnited States Department of Health & Human ServicesCenters for
   Disease Control & Prevention - USA [U01-PS000671]; NARSAD Young
   Investigator Grant (Young)NARSAD; NATIONAL CANCER INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI) [K07CA154862] Funding Source:
   NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Advancing Translational
   Sciences (NCATS) [UL1TR000460] Funding Source: NIH RePORTER; NATIONAL
   CENTER FOR HIV, VIRAL HEPATITIS, STDS AND TB PREVENTIONUnited States
   Department of Health & Human ServicesCenters for Disease Control &
   Prevention - USA [U01PS000671] Funding Source: NIH RePORTER; NATIONAL
   HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Heart Lung & Blood Institute (NHLBI) [R01HL127491] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Mental Health (NIMH) [R01MH064735, R01MH040859,
   R01MH064503, R01MH063042, K23MH071320, R01MH064707, R01MH064717,
   P30MH068685, K08MH072918, R01MH049155, R01MH052270] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Drug Abuse (NIDA)European Commission [R01DA007031,
   R01DA025894, R01DA018374, R01DA017462] Funding Source: NIH RePORTER
FX We gratefully acknowledge the National Institute of Mental Health
   Collaborative Data Synthesis for Adolescent Depression Trials Study
   Team, composed of our many colleagues who generously provided their data
   to be used in this study, obtained access to key datasets, reviewed
   coding decisions, provided substantive or methodologic recommendations,
   and reviewed this manuscript. We also thank NIMH for their support
   through grant number R01-MH040859 (Collaborative Data Synthesis for
   Adolescent Depression Trials, Brown PI) and NCATS for their support
   through grant number UL1-TR000460 (Miami Clinical and Translational
   Science Institute, Szapocznik PI), as well as the following grants that
   financially supported the trials: NIMH R01-MH048696 (Beardslee), NIMH
   R01-MH064717 (Beardslee & Gladstone), NIMH R01-MH064503 (Brent), NIMH
   R03-MH048118 (Clarke), NIDA R01-DA07031 (Dishion), NIDA R01-DA13773
   (Dishion), NIMH R01-MH064735 (Garber), WT Grant Foundation 961730
   (Garber), NIMH R01-MH064707 (Gonzales), NIDA R01-DA017462 (Pantin), NIDA
   R01-DA025894 (Prado), CDC U01-PS000671 (Prado), NIMH P30-MH068685
   (Sandler), NIMH R01-MH049155 (Sandler & Ayers), NIMH R01-MH052270
   (Seligman), NIDA R01-DA007029 (Spoth), NIDA R01-DA018374 (Stormshak),
   NIMH MH063042 (Szapocznik), NIMH K08-MH072918 (Van Voorhees), NIMH
   K23-MH071320 (Young), and NARSAD Young Investigator Grant (Young). The
   content of this paper is solely the responsibility of the authors and
   does not necessarily represent the official views of the funding
   agencies nor that of our collaborators who provided access to their
   data.
CR Barch DM, 2016, BIOL PSYCHIAT, V79, pE91, DOI 10.1016/j.biopsych.2015.07.006
   Bauer DJ, 2013, PSYCHOL METHODS, V18, P475, DOI 10.1037/a0032475
   Bauer DJ, 2009, PSYCHOL METHODS, V14, P101, DOI 10.1037/a0015583
   BOLLEN K, 1991, PSYCHOL BULL, V110, P305, DOI 10.1037/0033-2909.110.2.305
   Brown CH, 2007, INT REV PSYCHIATR, V19, P617, DOI 10.1080/09540260701797779
   Brown CH, 2018, PREV SCI, V19, pS74, DOI 10.1007/s11121-016-0737-1
   Brown CH, 2013, PREV SCI, V14, P144, DOI 10.1007/s11121-011-0207-8
   Brown CH, 2008, CHILD DEV PERSPECT, V2, P198
   BROWN CH, 1983, PSYCHOMETRIKA, V48, P269
   BROWN CH, 1990, BIOMETRICS, V46, P143, DOI 10.2307/2531637
   Curran PJ, 2008, DEV PSYCHOL, V44, P365, DOI 10.1037/0012-1649.44.2.365
   Curran PJ, 2009, PSYCHOL METHODS, V14, P81, DOI 10.1037/a0015914
   Curran PJ, 2009, PSYCHOL METHODS, V14, P77, DOI 10.1037/a0015972
   Dagne GA, 2016, STAT MED, V35, P2485, DOI 10.1002/sim.6883
   Edwards MC, 2012, CILVR SER LAT VAR, P289
   GIBBONS RD, 1992, PSYCHOMETRIKA, V57, P423, DOI 10.1007/BF02295430
   Gibbons RD, 2012, ARCH GEN PSYCHIAT, V69, P1104, DOI 10.1001/archgenpsychiatry.2012.14
   Hancock GR, 2001, STRUCT EQU MODELING, V8, P470, DOI 10.1207/S15328007SEM0803_7
   Hedges LV, 1998, PSYCHOL METHODS, V3, P486, DOI 10.1037/1082-989X.3.4.486
   Hendershot Tabitha, 2015, Curr Protoc Hum Genet, V86, DOI 10.1002/0471142905.hg0121s86
   Howe G. W., 2016, EVALUATING CON UNPUB
   Hussong AM, 2013, ANNU REV CLIN PSYCHO, V9, P61, DOI 10.1146/annurev-clinpsy-050212-185522
   Lavori PW, 2008, PSYCHIAT ANN, V38, P784, DOI 10.3928/00485713-20081201-04
   McArdle J.J., 1988, HDB MULTIVARIATE EXP, V2nd
   McCarty CA, 2014, BMC MED GENOMICS, V7, DOI 10.1186/1755-8794-7-16
   Muthen B, 2002, BIOSTATISTICS, V3, P459, DOI 10.1093/biostatistics/3.4.459
   Muthen B., 2010, CAUSALITY PSYCHOPATH, P159, DOI [10.1093/oso/9780199754649.003.0012, DOI 10.1093/OSO/9780199754649.003.0012]
   Muthen B, 2009, STAT MED, V28, P3363, DOI 10.1002/sim.3721
   Pan HQ, 2012, HUM MUTAT, V33, P849, DOI 10.1002/humu.22074
   Pathak Jyotishman, 2011, AMIA Jt Summits Transl Sci Proc, V2011, P41
   Perrino T, 2015, PREV SCI, V16, P642, DOI 10.1007/s11121-014-0518-7
   Perrino T, 2013, PERSPECT PSYCHOL SCI, V8, P433, DOI 10.1177/1745691613491579
   Raudenbush S. W., 2002, HIERARCHICAL LINEAR
   ROYALL RM, 1981, J AM STAT ASSOC, V76, P66, DOI 10.2307/2287043
   RUBIN DB, 1976, BIOMETRIKA, V63, P581, DOI 10.1093/biomet/63.3.581
   Sandler I, 2014, ANNU REV CLIN PSYCHO, V10, P243, DOI 10.1146/annurev-clinpsy-050212-185524
   Siddique J., 2016, PREV SCI, P1
   Siddique J, 2015, STAT MED, V34, P3399, DOI 10.1002/sim.6562
   Siddique J, 2011, STAT MED, V30, P160, DOI 10.1002/sim.4109
   Siddique J, 2008, PSYCHIAT ANN, V38, P793, DOI 10.3928/00485713-20081201-09
   Tisak J., 1990, STAT METHODS DEV RES, P387
   Wang CP, 2005, J AM STAT ASSOC, V100, P1054, DOI 10.1198/016214505000000501
NR 42
TC 11
Z9 11
U1 0
U2 7
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1389-4986
EI 1573-6695
J9 PREV SCI
JI Prev. Sci.
PD FEB
PY 2018
VL 19
IS 1
SU S
BP S60
EP S73
DI 10.1007/s11121-017-0769-1
PG 14
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA GB0DP
UT WOS:000428714300007
PM 28434055
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Burke, GW
   Fornoni, A
AF Burke, George W., III
   Fornoni, Alessia
TI The elusive podocyte crossmatch for recurrent focal segmental
   glomerulosclerosis
SO KIDNEY INTERNATIONAL
LA English
DT Editorial Material
AB Focal segmental glomerulosclerosis is a glomerular disorder with a high rate of recurrence. Although kidney biopsies remain the gold standard to diagnose recurrent focal segmental glomerulosclerosis, non-invasive prognostic assays could facilitate preventive treatments and offer insight into disease pathogenicity and heterogeneity. Srivastava et al. describe a simple, cell-based assay to predict recurrence of focal segmental glomerulosclerosis. Although the study needs to be optimized and validated, its novelty is that it does not depend on the specificity of a given permeability factor. Copyright (C) 2019, Published by Elsevier, Inc., on behalf of the International Society of Nephrology.
C1 [Burke, George W., III] Univ Miami, Miller Sch Med, Dept Surg, Miami, FL 33136 USA.
   [Burke, George W., III] Univ Miami, Miller Sch Med, Miami Transplant Inst, Miami, FL 33136 USA.
   [Burke, George W., III; Fornoni, Alessia] Univ Miami, Miller Sch Med, Peggy & Harold Katz Family Drug Discovery Ctr, Miami, FL 33136 USA.
   [Fornoni, Alessia] Univ Miami, Miller Sch Med, Dept Med, Katz Family Div Nephrol & Hypertens, Miami, FL 33136 USA.
RP Fornoni, A (corresponding author), Univ Miami, Katz Family Div Nephrol & Hypertens, 1580 NW 10th Ave, Miami, FL 33136 USA.; Fornoni, A (corresponding author), Univ Miami, Peggy & Harold Katz Family Drug Discovery Ctr, 1580 NW 10th Ave, Miami, FL 33136 USA.
OI fornoni, Alessia/0000-0002-1313-7773
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [1R01 DK 090316-01A1,
   R01DK117599, R01DK104753, R01CA227493, U54DK083912, UM1DK100846,
   U01DK116101, UL1TR000460]; NATIONAL CANCER INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI) [R01CA227493] Funding Source:
   NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Advancing Translational
   Sciences (NCATS) [UL1TR000460] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Diabetes & Digestive & Kidney Diseases
   (NIDDK) [R01DK104753, R01DK117599, U54DK083912, UM1DK100846,
   U01DK116101] Funding Source: NIH RePORTER
FX This work was supported by National Institutes of Health grant 1R01 DK
   090316-01A1 (AF/GB). AF is currently supported by the National
   Institutes of Health grants R01DK117599, R01DK104753, R01CA227493,
   U54DK083912, UM1DK100846, U01DK116101, and UL1TR000460 (Miami Clinical
   Translational Science Institute).
CR Chang JW, 2012, TRANSPLANTATION, V93, P1238, DOI 10.1097/TP.0b013e318250234a
   Cravedi P, 2013, AM J TRANSPLANT, V13, P266, DOI 10.1111/ajt.12045
   D'Agati VD, 2011, NEW ENGL J MED, V365, P2398, DOI 10.1056/NEJMra1106556
   Fornoni A, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002231
   Gallon L, 2012, NEW ENGL J MED, V366, P1648, DOI 10.1056/NEJMc1202500
   Gipson DS, 2016, CLIN J AM SOC NEPHRO, V11, P81, DOI 10.2215/CJN.02560315
   Hubsch H, 2005, PEDIATR NEPHROL, V20, P210, DOI 10.1007/s00467-004-1706-7
   Savin VJ, 1996, NEW ENGL J MED, V334, P878, DOI 10.1056/NEJM199604043341402
   Srivastava P, 2019, KIDNEY INT, V95, P708, DOI 10.1016/j.kint.2018.10.030
NR 9
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0085-2538
EI 1523-1755
J9 KIDNEY INT
JI Kidney Int.
PD MAR
PY 2019
VL 95
IS 3
BP 498
EP 500
DI 10.1016/j.kint.2018.11.032
PG 4
WC Urology & Nephrology
SC Urology & Nephrology
GA HM0TW
UT WOS:000459161300009
PM 30784659
DA 2021-10-30
ER

PT J
AU Szapocznik, J
   Muir, JA
   Duff, JH
   Schwartz, SJ
   Brown, CH
AF Szapocznik, Jose
   Muir, Joan A.
   Duff, Johnathan H.
   Schwartz, Seth J.
   Brown, C. Hendricks
TI Brief Strategic Family Therapy: Implementing evidence-based models in
   community settings
SO PSYCHOTHERAPY RESEARCH
LA English
DT Article
DE clinicians-researchers collaboration; practice-oriented research
ID ADOLESCENT DRUG-ABUSERS; STRUCTURAL FAMILY; EFFICACY; TRIAL; YOUTH
AB Objective: To review a 40-year collaborative partnership between clinical researchers and clinicians, in developing, investigating and implementing Brief Strategic Family Therapy (BSFT). Method: First, to review theory, practice and studies related to this evidenced-based therapy intervention targeting adolescent drug abuse and delinquency. Second, to present the BSFT Implementation Model created for the BSFT intervention-a model that parallels many of the recommendations from the implementation science literature. Results: Specific challenges encountered during the BSFT implementation process are reviewed, along with ways of conceptualizing and addressing these challenges from a systemic perspective. Conclusion: The BSFT implementation uses the same systemic principles and intervention techniques as those that underlie the BSFT clinical model. Building on our on-the-ground experiences, recommendations are proposed for advancing the field of implementation science.
C1 [Szapocznik, Jose; Muir, Joan A.; Duff, Johnathan H.; Schwartz, Seth J.] Univ Miami, Miami, FL 33136 USA.
   [Brown, C. Hendricks] Northwestern Univ, Chicago, IL 60611 USA.
RP Szapocznik, J (corresponding author), Univ Miami, Leonard M Miller Sch Med, Dept Publ Hlth Sci, 1120 NW 14th St,10th Floor, Miami, FL 33136 USA.
EM JSzapocz@med.miami.edu
OI Brown, C Hendricks/0000-0002-0294-2419
FU NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000460] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON
   ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Alcohol Abuse & Alcoholism (NIAAA) [R01AA021888] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Drug Abuse (NIDA)European Commission [RC2DA028864,
   U10DA013720, P30DA027828, UG1DA013720] Funding Source: NIH RePORTER;
   NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [1UL1TR000460, UL1 TR000460] Funding
   Source: Medline; NIAAA NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Alcohol Abuse & Alcoholism (NIAAA) [R01 AA021888, AA021888] Funding
   Source: Medline; NIDA NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Drug Abuse (NIDA) [P30 DA027828, RC2 DA028864, DA026595, U10
   DA013720] Funding Source: Medline
CR Bowen M., 1978, FAMILY THERAPY CLIN
   Breuk RE, 2006, J MARITAL FAM THER, V32, P515, DOI 10.1111/j.1752-0606.2006.tb01625.x
   Coatsworth JD, 2001, FAM PROCESS, V40, P313, DOI 10.1111/j.1545-5300.2001.4030100313.x
   Faggiano F, 2010, DRUG ALCOHOL DEPEN, V108, P56, DOI 10.1016/j.drugalcdep.2009.11.018
   Fernandez MA, 2009, J ABNORM CHILD PSYCH, V37, P431, DOI 10.1007/s10802-008-9281-1
   Fixsen D, 2011, J SAFETY RES, V42, P419, DOI 10.1016/j.jsr.2011.10.002
   Fixsen DL, 2011, AM J COMMUN PSYCHOL, V48, P133, DOI 10.1007/s10464-010-9410-1
   Fixsen DL, 2009, RES SOCIAL WORK PRAC, V19, P531, DOI 10.1177/1049731509335549
   Glisson Charles, 2005, Ment Health Serv Res, V7, P243, DOI 10.1007/s11020-005-7456-1
   Gorman-Smith D, 2000, J QUANT CRIMINOL, V16, P169, DOI 10.1023/A:1007564505850
   Gotham H, 2011, J SUBST ABUSE TREAT, V41, P169, DOI 10.1016/j.jsat.2011.02.006
   Haley J., 1976, PROBLEM SOLVING THER
   Henggeler SW, 2011, ANNU REV CLIN PSYCHO, V7, P351, DOI 10.1146/annurev-clinpsy-032210-104615
   *IOM, 2007, STAT QUAL IMPR IMPL
   Landsverk J, 2012, DISSEMINATION IMPLEM
   Madanes C., 1981, STRATEGIC FAMILY THE
   McCollister KE, 2010, DRUG ALCOHOL DEPEN, V108, P98, DOI 10.1016/j.drugalcdep.2009.12.002
   Minuchin S., 1981, FAMILY THERAPY TECHN
   Moran G, 2005, PSYCHOTHER RES, V15, P226, DOI 10.1080/10503300512331387780
   National Registry of Evidence- based Programs and Practices, 2012, BRIEF STRAT FAM THER
   Palinkas L.A., 2012, TRANSLATION IMPLEMEN
   Phares V, 2005, J PEDIATR PSYCHOL, V30, P631, DOI 10.1093/jpepsy/jsi050
   Robbins MS, 2011, J CONSULT CLIN PSYCH, V79, P713, DOI 10.1037/a0025477
   Robbins MS, 2011, J CONSULT CLIN PSYCH, V79, P43, DOI 10.1037/a0022146
   Robbins MS, 2006, J FAM PSYCHOL, V20, P108, DOI 10.1037/0893-3200.20.1.108
   Robbins MS, 2000, J FAM PSYCHOL, V14, P688, DOI 10.1037//0893-3200.14.4.688
   Santisteban DA, 1996, J FAM PSYCHOL, V10, P35, DOI 10.1037/0893-3200.10.1.35
   Santisteban DA, 2003, J FAM PSYCHOL, V17, P121, DOI 10.1037/0893-3200.17.1.121
   Santisteban DA, 1997, J COMMUNITY PSYCHOL, V25, P453, DOI 10.1002/(SICI)1520-6629(199709)25:5<453::AID-JCOP6>3.0.CO;2-T
   Schoenwald SK, 2004, J CLIN CHILD ADOLESC, V33, P94, DOI 10.1207/S15374424JCCP3301_10
   Steinberg L, 2001, J RES ADOLESCENCE, V11, P1, DOI 10.1111/1532-7795.00001
   SZAPOCZNIK J, 1991, J MARITAL FAM THER, V17, P295, DOI 10.1111/j.1752-0606.1991.tb00897.x
   SZAPOCZNIK J, 1988, J CONSULT CLIN PSYCH, V56, P552, DOI 10.1037/0022-006X.56.4.552
   SZAPOCZNIK J, 1989, J CONSULT CLIN PSYCH, V57, P571, DOI 10.1037/0022-006X.57.5.571
   Szapocznik J, 1978, J Community Psychol, V6, P112, DOI 10.1002/1520-6629(197804)6:2<112::AID-JCOP2290060203>3.0.CO;2-R
   Szapocznik J., 1999, DRUG ABUSE ORIGINS I, P331, DOI [10.1037/10341-014, DOI 10.1037/10341-014]
   Szapocznik J., 1978, MULTICULTURAL VIEW D, P563
   Szapocznik J, 2013, INTERVENTIONS FOR ADDICTION: COMPREHENSIVE ADDICTIVE BEHAVIORS AND DISORDERS, VOL 3, P97, DOI 10.1016/B978-0-12-398338-1.00011-7
   Tai B, 2011, SUBST ABUSE REHABIL, V2, P21, DOI 10.2147/SAR.S16756
   Tai B, 2010, J SUBST ABUSE TREAT, V38, pS4, DOI 10.1016/j.jsat.2010.01.011
   Veronneau MH, 2010, J ABNORM CHILD PSYCH, V38, P1125, DOI 10.1007/s10802-010-9431-0
   Watkins KE, 2011, ARCH GEN PSYCHIAT, V68, P577, DOI 10.1001/archgenpsychiatry.2011.53
NR 42
TC 11
Z9 11
U1 1
U2 31
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 1050-3307
EI 1468-4381
J9 PSYCHOTHER RES
JI Psychother. Res.
PD JAN 2
PY 2015
VL 25
IS 1
SI SI
BP 121
EP 133
DI 10.1080/10503307.2013.856044
PG 13
WC Psychology, Clinical
SC Psychology
GA AU3HJ
UT WOS:000345502700010
PM 24274187
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Fornoni, A
   Merscher, S
AF Fornoni, Alessia
   Merscher, Sandra
TI Previews Lipid Metabolism Gets in a JAML during Kidney Disease
SO CELL METABOLISM
LA English
DT Editorial Material
AB It is still unclear if the ability of key regulators of actin cytoskeletal remodeling to influence lipid metabolism contributes to kidney injury. In this issue of Cell Metabolism, Fu et al. (2020) show that junctional adhesion molecule-like (JAML) is a novel mediator of glomerular disease progression while suggesting a direct link between defects in cell adhesion and lipotoxicity.
C1 [Fornoni, Alessia; Merscher, Sandra] Univ Miami, Katz Family Div Nephrol & Hypertens, Dept Med, Miller Sch Med, Miami, FL 33136 USA.
   [Fornoni, Alessia; Merscher, Sandra] Univ Miami, Dept Med, Peggy & Harold Katz Family Drug Discovery Ctr, Miller Sch Med, Miami, FL 33136 USA.
RP Fornoni, A; Merscher, S (corresponding author), Univ Miami, Katz Family Div Nephrol & Hypertens, Dept Med, Miller Sch Med, Miami, FL 33136 USA.; Fornoni, A; Merscher, S (corresponding author), Univ Miami, Dept Med, Peggy & Harold Katz Family Drug Discovery Ctr, Miller Sch Med, Miami, FL 33136 USA.
EM afornoni@med.miami.edu; smerscher@med.miami.edu
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [U54DK083912, UM1DK100846, U01DK116101,
   UL1TR000460, R01DK117599, R01DK104753, R01CA227493]; Boehringer
   IngelheimBoehringer Ingelheim; National Center for Advancing
   Translational SciencesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS); National Institute on Minority
   Health and Health DisparitiesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Minority Health & Health Disparities (NIMHD); Katz family
FX A.F. and S.M. are supported by NIH grants R01DK117599, R01DK104753, and
   R01CA227493, and by Boehringer Ingelheim. A.F. is supported by NIH
   grants U54DK083912, UM1DK100846, U01DK116101, and UL1TR000460 (Miami
   Clinical Translational Science Institute, Translational Science
   Institute, from the National Center for Advancing Translational Sciences
   and the National Institute on Minority Health and Health Disparities).
   We give a special thanks to the Katz family for their continuous
   support. Figure was created with https://biorender.com/.
CR Bertolio R, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09152-7
   Bosch M, 2020, SCIENCE, V370, P309, DOI 10.1126/science.aay8085
   Ducasa GM, 2019, J CLIN INVEST, V129, P3387, DOI 10.1172/JCI125316
   Fu Y, 2020, CELL METAB, V32, DOI 10.1016/j.cmet.2020.10.019
   Heerspink HJL, 2020, NEW ENGL J MED, V383, P1436, DOI 10.1056/NEJMoa2024816
   Rachubik P, 2018, CELL PHYSIOL BIOCHEM, V51, P393, DOI 10.1159/000495236
   Rahman K, 2016, GASTROENTEROLOGY, V151, P733, DOI 10.1053/j.gastro.2016.06.022
   Schiffer M, 2015, NAT MED, V21, P601, DOI 10.1038/nm.3843
   Shi YY, 2020, AM J PHYSIOL-RENAL, V318, pF589, DOI 10.1152/ajprenal.00392.2019
   Yang XP, 2020, ADIPOCYTE, V9, P484, DOI 10.1080/21623945.2020.1807850
NR 10
TC 2
Z9 2
U1 0
U2 1
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1550-4131
EI 1932-7420
J9 CELL METAB
JI Cell Metab.
PD DEC 1
PY 2020
VL 32
IS 6
BP 903
EP 905
DI 10.1016/j.cmet.2020.11.002
PG 3
WC Cell Biology; Endocrinology & Metabolism
SC Cell Biology; Endocrinology & Metabolism
GA PH6WY
UT WOS:000600551500001
PM 33264600
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Jaimes, EA
   Zhou, MS
   Siddiqui, M
   Rezonzew, G
   Tian, RX
   Seshan, SV
   Muwonge, AN
   Wong, NJ
   Azeloglu, EU
   Fornoni, A
   Merscher, S
   Raij, L
AF Jaimes, Edgar A.
   Zhou, Ming-Sheng
   Siddiqui, Mohammed
   Rezonzew, Gabriel
   Tian, Runxia
   Seshan, Surya, V
   Muwonge, Alecia N.
   Wong, Nicholas J.
   Azeloglu, Evren U.
   Fornoni, Alessia
   Merscher, Sandra
   Raij, Leopoldo
TI Nicotine, smoking, podocytes, and diabetic nephropathy
SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY
LA English
DT Review
DE diabetes; nicotine; podocytes; reactive oxygen species; smoking
ID CHRONIC KIDNEY-DISEASE; SUPEROXIDE ANION PRODUCTION; ACTIVATED
   PROTEIN-KINASE; STAGE RENAL-DISEASE; CIGARETTE-SMOKING; ANGIOTENSIN-II;
   RISK-FACTORS; OXIDATIVE STRESS; UP-REGULATION; PROGRESSION
AB Diabetic nephropathy (DN) is the leading cause of end-stage kidney disease. Besides glycemic and blood pressure control, environmental factors such as cigarette smoking (CS) adversely affect the progression of DN. The effects of CS on DN progression have been attributed to combustion-generated molecules without consideration to the role of nicotine (NIC), responsible for the addictive properties of both CS and electronic cigarettes (ECs). Podocytes are essential to preserve the structure and function of the glomerular filtration barrier, and strong evidence indicates that early podocyte loss promotes DN progression. We performed experiments in human podocytes and in a mouse model of diabetes that develops nephropathy resembling human DN. We determined that NIC binding to podocytes in concentrations achieved with CS and ECs activated NADPH oxidase, which sets in motion a dysfunctional molecular network integrated by cyclooxygenase 2, known to induce podocyte injury; downregulation of AMP-activated protein kinase, important for maintaining cellular energy stores and antioxidation; and upregulation of CD36, which increased lipid uptake and promoted apoptosis. In diabetic mice, NIC increased proteinuria, a recognized marker of chronic kidney disease progression, accompanied by reduced glomerular podocyte synaptopodin, a crucial stabilizer of the podocyte cytoskeleton, and increased fibronectin expression. This novel study critically implicates NIC itself as a contributor to DN progression in CS and EC users.
   NEW & NOTEWORTHY In this study, we demonstrate that nicotine increases the production of reactive oxygen species, increases cyclooxygenase-2 expression, and upregulates Cd36 while inducing downregulation of AMP-activated protein kinase. In vivo nicotine increases proteinuria and fibronectin expression in diabetic mice. This study demonstrates that effects of nicotine on podocytes are responsible, at least in part, for the deleterious effects of smoking in the progression of chronic kidney disease, including diabetic nephropathy.
C1 [Jaimes, Edgar A.] Mem Sloan Kettering Canc Ctr, Renal Serv, 1275 York Ave, New York, NY 10021 USA.
   [Zhou, Ming-Sheng] Shenyang Med Univ, Dept Physiol, Shenyang, Peoples R China.
   [Siddiqui, Mohammed; Rezonzew, Gabriel] Univ Alabama Birmingham, Renal Div, Birmingham, AL USA.
   [Tian, Runxia] Miami Vet Affairs Med Ctr, Nephrol Sect, Miami, FL USA.
   [Seshan, Surya, V] Weill Cornell Med Coll, Dept Pathol, New York, NY USA.
   [Muwonge, Alecia N.; Wong, Nicholas J.; Azeloglu, Evren U.] Icahn Mt Sinai Sch Med, Dept Med, Div Nephrol, New York, NY USA.
   [Fornoni, Alessia; Merscher, Sandra; Raij, Leopoldo] Univ Miami, Miller Sch Med, Katz Family Div Nephrol & Hypertens, Miami, FL 33136 USA.
RP Jaimes, EA (corresponding author), Mem Sloan Kettering Canc Ctr, Renal Serv, 1275 York Ave, New York, NY 10021 USA.; Raij, L (corresponding author), Univ Miami, Miller Sch Med, Katz Family Div Nephrol & Hypertens, Miami, FL 33136 USA.
EM jaimese@mskcc.org; lraij@med.miami.edu
OI Wahl, Patricia/0000-0001-7902-2373
FU Miami Veterans Affairs Foundation for Research and Education; National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [RO1ES014948,
   P30CA008748, R01DK117599, R01DK104753, R01CA227493, U54DK083912,
   UM1DK100846, U01DK116101, UL1TR000460]
FX This work was supported by the Miami Veterans Affairs Foundation for
   Research and Education (to L.R.) and by National Institutes of Health
   Grants RO1ES014948 and P30CA008748 (to E.A.J.); R01DK117599,
   R01DK104753, and R01CA227493 (to A.F. and S.M.); and U54DK083912,
   UM1DK100846, U01DK116101, and UL1TR000460 (to A.F.).
CR Adkison SE, 2013, AM J PREV MED, V44, P207, DOI 10.1016/j.amepre.2012.10.018
   Akinboro O, 2019, CANCER EPIDEM BIOMAR, V28, P2087, DOI 10.1158/1055-9965.EPI-19-0105
   Arany I, 2013, NEPHROL DIAL TRANSPL, V28, P1417, DOI 10.1093/ndt/gfs596
   Brosius FC, 2009, J AM SOC NEPHROL, V20, P2503, DOI 10.1681/ASN.2009070721
   Calizo RC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09936-x
   Camici M, 2018, FEBS J, V285, P3337, DOI 10.1111/febs.14508
   Cammisotto PG, 2008, J MOL HISTOL, V39, P579, DOI 10.1007/s10735-008-9198-6
   Chalovich Joseph M, 2010, Biophys Rev, V2, P181, DOI 10.1007/s12551-010-0040-5
   CHASE HP, 1991, JAMA-J AM MED ASSOC, V265, P614, DOI 10.1001/jama.265.5.614
   Chen S, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/839761
   Cheng HF, 2011, J AM SOC NEPHROL, V22, P1240, DOI 10.1681/ASN.2010111149
   Christiansen J S, 1978, Diabetes Care, V1, P146, DOI 10.2337/diacare.1.3.146
   CHRISTIANSEN JS, 1978, LANCET, V1, P605
   Dasgupta C, 2012, REPROD TOXICOL, V34, P370, DOI 10.1016/j.reprotox.2012.05.100
   Dutra LM, 2014, JAMA PEDIATR, V168, P684, DOI 10.1001/jamapediatrics.2013.5488
   Eid AA, 2010, J BIOL CHEM, V285, P37503, DOI 10.1074/jbc.M110.136796
   Eid AA, 2009, DIABETES, V58, P1201, DOI 10.2337/db08-1536
   Feng WG, 2015, HYPERTENSION, V65, P813, DOI 10.1161/HYPERTENSIONAHA.114.04533
   Feodoroff M, 2016, ACTA DIABETOL, V53, P525, DOI 10.1007/s00592-015-0822-0
   Glantz SA, 2018, ANNU REV PUBL HEALTH, V39, P215, DOI 10.1146/annurev-publhealth-040617-013757
   Hajek P, 2019, NEW ENGL J MED, V380, P629, DOI 10.1056/NEJMoa1808779
   Hall ME, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.116.003280
   Hallan S, 2006, AM J KIDNEY DIS, V47, P396, DOI 10.1053/j.ajkd.2005.11.027
   Hallan SI, 2011, KIDNEY INT, V80, P516, DOI 10.1038/ki.2011.157
   Haroun MK, 2003, J AM SOC NEPHROL, V14, P2934, DOI 10.1097/01.ASN.0000095249.99803.85
   Heeschen C, 2001, NAT MED, V7, P833, DOI 10.1038/89961
   Heeschen C, 2006, J AM COLL CARDIOL, V48, P2553, DOI 10.1016/j.jacc.2006.07.066
   Heinrich J, 2005, J EXPO ANAL ENV EPID, V15, P74, DOI 10.1038/sj.jea.7500373
   Hua P, 2010, AM J PHYSIOL-RENAL, V299, pF732, DOI 10.1152/ajprenal.00293.2010
   Ishani A, 2006, J AM SOC NEPHROL, V17, P1444, DOI 10.1681/ASN.2005091012
   Jaimes EA, 2005, KIDNEY INT, V68, P2143, DOI 10.1111/j.1523-1755.2005.00670.x
   Jaimes EA, 2004, ARTERIOSCL THROM VAS, V24, P1031, DOI 10.1161/01.ATV.0000127083.88549.58
   Jaimes EA, 1998, KIDNEY INT, V54, P775, DOI 10.1046/j.1523-1755.1998.00068.x
   Jaimes EA, 2008, AM J PHYSIOL-RENAL, V294, pF385, DOI 10.1152/ajprenal.00302.2007
   Jaimes EA, 2007, AM J PHYSIOL-HEART C, V292, pH76, DOI 10.1152/ajpheart.00693.2006
   Jain G, 2013, BIOCHEM PHARMACOL, V86, P1215, DOI 10.1016/j.bcp.2013.07.014
   Kalkhoran S, 2018, CANCER MED-US, V7, P3484, DOI 10.1002/cam4.1585
   Kanetsuna Y, 2007, AM J PATHOL, V170, P1473, DOI 10.2353/ajpath.2007.060481
   Kasza KA, 2018, NEW ENGL J MED, V378, P492
   Kim YH, 2001, KIDNEY INT, V60, P957, DOI 10.1046/j.1523-1755.2001.060003957.x
   Klag MJ, 1996, NEW ENGL J MED, V334, P13, DOI 10.1056/NEJM199601043340103
   Kopprasch S, 2003, LUMINESCENCE, V18, P268, DOI 10.1002/bio.737
   Kunjathoor VV, 2002, J BIOL CHEM, V277, P49982, DOI 10.1074/jbc.M209649200
   Lee J, 2011, ATHEROSCLEROSIS, V215, P281, DOI 10.1016/j.atherosclerosis.2011.01.003
   Liao D, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210213
   Marsot A, 2016, Int J Toxicol, V35, P179, DOI 10.1177/1091581815618935
   Matsusaka T, 2011, J AM SOC NEPHROL, V22, P1275, DOI 10.1681/ASN.2010090963
   Mayhan WG, 1997, AM J PHYSIOL-HEART C, V272, pH2337, DOI 10.1152/ajpheart.1997.272.5.H2337
   Mitrofanova A, 2019, AM J PHYSIOL-RENAL, V317, pF1241, DOI 10.1152/ajprenal.00379.2019
   Pavenstadt H, 2000, AM J PHYSIOL-RENAL, V278, pF173, DOI 10.1152/ajprenal.2000.278.2.F173
   Raij L, 2016, AM J PHYSIOL-RENAL, V311, pF1308, DOI 10.1152/ajprenal.00162.2016
   Rangarajan S, 2020, AM J PHYSIOL-RENAL, V318, pF475, DOI 10.1152/ajprenal.00407.2019
   Rezonzew G, 2012, AM J PHYSIOL-RENAL, V303, pF304, DOI 10.1152/ajprenal.00661.2011
   Ruderman NB, 2013, J CLIN INVEST, V123, P2764, DOI 10.1172/JCI67227
   SAWICKI PT, 1994, DIABETES CARE, V17, P126, DOI 10.2337/diacare.17.2.126
   Schuit E, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011823.pub2
   Sharma K, 2008, J CLIN INVEST, V118, P1645, DOI 10.1172/JCI32691
   Soetikno V, 2013, MOL NUTR FOOD RES, V57, P1649, DOI 10.1002/mnfr.201200540
   STEDMAN RL, 1968, CHEM REV, V68, P153, DOI 10.1021/cr60252a002
   Stein SC, 2000, BIOCHEM J, V345, P437, DOI 10.1042/0264-6021:3450437
   Syamlal Girija, 2011, Morbidity and Mortality Weekly Report, V60, P1305
   Towler DA, 2013, J CLIN INVEST, V123, P4573, DOI 10.1172/JCI72326
   Vang A, 2017, AM J PHYSIOL-LUNG C, V312, P1748, DOI 10.1152/ajplung.00393.2016
   Vickerman KA, 2013, NICOTINE TOB RES, V15, P1787, DOI 10.1093/ntr/ntt061
   Villarreal R, 2016, J AM SOC NEPHROL, V27, P1029, DOI 10.1681/ASN.2015020210
   Vinet R, 2009, BIOL RES, V42, P261
   WAGENKNECHT LE, 1990, AM J PUBLIC HEALTH, V80, P1053, DOI 10.2105/AJPH.80.9.1053
   Wang LM, 2017, AM J PHYSIOL-RENAL, V313, pF430, DOI 10.1152/ajprenal.00614.2016
   Xu HL, 2018, INT UROL NEPHROL, V50, P911, DOI 10.1007/s11255-018-1825-x
   Yamagata K, 2007, KIDNEY INT, V71, P159, DOI 10.1038/sj.ki.5002017
   Yang XC, 2017, NAT REV NEPHROL, V13, P769, DOI 10.1038/nrneph.2017.126
   Zhou MS, 2013, AM J PHYSIOL-HEART C, V305, pH563, DOI 10.1152/ajpheart.00042.2013
NR 72
TC 1
Z9 1
U1 4
U2 6
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1931-857X
EI 1522-1466
J9 AM J PHYSIOL-RENAL
JI Am. J. Physiol.-Renal Physiol.
PD MAR
PY 2021
VL 320
IS 3
BP F442
EP F453
DI 10.1152/ajprenal.00194.2020
PG 12
WC Physiology; Urology & Nephrology
SC Physiology; Urology & Nephrology
GA QZ0RM
UT WOS:000630443500012
PM 33459165
OA Green Published
DA 2021-10-30
ER

PT J
AU Liu, XC
   Ducasa, GM
   Mallela, SK
   Kim, JJ
   Molina, J
   Mitrofanova, A
   Wilbon, SS
   Ge, MY
   Fontanella, A
   Pedigo, C
   Santos, JV
   Nelson, RG
   Drexler, Y
   Contreras, G
   Al-Ali, H
   Merscher, S
   Fornoni, A
AF Liu, Xiaochen
   Ducasa, Gloria Michelle
   Mallela, Shamroop Kumar
   Kim, Jin-Ju
   Molina, Judith
   Mitrofanova, Alla
   Wilbon, Sydney Symone
   Ge, Mengyuan
   Fontanella, Antonio
   Pedigo, Christopher
   Santos, Javier Varona
   Nelson, Robert G.
   Drexler, Yelena
   Contreras, Gabriel
   Al-Ali, Hassan
   Merscher, Sandra
   Fornoni, Alessia
TI Sterol-O-acyltransferase-1 has a role in kidney disease associated with
   diabetes and Alport syndrome
SO KIDNEY INTERNATIONAL
LA English
DT Article
DE Alport syndrome; cholesterol; diabetic kidney disease; podocyte injury;
   renal function; SOAT1 inhibitor
ID RENAL LIPID-METABOLISM; ACYL-COENZYME; CHOLESTEROL ACYLTRANSFERASE;
   DENSITY-LIPOPROTEIN; AMYLOID PATHOLOGY; GENETIC DELETION; FATTY-ACID;
   ACCUMULATION; INHIBITION; MICE
AB Defective cholesterol metabolism primarily linked to reduced ATP-binding cassette transporter A1 (ABCA1) expression is closely associated with the pathogenesis and progression of kidney diseases, including diabetic kidney disease and Alport Syndrome. However, whether the accumulation of free or esterified cholesterol contributes to progression in kidney disease remains unclear. Here, we demonstrate that inhibition of sterol-O-acyltransferase-1 (SOAT1), the enzyme at the endoplasmic reticulum that converts free cholesterol to cholesterol esters, which are then stored in lipid droplets, effectively reduced cholesterol ester and lipid droplet formation in human podocytes. Furthermore, we found that inhibition of SOAT1 in podocytes reduced lipotoxicity-mediated podocyte injury in diabetic kidney disease and Alport Syndrome in association with increased ABCA1 expression and ABCA1-mediated cholesterol efflux. In vivo, Soat1 deficient mice did not develop albuminuria or mesangial expansion at 10-12 months of age. However, Soat1 deficiency/inhibition in experimental models of diabetic kidney disease and Alport Syndrome reduced cholesterol ester content in kidney cortices and protected from disease progression. Thus, targeting SOAT1-mediated cholesterol metabolism may represent a new therapeutic strategy to treat kidney disease in patients with diabetic kidney disease and Alport Syndrome, like that suggested for Alzheimer's disease and cancer treatments.
C1 [Liu, Xiaochen; Ducasa, Gloria Michelle; Mallela, Shamroop Kumar; Kim, Jin-Ju; Molina, Judith; Mitrofanova, Alla; Wilbon, Sydney Symone; Ge, Mengyuan; Pedigo, Christopher; Drexler, Yelena; Contreras, Gabriel; Merscher, Sandra; Fornoni, Alessia] Univ Miami, Miller Sch Med, Dept Med, Katz Family Div Nephrol & Hypertens, Miami, FL 33136 USA.
   [Liu, Xiaochen; Ducasa, Gloria Michelle; Mallela, Shamroop Kumar; Kim, Jin-Ju; Molina, Judith; Mitrofanova, Alla; Wilbon, Sydney Symone; Ge, Mengyuan; Fontanella, Antonio; Pedigo, Christopher; Santos, Javier Varona; Drexler, Yelena; Contreras, Gabriel; Al-Ali, Hassan; Merscher, Sandra; Fornoni, Alessia] Univ Miami, Miller Sch Med, Peggy & Harold Katz Family Drug Discovery Ctr, Miami, FL 33136 USA.
   [Nelson, Robert G.] NIDDK, Phoenix, AZ USA.
RP Merscher, S; Fornoni, A (corresponding author), Univ Miami, Katz Family Div Nephrol & Hypertens, 1580 NW 10th Ave, Miami, FL 33136 USA.; Merscher, S; Fornoni, A (corresponding author), Univ Miami, Peggy & Harold Katz Family Drug Discovery Ctr, 1580 NW 10th Ave, Miami, FL 33136 USA.
EM smerscher@med.miami.edu; afornoni@med.miami.edu
RI Mallela, Shamroop kumar/W-6982-2019
OI Mallela, Shamroop kumar/0000-0002-4553-8504; fornoni,
   Alessia/0000-0002-1313-7773
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01DK117599,
   R01DK104753, R01CA227493]; Hoffmann-La RocheHoffmann-La Roche; Alport
   Syndrome Foundation; Miami Clinical Translational Science Institute
   [U54DK083912, UM1DK100846, U01DK116101, UL1TR000460]; Boehringer
   IngelheimBoehringer Ingelheim; Katz family
FX AF and SM are supported by National Institutes of Health grants
   R01DK117599, R01DK104753, and R01CA227493, by Hoffmann-La Roche and the
   Alport Syndrome Foundation. AF is supported by U54DK083912, UM1DK100846,
   U01DK116101, and UL1TR000460 (Miami Clinical Translational Science
   Institute), and by Boehringer Ingelheim. We thank Dr. Hazel Szeto and
   Dr. Shaoyi Liu for processing and taking images of transmission electron
   microscopy of kidney cortices. We thank Dr. Armando Mendez for
   supporting the cholesterol efflux studies. We give a special thanks to
   the Katz family for their continuous support.
CR Bobulescu IA, 2010, CURR OPIN NEPHROL HY, V19, P393, DOI 10.1097/MNH.0b013e32833aa4ac
   Bryleva EY, 2010, P NATL ACAD SCI USA, V107, P3081, DOI 10.1073/pnas.0913828107
   Calle P, 2019, LIPIDS HEALTH DIS, V18, DOI 10.1186/s12944-019-1156-7
   Chang CCY, 2000, J BIOL CHEM, V275, P28083
   Chang TY, 2006, ANNU REV CELL DEV BI, V22, P129, DOI 10.1146/annurev.cellbio.22.010305.104656
   Chang TY, 2009, AM J PHYSIOL-ENDOC M, V297, pE1, DOI 10.1152/ajpendo.90926.2008
   Chang TY, 2001, CURR OPIN LIPIDOL, V12, P289, DOI 10.1097/00041433-200106000-00008
   Choi SH, 2008, FASEB J, V22, P1491, DOI 10.1096/fj.07-9411com
   Christian AE, 1997, J LIPID RES, V38, P2264
   Dove DE, 2006, ATHEROSCLEROSIS, V186, P267, DOI 10.1016/j.atherosclerosis.2005.08.005
   Ducasa GM, 2019, J CLIN INVEST, V129, P3387, DOI 10.1172/JCI125316
   Geng F, 2016, CLIN CANCER RES, V22, P5337, DOI 10.1158/1078-0432.CCR-15-2973
   Grosser G, 2016, MOL CELL ENDOCRINOL, V428, P133, DOI 10.1016/j.mce.2016.03.028
   Herman-Edelstein M, 2014, J LIPID RES, V55, P561, DOI 10.1194/jlr.P040501
   Honzumi S, 2018, RENAL FAILURE, V40, P43, DOI 10.1080/0886022X.2017.1419974
   Huang LH, 2016, J BIOL CHEM, V291, P6232, DOI 10.1074/jbc.M116.713818
   Huttunen HJ, 2010, J NEUROPATH EXP NEUR, V69, P777, DOI 10.1097/NEN.0b013e3181e77ed9
   Kang HM, 2015, NAT MED, V21, P37, DOI 10.1038/nm.3762
   Kaushik S, 2018, LEUKEMIA, V32, P499, DOI 10.1038/leu.2017.206
   Kellner-Weibel G, 1998, ARTERIOSCL THROM VAS, V18, P423, DOI 10.1161/01.ATV.18.3.423
   Kim HJ, 2009, AM J PHYSIOL-RENAL, V296, pF1297, DOI 10.1152/ajprenal.90761.2008
   Knight ZA, 2007, CELL, V128, P425, DOI 10.1016/j.cell.2007.01.021
   Lee HT, 1996, J MED CHEM, V39, P5031, DOI 10.1021/jm960674d
   Lee JY, 2004, J NUTR, V134, P3239, DOI 10.1093/jn/134.12.3239
   Meiner VL, 1996, P NATL ACAD SCI USA, V93, P14041, DOI 10.1073/pnas.93.24.14041
   Merscher-Gomez S, 2013, DIABETES, V62, P3817, DOI 10.2337/db13-0399
   Mitrofanova A, 2018, KIDNEY INT, V94, P1151, DOI 10.1016/j.kint.2018.06.031
   Mundel P, 1997, EXP CELL RES, V236, P248, DOI 10.1006/excr.1997.3739
   Nosadini R, 2011, NUTR METAB CARDIOVAS, V21, P79, DOI 10.1016/j.numecd.2010.10.002
   Oelkers P, 1998, J BIOL CHEM, V273, P26765, DOI 10.1074/jbc.273.41.26765
   Pedigo CE, 2016, J CLIN INVEST, V126, P3336, DOI 10.1172/JCI85939
   Proctor G, 2006, DIABETES, V55, P2502, DOI 10.2337/db05-0603
   Puglielli L, 2001, NAT CELL BIOL, V3, P905, DOI 10.1038/ncb1001-905
   Rampanelli E, 2018, J PATHOL, V246, P470, DOI 10.1002/path.5150
   Rodriguez A, 2002, ATHEROSCLEROSIS, V161, P45, DOI 10.1016/S0021-9150(01)00620-7
   Saleem MA, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133630
   Scheek S, 1997, P NATL ACAD SCI USA, V94, P11179, DOI 10.1073/pnas.94.21.11179
   Schwartz GG, 2012, NEW ENGL J MED, V367, P2089, DOI 10.1056/NEJMoa1206797
   Shibuya Y, 2014, J NEUROSCI, V34, P14484, DOI 10.1523/JNEUROSCI.2567-14.2014
   SLISKOVIC DR, 1991, TRENDS PHARMACOL SCI, V12, P194, DOI 10.1016/0165-6147(91)90546-5
   Tabas I, 1997, TRENDS CARDIOVAS MED, V7, P256, DOI 10.1016/S1050-1738(97)00086-8
   TABAS I, 1986, J BIOL CHEM, V261, P3147
   WILLIAMS RJ, 1989, BIOCHIM BIOPHYS ACTA, V1003, P213, DOI 10.1016/0005-2760(89)90259-2
   Yagyu H, 2000, J BIOL CHEM, V275, P21324, DOI 10.1074/jbc.M002541200
   Yamauchi Y, 2004, J LIPID RES, V45, P1943, DOI 10.1194/jlr.M400264-JLR200
   Yuan J, 2009, NAT CHEM BIOL, V5, P765, DOI 10.1038/nchembio.215
   Yue SH, 2014, CELL METAB, V19, P393, DOI 10.1016/j.cmet.2014.01.019
   Zhao G, 2008, J MED CHEM, V51, P380, DOI 10.1021/jm7013887
NR 48
TC 4
Z9 5
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0085-2538
EI 1523-1755
J9 KIDNEY INT
JI Kidney Int.
PD NOV
PY 2020
VL 98
IS 5
BP 1275
EP 1285
DI 10.1016/j.kint.2020.06.040
PG 11
WC Urology & Nephrology
SC Urology & Nephrology
GA OH6WA
UT WOS:000582735200029
PM 32739420
DA 2021-10-30
ER

PT J
AU Marsh, EE
   Kappelman, MD
   Kost, RG
   Mudd-Martin, G
   Shannon, J
   Stark, LA
   Carrasquillo, O
AF Marsh, Erica E.
   Kappelman, Michael D.
   Kost, Rhonda G.
   Mudd-Martin, Gia
   Shannon, Jackilen
   Stark, Louisa A.
   Carrasquillo, Olveen
TI Community engagement during COVID: A field report from seven CTSAs
SO JOURNAL OF CLINICAL AND TRANSLATIONAL SCIENCE
LA English
DT Article
DE COVID; community engagement; CTSA; health disparities
AB Introduction: Prior to the COVID pandemic, many CTSAs employed face-to-face interactions to conduct most of their community engagement (CE) activities. During the COVID pandemic, such engagement had to be curtailed and alternatives needed to be formulated. In addition, Community Engaged Research (CEnR) teams refocused their efforts to address this public health crisis. Methods: To obtain a general understanding of how CTSAs have conducted CE and CEnR during the COVID pandemic, we invited seven CTSA CE leaders to provide brief field reports of their activities during the pandemic. This included how their approaches to CE and CEnR were modified during the COVID-19 pandemic and key lessons learned. Results: We found that despite numerous challenges, all seven CTSAs CE cores were able to successfully carry out CE and CEnR. We also found that the fundamental principles of meaningful and authentic stakeholder engagement were of paramount importance during the pandemic. Through virtual approaches, all sites had considerable success in maintaining CE in during the COVID pandemic. They also leveraged existing bi-directional community partnerships to carry out meaningful and impactful research. This included both new COVID CEnR and also innovative approaches to sustain prior non-COVID research. Conclusions: These findings suggest that academic-community partnerships must be fostered and sustained over the many years so that when such crises emerge, all partners can build on existing trust and mutual respect. The lessons learned and the new tools and approaches developed would be key in addressing any such future public health emergencies.
C1 [Marsh, Erica E.] Univ Michigan, Michigan Inst Clin & Hlth Res, Ann Arbor, MI 48109 USA.
   [Kappelman, Michael D.] Univ N Carolina, North Carolina Translat & Clin Sci NCTraCS Inst, Chapel Hill, NC 27515 USA.
   [Kost, Rhonda G.] Rockefeller Univ RU, Ctr Clin & Translat Sci CCTS, New York, NY USA.
   [Mudd-Martin, Gia] Univ Kentucky, Ctr Clin & Translat Sci, Lexington, KY USA.
   [Shannon, Jackilen] Oregon Hlth & Sci Univ, Oregon Clin & Translat Res Inst, Portland, OR 97201 USA.
   [Stark, Louisa A.] Univ Utah, Ctr Clin & Translat Sci, Salt Lake City, UT USA.
   [Carrasquillo, Olveen] Univ Miami UM, Clin & Translat Sci Inst, Miami, FL USA.
RP Carrasquillo, O (corresponding author), Univ Miami, Miller Sch Med, Med & Publ Hlth Sci, Clin Res Bldg Room 962 Locator Code C223, Miami, FL 33136 USA.
EM ocarrasquillo@med.miami.edu
OI Mudd-Martin, Gia/0000-0003-2585-5534; Kost, Rhonda
   G./0000-0002-5419-0589
FU NIH NCATSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1TR002240, UL1TR002489, UL1TR001866,
   UL1TR001998, UL1TR002369, UL1TR002538, UL1TR002736]; NCATSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [U24TR002260]; University of Rochester Center for Leading Innovation and
   Collaboration (CLIC)
FX This work was supported in part by the NIH NCATS through Grant Award
   Numbers: UL1TR002240 (Marsh), UL1TR002489 (Kappelman), UL1TR001866
   (Kost), UL1TR001998 (Mudd), UL1TR002369 (Shannon), UL1TR002538 (Stark),
   and UL1TR002736 (Carrasquillo). This work was also funded in part by the
   University of Rochester Center for Leading Innovation and Collaboration
   (CLIC), the CTSA coordinating center funded by NCATS (U24TR002260). This
   work is solely the responsibility of the authors and does not
   necessarily represent the official views of the NIH, NCATS,
   CTSA-affiliated institutions, or CLIC.
CR All Us Res Program Investigators, 2019, NEW ENGL J MED, V381, P668, DOI 10.1056/NEJMsr1809937
   Appalachian Translational Research Network Newsletter, 2000, COVID 19 IMP RESP AP
   Barnes CO, 2020, CELL, V182, P828, DOI 10.1016/j.cell.2020.06.025
   Carrasquillo O, 2020, TRIALS, V21, DOI 10.1186/s13063-020-4213-7
   Clinical and Translational Science Awards Consortium Community Engagement Key Function Committee, PRINC COMM ENG, V2nd
   Eder MM, 2018, PROG COMM HLTH PARTN, V12, P145, DOI 10.1353/cpr.2018.0034
   Florida Universities and Health Centers Partner on COVID-19 Community Engagement Research, 2020, S FLOR HOSP NEW 1118
   Hank D., 2020, THE MIAMI HERALD
   Holzer J, 2014, CTS-CLIN TRANSL SCI, V7, P38, DOI 10.1111/cts.12125
   Michener L, 2020, PREV CHRONIC DIS, V17, DOI 10.5888/pcd17.200250
   Minkler M, 2008, COMMUNITY BASED PART, P544
   Moore JT, 2020, MMWR-MORBID MORTAL W, V69, P1122, DOI 10.15585/mmwr.mm6933e1
   Organization WH, 2020, RISK COMM COMM ENG R
   Price-Haywood EG, 2020, NEW ENGL J MED, V382, P2534, DOI 10.1056/NEJMsa2011686
   Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9
   Schoenberg NE, 2021, PROG COMM HLTH PARTN, V15, P95, DOI 10.1353/cpr.2021.0009
   UK Football player and cancer survivor, J PASCHAL ENC BIG BL
   University of Kentucky Center for Clinical and Translational Science, COVID 19 RES COMM
   US Public Health Response to COVID-19 and Chronic Disease, 2020, PREV CHRONIC DIS
NR 19
TC 0
Z9 0
U1 0
U2 0
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
EI 2059-8661
J9 J CLIN TRANSL SCI
JI J. Clin. Transl. Sci.
PD APR 27
PY 2021
VL 5
IS 1
AR e104
DI 10.1017/cts.2021.785
PG 7
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA UE9EA
UT WOS:000688183600001
PM 34192058
OA gold, Green Published
DA 2021-10-30
ER

PT J
AU Matthews, E
   Alkhachroum, A
   Massad, N
   Letchinger, R
   Doyle, K
   Claassen, J
   Thakur, KT
AF Matthews, Elizabeth
   Alkhachroum, Ayham
   Massad, Nina
   Letchinger, Riva
   Doyle, Kevin
   Claassen, Jan
   Thakur, Kiran T.
TI New-onset super-refractory status epilepticus A case series of 26
   patients
SO NEUROLOGY
LA English
DT Article
ID NORSE
AB Objective
   To better understand the heterogeneous population of patients with new-onset refractory status epilepticus (NORSE), we studied the most severe cases in patients who presented with new-onset super-refractory status epilepticus (NOSRSE).
   Methods
   We report a retrospective case series of 26 adults admitted to the Columbia University Irving Medical Center neurologic intensive care unit (NICU) from February 2009 to February 2016 with NOSRSE. We evaluated demographics, diagnostic studies, and treatment course. Outcomes were modified Rankin Scale score (mRS) at hospital discharge and most recent followup visit (minimum of 2 months post discharge), NICU and hospital length of stay, and longterm antiepileptic drug use.
   Results
   Of the 252 patients with refractory status epilepticus, 27/252 had NORSE and 26/27 of those had NOSRSE. Age was bimodally distributed with peaks at 27 and 63 years. The majority (96%) had an infectious or psychiatric prodrome. Etiology was cryptogenic in 73%, autoimmune in 19%, and infectious in 8%. Seven patients (27%) underwent brain biopsy, autopsy, or both; 3 (12%) were diagnostic (herpes simplex encephalitis, candida encephalitis, and acute demyelinating encephalomyelitis). On discharge, 6 patients (23%) had good or fair outcome (mRS 0-3). Of the patients with long-term follow-up data (median 9 months, interquartile range 2-22 months), 12 patients (71%) had mRS 0-3.
   Conclusion
   Among our cohort, nearly all patients with NORSE had NOSRSE. The majority were cryptogenic with few antibody-positive cases identified. Neuropathology was diagnostic in 12% of cases. Although only 23% of patients had good or fair outcome on discharge, 71% met these criteria at follow-up.
C1 [Matthews, Elizabeth; Massad, Nina; Letchinger, Riva; Doyle, Kevin; Claassen, Jan; Thakur, Kiran T.] Columbia Univ, Dept Neurol, New York, NY 10027 USA.
   [Alkhachroum, Ayham] Univ Miami, Dept Neurol, Miami, FL USA.
RP Thakur, KT (corresponding author), Columbia Univ, Dept Neurol, New York, NY 10027 USA.
EM kt2115@cumc.columbia.edu
RI Alkhachroum, Ayham/V-6050-2019
OI Alkhachroum, Ayham/0000-0003-0352-5913
FU National Center for Advancing Translational Sciences of the NIH under
   the Miami CTSI KL2 Career Development Award [UL1TR002736 N]; NINDSUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Neurological Disorders &
   Stroke (NINDS) [R01 NS106014, R03 NS112760]; DANA
FX E. Matthews reports no disclosures relevant to the manuscript. A.
   Alkhachroum is supported by the National Center for Advancing
   Translational Sciences of the NIH under the Miami CTSI KL2 Career
   Development Award UL1TR002736 N. Massad, R. Letchinger, and K. Doyle
   report no disclosures relevant to the manuscript. J. Claassen reports
   federal funding: NINDS R01 NS106014, R03 NS112760; foundation funding:
   DANA; and minority shares at iCE. K.T. Thakur reports K23 NIH/NINDS
   NS105935: Clinical impact of early pathogen identification in acute
   neurological infections. Go to Neurology.org/N for full disclosures.
CR Aurangzeb S, 2020, SEIZURE-EUR J EPILEP, V75, P174, DOI 10.1016/j.seizure.2019.10.005
   Claassen J, 2001, NEUROLOGY, V57, P1036, DOI 10.1212/WNL.57.6.1036
   Costello DJ, 2009, J NEUROL SCI, V277, P26, DOI 10.1016/j.jns.2008.10.007
   Gaspard N, 2018, EPILEPSIA, V59, P745, DOI 10.1111/epi.14022
   Gaspard N, 2015, NEUROLOGY, V85, P1604, DOI 10.1212/WNL.0000000000001940
   Hoerth MT, 2007, EPILEPSIA, V48, P6
   Iizuka T, 2017, NEUROL-NEUROIMMUNOL, V4, DOI 10.1212/NXI.0000000000000396
   Shorvon S, 2011, EPILEPSIA, V52, P1, DOI 10.1111/j.1528-1167.2011.03221.x
   Shorvon S, 2011, BRAIN, V134, P2802, DOI 10.1093/brain/awr215
   Van Lierde I, 2003, ACTA NEUROL BELG, V103, P88
   Wilder-Smith EPV, 2005, ANN ACAD MED SINGAP, V34, P417
NR 11
TC 3
Z9 4
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD OCT 20
PY 2020
VL 95
IS 16
BP E2280
EP E2285
DI 10.1212/WNL.0000000000010787
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA OP1CO
UT WOS:000587818900024
PM 32943479
OA Green Published
DA 2021-10-30
ER

PT J
AU Towfighi, A
   Orechwa, AZ
   Aragon, TJ
   Atkins, M
   Brown, AF
   Brown, J
   Carrasquillo, O
   Carson, S
   Fleisher, P
   Gustafson, E
   Herman, DK
   Inkelas, M
   Liu, W
   Meeker, D
   Mehta, T
   Miller, DC
   Paul-Brutus, R
   Potter, MB
   Ritner, SS
   Rodriguez, B
   Rusch, D
   Skinner, A
   Yee, HF
AF Towfighi, Amytis
   Orechwa, Allison Zumberge
   Aragon, Tomas J.
   Atkins, Marc
   Brown, Arleen F.
   Brown, Jen
   Carrasquillo, Olveen
   Carson, Savanna
   Fleisher, Paula
   Gustafson, Erika
   Herman, Deborah K.
   Inkelas, Moira
   Liu, Wylie
   Meeker, Daniella
   Mehta, Tara
   Miller, Doriane C.
   Paul-Brutus, Rachelle
   Potter, Michael B.
   Ritner, Sarah S.
   Rodriguez, Brendaly
   Rusch, Dana
   Skinner, Anne
   Yee, Hal F., Jr.
TI Bridging the gap between research, policy, and practice: Lessons learned
   from academic-public partnerships in the CTSA network
SO JOURNAL OF CLINICAL AND TRANSLATIONAL SCIENCE
LA English
DT Article
DE Translational research; policy-relevant research; implementation
   science; community engagement; public health
ID HEALTH; IMPLEMENTATION; REDUCE
AB A primary barrier to translation of clinical research discoveries into care delivery and population health is the lack of sustainable infrastructure bringing researchers, policymakers, practitioners, and communities together to reduce silos in knowledge and action. As National Institutes of Healths (NIH) mechanism to advance translational research, Clinical and Translational Science Award (CTSA) awardees are uniquely positioned to bridge this gap. Delivering on this promise requires sustained collaboration and alignment between research institutions and public health and healthcare programs and services. We describe the collaboration of seven CTSA hubs with city, county, and state healthcare and public health organizations striving to realize this vision together. Partnership representatives convened monthly to identify key components, common and unique themes, and barriers in academic-public collaborations. All partnerships aligned the activities of the CTSA programs with the needs of the city/county/state partners, by sharing resources, responding to real-time policy questions and training needs, promoting best practices, and advancing community-engaged research, and dissemination and implementation science to narrow the knowledge-to-practice gap. Barriers included competing priorities, differing timelines, bureaucratic hurdles, and unstable funding. Academic-public health/health system partnerships represent a unique and underutilized model with potential to enhance community and population health.
C1 [Towfighi, Amytis; Aragon, Tomas J.; Meeker, Daniella] Univ Southern Calif, Southern Calif Clin & Translat Sci Inst, Los Angeles, CA 90007 USA.
   [Towfighi, Amytis; Brown, Arleen F.; Yee, Hal F., Jr.] Los Angeles Cty Dept Hlth Serv, Los Angeles, CA USA.
   [Aragon, Tomas J.] San Francisco Dept Publ Hlth, San Francisco, CA USA.
   [Atkins, Marc; Gustafson, Erika; Mehta, Tara] Univ Illinois, Ctr Clin Translat Sci, Chicago, IL USA.
   [Brown, Arleen F.; Carson, Savanna; Herman, Deborah K.; Inkelas, Moira; Skinner, Anne] Univ Calif Los Angeles, Clin & Translat Sci Inst, Los Angeles, CA USA.
   [Brown, Jen] Northwestern Univ, Clin & Translat Sci Inst, Chicago, IL 60611 USA.
   [Carrasquillo, Olveen] Univ Miami, Clin & Translat Sci Inst, Miami, FL USA.
   [Fleisher, Paula; Liu, Wylie; Potter, Michael B.] Univ Calif San Francisco, Clin & Translat Sci Inst, San Francisco, CA 94143 USA.
   [Miller, Doriane C.] Univ Chicago, Inst Translat Med, Chicago, IL 60637 USA.
   [Paul-Brutus, Rachelle] Chicago Dept Publ Hlth, Chicago, IL USA.
   [Ritner, Sarah S.] Alliance Chicago, Chicago, IL USA.
RP Towfighi, A (corresponding author), 1100 N State St,A4E, Los Angeles, CA 90033 USA.
EM atowfighi@dhs.lacounty.gov
OI Gustafson, Erika/0000-0003-2774-6745; Brown, Arleen/0000-0001-9948-8955
FU University of Rochester CLIC [U24TR002260]; NCATSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1TR001855, UL1TR001881, UL1TR002736, UL1TR001872, UL1TR001422,
   UL1TR000050, UL1TR002389]; NCATS at the National Institutes of Health
   (NIH)
FX This work was funded in part by the University of Rochester CLIC, under
   Grant U24TR002260. CLIC is the coordinating center for the CTSA Program,
   funded by the NCATS at the National Institutes of Health (NIH). This
   work was also supported by grants UL1TR001855, UL1TR001881, UL1TR002736,
   UL1TR001872, UL1TR001422, UL1TR000050, UL1TR002389 from NCATS. This work
   is solely the responsibility of the authors and does not necessarily
   represent the official views of the NIH.
CR Barnett ML, 2018, HEALTH AFFAIR, V37, P1509, DOI 10.1377/hlthaff.2018.0391
   Bradley E, 2013, AM HLTH CARE PARADOX
   Brownson RC, 2018, ANNU REV PUBL HEALTH, V39, P27, DOI 10.1146/annurev-publhealth-040617-014746
   Daskivich LP, 2017, JAMA INTERN MED, V177, P642, DOI 10.1001/jamainternmed.2017.0204
   Dircksen JC., 2016, HLTH CHICAGO 2 0 PAR
   Dodson EA., 2010, J PUBLIC HEALTH MAN, V16, pE9, DOI DOI 10.1097/PHH.0b013e3181d1f1e2
   Estabrooks PA, 2018, PREV CHRONIC DIS, V15, DOI 10.5888/pcd15.180525
   Gilliland CT, 2019, ACS PHARMACOL TRANSL, V2, P213, DOI 10.1021/acsptsci.9b00022
   Glasgow RE, 2012, AM J PUBLIC HEALTH, V102, P1274, DOI DOI 10.2105/AJPH.2012.300755
   Grumbach K, 2017, PREV CHRONIC DIS, V14, DOI 10.5888/pcd14.160469
   Hiatt RA, 2018, HEALTH AFFAIR, V37, P54, DOI 10.1377/hlthaff.2017.1260
   Marmot MG, 2009, JAMA-J AM MED ASSOC, V301, P1169, DOI 10.1001/jama.2009.363
   Marrero DG, 2013, CTS-CLIN TRANSL SCI, V6, P204, DOI 10.1111/cts.12061
   McGovern L., 2014, RELATIVE CONTRIBUTIO
   Meslin EM, 2013, CLIN TRANSL MED, V2, DOI 10.1186/2001-1326-2-14
   Soni SM, 2016, JAMA-J AM MED ASSOC, V315, P2163, DOI 10.1001/jama.2016.4255
   U.S. Department of Health Human Services, 2015, FY2016 BUDG BRIEF CT
   United States Census Bureau, 2018, QUICKFACTS MIAM DAD
   Woolf SH, 2008, JAMA-J AM MED ASSOC, V299, P211, DOI 10.1001/jama.2007.26
NR 19
TC 2
Z9 2
U1 1
U2 1
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
EI 2059-8661
J9 J CLIN TRANSL SCI
JI J. Clin. Transl. Sci.
PD JUN
PY 2020
VL 4
IS 3
SI SI
BP 201
EP 208
AR PII S2059866120000230
DI 10.1017/cts.2020.23
PG 8
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA UF0PU
UT WOS:000688285500010
PM 32695489
OA Green Published, gold
DA 2021-10-30
ER

PT J
AU Pai, RK
   Van Booven, DJ
   Parmar, M
   Lokeshwar, SD
   Shah, K
   Ramasamy, R
   Arora, H
AF Pai, Raghav K.
   Van Booven, Derek J.
   Parmar, Madhumita
   Lokeshwar, Soum D.
   Shah, Khushi
   Ramasamy, Ranjith
   Arora, Himanshu
TI A review of current advancements and limitations of artificial
   intelligence in genitourinary cancers
SO AMERICAN JOURNAL OF CLINICAL AND EXPERIMENTAL UROLOGY
LA English
DT Review
DE Artificial Intelligence; prostate cancer; renal cancer; bladder cancer;
   clinical trials; androgen deprivation therapy
ID RENAL-CELL CARCINOMA; DIAGNOSIS; ALGORITHM; THERAPY
AB Advances in deep learning and neural networking have allowed clinicians to understand the impact that artificial intelligence (AI) could have on improving clinical outcomes and resources expenditures. In the realm of genitourinary (GU) cancers, AI has had particular success in improving the diagnosis and treatment of prostate, renal, and bladder cancers. Numerous studies have developed methods to utilize neural networks to automate prognosis prediction, treatment plan optimization, and patient education. Furthermore, many groups have explored other techniques, including digital pathology and expert 3D modeling systems. Compared to established methods, nearly all the studies showed some level of improvement and there is evidence that AI pipelines can reduce the subjectivity in the diagnosis and management of GU malignancies. However, despite the many potential benefits of utilizing AI in urologic oncology, there are some notable limitations of AI when combating real-world data sets. Thus, it is vital that more prospective studies be conducted that will allow for a better understanding of the benefits of AI to both cancer patients and urologists.
C1 [Pai, Raghav K.; Parmar, Madhumita; Lokeshwar, Soum D.; Shah, Khushi; Ramasamy, Ranjith; Arora, Himanshu] Univ Miami, Miller Sch Med, Dept Urol, Miami, FL 33136 USA.
   [Van Booven, Derek J.] Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, Miami, FL 33136 USA.
   [Arora, Himanshu] Univ Miami, Miller Sch Med Miami, Interdisciplinary Stem Cell Inst, Miami, FL 33136 USA.
RP Ramasamy, R; Arora, H (corresponding author), Univ Miami, Miller Sch Med, Dept Urol, Miami, FL 33136 USA.
EM hxa287@miami.edu; rama-samy@miami.edu
OI Pai, Raghav/0000-0003-0835-5589; Shah, Khushi/0000-0003-2879-3607
FU Clinician Scientist Development Grant from American Cancer Society
   [133578-CSDG-19-016-01-CSM]; American Urological Association Research
   Scholar Award; NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [UL1TR002736]; Sexual
   Medicine Society of North America (SMSNA); Stanley Glaser Award
FX We thank all the mentors (Dr. Dipen J Parekh), collaborators (Dr. Joshua
   M Hare, Dr. Bonnie Blomberg and Dr. Andrew V Schally), and interns for
   their insights, suggestions and support during this study. Additionally,
   we would like to thank the Clinician Scientist Development Grant from
   American Cancer Society (133578-CSDG-19-016-01-CSM), American Urological
   Association Research Scholar Award and Clinical and Translational
   Science Institute sup-ported by NIH (UL1TR002736), and the Sexual
   Medicine Society of North America (SMSNA) for HA and RR. Supported by
   the American Urological Association Research Scholar Award and Stanley
   Glaser Award to HA.
CR Aizenberg I., 2000, MULTIVALUED UNIVERSA
   Albertsen PC, 2019, EUR UROL, V75, P908, DOI 10.1016/j.eururo.2018.10.024
   Anagnostou T, 2003, EUR UROL, V43, P596, DOI 10.1016/S0302-2838(03)00133-7
   Anwar SM, 2018, J MED SYST, V42, DOI 10.1007/s10916-018-1088-1
   Arvaniti E, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30535-1
   Auffenberg GB, 2019, EUR UROL, V75, P901, DOI 10.1016/j.eururo.2018.09.050
   Bagheri MH, 2017, UROL ONCOL-SEMIN ORI, V35, P473, DOI 10.1016/j.urolonc.2017.04.014
   Berdik C, 2017, NATURE, V551, pS34, DOI 10.1038/551S34a
   Bishop C., 2006, PATTERN RECOGN
   Buchner A, 2012, CLIN GENITOURIN CANC, V10, P37, DOI 10.1016/j.clgc.2011.10.001
   Buttigliero C, 2017, CANCER TREAT REV, V54, P1, DOI 10.1016/j.ctrv.2017.01.002
   Cha KH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09315-w
   Das N, 2018, CURR OPIN PULM MED, V24, P117, DOI 10.1097/MCP.0000000000000459
   Dreicer R, 2006, CLIN GENITOURIN CANC, V5, pS19, DOI 10.3816/CGC.2006.s.003
   Elmahdy MS, 2019, MED PHYS, V46, P3329, DOI 10.1002/mp.13620
   Eminaga O, 2018, JCO CLIN CANCER INFO, V2, DOI 10.1200/CCI.17.00126
   Fehr D, 2015, P NATL ACAD SCI USA, V112, pE6265, DOI 10.1073/pnas.1505935112
   Garapati SS, 2017, MED PHYS, V44, P5814, DOI 10.1002/mp.12510
   Hamet P, 2017, METABOLISM, V69, pS36, DOI 10.1016/j.metabol.2017.01.011
   Han S, 2019, J DIGIT IMAGING, V32, P638, DOI 10.1007/s10278-019-00230-2
   Hemal AK, 2004, CURR OPIN UROL, V14, P89, DOI 10.1097/00042307-200403000-00007
   Holdbrook DA, 2019, PHARMACOL RES, V147, DOI 10.1016/j.phrs.2019.104372
   Jonasch E, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4797
   Kooy HM, 2015, BRIT J RADIOL, V88, DOI 10.1259/bjr.20150195
   Koza J, 1998, AUTOMATED DESIGN BOT
   Krittanawong C, 2017, J AM COLL CARDIOL, V69, P2657, DOI 10.1016/j.jacc.2017.03.571
   Langlotz CP, 2019, RADIOLOGY, V291, P781, DOI 10.1148/radiol.2019190613
   Lin F, 2019, ABDOM RADIOL, V44, P2528, DOI 10.1007/s00261-019-01992-7
   Linder N, 2019, J CLIN PATHOL, V72, P157, DOI 10.1136/jclinpath-2018-205328
   Lucas M, 2019, VIRCHOWS ARCH, V475, P77, DOI 10.1007/s00428-019-02577-x
   Maas M, 2019, WORLD J UROL, V37, P1741, DOI 10.1007/s00345-018-2505-2
   Malats N, 2015, HEMATOL ONCOL CLIN N, V29, P177, DOI 10.1016/j.hoc.2014.10.001
   Muglia Valdair F., 2015, Radiol Bras, V48, P166, DOI 10.1590/0100-3984.2013.1927
   Nicolae A, 2017, INT J RADIAT ONCOL, V97, P822, DOI 10.1016/j.ijrobp.2016.11.036
   Obermeyer Z, 2019, SCIENCE, V366, P447, DOI 10.1126/science.aax2342
   Olczak J, 2017, ACTA ORTHOP, V88, P581, DOI 10.1080/17453674.2017.1344459
   Ozkan TA, 2016, SCAND J UROL, V50, P420, DOI 10.1080/21681805.2016.1206619
   Puri M., 2015, ARTIFICIAL NEURAL NE
   Rossi SH, 2018, WORLD J UROL, V36, P1341, DOI 10.1007/s00345-018-2286-7
   Sokolov I, 2018, P NATL ACAD SCI USA, V115, P12920, DOI 10.1073/pnas.1816459115
   Trogdon JG, 2019, JAMA ONCOL, V5, P60, DOI 10.1001/jamaoncol.2018.3701
   You WP, 2018, EVOL APPL, V11, P140, DOI 10.1111/eva.12523
NR 42
TC 3
Z9 4
U1 0
U2 0
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 2330-1910
J9 AM J CLIN EXP UROL
JI Am. J. Clin. Exp. Urol.
PY 2020
VL 8
IS 5
BP 152
EP 162
PG 11
WC Urology & Nephrology
SC Urology & Nephrology
GA PK4IE
UT WOS:000602410000001
PM 33235893
DA 2021-10-30
ER

PT J
AU Sur, NB
   Wang, KF
   Di Tullio, MR
   Gutierrez, CM
   Dong, CH
   Koch, S
   Gardener, H
   Garcia-Rivera, EJ
   Zevallos, JC
   Burgin, WS
   Rose, DZ
   Goldberger, JJ
   Romano, JG
   Sacco, RL
   Rundek, T
AF Sur, Nicole B.
   Wang, Kefeng
   Di Tullio, Marco R.
   Gutierrez, Carolina M.
   Dong, Chuanhui
   Koch, Sebastian
   Gardener, Hannah
   Garcia-Rivera, Enid J.
   Zevallos, Juan Carlos
   Burgin, W. Scott
   Rose, David Z.
   Goldberger, Jeffrey J.
   Romano, Jose G.
   Sacco, Ralph L.
   Rundek, Tatjana
TI Disparities and Temporal Trends in the Use of Anticoagulation in
   Patients With Ischemic Stroke and Atrial Fibrillation
SO STROKE
LA English
DT Article
DE atrial fibrillation; cerebrovascular disorders; humans; warfarin; women
ID ORAL ANTICOAGULANT; WARFARIN USE; RISK; ASPIRIN
AB Background and Purpose Ischemic stroke (IS) secondary to atrial fibrillation (AF) is largely preventable with the use of anticoagulation. We sought to identify race-ethnicity and sex disparities with the use of direct oral anticoagulants (DOACs), aspirin, and warfarin in IS patients with AF and to identify temporal trends in the utilization of these medications.
   Methods The FLiPER-AF Stroke Study (Florida Puerto Rico Atrial Fibrillation) included 24040 IS cases enrolled in the Florida-Puerto Rico Collaboration to Reduce Stroke Registry from 2010 to 2016. Multivariable logistic regression models were performed to evaluate the effect of race-ethnicity and sex on utilization of DOACs, aspirin, and warfarin for stroke prevention in AF after adjustment for sociodemographic, hospital, and clinical factors.
   Results Among 24040 IS cases, 54% were women and 10% black, 12% FL-Hispanics, 4% PR-Hispanic, and 74% whites. From 2010 to 2016, DOAC use increased from 0% to 36%, warfarin use decreased from 51% to 17%, and aspirin use remained relatively stable (42%-40%). After adjustment, blacks had higher odds of warfarin (odds ratio, 1.22; 95% CI, 1.07-1.40) prescription at discharge compared with whites. Men had higher rates of aspirin (42.1% versus 38.8%), warfarin (33.6% versus 28.9%), and DOAC (21.3% versus 19.3%) use compared with women. After adjustment, women had lower odds of being discharged on aspirin (odds ratio, 0.92; 95% CI, 0.86-0.98) or warfarin (odds ratio, 0.91; 95% CI, 0.84-0.99). There was no sex difference in use of DOACs.
   Conclusions Our study confirmed the increasing use of DOACs, downtrending use of warfarin, whereas aspirin use remained similar over the years. There are sex and race-ethnicity disparities in anticoagulation use in IS patients with AF. It is critical to understand underlying drivers of these disparities to develop better practice strategies for stroke prevention in patients with AF.
   Clinical Trial Registration
C1 [Sur, Nicole B.; Wang, Kefeng; Gutierrez, Carolina M.; Dong, Chuanhui; Koch, Sebastian; Gardener, Hannah; Romano, Jose G.; Sacco, Ralph L.; Rundek, Tatjana] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA.
   [Goldberger, Jeffrey J.] Univ Miami, Miller Sch Med, Div Cardiol, Miami, FL 33136 USA.
   [Di Tullio, Marco R.] Columbia Univ, Med Ctr, Dept Med, Div Cardiol, New York, NY USA.
   [Garcia-Rivera, Enid J.] Univ Puerto Rico, Sch Med, Endowed Hlth Serv Res Ctr, San Juan, PR 00936 USA.
   [Zevallos, Juan Carlos] Florida Int Univ, Herbert Wertheim Coll Med, Dept Med & Hlth Sci Res, Miami, FL 33199 USA.
   [Burgin, W. Scott; Rose, David Z.] Univ S Florida, Morsani Sch Med, Dept Neurol, Tampa, FL USA.
RP Rundek, T (corresponding author), Univ Miami, Miller Sch Med, 1120 NW 14th St,Clin Res Bldg,CRB 13, Miami, FL 33136 USA.
EM trundek@miami.edu
RI Sacco, Ralph/Y-9278-2019; Goldberger, Jeffrey J/AAB-3684-2020; Sur,
   Nicole/AAX-7577-2020
OI Burgin, William/0000-0001-5376-8302; Rose, David Z./0000-0002-9449-6494;
   Sur, Nicole/0000-0002-3541-3599
FU National Institute of Neurological Disorders and StrokeUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Neurological Disorders & Stroke (NINDS)
   [U54NS081763]; Bristol-Myers SquibbBristol-Myers Squibb [CV185-564];
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [KL2TR000461, KL2TR002737] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Neurological Disorders & Stroke (NINDS)
   [R01NS084288, U24NS107267, U54NS081763] Funding Source: NIH RePORTER;
   National Institute on Minority Health and Health DisparitiesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute on Minority Health & Health
   Disparities (NIMHD) [R01MD012467] Funding Source: NIH RePORTER
FX This work was supported by a grant from the National Institute of
   Neurological Disorders and Stroke (U54NS081763) and a grant from
   Bristol-Myers Squibb (CV185-564). FLiPER-AF (Florida Puerto Rico Atrial
   Fibrillation) is registered under https://www.clinicaltrials.gov; unique
   identifier: NCT03627806.
CR Akanksha GW, 2017, ANN INDIAN ACAD NEUR, V20, P289, DOI 10.4103/aian.AIAN_16_17
   Akinboboye O, 2015, J MULTIDISCIP HEALTH, V8, P217, DOI 10.2147/JMDH.S74529
   Casciano JP, 2013, J MANAGE CARE PHARM, V19, P302, DOI 10.18553/jmcp.2013.19.4.302
   Ciliberti-Vargas MA, 2017, SOUTH MED J, V110, P466, DOI [10.14423/smj.0000000000000667, 10.14423/SMJ.0000000000000667]
   Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561
   Fohtung RB, 2017, J AM GERIATR SOC, V65, P2405, DOI 10.1111/jgs.15058
   Gallagher AM, 2008, J THROMB HAEMOST, V6, P1500, DOI 10.1111/j.1538-7836.2008.03059.x
   Go AS, 1999, ANN INTERN MED, V131, P927, DOI 10.7326/0003-4819-131-12-199912210-00004
   Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039
   Hsu JC, 2016, J AM COLL CARDIOL, V67, P2913, DOI 10.1016/j.jacc.2016.03.581
   Kirley K, 2012, CIRC-CARDIOVASC QUAL, V5, P615, DOI 10.1161/CIRCOUTCOMES.112.967299
   Ko D, 2017, NAT REV CARDIOL, V14, P113, DOI 10.1038/nrcardio.2016.171
   Lin S, 2011, CEREBROVASC DIS, V31, P419, DOI 10.1159/000323221
   Lip GYH, 2015, CIRC-CARDIOVASC QUAL, V8, pS12, DOI 10.1161/CIRCOUTCOMES.114.001556
   Marini C, 2005, STROKE, V36, P1115, DOI 10.1161/01.STR.0000166053.83476.4a
   Marzec LN, 2017, J AM COLL CARDIOL, V69, P2475, DOI 10.1016/j.jacc.2017.03.540
   Meschia JF, 2010, STROKE, V41, P581, DOI 10.1161/STROKEAHA.109.573907
   Narayan SM, 1997, LANCET, V350, P943, DOI 10.1016/S0140-6736(97)06359-9
   Olesen JB, 2015, EUROPACE, V17, P187, DOI 10.1093/europace/euu225
   Patel MR, 2010, NEW ENGL J MED, V362, P886, DOI 10.1056/NEJMoa0907272
   Patel PA, 2015, CIRC-CARDIOVASC QUAL, V8, P383, DOI 10.1161/CIRCOUTCOMES.114.000907
   Reynolds MR, 2006, AM J CARDIOL, V97, P538, DOI 10.1016/j.amjcard.2005.09.086
   Rodriguez-Bernal CL, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00063
   Saran R, 2017, AM J KIDNEY DIS, V69, DOI 10.1053/j.ajkd.2016.12.004
   Steinberg BA, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000535
   Toyoda K, 2015, INT J STROKE, V10, P836, DOI 10.1111/ijs.12452
   van den Heuvel JM, 2018, THROMB J, V16, DOI 10.1186/s12959-017-0156-y
   WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983
   Yu AYX, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.007129
NR 29
TC 12
Z9 12
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0039-2499
EI 1524-4628
J9 STROKE
JI Stroke
PD JUN
PY 2019
VL 50
IS 6
BP 1452
EP 1459
DI 10.1161/STROKEAHA.118.023959
PG 8
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA IB2BW
UT WOS:000470074200043
PM 31084325
OA Green Accepted, Bronze
DA 2021-10-30
ER

PT J
AU Agarwal, NK
   Kim, CH
   Kunkalla, K
   Konno, H
   Tjendra, Y
   Kwon, D
   Blonska, M
   Kozloski, GA
   Moy, VT
   Verdun, RE
   Barber, GN
   Lossos, IS
   Vega, F
AF Agarwal, Nitin K.
   Kim, Chae H.
   Kunkalla, Kranthi
   Konno, Hiroyasu
   Tjendra, Youley
   Kwon, Deukwoo
   Blonska, Marzenna
   Kozloski, Goldi A.
   Moy, Vincent T.
   Verdun, Ramiro E.
   Barber, Glen N.
   Lossos, Izidore S.
   Vega, Francisco
TI Active IKK beta promotes the stability of GLI1 oncogene in diffuse large
   B-cell lymphoma
SO BLOOD
LA English
DT Article
ID CUBITUS-INTERRUPTUS PROTEIN; HEDGEHOG SIGNALING PATHWAY; FACTOR-KAPPA-B;
   TRANSCRIPTION FACTOR; ABERRANT ACTIVATION; UBIQUITIN LIGASE;
   BREAST-CANCER; PHOSPHORYLATION; DEGRADATION; TARGETS
AB GLI1 oncogene has been implicated in the pathobiology of several neoplasms including diffuse large B-cell lymphoma (DLBCL). However, mechanisms underlying GLI1-increased activity in DLBCL are poorly characterized. Herein, we demonstrate that IKK beta phosphorylates GLI1 in DLBCL. IKK beta activation increased GLI1 protein levels and transcriptional activity, whereas IKK beta silencing decreased GLI1 levels and transcriptional activity. Tumor necrosis factor-alpha (TNF alpha) mediated IKK beta activation-impaired GLI1 binding with the E3 ubiquitin ligase-ITCH, leading to decreased K48-linked ubiquitination/degradation of GLI1. We found 8 IKK beta-dependent phosphorylation sites that mediate GLI1 stability. Mutating or deleting these residues facilitated GLI1-ITCH interaction and decreased the protective effect of TNF alpha on GLI1 stability. IKK beta-GLI1 crosstalk is significant because combined inhibition of both molecules resulted in synergistic suppression of DLBCL viability in vivo and in vitro. By linking IKK beta-mediated nuclear factor-kappa B activity with GLI1, we identified a crosstalk between these 2 pathways that can inform the design of novel therapeutic strategies in DLBCL.
C1 [Agarwal, Nitin K.; Kim, Chae H.; Kunkalla, Kranthi; Tjendra, Youley; Vega, Francisco] Univ Miami, Sylvester Comprehens Canc Ctr, Dept Pathol, Div Hematopathol, Miami, FL 33136 USA.
   [Konno, Hiroyasu; Barber, Glen N.] Univ Miami, Sylvester Comprehens Canc Ctr, Dept Cell Biol, Miami, FL 33136 USA.
   [Kwon, Deukwoo] Univ Miami, Sylvester Comprehens Canc Ctr, Biostat & Bioinformat Core, Miami, FL 33136 USA.
   [Blonska, Marzenna; Kozloski, Goldi A.; Lossos, Izidore S.; Vega, Francisco] Univ Miami, Sylvester Comprehens Canc Ctr, Dept Med, Div Hematol Oncol, Miami, FL 33136 USA.
   [Moy, Vincent T.] Univ Miami, Sylvester Comprehens Canc Ctr, Dept Physiol & Biophys, Miami, FL 33136 USA.
   [Verdun, Ramiro E.] Univ Miami, Miller Sch Med, Dept Med, Div Gerontol & Geriatr Med, Miami, FL 33136 USA.
   [Lossos, Izidore S.] Univ Miami, Sylvester Comprehens Canc Ctr, Dept Mol & Cellular Pharmacol, Div Hematol Oncol, Miami, FL 33136 USA.
RP Agarwal, NK; Vega, F (corresponding author), Univ Miami, Sylvester Comprehens Canc Ctr, Dept Pathol, Div Hematopathol, Miami, FL 33136 USA.
EM n.agarwal1@med.miami.edu; fvega@med.miami.edu
RI Blonska, Marzenna/U-7751-2019
OI Vega, Francisco/0000-0001-5956-452X; Blonska,
   Marzenna/0000-0001-5237-8732
FU University of Miami, CTSI Pilot Award Program [1UL1TR000460];
   Translational Grant of The Leukemia & Lymphoma Society; National
   Institutes of Health K08 Physician-Scientist Award [1 K08 CA143151-01];
   Dwoskin family foundation; Recio family foundation; Rizzo family
   foundation; NATIONAL CANCER INSTITUTEUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Cancer Institute (NCI) [K08CA143151] Funding Source: NIH RePORTER;
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [KL2TR000461, UL1TR000460] Funding Source: NIH RePORTER
FX This work was supported by funds from University of Miami, CTSI Pilot
   Award Program 1UL1TR000460 (N.K.A., F.V.); The Translational Grant of
   The Leukemia & Lymphoma Society (F.V.); National Institutes of Health
   K08 Physician-Scientist Award 1 K08 CA143151-01 (F.V.); and the Dwoskin,
   Recio, and Rizzo family foundations (I.S.L.).
CR Agarwal NK, 2013, ONCOGENE, V32, P2521, DOI 10.1038/onc.2012.287
   Agarwal NK, 2013, J BIOL CHEM, V288, P15390, DOI 10.1074/jbc.M112.425249
   Agarwal NK, 2014, ONCOTARGET, V5, P815, DOI 10.18632/oncotarget.1774
   Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003
   Altaba ARI, 1999, TRENDS GENET, V15, P418, DOI 10.1016/S0168-9525(99)01840-5
   Archer TC, 2012, J CLIN ONCOL, V30, P2154, DOI 10.1200/JCO.2011.41.1181
   Aza-Blanc P, 2000, DEVELOPMENT, V127, P4293
   AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5
   Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506
   Blonska M, 2015, SEMIN CANCER BIOL, V34, P3, DOI 10.1016/j.semcancer.2015.03.002
   Boulbes D, 2010, MOL CANCER RES, V8, P896, DOI 10.1158/1541-7786.MCR-09-0409
   Canettieri G, 2010, NAT CELL BIOL, V12, P132, DOI 10.1038/ncb2013
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4
   Colavito SA, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0444-4
   Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906
   Davis RE, 2001, J EXP MED, V194, P1861, DOI 10.1084/jem.194.12.1861
   Di Marcotullio L, 2011, ONCOGENE, V30, P65, DOI 10.1038/onc.2010.394
   Di Marcotullio L, 2006, NAT CELL BIOL, V8, P1415, DOI 10.1038/ncb1510
   Dihazi H, 2005, MOL CELL PROTEOMICS, V4, P1445, DOI 10.1074/mcp.M400184-MCP200
   Furuya K, 2007, J BIOL CHEM, V282, P18365, DOI 10.1074/jbc.M610522200
   Georgescu MM, 2014, NEOPLASIA, V16, P365, DOI 10.1016/j.neo.2014.04.004
   Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1
   Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619
   Huntzicker EG, 2006, GENE DEV, V20, P276, DOI 10.1101/gad.1380906
   Jagani Z, 2010, NAT MED, V16, P1429, DOI 10.1038/nm.2251
   Kim JE, 2009, MODERN PATHOL, V22, P1312, DOI 10.1038/modpathol.2009.98
   KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634
   KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0
   Konno H, 2013, CELL, V155, P688, DOI 10.1016/j.cell.2013.09.049
   Kunkalla K, 2013, ANN HEMATOL, V92, P777, DOI 10.1007/s00277-013-1684-6
   Nilsson M, 2000, P NATL ACAD SCI USA, V97, P3438, DOI 10.1073/pnas.050467397
   Ok CY, 2012, AM J PATHOL, V180, P2, DOI 10.1016/j.ajpath.2011.09.009
   Pickart CM, 2004, CURR OPIN CHEM BIOL, V8, P610, DOI 10.1016/j.cbpa.2004.09.009
   Qu CJ, 2013, BLOOD, V121, P4718, DOI 10.1182/blood-2012-12-470153
   Rossi M, 2005, EMBO J, V24, P836, DOI 10.1038/sj.emboj.7600444
   Santoni M, 2013, CURR PROTEIN PEPT SC, V14, P133, DOI 10.2174/1389203711314020005
   Singh RR, 2011, ONCOGENE, V30, P4874, DOI 10.1038/onc.2011.195
   Singh RR, 2010, LEUKEMIA, V24, P1025, DOI 10.1038/leu.2010.35
   Taus T, 2011, J PROTEOME RES, V10, P5354, DOI 10.1021/pr200611n
   Theil T, 1999, CELL TISSUE RES, V296, P75, DOI 10.1007/s004410051268
   Xia YF, 2012, NAT CELL BIOL, V14, P257, DOI 10.1038/ncb2428
   Yeh PY, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-53
   Zhang Q, 2006, DEV CELL, V10, P719, DOI 10.1016/j.devcel.2006.05.004
   Zhang Q, 2009, P NATL ACAD SCI USA, V106, P21191, DOI 10.1073/pnas.0912008106
NR 44
TC 10
Z9 11
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD FEB 4
PY 2016
VL 127
IS 5
BP 605
EP 615
DI 10.1182/blood-2015-07-658781
PG 11
WC Hematology
SC Hematology
GA DI3IZ
UT WOS:000373393600015
PM 26603838
OA Bronze, Green Published
DA 2021-10-30
ER

PT J
AU Prado, G
   Lightfoot, M
   Brown, CH
AF Prado, Guillermo
   Lightfoot, Marguerita
   Brown, C. Hendricks
TI Macro-Level Approaches to HIV Prevention Among Ethnic Minority Youth
   State of the Science, Opportunities, and Challenges
SO AMERICAN PSYCHOLOGIST
LA English
DT Article
DE HIV prevention; ethnic minorities; youth; macro-level interventions
ID AFRICAN-AMERICAN ADOLESCENTS; SEXUALLY-TRANSMITTED DISEASE; RISK
   BEHAVIORS; YOUNG MEN; RACIAL DISPARITIES; STRUCTURAL INTERVENTIONS;
   GENDER IDEOLOGIES; UNITED-STATES; AIDS STIGMA; HEALTH
AB The HIV epidemic continues to disproportionately affect ethnic minority youth. These disconcerting health disparities indicate that although existing HIV preventive strategies for ethnic minority youth have been efficacious, they have not significantly reduced the impact of the epidemic in this population. Macro-level interventions, such as structural or policy interventions, have the potential to impact the HIV epidemic at a population level, and thus reduce the HIV health disparities that exist among ethnic minority youth and other segments of the U. S. population. This article calls for a paradigm shift to develop, evaluate, and disseminate interventions that target upstream/macro-level factors or that, at a minimum, integrate both a macro and individual level perspective. The article also discusses the challenges in developing and evaluating such interventions. Psychologists and other behavioral scientists can play a critical role in reducing the impact of HIV on ethnic minority youth by integrating macro-level approaches to future HIV prevention strategies.
C1 [Prado, Guillermo; Brown, C. Hendricks] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Ctr Prevent Implementat Methodol Drug Abuse & Sex, Miami, FL 33136 USA.
   [Prado, Guillermo; Brown, C. Hendricks] Univ Miami, Miller Sch Med, Miami Ctr AIDS Res, Miami, FL 33136 USA.
   [Lightfoot, Marguerita] Univ Calif San Francisco, Ctr AIDS Prevent Studies, San Francisco, CA 94143 USA.
RP Prado, G (corresponding author), Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, 1425 NW 10th Ave, Miami, FL 33136 USA.
EM gprado@med.miami.edu
OI Brown, C Hendricks/0000-0002-0294-2419
FU NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1 TR000460, UL1TR000460] Funding
   Source: Medline; NIAID NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [P30AI073961, P30 AI073961]
   Funding Source: Medline; NIDA NIH HHSUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute on Drug Abuse (NIDA) [P30DA027828, R01 DA025192, P30 DA027828,
   R01DA025192] Funding Source: Medline; NCHHSTP CDC HHS [U01PS0000671, U01
   PS000671] Funding Source: Medline; NCHHSTPUnited States Department of
   Health & Human ServicesCenters for Disease Control & Prevention - USA
   [5U01PS000671-04] Funding Source: Federal RePORTER; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000460]
   Funding Source: NIH RePORTER; NATIONAL CENTER FOR HIV, VIRAL HEPATITIS,
   STDS AND TB PREVENTIONUnited States Department of Health & Human
   ServicesCenters for Disease Control & Prevention - USA [U01PS000671]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [P30AI073961] Funding Source:
   NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Drug Abuse (NIDA)European Commission [R01DA025192,
   P30DA027828] Funding Source: NIH RePORTER
CR Aarons G. A., 2013, LEADERSHIP ORG UNPUB
   Adimora AA, 2005, J INFECT DIS, V191, pS115, DOI 10.1086/425280
   Adimora AA, 2002, EPIDEMIOLOGY, V13, P707, DOI 10.1097/00001648-200211000-00016
   Adimora AA, 2010, JAIDS-J ACQ IMM DEF, V55, pS132, DOI 10.1097/QAI.0b013e3181fbcb38
   Ahmed A, 2011, GLOB PUBLIC HEALTH, V6, pS357, DOI 10.1080/17441692.2011.623136
   Ahrold TK, 2010, ARCH SEX BEHAV, V39, P190, DOI 10.1007/s10508-008-9406-1
   Aidala A, 2005, AIDS BEHAV, V9, P251, DOI 10.1007/s10461-005-9000-7
   Alford S., 2003, SCI SUCCESS SEX ED O
   Angell SY, 2009, ANN INTERN MED, V151, P129, DOI 10.7326/0003-4819-151-2-200907210-00010
   Aral SO, 1999, SEX TRANSM DIS, V26, P262, DOI 10.1097/00007435-199905000-00004
   Aronowitz T, 2006, J COMMUN HEALTH NURS, V23, P113, DOI 10.1207/s15327655jchn2302_4
   AUERBACH JD, 2009, 24 AIDS 2031
   BALL J, 2004, J CHILD FAM STUD, V13, P21, DOI DOI 10.1023/B:JCFS
   BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191
   Blake SM, 2005, PREV MED, V40, P239, DOI 10.1016/j.ypmed.2004.05.028
   Blake SM, 2003, AM J PUBLIC HEALTH, V93, P955, DOI 10.2105/AJPH.93.6.955
   Blake SM, 2001, AM J PUBLIC HEALTH, V91, P940, DOI 10.2105/AJPH.91.6.940
   Blankenship KM, 2006, J URBAN HEALTH, V83, P59, DOI 10.1007/s11524-005-9007-4
   Boily MC, 2009, LANCET INFECT DIS, V9, P118, DOI 10.1016/S1473-3099(09)70021-0
   Bowleg L, 2012, AM J PUBLIC HEALTH, V102, P1267, DOI 10.2105/AJPH.2012.300750
   Boyer CB, 1999, J ADOLESCENT RES, V14, P448, DOI 10.1177/0743558499144004
   BRONFENBRENNER U, 1986, DEV PSYCHOL, V22, P723, DOI 10.1037/0012-1649.22.6.723
   Bronfenbrenner U., 1992, ANN CHILD DEV, P187
   Bronfenbrenner U., 1979, ECOLOGY HUMAN DEV EX
   Brown C. H., J AIDS IN PRESS
   Brown CH, 2009, ANNU REV PUBL HEALTH, V30, P1, DOI 10.1146/annurev.publhealth.031308.100223
   Browning CR, 2008, J HEALTH SOC BEHAV, V49, P269, DOI 10.1177/002214650804900303
   Browning CR, 2004, DEMOGRAPHY, V41, P697, DOI 10.1353/dem.2004.0029
   CARBALLODIEGUEZ A, 1989, J COUNS DEV, V68, P26, DOI 10.1002/j.1556-6676.1989.tb02487.x
   CDC, 2011, EST NEW HIV INF US 2
   *CDCP, 2012, HIV SURV AD YOUNG AD
   Centers for Disease Control and Prevention, 2011, HIV AIDS LAT
   Centers for Disease Control and Prevention, 2011, HIV YOUTH
   Centers for Disease Control and Prevention, 2011, CDC TRIALS PREEXP PR
   Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P429
   Centers for Disease Control and Prevention (CDC), 2011, HIV AFR AM
   Centers for Disease Control and Prevention (CDC), 2012, HIV SURVEILLANCE S, V17
   Comstock G.D., 1991, VIOLENCE LESBIANS GA
   Crosby R, 2007, SEX TRANSM DIS, V34, P744, DOI 10.1097/OLQ.0b013e31804f81de
   Darrow WW, 2009, AIDS BEHAV, V13, P1178, DOI 10.1007/s10461-009-9601-7
   Das M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011068
   Demmer C, 2002, J COMMUN HEALTH, V27, P63, DOI 10.1023/A:1013884310983
   Denning P. H., 2010, COMMUNITIES CRISIS I
   Diaz Rafael M, 2004, Cultur Divers Ethnic Minor Psychol, V10, P255, DOI 10.1037/1099-9809.10.3.255
   Dittus P., 2004, J CHILD FAM STUD, V13, P5, DOI DOI 10.1023/B:JCFS.0000010487.46007.08
   Duncan GJ, 1997, CONSEQUENCES GROWING
   Ellen JM, 1998, SEX TRANSM DIS, V25, P125, DOI 10.1097/00007435-199803000-00002
   FELLNER J, 2000, HUMAN RIGHTS WATCH, V12
   Fichtenberg CM, 2009, SEX TRANSM INFECT, V85, P493, DOI 10.1136/sti.2009.036681
   Fishbein M, 1999, AM J PUBLIC HEALTH, V89, P336, DOI 10.2105/AJPH.89.3.336
   Fishbein M., 1975, BELIEF ATTITUDE INTE
   FISHER JD, 1992, PSYCHOL BULL, V111, P455, DOI 10.1037/0033-2909.111.3.455
   Fitzpatrick LK, 2006, J NATL MED ASSOC, V98, P1906
   Freimuth VS, 2001, SOC SCI MED, V52, P797, DOI 10.1016/S0277-9536(00)00178-7
   Genberg BL, 2009, SOC SCI MED, V68, P2279, DOI 10.1016/j.socscimed.2009.04.005
   German D, 2012, AIDS BEHAV, V16, P168, DOI 10.1007/s10461-011-9882-5
   Hallfors DD, 2007, AM J PUBLIC HEALTH, V97, P125, DOI 10.2105/AJPH.2005.075747
   Harawa NT, 2004, JAIDS-J ACQ IMM DEF, V35, P526, DOI 10.1097/00126334-200404150-00011
   Haveman R. H., 1994, SUCCEEDING GENERATIO
   Herek GM, 2002, AM J PUBLIC HEALTH, V92, P371, DOI 10.2105/AJPH.92.3.371
   Herek GM, 1999, AM BEHAV SCI, V42, P1130, DOI 10.1177/00027649921954804
   Herek GM, 1997, J APPL SOC PSYCHOL, V27, P1, DOI 10.1111/j.1559-1816.1997.tb00621.x
   Herek GM, 2011, J SOC ISSUES, V67, P413, DOI 10.1111/j.1540-4560.2011.01705.x
   Herek GM, 2009, J COUNS PSYCHOL, V56, P32, DOI 10.1037/a0014672
   Hirsch JS, 2002, AM J PUBLIC HEALTH, V92, P1227, DOI 10.2105/AJPH.92.8.1227
   Holtgrave DR, 2003, SEX TRANSM INFECT, V79, P62, DOI 10.1136/sti.79.1.62
   Hopkins DP, 2001, AM J PREV MED, V20, P16, DOI 10.1016/S0749-3797(00)00297-X
   Institute of Medicine, 2001, NO TIM LOS GETT MOR
   JEMMOTT JB, 1992, AM J PUBLIC HEALTH, V82, P372, DOI 10.2105/AJPH.82.3.372
   JEMMOTT JB, 1996, HLTH PSYCHOL LIFE SP, P395, DOI DOI 10.1037/10220-024
   Kalichman S, 2002, Psychol Health Med, V7, P327, DOI 10.1080/13548500220139368
   Kann Laura, 2012, Morbidity and Mortality Weekly Report, V61, P556
   Kansal T., 2005, RACIAL DISPARITY SEN
   Kegeles SM, 1996, AM J PUBLIC HEALTH, V86, P1129, DOI 10.2105/AJPH.86.8_Pt_1.1129
   Kellam SG, 2014, PREV SCI, V15, pS6, DOI 10.1007/s11121-012-0296-z
   Kerrigan D, 2007, J SEX RES, V44, P172, DOI 10.1080/00224490701263785
   Kirby DB, 2007, J ADOLESCENT HEALTH, V40, P206, DOI 10.1016/j.jadohealth.2006.11.143
   Klein Susan J, 2002, J Public Health Manag Pract, V8, P44
   Kohler PK, 2008, J ADOLESCENT HEALTH, V42, P344, DOI 10.1016/j.jadohealth.2007.08.026
   Koniak-Griffin D, 2003, FAM COMMUNITY HEALTH, V26, P94, DOI 10.1097/00003727-200304000-00003
   Koniak-Griffin D, 2008, WESTERN J NURS RES, V30, P724, DOI 10.1177/0193945907310490
   Ku L, 2002, AM J PUBLIC HEALTH, V92, P1140, DOI 10.2105/AJPH.92.7.1140
   Landrine H, 2006, J BEHAV MED, V29, P79, DOI 10.1007/s10865-005-9029-0
   Lane SD, 2004, J HEALTH CARE POOR U, V15, P319, DOI 10.1353/hpu.2004.0043
   Laub C, 1999, HEALTH EDUC BEHAV, V26, P185, DOI 10.1177/109019819902600203
   Leon AM, 2000, CRISIS INTERV TIME-L, V6, P13, DOI 10.1080/10645130008951293
   Logie CH, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001124
   LUSTER T, 1994, J MARRIAGE FAM, V56, P622, DOI 10.2307/352873
   MacKinnon D P, 1994, NIDA Res Monogr, V139, P127
   MacKinnon DP, 2002, PSYCHOL METHODS, V7, P83, DOI 10.1037/1082-989X.7.1.83
   Markham CM, 2010, J ADOLESCENT HEALTH, V46, pS23, DOI 10.1016/j.jadohealth.2009.11.214
   Mays Vickie M, 2004, J Black Psychol, V30, P78, DOI 10.1177/0095798403260265
   McKevitt B. C., 2008, BEST PRACTICES SCH P, V3, P735
   Mechanic D, 2012, HEALTH AFFAIR, V31, P376, DOI 10.1377/hlthaff.2011.0623
   Mohr DC, 2011, J MED INTERNET RES, V13, DOI 10.2196/jmir.1602
   Mohr DC, 2010, J MED INTERNET RES, V12, DOI 10.2196/jmir.1370
   Morales ES, 2009, AM PSYCHOL, V64, P805, DOI 10.1037/0003-066X.64.8.805
   Murry VM, 2007, J ADOLESCENT HEALTH, V41, P333, DOI 10.1016/j.jadohealth.2007.04.003
   Nachega Jean B, 2012, J Int Assoc Physicians AIDS Care (Chic), V11, P172, DOI 10.1177/1545109712436723
   Organista K. C., 2012, HIV PREVENTION LATIN, P3, DOI DOI 10.1093/ACPR0F:0S0/9780199764303.001.0001
   Pantin H, 2004, AM J ORTHOPSYCHIAT, V74, P545, DOI 10.1037/0002-9432.74.4.545
   Parker R, 2003, SOC SCI MED, V57, P13, DOI 10.1016/S0277-9536(02)00304-0
   Paz-Bailey G, 2012, SEX TRANSM DIS, V39, P35, DOI 10.1097/OLQ.0b013e318231cf2d
   Philliber S., 1992, PREVENTING ADOLESCEN, V140, P139
   Pisani AR, 2013, J YOUTH ADOLESCENCE, V42, P807, DOI 10.1007/s10964-012-9884-2
   Pollini RA, 2011, AIDS PATIENT CARE ST, V25, P601, DOI 10.1089/apc.2010.0390
   Prado G, 2012, ARCH PEDIAT ADOL MED, V166, P127, DOI 10.1001/archpediatrics.2011.189
   Prado G, 2010, HEALTH EDUC BEHAV, V37, P97, DOI 10.1177/1090198109349218
   Preston DB, 2004, AIDS EDUC PREV, V16, P291, DOI 10.1521/aeap.16.4.291.40401
   PROCHASKA JO, 1983, J CONSULT CLIN PSYCH, V51, P390, DOI 10.1037/0022-006X.51.3.390
   Proctor E, 2011, ADM POLICY MENT HLTH, V38, P65, DOI 10.1007/s10488-010-0319-7
   Pronyk PM, 2006, LANCET, V368, P1973, DOI 10.1016/S0140-6736(06)69744-4
   Radcliffe J, 2010, AIDS PATIENT CARE ST, V24, P493, DOI 10.1089/apc.2010.0020
   Rao D, 2007, AIDS CARE, V19, P28, DOI 10.1080/09540120600652303
   Reynolds AJ, 2007, ARCH PEDIAT ADOL MED, V161, P730, DOI 10.1001/archpedi.161.8.730
   Rhodes SD, 2006, J NATL MED ASSOC, V98, P564
   Rosario M, 2006, AIDS EDUC PREV, V18, P444, DOI 10.1521/aeap.2006.18.5.444
   Ross MW, 2008, AIDS EDUC PREV, V20, P547, DOI 10.1521/aeap.2008.20.6.547
   Ryan C, 2010, J CHILD ADOL PS NURS, V23, P205, DOI 10.1111/j.1744-6171.2010.00246.x
   Schuster MA, 2005, J GEN INTERN MED, V20, P807, DOI 10.1111/j.1525-1497.2005.05049.x
   Sherman SG, 2006, AIDS CARE, V18, P1, DOI 10.1080/09540120500101625
   Siegel K, 2002, AIDS, V16, pS69, DOI 10.1097/00002030-200216004-00010
   Sifakis F, 2007, JAIDS-J ACQ IMM DEF, V46, P343, DOI 10.1097/QAI.0b013e31815724cc
   SIMONS RL, 1993, J MARRIAGE FAM, V55, P385, DOI 10.2307/352809
   Ssewamala FM, 2010, AM J PUBLIC HEALTH, V100, P483, DOI 10.2105/AJPH.2008.158840
   Stewart KE, 2005, AIDS CARE, V17, P350, DOI 10.1080/09540120412331299780
   Sutton MY, 2009, AM J PUBLIC HEALTH, V99, pS351, DOI 10.2105/AJPH.2008.157958
   Swenson RR, 2009, SEX TRANSM DIS, V36, P584, DOI 10.1097/OLQ.0b013e3181b4704c
   Szapocznik J., 1999, DRUG ABUSE ORIGINS I, P331, DOI [10.1037/10341-014, DOI 10.1037/10341-014]
   TANFER K, 1995, FAM PLANN PERSPECT, V27, P196, DOI 10.2307/2136275
   Teplin LA, 2003, AM J PUBLIC HEALTH, V93, P906, DOI 10.2105/AJPH.93.6.906
   Tinsley BJ, 2004, J FAM PSYCHOL, V18, P208, DOI 10.1037/0893-3200.18.1.208
   Traube DE, 2011, AIDS CARE, V23, P663, DOI 10.1080/09540121.2010.532532
   Valdiserri RO, 2002, AM J PUBLIC HEALTH, V92, P341, DOI 10.2105/AJPH.92.3.341
   Villarruel AM, 2005, J ASSOC NURSE AIDS C, V16, P23, DOI 10.1016/j.jana.2005.01.001
   Villarruel AM, 2006, ARCH PEDIAT ADOL MED, V160, P772, DOI 10.1001/archpedi.160.8.772
   Wagenaar AC, 2009, AM J PUBLIC HEALTH, V99, P1464, DOI 10.2105/AJPH.2007.131326
   Wilson DP, 2008, LANCET, V372, P314, DOI 10.1016/S0140-6736(08)61115-0
   Wu LL, 2001, J MARRIAGE FAM, V63, P682, DOI 10.1111/j.1741-3737.2001.00682.x
   Yon-Leau C, 2010, SEX RES SOC POLICY, V7, P105, DOI 10.1007/s13178-010-0009-y
NR 140
TC 34
Z9 35
U1 0
U2 14
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0003-066X
EI 1935-990X
J9 AM PSYCHOL
JI Am. Psychol.
PD MAY-JUN
PY 2013
VL 68
IS 4
SI SI
BP 286
EP 299
DI 10.1037/a0032917
PG 14
WC Psychology, Multidisciplinary
SC Psychology
GA 146FS
UT WOS:000319075900008
PM 23688095
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Galor, A
   Patel, S
   Small, LR
   Rodriguez, A
   Venincasa, MJ
   Valido, SE
   Feuer, W
   Levitt, RC
   Sarantopoulos, CD
   Felix, ER
AF Galor, Anat
   Patel, Sneh
   Small, Leslie R.
   Rodriguez, Adriana
   Venincasa, Michael J.
   Valido, Stephen E.
   Feuer, William
   Levitt, Roy C.
   Sarantopoulos, Constantine D.
   Felix, Elizabeth R.
TI Pregabalin Failed to Prevent Dry Eye Symptoms after Laser-Assisted in
   Situ Keratomileusis (LASIK) in a Randomized Pilot Study
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE dry eye symptoms; dry eye; ocular pain; pregabalin; refractive surgery;
   LASIK
ID PAIN CLINICAL-TRIALS; POSTOPERATIVE PAIN; NEUROPATHIC PAIN;
   PHOTOREFRACTIVE KERATECTOMY; PSYCHOMETRIC PROPERTIES; OUTCOME MEASURES;
   ORAL GABAPENTIN; RISK-FACTORS; INTENSITY; VALIDITY
AB Purpose: Perioperative pregabalin administration has been found to reduce the risk of persistent pain after a variety of surgical procedures. However, this approach has not been tested in relation to eye surgery. As such, the purpose of this study was to evaluate whether perioperative pregabalin can reduce the presence of dry eye (DE) symptoms, including eye pain, six months after laser-assisted in situ keratomileusis (LASIK). Methods: Prospective, masked, randomized single-center pilot study. Patients were treated with either pregabalin (oral solution of pregabalin 150 mg twice daily, first dose prior to surgery, continued for a total of 28 doses over 14 days) or placebo solution. The primary outcome was dry eye symptoms as measured by the Dry Eye Questionnaire 5 (DEQ-5). Secondary outcome measures included pain-related eye symptoms. Results: In total, 43 individuals were enrolled in the study and randomized to pregabalin (n = 21) or placebo (n = 22). Of those, 42 individuals completed the final visit after six months of follow-up. Some differences were noted between the two groups at baseline, including a higher frequency of females in the pregabalin group. At 6-months, there were no significant differences in the percentage of patients with DE symptoms (DEQ5 >= 6, 57% vs. 33%, p = 0.14), DE symptom severity (DEQ5, 6.6 +/- 5.0 vs. 4.5 +/- 4.2, p = 0.14), ocular pain intensity (numerical rating scale, 1.10 +/- 1.48 vs. 0.38 +/- 0.97, p = 0.08), or neuropathic pain complaints (Neuropathic Pain Symptom Inventory-Eye, 2.81 +/- 4.07 vs. 3.14 +/- 5.85, p = 0.83) between the pregabalin and control groups. Ocular signs were likewise similar between the groups, and of note, did not correlate with DE symptoms. The strongest predictor of DE symptoms six months post-surgery was the presence of DE symptoms prior to surgery. Conclusions: Perioperative pregabalin did not reduce the frequency or severity of DE symptoms at a six month follow-up after LASIK in this small pilot study.
C1 [Galor, Anat; Patel, Sneh] Miami Vet Adm Med Ctr, Dept Ophthalmol, Miami, FL 33136 USA.
   [Galor, Anat; Patel, Sneh; Small, Leslie R.; Rodriguez, Adriana; Venincasa, Michael J.; Valido, Stephen E.; Feuer, William; Levitt, Roy C.; Sarantopoulos, Constantine D.] Univ Miami, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   [Levitt, Roy C.; Sarantopoulos, Constantine D.] Univ Miami, Dept Anesthesiol Perioperat Med & Pain Management, Miami, FL 33136 USA.
   [Levitt, Roy C.] Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, Miami, FL 33136 USA.
   [Levitt, Roy C.] Univ Miami, Miller Sch Med, Dept Human Genet, John T Macdonald Fdn, Miami, FL 33136 USA.
   [Felix, Elizabeth R.] Univ Miami, Dept Phys Med & Rehabil, Miami, FL 33136 USA.
   [Felix, Elizabeth R.] Miami Vet Adm Med Ctr, Res Serv, Miami, FL 33136 USA.
RP Galor, A (corresponding author), Miami Vet Adm Med Ctr, Dept Ophthalmol, Miami, FL 33136 USA.; Galor, A (corresponding author), Univ Miami, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
EM agalor@med.miami.edu
RI Felix, Elizabeth/AAD-6356-2021
OI Venincasa, Michael/0000-0002-7439-4853
FU Department of Veterans Affairs, Veterans Health Administration, Office
   of Research and Development, Clinical Sciences ResearchUS Department of
   Veterans Affairs [EPID-006-15S, R01EY026174]; Miami CTSI Pilot Program
   FY16 [NIH UL1TR000460]; NIH Center Core GrantUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA
   [P30EY014801]; Research to Prevent BlindnessResearch to Prevent
   Blindness (RPB); NIH NINDSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Neurological Disorders & Stroke (NINDS) [R21 NS105880]; NIH
   NIDCRUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Dental &
   Craniofacial Research (NIDCR) [1R01DE022903]
FX This work was supported by the Department of Veterans Affairs, Veterans
   Health Administration, Office of Research and Development, Clinical
   Sciences Research EPID-006-15S (Galor), R01EY026174 (Galor), Miami CTSI
   Pilot Program FY16 (NIH UL1TR000460, Miami CTSI), NIH Center Core Grant,
   P30EY014801 and Research to Prevent Blindness Unrestricted Grant; and
   NIH NINDS R21 NS105880 (Levitt PI/PD); NIDCR 1R01DE022903 (Levitt PI/PD,
   Martin PI). No funders were involved in the design, conduct, or
   interpretation of the study.
CR AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365
   Al-Sabbagh Mohanad, 2015, Dent Clin North Am, V59, P131, DOI 10.1016/j.cden.2014.08.004
   Albietz JM, 2002, J REFRACT SURG, V18, P113, DOI 10.3928/1081-597X-20020301-02
   Bellamy N, 1997, J RHEUMATOL, V24, P799
   Bennett MI, 2004, PALLIATIVE MED, V18, P5, DOI 10.1191/0269216304pm845ra
   Bouhassira D, 2004, PAIN, V108, P248, DOI 10.1016/j.pain.2003.12.024
   Bron AJ, 2007, OCUL SURF, V5, P108
   Brooks P., 2001, Rheumatology (Oxford), V40, P896, DOI 10.1093/rheumatology/40.8.896
   Butrick CW, 2016, FEMALE PELVIC MED RE, V22, P390, DOI 10.1097/SPV.0000000000000298
   Buvanendran A, 2009, CURR OPIN ANESTHESIO, V22, P588, DOI 10.1097/ACO.0b013e328330373a
   Cao Y, 2013, J PAIN, V14, P193, DOI 10.1016/j.jpain.2012.11.005
   Caraceni A, 2002, J PAIN SYMPTOM MANAG, V23, P239, DOI 10.1016/S0885-3924(01)00409-2
   Castarlenas E, 2017, CLIN J PAIN, V33, P376, DOI 10.1097/AJP.0000000000000406
   Celik M, 2015, INT J NEUROSCI, V125, P845, DOI 10.3109/00207454.2014.978976
   Chalmers RL, 2010, CONTACT LENS ANTERIO, V33, P55, DOI 10.1016/j.clae.2009.12.010
   Chao C, 2014, OCUL SURF, V12, P32, DOI 10.1016/j.jtos.2013.09.001
   Chen SR, 2001, ANESTHESIOLOGY, V95, P1473, DOI 10.1097/00000542-200112000-00029
   De Paiva CS, 2006, AM J OPHTHALMOL, V141, P438, DOI 10.1016/j.ajo.2005.10.006
   Denoyer A, 2015, OPHTHALMOLOGY, V122, P669, DOI 10.1016/j.ophtha.2014.10.004
   Deyo RA, 2015, PHYS THER, V95, P159, DOI 10.2522/ptj.2015.95.2.e1
   Donnenfeld ED, 2003, OPHTHALMOLOGY, V110, P1023, DOI 10.1016/S0161-6420(03)00100-3
   Dworkin RH, 2005, PAIN, V113, P9, DOI 10.1016/j.pain.2004.09.012
   Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005
   Eydelman M, 2017, JAMA OPHTHALMOL, V135, P13, DOI 10.1001/jamaophthalmol.2016.4587
   Farhang M, 2019, PAIN, V160, P1541, DOI 10.1097/j.pain.0000000000001552
   Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9
   Galhardoni R., 2011, EUR J PAIN S, V5, P143, DOI [10.1016/S1754-3207(11)70489-8, DOI 10.1016/S1754-3207(11)70489-8]
   Galor A, 2015, EYE, V29, P301, DOI 10.1038/eye.2014.263
   Galor A, 2018, OCUL SURF, V16, P31, DOI 10.1016/j.jtos.2017.10.001
   Gilron I, 2009, LANCET, V374, P1252, DOI 10.1016/S0140-6736(09)61081-3
   Golan O, 2018, CURR OPIN OPHTHALMOL, V29, P307, DOI 10.1097/ICU.0000000000000486
   Hayek SM, 2016, PAIN MED, V17, P1302, DOI 10.1093/pm/pnv058
   Hovanesian JA, 2001, J CATARACT REFR SURG, V27, P577, DOI 10.1016/S0886-3350(00)00835-X
   Jensen MP, 1999, PAIN, V83, P157, DOI 10.1016/S0304-3959(99)00101-3
   JENSEN MP, 1986, PAIN, V27, P117, DOI 10.1016/0304-3959(86)90228-9
   Khan J, 2016, J ORAL MAXIL SURG, V74, P1120, DOI 10.1016/j.joms.2016.01.022
   Kuhnle MD, 2011, J CATARACT REFR SURG, V37, P364, DOI 10.1016/j.jcrs.2010.08.041
   Lavand'homme P, 2015, BONE JOINT J, V97B, P45, DOI 10.1302/0301-620X.97B10.36524
   Levitt AE, 2015, MOL PAIN, V11, DOI 10.1186/s12990-015-0020-7
   Lichtinger A, 2011, J REFRACT SURG, V27, P613, DOI 10.3928/1081597X-20110210-01
   Lovejoy TI, 2012, J PAIN, V13, P1250, DOI 10.1016/j.jpain.2012.09.011
   Martinez JD, 2019, INT OPHTHALMOL, V39, P2313, DOI 10.1007/s10792-018-01068-3
   Matsubayashi Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143350
   McGreevy Kai, 2011, Eur J Pain Suppl, V5, P365
   Niraj G, 2011, BRIT J ANAESTH, V107, P25, DOI 10.1093/bja/aer116
   Nissman SA, 2008, AM J OPHTHALMOL, V145, P623, DOI 10.1016/j.ajo.2007.11.012
   Pakravan M, 2012, EUR J OPHTHALMOL, V22, pS106, DOI 10.5301/ejo.5000143
   Pan HL, 1999, J PHARMACOL EXP THER, V288, P1026
   Safikhani Shima, 2017, J Patient Rep Outcomes, V2, P40, DOI 10.1186/s41687-018-0053-6
   Schiffman RM, 2000, ARCH OPHTHALMOL-CHIC, V118, P615, DOI 10.1001/archopht.118.5.615
   Schmidt PC, 2013, ANESTHESIOLOGY, V119, P1215, DOI 10.1097/ALN.0b013e3182a9a896
   Shoja MR, 2007, EUR J OPHTHALMOL, V17, P1
   Sommer C, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-104
   SPSS, 2013, IBM SPSS STAT WINDOW
   Tomlinson A, 2011, INVEST OPHTH VIS SCI, V52, P2006, DOI 10.1167/iovs.10-6997f
   Tuisku IS, 2007, J REFRACT SURG, V23, P338
   Turk DC, 2003, PAIN, V106, P337, DOI 10.1016/j.pain.2003.08.001
   Vadivelu N, 2014, LOCAL REG ANESTH, V7, P17, DOI 10.2147/LRA.S62160
   Whitlock EL, 2007, J RECONSTR MICROSURG, V23, P263, DOI 10.1055/s-2007-985207
   WOOLF CJ, 1993, ANESTH ANALG, V77, P362, DOI 10.1213/00000539-199377020-00026
   Wright KD, 2001, EUR J PAIN, V5, P279, DOI 10.1053/eujp.2001.0243
   Zinke JL, 2010, CLIN J PAIN, V26, P153, DOI 10.1097/AJP.0b013e3181b99f56
NR 62
TC 7
Z9 7
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD SEP
PY 2019
VL 8
IS 9
AR 1355
DI 10.3390/jcm8091355
PG 14
WC Medicine, General & Internal
SC General & Internal Medicine
GA JC3NA
UT WOS:000489184200089
PM 31480601
OA Green Published, gold
DA 2021-10-30
ER

PT J
AU Bozkurt, NC
   Peixoto, EML
   Froud, T
   Herrada, E
   Corrales, A
   Ricordi, C
   Alejandro, R
AF Bozkurt, Nujen Colak
   Peixoto, Eduardo Moraes Leao
   Froud, Tatiana
   Herrada, Eva
   Corrales, Andrea
   Ricordi, Camillo
   Alejandro, Rodolfo
TI Hepatic Hematoma After Islet Cell Transplantation
SO TRANSPLANTATION
LA English
DT Letter
ID DIABETES-MELLITUS; IMMUNOSUPPRESSION; INJECTION
C1 [Bozkurt, Nujen Colak; Peixoto, Eduardo Moraes Leao; Froud, Tatiana; Herrada, Eva; Corrales, Andrea; Ricordi, Camillo; Alejandro, Rodolfo] Univ Miami, Miller Sch Med, Diabet Res Inst, Miami, FL 33136 USA.
   [Bozkurt, Nujen Colak] Diskapi Yildirim Beyazit Training & Res Hosp, Dept Endocrinol & Metab, Ankara, Turkey.
   [Froud, Tatiana] Jackson Mem Hosp, Dept Radiol, Miami, FL 33136 USA.
   [Ricordi, Camillo] Univ Miami, Miller Sch Med, DeWitt Daughtry Family Dept Surg, Miami, FL 33136 USA.
   [Ricordi, Camillo] Univ Miami, Miller Sch Med, Transplant Inst, Jackson Mem Hosp, Miami, FL 33136 USA.
   [Alejandro, Rodolfo] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA.
RP Alejandro, R (corresponding author), Univ Miami, Miller Sch Med, Dept Med, 1450 Northwest 10th Ave, Miami, FL 33136 USA.
EM ralejand@med.miami.edu
RI Bozkurt, Nujen Colak/B-5085-2012; RICORDI, CAMILLO/AAA-4740-2019
OI Bozkurt, Nujen Colak/0000-0002-2011-5601; Ricordi,
   Camillo/0000-0001-8092-7153
FU NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1 TR000460, 1UL1TR000460] Funding
   Source: Medline; NCRR NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Research Resources (NCRR) [U42 RR016603, M01RR16587, IU42 RR016603, M01
   RR016587] Funding Source: Medline; NIDDK NIH HHSUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)
   [U01 DK070460, U01DK070460, 1R01 DK53347] Funding Source: Medline;
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000460] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH
   RESOURCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Research
   Resources (NCRR) [M01RR016587, U42RR016603] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Diabetes &
   Digestive & Kidney Diseases (NIDDK) [R01DK053347, U01DK070460] Funding
   Source: NIH RePORTER
CR Alejandro R, 2008, TRANSPLANTATION, V86, P1783, DOI 10.1097/TP.0b013e3181913f6a
   Baidal DA, 2003, CELL TRANSPLANT, V12, P809, DOI 10.3727/000000003108747280
   Bucher P, 2004, TRANSPL P, V36, P1119, DOI 10.1016/j.transproceed.2004.04.022
   Froud T, 2005, AM J TRANSPLANT, V5, P2037, DOI 10.1111/j.1600-6143.2005.00957.x
   Froud T, 2004, CELL TRANSPLANT, V13, P55, DOI 10.3727/000000004772664897
   Goss JA, 2003, TRANSPLANTATION, V76, P199, DOI 10.1097/01.TP.0000073976.26604.96
   Hafiz MM, 2005, TRANSPLANTATION, V80, P1718, DOI 10.1097/01.tp.0000187881.97068.77
   Journe S, 2004, SURG ENDOSC, V18, DOI 10.1007/s00464-003-4262-5
   Kawahara T, 2011, AM J TRANSPLANT, V11, P2700, DOI 10.1111/j.1600-6143.2011.03717.x
   Maleux G, 2005, J VASC INTERV RADIOL, V16, P1693, DOI 10.1097/01.RVI.0000182506.88739.39
   Merani S, 2008, BRIT J SURG, V95, P1449, DOI 10.1002/bjs.6391
   Moberg L, 2002, LANCET, V360, P2039, DOI 10.1016/S0140-6736(02)12020-4
   Onaca N, 2009, TRANSPL INT, V22, P663, DOI 10.1111/j.1432-2277.2008.00832.x
   Owen RJT, 2003, RADIOLOGY, V229, P165, DOI 10.1148/radiol.2291021632
   Pileggi A, 2006, ANN NY ACAD SCI, V1079, P383, DOI 10.1196/annals.1375.059
   Radeleff B, 2007, CARDIOVASC INTER RAD, V30, P129, DOI 10.1007/s00270-005-0372-x
   Ryan EA, 2005, DIABETES, V54, P2060, DOI 10.2337/diabetes.54.7.2060
   Schuster R, 2005, J TRAUMA, V59, P1022, DOI 10.1097/01.ta.0000188002.05695.a3
   Villiger P, 2005, AM J TRANSPLANT, V5, P2992, DOI 10.1111/j.1600-6143.2005.01108.x
NR 19
TC 2
Z9 2
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0041-1337
EI 1534-6080
J9 TRANSPLANTATION
JI Transplantation
PD JUN 27
PY 2013
VL 95
IS 12
BP E73
EP E76
DI 10.1097/TP.0b013e31829468e2
PG 5
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 299EF
UT WOS:000330377600002
PM 23774776
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Kim, JJ
   David, JM
   Wilbon, SS
   Santos, JV
   Patel, DM
   Ahmad, A
   Mitrofanova, A
   Liu, XC
   Mallela, SK
   Ducasa, GM
   Ge, MY
   Sloan, AJ
   Al-Ali, H
   Boulina, M
   Mendez, AJ
   Contreras, GN
   Prunotto, M
   Sohail, A
   Fridman, R
   Miner, JH
   Merscher, S
   Fornoni, A
AF Kim, Jin-Ju
   David, Judith M.
   Wilbon, Sydney S.
   Santos, Javier, V
   Patel, Devang M.
   Ahmad, Anis
   Mitrofanova, Alla
   Liu, Xiaochen
   Mallela, Shamroop K.
   Ducasa, Gloria M.
   Ge, Mengyuan
   Sloan, Alexis J.
   Al-Ali, Hassan
   Boulina, Marcia
   Mendez, Armando J.
   Contreras, Gabriel N.
   Prunotto, Marco
   Sohail, Anjum
   Fridman, Rafael
   Miner, Jeffrey H.
   Merscher, Sandra
   Fornoni, Alessia
TI Discoidin domain receptor 1 activation links extracellular matrix to
   podocyte lipotoxicity in Alport syndrome
SO EBIOMEDICINE
LA English
DT Article
DE Alport syndrome; Discoidin domain receptor; Podocyte lipotoxicity;
   Glomerular basement membrane
ID RENAL LIPID-METABOLISM; B SCAVENGER RECEPTOR; FATTY-ACID UPTAKE; IV
   COLLAGEN; GLOMERULAR PROTEIN; NEPHROTIC SYNDROME; MOLECULAR-BASIS;
   EXPRESSION; CD36; MUTATIONS
AB Background: Discoidin domain receptor 1 (DDR1) is a receptor tyrosine kinase that is activated by collagens that is involved in the pathogenesis of fibrotic disorders. Interestingly, de novo production of the collagen type I (Col I) has been observed in Col4a3 knockout mice, a mouse model of Alport Syndrome (AS mice). Deletion of the DDR1 in AS mice was shown to improve survival and renal function. However, the mechanisms driving DDR1-dependent fibrosis remain largely unknown.
   Methods: Podocyte pDDR1 levels, Collagen and cluster of differentiation 36 (CD36) expression was analyzed by Real-time PCR and Western blot. Lipid droplet accumulation and content was determined using Bodipy staining and enzymatic analysis. CD36 and DDR1 interaction was determined by co-immunoprecipitation. Creatinine, BUN, albuminuria, lipid content, and histological and morphological assessment of kidneys harvested from AS mice treated with Ezetimibe and/or Ramipril or vehicle was performed.
   Findings: We demonstrate that Col I-mediated DDR1 activation induces CD36-mediated podocyte lipotoxic injury. We show that Ezetimibe interferes with the CD36/DDR1 interaction in vitro and prevents lipotoxicity in AS mice thus preserving renal function similarly to ramipril.
   Interpretation: Our study suggests that Col I/DDR1-mediated lipotoxicity contributes to renal failure in AS and that targeting this pathway may represent a new therapeutic strategy for patients with AS and with chronic kidney diseases (CKD) associated with Col4 mutations. (C) 2020 Published by Elsevier B.V.
C1 [Kim, Jin-Ju; David, Judith M.; Wilbon, Sydney S.; Santos, Javier, V; Mitrofanova, Alla; Liu, Xiaochen; Mallela, Shamroop K.; Ducasa, Gloria M.; Ge, Mengyuan; Sloan, Alexis J.; Al-Ali, Hassan; Contreras, Gabriel N.; Merscher, Sandra; Fornoni, Alessia] Univ Miami, Drug Discovery Ctr, Dept Med, Katz Family Div Nephrol & Hypertens,Miller Sch Me, 1580 NW 10th Ave, Miami, FL 33136 USA.
   [Patel, Devang M.] Monash Univ, Cent Clin Sch, Dept Diabet, Melbourne, Vic, Australia.
   [Ahmad, Anis] Univ Miami, Dept Radiat Oncol, Miami, FL 33136 USA.
   [Mitrofanova, Alla] Univ Miami, Dept Surg, Miller Sch Med, Miami, FL 33136 USA.
   [Boulina, Marcia; Mendez, Armando J.] Univ Miami, Diabet Res Inst, Miller Sch Med, Miami, FL 33136 USA.
   [Prunotto, Marco] Roche Innovat Ctr, Roche Pharma Res & Early Dev, Basel, Switzerland.
   [Sohail, Anjum; Fridman, Rafael] Wayne State Univ, Dept Pathol, Sch Med, Detroit, MI 48201 USA.
   [Miner, Jeffrey H.] Washington Univ, Dept Med, Div Nephrol, Sch Med, St Louis, MO 63110 USA.
   [Prunotto, Marco] Univ Geneva, Sch Pharmaceut Sci, Geneva, Switzerland.
RP Kim, JJ (corresponding author), Univ Miami, Drug Discovery Ctr, Dept Med, Katz Family Div Nephrol & Hypertens,Miller Sch Me, 1580 NW 10th Ave, Miami, FL 33136 USA.
EM jjkim@med.miami.edu; afornoni@med.miami.edu
FU NIH (Miami Clinical Translational Science Institute, National Center for
   Advancing Translational Sciences) [R01DK117599, R01DK104753,
   R01CA227493, U54DK083912, UM1DK100846, U01DK116101, UL1TR000460];
   National Institute on Minority Health and Health DisparitiesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute on Minority Health & Health
   Disparities (NIMHD); Hoffmann-La RocheHoffmann-La Roche; Alport Syndrome
   Foundation; NIH/NIDDKUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Diabetes & Digestive & Kidney Diseases (NIDDK) [F32DK115109]
FX We thank C. Gu from Massachusetts General Hospital for analyz-ing actin
   remodeling in podocytes. AF is supported by the NIH grants R01DK117599,
   R01DK104753, R01CA227493, U54DK083912, UM1DK100846, U01DK116101 and
   UL1TR000460 (Miami Clinical Translational Science Institute, National
   Center for Advancing Translational Sciences and the National Institute
   on Minority Health and Health Disparities) . AF, SM are supported by
   Hoffmann-La Roche and Alport Syndrome Foundation. JJK is supported by
   postdoctoral fellow-ship of the NIH/NIDDK (F32DK115109) . We give a
   special thanks to the Katz family for continuous support.
CR Abdulhussein R, 2004, J BIOL CHEM, V279, P31462, DOI 10.1074/jbc.M400651200
   Abrahamson DR, 2009, J AM SOC NEPHROL, V20, P1471, DOI 10.1681/ASN.2008101086
   Altmann SW, 2004, SCIENCE, V303, P1201, DOI 10.1126/science.1093131
   Ashworth S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012626
   Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185
   BARKER DF, 1990, SCIENCE, V248, P1224, DOI 10.1126/science.2349482
   Borza CM, 2014, MATRIX BIOL, V34, P185, DOI 10.1016/j.matbio.2013.12.002
   Boute N, 2000, NAT GENET, V24, P349, DOI 10.1038/74166
   Buscher AK, 2012, CLIN NEPHROL, V78, P47, DOI 10.5414/CN107320
   Byron A, 2014, J AM SOC NEPHROL, V25, P953, DOI 10.1681/ASN.2013070795
   Chang TY, 2008, CELL METAB, V7, P469, DOI 10.1016/j.cmet.2008.05.001
   Cheng JL, 2009, HISTOCHEM CELL BIOL, V132, P281, DOI 10.1007/s00418-009-0615-z
   Choudhary V, 2015, J CELL BIOL, V211, P261, DOI 10.1083/jcb.201505067
   Chung JJ, 2015, J CLIN INVEST, V125, P2307, DOI 10.1172/JCI79641
   Curat CA, 2002, J AM SOC NEPHROL, V13, P2648, DOI 10.1097/01.ASN.0000032419.13208.0C
   Czabany T, 2008, J BIOL CHEM, V283, P17065, DOI 10.1074/jbc.M800401200
   Ding W, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.94818
   During A, 2005, J NUTR, V135, P2305, DOI 10.1093/jn/135.10.2305
   ENDEMANN G, 1993, J BIOL CHEM, V268, P11811
   Faul C, 2007, TRENDS CELL BIOL, V17, P428, DOI 10.1016/j.tcb.2007.06.006
   Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI14006
   Fornoni A, 2014, NAT REV NEPHROL, V10, P379, DOI 10.1038/nrneph.2014.87
   Franco C, 2008, CIRC RES, V102, P1202, DOI 10.1161/CIRCRESAHA.107.170662
   Fu HL, 2014, J BIOL CHEM, V289, P9275, DOI 10.1074/jbc.M113.541102
   Gast C, 2016, NEPHROL DIAL TRANSPL, V31, P961, DOI 10.1093/ndt/gfv325
   Gigante M, 2009, NEPHROL DIAL TRANSPL, V24, P1858, DOI 10.1093/ndt/gfn712
   Gribouval O, 2018, KIDNEY INT, V94, P1013, DOI 10.1016/j.kint.2018.07.024
   Groopman E, 2019, NEW ENGL J MED, V380, P2080, DOI 10.1056/NEJMc1903250
   Gross Oliver, 2012, ISRN Pediatr, V2012, P436046, DOI 10.5402/2012/436046
   Gross O, 2012, KIDNEY INT, V81, P494, DOI 10.1038/ki.2011.407
   Gross O, 2010, MATRIX BIOL, V29, P346, DOI 10.1016/j.matbio.2010.03.002
   Grunfeld JP, 2000, RENAL FAILURE, V22, P759, DOI 10.1081/JDI-100101961
   Guerrot D, 2011, AM J PATHOL, V179, P83, DOI 10.1016/j.ajpath.2011.03.023
   Hajri T, 2002, J CLIN INVEST, V109, P1381, DOI [10.1172/JCI200214596, 10.1172/JCI0214596]
   Han JH, 1997, J BIOL CHEM, V272, P21654, DOI 10.1074/jbc.272.34.21654
   Heidet L, 2000, AM J PATHOL, V156, P1901, DOI 10.1016/S0002-9440(10)65063-8
   Heidet L, 2009, J AM SOC NEPHROL, V20, P1210, DOI 10.1681/ASN.2008090984
   Herman-Edelstein M, 2014, J LIPID RES, V55, P561, DOI 10.1194/jlr.P040501
   Hua W, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127507
   HUDSON BG, 1993, J BIOL CHEM, V268, P26033
   Hudson BG, 2003, NEW ENGL J MED, V348, P2543, DOI 10.1056/NEJMra022296
   Hudson BG, 2004, J AM SOC NEPHROL, V15, P2514, DOI 10.1097/01.ASN.0000141462.00630.76
   Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6
   Ioannou GN, 2013, J LIPID RES, V54, P1326, DOI 10.1194/jlr.M034876
   Isoviita PM, 2010, STROKE, V41, P389, DOI 10.1161/STROKEAHA.109.567636
   JAT PS, 1991, P NATL ACAD SCI USA, V88, P5096, DOI 10.1073/pnas.88.12.5096
   Jay AG, 2015, J BIOL CHEM, V290, P4590, DOI 10.1074/jbc.M114.627026
   Kadler KE, 2007, J CELL SCI, V120, P1955, DOI 10.1242/jcs.03453
   Kalluri R, 1997, J CLIN INVEST, V99, P2470, DOI 10.1172/JCI119431
   Kang HM, 2015, NAT MED, V21, P37, DOI 10.1038/nm.3762
   KASHTAN CE, 1992, KIDNEY INT, V42, P115, DOI 10.1038/ki.1992.269
   Kashtan CE, 1997, KIDNEY INT S58 MAR, V58, pS69
   Kerroch M, 2016, SCI REP-UK, V6, DOI 10.1038/srep21262
   Kerroch M, 2012, FASEB J, V26, P4079, DOI 10.1096/fj.11-194902
   Kestila M, 1998, MOL CELL, V1, P575, DOI 10.1016/S1097-2765(00)80057-X
   Khoshnoodi J, 2008, MICROSC RES TECHNIQ, V71, P357, DOI 10.1002/jemt.20564
   Leitinger B, 2014, INT REV CEL MOL BIO, V310, P39, DOI 10.1016/B978-0-12-800180-6.00002-5
   Lennon R, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00160
   Lennon R, 2014, J AM SOC NEPHROL, V25, P939, DOI 10.1681/ASN.2013030233
   Longo I, 2002, KIDNEY INT, V61, P1947, DOI 10.1046/j.1523-1755.2002.00379.x
   Mehlem A, 2013, NAT PROTOC, V8, P1149, DOI 10.1038/nprot.2013.055
   Merscher-Gomez S, 2013, DIABETES, V62, P3817, DOI 10.2337/db13-0399
   Miner JH, 2014, KIDNEY INT, V86, P679, DOI 10.1038/ki.2014.229
   Mitrofanova A, 2018, KIDNEY INT, V94, P1151, DOI 10.1016/j.kint.2018.06.031
   Mizoguchi T, 2004, J LIPID RES, V45, P396, DOI 10.1194/jlr.D300024-JLR200
   Muckova P, 2015, J PROTEOME RES, V14, P5202, DOI 10.1021/acs.jproteome.5b00814
   Mundel P, 1997, EXP CELL RES, V236, P248, DOI 10.1006/excr.1997.3739
   Mundel P, 2010, KIDNEY INT, V77, P571, DOI 10.1038/ki.2009.424
   Murray CJL, 2013, NEW ENGL J MED, V369, P448, DOI 10.1056/NEJMra1201534
   Nagel Mato, 2005, Hum Mutat, V26, P60, DOI 10.1002/humu.9349
   Nassir F, 2007, J BIOL CHEM, V282, P19493, DOI 10.1074/jbc.M703330200
   Orso E, 2006, CYTOM PART A, V69A, P206, DOI 10.1002/cyto.a.20229
   Orth SR, 1998, NEW ENGL J MED, V338, P1202, DOI 10.1056/NEJM199804233381707
   Pedigo CE, 2016, J CLIN INVEST, V126, P3336, DOI 10.1172/JCI85939
   Pozzi A, 2008, DEV BIOL, V316, P288, DOI 10.1016/j.ydbio.2008.01.022
   Qin L, 2016, CLIN EXP PHARMACOL P, V43, P182, DOI 10.1111/1440-1681.12524
   Richter H, 2019, ACS CHEM BIOL, V14, P37, DOI 10.1021/acschembio.8b00866
   Romani P, 2019, NAT CELL BIOL, V21, P338, DOI 10.1038/s41556-018-0270-5
   Saleem MA, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133630
   Shi YY, 2020, AM J PHYSIOL-RENAL, V318, pF589, DOI 10.1152/ajprenal.00392.2019
   Sieber J, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00186
   Stewart CR, 2010, NAT IMMUNOL, V11, P155, DOI 10.1038/ni.1836
   Takahashi N, 2007, KIDNEY INT, V71, P266, DOI 10.1038/sj.ki.5002033
   Uehara Y, 2007, ATHEROSCLEROSIS, V191, P11, DOI 10.1016/j.atherosclerosis.2006.04.018
   van den Berg JG, 2004, KIDNEY INT, V66, P1901, DOI 10.1111/j.1523-1755.2004.00964.x
   Vogel W, 2000, J BIOL CHEM, V275, P5779, DOI 10.1074/jbc.275.8.5779
   Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9
   Wang ZW, 2005, DIABETES, V54, P2328, DOI 10.2337/diabetes.54.8.2328
   WILLIAMSON D, 1961, LANCET, V2, P1321
   Xu S, 2013, BIOCHEMISTRY-US, V52, P7254, DOI 10.1021/bi400914c
   Yoon JS, 2016, J KOREAN MED SCI, V31, P547, DOI 10.3346/jkms.2016.31.4.547
NR 91
TC 3
Z9 3
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2352-3964
J9 EBIOMEDICINE
JI EBioMedicine
PD JAN
PY 2021
VL 63
AR 103162
DI 10.1016/j.ebiom.2020.103162
PG 14
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA US5HB
UT WOS:000697459100006
PM 33340991
OA Green Published, gold
DA 2021-10-30
ER

PT J
AU Ishahak, M
   Hill, J
   Amin, Q
   Wubker, L
   Hernandez, A
   Mitrofanova, A
   Sloan, A
   Fornoni, A
   Agarwal, A
AF Ishahak, Matthew
   Hill, Jordan
   Amin, Quratulain
   Wubker, Laura
   Hernandez, Adiel
   Mitrofanova, Alla
   Sloan, Alexis
   Fornoni, Alessia
   Agarwal, Ashutosh
TI Modular Microphysiological System for Modeling of Biologic Barrier
   Function
SO FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
LA English
DT Article
DE organ-on-chip; lung-on-chip; glomerulus-on-chip; microphysiological
   system; microfluidic
ID SPHINGOSINE-1-PHOSPHATE; PODOCYTE; PDMS; POLY(DIMETHYLSILOXANE);
   2ND-MESSENGER; PLATFORM; INJURY
AB Microphysiological systems, also known as organs-on-chips, are microfluidic devices designed to model human physiology in vitro. Polydimethylsiloxane (PDMS) is the most widely used material for organs-on-chips due to established microfabrication methods, and properties that make it suitable for biological applications such as low cytotoxicity, optical transparency, gas permeability. However, absorption of small molecules and leaching of uncrosslinked oligomers might hinder the adoption of PDMS-based organs-on-chips for drug discovery assays. Here, we have engineered a modular, PDMS-free microphysiological system that is capable of recapitulating biologic barrier functions commonly demonstrated in PDMS-based devices. Our microphysiological system is comprised of a microfluidic chip to house cell cultures and pneumatic microfluidic pumps to drive flow with programmable pressure and shear stress. The modular architecture and programmable pumps enabled us to model multiple in vivo microenvironments. First, we demonstrate the ability to generate cyclic strain on the culture membrane and establish a model of the alveolar air-liquid interface. Next, we utilized three-dimensional finite element analysis modeling to characterize the fluid dynamics within the device and develop a model of the pressure-driven filtration that occurs at the glomerular filtration barrier. Finally, we demonstrate that our model can be used to recapitulate sphingolipid induced kidney injury. Together, our results demonstrate that a multifunctional and modular microphysiological system can be deployed without the use of PDMS. Further, the bio-inert plastic used in our microfluidic device is amenable to various established, high-throughput manufacturing techniques, such as injection molding. As a result, the development plastic organs-on-chips provides an avenue to meet the increasing demand for organ-on-chip technology.
C1 [Ishahak, Matthew; Hill, Jordan; Amin, Quratulain; Wubker, Laura; Hernandez, Adiel; Agarwal, Ashutosh] Univ Miami, Dept Biomed Engn, Coral Gables, FL 33124 USA.
   [Fornoni, Alessia; Agarwal, Ashutosh] Univ Miami, Miller Sch Med, DJTMF Biomed Nanotechnol Inst, Dept Biochem & Mol Biol, Miami, FL 33136 USA.
   [Mitrofanova, Alla; Sloan, Alexis; Fornoni, Alessia] Univ Miami, Miller Sch Med, Peggy & Harold Katz Family Drug Discovery Ctr, Katz Family Div Nephrol & Hypertens,Dept Med, Miami, FL 33136 USA.
RP Agarwal, A (corresponding author), Univ Miami, Dept Biomed Engn, Coral Gables, FL 33124 USA.; Fornoni, A; Agarwal, A (corresponding author), Univ Miami, Miller Sch Med, DJTMF Biomed Nanotechnol Inst, Dept Biochem & Mol Biol, Miami, FL 33136 USA.; Fornoni, A (corresponding author), Univ Miami, Miller Sch Med, Peggy & Harold Katz Family Drug Discovery Ctr, Katz Family Div Nephrol & Hypertens,Dept Med, Miami, FL 33136 USA.
EM AFornoni@med.miami.edu; a.agarwal2@miami.edu
OI Hill, Jordan/0000-0001-7560-005X
FU NIDDKUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Diabetes &
   Digestive & Kidney Diseases (NIDDK) [SCR_014393, UC4DK104209,
   UG3DK122638]; NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01DK117599,
   R01DK104753, R01CA227493, U54KD083912, UM1DK100846, U01DK116101,
   UL1TR000460];  [F31DK118860-01A1]
FX This work was supported by NIDDK-supported Human Islet Research Network
   (HIRN, RRID: SCR_014393; https://hirnetwork.org; UC4DK104209 and
   UG3DK122638 to AA). MI was supported by F31DK118860-01A1. AF was
   supported by the NIH grants R01DK117599, R01DK104753, R01CA227493,
   U54KD083912, UM1DK100846, U01DK116101, and UL1TR000460 (Miami Clinical
   Translational Science Institute).
CR Becker H, 2002, TALANTA, V56, P267, DOI 10.1016/S0039-9140(01)00594-X
   Berthier E, 2012, LAB CHIP, V12, P1224, DOI 10.1039/c2lc20982a
   Bhatia SN, 2014, NAT BIOTECHNOL, V32, P760, DOI 10.1038/nbt.2989
   Brinkkoetter PT, 2013, NAT REV NEPHROL, V9, P328, DOI 10.1038/nrneph.2013.78
   Chung HH, 2018, LAB CHIP, V18, P1671, DOI 10.1039/c7lc01248a
   Dimke H, 2015, CURR OPIN NEPHROL HY, V24, P231, DOI 10.1097/MNH.0000000000000117
   Duffy DC, 1998, ANAL CHEM, V70, P4974, DOI 10.1021/ac980656z
   Guckenberger DJ, 2015, LAB CHIP, V15, P2364, DOI 10.1039/c5lc00234f
   Guenat OT, 2018, BIOMICROFLUIDICS, V12, DOI 10.1063/1.5024895
   Huh D, 2007, P NATL ACAD SCI USA, V104, P18886, DOI 10.1073/pnas.0610868104
   Huh D, 2013, NAT PROTOC, V8, P2135, DOI 10.1038/nprot.2013.137
   Huh D, 2010, SCIENCE, V328, P1662, DOI 10.1126/science.1188302
   Kaipia A, 1996, ENDOCRINOLOGY, V137, P4864, DOI 10.1210/en.137.11.4864
   Lenguito G, 2017, LAB CHIP, V17, P772, DOI 10.1039/c6lc01504b
   Lovric S, 2017, J CLIN INVEST, V127, P912, DOI 10.1172/JCI89626
   Lu WJ, 2005, AM J PHYSIOL-LUNG C, V288, pL52, DOI 10.1152/ajplung.00104.2004
   Maceyka M, 2012, TRENDS CELL BIOL, V22, P50, DOI 10.1016/j.tcb.2011.09.003
   McDonald JC, 2002, ACCOUNTS CHEM RES, V35, P491, DOI 10.1021/ar010110q
   MERSCHER S, 2014, FRONT ENDOCRINOL, V0005
   Musah S, 2017, NAT BIOMED ENG, V1, DOI 10.1038/s41551-017-0069
   OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0
   Saleem MA, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133630
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Schumann J, 2015, TOXICOL PATHOL, V43, P694, DOI 10.1177/0192623314565650
   Sia SK, 2003, ELECTROPHORESIS, V24, P3563, DOI 10.1002/elps.200305584
   Sip CG, 2014, LAB CHIP, V14, P302, DOI 10.1039/c3lc51052b
   Srinivasan B, 2015, JALA-J LAB AUTOM, V20, P107, DOI 10.1177/2211068214561025
   van Meer BJ, 2017, BIOCHEM BIOPH RES CO, V482, P323, DOI 10.1016/j.bbrc.2016.11.062
NR 28
TC 3
Z9 3
U1 3
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-4185
J9 FRONT BIOENG BIOTECH
JI Front. Bioeng. Biotechnol.
PD NOV 12
PY 2020
VL 8
AR 581163
DI 10.3389/fbioe.2020.581163
PG 11
WC Biotechnology & Applied Microbiology; Multidisciplinary Sciences
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA OV4US
UT WOS:000592207600001
PM 33304889
OA Green Published, gold
DA 2021-10-30
ER

PT J
AU Manrique, PD
   Beier, JC
   Johnson, NF
AF Manrique, P. D.
   Beier, J. C.
   Johnson, N. F.
TI Simple visit behavior unifies complex Zika outbreaks
SO HELIYON
LA English
DT Article
DE Infectious disease; Public health; Applied mathematics
ID NETWORKS; MODEL
AB New outbreaks of Zika in the U.S. are imminent. Human nature dictates that many individuals will continue to revisit affected 'Ground Zero' patches, whether out of choice, work or family reasons - yet this feature is missing from traditional epidemiological analyses. Here we show that this missing visit-revisit mechanism is by itself capable of explaining quantitatively the 2016 human Zika outbreaks in all three Ground Zero patches. Our findings reveal counterintuitive ways in which this human flow can be managed to tailor any future outbreak's duration, severity and time-to-peak. Effective public health planning can leverage these results to impact the evolution of future outbreaks via soft control of the overall human flow, as well as to suggest best-practice visitation behavior for local residents.
C1 [Manrique, P. D.; Johnson, N. F.] Univ Miami, Dept Phys, Coral Gables, FL 33126 USA.
   [Beier, J. C.] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Coral Gables, FL 33126 USA.
RP Manrique, PD (corresponding author), Univ Miami, Dept Phys, Coral Gables, FL 33126 USA.
EM p.manriquecharry@umiami.edu
FU CDC grant [1U01CK000510-01]; National Science FoundationNational Science
   Foundation (NSF) [CNS 1522693]; Air Force (AFOSR) [FA9550-16-1-0247];
   Miami Clinical and Translational Science Institute; National Center for
   Advancing Translational SciencesUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS); National Institute
   on Minority Health and Health DisparitiesUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Minority Health & Health Disparities (NIMHD); 
   [UL1TR000460]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1TR000460] Funding Source: NIH
   RePORTER; Division Of Computer and Network SystemsNational Science
   Foundation (NSF)NSF - Directorate for Computer & Information Science &
   Engineering (CISE) [1522693] Funding Source: National Science Foundation
FX This work was supported by CDC grant 1U01CK000510-01: Southeastern
   Regional Center of Excellence in Vector-Borne Diseases: the Gateway
   Program. Neil Johnson was supported by National Science Foundation grant
   CNS 1522693 and Air Force (AFOSR) grant FA9550-16-1-0247. John Beier was
   supported by Grant Number UL1TR000460, Miami Clinical and Translational
   Science Institute, from the National Center for Advancing Translational
   Sciences and the National Institute on Minority Health and Health
   Disparities.
CR Alimi TO, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-2902-7
   Zuzek LGA, 2015, SCI REP-UK, V5, DOI 10.1038/srep12151
   Barrat A., 2008, DYNAMICAL PROCESSES
   Cantrell S., 2009, SPATIAL ECOLOGY
   Florida Department of Health, 2017, MOSQ BORN DIS SURV
   Grubaugh ND, 2017, NATURE, V546, P401, DOI 10.1038/nature22400
   Jo HH, 2014, PHYS REV X, V4, DOI 10.1103/PhysRevX.4.011041
   Karsai M, 2014, SCI REP-UK, V4, DOI 10.1038/srep04001
   Liu S, 2013, PHYS REV E, V87, DOI 10.1103/PhysRevE.87.022122
   Manrique PD, 2016, PHYS REV E, V94, DOI 10.1103/PhysRevE.94.022304
   Manrique PD, 2016, EPL-EUROPHYS LETT, V115, DOI 10.1209/0295-5075/115/18001
   Pastor-Satorras R, 2015, REV MOD PHYS, V87, P925, DOI 10.1103/RevModPhys.87.925
   Perra N., 2011, PLOS ONE
   Watts DJ, 2005, P NATL ACAD SCI USA, V102, P11157, DOI 10.1073/pnas.0501226102
NR 14
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2405-8440
J9 HELIYON
JI Heliyon
PD DEC
PY 2017
VL 3
IS 12
AR e00482
DI 10.1016/j.heliyon.2017.e00482
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GF5SZ
UT WOS:000432029400022
PM 29322105
OA gold, Green Published, Green Submitted
DA 2021-10-30
ER

PT J
AU Jiang, ZJ
   Cinti, C
   Taranta, M
   Mattioli, E
   Schena, E
   Singh, S
   Khurana, R
   Lattanzi, G
   Tsinoremas, NF
   Capobianco, E
AF Jiang, Zhijie
   Cinti, Caterina
   Taranta, Monia
   Mattioli, Elisabetta
   Schena, Elisa
   Singh, Sakshi
   Khurana, Rimpi
   Lattanzi, Giovanna
   Tsinoremas, Nicholas F.
   Capobianco, Enrico
TI Network assessment of demethylation treatment in melanoma: Differential
   transcriptome-methylome and antigen profile signatures
SO PLOS ONE
LA English
DT Article
ID DNA METHYLATION; GENE-EXPRESSION; CANCER; PACKAGE; EPIGENETICS;
   CLEAVAGE; TARGETS; VACCINE; MODULES; CELLS
AB Background
   In melanoma, like in other cancers, both genetic alterations and epigenetic underlie the metastatic process. These effects are usually measured by changes in both methylome and transcriptome profiles, whose cross-correlation remains uncertain. We aimed to assess at systems scale the significance of epigenetic treatment in melanoma cells with different metastatic potential.
   Methods and findings
   Treatment by DAC demethylation with 5-Aza-2'-deoxycytidine of two melanoma cell lines endowed with different metastatic potential, SKMEL-2 and HS294T, was performed and high-throughput coupled RNA-Seq and RRBS-Seq experiments delivered differential profiles (DiP) of both transcriptomes and methylomes. Methylation levels measured at both TSS and gene body were studied to inspect correlated patterns with wide-spectrum transcript abundance levels quantified in both protein coding and non-coding RNA (ncRNA) regions. The DiP were then mapped onto standard bio-annotation sources (pathways, biological processes) and network configurations were obtained. The prioritized associations for target identification purposes were expected to elucidate the reprogramming dynamics induced by the epigenetic therapy. The interactomic connectivity maps of each cell line were formed to support the analysis of epigenetically re-activated genes. i.e. those supposedly silenced by melanoma. In particular, modular protein interaction networks (PIN) were used, evidencing a limited number of shared annotations, with an example being MAPK13 (cascade of cellular responses evoked by extracellular stimuli). This gene is also a targetassociated to the PANDAR ncRNA, therapeutically relevant because of its aberrant expression observed in various cancers. Overall, the non-metastatic SKMEL-2 map reveals post-treatment re-activation of a richer pathway landscape, involving cadherins and integrins as signatures of cell adhesion and proliferation. Relatively more lncRNAs were also annotated, indicating more complex regulation patterns in view of target identification. Finally, the antigen maps matched to DiP display other differential signatures with respect to the metastatic potential of the cell lines. In particular, as demethylated melanomas show connected targets that grow with the increased metastatic potential, also the potential target actionability seems to depend to some degree on the metastatic state. However, caution is required when assessing the direct influence of re-activated genes over the identified targets. In light of the stronger treatment effects observed in non-metastatic conditions, some limitations likely refer to in silico data integration tools and resources available for the analysis of tumor antigens.
   Conclusion
   Demethylation treatment strongly affects early melanoma progression by re-activating many genes. This evidence suggests that the efficacy of this type of therapeutic intervention is potentially high at the pre-metastatic stages. The biomarkers that can be assessed through antigens seem informative depending on the metastatic conditions, and networks help to elucidate the assessment of possible targets actionability.
C1 [Jiang, Zhijie; Khurana, Rimpi; Tsinoremas, Nicholas F.; Capobianco, Enrico] Univ Miami, Ctr Computat Sci, Miami, FL 33146 USA.
   [Cinti, Caterina; Taranta, Monia; Singh, Sakshi] CNR, Inst Clin Physiol, Siena, Italy.
   [Mattioli, Elisabetta; Schena, Elisa; Lattanzi, Giovanna] CNR, Inst Mol Genet, Bologna, Italy.
   [Mattioli, Elisabetta; Lattanzi, Giovanna] IRCCS Rizzoli Orthoped Inst, Bologna, Italy.
   [Schena, Elisa] Alma Mater Studiorum Univ Bologna, S Orsola Malpighi Hosp, Dept Med & Surg Sci, Endocrinol Unit, Bologna, Italy.
   [Tsinoremas, Nicholas F.] Univ Miami, Dept Med, Miami, FL USA.
RP Capobianco, E (corresponding author), Univ Miami, Ctr Computat Sci, Miami, FL 33146 USA.
EM ecapobianco@med.miami.edu
RI Khurana, Rimpi/J-5050-2019; Lattanzi, Giovanna/AAY-3186-2020
OI Lattanzi, Giovanna/0000-0002-7103-8722; Khurana,
   Rimpi/0000-0002-0493-6266; Mattioli, Elisabetta/0000-0002-1395-1927;
   Schena, Elisa/0000-0001-5960-4157
FU Istituto Toscano Tumori, 2013 Oncology Competition; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR002736]
   Funding Source: NIH RePORTER
FX This work was supported by Istituto Toscano Tumori, 2013 Oncology
   Competition,
   http://www.ittumori.it/IttSanitaSrty/jsp/start_ENG.jsp?lang=ENG.The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Allis CD, 2016, NAT REV GENET, V17, P487, DOI 10.1038/nrg.2016.59
   Bartlett TE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084573
   Baylin SB, 2016, COLD SPRING HARB PER, V8
   Beisser D, 2010, BIOINFORMATICS, V26, P1129, DOI 10.1093/bioinformatics/btq089
   Bhartiya D, 2013, DATABASE-OXFORD, DOI 10.1093/database/bat034
   Bianconi D, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122037
   Blank CU, 2016, SCIENCE, V352, P658, DOI 10.1126/science.aaf2834
   Bonitsis N., 2006, Experimental Oncology, V28, P187
   Broers JLV, 2002, EUR J CELL BIOL, V81, P677, DOI 10.1078/0171-9335-00282
   Bruner HC, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a029330
   Capobianco E, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17337-7
   Carreno BM, 2015, SCIENCE, V348, P803, DOI 10.1126/science.aaa3828
   Celia-Terrassa T, 2016, GENE DEV, V30, P892, DOI 10.1101/gad.277681.116
   Columbaro M, 2001, FEBS LETT, V509, P423, DOI 10.1016/S0014-5793(01)03203-3
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067
   FALCIERI E, 1994, HISTOCHEMISTRY, V102, P221
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Hamidi H, 2016, BRIT J CANCER, V115, P1017, DOI 10.1038/bjc.2016.312
   Hoek KS, 2008, CANCER RES, V68, P650, DOI 10.1158/0008-5472.CAN-07-2491
   Imai-Okano K, 2016, CADHERIN SUPERFAMILY, DOI [10.1007/978-4-431-56033-3_11, DOI 10.1007/978-4-431-56033-3_11]
   Janji B, 1999, INT J CANCER, V83, P255, DOI 10.1002/(SICI)1097-0215(19991008)83:2<255::AID-IJC18>3.0.CO;2-X
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Kissick HT, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a033704
   Knijnenburg TA, 2014, NAT METHODS, V11, P689, DOI [10.1038/NMETH.2924, 10.1038/nmeth.2924]
   Konieczkowski DJ, 2014, CANCER DISCOV, V4, P816, DOI 10.1158/2159-8290.CD-13-0424
   Kulis M, 2010, ADV GENET, V70, P27, DOI [10.1016/B978-0-12-380866-0.60002-2, 10.1016/S0065-2660(10)70002-X]
   Li JL, 2013, SCI REP-UK, V3, DOI 10.1038/srep02962
   Liang YJ, 2012, J BIOL CHEM, V287, P33533, DOI 10.1074/jbc.M112.392332
   Ma XK, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1490-6
   Maere S, 2005, BIOINFORMATICS, V21, P3448, DOI 10.1093/bioinformatics/bti551
   Melief CJM, 2017, NATURE, V547, P165, DOI 10.1038/nature23093
   Micevic G, 2017, CLIN EPIGENETICS, V9, DOI 10.1186/s13148-017-0332-8
   Nguyen M, 2017, EPIGENOMES, V1, DOI 10.3390/epigenomes1010003
   Olsen LR, 2017, CANCER IMMUNOL IMMUN, V66, P731, DOI 10.1007/s00262-017-1978-y
   Ott PA, 2017, NATURE, V547, P217, DOI 10.1038/nature22991
   Pitcovski J, 2017, CRIT REV ONCOL HEMAT, V115, P36, DOI 10.1016/j.critrevonc.2017.05.001
   Riker AI, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-13
   Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Rodriguez FJ, 2012, BBA-REV CANCER, V1826, P23, DOI 10.1016/j.bbcan.2012.03.002
   Sahin U, 2017, NATURE, V547, P222, DOI 10.1038/nature23003
   Sarkar D, 2015, EPIGENETICS-US, V10, P103, DOI 10.1080/15592294.2014.1003746
   Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971
   Shrager J, 2014, NAT REV CLIN ONCOL, V11, P109, DOI 10.1038/nrclinonc.2013.244
   Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498
   Sun Q, 2017, ONCOTARGET, V8, P42983, DOI 10.18632/oncotarget.17785
   Tabaries S, 2017, ONCOGENE, V36, P1176, DOI 10.1038/onc.2016.289
   Teschendorff AE, 2018, NAT REV GENET, V19, P129, DOI 10.1038/nrg.2017.86
   Turinsky AL, 2011, NUCLEIC ACIDS RES, V39, pD889, DOI 10.1093/nar/gkq857
   van Roy F, 2014, NAT REV CANCER, V14, P121, DOI 10.1038/nrc3647
   Venza M, 2016, ONCOL REP, V35, P2451, DOI 10.3892/or.2016.4618
   Verfaillie A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7683
   Weisenberger DJ, 2018, ONCOGENE, V37, P566, DOI 10.1038/onc.2017.374
   Wijetunga NA, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1477-3
   Witte T, 2014, GENOME MED, V6, DOI 10.1186/s13073-014-0066-6
   Wolf DM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088309
   Yang XJ, 2014, CANCER CELL, V26, P577, DOI 10.1016/j.ccr.2014.07.028
   Zhang J, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-016-3259-0
   Zhang XY, 2016, ONCOL LETT, V12, P3041, DOI 10.3892/ol.2016.5093
   Zhao H, 2014, GENE, V548, P234, DOI 10.1016/j.gene.2014.07.038
NR 60
TC 1
Z9 1
U1 1
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 28
PY 2018
VL 13
IS 11
AR e0206686
DI 10.1371/journal.pone.0206686
PG 26
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA HC4EO
UT WOS:000451755800026
PM 30485296
OA Green Submitted, Green Published, gold
DA 2021-10-30
ER

PT J
AU Bhatt, N
   Marulanda-Londono, ET
   Atchaneeyasakul, K
   Malik, AM
   Asdaghi, N
   Akram, N
   D'Amour, D
   Hesse, K
   Zhang, T
   Sacco, RL
   Romano, JG
AF Bhatt, Nirav
   Marulanda-Londono, Erika T.
   Atchaneeyasakul, Kunakorn
   Malik, Amer M.
   Asdaghi, Negar
   Akram, Nida
   D'Amour, Daniel
   Hesse, Kathy
   Zhang, Tony
   Sacco, Ralph L.
   Romano, Jose G.
TI Target Stroke: Best Practice Strategies Cut Door to Thrombolysis Time to
   < 30 Minutes in a Large Urban Academic Comprehensive Stroke Center
SO NEUROHOSPITALIST
LA English
DT Article
DE thrombolysis; acute ischemic stroke; door to needle; target stroke
ID TISSUE-PLASMINOGEN ACTIVATOR; TO-NEEDLE TIMES; POOLED ANALYSIS; NINDS;
   ATLANTIS; ECASS
AB The therapeutic window for acute ischemic stroke with intravenous recombinant tissue plasminogen activator (IV rt-PA) is brief and crucial. The American Heart Association/American Stroke Association Target: Stroke Best Practice Strategies (TSBPS) aim to improve intravenous thrombolysis door-to-needle (DTN) time. We assessed the efficacy of implementation of selected TSBPS to reduce DTN time in a large tertiary care hospital. A multidisciplinary DTN committee assessed causes of delayed DTN time and implemented focused TSBPS in our urban academic medical center. We analyzed door-to-CT time, DTN time, and CT to IV rt-PA time in consecutive patients treated with IV rt-PA over 27 months preimplementation and 13 months postimplementation. One hundred forty-eight patients were included in the preimplementation and 126 in the postimplementation group. We found no significant difference between the groups in demographics, comorbidities, anticoagulation status, prethrombolysis hypertension treatment, arrival by EMS, after-hours arrival, or in stroke etiology. After implementation, median DTN time improved from 59 (interquartile range [IQR]: 52-80) to 29 (IQR: 20-41) minutes (P < .001). Door-to-CT time decreased from 17 (14-21) to 16 (12-19) minutes (P = .016), and CT-to-IV rt-PA time improved from 43 (IQR: 31-59) to 13 (IQR: 6-23) minutes (P < .001). Rates of symptomatic intracranial hemorrhage (2.7% vs 3.2%, P = .82) and treatment of stroke mimics (9% vs 13%, P = .31) were similar in both the groups. Individualized hospital gap analysis identifies targeted interventions that lead to rapid and sustained improvement in treatment times.
C1 [Bhatt, Nirav; Marulanda-Londono, Erika T.; Atchaneeyasakul, Kunakorn; Malik, Amer M.; Asdaghi, Negar; Zhang, Tony; Sacco, Ralph L.; Romano, Jose G.] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA.
   [Akram, Nida; D'Amour, Daniel; Hesse, Kathy] Jackson Mem Hosp, Miami, FL 33136 USA.
RP Bhatt, N (corresponding author), Univ Miami, Clin Res Ctr, Dept Neurol, Miller Sch Med, 1120 NW 14th St, Miami, FL 33136 USA.
EM drnrbhatt@gmail.com
RI Sacco, Ralph/Y-9278-2019; Bhatt, Nirav/S-4097-2019
OI Bhatt, Nirav/0000-0001-9838-6180; Zhang, Tony/0000-0002-1723-2129
FU NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1TR002736] Funding Source: NIH RePORTER
CR Fonarow GC, 2014, JAMA-J AM MED ASSOC, V311, P1632, DOI 10.1001/jama.2014.3203
   Fonarow GC, 2011, CIRCULATION, V123, P750, DOI 10.1161/CIRCULATIONAHA.110.974675
   Ford AL, 2012, STROKE, V43, P3395, DOI 10.1161/STROKEAHA.112.670687
   Hacke W, 2004, LANCET, V363, P768
   Lees KR, 2010, LANCET, V375, P1695, DOI 10.1016/S0140-6736(10)60491-6
   Lin CB, 2012, CIRC-CARDIOVASC QUAL, V5, P514, DOI 10.1161/CIRCOUTCOMES.112.965210
   MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401
   Marler JR, 2000, NEUROLOGY, V55, P1649, DOI 10.1212/WNL.55.11.1649
   Saver JL, 2013, JAMA-J AM MED ASSOC, V309, P2480, DOI 10.1001/jama.2013.6959
   Saver JL, 2006, STROKE, V37, P263, DOI 10.1161/01.STR.0000196957.55928.ab
NR 10
TC 0
Z9 0
U1 0
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1941-8744
EI 1941-8752
J9 NEUROHOSPITALIST
JI Neurohospitalist
PD JAN
PY 2019
VL 9
IS 1
BP 22
EP 25
DI 10.1177/1941874418801443
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA HF4NB
UT WOS:000454208800004
PM 30671160
OA Bronze, Green Published
DA 2021-10-30
ER

PT J
AU Al-Tahan, S
   Weiss, L
   Yu, H
   Tang, S
   Saporta, M
   Vihola, A
   Mozaffar, T
   Udd, B
   Kimonis, V
AF Al-Tahan, Sejad
   Weiss, Lan
   Yu, Howard
   Tang, Sha
   Saporta, Mario
   Vihola, Anna
   Mozaffar, Tahseen
   Udd, Bjarne
   Kimonis, Virginia
TI New family with HSPB8-associated autosomal dominant rimmed vacuolar
   myopathy
SO NEUROLOGY-GENETICS
LA English
DT Article
ID HEREDITARY MOTOR NEUROPATHY; PROTEIN AGGREGATION; HSPB8; MUTATIONS; GENE
AB Objective We clinically and molecularly characterize a new family with autosomal dominant rimmed vacuolar myopathy (RVM) caused by mutations in the HSPB8 gene. Methods We performed whole-exome and whole-genome sequencing in the family. Western blot and immunocytochemistry were used to analyze 3 patient fibroblasts, and findings were compared with their age- and sex-matched controls. Results Affected patients have distal and proximal myopathy, with muscle biopsy showing rimmed vacuoles, muscle fiber atrophy, and endomysial fibrosis typical of RVM. Muscle MRI showed severe relatively symmetric multifocal fatty degenerative changes of the lower extremities. We identified a duplication of C at position 515 of the HSPB8 gene (c.515dupC) by whole-genome sequencing, which caused a frameshift with a predicted alternate stop codon p.P173SFS*43 in all affected individuals, resulting in an elongated protein product. Western blot and immunocytochemistry studies revealed reduced expression of heat shock protein beta 8 in patient fibroblasts compared with control fibroblasts, in addition to disrupted autophagy pathology. Conclusions We report a novel family with autosomal dominant RVM caused by the c.515dupC mutation of the HSPB8 gene, causing a translational frameshift that results in an elongated protein. Understanding the mechanism for the RVM pathology caused by mutated chaperone will permit novel targeted strategies to alter the natural history progression. As next-generation sequencing becomes more available, additional myopathic families will be identified with HSPB8 mutations.
C1 [Al-Tahan, Sejad; Weiss, Lan; Yu, Howard] Univ Calif Irvine, Dept Pediat, Div Genet & Genom Med, Irvine, CA 92717 USA.
   [Al-Tahan, Sejad] West Anahe Med Ctr, Opti West, Anaheim, CA USA.
   [Tang, Sha] Ambry Genet, Mission Viejo, CA USA.
   [Saporta, Mario] Univ Miami, Miller Sch Med, Coral Gables, FL 33124 USA.
   [Vihola, Anna; Udd, Bjarne] Univ Helsinki, Med, Folkhalsan Inst Genet, Helsinki, Finland.
   [Vihola, Anna; Udd, Bjarne] Univ Helsinki, Med, Dept Med Genet, Helsinki, Finland.
   [Vihola, Anna; Udd, Bjarne] Tampere Univ, Neuromuscular Res Ctr, Tampere, Finland.
   [Vihola, Anna; Udd, Bjarne] Univ Hosp, Neurol, Tampere, Finland.
   [Mozaffar, Tahseen] Univ Calif Irvine, Dept Neurol, Neuromuscular Program, Orange, CA 92668 USA.
   [Udd, Bjarne] Vasa Cent Hosp, Neurol Dept, Vaasa, Finland.
EM vkimonis@uci.edu
RI Mozaffar, Tahseen/AAE-6971-2020
FU Volo Foundation; Hereditary Inclusion Body Myopathy Foundation; NATIONAL
   CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Advancing Translational Sciences (NCATS)
   [KL2TR002737] Funding Source: NIH RePORTER
FX The authors thank the Volo Foundation and the Hereditary Inclusion Body
   Myopathy Foundation for funding this project.
CR Arndt V, 2010, CURR BIOL, V20, P143, DOI 10.1016/j.cub.2009.11.022
   Bouhy D, 2018, ACTA NEUROPATHOL, V135, P131, DOI 10.1007/s00401-017-1756-0
   Carra S, 2005, HUM MOL GENET, V14, P1659, DOI 10.1093/hmg/ddi174
   Cortese A, 2018, EUR J NEUROL, V25, P154, DOI 10.1111/ene.13478
   Crippa V, 2016, HUM MOL GENET, V25, P3908, DOI 10.1093/hmg/ddw232
   Crippa V, 2010, HUM MOL GENET, V19, P3440, DOI 10.1093/hmg/ddq257
   Echaniz-Laguna A, 2017, ACTA NEUROPATHOL, V134, P163, DOI 10.1007/s00401-017-1724-8
   Echaniz-Laguna A, 2017, HUM MUTAT, V38, P556, DOI 10.1002/humu.23189
   Ehrlicher AJ, 2011, NATURE, V478, P260, DOI 10.1038/nature10430
   Ferrer Isidre, 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000793
   Fujita M, 2012, DEV BIOL, V361, P79, DOI 10.1016/j.ydbio.2011.10.008
   Ghaoui R, 2016, NEUROLOGY, V86, P391, DOI 10.1212/WNL.0000000000002324
   Hagman KDF, 2017, GENET MED, V19, P224, DOI 10.1038/gim.2016.95
   Irobi J, 2004, NAT GENET, V36, P597, DOI 10.1038/ng1328
   Irobi J, 2012, NEUROMUSCULAR DISORD, V22, P699, DOI 10.1016/j.nmd.2012.04.005
   Irobi J, 2010, HUM MOL GENET, V19, P3254, DOI 10.1093/hmg/ddq234
   Kley RA, 2012, BRAIN, V135, P2642, DOI 10.1093/brain/aws200
   Kostera-Pruszczyk A, 2015, J MUSCLE RES CELL M, V36, P423, DOI 10.1007/s10974-015-9431-3
   Kwok AS, 2011, J NEUROCHEM, V119, P1155, DOI 10.1111/j.1471-4159.2011.07521.x
   Llewellyn KJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176919
   Mitra A, 2012, ONCOGENE, V31, P4472, DOI 10.1038/onc.2011.623
   Nakhro K, 2013, NEUROMUSCULAR DISORD, V23, P656, DOI 10.1016/j.nmd.2013.05.009
   Nivon M, 2016, MOL BIOL CELL, V27, P1712, DOI 10.1091/mbc.E15-12-0835
   Rusmini P, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00176
   Sarparanta J, 2012, NAT GENET, V44, P450, DOI 10.1038/ng.1103
   Selcen D, 2009, ANN NEUROL, V65, P83, DOI 10.1002/ana.21553
   Tang BS, 2005, HUM GENET, V116, P222, DOI 10.1007/s00439-004-1218-3
NR 27
TC 10
Z9 10
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 2376-7839
J9 NEUROL-GENET
JI Neurol.-Genet.
PD AUG
PY 2019
VL 5
IS 4
AR e349
DI 10.1212/NXG.0000000000000349
PG 10
WC Genetics & Heredity; Clinical Neurology
SC Genetics & Heredity; Neurosciences & Neurology
GA IV5TW
UT WOS:000484334100014
PM 31403083
OA Green Published, gold
DA 2021-10-30
ER

PT J
AU Elfassy, T
   Grasset, L
   Glymour, MM
   Swift, S
   Zhang, LY
   Howard, G
   Howard, VJ
   Flaherty, M
   Rundek, T
   Osypuk, TL
   Al Hazzouri, AZ
AF Elfassy, Tali
   Grasset, Leslie
   Glymour, M. Maria
   Swift, Samuel
   Zhang, Lanyu
   Howard, George
   Howard, Virginia J.
   Flaherty, Matthew
   Rundek, Tatjana
   Osypuk, Theresa L.
   Al Hazzouri, Adina Zeki
TI Sociodemographic Disparities in Long-Term Mortality Among Stroke
   Survivors in the United States The REGARDS Study
SO STROKE
LA English
DT Article
DE income; mortality; social class; stroke; survivors
ID SOCIOECONOMIC-STATUS; RACIAL-DIFFERENCES; SEX-DIFFERENCES; FOLLOW-UP;
   POPULATION; RISK; CARE; CONTRIBUTORS; REASONS; DISEASE
AB Background and Purpose-It is unclear whether disparities in mortality among stroke survivors exist long term. Therefore, the purpose of the current study is to describe rates of longer term mortality among stroke survivors (ie, beyond 30 days) and to determine whether socioeconomic disparities exist.
   Methods-This analysis included 1329 black and white participants, aged >= 45 years, enrolled between 2003 and 2007 in the REGARDS study (Reasons for Geographic and Racial Differences in Stroke) who suffered a first stroke and survived at least 30 days after the event. Long-term mortality among stroke survivors was defined in person-years as time from 30 days after a first stroke to date of death or censoring. Mortality rate ratios (MRRs) were used to compare rates of poststroke mortality by demographic and socioeconomic characteristics.
   Results-Among adults who survived >= 30 days poststroke, the age-adjusted rate of mortality was 82.3 per 1000 person-years (95% CI, 75.4-89.2). Long-term mortality among stroke survivors was higher in older individuals (MRR for 75+ versus <65, 3.2; 95% CI, 2.6-4.1) and among men than women (MRR, 1.3; 95% CI, 1.1-1.6). It was also higher among those with less educational attainment (MRR for less than high-school versus college graduate, 1.5; 95% CI, 1.1-1.9), lower income (MRR for <$20k versus >50k, 1.4; 95% CI, 1.1-1.9), and lower neighborhood socioeconomic status (SES; MRR for low versus high neighborhood SES, 1.4; 95% CI, 1.1-1.7). There were no differences in age-adjusted rates of long-term poststroke mortality by race, rurality, or US region.
   Conclusions-Rates of long-term mortality among stroke survivors were higher among individuals with lower SES and among those residing in neighborhoods of lower SES. These results emphasize the need for improvements in long-term care poststroke, especially among individuals of lower SES.
C1 [Elfassy, Tali; Grasset, Leslie; Swift, Samuel; Zhang, Lanyu] Univ Miami, Dept Publ Hlth Sci, Div Epidemiol, Miami, FL USA.
   [Rundek, Tatjana] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA.
   [Glymour, M. Maria] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
   [Howard, George] Univ Alabama Birmingham, Sch Publ Hlth, Dept Biostat, Birmingham, AL USA.
   [Howard, Virginia J.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL USA.
   [Flaherty, Matthew] Univ Cincinnati, Dept Neurol & Rehabil Med, Cincinnati, OH 45221 USA.
   [Osypuk, Theresa L.] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN USA.
   [Al Hazzouri, Adina Zeki] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA.
RP Elfassy, T (corresponding author), Univ Miami, Dept Publ Hlth Sci, 1120 NW 14th St,Suite 1021, Miami, FL 33136 USA.
EM t.elfassy@med.miami.edu
RI Grasset, Leslie/T-8148-2019; Howard, Virginia J/AAY-7648-2020; Grasset,
   Leslie/A-3351-2016
OI Howard, Virginia J/0000-0003-4912-9975; Grasset,
   Leslie/0000-0003-2812-0103; Howard, George/0000-0002-3068-5720; rundek,
   tatjana/0000-0002-7115-9815
FU National Institute of Neurological Disorders and Stroke, National
   Institutes of Health (NIH), Department of Health and Human Service [U01
   NS041588]; American Heart AssociationAmerican Heart Association
   [17POST32490000]; University of Miami Clinical and Translational Science
   Institute; National Center for Advancing Translational SciencesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Advancing Translational
   Sciences (NCATS); National Institute on Minority Health and Health
   DisparitiesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Minority
   Health & Health Disparities (NIMHD) [KL2TR002737]; NIH, National
   Institute on AgingUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Aging (NIA) [K01AG047273]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE
   OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH Eunice
   Kennedy Shriver National Institute of Child Health & Human Development
   (NICHD) [P2CHD041023] Funding Source: NIH RePORTER; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [KL2TR002737]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL
   DISORDERS AND STROKEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Neurological Disorders & Stroke (NINDS) [U01NS041588] Funding Source:
   NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Aging (NIA) [K01AG047273] Funding Source: NIH
   RePORTER
FX This research project is supported by a cooperative agreement U01
   NS041588 from the National Institute of Neurological Disorders and
   Stroke, National Institutes of Health (NIH), Department of Health and
   Human Service. Representatives of the funding agency have been involved
   in the review of the manuscript but not directly involved in the
   collection, management, analysis, or interpretation of the data. The
   content is solely the responsibility of the authors and does not
   necessarily represent the official views of the National Institute of
   Neurological Disorders and Stroke or the NIH. Dr Elfassy was supported
   by the American Heart Association postdoctoral fellowship
   (17POST32490000) and is currently supported by the University of Miami
   Clinical and Translational Science Institute, from the National Center
   for Advancing Translational Sciences and the National Institute on
   Minority Health and Health Disparities (KL2TR002737). Dr Zeki Al
   Hazzouri was supported, in part, by a grant from the NIH, National
   Institute on Aging (K01AG047273).
CR Andersen KK, 2009, STROKE, V40, P2068, DOI 10.1161/STROKEAHA.108.540112
   [Anonymous], 1989, STROKE, V20, P1407
   Avendano M, 2006, STROKE, V37, P1368, DOI 10.1161/01.STR.0000221702.75002.66
   Benjamin EJ, 2018, CIRCULATION, V137, pE67, DOI 10.1161/CIR.0000000000000558
   Brown AF, 2013, NEUROLOGY, V80, P520, DOI 10.1212/WNL.0b013e31828154ae
   Cox AM, 2006, LANCET NEUROL, V5, P181, DOI 10.1016/S1474-4422(06)70351-9
   Gargano JW, 2008, STROKE, V39, P24, DOI 10.1161/STROKEAHA.107.493262
   Howard G, 1997, STROKE, V28, P936, DOI 10.1161/01.STR.28.5.936
   Howard G, 1999, AM J MED SCI, V317, P160
   Howard G, 2017, STROKE, V48, P1773, DOI [10.1161/STROKEAHA.117.017089, 10.1161/strokeaha.117.017089]
   Howard G, 2016, STROKE, V47, P1893, DOI 10.1161/STROKEAHA.115.012631
   Howard VJ, 2016, NEUROLOGY, V87, P2340, DOI 10.1212/WNL.0000000000003299
   Howard VJ, 2013, STROKE, V44, pS126, DOI 10.1161/STROKEAHA.111.000691
   Howard VJ, 2011, ANN NEUROL, V69, P619, DOI 10.1002/ana.22385
   Howard VJ, 2005, NEUROEPIDEMIOLOGY, V25, P135, DOI 10.1159/000086678
   Kapral MK, 2002, STROKE, V33, P268, DOI 10.1161/hs0102.101169
   Kleindorfer DO, 2006, ANN NEUROL, V60, P480, DOI 10.1002/ana.20974
   Kleindorfer DO, 2010, STROKE, V41, P1326, DOI 10.1161/STROKEAHA.109.575043
   Koifman J, 2016, J NEUROL SCI, V363, P16, DOI 10.1016/j.jns.2016.02.019
   Labarthe DR, 2016, NEUROEPIDEMIOLOGY, V47, P96, DOI 10.1159/000449102
   Lackland DT, 2014, STROKE, V45, P315, DOI 10.1161/01.str.0000437068.30550.cf
   Li OL, 2016, STROKE, V47, P255, DOI 10.1161/STROKEAHA.115.010485
   Mosca L, 2011, CIRCULATION, V124, P2145, DOI 10.1161/CIRCULATIONAHA.110.968792
   Osypuk TL, 2017, CIRC-CARDIOVASC QUAL, V10, DOI 10.1161/CIRCOUTCOMES.116.002547
   Perkins M, 2013, J GERONTOL B-PSYCHOL, V68, P504, DOI 10.1093/geronb/gbs084
   Rosamond WD, 1999, STROKE, V30, P736, DOI 10.1161/01.STR.30.4.736
   Roux AVD, 2001, ANN EPIDEMIOL, V11, P395, DOI 10.1016/S1047-2797(01)00221-6
   Wang YZ, 2013, STROKE, V44, P380, DOI 10.1161/STROKEAHA.112.680843
   Wolfe CDA, 2005, BMJ-BRIT MED J, V331, P431, DOI 10.1136/bmj.38510.458218.8F
   Xian Y, 2011, ANN INTERN MED, V154, P152, DOI 10.7326/0003-4819-154-3-201102010-00004
NR 30
TC 10
Z9 10
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0039-2499
EI 1524-4628
J9 STROKE
JI Stroke
PD APR
PY 2019
VL 50
IS 4
BP 805
EP 812
DI 10.1161/STROKEAHA.118.023782
PG 8
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA IA1UL
UT WOS:000469347900018
PM 30852967
OA Green Accepted, Bronze
DA 2021-10-30
ER

PT J
AU Moraskie, M
   Roshid, MHO
   O'Connor, G
   Dikici, E
   Zingg, JM
   Deo, S
   Daunert, S
AF Moraskie, MichaelY
   Roshid, Md Harun Or
   O'Connor, Gregory
   Dikici, Emre
   Zingg, Jean-Marc
   Deo, Sapna
   Daunert, Sylvia
TI Microbial whole-cell biosensors: Current applications, challenges, and
   future perspectives
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article
DE Microbial whole-cell biosensor; Living cells; Synthetic biology;
   Reporter protein; Environmental and agricultural monitoring; Biomedical
   diagnostics
ID ACYL-HOMOSERINE LACTONES; BACTERIAL BIOSENSORS; ESCHERICHIA-COLI;
   PSEUDOMONAS-FLUORESCENS; XYLOSE DEHYDROGENASE; HEAVY-METAL;
   ORGANOPHOSPHORUS HYDROLASE; BIOAVAILABLE TOLUENE; BETA-GALACTOSIDASE;
   REPORTER BACTERIA
AB Microbial Whole-Cell Biosensors (MWCBs) have seen rapid development with the arrival of 21st century biological and technological capabilities. They consist of microbial species which produce, or limit the production of, a reporter protein in the presence of a target analyte. The quantifiable signal from the reporter protein can be used to determine the bioavailable levels of the target analyte in a variety of sample types at a significantly lower cost than most widely used and well-established analytical instrumentation. Furthermore, the versatile and robust nature of MWCBs shows great potential for their use in otherwise unavailable settings and environments. While MWCBs have been developed for use in biomedical, environmental, and agricultural monitoring, they still face various challenges before they can transition from the laboratory into industrialized settings like their enzyme-based counterparts. In this comprehensive and critical review, we describe the underlying working principles of MWCBs, highlight developments for their use in a variety of fields, detail challenges and current efforts to address them, and discuss exciting implementations of MWCBs helping redefine what is thought to be possible with this expeditiously evolving technology.
C1 [Moraskie, MichaelY; Roshid, Md Harun Or; O'Connor, Gregory; Dikici, Emre; Zingg, Jean-Marc; Deo, Sapna; Daunert, Sylvia] Univ Miami, Dept Biochem & Mol Biol, Miller Sch Med, Miami, FL 33136 USA.
   [Moraskie, MichaelY; Roshid, Md Harun Or; O'Connor, Gregory; Dikici, Emre; Zingg, Jean-Marc; Deo, Sapna; Daunert, Sylvia] Univ Miami, Dr John T Macdonald Fdn, Biomed Nanotechnol Inst BioNIUM, Miami, FL 33136 USA.
   [Roshid, Md Harun Or; Daunert, Sylvia] Univ Miami, Dept Chem, Miami, FL 33146 USA.
   [Daunert, Sylvia] Univ Miami, Miami Clin & Translat Sci Inst, Miami, FL 33146 USA.
   [Daunert, Sylvia] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL 33146 USA.
RP Daunert, S (corresponding author), Univ Miami, Dept Biochem & Mol Biol, Miller Sch Med, Miami, FL 33136 USA.
EM sdaunert@med.miami.edu
OI Roshid, Md Harun Or/0000-0002-7573-9497; Daunert,
   Sylvia/0000-0003-4760-5528
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01GM127706, 1R01MH110415-01A1,
   R01MH104656, UL1TR002736]; NSFNational Science Foundation (NSF)
   [CBET-1841419, CBET-2041413]; Ministry of Defense Israel [4441018452];
   DoDUnited States Department of Defense [W81XWH2010697]; Firefighters
   Cancer Initiative State of Florida [2382A]; Miller School of Medicine of
   the University of Miami
FX SD and SKD thank the following grants from the NIH R01GM127706 and
   1R01MH110415-01A1; NSF-CBET-1841419 and CBET-2041413; Ministry of
   Defense Israel-4441018452; DoD-W81XWH2010697; and Firefighters Cancer
   Initiative State of Florida appropriation #2382A. SD is also grateful to
   the NIH for grants R01MH104656 and UL1TR002736, and to the Miller School
   of Medicine of the University of Miami for the Lucille P. Markey Chair
   of Biochemistry and Molecular Biology. Figs. 2, 4, 5 and 19 were created
   with BioRender.com.
CR Ahmed EM, 2015, J ADV RES, V6, P105, DOI 10.1016/j.jare.2013.07.006
   Munoz-Martin MA, 2014, SCI TOTAL ENVIRON, V475, P169, DOI 10.1016/j.scitotenv.2013.07.015
   [Anonymous], 2014, ENVIRONMENTAL RISK ASSESSMENT OF SOIL CONTAMINATION, DOI DOI 10.5772/57266
   Applegate BM, 1998, APPL ENVIRON MICROB, V64, P2730
   Arlyapov V, 2012, ENZYME MICROB TECH, V50, P215, DOI 10.1016/j.enzmictec.2012.01.002
   Asraf S.S., 2010, CURRENT RES TECHNOLO, P880
   Baird GS, 2000, P NATL ACAD SCI USA, V97, P11984, DOI 10.1073/pnas.97.22.11984
   Barnard AML, 2007, PHILOS T R SOC B, V362, P1165, DOI 10.1098/rstb.2007.2042
   BASSLER BL, 1994, MOL MICROBIOL, V13, P273, DOI 10.1111/j.1365-2958.1994.tb00422.x
   Belkin S, 2017, NAT BIOTECHNOL, V35, P308, DOI 10.1038/nbt.3791
   Berepiki A, 2020, ACS SYNTH BIOL, V9, P576, DOI 10.1021/acssynbio.9b00448
   Bereza-Malcolm L, 2017, BIOSENS BIOELECTRON, V94, P380, DOI 10.1016/j.bios.2017.03.029
   Bereza-Malcolm LT, 2015, ACS SYNTH BIOL, V4, P535, DOI 10.1021/sb500286r
   BLANCHE F, 1991, J BACTERIOL, V173, P4637, DOI 10.1128/jb.173.15.4637-4645.1991
   Brandt KK, 2002, APPL ENVIRON MICROB, V68, P3502, DOI 10.1128/AEM.68.7.3502-3508.2002
   Bronesky D, 2016, ANNU REV MICROBIOL, V70, P299, DOI 10.1146/annurev-micro-102215-095708
   BULICH AA, 1981, ISA T, V20, P29
   Burmolle M, 2003, MICROBIAL ECOL, V45, P226, DOI 10.1007/s00248-002-2028-6
   Burmolle M, 2005, MICROB ECOL, V50, P221, DOI 10.1007/s00248-004-0113-8
   Burns RC, 2012, NITROGEN FIXATION BA
   Cardemil CV, 2010, DNA CELL BIOL, V29, P519, DOI 10.1089/dna.2009.0984
   Casavant NC, 2003, ENVIRON MICROBIOL, V5, P238, DOI 10.1046/j.1462-2920.2003.00420.x
   Chan MCY, 2006, J BIOL CHEM, V281, P37813, DOI 10.1074/jbc.M606921200
   Chen F, 2020, ACS SENSORS, V5, P2205, DOI 10.1021/acssensors.0c00855
   Chen L, 2017, BIOTECHNOL PROGR, V33, P383, DOI 10.1002/btpr.2416
   Chen PH, 2017, RSC ADV, V7, P29302, DOI 10.1039/c7ra03778c
   Chillappagari S, 2009, J BACTERIOL, V191, P2362, DOI 10.1128/JB.01616-08
   Chong HQ, 2016, ACS SYNTH BIOL, V5, P1290, DOI 10.1021/acssynbio.6b00061
   Date A, 2010, ANAL BIOANAL CHEM, V398, P349, DOI 10.1007/s00216-010-3930-2
   Date A, 2007, ANAL CHEM, V79, P9391, DOI 10.1021/ac701606g
   Daunert S, 2000, CHEM REV, V100, P2705, DOI 10.1021/cr990115p
   de Kievit TR, 2000, INFECT IMMUN, V68, P4839, DOI 10.1128/IAI.68.9.4839-4849.2000
   DeAngelis KM, 2005, APPL ENVIRON MICROB, V71, P8537, DOI 10.1128/AEM.71.12.8537-8547.2005
   DeAngelis KM, 2007, APPL ENVIRON MICROB, V73, P3724, DOI 10.1128/AEM.02187-06
   Deng XM, 2014, J ENVIRON SCI-CHINA, V26, P415, DOI 10.1016/S1001-0742(13)60407-6
   Desnous C, 2010, CHEM REV, V110, P1213, DOI 10.1021/cr0781972
   Dey S, 2020, BIOSENS BIOELECTRON, V170, DOI 10.1016/j.bios.2020.112659
   Dikici E, 2008, ANAL BIOANAL CHEM, V390, P2073, DOI 10.1007/s00216-008-1983-2
   ENGEBRECHT J, 1983, CELL, V32, P773, DOI 10.1016/0092-8674(83)90063-6
   Fajardo-Cavazos P, 2005, ASTROBIOLOGY, V5, P726, DOI 10.1089/ast.2005.5.726
   Fan SQ, 2015, BIORESOURCE TECHNOL, V192, P821, DOI 10.1016/j.biortech.2015.05.090
   Feng RR, 2016, ENZYME MICROB TECH, V84, P78, DOI 10.1016/j.enzmictec.2015.12.002
   Gantner S, 2006, FEMS MICROBIOL ECOL, V56, P188, DOI 10.1111/j.1574-6941.2005.00037.x
   Goedhart J, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1738
   Gu MB, 2004, ADV BIOCHEM ENG BIOT, V87, P269
   Guo M, 2020, NAT BIOTECHNOL, V38, P1337, DOI 10.1038/s41587-020-0560-x
   Hall MP, 2012, ACS CHEM BIOL, V7, P1848, DOI 10.1021/cb3002478
   Hammer BK, 2003, MOL MICROBIOL, V50, P101, DOI 10.1046/j.1365-2958.2003.03688.x
   Han L, 2018, APPL BIOCHEM BIOTECH, V185, P396, DOI 10.1007/s12010-017-2662-6
   Han L, 2017, ACS APPL MATER INTER, V9, P6894, DOI 10.1021/acsami.6b15992
   Hay AG, 2000, APPL ENVIRON MICROB, V66, P4589, DOI 10.1128/AEM.66.10.4589-4594.2000
   Hu YN, 2013, ENVIRON SCI POLLUT R, V20, P6150, DOI 10.1007/s11356-013-1668-z
   Huber RE, 2003, BIOCHEMISTRY-US, V42, P1796, DOI 10.1021/bi0270642
   Ijspeert A., 2016, IEEE AUTO UNDER VEH, P381
   Ishida T, 2002, INT CONGR SER, V1233, P213, DOI 10.1016/S0531-5131(02)00149-8
   Jia XQ, 2018, FEMS MICROBIOL LETT, V365, DOI 10.1093/femsle/fny157
   Jiang B, 2017, CHEMOSPHERE, V184, P384, DOI 10.1016/j.chemosphere.2017.05.159
   Joe MH, 2012, BIOPROC BIOSYST ENG, V35, P265, DOI 10.1007/s00449-011-0610-3
   Kang Y, 2018, APPL MICROBIOL BIOT, V102, P1513, DOI 10.1007/s00253-017-8677-7
   Kelsey JW, 1997, ENVIRON SCI TECHNOL, V31, P214, DOI 10.1021/es960354j
   Kennedy A.C., 2005, ENCY SOILS ENV, P399, DOI 10.1016/B0-12-348530-4/00163-6
   Kim H, 2017, SCI REP-UK, V7, DOI 10.1038/srep40203
   Kleerebezem M, 1997, MOL MICROBIOL, V24, P895, DOI 10.1046/j.1365-2958.1997.4251782.x
   Knecht LD, 2016, EBIOMEDICINE, V9, P161, DOI 10.1016/j.ebiom.2016.05.037
   Knecht LD, 2011, ANAL BIOANAL CHEM, V400, P977, DOI 10.1007/s00216-011-4835-4
   Koch B, 2001, APPL ENVIRON MICROB, V67, P3363, DOI 10.1128/AEM.67.8.3363-3370.2001
   Kragelund L, 1997, APPL ENVIRON MICROB, V63, P4920, DOI 10.1128/AEM.63.12.4920-4928.1997
   Kumari A, 2008, ANAL BIOANAL CHEM, V391, P1619, DOI 10.1007/s00216-008-2002-3
   Kumari A, 2006, ANAL CHEM, V78, P7603, DOI 10.1021/ac061421n
   Kumari W., APPL MICROBIOL BIOT, V105, P2573
   Lang QL, 2014, BIOSENS BIOELECTRON, V51, P158, DOI 10.1016/j.bios.2013.07.021
   Layton AC, 1998, APPL ENVIRON MICROB, V64, P5023
   Lee KY, 2012, PROG POLYM SCI, V37, P106, DOI 10.1016/j.progpolymsci.2011.06.003
   Li L, 2012, BIOSENS BIOELECTRON, V33, P100, DOI 10.1016/j.bios.2011.12.027
   Li P, 2017, ACS APPL MATER INTER, V9, P22321, DOI 10.1021/acsami.7b07166
   Liang B, 2013, BIORESOURCE TECHNOL, V147, P492, DOI 10.1016/j.biortech.2013.08.088
   Liang B, 2012, ANAL CHEM, V84, P275, DOI 10.1021/ac202513u
   Liljeruhm J, 2018, J BIOL ENG, V12, DOI 10.1186/s13036-018-0100-0
   Liu AH, 2016, ENZYME MICROB TECH, V91, P59, DOI 10.1016/j.enzmictec.2016.06.002
   Liu PL, 2012, ENVIRON POLLUT, V164, P66, DOI 10.1016/j.envpol.2012.01.023
   Liu XY, 2017, P NATL ACAD SCI USA, V114, P2200, DOI 10.1073/pnas.1618307114
   Lobsiger N, 2019, ANAL SCI, V35, P839, DOI 10.2116/analsci.19R004
   Lopreside A, 2019, ANAL CHEM, V91, P15284, DOI 10.1021/acs.analchem.9b04444
   Lu MY, 2019, SENSORS-BASEL, V19, DOI 10.3390/s19183882
   Lu Y, 2015, IEEE T NANOBIOSCI, V14, P811, DOI 10.1109/TNB.2015.2478481
   Lubkowicz D, 2018, ACS SYNTH BIOL, V7, P1229, DOI 10.1021/acssynbio.8b00063
   Ma CH, 2019, SENSORS-BASEL, V19, DOI 10.3390/s19245556
   Ma Z, 2011, NUCLEIC ACIDS RES, V39, P9130, DOI 10.1093/nar/gkr625
   Mao N, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao2586
   Martin-Betancor K, 2017, CHEMOSPHERE, V189, P373, DOI 10.1016/j.chemosphere.2017.09.030
   McRae SR, 2005, PROTEIN EXPRES PURIF, V41, P121, DOI 10.1016/j.pep.2004.12.030
   Medina-Rodriguez EM., 2020, AM J PSYCHIAT, V177, P974, DOI DOI 10.1176/appi.ajp.2020.19090960
   Mendes R, 2011, SCIENCE, V332, P1097, DOI 10.1126/science.1203980
   Miller MB, 2001, ANNU REV MICROBIOL, V55, P165, DOI 10.1146/annurev.micro.55.1.165
   Mimee M, 2018, SCIENCE, V360, P915, DOI 10.1126/science.aas9315
   Mirasoli M, 2002, ANAL CHEM, V74, P5948, DOI 10.1021/ac0259008
   Mukherjee S, 2019, NAT REV MICROBIOL, V17, P371, DOI 10.1038/s41579-019-0186-5
   Muras A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66704-4
   MYLONA P, 1995, PLANT CELL, V7, P869, DOI 10.1105/tpc.7.7.869
   Naeem S, 2000, NATURE, V403, P762, DOI 10.1038/35001568
   Niwa K, 2010, PHOTOCHEM PHOTOBIOL, V86, P1046, DOI 10.1111/j.1751-1097.2010.00777.x
   O'Connor G, 2018, J NEUROTRAUM, V35, P2159, DOI 10.1089/neu.2017.5349
   OConnor G., 2015, ADV BIOCH ENG BIOTEC, V154
   Okada M, 2005, NAT CHEM BIOL, V1, P23, DOI 10.1038/nchembio709
   Packer MS, 2015, NAT REV GENET, V16, P379, DOI 10.1038/nrg3927
   Palmer G, 1998, CHEMOSPHERE, V36, P2683, DOI 10.1016/S0045-6535(97)10225-9
   Pandey C.M., 2019, BIOSENSORS FUNDAMENT, Vsecond
   PEARSON JP, 1995, P NATL ACAD SCI USA, V92, P1490, DOI 10.1073/pnas.92.5.1490
   Peca L, 2008, FEMS MICROBIOL LETT, V289, P258, DOI 10.1111/j.1574-6968.2008.01393.x
   Preveral S, 2017, ENVIRON SCI POLLUT R, V24, P25, DOI 10.1007/s11356-015-6000-7
   Ramanathan S, 1997, TRENDS BIOTECHNOL, V15, P500, DOI 10.1016/S0167-7799(97)01120-7
   Ramanathan S, 1998, ANAL CHIM ACTA, V369, P189, DOI 10.1016/S0003-2670(98)00244-X
   Raut N, 2013, ANAL CHEM, V85, P9604, DOI 10.1021/ac401776k
   Raut N, 2012, ANAL BIOANAL CHEM, V402, P3147, DOI 10.1007/s00216-012-5756-6
   Ravikumar S, 2012, PROCESS BIOCHEM, V47, P758, DOI 10.1016/j.procbio.2012.02.007
   Renella G, 2016, CHEM BIOL TECHNOL AG, V3, DOI 10.1186/s40538-016-0059-3
   Reyes S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21145015
   Reyes-Caballero H, 2011, BIOPHYS CHEM, V156, P103, DOI 10.1016/j.bpc.2011.03.010
   Riangrungroj P, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48907-6
   Robertson L.W, PCBS RECENT ADV ENV
   Roca C, 2001, J BIOTECHNOL, V86, P39, DOI 10.1016/S0168-1656(00)00401-6
   Rodriguez EA, 2017, TRENDS BIOCHEM SCI, V42, P111, DOI 10.1016/j.tibs.2016.09.010
   Rodriguez-Mozaz S, 2006, ANAL BIOANAL CHEM, V386, P1025, DOI 10.1007/s00216-006-0574-3
   Rothert A, 2005, ANAL BIOCHEM, V342, P11, DOI 10.1016/j.ab.2004.10.048
   Sakaguchi T, 2003, BIOSENS BIOELECTRON, V19, P115, DOI 10.1016/S0956-5663(03)00170-2
   Sakaguchi T, 2007, BIOSENS BIOELECTRON, V22, P1345, DOI 10.1016/j.bios.2006.06.008
   Sangal A, 2011, SENSOR ACTUAT B-CHEM, V158, P377, DOI 10.1016/j.snb.2011.06.039
   Scott DL, 1997, ANAL CHEM, V69, P16, DOI 10.1021/ac960788x
   Scott RA, 2006, MOL PLANT MICROBE IN, V19, P227, DOI 10.1094/MPMI-19-0227
   Sender R, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002533
   Sharma P, 2013, J BIOSCIENCES, V38, P251, DOI 10.1007/s12038-013-9305-z
   SHAW WV, 1991, ANNU REV BIOPHYS BIO, V20, P363, DOI 10.1146/annurev.biophys.20.1.363
   Shi YJ, 2013, ECOTOX ENVIRON SAFE, V92, P123, DOI 10.1016/j.ecoenv.2013.03.006
   Shing WL, 2013, SENSORS-BASEL, V13, P6394, DOI 10.3390/s130506394
   Si RW, 2016, ANAL CHEM, V88, P11222, DOI 10.1021/acs.analchem.6b03538
   Siegfried K, 2012, ENVIRON SCI TECHNOL, V46, P3281, DOI 10.1021/es203511k
   Singh PK, 2000, NATURE, V407, P762, DOI 10.1038/35037627
   Song JX, 2015, ENZYME MICROB TECH, V70, P72, DOI 10.1016/j.enzmictec.2014.12.002
   Song YZ, 2014, ENVIRON POLLUT, V195, P178, DOI 10.1016/j.envpol.2014.08.024
   Steidle A, 2001, APPL ENVIRON MICROB, V67, P5761, DOI 10.1128/AEM.67.12.5761-5770.2001
   Stiner L, 2002, APPL ENVIRON MICROB, V68, P1962, DOI 10.1128/AEM.68.4.1962-1971.2002
   Stocker J, 2003, ENVIRON SCI TECHNOL, V37, P4743, DOI 10.1021/es034258b
   Struss A, 2010, ANAL CHEM, V82, P4457, DOI 10.1021/ac100231a
   Svitel J, 1998, BIOTECHNOL APPL BIOC, V27, P153
   Tang XJ, 2014, BIOSENS BIOELECTRON, V60, P137, DOI 10.1016/j.bios.2014.04.001
   Tang XJ, 2014, ENZYME MICROB TECH, V55, P107, DOI 10.1016/j.enzmictec.2013.10.006
   Tecon R, 2010, ENVIRON SCI TECHNOL, V44, P1049, DOI 10.1021/es902849w
   Thorne N, 2010, CHEM BIOL, V17, P646, DOI 10.1016/j.chembiol.2010.05.012
   Tripathi A.D., 2019, ROL FUNCT FOOD SEC, DOI [DOI 10.1016/B978-0-12-813148-0.00001-3, 10.1016/B978-0-12-813148-0.00001-3]
   Turner A.P.F., 1987, BIOSENSORS FUNDAMENT
   Turner K, 2007, ANAL CHEM, V79, P5740, DOI 10.1021/ac0705162
   van der Meer JR, 2016, MICROB BIOTECHNOL, V9, P658, DOI 10.1111/1751-7915.12395
   Waidmann Mark S, 2011, Bioeng Bugs, V2, P8, DOI 10.4161/bbug.2.1.13566
   Wan XY, 2019, NAT CHEM BIOL, V15, P540, DOI 10.1038/s41589-019-0244-3
   Wang BJ, 2013, BIOSENS BIOELECTRON, V40, P368, DOI 10.1016/j.bios.2012.08.011
   Wang W, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1601984
   Wei H, 2014, INT J ENVIRON SCI TE, V11, P685, DOI 10.1007/s13762-013-0216-1
   Weitz HJ, 2001, FEMS MICROBIOL LETT, V197, P159, DOI 10.1111/j.1574-6968.2001.tb10598.x
   Whangsuk W, 2016, ANAL BIOCHEM, V493, P11, DOI 10.1016/j.ab.2015.09.022
   Winson MK, 1998, FEMS MICROBIOL LETT, V163, P185, DOI 10.1016/S0378-1097(98)00172-4
   Woo SG, 2020, BIOSENS BIOELECTRON, V168, DOI 10.1016/j.bios.2020.112523
   Wu CH, 2009, BIOTECHNOL PROGR, V25, P898, DOI 10.1002/btpr.203
   Wynn D, 2018, ANALYST, V143, P4774, DOI [10.1039/c8an00878g, 10.1039/C8AN00878G]
   Wynn D, 2017, METHOD ENZYMOL, V589, P51, DOI 10.1016/bs.mie.2017.02.005
   Yagur-Kroll S, 2015, APPL MICROBIOL BIOT, V99, P7177, DOI 10.1007/s00253-015-6607-0
   Yagur-Kroll S, 2014, APPL MICROBIOL BIOT, V98, P885, DOI 10.1007/s00253-013-4888-8
   Yoetz-Kopelman T, 2016, SENSOR ACTUAT B-CHEM, V232, P758, DOI 10.1016/j.snb.2016.03.132
   Yoon Y, 2016, APPL MICROBIOL BIOT, V100, P3713, DOI 10.1007/s00253-016-7338-6
   Zhang B, 2016, ENVIRON TECHNOL INNO, V5, P267, DOI 10.1016/j.eti.2016.05.001
NR 169
TC 0
Z9 0
U1 15
U2 15
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956-5663
EI 1873-4235
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD NOV 1
PY 2021
VL 191
AR 113359
DI 10.1016/j.bios.2021.113359
PG 18
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology - Other Topics
GA UC5XE
UT WOS:000686597800006
PM 34098470
DA 2021-10-30
ER

PT J
AU Bookman, RJ
   Cimino, JJ
   Harle, CA
   Kost, RG
   Mooney, S
   Pfaff, E
   Rojevsky, S
   Tobin, JN
   Wilcox, A
   Tsinoremas, NF
AF Bookman, Richard J.
   Cimino, James J.
   Harle, Christopher A.
   Kost, Rhonda G.
   Mooney, Sean
   Pfaff, Emily
   Rojevsky, Svetlana
   Tobin, Jonathan N.
   Wilcox, Adam
   Tsinoremas, Nick F.
TI Research informatics and the COVID-19 pandemic: Challenges, innovations,
   lessons learned, and recommendations
SO JOURNAL OF CLINICAL AND TRANSLATIONAL SCIENCE
LA English
DT Article
DE CTSA; COVID-19; informatics; N3C; research
AB The recipients of NIH's Clinical and Translational Science Awards (CTSA) have worked for over a decade to build informatics infrastructure in support of clinical and translational research. This infrastructure has proved invaluable for supporting responses to the current COVID-19 pandemic through direct patient care, clinical decision support, training researchers and practitioners, as well as public health surveillance and clinical research to levels that could not have been accomplished without the years of ground-laying work by the CTSAs. In this paper, we provide a perspective on our COVID-19 work and present relevant results of a survey of CTSA sites to broaden our understanding of the key features of their informatics programs, the informatics-related challenges they have experienced under COVID-19, and some of the innovations and solutions they developed in response to the pandemic. Responses demonstrated increased reliance by healthcare providers and researchers on access to electronic health record (EHR) data, both for local needs and for sharing with other institutions and national consortia. The initial work of the CTSAs on data capture, standards, interchange, and sharing policies all contributed to solutions, best illustrated by the creation, in record time, of a national clinical data repository in the National COVID-19 Cohort Collaborative (N3C). The survey data support seven recommendations for areas of informatics and public health investment and further study to support clinical and translational research in the post-COVID-19 era.
C1 [Bookman, Richard J.] Univ Miami, Clin & Translat Sci Inst, Dept Mol & Cell Pharmacol, Miami, FL USA.
   [Cimino, James J.] Univ Alabama Birmingham, Ctr Clin & Translat Sci, Inst Informat, Birmingham, AL USA.
   [Harle, Christopher A.] Univ Florida, Clin & Translat Sci Inst, Dept Hlth Outcomes & Biomed Informat, Gainesville, FL USA.
   [Kost, Rhonda G.] Rockefeller Univ, Ctr Clin & Translat Sci, 1230 York Ave, New York, NY 10021 USA.
   [Mooney, Sean] Univ Washington, Inst Translat Hlth Sci, Seattle, WA 98195 USA.
   [Pfaff, Emily] Univ North Carolina Chapel Hill, Dept Med, North Carolina Translat & Clin Sci Inst, Chapel Hill, NC USA.
   [Rojevsky, Svetlana] Tufts Med Ctr, Clin & Translat Inst, Boston, MA 02111 USA.
   [Tobin, Jonathan N.] Rockefeller Univ, Clin Directors Network, Ctr Clin & Translat Sci, 1230 York Ave, New York, NY 10021 USA.
   [Wilcox, Adam] Univ Washington, Inst Translat Hlth Sci, Dept Biomed Informat & Med Educ, Seattle, WA 98195 USA.
   [Tsinoremas, Nick F.] Univ Miami, Clin & Translat Sci Inst, Dept Biochem & Mol Biol, Miami, FL USA.
RP Tsinoremas, NF (corresponding author), Univ Miami, Miller Sch Med, Miami Inst Data Sci & Comp Hlth Sci Informat & Co, Gables One Tower,1320 S Dixie Highway, Coral Gables, FL 33146 USA.
EM ntsinoremas@med.miami.edu
OI Cimino, James/0000-0003-4101-1622
FU NIH/NCATSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1TR002544, UL1TR002489, UL1TR002736,
   UL1TR001427, U24TR002260, UL1TR001866, UL1TR003096, UL1TR002319]
FX The authors would like to thank the Steering Committee of the CTSAs for
   helpful discussions and guidance. We also extend our thanks to the
   Center for Leading Innovation and Collaboration (CLIC) at the University
   of Rochester Medical Center for providing valuable assistance with the
   survey and the collection of the data. Our special gratitude to Rebecca
   Laird, Laura Hassinger, and Julie Schwan for their administrative and
   logistical support. This work was supported by NIH/NCATS: UL1TR002544
   -Tufts (SR). UL1TR002489 -UNC/CH (EP). UL1TR002736 -UM (RJB and NT).
   UL1TR001427 -UF (CAH). U24TR002260 -Rochester CLIC. UL1TR001866
   -Rockefeller (RGK and JNT). UL1TR003096 -UAB (JC). UL1TR002319 -UW (SM
   and AW).
CR Awaysheh A, 2018, J VET DIAGN INVEST, V30, P17, DOI 10.1177/1040638717738276
   Doerr M, 2017, JMIR MHEALTH UHEALTH, V5, DOI 10.2196/mhealth.6521
   Haendel MA, 2021, J AM MED INFORM ASSN, V28, P427, DOI 10.1093/jamia/ocaa196
   Harris PA, 2019, J BIOMED INFORM, V95, DOI 10.1016/j.jbi.2019.103208
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Lawrence CE, 2020, J CLIN TRANSL SCI, V4, P345, DOI 10.1017/cts.2020.30
   Lin CT, 2020, J AM MED INFORM ASSN, V27, P1955, DOI 10.1093/jamia/ocaa171
   O'Reilly-Shah VN, 2020, ANESTH ANALG, V131, P340, DOI 10.1213/ANE.0000000000004945
   Reeves JJ, 2020, J AM MED INFORM ASSN, V27, P853, DOI 10.1093/jamia/ocaa037
   Schulz S, 2019, FUNDAMENTALS OF CLINICAL DATA SCIENCE, P19, DOI 10.1007/978-3-319-99713-1_3
   Topaloglu U, 2018, JCO CLIN CANCER INFO, V2, DOI 10.1200/CCI.17.00067
   Visweswaran S, 2018, JAMIA OPEN, V1, P147, DOI 10.1093/jamiaopen/ooy033
   Yaraghi N., 2020, US LACKS HLTH INFORM
NR 13
TC 0
Z9 0
U1 0
U2 0
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
EI 2059-8661
J9 J CLIN TRANSL SCI
JI J. Clin. Transl. Sci.
PD MAR 16
PY 2021
VL 5
IS 1
AR e110
DI 10.1017/cts.2021.26
PG 8
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA UE8YS
UT WOS:000688169300002
PM 34192063
OA gold, Green Published
DA 2021-10-30
ER

PT J
AU Medeiros, BC
   Fathi, AT
   DiNardo, CD
   Pollyea, DA
   Chan, SM
   Swords, R
AF Medeiros, B. C.
   Fathi, A. T.
   DiNardo, C. D.
   Pollyea, D. A.
   Chan, S. M.
   Swords, R.
TI Isocitrate dehydrogenase mutations in myeloid malignancies
SO LEUKEMIA
LA English
DT Review
ID IDH2 MUTATIONS; MYELODYSPLASTIC SYNDROMES; PROGNOSTIC-SIGNIFICANCE;
   OLDER PATIENTS; MUTANT IDH2; ONCOMETABOLITE 2-HYDROXYGLUTARATE; SOMATIC
   MUTATIONS; DNMT3A MUTATIONS; DOSE CYTARABINE; ENZYME ISOFORMS
AB Alterations to genes involved in cellular metabolism and epigenetic regulation are implicated in the pathogenesis of myeloid malignancies. Recurring mutations in isocitrate dehydrogenase (IDH) genes are detected in approximately 20% of adult patients with acute myeloid leukemia (AML) and 5% of adults with myelodysplastic syndromes (MDS). IDH proteins are homodimeric enzymes involved in diverse cellular processes, including adaptation to hypoxia, histone demethylation and DNA modification. The IDH2 protein is localized in the mitochondria and is a critical component of the tricarboxylic acid (also called the 'citric acid' or Krebs) cycle. Both IDH2 and IDH1 (localized in the cytoplasm) proteins catalyze the oxidative decarboxylation of isocitrate to alpha-ketoglutarate (alpha-KG). Mutant IDH enzymes have neomorphic activity and catalyze reduction of alpha-KG to the (R) enantiomer of 2-hydroxyglutarate, which is associated with DNA and histone hypermethylation, altered gene expression and blocked differentiation of hematopoietic progenitor cells. The prognostic significance of mutant IDH (mIDH) is controversial but appears to be influenced by co-mutational status and the specific location of the mutation (IDH1-R132, IDH2-R140, IDH2-R172). Treatments specifically or indirectly targeted to mIDH are currently under clinical investigation; these therapies have been generally well tolerated and, when used as single agents, have shown promise for inducing responses in some mIDH patients when used as first-line treatment or in relapsed or refractory AML or MDS. Use of mIDH inhibitors in combination with drugs with non-overlapping mechanisms of action is especially promising, as such regimens may address the clonal heterogeneity and the multifactorial pathogenic processes involved in mIDH myeloid malignancies. Advances in mutational analysis have made testing more rapid and convenient, and less expensive; such testing should become part of routine diagnostic workup and repeated at relapse to identify patients who may benefit from treatments that target mIDH.
C1 [Medeiros, B. C.] Stanford Univ, Sch Med, Stanford Canc Ctr, Div Hematol,Dept Med, 875 Blake Wilbur Dr,MC 5821, Stanford, CA 94305 USA.
   [Fathi, A. T.] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
   [DiNardo, C. D.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA.
   [Pollyea, D. A.] Univ Colorado, Sch Med, Div Hematol, Aurora, CO USA.
   [Chan, S. M.] Princess Margaret Canc Ctr, Toronto, ON, Canada.
   [Swords, R.] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA.
RP Medeiros, BC (corresponding author), Stanford Univ, Sch Med, Stanford Canc Ctr, Div Hematol,Dept Med, 875 Blake Wilbur Dr,MC 5821, Stanford, CA 94305 USA.
EM Bruno.medeiros@stanford.edu
FU Celgene CorporationBristol-Myers SquibbCelgene Corporation; NATIONAL
   CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Advancing Translational Sciences (NCATS)
   [KL2TR000461] Funding Source: NIH RePORTER
FX We received editorial support during manuscript development from Sheila
   Truten and Kelly Dittmore of MC2 Inc., Wynnewood, PA, USA who were
   funded by Celgene Corporation. Celgene did not contribute to content or
   participate in development of this paper. The authors are fully
   responsible for all content and editorial decisions.
CR Abbas S, 2010, BLOOD, V116, P2122, DOI 10.1182/blood-2009-11-250878
   Abdel-Karim I, 2011, INVEST NEW DRUG, V29, P323, DOI 10.1007/s10637-009-9369-7
   Abdel-Wahab O, 2013, BLOOD, V121, P3563, DOI 10.1182/blood-2013-01-451781
   Accari SL, 2015, INT REV CEL MOL BIO, V319, P165, DOI 10.1016/bs.ircmb.2015.07.003
   Albitar M, 2002, BLOOD, V100, P791, DOI 10.1182/blood.V100.3.791
   Aref S, 2015, CL LYMPH MYELOM LEUK, V15, P550, DOI 10.1016/j.clml.2015.05.009
   Balss J, 2012, ACTA NEUROPATHOL, V124, P883, DOI 10.1007/s00401-012-1060-y
   Boissel N, 2011, BLOOD, V117, P3696, DOI 10.1182/blood-2010-11-320937
   Boissel N, 2010, J CLIN ONCOL, V28, P3717, DOI 10.1200/JCO.2010.28.2285
   Boutzen H, 2015, BLOOD, V126, DOI 10.1182/blood.V126.23.2542.2542
   Brunner AM, 2015, BLOOD, V126, P2597
   Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981
   Chan SM, 2015, NAT MED, V21, P178, DOI 10.1038/nm.3788
   Chan SM, 2013, INT J HEMATOL, V98, P648, DOI 10.1007/s12185-013-1407-8
   Chaturvedi A, 2016, LEUKEMIA, V30, P1708, DOI 10.1038/leu.2016.71
   Chaturvedi A, 2013, BLOOD, V122, P2877, DOI 10.1182/blood-2013-03-491571
   Chotirat S, 2015, BLOOD CELL MOL DIS, V54, P286, DOI 10.1016/j.bcmd.2014.11.017
   Chotirat S, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-5
   Chou WC, 2011, LEUKEMIA, V25, P246, DOI 10.1038/leu.2010.267
   Chou WC, 2010, BLOOD, V115, P2749, DOI 10.1182/blood-2009-11-253070
   Chowdhury R, 2011, EMBO REP, V12, P463, DOI 10.1038/embor.2011.43
   Clark O., 2016, CLIN CANCER RES, V22, P1
   Conway O'Brien Emma, 2014, Adv Hematol, V2014, P103175, DOI 10.1155/2014/103175
   Corces-Zimmerman MR, 2014, P NATL ACAD SCI USA, V111, P2548, DOI 10.1073/pnas.1324297111
   Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617
   de Botton S, 2015, HAEMATOLOGICA, V100, P214
   Debarri H, 2015, ONCOTARGET, V6, P42345, DOI 10.18632/oncotarget.5645
   DiNardo CD, 2016, LEUKEMIA, V30, P980, DOI 10.1038/leu.2015.211
   DiNardo CD, 2015, BLOOD, V126, P1156, DOI 10.1182/blood-2015-07-657908
   DiNardo CD, 2015, AM J HEMATOL, V90, P732, DOI 10.1002/ajh.24072
   DiNardo CD, 2014, LEUKEMIA LYMPHOMA, V55, P1925, DOI 10.3109/10428194.2013.855309
   DiNardo CD, 2013, BLOOD, V121, P4917, DOI 10.1182/blood-2013-03-493197
   Dohner H, 2015, NEW ENGL J MED, V373, P1136, DOI 10.1056/NEJMra1406184
   Dombret H, 2015, BLOOD, V126, P291, DOI 10.1182/blood-2015-01-621664
   Emadi A, 2015, AM J HEMATOL, V90, pE77, DOI 10.1002/ajh.23965
   Emadi A, 2014, EXP HEMATOL, V42, P247, DOI 10.1016/j.exphem.2013.12.001
   Estey E, 2015, BLOOD, V125, P2461, DOI 10.1182/blood-2015-01-561373
   Fan B, 2015, HAEMATOLOGICA, V100, P379
   Fan B, 2015, BLOOD, V126, P1310
   Fathi AT, 2015, SEMIN HEMATOL, V52, P165, DOI 10.1053/j.seminhematol.2015.03.002
   Fathi AT, 2012, BLOOD, V120, P4649, DOI 10.1182/blood-2012-06-438267
   Fenaux P, 2009, LEUKEMIA RES, V33, pS7, DOI 10.1016/S0145-2126(09)70227-9
   Feng JH, 2012, AM J BLOOD RES, V2, P254
   Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015
   Gorniak P, 2016, EUR J HAEMATOL, V96, P181, DOI 10.1111/ejh.12566
   Graubert T, 2011, HEMATOL-AM SOC HEMAT, P543, DOI 10.1182/asheducation-2011.1.543
   Green CL, 2011, BLOOD, V118, P409, DOI 10.1182/blood-2010-12-322479
   Heuser M, 2015, EXP HEMATOL, V43, P685, DOI 10.1016/j.exphem.2015.05.005
   Horbinski C, 2010, J MOL DIAGN, V12, P487, DOI 10.2353/jmoldx.2010.090228
   Im AP, 2014, LEUKEMIA, V28, P1774, DOI 10.1038/leu.2014.124
   Janin M, 2014, J CLIN ONCOL, V32, P297, DOI 10.1200/JCO.2013.50.2047
   Jin GL, 2013, CANCER RES, V73, P496, DOI 10.1158/0008-5472.CAN-12-2852
   Jin J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100206
   Kantarjian HM, 2012, J CLIN ONCOL, V30, P2670, DOI 10.1200/JCO.2011.38.9429
   Kernytsky A, 2015, BLOOD, V125, P296, DOI 10.1182/blood-2013-10-533604
   Konopleva M, 2014, BLOOD, V124, DOI 10.1182/blood.V124.21.118.118
   Lasho TL, 2012, BLOOD, V120, P4168, DOI 10.1182/blood-2012-05-429696
   Li L, 2015, J OCEAN WIND ENERGY, V2, P1, DOI DOI 10.1371/J0URNAL.P0NE.0133813
   Lin CC, 2014, AM J HEMATOL, V89, P137, DOI 10.1002/ajh.23596
   Losman JA, 2013, GENE DEV, V27, P836, DOI 10.1101/gad.217406.113
   Losman JA, 2013, SCIENCE, V339, P1621, DOI 10.1126/science.1231677
   Mahdieh N, 2013, IRAN J PEDIATR, V23, P375
   Marcucci G, 2010, J CLIN ONCOL, V28, P2348, DOI 10.1200/JCO.2009.27.3730
   McKerrell T, 2015, CELL REP, V10, P1239, DOI 10.1016/j.celrep.2015.02.005
   Metzeler KH, 2016, BLOOD, V128, P686, DOI 10.1182/blood-2016-01-693879
   Molenaar RJ, 2015, LEUKEMIA, V29, P2134, DOI 10.1038/leu.2015.91
   Molenaar RJ, 2014, BBA-REV CANCER, V1846, P326, DOI 10.1016/j.bbcan.2014.05.004
   Papaemmanuil E, 2016, NEW ENGL J MED, V374, P2209, DOI 10.1056/NEJMoa1516192
   Pardanani A, 2010, LEUKEMIA, V24, P1146, DOI 10.1038/leu.2010.77
   Paschka P, 2010, J CLIN ONCOL, V28, P3636, DOI 10.1200/JCO.2010.28.3762
   Patel JP, 2012, NEW ENGL J MED, V366, P1079, DOI 10.1056/NEJMoa1112304
   Patel KP, 2011, J MOL DIAGN, V13, P678, DOI 10.1016/j.jmoldx.2011.06.004
   Patel KP, 2011, AM J CLIN PATHOL, V135, P35, DOI 10.1309/AJCPD7NR2RMNQDVF
   Patnaik MM, 2012, LEUKEMIA, V26, P101, DOI 10.1038/leu.2011.298
   Platt MY, 2015, J MOL DIAGN, V17, P661, DOI 10.1016/j.jmoldx.2015.06.004
   Pollyea DA, 2016, J CLIN ONCOL S, V34
   Prensner JR, 2011, NAT MED, V17, P291, DOI 10.1038/nm0311-291
   Rampal R, 2014, CELL REP, V9, P1841, DOI 10.1016/j.celrep.2014.11.004
   Ravandi F, 2012, CANCER-AM CANCER SOC, V118, P2665, DOI 10.1002/cncr.26580
   Reitman ZJ, 2010, CANCER CELL, V17, P215, DOI 10.1016/j.ccr.2010.02.024
   Rohle D, 2013, SCIENCE, V340, P626, DOI 10.1126/science.1236062
   Schenk T, 2012, NAT MED, V18, P605, DOI 10.1038/nm.2661
   Schnittger S, 2010, BLOOD, V116, P5486, DOI 10.1182/blood-2010-02-267955
   Shlush LI, 2014, NATURE, V506, P328, DOI 10.1038/nature13038
   Sloan CE, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153016
   Steensma DP, 2015, BLOOD, V126, P9, DOI 10.1182/blood-2015-03-631747
   Stein EM, 2015, BLOOD, V126, DOI 10.1182/blood.V126.23.323.323
   Stein EM, 2016, BLOOD, V127, P71, DOI 10.1182/blood-2015-07-604538
   Stein EM, 2016, CLIN CANCER RES, V22, P16, DOI 10.1158/1078-0432.CCR-15-0362
   Stein EM, 2015, BEST PRACT RES CL HA, V28, P112, DOI 10.1016/j.beha.2015.10.016
   Thol F, 2010, HAEMATOL-HEMATOL J, V95, P1668, DOI 10.3324/haematol.2010.025494
   Thol F, 2010, BLOOD, V116, P614, DOI 10.1182/blood-2010-03-272146
   Vardiman JW, 2009, BLOOD, V114, P937, DOI 10.1182/blood-2009-03-209262
   Wagner K, 2010, J CLIN ONCOL, V28, P2356, DOI 10.1200/JCO.2009.27.6899
   Wang ES, 2015, BLOOD, V126
   Wang F, 2016, J INHERIT METAB DIS, V39, P807, DOI 10.1007/s10545-016-9960-y
   Wang F, 2013, SCIENCE, V340, P622, DOI 10.1126/science.1234769
   Wang JH, 2013, P NATL ACAD SCI USA, V110, P17017, DOI 10.1073/pnas.1315558110
   Ward PS, 2013, J BIOL CHEM, V288, P3804, DOI 10.1074/jbc.M112.435495
   Willander K, 2014, BIOMARK RES, V2, DOI 10.1186/2050-7771-2-18
   Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014
   Yamaguchi S, 2014, EUR J HAEMATOL, V92, P471, DOI 10.1111/ejh.12271
   Yang H, 2012, CLIN CANCER RES, V18, P5562, DOI 10.1158/1078-0432.CCR-12-1773
   Yaqub F, 2015, LANCET ONCOL, V16, pE9, DOI 10.1016/S1470-2045(14)71140-4
NR 104
TC 178
Z9 187
U1 1
U2 28
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0887-6924
EI 1476-5551
J9 LEUKEMIA
JI Leukemia
PD FEB
PY 2017
VL 31
IS 2
BP 272
EP 281
DI 10.1038/leu.2016.275
PG 10
WC Oncology; Hematology
SC Oncology; Hematology
GA EK6UE
UT WOS:000394058800002
PM 27721426
OA Green Published, hybrid
HC Y
HP N
DA 2021-10-30
ER

PT J
AU Tamariz, L
   Medina, H
   Taylor, J
   Carrasquillo, O
   Kobetz, E
   Palacio, A
AF Tamariz, Leonardo
   Medina, Heidy
   Taylor, Janielle
   Carrasquillo, Olveen
   Kobetz, Erin
   Palacio, Ana
TI Are Research Ethics Committees Prepared for Community-Based
   Participatory Research?
SO JOURNAL OF EMPIRICAL RESEARCH ON HUMAN RESEARCH ETHICS
LA English
DT Article
DE community-based participatory research; IRB; REC forms; community
   involvement; community consent; community risk
ID SUGGESTIONS; BOARDS; SITES
AB Community-based participatory research (CBPR) is challenging to research ethics committees (RECs). We reviewed the REC preparedness when reviewing CBPR projects. We searched the MEDLINE database and included qualitative studies of CBPR researchers or REC members about their experiences with RECs. The search yielded 107 studies, of which 10 met our criteria. Barriers were that the community is not prepared to conduct research, the reluctance of RECs to work outside the university, the difficulty RECs have understanding CBPR, and that REC forms evaluate individual rather than community risk. Facilitators were having a CBPR expert as an REC member and educating RECs. Therefore, RECs are not prepared to evaluate CBPR projects leading to unnecessary delays in the approval process.
C1 [Tamariz, Leonardo; Medina, Heidy; Taylor, Janielle; Carrasquillo, Olveen; Kobetz, Erin; Palacio, Ana] Univ Miami, Miami, FL 33136 USA.
   [Tamariz, Leonardo; Palacio, Ana] Vet Affairs Med Ctr, Miami, FL 33125 USA.
RP Tamariz, L (corresponding author), Univ Miami, 1120 NW 14th St,Suite 967, Miami, FL 33136 USA.
EM ltamariz@med.miami.edu
OI Tamariz, Leonardo/0000-0003-1583-3534
FU NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1 TR000460] Funding Source: Medline;
   NCRR NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Research
   Resources (NCRR) [U54 RR026139] Funding Source: Medline; NHLBI NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [R01 HL117191, R01 HL079966] Funding Source: Medline;
   NIMHD NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Minority
   Health & Health Disparities (NIMHD) [U54 MD007587, P60 MD002261, P20
   MD000537] Funding Source: Medline
CR Blunt J, 1998, BMJ-BRIT MED J, V316, P58, DOI 10.1136/bmj.316.7124.58
   Brown P, 2010, ENVIRON HEALTH-GLOB, V9, DOI 10.1186/1476-069X-9-39
   Cann Cristina I, 1984, IRB, V6, P5
   Deeds BG, 2008, J EMPIR RES HUM RES, V3, P77, DOI 10.1525/jer.2008.3.2.77
   Flicker S, 2007, J URBAN HEALTH, V84, P478, DOI 10.1007/s11524-007-9165-7
   Guta A, 2012, J EMPIR RES HUM RES, V7, P17, DOI 10.1525/jer.2012.7.1.17
   Guta A, 2010, J EMPIR RES HUM RES, V5, P35, DOI 10.1525/jer.2010.5.2.35
   Hall DE, 2015, JAMA SURG, V150, P103, DOI 10.1001/jamasurg.2014.956
   Hershey Nathan, 1985, IRB, V7, P7, DOI 10.2307/3564145
   Horowitz CR, 2009, CIRCULATION, V119, P2633, DOI 10.1161/CIRCULATIONAHA.107.729863
   Israel BA, 2010, AM J PUBLIC HEALTH, V100, P2094, DOI 10.2105/AJPH.2009.170506
   Leung MW, 2004, INT J EPIDEMIOL, V33, P499, DOI 10.1093/ije/dyh010
   Malone RE, 2006, AM J PUBLIC HEALTH, V96, P1914, DOI 10.2105/AJPH.2005.082172
   Malpass A, 2009, SOC SCI MED, V68, P154, DOI 10.1016/j.socscimed.2008.09.068
   Marsolo K, 2012, MED CARE, V50, pS77, DOI 10.1097/MLR.0b013e31825a76eb
   Mikesell L, 2013, AM J PUBLIC HEALTH, V103, pE7, DOI 10.2105/AJPH.2013.301605
   Morin SF, 2008, CLIN TRIALS, V5, P147, DOI 10.1177/1740774508090211
   Pearson CR, 2014, J EMPIR RES HUM RES, V9, P46, DOI 10.1525/jer.2014.9.1.46
   Reith C, 2013, NEW ENGL J MED, V369, P1061, DOI 10.1056/NEJMsb1300760
   Savulescu J, 1996, BMJ-BRIT MED J, V313, P1390, DOI 10.1136/bmj.313.7069.1390
   Shore N, 2011, J EMPIR RES HUM RES, V6, P13, DOI 10.1525/jer.2011.6.2.13
   Solomon S, 2011, J EMPIR RES HUM RES, V6, P23, DOI 10.1525/jer.2011.6.2.23
   Studdert DM, 2010, MED J AUSTRALIA, V192, P275, DOI 10.5694/j.1326-5377.2010.tb03508.x
   Xuereb CB, 2012, PATIENT EDUC COUNS, V88, P330, DOI 10.1016/j.pec.2012.05.011
NR 24
TC 9
Z9 9
U1 0
U2 11
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1556-2646
EI 1556-2654
J9 J EMPIR RES HUM RES
JI J. Empir. Res. Hum. Res. Ethics
PD DEC
PY 2015
VL 10
IS 5
BP 488
EP 495
DI 10.1177/1556264615615008
PG 8
WC Ethics; Medical Ethics
SC Social Sciences - Other Topics; Medical Ethics
GA CW3EK
UT WOS:000364874600008
PM 26527370
DA 2021-10-30
ER

PT J
AU Ge, MY
   Molina, J
   Ducasa, GM
   Mallela, SK
   Santos, JV
   Mitrofanova, A
   Kim, JJ
   Liu, XC
   Sloan, A
   Mendez, AJ
   Banerjee, S
   Liu, SY
   Szeto, HH
   Shin, MK
   Hoek, M
   Kopp, JB
   Fontanesi, F
   Merscher, S
   Fornoni, A
AF Ge, Mengyuan
   Molina, Judith
   Ducasa, G. Michelle
   Mallela, Shamroop K.
   Santos, Javier Varona
   Mitrofanova, Alla
   Kim, Jin-Ju
   Liu, Xiaochen
   Sloan, Alexis
   Mendez, Armando J.
   Banerjee, Santanu
   Liu, Shaoyi
   Szeto, Hazel H.
   Shin, Myung K.
   Hoek, Maarten
   Kopp, Jeffrey B.
   Fontanesi, Flavia
   Merscher, Sandra
   Fornoni, Alessia
TI APOL1 risk variants affect podocyte lipid homeostasis and energy
   production in focal segmental glomerulosclerosis
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID KIDNEY-DISEASE; AFRICAN-AMERICAN; APOLIPOPROTEIN-L; MITOCHONDRIAL
   FISSION; BINDING PROTEIN; NEPHROPATHY; ASSOCIATION; CALCINEURIN;
   ACTIVATION; EXPRESSION
AB Lipotoxicity was recently reported in several forms of kidney disease, including focal segmental glomerulosclerosis (FSGS). Susceptibility to FSGS in African Americans is associated with the presence of genetic variants of the Apolipoprotein L1 gene (APOL1) named G1 and G2. If and how endogenous APOL1 may alter mitochondrial function by the modifying cellular lipid metabolism is unknown. Using transgenic mice expressing the APOL1 variants (G0, G1 or G2) under endogenous promoter, we show that APOL1 risk variant expression in transgenic mice does not impair kidney function at baseline. However, APOL1 G1 expression worsens proteinuria and kidney function in mice characterized by the podocyte inducible expression of nuclear factor of activated T-cells (NFAT), which we have found to cause FSGS. APOL1 G1 expression in this FSGS-model also results in increased triglyceride and cholesterol ester contents in kidney cortices, where lipid accumulation correlated with loss of renal function. In vitro, we show that the expression of endogenous APOL1 G1/G2 in human urinary podocytes is associated with increased cellular triglyceride content and is accompanied by mitochondrial dysfunction in the presence of compensatory oxidative phosphorylation (OXPHOS) complexes elevation. Our findings indicate that APOL1 risk variant expression increases the susceptibility to lipid-dependent podocyte injury, ultimately leading to mitochondrial dysfunction.
C1 [Ge, Mengyuan; Molina, Judith; Ducasa, G. Michelle; Mallela, Shamroop K.; Santos, Javier Varona; Mitrofanova, Alla; Kim, Jin-Ju; Liu, Xiaochen; Sloan, Alexis; Merscher, Sandra; Fornoni, Alessia] Univ Miami, Dept Med, Katz Family Div Nephrol & Hypertens, Miller Sch Med, Miami, FL 33136 USA.
   [Ge, Mengyuan; Molina, Judith; Ducasa, G. Michelle; Mallela, Shamroop K.; Santos, Javier Varona; Mitrofanova, Alla; Kim, Jin-Ju; Liu, Xiaochen; Sloan, Alexis; Merscher, Sandra; Fornoni, Alessia] Univ Miami, Peggy & Harold Katz Family Drug Discovery Ctr, Miller Sch Med, Miami, FL 33136 USA.
   [Mitrofanova, Alla; Banerjee, Santanu] Univ Miami, Dept Surg, Miller Sch Med, Miami, FL 33136 USA.
   [Mendez, Armando J.] Univ Miami, Diabet Res Inst, Miller Sch Med, Miami, FL 33136 USA.
   [Liu, Shaoyi; Szeto, Hazel H.] Alexandria Launch Labs, Social Profit Network Res Lab, New York, NY 10016 USA.
   [Shin, Myung K.; Hoek, Maarten] Merck & Co Inc, Kenilworth, NJ 07033 USA.
   [Kopp, Jeffrey B.] NIDDK, Kidney Dis Sect, NIH, Bethesda, MD 20892 USA.
   [Fontanesi, Flavia] Univ Miami, Dept Biochem & Mol Biol, Miller Sch Med, Miami, FL 33136 USA.
RP Fornoni, A (corresponding author), Univ Miami, Katz Family Div Nephrol & Hypertens, 1580 NW 10th Ave, Miami, FL 33136 USA.; Fornoni, A (corresponding author), Univ Miami, Peggy & Harold Katz Family Drug Discovery Ctr, 1580 NW 10th Ave, Miami, FL 33136 USA.
EM afornoni@med.miami.edu
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01DK117599,
   R01DK104753, R01CA227493]; Miami Clinical Translational Science
   Institute [U54DK083912, UM1DK100846, U01DK116101, UL1TR000460];
   Department of Defense (DoD) Discovery Award [PR180598]; American Heart
   AssociationAmerican Heart Association [18PRE34030042]; Katz family;
   vision core grant [EY14801]
FX A.F. and S.M. are supported by National Institutes of Health grants
   R01DK117599, R01DK104753 and R01CA227493. A.F. is also supported by
   Miami Clinical Translational Science Institute (U54DK083912,
   UM1DK100846, U01DK116101 and UL1TR000460). F.F. is supported by
   Department of Defense (DoD) Discovery Award (PR180598). M.G. is
   supported by a predoctoral fellowship of the American Heart Association
   (18PRE34030042). We would like to thank the Katz family for supporting
   this study, and the Ophthalmology mass spectrometry facility, vision
   core grant EY14801 and Miami Integrative Metabolomics Research Center
   (MIMRC) for mass spectrometry analysis.
CR Aghajan M, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.126124
   Barrientos A., 2009, CURR PROTOC HUM GENE
   Beckerman P, 2017, NAT MED, V23, P429, DOI 10.1038/nm.4287
   Blazer A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182483
   Bruggeman LA, 2016, J AM SOC NEPHROL, V27, P3600, DOI 10.1681/ASN.2015111220
   Campbell KN, 2018, AM J NEPHROL, V47, P14, DOI 10.1159/000481634
   Chen TK, 2017, ARTERIOSCL THROM VAS, V37, P1765, DOI [10.1161/ATVBAHA.117.309384, 10.1161/atvbaha.117.309384]
   Chun J, 2019, P NATL ACAD SCI USA, V116, P3712, DOI 10.1073/pnas.1820414116
   Cooper A, 2017, ELIFE, V6, DOI [10.7554/elife.25461, 10.7554/eLife.25461]
   Cribbs JT, 2007, EMBO REP, V8, P939, DOI 10.1038/sj.embor.7401062
   D'Agati VD, 2011, NEW ENGL J MED, V365, P2398, DOI 10.1056/NEJMra1106556
   Ducasa GM, 2019, J CLIN INVEST, V129, P3387, DOI 10.1172/JCI125316
   Duchateau PN, 1997, J BIOL CHEM, V272, P25576, DOI 10.1074/jbc.272.41.25576
   Dummer PD, 2015, SEMIN NEPHROL, V35, P222, DOI 10.1016/j.semnephrol.2015.04.008
   Freedman BI, 2018, AM J KIDNEY DIS, V72, pS8, DOI 10.1053/j.ajkd.2018.06.020
   Freedman BI, 2012, KIDNEY INT, V82, P805, DOI 10.1038/ki.2012.217
   Genovese G, 2010, SCIENCE, V329, P841, DOI 10.1126/science.1193032
   Granado D, 2017, J AM SOC NEPHROL, V28, P3226, DOI 10.1681/ASN.2016111220
   Horrevoets AJG, 1999, BLOOD, V93, P3418, DOI 10.1182/blood.V93.10.3418.410k23_3418_3431
   Imasawa T, 2017, FASEB J, V31, P294, DOI 10.1096/fj.201600293R
   Iyer SS, 2013, IMMUNITY, V39, P311, DOI 10.1016/j.immuni.2013.08.001
   Jin J, 2012, CELL, V151, P384, DOI 10.1016/j.cell.2012.08.037
   Kamoto K, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007603
   Kopp JB, 2011, J AM SOC NEPHROL, V22, P2129, DOI 10.1681/ASN.2011040388
   Kumar V, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39376-y
   Lan XQ, 2014, AM J PHYSIOL-RENAL, V307, pF326, DOI 10.1152/ajprenal.00647.2013
   Limou S, 2014, ADV CHRONIC KIDNEY D, V21, P426, DOI 10.1053/j.ackd.2014.06.005
   Lugli EB, 2004, MOL BIOCHEM PARASIT, V138, P9, DOI 10.1016/j.molbiopara.2004.07.004
   Ma LJ, 2020, KIDNEY INT REP, V5, P891, DOI 10.1016/j.ekir.2020.03.020
   Ma LJ, 2017, J AM SOC NEPHROL, V28, P1093, DOI 10.1681/ASN.2016050567
   Madhavan SM, 2011, J AM SOC NEPHROL, V22, P2119, DOI 10.1681/ASN.2011010069
   Meyrier A, 2005, EXPERT OPIN PHARMACO, V6, P1539, DOI 10.1517/14656566.6.9.1539
   Mitrofanova A, 2018, KIDNEY INT, V94, P1151, DOI 10.1016/j.kint.2018.06.031
   Mizoguchi T, 2004, J LIPID RES, V45, P396, DOI 10.1194/jlr.D300024-JLR200
   Monajemi H, 2002, GENOMICS, V79, P539, DOI 10.1006/geno.2002.6729
   Ng DK, 2017, NEPHROL DIAL TRANSPL, V32, P983, DOI 10.1093/ndt/gfw061
   Nichols B, 2015, KIDNEY INT, V87, P332, DOI 10.1038/ki.2014.270
   Panday N, 2006, BIOORG MED CHEM LETT, V16, P5231, DOI 10.1016/j.bmcl.2006.06.081
   Paradies G, 2014, BBA-BIOENERGETICS, V1837, P408, DOI 10.1016/j.bbabio.2013.10.006
   Parsa A, 2013, NEW ENGL J MED, V369, P2183, DOI 10.1056/NEJMoa1310345
   Pedigo CE, 2016, J CLIN INVEST, V126, P3336, DOI 10.1172/JCI85939
   Rao A, 2009, NAT IMMUNOL, V10, P3, DOI 10.1038/ni0109-3
   Ryu JH, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211559
   Sakairi T, 2010, AM J PHYSIOL-RENAL, V298, pF557, DOI 10.1152/ajprenal.00509.2009
   Schlondorff J, 2009, AM J PHYSIOL-CELL PH, V296, pC558, DOI 10.1152/ajpcell.00077.2008
   Shah SS, 2019, J AM SOC NEPHROL, V30, P2355, DOI 10.1681/ASN.2019020114
   Shankland SJ, 2007, KIDNEY INT, V72, P26, DOI 10.1038/sj.ki.5002291
   Shutt TE, 2013, BBA-MOL CELL RES, V1833, P417, DOI 10.1016/j.bbamcr.2012.05.024
   Smith EE, 2009, GENOME RES, V19, P850, DOI 10.1101/gr.085647.108
   Thomson R, 2014, P NATL ACAD SCI USA, V111, pE2130, DOI 10.1073/pnas.1400699111
   Uzureau S, 2020, CELL REP, V30, P3821, DOI 10.1016/j.celrep.2020.02.064
   Vanwalleghem G, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9078
   Vincent AE, 2016, SCI REP-UK, V6, DOI 10.1038/srep30610
   Wan GH, 2008, J BIOL CHEM, V283, P21540, DOI 10.1074/jbc.M800214200
   Wang YQ, 2010, J AM SOC NEPHROL, V21, P1657, DOI 10.1681/ASN.2009121253
   Youle RJ, 2012, SCIENCE, V337, P1062, DOI 10.1126/science.1219855
   Zhaorigetu S, 2008, AUTOPHAGY, V4, P1079, DOI 10.4161/auto.7066
NR 57
TC 2
Z9 2
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD FEB 1
PY 2021
VL 30
IS 3-4
BP 182
EP 197
DI 10.1093/hmg/ddab022
PG 16
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA SI3TL
UT WOS:000654750200005
PM 33517446
DA 2021-10-30
ER

PT J
AU Elfassy, T
   Al Hazzouri, AZ
   Cai, JW
   Baldoni, PL
   Llabre, MM
   Rundek, T
   Raij, L
   Lash, JP
   Talavera, GA
   Wassertheil-Smoller, S
   Daviglus, M
   Booth, JN
   Castaneda, SF
   Garcia, M
   Schneiderman, N
AF Elfassy, Tali
   Al Hazzouri, Adina Zeki
   Cai, Jianwen
   Baldoni, Pedro L.
   Llabre, Maria M.
   Rundek, Tatjana
   Raij, Leopoldo
   Lash, James P.
   Talavera, Gregory A.
   Wassertheil-Smoller, Sylvia
   Daviglus, Martha
   Booth, John N., III
   Castaneda, Sheila F.
   Garcia, Melawhy
   Schneiderman, Neil
TI Incidence of Hypertension Among US Hispanics/Latinos: The Hispanic
   Community Health Study/Study of Latinos, 2008 to 2017
SO JOURNAL OF THE AMERICAN HEART ASSOCIATION
LA English
DT Article
DE blood pressure; Hispanics; Latinos; hypertension
ID ASSOCIATION TASK-FORCE; HIGH BLOOD-PRESSURE; CARDIOVASCULAR-DISEASE;
   SALT SENSITIVITY; RISK-FACTORS; SOCIOECONOMIC-STATUS; AMERICAN-COLLEGE;
   UNITED-STATES; PREVALENCE; PREVENTION
AB BACKGROUND: Among US Hispanics/Latinos, the largest ethnic minority population in the United States, hypertension incidence has not been thoroughly reported. The goal of this study was to describe the incidence of hypertension among US Hispanic/Latino men and women of diverse Hispanic/Latino background.
   METHODS AND RESULTS: We studied 6171 participants of the Hispanic Community Health Study/Study of Latinos, a diverse group of self-identified Hispanics/Latinos from 4 US urban communities, aged 18 to 74 years, and free from hypertension in 2008 to 2011 and re-examined in 2014 to 2017. Hypertension was defined as self-reported use of anti-hypertension medication, or measured systolic blood pressure >= 130 mm Hg, or diastolic blood pressure >= 80 mm Hg. Results were weighted given the complex survey design to reflect the target population. Among men, the 6-year age-adjusted probability of developing hypertension was 21.7% (95% CI, 19.5-24.1) and differed by Hispanic/Latino background. Specifically, the probability was significantly higher among men of Cuban (27.1%; 95% CI, 20.2-35.2) and Dominican (28.1%; 95% CI, 19.5-38.8) backgrounds compared with Mexican Americans (17.6%; 95% CI: 14.5-21.2). Among women, the 6-year age-adjusted probability of developing hypertension was 19.7% (95% CI, 18.1-21.5) and also differed by Hispanic/Latino background. Specifically, the probability was significantly higher among women of Cuban (22.6%; 95% CI, 18.3-27.5), Dominican (23.3%; 95% CI, 18.0-29.5), and Puerto Rican (28.2%; 95% CI, 22.7-34.4) backgrounds compared with Mexican Americans (16.0%; 95% CI, 13.9-18.4).
   CONCLUSIONS: Hypertension incidence varies by Hispanic/Latino background, with highest incidence among those of Caribbean background.
C1 [Elfassy, Tali] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA.
   [Al Hazzouri, Adina Zeki] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY USA.
   [Cai, Jianwen; Baldoni, Pedro L.] Univ N Carolina, Dept Biostat, Chapel Hill, NC 27515 USA.
   [Llabre, Maria M.; Schneiderman, Neil] Univ Miami, Dept Psychol, Miami, FL 33136 USA.
   [Raij, Leopoldo] Univ Miami, Dept Med, Miami, FL 33136 USA.
   [Rundek, Tatjana] Univ Miami, Dept Neurol, Evelyn F McKnight Brain Inst, Miami, FL 33136 USA.
   [Lash, James P.] Univ Illinois, Dept Med, Chicago, IL USA.
   [Talavera, Gregory A.; Castaneda, Sheila F.] San Diego State Univ, Sch Publ Hlth, San Diego, CA 92182 USA.
   [Garcia, Melawhy] Calif State Univ Long Beach, Dept Hlth Sci, Long Beach, CA 90840 USA.
   [Wassertheil-Smoller, Sylvia] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA.
   [Daviglus, Martha] Univ Illinois, Inst Minor Hlth Res, Chicago, IL USA.
   [Booth, John N., III] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA.
RP Elfassy, T (corresponding author), Univ Miami, Dept Publ Hlth Sci, Div Epidemiol & Populat Hlth Sci, 1120 NW 14th St,Suite 1021, Miami, FL 33136 USA.
EM t.elfassy@med.miami.edu
RI ; Castaneda, Sheila/I-4132-2014
OI Baldoni, Pedro L./0000-0002-9510-8326; Castaneda,
   Sheila/0000-0002-1975-0544
FU National Heart, Lung, and Blood InstituteUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [N01-HC65233, N01-HC65234,
   N01-HC65235, N01-HC65236, N01-HC65237]; University of Miami Clinical and
   Translational Science Institute, from National Institutes of
   Health/National Center for Advancing Translational Sciences
   [KL2TR002737]; National Institutes of Health/National Institute on
   Minority Health and Health Disparities [K01MD014158]
FX The Hispanic Community Health Study/Study of Latinos was performed as a
   collaborative study supported by contracts from the National Heart,
   Lung, and Blood Institute to the University of North Carolina
   (N01-HC65233), University of Miami (N01-HC65234), Albert Einstein
   College of Medicine (N01-HC65235), Northwestern University
   (N01-HC65236), and San Diego State University (N01-HC65237). Dr Elfassy
   was supported by the University of Miami Clinical and Translational
   Science Institute, from National Institutes of Health/National Center
   for Advancing Translational Sciences (KL2TR002737), she is currently
   supported by National Institutes of Health/National Institute on
   Minority Health and Health Disparities (K01MD014158).
CR a R-M, 2020, J CLIN MED, V9
   Adrogue HJ, 2007, NEW ENGL J MED, V356, P1966, DOI 10.1056/NEJMra064486
   Allison MA, 2008, AM J EPIDEMIOL, V167, P962, DOI 10.1093/aje/kwm402
   Amer Diabet Assoc, 2010, DIABETES CARE, V33, pS62, DOI 10.2337/dc10-s062
   [Anonymous], 2015, GLOB PHYS ACT SURV
   [Anonymous], 2017, DIABETOLOGIE STOF S2, V12, pS94, DOI 10.1055/s-0043-115953
   Arredondo EM, 2016, AM J PREV MED, V50, P500, DOI 10.1016/j.amepre.2015.08.029
   Back JH, 2011, ARCH GERONTOL GERIAT, V52, pE140, DOI 10.1016/j.archger.2010.09.012
   Balfour PC, 2016, J LAT O PSYCHOL, V4, P98, DOI 10.1037/lat0000056
   Brondolo E, 2011, AM J HYPERTENS, V24, P518, DOI 10.1038/ajh.2011.9
   Brook RD, 2018, J AM SOC HYPERTENS, V12, P238, DOI 10.1016/j.jash.2018.01.004
   Chiuve SE, 2012, J NUTR, V142, P1009, DOI 10.3945/jn.111.157222
   Chobanian AV., 2003, HYPERTENSION, V42, P1206, DOI DOI 10.1161/01.HYP.0000107251.49515.c2
   Colby SL., 2014, CURRENT POPULATION R, P25
   Commodore-Mensah Y, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.116.004059
   Conomos MP, 2016, AM J HUM GENET, V98, P165, DOI 10.1016/j.ajhg.2015.12.001
   Daviglus ML, 2014, PROG CARDIOVASC DIS, V57, P230, DOI 10.1016/j.pcad.2014.07.006
   Egan BM, 2010, JAMA-J AM MED ASSOC, V303, P2043, DOI 10.1001/jama.2010.650
   Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939
   Elfassy T, 2020, J HUM HYPERTENS, V34, P624, DOI 10.1038/s41371-019-0285-9
   Elfassy T, 2019, AM J HYPERTENS, V32, P868, DOI 10.1093/ajh/hpz073
   Elijovich F, 2016, HYPERTENSION, V68, pE7, DOI 10.1161/HYP.0000000000000047
   Foti K, 2019, AM J EPIDEMIOL, V188, P2165, DOI 10.1093/aje/kwz177
   Franco OH, 2005, HYPERTENSION, V46, P280, DOI 10.1161/01.HYP.0000173433.67426.9b
   Goff DC, 2014, J AM COLL CARDIOL, V63, P2935, DOI [10.1016/j.jacc.2013.11.005, 10.1161/01.cir.0000437741.48606.98]
   Haffner SM, 1996, PUBLIC HEALTH REP, V111, P11
   HAFFNER SM, 1992, AM J HYPERTENS, V5, P147, DOI 10.1093/ajh/5.3.147
   Jenkins KR, 2014, WOMEN HEALTH, V54, P15, DOI 10.1080/03630242.2013.858098
   Lavange LM, 2010, ANN EPIDEMIOL, V20, P642, DOI 10.1016/j.annepidem.2010.05.006
   Morales LS, 2011, J IMMIGR MINOR HEALT, V13, P61, DOI 10.1007/s10903-009-9262-7
   Morales LS, 2002, J HEALTH CARE POOR U, V13, P477, DOI 10.1177/104920802237532
   Moran A, 2007, AM J HYPERTENS, V20, P354, DOI 10.1016/j.amjhyper.2006.09.025
   Muntner P, 2018, J AM COLL CARDIOL, V71, P109, DOI 10.1016/j.jacc.2017.10.073
   Non AL, 2012, AM J PUBLIC HEALTH, V102, P1559, DOI 10.2105/AJPH.2011.300448
   Norris KC, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.116.005130
   Ogden Cynthia L, 2010, NCHS Data Brief, P1
   Richardson SI, 2013, J AM SOC HYPERTENS, V7, P170, DOI 10.1016/j.jash.2013.01.003
   Rodriguez CJ, 2014, CIRCULATION, V130, P593, DOI 10.1161/CIR.0000000000000071
   Siega-Riz AM, 2014, AM J CLIN NUTR, V99, P1487, DOI 10.3945/ajcn.113.082685
   Sorlie PD, 2014, AM J HYPERTENS, V27, P793, DOI 10.1093/ajh/hpu003
   Sorlie PD, 2010, ANN EPIDEMIOL, V20, P629, DOI 10.1016/j.annepidem.2010.03.015
   SORLIE PD, 1994, ARCH INTERN MED, V154, P2409, DOI 10.1001/archinte.154.21.2409
   Svetkey LP, 1996, HYPERTENSION, V28, P854, DOI 10.1161/01.HYP.28.5.854
   Virani SS, 2020, CIRCULATION, V141, pE139, DOI 10.1161/CIR.0000000000000757
   Yi S, 2014, AM J HYPERTENS, V27, P237, DOI 10.1093/ajh/hpt209
NR 45
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-9980
J9 J AM HEART ASSOC
JI J. Am. Heart Assoc.
PD JUN 16
PY 2020
VL 9
IS 12
AR e015031
DI 10.1161/JAHA.119.015031
PG 16
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA MN6XP
UT WOS:000550987700011
PM 32476602
OA gold, Green Published
DA 2021-10-30
ER

PT J
AU Seay, JS
   Kobetz, E
AF Seay, Julia S.
   Kobetz, Erin
TI Optimizing Cervical Cancer Screening and Triage in Low-Resource Settings
SO JOURNAL OF GLOBAL ONCOLOGY
LA English
DT Editorial Material
ID PREVENTION; CAREHPV
C1 [Seay, Julia S.; Kobetz, Erin] Univ Miami, Sch Med, Miami, FL USA.
RP Seay, JS (corresponding author), Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
EM j.seay@med.miami.edu
FU NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1TR002736] Funding Source: NIH RePORTER
CR Bradford L, 2013, CLIN OBSTET GYNECOL, V56, P76, DOI 10.1097/GRF.0b013e31828237ac
   Gustafsson L, 1997, CANCER CAUSE CONTROL, V8, P755, DOI 10.1023/A:1018435522475
   Hoppenot C, 2012, OBSTET GYNECOL SURV, V67, P658, DOI 10.1097/OGX.0b013e3182732375
   Jeronimo J, 2014, INT J GYNECOL CANCER, V24, P576, DOI 10.1097/IGC.0000000000000084
   Poli UR, 2017, J GLOB ONCOL, V4, DOI 10.1200/JGO.2016.008078
   Shi JF, 2011, BMC CANCER, V11, DOI [10.1186/1472-6750-11-77, 10.1186/1471-2407-11-239]
   Trope LA, 2013, J LOW GENIT TRACT DI, V17, P315, DOI 10.1097/LGT.0b013e31826b7b70
NR 7
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 2378-9506
J9 J GLOB ONCOL
JI J. Glob. Oncol.
PD SEP 25
PY 2018
VL 4
DI 10.1200/JGO.18.00192
PG 2
WC Oncology
SC Oncology
GA HQ6DT
UT WOS:000462503100001
PM 30252572
OA Green Published, gold, Green Submitted
DA 2021-10-30
ER

PT J
AU Bruce, CJ
   Bu, G
   Centanni, JM
   Davis, MD
   Dobson, J
   Hare, JM
   Fields, GB
   Jove, R
   Kenyon, N
   Khan, A
   March, K
   Matosevic, S
   Mahmood, A
   Pepine, CJ
   Ricordi, C
   Shapiro, SA
   Zylberberg, C
   Zylberberg, E
AF Bruce, Charles J.
   Bu, Guojun
   Centanni, John M.
   Davis, Mary D.
   Dobson, Jon
   Hare, Joshua M.
   Fields, Gregg B.
   Jove, Richard
   Kenyon, Norma
   Khan, Aisha
   March, Keith
   Matosevic, Sandro
   Mahmood, Ayesha
   Pepine, Carl J.
   Ricordi, Camillo
   Shapiro, Shane A.
   Zylberberg, Claudia
   Zylberberg, Ezequiel
TI Regenerative Medicine in the State of Florida: Letter Outlining the
   Florida Organization for Regenerative Medicine
SO STEM CELLS TRANSLATIONAL MEDICINE
LA English
DT Letter
C1 [Bruce, Charles J.] Mayo Clin, Dept Cardiovasc Med, Jacksonville, FL 32224 USA.
   [Bu, Guojun; Davis, Mary D.] Mayo Clin, Dept Neurosci, Jacksonville, FL 32224 USA.
   [Bu, Guojun; Davis, Mary D.; Shapiro, Shane A.] Mayo Clin, Ctr Regenerat Med, Jacksonville, FL 32224 USA.
   [Centanni, John M.] AxoGen Corp, Alachua, FL USA.
   [Dobson, Jon] Univ Florida, J Crayton Pruitt Family Dept Biomed Engn, Gainesville, FL USA.
   [Dobson, Jon] Univ Florida, Dept Mat Sci & Engn, Gainesville, FL 32611 USA.
   [Hare, Joshua M.] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA.
   [Hare, Joshua M.; Khan, Aisha] Univ Miami, Miller Sch Med, Interdisciplinary Stem Cell Inst, Miami, FL 33136 USA.
   [Fields, Gregg B.] Florida Atlantic Univ, Dept Chem & Biochem, Boca Raton, FL 33431 USA.
   [Jove, Richard] Nova Southeastern Univ, Cell Therapy Inst, Ft Lauderdale, FL 33314 USA.
   [Kenyon, Norma; Ricordi, Camillo] Univ Miami, Miller Sch Med, Diabet Res Inst, Miami, FL 33136 USA.
   [March, Keith; Pepine, Carl J.] Univ Florida, Coll Med, Div Cardiovasc Med, Gainesville, FL USA.
   [March, Keith; Pepine, Carl J.] Univ Florida, Coll Med, Ctr Regenerat Med, Gainesville, FL USA.
   [Matosevic, Sandro] Purdue Univ, Dept Ind & Phys Pharm, W Lafayette, IN 47907 USA.
   [Matosevic, Sandro; Zylberberg, Claudia] Akron Biotechnol, Boca Raton, FL USA.
   [Mahmood, Ayesha] Lifelink Fdn, Tampa, FL USA.
   [Shapiro, Shane A.] Mayo Clin, Dept Orthoped Surg, Jacksonville, FL 32224 USA.
   [Zylberberg, Ezequiel] Akron Biotechnol, Ind Performance Ctr, Boca Raton, FL USA.
RP Bruce, CJ (corresponding author), Mayo Clin, Dept Cardiovasc Med, Jacksonville, FL 32224 USA.
RI Matosevic, Sandro/L-3611-2019; Dobson, Jon P/C-8323-2009; RICORDI,
   CAMILLO/AAA-4740-2019
OI Matosevic, Sandro/0000-0001-5118-2455; Dobson, Jon
   P/0000-0002-8108-5362; Pepine, Carl/0000-0002-6011-681X
FU NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1TR002736] Funding Source: NIH RePORTER
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2157-6564
EI 2157-6580
J9 STEM CELL TRANSL MED
JI Stem Cells Transl. Med.
PD JUL
PY 2018
VL 7
IS 7
BP 511
EP 512
DI 10.1002/sctm.18-0066
PG 2
WC Cell & Tissue Engineering
SC Cell Biology
GA GO3FU
UT WOS:000439875400003
PM 30403444
OA Green Published, gold
DA 2021-10-30
ER

PT J
AU Kurtz, SE
   Eide, CA
   Kaempf, A
   Khanna, V
   Savage, SL
   Rofelty, A
   English, I
   Ho, H
   Pandya, R
   Bolosky, WJ
   Poon, H
   Deininger, MW
   Collins, R
   Swords, RT
   Watts, J
   Pollyea, DA
   Medeiros, BC
   Traer, E
   Tognon, CE
   Mori, M
   Druker, BJ
   Tyner, JW
AF Kurtz, Stephen E.
   Eide, Christopher A.
   Kaempf, Andy
   Khanna, Vishesh
   Savage, Samantha L.
   Rofelty, Angela
   English, Isabel
   Ho, Hibery
   Pandya, Ravi
   Bolosky, William J.
   Poon, Hoifung
   Deininger, Michael W.
   Collins, Robert
   Swords, Ronan T.
   Watts, Justin
   Pollyea, Daniel A.
   Medeiros, Bruno C.
   Traer, Elie
   Tognon, Cristina E.
   Mori, Motomi
   Druker, Brian J.
   Tyner, Jeffrey W.
TI Molecularly targeted drug combinations demonstrate selective
   effectiveness for myeloid- and lymphoidderived hematologic malignancies
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE targeted therapies; drug combinations; ex vivo assay; hematologic
   malignancies
ID CHRONIC LYMPHOCYTIC-LEUKEMIA; CIRCULATING TUMOR-CELLS; BCL-2 INHIBITION;
   STEM-CELLS; CANCER; MUTATIONS; IDENTIFICATION; APOPTOSIS; THERAPY; FLT3
AB Translating the genetic and epigenetic heterogeneity underlying human cancers into therapeutic strategies is an ongoing challenge. Large-scale sequencing efforts have uncovered a spectrum of mutations in many hematologic malignancies, including acute myeloid leukemia (AML), suggesting that combinations of agents will be required to treat these diseases effectively. Combinatorial approaches will also be critical for combating the emergence of genetically heterogeneous subclones, rescue signals in the micro-environment, and tumor-intrinsic feedback pathways that all contribute to disease relapse. To identify novel and effective drug combinations, we performed ex vivo sensitivity profiling of 122 primary patient samples from a variety of hematologic malignancies against a panel of 48 drug combinations. The combinations were designed as drug pairs that target nonoverlapping biological pathways and comprise drugs from different classes, preferably with Food and Drug Administration approval. A combination ratio (CR) was derived for each drug pair, and CRs were evaluated with respect to diagnostic categories as well as against genetic, cytogenetic, and cellular phenotypes of specimens from the two largest disease categories: AML and chronic lymphocytic leukemia (CLL). Nearly all tested combinations involving a BCL2 inhibitor showed additional benefit in patients with myeloid malignancies, whereas select combinations involving PI3K, CSF1R, or bromodomain inhibitors showed preferential benefit in lymphoid malignancies. Expanded analyses of patients with AML and CLL revealed specific patterns of ex vivo drug combination efficacy that were associated with select genetic, cytogenetic, and phenotypic disease subsets, warranting further evaluation. These findings highlight the heuristic value of an integrated functional genomic approach to the identification of novel treatment strategies for hematologic malignancies.
C1 [Kurtz, Stephen E.; Eide, Christopher A.; Khanna, Vishesh; Savage, Samantha L.; Rofelty, Angela; English, Isabel; Ho, Hibery; Traer, Elie; Tognon, Cristina E.; Druker, Brian J.] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97239 USA.
   [Eide, Christopher A.; Khanna, Vishesh; Druker, Brian J.] Oregon Hlth & Sci Univ, Howard Hughes Med Inst, Portland, OR 97239 USA.
   [Kaempf, Andy; Mori, Motomi] Oregon Hlth & Sci Univ, Biostat Shared Resource, Knight Canc Inst, Portland, OR 97239 USA.
   [Pandya, Ravi; Bolosky, William J.; Poon, Hoifung] Microsoft Res, Redmond, WA 98052 USA.
   [Deininger, Michael W.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.
   [Collins, Robert] UT Southwestern Med Ctr, Dallas, TX 75390 USA.
   [Swords, Ronan T.; Watts, Justin] Univ Miami, Sch Med, Miami, FL 33136 USA.
   [Pollyea, Daniel A.] Univ Colorado, Sch Med, Div Hematol, Aurora, CO 80045 USA.
   [Medeiros, Bruno C.] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
   [Mori, Motomi] Oregon Hlth & Sci Univ Portland State Univ Sch Pu, Portland, OR 97239 USA.
   [Tyner, Jeffrey W.] Oregon Hlth & Sci Univ, Dept Cell Dev & Canc Biol, Portland, OR 97239 USA.
RP Druker, BJ (corresponding author), Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97239 USA.; Druker, BJ (corresponding author), Oregon Hlth & Sci Univ, Howard Hughes Med Inst, Portland, OR 97239 USA.; Tyner, JW (corresponding author), Oregon Hlth & Sci Univ, Dept Cell Dev & Canc Biol, Portland, OR 97239 USA.
EM drukerb@ohsu.edu; tynerj@ohsu.edu
RI He, Liye/C-8843-2015
OI He, Liye/0000-0002-6632-2112; Eide, Christopher/0000-0001-8835-8928;
   Druker, Brian/0000-0001-8331-8206; English, Isabel/0000-0002-0566-9585;
   Savage Stevens, Samantha/0000-0003-3961-2197
FU The Leukemia & Lymphoma SocietyLeukemia and Lymphoma Society; National
   Human Genome Research InstituteUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Human Genome Research Institute (NHGRI) [U54HG007990]; V Foundation for
   Cancer Research; Gabrielle's Angel Foundation for Cancer Research;
   National Cancer InstituteUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [1R01CA183947-01]; University of Miami Clinical and
   Translational Science Institute [KL2TR000461]; Howard Hughes Medical
   Institute Medical ResearchHoward Hughes Medical Institute; Biostatistics
   Shared Resource of the Oregon Health & Science University Knight Cancer
   Institute via National Cancer Institute [5P30CA69533]; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [P30CA069533, U01CA217862, R01CA178397] Funding Source: NIH RePORTER;
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [KL2TR000461] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME
   RESEARCH INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Human
   Genome Research Institute (NHGRI) [U54HG007990] Funding Source: NIH
   RePORTER
FX We thank the 122 patients who contributed samples to enable this study;
   David Patterson, David Haussler, and Pierrette Lo for helpful
   discussions; and Brian Junio for sample coordination. This work was
   supported by The Leukemia & Lymphoma Society (B.J.D.), National Human
   Genome Research Institute Grant U54HG007990 (to S.E.K.), the V
   Foundation for Cancer Research (J.W.T.), the Gabrielle's Angel
   Foundation for Cancer Research (J.W.T.), National Cancer Institute Grant
   1R01CA183947-01 (to J.W.T.), University of Miami Clinical and
   Translational Science Institute Award KL2TR000461 (to J.W.), a Howard
   Hughes Medical Institute Medical Research Fellows Program (to V.K.), and
   the Biostatistics Shared Resource of the Oregon Health & Science
   University Knight Cancer Institute via National Cancer Institute Grant
   5P30CA69533 (to A.K. and M.M.). B.J.D. is a Howard Hughes Medical
   Institute investigator.
CR Alix-Panabieres C, 2013, CLIN CHEM, V59, P110, DOI 10.1373/clinchem.2012.194258
   ALTSHULER B, 1981, ENVIRON HEALTH PERSP, V42, P23, DOI 10.2307/3429186
   Anderson MA, 2016, BLOOD, V127, P3215, DOI 10.1182/blood-2016-01-688796
   Baker SD, 2013, CLIN CANCER RES, V19, P5758, DOI 10.1158/1078-0432.CCR-13-1323
   Behinaein B, 2018, IEEE ACM T COMPUT BI, V15, P231, DOI 10.1109/TCBB.2016.2614301
   Benjamini Y, 2000, J EDUC BEHAV STAT, V25, P60, DOI 10.2307/1165312
   Carter BZ, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aag1180
   Chang E, 2016, LEUKEMIA, V30, P1025, DOI 10.1038/leu.2015.346
   Chao MP, 2008, COLD SH Q B, V73, P439, DOI 10.1101/sqb.2008.73.031
   Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10
   Croce CM, 2016, CANCER RES, V76, P5914, DOI 10.1158/0008-5472.CAN-16-1248
   Davids MS, 2013, LEUKEMIA LYMPHOMA, V54, P1823, DOI 10.3109/10428194.2013.796051
   Dienstmann R, 2015, CANCER DISCOV, V5, P118, DOI 10.1158/2159-8290.CD-14-1118
   Dohner H, 2015, NEW ENGL J MED, V373, P1136, DOI 10.1056/NEJMra1406184
   Dohner H, 2010, BLOOD, V115, P453, DOI 10.1182/blood-2009-07-235358
   Doudna JA, 2014, SCIENCE, V346, P1077, DOI 10.1126/science.1258096
   Foucquier J, 2015, PHARMACOL RES PERSPE, V3, DOI 10.1002/prp2.149
   Friedman AA, 2017, CLIN CANCER RES, DOI [10.1158/1078-0432.CCR-16-3029, DOI 10.1158/1078-0432]
   Friedman AA, 2015, NAT REV CANCER, V15, P747, DOI 10.1038/nrc4015
   Galletti G, 2016, LEUKEMIA, V30, P2293, DOI 10.1038/leu.2016.261
   Galletti G, 2016, CELL REP, V14, P1748, DOI 10.1016/j.celrep.2016.01.042
   Hayes DF, 2010, PROG MOL BIOL TRANSL, V95, P95, DOI 10.1016/B978-0-12-385071-3.00005-8
   Irish JM, 2004, CELL, V118, P217, DOI 10.1016/j.cell.2004.06.028
   Klco JM, 2013, BLOOD, V121, P1633, DOI 10.1182/blood-2012-09-459313
   Konopleva M, 2016, CANCER DISCOV, V6, P1106, DOI 10.1158/2159-8290.CD-16-0313
   Kornblau SM, 2010, CLIN CANCER RES, V16, P3721, DOI 10.1158/1078-0432.CCR-10-0093
   Leonard JT, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf5309
   Leonard JT, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0258-1
   Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689
   Lo-Coco F, 2013, NEW ENGL J MED, V369, P1472, DOI 10.1056/NEJMc1309895
   Maddocks K, 2016, SEMIN ONCOL, V43, P251, DOI 10.1053/j.seminoncol.2016.02.008
   Man CH, 2012, BLOOD, V119, P5133, DOI 10.1182/blood-2011-06-363960
   Maxson JE, 2016, CANCER RES, V76, P127, DOI 10.1158/0008-5472.CAN-15-0817
   Maxson JE, 2015, CANCER RES, V75, P2146, DOI 10.1158/0008-5472.CAN-14-1576
   Maxson JE, 2013, NEW ENGL J MED, V368, P1781, DOI 10.1056/NEJMoa1214514
   Medeiros BC, 2015, ANN HEMATOL, V94, P1127, DOI 10.1007/s00277-015-2351-x
   Moore VD, 2013, CANCER LETT, V332, P202, DOI 10.1016/j.canlet.2011.12.021
   Nakao M, 1996, LEUKEMIA, V10, P1911
   Oran B, 2012, HAEMATOL-HEMATOL J, V97, P1916, DOI 10.3324/haematol.2012.066100
   Pabst C, 2014, NAT METHODS, V11, P436, DOI 10.1038/nmeth.2847
   Pan RQ, 2014, CANCER DISCOV, V4, P362, DOI 10.1158/2159-8290.CD-13-0609
   Pemovska T, 2013, CANCER DISCOV, V3, P1416, DOI 10.1158/2159-8290.CD-13-0350
   Polk A, 2016, CLIN CANCER RES, V22, P6118, DOI 10.1158/1078-0432.CCR-15-3099
   Ravandi F, 2009, J CLIN ONCOL, V27, P504, DOI 10.1200/JCO.2008.18.6130
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Roberts AW, 2016, NEW ENGL J MED, V374, P311, DOI 10.1056/NEJMoa1513257
   Shafer D, 2016, BLOOD REV, V30, P275, DOI 10.1016/j.blre.2016.02.001
   Shah NP, 2013, BRIT J HAEMATOL, V162, P548, DOI 10.1111/bjh.12382
   Somervaille TCP, 2006, CANCER CELL, V10, P257, DOI 10.1016/j.ccr.2006.08.020
   Spain L, 2016, EXPERT OPIN PHARMACO, V17, P1031, DOI 10.1517/14656566.2016.1168805
   Tang J, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003226
   Touzeau C, 2016, LEUKEMIA, V30, P761, DOI 10.1038/leu.2015.184
   Tyner JW, 2013, CANCER RES, V73, P285, DOI 10.1158/0008-5472.CAN-12-1906
   Tyner JW, 2009, P NATL ACAD SCI USA, V106, P8695, DOI 10.1073/pnas.0903233106
   Yamamoto Y, 2001, BLOOD, V97, P2434, DOI 10.1182/blood.V97.8.2434
NR 55
TC 53
Z9 54
U1 1
U2 8
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD SEP 5
PY 2017
VL 114
IS 36
BP E7554
EP E7563
DI 10.1073/pnas.1703094114
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FF7FP
UT WOS:000409182200017
PM 28784769
OA Bronze, Green Published
DA 2021-10-30
ER

PT J
AU DeBose-Scarlett, A
   Balise, R
   Kwon, D
   Vadaparampil, S
   Chen, SX
   Schiff, ER
   Ayala, GP
   Thomas, E
AF DeBose-Scarlett, Alexandra
   Balise, Raymond
   Kwon, Deukwoo
   Vadaparampil, Susan
   Chen, Steven Xi
   Schiff, Eugene R.
   Ayala, Gladys Patricia
   Thomas, Emmanuel
TI Obstacles to successful treatment of hepatitis C in uninsured patients
   from a minority population
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE Hepatitis C virus; Sustained virologic response; Direct acting
   antivirals; Uninsured; Minority
ID VIRUS-INFECTION; HEALTH; BARRIERS; HCV; INSIGHTS; THERAPY; CARE
AB Background: Hepatitis C virus (HCV) treatment regimens (DAAs) are well tolerated, efficacious but costly. Their high cost and restricted availability, raises concerns about the outcome of treatment in uninsured patients. This study investigated sustained virologic response (SVR) outcomes in a predominately uninsured patient population and completion of four steps along the HCV treatment cascade.
   Methods: A retrospective chart review was conducted to characterize the patient population and analyze covariates to determine association with insurance status, attainment of SVR and progression through the HCV treatment cascade.
   Results: Out of a total of 216 patients, 154 (71%) were uninsured. Approximately 50% of patients (109 of 216 patients) were male and 57% were Hispanic (123 of 216 patients). Sex, race, ethnicity, treatment compliance, and rates of complications were not associated with insurance status. Insured patients were older (median 60 years vs 57 years, p-value < 0.001) and had higher rates of cirrhosis: 32 out of 62 patients (52%) vs 48 out of 154 patients (31%) (p-value = 0.005). Insured patients were tested for SVR at similar rates as uninsured patients: 84% (52 of 62 patients) vs 81% (125 of 154 patients), respectively. Of those tested for SVR, the cure rate for insured patients was 98% (51 out of 52 patients) compared to 97% (121 out of 125 patients) in the uninsured. Out of those who completed treatment, 177 of 189 (94%) were tested for attainment of SVR. Compliance rates were significantly different between tested and untested patients: 88% (156 of 177 patients) vs 0% (0 of 12 patients), respectively (p-value < 0.001). However, insurance status, race ethnicity, cirrhosis, and complications were not associated with being tested for SVR.
   Conclusions: These results demonstrate that insured and uninsured patients with chronic HCV infection, with access to patient assistance programs, can be treated and have comparable clinical outcomes. In addition, testing for SVR remains an important obstacle in completion of the HCV treatment cascade. Nevertheless, patient assistance programs remove a significant barrier for treatment access in real-world HCV infected populations.
C1 [DeBose-Scarlett, Alexandra; Balise, Raymond; Kwon, Deukwoo; Chen, Steven Xi; Thomas, Emmanuel] Univ Miami, Sch Med, 1600 NW 10th Ave 1140, Miami, FL 33136 USA.
   [Vadaparampil, Susan] H Lee Moffitt Canc Ctr & Res Inst, 12902 USF Magnolia Dr, Tampa, FL 33612 USA.
   [Schiff, Eugene R.; Thomas, Emmanuel] Schiff Ctr Liver Dis, 1500 NW 12th Ave 1101, Miami, FL 33136 USA.
   [Ayala, Gladys Patricia] Jackson Hlth Syst, 1005,1611 NW 12th Ave, Miami, FL 33136 USA.
   [Balise, Raymond; Kwon, Deukwoo; Chen, Steven Xi; Schiff, Eugene R.; Thomas, Emmanuel] Sylvester Comprehens Canc Ctr, 1550 NW 10th Ave,Papanicolaou Bldg,PAP 514, Miami, FL 33136 USA.
   [Thomas, Emmanuel] Schiff Ctr Liver Dis, 1550 NW 10th Ave,Papanicolaou Bldg,PAP 514, Miami, FL 33136 USA.
RP Thomas, E (corresponding author), Univ Miami, Sch Med, 1600 NW 10th Ave 1140, Miami, FL 33136 USA.; Thomas, E (corresponding author), Schiff Ctr Liver Dis, 1500 NW 12th Ave 1101, Miami, FL 33136 USA.; Thomas, E (corresponding author), Sylvester Comprehens Canc Ctr, 1550 NW 10th Ave,Papanicolaou Bldg,PAP 514, Miami, FL 33136 USA.; Thomas, E (corresponding author), Schiff Ctr Liver Dis, 1550 NW 10th Ave,Papanicolaou Bldg,PAP 514, Miami, FL 33136 USA.
EM ethomas1@med.miami.edu
OI Thomas, Emmanuel/0000-0003-1416-3903; Balise,
   Raymond/0000-0002-9856-5901
FU Schiff Center for Liver Diseases; Sylvester Comprehensive Cancer Center
   at the University of Miami School of Medicine; Florida Department of
   Health Bankhead-Coley Cancer Research Program [7BC03]; Miami Clinical
   and Translation Science Institute KL2 Program; NIH Loan Repayment
   Program for Extramural Clinical ResearchUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA;
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [KL2TR000461] Funding Source: NIH RePORTER
FX This work was supported by the Schiff Center for Liver Diseases and the
   Sylvester Comprehensive Cancer Center at the University of Miami School
   of Medicine. Grant support was received from the Florida Department of
   Health Bankhead-Coley Cancer Research Program 7BC03 (to ET), the Miami
   Clinical and Translation Science Institute KL2 Program (to ET) and the
   NIH Loan Repayment Program for Extramural Clinical Research (to ET).
CR Administration SS, 2018, DIS EV SOC SEC DIG S
   Altman D, 2015, JAMA-J AM MED ASSOC, V314, P384, DOI 10.1001/jama.2015.7811
   Backus LI, 2014, AM J PUBLIC HEALTH, V104, pS555, DOI 10.2105/AJPH.2014.302090
   CDC, 2017, HEP C FAQS HLTH PROF
   Chhatwal J, 2016, HEPATOLOGY, V64, P1442, DOI 10.1002/hep.28571
   Chung RT, 2015, HEPATOLOGY, V62, P932, DOI 10.1002/hep.27950
   Curry MP, 2017, ALIMENT PHARM THER, V46, P540, DOI 10.1111/apt.14204
   Ditah I, 2015, AM J GASTROENTEROL, V110, P1126, DOI 10.1038/ajg.2015.31
   Do A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135645
   Donepudi I, 2015, DIGEST DIS SCI, V60, P1092, DOI 10.1007/s10620-014-3416-8
   Falade-Nwulia O, 2017, ANN INTERN MED, V166, P637, DOI [10.7326/M16-2575, 10.7326/m16-2575]
   Feldman EB, 2017, J COMMUN HEALTH, V42, P921, DOI 10.1007/s10900-017-0335-6
   Fischer WA, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx155
   Kattakuzhy S, 2017, ANN INTERN MED, V167, P311, DOI [10.7326/M17-0118, 10.7326/m17-0118]
   King A, 2016, PUBLIC HEALTH REP, V131, P430, DOI 10.1177/003335491613100309
   Mishra P, 2015, HEPATOLOGY, V62, P1298, DOI 10.1002/hep.27880
   Morrill JA, 2005, J GEN INTERN MED, V20, P754, DOI 10.1111/j.1525-1497.2005.0161.x
   Noureddin M, 2013, HEPATOLOGY, V58, P1548, DOI 10.1002/hep.26506
   Papatheodoridis G, 2012, BEST PRACT RES CL GA, V26, P371, DOI 10.1016/j.bpg.2012.09.012
   Puenpatom A, 2017, INFECT DIS THER, V6, P423, DOI 10.1007/s40121-017-0163-0
   Sims OT, 2017, EUR J GASTROEN HEPAT, V29, P1219, DOI 10.1097/MEG.0000000000000961
   Southern WN, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1283-3
   Spradling PR, 2018, J CLIN GASTROENTEROL, V52, P641, DOI 10.1097/MCG.0000000000000857
   Stepanova M, 2015, DIGEST DIS SCI, V60, P3248, DOI 10.1007/s10620-015-3709-6
   Thomas E, 2016, NAT REV GASTRO HEPAT, V13, P362, DOI 10.1038/nrgastro.2016.37
   Thomas E, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a021345
   Thomas Emmanuel, 2012, Antiviral Chemistry & Chemotherapy, V23, P1, DOI 10.3851/IMP2125
   Trooskin SB, 2015, J GEN INTERN MED, V30, P950, DOI 10.1007/s11606-015-3209-6
   Yehia BR, 2014, PLOS ONE, V9, P3, DOI DOI 10.1371/J0URNAL.P0NE.0101554]
   Yek C, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0969-3
   Younossi ZM, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005048
NR 31
TC 7
Z9 7
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1479-5876
J9 J TRANSL MED
JI J. Transl. Med.
PD JUN 28
PY 2018
VL 16
AR 178
DI 10.1186/s12967-018-1555-y
PG 12
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA GL3FE
UT WOS:000437014000003
PM 29954391
OA Green Published, gold
DA 2021-10-30
ER

PT J
AU Levitt, AE
   Galor, A
   Small, L
   Feuer, W
   Felix, ER
AF Levitt, Alexandra E.
   Galor, Anat
   Small, Leslie
   Feuer, William
   Felix, Elizabeth R.
TI Pain sensitivity and autonomic nervous system parameters as predictors
   of dry eye symptoms after LASIK
SO OCULAR SURFACE
LA English
DT Article
DE Neuropathic ocular pain; LASIK; Dry eye; Central sensitization; Pain
   sensitivity; Autonomic nervous system; Eye pain; Chronic pain
AB Purpose: Differences in pain processing and autonomic function among patients have been implicated in the development of chronic pain after surgery. This study was designed to evaluate whether pain and autonomic metrics predict severity of chronic dry eye (DE) symptoms after LASIK, as there is increasing evidence that DE symptoms may be manifestations of persistent post-operative ocular pain.
   Methods: Secondary analysis of prospective randomized clinical trial. Patients were treated with either pregabalin or placebo. As no significant differences in DE symptoms were detected by treatment allocation at six months, all participants were grouped together for the present analyses. Subjects were evaluated pre-LASIK with regard to evoked pain sensitivity (utilizing quantitative sensory testing), autonomic metrics and DE and ocular pain symptoms (via validated questionnaires). Measures of DE and ocular pain were assessed post-LASIK, and the Dry Eye Questionnaire 5 (DEQ5) score 6-months after surgery was the primary outcome of interest. Results: 43 individuals were randomized to pregabalin (n = 21) or placebo (n = 22). 42 completed the 6-month visit. Several baseline autonomic metrics correlated with 6-month post-operative DEQ5 scores, including lower systolic (r-0.37, p = 0.02) and diastolic blood pressure (r-0.32, p = 0.04). Ocular pain at 6 months was also negatively correlated with blood pressure (r-0.31, p = 0.047). The presence of painful aftersensations was a significant predictor of chronic DE symptoms at 6 months (mean DEQ5 scores: 8.0 +/- 1.9 versus 5.0 +/- 5.0, p = 0.009).
   Conclusions: Heightened parasympathetic tone and prolonged pain sensitivity measured prior to surgery predicted greater DE symptom severity 6 months after LASIK.
   Trial registration: NCT02701764.
C1 [Levitt, Alexandra E.; Galor, Anat; Small, Leslie; Feuer, William] Univ Miami, Bascom Palmer Eye Inst, Miami, FL USA.
   [Galor, Anat] Miami Vet Adm Med Ctr, Dept Ophthalmol, Miami, FL USA.
   [Felix, Elizabeth R.] Univ Miami, Dept Phys Med & Rehabil, Miami, FL USA.
   [Felix, Elizabeth R.] Miami Vet Adm Med Ctr, Res Serv, Miami, FL USA.
RP Galor, A (corresponding author), Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, 900 NW 17th St, Miami, FL 33136 USA.
EM agalor@med.miami.edu
FU Department of Veterans Affairs, Veterans Health Administration, Office
   of Research and Development, Clinical Sciences RD (CSRD)US Department of
   Veterans Affairs [I01 CX002015]; Biomedical Laboratory R&D (BLRD)
   Service [I01 BX004893]; Department of Defense Gulf War Illness Research
   Program (GWIRP) [W81XWH-20-1-0579]; Vision Research Program (VRP)
   [W81XWH2010820]; National Eye InstituteUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Eye Institute (NEI) [R01EY026174, R61EY032468]; NIH Center Core
   GrantUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [P30EY014801]; Research to Prevent
   Blindness Unrestricted GrantResearch to Prevent Blindness (RPB); CTSI
   Pilot Program FY16 (Miami CTSI) [NIH UL1TR000460]
FX Supported by the Department of Veterans Affairs, Veterans Health
   Administration, Office of Research and Development, Clinical Sciences
   R&D (CSRD) I01 CX002015 (Dr. Galor) and Biomedical Laboratory R&D (BLRD)
   Service I01 BX004893 (Dr. Galor), Department of Defense Gulf War Illness
   Research Program (GWIRP) W81XWH-20-1-0579 (Dr. Galor) and Vision
   Research Program (VRP) W81XWH2010820 (Dr. Galor), National Eye Institute
   R01EY026174(Dr. Galor) and R61EY032468 (Dr. Galor), NIH Center Core
   Grant P30EY014801 (institutional) and Research to Prevent Blindness
   Unrestricted Grant (institutional) and the CTSI Pilot Program FY16 (NIH
   UL1TR000460, Miami CTSI) (Dr. Galor).
CR Agca A, 2015, J REFRACT SURG, V31, P594, DOI 10.3928/1081597X-20150820-04
   Al-Sabbagh Mohanad, 2015, Dent Clin North Am, V59, P143, DOI 10.1016/j.cden.2014.08.005
   [Anonymous], MEIBOSCALE
   Backonja M, 2013, PAIN, V154, P1807, DOI 10.1016/j.pain.2013.05.047
   Borsook D, 2013, ANN SURG, V257, P403, DOI 10.1097/SLA.0b013e3182701a7b
   Bossmann T, 2017, PAIN MANAG, V7, P391, DOI 10.2217/pmt-2017-0023
   Brawn J, 2014, HUM REPROD UPDATE, V20, P737, DOI 10.1093/humupd/dmu025
   Bron AJ, 2007, OCUL SURF, V5, P108
   Brusselmans G, 2015, ACTA ANAESTH BELG, V66, P19
   Chalmers RL, 2010, CONTACT LENS ANTERIO, V33, P55, DOI 10.1016/j.clae.2009.12.010
   Chao C, 2016, J REFRACT SURG, V32, P518, DOI 10.3928/1081597X-20160603-01
   Chao C, 2014, OCUL SURF, V12, P32, DOI 10.1016/j.jtos.2013.09.001
   Chen A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05368-z
   Cohen J., 1988, STAT POWER ANAL BEHA, V2, DOI 10.1016/C2013-0-10517-X
   Crane AM, 2017, BRIT J OPHTHALMOL, V101, P227, DOI 10.1136/bjophthalmol-2015-308214
   De Paiva CS, 2006, AM J OPHTHALMOL, V141, P438, DOI 10.1016/j.ajo.2005.10.006
   Farhang M, 2019, PAIN, V160, P1541, DOI 10.1097/j.pain.0000000000001552
   Fillingim RB, 2008, ORAL DIS, V14, P673, DOI 10.1111/j.1601-0825.2008.01458.x
   Fillingim RB, 2017, PAIN, V158, pS11, DOI 10.1097/j.pain.0000000000000775
   France C.R., 1999, PAIN RES MANAG, V4, P100, DOI [10.1155/1999/460391, DOI 10.1155/1999/460391]
   France CR, 1999, PSYCHOPHYSIOLOGY, V36, P683, DOI 10.1017/S0048577299990030
   Furquim Bruno D'Aurea, 2015, Dental Press J. Orthod., V20, P127, DOI 10.1590/2176-9451.20.1.127-133.sar
   Galor A, 2019, J CLIN MED, V8, DOI 10.3390/jcm8091355
   Gescheider GA, 1997, SOMATOSENS MOT RES, V14, P181
   Granovsky Y, 2013, CURR PAIN HEADACHE R, V17, DOI 10.1007/s11916-013-0361-8
   Hinrichs-Rocker A, 2009, EUR J PAIN, V13, P719, DOI 10.1016/j.ejpain.2008.07.015
   Izumi M, 2017, PAIN, V158, P323, DOI 10.1097/j.pain.0000000000000764
   Katz J, 2009, EXPERT REV NEUROTHER, V9, P723, DOI [10.1586/ern.09.20, 10.1586/ERN.09.20]
   Kennedy DL, 2016, PAIN, V157, P2410, DOI 10.1097/j.pain.0000000000000689
   Lavand'homme P, 2015, BONE JOINT J, V97B, P45, DOI 10.1302/0301-620X.97B10.36524
   Lee CJ, 2017, PAIN REP, V2, DOI 10.1097/PR9.0000000000000629
   Levitt AE, 2015, MOL PAIN, V11, DOI 10.1186/s12990-015-0020-7
   Lewis GN, 2012, J PAIN, V13, P936, DOI 10.1016/j.jpain.2012.07.005
   MARFURT CF, 1993, J COMP NEUROL, V336, P517, DOI 10.1002/cne.903360405
   McDougal DH, 2015, COMPR PHYSIOL, V5, P439, DOI 10.1002/cphy.c140014
   Meretoja TJ, 2017, J CLIN ONCOL, V35, P1660, DOI 10.1200/JCO.2016.70.3413
   Nettune GR, 2010, OCUL SURF, V8, P135, DOI 10.1016/S1542-0124(12)70224-0
   Nielsen R, 2015, ACTA ANAESTH SCAND, V59, P475, DOI 10.1111/aas.12457
   Peerdeman KJ, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.01270
   Petersen KK, 2018, CLIN J PAIN, V34, P193, DOI 10.1097/AJP.0000000000000528
   Petersen KK, 2016, PAIN, V157, P1400, DOI 10.1097/j.pain.0000000000000531
   Petersen KK, 2015, PAIN, V156, P55, DOI 10.1016/j.pain.0000000000000022
   Pouyeh B, 2012, AM J OPHTHALMOL, V153, P1061, DOI 10.1016/j.ajo.2011.11.030
   Pud D, 2009, PAIN, V144, P16, DOI 10.1016/j.pain.2009.02.015
   Recchioni A, 2020, CORNEA, V39, P851, DOI 10.1097/ICO.0000000000002312
   Rolke R, 2006, EUR J PAIN, V10, P77, DOI 10.1016/j.ejpain.2005.02.003
   Sandoval HP, 2016, J CATARACT REFR SURG, V42, P1224, DOI 10.1016/j.jcrs.2016.07.012
   Sangesland A, 2017, SCAND J PAIN, V15, P44, DOI 10.1016/j.sjpain.2016.12.002
   Schiffman RM, 2000, ARCH OPHTHALMOL-CHIC, V118, P615, DOI 10.1001/archopht.118.5.615
   Schreiber KL, 2017, J PAIN, V18, P855, DOI 10.1016/j.jpain.2017.02.437
   Schreiber KL, 2013, PAIN, V154, P660, DOI 10.1016/j.pain.2012.11.015
   Shaheen BS, 2014, SURV OPHTHALMOL, V59, P263, DOI 10.1016/j.survophthal.2013.09.002
   Shoja MR, 2007, EUR J OPHTHALMOL, V17, P1
   Siak Jjt L, 2010, IOVS INVESTIG OPHTHA, V51
   Sollgruber A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203336
   Staud R, 2001, PAIN MED, V2, P208, DOI 10.1046/j.1526-4637.2001.01030.x
   Theophanous C, 2015, OPTOMETRY VISION SCI, V92, pE233, DOI 10.1097/OPX.0000000000000652
   Theunissen M, 2012, CLIN J PAIN, V28, P819, DOI 10.1097/AJP.0b013e31824549d6
   Toda I, 2018, INVEST OPHTH VIS SCI, V59, DOI 10.1167/iovs.17-23538
   Tracy LM, 2016, PAIN, V157, P7, DOI 10.1097/j.pain.0000000000000360
   Treede RD, 2015, PAIN, V156, P1003, DOI 10.1097/j.pain.0000000000000160
   VanDenKerkhof EG, 2013, CLIN J PAIN, V29, P2, DOI 10.1097/AJP.0b013e31824730c2
   Weissman-Fogel I, 2009, J PAIN, V10, P628, DOI 10.1016/j.jpain.2008.12.009
NR 63
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1542-0124
EI 1937-5913
J9 OCUL SURF
JI Ocul. Surf.
PD JAN
PY 2021
VL 19
BP 275
EP 281
DI 10.1016/j.jtos.2020.10.004
PG 7
WC Ophthalmology
SC Ophthalmology
GA QE3TH
UT WOS:000616131100013
PM 33096271
DA 2021-10-30
ER

PT J
AU Corp, DT
   Bereznicki, HGK
   Clark, GM
   Youssef, GJ
   Fried, PJ
   Jannati, A
   Davies, CB
   Gomes-Osman, J
   Stamm, J
   Chung, SW
   Bowe, SJ
   Rogasch, NC
   Fitzgerald, PB
   Koch, G
   Di Lazzaro, V
   Pascual-Leone, A
   Enticott, PG
AF Corp, Daniel T.
   Bereznicki, Hannah G. K.
   Clark, Gillian M.
   Youssef, George J.
   Fried, Peter J.
   Jannati, Ali
   Davies, Charlotte B.
   Gomes-Osman, Joyce
   Stamm, Julie
   Chung, Sung Wook
   Bowe, Steven J.
   Rogasch, Nigel C.
   Fitzgerald, Paul B.
   Koch, Giacomo
   Di Lazzaro, Vincenzo
   Pascual-Leone, Alvaro
   Enticott, Peter G.
CA Big TMS Data Collaboration
TI Large-scale analysis of interindividual variability in theta-burst
   stimulation data: Results from the 'Big TMS Data Collaboration'
SO BRAIN STIMULATION
LA English
DT Article
DE Theta-burst stimulation; Variability; Big data; Transcranial, and
   magnetic stimulation
ID TRANSCRANIAL MAGNETIC STIMULATION; NONINVASIVE BRAIN-STIMULATION; MOTOR
   CORTICAL PLASTICITY; CORTICOSPINAL EXCITABILITY; SUBJECT VARIABILITY;
   DIFFERENT PROTOCOLS; CORTEX; RELIABILITY; MODULATION; INDUCTION
AB Background: Many studies have attempted to identify the sources of interindividual variability in response to theta-burst stimulation (TBS). However, these studies have been limited by small sample sizes, leading to conflicting results.
   Objective/Hypothesis: This study brought together over 60 TMS researchers to form the 'Big TMS Data Collaboration', and create the largest known sample of individual participant TBS data to date. The goal was to enable a more comprehensive evaluation of factors driving TBS response variability.
   Methods: 118 corresponding authors of TMS studies were emailed and asked to provide deidentifled individual TMS data. Mixed-effects regression investigated a range of individual and study level variables for their contribution to iTBS and cTBS response variability.
   Results: 430 healthy participants' TBS data was pooled across 22 studies (mean age = 41.9; range = 17-82; females = 217). Baseline MEP amplitude, age, target muscle, and time of day significantly predicted iTBS-induced plasticity. Baseline MEP amplitude and timepoint after TBS significantly predicted cTBS-induced plasticity.
   Conclusions: This is the largest known study of interindividual variability in TBS. Our findings indicate that a significant portion of variability can be attributed to the methods used to measure the modulatory effects of TBS. We provide specific methodological recommendations in order to control and mitigate these sources of variability. (C) 2020 The Authors. Published by Elsevier Inc.
C1 [Corp, Daniel T.; Bereznicki, Hannah G. K.; Clark, Gillian M.; Youssef, George J.; Davies, Charlotte B.; Enticott, Peter G.] Deakin Univ, Sch Psychol, Cognit Neurosci Unit, Geelong, Vic, Australia.
   [Corp, Daniel T.; Fried, Peter J.; Jannati, Ali; Gomes-Osman, Joyce] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Berenson Allen Ctr Noninvas Brain Stimulat, Boston, MA 02115 USA.
   [Youssef, George J.] Murdoch Childrens Res Inst, Ctr Adolescent Hlth, Parkville, Vic, Australia.
   [Jannati, Ali] Harvard Med Sch, Boston Childrens Hosp, Dept Neurol, Neuromodulat Program, Boston, MA 02115 USA.
   [Jannati, Ali] Harvard Med Sch, Boston Childrens Hosp, Dept Neurol, Div Epilepsy & Clin Neurophysiol, Boston, MA 02115 USA.
   [Gomes-Osman, Joyce] Univ Miami, Miller Sch Med, Dept Phys Therapy, Miami, FL 33136 USA.
   [Stamm, Julie] Univ Wisconsin, Dept Kinesiol, Madison, WI USA.
   [Chung, Sung Wook; Fitzgerald, Paul B.] Alfred & Monash Univ, Monash Alfred Psychiat Res Ctr, Cent Clin Sch, Melbourne, Vic, Australia.
   [Bowe, Steven J.] Deakin Univ, Deakin Biostat Unit, Fac Hlth, Geelong, Vic, Australia.
   [Rogasch, Nigel C.] Univ Adelaide, Adelaide Med Sch, Discipline Psychiat, Adelaide, SA, Australia.
   [Rogasch, Nigel C.] South Australian Hlth & Med Res Inst, Hopwood Ctr Neurobiol, Lifelong Hlth Theme, Adelaide, SA, Australia.
   [Rogasch, Nigel C.] Monash Univ, Sch Psychol Sci, Turner Inst Brain & Mental Hlth, Melbourne, Vic, Australia.
   [Fitzgerald, Paul B.] Epworth Ctr Innovat Mental Hlth, Epworth HealthCare & Cent Clin Sch, Melbourne, Vic, Australia.
   [Koch, Giacomo] IRCCS Santa Lucia Fdn, Dept Clin & Behav Neurol, Noninvas Brain Stimulat Unit, Rome, Italy.
   [Koch, Giacomo] Univ Ferrara, Dept Biomed & Specialty Surg Sci, Sect Human Physiol, Ferrara, Italy.
   [Di Lazzaro, Vincenzo] Univ Campus Biomed, Unit Neurol Neurophysiol & Neurobiol, Rome, Italy.
   [Pascual-Leone, Alvaro] Hebrew SeniorLife, Hinda & Arthur Marcus Inst Aging Res, Boston, MA USA.
   [Pascual-Leone, Alvaro] Harvard Med Sch, Dept Neurol, Boston, MA 02115 USA.
   [Pascual-Leone, Alvaro] Univ Autonoma Barcelona, Guttmann Brain Hlth Inst, Inst Guttmann Neurorehabil, Barcelona, Spain.
RP Corp, DT (corresponding author), Deakin Univ, Sch Psychol, Cognit Neurosci Unit, Geelong, Vic, Australia.
EM daniel.corp@deakin.edu.au
RI Jannati, Ali/J-6453-2012; Bereznicki, Hannah/AAW-6032-2021; Clark,
   Gillian/AAC-3917-2020; Enticott, Peter/G-6923-2017
OI Jannati, Ali/0000-0003-0826-1275; Bereznicki,
   Hannah/0000-0001-9149-9588; Clark, Gillian/0000-0002-6541-5130;
   Kirkovski, Melissa/0000-0003-3395-8525; Enticott,
   Peter/0000-0002-6638-951X; KOch, Giacomo/0000-0001-6155-9439; Corp,
   Daniel/0000-0003-2435-077X
FU Natural Sciences and Engineering Research Council of CanadaNatural
   Sciences and Engineering Research Council of Canada (NSERC)CGIAR [NSERC
   454617]; Canadian Institutes of Health ResearchCanadian Institutes of
   Health Research (CIHR) [CIHR 41791]; Sidney R. Baer Jr.; National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA; National Science
   FoundationNational Science Foundation (NSF); DARPAUnited States
   Department of DefenseDefense Advanced Research Projects Agency (DARPA);
   National Center for Advancing Translational Sciences of the National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [KL2TR002737]; NHMRC
   Practitioner FellowshipNational Health and Medical Research Council of
   Australia [1078567]; MagVenture A/S; Medtronic Ltd, Neuronetics and
   Brainsway Ltd.; Australian Research CouncilAustralian Research Council
   [FT160100077]; Discovery Early Career Researcher Award from the
   Australian Research CouncilAustralian Research Council [DE180100741]
FX A.J. was supported by postdoctoral fellowships from the Natural Sciences
   and Engineering Research Council of Canada (NSERC 454617) and the
   Canadian Institutes of Health Research (CIHR 41791). A.P.-L. was partly
   supported by the Sidney R. Baer Jr. Foundation, the National Institutes
   of Health, the National Science Foundation, and DARPA. A.P.-L. serves on
   the scientific advisory boards for Starlab Neuroscience, Neuroelectrics,
   Magstim Inc., Nexstim, and Cognito; and is listed as an inventor on
   several issued and pending patents on the real-time integration of
   transcranial magnetic stimulation with electroencephalography and
   magnetic resonance imaging. J.G.O. was supported by the National Center
   for Advancing Translational Sciences of the National Institutes of
   Health under Award Number KL2TR002737. P.B.F. is supported by a NHMRC
   Practitioner Fellowship (1078567). P.B.F. has received equipment for
   research from MagVenture A/S, Medtronic Ltd, Neuronetics and Brainsway
   Ltd. and funding for research from Neuronetics. He is on scientific
   advisory boards for Bionomics Ltd and LivaNova and is a founder of TMS
   Clinics Australia. P.G.E. is supported by a Future Fellowship from the
   Australian Research Council (FT160100077). N.C.R. was supported by a
   Discovery Early Career Researcher Award from the Australian Research
   Council (DE180100741).
CR Acuna C, 2012, FRONT SYST NEUROSCI, V6, DOI 10.3389/fnsys.2012.00062
   Amandusson A, 2017, CLIN NEUROPHYS PRACT, V2, P91, DOI 10.1016/j.cnp.2017.04.001
   Antal A, 2010, BRAIN STIMUL, V3, P230, DOI 10.1016/j.brs.2009.12.003
   BENDEL RB, 1977, J AM STAT ASSOC, V72, P46, DOI 10.2307/2286904
   BLAND JM, 1994, BRIT MED J, V309, P780, DOI 10.1136/bmj.309.6957.780
   Blumberger DM, 2018, LANCET, V391, P1683, DOI 10.1016/S0140-6736(18)30295-2
   BRASILNETO JP, 1992, ELECTROEN CLIN NEURO, V85, P9, DOI 10.1016/0168-5597(92)90095-S
   BRASILNETO JP, 1994, MUSCLE NERVE, V17, P713, DOI 10.1002/mus.880170702
   Brown KE, 2017, BRAIN STIMUL, V10, P1102, DOI 10.1016/j.brs.2017.07.011
   Carmi L, 2018, BRAIN STIMUL, V11, P158, DOI 10.1016/j.brs.2017.09.004
   Chang WH, 2016, CLIN NEUROPHYSIOL, V127, P2892, DOI 10.1016/j.clinph.2016.04.001
   Chung SW, 2016, NEUROSCI BIOBEHAV R, V63, P43, DOI 10.1016/j.neubiorev.2016.01.008
   Cocchi L, 2015, J NEUROPHYSIOL, V113, P3375, DOI 10.1152/jn.00850.2014
   Conte A, 2012, CEREB CORTEX, V22, P693, DOI 10.1093/cercor/bhr149
   Corp D.T., LARGE SCALE ANAL INT
   Daskalakis ZJ, 2006, EXP BRAIN RES, V174, P403, DOI 10.1007/s00221-006-0472-0
   Davidson R., 1993, ESTIMATION INFERENCE
   Devanne H, 1997, EXP BRAIN RES, V114, P329, DOI 10.1007/PL00005641
   Di Lazzaro V, 2008, CLIN NEUROPHYSIOL, V119, P715, DOI 10.1016/j.clinph.2007.11.049
   Di Lazzaro V, 2011, J NEUROPHYSIOL, V105, P2150, DOI 10.1152/jn.00781.2010
   Di Lazzaro V, 2001, EXP BRAIN RES, V141, P121
   Di Lazzaro V, 2014, J PHYSIOL-LONDON, V592, P4115, DOI 10.1113/jphysiol.2014.274316
   Dickins DSE, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/323409
   Dileone M, 2016, BRAIN STIMUL, V9, P33, DOI 10.1016/j.brs.2015.08.012
   Do M, 2018, FRONT HUM NEUROSCI, V12, DOI 10.3389/fnhum.2018.00123
   Fathi D, 2010, CLIN NEUROPHYSIOL, V121, P90, DOI 10.1016/j.clinph.2009.07.048
   Freitas C, 2011, FRONT AGING NEUROSCI, V3, DOI [10.3389/fnagi.2011.00006, 10.3389/fnagi.2011.00005]
   Fried PJ, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00263
   Fried PJ, 2017, J ALZHEIMERS DIS, V55, P89, DOI 10.3233/JAD-160505
   Gelman A., 2014, BAYESIAN DATA ANAL, V2
   Goldsworthy MR, 2016, NEUROSCIENCE, V320, P205, DOI 10.1016/j.neuroscience.2016.02.012
   Goldsworthy MR, 2016, CLIN NEUROPHYSIOL, V127, P740, DOI 10.1016/j.clinph.2015.06.014
   Goldsworthy MR, 2014, BRAIN STIMUL, V7, P864, DOI 10.1016/j.brs.2014.08.004
   Hallett M, 2000, NATURE, V406, P147, DOI 10.1038/35018000
   Hamada M, 2012, CEREB CORTEX
   Higgins JET, 2019, COCHRANE HDB SYSTEMA
   Hinder MR, 2014, BRAIN STIMUL, V7, P365, DOI 10.1016/j.brs.2014.01.004
   Hordacre B, 2017, BRAIN STIMUL, V10, P588, DOI 10.1016/j.brs.2016.12.001
   Houdayer E, 2008, EXP BRAIN RES, V187, P207, DOI 10.1007/s00221-008-1294-z
   Huang G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133893
   Huang YZ, 2005, NEURON, V45, P201, DOI 10.1016/j.neuron.2004.12.033
   Jannati A, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00447
   Jannati A, 2017, CLIN NEUROPHYSIOL, V128, P2268, DOI 10.1016/j.clinph.2017.08.023
   Koch G, 2016, J ALZHEIMERS DIS, V50, P605, DOI 10.3233/JAD-150813
   Koch G, 2014, NEUROPSYCHOPHARMACOL, V39, P2654, DOI 10.1038/npp.2014.119
   Lee NJ, 2014, ANN REHABIL MED-ARM, V38, P658, DOI 10.5535/arm.2014.38.5.658
   Liberati A, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2700
   Lopez-Alonso V, 2014, BRAIN STIMUL, V7, P372, DOI 10.1016/j.brs.2014.02.004
   Massie CL, 2013, INT J NEUROSCI, V123, P175, DOI 10.3109/00207454.2012.738734
   McAllister CJ, 2013, J NEUROSCI, V33, P7919, DOI 10.1523/JNEUROSCI.5624-12.2013
   McDonnell MN, 2013, J APPL PHYSIOL, V114, P1174, DOI 10.1152/japplphysiol.01378.2012
   Muller-Dahlhaus JFM, 2008, EXP BRAIN RES, V187, P467, DOI 10.1007/s00221-008-1319-7
   Munneke MAM, 2013, MUSCLE NERVE, V48, P733, DOI 10.1002/mus.23818
   Nettekoven C, 2014, J NEUROSCI, V34, P6849, DOI 10.1523/JNEUROSCI.4993-13.2014
   Opie GM, 2013, EUR J NEUROSCI, V37, P1844, DOI 10.1111/ejn.12203
   Opitz A, 2014, NEUROIMAGE-CLIN, V4, P500, DOI 10.1016/j.nicl.2014.03.004
   PASCUALLEONE A, 1994, ELECTROEN CLIN NEURO, V93, P42, DOI 10.1016/0168-5597(94)90090-6
   PascualLeone A, 1996, LANCET, V348, P233, DOI 10.1016/S0140-6736(96)01219-6
   Pitcher JB, 2015, CLIN NEUROPHYSIOL, V126, P2337, DOI 10.1016/j.clinph.2015.02.011
   Puri R, 2016, EXP BRAIN RES, V234, P3411, DOI 10.1007/s00221-016-4740-3
   Raffin E, 2015, NEUROIMAGE, V120, P164, DOI 10.1016/j.neuroimage.2015.07.024
   Riley RD, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c221
   Rocchi L, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00400
   Royston P, 2004, STATA J, V4, P227, DOI 10.1177/1536867X0400400301
   Schilberg L, 2017, J COGNITIVE NEUROSCI, V29, P1022, DOI 10.1162/jocn_a_01100
   Schmidt S, 2009, CLIN NEUROPHYSIOL, V120, P987, DOI 10.1016/j.clinph.2009.02.164
   Singh AM, 2016, NEUROSCI LETT, V633, P215, DOI 10.1016/j.neulet.2016.09.027
   Stigler S M, 1997, Stat Methods Med Res, V6, P103
   Suppa A, 2016, BRAIN STIMUL, V9, P323, DOI 10.1016/j.brs.2016.01.006
   Tecchio F, 2008, CLIN NEUROPHYSIOL, V119, P675, DOI 10.1016/j.clinph.2007.10.023
   Thompson PM, 2014, BRAIN IMAGING BEHAV, V8, P153, DOI 10.1007/s11682-013-9269-5
   TUKEY JW, 1962, ANN MATH STAT, V33, P1, DOI 10.1214/aoms/1177704711
   Vallence AM, 2015, NEUROSCIENCE, V304, P266, DOI 10.1016/j.neuroscience.2015.07.043
   Vernet M, 2014, CLIN NEUROPHYSIOL, V125, P320, DOI 10.1016/j.clinph.2013.07.004
   Williams R, 2012, STATA J, V12, P308, DOI 10.1177/1536867X1201200209
   Young-Bernier M, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00182
NR 76
TC 12
Z9 12
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1935-861X
EI 1876-4754
J9 BRAIN STIMUL
JI Brain Stimul.
PD SEP-OCT
PY 2020
VL 13
IS 5
BP 1476
EP 1488
DI 10.1016/j.brs.2020.07.018
PG 13
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA NU9MT
UT WOS:000573960600009
PM 32758665
OA hybrid, Green Accepted, Green Published
DA 2021-10-30
ER

PT J
AU Swords, RT
   Coutre, S
   Maris, MB
   Zeidner, JF
   Foran, JM
   Cruz, J
   Erba, HP
   Berdeja, JG
   Tam, W
   Vardhanabhuti, S
   Pawlikowska-Dobler, I
   Faessel, HM
   Dash, AB
   Sedarati, F
   Dezube, BJ
   Faller, DV
   Savona, MR
AF Swords, Ronan T.
   Coutre, Steven
   Maris, Michael B.
   Zeidner, Joshua F.
   Foran, James M.
   Cruz, Jose
   Erba, Harry P.
   Berdeja, Jesus G.
   Tam, Wayne
   Vardhanabhuti, Saran
   Pawlikowska-Dobler, Iwona
   Faessel, Helene M.
   Dash, Ajeeta B.
   Sedarati, Farhad
   Dezube, Bruce J.
   Faller, Douglas V.
   Savona, Michael R.
TI Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor,
   combined with azacitidine in patients with AML
SO BLOOD
LA English
DT Article
ID ACUTE MYELOID-LEUKEMIA; RISK MYELODYSPLASTIC SYNDROME; CONVENTIONAL CARE
   REGIMENS; CANCER-CELLS; OVARIAN-CANCER; OLDER PATIENTS; IN-VIVO;
   PHASE-I; MLN4924; APOPTOSIS
AB Pevonedistat (TAK-924/MLN4924) is a novel inhibitor of NEDD8-activating enzyme (NAE) with single-agent activity in relapsed/refractory acute myeloid leukemia (AML). We performed a phase 1b study of pevonedistat (PEV) with azacitidine (AZA) based on synergistic activity seen preclinically. Primary objectives included safety and tolerability, and secondary objectives included pharmacokinetics (PK) and disease response. Patients >= 60 years with treatment-naive AML (unfit for standard induction therapy) received PEV 20 or 30 mg/m(2) IV on days 1, 3, and 5 combined with fixed-dose AZA (75 mg/m(2) IV/subcutaneously) on days 1 to 5, 8, and 9, every 28 days. The most common treatment-emergent adverse events were constipation (48%), nausea (42%), fatigue (42%), and anemia (39%). In total, 11 deaths were observed and considered unrelated to study therapy by the investigators. Transient elevations in aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were dose limiting. The recommended phase 2 dose (RP2D) of PEV in this combination is 20 mg/m(2). PEV PK was not altered by the addition of AZA. Overall response rate (ORR) based on an intent-to-treat analysis was 50% (20 complete remissions [CRs], 5 complete remission with incomplete peripheral count recovery, 7 partial remissions [PRs]), with an 8.3-month median duration of remission. In patients receiving >= 6 cycles of therapy (n = 23, 44%), ORR was 83%. In patients with TP53 mutations, the composite CR/PR rate was 80% (4/5). Two of these patients stayed on study for >10 cycles. Baseline bone marrow blast percentage or cytogenetic/molecular risk did not influence ORR.
C1 [Swords, Ronan T.] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA.
   [Coutre, Steven] Stanford Univ, Dept Med, Stanford, CA 94305 USA.
   [Maris, Michael B.] Colorado Blood Canc Inst, Denver, CO USA.
   [Zeidner, Joshua F.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
   [Foran, James M.] Mayo Clin, Ctr Canc, Jacksonville, FL 32224 USA.
   [Cruz, Jose] Texas Transplant Inst, San Antonio, TX USA.
   [Erba, Harry P.] Univ Alabama Birmingham, UAB Comprehens Canc Ctr, Birmingham, AL USA.
   [Berdeja, Jesus G.] Sarah Cannon Res Inst, Nashville, TN USA.
   [Tam, Wayne] Weill Cornell Med, Dept Pathol & Lab Med, New York, NY USA.
   [Vardhanabhuti, Saran; Pawlikowska-Dobler, Iwona; Faessel, Helene M.; Dash, Ajeeta B.; Sedarati, Farhad; Dezube, Bruce J.; Faller, Douglas V.] Millennium Pharmaceut Inc, Cambridge, MA USA.
   [Savona, Michael R.] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA.
RP Swords, RT (corresponding author), Univ Miami, Sylvester Comprehens Canc Ctr, Miller Sch Med, Leukemia Program, 1475 NW 12th Ave,CRB,610G, Miami, FL 33136 USA.; Savona, MR (corresponding author), Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Div Hematol Oncol, 777 Preston Res Bldg,2200 Pierce Ave, Nashville, TN 37232 USA.
EM rswords@med.miami.edu; michael.savona@vanderbilt.edu
OI Zeidner, Joshua/0000-0002-9014-1514; Tam, Wayne/0000-0003-4283-0005;
   Cruz, Jose Carlos/0000-0002-2923-675X; Coutre,
   Steven/0000-0001-8420-5748
FU Takeda Pharmaceuticals, Inc.Takeda Pharmaceutical Company Ltd; NATIONAL
   CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [P30CA016086] Funding Source: NIH RePORTER; NATIONAL
   CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Advancing Translational Sciences (NCATS)
   [KL2TR000461] Funding Source: NIH RePORTER
FX This research was supported by Takeda Pharmaceuticals, Inc.
CR BHATIA S, 2011, J CLIN ONCOL S, V29
   Brownell JE, 2010, MOL CELL, V37, P102, DOI 10.1016/j.molcel.2009.12.024
   Burnett AK, 2007, CANCER, V109, P1114, DOI 10.1002/cncr.22496
   Burnett AK, 2010, J CLIN ONCOL, V28, P2389, DOI 10.1200/JCO.2009.26.4242
   Burnett AK, 2009, BRIT J HAEMATOL, V145, P318, DOI 10.1111/j.1365-2141.2009.07604.x
   Celgene Corporation, VID PRESCR INF
   Chen GD, 2010, INT J ONCOL, V37, P1339, DOI 10.3892/ijo_00000786
   Cheson BD, 2003, J CLIN ONCOL, V21, P4642, DOI 10.1200/JCO.2003.04.036
   Chiba T, 2004, CURR PROTEIN PEPT SC, V5, P177, DOI 10.2174/1389203043379783
   Cooper BW, 2015, CL LYMPH MYELOM LEUK, V15, P428, DOI 10.1016/j.clml.2015.02.017
   Crusio KM, 2010, ONCOGENE, V29, P4865, DOI 10.1038/onc.2010.222
   Czuczman NM, 2016, BLOOD, V127, P1128, DOI 10.1182/blood-2015-04-640920
   Dombret H, 2015, BLOOD, V126, P291, DOI 10.1182/blood-2015-01-621664
   El-Mesery M, 2015, BRIT J PHARMACOL, V172, P1222, DOI 10.1111/bph.12998
   Fenaux P, 2010, J CLIN ONCOL, V28, P562, DOI 10.1200/JCO.2009.23.8329
   Garcia K, 2014, MOL CANCER THER, V13, P1625, DOI 10.1158/1535-7163.MCT-13-0634
   GARCIAMANERO G, 2015, BLOOD, V126, P453
   Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898
   Harvey R., 2012, 17 C EUR HEM ASS 14
   Herrmann J, 2007, CIRC RES, V100, P1276, DOI 10.1161/01.RES.0000264500.11888.f0
   Ho IL, 2015, SCI REP, V5, P16498
   Hou HA, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.59
   Jazaeri AA, 2013, MOL CANCER THER, V12, P1958, DOI 10.1158/1535-7163.MCT-12-1028
   KAUH JS, 2011, J CLIN ONCOL S, V29
   KAUH JS, 2009, J CLIN ONCOL S, V27
   Kenealy M, 2017, LEUKEMIA LYMPHOMA, V58, P298, DOI 10.1080/10428194.2016.1190971
   Khalife J, 2015, LEUKEMIA, V29, P1981, DOI 10.1038/leu.2015.106
   Knorr KLB, 2015, CELL DEATH DIFFER, V22, P2133, DOI 10.1038/cdd.2015.74
   Lin JJ, 2010, CANCER RES, V70, P10310, DOI 10.1158/0008-5472.CAN-10-2062
   Lin WC, 2015, AM J CANCER RES, V5, P3350
   Milhollen MA, 2011, CANCER RES, V71, P3042, DOI 10.1158/0008-5472.CAN-10-2122
   Milhollen MA, 2010, BLOOD, V116, P1515, DOI 10.1182/blood-2010-03-272567
   National Cancer Institute Cancer Therapy Evaluation Program (NCI CTEP), 2006, MESQUITE MODULAR SYS, V3, P2011
   Nawrocki ST, 2013, CLIN CANCER RES, V19, P3577, DOI 10.1158/1078-0432.CCR-12-3212
   Nawrocki ST, 2012, EXPERT OPIN INV DRUG, V21, P1563, DOI 10.1517/13543784.2012.707192
   Nawrocki ST, 2010, BLOOD, V116, P1335, DOI 10.1182/blood.V116.21.3255.3255
   O'Donnell MR, 2012, J NATL COMPR CANC NE, V10, P984, DOI 10.6004/jnccn.2012.0103
   Ofran Y, 2016, BLOOD, V128, P488, DOI 10.1182/blood-2016-01-635060
   Oladghaffari Maryam, 2015, Asian Pac J Cancer Prev, V16, P5471
   Papaemmanuil E, 2016, NEW ENGL J MED, V374, P2209, DOI 10.1056/NEJMoa1516192
   Pleyer L, 2014, ANN HEMATOL, V93, P1825, DOI 10.1007/s00277-014-2126-9
   Ramsingh G, 2013, LEUKEMIA, V27, P725, DOI 10.1038/leu.2012.214
   Rowe JM, 2010, BLOOD, V116, P3147, DOI 10.1182/blood-2010-05-260117
   Sarantopoulos J, 2016, CLIN CANCER RES, V22, P847, DOI 10.1158/1078-0432.CCR-15-1338
   Sekeres MA, 2014, BLOOD, V124
   Shah JJ, 2016, CLIN CANCER RES, V22, P34, DOI 10.1158/1078-0432.CCR-15-1237
   Shah JJ, 2009, BLOOD, V114, P735, DOI 10.1182/blood.V114.22.1854.1854
   Smith PG., 2011, BLOOD, V118, P578, DOI [10.1182/blood.V118.21.578.578, DOI 10.1182/BLOOD.V118.21.578.578]
   Soucy Teresa A, 2010, Genes Cancer, V1, P708, DOI 10.1177/1947601910382898
   Soucy TA, 2009, CLIN CANCER RES, V15, P3912, DOI 10.1158/1078-0432.CCR-09-0343
   Soucy TA, 2009, NATURE, V458, P732, DOI 10.1038/nature07884
   Sumi H, 2016, BIOCHEM BIOPH RES CO, V480, P380, DOI 10.1016/j.bbrc.2016.10.058
   Swords RT, 2017, BLOOD CANCER J, V7, DOI 10.1038/bcj.2017.1
   Swords RT, 2015, BRIT J HAEMATOL, V169, P534, DOI 10.1111/bjh.13323
   Swords RT, 2010, BLOOD, V115, P3796, DOI 10.1182/blood-2009-11-254862
   Traore Tea, 2010, J CLIN ONCOL, V29, P8594
   Visconte V, 2016, LEUKEMIA, V30, P1190, DOI 10.1038/leu.2015.250
   Wan JF, 2016, TECHNOL CANCER RES T, V15, P527, DOI 10.1177/1533034615588197
   Wang M, 2011, EXPERT OPIN THER TAR, V15, P253, DOI 10.1517/14728222.2011.550877
   Wei DP, 2012, CANCER RES, V72, P282, DOI 10.1158/0008-5472.CAN-11-2866
   Welch JS, 2016, NEW ENGL J MED, V375, P2023, DOI 10.1056/NEJMoa1605949
   Wolenski FS, 2015, CELL DEATH DISCOV, V1, DOI 10.1038/cddiscovery.2015.34
   Zhao LQ, 2011, MOL CANCER THER, V10, P2415, DOI 10.1158/1535-7163.MCT-11-0401
   Zhou L, 2016, BLOOD, V127, P2219, DOI 10.1182/blood-2015-06-653717
NR 64
TC 107
Z9 108
U1 1
U2 12
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD MAR 29
PY 2018
VL 131
IS 13
BP 1415
EP 1424
DI 10.1182/blood-2017-09-805895
PG 10
WC Hematology
SC Hematology
GA GD7JK
UT WOS:000430687900007
PM 29348128
OA Green Published, Bronze
HC Y
HP N
DA 2021-10-30
ER

PT J
AU Wright, MB
   Santos, JV
   Kemmer, C
   Maugeais, C
   Carralot, JP
   Roever, S
   Molina, J
   Ducasa, GM
   Mitrofanova, A
   Sloan, A
   Ahmad, A
   Pedigo, C
   Ge, MY
   Pressly, J
   Barisoni, L
   Mendez, A
   Sgrignani, J
   Cavalli, A
   Merscher, S
   Prunotto, M
   Fornoni, A
AF Wright, Matthew B.
   Santos, Javier Varona
   Kemmer, Christian
   Maugeais, Cyrille
   Carralot, Jean-Philippe
   Roever, Stephan
   Molina, Judith
   Ducasa, G. Michelle
   Mitrofanova, Alla
   Sloan, Alexis
   Ahmad, Anis
   Pedigo, Christopher
   Ge, Mengyuan
   Pressly, Jeffrey
   Barisoni, Laura
   Mendez, Armando
   Sgrignani, Jacopo
   Cavalli, Andrea
   Merscher, Sandra
   Prunotto, Marco
   Fornoni, Alessia
TI Compounds targeting OSBPL7 increase ABCA1-dependent cholesterol efflux
   preserving kidney function in two models of kidney disease
SO NATURE COMMUNICATIONS
LA English
DT Article
ID OXYSTEROL-BINDING-PROTEIN; HAMSTER OVARY CELLS; RENAL LIPID-METABOLISM;
   LIVER X RECEPTORS; ADRIAMYCIN NEPHROPATHY; MOUSE MODEL; MICE;
   ATHEROSCLEROSIS; ACCUMULATION; FIBROSIS
AB Impaired cellular cholesterol efflux is a key factor in the progression of renal, cardiovascular, and autoimmune diseases. Here we describe a class of 5-arylnicotinamide compounds, identified through phenotypic drug discovery, that upregulate ABCA1-dependent cholesterol efflux by targeting Oxysterol Binding Protein Like 7 (OSBPL7). OSBPL7 was identified as the molecular target of these compounds through a chemical biology approach, employing a photoactivatable 5-arylnicotinamide derivative in a cellular cross-linking/immunoprecipitation assay. Further evaluation of two compounds (Cpd A and Cpd G) showed that they induced ABCA1 and cholesterol efflux from podocytes in vitro and normalized proteinuria and prevented renal function decline in mouse models of proteinuric kidney disease: Adriamycin-induced nephropathy and Alport Syndrome. In conclusion, we show that small molecule drugs targeting OSBPL7 reveal an alternative mechanism to upregulate ABCA1, and may represent a promising new therapeutic strategy for the treatment of renal diseases and other disorders of cellular cholesterol homeostasis. This study describes a class of small molecule compounds that promote ABCA1-dependent cholesterol efflux via a non-transcriptional mechanism, the identification of the molecular target by a chemical biology approach, and the potential of these agents for the treatment of chronic kidney diseases and potentially other diseases where lipid accumulation drives disease progression.
C1 [Wright, Matthew B.; Kemmer, Christian; Maugeais, Cyrille; Carralot, Jean-Philippe; Roever, Stephan; Prunotto, Marco] F Hoffmann La Roche Ltd, Roche Innovat Ctr Basel, Pharma Res & Early Dev pRED, Basel, Switzerland.
   [Santos, Javier Varona; Molina, Judith; Ducasa, G. Michelle; Mitrofanova, Alla; Sloan, Alexis; Pedigo, Christopher; Ge, Mengyuan; Pressly, Jeffrey; Merscher, Sandra; Fornoni, Alessia] Univ Miami, Miller Sch Med, Katz Family Div Nephrol & Hypertens, Dept Med, Miami, FL 33136 USA.
   [Santos, Javier Varona; Molina, Judith; Ducasa, G. Michelle; Mitrofanova, Alla; Sloan, Alexis; Pedigo, Christopher; Ge, Mengyuan; Pressly, Jeffrey; Merscher, Sandra; Fornoni, Alessia] Univ Miami, Miller Sch Med, Peggy & Harold Katz Family Drug Discovery Ctr, Miami, FL 33136 USA.
   [Ducasa, G. Michelle] Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA.
   [Ahmad, Anis] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA.
   [Barisoni, Laura] Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL 33136 USA.
   [Mendez, Armando] Univ Miami, Miller Sch Med, Diabet Res Inst, Miami, FL 33136 USA.
   [Sgrignani, Jacopo; Cavalli, Andrea] Univ Svizzera Italiana, Inst Res Biomed, Bellinzona, Switzerland.
   [Cavalli, Andrea] Swiss Inst Bioinformat, Lausanne, Switzerland.
   [Prunotto, Marco] Univ Geneva, Sch Pharmaceut Sci, Geneva, Switzerland.
RP Prunotto, M (corresponding author), F Hoffmann La Roche Ltd, Roche Innovat Ctr Basel, Pharma Res & Early Dev pRED, Basel, Switzerland.; Fornoni, A (corresponding author), Univ Miami, Miller Sch Med, Katz Family Div Nephrol & Hypertens, Dept Med, Miami, FL 33136 USA.; Fornoni, A (corresponding author), Univ Miami, Miller Sch Med, Peggy & Harold Katz Family Drug Discovery Ctr, Miami, FL 33136 USA.; Prunotto, M (corresponding author), Univ Geneva, Sch Pharmaceut Sci, Geneva, Switzerland.
EM marco.prunotto@unige.ch; afornoni@med.miami.edu
OI Varona Santos, Javier/0000-0002-6844-4500
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01DK117599, R01DK104753, R01CA227493,
   U54DK083912, UM1DK100846, U01DK116101, UL1TR000460]; F. Hoffman-La
   Roche; Boehringer IngelheimBoehringer Ingelheim; American Heart
   AssociationAmerican Heart Association [16PRE30200010, 14PRE20380743,
   18PRE34030042]
FX We would like to acknowledge the contribution of Constantinos Panousis,
   Thomas Hartung (for the tritiated azide), Beat Frei, Fabienne Ricklin,
   Paul Hebeisen and Ulrike Obst (for the synthesis of individual
   compounds), Uwe Grether (for medicinal chemistry guidance), and
   Alejandro Ruiz (for the blinded analysis of PAS-stained kidney
   sections). A.F. and S.M. are supported by the NIH grants R01DK117599,
   R01DK104753, R01CA227493. A.F. is supported by NIH grants U54DK083912,
   UM1DK100846, U01DK116101, and UL1TR000460 (Miami Clinical Translational
   Science Institute). A.F. and S.M. are supported by F. Hoffman-La Roche
   and by Boehringer Ingelheim. G.M.D., C.P., and M.G. were supported by a
   Predoctoral Fellowship of the American Heart Association (16PRE30200010,
   14PRE20380743, and 18PRE34030042, respectively).
CR Bowden K, 2008, J BIOL CHEM, V283, P18210, DOI 10.1074/jbc.M800918200
   Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161
   Caldas YA, 2011, KIDNEY INT, V80, P535, DOI 10.1038/ki.2011.159
   Cosgrove D, 1996, GENE DEV, V10, P2981, DOI 10.1101/gad.10.23.2981
   Dong JQ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08791-0
   Ducasa GM, 2019, J CLIN INVEST, V129, P3387, DOI 10.1172/JCI125316
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Fu B, 2014, J COMPUT CHEM, V35, P1101, DOI 10.1002/jcc.23588
   Gaede P, 2008, NEW ENGL J MED, V358, P580, DOI 10.1056/NEJMoa0706245
   Gast C, 2016, NEPHROL DIAL TRANSPL, V31, P961, DOI 10.1093/ndt/gfv325
   Groopman EE, 2019, NEW ENGL J MED, V380, P142, DOI 10.1056/NEJMoa1806891
   Gross O, 2004, NEPHROL DIAL TRANSPL, V19, P1716, DOI 10.1093/ndt/gfh219
   Gross O, 2003, KIDNEY INT, V63, P438, DOI 10.1046/j.1523-1755.2003.00779.x
   Hara S, 2015, AM J PATHOL, V185, P2118, DOI 10.1016/j.ajpath.2015.04.007
   Heerspink HJL, 2020, NEW ENGL J MED, V383, P1436, DOI 10.1056/NEJMoa2024816
   Herman-Edelstein M, 2014, J LIPID RES, V55, P561, DOI 10.1194/jlr.P040501
   Hill NR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158765
   Hiruma S, 2021, CARDIOVASC DIABETOL, V20, DOI 10.1186/s12933-021-01228-3
   Hovind P, 2003, DIABETES CARE, V26, P1258, DOI 10.2337/diacare.26.4.1258
   Hsu FY, 2017, KIDNEY BLOOD PRESS R, V42, P358, DOI 10.1159/000477946
   Iseki K, 1996, KIDNEY INT, V49, P800, DOI 10.1038/ki.1996.111
   Jaworski CJ, 2001, GENOMICS, V78, P185, DOI 10.1006/geno.2001.6663
   Jiang LS, 2009, CARDIOVASC RES, V81, P805, DOI 10.1093/cvr/cvn344
   Joseph SB, 2002, P NATL ACAD SCI USA, V99, P7604, DOI 10.1073/pnas.112059299
   Kaseda R, 2018, BMC NEPHROL, V19, DOI 10.1186/s12882-018-0814-8
   Kim JJ, 2021, EBIOMEDICINE, V63, DOI 10.1016/j.ebiom.2020.103162
   Kiss E, 2013, AM J PATHOL, V182, P727, DOI 10.1016/j.ajpath.2012.11.033
   Kiss E, 2011, AM J PATHOL, V179, P92, DOI 10.1016/j.ajpath.2011.03.019
   Koepke ML, 2007, NEPHROL DIAL TRANSPL, V22, P1062, DOI 10.1093/ndt/gfl810
   Lagace TA, 1997, BIOCHEM J, V326, P205, DOI 10.1042/bj3260205
   Lagace TA, 1999, J LIPID RES, V40, P109
   Lee VWS, 2011, NEPHROLOGY, V16, P30, DOI 10.1111/j.1440-1797.2010.01383.x
   Lehto M, 2001, J LIPID RES, V42, P1203
   Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303
   Lund EG, 2003, ARTERIOSCL THROM VAS, V23, P1169, DOI 10.1161/01.ATV.0000056743.42348.59
   Ma ZQ, 2017, CURR ISSUES MOL BIOL, V22, P41, DOI 10.21775/cimb.022.041
   Merscher-Gomez S, 2013, DIABETES, V62, P3817, DOI 10.2337/db13-0399
   Mitrofanova A, 2018, KIDNEY INT, V94, P1151, DOI 10.1016/j.kint.2018.06.031
   Mizoguchi T, 2004, J LIPID RES, V45, P396, DOI 10.1194/jlr.D300024-JLR200
   Moffat JG, 2017, NAT REV DRUG DISCOV, V16, P531, DOI 10.1038/nrd.2017.111
   Panday N, 2006, BIOORG MED CHEM LETT, V16, P5231, DOI 10.1016/j.bmcl.2006.06.081
   Patel M, 2014, DIABETOLOGIA, V57, P435, DOI 10.1007/s00125-013-3095-6
   Pedigo CE, 2016, J CLIN INVEST, V126, P3336, DOI 10.1172/JCI85939
   Pergola PE, 2011, NEW ENGL J MED, V365, P327, DOI 10.1056/NEJMoa1105351
   Proctor G, 2006, DIABETES, V55, P2502, DOI 10.2337/db05-0603
   Puntoni M, 2012, AM J CARDIOVASC DRUG, V12, P303, DOI 10.2165/11634140-000000000-00000
   Rover S, 2013, J MED CHEM, V56, P9874, DOI 10.1021/jm4010708
   Ruggenenti P, 1997, LANCET, V349, P1857
   Storey MK, 1998, BIOCHEM J, V336, P247, DOI 10.1042/bj3360247
   Su XL, 2016, AM J KIDNEY DIS, V67, P881, DOI 10.1053/j.ajkd.2016.01.016
   Sugamura K, 2010, J ATHEROSCLER THROMB, V17, P141, DOI 10.5551/jat.2865
   Terasaka N, 2003, FEBS LETT, V536, P6, DOI 10.1016/S0014-5793(02)03578-0
   Teslovich TM, 2010, NATURE, V466, P707, DOI 10.1038/nature09270
   Wang K, 2018, KIDNEY BLOOD PRESS R, V43, P768, DOI DOI 10.1159/000489913
   Wang Y, 2000, KIDNEY INT, V58, P1797, DOI 10.1046/j.1523-1755.2000.00342.x
   Wang ZW, 2005, DIABETES, V54, P2328, DOI 10.2337/diabetes.54.8.2328
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Yamamura T., 2019, MOL GENET GENOM MED, V7, DOI [10.1002/mgg3.883, DOI 10.1002/mgg3.883]
   Yan D, 2008, J BIOL CHEM, V283, P332, DOI 10.1074/jbc.M705313200
NR 59
TC 1
Z9 1
U1 0
U2 0
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD AUG 2
PY 2021
VL 12
IS 1
AR 4662
DI 10.1038/s41467-021-24890-3
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA TY0GU
UT WOS:000683463400003
PM 34341345
OA gold, Green Published
DA 2021-10-30
ER

PT J
AU Smith, SM
   McAuliffe, K
   Hall, JM
   McDonough, CW
   Gurka, MJ
   Robinson, TO
   Sacco, RL
   Pepine, C
   Shenkman, E
   Cooper-DeHoff, RM
AF Smith, Steven M.
   McAuliffe, Kathryn
   Hall, Jaclyn M.
   McDonough, Caitrin W.
   Gurka, Matthew J.
   Robinson, Temple O.
   Sacco, Ralph L.
   Pepine, Carl
   Shenkman, Elizabeth
   Cooper-DeHoff, Rhonda M.
TI Hypertension in Florida: Data From the OneFlorida Clinical Data Research
   Network
SO PREVENTING CHRONIC DISEASE
LA English
DT Article
ID NUTRITION EXAMINATION SURVEY; BLOOD-PRESSURE CONTROL; UNITED-STATES
   ADULTS; NATIONAL-HEALTH; TRENDS; PREVALENCE
AB Introduction
   Hypertension is highly prevalent in Florida, but surveillance through the Behavioral Risk Factor Surveillance System (BRFSS) is limited to self-reported hypertension and does not capture data on undiagnosed hypertension or measure blood pressure. We aimed to characterize the hypertensive population in the One-Florida Clinical Research Consortium by using electronic health records and provide proof-of-concept for using routinely collected clinical data to augment surveillance efforts.
   Methods
   We identified patients with hypertension, defined as having at least 1 outpatient visit from January 2012 through June 2016 with an ICD-9-CM or ICD-10-CM diagnosis code for hypertension, or in the absence of a diagnosis, an elevated blood pressure (systolic >= 140 mm Hg or diastolic >= 90 mm Hg) recorded in the electronic health record at the most recent visit. The hypertensive population was characterized and mapped by zip code of patient residence to county prevalence.
   Results
   Of 838,469 patients (27.9% prevalence) who met the criteria for hypertension, 68% had received a diagnosis and 61% had elevated blood pressure. The geographic distribution of hypertension differed between diagnosed hypertension (highest prevalence in northern Florida) and undiagnosed hypertension (highest prevalence along eastern coast, in southern Florida, and in some rural western Panhandle counties). Uncontrolled hypertension was concentrated in southern Florida and the western Panhandle.
   Conclusion
   Our use of clinical data, representing usual care for Floridians, allows for identifying cases of uncontrolled hypertension and potentially undiagnosed cases, which are not captured by existing surveillance methods. Large-scale pragmatic research networks, like OneFlorida, may be increasingly important for tailoring future health care services, trials, and public health programs.
C1 [Smith, Steven M.; McDonough, Caitrin W.; Cooper-DeHoff, Rhonda M.] Univ Florida, Coll Pharm, Dept Pharmacotherapy & Translat Res, Gainesville, FL 32611 USA.
   [Smith, Steven M.] Univ Florida, Coll Med, Dept Community Hlth & Family Med, Gainesville, FL 32611 USA.
   [McAuliffe, Kathryn; Hall, Jaclyn M.; Gurka, Matthew J.; Shenkman, Elizabeth] Univ Florida, Coll Med, Dept Hlth Outcomes & Biomed Informat, Gainesville, FL 32611 USA.
   [Robinson, Temple O.; Cooper-DeHoff, Rhonda M.] Bond Community Hlth Ctr Inc, Tallahassee, FL USA.
   [Robinson, Temple O.; Cooper-DeHoff, Rhonda M.] Florida State Univ, Coll Med, Tallahassee, FL 32306 USA.
   [Sacco, Ralph L.] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL USA.
   [Sacco, Ralph L.] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL USA.
   [Pepine, Carl; Cooper-DeHoff, Rhonda M.] Univ Florida, Coll Med, Dept Med, Div Cardiovasc Med, Gainesville, FL 32611 USA.
RP Cooper-DeHoff, RM (corresponding author), POB 100486, Gainesville, FL 32610 USA.
EM dehoff@cop.ufl.edu
RI Sacco, Ralph/Y-9278-2019; Smith, Steven/ABC-9691-2020
OI Pepine, Carl/0000-0002-6011-681X
FU OneFlorida Clinical Data Network - Patient-Centered Outcomes Research
   InstitutePatient-Centered Outcomes Research Institute - PCORI
   [CDRN-1501-26692]; OneFlorida Cancer Control Alliance - Florida
   Department of Health's James and Esther King Biomedical Research
   ProgramPatient-Centered Outcomes Research Institute - PCORI [4KB16];
   University of Florida Clinical and Translational Science Institute
   [UL1TR001427]; University of Miami Clinical and Translational Science
   Institute - National Institutes of Health's National Center for
   Advancing Translational Sciences [UL1TR000460]; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR001427,
   UL1TR000460] Funding Source: NIH RePORTER
FX We thank Myrtle Graham, Janelle Johnson, and Carlos Maeztu, citizen
   scientists for OneFlorida, for their contributions to the OneFlorida
   hypertension working group and continued interest in hypertension. We
   thank Hongzhi Xu for providing statistical expertise in the analysis of
   these data. We also acknowledge Eileen Handberg, PhD, David R. Nelson,
   MD, and William R. Hogan, MD, MS, for their leadership roles in
   OneFlorida and review and input on this article. Research reported in
   this article was supported in part by the OneFlorida Clinical Data
   Network, funded by the Patient-Centered Outcomes Research Institute (no.
   CDRN-1501-26692); in part by the OneFlorida Cancer Control Alliance,
   funded by the Florida Department of Health's James and Esther King
   Biomedical Research Program no. 4KB16; and in part by the University of
   Florida Clinical and Translational Science Institute and the University
   of Miami Clinical and Translational Science Institute, which are
   supported in part by the National Institutes of Health's National Center
   for Advancing Translational Sciences under award nos. UL1TR001427 and
   UL1TR000460, respectively. The content is solely the responsibility of
   the authors and does not necessarily represent the official views of the
   Patient-Centered Outcomes Research Institute, its board of governors or
   methodology, the OneFlorida Clinical Research Consortium, the University
   of Florida's Clinical and Translational Science Institute, the Florida
   Department of Health, or the National Institutes of Health.
CR [Anonymous], 2017, Circulation, V136, pe196, DOI 10.1161/CIR.0000000000000530
   Birman-Deych E, 2005, MED CARE, V43, P480, DOI 10.1097/01.mlr.0000160417.39497.a9
   Bullano MF, 2006, MED CARE, V44, P486, DOI 10.1097/01.mlr.0000207482.02503.55
   Dwyer-Lindgren L, 2017, JAMA INTERN MED, V177, P1003, DOI 10.1001/jamainternmed.2017.0918
   Dwyer-Lindgren L, 2016, JAMA-J AM MED ASSOC, V316, P2385, DOI 10.1001/jama.2016.13645
   Fleurence RL, 2014, J AM MED INFORM ASSN, V21, P578, DOI 10.1136/amiajnl-2014-002747
   Florida Department of Health, 2012, FLOR STAT HLTH IMPR
   Florida Department of Health, 2016, FLOR BEH RISK FACT S
   Florida Office of Economic and Demographic Research, 2017, POP DEM DAT COUNT AG
   Gu QP, 2008, AM J HYPERTENS, V21, P789, DOI 10.1038/ajh.2008.185
   Gu QP, 2012, CIRCULATION, V126, P2105, DOI 10.1161/CIRCULATIONAHA.112.096156
   Kearney PM, 2005, LANCET, V365, P217, DOI 10.1016/S0140-6736(05)70151-3
   Kung Hsiang-Ching, 2015, NCHS Data Brief, P1
   Leng B, 2015, J HYPERTENS, V33, P221, DOI 10.1097/HJH.0000000000000428
   Loop MS, 2017, CIRC-CARDIOVASC QUAL, V10, DOI 10.1161/CIRCOUTCOMES.116.003350
   McDonald M, 2009, J GERONTOL A-BIOL, V64, P256, DOI 10.1093/gerona/gln016
   Mills KT, 2016, CIRCULATION, V134, P441, DOI 10.1161/CIRCULATIONAHA.115.018912
   National Center for Health Statistics Centers for Disease Control and Prevention, INT CLASS DIS 10 REV
   Olives C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060308
   Patel SA, 2015, ANN INTERN MED, V163, P245, DOI 10.7326/M14-1753
   Sacco RL, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.116.004073
   Sampson UKA, 2016, J AM COLL CARDIOL, V68, P517, DOI 10.1016/j.jacc.2016.04.059
   Shenkman E, 2017, ACAD MED
   The National Center for Health Statistics Centers for Disease Control and Prevention., INT CLASS DIS 9 REV
   Yuan JW, 2017, J BIOMED INFORM, V66, P42, DOI 10.1016/j.jbi.2016.12.008
NR 25
TC 6
Z9 6
U1 0
U2 0
PU CENTERS  DISEASE CONTROL & PREVENTION
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1545-1151
J9 PREV CHRONIC DIS
JI Prev. Chronic Dis.
PD MAR
PY 2018
VL 15
AR 170332
DI 10.5888/pcd15.170332
PG 12
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA GI9EU
UT WOS:000434828700001
PM 29494332
OA Bronze, Green Published
DA 2021-10-30
ER

PT J
AU Ducasa, GM
   Mitrofanova, A
   Mallela, SK
   Liu, XC
   Molina, J
   Sloan, A
   Pedigo, CE
   Ge, MY
   Santos, JV
   Hernandez, Y
   Kim, JJ
   Maugeais, C
   Mendez, AJ
   Nair, V
   Kretzler, M
   Burke, GW
   Nelson, RG
   Ishimoto, Y
   Inagi, R
   Banerjee, S
   Liu, SY
   Szeto, HH
   Merscher, S
   Fontanesi, F
   Fornoni, A
AF Ducasa, G. Michelle
   Mitrofanova, Alla
   Mallela, Shamroop K.
   Liu, Xiaochen
   Molina, Judith
   Sloan, Alexis
   Pedigo, Christopher E.
   Ge, Mengyuan
   Santos, Javier Varona
   Hernandez, Yanio
   Kim, Jin-Ju
   Maugeais, Cyrille
   Mendez, Armando J.
   Nair, Viji
   Kretzler, Matthias
   Burke, George W.
   Nelson, Robert G.
   Ishimoto, Yu
   Inagi, Reiko
   Banerjee, Santanu
   Liu, Shaoyi
   Szeto, Hazel H.
   Merscher, Sandra
   Fontanesi, Flavia
   Fornoni, Alessia
TI ATP-binding cassette A1 deficiency causes cardiolipin-driven
   mitochondrial dysfunction in podocytes
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID DIABETIC KIDNEY-DISEASE; RENAL LIPID-METABOLISM; FATTY-ACID OXIDATION;
   CYTOCHROME-C; TANGIER-DISEASE; CHOLESTEROL ACCUMULATION;
   ENERGY-METABOLISM; ROS PRODUCTION; PALMITIC ACID; APOPTOSIS
AB Fibroblasts from patients with Tangier disease carrying ATP-binding cassette A1 (ABCA1) loss-of-function mutations are characterized by cardiolipin accumulation, a mitochondrial-specific phospholipid. Suppression of ABCA1 expression occurs in glomeruli from patients with diabetic kidney disease (DKD) and in human podocytes exposed to DKD sera collected prior to the development of DKD. We demonstrated that siRNA ABCA1 knockdown in podocytes led to reduced oxygen consumption capabilities associated with alterations in the oxidative phosphorylation (OXPHOS) complexes and with cardiolipin accumulation. Podocyte-specific deletion of Abca1 (Abca1(fl/fl)) rendered mice susceptible to DKD, and pharmacological induction of ABCA1 improved established DKD. This was not mediated by free cholesterol, as genetic deletion of sterol-o-acyltransferase-1 (SOAT1) in Abca1(fl/fl) mice was sufficient to cause free cholesterol accumulation but did not cause glomerular injury. Instead, cardiolipin mediates ABCA1-dependent susceptibility to podocyte injury, as inhibition of cardiolipin peroxidation with elamipretide improved DKD in vivo and prevented ABCA1-dependent podocyte injury in vitro and in vivo. Collectively, we describe a pathway definitively linking ABCA1 deficiency to cardiolipin-driven mitochondrial dysfunction. We demonstrated that this pathway is relevant to DKD and that ABCA1 inducers or inhibitors of cardiolipin peroxidation may each represent therapeutic strategies for the treatment of established DKD.
C1 [Ducasa, G. Michelle; Mitrofanova, Alla; Mallela, Shamroop K.; Liu, Xiaochen; Molina, Judith; Sloan, Alexis; Ge, Mengyuan; Santos, Javier Varona; Hernandez, Yanio; Kim, Jin-Ju; Merscher, Sandra; Fornoni, Alessia] Univ Miami, Dept Med, Drug Discovery Ctr, Katz Family Div Nephrol & Hypertens, Miami, FL USA.
   [Mitrofanova, Alla; Burke, George W.; Banerjee, Santanu] Univ Miami, Dept Surg, Miami, FL USA.
   [Pedigo, Christopher E.] Yale Univ, Dept Internal Med, New Haven, CT USA.
   [Maugeais, Cyrille] F Hoffmann La Roche Ltd, Roche Innovat Ctr Basel, Basel, Switzerland.
   [Mendez, Armando J.] Univ Miami, Diabet Res Inst, Miami, FL USA.
   [Nair, Viji; Kretzler, Matthias] Univ Michigan, Dept Internal Med, Div Nephrol, Ann Arbor, MI 48109 USA.
   [Nelson, Robert G.] NIDDK, Phoenix, AZ USA.
   [Ishimoto, Yu; Inagi, Reiko] Univ Tokyo, Div CKD Pathophysiol, Tokyo, Japan.
   [Liu, Shaoyi; Szeto, Hazel H.] Alexandria LaunchLabs, Social Profit Network Res Lab, New York, NY USA.
   [Fontanesi, Flavia] Univ Miami, Dept Biochem & Mol Biol, Neurosci Res Bldg 103B,1420 NW 9th Ave, Miami, FL 33136 USA.
RP Fontanesi, F (corresponding author), Univ Miami, Dept Biochem & Mol Biol, Neurosci Res Bldg 103B,1420 NW 9th Ave, Miami, FL 33136 USA.; Fornoni, A (corresponding author), Univ Miami, Katz Family Div Nephrol & Hypertens, 1580 NW 10th Ave, Miami, FL 33136 USA.; Fornoni, A (corresponding author), Univ Miami, Peggy & Harold Katz Family Drug Discovery Ctr, 1580 NW 10th Ave, Miami, FL 33136 USA.
EM ffontanesi@med.miami.edu; afornoni@med.miami.edu
RI Mallela, Shamroop kumar/W-6982-2019
OI Mallela, Shamroop kumar/0000-0002-4553-8504; Merscher,
   Sandra/0000-0002-4757-7494; Liu, xiaochen/0000-0003-0617-1401; fornoni,
   Alessia/0000-0002-1313-7773; Mitrofanova, Alla/0000-0001-5065-9522; KIM,
   JINJU/0000-0001-8432-7956
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01DK117599, R01DK104753, R01CA227493,
   U54DK083912, UM1DK100846, U01DK116101, UL1TR000460]; Intramural Research
   Program of the National Institute of Diabetes and Digestive and Kidney
   Disease; American Heart AssociationAmerican Heart Association
   [16PRE30200010]; Scientist Development Grant of the American Heart
   AssociationAmerican Heart Association [14SDG20040003]; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [R01CA227493] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)
   [ZIADK069062, U54DK083912, R01DK117599, UM1DK100846, R01DK104753,
   U01DK116101] Funding Source: NIH RePORTER
FX AF is supported by NIH grants R01DK117599, R01DK104753, R01CA227493,
   U54DK083912, UM1DK100846, U01DK116101, and UL1TR000460 (Miami Clinical
   Translational Science Institute). RGN was supported by the Intramural
   Research Program of the National Institute of Diabetes and Digestive and
   Kidney Disease. GMD was supported by a predoctoral fellowship of the
   American Heart Association (16PRE30200010). FF is supported by a
   Scientist Development Grant of the American Heart Association
   (14SDG20040003). We thank Dr John Parks for the Abca1<SUP>fl/fl</SUP>
   mice and Dr Laura Barisoni for her histological assessments of the
   Abca1<SUP>fl/fl</SUP> ob/ob mouse model. We thank Kevin Johnson for the
   PAS stainings done in all mouse models and Dr Mayrin Correa for
   technical assistance in some of the in vitro experiments. We give a
   special thanks to the Katz family for continuous support.
CR Acin-Perez R, 2008, MOL CELL, V32, P529, DOI 10.1016/j.molcel.2008.10.021
   Anders HJ, 2018, NAT REV NEPHROL, V14, P361, DOI 10.1038/s41581-018-0001-y
   [Anonymous], 2017, Am J Kidney Dis, V69, pA4, DOI 10.1053/j.ajkd.2017.01.036
   BALE PM, 1971, J CLIN PATHOL, V24, P609, DOI 10.1136/jcp.24.7.609
   Barrientos A, 2013, CELL METAB, V18, P147, DOI 10.1016/j.cmet.2013.07.010
   Basova LV, 2007, BIOCHEMISTRY-US, V46, P3423, DOI 10.1021/bi061854k
   Bazan S, 2013, J BIOL CHEM, V288, P401, DOI 10.1074/jbc.M112.425876
   Belikova NA, 2006, BIOCHEMISTRY-US, V45, P4998, DOI 10.1021/bi0525573
   Birk AV, 2014, BRIT J PHARMACOL, V171, P2017, DOI 10.1111/bph.12468
   Birk AV, 2013, J AM SOC NEPHROL, V24, P1250, DOI 10.1681/ASN.2012121216
   Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914
   Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905
   Claypool SM, 2012, TRENDS BIOCHEM SCI, V37, P32, DOI 10.1016/j.tibs.2011.09.003
   CLIFTONBLIGH P, 1972, NEW ENGL J MED, V286, P567, DOI 10.1056/NEJM197203162861103
   Czajka A, 2015, EBIOMEDICINE, V2, P499, DOI 10.1016/j.ebiom.2015.04.002
   de Borst MH, 2015, NAT REV NEPHROL, V11, P5, DOI 10.1038/nrneph.2014.209
   FERRANS VJ, 1975, AM J PATHOL, V78, P101
   Fobker M, 2001, FEBS LETT, V500, P157, DOI 10.1016/S0014-5793(01)02578-9
   Forbes JM, 2018, NAT REV NEPHROL, V14, P291, DOI 10.1038/nrneph.2018.9
   FRY M, 1981, J BIOL CHEM, V256, P1874
   Galvan DL, 2017, KIDNEY INT, V92, P1282, DOI 10.1016/j.kint.2017.05.015
   Griparic L, 2004, J BIOL CHEM, V279, P18792, DOI 10.1074/jbc.M400920200
   Herman-Edelstein M, 2014, J LIPID RES, V55, P561, DOI 10.1194/jlr.P040501
   Hong MY, 2002, CARCINOGENESIS, V23, P1919, DOI 10.1093/carcin/23.11.1919
   Horie T, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3883
   Huang ZT, 2008, FREE RADICAL BIO MED, V44, P1935, DOI 10.1016/j.freeradbiomed.2008.02.016
   Hudkins KL, 2010, J AM SOC NEPHROL, V21, P1533, DOI 10.1681/ASN.2009121290
   Imasawa T, 2017, FASEB J, V31, P294, DOI 10.1096/fj.201600293R
   Imasawa T, 2013, INT J BIOCHEM CELL B, V45, P2109, DOI 10.1016/j.biocel.2013.06.013
   Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706
   Kagan VE, 2005, NAT CHEM BIOL, V1, P223, DOI 10.1038/nchembio727
   Kampe K, 2014, AM J PHYSIOL-RENAL, V306, pF401, DOI 10.1152/ajprenal.00454.2013
   Kang HM, 2015, NAT MED, V21, P37, DOI 10.1038/nm.3762
   Karunakaran D, 2015, CIRC RES, V117, P266, DOI 10.1161/CIRCRESAHA.117.305624
   Kitada M, 2014, WORLD J DIABETES, V5, P342, DOI 10.4239/wjd.v5.i3.342
   Kohl I, 2013, J BREATH RES, V7, DOI 10.1088/1752-7155/7/1/017110
   Kolavennu V, 2008, DIABETES, V57, P714, DOI 10.2337/db07-1241
   Leadsham JE, 2013, CELL METAB, V18, P279, DOI 10.1016/j.cmet.2013.07.005
   Merscher-Gomez S, 2013, DIABETES, V62, P3817, DOI 10.2337/db13-0399
   Meyer TW, 1999, DIABETOLOGIA, V42, P1341, DOI 10.1007/s001250051447
   Montero J, 2010, BBA-BIOENERGETICS, V1797, P1217, DOI 10.1016/j.bbabio.2010.02.010
   Murphy MP, 2013, CELL METAB, V18, P145, DOI 10.1016/j.cmet.2013.07.006
   Oram JF, 2001, J LIPID RES, V42, P1173
   Pagtalunan ME, 1997, J CLIN INVEST, V99, P342, DOI 10.1172/JCI119163
   Paradies G, 2014, BBA-BIOENERGETICS, V1837, P408, DOI 10.1016/j.bbabio.2013.10.006
   Patney Vikram, 2015, Diabetes Spectr, V28, P175, DOI 10.2337/diaspect.28.3.175
   Pavenstadt H, 2003, PHYSIOL REV, V83, P253, DOI 10.1152/physrev.00020.2002
   Pedigo CE, 2016, J CLIN INVEST, V126, P3336, DOI 10.1172/JCI85939
   Proctor G, 2006, DIABETES, V55, P2502, DOI 10.2337/db05-0603
   Qi HY, 2017, DIABETES, V66, P763, DOI 10.2337/db16-0695
   Sakamoto Y, 2017, EUR J PHARMACOL, V800, P48, DOI 10.1016/j.ejphar.2017.02.025
   Schlame M, 2009, BBA-BIOMEMBRANES, V1788, P2080, DOI 10.1016/j.bbamem.2009.04.019
   Sharma K, 2013, J AM SOC NEPHROL, V24, P1901, DOI 10.1681/ASN.2013020126
   Sieber J, 2013, AM J PATHOL, V183, P735, DOI 10.1016/j.ajpath.2013.05.023
   Sullivan EM, 2018, J BIOL CHEM, V293, P466, DOI [10.1074/jbc.M117.812834, 10.1074/jbc.m117.812834]
   Susztak K, 2006, DIABETES, V55, P225, DOI 10.2337/diabetes.55.1.225
   Szeto HH, 2014, BRIT J PHARMACOL, V171, P2029, DOI 10.1111/bph.12461
   Tabas I, 2002, J CLIN INVEST, V110, P905, DOI 10.1172/JCI200216452
   Tsun JGS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105787
   Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200
   Wang XXX, 2010, DIABETES, V59, P2916, DOI 10.2337/db10-0019
   Wang ZW, 2005, DIABETES, V54, P2328, DOI 10.2337/diabetes.54.8.2328
   WARNER GJ, 1995, J BIOL CHEM, V270, P5772, DOI 10.1074/jbc.270.11.5772
   Watkins SM, 1998, J LIPID RES, V39, P1583
   Wijesekara N, 2012, DIABETES, V61, P653, DOI 10.2337/db11-0944
   Xiao L, 2017, REDOX BIOL, V11, P297, DOI 10.1016/j.redox.2016.12.022
   Yin HY, 2012, FREE RADICAL RES, V46, P959, DOI 10.3109/10715762.2012.676642
   Zhang GS, 2018, SEMIN NEPHROL, V38, P111, DOI 10.1016/j.semnephrol.2018.01.002
   Zou HH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00686-8
NR 69
TC 33
Z9 35
U1 1
U2 4
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD AUG 1
PY 2019
VL 129
IS 8
BP 3387
EP 3400
DI 10.1172/JCI125316
PG 14
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA IM6BA
UT WOS:000478076500039
PM 31329164
OA Green Published, Bronze
DA 2021-10-30
ER

PT J
AU Yavagal, DR
   Lin, BW
   Raval, AP
   Garza, PS
   Dong, CH
   Zhao, WZ
   Rangel, EB
   McNiece, I
   Rundek, T
   Sacco, RL
   Perez-Pinzon, M
   Hare, JM
AF Yavagal, Dileep R.
   Lin, Baowan
   Raval, Ami P.
   Garza, Philip S.
   Dong, Chuanhui
   Zhao, Weizhao
   Rangel, Erika B.
   McNiece, Ian
   Rundek, Tatjana
   Sacco, Ralph L.
   Perez-Pinzon, Miguel
   Hare, Joshua M.
TI Efficacy and Dose-Dependent Safety of Intra-Arterial Delivery of
   Mesenchymal Stem Cells in a Rodent Stroke Model
SO PLOS ONE
LA English
DT Article
ID FOCAL CEREBRAL-ISCHEMIA; MARROW STROMAL CELLS; MYOCARDIAL-INFARCTION;
   THERAPEUTIC BENEFIT; ARTERY OCCLUSION; PROGENITOR CELLS;
   TRANSPLANTATION; RAT; NEUROPROTECTION; INJECTION
AB Intra-arterial (IA) delivery of mesenchymal stem cells (MSCs) for acute ischemic stroke is attractive for clinical translation. However, studies using rat model of stroke have demonstrated that IA MSCs delivery can decrease middle cerebral artery (MCA) flow, which may limit its clinical translation. The goal of this study is to identify a dose of IA MSCs (maximum tolerated dose; MTD) that does not compromise MCA flow and evaluate its efficacy and optimal timing in a rat model of reversible middle cerebral artery occlusion (rMCAo). We sought to determine if there is a difference in efficacy of acute (1 h) versus sub-acute (24 h) IA MSCs treatment after rMCAo. Adult female Sprague-Dawley rats underwent rMCAo (90 min) and an hour later a single dose of MSCs (at de-escalating doses 1 x10(6), 5 x 10(5), 2 x 10(5), 1 x 10(5) and 5 x 10(4)) was given using IA route. MSCs were suspended in phosphate buffered saline (PBS) and PBS alone was used for control experiments. We measured the percent change in mean laser Doppler flow signal over the ipsilateral MCA in de-escalating doses groups to determine MTD. The results demonstrated that the lowering of IA MSC dose to 1 x 10(5) and below did not compromise MCA flow and hence an IA MSC dose of 1 x 10(5) considered as MTD. Subsequently, 1 h and 24 h after rMCAo, rats were treated with IA MSCs or PBS. The 24 h delivery of IA MSCs significantly improved neurodeficit score and reduced the mean infarct volume at one month as compared to control, but not the 1 h delivery. Overall, this study suggests that the IA delivery of MSCs can be performed safely and efficaciously at the MTD of 1 x 10(5) delivered at 24 hours in rodent model of stroke.
C1 [Yavagal, Dileep R.; Lin, Baowan; Raval, Ami P.; Garza, Philip S.; Perez-Pinzon, Miguel] Univ Miami, Leonard M Miller Sch Med, Cerebral Vasc Dis Res Labs, Miami, FL 33136 USA.
   [Yavagal, Dileep R.; Raval, Ami P.; Dong, Chuanhui; Zhao, Weizhao; Rundek, Tatjana; Sacco, Ralph L.; Perez-Pinzon, Miguel] Univ Miami, Dept Neurol, Leonard M Miller Sch Med, Miami, FL USA.
   [Yavagal, Dileep R.; Rangel, Erika B.; McNiece, Ian; Hare, Joshua M.] Univ Miami, Leonard M Miller Sch Med, Interdisciplinary Stem Cell Inst, Miami, FL USA.
   [Hare, Joshua M.] Univ Miami, Dept Med, Leonard M Miller Sch Med, Miami, FL USA.
RP Yavagal, DR (corresponding author), Univ Miami, Leonard M Miller Sch Med, Cerebral Vasc Dis Res Labs, Miami, FL 33136 USA.
EM dyavagal@med.miami.edu
RI Sacco, Ralph/Y-9278-2019; Rangel, Erika Bevilaqua/H-3066-2013
OI Rangel, Erika Bevilaqua/0000-0003-0982-2484; Lin,
   Binshan/0000-0002-8481-302X
FU Department of Neurology, University of Miami (DRY); James and Esther
   King Biomedical Research Program; Florida Department of Health [2KN09];
   University of Miami intramural grant:Interdepartmental Research
   Development Initiative; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1TR000460] Funding Source: NIH
   RePORTER
FX This study was supported by Department of Neurology, University of Miami
   (DRY); James and Esther King Biomedical Research Program, Florida
   Department of Health Grant # 2KN09 (DRY); University of Miami intramural
   grant: Interdepartmental Research Development Initiative grant 2009-2010
   (DRY) and the Anderson Family Gift 2010-2011, 2012-2014 (DRY). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD
   Belayev L, 1999, BRAIN RES, V833, P181, DOI 10.1016/S0006-8993(99)01528-0
   Bhatia Rinky, 2005, Congest Heart Fail, V11, P87, DOI 10.1111/j.1527-5299.2005.03618.x
   Bliss T, 2007, STROKE, V38, P817, DOI 10.1161/01.STR.0000247888.25985.62
   Blum A, 2012, ATHEROSCLEROSIS, V223, P269, DOI 10.1016/j.atherosclerosis.2012.03.017
   Brenneman M, 2010, J CEREBR BLOOD F MET, V30, P140, DOI 10.1038/jcbfm.2009.198
   BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127
   Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005
   Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3
   Cloft HJ, 2009, AM J NEURORADIOL, V30, P453, DOI 10.3174/ajnr.A1462
   del Zoppo GJ, 2009, STROKE, V40, P2945, DOI 10.1161/STROKEAHA.109.192535
   del Zoppo Gregory J., 2009, V25, P34, DOI 10.1159/000209471
   Fischer UM, 2009, STEM CELLS DEV, V18, P683, DOI 10.1089/scd.2008.0253
   Friedrich MAG, 2012, CELL TRANSPLANT, V21, pS13, DOI 10.3727/096368912X612512
   Guzman R, 2008, STROKE, V39, P1300, DOI 10.1161/STROKEAHA.107.500470
   Ikeda N, 2005, STROKE, V36, P2725, DOI 10.1161/01.STR.0000190006.88896.d3
   Janowski M, 2013, J CEREBR BLOOD F MET, V33, P921, DOI 10.1038/jcbfm.2013.32
   Kamiya N, 2008, LIFE SCI, V83, P433, DOI 10.1016/j.lfs.2008.07.018
   Ley JJ, 2005, J PHARMACOL EXP THER, V313, P1090, DOI 10.1124/jpet.105.083386
   Li L, 2010, J CEREBR BLOOD F MET, V30, P653, DOI 10.1038/jcbfm.2009.238
   Li Y, 2001, NEUROLOGY, V56, P1666, DOI 10.1212/WNL.56.12.1666
   Lin BW, 2000, BRAIN RES, V865, P237, DOI 10.1016/S0006-8993(00)02228-9
   Liu X, 2013, PROG NEUROBIOL
   Lloyd-Jones D, 2010, CIRCULATION, V121, P948, DOI 10.1161/CIRCULATIONAHA.109.192666
   LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84
   Mimura T, 2005, J NEUROPATH EXP NEUR, V64, P1108, DOI 10.1097/01.jnen.0000190068.03009.b5
   Minnerup Jens, 2010, Exp Transl Stroke Med, V2, P3, DOI 10.1186/2040-7378-2-3
   Pendharkar AV, 2010, STROKE, V41, P2064, DOI 10.1161/STROKEAHA.109.575993
   Pittenger MF, 2004, CIRC RES, V95, P9, DOI 10.1161/01.RES.0000135902.99383.6f
   Pluchino S, 2005, NATURE, V436, P266, DOI 10.1038/nature03889
   Raval AP, 2009, NEUROSCIENCE, V160, P307, DOI 10.1016/j.neuroscience.2009.02.065
   Rosenblum S, 2012, STROKE, V43, P1624, DOI 10.1161/STROKEAHA.111.637884
   Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C
   Uccelli A, 2006, EUR J IMMUNOL, V36, P2566, DOI 10.1002/eji.200636416
   Walczak P, 2008, STROKE, V39, P1569, DOI 10.1161/STROKEAHA.107.502047
   Wechsler L, 2009, STROKE, V40, P510, DOI 10.1161/STROKEAHA.108.526863
   Williams AR, 2011, CIRC RES, V109, P923, DOI 10.1161/CIRCRESAHA.111.243147
   Williams BA, 2008, GERONTOLOGY, V54, P300, DOI 10.1159/000156223
   Woitzik J, 2007, J NEUROSURG, V106, P872, DOI 10.3171/jns.2007.106.5.872
   Zhang L, 2012, BRAIN RES, V1489, P104, DOI 10.1016/j.brainres.2012.10.017
NR 40
TC 50
Z9 51
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 7
PY 2014
VL 9
IS 5
AR e93735
DI 10.1371/journal.pone.0093735
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AG9HB
UT WOS:000335728900007
PM 24807059
OA gold, Green Submitted, Green Published
DA 2021-10-30
ER

PT J
AU Fiore, RN
   Goodman, KW
AF Fiore, Robin N.
   Goodman, Kenneth W.
TI Precision medicine ethics: selected issues and developments in
   next-generation sequencing, clinical oncology, and ethics
SO CURRENT OPINION IN ONCOLOGY
LA English
DT Review
DE ethics; next-generation sequencing; precision medicine
ID SECONDARY-FINDINGS; INCIDENTAL FINDINGS; PUBLIC-HEALTH; RETURN;
   INFORMATION; ENGAGEMENT; CHALLENGES; PROJECT; CONSENT; EXOME
AB Purpose of review
   In early 2015 the National Institutes of Health launched a new, national Precision Medicine Initiative with the primary goal of rapidly improving the prevention, diagnosis, and treatment of cancers. The first-stage emphasis on oncology presents unique opportunities for clinical oncology to influence how the ethical challenges of precision medicine are to be articulated and addressed. Thus, a review of recent developments in connection with the Initiative, in particular on core ethics issues in clinical genomics, is a useful starting point.
   Recent findings
   Unique ethical issues arise in precision medicine because of the enormous amounts of data generated by clinical whole-genome or whole-exome sequencing and the extent of current uncertainties with respect to data interpretations and disease associations. Among the most ethically challenging issues for clinicians are complicated informed consent processes, returning results - particularly secondary and incidental findings-and privacy and confidentiality.
   Summary
   The first tests of precision medicine ethics in practice will be in clinical oncology, providing a rare opportunity to shape the agenda and integrate practical ethics considerations. These efforts can benefit from pre-existing research ethics analyses and recommendations from clinical and translational genetics research.
C1 [Fiore, Robin N.; Goodman, Kenneth W.] Univ Miami, Miller Sch Med, Inst Bioeth & Hlth Policy, POB 016960, Miami, FL 33136 USA.
RP Fiore, RN (corresponding author), Univ Miami, Miller Sch Med, POB 016960, Miami, FL 33136 USA.
EM rfiore@miami.edu
RI Fiore, Robin N./V-5645-2019
FU University of Miami CTSI; National Center for Advancing Translational
   SciencesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [1UL1TR000460]; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000460]
   Funding Source: NIH RePORTER
FX This article is supported by the University of Miami CTSI, funded by the
   National Center for Advancing Translational Sciences grant
   #1UL1TR000460.
CR Appelbaum PS, 2014, HASTINGS CENT REP, V44, P22, DOI 10.1002/hast.328
   Ashley EA, 2015, JAMA-J AM MED ASSOC, V313, P2119, DOI 10.1001/jama.2015.3595
   Bayer R, 2015, NEW ENGL J MED, V373, P499, DOI 10.1056/NEJMp1506241
   Bollinger JM, 2014, GENET MED, V16, P932, DOI 10.1038/gim.2014.50
   Burke W, 2014, UROL ONCOL-SEMIN ORI, V32, P193, DOI 10.1016/j.urolonc.2013.09.002
   Collins FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMp1500523
   Coote JH, 2015, LANCET, V385, P1617, DOI 10.1016/S0140-6736(15)60786-3
   Dzau VJ, 2015, LANCET, V385, P2118, DOI 10.1016/S0140-6736(15)60722-X
   Fleck LM, 2014, UROL ONCOL-SEMIN ORI, V32, P202, DOI 10.1016/j.urolonc.2013.09.013
   Garrett SB, 2015, AM J BIOETHICS, V15, P56, DOI 10.1080/15265161.2015.1062177
   Green RC, 2015, NEW ENGL J MED, V372, P397, DOI 10.1056/NEJMp1404776
   Green RC, 2013, JAMA-J AM MED ASSOC, V310, P365, DOI 10.1001/jama.2013.41703
   Haga SB, 2014, GENOME MED, V6, DOI 10.1186/s13073-014-0058-6
   Hazin R, 2013, GENET MED, V15, P810, DOI 10.1038/gim.2013.117
   Hsu W, 2013, J AM MED INFORM ASSN, V20, P1010, DOI 10.1136/amiajnl-2013-002315
   Jarvik GP, 2014, AM J HUM GENET, V94, P818, DOI 10.1016/j.ajhg.2014.04.009
   Joyner MJ, 2015, NY TIMES
   Kaphingst KA, 2015, HEALTH PSYCHOL, V34, P101, DOI 10.1037/hea0000177
   Khoury MJ, 2015, JAMA-J AM MED ASSOC, V313, P2117, DOI 10.1001/jama.2015.3382
   Knoppers BM, 2015, NAT REV GENET, V16, P553, DOI 10.1038/nrg3960
   Koenig BA, 2014, HASTINGS CENT REP, V44, P33, DOI 10.1002/hast.329
   Liu YQ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133636
   McGowan ML, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108484
   McGowan ML, 2014, UROL ONCOL-SEMIN ORI, V32, P187, DOI 10.1016/j.urolonc.2013.10.009
   Ormond KE, 2014, PERS MED, V11, P211, DOI 10.2217/pme.13.104
   Presidential Commission for the Study of Bioethical Issues, 2013, ANT COMM ETH MAN INC
   Regier DA, 2015, CAN MED ASSOC J, V187, pE190, DOI 10.1503/cmaj.140697
   Rehm HL, 2015, NEW ENGL J MED, V372, P2235, DOI 10.1056/NEJMsr1406261
   Rubin R, 2015, JAMA-J AM MED ASSOC, V313, P1089, DOI 10.1001/jama.2015.0957
   Scheuner MT, 2015, GENET MED, V17, P27, DOI 10.1038/gim.2014.165
   Schmidlen TJ, 2015, J GENET COUNS
   Schuol S, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0198-3
   Shahmirzadi L, 2014, GENET MED, V16, P395, DOI 10.1038/gim.2013.153
   Stuckey H, 2015, AM J MED GENET A
   U. S. Food and Drug Administration, 2015, FDA PERM MARK 1 DIR
   Vassy JL, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-85
   Veltman JA, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0200-0
   Wagner JK, 2014, UROL ONCOL-SEMIN ORI, V32, P198, DOI 10.1016/j.urolonc.2013.09.016
   Watson MS, 2015, GENET MED, V17, DOI [10.1038/gim.2015.94, 10.1038/gim.2014.151]
   Weiner C, 2014, AM J EPIDEMIOL, V180, P562, DOI 10.1093/aje/kwu217
   Wilson BJ, 2015, RISK MANAG HEALTHC P, V8, P9, DOI 10.2147/RMHP.S58728
   Yu JH, 2014, AM J HUM GENET, V95, P77, DOI 10.1016/j.ajhg.2014.06.004
NR 42
TC 26
Z9 31
U1 1
U2 61
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8746
EI 1531-703X
J9 CURR OPIN ONCOL
JI Curr. Opin. Oncol.
PD JAN
PY 2016
VL 28
IS 1
BP 83
EP 87
DI 10.1097/CCO.0000000000000247
PG 5
WC Oncology
SC Oncology
GA DK2SN
UT WOS:000374764800013
PM 26569425
DA 2021-10-30
ER

PT J
AU Chavez, H
   Peterson, RE
   Lo, KM
   Arel, M
AF Chavez, Hector
   Peterson, Robert E.
   Lo, KaMing
   Arel, Marc
TI Weight estimation in an inner-city pediatric ED: the effect of obesity
SO AMERICAN JOURNAL OF EMERGENCY MEDICINE
LA English
DT Article
ID BROSELOW TAPE; CHILDREN; PREVALENCE
AB Background and Objective: Weight estimation for pediatric resuscitation occurs frequently in emergency departments. Historically, different approaches to estimation have been studied with varied results. With increasing obesity rates among inner-city children, this study aims to determine the best method for pediatric weight estimation in our population.
   Methods: This is a prospective, nonblinded, observational study. A total of 324 patients (aged 1 month to 12 years) were enrolled in the study to exceed sample size calculations. The accuracy of 4 methods for weight estimation-the Broselow tape, advanced pediatric life support formulas, the PAWPER tape, and mid-arm circumference formula-were compared across age ranges and body sizes to determine the most appropriate method for our population.
   Results: In this inner-city population, 32% of the patients 2 to 12 years of age were found to be overweight or obese. This rate increased to 41% for patients 6 to 12 years of age. In this setting, the PAWPER tape outperformed the other 3 methods, estimating patients' weight within +/-5% of actual weight in 35.2% of our cohort. When compared with the other 3 methods tested, the PAWPER tape was statistically superior with a P value less than .02 in each case.
   Conclusion: Each of the methods tested in our population performed poorly. Current methods for weight estimation should be used with caution, especially for populations with an increased prevalence of obesity. Efforts should be dedicated to improving or deriving new methods for weight estimation that perform better in this vulnerable population. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Chavez, Hector; Peterson, Robert E.] Univ Miami, Dept Pediat, Miami, FL 33152 USA.
   [Chavez, Hector; Peterson, Robert E.; Arel, Marc] Jackson Mem Hosp, Miami, FL 33166 USA.
   [Lo, KaMing] Univ Miami, Miller Sch Med, Div Biostat, Miami, FL 33136 USA.
RP Peterson, RE (corresponding author), Jackson Mem Hosp, Pediat Emergency Dept, 1611 NW 12th Ave,6006, Miami, FL 33166 USA.
EM Hchavez@jhsmiami.org; Robpeterson61@gmail.com
FU Miami Clinical and Translational Sciences Institute via National Agency
   for Advancing Translational Services [1UL1TR000460]; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000460]
   Funding Source: NIH RePORTER
FX Funding for statistical analysis provided by Miami Clinical and
   Translational Sciences Institute via National Agency for Advancing
   Translational Services (Grant No. 1UL1TR000460).
CR Abdel-Rahman SM, 2013, ANN EMERG MED, V62, P332, DOI 10.1016/j.annemergmed.2013.02.021
   Argall JAW, 2003, ARCH DIS CHILD, V88, P789, DOI 10.1136/adc.88.9.789
   Cattermole GN, 2010, RESUSCITATION, V81, P1105, DOI 10.1016/j.resuscitation.2010.05.015
   Chameides L., 2011, PEDIAT ADV LIFE SUPP
   Graves L, 2014, RESUSCITATION, V85, P392, DOI 10.1016/j.resuscitation.2013.11.024
   Lin BW, 2009, AM J EMERG MED, V27, P1060, DOI 10.1016/j.ajem.2008.08.018
   LUBITZ DS, 1988, ANN EMERG MED, V17, P576, DOI 10.1016/S0196-0644(88)80396-2
   Mackway-Jones K, 2005, ADV PAEDIAT LIFE SUP
   Margellos-Anast H, 2008, PUBLIC HEALTH REP, V123, P117, DOI 10.1177/003335490812300204
   National Hospital Ambulatory Medical Care Survey, 2010, EM DEP SUMM TABL 201
   Nieman CT, 2006, ACAD EMERG MED, V13, P1011, DOI 10.1197/j.aem.2006.06.042
   Ogden CL, 2012, JAMA-J AM MED ASSOC, V307, P483, DOI 10.1001/jama.2012.40
   Park J, 2012, RESUSCITATION, V83, P1129, DOI 10.1016/j.resuscitation.2012.01.023
   Rasooly IR, 2014, PEDIATR EMERG CARE, V30, P602, DOI 10.1097/PEC.0000000000000204
   RUTISHAUSER I. H. E., 1969, Journal of Tropical Pediatrics, V15, P196
   Seddon C, 2012, ISRN PEDIAT, V2012, P4
   Susan Schappert, 2012, NATL HLTH STAT REPOR, V47
   Wells M, 2013, RESUSCITATION, V84, P227, DOI 10.1016/j.resuscitation.2012.05.028
NR 18
TC 19
Z9 19
U1 0
U2 5
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0735-6757
EI 1532-8171
J9 AM J EMERG MED
JI Am. J. Emerg. Med.
PD OCT
PY 2015
VL 33
IS 10
BP 1364
EP 1367
DI 10.1016/j.ajem.2015.07.040
PG 4
WC Emergency Medicine
SC Emergency Medicine
GA CS1PM
UT WOS:000361839300007
PM 26321165
DA 2021-10-30
ER

PT J
AU Tang, F
   Messinger, S
   Cray, C
AF Tang, Fei
   Messinger, Shari
   Cray, Carolyn
TI Use of an Indirect Sampling Method to Produce Reference Intervals for
   Hematologic and Biochemical Analyses in Psittaciform Species
SO JOURNAL OF AVIAN MEDICINE AND SURGERY
LA English
DT Article
DE indirect sampling method; biochemical analyses; hematology; avian;
   reference intervals; psittaciform species
ID BUDGERIGARS MELOPSITTACUS-UNDULATUS; CLINICAL-CHEMISTRY; REFERENCE
   VALUES; PATIENT DATA; PLASMA; PARAMETERS
AB As with other animal species, comprehensive reference intervals (RI) for psittaciform species are rare and plagued by common issues, including sparse information regarding methods used to analyze specimens, low sample sizes, and improper statistical analyses. The purpose of this study was to examine the use of an indirect sampling method of RI generation from several years of data collected from specimens of multiple psittaciform species submitted to a veterinary diagnostic laboratory. These data were unselected for health status. A previously published method for indirect RI generation was applied to data collected for routine hematologic and biochemical analyses. Seven species groups were examined, and sample size ranged from 346 to 2358. Results showed that RI varied by species and appeared to represent a broader range than expected compared with other RI and traditional clinical expectations for core health assessments, such as total white blood cell count and white blood cell differential results. Some biochemical results reflected more narrow ranges, and a few were consistent with other published ranges. The intervals were likely influenced by changes related to stress and underlying disease. The results of the current study reflect the imprecision of this method related to data obtained from the population served by this laboratory. Overall, this method is not suitable for the production of comprehensive RI, although it may provide rough estimates for some limited analyses until traditional RI can be generated.
C1 [Tang, Fei; Messinger, Shari] Univ Miami, Miller Sch Med, Dept Epidemiol & Publ Hlth, Div Stat, Miami, FL 33101 USA.
   [Cray, Carolyn] Univ Miami, Miller Sch Med, Dept Pathol, Div Comparat Pathol, Miami, FL 33101 USA.
RP Tang, F (corresponding author), Univ Miami, Miller Sch Med, Dept Epidemiol & Publ Hlth, Div Stat, POB 016960 R-46, Miami, FL 33101 USA.
OI CRAY, CAROLYN/0000-0002-7180-153X
FU Miami Clinical and Translational Sciences Institute (National Center for
   Advancing Translational Science) [1UL1TR000460]; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000460]
   Funding Source: NIH RePORTER
FX This work was conducted with support from the Miami Clinical and
   Translational Sciences Institute (National Center for Advancing
   Translational Science (grant 1UL1TR000460)).
CR BAADENHUIJSEN H, 1985, J CLIN CHEM CLIN BIO, V23, P829
   BHATTACHARYA CG, 1967, BIOMETRICS, V23, P115, DOI 10.2307/2528285
   Blanco, ASVCP QUALITY ASSURA
   BOX GEP, 1964, J ROY STAT SOC B, V26, P211, DOI 10.1111/j.2517-6161.1964.tb00553.x
   Cambell T. W., 2000, SCHALMS VET HEMATOLO, P1155
   Campbell T. W., 1995, AVIAN HEMATOLOGY CYT, P3
   Campbell TW, 2006, VET HEMATOLOGY CHEM, P479
   Campbell TW, 2006, VET HEMATOLOGY CLIN, P225
   CLSI, 2008, DEF EST VER REF INT, VC28-A3
   Clubb S.L., 1991, Journal of the Association of Avian Veterinarians, V5, P16, DOI 10.2307/27671000
   Clubb S.L., 1990, Journal of the Association of Avian Veterinarians, V4, P218, DOI 10.2307/27670971
   Clubb S. L., 1991, Journal of the Association of Avian Veterinarians, V5, P154, DOI 10.2307/27671042
   Concordet D, 2009, CLIN CHIM ACTA, V405, P43, DOI 10.1016/j.cca.2009.03.057
   Cray C, U MIAMI AVIAN WILDLI
   Cray C, 2008, VET CLIN PATH, V37, P438, DOI 10.1111/j.1939-165X.2008.00075.x
   Cray C, 2007, VET CLIN PATH, V36, P64, DOI 10.1111/j.1939-165X.2007.tb00184.x
   de Carvalho FM, 2009, J ZOO WILDLIFE MED, V40, P675, DOI 10.1638/2009-0012.1
   Dimauro C, 2008, VET J, V178, P278, DOI 10.1016/j.tvjl.2007.08.002
   Ferre-Masferrer M, 1999, CLIN CHIM ACTA, V279, P97, DOI 10.1016/S0009-8981(98)00164-8
   Foldenauer U, 2007, J AVIAN MED SURG, V21, P275, DOI 10.1647/2007-004R.1
   Friedrichs KR, 2010, VET CLIN PATH, V39, P131, DOI 10.1111/j.1939-165X.2010.00235.x
   FUDGE AM, 2000, LAB MED AVIAN EXOTIC, P376
   Geffre A, 2009, VET CLIN PATH, V38, P477, DOI 10.1111/j.1939-165X.2009.00155.x
   Geffre A, 2011, VET CLIN PATH, V40, P107, DOI 10.1111/j.1939-165X.2011.00287.x
   Geffre A, 2009, VET CLIN PATH, V38, P288, DOI 10.1111/j.1939-165X.2009.00179.x
   George JW, 2010, VET CLIN PATH, V39, P138, DOI 10.1111/j.1939-165X.2009.00208.x
   Greenacre CB, 2008, J AVIAN MED SURG, V22, P291, DOI 10.1647/2007-034.1
   Harr KE, 2002, VET CLIN PATH, V31, P140, DOI 10.1111/j.1939-165X.2002.tb00295.x
   Hawkins MG, 2006, VET CLIN PATH, V35, P219, DOI 10.1111/j.1939-165X.2006.tb00118.x
   Hochleithner Manfred, 1994, P223
   Horn PS, 2001, CLIN CHEM, V47, P2137
   Ilcol YO, 2006, CLIN CHEM LAB MED, V44, P867, DOI 10.1515/CCLM.2006.139
   LINNET K, 1988, J R STAT SOC C-APPL, V37, P180
   Parga ML, 2001, J AVIAN MED SURG, V15, P162, DOI 10.1647/1082-6742(2001)015[0162:TEOTOH]2.0.CO;2
   Polo FJ, 1998, AVIAN DIS, V42, P523, DOI 10.2307/1592679
   Scope A, 2005, VET REC, V156, P310, DOI 10.1136/vr.156.10.310
   Scope A, 2005, RES VET SCI, V78, P85, DOI 10.1016/j.rvsc.2004.07.001
   Scope A, 2000, AVIAN DIS, V44, P885, DOI 10.2307/1593061
   Speer BL, 1995, P ANN C ASS AV VET, P43
NR 39
TC 3
Z9 3
U1 1
U2 8
PU ASSOC AVIAN VETERINARIANS
PI BOCA RATON
PA PO BOX 811720, BOCA RATON, FL 33481 USA
SN 1082-6742
EI 1938-2871
J9 J AVIAN MED SURG
JI J. Avian Med. Surg.
PD SEP
PY 2013
VL 27
IS 3
BP 194
EP 203
DI 10.1647/1082-6742-27.3.194
PG 10
WC Veterinary Sciences
SC Veterinary Sciences
GA 239EV
UT WOS:000326006300004
PM 24344510
DA 2021-10-30
ER

PT J
AU Amber, KT
   Dhiman, G
   Goodman, KW
AF Amber, Kyle T.
   Dhiman, Gaurav
   Goodman, Kenneth W.
TI Conflict of interest in online point-of-care clinical support websites
SO JOURNAL OF MEDICAL ETHICS
LA English
DT Article
ID UPTODATE; CONSULT
AB Point-of-care evidence-based medicine websites allow physicians to answer clinical queries using recent evidence at the bedside. Despite significant research into the function, usability and effectiveness of these programmes, little attention has been paid to their ethical issues. As many of these sites summarise the literature and provide recommendations, we sought to assess the role of conflicts of interest in two widely used websites: UpToDate and Dynamed. We recorded all conflicts of interest for six articles detailing treatment for the following conditions: erectile dysfunction, fibromyalgia, hypogonadism, psoriasis, rheumatoid arthritis and Crohn's disease. These diseases were chosen as their medical management is either controversial, or they are treated using biological drugs which are mostly available by brand name only. Thus, we hypothesised that the role of conflict of interest would be more significant in these conditions than in an illness treated with generic medications or by strict guidelines. All articles from the UpToDate articles demonstrated a conflict of interest. At times, the editor and author would have a financial relationship with a company whose drug was mentioned within the article. This is in contrast with articles on the Dynamed website, in which no author or editor had a documented conflict. We offer recommendations regarding the role of conflict of interest disclosure in these point-of-care evidence-based medicine websites.
C1 [Amber, Kyle T.; Dhiman, Gaurav; Goodman, Kenneth W.] Univ Miami, Miller Sch Med, Eth Program, Miami, FL 33156 USA.
RP Amber, KT (corresponding author), Univ Miami, Miller Sch Med, Eth Program, 10660 SW 75th Ave, Miami, FL 33156 USA.
EM KAmber@med.miami.edu
OI Amber, Kyle/0000-0002-2906-2454
FU University of Miami CTSI - National Center for Advancing Translational
   Sciences [1UL1TR000460]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1TR000460] Funding Source: NIH
   RePORTER
FX KWG's work on this paper was supported in part by the University of
   Miami CTSI, funded by the National Center for Advancing Translational
   Sciences grant #1UL1TR000460.
CR Ahmadi SF, 2011, MED TEACH, V33, P724, DOI 10.3109/0142159X.2010.531155
   [Anonymous], 1995, DYNAMED
   Basow DS, 2013, UPTODATE
   Bonis PA, 2008, INT J MED INFORM, V77, P745, DOI 10.1016/j.ijmedinf.2008.04.002
   Campbell R, 2006, J MED LIBR ASSOC, V94, P435
   Davies K, 2007, HEALTH INFO LIBR J, V24, P78, DOI 10.1111/j.1471-1842.2007.00713.x
   Goodyear-Smith F, 2008, AUST FAM PHYSICIAN, V37, P878
   McCord G, 2007, ACAD MED, V82, P298, DOI 10.1097/ACM.0b013e3180307fed
   Moynihan R, 2002, BRIT MED J, V324, P886, DOI 10.1136/bmj.324.7342.886
   Prorok JC, 2012, J CLIN EPIDEMIOL, V65, P1289, DOI 10.1016/j.jclinepi.2012.05.003
   Steinbrook R, 2009, NEW ENGL J MED, V360, P2160, DOI 10.1056/NEJMp0810200
NR 11
TC 11
Z9 11
U1 0
U2 16
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0306-6800
EI 1473-4257
J9 J MED ETHICS
JI J. Med. Ethics
PD AUG
PY 2014
VL 40
IS 8
BP 578
EP 580
DI 10.1136/medethics-2013-101625
PG 3
WC Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical
SC Social Sciences - Other Topics; Medical Ethics; Social Issues;
   Biomedical Social Sciences
GA AL6VL
UT WOS:000339271000017
PM 24493079
DA 2021-10-30
ER

PT J
AU Ramos, AR
   Seixas, A
   Dib, SI
AF Ramos, Alberto R.
   Seixas, Azizi
   Dib, Salim I.
TI Obstructive sleep apnea and stroke: links to health disparities
SO SLEEP HEALTH
LA English
DT Review
DE Obstructive sleep apnea; Stroke; Sleep duration; Vascular cognitive
   impairment; Health disparities; Black; Hispanics/Latinos
ID AFRICAN-AMERICANS; ATRIAL-FIBRILLATION; TEMPORAL TRENDS;
   ISCHEMIC-STROKE; RISK-FACTOR; DURATION; RACE; ASSOCIATION; DISORDERS;
   SYMPTOMS
AB Obstructive sleep apnea (OSA) is a novel cardiovascular and cerebrovascular risk factor that presents unique opportunities to understand and reduce seemingly intractable stroke disparity among non-Hispanic blacks and Hispanic/Latinos. Individuals from these 2 groups have up to a 2-fold risk of stroke and greater burden of OSA. Obstructive sleep apnea directly and indirectly increases risk of stroke through a variety of autonomic, chemical, and inflammatorymechanisms and vascular risk factors such as hypertension, obesity, and diabetes mellitus. Untreated OSA exacerbates poststroke prognosis, as it may also influence rehabilitation efforts and functional outcomes such as cognitive function after a stroke. Conversely, treatment of OSA may reduce the risk of stroke and may yield better poststroke prognosis. Unfortunately, in racial/ethnic minority groups, there are limited awareness, knowledge, and screening opportunities for OSA. Increasing awareness and improving screening strategies for OSA in minorities may alleviate stroke risk burden and improve stroke outcomes in these populations. This review article is intended to highlight the epidemiology, clinical characteristics, pathophysiology, diagnosis, and treatment of OSA in relation to stroke risk, with an emphasis on race-ethnic disparities. (C) 2015 National Sleep Foundation. Published by Elsevier Inc. All rights reserved.
C1 [Ramos, Alberto R.; Dib, Salim I.] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA.
   [Ramos, Alberto R.; Dib, Salim I.] Univ Miami, Miller Sch Med, Sleep Disorders Program, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   [Seixas, Azizi] NYU, Sch Med, Ctr Healthful Behav Change, Dept Populat Hlth, New York, NY USA.
RP Ramos, AR (corresponding author), Univ Miami, Miller Sch Med, UHlth Sleep Med Program, Miami, FL 33136 USA.
EM aramos@med.miami.edu
RI Ramos, Alberto/X-4249-2019
OI Seixas, Azizi/0000-0003-0843-2679
FU National Center for Advancing Translational SciencesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [1KL2TR000461]; National Institute on Minority Health and Health
   DisparitiesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Minority
   Health & Health Disparities (NIMHD); NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [KL2TR000461] Funding Source:
   NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND
   STROKEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Neurological
   Disorders & Stroke (NINDS) [U54NS081765] Funding Source: NIH RePORTER
FX The project described was also supported by grant number 1KL2TR000461
   (ARR), Miami Clinical and Translational Science Institute, from the
   National Center for Advancing Translational Sciences and the National
   Institute on Minority Health and Health Disparities. Its contents are
   solely the responsibility of the authors and do not necessarily
   represent the official views of the National Institutes of Health.
CR Adenekan B, 2013, SLEEP MED REV, V17, P255, DOI 10.1016/j.smrv.2012.07.002
   Alzheimer's Association, 2010, Alzheimers Dement, V6, P158, DOI 10.1016/j.jalz.2010.01.009
   Andreou G, 2007, ARCH CLIN NEUROPSYCH, V22, P225, DOI 10.1016/j.acn.2006.12.008
   Martinez-Garcia MA, 2009, AM J RESP CRIT CARE, V180, P36, DOI 10.1164/rccm.200808-1341OC
   Arzt M, 2005, AM J RESP CRIT CARE, V172, P1447, DOI 10.1164/rccm.200505-702OC
   Bade BC, 2014, AM J MED SCI, V348, P215, DOI 10.1097/MAJ.0000000000000233
   Barone MTU, 2011, DIABETES RES CLIN PR, V91, P129, DOI 10.1016/j.diabres.2010.07.011
   Cappuccio FP, 2011, EUR HEART J, V32, P1484, DOI 10.1093/eurheartj/ehr007
   Coelho FM, 2012, SLEEP MED, V13, P450, DOI 10.1016/j.sleep.2012.01.008
   Cohen-Zion M, 2001, J AM GERIATR SOC, V49, P1622, DOI 10.1111/j.1532-5415.2001.49270.x
   Culebras A, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-014-0503-3
   De Lott LB, 2014, SLEEP MED, V15, P1582, DOI 10.1016/j.sleep.2014.09.007
   Diaz J, 2004, CEREBROVASC DIS, V17, P43, DOI 10.1159/000074794
   Elwood PC, 2011, J EPIDEMIOL COMMUN H, V65, P820, DOI 10.1136/jech.2009.100503
   Enciso R, 2011, SLEEP BREATH, V15, P83, DOI 10.1007/s11325-010-0328-5
   Fulop T, 2012, SLEEP MED, V13, P1039, DOI 10.1016/j.sleep.2012.06.005
   Gangwisch JE, 2006, HYPERTENSION, V47, P833, DOI 10.1161/01.HYP.0000217362.34748.e0
   Go AS, 2014, CIRCULATION, V129, pE28, DOI 10.1161/01.cir.0000441139.02102.80
   Goldstein LB, 2011, STROKE, V42, P517, DOI 10.1161/STR.0b013e3181fcb238
   Gorelick PB, 2013, STROKE, V44, P307, DOI 10.1161/STROKEAHA.111.000219
   Gottlieb DJ, 2005, ARCH INTERN MED, V165, P863, DOI 10.1001/archinte.165.8.863
   Grandner MA, 2007, SLEEP MED REV, V11, P341, DOI 10.1016/j.smrv.2007.03.010
   Howard G, 2011, STROKE, V42, P3369, DOI 10.1161/STROKEAHA.111.625277
   Jelic S, 2008, CIRCULATION, V117, P2270, DOI 10.1161/CIRCULATIONAHA.107.741512
   Kepplinger J, 2013, J NEUROL, V260, P1343, DOI 10.1007/s00415-012-6803-0
   Kissela BM, 2012, NEUROLOGY, V79, P1781, DOI 10.1212/WNL.0b013e318270401d
   Kleindorfer DO, 2010, STROKE, V41, P1326, DOI 10.1161/STROKEAHA.109.575043
   Kohler M, 2008, AM J RESP CRIT CARE, V178, P984, DOI 10.1164/rccm.200805-717OC
   Leng Y, 2015, NEUROLOGY, V84, P1072, DOI 10.1212/WNL.0000000000001371
   Loredo JS, 2010, SLEEP, V33, P962, DOI 10.1093/sleep/33.7.962
   Malhotra A, 2014, J AM COLL CARDIOL, V64, P2024, DOI 10.1016/j.jacc.2014.07.990
   Martinez-Garcia MA, 2012, EUR RESPIR J, V39, P906, DOI 10.1183/09031936.00011311
   Meetze K, 2002, LARYNGOSCOPE, V112, P1271, DOI 10.1097/00005537-200207000-00024
   Morgenstern LB, 2013, ANN NEUROL, V74, P778, DOI 10.1002/ana.23972
   Neilan TG, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000421
   Netzer NC, 1999, ANN INTERN MED, V131, P485, DOI 10.7326/0003-4819-131-7-199910050-00002
   O'Connor GT, 2003, SLEEP, V26, P74
   Olafiranye O, 2013, AM HEART J, V165, P468, DOI 10.1016/j.ahj.2012.12.018
   Pandey A, 2013, INT J HYPERTENS, V2013, DOI 10.1155/2013/436502
   Pandey A, 2011, CURR DIABETES REP, V11, P35, DOI 10.1007/s11892-010-0164-9
   Petrov ME, 2016, SLEEP MED, V18, P74, DOI 10.1016/j.sleep.2015.01.011
   Placidi F, 1998, J SLEEP RES, V7, P288, DOI 10.1046/j.1365-2869.1998.00120.x
   Ramos AR, 2013, CURR GERIATR REP, V2, P188, DOI 10.1007/s13670-013-0054-5
   Ramos AR, 2015, NEUROLOGY, V84, P391, DOI 10.1212/WNL.0000000000001181
   Ramos AR, 2014, J SLEEP RES, V23, P524, DOI 10.1111/jsr.12177
   Ramos AR, 2014, SLEEP BREATH, V18, P165, DOI 10.1007/s11325-013-0865-9
   Ramos AR, 2013, AM J CARDIOL, V112, P599, DOI 10.1016/j.amjcard.2013.04.029
   Ramos AR, 2011, NEUROEPIDEMIOLOGY, V37, P210, DOI 10.1159/000334315
   Redline S, 1997, AM J RESP CRIT CARE, V155, P186, DOI 10.1164/ajrccm.155.1.9001310
   Redline S, 2014, AM J RESP CRIT CARE, V189, P335, DOI 10.1164/rccm.201309-1735OC
   Redline S, 2010, AM J RESP CRIT CARE, V182, P269, DOI 10.1164/rccm.200911-1746OC
   Ruiter ME, 2010, BEHAV SLEEP MED, V8, P246, DOI 10.1080/15402002.2010.509251
   Sacco RL, 2001, STROKE, V32, P1725, DOI 10.1161/01.STR.32.8.1725
   Seixas AA, 2015, SLEEP, V38, pA293
   Shah RV, 2014, AM HEART J, V167, P620, DOI 10.1016/j.ahj.2014.01.002
   Srijithesh PR, 2011, J CLIN NEUROSCI, V18, P340, DOI 10.1016/j.jocn.2010.04.048
   de Mello MT, 2013, INT J PREVENTIVE MED, V4, P246
   Virtanen J, 2012, SLEEP BREATH, V16, P309, DOI 10.1007/s11325-011-0526-9
   Wallace DM, 2014, J CLIN SLEEP MED, V10, P1083, DOI 10.5664/jcsm.4106
   Wallace DM, 2012, INT J STROKE, V7, P231, DOI 10.1111/j.1747-4949.2011.00760.x
   Williams NJ, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-225
   Wright CB, 2008, STROKE, V39, P800, DOI 10.1161/STROKEAHA.107.484147
   Yaffe K, 2011, JAMA-J AM MED ASSOC, V306, P613, DOI 10.1001/jama.2011.1115
   Yaggi HK, 2005, NEW ENGL J MED, V353, P2034, DOI 10.1056/NEJMoa043104
NR 64
TC 8
Z9 8
U1 0
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2352-7218
EI 2352-7226
J9 SLEEP HEALTH
JI Sleep Health
PD DEC
PY 2015
VL 1
IS 4
BP 244
EP 248
DI 10.1016/j.sleh.2015.09.005
PG 5
WC Clinical Neurology
SC Neurosciences & Neurology
GA VD5ZF
UT WOS:000437200600006
PM 29073399
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Swords, RT
   Watts, J
   Erba, HP
   Altman, JK
   Maris, M
   Anwer, F
   Hua, Z
   Stein, H
   Faessel, H
   Sedarati, F
   Dezube, BJ
   Giles, FJ
   Medeiros, BC
   DeAngelo, DJ
AF Swords, R. T.
   Watts, J.
   Erba, H. P.
   Altman, J. K.
   Maris, M.
   Anwer, F.
   Hua, Z.
   Stein, H.
   Faessel, H.
   Sedarati, F.
   Dezube, B. J.
   Giles, F. J.
   Medeiros, B. C.
   DeAngelo, D. J.
TI Expanded safety analysis of pevonedistat, a first-in-class
   NEDD8-activating enzyme inhibitor, in patients with acute myeloid
   leukemia and myelodysplastic syndromes
SO BLOOD CANCER JOURNAL
LA English
DT Letter
ID MLN4924; CANCER; CELLS
C1 [Swords, R. T.; Watts, J.] Sylvester Comprehens Canc Ctr, Leukemia Program, Miami, FL 33136 USA.
   [Erba, H. P.] Univ Michigan, Div Hematol Oncol, Ann Arbor, MI 48109 USA.
   [Altman, J. K.; Giles, F. J.] Northwestern Univ, Northwestern Med Dev Therapeut Inst, Chicago, IL 60611 USA.
   [Maris, M.] Colorado Blood Canc Inst, Denver, CO USA.
   [Anwer, F.] Univ Arizona, Ctr Canc, Tucson, AZ USA.
   [Hua, Z.; Stein, H.; Faessel, H.; Sedarati, F.; Dezube, B. J.] T Takeda Pharmaceut Int Co, Cambridge, MA USA.
   [Medeiros, B. C.] Stanford Univ, Sch Med, Div Hematol, Stanford, CA 94305 USA.
   [DeAngelo, D. J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
RP Swords, RT (corresponding author), Sylvester Comprehens Canc Ctr, Leukemia Program, Miami, FL 33136 USA.
EM rswords@med.miami.edu
RI Anwer, Faiz/S-4575-2019
OI Anwer, Faiz/0000-0001-6914-7439; DeAngelo, Daniel/0000-0001-7865-2306
FU Takeda Pharmaceuticals, Inc.Takeda Pharmaceutical Company Ltd; NIHUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA [1KL2TR000461]; NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [KL2TR000461] Funding Source:
   NIH RePORTER
FX This research was supported by Takeda Pharmaceuticals, Inc. This study
   is registered with ClinicalTrials.gov, number NCT00677170. RTS received
   support from grant NIH 1KL2TR000461.
CR Chen YZ, 2009, MOL CELL, V35, P841, DOI 10.1016/j.molcel.2009.09.004
   Chiba T, 2004, CURR PROTEIN PEPT SC, V5, P177, DOI 10.2174/1389203043379783
   Mathewson N, 2013, BLOOD, V122, P2062, DOI 10.1182/blood-2013-02-486373
   McCormack R. M., 2015, ELIFE, V4, DOI [10.7554/eLife.06505, DOI 10.7554/eLife.06505]
   Milhollen MA, 2012, CANCER CELL, V21, P388, DOI 10.1016/j.ccr.2012.02.009
   Milhollen MA, 2011, CANCER RES, V71, P3042, DOI 10.1158/0008-5472.CAN-10-2122
   Sarantopoulos J, 2016, CLIN CANCER RES, V22, P847, DOI 10.1158/1078-0432.CCR-15-1338
   Shah JJ, 2016, CLIN CANCER RES, V22, P34, DOI 10.1158/1078-0432.CCR-15-1237
   Soucy TA, 2009, CLIN CANCER RES, V15, P3912, DOI 10.1158/1078-0432.CCR-09-0343
   Soucy TA, 2009, NATURE, V458, P732, DOI 10.1038/nature07884
   Swords R, 2014, 1 IN CLASS NAE INHIB
   Swords RT, 2015, BRIT J HAEMATOL, V169, P534, DOI 10.1111/bjh.13323
   Swords RT, 2010, BLOOD, V115, P3796, DOI 10.1182/blood-2009-11-254862
   Wolenski FS, 2015, CELL DEATH DISCOV, V1, DOI 10.1038/cddiscovery.2015.34
   Zhou L, 2016, BLOOD, V127, P2219, DOI 10.1182/blood-2015-06-653717
NR 15
TC 23
Z9 23
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2044-5385
J9 BLOOD CANCER J
JI Blood Cancer J.
PD FEB
PY 2017
VL 7
AR e520
DI 10.1038/bcj.2017.1
PG 4
WC Oncology; Hematology
SC Oncology; Hematology
GA EO8BD
UT WOS:000396912900001
PM 28157218
OA Green Published, gold
DA 2021-10-30
ER

PT J
AU McClure, LA
   Koru-Sengul, T
   Hernandez, MN
   Mackinnon, JA
   Solle, NS
   Caban-Martinez, AJ
   Lee, DJ
   Kobetz, E
AF McClure, Laura A.
   Koru-Sengul, Tulay
   Hernandez, Monique N.
   Mackinnon, Jill A.
   Solle, Natasha Schaefer
   Caban-Martinez, Alberto J.
   Lee, David J.
   Kobetz, Erin
TI Availability and accuracy of occupation in cancer registry data among
   Florida firefighters
SO PLOS ONE
LA English
DT Article
ID INDUSTRY
AB Objectives
   Occupational exposures significantly contribute to the risk of adverse cancer outcomes, and firefighters face many carcinogenic exposures. Occupational research using cancer registry data, however, is limited by missing and inaccurate occupation-related fields. The objective of this study is to determine the frequency and predictors of missing and inaccurate occupation data for a cohort of career firefighters in a state cancer registry.
   Methods
   We conducted a linkage between data from the Florida Cancer Data System (1981-2014) and the Florida State Fire Marshal's Office (1972-2012). The percentage and the odds of having a firefighting-related occupation code in the cancer record were calculated, adjusting for other occupation and cancer-related factors.
   Results
   Among 3,928 career firefighters, nearly half (47%) were missing a registry-dervived occupation code and only 17% had a firefighting-related code. Males were more likely to have a firefighting-related code (OR = 2.31; 95% CI: 1.41-3.76), as were those with more recent diagnoses (OR1992-2002 = 2.98; 95% CI: 1.57-5.67; OR2003-2014 = 11.40; 95% CI: 6.17-21.03), and those of younger ages (OR45-64y = 1.26; 95% CI: 1.03-1.54; OR20-44y = 2.26; 95% CI: 1.73-2.95).
   Conclusions
   Accurate occupation data is key for identifying increased risk of advserse cancer outcomes. Cancer registry occupation fields, however, are overwhelmingly missing for firefighters and are missing disproportionally by sociodemographic and diagnosis characteristics. This study highlights the lack of accurate occupation data available for hypothesis-driven cancer research. Cancer registry linkage with external occupational data sources represents an essential resource for conducting studies among at-risk populations such as firefighters.
C1 [McClure, Laura A.; Koru-Sengul, Tulay; Solle, Natasha Schaefer; Caban-Martinez, Alberto J.; Lee, David J.; Kobetz, Erin] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA.
   [Koru-Sengul, Tulay; Caban-Martinez, Alberto J.; Lee, David J.] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA.
   [Hernandez, Monique N.; Mackinnon, Jill A.; Lee, David J.; Kobetz, Erin] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Florida Canc Data Syst, Miami, FL 33136 USA.
   [Kobetz, Erin] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA.
RP Lee, DJ (corresponding author), Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA.; Lee, DJ (corresponding author), Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA.; Lee, DJ (corresponding author), Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Florida Canc Data Syst, Miami, FL 33136 USA.
EM Dlee@miami.edu
RI Caban-Martinez, Alberto/AAG-1499-2019
OI Caban-Martinez, Alberto/0000-0002-5960-1308; Koru-Sengul,
   Tulay/0000-0003-0974-8405
FU State of Florida [2382A]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1TR002736] Funding Source: NIH
   RePORTER
FX EK received funding for this work from State of Florida appropriation
   #2382A. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Centers for Disease Control and Prevention National Institute of Occupational Safety and Health (NIOSH), 2018, NIOSH IND OCC COMP C
   Department of Health and Human Services Centers for Disease Control and Prevention National Institute for Occupational Safety and Health, 2011, DHHS NIOSH PUBLICATI, V2011-173
   Enamorado T, 2017, AM POLITICAL SCI REV
   Freeman MB, 2017, AM J IND MED, V60, P689, DOI 10.1002/ajim.22739
   Kahn SA, 2019, J BURN CARE RES, V40, P196, DOI 10.1093/jbcr/iry037
   Levy J, 2001, AM J IND MED, V40, P98, DOI 10.1002/ajim.1076
   Ma FC, 2006, J OCCUP ENVIRON MED, V48, P883, DOI 10.1097/01.jom.0000235862.12518.04
   McClure Laura A, 2016, J Registry Manag, V43, P16
   Miller E, 2014, VITAL HLTH STAT, V2
   National Institute for Occupational Safety and Health, 2018, SIMPL QUICKL COD IND
   National Institute for Occupational Safety and Health (NIOSH), CANC REPR CARD OTH C
   Petersen KU, 2018, INT ARCH OCC ENV HEA, V91, P759, DOI 10.1007/s00420-018-1323-6
   Proudfoot S., 2006, Morbidity and Mortality Weekly Report, V55, P453
   Purdue MP, 2015, ANN EPIDEMIOL, V25, P188, DOI 10.1016/j.annepidem.2014.11.009
   Silver SR, 2018, AM J IND MED, V61, P524, DOI 10.1002/ajim.22840
   Tsai RJ, 2015, AM J IND MED, V58, P715, DOI 10.1002/ajim.22466
   Weiss NS, 2015, J REGISTRY MANAG, V42, P103
   World Health Organization International Agency for Research on Cancer, 2010, IARC MONOGRAPHS EVAL, V98
   2006, J OCCUP ENVIRON MED, V48, P1189, DOI DOI 10.1097/01.JOM.0000246229.68697.90
NR 19
TC 3
Z9 3
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 30
PY 2019
VL 14
IS 4
AR e0215867
DI 10.1371/journal.pone.0215867
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA HW0IT
UT WOS:000466364800015
PM 31039169
OA Green Submitted, Green Published, gold
DA 2021-10-30
ER

PT J
AU Pahwa, R
   Isaacson, SH
   Torres-Russotto, D
   Nahab, FB
   Lynch, PM
   Kotschet, KE
AF Pahwa, Rajesh
   Isaacson, Stuart H.
   Torres-Russotto, Diego
   Nahab, Fatta B.
   Lynch, Peter M.
   Kotschet, Katya E.
TI Role of the Personal KinetiGraph in the routine clinical assessment of
   Parkinson's disease: recommendations from an expert panel
SO EXPERT REVIEW OF NEUROTHERAPEUTICS
LA English
DT Review
DE Parkinson's disease; bradykinesia; dyskinesia; technology; wearable;
   assessment; ambulatory monitoring; continuous objective monitoring
ID MOVEMENT-DISORDER SOCIETY; QUALITY-OF-LIFE; MOTOR FLUCTUATIONS;
   WEARING-OFF; OBJECTIVE MEASUREMENT; NATURAL-HISTORY; LEVODOPA;
   DYSKINESIAS; BRADYKINESIA; CARE
AB Introduction: Evaluation of people with Parkinson's disease (PD) is often complex due to heterogeneity of symptoms and disease course, including the variability of motor fluctuations and dyskinesia. Routine clinical evaluations may be incomplete, may not accurately capture important symptoms, and may not reflect day-to-day variability. While significant advances have been made in wearable ambulatory continuous objective monitoring (COM) technologies, many clinicians remain uncertain of how to incorporate them in clinical practice, including the value to clinical decision-making. The Personal KinetiGraph (TM) (PKG) has FDA clearance in the United States, and has recently been used in several clinical studies.
   Areas covered: An expert group of movement disorders neurologists convened to discuss the clinical utility of the PKG in the routine assessment of people with PD. Based on their experience, the group identified clinical scenarios where objective information gained from review of PKG reports can provide useful information to improve clinical management.
   Expert commentary: PKG provides clinically meaningful data in patients with PD that can aid the clinician in evaluating patients and optimizing their pharmacologic therapy. Early clinical experience and expert opinion suggest that utilization of COM technologies such as the PKG have the potential to improve medical care in people with PD.
C1 [Pahwa, Rajesh] Univ Kansas, Med Ctr, Dept Neurol, Kansas City, KS 66103 USA.
   [Isaacson, Stuart H.] Parkinsons Dis & Movement Disorders Ctr, Boca Raton, FL USA.
   [Torres-Russotto, Diego] Univ Nebraska Med Ctr, Dept Neurol, Omaha, NE USA.
   [Nahab, Fatta B.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.
   [Lynch, Peter M.] Global Kinetics Corp, Melbourne, Vic, Australia.
   [Kotschet, Katya E.] Univ Melbourne, Florey Neurosci Inst, Parkville, Vic, Australia.
   [Kotschet, Katya E.] St Vincents Hosp, Dept Neurol, Fitzroy, Vic, Australia.
RP Pahwa, R (corresponding author), Univ Kansas, Med Ctr, 3599 Rainbow Blvd, Kansas City, KS 66160 USA.
EM rpahwa@kumc.edu
OI Torres-Russotto, Diego/0000-0002-0567-6435
FU Global Kinetics Corporation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1TR001442, UL1TR000460] Funding
   Source: NIH RePORTER
FX This paper is the result of a meeting of US and Australian based
   movement disorder neurologists with expertise in the use of Personal
   KinetiGraph in clinical assessment. Participation at the meeting
   (honoraria and expenses) was funded by Global Kinetics Corporation.
   Medical writing support was funded by Global Kinetics Corporation.
CR Ahlskog JE, 2001, MOVEMENT DISORD, V16, P448, DOI 10.1002/mds.1090
   [Anonymous], 2014, WHAT DO YOUR PAT IS
   Antonini A, 2011, MOVEMENT DISORD, V26, P2169, DOI 10.1002/mds.23875
   Aquino CC, 2015, MOVEMENT DISORD, V30, P80, DOI 10.1002/mds.26125
   Arnulf I, 2005, SLEEP MED REV, V9, P185, DOI 10.1016/j.smrv.2005.01.001
   Arnulf I, 2009, PARKINSONISM RELAT D, V15, pS101, DOI 10.1016/S1353-8020(09)70792-8
   Beck CA, 2017, NEUROLOGY, V89, P1152, DOI 10.1212/WNL.0000000000004357
   Braybrook M, 2016, J PARKINSON DIS, V6, P723, DOI 10.3233/JPD-160898
   Chapuis S, 2005, MOVEMENT DISORD, V20, P224, DOI 10.1002/mds.20279
   Deuschl G, 1998, MOVEMENT DISORD, V13, P2, DOI 10.1002/mds.870131303
   Espay AJ, 2016, MOVEMENT DISORD, V31, P1272, DOI 10.1002/mds.26642
   Evans AH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089319
   Evans JR, 2011, J NEUROL NEUROSUR PS, V82, P1112, DOI 10.1136/jnnp.2011.240366
   Farzanehfar P, 2017, MOV DISORD S2, V32
   Farzanehfar P, 2018, NPJ PARKINSON DIS, V4, DOI 10.1038/s41531-018-0046-4
   Farzanehfar P, 2017, EXPERT REV MED DEVIC, V14, P583, DOI 10.1080/17434440.2017.1349608
   Garcia-Ruiz PJ, 2012, CLIN NEUROPHARMACOL, V35, P1, DOI 10.1097/WNF.0b013e31823dec73
   Goetz CG, 2008, MOVEMENT DISORD, V23, P2129, DOI 10.1002/mds.22340
   Griffiths RI, 2012, J PARKINSON DIS, V2, P47, DOI 10.3233/JPD-2012-11071
   Grosset KA, 2005, MOVEMENT DISORD, V20, P1502, DOI 10.1002/mds.20602
   Hechtner MC, 2014, PARKINSONISM RELAT D, V20, P969, DOI 10.1016/j.parkreldis.2014.06.001
   Horne M., 2016, ORUEN CNS J, V1, P16
   Horne M., 2017, MOV DISORD S2, V32
   Horne MK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124522
   Hughes AJ, 2001, NEUROLOGY, V57, pS34
   Isaacson S, 2017, MOV DISORD CLIN PRAC, V4, P78, DOI 10.1002/mdc3.12350
   Jitkritsadakul Onanong, 2016, J Clin Mov Disord, V3, P14
   Koivu M, 2017, MOV DISORD S2, V32
   Kotschet K, 2014, PARKINSONISM RELAT D, V20, P578, DOI 10.1016/j.parkreldis.2014.02.011
   Kumar N, 2005, MOVEMENT DISORD, V20, P342, DOI 10.1002/mds.20360
   Matthews H, 2015, J PARKINSON DIS, V5, P533, DOI 10.3233/JPD-150547
   MELAMED E, 1986, CLIN NEUROPHARMACOL, V9, P182, DOI 10.1097/00002826-198604000-00009
   Merino-Andreu M, 2003, NEUROLOGY, V60, P1553, DOI 10.1212/01.WNL.0000058905.71369.97
   Nonnekes J, 2016, MOVEMENT DISORD, V31, P1602, DOI 10.1002/mds.26712
   OBoyle DJ, 1996, BRAIN, V119, P51, DOI 10.1093/brain/119.1.51
   Odin P, 2018, NPJ PARKINSON DIS, V4, DOI 10.1038/s41531-018-0051-7
   Olanow CW, 2009, NEUROLOGY, V72, pS1, DOI 10.1212/WNL.0b013e3181a1d44c
   Olanow CW, 2004, MOVEMENT DISORD, V19, P997, DOI 10.1002/mds.20243
   Ossig C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161559
   Pahwa R, 2006, PRACTICE PARAMETER T
   Papapetropoulos S, 2012, CNS NEUROSCI THER, V18, P380, DOI 10.1111/j.1755-5949.2011.00253.x
   Pasluosta CF, 2015, IEEE J BIOMED HEALTH, V19, P1873, DOI 10.1109/JBHI.2015.2461555
   Pietracupa S, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00032
   Postuma RB, 2015, MOVEMENT DISORD, V30, P1591, DOI 10.1002/mds.26424
   Price J, 2017, MOVEMENT DISORD, V32
   Rascol O, 2016, MOVEMENT DISORD, V31, P1489, DOI 10.1002/mds.26724
   Saha RA, 2015, ACNR, V14, P12
   Schneider RB, 2017, LANCET NEUROL, V16, P541, DOI 10.1016/S1474-4422(17)30167-9
   Sitek EJ, 2011, FUNCT NEUROL, V26, P121
   Stacy M, 2006, MOVEMENT DISORD, V21, pS590
   Stacy M, 2005, MOVEMENT DISORD, V20, P726, DOI 10.1002/mds.20383
   Stocchi F, 2010, EUR NEUROL, V63, P257, DOI 10.1159/000300647
   Stone AA, 2002, BMJ-BRIT MED J, V324, P1193, DOI 10.1136/bmj.324.7347.1193
   Thanvi B, 2007, POSTGRAD MED J, V83, P384, DOI 10.1136/pgmj.2006.054759
   Titova N, 2017, J NEURAL TRANSM, V124, P1529, DOI 10.1007/s00702-017-1799-3
   Titova N, 2017, J NEURAL TRANSM, V124, P907, DOI 10.1007/s00702-016-1667-6
   Tysnes OB, 2017, J NEURAL TRANSM, V124, P901, DOI 10.1007/s00702-017-1686-y
   van Hilten JJ, 1998, J NEURAL TRANSM, V105, P229, DOI 10.1007/s007020050051
   Vitale C, 2001, NEUROL SCI, V22, P105, DOI 10.1007/s100720170066
   Willis AW, 2011, NEUROLOGY, V77, P851, DOI 10.1212/WNL.0b013e31822c9123
   Willows T, 2017, J PARKINSON DIS, V7, P719, DOI 10.3233/JPD-161048
   YANAGISAWA N, 1989, EUR NEUROL, V29, P19, DOI 10.1159/000116449
NR 62
TC 22
Z9 23
U1 0
U2 6
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1473-7175
EI 1744-8360
J9 EXPERT REV NEUROTHER
JI Expert Rev. Neurother.
PY 2018
VL 18
IS 8
BP 669
EP 680
DI 10.1080/14737175.2018.1503948
PG 12
WC Clinical Neurology; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA GR6JM
UT WOS:000442755800005
PM 30032695
DA 2021-10-30
ER

PT J
AU Shah, AH
   Bregy, A
   Heros, DO
   Komotar, RJ
   Goldberg, J
AF Shah, Ashish H.
   Bregy, Amade
   Heros, Deborah O.
   Komotar, Ricardo J.
   Goldberg, John
TI Dendritic Cell Vaccine for Recurrent High-Grade Gliomas in Pediatric and
   Adult Subjects: Clinical Trial Protocol
SO NEUROSURGERY
LA English
DT Article
DE Clinical trial; Dendritic cell vaccine; Malignant gliomas
ID GLIOBLASTOMA-MULTIFORME; NATURAL-HISTORY; IMMUNOTHERAPY; PATHOLOGY;
   RESPONSES; FUSIONS
AB BACKGROUND: Although there have been significant advances in understanding the basic pathogenesis of glioblastoma multiforme, the median survival of patients has changed little in the past 25 years. Recent studies have suggested that immune modulation through dendritic cell (DC) vaccines may stimulate the immune system against tumor antigens and potentially increase survival.
   OBJECTIVE: To determine whether the use of adjuvant vaccination with autologous DCs (matured in situ after being loaded with tumor cell lysate derived from autologous refractory gliomas) is safe, feasible, and beneficial for adult and pediatric patients with recurrent high-grade gliomas.
   METHODS: The study design is a single-center, nonrandomized, open phase I clinical trial. A total of 20 patients with malignant gliomas will be enrolled preoperatively over 2 years. Patients will be given adjuvant vaccination with autologous DCs loaded with tumor lysate after maximal safe surgical resection.
   EXPECTED OUTCOMES: Using topical imiquimod before vaccination, it is anticipated that the immune response in vaccinated patients and potentially Overall survival will be greater than that demonstrated in the literature. We anticipate that there will be minimal side effects (minor dermatitis) associated with this treatment.
   DISCUSSION: In the current trial, we assess immune response, safety, and survival using a novel vaccine protocol developed in Belgium that seems to markedly increase survival of certain subjects. Nevertheless, larger randomized clinical studies need to be performed to evaluate fully the efficacy of this therapy for both recurrent and newly diagnosed glioblastoma.
C1 [Shah, Ashish H.; Bregy, Amade; Komotar, Ricardo J.] Univ Miami, Dept Neurol Surg, Miller Sch Med, Miami, FL 33101 USA.
   [Heros, Deborah O.] Univ Miami, Dept Neurol, Miller Sch Med, Miami, FL 33101 USA.
   [Goldberg, John] Univ Miami, Dept Pediat, Miller Sch Med, Miami, FL 33101 USA.
RP Goldberg, J (corresponding author), Univ Miami, Dept Pediat, Miller Sch Med, POB 016960 D 820, Miami, FL 33101 USA.
EM jgoldberg2@med.miami.edu
OI Shah, Ashish/0000-0002-0183-1274
FU University of Miami Clinical and Translational Science Institute
   [1UL1TR000460]; National Center for Advancing Translational
   SciencesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS); National Institute on Minority Health
   and Health Disparities, a branch of the National Institutes of Health;
   University of Miami Sylvester Comprehensive Cancer Center; NATIONAL
   CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000460] Funding Source: NIH RePORTER
FX Financial support was provided by grant 1UL1TR000460, University of
   Miami Clinical and Translational Science Institute, from the National
   Center for Advancing Translational Sciences and the National Institute
   on Minority Health and Health Disparities, a branch of the National
   Institutes of Health and from the University of Miami Sylvester
   Comprehensive Cancer Center. The authors have no personal financial or
   institutional interests to disclose at this time.
CR Ardon H, 2012, CANCER IMMUNOL IMMUN, V61, P2033, DOI 10.1007/s00262-012-1261-1
   Ardon H, 2010, J NEURO-ONCOL, V99, P261, DOI 10.1007/s11060-010-0131-y
   Bregy A, 2013, CANCER TREAT REV, V39, P891, DOI 10.1016/j.ctrv.2013.05.007
   Chang CN, 2011, J CLIN NEUROSCI, V18, P1048, DOI 10.1016/j.jocn.2010.11.034
   Cho DY, 2012, WORLD NEUROSURG, V77, P736, DOI 10.1016/j.wneu.2011.08.020
   FRANKEL SA, 1958, J NEUROSURG, V15, P489, DOI 10.3171/jns.1958.15.5.0489
   KELLY KA, 1984, CANCER TREAT REV, V11, P1, DOI 10.1016/0305-7372(84)90014-8
   Kikuchi T, 2001, CANCER IMMUNOL IMMUN, V50, P337, DOI 10.1007/s002620100205
   Kikuchi T, 2004, J IMMUNOTHER, V27, P452, DOI 10.1097/00002371-200411000-00005
   Kim Y, 2012, LAB INVEST, V92, P466, DOI 10.1038/labinvest.2011.161
   Lai A, 2011, J CLIN ONCOL, V29, P4482, DOI 10.1200/JCO.2010.33.8715
   Liau L M, 2000, Neurosurg Focus, V9, pe8
   Liau LM, 2005, CLIN CANCER RES, V11, P5515, DOI 10.1158/1078-0432.CCR-05-0464
   Nair S, 2003, J IMMUNOL, V171, P6275, DOI 10.4049/jimmunol.171.11.6275
   Phuphanich S, 2013, CANCER IMMUNOL IMMUN, V62, P125, DOI 10.1007/s00262-012-1319-0
   Rock K, 2012, BRIT J RADIOL, V85, pE729, DOI 10.1259/bjr/83796755
   Sarica EB, 2010, J NEUROSURG SCI, V54, P7
   Wheeler CJ, 2008, CANCER RES, V68, P5955, DOI 10.1158/0008-5472.CAN-07-5973
   Yu JS, 2001, CANCER RES, V61, P842
NR 19
TC 10
Z9 13
U1 0
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0148-396X
EI 1524-4040
J9 NEUROSURGERY
JI Neurosurgery
PD NOV
PY 2013
VL 73
IS 5
BP 863
EP 867
DI 10.1227/NEU.0000000000000107
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA 300MH
UT WOS:000330467500034
PM 23867302
DA 2021-10-30
ER

PT J
AU Asdaghi, N
   Yavagal, DR
   Wang, KF
   Mueller-Kronast, N
   Bhatt, N
   Gardener, HE
   Gutierrez, CM
   Marulanda-Londono, E
   Koch, S
   Dong, CH
   Oluwole, SA
   Hanel, R
   Mehta, B
   Robichaux, M
   Nobo, U
   Zevallos, JC
   Rundek, T
   Sacco, RL
   Romano, JG
AF Asdaghi, Negar
   Yavagal, Dileep R.
   Wang, Kefeng
   Mueller-Kronast, Nils
   Bhatt, Nirav
   Gardener, Hannah E.
   Gutierrez, Carolina M.
   Marulanda-Londono, Erika
   Koch, Sebastian
   Dong, Chuanhui
   Oluwole, Sophia A.
   Hanel, Ricardo
   Mehta, Brijesh
   Robichaux, Mary
   Nobo, Ulises
   Zevallos, Juan C.
   Rundek, Tatjana
   Sacco, Ralph L.
   Romano, Jose G.
TI Patterns and Outcomes of Endovascular Therapy in Mild Stroke: A
   Florida-Puerto Rico Collaboration
SO STROKE
LA English
DT Article
DE embolectomy; Florida; hospitals; stroke
ID ACUTE ISCHEMIC-STROKE; VESSEL OCCLUSION STROKES; MIDDLE CEREBRAL-ARTERY;
   MECHANICAL THROMBECTOMY; MINIMAL SYMPTOMS; GUIDELINES; ASSOCIATION;
   MANAGEMENT
AB Background and Purpose- We aimed to evaluate the current practice patterns, safety and outcomes of patients who receive endovascular therapy (EVT) having mild neurological symptoms.
   Methods- From Jan 2010 to Jan 2018, 127,794 ischemic stroke patients were enrolled in the Florida-Puerto Rico Stroke Registry. Patients presenting within 24 hours of symptoms who received EVT were classified into mild (National Institutes of Health Stroke Scale [NIHSS] <= 5) or moderate/severe (NIHSS>5) categories. Differences in clinical characteristics and outcomes were evaluated using multivariable logistic regression.
   Results- Among 4110 EVT patients (median age, 73 [interquartile range=20] years; 50% women), 446 (11%) had NIHSS <= 5. Compared with NIHSS >5, those with NIHSS <= 5 arrived later to the hospital (median, 138 versus 101 minutes), were less likely to receive intravenous alteplase (30% versus 43%), had a longer door-to-puncture time (median, 167 versus 115 minutes) and more likely treated in South Florida (64% versus 53%). In multivariable analysis younger age, private insurance (versus Medicare), history of hypertension, prior independent ambulation and hospital size were independent characteristics associated with NIHSS <= 5. Among EVT patients with NIHSS <= 5, 76% were discharged home/rehabilitation and 64% were able to ambulate independently at discharge as compared with 53% and 32% of patients with NIHSS >5. Symptomatic intracerebral hemorrhage occurred in 4% of mild stroke EVT patients and 6.4% in those with NIHSS >5.
   Conclusions- Despite lack of evidence-based recommendations, 11% of patients receiving EVT in clinical practice have mild neurological presentations. Individual, hospital and geographic disparities are observed among endovascularly treated patients based on the severity of clinical symptoms. Our data suggest safety and overall favorable outcomes for EVT patients with mild stroke.
C1 [Asdaghi, Negar; Yavagal, Dileep R.; Wang, Kefeng; Gardener, Hannah E.; Gutierrez, Carolina M.; Marulanda-Londono, Erika; Koch, Sebastian; Dong, Chuanhui; Oluwole, Sophia A.; Rundek, Tatjana; Sacco, Ralph L.; Romano, Jose G.] Univ Miami, Dept Neurol, Leonard M Miller Sch Med, Miami, FL 33136 USA.
   [Mueller-Kronast, Nils] Delray Med Ctr, Div Neurol, Delray Beach, FL USA.
   [Bhatt, Nirav] Emory Univ, Dept Neurol, Grady Mem Hosp, Atlanta, GA 30322 USA.
   [Hanel, Ricardo] Baptist Neurol Inst, Dept Neurosurg, Jacksonville, FL USA.
   [Mehta, Brijesh] Mem Reg Hosp, Dept Neurosurg, Hollywood, FL USA.
   [Robichaux, Mary] VP Parotis Healthcare LLC, Roswell, GA USA.
   [Nobo, Ulises] HIMA San Pablo Hosp, Dept Neurol, Caguas, PR USA.
   [Zevallos, Juan C.] Florida Int Univ, Dept Neurol, Miami, FL 33199 USA.
RP Asdaghi, N (corresponding author), Univ Miami, 1120 NW 14th St,Clin Res Bldg,13th Floor, Miami, FL 33136 USA.
EM nasdaghi@med.miami.edu
RI Sacco, Ralph/Y-9278-2019; Bhatt, Nirav/S-4097-2019
OI Bhatt, Nirav/0000-0001-9838-6180
FU National Institutes of Health/National Institute of Neurological
   Disorders through the Stroke Prevention and Intervention Research
   Program cooperative grant [U54NS081763]; Florida Department of Health;
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1TR002736] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Neurological Disorders & Stroke (NINDS) [U54NS081763]
   Funding Source: NIH RePORTER
FX This study was funded by the National Institutes of Health/National
   Institute of Neurological Disorders through the Stroke Prevention and
   Intervention Research Program cooperative grant (grant No. U54NS081763)
   and the Florida Department of Health.
CR Albers GW, 2018, NEW ENGL J MED, V378, P708, DOI 10.1056/NEJMoa1713973
   Asdaghi N, 2018, STROKE, V49, P638, DOI 10.1161/STROKEAHA.117.019341
   Asdaghi N, 2016, STROKE, V47, P2618, DOI 10.1161/STROKEAHA.116.013059
   Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587
   Campbell BCV, 2015, NEW ENGL J MED, V372, P1009, DOI 10.1056/NEJMoa1414792
   Goyal M, 2015, NEW ENGL J MED, V372, P1019, DOI 10.1056/NEJMoa1414905
   Goyal M, 2016, LANCET, V387, P1723, DOI 10.1016/S0140-6736(16)00163-X
   Griessenauer CJ, 2018, WORLD NEUROSURG, V110, P263, DOI 10.1016/j.wneu.2017.11.076
   Haussen DC, 2018, J NEUROINTERV SURG, V10, P325, DOI 10.1136/neurintsurg-2017-013243
   Haussen DC, 2017, J NEUROINTERV SURG, V9, P917, DOI 10.1136/neurintsurg-2016-012633
   Heldner MR, 2015, J NEUROL NEUROSUR PS, V86, P755, DOI 10.1136/jnnp-2014-308401
   Jovin TG, 2015, NEW ENGL J MED, V372, P2296, DOI 10.1056/NEJMoa1503780
   Khatri P, 2018, JAMA-J AM MED ASSOC, V320, P156, DOI 10.1001/jama.2018.8496
   Li LL, 2013, STAT METHODS MED RES, V22, P14, DOI 10.1177/0962280211403597
   Menon BK, 2016, CIRCULATION, V133, P2279, DOI 10.1161/CIRCULATIONAHA.115.019983
   Menon BK, 2015, STROKE, V46, P989, DOI 10.1161/STROKEAHA.114.007542
   Menon BK, 2014, STROKE, V45, P2024, DOI 10.1161/STROKEAHA.114.005050
   Messer MP, 2017, AM J NEURORADIOL, V38, P1177, DOI 10.3174/ajnr.A5164
   Nogueira RG, 2018, NEW ENGL J MED, V378, P11, DOI 10.1056/NEJMoa1706442
   Powers WJ, 2015, STROKE, V46, P3020, DOI 10.1161/STR.0000000000000074
   Sacco RL, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.116.004073
   Sarraj A, 2016, JAMA NEUROL, V73, P1291, DOI 10.1001/jamaneurol.2016.2773
   Saver JL, 2015, NEW ENGL J MED, V372, P2285, DOI 10.1056/NEJMoa1415061
   Smaha LA, 2004, AM HEART J, V148, pS46, DOI 10.1016/j.ahj.2004.09.015
   Sun CHJ, 2013, CIRCULATION, V127, P1139, DOI 10.1161/CIRCULATIONAHA.112.000506
   Urra X, 2014, CEREBROVASC DIS, V38, P418, DOI 10.1159/000369121
NR 26
TC 8
Z9 8
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0039-2499
EI 1524-4628
J9 STROKE
JI Stroke
PD AUG
PY 2019
VL 50
IS 8
BP 2101
EP 2107
DI 10.1161/STROKEAHA.118.023893
PG 7
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA IN7CA
UT WOS:000478838200047
PM 31303151
OA Bronze, Green Accepted
DA 2021-10-30
ER

PT J
AU Myers, ND
   Jin, Y
   Ahn, S
   Celimli, S
   Zopluoglu, C
AF Myers, Nicholas D.
   Jin, Ying
   Ahn, Soyeon
   Celimli, Seniz
   Zopluoglu, Cengiz
TI Rotation to a partially specified target matrix in exploratory factor
   analysis in practice
SO BEHAVIOR RESEARCH METHODS
LA English
DT Article
DE Monte Carlo; Simulation; Exploratory structural equation modeling;
   Target error; Model error
ID CONFIRMATORY FACTOR-ANALYSIS; SAMPLE-SIZE; MODEL; IDENTIFICATION;
   VALIDATION; OBLIQUE; ERROR
AB The purpose of the present study was to explore the influence of the number of targets specified on the quality of exploratory factor analysis solutions with a complex underlying structure and incomplete substantive measurement theory. We extended previous research in this area by (a) exploring this phenomenon in situations in which both the common factor model and the targeted pattern matrix contained specification errors and (b) comparing the performance of target rotation to an easier-to-use default rotation criterion (i.e., geomin) under conditions commonly observed in practice. A Monte Carlo study manipulated target error, number of targets, model error, overdetermination, communality, and sample size. Outcomes included bias (i.e., accuracy) and variability (i.e., stability) with regard to the rotated pattern matrix. The effects of target error were negligible for both accuracy and stability, whereas small effects were observed for the number of targets for both outcomes. Further, target rotation outperformed geomin rotation with regard to accuracy but generally performed worse than geomin rotation with regard to stability. These findings underscore the potential importance (or caution, in the case of stability) of using extant, even if incomplete and somewhat inaccurate, substantive measurement theory to inform the rotation criterion in a nonmechanical way.
C1 [Myers, Nicholas D.; Ahn, Soyeon; Celimli, Seniz; Zopluoglu, Cengiz] Univ Miami, Dept Educ & Psychol Studies, Coral Gables, FL 33124 USA.
   [Jin, Ying] Middle Tennessee State Univ, Dept Psychol, Murfreesboro, TN 37132 USA.
RP Myers, ND (corresponding author), Univ Miami, Dept Educ & Psychol Studies, Merrick Bldg 311E, Coral Gables, FL 33124 USA.
EM nmyers@miami.edu
OI Ahn, Soyeon/0000-0003-2581-306X; Zopluoglu, Cengiz/0000-0002-9397-0262;
   Myers, Nicholas/0000-0001-9069-9940
FU Miami Clinical and Translational Science Institute [1UL1TR000460];
   National Center for Advancing Translational SciencesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS);
   National Institute on Minority Health and Health DisparitiesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute on Minority Health & Health
   Disparities (NIMHD); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1TR000460] Funding Source: NIH
   RePORTER
FX This project was supported by Grant No. 1UL1TR000460, Miami Clinical and
   Translational Science Institute, from the National Center for Advancing
   Translational Sciences and the National Institute on Minority Health and
   Health Disparities. Its contents are solely the responsibility of the
   authors and do not necessarily represent the official views of the
   National Institutes of Health.
CR ALGINA J, 1980, PSYCHOMETRIKA, V45, P393, DOI 10.1007/BF02293911
   Asparouhov T, 2009, STRUCT EQU MODELING, V16, P397, DOI 10.1080/10705510903008204
   Bandalos DL, 2006, QUANT METH EDUC BEHA, P385
   BROWNE MW, 1972, BRIT J MATH STAT PSY, V25, P115, DOI 10.1111/j.2044-8317.1972.tb00482.x
   Browne MW, 2001, MULTIVAR BEHAV RES, V36, P111, DOI 10.1207/S15327906MBR3601_05
   BROWNE MW, 1972, BRIT J MATH STAT PSY, V25, P207, DOI 10.1111/j.2044-8317.1972.tb00492.x
   BROWNE MW, 1992, SOCIOL METHOD RES, V21, P230
   Cohen J., 1988, STAT POWER BEHAV SCI, V2nd ed.
   Comrey A.L., 1992, 1 COURSE FACTOR ANAL, Vsecond
   CUDECK R, 1991, PSYCHOL BULL, V109, P512, DOI 10.1037/0033-2909.109.3.512
   DiStefano C, 2005, J PSYCHOEDUC ASSESS, V23, P225, DOI 10.1177/073428290502300303
   Fava JL, 1996, EDUC PSYCHOL MEAS, V56, P907, DOI 10.1177/0013164496056006001
   GRUVAEUS GT, 1970, PSYCHOMETRIKA, V35, P493, DOI 10.1007/BF02291822
   Hayashi K, 2006, STRUCT EQU MODELING, V13, P631, DOI 10.1207/s15328007sem1304_7
   Henson RK, 2006, EDUC PSYCHOL MEAS, V66, P393, DOI 10.1177/0013164405282485
   Hong SH, 1999, BEHAV RES METH INS C, V31, P727, DOI 10.3758/BF03200754
   Hoogland JJ, 1998, SOCIOL METHOD RES, V26, P329, DOI 10.1177/0049124198026003003
   Horst P, 1941, PSYCHOMETRIKA, V6, P79, DOI 10.1007/BF02292176
   Jackson DL, 2009, PSYCHOL METHODS, V14, P6, DOI 10.1037/a0014694
   Jennrich R. I., 2007, FACTOR ANAL 100 HIST, P315
   JENNRICH RI, 1966, PSYCHOMETRIKA, V31, P313, DOI 10.1007/BF02289465
   MacCallum RC, 1999, PSYCHOL METHODS, V4, P84, DOI 10.1037/1082-989x.4.1.84
   MacCallum RC, 2001, MULTIVAR BEHAV RES, V36, P611, DOI 10.1207/S15327906MBR3604_06
   MacCallum RC, 2003, MULTIVAR BEHAV RES, V38, P113, DOI 10.1207/S15327906MBR3801_5
   MACCALLUM RC, 1992, PSYCHOL BULL, V111, P490, DOI 10.1037/0033-2909.111.3.490
   MACCALLUM RC, 1991, PSYCHOL BULL, V109, P502, DOI 10.1037/0033-2909.109.3.502
   Marsh HW, 2009, STRUCT EQU MODELING, V16, P439, DOI 10.1080/10705510903008220
   Marsh HW, 1998, MULTIVAR BEHAV RES, V33, P181, DOI 10.1207/s15327906mbr3302_1
   McDonald RP, 2005, STRUCT EQU MODELING, V12, P163, DOI 10.1207/s15328007sem1201_9
   Morin AJS, 2011, PSYCHOL SPORT EXERC, V12, P540, DOI 10.1016/j.psychsport.2011.04.003
   Muthen L.K., 1998, MPLUS USERS GUIDE, V8th ed.
   Myers ND, 2013, STRUCT EQU MODELING, V20, P131, DOI 10.1080/10705511.2013.742399
   Myers ND, 2011, J SPORT EXERCISE PSY, V33, P779, DOI 10.1123/jsep.33.6.779
   Nunnally J., 1978, PSYCHOMETRIC THEORY
   Sass DA, 2010, MULTIVAR BEHAV RES, V45, P73, DOI 10.1080/00273170903504810
   Steiger JH, 1989, CAUSAL MODELING SUPP
   Thurstone L.L., 1947, MULTIPLE FACTOR ANAL
   TUCKER LR, 1969, PSYCHOMETRIKA, V34, P421, DOI 10.1007/BF02290601
   Tucker LR, 1944, PSYCHOMETRIKA, V9, P777, DOI [10.1007/BF02288713, DOI 10.1007/BF02288713]
   Velicer WF, 1998, PSYCHOL METHODS, V3, P231, DOI 10.1037/1082-989X.3.2.231
   Yates A., 1987, MULTIVARIATE EXPLORA
NR 41
TC 13
Z9 13
U1 0
U2 8
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1554-351X
EI 1554-3528
J9 BEHAV RES METHODS
JI Behav. Res. Methods
PD JUN
PY 2015
VL 47
IS 2
BP 494
EP 505
DI 10.3758/s13428-014-0486-7
PG 12
WC Psychology, Mathematical; Psychology, Experimental
SC Psychology
GA CM3UL
UT WOS:000357610200014
PM 24903693
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Goldberg, JM
AF Goldberg, John M.
TI Immunotherapy of sarcomas
SO CURRENT OPINION IN ONCOLOGY
LA English
DT Review
DE antibody; cancer immunotherapy; cancer vaccines; dendritic cells;
   sarcoma
ID COLONY-STIMULATING FACTOR; CHILDRENS ONCOLOGY GROUP;
   LYMPHOCYTE-ASSOCIATED ANTIGEN-4; MYELOID SUPPRESSOR-CELLS; MURAMYL
   TRIPEPTIDE; EWING SARCOMA; CANCER VACCINES; GM-CSF; OSTEOSARCOMA; TUMOR
AB Purpose of reviewTo describe the current advances in immunotherapy and how they can be applied to sarcoma. This review will discuss the recent literature and selected clinical trials. Evidence supporting treatment with immunotherapy alone in sarcoma will be reviewed, as will the potential incorporation of immunotherapy into treatment for sarcoma.Recent findingsSarcoma, cancer of the connective tissues, frequently strikes young people, comprising a large percentage of cancer in children and young adults, but may occur at any age. Although molecularly targeted inhibitors are of great interest in treating sarcoma patients, immunotherapy is emerging as a plausible therapeutic modality because of the recent advances in other cancer types that may be translated to sarcoma. The licensing of ipilimumab and sipuleucel-T for cancer, and the remarkable success of immunotherapy for some childhood cancers, suggest a role for immunotherapy in the treatment of tumors like sarcoma.SummarySarcoma is a disease for which new treatments are needed. Immunotherapies have different mechanisms of action from most current therapies and could work in concert with them. Recent advances in sarcoma biology and cancer immunotherapy suggest that our knowledge of the immune system has reached the point where it can be used to augment both targeted and multimodality therapy for sarcoma.
C1 [Goldberg, John M.] Univ Miami, Miller Sch Med, Dept Pediat, Miami, FL 33136 USA.
   [Goldberg, John M.] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA.
RP Goldberg, JM (corresponding author), POB 016960,D-820, Miami, FL 33101 USA.
EM jgoldberg2@med.miami.edu
FU University of Miami Clinical and Translational Science Institute
   [1UL1TR000460]; National Center for Advancing Translational
   SciencesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS); National Institute on Minority Health
   and Health DisparitiesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Minority Health & Health Disparities (NIMHD); NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000460]
   Funding Source: NIH RePORTER
FX J.M.G. has no relevant conflicts of interest. J.M.G. is supported by the
   grant number 1UL1TR000460, University of Miami Clinical and
   Translational Science Institute, from the National Center for Advancing
   Translational Sciences, and the National Institute on Minority Health
   and Health Disparities.
CR Arndt CAS, 2010, CLIN CANCER RES, V16, P4024, DOI 10.1158/1078-0432.CCR-10-0662
   Brinkrolf P, 2009, INT J CANCER, V125, P879, DOI 10.1002/ijc.24461
   Burdach S, 2000, ANN ONCOL, V11, P1451, DOI 10.1023/A:1026539908115
   Capitini Christian M, 2009, Am J Immunol, V5, P65
   Carballido E, 2011, CURR ONCOL REP, V13, P112, DOI 10.1007/s11912-011-0152-5
   Chen DK, 2012, ATMOS OCEAN, V50, P1, DOI 10.1080/07055900.2012.741787
   Coley II WB, 1891, ANN SURG
   Dagher R, 2002, MED PEDIATR ONCOL, V38, P158, DOI 10.1002/mpo.1303
   de Camargo VP, 2009, SEMIN ONCOL, V36, P358, DOI 10.1053/j.seminoncol.2009.06.008
   DeMatteo RP, 2009, LANCET, V373, P1097, DOI 10.1016/S0140-6736(09)60500-6
   Dranoff G, 2002, IMMUNOL REV, V188, P147, DOI 10.1034/j.1600-065X.2002.18813.x
   Dranoff G, 2005, J CLIN ONCOL, V23, P662, DOI 10.1200/JCO.2005.09.923
   Finkelstein SE, 2012, INT J RADIAT ONCOL, V82, P924, DOI 10.1016/j.ijrobp.2010.12.068
   Gilboa E, 2007, J CLIN INVEST, V117, P1195, DOI 10.1172/JCI31205
   Goldberg J, 2008, AACR SPEC C CANC RES
   Goldberg J. M., 2012, J CLIN ONCOL S, P30
   GOORIN AM, 1984, J CLIN ONCOL, V2, P425, DOI 10.1200/JCO.1984.2.5.425
   Gorlick R, 2013, PEDIATR BLOOD CANCER, V60, P1009, DOI 10.1002/pbc.24429
   Granowetter L, 2009, J CLIN ONCOL, V27, P2536, DOI 10.1200/JCO.2008.19.1478
   Hodi FS, 2008, P NATL ACAD SCI USA, V105, P3005, DOI 10.1073/pnas.0712237105
   Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466
   Indelicato DJ, 2012, IMMUNOTHERAPY-UK, V4, P1023, DOI [10.2217/IMT.12.106, 10.2217/imt.12.106]
   Kawaguchi S, 2012, CANCER SCI, V103, P1625, DOI 10.1111/j.1349-7006.2012.02370.x
   KLEINERMAN ES, 1995, AM J CLIN ONCOL-CANC, V18, P93, DOI 10.1097/00000421-199504000-00001
   Mackall CL, 2008, CLIN CANCER RES, V14, P4850, DOI 10.1158/1078-0432.CCR-07-4065
   Maki Robert G., 2013, Sarcoma, V2013, P168145, DOI 10.1155/2013/168145
   Meyers PA, 2005, J CLIN ONCOL, V23, P2004, DOI 10.1200/JCO.2005.06.031
   Meyers PA, 2008, J CLIN ONCOL, V26, P633, DOI 10.1200/JCO.2008.14.0095
   Nair S, 2003, J IMMUNOL, V171, P6275, DOI 10.4049/jimmunol.171.11.6275
   Okada H, 2011, J CLIN ONCOL, V29, P330, DOI 10.1200/JCO.2010.30.7744
   Olmos David, 2011, Sarcoma, V2011, P402508, DOI 10.1155/2011/402508
   Pappo AS, J CLIN ONCOL, V29, P4541
   Pastor F, 2011, MOL THER, V19, P1878, DOI 10.1038/mt.2011.145
   Pastor F, 2010, NATURE, V465, P227, DOI 10.1038/nature08999
   Reyes-Reyes EM, 2010, CANCER RES, V70, P8617, DOI 10.1158/0008-5472.CAN-10-0920
   Robbins PF, 2011, J CLIN ONCOL, V29, P917, DOI 10.1200/JCO.2010.32.2537
   Rosenberg SA, 2004, NAT MED, V10, P909, DOI 10.1038/nm1100
   Salama AKS, 2011, CLIN CANCER RES, V17, P4622, DOI 10.1158/1078-0432.CCR-10-2232
   Serafini P, 2004, CANCER RES, V64, P6337, DOI 10.1158/0008-5472.CAN-04-0757
   Serafini P, 2006, SEMIN CANCER BIOL, V16, P53, DOI 10.1016/j.semcancer.2005.07.005
   Soiffer R, 2003, J CLIN ONCOL, V21, P3343, DOI 10.1200/JCO.2003.07.005
   Strbo N, 2008, AM J REPROD IMMUNOL, V59, P407, DOI 10.1111/j.1600-0897.2008.00594.x
   Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690
   Van Gool S, 2009, BRAIN PATHOL, V19, P694, DOI 10.1111/j.1750-3639.2009.00316.x
   Yu AL, 2010, NEW ENGL J MED, V363, P1324, DOI 10.1056/NEJMoa0911123
NR 45
TC 4
Z9 6
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-8746
EI 1531-703X
J9 CURR OPIN ONCOL
JI Curr. Opin. Oncol.
PD JUL
PY 2013
VL 25
IS 4
BP 390
EP 397
DI 10.1097/CCO.0b013e3283622c8a
PG 8
WC Oncology
SC Oncology
GA 247DJ
UT WOS:000326594500009
PM 23736878
DA 2021-10-30
ER

PT J
AU Lewis, JE
   Atlas, SE
   Higuera, OL
   Fiallo, A
   Rasul, A
   Farooqi, A
   Kromo, O
   Lantigua, LA
   Tiozzo, E
   Woolger, JM
   Goldberg, S
   Mendez, A
   Rodriguez, AE
   Konefal, J
AF Lewis, John E.
   Atlas, Steven E.
   Higuera, Oscar L.
   Fiallo, Andrea
   Rasul, Ammar
   Farooqi, Ashar
   Kromo, Olga
   Lantigua, Laura A.
   Tiozzo, Eduard
   Woolger, Judi M.
   Goldberg, Sharon
   Mendez, Armando
   Rodriguez, Allan E.
   Konefal, Janet
TI The Effect of a Hydrolyzed Polysaccharide Dietary Supplement on
   Biomarkers in Adults with Nonalcoholic Fatty Liver Disease
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID RICE BRAN MGN-3/BIOBRAN; MODIFIED ARABINOXYLAN; LYMPHOCYTE RATIO;
   STEATOHEPATITIS; PATHOGENESIS; CELLS; MGN-3; CARCINOGENESIS; PREVALENCE;
   NEUTROPHIL
AB The primary objective of the study was to evaluate the effect of a hydrolyzed polysaccharide, Rice Bran Arabinoxylan Compound (RBAC), on biomarkers in adults with nonalcoholic fatty liver disease (NAFLD). A 90-day randomized double-blind placebo-controlled trial examined the effect of RBAC on complete blood count, liver enzymes, lipids, oxidative stress markers, cytokines, and growth factors. Twenty-three adults with NAFLD were enrolled and randomly assigned to one of the two study conditions (n = 12 RBAC and n = 11 placebo) and consumed 1 gram/day of either compound for 90 days. Subjects were assessed at baseline and 45 and 90 days. No adverse effects were reported. Alkaline phosphatase significantly decreased (-3.1%; SD = 19.9; F11, 191 = 5.1, p = 0.03) in the RBAC group compared to placebo. Percent monocytes (17.9%; SD - 18.3; F[1, 19] - 5.9, p- 0.02) and percent eosinophils (30.6%; SD = 30.5; F[1,19] = 12.3, p < 0.01) increased in the RBAC group. IFN-gamma (156%; SD = 131.8; F[1,19] = 4.2, p = 0.06) and IL-18 (29.1%; SD = 64; F[1,19] - 5.3, p = 0.03) increased in the RBAC group compared to placebo. Other improvements were noted for platelets, neutrophils, neutrophil-lymphocyte ratio, gamma-glutamyl transferase, and 4-hydroxynonenal. RBAC had beneficial effects on several biomarkers that add to the known immunomodulatory activities of RBAC, which may be promising for people with NAFLD.
C1 [Lewis, John E.; Atlas, Steven E.; Higuera, Oscar L.; Fiallo, Andrea; Rasul, Ammar; Farooqi, Ashar; Lantigua, Laura A.; Tiozzo, Eduard] Univ Miami, Miller Sch Med, Dept Psychiat & Behav Sci, Miami, FL 33136 USA.
   [Kromo, Olga] Rheumat Wellness Inst LLC, South Miami, FL USA.
   [Woolger, Judi M.; Mendez, Armando; Rodriguez, Allan E.] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA.
   [Goldberg, Sharon] Glow Hlth PA, Bay Harbor Isl, FL USA.
   [Konefal, Janet] Univ Miami, Miller Sch Med, Dept Family Med & Community Hlth, Miami, FL 33136 USA.
RP Lewis, JE (corresponding author), Univ Miami, Miller Sch Med, Dept Psychiat & Behav Sci, Miami, FL 33136 USA.
EM jelewis@miami.edu
OI Lewis, John/0000-0002-8490-7368; fiallo, andrea/0000-0002-3722-0790
FU Miami Clinical and Translational Science Institute from the National
   Center for Advancing Translational Sciences; National Institute on
   Minority Health and Health DisparitiesUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute on Minority Health & Health Disparities (NIMHD)
   [1UL1TR000460]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1TR000460] Funding Source: NIH
   RePORTER
FX The authors are thankful to all of the volunteers who participated in
   this study. Daiwa Health Development participated in the design of the
   protocol for the study. This work was supported by a gift from Daiwa
   Health Development. The study was also supported by Miami Clinical and
   Translational Science Institute from the National Center for Advancing
   Translational Sciences and the National Institute on Minority Health and
   Health Disparities [Grant no. 1UL1TR000460].
CR Abdel-Razik A, 2016, EUR J GASTROEN HEPAT, V28, pe1, DOI 10.1097/MEG.0000000000000486
   Ali KH, 2012, FUNCT FOODS HEALTH D, V2, P265, DOI 10.31989/ffhd.v2i7.84
   Alkhouri N, 2012, LIVER INT, V32, P297, DOI 10.1111/j.1478-3231.2011.02639.x
   Bahcecioglu IH, 2005, HEPATO-GASTROENTEROL, V52, P1549
   Berger B. J., 2013, LAB TESTS DIAGNOSTIC, P440
   Brenner C, 2013, J HEPATOL, V59, P583, DOI 10.1016/j.jhep.2013.03.033
   Broderick G, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-191
   Browning JD, 2004, HEPATOLOGY, V40, P1387, DOI 10.1002/hep.20466
   Burtis C. A., 1994, TIETZ TXB CLIN CHEM
   Byrne CD, 2009, CLIN SCI, V116, P539, DOI 10.1042/CS20080253
   Cai C, 2017, INFLAMMATION, V40, P1875, DOI 10.1007/s10753-017-0628-z
   Chaix J, 2008, J IMMUNOL, V181, P1627, DOI 10.4049/jimmunol.181.3.1627
   Chernecky C. C., 2013, LAB TESTS DIAGNOSTIC, P559
   Cholujova D, 2013, CANCER IMMUNOL IMMUN, V62, P437, DOI 10.1007/s00262-012-1344-z
   de Veerdonk FLV, 2011, TRENDS IMMUNOL, V32, P110, DOI 10.1016/j.it.2011.01.003
   Del Ben M, 2017, BRIT J CLIN PHARMACO, V83, P88, DOI 10.1111/bcp.12899
   Dowman JK, 2011, DIABETES OBES METAB, V13, P692, DOI 10.1111/j.1463-1326.2011.01403.x
   El-Din NKB, 2016, INTEGR CANCER THER, V15, pNP26, DOI 10.1177/1534735416642287
   Eslamparast T, 2015, WORLD J HEPATOL, V7, P204, DOI 10.4254/wjh.v7.i2.204
   Gasparyan AY, 2011, CURR PHARM DESIGN, V17, P47
   Ghoneum M, 1998, INT J IMMUNOTHER, V14, P89
   Ghoneum M, 2004, INT J IMMUNOPATH PH, V17, P283, DOI 10.1177/039463200401700308
   Ghoneum M, 2014, INT J IMMUNOPATH PH, V27, P523, DOI 10.1177/039463201402700408
   Ghoneum M., 2016, AUSTIN IMMUNOLOGY, V1, P1
   Ghoneum M, 2006, CLIN IMMUNOL, V119, pS191, DOI 10.1016/j.clim.2006.04.521
   Ghoneum M, 2013, J RADIAT RES, V54, P419, DOI 10.1093/jrr/rrs119
   Gopal DV, 2000, POSTGRAD MED, V107, P100, DOI 10.3810/pgm.2000.02.869
   Hutchison R. E., 2017, HENRYS CLIN DIAGNOSI
   Khodadoostan Mahsa, 2016, Adv Biomed Res, V5, P40, DOI 10.4103/2277-9175.178785
   LUM G, 1972, CLIN CHEM, V18, P358
   Macek Jilkova Z, 2016, LIVER INT, V36, P1116, DOI 10.1111/liv.13060
   Musso G, 2010, HEPATOLOGY, V52, P79, DOI 10.1002/hep.23623
   Nakanishi K, 2001, ANNU REV IMMUNOL, V19, P423, DOI 10.1146/annurev.immunol.19.1.423
   Neuschwander-Tetri BA, 2003, HEPATOLOGY, V37, P1202, DOI 10.1053/jhep.2003.50193
   Okazaki I, 2014, CANCERS, V6, P1220, DOI 10.3390/cancers6031220
   Paquissi FC, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00490
   Paquissi FC, 2016, THER CLIN RISK MANAG, V12, P851, DOI 10.2147/TCRM.S107635
   Parnell JA, 2012, LIVER INT, V32, P701, DOI 10.1111/j.1478-3231.2011.02730.x
   Patel AA, 2009, J CLIN GASTROENTEROL, V43, P970, DOI 10.1097/MCG.0b013e3181b57475
   Pratt D. S., 2016, SLEISENGER FORDTRANS
   Preiss D, 2008, CLIN SCI, V115, P141, DOI 10.1042/CS20070402
   Proctor MJ, 2012, BRIT J CANCER, V107, P695, DOI 10.1038/bjc.2012.292
   Rolo AP, 2012, FREE RADICAL BIO MED, V52, P59, DOI 10.1016/j.freeradbiomed.2011.10.003
   SCHARSCHMIDT BF, 1983, NEW ENGL J MED, V308, P1515, DOI 10.1056/NEJM198306233082507
   Schwenger KJP, 2014, WORLD J GASTROENTERO, V20, P1712, DOI 10.3748/wjg.v20.i7.1712
   Selley ML, 1998, FREE RADICAL BIO MED, V25, P169, DOI 10.1016/S0891-5849(98)00021-5
   Selley ML, 2002, NEUROBIOL AGING, V23, P383, DOI 10.1016/S0197-4580(01)00327-X
   Serviddio G, 2013, FREE RADICAL BIO MED, V65, P952, DOI 10.1016/j.freeradbiomed.2013.08.174
   Shirato K, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/9290416
   Siddique A, 2012, CLIN LIVER DIS, V16, P199, DOI 10.1016/j.cld.2012.03.012
   Slaats J, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005973
   Tazawa K., 2000, BIOTHERAPY, V14, P493
   Tefferi A, 2017, AM J HEMATOL, V92, P95, DOI 10.1002/ajh.24607
   Valenti L, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/145421
   Zheng S, 2012, INT IMMUNOPHARMACOL, V14, P764, DOI 10.1016/j.intimp.2012.10.012
   Zheng S, 2012, BIOSCI BIOTECH BIOCH, V76, P942, DOI 10.1271/bbb.110968
   Zhong HQ, 2015, REDOX BIOL, V4, P193, DOI 10.1016/j.redox.2014.12.011
NR 57
TC 5
Z9 7
U1 0
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PY 2018
VL 2018
AR 1751583
DI 10.1155/2018/1751583
PG 10
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA GF5HR
UT WOS:000431997800001
PM 29853945
OA gold, Green Published, Green Submitted
DA 2021-10-30
ER

PT J
AU Ramos, AR
   Figueredo, P
   Shafazand, S
   Chediak, AD
   Abreu, AR
   Dib, SI
   Torre, C
   Wallace, DM
AF Ramos, Alberto R.
   Figueredo, Pedro
   Shafazand, Shirin
   Chediak, Alejandro D.
   Abreu, Alexandre R.
   Dib, Salim I.
   Torre, Carlos
   Wallace, Douglas M.
TI Obstructive Sleep Apnea Phenotypes and Markers of vascular Disease: A
   Review
SO FRONTIERS IN NEUROLOGY
LA English
DT Review
DE obstructive sleep apnea; phenotype; stroke; cardiovascular disease;
   sleep disordered breathing
ID CARDIOVASCULAR EVENTS; BLOOD-PRESSURE; ASSOCIATION; HEALTH; STROKE;
   HYPOPNEA; EPIDEMIOLOGY; SEVERITY; CPAP
AB Obstructive sleep apnea (OSA) is a chronic and heterogeneous disorder that leads to early mortality, stroke, and cardiovascular disease (CVD). OSA is defined by the apneahypopnea index, which is an index of OSA severity that combines apneas (pauses in breathing) and hypopneas (partial obstructions in breathing) associated with hypoxemia. Yet, other sleep metrics (i.e., oxygen nadir, arousal frequency), along with clinical symptoms and molecular markers could be better predictors of stroke and CVD outcomes in OSA. The recent focus on personalized medical care introduces the possibility of a unique approach to the treatment of OSA based on its phenotypes, defined by pathophysiological mechanisms and/or clinical presentation. We summarized what is known about OSA and its phenotypes, and review the literature on factors or intermediate markers that could increase stroke risk and CVD in patients with OSA. The OSA phenotypes where divided across three different domains (1) clinical symptoms (i.e., daytime sleepiness), (2) genetic/molecular markers, and (3) experimental data-driven approach (e.g., cluster analysis). Finally, we further highlight gaps in the literature framing a research agenda.
C1 [Ramos, Alberto R.; Figueredo, Pedro; Dib, Salim I.; Wallace, Douglas M.] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA.
   [Ramos, Alberto R.; Shafazand, Shirin; Chediak, Alejandro D.; Abreu, Alexandre R.; Dib, Salim I.; Torre, Carlos] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Sleep Disorders Ctr, Miami, FL 33136 USA.
   [Shafazand, Shirin; Chediak, Alejandro D.; Abreu, Alexandre R.] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA.
   [Torre, Carlos] Univ Miami, Miller Sch Med, Dept Otolaryngol Head & Neck Surg, Miami, FL 33136 USA.
   [Wallace, Douglas M.] Bruce W Carter VA Med Ctr, Sleep Disorders Ctr, Miami, FL USA.
RP Ramos, AR (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA.; Ramos, AR (corresponding author), Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Sleep Disorders Ctr, Miami, FL 33136 USA.
EM aramos@med.miami.edu
RI Ramos, Alberto/X-4249-2019; Wallace, Douglas/AAL-3719-2020
OI Wallace, Douglas/0000-0002-8982-1088
FU National Institute On Aging of the National Institutes of HealthUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute on Aging (NIA) [R21AG056952];
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [KL2TR000461] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON
   AGINGUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)
   [R21AG056952] Funding Source: NIH RePORTER
FX Research reported in this publication was supported by the National
   Institute On Aging of the National Institutes of Health under Award
   Number R21AG056952. The content is solely the responsibility of the
   authors and does not necessarily represent the official views of the
   National Institutes of Health.
CR Andaku DK, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0166-x
   Arzt M, 2005, AM J RESP CRIT CARE, V172, P1447, DOI 10.1164/rccm.200505-702OC
   Bailly S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157318
   Barbe F, 2012, JAMA-J AM MED ASSOC, V307, P2161, DOI 10.1001/jama.2012.4366
   Chen YC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176575
   Chen YC, 2016, SLEEP, V39, P743, DOI 10.5665/sleep.5620
   Culebras A, 2009, SEMIN NEUROL, V29, P438, DOI 10.1055/s-0029-1237121
   Drager LF, 2017, CIRCULATION, V136, P1840, DOI 10.1161/CIRCULATIONAHA.117.029400
   Dudley KA, 2016, SLEEP MED, V18, P96, DOI 10.1016/j.sleep.2015.01.015
   Eckert DJ, 2018, SLEEP MED REV, V37, P45, DOI 10.1016/j.smrv.2016.12.003
   Javaheri S, 2017, J AM COLL CARDIOL, V69, P841, DOI 10.1016/j.jacc.2016.11.069
   Joosten SA, 2012, RESPIROLOGY, V17, P99, DOI 10.1111/j.1440-1843.2011.02037.x
   Khalyfa A, 2016, SLEEP, V39, P2077, DOI 10.5665/sleep.6302
   Koyama RG, 2009, SLEEP MED, V10, P1107, DOI 10.1016/j.sleep.2008.12.012
   Lavie L, 2016, CHEST, V150, P5, DOI 10.1016/j.chest.2016.02.659
   Li Y, 2017, SLEEP, V40, DOI 10.1093/sleep/zsw033
   Liberati Alessandro, 2009, J Clin Epidemiol, V62, pe1, DOI 10.1016/j.jclinepi.2009.06.006
   Lim DC, 2017, ANNU REV MED, V68, P99, DOI 10.1146/annurev-med-042915-102623
   Luyster FS, 2012, J CLIN SLEEP MED, V8, P155, DOI 10.5664/jcsm.1768
   Malhotra A, 2015, LANCET RESP MED, V3, P397, DOI 10.1016/S2213-2600(15)00051-X
   Masa JF, 2016, CHEST, V150, P68, DOI 10.1016/j.chest.2016.02.647
   McEvoy RD, 2016, NEW ENGL J MED, V375, P2302, DOI 10.1056/NEJMc1613219
   McEvoy RD, 2016, NEW ENGL J MED, V375, P919, DOI 10.1056/NEJMoa1606599
   Pack AI, 2016, ANN AM THORAC SOC, V13, P1456, DOI 10.1513/AnnalsATS.201604-235PS
   Palma JA, 2014, CLIN NEUROPHYSIOL, V125, P1783, DOI 10.1016/j.clinph.2014.01.029
   Patel SR, 2007, SLEEP, V30, P531, DOI 10.1093/sleep/30.4.531
   Punjabi Naresh M, 2008, Proc Am Thorac Soc, V5, P136, DOI 10.1513/pats.200709-155MG
   Punjabi NM, 2016, CHEST, V149, P16, DOI 10.1378/chest.14-2261
   Ramos AR, 2015, SLEEP HEALTH, V1, P244, DOI 10.1016/j.sleh.2015.09.005
   Redline S, 2017, JAMA-J AM MED ASSOC, V317, P368, DOI 10.1001/jama.2016.18630
   Redline S, 2010, AM J RESP CRIT CARE, V182, P269, DOI 10.1164/rccm.200911-1746OC
   Saaresranta T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163439
   Shah N, 2016, CHEST, V149, P1409, DOI 10.1016/j.chest.2016.01.013
   Somers VK, 2008, CIRCULATION, V118, P1080, DOI [10.1161/CIRCULATIONAHA.107.189420, 10.1161/CIRCULATIONAHA.107.189375]
   Vavougios GD, 2016, J SLEEP RES, V25, P31, DOI 10.1111/jsr.12344
   Wallace DM, 2012, INT J STROKE, V7, P231, DOI 10.1111/j.1747-4949.2011.00760.x
   Wang QM, 2014, INT J MED SCI, V11, P713, DOI 10.7150/ijms.7487
   Watson NF, 2016, J CLIN SLEEP MED, V12, P1075, DOI 10.5664/jcsm.6034
   Yaggi HK, 2005, NEW ENGL J MED, V353, P2034, DOI 10.1056/NEJMoa043104
   Ye LC, 2014, EUR RESPIR J, V44, P1600, DOI 10.1183/09031936.00032314
   Yeboah J, 2011, ATHEROSCLEROSIS, V219, P963, DOI 10.1016/j.atherosclerosis.2011.08.021
   Young T, 2002, AM J RESP CRIT CARE, V165, P1217, DOI 10.1164/rccm.2109080
   Zinchuk AV, 2017, SLEEP MED REV, V35, P113, DOI 10.1016/j.smrv.2016.10.002
   Zinchuk AV, 2017, THORAX, DOI [10.1136/thoraxjnl-2017-210431, DOI 10.1136/TH0RAXJNL-2017-210431]
NR 44
TC 8
Z9 9
U1 1
U2 8
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2295
J9 FRONT NEUROL
JI Front. Neurol.
PD DEC 5
PY 2017
VL 8
AR 659
DI 10.3389/fneur.2017.00659
PG 6
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA FO7LS
UT WOS:000417056900001
PM 29259576
OA gold, Green Published
DA 2021-10-30
ER

PT J
AU Campuzano-Zuluaga, G
   Deutsch, Y
   Salzberg, M
   Gomez, A
   Vargas, F
   Elias, R
   Kwon, D
   Goodman, M
   Ikpatt, OF
   Chapman, JR
   Watts, J
   Vega, F
   Swords, R
AF Campuzano-Zuluaga, German
   Deutsch, Yehuda
   Salzberg, Matthew
   Gomez, Alexandra
   Vargas, Fernando
   Elias, Roy
   Kwon, Deukwoo
   Goodman, Mark
   Ikpatt, Offiong F.
   Chapman, Jennifer R.
   Watts, Justin
   Vega, Francisco
   Swords, Ronan
TI Routine interim disease assessment in patients undergoing induction
   chemotherapy for acute myeloid leukemia: Can we do better?
SO AMERICAN JOURNAL OF HEMATOLOGY
LA English
DT Article
ID BONE-MARROW ANGIOGENESIS; BLOOD BLAST CLEARANCE; COMPLETE REMISSION;
   GROUP-B; THERAPY; TRIAL; PREDICTS; SURVIVAL; ACHIEVEMENT; BIOPSY
AB The presence of >5% blasts at day 14 (D14), in patients undergoing induction chemotherapy for acute myeloid leukemia (AML) is problematic. It is unclear if a second course of chemotherapy for early persistent disease will alter outcome in these patients. We conducted a retrospective study of AML patients undergoing induction chemotherapy where diagnostic, interim (around day 14), and recovery (days 21-42) bone marrow (BM) evaluations were available for review. Of the 113 patients included in the final analysis, 99 (87.6%) achieved CR at hematologic recovery. At D14, 90 patients (79.6%) had <5% blasts and of these, 87 (96.7%) ultimately achieved CR. At D14, Twenty-three (20.4%) patients had residual leukemia (>5% blasts). Of these, 11 (47.8%) received a second course of chemotherapy (double induction [DI]) and 12 (52.2%) were observed until count recovery (single induction [SI]). No significant difference in CR rates was observed between these two groups (58.3% DI group vs. 45.5% SI group, P value=0.684). In our analysis, D14 BM evaluation did not uniformly identify patients with primary induction failure. To unequivocally determine the value of a D14 marrow assessment in AML, prospective studies in the context of large cooperative group trials are required. Considering our findings and similar reports from others, we propose that D14 marrow assessment should be individualized, and that other factors, such as cytogenetics and early peripheral blood blast clearance should be considered, to identify patients most likely to benefit from interim disease assessment during AML induction therapy. Am. J. Hematol. 91:277-282, 2016. (c) 2015 Wiley Periodicals, Inc.
C1 [Deutsch, Yehuda; Salzberg, Matthew; Gomez, Alexandra; Vargas, Fernando; Elias, Roy; Goodman, Mark; Watts, Justin; Swords, Ronan] Univ Miami, Dept Med, Div Hematol & Oncol, Miami, FL USA.
   [Campuzano-Zuluaga, German; Deutsch, Yehuda; Salzberg, Matthew; Gomez, Alexandra; Vargas, Fernando; Elias, Roy; Goodman, Mark; Ikpatt, Offiong F.; Chapman, Jennifer R.; Watts, Justin; Vega, Francisco; Swords, Ronan] Sylvester Comprehens Canc Ctr, Miami, FL USA.
   [Campuzano-Zuluaga, German; Deutsch, Yehuda; Salzberg, Matthew; Gomez, Alexandra; Vargas, Fernando; Elias, Roy; Goodman, Mark; Ikpatt, Offiong F.; Chapman, Jennifer R.; Watts, Justin; Vega, Francisco; Swords, Ronan] Jackson Mem Hosp, Miami, FL 33136 USA.
   [Campuzano-Zuluaga, German; Ikpatt, Offiong F.; Chapman, Jennifer R.; Vega, Francisco] Univ Miami, Dept Pathol & Lab Med, Div Hematopathol, Miami, FL USA.
   [Kwon, Deukwoo] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA.
RP Campuzano-Zuluaga, G (corresponding author), Univ Miami Hosp, 400 NW 12th Ave,Suite 4076, Miami, FL 33136 USA.
EM german.campuzanozul@jhsmiami.org
RI GOMEZ-ARTEAGA, ALEXANDRA/Y-1221-2019
OI GOMEZ-ARTEAGA, ALEXANDRA/0000-0003-0897-3790; Elias,
   Roy/0000-0002-8555-4322; CAMPUZANO-ZULUAGA, GERMAN/0000-0002-4356-3490;
   Vega, Francisco/0000-0001-5956-452X
FU NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [KL2TR000461] Funding Source: NIH RePORTER; NCATS NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [1KL2TR000461] Funding Source: Medline
CR Arellano M, 2012, CANCER-AM CANCER SOC, V118, P5278, DOI 10.1002/cncr.27494
   Bertoli S, 2014, HAEMATOLOGICA, V99, P46, DOI 10.3324/haematol.2013.091819
   Cavazzini F, 2015, CYTOM PART B-CLIN CY, DOI [10.1002/cyto.b.21267, DOI 10.1002/CYTO.B.21267.[]
   Chen BB, 2011, RADIOLOGY, V258, P821, DOI 10.1148/radiol.10100995
   Cheson BD, 2003, J CLIN ONCOL, V21, P4642, DOI 10.1200/JCO.2003.04.036
   Elliott MA, 2007, BLOOD, V110, P4172, DOI 10.1182/blood-2007-07-104091
   Frohling S, 2006, BLOOD, V108, P3280, DOI 10.1182/blood-2006-04-014324
   Gianfaldoni G, 2008, BLOOD, V111, P1746, DOI 10.1182/blood-2007-10-121103
   Gianfaldoni G, 2010, HAEMATOL-HEMATOL J, V95, P833, DOI 10.3324/haematol.2009.011908
   Grimwade D, 2010, BLOOD, V116, P354, DOI 10.1182/blood-2009-11-254441
   Grosicki S, 2011, AM J HEMATOL, V86, P437, DOI 10.1002/ajh.21996
   Hayun M, 2013, BLOOD, V122, P3893
   Heil G, 2004, ANN HEMATOL, V83, P336, DOI 10.1007/s00277-004-0853-z
   Hou HA, 2010, HAEMATOL-HEMATOL J, V95, P1420, DOI 10.3324/haematol.2009.019364
   Hussein K, 2008, AM J HEMATOL, V83, P446, DOI 10.1002/ajh.21133
   Kern W, 2003, BLOOD, V101, P64, DOI 10.1182/blood-2002-02-0532
   Liso V, 2000, HAEMATOLOGICA, V85, P1285
   Morris TA, 2013, LEUKEMIA RES, V37, P28, DOI 10.1016/j.leukres.2012.09.016
   National Cancer Institute, AD AC MYEL LEUK TREA
   NCCN Clinical Practice Guidelines in Oncology, AC MYEL LEUK VERS 1
   Panzer-Grumayer ER, 2000, BLOOD, V95, P790, DOI 10.1182/blood.V95.3.790.003k48_790_794
   PREISLER H, 1987, BLOOD, V69, P1441
   Pullarkat V, 2015, CRIT REV ONCOL HEMAT, V95, P38, DOI 10.1016/j.critrevonc.2015.01.005
   R Core Team, 2018, R LANG ENV STAT COMP
   RAI KR, 1981, BLOOD, V58, P1203
   Rowe JM, 2010, CANCER-AM CANCER SOC, V116, P5012, DOI 10.1002/cncr.25263
   Shih TTF, 2009, BLOOD, V113, P3161, DOI 10.1182/blood-2008-08-173104
   Wheatley K, 1999, BRIT J HAEMATOL, V107, P69, DOI 10.1046/j.1365-2141.1999.01684.x
   Xie H, 2013, BLOOD, V122, P5002
   Yanada M, 2008, HAEMATOL-HEMATOL J, V93, P1263, DOI 10.3324/haematol.12825
NR 30
TC 6
Z9 6
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0361-8609
EI 1096-8652
J9 AM J HEMATOL
JI Am. J. Hematol.
PD MAR
PY 2016
VL 91
IS 3
BP 277
EP 282
DI 10.1002/ajh.24271
PG 6
WC Hematology
SC Hematology
GA DF2HI
UT WOS:000371162800249
PM 26663264
OA Bronze
DA 2021-10-30
ER

PT J
AU Lewis, JE
   Atlas, SE
   Rasul, A
   Farooqi, A
   Lantigua, L
   Higuera, OL
   Fiallo, A
   Laria, L
   Picciani, R
   Wals, K
   Yehoshua, Z
   Mendez, A
   Konefal, J
   Goldberg, S
   Woolger, J
AF Lewis, John E.
   Atlas, Steven E.
   Rasul, Ammar
   Farooqi, Ashar
   Lantigua, Laura
   Higuera, Oscar L.
   Fiallo, Andrea
   Laria, Lianette
   Picciani, Renata
   Wals, Ken
   Yehoshua, Zohar
   Mendez, Armando
   Konefal, Janet
   Goldberg, Sharon
   Woolger, Judi
TI New method of sudomotor function measurement to detect microvascular
   disease and sweat gland nerve or unmyelinated C fiber dysfunction in
   adults with retinopathy
SO JOURNAL OF DIABETES AND METABOLIC DISORDERS
LA English
DT Article
DE Retinopathy; ANS-1; Sudomotor test; NO Sweat Peak; iSweat Peak;
   Microvascular diseases; C fiber dysfunction; Diabetes complications
ID SPECTRAL-ANALYSIS; BLOOD-FLOW; NEUROPATHY; MICROCIRCULATION;
   COMPLICATIONS; RESPONSES; TISSUE; TOOL
AB Background: Diabetes-associated microvascular complications such as retinopathy and neuropathy often lead to end-organ and tissue damage. Impaired skin microcirculation often precedes the detection of other advanced diabetic complications. The ANS-1 system contains a redesigned sympathetic skin response (ANS-1 SSR) device that measures sudomotor function, a photoplethysmography sensor, and a blood pressure device to comprehensively assess cardiac autonomic neuropathy and endothelial dysfunction. The purpose of this study was to determine the relationships between the ANS-1 SSR amplitude measured at the: (a) negative electrode (Nitric Oxide [NO] Sweat Peak) with microvascular diseases and associated vascular blood markers and (b) positive electrode (iSweat Peak) with C fiber function.
   Methods: All participants (healthy controls n = 50 and retinopathy patients n = 50) completed the ANS-1 system evaluation and a basic sociodemographic and medical history questionnaire, including a quality of life measure (SF-36). A small sample of blood was drawn to determine levels of homocysteine, blood urea nitrogen (BUN), C-reactive protein (CRP), and fibrinogen. Symptoms of peripheral foot neuropathy were assessed with a scale from 1 (none) to 10 (the worst). We used Spearman rank correlations, independent samples t-tests, and receiver operating characteristic curves to determine the specificity and sensitivity of the NO Sweat Peak as a potential screening marker of retinopathy.
   Results: The ANS-1 System Cardiometabolic Risk Score and all indicators of quality of life on the SF-36, other than Emotional Role Functioning, were significantly worse in the retinopathy patients. The sudomotor response marker NO Sweat Peak had a sensitivity of 88% and a specificity of 68% (Area Under the Curve = 0.81, p < 0.0001) to detect retinopathy. The NO Sweat Peak response marker inversely correlated with BUN (rho = -0.41, p < 0.0001), homocysteine (rho = -0.44, p < 0.0001), fibrinogen (rho = -0.41, p < 0.0001), the Cardiac Autonomic Neuropathy score (rho = -0.68, p < 0. 0001), and the heart rate variability Total Power (rho = -0.57, p < 0.0001), and it positively correlated with the Photoplethysmography Index (PTGi; rho = 0.53 p < 0.0001). The ANS-1 system sudomotor response marker iSweat Peak inversely correlated with the severity of symptoms on the peripheral neuropathy scale (rho = -0.56, p < 0.0001).
   Conclusion: The results of the study show that this new method of measuring sympathetic skin response should be useful for detecting the earliest manifestations of microvascular disease and symptoms of C fiber dysfunction.
C1 [Lewis, John E.; Rasul, Ammar; Farooqi, Ashar; Lantigua, Laura; Higuera, Oscar L.; Fiallo, Andrea] Univ Miami, Miller Sch Med, Dept Psychiat & Behav Sci, 1120 NW 14th St Suite 1482A, Miami, FL 33136 USA.
   [Atlas, Steven E.; Mendez, Armando; Woolger, Judi] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA.
   [Laria, Lianette] Laria Eye Care, Miami, FL USA.
   [Picciani, Renata; Wals, Ken] Aran Eye Associates, Miami, FL USA.
   [Yehoshua, Zohar] Univ Miami, Miller Sch Med, Dept Ophthalmol, Miami, FL 33136 USA.
   [Konefal, Janet] Univ Miami, Miami Miller Sch Med, Dept Family Med & Community Hlth, Miami, FL USA.
   [Goldberg, Sharon] Glow Hlth PA, Bay Harbor Isl, FL USA.
RP Lewis, JE (corresponding author), Univ Miami, Miller Sch Med, Dept Psychiat & Behav Sci, 1120 NW 14th St Suite 1482A, Miami, FL 33136 USA.
EM jelewis@miami.edu
OI fiallo, andrea/0000-0002-3722-0790
FU Miami Clinical and Translational Science Institute, from the National
   Center for Advancing Translational Sciences [1UL1TR000460]; National
   Institute on Minority Health and Health DisparitiesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Minority Health & Health Disparities
   (NIMHD); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Advancing Translational
   Sciences (NCATS) [UL1TR000460] Funding Source: NIH RePORTER
FX This work was supported by a gift from LD Technology, Inc. The study was
   also supported by Grant Number 1UL1TR000460, Miami Clinical and
   Translational Science Institute, from the National Center for Advancing
   Translational Sciences and the National Institute on Minority Health and
   Health Disparities. Its contents are solely the responsibility of the
   authors and do not necessarily represent the official views of the
   National Institutes of Health.
CR Abdollahi A, 2009, INT J OPHTHALMOL-CHI, V2, P57
   Abularrage CJ, 2005, J VASC SURG, V42, P574, DOI 10.1016/j.jvs.2005.05.019
   Alport Adina R, 2012, Continuum (Minneap Minn), V18, P13, DOI 10.1212/01.CON.0000411546.13207.b1
   Berg AH, 2005, CIRC RES, V96, P939, DOI 10.1161/01.RES.0000163635.62927.34
   Boyko EJ, 2001, FOOT ANKLE INT, V22, P711, DOI 10.1177/107110070102200904
   Candrilli SD, 2007, J DIABETES COMPLICAT, V21, P306, DOI 10.1016/j.jdiacomp.2006.08.002
   De Souza AL, 2017, J DIABETES COMPLICAT, V31, P128, DOI 10.1016/j.jdiacomp.2016.10.018
   Eranki VG, 2013, DIABETES RES CLIN PR, V101, pE11, DOI 10.1016/j.diabres.2013.07.003
   Gandhi PG, 2015, DEGENER NEUROL NEURO, V5, DOI 10.2147/DNND.S75857
   Gandhi PG, 2014, INT J GEN MED, V7, P539, DOI 10.2147/IJGM.S70892
   Grimnes S, 2008, ELECTROLYTICS BIOIMP
   Hsiu H, 2014, CLIN HEMORHEOL MICRO, V57, P375, DOI 10.3233/CH-131794
   Jonsson B, 2002, DIABETOLOGIA, V45, pS5, DOI 10.1007/s00125-002-0858-x
   Kawasaki R, 2011, DIABETOLOGIA, V54, P2288, DOI 10.1007/s00125-011-2199-0
   Kilo S, 2000, NEUROLOGY, V54, P1246, DOI 10.1212/WNL.54.6.1246
   Kircher M, 2017, CURR CARDIOVASC IMAG, V10, DOI 10.1007/s12410-017-9400-x
   Lewis JE, 2014, J DIABETES METAB DIS, V13, DOI 10.1186/s40200-014-0118-x
   Lewis JE, 2011, MED DEVICES-EVID RES, V4, P169, DOI 10.2147/MDER.S24291
   Low PA, 2004, CLIN NEUROPHYSIOL, V115, P1506, DOI 10.1016/j.clinph.2004.01.023
   Low VA, 2006, MUSCLE NERVE, V34, P57, DOI 10.1002/mus.20551
   Muggeo M, 1998, DIABETIC MED, V15, pS60, DOI 10.1002/(SICI)1096-9136(1998120)15:4+<S60::AID-DIA736>3.3.CO;2-A
   Overland J, 2001, DIABETIC MED, V18, P554, DOI 10.1046/j.1464-5491.2001.00521.x
   Quattrini C, 2007, DIABETES CARE, V30, P655, DOI 10.2337/dc06-2154
   Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207
   Sommer P, 2011, AUTON NEUROSCI-BASIC, V159, P111, DOI 10.1016/j.autneu.2010.09.004
   Spallone V, 2009, DIABETIC MED, V26, P686, DOI 10.1111/j.1464-5491.2009.02760.x
   STANLEY EF, 1993, NEURON, V11, P1007, DOI 10.1016/0896-6273(93)90214-C
   Stansberry KB, 1997, DIABETES CARE, V20, P1711, DOI 10.2337/diacare.20.11.1711
   Ulleryd MA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174974
   Vinik AI, 2007, CIRCULATION, V115, P387, DOI 10.1161/CIRCULATIONAHA.106.634949
   Ware JE, 2000, SCORE VERSION 2 SF 3
NR 31
TC 3
Z9 3
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2251-6581
J9 J DIABETES METAB DIS
JI J. Diabetes Metab. Disord.
PD JUN 12
PY 2017
VL 16
AR 26
DI 10.1186/s40200-017-0307-5
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA EX6VM
UT WOS:000403380200001
PM 28616394
OA hybrid, Green Published
DA 2021-10-30
ER

PT J
AU Fiore, RN
   Cushman, R
AF Fiore, Robin N.
   Cushman, Reid
TI Informed Consent and Parental Permission for Research: Rules, Roles, and
   Relationships
SO AMERICAN JOURNAL OF BIOETHICS
LA English
DT Editorial Material
C1 [Fiore, Robin N.; Cushman, Reid] Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
RP Fiore, RN (corresponding author), Univ Miami, Miller Sch Med, Eth Programs, Med, POB 016960 M825, Miami, FL 33136 USA.
EM rfiore@miami.edu
RI Fiore, Robin N./V-5645-2019
FU Miami Clinical and Translational Science Institute [1UL1TR000460];
   National Center for Advancing Translational SciencesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS);
   National Institute on Minority Health and Health DisparitiesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute on Minority Health & Health
   Disparities (NIMHD); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1TR000460] Funding Source: NIH
   RePORTER
FX This project was supported by Grant Number 1UL1TR000460, Miami Clinical
   and Translational Science Institute, from the National Center for
   Advancing Translational Sciences and the National Institute on Minority
   Health and Health Disparities.
CR Food and Drug Administration, 2014, FED REG, V78
   Food and Drug Administration, 2014, DRAFT GUID JUL INF C
   Lidz CW, 2002, MED CARE, V40, P55, DOI 10.1097/01.MLR.0000023956.25813.18
   Office for Human Research Protections, 2011, POL GUID FREQ ASK QU
NR 4
TC 2
Z9 2
U1 0
U2 3
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 1526-5161
EI 1536-0075
J9 AM J BIOETHICS
JI Am. J. Bioeth.
PD APR 3
PY 2015
VL 15
IS 4
BP 77
EP 78
DI 10.1080/15265161.2015.1011005
PG 2
WC Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical
SC Social Sciences - Other Topics; Medical Ethics; Social Issues;
   Biomedical Social Sciences
GA CF5RO
UT WOS:000352614900026
PM 25856615
DA 2021-10-30
ER

PT J
AU Eshraghi, AA
   Nazarian, R
   Telischi, FF
   Martinez, D
   Hodges, A
   Velandia, S
   Cejas-Cruz, I
   Balkany, TJ
   Lo, KM
   Lang, D
AF Eshraghi, Adrien A.
   Nazarian, Ronen
   Telischi, Fred F.
   Martinez, Diane
   Hodges, Annelle
   Velandia, Sandra
   Cejas-Cruz, Ivette
   Balkany, Thomas J.
   Lo, Kaming
   Lang, Dustin
TI Cochlear Implantation in Children With Autism Spectrum Disorder
SO OTOLOGY & NEUROTOLOGY
LA English
DT Article
DE Cochlear implant surgery; Autism; Autism spectrum disorders; Pervasive
   developmental disorders; Hearing loss; Speech delay; Ear surgery;
   Developmental delay; Deafness
ID PERVASIVE DEVELOPMENTAL DISORDERS; LANGUAGE; MENINGITIS; PREVALENCE;
   REGRESSION; OUTCOMES; BRAIN
AB Objective To assess the outcome of cochlear implantation in children with autism spectrum disorder (ASD).
   Study Design Retrospective case review and survey.
   Setting Tertiary referral center.
   Patients Children who meet criteria for cochlear implantation and diagnosis of ASD.
   Main Outcome Measures Receptive and expressive language scores and parental survey data.
   Results Fifteen patients with history of ASD and cochlear implantation were analyzed and compared with 15 patients who received cochlear implant and have no other disability. Postoperatively, more than 67% of children with ASD significantly improved their speech perception skills, and 60% significantly improved their speech expression skills, whereas all patients in the control group showed significant improvement in both aspects. The top 3 reported improvements after cochlear implantation were name recognition, response to verbal requests, and enjoyment of music. Of all behavioral aspects, the use of eye contact was the least improved. Survey results in regard to improvements in patient interaction were more subtle when compared with those related to sound and speech perception. The most improved aspects in the ASD patients' lives after cochlear implantation seemed to be attending to other people's requests and conforming to family routines. Of note, awareness of the child's environment is the most highly ranked improvement attributed to the cochlear implant.
   Conclusion Cochlear implants are effective and beneficial for hearing impaired members of the ASD population, although development of language may lag behind that of implanted children with no additional disabilities. Significant speech perception and overall behavior improvement are noted.
C1 [Eshraghi, Adrien A.; Nazarian, Ronen; Telischi, Fred F.; Martinez, Diane; Hodges, Annelle; Velandia, Sandra; Cejas-Cruz, Ivette; Balkany, Thomas J.; Lo, Kaming; Lang, Dustin] Univ Miami, Miller Sch Med, Dept Otolaryngol, Miami, FL 33136 USA.
RP Eshraghi, AA (corresponding author), Univ Miami, Ear Inst, Clin Res Bldg,1120 NW 14 St,Fifth Floor, Miami, FL 33136 USA.
EM AEshraghi@med.miami.edu
FU University of Miami Clinical and Translational Science Institute from
   the National Center for Advancing Translational Sciences [1UL1TR000460];
   National Institute on Minority Health and Health DisparitiesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute on Minority Health & Health
   Disparities (NIMHD); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1TR000460] Funding Source: NIH
   RePORTER
FX The project described was supported by Grant Number 1UL1TR000460,
   University of Miami Clinical and Translational Science Institute, from
   the National Center for Advancing Translational Sciences and the
   National Institute on Minority Health and Health Disparities. Its
   contents are solely the responsibility of the authors and do not
   necessarily represent the official views of the NIH.
CR Baio Jon, 2012, Morbidity and Mortality Weekly Report, V61, P1
   Baldassari CM, 2009, OTOLARYNG HEAD NECK, V140, P114, DOI 10.1016/j.otohns.2008.09.008
   Bazzano A, 2012, AJIDD-AM J INTELLECT, V117, P233, DOI 10.1352/1944-7558-117.3.233
   Beers AN, 2014, INT J PEDIATR OTORHI, V78, P96, DOI 10.1016/j.ijporl.2013.10.063
   Chakrabarti S, 2005, AM J PSYCHIAT, V162, P1133, DOI 10.1176/appi.ajp.162.6.1133
   Chauhan Abha, 2006, Pathophysiology, V13, P171, DOI 10.1016/j.pathophys.2006.05.007
   Chez Michael G, 2004, Semin Pediatr Neurol, V11, P214, DOI 10.1016/j.spen.2004.07.005
   Cohen NL, 2010, OTOL NEUROTOL, V31, P1325, DOI 10.1097/MAO.0b013e3181f2ed06
   Cohly HHP, 2005, INT REV NEUROBIOL, V71, P317, DOI 10.1016/S0074-7742(05)71013-8
   Cruz I, 2012, OTOL NEUROTOL, V33, P751, DOI 10.1097/MAO.0b013e3182595309
   Daneshi A, 2007, J LARYNGOL OTOL, V121, P635, DOI 10.1017/S0022215107005051
   Dhillon S, 2011, CURR GENOMICS, V12, P322, DOI 10.2174/138920211796429745
   Donaldson AI, 2004, ARCH OTOLARYNGOL, V130, P666, DOI 10.1001/archotol.130.5.666
   Duchan E, 2012, PEDIATR CLIN N AM, V59, P27, DOI 10.1016/j.pcl.2011.10.003
   Easterbrooks SR, 2005, AM ANN DEAF, V150, P401, DOI 10.1353/aad.2006.0001
   Edwards LC, 2007, J DEAF STUD DEAF EDU, V12, P258, DOI 10.1093/deafed/enm007
   Filipo R, 2004, ACTA OTO-LARYNGOL, V124, P74, DOI 10.1080/03655230410017193
   Forli F, 2011, ACTA OTORHINOLARYNGO, V31, P281
   Gomes Erissandra, 2008, Pró-Fono R. Atual. Cient., V20, P279, DOI 10.1590/S0104-56872008000400013
   Grabrucker Andreas M, 2012, Front Psychiatry, V3, P118, DOI 10.3389/fpsyt.2012.00118
   Hamzavi J, 2000, INT J PEDIATR OTORHI, V56, P169, DOI 10.1016/S0165-5876(00)00420-1
   Heman-Ackah SE, 2012, OTOLARYNG CLIN N AM, V45, P41, DOI 10.1016/j.otc.2011.08.016
   Holler K, 2012, MO MED, V109, P16
   James SJ, 2004, AM J CLIN NUTR, V80, P1611, DOI 10.1093/ajcn/80.6.1611
   Johnson CP, 2007, PEDIATRICS, V120, P1183, DOI 10.1542/peds.2007-2361
   Jyonouchi H, 2001, J NEUROIMMUNOL, V120, P170, DOI 10.1016/S0165-5728(01)00421-0
   Lalwani AK, 2012, OTOL NEUROTOL, V33, P93, DOI 10.1097/MAO.0b013e31823dbb08
   Meinzen-Derr J, 2011, RES DEV DISABIL, V32, P757, DOI 10.1016/j.ridd.2010.11.004
   Niparko JK, 2010, JAMA-J AM MED ASSOC, V303, P1498, DOI 10.1001/jama.2010.451
   Poling JS, 2006, J CHILD NEUROL, V21, P170, DOI 10.1177/08830738060210021401
   Prizant BM, 1996, J AUTISM DEV DISORD, V26, P173, DOI 10.1007/BF02172007
   Reefhuis J, 2010, OTOL NEUROTOL, V31, P1329, DOI 10.1097/MAO.0b013e3181f2f05f
   Rogers SJ, 1996, J AUTISM DEV DISORD, V26, P243, DOI 10.1007/BF02172020
   Rose S, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.61
   Sharpe MA, 2012, J TOXICOL-US, V2012, DOI 10.1155/2012/373678
   SPITZER RL, 1990, J AM ACAD CHILD PSY, V29, P855, DOI 10.1097/00004583-199011000-00003
   Vargas DL, 2005, ANN NEUROL, V57, P67, DOI 10.1002/ana.20315
   Wackym AP, 2010, CUMMINGS OTOLARYNGOL, pChapter 158
   Wiley S, 2008, ANN OTO RHINOL LARYN, V117, P711, DOI 10.1177/000348940811701001
NR 39
TC 10
Z9 12
U1 0
U2 20
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1531-7129
EI 1537-4505
J9 OTOL NEUROTOL
JI Otol. Neurotol.
PD SEP
PY 2015
VL 36
IS 8
BP E121
EP E128
DI 10.1097/MAO.0000000000000757
PG 8
WC Clinical Neurology; Otorhinolaryngology
SC Neurosciences & Neurology; Otorhinolaryngology
GA CQ3FX
UT WOS:000360488500001
PM 25899551
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Rice, TW
   Ishwaran, H
   Hofstetter, WL
   Schipper, PH
   Kesler, KA
   Law, S
   Lerut, T
   Denlinger, CE
   Salo, JA
   Scott, WJ
   Watson, TJ
   Allen, MS
   Chen, LQ
   Rusch, VW
   Cerfolio, RJ
   Luketich, JD
   Duranceau, A
   Darling, GE
   Pera, M
   Apperson-Hansen, C
   Blackstone, EH
AF Rice, Thomas W.
   Ishwaran, Hemant
   Hofstetter, Wayne L.
   Schipper, Paul H.
   Kesler, Kenneth A.
   Law, Simon
   Lerut, Toni
   Denlinger, Chadrick E.
   Salo, Jarmo A.
   Scott, Walter J.
   Watson, Thomas J.
   Allen, Mark S.
   Chen, Long-Qi
   Rusch, Valerie W.
   Cerfolio, Robert J.
   Luketich, James D.
   Duranceau, Andre
   Darling, Gail E.
   Pera, Manuel
   Apperson-Hansen, Carolyn
   Blackstone, Eugene H.
TI Esophageal Cancer: Associations With (pN plus ) Lymph Node Metastases
SO ANNALS OF SURGERY
LA English
DT Article
DE esophageal cancer; pN; Worldwide Esophageal Cancer Collaboration (WECC)
ID CARCINOMA; TUMOR; NUMBER
AB Objectives: To identify the associations of lymph node metastases (pN+), number of positive nodes, and pN subclassification with cancer, treatment, patient, geographic, and institutional variables, and to recommend extent of lymphadenectomy needed to accurately detect pN+ for esophageal cancer.
   Summary Background Data: Limited data and traditional analytic techniques have precluded identifying intricate associations of pN+ with other cancer, treatment, and patient characteristics.
   Methods: Data on 5806 esophagectomy patients from the Worldwide Esophageal Cancer Collaboration were analyzed by Random Forest machine learning techniques.
   Results: pN+, number of positive nodes, and pN subclassification were associated with increasing depth of cancer invasion (pT), increasing cancer length, decreasing cancer differentiation (G), and more regional lymph nodes resected. Lymphadenectomy necessary to accurately detect pN+ is 60 for shorter, well-differentiated cancers (<2.5 cm) and 20 for longer, poorly differentiated ones.
   Conclusions: In esophageal cancer, pN+, increasing number of positive nodes, and increasing pN classification are associated with deeper invading, longer, and poorly differentiated cancers. Consequently, if the goal of lymphadenectomy is to accurately define pN+ status of such cancers, few nodes need to be removed. Conversely, superficial, shorter, and well-differentiated cancers require a more extensive lymphadenectomy to accurately define pN+ status.
C1 [Rice, Thomas W.; Apperson-Hansen, Carolyn; Blackstone, Eugene H.] Cleveland Clin, Cleveland, OH 44106 USA.
   [Ishwaran, Hemant] Univ Miami, Miami, FL USA.
   [Hofstetter, Wayne L.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   [Schipper, Paul H.] Oregon Hlth & Sci Ctr, Portland, OR USA.
   [Kesler, Kenneth A.] Indiana Univ, Indianapolis, IN 46204 USA.
   [Law, Simon] Univ Hong Kong, Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China.
   [Lerut, Toni] Univ Hosp Leuven, Leuven, Belgium.
   [Denlinger, Chadrick E.] Med Univ South Carolina, Charleston, SC USA.
   [Salo, Jarmo A.] Helsinki Univ Hosp, Helsinki, Finland.
   [Scott, Walter J.] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA.
   [Watson, Thomas J.] Univ Rochester, New York, NY USA.
   [Allen, Mark S.] Mayo Clin, Rochester, MN USA.
   [Chen, Long-Qi] Sichuan Univ, West China Hosp, Chengdu, Sichuan, Peoples R China.
   [Rusch, Valerie W.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
   [Cerfolio, Robert J.] Univ Alabama Birmingham, Birmingham, AL USA.
   [Luketich, James D.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
   [Duranceau, Andre] Univ Montreal, Montreal, PQ, Canada.
   [Darling, Gail E.] Toronto Gen Hosp, Toronto, ON, Canada.
   [Pera, Manuel] Univ Autonoma Barcelona, Hosp Univ Mar, Inst Hosp Mar Invest Med, Barcelona, Spain.
RP Rice, TW (corresponding author), Cleveland Clin, Dept Thorac & Cardiovasc Surg, 9500 Euclid Ave,Desk JJ-4, Cleveland, OH 44195 USA.
EM ricet@ccf.org
RI luketich, james/AAY-6230-2020; Law, Simon/C-4324-2009
OI Law, Simon/0000-0002-6518-5806; Chen, Longqi/0000-0002-5036-5345; Rusch,
   Valerie/0000-0003-2345-6900; Cerfolio, Robert/0000-0002-5598-599X; Pera,
   Manuel/0000-0002-9449-1810
FU Gus P. Karos Registry Fund; Daniel and Karen Lee Endowed Chair in
   Thoracic Surgery; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1TR000460, UL1TR000439] Funding
   Source: NIH RePORTER
FX This publication was made possible in part by the Clinical and
   Translational Science Collaborative of Cleveland, UL1TR000439 from the
   National Center for Advancing Translational Sciences (NCATS) component
   of the National Institutes of Health and NIH Roadmap for Medical
   Research. Its contents are solely the responsibility of the authors and
   do not necessarily represent the official views of the NIH. Other
   sources of funding included the Gus P. Karos Registry Fund, the Daniel
   and Karen Lee Endowed Chair in Thoracic Surgery, held by Rice, and the
   Kenneth Gee and Paula Shaw, PhD, Chair in Heart Research, held by
   Blackstone. The authors declare no conflicts of interest.
CR Bollschweiler E, 2006, J SURG ONCOL, V94, P355, DOI 10.1002/jso.20569
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Breiman L, 1996, MACH LEARN, V24, P123, DOI 10.1023/A:1018054314350
   Dutkowski P, 2002, HEPATO-GASTROENTEROL, V49, P176
   Edge SB, 2010, AM JOINT COMMITTEE C
   Ishwaran H., 2015, RANDOM FORESTS SURVI
   Ishwaran H, 2008, ANN APPL STAT, V2, P841, DOI 10.1214/08-AOAS169
   Ishwaran H, 2010, J AM STAT ASSOC, V105, P205, DOI 10.1198/jasa.2009.tm08622
   Ishwaran H, 2009, BIOSTATISTICS, V10, P603, DOI 10.1093/biostatistics/kxp016
   Peyre CG, 2008, ANN SURG, V248, P979, DOI 10.1097/SLA.0b013e3181904f3c
   Rice TW, 2009, DIS ESOPHAGUS, V22, P1, DOI 10.1111/j.1442-2050.2008.00901.x
   Rice TW, 2013, ANN THORAC SURG, V96, P744, DOI 10.1016/j.athoracsur.2013.03.102
   Rice TW, 2010, CANCER-AM CANCER SOC, V116, P3763, DOI 10.1002/cncr.25146
   Rice TW, 1998, ANN THORAC SURG, V65, P787, DOI 10.1016/S0003-4975(97)01387-8
   Rizk NP, 2010, ANN SURG, V251, P46, DOI 10.1097/SLA.0b013e3181b2f6ee
   Siewert JR, 2001, ANN SURG, V234, P360, DOI 10.1097/00000658-200109000-00010
   Tajima Y, 2000, CANCER, V88, P1285
NR 17
TC 54
Z9 61
U1 2
U2 21
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-4932
EI 1528-1140
J9 ANN SURG
JI Ann. Surg.
PD JAN
PY 2017
VL 265
IS 1
BP 122
EP 129
DI 10.1097/SLA.0000000000001594
PG 8
WC Surgery
SC Surgery
GA EH9QS
UT WOS:000392106500026
PM 28009736
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Goodman, KW
AF Goodman, Kenneth W.
TI Guest Editorial Addressing Ethical Issues in Health Information
   Technology
SO CAMBRIDGE QUARTERLY OF HEALTHCARE ETHICS
LA English
DT Editorial Material
C1 [Goodman, Kenneth W.] Univ Miami, Miller Sch Med, Med, Miami, FL 33136 USA.
   [Goodman, Kenneth W.] Univ Miami, Miller Sch Med, Bioeth Program, Miami, FL 33136 USA.
RP Goodman, KW (corresponding author), Univ Miami, Miller Sch Med, Med, Miami, FL 33136 USA.
FU University of Miami CTSI - National Center for Advancing Translational
   Sciences [1UL1TR000460]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1TR000460] Funding Source: NIH
   RePORTER
FX This introduction and work on this special section are supported in part
   by the University of Miami CTSI, funded by the National Center for
   Advancing Translational Sciences grant number 1UL1TR000460.
NR 0
TC 2
Z9 3
U1 0
U2 4
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0963-1801
EI 1469-2147
J9 CAMB Q HEALTHC ETHIC
JI Camb. Q. Healthc. Ethics
PD JUL
PY 2015
VL 24
IS 3
BP 252
EP 254
DI 10.1017/S0963180114000577
PG 3
WC Health Care Sciences & Services; Health Policy & Services; Social
   Sciences, Biomedical
SC Health Care Sciences & Services; Biomedical Social Sciences
GA CK4CZ
UT WOS:000356169200002
PM 26059951
OA Bronze
DA 2021-10-30
ER

PT J
AU Wilky, BA
   Goldberg, JM
AF Wilky, Breelyn A.
   Goldberg, John M.
TI Immunotherapy in Sarcoma: A New Frontier
SO DISCOVERY MEDICINE
LA English
DT Article
ID ANTIGEN; CELLS; RISK; BONE; VACCINATION; BLOCKADE; TARGET
AB Sarcomas are rare cancers of soft tissue and bone, and remain incurable when refractory to standard multimodality treatments. With the recent advances in immunotherapy for other solid tumors, there is heightened interest in the potential link of the immune system with sarcoma physiology. This review aims to summarize the ongoing laboratory and clinical research investigating the applications of immunotherapy in the treatment of sarcomas. With ongoing opportunities in vaccine therapy, adoptive transfer of immune cells, biochemotherapy, and immune checkpoint inhibitors, enrollment in immunotherapy clinical trials is an appealing option for sarcoma patients either in conjunction with traditional treatment modalities, or for those with few standard treatment options.
C1 [Wilky, Breelyn A.] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Dept Med,Div Hematol Oncol, Miami, FL 33136 USA.
   [Goldberg, John M.] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Dept Pediat, Miami, FL 33136 USA.
RP Goldberg, JM (corresponding author), Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Dept Pediat, Miami, FL 33136 USA.
EM JGoldberg2@med.miami.edu
FU Sylvester Comprehensive Cancer Center; University of Miami Clinical and
   Translational Science Institute, from the National Center for Advancing
   Translational Sciences [1UL1TR000460]; National Institute on Minority
   Health and Health DisparitiesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Minority Health & Health Disparities (NIMHD); NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000460]
   Funding Source: NIH RePORTER
FX Dr. Goldberg is supported by the Sylvester Comprehensive Cancer Center
   and by Grant Number 1UL1TR000460, University of Miami Clinical and
   Translational Science Institute, from the National Center for Advancing
   Translational Sciences and the National Institute on Minority Health and
   Health Disparities.
CR Coley W B, 1891, Ann Surg, V14, P199, DOI 10.1097/00000658-189112000-00015
   Feng DP, 2013, GENET TEST MOL BIOMA, V17, P458, DOI 10.1089/gtmb.2012.0488
   Finkelstein SE, 2012, INT J RADIAT ONCOL, V82, P924, DOI 10.1016/j.ijrobp.2010.12.068
   Goldberg J, 2008, AACR SPEC C CANC RES
   GOORIN AM, 1984, J CLIN ONCOL, V2, P425, DOI 10.1200/JCO.1984.2.5.425
   Jungbluth A, 2012, INT J CANCER, V94, P252
   Kim J, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0077972, 10.1371/journal.pone.0062068, 10.1371/journal.pone.0060505]
   Krishnadas D, 2014, TUMOUR BIOL
   Li QS, 2012, J IMMUNOL, V188, P3080, DOI 10.4049/jimmunol.1103365
   Mackall CL, 2008, CLIN CANCER RES, V14, P4850, DOI 10.1158/1078-0432.CCR-07-4065
   Maki Robert G., 2013, Sarcoma, V2013, P168145, DOI 10.1155/2013/168145
   Noguchi Go, 2012, Nihon Hinyokika Gakkai Zasshi, V103, P697
   Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239
   Peters HL, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.26293
   Peters HL, 2013, CANCER BIOL THER, V14, P752, DOI 10.4161/cbt.25183
   Pollack SM, 2012, CANCER-AM CANCER SOC, V118, P4564, DOI 10.1002/cncr.27446
   Pollack SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032165
   Ratnavelu K, 2013, ONCOL LETT, V5, P1457, DOI 10.3892/ol.2013.1247
   Robbins PF, 2011, J CLIN ONCOL, V29, P917, DOI 10.1200/JCO.2010.32.2537
   Rosenberg SA, 2004, NAT MED, V10, P909, DOI 10.1038/nm1100
   Sangiolo D, 2014, CANCER RES, V74, P119, DOI 10.1158/0008-5472.CAN-13-1559
   Simon-Keller K, 2013, AM J PATHOL, V182, P2121, DOI 10.1016/j.ajpath.2013.02.017
   Takahashi R, 2013, CANCER SCI, V104, P1285, DOI 10.1111/cas.12226
   Weber JS, 2011, J IMMUNOTHER, V34, P556, DOI 10.1097/CJI.0b013e3182280db1
   Yu FB, 2013, TUMOR BIOL, V34, P3371, DOI 10.1007/s13277-013-0908-7
   Zhang H, 2013, BLOOD, V122, P1105, DOI 10.1182/blood-2012-08-449413
   Zhu S, 2013, PHARM RES
NR 27
TC 11
Z9 12
U1 0
U2 4
PU DISCOVERY MEDICINE
PI TIMONIUM
PA 10 GERARD AVE, STE 201, TIMONIUM, MD 21093 USA
SN 1539-6509
EI 1944-7930
J9 DISCOV MED
JI Discov. Med.
PD APR
PY 2014
VL 17
IS 94
BP 201
EP 206
PG 6
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA AG5ZO
UT WOS:000335498100004
PM 24759624
DA 2021-10-30
ER

PT J
AU Watts, JM
   Dumitriu, B
   Hilden, P
   Kishtagari, A
   Rapaport, F
   Chen, C
   Ahn, J
   Devlin, SM
   Stein, EM
   Rampal, R
   Levine, RL
   Young, N
   Tallman, MS
AF Watts, Justin M.
   Dumitriu, Bogdan
   Hilden, Patrick
   Kishtagari, Ashwin
   Rapaport, Franck
   Chen, Christina
   Ahn, Jihae
   Devlin, Sean M.
   Stein, Eytan M.
   Rampal, Raajit
   Levine, Ross L.
   Young, Neal
   Tallman, Martin S.
TI Telomere length and associations with somatic mutations and clinical
   outcomes in acute myeloid leukemia
SO LEUKEMIA RESEARCH
LA English
DT Article
DE Acute myeloid leukemia; Telomere length; Clinical outcomes; Somatic
   mutations
ID STEM-CELLS; ABNORMALITIES; CANCER
AB We examined the genetic implications and clinical impact of telomere length (TL) in 67 patients with acute myeloid leukemia (AML). There was a trend toward improved survival at 6 months in patients with longer TL. We found that patients with activating mutations, such as FLT3-ITD, had shorter TL, while those with mutations in epigenetic modifying enzymes, particularly IDH1 and IDH2, had longer TL. These are intriguing findings that warrant further investigation in larger cohorts. Our data show the potential of TL as a predictive biomarker in AML and identify genetic subsets that may be particularly vulnerable to telomere-targeted therapies. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Watts, Justin M.] Univ Miami, Sylvester Comprehens Canc Ctr, Miller Sch Med, Div Hematol Oncol,Dept Med, Miami, FL USA.
   [Watts, Justin M.; Kishtagari, Ashwin; Rapaport, Franck; Ahn, Jihae; Stein, Eytan M.; Rampal, Raajit; Levine, Ross L.; Tallman, Martin S.] Weill Cornell Med Coll, Mem Sloan Kettering Canc Ctr, Leukemia Serv, Dept Med,Human Oncol & Pathogenesis Program, New York, NY USA.
   [Dumitriu, Bogdan; Young, Neal] NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA.
   [Hilden, Patrick; Devlin, Sean M.] Weill Cornell Med Coll, Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY USA.
   [Kishtagari, Ashwin] Mt Sinai St Lukes Roosevelt Hosp, Dept Med, New York, NY USA.
RP Watts, JM (corresponding author), Clin Res Bldg,1120NW 14th St,Suite 610C, Miami, FL 33145 USA.
EM jwatts@med.miami.edu
RI Kishtagari, Ashwin/AAU-9417-2020; levine, ross/AAE-7658-2019
OI Rapaport, Franck/0000-0001-6553-2110
FU American Society of Clinical Oncology (ASCO) Young Investigator Award
   (YIA); Memorial Sloan Kettering Cancer Center; National Heart, Lung, and
   Blood InstituteUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI); NATIONAL CANCER INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI) [K08CA188529, P30CA008748]
   Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [KL2TR000461] Funding Source:
   NIH RePORTER
FX This research was supported by an American Society of Clinical Oncology
   (ASCO) Young Investigator Award (YIA) (recipient: Justin Watts, mentor:
   Martin Tallman). This work was also supported by and completed at
   Memorial Sloan Kettering Cancer Center and the National Heart, Lung, and
   Blood Institute in equal collaboration.
CR Byrd JC, 2002, BLOOD, V100, P4325, DOI 10.1182/blood-2002-03-0772
   Calado RT, 2009, NEW ENGL J MED, V361, P2353, DOI 10.1056/NEJMra0903373
   Calado RT, 2009, P NATL ACAD SCI USA, V106, P1187, DOI 10.1073/pnas.0807057106
   Cull E. H., 2014, LEUK LYMPHOMA, V55
   Ghaffari S. H., ANN ONCOL, V19
   Hartmann U, 2005, HAEMATOLOGICA, V90, P307
   Lansdorp PM, 2008, BLOOD, V111, P1759, DOI 10.1182/blood-2007-09-084913
   Mrozek K, 2004, BLOOD REV, V18, P115, DOI 10.1016/S0268-960X(03)00040-7
   Okamoto K, 2013, NATURE, V494, P502, DOI 10.1038/nature11873
   Patel JP, 2012, N ENGL J MED, V366
   Scheinberg P., 2010, JAMA, V304
   Schlenk RF, 2008, N ENGL J MED, V358
   Sharpless NE, 2004, J CLIN INVEST, V113, P160, DOI 10.1172/JCI200420761
   Sieglova Z, 2004, LEUKEMIA RES, V28, P1013, DOI 10.1016/j.leukres.2003.11.020
   Swiggers SJJ, 2006, GENE CHROMOSOME CANC, V45, P247, DOI 10.1002/gcc.20286
   Townsley DM, 2014, BLOOD, V124, P2775, DOI 10.1182/blood-2014-05-526285
NR 16
TC 9
Z9 10
U1 1
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0145-2126
EI 1873-5835
J9 LEUKEMIA RES
JI Leuk. Res.
PD OCT
PY 2016
VL 49
BP 62
EP 65
DI 10.1016/j.leukres.2016.07.013
PG 4
WC Oncology; Hematology
SC Oncology; Hematology
GA EC7JQ
UT WOS:000388314100010
PM 27568819
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Rice, TW
   Ishwaran, H
   Ferguson, MK
   Blackstone, EH
   Goldstraw, P
AF Rice, Thomas W.
   Ishwaran, Hemant
   Ferguson, Mark K.
   Blackstone, Eugene H.
   Goldstraw, Peter
TI Cancer of the Esophagus and Esophagogastric Junction: An Eighth Edition
   Staging Primer
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Article
DE Esophageal cancer; Esophagogastric cancer; Staging; AJCC/UICC eighth
   edition staging
ID RECOMMENDATIONS; MANUALS
AB This primer for eighth edition staging of esophageal and esophagogastric epithelial cancers presents separate classifications for the clinical (cTNM), pathologic (pTNM), and postneoadjuvant pathologic (ypTNM) stage groups, which are no longer shared. For pTNM, pT1 has been sub-categorized as pT1a and pT1b for the subgrouping pStage I adenocarcinoma and squamous cell carcinoma. A new, simplified esophagus-specific regional lymph node map has been introduced. Undifferentiated histologic grade (G4) has been eliminated; additional analysis is required to expose histopathologic cell type. Location has been removed as a category for pT2N0M0 squamous cell cancer. The definition of the esophagogastric junction has been revised. ypTNM stage groups are identical for both histopathologic cell types, unlike those for cTNM and pTNM. (C) 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
C1 [Rice, Thomas W.; Blackstone, Eugene H.] Cleveland Clin, Cleveland, OH 44106 USA.
   [Ishwaran, Hemant] Univ Miami, Miami, FL USA.
   [Ferguson, Mark K.] Univ Chicago, Chicago, IL 60637 USA.
   [Goldstraw, Peter] Imperial Coll, Natl Heart & Lung Inst, London, England.
RP Rice, TW (corresponding author), Cleveland Clin, Dept Thorac & Cardiovasc Surg, 9500 Euclid Ave,Desk JJ-40, Cleveland, OH 44195 USA.
EM ricet@ccf.org
FU Daniel and Karen Lee Chair in Thoracic Surgery at Cleveland Clinic;
   Kenneth Gee and Paula Shaw, PhD, Chair in Heart Research at Cleveland
   Clinic; NATIONAL CANCER INSTITUTEUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Cancer Institute (NCI) [R01CA163739] Funding Source: NIH RePORTER;
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000460] Funding Source: NIH RePORTER
FX This work was funded in part by the Daniel and Karen Lee Chair in
   Thoracic Surgery at Cleveland Clinic, which is held by Dr. Rice, and by
   the Kenneth Gee and Paula Shaw, PhD, Chair in Heart Research at
   Cleveland Clinic, which is held by Dr. Blackstone. These funders played
   no role in the collection of data or analysis and interpretation of the
   data, and they had no right to approve or disapprove publication of the
   finished manuscript. All the authors are responsible for conception or
   design of the experiment(s), or collection and analysis or
   interpretation of data. Drs. Rice, Ishwaran, and Blackstone are
   responsible for drafting the manuscript or revising its intellectual
   content. All authors approved the final version of the submitted
   manuscript.
CR Brierley JD, 2017, TNM CLASSIFICATION M, V8, P57
   Edge SB, 2010, AM JOINT COMMITTEE C
   Hayakawa Y, 2016, NAT REV CANCER, V16, P305, DOI 10.1038/nrc.2016.24
   Rice TW, 2016, DIS ESOPHAGUS, V29, P897, DOI 10.1111/dote.12533
   Rice TW, 2016, DIS ESOPHAGUS, V29, P715, DOI 10.1111/dote.12513
   Rice TW, 2016, DIS ESOPHAGUS, V29, P724, DOI 10.1111/dote.12520
   Rice T W, 2016, Dis Esophagus, V29, P707, DOI 10.1111/dote.12493
   Rice TW, 2016, DIS ESOPHAGUS, V29, P913, DOI 10.1111/dote.12540
   Rice TW, 2016, DIS ESOPHAGUS, V29, P906, DOI 10.1111/dote.12538
   Rice TW, 2017, AJCC CANC STAGING MA, V8th, P185, DOI DOI 10.1007/978-3-319-40618-3_16
   Sobin LH., 2009, INT UNION CANC TNM C
NR 11
TC 206
Z9 234
U1 8
U2 38
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1556-0864
EI 1556-1380
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD JAN
PY 2017
VL 12
IS 1
BP 36
EP 42
DI 10.1016/j.jtho.2016.10.016
PG 7
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA EH1IP
UT WOS:000391518500005
PM 27810391
OA Green Accepted, Bronze
HC Y
HP N
DA 2021-10-30
ER

PT J
AU Kenya, S
   Okoro, I
   Wallace, K
   Carrasquillo, O
   Prado, G
AF Kenya, Sonjia
   Okoro, Ikenna
   Wallace, Kiera
   Carrasquillo, Olveen
   Prado, Guillermo
TI Strategies to Improve HIV Testing in African Americans
SO JANAC-JOURNAL OF THE ASSOCIATION OF NURSES IN AIDS CARE
LA English
DT Article
DE African Americans; community health workers (CHW); focus groups; HIV;
   HIV rapid testing
ID RISK
AB Only 17% of Miami-Dade County residents are African American, yet this population accounts for 59% of the county's HIV-related mortality. The Centers for Disease Control and Prevention recommend annual testing for persons at increased risk for HIV, but 40% of African Americans have never been tested. OraQuick (R) (OraSure Technologies, Inc., Bethlehem, PA), the first US Food and Drug Administration-approved home-based HIV rapid test (HBHRT), has the potential to increase testing rates; however, there are concerns about HBHRT in vulnerable populations. We conducted focus groups in an underserved Miami neighborhood to obtain community input regarding HBHRT as a potential mechanism to increase HIV testing in African Americans. We queried HIV knowledge, attitudes toward research, and preferred intervention methods. Several HIV misconceptions were identified, and participants expressed support for HIV research and introducing HBHRT into the community by culturally appropriate individuals trained to provide support. We concluded that community health workers paired with HBHRT were a promising strategy to increase HIV testing in this population. Copyright (C) 2015 Association of Nurses in AIDS Care
C1 [Kenya, Sonjia; Okoro, Ikenna; Wallace, Kiera] Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
   [Carrasquillo, Olveen] Univ Miami, Miller Sch Med, Div Gen Internal Med, Miami, FL 33136 USA.
   [Prado, Guillermo] Univ Miami, Sch Nursing & Hlth Studies, Miami, FL USA.
RP Kenya, S (corresponding author), Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
FU Miami Clinical and Translational Science Institute, from the National
   Center for Advancing Translational Sciences [1UL1TR000460]; National
   Institute on Minority Health and Health DisparitiesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Minority Health & Health Disparities
   (NIMHD); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Advancing Translational
   Sciences (NCATS) [UL1TR000460] Funding Source: NIH RePORTER
FX The project described was supported by Grant Number 1UL1TR000460, Miami
   Clinical and Translational Science Institute, from the National Center
   for Advancing Translational Sciences and the National Institute on
   Minority Health and Health Disparities. Its contents are solely the
   responsibility of the authors and do not necessarily represent the
   official views of the National Institutes of Health. We would like to
   thank Saliha Nelson and Candice Anderson from Urgent, Inc. for allowing
   our team to conduct research in their space. We are most grateful to Rai
   Johnson from Lotus House Shelter and Emanuel Washington, Sr., from the
   Overtown Optimists for facilitating participation in focus groups.
CR Baiden F, 2007, J BIOSOC SCI, V39, P721, DOI 10.1017/S0021932006001829
   Bateganya M, 2010, COCHRANE DATABASE SY
   Bhutta AZ, 2010, GLOBAL EXPERIENCE CO
   Centers for Disease Control and Prevention, 2013, HIV SURV REP 2011
   Centers for Disease Control and Prevention, 2010, VIT SIGNS HIV TEST D
   City-Data. com, 2011, DEM OV
   Del Rio C, 2012, CASCADE HIV CARE US
   Dunn KM, 2004, AM J EPIDEMIOL, V159, P1087, DOI 10.1093/aje/kwh141
   Havlir D, 2012, NEW ENGL J MED, V367, P685, DOI 10.1056/NEJMp1207138
   Hayden JA, 2013, INTRO HLTH BEHAV THE
   Helleringer S, 2009, JAIDS-J ACQ IMM DEF, V51, P185, DOI 10.1097/QAI.0b013e31819c1726
   Israel B A, 2001, Educ Health (Abingdon), V14, P182
   Metsch LR, 2012, AM J PUBLIC HEALTH, V102, P1160, DOI 10.2105/AJPH.2011.300460
   Miami-Dade County Health Department, 2013, HIV BLACKS AFR AM
   Miami-Dade County Health Department, 2012, FLOR DEP HLTH MIAM D
   Murphy SL, 2013, NATL VITAL STAT REPO, P61
   Nelson AK, 2012, AM J TROP MED HYG, V87, P399, DOI 10.4269/ajtmh.2012.12-0036
   Pai NP, 2007, EXPERT REV MOL DIAGN, V7, P325, DOI 10.1586/14737159.7.4.325
   Pai NP, 2008, FUTURE HIV THERAPY, V2, P515, DOI DOI 10.2217/17469600.2.6.515
   Paltiel AD, 2012, ANN INTERN MED, V157, P744, DOI 10.7326/0003-4819-157-10-201211200-00545
   Realprogroup. com, 2011, MIAM DAD COUNT ZIP C
   Rubin MS, 2010, AM J PUBLIC HEALTH, V100, P1053, DOI 10.2105/AJPH.2009.170241
   Sena AC, 2010, AIDS PATIENT CARE ST, V24, P165, DOI 10.1089/apc.2009.0135
   Sullivan PS, 2004, JAIDS-J ACQ IMM DEF, V35, P511, DOI 10.1097/00126334-200404150-00009
   U.S. Department of Health and Human Services, 2010, NAT HIV AIDS STRAT
NR 25
TC 4
Z9 4
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1055-3290
EI 1552-6917
J9 J ASSOC NURSE AIDS C
JI J. Assoc. Nurses Aids Care
PD JUL-AUG
PY 2015
VL 26
IS 4
BP 357
EP 367
DI 10.1016/j.jana.2015.04.001
PG 11
WC Nursing
SC Nursing
GA CO2QI
UT WOS:000359001300008
PM 26066691
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Baidal, DA
   Ricordi, C
   Berman, DM
   Alvarez, A
   Padilla, N
   Ciancio, G
   Linetsky, E
   Pileggi, A
   Alejandro, R
AF Baidal, David A.
   Ricordi, Camillo
   Berman, Dora M.
   Alvarez, Ana
   Padilla, Nathalia
   Ciancio, Gaetano
   Linetsky, Elina
   Pileggi, Antonello
   Alejandro, Rodolfo
TI Bioengineering of an Intraabdominal Endocrine Pancreas
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Letter
ID ISLET TRANSPLANTATION; SCAFFOLD
C1 [Baidal, David A.; Ricordi, Camillo; Berman, Dora M.; Alvarez, Ana; Padilla, Nathalia; Ciancio, Gaetano; Linetsky, Elina; Pileggi, Antonello; Alejandro, Rodolfo] Univ Miami, Leonard M Miller Sch Med, Miami, FL 33136 USA.
RP Baidal, DA (corresponding author), Univ Miami, Leonard M Miller Sch Med, Miami, FL 33136 USA.
EM dbaidal@med.miami.edu
RI Pileggi, Antonello/A-2394-2008; RICORDI, CAMILLO/AAA-4740-2019; Padilla,
   Nathalia/AAQ-9596-2020
OI Pileggi, Antonello/0000-0001-7819-2813; Padilla,
   Nathalia/0000-0002-7177-1107; Berman-Weinberg, Dora/0000-0001-7817-9387
FU Juvenile Diabetes Research FoundationJuvenile Diabetes Research
   Foundation; Helmsley Charitable Trust; Diabetes Research Institute
   Foundation; National Center for Advancing Translational SciencesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Advancing Translational
   Sciences (NCATS) [1UL1TR000460]; National Institute on Minority Health
   and Health DisparitiesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Minority Health & Health Disparities (NIMHD); NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000460]
   Funding Source: NIH RePORTER
FX Supported by the Juvenile Diabetes Research Foundation and the Helmsley
   Charitable Trust, the Diabetes Research Institute Foundation, and a
   grant (1UL1TR000460, to the University of Miami Clinical and
   Translational Science Institute) from the National Center for Advancing
   Translational Sciences and the National Institute on Minority Health and
   Health Disparities.
CR Berman DM, 2009, AM J TRANSPLANT, V9, P91, DOI 10.1111/j.1600-6143.2008.02489.x
   Berman DM, 2016, DIABETES, V65, P1350, DOI 10.2337/db15-1525
   Cantarelli E, 2011, CURR DIABETES REP, V11, P364, DOI 10.1007/s11892-011-0216-9
   Forbes S, 2016, AM J TRANSPLANT, V16, P2704, DOI 10.1111/ajt.13807
   Hering BJ, 2016, DIABETES CARE, V39, P1230, DOI 10.2337/dc15-1988
NR 5
TC 61
Z9 65
U1 0
U2 19
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 11
PY 2017
VL 376
IS 19
BP 1887
EP 1889
DI 10.1056/NEJMc1613959
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA EU2WR
UT WOS:000400891100018
PM 28489987
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Patel, N
   Deshmukh, A
   Thakkar, B
   Coffey, JO
   Agnihotri, K
   Patel, A
   Ainani, N
   Nalluri, N
   Patel, N
   Patel, N
   Patel, N
   Badheka, AO
   Kowalski, M
   Hendel, R
   Viles-Gonzalez, J
   Noseworthy, PA
   Asirvatham, S
   Lo, KM
   Myerburg, RJ
   Mitrani, RD
AF Patel, Nileshkumar
   Deshmukh, Abhishek
   Thakkar, Badal
   Coffey, James O.
   Agnihotri, Kanishk
   Patel, Achint
   Ainani, Nitesh
   Nalluri, Nikhil
   Patel, Nilay
   Patel, Nish
   Patel, Neil
   Badheka, Apurva O.
   Kowalski, Marcin
   Hendel, Robert
   Viles-Gonzalez, Juan
   Noseworthy, Peter A.
   Asirvatham, Samuel
   Lo, Kaming
   Myerburg, Robert J.
   Mitrani, Raul D.
TI Gender, Race, and Health Insurance Status in Patients Undergoing
   Catheter Ablation for Atrial Fibrillation
SO AMERICAN JOURNAL OF CARDIOLOGY
LA English
DT Article
ID UNITED-STATES; RADIOFREQUENCY ABLATION; ANTIARRHYTHMIC-DRUGS;
   PREVENTION; CARE; SEX; DISPARITIES; TRENDS; RISK; PROGRESS
AB Catheter ablation for atrial fibrillation (AF) has emerged as a popular procedure. The purpose of this study was to examine whether there exist differences or disparities in ablation utilization across gender, socioeconomic class, insurance, or race. Using the Nationwide Inpatient Sample (2000 to 2012), we identified adults hospitalized with a principal diagnosis of AF by ICD 9 code 427.31 who had catheter ablation (ICD 9 code-37.34). We stratified patients by race, insurance status, age, gender, and hospital characteristics. A hierarchical multivariate mixed-effect model was created to identify the independent predictors of AF ablation. Among an estimated total of 3,508,122 patients (extrapolated from 20% Nationwide Inpatient Sample) hospitalized with a diagnosis of AF in the United States from the year 2000 to 2012, 102,469 patients (2.9%) underwent catheter ablations. The number of ablations was increased by 940%, from 1,439 in 2000 to 15,090 in 2012. There were significant differences according to gender, race, and health insurance status, which persisted even after adjustment for other risk factors. Female gender (0.83 [95% CI 0.79 to 0.87; p <0.001]), black (0.49 [95% CI 0.44 to 0.55; p <0.001]), and Hispanic race (0.64 [95% CI 0.56 to 0.72; p <0.001]) were associated with lower likelihoods of undergoing an AF ablation. Medicare (0.93, 0.88 to 0.98, <0.001) or Medicaid (0.67, 0.59 to 0.76, <0.001) coverage and uninsured patients (0.55, 0.49 to 0.62, <0.001) also had lower rates of AF ablation compared to patients with private insurance. In conclusion we found differences in utilization of catheter ablation for AF based on gender, race, and insurance status that persisted over time. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Patel, Nileshkumar; Coffey, James O.; Patel, Nish; Hendel, Robert; Viles-Gonzalez, Juan; Lo, Kaming; Myerburg, Robert J.; Mitrani, Raul D.] Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
   [Deshmukh, Abhishek; Noseworthy, Peter A.; Asirvatham, Samuel] Mayo Clin, Rochester, MN USA.
   [Thakkar, Badal] Tulane Sch Publ Hlth & Trop Med, New Orleans, LA USA.
   [Agnihotri, Kanishk; Patel, Nilay] St Peters Univ Hosp, New Brunswick, NJ USA.
   [Patel, Achint; Patel, Neil] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
   [Ainani, Nitesh] Tufts Univ, Sch Med, Baystate Med Ctr, Springfield, MA 01199 USA.
   [Nalluri, Nikhil; Kowalski, Marcin] Staten Isl Univ Hosp, Staten Isl, NY USA.
   [Badheka, Apurva O.] Yale Univ, Sch Med, New Haven, CT USA.
RP Mitrani, RD (corresponding author), Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
EM rmitrani@miami.edu
RI Patel, Achint/AAM-5379-2020
OI Patel, Achint/0000-0003-4270-0825
FU Miami Clinical and Translational Sciences Institute from National Center
   for Advancing Translational Science, Miami, Florida [1UL1TR000460];
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000460] Funding Source: NIH RePORTER
FX This work was conducted with support from the Miami Clinical and
   Translational Sciences Institute (grant # 1UL1TR000460 from National
   Center for Advancing Translational Science, Miami, Florida). The content
   is solely the responsibility of the authors and does not necessarily
   represent the official views of the Miami CTSI, The University of Miami,
   and its affiliated academic health care centers, or the National
   Institutes of Health.
CR Armitage P, 1955, BIOMETRICS, V11, P11
   Badheka AO, 2014, AM J MED, V127, P744, DOI 10.1016/j.amjmed.2014.02.025
   Bhave PD, 2015, HEART RHYTHM, V12, P1406, DOI 10.1016/j.hrthm.2015.03.031
   Calkins H, 2009, CIRC-ARRHYTHMIA ELEC, V2, P349, DOI 10.1161/CIRCEP.108.824789
   Curtis LH, 2007, JAMA-J AM MED ASSOC, V298, P1517, DOI 10.1001/jama.298.13.1517
   Deshmukh A, 2013, CIRCULATION, V128, P2104, DOI 10.1161/CIRCULATIONAHA.113.003862
   DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8
   Epstein AJ, 2011, JAMA-J AM MED ASSOC, V305, P1769, DOI 10.1001/jama.2011.551
   Gerstenfeld EP, 2007, J CARDIOVASC ELECTR, V18, P23, DOI 10.1111/j.1540-8167.2006.00662.x
   Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370
   Hoyt H, 2011, J CARDIOVASC ELECTR, V22, P994, DOI 10.1111/j.1540-8167.2011.02043.x
   Huikuri HV, 2013, PROG CARDIOVASC DIS, V56, P153, DOI 10.1016/j.pcad.2013.07.003
   January CT, 2014, CIRCULATION, V130, pE270, DOI [10.1161/CIR.0000000000000142, 10.1016/j.jacc.2014.03.022, 10.1161/CIR.0000000000000041]
   Lampert R, 2015, HEART RHYTHM, V12, P1413, DOI 10.1016/j.hrthm.2015.04.010
   Morillo CA, 2014, JAMA-J AM MED ASSOC, V311, P692, DOI 10.1001/jama.2014.467
   Moy E, 2005, HEALTH AFFAIR, V24, P376, DOI 10.1377/hlthaff.24.2.376
   Naderi S, 2014, ETHNIC DIS, V24, P144
   Nielsen JC, 2012, NEW ENGL J MED, V367, P1587, DOI 10.1056/NEJMoa1113566
   Patel NJ, 2014, CIRCULATION, V129, P2371, DOI 10.1161/CIRCULATIONAHA.114.008201
   Piccini JP, 2012, CIRCULATION, V126, P2200, DOI 10.1161/CIRCULATIONAHA.112.109330
   Rathore SS, 2004, ANN INTERN MED, V141, P635, DOI 10.7326/0003-4819-141-8-200410190-00011
   Reynolds MR, 2006, AM HEART J, V152, P1097, DOI 10.1016/j.ahj.2006.08.011
   Santangeli P, 2010, HEART RHYTHM, V7, P876, DOI 10.1016/j.hrthm.2010.03.042
   Shah RU, 2012, J AM COLL CARDIOL, V59, P143, DOI 10.1016/j.jacc.2011.08.068
   Smedley BD, 2003, UNEQUAL TREATMENT CO
   Van Wagoner DR, 2015, HEART RHYTHM, V12, pE5, DOI 10.1016/j.hrthm.2014.11.011
   Volgman AS, 2009, GENDER MED, V6, P419, DOI 10.1016/j.genm.2009.09.008
   Wilber DJ, 2010, JAMA-J AM MED ASSOC, V303, P333, DOI 10.1001/jama.2009.2029
NR 28
TC 37
Z9 37
U1 0
U2 1
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9149
EI 1879-1913
J9 AM J CARDIOL
JI Am. J. Cardiol.
PD APR 1
PY 2016
VL 117
IS 7
BP 1117
EP 1126
DI 10.1016/j.amjcard.2016.01.040
PG 10
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DI5FH
UT WOS:000373523800015
PM 26899494
DA 2021-10-30
ER

PT J
AU Lemos, JRN
   Baidal, DA
   Ricordi, C
   Fuenmayor, V
   Alvarez, A
   Alejandro, R
AF Lemos, Joana R. N.
   Baidal, David A.
   Ricordi, Camillo
   Fuenmayor, Virginia
   Alvarez, Ana
   Alejandro, Rodolfo
TI Survival After Islet Transplantation in Subjects With Type 1 Diabetes:
   Twenty-Year Follow-Up
SO DIABETES CARE
LA English
DT Editorial Material
ID COMPLICATIONS
C1 [Lemos, Joana R. N.; Baidal, David A.; Ricordi, Camillo; Fuenmayor, Virginia; Alvarez, Ana; Alejandro, Rodolfo] Univ Miami, Miller Sch Med, Diabet Res Inst, Miami, FL 33136 USA.
   [Lemos, Joana R. N.; Baidal, David A.; Ricordi, Camillo; Fuenmayor, Virginia; Alvarez, Ana; Alejandro, Rodolfo] Univ Miami, Miller Sch Med, Clin Cell Transplant Program, Miami, FL 33136 USA.
   [Baidal, David A.; Alejandro, Rodolfo] Univ Miami, Miller Sch Med, Dept Med, Div Endocrinol Diabet & Metab, Miami, FL 33136 USA.
   [Ricordi, Camillo] Univ Miami, Miller Sch Med, Dept Surg, Div Cellular Transplantat, Miami, FL 33136 USA.
RP Alejandro, R (corresponding author), Univ Miami, Miller Sch Med, Diabet Res Inst, Miami, FL 33136 USA.; Alejandro, R (corresponding author), Univ Miami, Miller Sch Med, Clin Cell Transplant Program, Miami, FL 33136 USA.; Alejandro, R (corresponding author), Univ Miami, Miller Sch Med, Dept Med, Div Endocrinol Diabet & Metab, Miami, FL 33136 USA.
EM ralejand@med.miami.edu
FU National Institutes of Health National Institute of Diabetes and
   Digestive and Kidney DiseasesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01 DK55347, R01
   DK056953, R01 DK025802, DK070460]; Miami Clinical and Translational
   Science Institute from the National Center for Advancing Translational
   Sciences [UL1TR000460]; National Institute on Minority Health and Health
   Disparities, JDRF International [4-200-946, 4-2004-361, 17-2012-361,
   3-SRA-2017-347-M-B]; State of Florida; Diabetes Research Institute
   Foundation
FX This work was supported by grants from the National Institutes of Health
   National Institute of Diabetes and Digestive and Kidney Diseases (R01
   DK55347, R01 DK056953, R01 DK025802, DK070460), the Miami Clinical and
   Translational Science Institute from the National Center for Advancing
   Translational Sciences (UL1TR000460) and the National Institute on
   Minority Health and Health Disparities, JDRF International (4-200-946,
   4-2004-361, 17-2012-361, 3-SRA-2017-347-M-B), the State of Florida, and
   the Diabetes Research Institute Foundation.
CR Feltbower RG, 2008, DIABETES CARE, V31, P922, DOI 10.2337/dc07-2029
   Hering BJ, 2016, DIABETES CARE, V39, P1230, DOI 10.2337/dc15-1988
   Miller RG, 2012, DIABETES, V61, P2987, DOI 10.2337/db11-1625
   Orchard TJ, 2015, JAMA-J AM MED ASSOC, V313, P45, DOI 10.1001/jama.2014.16107
   Senior P, 2020, CURR DIABETES REP, V20, DOI 10.1007/s11892-020-01339-3
NR 5
TC 4
Z9 4
U1 2
U2 3
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
EI 1935-5548
J9 DIABETES CARE
JI Diabetes Care
PD APR
PY 2021
VL 44
IS 4
BP E67
EP E68
DI 10.2337/dc20-2458
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA QZ5GR
UT WOS:000630755000003
PM 33579716
OA Bronze
DA 2021-10-30
ER

PT J
AU Swords, R
   Sznol, J
   Elias, R
   Watts, J
   Zelent, A
   Martin, E
   Vargas, F
   Bethel-Ellison, S
   Kobetz, E
AF Swords, R.
   Sznol, J.
   Elias, R.
   Watts, J.
   Zelent, A.
   Martin, E.
   Vargas, F.
   Bethel-Ellison, S.
   Kobetz, E.
TI Acute leukemia in adult Hispanic Americans: a large-population study
SO BLOOD CANCER JOURNAL
LA English
DT Letter
ID ACUTE PROMYELOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA;
   UNITED-STATES; CLASSIFICATION; CHILDREN; WORLD
C1 [Swords, R.; Elias, R.; Watts, J.; Zelent, A.; Vargas, F.] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Leukemia Program, Miami, FL 33136 USA.
   [Sznol, J.; Kobetz, E.] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Jay Weiss Inst Publ Hlth Sci, Miami, FL 33136 USA.
   [Martin, E.] Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, Ctr Genet Epidemiol & Stat Genet, Miami, FL 33136 USA.
   [Bethel-Ellison, S.] Univ Miami, JFK Med Ctr Palm Beach Reg GME Consortium, Internal Med Residency Program, Miami, FL USA.
RP Swords, R (corresponding author), Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Leukemia Program, Miami, FL 33136 USA.
EM rswords@med.miami.edu
OI Zelent, Arthur/0000-0002-7968-9888; Elias, Roy/0000-0002-8555-4322
FU [NIH 1KL2TR000461]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [KL2TR000461] Funding Source: NIH
   RePORTER
FX RS received support from grant NIH 1KL2TR000461.
CR Bacher U, 2005, ANN HEMATOL, V84, P785, DOI 10.1007/s00277-005-1099-0
   CRANE MM, 1989, JAMA-J AM MED ASSOC, V262, P634, DOI 10.1001/jama.262.5.634
   Delsol G, 2008, ANN PATHOL, V28, pS20, DOI 10.1016/j.annpat.2008.09.002
   Dores GM, 2012, BLOOD, V119, P34, DOI 10.1182/blood-2011-04-347872
   Douer D, 2003, BRIT J HAEMATOL, V122, P563, DOI 10.1046/j.1365-2141.2003.04480.x
   Kamangar F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308
   Macartney S. E., 2013, POVERTY RATES SELECT
   Matasar MJ, 2006, EUR J CANCER PREV, V15, P367, DOI 10.1097/00008469-200608000-00011
   Pang JWY, 2002, CANCER CAUSE CONTROL, V13, P791, DOI 10.1023/A:1020608328969
   PENDERGRASS TW, 1985, SEMIN ONCOL, V12, P80
   Pollyea D. A., 2014, J CANC PREV CURR RES, P1, DOI DOI 10.15406/JCPER.2014.01.00005
   Swinney RM, 2011, CANCER EPIDEM BIOMAR, V20, P1537, DOI 10.1158/1055-9965.EPI-10-1265
   Vardiman JW, 2009, BLOOD, V114, P937, DOI 10.1182/blood-2009-03-209262
   Walsh KM, 2013, BLOOD, V122, P3385, DOI 10.1182/blood-2013-08-524124
NR 14
TC 6
Z9 6
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2044-5385
J9 BLOOD CANCER J
JI Blood Cancer J.
PD OCT
PY 2016
VL 6
AR e484
DI 10.1038/bcj.2016.94
PG 3
WC Oncology; Hematology
SC Oncology; Hematology
GA EH5HR
UT WOS:000391803900006
PM 27740629
OA Green Published, gold
DA 2021-10-30
ER

PT J
AU Stoutenberg, M
   Falcon, A
   Arheart, K
   Stasi, S
   Portacio, F
   Stepanenko, B
   Lan, ML
   Castruccio-Prince, C
   Nackenson, J
AF Stoutenberg, Mark
   Falcon, Ashley
   Arheart, Kris
   Stasi, Selina
   Portacio, Francia
   Stepanenko, Bryan
   Lan, Mary L.
   Castruccio-Prince, Catarina
   Nackenson, Joshua
TI Implementation of Lifestyle Modification Program Focusing on Physical
   Activity and Dietary Habits in a Large Group, Community-Based Setting
SO HEALTH EDUCATION & BEHAVIOR
LA English
DT Article
DE community; healthy eating; implementation; lifestyle modification;
   physical activity
ID ACTIVITY BEHAVIOR; CARDIOVASCULAR-DISEASE; VEGETABLE CONSUMPTION;
   ADULTS; INTERVENTION; METAANALYSIS; PREVENTION; MEDIATORS; FRUIT; RISK
AB Background. Lifestyle modification programs improve several health-related behaviors, including physical activity (PA) and nutrition. However, few of these programs have been expanded to impact a large number of individuals in one setting at one time. Therefore, the purpose of this study was to determine whether a PA-and nutrition-based lifestyle modification program could be effectively conducted using a large group format in a community-based setting. Method. One hundred twenty-one participants enrolled in a 16-week, community-based lifestyle modification program and separated in small teams of 13 to 17 individuals. Height, weight, fruit and vegetable (FAV) consumption, physical fitness, and several psychosocial measures were assessed before and after the program. Results. Significant improvements in 6-minute walk distance (+68.3 m; p < .001), chair stands (+6.7 repetitions; p < .001), FAV servings (+1.8 servings/day; p < .001), body weight (-3.2 lbs; p < .001), as well as PA social support and eating habits self-efficacy were observed. Our lifestyle modification program was also successful in shifting participants to higher levels of stages of change for nutrition and PA, increasing overall levels of self-efficacy for healthy eating, and improving levels of social support for becoming more active. Conclusions. A lifestyle modification program can be successfully implemented in a community setting using a large group format to improve PA and FAV attitudes and behaviors.
C1 [Stoutenberg, Mark; Arheart, Kris; Portacio, Francia; Stepanenko, Bryan; Lan, Mary L.; Castruccio-Prince, Catarina; Nackenson, Joshua] Univ Miami, Miami, FL USA.
   [Falcon, Ashley] Univ Miami, Coral Gables, FL 33124 USA.
   [Stasi, Selina] Texas A&M Univ, College Stn, TX USA.
RP Stoutenberg, M (corresponding author), Univ Miami, Dept Publ Hlth Sci, 1120 NW 14th St,Suite 1008, Miami, FL 33136 USA.
EM mstoutenberg@med.miami.edu
RI Stasi, Selina/S-7124-2019
FU Health Foundation of South Florida [202488]; Miami Clinical and
   Translational Science Institute from the National Center for Advancing
   Translational Sciences [1KL2TR000461]; National Institute on Minority
   Health and Health DisparitiesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Minority Health & Health Disparities (NIMHD); NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [KL2TR000461]
   Funding Source: NIH RePORTER
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: This study was
   supported by Grant Number 202488 from the Health Foundation of South
   Florida. Dr. Stoutenberg is supported by Grant Number 1KL2TR000461 of
   the Miami Clinical and Translational Science Institute from the National
   Center for Advancing Translational Sciences and the National Institute
   on Minority Health and Health Disparities.
CR Bandura A, 1998, PSYCHOL HEALTH, V13, P623, DOI 10.1080/08870449808407422
   Bauer UE, 2014, LANCET, V384, P45, DOI 10.1016/S0140-6736(14)60648-6
   Carpenter RA, 2004, J NUTR EDUC BEHAV, V36, P20, DOI 10.1016/S1499-4046(06)60124-3
   Centers for Disease Control and Prevention, 2011, STRAT PREV OB OTH CH
   Dauchet L, 2006, J NUTR, V136, P2588, DOI 10.1093/jn/136.10.2588
   Du H, 2009, EUR J CARDIOVASC NUR, V8, P2, DOI 10.1016/j.ejcnurse.2008.07.001
   Dunn AL, 1997, PREV MED, V26, P883, DOI 10.1006/pmed.1997.0218
   Dutton GR, 2014, INT J BEHAV NUTR PHY, V11, DOI 10.1186/s12966-014-0123-y
   Focht BC, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-354
   Garfield SA, 2003, DIABETES CARE, V26, P2670, DOI 10.2337/diacare.26.9.2670
   Grimm K. A., 2010, Morbidity and Mortality Weekly Report, V59, P1125
   Harris CD, 2013, MMWR-MORBID MORTAL W, V62, P326
   Jones CJ, 1999, RES Q EXERCISE SPORT, V70, P113, DOI 10.1080/02701367.1999.10608028
   KENDZIERSKI D, 1991, J SPORT EXERCISE PSY, V13, P50, DOI 10.1123/jsep.13.1.50
   King AC, 2013, ANN BEHAV MED, V46, P157, DOI 10.1007/s12160-013-9501-y
   Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512
   Kramer MK, 2011, DIABETES EDUCATOR, V37, P659, DOI 10.1177/0145721711411930
   Lewis BA, 2002, AM J PREV MED, V23, P26, DOI 10.1016/S0749-3797(02)00471-3
   Lin JS, 2010, ANN INTERN MED, V153, P736, DOI 10.7326/0003-4819-153-11-201012070-00007
   Ling AMC, 2001, J NUTR EDUC, V33, P257
   MARCUS BH, 1992, HEALTH PSYCHOL, V11, P257, DOI 10.1037/0278-6133.11.4.257
   Marshall SJ, 2001, ANN BEHAV MED, V23, P229, DOI 10.1207/S15324796ABM2304_2
   Office of Disease Prevention and Health Promotion, 2008, 2008 PHYS ACT GUID A, VU0036
   Rhodes RE, 2010, INT J BEHAV NUTR PHY, V7, DOI 10.1186/1479-5868-7-37
   SALLIS J F, 1988, Health Education Research, V3, P283, DOI 10.1093/her/3.3.283
   SALLIS JF, 1987, PREV MED, V16, P825, DOI 10.1016/0091-7435(87)90022-3
   Shaikh AR, 2008, AM J PREV MED, V34, P535, DOI 10.1016/j.amepre.2007.12.028
   Tsai AG, 2005, ANN INTERN MED, V142, P56, DOI 10.7326/0003-4819-142-1-200501040-00012
   Ward BW, 2010, PREV CHRONIC DIS, V10, pE65, DOI DOI 10.5888/PCD10.120203
   Wilcox S, 2008, AM J PREV MED, V35, P340, DOI 10.1016/j.amepre.2008.07.001
   Williams SL, 2011, HEALTH EDUC RES, V26, P308, DOI 10.1093/her/cyr005
   Wing RR, 2010, ARCH INTERN MED, V170, P1566, DOI 10.1001/archinternmed.2010.334
   Yoon PW, 2014, MMWR-MORBID MORTAL W, V63, P369
NR 33
TC 3
Z9 3
U1 0
U2 9
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1090-1981
EI 1552-6127
J9 HEALTH EDUC BEHAV
JI Health Educ. Behav.
PD JUN
PY 2017
VL 44
IS 3
BP 421
EP 430
DI 10.1177/1090198116668827
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA EZ1MP
UT WOS:000404475400011
PM 27638654
DA 2021-10-30
ER

PT J
AU Rice, TW
   Lu, M
   Ishwaran, H
   Blackstone, EH
AF Rice, Thomas W.
   Lu, Min
   Ishwaran, Hemant
   Blackstone, Eugene H.
CA Worldwide Esophageal Canc Collabor
TI Precision Surgical Therapy for Adenocarcinoma of the Esophagus and
   Esophagogastric Junction
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Article
DE Real-world data; Machine learning; Artificial intelligence; Survival
   analysis
ID NEOADJUVANT CHEMORADIOTHERAPY; CONTROLLED-TRIALS; CANCER; CHEMOTHERAPY;
   RECOMMENDATIONS; SURVIVAL; SURGERY; CHEMORADIATION; METAANALYSIS;
   ADJUVANT
AB Introduction: To facilitate the initial clinical decision regarding whether to use esophagectomy alone or neoadjuvant therapy in surgical care for individual patients with adenocarcinoma of the esophagus and esophagogastric junction-information not available from randomized trials-a machine-learning analysis was performed using worldwide real-world data on patients undergoing different therapies for this rare adenocarcinoma.
   Methods: Using random forest technology in a sequential analysis, we (1) identified eligibility for each of four therapies among 13,365 patients: esophagectomy alone (n = 6649), neoadjuvant therapy (n = 4706), esophagectomy and adjuvant therapy (n = 998), and neoadjuvant and adjuvant therapy (n = 1022); (2) performed survival analyses incorporating interactions of patient and cancer characteristics with therapy; (3) determined optimal therapy as that predicted to maximize lifetime within 10 years (restricted mean survival time; RMST) for each patient; and (4) compared lifetime gained from optimal versus actual therapies.
   Results: Actual therapy was optimal in 61% of those receiving esophagectomy alone; neoadjuvant therapy was optimal for 36% receiving neoadjuvant therapy. Many patients were predicted to benefit from postoperative adjuvant therapy. Total RMST for actual therapy received was 58,825 years. Had patients received optimal therapy, total RMST was predicted to be 62,982 years, a 7% gain.
   Conclusions: Average treatment effect for adenocarcinoma of the esophagus yields only crude evidence-based therapy guidelines. However, patient response to therapy is widely variable, and survival after data-driven predicted optimal therapy often differs from actual therapy received. Therapy must address an individual patient's cancer and clinical characteristics to provide precision surgical therapy for adenocarcinoma of the esophagus and esophagogastric junction. (C) 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
C1 [Rice, Thomas W.; Blackstone, Eugene H.] Cleveland Clin, Dept Thorac & Cardiovasc Surg, 9500 Euclid Ave Desk JJ-40, Cleveland, OH 44195 USA.
   [Lu, Min; Ishwaran, Hemant] Univ Miami, Dept Publ Hlth Sci, Div Biostat, Coral Gables, FL 33124 USA.
   [Blackstone, Eugene H.] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44195 USA.
RP Blackstone, EH (corresponding author), Cleveland Clin, Dept Thorac & Cardiovasc Surg, 9500 Euclid Ave Desk JJ-40, Cleveland, OH 44195 USA.
EM blackse@ccf.org
RI Lu, Min/AAX-1605-2021
OI Lu, Min/0000-0002-1386-1315
FU International Society for Diseases of the Esophagus (ISDE); Daniel and
   Karen Lee Chair in Thoracic Surgery at Cleveland Clinic; Drs. Sidney and
   Becca Fleischer Heart and Vascular Education Chair; Clinical and
   Translational Science Collaborative at the Case Western Reserve
   University School of Medicine from the National Institutes of Health
   (NIH) National Center for Advancing Translational Sciences; NIH Roadmap
   for Medical ResearchUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [UL1TR000439];
   National Institute of General Medical SciencesUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of General Medical Sciences (NIGMS) [R01GM125072];
   Gus P. Karos Registry Fund at Cleveland Clinic; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR002736]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [R01GM125072] Funding Source: NIH RePORTER
FX This work was supported by the International Society for Diseases of the
   Esophagus (ISDE); the Daniel and Karen Lee Chair in Thoracic Surgery at
   Cleveland Clinic (TWR); the Drs. Sidney and Becca Fleischer Heart and
   Vascular Education Chair (EHB); Clinical and Translational Science
   Collaborative at the Case Western Reserve University School of Medicine
   from the National Institutes of Health (NIH) National Center for
   Advancing Translational Sciences and NIH Roadmap for Medical Research
   (grant number UL1TR000439); National Institute of General Medical
   Sciences (grant number R01GM125072 (HI)); and the Gus P. Karos Registry
   Fund at Cleveland Clinic. These funding sources played no role in the
   collection, analysis, or interpretation of data; writing of the report;
   or decision to submit the article for publication. The contents of this
   article are solely the responsibility of the authors and do not
   necessarily represent the official views of the ISDE, Cleveland Clinic,
   or NIH.
CR Abrams Jeffrey, 2014, Am Soc Clin Oncol Educ Book, P71, DOI 10.14694/EdBook_AM.2014.34.71
   Amin MB, 2017, AJCC CANC STAGING MA
   Atay SM, 2017, J THORAC DIS, V9, P3626, DOI 10.21037/jtd.2017.09.68
   Coleman HG, 2018, GASTROENTEROLOGY, V154, P390, DOI 10.1053/j.gastro.2017.07.046
   Deng HY, 2017, EUR J CARDIO-THORAC, V51, P421, DOI 10.1093/ejcts/ezw315
   Duan Xiao-Feng, 2014, Cancer Biology Medicine, V11, P191, DOI 10.7497/j.issn.2095-3941.2014.03.005
   Edge SB, 2010, AJCC CANC STAGING MA
   Eng OS, 2018, DIS ESOPHAGUS, V31, DOI 10.1093/dote/doy020
   Favi F, 2017, EJSO-EUR J SURG ONC, V43, P1572, DOI 10.1016/j.ejso.2017.06.003
   Feng HM, 2018, MOL CLIN ONCOL, V8, P342, DOI 10.3892/mco.2017.1534
   Glatz T, 2015, EJSO-EUR J SURG ONC, V41, P1300, DOI 10.1016/j.ejso.2015.07.010
   Goense L, 2018, EJSO-EUR J SURG ONC, V44, P620, DOI 10.1016/j.ejso.2018.02.005
   GOLDMAN AI, 1992, AM STAT, V46, P13, DOI 10.2307/2684402
   Hardacker TJ, 2014, ANN SURG ONCOL, V21, P3739, DOI [10.1245/s10434-014-3935-8, 10.1245/s10434-014-3929-6]
   Huang B, 2018, PHARM STAT, V17, P202, DOI 10.1002/pst.1846
   Ishwaran H, 2018, RANDOMFORESTSRC RAND
   Jiang RC, 2017, ANN APPL STAT, V11, P1763, DOI 10.1214/17-AOAS1057
   KIRKLIN JW, 1991, J AM COLL CARDIOL, V17, P543
   Lu M, 2018, J COMPUT GRAPH STAT, V27, P209, DOI 10.1080/10618600.2017.1356325
   Makady A, 2017, VALUE HEALTH, V20, P858, DOI 10.1016/j.jval.2017.03.008
   Markar SR, 2016, EUR J CANCER, V56, P59, DOI 10.1016/j.ejca.2015.11.024
   Moorcraft SY, 2015, GASTRIC CANCER, V18, P1, DOI 10.1007/s10120-014-0356-0
   Mota FC, 2018, INT J SURG, V54, P176, DOI 10.1016/j.ijsu.2018.04.053
   Munch S, 2018, STRAHLENTHER ONKOL, V194, P125, DOI 10.1007/s00066-017-1225-7
   Pak K, 2017, JAMA ONCOL, V3, P1692, DOI 10.1001/jamaoncol.2017.2797
   Purim O, 2018, TARGET ONCOL, V13, P217, DOI 10.1007/s11523-017-0548-8
   Rice TW, 2016, DIS ESOPHAGUS, V29, P897, DOI 10.1111/dote.12533
   Rice TW, 2016, DIS ESOPHAGUS, V29, P715, DOI 10.1111/dote.12513
   Rice TW, 2016, DIS ESOPHAGUS, V29, P724, DOI 10.1111/dote.12520
   Rice T W, 2016, Dis Esophagus, V29, P707, DOI 10.1111/dote.12493
   Rice TW, 2007, J THORAC CARDIOV SUR, V133, P317, DOI 10.1016/j.jtcvs.2006.09.023
   Rice TW, 2017, J THORAC ONCOL, V12, P36, DOI 10.1016/j.jtho.2016.10.016
   Rice TW, 2016, DIS ESOPHAGUS, V29, P913, DOI 10.1111/dote.12540
   Rice TW, 2016, DIS ESOPHAGUS, V29, P906, DOI 10.1111/dote.12538
   Riley WT, 2015, TRANSL BEHAV MED, V5, P243, DOI 10.1007/s13142-015-0320-5
   Secrier M, 2016, NAT GENET, V48, P1131, DOI 10.1038/ng.3659
   Shapiro J, 2015, LANCET ONCOL, V16, P1090, DOI 10.1016/S1470-2045(15)00040-6
   Shen LL, 2015, INT CONF BIOMETR, P416, DOI 10.1109/ICB.2015.7139104
   Tang F, 2017, STAT ANAL DATA MIN, V10, P363, DOI 10.1002/sam.11348
   Tonelli MR, 2017, JAMA-J AM MED ASSOC, V318, P1649, DOI 10.1001/jama.2017.11914
   van Hagen P, 2012, NEW ENGL J MED, V366, P2074, DOI 10.1056/NEJMoa1112088
   Visser E, 2018, J SURG ONCOL, V117, P1687, DOI 10.1002/jso.25089
   Vittinghoff E, 2010, STAT MED, V29, P1127, DOI 10.1002/sim.3870
   Wang CN, 2017, CHIN J CANCER, V36, DOI 10.1186/s40880-017-0232-5
   Yoon DY, 2010, J THORAC CARDIOV SUR, V139, P283, DOI 10.1016/j.jtcvs.2009.08.055
   Zanoni A, 2016, ANN SURG ONCOL, V23, pS998, DOI 10.1245/s10434-016-5440-8
NR 46
TC 2
Z9 2
U1 3
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1556-0864
EI 1556-1380
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD DEC
PY 2019
VL 14
IS 12
BP 2164
EP 2175
DI 10.1016/j.jtho.2019.08.004
PG 12
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA JP0OO
UT WOS:000497971700026
PM 31442498
OA Green Accepted, Bronze
DA 2021-10-30
ER

PT J
AU Feldman, EB
   Balise, R
   Schiff, E
   Whitehead, N
   Thomas, E
AF Feldman, Erica B.
   Balise, Raymond
   Schiff, Eugene
   Whitehead, Nicole
   Thomas, Emmanuel
TI Barriers to Hepatitis C Screening in a Minority Population: A Comparison
   of Hepatitis C and Human Immunodeficiency Virus Screening Rates at a
   Community STD Clinic in Miami, Florida
SO JOURNAL OF COMMUNITY HEALTH
LA English
DT Article
DE HCV; HIV; Screening; Miami; Infectious disease
ID DRUG-USERS
AB 357 patients at a free STD clinic in Miami, FL were screened for HCV. Surveys were administered assessing risk factors for infectious disease transmission, and HCV and HIV screening history.
   15.1% of participants had been screened for HCV before whereas 83.8% had been screened for HIV (n = 356). Of the patients previously screened for HCV (n = 54), 98.2% of these patients had previously been screened for HIV as well.
   This data shows the low prevalence of prior HCV screenings in a high-risk population in Miami, FL. Participants who had previously received an HIV screening test were more likely to report receiving a prior HCV screening. Despite the high prevalence of HCV, most HCV infections are undiagnosed. Mortality from HIV has been declining in the United States while mortality from HCV is increasing. To decrease HCV related mortality, we recommend offering HCV screening in conjunction with HIV screening.
C1 [Feldman, Erica B.; Balise, Raymond; Schiff, Eugene; Thomas, Emmanuel] Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
   [Whitehead, Nicole] Univ Florida, Gainesville, FL USA.
   [Thomas, Emmanuel] Sylvester Comprehens Canc Ctr, Schiff Ctr Liver Dis, 1550 NW 10th Ave,Papanicolaou Bldg Rm PAP 514, Miami, FL 33136 USA.
RP Thomas, E (corresponding author), Univ Miami, Miller Sch Med, Miami, FL 33136 USA.; Thomas, E (corresponding author), Sylvester Comprehens Canc Ctr, Schiff Ctr Liver Dis, 1550 NW 10th Ave,Papanicolaou Bldg Rm PAP 514, Miami, FL 33136 USA.
EM ethomas1@med.miami.edu
OI Balise, Raymond/0000-0002-9856-5901
FU Union Positiva; Schiff Center for Liver Diseases, MiamiCenter for AIDS
   Research at the University of Miami Miller School of Medicine; National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [P30AI073961];
   MiamiClinical and Translational Science Institute KL2 program; NATIONAL
   CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Advancing Translational Sciences (NCATS)
   [KL2TR000461] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [P30AI073961] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Drug Abuse (NIDA)European Commission
   [K23DA039769] Funding Source: NIH RePORTER
FX This work was supported by Union Positiva, the Schiff Center for Liver
   Diseases, MiamiCenter for AIDS Research at the University of Miami
   Miller School of Medicine, supported by National Institutes of Health
   Grant P30AI073961 (to E.T.), and the MiamiClinical and Translational
   Science Institute KL2 program (to E.T.).
CR Ditah I, 2015, AM J GASTROENTEROL, V110, P1126, DOI 10.1038/ajg.2015.31
   Frimpong JA, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1225-4
   Hanafiah KM, 2013, HEPATOLOGY, V57, P1333, DOI 10.1002/hep.26141
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Heimer R, 2002, ADDICTION, V97, P1277, DOI 10.1046/j.1360-0443.2002.t01-1-00211.x
   Ly KN, 2012, ANN INTERN MED, V156, P271, DOI 10.7326/0003-4819-156-4-201202210-00004
   Norton BL, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-74
   O'Brien S, 2008, ADDICT BEHAV, V33, P1602, DOI 10.1016/j.addbeh.2008.07.005
   Pearlman BL, 2011, CLIN INFECT DIS, V52, P889, DOI 10.1093/cid/cir076
   Southern WN, 2014, QUAL MANAG HEALTH CA, V23, P1, DOI 10.1097/QMH.0000000000000007
   Whitehead NE, 2014, J COMMUN HEALTH, V39, P487, DOI 10.1007/s10900-013-9782-x
NR 11
TC 6
Z9 6
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0094-5145
EI 1573-3610
J9 J COMMUN HEALTH
JI J. Community Health
PD OCT
PY 2017
VL 42
IS 5
BP 921
EP 925
DI 10.1007/s10900-017-0335-6
PG 5
WC Health Policy & Services; Public, Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
GA FG6HK
UT WOS:000410472900012
PM 28353008
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Rice, TW
   Ishwaran, H
   Blackstone, EH
   Hofstetter, WL
   Kelsen, DP
   Apperson-Hansen, C
AF Rice, Thomas W.
   Ishwaran, Hemant
   Blackstone, Eugene H.
   Hofstetter, Wayne L.
   Kelsen, David P.
   Apperson-Hansen, Carolyn
CA Worldwide Esophageal Canc Collabor
TI Recommendations for clinical staging (cTNM) of cancer of the esophagus
   and esophagogastric junction for the 8th edition AJCC/UICC staging
   manuals
SO DISEASES OF THE ESOPHAGUS
LA English
DT Article
DE esophageal malignancy; staging; statistics; squamous cell carcinoma;
   adenocarcinoma
ID 7TH EDITION; SURVIVAL; MORTALITY
AB We report analytic and consensus processes that produced recommendations for clinical stage groups (cTNM) of esophageal and esophagogastric junction cancer for the AJCC/UICC cancer staging manuals, 8th edition. The Worldwide Esophageal Cancer Collaboration (WECC) provided data on 22,123 clinically staged patients with epithelial esophageal cancers. Risk-adjusted survival for each patient was developed using random survival forest analysis from which (1) data-driven clinical stage groups were identified wherein survival decreased monotonically and was distinctive between and homogeneous within groups and (2) data-driven anatomic clinical stage groups based only on cTNM. The AJCC Upper GI Task Force, by smoothing, simplifying, expanding, and assessing clinical applicability, produced (3) consensus clinical stage groups. Compared with pTNM, cTNM survival was pinched, with poorer survival for early cStage groups and better survival for advanced ones. Histologic grade was distinctive for data-driven grouping of cT2N0M0 squamous cell carcinoma (SCC) and cT1-2N0M0 adenocarcinoma, but consensus removed it. Grouping was different by histopathologic cell type. For SCC, cN0-1 was distinctive for cT3 but not cT1-2, and consensus removed cT4 subclassification and added subgroups 0, IVA, and IVB. For adenocarcinoma, N0-1 was distinctive for cT1-2 but not cT3-4a, cStage II subgrouping was necessary (T1N1M0 [IIA] and T2N0M0 [IIB]), advanced cancers cT3-4aN0-1M0 plus cT2N1M0 comprised cStage III, and consensus added subgroups 0, IVA, and IVB. Treatment decisions require accurate cStage, which differs from pStage. Understaging and overstaging are problematic, and additional factors, such as grade, may facilitate treatment decisions and prognostication until clinical staging techniques are uniformly applied and improved.
C1 [Rice, Thomas W.; Blackstone, Eugene H.] Cleveland Clin, 9500 Euclid Ave Desk JJ 40, Cleveland, OH 44195 USA.
   [Ishwaran, Hemant] Univ Miami, Miami, FL USA.
   [Hofstetter, Wayne L.] Univ Texas MD Anderson Hosp, Houston, TX USA.
   [Kelsen, David P.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
   [Apperson-Hansen, Carolyn] Case Western Reserve Univ, Cleveland, OH 44106 USA.
RP Rice, TW (corresponding author), Cleveland Clin, Dept Thorac & Cardiovasc Surg, 9500 Euclid Ave Desk JJ 40, Cleveland, OH 44195 USA.
EM ricet@ccf.org
RI Cecconello, Ivan/A-3918-2013; Smithers, Bernard M/F-2060-2010; Rasanen,
   Jari/AAV-1231-2020
OI Cecconello, Ivan/0000-0002-3535-4170; Smithers, Bernard
   M/0000-0002-8333-8685; Rasanen, Jari/0000-0002-7826-532X; Zylstra,
   Janine/0000-0002-9839-7629; Griffin, Selwyn Michael/0000-0003-1583-7009;
   Barbour, Andrew/0000-0002-0991-7662; Gotley, David/0000-0002-8604-253X;
   D'journo, Xavier Benoit/0000-0001-6747-4583
FU International Society for Diseases of the Esophagus (ISDE); Daniel and
   Karen Lee Chair in Thoracic Surgery at Cleveland Clinic; Kenneth Gee and
   Paula Shaw, PhD, Chair in Heart Research at Cleveland Clinic; Clinical
   and Translational Science Collaborative of Cleveland, from the National
   Center for Advancing Translational Services (NCATS) component of the
   National Institutes of Health and NIH roadmap for Medical Research
   [UL1TR000439]; NATIONAL CANCER INSTITUTEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Cancer Institute (NCI) [R01CA163739] Funding Source: NIH
   RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Advancing Translational
   Sciences (NCATS) [UL1TR000439, UL1TR000460] Funding Source: NIH RePORTER
FX Funded in part by (1) the International Society for Diseases of the
   Esophagus (ISDE), (2) the Daniel and Karen Lee Chair in Thoracic Surgery
   at Cleveland Clinic (TWR), (3) the Kenneth Gee and Paula Shaw, PhD,
   Chair in Heart Research at Cleveland Clinic (EHB), and (4) the Clinical
   and Translational Science Collaborative of Cleveland, UL1TR000439 from
   the National Center for Advancing Translational Services (NCATS)
   component of the National Institutes of Health and NIH roadmap for
   Medical Research. Its contents are solely the responsibility of the
   authors and do not necessarily represent the official views of the ISDE,
   Cleveland Clinic, or the NIH.
CR Agoston AT, 2015, AM J SURG PATHOL, V39, P1085, DOI 10.1097/PAS.0000000000000420
   Black WC, 2002, JNCI-J NATL CANCER I, V94, P167, DOI 10.1093/jnci/94.3.167
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Davison JM, 2016, CLIN GASTROENTEROL H, V14, P369, DOI 10.1016/j.cgh.2015.10.020
   GOLDMAN AI, 1992, AM STAT, V46, P13, DOI 10.2307/2684402
   International Union Against Cancer (UICC), 1968, TNM CLASSIFICATION M
   Ishwaran H., 2016, RANDOMFORESTSRC RAND
   Ishwaran H, 2008, ANN APPL STAT, V2, P841, DOI 10.1214/08-AOAS169
   Lauer MS, 1999, J AM COLL CARDIOL, V34, P618, DOI 10.1016/S0735-1097(99)00250-8
   Manual for Staging of Cancer, 1977, MAN STAG CANC
   Rice T W, 2016, Dis Esophagus, V29, P707, DOI 10.1111/dote.12493
   Rice T W, DIS ESOPHAG IN PRESS
   Rice TW, 2013, THORAC SURG CLIN, V23, P461, DOI 10.1016/j.thorsurg.2013.07.004
   Rice TW, 2010, CANCER-AM CANCER SOC, V116, P3763, DOI 10.1002/cncr.25146
   Stekhoven DJ, 2012, BIOINFORMATICS, V28, P112, DOI 10.1093/bioinformatics/btr597
   Strong VE, 2013, J NATL COMPR CANC NE, V11, P60, DOI 10.6004/jnccn.2013.0009
   Tang F, STAT METHOD IN PRESS
   van Leeuwen PJ, 2010, J MED SCREEN, V17, P204, DOI 10.1258/jms.2010.010074
NR 18
TC 57
Z9 62
U1 1
U2 9
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1120-8694
EI 1442-2050
J9 DIS ESOPHAGUS
JI Dis. Esophagus
PD NOV-DEC
PY 2016
VL 29
IS 8
BP 913
EP 919
DI 10.1111/dote.12540
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA EE1GJ
UT WOS:000389328700003
PM 27905171
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Rice, TW
   Ishwaran, H
   Kelsen, DP
   Hofstetter, WL
   Apperson-Hansen, C
   Blackstone, EH
AF Rice, Thomas W.
   Ishwaran, Hemant
   Kelsen, David P.
   Hofstetter, Wayne L.
   Apperson-Hansen, Carolyn
   Blackstone, Eugene H.
CA Worldwide Esophageal Canc Collabor
TI Recommendations for neoadjuvant pathologic staging (ypTNM) of cancer of
   the esophagus and esophagogastric junction for the 8th edition AJCC/UICC
   staging manuals
SO DISEASES OF THE ESOPHAGUS
LA English
DT Article
DE chemotherapy; epidemiology; esophagectomy; oncology; radiotherapy
ID 7TH EDITION; SURVIVAL; CHEMORADIATION; SURGERY; SYSTEM; UNION
AB We report analytic and consensus processes that produced recommendations for neoadjuvant pathologic stage groups (ypTNM) of esophageal and esophagogastric junction cancer for the AJCC/UICC cancer staging manuals, 8th edition. The Worldwide Esophageal Cancer Collaboration provided data for 22,654 patients with epithelial esophageal cancers; 7,773 had pathologic assessment after neoadjuvant therapy. Risk-adjusted survival for each patient was developed. Random forest analysis identified data-driven neoadjuvant pathologic stage groups wherein survival decreased monotonically with increasing group, was distinctive between groups, and homogeneous within groups. An additional analysis produced data-driven anatomic neoadjuvant pathologic stage groups based only on ypT, ypN, and ypM categories. The AJCC Upper GI Task Force, by smoothing, simplifying, expanding, and assessing clinical applicability, produced consensus neoadjuvant pathologic stage groups. Grade and location were much less discriminating for stage grouping ypTNM than pTNM. Data-driven stage grouping without grade and location produced nearly identical groups for squamous cell carcinoma and adenocarcinoma. However, ypTNM groups and their associated survival differed from pTNM. The need for consensus process was minimal. The consensus groups, identical for both cell types were as follows: ypStage I comprised ypT0-2N0M0; ypStage II ypT3N0M0; ypStage IIIA ypT0-2N1M0; ypStage IIIB ypT3N1M0, ypT0-3N2, and ypT4aN0M0; ypStage IVA ypT4aN1-2, ypT4bN0-2, and ypTanyN3M0; and ypStage IVB ypTanyNanyM1. Absence of equivalent pathologic (pTNM) categories for the peculiar neoadjuvant pathologic categories ypTisN0-3M0 and ypT0N0-3M0, dissimilar stage group compositions, and markedly different early- and intermediate-stage survival necessitated a unified, unique set of stage grouping for patients of either cell type who receive neoadjuvant therapy.
C1 [Rice, Thomas W.; Blackstone, Eugene H.] Cleveland Clin, 9500 Euclid Ave Desk JJ 40, Cleveland, OH 44195 USA.
   [Ishwaran, Hemant] Univ Miami, Miami, FL USA.
   [Kelsen, David P.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
   [Hofstetter, Wayne L.] Univ Texas MD Anderson Hosp, Houston, TX USA.
   [Apperson-Hansen, Carolyn] Case Western Reserve Univ, Cleveland, OH 44106 USA.
RP Rice, TW (corresponding author), Cleveland Clin, Dept Thorac & Cardiovasc Surg, 9500 Euclid Ave Desk JJ 40, Cleveland, OH 44195 USA.
EM ricet@ccf.org
RI Rasanen, Jari/AAV-1231-2020; Smithers, Bernard M/F-2060-2010;
   Cecconello, Ivan/A-3918-2013
OI Rasanen, Jari/0000-0002-7826-532X; Smithers, Bernard
   M/0000-0002-8333-8685; Cecconello, Ivan/0000-0002-3535-4170; Gotley,
   David/0000-0002-8604-253X; Barbour, Andrew/0000-0002-0991-7662;
   D'journo, Xavier Benoit/0000-0001-6747-4583; Griffin, Selwyn
   Michael/0000-0003-1583-7009; Zylstra, Janine/0000-0002-9839-7629
FU International Society for Diseases of the Esophagus (ISDE); Daniel and
   Karen Lee Chair in Thoracic Surgery at Cleveland Clinic; Kenneth Gee and
   Paula Shaw, PhD, Chair in Heart Research at Cleveland Clinic; Clinical
   and Translational Science Collaborative of Cleveland, from the National
   Center for Advancing Translational Services (NCATS) component of the
   National Institutes of Health [UL1TR000439]; NIH roadmap for Medical
   ResearchUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA; NATIONAL CANCER INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI) [R01CA163739] Funding Source:
   NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Advancing Translational
   Sciences (NCATS) [UL1TR000460, UL1TR000439] Funding Source: NIH RePORTER
FX Funded in part by (1) the International Society for Diseases of the
   Esophagus (ISDE), (2) the Daniel and Karen Lee Chair in Thoracic Surgery
   at Cleveland Clinic (TWR), (3) the Kenneth Gee and Paula Shaw, PhD,
   Chair in Heart Research at Cleveland Clinic (EHB), and (4) Clinical and
   Translational Science Collaborative of Cleveland, UL1TR000439 from the
   National Center for Advancing Translational Services (NCATS) component
   of the National Institutes of Health and NIH roadmap for Medical
   Research. Its contents are solely the responsibility of the authors and
   do not necessarily represent the official views of the ISDE, Cleveland
   Clinic, or the NIH.
CR Black WC, 2002, JNCI-J NATL CANCER I, V94, P167, DOI 10.1093/jnci/94.3.167
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Davies AR, 2014, J CLIN ONCOL, V32, P2983, DOI 10.1200/JCO.2014.55.9070
   GOLDMAN AI, 1992, AM STAT, V46, P13, DOI 10.2307/2684402
   Ishwaran H., 2016, RANDOMFORESTSRC RAND
   Ishwaran H, 2008, ANN APPL STAT, V2, P841, DOI 10.1214/08-AOAS169
   Lauer MS, 1999, J AM COLL CARDIOL, V34, P618, DOI 10.1016/S0735-1097(99)00250-8
   Mehta SP, 2013, DIS ESOPHAGUS, V26, P182, DOI 10.1111/j.1442-2050.2012.01350.x
   Rice TW, 2016, DIS ESOPHAGUS, V29, P715, DOI 10.1111/dote.12513
   Rice TW, 2016, DIS ESOPHAGUS, V29, P724, DOI 10.1111/dote.12520
   Rice T W, 2016, Dis Esophagus, V29, P707, DOI 10.1111/dote.12493
   Rice TW, 2013, THORAC SURG CLIN, V23, P461, DOI 10.1016/j.thorsurg.2013.07.004
   Rice TW, 2010, CANCER-AM CANCER SOC, V116, P3763, DOI 10.1002/cncr.25146
   Schneider PM, 2005, ANN SURG, V242, P684, DOI 10.1097/01.sla.0000186170.38348.7b
   Shapiro J, 2015, LANCET ONCOL, V16, P1090, DOI 10.1016/S1470-2045(15)00040-6
   Stekhoven DJ, 2012, BIOINFORMATICS, V28, P112, DOI 10.1093/bioinformatics/btr597
   Strong VE, 2013, J NATL COMPR CANC NE, V11, P60, DOI 10.6004/jnccn.2013.0009
   Swisher SG, 2005, ANN SURG, V241, P810, DOI 10.1097/01.sla.0000161983.82345.85
   Tang F, 2016, STAT METHOD IN PRESS
   Wang CC, 2015, RADIOTHER ONCOL, V115, P9, DOI 10.1016/j.radonc.2015.03.019
NR 20
TC 40
Z9 41
U1 0
U2 13
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1120-8694
EI 1442-2050
J9 DIS ESOPHAGUS
JI Dis. Esophagus
PD NOV-DEC
PY 2016
VL 29
IS 8
BP 906
EP 912
DI 10.1111/dote.12538
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA EE1GJ
UT WOS:000389328700002
PM 27905170
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Saltzman, RG
   Jayaweera, DT
   Caceres, LV
   Tovar, JA
   Vidro-Casiano, M
   Karakeshishyan, V
   Soto, J
   Khan, A
   Mitrani, RD
   Schulman, IH
   Hare, JM
AF Saltzman, Russell G.
   Jayaweera, Dushyantha T.
   Caceres, Lina, V
   Tovar, Jairo A.
   Vidro-Casiano, Mayra
   Karakeshishyan, Vela
   Soto, Jeanette
   Khan, Aisha
   Mitrani, Raul D.
   Schulman, Ivonne H.
   Hare, Joshua M.
TI Demographic representation in clinical trials for cell-based therapy
SO CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS
LA English
DT Article
DE Clinical trials; Cell-based therapy; Health equity; Generalizability;
   Diversity; Inclusion
AB Inclusion of women and minorities in clinical research is critical to fully assess the safety and efficacy of innovative therapies. With inadequate representation of demography, generalizability is impaired since pharmacokinetics and pharmacodynamics differ in these patient populations. This study was designed to analyze the voluntary participation rates of different demographic groups in cell-based therapy clinical trials conducted by the Interdisciplinary Stem Cell Institute (ISCI) at the University of Miami, Miller School of Medicine. ISCI conducted eight clinical trials between 2007 and 2017. The trials enrolled patients with ischemic and non-ischemic cardiomyopathy, idiopathic pulmonary fibrosis (IPF), aging-frailty, and Type-2 Diabetes. Participants received cell-based therapy (n = 218) or placebo (n = 33). Among the 251 participants, 29.5% were Hispanic and 20% were women. The proportion of individuals participating in each trial was compared to that of the respective disease populations attending University of Miami Health System clinics to calculate the participation to prevalence ratio (PPR). Distribution of women accurately reflected the population attending the University of Miami Health System in trials for dilated cardiomyopathy (DCM) and aging-frailty but was under-represented in others. Similarly, Hispanics and whites were accurately represented in three of the five disease fields, with Hispanics under-represented in frailty and diabetes, and whites over-represented in DCM and IPF. Black patients were accurately represented in the diabetes trial but were under-represented in all others. This study provides insight into challenges of achieving representative inclusion in research. Novel community engagement strategies are necessary to improve inclusion of women and under-represented minorities in clinical research of cell-based therapy.
C1 [Saltzman, Russell G.; Jayaweera, Dushyantha T.; Caceres, Lina, V; Tovar, Jairo A.; Vidro-Casiano, Mayra; Karakeshishyan, Vela; Soto, Jeanette; Khan, Aisha; Mitrani, Raul D.; Schulman, Ivonne H.; Hare, Joshua M.] Univ Miami, Interdisciplinary Stem Cell Inst, Miller Sch Med, Miami, FL 33136 USA.
   [Jayaweera, Dushyantha T.; Soto, Jeanette; Mitrani, Raul D.; Schulman, Ivonne H.; Hare, Joshua M.] Univ Miami, Dept Med, Miller Sch Med, Miami, FL 33136 USA.
RP Schulman, IH (corresponding author), Univ Miami, Interdisciplinary Stem Cell Inst, Miller Sch Med, Miami, FL 33136 USA.
EM ischulman@med.miami.edu; JHare@med.miami.edu
OI Saltzman, Russell/0000-0003-0494-3869
FU National Heart, Lung, and Blood Institute of Health (NHLBI) [1R01
   HL134558, 5UM 1HL113460, R01 HL137355]; Starr and Soffer Family
   Foundations; Production Assistance for Cell Therapy grants [PCT0013-01,
   PCT0004-02, PCT0009-01]; Marcus Foundation;  [NHLBI-ECB-HB-2016-09-JB]; 
   [4UM1HL087318-10];  [UL1TR002736]
FX This study was supported by National Heart, Lung, and Blood Institute of
   Health (NHLBI) grants, 1R01 HL134558, 5UM 1HL113460, and R01 HL137355
   and by the Starr and Soffer Family Foundations. AK and JMH are also
   supported by grants, NHLBI-ECB-HB-2016-09-JB and 4UM1HL087318-10, as
   well as by Production Assistance for Cell Therapy grants, PCT0013-01,
   PCT0004-02, and PCT0009-01, along with the Marcus Foundation. URIDE was
   designed and developed by the Software Engineering team at the
   University of Miami Institute for Data Science and Computing under the
   Informatics Program of the Miami Miami Clinical and Translational
   Science Institute and supported by Grant Award Number UL1TR002736.
CR Anderson GD, 2005, J WOMENS HEALTH, V14, P19, DOI 10.1089/jwh.2005.14.19
   Bolli R, 2020, JACC-CARDIOONCOL, V2, P581, DOI 10.1016/j.jaccao.2020.09.001
   Chen A, 2018, J WOMENS HEALTH, V27, P418, DOI 10.1089/jwh.2016.6272
   ELSADR W, 1992, JAMA-J AM MED ASSOC, V267, P954, DOI 10.1001/jama.267.7.954
   Eshera N, 2015, AM J THER, V22, P435, DOI 10.1097/MJT.0000000000000177
   Florea V, 2020, CARDIOVASC RES, V116, P2131, DOI 10.1093/cvr/cvaa004
   Florea V, 2017, CIRC RES, V121, P1279, DOI 10.1161/CIRCRESAHA.117.311827
   Fouad MN, 2000, ANN EPIDEMIOL, V10, pS35, DOI 10.1016/S1047-2797(00)00199-X
   Gandhi M, 2004, ANNU REV PHARMACOL, V44, P499, DOI [10.1146/annurev.pharmtox.44.101802.121453, 10.2165/00003088-200948030-00001]
   Glassberg MK, 2017, CHEST, V151, P971, DOI 10.1016/j.chest.2016.10.061
   Golpanian S, 2017, J GERONTOL A-BIOL, V72, P1505, DOI 10.1093/gerona/glx056
   HANSON AE, 1975, SIGNS, V1, P567, DOI 10.1086/493243
   Hare JM, 2017, J AM COLL CARDIOL, V69, P526, DOI 10.1016/j.jacc.2016.11.009
   Hare JM, 2012, JAMA-J AM MED ASSOC, V308, P2369, DOI 10.1001/jama.2012.25321
   Heldman AW, 2014, JAMA-J AM MED ASSOC, V311, P62, DOI 10.1001/jama.2013.282909
   Heller C, 2014, CONTEMP CLIN TRIALS, V39, P169, DOI 10.1016/j.cct.2014.08.004
   Horowitz CR, 2009, AM J PREV MED, V37, pS195, DOI 10.1016/j.amepre.2009.08.006
   Jacobs EA, 2006, J GEN INTERN MED, V21, P642, DOI 10.1111/j.1525-1497.2006.00485.x
   Karantalis V, 2014, CIRC RES, V114, P1302, DOI 10.1161/CIRCRESAHA.114.303180
   Liu Katherine A., 2016, Pharmacy Pract (Granada), V14, DOI 10.18549/PharmPract.2016.01.708
   Mersha TB, 2015, HUM GENOMICS, V9, DOI 10.1186/s40246-014-0023-x
   National Institutes of Health (NIH), 2019, INCL WOM MIN PART RE
   Oh SS, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001918
   Pinsonneault J, 2003, AAPS PHARMSCI, V5
   Pittenger MF, 2019, NPJ REGEN MED, V4, DOI 10.1038/s41536-019-0083-6
   Rieger AC, 2019, EBIOMEDICINE, V48, P377, DOI 10.1016/j.ebiom.2019.09.043
   Rotimi CN, 2010, NEW ENGL J MED, V363, P1551, DOI 10.1056/NEJMra0911564
   Schulman I.H., 2018, STROMAL CELLS STRUCT, P143, DOI [10.5772/intechopen.78586, DOI 10.5772/INTECHOPEN.78586]
   Schulman IH, 2018, CIRC RES, V123, P1030, DOI 10.1161/CIRCRESAHA.118.310426
   Schwarzschild MA, 2019, NEUROLOGY, V93, pE1328, DOI 10.1212/WNL.0000000000008194
   Scott PE, 2018, J AM COLL CARDIOL, V71, P1960, DOI 10.1016/j.jacc.2018.02.070
   SWANSON GM, 1995, J NATL CANCER I, V87, P1747, DOI 10.1093/jnci/87.23.1747
   Thompson M, 2020, ECLINICALMEDICINE, V19, DOI 10.1016/j.eclinm.2019.100249
   Tompkins BA, 2017, J GERONTOL A-BIOL, V72, P1513, DOI 10.1093/gerona/glx137
   Yap KK, 2016, STEM CELL TRANSL MED, V5, P265, DOI 10.5966/sctm.2015-0232
NR 35
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
EI 2451-8654
J9 CONT CLIN TRIAL COMM
JI Contemp. Clin. Trials Commun.
PD MAR
PY 2021
VL 21
AR 100702
DI 10.1016/j.conctc.2021.100702
PG 6
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA RH5RT
UT WOS:000636276300003
PM 33511300
OA Green Published, gold
DA 2021-10-30
ER

PT J
AU Elfassy, T
   Sotres-Alvarez, D
   Van Horn, L
   Angell, S
   Schneiderman, N
   Rundek, T
   Raij, L
   Smoller, SW
   Mossavar-Rahmani, Y
   Daviglus, ML
   Hanna, DB
   Al Hazzouri, AZ
AF Elfassy, Tali
   Sotres-Alvarez, Daniela
   Van Horn, Linda
   Angell, Sonia
   Schneiderman, Neil
   Rundek, Tatjana
   Raij, Leopoldo
   Smoller, Sylvia W.
   Mossavar-Rahmani, Yasmin
   Daviglus, Martha L.
   Hanna, David B.
   Al Hazzouri, Adina Zeki
TI Daily Intake of Sodium and Potassium Among Diverse US Hispanics/Latinos,
   the Hispanic Community Health Study/Study of Latinos
SO AMERICAN JOURNAL OF HYPERTENSION
LA English
DT Article
DE blood pressure; Hispanics; hypertension; Latinos; potassium;
   recommendations; sodium
ID CARDIOVASCULAR-DISEASE; DIETARY-SODIUM; BLOOD-PRESSURE; RISK-FACTORS;
   ADULTS; HYPERTENSION; STROKE; BACKGROUNDS; DESIGN; SAMPLE
AB BACKGROUND
   High sodium and low potassium consumption are risk factors for hypertension. The objectives of this study were to describe usual daily intake of sodium and potassium among US Hispanics/Latinos of diverse background groups and estimate the proportion meeting guidelines for dietary sodium and potassium intake.
   METHODS
   We studied 16,171 participants of the Hispanic Community Health Study/Study of Latinos (HCHS/SOL), a diverse group of self-identified Hispanics/Latinos aged 18-74 years from 4 US communities. In 2008-2011, all HCHS/SOL participants underwent a standardized examination. Median usual daily intake of dietary sodium and potassium were derived from two 24-hour diet recalls; standard errors and 95% confidence intervals (CIs) were calculated using boot strap methods. Meeting 2015 US Department of Agriculture guidelines was defined as an intake of <2,300 mg/day of sodium and >= 4,700 mg/day of potassium.
   RESULTS
   Among US Hispanics/Latinos, median usual daily intake of sodium was 2,574 mg (95% CI: 2,547, 2,600) among women and 3,747 mg (95% CI: 3,697, 3,796) among men. Median usual daily intake of potassium was 2,069 mg (95% CI: 2,046, 2,092) among women and 2,649 mg (95% CI: 2,615, 2,683) among men. Overall, only 21.3% (95% CI: 20.2%, 22.4%) of the US Hispanic/Latino population met 2015 recommendations for sodium and 0.6% (95% CI: 0.4%, 0.8%) for potassium.
   CONCLUSIONS
   \Among US Hispanics/Latinos intake of sodium is too high and potassium too low. Strategies to reduce sodium intake while simultaneously increasing intake of potassium in this US population are warranted.
C1 [Elfassy, Tali] Univ Miami, Miller Sch Med, Dept Epidemiol, Miami, FL 33136 USA.
   [Sotres-Alvarez, Daniela] Univ North Carolina Chapel Hill, Dept Biostat, Chapel Hill, NC USA.
   [Van Horn, Linda; Daviglus, Martha L.] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Evanston, IL USA.
   [Angell, Sonia] New York City Dept Hlth & Mental Hyg, Div Prevent & Primary Care, New York, NY USA.
   [Schneiderman, Neil] Univ Miami, Dept Psychol, Miami, FL USA.
   [Rundek, Tatjana] Univ Miami, Dept Neurol, Miami, FL USA.
   [Raij, Leopoldo] Univ Miami, Dept Med, Miami, FL USA.
   [Smoller, Sylvia W.; Mossavar-Rahmani, Yasmin; Hanna, David B.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA.
   [Al Hazzouri, Adina Zeki] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA.
RP Elfassy, T (corresponding author), Univ Miami, Miller Sch Med, Dept Epidemiol, Miami, FL 33136 USA.
EM t.elfassy@med.miami.edu
OI Mossavar-Rahmani, Yasmin/0000-0002-9214-6124
FU National Heart, Lung, and Blood InstituteUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [R01HL095856]; National
   Heart, Lung, and Blood Institute (NHLBI)United States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [N01-HC65233, N01-HC65234,
   N01-HC65235, N01-HC65236, N01-HC65237]; American Heart
   AssociationAmerican Heart Association [17POST32490000]; University of
   Miami Clinical and Translational Science Institute, from the National
   Center for Advancing Translational Sciences; National Institute on
   Minority Health and Health DisparitiesUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute on Minority Health & Health Disparities (NIMHD) [KL2TR002737];
   National Institutes of Health, National Heart, Lung, and Blood
   InstituteUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [K01HL137557]; National Institutes of Health, National
   Institute on AgingUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Aging (NIA) [K01AG047273]; NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [KL2TR002737] Funding Source:
   NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [K01HL137557]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Aging (NIA) [K01AG047273] Funding Source:
   NIH RePORTER
FX We thank Nicole Butera, MPH, and Pamela Shaw, PhD, for their help with
   the statistical methodology. The Study of Latinos: Nutrition & Physical
   Activity Assessment Study was supported by R01HL095856 from the National
   Heart, Lung, and Blood Institute. The Hispanic Community Health
   Study/Study of Latinos was carried out as a collaborative study
   supported by contracts from the National Heart, Lung, and Blood
   Institute (NHLBI) to the University of North Carolina (N01-HC65233),
   University of Miami (N01-HC65234), Albert Einstein College of Medicine
   (N01-HC65235), Northwestern University (N01-HC65236), and San Diego
   State University (N01-HC65237).; T.E. was supported by the American
   Heart Association post-doctoral fellowship (17POST32490000) and is
   currently supported by the University of Miami Clinical and
   Translational Science Institute, from the National Center for Advancing
   Translational Sciences and the National Institute on Minority Health and
   Health Disparities (KL2TR002737). D.B.H. was supported by a grant from
   the National Institutes of Health, National Heart, Lung, and Blood
   Institute (K01HL137557). A.Z.A.H. was supported by a grant from the
   National Institutes of Health, National Institute on Aging
   (K01AG047273).
CR Adrogue HJ, 2007, NEW ENGL J MED, V356, P1966, DOI 10.1056/NEJMra064486
   Allen VC, 2011, HISPANIC J BEHAV SCI, V33, P411, DOI 10.1177/0739986311422880
   Amer Diabet Assoc, 2010, DIABETES CARE, V33, pS62, DOI 10.2337/dc10-s062
   Angell SY, 2014, AM J PUBLIC HEALTH, V104, P2409, DOI 10.2105/AJPH.2013.301542
   [Anonymous], 1998, NUTR DAT SYST RES ND
   Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601
   Benjamin EJ, 2018, CIRCULATION, V137, pE67, DOI 10.1161/CIR.0000000000000558
   Black AE, 2000, INT J OBESITY, V24, P1119, DOI 10.1038/sj.ijo.0801376
   Castro H, 2013, SEMIN NEPHROL, V33, P277, DOI 10.1016/j.semnephrol.2013.04.008
   Cobb Laura K, 2012, Curr Treat Options Cardiovasc Med, V14, P425, DOI 10.1007/s11936-012-0182-9
   Cogswell ME, 2018, JAMA-J AM MED ASSOC, V319, P1209, DOI 10.1001/jama.2018.1156
   Cogswell ME, 2012, AM J CLIN NUTR, V96, P647, DOI 10.3945/ajcn.112.034413
   Cordain L, 2005, AM J CLIN NUTR, V81, P341, DOI 10.1093/ajcn.81.2.341
   Daviglus ML, 2014, PROG CARDIOVASC DIS, V57, P230, DOI 10.1016/j.pcad.2014.07.006
   Daviglus ML, 2012, JAMA-J AM MED ASSOC, V308, P1775, DOI 10.1001/jama.2012.14517
   Drewnowski A, 2015, J HUM HYPERTENS, V29, P14, DOI 10.1038/jhh.2014.38
   Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939
   Elfassy T, 2018, OBESITY, V26, P442, DOI 10.1002/oby.22089
   Elfassy T, 2015, J ACAD NUTR DIET, V115, P278, DOI 10.1016/j.jand.2014.08.027
   Freedman LS, 2015, AM J EPIDEMIOL, V181, P473, DOI 10.1093/aje/kwu325
   Gardener H, 2012, STROKE, V43, P1200, DOI 10.1161/STROKEAHA.111.641043
   Harnack LJ, 2017, CIRCULATION, V135, P1775, DOI 10.1161/CIRCULATIONAHA.116.024446
   James PA, 2014, JAMA-J AM MED ASSOC, V311, P1809, DOI 10.1001/jama.2013.284427
   Kuczmarski M. F., 1995, Nutrition Today, V30, P30
   Lavange LM, 2010, ANN EPIDEMIOL, V20, P642, DOI 10.1016/j.annepidem.2010.05.006
   Loftfield E, 2015, J NUTR EDUC BEHAV, V47, P181, DOI 10.1016/j.jneb.2014.09.003
   Loftfield E, 2013, AM J CLIN NUTR, V98, P1282, DOI 10.3945/ajcn.113.059204
   McLean RM, 2014, NUTRIENTS, V6, P4651, DOI 10.3390/nu6114651
   Mossavar-Rahmani Y, 2017, J HUM HYPERTENS, V31, P860, DOI 10.1038/jhh.2017.74
   National Cancer Institute, 2018, US DIET INT NCI METH
   Rodriguez CJ, 2014, CIRCULATION, V130, P593, DOI 10.1161/CIR.0000000000000071
   Sacks FM, 2001, NEW ENGL J MED, V344, P3, DOI 10.1056/NEJM200101043440101
   Siega-Riz AM, 2014, AM J CLIN NUTR, V99, P1487, DOI 10.3945/ajcn.113.082685
   Sorlie PD, 2010, ANN EPIDEMIOL, V20, P629, DOI 10.1016/j.annepidem.2010.03.015
   Stolarz-Skrzypek K, 2011, JAMA-J AM MED ASSOC, V305, P1777, DOI 10.1001/jama.2011.574
   Strazzullo P, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b4567
   Strom B. L., 2013, SOD INT POP ASEV
   Tooze JA, 2010, STAT MED, V29, P2857, DOI 10.1002/sim.4063
   United States Department of Agriculture, 2015, SCI REP 2015 DIET GU
   *USDA, 2010, DIET GUID AM
   USDA Agricultural Research Service Beltsville Human Nutrition Research Center Food Surveys Research Group U.S. Department of Health and Human Services Centers for Disease Control and Prevention, WHAT WE EAT AM NHANE
   Van Horn L, 2016, CIRCULATION, V134, pE505, DOI 10.1161/CIR.0000000000000462
   WHO, 2012, GUID POT INT AD CHIL
   WHO and FAO, 2003, DIET NUTR PREV CHRON
NR 44
TC 2
Z9 2
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0895-7061
EI 1941-7225
J9 AM J HYPERTENS
JI Am. J. Hypertens.
PD SEP
PY 2019
VL 32
IS 9
BP 868
EP 879
DI 10.1093/ajh/hpz073
PG 12
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA JC2TL
UT WOS:000489129300010
PM 31056652
OA Bronze, Green Published
DA 2021-10-30
ER

PT J
AU Rice, TW
   Ishwaran, H
   Hofstetter, WL
   Kelsen, DP
   Apperson-Hansen, C
   Blackstone, EH
AF Rice, T. W.
   Ishwaran, H.
   Hofstetter, W. L.
   Kelsen, D. P.
   Apperson-Hansen, C.
   Blackstone, E. H.
CA Worldwide Esophageal Canc Collabor
TI Recommendations for pathologic staging (pTNM) of cancer of the esophagus
   and esophagogastric junction for the 8th edition AJCC/UICC staging
   manuals
SO DISEASES OF THE ESOPHAGUS
LA English
DT Article
DE epidemiology; esophagectomy; esophagogastric junction; oncology
ID AMERICAN JOINT COMMITTEE; SQUAMOUS-CELL CARCINOMA; 7TH EDITION;
   SURVIVAL; ADENOCARCINOMA; SYSTEM; IMPACT; 6TH
AB We report analytic and consensus processes that produced recommendations for pathologic stage groups (pTNM) of esophageal and esophagogastric junction cancer for the AJCC/UICC cancer staging manuals, 8th edition. The Worldwide Esophageal Cancer Collaboration provided data for 22,654 patients with epithelial esophageal cancers; 13,300 without preoperative therapy had pathologic assessment after esophagectomy or endoscopic treatment. Risk-adjusted survival for each patient was developed using random survival forest analysis to identify data-driven pathologic stage groups wherein survival decreased monotonically with increasing group, was distinctive between groups, and homogeneous within groups. The AJCC Upper GI Task Force, by smoothing, simplifying, expanding, and assessing clinical applicability, produced consensus pathologic stage groups. For pT1-3N0M0 squamous cell carcinoma (SCC) and pT1-2N0M0 adenocarcinoma, pT was inadequate for grouping; subcategorizing pT1 and adding histologic grade enhanced staging; cancer location improved SCC staging. Consensus eliminated location for pT2N0M0 and pT3N0M0G1 SCC groups, and despite similar survival, restricted stage 0 to pTis, excluding pT1aN0M0G1. Metastases markedly reduced survival; pT, pN, and pM sufficiently grouped advanced cancers. Stage IIA and IIB had different compositions for SCC and adenocarcinoma, but similar survival. Consensus stage IV subgrouping acknowledged pT4N+ and pN3 cancers had poor survival, similar to pM1. Anatomic pathologic stage grouping, based on pTNM only, produced identical consensus stage groups for SCC and adenocarcinoma at the cost of homogeneity in early groups. Pathologic staging can neither direct pre-treatment decisions nor aid in prognostication for treatment other than esophagectomy or endoscopic therapy. However, it provides a clean, single therapy reference point for esophageal cancer.
C1 [Rice, T. W.; Blackstone, E. H.] Cleveland Clin, 9500 Euclid Ave Desk JJ 40, Cleveland, OH 44195 USA.
   [Ishwaran, H.] Univ Miami, Miami, FL USA.
   [Hofstetter, W. L.] Univ Texas MD Anderson Hosp, Houston, TX USA.
   [Kelsen, D. P.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
   [Apperson-Hansen, C.] Case Western Reserve Univ, Cleveland, OH 44106 USA.
RP Rice, TW (corresponding author), Cleveland Clin, Dept Thorac & Cardiovasc Surg, 9500 Euclid Ave Desk JJ 40, Cleveland, OH 44195 USA.
EM ricet@ccf.org
RI Smithers, Bernard M/F-2060-2010; Rasanen, Jari/AAV-1231-2020;
   Cecconello, Ivan/A-3918-2013
OI Smithers, Bernard M/0000-0002-8333-8685; Rasanen,
   Jari/0000-0002-7826-532X; Cecconello, Ivan/0000-0002-3535-4170; Barbour,
   Andrew/0000-0002-0991-7662; Zylstra, Janine/0000-0002-9839-7629;
   D'journo, Xavier Benoit/0000-0001-6747-4583; Rusch,
   Valerie/0000-0003-2345-6900; Gotley, David/0000-0002-8604-253X; Griffin,
   Selwyn Michael/0000-0003-1583-7009
FU International Society for Diseases of the Esophagus (ISDE); Daniel and
   Karen Lee Chair in Thoracic Surgery at Cleveland Clinic; Kenneth Gee and
   Paula Shaw, PhD, Chair in Heart Research at Cleveland Clinic; Clinical
   and Translational Science Collaborative of ClevelandUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS);
   National Center for Advancing Translational Services component of the
   National Institutes of Health (NIH) [UL1TR000439]; NIH Roadmap for
   Medical ResearchUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [R01CA163739] Funding Source: NIH RePORTER; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000439,
   UL1TR000460] Funding Source: NIH RePORTER
FX Funded in part by (1) the International Society for Diseases of the
   Esophagus (ISDE), (2) the Daniel and Karen Lee Chair in Thoracic Surgery
   at Cleveland Clinic (TWR), (3) the Kenneth Gee and Paula Shaw, PhD,
   Chair in Heart Research at Cleveland Clinic (EHB), and (4) the Clinical
   and Translational Science Collaborative of Cleveland, UL1TR000439 from
   the National Center for Advancing Translational Services component of
   the National Institutes of Health (NIH) and NIH Roadmap for Medical
   Research. The contents of this article are solely the responsibility of
   the authors and do not necessarily represent the official views of the
   ISDE, Cleveland Clinic, or NIH.
CR Black WC, 2002, JNCI-J NATL CANCER I, V94, P167, DOI 10.1093/jnci/94.3.167
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Edge SB, 2010, AM JOINT COMMITTEE C
   GOLDMAN AI, 1992, AM STAT, V46, P13, DOI 10.2307/2684402
   Hsu PK, 2010, ANN THORAC SURG, V89, P1024, DOI 10.1016/j.athoracsur.2010.01.017
   International Union Against Cancer (UICC), 1968, TNM CLASSIFICATION M
   Ishwaran H., 2016, RANDOMFORESTSRC RAND
   Ishwaran H, 2008, ANN APPL STAT, V2, P841, DOI 10.1214/08-AOAS169
   Kim HI, 2013, ANN SURG ONCOL, V20, P2713, DOI 10.1245/s10434-013-2898-5
   Lauer MS, 1999, J AM COLL CARDIOL, V34, P618, DOI 10.1016/S0735-1097(99)00250-8
   Nafteux PR, 2015, ANN SURG, V262, P809, DOI 10.1097/SLA.0000000000001463
   Ning ZH, 2015, J THORAC ONCOL, V10, P1091, DOI 10.1097/JTO.0000000000000580
   Rice TW, 2016, DIS ESOPHAGUS, V29, P715, DOI 10.1111/dote.12513
   Rice TW, 2016, DIS ESOPHAGUS, V29, P724, DOI 10.1111/dote.12520
   Rice T W, 2016, Dis Esophagus, V29, P707, DOI 10.1111/dote.12493
   Rice TW, 2013, THORAC SURG CLIN, V23, P461, DOI 10.1016/j.thorsurg.2013.07.004
   Rice TW, 2010, CANCER-AM CANCER SOC, V116, P3763, DOI 10.1002/cncr.25146
   Situ D, 2013, ANN SURG ONCOL, V20, P580, DOI 10.1245/s10434-012-2656-0
   Sobin L, 2009, TNM CLASSIFICATION M
   Stekhoven DJ, 2012, BIOINFORMATICS, V28, P112, DOI 10.1093/bioinformatics/btr597
   Talsma K, 2012, ANN SURG ONCOL, V19, P2142, DOI 10.1245/s10434-012-2218-5
   Tang F, 2016, STAT METHOD IN PRESS
   van Leeuwen PJ, 2010, J MED SCREEN, V17, P204, DOI 10.1258/jms.2010.010074
   Yamasaki M, 2014, ANN SURG ONCOL, V21, P2850, DOI 10.1245/s10434-014-3696-4
   Zahoor Haris, 2015, Am J Surg, V210, P610, DOI 10.1016/j.amjsurg.2015.05.010
NR 25
TC 74
Z9 81
U1 1
U2 15
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1120-8694
EI 1442-2050
J9 DIS ESOPHAGUS
JI Dis. Esophagus
PD NOV-DEC
PY 2016
VL 29
IS 8
BP 897
EP 905
DI 10.1111/dote.12533
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA EE1GJ
UT WOS:000389328700001
PM 27905172
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Stoutenberg, M
   Rethorst, CD
   Lawson, O
   Read, JP
AF Stoutenberg, Mark
   Rethorst, Chad D.
   Lawson, Olivia
   Read, Jennifer P.
TI Exercise training - A beneficial intervention in the treatment of
   alcohol use disorders?
SO DRUG AND ALCOHOL DEPENDENCE
LA English
DT Review
DE Alcohol; Anxiety; Depression; Exercise; Impulsivity; Neurobiology;
   Stress
ID POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED CONTROLLED-TRIAL; SUBSTANCE
   USE DISORDERS; QUALITY-OF-LIFE; PHYSICAL-ACTIVITY; ANXIETY DISORDERS;
   AEROBIC EXERCISE; DEPRESSIVE SYMPTOMS; VOLUNTARY EXERCISE;
   SMOKING-CESSATION
AB Background: A growing body of evidence suggests that exercise training may have multiple beneficial effects in individuals with mental health or substance use disorders. Yet, relatively little knowledge exists regarding the benefits of exercise training to augment treatment for alcohol use disorders (AUDs). Purpose: The purpose of this narrative review is to present a summary of the growing body of published literature supporting exercise training as a treatment strategy for individuals with AUDs. We will provide evidence on the myriad of ways in which exercise may exert a positive effect on AUD outcomes including stress, anxiety, impulsivity, and depression. Further, we will explore how these mechanisms share common neurobiological pathways. The role of exercise in enhancing the social environment and increasing individual self-efficacy to reduce excess and/or inappropriate alcohol consumption will also be discussed. Discussion: We will conclude with a description of completed investigations involving exercise training and provide suggestions for next steps in this innovative field of study. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
C1 [Stoutenberg, Mark; Lawson, Olivia] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, 1120 NW 14th St,Clin Res Bldg,Suite 1008, Miami, FL 33136 USA.
   [Rethorst, Chad D.] Univ Texas SW Med Ctr Dallas, Dept Psychiat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
   [Read, Jennifer P.] SUNY Buffalo, Dept Psychol, 213 Pk Hall, Buffalo, NY 14260 USA.
RP Stoutenberg, M (corresponding author), Univ Miami, Dept Publ Hlth Sci, 1120 NW 14th St,Clin Res Bldg,Suite 1008, Miami, FL 33136 USA.
EM mstoutenberg@med.miami.edu; Chad.Rethorst@UTSouthwestern.edu;
   jpread@buffalo.edu
OI Rethorst, Chad/0000-0002-8168-2829
FU Miami Clinical and Translational Science Institute from the National
   Center for Advancing Translational Sciences [1KL2TR000461]; National
   Institute on Minority Health and Health DisparitiesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Minority Health & Health Disparities
   (NIMHD); NIMHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH) [K01MH097847]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [KL2TR000461] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Mental Health (NIMH) [K01MH097847] Funding Source:
   NIH RePORTER
FX Mark Stoutenberg is supported by Grant Number 1KL2TR000461 of the Miami
   Clinical and Translational Science Institute from the National Center
   for Advancing Translational Sciences and the National Institute on
   Minority Health and Health Disparities. Chad D. Rethorst is supported by
   NIMH K01MH097847. The contents of this manuscript are solely the
   responsibility of the authors and do not represent the official views of
   the NIH.
CR Abramovitch A, 2013, ISR J PSYCHIATR REL, V50, P47
   Abrantes AM, 2014, NICOTINE TOB RES, V16, P1094, DOI 10.1093/ntr/ntu036
   Adinoff B, 2005, ALCOHOL CLIN EXP RES, V29, P1351, DOI 10.1097/01.ALC.0000176356.97620.84
   Adinoff B, 2005, ALCOHOL CLIN EXP RES, V29, P528, DOI 10.1097/01.ALC.0000158939.25531.EE
   Adinoff B, 1998, ALCOHOL HEALTH RES W, V22, P67
   Aidar FJ, 2012, STROKE RES TREAT, V2012, DOI 10.1155/2012/298375
   Anestis MD, 2007, BEHAV RES THER, V45, P3018, DOI 10.1016/j.brat.2007.08.012
   Angelo DL, 2013, J GAMBL STUD, V29, P589, DOI 10.1007/s10899-012-9320-2
   Anthenelli RM, 2001, ALCOHOL CLIN EXP RES, V25, P692, DOI 10.1097/00000374-200105000-00010
   Apodaca TR, 2013, J CONSULT CLIN PSYCH, V81, P35, DOI 10.1037/a0030881
   Baker AL, 2010, ADDICTION, V105, P87, DOI 10.1111/j.1360-0443.2009.02757.x
   BALDWIN D, 1995, INT CLIN PSYCHOPHARM, V9, P41, DOI 10.1097/00004850-199501004-00006
   Bandura A., 1986, SOCIAL FDN THOUGHT A
   Bartholomew JB, 2005, MED SCI SPORT EXER, V37, P2032, DOI 10.1249/01.mss.0000178101.78322.dd
   Bernardy NC, 1996, ALCOHOL, V13, P493, DOI 10.1016/0741-8329(96)00043-2
   Bickel WK, 2014, ANNU REV CLIN PSYCHO, V10, P641, DOI 10.1146/annurev-clinpsy-032813-153724
   Binder E, 2004, BEHAV BRAIN RES, V155, P197, DOI 10.1016/j.bbr.2004.04.017
   Bischof G, 2007, ADDICTION, V102, P904, DOI 10.1111/j.1360-0443.2007.01834.x
   Blumenthal JA, 2007, PSYCHOSOM MED, V69, P587, DOI 10.1097/PSY.0b013e318148c19a
   Bock BC, 2012, J WOMENS HEALTH, V21, P240, DOI 10.1089/jwh.2011.2963
   Boileau I, 2003, SYNAPSE, V49, P226, DOI 10.1002/syn.10226
   Bolton J, 2006, J NERV MENT DIS, V194, P818, DOI 10.1097/01.nmd.0000244481.63148.98
   Bottlender M, 2006, FORTSCHR NEUROL PSYC, V74, P19, DOI 10.1055/s-2004-830282
   Bottlender M, 2004, ALCOHOL ALCOHOLISM, V39, P357, DOI 10.1093/alcalc/agh073
   Brown RA, 2014, J SUBST ABUSE TREAT, V47, P1, DOI 10.1016/j.jsat.2014.02.004
   Brown Richard A, 2010, Ment Health Phys Act, V3, P27
   Buchowski MS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017465
   Buckholtz JW, 2010, SCIENCE, V329, P532, DOI 10.1126/science.1185778
   Burns L, 2005, ADDICTION, V100, P787, DOI 10.1111/j.1360-0443.2005.001069.x
   Burns L, 2002, DRUG ALCOHOL DEPEN, V68, P299, DOI 10.1016/S0376-8716(02)00220-X
   CAMACHO TC, 1991, AM J EPIDEMIOL, V134, P220, DOI 10.1093/oxfordjournals.aje.a116074
   Campbell JE, 2009, J APPL PHYSIOL, V106, P66, DOI 10.1152/japplphysiol.91128.2008
   Center for Behavioral Health Statistics and Quality, 2013, RES 2012 NAT SURV DR
   Centers for Disease Control and Prevention (CDC), 2014, ALC US YOUR HLTH
   Chaouloff F, 1997, MED SCI SPORT EXER, V29, P58, DOI 10.1097/00005768-199701000-00009
   Chi FW, 2009, ADDICTION, V104, P927, DOI 10.1111/j.1360-0443.2009.02524.x
   Cornelius JR, 2001, ADDICT BEHAV, V26, P735, DOI 10.1016/S0306-4603(00)00152-0
   Cornelius JR, 1997, ARCH GEN PSYCHIAT, V54, P700
   Correia CJ, 2005, ADDICT BEHAV, V30, P19, DOI 10.1016/j.addbeh.2004.04.006
   Correia CJ., 2010, J BEHAV HLTH MED, V1, P216
   Darlington TM, 2014, BEHAV BRAIN RES, V259, P313, DOI 10.1016/j.bbr.2013.11.011
   Dawe S, 2004, NEUROSCI BIOBEHAV R, V28, P343, DOI 10.1016/j.neubiorev.2004.03.007
   Debell F, 2014, SOC PSYCH PSYCH EPID, V49, P1401, DOI 10.1007/s00127-014-0855-7
   DECASTRO JM, 1985, PHARMACOL BIOCHEM BE, V23, P495, DOI 10.1016/0091-3057(85)90407-1
   Dishman RK, 2006, OBESITY, V14, P345, DOI 10.1038/oby.2006.46
   Dishman RK, 2012, AM J PREV MED, V43, P361, DOI 10.1016/j.amepre.2012.06.011
   Dixit AR, 2000, AM J PSYCHIAT, V157, P751, DOI 10.1176/appi.ajp.157.5.751
   Dolan SL, 2013, DRUG ALCOHOL DEPEN, V128, P8, DOI 10.1016/j.drugalcdep.2012.07.010
   Dom G, 2006, ADDICT BEHAV, V31, P298, DOI 10.1016/j.addbeh.2005.05.009
   Donovan D, 2005, J STUD ALCOHOL, P119, DOI 10.15288/jsas.2005.s15.119
   Driessen M, 2001, ALCOHOL ALCOHOLISM, V36, P249, DOI 10.1093/alcalc/36.3.249
   Droste SK, 2003, ENDOCRINOLOGY, V144, P3012, DOI 10.1210/en.2003-0097
   Dunton GF, 2008, PREV MED, V47, P519, DOI 10.1016/j.ypmed.2008.07.001
   Ehrenreich H, 1997, ALCOHOL CLIN EXP RES, V21, P1285, DOI 10.1111/j.1530-0277.1997.tb04450.x
   Ehringer MA, 2009, ALCOHOL, V43, P443, DOI 10.1016/j.alcohol.2009.06.003
   Ekkekakis P, 2011, SPORTS MED, V41, P641, DOI 10.2165/11590680-000000000-00000
   Engel JA, 2014, PROG BRAIN RES, V211, P201, DOI 10.1016/B978-0-444-63425-2.00009-X
   Engelmann AJ, 2014, BRAIN STRUCT FUNCT, V219, P657, DOI 10.1007/s00429-013-0525-7
   Esel E, 2001, ALCOHOL ALCOHOLISM, V36, P572, DOI 10.1093/alcalc/36.6.572
   Evren C, 2012, DRUG ALCOHOL REV, V31, P81, DOI 10.1111/j.1465-3362.2011.00303.x
   Farley AC, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006219.pub3
   FARMER ME, 1988, AM J EPIDEMIOL, V128, P1340, DOI 10.1093/oxfordjournals.aje.a115087
   Fediuc S, 2006, J APPL PHYSIOL, V100, P1867, DOI 10.1152/japplphysiol.01416.2005
   Fetzner MG, 2015, COGN BEHAV THERAPY, V44, P301, DOI 10.1080/16506073.2014.916745
   Flannery BA, 2001, ALCOHOL CLIN EXP RES, V25, P299, DOI 10.1097/00000374-200102000-00021
   FRANKEL A, 1974, Q J STUD ALCOHOL, V35, P1272
   Galanter M, 2007, J SUBST ABUSE TREAT, V33, P265, DOI 10.1016/j.jsat.2007.04.016
   Giesen ES, 2015, J SUBST ABUSE TREAT, V52, P1, DOI 10.1016/j.jsat.2014.12.001
   GILLIAM PE, 1984, PHARMACOL BIOCHEM BE, V20, P863, DOI 10.1016/0091-3057(84)90008-X
   Grant BF, 2004, ARCH GEN PSYCHIAT, V61, P807, DOI 10.1001/archpsyc.61.8.807
   Greenwood BN, 2011, EXERC SPORT SCI REV, V39, P140, DOI 10.1097/JES.0b013e31821f7e45
   Greenwood BN, 2011, BEHAV BRAIN RES, V217, P354, DOI 10.1016/j.bbr.2010.11.005
   Greenwood BN, 2005, BIOL PSYCHIAT, V57, P559, DOI 10.1016/j.biopsych.2004.11.025
   Haasova M, 2013, ADDICTION, V108, P26, DOI 10.1111/j.1360-0443.2012.04034.x
   Hammer SB, 2010, ALCOHOL CLIN EXP RES, V34, P1651, DOI 10.1111/j.1530-0277.2010.01251.x
   HATTORI S, 1994, BRAIN RES BULL, V35, P41, DOI 10.1016/0361-9230(94)90214-3
   Havassy BE, 2009, PSYCHIAT SERV, V60, P217, DOI 10.1176/appi.ps.60.2.217
   Heinz A, 1998, AM J PSYCHIAT, V155, P1544, DOI 10.1176/ajp.155.11.1544
   Heinz A, 2004, AM J PSYCHIAT, V161, P1783, DOI 10.1176/appi.ajp.161.10.1783
   HEINZ A, 1995, PSYCHIAT RES, V56, P81, DOI 10.1016/0165-1781(94)02580-C
   Herring MP, 2012, ARCH INTERN MED, V172, P101, DOI 10.1001/archinternmed.2011.696
   Herring MP, 2012, PSYCHOTHER PSYCHOSOM, V81, P21, DOI 10.1159/000327898
   Herring MP, 2010, ARCH INTERN MED, V170, P321, DOI 10.1001/archinternmed.2009.530
   HEYES MP, 1988, LIFE SCI, V42, P1537, DOI 10.1016/0024-3205(88)90011-2
   JAKEMAN PM, 1994, EXP PHYSIOL, V79, P461, DOI 10.1113/expphysiol.1994.sp003780
   Jayakody K, 2014, BRIT J SPORT MED, V48, P187, DOI 10.1136/bjsports-2012-091287
   Joos L, 2013, PSYCHOPHARMACOLOGY, V226, P273, DOI 10.1007/s00213-012-2905-8
   Junghanns K, 2003, ALCOHOL ALCOHOLISM, V38, P189, DOI 10.1093/alcalc/agg052
   Kawachi I, 1996, AM J PUBLIC HEALTH, V86, P999, DOI 10.2105/AJPH.86.7.999
   Keedwell PA, 2001, ADDICT BIOL, V6, P247, DOI 10.1080/13556210120056580
   Kelly JF, 2014, PSYCHOL ADDICT BEHAV, V28, P928, DOI 10.1037/a0034727
   Kessler RC, 1997, ARCH GEN PSYCHIAT, V54, P313
   Kiefer F, 2002, PSYCHOPHARMACOLOGY, V164, P239, DOI 10.1007/s00213-002-1255-3
   Kim Mun Hee, 2014, J Exerc Nutrition Biochem, V18, P97, DOI 10.5717/jenb.2014.18.1.97
   KLEIN MH, 1985, INT J MENT HEALTH, V13, P148, DOI 10.1080/00207411.1984.11448982
   KLEIN SA, 1977, PERCEPT MOTOR SKILL, V45, P1159, DOI 10.2466/pms.1977.45.3f.1159
   Kushner MG, 2000, CLIN PSYCHOL REV, V20, P149, DOI 10.1016/S0272-7358(99)00027-6
   Lai HMX, 2015, DRUG ALCOHOL DEPEN, V154, P1, DOI 10.1016/j.drugalcdep.2015.05.031
   Laine TPJ, 1999, MOL PSYCHIATR, V4, P189, DOI 10.1038/sj.mp.4000514
   Landale S, 2014, INT REV SOCIOL SPORT, V49, P468, DOI 10.1177/1012690213507273
   Laudet AB, 2002, J PSYCHOACTIVE DRUGS, V34, P305, DOI 10.1080/02791072.2002.10399968
   Laudet AB, 2010, J SUBST ABUSE TREAT, V38, P317, DOI 10.1016/j.jsat.2010.01.007
   Lawson HA, 2005, SPORT EDUC SOC, V10, P135, DOI 10.1080/1357332052000308800
   Lee S, 1997, J NEUROSCI, V17, P8856
   Lejuez CW, 2010, ALCOHOL CLIN EXP RES, V34, P1334, DOI 10.1111/j.1530-0277.2010.01217.x
   LEMARQUAND D, 1994, BIOL PSYCHIAT, V36, P326, DOI 10.1016/0006-3223(94)90630-0
   LEMARQUAND D, 1994, BIOL PSYCHIAT, V36, P395, DOI 10.1016/0006-3223(94)91215-7
   Litt MD, 2007, J CONSULT CLIN PSYCH, V75, P542, DOI 10.1037/0022-006X.75.4.542
   Logrip ML, 2012, ADDICT BIOL, V17, P920, DOI 10.1111/j.1369-1600.2012.00460.x
   Longabaugh R, 2010, J STUD ALCOHOL DRUGS, V71, P837, DOI 10.15288/jsad.2010.71.837
   LUGER A, 1987, NEW ENGL J MED, V316, P1309, DOI 10.1056/NEJM198705213162105
   Lynch WJ, 2013, NEUROSCI BIOBEHAV R, V37, P1622, DOI 10.1016/j.neubiorev.2013.06.011
   Lynskey MT, 1998, DRUG ALCOHOL DEPEN, V52, P201, DOI 10.1016/S0376-8716(98)00095-7
   MACRAE PG, 1987, PSYCHOPHARMACOLOGY, V92, P236
   Maisto S., 1999, SOCIAL LEARNING THEO, P106
   Marcus BH, 1999, ARCH INTERN MED, V159, P1229, DOI 10.1001/archinte.159.11.1229
   Marcus BH, 2005, NICOTINE TOB RES, V7, P871, DOI 10.1080/14622200500266056
   Marlatt G. A., 1985, RELAPSE PREVENTION M
   Marshall EJ, 2014, ALCOHOL ALCOHOLISM, V49, P160, DOI 10.1093/alcalc/agt180
   Mather AS, 2002, BRIT J PSYCHIAT, V180, P411, DOI 10.1192/bjp.180.5.411
   MCAULEY E, 1993, J GERONTOL, V48, pP218, DOI 10.1093/geronj/48.4.P218
   McAuley E, 2000, Exerc Sport Sci Rev, V28, P85
   McBride WJ, 2002, ALCOHOL CLIN EXP RES, V26, P280, DOI 10.1097/00000374-200202000-00017
   McGrath PJ, 1996, ARCH GEN PSYCHIAT, V53, P232
   McGuigan MR, 2004, J SPORT SCI MED, V3, P8
   Meeusen R, 2001, SPORTS MED, V31, P965, DOI 10.2165/00007256-200131140-00002
   Meyer EM, 2013, ALCOHOL CLIN EXP RES, V37, P566, DOI 10.1111/acer.12012
   Meyers RJ, 2011, ALCOHOL RES HEALTH, V33, P380
   MILLER L, 1991, J SUBST ABUSE TREAT, V8, P277, DOI 10.1016/0740-5472(91)90051-B
   Miller NS, 1996, J PSYCHOACTIVE DRUGS, V28, P111, DOI 10.1080/02791072.1996.10524384
   Moeller FG, 2001, AM J PSYCHIAT, V158, P1783, DOI 10.1176/appi.ajp.158.11.1783
   Morley KC, 2013, ADDICT SCI CLIN PRAC, V8, DOI 10.1186/1940-0640-8-19
   MURPHY TJ, 1986, ADDICT BEHAV, V11, P175, DOI 10.1016/0306-4603(86)90043-2
   Nabkasorn C, 2006, EUR J PUBLIC HEALTH, V16, P179, DOI 10.1093/eurpub/cki159
   National Institute on Alcohol Abuse and Alcoholism, 2010, EXPL TREATM OPT ALC
   O'Dell SJ, 2012, SYNAPSE, V66, P71, DOI 10.1002/syn.20989
   Oh H, 2013, APPETITE, V71, P144, DOI 10.1016/j.appet.2013.07.015
   Ozburn AR, 2008, ALCOHOL, V42, P417, DOI 10.1016/j.alcohol.2008.04.006
   PAFFENBARGER RS, 1994, ACTA PSYCHIAT SCAND, V89, P16, DOI 10.1111/j.1600-0447.1994.tb05796.x
   PALMER J, 1988, J STUD ALCOHOL, V49, P418, DOI 10.15288/jsa.1988.49.418
   PALMER JA, 1995, PERCEPT MOTOR SKILL, V80, P523, DOI 10.2466/pms.1995.80.2.523
   Parschau L, 2013, BRIT J HEALTH PSYCH, V18, P395, DOI 10.1111/j.2044-8287.2012.02099.x
   Peirce RS, 2000, HEALTH PSYCHOL, V19, P28, DOI 10.1037/0278-6133.19.1.28
   Penedo FJ, 2005, CURR OPIN PSYCHIATR, V18, P189, DOI 10.1097/00001504-200503000-00013
   Pettinati HM, 2010, AM J PSYCHIAT, V167, P668, DOI 10.1176/appi.ajp.2009.08060852
   Pettinati HM, 2004, BIOL PSYCHIAT, V56, P785, DOI 10.1016/j.biopsych.2004.07.016
   Pichard C, 2009, ALCOHOL, V43, P593, DOI 10.1016/j.alcohol.2009.10.007
   Porter S. S., 1984, EXCEPT CHILDREN, V31, P54, DOI DOI 10.1080/0156655840310107
   Ralevski E, 2014, SUBST ABUSE REHABIL, V5, P25, DOI 10.2147/SAR.S37399
   Randall C., 2003, PRIMARY TREATMENT OU, P135
   Read JP, 2001, J SUBST ABUSE TREAT, V21, P199, DOI 10.1016/S0740-5472(01)00203-3
   Reed J, 2006, PSYCHOL SPORT EXERC, V7, P477, DOI 10.1016/j.psychsport.2005.11.003
   Rethorst CD, 2013, J PSYCHIATR PRACT, V19, P204, DOI 10.1097/01.pra.0000430504.16952.3e
   Rimer J., 2012, COCHRANE DB SYST REV, V11, P7
   Rimmele U, 2007, PSYCHONEUROENDOCRINO, V32, P627, DOI 10.1016/j.psyneuen.2007.04.005
   Roberts V, 2012, PSYCHOPHARMACOLOGY, V222, P1, DOI 10.1007/s00213-012-2731-z
   Robinson J, 2009, J ANXIETY DISORD, V23, P38, DOI 10.1016/j.janxdis.2008.03.013
   Roessler KK, 2010, SCAND J PUBLIC HEALT, V38, P664, DOI 10.1177/1403494810371249
   Rosenbaum S, 2015, ACTA PSYCHIAT SCAND, V131, P350, DOI 10.1111/acps.12371
   Rubio G, 2008, ALCOHOL CLIN EXP RES, V32, P1681, DOI 10.1111/j.1530-0277.2008.00746.x
   Salgado JV, 2009, REV BRAS PSIQUIATR, V31, P4, DOI 10.1590/S1516-44462009000100003
   Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55
   Schmidt LG, 2000, EUR PSYCHIAT, V15, P135, DOI 10.1016/S0924-9338(00)00220-0
   Schuckit MA, 1997, AM J PSYCHIAT, V154, P948
   Shield KD, 2013, ALCOHOL RES-CURR REV, V35, P155
   Shin SH, 2012, ADDICT BEHAV, V37, P102, DOI 10.1016/j.addbeh.2011.09.006
   Sinha R, 2001, PSYCHOPHARMACOLOGY, V158, P343, DOI 10.1007/s002130100917
   SINYOR D, 1982, J STUD ALCOHOL, V43, P380, DOI 10.15288/jsa.1982.43.380
   Smith KW, 2003, AM J DRUG ALCOHOL AB, V29, P323, DOI 10.1081/ADA-120020517
   Spanagel R, 1999, TRENDS NEUROSCI, V22, P521, DOI 10.1016/S0166-2236(99)01447-2
   Stahre M, 2014, PREV CHRONIC DIS, V11, DOI 10.5888/pcd11.130293
   Stephens MAC, 2012, ALCOHOL RES-CURR REV, V34, P468
   Stoutenberg M, 2015, J SUBST ABUSE TREAT, V49, P43, DOI 10.1016/j.jsat.2014.08.008
   Stoutenberg Mark, 2012, Ment Health Phys Act, V5, P175
   Strickland JC, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00753
   Strohle A, 2005, AM J PSYCHIAT, V162, P2376, DOI 10.1176/appi.ajp.162.12.2376
   Struder HK, 2001, INT J SPORTS MED, V22, P482, DOI 10.1055/s-2001-17606
   Struder HK, 1999, EUR J APPL PHYSIOL O, V79, P318, DOI 10.1007/s004210050514
   Teesson M, 2009, AUST NZ J PSYCHIAT, V43, P606, DOI 10.1080/00048670902970908
   Traustadottir T, 2005, PSYCHONEUROENDOCRINO, V30, P392, DOI 10.1016/j.psyneuen.2004.11.002
   Trivedi Madhukar H, 2006, J Psychiatr Pract, V12, P205, DOI 10.1097/00131746-200607000-00002
   Trivedi MH, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-206
   Trivedi MH, 2011, J CLIN PSYCHIAT, V72, P677, DOI 10.4088/JCP.10m06743
   US Department of Health and Human Services, 2008, 2008 PHYS ACT GUID A
   Ussher M, 2004, ADDICTION, V99, P1542, DOI 10.1111/j.1360-0443.2004.00919.x
   Vega SR, 2006, BRAIN RES, V1121, P59, DOI 10.1016/j.brainres.2006.08.105
   Wackernah RC, 2014, SUBST ABUSE REHABIL, V5, P1, DOI 10.2147/SAR.S37907
   Wang DS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110728
   Watt M., 2006, J MENT HEALTH, V15, P683, DOI [10.1080/09638230600998938, DOI 10.1080/09638230600998938]
   Weicker H, 2001, AMINO ACIDS, V20, P35, DOI 10.1007/s007260170064
   Whitaker AM, 2014, BEHAV PHARMACOL, V25, P398, DOI 10.1097/FBP.0000000000000069
   Willinger U, 2002, ALCOHOL ALCOHOLISM, V37, P609, DOI 10.1093/alcalc/37.6.609
   Wipfli B, 2011, SCAND J MED SCI SPOR, V21, P474, DOI 10.1111/j.1600-0838.2009.01049.x
   Wipfli BM, 2008, J SPORT EXERCISE PSY, V30, P392, DOI 10.1123/jsep.30.4.392
   Witkiewitz K, 2004, AM PSYCHOL, V59, P224, DOI 10.1037/0003-066X.59.4.224
   Wolitzky-Taylor K, 2015, J ANXIETY DISORD, V30, P88, DOI 10.1016/j.janxdis.2014.12.011
   Wolitzky-Taylor K, 2011, J ADDICT MED, V5, P233, DOI 10.1097/ADM.0b013e31823276d7
   Young SN, 2007, J PSYCHIATR NEUROSCI, V32, P394
   Zheng H, 2006, BEHAV BRAIN RES, V168, P47, DOI 10.1016/j.bbr.2005.10.007
   Zschucke E, 2012, SCI WORLD J, DOI 10.1100/2012/901741
NR 200
TC 18
Z9 18
U1 0
U2 39
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0376-8716
EI 1879-0046
J9 DRUG ALCOHOL DEPEN
JI Drug Alcohol Depend.
PD MAR 1
PY 2016
VL 160
BP 2
EP 11
DI 10.1016/j.drugalcdep.2015.11.019
PG 10
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA DG1OK
UT WOS:000371837200002
PM 26652900
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Tamames, I
   King, C
   Huang, CY
   Telischi, FF
   Hoffer, ME
   Rajguru, SM
AF Tamames, Ilmar
   King, Curtis
   Huang, Chin-Yuh
   Telischi, Fred F.
   Hoffer, Michael E.
   Rajguru, Suhrud M.
TI Theoretical Evaluation and Experimental Validation of Localized
   Therapeutic Hypothermia Application to Preserve Residual Hearing After
   Cochlear Implantation
SO EAR AND HEARING
LA English
DT Article
DE Therapeutic hypothermia; Cochlear implant; Residual hearing; Auditory;
   Deafness; Trauma; Neuroprotection
ID SPINAL-CORD-INJURY; APICAL DIFFERENCES; INSERTION TRAUMA;
   FINITE-ELEMENT; MODEL; ISCHEMIA; PROTECTS; BRAIN; STIMULATION; PERILYMPH
AB Objectives: Cochlear implantation surgery has been shown to result in trauma to inner ear sensory structures, resulting in loss of residual hearing. Localized therapeutic hypothermia has been shown in clinical care to be a neuroprotective intervention. Previously, we have shown in an experimental model that localized hypothermia protects cochlear hair cells and residual hearing function against surgical and cochlear implantation trauma. Using experimental temperature measurements carried out in human cadaver temporal bones and a finite element model of the inner ear, the present study examined the temperature distribution of a custom-designed hypothermia delivery system in the human inner ear organs.
   Design: The efficacy of the hypothermia probe and resulting heat distribution across human cochlea and surrounding tissues were modeled in three-dimensional in COMSOL. The geometry and dimensions of inner ear and temporal bones were derived from computed tomographic and magnetic resonance imaging images. Model predictions were compared with experimental observations from five human temporal bones.
   Results: In both the modeling and experimental studies, the cochlear temperature was lowered by 4 to 6 degrees C on the round window from a baseline of 37 degrees C within 16 to 18 minutes. The model simulations showed uniformly distributed cooling across the cochlea. This study provides insight for design, operation, and protocols for efficacious delivery of mild therapeutic hypothermia to the human cochlea that may significantly benefit patients undergoing surgical cochlear implantation by preserving residual hearing.
   Conclusion: There was a close correlation between the results of the numerical simulations and experimental observations in this study. Our custom-designed system is capable of effectively providing mild therapeutic hypothermia locally to the human cochlea. When combined with results from in vivo animal experiments, the present study suggests that the application of localized therapeutic hypothermia may hold potential for patients with an aim to preserve residual hearing after cochlear implantation.
C1 [Tamames, Ilmar; Huang, Chin-Yuh; Rajguru, Suhrud M.] Univ Miami, Dept Biomed Engn, Miami, FL USA.
   [King, Curtis] Lucent Med Syst, Seattle, WA USA.
   [Telischi, Fred F.; Hoffer, Michael E.; Rajguru, Suhrud M.] Univ Miami, Dept Otolaryngol, Miami, FL USA.
RP Rajguru, SM (corresponding author), Univ Miami, Ear Inst, Sensory Electrophysiol Lab, 1600 NW 10th Ave,RMSB 3158, Miami, FL 33136 USA.
EM s.rajguru@miami.edu
FU Cochlear Americas; NIDCDUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Deafness & Other Communication Disorders (NIDCD) [R21DC014324,
   R01DC013798]; Cochlear; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1TR000460] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION
   DISORDERSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Deafness &
   Other Communication Disorders (NIDCD) [R01DC013798, R21DC014324] Funding
   Source: NIH RePORTER
FX S.M.R. and M.H. are funded by Cochlear Americas to develop the
   therapeutic hypothermia application for cochlear implant surgery. S.M.R.
   and C.K. are named inventors on a patent for the hypothermia system used
   in this study. Funding for this study was provided by NIDCD R21DC014324,
   NIDCD R01DC013798, and Cochlear to S.M.R.
CR [Anonymous], 2016, 2016 COCHLEAR ANN RE
   Ateshian GA, 2015, J BIOMECH, V48, P779, DOI 10.1016/j.jbiomech.2014.12.020
   Balkany TJ, 2005, LARYNGOSCOPE, V115, P1543, DOI 10.1097/01.mlg.0000173169.45262.ae
   Bas E, 2012, ANAT REC, V295, P1909, DOI 10.1002/ar.22574
   BROWN MC, 1983, J ACOUST SOC AM, V73, P1662, DOI 10.1121/1.389387
   Cappuccino A, 2010, SPINE, V35, pE57, DOI 10.1097/BRS.0b013e3181b9dc28
   Cignoni P., 2008, P EUR IT CHAPT C, P129, DOI DOI 10.2312/LOCALCHAPTEREVENTS/ITALCHAP/ITALIANCHAPCONF2008/129-136
   De Paolis A, 2017, J BIOMECH, V50, P209, DOI 10.1016/j.jbiomech.2016.11.020
   Dietrich WD, 2011, NEUROTHERAPEUTICS, V8, P229, DOI 10.1007/s13311-011-0035-3
   Dietrich WD, 2010, NEUROTHERAPEUTICS, V7, P43, DOI 10.1016/j.nurt.2009.10.015
   Dietrich WD, 2009, J NEUROTRAUM, V26, P301, DOI 10.1089/neu.2008.0806
   Erixon E, 2009, OTOL NEUROTOL, V30, P14, DOI 10.1097/MAO.0b013e31818a08e8
   Eshraghi AA, 2005, OTOL NEUROTOL, V26, P442, DOI 10.1097/01.mao.0000169791.53201.e1
   Eshraghi AA, 2007, OTOL NEUROTOL, V28, P842, DOI 10.1097/MAO.0b013e31805778fc
   FDA, 2015, FDA EX SUMM PREM POS
   Henry KR, 2003, HEARING RES, V179, P88, DOI 10.1016/S0378-5955(03)00097-2
   HENRY KR, 1984, HEARING RES, V16, P225, DOI 10.1016/0378-5955(84)90111-4
   Hyodo J, 2001, NEUROREPORT, V12, P1983, DOI 10.1097/00001756-200107030-00041
   Jackson AR, 2011, J BIOMECH ENG-T ASME, V133, DOI 10.1115/1.4004944
   Kawai N, 2000, STROKE, V31, P1982, DOI 10.1161/01.STR.31.8.1982
   Keller E, 2009, J NEUROSCI METH, V178, P345, DOI 10.1016/j.jneumeth.2008.12.030
   Klopp-Dutote N, 2016, EUR ANN OTORHINOLARY, V133, P91, DOI 10.1016/j.anorl.2015.11.001
   Levi AD, 2010, NEUROSURGERY, V66, P670, DOI 10.1227/01.NEU.0000367557.77973.5F
   LIBERMAN MC, 1984, HEARING RES, V16, P43, DOI 10.1016/0378-5955(84)90024-8
   Lienhard JH., 2013, HEAT TRANSFER TXB
   Liljemalm R, 2013, LASER SURG MED, V45, P469, DOI 10.1002/lsm.22158
   Manoussaki D, 2000, SIAM J APPL MATH, V61, P369, DOI 10.1137/S0036139999358404
   Markman TM, 2011, J NEURODEV DISORD, V3, P388, DOI 10.1007/s11689-011-9098-z
   Nikolopoulos TP, 1999, LARYNGOSCOPE, V109, P595, DOI 10.1097/00005537-199904000-00014
   OHLEMILLER KK, 1994, HEARING RES, V80, P174, DOI 10.1016/0378-5955(94)90109-0
   OHLEMILLER KK, 1992, HEARING RES, V63, P79, DOI 10.1016/0378-5955(92)90076-Y
   Olson ES, 1999, NATURE, V402, P526, DOI 10.1038/990092
   Park HK, 2001, CHILD NERV SYST, V17, P87, DOI 10.1007/s003819900245
   Petrov PI, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178952
   Rebscher SJ, 2008, J REHABIL RES DEV, V45, P731, DOI 10.1682/JRRD.2007.08.0119
   Salt AN, 2001, HEARING RES, V154, P88, DOI 10.1016/S0378-5955(01)00223-4
   SALT AN, 1986, HEARING RES, V23, P141, DOI 10.1016/0378-5955(86)90011-0
   Smith KD, 2011, P I MECH ENG H, V225, P533, DOI 10.1177/0954411911400156
   Smith LP, 2007, ACTA OTO-LARYNGOL, V127, P228, DOI 10.1080/00016480600794487
   Takeda S, 2008, NEUROREPORT, V19, P1325, DOI 10.1097/WNR.0b013e32830b5f73
   Tamames I, 2016, HEARING RES, V339, P32, DOI 10.1016/j.heares.2016.05.015
   Tobey EA, 2013, INT J AUDIOL, V52, P219, DOI 10.3109/14992027.2012.759666
   Wardrop P, 2005, HEARING RES, V203, P54, DOI 10.1016/j.heares.2004.11.006
   Watanabe F, 2001, NEUROSCIENCE, V102, P639, DOI 10.1016/S0306-4522(00)00510-8
   Zhang KY, 2015, BIOMED ENG ONLINE, V14, DOI 10.1186/s12938-015-0017-5
NR 45
TC 7
Z9 7
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0196-0202
EI 1538-4667
J9 EAR HEARING
JI Ear Hear.
PD JUL-AUG
PY 2018
VL 39
IS 4
BP 712
EP 719
DI 10.1097/AUD.0000000000000529
PG 8
WC Audiology & Speech-Language Pathology; Otorhinolaryngology
SC Audiology & Speech-Language Pathology; Otorhinolaryngology
GA GQ9WZ
UT WOS:000442151500012
PM 29240567
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Ajelli, M
   Moise, IK
   Hutchings, TCSG
   Brown, SC
   Kumar, N
   Johnson, NF
   Beier, JC
AF Ajelli, Marco
   Moise, Imelda K.
   Hutchings, Tricia Caroline S. G.
   Brown, Scott C.
   Kumar, Naresh
   Johnson, Neil F.
   Beier, John C.
TI Host outdoor exposure variability affects the transmission and spread of
   Zika virus: Insights for epidemic control
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID AEDES-AEGYPTI DIPTERA; MIAMI-DADE; DISPERSAL; SURVIVAL; TEMPERATURE;
   CHIKUNGUNYA; POPULATION; CULICIDAE; VECTOR; IMPACT
AB Background
   Zika virus transmission dynamics in urban environments follow a complex spatiotemporal pattern that appears unpredictable and barely related to high mosquito density areas. In this context, human activity patterns likely have a major role in Zika transmission dynamics. This paper examines the effect of host variability in the amount of time spent outdoors on Zika epidemiology in an urban environment.
   Methodology/Principal findings
   First, we performed a survey on time spent outdoors by residents of Miami-Dade County, Florida. Second, we analyzed both the survey and previously published national data on outdoors time in the U.S. to provide estimates of the distribution of the time spent outdoors. Third, we performed a computational modeling evaluation of Zika transmission dynamics, based on the time spent outdoors by each person. Our analysis reveals a strong heterogeneity of the host population in terms of time spent outdoors-data are well captured by skewed gamma distributions. Our model-based evaluation shows that in a heterogeneous population, Zika would cause a lower number of infections than in a more homogenous host population (up to 4-fold differences), but, at the same time, the epidemic would spread much faster. We estimated that in highly heterogeneous host populations the timing of the implementation of vector control measures is the major factor for limiting the number of Zika infections.
   Conclusions/Significance
   Our findings highlight the need of considering host variability in exposure time for managing mosquito-borne infections and call for the revision of the triggers for vector control strategies, which should integrate mosquito density data and human outdoor activity patterns in specific areas.
C1 [Ajelli, Marco] Northeastern Univ, Network Sci Inst, Lab Modeling Biol & Sociotech Syst, Boston, MA 02115 USA.
   [Ajelli, Marco] Bruno Kessler Fdn, Ctr Informat & Commun Technol, Trento, Italy.
   [Moise, Imelda K.; Hutchings, Tricia Caroline S. G.] Univ Miami, Dept Geog & Reg Studies, Coll Arts & Sci, Coral Gables, FL 33124 USA.
   [Moise, Imelda K.; Brown, Scott C.; Kumar, Naresh; Beier, John C.] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA.
   [Brown, Scott C.] Univ Miami, Sch Architecture, Coral Gables, FL 33124 USA.
   [Johnson, Neil F.] Univ Miami, Dept Phys, Coll Arts & Sci, Coral Gables, FL 33124 USA.
RP Ajelli, M (corresponding author), Northeastern Univ, Network Sci Inst, Lab Modeling Biol & Sociotech Syst, Boston, MA 02115 USA.; Ajelli, M (corresponding author), Bruno Kessler Fdn, Ctr Informat & Commun Technol, Trento, Italy.
EM aielli@fbk.eu
RI Ajelli, Marco/AAX-1113-2020; Moise, Imelda K/AAL-7226-2020
OI Ajelli, Marco/0000-0003-1753-4749; Moise, Imelda K/0000-0003-0222-780X
FU CDCUnited States Department of Health & Human ServicesCenters for
   Disease Control & Prevention - USA [1U01CK000510-01]; NATIONAL CENTER
   FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000460]
   Funding Source: NIH RePORTER
FX This research was supported by CDC (https://www-cdc-gov.access.library.miami.edu/) grant
   1U01CK000510-01: Southeastern Regional Center of Excellence in
   Vector-Borne Diseases: the Gateway Program. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Ajelli M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001519
   ANDERSON R M, 1991
   Barabasi AL, 2005, NATURE, V435, P207, DOI 10.1038/nature03459
   Barrera R, 2017, J MED ENTOMOL, V54, P387, DOI 10.1093/jme/tjw187
   Bogoch II, 2016, LANCET, V387, P335, DOI 10.1016/S0140-6736(16)00080-5
   Chadee DD, 2000, J VECTOR ECOL, V25, P158
   Chowell Gerardo, 2016, PLoS Curr, V8, DOI 10.1371/currents.outbreaks.f14b2217c902f453d9320a43a35b9583
   Diffey BL, 2011, BRIT J DERMATOL, V164, P848, DOI 10.1111/j.1365-2133.2010.10165.x
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Ferguson NM, 2006, NATURE, V442, P448, DOI 10.1038/nature04795
   Ferguson NM, 2016, SCIENCE, V353, P353, DOI 10.1126/science.aag0219
   Florida Department of Health, MOSQ BORN DIS SURV
   FOCKS DA, 1993, J MED ENTOMOL, V30, P1003, DOI 10.1093/jmedent/30.6.1003
   Germann TC, 2006, P NATL ACAD SCI USA, V103, P5935, DOI 10.1073/pnas.0601266103
   Gilks W. R., 1995, MARKOV CHAIN MONTE C
   Griffin JT, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000324
   Grubaugh ND, 2017, NATURE, V546, P401, DOI 10.1038/nature22400
   Huff A, 2016, PLOS CURR
   Klepeis NE, 2001, J EXPO ANAL ENV EPID, V11, P231, DOI 10.1038/sj.jea.7500165
   Kraemer MUG, 2015, ELIFE, V4, DOI 10.7554/eLife.08347
   Kucharski AJ, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004726
   Lambrechts L, 2011, P NATL ACAD SCI USA, V108, P7460, DOI 10.1073/pnas.1101377108
   Likos A, 2016, MMWR-MORBID MORTAL W, V65, P1032, DOI 10.15585/mmwr.mm6538e1
   Lloyd AL, 2007, J R SOC INTERFACE, V4, P851, DOI 10.1098/rsif.2007.1064
   Mabaso MLH, 2004, TROP MED INT HEALTH, V9, P846, DOI 10.1111/j.1365-3156.2004.01263.x
   Mammen MP, 2008, PLOS MED, V5, P1605, DOI 10.1371/journal.pmed.0050205
   Merler S, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-252
   Messina JP, 2016, ELIFE, V5, DOI 10.7554/eLife.15272
   Min B, 2011, PHYS REV E, V83, DOI 10.1103/PhysRevE.83.036102
   Moore KJ, 2017, J OCCUP ENVIRON MED, V59, pE17, DOI 10.1097/JOM.0000000000000960
   Moreno-Madrinan MJ, 2017, J MED ENTOMOL, V54, P251, DOI 10.1093/jme/tjw212
   Muir LE, 1998, AM J TROP MED HYG, V58, P277, DOI 10.4269/ajtmh.1998.58.277
   Nishiura H, 2016, TRAVEL MED INFECT DI, V14, P274, DOI 10.1016/j.tmaid.2016.03.016
   Poletti P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018860
   Reiter P, 2003, EMERG INFECT DIS, V9, P86
   REITER P, 1995, AM J TROP MED HYG, V52, P177, DOI 10.4269/ajtmh.1995.52.177
   Reiter P, 2007, VECTOR-BORNE ZOONOT, V7, P261, DOI 10.1089/vbz.2006.0630
   Salje H, 2016, P NATL ACAD SCI USA, V113, P13420, DOI 10.1073/pnas.1611391113
   Salje H, 2016, J INFECT DIS, V213, P604, DOI 10.1093/infdis/jiv470
   Scott TW, 2000, J MED ENTOMOL, V37, P89, DOI 10.1603/0022-2585-37.1.89
   SHEPPARD PM, 1969, J ANIM ECOL, V38, P661, DOI 10.2307/3042
   Simard F, 2005, J MED ENTOMOL, V42, P726, DOI 10.1603/0022-2585(2005)042[0726:GDABSP]2.0.CO;2
   Vazquez A., 2013, TEMPORAL NETWORKS, P161, DOI DOI 10.1007/978-3-642-36461-7_8
   Woolhouse MEJ, 1997, P NATL ACAD SCI USA, V94, P338, DOI 10.1073/pnas.94.1.338
   World Health Organization, ZIK VIR DIS
   Yang HM, 2009, EPIDEMIOL INFECT, V137, P1188, DOI 10.1017/S0950268809002040
   Yoon IK, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001730
   Zhang Q, 2017, P NATL ACAD SCI USA, V114, pE4334, DOI 10.1073/pnas.1620161114
   Zhu L, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0555-0
NR 49
TC 22
Z9 22
U1 0
U2 30
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD SEP
PY 2017
VL 11
IS 9
AR e0005851
DI 10.1371/journal.pntd.0005851
PG 15
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA FI6YN
UT WOS:000412142800020
PM 28910292
OA gold, Green Published, Green Submitted
DA 2021-10-30
ER

PT J
AU Khambaty, T
   Schneiderman, N
   Llabre, MM
   Elfassy, T
   Moncrieft, AE
   Daviglus, M
   Talavera, GA
   Isasi, CR
   Gallo, LC
   Reina, SA
   Vidot, D
   Heiss, G
AF Khambaty, Tasneem
   Schneiderman, Neil
   Llabre, Maria M.
   Elfassy, Tali
   Moncrieft, Ashley E.
   Daviglus, Martha
   Talavera, Gregory A.
   Isasi, Carmen R.
   Gallo, Linda C.
   Reina, Samantha A.
   Vidot, Denise
   Heiss, Gerardo
TI Elucidating the Multidimensionality of Socioeconomic Status in Relation
   to Metabolic Syndrome in the Hispanic Community Health Study/Study of
   Latinos (HCHS/SOL)
SO INTERNATIONAL JOURNAL OF BEHAVIORAL MEDICINE
LA English
DT Article
DE Health disparities; Hispanics; Latinos; Latent models; Metabolic
   syndrome; Socioeconomic status; Women's health
ID CARDIOVASCULAR-DISEASE; CARDIOMETABOLIC RISK; PREVALENCE;
   HISPANICS/LATINOS; DISPARITIES; BIOMARKERS; DESIGN; WOMEN; ASSOCIATION;
   AMERICANS
AB Background Socioeconomic (SES) factors underlying disparities in the prevalence of metabolic syndrome (MetSyn) and consequently, type 2 diabetes among Hispanics/Latino populations are of considerable clinical and public health interest. However, incomplete and/or imprecise measurement of the multidimensional SES construct has impeded a full understanding of how SES contributes to disparities in metabolic disease. Consequently, a latent-variable model of the SES-MetSyn association was investigated and compared with the more typical proxy-variable model. Methods A community-based cross-sectional probability sample (2008-2011) of 14,029 Hispanic/Latino individuals of Puerto Rican, Cuban, Dominican, Central American, South American, and Mexican ancestry living in the USA was used. SES proxy's education, income, and employment were examined as effect indicators of a latent variable, and as individual predictors. MetSyn was defined using 2009 harmonized guidelines, and MetSyn components were also examined individually. Results In multivariate regression analyses, the SES latent variable was associated with 9% decreased odds of MetSyn (95% confidence interval: 0.85, 0.96, P < .001) and was associated with all MetSyn components, except diastolic blood pressure. Additionally, greater income, education, and employment status were associated with 4%, 3%, and 24% decreased odds of having MetSyn, respectively (Ps < .001). The income-MetSyn association was only significant for women and those with current health insurance. Conclusions Hispanic/Latinos exhibit an inverse association between SES and MetSyn of varying magnitudes across SES variables. Public health research is needed to further probe these relationships, particularly among Hispanic/Latina women, to ultimately improve healthcare access to prevent diabetes in this underserved population.
C1 [Khambaty, Tasneem] Univ Maryland Baltimore Cty, Dept Psychol, 1000 Hilltop Circle,Math Psychol 326, Baltimore, MD 21250 USA.
   [Schneiderman, Neil; Llabre, Maria M.; Elfassy, Tali; Moncrieft, Ashley E.; Reina, Samantha A.; Vidot, Denise] Univ Miami, Dept Psychol, 5665 Ponce De Leon Blvd, Coral Gables, FL 33124 USA.
   [Schneiderman, Neil; Llabre, Maria M.; Elfassy, Tali; Moncrieft, Ashley E.; Reina, Samantha A.; Vidot, Denise] Univ Miami, Behav Med Res Ctr, 5665 Ponce De Leon Blvd, Coral Gables, FL 33124 USA.
   [Daviglus, Martha] Univ Illinois, Dept Med, Chicago, IL USA.
   [Talavera, Gregory A.] San Diego State Univ, Grad Sch Publ Hlth, San Diego, CA 92182 USA.
   [Isasi, Carmen R.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA.
   [Gallo, Linda C.] San Diego State Univ, Dept Psychol, San Diego, CA 92182 USA.
   [Heiss, Gerardo] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27515 USA.
RP Khambaty, T (corresponding author), Univ Maryland Baltimore Cty, Dept Psychol, 1000 Hilltop Circle,Math Psychol 326, Baltimore, MD 21250 USA.
EM khambaty@umbc.edu; nschneid@miami.edu; MLlabre@med.miami.edu;
   t.elfassy@med.miami.edu; amoncrieft@miami.edu; daviglus@uic.edu;
   gtalavera@mail.sdsu.edu; carmen.isasi@einsteinmed.org;
   Igallo@mail.sdsu.edu; s.foti@miami.edu; dvidot@miami.edu;
   gerardo_heiss@unc.edu
FU NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [KL2 TR002737] Funding Source: Medline;
   NHLBI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [N01HC65236, T32 HL007426, N01-HC65237, N01-HC65236,
   N01HC65237, T32 HL07426, N01HC65234, N01-HC65235, N01HC65235,
   N01-HC25233, N01-HC65234, N01HC65233] Funding Source: Medline; NIDDK NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Diabetes &
   Digestive & Kidney Diseases (NIDDK) [P30 DK111022] Funding Source:
   Medline
CR Adler NE, 2010, ANN NY ACAD SCI, V1186, P1, DOI 10.1111/j.1749-6632.2009.05385.x
   Arguelles W, 2015, INT J CARDIOL, V184, P373, DOI 10.1016/j.ijcard.2015.02.100
   Ballantyne CM, 2008, INT J OBESITY, V32, pS21, DOI 10.1038/ijo.2008.31
   Blumenthal JA, 2010, ARCH INTERN MED, V170, P126, DOI 10.1001/archinternmed.2009.470
   Bradley RH, 2002, ANNU REV PSYCHOL, V53, P371, DOI 10.1146/annurev.psych.53.100901.135233
   Chichlowska KL, 2008, PSYCHOSOM MED, V70, P986, DOI 10.1097/PSY.0b013e318183a491
   Dallongeville J, 2005, DIABETES CARE, V28, P409, DOI 10.2337/diacare.28.2.409
   DeVoe JE, 2003, AM J PUBLIC HEALTH, V93, P786, DOI 10.2105/AJPH.93.5.786
   DeVoe JE, 2012, MATERN CHILD HLTH J, V16, P306, DOI 10.1007/s10995-011-0762-4
   Elovainio M, 2011, AM J EPIDEMIOL, V174, P779, DOI 10.1093/aje/kwr149
   Ennis S, 2011, HISPANIC POPULATION, V2014
   Ford ES, 2008, DIABETES CARE, V31, P1898, DOI 10.2337/dc08-0423
   Galanti Geri-Ann, 2003, J Transcult Nurs, V14, P180, DOI 10.1177/1043659603014003004
   Gallo LC, 2014, ETHNIC DIS, V24, P77
   Gallo LC, 2012, HEALTH PSYCHOL, V31, P334, DOI 10.1037/a0025689
   Go AS, 2013, CIRCULATION, V127, pE6, DOI 10.1161/CIR.0b013e31828124ad
   Gonzalez HM, 2009, J GEN INTERN MED, V24, P528, DOI 10.1007/s11606-009-1076-8
   Gupta R, 2012, ASS ED OCCUPATIONAL
   Heisler M, 2007, ARCH INTERN MED, V167, P1853, DOI 10.1001/archinte.167.17.1853
   Heiss G, 2014, DIABETES CARE, V37, P2391, DOI 10.2337/dc13-2505
   Kagura J, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-008805
   Kang HT, 2014, MENOPAUSE, V21, P221, DOI 10.1097/GME.0b013e3182987078
   Kavanagh A, 2010, SOC SCI MED, V71, P1150, DOI 10.1016/j.socscimed.2010.05.038
   Kutner M., 2006, 2006483 NCES
   Lavange LM, 2010, ANN EPIDEMIOL, V20, P642, DOI 10.1016/j.annepidem.2010.05.006
   Llabre MM, 2015, ANN EPIDEMIOL, V25, P480, DOI 10.1016/j.annepidem.2015.02.010
   Loucks EB, 2007, ANN EPIDEMIOL, V17, P19, DOI 10.1016/j.annepidem.2006.07.002
   Lucove JC, 2007, AM J PUBLIC HEALTH, V97, P234, DOI 10.2105/AJPH.2006.087429
   McClurkin MA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141534
   McCurley JL, 2017, ANN BEHAV MED, V51, P477, DOI 10.1007/s12160-016-9871-z
   Pampel FC, 2010, ANNU REV SOCIOL, V36, P349, DOI 10.1146/annurev.soc.012809.102529
   Piccolo RS, 2016, DIABETES CARE, V39, P1208, DOI 10.2337/dc15-2255
   Rosero-Bixby L, 2009, J GERONTOL B-PSYCHOL, V64, P105, DOI 10.1093/geronb/gbn004
   Ruiz JM, 2016, GROUP PROCESS INTERG, V19, P462, DOI 10.1177/1368430216638540
   Salsberry PJ, 2007, AM J PREV MED, V33, P114, DOI 10.1016/j.amepre.2007.03.017
   Schneiderman N, 2014, DIABETES CARE, V37, P2233, DOI 10.2337/dc13-2939
   Schumacher JR, 2013, MED CARE, V51, P654, DOI 10.1097/MLR.0b013e3182992c5a
   Sokka T, 2008, CLIN EXP RHEUMATOL, V26, pS35, DOI 10.1161/CIRCULATIONAHA.109.192644
   Sorlie PD, 2010, ANN EPIDEMIOL, V20, P629, DOI 10.1016/j.annepidem.2010.03.015
   Stringhini S., 2012, CONTRIBUTION MODIFIA
   Thurston RC, 2005, AM J EPIDEMIOL, V162, P57, DOI 10.1093/aje/kwi159
   United States Department of Health and Human Services, 2011, HHS ACT PLAN RED RAC
   Yang XH, 2012, INT J PUBLIC HEALTH, V57, P551, DOI 10.1007/s00038-012-0347-z
NR 43
TC 1
Z9 1
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1070-5503
EI 1532-7558
J9 INT J BEHAV MED
JI Int. J. Behav. Med.
PD APR
PY 2020
VL 27
IS 2
BP 188
EP 199
DI 10.1007/s12529-020-09847-y
PG 12
WC Psychology, Clinical
SC Psychology
GA KY5XY
UT WOS:000522647700006
PM 31933127
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Vendrame, F
   Padilla, N
   Peixoto, E
   Baidal, D
   Lagari, V
   Gil, AA
   Mantero, A
   Messinger, S
   Ricordi, C
   Alejandro, R
AF Vendrame, Francesco
   Padilla, Nathalia
   Peixoto, Eduardo
   Baidal, David
   Lagari, Violet
   Gil, Ana Alvarez
   Mantero, Alejandro
   Messinger, Shari
   Ricordi, Camillo
   Alejandro, Rodolfo
TI Chronic Liraglutide Administration Fails to Suppress Postprandial
   Glucagon Levels in Type 1 Diabetic Islet Allograft Recipients With Graft
   Dysfunction
SO TRANSPLANTATION
LA English
DT Letter
ID IMPACT
C1 [Vendrame, Francesco; Padilla, Nathalia; Peixoto, Eduardo; Baidal, David; Lagari, Violet; Gil, Ana Alvarez; Ricordi, Camillo; Alejandro, Rodolfo] Univ Miami, Miller Sch Med, Diabet Res Inst, Miami, FL 33136 USA.
   [Vendrame, Francesco; Baidal, David; Lagari, Violet; Alejandro, Rodolfo] Univ Miami, Miller Sch Med, Div Endocrinol Diabet & Metab, Dept Med, Miami, FL 33136 USA.
   [Peixoto, Eduardo] Framingham Union Hosp, Dept Internal Med, Metrowest Med Ctr, Boston, MA USA.
   [Mantero, Alejandro; Messinger, Shari] Univ Miami, Dept Publ Hlth Sci, Miami, FL 33136 USA.
RP Alejandro, R (corresponding author), Univ Miami, Miller Sch Med, 1450 NW 10th Ave, Miami, FL 33136 USA.
EM ralejand@med.miami.edu
RI Padilla, Nathalia/AAQ-9596-2020; RICORDI, CAMILLO/AAA-4740-2019;
   Mantero, Alejandro/AAS-6415-2021
OI Padilla, Nathalia/0000-0002-7177-1107; 
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [MO1RR16587, 1RO1-DK55347, IU42
   RR016603, 1UL1TR000460]; Miami Clinical and Translational Science
   Institute; National Center for Advancing Translational SciencesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Advancing Translational
   Sciences (NCATS); National Institute on Minority Health and Health
   DisparitiesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Minority
   Health & Health Disparities (NIMHD); Juvenile Diabetes Research
   Foundation InternationalJuvenile Diabetes Research Foundation
   [4-200-946]; State of Florida; Diabetes Research Institute Foundation;
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [KL2TR000461, UL1TR000460] Funding Source: NIH RePORTER; NATIONAL CENTER
   FOR RESEARCH RESOURCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Research Resources (NCRR) [U42RR016603, M01RR016587] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Diabetes &
   Digestive & Kidney Diseases (NIDDK) [R01DK055347] Funding Source: NIH
   RePORTER
FX This work was supported by NIH grants MO1RR16587, 1RO1-DK55347, IU42
   RR016603, and 1UL1TR000460, Miami Clinical and Translational Science
   Institute, from the National Center for Advancing Translational Sciences
   and the National Institute on Minority Health and Health Disparities,
   Juvenile Diabetes Research Foundation International 4-200-946, State of
   Florida, and the Diabetes Research Institute Foundation.
CR Faradji RN, 2009, CELL TRANSPLANT, V18, P1247, DOI 10.3727/096368909X474456
   Fiorina P, 2008, AM J TRANSPLANT, V8, P1990, DOI 10.1111/j.1600-6143.2008.02353.x
   Kramer CK, 2015, J CLIN ENDOCR METAB, V100, P3702, DOI 10.1210/jc.2015-2725
NR 3
TC 1
Z9 1
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0041-1337
EI 1534-6080
J9 TRANSPLANTATION
JI Transplantation
PD JAN
PY 2018
VL 102
IS 1
BP e39
EP e40
DI 10.1097/TP.0000000000001964
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA FS0HD
UT WOS:000419453800017
PM 28957843
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Santander, AM
   Lopez-Ocejo, O
   Casas, O
   Agostini, T
   Sanchez, L
   Lamas-Basulto, E
   Carrio, R
   Cleary, MP
   Gonzalez-Perez, RR
   Torroella-Kouri, M
AF Santander, Ana M.
   Lopez-Ocejo, Omar
   Casas, Olivia
   Agostini, Thais
   Sanchez, Lidia
   Lamas-Basulto, Eduardo
   Carrio, Roberto
   Cleary, Margot P.
   Gonzalez-Perez, Ruben R.
   Torroella-Kouri, Marta
TI Paracrine Interactions between Adipocytes and Tumor Cells Recruit and
   Modify Macrophages to the Mammary Tumor Microenvironment: The Role of
   Obesity and Inflammation in Breast Adipose Tissue
SO CANCERS
LA English
DT Article
DE breast cancer; obesity; breast adipose tissue; inflammation; tumor
   microenvironment; macrophages; adipocytes; breast tumor cells;
   chemotaxis; diet-induced obesity; tumor progression
ID BEARING MICE; AROMATASE EXPRESSION; GROWTH-FACTOR; CANCER-RISK; KAPPA-B;
   LEPTIN; PROGRESSION; INFILTRATION; MECHANISMS; INITIATION
AB The relationship between obesity and breast cancer (BC) has focused on serum factors. However, the mammary gland contains adipose tissue (AT) which may enable the crosstalk between adipocytes and tumor cells contributing to tumor macrophage recruitment. We hypothesize that the breast AT (bAT) is inflamed in obese females and plays a major role in breast cancer development. The effects of this interplay on macrophage chemotaxis were examined in vitro, using co-cultures of mouse macrophages, mammary tumor cells and adipocytes. Macrophages were exposed to the adipocyte and tumor paracrine factors leptin, CCL2 and lauric acid (alone or in combinations). In cell supernatants Luminex identified additional molecules with chemotactic and other pro-tumor functions. Focus on the adipokine leptin, which has been shown to have a central role in breast cancer pathogenesis, indicated it modulates macrophage phenotypes and functions. In vivo experiments demonstrate that mammary tumors from obese mice are larger and that bAT from obese tumor-bearers contains higher numbers of macrophages/CLS and hypertrophic adipocytes than bAT from lean tumor-bearers, thus confirming it is more inflamed. Also, bAT distal from the tumor is more inflamed in obese than in lean mice. Our results reveal that bAT plays a role in breast cancer development in obesity.
C1 [Santander, Ana M.; Lopez-Ocejo, Omar; Casas, Olivia; Agostini, Thais; Sanchez, Lidia; Lamas-Basulto, Eduardo; Carrio, Roberto; Torroella-Kouri, Marta] Univ Miami Miller Sch Med, Dept Microbiol & Immunol, 1600 NW 10th Ave, Miami, FL 33136 USA.
   [Cleary, Margot P.] Univ Minnesota, Hormel Inst, Austin, MN 55912 USA.
   [Gonzalez-Perez, Ruben R.] Morehouse Sch Med, Dept Microbiol Biochem & Immunol, Atlanta, GA 30314 USA.
   [Torroella-Kouri, Marta] Univ Miami Miller Sch Med, Sylvester Comprehens Canc Ctr, 1475 NW 12th Ave, Miami, FL 33136 USA.
RP Torroella-Kouri, M (corresponding author), Univ Miami Miller Sch Med, Dept Microbiol & Immunol, 1600 NW 10th Ave, Miami, FL 33136 USA.; Torroella-Kouri, M (corresponding author), Univ Miami Miller Sch Med, Sylvester Comprehens Canc Ctr, 1475 NW 12th Ave, Miami, FL 33136 USA.
EM AMsantander@med.miami.edu; olopez2@med.miami.edu; o.casas1@umiami.edu;
   Thais.Agostini@treetop.com; lgs20@miami.edu; e.lamasbasulto@umiami.edu;
   rcarrio@med.miami.edu; mpcleary@hi.umn.edu; rgonzalez@msm.edu;
   mtorroella@med.miami.edu
OI Carrio, Roberto/0000-0001-5527-8403
FU National Institute of Health (NIH)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [R21CA153172];
   The Hormel Foundation and Paint the Town Pink to MPC [R01CA157012];
   NATIONAL CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [R01CA157012, R21CA153172] Funding Source: NIH RePORTER;
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000460] Funding Source: NIH RePORTER
FX This work was supported by the National Institute of Health (NIH) grant
   R21CA153172 to MTK and grants R01CA157012, The Hormel Foundation and
   Paint the Town Pink to MPC.
CR American Cancer Society, 2012, AMERICAN CANCER SOCI
   Ando S, 2012, NAT REV ENDOCRINOL, V8, P263, DOI 10.1038/nrendo.2011.184
   Arendt LM, 2013, CANCER RES, V73, P6080, DOI 10.1158/0008-5472.CAN-13-0926
   Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013
   Battle M, 2014, INT J CANCER, V134, P1605, DOI 10.1002/ijc.28496
   Ben-Neriah Y, 2011, NAT IMMUNOL, V12, P715, DOI 10.1038/ni.2060
   Bingle L, 2002, J PATHOL, V196, P254, DOI 10.1002/path.1027
   Calderon CL, 2008, INT J ONCOL, V32, P713
   Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423
   Caso R, 2010, INT J ONCOL, V37, P891, DOI 10.3892/ijo_00000740
   Cinti S, 2005, J LIPID RES, V46, P2347, DOI 10.1194/jlr.M500294-JLR200
   Cleary MP, 2004, INT J OBESITY, V28, P956, DOI 10.1038/sj.ijo.0802664
   Cleary MP, 2004, EXP BIOL MED, V229, P182, DOI 10.1177/153537020422900207
   Cleary MP, 1997, P SOC EXP BIOL MED, V216, P28, DOI 10.3181/00379727-216-44153B
   Dethlefsen C, 2013, BREAST CANCER RES TR, V138, P657, DOI 10.1007/s10549-013-2488-z
   Dirat B, 2011, CANCER RES, V71, P2455, DOI 10.1158/0008-5472.CAN-10-3323
   Dogan S, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1840
   Fontana L, 2007, DIABETES, V56, P1010, DOI 10.2337/db06-1656
   Fujimoto H, 2009, INT J CANCER, V125, P1276, DOI 10.1002/ijc.24378
   Gilbert CA, 2013, ANNU REV MED, V64, P45, DOI 10.1146/annurev-med-121211-091527
   Gonzalez RR, 2006, J BIOL CHEM, V281, P26320, DOI 10.1074/jbc.M601991200
   Gonzalez RR, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2321
   Gruen ML, 2007, AM J PHYSIOL-CELL PH, V293, pC1481, DOI 10.1152/ajpcell.00062.2007
   Guo SC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021467
   Guo SC, 2011, BBA-REV CANCER, V1815, P197, DOI 10.1016/j.bbcan.2010.12.002
   Gutierrez DA, 2012, J ENDOCRINOL, V212, P343, DOI 10.1530/JOE-11-0338
   Hendrayani SF, 2014, J BIOL CHEM, V289, P30962, DOI 10.1074/jbc.M114.594044
   Hu X, 2002, J NATL CANCER I, V94, P1704, DOI 10.1093/jnci/94.22.1704
   Huang SR, 2012, J LIPID RES, V53, P2002, DOI 10.1194/jlr.D029546
   Lee FYJ, 1999, AM J PHYSIOL-CELL PH, V276, pC386, DOI 10.1152/ajpcell.1999.276.2.C386
   Lumeng CN, 2007, DIABETES, V56, P16, DOI 10.2337/db06-1076
   Lumeng CN, 2007, J CLIN INVEST, V117, P175, DOI 10.1172/JCI29881
   Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205
   Matarese G, 2005, J IMMUNOL, V174, P3137, DOI 10.4049/jimmunol.174.6.3137
   Morris PG, 2011, CANCER PREV RES, V4, P1021, DOI 10.1158/1940-6207.CAPR-11-0110
   Nicolini A, 2006, CYTOKINE GROWTH F R, V17, P325, DOI 10.1016/j.cytogfr.2006.07.002
   Ogden Cynthia L, 2012, NCHS Data Brief, P1
   Pollard JW, 2008, J LEUKOCYTE BIOL, V84, P623, DOI 10.1189/jlb.1107762
   Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256
   Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014
   Rodriguez D, 2013, CELL IMMUNOL, V283, P51, DOI 10.1016/j.cellimm.2013.06.008
   Rogers NH, 2009, ENDOCRINOLOGY, V150, P2161, DOI 10.1210/en.2008-1405
   Rose DP, 2014, BIOFACTORS, V40, P1, DOI 10.1002/biof.1109
   Rose DP, 2010, MATURITAS, V66, P33, DOI 10.1016/j.maturitas.2010.01.019
   Sabatino R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101260
   Suba Z, 2013, RECENT PAT ANTI-CANC, V8, P154
   Subbaramaiah K, 2011, CANCER PREV RES, V4, P329, DOI 10.1158/1940-6207.CAPR-10-0381
   SUGIURA K, 1952, CANCER, V5, P382, DOI 10.1002/1097-0142(195203)5:2<382::AID-CNCR2820050229>3.0.CO;2-3
   Surmi BK, 2008, FUTURE LIPIDOL, V3, P545, DOI 10.2217/17460875.3.5.545
   Tartaglia LA, 1997, J BIOL CHEM, V272, P6093, DOI 10.1074/jbc.272.10.6093
   Torroella-Kouri M, 2005, CANCER RES, V65, P10578, DOI 10.1158/0008-5472.CAN-05-0365
   Torroella-Kouri M, 2013, IMMUNOL RES, V57, P86, DOI 10.1007/s12026-013-8438-3
   Torroella-Kouri M, 2009, CANCER RES, V69, P4800, DOI 10.1158/0008-5472.CAN-08-3427
   Ueno T, 2000, CLIN CANCER RES, V6, P3282
   Vaughan T, 2010, MOL IMMUNOL, V47, P2515, DOI 10.1016/j.molimm.2010.06.006
   Vona-Davis L, 2007, ENDOCR-RELAT CANCER, V14, P189, DOI 10.1677/ERC-06-0068
   Wong SW, 2009, J BIOL CHEM, V284, P27384, DOI 10.1074/jbc.M109.044065
NR 57
TC 55
Z9 57
U1 0
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD MAR
PY 2015
VL 7
IS 1
BP 143
EP 178
DI 10.3390/cancers7010143
PG 36
WC Oncology
SC Oncology
GA V47KP
UT WOS:000209951000006
PM 25599228
OA Green Submitted, gold, Green Published
DA 2021-10-30
ER

PT J
AU Valencia, WM
   Stoutenberg, M
   Florez, H
AF Valencia, Willy Marcos
   Stoutenberg, Mark
   Florez, Hermes
TI Weight Loss and Physical Activity for Disease Prevention in Obese Older
   Adults: an Important Role for Lifestyle Management
SO CURRENT DIABETES REPORTS
LA English
DT Article
DE Obese older adult; Physical activity; Intentional weight loss; Diabetes;
   Obesity paradox; Cardiorespiratory fitness; Lifestyle interventions;
   Disease prevention
ID BODY-MASS INDEX; METABOLICALLY HEALTHY OBESITY; TYPE-2
   DIABETES-MELLITUS; ALL-CAUSE MORTALITY; CARDIORESPIRATORY FITNESS;
   CARDIOVASCULAR-DISEASE; SARCOPENIC OBESITY; LOSS INTERVENTION;
   RISK-FACTORS; PARADOX
AB Weight loss in older adults has been a controversial topic for more than a decade. An obesity paradox has been previously described and the issue of weight status on health outcomes remains a highly debated topic. However, there is little doubt that physical activity (PA) has a myriad of benefits in older adults, especially in obese individuals who are inactive and have a poor cardiometabolic profile. In this review, we offer a critical view to clarify misunderstandings regarding the obesity paradox, particularly as it relates to obese older adults. We also review the evidence on PA and lifestyle interventions for the improvement of cardiorespiratory fitness, which can prevent disease and provide benefits to obese older adults, independent of weight changes.
C1 [Valencia, Willy Marcos; Florez, Hermes] Miami VA Healthcare Syst, GRECC, Miami, FL 33125 USA.
   [Valencia, Willy Marcos; Stoutenberg, Mark; Florez, Hermes] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA.
   [Florez, Hermes] Univ Miami, Miller Sch Med, Dept Med, Div Geriatr Med & Endocrinol, Miami, FL 33136 USA.
RP Valencia, WM (corresponding author), Miami VA Healthcare Syst, GRECC, Miami, FL 33125 USA.
EM wvalenciarodrigo@med.miami.edu; mstoutenberg@med.miami.edu;
   hflorez@med.miami.edu
FU NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [1KL2TR000461] Funding Source: Medline;
   ASPE HHS [1R18AE000049-01] Funding Source: Medline; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [KL2TR000461]
   Funding Source: NIH RePORTER
CR AHA, 2013, AHA FACTS VER HEAV H
   AHA, 2014, TREAT OB DIS
   Ali MK, 2012, HEALTH AFFAIR, V31, P67, DOI 10.1377/hlthaff.2011.1009
   Allison DB, 2008, OBESITY, V16, P1161, DOI 10.1038/oby.2008.231
   Alpert MA, 2014, PROG CARDIOVASC DIS, V56, P391, DOI 10.1016/j.pcad.2013.09.003
   AMA News Room, 2013, AMA NEWS ROOM
   Atkins JL, 2014, J AM GERIATR SOC, V62, P253, DOI 10.1111/jgs.12652
   Avenell A, 2004, HEALTH TECHNOL ASSES, V8, P1
   Banack HR, 2014, PREV MED, V62, P96, DOI 10.1016/j.ypmed.2014.02.003
   Barnes PM, 2003, CDC NATL CTR HLTH ST, V333, P15
   Barry VW, 2014, PROG CARDIOVASC DIS, V56, P382, DOI 10.1016/j.pcad.2013.09.002
   Bastien M, 2014, PROG CARDIOVASC DIS, V56, P369, DOI 10.1016/j.pcad.2013.10.016
   Basu S, 2014, AM J PUBLIC HEALTH, V104, P1209, DOI 10.2105/AJPH.2013.301674
   Biedenweg K, 2014, J PRIM PREV, V35, P1, DOI 10.1007/s10935-013-0331-2
   Bluher S, 2012, CURR DIABETES REP, V12, P147, DOI 10.1007/s11892-012-0255-x
   Bouchonville MF, 2013, CURR OPIN ENDOCRINOL, V20, P412, DOI 10.1097/01.med.0000433071.11466.7f
   Brown CJ, 2013, JAMA-J AM MED ASSOC, V310, P1168, DOI 10.1001/jama.2013.276566
   Carnethon MR, 2012, JAMA-J AM MED ASSOC, V308, P581, DOI 10.1001/jama.2012.9282
   CDC, 2014, CDC OV OB FACTS
   Chrostowska M, 2013, BEST PRACT RES CL EN, V27, P147, DOI 10.1016/j.beem.2013.01.004
   Chrysant SG, 2013, J AM SOC HYPERTENS, V7, P85, DOI 10.1016/j.jash.2012.11.008
   Chung JY, 2013, ARCH GERONTOL GERIAT, V56, P270, DOI 10.1016/j.archger.2012.09.007
   Church TS, 2005, ARCH INTERN MED, V165, P2114, DOI 10.1001/archinte.165.18.2114
   Clark AL, 2014, PROG CARDIOVASC DIS, V56, P409, DOI 10.1016/j.pcad.2013.10.004
   Crandall J, 2006, J GERONTOL A-BIOL, V61, P1075
   Darmon P, 2013, CURR OPIN CLIN NUTR, V16, P284, DOI 10.1097/MCO.0b013e32835f503f
   Davis NJ, 2013, J ACAD NUTR DIET, V113, P1455, DOI 10.1016/j.jand.2013.07.003
   De Schutter A, 2014, PROG CARDIOVASC DIS, V56, P401, DOI 10.1016/j.pcad.2013.08.003
   DeFronzo RA, 2011, J CLIN ENDOCR METAB, V96, P2354, DOI 10.1210/jc.2011-0246
   Delahanty LM, 2014, J ACAD NUTR DIET, V114, P537, DOI 10.1016/j.jand.2014.01.008
   Delahanty LM, 2013, DIABETES CARE, V36, P34, DOI 10.2337/dc12-0733
   Espeland MA, 2013, J AM GERIATR SOC, V61, P912, DOI 10.1111/jgs.12271
   Flegal KM, 2013, JAMA-J AM MED ASSOC, V309, P71, DOI 10.1001/jama.2012.113905
   Florez H, 2012, J GEN INTERN MED, V27, P1594, DOI 10.1007/s11606-012-2122-5
   Florez H, 2012, JAMA-J AM MED ASSOC, V308, P619, DOI 10.1001/jama.2012.9776
   Gaesser GA, 2011, PHYSICIAN SPORTSMED, V39, P87, DOI 10.3810/psm.2011.05.1898
   Grabowski DC, 2001, J AM GERIATR SOC, V49, P968, DOI 10.1046/j.1532-5415.2001.49189.x
   Gruberg L, 2002, J AM COLL CARDIOL, V39, P578, DOI 10.1016/S0735-1097(01)01802-2
   Hainer V, 2013, DIABETES CARE, V36, pS276, DOI 10.2337/dcS13-2023
   Hamer M, 2012, J CLIN ENDOCR METAB, V97, P2482, DOI 10.1210/jc.2011-3475
   Harwell TS, 2011, PRIM CARE DIABETES, V5, P125, DOI 10.1016/j.pcd.2010.12.001
   Herman WH, 2013, AM J MANAG CARE, V19, P194
   Hinnouho GM, 2013, DIABETES CARE, V36, P2294, DOI 10.2337/dc12-1654
   Jakicic JM, 2009, INT J OBESITY, V33, P305, DOI 10.1038/ijo.2008.280
   Jensen GL, 2010, CURR OPIN CLIN NUTR, V13, P46, DOI 10.1097/MCO.0b013e32833309cf
   Jensen MK, 2013, CIRCULATION, V127, DOI 10.1161/01.cir.0000437739.71477.ee
   Johnson JA, 2013, J GERIATR PHYS THER, V36, P175, DOI 10.1519/JPT.0b013e318282d2d3
   Kalyani RR, 2014, LANCET DIABETES ENDO, V2, P819, DOI 10.1016/S2213-8587(14)70034-8
   Kannel WB, 2002, AM J CARDIOL, V90, P697, DOI 10.1016/S0002-9149(02)02592-4
   Kirkman MS, 2012, J AM GERIATR SOC, V60, P2342, DOI 10.1111/jgs.12035
   Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512
   Korytkowski Mary T, 2013, Indian J Endocrinol Metab, V17, pS650, DOI 10.4103/2230-8210.123557
   Kowall B, 2012, INT J OBESITY, V36, P826, DOI 10.1038/ijo.2011.161
   Kramer CK, 2013, ANN INTERN MED, V159, P758, DOI 10.7326/0003-4819-159-11-201312030-00008
   Krukowski RA, 2013, PREV MED, V57, P400, DOI 10.1016/j.ypmed.2013.06.027
   Krukowski RA, 2013, GERONTOLOGIST, V53, P162, DOI 10.1093/geront/gns094
   Labounty TM, 2013, EUR HEART J-CARD IMG, V14, P456, DOI 10.1093/ehjci/jes179
   Lavie CJ, 2014, J AM COLL CARDIOL, V63, P1345, DOI 10.1016/j.jacc.2014.01.022
   Lavie CJ, 2013, JACC-HEART FAIL, V1, P93, DOI 10.1016/j.jchf.2013.01.006
   Loef M, 2013, OBESITY, V21, pE51, DOI 10.1002/oby.20037
   Manini TM, 2012, J GERONTOL A-BIOL, V67, P28, DOI 10.1093/gerona/glr010
   McAuley PA, 2014, PROG CARDIOVASC DIS, V56, P434, DOI 10.1016/j.pcad.2013.09.006
   McClain J, 2013, OBESITY, V21, P1056, DOI 10.1002/oby.20090
   Mechanick JI, 2012, ENDOCR PRACT, V18, P642, DOI 10.4158/EP12160.PS
   Michael YL, 2014, SOC SCI MED, V102, P129, DOI 10.1016/j.socscimed.2013.11.047
   National Council on Aging. Center for aging, ENH FITN
   Pahor M, 2014, JAMA-J AM MED ASSOC, V311, P2387, DOI 10.1001/jama.2014.5616
   Preston SH, 2014, EPIDEMIOLOGY, V25, P454, DOI 10.1097/EDE.0000000000000075
   Prohaska T, 2006, J GERONTOL B-PSYCHOL, V61, pS267, DOI 10.1093/geronb/61.5.S267
   Reed JL, 2013, CAN J DIABETES, V37, P121, DOI 10.1016/j.jcjd.2013.03.022
   Rejeski WJ, 2012, NEW ENGL J MED, V366, P1209, DOI 10.1056/NEJMoa1110294
   Stenholm S, 2008, CURR OPIN CLIN NUTR, V11, P693, DOI 10.1097/MCO.0b013e328312c37d
   Swift DL, 2014, PROG CARDIOVASC DIS, V56, P441, DOI 10.1016/j.pcad.2013.09.012
   Tabak AG, 2012, LANCET, V379, P2279, DOI 10.1016/S0140-6736(12)60283-9
   Tobias DK, 2014, NEW ENGL J MED, V370, P233, DOI 10.1056/NEJMoa1304501
   TOS, 2014, ATOS OB BIAS STIGM
   Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801
   Villareal DT, 2004, OBES RES, V12, P913, DOI 10.1038/oby.2004.111
   Visser M, 2011, P NUTR SOC, V70, P114, DOI 10.1017/S0029665110003939
   Wang FF, 2005, OBES RES, V13, P1450, DOI 10.1038/oby.2005.175
   Wassel CL, 2013, OBESITY, V21, P1704, DOI 10.1002/oby.20111
   Waters DL, 2013, EXP GERONTOL, V48, P1054, DOI 10.1016/j.exger.2013.02.005
   West DS, 2011, AM J PREV MED, V41, P385, DOI 10.1016/j.amepre.2011.06.041
   WHO, 2013, WHO 10 FACTS OB
   [WHO] World Health Organization, 2003, WHO GLOB STRAT DIET
   Wildman RP, 2008, ARCH INTERN MED, V168, P1617, DOI 10.1001/archinte.168.15.1617
   Wing RR, 2004, OBES RES, V12, P1426
   Zheng H, 2013, AM J EPIDEMIOL, V178, P1591, DOI 10.1093/aje/kwt179
NR 88
TC 17
Z9 17
U1 0
U2 26
PU CURRENT MEDICINE GROUP
PI PHILADELPHIA
PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA
SN 1534-4827
EI 1539-0829
J9 CURR DIABETES REP
JI Curr. Diabetes Rep.
PD OCT
PY 2014
VL 14
IS 10
AR 539
DI 10.1007/s11892-014-0539-4
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AP1EX
UT WOS:000341810900011
PM 25183491
DA 2021-10-30
ER

PT J
AU Tenenbaum, JD
   Goodman, KW
AF Tenenbaum, Jessica D.
   Goodman, Kenneth W.
TI Beyond the Genetic Information Nondiscrimination Act: ethical and
   economic implications of the exclusion of disability, long-term care and
   life insurance
SO PERSONALIZED MEDICINE
LA English
DT Article
DE economics; ethical issues; genomics; policy issues; regulatory issues
AB The Genetic Information Nondiscrimination Act (GINA) was intended to protect individuals in the USA from discrimination based on their genetic data, but does not apply to life, long-term care or disability insurance. Patient advocates and ethicists have argued that GINA does not go far enough. Others express concerns for the viability of insurance companies if millions of potential customers know more than professional actuaries. Here we discuss the exclusion of certain insurance types from GINA. We explore the ethical and economic implications of this distinction, and potential paths forward. We suggest that because long-term care and disability insurance can be essential for well-being, there is no good reason to place them in a class with life insurance and therefore beyond GINA's reach.
C1 [Tenenbaum, Jessica D.] Duke Univ, Dept Biostat & Bioinformat, Durham, NC 27710 USA.
   [Goodman, Kenneth W.] Univ Miami, Inst Bioeth & Hlth Policy, Miami, FL 33101 USA.
RP Tenenbaum, JD (corresponding author), Duke Univ, Dept Biostat & Bioinformat, Durham, NC 27710 USA.
EM jessie.tenenbaum@duke.edu
FU Duke Translational Medicine Institute; National Center for Advancing
   Translational SciencesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [UL1RR024128, 1UL1TR000460];
   University of Miami CTSI; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1TR000460] Funding Source: NIH
   RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Research Resources (NCRR) [UL1RR024128] Funding
   Source: NIH RePORTER
FX JD Tenenbaum's work on this paper is supported by the Duke Translational
   Medicine Institute, funded by the National Center for Advancing
   Translational Sciences grant UL1RR024128. KW Goodman's work on this
   paper is supported by the University of Miami CTSI, funded by the
   National Center for Advancing Translational Sciences grant 1UL1TR000460.
   The authors have no other relevant affiliations or financial involvement
   with any organization or entity with a financial interest in or
   financial conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR Collins F, 2015, THE DIANE REHM SHOW
   Goodman KW, 2015, ETHICS MED INFORM TE
   Ioannidis JPA, 2005, PLOS MED, V2, P696, DOI 10.1371/journal.pmed.0020124
   Maruthappu M, 2013, ANN MED SURG, V2, P15, DOI 10.1016/S2049-0801(13)70021-9
   McCall N, 2001, LONG TERM CARE DEFIN, P3
   McGuire AL, 2009, GENOME MED, V1, DOI 10.1186/gm6
   Papadimos Thomas J, 2007, Philos Ethics Humanit Med, V2, P2, DOI 10.1186/1747-5341-2-2
   Parkman AA, 2015, J GENET COUNS, V24, P512, DOI 10.1007/s10897-014-9771-y
   Rosenbaum S, 2003, J LAW MED ETHICS, V31, P94, DOI 10.1111/j.1748-720X.2003.tb00767.x
   Rothstein MA, 2007, AM J BIOETHICS, V7, P38, DOI 10.1080/15265160601171887
   Shulman MA, 2015, ANESTHESIOLOGY, V122, P524, DOI 10.1097/ALN.0000000000000586
   Tenenbaum JD, 2012, J PERS MED, V2, P192, DOI 10.3390/jpm2040192
NR 12
TC 3
Z9 3
U1 0
U2 18
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1741-0541
EI 1744-828X
J9 PERS MED
JI Pers. Med.
PD MAR
PY 2017
VL 14
IS 2
BP 153
EP 157
DI 10.2217/pme-2016-0078
PG 5
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA EK9CJ
UT WOS:000394221200009
PM 29754558
OA Green Published
DA 2021-10-30
ER

PT J
AU Li, L
   Mao, HZ
   Ishwaran, H
   Rajeswaran, J
   Ehrlinger, J
   Blackstone, EH
AF Li, Liang
   Mao, Huzhang
   Ishwaran, Hemant
   Rajeswaran, Jeevanantham
   Ehrlinger, John
   Blackstone, Eugene H.
TI Estimating the prevalence of atrial fibrillation from a three-class
   mixture model for repeated diagnoses
SO BIOMETRICAL JOURNAL
LA English
DT Article
DE Atrial fibrillation; Latent class model; Mixture model; Two-part model;
   Zero-inflated binomial
AB Atrial fibrillation (AF) is an abnormal heart rhythm characterized by rapid and irregular heartbeat, with or without perceivable symptoms. In clinical practice, the electrocardiogram (ECG) is often used for diagnosis of AF. Since the AF often arrives as recurrent episodes of varying frequency and duration and only the episodes that occur at the time of ECG can be detected, the AF is often underdiagnosed when a limited number of repeated ECGs are used. In studies evaluating the efficacy of AF ablation surgery, each patient undergoes multiple ECGs and the AF status at the time of ECG is recorded. The objective of this paper is to estimate the marginal proportions of patients with or without AF in a population, which are important measures of the efficacy of the treatment. The underdiagnosis problem is addressed by a three-class mixture regression model in which a patient's probability of having no AF, paroxysmal AF, and permanent AF is modeled by auxiliary baseline covariates in a nested logistic regression. A binomial regression model is specified conditional on a subject being in the paroxysmal AF group. The model parameters are estimated by the Expectation-Maximization (EM) algorithm. These parameters are themselves nuisance parameters for the purpose of this research, but the estimators of the marginal proportions of interest can be expressed as functions of the data and these nuisance parameters and their variances can be estimated by the sandwich method. We examine the performance of the proposed methodology in simulations and two real data applications.
C1 [Li, Liang] MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA.
   [Mao, Huzhang] Univ Texas Hlth Sci Ctr Houston, Dept Biostat, Houston, TX 77030 USA.
   [Ishwaran, Hemant] Univ Miami, Dept Biostat, Miami, FL USA.
   [Rajeswaran, Jeevanantham; Ehrlinger, John] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44106 USA.
   [Blackstone, Eugene H.] Cleveland Clin, Dept Cardiothorac Surg, Cleveland, OH 44106 USA.
RP Li, L (corresponding author), MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA.
EM LLi15@mdanderson.org
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01HL103552, P30CA016672]; NATIONAL
   CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [P30CA016672] Funding Source: NIH RePORTER; NATIONAL
   CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000460] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND
   BLOOD INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [R01HL103552] Funding Source: NIH RePORTER
FX This research is funded by NIH grants R01HL103552 and P30CA016672. We
   want to thank the two referees and the Associate Editor for constructive
   comments that improved this paper.
CR Arya A, 2007, PACE, V30, P458, DOI 10.1111/j.1540-8159.2007.00693.x
   Biernacki C, 2003, COMPUT STAT DATA AN, V41, P561, DOI 10.1016/S0167-9473(02)00163-9
   FAREWELL VT, 1982, BIOMETRICS, V38, P1041, DOI 10.2307/2529885
   Faucett CL, 2002, BIOMETRICS, V58, P37, DOI 10.1111/j.0006-341X.2002.00037.x
   Fuster V, 2006, CIRCULATION, V114, pE257, DOI 10.1161/CIRCULATIONAHA.106.177292
   Gaillard N, 2010, NEUROLOGY, V74, P1666, DOI 10.1212/WNL.0b013e3181e0427e
   Gillinov AM, 2006, ANN THORAC SURG, V82, P502, DOI 10.1016/j.athoracsur.2006.02.030
   Hall DB, 2004, STAT MODEL, V4, P161, DOI 10.1191/1471082X04st076oa
   Hall DB, 2000, BIOMETRICS, V56, P1030, DOI 10.1111/j.0006-341X.2000.01030.x
   R Core Team, 2014, R LANG ENV STAT COMP
   Senatore G, 2005, J AM COLL CARDIOL, V45, P873, DOI 10.1016/j.jacc.2004.11.050
   Stefanski LA, 2002, AM STAT, V56, P29, DOI 10.1198/000313002753631330
NR 12
TC 3
Z9 3
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0323-3847
EI 1521-4036
J9 BIOMETRICAL J
JI Biom. J.
PD MAR
PY 2017
VL 59
IS 2
BP 331
EP 343
DI 10.1002/bimj.201600098
PG 13
WC Mathematical & Computational Biology; Statistics & Probability
SC Mathematical & Computational Biology; Mathematics
GA EO1IR
UT WOS:000396452500008
PM 27983754
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Quittner, AL
   Cejas, I
   Wang, NY
   Niparko, JK
   Barker, DH
AF Quittner, Alexandra L.
   Cejas, Ivette
   Wang, Nae-Yuh
   Niparko, John K.
   Barker, David H.
CA CDaCI Investigative Team
TI Symbolic Play and Novel Noun Learning in Deaf and Hearing Children:
   Longitudinal Effects of Access to Sound on Early Precursors of Language
SO PLOS ONE
LA English
DT Article
ID COCHLEAR IMPLANT USERS; ATTENTION; SPEECH; SKILLS; PRESCHOOLERS;
   ALGORITHM; ABILITIES; AUDITION; IMPACT
AB In the largest, longitudinal study of young, deaf children before and three years after cochlear implantation, we compared symbolic play and novel noun learning to age-matched hearing peers. Participants were 180 children from six cochlear implant centers and 96 hearing children. Symbolic play was measured during five minutes of videotaped, structured solitary play. Play was coded as "symbolic" if the child used substitution (e.g., a wooden block as a bed). Novel noun learning was measured in 10 trials using a novel object and a distractor. Cochlear implant vs. normal hearing children were delayed in their use of symbolic play, however, those implanted before vs. after age two performed significantly better. Children with cochlear implants were also delayed in novel noun learning (median delay 1.54 years), with minimal evidence of catch-up growth. Quality of parent-child interactions was positively related to performance on the novel noun learning, but not symbolic play task. Early implantation was beneficial for both achievement of symbolic play and novel noun learning. Further, maternal sensitivity and linguistic stimulation by parents positively affected noun learning skills, although children with cochlear implants still lagged in comparison to hearing peers.
C1 [Quittner, Alexandra L.] Univ Miami, Dept Psychol, POB 248185, Coral Gables, FL 33124 USA.
   [Cejas, Ivette] Univ Miami, Miller Sch Med, Barton G Kids Hear Now Cochlear Implant Family Re, Dept Otolaryngol, Miami, FL 33136 USA.
   [Wang, Nae-Yuh] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
   [Niparko, John K.] Univ So Calif, Dept Otolaryngol Head & Neck Surg, Los Angeles, CA USA.
   [Barker, David H.] Brown Univ, Dept Child & Adolescent Psychiat, Providence, RI 02912 USA.
RP Quittner, AL (corresponding author), Univ Miami, Dept Psychol, POB 248185, Coral Gables, FL 33124 USA.
EM aquittner@miami.edu
OI Wang, Nae-Yuh/0000-0001-6513-9730
FU National Institute on Deafness and Other Communication DisordersUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute on Deafness & Other
   Communication Disorders (NIDCD) [R01 DC004797]; CityBridge Foundation;
   Sidgmore Family Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1TR000460] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION
   DISORDERSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Deafness &
   Other Communication Disorders (NIDCD) [R01DC004797] Funding Source: NIH
   RePORTER
FX The CDaCI Study was supported by grant R01 DC004797 from the National
   Institute on Deafness and Other Communication Disorders, the CityBridge
   Foundation, and the Sidgmore Family Foundation. The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Appelbaum M, 1999, DEV PSYCHOL, V35, P1399
   Appelbaum M, 2000, CHILD DEV, V71, P960
   Barker DH, 2009, DEV PSYCHOPATHOL, V21, P373, DOI 10.1017/S0954579409000212
   Barnard JM, 2015, OTOL NEUROTOL, V36, P985, DOI 10.1097/MAO.0000000000000723
   BELSKY J, 1981, DEV PSYCHOL, V17, P630, DOI 10.1037/0012-1649.17.5.630
   Blamey PJ, 2011, OXFORD HDB DEAF STUD, P241
   Bornstein MH, 1999, CHILD DEV, V70, P833, DOI 10.1111/1467-8624.00060
   Bortoli A., 2001, J DEAF STUD DEAF EDU, V6, P15, DOI [10.1093/deafed/6.1.15, DOI 10.1093/DEAFED/6.1.15]
   Cruz I, 2013, CHILD DEV, V84, P543, DOI 10.1111/j.1467-8624.2012.01863.x
   Cruz I, 2012, OTOL NEUROTOL, V33, P751, DOI 10.1097/MAO.0b013e3182595309
   Davidson Lisa S, 2014, Cochlear Implants Int, V15, P211, DOI 10.1179/1754762813Y.0000000051
   DesJardin JL, 2009, J DEAF STUD DEAF EDU, V14, P22, DOI 10.1093/deafed/enn011
   Dunn CC, 2014, EAR HEARING, V35, P148, DOI 10.1097/AUD.0b013e3182a4a8f0
   FEIN GG, 1981, CHILD DEV, V52, P1095, DOI 10.1111/j.1467-8624.1981.tb03157.x
   Fenson L, 1993, MACARTUR COMMUNICATI
   Fink Nancy E, 2007, Cochlear Implants Int, V8, P92, DOI 10.1002/cii.333
   Geers AE, 2003, EAR HEARING, V24, p46S, DOI 10.1097/01.AUD.0000051689.57380.1B
   Gentleman R, 2008, ICENS NPMLE CENSORED
   Gershkoff-Stowe L, 2004, CHILD DEV, V75, P1098, DOI 10.1111/j.1467-8624.2004.00728.x
   GILBERTSON M, 1995, J SPEECH HEAR RES, V38, P630, DOI 10.1044/jshr.3803.630
   Gomez G, 2009, STAT MODEL, V9, P259, DOI 10.1177/1471082X0900900402
   Gregory S, 1983, ACQUISITION SYMBOLIC, P221
   Henschel V, 2007, INTCOX COMPENDIUM AP
   Holt RF, 2008, EAR HEARING, V29, P492, DOI 10.1097/AUD.0b013e31816c409f
   Houston DM, 2012, DEVELOPMENTAL SCI, V15, P448, DOI 10.1111/j.1467-7687.2012.01140.x
   Kirk KI, 2002, ANN OTO RHINOL LARYN, V111, P69, DOI 10.1177/00034894021110S515
   Kluwin TN, 2000, AM ANN DEAF, V145, P26, DOI 10.1353/aad.2012.0247
   Kral Andrej, 2006, Adv Otorhinolaryngol, V64, P89, DOI 10.1159/000094647
   Laing GJ, 2002, BRIT MED J, V325, P1152, DOI 10.1136/bmj.325.7373.1152
   Lederberg AR, 2009, J DEAF STUD DEAF EDU, V14, P44, DOI 10.1093/deafed/enn021
   Lederberg AR, 2000, CHILD DEV, V71, P1571, DOI 10.1111/1467-8624.00249
   Lee DS, 2001, NATURE, V409, P149, DOI 10.1038/35051653
   Mayne AM, 1998, VOLTA REV, V100, P29
   MCCUNENICOLICH L, 1981, CHILD DEV, V52, P785, DOI 10.2307/1129078
   Niparko JK, 2010, JAMA-J AM MED ASSOC, V303, P1498, DOI 10.1001/jama.2010.451
   Pan W, 1999, J COMPUT GRAPH STAT, V8, P109, DOI 10.2307/1390923
   Parmet Sharon, 2004, JAMA, V291, P2398, DOI 10.1001/jama.291.19.2398
   Quittner AL, 2004, ARCH OTOLARYNGOL, V130, P547, DOI 10.1001/archotol.130.5.547
   QUITTNER AL, 1994, PSYCHOL SCI, V5, P347, DOI 10.1111/j.1467-9280.1994.tb00284.x
   Quittner AL, 2007, AUDIOL MED, V5, P242, DOI DOI 10.1080/16513860701745401
   Quittner AL, 2013, J PEDIATR-US, V162, P343, DOI 10.1016/j.jpeds.2012.08.003
   Quittner AL, 2010, PARENT-SCI PRACT, V10, P136, DOI 10.1080/15295190903212851
   Reynell J. K, 1990, REYNELL DEV LANGUAGE REYNELL DEV LANGUAGE
   Samuelson LK, 2005, DEVELOPMENTAL SCI, V8, P182, DOI 10.1111/j.1467-7687.2005.00405.x
   Sharma A, 2009, J COMMUN DISORD, V42, P272, DOI 10.1016/j.jcomdis.2009.03.003
   Smith LB, 1998, DEV PSYCHOL, V34, P840, DOI 10.1037/0012-1649.34.5.840
   Smith LB, 2002, PSYCHOL SCI, V13, P13, DOI 10.1111/1467-9280.00403
   Smith LB, 1993, DYNAMIC SYSTEMS APPR
   Spencer PE, 1996, CHILD DEV, V67, P867, DOI 10.2307/1131866
   Stelmachowicz PG, 2004, EAR HEARING, V25, P47, DOI 10.1097/01.AUD.0000111258.98509.DE
   Svirsky MA, 2000, PSYCHOL SCI, V11, P153, DOI 10.1111/1467-9280.00231
   Thal DJ, 1999, J SPEECH LANG HEAR R, V42, P482, DOI 10.1044/jslhr.4202.482
   VYGOTSKY LS, 1967, SOV PSYCHOL-USSR, V5, P6, DOI 10.2753/RPO1061-040505036
   Walker EA, 2013, J SPEECH LANG HEAR R, V56, P375, DOI 10.1044/1092-4388(2012/11-0343)
   Wellner JA, 1997, J AM STAT ASSOC, V92, P945, DOI 10.2307/2965558
NR 55
TC 16
Z9 16
U1 0
U2 18
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 26
PY 2016
VL 11
IS 5
AR e0155964
DI 10.1371/journal.pone.0155964
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DN2GQ
UT WOS:000376882500047
PM 27228032
OA gold, Green Published, Green Submitted
DA 2021-10-30
ER

PT S
AU Sandler, I
   Wolchik, SA
   Cruden, G
   Mahrer, NE
   Ahn, S
   Brincks, A
   Brown, CH
AF Sandler, Irwin
   Wolchik, Sharlene A.
   Cruden, Gracelyn
   Mahrer, Nicole E.
   Ahn, Soyeon
   Brincks, Ahnalee
   Brown, C. Hendricks
BE Cannon, TD
   Widiger, T
TI Overview of Meta-Analyses of the Prevention of Mental Health, Substance
   Use, and Conduct Problems
SO ANNUAL REVIEW OF CLINICAL PSYCHOLOGY, VOL 10
SE Annual Review of Clinical Psychology
LA English
DT Article; Book Chapter
DE prevention; meta-analysis; mental health; substance use
ID COLLEGE-STUDENT DRINKING; SCHOOL-BASED PREVENTION; ANTISOCIAL-BEHAVIOR;
   SMOKING PREVENTION; DRUG PREVENTION; SOCIAL-SKILLS; PROGRAMS;
   INTERVENTIONS; CHILDREN; EFFICACY
AB This review presents findings from an overview of meta-analyses of the effects of prevention and promotion programs to prevent mental health, substance use, and conduct problems. The review of 48 meta-analyses found small but significant changes that reduce depression, anxiety, antisocial behavior, and substance use. Furthermore, the results were sustained over time. Meta-analyses often found that the effects were heterogeneous. A conceptual model is proposed to guide the study of moderators of program effects in future meta-analyses, and methodological issues in synthesizing findings across preventive interventions are discussed.
C1 [Sandler, Irwin; Wolchik, Sharlene A.; Mahrer, Nicole E.] Arizona State Univ, Dept Psychol, Tempe, AZ 85287 USA.
   [Sandler, Irwin; Wolchik, Sharlene A.; Mahrer, Nicole E.] Arizona State Univ, Prevent Res Ctr, Tempe, AZ 85287 USA.
   [Cruden, Gracelyn; Brincks, Ahnalee; Brown, C. Hendricks] Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA.
   [Ahn, Soyeon] Univ Miami, Coll Educ, Coral Gables, FL 33146 USA.
RP Sandler, I (corresponding author), Arizona State Univ, Dept Psychol, Tempe, AZ 85287 USA.
EM irwin.sandler@asu.edu
OI Brown, C Hendricks/0000-0002-0294-2419; Ahn, Soyeon/0000-0003-2581-306X
FU NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000460] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL
   HEALTHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH) [R01MH040859] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON
   DRUG ABUSEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Drug Abuse
   (NIDA)European Commission [R01DA026874] Funding Source: NIH RePORTER;
   NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1TR000460-01A1] Funding Source:
   Medline; NIDA NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Drug Abuse (NIDA) [R01 DA026874, R01DA026874] Funding Source:
   Medline; NIMH NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Mental Health (NIMH) [R01MH040859, R01 MH040859] Funding Source:
   Medline
CR Ahn S, 2011, J EDUC BEHAV STAT, V36, P555, DOI 10.3102/1076998610393968
   Aos S., 2004, BENEFITS COSTS PREVE
   Barlow J, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003680.pub2
   BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173
   Becker B. J., 1994, HDB RES SYNTHESIS, P357
   Beelmann A, 2006, PSICOTHEMA, V18, P603
   Berkel C, 2011, PREV SCI, V12, P23, DOI 10.1007/s11121-010-0186-1
   Brown CH, 2013, PREV SCI, V14, P144, DOI 10.1007/s11121-011-0207-8
   Brown CH, 2012, ADM POLICY MENT HLTH, V39, P301, DOI 10.1007/s10488-011-0387-3
   Brown CH, 2008, CHILD DEV PERSPECT, V2, P198
   Brunwasser SM, 2009, J CONSULT CLIN PSYCH, V77, P1042, DOI 10.1037/a0017671
   Burrus B, 2012, AM J PREV MED, V42, P316, DOI 10.1016/j.amepre.2011.12.001
   Carey KB, 2007, ADDICT BEHAV, V32, P2469, DOI 10.1016/j.addbeh.2007.05.004
   Carey KB, 2012, CLIN PSYCHOL REV, V32, P690, DOI 10.1016/j.cpr.2012.08.001
   Cooper H, 2012, AM PSYCHOL, V67, P446, DOI 10.1037/a0027119
   Cuijpers P, 2002, J DRUG EDUC, V32, P107, DOI 10.2190/LPN9-KBDC-HPVB-JPTM
   Currier JM, 2007, J CLIN CHILD ADOLESC, V36, P253, DOI 10.1080/15374410701279669
   Dekovic M, 2011, CLIN PSYCHOL REV, V31, P532, DOI 10.1016/j.cpr.2010.12.003
   Derzon J. H., 2006, HDB SCH VIOLENCE SCH, P429
   DuBois DL, 2011, PSYCHOL SCI PUBL INT, V12, P57, DOI 10.1177/1529100611414806
   Durlak JA, 2008, AM J COMMUN PSYCHOL, V41, P327, DOI 10.1007/s10464-008-9165-0
   Durlak JA, 2011, CHILD DEV, V82, P405, DOI 10.1111/j.1467-8624.2010.01564.x
   Durlak JA, 2010, AM J COMMUN PSYCHOL, V45, P294, DOI 10.1007/s10464-010-9300-6
   Fachini A, 2012, SUBST ABUSE TREAT PR, V7, DOI 10.1186/1747-597X-7-40
   Fackrell TA, 2011, FAM COURT REV, V49, P107, DOI 10.1111/j.1744-1617.2010.01356.x
   Faggiano F, 2008, PREV MED, V46, P385, DOI 10.1016/j.ypmed.2007.11.012
   Farrington DP, 2003, AUST NZ J CRIMINOL, V36, P127, DOI 10.1375/000486503768293784
   Fisak BJ, 2011, PREV SCI, V12, P255, DOI 10.1007/s11121-011-0210-0
   Fixsen D.L., 2005, IMPLEMENTATION RES S
   Flay BR, 2005, PREV SCI, V6, P151, DOI 10.1007/s11121-005-5553-y
   Gleser L. J., 1994, HDB RES SYNTHESIS ME, P339
   Gottfredson Denise C, 2003, Prev Sci, V4, P27, DOI 10.1023/A:1021782710278
   Hedges L. V., 1985, STAT METHODS META AN, DOI 10.1016/C2009-0-03396-0
   Higgins JP, 2008, COCHRANE HDB SYSTEMA, V5
   Horowitz JL, 2006, J CONSULT CLIN PSYCH, V74, P401, DOI 10.1037/0022-006X.74.3.401
   Hwang MS, 2004, HEALTH EDUC BEHAV, V31, P702, DOI 10.1177/1090198104263361
   Isensee B, 2012, EUR ADDICT RES, V18, P110, DOI 10.1159/000335085
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Juni P, 2001, BMJ-BRIT MED J, V323, P42, DOI 10.1136/bmj.323.7303.42
   Kaminski JW, 2008, J ABNORM CHILD PSYCH, V36, P567, DOI 10.1007/s10802-007-9201-9
   Kessler RC, 2012, PSYCHOL MED, V42, P1997, DOI 10.1017/S0033291712000025
   Knerr W, 2013, PREV SCI, V14, P352, DOI 10.1007/s11121-012-0314-1
   Larun L, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004691.pub2
   Lipsey MW, 2012, NCSER20133000 US DEP
   Lundahl BW, 2006, APSAC ADVIS, V18, P7
   MacArthur G., 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD009927, DOI 10.1002/14651858.CD009927]
   MacKinnon D. P., 2008, INTRO STAT MEDIATION, DOI 10.4324/9780203809556
   Manning M, 2010, CHILD YOUTH SERV REV, V32, P506, DOI 10.1016/j.childyouth.2009.11.003
   Merry SN, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003380.pub3
   Mikton C, 2009, B WORLD HEALTH ORGAN, V87, P353, DOI 10.2471/BLT.08.057075
   Mytton J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004606.pub2
   Nation M, 2003, AM PSYCHOL, V58, P449, DOI 10.1037/0003-066X.58.6-7.449
   Nelson G., 2003, PREVENTION TREATMENT, V6, p31a
   Nowak C, 2008, CLIN CHILD FAM PSYCH, V11, P114, DOI 10.1007/s10567-008-0033-0
   OConnell ME, 2009, PREVENTING MENTAL, EMOTIONAL, AND BEHAVIORAL DISORDERS AMONG YOUNG PEOPLE: PROGRESS AND POSSIBILITIES, P1
   Park-Higgerson HK, 2008, J SCHOOL HEALTH, V78, P465, DOI 10.1111/j.1746-1561.2008.00332.x
   Perrino T, 2013, PERSPECT PSYCHOL SCI, V8, P433, DOI 10.1177/1745691613491579
   Peterson AV, 2000, JNCI-J NATL CANCER I, V92, P1979, DOI 10.1093/jnci/92.24.1979
   Piquero A. R., 2010, SELF CONTROL INTERVE
   Piquero AR, 2009, J EXP CRIMINOL, V5, P83, DOI 10.1007/s11292-009-9072-x
   Porath-Waller AJ, 2010, HEALTH EDUC BEHAV, V37, P709, DOI 10.1177/1090198110361315
   Preacher KJ, 2004, BEHAV RES METH INS C, V36, P717, DOI 10.3758/BF03206553
   RAUDENBUSH SW, 1988, PSYCHOL BULL, V103, P111, DOI 10.1037/0033-2909.103.1.111
   Regehr C, 2013, J AFFECT DISORDERS, V148, P1, DOI 10.1016/j.jad.2012.11.026
   Rosner R, 2010, DEATH STUD, V34, P99, DOI 10.1080/07481180903492422
   Scott-Sheldon LAJ, 2012, PSYCHOL ADDICT BEHAV, V26, P393, DOI 10.1037/a0027565
   SHADISH WR, 1991, J CONSULT CLIN PSYCH, V59, P883, DOI 10.1037/0022-006X.59.6.883
   Shadish WR, 1996, PSYCHOL METHODS, V1, P47, DOI 10.1037/1082-989X.1.1.47
   Shamblen SR, 2009, J PRIM PREV, V30, P89, DOI 10.1007/s10935-009-0168-x
   Siegenthaler E, 2012, J AM ACAD CHILD PSY, V51, P8, DOI 10.1016/j.jaac.2011.10.018
   Soole DW, 2008, AUST NZ J CRIMINOL, V41, P259, DOI 10.1375/acri.41.2.259
   Spoth R, 2013, PREV SCI, V14, P319, DOI 10.1007/s11121-012-0362-6
   STATHAKOS P, 2003, INT J MENT HEALTH PR, V5, P31
   Stice E, 2009, J CONSULT CLIN PSYCH, V77, P486, DOI 10.1037/a0015168
   Sweet MA, 2004, CHILD DEV, V75, P1435, DOI 10.1111/j.1467-8624.2004.00750.x
   Tein JY, 2004, J CONSULT CLIN PSYCH, V72, P617, DOI 10.1037/0022-006X.72.4.617
   Teubert D, 2011, J ANXIETY DISORD, V25, P1046, DOI 10.1016/j.janxdis.2011.07.001
   Thomas R, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001293.pub2
   Tobler N. S., 2000, J PRIM PREV, V20, P275, DOI DOI 10.1023/A:1021314704811
   Tolan P, 2008, CAMPBELL SYST REV, P16
   Weiss M. J., 2013, CONCEPTUAL FRAMEWORK
   Wilson SJ, 2007, AM J PREV MED, V33, pS130, DOI 10.1016/j.amepre.2007.04.011
   Yoshikawa H, 2012, AM PSYCHOL, V67, P272, DOI 10.1037/a0028015
NR 83
TC 85
Z9 86
U1 0
U2 49
PU ANNUAL REVIEWS
PI PALO ALTO
PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA
SN 1548-5943
BN 978-0-8243-3910-4
J9 ANNU REV CLIN PSYCHO
JI Annu. Rev. Clin. Psychol.
PY 2014
VL 10
BP 243
EP 273
DI 10.1146/annurev-clinpsy-050212-185524
PG 31
WC Psychology, Clinical; Psychology
SC Psychology
GA BA4XX
UT WOS:000336428200011
PM 24471372
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Tang, F
   Ishwaran, H
AF Tang, Fei
   Ishwaran, Hemant
TI Random forest missing data algorithms
SO STATISTICAL ANALYSIS AND DATA MINING
LA English
DT Article
DE correlation; imputation; machine learning; missingness; splitting
   (random, univariate, multivariate, unsupervised)
ID MULTIPLE IMPUTATION; MODELS
AB Random forest (RF) missing data algorithms are an attractive approach for imputing missing data. They have the desirable properties of being able to handle mixed types of missing data, they are adaptive to interactions and nonlinearity, and they have the potential to scale to big data settings. Currently there are many different RF imputation algorithms, but relatively little guidance about their efficacy. Using a large, diverse collection of data sets, imputation performance of various RF algorithms was assessed under different missing data mechanisms. Algorithms included proximity imputation, on the fly imputation, and imputation utilizing multivariate unsupervised and supervised splittingthe latter class representing a generalization of a new promising imputation algorithm called missForest. Our findings reveal RF imputation to be generally robust with performance improving with increasing correlation. Performance was good under moderate to high missingness, and even (in certain cases) when data was missing not at random.
C1 [Tang, Fei; Ishwaran, Hemant] Univ Miami, Div Biostat, 1320 S Dixie Hwy, Coral Gables, FL 33146 USA.
RP Ishwaran, H (corresponding author), Univ Miami, Div Biostat, 1320 S Dixie Hwy, Coral Gables, FL 33146 USA.
EM hemant.ishwaran@gmail.com
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01CA163739];
   NATIONAL CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [R01CA163739] Funding Source: NIH RePORTER; NATIONAL
   CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000460] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND
   BLOOD INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [R01HL141892] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of General Medical Sciences (NIGMS) [R01GM125072]
   Funding Source: NIH RePORTER
FX National Institutes of Health, R01CA163739.
CR Aittokallio T, 2010, BRIEF BIOINFORM, V11, P253, DOI 10.1093/bib/bbp059
   Bartlett JW, 2015, STAT METHODS MED RES, V24, P462, DOI 10.1177/0962280214521348
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Breiman L., 1984, CLASSIFICATION REGRE
   Breiman L., 2003, MANUAL SETTING USING
   Doove LL, 2014, COMPUT STAT DATA AN, V72, P92, DOI 10.1016/j.csda.2013.10.025
   Enders C.K., 2010, APPL MISSING DATA AN
   Ishwaran H., 2017, RANDOMFORESTSRC RAND
   Ishwaran H, 2008, ANN APPL STAT, V2, P841, DOI 10.1214/08-AOAS169
   Ishwaran H, 2015, MACH LEARN, V99, P75, DOI 10.1007/s10994-014-5451-2
   Liao SG, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/s12859-014-0346-6
   Liaw A., 2002, R NEWS, V2, P18
   LITTLE RJA, 1993, J AM STAT ASSOC, V88, P125, DOI 10.1080/01621459.1993.10594302
   Loh P.-L., 2011, ADV NEURAL INFORM PR, P2726
   Rubin DB, 1996, J AM STAT ASSOC, V91, P473, DOI 10.1080/01621459.1996.10476908
   RUBIN DB, 1976, BIOMETRIKA, V63, P581, DOI 10.1093/biomet/63.3.581
   Segal M, 2011, WIRES DATA MIN KNOWL, V1, P80, DOI 10.1002/widm.12
   Shah AD, 2014, AM J EPIDEMIOL, V179, P764, DOI 10.1093/aje/kwt312
   Stekhoven DJ, 2012, BIOINFORMATICS, V28, P112, DOI 10.1093/bioinformatics/btr597
   Troyanskaya O, 2001, BIOINFORMATICS, V17, P520, DOI 10.1093/bioinformatics/17.6.520
   Twala BETH, 2008, PATTERN RECOGN LETT, V29, P950, DOI 10.1016/j.patrec.2008.01.010
   Twala B, 2010, INTELL DATA ANAL, V14, P299, DOI 10.3233/IDA-2010-0423
   van Buuren S, 2007, STAT METHODS MED RES, V16, P219, DOI 10.1177/0962280206074463
   Waljee AK, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002847
NR 24
TC 125
Z9 127
U1 5
U2 51
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1932-1864
EI 1932-1872
J9 STAT ANAL DATA MIN
JI Stat. Anal. Data Min.
PD DEC
PY 2017
VL 10
IS 6
BP 363
EP 377
DI 10.1002/sam.11348
PG 15
WC Computer Science, Artificial Intelligence; Computer Science,
   Interdisciplinary Applications; Statistics & Probability
SC Computer Science; Mathematics
GA FN1GM
UT WOS:000415735500001
PM 29403567
OA Green Submitted, Green Accepted
DA 2021-10-30
ER

PT J
AU Markmann, JF
   Rickels, MR
   Eggerman, TL
   Bridges, ND
   Lafontant, DE
   Qidwai, J
   Foster, E
   Clarke, WR
   Kamoun, M
   Alejandro, R
   Bellin, MD
   Chaloner, K
   Czarniecki, CW
   Goldstein, JS
   Hering, BJ
   Hunsicker, LG
   Kaufman, DB
   Korsgren, O
   Larsen, CP
   Luo, XR
   Naji, A
   Oberholzer, J
   Posselt, AM
   Ricordi, C
   Senior, PA
   Shapiro, AMJ
   Stock, PG
   Turgeon, NA
AF Markmann, James F.
   Rickels, Michael R.
   Eggerman, Thomas L.
   Bridges, Nancy D.
   Lafontant, David E.
   Qidwai, Julie
   Foster, Eric
   Clarke, William R.
   Kamoun, Malek
   Alejandro, Rodolfo
   Bellin, Melena D.
   Chaloner, Kathryn
   Czarniecki, Christine W.
   Goldstein, Julia S.
   Hering, Bernhard J.
   Hunsicker, Lawrence G.
   Kaufman, Dixon B.
   Korsgren, Olle
   Larsen, Christian P.
   Luo, Xunrong
   Naji, Ali
   Oberholzer, Jose
   Posselt, Andrew M.
   Ricordi, Camillo
   Senior, Peter A.
   Shapiro, A. M. James
   Stock, Peter G.
   Turgeon, Nicole A.
TI Phase 3 trial of human islet-after-kidney transplantation in type 1
   diabetes
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE basic (laboratory) research; science; clinical research; practice;
   diabetes; diabetes; type 1; islet transplantation
ID QUALITY-OF-LIFE; GLYCEMIC LABILITY; HYPOGLYCEMIA; COUNTERREGULATION;
   ASSOCIATION; SEVERITY; DISTRESS; PANCREAS; ADULTS; SF-36
AB Allogeneic islet transplant offers a minimally invasive option for beta cell replacement in the treatment of type 1 diabetes (T1D). The CIT consortium trial of purified human pancreatic islets (PHPI) in patients with T1D after kidney transplant (CIT06), a National Institutes of Health-sponsored phase 3, prospective, open-label, single-arm pivotal trial of PHPI, was conducted in 24 patients with impaired awareness of hypoglycemia while receiving intensive insulin therapy. PHPI were manufactured using standardized processes. PHPI transplantation was effective with 62.5% of patients achieving the primary endpoint of freedom from severe hypoglycemic events and HbA(1c) <= 6.5% or reduced by >= 1 percentage point at 1 year posttransplant. Median HbA(1c)declined from 8.1% before to 6.0% at 1 year and 6.3% at 2 and 3 years following transplant (P < .001 for all vs baseline), with related improvements in hypoglycemia awareness and glucose variability. The improved metabolic control was associated with better health-related and diabetes-related quality of life. The procedure was safe and kidney allograft function remained stable after 3 years. These results add to evidence establishing allogeneic islet transplant as a safe and effective treatment for patients with T1D and unstable glucose control despite intensive insulin treatment, supporting the indication for PHPI in the post-renal transplant setting.
C1 [Markmann, James F.] Harvard Med Sch, Div Transplant Surg, Massachusetts Gen Hosp, Boston, MA 02115 USA.
   [Rickels, Michael R.] Univ Penn, Div Endocrinol Diabet & Metab, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA.
   [Eggerman, Thomas L.] NIDDK, NIH, Bethesda, MD 20892 USA.
   [Bridges, Nancy D.; Czarniecki, Christine W.; Goldstein, Julia S.] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Lafontant, David E.; Qidwai, Julie; Clarke, William R.; Chaloner, Kathryn; Hunsicker, Lawrence G.] Univ Iowa, Clin Trials Stat & Data Management Ctr, Iowa City, IA USA.
   [Foster, Eric] Ferring Pharmaceut, Parsippany, NJ USA.
   [Kamoun, Malek] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
   [Alejandro, Rodolfo; Ricordi, Camillo] Univ Miami, Miller Sch Med, Diabet Res Inst, Miami, FL 33136 USA.
   [Alejandro, Rodolfo; Ricordi, Camillo] Univ Miami, Miller Sch Med, Clin Cell Transplant Program, Miami, FL 33136 USA.
   [Bellin, Melena D.] Univ Minnesota, Dept Endocrinol, Minneapolis, MN USA.
   [Hering, Bernhard J.] Univ Minnesota, Schulze Diabet Inst, Minneapolis, MN USA.
   [Hering, Bernhard J.] Univ Minnesota, Dept Surg, Box 242 UMHC, Minneapolis, MN 55455 USA.
   [Kaufman, Dixon B.] Univ Wisconsin, Dept Surg, Div Transplantat, Madison, WI USA.
   [Korsgren, Olle] Uppsala Univ, Dept Immunol Genet & Pathol, Uppsala, Sweden.
   [Larsen, Christian P.] Emory Univ, Emory Transplant Ctr, Atlanta, GA 30322 USA.
   [Luo, Xunrong] Duke Univ, Dept Med, Durham, NC USA.
   [Naji, Ali] Univ Penn, Perelman Sch Med, Dept Surg, Div Transplantat, Philadelphia, PA 19104 USA.
   [Oberholzer, Jose] Univ Illinois, Dept Surg, Chicago, IL 60680 USA.
   [Posselt, Andrew M.; Stock, Peter G.] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA.
   [Senior, Peter A.; Shapiro, A. M. James] Univ Alberta, Clin Islet Transplant Program, Edmonton, AB, Canada.
   [Senior, Peter A.; Shapiro, A. M. James] Univ Alberta, Fac Med & Dent, Edmonton, AB, Canada.
   [Turgeon, Nicole A.] Univ Texas Med Sch, Dept Surg, Austin, TX USA.
RP Markmann, JF (corresponding author), Harvard Med Sch, Div Transplant Surg, Massachusetts Gen Hosp, Boston, MA 02115 USA.
EM jmarkmann@mgh.harvard.edu
RI Rickels, Michael/D-1380-2009; Kaufman, Dixon B/E-4524-2016; Senior,
   Peter/E-3031-2013
OI Rickels, Michael/0000-0002-9253-838X; Senior, Peter/0000-0003-1033-8673
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [U01AI089317, U01AI089316, U01AI065191, U01DK085531, 5U01DK070431,
   U01DK070431, U01DK070460, U01AI065193, U01DK070430, U01AI065192];
   National Institute for Diabetes and Digestive and Kidney DiseasesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Diabetes & Digestive &
   Kidney Diseases (NIDDK) [U01AI089317, U01AI089316, U01AI065191,
   U01DK085531, 5U01DK070431, U01DK070431, U01DK070460, U01AI065193,
   U01DK070430, U01AI065192]; GCRCUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Research Resources (NCRR) [UL1TR000454, UL1RR025741,
   UL1TR000150, UL1TR000004, UL1TR000050, UL1TR000460, M01-RR000400,
   UL1TR000114, M01-RR00040, UL1TR000003]; CTSAUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000454, UL1RR025741, UL1TR000150, UL1TR000004, UL1TR000050,
   UL1TR000460, M01-RR000400, UL1TR000114, M01-RR00040, UL1TR000003]
FX Supported by grants from the National Institute of Allergy and
   Infectious Diseases and the National Institute for Diabetes and
   Digestive and Kidney Diseases to the following institutions: Emory
   University (U01AI089317), Northwestern University (U01AI089316),
   University of Alberta, Edmonton (U01AI065191), University of California
   San Francisco (U01DK085531), University of Illinois, Chicago
   (5U01DK070431), University of Iowa (U01DK070431), University of Miami
   (U01DK070460), University of Minnesota (U01AI065193), University of
   Pennsylvania (U01DK070430), and Uppsala University (U01AI065192). In
   addition, the study was supported by the following GCRC and CTSA awards
   to the following institutions: Emory University (UL1TR000454),
   Northwestern University (UL1RR025741 and UL1TR000150), University of
   California San Francisco (UL1TR000004), University of Illinois, Chicago
   (UL1TR000050), University of Miami (UL1TR000460), University of
   Minnesota, (M01-RR000400 and UL1TR000114), and University of
   Pennsylvania (M01-RR00040 and UL1TR000003).
CR Ahroni JH, 2000, J DIABETES COMPLICAT, V14, P31, DOI 10.1016/S1056-8727(00)00066-0
   Amer Diabet Assoc, 2016, DIABETES CARE, V39, pS39, DOI 10.2337/dc16-S008
   American College of of Endocrinology consensus statement on guidelines for glycemic control, 2002, ENDOCRINE PRACTIC S1, V8, P5
   Bjorner JB, 2013, VALUE HEALTH, V16, P993, DOI 10.1016/j.jval.2013.06.022
   Choudhary P, 2015, DIABETES CARE, V38, P1016, DOI 10.2337/dc15-0090
   CLARKE WL, 1995, DIABETES CARE, V18, P517, DOI 10.2337/diacare.18.4.517
   COX DJ, 1987, DIABETES CARE, V10, P617, DOI 10.2337/diacare.10.5.617
   Fisher L, 2012, DIABETES CARE, V35, P259, DOI 10.2337/dc11-1572
   Foster ED, 2018, DIABETES CARE, V41, P1001, DOI 10.2337/dc17-1779
   Handelsman Y, 2015, ENDOCR PRACT, V21, P1, DOI [10.4158/EP15672.GL, 10.4158/EP15672.GLSUPPL]
   Hart HE, 2003, QUAL LIFE RES, V12, P1089, DOI 10.1023/A:1026197119569
   Hering BJ, 2016, DIABETES CARE, V39, P1230, DOI 10.2337/dc15-1988
   IRVINE AA, 1992, HEALTH PSYCHOL, V11, P135, DOI 10.1037/0278-6133.11.2.135
   JACOBSON AM, 1994, DIABETES CARE, V17, P267, DOI 10.2337/diacare.17.4.267
   Janssen MF, 2011, DIABETIC MED, V28, P395, DOI 10.1111/j.1464-5491.2010.03136.x
   Naesens M, 2009, CLIN J AM SOC NEPHRO, V4, P481, DOI 10.2215/CJN.04800908
   Nijhoff MF, 2016, AM J TRANSPLANT, V16, P246, DOI 10.1111/ajt.13425
   Norman GR, 2003, MED CARE, V41, P582, DOI 10.1097/00005650-200305000-00004
   Paty BW, 2013, CAN J DIABETES, V37, pS94, DOI 10.1016/j.jcjd.2013.01.028
   Polonsky WH, 2005, DIABETES CARE, V28, P626, DOI 10.2337/diacare.28.3.626
   Rickels MR, 2019, ANN NY ACAD SCI, V1454, P68, DOI 10.1111/nyas.14214
   Rickels MR, 2018, J CLIN ENDOCR METAB, V103, P105, DOI 10.1210/jc.2017-01516
   Rickels MR, 2016, J CLIN ENDOCR METAB, V101, P4421, DOI 10.1210/jc.2016-1649
   Ricordi C, 2016, DIABETES, V65, P3418, DOI 10.2337/db16-0234
   Ryan EA, 2004, DIABETES, V53, P955, DOI 10.2337/diabetes.53.4.955
   Seaquist ER, 2013, DIABETES CARE, V36, P1384, DOI 10.2337/dc12-2480
   Senior PA, 2015, DIABETES TECHNOL THE, V17, P235, DOI 10.1089/dia.2014.0289
   SERVICE FJ, 1970, DIABETES, V19, P644, DOI 10.2337/diab.19.9.644
   SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401
   Tiwari JL, 2012, AM J TRANSPLANT, V12, P1898, DOI 10.1111/j.1600-6143.2012.04038.x
   U.S. Food and Drug Administration, 2009, GUID IND CONS ALL PA
   Vantyghem MC, 2012, J CLIN ENDOCR METAB, V97, pE2078, DOI 10.1210/jc.2012-2115
   Venstrom JM, 2003, JAMA-J AM MED ASSOC, V290, P2817, DOI 10.1001/jama.290.21.2817
   WILLIAMS A, 1990, HEALTH POLICY, V16, P199
NR 34
TC 13
Z9 13
U1 4
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2021
VL 21
IS 4
BP 1477
EP 1492
DI 10.1111/ajt.16174
EA AUG 2020
PG 16
WC Surgery; Transplantation
SC Surgery; Transplantation
GA RG1FR
UT WOS:000557250400001
PM 32627352
DA 2021-10-30
ER

PT J
AU Alcaide, ML
   Strbo, N
   Romero, L
   Jones, DL
   Rodriguez, VJ
   Arheart, K
   Martinez, O
   Bolivar, H
   Podack, ER
   Fischl, MA
AF Alcaide, Maria L.
   Strbo, Natasa
   Romero, Laura
   Jones, Deborah L.
   Rodriguez, Violeta J.
   Arheart, Kristopher
   Martinez, Octavio
   Bolivar, Hector
   Podack, Eckhard R.
   Fischl, Margaret A.
TI Bacterial Vaginosis Is Associated with Loss of Gamma Delta T Cells in
   the Female Reproductive Tract in Women in the Miami Women Interagency
   HIV Study (WIHS): A Cross Sectional Study
SO PLOS ONE
LA English
DT Article
ID HIGH-RISK; INTRAVAGINAL PRACTICES; VAGINAL INFECTIONS; UNINFECTED WOMEN;
   CYTOKINE LEVELS; AFRICAN WOMEN; MUCOSAL; VIRUS; TRANSMISSION;
   ACQUISITION
AB Bacterial vaginosis (BV) is the most common female reproductive tract infection and is associated with an increased risk of acquiring and transmitting HIV by a mechanism that is not well understood. Gamma delta (GD) T cells are essential components of the adaptive and innate immune system, are present in the female reproductive tract, and play an important role in epithelial barrier protection. GD1 cells predominate in the mucosal tissue and are important in maintaining mucosal integrity. GD2 cells predominate in peripheral blood and play a role in humoral immunity and in the immune response to pathogens. HIV infection is associated with changes in GD T cells frequencies in the periphery and in the female reproductive tract. The objective of this study is to evaluate if changes in vaginal flora occurring with BV are associated with changes in endocervical GD T cell responses, which could account for increased susceptibility to HIV. Seventeen HIV-infected (HIV+) and 17 HIV-uninfected (HIV-) pre-menopausal women underwent collection of vaginal swabs and endocervical cytobrushes. Vaginal flora was assessed using the Nugent score. GD T cells were assessed in cytobrush samples by flow cytometry. Median Nugent score was 5.0 and 41% of women had abnormal vaginal flora. In HIV uninfected women there was a negative correlation between Nugent score and cervical GD1 T cells (b for interaction = -0.176, p<0.01); cervical GD1 T cells were higher in women with normal vaginal flora than in those with abnormal flora (45.00% vs 9.95%, p = 0.005); and cervical GD2 T cells were higher in women with abnormal flora than in those with normal flora (1.70% vs 0.35%, p = 0.023). GD T cells in the genital tract are protective (GD1) and are targets for HIV entry (GD2). The decrease in cervical GD1 and increase in GD2 T cells among women with abnormal vaginal flora predisposes women with BV to HIV acquisition. We propose to use GD T cell as markers of female genital tract vulnerability to HIV.
C1 [Alcaide, Maria L.; Bolivar, Hector; Fischl, Margaret A.] Univ Miami, Miller Sch Med, Dept Med, Div Infect Dis, Miami, FL 33136 USA.
   [Strbo, Natasa; Romero, Laura; Podack, Eckhard R.] Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA.
   [Jones, Deborah L.; Rodriguez, Violeta J.] Univ Miami, Miller Sch Med, Dept Psychiat & Behav Sci, Miami, FL 33136 USA.
   [Arheart, Kristopher] Univ Miami, Miller Sch Med, Dept Epidemiol & Publ Hlth, Miami, FL 33136 USA.
   [Martinez, Octavio] Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL 33136 USA.
RP Alcaide, ML (corresponding author), Univ Miami, Miller Sch Med, Dept Med, Div Infect Dis, Miami, FL 33136 USA.
EM malcaide@med.miami.edu
RI Rodriguez, Violeta J/I-6290-2019
OI Rodriguez, Violeta J/0000-0001-8543-2061; Alcaide,
   Maria/0000-0003-4648-0145
FU National Institutes of Health though: the Miami Center for AIDS Research
   (CFAR) at the University of Miami Miller School of Medicine
   [P30AI073961]; Miami Women's Interagency HIV Infection Study (WIHS) [U01
   AI103397]; Eunice Kennedy Shriver National Institute of Child Health and
   Human DevelopmentUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD)
   [K23HD074489]; University of Miami National Center for Advancing
   Translational Sciences; National Institute on Minority Health and Health
   DisparitiesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Minority
   Health & Health Disparities (NIMHD) [UL1TR000460, 1KL2TR000461];
   National Institute of Allergy and Infectious Diseases (NIAID)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child
   Health and Human Development (NICHD)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH Eunice
   Kennedy Shriver National Institute of Child Health & Human Development
   (NICHD); National Cancer Institute (NCI)United States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Cancer Institute (NCI); National Institute on Drug Abuse
   (NIDA)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Drug Abuse
   (NIDA); National Institute on Mental Health (NIMH)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Mental Health (NIMH); National Institute
   of Dental and Craniofacial Research (NIDCR)United States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Dental & Craniofacial Research (NIDCR); National
   Institute on Alcohol Abuse and Alcoholism (NIAAA)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA);
   National Institute on Deafness and other Communication Disorders
   (NIDCD)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Deafness &
   Other Communication Disorders (NIDCD); NIH Office of Research on Women's
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Office of Research on Women's Health
   (ORWH); UCSF CTSAUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [UL1-TR000004]; Atlanta
   CTSAUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1-TR000454]; EUNICE KENNEDY SHRIVER
   NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH Eunice Kennedy Shriver National Institute of Child Health &
   Human Development (NICHD) [K23HD074489, U01HD032632] Funding Source: NIH
   RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Advancing Translational
   Sciences (NCATS) [UL1TR000454, UL1TR000004, KL2TR000461, UL1TR000460]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [U01AI042590, U01AI031834,
   U01AI103397, U01AI103401, U01AI103390, U01AI035004, U01AI034993,
   P30AI073961, U01AI034989, U01AI034994, U01AI103408] Funding Source: NIH
   RePORTER
FX This study was funded by the National Institutes of Health though: the
   Miami Center for AIDS Research (CFAR) at the University of Miami Miller
   School of Medicine [P30AI073961], Miami Women's Interagency HIV
   Infection Study (WIHS) [U01 AI103397], the Eunice Kennedy Shriver
   National Institute of Child Health and Human Development [K23HD074489],
   University of Miami National Center for Advancing Translational Sciences
   and the National Institute on Minority Health and Health Disparities
   [UL1TR000460 and 1KL2TR000461]. The WIHS is funded primarily by the
   National Institute of Allergy and Infectious Diseases (NIAID), with
   additional co-funding from the Eunice Kennedy Shriver National Institute
   of Child Health and Human Development (NICHD), the National Cancer
   Institute (NCI), the National Institute on Drug Abuse (NIDA), and the
   National Institute on Mental Health (NIMH). Targeted supplemental
   funding for specific projects is also provided by the National Institute
   of Dental and Craniofacial Research (NIDCR), the National Institute on
   Alcohol Abuse and Alcoholism (NIAAA), the National Institute on Deafness
   and other Communication Disorders (NIDCD), and the NIH Office of
   Research on Women's Health. WIHS data collection is also supported by
   UL1-TR000004 (UCSF CTSA) and UL1-TR000454 (Atlanta CTSA). Data in this
   manuscript were collected by the Women's Interagency HIV Study (WIHS).
   The contents of this publication are solely the responsibility of the
   authors and do not represent the official views of the National
   Institutes of Health (NIH). WIHS (Principal Investigators): UAB-MS WIHS
   (Michael Saag, Mirjam-Colette Kempf, and Deborah Konkle-Parker),
   U01-AI-103401; Atlanta WIHS (Ighovwerha Ofotokun and Gina Wingood),
   U01-AI-103408; Bronx WIHS (Kathryn Anastos), U01-AI-035004; Brooklyn
   WIHS (Howard Minkoff and Deborah Gustafson), U01-AI-031834; Chicago WIHS
   (Mardge Cohen and Audrey French), U01-AI-034993; Metropolitan Washington
   WIHS (Mary Young), U01-AI-034994; Miami WIHS (Margaret Fischl and Lisa
   Metsch), U01-AI-103397; UNC WIHS (Adaora Adimora), U01-AI-103390; Connie
   Wofsy Women's HIV Study, Northern California (Ruth Greenblatt, Bradley
   Aouizerat, and Phyllis Tien), U01-AI-034989; WIHS Data Management and
   Analysis Center (Stephen Gange and Elizabeth Golub), U01-AI-042590;
   Southern California WIHS (Alexandra Levine and Marek Nowicki),
   U01-HD-032632 (WIHS I - WIHS IV). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Allsworth JE, 2007, OBSTET GYNECOL, V109, P114, DOI 10.1097/01.AOG.0000247627.84791.91
   Anahtar MN, 2015, IMMUNITY, V42, P965, DOI 10.1016/j.immuni.2015.04.019
   AUTRAN B, 1989, CLIN EXP IMMUNOL, V75, P206
   Bloom BS, 1996, NEW ENGL J MED, V334, P1338
   Brotman RM, 2008, AM J EPIDEMIOL, V168, P188, DOI 10.1093/aje/kwn103
   Carding SR, 2002, NAT REV IMMUNOL, V2, P336, DOI 10.1038/nri797
   Cohen CR, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001251
   Eade CR, 2015, PROTEIN PEPTIDE LETT, V22, P672, DOI 10.2174/0929866522666150309155735
   Farquhar C, 2010, AIDS, V24, P153, DOI 10.1097/QAD.0b013e32832326d8
   Fethers KA, 2008, CLIN INFECT DIS, V47, P1426, DOI 10.1086/592974
   Ghosh M, 2014, AM J REPROD IMMUNOL, V71, P575, DOI 10.1111/aji.12250
   Greenblatt RM, 1999, SEX TRANSM DIS, V26, P143, DOI 10.1097/00007435-199903000-00004
   Hayday A, 2003, NAT REV IMMUNOL, V3, P233, DOI 10.1038/nri1030
   Hayday AC, 2009, IMMUNITY, V31, P184, DOI 10.1016/j.immuni.2009.08.006
   Hedges SR, 2006, J INFECT DIS, V193, P556, DOI 10.1086/499824
   Hilber AM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009119
   Hladik F, 2007, IMMUNITY, V26, P257, DOI 10.1016/j.immuni.2007.01.007
   Holmes KK, 2008, SEXUALLY TRANSMITTED
   Klebanoff MA, 2010, SEX TRANSM DIS, V37, P184, DOI 10.1097/OLQ.0b013e3181c04865
   Koumans EH, 2007, SEX TRANSM DIS, V34, P864, DOI 10.1097/OLQ.0b013e318074e565
   Kyongo JK, 2015, CLIN VACCINE IMMUNOL, V22, P526, DOI 10.1128/CVI.00762-14
   Laxmi U, 2012, J MATERN-FETAL NEO M, V25, P64, DOI 10.3109/14767058.2011.565390
   Low N, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000416
   Mares D, 2008, J REPROD IMMUNOL, V77, P91, DOI 10.1016/j.jri.2007.04.004
   McClelland RS, 2006, AIDS, V20, P269, DOI 10.1097/01.aids.0000196165.48518.7b
   Mincheva-Nilsson L, 2000, INT IMMUNOL, V12, P585, DOI 10.1093/intimm/12.5.585
   Mincheva-Nilsson Lucia, 2003, Reprod Biol Endocrinol, V1, P120, DOI 10.1186/1477-7827-1-120
   Mirmonsef P, 2012, CURR HIV RES, V10, P202, DOI 10.2174/157016212800618165
   Mitchell CM, 2008, AIDS RES HUM RETROV, V24, P667, DOI 10.1089/aid.2008.0268
   Mukura LR, 2012, AIDS RES HUM RETROV, V28, P1533, DOI [10.1089/aid.2011.0394, 10.1089/AID.2011.0394]
   Muzny CA, 2014, SEX TRANSM DIS, V41, P58, DOI 10.1097/OLQ.0000000000000057
   Myer L, 2005, LANCET INFECT DIS, V5, P786, DOI 10.1016/S1473-3099(05)70298-X
   Nakasone C, 2007, MICROBES INFECT, V9, P251, DOI 10.1016/j.micinf.2006.11.015
   Novak RM, 2007, CLIN VACCINE IMMUNOL, V14, P1102, DOI 10.1128/CVI.00386-06
   Pauza CD, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00687
   Poles MA, 2003, J VIROL, V77, P10456, DOI 10.1128/JVI.77.19.10456-10467.2003
   Saba E, 2010, MUCOSAL IMMUNOL, V3, P280, DOI 10.1038/mi.2010.2
   Shires J, 2001, IMMUNITY, V15, P419, DOI 10.1016/S1074-7613(01)00192-3
   Strbo N, 2016, AM J REPROD IMMUNOL, V75, P134, DOI 10.1111/aji.12458
   Thurman AR, 2015, AIDS RES HUM RETROV, V31, P1139, DOI 10.1089/aid.2015.0006
   Watts DH, 2006, JAIDS-J ACQ IMM DEF, V43, P161, DOI 10.1097/01.qai.0000242448.90026.13
   Zariffard MR, 2005, J INFECT DIS, V191, P1913, DOI 10.1086/429922
NR 42
TC 18
Z9 18
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 14
PY 2016
VL 11
IS 4
AR e0153045
DI 10.1371/journal.pone.0153045
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DJ3UH
UT WOS:000374131700017
PM 27078021
OA Green Published, Green Submitted, gold
DA 2021-10-30
ER

PT J
AU Balamurugan, AN
   Naziruddin, B
   Lockridge, A
   Tiwari, M
   Loganathan, G
   Takita, M
   Matsumoto, S
   Papas, K
   Trieger, M
   Rainis, H
   Kin, T
   Kay, TW
   Wease, S
   Messinger, S
   Ricordi, C
   Alejandro, R
   Markmann, J
   Kerr-Conti, J
   Rickels, MR
   Liu, C
   Zhang, X
   Witkowski, P
   Posselt, A
   Maffi, P
   Secchi, A
   Berney, T
   O'Connell, PJ
   Hering, BJ
   Barton, FB
AF Balamurugan, A. N.
   Naziruddin, B.
   Lockridge, A.
   Tiwari, M.
   Loganathan, G.
   Takita, M.
   Matsumoto, S.
   Papas, K.
   Trieger, M.
   Rainis, H.
   Kin, T.
   Kay, T. W.
   Wease, S.
   Messinger, S.
   Ricordi, C.
   Alejandro, R.
   Markmann, J.
   Kerr-Conti, J.
   Rickels, M. R.
   Liu, C.
   Zhang, X.
   Witkowski, P.
   Posselt, A.
   Maffi, P.
   Secchi, A.
   Berney, T.
   O'Connell, P. J.
   Hering, B. J.
   Barton, F. B.
TI Islet Product Characteristics and Factors Related to Successful Human
   Islet Transplantation From the Collaborative Islet Transplant Registry
   (CITR) 1999-2010
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE Clinical research; practice; diabetes: type 1; endocrinology;
   diabetology; health services and outcomes research; islet isolation;
   islet transplantation; Organ Procurement and Transplantation Network
   (OPTN); pancreas; simultaneous pancreas-kidney transplantation;
   registry; registry analysis
ID HISTIDINE-TRYPTOPHAN-KETOGLUTARATE; OF-WISCONSIN SOLUTION;
   ISOLATION-RELATED VARIABLES; PANCREAS PRESERVATION; ISOLATION OUTCOMES;
   2-LAYER METHOD; CLINICAL TRANSPLANTATION; COLLAGENASE NB1;
   GRAFT-SURVIVAL; CULTURE
AB The Collaborative Islet Transplant Registry (CITR) collects data on clinical islet isolations and transplants. This retrospective report analyzed 1017 islet isolation procedures performed for 537 recipients of allogeneic clinical islet transplantation in 1999-2010. This study describes changes in donor and islet isolation variables by era and factors associated with quantity and quality of final islet products. Donor body weight and BMI increased significantly over the period (p<0.001). Islet yield measures have improved with time including islet equivalent (IEQ)/particle ratio and IEQs infused. The average dose of islets infused significantly increased in the era of 2007-2010 when compared to 1999-2002 (445.4156.8 vs. 421.3 +/- 155.4x10(3) IEQ; p<0.05). Islet purity and total number of cells significantly improved over the study period (p<0.01 and <0.05, respectively). Otherwise, the quality of clinical islets has remained consistently very high through this period, and differs substantially from nonclinical islets. In multivariate analysis of all recipient, donor and islet factors, and medical management factors, the only islet product characteristic that correlated with clinical outcomes was total IEQs infused. This analysis shows improvements in both quantity and some quality criteria of clinical islets produced over 1999-2010, and these parallel improvements in clinical outcomes over the same period.
   Product criteria from clinical grade allogeneic human islets exhibit consistently superior-quality characteristics and significantly increasing islet equivalent yield, paralleling improving success rates of islet transplantation for type I diabetes.
C1 [Balamurugan, A. N.; Lockridge, A.; Tiwari, M.; Loganathan, G.; Hering, B. J.] Univ Minnesota, Dept Surg, Schulze Diabet Inst, Minneapolis, MN 55455 USA.
   [Naziruddin, B.; Takita, M.] Baylor Annette C & Harold C Simmons Transplant In, Dallas, TX USA.
   [Matsumoto, S.] Otsuka Pharmaceut Factory Inc, Ctr Res & Dev, Tokushima, Japan.
   [Papas, K.] Univ Arizona, Inst Cellular Transplantat, Tucson, AZ USA.
   [Trieger, M.; Rainis, H.; Wease, S.; Barton, F. B.] EMMES Corp, Rockville, MD USA.
   [Kin, T.] Univ Alberta, Clin Islet Lab, Edmonton, AB, Canada.
   [Kay, T. W.] St Vincents Hosp, Melbourne, Vic, Australia.
   [Messinger, S.] Univ Miami, Dept Publ Hlth Serv, Miami, FL USA.
   [Ricordi, C.; Alejandro, R.] Univ Miami, Diabet Res Inst, Miami, FL USA.
   [Markmann, J.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
   [Kerr-Conti, J.] Lille Univ Hosp, Lille, France.
   [Rickels, M. R.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
   [Liu, C.] Univ Penn, Dept Surg, Philadelphia, PA 19104 USA.
   [Zhang, X.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Witkowski, P.] Univ Chicago, Dept Surg, Chicago, IL 60637 USA.
   [Posselt, A.] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA.
   [Maffi, P.; Secchi, A.] San Raffaele Univ, Vita Salute, Milan, Italy.
   [Berney, T.] Univ Hosp Geneva, Dept Surg, Geneva, Switzerland.
   [O'Connell, P. J.] Univ Sydney, Westmead Hosp, Natl Pancreas Transplant Unit, Sydney, NSW 2006, Australia.
RP Balamurugan, AN (corresponding author), Univ Louisville, Dept Surg, Cardiovasc Innovat Inst, Islet Cell Lab, Louisville, KY 40292 USA.
EM isletologist@hotmail.com; fbarton@emmes.com
RI Rickels, Michael/D-1380-2009; Loganathan, Gopalakrishnan/D-8762-2014;
   RICORDI, CAMILLO/AAA-4740-2019; Kin, Tatsuya/A-3776-2012
OI Rickels, Michael/0000-0002-9253-838X; Kin, Tatsuya/0000-0002-5179-6067;
   Lockridge, Amber/0000-0003-1122-6286; Ricordi,
   Camillo/0000-0001-8092-7153
FU NIDDKUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Diabetes &
   Digestive & Kidney Diseases (NIDDK); National Institutes of HealthUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA; JDRF InternationalJuvenile Diabetes Research
   Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Advancing Translational
   Sciences (NCATS) [UL1TR000460] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Diabetes & Digestive & Kidney Diseases
   (NIDDK) [UC4DK098086, P30DK020595, P30DK063720] Funding Source: NIH
   RePORTER
FX The CITR is funded by the NIDDK, National Institutes of Health and by a
   supplemental grant from the JDRF International. Additional data were
   made available through cooperative agreements with the U. S. United
   Network for Organ Sharing (UNOS), Alexandria, Virginia, the
   Administrative and Bioinformatics Coordinating Center of the City of
   Hope, Duarte, California (1999-2009) and the NIDDK-sponsored CIT
   (www.citisletstudy.org), coordinated by the University of Iowa Clinical
   Trials and Data Management Center (2008-present).
CR Balamurugan AN, 2012, TRANSPLANTATION, V93, P693, DOI 10.1097/TP.0b013e318247281b
   Balamurugan AN, 2010, TRANSPLANTATION, V89, P954, DOI 10.1097/TP.0b013e3181d21e9a
   Balamurugan AN, 2005, AM J TRANSPLANT, V5, P2671, DOI 10.1111/j.1600-6143.2005.01078.x
   Barton FB, 2012, DIABETES CARE, V35, P1436, DOI 10.2337/dc12-0063
   Brandhorst H, 2010, CELL TRANSPLANT, V19, P3, DOI 10.3727/096368909X477507
   Brandhorst H, 1995, EXP CLIN ENDOCR DIAB, V103, P23, DOI 10.1055/s-0029-1211388
   BRENDEL MD, 1994, CELL TRANSPLANT, V3, P427, DOI 10.1177/096368979400300510
   Bucher P, 2004, TRANSPL P, V36, P1143, DOI 10.1016/j.transproceed.2004.04.023
   Caballero-Corbalan J, 2007, TRANSPLANTATION, V84, P864, DOI 10.1097/01.tp.0000284584.60600.ab
   Center CC, 2011, 7 CTR CC
   Cosimi S, 1995, TRANSPLANT P, V27, P3355
   Fraker CA, 2013, CELL TRANSPLANT, V22, P1723, DOI 10.3727/096368912X657873
   Friberg AS, 2013, TRANSPLANTATION, V95, pE36, DOI 10.1097/TP.0b013e318283a859
   Gaber AO, 2001, TRANSPLANTATION, V72, P1730, DOI 10.1097/00007890-200112150-00005
   Goto M, 2005, TRANSPLANT P, V37, P1315, DOI 10.1016/j.transproceed.2004.11.042
   Hilling DE, 2014, CELL TRANSPLANT, V23, P921, DOI 10.3727/096368913X666412
   Iglesias I, 2012, CELL TRANSPLANT, V21, P649, DOI 10.3727/096368911X623826
   Itoh T, 2012, CELL TRANSPLANT, V21, P1371, DOI 10.3727/096368912X640592
   Kaddis JS, 2010, AM J TRANSPLANT, V10, P646, DOI 10.1111/j.1600-6143.2009.02962.x
   Kaddis JS, 2009, JAMA-J AM MED ASSOC, V301, P1580, DOI 10.1001/jama.2009.482
   KEDINGER M, 1977, NATURE, V270, P736, DOI 10.1038/270736a0
   Kim SC, 2005, TRANSPL P, V37, P3402, DOI 10.1016/j.transproceed.2005.09.055
   Kin T, 2008, TRANSPL INT, V21, P1029, DOI 10.1111/j.1432-2277.2008.00719.x
   Kin T, 2006, TRANSPLANTATION, V82, P1286, DOI 10.1097/01.tp.0000244347.61060.af
   Kitamura T, 2002, J CLIN INVEST, V110, P1839, DOI 10.1172/JCI200216857
   Koh A, 2008, TRANSPLANTATION, V86, P1622, DOI 10.1097/TP.0b013e31818c2559
   KORBUTT GS, 1994, CELL TRANSPLANT, V3, P291, DOI 10.1177/096368979400300405
   KURODA Y, 1988, TRANSPLANTATION, V46, P457
   LACY PE, 1979, SCIENCE, V204, P312, DOI 10.1126/science.107588
   LAFFERTY KJ, 1983, ANNU REV IMMUNOL, V1, P143, DOI 10.1146/annurev.iy.01.040183.001043
   Lakey JRT, 1996, TRANSPLANTATION, V61, P1047, DOI 10.1097/00007890-199604150-00010
   Liu XL, 2008, CELL TRANSPLANT, V17, P649, DOI 10.3727/096368908786092711
   MARKMANN JF, 1990, TRANSPLANTATION, V49, P272, DOI 10.1097/00007890-199002000-00009
   Matsumoto S, 2002, CELL TRANSPLANT, V11, P769
   Matsumoto S, 2009, CELL TRANSPLANT, V18, P549, DOI 10.1177/096368970901805-610
   Movassat J, 1997, DIABETES, V46, P1445, DOI 10.2337/diabetes.46.9.1445
   Nano R, 2005, DIABETOLOGIA, V48, P906, DOI 10.1007/s00125-005-1725-3
   Niclauss N, 2008, TRANSPLANTATION, V86, P1603, DOI 10.1097/TP.0b013e31818f671a
   Niclauss N, 2011, TRANSPLANTATION, V91, P360, DOI 10.1097/TP.0b013e31820385e6
   Noguchi H, 2007, TRANSPLANTATION, V84, P655, DOI 10.1097/01.tp.0000277625.42147.62
   Noguchi H, 2012, CELL TRANSPLANT, V21, P517, DOI 10.3727/096368911X605439
   O'Gorman D, 2005, TRANSPLANTATION, V80, P801, DOI 10.1097/01.tp.0000172216.47547.d5
   O'Gorman D, 2013, ISLETS, V5, P111, DOI 10.4161/isl.25222
   Papas KK, 2007, AM J TRANSPLANT, V7, P707, DOI 10.1111/j.1600-6143.2006.01655.x
   Ponte GM, 2007, CELL TRANSPLANT, V16, P595, DOI 10.3727/000000007783465082
   Qin HY, 2011, CELL TRANSPLANT, V20, P1127, DOI 10.3727/096368910X544942
   Ricordi C, 2003, DIABETES, V52, P1595, DOI 10.2337/diabetes.52.7.1595
   ROBERTSON GSM, 1993, ACTA DIABETOL, V30, P93, DOI 10.1007/BF00578221
   Sabek OM, 2008, CELL TRANSPLANT, V17, P785, DOI 10.3727/096368908786516747
   Salehi P, 2006, TRANSPLANTATION, V82, P983, DOI 10.1097/01.tp.0000232310.49237.06
   Shimoda M, 2012, ISLETS, V4, P130, DOI 10.4161/isl.19255
   SOCCI C, 1993, TRANSPLANTATION, V55, P661
   Stahle M, 2013, TRANSPLANTATION, V96, pE91, DOI [10.1097/01.tp.0000437562.31212.d5, 10.1097/01.TP.0000437562.31212.d5]
   Stewart ZA, 2009, AM J TRANSPLANT, V9, P217, DOI 10.1111/j.1600-6143.2008.02449.x
   Tanioka Y, 1997, SURGERY, V122, P435, DOI 10.1016/S0039-6060(97)90037-4
   Wang Y, 2013, CELL TRANSPLANT, V22, P2323, DOI 10.3727/096368912X662417
   Webb MA, 2012, BIOTECHNOL GENET ENG, V28, P101, DOI 10.5661/bger-28-101
   Wei Guo-hong, 2007, Nan Fang Yi Ke Da Xue Xue Bao, V27, P1352
NR 58
TC 101
Z9 104
U1 0
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD NOV
PY 2014
VL 14
IS 11
BP 2595
EP 2606
DI 10.1111/ajt.12872
PG 12
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AS3LH
UT WOS:000344178800020
PM 25278159
OA Green Published, hybrid
DA 2021-10-30
ER

PT J
AU Tamames, I
   King, C
   Bas, E
   Dietrich, WD
   Telischi, F
   Rajguru, SM
AF Tamames, Ilmar
   King, Curtis
   Bas, Esperanza
   Dietrich, W. Dalton
   Telischi, Fred
   Rajguru, Suhrud M.
TI A cool approach to reducing electrode-induced trauma: Localized
   therapeutic hypothermia conserves residual hearing in cochlear
   implantation
SO HEARING RESEARCH
LA English
DT Article
DE Therapeutic hypothermia; Cochlear implant; Trauma; Electrode insertion;
   Residual hearing; Hair cell loss
ID SPINAL-CORD-INJURY; NECROSIS-FACTOR-ALPHA; MILD HYPOTHERMIA;
   CEREBRAL-ISCHEMIA; POSTISCHEMIC HYPOTHERMIA; SYSTEMIC HYPOTHERMIA;
   APICAL DIFFERENCES; MODEL; DEXAMETHASONE; DAMAGE
AB Objective: The trauma caused during cochlear implant insertion can lead to cell death and a loss of residual hair cells in the cochlea. Various therapeutic approaches have been studied to prevent cochlear implant-induced residual hearing loss with limited success. In the present study, we show the efficacy of mild to moderate therapeutic hypothermia of 4 to 6 degrees C applied to the cochlea in reducing residual hearing loss associated with the electrode insertion trauma.
   Approach: Rats were randomly distributed in three groups: control contralateral cochleae, normothermic implanted cochleae and hypothermic implanted cochleae. Localized hypothermia was delivered to the middle turn of the cochlea for 20 min before and after implantation using a custom-designed probe perfused with cooled fluorocarbon. Auditory brainstem responses (ABRs) were recorded to assess the hearing function prior to and post-cochlear implantation at various time points up to 30 days. At the conclusion of the trials, inner ears were harvested for histology and cell count. The approach was extended to cadaver temporal bones to study the potential surgical approach and efficacy of our device. In this case, the hypothermia probe was placed next to the round window niche via the facial recess or a myringotomy.
   Main results: A significant loss of residual hearing was observed in the normothermic implant group. Comparatively, the residual hearing in the cochleae receiving therapeutic hypothermia was significantly conserved. Histology confirmed a significant loss of outer hair cells in normothermic cochleae receiving the surgical trauma when compared to the hypothermia treated group. In human temporal bones, a controlled and effective cooling of the cochlea was achieved using our approach.
   Significance: Collectively, these results suggest that therapeutic hypothermia during cochlear implantation may reduce traumatic effects of electrode insertion and improve conservation of residual hearing. (C) 2016 The Authors. Published by Elsevier B.V.
C1 [Tamames, Ilmar; Rajguru, Suhrud M.] Dept Biomed Engn, Seattle, WA USA.
   [King, Curtis] Lucent Med Syst, Seattle, WA USA.
   [Bas, Esperanza; Telischi, Fred; Rajguru, Suhrud M.] Univ Miami, Dept Otolaryngol, Miami, FL 33136 USA.
   [Dietrich, W. Dalton] Univ Miami, Dept Neurol Surg, Miami, FL 33136 USA.
RP Rajguru, SM (corresponding author), Univ Miami, Ear Inst, 1600 NW 10th Ave,RMSB 3158, Miami, FL 33136 USA.
EM s.rajguru@miami.edu
FU Miami Clinical and Translational Science Institute [1UL1TR000460]; 
   [R21DC014324]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [KL2TR000146, UL1TR000460] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER
   COMMUNICATION DISORDERSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Deafness & Other Communication Disorders (NIDCD) [R21DC014324]
   Funding Source: NIH RePORTER
FX This work was supported by R21DC014324 (SMR) and Pilot Award (SMR) from
   Grant Number 1UL1TR000460 (Miami Clinical and Translational Science
   Institute).
CR Adunka O, 2005, CLIN OTOLARYNGOL, V30, P121, DOI 10.1111/j.1365-2273.2004.00935.x
   Ahmad FI, 2012, LARYNGOSCOPE, V122, P636, DOI 10.1002/lary.22488
   Atkins CM, 2010, EUR J NEUROSCI, V32, P1912, DOI 10.1111/j.1460-9568.2010.07467.x
   Balkany TJ, 2006, OTOL NEUROTOL, V27, P1083, DOI 10.1097/01.mao.0000244355.34577.85
   Balkany TJ, 2005, LARYNGOSCOPE, V115, P1543, DOI 10.1097/01.mlg.0000173169.45262.ae
   Bas E, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00303
   Bas E, 2012, ANAT REC, V295, P1944, DOI 10.1002/ar.22585
   Briggs R J, 2001, Cochlear Implants Int, V2, P135, DOI 10.1179/cim.2001.2.2.135
   BROWN MC, 1983, J ACOUST SOC AM, V73, P1662, DOI 10.1121/1.389387
   Cappuccino A, 2010, SPINE, V35, pE57, DOI 10.1097/BRS.0b013e3181b9dc28
   Carlson ML, 2015, OTOL NEUROTOL, V36, P43, DOI 10.1097/MAO.0000000000000607
   Ching Teresa Y C, 2014, Cochlear Implants Int, V15 Suppl 1, pS43, DOI 10.1179/1467010014Z.000000000168
   Darwazeh R, 2013, NEURAL REGEN RES, V8, P2677, DOI 10.3969/j.issn.1673-5374.2013.28.010
   Dietrich WD, 2011, NEUROTHERAPEUTICS, V8, P229, DOI 10.1007/s13311-011-0035-3
   Dietrich WD, 2009, J NEUROTRAUM, V26, P301, DOI 10.1089/neu.2008.0806
   Dinh C, 2008, OTOL NEUROTOL, V29, P1012, DOI 10.1097/MAO.0b013e3181859a1f
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Eshraghi AA, 2005, OTOL NEUROTOL, V26, P442, DOI 10.1097/01.mao.0000169791.53201.e1
   Eshraghi AA, 2013, LARYNGOSCOPE, V123, pS1, DOI 10.1002/lary.23902
   Friedland David R, 2009, Trends Amplif, V13, P124, DOI 10.1177/1084713809336422
   HENRY KR, 1984, HEARING RES, V16, P225, DOI 10.1016/0378-5955(84)90111-4
   Irving S, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/350504
   James DP, 2008, AUDIOL NEURO-OTOL, V13, P86, DOI 10.1159/000111780
   Jolly C, 2010, ADV OTO-RHINO-LARYNG, V67, P28, DOI 10.1159/000262594
   Kawai N, 2000, STROKE, V31, P1982, DOI 10.1161/01.STR.31.8.1982
   Keithley EM, 2008, OTOL NEUROTOL, V29, P854, DOI 10.1097/MAO.0b013e31818256a9
   Kiefer J, 2004, ACTA OTO-LARYNGOL, V124, P272, DOI 10.1080/00016480310000755a
   Levi AD, 2010, NEUROSURGERY, V66, P670, DOI 10.1227/01.NEU.0000367557.77973.5F
   LIBERMAN MC, 1984, HEARING RES, V16, P43, DOI 10.1016/0378-5955(84)90024-8
   Matsui T, 2006, J NEUROSURG ANESTH, V18, P189, DOI 10.1097/01.ana.0000188639.39844.f6
   MULLER M, 1991, HEARING RES, V51, P247, DOI 10.1016/0378-5955(91)90041-7
   OHLEMILLER KK, 1994, HEARING RES, V80, P174, DOI 10.1016/0378-5955(94)90109-0
   OHLEMILLER KK, 1992, HEARING RES, V63, P79, DOI 10.1016/0378-5955(92)90076-Y
   Ohta H, 2007, NEUROSCI RES, V57, P424, DOI 10.1016/j.neures.2006.12.002
   Polderman KH, 2009, CRIT CARE MED, V37, P1101, DOI 10.1097/CCM.0b013e3181962ad5
   Purdy PD, 2013, AM J NEURORADIOL, V34, P252, DOI 10.3174/ajnr.A3175
   Shintani Y., 2010, STROKE RES TREAT, V2011
   Tharpe Anne Marie, 2008, Trends Amplif, V12, P17, DOI 10.1177/1084713807313085
   Touzani O, 1999, J NEUROIMMUNOL, V100, P203, DOI 10.1016/S0165-5728(99)00202-7
   Tzen YT, 2013, J SPINAL CORD MED, V36, P357, DOI 10.1179/2045772312Y.0000000085
   Van De Water Thomas R, 2010, Cochlear Implants Int, V11 Suppl 1, P42, DOI 10.1179/146701010X12671178390834
   Vivero RJ, 2008, LARYNGOSCOPE, V118, P2028, DOI 10.1097/MLG.0b013e31818173ec
   Wardrop P, 2005, HEARING RES, V203, P54, DOI 10.1016/j.heares.2004.11.006
   Watanabe F, 2001, NEUROSCIENCE, V102, P639, DOI 10.1016/S0306-4522(00)00510-8
   Yanamoto H, 1999, STROKE, V30, P2720, DOI 10.1161/01.STR.30.12.2720
   Yokobori S, 2011, THER HYPOTHERMIA TEM, V1, P185, DOI 10.1089/ther.2011.0012
   Zhang H, 2010, NEUROL RES, V32, P384, DOI 10.1179/016164110X12670144526228
NR 47
TC 11
Z9 11
U1 0
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5955
EI 1878-5891
J9 HEARING RES
JI Hear. Res.
PD SEP
PY 2016
VL 339
BP 32
EP 39
DI 10.1016/j.heares.2016.05.015
PG 8
WC Audiology & Speech-Language Pathology; Neurosciences;
   Otorhinolaryngology
SC Audiology & Speech-Language Pathology; Neurosciences & Neurology;
   Otorhinolaryngology
GA DW8ZP
UT WOS:000383944300004
PM 27260269
OA hybrid, Green Accepted
DA 2021-10-30
ER

PT J
AU Ramos, AR
   Wallace, DM
   Pandi-Perumal, SR
   Williams, NJ
   Castor, C
   Sevick, MA
   Mcfarlane, SI
   Jean-Louis, G
AF Ramos, Alberto R.
   Wallace, Douglas M.
   Pandi-Perumal, Seithikurippu Ratnas
   Williams, Natasha J.
   Castor, Chimene
   Sevick, Mary Ann
   Mcfarlane, Samy I.
   Jean-Louis, Girardin
TI Associations between sleep disturbances and diabetes mellitus among
   blacks with metabolic syndrome: Results from the Metabolic Syndrome
   Outcome Study (MetSO)
SO ANNALS OF MEDICINE
LA English
DT Article
DE Black race/ethnicity; diabetes mellitus; metabolic syndrome; sleep apnea
ID INSULIN-RESISTANCE; RACIAL-DIFFERENCES; AFRICAN-AMERICANS; DURATION;
   APNEA; INDIVIDUALS; DISPARITIES; POPULATION; PREVALENCE; GLUCOSE
AB Introduction. The association between sleep disturbances and cardiometabolic diseases has been understudied in blacks with metabolic syndrome.
   Methods. This study is a cross-sectional analysis of the Metabolic Syndrome Outcome Study (MetSO) trial. We assessed insomnia symptoms, sleep duration, and risk for sleep apnea. Multivariate logistic regression models evaluated the association between sleep disturbances with diabetes mellitus (DM) and the combined outcomes of DM and hypertension as well as DM and dyslipidemia.
   Results. The sample consisted of 1,013 participants, mean age of 62 +/- 14 years and 61% female. DM was diagnosed in 60% of the sample. Sleep apnea risk was observed in 48% of the sample, while 10% had insomnia symptoms and 65% reported short sleep duration (<6 hours). Sleep apnea risk, but not insomnia or sleep duration, was associated with DM (OR 1.66; 95% CI 1.21-2.28), adjusting for age, sex, income, obesity (BMI >= 30 kg/m(2)), tobacco use, alcohol use, hypertension, dyslipidemia, and depression. In fully adjusted models, sleep apnea risk was associated with the combined outcome of DM-hypertension (OR 1.95; 95% CI 1.42-2.69), but not with diabetes-dyslipidemia.
   Conclusion. We observed a strong association between sleep apnea risk and diabetes mellitus among blacks with metabolic syndrome.
C1 [Ramos, Alberto R.; Wallace, Douglas M.] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA.
   [Pandi-Perumal, Seithikurippu Ratnas; Williams, Natasha J.; Sevick, Mary Ann; Jean-Louis, Girardin] NYU, CHBC, Div Hlth & Behav, Dept Populat Hlth,Langone Med Ctr, New York, NY USA.
   [Castor, Chimene] Howard Univ, Dept Nutr Sci, Washington, DC 20059 USA.
   [Mcfarlane, Samy I.] Suny Downstate Med Ctr, Dept Med, New York, NY USA.
RP Ramos, AR (corresponding author), Univ Miami, Miller Sch Med, UHlth Sleep Med Program, Miami, FL 33136 USA.
EM aramos@med.miami.edu
RI Wallace, Douglas/AAL-3719-2020; Pandi-Perumal, Seithikurippu
   R./Q-8281-2016; Sevick, Mary/V-6503-2019; Ramos, Alberto/X-4249-2019
OI Pandi-Perumal, Seithikurippu R./0000-0002-8686-7259; Wallace,
   Douglas/0000-0002-8982-1088; Jean-Louis, Girardin/0000-0001-6777-2724
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01MD004113,
   1KL2TR000461, NCT01946659]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [KL2TR000461] Funding Source: NIH
   RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [R25HL116378]
   Funding Source: NIH RePORTER; National Institute on Minority Health and
   Health DisparitiesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Minority Health & Health Disparities (NIMHD) [R01MD004113] Funding
   Source: NIH RePORTER
FX The authors sincerely acknowledge the financial support received from
   National Institutes of Health R01MD004113, 1KL2TR000461 (A.R.R.),
   NCT01946659.
CR Adenekan B, 2013, SLEEP MED REV, V17, P255, DOI 10.1016/j.smrv.2012.07.002
   Altman NG, 2012, SLEEP MED, V13, P1261, DOI 10.1016/j.sleep.2012.08.005
   American Diabetes Association, 2004, Diabetes Care, V27 Suppl 1, pS5, DOI 10.2337/diacare.27.2007.S5
   ANCOLIISRAEL S, 1995, AM J RESP CRIT CARE, V152, P1946, DOI 10.1164/ajrccm.152.6.8520760
   Barone MTU, 2011, DIABETES RES CLIN PR, V91, P129, DOI 10.1016/j.diabres.2010.07.011
   Bayon V, 2014, ANN MED, V46, P264, DOI 10.3109/07853890.2014.931103
   Cappuccio FP, 2011, EUR HEART J, V32, P1484, DOI 10.1093/eurheartj/ehr007
   Demede M, 2011, INT J HYPERTENS, V2011, DOI 10.4061/2011/340929
   Donat M, 2013, CLIN PRACT LOND, P10
   Fulop T, 2012, SLEEP MED, V13, P1039, DOI 10.1016/j.sleep.2012.06.005
   Gallicchio L, 2009, J SLEEP RES, V18, P148, DOI 10.1111/j.1365-2869.2008.00732.x
   Gangwisch JE, 2007, SLEEP, V30, P1667, DOI 10.1093/sleep/30.12.1667
   Grandner MA, 2013, SLEEP, V36, P769, DOI 10.5665/sleep.2646
   Hale L, 2007, SLEEP, V30, P1096, DOI 10.1093/sleep/30.9.1096
   Ip MSM, 2002, AM J RESP CRIT CARE, V165, P670, DOI 10.1164/ajrccm.165.5.2103001
   JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540
   Kirk JK, 2006, DIABETES CARE, V29, P2130, DOI 10.2337/dc05-1973
   Lauderdale DS, 2008, EPIDEMIOLOGY, V19, P838, DOI 10.1097/EDE.0b013e318187a7b0
   Levendowski DJ, 2008, SLEEP BREATH, V12, P303, DOI 10.1007/s11325-008-0180-z
   Levine DA, 2009, ETHNIC DIS, V19, P97
   Mahmood K, 2009, J CLIN SLEEP MED, V5, P215
   Nunes J, 2008, J NATL MED ASSOC, V100, P317, DOI 10.1016/S0027-9684(15)31244-X
   Pandey A, 2011, CURR DIABETES REP, V11, P35, DOI 10.1007/s11892-010-0164-9
   Peek ME, 2007, MED CARE RES REV, V64, p101S, DOI 10.1177/1077558707305409
   Punjabi NM, 2004, AM J EPIDEMIOL, V160, P521, DOI 10.1093/aje/kwh261
   Pyykkonen AJ, 2014, ANN MED, V46, P324, DOI 10.3109/07853890.2014.902226
   Redline S, 1997, AM J RESP CRIT CARE, V155, P186, DOI 10.1164/ajrccm.155.1.9001310
   Redline S, 2014, AM J RESP CRIT CARE, V189, P335, DOI 10.1164/rccm.201309-1735OC
   Somers VK, 2008, CIRCULATION, V118, P1080, DOI [10.1161/CIRCULATIONAHA.107.189420, 10.1161/CIRCULATIONAHA.107.189375]
   de Mello MT, 2013, INT J PREVENTIVE MED, V4, P246
   Williams NJ, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-225
   Zizi F, 2012, AM J MED, V125, P162, DOI 10.1016/j.amjmed.2011.08.020
NR 32
TC 10
Z9 10
U1 0
U2 11
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0785-3890
EI 1365-2060
J9 ANN MED
JI Ann. Med.
PD MAY
PY 2015
VL 47
IS 3
BP 233
EP 237
DI 10.3109/07853890.2015.1015601
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA CJ5WD
UT WOS:000355562200006
PM 25856540
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Pedigo, CE
   Ducasa, GM
   Leclercq, F
   Sloan, A
   Mitrofanova, A
   Hashmi, T
   Molina-David, J
   Ge, MY
   Lassenius, MI
   Forsblom, C
   Lehto, M
   Groop, PH
   Kretzler, M
   Eddy, S
   Martini, S
   Reich, H
   Wahl, P
   Ghiggeri, G
   Faul, C
   Burke, GW
   Kretz, O
   Huber, TB
   Mendez, AJ
   Merscher, S
   Fornoni, A
AF Pedigo, Christopher E.
   Ducasa, Gloria Michelle
   Leclercq, Farah
   Sloan, Alexis
   Mitrofanova, Alla
   Hashmi, Tahreem
   Molina-David, Judith
   Ge, Mengyuan
   Lassenius, Mariann I.
   Forsblom, Carol
   Lehto, Markku
   Groop, Per-Henrik
   Kretzler, Matthias
   Eddy, Sean
   Martini, Sebastian
   Reich, Heather
   Wahl, Patricia
   Ghiggeri, GianMarco
   Faul, Christian
   Burke, George W., III
   Kretz, Oliver
   Huber, Tobias B.
   Mendez, Armando J.
   Merscher, Sandra
   Fornoni, Alessia
TI Local TNF causes NFATc1-dependent cholesterol-mediated podocyte injury
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID TUMOR-NECROSIS-FACTOR; SHARED TRANSCRIPTIONAL NETWORKS;
   DIABETIC-NEPHROPATHY; EFFLUX CAPACITY; FACTOR-ALPHA; RECEPTORS 1;
   KIDNEY; CYCLOSPORINE; INFLAMMATION; EXPRESSION
AB High levels of circulating TNF and its receptors, TNFR1 and TNFR2, predict the progression of diabetic kidney disease (DKD), but their contribution to organ damage in DIM remains largely unknown. Here, we investigated the function of local and systemic TNF in podocyte injury. We cultured human podocytes with sera collected from DKD patients, who displayed elevated TNF levels, and focal segmental glomerulosclerosis (FSGS) patients, whose TNF levels resembled those of healthy patients. Exogenous TNF administration or local TNF expression was equally sufficient to cause free cholesterol dependent apoptosis in podocytes by acting through a dual mechanism that required a reduction in ATP-binding cassette transporter A1-mediated (ABCA1-mediated) cholesterol efflux and reduced cholesterol esterification by sterol-0-acyltransferase 1 (SOAT1). TNF-induced albuminuria was aggravated in mice with podocyte-specific ABCA1 deficiency and was partially prevented by cholesterol depletion with cyclodextrin. TNF-stimulated free cholesterol-dependent apoptosis in podocytes was mediated by nuclear factor of activated T cells 1 (NFATc1). ABCA1 overexpression or cholesterol depletion was sufficient to reduce albuminuria in mice with podocyte-specific NFATc1 activation. Our data implicate an NFATc1/ABCA1-dependent mechanism in which local TNF is sufficient to cause free cholesterol-dependent podocyte injury irrespective of TNF, TNFR1, or TNFR2 serum levels.
C1 [Pedigo, Christopher E.; Ducasa, Gloria Michelle; Leclercq, Farah; Sloan, Alexis; Mitrofanova, Alla; Hashmi, Tahreem; Molina-David, Judith; Ge, Mengyuan; Wahl, Patricia; Faul, Christian; Merscher, Sandra; Fornoni, Alessia] Univ Miami, Miller Sch Med, Div Nephrol & Hypertens, 1580 NW 10th Ave, Miami, FL 33136 USA.
   [Pedigo, Christopher E.; Ducasa, Gloria Michelle; Leclercq, Farah; Sloan, Alexis; Mitrofanova, Alla; Hashmi, Tahreem; Molina-David, Judith; Ge, Mengyuan; Wahl, Patricia; Faul, Christian; Burke, George W., III; Merscher, Sandra; Fornoni, Alessia] Univ Miami, Miller Sch Med, Peggy & Harold Katz Drug Discovery Ctr, 1580 NW 10th Ave, Miami, FL 33136 USA.
   [Lassenius, Mariann I.; Forsblom, Carol; Lehto, Markku; Groop, Per-Henrik] Folkhalsan Res Ctr, Folkhalsan Inst Genet, Helsinki, Finland.
   [Lassenius, Mariann I.; Forsblom, Carol; Lehto, Markku; Groop, Per-Henrik] Univ Helsinki, Abdominal Ctr Nephrol, Helsinki, Finland.
   [Lassenius, Mariann I.; Forsblom, Carol; Lehto, Markku; Groop, Per-Henrik] Univ Helsinki, Res Programs Unit Diabetes & Obes, Helsinki, Finland.
   [Lassenius, Mariann I.; Forsblom, Carol; Lehto, Markku; Groop, Per-Henrik] Univ Helsinki, Cent Hosp, Helsinki, Finland.
   [Groop, Per-Henrik] Baker IDI Heart & Diabet Inst, Melbourne, Vic, Australia.
   [Kretzler, Matthias; Eddy, Sean; Martini, Sebastian] Univ Michigan, Dept Internal Med, Div Nephrol, Ann Arbor, MI 48109 USA.
   [Reich, Heather] Univ Toronto, Div Nephrol, Toronto, ON, Canada.
   [Ghiggeri, GianMarco] Giannina Gaslini Childrens Hosp, Div Nephrol, Genoa, Italy.
   [Burke, George W., III] Univ Miami, Miller Sch Med, Dept Surg, Miami, FL 33136 USA.
   [Burke, George W., III; Mendez, Armando J.] Univ Miami, Miller Sch Med, Diabet Res Inst, Miami, FL 33136 USA.
   [Kretz, Oliver; Huber, Tobias B.] Univ Freiburg, Fac Med, Med Ctr, Div Renal, Freiburg, Germany.
   [Kretz, Oliver] Univ Freiburg, Fac Med, Dept Neuroanat, Freiburg, Germany.
   [Huber, Tobias B.] Univ Freiburg, BIOSS Ctr Biol Signalling Studies, Freiburg, Germany.
   [Huber, Tobias B.] Freiburg Inst Adv Studies, Freiburg, Germany.
   [Huber, Tobias B.] Ctr Biol Syst Anal ZBSA, Freiburg, Germany.
RP Merscher, S; Fornoni, A (corresponding author), Univ Miami, Miller Sch Med, Div Nephrol & Hypertens, 1580 NW 10th Ave, Miami, FL 33136 USA.; Merscher, S; Fornoni, A (corresponding author), Univ Miami, Miller Sch Med, Peggy & Harold Katz Drug Discovery Ctr, 1580 NW 10th Ave, Miami, FL 33136 USA.
EM smerscher@med.miami.edu; afornoni@med.miami.edu
RI Mitrofanova, Alla/L-1590-2019
OI Mitrofanova, Alla/0000-0001-5065-9522; Ghiggeri, Gian
   Marco/0000-0003-3659-9062; Eddy, Sean/0000-0001-8578-3443; Huber, Tobias
   B./0000-0001-7175-5062; Merscher, Sandra/0000-0002-4757-7494; Kretz,
   Oliver/0000-0003-1152-5956; fornoni, Alessia/0000-0002-1313-7773
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01DK090316, R01DK104753,
   U-24-DK076169, U-54-DK083912, U-M1-DK100846, 1U-L1-TR000460,
   R01HL128714]; Hoffman-La Roche; American Heart Association predoctoral
   fellowshipAmerican Heart Association [14PRE20380743]; Folkhalsan
   Research Foundation; Wilhelm and Else Stockmann Foundation; Liv och
   Halsa Foundation; Waldemar von Frenckells stiftelse; Kyllikki ja Uolevi
   Lehikoinen Foundation; Svenska Kulturfonden; Academy of FinlandAcademy
   of FinlandEuropean Commission; Novo Nordisk FoundationNovo Nordisk
   FoundationNovocure Limited [NNF14SA0003]; Diabetes Research Foundation;
   NIH Rare Disease Clinical Research NetworkUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA
   [U54-DK-083912]; University of MichiganUniversity of Michigan System;
   NephCure Kidney International; Halpin Foundation; German Research
   FoundationGerman Research Foundation (DFG) [CRC 1140, CRC 992]; European
   Research Council (ERC grant)European Research Council (ERC); Excellence
   Initiative of the German Federal and State Governments; NATIONAL CENTER
   FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000460]
   Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [R01HL128714] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Diabetes & Digestive & Kidney Diseases
   (NIDDK) [R01DK104753, UM1DK100846, U24DK076169, P30DK081943,
   U54DK083912, R01DK090316] Funding Source: NIH RePORTER; Novo Nordisk
   FondenNovo Nordisk Foundation [NNF14OC0013659] Funding Source:
   researchfish
FX AF is supported by NIH grants R01DK090316, R01DK104753, U-24-DK076169,
   U-54-DK083912, U-M1-DK100846, and 1U-L1-TR000460. AF, S. Merscher, and
   C. Faul are supported by Hoffman-La Roche. CP is supported by American
   Heart Association predoctoral fellowship 14PRE20380743. C. Faul is
   supported by grant R01HL128714 from the NIH. The study was also
   supported by the Folkhalsan Research Foundation (P-HG), the Wilhelm and
   Else Stockmann Foundation (P-HG, MIL, ML), the Liv och Halsa Foundation
   (P-HG, MIL), Waldemar von Frenckells stiftelse (MIL), Kyllikki ja Uolevi
   Lehikoinen Foundation (MIL), Svenska Kulturfonden (MIL), Academy of
   Finland (P-HG), the Novo Nordisk Foundation (P-HG, NNF14SA0003), and the
   Diabetes Research Foundation (ML). We thank nurses Anna Sandelin, Jaana
   Tuomikangas, and Tuula Soppela at the Folkhalsan Institute of Genetics
   for technical assistance. The Nephrotic Syndrome Study Network
   Consortium (NEPTUNE), U54-DK-083912, is a part of the NIH Rare Disease
   Clinical Research Network, supported through a collaboration between the
   Office of Rare Diseases Research, the National Center for Advancing
   Translational Sciences, and the National Institute of Diabetes and
   Digestive and Kidney Diseases. Additional funding and/or programmatic
   support for this project has also been provided by the University of
   Michigan, NephCure Kidney International, and the Halpin Foundation. This
   study was further supported by the German Research Foundation (CRC 1140,
   CRC 992, and Heisenberg program to TBH), by the European Research
   Council (ERC grant to TBH), and by the Excellence Initiative of the
   German Federal and State Governments (BIOSS to TBH). A special thanks to
   the Katz Family naming the center where these studies were conducted.
CR Bagnis CI, 2002, J AM SOC NEPHROL, V13, P2962, DOI 10.1097/01.ASN.0000034945.61533.26
   Cattran DC, 2007, KIDNEY INT, V72, P1429, DOI 10.1038/sj.ki.5002553
   Chang YC, 2012, J LIPID RES, V53, P1840, DOI 10.1194/jlr.M024471
   Cherney DZI, 2011, DIABETES CARE, V34, P177, DOI 10.2337/dc10-1219
   Delville M, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008538
   DeVries-Seimon T, 2005, J CELL BIOL, V171, P61, DOI 10.1083/jcb.200502078
   Enocsson H, 2013, TRANSL RES, V162, P287, DOI 10.1016/j.trsl.2013.07.003
   Faul C, 2008, NAT MED, V14, P931, DOI 10.1038/nm.1857
   Fazio S, 2001, J CLIN INVEST, V107, P163, DOI 10.1172/JCI10310
   Field FJ, 2010, J LIPID RES, V51, P1407, DOI 10.1194/jlr.M002410
   Fitzgerald ML, 2001, J BIOL CHEM, V276, P15137, DOI 10.1074/jbc.M100474200
   FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0
   Fomoni A, 2011, SCI TRANSL MED, V3
   Fornoni A, 2014, NAT REV NEPHROL, V10, P379, DOI 10.1038/nrneph.2014.87
   Forsblom C, 2014, DIABETES CARE, V37, P2334, DOI 10.2337/dc14-0225
   Gerbod-Giannone MC, 2006, P NATL ACAD SCI USA, V103, P3112, DOI 10.1073/pnas.0510345103
   Gohda T, 2012, J AM SOC NEPHROL, V23, P516, DOI 10.1681/ASN.2011060628
   Gomez-Sintes R, 2010, J CLIN INVEST, V120, P2432, DOI 10.1172/JCI37873
   Grabner A, 2015, CELL METAB, V22, P1020, DOI 10.1016/j.cmet.2015.09.002
   Harrison BC, 2004, MOL CELL BIOL, V24, P10636, DOI 10.1128/MCB.24.24.10636-10649.2004
   Herman-Edelstein M, 2014, J LIPID RES, V55, P561, DOI 10.1194/jlr.P040501
   Hodgin JB, 2013, DIABETES, V62, P299, DOI 10.2337/db11-1667
   Johnson AMF, 2013, CELL, V152, P673, DOI 10.1016/j.cell.2013.01.041
   Joy MS, 2010, AM J KIDNEY DIS, V55, P50, DOI 10.1053/j.ajkd.2009.08.019
   Ju WJ, 2013, GENOME RES, V23, P1862, DOI 10.1101/gr.155697.113
   Kato H, 2011, J BIOL CHEM, V286, P26003, DOI 10.1074/jbc.M111.223164
   Kellner-Weibel G, 1998, ARTERIOSCL THROM VAS, V18, P423, DOI 10.1161/01.ATV.18.3.423
   Khera AV, 2011, NEW ENGL J MED, V364, P127, DOI 10.1056/NEJMoa1001689
   Lassenius MI, 2011, DIABETES CARE, V34, P1809, DOI 10.2337/dc10-2197
   Maitra U, 2009, MOL CELL BIOL, V29, P5989, DOI 10.1128/MCB.00541-09
   Martini S, 2014, J AM SOC NEPHROL, V25, P2559, DOI 10.1681/ASN.2013080906
   Maxfield FR, 2005, NATURE, V438, P612, DOI 10.1038/nature04399
   McKellar GE, 2009, NAT REV CARDIOL, V6, P410, DOI 10.1038/nrcardio.2009.57
   Mendez AJ, 1997, J LIPID RES, V38, P1807
   Merscher-Gomez S, 2013, DIABETES, V62, P3817, DOI 10.2337/db13-0399
   Moriwaki Y, 2003, METABOLISM, V52, P605, DOI 10.1053/meta.2003.50096
   Navarro JF, 2003, AM J KIDNEY DIS, V42, P53, DOI 10.1016/S0272-6386(03)00408-6
   Niewczas MA, 2012, J AM SOC NEPHROL, V23, P507, DOI 10.1681/ASN.2011060627
   Nijenhuis T, 2011, AM J PATHOL, V179, P1719, DOI 10.1016/j.ajpath.2011.06.033
   Pavkov ME, 2016, KIDNEY INT, V89, P226, DOI 10.1038/ki.2015.278
   Paykov ME, 2015, KIDNEY INT, V87, P812, DOI 10.1038/ki.2014.330
   Peyser A, 2010, BMC NEPHROL, V11, DOI 10.1186/1471-2369-11-2
   Pierine DT, 2014, NUTR DIABETES, V4, DOI 10.1038/nutd.2014.39
   Pramanik R, 2003, J BIOL CHEM, V278, P4831, DOI 10.1074/jbc.M207732200
   Rohatgi A, 2014, NEW ENGL J MED, V371, P2383, DOI 10.1056/NEJMoa1409065
   Saleem MA, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133630
   Sampson MG, 2016, J AM SOC NEPHROL, V27, P814, DOI 10.1681/ASN.2014111131
   Saurus P, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.125
   Savin VJ, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/714964
   Scott DL, 2006, NEW ENGL J MED, V355, P704, DOI 10.1056/NEJMct055183
   SELMAJ K, 1991, J CLIN INVEST, V87, P949, DOI 10.1172/JCI115102
   Silverstein DM, 2009, PEDIATR NEPHROL, V24, P1445, DOI 10.1007/s00467-008-1046-0
   Stanley AC, 2014, IMMUNOL CELL BIOL, V92, P275, DOI 10.1038/icb.2013.90
   Tall AR, 2015, NAT REV IMMUNOL, V15, P104, DOI 10.1038/nri3793
   Tejada T, 2008, KIDNEY INT, V73, P1385, DOI 10.1038/ki.2008.109
   Timmins JM, 2005, J CLIN INVEST, V115, P1333, DOI 10.1172/JCI200523915
   Trachtman H, 2015, BMC NEPHROL, V16, DOI 10.1186/s12882-015-0094-5
   TSUKADA N, 1991, J NEUROL SCI, V104, P230, DOI 10.1016/0022-510X(91)90315-X
   Vernooy JH, 2002, AM J RESP CRIT CARE, V166, P1218, DOI 10.1164/rccm.2202023
   Vincent FB, 2013, ANN RHEUM DIS, V72, P165, DOI 10.1136/annrheumdis-2012-202545
   Wang YQ, 2010, J AM SOC NEPHROL, V21, P1657, DOI 10.1681/ASN.2009121253
   Wei CL, 2011, NAT MED, V17, P952, DOI 10.1038/nm.2411
   Wilkins BJ, 2004, CIRC RES, V94, P110, DOI 10.1161/01.RES.0000109415.17511.18
   Winslow MM, 2006, DEV CELL, V10, P771, DOI 10.1016/j.devcel.2006.04.006
   Yabal M, 2014, CELL REP, V7, P1796, DOI 10.1016/j.celrep.2014.05.008
   Yoo TH, 2015, J AM SOC NEPHROL, V26, P133, DOI 10.1681/ASN.2013111213
   Zhang YZ, 2010, CIRCULATION, V121, P1347, DOI 10.1161/CIRCULATIONAHA.109.897330
   Zimmer S, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad6100
NR 68
TC 70
Z9 74
U1 1
U2 7
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD SEP
PY 2016
VL 126
IS 9
BP 3336
EP 3350
DI 10.1172/JCI85939
PG 15
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA DU9CI
UT WOS:000382513400016
PM 27482889
OA Bronze, Green Published
DA 2021-10-30
ER

PT J
AU Kenya, S
   Carrasquillo, O
   Fatil, M
   Jones, J
   Jean, C
   Huff, I
   Kobetz, E
AF Kenya, Sonjia
   Carrasquillo, Olveen
   Fatil, Marie
   Jones, Jamal
   Jean, Chrystelle
   Huff, India
   Kobetz, Erin
TI Human Papilloma Virus and Cervical Cancer Education Needs among
   HIV-Positive Haitian Women in Miami
SO WOMENS HEALTH ISSUES
LA English
DT Article
ID HEALTH-CARE; DADE COUNTY; PREVENTION; HPV; DISPARITIES; BARRIERS
AB Background: Haitian immigrant women, the largest growing Black ethnic group in Miami, experience the highest rates of cervical cancer and account for one of the largest populations diagnosed with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) in South Florida. Using community-based participatory research methods, we conducted a pilot study to examine human papilloma virus (HPV)/cervical cancer knowledge and identify intervention preferences among HIV positive Haitian women.
   Methods: Community health workers conducted three focus groups with 21 HIV-positive Haitian women. All sessions were conducted in Haitian Kreyol, digitally recorded, and subsequently interpreted and transcribed into English. The first focus group assessed HPV/cervical cancer knowledge, the second session explored HPV/cervical cancer considerations specific to HIV-positive women, and the third focus group discussed HPV/cervical cancer screening and intervention preferences. Data analysis was guided by a grounded theory approach.
   Findings: Our sample had limited HPV/cervical cancer knowledge. Misconceptions about screening, transmission, and treatment were common. Participants felt that stigma by providers impacted negatively the care they received and that stigma by the community diminished social support. Strong support for culturally tailored interventions to improve HPV/cervical cancer knowledge was expressed. Although no participants had participated in research previously, all were willing to participate in future trials.
   Conclusions: There is critical need for culturally relevant interventions to improve HPV/cervical cancer knowledge among HIV-positive Haitian women. Copyright (C) 2015 by the Jacobs Institute of Women's Health. Published by Elsevier Inc.
C1 [Kenya, Sonjia; Carrasquillo, Olveen; Jones, Jamal; Huff, India] Univ Miami, Miller Sch Med, Div Gen Med, Miami, FL 33136 USA.
   [Fatil, Marie; Jean, Chrystelle; Kobetz, Erin] Univ Miami, Miller Sch Med, Dept Epidemiol & Publ Hlth, Div Gen Med, Miami, FL 33136 USA.
RP Kenya, S (corresponding author), Univ Miami, Miller Sch Med, Div Gen Med, 1400 NW 10th Ave,Suite 801, Miami, FL 33136 USA.
EM sonjia@drsonjia.com
FU National Cancer InstitutesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [1UL1TR000460]; NATIONAL CANCER INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI) [U54CA153705] Funding Source:
   NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Advancing Translational
   Sciences (NCATS) [UL1TR000460] Funding Source: NIH RePORTER; National
   Institute on Minority Health and Health DisparitiesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Minority Health & Health Disparities
   (NIMHD) [U01MD010614] Funding Source: NIH RePORTER
FX The project described was supported by Grant Number 1UL1TR000460, from
   the National Cancer Institutes.
CR AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T
   Barbee L, 2010, CANCER CAUSE CONTROL, V21, P421, DOI 10.1007/s10552-009-9474-0
   Cene CW, 2013, DIABETES EDUCATOR, V39, P776, DOI 10.1177/0145721713507114
   Centers for Disease Control and Prevention, 2013, HUM PAP HPV VACC
   Colasanti J, 2012, J HEALTH CARE POOR U, V23, P179, DOI 10.1353/hpu.2012.0004
   Cook Ross Inc, 2010, BACKGR HAIT HAIT HLT
   Corbin J., 2007, BASICS QUALITATIVE R
   Flores G, 1998, ARCH PEDIAT ADOL MED, V152, P1119
   Florida Cancer Data System (FCDS), 2004, CERV CANC INC STAG D
   Florida Department of Health, 2012, HIV HAIT BORN FLOR M
   Franco EL, 2001, CAN MED ASSOC J, V164, P1017
   Guendelman S, 2001, HEALTH AFFAIR, V20, P257, DOI 10.1377/hlthaff.20.1.257
   Henderson VA, 2013, PROG COMM HLTH PARTN, V7, P171, DOI 10.1353/cpr.2013.0024
   Henry Kaiser Family Foundation, 2000, KAIS COMM MED UN IMM
   Huicho L., 2010, GLOBAL EXPERIENCE CO
   Israel B A, 2001, Educ Health (Abingdon), V14, P182
   Kobetz E., 2013, COMMUNITY ENGAGED SC
   Kobetz E, 2012, J ONCOL, V2012, DOI 10.1155/2012/728397
   Kobetz Erin, 2009, Prog Community Health Partnersh, V3, P133, DOI 10.1353/cpr.0.0072
   Kobetz E, 2009, AM J PUBLIC HEALTH, V99, P1163, DOI 10.2105/AJPH.2008.142794
   Konopnicki D, 2013, FUTURE VIROL, V8, P903, DOI 10.2217/fvl.13.69
   Lillie-Blanton M, 2001, AM J PUBLIC HEALTH, V91, P1736, DOI 10.2105/AJPH.91.11.1736
   Markowitz LE, 2014, MMWR RECOMM REP, V63, P1
   McCarey C, 2011, BMC WOMENS HEALTH, V11, DOI 10.1186/1472-6874-11-45
   Moyer VA, 2012, ANN INTERN MED, V156, P880, DOI 10.7326/0003-4819-156-12-201206190-00424
   Oster AM, 2009, JAIDS-J ACQ IMM DEF, V51, P430, DOI 10.1097/QAI.0b013e3181acb64a
   PITCHENIK AE, 1983, ANN INTERN MED, V98, P277, DOI 10.7326/0003-4819-98-3-277
   QSR International, 2013, NVIVO QUAL AN SOFTW
   Saint-Jean G, 2005, J HEALTH CARE POOR U, V16, P29, DOI 10.1353/hpu.2005.0016
   Saint-Jean G, 2011, AIDS CARE, V23, P486, DOI 10.1080/09540121.2010.516339
   Schiffman M, 2007, LANCET, V370, P890, DOI 10.1016/S0140-6736(07)61416-0
   Sohmer R., 2005, HAITIAN COMMUNITY MI
NR 32
TC 12
Z9 16
U1 0
U2 21
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1049-3867
EI 1878-4321
J9 WOMEN HEALTH ISS
JI Womens Health Iss.
PD MAY-JUN
PY 2015
VL 25
IS 3
BP 262
EP 266
DI 10.1016/j.whi.2014.12.007
PG 5
WC Public, Environmental & Occupational Health; Women's Studies
SC Public, Environmental & Occupational Health; Women's Studies
GA CN7HG
UT WOS:000358604400011
PM 25864021
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Zaidat, OO
   Yoo, AJ
   Khatri, P
   Tomsick, TA
   von Kummer, R
   Saver, JL
   Marks, MP
   Prabhakaran, S
   Kallmes, DF
   Fitzsimmons, BFM
   Mocco, J
   Wardlaw, JM
   Barnwell, SL
   Jovin, TG
   Linfante, I
   Siddiqui, AH
   Alexander, MJ
   Hirsch, JA
   Wintermark, M
   Albers, G
   Woo, HH
   Heck, DV
   Lev, M
   Aviv, R
   Hacke, W
   Warach, S
   Broderick, J
   Derdeyn, CP
   Furlan, A
   Nogueira, RG
   Yavagal, DR
   Goyal, M
   Demchuk, AM
   Bendszus, M
   Liebeskind, DS
AF Zaidat, Osama O.
   Yoo, Albert J.
   Khatri, Pooja
   Tomsick, Thomas A.
   von Kummer, Ruediger
   Saver, Jeffrey L.
   Marks, Michael P.
   Prabhakaran, Shyam
   Kallmes, David F.
   Fitzsimmons, Brian-Fred M.
   Mocco, J.
   Wardlaw, Joanna M.
   Barnwell, Stanley L.
   Jovin, Tudor G.
   Linfante, Italo
   Siddiqui, Adnan H.
   Alexander, Michael J.
   Hirsch, Joshua A.
   Wintermark, Max
   Albers, Gregory
   Woo, Henry H.
   Heck, Donald V.
   Lev, Michael
   Aviv, Richard
   Hacke, Werner
   Warach, Steven
   Broderick, Joseph
   Derdeyn, Colin P.
   Furlan, Anthony
   Nogueira, Raul G.
   Yavagal, Dileep R.
   Goyal, Mayank
   Demchuk, Andrew M.
   Bendszus, Martin
   Liebeskind, David S.
CA Cerebral Angiographic Revasc
   STIR Revascularization Working Grp
   STIR Thrombolysis Cerebral
TI Recommendations on Angiographic Revascularization Grading Standards for
   Acute Ischemic Stroke A Consensus Statement
SO STROKE
LA English
DT Article
DE AOL; embolectomy; endovascular therapy; grading; IA therapy;
   recanalization; revascularization; score; scoring; stent-retrievers;
   stroke; thrombectomy; TICI; TIMI
ID TISSUE-PLASMINOGEN-ACTIVATOR; MECHANICAL EMBOLUS REMOVAL;
   CEREBRAL-ARTERY OCCLUSION; INTRAARTERIAL THROMBOLYSIS; INTERVENTIONAL
   MANAGEMENT; ENDOVASCULAR REPERFUSION; TRIAL DESIGN; RECANALIZATION;
   THROMBECTOMY; THERAPY
C1 [Zaidat, Osama O.; Fitzsimmons, Brian-Fred M.] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA.
   [Yoo, Albert J.; Hirsch, Joshua A.; Lev, Michael] Harvard Med Ctr, Dept Radiol, Boston, MA USA.
   [Khatri, Pooja; Broderick, Joseph] Univ Cincinnati, Dept Neurol, Cincinnati, OH USA.
   [Tomsick, Thomas A.] Univ Cincinnati, Dept Radiol, Cincinnati, OH USA.
   [von Kummer, Ruediger] Tech Univ Dresden, Dept Radiol, D-01062 Dresden, Germany.
   [Saver, Jeffrey L.; Liebeskind, David S.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA.
   [Marks, Michael P.] Stanford Univ, Dept Radiol, San Francisco, CA USA.
   [Albers, Gregory] Stanford Univ, Dept Neurol, San Francisco, CA USA.
   [Prabhakaran, Shyam] Northwestern Univ, Dept Neurol, Chicago, IL 60611 USA.
   [Kallmes, David F.] Mayo Clin, Dept Radiol, Rochester, MN USA.
   [Mocco, J.] Vanderbilt Univ, Dept Neurosurg, Nashville, TN USA.
   [Wardlaw, Joanna M.] Univ Edinburgh, Dept Clin Neurosci, Edinburgh, Midlothian, Scotland.
   [Barnwell, Stanley L.] Oregon State Univ, Dept Neurosurg, Portland, OR USA.
   [Jovin, Tudor G.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA.
   [Linfante, Italo] Baptist Vasc Ctr, Miami, FL USA.
   [Siddiqui, Adnan H.] SUNY Buffalo, Dept Neurosurg, Buffalo, NY 14260 USA.
   [Alexander, Michael J.] Mt Sinai Med Ctr, Dept Neurosurg, Los Angeles, CA USA.
   [Wintermark, Max] Univ Virginia, Dept Radiol, Charlottesville, VA USA.
   [Woo, Henry H.] SUNY Stony Brook, Dept Neurosurg, East Setauket, NY USA.
   [Heck, Donald V.] Forsyth Med Ctr, Dept Radiol, Kernersville, NC USA.
   [Aviv, Richard] Univ Toronto, Dept Med Imaging, Toronto, ON, Canada.
   [Hacke, Werner] Heidelberg Univ, Dept Neurol, Heidelberg, Germany.
   [Bendszus, Martin] Heidelberg Univ, Dept Neuroradiol, Heidelberg, Germany.
   [Warach, Steven] Univ Med Ctr, Dept Neurol, Bethesda, MD USA.
   [Derdeyn, Colin P.] Washington Univ, Dept Radiol, St Louis, MO USA.
   [Furlan, Anthony] Case Western Reserve Univ, Dept Neurol, Cleveland, OH 44106 USA.
   [Nogueira, Raul G.] Emory Univ, Dept Neurol, Atlanta, GA 30322 USA.
   [Yavagal, Dileep R.] Univ Miami, Dept Neurol, Miami, FL USA.
   [Goyal, Mayank] Univ Calgary, Dept Radiol, Calgary, AB, Canada.
   [Demchuk, Andrew M.] Univ Calgary, Dept Neurol, Calgary, AB, Canada.
RP Zaidat, OO (corresponding author), Froedtert Hosp, Dept Neurol Neurosurg & Radiol, 9200 W Wisconsin Ave, Milwaukee, WI USA.
EM szaidat@mcw.edu
RI Siddiqui, Adnan H./AAG-9781-2019; Goyal, Mayank/AAE-7323-2019; Wardlaw,
   Joanna M/Y-3456-2019; Warach, Steven/R-5074-2019; Hacke,
   Werner/ABE-8661-2020; Demchuk, Andrew M/E-1103-2012; von Kummer,
   Rudiger/AAA-4478-2019
OI Wardlaw, Joanna M/0000-0002-9812-6642; Demchuk, Andrew
   M/0000-0002-4930-7789; von Kummer, Rudiger/0000-0003-0119-4604; Saver,
   Jeffrey/0000-0001-9141-2251; Wintermark, Max/0000-0002-6726-3951;
   Derdeyn, Colin/0000-0002-5932-2683; Alexander,
   Michael/0000-0003-0280-809X
FU Codman Neurovascular (Boston, MA); Medical Research CouncilUK Research &
   Innovation (UKRI)Medical Research Council UK (MRC)European Commission
   [MC_G1002455] Funding Source: researchfish; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000460]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL
   DISORDERS AND STROKEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Neurological Disorders & Stroke (NINDS) [K24NS072272] Funding Source:
   NIH RePORTER
FX An investigator-initiated, independent, unrestricted research grant was
   submitted to Codman Neurovascular (Boston, MA) to support the cerebral
   angiographic revascularization grading consensus meeting. The meeting
   was academically, administratively, and financially managed by the
   statement group, with no control, oversight, or conditions by the
   sponsors.
CR Al-Ali F, 2013, J NEUROINTERV SURG, V5, P139, DOI 10.1136/neurintsurg-2011-010146
   Albers GW, 2011, STROKE, V42, P2645, DOI 10.1161/STROKEAHA.111.618850
   Arnold M, 2005, J NEUROL NEUROSUR PS, V76, P1373, DOI 10.1136/jnnp.2004.055160
   Arnold M, 2004, J NEUROL NEUROSUR PS, V75, P857, DOI 10.1136/jnnp.2003.020479
   Bang OY, 2008, J NEUROL NEUROSUR PS, V79, P625, DOI 10.1136/jnnp.2007.132100
   Bang OY, 2011, STROKE, V42, P693, DOI 10.1161/STROKEAHA.110.595256
   Bar M, 2012, AM J NEURORADIOL, V33, P972, DOI 10.3174/ajnr.A2896
   Bose A, 2008, AM J NEURORADIOL, V29, P1409, DOI 10.3174/ajnr.A1110
   Broderick JP, 2007, STROKE, V38, P2127, DOI 10.1161/STROKEAHA.107.483131
   Broderick JP, 2013, NEW ENGL J MED, V368, P893, DOI 10.1056/NEJMoa1214300
   CANNON CP, 1995, J INTERV CARDIOL, V8, P117, DOI 10.1111/j.1540-8183.1995.tb00526.x
   Castano C, 2010, STROKE, V41, P1836, DOI 10.1161/STROKEAHA.110.584904
   CHESEBRO JH, 1987, CIRCULATION, V76, P142, DOI 10.1161/01.CIR.76.1.142
   Christoforidis GA, 2005, AM J NEURORADIOL, V26, P1789
   Davalos A, 2012, STROKE, V43, P2699, DOI 10.1161/STROKEAHA.112.663328
   Dorn F, 2012, NEURORADIOLOGY, V54, P745, DOI 10.1007/s00234-011-0966-8
   Eesa M, 2011, INTERV NEURORADIOL, V17, P228, DOI 10.1177/159101991101700215
   Fields JD, 2011, AM J NEURORADIOL, V32, P2170, DOI 10.3174/ajnr.A2709
   Flint AC, 2007, STROKE, V38, P1274, DOI 10.1161/01.STR.0000260187.33864.a7
   Fredieu A, 2002, STROKE, V33, P352
   Furlan A, 1999, JAMA-J AM MED ASSOC, V282, P2003, DOI 10.1001/jama.282.21.2003
   GLASER EM, 1980, J APPL BEHAV SCI, V16, P79, DOI 10.1177/002188638001600107
   Gobin YP, 2004, STROKE, V35, P2848, DOI 10.1161/01.STR.0000147718.12954.60
   Goyal M, 2013, J NEUROINTERV SURG
   Gupta R, 2013, J NEUROINTERV SURG, V5, P294, DOI 10.1136/neurintsurg-2011-010245
   Gupta R, 2009, J NEUROIMAGING, V19, P61, DOI 10.1111/j.1552-6569.2008.00197.x
   Higashida RT, 2003, STROKE, V34, pE109, DOI 10.1161/01.STR.0000082721.62796.09
   Janjua N, 2008, AM J NEURORADIOL, V29, P253, DOI 10.3174/ajnr.A0825
   Kallmes DF, 2012, AM J NEURORADIOL, V33, P975, DOI 10.3174/ajnr.A2905
   Khatri P, 2005, STROKE, V36, P2400, DOI 10.1161/01.STR.0000185698.45720.58
   Khatri P, 2009, NEUROLOGY, V73, P1066, DOI 10.1212/WNL.0b013e3181b9c847
   Khatri P, 2008, INT J STROKE, V3, P130, DOI 10.1111/j.1747-4949.2008.00151.x
   Kidwell CS, 2013, NEW ENGL J MED, V368, P914, DOI 10.1056/NEJMoa1212793
   King S, 2007, AM J NEURORADIOL, V28, P1890, DOI 10.3174/ajnr.A0702
   Langer D, 2009, STROKE, V40, P2761, DOI 10.1161/STROKEAHA.108.544957
   Lansberg MG, 2012, LANCET NEUROL, V11, P860, DOI 10.1016/S1474-4422(12)70203-X
   Liebeskind DS, 2010, J NEUROIMAGING, V20, P78, DOI 10.1111/j.1552-6569.2008.00295.x
   Lin R, 2009, STROKE, V40, P2092, DOI 10.1161/STROKEAHA.108.544783
   Marks MP, 2013, STROKE, V44, pA63
   McVerry F, 2012, AM J NEURORADIOL, V33, P576, DOI 10.3174/ajnr.A2794
   Miteff F, 2009, BRAIN, V132, P2231, DOI 10.1093/brain/awp155
   MORI E, 1992, NEUROLOGY, V42, P976, DOI 10.1212/WNL.42.5.976
   Nam HS, 2011, EUR J NEUROL, V18, P1171, DOI 10.1111/j.1468-1331.2011.03360.x
   National Institute of Health, NIH CONS DEV PROGR
   Nogueira RG, 2012, LANCET, V380, P1231, DOI 10.1016/S0140-6736(12)61299-9
   Nogueira RG, 2009, STROKE, V40, P3777, DOI 10.1161/STROKEAHA.109.561431
   Ogawa A, 2007, STROKE, V38, P2633, DOI 10.1161/STROKEAHA.107.488551
   Ohta H, 2004, STROKE, V35, P893, DOI 10.1161/01.STR.0000119751.92640.7F
   PASSAMANI E, 1985, NEW ENGL J MED, V312, P932
   Qureshi AI, 2002, NEUROSURGERY, V50, P1405, DOI 10.1097/00006123-200206000-00049
   Rha JH, 2007, STROKE, V38, P967, DOI 10.1161/01.STR.0000258112.14918.24
   Saver JL, 2012, LANCET, V380, P1241, DOI 10.1016/S0140-6736(12)61384-1
   Saver JL, 2010, STROKE, V41, pE115, DOI 10.1161/STROKEAHA.109.566406
   Schonewille WJ, 2009, LANCET NEUROL, V8, P724, DOI 10.1016/S1474-4422(09)70173-5
   Shah QA, 2007, NEUROCRIT CARE, V7, P53, DOI 10.1007/s12028-007-0035-7
   Smith WS, 2006, AM J NEURORADIOL, V27, P1177
   Smith WS, 2005, STROKE, V36, P1432, DOI 10.1161/01.STR.0000171066.25248.1d
   Soares BP, 2010, STROKE, V41, pE34, DOI 10.1161/STROKEAHA.109.568766
   Sugg R, 2011, J NEUROINTERV SURG, V3, pA1
   Suh HS, 2013, STROKE IN PRESS
   Sun CHJ, 2013, CIRCULATION, V127, P1139, DOI 10.1161/CIRCULATIONAHA.112.000506
   Tomsick T, 2008, AM J NEURORADIOL, V29, P582, DOI 10.3174/ajnr.A0843
   Tomsick T, 2013, ISC FEB 7 HON HA
   Tomsick T, 2007, AM J NEURORADIOL, V28, P382
   VONKUMMER R, 1995, STROKE, V26, P581, DOI 10.1161/01.STR.26.4.581
   Wheeler HM, 2013, STROKE, V44, P681, DOI 10.1161/STROKEAHA.111.000135
   YOO AJ, 2013, STROKE, V44, pA62, DOI DOI 10.1161/STROKEAHA.113.001990
   Yoo AJ, 2012, STROKE, V43, P1323, DOI 10.1161/STROKEAHA.111.639401
   Yoo AJ, 2009, STROKE, V40, P2046, DOI 10.1161/STROKEAHA.108.541656
   Zaidat OO, 2012, NEUROLOGY, V79, pS110, DOI 10.1212/WNL.0b013e3182695916
   Zaidat OO, 2005, AM J NEURORADIOL, V26, P880
   Zaidat OO, 2002, STROKE, V33, P1821, DOI 10.1161/01.STR.0000020363.23725.67
   Zaidat OO, 2012, NEUROLOGY, V79, pS221, DOI 10.1212/WNL.0b013e31826992cf
NR 73
TC 737
Z9 768
U1 2
U2 32
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0039-2499
EI 1524-4628
J9 STROKE
JI Stroke
PD SEP
PY 2013
VL 44
IS 9
BP 2650
EP 2663
DI 10.1161/STROKEAHA.113.001972
PG 14
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 293OP
UT WOS:000329982500066
PM 23920012
OA Green Accepted, Bronze
HC Y
HP N
DA 2021-10-30
ER

PT J
AU Magnani, DM
   Silveira, CGT
   Rosen, BC
   Ricciardi, MJ
   Pedreno-Lopez, N
   Gutman, MJ
   Bailey, VK
   Maxwell, HS
   Domingues, A
   Gonzalez-Nieto, L
   Avelino-Silva, VI
   Trindade, M
   Nogueira, J
   Oliveira, CS
   Maestri, A
   Felix, AC
   Levi, JE
   Nogueira, ML
   Martins, MA
   Martinez-Navio, JM
   Fuchs, SP
   Whitehead, SS
   Burton, DR
   Desrosiers, RC
   Kallas, EG
   Watkins, DI
AF Magnani, Diogo M.
   Silveira, Cassia G. T.
   Rosen, Brandon C.
   Ricciardi, Michael J.
   Pedreno-Lopez, Nuria
   Gutman, Martin J.
   Bailey, Varian K.
   Maxwell, Helen S.
   Domingues, Aline
   Gonzalez-Nieto, Lucas
   Avelino-Silva, Vivian I.
   Trindade, Mateus
   Nogueira, Juliana
   Oliveira, Consuelo S.
   Maestri, Alvino
   Felix, Alvina Clara
   Levi, Jose Eduardo
   Nogueira, Mauricio L.
   Martins, Mauricio A.
   Martinez-Navio, Jose M.
   Fuchs, Sebastian P.
   Whitehead, Stephen S.
   Burton, Dennis R.
   Desrosiers, Ronald C.
   Kallas, Esper G.
   Watkins, David I.
TI A human inferred germline antibody binds to an immunodominant epitope
   and neutralizes Zika virus
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID INTERIM GUIDELINES; UNITED-STATES; MONOCLONAL-ANTIBODIES; SOMATIC
   HYPERMUTATION; PREGNANT-WOMEN; HIV-1 VACCINE; B-CELLS; RESPONSES;
   INFECTION; IMMUNOGLOBULIN
AB The isolation of neutralizing monoclonal antibodies (nmAbs) against the Zika virus (ZIKV) might lead to novel preventative strategies for infections in at-risk individuals, primarily pregnant women. Here we describe the characterization of human mAbs from the plasmablasts of an acutely infected patient. One of the 18 mAbs had the unusual feature of binding to and neutralizing ZIKV despite not appearing to have been diversified by affinity maturation. This mAb neutralized ZIKV (Neut(50) similar to 2 mu g/ml) but did not react with any of the four dengue virus serotypes. Except for the expected junctional diversity created by the joining of the V-(D)-J genes, there was no deviation from immunoglobulin germline genes. This is a rare example of a human mAb with neutralizing activity in the absence of detectable somatic hypermutation. Importantly, binding of this mAb to ZIKV was specifically inhibited by human plasma from ZIKV-exposed individuals, suggesting that it may be of value in a diagnostic setting.
C1 [Magnani, Diogo M.; Rosen, Brandon C.; Ricciardi, Michael J.; Pedreno-Lopez, Nuria; Gutman, Martin J.; Bailey, Varian K.; Maxwell, Helen S.; Domingues, Aline; Gonzalez-Nieto, Lucas; Martins, Mauricio A.; Martinez-Navio, Jose M.; Fuchs, Sebastian P.; Desrosiers, Ronald C.; Watkins, David I.] Univ Miami, Dept Pathol, Miami, FL 33136 USA.
   [Silveira, Cassia G. T.; Maestri, Alvino; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, SP, Brazil.
   [Avelino-Silva, Vivian I.; Trindade, Mateus] Hosp Sirio Libanes, Sao Paulo, SP, Brazil.
   [Trindade, Mateus] Univ Sao Paulo, Sch Med, Neurol Dept, Sao Paulo, SP, Brazil.
   [Nogueira, Juliana] Adolfo Lutz Inst, Sao Paulo, SP, Brazil.
   [Oliveira, Consuelo S.] Inst Evandro Chagas, Belem, Para, Brazil.
   [Felix, Alvina Clara; Levi, Jose Eduardo] Univ Sao Paulo, Inst Med Trop Sao Paulo, Dept Molestias Infecciosas & Parasitarias LIM 52, Sao Paulo, SP, Brazil.
   [Felix, Alvina Clara; Levi, Jose Eduardo] Univ Sao Paulo, Fac Med, Sao Paulo, SP, Brazil.
   [Nogueira, Mauricio L.] Fac Med Sao Jose do Rio Preto, Dept Doencas Dermatol Infecciosas & Parasitarias, Lab Pesquisas Virol, Sao Jose Do Rio Preto, SP, Brazil.
   [Whitehead, Stephen S.] NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA.
   [Burton, Dennis R.] Scripps Res Inst, Dept Immunol & Microbiol, La Jolla, CA 92037 USA.
   [Burton, Dennis R.] Ragon Inst Massachusetts Gen Hosp Massachusetts I, Cambridge, MA USA.
RP Watkins, DI (corresponding author), Univ Miami, Dept Pathol, Miami, FL 33136 USA.
EM dwatkins@med.miami.edu
RI Lopez, Nuria Pedreno/AAG-9496-2021; Whitehead, Stephen/AAG-2787-2019;
   Nogueira, Mauricio L/B-7599-2012; amsalu, ribka/G-8780-2019; Martins,
   Mauricio/AAU-9226-2020; Avelino-Silva, Vivian I/L-2640-2013; Silveira,
   Cassia G Terrassani/M-8057-2017
OI Lopez, Nuria Pedreno/0000-0001-6927-2301; Nogueira, Mauricio
   L/0000-0003-1102-2419; Martins, Mauricio/0000-0001-8336-216X;
   Avelino-Silva, Vivian I/0000-0002-6660-3088; Martinez-Navio,
   Jose/0000-0003-0560-5407; Magnani, Diogo/0000-0002-1773-2406; Kallas,
   Esper/0000-0003-2026-6925
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [4P01AI094420-05]; Wallace H. Coulter
   Center for Translational Research at University of Miami; Miami Clinical
   and Translational Science Institute (CTSI); NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000460]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [ZIAAI000891] Funding Source:
   NIH RePORTER
FX This work was supported by the NIH grant 4P01AI094420-05, the Wallace H.
   Coulter Center for Translational Research at the University of Miami
   [http://www.miami.edu.access.library.miami.edu/index.php/u innovation/about_us/whcc/], and the
   Miami Clinical and Translational Science Institute (CTSI) [http://.access.library.miami.edu   miamictsi.org].The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Barba-Spaeth G, 2016, NATURE, V536, P48, DOI 10.1038/nature18938
   Bonsignori M, 2016, CELL, V165, P449, DOI 10.1016/j.cell.2016.02.022
   BOORMAN J. P. T., 1956, Transactions of the Royal Society of Tropical Medicine and Hygiene, V50, P238, DOI 10.1016/0035-9203(56)90029-3
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Brasil P, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004636
   Burton DR, 2016, ANNU REV IMMUNOL, V34, P635, DOI 10.1146/annurev-immunol-041015-055515
   Calvet G, 2016, LANCET INFECT DIS, V16, P653, DOI 10.1016/S1473-3099(16)00095-5
   Corti D, 2016, SCIENCE, V351, P1339, DOI 10.1126/science.aad5224
   Davidson E, 2014, IMMUNOLOGY, V143, P13, DOI 10.1111/imm.12323
   de Alwis R, 2014, METHODS MOL BIOL, V1138, P27, DOI 10.1007/978-1-4939-0348-1_3
   de Paula Freitas B, 2016, JAMA OPHTHALMOL
   Dejnirattisai W, 2015, NAT IMMUNOL, V16, P170, DOI 10.1038/ni.3058
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Durbin AP, 2001, AM J TROP MED HYG, V65, P405, DOI 10.4269/ajtmh.2001.65.405
   Dyer O, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h6983
   Eisen HN, 2014, CANCER IMMUNOL RES, V2, P381, DOI 10.1158/2326-6066.CIR-14-0029
   Faye O, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002636
   Fields B.N., 2007, FIELDS VIROLOGY
   Fink K, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00078
   Gatherer D, 2016, J GEN VIROL, V97, P269, DOI 10.1099/jgv.0.000381
   Giudicelli V., 2011, COLD SPRING HARB PRO, V6, P695, DOI DOI 10.1101/PDB.PR0T5633
   Godoy-Lozano EE, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0276-1
   HADDOW AJ, 1964, B WORLD HEALTH ORGAN, V31, P57
   Hangartner L, 2006, NAT REV IMMUNOL, V6, P231, DOI 10.1038/nri1783
   Hayes EB, 2009, EMERG INFECT DIS, V15, P1347, DOI 10.3201/eid1509.090442
   Hennessey M, 2016, MMWR-MORBID MORTAL W, V65, P55, DOI 10.15585/mmwr.mm6503e1
   Hessell AJ, 2007, NATURE, V449, P101, DOI 10.1038/nature06106
   Honein MA, 2017, JAMA-J AM MED ASSOC, V317, P59, DOI 10.1001/jama.2016.19006
   Huzly D, 2016, EUROSURVEILLANCE, V21, P9, DOI 10.2807/1560-7917.ES.2016.21.16.30203
   Kalinke U, 2000, P NATL ACAD SCI USA, V97, P10126, DOI 10.1073/pnas.97.18.10126
   Kalinke U, 1996, IMMUNITY, V5, P639, DOI 10.1016/S1074-7613(00)80277-0
   Kato M, 2015, J VIROL, V89, P1468, DOI 10.1128/JVI.02293-14
   KAVERI SV, 1991, CLIN EXP IMMUNOL, V86, P192
   Klein F, 2013, SCIENCE, V341, P1199, DOI 10.1126/science.1241144
   Klein F, 2013, CELL, V153, P126, DOI 10.1016/j.cell.2013.03.018
   Kraus AA, 2007, J CLIN MICROBIOL, V45, P3777, DOI 10.1128/JCM.00827-07
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lefranc MP, 2003, DEV COMP IMMUNOL, V27, P55, DOI 10.1016/S0145-305X(02)00039-3
   Likos A, 2016, MMWR-MORBID MORTAL W, V65, P1032, DOI 10.15585/mmwr.mm6538e1
   Martines RB, 2016, LANCET, V388, P898, DOI 10.1016/S0140-6736(16)30883-2
   Martines RB, 2016, MMWR-MORBID MORTAL W, V65, P159, DOI 10.15585/mmwr.mm6506e1
   Mascola JR, 2013, IMMUNOL REV, V254, P225, DOI 10.1111/imr.12075
   McCarthy M, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i1180
   McCarthy M, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i720
   Melo ASO, 2016, ULTRASOUND OBST GYN, V47, P6, DOI 10.1002/uog.15831
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Mor G, 2016, AM J REPROD IMMUNOL, V75, P421, DOI 10.1111/aji.12505
   Oduyebo T, 2016, MMWR-MORBID MORTAL W, V65, P122, DOI 10.15585/mmwr.mm6505e2
   Oster AM, 2016, MMWR-MORBID MORTAL W, V65, P120, DOI 10.15585/mmwr.mm6505e1
   Petersen EE, 2016, MMWR-MORBID MORTAL W, V65, P30, DOI 10.15585/mmwr.mm6502e1
   Priyamvada L, 2016, P NATL ACAD SCI USA, V113, P7852, DOI 10.1073/pnas.1607931113
   Qiu XG, 2014, NATURE, V514, P47, DOI 10.1038/nature13777
   Rabe IB, 2016, MMWR-MORBID MORTAL W, V65, P543, DOI 10.15585/mmwr.mm6521e1
   ROOST HP, 1995, P NATL ACAD SCI USA, V92, P1257, DOI 10.1073/pnas.92.5.1257
   Sapparapu G, 2016, NATURE, V540, P443, DOI 10.1038/nature20564
   Sarno M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004517
   Schuler-Faccini L, 2016, MMWR-MORBID MORTAL W, V65, P59, DOI 10.15585/mmwr.mm6503e2
   Sok D, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003754
   Speer SD, 2016, SCIENCE, V353, P750, DOI 10.1126/science.aah6187
   Staples JE, 2016, MMWR-MORBID MORTAL W, V65, P63, DOI 10.15585/mmwr.mm6503e3
   Stettler K, 2016, SCIENCE, V353, P823, DOI 10.1126/science.aaf8505
   Sukupolvi-Petty S, 2010, J VIROL, V84, P9227, DOI 10.1128/JVI.01087-10
   Takemori T, 2014, EUR J IMMUNOL, V44, P1258, DOI 10.1002/eji.201343716
   Thornburg NJ, 2016, J CLIN INVEST, V126, P1482, DOI 10.1172/JCI85317
   Tiller T, 2008, J IMMUNOL METHODS, V329, P112, DOI 10.1016/j.jim.2007.09.017
   Tiller T, 2007, IMMUNITY, V26, P205, DOI 10.1016/j.immuni.2007.01.009
   Wakerley BR, 2014, NAT REV NEUROL, V10, P537, DOI 10.1038/nrneurol.2014.138
   Wang QH, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aai8336
   West AP, 2014, CELL, V156, P633, DOI 10.1016/j.cell.2014.01.052
   Wrammert J, 2012, J VIROL, V86, P2911, DOI 10.1128/JVI.06075-11
   Xiao XD, 2009, BIOCHEM BIOPH RES CO, V390, P404, DOI 10.1016/j.bbrc.2009.09.029
   Ye J, 2013, NUCLEIC ACIDS RES, V41, pW34, DOI 10.1093/nar/gkt382
NR 72
TC 7
Z9 7
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD JUN
PY 2017
VL 11
IS 6
AR e0005655
DI 10.1371/journal.pntd.0005655
PG 17
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA EZ9WL
UT WOS:000405080700038
OA Green Submitted, Green Published, gold
DA 2021-10-30
ER

PT J
AU Palacio, AM
   Vidot, DC
   Tamariz, LJ
   Uribe, C
   Hazel-Fernandez, L
   Li, H
   Garay, SD
   Carrasquillo, O
AF Palacio, Ana M.
   Vidot, Denise C.
   Tamariz, Leonardo J.
   Uribe, Claudia
   Hazel-Fernandez, Leslie
   Li, Hua
   Garay, Sylvia D.
   Carrasquillo, Olveen
TI Can We Identify Minority Patients at Risk of Nonadherence to
   Antiplatelet Medication at the Time of Coronary Stent Placement?
SO JOURNAL OF CARDIOVASCULAR NURSING
LA English
DT Article
DE medication adherence; minorities; motivational interviewing;
   percutaneous coronary intervention
ID DRUG-ELUTING STENTS; ADMINISTRATIVE DATABASES; COMORBIDITY INDEX; HEALTH
   LITERACY; CLOPIDOGREL USE; ADHERENCE; DEPRESSION; MORTALITY; OUTCOMES;
   STATINS
AB Background: Lack of medication adherence is associated with significant morbidity and mortality, particularly among minorities. We aim to identify predictors of nonadherence to antiplatelet medications at the time of percutaneous coronary intervention (PCI) with stent among African American and Hispanic patients. Methods: We used data collected for a randomized clinical trial that recruited 452 minority patients from a large US health insurance organization in 2010 post-PCI to compare telephone-based motivational interviewing by trained nurses with an educational video. The primary outcome was 12-month adherence to antiplatelet medications measured by the claims-based medication possession ratio (MPR). Adequate adherence was defined as an MPR of 0.80 or higher. Results: More than half of the sample (age, 69.52 +/- 8.8 years) was male (57%) and Hispanic (57%). Most (78%) had a median income below $30 000 and 22% completed high school or higher. Univariate analyses revealed that symptoms of depression (<.01) and not having a spouse (P = .03) were associated with inadequate adherence. In multivariate analysis, baseline self-reported adherence (1.4; 95% confidence interval [CI], 1.05-1.89), depressive symptoms (0.49; 95% CI, 0.7-0.90), comorbidity (0.89; 95% CI, 0.80-0.98), and telephone-based motivational interviewing by trained nurses (3.5; 95% CI, 1.9-2.70) were associated with adherence. Conclusions: Having multiple comorbidities, depression, suboptimal adherence to medications, and low English proficiency at the time of PCI increase the risk of poor 12-month adherence to antiplatelets among minorities. Identifying these risk factors can guide PCI therapy and the use of evidence-based strategies to improve long-term adherence.
C1 [Palacio, Ana M.; Tamariz, Leonardo J.; Li, Hua; Garay, Sylvia D.; Carrasquillo, Olveen] Univ Miami Miller, Dept Med, Sch Med, Miami, FL USA.
   [Palacio, Ana M.; Tamariz, Leonardo J.; Li, Hua; Carrasquillo, Olveen] Univ Miami Miller, Dept Publ Hlth Sci, Sch Med, Miami, FL USA.
   [Palacio, Ana M.; Tamariz, Leonardo J.; Li, Hua] Univ Miami Miller, Vet Affairs Med Ctr, Miami, FL USA.
   [Vidot, Denise C.] Univ Miami, Sch Nursing & Hlth Studies, Miami, FL USA.
   [Uribe, Claudia; Hazel-Fernandez, Leslie] Comprehens Hlth Insights, Miami, FL USA.
RP Palacio, AM (corresponding author), Univ Miami, Miller Sch Med, 1120 NW 14th St,Suite 964, Miami, FL 33136 USA.
EM APalacio2@med.miami.edu
OI Tamariz, Leonardo/0000-0003-1583-3534
FU National Center on Minority Health and Health Disparities under Recovery
   Act (ARRA) grant [RC1 MD004327]; NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [UL1TR000460] Funding Source:
   NIH RePORTER; NATIONAL CENTER ON MINORITY HEALTH AND HEALTH
   DISPARITIESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Minority
   Health & Health Disparities (NIMHD) [RC1MD004327] Funding Source: NIH
   RePORTER
FX The study was sponsored by National Center on Minority Health and Health
   Disparities under Recovery Act (ARRA) grant RC1 MD004327.
CR ANDA R, 1993, EPIDEMIOLOGY, V4, P285, DOI 10.1097/00001648-199307000-00003
   Berkman ND, 2011, ANN INTERN MED, V155, P97, DOI 10.7326/0003-4819-155-2-201107190-00005
   Carney RM, 2003, BIOL PSYCHIAT, V54, P241, DOI 10.1016/S0006-3223(03)00111-2
   Carney RM, 2002, J PSYCHOSOM RES, V53, P897, DOI 10.1016/S0022-3999(02)00311-2
   Chew LD, 2008, J GEN INTERN MED, V23, P561, DOI 10.1007/s11606-008-0520-5
   DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8
   Eisenstein EL, 2007, JAMA-J AM MED ASSOC, V297, P159, DOI 10.1001/jama.297.2.joc60179
   Epstein AJ, 2012, MED CARE, V50, P1, DOI 10.1097/MLR.0b013e31822d5de9
   Federspiel JJ, 2013, J EVAL CLIN PRACT, V19, P256, DOI 10.1111/j.1365-2753.2011.01809.x
   Fisher L, 2013, DIABETES CARE, V36, P2551, DOI 10.2337/dc12-2493
   Gellad WF, 2011, AM J GERIATR PHARMAC, V9, P11, DOI 10.1016/j.amjopharm.2011.02.004
   Hannan EL, 2007, AM J CARDIOL, V100, P1192, DOI 10.1016/j.amjcard.2007.05.039
   Haynes RB, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000011.pub3
   Heisler M, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-95
   Hermanns N, 2015, DIABETES CARE, V38, P551, DOI 10.2337/dc14-1416
   Hess LM, 2006, ANN PHARMACOTHER, V40, P1280, DOI 10.1345/aph.1H018
   Jiang W, 2001, ARCH INTERN MED, V161, P1849, DOI 10.1001/archinte.161.15.1849
   King Spencer B 3rd, 2008, J Am Coll Cardiol, V51, P172, DOI 10.1016/j.jacc.2007.10.002
   Klamerus ML, 2014, CHRONIC ILLN, V10, P60, DOI 10.1177/1742395313496590
   Kripalani S, 2015, J HEALTH COMMUN, V20, P34, DOI 10.1080/10810730.2015.1080331
   Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x
   Lett HS, 2004, PSYCHOSOM MED, V66, P305, DOI 10.1097/01.psy.0000126207.43307.c0
   Levine GN, 2011, J AM COLL CARDIOL, V58, pE44, DOI 10.1016/j.jacc.2011.08.007
   Maisel WH, 2007, NEW ENGL J MED, V356, P981, DOI 10.1056/NEJMp068305
   Mann DM, 2010, ANN PHARMACOTHER, V44, P1410, DOI 10.1345/aph.1P150
   Miller NH, 2012, J CARDIOPULM REHABIL, V32, P63, DOI 10.1097/HCR.0b013e318235c729
   Miller WR., 2013, MOTIVATIONAL INTERVI, V3rd ed
   MORISKY DE, 1990, HEALTH EDUC QUART, V17, P253, DOI 10.1177/109019819001700303
   Morisky DE, 1986, MED CARE
   Morisky DE, 2011, J CLIN EPIDEMIOL, V64, P255, DOI 10.1016/j.jclinepi.2010.09.002
   Needham DM, 2005, J CRIT CARE, V20, P12, DOI 10.1016/j.jcrc.2004.09.007
   Ogedegbe G, 2008, AM J HYPERTENS, V21, P1137, DOI 10.1038/ajh.2008.240
   Olafiranye O, 2015, INT J CARDIOL, V184, P79, DOI 10.1016/j.ijcard.2015.01.071
   Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100
   Palacio AM, 2015, J GEN INTERN MED, V30, P469, DOI 10.1007/s11606-014-3139-8
   Palacio AM, 2012, HEALTH SERV RES, V47, P770, DOI 10.1111/j.1475-6773.2011.01316.x
   Pallares MJ, 2009, ANN PHARMACOTHER, V43, P259, DOI 10.1345/aph.1L286
   Park DW, 2006, AM J CARDIOL, V98, P352, DOI 10.1016/j.amjcard.2006.02.039
   Park DW, 2008, JACC-CARDIOVASC INTE, V1, P494, DOI 10.1016/j.jcin.2008.06.011
   Perreault S, 2005, BRIT J CLIN PHARMACO, V59, P564, DOI 10.1111/j.1365-2125.2005.02355.x
   Prochaska J O, 1992, Prog Behav Modif, V28, P183
   Rasmussen JN, 2007, J EPIDEMIOL COMMUN H, V61, P1091, DOI 10.1136/jech.2006.055525
   ROLLNICK S, 2008, COPD, V5, P203, DOI DOI 10.1080/15412550802093108
   Schectman JM, 2002, DIABETES CARE, V25, P1015, DOI 10.2337/diacare.25.6.1015
   Sorlie PD, 2010, ANN EPIDEMIOL, V20, P629, DOI 10.1016/j.annepidem.2010.03.015
   Tamariz L, 2008, J AM COLL CARDIOL, V51, pA360
   Vinker S, 2008, AM J MANAG CARE, V14, P388
NR 47
TC 3
Z9 5
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0889-4655
EI 1550-5049
J9 J CARDIOVASC NURS
JI J. Cardiovasc. Nurs.
PD NOV-DEC
PY 2017
VL 32
IS 6
BP 522
EP 529
DI 10.1097/JCN.0000000000000387
PG 8
WC Cardiac & Cardiovascular Systems; Nursing
SC Cardiovascular System & Cardiology; Nursing
GA FT6KG
UT WOS:000423262400009
PM 28060084
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Glynn, TR
   Safren, SA
   Carrico, AW
   Mendez, NA
   Duthely, LM
   Dale, SK
   Jones, DL
   Feaster, DJ
   Rodriguez, AE
AF Glynn, Tiffany R.
   Safren, Steven A.
   Carrico, Adam W.
   Mendez, Noelle A.
   Duthely, Lunthita M.
   Dale, Sannisha K.
   Jones, Deborah L.
   Feaster, Daniel J.
   Rodriguez, Allan E.
TI High Levels of Syndemics and Their Association with Adherence, Viral
   Non-suppression, and Biobehavioral Transmission Risk in Miami, a US City
   with an HIV/AIDS Epidemic
SO AIDS AND BEHAVIOR
LA English
DT Article
DE HIV/AIDS; Syndemics; Adherence; Unsuppressed virus; Biobehavioral
   transmission risk
ID HIV DISEASE PROGRESSION; ANTIRETROVIRAL THERAPY; MEDICATION ADHERENCE;
   PSYCHOSOCIAL PROBLEMS; EMPIRICAL TESTS; SUBSTANCE-ABUSE;
   CANCER-PATIENTS; POSITIVE MEN; HEALTH; CARE
AB Miami is a Southeastern United States (U.S.) city with high health, mental health, and economic disparities, high ethnic/racial diversity, low resources, and the highest HIV incidence and prevalence in the country. Syndemic theory proposes that multiple, psychosocial comorbidities synergistically fuel the HIV/AIDS epidemic. People living with HIV/AIDS in Miami may be particularly affected by this due to the unique socioeconomic context. From April 2017 to October 2018, 800 persons living with HIV/AIDS in a public HIV clinic in Miami completed an interviewer-administered behavioral and chart-review cross-sectional assessment to examine the prevalence and association of number of syndemics (unstable housing, low education, depression, anxiety, binge drinking, drug use, violence, HIV-related stigma) with poor ART adherence, unsuppressed HIV viral load (>= 200 copies/mL), and biobehavioral transmission risk (condomless sex in the context of unsuppressed viral load). Overall, the sample had high prevalence of syndemics (M = 3.8), with almost everyone (99%) endorsing at least one. Each syndemic endorsed was associated with greater odds of: less than 80% ART adherence (aOR 1.64, 95% CI 1.38, 1.98); having unsuppressed viral load (aOR 1.16, 95% CI 1.01, 1.33); and engaging in condomless sex in the context of unsuppressed viral load (1.78, 95% CI 1.30, 2.46). The complex syndemic of HIV threatens to undermine the benefits of HIV care and are important to consider in comprehensive efforts to address the disproportionate burden of HIV/AIDS in the Southern U.S. Achieving the 90-90-90 UNAIDS and the recent U.S. "ending the epidemic" targets will require efforts addressing the structural, social, and other syndemic determinants of HIV treatment and prevention.
C1 [Glynn, Tiffany R.; Safren, Steven A.; Mendez, Noelle A.; Dale, Sannisha K.] Univ Miami, Dept Psychol, POB 248185, Coral Gables, FL 33124 USA.
   [Carrico, Adam W.; Feaster, Daniel J.] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA.
   [Duthely, Lunthita M.] Univ Miami, Miller Sch Med, Obstet & Gynecol, Miami, FL 33136 USA.
   [Jones, Deborah L.] Univ Miami, Miller Sch Med, Dept Psychiat Sr Behav Sci, Miami, FL 33136 USA.
   [Rodriguez, Allan E.] Univ Miami, Miller Sch Med, Div Infect Dis, Miami, FL 33136 USA.
RP Safren, SA (corresponding author), Univ Miami, Dept Psychol, POB 248185, Coral Gables, FL 33124 USA.
EM ssafren@miami.edu
FU University Of Miami Developmental HIV/AIDS Mental Health Research Center
   (D-ARC) [P30MH116867]; Miami Center for AIDS Research (CFAR) at the
   University of Miami Miller School of Medicine [P30AI073961]; Department
   of Psychology at the University of Miami;  [K24DA040489]; NATIONAL
   CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Advancing Translational Sciences (NCATS)
   [KL2TR002737] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [P30AI073961] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Mental Health (NIMH) [P30MH116867]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European
   Commission [UG1DA013720, K24DA040489] Funding Source: NIH RePORTER
FX The project described was supported by the University Of Miami
   Developmental HIV/AIDS Mental Health Research Center (D-ARC) funded by
   P30MH116867 (Safren), the Miami Center for AIDS Research (CFAR) at the
   University of Miami Miller School of Medicine funded by P30AI073961
   (Rodriguez [Behavioral, Social Sciences and Community Outreach Core]),
   the Department of Psychology at the University of Miami, and from
   K24DA040489 (Safren). The content is solely the responsibility of the
   authors and does not necessarily represent the official views of the
   National Institutes of Health or any of the other funders.
CR Aidala AA, 2016, AM J PUBLIC HEALTH, V106, pE1, DOI 10.2105/AJPH.2015.302905
   [Anonymous], 2013, DIAGN STAT MAN MENT, VFifth
   [Anonymous], 2018, HIV SURV REP 2017
   Azar A, 2019, ENDING HIV EPIDEMIC
   Barai N, 2017, AIDS BEHAV, V21, P1836, DOI 10.1007/s10461-016-1580-x
   Baral S, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-482
   Bavinton BR, 2018, LANCET HIV, V5, pE438, DOI 10.1016/S2352-3018(18)30132-2
   Beck KR, 2016, ASIA-PAC J CLIN ONCO, V12, pE241, DOI 10.1111/ajco.12180
   Bekker LG, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a007435
   Biello KB, 2016, AIDS CARE, V28, P84, DOI 10.1080/09540121.2016.1146205
   Blashill AJ, 2015, AIDS BEHAV, V19, P981, DOI 10.1007/s10461-014-0925-6
   Brezing C, 2015, PSYCHOSOMATICS, V56, P107, DOI 10.1016/j.psym.2014.10.006
   Carrico AW, 2011, LIFE SCI, V88, P940, DOI 10.1016/j.lfs.2010.10.002
   Centers for Disease Control and Prevention, 2018, HIV US REG
   Centers for Disease Control and Prevention (CDC), 2019, HIV TRANSG PEOPL ATL
   Centers for Disease Control and Prevention (CDC), 2018, HIV GAY BIS MEN ATL
   Centers for Disease Control and Prevention (CDC), 2018, RISK RAC ETHN GROUPS
   Centers for Disease Control and Prevention (CDC), 2019, HIV AIDS BAS STAT AT
   Centers for Disease Control and Prevention (CDC), 2019, HIV WOM ATL GA
   Coates TJ, 2008, LANCET, V372, P669, DOI 10.1016/S0140-6736(08)60886-7
   Cohen MS, 2016, NEW ENGL J MED, V375, P830, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]
   Feldman MB, 2019, DRUG ALCOHOL DEPEN, V197, P15, DOI 10.1016/j.drugalcdep.2018.12.015
   Florida Department of Health, 2019, BLACKS LIV HIV DIAGN
   Foster S, 2018, ATLANTA RANKSWORST I
   Friedman MR, 2015, AIDS, V29, P1087, DOI 10.1097/QAD.0000000000000657
   Guadamuz TE, 2014, AIDS BEHAV, V18, P2089, DOI 10.1007/s10461-014-0826-8
   Harkness A, 2019, ARCH SEX BEHAV, V48, P1159, DOI 10.1007/s10508-018-1329-x
   Harkness A, 2018, AIDS BEHAV, V22, P2564, DOI 10.1007/s10461-018-2180-8
   Hatcher AM, 2015, AIDS, V29, P2183, DOI 10.1097/QAD.0000000000000842
   Ironson G, 2015, AIDS BEHAV, V19, P1388, DOI 10.1007/s10461-014-0877-x
   Jacobsen PB, 2005, CANCER-AM CANCER SOC, V103, P1494, DOI 10.1002/cncr.20940
   Jewkes R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122001
   Joint United Nations Programme on HIV/AIDS, 2010, COMB HIV PREV TAIL C
   Joy R, 2008, JAIDS-J ACQ IMM DEF, V47, P500, DOI 10.1097/QAI.0b013e3181648dfd
   Kalichman SC, 2009, AIDS CARE, V21, P87, DOI 10.1080/09540120802032627
   Kalokhe AS, 2012, AIDS PATIENT CARE ST, V26, P234, DOI 10.1089/apc.2011.0275
   Koblin BA, 2015, J URBAN HEALTH, V92, P572, DOI 10.1007/s11524-015-9944-5
   Kuhns LM, 2016, AIDS PATIENT CARE ST, V30, P185, DOI 10.1089/apc.2015.0328
   Leserman J, 2008, PSYCHOSOM MED, V70, P539, DOI 10.1097/PSY.0b013e3181777a5f
   Lynn C, 2019, AIDS CARE, V31, P1261, DOI 10.1080/09540121.2019.1587354
   May MT, 2014, AIDS, V28, P1193, DOI 10.1097/QAD.0000000000000243
   MCLELLAN AT, 1980, J NERV MENT DIS, V168, P26, DOI 10.1097/00005053-198001000-00006
   Miami Matters, 2018, MIAM MATT 2018 DEM S
   Mimiaga MJ, 2015, JAIDS-J ACQ IMM DEF, V68, P329, DOI 10.1097/QAI.0000000000000475
   Mizuno Y, 2015, AIDS BEHAV, V19, P684, DOI 10.1007/s10461-014-0890-0
   Mustanski B, 2017, AIDS BEHAV, V21, P845, DOI 10.1007/s10461-016-1607-3
   National Comprehensive Cancer Network, 2018, NCCN DISTR THERM PRO
   Okafor CN, 2018, AIDS BEHAV, V22, P3962, DOI 10.1007/s10461-018-2227-x
   Pantalone DW, 2018, J GAY LESBIAN MENT H, V22, P71, DOI 10.1080/19359705.2017.1389794
   Poorolajal J, 2015, AIDS CARE, V27, P1205, DOI 10.1080/09540121.2015.1045405
   Poteat T, 2016, JAIDS-J ACQ IMM DEF, V72, pS210, DOI 10.1097/QAI.0000000000001087
   R Core Team, 2018, R LANG ENV STAT COMP
   Redd AD, 2013, LANCET INFECT DIS, V13, P622, DOI 10.1016/S1473-3099(13)70066-5
   Rodger AJ, 2018, 22 INT AIDS C JUL 23
   Rodger AJ, 2016, JAMA-J AM MED ASSOC, V316, P171, DOI 10.1001/jama.2016.5148
   Rotheram-Borus MJ, 2009, ANNU REV CLIN PSYCHO, V5, P143, DOI 10.1146/annurev.clinpsy.032408.153530
   Safren SA, 2011, AIDS BEHAV, V15, pS30, DOI 10.1007/s10461-011-9898-x
   Santos GM, 2014, SEX TRANSM INFECT, V90, P250, DOI 10.1136/sextrans-2013-051318
   Schnurr P., 1999, BRIEF TRAUMA QUESTIO
   Sheward DJ, 2015, J INFECT DIS, V212, P904, DOI 10.1093/infdis/jiv136
   Singer M, 2017, LANCET, V389, P941, DOI 10.1016/S0140-6736(17)30003-X
   Spinner CD, 2016, INFECTION, V44, P151, DOI 10.1007/s15010-015-0850-2
   Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737
   Stall R, 2015, SOC SCI MED, V145, P129, DOI 10.1016/j.socscimed.2015.07.016
   Sullivan KA, 2015, AIDS PATIENT CARE ST, V29, pS42, DOI 10.1089/apc.2014.0278
   Teeraananchai S, 2017, HIV MED, V18, P256, DOI 10.1111/hiv.12421
   Tsai AC, 2015, SOC SCI MED, V139, P26, DOI 10.1016/j.socscimed.2015.06.024
   UNAIDS, 2014, 90 90 90 AMB TREATM
   United States Census Bureau, 2018, MIAM CIT FLOR
   Vanable PA, 2006, AIDS BEHAV, V10, P473, DOI 10.1007/s10461-006-9099-1
   Wagner GA, 2016, AIDS, V30, P2591, DOI 10.1097/QAD.0000000000001237
   Wawrzyniak AJ, 2015, JAIDS-J ACQ IMM DEF, V69, pS63, DOI 10.1097/QAI.0000000000000572
   Weiser SD, 2009, JAIDS-J ACQ IMM DEF, V52, P342, DOI 10.1097/QAI.0b013e3181b627c2
NR 73
TC 18
Z9 18
U1 1
U2 3
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-7165
EI 1573-3254
J9 AIDS BEHAV
JI AIDS Behav.
PD NOV
PY 2019
VL 23
IS 11
BP 2956
EP 2965
DI 10.1007/s10461-019-02619-0
PG 10
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA JT4XW
UT WOS:000500995200007
PM 31392443
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Seo, SK
   Lo, K
   Abbo, LM
AF Seo, Susan K.
   Lo, Kaming
   Abbo, Lilian M.
TI Current State of Antimicrobial Stewardship at Solid Organ and
   Hematopoietic Cell Transplant Centers in the United States
SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
LA English
DT Article
ID INFECTIOUS-DISEASES SOCIETY; CANCER-PATIENTS; NEUTROPENIC PATIENTS;
   FEBRILE NEUTROPENIA; GUIDELINES; RECIPIENTS; PROGRAM; IMPACT; CARE;
   EPIDEMIOLOGY
AB OBJECTIVE. To assess the extent of antimicrobial stewardship programs (ASPs) at solid organ transplant (SOT) and hematopoietic cell transplant (HCT) centers in the United States.
   DESIGN. An 18-item voluntary survey was developed to gauge current antimicrobial stewardship practices in transplant patients, examine the availability and perceived usefulness of novel diagnostics and azole levels to guide therapy, and identify challenges for implementation of ASPs at these centers.
   PARTICIPANTS. The survey was distributed electronically to infectious disease physicians and pharmacists at adult and pediatric SOT and. HCT centers during May 1-22, 2015. Facilities were deidentified.
   RESULTS. After duplicate removal, 71 (56%) of 127 unique transplant centers in 32 stales were analyzed. Forty-four sites (62%) performed at least 100 SOT annually, and 40 (56%) performed at least 100 HCT annually. Top 5 stewardship activities encompassing transplant patients were formulary restriction, guideline development, prospective audit and feedback, education, and dose optimization. Respiratory viral panels (66/66 [100%]), azole levels (64/66 [97%]), and serum/bronchoalveolar lavage galactomannan (58/66 [88%]) were perceived as most useful to guide therapy. Apparent challenges to antimicrobial stewardship included undefined duration for certain infections (53/59 [90%]), diagnostic uncertainty (47/59 [80%]), the perception that antibiotic-resistant infections required escalation (42/59 [71%]), prescriber opposition (41/59 [69%]), and costly drugs (37/59 [63%]).
   CONCLUSIONS. ASP activities were performed at many adult and pediatric SOT and HCT centers in the United States. Diagnostic and therapeutic uncertainty in transplant patients is challenging for ASPs. Collaborative research should examine the impact of antimicrobial stewardship practices in SOT and HCT.
C1 [Seo, Susan K.] Mem Sloan Kettering Cancel Ctr, Dept Med, Infect Dis Serv, New York, NY USA.
   [Lo, Kaming] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Div Biostat,Biostat Collaborat & Consulting Core, Miami, FL 33136 USA.
   [Abbo, Lilian M.] Univ Miami, Miller Sch Med, Dept Med, Div Infect Dis, Miami, FL 33136 USA.
RP Seo, SK (corresponding author), 1275 York Ave, New York, NY 10065 USA.
EM seos@mskcc.org
FU NIH/NCI Cancer CenterUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [P30 CA008748]; NATIONAL CANCER INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI) [P30CA008748] Funding Source:
   NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Advancing Translational
   Sciences (NCATS) [UL1TR000460] Funding Source: NIH RePORTER
FX This research was funded in part through the NIH/NCI Cancer Center
   Support Grant P30 CA008748 (S.K.S).
CR Abbo LM, 2014, INFECT DIS CLIN N AM, V28, P263, DOI 10.1016/j.idc.2014.01.008
   Aitken SL, 2013, AM J TRANSPLANT, V13, P2499, DOI 10.1111/ajt.12364
   [Anonymous], BE MATCH TRANSPL CTR
   [Anonymous], 2012, INFECT CONT HOSP EP, V33, P322, DOI DOI 10.1086/665010
   Barlam TF, 2016, CLIN INFECT DIS, V62, pE51, DOI 10.1093/cid/ciw118
   Blumberg EA, 2013, AM J TRANSPLANT, V13, P1, DOI 10.1111/ajt.12129
   Centers for Medicaid & Medicaid Services, HOSP INF CONTR WORKS
   Cervera C, 2014, CLIN MICROBIOL INFEC, V20, P49, DOI 10.1111/1469-0691.12687
   Chou SW, 2015, CURR OPIN INFECT DIS, V28, P293, DOI 10.1097/QCO.0000000000000170
   Cosgrove SE, 2012, INFECT CONT HOSP EP, V33, P374, DOI 10.1086/664771
   Freifeld AG, 2011, CLIN INFECT DIS, V52, pE56, DOI 10.1093/cid/cir073
   Frobert E, 2014, ANTIVIR RES, V111, P36, DOI 10.1016/j.antiviral.2014.08.013
   Kamboj M, 2012, INFECT CONT HOSP EP, V33, P1162, DOI 10.1086/668023
   Macesic N, 2014, TRANSPL INFECT DIS, V16, P887, DOI 10.1111/tid.12298
   Mihu CN, 2011, CURR CLIN ONCOL, P491, DOI 10.1007/978-1-60761-644-3_43
   Mondain V, 2013, INFECTION, V41, P621, DOI 10.1007/s15010-013-0431-1
   Nucci M, 2001, INFECT CONT HOSP EP, V22, P651, DOI 10.1086/501839
   Pakakasama S, 2011, PEDIATR INT, V53, P902, DOI 10.1111/j.1442-200X.2011.03363.x
   Paskovaty A, 2015, INTENS CARE MED, V41, P2022, DOI 10.1007/s00134-015-4016-6
   Procop GW, 2003, ARCH PATHOL LAB MED, V127, P623
   Rosa RG, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-286
   Standiford HC, 2012, INFECT CONT HOSP EP, V33, P338, DOI 10.1086/664909
   Steinmann J, 2015, J ANTIMICROB CHEMOTH, V70, P1522, DOI 10.1093/jac/dku566
   The Leapfrog Group, SURV CPOE MAT
   The White House, NAT ACT PLAN COMB AN
   Tomblyn M, 2009, BIOL BLOOD MARROW TR, V15, P1143, DOI 10.1016/j.bbmt.2009.06.019
   Trubiano JA, 2015, ANTIMICROB RESIST IN, V4, DOI 10.1186/s13756-015-0063-6
   Tverdek FP, 2012, PHARMACOTHERAPY, V32, P722, DOI 10.1002/j.1875-9114.2012.01162.x
   Wolf J, 2016, INFECT CONT HOSP EP, V37, P343, DOI 10.1017/ice.2015.295
   Yeo CL, 2012, EUR J CLIN MICROBIOL, V31, P583, DOI 10.1007/s10096-011-1351-6
   Zuckermann J, 2008, ANN HEMATOL, V87, P139, DOI 10.1007/s00277-007-0390-7
NR 31
TC 34
Z9 34
U1 0
U2 8
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0899-823X
EI 1559-6834
J9 INFECT CONT HOSP EP
JI Infect. Control Hosp. Epidemiol.
PD OCT
PY 2016
VL 37
IS 10
BP 1195
EP 1200
DI 10.1017/ice.2016.149
PG 6
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA DY4GS
UT WOS:000385057600010
PM 27457099
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Caban-Martinez, AJ
   Kropa, B
   Niemczyk, N
   Moore, KJ
   Baum, J
   Solle, NS
   Sterling, DA
   Kobetz, EN
AF Caban-Martinez, Alberto J.
   Kropa, Bob
   Niemczyk, Neal
   Moore, Kevin J.
   Baum, Jeramy
   Solle, Natasha Schaefer
   Sterling, David A.
   Kobetz, Erin N.
TI The "Warm Zone" Cases: Environmental Monitoring Immediately Outside the
   Fire Incident Response Arena by Firefighters
SO SAFETY AND HEALTH AT WORK
LA English
DT Article
DE Firefighters; Multigas detectors; Respiratory protection; Warm zone
ID POLYCYCLIC AROMATIC-HYDROCARBONS; EXPOSURE; OVERHAUL; SMOKE; RISK
AB Hazardous work zones (i.e., hot, warm, and cold) are typically established by emergency response teams during hazardous materials (HAZMAT) calls but less consistently for fire responses to segment personnel and response activities in the immediate geographic area around the fire. Despite national guidelines, studies have documented the inconsistent use of respiratory protective equipment by firefighters at the fire scene. In this case-series report, we describe warm zone gas levels using multigas detectors across five independent fire incident responses all occurring in a large South Florida fire department. Multigas detector data collected at each fire response indicate the presence of sustained levels of volatile organic compounds in the "warm zone" of each fire event. These cases suggest that firefighters should not only implement strategies for multigas detector use within the warm zone but also include respiratory protection to provide adequate safety from toxic exposures in the warm zone. (C) 2017 Occupational Safety and Health Research Institute, Published by Elsevier Korea LLC.
C1 [Caban-Martinez, Alberto J.; Moore, Kevin J.] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Div Environm & Publ Hlth, Miami, FL 33136 USA.
   [Caban-Martinez, Alberto J.; Solle, Natasha Schaefer; Kobetz, Erin N.] Univ Miami, Sylvester Comprehens Canc Ctr, Coral Gables, FL 33124 USA.
   [Solle, Natasha Schaefer; Kobetz, Erin N.] Univ Miami, Dept Med, Coral Gables, FL 33124 USA.
   [Baum, Jeramy] Univ Miami, Coll Arts & Sci, Dept Chem, Coral Gables, FL 33124 USA.
   [Kropa, Bob; Niemczyk, Neal] Palm Beach Cty Fire Rescue, W Palm Beach, FL USA.
   [Sterling, David A.] Univ North Texas, Hlth Sci Ctr, Sch Publ Hlth, Ft Worth, TX USA.
RP Caban-Martinez, AJ (corresponding author), Univ Miami, Miller Sch Med, Leonard M Miller Sch Med, Dept Publ Hlth Sci, 1120 NW 14th St,Room 1025, Miami, FL 33136 USA.
EM acaban@med.miami.edu
RI Sterling, David/H-6738-2019; Caban-Martinez, Alberto/AAG-1499-2019
OI Caban-Martinez, Alberto/0000-0002-5960-1308; Sterling,
   David/0000-0003-4867-7259
FU State of Florida [2382A]; American Cancer SocietyAmerican Cancer Society
   [IRG 98-277-13]; Sylvester Comprehensive Cancer Center; NATIONAL CENTER
   FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR002736]
   Funding Source: NIH RePORTER
FX The authors would like to acknowledge funding support from State of
   Florida appropriation #2382A (Principal Investigator Dr. Kobetz) to the
   University of Miami (UM) Sylvester Comprehensive Cancer Center, Grant
   IRG 98-277-13 from the American Cancer Society (Principal Investigator
   Dr Caban-Martinez), and funds from the Sylvester Comprehensive Cancer
   Center.
CR Adetona O, 2017, J EXPO SCI ENV EPID, V27, P78, DOI 10.1038/jes.2015.75
   Association NFP, 2013, 1981 NFPA
   Austin CC, 2001, J TOXICOL ENV HEAL A, V63, P437, DOI 10.1080/152873901300343470
   Baxter CS, 2014, J OCCUP ENVIRON HYG, V11, pD85, DOI 10.1080/15459624.2014.890286
   Bolstad-Johnson DM, 2000, AIHAJ, V61, P636, DOI 10.1080/15298660008984572
   BRANDTRAUF PW, 1988, BRIT J IND MED, V45, P606
   Burgess JL, 2001, J OCCUP ENVIRON MED, V43, P467, DOI 10.1097/00043764-200105000-00007
   Chilcott RP, 2013, DISASTER MANAGEMENT: MEDICAL PREPAREDNESS, RESPONSE AND HOMELAND SECURITY, P311, DOI 10.1079/9781845939298.0311
   Coleman J, 2007, FIRE ENG, V160, P34
   Daniels RD, 2014, OCCUP ENVIRON MED, V71, P388, DOI 10.1136/oemed-2013-101662
   Eller P.M., 1994, NIOSH MANUAL ANAL ME, V4th
   EPA U, 2018, SAF ZON OV FACTSH
   Fabian TZ, 2014, FIRE TECHNOL, V50, P993, DOI 10.1007/s10694-011-0212-2
   Fent KW, 2014, ANN OCCUP HYG, V58, P830, DOI 10.1093/annhyg/meu036
   Grace A.M., 2014, CARBON MONOXIDE EXPO
   Haddock CK, 2012, OCCUP MED-OXFORD, V62, P661, DOI 10.1093/occmed/kqs162
   JANKOVIC J, 1991, ANN OCCUP HYG, V35, P581, DOI 10.1093/annhyg/35.6.581
   Kahn SA, 2014, J BURN CARE RES, V35, P426, DOI 10.1097/BCR.0000000000000016
   Krusen JM, 2010, FIRE ENG, V163
   Kunadharaju K, 2011, ACCIDENT ANAL PREV, V43, P1171, DOI 10.1016/j.aap.2010.12.030
   LeMasters GK, 2006, J OCCUP ENVIRON MED, V48, P1189, DOI 10.1097/01.jom.0000246229.68697.90
   Mackay C, 2015, FIRE TECHNOL, V51, P1167, DOI 10.1007/s10694-015-0456-3
   Oliveira M, 2017, J HAZARD MATER, V323, P184, DOI 10.1016/j.jhazmat.2016.03.012
NR 23
TC 3
Z9 3
U1 1
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2093-7911
EI 2093-7997
J9 SAF HEALTH WORK-KR
JI Saf. Health Work
PD SEP
PY 2018
VL 9
IS 3
BP 352
EP 355
DI 10.1016/j.shaw.2017.12.003
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA GS9LW
UT WOS:000444041200015
PM 30370169
OA Green Published, gold
DA 2021-10-30
ER

PT J
AU Selinger, C
   Strbo, N
   Gonzalez, L
   Aicher, L
   Weiss, JM
   Law, GL
   Palermo, RE
   Vaccari, M
   Franchini, G
   Podack, ER
   Katze, MG
AF Selinger, Christian
   Strbo, Natasa
   Gonzalez, Louis
   Aicher, Lauri
   Weiss, Jeffrey M.
   Law, G. Lynn
   Palermo, Robert E.
   Vaccari, Monica
   Franchini, Genoveffa
   Podack, Eckhard R.
   Katze, Michael G.
TI Multiple Low-Dose Challenges in a Rhesus Macaque AIDS Vaccine Trial
   Result in an Evolving Host Response That Affects Protective Outcome
SO CLINICAL AND VACCINE IMMUNOLOGY
LA English
DT Article
ID SIMIAN IMMUNODEFICIENCY VIRUS; I INTERFERON RESPONSES; AFRICAN-GREEN
   MONKEYS; T-CELL RESPONSES; SIV INFECTION; CUTTING EDGE; ANTIVIRAL
   ACTIVITY; CROSS-PRESENTATION; DENDRITIC CELLS; PROTEIN
AB Using whole-blood transcriptional profiling, we investigated differences in the host response to vaccination and challenge in a rhesus macaque AIDS vaccine trial. Samples were collected from animals prior to and after vaccination with live, irradiated vaccine cells secreting the modified endoplasmic reticulum chaperone gp96-Ig loaded with simian immunodeficiency virus (SIV) peptides, either alone or in combination with a SIV-gp120 protein boost. Additional samples were collected following multiple low-dose rectal challenges with SIVmac251. Animals in the boosted group had a 73% reduced risk of infection. Surprisingly, few changes in gene expression were observed during the vaccination phase. Focusing on postchallenge comparisons, in particular for protected animals, we identified a host response signature of protection comprised of strong interferon signaling after the first challenge, which then largely abated after further challenges. We also identified a host response signature, comprised of early macrophage-mediated inflammatory responses, in animals with undetectable viral loads 5 days after the first challenge but with unusually high viral titers after subsequent challenges. Statistical analysis showed that prime-boost vaccination significantly lowered the probability of infection in a time-consistent manner throughout several challenges. Given that humoral responses in the prime-boost group were highly significant prechallenge correlates of protection, the strong innate signaling after the first challenge suggests that interferon signaling may enhance vaccine-induced antibody responses and is an important contributor to protection from infection during repeated low-dose exposure to SIV.
C1 [Selinger, Christian; Aicher, Lauri; Weiss, Jeffrey M.; Law, G. Lynn; Palermo, Robert E.; Katze, Michael G.] Univ Washington, Dept Microbiol, Seattle, WA 98195 USA.
   [Palermo, Robert E.; Katze, Michael G.] Univ Washington, Washington Natl Primate Res Ctr, Seattle, WA 98195 USA.
   [Strbo, Natasa; Gonzalez, Louis; Podack, Eckhard R.] Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA.
   [Vaccari, Monica; Franchini, Genoveffa] NCI, Bethesda, MD 20892 USA.
RP Katze, MG (corresponding author), Univ Washington, Dept Microbiol, Seattle, WA 98195 USA.
EM honey@uw.edu
OI Selinger, Christian/0000-0002-4361-549X
FU National Institutes of Health, Department of Health and Human Services,
   under National Institute of Allergy and Infectious Diseases
   [HHSN272201300010C, P01AI096396]; DAIDS Reagent Resource Support Program
   for AIDS Vaccine Development, Quality Biological, Gaithersburg, MD
   [N01-A30018]; Office of the DirectorNational Science Foundation (NSF)NSF
   - Office of the Director (OD) [P51OD010425]; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [KL2TR000461]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [P01AI096396] Funding Source:
   NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF
   HEALTHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [P51OD010425] Funding Source: NIH
   RePORTER
FX This project was funded with federal funds from the National Institutes
   of Health, Department of Health and Human Services, under National
   Institute of Allergy and Infectious Diseases contract HHSN272201300010C
   (grant P01AI096396), by the DAIDS Reagent Resource Support Program for
   AIDS Vaccine Development, Quality Biological, Gaithersburg, MD (contract
   N01-A30018), and by the Office of the Director (grant P51OD010425).
CR Abel K, 2004, J VIROL, V78, P841, DOI 10.1128/JVI.78.2.841-854.2004
   BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183
   Bergamini A, 2000, J INFECT DIS, V182, P776, DOI 10.1086/315803
   Binder RJ, 2005, NAT IMMUNOL, V6, P593, DOI 10.1038/ni1201
   Bowers NL, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003993
   Cho BK, 2000, IMMUNITY, V12, P263, DOI 10.1016/S1074-7613(00)80179-X
   Contreras X, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-37
   Espert L, 2005, J GEN VIROL, V86, P2221, DOI 10.1099/vir.0.81074-0
   GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936
   Harris LD, 2010, J VIROL, V84, P7886, DOI 10.1128/JVI.02612-09
   Harty RN, 2009, J INNATE IMMUN, V1, P397, DOI 10.1159/000226245
   Haynes BF, 1996, LANCET, V348, P1531, DOI 10.1016/S0140-6736(05)66165-X
   Herbein G, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-33
   Jacquelin B, 2009, J CLIN INVEST, V119, P3544, DOI 10.1172/JCI40093
   Koopman G, 2013, AIDS, V27, P2841, DOI 10.1097/QAD.0000000000000047
   Kornfeld C, 2005, J CLIN INVEST, V115, P1082, DOI 10.1172/JCI200523006
   Le Bon A, 2006, J IMMUNOL, V176, P2074, DOI 10.4049/jimmunol.176.4.2074
   Le Bon A, 2001, IMMUNITY, V14, P461, DOI 10.1016/S1074-7613(01)00126-1
   Lederer S, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000296
   Lehner T, 2011, Adv Dent Res, V23, P19, DOI 10.1177/0022034511399081
   Li B, 2010, J VIROL, V84, P6248, DOI 10.1128/JVI.00295-10
   Li C, 2011, CATAL TODAY, V175, P1, DOI 10.1016/j.cattod.2011.08.002
   Mandraju R, 2014, J IMMUNOL, V192, P4303, DOI 10.4049/jimmunol.1302244
   Novitsky V, 2009, VIROLOGY, V383, P47, DOI 10.1016/j.virol.2008.09.017
   Oizumi S, 2007, J IMMUNOL, V179, P2310, DOI 10.4049/jimmunol.179.4.2310
   Palliser D, 2005, J IMMUNOL, V174, P1879, DOI 10.4049/jimmunol.174.4.1879
   Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582
   Regoes RR, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002767
   ROY S, 1990, SCIENCE, V247, P1216, DOI 10.1126/science.2180064
   Sandler NG, 2014, NATURE, V511, P601, DOI 10.1038/nature13554
   Shetty RD, 2012, J CLIN INVEST, V122, P1712, DOI 10.1172/JCI60612
   Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23
   Sodora DL, 2009, NAT MED, V15, P861, DOI 10.1038/nm.2013
   Strbo N, 2010, MUCOSAL IMMUNOL, V3, P182, DOI 10.1038/mi.2009.127
   Strbo N, 2013, IMMUNOL RES, V57, P311, DOI 10.1007/s12026-013-8468-x
   Strbo N, 2013, J IMMUNOL, V190, P2495, DOI 10.4049/jimmunol.1202655
   Strbo N, 2011, VACCINE, V29, P2619, DOI 10.1016/j.vaccine.2011.01.044
   Stumptner-Cuvelette P, 2001, P NATL ACAD SCI USA, V98, P12144, DOI 10.1073/pnas.221256498
   Tyagi M, 2012, MOL MED, V18, P1096, DOI 10.2119/molmed.2012.00194
   VANCOTT TC, 1995, J IMMUNOL, V155, P4100
   Verhoeven D, 2014, J IMMUNOL, V192, P3308, DOI 10.4049/jimmunol.1302415
   Vingert B, 2012, J VIROL, V86, P10661, DOI 10.1128/JVI.00056-12
   Yamazaki K, 1999, J IMMUNOL, V163, P5178
   Zak DE, 2012, P NATL ACAD SCI USA, V109, pE3503, DOI 10.1073/pnas.1208972109
   Zhou Z, 2011, VIROLOGY, V409, P175, DOI 10.1016/j.virol.2010.10.008
NR 45
TC 8
Z9 8
U1 0
U2 6
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 1556-6811
EI 1556-679X
J9 CLIN VACCINE IMMUNOL
JI Clin. Vaccine Immunol.
PD DEC
PY 2014
VL 21
IS 12
BP 1650
EP 1660
DI 10.1128/CVI.00455-14
PG 11
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AU3RX
UT WOS:000345532300007
PM 25274805
OA Green Published, gold
DA 2021-10-30
ER

PT J
AU Sherman, RL
   Henry, KA
   Tannenbaum, SL
   Feaster, DJ
   Kobetz, E
   Lee, DJ
AF Sherman, Recinda L.
   Henry, Kevin A.
   Tannenbaum, Stacey L.
   Feaster, Daniel J.
   Kobetz, Erin
   Lee, David J.
TI Applying Spatial Analysis Tools in Public Health: An Example Using
   SaTScan to Detect Geographic Targets for Colorectal Cancer Screening
   Interventions
SO PREVENTING CHRONIC DISEASE
LA English
DT Article
ID STAGE BREAST-CANCER; UPPER CAPE-COD; NEW-JERSEY; SURVIVAL; MORTALITY;
   PATTERNS; WOMEN
AB Epidemiologists are gradually incorporating spatial analysis into health-related research as geocoded cases of disease become widely available and health-focused geospatial computer applications are developed. One health-focused application of spatial analysis is cluster detection. Using cluster detection to identify geographic areas with high-risk populations and then screening those populations for disease can improve cancer control. SaTScan is a free clusterdetection software application used by epidemiologists around the world to describe spatial clusters of infectious and chronic disease, as well as disease vectors and risk factors. The objectives of this article are to describe how spatial analysis can be used in cancer control to detect geographic areas in need of colorectal cancer screening intervention, identify issues commonly encountered by SaTScan users, detail how to select the appropriate methods for using SaTScan, and explain how method selection can affect results. As an example, we used various methods to detect areas in Florida where the population is at high risk for late-stage diagnosis of colorectal cancer. We found that much of our analysis was underpowered and that no single method detected all clusters of statistical or public health significance. However, all methods detected 1 area as high risk; this area is potentially a priority area for a screening intervention. Cluster detection can be incorporated into routine public health operations, but the challenge is to identify areas in which the burden of disease can be alleviated through public health intervention. Reliance on SaTScan's default settings does not always produce pertinent results.
C1 [Henry, Kevin A.] Rutgers State Univ, Sch Publ Hlth, Canc Inst New Jersey, Piscataway, NJ 08855 USA.
   [Tannenbaum, Stacey L.; Feaster, Daniel J.; Kobetz, Erin; Lee, David J.] Univ Miami, Miller Sch Med, Coral Gables, FL 33124 USA.
   [Tannenbaum, Stacey L.] Univ Miami, Sylvester Comprehens Canc Ctr, Coral Gables, FL 33124 USA.
RP Sherman, RL (corresponding author), Cent Canc Registries Inc, North Amer Assoc Cent Canc Registries, 2121 West White Oaks Dr,Suite B, Springfield, IL 62704 USA.
EM rsherman@naaccr.org
FU Florida Bankhead-Coley Cancer Research Program [1BG06-34193]; Florida
   Department of Health (FDOH); NATIONAL CANCER INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI) [U54CA153705] Funding Source:
   NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Advancing Translational
   Sciences (NCATS) [UL1TR000460] Funding Source: NIH RePORTER
FX We acknowledge the support of Florida Bankhead-Coley Cancer Research
   Program Grant Number 1BG06-34193 for funding a portion of this research.
   We also acknowledge the Florida Cancer Data System (FCDS). The Florida
   cancer incidence data used in this report were collected by the FCDS
   under contract with the Florida Department of Health (FDOH). The views
   expressed herein are solely those of the authors and do not necessarily
   reflect those of the FCDS or FDOH. Work was performed while Ms Sherman
   was affiliated with the University of Miami Miller Medical School,
   Public Health Sciences, Miami, Florida.
CR Abe T, 2006, AM J PREV MED, V30, pS60, DOI 10.1016/j.amepre.2005.09.003
   Abrams AM, 2010, INT J HEALTH GEOGR, V9, DOI 10.1186/1476-072X-9-61
   [Anonymous], 2011, FLOR CANC DAT SYST
   Boscoe FP, 2003, HEALTH PLACE, V9, P273, DOI 10.1016/S1353-8292(02)00060-6
   Centers for Disease Control and Prevention, 2010, BEH RISK FACT SURV S
   Chen J, 2008, INT J HEALTH GEOGR, V7, DOI 10.1186/1476-072X-7-57
   Gotway C. A., 2004, APPL SPATIAL STAT PU
   Gregorio DI, 2002, INT J CANCER, V100, P194, DOI 10.1002/ijc.10431
   Han J, 2011, LOU KY ANN M N AM AS
   Henry KA, 2009, INT J HEALTH GEOGR, V8, DOI 10.1186/1476-072X-8-48
   Henry KA, 2009, HEALTH PLACE, V15, P505, DOI 10.1016/j.healthplace.2008.09.003
   Horner MJ, 2011, CANCER EPIDEM BIOMAR, V20, P591, DOI 10.1158/1055-9965.EPI-10-1183
   Huang L, 2008, STAT MED, V27, P5111, DOI 10.1002/sim.3342
   Jackson MC, 2009, INT J HEALTH GEOGR, V8, DOI 10.1186/1476-072X-8-55
   Johnson GD, 2004, INT J HEALTH GEOGR, V3, P29, DOI [2004, DOI 10.1186/1476-072X-3-29]
   Klassen A. C., 2005, International Journal of Health Geographics, V4, DOI 10.1186/1476-072X-4-1
   Krapcho M., 2013, SEER CANC STAT REV 1
   Kulldorff M, 2010, SATSCAN USER GUIDE V
   Kulldorff M, 2006, STAT MED, V25, P3929, DOI 10.1002/sim.2490
   Kulldorff M, 2009, INT J HEALTH GEOGR, V8, DOI 10.1186/1476-072X-8-58
   Lian M, 2011, AM J EPIDEMIOL, V174, P828, DOI 10.1093/aje/kwr162
   Mather FJ, 2006, AM J PREV MED, V30, pS88, DOI 10.1016/j.amepre.2005.09.012
   Meliker JR, 2009, CANCER CAUSE CONTROL, V20, P1061, DOI 10.1007/s10552-009-9312-4
   Melnick A. L., 2002, INTRO GEOGRAPHIC INF
   National Cancer Institute, 2013, PDQ GEN COL CANC
   Pinheiro Paulo S, 2009, J Registry Manag, V36, P42
   Roche Lisa M, 2002, J Public Health Manag Pract, V8, P26
   Rushton G., 2007, GEOCODING HLTH DATA
   Rushton Gerard, 2004, J Med Syst, V28, P223, DOI 10.1023/B:JOMS.0000032841.39701.36
   Schootman M, 2009, AM J EPIDEMIOL, V169, P554, DOI 10.1093/aje/kwn369
   Sherman R, 2012, C P 20 ACM SIGSPATIA
   TAGNON I, 1980, CANCER RES, V40, P3875
   Talbot T.O., 2010, GEOGRAPHIC AGGREGATI
   Talbot TO, 2000, STAT MED, V19, P2399, DOI 10.1002/1097-0258(20000915/30)19:17/18<2399::AID-SIM577>3.0.CO;2-R
   Vieira V, 2009, ENVIRON HEALTH-GLOB, V8, DOI 10.1186/1476-069X-8-3
   Vieira VM, 2008, INT J HEALTH GEOGR, V7, DOI 10.1186/1476-072X-7-46
   Wang FH, 2012, APPL GEOGR, V35, P1, DOI 10.1016/j.apgeog.2012.04.005
   WINN DM, 1981, NEW ENGL J MED, V304, P745, DOI 10.1056/NEJM198103263041301
NR 38
TC 33
Z9 36
U1 0
U2 21
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1545-1151
J9 PREV CHRONIC DIS
JI Prev. Chronic Dis.
PD MAR
PY 2014
VL 11
DI 10.5888/pcd11.130264
PG 15
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AR3XF
UT WOS:000343521800014
PM 24650619
OA Bronze, Green Published, Green Submitted
DA 2021-10-30
ER

PT J
AU Salamo, O
   Roghaee, S
   Schweitzer, MD
   Mantero, A
   Shafazand, S
   Campos, M
   Mirsaeidi, M
AF Salamo, Oriana
   Roghaee, Shiva
   Schweitzer, Michael D.
   Mantero, Alejandro
   Shafazand, Shirin
   Campos, Michael
   Mirsaeidi, Mehdi
TI White donor, younger donor and double lung transplant are associated
   with better survival in sarcoidosis patients
SO SCIENTIFIC REPORTS
LA English
DT Article
ID PULMONARY SARCOIDOSIS; INTERNATIONAL-SOCIETY; UNITED-STATES; FIBROSIS;
   PREVALENCE; RECURRENCE; GUIDELINES; RECIPIENTS; OUTCOMES; ADULTS
AB Sarcoidosis commonly affects the lung. Lung transplantation (LT) is required when there is a severe and refractory involvement. We compared post-transplant survival rates of sarcoidosis patients with chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). We also explored whether the race and age of the donor, and double lung transplant have any effect on the survival in the post transplant setting. We analyzed 9,727 adult patients with sarcoidosis, COPD, and IPF who underwent LT worldwide between 2005-2015 based on United Network for Organ Sharing (UNOS) database. Survival rates were compared with Kaplan-Meier, and risk factors were investigated by Cox-regression analysis. 469 (5%) were transplanted because of sarcoidosis, 3,688 (38%) for COPD and 5,570 (57%) for IPF. Unadjusted survival analysis showed a better post-transplant survival rate for patients with sarcoidosis (p < 0.001, Log-rank test). In Cox-regression analysis, double lung transplant and white race of the lung donor showed to have a significant survival advantage. Since double lung transplant, those who are younger and have lower Lung Allocation Score (LAS) at the time of transplant have a survival advantage, we suggest double lung transplant as the procedure of choice, especially in younger sarcoidosis subjects and with lower LAS scores.
C1 [Salamo, Oriana; Roghaee, Shiva; Schweitzer, Michael D.; Campos, Michael; Mirsaeidi, Mehdi] Miami VA Healthcare Syst, Sect Pulm, Miami, FL 33125 USA.
   [Mantero, Alejandro] Univ Miami, Dept Publ Hlth, Div Biostat, Miami, FL USA.
   [Salamo, Oriana; Schweitzer, Michael D.; Shafazand, Shirin; Campos, Michael; Mirsaeidi, Mehdi] Univ Miami, Div Pulm & Crit Care, Miami, FL 33136 USA.
RP Mirsaeidi, M (corresponding author), Miami VA Healthcare Syst, Sect Pulm, Miami, FL 33125 USA.; Mirsaeidi, M (corresponding author), Univ Miami, Div Pulm & Crit Care, Miami, FL 33136 USA.
EM msm249@med.miami.edu
RI Mantero, Alejandro/AAS-6415-2021; Campos, Michael/X-2025-2019
OI Mirsaeidi, Mehdi/0000-0001-5298-8442
FU Health Resources and Services AdministrationUnited States Department of
   Health & Human ServicesUnited States Health Resources & Service
   Administration (HRSA) [234-2005-37011C]; Mallinckrodt Pharmaceuticals;
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000460] Funding Source: NIH RePORTER
FX The authors acknowledge the support of Dr. Golnaz Ebrahimi. This work
   was supported in part by Health Resources and Services Administration
   contract 234-2005-37011C, and Mallinckrodt Pharmaceuticals for research
   grant support. The content is the responsibility of the authors alone
   and does not necessarily reflect the views or policies of the Department
   of Health and Human Services, nor does mention of trade names,
   commercial products, or organizations imply endorsement by the U.S.
   Government.
CR Adeloye D, 2015, J GLOB HEALTH, V5, P186, DOI [10.7189/jogh.05-020415, 10.7189/jogh.05.020415]
   Banga A, 2015, TRANSPLANTATION, V99, P1940, DOI 10.1097/TP.0000000000000673
   Baughman RP, 2016, ANN AM THORAC SOC, V13, P1244, DOI 10.1513/AnnalsATS.201511-760OC
   Callender CO, 2009, TRANSPL P, V41, P4125, DOI 10.1016/j.transproceed.2009.06.182
   Egan TM, 2006, AM J TRANSPLANT, V6, P1212, DOI 10.1111/j.1600-6143.2006.01276.x
   Erdal BS, 2012, RESP MED, V106, P893, DOI 10.1016/j.rmed.2012.02.007
   Gutierrez C, 2007, AM J TRANSPLANT, V7, P1271, DOI 10.1111/j.1600-6143.2006.01681.x
   Korsten P, 2013, CURR OPIN PULM MED, V19, P516, DOI 10.1097/MCP.0b013e3283642ad0
   Mirsaeidi M, 2016, SARCOIDOSIS VASC DIF, V33, P29
   Mirsaeidi M, 2015, CHEST, V147, P438, DOI 10.1378/chest.14-1120
   Mortaz E, 2015, J INFLAMM-LOND, V12, DOI 10.1186/s12950-015-0066-3
   Nathan SD, 2005, CHEST, V127, P1006, DOI 10.1378/chest.127.3.1006
   Newman LS, 1997, NEW ENGL J MED, V336, P1224, DOI 10.1056/NEJM199704243361706
   Orens JB, 2006, J HEART LUNG TRANSPL, V25, P745, DOI 10.1016/j.healun.2006.03.011
   Patterson Karen C, 2013, Ann Am Thorac Soc, V10, P362, DOI 10.1513/AnnalsATS.201303-069FR
   Puri V, 2015, THORAC SURG CLIN, V25, P47, DOI 10.1016/j.thorsurg.2014.09.007
   Raghu G, 2016, EUR RESPIR J, V48, P179, DOI 10.1183/13993003.01653-2015
   SARTWELL PE, 1974, AM J EPIDEMIOL, V99, P250, DOI 10.1093/oxfordjournals.aje.a121609
   Schultz HH, 2014, SARCOIDOSIS VASC DIF, V31, P149
   Sommer W, 2015, J HEART LUNG TRANSPL, V34, P1325, DOI 10.1016/j.healun.2015.06.002
   Stephenson AL, 2015, J HEART LUNG TRANSPL, V34, P1139, DOI 10.1016/j.healun.2015.05.003
   Taimeh Z, 2016, THORAX, V71, P378, DOI 10.1136/thoraxjnl-2015-207497
   Titman A, 2009, AM J TRANSPLANT, V9, P1640, DOI 10.1111/j.1600-6143.2009.02613.x
   Walker S, 1998, THORAX, V53, P281, DOI 10.1136/thx.53.4.281
   Watson CJE, 2012, BRIT J ANAESTH, V108, pI29, DOI 10.1093/bja/aer384
   Yusen RD, 2015, J HEART LUNG TRANSPL, V34, P1264, DOI 10.1016/j.healun.2015.08.014
NR 26
TC 3
Z9 3
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAY 3
PY 2018
VL 8
AR 6968
DI 10.1038/s41598-018-25144-x
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GE5VK
UT WOS:000431291500020
PM 29725035
OA Green Published, gold
DA 2021-10-30
ER

PT J
AU Kenya, S
   Lebron, CN
   Chang, AYH
   Li, H
   Alonzo, YA
   Carrasquillo, O
AF Kenya, Sonjia
   Lebron, Cynthia Nicole
   Chang, Aileen Yu Hen
   Li, Hua
   Alonzo, Yisel A.
   Carrasquillo, Olveen
TI A profile of Latinos with poorly controlled diabetes in South Florida
SO JOURNAL OF COMMUNITY HOSPITAL INTERNAL MEDICINE PERSPECTIVES
LA English
DT Article
DE diabetes among Latinos; South Florida; diabetes disparities; Hispanics
   with diabetes
ID COLLABORATIVE CARE MANAGEMENT; LOW-INCOME; COST-EFFECTIVENESS; MAJOR
   DEPRESSION; ACCULTURATION; QUESTIONNAIRE; INTERVENTION; CONSUMPTION;
   PREVALENCE; HISPANICS
AB Introduction: Latinos are the largest minority group in the United States and diabetes or pre-diabetes affects more than 70% of Latinos aged 45 years and older. Miami-Dade County is home to one of the highest populations of diverse Latinos. In this descriptive manuscript, we present baseline characteristics of participants enrolled in the Miami Healthy Heart Initiative (MHHI). This was a study conducted to determine the effects of a community health worker (CHW) intervention among Latinos with poorly controlled diabetes in South Florida.
   Methods: We recruited 300 diverse Latino adults with suboptimal diabetes outcomes (HbA1c >= 8) into MHHI. This randomized control trial examined the impact of a 1-year CHW-led intervention on glycemic control, blood pressure, and cholesterol levels. At baseline, physiologic measures, including HbA1c, LDL, blood pressure, and BMI, were assessed. Data on socio-demographic characteristics and additional determinants of health such as depression status, provider communication, diet, exercise, cigarette smoking, readiness to change diabetes management behaviors (stages of change), and confidence in ability to improve diabetes self-care (self-efficacy) were collected.
   Results: Participants came from 20 different countries, with Cuban Americans representing 38% of the sample. Most had lived in the US for more than 10 years, had completed at least 12 years of school, and had high levels of health literacy, yet 48% had very low acculturation. Nearly 80% had poor self-efficacy, 80% met the criteria for depression, and 83% were not adherent to their medications. More than half the population was not at their target for blood pressure, 50% were above the recommended LDL goal, and most were obese.
   Conclusion: In a diverse population of Latinos with poorly controlled diabetes in Miami, we found high rates of depression, obesity, medication non-adherence, poor self-efficacy, and provider communication. These may contribute to poor diabetes control, high blood pressure, and elevated cholesterol.
C1 [Kenya, Sonjia; Chang, Aileen Yu Hen; Li, Hua; Alonzo, Yisel A.; Carrasquillo, Olveen] Univ Miami, Miller Sch Med, Div Gen Internal Med, 1120 NW 14th St,Room 968, Miami, FL 33136 USA.
   [Lebron, Cynthia Nicole] Univ Miami, Miller Sch Med, Sylvester Canc Ctr, Jay Weiss Inst, Miami, FL 33136 USA.
RP Kenya, S (corresponding author), Univ Miami, Miller Sch Med, Div Gen Internal Med, 1120 NW 14th St,Room 968, Miami, FL 33136 USA.
EM skenya@med.miami.edu
OI Chang, Aileen/0000-0001-7410-9867
FU NIH/NHLBIUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [R01 HL083857]; NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [UL1TR000460] Funding Source:
   NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL083857]
   Funding Source: NIH RePORTER; National Institute on Minority Health and
   Health DisparitiesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Minority Health & Health Disparities (NIMHD) [U01MD010614] Funding
   Source: NIH RePORTER
FX This research was supported by an award from NIH/NHLBI R01 HL083857.
CR Amer Diabet Assoc, 2013, DIABETES CARE, V36, pS11, DOI 10.2337/dc13-S011
   Bush K, 1998, ARCH INTERN MED, V158, P1789, DOI 10.1001/archinte.158.16.1789
   Carrasquillo O, 2014, INT J GEN MED, V7, P115, DOI 10.2147/IJGM.S56250
   Centers for Disease Control, HISP LAT POP
   Centers for Disease Control and Prevention, AD CIG SMOK US CURR
   Centers for Disease Control and Prevention, 2013, STAT IND REP FRUITS
   Chatterji P, 2012, DIABETES CARE, V35, P305, DOI 10.2337/dc11-1405
   Craig CL, 2003, MED SCI SPORT EXER, V35, P1381, DOI 10.1249/01.MSS.0000078924.61453.FB
   DiIorio Colleen, 2003, J Assoc Nurses AIDS Care, V14, P52
   Ell K, 2010, DIABETES CARE, V33, P706, DOI 10.2337/dc09-1711
   Gonzalez HM, 2001, J AM GERIATR SOC, V49, P948, DOI 10.1046/j.1532-5415.2001.49186.x
   Gross R, 2005, J GEN INTERN MED, V20, P460, DOI 10.1111/j.1525-1497.2005.30003.x
   Hay JW, 2012, VALUE HEALTH, V15, P249, DOI 10.1016/j.jval.2011.09.008
   Katon W, 2012, ARCH GEN PSYCHIAT, V69, P506, DOI 10.1001/archgenpsychiatry.2011.1548
   Lee SYD, 2006, HEALTH SERV RES, V41, P1392, DOI 10.1111/j.1475-6773.2006.00532.x
   Lorig K, 1996, OUTCOME MEASURES HLT, P24
   March D, 2014, J HEALTH CARE POOR U, V25, P321, DOI 10.1353/hpu.2014.0027
   MARIN G, 1987, HISPANIC J BEHAV SCI, V9, P183, DOI 10.1177/07399863870092005
   MORISKY DE, 1986, MED CARE, V24, P67, DOI 10.1097/00005650-198601000-00007
   Pickering TG, 2005, HYPERTENSION, V45, P142, DOI 10.1161/01.HYP.0000150859.47929.8e
   Pleis JR, 2009, VITAL HLTH STAT, V10, P6
   Polonsky WH, 2005, DIABETES CARE, V28, P626, DOI 10.2337/diacare.28.3.626
   Prince MJ, 1999, BRIT J PSYCHIAT, V174, P330, DOI 10.1192/bjp.174.4.330
   Prochaska JO, 1997, AM J HEALTH PROMOT, V12, P38, DOI 10.4278/0890-1171-12.1.38
   Sarkar U, 2006, DIABETES CARE, V29, P823, DOI 10.2337/diacare.29.04.06.dc05-1615
   Schmaling KB, 2001, J CLIN PSYCHOL MED S, V8, P167, DOI 10.1023/A:1011365519345
   SERDULA M, 1993, EPIDEMIOLOGY, V4, P455, DOI 10.1097/00001648-199309000-00012
   Stoney S, 2013, CENTRAL AM US
   Stoney S, 2013, S AM US
   Substance Abuse and Mental Health Services Administration (SAMHSA), 2012 NAT SURV DRUG U
   U.S. Department of Health and Human Services National Institutes of Health National Heart Lung and Blood Institute, 2013, NIH PUBLICATION, V13-7951
   US Census Bureau, STAT COUNT QUICKFACT
   Vouri SM, 2011, J MANAGE CARE PHARM, V17, P304, DOI 10.18553/jmcp.2011.17.4.304
NR 33
TC 2
Z9 2
U1 0
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 2000-9666
J9 J COMMUNITY HOSP INT
JI J. Community Hosp. Intern. Med. Perspect.
PY 2015
VL 5
IS 2
AR 26586
DI 10.3402/jchimp.v5.26586
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA DE6EK
UT WOS:000370726300003
PM 25846350
OA gold, Green Published
DA 2021-10-30
ER

PT J
AU Brown, CH
   Mohr, DC
   Gallo, CG
   Mader, C
   Palinkas, L
   Wingood, G
   Prado, G
   Kellam, SG
   Pantin, H
   Poduska, J
   Gibbons, R
   McManus, J
   Ogihara, M
   Valente, T
   Wulczyn, F
   Czaja, S
   Sutcliffe, G
   Villamar, J
   Jacobs, C
AF Brown, C. Hendricks
   Mohr, David C.
   Gallo, Carlos G.
   Mader, Christopher
   Palinkas, Lawrence
   Wingood, Gina
   Prado, Guillermo
   Kellam, Sheppard G.
   Pantin, Hilda
   Poduska, Jeanne
   Gibbons, Robert
   McManus, John
   Ogihara, Mitsunori
   Valente, Thomas
   Wulczyn, Fred
   Czaja, Sara
   Sutcliffe, Geoff
   Villamar, Juan
   Jacobs, Christopher
TI A Computational Future for Preventing HIV in Minority Communities: How
   Advanced Technology Can Improve Implementation of Effective Programs
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE implementation science; systems science; behavioral intervention
   technology; machine learning; computational linguistics; timecast;
   scientific equity
ID RISK-REDUCTION INTERVENTION; RANDOMIZED CONTROLLED-TRIAL; HIV/STI
   BEHAVIORAL INTERVENTIONS; SEXUALLY-TRANSMITTED-DISEASE; AGENT-BASED
   MODELS; UNITED-STATES; PUBLIC-HEALTH; MENTAL-HEALTH; DISRUPTIVE
   BEHAVIOR; AGGRESSIVE-BEHAVIOR
AB African Americans and Hispanics in the United States have much higher rates of HIV than non-minorities. There is now strong evidence that a range of behavioral interventions are efficacious in reducing sexual risk behavior in these populations. Although a handful of these programs are just beginning to be disseminated widely, we still have not implemented effective programs to a level that would reduce the population incidence of HIV for minorities. We proposed that innovative approaches involving computational technologies be explored for their use in both developing new interventions and in supporting wide-scale implementation of effective behavioral interventions. Mobile technologies have a place in both of these activities. First, mobile technologies can be used in sensing contexts and interacting to the unique preferences and needs of individuals at times where intervention to reduce risk would be most impactful. Second, mobile technologies can be used to improve the delivery of interventions by facilitators and their agencies. Systems science methods including social network analysis, agent-based models, computational linguistics, intelligent data analysis, and systems and software engineering all have strategic roles that can bring about advances in HIV prevention in minority communities. Using an existing mobile technology for depression and 3 effective HIV prevention programs, we illustrated how 8 areas in the intervention/implementation process can use innovative computational approaches to advance intervention adoption, fidelity, and sustainability.
C1 [Brown, C. Hendricks; Gallo, Carlos G.; Prado, Guillermo; Pantin, Hilda; Villamar, Juan] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Coral Gables, FL 33124 USA.
   [Mohr, David C.] Northwestern Univ, Dept Prevent Med, Chicago, IL 60611 USA.
   [Mader, Christopher] Univ Miami, Miller Sch Med, Ctr Computat Sci, Coral Gables, FL 33124 USA.
   [Palinkas, Lawrence] Univ So Calif, Sch Social Work, Los Angeles, CA 90089 USA.
   [Wingood, Gina] Emory Univ, Rollins Sch Publ Hlth, Dept Behav Sci & Hlth Educ, Atlanta, GA 30322 USA.
   [Kellam, Sheppard G.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA.
   [Poduska, Jeanne] Amer Inst Res, Washington, DC USA.
   [Gibbons, Robert] Univ Chicago, Dept Hlth Stat, Chicago, IL 60637 USA.
   [McManus, John] Univ Miami, Dept Marine Biol & Fisheries, Rosenstiel Sch Marine & Atmospher Sci, Coral Gables, FL 33124 USA.
   [Ogihara, Mitsunori; Czaja, Sara] Univ Miami, Miller Sch Med, Dept Psychiat & Behav Sci, Coral Gables, FL 33124 USA.
   [Valente, Thomas] Univ So Calif, Dept Prevent Med, Los Angeles, CA 90089 USA.
   [Wulczyn, Fred] Univ Chicago, Chicago, IL 60637 USA.
   [Villamar, Juan; Jacobs, Christopher] Univ Miami, Dept Comp Sci, Coral Gables, FL 33124 USA.
RP Brown, CH (corresponding author), Univ Miami, Ctr Studies Family, Miller Sch Med, 1425 NW 10th Ave, Miami, FL 33136 USA.
EM chbrown@med.miami.edu
RI Ogihara, Mitsunori/AAB-8275-2020
OI Ogihara, Mitsunori/0000-0002-5690-7854; Brown, C
   Hendricks/0000-0002-0294-2419; Sutcliffe, Geoff/0000-0001-9120-3927;
   Mohr, David/0000-0002-5443-7596
FU NIDAUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Drug Abuse
   (NIDA) [Ce-PIM: P30DA027828, R01DA025192, R01DA030452, P30AI073961];
   OBSSR [Ce-PIM: P30DA027828]; NIMHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Mental Health (NIMH) [P30AI073961, CBITS: P20MH090318];
   Advanced Center to Improve Pediatric Mental Health Care [ACIPMC:
   P30MH074678]; NIAIDUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [P30AI073961, CFAR:
   P30AI050409]; NCIUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [P30AI073961]; NICHDUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH Eunice
   Kennedy Shriver National Institute of Child Health & Human Development
   (NICHD) [P30AI073961]; NHLBIUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [P30AI073961]; NIAUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Aging (NIA) [P30AI073961]; FIC [P30AI073961]; OAR
   [P30AI073961]; National Center for HIV/AIDS; Viral Hepatitis; STD; TB
   Prevention (NCHHSTP) [U01-PS000671]; NCHHSTPUnited States Department of
   Health & Human ServicesCenters for Disease Control & Prevention - USA
   [R18PS001157]; NCATSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [CTSI: UL1TR000460]; NIMHD
   [CTSI: UL1TR000460]; IESUS Department of Education [R305A090446];
   William T. Grant Foundation [10648];  [P20 MH090318];  [R01MH066302]; 
   [R13 MH-081733-01A1]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD
   HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD)
   [R13HD074468] Funding Source: NIH RePORTER; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000150,
   UL1TR000460] Funding Source: NIH RePORTER; NATIONAL CENTER FOR HIV,
   VIRAL HEPATITIS, STDS AND TB PREVENTIONUnited States Department of
   Health & Human ServicesCenters for Disease Control & Prevention - USA
   [U01PS000671] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [P30AI073961,
   P30AI050409] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL
   HEALTHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH) [R13MH081733, R01MH066302, P20MH090318, P30MH074678] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Drug Abuse (NIDA)European Commission
   [R01DA025192, R01DA030452, P30DA027828] Funding Source: NIH RePORTER
FX The authors gratefully acknowledge the support of the NIDA and OBSSR for
   funding on the Center for Prevention Implementation Methodology (Ce-PIM:
   P30DA027828; CHB, GP, HP, SGK, MO, CG, JV, CM, CJ, GS, TV, LAP, SC, JM,
   RDG) and NIDA as well for R01DA025192 (GP, HP, CHB) and R01DA030452 (JP,
   CHB); NIMH for funding of the Center for Behavioral Intervention
   Technologies (CBITS: P20MH090318; DCM) and the Advanced Center to
   Improve Pediatric Mental Health Care (ACIPMC: P30MH074678; LAP, FW, CHB)
   as well as grants P20 MH090318 (DCM) and R01MH066302 (RDG); NIAID, NCI,
   NICHD, NHLBI, NIDA, NIMH, NIA, FIC, and OAR for supporting the Miami
   Center for AIDS Research (CFAR; P30AI073961; GP, CHB); NIAID for
   supporting the Emory Center for AIDS Research (CFAR: P30AI050409; GW),
   the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB
   Prevention (NCHHSTP) for U01-PS000671 (GP), NCHHSTP for supporting
   R18PS001157 (GW), NCATS and NIMHD for supporting the Miami Clinical and
   Translational Science Institute (CTSI: UL1TR000460; CHB, SC, CM), IES
   for R305A090446 (JP, CHB) and the William T. Grant Foundation (Grant ID#
   10648; LAP, CHB). We also thank the Center for Computational Science at
   the University of Miami (CG, CM, CHB). Additional support for the
   supplement was provided by R13 MH-081733-01A1.
CR Aarons GA, 2011, ADM POLICY MENT HLTH, V38, P4, DOI 10.1007/s10488-010-0327-7
   American Institutes for Research, 2005, CONC OV COACH COMP R
   Axelrod R. M., 1997, COMPLEXITY COOPERATI
   Balas EA, 1998, PEDIATR ANN, V27, P581, DOI 10.3928/0090-4481-19980901-11
   BARRISH HH, 1969, J APPL BEHAV ANAL, V2, P119, DOI 10.1901/jaba.1969.2-119
   Begun AL, 2010, SOC WORK, V55, P54, DOI 10.1093/sw/55.1.54
   Beigi H, 2011, FUNDAMENTALS OF SPEAKER RECOGNITION, P1, DOI 10.1007/978-0-387-77592-0
   Bennett GG, 2009, ANNU REV PUBL HEALTH, V30, P273, DOI 10.1146/annurev.publhealth.031308.100235
   Braveman P, 2003, J EPIDEMIOL COMMUN H, V57, P254, DOI 10.1136/jech.57.4.254
   Brown CH, 2008, DRUG ALCOHOL DEPEN, V95, pS74, DOI 10.1016/j.drugalcdep.2007.11.013
   Brown CH, 2012, ADM POLICY MENT HLTH, V39, P301, DOI 10.1007/s10488-011-0387-3
   Brown CH, 2007, RECOGNITION AND PREVENTION OF MAJOR MENTAL AND SUBSTANCE USE DISORDERS, P347
   Bull S, 2009, AIDS BEHAV, V13, P474, DOI 10.1007/s10461-008-9487-9
   Burns MN, 2011, J MED INTERNET RES, V13, DOI 10.2196/jmir.1838
   Capaldi DM, 2002, DEV PSYCHOL, V38, P394, DOI 10.1037//0012-1649.38.3.394
   Carey MP, 2010, AIDS BEHAV, V14, P504, DOI 10.1007/s10461-009-9587-1
   Chamberlain P., 2010, EMPIRICALLY SUPPORTE, P218
   Chambers DA, 2008, ADM POLICY MENT HLTH, V35, P3, DOI 10.1007/s10488-007-0146-7
   Christensen H, 2010, MED J AUSTRALIA, V192, pS2
   Crepaz N, 2007, SEX TRANSM DIS, V34, P319, DOI 10.1097/01.olq.0000240342.12960.73
   Crepaz N, 2009, AM J PUBLIC HEALTH, V99, P2069, DOI 10.2105/AJPH.2008.139519
   Czaja SJ, 2006, HDB HUMAN FACTORS ER, P32
   Darbes L, 2008, AIDS, V22, P1177, DOI 10.1097/QAD.0b013e3282ff624e
   Davies P, 2010, IMPLEMENT SCI, V5, DOI 10.1186/1748-5908-5-14
   Di Noia J, 2004, J ADOLESCENT HEALTH, V35, P62, DOI 10.1016/j.jadohealth.2003.09.006
   DiClemente RJ, 2009, ARCH PEDIAT ADOL MED, V163, P1112, DOI 10.1001/archpediatrics.2009.205
   DICLEMENTE RJ, 1995, JAMA-J AM MED ASSOC, V274, P1271, DOI 10.1001/jama.274.16.1271
   Dishion T.J., 1992, ANTISOCIAL BOYS
   Dolan L. J., 1993, J APPL DEV PSYCHOL, V14, P317, DOI [10.1016/0193-3973(93)90013-L, DOI 10.1016/0193-3973(93)90013-L]
   Epstein J., 2007, GENERATIVE SOCIAL SC
   Fixsen D., 2005, FMHI PUBLICATION, V#231
   Food and Drug Administration (FDA), 2011, FDA OUTL OV MOB MED
   Gibbons RD, 2008, PSYCHIAT SERV, V59, P361, DOI 10.1176/ps.2008.59.4.361
   Gibbons RD, 2012, ARCH GEN PSYCHIAT, V69, P1104, DOI 10.1001/archgenpsychiatry.2012.14
   Glasgow RE, 1999, AM J PUBLIC HEALTH, V89, P1322, DOI 10.2105/AJPH.89.9.1322
   Glass TA, 2006, SOC SCI MED, V62, P1650, DOI 10.1016/j.socscimed.2005.08.044
   Goldhaber-Fiebert JD, 2012, ADM POLICY MENT HLTH, V39, P466, DOI 10.1007/s10488-011-0370-z
   Gratch J, 2007, 7 INT C INT VIRT AG
   Griffith DM, 2010, J PRIM PREV, V31, P31, DOI 10.1007/s10935-010-0202-z
   Grimm V, 2005, SCIENCE, V310, P987, DOI 10.1126/science.1116681
   Hall M., 2009, SIGKDD EXPLOR NEWSL, V11, P10, DOI [10.1145/1656274.1656278, DOI 10.1145/1656274.1656278]
   Heath B, 2009, JASSS-J ARTIF SOC S, V12, pA143
   Henny KD, 2012, AIDS BEHAV, V16, P1092, DOI 10.1007/s10461-011-0100-2
   Herbst JH, 2007, AIDS BEHAV, V11, P25, DOI 10.1007/s10461-006-9151-1
   Horwitz SM, 2010, ADM POLICY MENT HLTH, V37, P27, DOI 10.1007/s10488-010-0274-3
   Hoste L, 2012, PROCEEDINGS OF THE INTERNATIONAL WORKING CONFERENCE ON ADVANCED VISUAL INTERFACES, P156, DOI 10.1145/2254556.2254585
   Jemmott JB, 2010, AM J PUBLIC HEALTH, V100, P720, DOI 10.2105/AJPH.2008.140657
   Jeong Y.M., 2012, ADV EECM, V139, P383
   Jurafsky D., 2009, SPEECH LANGUAGE PROC, V2nd ed.
   Kellam SG, 1999, AM J COMMUN PSYCHOL, V27, P463, DOI 10.1023/A:1022129127298
   KELLAM SG, 1994, J CHILD PSYCHOL PSYC, V35, P259, DOI 10.1111/j.1469-7610.1994.tb01161.x
   Kellam SG, 2008, DRUG ALCOHOL DEPEN, V95, pS5, DOI 10.1016/j.drugalcdep.2008.01.004
   Kellam SG, 2008, DRUG ALCOHOL DEPEN, V95, pS1, DOI 10.1016/j.drugalcdep.2008.01.006
   Kellam SG, 2014, PREV SCI, V15, pS6, DOI 10.1007/s11121-012-0296-z
   Kellam SG, 2012, ADM POLICY MENT HLTH, V39, P317, DOI 10.1007/s10488-011-0402-8
   Kellam Sheppard G, 2011, Addict Sci Clin Pract, V6, P73
   Kiene SM, 2006, J ADOLESCENT HEALTH, V39, P404, DOI 10.1016/j.jadohealth.2005.12.029
   Kossiakoff A, 2003, SYSTEMS ENG PRINCIPE
   Landsverk J, 2012, DESIGN ANAL DISSEMIN
   Landsverk J, 2011, ADM POLICY MENT HLTH, V38, P54, DOI 10.1007/s10488-010-0315-y
   Lansford JE, 2010, J RES ADOLESCENCE, V20, P651, DOI 10.1111/j.1532-7795.2010.00654.x
   Latham TP, 2010, HEALTH PROMOT PRACT, V11, p53S, DOI 10.1177/1524839910361433
   Lester RT, 2010, LANCET, V376, P1838, DOI 10.1016/S0140-6736(10)61997-6
   Levine D, 2008, PLOS MED, V5, P1428, DOI 10.1371/journal.pmed.0050213
   Lich KH, 2013, PREV SCI, V14, P279, DOI 10.1007/s11121-012-0285-2
   Mabry PM, 2008, AM J PREV MED, V35, P611
   Madison SM, 2000, AIDS EDUC PREV, V12, P281
   Maglio PP, 2011, AM J PREV MED, V40, P392, DOI 10.1016/j.amepre.2010.11.010
   Markham CM, 2009, AIDS CARE, V21, P622, DOI 10.1080/09540120802385637
   Marshall K, 2010, AFRICAN AM HIV AIDS, P181
   Martell CR., 2010, BEHAV ACTIVATION DEP
   Martin M, 2011, IMPACT EC WORKING PA, V2
   Miller JH, 2007, PRINC STUD COMPLEX, P1, DOI 10.1007/1-4020-5602-8_1
   Miller-Johnson S, 1999, DEV PSYCHOPATHOL, V11, P85, DOI 10.1017/S0954579499001960
   Miner G, 2012, PRACTIAL TEXT MINING
   Mohr DC, 2011, J MED INTERNET RES, V13, DOI 10.2196/jmir.1602
   Mohr DC, 2010, J MED INTERNET RES, V12, DOI 10.2196/jmir.1370
   Morell J. A., 2010, J MULTIDISCIPLINARY, V6, P32
   Munoz RF, 2006, NICOTINE TOB RES, V8, P77, DOI 10.1080/14622200500431940
   Munoz RF, 2012, AM PSYCHOL, V67, P285, DOI 10.1037/a0027666
   Murry VM, 2007, J ADOLESCENT HEALTH, V41, P333, DOI 10.1016/j.jadohealth.2007.04.003
   Muthen B, 2002, BIOSTATISTICS, V3, P459, DOI 10.1093/biostatistics/3.4.459
   National Cancer Institute, CANC BIOM INF GRID
   National Institute for Health and Excellence (NICE), 2013, REV AT
   Norman CD, 2009, J EVAL CLIN PRACT, V15, P868, DOI 10.1111/j.1365-2753.2009.01273.x
   Ormerod P, 2009, LECT NOTES ARTIF INT, V5466, P130, DOI 10.1007/978-3-642-01109-2_10
   Palinkas L.A., 2012, TRANSLATION IMPLEMEN
   PANTIN H, 2007, PREVENTING YOUTH SUB, P211, DOI DOI 10.1037/11488-009
   Pantin H, 2009, PSYCHOSOM MED, V71, P987, DOI 10.1097/PSY.0b013e3181bb2913
   Perrino T, PERSP PSYCH IN PRESS
   Petras H, 2008, DRUG ALCOHOL DEPEN, V95, pS45, DOI 10.1016/j.drugalcdep.2007.10.015
   Poduska J, 2012, ADM POLICY MENT HLTH, V39, P258, DOI 10.1007/s10488-011-0383-7
   Poduska J, 2009, IMPLEMENT SCI, V4, DOI 10.1186/1748-5908-4-56
   Povey K, 2011, KALDI SPEECH RECOGNI
   Prado G, 2007, J CONSULT CLIN PSYCH, V75, P914, DOI 10.1037/0022-006X.75.6.914
   Prado G, 2012, ARCH PEDIAT ADOL MED, V166, P127, DOI 10.1001/archpediatrics.2011.189
   Prejean J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017502
   Proctor EK, 2009, ADM POLICY MENT HLTH, V36, P24, DOI 10.1007/s10488-008-0197-4
   Rebok G., 1992, PREVENTING ANTISOCIA, P162
   Reid J. B., 1997, HDB ANTISOCIAL BEHAV, P343
   REID JB, 1993, DEV PSYCHOPATHOL, V5, P243, DOI 10.1017/S0954579400004375
   Riedl M, 2012, P NAACL HLT MONTR CA, P12
   Rivera DE, 2007, DRUG ALCOHOL DEPEN, V88, pS31, DOI 10.1016/j.drugalcdep.2006.10.020
   Rotheram-Borus MJ, 2009, ANNU REV CLIN PSYCHO, V5, P143, DOI 10.1146/annurev.clinpsy.032408.153530
   SAMHSA, NREPP SAMHSAS NAT RE
   Schaeffer CM, 2006, J CONSULT CLIN PSYCH, V74, P500, DOI 10.1037/0022-006X.74.3.500
   Schaeffer CM, 2003, DEV PSYCHOL, V39, P1020, DOI 10.1037/0012-1649.39.6.1020
   Schensul JJ, 2009, AM J COMMUN PSYCHOL, V43, P241, DOI 10.1007/s10464-009-9228-x
   Schoenwald SK, 2004, J CLIN CHILD ADOLESC, V33, P94, DOI 10.1207/S15374424JCCP3301_10
   Schoenwald SK, 2011, ADM POLICY MENT HLTH, V38, P32, DOI 10.1007/s10488-010-0321-0
   Smith A, 2010, MOBILE ACCESS 2010 P
   Snyder J., 2002, ANTISOCIAL BEHAV CHI, P65, DOI [DOI 10.1037/10468-000, 10.1037/10468-000]
   Spouse J, 2001, J ADV NURS, V33, P512, DOI 10.1046/j.1365-2648.2001.01683.x
   Sweeney D., 2003, LEARNING ALONG WAY P
   Swendeman D, 2010, CURR OPIN PSYCHIATR, V23, P139, DOI 10.1097/YCO.0b013e328336656a
   Tamarit V, 2012, NAT LANG ENG, V18, P1, DOI 10.1017/S135132491000032X
   Tervalon M, 1998, J HEALTH CARE POOR U, V9, P117
   Valente T, 2010, SOCIAL NETWORKS HLTH
   Valente TW, 2007, HEALTH EDUC BEHAV, V34, P881, DOI 10.1177/1090198106297855
   Valente TW, 2007, ADDICTION, V102, P1804, DOI 10.1111/j.1360-0443.2007.01992.x
   Valente TW, 2006, BRIT MED J, V333, P1082, DOI 10.1136/bmj.39042.435984.43
   Valente TW, 2012, SCIENCE, V337, P49, DOI 10.1126/science.1217330
   Valente TW, 1999, ANN AM ACAD POLIT SS, V566, P55, DOI 10.1177/0002716299566001005
   Villarruel AM, 2006, J SPEC PEDIATR NURS, V11, P244, DOI 10.1111/j.1744-6155.2006.00076.x
   Villarruel AM, 2006, ARCH PEDIAT ADOL MED, V160, P772, DOI 10.1001/archpedi.160.8.772
   Walker W, 2004, SHINX 4 FLEXIBLE OPE, DOI 10.1.1.91.4704
   Wallerstein NB, 2006, HEALTH PROMOT PRACT, V7, P312, DOI 10.1177/1524839906289376
   Watson A, 2012, J MED INTERNET RES, V14, DOI 10.2196/jmir.1629
   Wilcox HC, 2008, DRUG ALCOHOL DEPEN, V95, pS60, DOI 10.1016/j.drugalcdep.2008.01.005
   Williamson D.M., 2012, EDUC MEAS-ISSUES PRA, V31, P2, DOI [10.1111/j.1745-3992.2011.00223.x, DOI 10.1111/J.1745-3992.2011.00223.X]
   Wingood GM, 2006, AIDS EDUC PREV, V18, P161, DOI 10.1521/aeap.2006.18.supp.161
   Wingood GM, 2013, JAIDS-J ACQ IMM DEF, V63, pS36, DOI 10.1097/QAI.0b013e3182920031
   Wingood GM, 2011, AM J PUBLIC HEALTH, V101, P2245, DOI 10.2105/AJPH.2011.300340
   Wingood GM, 2011, HEALTH PROMOT PRACT, V12, P823, DOI 10.1177/1524839910372039
   Wulczyn F, 2001, SOC SERV REV, V75, P292, DOI 10.1086/322210
   Xie S, 2012, P NAACL HLT MONTR CA
NR 136
TC 39
Z9 39
U1 3
U2 25
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD JUN 1
PY 2013
VL 63
SU 1
BP S72
EP S84
DI 10.1097/QAI.0b013e31829372bd
PG 13
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 300IU
UT WOS:000330458400013
PM 23673892
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Kidwell, CS
   Jahan, R
   Gornbein, J
   Alger, JR
   Nenov, V
   Ajani, Z
   Feng, L
   Meyer, BC
   Olson, S
   Schwamm, LH
   Yoo, AJ
   Marshall, RS
   Meyers, PM
   Yavagal, DR
   Wintermark, M
   Guzy, J
   Starkman, S
   Saver, JL
AF Kidwell, Chelsea S.
   Jahan, Reza
   Gornbein, Jeffrey
   Alger, Jeffry R.
   Nenov, Val
   Ajani, Zahra
   Feng, Lei
   Meyer, Brett C.
   Olson, Scott
   Schwamm, Lee H.
   Yoo, Albert J.
   Marshall, Randolph S.
   Meyers, Philip M.
   Yavagal, Dileep R.
   Wintermark, Max
   Guzy, Judy
   Starkman, Sidney
   Saver, Jeffrey L.
CA MR RESCUE Investigators
TI A Trial of Imaging Selection and Endovascular Treatment for Ischemic
   Stroke
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID THROMBECTOMY; ALTEPLASE; REVASCULARIZATION; REPERFUSION; MANAGEMENT;
   DIFFUSION; PERFUSION; DEVICE; SAFETY; MRI
AB BACKGROUND
   Whether brain imaging can identify patients who are most likely to benefit from therapies for acute ischemic stroke and whether endovascular thrombectomy improves clinical outcomes in such patients remains unclear.
   METHODS
   In this study, we randomly assigned patients within 8 hours after the onset of large-vessel, anterior-circulation strokes to undergo mechanical embolectomy (Merci Retriever or Penumbra System) or receive standard care. All patients underwent pretreatment computed tomography or magnetic resonance imaging of the brain. Randomization was stratified according to whether the patient had a favorable penumbral pattern (substantial salvageable tissue and small infarct core) or a nonpenumbral pattern (large core or small or absent penumbra). We assessed outcomes using the 90-day modified Rankin scale, ranging from 0 (no symptoms) to 6 (dead).
   RESULTS
   Among 118 eligible patients, the mean age was 65.5 years, the mean time to enrollment was 5.5 hours, and 58% had a favorable penumbral pattern. Revascularization in the embolectomy group was achieved in 67% of the patients. Ninety-day mortality was 21%, and the rate of symptomatic intracranial hemorrhage was 4%; neither rate differed across groups. Among all patients, mean scores on the modified Rankin scale did not differ between embolectomy and standard care (3.9 vs. 3.9, P = 0.99). Embolectomy was not superior to standard care in patients with either a favorable penumbral pattern (mean score, 3.9 vs. 3.4; P = 0.23) or a nonpenumbral pattern (mean score, 4.0 vs. 4.4; P = 0.32). In the primary analysis of scores on the 90-day modified Rankin scale, there was no interaction between the pretreatment imaging pattern and treatment assignment (P = 0.14).
   CONCLUSIONS
   A favorable penumbral pattern on neuroimaging did not identify patients who would differentially benefit from endovascular therapy for acute ischemic stroke, nor was embolectomy shown to be superior to standard care. (Funded by the National Institute of Neurological Disorders and Stroke; MR RESCUE ClinicalTrials.gov number, NCT00389467.)
C1 [Kidwell, Chelsea S.] Georgetown Univ, Dept Neurol, Washington, DC 20007 USA.
   [Kidwell, Chelsea S.] Georgetown Univ, Stroke Ctr, Washington, DC 20007 USA.
   [Jahan, Reza] Univ Calif Los Angeles, Dept Radiol & Neurosurg, Los Angeles, CA USA.
   [Gornbein, Jeffrey] Univ Calif Los Angeles, Dept Biomath, Los Angeles, CA USA.
   [Alger, Jeffry R.; Saver, Jeffrey L.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA.
   [Nenov, Val] Univ Calif Los Angeles, Dept Neurosurg, Los Angeles, CA USA.
   [Guzy, Judy; Starkman, Sidney] Univ Calif Los Angeles, Dept Emergency Med & Neurol, Los Angeles, CA USA.
   [Jahan, Reza; Alger, Jeffry R.; Guzy, Judy; Starkman, Sidney; Saver, Jeffrey L.] Univ Calif Los Angeles, Stroke Ctr, Los Angeles, CA USA.
   [Ajani, Zahra] Kaiser Permanente, Dept Neurol, Los Angeles, CA USA.
   [Feng, Lei] Kaiser Permanente, Dept Radiol, Los Angeles, CA USA.
   [Meyer, Brett C.] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA.
   [Olson, Scott] Univ Calif San Diego, Dept Radiol, San Diego, CA 92103 USA.
   [Meyer, Brett C.] Univ Calif San Diego, Stroke Ctr, San Diego, CA 92103 USA.
   [Olson, Scott] Scripps Clin, Div Neurosurg, La Jolla, CA 92037 USA.
   [Schwamm, Lee H.] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA.
   [Yoo, Albert J.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
   [Marshall, Randolph S.] Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA.
   [Meyers, Philip M.] Columbia Univ Coll Phys & Surg, Dept Neurol Surg & Radiol, New York, NY 10032 USA.
   [Yavagal, Dileep R.] Univ Miami, Jackson Mem Hosp, Dept Neurol, Miami, FL 33136 USA.
   [Yavagal, Dileep R.] Univ Miami, Jackson Mem Hosp, Dept Neurosurg, Miami, FL 33136 USA.
   [Wintermark, Max] Univ Virginia, Dept Radiol, Neuroradiol Div, Charlottesville, VA USA.
RP Kidwell, CS (corresponding author), Georgetown Univ, Bldg D,Suite 150,4000 Reservoir Rd NW, Washington, DC 20007 USA.
EM ck256@georgetown.edu
RI Meyers, Philip M./N-9776-2019; McCullough-Hicks, Margy/AAG-6566-2019;
   Demchuk, Andrew M/E-1103-2012; Buck, Brian H/B-8482-2009
OI Meyers, Philip M./0000-0002-3250-5543; Demchuk, Andrew
   M/0000-0002-4930-7789; Buck, Brian H/0000-0002-7984-6062; Wintermark,
   Max/0000-0002-6726-3951; Barest, Glenn/0000-0002-5402-5372;
   McCullough-Hicks, Margy/0000-0003-3770-8689; Saver,
   Jeffrey/0000-0001-9141-2251; Hayakawa, Minako/0000-0002-9498-4711;
   Jumaa, Mouhammad/0000-0002-7165-797X; Molyneaux,
   Bradley/0000-0002-3377-1229; Gonzalez, Nestor/0000-0002-8277-6317;
   Schwamm, Lee/0000-0003-0592-9145; Kummer, Terrance/0000-0001-8938-8280;
   Ajani, Zahra/0000-0001-6187-5204; Mir, Osman/0000-0002-0226-3299
FU National Institute of Neurological Disorders and StrokeUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Neurological Disorders & Stroke (NINDS);
   NINDSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Neurological
   Disorders & Stroke (NINDS) [P50 NS044378]; NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [UL1TR000460] Funding Source:
   NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND
   STROKEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Neurological
   Disorders & Stroke (NINDS) [K24NS072272, P50NS044378] Funding Source:
   NIH RePORTER
FX Funded by the National Institute of Neurological Disorders and Stroke;
   MR RESCUE ClinicalTrials.gov number, NCT00389467.); Supported by a grant
   (P50 NS044378) from NINDS. Concentric Medical provided study catheters
   and devices from the initiation of the study until August 2007;
   thereafter, costs for all study catheters and devices were covered by
   study funds or third-party payers.
CR Albers GW, 2006, ANN NEUROL, V60, P508, DOI 10.1002/ana.20976
   Barber PA, 1998, NEUROLOGY, V51, P418, DOI 10.1212/WNL.51.2.418
   Bateman BT, 2003, STROKE, V34, P1317, DOI 10.1161/01.STR.0000065230.00053.B4
   Costalat V, 2011, STROKE, V42, P1929, DOI 10.1161/STROKEAHA.110.608976
   Davis SM, 2008, LANCET NEUROL, V7, P299, DOI 10.1016/S1474-4422(08)70044-9
   Fisher M, 1997, STROKE, V28, P866, DOI 10.1161/01.STR.28.4.866
   Furlan A, 1999, JAMA-J AM MED ASSOC, V282, P2003, DOI 10.1001/jama.282.21.2003
   Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656
   Kidwell CS, 2013, STROKE, V44, P73, DOI 10.1161/STROKEAHA.112.670034
   Kidwell CS, 2012, STROKE
   Kidwell CS, 2012, INT J STROKE
   Langer D, 2009, STROKE, V40, P2761, DOI 10.1161/STROKEAHA.108.544957
   Lansberg MG, 2012, LANCET NEUROL, V11, P860, DOI 10.1016/S1474-4422(12)70203-X
   Lansberg MG, 2012, STROKE, V43, pA73
   MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401
   Nogueira RG, 2012, LANCET, V380, P1231, DOI 10.1016/S0140-6736(12)61299-9
   Parsons M, 2012, NEW ENGL J MED, V366, P1099, DOI 10.1056/NEJMoa1109842
   Saver JL, 2012, LANCET, V380, P1241, DOI 10.1016/S0140-6736(12)61384-1
   Shuaib A, 2011, LANCET NEUROL, V10, P909, DOI 10.1016/S1474-4422(11)70195-8
   Smith WS, 2008, STROKE, V39, P1205, DOI 10.1161/STROKEAHA.107.497115
   Smith WS, 2005, STROKE, V36, P1432, DOI 10.1161/01.STR.0000171066.25248.1d
   Tomsick T, 2008, AM J NEURORADIOL, V29, P582, DOI 10.3174/ajnr.A0843
NR 22
TC 939
Z9 977
U1 2
U2 105
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAR 7
PY 2013
VL 368
IS 10
BP 914
EP 923
DI 10.1056/NEJMoa1212793
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 100BG
UT WOS:000315669100007
PM 23394476
OA Green Accepted
HC Y
HP N
DA 2021-10-30
ER

PT J
AU Espana-Irla, G
   Gomes-Osman, J
   Cattaneo, G
   Albu, S
   Cabello-Toscano, M
   Solana-Sanchez, J
   Redondo-Camos, M
   Delgado-Gallen, S
   Alviarez-Schulze, V
   Pachon-Garcia, C
   Tormos, JM
   Bartres-Faz, D
   Morris, TP
   Pascual-Leone, A
AF Espana-Irla, Goretti
   Gomes-Osman, Joyce
   Cattaneo, Gabriele
   Albu, Sergiu
   Cabello-Toscano, Maria
   Solana-Sanchez, Javier
   Redondo-Camos, Maria
   Delgado-Gallen, Selma
   Alviarez-Schulze, Vanessa
   Pachon-Garcia, Catherine
   Tormos, Josep M.
   Bartres-Faz, David
   Morris, Timothy P.
   Pascual-Leone, Alvaro
TI Associations Between Cardiorespiratory Fitness, Cardiovascular Risk, and
   Cognition Are Mediated by Structural Brain Health in Midlife
SO JOURNAL OF THE AMERICAN HEART ASSOCIATION
LA English
DT Article
DE cardiorespiratory fitness; cardiovascular health; cognition; exercise;
   mediation; midlife; structural brain health
ID PHYSICAL-ACTIVITY QUESTIONNAIRE; HUMAN CEREBRAL-CORTEX; DEMENTIA RISK;
   OLDER-ADULTS; VISUOSPATIAL SPAN; AEROBIC FITNESS; SEX-DIFFERENCES;
   BLOOD-PRESSURE; PROJECT NORMS; OXYGEN-UPTAKE
AB Background Evidence in older adults suggests that higher cardiorespiratory fitness and lower cardiovascular risk are associated with greater cognition. However, given that changes in the brain that lead to cognitive decline begin decades before the onset of symptoms, understanding the mechanisms by which modifiable cardiovascular factors are associated with brain health in midlife is critical and can lead to the development of strategies to promote and maintain brain health as we age. Methods and Results In 501 middle-aged (aged 40-65 years) adult participants of the BBHI (Barcelona Brain Health Initiative), we found differential associations among cardiorespiratory fitness, cardiovascular risk, and cognition and cortical thickness. Higher cardiorespiratory fitness was significantly associated with better visuospatial abilities and frontal loading abstract problem solving (beta=3.16, P=0.049) in the older middle-aged group (aged 55-65 years). In contrast, cardiovascular risk was negatively associated with better visuospatial reasoning and problem-solving abilities (beta=-0.046, P=0.002), flexibility (beta=-0.054, P<0.001), processing speed (beta=-0.115, P<0.001), and memory (beta=-0.120, P<0.001). Cortical thickness in frontal regions mediated the relationship between cardiorespiratory fitness and cognition, whereas cortical thickness in a disperse network spanning multiple cortical regions across both hemispheres mediated the relationship between cardiovascular risk and cognition. Conclusions The relationships between modifiable cardiovascular factors, cardiorespiratory fitness, and cardiovascular risk, and cognition are present in healthy middle-aged adults. These relationships are also mediated by brain structure highlighting a potential mechanistic pathway through which higher cardiorespiratory fitness and lower cardiovascular risk can positively impact cognitive function in midlife.
C1 [Espana-Irla, Goretti; Cattaneo, Gabriele; Albu, Sergiu; Cabello-Toscano, Maria; Solana-Sanchez, Javier; Redondo-Camos, Maria; Delgado-Gallen, Selma; Alviarez-Schulze, Vanessa; Pachon-Garcia, Catherine; Tormos, Josep M.; Bartres-Faz, David; Pascual-Leone, Alvaro] UAB, Guttmann Brain Hlth Inst, Inst Guttmann, Inst Univ Neurorehabil Adscrit, Badalona, Spain.
   [Gomes-Osman, Joyce] Univ Miami, Dept Neurol, Miller Sch Med, Miami, FL USA.
   [Espana-Irla, Goretti; Cattaneo, Gabriele; Albu, Sergiu; Solana-Sanchez, Javier; Redondo-Camos, Maria; Delgado-Gallen, Selma; Alviarez-Schulze, Vanessa; Pachon-Garcia, Catherine; Tormos, Josep M.] Univ Autonoma Barcelona, Dept Med, Bellaterra, Spain.
   [Cabello-Toscano, Maria; Bartres-Faz, David] Univ Barcelona, Dept Med, Fac Med & Ciencies Salut, Barcelona, Spain.
   [Cabello-Toscano, Maria; Bartres-Faz, David] Univ Barcelona, Inst Neurociencies, Barcelona, Spain.
   [Pascual-Leone, Alvaro] Harvard Med Sch, Dept Neurol, Boston, MA USA.
   [Pascual-Leone, Alvaro] Hebrew SeniorLife, Hinda & Arthur Marcus Inst Aging Res, Boston, MA USA.
   [Pascual-Leone, Alvaro] Hebrew SeniorLife, Deanna & Sidney Wolk Ctr Memory Hlth, Boston, MA USA.
   [Morris, Timothy P.] Northeastern Univ, Ctr Cognit & Brain Hlth, Dept Psychol, Boston, MA USA.
RP Morris, TP (corresponding author), Northeastern Univ, Dept Psychol, 606 ISEC,360 Huntington Ave, Boston, MA 02115 USA.; Pascual-Leone, A (corresponding author), Inst Guttmann, Barcelona Brain Hlth Initiat, Cami Can Ruti S-N, Barcelona 08916, Spain.
EM t.morris@northeastern.edu; apleone@guttmann.com
OI Pachon Garcia, Catherine/0000-0003-0055-4161; Redondo-Camos,
   Maria/0000-0002-3890-5070; Cabello Toscano, Maria del
   Rocio/0000-0001-5066-3476; Alviarez Schulze,
   Vanessa/0000-0002-9702-8688; Gomes-Osman, Joyce R/0000-0001-6510-0780
FU La Caixa FoundationLa Caixa Foundation [LCF/PR/PR16/11110004]; Institut
   Guttmann; Fundacio Abertis; National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [R24AG06142, P01 AG031720]; National Science FoundationNational
   Science Foundation (NSF); Spanish Ministry of Science, Innovation,
   Universities [RTI2018-095181-B-C21]; ICREA Academia 2019 award research
   grants; Fundacio Joan Ribas Araquistain_Fjra; AGAUR, Agencia de Gestio
   d'Ajuts Universitaris i de RecercaAgencia de Gestio D'Ajuts
   Universitaris de Recerca Agaur (AGAUR) [2018 PROD 00172]; FUNDACIO LA
   MARATO DE TV3 [201735.10]; European CommissionEuropean
   CommissionEuropean Commission Joint Research Centre
   [H2020-SC1-2016-2017_ RIA_777107]; National Center for Advancing
   Translational Sciences of the National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [KL2TR002737]
FX The research leading to the reported results is funded by Q12 grants
   from the La Caixa Foundation (grant agreement LCF/PR/PR16/11110004),
   Institut Guttmann, and Fundacio Abertis. Dr Pascual-Leone was partly
   supported by the National Institutes of Health (R24AG06142 and P01
   AG031720) and the National Science Foundation. Dr Bartres-Faz was funded
   by the Spanish Ministry of Science, Innovation, Universities
   (RTI2018-095181-B-C21) and ICREA Academia 2019 award research grants. Dr
   Tormos was partly supported by Fundacio Joan Ribas Araquistain_Fjra,
   AGAUR, Agencia de Gestio d'Ajuts Universitaris i de Recerca (2018 PROD
   00172), FUNDACIO LA MARATO DE TV3 (201735.10), and the European
   Commission (Call H2020-SC1-2016-2017_ RIA_777107). Dr Gomes-Osman was
   supported by the National Center for Advancing Translational Sciences of
   the National Institutes of Health under award KL2TR002737. The content
   is solely the responsibility of the authors and does not necessarily
   represent the official views of the National Institutes of Health.
CR Adams R, 1999, CAN FAM PHYSICIAN, V45, P992
   Al-Mallah MH, 2016, MAYO CLIN PROC, V91, P755, DOI 10.1016/j.mayocp.2016.04.002
   ANDERSON KM, 1991, AM HEART J, V121, P293, DOI 10.1016/0002-8703(91)90861-B
   Anstey KJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086141
   Aros F, 2000, REV ESP CARDIOL, V53, P1063, DOI 10.1016/S0300-8932(00)75210-9
   Aspenes ST, 2011, MED SCI SPORT EXER, V43, P1465, DOI 10.1249/MSS.0b013e31820ca81c
   Barnes DE, 2009, NEUROLOGY, V73, P173, DOI 10.1212/WNL.0b013e3181a81636
   Barnes DE, 2003, J AM GERIATR SOC, V51, P459, DOI 10.1046/j.1532-5415.2003.51153.x
   Bateman RJ, 2012, NEW ENGL J MED, V367, P795, DOI 10.1056/NEJMoa1202753
   Baumgart M, 2015, ALZHEIMERS DEMENT, V11, P718, DOI 10.1016/j.jalz.2015.05.016
   Beason-Held LL, 2013, J NEUROSCI, V33, P18008, DOI 10.1523/JNEUROSCI.1402-13.2013
   Boots EA, 2015, BRAIN IMAGING BEHAV, V9, P639, DOI 10.1007/s11682-014-9325-9
   Borg G A, 1974, Exerc Sport Sci Rev, V2, P131
   Cattaneo G, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228754
   Cattaneo G, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00321
   Cheval B, 2020, HEALTH PSYCHOL, V39, P519, DOI 10.1037/hea0000857
   Colcombe S, 2003, PSYCHOL SCI, V14, P125, DOI 10.1111/1467-9280.t01-1-01430
   Colcombe SJ, 2006, J GERONTOL A-BIOL, V61, P1166, DOI 10.1093/gerona/61.11.1166
   Crimmins EM, 2015, GERONTOLOGIST, V55, P901, DOI 10.1093/geront/gnv130
   Cuschieri S, 2019, SAUDI J ANAESTH, V13, P31, DOI 10.4103/sja.SJA_543_18
   Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021
   Erickson KI., 2009, HIPPOCAMPUS, V19, P1030, DOI [DOI 10.1002/hipo.20547, 10.1002/hipo.20547]
   Erickson KI, 2014, NEUROBIOL AGING, V35, pS20, DOI 10.1016/j.neurobiolaging.2014.03.034
   Erickson KI, 2011, P NATL ACAD SCI USA, V108, P3017, DOI 10.1073/pnas.1015950108
   Erkinjuntti T, 2000, ANN NY ACAD SCI, V903, P262, DOI 10.1111/j.1749-6632.2000.tb06376.x
   Exalto LG, 2014, ALZHEIMERS DEMENT, V10, P562, DOI 10.1016/j.jalz.2013.05.1772
   Exalto LG, 2013, LANCET DIABETES ENDO, V1, P183, DOI 10.1016/S2213-8587(13)70048-2
   Feart C, 2013, P NUTR SOC, V72, P140, DOI 10.1017/S0029665112002959
   Ferguson B., 2014, J CAN CHIROPR ASS, V58, P328
   Fischl B, 2001, IEEE T MED IMAGING, V20, P70, DOI 10.1109/42.906426
   Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396
   Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797
   Flicker L, 2010, CLIN GERIATR MED, V26, P17, DOI 10.1016/j.cger.2009.12.005
   Gardener H, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.002731
   Gomes-Osman J, 2018, NEUROL-CLIN PRACT, V8, P257, DOI 10.1212/CPJ.0000000000000460
   Gorelick PB, 2017, STROKE, V48, pE284, DOI 10.1161/STR.0000000000000148
   Gorelick PB, 2011, STROKE, V42, P2672, DOI 10.1161/STR.0b013e3182299496
   Hagler DJ, 2006, NEUROIMAGE, V33, P1093, DOI 10.1016/j.neuroimage.2006.07.036
   Hair J.F., 1998, MULTIVARIATE DATA AN, V5th ed.
   Hardman RJ, 2016, FRONT NUTR, V3, DOI 10.3389/fnut.2016.00022
   Hoppeler H, 2018, J EXP BIOL, V221, DOI 10.1242/jeb.164327
   Horder H, 2018, NEUROLOGY, V90, pE1298, DOI 10.1212/WNL.0000000000005290
   Joosten H, 2013, STROKE, V44, P1543, DOI 10.1161/STROKEAHA.111.000496
   Kathiresan S, 2012, CELL, V148, P1242, DOI 10.1016/j.cell.2012.03.001
   Kivipelto M, 2006, LANCET NEUROL, V5, P735, DOI 10.1016/S1474-4422(06)70537-3
   Kramer AF, 2018, PERSPECT PSYCHOL SCI, V13, P213, DOI 10.1177/1745691617707316
   Launer LJ, 2000, NEUROBIOL AGING, V21, P49, DOI 10.1016/S0197-4580(00)00096-8
   Launer LJ, 2005, NEUROBIOL AGING, V26, P335, DOI 10.1016/j.neurobiolaging.2004.03.016
   LEE SY, 1979, PSYCHOMETRIKA, V44, P99, DOI 10.1007/BF02293789
   Leritz EC, 2011, CURR CARDIOVASC RISK, V5, P407, DOI 10.1007/s12170-011-0189-x
   Levin BE, 2014, J INT NEUROPSYCH SOC, V20, P951, DOI 10.1017/S1355617714000861
   Lin XC, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.002014
   Lolli L, 2017, SPORTS MED, V47, P1405, DOI 10.1007/s40279-016-0655-1
   Ludyga S, 2020, NAT HUM BEHAV, V4, P603, DOI 10.1038/s41562-020-0851-8
   Marrugat J, 2003, REV ESP CARDIOL, V56, P253, DOI 10.1157/13043951
   Marrugat J, 2011, REV ESP CARDIOL, V64, P385, DOI 10.1016/j.recesp.2010.12.011
   Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442
   McCarrey AC, 2016, PSYCHOL AGING, V31, P166, DOI 10.1037/pag0000070
   Mielke MM, 2007, NEUROLOGY, V69, P1850, DOI 10.1212/01.wnl.0000279520.59792.fe
   Mosca L, 2011, CIRCULATION, V124, P2145, DOI 10.1161/CIRCULATIONAHA.110.968792
   National Association of Area Agencies on Aging NC on A and UH, 2015 US AG SURV
   Newson RS, 2006, J CLIN EXP NEUROPSYC, V28, P949, DOI 10.1080/13803390591004356
   Nissim NR, 2017, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00328
   Oberlin LE, 2016, NEUROIMAGE, V131, P91, DOI 10.1016/j.neuroimage.2015.09.053
   Ott A, 1997, STROKE, V28, P316, DOI 10.1161/01.STR.28.2.316
   Pace-Schott EF, 2011, PROG BRAIN RES, V191, P75, DOI 10.1016/B978-0-444-53752-2.00012-6
   Pascual-Leone A, 2011, BRAIN TOPOGR, V24, P302, DOI 10.1007/s10548-011-0196-8
   Paterson DH, 1999, MED SCI SPORT EXER, V31, P1813, DOI 10.1097/00005768-199912000-00018
   Pena-Casanova J, 2009, ARCH CLIN NEUROPSYCH, V24, P321, DOI 10.1093/arclin/acp038
   Pentikainen H, 2019, J ALZHEIMERS DIS, V68, P961, DOI 10.3233/JAD-180897
   Perissiou M, 2020, NUTRIENTS, V12, DOI 10.3390/nu12020482
   Pettigrew C, 2016, NEUROIMAGE-CLIN, V12, P116, DOI 10.1016/j.nicl.2016.06.010
   Qiu CX, 2015, NAT REV CARDIOL, V12, P267, DOI 10.1038/nrcardio.2014.223
   Reis JP, 2013, ANN NEUROL, V73, P170, DOI 10.1002/ana.23836
   Reitan RM., 1985, HALSTEAD REITAN NEUR
   Reitz C, 2010, ARCH NEUROL-CHICAGO, V67, P835, DOI 10.1001/archneurol.2010.136
   Rey A., 1958, EXAMEN CLINIQUE PSYC
   Vinas BR, 2013, GAC SANIT, V27, P254, DOI 10.1016/j.gaceta.2012.05.013
   Roman-Vinas B, 2010, EUR J SPORT SCI, V10, P297, DOI 10.1080/17461390903426667
   Sabia S, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j2709
   Salat DH, 2004, CEREB CORTEX, V14, P721, DOI 10.1093/cercor/bhh032
   Scullin MK, 2015, PERSPECT PSYCHOL SCI, V10, P97, DOI 10.1177/1745691614556680
   Segonne F, 2004, NEUROIMAGE, V22, P1060, DOI 10.1016/j.neuroimage.2004.03.032
   SHIMOYAMA I, 1990, ARCH NEUROL-CHICAGO, V47, P681, DOI 10.1001/archneur.1990.00530060095025
   Skoog I, 1996, LANCET, V347, P1141, DOI 10.1016/S0140-6736(96)90608-X
   Sled JG, 1998, IEEE T MED IMAGING, V17, P87, DOI 10.1109/42.668698
   Sperling RA, 2011, ALZHEIMERS DEMENT, V7, P280, DOI 10.1016/j.jalz.2011.03.003
   Spira AP, 2014, CURR OPIN PSYCHIATR, V27, P478, DOI 10.1097/YCO.0000000000000106
   Stern Y, 2020, ALZHEIMERS DEMENT, V16, P1305, DOI 10.1016/j.jalz.2018.07.219
   Tamayo F, 2012, NEUROLOGIA, V27, P319, DOI 10.1016/j.nrl.2011.12.020
   Tarraf W, 2020, J ALZHEIMERS DIS, V73, P103, DOI 10.3233/JAD-190830
   Tingley D, 2014, J STAT SOFTW, V59
   Tournoux, 1988, COPLANAR STEREOTAXIC
   Vanderburgh PM, 1996, MED SCI SPORT EXER, V28, P626, DOI 10.1097/00005768-199605000-00015
   VANDERBURGH PM, 1995, RES Q EXERCISE SPORT, V66, P80, DOI 10.1080/02701367.1995.10607658
   Wang CY, 2010, AM J EPIDEMIOL, V171, P426, DOI 10.1093/aje/kwp412
   Wasserman K., 2004, PRINCIPLES EXERCISE, V4
   Watson CE, 2012, NEUROIMAGE, V59, P2831, DOI 10.1016/j.neuroimage.2011.09.030
   Wechsler D., 2008, APA PSYCTESTS
   Wechsler D, 2012, WAIS 4 ESCALA INTELI
   Weinstein AM, 2012, BRAIN BEHAV IMMUN, V26, P811, DOI 10.1016/j.bbi.2011.11.008
   WELTMAN A, 1994, J CLIN ENDOCR METAB, V78, P543, DOI 10.1210/jc.78.3.543
   Wendell CR, 2014, J GERONTOL A-BIOL, V69, P455, DOI 10.1093/gerona/glt144
   Williams CJ, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-4192-6
   Younes L, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00074
   Yu CCW, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213674
   Zhu N, 2014, NEUROLOGY, V82, P1339, DOI 10.1212/WNL.0000000000000310
NR 107
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
EI 2047-9980
J9 J AM HEART ASSOC
JI J. Am. Heart Assoc.
PD SEP 21
PY 2021
VL 10
IS 18
AR e020688
DI 10.1161/JAHA.120.020688
PG 35
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA US6AA
UT WOS:000697508400059
PM 34514813
OA gold
DA 2021-10-30
ER

PT J
AU Gardener, H
   Leifheit, EC
   Lichtman, JH
   Wang, KF
   Wang, Y
   Gutierrez, CM
   Ciliberti-Vargas, MA
   Dong, CH
   Robichaux, M
   Romano, JG
   Sacco, RL
   Rundek, T
AF Gardener, Hannah
   Leifheit, Erica C.
   Lichtman, Judith H.
   Wang, Kefeng
   Wang, Yun
   Gutierrez, Carolina M.
   Ciliberti-Vargas, Maria A.
   Dong, Chuanhui
   Robichaux, Mary
   Romano, Jose G.
   Sacco, Ralph L.
   Rundek, Tatjana
CA FL-PR CreSD Investigators Collabor
TI Race-Ethnic Disparities in 30-Day Readmission After Stroke Among
   Medicare Beneficiaries in the Florida Stroke Registry
SO JOURNAL OF STROKE & CEREBROVASCULAR DISEASES
LA English
DT Article
DE Race-ethnicity; disparities; rehospitalization; stroke
ID ISCHEMIC-STROKE; CAROTID-ENDARTERECTOMY; WHITE; BLACK; CARE
AB Objective: To examine racial/ethnic disparities in 30-day all-cause readmission after stroke. Methods: Thirty-day all-cause readmission was compared by race/ethnicity among Medicare fee-for-service beneficiaries discharged for ischemic stroke from hospitals in the Florida Stroke Registry from 2010 to 2013. We fit a Cox proportional hazards model that censored for death and adjusted for age, sex, length of stay, discharge home, and comorbidities to assess racial/ethnic differences in readmission. Results: Among 16,952 stroke patients (54% women, 75% white, 8% black, and 15% Hispanic), 30-day all-cause readmission was 15% (17.2% for blacks, 16.7% for Hispanics, 14.4% for whites, and 14.7% for others; P = .003). There was a median of 11 days between discharge and first readmission. In adjusted analyses, there was no significant difference in readmission for blacks (hazard ratio 1.15, 95% confidence interval 0.99-1.33), Hispanics (1.00, .90-1.13), and those of other race/ethnicity (.91, .71-1.16) compared with whites. Nearly 1 in 4 readmissions were attributable to acute cerebrovascular events: 16.6% ischemic stroke or transient ischemic attack, 1.5% hemorrhagic stroke, and 5.2% cerebral artery interventions. Interventions were more common among whites and those of other race than blacks and Hispanics (P = .029). Readmission due to pneumonia or urinary tract infection was 8.2%. Conclusions: Readmissions attributable to acute cerebrovascular events were common and generally occurred within 2 weeks of hospital discharge. Racial/ethnic disparities were present in readmissions for arterial interventions. Our results underscore the importance of postdischarge transitional care and the need for better secondary prevention strategies after ischemic stroke, particularly among minority populations.
C1 [Gardener, Hannah; Wang, Kefeng; Gutierrez, Carolina M.; Ciliberti-Vargas, Maria A.; Dong, Chuanhui; Robichaux, Mary; Romano, Jose G.; Sacco, Ralph L.; Rundek, Tatjana] Univ Miami, Dept Neurol, Miller Sch Med, 1120 NW 14th St, Miami, FL 33136 USA.
   [Leifheit, Erica C.; Lichtman, Judith H.; Wang, Yun] Yale Sch Publ Hlth, Dept Epidemiol, New Haven, CT USA.
RP Gardener, H (corresponding author), Univ Miami, Dept Neurol, Miller Sch Med, 1120 NW 14th St, Miami, FL 33136 USA.
EM hgardener@med.miami.edu
OI Gutierrez, Carolina/0000-0002-9879-3912
FU National Institute of Neurological Disorders and StrokeUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Neurological Disorders & Stroke (NINDS)
   [U54-NS081763]; National Institute on Minority Health and Health
   Disparities grant [1R01MD012467]; NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [UL1TR002736] Funding Source:
   NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND
   STROKEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Neurological
   Disorders & Stroke (NINDS) [U54NS081763] Funding Source: NIH RePORTER;
   National Institute on Minority Health and Health DisparitiesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute on Minority Health & Health
   Disparities (NIMHD) [R01MD012467] Funding Source: NIH RePORTER
FX National Institute of Neurological Disorders and Stroke grant
   U54-NS081763 and National Institute on Minority Health and Health
   Disparities grant 1R01MD012467.
CR Cruz-Flores S, 2011, STROKE, V42, P2091, DOI 10.1161/STR.0b013e3182213e24
   Fonarow GC, 2012, JAMA-J AM MED ASSOC, V308, P257, DOI 10.1001/jama.2012.7870
   Lichtman JH, 2017, JAMA-J AM MED ASSOC, V318, P1035, DOI 10.1001/jama.2017.12882
   Lichtman JH, 2013, STROKE, V44, P3429, DOI 10.1161/STROKEAHA.113.003165
   Lichtman JH, 2010, STROKE, V41, P2525, DOI 10.1161/STROKEAHA.110.599159
   Martin KD, 2012, J STROKE CEREBROVASC, V21, P600, DOI 10.1016/j.jstrokecerebrovasdis.2011.02.002
   Oluwole SA, 2017, STROKE, V48, P2192, DOI 10.1161/STROKEAHA.116.016183
   Qian F, 2013, CIRC-CARDIOVASC QUAL, V6, P284, DOI 10.1161/CIRCOUTCOMES.113.000211
   Sacco RL, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.116.004073
   Sacco RL, 1998, AM J EPIDEMIOL, V147, P259, DOI 10.1093/oxfordjournals.aje.a009445
   Skolarus LE, 2012, NEUROLOGY, V78, P1590, DOI 10.1212/WNL.0b013e3182563bf5
   Thompson MP, 2017, CIRC-CARDIOVASC QUAL, V10, DOI 10.1161/CIRCOUTCOMES.117.003604
   White H, 2005, CIRCULATION, V111, P1327, DOI 10.1161/01.CIR.0000157736.19739.D0
   Zhong WB, 2016, NEUROL SCI, V37, P1195, DOI 10.1007/s10072-016-2570-5
NR 14
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1052-3057
EI 1532-8511
J9 J STROKE CEREBROVASC
JI J. Stroke Cerebrovasc. Dis.
PD DEC
PY 2019
VL 28
IS 12
AR 104399
DI 10.1016/j.jstrokecerebrovasdis.2019.104399
PG 5
WC Neurosciences; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA JQ3SL
UT WOS:000498868800022
PM 31611168
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Ha, CS
   Michalek, JE
   Elledge, R
   Kelly, KR
   Ganapathy, S
   Su, H
   Jenkins, CA
   Argiris, A
   Swords, R
   Eng, TY
   Karnad, A
   Crownover, RL
   Swanson, GP
   Goros, M
   Pollock, BH
   Yuan, ZM
AF Ha, Chul S.
   Michalek, Joel E.
   Elledge, Richard
   Kelly, Kevin R.
   Ganapathy, Suthakar
   Su, Hang
   Jenkins, Carol A.
   Argiris, Athanassios
   Swords, Ronan
   Eng, Tony Y.
   Karnad, Anand
   Crownover, Richard L.
   Swanson, Gregory P.
   Goros, Martin
   Pollock, Brad H.
   Yuan, Zhi-Min
TI p53-Based strategy to reduce hematological toxicity of chemotherapy: A
   proof of principle study
SO MOLECULAR ONCOLOGY
LA English
DT Article
DE p53; Arsenic; Myelosuppression; Hematological toxicity; Chemoprotection
ID CELL LUNG-CANCER; OPEN-LABEL; IN-VITRO; P53; THERAPY; CYCLOPHOSPHAMIDE;
   DOXORUBICIN; PROTECTION; DOCETAXEL; ETOPOSIDE
AB p53 activation is a primary mechanism underlying pathological responses to DNA damaging agents such as chemotherapy and radiotherapy. Our recent animal studies showed that low dose arsenic (LDA)-induced transient p53 inhibition selectively protected normal tissues from chemotherapy -induced toxicity.
   Study objectives were to: 1) define the lowest safe dose of arsenic trioxide that transiently blocks p53 activation in patients and 2) assess the potential of LDA to decrease hematological toxicity from chemotherapy.
   Patients scheduled to receive minimum 4 cycles of myelosuppressive chemotherapy were eligible. For objective 1, dose escalation of LDA started at 0.005 mg/kg/day for 3 days. This dose satisfied objective 1 and was administered before chemotherapy cycles 2, 4, and 6 for objective 2. p53 level in peripheral lymphocytes was measured on day 1 of each cycle by ELISA assay. Chemotherapy cycles 1, 3, and 5 served as the baseline for the subsequent cycles of 2, 4, and 6 respectively. If p53 level for the subsequent cycle was lower (or higher) than the baseline cycle, p53 was defined as "suppressed" (or "activated") for the pair of cycles. Repeated measures linear models of CBC in terms of day, cycle, p53 activity and interaction terms were used.
   Twenty-six patients treated with 3 week cycle regimens form the base of analyses. The mean white blood cell, hemoglobin and absolute neutrophil counts were significantly higher in the "suppressed" relative to the "activated" group.
   These data support the proof of principle that suppression of p53 could lead to protection of bone marrow in patients receiving chemotherapy. (C) 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
C1 [Ha, Chul S.; Ganapathy, Suthakar; Su, Hang; Jenkins, Carol A.; Eng, Tony Y.; Crownover, Richard L.; Swanson, Gregory P.; Yuan, Zhi-Min] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiat Oncol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
   [Michalek, Joel E.; Goros, Martin; Pollock, Brad H.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
   [Elledge, Richard; Kelly, Kevin R.; Argiris, Athanassios; Swords, Ronan; Karnad, Anand] Univ Texas Hlth Sci Ctr San Antonio, Div Hematol Oncol, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
   [Kelly, Kevin R.] Univ So Calif, Jane Anne Nohl Div Hematol, Keck Sch Med, 1975 Zonal Ave, Los Angeles, CA 90030 USA.
   [Ganapathy, Suthakar] Northeastern Univ, Ctr Drug Discovery, 360 Huntington Ave, Boston, MA 02115 USA.
   [Argiris, Athanassios] Hygeia Hosp, 5 Erythrou Stavrou,6th Floor,Off 6-12, Athens 15123, Greece.
   [Swords, Ronan] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Leukemia Serv,Div Hematol Oncol, 1600 NW 10th Ave, Miami, FL 33136 USA.
   [Pollock, Brad H.] Univ Calif Davis, Dept Publ Hlth Sci, Sch Med, One Shields Ave, Davis, CA 95616 USA.
   [Yuan, Zhi-Min] Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, 677 Huntington Ave, Boston, MA 02115 USA.
RP Ha, CS (corresponding author), Dept Radiat Oncol, MSC 7889,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM HAC@UTHSCSA.EDU
OI Swanson, Gregory/0000-0002-7959-1493; Eng, Tony/0000-0002-4352-845X
FU ASPECT Oncology;  [RO1 CA183074]; NATIONAL CANCER INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI) [R01CA183074, R01CA167814]
   Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [KL2TR000461] Funding Source:
   NIH RePORTER
FX This clinical trial was supported by ASPECT Oncology and RO1 CA183074.
   Parts of the data in the manuscript were presented at the annual meeting
   of the American Society of Hematology and San Antonio Breast Cancer
   Symposium in December 2014.
CR Andrew AS, 2003, ENVIRON HEALTH PERSP, V111, P825, DOI 10.1289/ehp.111-1241504
   Baskar R, 2012, INT J MED SCI, V9, P193, DOI 10.7150/ijms.3635
   Christophorou MA, 2006, NATURE, V443, P214, DOI 10.1038/nature05077
   Christophorou MA, 2005, NAT GENET, V37, P718, DOI 10.1038/ng1572
   Colognato R, 2008, MUTAGENESIS, V23, P377, DOI 10.1093/mutage/gen024
   Eisbruch A, 2011, J CLIN ONCOL, V29, P119, DOI 10.1200/JCO.2010.31.5051
   Ganapathy S, 2014, ONCOGENE, V33, P1359, DOI 10.1038/onc.2013.81
   Ganapathy S, 2014, J BIOL CHEM, V289, P5340, DOI 10.1074/jbc.M113.531020
   Gudkov AV, 2007, HUM MOL GENET, V16, pR67, DOI 10.1093/hmg/ddm052
   Gudkov AV, 2005, BIOCHEM BIOPH RES CO, V331, P726, DOI 10.1016/j.bbrc.2005.03.153
   Hensley ML, 2009, J CLIN ONCOL, V27, P127, DOI 10.1200/JCO.2008.17.2627
   Jones S, 2009, J CLIN ONCOL, V27, P1177, DOI 10.1200/JCO.2008.18.4028
   Junttila MR, 2009, NAT REV CANCER, V9, P821, DOI 10.1038/nrc2728
   KLASTERSKY J, 1990, J CLIN ONCOL, V8, P1556, DOI 10.1200/JCO.1990.8.9.1556
   Patel JD, 2009, CLIN LUNG CANCER, V10, P252, DOI 10.3816/CLC.2009.n.035
   Richardson PG, 2010, BLOOD, V116, P679, DOI 10.1182/blood-2010-02-268862
   Rummel MJ, 2013, LANCET, V381, P1203, DOI 10.1016/S0140-6736(12)61763-2
   Salazar AM, 2004, MOL CELL BIOCHEM, V255, P25, DOI 10.1023/B:MCBI.0000007258.33942.f8
   Snow Elizabeth T, 2005, Toxicol Appl Pharmacol, V207, P557, DOI 10.1016/j.taap.2005.01.048
   Su H., 2015, INT J RAD ONCOL BIOL
   Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720
   Wexler LH, 1996, CANCER, V78, P901
   Zhou BBS, 2004, NAT REV CANCER, V4, P216, DOI 10.1038/nrc1296
NR 23
TC 6
Z9 7
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1574-7891
EI 1878-0261
J9 MOL ONCOL
JI Mol. Oncol.
PD JAN
PY 2016
VL 10
IS 1
BP 148
EP 156
DI 10.1016/j.molonc.2015.09.004
PG 9
WC Oncology
SC Oncology
GA DC9SC
UT WOS:000369560300011
PM 26440706
OA hybrid, Green Accepted, Green Published, Green Submitted
DA 2021-10-30
ER

PT J
AU Berman, DM
   Molano, D
   Fotino, C
   Ulissi, U
   Gimeno, J
   Mendez, AJ
   Kenyon, NM
   Kenyon, NS
   Andrews, DM
   Ricordi, C
   Pileggi, A
AF Berman, Dora M.
   Molano, Damaris
   Fotino, Carmen
   Ulissi, Ulisse
   Gimeno, Jennifer
   Mendez, Armando J.
   Kenyon, Norman M.
   Kenyon, Norma S.
   Andrews, David M.
   Ricordi, Camillo
   Pileggi, Antonello
TI Bioengineering the Endocrine Pancreas: Intraomental Islet
   Transplantation Within a Biologic Resorbable Scaffold
SO DIABETES
LA English
DT Article
ID MEDIATED INFLAMMATORY REACTION; OMENTAL POUCH SITE; LONG-TERM; TISSUE
   FACTOR; DIABETES-MELLITUS; HEPATIC STEATOSIS; COLD PRESERVATION;
   GRAFT-SURVIVAL; BLOOD; CELLS
AB Transplantation of pancreatic islets is a therapeutic option to preserve or restore -cell function. Our study was aimed at developing a clinically applicable protocol for extrahepatic transplantation of pancreatic islets. The potency of islets implanted onto the omentum, using an in situ-generated adherent, resorbable plasma-thrombin biologic scaffold, was evaluated in diabetic rat and nonhuman primate (NHP) models. Intraomental islet engraftment in the biologic scaffold was confirmed by achievement of improved metabolic function and preservation of islet cytoarchitecture, with reconstitution of rich intrainsular vascular networks in both species. Long-term nonfasting normoglycemia and adequate glucose clearance (tolerance tests) were achieved in both intrahepatic and intraomental sites in rats. Intraomental graft recipients displayed lower levels of serum biomarkers of islet distress (e.g., acute serum insulin) and inflammation (e.g., leptin and 2-macroglobulin). Importantly, low-purity (30:70% endocrine:exocrine) syngeneic rat islet preparations displayed function equivalent to that of pure (>95% endocrine) preparations after intraomental biologic scaffold implantation. Moreover, the biologic scaffold sustained allogeneic islet engraftment in immunosuppressed recipients. Collectively, our feasibility/efficacy data, along with the simplicity of the procedure and the safety of the biologic scaffold components, represented sufficient preclinical testing to proceed to a pilot phase I/II clinical trial.
C1 [Berman, Dora M.; Molano, Damaris; Fotino, Carmen; Ulissi, Ulisse; Gimeno, Jennifer; Mendez, Armando J.; Kenyon, Norman M.; Kenyon, Norma S.; Ricordi, Camillo; Pileggi, Antonello] Univ Miami, Diabet Res Inst, Cell Transplant Ctr, Miami, FL USA.
   [Berman, Dora M.; Kenyon, Norman M.; Kenyon, Norma S.; Ricordi, Camillo; Pileggi, Antonello] Univ Miami, DeWitt Daughtry Family Dept Surg, Miami, FL USA.
   [Mendez, Armando J.; Ricordi, Camillo] Univ Miami, Dept Med, Miami, FL USA.
   [Kenyon, Norma S.; Ricordi, Camillo; Pileggi, Antonello] Univ Miami, Dept Microbiol & Immunol, Miami, FL USA.
   [Kenyon, Norma S.; Ricordi, Camillo; Pileggi, Antonello] Univ Miami, Dept Biomed Engn, Miami, FL USA.
   [Andrews, David M.] Univ Miami, Dept Pathol, Miami, FL USA.
RP Berman, DM; Ricordi, C; Pileggi, A (corresponding author), Univ Miami, Diabet Res Inst, Cell Transplant Ctr, Miami, FL USA.; Berman, DM; Ricordi, C; Pileggi, A (corresponding author), Univ Miami, DeWitt Daughtry Family Dept Surg, Miami, FL USA.; Ricordi, C (corresponding author), Univ Miami, Dept Med, Miami, FL USA.; Ricordi, C; Pileggi, A (corresponding author), Univ Miami, Dept Microbiol & Immunol, Miami, FL USA.; Ricordi, C; Pileggi, A (corresponding author), Univ Miami, Dept Biomed Engn, Miami, FL USA.
EM dberman2@med.miami.edu; ricordi@miami.edu; antonello.pileggi@nih.gov
RI Pileggi, Antonello/A-2394-2008; RICORDI, CAMILLO/AAA-4740-2019
OI Pileggi, Antonello/0000-0001-7819-2813; Fotino,
   Carmen/0000-0002-2645-6546; Ricordi, Camillo/0000-0001-8092-7153;
   Berman-Weinberg, Dora/0000-0001-7817-9387
FU Diabetes Research Institute Foundation; Leona M. and Harry B. Helmsley
   Charitable Trust; JDRF InternationalJuvenile Diabetes Research
   Foundation [17-2012-361]; UM Clinical and Translational Science
   Institute; National Center for Advancing Translational SciencesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Advancing Translational
   Sciences (NCATS); National Institute on Minority Health and Health
   DisparitiesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Minority
   Health & Health Disparities (NIMHD) [1UL1TR000460]; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000460]
   Funding Source: NIH RePORTER
FX This study was partially supported by the Diabetes Research Institute
   Foundation (www.diabetesresearch.org), by the Leona M. and Harry B.
   Helmsley Charitable Trust, and by JDRF International (17-2012-361). The
   project was part of A.P.'s Master of Science in Clinical and
   Translational Investigation training, a program supported by the UM
   Clinical and Translational Science Institute, from the National Center
   for Advancing Translational Sciences and the National Institute on
   Minority Health and Health Disparities (1UL1TR000460).
CR ACKERMANN PC, 1991, ACTA ANAT, V140, P146
   ALEJANDRO R, 1986, J CLIN INVEST, V78, P1339, DOI 10.1172/JCI112720
   AO Z, 1992, TRANSPLANT P, V24, P2789
   AO ZL, 1993, TRANSPLANTATION, V56, P524, DOI 10.1097/00007890-199309000-00007
   Badell IR, 2012, AM J TRANSPLANT, V12, P1918, DOI 10.1111/j.1600-6143.2012.04029.x
   Bartholomeus K, 2013, TRANSPLANTATION, V96, P1026, DOI 10.1097/TP.0b013e3182a6ee41
   Bennet W, 2000, UPSALA J MED SCI, V105, P125, DOI 10.1517/03009734000000059
   Berman DM, 2009, AM J TRANSPLANT, V9, P91, DOI 10.1111/j.1600-6143.2008.02489.x
   Berman DM, 2007, TRANSPLANTATION, V84, P308, DOI 10.1097/01.tp.0000275401.80187.1e
   Berney T, 2006, AM J TRANSPLANT, V6, P1704, DOI 10.1111/j.1600-6143.2006.01373.x
   Bhargava R, 2004, DIABETES, V53, P1311, DOI 10.2337/diabetes.53.5.1311
   Brady AC, 2010, AM J TRANSPLANT, V10, P76
   Chaffanjon PCJ, 2005, SURG RADIOL ANAT, V27, P287, DOI 10.1007/s00276-005-0329-4
   Chinnakotla S, 2014, ANN SURG, V260, P56, DOI 10.1097/SLA.0000000000000569
   Cray C, 2009, COMPARATIVE MED, V59, P517
   Eckhard M, 2004, TRANSPL P, V36, P1111, DOI 10.1016/j.transproceed.2004.04.047
   Faradji RN, 2005, TRANSPL P, V37, P3433, DOI 10.1016/j.transproceed.2005.09.090
   Fotino N, 2015, PHARMACOL RES, V98, P76, DOI 10.1016/j.phrs.2015.02.010
   Guan J, 1995, TRANSPLANT P, V27, P3236
   Guan JY, 1998, DIABETES, V47, P1020, DOI 10.2337/diabetes.47.7.1020
   Ham SW, 2010, J BLOOD MED, V1, P135, DOI 10.2147/JBM.S6622
   Hefty TR, 2010, J SURG RES, V161, P134, DOI 10.1016/j.jss.2008.11.842
   Hogan AR, 2012, CELL TRANSPLANT, V21, P1349, DOI 10.3727/096368911X623853
   Ichii H, 2005, AM J TRANSPLANT, V5, P21, DOI 10.1111/j.1600-6143.2005.00698.x
   Ichii H, 2008, LAB INVEST, V88, P1167, DOI 10.1038/labinvest.2008.87
   Jackson S, 2013, ISLETS, V5, P16, DOI 10.4161/isl.24058
   Jacobs-Tulleneers-Thevissen D, 2010, DIABETOLOGIA, V53, P1690, DOI 10.1007/s00125-010-1721-0
   Johansson H, 2005, DIABETES, V54, P1755, DOI 10.2337/diabetes.54.6.1755
   Kakabadze Z, 2013, AM J TRANSPLANT, V13, P2550, DOI 10.1111/ajt.12412
   Kim HI, 2010, J KOREAN MED SCI, V25, P203, DOI 10.3346/jkms.2010.25.2.203
   Leitao CB, 2014, CELL TRANSPLANT, V23, P1221, DOI 10.3727/096368913X668663
   Maffi P, 2005, CELL TRANSPLANT, V14, P727, DOI 10.3727/000000005783982567
   Markmann JF, 2003, DIABETES, V52, P1591, DOI 10.2337/diabetes.52.7.1591
   Moberg L, 2002, LANCET, V360, P2039, DOI 10.1016/S0140-6736(02)12020-4
   Ozmen L, 2002, DIABETES, V51, P1779, DOI 10.2337/diabetes.51.6.1779
   Pedraza E, 2013, CELL TRANSPLANT, V22, P1123, DOI 10.3727/096368912X657440
   Perez VL, 2011, DIABETOLOGIA, V54, P1121, DOI 10.1007/s00125-011-2091-y
   Philosophe B, 2001, ANN SURG, V234, P689, DOI 10.1097/00000658-200111000-00016
   Piemonti L., 2013, CELLR4, VR4, P8
   Pileggi Antonello, 2004, Clin Transpl, P177
   Pileggi A, 2006, TRANSPLANTATION, V81, P1318, DOI 10.1097/01.tp.0000203858.41105.88
   Pileggi A, 2013, DIABETES, V62, P3333, DOI 10.2337/db13-1039
   Pileggi A, 2009, TRANSPLANTATION, V87, P1442, DOI 10.1097/TP.0b013e3181a36b1e
   Platell C, 2000, WORLD J GASTROENTERO, V6, P169
   Posselt AM, 2010, TRANSPLANTATION, V90, P1595, DOI 10.1097/TP.0b013e3181fe1377
   Procaccini C, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00143
   RICORDI C, 1988, DIABETES, V37, P413, DOI 10.2337/diabetes.37.4.413
   Ricordi C, 2003, DIABETES, V52, P1595, DOI 10.2337/diabetes.52.7.1595
   Ricordi C, 1995, TRANSPLANT P, V27, P3382
   Safley SA, 2014, XENOTRANSPLANTATION, V21, P127, DOI [10.1111/xen.12086, 10.1111/xen.12077]
   SIMEONOVIC CJ, 1986, AUST J EXP BIOL MED, V64, P37, DOI 10.1038/icb.1986.4
   Street CN, 2004, DIABETES, V53, P3107, DOI 10.2337/diabetes.53.12.3107
   Vergani A, 2010, DIABETES, V59, P2253, DOI 10.2337/db09-1264
   YASUNAMI Y, 1983, TRANSPLANTATION, V36, P181, DOI 10.1097/00007890-198308000-00014
   2014, CELLR4, V2, pe891
NR 55
TC 72
Z9 76
U1 1
U2 10
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
EI 1939-327X
J9 DIABETES
JI Diabetes
PD MAY
PY 2016
VL 65
IS 5
BP 1350
EP 1361
DI 10.2337/db15-1525
PG 12
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DK6JA
UT WOS:000375028000024
PM 26916086
OA Green Published, Bronze
DA 2021-10-30
ER

PT J
AU Hsich, EM
   Blackstone, EH
   Thuita, L
   McNamara, DM
   Rogers, JG
   Ishwaran, H
   Schold, JD
AF Hsich, Eileen M.
   Blackstone, Eugene H.
   Thuita, Lucy
   McNamara, Dennis M.
   Rogers, Joseph G.
   Ishwaran, Hemant
   Schold, Jesse D.
TI Sex Differences in Mortality Based on United Network for Organ Sharing
   Status While Awaiting Heart Transplantation
SO CIRCULATION-HEART FAILURE
LA English
DT Article
DE dilated cardiomyopathy; heart failure; heart-assist devices; sex;
   survival; transplantation
ID RISK STRATIFICATION; AMBULATORY PATIENTS; PREDICT SURVIVAL; ALBUMIN
   LEVELS; SERUM-ALBUMIN; FAILURE; WOMEN; OUTCOMES; SUPPORT; MEN
AB Background-There are sex differences in mortality while awaiting heart transplantation, and the reason remains unclear.
   Methods and Results-We included all adults in the Scientific Registry of Transplant Recipients placed on the heart transplant active waitlist from 2004 to 2015. The primary end point was all-cause mortality. Multivariable Cox proportional hazards models were performed to evaluate survival by United Network for Organ Sharing (UNOS) status at the time of listing. Random survival forest was used to identify sex interactions for the competing risk of death and transplantation. There were 33 069 patients (25% women) awaiting heart transplantation. This cohort included 7681 UNOS status 1A (26% women), 13 027 UNOS status 1B (25% women), and 12 361 UNOS status 2 (26% women). During a median follow-up of 4.3 months, 1351 women and 4052 men died. After adjusting for >20 risk factors, female sex was associated with a significant risk of death among UNOS status 1A (adjusted hazard ratio, 1.14; 95% confidence interval, 1.01-1.29) and UNOS status 1B (adjusted hazard ratio, 1.17; 95% confidence interval, 1.05-1.30). In contrast, female sex was significantly protective for time to death among UNOS status 2 (adjusted hazard ratio, 0.85; 95% confidence interval, 0.76-0.95). Sex differences in probability of transplantation were present for every UNOS status, and >20 sex interactions were identified for mortality and transplantation.
   Conclusions-When stratified by initial UNOS status, women had a higher mortality than men as UNOS status 1 and a lower mortality as UNOS status 2. With >20 sex interactions for mortality and transplantation, further evaluation is warranted to form a more equitable allocation system.
C1 [Hsich, Eileen M.; Blackstone, Eugene H.] Cleveland Clin, Inst Heart & Vasc, Cleveland, OH USA.
   [Hsich, Eileen M.; Blackstone, Eugene H.] Case Western Reserve Univ, Sch Med, Cleveland Clin, Lerner Coll Med, Cleveland, OH 44106 USA.
   [Hsich, Eileen M.; Thuita, Lucy; Schold, Jesse D.] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH USA.
   [McNamara, Dennis M.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA.
   [Rogers, Joseph G.] Duke Univ, Div Cardiol, Durham, NC USA.
   [Ishwaran, Hemant] Univ Miami, Dept Publ Hlth Sci, Div Biostat, Coral Gables, FL 33124 USA.
RP Hsich, EM (corresponding author), Cleveland Clin, Inst Heart & Vasc, Kaufman Ctr Heart Failure, J3-4,9500 Euclid Ave, Cleveland, OH 44195 USA.
EM Hsiche@ccf.org
RI Schold, Jesse/AAC-5844-2019
FU National Heart, Lung and Blood Institute of the National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [R56HL125420-01A1]; NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [UL1TR000460] Funding Source:
   NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [R56HL125420]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [R01GM125072] Funding Source: NIH RePORTER
FX This study was supported by the National Heart, Lung and Blood Institute
   of the National Institutes of Health under Award Number
   R56HL125420-01A1.
CR Aaronson KD, 1997, CIRCULATION, V95, P2660, DOI 10.1161/01.CIR.95.12.2660
   Biegus J, 2016, EUR J HEART FAIL, V18, P830, DOI 10.1002/ejhf.532
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Cowger J, 2013, J AM COLL CARDIOL, V61, P313, DOI 10.1016/j.jacc.2012.09.055
   Fonarow GC, 2005, JAMA-J AM MED ASSOC, V293, P572, DOI 10.1001/jama.293.5.572
   Horwich TB, 2008, AM HEART J, V155, P883, DOI 10.1016/j.ahj.2007.11.043
   Hsich E, 2007, AM J CARDIOL, V100, P291, DOI 10.1016/j.amjcard.2007.02.096
   Hsich EM, 2014, JACC-HEART FAIL, V2, P347, DOI 10.1016/j.jchf.2014.03.008
   Hsich EM, 2012, CIRC-HEART FAIL, V5, P234, DOI 10.1161/CIRCHEARTFAILURE.111.963272
   Ishwaran H, RANDOMFORESTSRC RAND
   Ishwaran H, 2008, ANN APPL STAT, V2, P841, DOI 10.1214/08-AOAS169
   Kato TS, 2013, AM J CARDIOL, V112, P1484, DOI 10.1016/j.amjcard.2013.06.023
   Kato TS, 2013, J HEART LUNG TRANSPL, V32, P333, DOI 10.1016/j.healun.2012.11.026
   Kempny A, 2015, HEART, V101, P699, DOI 10.1136/heartjnl-2014-306970
   Khush KK, 2012, J HEART LUNG TRANSPL, V31, P459, DOI 10.1016/j.healun.2012.02.005
   Leppke S, 2013, TRANSPLANT REV-ORLAN, V27, P50, DOI 10.1016/j.trre.2013.01.002
   Levy WC, 2006, CIRCULATION, V113, P1424, DOI 10.1161/CIRCULATIONAHA.105.584102
   Morris AA, 2015, J CARD FAIL, V21, P555, DOI 10.1016/j.cardfail.2015.03.009
   Politis D.N., 1999, SUBSAMPLING
   Rahimi K, 2014, JACC-HEART FAIL, V2, P440, DOI 10.1016/j.jchf.2014.04.008
   Rodriguez F, 2013, J CARD FAIL, V19, P542, DOI 10.1016/j.cardfail.2013.05.016
   Stekhoven DJ, 2012, BIOINFORMATICS, V28, P112, DOI 10.1093/bioinformatics/btr597
   Uthamalingam S, 2010, AM HEART J, V160, P1149, DOI 10.1016/j.ahj.2010.09.004
   Weidner G, 2011, PROG TRANSPLANT, V21, P106, DOI 10.7182/prtr.21.2.j779w1q6k61k0jk4
NR 24
TC 23
Z9 23
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1941-3289
EI 1941-3297
J9 CIRC-HEART FAIL
JI Circ.-Heart Fail.
PD JUN
PY 2017
VL 10
IS 6
AR e003635
DI 10.1161/CIRCHEARTFAILURE.116.003635
PG 17
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA EY0MK
UT WOS:000403652100002
PM 28611123
OA Green Accepted, Bronze
DA 2021-10-30
ER

PT J
AU Schwartz, SJ
   Unger, JB
   Baezconde-Garbanati, L
   Zamboanga, BL
   Lorenzo-Blanco, EI
   Rosiers, SED
   Romero, AJ
   Cano, MA
   Gonzales-Backen, MA
   Cordova, D
   Pina-Watson, BM
   Huang, S
   Villamar, JA
   Soto, DW
   Pattarroyo, M
   Szapocznik, J
AF Schwartz, Seth J.
   Unger, Jennifer B.
   Baezconde-Garbanati, Lourdes
   Zamboanga, Byron L.
   Lorenzo-Blanco, Elma I.
   Rosiers, Sabrina E. Des
   Romero, Andrea J.
   Cano, Miguel Angel
   Gonzales-Backen, Melinda A.
   Cordova, David
   Pina-Watson, Brandy M.
   Huang, Shi
   Villamar, Juan A.
   Soto, Daniel W.
   Pattarroyo, Monica
   Szapocznik, Jose
TI Trajectories of Cultural Stressors and Effects on Mental Health and
   Substance Use Among Hispanic Immigrant Adolescents
SO JOURNAL OF ADOLESCENT HEALTH
LA English
DT Article
DE Cultural stress; Discrimination; Context of reception; Hispanic;
   Adolescent; Immigrant; Positive youth development; Depressive symptoms;
   Conduct problems; Substance use
ID SEXUAL-BEHAVIOR; UNITED-STATES; DISCRIMINATION; ACCULTURATION; YOUTH;
   MINORITY; PARENT; SELF
AB Purpose: We sought to determine the extent to which initial levels and over-time trajectories of cultural stressors (discrimination, negative context of reception, and bicultural stress) predicted well-being, internalizing symptoms, conduct problems, and health risk behaviors among recently immigrated Hispanic adolescents. Addressing this research objective involved creating a latent factor for cultural stressors, establishing invariance for this factor over time, estimating a growth curve for this factor over time, and examining the effects of initial levels (intercepts) and trajectories (slopes) of cultural stressors on adolescent outcomes.
   Methods: A sample of 302 recently immigrated Hispanic adolescents in Miami (median of 1 year in the United States at baseline) and Los Angeles (median of 3 years in the United States at baseline) was recruited from public schools and assessed six times over a 3-year period.
   Results: Perceived discrimination, context of reception, and bicultural stress loaded onto a latent factor at each of the first five timepoints. A growth curve conducted on this factor over the first five timepoints significantly predicted lower self-esteemand optimism, more depressive symptoms, greater aggressive behavior and rule breaking, and increased likelihood of drunkenness and marijuana use.
   Conclusions: The present results may be important in designing interventions for Hispanic immigrant children and adolescents, including those within the present wave of unaccompanied child migrants. Results indicate targeting cultural stressors in interventions may have potential to improve well-being and decrease externalizing behaviors and substance use within this population. (C) 2015 Society for Adolescent Health and Medicine. All rights reserved.
C1 [Schwartz, Seth J.; Huang, Shi; Szapocznik, Jose] Univ Miami, Leonard M Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA.
   [Unger, Jennifer B.; Baezconde-Garbanati, Lourdes; Soto, Daniel W.; Pattarroyo, Monica] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA.
   [Zamboanga, Byron L.] Smith Coll, Dept Psychol, Northampton, MA 01063 USA.
   [Lorenzo-Blanco, Elma I.] Univ S Carolina, Dept Psychol, Columbia, SC 29208 USA.
   [Rosiers, Sabrina E. Des] Barry Univ, Dept Psychol, Miami Shores, FL USA.
   [Romero, Andrea J.] Univ Arizona, Dept Family Studies & Human Dev, Tucson, AZ USA.
   [Cano, Miguel Angel] Florida Int Univ, Dept Epidemiol, Miami, FL 33199 USA.
   [Gonzales-Backen, Melinda A.] Florida State Univ, Dept Family & Child Sci, Tallahassee, FL 32306 USA.
   [Cordova, David] Univ Michigan, Dept Social Work, Ann Arbor, MI 48109 USA.
   [Pina-Watson, Brandy M.] Texas Tech Univ, Dept Psychol Sci, Lubbock, TX 79409 USA.
   [Villamar, Juan A.] Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA.
RP Schwartz, SJ (corresponding author), Univ Miami, 1120 NW 14th St,10th Floor, Miami, FL 33136 USA.
EM SSchwartz@med.miami.edu
RI Cano, Miguel Angel/V-8215-2017
OI Cano, Miguel Angel/0000-0002-9847-1358; Unger,
   Jennifer/0000-0001-9064-6603
FU National Institute on Drug AbuseUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute on Drug Abuse (NIDA)European Commission [DA026594]; National
   Institute on Alcohol Abuse and AlcoholismUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Alcohol Abuse & Alcoholism (NIAAA) [AA021888];
   National Center for Advancing Translational SciencesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [1UL1TR000460]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1TR000460] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Drug Abuse (NIDA)European Commission [R01DA025694]
   Funding Source: NIH RePORTER
FX Preparation of this article was supported by grants DA026594 from the
   National Institute on Drug Abuse and AA021888 from the National
   Institute on Alcohol Abuse and Alcoholism to S.J.S., and by National
   Center for Advancing Translational Sciences, grant 1UL1TR000460 to J.S.
CR Achenbach TM, 2002, J EMOT BEHAV DISORD, V10, P194, DOI 10.1177/10634266020100040101
   Buchanan Patrick J, 2011, SUICIDE SUPERPOWER W
   Carlo G, 2002, J YOUTH ADOLESCENCE, V31, P31, DOI 10.1023/A:1014033032440
   Cervantes R, 2011, J PRIM PREV, V32, P225, DOI 10.1007/s10935-011-0251-y
   Coenders M, 2008, J SOC ISSUES, V64, P269, DOI 10.1111/j.1540-4560.2008.00561.x
   Dimitrov DM, 2010, MEAS EVAL COUNS DEV, V43, P121, DOI 10.1177/0748175610373459
   Edwards LM, 2007, HISPANIC J BEHAV SCI, V29, P225, DOI 10.1177/0739986307299692
   Forster M, 2014, J INTERPERS VIOLENCE, DOI 10.1177/0886260514549052
   Gibson CL, CRIME VICTIMIZATION
   Hammack PL, 2006, J ADOLESCENT RES, V21, P323, DOI 10.1177/0743558406289745
   Huntington S.P., 2004, WHO ARE WE CHALLENGE
   Johnston LD, 2014, MONITORING FUTURE NA, VI
   Kann L, 2014, MMWR SURVEILL SUMM, V63, P1
   Keyes CLM, 2006, AM J ORTHOPSYCHIAT, V76, P395, DOI 10.1037/0002-9432.76.3.395
   KNIGHT GP, 2009, METHODOLOGICAL CHALL
   Little T., 2013, LONGITUDINAL STRUCTU
   Little TD, 2002, STRUCT EQU MODELING, V9, P151, DOI 10.1207/S15328007SEM0902_1
   McLaughlin KA, 2007, J ABNORM CHILD PSYCH, V35, P801, DOI 10.1007/s10802-007-9128-1
   Muthen LK, 2010, MPLUS USERS GUIDE VE
   Newland K., CHILD MIGRATION CRIS
   Okamoto J, 2009, AM J HEALTH BEHAV, V33, P718
   Phinney JS, 1998, J APPL SOC PSYCHOL, V28, P937, DOI 10.1111/j.1559-1816.1998.tb01661.x
   Portes A, 2006, IMMIGRANT AM PORTRAI, V3
   RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306
   Romero Andrea J, 2003, Cultur Divers Ethnic Minor Psychol, V9, P171, DOI 10.1037/1099-9809.9.2.171
   Rosenberg M., 1968, SOC ADOLESCENT SELF
   Roth B., 2010, PERILS DIVERSITY IMM
   Sawyer PJ, 2012, AM J PUBLIC HEALTH, V102, P1020, DOI 10.2105/AJPH.2011.300620
   Schwartz SJ, 2014, PREV SCI, V15, P385, DOI 10.1007/s11121-013-0419-1
   Schwartz SJ, 2014, CULT DIVERS ETHN MIN, V20, P1, DOI 10.1037/a0033391
   Schwartz SJ, 2012, DRUG ALCOHOL DEPEN, V125, pS26, DOI 10.1016/j.drugalcdep.2012.05.020
   Schwartz SJ, 2015, CHILD DEV, DOI 10.1111/cdev.12341
   Steiner N., 2009, INT MIGRATION CITIZE
   Suarez-Orozco C., 2001, CHILDREN IMMIGRATION
   Subasic E, 2008, PERS SOC PSYCHOL REV, V12, P330, DOI 10.1177/1088868308323223
   Torney-Purta J, 2007, J YOUTH ADOLESCENCE, V36, P111, DOI 10.1007/s10964-006-9121-y
   Turner CF, 1998, SCIENCE, V280, P867, DOI 10.1126/science.280.5365.867
   Viruell-Fuentes EA, 2007, SOC SCI MED, V65, P1524, DOI 10.1016/j.socscimed.2007.05.010
   West SG, 2012, HDB STRUCTURAL EQUAT, P209
   Zagefka H, 2011, BRIT J SOC PSYCHOL, V50, P216, DOI 10.1348/014466610X512211
NR 40
TC 72
Z9 72
U1 3
U2 52
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1054-139X
EI 1879-1972
J9 J ADOLESCENT HEALTH
JI J. Adolesc. Health
PD APR
PY 2015
VL 56
IS 4
BP 433
EP 439
DI 10.1016/j.jadohealth.2014.12.011
PG 7
WC Psychology, Developmental; Public, Environmental & Occupational Health;
   Pediatrics
SC Psychology; Public, Environmental & Occupational Health; Pediatrics
GA CE3BC
UT WOS:000351698100014
PM 25650112
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Ahmad, A
   Mitrofanova, A
   Bielawski, J
   Yang, YD
   Marples, B
   Fornoni, A
   Zeidan, YH
AF Ahmad, Anis
   Mitrofanova, Alla
   Bielawski, Jacek
   Yang, Yidong
   Marples, Brian
   Fornoni, Alessia
   Zeidan, Youssef H.
TI Sphingomyelinase-like phosphodiesterase 3b mediates radiation-induced
   damage of renal podocytes
SO FASEB JOURNAL
LA English
DT Article
DE lipids; cancer; ceramide; radioprotection
ID ACID CERAMIDASE; RESISTANCE; SPHINGOLIPIDS; NEPHROPATHY; RITUXIMAB;
   PREVENTS; NEPHRIN; PATHWAY
AB The molecular mechanisms responsible for the development of proteinuria and glomerulosclerosis in radiation nephropathy remain largely unknown. Podocytes are increasingly recognized as key players in the pathogenesis of proteinuria in primary and secondary glomerular disorders. The lipid-modulating enzyme sphingomyelin phosphodiesterase acid-like 3B (SMPDL3b) is a key determinant of podocyte injury and a known off target of the anti-CD20 antibody rituximab (RTX). The current study investigates the role of sphingolipids in radiation-induced podocytopathy. After a single dose of radiation (8 Gy), several ceramide species were significantly elevated. In particular, C16:00, C24:00, and C24:1 ceramides were the most abundant ceramide species detected. These changes were paralleled by a time-dependent drop in SMPDL3b protein, sphingosine, and sphingosine-1-phosphate levels. Interestingly, SMPDL3b-overexpressing podocytes had higher basal levels of sphingosine-1-phosphate and maintained basal ceramide levels after irradiation. Morphologically, irradiated podocytes demonstrated loss of filopodia and remodeling of cortical actin. Furthermore, the actin binding protein ezrin relocated from the plasma membrane to the cytosol as early as 2 h after radiation. In contrast, SMPDL3b overexpressing podocytes were protected from radiation-induced cytoskeletal remodeling. Treatment with RTX before radiation exposure partially protected podocytes from SMPDL3b loss, cytoskeletal remodeling, and caspase 3 cleavage. Our results demonstrate that radiation injury induces early cytoskeletal remodeling, down-regulation of SMPDL3b, and elevation of cellular ceramide levels. Overexpression of SMPDL3b and pretreatment with RTX confer a radioprotective effect in cultured podocytes. These findings indicate a potential role for SMPDL3b and RTX in radiation-induced podocytopathy.
C1 [Ahmad, Anis; Yang, Yidong; Marples, Brian; Zeidan, Youssef H.] Univ Miami, Miller Sch Med, Sylvester Canc Ctr, Dept Radiat Oncol, Miami, FL 33136 USA.
   [Mitrofanova, Alla; Fornoni, Alessia] Univ Miami, Peggy & Harold Katz Family Drug Discovery Ctr, Miami, FL 33136 USA.
   [Mitrofanova, Alla] Univ Miami, Dept Surg, Miami, FL 33136 USA.
   [Fornoni, Alessia] Univ Miami, Div Nephrol, Miami, FL 33136 USA.
   [Mitrofanova, Alla; Fornoni, Alessia] Univ Miami, Dept Med, Miami, FL 33136 USA.
   [Bielawski, Jacek] Med Univ South Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.
   [Zeidan, Youssef H.] Amer Univ Beirut, Dept Radiat Oncol, Beirut, Lebanon.
RP Zeidan, YH (corresponding author), Amer Univ Beirut, Med Ctr, Dept Radiat Oncol, POB 11-0236, Beirut 11072020, Lebanon.
EM yz09@aub.edu.lb
RI Ahmad, Anis/AAA-7263-2019; Mitrofanova, Alla/L-1590-2019; Zeidan,
   Youssef H./H-7578-2019
OI Ahmad, Anis/0000-0001-9820-2126; Mitrofanova, Alla/0000-0001-5065-9522;
   Zeidan, Youssef H./0000-0002-1951-8585; fornoni,
   Alessia/0000-0002-1313-7773
FU U.S. National Institutes of HealthUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [DK104753,
   DK090316]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Advancing Translational
   Sciences (NCATS) [UL1TR000460] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Diabetes & Digestive & Kidney Diseases
   (NIDDK) [R01DK090316, R01DK104753] Funding Source: NIH RePORTER
FX A.F. is an inventor of pending patents aimed to diagnose or treat
   proteinuric renal diseases, and stands to gain royalties from their
   future commercialization. A.F. is also a consultant for Hoffman-La
   Roche, Genentech, Jannsen, Mesoblast, Abbvie, Boehringer Ingelheim,
   Alexion, and Bristol- Myers Squibb. A.F. is funded by U.S. National
   Institutes of Health Grants DK104753 and DK090316.
CR Aureli M, 2014, GLYCOCONJUGATE J, V31, P449, DOI 10.1007/s10719-014-9541-y
   Basic-Jukic N, 2013, CURR PHARM DESIGN, V19, P6046
   Bielawski J, 2006, METHODS, V39, P82, DOI 10.1016/j.ymeth.2006.05.004
   CASSADY JR, 1995, INT J RADIAT ONCOL, V31, P1249, DOI 10.1016/0360-3016(94)00428-N
   Cheng JC, 2008, INT J RADIAT ONCOL, V71, P1436, DOI 10.1016/j.ijrobp.2007.12.009
   Cheng JC, 2013, J CLIN INVEST, V123, P4344, DOI 10.1172/JCI64791
   Cohen EP, 2003, SEMIN NEPHROL, V23, P486, DOI 10.1016/S0270-9295(03)00093-7
   Dawson LA, 2010, INT J RADIAT ONCOL, V76, pS108, DOI 10.1016/j.ijrobp.2009.02.089
   Fornoni A, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002231
   Gandy KAO, 2013, BIOCHEM J, V449, P661, DOI 10.1042/BJ20120213
   Geoffroy K, 2004, J BIOL CHEM, V279, P34343, DOI 10.1074/jbc.M403273200
   Heinz LX, 2015, CELL REP, V11, P1919, DOI 10.1016/j.celrep.2015.05.006
   Lacour S, 2004, CANCER RES, V64, P3593, DOI 10.1158/0008-5472.CAN-03-2787
   Lennon R, 2009, NEPHROL DIAL TRANSPL, V24, P3288, DOI 10.1093/ndt/gfp302
   LUXTON RW, 1961, LANCET, V2, P1221
   Mahdy AEM, 2009, MOL THER, V17, P430, DOI 10.1038/mt.2008.281
   Merscher S, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00127
   Oikawa T, 1997, KIDNEY INT, V51, P164, DOI 10.1038/ki.1997.20
   Perosa F, 2006, BLOOD, V107, P1070, DOI 10.1182/blood-2005-04-1769
   Ruotsalainen V, 1999, P NATL ACAD SCI USA, V96, P7962, DOI 10.1073/pnas.96.14.7962
   Saleem MA, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133630
   Sera N, 2013, RADIAT RES, V179, P46, DOI 10.1667/RR2863.1
   Sha H, 2016, ONCOTARGET, V7, P18825, DOI 10.18632/oncotarget.7939
   STEPHENS LC, 1995, INT J RADIAT ONCOL, V31, P865
   Tasaki M, 2014, J AM SOC NEPHROL, V25, P737, DOI 10.1681/ASN.2013040363
   Truman JP, 2010, PLOS ONE, V5, DOI [10.1371/journal.pone.0012310, 10.1371/annotation/6e222ad5-b175-4a00-9d04-4d120568a897]
   Uehara N, 2008, MOL CANCER RES, V6, P186, DOI 10.1158/1541-7786.MCR-07-0254
   Wu BX, 2007, J LIPID RES, V48, P600, DOI 10.1194/jlr.M600423-JLR200
   Yang GY, 2010, INT J RADIAT ONCOL, V78, P539, DOI 10.1016/j.ijrobp.2009.07.1744
   Yoo TH, 2015, J AM SOC NEPHROL, V26, P133, DOI 10.1681/ASN.2013111213
   Zeidan YH, 2010, CURR MOL MED, V10, P454, DOI 10.2174/156652410791608225
   Zeidan YH, 2008, CURR DRUG TARGETS, V9, P653, DOI 10.2174/138945008785132358
   Zeidan YH, 2008, J CELL BIOL, V181, P335, DOI 10.1083/jcb.200705060
   Zeidan YH, 2007, TRENDS MOL MED, V13, P327, DOI 10.1016/j.molmed.2007.06.002
   Zeng J, 2014, LANCET ONCOL, V15, pE426, DOI 10.1016/S1470-2045(14)70026-9
NR 35
TC 20
Z9 21
U1 0
U2 6
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD FEB
PY 2017
VL 31
IS 2
BP 771
EP 780
DI 10.1096/fj.201600618R
PG 10
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA EK9HR
UT WOS:000394235400029
PM 27836988
OA Green Published
DA 2021-10-30
ER

PT J
AU Kistler, AD
   Caicedo, A
   Abdulreda, MH
   Faul, C
   Kerjaschki, D
   Berggren, PO
   Reiser, J
   Fornoni, A
AF Kistler, Andreas D.
   Caicedo, Alejandro
   Abdulreda, Midhat H.
   Faul, Christian
   Kerjaschki, Dontscho
   Berggren, Per-Olof
   Reiser, Jochen
   Fornoni, Alessia
TI In vivo imaging of kidney glomeruli transplanted into the anterior
   chamber of the mouse eye
SO SCIENTIFIC REPORTS
LA English
DT Article
ID HIGH-RESOLUTION; ALBUMIN; CELLS; EXPRESSION; CONTROVERSIES; NEPHROLOGY;
   MICROSCOPY; PODOCYTE; GRAFTS; FACTS
AB Multiphoton microscopy enables live imaging of the renal glomerulus. However, repeated in vivo imaging of the same glomerulus over extended periods of time and the study of glomerular function independent of parietal epithelial and proximal tubular cell effects has not been possible so far. Here, we report a novel approach for non-invasive imaging of acapsular glomeruli transplanted into the anterior chamber of the mouse eye. After microinjection, glomeruli were capable of engrafting on the highly vascularized iris. Glomerular structure was preserved, as demonstrated by podocyte specific expression of cyan fluorescent protein and by electron microscopy. Injection of fluorescence-labeled dextrans of various molecular weights allowed visualization of glomerular filtration and revealed leakage of 70 kDa dextran in an inducible model of proteinuria. Our findings demonstrate functionality and long-term survival of glomeruli devoid of Bowman's capsule and provide a novel approach for non-invasive longitudinal in vivo study of glomerular physiology and pathophysiology.
C1 [Kistler, Andreas D.; Faul, Christian; Reiser, Jochen; Fornoni, Alessia] Univ Miami, Miller Sch Med, Div Nephrol & Hypertens, Dept Med, Miami, FL 33136 USA.
   [Kistler, Andreas D.] Univ Zurich Hosp, Div Nephrol, CH-8091 Zurich, Switzerland.
   [Caicedo, Alejandro] Univ Miami, Miller Sch Med, Div Endocrinol Diabet & Metab, Dept Med, Miami, FL 33136 USA.
   [Abdulreda, Midhat H.; Berggren, Per-Olof; Fornoni, Alessia] Univ Miami, Miller Sch Med, Diabet Res Ctr, Miami, FL 33136 USA.
   [Kerjaschki, Dontscho] Med Univ Vienna, Clin Inst Pathol, Vienna, Austria.
   [Berggren, Per-Olof] Karolinska Inst, Rolf Luft Res Ctr Diabet & Endocrinol, Stockholm, Sweden.
   [Reiser, Jochen] Rush Univ, Med Ctr, Dept Med, Chicago, IL 60612 USA.
RP Kistler, AD (corresponding author), Univ Miami, Miller Sch Med, Div Nephrol & Hypertens, Dept Med, Miami, FL 33136 USA.
EM andreas.kistler@usz.ch; afornoni@med.miami.edu
RI Caicedo, Alejandro/AAC-8544-2020
OI Kistler, Andreas/0000-0002-4114-9560; fornoni,
   Alessia/0000-0002-1313-7773; Berggren, Per-Olof/0000-0001-8991-413X
FU Swiss National Science FoundationSwiss National Science Foundation
   (SNSF)European Commission; Swiss Society for Medical and Biological
   Scholarships; Amgen-FROMO scholarship; National Institute of Health
   (NIH) through the National Institute of Diabetes and Digestive and
   Kidney Diseases (NIDDK) [R01DK090316]; Diabetes Research Institute
   Foundation (DRIF); Peggy and Harold Katz Family Foundation;
   NIH/NIDDKUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Diabetes &
   Digestive & Kidney Diseases (NIDDK) [F32DK083226]; DRIF; NATIONAL CENTER
   FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000460]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND
   DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK090316,
   F32DK083226, R01DK084321, K01DK097194] Funding Source: NIH RePORTER
FX We thank Dr. Susan E. Quaggin (Samuel Lunenfeld Research Institute,
   Toronto, Canada) for providing the NPHS1-CFPmice. A. D. K. was supported
   by a grant of the Swiss National Science Foundation, a grant by the
   Swiss Society for Medical and Biological Scholarships and an Amgen-FROMO
   scholarship. A. F. is supported by the National Institute of Health
   (NIH) through the National Institute of Diabetes and Digestive and
   Kidney Diseases (NIDDK grant Number R01DK090316), by the Diabetes
   Research Institute Foundation (DRIF; diabetesresearch.org) and by the
   Peggy and Harold Katz Family Foundation. M. H. A. was supported by the
   NIH/NIDDK (grant number F32DK083226) and the DRIF.
CR Abdulreda MH, 2011, P NATL ACAD SCI USA, V108, P12863, DOI 10.1073/pnas.1105002108
   ABRAHAMSON DR, 1991, LAB INVEST, V64, P629
   Appel D, 2009, J AM SOC NEPHROL, V20, P333, DOI 10.1681/ASN.2008070795
   Christensen E, 2007, KIDNEY INT, V72, P1192, DOI 10.1038/sj.ki.5002526
   Cui SY, 2005, J AM SOC NEPHROL, V16, P3247, DOI 10.1681/ASN.2005030278
   Eremina V, 2003, J CLIN INVEST, V111, P707, DOI 10.1172/JCI200317423
   Eremina V, 2007, NEPHRON PHYSIOL, V106, P32, DOI 10.1159/000101798
   Haraldsson B, 2008, PHYSIOL REV, V88, P451, DOI 10.1152/physrev.00055.2006
   Hyink DP, 1996, AM J PHYSIOL-RENAL, V270, pF886, DOI 10.1152/ajprenal.1996.270.5.F886
   Kerjaschki D, 1997, J CLIN INVEST, V100, P2303, DOI 10.1172/JCI119768
   Kriz W, 2002, MICROSC RES TECHNIQ, V57, P189, DOI 10.1002/jemt.10072
   Motoike T, 2000, GENESIS, V28, P75, DOI 10.1002/1526-968X(200010)28:2<75::AID-GENE50>3.0.CO;2-S
   Neal CR, 2005, J AM SOC NEPHROL, V16, P1223, DOI 10.1681/ASN.2004100822
   Nijenhuis T, 2011, AM J PATHOL, V179, P1719, DOI 10.1016/j.ajpath.2011.06.033
   Nyqvist D, 2011, DIABETES, V60, P2571, DOI 10.2337/db10-1711
   Peti-Peterdi J, 2012, AM J PHYSIOL-RENAL, V302, pF227, DOI 10.1152/ajprenal.00561.2011
   Peti-Peterdi J, 2010, J AM SOC NEPHROL, V21, P1835, DOI 10.1681/ASN.2010040378
   Peti-Peterdi J, 2009, AM J PHYSIOL-RENAL, V296, pF1255, DOI 10.1152/ajprenal.00144.2009
   Russo LM, 2007, KIDNEY INT, V72, P1195, DOI 10.1038/sj.ki.5002528
   Russo LM, 2007, KIDNEY INT, V71, P504, DOI 10.1038/sj.ki.5002041
   Salmon AHJ, 2007, AM J PHYSIOL-RENAL, V293, pF1777, DOI 10.1152/ajprenal.00187.2007
   SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C
   Smeets B, 2011, J AM SOC NEPHROL, V22, P1262, DOI 10.1681/ASN.2010090970
   Smeets B, 2009, J AM SOC NEPHROL, V20, P2604, DOI 10.1681/ASN.2009010122
   Speier S, 2008, NAT PROTOC, V3, P1278, DOI 10.1038/nprot.2008.118
   Speier S, 2008, NAT MED, V14, P574, DOI 10.1038/nm1701
   Tanner GA, 2009, AM J PHYSIOL-RENAL, V296, pF1258, DOI 10.1152/ajprenal.90638.2008
   TOJO A, 1992, AM J PHYSIOL, V263, pF601, DOI 10.1152/ajprenal.1992.263.4.F601
NR 28
TC 14
Z9 14
U1 0
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JAN 27
PY 2014
VL 4
AR 3872
DI 10.1038/srep03872
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AA4WM
UT WOS:000331097300002
PM 24464028
OA Green Accepted, gold, Green Published
DA 2021-10-30
ER

PT J
AU Ramos, AR
   Wallace, DM
   Williams, NJ
   Spence, DW
   Pandi-Perumal, SR
   Zizi, F
   Jean-Louis, G
AF Ramos, Alberto R.
   Wallace, Douglas M.
   Williams, Natasha J.
   Spence, David Warren
   Pandi-Perumal, Seithikurippu Ratnas
   Zizi, Ferdinand
   Jean-Louis, Girardin
TI Association between visual impairment and sleep duration: analysis of
   the 2009 National Health Interview Survey (NHIS)
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Visual Impairment; Sleep Duration; Race/ethnicity
ID FUNCTION QUESTIONNAIRE; RACIAL-DIFFERENCES; LONG SLEEPERS; EYE;
   MORTALITY; GLAUCOMA; PREVALENCE; RISK; AMERICANS; OUTCOMES
AB Background: Visual impairment (VI) is associated with increased mortality and health factors such as depression and cardiovascular disease. Epidemiologic studies consistently show associations between sleep duration with adverse health outcomes, but these have not systematically considered the influence of VI. The aim of this study was to ascertain the independent association between VI and sleep duration using the National Health Interview Survey (NHIS) data. We also examined whether race/ethnicity influenced these associations independently of sociodemographic and medical characteristics.
   Methods: Our analysis was based on the 2009 NHIS, providing valid sleep and vision data for 29,815 participants. The NHIS is a cross-sectional household interview survey utilizing a multistage area probability design. Trained personnel from the US census bureau gathered data during face-to-face interview and obtained socio-demographic, self-reported habitual sleep duration and physician-diagnosed chronic conditions.
   Results: The mean age of the sample was 48 years and 56% were female. Short sleep and long sleep durations were reported by 49% and 23% of the participants, respectively. Visual impairment was observed in 10%. Multivariate-adjusted logistic regression models showed significant associations between VI and short sleep (OR = 1.6, 95% CI = 1.5-1.9 and long sleep durations (OR = 1.6, 95% CI = 1.3-1.9). These associations persisted in multivariate models stratified by race-ethnic groups.
   Conclusion: Visual impairment was associated with both short and long sleep durations. Analysis of epidemiologic sleep data should consider visual impairment as an important factor likely to influence the amount of sleep experienced habitually.
C1 [Ramos, Alberto R.; Wallace, Douglas M.] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA.
   [Williams, Natasha J.; Pandi-Perumal, Seithikurippu Ratnas; Zizi, Ferdinand; Jean-Louis, Girardin] NYU, Langone Med Ctr, CHBC, Dept Populat Hlth,Div Hlth & Behav, New York, NY 10016 USA.
RP Jean-Louis, G (corresponding author), NYU, Langone Med Ctr, CHBC, Dept Populat Hlth,Div Hlth & Behav, 227 East 30th St,Floor 6-615, New York, NY 10016 USA.
EM Girardin.Jean-Louis@nyumc.org
RI Ramos, Alberto/X-4249-2019; Pandi-Perumal, Seithikurippu R./Q-8281-2016;
   Wallace, Douglas/AAL-3719-2020
OI Pandi-Perumal, Seithikurippu R./0000-0002-8686-7259; Jean-Louis,
   Girardin/0000-0001-6777-2724; Wallace, Douglas/0000-0002-8982-1088
FU [1KL2TR000461];  [R25HL105444];  [U54NS081765];  [R01MD004113]; NATIONAL
   CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Advancing Translational Sciences (NCATS)
   [KL2TR000461] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND
   BLOOD INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [R25HL105444, R25HL116378] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Neurological Disorders &
   Stroke (NINDS) [U54NS081765] Funding Source: NIH RePORTER; National
   Institute on Minority Health and Health DisparitiesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Minority Health & Health Disparities
   (NIMHD) [R01MD004113] Funding Source: NIH RePORTER
FX The authors want to thank the participants for their time and
   contribution to this study. The project described was supported by Grant
   Number 1KL2TR000461 (ARR), R25HL105444, U54NS081765, and R01MD004113.
CR Asplund R, 2000, ARCH GERONTOL GERIAT, V30, P7, DOI 10.1016/S0167-4943(99)00045-X
   Augustin A, 2007, INVEST OPHTH VIS SCI, V48, P1498, DOI 10.1167/iovs.06-0761
   Bendel RE, 2008, EYE, V22, P1105, DOI 10.1038/sj.eye.6702846
   Campbell JA, 2012, ENDOCRINE, V42, P471, DOI 10.1007/s12020-012-9744-6
   Cappuccio FP, 2011, EUR HEART J, V32, P1484, DOI 10.1093/eurheartj/ehr007
   El-Gasim M, 2012, OPHTHALMOLOGY, V119, P106, DOI 10.1016/j.ophtha.2011.07.005
   Lanzani MF, 2012, CHRONOBIOL INT, V29, P911, DOI 10.3109/07420528.2012.691146
   Grandner MA, 2007, SLEEP MED REV, V11, P341, DOI 10.1016/j.smrv.2007.03.010
   Hale L, 2007, SLEEP, V30, P1096, DOI 10.1093/sleep/30.9.1096
   Jean-Louis G, 2005, PHYSIOL BEHAV, V84, P479, DOI 10.1016/j.physbeh.2005.01.011
   Karpa MJ, 2009, ARCH OPHTHALMOL-CHIC, V127, P1347, DOI 10.1001/archophthalmol.2009.240
   Knutson KL, 2010, BEST PRACT RES CL EN, V24, P731, DOI 10.1016/j.beem.2010.07.001
   Kronholm E, 2011, SLEEP MED, V12, P215, DOI 10.1016/j.sleep.2010.07.021
   Lam BL, 2006, ARCH OPHTHALMOL-CHIC, V124, P95, DOI 10.1001/archopht.124.1.95
   Leske MC, 2001, ARCH OPHTHALMOL-CHIC, V119, P89
   Lin PW, 2011, J GLAUCOMA, V20, P553, DOI 10.1097/IJG.0b013e3181f3eb81
   Lockley Steven W, 2007, Dialogues Clin Neurosci, V9, P301
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   Mensah GA, 2005, CIRCULATION, V111, P1233, DOI 10.1161/01.CIR.0000158136.76824.04
   Mojon DS, 1999, OPHTHALMOLOGY, V106, P1009, DOI 10.1016/S0161-6420(99)00525-4
   Nunes J, 2008, J NATL MED ASSOC, V100, P317, DOI 10.1016/S0027-9684(15)31244-X
   Patel SR, 2012, SLEEP, V35, P641, DOI 10.5665/sleep.1822
   Pleis JR, 2010, VITAL HLTH STAT, V249, P1
   Ram S, 2010, SLEEP BREATH, V14, P63, DOI 10.1007/s11325-009-0281-3
   Stepanski EJ, 2002, SLEEP, V25, P268, DOI 10.1093/sleep/25.3.268
   Wee R, 2004, OPHTHALMOLOGY, V111, P297, DOI 10.1016/j.ophtha.2003.05.014
   Youngstedt SD, 2004, SLEEP MED REV, V8, P159, DOI 10.1016/j.smrv.2003.10.002
   Zizi F, 2002, J GERONTOL A-BIOL, V57, pM691, DOI 10.1093/gerona/57.10.M691
   Zizi F, 2012, AM J MED, V125, P162, DOI 10.1016/j.amjmed.2011.08.020
NR 30
TC 14
Z9 15
U1 0
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD OCT 1
PY 2014
VL 14
AR 115
DI 10.1186/1471-2415-14-115
PG 5
WC Ophthalmology
SC Ophthalmology
GA AW5LC
UT WOS:000346315700001
PM 25274449
OA Green Published, gold
DA 2021-10-30
ER

PT J
AU Rech, AJ
   Balli, D
   Mantero, A
   Ishwaran, H
   Nathanson, KL
   Stanger, BZ
   Vonderheide, RH
AF Rech, Andrew J.
   Balli, David
   Mantero, Alejandro
   Ishwaran, Hemant
   Nathanson, Katherine L.
   Stanger, Ben Z.
   Vonderheide, Robert H.
TI Tumor Immunity and Survival as a Function of Alternative Neopeptides in
   Human Cancer
SO CANCER IMMUNOLOGY RESEARCH
LA English
DT Article
ID GENERATION SEQUENCING DATA; PANCREATIC-CANCER; T-CELLS; METASTATIC
   MELANOMA; CHECKPOINT BLOCKADE; CYTOLYTIC ACTIVITY; PATIENT SURVIVAL;
   PD-1 BLOCKADE; FORESTS; NEOANTIGENS
AB The immune system exerts antitumor activity via T cell-dependent recognition of tumor-specific antigens. Although the number of tumor neopeptides-peptides derived from somatic mutations-often correlates with immune activity and survival, most classically defined high-affinity neopeptides (CDNs) are not immunogenic, and only rare CDNs have been linked to tumor rejection. Thus, the rules of tumor antigen recognition remain incompletely understood. Here, we analyzed neopeptides, immune activity, and clinical outcome from 6,324 patients across 27 tumor types. We characterized a class of "alternatively defined neopeptides" (ADNs), which are mutant peptides predicted to bind MHC (class I or II) with improved affinity relative to their nonmutated counterpart. ADNs are abundant and molecularly distinct from CDNs. The load of ADNs correlated with intratumoral T-cell responses and immune suppression, and ADNs were also strong predictors of patient survival across tumor types. These results expand the spectrum of mutation-derived tumor antigens with potential clinical relevance. (C) 2018 AACR.
C1 [Rech, Andrew J.; Balli, David; Stanger, Ben Z.; Vonderheide, Robert H.] Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.
   [Mantero, Alejandro; Ishwaran, Hemant] Univ Miami, Dept Publ Hlth Sci, Div Biostat, Miami, FL USA.
   [Nathanson, Katherine L.; Stanger, Ben Z.; Vonderheide, Robert H.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
   [Nathanson, Katherine L.; Stanger, Ben Z.] Univ Penn, Perelman Sch Med, Inst Regenerat Med, Philadelphia, PA 19104 USA.
   [Stanger, Ben Z.] Univ Penn, Perelman Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA.
   [Stanger, Ben Z.; Vonderheide, Robert H.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
RP Vonderheide, RH (corresponding author), Univ Penn, 12-114 South Pavil, Philadelphia, PA 19104 USA.
EM rhv@upenn.edu
RI Mantero, Alejandro/AAS-6415-2021
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01-CA169123]; Parker Institute for
   Cancer Immunotherapy; NATIONAL CANCER INSTITUTEUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Cancer Institute (NCI) [R01CA169123] Funding Source: NIH
   RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Advancing Translational
   Sciences (NCATS) [UL1TR000460] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of General Medical Sciences (NIGMS) [R01GM125072] Funding
   Source: NIH RePORTER
FX This work was supported by the NIH (R01-CA169123 to B.Z. Stanger and
   R.H. Vonderheide) and the Parker Institute for Cancer Immunotherapy
   (A.J. Rech, K.L. Nathanson, B.Z. Stanger, R.H. Vonderheide).
CR Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044
   Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965
   Balachandran VP, 2017, NATURE, V551, P512, DOI 10.1038/nature24462
   Balli D, 2017, CLIN CANCER RES, V23, P3129, DOI 10.1158/1078-0432.CCR-16-2128
   Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480
   Boulesteix AL, 2012, WIRES DATA MIN KNOWL, V2, P493, DOI 10.1002/widm.1072
   Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694
   Breiman L., 2001, RANDOM FORESTS MACHI
   Brown SD, 2014, GENOME RES, V24, P743, DOI 10.1101/gr.165985.113
   Carreno BM, 2015, SCIENCE, V348, P803, DOI 10.1126/science.aaa3828
   Carter SL, 2012, NAT BIOTECHNOL, V30, P413, DOI 10.1038/nbt.2203
   Chen X, 2012, GENOMICS, V99, P323, DOI 10.1016/j.ygeno.2012.04.003
   Cingolani P, 2012, FLY, V6, P80, DOI 10.4161/fly.19695
   Colli LM, 2016, CANCER RES, V76, P3767, DOI 10.1158/0008-5472.CAN-16-0170
   Duan F, 2014, J EXP MED, V211, P2231, DOI 10.1084/jem.20141308
   Favero F, 2015, ANN ONCOL, V26, P64, DOI 10.1093/annonc/mdu479
   Fritsch EF, 2014, CANCER IMMUNOL RES, V2, P522, DOI 10.1158/2326-6066.CIR-13-0227
   Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139
   Gao J, 2017, NAT MED, V57, P3325
   Giannakis M, 2016, CELL REP, V15, P857, DOI 10.1016/j.celrep.2016.03.075
   Gonzalez-Galarza FF, 2015, NUCLEIC ACIDS RES, V43, pD784, DOI 10.1093/nar/gku1166
   Gros A, 2016, NAT MED, V22, P433, DOI 10.1038/nm.4051
   Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7
   Huang YZ, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0145-3
   Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065
   Ishwaran H, 2008, ANN APPL STAT, V2, P841, DOI 10.1214/08-AOAS169
   Ishwaran H, 2014, BIOSTATISTICS, V15, P757, DOI 10.1093/biostatistics/kxu010
   Ishwaran H, 2010, STAT PROBABIL LETT, V80, P1056, DOI 10.1016/j.spl.2010.02.020
   Ishwaran H, 2010, J AM STAT ASSOC, V105, P205, DOI 10.1198/jasa.2009.tm08622
   Jimenez-Sanchez A, 2017, CELL, V170, P927, DOI 10.1016/j.cell.2017.07.025
   Johnson BJ, 2003, P NATL ACAD SCI USA, V100, P2657, DOI 10.1073/pnas.0538056100
   Kim Y, 2012, NUCLEIC ACIDS RES, V40, pW525, DOI 10.1093/nar/gks438
   Kreiter S, 2015, NATURE, V520, P692, DOI 10.1038/nature14426
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Lu YC, 2013, J IMMUNOL, V190, P6034, DOI 10.4049/jimmunol.1202830
   Luksza M, 2017, NATURE, V551, P517, DOI 10.1038/nature24473
   Maoz A, 2017, NEW ENGL J MED, V376, DOI 10.1056/NEJMc1616637
   McGranahan N, 2016, SCIENCE, V351, P1463, DOI 10.1126/science.aaf1490
   Mlecnik B, 2016, IMMUNITY, V44, P698, DOI 10.1016/j.immuni.2016.02.025
   Nathanson T, 2017, CANCER IMMUNOL RES, V5, P84, DOI 10.1158/2326-6066.CIR-16-0019
   Paul S, 2013, J IMMUNOL, V191, P5831, DOI 10.4049/jimmunol.1302101
   Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348
   Rooney MS, 2015, CELL, V160, P48, DOI 10.1016/j.cell.2014.12.033
   Rosenberg JE, 2016, LANCET, V387, P1909, DOI 10.1016/S0140-6736(16)00561-4
   Schietinger A, 2016, IMMUNITY, V45, P389, DOI 10.1016/j.immuni.2016.07.011
   Schumacher K, 2001, CANCER RES, V61, P3932
   Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971
   Senbabaoglu Y, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1092-z
   Shukla SA, 2015, NAT BIOTECHNOL, V33, P1152, DOI 10.1038/nbt.3344
   Snyder A, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1029705
   Spranger S, 2016, P NATL ACAD SCI USA, V113, pE7759, DOI 10.1073/pnas.1609376113
   Strobl C, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-307
   Stronen E, 2016, SCIENCE, V352, P1337, DOI 10.1126/science.aaf2288
   Szolek A, 2014, BIOINFORMATICS, V30, P3310, DOI 10.1093/bioinformatics/btu548
   Topalian SL, 2015, CANCER CELL, V27, P450, DOI 10.1016/j.ccell.2015.03.001
   Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690
   Tran E, 2016, NEW ENGL J MED, V375, P2255, DOI 10.1056/NEJMoa1609279
   Twyman-Saint Victor C, 2015, NATURE, V520, P373, DOI 10.1038/nature14292
   Van Allen EM, 2015, SCIENCE, V350, P207, DOI 10.1126/science.aad0095
   Wang P, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000048
   Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764
   Wickham H., 2016, GGPLOT2 ELEGANT GRAP
   Yu X, 2009, NAT IMMUNOL, V10, P48, DOI 10.1038/ni.1674
NR 63
TC 34
Z9 35
U1 0
U2 7
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2326-6066
EI 2326-6074
J9 CANCER IMMUNOL RES
JI Cancer Immunol. Res.
PD MAR
PY 2018
VL 6
IS 3
BP 276
EP 287
DI 10.1158/2326-6066.CIR-17-0559
PG 12
WC Oncology; Immunology
SC Oncology; Immunology
GA FY6UH
UT WOS:000426997900004
PM 29339376
OA Bronze, Green Accepted
DA 2021-10-30
ER

PT J
AU Fornoni, A
   Merscher, S
   Kopp, JB
AF Fornoni, Alessia
   Merscher, Sandra
   Kopp, Jeffrey B.
TI Lipid biology of the podocyte-new perspectives offer new opportunities
SO NATURE REVIEWS NEPHROLOGY
LA English
DT Review
ID LECITHIN-CHOLESTEROL ACYLTRANSFERASE; DEPENDENT DIABETIC-PATIENTS; TNF
   RECEPTORS 1; INSULIN-RESISTANCE; GLOMERULAR PODOCYTES; FATTY-ACID;
   TRANSGENIC EXPRESSION; ALBUMIN EXCRETION; BINDING PROTEIN;
   KIDNEY-DISEASE
AB In the past 15 years, major advances have been made in understanding the role of lipids in podocyte biology. First, susceptibility to focal segmental glomerulosclerosis (FSGS) and glomerular disease is associated with an APOL1 sequence variant, is expressed in podocytes and encodes apolipoprotein L1, an important component of HDL. Second, acid sphingomyelinase-like phosphodiesterase 3b encoded by SMPDL3b has a role in the conversion of sphingomyelin to ceramide and its levels are reduced in renal biopsy samples from patients with recurrent FSGS. Furthermore, decreased SMPDL3b expression is associated with increased susceptibility of podocytes to injury after exposure to sera from these patients. Third, in many individuals with membranous nephropathy, autoantibodies against the phospholipase A(2) (PLA(2)) receptor, which is expressed in podocytes, have been identified. Whether these autoantibodies affect the activity of PLA(2), which liberates arachidonic acid from glycerophospholipids and modulates podocyte function, is unknown. Fourth, clinical and experimental evidence support a role for ATP-binding cassette sub-family A member 1-dependent cholesterol efflux, free fatty acids and glycerophospolipids in the pathogenesis of diabetic kidney disease. An improved understanding of lipid biology in podocytes might provide insights to develop therapeutic targets for primary and secondary glomerulopathies.
C1 [Fornoni, Alessia; Merscher, Sandra] Univ Miami, Miller Sch Med, Peggy & Harold Katz Family Drug Discovery Ctr, Div Nephrol & Hypertens, Miami, FL 33136 USA.
   [Kopp, Jeffrey B.] NIDDK, Kidney Dis Sect, Kidney Dis Branch, NIH, Bethesda, MD 20892 USA.
RP Fornoni, A (corresponding author), Univ Miami, Miller Sch Med, Peggy & Harold Katz Family Drug Discovery Ctr, Div Nephrol & Hypertens, 1580 North West 10th Ave, Miami, FL 33136 USA.
EM afornoni@med.miami.edu
RI Kopp, Jeffrey B/O-2681-2015
OI Kopp, Jeffrey B/0000-0001-9052-186X; Merscher,
   Sandra/0000-0002-4757-7494; fornoni, Alessia/0000-0002-1313-7773
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA; NIDDKUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)
   [DK090316, 5U24DX076169]; National Center for Advancing Translational
   SciencesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [1UL1TR000460]; Diabetes Research
   Institute Foundation; Nephcure Foundation; Peggy and Harold Katz Family
   Foundation; Stanley J. Glaser Foundation; NIDDK Intramural Research
   ProgramUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Diabetes &
   Digestive & Kidney Diseases (NIDDK); NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [UL1TR000460] Funding Source:
   NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Diabetes &
   Digestive & Kidney Diseases (NIDDK) [R01DK090316] Funding Source: NIH
   RePORTER
FX A.F. and S.M. are supported by the NIH and NIDDK (grant numbers DK090316
   and 5U24DX076169), the National Center for Advancing Translational
   Sciences (grant number 1UL1TR000460), the Diabetes Research Institute
   Foundation, the Nephcure Foundation and the Peggy and Harold Katz Family
   Foundation. S.M. is supported by the Stanley J. Glaser Foundation
   Research Award. J.B.K. is supported by the NIDDK Intramural Research
   Program.
CR Abi-Mosleh L, 2009, P NATL ACAD SCI USA, V106, P19316, DOI 10.1073/pnas.0910916106
   Agarwal R, 2006, AM J CARDIOL, V97, P748, DOI 10.1016/j.amjcard.2005.09.110
   Allyson J, 2012, NEURAL PLAST, V2012, DOI 10.1155/2012/569149
   Alroy J, 2002, J AM SOC NEPHROL, V13, pS134, DOI 10.1097/01.ASN.0000016684.07368.75
   Araki S, 2000, DIABETOLOGIA, V43, P1540, DOI 10.1007/s001250051566
   Arima H, 2005, BIOCHEM PHARMACOL, V70, P1506, DOI 10.1016/j.bcp.2005.08.021
   Asami T, 1999, PEDIATR NEPHROL, V13, P233, DOI 10.1007/s004670050599
   Augert A, 2009, EMBO REP, V10, P271, DOI 10.1038/embor.2008.255
   Awad AS, 2011, KIDNEY INT, V79, P1090, DOI 10.1038/ki.2010.544
   Balasubramanyam A, 2007, AM J PHYSIOL-ENDOC M, V292, pE40, DOI 10.1152/ajpendo.00163.2006
   Beck LH, 2009, NEW ENGL J MED, V361, P11, DOI 10.1056/NEJMoa0810457
   Bentley AR, 2012, INT J NEPHROL, V2012, DOI 10.1155/2012/748984
   Berkovic SE, 2008, AM J HUM GENET, V82, P673, DOI 10.1016/j.ajhg.2007.12.019
   Bie JH, 2010, J BIOL CHEM, V285, P13630, DOI 10.1074/jbc.M109.069781
   Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041
   Bussolati B, 2005, J AM SOC NEPHROL, V16, P1936, DOI 10.1681/ASN.2004080629
   Calabresi L, 2010, TRENDS CARDIOVAS MED, V20, P50, DOI 10.1016/j.tcm.2010.03.007
   CHANDER PN, 1979, ARCH PATHOL LAB MED, V103, P440
   Chen H. M., 2011, PLOS ONE, V7
   Chen YY, 2012, J GASTROEN HEPATOL, V27, P974, DOI 10.1111/j.1440-1746.2011.06986.x
   Christian AE, 1997, J LIPID RES, V38, P2264
   Colhoun HM, 2009, AM J KIDNEY DIS, V54, P810, DOI 10.1053/j.ajkd.2009.03.022
   Collins A, 2014, AM J KIDNEY DIS, V63, pE1
   Cui HL, 2012, J LIPID RES, V53, P696, DOI 10.1194/jlr.M023119
   Douglas K, 2006, ANN INTERN MED, V145, P117, DOI 10.7326/0003-4819-145-2-200607180-00009
   Duchateau PN, 1997, J BIOL CHEM, V272, P25576, DOI 10.1074/jbc.272.41.25576
   Ekstrand AV, 1998, NEPHROL DIAL TRANSPL, V13, P3079, DOI 10.1093/ndt/13.12.3079
   Elmaci AM, 2007, PEDIATR NEPHROL, V22, P1803, DOI 10.1007/s00467-007-0534-y
   Fang LH, 2013, NATURE, V498, P118, DOI 10.1038/nature12166
   Fessler MB, 2011, J IMMUNOL, V187, P1529, DOI 10.4049/jimmunol.1100253
   Field FJ, 2010, J LIPID RES, V51, P1407, DOI 10.1194/jlr.M002410
   Fielding CJ, 2001, BBA-MOL CELL BIOL L, V1533, P175, DOI 10.1016/S1388-1981(01)00162-7
   Fornoni A, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002231
   FORSBLOM CM, 1995, DIABETOLOGIA, V38, P363, DOI 10.1007/s001250050294
   Gaede P, 2008, NEW ENGL J MED, V358, P580, DOI 10.1056/NEJMoa0706245
   Galeano B, 2007, J CLIN INVEST, V117, P1585, DOI 10.1172/JCI30954
   Genovese G, 2010, SCIENCE, V329, P841, DOI 10.1126/science.1193032
   Giardino L, 2009, J AM SOC NEPHROL, V20, P1929, DOI 10.1681/ASN.2008121286
   Gibellini D, 2013, J CARDIOVASC MED, V14, P780, DOI 10.2459/JCM.0b013e3283619331
   Gohda T, 2012, J AM SOC NEPHROL, V23, P516, DOI 10.1681/ASN.2011060628
   Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022
   Grefhorst A, 2002, J BIOL CHEM, V277, P34182, DOI 10.1074/jbc.M204887200
   GROOP L, 1993, DIABETOLOGIA, V36, P642, DOI 10.1007/BF00404074
   Gutwein P, 2009, AM J PATHOL, V174, P2061, DOI 10.2353/ajpath.2009.080960
   Hartleben B, 2014, SEMIN NEPHROL, V34, P42, DOI 10.1016/j.semnephrol.2013.11.007
   Hashizume M, 2012, CYTOKINE, V58, P424, DOI 10.1016/j.cyto.2012.02.010
   Herman-Edelstein M, 2014, J LIPID RES, V55, P561, DOI 10.1194/jlr.P040501
   Holthofer H, 1996, AM J PATHOL, V149, P1009
   Horvath EM, 2008, BIOCHEM BIOPH RES CO, V372, P639, DOI 10.1016/j.bbrc.2008.05.095
   Horvath EM, 2008, MOL ENDOCRINOL, V22, P937, DOI 10.1210/me.2007-0410
   Hovind P, 2003, DIABETES CARE, V26, P1258, DOI 10.2337/diacare.26.4.1258
   Huber TB, 2006, P NATL ACAD SCI USA, V103, P17079, DOI 10.1073/pnas.0607465103
   Hyvonen ME, 2010, MOL CELL ENDOCRINOL, V328, P70, DOI 10.1016/j.mce.2010.07.016
   Ito K, 2014, CIRC RES, V114, P845, DOI 10.1161/CIRCRESAHA.114.302347
   Jiang T, 2005, J BIOL CHEM, V280, P32317, DOI 10.1074/jbc.M500801200
   Jimi S, 1999, ARTERIOSCL THROM VAS, V19, P794, DOI 10.1161/01.ATV.19.3.794
   Jin J, 2012, CELL, V151, P384, DOI 10.1016/j.cell.2012.08.037
   Jo SK, 2008, KIDNEY INT, V73, P1220, DOI 10.1038/ki.2008.34
   Kambham N, 2001, KIDNEY INT, V59, P1498, DOI 10.1046/j.1523-1755.2001.0590041498.x
   Kao WHL, 2008, NAT GENET, V40, P1185, DOI 10.1038/ng.232
   Katz A, 2009, J CLIN PHARMACOL, V49, P643, DOI 10.1177/0091270009335768
   Keech A., LANCET, V366
   Khera AV, 2011, NEW ENGL J MED, V364, P127, DOI 10.1056/NEJMoa1001689
   Kiss E, 2013, AM J PATHOL, V182, P727, DOI 10.1016/j.ajpath.2012.11.033
   Kopp JB, 2008, NAT GENET, V40, P1175, DOI 10.1038/ng.226
   Kopp JB, 2011, J AM SOC NEPHROL, V22, P2129, DOI 10.1681/ASN.2011040388
   KramerGuth A, 1997, NEPHROL DIAL TRANSPL, V12, P1336, DOI 10.1093/ndt/12.7.1336
   Kunnen S, 2012, J LIPID RES, V53, P1783, DOI 10.1194/jlr.R024513
   Kwak DH, 2003, LIFE SCI, V72, P1997, DOI 10.1016/S0024-3205(03)00090-0
   Le Lay S, 2001, J BIOL CHEM, V276, P16904, DOI 10.1074/jbc.M010955200
   LEE HS, 1993, MINER ELECTROL METAB, V19, P144
   Lee HS, 2003, NEPHROLOGY, V8, P224, DOI 10.1046/j.1440-1797.2003.00160.x
   Lee HS, 2011, HISTOL HISTOPATHOL, V26, P1599, DOI 10.14670/HH-26.1599
   Lennon R, 2009, NEPHROL DIAL TRANSPL, V24, P3288, DOI 10.1093/ndt/gfp302
   Liu P, 2004, AM J PHYSIOL-CELL PH, V286, pC317, DOI 10.1152/ajpcell.00073.2003
   Maxfield FR, 2002, J CLIN INVEST, V110, P891, DOI 10.1172/JCI200216500
   Mayrhofer C, 2009, AM J PATHOL, V174, P1191, DOI 10.2353/ajpath.2009.080654
   McCullough PA, 2011, AM J KIDNEY DIS, V57, pS1, DOI 10.1053/j.ajkd.2010.11.011
   Medapalli RK, 2011, CURR OPIN NEPHROL HY, V20, P306, DOI 10.1097/MNH.0b013e328345359a
   Merscher-Gomez S, 2013, DIABETES, V62, P3817, DOI 10.2337/db13-0399
   Meyer TW, 1999, DIABETOLOGIA, V42, P1341, DOI 10.1007/s001250051447
   Miller YI, 2009, TRENDS CARDIOVAS MED, V19, P227, DOI 10.1016/j.tcm.2010.02.001
   Mulya A, 2008, J LIPID RES, V49, P2390, DOI 10.1194/jlr.M800241-JLR200
   Mykkanen L, 1998, DIABETES, V47, P793, DOI 10.2337/diabetes.47.5.793
   Najafian B, 2011, KIDNEY INT, V79, P663, DOI 10.1038/ki.2010.484
   Niewczas MA, 2012, J AM SOC NEPHROL, V23, P507, DOI 10.1681/ASN.2011060627
   Nosadini R, 2011, NUTR METAB CARDIOVAS, V21, P79, DOI 10.1016/j.numecd.2010.10.002
   Novak A, 2013, J PHYSIOL BIOCHEM, V69, P727, DOI 10.1007/s13105-013-0249-4
   Pagtalunan ME, 1997, J CLIN INVEST, V99, P342, DOI 10.1172/JCI119163
   Parsa A, 2013, NEW ENGL J MED, V369, P2183, DOI 10.1056/NEJMoa1310345
   Parvanova AI, 2006, DIABETES, V55, P1456, DOI 10.2337/db05-1484
   Pays E, 2006, NAT REV MICROBIOL, V4, P477, DOI 10.1038/nrmicro1428
   Peake KB, 2010, FEBS LETT, V584, P2731, DOI 10.1016/j.febslet.2010.04.047
   Precourt LP, 2011, ATHEROSCLEROSIS, V214, P20, DOI 10.1016/j.atherosclerosis.2010.08.076
   Proctor G, 2006, DIABETES, V55, P2502, DOI 10.2337/db05-0603
   Qi MS, 2009, J CELL BIOCHEM, V106, P1031, DOI 10.1002/jcb.22081
   REIVINEN J, 1992, KIDNEY INT, V42, P624, DOI 10.1038/ki.1992.327
   Rousset X, 2011, CURR ATHEROSCLER REP, V13, P249, DOI 10.1007/s11883-011-0171-6
   Saltiel AR, 2003, TRAFFIC, V4, P711, DOI 10.1034/j.1600-0854.2003.00119.x
   Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a
   Sanchez-Nino MD, 2011, NEPHROL DIAL TRANSPL, V26, P1797, DOI 10.1093/ndt/gfq306
   SCHONHOLZER KW, 1992, NEPHRON, V62, P130, DOI 10.1159/000187020
   Schwartz GG, 2012, NEW ENGL J MED, V367, P2089, DOI 10.1056/NEJMoa1206797
   Schwarz K, 2001, J CLIN INVEST, V108, P1621, DOI 10.1172/JCI200112849
   Shi H, 2006, J CLIN INVEST, V116, P3015, DOI 10.1172/JCI28898
   Shrivastav S, 2013, MOL ENDOCRINOL, V27, P1564, DOI 10.1210/me.2012-1370
   Sieber J, 2013, AM J PATHOL, V183, P735, DOI 10.1016/j.ajpath.2013.05.023
   Sieber J, 2010, AM J PHYSIOL-RENAL, V299, pF821, DOI 10.1152/ajprenal.00196.2010
   Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408
   Simons M, 2001, AM J PATHOL, V159, P1069, DOI 10.1016/S0002-9440(10)61782-8
   Soetikno V, 2013, J NUTR BIOCHEM, V24, P796, DOI 10.1016/j.jnutbio.2012.04.013
   Sorensson J, 2002, J AM SOC NEPHROL, V13, P2639, DOI 10.1097/01.ASN.0000033277.32822.23
   Sreckovic I, 2013, BBA-MOL CELL BIOL L, V1831, P737, DOI 10.1016/j.bbalip.2012.12.015
   Steffes MW, 2001, KIDNEY INT, V59, P2104, DOI 10.1046/j.1523-1755.2001.0590062104.x
   Stella VJ, 2008, TOXICOL PATHOL, V36, P30, DOI 10.1177/0192623307310945
   Tachibana H, 2012, J AM SOC NEPHROL, V23, P1835, DOI 10.1681/ASN.2012010022
   Tam J, 2012, CELL METAB, V16, P167, DOI 10.1016/j.cmet.2012.07.002
   Tang CR, 2010, J LIPID RES, V51, P1719, DOI 10.1194/jlr.M003525
   Tasaki M, 2014, J AM SOC NEPHROL, V25, P737, DOI 10.1681/ASN.2013040363
   TATEMATSU M, 1981, ACTA PATHOL JAPON, V31, P503
   Thurberg BL, 2002, KIDNEY INT, V62, P1933, DOI 10.1046/j.1523-1755.2002.00675.x
   TOWNSEND RR, 1978, J CLIN INVEST, V62, P119, DOI 10.1172/JCI109095
   Uhles S, 2003, J CELL BIOL, V163, P1327, DOI 10.1083/jcb.200306093
   Verzola D, 2007, KIDNEY INT, V72, P1262, DOI 10.1038/sj.ki.5002531
   Wan GH, 2008, J BIOL CHEM, V283, P21540, DOI 10.1074/jbc.M800214200
   Wang XXX, 2010, DIABETES, V59, P2916, DOI 10.2337/db10-0019
   Wang XX, 2009, AM J PHYSIOL-RENAL, V297, pF1587, DOI 10.1152/ajprenal.00404.2009
   Wang ZW, 2005, DIABETES, V54, P2328, DOI 10.2337/diabetes.54.8.2328
   Wei C, 2008, NAT MED, V14, P55, DOI 10.1038/nm1696
   Wei CL, 2011, NAT MED, V17, P952, DOI 10.1038/nm.2411
   White KE, 2002, DIABETES, V51, P3083, DOI 10.2337/diabetes.51.10.3083
   WHITE MF, 1994, J BIOL CHEM, V269, P1
   Willer CJ, 2008, NAT GENET, V40, P161, DOI 10.1038/ng.76
   YIP J, 1993, LANCET, V342, P883, DOI 10.1016/0140-6736(93)91943-G
   YIP J, 1993, LANCET, V341, P369, DOI 10.1016/0140-6736(93)90167-F
   Yu BL, 2010, OBES REV, V11, P560, DOI 10.1111/j.1467-789X.2009.00699.x
   ZADOR IZ, 1993, J CLIN INVEST, V91, P797, DOI 10.1172/JCI116299
   Zhang GF, 2011, MOL CELL BIOCHEM, V346, P197, DOI 10.1007/s11010-010-0605-4
   Zhaorigetu S, 2008, AUTOPHAGY, V4, P1079, DOI 10.4161/auto.7066
   Zhou HL, 2008, DIABETES-METAB RES, V24, P617, DOI 10.1002/dmrr.895
   Zhou XY, 2008, J BIOL CHEM, V283, P2129, DOI 10.1074/jbc.M706636200
NR 141
TC 55
Z9 63
U1 1
U2 27
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1759-5061
EI 1759-507X
J9 NAT REV NEPHROL
JI Nat. Rev. Nephrol.
PD JUL
PY 2014
VL 10
IS 7
BP 379
EP 388
DI 10.1038/nrneph.2014.87
PG 10
WC Urology & Nephrology
SC Urology & Nephrology
GA AK5PY
UT WOS:000338479500005
PM 24861084
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Pratt, SI
   Jerome, GJ
   Schneider, KL
   Craft, LL
   Buman, MP
   Stoutenberg, M
   Daumit, GL
   Bartels, SJ
   Goodrich, DE
AF Pratt, Sarah I.
   Jerome, Gerald J.
   Schneider, Kristin L.
   Craft, Lynette L.
   Buman, Matthew P.
   Stoutenberg, Mark
   Daumit, Gail L.
   Bartels, Stephen J.
   Goodrich, David E.
TI Increasing US health plan coverage for exercise programming in community
   mental health settings for people with serious mental illness: a
   position statement from the Society of Behavior Medicine and the
   American College of Sports Medicine
SO TRANSLATIONAL BEHAVIORAL MEDICINE
LA English
DT Article
DE Exercise; Physical activity; Serious mental illness; Bipolar disorder;
   Schizophrenia; Health policy
ID PHYSICAL-ACTIVITY INTERVENTIONS; WEIGHT-LOSS; RANDOMIZED-TRIAL;
   RISK-FACTORS; ADULTS; METAANALYSIS; PROMOTION; FITNESS; OBESITY; CARE
AB Adults with serious mental illness die more than 10 years earlier than the average American. Premature mortality is due to the high prevalence of preventable diseases including cardiovascular disease and diabetes. Poor lifestyle behaviors including lack of exercise and physical inactivity contribute to the epidemic levels of obesity, diabetes, and cardiovascular disease observed among adults with serious mental illness. Not surprisingly, people with serious mental illness are among the most costly consumers of health services due to increased visits for poorly managed mental and physical health. Recent studies have demonstrated that exercise interventions based on community mental health settings can significantly improve physical and mental health in people with serious mental illness. However, current funding regulations limit the ability of community mental health settings to offer exercise programming services to people with serious mental illness. Policy efforts are needed to improve the dissemination and sustainability of exercise programs for people with serious mental illness.
C1 [Pratt, Sarah I.; Bartels, Stephen J.] Dartmouth Coll, Dept Psychiat, Geisel Sch Med Dartmouth, 105 Pleasant St,Main Bldg, Concord, NH 03301 USA.
   [Jerome, Gerald J.] Towson Univ, Dept Kinesiol, Towson, MD USA.
   [Jerome, Gerald J.; Daumit, Gail L.] Johns Hopkins Univ, Sch Med, Div Gen Internal Med, Baltimore, MD USA.
   [Schneider, Kristin L.] Rosalind Franklin Univ Med & Sci, Chicago, IL USA.
   [Craft, Lynette L.; Stoutenberg, Mark] Amer Coll Sports Med, Indianapolis, IN USA.
   [Buman, Matthew P.] Arizona State Univ, Sch Nutr & Hlth Promot, Phoenix, AZ USA.
   [Stoutenberg, Mark] Univ Miami, Dept Publ Hlth Sci, Miami, FL USA.
   [Goodrich, David E.] VA Ann Arbor Healthcare Syst, VA Ctr Clin Management Res, Ann Arbor, MI 48105 USA.
RP Pratt, SI (corresponding author), Dartmouth Coll, Dept Psychiat, Geisel Sch Med Dartmouth, 105 Pleasant St,Main Bldg, Concord, NH 03301 USA.
EM Sarah.I.Pratt@Dartmouth.edu
RI Buman, Matthew/AAJ-4447-2020; Jerome, Gerald/R-2979-2018
OI Buman, Matthew/0000-0002-5130-3162; Goodrich, David/0000-0003-3232-2189;
   Jerome, Gerald/0000-0003-0612-2626
FU National Institute of Mental HealthUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Mental Health (NIMH) [R34MH086678-01]; Centers for Disease
   Control and PreventionUnited States Department of Health & Human
   ServicesCenters for Disease Control & Prevention - USA [U48DP005018];
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [KL2TR000461] Funding Source: NIH RePORTER; NATIONAL CENTER FOR CHRONIC
   DISEASE PREV AND HEALTH PROMOUnited States Department of Health & Human
   ServicesCenters for Disease Control & Prevention - USA [U48DP005018]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Mental Health (NIMH)
   [R34MH086678, R01MH102325, K24MH093763] Funding Source: NIH RePORTER
FX The authors wish to acknowledge the expert review provided by the
   Society of Behavioral Medicine's (SBM) Integrated Primary Care and
   Physical Activity Special Interest Groups, the SBM Scientific and
   Professional Liaison Council, and the American College of Sports
   Medicine's Health and Science Policy Committee. This work was supported
   by the National Institute of Mental Health grant R34MH086678-01 (KS) and
   is a product of the Yale Health Promotion and Disease Prevention
   Research Center supported by Cooperative Agreement Number U48DP005018
   from the Centers for Disease Control and Prevention (SB, SP). The
   findings and conclusions in this statement are those of the authors and
   do not necessarily represent the official position of the Centers for
   Disease Control and Prevention, the Veterans Health Administration, or
   the In-SHAPE Implementation study (R01MH102325, Bartels, PI).
CR Ackermann RT, 2008, J AM GERIATR SOC, V56, P1459, DOI 10.1111/j.1532-5415.2008.01804.x
   Ades PA, 2015, PREV MED, V80, P50, DOI 10.1016/j.ypmed.2015.03.014
   Allison DB, 2009, AM J PREV MED, V36, P341, DOI 10.1016/j.amepre.2008.11.020
   Bartels SJ, 2015, AM J PSYCHIAT, V172, P344, DOI 10.1176/appi.ajp.2014.14030357
   Bartels SJ, 2013, PSYCHIAT SERV, V64, P729, DOI 10.1176/appi.ps.003622012
   Beals R. K., 2012, US NEWS WORLD REPORT
   BLAIR SN, 1995, JAMA-J AM MED ASSOC, V273, P1093, DOI 10.1001/jama.273.14.1093
   Chwastiak L, 2015, J CLIN PSYCHIAT, V76, pE519, DOI 10.4088/JCP.14com09503
   Daumit GL, 2013, NEW ENGL J MED, V368, P1594, DOI 10.1056/NEJMoa1214530
   Daumit GL, 2005, J NERV MENT DIS, V193, P641, DOI 10.1097/01.nmd.0000180737.85895.60
   Desilets RA, 2012, HLTH PROMOTION PROGR
   Drake RE, 2009, HEALTH AFFAIR, V28, P761, DOI 10.1377/hlthaff.28.3.761
   Druss BG, 2014, AM J PSYCHIAT, V171, P1142, DOI 10.1176/appi.ajp.2014.14070900
   Frean ME, 2012, WHAT IS OPTIMAL SUBS
   Gierisch JM, 2014, J CLIN PSYCHIAT, V75, pE424, DOI 10.4088/JCP.13r08558
   Goldstein BI, 2009, J CLIN PSYCHIAT, V70, P1078, DOI 10.4088/JCP.08r04505
   Goodpaster BH, 2010, JAMA-J AM MED ASSOC, V304, P1795, DOI 10.1001/jama.2010.1505
   Green CA, 2015, AM J PSYCHIAT, V172, P71, DOI 10.1176/appi.ajp.2014.14020173
   Jerome GJ, 2009, SCHIZOPHR RES, V108, P252, DOI 10.1016/j.schres.2008.12.006
   Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593
   Lobelo F, 2014, BRIT J SPORT MED, V48, P1627, DOI 10.1136/bjsports-2013-093080
   Maust DT, 2013, PSYCHIAT SERV, V64, P908, DOI 10.1176/appi.ps.201200330
   Mitchell MS, 2013, AM J PREV MED, V45, P658, DOI 10.1016/j.amepre.2013.06.017
   Nguyen HQ, 2008, PREV CHRONIC DIS, P5
   Nguyen HQ, 2008, DIABETES CARE, V31, P1562, DOI 10.2337/dc08-0624
   O'Donnell AN, 2013, J GEN INTERN MED, V28, P1667, DOI 10.1007/s11606-013-2496-z
   O'Donnell AN, 2013, AM J MANAG CARE, V19, P180
   Pronk NP, 2015, ANN INTERN MED, V163, P465, DOI 10.7326/M15-1029
   Prost SG, 2015, J EVID INF SOC WORK, P1
   Radke AQ, 2010, PSYCHIAT SERV, V61, P617, DOI 10.1176/ps.2010.61.6.617
   Rosenbaum S, 2014, J CLIN PSYCHIAT, V75, P964, DOI 10.4088/JCP.13r08765
   Saha S, 2007, ARCH GEN PSYCHIAT, V64, P1123, DOI 10.1001/archpsyc.64.10.1123
   Stumbo SP, 2015, TRANSL BEHAV MED, V5, P269, DOI 10.1007/s13142-015-0322-3
   Substance Abuse and Mental Health Services Administration (SAMHSA), 2012, 2012 CMHS UN REP SYS
   Vancampfort D, 2015, ACTA PSYCHIAT SCAND, V132, P131, DOI 10.1111/acps.12407
   Wang DS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110728
NR 36
TC 21
Z9 21
U1 1
U2 21
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 1869-6716
EI 1613-9860
J9 TRANSL BEHAV MED
JI Transl. Behav. Med.
PD SEP
PY 2016
VL 6
IS 3
BP 478
EP 481
DI 10.1007/s13142-016-0407-7
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DY6TP
UT WOS:000385261500018
PM 27146275
OA Green Published
DA 2021-10-30
ER

PT J
AU Pollack, HA
   Pereyra, M
   Parish, CL
   Abel, S
   Messinger, S
   Singer, R
   Kunzel, C
   Greenberg, B
   Gerbert, B
   Glick, M
   Metsch, LR
AF Pollack, Harold A.
   Pereyra, Margaret
   Parish, Carrigan L.
   Abel, Stephen
   Messinger, Shari
   Singer, Richard
   Kunzel, Carol
   Greenberg, Barbara
   Gerbert, Barbara
   Glick, Michael
   Metsch, Lisa R.
TI Dentists' Willingness to Provide Expanded HIV Screening in Oral Health
   Care Settings: Results From a Nationally Representative Survey
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID PATIENTS ATTITUDES; MEDICAL CONDITIONS; DENTAL PRACTICES; PERSONS AWARE;
   UNITED-STATES; INFECTION; URBAN; RISK; RECOMMENDATIONS; PREVENTION
AB Objectives. Using a nationally representative survey, we determined dentists' willingness to provide oral rapid HIV screening in the oral health care setting.
   Methods. From November 2010 through November 2011, a nationally representative survey of general dentists (sampling frame obtained from American Dental Association Survey Center) examined barriers and facilitators to offering oral HIV rapid testing (n = 1802; 70.7% response). Multiple logistic regression analysis examined dentists' willingness to conduct this screening and perceived compatibility with their professional role.
   Results. Agreement with the importance of annual testing for high-risk persons and familiarity with the Centers for Disease Control and Prevention's recommendations regarding routine HIV testing were positively associated with willingness to conduct such screening. Respondents' agreement with patients' acceptance of HIV testing and colleagues' improved perception of them were also positively associated with willingness.
   Conclusions. Oral HIV rapid testing is potentially well suited to the dental setting. Although our analysis identified many predictors of dentists' willingness to offer screening, there are many barriers, including dentists' perceptions of patients' acceptance, that must be addressed before such screening is likely to be widely implemented.
C1 [Pollack, Harold A.] Univ Chicago, Sch Social Serv Adm, Chicago, IL 60637 USA.
   [Pereyra, Margaret; Singer, Richard; Metsch, Lisa R.] Univ Miami, Miller Sch Med, Dept Epidemiol & Publ Hlth, Miami, FL 33136 USA.
   [Messinger, Shari] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA.
   [Parish, Carrigan L.] Columbia Univ, Dept Sociomed Sci, Mailman Sch Publ Hlth, New York, NY USA.
   [Abel, Stephen] Nova Southestern Coll Dent Med, Ft Lauderdale, FL USA.
   [Kunzel, Carol] Columbia Univ, Coll Dent Med, Div Behav Sci, New York, NY USA.
   [Greenberg, Barbara] Univ Med & Dent New Jersey, Dept Diagnost Sci, Newark, NJ 07103 USA.
   [Greenberg, Barbara] Univ Med & Dent New Jersey, Dept Community Hlth, Newark, NJ 07103 USA.
   [Gerbert, Barbara] Univ Calif San Francisco, Ctr Hlth Improvement & Prevent Studies, San Francisco, CA 94143 USA.
   [Glick, Michael] SUNY Buffalo, Sch Dent Med, Buffalo, NY 14260 USA.
RP Pollack, HA (corresponding author), Univ Chicago, Sch Social Serv Adm, 969 East 60th St, Chicago, IL 60637 USA.
EM haroldp@uchicago.edu
FU National Institute of Dental Craniofacial ResearchUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Dental & Craniofacial Research (NIDCR)
   [R01 DE01961501]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1TR000460, UL1TR000430] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [P30AI073961] Funding Source: NIH RePORTER
FX Funding for this study and analysis was provided by the National
   Institute of Dental Craniofacial Research (cooperative agreement R01
   DE01961501).
CR Ajzen I., 1980, UNDERSTANDING ATTITU
   Blackstock OJ, 2010, AIDS PATIENT CARE ST, V24, P781, DOI 10.1089/apc.2010.0159
   Bozzette SA, 2005, NEW ENGL J MED, V352, P620, DOI 10.1056/NEJMe048347
   Branson Bernard M., 2006, Morbidity and Mortality Weekly Report, V55, P1
   Campsmith M. L., 2008, Morbidity and Mortality Weekly Report, V57, P1073
   Centers for Disease Control and Prevention, 2012, NEW HIV INFECTIONS I
   Centers for Disease Control and Prevention, 2010, HIV SURVEILLANCE SUP, V21
   Chiodo G T, 1997, Gen Dent, V45, P228
   Chiodo GT, 1997, GEN DENT, V45, p[232, 234]
   Cohen MS, 2016, NEW ENGL J MED, V375, P830, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]
   D'Aunno T, 2002, JAMA-J AM MED ASSOC, V288, P850, DOI 10.1001/jama.288.7.850
   Dietz CA, 2008, AIDS PATIENT CARE ST, V22, P205, DOI 10.1089/apc.2007.0235
   DILLMAN DA, 1991, ANNU REV SOCIOL, V17, P225, DOI 10.1146/annurev.so.17.080191.001301
   Fishbein M., 1975, BELIEF ATTITUDE INTE
   Glick M, 2005, J AM DENT ASSOC, V136, P1541, DOI 10.14219/jada.archive.2005.0084
   Greenberg BL, 2012, J PUBLIC HEALTH DENT, V72, P28, DOI 10.1111/j.1752-7325.2011.00280.x
   Greenberg BL, 2010, J AM DENT ASSOC, V141, P52, DOI 10.14219/jada.archive.2010.0021
   Holmberg SD, 2004, CLIN INFECT DIS, V39, P1699, DOI 10.1086/425743
   Hutchinson MK, 2012, BMC ORAL HEALTH, V12, DOI 10.1186/1472-6831-12-11
   Lee YH, 2009, AM J DENT, V22, P241
   Likert R., 1932, ARCH PSYCHOL, V140, P1
   Malamud D, 2006, J AM DENT ASSOC, V137, P284, DOI 10.14219/jada.archive.2006.0158
   Marks G, 2005, JAIDS-J ACQ IMM DEF, V39, P446, DOI 10.1097/01.qai.0000151079.33935.79
   Marks G, 2006, AIDS, V20, P1447, DOI 10.1097/01.aids.0000233579.79714.8d
   Nassry DD, 2012, J DENT EDUC, V76, P1150
   Office of National AIDS Policy, 2010, NATIONAL HIV AIDS ST
   Patton Lauren L, 2002, J Dent Educ, V66, P1169
   Pfaffe T, 2011, CLIN CHEM, V57, P675, DOI 10.1373/clinchem.2010.153767
   Pollack HA, 2010, AM J PUBLIC HEALTH, V100, P88, DOI 10.2105/AJPH.2008.157230
   Santella AJ, 2013, INT J DENT HYG, V11, P287, DOI 10.1111/idh.12022
   Siegel K, 2012, AM J PUBLIC HEALTH, V102, P625, DOI 10.2105/AJPH.2011.300509
   Strauss SM, 2012, AM J PUBLIC HEALTH, V102, P253, DOI 10.2105/AJPH.2011.300420
   Thompson MA, 2012, JAMA-J AM MED ASSOC, V308, P387, DOI 10.1001/jama.2012.7961
   US Dept of Health Services, 2012, HEALTHY PEOPLE 2020
   US Preventive Services Task Force, 2010, USPSTF A AND B RECOM
   US Preventive Services Task Force, 2012, SCREENING FOR HIV DR
   VanDevanter Nancy, 2012, Nurs Res Pract, V2012, P803169, DOI 10.1155/2012/803169
   Vernillo AT, 2007, J DENT EDUC, V71, P1534
NR 38
TC 25
Z9 26
U1 0
U2 9
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD MAY
PY 2014
VL 104
IS 5
BP 872
EP 880
DI 10.2105/AJPH.2013.301700
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AP0XU
UT WOS:000341790600030
PM 24625163
OA Green Published
DA 2021-10-30
ER

PT J
AU Saver, JL
   Jovin, TG
   Smith, WS
   Albers, GW
AF Saver, Jeffrey L.
   Jovin, Tudor G.
   Smith, Wade S.
   Albers, Gregory W.
CA STAIR VIII Consortium
TI Stroke Treatment Academic Industry Roundtable Research Priorities in the
   Assessment of Neurothrombectomy Devices
SO STROKE
LA English
DT Article
DE endovascular recanalization; ischemic; reperfusion; stroke
ID ACUTE ISCHEMIC-STROKE; TISSUE-PLASMINOGEN-ACTIVATOR; ENDOVASCULAR
   TREATMENT; REPERFUSION TIME; INFORMED-CONSENT; RANDOMIZED-TRIAL; POOLED
   ANALYSIS; THERAPY; THROMBECTOMY; OUTCOMES
AB Background and Purpose The goal of the Stroke Treatment Academic Industry Roundtable (STAIR) meetings is to advance the development of stroke therapies. At STAIR VIII, consensus recommendations were developed for clinical trial strategies to demonstrate the benefit of endovascular reperfusion therapies for acute ischemic stroke.
   Summary of Review Prospects for success with forthcoming endovascular trials are robust, because new neurothrombectomy devices have superior reperfusion efficacy compared with earlier-generation interventions. Specific recommendations are provided for trial designs in 3 populations: (1) patients undergoing intravenous fibrinolysis, (2) early patients ineligible for or having failed intravenous fibrinolysis, and (3) wake-up and other late-presenting patients. Among intravenous fibrinolysis-eligible patients, key principles are that CT or MRI confirmation of target arterial occlusions should precede randomization; endovascular intervention should be pursued with the greatest rapidity possible; and combined intravenous and neurothrombectomy therapy is more promising than neurothrombectomy alone. Among patients ineligible for or having failed intravenous fibrinolysis, scientific equipoise was affirmed and the need to randomize all eligible patients emphasized. Vessel imaging to confirm occlusion is mandatory, and infarct core and penumbral imaging is desirable in later time windows. Additional STAIR VIII recommendations include approaches to test multiple devices in a single trial, utility weighting of disability end points, and adaptive designs to delineate time and tissue injury thresholds at which benefits from intervention no longer accrue.
   Conclusions Endovascular research priorities in acute ischemic stroke are to perform trials testing new, highly effective neuro thrombectomy devices rapidly deployed in patients confirmed to have target vessel occlusions.
C1 [Saver, Jeffrey L.] Univ Calif Los Angeles, David Geffen Sch Med, Stroke Ctr, Los Angeles, CA 90095 USA.
   [Saver, Jeffrey L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.
   [Jovin, Tudor G.] Univ Pittsburgh, Dept Neurol, Med Ctr, Stroke Inst, Pittsburgh, PA 15260 USA.
   [Smith, Wade S.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
   [Albers, Gregory W.] Stanford Univ, Sch Med, Stroke Ctr, Stanford, CA 94305 USA.
   [Albers, Gregory W.] Stanford Univ, Sch Med, Dept Neurol, Stanford, CA 94305 USA.
RP Saver, JL (corresponding author), UCLA Stroke Ctr, 710 Westwood Plaza, Los Angeles, CA 90095 USA.
EM jsaver@mednet.ucla.edu
RI Demchuk, Andrew M/E-1103-2012; Muir, Keith W/A-7670-2011
OI Demchuk, Andrew M/0000-0002-4930-7789; Muir, Keith
   W/0000-0001-9535-022X; Wintermark, Max/0000-0002-6726-3951; Wu,
   Ona/0000-0002-5509-9461; Saver, Jeffrey/0000-0001-9141-2251; Boltze,
   Johannes/0000-0003-3956-4164; baron, jean-claude/0000-0002-5264-2588
FU University of California (UC)University of California System;
   LundbeckLundbeck Corporation; Covidien; Stroke Association [TSA2011/06]
   Funding Source: researchfish; NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [UL1TR000460] Funding Source:
   NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND
   STROKEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Neurological
   Disorders & Stroke (NINDS) [ZIANS003043, K24NS072272] Funding Source:
   NIH RePORTER
FX The University of California (UC) Regents receive funding for Dr Saver's
   services as a scientific consultant regarding trial design and conduct
   to Covidien, CoAxia, BrainsGate, Genervon, and Grifols. Dr Saver has
   served as an unpaid site investigator in multicenter trials run by
   Lundbeck and Covidien for which the UC Regents received payments on the
   basis of clinical trial contracts for the number of subjects enrolled.
   Dr Smith is a consultant to Stryker. Dr Albers has served as a
   consultant/steering committee member for Covidien, Codman, Lundbeck, and
   Genentech; was the Chair of the Data and Safety Monitoring Board for
   Thrombectomy Revascularization of Large Vessel Occlusions 2 (Concentric
   Medical); and has equity interest in iSchemaView. Dr Jovin has served as
   a consultant and has equity interest in Silk Road Medical.
CR Abou-Chebl A, 2010, STROKE, V41, P1175, DOI 10.1161/STROKEAHA.109.574129
   Albers GW, 2006, ANN NEUROL, V60, P508, DOI 10.1002/ana.20976
   Alexandrov AV, 2004, J NEUROIMAGING, V14, P113, DOI 10.1177/1051228403261462
   Almekhlafi MA, 2013, J NEUROINTERV SURG, V5, P58, DOI 10.1136/neurintsurg-2012-010486
   [Anonymous], 2009, STROKE, V40, P2761
   Bath PMW, 2012, STROKE, V43, P1171, DOI 10.1161/STROKEAHA.111.641456
   Bhatia R, 2010, STROKE, V41, P2254, DOI 10.1161/STROKEAHA.110.592535
   Broderick JP, 2013, STROKE, V44, P1215, DOI 10.1161/STROKEAHA.113.001442
   Broderick JP, 2013, NEW ENGL J MED, V368, P893, DOI 10.1056/NEJMoa1214300
   Ciccone A, 2013, NEW ENGL J MED, V368, P904, DOI 10.1056/NEJMoa1213701
   Davis SM, 2008, LANCET NEUROL, V7, P299, DOI 10.1016/S1474-4422(08)70044-9
   DELZOPPO GJ, 1992, ANN NEUROL, V32, P78, DOI 10.1002/ana.410320113
   Enama ME, 2012, CONTEMP CLIN TRIALS, V33, P895, DOI 10.1016/j.cct.2012.04.005
   Furlan A, 1999, JAMA-J AM MED ASSOC, V282, P2003, DOI 10.1001/jama.282.21.2003
   Hong KS, 2009, STROKE, V40, P3828, DOI 10.1161/STROKEAHA.109.561365
   Inoue M, 2012, STROKE, V43, P2494, DOI 10.1161/STROKEAHA.112.653329
   Jumaa MA, 2010, STROKE, V41, P1180, DOI 10.1161/STROKEAHA.109.574194
   Kairalla JA, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-145
   Kamalian S, 2011, STROKE, V42, P1923, DOI 10.1161/STROKEAHA.110.610618
   Kasner SE, 2011, ANN EMERG MED, V57, P346, DOI 10.1016/j.annemergmed.2010.07.009
   Kidwell CS, 2013, NEW ENGL J MED, V368, P914, DOI 10.1056/NEJMoa1212793
   Lansberg MG, 2012, LANCET NEUROL, V11, P860, DOI 10.1016/S1474-4422(12)70203-X
   Lee M, 2010, STROKE, V41, P932, DOI 10.1161/STROKEAHA.109.574335
   Lees KR, 2010, LANCET, V375, P1695, DOI 10.1016/S0140-6736(10)60491-6
   Lyden PD, 2010, ANN NEUROL, V67, P434, DOI 10.1002/ana.21997
   Mazighi M, 2013, CIRCULATION, V127, P1980, DOI 10.1161/CIRCULATIONAHA.112.000311
   Menon BK, 2011, INTERV NEURORADIOL, V17, P296, DOI 10.1177/159101991101700303
   Nogueira RG, 2012, LANCET, V380, P1231, DOI 10.1016/S0140-6736(12)61299-9
   Pulli B, 2012, RADIOLOGY, V262, P593, DOI 10.1148/radiol.11110896
   Riedel CH, 2011, STROKE, V42, P1775, DOI 10.1161/STROKEAHA.110.609693
   Rivero-Arias O, 2010, MED DECIS MAKING, V30, P341, DOI 10.1177/0272989X09349961
   Sanossian N, 2008, STROKE, V39, P708
   Saver JL, 2011, J THROMB HAEMOST, V9, P333, DOI 10.1111/j.1538-7836.2011.04371.x
   Saver JL, 2013, JAMA-J AM MED ASSOC, V309, P2480, DOI 10.1001/jama.2013.6959
   Saver JL, 2012, LANCET, V380, P1241, DOI 10.1016/S0140-6736(12)61384-1
   Saver JL, 2006, STROKE, V37, P263, DOI 10.1161/01.STR.0000196957.55928.ab
   Shi ZS, 2010, STROKE, V41, P1185, DOI 10.1161/STROKEAHA.109.568451
   Wason J., 2012, STAT METHODS MED RES
NR 38
TC 19
Z9 20
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0039-2499
EI 1524-4628
J9 STROKE
JI Stroke
PD DEC
PY 2013
VL 44
IS 12
BP 3596
EP 3601
DI 10.1161/STROKEAHA.113.002769
PG 6
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 257LR
UT WOS:000327386300346
PM 24193797
OA Green Accepted, Bronze
DA 2021-10-30
ER

PT J
AU Pande, A
   Li, L
   Rajeswaran, J
   Ehrlinger, J
   Kogalur, UB
   Blackstone, EH
   Ishwaran, H
AF Pande, Amol
   Li, Liang
   Rajeswaran, Jeevanantham
   Ehrlinger, John
   Kogalur, Udaya B.
   Blackstone, Eugene H.
   Ishwaran, Hemant
TI Boosted multivariate trees for longitudinal data
SO MACHINE LEARNING
LA English
DT Article
DE Gradient boosting; Marginal model; Multivariate regression tree;
   P-splines; Smoothing parameter
ID MIXED MODELS; SELECTION
AB Machine learning methods provide a powerful approach for analyzing longitudinal data in which repeated measurements are observed for a subject over time. We boost multivariate trees to fit a novel flexible semi-nonparametric marginal model for longitudinal data. In this model, features are assumed to be nonparametric, while feature-time interactions are modeled semi-nonparametrically utilizing P-splines with estimated smoothing parameter. In order to avoid overfitting, we describe a relatively simple in sample cross-validation method which can be used to estimate the optimal boosting iteration and which has the surprising added benefit of stabilizing certain parameter estimates. Our new multivariate tree boosting method is shown to be highly flexible, robust to covariance misspecification and unbalanced designs, and resistant to overfitting in high dimensions. Feature selection can be used to identify important features and feature-time interactions. An application to longitudinal data of forced 1-second lung expiratory volume (FEV1) for lung transplant patients identifies an important feature-time interaction and illustrates the ease with which our method can find complex relationships in longitudinal data.
C1 [Pande, Amol; Ishwaran, Hemant] Univ Miami, Div Biostat, Miami, FL 33146 USA.
   [Li, Liang] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   [Rajeswaran, Jeevanantham; Ehrlinger, John; Kogalur, Udaya B.] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44106 USA.
   [Blackstone, Eugene H.] Cleveland Clin, Dept Heart & Vasc Inst, Cleveland, OH 44106 USA.
RP Ishwaran, H (corresponding author), Univ Miami, Div Biostat, Miami, FL 33146 USA.
EM hemant.ishwaran@gmail.com
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01CA16373,
   RO1HL103552]; NATIONAL CANCER INSTITUTEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Cancer Institute (NCI) [R01CA163739, P30CA016672] Funding
   Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1TR000460] Funding Source: NIH
   RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL103552]
   Funding Source: NIH RePORTER
FX This work was supported by the National Institutes of Health (R01CA16373
   to H.I. and U.B.K., RO1HL103552 to H.I., J.R., J.E., U.B.K. and E.H.B).
CR Breiman L., 1984, CLASSIFICATION REGRE
   De Boor C., 1978, PRACTICAL GUIDE SPLI
   Diggle P., 2002, ANAL LONGITUDINAL DA
   Duchon J., 1977, CONSTRUCTIVE THEORY, P85, DOI [10.1007/BFb0086566, DOI 10.1007/BFB0086566]
   Eilers PHC, 1996, STAT SCI, V11, P89, DOI 10.1214/ss/1038425655
   Friedman JH, 2001, ANN STAT, V29, P1189, DOI 10.1214/aos/1013203451
   Friedman JH, 2002, COMPUT STAT DATA AN, V38, P367, DOI 10.1016/S0167-9473(01)00065-2
   Groll A, 2012, METHOD INFORM MED, V51, P168, DOI 10.3414/ME11-02-0021
   Hastie T. J., 1990, GEN ADDITIVE MODELS, V43
   Hoover DR, 1998, BIOMETRIKA, V85, P809, DOI 10.1093/biomet/85.4.809
   Hothorn T., 2016, MBOOST MODEL BASED B, P32
   Hothorn T, 2006, J COMPUT GRAPH STAT, V15, P651, DOI 10.1198/106186006X133933
   Hothorn T, 2010, J MACH LEARN RES, V11, P2109
   Ishwaran H., 2016, BOOSTMTREE BOOSTED M
   Ishwaran H., 2016, RANDOM FORESTS FORSU
   Loh WY, 1997, STAT SINICA, V7, P815
   MALLAT SG, 1993, IEEE T SIGNAL PROCES, V41, P3397, DOI 10.1109/78.258082
   Mason DP, 2012, J THORAC CARDIOV SUR, V144, P197, DOI 10.1016/j.jtcvs.2012.03.028
   Mayr A, 2012, METHOD INFORM MED, V51, P178, DOI 10.3414/ME11-02-0030
   Mayr A, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-6
   Pan W, 2001, BIOMETRICS, V57, P120, DOI 10.1111/j.0006-341X.2001.00120.x
   Pinheiro J., 2014, R PACKAGE VERSION, V3, P1, DOI DOI 10.1007/S00338-010-0593-6
   Pinheiro JC, 2000, MIXED EFFECTS MODELS
   Robinson G. K., 1991, STAT SCI, V6, P15, DOI DOI 10.1214/SS/1177011926
   Ruppert D., 2003, SEMIPARAMETRIC REGRE, V12
   Schapire R., 1996, P ICML, V13, P148
   Sela RJ, 2012, MACH LEARN, V86, P169, DOI 10.1007/s10994-011-5258-3
   Tutz G, 2007, STAT MED, V26, P2872, DOI 10.1002/sim.2738
   Tutz G, 2006, BIOMETRICS, V62, P961, DOI 10.1111/j.1541-0420.2006.00578.x
   Wahba Grace, 1990, SPLINE MODELS OBSERV, V59
NR 30
TC 5
Z9 5
U1 1
U2 7
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0885-6125
EI 1573-0565
J9 MACH LEARN
JI Mach. Learn.
PD FEB
PY 2017
VL 106
IS 2
BP 277
EP 305
DI 10.1007/s10994-016-5597-1
PG 29
WC Computer Science, Artificial Intelligence
SC Computer Science
GA EL1BR
UT WOS:000394356000004
PM 29249866
OA Bronze, Green Accepted
DA 2021-10-30
ER

PT J
AU Schwartz, SJ
   Unger, JB
   Baezconde-Garbanati, L
   Benet-Martinez, V
   Meca, A
   Zamboanga, BL
   Lorenzo-Blanco, EI
   Rosiers, SED
   Oshri, A
   Sabet, RF
   Soto, DW
   Pattarroyo, M
   Huang, S
   Villamar, JA
   Lizzi, KM
   Szapocznik, J
AF Schwartz, Seth J.
   Unger, Jennifer B.
   Baezconde-Garbanati, Lourdes
   Benet-Martinez, Veronica
   Meca, Alan
   Zamboanga, Byron L.
   Lorenzo-Blanco, Elma I.
   Rosiers, Sabrina E. Des
   Oshri, Assaf
   Sabet, Raha F.
   Soto, Daniel W.
   Pattarroyo, Monica
   Huang, Shi
   Villamar, Juan A.
   Lizzi, Karina M.
   Szapocznik, Jose
TI Longitudinal trajectories of bicultural identity integration in recently
   immigrated Hispanic adolescents: Links with mental health and family
   functioning
SO INTERNATIONAL JOURNAL OF PSYCHOLOGY
LA English
DT Article
DE Biculturalism; Acculturation; Hispanic; Identity; Mental health; Family
   functioning
ID ETHNIC-IDENTITY; ACCULTURATION; ADJUSTMENT; BEHAVIOR
AB This study examined, in a sample of recently immigrated Hispanic adolescents in Miami and Los Angeles, the extent to which bicultural identity integration (BII; involving the ability to synthesise one's heritage and receiving cultural streams and to identify as a member of both cultures) is best understood as a developmental construct that changes over time or as an individual-difference construct that is largely stable over time. We were also interested in the extent to which these trajectories predicted mental health and family functioning. Recent-immigrant 9th graders (N = 302) were assessed 6 times from 9th to 12th grade. Latent class growth analyses using the first 5 timepoints identified 2 trajectory classes-one with lower BII scores over time and another with higher BII scores over time. Higher heritage and US identity at baseline predicted membership in the higher BII class. At the 6th study timepoint, lower BII adolescents reported significantly poorer self-esteem, optimism, prosocial behaviour and family relationships compared with their higher BII counterparts. These findings are discussed in terms of further research on the over-time trajectory of biculturalism, and on the need to develop interventions to promote BII as a way of facilitating well-being and positive family functioning.
C1 [Schwartz, Seth J.; Meca, Alan; Sabet, Raha F.; Huang, Shi; Lizzi, Karina M.; Szapocznik, Jose] Univ Miami, Dept Publ Hlth Sci, Miami, FL USA.
   [Unger, Jennifer B.; Baezconde-Garbanati, Lourdes; Soto, Daniel W.; Pattarroyo, Monica] Univ So Calif, Dept Prevent Med, Los Angeles, CA 90089 USA.
   [Benet-Martinez, Veronica] Univ Pompeu Fabra, Inst Catalana Recerca & Estudis Avancats, Dept Polit & Social Sci, Barcelona, Spain.
   [Zamboanga, Byron L.] Smith Coll, Dept Psychol, Northampton, MA 01063 USA.
   [Lorenzo-Blanco, Elma I.] Univ S Carolina, Dept Psychol, Columbia, SC 29208 USA.
   [Rosiers, Sabrina E. Des] Barry Univ, Dept Psychol, Miami Shores, FL USA.
   [Oshri, Assaf] Univ Georgia, Dept Human Dev & Family Sci, Athens, GA 30602 USA.
   [Villamar, Juan A.] Northwestern Univ, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA.
RP Schwartz, SJ (corresponding author), Univ Miami, Dept Publ Hlth Sci, Miami, FL USA.
EM SSchwartz@med.miami.edu
RI Benet-Martinez, Veronica/AAS-8624-2020; Benet-Martinez,
   Veronica/B-5398-2011; Meca, Alan/S-6317-2016
OI Benet-Martinez, Veronica/0000-0002-3352-9731; Benet-Martinez,
   Veronica/0000-0002-3352-9731; Meca, Alan/0000-0002-3272-7701; Unger,
   Jennifer/0000-0001-9064-6603
FU National Institute on Drug AbuseUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute on Drug Abuse (NIDA)European Commission [DA026594]; National
   Institute on Alcohol Abuse and AlcoholismUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Alcohol Abuse & Alcoholism (NIAAA) [AA021888];
   National Center for Advancing Translational SciencesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [1UL1TR000460]; EUEuropean Commission; NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [UL1TR000460] Funding Source:
   NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism
   (NIAAA) [R01AA021888] Funding Source: NIH RePORTER; NATIONAL INSTITUTE
   ON DRUG ABUSEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Drug Abuse
   (NIDA)European Commission [R01DA025694] Funding Source: NIH RePORTER;
   ICREAICREA Funding Source: Custom
FX Preparation of this article was supported by Grants DA026594 from the
   National Institute on Drug Abuse and AA021888 from the National
   Institute on Alcohol Abuse and Alcoholism to Seth J. Schwartz, by
   National Center for Advancing Translational Sciences Grant 1UL1TR000460
   to Jose Szapocznik and by a EU FP7-PEOPLE-2011 grant to Veronica
   Benet-Martinez. We thank Maria-Rosa Velazquez, Tatiana Clavijo, Mercedes
   Prado, Alba Alfonso, Aleyda Marcos, Daisy Ramirez, Lissette Ramirez and
   Perlita Carrillo for their hardwork in conducting assessments and
   tracking families; Dr. Judy Arroyo for her guidance and wisdom and the
   study families for sharing their experiences with us.
CR Bandeen-Roche K, 1997, J AM STAT ASSOC, V92, P1375, DOI 10.2307/2965407
   BARNES HL, 1985, CHILD DEV, V56, P438, DOI 10.1111/j.1467-8624.1985.tb00118.x
   Benet-Martinez V, 2005, J PERS, V73, P1015, DOI 10.1111/j.1467-6494.2005.00337.x
   Benet-Martinez V, 2002, J CROSS CULT PSYCHOL, V33, P492, DOI 10.1177/0022022102033005005
   Carlo G, 2002, J YOUTH ADOLESCENCE, V31, P31, DOI 10.1023/A:1014033032440
   Chen SX, 2008, J PERS, V76, P803, DOI 10.1111/j.1467-6494.2008.00505.x
   Cheng CY, 2013, J CROSS CULT PSYCHOL, V44, P1235, DOI 10.1177/0022022113490071
   Cheung BY, 2011, PSYCHOL SCI, V22, P147, DOI 10.1177/0956797610394661
   Edwards LM, 2007, HISPANIC J BEHAV SCI, V29, P225, DOI 10.1177/0739986307299692
   Ennis S. R., 2011, HISPANIC POPULATION
   Erikson E., 1950, CHILDHOOD SOC
   Fry R., 2009, LATINO CHILDREN MAJO
   Geiser C., 2013, DATA ANAL MPLUS
   GormanSmith D, 1996, J FAM PSYCHOL, V10, P115, DOI 10.1037/0893-3200.10.2.115
   Hofstede G., 2001, CULTURES CONSEQUENCE, V2nd
   Light I., 2006, DEFLECTING IMMIGRATI
   Little T., 2013, LONGITUDINAL STRUCTU
   Muthen LK, 2010, MPLUS USERS GUIDE VE
   Nagin D. S., 2005, GROUP BASED MODELING
   Nguyen AMD, 2013, J CROSS CULT PSYCHOL, V44, P122, DOI 10.1177/0022022111435097
   Nylund KL, 2007, STRUCT EQU MODELING, V14, P535, DOI 10.1080/10705510701575396
   Phinney JS, 2007, J COUNS PSYCHOL, V54, P271, DOI 10.1037/0022-0167.54.3.271
   Roberts RE, 1999, J EARLY ADOLESCENCE, V19, P301, DOI 10.1177/0272431699019003001
   Sam DL, 2010, PERSPECT PSYCHOL SCI, V5, P472, DOI 10.1177/1745691610373075
   Schwartz SJ, 2014, PREV SCI, V15, P385, DOI 10.1007/s11121-013-0419-1
   Schwartz SJ, 2012, IDENTITY, V12, P93, DOI 10.1080/15283488.2012.668730
   Schwartz SJ, 2011, J YOUTH ADOLESCENCE, V40, P839, DOI 10.1007/s10964-010-9606-6
   Schwartz SJ, 2010, AM PSYCHOL, V65, P237, DOI 10.1037/a0019330
   Schwartz SJ, 2005, J ADOLESCENT RES, V20, P293, DOI 10.1177/0743558405274890
   Smokowski P. R., 2011, BECOMING BICULTURAL
   Stepick A, 2003, THIS LAND IS OUR LAND: IMMIGRANTS AND POWER IN MIAMI, P1
   Syed M, 2013, EMERG ADULTHOOD, V1, P83, DOI 10.1177/2167696813480503
   Tolan PH, 1997, PSYCHOL ASSESSMENT, V9, P212, DOI 10.1037/1040-3590.9.3.212
   Triandis H.C., 2018, INDIVIDUALISM COLLEC
   Walters N., 2011, NEWLY ARRIVED FOREIG
NR 35
TC 49
Z9 50
U1 3
U2 20
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 0020-7594
EI 1464-066X
J9 INT J PSYCHOL
JI Int. J. Psychol.
PD DEC
PY 2015
VL 50
IS 6
BP 440
EP 450
DI 10.1002/ijop.12196
PG 11
WC Psychology, Multidisciplinary
SC Psychology
GA DD3UI
UT WOS:000369848100005
PM 26212218
DA 2021-10-30
ER

PT J
AU Thomas, JM
   Pos, Z
   Reinboth, J
   Wang, RY
   Wang, E
   Frank, GM
   Lusso, P
   Trinchieri, G
   Alter, HJ
   Marincola, FM
   Thomas, E
AF Thomas, Jaime M.
   Pos, Zoltan
   Reinboth, Jennifer
   Wang, Richard Y.
   Wang, Ena
   Frank, Gregory M.
   Lusso, Paolo
   Trinchieri, Giorgio
   Alter, Harvey J.
   Marincola, Francesco M.
   Thomas, Emmanuel
TI Differential Responses of Plasmacytoid Dendritic Cells to Influenza
   Virus and Distinct Viral Pathogens
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID INNATE IMMUNE-RESPONSE; INFECTION; INTERFERONS; TRAFFICKING;
   RECOGNITION; IMPACT
AB Plasmacytoid dendritic cells (pDCs) are key components of the innate immune response that are capable of synthesizing and rapidly releasing vast amounts of type I interferons (IFNs), particularly IFN-alpha. Here we investigated whether pDCs, often regarded as a mere source of IFN, discriminate between various functionally discrete stimuli and to what extent this reflects differences in pDC responses other than IFN-alpha release. To examine the ability of pDCs to differentially respond to various doses of intact and infectious HIV, hepatitis C virus, and H1N1 influenza virus, whole-genome gene expression analysis, enzyme-linked immunosorbent assays, and flow cytometry were used to investigate pDC responses at the transcriptional, protein, and cellular levels. Our data demonstrate that pDCs respond differentially to various viral stimuli with significant changes in gene expression, including those involved in pDC activation, migration, viral endocytosis, survival, or apoptosis. In some cases, the expression of these genes was induced even at levels comparable to that of IFN-alpha. Interestingly, we also found that depending on the viral entity and the viral titer used for stimulation, induction of IFN-alpha gene expression and the actual release of IFN-alpha are not necessarily temporally coordinated. In addition, our data suggest that high-titer influenza A (H1N1) virus infection can stimulate rapid pDC apoptosis.
   IMPORTANCE
   Plasmacytoid dendritic cells (pDCs) are key players in the viral immune response. With the host response to viral infection being dependent on specific virus characteristics, a thorough examination and comparison of pDC responses to various viruses at various titers is beneficial for the field of virology. Our study illustrates that pDC infection with influenza virus, HIV, or hepatitis C virus results in a unique and differential response to each virus. These results have implications for future virology research, vaccine development, and virology as a whole.
C1 [Thomas, Jaime M.; Pos, Zoltan; Reinboth, Jennifer; Wang, Richard Y.; Wang, Ena; Alter, Harvey J.; Marincola, Francesco M.] NIH, Infect Dis & Immunogenet Sect, Dept Transfus Med, CC, Bethesda, MD 20892 USA.
   [Thomas, Jaime M.; Pos, Zoltan; Reinboth, Jennifer; Wang, Richard Y.; Wang, Ena; Alter, Harvey J.; Marincola, Francesco M.] NIH, Trans NIH Ctr Human Immunol CHI, Bethesda, MD 20892 USA.
   [Pos, Zoltan] MTA Semmelweis Univ, Lendulet Expt & Translat Immun Res Grp, Budapest, Hungary.
   [Frank, Gregory M.] NIAID, Viral Dis Lab, Bethesda, MD 20892 USA.
   [Lusso, Paolo] NIAID, Immunoregulat Lab, Immunopathogenesis Sect, NIH, Bethesda, MD 20892 USA.
   [Trinchieri, Giorgio] Frederick Natl Lab, Canc Immunobiol Sect, Expt Immunol Lab, Frederick, MD USA.
   [Wang, Ena; Marincola, Francesco M.] Sidra Med & Res Ctr, Doha, Qatar.
   [Thomas, Emmanuel] Univ Miami, Miller Sch Med, Schiff Ctr Liver Dis, Sylvester Comprehens Canc Ctr,Dept Cell Biol, Miami, FL 33136 USA.
RP Marincola, FM (corresponding author), Sidra Med & Res Ctr, Doha, Qatar.
EM fmarincola@sidra.org; ethomas1@med.miami.edu
RI Buonaguro, Franco M./T-6028-2019; Trinchieri, Giorgio/F-9369-2015; Pos,
   Zoltan/C-3623-2014
OI Buonaguro, Franco M./0000-0002-7491-7220; Trinchieri,
   Giorgio/0000-0001-5892-7464; Pos, Zoltan/0000-0002-2574-7616
FU NIH intramural research programUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA; Miami Center
   for AIDS Research (CFAR) at the University of Miami Miller School of
   Medicine - an NIH grant [P30AI073961]; NATIONAL CANCER INSTITUTEUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Cancer Institute (NCI) [ZIABC011153]
   Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [KL2TR000461] Funding Source:
   NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [ZIAAI001041, ZIAAI000976, P30AI073961]
   Funding Source: NIH RePORTER; CLINICAL CENTER [ZIACL002068, ZIACL002121]
   Funding Source: NIH RePORTER
FX This work was completed through funds from the NIH intramural research
   program. E.T. acknowledges support from the Miami Center for AIDS
   Research (CFAR) at the University of Miami Miller School of Medicine
   funded by an NIH grant (P30AI073961).
CR Benito M, 2004, BIOINFORMATICS, V20, P105, DOI 10.1093/bioinformatics/btg385
   Borden EC, 2007, NAT REV DRUG DISCOV, V6, P975, DOI 10.1038/nrd2422
   Chung E, 2005, CLIN DIAGN LAB IMMUN, V12, P426, DOI 10.1128/CDLI.12.3.426-435.2005
   Darnell JE, 1998, J INTERF CYTOK RES, V18, P549, DOI 10.1089/jir.1998.18.549
   Gale M, 2009, J INTERF CYTOK RES, V29, P475, DOI 10.1089/jir.2009.0078
   Gibbs JS, 2003, J VIROL, V77, P7214, DOI 10.1128/JVI.77.13.7214-7224.2003
   Kawai T, 2009, INT IMMUNOL, V21, P317, DOI 10.1093/intimm/dxp017
   Kumar H, 2009, BIOCHEM J, V420, P1, DOI 10.1042/BJ20090272
   Lo CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037052
   Lui G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007111
   Newton K, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a006049
   Reizis B, 2011, ANNU REV IMMUNOL, V29, P163, DOI 10.1146/annurev-immunol-031210-101345
   Rosenberg YJ, 1998, IMMUNOL TODAY, V19, P10, DOI 10.1016/S0167-5699(97)01183-3
   Salazar-Mather TP, 2003, VIRAL IMMUNOL, V16, P291, DOI 10.1089/088282403322396109
   Sanders CJ, 2011, CELL TISSUE RES, V343, P13, DOI 10.1007/s00441-010-1043-z
   Simon R, 2007, CANCER INFORM, V3, P11
   Swiecki M, 2011, CURR OPIN VIROL, V1, P463, DOI 10.1016/j.coviro.2011.10.026
   Swiecki M, 2011, J EXP MED, V208, P2367, DOI 10.1084/jem.20110654
   Swiecki M, 2010, IMMUNITY, V33, P955, DOI 10.1016/j.immuni.2010.11.020
   Swiecki M, 2010, IMMUNOL REV, V234, P142, DOI 10.1111/j.0105-2896.2009.00881.x
   Szabo G, 2008, CRIT REV IMMUNOL, V28, P61, DOI 10.1615/CritRevImmunol.v28.i1.40
   Takahashi K, 2010, P NATL ACAD SCI USA, V107, P7431, DOI 10.1073/pnas.1002301107
   Thomas E, 2012, GASTROENTEROLOGY, V142, P978, DOI 10.1053/j.gastro.2011.12.055
   Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11
   Troyanskaya O, 2001, BIOINFORMATICS, V17, P520, DOI 10.1093/bioinformatics/17.6.520
   Virgin HW, 2009, CELL, V138, P30, DOI 10.1016/j.cell.2009.06.036
   Wang YM, 2012, CELL HOST MICROBE, V11, P631, DOI 10.1016/j.chom.2012.05.003
   Wilkin TJ, 2007, CLIN INFECT DIS, V44, P591, DOI 10.1086/511035
   Wolf AI, 2009, J IMMUNOL, V182, P871, DOI 10.4049/jimmunol.182.2.871
   Zhang Z, 2005, CELL MOL IMMUNOL, V2, P411
NR 30
TC 18
Z9 19
U1 0
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD SEP
PY 2014
VL 88
IS 18
BP 10758
EP 10766
DI 10.1128/JVI.01501-14
PG 9
WC Virology
SC Virology
GA AO3MQ
UT WOS:000341234900043
PM 25008918
OA Green Published, Green Accepted, Bronze
DA 2021-10-30
ER

PT J
AU Swift, SL
   Glymour, MM
   Elfassy, T
   Lewis, C
   Kiefe, CI
   Sidney, S
   Calonico, S
   Feaster, D
   Bailey, Z
   Al Hazzouri, AZ
AF Swift, Samuel L.
   Glymour, M. Maria
   Elfassy, Tali
   Lewis, Cora
   Kiefe, Catarina I.
   Sidney, Stephen
   Calonico, Sebastian
   Feaster, Daniel
   Bailey, Zinzi
   Al Hazzouri, Adina Zeki
TI Racial discrimination in medical care settings and opioid pain reliever
   misuse in a US cohort: 1992 to 2015
SO PLOS ONE
LA English
DT Article
ID SELF-REPORTED EXPERIENCES; SUBSTANCE USE DISORDERS; PERCEIVED
   DISCRIMINATION; MEDIATION ANALYSIS; AFRICAN-AMERICANS; HEALTH; BLACK;
   CRISIS; TRENDS; CARDIA
AB Background
   In the United States whites are more likely to misuse opioid pain relievers (OPRs) than blacks, and blacks are less likely to be prescribed OPRs than whites. Our objective is to determine whether racial discrimination in medical settings is protective for blacks against OPR misuse, thus mediating the black-white disparities in OPR misuse.
   Methods
   We used data from 3528 black and white adults in the Coronary Artery Risk Development in Young Adults (CARDIA) study, an ongoing multi-site cohort. We employ causal mediation methods, with race (black vs white) as the exposure, lifetime discrimination in medical settings prior to year 2000 as the mediator, and OPR misuse after 2000 as the outcome.
   Results
   We found black participants were more likely to report discrimination in a medical setting (20.3% vs 0.9%) and less likely to report OPR misuse (5.8% vs 8.0%, OR = 0.71, 95% CI = 0.55, 0.93, adjusted for covariates). Our mediation models suggest that when everyone is not discriminated against, the disparity is wider with black persons having even lower odds of reporting OPR misuse (OR = 0.63, 95% CI = 0.45, 0.89) compared to their white counterparts, suggesting racial discrimination in medical settings is a risk factor for OPR misuse rather than protective.
   Conclusions
   These results suggest that racial discrimination in a medical setting is a risk factor for OPR misuse rather than being protective, and thus could not explain the seen black-white disparity in OPR misuse.
C1 [Swift, Samuel L.] Univ New Mexico, Sch Med, Ctr Hlth Equ Kidney Dis, Albuquerque, NM 87131 USA.
   [Glymour, M. Maria] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA USA.
   [Elfassy, Tali] Univ Miami, Div Epidemiol, Dept Publ Hlth Sci, Miami, FL USA.
   [Lewis, Cora] Univ Alabama, Dept Med, Div Preventat Med, Tuscaloosa, AL USA.
   [Kiefe, Catarina I.] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Boston, MA 02125 USA.
   [Sidney, Stephen] Kaiser Permanente Northern Calif, Div Res, Oakland, CA USA.
   [Calonico, Sebastian] Columbia Univ, Dept Hlth Policy & Management, New York, NY USA.
   [Feaster, Daniel] Univ Miami, Div Biostat, Dept Publ Hlth Sci, Miami, FL USA.
   [Bailey, Zinzi] Univ Miami, Jay Weiss Inst Hlth Equ, Sylvester Comprehens Canc Ctr, Miami, FL USA.
   [Al Hazzouri, Adina Zeki] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY USA.
RP Swift, SL (corresponding author), Univ New Mexico, Sch Med, Ctr Hlth Equ Kidney Dis, Albuquerque, NM 87131 USA.
EM samswift@salud.unm.edu
OI Swift, Samuel/0000-0001-5858-8247
FU National Heart, Lung, and Blood InstituteUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [HHSN268201300025C,
   HHSN268201300026C, HHSN268201300027C, HHSN268201300028C,
   HHSN268201300029C, HHSN268200900041C]; Intramural Research Program of
   the National Institute on AgingUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute on Aging (NIA); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [KL2TR002737] Funding Source: NIH
   RePORTER
FX The Coronary Artery Risk Development in Young Adults Study (CARDIA) is
   supported by contracts HHSN268201300025C, HHSN268201300026C,
   HHSN268201300027C, HHSN268201300028C, HHSN268201300029C, and
   HHSN268200900041C from the National Heart, Lung, and Blood Institute and
   the Intramural Research Program of the National Institute on Aging.
CR Alexander MJ, 2018, EPIDEMIOLOGY, V29, P707, DOI [10.1097/EDE.0000000000000858, 10.1097/ede.0000000000000858]
   [Anonymous], 2002, SAS SOFTW VERS 9 4
   Borrell LN, 2007, AM J EPIDEMIOL, V166, P1068, DOI 10.1093/aje/kwm180
   Case A, 2015, P NATL ACAD SCI USA, V112, P15078, DOI 10.1073/pnas.1518393112
   Centers for Disease Control and Prevention NCfHS, 2017, UND CAUS DEATH 1999
   Chavez LJ, 2015, AM J PREV MED, V48, P42, DOI 10.1016/j.amepre.2014.08.013
   Clark TT, 2015, ADDICT BEHAV, V40, P119, DOI 10.1016/j.addbeh.2014.08.006
   Cunningham TJ, 2013, J BIOSOC SCI, V45, P267, DOI 10.1017/S0021932012000429
   FRIEDMAN GD, 1988, J CLIN EPIDEMIOL, V41, P1105, DOI 10.1016/0895-4356(88)90080-7
   Hausmann LRM, 2008, J GEN INTERN MED, V23, P1679, DOI 10.1007/s11606-008-0730-x
   James K, 2018, J LAW MED ETHICS, V46, P404, DOI 10.1177/1073110518782949
   Kolodny A, 2015, ANNU REV PUBL HEALTH, V36, P559, DOI 10.1146/annurev-publhealth-031914-122957
   Krieger N, 2005, SOC SCI MED, V61, P1576, DOI 10.1016/j.socscimed.2005.03.006
   Krieger N, 2010, AM J PUBLIC HEALTH, V100, pS132, DOI 10.2105/AJPH.2009.181628
   Landrine H., 1996, J BLACK PSYCHOL, V22, P144, DOI [10.1177/00957984960222002, DOI 10.1177/00957984960222002]
   Lyapustina T, 2017, PAIN PRACT, V17, P1097, DOI 10.1111/papr.12568
   Martin JK, 2003, J HEALTH SOC BEHAV, V44, P408, DOI 10.2307/1519787
   McCabe SE, 2010, AM J PUBLIC HEALTH, V100, P1946, DOI 10.2105/AJPH.2009.163147
   McLaughlin KA, 2010, AM J PUBLIC HEALTH, V100, P1477, DOI 10.2105/AJPH.2009.181586
   Mossey JM, 2011, CLIN ORTHOP RELAT R, V469, P1859, DOI 10.1007/s11999-011-1770-9
   Mouton CP, 2010, J HEALTH CARE POOR U, V21, P287, DOI 10.1353/hpu.0.0273
   Mustillo S, 2004, AM J PUBLIC HEALTH, V94, P2125, DOI 10.2105/AJPH.94.12.2125
   Nandi A, 2012, EPIDEMIOLOGY, V23, P223, DOI 10.1097/EDE.0b013e31824570bd
   Nelson A, 2002, J NATL MED ASSOC, V94, P666
   (NIDA) NIoDA, 2016, MIS PRESCR DRUGS
   Pascoe EA, 2009, PSYCHOL BULL, V135, P531, DOI 10.1037/a0016059
   Pletcher MJ, 2008, JAMA-J AM MED ASSOC, V299, P70, DOI 10.1001/jama.2007.64
   RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306
   Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1
   Schulman KA, 1999, NEW ENGL J MED, V340, P618, DOI 10.1056/NEJM199902253400806
   Shiels MS, 2018, ANN INTERN MED, V168, P453, DOI 10.7326/M17-1812
   Unick GJ, 2017, INT J DRUG POLICY, V46, P112, DOI 10.1016/j.drugpo.2017.06.003
   Valeri L, 2013, PSYCHOL METHODS, V18, P137, DOI 10.1037/a0031034
   VanderWeele TJ, 2010, AM J EPIDEMIOL, V172, P1339, DOI 10.1093/aje/kwq332
   Womack VY, 2014, AM J HEALTH BEHAV, V38, P641, DOI 10.5993/AJHB.38.5.1
NR 35
TC 3
Z9 3
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 20
PY 2019
VL 14
IS 12
AR e0226490
DI 10.1371/journal.pone.0226490
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA LP3ZM
UT WOS:000534257500017
PM 31860661
OA Green Published, gold
DA 2021-10-30
ER

PT J
AU Rao, JS
   Liu, HM
AF Rao, J. Sunil
   Liu, Hongmei
TI Discordancy Partitioning for Validating Potentially Inconsistent
   Pharmacogenomic Studies
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ANTICANCER DRUG-SENSITIVITY; IN-VITRO RESPONSE; CANCER-CELLS;
   ELASTIC-NET; REGRESSION; SELECTION; NUMBER; LASSO
AB The Genomics of Drug Sensitivity in Cancer (GDSC) and Cancer Cell Line Encyclopedia (CCLE) are two major studies that can be used to mine for therapeutic biomarkers for cancers of a large variety. Model validation using the two datasets however has proved challenging. Both predictions and signatures do not consistently validate well for models built on one dataset and tested on the other. While the genomic profiling seems consistent, the drug response data is not. Some efforts at harmonizing experimental designs has helped but not entirely removed model validation difficulties. In this paper, we present a partitioning strategy based on a data sharing concept which directly acknowledges a potential lack of concordance between datasets and in doing so, also allows for extraction of reproducible novel gene-drug interaction signatures as well as accurate test set predictions. We demonstrate these properties in a re-analysis of the GDSC and CCLE datasets.
C1 [Rao, J. Sunil; Liu, Hongmei] Univ Miami, Div Biostat, Dept Publ Hlth Sci, Coral Gables, FL 33124 USA.
   [Rao, J. Sunil] Univ Miami, Sylvester Comprehens Canc Ctr, Coral Gables, FL 33124 USA.
RP Rao, JS (corresponding author), Univ Miami, Div Biostat, Dept Publ Hlth Sci, Coral Gables, FL 33124 USA.; Rao, JS (corresponding author), Univ Miami, Sylvester Comprehens Canc Ctr, Coral Gables, FL 33124 USA.
EM jrao@miami.edu
FU NSFNational Science Foundation (NSF) [DMS 1513266]; Sylvester
   Comprehensive Cancer Center at the University of Miami;  [R01
   CA160593A1]; NATIONAL CANCER INSTITUTEUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Cancer Institute (NCI) [R01CA160593] Funding Source: NIH RePORTER;
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000460] Funding Source: NIH RePORTER
FX J.S.R. was supported in part by grant R01 CA160593A1 and NSF grant DMS
   1513266. H.L. was supported in part by a graduate student fellowship
   from the Sylvester Comprehensive Cancer Center at the University of
   Miami.
CR Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003
   Chen AY, 2015, ELECTRON J STAT, V9, P1078, DOI 10.1214/15-EJS1027
   Fan JQ, 2008, J R STAT SOC B, V70, P849, DOI 10.1111/j.1467-9868.2008.00674.x
   Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005
   Greshock J, 2010, CANCER RES, V70, P3677, DOI 10.1158/0008-5472.CAN-09-3788
   Gross SM, 2016, COMPUT STAT DATA AN, V101, P226, DOI 10.1016/j.csda.2016.02.015
   Haibe-Kains B, 2013, NATURE, V504, P389, DOI 10.1038/nature12831
   Hamidi H, 2014, BRIT J CANCER, V111, P1788, DOI 10.1038/bjc.2014.475
   Haverty PM, 2016, NATURE, V533, P333, DOI 10.1038/nature17987
   Ishwaran H, 2014, CONTEMP MATH, V622, P81, DOI 10.1090/conm/622/12438
   Liu H., 2017, ARXIV170202264
   Mpindi JP, 2016, NATURE, V540, pE5, DOI 10.1038/nature20171
   Papillon-Cavanagh S, 2013, J AM MED INFORM ASSN, V20, P597, DOI 10.1136/amiajnl-2012-001442
   Safikhani Zhaleh, 2016, F1000Res, V5, P825, DOI 10.12688/f1000research.8705.1
   Stransky N, 2015, NATURE, V528, P84, DOI 10.1038/nature15736
   Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x
   Yang WJ, 2013, NUCLEIC ACIDS RES, V41, pD955, DOI 10.1093/nar/gks1111
   Zou H, 2005, J R STAT SOC B, V67, P301, DOI 10.1111/j.1467-9868.2005.00503.x
   Zou H, 2009, ANN STAT, V37, P1733, DOI 10.1214/08-AOS625
NR 19
TC 6
Z9 6
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 9
PY 2017
VL 7
AR 15169
DI 10.1038/s41598-017-15590-4
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FM2JI
UT WOS:000414810600052
PM 29123200
OA gold, Green Published
DA 2021-10-30
ER

PT J
AU Shaffer, KM
   Kim, Y
   Llabre, MM
   Carver, CS
AF Shaffer, Kelly M.
   Kim, Youngmee
   Llabre, Maria M.
   Carver, Charles S.
TI Dyadic associations between cancer-related stress and fruit and
   vegetable consumption among colorectal cancer patients and their family
   caregivers
SO JOURNAL OF BEHAVIORAL MEDICINE
LA English
DT Article
DE Perceived cancer-related stress; Fruit and vegetable consumption; Cancer
   patients; Family caregivers; Dyadic data analysis
ID QUALITY-OF-LIFE; COVARIANCE STRUCTURE-ANALYSIS; BREAST-CANCER;
   PROSTATE-CANCER; RHEUMATOID-ARTHRITIS; SPOUSAL CAREGIVERS; TEACHABLE
   MOMENT; HEALTH PRACTICES; STYLE BEHAVIORS; CHRONIC ILLNESS
AB This study examined how stress from cancer affects fruit and vegetable consumption (FVC) in cancer patients and their family caregivers during the year following diagnosis. Colorectal cancer patients and their caregivers (92 dyads) completed questionnaires at two (T1), six (T2), and 12 months post-diagnosis (T3). Individuals reported perceived cancer-related stress (CRS) at T1 and days of adequate FVC at T1 through T3. Both patients and caregivers reported inadequate FVC during the first year post-diagnosis. Latent growth modeling with actor-partner interdependence modeling revealed that, at T1, one's own greater CRS was associated with one's partner having fewer concurrent days of adequate FVC (ps = .01). Patients' greater CRS predicted their own more pronounced rebound pattern in FVC (p = .01); both patients' and caregivers' CRS marginally predicted their partners' change in FVC (p = .09). Findings suggest that perceived stress from cancer hinders FVC around the diagnosis, but motivates positive dietary changes by the end of the first year.
C1 [Shaffer, Kelly M.; Kim, Youngmee; Llabre, Maria M.; Carver, Charles S.] Univ Miami, Dept Psychol, 5665 Ponce Leon Blvd, Coral Gables, FL 33146 USA.
   [Shaffer, Kelly M.] Massachusetts Gen Hosp, Dept Psychiat, Behav Med, Boston, MA 02114 USA.
   [Kim, Youngmee; Carver, Charles S.] Stanford Univ, Ctr Adv Study Behav Sci, Stanford, CA 94305 USA.
RP Shaffer, KM (corresponding author), Univ Miami, Dept Psychol, 5665 Ponce Leon Blvd, Coral Gables, FL 33146 USA.; Shaffer, KM (corresponding author), Massachusetts Gen Hosp, Dept Psychiat, Behav Med, Boston, MA 02114 USA.
EM k.shaffer3@umail.miami.edu
RI Shaffer, Kelly/AAG-9849-2020; Carver, Charles S./F-6567-2011
OI Shaffer, Kelly/0000-0002-9749-8006; Kim, Youngmee/0000-0002-3109-6362;
   carver, charles/0000-0002-3688-8545
FU American Cancer Society National Home OfficeAmerican Cancer Society;
   National Cancer Institute (NCI)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Cancer Institute (NCI) [F31 CA189431-01A1]; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [F31CA189431, T32CA009461] Funding Source: NIH RePORTER; NATIONAL CENTER
   FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000460]
   Funding Source: NIH RePORTER
FX This study was funded by the American Cancer Society National Home
   Office, intramural research to Dr. Kim, and National Cancer Institute
   (NCI) grant F31 CA189431-01A1 funded Ms. Shaffer's time.
CR Acton GJ, 2002, WESTERN J NURS RES, V24, P73, DOI 10.1177/01939450222045716
   American Cancer Society, 2013, UND RAD THER GUID PA
   American Cancer Society, 2013, COL CAN
   American Cancer Society, 2013, UND CHEM GUID PAT FA
   Beach SR, 2000, PSYCHOL AGING, V15, P259, DOI 10.1037//0882-7974.15.2.259
   Blanchard CM, 2008, J CLIN ONCOL, V26, P2198, DOI 10.1200/JCO.2007.14.6217
   Blanchard CM, 2004, PSYCHOL HEALTH, V19, P1, DOI 10.1080/08870440310001606507
   Bollen K. A., 2006, LATENT GROWTH CURVE
   Bowman KF, 2003, PSYCHO-ONCOLOGY, V12, P226, DOI 10.1002/pon.630
   Centers for Disease Control and Prevention & Association of State and Territorial Chronic Disease Program Directors, 2004, MMWR-MORBID MORTAL W, V53, P1
   Cook WL, 2005, INT J BEHAV DEV, V29, P101, DOI 10.1080/01650250444000405
   Costanzo ES, 2005, PSYCHOSOM MED, V67, P972, DOI 10.1097/01.psy.0000188402.95398.c0
   Demark-Wahnefried W, 2000, CANCER-AM CANCER SOC, V88, P674, DOI 10.1002/(SICI)1097-0142(20000201)88:3&lt;674::AID-CNCR26&gt;3.0.CO;2-R
   Demark-Wahnefried W, 2005, J CLIN ONCOL, V23, P5814, DOI 10.1200/JCO.2005.01.230
   Demark-Wahnefried W, 2008, HEMATOL ONCOL CLIN N, V22, P319, DOI 10.1016/j.hoc.2008.01.012
   Fridlund B, 1991, Scand J Caring Sci, V5, P23
   Groesz LM, 2012, APPETITE, V58, P717, DOI 10.1016/j.appet.2011.11.028
   Hartmann M, 2010, PSYCHOTHER PSYCHOSOM, V79, P136, DOI 10.1159/000286958
   Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118
   Institute of Medicine, 2005, CANC PATIENT CANC SU
   Kashy D. A., 2000, HDB RES METHODS SOCI, P451, DOI DOI 10.1017/CBO9780511996481
   Kenny D.A., 2006, DYADIC DATA ANAL
   Kenny DA, 1999, PERS RELATIONSHIP, V6, P433, DOI 10.1111/j.1475-6811.1999.tb00202.x
   Kim Y, 2008, J AGING HEALTH, V20, P483, DOI 10.1177/0898264308317533
   Kim Y, 2012, QUAL LIFE RES, V21, P517, DOI 10.1007/s11136-011-9953-0
   Kim Y, 2011, PSYCHO-ONCOLOGY, V20, P762, DOI 10.1002/pon.1778
   Kline R., 2011, PRINCIPLES PRACTICE
   Kushi LH, 2012, CA-CANCER J CLIN, V62, P30, DOI 10.3322/caac.20140
   Martire LM, 2004, HEALTH PSYCHOL, V23, P599, DOI 10.1037/0278-6133.23.6.599
   Martire LM, 2010, ANN BEHAV MED, V40, P325, DOI 10.1007/s12160-010-9216-2
   Marzec ML, 2013, AM J HEALTH BEHAV, V37, P478, DOI 10.5993/AJHB.37.4.6
   Maskarinec G, 2001, EUR J CANCER CARE, V10, P12, DOI 10.1046/j.1365-2354.2001.00245.x
   Maunsell E, 2002, J CLIN ONCOL, V20, P1017, DOI 10.1200/JCO.20.4.1017
   McBride CM, 2003, HEALTH EDUC RES, V18, P156, DOI 10.1093/her/18.2.156
   McBride CM, 2008, SOC SCI MED, V66, P790, DOI 10.1016/j.socscimed.2007.10.014
   McCullough ML, 2011, CANCER EPIDEM BIOMAR, V20, P1089, DOI 10.1158/1055-9965.EPI-10-1173
   Mroz LW, 2010, APPETITE, V55, P398, DOI 10.1016/j.appet.2010.07.009
   Muthen B. O., 2012, MPLUS USERS GUIDE
   Muthen BO, 1997, PSYCHOL METHODS, V2, P371, DOI 10.1037/1082-989X.2.4.371
   Northouse L, 2001, J BEHAV MED, V24, P115, DOI 10.1023/A:1010772913717
   Orlich MJ, 2015, JAMA INTERN MED, V175, P767, DOI 10.1001/jamainternmed.2015.59
   Pinto BM, 2000, ANN BEHAV MED, V22, P38, DOI 10.1007/BF02895166
   Reardon K.K., 1993, HEALTH COMMUN, V5, P263, DOI [10.1207/s15327027hc0504_2, DOI 10.1207/S15327027HC0504_2]
   Riemsma RP, 2003, ARTHRIT RHEUM-ARTHR, V49, P556, DOI 10.1002/art.11207
   Salminen E, 2002, PREV MED, V34, P529, DOI 10.1006/pmed.2002.1015
   Satia JA, 2004, CANCER EPIDEM BIOMAR, V13, P1022
   Scharlach AE, 1997, PREV MED, V26, P155, DOI 10.1006/pmed.1996.0128
   Segrin C, 2014, PSYCHOL HEALTH MED, V19, P716, DOI 10.1080/13548506.2013.871304
   Shields CG, 2012, J MARITAL FAM THER, V38, P265, DOI 10.1111/j.1752-0606.2011.00269.x
   Sisk RJ, 2000, INT J NURS STUD, V37, P37, DOI 10.1016/S0020-7489(99)00053-X
   Terry P, 2001, JNCI-J NATL CANCER I, V93, P525, DOI 10.1093/jnci/93.7.525
   Torres SJ, 2007, NUTRITION, V23, P887, DOI 10.1016/j.nut.2007.08.008
   Wayne SJ, 2004, J AM DIET ASSOC, V104, P1561, DOI 10.1016/j.jada.2004.07.028
   WILLETT JB, 1994, PSYCHOL BULL, V116, P363, DOI 10.1037/0033-2909.116.2.363
   WING RR, 1991, J CONSULT CLIN PSYCH, V59, P156, DOI 10.1037/0022-006X.59.1.156
   Zhou ES, 2011, PSYCHO-ONCOLOGY, V20, P1353, DOI 10.1002/pon.1855
NR 56
TC 4
Z9 5
U1 1
U2 10
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0160-7715
EI 1573-3521
J9 J BEHAV MED
JI J. Behav. Med.
PD FEB
PY 2016
VL 39
IS 1
BP 75
EP 84
DI 10.1007/s10865-015-9665-y
PG 10
WC Psychology, Clinical
SC Psychology
GA DH8AC
UT WOS:000373014500007
PM 26245160
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Isakova, T
   Barchi-Chung, A
   Enfield, G
   Smith, K
   Vargas, G
   Houston, J
   Xie, HL
   Wahl, P
   Schiavenato, E
   Dosch, A
   Gutierrez, OM
   Diego, J
   Lenz, O
   Contreras, G
   Mendez, A
   Weiner, RB
   Wolf, M
AF Isakova, Tamara
   Barchi-Chung, Allison
   Enfield, Gwen
   Smith, Kelsey
   Vargas, Gabriella
   Houston, Jessica
   Xie, Huiliang
   Wahl, Patricia
   Schiavenato, Eva
   Dosch, Austin
   Gutierrez, Orlando M.
   Diego, Jorge
   Lenz, Oliver
   Contreras, Gabriel
   Mendez, Armando
   Weiner, Rory B.
   Wolf, Myles
TI Effects of Dietary Phosphate Restriction and Phosphate Binders on FGF23
   Levels in CKD
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID GROWTH-FACTOR 23; CHRONIC KIDNEY-DISEASE; CARDIOVASCULAR EVENTS;
   PARATHYROID-HORMONE; PHOSPHORUS; FGF-23; INITIATION; CALCIUM; TARGET
AB Background Elevated levels of fibroblast growth factor 23 (FGF23) are associated with increased risk of adverse outcomes in patients with CKD. Reducing dietary phosphate intake or absorption may decrease FGF23 levels, but data on the combined effects of dietary phosphate restriction and phosphate binders in CKD are limited.
   Design, setting, participants, & measurements In this 2 X 2 factorial, single-blinded, placebo-controlled, 3-month study, conducted between July 2009 and March 2012, 39 patients with CKD stages 3 or 4 and normal serum phosphate levels were randomly assigned to one of four groups: ad libitum diet plus lanthanum carbonate (LC) placebo (n=10), 900-mg phosphate diet plus LC placebo (n=10), ad libitum diet plus LC (n=11), or 900-mg phosphate diet plus LC (n=8). The dose of LC was 1000 mg three times daily with meals. Dietary restriction was accomplished with outpatient counseling. The primary end point was change in FGF23 levels from baseline.
   Results Compared with ad libitum diet, the 900-mg phosphate diet did not significantly reduce FGF23 levels (diet X time interaction, P=0.05). Compared with placebo, LC alone also did not significantly reduce FGF23 levels (LC X time interaction, P=0.21). However, the dual intervention significantly decreased FGF23 levels throughout the study period (diet X LC X time interaction, P=0.02), resulting in a 35% (95% confidence interval, 8%-62%) reduction by study end.
   Conclusion The combination of LC plus counseling for a phosphate-restricted diet decreased FGF23 levels in patients with CKD stages 3-4 and normal serum phosphate levels.
C1 [Isakova, Tamara; Barchi-Chung, Allison; Smith, Kelsey; Vargas, Gabriella; Houston, Jessica; Wahl, Patricia; Schiavenato, Eva; Dosch, Austin; Diego, Jorge; Lenz, Oliver; Contreras, Gabriel; Wolf, Myles] Univ Miami, Miller Sch Med, Div Nephrol & Hypertens, Dept Med, Miami, FL 33136 USA.
   [Enfield, Gwen] Univ Miami, Miller Sch Med, Clin Res Ctr, Miami, FL 33136 USA.
   [Xie, Huiliang] Univ Miami, Miller Sch Med, Dept Epidemiol & Publ Hlth, Miami, FL 33136 USA.
   [Mendez, Armando] Univ Miami, Miller Sch Med, Div Endocrinol Diabet & Metab, Dept Med,Diabet Res Inst, Miami, FL 33136 USA.
   [Gutierrez, Orlando M.] Univ Alabama Birmingham, Dept Med, Div Nephrol, Birmingham, AL 35294 USA.
   [Weiner, Rory B.] Massachusetts Gen Hosp, Dept Med, Cardiol Unit, Boston, MA 02114 USA.
RP Wolf, M (corresponding author), Univ Miami, Miller Sch Med, Div Nephrol & Hypertens, 1120 NW 14th St,CRB 819, Miami, FL 33136 USA.
EM mwolf2@med.miami.edu
RI Lenz, Oliver/M-4672-2016
OI Lenz, Oliver/0000-0003-2997-3976
FU Shire Pharmaceuticals; National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA; National Institute of Diabetes and Digestive and Kidney
   DiseasesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Diabetes &
   Digestive & Kidney Diseases (NIDDK) [K23DK087858, R01DK076116,
   R01DK081374]; University of Miami Clinical and Translational Science
   Institute, from the National Center for Advancing Translational Sciences
   [1UL1TR000460]; National Institute on Minority Health and Health
   DisparitiesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Minority
   Health & Health Disparities (NIMHD); NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [UL1TR000460] Funding Source:
   NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Diabetes &
   Digestive & Kidney Diseases (NIDDK) [R01DK081374, K24DK093723,
   R01DK076116, K23DK087858] Funding Source: NIH RePORTER
FX This study was supported by a grant from Shire Pharmaceuticals and by
   grants from the National Institutes of Health and the National Institute
   of Diabetes and Digestive and Kidney Diseases: K23DK087858 (T.I.),
   R01DK076116 (M.W.) and R01DK081374 (M.W.).; The project described was
   supported by grant no. 1UL1TR000460, University of Miami Clinical and
   Translational Science Institute, from the National Center for Advancing
   Translational Sciences and the National Institute on Minority Health and
   Health Disparities. Its contents are solely the responsibility of the
   authors and do not necessarily represent the official views of the
   National Institutes of Health.
CR Antoniucci DM, 2006, J CLIN ENDOCR METAB, V91, P3144, DOI 10.1210/jc.2006-0021
   Block GA, 2012, J AM SOC NEPHROL, V23, P1407, DOI 10.1681/ASN.2012030223
   Burnett SAM, 2006, J BONE MINER RES, V21, P1187, DOI 10.1359/JBMR.060507
   Di Iorio B, 2012, CLIN J AM SOC NEPHRO, V7, P581, DOI 10.2215/CJN.07640711
   Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272-6386(03)00111-2
   Faul C, 2011, J CLIN INVEST, V121, P4393, DOI 10.1172/JCI46122
   Ferrari SL, 2005, J CLIN ENDOCR METAB, V90, P1519, DOI 10.1210/jc.2004-1039
   Gonzalez-Parra E, 2011, NEPHROL DIAL TRANSPL, V26, P2567, DOI 10.1093/ndt/gfr144
   Isakova T, 2012, CLIN J AM SOC NEPHRO, V7, P820, DOI 10.2215/CJN.11721111
   Isakova T, 2011, JAMA-J AM MED ASSOC, V305, P2432, DOI 10.1001/jama.2011.826
   Isakova T, 2011, KIDNEY INT, V79, P1370, DOI 10.1038/ki.2011.47
   Isakova T, 2011, NEPHROL DIAL TRANSPL, V26, P584, DOI 10.1093/ndt/gfq419
   Kendrick J, 2011, J AM SOC NEPHROL, V22, P1913, DOI 10.1681/ASN.2010121224
   Moe SM, 2011, CLIN J AM SOC NEPHRO, V6, P257, DOI 10.2215/CJN.05040610
   Oliveira RB, 2010, CLIN J AM SOC NEPHRO, V5, P286, DOI 10.2215/CJN.05420709
   PORTALE AA, 1984, J CLIN INVEST, V73, P1580, DOI 10.1172/JCI111365
   Seiler S, 2010, NEPHROL DIAL TRANSPL, V25, P3983, DOI 10.1093/ndt/gfq309
   Sprague SM, 2009, CLIN J AM SOC NEPHRO, V4, P178, DOI 10.2215/CJN.02830608
   Yilmaz MI, 2012, AM J KIDNEY DIS, V59, P177, DOI 10.1053/j.ajkd.2011.11.007
NR 19
TC 89
Z9 94
U1 0
U2 36
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555-9041
EI 1555-905X
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD JUN
PY 2013
VL 8
IS 6
BP 1009
EP 1018
DI 10.2215/CJN.09250912
PG 10
WC Urology & Nephrology
SC Urology & Nephrology
GA 160VZ
UT WOS:000320149900018
PM 23471131
OA Bronze, Green Published
DA 2021-10-30
ER

PT J
AU Miguez-Burbano, MJ
   Vargas, M
   Quiros, C
   Lewis, JE
   Espinoza, L
   Deshratan, A
AF Miguez-Burbano, Maria Jose
   Vargas, Mayra
   Quiros, Clery
   Lewis, John E.
   Espinoza, Luis
   Deshratan, Asthana
TI Menthol Cigarettes and the Cardiovascular Risks of People Living With
   HIV
SO JANAC-JOURNAL OF THE ASSOCIATION OF NURSES IN AIDS CARE
LA English
DT Article
DE blood pressure; cardiovascular risks; HIV; mentholated cigarettes;
   obesity
ID INFECTED PATIENTS; DISEASE; ASSOCIATION; NICOTINE
AB The possibility that menthol cigarettes add to the deleterious cardiovascular effects of smoking has been barely discussed. Although cardiovascular diseases (CVD) are at the forefront of medical concerns of people living with HIV (PLWH), an important, yet unknown, issue for clinicians and public health authorities is whether use of menthol-flavored cigarettes heightens CVD risk factors. Our study aims to assess traditional (10-year risk using the Framingham Risk Model) and nontraditional CVD risk factors and to contrast the effects of menthol-flavored versus non-menthol-flavored cigarettes on these risk factors. Compared to controls, menthol smokers were twice as likely to have hypertension. Users of menthol-flavored cigarettes had higher body mass index values, and increased risk of abdominal obesity. Multivariate analyses indicated that menthol smokers doubled the odds of having moderate to high CVD risk. This finding is highly significant given the widespread use of menthol-flavored cigarettes, particularly among women, minorities, and PLWH. (C) 2014 Association of Nurses in AIDS Care
C1 [Miguez-Burbano, Maria Jose] Florida Int Univ, Dept Art & Sci, Sch Integrated Sci & Humanity, Miami, FL 33199 USA.
   [Vargas, Mayra; Quiros, Clery] Florida Int Univ, Dept Art & Sci, Sch Integrated Hlth & Sci, Miami, FL 33199 USA.
   [Lewis, John E.; Deshratan, Asthana] Univ Miami, Sch Med, Dept Psychiat & Behav Sci, Miami, FL USA.
   [Espinoza, Luis] Univ Miami, Sch Med, Dept Med, Miami, FL USA.
RP Miguez-Burbano, MJ (corresponding author), Florida Int Univ, Dept Art & Sci, Sch Integrated Sci & Humanity, Miami, FL 33199 USA.
OI Espinoza, Luis/0000-0003-3279-3116
FU James and Esther King Florida Health Department Tobacco Grant [KG 10
   MJM]; CRCAustralian GovernmentDepartment of Industry, Innovation and
   ScienceCooperative Research Centres (CRC) Programme [1UL1TR000460];
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000460] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON
   ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Alcohol Abuse & Alcoholism (NIAAA) [U24AA022002] Funding Source: NIH
   RePORTER
FX The grant was funded by the James and Esther King Florida Health
   Department Tobacco Grant (KG 10 MJM). The study described used the CRC
   facilities supported by Grant Number 1UL1TR000460, Miami Clinical and
   Translational Science Institute, from the National Center for Advancing
   Translational Sciences and the National Institute on Minority Health and
   Health Disparities.
CR Amorosa V, 2005, JAIDS-J ACQ IMM DEF, V39, P557
   [Anonymous], 2004, 3 NAT HEART LUNG BLO
   Centers for Disease Control and Prevention, 1994, MMWR-MORBID MORTAL W, V43, P342
   Ciftci O, 2009, TURK KARDIYOL DERN A, V37, P234
   Das S, 2010, J ANTIMICROB CHEMOTH, V65, P386, DOI 10.1093/jac/dkp460
   Dervaux N, 2008, ATHEROSCLEROSIS, V201, P413, DOI 10.1016/j.atherosclerosis.2007.11.032
   El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283, DOI 10.1056/NEJMoa062360
   Friis-Moller N, 2010, EUR J CARDIOV PREV R, V17, P491, DOI 10.1097/HJR.0b013e328336a150
   Giovino GA, 2004, NICOTINE TOB RES, V6, pS67, DOI 10.1080/14622203710001649696
   Grundy SM, 2004, ARTERIOSCL THROM VAS, V24, pE149, DOI 10.1161/01.ATV.0000133317.49796.0E
   HEATHERTON TF, 1991, BRIT J ADDICT, V86, P1119
   Ho JE, 2012, AIDS, V26, P1115, DOI 10.1097/QAD.0b013e328352ce54
   Johnson CD, 2009, AM J PHYSIOL-HEART C, V296, pH1868, DOI 10.1152/ajpheart.01112.2008
   Kearney F, 2010, AGE AGEING, V39, P536, DOI 10.1093/ageing/afq083
   Lamendola B., 2013, DOH CANCELS STUDIES
   Miguez MJ, 2012, J AIDS CLIN RES, V3, pe109, DOI [10.4172/2155-6113.1000e109, DOI 10.4172/2155-6113.1000E109]
   Neunteufl T, 2002, J AM COLL CARDIOL, V39, P251, DOI 10.1016/S0735-1097(01)01732-6
   Newman AB, 2009, J GERONTOL A-BIOL, V64, P1251, DOI 10.1093/gerona/glp127
   Petrosillo N, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-16
   Roger VL, 2012, CIRCULATION, V125, pE2, DOI 10.1161/CIR.0b013e31823ac046
   Watanabe H, 2009, COLLOID SURFACE B, V73, P116, DOI 10.1016/j.colsurfb.2009.05.007
NR 21
TC 7
Z9 7
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1055-3290
EI 1552-6917
J9 J ASSOC NURSE AIDS C
JI J. Assoc. Nurses Aids Care
PD SEP-OCT
PY 2014
VL 25
IS 5
BP 427
EP 435
DI 10.1016/j.jana.2014.01.006
PG 9
WC Nursing
SC Nursing
GA AS7EK
UT WOS:000344419900006
PM 24581861
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Ramos, AR
   Wohlgemuth, WK
   Dong, CH
   Gardener, H
   Wright, CB
   Boden-Albala, B
   Elkind, MSV
   Sacco, RL
   Rundek, T
AF Ramos, Alberto R.
   Wohlgemuth, William K.
   Dong, Chuanhui
   Gardener, Hannah
   Wright, Clinton B.
   Boden-Albala, Bernadette
   Elkind, Mitchel S. V.
   Sacco, Ralph L.
   Rundek, Tatjana
TI Race-Ethnic Differences of Sleep Symptoms in an Elderly Multi-Ethnic
   Cohort: The Northern Manhattan Study
SO NEUROEPIDEMIOLOGY
LA English
DT Article
DE Sleep symptoms; Snoring; Sleepiness; Sleep duration; Race; Ethnicity
ID CORONARY-HEART-DISEASE; CARDIOVASCULAR OUTCOMES; DAYTIME SLEEPINESS;
   RACIAL-DIFFERENCES; ISCHEMIC-STROKE; APNEA-HYPOPNEA; UNITED-STATES;
   WHITEHALL-II; RISK-FACTORS; DURATION
AB Background: Sleep disorders are associated with stroke and may vary among elderly Hispanics, Blacks and Whites. We evaluated differences in sleep symptoms by race-ethnicity in an elderly population-based urban community sample. Methods: Snoring, daytime sleepiness and reported sleep duration were ascertained by standardized interviews as a part of the Northern Manhattan Study, a prospective cohort study of vascular risk factors and stroke risk in a multi-ethnic urban population. Sleep symptoms were compared amongst race-ethnic groups using logistic regression models. Results: A total of 1,964 stroke-free participants completed sleep questionnaires. The mean age was 75 8 9 years, with 37% men, with 60% Hispanics, 21% Blacks and 19% Whites. In models adjusted for demographic and vascular risk factors, Hispanics had increased odds of frequent snoring (odds ratio, OR: 3.6, 95% confidence interval, CI: 2.3-5.8) and daytime sleepiness (OR: 2.8, 95% CI: 1.7-4.5) compared to White participants. Hispanics were more likely to report long sleep (>= 9 h of sleep, OR: 1.8, 95% CI: 1.1-3.1). There was no difference in sleep symptoms between Black and White participants. Conclusion: In this cross-sectional analysis among an elderly community cohort, snoring, sleepiness and long sleep duration were more common in Hispanics. Sleep symptoms may be surrogate markers for an underlying sleep disorder which may be associated with an elevated risk of stroke and may be modified by clinical intervention. Copyright (C) 2011 S. Karger AG, Basel
C1 [Ramos, Alberto R.] Univ Miami, Miller Sch Med, Dept Neurol, Sleep Med Program, Miami, FL 33136 USA.
   [Wright, Clinton B.; Sacco, Ralph L.; Rundek, Tatjana] Univ Miami, Dept Epidemiol & Publ Hlth, Miami, FL 33136 USA.
   [Sacco, Ralph L.] Univ Miami, Dept Human Genet, Miami, FL 33136 USA.
   [Boden-Albala, Bernadette; Elkind, Mitchel S. V.] Columbia Univ, Dept Neurol, Coll Phys & Surg, New York, NY USA.
   [Boden-Albala, Bernadette] Columbia Univ, Mailman Sch Publ Hlth, Dept Sociomed Sci, New York, NY USA.
   [Elkind, Mitchel S. V.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA.
RP Ramos, AR (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol, Sleep Med Program, 1120 NW 14th St,Suite 1350, Miami, FL 33136 USA.
EM aramos@med.miami.edu
RI Ramos, Alberto/X-4249-2019; Sacco, Ralph/Y-9278-2019; Albala, Bernadette
   Boden/J-5703-2013
OI Albala, Bernadette Boden/0000-0001-5664-2342; Wright,
   Clinton/0000-0002-9797-6215; Boden-Albala,
   Bernadette/0000-0002-3752-329X
FU National Institute of Neurological Disorders and StrokeUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Neurological Disorders & Stroke (NINDS)
   [R37 NS029993, K24 NS 062737]; Evelyn F. McKnight Brain Institute;
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [KL2TR000461] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Neurological Disorders & Stroke (NINDS) [K24NS062737,
   R37NS029993] Funding Source: NIH RePORTER
FX work was supported by grants from the National Institute of Neurological
   Disorders and Stroke: Supplement to R37 NS029993 (to A. R. R.); R37
   NS029993 (to R. L. S., M. S. V. E., T. R., C. B. W., B.B.-A.); K24 NS
   062737 (to T. R.), and Evelyn F. McKnight Brain Institute (to C. B. W.,
   R. L. S., and T. R.). We are thankful to the study participants for
   their collaboration, to all staff of the NOMAS for their efforts towards
   this study and in particular to Edison Sabala and Janet DeRosa.
CR ANCOLIISRAEL S, 1995, AM J RESP CRIT CARE, V152, P1946, DOI 10.1164/ajrccm.152.6.8520760
   Ayas NT, 2003, DIABETES CARE, V26, P380, DOI 10.2337/diacare.26.2.380
   Ayas NT, 2003, ARCH INTERN MED, V163, P205, DOI 10.1001/archinte.163.2.205
   Baldwin CM, 2010, J CLIN SLEEP MED, V6, P176
   BLIWISE DL, 1994, J CLIN EPIDEMIOL, V47, P35, DOI 10.1016/0895-4356(94)90031-0
   Bliwise DL, 1996, NEUROEPIDEMIOLOGY, V15, P161, DOI 10.1159/000109903
   Boden-Albala B, 2009, NEUROEPIDEMIOLOGY, V32, P296, DOI 10.1159/000204914
   Cappuccio FP, 2007, HYPERTENSION, V50, P693, DOI 10.1161/HYPERTENSIONAHA.107.095471
   Cappuccio FP, 2011, EUR HEART J, V32, P1484, DOI 10.1093/eurheartj/ehr007
   Mesas AE, 2011, AGE AGEING, V40, P318, DOI 10.1093/ageing/afr004
   Gale C, 1998, BRIT MED J, V317, P1675, DOI 10.1136/bmj.317.7174.1675
   Gallicchio L, 2009, J SLEEP RES, V18, P148, DOI 10.1111/j.1365-2869.2008.00732.x
   Gangwisch JE, 2008, SLEEP, V31, P1087
   Gottlieb DJ, 2006, SLEEP, V29, P1009, DOI 10.1093/sleep/29.8.1009
   Grandner MA, 2007, SLEEP MED REV, V11, P341, DOI 10.1016/j.smrv.2007.03.010
   Hale L, 2007, SLEEP, V30, P1096, DOI 10.1093/sleep/30.9.1096
   Hayes AL, 2009, J CLIN SLEEP MED, V5, P344
   Hermann DM, 2009, NEUROLOGY, V73, P1313, DOI 10.1212/WNL.0b013e3181bd137c
   JOHNS MW, 1992, SLEEP, V15, P376, DOI 10.1093/sleep/15.4.376
   JOHNS MW, 1993, CHEST, V103, P30, DOI 10.1378/chest.103.1.30
   JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540
   Kojima M, 2000, J Epidemiol, V10, P87
   Kripke DF, 2002, ARCH GEN PSYCHIAT, V59, P131, DOI 10.1001/archpsyc.59.2.131
   Krueger PM, 2009, AM J EPIDEMIOL, V169, P1052, DOI 10.1093/aje/kwp023
   Loredo JS, 2010, SLEEP, V33, P962, DOI 10.1093/sleep/33.7.962
   Marin JM, 2005, LANCET, V365, P1046, DOI 10.1016/S0140-6736(05)71141-7
   McKnight-Eily MC, 2009, MMWR-MORBID MORTAL W, V58, P1175
   Moore PJ, 2002, PSYCHOSOM MED, V64, P337, DOI 10.1097/00006842-200203000-00018
   Netzer NC, 1999, ANN INTERN MED, V131, P485, DOI 10.7326/0003-4819-131-7-199910050-00002
   O'Connor GT, 2003, SLEEP, V26, P74
   Patel SR, 2007, SLEEP, V30, P1077, DOI 10.1093/sleep/30.9.1077
   Patel SR, 2006, SLEEP, V29, P881, DOI 10.1093/sleep/29.7.881
   Punjabi NM, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000132
   Qureshi AI, 1997, NEUROLOGY, V48, P904, DOI 10.1212/WNL.48.4.904
   Ram S, 2010, SLEEP BREATH, V14, P63, DOI 10.1007/s11325-009-0281-3
   Ramos-Sepulveda A, 2010, INT J STROKE, V5, P264, DOI 10.1111/j.1747-4949.2010.00438.x
   Redline S, 1997, AM J RESP CRIT CARE, V155, P186, DOI 10.1164/ajrccm.155.1.9001310
   Redline S, 2010, AM J RESP CRIT CARE, V182, P269, DOI 10.1164/rccm.200911-1746OC
   Sacco RL, 2001, STROKE, V32, P1725, DOI 10.1161/01.STR.32.8.1725
   Sacco RL, 1998, AM J EPIDEMIOL, V147, P259, DOI 10.1093/oxfordjournals.aje.a009445
   SCHMIDTNOWARA WW, 1990, ARCH INTERN MED, V150, P597, DOI 10.1001/archinte.150.3.597
   Stranges S, 2008, AM J EPIDEMIOL, V168, P1353, DOI 10.1093/aje/kwn337
   Will MJ, 1995, SLEEP, V18, P873, DOI 10.1093/sleep/18.10.873
   Wright CB, 2006, NEUROEPIDEMIOLOGY, V27, P201, DOI 10.1159/000096300
   Young T, 2002, ARCH INTERN MED, V162, P893, DOI 10.1001/archinte.162.8.893
NR 45
TC 22
Z9 22
U1 0
U2 8
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0251-5350
J9 NEUROEPIDEMIOLOGY
JI Neuroepidemiology
PY 2011
VL 37
IS 3-4
BP 210
EP 215
DI 10.1159/000334315
PG 6
WC Public, Environmental & Occupational Health; Clinical Neurology
SC Public, Environmental & Occupational Health; Neurosciences & Neurology
GA 871OI
UT WOS:000298747100012
PM 22123526
OA Bronze, Green Published
DA 2021-10-30
ER

PT J
AU Headley, A
   De Leon-Benedetti, A
   Dong, CH
   Levin, B
   Loewenstein, D
   Camargo, C
   Rundek, T
   Zetterberg, H
   Blennow, K
   Wright, CB
   Sun, XY
AF Headley, Alison
   De Leon-Benedetti, Andres
   Dong, Chuanhui
   Levin, Bonnie
   Loewenstein, David
   Camargo, Christian
   Rundek, Tatjana
   Zetterberg, Henrik
   Blennow, Kaj
   Wright, Clinton B.
   Sun, Xiaoyan
CA Alzheimers Dis Neuroimaging
TI Neurogranin as a predictor of memory and executive function decline in
   MCI patients
SO NEUROLOGY
LA English
DT Article
ID MILD COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; CEREBROSPINAL-FLUID;
   AMYLOID-BETA; COMPOSITE SCORE; DYSFUNCTION; BIOMARKERS; PLASMA;
   SYNAPSES; SPECTRUM
AB ObjectiveTo determine whether high CSF levels of neurogranin (Ng) predict longitudinal decline in memory and executive function during early-stage Alzheimer disease (AD).MethodsBaseline levels of CSF Ng were studied in relation to cross-sectional and longitudinal cognitive performance over 8 years. Data were obtained from the Alzheimer's Disease Neuroimaging Initiative database, and participants with normal cognition (n = 111) and mild cognitive impairment (MCI) (n = 193) were included.ResultsHigh levels of CSF Ng were associated with poor baseline memory scores ( = -0.21, p < 0.0001). CSF Ng predicted both memory and executive function decline over time ( = -0.0313, p = 0.0068 and = -0.0346, p = 0.0169, respectively) independently of age, sex, education, and APOE epsilon 4 status. When the rate of decline by tertiles was examined, CSF Ng was a level-dependent predictor of memory function, whereby the group with highest levels of Ng showed the fastest rates of decline in both memory and executive function. When examined separately, elevated Ng was associated with cognitive decline in participants with MCI but not in those with normal cognition. The levels of CSF Ng were not associated with cognitive measures when tau and amyloid 42 (A(42)) were controlled for in these analyses.ConclusionsHigh CSF Ng associates with poor memory scores in participants with MCI cross-sectionally and with poor memory and executive function longitudinally. The association of Ng with cognitive measures disappears when tau and A(42) are included in the statistical models. Our findings suggest that CSF Ng may serve as a biomarker of cognition. Synaptic dysfunction contributes to cognitive impairment in early-stage AD.
C1 [Headley, Alison] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.
   [De Leon-Benedetti, Andres; Dong, Chuanhui; Levin, Bonnie; Camargo, Christian; Rundek, Tatjana; Sun, Xiaoyan] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA.
   [Levin, Bonnie; Camargo, Christian; Rundek, Tatjana; Sun, Xiaoyan] Univ Miami, Miller Sch Med, Evelyn F McKnight Brain Inst, Miami, FL 33136 USA.
   [Loewenstein, David] Univ Miami, Miller Sch Med, Psychiat & Behav Sci, Miami, FL 33136 USA.
   [Zetterberg, Henrik; Blennow, Kaj] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Molndal, Sweden.
   [Zetterberg, Henrik] UCL Inst Neurol, Dept Mol Neurosci, Queen Sq, London, England.
   [Zetterberg, Henrik] UK Dementia Res Inst, London, England.
   [Wright, Clinton B.] NINDS, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.
RP Sun, XY (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA.; Sun, XY (corresponding author), Univ Miami, Miller Sch Med, Evelyn F McKnight Brain Inst, Miami, FL 33136 USA.
EM XXS356@med.miami.edu
RI De Leon, Andres M/Y-5740-2019
OI De Leon, Andres M/0000-0002-1938-0694
FU Swedish Alzheimer Foundation; Brain Foundation, Sweden; Torsten
   Soderberg Foundation; ADNI (NIH grant)United States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USA [U01
   AG024904]; Department of Defense ADNIUnited States Department of Defense
   [W81XWH-12-2-0012]; National Institute on AgingUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Aging (NIA); National Institute of Biomedical
   Imaging and BioengineeringUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Biomedical Imaging & Bioengineering (NIBIB); AbbVieAbbVie;
   Alzheimer's AssociationAlzheimer's Association; Alzheimer's Drug
   Discovery Foundation; Araclon Biotech; BioClinica, Inc; BiogenBiogen;
   Bristol-Myers Squibb CoBristol-Myers Squibb; CereSpir, Inc; Eisai
   IncEisai Co Ltd; Elan Pharmaceuticals, Inc; Eli Lilly and CoEli Lilly;
   EuroImmun; F. Hoffmann-La Roche LtdHoffmann-La Roche; Genentech,
   IncRoche HoldingGenentech; Fujirebio; GE HealthcareGeneral ElectricGE
   Healthcare; IXICO Ltd; Janssen Alzheimer Immunotherapy Research &
   Development, LLC; Johnson & Johnson Pharmaceutical Research &
   Development LLCJohnson & JohnsonJohnson & Johnson USA; Lumosity;
   LundbeckLundbeck Corporation; Merck Co, IncMerck & Company; Meso Scale
   Diagnostics, LLC; NeuroRx Research; Neurotrack Technologies; Novartis
   Pharmaceuticals CorpNovartis; Pfizer IncPfizer; Piramal Imaging;
   ServierServier; Takeda Pharmaceutical CoTakeda Pharmaceutical Company
   Ltd; Transition Therapeutics; Canadian Institutes of Health
   ResearchCanadian Institutes of Health Research (CIHR); NATIONAL CENTER
   FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR002736]
   Funding Source: NIH RePORTER
FX This study was supported by the Swedish Alzheimer Foundation, the Brain
   Foundation, Sweden, and the Torsten Soderberg Foundation. Data
   collection and sharing for this project were funded by the ADNI (NIH
   grant U01 AG024904) and Department of Defense ADNI (award
   W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, by
   the National Institute of Biomedical Imaging and Bioengineering, and
   through generous contributions from the following: AbbVie, Alzheimer's
   Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech;
   BioClinica, Inc; Biogen; Bristol-Myers Squibb Co; CereSpir, Inc; Eisai
   Inc; Elan Pharmaceuticals, Inc; Eli Lilly and Co; EuroImmun; F.
   Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc;
   Fujirebio; GE Healthcare; IXICO Ltd; Janssen Alzheimer Immunotherapy
   Research & Development, LLC; Johnson & Johnson Pharmaceutical Research &
   Development LLC; Lumosity; Lundbeck; Merck & Co, Inc; Meso Scale
   Diagnostics, LLC; NeuroRx Research; Neurotrack Technologies; Novartis
   Pharmaceuticals Corp; Pfizer Inc; Piramal Imaging; Servier; Takeda
   Pharmaceutical Co; and Transition Therapeutics. The Canadian Institutes
   of Health Research is providing funds to support ADNI clinical sites in
   Canada. Private sector contributions are facilitated by the Foundation
   for the NIH (www.fnih.org). The grantee organization is the Northern
   California Institute for Research and Education, and the study is
   coordinated by the Alzheimer's Disease Cooperative Study at the
   University of California, San Diego. ADNI data are disseminated by the
   Laboratory for Neuro Imaging at the University of Southern California.
CR Blennow K, 2015, FRONT NEUROSCI-SWITZ, V9, DOI [10.3389/fnins.7015.00345, 10.3389/fnins.2015.00345]
   Blennow K, 2010, NAT REV NEUROL, V6, P131, DOI 10.1038/nrneurol.2010.4
   Crane PK, 2012, BRAIN IMAGING BEHAV, V6, P502, DOI 10.1007/s11682-012-9186-z
   Davidsson P, 1998, Int Psychogeriatr, V10, P11, DOI 10.1017/S1041610298005110
   De Vos A, 2015, ALZHEIMERS DEMENT, V11, P1461, DOI 10.1016/j.jalz.2015.05.012
   Dickerson BC, 2011, J NEUROL NEUROSUR PS, V82, P45, DOI 10.1136/jnnp.2009.199505
   Gibbons LE, 2012, BRAIN IMAGING BEHAV, V6, P517, DOI 10.1007/s11682-012-9176-1
   Grober E, 2008, J INT NEUROPSYCH SOC, V14, P266, DOI 10.1017/S1355617708080302
   Hyman BT, 2011, ARCH NEUROL-CHICAGO, V68, P1062, DOI 10.1001/archneurol.2011.70
   Johnson JK, 2004, DEMENT GERIATR COGN, V17, P360, DOI 10.1159/000078183
   Kester MI, 2015, JAMA NEUROL, V72, P1275, DOI 10.1001/jamaneurol.2015.1867
   Knopman DS, 2003, MAYO CLIN PROC, V78, P1290, DOI 10.4065/78.10.1290
   Knott GW, 2006, NAT NEUROSCI, V9, P1117, DOI 10.1038/nn1747
   Kubota Y, 2007, BIOPHYS J, V93, P3848, DOI 10.1529/biophysj.107.106849
   Kvartsberg H, 2015, ALZHEIMERS DEMENT, V11, P1180, DOI 10.1016/j.jalz.2014.10.009
   Mez J, 2016, NEUROBIOL AGING, V41, P115, DOI 10.1016/j.neurobiolaging.2016.02.015
   Miyakawa T, 2001, HIPPOCAMPUS, V11, P763, DOI 10.1002/hipo.1092
   Palop JJ, 2010, NAT NEUROSCI, V13, P812, DOI 10.1038/nn.2583
   Pereira JB, 2017, NEUROBIOL AGING, V58, P14, DOI 10.1016/j.neurobiolaging.2017.06.002
   PORTELIUS E, 2015, BRAIN 11, V138, DOI DOI 10.1093/BRAIN/AWV267
   Ralph MAL, 2003, BRAIN, V126, P2350, DOI 10.1093/brain/awg236
   SCOTT SA, 1991, NEUROLOGY, V41, P351, DOI 10.1212/WNL.41.3.351
   Selkoe DJ, 2008, BEHAV BRAIN RES, V192, P106, DOI 10.1016/j.bbr.2008.02.016
   Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069
   Spires-Jones TL, 2014, NEURON, V82, P756, DOI 10.1016/j.neuron.2014.05.004
   Sun XY, 2016, ALZHEIMERS DEMENT, V12, P1159, DOI 10.1016/j.jalz.2016.05.003
   Tarawneh R, 2012, COLD SPRING HARB PER, V2, DOI DOI 10.1101/CSHPERSPECT.A006148
   Tarawneh R, 2016, JAMA NEUROL, V73, P561, DOI 10.1001/jamaneurol.2016.0086
   Thorsell A, 2010, BRAIN RES, V1362, P13, DOI 10.1016/j.brainres.2010.09.073
   Tu SC, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-48
   Zhong L, 2009, EMBO J, V28, P3027, DOI 10.1038/emboj.2009.236
NR 31
TC 23
Z9 25
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD MAR 6
PY 2018
VL 90
IS 10
BP E887
EP E895
DI 10.1212/WNL.0000000000005057
PG 9
WC Clinical Neurology
SC Neurosciences & Neurology
GA GA0UC
UT WOS:000428028800009
PM 29429972
OA Green Published
DA 2021-10-30
ER

PT J
AU Schwartz, SJ
   Unger, JB
   Zamboanga, BL
   Cordova, D
   Mason, CA
   Huang, S
   Baezconde-Garbanati, L
   Lorenzo-Blanco, EI
   Des Rosiers, SE
   Soto, DW
   Villamar, JA
   Pattarroyo, M
   Lizzi, KM
   Szapocznik, J
AF Schwartz, Seth J.
   Unger, Jennifer B.
   Zamboanga, Byron L.
   Cordova, David
   Mason, Craig A.
   Huang, Shi
   Baezconde-Garbanati, Lourdes
   Lorenzo-Blanco, Elma I.
   Des Rosiers, Sabrina E.
   Soto, Daniel W.
   Villamar, Juan A.
   Pattarroyo, Monica
   Lizzi, Karina M.
   Szapocznik, Jose
TI Developmental Trajectories of Acculturation: Links With Family
   Functioning and Mental Health in Recent-Immigrant Hispanic Adolescents
SO CHILD DEVELOPMENT
LA English
DT Article
ID MEXICAN-AMERICAN; ETHNIC-IDENTITY; PROSOCIAL BEHAVIORS; MEASUREMENT
   EQUIVALENCE; LATINO ADOLESCENTS; SEXUAL-BEHAVIOR; SUBSTANCE USE;
   SELF-ESTEEM; RISK; BICULTURALISM
AB The present study was designed to examine acculturative changes, and their effects on mental health and family functioning, in recent-immigrant Hispanic adolescents. A sample of 302 Hispanic adolescents was assessed five times over a 21/2-year period. Participants completed measures of Hispanic and U.S. practices, collectivist and individualist values, and ethnic and U.S. identity at each time point. Baseline and Time 5 levels of mental health and family functioning were also assessed. Latent class growth analyses produced two-class solutions for practices, values, and identifications. Adolescents who increased over time in practices and values reported the most adaptive mental health and family functioning. Adolescents who did not change in any acculturation domain reported the least favorable mental health and family functioning.
C1 [Schwartz, Seth J.; Huang, Shi; Lizzi, Karina M.; Szapocznik, Jose] Univ Miami, Miami, FL 33136 USA.
   [Unger, Jennifer B.; Baezconde-Garbanati, Lourdes; Soto, Daniel W.; Pattarroyo, Monica] Univ So Calif, Los Angeles, CA USA.
   [Zamboanga, Byron L.] Smith Coll, Northampton, MA 01063 USA.
   [Cordova, David] Univ Michigan, Ann Arbor, MI 48109 USA.
   [Mason, Craig A.] Univ Maine, Orono, ME 04469 USA.
   [Lorenzo-Blanco, Elma I.] Univ S Carolina, Columbia, SC 29208 USA.
   [Des Rosiers, Sabrina E.] Barry Univ, Miami, FL USA.
   [Villamar, Juan A.] Northwestern Univ, Evanston, IL 60208 USA.
RP Schwartz, SJ (corresponding author), Univ Miami, Dept Publ Hlth Sci, Leonard M Miller Sch Med, Miami, FL 33136 USA.
EM sschwartz@med.miami.edu
OI Unger, Jennifer/0000-0001-9064-6603; Mason, Craig/0000-0002-9690-1692
FU National Institute on Drug AbuseUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute on Drug Abuse (NIDA)European Commission [DA026594]; National
   Institute on Alcohol Abuse and AlcoholismUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Alcohol Abuse & Alcoholism (NIAAA) [AA021888];
   National Center for Advancing Translational SciencesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [1UL1TR000460]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1TR000460] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism
   (NIAAA) [R01AA021888] Funding Source: NIH RePORTER; NATIONAL INSTITUTE
   ON DRUG ABUSEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Drug Abuse
   (NIDA)European Commission [R01DA025694] Funding Source: NIH RePORTER
FX Preparation of this article was supported by Grants DA026594 from the
   National Institute on Drug Abuse and AA021888 from the National
   Institute on Alcohol Abuse and Alcoholism to Seth J. Schwartz, and by
   National Center for Advancing Translational Sciences Grant 1UL1TR000460
   to Jose Szapocznik. We thank Maria-Rosa Velazquez, Tatiana Clavijo,
   Mercedes Prado, Alba Alfonso, Aleyda Marcos, Daisy Ramirez, Lissette
   Ramirez, and Perlita Carrillo for their hard work conducting assessments
   and tracking families; Dr. Judy Arroyo for her guidance and wisdom; and
   the study families for sharing their experiences with us.
CR BARNES HL, 1985, CHILD DEV, V56, P438, DOI 10.1111/j.1467-8624.1985.tb00118.x
   Berry J. W., 2006, IMMIGRANT YOUTH CULT
   Berry JW, 1997, APPL PSYCHOL-INT REV, V46, P5, DOI 10.1080/026999497378467
   Carlo G, 2002, J YOUTH ADOLESCENCE, V31, P31, DOI 10.1023/A:1014033032440
   Carlo G, 2010, J RES ADOLESCENCE, V20, P334, DOI 10.1111/j.1532-7795.2010.00637.x
   Castillo LG, 2009, REHABIL PSYCHOL, V54, P351, DOI 10.1037/a0017801
   Cheung BY, 2011, PSYCHOL SCI, V22, P147, DOI 10.1177/0956797610394661
   Cole DA, 2003, J ABNORM PSYCHOL, V112, P558, DOI 10.1037/0021-843X.112.4.558
   Coll CG, 2000, DEV PSYCHOPATHOL, V12, P333, DOI 10.1017/S0954579400003059
   Cooper C.R., 2011, BRIDGING MULTIPLE WO
   Edwards LM, 2007, HISPANIC J BEHAV SCI, V29, P225, DOI 10.1177/0739986307299692
   Falicov C. J., 2013, LATINO FAMILIES THER
   FerrerWreder L., 2014, HDB CHILD WELL BEING, VV, P3025
   Flannery WP, 2001, PERS SOC PSYCHOL B, V27, P1035, DOI 10.1177/0146167201278010
   Forster M, 2015, J INTERPERS VIOLENCE, V30, P1807, DOI 10.1177/0886260514549052
   Fuller B, 2010, DEV PSYCHOL, V46, P559, DOI 10.1037/a0019412
   Gonzales NA, 2006, FAM RELAT, V55, P318, DOI 10.1111/j.1741-3729.2006.00405.x
   GORDON M., 1964, ASSIMILATION AM LIFE
   GormanSmith D, 1996, J FAM PSYCHOL, V10, P115, DOI 10.1037/0893-3200.10.2.115
   Grieco E. M., 2012, 96 POP DIV US CENS B
   HayesBautista DE, 2004, NUEVA CALIFORNIA: LATINOS IN THE GOLDEN STATE, P1
   Henderson Timothy J., 2011, BORDERS HIST MEXICAN
   Hirschman EC, 2003, J ADVERTISING, V32, P9, DOI 10.1080/00913367.2003.10601001
   Huntington S.P., 2004, WHO ARE WE CHALLENGE
   Kasinitz Philip., 2008, INHERITING CITY CHIL
   Kauermann G, 2001, J AM STAT ASSOC, V96, P1387, DOI 10.1198/016214501753382309
   Kiang L, 2009, J YOUTH ADOLESCENCE, V38, P732, DOI 10.1007/s10964-008-9278-7
   Kline R. B., 2010, PRINCIPLES PRACTICES, V3rd
   Kline RB., 2004, SIGNIFICANCE TESTING
   Knight GP, 2014, J YOUTH ADOLESCENCE, V43, P2012, DOI 10.1007/s10964-013-9983-8
   Knight GP, 2010, J EARLY ADOLESCENCE, V30, P444, DOI 10.1177/0272431609338178
   Knight GP, 2009, J RES ADOLESCENCE, V19, P625, DOI 10.1111/j.1532-7795.2009.00614.x
   KNIGHT GP, 2009, METHODOLOGICAL CHALL
   LAFROMBOISE T, 1993, PSYCHOL BULL, V114, P395, DOI 10.1037/0033-2909.114.3.395
   Lau AS, 2005, J FAM PSYCHOL, V19, P367, DOI 10.1037/0893-3200.19.3.367
   Lerner RM, 1998, ANNU REV PSYCHOL, V49, P413, DOI 10.1146/annurev.psych.49.1.413
   Light I., 2006, DEFLECTING IMMIGRATI
   Marks AK, 2007, INT J BEHAV DEV, V31, P501, DOI 10.1177/0165025407081462
   Muthen LK, 2010, MPLUS USERS GUIDE VE
   Nguyen AMD, 2013, J CROSS CULT PSYCHOL, V44, P122, DOI 10.1177/0022022111435097
   Nylund KL, 2007, STRUCT EQU MODELING, V14, P535, DOI 10.1080/10705510701575396
   Oyserman D, 2002, PSYCHOL BULL, V128, P3, DOI 10.1037/0033-2909.128.1.3
   Phinney JS, 2007, J COUNS PSYCHOL, V54, P271, DOI 10.1037/0022-0167.54.3.271
   Portes A, 2006, IMMIGRANT AM PORTRAI, V3
   RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306
   Roberts RE, 1999, J EARLY ADOLESCENCE, V19, P301, DOI 10.1177/0272431699019003001
   Rosenberg M., 1968, SOC ADOLESCENT SELF
   Rumbaut RG, 2008, APPL DEV SCI, V12, P108, DOI 10.1080/10888690801997341
   Sam DL, 2010, PERSPECT PSYCHOL SCI, V5, P472, DOI 10.1177/1745691610373075
   Schmitt DP, 2005, J PERS SOC PSYCHOL, V89, P623, DOI 10.1037/0022-3514.89.4.623
   Schwartz S.J., 2014, OXFORD HDB MULTICULT, P57
   Schwartz SJ, 2014, PSYCHOL ASSESSMENT, V26, P100, DOI 10.1037/a0034717
   Schwartz SJ, 2014, CULT DIVERS ETHN MIN, V20, P1, DOI 10.1037/a0033391
   Schwartz SJ, 2013, CHILD DEV, V84, P1355, DOI 10.1111/cdev.12047
   Schwartz SJ, 2012, IDENTITY, V12, P93, DOI 10.1080/15283488.2012.668730
   Schwartz SJ, 2012, DRUG ALCOHOL DEPEN, V125, pS26, DOI 10.1016/j.drugalcdep.2012.05.020
   Schwartz SJ, 2011, J COUNS PSYCHOL, V58, P27, DOI 10.1037/a0021356
   Schwartz SJ, 2010, AM PSYCHOL, V65, P237, DOI 10.1037/a0019330
   Schwartz SJ, 2010, HUM DEV, V53, P26, DOI 10.1159/000268137
   Schwartz SJ, 2007, CULT DIVERS ETHN MIN, V13, P364, DOI 10.1037/1099-9809.13.4.364
   Schwartz SJ, 2008, CULT DIVERS ETHN MIN, V14, P275, DOI 10.1037/a0012818
   Schwartz SJ, 2006, J CROSS CULT PSYCHOL, V37, P345, DOI 10.1177/0022022106286928
   Sessa FM, 2001, J FAM PSYCHOL, V15, P53, DOI 10.1037/0893-3200.15.1.53
   Smith PB, 2013, UNDERSTANDING SOCIAL
   Smokowski P. R., 2011, BECOMING BICULTURAL
   Smokowski PR, 2007, CHILD PSYCHIAT HUM D, V37, P273, DOI 10.1007/s10578-006-0035-4
   Smokowski PR, 2010, CHILD PSYCHIAT HUM D, V41, P133, DOI 10.1007/s10578-009-0157-6
   Steiner N., 2009, INT MIGRATION CITIZE
   Stepick A, 2003, THIS LAND IS OUR LAND: IMMIGRANTS AND POWER IN MIAMI, P1
   Suarez-Orozco C., 2008, LEARNING NEW LAND
   Suarez-Orozco C., 2001, CHILDREN IMMIGRATION
   SZAPOCZNIK J, 1986, HISPANIC J BEHAV SCI, V8, P303, DOI 10.1177/07399863860084001
   Szapocznik J., 1980, INT J INTERCULT REL, V4, P353, DOI [10.1016/0147-1767(80)90010-3, DOI 10.1016/0147-1767(80)90010-3]
   Todorova ILG, 2010, SOCIOL HEALTH ILL, V32, P843, DOI 10.1111/j.1467-9566.2010.01257.x
   Tolan PH, 1997, PSYCHOL ASSESSMENT, V9, P212, DOI 10.1037/1040-3590.9.3.212
   Triandis H.C., 2018, INDIVIDUALISM COLLEC
   Triandis HC, 1998, J PERS SOC PSYCHOL, V74, P118, DOI 10.1037/0022-3514.74.1.118
   Tropp LR, 1999, EDUC PSYCHOL MEAS, V59, P351, DOI 10.1177/00131649921969794
   Turner CF, 1998, SCIENCE, V280, P867, DOI 10.1126/science.280.5365.867
   Umana-Taylor AJ, 2014, CHILD DEV, V85, P21, DOI 10.1111/cdev.12196
   Umana-Taylor AJ, 2009, CHILD DEV, V80, P391, DOI 10.1111/j.1467-8624.2009.01267.x
   Unger JB, 2009, J IMMIGR MINOR HEALT, V11, P149, DOI 10.1007/s10903-007-9083-5
   Wahl AMG, 2010, J IMMIGR MINOR HEALT, V12, P153, DOI 10.1007/s10903-008-9179-6
   West S. G., 2012, HDB STRUCTURAL EQUAT, P209, DOI DOI 10.1016/J.SURFCOAT.2015.05.023
NR 84
TC 54
Z9 55
U1 2
U2 24
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-3920
EI 1467-8624
J9 CHILD DEV
JI Child Dev.
PD MAY-JUN
PY 2015
VL 86
IS 3
BP 726
EP 748
DI 10.1111/cdev.12341
PG 23
WC Psychology, Educational; Psychology, Developmental
SC Psychology
GA CH8KN
UT WOS:000354285400005
PM 25644262
OA Green Published, Green Accepted
DA 2021-10-30
ER

PT J
AU Chang, VS
   Rose, TP
   Karp, CL
   Levitt, RC
   Sarantopoulos, C
   Galor, A
AF Chang, Victoria S.
   Rose, Terri P.
   Karp, Carol L.
   Levitt, Roy C.
   Sarantopoulos, Constantine
   Galor, Anat
TI Neuropathic-Like Ocular Pain and Nonocular Comorbidities Correlate With
   Dry Eye Symptoms
SO EYE & CONTACT LENS-SCIENCE AND CLINICAL PRACTICE
LA English
DT Article
DE Dry eye; Neuropathic pain; Chronic pain
ID QUALITY-OF-LIFE; UNITED-STATES; CENTRAL SENSITIZATION; INCOMPLETE
   RESPONSE; GENE POLYMORPHISMS; TEAR FILM; PREVALENCE; DISEASE;
   DEPRESSION; CYTOKINES
AB Objective: To evaluate the association between dry eye (DE) symptoms and neuropathic-like ocular pain (NOP) features, chronic pain conditions, depression, and anxiety in patients presenting for routine ophthalmic examinations.
   Methods: Two hundred thirty-three consecutive patients >= 18 years of age presenting to a comprehensive eye clinic between January and August 2016 were included in this study. Information on demographics, chronic pain conditions, medication use, DE symptoms (dry eye questionnaire, DEQ5), NOP complaints (burning; wind, light, and temperature sensitivity), depression, and anxiety indices (patient health questionnaire 9, PHQ-9 and symptom checklist 90-revised, SCL-90-R) were collected for each individual. Pearson correlation was used to evaluate strengths of association. Logistic regression analysis examined risk factors for any (DEQ5 >= 6) and severe (DEQ5 >= 12) DE symptoms.
   Results: The mean age of the population was 46.3 years (+/- 13.0); 67.8% (n=158) were female. Per the DEQ5, 40.3% (n=94) had mild or greater DE symptoms and 12% (n=24) had severe symptoms. Severity of DE symptoms correlated with NOP complaints: burning (Pearson r=0.37, P<0.001); sensitivity to wind (r=0.37, P<0.001), sensitivity to light (r=0.34, P<0.001), and sensitivity to temperature (r=0.30, P<0.001). Sex, race, and ethnicity were not significant risk factors for DE symptoms. Risk factors for mild or greater DE symptoms included a greater number of chronic nonocular pain conditions (odds ratio [OR]=1.38, P<0.001), arthritic pain (OR=6.34, P<0.001), back pain (OR=2.47, P=0.004), headaches (OR=2.14, P=0.02), depression (OR=1.17, P<0.001), and anxiety (OR=1.13, P=0.02).
   Conclusion: Dry eye severity positively associated with NOP complaints, comorbid chronic pain conditions, and symptoms of depression and anxiety.
C1 [Chang, Victoria S.; Rose, Terri P.; Karp, Carol L.; Galor, Anat] Univ Miami, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL USA.
   [Levitt, Roy C.; Galor, Anat] Univ Miami, Miller Sch Med, Dept Ophthalmol, Miami, FL 33136 USA.
   [Levitt, Roy C.; Sarantopoulos, Constantine] Univ Miami, Miller Sch Med, Miami Vet Affairs Med Ctr, Dept Anesthesiol Perioperat Med & Pain Management, Miami, FL 33136 USA.
   [Levitt, Roy C.] Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, Miami, FL 33136 USA.
   [Levitt, Roy C.] Univ Miami, Miller Sch Med, John T Macdonald Fdn, Dept Human Genet, Miami, FL 33136 USA.
RP Chang, VS (corresponding author), 3880 Tamiami Trail North, Naples, FL 34103 USA.
EM vchang@med.miami.edu
OI Chang, Victoria/0000-0001-7147-7402
FU Department of Veterans Affairs, Veterans Health Administration, Office
   of Research and Development, Clinical Sciences ResearchUS Department of
   Veterans Affairs [EPID-006-15S, R01EY026174]; NIH Center Core
   GrantUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [P30EY014801]; Research to Prevent
   BlindnessResearch to Prevent Blindness (RPB); Ronald and Alicia Lepke
   Grant; Lee and Claire Hager Grant; Jimmy and Gaye Bryan Grant; Robert
   Baer Family Grant; Gordon Charitable Foundation; Richard Azar Family
   Grant; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000460] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTEUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Eye Institute (NEI) [R01EY026174,
   P30EY014801] Funding Source: NIH RePORTER; Veterans AffairsUS Department
   of Veterans Affairs [I01CX001089] Funding Source: NIH RePORTER
FX Supported by the Department of Veterans Affairs, Veterans Health
   Administration, Office of Research and Development, Clinical Sciences
   Research EPID-006-15S (A.G.), R01EY026174 (A.G.), NIH Center Core Grant
   P30EY014801, Research to Prevent Blindness Unrestricted Grant, The
   Ronald and Alicia Lepke Grant, The Lee and Claire Hager Grant, The Jimmy
   and Gaye Bryan Grant, The H. Scott Huizenga Grant, The Robert Baer
   Family Grant, The Gordon Charitable Foundation and The Richard Azar
   Family Grant (institutional grants).
CR Chalmers RL, 2010, CONTACT LENS ANTERIO, V33, P55, DOI 10.1016/j.clae.2009.12.010
   Costigan M, 2009, ANNU REV NEUROSCI, V32, P1, DOI 10.1146/annurev.neuro.051508.135531
   Crane AM, 2017, BRIT J OPHTHALMOL, V101, P1238, DOI 10.1136/bjophthalmol-2016-309658
   Crane AM, 2017, BRIT J OPHTHALMOL, V101, P227, DOI 10.1136/bjophthalmol-2015-308214
   Diatchenko L, 2005, HUM MOL GENET, V14, P135, DOI 10.1093/hmg/ddi013
   Digre KB, 2012, J NEURO-OPHTHALMOL, V32, P68, DOI 10.1097/WNO.0b013e3182474548
   Farrand KF, 2017, AM J OPHTHALMOL, V182, P90, DOI 10.1016/j.ajo.2017.06.033
   Fiore NT, 2016, BRAIN BEHAV IMMUN, V56, P397, DOI 10.1016/j.bbi.2016.04.012
   Galor A, 2016, JAMA OPHTHALMOL, V134, P1290, DOI 10.1001/jamaophthalmol.2016.3642
   Galor A, 2016, BRIT J OPHTHALMOL, V100, P745, DOI 10.1136/bjophthalmol-2015-307094
   Galor A, 2016, J PAIN, V17, P310, DOI 10.1016/j.jpain.2015.10.019
   Galor A, 2015, BRIT J OPHTHALMOL, V99, P1126, DOI 10.1136/bjophthalmol-2014-306481
   Galor A, 2015, BRIT J OPHTHALMOL, V99, P665, DOI 10.1136/bjophthalmol-2014-306057
   Galor A, 2013, INVEST OPHTH VIS SCI, V54, P1426, DOI 10.1167/iovs.12-10819
   Galor A, 2012, AM J OPHTHALMOL, V154, P340, DOI 10.1016/j.ajo.2012.02.009
   Hayek SM, 2016, PAIN MED, V17, P1302, DOI 10.1093/pm/pnv058
   Hirata A, 2006, J NEUROSCI, V26, P4426, DOI 10.1523/JNEUROSCI.5298-05.2006
   Jie Y, 2009, EYE, V23, P688, DOI 10.1038/sj.eye.6703101
   Kalangara JP, 2016, PAIN MED, V17, P746, DOI 10.1093/pm/pnv070
   Kim KW, 2011, INVEST OPHTH VIS SCI, V52, P7954, DOI 10.1167/iovs.11-8050
   Kovacs D, 2016, J NEURAL TRANSM, V123, P541, DOI 10.1007/s00702-016-1506-9
   Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x
   Lee SY, 2013, AM J OPHTHALMOL, V156, P247, DOI 10.1016/j.ajo.2013.04.003
   Lees JG, 2015, MOD TR PHARMACOPSYCH, V30, P51, DOI 10.1159/000435932
   Lichtinger A, 2011, J REFRACT SURG, V27, P613, DOI 10.3928/1081597X-20110210-01
   Lin PY, 2003, OPHTHALMOLOGY, V110, P1096, DOI 10.1016/S0161-6420(03)00262-8
   Maixner W, 2016, J PAIN, V17, pT93, DOI 10.1016/j.jpain.2016.06.002
   Massingale ML, 2009, CORNEA, V28, P1023, DOI 10.1097/ICO.0b013e3181a16578
   Milosevic N, 2015, J ORAL FACIAL PAIN H, V29, P279, DOI 10.11607/ofph.1343
   Mogil JS, 2003, P NATL ACAD SCI USA, V100, P4867, DOI 10.1073/pnas.0730053100
   Na KS, 2015, CORNEA, V34, P733, DOI 10.1097/ICO.0000000000000464
   Na KS, 2011, MOL VIS, V17, P2818
   Nichols JJ, 2006, INVEST OPHTH VIS SCI, V47, P1319, DOI 10.1167/iovs.05-1392
   Noseda R, 2010, J NEUROSCI, V30, P14420, DOI 10.1523/JNEUROSCI.3025-10.2010
   Omair A, 2016, EUR SPINE J, V25, P2, DOI 10.1007/s00586-015-4181-x
   Pouyeh B, 2012, AM J OPHTHALMOL, V153, P1061, DOI 10.1016/j.ajo.2011.11.030
   Prinz U, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-104
   Raison CL, 2006, TRENDS IMMUNOL, V27, P24, DOI 10.1016/j.it.2005.11.006
   Rial D, 2016, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00521
   Rosenthal P, 2016, BRIT J OPHTHALMOL, V100, P128, DOI 10.1136/bjophthalmol-2014-306280
   Sambursky R, 2013, JAMA OPHTHALMOL, V131, P24, DOI 10.1001/jamaophthalmol.2013.561
   Satitpitakul V, 2017, AM J OPHTHALMOL, V179, P198, DOI 10.1016/j.ajo.2017.05.009
   Schaumberg DA, 2003, AM J OPHTHALMOL, V136, P318, DOI 10.1016/S0002-9394(03)00218-6
   Schaumberg DA, 2009, ARCH OPHTHALMOL-CHIC, V127, P763, DOI 10.1001/archophthalmol.2009.103
   Schein OD, 1997, AM J OPHTHALMOL, V124, P723, DOI 10.1016/S0002-9394(14)71688-5
   Schiffman RM, 2003, OPHTHALMOLOGY, V110, P1412, DOI 10.1016/S0161-6420(03)00462-7
   Sessle B J, 2005, Minerva Anestesiol, V71, P117
   Sidebottom AC, 2012, ARCH WOMEN MENT HLTH, V15, P367, DOI 10.1007/s00737-012-0295-x
   Smith JA, 2007, OCUL SURF, V5, P93
   Spierer O, 2016, INVEST OPHTH VIS SCI, V57, P617, DOI 10.1167/iovs.15-18133
   Vehof J, 2016, AM J OPHTHALMOL, V166, P203, DOI 10.1016/j.ajo.2016.03.023
   Vehof J, 2014, BRIT J OPHTHALMOL, V98, P1712, DOI 10.1136/bjophthalmol-2014-305201
   Vehof J, 2014, INVEST OPHTH VIS SCI, V55, P7278, DOI 10.1167/iovs.14-15200
   WOOLF CJ, 1983, NATURE, V306, P686, DOI 10.1038/306686a0
   Woolf CJ, 2011, PAIN, V152, pS2, DOI 10.1016/j.pain.2010.09.030
   Yunus MB, 2015, CURR RHEUMATOL REV, V11, P70, DOI 10.2174/157339711102150702112236
NR 56
TC 3
Z9 3
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1542-2321
EI 1542-233X
J9 EYE CONTACT LENS
JI Eye Contact Lens-Sci. Clin. Pra.
PD NOV
PY 2018
VL 44
SU 2
BP S307
EP S313
DI 10.1097/ICL.0000000000000463
PG 7
WC Ophthalmology
SC Ophthalmology
GA HK3TH
UT WOS:000457840400052
PM 29227460
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Brown, SC
   Lombard, J
   Toro, M
   Huang, S
   Perrino, T
   Perez-Gomez, G
   Plater-Zyberk, E
   Pantin, H
   Affuso, O
   Kumar, N
   Wang, KF
   Szapocznik, J
AF Brown, Scott C.
   Lombard, Joanna
   Toro, Matthew
   Huang, Shi
   Perrino, Tatiana
   Perez-Gomez, Gianna
   Plater-Zyberk, Elizabeth
   Pantin, Hilda
   Affuso, Olivia
   Kumar, Naresh
   Wang, Kefeng
   Szapocznik, Jose
TI Walking and Proximity to the Urban Growth Boundary and Central Business
   District
SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE
LA English
DT Article
ID PHYSICAL-ACTIVITY; NEIGHBORHOOD DESIGN; BUILT ENVIRONMENT;
   TRANSPORTATION; SCORE(R); QUESTIONNAIRE; ASSOCIATIONS; VALIDATION;
   DISEASE; TRAVEL
AB Background: Planners have relied on the urban development boundary (UDB)/urban growth boundary (UGB) and central business district (CBD) to encourage contiguous urban development and conserve infrastructure. However, no studies have specifically examined the relationship between proximity to the UDB/UGB and CBD and walking behavior.
   Purpose: To examine the relationship between UDB and CBD distance and walking in a sample of recent Cuban immigrants, who report little choice in where they live after arrival to the U.S.
   Methods: Data were collected in 2008-2010 from 391 healthy, recent Cuban immigrants recruited and assessed within 90 days of arrival to the U.S. who resided throughout Miami-Dade County FL. Analyses in 2012-2013 examined the relationship between UDB and CBD distances for each participant's residential address and purposive walking, controlling for key sociodemographics. Follow-up analyses examined whether Walk Score (R), a built-environment walkability metric based on distance to amenities such as stores and parks, mediated the relationship between purposive walking and each of UDB and CBD distance.
   Results: Each one-mile increase in distance from the UDB corresponded to an 11% increase in the number of minutes of purposive walking, whereas each one-mile increase from the CBD corresponded to a 5% decrease in the amount of purposive walking. Moreover, Walk Score mediated the relationship between walking and each of UDB and CBD distance.
   Conclusions: Given the lack of walking and walkable destinations observed in proximity to the UDB/UGB boundary, a sprawl repair approach could be implemented, which strategically introduces mixed-use zoning to encourage walking throughout the boundary's zone. (C) 2014 American Journal of Preventive Medicine
C1 [Brown, Scott C.; Lombard, Joanna; Toro, Matthew; Huang, Shi; Perrino, Tatiana; Perez-Gomez, Gianna; Plater-Zyberk, Elizabeth; Pantin, Hilda; Kumar, Naresh; Wang, Kefeng; Szapocznik, Jose] Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
   [Brown, Scott C.; Lombard, Joanna; Plater-Zyberk, Elizabeth; Szapocznik, Jose] Univ Miami, Sch Architecture, Coral Gables, FL 33124 USA.
   [Affuso, Olivia] Univ Alabama Birmingham, Sch Publ Hlth, Birmingham, AL 35294 USA.
RP Brown, SC (corresponding author), Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, 1120 NW 14th St,Clinical Res Bldg,Room 1065, Miami, FL 33136 USA.
EM sbrown@med.miami.edu
RI Wang, Kefeng/T-7938-2017
OI Wang, Kefeng/0000-0001-5241-6233; Lombard, Joanna/0000-0002-4925-9633;
   Affuso, Olivia/0000-0003-2268-5074
FU National Institute of Diabetes and Digestive and Kidney DiseasesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Diabetes & Digestive &
   Kidney Diseases (NIDDK) [1R01-DK-074687]; National Center for
   Advancement of Translational Sciences [1UL1TR000460]; NATIONAL CENTER
   FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000460]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND
   DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Diabetes & Digestive & Kidney Diseases (NIDDK) [P30DK079626,
   R01DK074687] Funding Source: NIH RePORTER
FX The work presented in this paper was supported by a research grant from
   the National Institute of Diabetes and Digestive and Kidney Diseases
   (Grant No. 1R01-DK-074687, J. Szapocznik, PI; T. Perrino, Project
   Director), and a grant from the National Center for Advancement of
   Translational Sciences (Grant No. 1UL1TR000460, J. Szapocznik, Principal
   Investigator).
CR ARBUCKLE J, 2005, AMOS 6 0 USERS GUIDE
   BAECKE JAH, 1982, AM J CLIN NUTR, V36, P936
   Brown BB, 2013, AM J PREV MED, V44, P231, DOI 10.1016/j.amepre.2012.10.024
   Brown SC, 2013, AM J PREV MED, V45, P202, DOI 10.1016/j.amepre.2013.03.021
   Burnett V, 2011, NY TIMES, pA1
   Carr LJ, 2011, BRIT J SPORT MED, V45, P1144, DOI 10.1136/bjsm.2009.069609
   Carr LJ, 2010, AM J PREV MED, V39, P460, DOI 10.1016/j.amepre.2010.07.007
   Centers for Disease Control and Prevention, 2012, MOR PEOPL WALK BETT
   Craig CL, 2003, MED SCI SPORT EXER, V35, P1381, DOI 10.1249/01.MSS.0000078924.61453.FB
   Duany A., 2000, SUBURBAN NATION RISE
   Duncan DT, 2011, INT J ENV RES PUB HE, V8, P4160, DOI 10.3390/ijerph8114160
   Eitler TW, 2013, 10 PRINCIPLES BUILDI
   Environmental Protection Agency (EPA), 2012, GROW SUST FUT MIAM D
   Ewing R, 2010, J AM PLANN ASSOC, V76, P265, DOI 10.1080/01944361003766766
   Folsom AR, 1997, MED SCI SPORT EXER, V29, P901, DOI 10.1097/00005768-199707000-00009
   Franco M, 2007, AM J EPIDEMIOL, V166, P1374, DOI 10.1093/aje/kwm226
   Frank LD, 2007, SOC SCI MED, V65, P1898, DOI 10.1016/j.socscimed.2007.05.053
   Goodkin LM, 2012, DECADE CHANGE DOWNTO
   Handy SL, 2008, AM J HEALTH PROMOT, V22, P350, DOI 10.4278/ajhp.22.5.350
   Herold M, 2003, REMOTE SENS ENVIRON, V86, P286, DOI 10.1016/S0034-4257(03)00075-0
   Hirsch JA, 2013, AM J PREV MED, V45, P158, DOI 10.1016/j.amepre.2013.03.018
   Kline R.B., 2015, PRINCIPLES PRACTICE, V4
   Kruger J, 2008, PREV MED, V47, P329, DOI 10.1016/j.ypmed.2008.02.018
   Lee IM, 2009, AM J PREV MED, V37, P293, DOI 10.1016/j.amepre.2009.06.007
   Long Y, 2011, COMPUT ENVIRON URBAN, V35, P297, DOI 10.1016/j.compenvurbsys.2011.02.004
   MacKinnon DP, 2002, PSYCHOL METHODS, V7, P83, DOI 10.1037/1082-989X.7.1.83
   Manaugh K, 2011, TRANSPORT RES D-TR E, V16, P309, DOI 10.1016/j.trd.2011.01.009
   Miami Downtown Development Authority (DDA), 2013, CENTR BUS DISTR DDA
   Nelson A., 2004, URBAN CONTAINMENT US
   Pendall R., 2002, HOLDING LINE URBAN C
   Pitts SBJ, 2012, ECOL FOOD NUTR, V51, P526, DOI 10.1080/03670244.2012.705749
   Pivo G, 2011, REAL ESTATE ECON, V39, P185, DOI 10.1111/j.1540-6229.2010.00296.x
   Reis RS, 2013, AM J PREV MED, V44, pE9, DOI 10.1016/j.amepre.2012.10.014
   Rodriguez DA, 2009, ACTIVE TRANSPORTATIO
   Sallis JF, 2004, TRANSPORT RES A-POL, V38, P249, DOI 10.1016/j.tra.2003.11.003
   Siu VW, 2012, J ENVIRON PUBLIC HEA, V2012, DOI 10.1155/2012/203141
   Song Y, 2004, J AM PLANN ASSOC, V70, P210, DOI 10.1080/01944360408976371
   Tachieva G., 2010, SPRAWL REPAIR MANUAL
   Turrell G, 2013, HEALTH PLACE, V19, P89, DOI 10.1016/j.healthplace.2012.10.008
   Urban Land Institute, 2013, INT HLTH BUILT ENV
   Walk Score, 2014, WALK SCOR WALK SCOR
   Yamada I, 2012, PROF GEOGR, V64, P157, DOI 10.1080/00330124.2011.583592
NR 42
TC 11
Z9 11
U1 0
U2 34
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0749-3797
EI 1873-2607
J9 AM J PREV MED
JI Am. J. Prev. Med.
PD OCT
PY 2014
VL 47
IS 4
BP 481
EP 486
DI 10.1016/j.amepre.2014.05.008
PG 6
WC Public, Environmental & Occupational Health; Medicine, General &
   Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA AP9GJ
UT WOS:000342386700016
PM 24975010
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Guzman, J
   Jauregui, AN
   Merscher-Gomez, S
   Maiguel, D
   Muresan, C
   Mitrofanova, A
   Diez-Sampedro, A
   Szust, J
   Yoo, TH
   Villarreal, R
   Pedigo, C
   Molano, RD
   Johnson, K
   Kahn, B
   Hartleben, B
   Huber, TB
   Saha, J
   Burke, GW
   Abel, ED
   Brosius, FC
   Fornoni, A
AF Guzman, Johanna
   Jauregui, Alexandra N.
   Merscher-Gomez, Sandra
   Maiguel, Dony
   Muresan, Cristina
   Mitrofanova, Alla
   Diez-Sampedro, Ana
   Szust, Joel
   Yoo, Tae-Hyun
   Villarreal, Rodrigo
   Pedigo, Christopher
   Molano, R. Damaris
   Johnson, Kevin
   Kahn, Barbara
   Hartleben, Bjoern
   Huber, Tobias B.
   Saha, Jharna
   Burke, George W., III
   Abel, E. Dale
   Brosius, Frank C.
   Fornoni, Alessia
TI Podocyte-Specific GLUT4-Deficient Mice Have Fewer and Larger Podocytes
   and Are Protected From Diabetic Nephropathy
SO DIABETES
LA English
DT Article
ID FOCAL SEGMENTAL GLOMERULOSCLEROSIS; URINARY ALBUMIN EXCRETION;
   INSULIN-RESISTANCE; GLUCOSE-TRANSPORTER; GLOMERULAR PODOCYTE; ACTIN
   CYTOSKELETON; MAMMALIAN TARGET; RENAL-DISEASE; MICROALBUMINURIA; MTOR
AB Podocytes are a major component of the glomerular filtration barrier, and their ability to sense insulin is essential to prevent proteinuria. Here we identify the insulin downstream effector GLUT4 as a key modulator of podocyte function in diabetic nephropathy (DN). Mice with a podocyte-specific deletion of GLUT4 (G4 KO) did not develop albuminuria despite having larger and fewer podocytes than wild-type (WT) mice. Glomeruli from G4 KO mice were protected from diabetes-induced hypertrophy, mesangial expansion, and albuminuria and failed to activate the mammalian target of rapamycin (mTOR) pathway. In order to investigate whether the protection observed in G4 KO mice was due to the failure to activate mTOR, we used three independent in vivo experiments. G4 KO mice did not develop lipopolysaccharide-induced albuminuria, which requires mTOR activation. On the contrary, G4 KO mice as well as WT mice treated with the mTOR inhibitor rapamycin developed worse adriamycin-induced nephropathy than WT mice, consistent with the fact that adriamycin toxicity is augmented by mTOR inhibition. In summary, GLUT4 deficiency in podocytes affects podocyte nutrient sensing, results in fewer and larger cells, and protects mice from the development of DN. This is the first evidence that podocyte hypertrophy concomitant with podocytopenia may be associated with protection from proteinuria.
C1 [Guzman, Johanna; Jauregui, Alexandra N.; Maiguel, Dony; Szust, Joel; Villarreal, Rodrigo; Molano, R. Damaris; Johnson, Kevin; Fornoni, Alessia] Univ Miami, Miller Sch Med, Diabet Res Inst, Miami, FL 33136 USA.
   [Guzman, Johanna; Merscher-Gomez, Sandra; Muresan, Cristina; Mitrofanova, Alla; Yoo, Tae-Hyun; Villarreal, Rodrigo; Pedigo, Christopher; Fornoni, Alessia] Univ Miami, Miller Sch Med, Dept Med, Div Nephrol & Hypertens, Miami, FL 33136 USA.
   [Diez-Sampedro, Ana] Univ Miami, Miller Sch Med, Dept Physiol, Miami, FL 33136 USA.
   [Yoo, Tae-Hyun; Burke, George W., III] Univ Miami, Miller Sch Med, Dept Surg, Miami, FL 33136 USA.
   [Kahn, Barbara] Harvard Univ, Sch Med, Dept Med, Beth Israel Deaconess Med Ctr, Boston, MA USA.
   [Hartleben, Bjoern; Huber, Tobias B.] Univ Freiburg, Div Nephrol, D-79106 Freiburg, Germany.
   [Saha, Jharna; Brosius, Frank C.] Univ Michigan, Div Nephrol, Ann Arbor, MI 48109 USA.
   [Abel, E. Dale] Univ Utah, Div Endocrinol Metab & Diabet, Salt Lake City, UT USA.
   [Abel, E. Dale] Univ Utah, Program Mol Med, Salt Lake City, UT USA.
RP Fornoni, A (corresponding author), Univ Miami, Miller Sch Med, Diabet Res Inst, Miami, FL 33136 USA.
EM afornoni@med.miami.edu
RI Molano, Ruth Damaris/B-8633-2015; Mitrofanova, Alla/L-1590-2019
OI Molano, Ruth Damaris/0000-0002-6132-8750; Mitrofanova,
   Alla/0000-0001-5065-9522; Huber, Tobias B./0000-0001-7175-5062; Abel, E.
   Dale/0000-0001-5290-0738; fornoni, Alessia/0000-0002-1313-7773
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [U01HL087947,
   DK-090316]; Forest County Potawatomi Community Foundation; Max and Yetta
   Karasik Family Foundation; Diabetes Research Institute Foundation;
   Diabetic Complications Consortium (DiaComp); Peggy and Harold Katz
   Family Foundation; Stanley J. Glaser Foundation Research Award;
   University of Miami Clinical and Translational Science Institute, from
   the National Center for Advancing Translational Sciences [1UL1TR000460];
   National Institute on Minority Health and Health DisparitiesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute on Minority Health & Health
   Disparities (NIMHD); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1TR000460] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Diabetes &
   Digestive & Kidney Diseases (NIDDK) [R37DK043051, P30DK020572] Funding
   Source: NIH RePORTER
FX E.D.A. was supported by National Institutes of Health grant U01HL087947.
   A.F. and S.M.-G. were supported by National Institutes of Health grant
   DK-090316, the Forest County Potawatomi Community Foundation, the Max
   and Yetta Karasik Family Foundation, the Diabetes Research Institute
   Foundation (diabetesresearch.org), the Diabetic Complications Consortium
   (DiaComp), and the Peggy and Harold Katz Family Foundation. S.M.-G. was
   also supported by the Stanley J. Glaser Foundation Research Award. A.F.
   was also supported by grant 1UL1TR000460, University of Miami Clinical
   and Translational Science Institute, from the National Center for
   Advancing Translational Sciences, and the National Institute on Minority
   Health and Health Disparities.
CR Abel ED, 1999, J CLIN INVEST, V104, P1703, DOI 10.1172/JCI7605
   Atkins KB, 2007, AM J PHYSIOL-HEART C, V293, pH402, DOI 10.1152/ajpheart.00854.2006
   Buller CL, 2011, AM J PHYSIOL-RENAL, V301, pF588, DOI 10.1152/ajprenal.00472.2010
   Cho ME, 2007, AM J KIDNEY DIS, V49, P310, DOI 10.1053/j.ajkd.2006.10.020
   Coward RJM, 2005, DIABETES, V54, P3095, DOI 10.2337/diabetes.54.11.3095
   Eid AA, 2010, J BIOL CHEM, V285, P37503, DOI 10.1074/jbc.M110.136796
   Ekstrand AV, 1998, NEPHROL DIAL TRANSPL, V13, P3079, DOI 10.1093/ndt/13.12.3079
   Faul C, 2008, NAT MED, V14, P931, DOI 10.1038/nm.1857
   Faul C, 2007, TRENDS CELL BIOL, V17, P428, DOI 10.1016/j.tcb.2007.06.006
   Fornoni A, 2010, NEW ENGL J MED, V363, P2068, DOI 10.1056/NEJMcibr1008395
   FORSBLOM CM, 1995, DIABETOLOGIA, V38, P363, DOI 10.1007/s001250050294
   Fukuda A, 2012, J AM SOC NEPHROL, V23, P1351, DOI 10.1681/ASN.2012030271
   Godel M, 2011, J CLIN INVEST, V121, P2197, DOI 10.1172/JCI44774
   GROOP L, 1993, DIABETOLOGIA, V36, P642, DOI 10.1007/BF00404074
   Hallows KR, 2010, AM J PHYSIOL-RENAL, V298, pF1067, DOI 10.1152/ajprenal.00005.2010
   Inoki K, 2011, J CLIN INVEST, V121, P2181, DOI 10.1172/JCI44771
   Kao AW, 1999, J BIOL CHEM, V274, P17742, DOI 10.1074/jbc.274.25.17742
   Kim DK, 2012, DIABETOLOGIA, V55, P1205, DOI 10.1007/s00125-012-2467-7
   Kim JS, 2012, CELL BIOL INT, V36, P305, DOI 10.1042/CBI20100524
   Kolavennu V, 2008, DIABETES, V57, P714, DOI 10.2337/db07-1241
   Kume S, 2012, DIABETES, V61, P23, DOI 10.2337/db11-0555
   Lee VWS, 2011, NEPHROLOGY, V16, P30, DOI 10.1111/j.1440-1797.2010.01383.x
   Lennon R, 2009, DIABETOLOGIA, V52, P1944, DOI 10.1007/s00125-009-1423-7
   Lennon R, 2009, NEPHROL DIAL TRANSPL, V24, P3288, DOI 10.1093/ndt/gfp302
   Lewko B, 2005, KIDNEY BLOOD PRESS R, V28, P1, DOI 10.1159/000080889
   Liu L, 2010, J BIOL CHEM, V285, P38362, DOI 10.1074/jbc.M110.141168
   Lorne E, 2009, AM J RESP CELL MOL, V41, P237, DOI 10.1165/rcmb.2008-0290OC
   Miyazaki Y, 2007, KIDNEY INT, V72, P1367, DOI 10.1038/sj.ki.5002516
   Moeller MJ, 2003, GENESIS, V35, P39, DOI 10.1002/gene.10164
   MOGENSEN CE, 1980, DIABETOLOGIA, V18, P453
   Moutzouris DAD, 2007, RENAL FAILURE, V29, P353, DOI 10.1080/08860220601184126
   Musso C, 2006, CLIN J AM SOC NEPHRO, V1, P616, DOI 10.2215/CJN.01271005
   Mykkanen L, 1998, DIABETES, V47, P793, DOI 10.2337/diabetes.47.5.793
   Ohtomo S, 2007, KIDNEY INT, V72, P1512, DOI 10.1038/sj.ki.5002570
   Parvanova AI, 2006, DIABETES, V55, P1456, DOI 10.2337/db05-1484
   Peng FF, 2008, DIABETES, V57, P1683, DOI 10.2337/db07-1149
   Pessin JE, 2000, J CLIN INVEST, V106, P165, DOI 10.1172/JCI10582
   Piguet AC, 2008, J HEPATOL, V49, P78, DOI 10.1016/j.jhep.2008.03.024
   Sanden SK, 2003, J AM SOC NEPHROL, V14, P2484, DOI 10.1097/01.ASN.0000089829.45296.7C
   Schernthaner G, 2004, J CLIN ENDOCR METAB, V89, P6068, DOI 10.1210/jc.2003-030861
   Schiffer M, 2005, AM J PHYSIOL-RENAL, V289, pF186, DOI 10.1152/ajprenal.00234.2004
   Shen WH, 2008, J BIOL CHEM, V283, P13842, DOI 10.1074/jbc.M801510200
   Stuart CA, 2010, MED SCI SPORT EXER, V42, P96, DOI 10.1249/MSS.0b013e3181ad7f36
   Tejada T, 2008, KIDNEY INT, V73, P1385, DOI 10.1038/ki.2008.109
   Wang YL, 2010, AM J PHYSIOL-RENAL, V299, pF99, DOI 10.1152/ajprenal.00466.2009
   Wellen KE, 2010, MOL CELL, V40, P323, DOI 10.1016/j.molcel.2010.10.004
   Welsh GI, 2010, CELL METAB, V12, P329, DOI 10.1016/j.cmet.2010.08.015
   Wharram BL, 2005, J AM SOC NEPHROL, V16, P2941, DOI 10.1681/ASN.2005010055
   Wiggins JE, 2005, J AM SOC NEPHROL, V16, P2953, DOI 10.1681/ASN.2005050488
   YIP J, 1993, LANCET, V342, P883, DOI 10.1016/0140-6736(93)91943-G
   YIP J, 1993, LANCET, V341, P369, DOI 10.1016/0140-6736(93)90167-F
   Zhang HY, 2008, AM J PHYSIOL-RENAL, V295, pF1071, DOI 10.1152/ajprenal.90208.2008
   Zhang HY, 2010, AM J PHYSIOL-RENAL, V299, pF91, DOI 10.1152/ajprenal.00021.2010
   Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025
NR 54
TC 37
Z9 37
U1 0
U2 10
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
EI 1939-327X
J9 DIABETES
JI Diabetes
PD FEB
PY 2014
VL 63
IS 2
BP 701
EP 714
DI 10.2337/db13-0752
PG 14
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AA5BG
UT WOS:000331110000036
PM 24101677
OA Green Published, hybrid
DA 2021-10-30
ER

PT J
AU Thomas, E
   Liang, TJ
AF Thomas, Emmanuel
   Liang, T. Jake
TI Experimental models of hepatitis B and C - new insights and progress
SO NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
LA English
DT Review
ID ADULT HUMAN HEPATOCYTES; INNATE IMMUNE-RESPONSE; HEPATOMA-CELL LINE;
   IN-VITRO INFECTION; VIRUS GENOTYPE 3A; NON-A; EFFICIENT REPLICATION;
   DRUG-METABOLISM; MOUSE MODEL; TRANSIENT EXPRESSION
AB Viral hepatitis is a major cause of morbidity and mortality, affecting hundreds of millions of people worldwide. Hepatitis-causing viruses initiate disease by establishing both acute and chronic infections, and several of these viruses are specifically associated with the development of hepatocellular carcinoma. Consequently, intense research efforts have been focusing on increasing our understanding of hepatitis virus biology and on improving antiviral therapy and vaccination strategies. Although valuable information on viral hepatitis emerged from careful epidemiological studies on sporadic outbreaks in humans, experimental models using cell culture, rodent and non-human primates were essential in advancing the field. Through the use of these experimental models, improvement in both the treatment and prevention of viral hepatitis has progressed rapidly; however, agents of viral hepatitis are still among the most common pathogens infecting humans. In this Review, we describe the important part that these experimental models have played in the study of viral hepatitis and led to monumental advances in our understanding and treatment of these pathogens. Ongoing developments in experimental models are also described.
C1 [Thomas, Emmanuel] Schiff Ctr Liver Dis, Room PAP514,Papanicolaou Bldg,1550 NW 10th Ave, Miami, FL 33136 USA.
   [Thomas, Emmanuel] Sylvester Canc Ctr, Room PAP514,Papanicolaou Bldg,1550 NW 10th Ave, Miami, FL 33136 USA.
   [Liang, T. Jake] NIH, Liver Dis Branch, Bldg 10-9B16, Bethesda, MD 20892 USA.
RP Liang, TJ (corresponding author), NIH, Liver Dis Branch, Bldg 10-9B16, Bethesda, MD 20892 USA.
EM jliang@nih.gov
FU Miami Center for AIDS Research, Leonard M. Miller School of Medicine,
   USA [P30AI073961]; Miami CTSI KL2 program; NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [KL2TR000461] Funding Source:
   NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [P30AI073961] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Diabetes & Digestive &
   Kidney Diseases (NIDDK) [ZIADK054505, ZIADK054503, ZIADK054500,
   ZIADK054511, ZIADK054504] Funding Source: NIH RePORTER
FX E.T. acknowledges funding support from the Miami Center for AIDS
   Research, Leonard M. Miller School of Medicine, USA (P30AI073961) and a
   the Miami CTSI KL2 program.
CR ALTER HJ, 1978, LANCET, V1, P459
   Altevogt BM, 2012, SCIENCE, V335, P41, DOI 10.1126/science.1217521
   Andersson TB, 2012, EXPERT OPIN DRUG MET, V8, P909, DOI 10.1517/17425255.2012.685159
   Andrus L, 2011, HEPATOLOGY, V54, P1901, DOI 10.1002/hep.24557
   BARTENSCHLAGER R, 1992, EMBO J, V11, P3413, DOI 10.1002/j.1460-2075.1992.tb05420.x
   Bartenschlager R, 2002, NAT REV DRUG DISCOV, V1, P911, DOI 10.1038/nrd942
   Bartenschlager R, 2000, BEST PRACT RES CL GA, V14, P241, DOI 10.1053/bega.1999.0073
   Ben Ari Z, 2015, CLIN LIVER DIS, V19, P341, DOI 10.1016/j.cld.2015.01.006
   Bigger CB, 2004, J VIROL, V78, P13779, DOI 10.1128/JVI.78.24.13779-13792.2004
   Bility MT, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004032
   Bissig KD, 2010, J CLIN INVEST, V120, P924, DOI 10.1172/JCI40094
   Blight KJ, 2002, J VIROL, V76, P13001, DOI 10.1128/JVI.76.24.13001-13014.2002
   Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972
   BLUMBERG BS, 1965, J AMER MED ASSOC, V191, P541, DOI 10.1001/jama.1965.03080070025007
   BRIGHTON WD, 1971, NATURE-NEW BIOL, V232, P57, DOI 10.1038/newbio232057a0
   Bukh J, 2002, P NATL ACAD SCI USA, V99, P14416, DOI 10.1073/pnas.212532699
   Bukh J, 2004, HEPATOLOGY, V39, P1469, DOI 10.1002/hep.20268
   Bukh J, 2012, GASTROENTEROLOGY, V142, P1279, DOI 10.1053/j.gastro.2012.02.016
   Cai J., 2008, STEM BOOK
   Carpentier A, 2014, J CLIN INVEST, V124, P4953, DOI 10.1172/JCI75456
   Catanese MT, 2015, VIROLOGY, V479, P221, DOI 10.1016/j.virol.2015.03.014
   CHANG CM, 1987, EMBO J, V6, P675, DOI 10.1002/j.1460-2075.1987.tb04807.x
   Chavez D, 2009, VIROLOGY, V390, P186, DOI 10.1016/j.virol.2009.05.005
   Chen JZ, 2014, CELL RES, V24, P1050, DOI 10.1038/cr.2014.116
   Cheng L, 2015, ANTIVIR RES, V121, P1, DOI 10.1016/j.antiviral.2015.06.012
   CHISARI FV, 1985, SCIENCE, V230, P1157, DOI 10.1126/science.3865369
   CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562
   CHOO QL, 1994, P NATL ACAD SCI USA, V91, P1294, DOI 10.1073/pnas.91.4.1294
   Cormier EG, 2004, P NATL ACAD SCI USA, V101, P7270, DOI 10.1073/pnas.0402253101
   Dandri M, 2001, HEPATOLOGY, V34, P824, DOI 10.1053/jhep.2001.28189
   Dandri M, 2013, SEMIN IMMUNOPATHOL, V35, P7, DOI 10.1007/s00281-012-0335-7
   Deinhard F, 1985, J EXP MED, V125, P673
   DEINHARDT F, 1962, AM J HYG, V75, P311, DOI 10.1093/oxfordjournals.aje.a120252
   Delaney WE, 1998, HEPATOLOGY, V28, P1134, DOI 10.1002/hep.510280432
   Di Q, 1997, VIROLOGY, V229, P25, DOI 10.1006/viro.1996.8422
   Dorner M, 2013, NATURE, V501, P237, DOI 10.1038/nature12427
   Dorner M, 2011, NATURE, V474, P208, DOI 10.1038/nature10168
   Elaut G, 2006, CURR DRUG METAB, V7, P629, DOI 10.2174/138920006778017759
   FEINSTONE SM, 1973, SCIENCE, V182, P1026, DOI 10.1126/science.182.4116.1026
   FEINSTONE SM, 1975, NEW ENGL J MED, V292, P767, DOI 10.1056/NEJM197504102921502
   Fournier C, 1998, J GEN VIROL, V79, P2367, DOI 10.1099/0022-1317-79-10-2367
   Friebe P, 2005, J VIROL, V79, P380, DOI 10.1128/JVI.79.1.380-392.2005
   GALLE PR, 1994, GASTROENTEROLOGY, V106, P664, DOI 10.1016/0016-5085(94)90700-5
   Gao M, 2010, NATURE, V465, P96, DOI 10.1038/nature08960
   Gerlich WH, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-239
   Giersch K, 2014, J HEPATOL, V60, P538, DOI 10.1016/j.jhep.2013.11.010
   Gomez-Lechon MJ, 2004, CURR DRUG METAB, V5, P443, DOI 10.2174/1389200043335414
   Gottwein JM, 2010, J VIROL, V84, P5277, DOI 10.1128/JVI.02667-09
   Gripon P, 2002, P NATL ACAD SCI USA, V99, P15655, DOI 10.1073/pnas.232137699
   GRIPON P, 1988, J VIROL, V62, P4136, DOI 10.1128/JVI.62.11.4136-4143.1988
   Guillouzo A, 2007, CHEM-BIOL INTERACT, V168, P66, DOI 10.1016/j.cbi.2006.12.003
   He WH, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004840
   Heller T, 2005, P NATL ACAD SCI USA, V102, P2579, DOI 10.1073/pnas.0409666102
   HILLIS WD, 1961, AM J HYG, V73, P316, DOI 10.1093/oxfordjournals.aje.a120191
   Hyun I, 2014, NATURE, V509, P27, DOI 10.1038/509027a
   Israelow B, 2014, HEPATOLOGY, V60, P1170, DOI 10.1002/hep.27227
   Jopling CL, 2005, SCIENCE, V309, P1577, DOI 10.1126/science.1113329
   Jost S, 2007, J VIROL, V81, P10588, DOI 10.1128/JVI.02489-06
   Kahn J, 2012, HASTINGS CENT REP, V42, pS27, DOI 10.1002/hast.105
   Kanwal F, 2011, GASTROENTEROLOGY, V140, P1182, DOI 10.1053/j.gastro.2010.12.032
   Kapoor A, 2011, P NATL ACAD SCI USA, V108, P11608, DOI 10.1073/pnas.1101794108
   Kato T, 2003, GASTROENTEROLOGY, V125, P1808, DOI 10.1053/j.gastro.2003.09.023
   Kato T, 2007, J VIROL, V81, P4405, DOI 10.1128/JVI.02334-06
   Kawamura T, 1997, HEPATOLOGY, V25, P1014, DOI 10.1002/hep.510250437
   Kennedy EM, 2015, VIROLOGY, V476, P196, DOI 10.1016/j.virol.2014.12.001
   KHUROO MS, 1980, AM J MED, V68, P818, DOI 10.1016/0002-9343(80)90200-4
   Kock J, 2001, J VIROL, V75, P5084, DOI 10.1128/JVI.75.11.5084-5089.2001
   Kolykhalov AA, 1997, SCIENCE, V277, P570, DOI 10.1126/science.277.5325.570
   KRUGMAN S, 1967, J AMER MED ASSOC, V200, P365, DOI 10.1001/jama.200.5.365
   Ladner SK, 1997, ANTIMICROB AGENTS CH, V41, P1715, DOI 10.1128/AAC.41.8.1715
   Lagaye S, 2013, FUTURE VIROL, V8, P493, DOI 10.2217/FVL.13.29
   Lan KH, 2002, ONCOGENE, V21, P4801, DOI 10.1038/sj.onc.1205589
   Lanford RE, 2010, SCIENCE, V327, P198, DOI 10.1126/science.1178178
   Levy G, 2015, NAT BIOTECHNOL, V33, P1264, DOI 10.1038/nbt.3377
   Li K, 2005, J BIOL CHEM, V280, P16739, DOI 10.1074/jbc.M414139200
   Li YP, 2015, J VIROL, V89, P811, DOI 10.1128/JVI.02877-14
   Liang TJ, 2015, HEPATOLOGY, V62, P1893, DOI 10.1002/hep.28025
   Liang TJ, 2014, NEW ENGL J MED, V370, P2043, DOI 10.1056/NEJMe1403619
   Liang TJ, 2013, NAT MED, V19, P869, DOI 10.1038/nm.3183
   Liang TJ, 2013, NEW ENGL J MED, V368, P1907, DOI 10.1056/NEJMra1213651
   Lindenbach BD, 2005, SCIENCE, V309, P623, DOI 10.1126/science.1114016
   Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110
   Lohmann V, 2014, J MED CHEM, V57, P1627, DOI 10.1021/jm401401n
   Lu YH, 2012, BIOTECHNOL BIOENG, V109, P595, DOI 10.1002/bit.23349
   Lucifora J, 2014, SCIENCE, V343, P1221, DOI 10.1126/science.1243462
   Lyons S, 2014, J GEN VIROL, V95, P1701, DOI 10.1099/vir.0.065094-0
   Maher J, 1999, HEPATOLOGY, V29, P990, DOI 10.1002/hep.510290356
   Manickam C, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00690
   Mason WS, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a021352
   MASON WS, 1982, P NATL ACAD SCI-BIOL, V79, P3997, DOI 10.1073/pnas.79.13.3997
   McPhee F, 2012, ANTIMICROB AGENTS CH, V56, P5387, DOI 10.1128/AAC.01186-12
   MELNICK JL, 1972, CAN MED ASSOC J, V106, P461
   Mercer DF, 2001, NAT MED, V7, P927, DOI 10.1038/90968
   Murray CL, 2011, ANNU REV MICROBIOL, V65, P307, DOI 10.1146/annurev-micro-090110-102954
   Naik S, 2009, EXPERT OPIN BIOL TH, V9, P1163, DOI 10.1517/14712590903170653
   Nair S, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-363
   Naka K, 2006, VIROLOGY, V346, P348, DOI 10.1016/j.virol.2005.10.023
   NAKABAYASHI H, 1982, CANCER RES, V42, P3858
   Narbus CM, 2011, J VIROL, V85, P12087, DOI 10.1128/JVI.05843-11
   Ndongo-Thiam N, 2011, HEPATOLOGY, V54, P406, DOI 10.1002/hep.24386
   O'Connell J. F., 1999, METH MOLEC MED, V19, P495
   OCHIYA T, 1989, P NATL ACAD SCI USA, V86, P1875, DOI 10.1073/pnas.86.6.1875
   Park US, 2000, ONCOGENE, V19, P3384, DOI 10.1038/sj.onc.1203674
   Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938
   Ploss A, 2010, P NATL ACAD SCI USA, V107, P3141, DOI 10.1073/pnas.0915130107
   Ploss A, 2009, NATURE, V457, P882, DOI 10.1038/nature07684
   Podevin P, 2010, GASTROENTEROLOGY, V139, P1355, DOI 10.1053/j.gastro.2010.06.058
   Pollicino T, 2006, GASTROENTEROLOGY, V130, P823, DOI 10.1053/j.gastro.2006.01.001
   Prokunina-Olsson L, 2013, NAT GENET, V45, P164, DOI 10.1038/ng.2521
   Protzer U, 2007, GASTROENTEROLOGY, V133, P1156, DOI 10.1053/j.gastro.2007.07.021
   Quan PL, 2013, P NATL ACAD SCI USA, V110, P8194, DOI 10.1073/pnas.1303037110
   Ramanan V, 2015, SCI REP-UK, V5, DOI 10.1038/srep10833
   REYES GR, 1990, SCIENCE, V247, P1335, DOI 10.1126/science.2107574
   RIJNTJES PJM, 1988, VIRUS RES, V10, P95, DOI 10.1016/0168-1702(88)90060-3
   RIZZETTO M, 1977, GUT, V18, P997, DOI 10.1136/gut.18.12.997
   Rizzetto M, 2010, DIGEST DIS, V28, P139, DOI 10.1159/000282077
   Roelandt P, 2012, J HEPATOL, V57, P246, DOI 10.1016/j.jhep.2012.03.030
   Saeed M, 2015, NATURE, V524, P471, DOI 10.1038/nature14899
   Saeed M, 2013, GASTROENTEROLOGY, V144, P56, DOI 10.1053/j.gastro.2012.09.017
   Saeed M, 2012, ANTIMICROB AGENTS CH, V56, P5365, DOI 10.1128/AAC.01256-12
   Sandmann L, 2013, VIROLOGY, V435, P70, DOI 10.1016/j.virol.2012.09.044
   Schulze A, 2007, HEPATOLOGY, V46, P1759, DOI 10.1002/hep.21896
   SCHWARTZ RE, 2013, GASTROENTEROLOGY S1, V144, pS1025
   Schwartz RE, 2012, P NATL ACAD SCI USA, V109, P2544, DOI 10.1073/pnas.1121400109
   Sedano CD, 2015, SEMIN LIVER DIS, V35, P75, DOI 10.1055/s-0034-1397351
   Seeger C., 2015, VIROLOGY, V1, P24
   Seeger C, 2015, VIROLOGY, V479, P672, DOI 10.1016/j.virol.2015.02.031
   Seeger C, 2014, MOL THER-NUCL ACIDS, V3, DOI 10.1038/mtna.2014.68
   SELLS MA, 1987, P NATL ACAD SCI USA, V84, P1005, DOI 10.1073/pnas.84.4.1005
   Shan J, 2013, NAT CHEM BIOL, V9, P514, DOI 10.1038/nchembio.1270
   Sheahan T, 2014, CELL HOST MICROBE, V15, P190, DOI 10.1016/j.chom.2014.01.007
   Shlomai A, 2014, P NATL ACAD SCI USA, V111, P12193, DOI 10.1073/pnas.1412631111
   SIMONS JN, 1995, P NATL ACAD SCI USA, V92, P3401, DOI 10.1073/pnas.92.8.3401
   Sivaraman A, 2005, CURR DRUG METAB, V6, P569, DOI 10.2174/138920005774832632
   Smith Bryce D., 2012, Morbidity and Mortality Weekly Report, V61, P1
   Sourisseau M, 2013, GASTROENTEROLOGY, V145, P966, DOI 10.1053/j.gastro.2013.07.026
   SPRENGEL R, 1985, J MED VIROL, V15, P323, DOI 10.1002/jmv.1890150402
   Sprinzl MF, 2001, J VIROL, V75, P5108, DOI 10.1128/JVI.75.11.5108-5118.2001
   Stapleton JT, 2011, J GEN VIROL, V92, P233, DOI 10.1099/vir.0.027490-0
   Stumper R, 2005, J VIROL, V79, P2689, DOI 10.1128/JVI.79.5.2689-2699.2005
   SUMMERS J, 1978, P NATL ACAD SCI USA, V75, P4533, DOI 10.1073/pnas.75.9.4533
   SUREAU C, 1986, CELL, V47, P37, DOI 10.1016/0092-8674(86)90364-8
   TABOR E, 1978, LANCET, V1, P463, DOI 10.1016/s0140-6736(78)90132-0
   Takebe T, 2013, NATURE, V499, P481, DOI 10.1038/nature12271
   Tesfaye A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077298
   Thomas DL, 2009, NATURE, V461, P798, DOI 10.1038/nature08463
   Thomas E, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a021345
   Thomas E, 2012, GASTROENTEROLOGY, V142, P978, DOI 10.1053/j.gastro.2011.12.055
   Tsai NC, 2015, DIGEST DIS SCI, V60, P260, DOI 10.1007/s10620-014-3336-7
   Tsukiyama-Kohara K, 2014, EXP ANIM TOKYO, V63, P367, DOI 10.1538/expanim.14-0007
   von Schaewen M, 2014, ANTIVIR RES, V104, P15, DOI 10.1016/j.antiviral.2014.01.007
   Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268
   Walter E, 1996, HEPATOLOGY, V24, P1, DOI 10.1002/hep.510240101
   Wang JL, 2015, WORLD J GASTROENTERO, V21, P9598, DOI 10.3748/wjg.v21.i32.9598
   WANG KS, 1986, NATURE, V323, P508, DOI 10.1038/323508a0
   Washburn ML, 2011, GASTROENTEROLOGY, V140, P1334, DOI 10.1053/j.gastro.2011.01.001
   Wieland SF, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a021469
   Woerz I, 2009, J VIRAL HEPATITIS, V16, P1, DOI 10.1111/j.1365-2893.2008.01066.x
   Wu X. F., 2014, PLOS PATHOG, V8
   Xia L, 2009, BIOMATERIALS, V30, P5927, DOI 10.1016/j.biomaterials.2009.07.022
   YAGINUMA K, 1987, P NATL ACAD SCI USA, V84, P2678, DOI 10.1073/pnas.84.9.2678
   Yan H, 2015, ANTIVIR RES, V121, P24, DOI 10.1016/j.antiviral.2015.06.002
   Yan H, 2012, ELIFE, V1, DOI 10.7554/eLife.00049
   Yang PL, 2002, P NATL ACAD SCI USA, V99, P13825, DOI 10.1073/pnas.202398599
   Yi M, 2006, P NATL ACAD SCI USA, V103, P2310, DOI 10.1073/pnas.0510727103
   Yu SY, 2010, J GEN VIROL, V91, P2080, DOI 10.1099/vir.0.020552-0
   Zeisel MB, 2015, GUT, V64, P1314, DOI 10.1136/gutjnl-2014-308943
   Zeissig S, 2012, NAT MED, V18, P1060, DOI 10.1038/nm.2811
   Zhang J, 2015, NEW ENGL J MED, V372, P914, DOI 10.1056/NEJMoa1406011
   Zhong J, 2005, P NATL ACAD SCI USA, V102, P9294, DOI 10.1073/pnas.0503596102
NR 170
TC 46
Z9 48
U1 2
U2 26
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1759-5045
EI 1759-5053
J9 NAT REV GASTRO HEPAT
JI Nat. Rev. Gastroenterol. Hepatol.
PD JUN
PY 2016
VL 13
IS 6
BP 362
EP 374
DI 10.1038/nrgastro.2016.37
PG 13
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DO0SB
UT WOS:000377487500008
PM 27075261
OA Green Accepted, Bronze
DA 2021-10-30
ER

PT J
AU Schwartz, SJ
   Unger, JB
   Baezconde-Garbanati, L
   Zamboanga, BL
   Cordova, D
   Lorenzo-Blanco, EI
   Huang, S
   Des Rosiers, SE
   Soto, DW
   Lizzi, KM
   Villamar, JA
   Pattarroyo, M
   Szapocznik, J
AF Schwartz, Seth J.
   Unger, Jennifer B.
   Baezconde-Garbanati, Lourdes
   Zamboanga, Byron L.
   Cordova, David
   Lorenzo-Blanco, Elma I.
   Huang, Shi
   Des Rosiers, Sabrina E.
   Soto, Daniel W.
   Lizzi, Karina M.
   Villamar, Juan A.
   Pattarroyo, Monica
   Szapocznik, Jose
TI Testing the Parent-Adolescent Acculturation Discrepancy Hypothesis: A
   Five-Wave Longitudinal Study
SO JOURNAL OF RESEARCH ON ADOLESCENCE
LA English
DT Article
ID HISPANIC ADOLESCENTS; SUBSTANCE USE; LATINO ADOLESCENTS; DRUG-USE;
   YOUTH; BEHAVIOR; RISK; BICULTURALISM; INTERVENTION; TRAJECTORIES
AB This 2 1/2-year, 5-wave longitudinal study tests the hypothesis that acculturation discrepancies between Hispanic immigrant parents and adolescents would lead to compromised family functioning, which would then lead to problematic adolescent outcomes. Recent-immigrant Hispanic parent-adolescent dyads (N = 302) completed measures of acculturation and family functioning. Adolescents completed measures of positive youth development, depressive symptoms, problem behavior, and substance use. Results indicated that Time 1 discrepancies in Hispanic culture retention, and linear trajectories in some of these discrepancies, negatively predicted adolescent positive youth development, and positively predicted adolescent depressive symptoms and binge drinking, indirectly through adolescent-reported family functioning. The vast majority of effects were mediated rather than direct, supporting the acculturation discrepancy hypothesis. Implications for further research and intervention are discussed.
C1 [Schwartz, Seth J.; Huang, Shi; Lizzi, Karina M.; Szapocznik, Jose] Univ Miami, Coral Gables, FL 33124 USA.
   [Unger, Jennifer B.; Baezconde-Garbanati, Lourdes; Pattarroyo, Monica] Univ Southern Calif, Los Angeles, CA USA.
   [Zamboanga, Byron L.] Smith Coll, Northampton, MA 01063 USA.
   [Cordova, David] Univ Michigan, Ann Arbor, MI 48109 USA.
   [Lorenzo-Blanco, Elma I.; Soto, Daniel W.] Univ South Carolina, Columbia, SC USA.
   [Des Rosiers, Sabrina E.] Barry Univ, Miami Shores, FL USA.
   [Villamar, Juan A.] Northwestern Univ, Evanston, IL 60208 USA.
RP Schwartz, SJ (corresponding author), Univ Miami, Dept Publ Hlth Sci, Leonard M Miller Sch Med, 1120 NW 14th St,Suite 1073, Miami, FL 33136 USA.
EM sschwartz@med.miami.edu
OI Unger, Jennifer/0000-0001-9064-6603
FU National Institute on Drug AbuseUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute on Drug Abuse (NIDA)European Commission [DA026594]; National
   Institute on Alcohol Abuse and AlcoholismUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Alcohol Abuse & Alcoholism (NIAAA) [AA021888];
   National Center for Advancing Translational SciencesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [1UL1TR000460]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD
   HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD)
   [R25HD045810] Funding Source: NIH RePORTER; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000460]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND
   ALCOHOLISMUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse
   & Alcoholism (NIAAA) [R01AA021888] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute on Drug Abuse (NIDA)European Commission [R01DA025694] Funding
   Source: NIH RePORTER
FX Preparation of this article was supported by Grants DA026594 from the
   National Institute on Drug Abuse to Seth J. Schwartz and Jennifer B.
   Unger, by Grant AA021888 from the National Institute on Alcohol Abuse
   and Alcoholism to Jonathan G. Tubman and Seth J. Schwartz, and by
   National Center for Advancing Translational Sciences Grant 1UL1TR000460
   to Jose Szapocznik. We thank Maria-Rosa Velazquez, Tatiana Clavijo,
   Mercedes Prado, Alba Alfonso, Aleyda Marcos, Daisy Ramirez, Lissette
   Ramirez, and Perlita Carrillo for their hard work conducting assessments
   and tracking families; Dr. Judy Arroyo for her guidance and wisdom; and
   the study families for sharing their experiences with us.
CR Achenbach T. M., 2002, MANUAL ASEBA ADULT F
   Achenbach TM, 2002, J EMOT BEHAV DISORD, V10, P194, DOI 10.1177/10634266020100040101
   Bacallao ML, 2007, FAM RELAT, V56, P52, DOI 10.1111/j.1741-3729.2007.00439.x
   Bamaca-Colbert MY, 2010, J YOUTH ADOLESCENCE, V39, P1274, DOI 10.1007/s10964-009-9447-3
   BARNES HL, 1985, CHILD DEV, V56, P438, DOI 10.1111/j.1467-8624.1985.tb00118.x
   BERRY J. W., 1980, ACCULTURATION THEORY, P9, DOI DOI 10.1525/AE.1981.8.4.02A00200
   Berry JW., 1988, HLTH CROSS CULTURAL, P207
   Cespedes YM, 2008, CULT DIVERS ETHN MIN, V14, P168, DOI 10.1037/1099-9809.14.2.168
   Cole DA, 2003, J ABNORM PSYCHOL, V112, P558, DOI 10.1037/0021-843X.112.4.558
   Cordova D, 2012, PSYCHOL ADDICT BEHAV, V26, P655, DOI 10.1037/a0026438
   Costigan CL, 2010, HUM DEV, V53, P341, DOI 10.1159/000322607
   Crockett L. C., 2009, HDB US LATINO PSYCHO, P379
   Edwards LM, 2007, HISPANIC J BEHAV SCI, V29, P225, DOI 10.1177/0739986307299692
   Falicov C. J., 2013, LATINOFAMILIES THERA, V2
   FORNELL C, 1981, J MARKETING RES, V18, P39, DOI 10.2307/3151312
   Fuligni AJ, 2001, HARVARD EDUC REV, V71, P566
   Gibson C. L., 2010, J CONTEMP CRIM JUST, V27, P4
   GormanSmith D, 1996, J FAM PSYCHOL, V10, P115, DOI 10.1037/0893-3200.10.2.115
   Hancock GR, 2001, EDUC PSYCHOL MEAS, V61, P741, DOI 10.1177/00131640121971491
   Henderson Timothy J., 2011, BORDERS HIST MEXICAN
   Hofstede G., 2001, CULTURES CONSEQUENCE, V2nd
   Hussey Jon M, 2007, J Immigr Minor Health, V9, P85
   Johnston LD, 2011, MONITORING FUTURE NA, VI
   Kasinitz Philip., 2008, INHERITING CITY CHIL
   Keyes CLM, 2006, AM J ORTHOPSYCHIAT, V76, P395, DOI 10.1037/0002-9432.76.3.395
   Kim SY, 2013, DEV PSYCHOL, V49, P900, DOI 10.1037/a0029169
   Kline R. B., 2012, PRINCIPLES PRACTICES, V3
   Knight G. P., 2009, STUDYING ETHNIC MINO
   Knight GP, 2010, J EARLY ADOLESCENCE, V30, P444, DOI 10.1177/0272431609338178
   Knight GP, 2009, J RES ADOLESCENCE, V19, P625, DOI 10.1111/j.1532-7795.2009.00614.x
   Lau AS, 2005, J FAM PSYCHOL, V19, P367, DOI 10.1037/0893-3200.19.3.367
   MacKinnon D. P., 2008, INTRO STAT MEDIATION, DOI 10.4324/9780203809556
   Martinez CR, 2006, FAM RELAT, V55, P306, DOI 10.1111/j.1741-3729.2006.00404.x
   Martinez CR, 2005, J CONSULT CLIN PSYCH, V73, P841, DOI 10.1037/0022-006X.73.5.841
   McLaughlin KA, 2007, J ABNORM CHILD PSYCH, V35, P801, DOI 10.1007/s10802-007-9128-1
   Muthen L.K., 2010, MPLUS USERS GUIDE
   National Highway Traffic Safety Administration, 2009, DOTHS810985
   Nguyen AMD, 2013, J CROSS CULT PSYCHOL, V44, P122, DOI 10.1177/0022022111435097
   Olson D., 1989, CIRCUMPLEX MODEL SYS
   Pantin Hilda, 2003, Prev Sci, V4, P189, DOI 10.1023/A:1024601906942
   Prado G, 2007, J CONSULT CLIN PSYCH, V75, P914, DOI 10.1037/0022-006X.75.6.914
   Prado Guillermo, 2011, Psychosocial Intervention, V20, P63, DOI 10.5093/in2011v20n1a6
   RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306
   Redfield R., 1936, AM ANTHROPOL, V38, P149, DOI DOI 10.1525/AA.1936.38.1.02A00330
   Roberts RE, 1999, J EARLY ADOLESCENCE, V19, P301, DOI 10.1177/0272431699019003001
   Rosenberg M., 1968, SOC ADOLESCENT SELF
   Rumbalt R., 2006, IMMIGRANT AM PORTRAI
   Sam DL, 2010, PERSPECT PSYCHOL SCI, V5, P472, DOI 10.1177/1745691610373075
   Schwartz SJ, 2014, CULT DIVERS ETHN MIN, V20, P1, DOI 10.1037/a0033391
   Schwartz SJ, 2013, CHILD DEV, V84, P1355, DOI 10.1111/cdev.12047
   Schwartz SJ, 2012, IDENTITY, V12, P93, DOI 10.1080/15283488.2012.668730
   Schwartz SJ, 2010, AM PSYCHOL, V65, P237, DOI 10.1037/a0019330
   Schwartz SJ, 2005, J EARLY ADOLESCENCE, V25, P392, DOI 10.1177/0272431605279843
   Smokowski P. R., 2011, BECOMING BICULTURAL
   Smokowski PR, 2008, FAM RELAT, V57, P295, DOI 10.1111/j.1741-3729.2008.00501.x
   Smokowski PR, 2010, CHILD PSYCHIAT HUM D, V41, P133, DOI 10.1007/s10578-009-0157-6
   Stepick A, 2003, THIS LAND IS OUR LAND: IMMIGRANTS AND POWER IN MIAMI, P1
   Suarez-Orozco C., 2001, CHILDREN IMMIGRATION
   SZAPOCZNIK J, 1993, AM PSYCHOL, V48, P400, DOI 10.1037/0003-066X.48.4.400
   SZAPOCZNIK J, 1986, HISPANIC J BEHAV SCI, V8, P303, DOI 10.1177/07399863860084001
   Szapocznik J., 1980, INT J INTERCULT REL, V4, P353, DOI [10.1016/0147-1767(80)90010-3, DOI 10.1016/0147-1767(80)90010-3]
   Telzer EH, 2010, HUM DEV, V53, P313, DOI 10.1159/000322476
   Tolan PH, 1997, PSYCHOL ASSESSMENT, V9, P212, DOI 10.1037/1040-3590.9.3.212
   Torney-Purta J, 2007, J YOUTH ADOLESCENCE, V36, P111, DOI 10.1007/s10964-006-9121-y
   Triandis HC, 1998, J PERS SOC PSYCHOL, V74, P118, DOI 10.1037/0022-3514.74.1.118
   Turner CF, 1998, SCIENCE, V280, P867, DOI 10.1126/science.280.5365.867
   U. S. Census Bureau, 2011, AM FOR BORN LAST 50
   U. S. Department of State, 2014, SAL COST LIV REL
   Unger JB, 2009, J PRIM PREV, V30, P293, DOI 10.1007/s10935-009-0178-8
   Zane N., 2003, ACCULTURATION ADV TH, P39, DOI DOI 10.1037/10472-005
   Zayas L. H., 2011, LATINAS ATTEMPTING S
NR 71
TC 27
Z9 27
U1 2
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1050-8392
EI 1532-7795
J9 J RES ADOLESCENCE
JI J. Res. Adolesc.
PD SEP
PY 2016
VL 26
IS 3
BP 567
EP 586
DI 10.1111/jora.12214
PG 20
WC Family Studies; Psychology, Developmental
SC Family Studies; Psychology
GA DU0LH
UT WOS:000381895900015
PM 27616871
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Palmas, W
   March, D
   Darakjy, S
   Findley, SE
   Teresi, J
   Carrasquillo, O
   Luchsinger, JA
AF Palmas, Walter
   March, Dana
   Darakjy, Salima
   Findley, Sally E.
   Teresi, Jeanne
   Carrasquillo, Olveen
   Luchsinger, Jose A.
TI Community Health Worker Interventions to Improve Glycemic Control in
   People with Diabetes: A Systematic Review and Meta-Analysis
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Review
ID RANDOMIZED-CONTROLLED-TRIAL; BASE-LINE CHARACTERISTICS; SELF-MANAGEMENT
   SUPPORT; MEXICAN-AMERICANS; AFRICAN-AMERICAN; CARE; EDUCATION; ADULTS;
   OUTREACH; DESIGN
AB We set out to review the efficacy of Community Health Worker (CHW) interventions to improve glycemia in people with diabetes.
   Data sources included the Cochrane Central Register of Controlled Trials, Medline, clinicaltrials.gov, Google Scholar, and reference lists of previous publications. We reviewed randomized controlled trials (RCTs) that assessed the efficacy of CHW interventions, as compared to usual care, to lower hemoglobin A1c (A1c). Two investigators independently reviewed the RCTs and assessed their quality. Only RCTs with a follow-up of at least 12 months were meta-analyzed. A random effects model was used to estimate, from unadjusted within-group mean reductions, the standardized mean difference (SMD) in A1c achieved by the CHW intervention, beyond usual care.
   Thirteen RCTs were included in the narrative review, and nine of them, which had at least 12 months of follow-up, were included in the meta-analysis. Publication bias could not be ruled-out due to the small number of trials. Outcome heterogeneity was moderate (I-2= 37 %). The SMD in A1c (95 % confidence interval) was 0.21 (0.11-0.32). Meta-regression showed an association between higher baseline A1c and a larger effect size.
   CHW interventions showed a modest reduction in A1c compared to usual care. A1c reduction was larger in studies with higher mean baseline A1c. Caution is warranted, given the small number of studies.
C1 [Palmas, Walter; Luchsinger, Jose A.] Columbia Univ, Med Ctr, Dept Med, New York, NY 10032 USA.
   [March, Dana; Darakjy, Salima; Luchsinger, Jose A.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA.
   [Findley, Sally E.] Columbia Univ, Mailman Sch Publ Hlth, Dept Sociomed Sci, New York, NY USA.
   [Teresi, Jeanne] Columbia Univ, Stroud Ctr, New York State Psychiat Inst, New York, NY USA.
   [Teresi, Jeanne] Hebrew Home Riverdale, Div Res, Bronx, NY USA.
   [Carrasquillo, Olveen] Univ Miami, Dept Med, Miami, FL USA.
RP Palmas, W (corresponding author), Columbia Univ, Med Ctr, Dept Med, PH9 East,Room 107,622 West 168th St, New York, NY 10032 USA.
EM wp56@cumc.columbia.edu
OI Luchsinger, Jose/0000-0002-5886-3648
FU National Institute on Minority Health and Health DisparitiesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute on Minority Health & Health
   Disparities (NIMHD) [P60 MD000206, P60 MD000206-08S1]; NATIONAL CENTER
   FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000460]
   Funding Source: NIH RePORTER; National Institute on Minority Health and
   Health DisparitiesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Minority Health & Health Disparities (NIMHD) [P60MD000206] Funding
   Source: NIH RePORTER
FX These analyses were supported by grants P60 MD000206 and P60
   MD000206-08S1 from the National Institute on Minority Health and Health
   Disparities.
CR Allen JK, 2011, CIRC-CARDIOVASC QUAL, V4, P595, DOI 10.1161/CIRCOUTCOMES.111.961573
   Babamoto KS, 2009, HEALTH EDUC BEHAV, V36, P113, DOI 10.1177/1090198108325911
   Brown SA, 2002, DIABETES CARE, V25, P259, DOI 10.2337/diacare.25.2.259
   Carrasquillo O, 2014, INT J GEN MED, V7, P115, DOI 10.2147/IJGM.S56250
   Centre TNC, 2011, REV MAN REVMAN
   Cherrington A, 2008, DIABETES EDUCATOR, V34, P824, DOI 10.1177/0145721708323643
   Corkery E, 1997, DIABETES CARE, V20, P254, DOI 10.2337/diacare.20.3.254
   Cummings DM, 2013, CONTEMP CLIN TRIALS, V36, P147, DOI 10.1016/j.cct.2013.06.006
   DePue JD, 2013, DIABETES CARE, V36, P1947, DOI 10.2337/dc12-1969
   Durlak JA, 2009, J PEDIATR PSYCHOL, V34, P917, DOI 10.1093/jpepsy/jsp004
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fritz CO, 2012, J EXP PSYCHOL GEN, V141, P2, DOI 10.1037/a0024338
   Gary TL, 2009, ARCH INTERN MED, V169, P1788, DOI 10.1001/archinternmed.2009.338
   Harkness E, 2010, DIABETES CARE, V33, P926, DOI 10.2337/dc09-1519
   Harris MI, 2001, DIABETES CARE, V24, P454, DOI 10.2337/diacare.24.3.454
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hoff T, 2012, MED CARE RES REV, V69, P619, DOI 10.1177/1077558712447688
   Islam N, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-177
   Lewin SA, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004015.pub2
   Lujan J, 2007, DIABETES EDUCATOR, V33, P660, DOI 10.1177/0145721707304080
   Mainous AG, 2007, DIABETOLOGIA, V50, P934, DOI 10.1007/s00125-006-0528-5
   Nelson K, 2014, CONTEMP CLIN TRIALS, V38, P361, DOI 10.1016/j.cct.2014.06.011
   Norris SL, 2006, DIABETIC MED, V23, P544, DOI 10.1111/j.1464-5491.2006.01845.x
   Palmas W, 2014, DIABETES CARE, V37, P963, DOI 10.2337/dc13-2142
   Perez LM, 2008, AM J PUBLIC HEALTH, V98, P11, DOI 10.2105/AJPH.2006.100842
   Perez-Escamilla R, 2014, DIABETES CARE
   Polisena J, 2009, DIABETES OBES METAB, V11, P913, DOI 10.1111/j.1463-1326.2009.01057.x
   Prezio EA, 2013, DIABETES RES CLIN PR, V100, P19, DOI 10.1016/j.diabres.2013.01.027
   Rosal MC, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-81
   Rosenthal EL, 2010, HEALTH AFFAIR, V29, P1338, DOI 10.1377/hlthaff.2010.0081
   Rothschild SK, 2013, AM J PUBLIC HLTH
   Scottish Intercollegiate Guidelines Network 50, GUID DEV HDB
   Spencer MS, 2011, AM J PUBLIC HEALTH, V101, P2253, DOI 10.2105/AJPH.2010.300106
   Sterne JAC, 2000, J CLIN EPIDEMIOL, V53, P1119, DOI 10.1016/S0895-4356(00)00242-0
   Tang TS, 2014, DIABETES CARE, V37, P1525, DOI 10.2337/dc13-2161
   Thompson SG, 2002, STAT MED, V21, P1559, DOI 10.1002/sim.1187
   Tsai AC, 2005, AM J MANAG CARE, V11, P478
   Whitley EM, 2006, J HEALTH CARE POOR U, V17, P6, DOI 10.1353/hpu.2006.0052
NR 38
TC 73
Z9 73
U1 2
U2 26
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUL
PY 2015
VL 30
IS 7
BP 1004
EP 1012
DI 10.1007/s11606-015-3247-0
PG 9
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA CK8AL
UT WOS:000356459400028
PM 25735938
OA Green Published, Bronze
DA 2021-10-30
ER

PT J
AU Metsch, LR
   Pereyra, M
   Messinger, S
   Jeanty, Y
   Parish, C
   Valverde, E
   Cardenas, G
   Boza, H
   Tomar, S
AF Metsch, Lisa R.
   Pereyra, Margaret
   Messinger, Shari
   Jeanty, Yves
   Parish, Carrigan
   Valverde, Eduardo
   Cardenas, Gabriel
   Boza, Henry
   Tomar, Scott
TI Effects of a Brief Case Management Intervention Linking People With HIV
   to Oral Health Care: Project SMILE
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; DENTAL CASE-MANAGEMENT; MEDICAL PATIENTS;
   INCREASING ACCESS; POSITIVE PATIENTS; INFECTED PERSONS; UNMET NEEDS;
   HIV/AIDS; SERVICES; MANIFESTATIONS
AB Objectives. Although people with HIV experience significant oral health problems, many consistently identify oral health as an unmet health care need. We conducted a randomized controlled trial to evaluate the impact of a dental case management intervention on dental care use.
   Methods. We evaluated the intervention according to self-reported dental care use at 6-, 12-, and 18-month follow-ups. Multivariable logistic models with generalized estimating equations were used to assess the effects of the intervention over time.
   Results. The odds of having a dental care visit were about twice as high in the intervention group as in the standard care group at 6 months (adjusted odds ratio [OR] = 2.52; 95% confidence interval [CI] = 1.58, 4.08) and 12 months (adjusted OR = 1.98; 95% CI= 1.17, 3.35), but the odds were comparable in the 2 groups by 18 months (adjustedOR = 1.07; 95% CI = 0.62, 1.86). Factors significantly associated with having a dental care visit included frequent physician visits and dental care referrals.
   Conclusions. We demonstrated that a dental case management intervention targeting people with HIV was efficacious but not sustainable over time. Barriers not addressed in the intervention must be considered to sustain its use over time.
C1 [Metsch, Lisa R.; Pereyra, Margaret; Jeanty, Yves; Valverde, Eduardo] Univ Miami, Miller Sch Med, Dept Epidemiol & Publ Hlth, Miami, FL 33136 USA.
   [Messinger, Shari; Cardenas, Gabriel; Boza, Henry] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA.
   [Metsch, Lisa R.; Parish, Carrigan] Columbia Univ, Mailman Sch Publ Hlth, Dept Sociomed Sci, New York, NY 10032 USA.
   [Tomar, Scott] Univ Florida, Coll Dent, Dept Community Dent & Behav Sci, Gainesville, FL USA.
RP Metsch, LR (corresponding author), Columbia Univ, Mailman Sch Publ Hlth, Dept Sociomed Sci, 722 W 168th St,Room 918, New York, NY 10032 USA.
EM lm2892@columbia.edu
RI Tomar, Scott/AAT-6796-2021
OI TOMAR, SCOTT/0000-0002-3108-1945
FU National Institute of Dental and Craniofacial Research (NIH)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Dental & Craniofacial
   Research (NIDCR) [R01 DE015523]; NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [UL1TR000460] Funding Source:
   NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [P30AI073961] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Dental & Craniofacial Research (NIDCR)
   [R01DE015523] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL
   HEALTHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH) [P30MH043520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON
   DRUG ABUSEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Drug Abuse
   (NIDA)European Commission [T32DA037801] Funding Source: NIH RePORTER
FX Funding for this study was provided by the National Institute of Dental
   and Craniofacial Research (NIH grant number R01 DE015523).
CR *AM DENT ASS, ENH DENT MED OUTR CA
   Andersen R., 1968, BEHAV MODEL FAMILIES
   ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V36, P1, DOI 10.2307/2137284
   Anderson R, 2006, DISPARITIES CARE HIV
   Bodhade Ashish S, 2011, J Oral Sci, V53, P203
   Bonuck KA, 1996, J COMMUN HEALTH, V21, P183, DOI 10.1007/BF01557998
   Boston Public Health Commission, HIV DENT PROGR DENT
   CAPILOUTO EI, 1991, MED CARE, V29, P745, DOI 10.1097/00005650-199108000-00007
   Cherry-Peppers Gail, 2003, J Natl Med Assoc, V95, p21S
   Cleveland Jennifer L, 2003, Dent Clin North Am, V47, P681, DOI 10.1016/S0011-8532(03)00041-7
   Coogan MM, 2005, B WORLD HEALTH ORGAN, V83, P700
   Coulter ID, 2000, J DENT RES, V79, P1356, DOI 10.1177/00220345000790060201
   Craw JA, 2008, JAIDS-J ACQ IMM DEF, V47, P597, DOI 10.1097/QAI.0b013e3181684c51
   Feaster DJ, 2011, AM J DRUG ALCOHOL AB, V37, P383, DOI 10.3109/00952990.2011.600386
   Fox JE, 2012, PUBLIC HEALTH REP, V127, P5, DOI 10.1177/00333549121270S203
   Freed JR, 2005, J AM DENT ASSOC, V136, P1396, DOI 10.14219/jada.archive.2005.0053
   Gardner LI, 2005, AIDS, V19, P423, DOI 10.1097/01.aids.0000161772.51900.eb
   Gilbert GH, 2002, COMMUNITY DENT ORAL, V30, P352, DOI 10.1034/j.1600-0528.2002.00062.x
   Giuliani M, 2011, INT J DENT HYG, V9, P204, DOI 10.1111/j.1601-5037.2010.00472.x
   Greenberg BJS, 2008, J AM DENT ASSOC, V139, P1114, DOI 10.14219/jada.archive.2008.0314
   Hastreiter RJ, 2002, J AM DENT ASSOC, V133, P1343, DOI 10.14219/jada.archive.2002.0049
   Health Resources and Services Administration, INCR ACC DENT CAR
   Heslin KC, 2001, J PUBLIC HEALTH DENT, V61, P14, DOI 10.1111/j.1752-7325.2001.tb03350.x
   Institute of Medicine, 2011, ADV OR HLTH AM
   Jeanty Y, 2012, PUBLIC HEALTH REP, V127, P17, DOI 10.1177/00333549121270S204
   Johnson NW, 2010, AUST DENT J, V55, P85, DOI 10.1111/j.1834-7819.2010.01203.x
   Kenagy GP, 2003, AIDS PATIENT CARE ST, V17, P235, DOI 10.1089/108729103321655881
   Lemay CA, 2012, PREV CHRONIC DIS, V9, DOI 10.5888/pcd9.110297
   Lemay CA, 2013, SPEC CARE DENT, V33, P70, DOI 10.1111/j.1754-4505.2012.00293.x
   Lemay CA, 2010, J COMMUN HEALTH, V35, P43, DOI 10.1007/s10900-009-9195-z
   Levett T, 2009, INT J STD AIDS, V20, P782, DOI 10.1258/ijsa.2009.009182
   Marcus M, 2000, AM J PUBLIC HEALTH, V90, P1059, DOI 10.2105/AJPH.90.7.1059
   Marx R, 1997, J ACQ IMMUN DEF SYND, V14, P44, DOI 10.1097/00042560-199701010-00008
   Mascarenhas AK, 2000, J PUBLIC HEALTH DENT, V60, P172, DOI 10.1111/j.1752-7325.2000.tb03324.x
   Nittayananta W, 2010, J ORAL PATHOL MED, V39, P397, DOI 10.1111/j.1600-0714.2009.00875.x
   Patton LL, 2000, ORAL SURG ORAL MED O, V89, P299, DOI 10.1016/S1079-2104(00)70092-8
   Patton LL, 2003, J PUBLIC HEALTH DENT, V63, P86, DOI 10.1111/j.1752-7325.2003.tb03480.x
   Peduzzi P, 2002, EPIDEMIOL REV, V24, P26, DOI 10.1093/epirev/24.1.26
   Pereyra M, 2009, AIDS CARE, V21, P1578, DOI 10.1080/09540120902923030
   Rajabiun S, 2012, PUBLIC HEALTH REP, V127, P73, DOI 10.1177/00333549121270S210
   Rajabiun S, 2011, J PUBLIC HEALTH DENT, V71, P212, DOI 10.1111/j.1752-7325.2011.00249.x
   Reznik David A, 2005, Top HIV Med, V13, P143
   Schwarzer R, 1995, MEASURES HLTH PSYCHO, P35
   Seacat JD, 2009, J DENT EDUC, V73, P437
   Shiboski CH, 2005, J AM DENT ASSOC, V136, P1242, DOI 10.14219/jada.archive.2005.0340
   Shiboski CH, 1999, AM J PUBLIC HEALTH, V89, P834, DOI 10.2105/AJPH.89.6.834
   Singer R, 2012, PUBLIC HEALTH REP, V127, P36, DOI 10.1177/00333549121270S206
   Slade G D, 1994, Community Dent Health, V11, P3
   Tomar SL, 2011, J PUBLIC HEALTH DENT, V71, P241, DOI 10.1111/j.1752-7325.2011.00260.x
   US Department of Health and Human Services Health Resources and Services Administration, DENT PROGR F
   Weinert M, 1996, ANN INTERN MED, V125, P485, DOI 10.7326/0003-4819-125-6-199609150-00010
   Weissman JS, 1994, AM J PUBLIC HEALTH, V84, P1997
   Younai Fariba S, 2009, J Calif Dent Assoc, V37, P811
   ZIMET GD, 1988, J PERS ASSESS, V52, P30, DOI 10.1207/s15327752jpa5201_2
NR 54
TC 9
Z9 10
U1 0
U2 8
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD JAN
PY 2015
VL 105
IS 1
BP 77
EP 84
DI 10.2105/AJPH.2014.301871
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA CE6BG
UT WOS:000351920100030
PM 24832421
OA Green Published
DA 2021-10-30
ER

PT J
AU Andersen, HH
   Yosipovitch, G
   Galor, A
AF Andersen, Hjalte H.
   Yosipovitch, Gil
   Galor, Anat
TI Neuropathic symptoms of the ocular surface: dryness, pain, and itch
SO CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Review
DE central sensitization; dry eye; itch; neuropathic pain; pain; peripheral
   sensitization
ID PRIMARY SJOGRENS-SYNDROME; NERVE GROWTH-FACTOR; GENOME-WIDE ASSOCIATION;
   DRY EYE SYNDROME; CHRONIC PRURITUS; DOUBLE-BLIND; MECHANISMS; DISEASE;
   CELLS; PREVALENCE
AB Purpose of review
   This review aims to describe the recent findings on epidemiology, pathophysiology, and management of neuropathic symptoms of the ocular surface, with a focus on potential similarities between sensations of dry eye, pain and itch.
   Recent findings
   A narrative review of the literature was undertaken. Key references from research in dry eye, neuropathic symptoms of the ocular surface, ocular pain and itch, as well as general references on itch and pain neurobiology were included. Recent findings suggest aspects of dry eye, chronic ocular pain and itch symptomatology are driven by neuropathic pain mechanisms involving peripheral and central sensitization processes.
   Summary
   Ocular dryness, pain, and itch are prevalent complaints with several of shared features. Multiple lines of evidence suggest that peripheral and central neuronal sensitization processes are involved in generating and maintaining ocular sensory symptoms. Research is warranted on the epidemiology of ocular sensations, molecular mechanisms involved in nociception and pruriception in the eye, electrophysiological alterations in animal models of eye conditions, and therapeutic modalities that can alleviate unpleasant ocular sensations.
C1 [Andersen, Hjalte H.; Yosipovitch, Gil] Univ Miami, Miller Sch Med, Dept Dermatol, Miami, FL 33136 USA.
   [Andersen, Hjalte H.; Yosipovitch, Gil] Univ Miami, Miami Itch Ctr, Miami, FL 33136 USA.
   [Andersen, Hjalte H.] Aalborg Univ, Fac Med, Lab Expt Cutaneous Pain Res, SMI, Aalborg, Denmark.
   [Galor, Anat] Miami Vet Adm Med Ctr, Miami, FL USA.
   [Galor, Anat] Univ Miami, Dept Ophthalmol, Bascom Palmer Eye Inst, 900 NW 17th St, Miami, FL 33136 USA.
RP Galor, A (corresponding author), Univ Miami, Dept Ophthalmol, Bascom Palmer Eye Inst, 900 NW 17th St, Miami, FL 33136 USA.
EM agalor@med.miami.edu
RI Yosipovitch, Gil/K-3517-2019
FU Department of Veterans Affairs, Veterans Health Administration, Office
   of Research and Development, Clinical Sciences ResearchUS Department of
   Veterans Affairs [EPID-006-15S]; NIH Center Core GrantUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [P30EY014801]; Research to Prevent Blindness Unrestricted
   GrantResearch to Prevent Blindness (RPB); EliteForsk Travel-Stipend -
   Danish Ministry of Higher Education and Science; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000460]
   Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Eye Institute (NEI) [R01EY026174, P30EY014801] Funding
   Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs
   [I01CX001089] Funding Source: NIH RePORTER
FX The sponsors or funding organizations had no role in the design or
   conduct of this research. The financial and material support of this
   review comes from the Department of Veterans Affairs, Veterans Health
   Administration, Office of Research and Development, Clinical Sciences
   Research EPID-006-15S (A.G.), NIH Center Core Grant P30EY014801, and
   Research to Prevent Blindness Unrestricted Grant. H.H.A. received
   support from the EliteForsk 2016 Travel-Stipend granted by the Danish
   Ministry of Higher Education and Science.
CR Ackerman S, 2016, THER ADV CHRONIC DIS, V7, P52, DOI 10.1177/2040622315612745
   Aggarwal S, 2015, OCUL SURF, V13, P250, DOI 10.1016/j.jtos.2015.01.005
   Andersen HH, 2015, ACTA DERM-VENEREOL, V95, P771, DOI 10.2340/00015555-2146
   Andrade EL, 2012, PHARMACOL THERAPEUT, V133, P189, DOI 10.1016/j.pharmthera.2011.10.008
   Ball JM, 2010, CISM COUR L, V516, P1
   BandeenRoche R, 1997, INVEST OPHTH VIS SCI, V38, P2469
   Baron R, 2000, CLIN J PAIN, V16, pS12, DOI 10.1097/00002508-200006001-00004
   Baron R, 2017, PAIN, V158, P261, DOI 10.1097/j.pain.0000000000000753
   Baron R, 2012, LANCET NEUROL, V11, P999, DOI 10.1016/S1474-4422(12)70189-8
   Baron R, 2010, LANCET NEUROL, V9, P807, DOI 10.1016/S1474-4422(10)70143-5
   Basbaum AI, 2016, PAIN, V157, pS42, DOI 10.1097/j.pain.0000000000000441
   Basbaum AI, 2009, CELL, V139, P267, DOI 10.1016/j.cell.2009.09.028
   Bautista DM, 2014, NAT NEUROSCI, V17, P175, DOI 10.1038/nn.3619
   Belmonte C, 2004, EXP EYE RES, V78, P513, DOI 10.1016/j.exer.2003.09.023
   Belmonte C, 2006, WALL MELZACK TXB PAI, P891
   Bereiter DA, 2005, J NEUROPHYSIOL, V94, P3815, DOI 10.1152/jn.00616.2005
   Bouhassira D, 2004, PAIN, V108, P248, DOI 10.1016/j.pain.2003.12.024
   Burbelo PD, 2014, AUTOIMMUN REV, V13, P756, DOI 10.1016/j.autrev.2014.02.002
   Carstens E, 2016, EUR J PAIN, V20, P5, DOI 10.1002/ejp.778
   Chia EM, 2003, CLIN EXP OPHTHALMOL, V31, P229, DOI 10.1046/j.1442-9071.2003.00634.x
   Chotikavanich S, 2009, INVEST OPHTH VIS SCI, V50, P3203, DOI 10.1167/iovs.08-2476
   Demant DT, 2014, PAIN, V155, P2263, DOI 10.1016/j.pain.2014.08.014
   Enriquez-de-Salamanca A, 2010, MOL VIS, V16, P862
   Gabbriellini G, 2015, MOD RHEUMATOL, V25, P585, DOI 10.3109/14397595.2014.979523
   Galer BS, 1997, NEUROLOGY, V48, P332, DOI 10.1212/WNL.48.2.332
   Galor A, 2015, EYE, V29, P301, DOI 10.1038/eye.2014.263
   Galor A, 2016, BRIT J OPHTHALMOL, V100, P745, DOI 10.1136/bjophthalmol-2015-307094
   Galor A, 2015, BRIT J OPHTHALMOL, V99, P665, DOI 10.1136/bjophthalmol-2014-306057
   Galor A, 2013, INVEST OPHTH VIS SCI, V54, P1426, DOI 10.1167/iovs.12-10819
   Gouin O, 2015, EXP DERMATOL, V24, P723, DOI 10.1111/exd.12798
   Gunal AI, 2004, NEPHROL DIAL TRANSPL, V19, P3137, DOI 10.1093/ndt/gfh496
   GUTWALD J, 1991, J INVEST DERMATOL, V96, P695, DOI 10.1111/1523-1747.ep12470630
   HANDWERKER HO, 1992, APS J, V1, P135
   Himebaugh N., 2007, THESIS
   Hirata H, 2003, J NEUROPHYSIOL, V90, P2837, DOI 10.1152/jn.00544.2003
   Hussain M, 2014, CORNEA, V33, P1245, DOI 10.1097/ICO.0000000000000271
   Ji RR, 2016, SCIENCE, V354, P572, DOI 10.1126/science.aaf8924
   Kalangara JP, 2017, EYE CONTACT LENS, V43, P192, DOI 10.1097/ICL.0000000000000249
   Kurose M, 2013, J NEUROPHYSIOL, V110, P495, DOI 10.1152/jn.00222.2013
   Lam H, 2009, AM J OPHTHALMOL, V147, P198, DOI 10.1016/j.ajo.2008.08.032
   Lambiase A, 2012, CURR OPIN OPHTHALMOL, V23, P296, DOI 10.1097/ICU.0b013e3283543b61
   LaMotte RH, 2014, NAT REV NEUROSCI, V15, P19, DOI 10.1038/nrn3641
   Lessard CJ, 2013, NAT GENET, V45, P1284, DOI 10.1038/ng.2792
   Levitt AE, 2015, MOL PAIN, V11, DOI 10.1186/s12990-015-0020-7
   Li MY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081435
   Li YZ, 2013, NAT GENET, V45, P1361, DOI 10.1038/ng.2779
   Liu F, 2017, BRAIN BEHAV IMMUN, V61, P165, DOI 10.1016/j.bbi.2016.11.017
   Liu T, 2013, PFLUG ARCH EUR J PHY, V465, P1671, DOI 10.1007/s00424-013-1284-2
   Lovejoy TI, 2012, J PAIN, V13, P1250, DOI 10.1016/j.jpain.2012.09.011
   MACIVER MB, 1993, J NEUROSCI, V13, P4511
   Martinez JD, 2016, CLIN OPHTHALMOL, V10, P1335, DOI 10.2147/OPTH.S106451
   McCarty CA, 1998, OPHTHALMOLOGY, V105, P1114, DOI 10.1016/S0161-6420(98)96016-X
   Mollanazar NK, 2016, CLIN REV ALLERG IMMU, V51, P263, DOI 10.1007/s12016-015-8488-5
   Na KS, 2011, MOL VIS, V17, P2818
   Namer B, 2013, NAT NEUROSCI, V16, P117, DOI 10.1038/nn.3316
   Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767
   Pan Q, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009327.pub3
   Parra A, 2014, PAIN, V155, P1481, DOI 10.1016/j.pain.2014.04.025
   Parra A, 2010, NAT MED, V16, P1396, DOI 10.1038/nm.2264
   Peirs C, 2016, SCIENCE, V354, P578, DOI 10.1126/science.aaf8933
   Pereira MP, 2017, DRUGS, V77, P999, DOI 10.1007/s40265-017-0746-9
   Pud D, 2009, PAIN, V144, P16, DOI 10.1016/j.pain.2009.02.015
   Rahman M, 2015, PAIN, V156, P942, DOI 10.1097/j.pain.0000000000000135
   Reinach PS, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0135-7
   Ross SE, 2010, NEURON, V65, P886, DOI 10.1016/j.neuron.2010.02.025
   Rukwied RR, 2013, J INVEST DERMATOL, V133, P268, DOI 10.1038/jid.2012.242
   Sandkuhler J, 2009, PHYSIOL REV, V89, P707, DOI 10.1152/physrev.00025.2008
   Schaumberg DA, 2003, AM J OPHTHALMOL, V136, P318, DOI 10.1016/S0002-9394(03)00218-6
   Schaumberg DA, 2009, ARCH OPHTHALMOL-CHIC, V127, P763, DOI 10.1001/archophthalmol.2009.103
   Schein OD, 1997, OPHTHALMOLOGY, V104, P1395, DOI 10.1016/S0161-6420(97)30125-0
   Schmelz M, 2000, NEUROREPORT, V11, P645, DOI 10.1097/00001756-200002280-00041
   Schmelz M, 2003, J NEUROPHYSIOL, V89, P2441, DOI 10.1152/jn.01139.2002
   Schmelz M, 1997, J NEUROSCI, V17, P8003
   Schmelz M, 2015, HANDB EXP PHARMACOL, V227, P285, DOI 10.1007/978-3-662-46450-2_14
   Sergeant A, 2009, J INVEST DERMATOL, V129, P1042, DOI 10.1038/jid.2008.324
   Shaheen BS, 2014, SURV OPHTHALMOL, V59, P263, DOI 10.1016/j.survophthal.2013.09.002
   Shim J, 2012, OPHTHALMOLOGY, V119, P2211, DOI 10.1016/j.ophtha.2012.05.038
   Skaper SD, 2014, IMMUNOLOGY, V141, P314, DOI 10.1111/imm.12170
   Smith JA, 2007, OCUL SURF, V5, P93
   Solomon A, 1998, J ALLERGY CLIN IMMUN, V102, P454, DOI 10.1016/S0091-6749(98)70135-6
   Sonkoly E, 2006, J ALLERGY CLIN IMMUN, V117, P411, DOI 10.1016/j.jaci.2005.10.033
   Staaf S, 2009, PAIN, V144, P187, DOI 10.1016/j.pain.2009.04.013
   Stander S, 2007, ACTA DERM-VENEREOL, V87, P291, DOI 10.2340/00015555-0305
   Steinhoff M, 2003, J NEUROSCI, V23, P6176
   Stern ME, 2002, INVEST OPHTH VIS SCI, V43, P2609
   Stull C, 2017, PREVALENCE CHARACTER, V2, pe4
   Tashiro A, 2010, NEUROSCIENCE, V169, P455, DOI 10.1016/j.neuroscience.2010.04.034
   Treede RD, 2008, NEUROLOGY, V70, P1630, DOI 10.1212/01.wnl.0000282763.29778.59
   TREEDE RD, 1992, PROG NEUROBIOL, V38, P397, DOI 10.1016/0301-0082(92)90027-C
   Valdes-Rodriguez R, 2017, ACTA DERM-VENEREOL, V97, P385, DOI 10.2340/00015555-2524
   Vehof J, 2017, OPHTHALMOLOGY, V124, P280, DOI 10.1016/j.ophtha.2016.11.008
   Vehof J, 2014, INVEST OPHTH VIS SCI, V55, P7278, DOI 10.1167/iovs.14-15200
   Vehof J, 2014, PAIN, V155, P1562, DOI 10.1016/j.pain.2014.05.002
   Weidner C, 2000, J INVEST DERMATOL, V115, P1015, DOI 10.1046/j.1523-1747.2000.00142.x
   Weinkauf B, 2016, EUR J PAIN, V20, P215, DOI 10.1002/ejp.710
   Woolf CJ, 2011, PAIN, V152, pS2, DOI 10.1016/j.pain.2010.09.030
   Yamaguchi J, 2009, J DERMATOL SCI, V53, P48, DOI 10.1016/j.jdermsci.2008.08.011
   Yarnitsky D, 2010, CURR OPIN ANESTHESIO, V23, P611, DOI 10.1097/ACO.0b013e32833c348b
   Yau MK, 2016, EXPERT OPIN THER PAT, V26, P471, DOI 10.1517/13543776.2016.1154540
   Yosipovitch G, 2007, PAIN, V131, P4, DOI 10.1016/j.pain.2007.04.017
NR 100
TC 15
Z9 15
U1 0
U2 18
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1528-4050
EI 1473-6322
J9 CURR OPIN ALLERGY CL
JI Curr. Opin. Allergy Clin. Immunol.
PD OCT
PY 2017
VL 17
IS 5
BP 373
EP 381
DI 10.1097/ACI.0000000000000389
PG 9
WC Allergy; Immunology
SC Allergy; Immunology
GA V9Q1M
UT WOS:000408990100010
PM 28858914
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Blackstone, EH
   Chang, HL
   Rajeswaran, J
   Parides, MK
   Ishwaran, H
   Li, L
   Ehrlinger, J
   Gelijns, AC
   Moskowitz, AJ
   Argenziano, M
   DeRose, JJ
   Couderc, JP
   Balda, D
   Dagenais, F
   Mack, MJ
   Ailawadi, G
   Smith, PK
   Acker, MA
   O'Gara, PT
   Gillinov, AM
AF Blackstone, Eugene H.
   Chang, Helena L.
   Rajeswaran, Jeevanantham
   Parides, Michael K.
   Ishwaran, Hemant
   Li, Liang
   Ehrlinger, John
   Gelijns, Annetine C.
   Moskowitz, Alan J.
   Argenziano, Michael
   DeRose, Joseph J., Jr.
   Couderc, Jean-Phillipe
   Balda, Dan
   Dagenais, Francois
   Mack, Michael J.
   Ailawadi, Gorav
   Smith, Peter K.
   Acker, Michael A.
   O'Gara, Patrick T.
   Gillinov, A. Marc
CA Cardiothoracic Surgical Trials Net
TI Biatrial maze procedure versus pulmonary vein isolation for atrial
   fibrillation during mitral valve surgery: New analytical approaches and
   end points
SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
LA English
DT Article; Proceedings Paper
CT 97th Annual Meeting of the American-Association-for-Thoracic-Surgery
CY APR 29-MAY 03, 2017
CL Boston, MA
SP Amer Assoc Thorac Surg
DE ablation; atrial arrhythmia; Cardiothoracic Surgical Trials Network;
   postablation heart rhythm monitoring; transtelephonic monitoring
ID TIP RADIOFREQUENCY ABLATION; SURGICAL ABLATION; BIPOLAR RADIOFREQUENCY;
   CONSENSUS-STATEMENT; THORACIC SURGEONS; CARDIAC-SURGERY; FOLLOW-UP;
   PREDICTORS; GUIDELINES; SOCIETY
AB Objective: To use novel statistical methods for analyzing the effect of lesion set on (long-standing) persistent atrial fibrillation (AF) in the Cardiothoracic Surgical Trials Network trial of surgical ablation during mitral valve surgery (MVS).
   Methods: Two hundred sixty such patients were randomized to MVS thorn surgical ablation or MVS alone. Ablation was randomized between pulmonary vein isolation and biatrial maze. During 12 months postsurgery, 228 patients (88%) submitted 7949 transtelephonic monitoring (TTM) recordings, analyzed for AF, atrial flutter (AFL), or atrial tachycardia (AT). As previously reported, more ablation than MVS-alone patients were free of AF or AF/AFL at 6 and 12 months (63% vs 29%; P < .001) by 72-hour Holter monitoring, without evident difference between lesion sets (for which the trial was underpowered).
   Results: Estimated freedom from AF/AFL/ATon any transmission trended higher after biatrial maze than pulmonary vein isolation (odds ratio, 2.31; 95% confidence interval, 0.95-5.65; P = .07) 3 to 12 months postsurgery; estimated AF/AFL/AT load (ie, proportion of TTM strips recording AF/AFL/AT) was similar (odds ratio, 0.90; 95% confidence interval, 0.57-1.43; P = .6). Within 12 months, estimated prevalence of AF/AFL/AT by TTM was 58% after MVS alone, and 36% versus 23% after pulmonary vein isolation versus biatrial maze (P < .02).
   Conclusions: Statistical modeling using TTM recordings after MVS in patients with (long-standing) persistent AF suggests that a biatrial maze is associated with lower AF/AFL/AT prevalence, but not a lower load, compared with pulmonary vein isolation. The discrepancy between AF/AFL/AT prevalence assessed at 2 time points by Holter monitoring versus weekly TTM suggests the need for a confirmatory trial, reassessment of definitions for failure after ablation, and validation of statistical methods for assessing atrial rhythms longitudinally.
C1 [Blackstone, Eugene H.; Gillinov, A. Marc] Cleveland Clin, Dept Thorac & Cardiovasc Surg, 9500 Euclid Ave,Desk JJ 40, Cleveland, OH 44195 USA.
   [Blackstone, Eugene H.; Rajeswaran, Jeevanantham; Ehrlinger, John] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44195 USA.
   [Chang, Helena L.; Parides, Michael K.; Gelijns, Annetine C.; Moskowitz, Alan J.] Icahn Sch Med Mt Sinai, Dept Populat Hlth Sci & Policy, New York, NY 10029 USA.
   [Ishwaran, Hemant] Univ Miami, Dept Publ Hlth Sci, Div Biostat, Miami, FL USA.
   [Li, Liang] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA.
   [Argenziano, Michael] Columbia Univ, Dept Surg, Div Cardiothorac Surg, Coll Phys & Surg, New York, NY USA.
   [DeRose, Joseph J., Jr.] Montefiore Einstein Heart Ctr, Dept Cardiovasc & Thorac Surg, Bronx, NY USA.
   [Couderc, Jean-Phillipe] Univ Rochester, Med Ctr, Cardiol Dept, Heart Res Follow Up Program, Rochester, NY 14642 USA.
   [Balda, Dan] Medicomp Inc, Melbourne, FL USA.
   [Dagenais, Francois] Inst Univ Cardiol Quebec, Hop Laval, Dept Cardiac Surg, Quebec City, PQ, Canada.
   [Mack, Michael J.] Baylor Hlth Care Syst, Baylor Res Inst, Dept Cardiothorac Surg, Plano, TX USA.
   [Ailawadi, Gorav] Univ Virginia, Sch Med, Div Thorac & Cardiovasc Surg, Charlottesville, VA USA.
   [Smith, Peter K.] Duke Univ, Med Ctr, Dept Surg, Div Cardiovasc & Thorac Surg, Durham, NC 27710 USA.
   [Acker, Michael A.] Univ Penn, Sch Med, Dept Surg, Div Cardiovasc Surg, Philadelphia, PA 19104 USA.
   [O'Gara, Patrick T.] Brigham & Womens Hosp, Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA.
RP Blackstone, EH (corresponding author), Cleveland Clin, Dept Thorac & Cardiovasc Surg, 9500 Euclid Ave,Desk JJ 40, Cleveland, OH 44195 USA.
EM blackse@ccf.org
FU National Heart, Lung, and Blood InstituteUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [R01 HL103552, U01
   HL088942]; National Institute of Neurological Disorders and StrokeUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Neurological Disorders &
   Stroke (NINDS); Canadian Institutes of Health ResearchCanadian
   Institutes of Health Research (CIHR); NATIONAL CANCER INSTITUTEUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA016672]
   Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [UL1TR002736] Funding Source:
   NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [U01HL088942]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [R01GM125072] Funding Source: NIH RePORTER
FX Supported by grant No. R01 HL103552 and by a cooperative agreement (No.
   U01 HL088942) with the National Heart, Lung, and Blood Institute,
   including funding by the National Institute of Neurological Disorders
   and Stroke and the Canadian Institutes of Health Research.
CR Abreu CAC, 2005, CIRCULATION, V112, pI20, DOI 10.1161/CIRCULATIONAHA.104.526301
   Ad N, 2017, J THORAC CARDIOV SUR, V153, P1330, DOI 10.1016/j.jtcvs.2017.02.027
   Ad N, 2012, J THORAC CARDIOV SUR, V144, P1051, DOI 10.1016/j.jtcvs.2012.07.065
   Ad N, 2010, INNOVATIONS, V5, P74, DOI 10.1097/IMI.0b013e3181d72939
   Akpinar B, 2003, EUR J CARDIO-THORAC, V24, P223, DOI 10.1016/S1010-7940(03)00258-6
   Albrecht A, 2009, J THORAC CARDIOV SUR, V138, P454, DOI 10.1016/j.jtcvs.2009.04.023
   Badhwar V, 2017, ANN THORAC SURG, V103, P329, DOI 10.1016/j.athoracsur.2016.10.076
   Blomstrom Lundqvist C, 2007, EUR HEART J, V28, P2902, DOI 10.1093/eurheartj/ehm378
   Budera P, 2012, EUR HEART J, V33, P2644, DOI 10.1093/eurheartj/ehs290
   Calkins H, 2017, J ARRYTHM, V33, P369, DOI 10.1016/j.joa.2017.08.001
   Calkins H, 2012, J INTERV CARD ELECTR, V33, P171, DOI 10.1007/s10840-012-9672-7
   Charitos EI, 2012, CIRCULATION, V126, P806, DOI 10.1161/CIRCULATIONAHA.112.098079
   Damiano RJ, 2011, J THORAC CARDIOV SUR, V141, P113, DOI 10.1016/j.jtcvs.2010.08.067
   de Lima GG, 2004, ANN THORAC SURG, V77, P2089, DOI 10.1016/j.athoracsur.2003.11.018
   Doukas G, 2005, JAMA-J AM MED ASSOC, V294, P2323, DOI 10.1001/jama.294.18.2323
   Gillinov AM, 2007, SEMIN THORAC CARDIOV, V19, P25, DOI 10.1053/j.semtcvs.2007.01.002
   Gillinov AM, 2006, ANN THORAC SURG, V82, P502, DOI 10.1016/j.athoracsur.2006.02.030
   Gillinov AM, 2015, NEW ENGL J MED, V372, P1399, DOI 10.1056/NEJMoa1500528
   Gillinov AM, 2011, J THORAC CARDIOV SUR, V142, P257, DOI 10.1016/j.jtcvs.2011.04.010
   Gillinov AM, 2006, ANN THORAC SURG, V81, P19, DOI 10.1016/j.athoracsur.2005.04.060
   Gillinov AM, 2005, J THORAC CARDIOV SUR, V130, P1653, DOI 10.1016/j.jtcvs.2005.07.028
   Gillinov AM, 2005, J THORAC CARDIOV SUR, V129, P1322, DOI 10.1016/j.jtcvs.2004.12.010
   Gillinov AM, 2005, CURR OPIN CARDIOL, V20, P107, DOI 10.1097/01.hco.0000153554.48122.86
   Gillinov AM, 2004, HEART SURG FORUM, V7, pE147, DOI 10.1532/HSF98.200310353
   Gillinov AM, 2002, ANN THORAC SURG, V74, P2210, DOI 10.1016/S0003-4975(02)03977-2
   Gillinov M, 2013, SEMIN THORAC CARDIOV, V25, P197, DOI 10.1053/j.semtcvs.2013.09.003
   Gosciniak P, 2013, CARDIOL J, V20, P499, DOI 10.5603/CJ.2013.0135
   Hanke T, 2009, CIRCULATION, V120, pS177, DOI 10.1161/CIRCULATIONAHA.108.838474
   Huang B, 2018, PHARM STAT, V17, P202, DOI 10.1002/pst.1846
   January CT, 2014, J AM COLL CARDIOL, V64, P2246, DOI 10.1016/j.jacc.2014.03.021
   Jessurun ER, 2003, J CARDIOVASC SURG, V44, P9
   Khargi K, 2001, ANN THORAC SURG, V72, pS1090, DOI 10.1016/S0003-4975(01)02940-X
   Lee R, 2012, J THORAC CARDIOV SUR, V143, P1341, DOI 10.1016/j.jtcvs.2012.02.006
   Li L, 2017, BIOMETRICAL J, V59, P331, DOI 10.1002/bimj.201600098
   Pak K, 2017, JAMA ONCOL, V3, P1692, DOI 10.1001/jamaoncol.2017.2797
   Rajeswaran J, 2018, STAT METHODS MED RES, V27, P126, DOI 10.1177/0962280215623583
   Reddy VY, 2008, HEART RHYTHM, V5, P353, DOI 10.1016/j.hrthm.2007.11.006
   Schuetz A, 2003, EUR J CARDIO-THORAC, V24, P475, DOI 10.1016/S1010-7940(03)00377-4
   Shemin RJ, 2007, ANN THORAC SURG, V83, P1225, DOI 10.1016/j.athoracsur.2006.11.094
   Vasconcelos JT, 2004, ARQ BRAS CARDIOL, V83, P203
   von Oppell UO, 2009, EUR J CARDIO-THORAC, V35, P641, DOI 10.1016/j.ejcts.2008.12.042
   Willems S, 2016, CIRC-ARRHYTHMIA ELEC, V9, DOI 10.1161/CIRCEP.115.003909
NR 42
TC 9
Z9 10
U1 1
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5223
EI 1097-685X
J9 J THORAC CARDIOV SUR
JI J. Thorac. Cardiovasc. Surg.
PD JAN
PY 2019
VL 157
IS 1
BP 234
EP +
DI 10.1016/j.jtcvs.2018.06.093
PG 19
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA HE1FF
UT WOS:000453015500061
PM 30557941
OA Green Accepted, Bronze
DA 2021-10-30
ER

PT J
AU Shaw, AM
   Timpano, KR
   Steketee, G
   Tolin, DF
   Frost, RO
AF Shaw, A. M.
   Timpano, K. R.
   Steketee, G.
   Tolin, D. F.
   Frost, R. O.
TI Hoarding and emotional reactivity: The link between negative emotional
   reactions and hoarding symptomatology
SO JOURNAL OF PSYCHIATRIC RESEARCH
LA English
DT Article
DE Hoarding; Emotional reactivity; Negative emotions; Decision-making;
   Memory
ID ANXIETY STRESS SCALES; EXPERIENTIAL AVOIDANCE; NEURAL MECHANISMS;
   BEHAVIOR-THERAPY; DECISION-MAKING; EXPLORATION; DIMENSIONS; COGNITIONS;
   TOLERANCE; CONSTRUCT
AB Hoarding disorder (HD) is characterized by difficulty discarding, clutter, and frequently excessive acquiring. Theories have pointed to intense negative emotional reactions (e.g., sadness) as one factor that may play a critical role in HD's etiology. Preliminary work with an analogue sample indicated that more intense negative emotions following emotional films were linked with greater hoarding symptoms. Symptom provocation imaging studies with HD patients have also found evidence for excessive activation in brain regions implicated in processing emotions. The current study utilized a sample with self-reported serious hoarding difficulties to examine how hoarding symptoms related to both general and hoarding-related emotional reactivity, taking into account the specificity of these relationships. We also examined how two cognitive factors, fear of decision-making and confidence in memory, modified this relationship. 628 participants with self-identified hoarding difficulties completed questionnaires about general emotional reactivity, depression, anxiety, decision-making, and confidence in memory. To assess hoarding-related emotional reactivity, participants reported their emotional reactions when imagining discarding various items. Heightened general emotional reactivity and more intense emotional reactions to imagined discarding were associated with both difficulty discarding and acquisition, but not clutter, controlling for age, gender, and co-occurring mood and anxiety symptoms. Fear of decision-making and confidence in memory interacted with general emotional reactivity to predict hoarding symptoms. These findings provide support for cognitive-behavioral models of hoarding. Experimental research should be conducted to discover whether emotional reactivity increases vulnerability for HD. Future work should also examine whether emotional reactivity should be targeted in interventions for hoarding. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Shaw, A. M.; Timpano, K. R.] Univ Miami, Coral Gables, FL 33124 USA.
   [Steketee, G.] Boston Univ, Sch Social Work, Boston, MA 02215 USA.
   [Tolin, D. F.] Anxiety Disorders Ctr, Inst Living, Hartford, CT 06106 USA.
   [Tolin, D. F.] Yale Univ, Sch Med, New Haven, CT 06510 USA.
   [Frost, R. O.] Smith Coll, Northampton, MA 01063 USA.
RP Timpano, KR (corresponding author), Univ Miami, Dept Psychol, 5665 Ponce de Leon Blvd, Coral Gables, FL 33146 USA.
EM kiaratimpano@gmail.com
OI Timpano, Kiara/0000-0002-0665-8722
FU National Institute of Mental Health (NIMH)United States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Mental Health (NIMH) [MH068008, MH068007, R21
   MH068539]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Advancing Translational
   Sciences (NCATS) [UL1TR000460] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Mental Health (NIMH) [R01MH068008, R01MH068007, R21MH068539] Funding
   Source: NIH RePORTER
FX This study was partly funded by National Institute of Mental Health
   (NIMH) linked R01 grants MH068008 and MH068007 (Frost & Steketee), and
   R21 MH068539 (Steketee). NIMH did not play a role in the study design,
   analysis and interpretation of data, in the writing of this report, or
   in the decision to submit this article for publication.
CR Abramowitz JS, 2003, J CONSULT CLIN PSYCH, V71, P1049, DOI 10.1037/0022-006X.71.6.1049
   American Psychiatric Association, 2013, DIAGN STAT MAN MENT, DOI [10.1176/appi.books.9780890425596, DOI 10.1176/APPI.BOOKS.9780890425596]
   An SK, 2009, MOL PSYCHIATR, V14, P318, DOI 10.1038/sj.mp.4002129
   Antony MM, 1998, PSYCHOL ASSESSMENT, V10, P176, DOI 10.1037/1040-3590.10.2.176
   Ayers CR, 2014, J BEHAV THER EXP PSY, V45, P408, DOI 10.1016/j.jbtep.2014.04.005
   Christensen DD, 2001, PRIMARY PSYCHIAT, V8, P79
   Coles ME, 2003, BEHAV RES THER, V41, P179, DOI 10.1016/S0005-7967(01)00136-X
   Conklin CZ, 2006, J NERV MENT DIS, V194, P69, DOI 10.1097/01.nmd.0000198138.41709.4f
   Davidson RJ, 2003, PSYCHOPHYSIOLOGY, V40, P655, DOI 10.1111/1469-8986.00067
   Davidson RJ, 2002, BIOL PSYCHIAT, V52, P478, DOI 10.1016/S0006-3223(02)01458-0
   Fernandez de la Cruz L, 2013, J ANXIETY DISORD, V27, P204, DOI 10.1016/j.janxdis.2013.01.004
   Frost R., 1999, COGN BEHAV PRACT, V6, P397, DOI [10.1016/S1077-7229(99)80058-3, DOI 10.1016/S1077-7229(99)80058-3]
   Frost RO, 2013, J OBSESS-COMPULS REL, V2, P85, DOI 10.1016/j.jocrd.2012.12.004
   Frost RO, 2004, BEHAV RES THER, V42, P1163, DOI 10.1016/j.brat.2003.07.006
   Frost RO, 2000, HEALTH SOC CARE COMM, V8, P229, DOI 10.1046/j.1365-2524.2000.00245.x
   FROST RO, 1993, BEHAV RES THER, V31, P367, DOI 10.1016/0005-7967(93)90094-B
   Frost RO, 1996, BEHAV RES THER, V34, P341, DOI 10.1016/0005-7967(95)00071-2
   FROST RO, 1993, BEHAV RES THER, V31, P683, DOI 10.1016/0005-7967(93)90121-A
   Frost RO, 1998, OBSESSIVE COMPULSIVE, P533
   Ghisi M, 2010, J ANXIETY DISORD, V24, P879, DOI 10.1016/j.janxdis.2010.06.011
   Greenberg D, 1987, AM J PSYCHOTHER, VXLI
   Grisham JR, 2010, BEHAV RES THER, V48, P866, DOI 10.1016/j.brat.2010.05.011
   Grisham Jessica R, 2008, Depress Anxiety, V25, pE63, DOI 10.1002/da.20327
   Gross JJ, 2011, COGNITION EMOTION, V25, P765, DOI 10.1080/02699931.2011.555753
   GROSS JJ, 1995, COGNITION EMOTION, V9, P87, DOI 10.1080/02699939508408966
   Gross JJ, 2002, PSYCHOPHYSIOLOGY, V39, P281, DOI 10.1017/S0048577201393198
   Gross JJ, 2011, HDB EMOTION REGULATI, P7
   Hartl TL, 2004, DEPRESS ANXIETY, V20, P59, DOI 10.1002/da.20010
   Henry JD, 2005, BRIT J CLIN PSYCHOL, V44, P227, DOI 10.1348/014466505X29657
   Holmbeck GN, 2002, J PEDIATR PSYCHOL, V27, P87, DOI 10.1093/jpepsy/27.1.87
   Jazaieri H, 2015, CURR PSYCHIAT REP, V17, DOI 10.1007/s11920-014-0531-3
   Johnson-Laird PN, 2006, PSYCHOL REV, V113, P822, DOI 10.1037/0033-295X.113.4.822
   Kraut R, 2004, AM PSYCHOL, V59, P105, DOI 10.1037/0003-066X.59.2.105
   Kyrios M, 2004, COGNITIVE THER RES, V28, P241, DOI 10.1023/B:COTR.0000021543.62799.32
   Linehan MM., 1993, DIAGNOSIS TREATMENT
   Mataix-Cols D, 2004, ARCH GEN PSYCHIAT, V61, P564, DOI 10.1001/archpsyc.61.6.564
   Mataix-Cols D, 2002, PSYCHOTHER PSYCHOSOM, V71, P255, DOI 10.1159/000064812
   Mataix-Cols D, 2010, DEPRESS ANXIETY, V27, P556, DOI 10.1002/da.20693
   Mennin DS, 2005, BEHAV RES THER, V43, P1281, DOI 10.1016/j.brat.2004.08.008
   Mennin DS, 2004, CLIN PSYCHOL PSYCHOT, V11, P17, DOI 10.1002/cpp.389
   Nedeljkovic M, 2007, BEHAV RES THER, V45, P2899, DOI 10.1016/j.brat.2007.08.001
   Nock MK, 2008, BEHAV THER, V39, P107, DOI 10.1016/j.beth.2007.05.005
   Pertusa A, 2010, CLIN PSYCHOL REV, V30, P371, DOI 10.1016/j.cpr.2010.01.007
   Safer DL, 2001, AM J PSYCHIAT, V158, P632, DOI 10.1176/appi.ajp.158.4.632
   Sawchuk CN, 1999, BEHAV RES THER, V37, P249, DOI 10.1016/S0005-7967(98)00127-2
   Steketee Gail, 2003, Clin Psychol Rev, V23, P905, DOI 10.1016/j.cpr.2003.08.002
   Timpano K. R, 2014, OXFORD HDB HOARDING, P100
   Timpano KR, 2014, BEHAV THER, V45, P690, DOI 10.1016/j.beth.2014.04.002
   Timpano KR, 2013, J PSYCHIATR RES, V47, P363, DOI 10.1016/j.jpsychires.2012.10.017
   Timpano KR, 2011, INT J COGN THER, V4, P263, DOI 10.1521/ijct.2011.4.3.263
   Timpano KR, 2011, J CLIN PSYCHIAT, V72, P780, DOI 10.4088/JCP.10m06380
   Timpano KR, 2009, DEPRESS ANXIETY, V26, P343, DOI 10.1002/da.20469
   Tolin DF, 2009, PSYCHOL MED, V39, P325, DOI 10.1017/S0033291708003371
   Tolin DF, 2008, BEHAV RES THER, V46, P334, DOI 10.1016/j.brat.2007.12.008
   Tolin DF, 2012, ARCH GEN PSYCHIAT, V69, P832, DOI 10.1001/archgenpsychiatry.2011.1980
   Tolin DF, 2010, PSYCHIAT RES, V178, P147, DOI 10.1016/j.psychres.2009.05.001
   Wheaton MG, 2011, COGNITIVE THER RES, V35, P511, DOI 10.1007/s10608-010-9338-7
   Williams AD, 2012, AUST J PSYCHOL, V64, P217, DOI 10.1111/j.1742-9536.2012.00055.x
NR 58
TC 48
Z9 49
U1 2
U2 37
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-3956
EI 1879-1379
J9 J PSYCHIATR RES
JI J. Psychiatr. Res.
PD APR
PY 2015
VL 63
BP 84
EP 90
DI 10.1016/j.jpsychires.2015.02.009
PG 7
WC Psychiatry
SC Psychiatry
GA CH0WL
UT WOS:000353743000011
PM 25732668
OA Green Accepted, Green Published
DA 2021-10-30
ER

PT J
AU Ramos, AR
   Dong, CH
   Elkind, MSV
   Boden-Albala, B
   Sacco, RL
   Rundek, T
   Wright, CB
AF Ramos, Alberto R.
   Dong, Chuanhui
   Elkind, Mitchell S. V.
   Boden-Albala, Bernadette
   Sacco, Ralph L.
   Rundek, Tatjana
   Wright, Clinton B.
TI Association between Sleep Duration and the Mini-Mental Score: The
   Northern Manhattan Study
SO JOURNAL OF CLINICAL SLEEP MEDICINE
LA English
DT Article
DE Sleep duration; cognition; short sleep; long sleep; cognitive
   impairment; mini mental score
ID COGNITIVE IMPAIRMENT; DAYTIME SLEEPINESS; OLDER-ADULTS; LONG-SLEEP;
   HEART HEALTH; POPULATION; RISK; DEMENTIA; MORTALITY; COMMUNITY
AB Background: Short and long sleep duration are associated with increased mortality and worse global cognitive function, but is unclear if these relations persist after accounting for the risk of sleep disordered breathing (SDB). The aim of our study is determine the association between short and long sleep duration with worse global cognitive function in a racially/ethnically diverse elderly cohort.
   Methods: We examined sleep hours and global cognitive function cross-sectionally within the population-based Northern Manhattan Study cohort. We conducted nonparametric and logistic regression to examine associations between continuous, short (< 6 h) and long (>= 9 h) sleep hours with performance on the Mini Mental State Examination (MMSE).
   Results: There were 927 stroke-free participants with data on self-reported sleep hours and MMSE scores (mean age 75 +/- 9 years, 61% women, 68% Hispanics). The median (interquartile range) MMSE was 28 (10-30). Sleep hours (centered at 7 h) was associated with worse MMSE (beta = -0.01; SE [0.004], p = 0.0113) adjusting for demographics, vascular risk factors, medications, and risk for SDB. Reporting long sleep (>= 9 h) compared to 6 to 8 h of sleep (reference) was significantly and inversely associated with MMSE (adjusted beta = -0.06; SE [0.03], p = 0.012), while reporting short sleep was not significantly associated with MMSE performance. Long sleep duration was also associated with low MMSE score when dichotomized (adjusted OR: 2.4, 95% Cl: 1.1-5.0).
   Conclusion: In this cross-sectional analysis among an elderly community cohort, long sleep duration was associated with worse MMSE performance.
C1 [Ramos, Alberto R.; Dong, Chuanhui; Sacco, Ralph L.; Rundek, Tatjana; Wright, Clinton B.] Univ Miami, Miller Sch Med, Dept Neurol, Evelyn F McKnight Brain Inst, Miami, FL 33136 USA.
   [Elkind, Mitchell S. V.] Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA.
   [Elkind, Mitchell S. V.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA.
   [Boden-Albala, Bernadette] Mt Sinai Sch Med, Div Social Epidemiol, Dept Hlth Policy, New York, NY USA.
   [Sacco, Ralph L.; Rundek, Tatjana; Wright, Clinton B.] Univ Miami, Dept Epidemiol & Publ Hlth, Miami, FL 33136 USA.
   [Sacco, Ralph L.] Univ Miami, Dept Human Genet, Miami, FL 33136 USA.
   [Wright, Clinton B.] Univ Miami, Neurosci Program, Miami, FL 33136 USA.
RP Ramos, AR (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol, Sleep Med Program, 1120 NW 14th St,Suite 1350, Miami, FL 33136 USA.
RI Ramos, Alberto/X-4249-2019; Sacco, Ralph/Y-9278-2019; Albala, Bernadette
   Boden/J-5703-2013
OI Albala, Bernadette Boden/0000-0001-5664-2342; Wright,
   Clinton/0000-0002-9797-6215; Boden-Albala,
   Bernadette/0000-0002-3752-329X
FU National Institute of Neurological Disorders and StrokeUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Neurological Disorders & Stroke (NINDS)
   [R37 NS029993, K24 NS 062737]; Evelyn F. McKnight Brain Institute;
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [KL2TR000461] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Neurological Disorders & Stroke (NINDS) [R37NS029993,
   K24NS062737] Funding Source: NIH RePORTER
FX This work was supported by grants from the National Institute of
   Neurological Disorders and Stroke: Supplement to R37 NS029993 (to Dr.
   Ramos); R37 NS029993 (to Drs. Sacco, Elkind, Rundek, Wright,
   Boden-Albala); K24 NS 062737 (to Dr. Rundek); and Evelyn F. McKnight
   Brain Institute (to Drs. Wright, Sacco, Rundek). All authors had access
   to the data and contributed substantially to the design, acquisition,
   and analysis of data, and writing of manuscript. The Northern Manhattan
   study cohort is followed at Columbia University. The administrative
   support and statistical analysis was performed at the University of
   Miami-Miller School of Medicine. The authors are thankful to the study
   participants for their collaboration and to all staff of the Northern
   Manhattan Study for their efforts to this study, and in particular
   Edison Sabala and Janet DeRosa.
CR Alzheimer's Association, 2010, Alzheimers Dement, V6, P158, DOI 10.1016/j.jalz.2010.01.009
   ANCOLIISRAEL S, 1991, SLEEP, V14, P486, DOI 10.1093/sleep/14.6.486
   Baldwin CM, 2010, J CLIN SLEEP MED, V6, P176
   Benito-Leon J, 2009, EUR J NEUROL, V16, P990, DOI 10.1111/j.1468-1331.2009.02618.x
   Blackwell T, 2011, SLEEP, V34, P1347, DOI 10.5665/SLEEP.1276
   Boden-Albala B, 2012, CIRC-CARDIOVASC QUAL, V5, P500, DOI 10.1161/CIRCOUTCOMES.111.963801
   Boustani M, 2003, ANN INTERN MED, V138, P927, DOI 10.7326/0003-4819-138-11-200306030-00015
   Byers AL, 2011, NAT REV NEUROL, V7, P323, DOI 10.1038/nrneurol.2011.60
   Cappuccio FP, 2011, EUR HEART J, V32, P1484, DOI 10.1093/eurheartj/ehr007
   Mesas AE, 2011, AGE AGEING, V40, P318, DOI 10.1093/ageing/afr004
   Faubel R, 2009, J SLEEP RES, V18, P427, DOI 10.1111/j.1365-2869.2009.00759.x
   Ferrie JE, 2011, SLEEP, V34, P565, DOI 10.1093/sleep/34.5.565
   Gallicchio L, 2009, J SLEEP RES, V18, P148, DOI 10.1111/j.1365-2869.2008.00732.x
   Goel N, 2009, SEMIN NEUROL, V29, P320, DOI 10.1055/s-0029-1237117
   Grandner MA, 2007, SLEEP MED REV, V11, P341, DOI 10.1016/j.smrv.2007.03.010
   Hale L, 2007, SLEEP, V30, P1096, DOI 10.1093/sleep/30.9.1096
   JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540
   Korczyn AD, 2005, J NEUROL SCI, V229, P3, DOI 10.1016/j.jns.2004.11.011
   Kripke DF, 2002, ARCH GEN PSYCHIAT, V59, P131, DOI 10.1001/archpsyc.59.2.131
   Kronholm E, 2011, J SLEEP RES, V20, P288, DOI 10.1111/j.1365-2869.2010.00899.x
   Kronholm E, 2009, J SLEEP RES, V18, P436, DOI 10.1111/j.1365-2869.2009.00765.x
   Lavie P, 2009, J SLEEP RES, V18, P385, DOI 10.1111/j.1365-2869.2009.00813.x
   Lim ASP, 2012, SLEEP, V35, P633, DOI 10.5665/sleep.1820
   Loredo JS, 2010, SLEEP, V33, P962, DOI 10.1093/sleep/33.7.962
   Mezick EJ, 2011, SLEEP MED REV, V15, P51, DOI 10.1016/j.smrv.2010.03.001
   Netzer NC, 1999, ANN INTERN MED, V131, P485, DOI 10.7326/0003-4819-131-7-199910050-00002
   Ohayon MM, 2002, ARCH INTERN MED, V162, P201, DOI 10.1001/archinte.162.2.201
   Patel SR, 2007, SLEEP, V30, P1077, DOI 10.1093/sleep/30.9.1077
   Patel SR, 2006, SLEEP, V29, P881, DOI 10.1093/sleep/29.7.881
   Patel SR, 2012, SLEEP, V35, P641, DOI 10.5665/sleep.1822
   Potvin O, 2012, SLEEP, V35, P491, DOI 10.5665/sleep.1732
   Ramos AR, 2011, NEUROEPIDEMIOLOGY, V37, P210, DOI 10.1159/000334315
   Sacco RL, 1998, AM J EPIDEMIOL, V147, P259, DOI 10.1093/oxfordjournals.aje.a009445
   Salaycik KJ, 2007, STROKE, V38, P16, DOI 10.1161/01.STR.0000251695.39877.ca
   Tombaugh TN, 1996, PSYCHOL ASSESSMENT, V8, P48, DOI 10.1037/1040-3590.8.1.48
   Wright CB, 2006, STROKE, V37, P1160, DOI 10.1161/01.STR.0000217439.73041.b4
   Xu L, 2011, SLEEP, V34, P575, DOI 10.1093/sleep/34.5.575
   Yaffe K, 2011, JAMA-J AM MED ASSOC, V306, P613, DOI 10.1001/jama.2011.1115
   Young T, 2002, AM J RESP CRIT CARE, V165, P1217, DOI 10.1164/rccm.2109080
   Young T, 2002, ARCH INTERN MED, V162, P893, DOI 10.1001/archinte.162.8.893
   Youngstedt SD, 2004, SLEEP MED REV, V8, P159, DOI 10.1016/j.smrv.2003.10.002
   Zimmerman ME, 2012, CURR NEUROL NEUROSCI, V12, P537, DOI 10.1007/s11910-012-0298-z
NR 42
TC 56
Z9 59
U1 0
U2 18
PU AMER ACAD SLEEP MEDICINE
PI WESTCHESTER
PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA
SN 1550-9389
J9 J CLIN SLEEP MED
JI J. Clin. Sleep Med.
PY 2013
VL 9
IS 7
BP 669
EP 673
DI 10.5664/jcsm.2834
PG 5
WC Clinical Neurology
SC Neurosciences & Neurology
GA 181WY
UT WOS:000321702000006
PM 23853560
OA Green Published
DA 2021-10-30
ER

PT J
AU Shaffer, KM
   Kim, Y
   Carver, CS
AF Shaffer, Kelly M.
   Kim, Youngmee
   Carver, Charles S.
TI Physical and mental health trajectories of cancer patients and
   caregivers across the year post-diagnosis: a dyadic investigation
SO PSYCHOLOGY & HEALTH
LA English
DT Article
DE cancer; caregiving; physical health; mental health; actor partner
   interdependence model; latent growth model
ID QUALITY-OF-LIFE; COVARIANCE STRUCTURE-ANALYSIS; LONGITUDINAL FOLLOW-UP;
   BREAST-CANCER; PSYCHOLOGICAL DISTRESS; FAMILY CAREGIVERS; SYMPTOM
   PREVALENCE; SPOUSAL CAREGIVERS; MISSING-DATA; MORTALITY
AB Objective: Evidence suggests interdependence between cancer patients' and their caregivers' physical and mental health. However, the extent to which caregivers' health relates to their patients' recovery, or patients' health affects their caregivers' outcomes, is largely unknown. This dyadic investigation reports the relations between cancer patients' and their caregivers' physical and mental health trajectories during the year following diagnosis.Design: Ninety-two colorectal cancer patient-caregiver dyads completed questionnaires at 2, 6 and 12 months post-diagnosis.Outcome measures: Self-reported physical and mental health using the Medical Outcomes Study Short Form Health Survey-12.Results: Patients reported improved physical health over the year following their diagnosis, whereas caregivers reported declining physical health. Patients with lower mental health at diagnosis had stagnated physical health recovery. Caregivers' physical health declined most noticeably among those reporting low mental health at diagnosis and whose patients reported low physical health at diagnosis.Conclusion: Findings suggest targeting health interventions to cancer patients and caregivers reporting poor mental health at diagnosis may mitigate their long-term physical morbidity. Limited evidence of dyadic interdependence between patients' and caregivers' physical and mental health trajectories suggests future studies are warranted to identify psychosocial and medical characteristics moderating the relations between patients' and caregivers' health.
C1 [Shaffer, Kelly M.; Kim, Youngmee; Carver, Charles S.] Univ Miami, Dept Psychol, POB 248185, Coral Gables, FL 33124 USA.
   [Shaffer, Kelly M.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
   [Kim, Youngmee; Carver, Charles S.] Stanford Univ, Ctr Adv Study Behav Sci, Stanford, CA 94305 USA.
RP Shaffer, KM (corresponding author), Univ Miami, Dept Psychol, POB 248185, Coral Gables, FL 33124 USA.; Shaffer, KM (corresponding author), Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
EM kmshaffer@mgh.harvard.edu
RI Shaffer, Kelly/AAG-9849-2020; Carver, Charles S./F-6567-2011
OI Shaffer, Kelly/0000-0002-9749-8006; Kim, Youngmee/0000-0002-3109-6362
FU American Cancer Society National Home OfficeAmerican Cancer Society;
   National Cancer InstituteUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [1 F31 CA189431-01A1]; NATIONAL CANCER INSTITUTEUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Cancer Institute (NCI) [F31CA189431,
   T32CA009461] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [UL1TR000460] Funding Source:
   NIH RePORTER
FX This work was supported by the American Cancer Society National Home
   Office, intramural research, and the National Cancer Institute [grant
   number 1 F31 CA189431-01A1].
CR Beach SR, 2005, J AM GERIATR SOC, V53, P255, DOI 10.1111/j.1532-5415.2005.53111.x
   Berg CA, 2007, PSYCHOL BULL, V133, P920, DOI 10.1037/0033-2909.133.6.920
   Bevans M, 2012, JAMA-J AM MED ASSOC, V307, P398, DOI 10.1001/jama.2012.29
   Bodenmann G., 2005, COUPLES COPING STRES, P33, DOI [DOI 10.1037/11031-002, 10.1037/11031-002]
   Bollen KA, 2006, WILEY SER PROBAB ST, P1
   Bower JE, 2013, BRAIN BEHAV IMMUN, V30, pS48, DOI 10.1016/j.bbi.2012.06.011
   Braun M, 2007, J CLIN ONCOL, V25, P4829, DOI 10.1200/JCO.2006.10.0909
   Brown SL, 2009, PSYCHOL SCI, V20, P488, DOI 10.1111/j.1467-9280.2009.02323.x
   Cella D, 2001, J CLIN ONCOL, V19, P3385, DOI 10.1200/JCO.2001.19.14.3385
   Chida Y, 2008, NAT CLIN PRACT ONCOL, V5, P466, DOI 10.1038/ncponc1134
   Chung ML, 2009, J PSYCHOSOM RES, V67, P29, DOI 10.1016/j.jpsychores.2009.01.009
   Cook WL, 2005, INT J BEHAV DEV, V29, P101, DOI 10.1080/01650250444000405
   Enders C.K., 2010, APPL MISSING DATA AN
   Enders CK, 2006, PSYCHOSOM MED, V68, P427, DOI 10.1097/01.psy.0000221275.75056.d8
   Faul F, 2014, G POWER
   Goudas LC, 2005, CANCER INVEST, V23, P182, DOI 10.1081/CNV-200050482
   Grunfeld E, 2004, CAN MED ASSOC J, V170, P1795, DOI 10.1503/cmaj.1031205
   Hagedoorn M, 2008, PSYCHOL BULL, V134, P1, DOI 10.1037/0033-2909.134.1.1
   Hodges LJ, 2005, SOC SCI MED, V60, P1, DOI 10.1016/j.socscimed.2004.04.018
   Hoppe S, 2013, J CLIN ONCOL, V31, P3877, DOI 10.1200/JCO.2012.47.7430
   Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118
   Janda M, 2007, J PSYCHOSOM RES, V63, P617, DOI 10.1016/j.jpsychores.2007.06.018
   Ji JG, 2012, CIRCULATION, V125, P1742, DOI 10.1161/CIRCULATIONAHA.111.057018
   Kashy D. A., 2000, HDB RES METHODS SOCI, P451, DOI DOI 10.1017/CBO9780511996481
   Kenny D.A., 2006, DYADIC DATA ANAL
   Kenny DA, 1999, PERS RELATIONSHIP, V6, P433, DOI 10.1111/j.1475-6811.1999.tb00202.x
   Kim JEE, 2009, J PAIN SYMPTOM MANAG, V37, P715, DOI 10.1016/j.jpainsymman.2008.04.018
   Kim Y, 2005, PSYCHOSOMATICS, V46, P123, DOI 10.1176/appi.psy.46.2.123
   Kim Y, 2008, ANN BEHAV MED, V35, P230, DOI 10.1007/s12160-008-9026-y
   Kim Y, 2016, PSYCHO-ONCOLOGY, V25, P266, DOI 10.1002/pon.3843
   Kim Y, 2015, PSYCHO-ONCOLOGY, V24, P95, DOI 10.1002/pon.3580
   Kim Y, 2015, CANCER-AM CANCER SOC, V121, P302, DOI 10.1002/cncr.29040
   Kim Y, 2014, J CONSULT CLIN PSYCH, V82, P1, DOI 10.1037/a0035116
   Kim Y, 2010, PSYCHO-ONCOLOGY, V19, P431, DOI 10.1002/pon.1576
   Kim Y, 2008, PSYCHO-ONCOLOGY, V17, P1129, DOI 10.1002/pon.1328
   Kline R., 2011, PRINCIPLES PRACTICE
   Lambert SD, 2012, ANN BEHAV MED, V44, P225, DOI 10.1007/s12160-012-9385-2
   Li QP, 2013, EUR J ONCOL NURS, V17, P578, DOI 10.1016/j.ejon.2013.01.007
   Martire L. M., 2005, FAMILIES SYSTEMS HEA, V23, P312, DOI [10.1037/1091-7527.23.3.312, DOI 10.1037/1091-7527.23.3.312]
   Martire LM, 2004, HEALTH PSYCHOL, V23, P599, DOI 10.1037/0278-6133.23.6.599
   Massie Mary Jane, 2004, J Natl Cancer Inst Monogr, P57
   Meuser T, 2001, PAIN, V93, P247, DOI 10.1016/S0304-3959(01)00324-4
   Milbury K, 2013, SUPPORT CARE CANCER, V21, P2371, DOI 10.1007/s00520-013-1795-6
   Mitchell AJ, 2011, LANCET ONCOL, V12, P160, DOI 10.1016/S1470-2045(11)70002-X
   Moser MT, 2013, PSYCHO-ONCOLOGY, V22, P2693, DOI 10.1002/pon.3331
   Muthen BO, 1997, PSYCHOL METHODS, V2, P371, DOI 10.1037/1082-989X.2.4.371
   Muthen L.K., 2014, MPLUS USERS GUIDE, V7th ed.
   National Alliance for Caregiving, 2009, CAR US FOC LOOK THOS
   National Comprehensive Cancer Network, 2012, CLIN PRACT GUID ONC
   Nijboer C, 2001, PSYCHOL HEALTH, V16, P471, DOI 10.1080/08870440108405520
   Nordin K, 2001, EUR J CANCER, V37, P376, DOI 10.1016/S0959-8049(00)00398-1
   Northouse LL, 2010, CA-CANCER J CLIN, V60, P317, DOI 10.3322/caac.20081
   Pachman DR, 2012, J CLIN ONCOL, V30, P3687, DOI 10.1200/JCO.2012.41.7238
   Palos GR, 2011, CANCER-AM CANCER SOC, V117, P1070, DOI 10.1002/cncr.25695
   Patterson RE, 2011, BREAST CANCER RES TR, V127, P541, DOI 10.1007/s10549-010-1236-x
   Pinquart M, 2010, PSYCHOL MED, V40, P1797, DOI 10.1017/S0033291709992285
   Pinquart M, 2007, J GERONTOL B-PSYCHOL, V62, pP126, DOI 10.1093/geronb/62.2.P126
   Pirl William F, 2004, J Natl Cancer Inst Monogr, P32
   Pitceathly C, 2003, EUR J CANCER, V39, P1517, DOI 10.1016/S0959-8049(03)00309-5
   Rohleder N, 2009, J CLIN ONCOL, V27, P2909, DOI 10.1200/JCO.2008.18.7435
   Satin JR, 2009, CANCER-AM CANCER SOC, V115, P5349, DOI 10.1002/cncr.24561
   Schafer JL, 2002, PSYCHOL METHODS, V7, P147, DOI 10.1037//1082-989X.7.2.147
   Schulz R, 1999, JAMA-J AM MED ASSOC, V282, P2215, DOI 10.1001/jama.282.23.2215
   Segrin C, 2005, J SOC PERS RELAT, V22, P673, DOI 10.1177/0265407505056443
   Segrin C, 2007, PSYCHO-ONCOLOGY, V16, P634, DOI 10.1002/pon.1111
   Segrin C, 2014, PSYCHOL HEALTH MED, V19, P716, DOI 10.1080/13548506.2013.871304
   vantSpijker A, 1997, PSYCHOSOM MED, V59, P280, DOI 10.1097/00006842-199705000-00011
   Vitaliano PP, 2002, PSYCHOSOM MED, V64, P418, DOI 10.1097/00006842-200205000-00006
   WARE JE, 1995, MED CARE, V33, pAS264, DOI 10.1097/00005650-199501001-00005
   Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003
   WILLETT JB, 1994, PSYCHOL BULL, V116, P363, DOI 10.1037/0033-2909.116.2.363
   Wong CKH, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-337
   Wong CKH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058341
   Yamagishi A, 2009, J PAIN SYMPTOM MANAG, V37, P823, DOI 10.1016/j.jpainsymman.2008.04.015
NR 74
TC 28
Z9 28
U1 0
U2 14
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0887-0446
EI 1476-8321
J9 PSYCHOL HEALTH
JI Psychol. Health
PY 2016
VL 31
IS 6
BP 655
EP 674
DI 10.1080/08870446.2015.1131826
PG 20
WC Public, Environmental & Occupational Health; Psychology,
   Multidisciplinary
SC Public, Environmental & Occupational Health; Psychology
GA DS0IL
UT WOS:000380278800002
PM 26680247
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Ramos, AR
   Gardener, H
   Rundek, T
   Elkind, MSV
   Boden-Albala, B
   Dong, CH
   Cheung, YK
   Stern, Y
   Sacco, RL
   Wright, CB
AF Ramos, Alberto R.
   Gardener, Hannah
   Rundek, Tatjana
   Elkind, Mitchell S. V.
   Boden-Albala, Bernadette
   Dong, Chuanhui
   Cheung, Ying Kuen
   Stern, Yaakov
   Sacco, Ralph L.
   Wright, Clinton B.
TI Sleep disturbances and cognitive decline in the Northern Manhattan Study
SO NEUROLOGY
LA English
DT Article
ID MATTER HYPERINTENSITY VOLUME; DAYTIME SLEEPINESS; MULTIETHNIC COHORT;
   RISK; DURATION; IMPAIRMENT; DEMENTIA; STROKE; HEALTH; APNEA
AB Objective: To examine frequent snoring, sleepiness, and sleep duration with baseline and longitudinal performance on neuropsychological (NP) battery.
   Methods: The analysis consists of 711 participants of the Northern Manhattan Study (NOMAS) with sleep data and NP assessment (age 63 +/- 8 years, 62% women, 18% white, 17% black, 67% Hispanic) and 687 with repeat NP testing (at a mean of 6 +/- 2 years). The main exposures were snoring, sleepiness, and sleep duration obtained during annual follow-up. Using factor analysis-derived domain-specific Z scores for episodic memory, language, executive function, and processing speed, we constructed multivariable regression models to evaluate sleep symptoms with baseline NP performance and change in performance in each NP domain.
   Results: In the cross-sectional analysis, adjusting for demographics and the NOMAS vascular risk score, participants with frequent snoring had worse executive function (beta = -12; p = 0.04) and processing speed (beta = -13; p = 0.02), but no difference in with episodic memory or language. Those with severe daytime sleepiness (beta = -26; p = 0.009) had worse executive function, but no changes in the other NP domains. There was no cross-sectional association between sleep duration and NP performance. Frequent snoring (beta = -29; p = 0.0007), severe daytime sleepiness (beta = -29; p = 0.05), and long sleep duration (beta = -29; p = 0.04) predicted decline in executive function, adjusting for demographic characteristics and NOMAS vascular risk score. Sleep symptoms did not explain change in episodic memory, language, or processing speed.
   Conclusions: In this race-ethnically diverse community-based cohort, sleep symptoms led to worse cognitive performance and predicted decline in executive function.
C1 [Ramos, Alberto R.; Gardener, Hannah; Rundek, Tatjana; Dong, Chuanhui; Sacco, Ralph L.; Wright, Clinton B.] Univ Miami, Miller Sch Med, Evelyn F McKnight Brain Inst, Dept Neurol, Coral Gables, FL 33124 USA.
   [Elkind, Mitchell S. V.; Stern, Yaakov] Columbia Univ, Dept Neurol, Coll Phys & Surg, Mailman Sch Publ Hlth, New York, NY USA.
   [Elkind, Mitchell S. V.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA.
   [Cheung, Ying Kuen] Columbia Univ, Mailman Sch Publ Hlth, Dept Biostat, New York, NY USA.
   [Boden-Albala, Bernadette] NYU, New York, NY USA.
RP Wright, CB (corresponding author), Univ Miami, Miller Sch Med, Evelyn F McKnight Brain Inst, Dept Neurol, Coral Gables, FL 33124 USA.
EM c.wright21@med.miami.edu
RI Sacco, Ralph/Y-9278-2019; Ramos, Alberto/X-4249-2019
OI Boden-Albala, Bernadette/0000-0002-3752-329X; Stern,
   Yaakov/0000-0001-7542-3241
FU NIH/NINDSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Neurological
   Disorders & Stroke (NINDS) [R37 NS 29993, R01 NS 48134]; Miami Clinical
   and Translational Science Institute; National Center for Advancing
   Translational SciencesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS); National Institute on Minority
   Health and Health DisparitiesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Minority Health & Health Disparities (NIMHD);  [1KL2TR000461];
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [KL2TR000461] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Neurological Disorders & Stroke (NINDS) [R01NS029993]
   Funding Source: NIH RePORTER
FX This work was supported by the NIH/NINDS (R37 NS 29993 and R01 NS
   48134). The project was supported specifically by grant number
   1KL2TR000461 (A.R.R.), Miami Clinical and Translational Science
   Institute, from the National Center for Advancing Translational Sciences
   and the National Institute on Minority Health and Health Disparities.
   The sponsors did not have a role in the design, interpretation, or draft
   of the manuscript.
CR Alzheimers Assoc, 2015, ALZHEIMERS DEMENT, V11, P332, DOI 10.1016/j.jalz.2015.02.003
   Benito-Leon J, 2009, EUR J NEUROL, V16, P990, DOI 10.1111/j.1468-1331.2009.02618.x
   Benito-Leon J, 2014, NEUROLOGY, V83, P1530, DOI 10.1212/WNL.0000000000000915
   Berry DC, 1997, Q J EXP PSYCHOL-A, V50, P1
   Boden-Albala B, 2012, CIRC-CARDIOVASC QUAL, V5, P500, DOI 10.1161/CIRCOUTCOMES.111.963801
   Cho ER, 2013, J SLEEP RES, V22, P452, DOI 10.1111/jsr.12034
   Cohen-Zion M, 2001, J AM GERIATR SOC, V49, P1622, DOI 10.1111/j.1532-5415.2001.49270.x
   Dichgans M, 2012, STROKE, V43, P3137, DOI 10.1161/STROKEAHA.112.651778
   Duff K, 2012, ARCH CLIN NEUROPSYCH, V27, P248, DOI 10.1093/arclin/acr120
   Elwood PC, 2011, J EPIDEMIOL COMMUN H, V65, P820, DOI 10.1136/jech.2009.100503
   Faubel R, 2009, J SLEEP RES, V18, P427, DOI 10.1111/j.1365-2869.2009.00759.x
   Foley DJ, 2003, SLEEP, V26, P596, DOI 10.1093/sleep/26.5.596
   Gardener H, 2012, ARCH NEUROL-CHICAGO, V69, P251, DOI 10.1001/archneurol.2011.548
   Gorelick PB, 2013, STROKE, V44, P307, DOI 10.1161/STROKEAHA.111.000219
   Gorelick PB, 2011, STROKE, V42, P2672, DOI 10.1161/STR.0b013e3182299496
   Jaussent I, 2012, SLEEP, V35, P1201, DOI 10.5665/sleep.2070
   Ju YES, 2014, NAT REV NEUROL, V10, P115, DOI 10.1038/nrneurol.2013.269
   Knutson KL, 2010, BEST PRACT RES CL EN, V24, P731, DOI 10.1016/j.beem.2010.07.001
   Lim DC, 2014, SLEEP MED REV, V18, P35, DOI 10.1016/j.smrv.2012.12.003
   Loredo JS, 2010, SLEEP, V33, P962, DOI 10.1093/sleep/33.7.962
   Marquine MJ, 2010, STROKE, V41, P1946, DOI 10.1161/STROKEAHA.110.587717
   Osorio RS, 2015, NEUROLOGY, V84, P1964, DOI 10.1212/WNL.0000000000001566
   Ramos A, 2013, AM J CARDIOL, P111
   Ramos AR, 2015, NEUROLOGY, V84, P391, DOI 10.1212/WNL.0000000000001181
   Ramos AR, 2014, J SLEEP RES, V23, P524, DOI 10.1111/jsr.12177
   Ramos AR, 2013, J CLIN SLEEP MED, V9, P669, DOI 10.5664/jcsm.2834
   Ramos AR, 2011, NEUROEPIDEMIOLOGY, V37, P210, DOI 10.1159/000334315
   Redline S, 1997, AM J RESP CRIT CARE, V155, P186, DOI 10.1164/ajrccm.155.1.9001310
   Redline S, 2014, AM J RESP CRIT CARE, V189, P335, DOI 10.1164/rccm.201309-1735OC
   Sacco RL, 2009, J AM COLL CARDIOL, V54, P2303, DOI 10.1016/j.jacc.2009.07.047
   Sacco RL, 2001, STROKE, V32, P1725, DOI 10.1161/01.STR.32.8.1725
   Scullin MK, 2015, PERSPECT PSYCHOL SCI, V10, P97, DOI 10.1177/1745691614556680
   Siedlecki KL, 2009, J INT NEUROPSYCH SOC, V15, P558, DOI 10.1017/S1355617709090857
   Walsleben JA, 2004, SLEEP, V27, P293, DOI 10.1093/sleep/27.2.293
   Whitney CW, 1998, SLEEP, V21, P27, DOI 10.1093/sleep/21.1.27
   Willey JZ, 2014, NEUROEPIDEMIOLOGY, V42, P100, DOI 10.1159/000355975
   Wright CB, 2006, NEUROEPIDEMIOLOGY, V27, P201, DOI 10.1159/000096300
   Yaffe K, 2014, LANCET NEUROL, V13, P1017, DOI 10.1016/S1474-4422(14)70172-3
   Yaffe K, 2011, JAMA-J AM MED ASSOC, V306, P613, DOI 10.1001/jama.2011.1115
   Young T, 2002, ARCH INTERN MED, V162, P893, DOI 10.1001/archinte.162.8.893
NR 40
TC 16
Z9 18
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD OCT 4
PY 2016
VL 87
IS 14
BP 1511
EP 1516
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA DZ2FC
UT WOS:000385656700020
PM 27590286
DA 2021-10-30
ER

PT J
AU Otalora, L
   Chavez, E
   Watford, D
   Tueros, L
   Correa, M
   Nair, V
   Ruiz, P
   Wahl, P
   Eddy, S
   Martini, S
   Kretzler, M
   Burke, GW
   Fornoni, A
   Merscher, S
AF Otalora, Lilian
   Chavez, Efren
   Watford, Daniel
   Tueros, Lissett
   Correa, Mayrin
   Nair, Viji
   Ruiz, Philip
   Wahl, Patricia
   Eddy, Sean
   Martini, Sebastian
   Kretzler, Matthias
   Burke, George W., III
   Fornoni, Alessia
   Merscher, Sandra
TI Identification of glomerular and podocyte-specific genes and pathways
   activated by sera of patients with focal segmental glomerulosclerosis
SO PLOS ONE
LA English
DT Article
ID MICROARRAY ANALYSIS; NEPHROTIC SYNDROME; PERMEABILITY; CHANNELS;
   CHILDREN
AB Focal segmental glomerulosclerosis (FSGS) accounts for about 40% of all nephrotic syndrome cases in adults. The presence of several potential circulating factors has been suggested in patients with primary FSGS and particularly in patients with recurrent disease after transplant. Irrespectively of the nature of the circulating factors, this study was aimed at identifying early glomerular/podocyte-specific pathways that are activated by the sera of patients affected by FSGS. Kidney biopsies were obtained from patients undergoing kidney transplantation due to primary FSGS. Donor kidneys were biopsied pre-reperfusion (PreR) and a subset 1-2 hours after reperfusion of the kidney (PostR). Thirty-one post reperfusion (PostR) and 36 PreR biopsy samples were analyzed by microarray and gene enrichment KEGG pathway analysis. Data were compared to those obtained from patients with incident primary FSGS enrolled in other cohorts as well as with another cohort to correct for pathways activated by ischemia reperfusion. Using an ex-vivo cell-based assay in which human podocytes were cultured in the presence of sera from patients with recurrent and non recurrent FSGS, the molecular signature of podocytes exposed to sera from patients with REC was compared to the one established from patients with NON REC. We demonstrate that inflammatory pathways, including the TNF pathway, are primarily activated immediately after exposure to the sera of patients with primary FSGS, while phagocytotic pathways are activated when proteinuria becomes clinically evident. The TNF pathway activation by one or more circulating factors present in the sera of patients with FSGS supports prior experimental findings from our group demonstrating a causative role of local TNF in podocyte injury in FSGS. Correlation analysis with clinical and histological parameters of disease was performed and further supported a possible role for TNF pathway activation in FSGS. Additionally, we identified a unique set of genes that is specifically activated in podocytes when cultured in the presence of serum of patients with REC FSGS. This clinical translational study supports our prior experimental findings describing a potential role of the TNF pathway in the pathogenesis of FSGS. Validation of these findings in larger cohorts may lay the ground for the implementation of integrated system biology approaches to risk stratify patients affected by FSGS and to identify novel pathways relevant to podocyte injury.
C1 [Otalora, Lilian; Chavez, Efren; Wahl, Patricia; Fornoni, Alessia; Merscher, Sandra] Univ Miami, Miller Sch Med, Dept Med, Katz Family Div Nephrol & Hypertens, Miami, FL 33136 USA.
   [Otalora, Lilian; Chavez, Efren; Wahl, Patricia; Burke, George W., III; Fornoni, Alessia; Merscher, Sandra] Univ Miami, Peggy & Harold Katz Family Drug Discovery Ctr, Miller Sch Med, Miami, FL 33136 USA.
   [Chavez, Efren; Watford, Daniel] Univ Miami, Jackson Mem Hosp, Dept Internal Med, Miami, FL 33136 USA.
   [Tueros, Lissett; Ruiz, Philip; Burke, George W., III] Univ Miami, Miller Sch Med, Dept Surg, Miami, FL 33136 USA.
   [Tueros, Lissett; Ruiz, Philip; Burke, George W., III] Univ Miami, Miami Transplant Inst, Miller Sch Med, Miami, FL 33136 USA.
   [Correa, Mayrin; Ruiz, Philip] Univ Miami, Dept Pathol, Miller Sch Med, Miami, FL 33136 USA.
   [Nair, Viji; Eddy, Sean; Martini, Sebastian; Kretzler, Matthias] Univ Michigan, Sch Med, Dept Internal Med, Div Nephrol, Ann Arbor, MI USA.
   [Burke, George W., III] Univ Miami, Miller Sch Med, Diabet Res Inst, Miami, FL 33136 USA.
RP Fornoni, A; Merscher, S (corresponding author), Univ Miami, Miller Sch Med, Dept Med, Katz Family Div Nephrol & Hypertens, Miami, FL 33136 USA.; Fornoni, A; Merscher, S (corresponding author), Univ Miami, Peggy & Harold Katz Family Drug Discovery Ctr, Miller Sch Med, Miami, FL 33136 USA.
EM afornoni@med.miami.edu; smerscher@med.miami.edu
OI fornoni, Alessia/0000-0002-1313-7773; Eddy, Sean/0000-0001-8578-3443;
   Merscher, Sandra/0000-0002-4757-7494
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [DK090316, DK104753]; National
   Institutes of Health (NIH) Rare Disease Clinical Research Network
   (RDCRN) through NCATS [U54-DK083912]; National Institutes of Health
   (NIH) Rare Disease Clinical Research Network (RDCRN) through National
   Institute of Diabetes, Digestive, and Kidney Diseases [U54-DK083912];
   University of MichiganUniversity of Michigan System; NephCure Kidney
   International; Halpin Foundation; National Institutes of Health (NIH)
   Rare Disease Clinical Research Network (RDCRN) through Office of Rare
   Diseases Research (ORDR)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [U54-DK083912]; 
   [U24DK076169];  [U54DK083912];  [UM1DK100846];  [1UL1TR000460]; NATIONAL
   CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000460] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)
   [U24DK076169, UM1DK100846, U54DK083912] Funding Source: NIH RePORTER
FX AF and S. Merscher are supported by the NIH grants DK090316, DK104753.
   AF is supported by U24DK076169, U54DK083912, UM1DK100846, and
   1UL1TR000460. G.W.B. is supported by the NIH grant DK090316. The
   Nephrotic Syndrome Study Network Consortium (NEPTUNE), U54-DK083912, is
   a part of the National Institutes of Health (NIH) Rare Disease Clinical
   Research Network (RDCRN), supported through a collaboration between the
   Office of Rare Diseases Research (ORDR), NCATS, and the National
   Institute of Diabetes, Digestive, and Kidney Diseases. Additional
   funding and/or programmatic support for this project has also been
   provided by the University of Michigan, the NephCure Kidney
   International and the Halpin Foundation.
CR Beaudreuil S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219353
   Bennett MR, 2007, NEPHRON EXP NEPHROL, V107, pE30, DOI 10.1159/000106775
   Besbas N, 2015, RENAL FAILURE, V37, P1435, DOI 10.3109/0886022X.2015.1074474
   Braden GL, 2000, AM J KIDNEY DIS, V35, P878, DOI 10.1016/S0272-6386(00)70258-7
   Chung CF, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216426
   Dryer SE, 2019, BBA-MOL BASIS DIS, V1865, P1041, DOI 10.1016/j.bbadis.2019.04.001
   Fogo AB, 2015, NAT REV NEPHROL, V11, P76, DOI 10.1038/nrneph.2014.216
   Fornoni A, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002231
   HAAS M, 1995, AM J KIDNEY DIS, V26, P740, DOI 10.1016/0272-6386(95)90437-9
   Hickson LJ, 2009, TRANSPLANTATION, V87, P1232, DOI 10.1097/TP.0b013e31819f12be
   Hodgin JB, 2010, AM J PATHOL, V177, P1674, DOI 10.2353/ajpath.2010.090746
   Huang K, 2004, AM J KIDNEY DIS, V43, P1082, DOI 10.1053/j.ajkd.2004.03.017
   Joy MS, 2010, AM J KIDNEY DIS, V55, P50, DOI 10.1053/j.ajkd.2009.08.019
   Kim EY, 2017, BBA-MOL BASIS DIS, V1863, P2342, DOI 10.1016/j.bbadis.2017.06.010
   Kim EY, 2012, AM J PHYSIOL-RENAL, V302, pF298, DOI 10.1152/ajprenal.00423.2011
   Kreepala C, 2013, AM J TRANSPLANT, V13, P415, DOI 10.1111/ajt.12043
   Maas RJH, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-47
   Mariani LH, 2018, BIORXIV, DOI [10.1101/427880, DOI 10.1101/427880]
   McCarthy ET, 2010, CLIN J AM SOC NEPHRO, V5, P2115, DOI 10.2215/CJN.03800609
   Nehus EJ, 2013, TRANSPLANTATION, V96, P550, DOI 10.1097/TP.0b013e31829c2431
   Pedigo CE, 2016, J CLIN INVEST, V126, P3336, DOI 10.1172/JCI85939
   Peyser A, 2010, BMC NEPHROL, V11, DOI 10.1186/1471-2369-11-2
   Rosenberg AZ, 2017, CLIN J AM SOC NEPHRO, V12, P502, DOI 10.2215/CJN.05960616
   Savin VJ, 1996, NEW ENGL J MED, V334, P878, DOI 10.1056/NEJM199604043341402
   Schwab K, 2004, AM J NEPHROL, V24, P438, DOI 10.1159/000080188
   SURANYI MG, 1993, AM J KIDNEY DIS, V21, P251, DOI 10.1016/S0272-6386(12)80742-6
   Tong J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140453
   Wasilewska A, 2011, SCAND J UROL NEPHROL, V45, P52, DOI 10.3109/00365599.2010.526140
   Wei CL, 2012, J AM SOC NEPHROL, V23, P2051, DOI 10.1681/ASN.2012030302
   Wei CL, 2011, NAT MED, V17, P952, DOI 10.1038/nm.2411
   Wen YM, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00098
NR 31
TC 3
Z9 4
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 3
PY 2019
VL 14
IS 10
AR e0222948
DI 10.1371/journal.pone.0222948
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA LM6ZN
UT WOS:000532398600023
PM 31581251
OA Green Published, gold
DA 2021-10-30
ER

PT J
AU Alachkar, N
   Wei, C
   Arend, LJ
   Jackson, AM
   Racusen, LC
   Fornoni, A
   Burke, G
   Rabb, H
   Kakkad, K
   Reiser, J
   Estrella, MM
AF Alachkar, Nada
   Wei, Changli
   Arend, Lois J.
   Jackson, Annette M.
   Racusen, Lorraine C.
   Fornoni, Alessia
   Burke, George
   Rabb, Hamid
   Kakkad, Kavita
   Reiser, Jochen
   Estrella, Michelle M.
TI Podocyte Effacement Closely Links to suPAR Levels at Time of
   Posttransplantation Focal Segmental Glomerulosclerosis Occurrence and
   Improves With Therapy
SO TRANSPLANTATION
LA English
DT Article
DE Kidney transplant; Podocyte effacement; FSGS; suPAR; Rituximab
ID GLOMERULAR-PERMEABILITY; NEPHROTIC SYNDROME; TRANSPLANTATION;
   RECURRENCE; BIOPSIES; RECEPTOR
AB Background. Focal segmental glomerulosclerosis (FSGS) recurs after kidney transplantation in more than 30% of cases and can lead to allograft loss. Serum soluble urokinase-type plasminogen activator receptor (suPAR) is implicated in the pathogenesis of native and recurrent FSGS.
   Methods. We conducted a retrospective study of 25 adults with posttransplantation FSGS. We investigated the relationship between suPAR levels and podocyte changes and the impact of therapy on podocyte structure. We assessed response to therapy by improvement in proteinuria, allograft function, and resolution of histologic changes.
   Results. A median (interquartile range) of 15 (10-23) plasmapheresis sessions was administered; 13 of the subjects also received rituximab. Median pretreatment suPAR levels were higher among those with severe (>= 75%) versus those with mild (<= 25%) podocyte foot process effacement (13,030 vs. 4806 pg/mL; P=0.02). Overall, mean +/- SD of proteinuria improved from 5.1 +/- 3.8 to 2.1 +/- 2.8 mg/dL (P=0.003), mean podocyte effacement decreased from 57%+/- 33% to 22%+/- 22% (P=0.0001), estimated glomerular filtration rates increased from median (interquartile range) of 32.9 (20.6 +/- 44.2) to 39.3 (28.8 +/- 63.4; P<0.0001), and suPAR levels decreased from a median of 6.781 to 4.129 pg/mL (P=0.02) with therapy.
   Conclusions. Podocyte effacement is the first pathologic manifestation of FSGS after transplantation. The degree of podocyte effacement correlates with suPAR levels at time of diagnosis. Response to therapy results in significant reduction of suPAR levels and complete or significant improvement of podocyte effacement.
C1 [Alachkar, Nada; Jackson, Annette M.; Rabb, Hamid; Estrella, Michelle M.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
   [Wei, Changli; Reiser, Jochen] Rush Univ, Dept Med, Med Ctr, Chicago, IL 60612 USA.
   [Arend, Lois J.; Racusen, Lorraine C.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.
   [Fornoni, Alessia] Univ Miami, Miller Sch Med, Sch Med, Miami, FL 33136 USA.
   [Burke, George] Univ Miami, Miller Sch Med, Sch Med, Miami, FL 33136 USA.
   [Kakkad, Kavita] Union Mem Hosp, Dept Med, Baltimore, MD USA.
RP Alachkar, N (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, 720 Rutland Ave,Ross 971, Baltimore, MD 21205 USA.
EM nalachk1@jhmi.edu; jochen_reiser@rush.edu
RI Arend, Lois/ABE-2002-2020
OI Arend, Lois/0000-0001-5434-7630; Alachkar, Nada/0000-0003-1249-2455;
   fornoni, Alessia/0000-0002-1313-7773
FU National Institutes of Health (NIH)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [DK073495,
   DK089394]; NIH/National Institute of Diabetes and Digestive and Kidney
   DiseasesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Diabetes &
   Digestive & Kidney Diseases (NIDDK) [R01DK090316, 1K23DK081317];
   Nephcure Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1TR000460] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Diabetes &
   Digestive & Kidney Diseases (NIDDK) [R01DK089394, R01DK073495,
   R01DK090316, K23DK081317] Funding Source: NIH RePORTER
FX J.R. was supported in part by the National Institutes of Health (NIH)
   grants DK073495 and DK089394. A.F. was supported by the NIH/National
   Institute of Diabetes and Digestive and Kidney Diseases grant
   R01DK090316 and by the Nephcure Foundation. M.M.E. was supported by the
   NIH/National Institute of Diabetes and Digestive and Kidney Diseases
   grant 1K23DK081317.
CR Abbott KC, 2001, AM J KIDNEY DIS, V37, P366, DOI 10.1053/ajkd.2001.21311
   ARTERO M, 1992, AM J MED, V92, P375, DOI 10.1016/0002-9343(92)90267-F
   Chang JW, 2012, TRANSPLANTATION, V93, P1238, DOI 10.1097/TP.0b013e318250234a
   Cheong HI, 2000, NEPHROL DIAL TRANSPL, V15, P78, DOI 10.1093/ndt/15.1.78
   D'Agati VD, 2004, AM J KIDNEY DIS, V43, P368, DOI 10.1053/j.ajkd.2003.10.024
   FOGO A, 1990, KIDNEY INT, V38, P115, DOI 10.1038/ki.1990.175
   Fornoni A, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002231
   Gallon L, 2012, NEW ENGL J MED, V366, P1648, DOI 10.1056/NEJMc1202500
   HARRISON DJ, 1988, J CLIN PATHOL, V41, P155, DOI 10.1136/jcp.41.2.155
   Hickson LJ, 2009, TRANSPLANTATION, V87, P1232, DOI 10.1097/TP.0b013e31819f12be
   HOYER JR, 1972, LANCET, V2, P343
   Ijpelaar DHT, 2008, J AM SOC NEPHROL, V19, P2219, DOI 10.1681/ASN.2007121365
   Kemper MJ, 2013, AM J KIDNEY DIS, V61, P352, DOI 10.1053/j.ajkd.2012.10.011
   Kitiyakara C, 2004, AM J KIDNEY DIS, V44, P815, DOI 10.1016/S0272-6386(04)01081-9
   Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006
   Sakai K, 2010, CLIN TRANSPLANT, V24, P60, DOI 10.1111/j.1399-0012.2010.01279.x
   Savin VJ, 1996, NEW ENGL J MED, V334, P878, DOI 10.1056/NEJM199604043341402
   Vijayan KV, 2000, J CLIN INVEST, V105, P793, DOI 10.1172/JCI6982
   Vincenti F, 2005, AM J TRANSPLANT, V5, P1179, DOI 10.1111/j.1600-6143.2005.00968.x
   Wei CL, 2012, J AM SOC NEPHROL, V23, P2051, DOI 10.1681/ASN.2012030302
   Wei CL, 2011, NAT MED, V17, P952, DOI 10.1038/nm.2411
NR 21
TC 42
Z9 45
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0041-1337
EI 1534-6080
J9 TRANSPLANTATION
JI Transplantation
PD OCT 15
PY 2013
VL 96
IS 7
BP 649
EP 656
DI 10.1097/TP.0b013e31829eda4f
PG 8
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 299GV
UT WOS:000330385100015
PM 23842190
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Thomas, E
   Gonzalez, VD
   Li, QS
   Modi, AA
   Chen, WP
   Noureddin, M
   Rotman, Y
   Liang, TJ
AF Thomas, Emmanuel
   Gonzalez, Veronica D.
   Li, Qisheng
   Modi, Ankit A.
   Chen, Weiping
   Noureddin, Mazen
   Rotman, Yaron
   Liang, T. Jake
TI HCV Infection Induces a Unique Hepatic Innate Immune Response Associated
   With Robust Production of Type III Interferons
SO GASTROENTEROLOGY
LA English
DT Article
DE IRF; Cytokine; IL29; Nonresponder
ID C VIRUS-INFECTION; ADAPTIVE IMMUNITY; REPLICATION; ALPHA; TLRS
AB BACKGROUND & AIMS: Polymorphisms in the IL28B gene have been associated with clearance of hepatitis C virus (HCV), indicating a role for type III interferons (IFNs) in HCV infection. Little is known about the function of type III IFNs in intrinsic antiviral innate immunity. METHODS: We used in vivo and in vitro models to characterize the role of the type III IFNs in HCV infection and analyzed gene expression in liver biopsy samples from HCV-infected chimpanzees and patients. Messenger RNA and protein expression were studied in HCV-infected hepatoma cell lines and primary human hepatocytes. RESULTS: HCV infection of primary human hepatocytes induced production of chemokines and type III IFNs, including interleukin (IL)-28, and led to expression of IFN-stimulated genes (ISGs). Chimpanzees infected with HCV showed rapid induction of hepatic type III IFN, associated with up-regulation of ISGs and minimal induction of type I IFNs. In liver biopsy specimens from HCV-infected patients, hepatic expression of IL-28 correlated with levels of ISGs but not of type I IFNs. HCV infection produced extensive changes with gene expression in addition to ISGs in primary human hepatocytes. The induction of type III IFNs is regulated by IFN regulatory factor 3 and nuclear factor kappa B. Type III IFNs up-regulate ISGs with a different kinetic profile than type 1 IFNs and induce a distinct set of genes, which might account for their functional differences. CONCLUSIONS: HCV infection results predominantly in induction of type III IFNs in livers of humans and chimpanzees; the level of induction correlates with hepatic levels of ISGs. These findings might account for the association among IL-28, level of ISGs, and recovery from HCV infection and provide a therapeutic strategy for patients who do not respond to IFN therapy.
C1 [Thomas, Emmanuel; Gonzalez, Veronica D.; Li, Qisheng; Modi, Ankit A.; Noureddin, Mazen; Rotman, Yaron; Liang, T. Jake] NIDDK, Liver Dis Branch, NIH, Bethesda, MD 20892 USA.
   [Chen, Weiping] NIDDK, Microarray Core Facil, NIH, Bethesda, MD 20892 USA.
RP Liang, TJ (corresponding author), NIDDK, Liver Dis Branch, NIH, 10 Ctr Dr,Bldg 10,Room 9B16, Bethesda, MD 20892 USA.
EM jakel@bdg10.niddk.nih.gov
RI Rotman, Yaron/AAK-8032-2020; Li, Qisheng/K-1909-2013; Chen,
   Weiping/C-9550-2011
OI Rotman, Yaron/0000-0002-7549-8216; Li, Qisheng/0000-0002-4181-1972
FU National Institute of Diabetes and Digestive and Kidney DiseasesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Diabetes & Digestive &
   Kidney Diseases (NIDDK); National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [N01-DK-7-0004/HHSN26700700004C]; Swedish Research CouncilSwedish
   Research CouncilEuropean Commission; Wenner-Gren Foundation; NATIONAL
   CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Advancing Translational Sciences (NCATS)
   [KL2TR000461] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)
   [ZIADK054504, ZIADK054505, ZICDK071001, ZIADK054511] Funding Source: NIH
   RePORTER
FX Supported by the Intramural Research Program of the National Institute
   of Diabetes and Digestive and Kidney Diseases. E. T. was supported by
   funding from the National Institutes of Health Loan Repayment Program.
   V. D. G. was supported by the Swedish Research Council and the
   Wenner-Gren Foundation. PHH cultures were provided by the National
   Institutes of Health-funded Liver Tissue Procurement and Cell
   Distribution System (N01-DK-7-0004/HHSN26700700004C) (principal
   investigator: Stephen Strom, University of Pittsburgh).
CR Balachandran S, 2004, NATURE, V432, P401, DOI 10.1038/nature03124
   Balachandran S, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002165
   Barth H, 2011, HEPATOLOGY, V54, P1135, DOI 10.1002/hep.24489
   Beutler BA, 2009, BLOOD, V113, P1399, DOI 10.1182/blood-2008-07-019307
   Bigger CB, 2004, J VIROL, V78, P13779, DOI 10.1128/JVI.78.24.13779-13792.2004
   Henke JI, 2008, EMBO J, V27, P3300, DOI 10.1038/emboj.2008.244
   Iwasaki A, 2010, SCIENCE, V327, P291, DOI 10.1126/science.1183021
   Kato T, 2008, HEPATOLOGY, V48, P732, DOI 10.1002/hep.22422
   Kawai T, 2009, INT IMMUNOL, V21, P317, DOI 10.1093/intimm/dxp017
   Kotenko SV, 2003, NAT IMMUNOL, V4, P69, DOI 10.1038/ni875
   Lagging M, 2006, HEPATOLOGY, V44, P1617, DOI 10.1002/hep.21407
   Lindenbach BD, 2005, SCIENCE, V309, P623, DOI 10.1126/science.1114016
   Major ME, 2004, HEPATOLOGY, V39, P1709, DOI 10.1002/hep.20239
   Marcello T, 2006, GASTROENTEROLOGY, V131, P1887, DOI 10.1053/j.gastro.2006.09.052
   Onoguchi K, 2007, J BIOL CHEM, V282, P7576, DOI 10.1074/jbc.M608618200
   Onomoto K, 2010, J INTERF CYTOK RES, V30, P875, DOI 10.1089/jir.2010.0117
   Owsianka A, 2005, J VIROL, V79, P11095, DOI 10.1128/JVI.79.17.11095-11104.2005
   Podevin P, 2010, GASTROENTEROLOGY, V139, P1355, DOI 10.1053/j.gastro.2010.06.058
   Saito T, 2008, NATURE, V454, P523, DOI 10.1038/nature07106
   Sarasin-Filipowicz M, 2008, P NATL ACAD SCI USA, V105, P7034, DOI 10.1073/pnas.0707882105
   Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226
   Stumper R, 2005, J VIROL, V79, P2689, DOI 10.1128/JVI.79.5.2689-2699.2005
   Su AI, 2002, P NATL ACAD SCI USA, V99, P15669, DOI 10.1073/pnas.202608199
   Takeuchi O, 2009, IMMUNOL REV, V227, P75, DOI 10.1111/j.1600-065X.2008.00737.x
   Tanaka Y, 2009, NAT GENET, V41, P1105, DOI 10.1038/ng.449
   Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268
   Walters KA, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000269
NR 27
TC 206
Z9 213
U1 0
U2 16
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
EI 1528-0012
J9 GASTROENTEROLOGY
JI Gastroenterology
PD APR
PY 2012
VL 142
IS 4
BP 978
EP 988
DI 10.1053/j.gastro.2011.12.055
PG 11
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 919BU
UT WOS:000302296400047
PM 22248663
OA Green Accepted
HC Y
HP N
DA 2021-10-30
ER

PT J
AU Stoutenberg, M
   Rethorst, CD
   Vidot, DC
   Greer, TL
   Trivedi, MH
AF Stoutenberg, Mark
   Rethorst, Chad D.
   Vidot, Denise C.
   Greer, Tracy L.
   Trivedi, Madhukar H.
TI Cardiorespiratory fitness and body composition of stimulant users: A
   baseline analysis of the STRIDE cohort
SO JOURNAL OF SUBSTANCE ABUSE TREATMENT
LA English
DT Article
DE Body mass index; Cardiorespiratory fitness; Stimulant use; Waist
   circumference
ID RANDOMIZED CONTROLLED-TRIAL; SUBSTANCE USE DISORDERS; OLDER-ADULTS;
   RISK-FACTORS; DRUG-ABUSE; MASS INDEX; EXERCISE; COCAINE; MORTALITY; MEN
AB Introduction: Relatively little has been reported about the physical characteristics, such as cardiorespiratory fitness (CRF) and body composition, of stimulant users. Identifying risk factors associated with the physical health of stimulant users is an important public health issue as new treatments should better address the entire range of health concerns experienced by this population.
   Methods: We examined cross-sectional data gathered at baseline from the STimulant Reduction Intervention using Dosed Exercise (STRIDE) study, a multisite randomized clinical trial that examined exercise as an adjunct to treatment as usual for individuals in residential treatment programs (RTPs). Clients were approached after intake to the RTP. Prior to randomization, eligible individuals underwent a comprehensive screening process that included medical screening, where CRF was assessed through a maximal exercise test (time on treadmill), and a series of baseline examinations assessing domains of substance use and mental health.
   Results: Data from 295 individuals with recent stimulant use disorders were analyzed. The mean body mass index (BMI) and waist circumference (WC) and for all participants was 27.8 +/- 5.7 kg/m(2) and 93.5 +/- 14.2 cm, respectively, while the mean time on treadmill was 13.7 +/- 2.9 min. Few significant associations were observed between CRF, BMI, or WC and substance use and mental health measures.
   Conclusions: Stimulant users in this study presented with low CRF levels and would be considered overweight based on their BMI. These individuals would likely benefit from interventions that address both their stimulant use, as well as their physical health. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Stoutenberg, Mark] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA.
   [Rethorst, Chad D.; Greer, Tracy L.; Trivedi, Madhukar H.] Univ Texas Southwestern Med Ctr Dallas, Dept Psychiat, Dallas, TX USA.
   [Vidot, Denise C.] Univ Miami, Sch Nursing & Hlth Studies, Coral Gables, FL 33124 USA.
RP Stoutenberg, M (corresponding author), Univ Miami, Clin Res Bldg,Suite 1008,1120 NW 14th St, Miami, FL 33139 USA.
EM mstoutenberg@med.miami.edu
OI Trivedi, Madhukar/0000-0002-2983-1110; Rethorst,
   Chad/0000-0002-8168-2829
FU National Institute on Drug Abuse through the Clinical Trials Network for
   the Texas Node [3U10DA020024-06S1]; Stimulant Reduction Intervention
   using Dosed Exercise (STRIDE) [2U10DA020024-06]; Miami Clinical and
   Translational Science Institute from the National Center for Advancing
   Translational Sciences [1KL2TR000461]; National Institute on Minority
   Health and Health DisparitiesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Minority Health & Health Disparities (NIMHD); National Institute of
   Mental Health of the National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Mental Health (NIMH) [K01MH097847];
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [KL2TR000461] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL
   HEALTHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH) [K01MH097847] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON
   DRUG ABUSEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Drug Abuse
   (NIDA)European Commission [UG1DA020024, UG1DA013720, U10DA020024]
   Funding Source: NIH RePORTER
FX This work was supported by the National Institute on Drug Abuse through
   the Clinical Trials Network for the Texas Node [3U10DA020024-06S1],
   Madhukar H. Trivedi, M.D., Principal Investigator; and the Stimulant
   Reduction Intervention using Dosed Exercise (STRIDE) study
   [2U10DA020024-06]. Dr. Stoutenberg is supported by Grant Number
   1KL2TR000461 of the Miami Clinical and Translational Science Institute
   from the National Center for Advancing Translational Sciences and the
   National Institute on Minority Health and Health Disparities. Chad D.
   Rethorst is supported by the National Institute of Mental Health of the
   National Institutes of Health under Award Number K01MH097847. The
   content is solely the responsibility of the authors and does not
   necessarily represent the official views of the National Institutes of
   Health. The authors alone are responsible for the content and writing of
   this paper.
CR Bardo MT, 2015, DRUG ALCOHOL DEPEN, V153, P3, DOI 10.1016/j.drugalcdep.2015.05.037
   Biggs ML, 2010, JAMA-J AM MED ASSOC, V303, P2504, DOI 10.1001/jama.2010.843
   BILLMAN GE, 1995, CRIT REV TOXICOL, V25, P113, DOI 10.3109/10408449509021610
   Bize R, 2007, PREV MED, V45, P401, DOI 10.1016/j.ypmed.2007.07.017
   BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395
   Carnethon MR, 2003, JAMA-J AM MED ASSOC, V290, P3092, DOI 10.1001/jama.290.23.3092
   Cofrancesco J, 2007, AM J DRUG ALCOHOL AB, V33, P467, DOI 10.1080/00952990701301616
   Cowan J, 2008, APPETITE, V50, P33, DOI 10.1016/j.appet.2007.05.006
   de la Cruz A. M., 2016, AM J ADDICT IN PRESS
   dela Cruz AM, 2014, J PSYCHIATR RES, V59, P155, DOI 10.1016/j.jpsychires.2014.08.003
   Devlin RJ, 2008, CRIT CARE, V12, DOI 10.1186/cc6166
   Dishman RK, 2012, AM J PREV MED, V43, P361, DOI 10.1016/j.amepre.2012.06.011
   Dolezal BA, 2013, J ADDICT MED, V7, P122, DOI 10.1097/ADM.0b013e318282475e
   Ersche KD, 2013, APPETITE, V71, P75, DOI 10.1016/j.appet.2013.07.011
   Flemmen G, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001914
   Forrester JE, 2005, PUBLIC HEALTH NUTR, V8, P61, DOI [10.1079/PHN2004667, 10.1079/PHN2005667]
   Guh DP, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-88
   Havranek EP, 1996, J AM COLL CARDIOL, V28, P1168, DOI 10.1016/S0735-1097(96)00299-9
   Henry BL, 2010, ADDICT BEHAV, V35, P593, DOI 10.1016/j.addbeh.2010.01.013
   Kaminsky LA, 2013, CIRCULATION, V127, P652, DOI 10.1161/CIR.0b013e31827ee100
   King AC, 1997, JAMA-J AM MED ASSOC, V277, P32, DOI 10.1001/jama.277.1.32
   Koster A, 2008, AM J EPIDEMIOL, V167, P1465, DOI 10.1093/aje/kwn079
   LaMonte MJ, 2005, CIRCULATION, V112, P505, DOI 10.1161/CIRCULATIONAHA.104.503805
   Lee CMY, 2008, J CLIN EPIDEMIOL, V61, P646, DOI 10.1016/j.jclinepi.2007.08.012
   Lee DC, 2010, J PSYCHOPHARMACOL, V24, P27, DOI 10.1177/1359786810382057
   MacMahon M. J., 2010, BRIT J DIABETES VASC, V10, P251
   Maynard C, 2015, J ADDICT DIS, V34, P323, DOI 10.1080/10550887.2015.1078133
   McPherson S, 2016, J SUBST ABUSE TREAT, V61, P18, DOI 10.1016/j.jsat.2015.08.008
   Mittleman MA, 1999, CIRCULATION, V99, P2737, DOI 10.1161/01.CIR.99.21.2737
   Morgan PT, 2006, DRUG ALCOHOL DEPEN, V82, P238, DOI 10.1016/j.drugalcdep.2005.09.014
   National Heart Lung and Blood Institute (NHLBI) Obesity Education Initiative Expert Panel on the Identification Evaluation and Treatment of Obesity in Adults (US), 1998, 984083 NHLBI OB ED I
   Neumark YD, 2000, SUBST USE MISUSE, V35, P313, DOI 10.3109/10826080009147699
   Qureshi Adnan I, 2014, J Vasc Interv Neurol, V7, P76
   Scheewe TW, 2012, MED SCI SPORT EXER, V44, P1834, DOI 10.1249/MSS.0b013e318258e120
   Schwartz BG, 2010, CIRCULATION, V122, P2558, DOI 10.1161/CIRCULATIONAHA.110.940569
   STRUENING EL, 1990, J SOC ISSUES, V46, P65, DOI 10.1111/j.1540-4560.1990.tb01799.x
   Sui X, 2008, DIABETES CARE, V31, P550, DOI 10.2337/dc07-1870
   TAMESIS B, 1993, AM J CARDIOL, V72, P715, DOI 10.1016/0002-9149(93)90891-F
   Thompson WR, 2010, ACSM GUIDELINES EXER
   Trivedi MH, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-206
   VanBuskirk KA, 2010, J ADDICT MED, V4, P1, DOI 10.1097/ADM.0b013e3181ce38e7
   Warden D, 2016, PSYCHIAT RES, V246, P136, DOI 10.1016/j.psychres.2016.09.007
   Westover AN, 2015, J PSYCHIATR RES, V64, P32, DOI 10.1016/j.jpsychires.2015.03.011
   Whiteford HA, 2013, LANCET, V382, P1575, DOI 10.1016/S0140-6736(13)61611-6
   Whitlock G, 2009, LANCET, V373, P1083, DOI 10.1016/S0140-6736(09)60318-4
NR 45
TC 1
Z9 1
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0740-5472
J9 J SUBST ABUSE TREAT
JI J. Subst. Abus. Treat.
PD JUL
PY 2017
VL 78
BP 74
EP 79
DI 10.1016/j.jsat.2017.05.005
PG 6
WC Psychology, Clinical; Substance Abuse
SC Psychology; Substance Abuse
GA EX3LR
UT WOS:000403134100012
PM 28554607
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Asfour, L
   Koussa, M
   Perrino, T
   Stoutenberg, M
   Prado, G
AF Asfour, Lila
   Koussa, Maryann
   Perrino, Tatiana
   Stoutenberg, Mark
   Prado, Guillermo
TI The association of organized and unorganized physical activity and
   sedentary behavior with internalizing and externalizing symptoms in
   Hispanic adolescents
SO CHILD AND ADOLESCENT MENTAL HEALTH
LA English
DT Article
DE Physical activity; sedentary behavior; mental health; adolescent;
   Hispanic
ID MENTAL-HEALTH; YOUTH; CHILDREN; IMMIGRANT; STRESS; GENDER; MODEL
AB BackgroundLiterature suggests that physical activity (PA) and sedentary behavior may be associated with adolescent mental health symptoms. A gap in the literature is whether different types of PA have unique impacts on internalizing and externalizing symptoms. This study separately assesses the association of organized PA, unorganized PA, and sedentary behavior with internalizing and externalizing symptoms.
   MethodThis study analyzed baseline data from a randomized controlled trial of a preventive intervention with 575 Hispanic adolescents. Using separate multivariable linear mixed models, the relationship between the independent variables of PA and sedentary behavior and the dependent variables of internalizing and externalizing symptoms was evaluated.
   ResultsOrganized PA was not associated with internalizing or externalizing symptoms; however, higher levels of unorganized PA were associated with greater internalizing and externalizing symptoms. Increased sedentary behavior was also associated with higher levels of externalizing symptoms, but not internalizing symptoms.
   ConclusionsImplications of this study highlight the need to examine types of PA separately as they may differentially influence adolescent mental health symptoms. Potential explanations for these findings and suggested further analyses are discussed.
C1 [Asfour, Lila; Koussa, Maryann; Stoutenberg, Mark] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA.
   [Perrino, Tatiana; Prado, Guillermo] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Div Prevent Sci & Community Hlth, 1120 NW 14th St, Miami, FL 33136 USA.
RP Prado, G (corresponding author), Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Div Prevent Sci & Community Hlth, 1120 NW 14th St, Miami, FL 33136 USA.
EM gprado@med.miami.edu
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01 DA025192, R01 DA025192 S1];
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [KL2TR000461] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG
   ABUSEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Drug Abuse
   (NIDA)European Commission [R01DA025192, R01DA040756] Funding Source: NIH
   RePORTER; National Institute on Minority Health and Health
   DisparitiesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Minority
   Health & Health Disparities (NIMHD) [R01MD007724] Funding Source: NIH
   RePORTER
FX This study was supported by NIH grants R01 DA025192 and R01 DA025192 S1
   awarded to G.P. The authors declare that they have no competing or
   potential conflicts of interest.
CR Achenbach T. M., 1991, MANUAL CHILD BEHAV C, P288
   Alegria M, 2008, AM J PSYCHIAT, V165, P359, DOI 10.1176/appi.ajp.2007.07040704
   Anderson ER, 2010, CLIN PSYCHOL REV, V30, P338, DOI 10.1016/j.cpr.2009.12.008
   Bengoechea EG, 2010, RES Q EXERCISE SPORT, V81, P7, DOI 10.1080/02701367.2010.10599623
   Biddle SJH, 2011, BRIT J SPORT MED, V45, P886, DOI 10.1136/bjsports-2011-090185
   Cano MA, 2015, J ADOLESCENCE, V42, P31, DOI 10.1016/j.adolescence.2015.03.017
   Centers for Disease Control and Prevention, 2013, YOUTH RISK BEH SURV
   Dawson BA, 2008, J YOUTH ADOLESCENCE, V37, P399, DOI 10.1007/s10964-007-9233-z
   DeLisi M, 2013, YOUTH VIOLENCE JUV J, V11, P132, DOI 10.1177/1541204012460874
   Dinh KT, 2002, J ABNORM CHILD PSYCH, V30, P295, DOI 10.1023/A:1015111014775
   Dishion T J, 1998, Clin Child Fam Psychol Rev, V1, P61, DOI 10.1023/A:1021800432380
   Dishion TJ, 2011, ANNU REV PSYCHOL, V62, P189, DOI 10.1146/annurev.psych.093008.100412
   Epstein LH, 2005, ANN BEHAV MED, V29, P200, DOI 10.1207/s15324796abm2903_6
   HARTE JL, 1995, BIOL PSYCHOL, V40, P251, DOI 10.1016/0301-0511(95)05118-T
   Hoare E, 2014, OBES REV, V15, P40, DOI 10.1111/obr.12069
   Holtz P, 2011, J ADOLESCENCE, V34, P49, DOI 10.1016/j.adolescence.2010.02.004
   Janz KF, 2008, MED SCI SPORT EXER, V40, P767, DOI 10.1249/MSS.0b013e3181620ed1
   Johnson JG, 2002, SCIENCE, V295, P2468, DOI 10.1126/science.1062929
   Karnik NS, 2006, COMMUNITY MENT HLT J, V42, P477, DOI 10.1007/s10597-006-9056-5
   Kowalski KC, 2004, PHYS ACTIVITY QUESTI, P87
   Leadbeater BJ, 1999, DEV PSYCHOL, V35, P1268, DOI 10.1037/0012-1649.35.5.1268
   Martinez-Gomez D, 2011, MED CLIN-BARCELONA, V136, P13, DOI 10.1016/j.medcli.2010.05.013
   McLaughlin KA, 2007, J ABNORM CHILD PSYCH, V35, P801, DOI 10.1007/s10802-007-9128-1
   NORRIS R, 1992, J PSYCHOSOM RES, V36, P55, DOI 10.1016/0022-3999(92)90114-H
   O'Connell M., 2009, PREVENTING MENTAL EM, P49
   Prado G, 2012, ARCH PEDIAT ADOL MED, V166, P127, DOI 10.1001/archpediatrics.2011.189
   Reiss F, 2013, SOC SCI MED, V90, P24, DOI 10.1016/j.socscimed.2013.04.026
   Robinson M, 2011, J PAEDIATR CHILD H, V47, P54, DOI 10.1111/j.1440-1754.2010.01891.x
   Ronnlund M, 2006, J GENET PSYCHOL, V167, P47, DOI 10.3200/GNTP.167.1.47-63
   Rusby JC, 2014, HEALTH EDUC BEHAV, V41, P42, DOI 10.1177/1090198113485753
   U.S. Department of Health and Human Services, 2015, ANN UPD HHS POV GUID
   US Department of Health and Human Services, 2012, HLTH PEOPL 2020
NR 32
TC 7
Z9 7
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1475-357X
EI 1475-3588
J9 CHILD ADOL MENT H-UK
JI Child Adolesc. Ment. Health
PD MAY
PY 2016
VL 21
IS 2
BP 109
EP 114
DI 10.1111/camh.12139
PG 6
WC Psychology, Clinical; Pediatrics; Psychiatry
SC Psychology; Pediatrics; Psychiatry
GA DK1QY
UT WOS:000374689700007
PM 27346986
OA Bronze, Green Accepted
DA 2021-10-30
ER

PT J
AU Pullen, N
   Fornoni, A
AF Pullen, Nick
   Fornoni, Alessia
TI Drug discovery in focal and segmental glomerulosclerosis
SO KIDNEY INTERNATIONAL
LA English
DT Review
DE focal segmental glomerulosclerosis; podocyte; proteinuria
ID NEPHROTIC SYNDROME; PODOCYTE INJURY; DIABETIC-NEPHROPATHY;
   GLOMERULAR-DISEASE; PROTECTS PODOCYTES; KIDNEY-DISEASE; SLIT DIAPHRAGM;
   GROWTH-FACTOR; TGF-BETA; IN-VIVO
AB Despite the high medical burden experienced by patients with focal segmental glomerulosclerosis, the etiology of the condition remains largely unknown. Focal segmental glomerulosclerosis is highly heterogeneous in clinical and morphologic manifestations. While this presents challenges for the development of new treatments, research investments over the last 2 decades have yielded a surfeit of potential avenues for therapeutic intervention. The development of many of those ideas and concepts into new therapies, however, has been very disappointing. Here, we describe some of the factors that have potentially contributed to the poor translational performance from this research investment, including the confidence we ascribe to a target, the conduct of experimental studies, and the availability of selective reagents to test hypotheses. We will discuss the significance of genetic and systems traits as well as other methods for reducing bias. We will analyze the limitations of a successful drug development. We will use specific examples hoping that these will guide a consensus for investment and drive greater translational quality. We hope that this substrate will serve to exemplify the tremendous opportunity for intervention as well as facilitate greater collaborative effort between industry, academia, and private foundations in promoting appropriate validation of these targets. Only then will we have achieved our goal for curative therapies for this devastating disease.
C1 [Pullen, Nick] Pfizer Global Res & Dev, 610 Main St, Cambridge, MA 02139 USA.
   [Fornoni, Alessia] Univ Miami, Miller Sch Med, Katz Family Drug Discovery Ctr, Miami, FL 33136 USA.
   [Fornoni, Alessia] Univ Miami, Miller Sch Med, Div Nephrol & Hypertens, Miami, FL 33136 USA.
RP Pullen, N (corresponding author), Pfizer Global Res & Dev, 610 Main St, Cambridge, MA 02139 USA.; Fornoni, A (corresponding author), Univ Miami, Miller Sch Med, Peggy & Harold Katz Family Drug Discovery Ctr, Batchelor Childrens Res Inst, 1580 NW 10th Ave,633A, Miami, FL 33136 USA.
EM nick.pullen@pfizer.com; afornoni@med.miami.edu
OI fornoni, Alessia/0000-0002-1313-7773
FU National Institute of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [DK090316, DK104753,
   U24DK076169, U54DK083912, UM1DK100846, 1UL1TR000460]; NATIONAL CENTER
   FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000460]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND
   DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Diabetes & Digestive & Kidney Diseases (NIDDK) [U24DK076169,
   R01DK104753, U54DK083912, UM1DK100846, R01DK090316] Funding Source: NIH
   RePORTER
FX AF is supported by National Institute of Health grants DK090316,
   DK104753, U24DK076169, U54DK083912, UM1DK100846, and 1UL1TR000460.
CR Agrawal S, 2014, KIDNEY INT, V86, P1150, DOI 10.1038/ki.2014.196
   Anderson M, 2013, AM J PHYSIOL-CELL PH, V305, pC276, DOI 10.1152/ajpcell.00095.2013
   Arif E, 2013, ANN CLIN EXP HYPERTE, V1, P1003
   Asanuma Katsuhiko, 2003, Clin Exp Nephrol, V7, P255, DOI 10.1007/s10157-003-0259-6
   Ashraf S, 2013, J CLIN INVEST, V123, P5179, DOI 10.1172/JCI69000
   Banas MC, 2008, J AM SOC NEPHROL, V19, P704, DOI 10.1681/ASN.2007040395
   Barton M, 2015, SEMIN NEPHROL, V35, P156, DOI 10.1016/j.semnephrol.2015.02.005
   Begley CG, 2012, NATURE, V483, P531, DOI 10.1038/483531a
   Boerries M, 2013, KIDNEY INT, V83, P1052, DOI 10.1038/ki.2012.487
   Borza CM, 2012, J AM SOC NEPHROL, V23, P1027, DOI 10.1681/ASN.2011040367
   Brosius FC, 2015, CURR OPIN NEPHROL HY, V24, P88, DOI 10.1097/MNH.0000000000000079
   Bu X, 2011, AM J PHYSIOL-RENAL, V301, pF784, DOI 10.1152/ajprenal.00210.2011
   Buelli S, 2014, J AM SOC NEPHROL, V25, P523, DOI 10.1681/ASN.2013040362
   Cherney DZI, 2014, CIRCULATION, V129, P587, DOI 10.1161/CIRCULATIONAHA.113.005081
   Clement LC, 2014, NAT MED, V20, P37, DOI 10.1038/nm.3396
   Cook D, 2014, NAT REV DRUG DISCOV, V13, P419, DOI 10.1038/nrd4309
   Coresh J, 2014, JAMA-J AM MED ASSOC, V311, P2518, DOI 10.1001/jama.2014.6634
   D'Agati VD, 2011, NEW ENGL J MED, V365, P2398, DOI 10.1056/NEJMra1106556
   Da Sacco S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081812
   Delville M, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008538
   Djudjaj S, 2016, J AM SOC NEPHROL
   Faul C, 2008, NAT MED, V14, P931, DOI 10.1038/nm.1857
   Fornoni A, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002231
   Forst AL, 2016, J AM SOC NEPHROL, V27, P848, DOI 10.1681/ASN.2014111144
   Fukuda A, 2012, KIDNEY INT, V81, P40, DOI 10.1038/ki.2011.306
   Gee HY, 2013, J CLIN INVEST, V123, P3243, DOI 10.1172/JCI69134
   George B, 2012, J CLIN INVEST, V122, P674, DOI 10.1172/JCI60070
   George B, 2011, AM J PHYSIOL-RENAL, V300, pF1152, DOI 10.1152/ajprenal.00373.2010
   Giardino L, 2009, J AM SOC NEPHROL, V20, P1929, DOI 10.1681/ASN.2008121286
   Godel M, 2011, J CLIN INVEST, V121, P2197, DOI 10.1172/JCI44774
   Gorin Y, 2015, AM J PHYSIOL-RENAL, V308, pF1276, DOI 10.1152/ajprenal.00396.2014
   Grgic I, 2014, KIDNEY INT, V86, P1116, DOI 10.1038/ki.2014.204
   Gu LY, 2012, KIDNEY INT, V81, P458, DOI 10.1038/ki.2011.406
   Hall G, 2014, AM J PHYSIOL-RENAL, V306, pF1442, DOI 10.1152/ajprenal.00212.2013
   Harris JJ, 2013, J PATHOL, V229, P660, DOI 10.1002/path.4149
   Hauser PV, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009463
   Heeringa SF, 2011, J CLIN INVEST, V121, P2013, DOI 10.1172/JCI45693
   Helmering J, 2014, LIPIDS HEALTH DIS, V13, DOI 10.1186/1476-511X-13-167
   Hodgin JB, 2015, J AM SOC NEPHROL, V26, P3162, DOI 10.1681/ASN.2014080752
   Huh D, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004249
   Ijaz A, 2009, KIDNEY INT, V75, P381, DOI 10.1038/ki.2008.559
   Inker LA, 2014, AM J KIDNEY DIS, V64, P74, DOI 10.1053/j.ajkd.2014.02.020
   Ito T, 2010, SCIENCE, V327, P1345, DOI 10.1126/science.1177319
   Jang KJ, 2013, INTEGR BIOL-UK, V5, P1119, DOI 10.1039/c3ib40049b
   Janiak P, 2007, KIDNEY INT, V72, P1345, DOI 10.1038/sj.ki.5002540
   Jo SK, 2008, KIDNEY INT, V73, P1220, DOI 10.1038/ki.2008.34
   Joy MS, 2010, AM J KIDNEY DIS, V55, P50, DOI 10.1053/j.ajkd.2009.08.019
   Ju WJ, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac7071
   Kawakami T, 2015, J AM SOC NEPHROL, V26, P1040, DOI 10.1681/ASN.2013111202
   Kerjaschki D, 2001, J CLIN INVEST, V108, P1583, DOI 10.1172/JCI200114629
   Kimura J, 2014, SCI REP-UK, V4, DOI 10.1038/srep07290
   Koshikawa M, 2005, J AM SOC NEPHROL, V16, P2690, DOI 10.1681/ASN.2004121084
   Kretzler M, 2015, SEMIN NEPHROL, V35, P209, DOI 10.1016/j.semnephrol.2015.04.001
   Lai JY, 2015, J AM SOC NEPHROL, V26, P805, DOI 10.1681/ASN.2013121274
   Lal MA, 2015, J AM SOC NEPHROL, V26, P647, DOI 10.1681/ASN.2013111195
   Lee HW, 2015, J AM SOC NEPHROL, V26, P2741, DOI 10.1681/ASN.2014090859
   Leeson PD, 2007, NAT REV DRUG DISCOV, V6, P881, DOI 10.1038/nrd2445
   Lin CL, 2014, J AM SOC NEPHROL, V25, P1698, DOI 10.1681/ASN.2013050527
   Lindskog A, 2010, J AM SOC NEPHROL, V21, P1290, DOI 10.1681/ASN.2009101025
   Ma H, 2010, J AM SOC NEPHROL, V21, P1145, DOI 10.1681/ASN.2009090991
   Martini S, 2014, J AM SOC NEPHROL, V25, P2559, DOI 10.1681/ASN.2013080906
   Mathieson PW, 2012, NAT REV NEPHROL, V8, P52, DOI 10.1038/nrneph.2011.171
   McCarthy ET, 2010, CLIN J AM SOC NEPHRO, V5, P2115, DOI 10.2215/CJN.03800609
   Menne J, 2013, DIABETES, V62, P1167, DOI 10.2337/db12-0534
   Merscher-Gomez S, 2013, DIABETES, V62, P3817, DOI 10.2337/db13-0399
   Miller M, 2011, J BIOL CHEM, V286, P33436, DOI 10.1074/jbc.M111.274167
   Miyazaki Y, 2014, NEPHROL DIAL TRANSPL, V29, P783, DOI 10.1093/ndt/gfu002
   Moeller CC, 2007, J AM SOC NEPHROL, V18, P29, DOI 10.1681/ASN.2006091010
   Morgan P, 2012, DRUG DISCOV TODAY, V17, P419, DOI 10.1016/j.drudis.2011.12.020
   Murray CJL, 2013, NEW ENGL J MED, V369, P448, DOI 10.1056/NEJMra1201534
   Naves MA, 2012, J NEPHROL, V25, P401, DOI 10.5301/jn.5000017
   Nelson MR, 2015, NAT GENET, V47, P856, DOI 10.1038/ng.3314
   Ni L, 2012, NEPHROLOGY, V17, P525, DOI 10.1111/j.1440-1797.2012.01619.x
   Nijenhuis T, 2011, AM J PATHOL, V179, P1719, DOI 10.1016/j.ajpath.2011.06.033
   Niranjan T, 2008, NAT MED, V14, P290, DOI 10.1038/nm1731
   Oh J, 2011, KIDNEY INT, V80, P483, DOI 10.1038/ki.2011.105
   Palmer SC, 2011, AM J KIDNEY DIS, V58, P335, DOI 10.1053/j.ajkd.2011.06.006
   Peired A, 2014, NEPHRON EXP NEPHROL, V126, P70, DOI 10.1159/000360669
   Pengal R, 2011, AM J PHYSIOL-RENAL, V301, pF509, DOI 10.1152/ajprenal.00661.2010
   Pereira RL, 2011, KIDNEY INT, V79, P1217, DOI 10.1038/ki.2011.14
   Peti-Peterdi J, 2015, KIDNEY INT, V88, P44, DOI 10.1038/ki.2015.65
   Plenge RM, 2013, NAT REV DRUG DISCOV, V12, P581, DOI 10.1038/nrd4051
   Prinz F, 2011, NAT REV DRUG DISCOV, V10, P712, DOI 10.1038/nrd3439-c1
   Pullen N, 2011, HUM REPROD UPDATE, V17, P791, DOI 10.1093/humupd/dmr030
   Ravani P, 2013, KIDNEY INT, V84, P1025, DOI 10.1038/ki.2013.211
   Reiser J, 2005, NAT GENET, V37, P739, DOI 10.1038/ng1592
   Ruotsalainen V, 1999, P NATL ACAD SCI USA, V96, P7962, DOI 10.1073/pnas.96.14.7962
   Saleem MA, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133630
   Sampson MG, 2016, J AM SOC NEPHROL, V27, P814, DOI 10.1681/ASN.2014111131
   Saurus P, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.125
   Savin VJ, 1996, NEW ENGL J MED, V334, P878, DOI 10.1056/NEJM199604043341402
   Schaldecker T, 2013, J CLIN INVEST, V123, P5298, DOI 10.1172/JCI71165
   Schiffer M, 2015, NAT MED, V21, P601, DOI 10.1038/nm.3843
   Somlo S, 2000, NAT GENET, V24, P333, DOI 10.1038/74139
   Song B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046453
   Spinale JM, 2015, KIDNEY INT, V87, P564, DOI 10.1038/ki.2014.346
   Stitt-Cavanagh EM, 2010, J AM SOC NEPHROL, V21, P1678, DOI 10.1681/ASN.2009121234
   Sugano Y, 2015, KIDNEY INT, V88, P1047, DOI 10.1038/ki.2015.197
   Sun H, 2013, J AM SOC NEPHROL, V24, P917, DOI 10.1681/ASN.2012080834
   Takagi N, 2012, NEPHRON EXTRA, V2, P17, DOI 10.1159/000334961
   Tamura Y, 2012, AM J PHYSIOL-RENAL, V303, pF339, DOI 10.1152/ajprenal.00158.2012
   Thompson A, 2015, J AM SOC NEPHROL, V26, P2930, DOI 10.1681/ASN.2015010091
   Tossidou I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010185
   Trachtman H, 2011, KIDNEY INT, V79, P1236, DOI 10.1038/ki.2011.33
   Tryggvason K, 1999, J AM SOC NEPHROL, V10, P2440
   US Renal Data System, 2011, 2011 ANN DAT REP ATL
   van Roeyen CRC, 2011, KIDNEY INT, V80, P1292, DOI 10.1038/ki.2011.278
   Wang LM, 2008, KIDNEY BLOOD PRESS R, V31, P111, DOI 10.1159/000121531
   Wang LM, 2015, J CLIN INVEST, V125, P1913, DOI 10.1172/JCI76767
   Wang YL, 2012, J AM SOC NEPHROL, V23, P1977, DOI 10.1681/ASN.2012040383
   Wei C, 2008, NAT MED, V14, P55, DOI 10.1038/nm1696
   Wickman L, 2013, J AM SOC NEPHROL, V24, P2081, DOI 10.1681/ASN.2013020173
   Winn MP, 2005, SCIENCE, V308, P1801, DOI 10.1126/science.1106215
   Wu JN, 2015, J CLIN INVEST, V125, P4091, DOI 10.1172/JCI81061
   Yaddanapudi S, 2011, J CLIN INVEST, V121, P3965, DOI 10.1172/JCI58552
   Yamada S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089135
   Yokoi H, 2008, KIDNEY INT, V73, P446, DOI 10.1038/sj.ki.5002722
   Yoshida S, 2008, NEPHRON EXP NEPHROL, V108, pE57, DOI 10.1159/000124236
   Yu CC, 2013, NEW ENGL J MED, V369, P2416, DOI 10.1056/NEJMoa1304572
   Zhou LL, 2012, KIDNEY INT, V82, P759, DOI 10.1038/ki.2012.184
NR 120
TC 10
Z9 10
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0085-2538
EI 1523-1755
J9 KIDNEY INT
JI Kidney Int.
PD JUN
PY 2016
VL 89
IS 6
BP 1211
EP 1220
DI 10.1016/j.kint.2015.12.058
PG 10
WC Urology & Nephrology
SC Urology & Nephrology
GA DL5QY
UT WOS:000375693100010
PM 27165834
OA Bronze, Green Accepted
DA 2021-10-30
ER

PT J
AU Horigian, VE
   Marin-Navarrete, RA
   Verdeja, RE
   Alonso, E
   Perez, MA
   Fernandez-Mondragon, J
   Berlanga, C
   Medina-Mora, ME
   Szapocznik, J
AF Horigian, Viviana E.
   Marin-Navarrete, Rodrigo A.
   Verdeja, Rosa E.
   Alonso, Elizabeth
   Perez, Maria A.
   Fernandez-Mondragon, Jose
   Berlanga, Carlos
   Elena Medina-Mora, Maria
   Szapocznik, Jose
TI Technology transfer for the implementation of a clinical trials network
   on drug abuse and mental health treatment in Mexico
SO REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC
   HEALTH
LA English
DT Article
DE Technology transfer; clinical trials as topic; evidence-based practice;
   science and technology information networks; substance-related
   disorders; mental health; health services research; methods; Mexico
ID SUBSTANCE-ABUSE; ORGANIZATIONAL READINESS; ADDICTION TREATMENT;
   DISSEMINATION; INNOVATION; INTEGRATION; KNOWLEDGE; ADOPTION; LESSONS;
   TIME
AB Low- and middle-income countries (LMIC) lack the research infrastructure and capacity to conduct rigorous substance abuse and mental health effectiveness clinical trials to guide clinical practice. A partnership between the Florida Node Alliance of the United States National Drug Abuse Treatment Clinical Trials Network and the National Institute of Psychiatry in Mexico was established in 2011 to improve substance abuse practice in Mexico. The purpose of this partnership was to develop a Mexican national clinical trials network of substance abuse researchers and providers capable of implementing effectiveness randomized clinical trials in community-based settings. A technology transfer model was implemented and ran from 2011-2013. The Florida Node Alliance shared the "know how" for the development of the research infrastructure to implement randomized clinical trials in community programs through core and specific training modules, role-specific coaching, pairings, modeling, monitoring, and feedback. The technology transfer process was bi-directional in nature in that it was informed by feedback on feasibility and cultural appropriateness for the context in which practices were implemented. The Institute, in turn, led the effort to create the national network of researchers and practitioners in Mexico and the implementation of the first trial. A collaborative model of technology transfer was useful in creating a Mexican researcher-provider network that is capable of changing national practice in substance abuse research and treatment. Key considerations for transnational technology transfer are presented.
C1 [Horigian, Viviana E.; Verdeja, Rosa E.; Alonso, Elizabeth; Perez, Maria A.; Szapocznik, Jose] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA.
   [Marin-Navarrete, Rodrigo A.; Fernandez-Mondragon, Jose; Berlanga, Carlos; Elena Medina-Mora, Maria] Inst Nacl Psiquiatria Ramon de La Fuente, Mexico City, DF, Mexico.
RP Horigian, VE (corresponding author), Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA.
EM vhorigian@med.miami.edu
RI Medina-Mora, Maria Elena I/T-5937-2018
OI Medina-Mora, Maria Elena I/0000-0001-9300-0752; Marin-Navarrete,
   Rodrigo/0000-0002-6084-8199
FU United States Department of State [SINLEC11GR0015, S-INLEC-11GR020];
   National Drug Abuse Treatment Clinical Trials Network [U10DA13720];
   National Center for the Advancement of Translational Sciences
   [1UL-1TR000460]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1TR000460] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Drug Abuse (NIDA)European Commission [U10DA013720]
   Funding Source: NIH RePORTER
FX This work was funded by the United States Department of State (grants
   SINLEC11GR0015 and S-INLEC-11GR020) awarded to the Instituto Nacional de
   Psiquiatria Ramon de la Fuente (Mexico City, Mexico) and the University
   of Miami (Miami, Florida, United States), respectively. Support for this
   work was also provided by the National Drug Abuse Treatment Clinical
   Trials Network (grant U10DA13720) and by the National Center for the
   Advancement of Translational Sciences (grant 1UL-1TR000460) both awarded
   to the University of Miami. The opinions, findings and conclusions
   stated herein are those of the authors and do not necessarily reflect
   those of the funding organizations.
CR Aarons GA, 2011, ADM POLICY MENT HLTH, V38, P4, DOI 10.1007/s10488-010-0327-7
   Abraham AJ, 2014, J SUBST ABUSE TREAT, V46, P232, DOI 10.1016/j.jsat.2013.08.021
   Abraham AJ, 2009, J STUD ALCOHOL DRUGS, V70, P628, DOI 10.15288/jsad.2009.70.628
   Addiction Technology Transfer Center (ATTC) Network Technology Transfer Workgroup, 2011, J Subst Abuse Treat, V41, P169, DOI 10.1016/j.jsat.2011.02.006
   Balas E A, 2000, Yearb Med Inform, P65
   Borges G, 2007, AM J PUBLIC HEALTH, V97, P1638, DOI 10.2105/AJPH.2006.090985
   Carroll KM, 2011, AM J DRUG ALCOHOL AB, V37, P275, DOI 10.3109/00952990.2011.596978
   Carroll KM, 2009, J CONSULT CLIN PSYCH, V77, P993, DOI 10.1037/a0016489
   Carroll KM, 2003, PSYCHIAT SERV, V54, P333, DOI 10.1176/appi.ps.54.3.333
   Castro FG, 2010, ANNU REV CLIN PSYCHO, V6, P213, DOI 10.1146/annurev-clinpsy-033109-132032
   Coloma J, 2008, ANN NY ACAD SCI, V1136, P358, DOI 10.1196/annals.1425.014
   Fernandez-Mondragon J, 2013, 15 INT C ORG CTR INT
   Fixsen DL, 2009, RES SOCIAL WORK PRAC, V19, P531, DOI 10.1177/1049731509335549
   Gagnon MP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114338
   Green LW, 2009, ANNU REV PUBL HEALTH, V30, P151, DOI 10.1146/annurev.publhealth.031308.100049
   Hanney SR, 2015, HEALTH RES POLICY SY, V13, DOI [10.1186/1478-4505-13-1, 10.1186/s12961-015-0006-y]
   Horigian VE, 2013, 27 RES ANN M NAT I P
   Horigian VE, SUBST USE M IN PRESS
   Horigian VE, 2015, PAN IMPL SCI EV BAS
   Horigian VE, 2014, 16 WORLD C PSYCH FOC
   Horigian VE, 2013, COLL PROBL DRUG DEP
   Horigian VE., 2013, PAN TECHN TRANSF IMP
   Horigian VE, ALCOHOL ALCOHOL S1, V49, pi44, DOI [10.1093/al-calc/agu053.29, DOI 10.1093/AL-CALC/AGU053.29]
   Kumpfer KL, 2008, EVAL HEALTH PROF, V31, P226, DOI 10.1177/0163278708315926
   Lehman WEK, 2011, PSYCHOL ADDICT BEHAV, V25, P252, DOI 10.1037/a0022682
   Marin-Navarrete R, 2013, 15 INT C ORG CTR INT
   Marin-Navarrete R, 2014, 76 ANN M COLL PROBL
   Marin-Navarrete R, 2014, SUBST USE MISUSE, V49, P1784, DOI 10.3109/10826084.2014.931972
   Marin-Navarrete R, 2013, SALUD MENT, V36, P253, DOI 10.17711/SM.0185-3325.2013.032
   Martino S, 2010, J SUBST ABUSE TREAT, V38, pS31, DOI 10.1016/j.jsat.2009.12.013
   Medina-Mora ME, 2014, GLOBAL MENTAL HLTH T
   Miller WR, 2006, J SUBST ABUSE TREAT, V31, P25, DOI 10.1016/j.jsat.2006.03.005
   Morris ZS, 2011, J ROY SOC MED, V104, P510, DOI 10.1258/jrsm.2011.110180
   Moullin JC, 2015, HEALTH RES POLICY SY, V13, DOI 10.1186/s12961-015-0005-z
   Perl HI, 2011, APS OBS, V24
   Rojas E, 2011, SALUD MENT, V34, P351
   Roll JM, 2009, BEHAV ANAL PRACT, V2, P4
   Roman PM, 2010, J SUBST ABUSE TREAT, V38, pS44, DOI 10.1016/j.jsat.2009.12.008
   Simpson DD, 2007, J SUBST ABUSE TREAT, V33, P111, DOI 10.1016/j.jsat.2006.12.023
   Tai B, 2010, J SUBST ABUSE TREAT, V38, pS4, DOI 10.1016/j.jsat.2010.01.011
   Villalobos-Gallegos L, 2013, 15 INT C ORG CTR INT
   Villatoro J, 2012, SALUD MENT, V35, P447
   Wahab SA, 2012, INT BUS RES, V5, P62
   Ward V, 2009, J HEALTH SERV RES PO, V14, P156, DOI 10.1258/jhsrp.2009.008120
   Weiner BJ, 2008, MED CARE RES REV, V65, P379, DOI 10.1177/1077558708317802
   Williams I, 2011, HEALTH SERV MANAG RE, V24, P213, DOI 10.1258/hsmr.2011.011014
   World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053
NR 47
TC 5
Z9 5
U1 0
U2 16
PU PAN AMER HEALTH ORGANIZATION
PI WASHINGTON
PA 525 23RD ST NW, WASHINGTON, DC 20037 USA
SN 1020-4989
J9 REV PANAM SALUD PUBL
JI Rev. Panam. Salud Publica
PD SEP
PY 2015
VL 38
IS 3
BP 233
EP 242
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA CZ9DF
UT WOS:000367397300008
PM 26758002
DA 2021-10-30
ER

PT J
AU Galor, A
   Moein, HR
   Lee, C
   Rodriguez, A
   Felix, ER
   Sarantopoulos, KD
   Levitt, RC
AF Galor, Anat
   Moein, Hamid-Reza
   Lee, Charity
   Rodriguez, Adriana
   Felix, Elizabeth R.
   Sarantopoulos, Konstantinos D.
   Levitt, Roy C.
TI Neuropathic pain and dry eye
SO OCULAR SURFACE
LA English
DT Review
DE Dry eye; Genetics; Inflammation; Nerve sensitization; Neuropathic pain;
   Treatment
ID NERVE GROWTH-FACTOR; POSTTRAUMATIC-STRESS-DISORDER; OCULAR SURFACE
   SYMPTOMS; AUTOLOGOUS SERUM EYE; RISK-FACTORS; CORNEAL SENSITIVITY;
   UNITED-STATES; CENTRAL SENSITIZATION; COLD THERMORECEPTORS; INCOMPLETE
   RESPONSE
AB Dry eye is a common, multifactorial disease currently diagnosed by a combination of symptoms and signs. Its epidemiology and clinical presentation have many similarities with neuropathic pain outside the eye. This review highlights the similarities between dry eye and neuropathic pain, focusing on clinical features, somatosensory function, and underlying pathophysiology. Implications of these similarities on the diagnosis and treatment of dry eye are discussed. Published by Elsevier Inc.
C1 [Galor, Anat; Felix, Elizabeth R.] Miami Vet Adm Med Ctr, Miami, FL USA.
   [Galor, Anat; Lee, Charity; Rodriguez, Adriana] Univ Miami, Dept Ophthalmol, Bascom Palmer Eye Inst, Miami, FL USA.
   [Moein, Hamid-Reza] Tufts Univ, Sch Med, Dept Ophthalmol, Tufts Med Ctr, Boston, MA 02111 USA.
   [Felix, Elizabeth R.] Univ Miami, Phys Med & Rehabil, Coral Gables, FL 33124 USA.
   [Sarantopoulos, Konstantinos D.; Levitt, Roy C.] Univ Miami, Miller Sch Med, Dept Anesthesiol Perioperat Med & Pain Management, Miami, FL 33136 USA.
   [Levitt, Roy C.] Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, Miami, FL 33136 USA.
   [Levitt, Roy C.] Univ Miami, Miller Sch Med, John T Macdonald Fdn Dept Human Genet, Miami, FL 33136 USA.
RP Galor, A (corresponding author), 900 NW 17th St, Miami, FL 33136 USA.
EM agalor@med.miami.edu
RI Felix, Elizabeth/AAD-6356-2021
OI Felix, Elizabeth/0000-0002-6239-715X; Levitt, Roy/0000-0002-6168-2274
FU Department of Veterans Affairs, Veterans Health Administration, Office
   of Research and Development, Clinical Sciences ResearchUS Department of
   Veterans Affairs [EPID-006-15S, R01EY026174]; NIH CenterUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [P30EY014801]; Research to Prevent BlindnessResearch to Prevent
   Blindness (RPB); NIH NIDCRUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Dental & Craniofacial Research (NIDCR) [R01 DE022903]; Department of
   Anesthesiology, Perioperative Medicine, and Pain Management, University
   of Miami Miller School of Medicine, Miami, Florida; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000460]
   Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Eye Institute (NEI) [R01EY026174, P30EY014801] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL
   RESEARCHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Dental &
   Craniofacial Research (NIDCR) [R01DE022903] Funding Source: NIH
   RePORTER; Veterans AffairsUS Department of Veterans Affairs
   [I01CX001089] Funding Source: NIH RePORTER
FX Supported by the Department of Veterans Affairs, Veterans Health
   Administration, Office of Research and Development, Clinical Sciences
   Research EPID-006-15S (Dr. Galor), R01EY026174 (Dr. Galor), NIH Center
   Core Grant P30EY014801, Research to Prevent Blindness Unrestricted
   Grant, NIH NIDCR R01 DE022903 (Dr. Levitt), and the Department of
   Anesthesiology, Perioperative Medicine, and Pain Management, University
   of Miami Miller School of Medicine, Miami, Florida.
CR Abdulla A, 2013, AGE AGEING, V42, pI1, DOI 10.1093/ageing/afs200
   Acosta MC, 2004, INVEST OPHTH VIS SCI, V45, P2333, DOI 10.1167/iovs.03-1366
   Adatia FA, 2004, CAN J OPHTHALMOL, V39, P767, DOI 10.1016/S0008-4182(04)80071-1
   Aggarwal S, 2015, OCUL SURF, V13, P250, DOI 10.1016/j.jtos.2015.01.005
   American Academy of Pain Medicine, AAPM FACTS FIG PAIN
   Ames Philip, 2015, Clin Investig (Lond), V5, P267, DOI 10.4155/cli.14.135
   [Anonymous], 2015, 2015 ANAL POLICY REC
   Ansari Z, 2015, CORNEA, V34, P32, DOI 10.1097/ICO.0000000000000286
   Attal N, 2008, PAIN, V138, P343, DOI 10.1016/j.pain.2008.01.006
   Attal Nadine, 2012, Continuum (Minneap Minn), V18, P161, DOI 10.1212/01.CON.0000411564.41709.2d
   BandeenRoche R, 1997, INVEST OPHTH VIS SCI, V38, P2469
   Barr MS, 2013, J NEUROIMMUNE PHARM, V8, P535, DOI 10.1007/s11481-012-9383-y
   Begley CG, 2001, CORNEA, V20, P610, DOI 10.1097/00003226-200108000-00011
   Belmonte C, 1999, INVEST OPHTH VIS SCI, V40, P513
   Belmonte C, 2004, EXP EYE RES, V78, P513, DOI 10.1016/j.exer.2003.09.023
   Belmonte C, 2011, INVEST OPHTH VIS SCI, V52, P3888, DOI 10.1167/iovs.09-5119
   Benitez-del-Castillo JM, 2007, INVEST OPHTH VIS SCI, V48, P173, DOI 10.1167/iovs.06-0127
   Bonini S, 2000, OPHTHALMOLOGY, V107, P1347, DOI 10.1016/S0161-6420(00)00163-9
   Bonini S, 2000, OPHTHALMOLOGY, V107, p[1347, 51]
   Borsook D, 2011, PAIN, V152, P2427, DOI 10.1016/j.pain.2011.06.006
   Bouhassira D, 2004, PAIN, V108, P248, DOI 10.1016/j.pain.2003.12.024
   Bourcier T, 2005, INVEST OPHTH VIS SCI, V46, P2341, DOI 10.1167/iovs.04-1426
   Brignole-Baudouin F, 2011, ACTA OPHTHALMOL, V89, pE591, DOI 10.1111/j.1755-3768.2011.02196.x
   Bron AJ, 2007, OCUL SURF, V5, P108
   Busserolles J, 2016, PAIN, V157, pS7, DOI 10.1097/j.pain.0000000000000368
   Caraceni A, 2002, J PAIN SYMPTOM MANAG, V23, P239, DOI 10.1016/S0885-3924(01)00409-2
   Chaturvedi A, 2001, J Indian Med Assoc, V99, P698
   Chen W, 2017, OCUL SURF, V15, P193, DOI 10.1016/j.jtos.2016.12.002
   Chhadva P, 2016, CORNEA, V35, P531, DOI 10.1097/ICO.0000000000000786
   Chhadva P, 2015, INVEST OPHTH VIS SCI, V56, P2867, DOI 10.1167/iovs.14-16337
   Chia EM, 2003, CLIN EXP OPHTHALMOL, V31, P229, DOI 10.1046/j.1442-9071.2003.00634.x
   Chotikavanich S, 2009, INVEST OPHTH VIS SCI, V50, P3203, DOI 10.1167/iovs.08-2476
   Costigan M, 2010, BRAIN, V133, P2519, DOI 10.1093/brain/awq195
   Crane AM, 2017, BRIT J OPHTHALMOL, V101, P1238, DOI 10.1136/bjophthalmol-2016-309658
   Crane AM, 2017, BRIT J OPHTHALMOL, V101, P227, DOI 10.1136/bjophthalmol-2015-308214
   Cuadrado ML, 2017, HEADACHE, V57, P460, DOI 10.1111/head.12985
   De Paiva CS, 2004, AM J OPHTHALMOL, V137, P109, DOI 10.1016/S0002-9394(03)00897-3
   del Castillo JMB, 2004, INVEST OPHTH VIS SCI, V45, P3030, DOI 10.1167/iovs.04-0251
   Diatchenko L, 2007, TRENDS GENET, V23, P605, DOI 10.1016/j.tig.2007.09.004
   Dworkin RH, 2005, PAIN, V113, P9, DOI 10.1016/j.pain.2004.09.012
   Ebbinghaus M, 2012, ARTHRITIS RHEUM-US, V64, P3897, DOI 10.1002/art.34675
   Enriquez-de-Salamanca A, 2010, MOL VIS, V16, P862
   Ezuddin NS, 2015, DRUG AGING, V32, P505, DOI 10.1007/s40266-015-0277-6
   Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9
   Fernandez CA, 2013, INVEST OPHTH VIS SCI, V54, P3666, DOI 10.1167/iovs.13-11635
   Ferreira-Valente MA, 2011, PAIN, V152, P2399, DOI 10.1016/j.pain.2011.07.005
   Finnerup NB, 2016, PAIN, V157, P1599, DOI 10.1097/j.pain.0000000000000492
   Finnerup NB, 2015, LANCET NEUROL, V14, P162, DOI 10.1016/S1474-4422(14)70251-0
   Freilinger T, 2012, NAT GENET, V44, P777, DOI 10.1038/ng.2307
   Galor A, 2017, EYE CONTACT LENS
   Galor A, 2016, JAMA OPHTHALMOL, V134, P1290, DOI 10.1001/jamaophthalmol.2016.3642
   Galor A, 2016, BRIT J OPHTHALMOL, V100, P745, DOI 10.1136/bjophthalmol-2015-307094
   Galor A, 2016, J PAIN, V17, P310, DOI 10.1016/j.jpain.2015.10.019
   Galor A, 2015, BRIT J OPHTHALMOL, V99, P1126, DOI 10.1136/bjophthalmol-2014-306481
   Galor A, 2015, BRIT J OPHTHALMOL, V99, P665, DOI 10.1136/bjophthalmol-2014-306057
   Galor A, 2014, OPHTHALMOLOGY, V121, P972, DOI 10.1016/j.ophtha.2013.11.036
   Galor A, 2013, INVEST OPHTH VIS SCI, V54, P1426, DOI 10.1167/iovs.12-10819
   Galor A, 2012, AM J OPHTHALMOL, V154, P340, DOI 10.1016/j.ajo.2012.02.009
   George SZ, 2014, MED SCI SPORT EXER, V46, P1871, DOI 10.1249/MSS.0000000000000328
   Ghaffariyeh A, 2008, J REFRACT SURG, V24, P770, DOI 10.3928/1081597X-20081001-01
   Gow JM, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0797-9
   Gustin SM, 2011, J NEUROSCI, V31, P5956, DOI 10.1523/JNEUROSCI.5980-10.2011
   Hamrah P, 2017, OCUL SURF, V15, P139, DOI 10.1016/j.jtos.2016.10.002
   Hayek SM, 2016, PAIN MED, V17, P1302, DOI 10.1093/pm/pnv058
   Health UDo Services H. Health, 2006, US 2005 CHARTB TREND
   Hirata H, 2003, J NEUROPHYSIOL, V90, P2837, DOI 10.1152/jn.00544.2003
   Holland EJ, 2017, OPHTHALMOLOGY, V124, P53, DOI 10.1016/j.ophtha.2016.09.025
   Hosal BM, 2005, EYE, V19, P1276, DOI 10.1038/sj.eye.6701760
   Jain P, 2011, EXP EYE RES, V93, P503, DOI 10.1016/j.exer.2011.06.014
   JENSEN MP, 1994, PAIN, V58, P387, DOI 10.1016/0304-3959(94)90133-3
   Jensen TS, 2002, EUR J PAIN, V6, P61, DOI 10.1053/eujp.2001.0324
   Ji RR, 2016, SCIENCE, V354, P572, DOI 10.1126/science.aaf8924
   Jie Y, 2009, EYE, V23, P688, DOI 10.1038/sj.eye.6703101
   Kalangara JP, 2017, EYE CONTACT LENS, V43, P192, DOI 10.1097/ICL.0000000000000249
   Karppinen J, 2008, EUR J PAIN, V12, P1018, DOI 10.1016/j.ejpain.2008.01.009
   Katz J, 2009, EXPERT REV NEUROTHER, V9, P723, DOI [10.1586/ern.09.20, 10.1586/ERN.09.20]
   Kheirkhah A, 2015, OPHTHALMOLOGY, V122, P662, DOI 10.1016/j.ophtha.2014.11.006
   Kim KW, 2011, INVEST OPHTH VIS SCI, V52, P7954, DOI 10.1167/iovs.11-8050
   Kinard KI, 2015, HEADACHE, V55, P543, DOI 10.1111/head.12547
   Ko GD, 2010, CLIN J PAIN, V26, P168, DOI 10.1097/AJP.0b013e3181bb8533
   Kojima T, 2005, AM J OPHTHALMOL, V139, P242, DOI 10.1016/j.ajo.2004.08.040
   Kurose M, 2013, J NEUROPHYSIOL, V110, P495, DOI 10.1152/jn.00222.2013
   Labbe A, 2013, BRIT J OPHTHALMOL, V97, P1399, DOI 10.1136/bjophthalmol-2013-303838
   Labbe A, 2013, INVEST OPHTH VIS SCI, V54, P5144, DOI 10.1167/iovs.13-12370
   Labbe A, 2012, INVEST OPHTH VIS SCI, V53, P4926, DOI 10.1167/iovs.11-8708
   Lam H, 2009, AM J OPHTHALMOL, V147, P198, DOI 10.1016/j.ajo.2008.08.032
   Lambiase A, 1998, NEW ENGL J MED, V338, P1174, DOI 10.1056/NEJM199804233381702
   Lambiase A, 2012, CURR OPIN OPHTHALMOL, V23, P296, DOI 10.1097/ICU.0b013e3283543b61
   Lanza NL, 2016, OCUL SURF, V14, P216, DOI 10.1016/j.jtos.2015.12.007
   Lee AJ, 2002, BRIT J OPHTHALMOL, V86, P1347, DOI 10.1136/bjo.86.12.1347
   Lemp MA, 2007, OCUL SURF, V5, P75
   Lemp MA, 2012, CORNEA, V31, P472, DOI 10.1097/ICO.0b013e318225415a
   Levitt AE, 2015, MOL PAIN, V11, DOI 10.1186/s12990-015-0020-7
   Li W, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154753
   Lin PY, 2003, OPHTHALMOLOGY, V110, P1096, DOI 10.1016/S0161-6420(03)00262-8
   Lovejoy TI, 2012, J PAIN, V13, P1250, DOI 10.1016/j.jpain.2012.09.011
   Maier C, 2010, PAIN, V150, P439, DOI 10.1016/j.pain.2010.05.002
   Maixner W, 2016, J PAIN, V17, pT93, DOI 10.1016/j.jpain.2016.06.002
   Mann R, 2013, SPINAL CORD, V51, P564, DOI 10.1038/sc.2013.34
   Martinez JD, 2016, CLIN OPHTHALMOL, V10, P1335, DOI 10.2147/OPTH.S106451
   McCarty CA, 1998, OPHTHALMOLOGY, V105, P1114, DOI 10.1016/S0161-6420(98)96016-X
   Meerovitch K, 2013, CLIN OPHTHALMOL, V7, P1275, DOI 10.2147/OPTH.S44688
   Meyer RA, 2005, J HOPKINS APL TECH D, V26, P56
   Mian SI, 2009, J CATARACT REFR SURG, V35, P2092, DOI 10.1016/j.jcrs.2009.07.009
   Midena Edoardo, 2009, J Refract Surg, V25, pS125, DOI 10.3928/1081597X-20090115-09
   Moen A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107301
   Moore RA, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008242.pub3
   Moss SE, 2000, ARCH OPHTHALMOL-CHIC, V118, P1264
   Muller LJ, 2003, EXP EYE RES, V76, P521, DOI 10.1016/S0014-4835(03)00050-2
   Na KS, 2011, MOL VIS, V17, P2818
   Nahin RL, 2015, J PAIN, V16, P769, DOI 10.1016/j.jpain.2015.05.002
   Ogawa Y, 2003, BONE MARROW TRANSPL, V31, P579, DOI 10.1038/sj.bmt.1703862
   Ong ES, 2016, JAMA OPHTHALMOL
   Onouchi K, 2014, J PAIN RES, V7, P439, DOI 10.2147/JPR.S63028
   Oudejans L, 2016, SCI REP-UK, V6, DOI 10.1038/srep23573
   Paice JA, 1997, CANCER NURS, V20, P88, DOI 10.1097/00002820-199704000-00002
   Parissi M, 2013, INVEST OPHTH VIS SCI, V54, P7091, DOI 10.1167/iovs.13-12999
   Parra A, 2014, PAIN, V155, P1481, DOI 10.1016/j.pain.2014.04.025
   Parra A, 2010, NAT MED, V16, P1396, DOI 10.1038/nm.2264
   Pavan-Langston D, 2008, OPHTHALMOLOGY, V115, pS13, DOI 10.1016/j.ophtha.2007.10.012
   Phasukkijwatana N, 2011, CURR EYE RES, V36, P775, DOI 10.3109/02713683.2011.587935
   Pouyeh B, 2012, AM J OPHTHALMOL, V153, P1061, DOI 10.1016/j.ajo.2011.11.030
   Qazi Y, 2016, OPHTHALMOLOGY, V123, P1458, DOI 10.1016/j.ophtha.2016.03.006
   Le QV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114258
   Rahman M, 2015, PAIN, V156, P942, DOI 10.1097/j.pain.0000000000000135
   Ramirez M, 2015, SEMIN ARTHRITIS RHEU, V45, P214, DOI 10.1016/j.semarthrit.2015.03.003
   Robbins MS, 2016, HEADACHE, V56, P240, DOI 10.1111/head.12729
   Robles CRF, 2012, CURR OPIN ANESTHESIO, V25, P444, DOI 10.1097/ACO.0b013e3283556228
   Rosenthal P, 2016, BRIT J OPHTHALMOL, V100, P128, DOI 10.1136/bjophthalmol-2014-306280
   Rosenthal P, 2009, OCUL SURF, V7, P28, DOI 10.1016/S1542-0124(12)70290-2
   Sarantopoulos C, 2002, REGION ANESTH PAIN M, V27, P47, DOI 10.1053/rapm.2002.29124
   Scarpa F, 2008, INVEST OPHTH VIS SCI, V49, P4801, DOI 10.1167/iovs.08-2061
   Schaumberg DA, 2003, AM J OPHTHALMOL, V136, P318, DOI 10.1016/S0002-9394(03)00218-6
   Schiffman RM, 2003, OPHTHALMOLOGY, V110, P1412, DOI 10.1016/S0161-6420(03)00462-7
   Schiffman RM, 2000, ARCH OPHTHALMOL-CHIC, V118, P615, DOI 10.1001/archopht.118.5.615
   Schistad EI, 2014, CLIN J PAIN, V30, P869, DOI 10.1097/AJP.0000000000000048
   Scholz J, 2007, NAT NEUROSCI, V10, P1361, DOI 10.1038/nn1992
   Schwartz DM, 1998, CORNEA, V17, P196, DOI 10.1097/00003226-199803000-00014
   Shim J, 2012, OPHTHALMOLOGY, V119, P2211, DOI 10.1016/j.ophtha.2012.05.038
   Shimmura S, 1999, CORNEA, V18, P408, DOI 10.1097/00003226-199907000-00003
   Situ P, 2008, INVEST OPHTH VIS SCI, V49, P2971, DOI 10.1167/iovs.08-1734
   Situ P, 2010, INVEST OPHTH VIS SCI, V51, P5640, DOI 10.1167/iovs.10-5502
   Skaper SD, 2014, IMMUNOLOGY, V141, P314, DOI 10.1111/imm.12170
   Smith JA, 2007, OCUL SURF, V5, P93
   Sommer C, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-104
   Spierer O, 2016, INVEST OPHTH VIS SCI, V57, P617, DOI 10.1167/iovs.15-18133
   Spilker B, 1991, GUIDE CLIN TRIALS
   Staud R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089086
   Stepp MA, 2017, GLIA, V65, P851, DOI 10.1002/glia.23102
   Stern ME, 2002, INVEST OPHTH VIS SCI, V43, P2609
   Su L, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-120
   Tan MH, 2006, CORNEA, V25, P352, DOI 10.1097/01.ico.0000176609.42838.df
   Tepelus TC, 2017, GRAEFES ARCH CLIN EX
   Thomas DA, 2016, CURR PAIN HEADACHE R, V20, DOI 10.1007/s11916-016-0562-z
   Tremont-Lukats IW, 2000, DRUGS, V60, P1029, DOI 10.2165/00003495-200060050-00005
   Tsubota K, 1999, BRIT J OPHTHALMOL, V83, P390, DOI 10.1136/bjo.83.4.390
   Tuisku IS, 2008, EXP EYE RES, V86, P879, DOI 10.1016/j.exer.2008.03.002
   Tuominen ISJ, 2003, INVEST OPHTH VIS SCI, V44, P2545, DOI 10.1167/iovs.02-1260
   Uchino M, 2006, OPTOMETRY VISION SCI, V83, P797, DOI 10.1097/01.opx.0000232814.39651.fa
   Vaitla PM, 2011, ARTHRITIS RHEUM-US, V63, P1151, DOI 10.1002/art.30215
   Vehof J, 2017, OPHTHALMOLOGY, V124, P280, DOI 10.1016/j.ophtha.2016.11.008
   Vehof J, 2016, AM J OPHTHALMOL, V166, P203, DOI 10.1016/j.ajo.2016.03.023
   Vehof J, 2014, BRIT J OPHTHALMOL, V98, P1712, DOI 10.1136/bjophthalmol-2014-305201
   Vehof J, 2014, INVEST OPHTH VIS SCI, V55, P7278, DOI 10.1167/iovs.14-15200
   Vehof J, 2013, JAMA OPHTHALMOL, V131, P1304, DOI 10.1001/jamaophthalmol.2013.4399
   Villani E, 2007, INVEST OPHTH VIS SCI, V48, P2017, DOI 10.1167/iovs.06-1129
   Villani E, 2013, OPTOMETRY VISION SCI, V90, P576, DOI 10.1097/OPX.0b013e318294c184
   Villar-Quiles RN, 2017, CEPHALALGIA
   von Hehn CA, 2012, NEURON, V73, P638, DOI 10.1016/j.neuron.2012.02.008
   Walter SD, 2016, INVEST OPHTH VIS SCI, V57, P2472, DOI 10.1167/iovs.16-19131
   Wiffen PJ, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007938.pub4
   Wilcox SL, 2015, J NEUROSCI, V35, P2508, DOI 10.1523/JNEUROSCI.3756-14.2015
   Wilcox SL, 2013, J PAIN, V14, P865, DOI 10.1016/j.jpain.2013.02.014
   Woolf CJ, 1999, LANCET, V353, P1959, DOI 10.1016/S0140-6736(99)01307-0
   Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765
   Woolf CJ, 2011, PAIN, V152, pS2, DOI 10.1016/j.pain.2010.09.030
   Wu ZZ, 2017, J NEUROTRAUM, V34, P1260, DOI 10.1089/neu.2016.4789
   Xing H, 2007, J NEUROSCI, V27, P13680, DOI 10.1523/JNEUROSCI.2203-07.2007
   Xu KP, 1996, CORNEA, V15, P235, DOI 10.1097/00003226-199605000-00002
   YANG S, 2017, CURR EYE RES, P1
   Yeh TN, 2015, OPTOMETRY VISION SCI, V92, pE264, DOI 10.1097/OPX.0000000000000649
   Young EE, 2012, J MED GENET, V49, P1, DOI 10.1136/jmedgenet-2011-100386
   Yunus MB, 2015, CURR RHEUMATOL REV, V11, P70, DOI 10.2174/157339711102150702112236
   Zelman DC, 2005, PAIN, V115, P29, DOI 10.1016/j.pain.2005.01.028
   Zhang M, 2005, CORNEA, V24, P818, DOI 10.1097/01.ico.0000154402.01710.95
   Zhang XB, 2011, OPHTHALMOLOGY, V118, P902, DOI 10.1016/j.ophtha.2010.08.033
   Zhang XR, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-198
   Zhivov A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052157
NR 188
TC 70
Z9 71
U1 0
U2 16
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1542-0124
EI 1937-5913
J9 OCUL SURF
JI Ocul. Surf.
PD JAN
PY 2018
VL 16
IS 1
BP 31
EP 44
DI 10.1016/j.jtos.2017.10.001
PG 14
WC Ophthalmology
SC Ophthalmology
GA FR7CW
UT WOS:000419225000004
PM 29031645
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Ramos, AR
   Dong, CH
   Rundek, T
   Elkind, MSV
   Boden-Albala, B
   Sacco, RL
   Wright, CB
AF Ramos, Alberto R.
   Dong, Chuanhui
   Rundek, Tatjana
   Elkind, Mitchell S. V.
   Boden-Albala, Bernadette
   Sacco, Ralph L.
   Wright, Clinton B.
TI Sleep duration is associated with white matter hyperintensity volume in
   older adults: the Northern Manhattan Study
SO JOURNAL OF SLEEP RESEARCH
LA English
DT Article
DE diabetes; elderly; hyperintensities; leukoaraiosis; long sleep;
   multi-ethnic; short sleep; white matter
ID AMBULATORY BLOOD-PRESSURE; RISK-FACTOR; LONG SLEEPERS; HEALTH-STATUS;
   HEART HEALTH; MORTALITY; HYPERTENSION; METAANALYSIS; RESTRICTION; STROKE
AB Self-reports of long or short sleep durations have indicated an association with cardiovascular morbidity and mortality, but there are limited data evaluating their association with white matter hyperintensity volume (WMHV), a marker of cerebral small vessel disease. We conducted a cross-sectional analysis of self-reported sleep duration to test for a correlation with white matter hyperintensities, measured by quantitative magnetic resonance imaging (MRI), in the Northern Manhattan Study. We used multivariable linear regression models to assess associations between both short (<6 h) and long (>= 9 h) sleep durations and log-transformed WMHV, adjusting for demographic, behavioural and vascular risk factors. A total of 1244 participants, mean age 70 +/- 9 years, 61% women and 68% Hispanics were analysed with magnetic resonance brain imaging and self-reported sleep duration. Short sleep was reported by 23% (n = 293) and long sleep by 10% (n = 121) of the sample. Long sleep (beta = 0.178; P = 0.035), but not short sleep (beta = -0.053; P = 0.357), was associated with greater log-WMHV in fully adjusted models. We observed an interaction between sleep duration, diabetes mellitus and log-WMHV (P = 0.07). In fully adjusted models, stratified analysis showed that long sleep duration was associated with greater WMHV only in those with diabetes (beta = 0.78; P = 0.0314), but not in those without diabetes (beta = 0.022; P = 0.2), whereas short sleep was not associated with white matter hyperintensities in those with or without diabetes. In conclusion, long sleep duration was associated with a greater burden of white matter lesions in this stroke-free urban sample. The association was seen mainly among those with diabetes mellitus.
C1 [Ramos, Alberto R.; Dong, Chuanhui; Rundek, Tatjana; Sacco, Ralph L.; Wright, Clinton B.] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA.
   [Rundek, Tatjana; Sacco, Ralph L.; Wright, Clinton B.] Univ Miami, Dept Epidemiol & Publ Hlth, Miami, FL 33136 USA.
   [Elkind, Mitchell S. V.] Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY USA.
   [Elkind, Mitchell S. V.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA.
   [Boden-Albala, Bernadette] Mt Sinai Sch Med, Dept Hlth Policy, Div Social Epidemiol, New York, NY USA.
   [Sacco, Ralph L.] Univ Miami, Dept Human Genet, Miami, FL 33136 USA.
   [Wright, Clinton B.] Univ Miami, Neurosci Program, Miami, FL 33136 USA.
RP Ramos, AR (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol, Sleep Med Program, 1120 NW 14th St, Miami, FL 33136 USA.
EM aramos@med.miami.edu
RI Sacco, Ralph/Y-9278-2019; Ramos, Alberto/X-4249-2019
OI Wright, Clinton/0000-0002-9797-6215; Boden-Albala,
   Bernadette/0000-0002-3752-329X
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [5KL2TR000461-02, R37
   NS029993, K24 NS 062737]; Evelyn F. McKnight Brain Institute; NATIONAL
   CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Advancing Translational Sciences (NCATS)
   [KL2TR000461] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Neurological Disorders & Stroke (NINDS) [R37NS029993,
   K24NS062737] Funding Source: NIH RePORTER
FX We are thankful to the study participants for their collaboration and to
   all staff of the Northern Manhattan Study for their efforts to this
   study, in particular Edison Sabala and Janet DeRosa. This work was
   supported by grants from the National Institutes of Health:
   5KL2TR000461-02 (AR); R35 (Supplement) to R37 NS029993 (AR); R37
   NS029993 (RLS, MSVE, TR, CW, BBA); K24 NS 062737 (TR); and Evelyn F.
   McKnight Brain Institute (CW, RLS and TR).
CR Barone MTU, 2011, DIABETES RES CLIN PR, V91, P129, DOI 10.1016/j.diabres.2010.07.011
   Biessels GJ, 2006, J NEUROL, V253, P477, DOI 10.1007/s00415-005-0036-4
   Boden-Albala B, 2012, CIRC-CARDIOVASC QUAL, V5, P500, DOI 10.1161/CIRCOUTCOMES.111.963801
   Cappuccio FP, 2011, EUR HEART J, V32, P1484, DOI 10.1093/eurheartj/ehr007
   Cohen-Mansfield J, 2012, SLEEP, V35, P1003, DOI 10.5665/sleep.1970
   Debette S, 2010, STROKE, V41, P600, DOI 10.1161/STROKEAHA.109.570044
   Mesas AE, 2011, AGE AGEING, V40, P318, DOI 10.1093/ageing/afr004
   Mesas AE, 2010, J AM GERIATR SOC, V58, P1870, DOI 10.1111/j.1532-5415.2010.03071.x
   Gale C, 1998, BRIT MED J, V317, P1675, DOI 10.1136/bmj.317.7174.1675
   Gallicchio L, 2009, J SLEEP RES, V18, P148, DOI 10.1111/j.1365-2869.2008.00732.x
   Gangwisch JE, 2007, SLEEP, V30, P1667, DOI 10.1093/sleep/30.12.1667
   Gangwisch JE, 2006, HYPERTENSION, V47, P833, DOI 10.1161/01.HYP.0000217362.34748.e0
   Gardener H, 2012, ARCH NEUROL-CHICAGO, V69, P251, DOI 10.1001/archneurol.2011.548
   Gottlieb DJ, 2006, SLEEP, V29, P1009, DOI 10.1093/sleep/29.8.1009
   Grandner MA, 2012, J SLEEP RES, V21, P427, DOI 10.1111/j.1365-2869.2011.00990.x
   Hudson BI, 2011, ATHEROSCLEROSIS, V216, P192, DOI 10.1016/j.atherosclerosis.2011.01.024
   Kim BK, 2011, KOREAN CIRC J, V41, P191, DOI 10.4070/kcj.2011.41.4.191
   Kojima M, 2000, J Epidemiol, V10, P87
   Nakajima H, 2008, SLEEP MED, V9, P745, DOI 10.1016/j.sleep.2007.07.017
   Nakano S, 2004, HYPERTENS RES, V27, P647, DOI 10.1291/hypres.27.647
   Netzer NC, 1999, ANN INTERN MED, V131, P485, DOI 10.7326/0003-4819-131-7-199910050-00002
   Novak V, 2006, DIABETES CARE, V29, P1529, DOI 10.2337/dc06-0261
   Ohkubo T, 2002, J HYPERTENS, V20, P2183, DOI 10.1097/00004872-200211000-00017
   Patel SR, 2012, SLEEP, V35, P641, DOI 10.5665/sleep.1822
   Patel SR, 2009, SLEEP, V32, P200, DOI 10.1093/sleep/32.2.200
   Perk G, 2002, J HUM HYPERTENS, V16, P435, DOI 10.1038/sj.jhh.1001412
   Ramos AR, 2013, AM J CARDIOL, V112, P599, DOI 10.1016/j.amjcard.2013.04.029
   Ramos-Sepulveda A, 2010, INT J STROKE, V5, P264, DOI 10.1111/j.1747-4949.2010.00438.x
   Sacco RL, 2001, STROKE, V32, P1725, DOI 10.1161/01.STR.32.8.1725
   Schwartz GL, 2007, HYPERTENSION, V49, P1228, DOI 10.1161/HYPERTENSIONAHA.106.078691
   Shaw JE, 2008, DIABETES RES CLIN PR, V81, P2, DOI 10.1016/j.diabres.2008.04.025
   van Harten B, 2006, DIABETES CARE, V29, P2539, DOI 10.2337/dc06-1637
   Wright CB, 2009, STROKE, V40, P3466, DOI 10.1161/STROKEAHA.109.559567
   Yaggi HK, 2006, DIABETES CARE, V29, P657, DOI 10.2337/diacare.29.03.06.dc05-0879
   Young T, 2002, ARCH INTERN MED, V162, P893, DOI 10.1001/archinte.162.8.893
   Youngstedt SD, 2004, SLEEP MED REV, V8, P159, DOI 10.1016/j.smrv.2003.10.002
   Youngstedt SD, 2013, CONTEMP CLIN TRIALS, V36, P175, DOI 10.1016/j.cct.2013.06.014
   Zizi F, 2012, AM J MED, V125, P162, DOI 10.1016/j.amjmed.2011.08.020
   Zizi F, 2010, CURR DIABETES REP, V10, P43, DOI 10.1007/s11892-009-0082-x
NR 39
TC 47
Z9 48
U1 0
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0962-1105
EI 1365-2869
J9 J SLEEP RES
JI J. Sleep Res.
PD OCT
PY 2014
VL 23
IS 5
BP 524
EP 530
DI 10.1111/jsr.12177
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA AQ7PV
UT WOS:000343012400006
PM 25040435
OA Green Accepted, Bronze
DA 2021-10-30
ER

PT J
AU Stein, EM
   DiNardo, CD
   Pollyea, DA
   Fathi, AT
   Roboz, GJ
   Altman, JK
   Stone, RM
   DeAngelo, DJ
   Levine, RL
   Flinn, IW
   Kantarjian, HM
   Collins, R
   Patel, MR
   Frankel, AE
   Stein, A
   Sekeres, MA
   Swords, RT
   Medeiros, BC
   Willekens, C
   Vyas, P
   Tosolini, A
   Xu, Q
   Knight, RD
   Yen, KE
   Agresta, S
   de Botton, S
   Tallman, MS
AF Stein, Eytan M.
   DiNardo, Courtney D.
   Pollyea, Daniel A.
   Fathi, Amir T.
   Roboz, Gail J.
   Altman, Jessica K.
   Stone, Richard M.
   DeAngelo, Daniel J.
   Levine, Ross L.
   Flinn, Ian W.
   Kantarjian, Hagop M.
   Collins, Robert
   Patel, Manish R.
   Frankel, Arthur E.
   Stein, Anthony
   Sekeres, Mikkael A.
   Swords, Ronan T.
   Medeiros, Bruno C.
   Willekens, Christophe
   Vyas, Paresh
   Tosolini, Alessandra
   Xu, Qiang
   Knight, Robert D.
   Yen, Katharine E.
   Agresta, Sam
   de Botton, Stephane
   Tallman, Martin S.
TI Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
SO BLOOD
LA English
DT Article
ID ISOCITRATE DEHYDROGENASE MUTATIONS; MYELODYSPLASTIC SYNDROMES;
   DIFFERENTIATION SYNDROME; OLDER PATIENTS; OPEN-LABEL; PHASE-III;
   2-HYDROXYGLUTARATE; RECOMMENDATIONS; CYTARABINE; INHIBITOR
AB Recurrent mutations in isocitrate dehydrogenase 2 (IDH2) occur in similar to 12% of patients with acute myeloid leukemia (AML). Mutated IDH2 proteins neomorphically synthesize 2-hydroxyglutarate resulting in DNA and histone hypermethylation, which leads to blocked cellular differentiation. Enasidenib (AG-221/CC-90007) is a first-in-class, oral, selective inhibitor of mutant-IDH2 enzymes. This first-in-human phase 1/2 study assessed the maximum tolerated dose (MTD), pharmacokinetic and pharmacodynamic profiles, safety, and clinical activity of enasidenib in patients with mutant-IDH2 advanced myeloid malignancies. We assessed safety outcomes for all patients and clinical efficacy in the largest patient subgroup, those with relapsed or refractory AML, from the phase 1 dose-escalation and expansion phases of the study. In the dose-escalation phase, an MTD was not reached at doses ranging from 50 to 650 mg per day. Enasidenib 100 mg once daily was selected for the expansion phase on the basis of pharmacokinetic and pharmacodynamic profiles and demonstrated efficacy. Grade 3 to 4 enasidenib-related adverse events included indirect hyperbilirubinemia (12%) and IDH-inhibitor-associated differentiation syndrome (7%). Among patients with relapsed or refractory AML, overall response rate was 40.3%, with a median response duration of 5.8 months. Responses were associated with cellular differentiation and maturation, typically without evidence of aplasia. Median overall survival among relapsed/refractory patients was 9.3 months, and for the 34 patients (19.3%) who attained complete remission, overall survival was 19.7 months. Continuous daily enasidenib treatment was generally well tolerated and induced hematologic responses in patients for whom prior AML therapy had failed. Inducing differentiation of myeloblasts, not cytotoxicity, seems to drive the clinical efficacy of enasidenib. This trial was registered at www.clinicaltrials.gov as #NCT01915498.
C1 [Stein, Eytan M.; Stone, Richard M.; Tallman, Martin S.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
   [Stein, Eytan M.; Roboz, Gail J.; Tallman, Martin S.] Weill Cornell Med Coll, New York, NY USA.
   [DiNardo, Courtney D.; Kantarjian, Hagop M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   [Pollyea, Daniel A.] Univ Colorado, Sch Med, Div Hematol, Aurora, CO USA.
   [Fathi, Amir T.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
   [Fathi, Amir T.] Harvard Med Sch, Dept Med, Boston, MA USA.
   [Roboz, Gail J.] New York Presbyterian Hosp, New York, NY USA.
   [Altman, Jessica K.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL USA.
   [Stone, Richard M.; DeAngelo, Daniel J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
   [Flinn, Ian W.] Sarah Cannon Res Inst, Nashville, TN USA.
   [Collins, Robert; Frankel, Arthur E.] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA.
   [Patel, Manish R.] Florida Canc Specialists, Sarasota, FL USA.
   [Patel, Manish R.] Sarah Cannon Res Inst, Sarasota, FL USA.
   [Stein, Anthony] City Hope Comprehens Canc Ctr, Duarte, CA USA.
   [Sekeres, Mikkael A.] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA.
   [Swords, Ronan T.] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA.
   [Medeiros, Bruno C.] Stanford Univ, Stanford Comprehens Canc Ctr, Stanford, CA 94305 USA.
   [Willekens, Christophe; de Botton, Stephane] Gustave Roussy, Dept Hematol, Villejuif, France.
   [Willekens, Christophe; de Botton, Stephane] Gustave Roussy, Dept Innovat Therapeut, Villejuif, France.
   [Willekens, Christophe; de Botton, Stephane] Univ Paris Sud, Le Kremlin Bicetre, France.
   [Willekens, Christophe; de Botton, Stephane] Univ Paris Saclay, Le Kremlin Bicetre, France.
   [Vyas, Paresh] Univ Oxford, Weatherall Inst Mol Med, Med Res Council, Mol Haematol Unit, Oxford, England.
   [Vyas, Paresh] Oxford Univ Hosp, Natl Inst Hlth Res, Oxford Biomed Res Ctr, Oxford, England.
   [Tosolini, Alessandra; Xu, Qiang; Knight, Robert D.] Celgene Corp, Summit, NJ USA.
   [Yen, Katharine E.; Agresta, Sam] Agios Pharmaceut Inc, Cambridge, MA USA.
RP Stein, EM (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, 1275 York Ave, New York, NY 10065 USA.
EM steine@mskcc.org
RI levine, ross/AAE-7658-2019; Vyas, Paresh/B-5708-2009
OI Vyas, Paresh/0000-0003-3931-0914; Sekeres, Mikkael/0000-0003-2009-6524;
   Flinn, Ian/0000-0001-6724-290X; DeAngelo, Daniel/0000-0001-7865-2306;
   Willekens, Christophe/0000-0001-9814-8537; DE BOTTON,
   stephane/0000-0002-8126-4942
FU Celgene CorporationBristol-Myers SquibbCelgene Corporation; Medical
   Research CouncilUK Research & Innovation (UKRI)Medical Research Council
   UK (MRC)European Commission [G1000801c, MR/L008963/1, G1000729,
   MC_UU_12009/11] Funding Source: researchfish; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [P30CA016672] Funding Source: NIH RePORTER; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [KL2TR000461]
   Funding Source: NIH RePORTER
FX This work was supported by Celgene Corporation.
CR Abbas S, 2010, BLOOD, V116, P2122, DOI 10.1182/blood-2009-11-250878
   [Anonymous], 2017, CLIN PRACT GUID ONC
   Baljeyic M, 2011, HEMATOL ONCOL CLIN N, V25, P1215, DOI 10.1016/j.hoc.2011.10.002
   Birendra KC, 2016, CL LYMPH MYELOM LEUK, V16, P460, DOI 10.1016/j.clml.2016.04.006
   Cheson BD, 2003, J CLIN ONCOL, V21, P4642, DOI 10.1200/JCO.2003.04.036
   DiNardo CD, 2016, LEUKEMIA, V30, P980, DOI 10.1038/leu.2015.211
   DiNardo CD, 2015, AM J HEMATOL, V90, P732, DOI 10.1002/ajh.24072
   DiNardo CD, 2013, BLOOD, V121, P4917, DOI 10.1182/blood-2013-03-493197
   Dohner H, 2017, BLOOD, V129, P424, DOI 10.1182/blood-2016-08-733196
   Dohner H, 2015, NEW ENGL J MED, V373, P1136, DOI 10.1056/NEJMra1406184
   Fan B, HAEMATOLOGICA
   Fathi AT, 2012, BLOOD, V120, P4649, DOI 10.1182/blood-2012-06-438267
   Fenaux P, 2009, LANCET ONCOL, V10, P223, DOI 10.1016/S1470-2045(09)70003-8
   Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015
   Hamalainen S, 2008, LEUKEMIA LYMPHOMA, V49, P495, DOI 10.1080/10428190701809172
   Janin M, 2014, J CLIN ONCOL, V32, P297, DOI 10.1200/JCO.2013.50.2047
   Kantarjian HM, 2012, J CLIN ONCOL, V30, P2670, DOI 10.1200/JCO.2011.38.9429
   Kats LM, 2014, CELL STEM CELL, V14, P329, DOI 10.1016/j.stem.2013.12.016
   Lu C, 2012, NATURE, V483, P474, DOI 10.1038/nature10860
   Marcucci G, 2010, J CLIN ONCOL, V28, P2348, DOI 10.1200/JCO.2009.27.3730
   Medeiros BC, 2017, LEUKEMIA, V31, P272, DOI 10.1038/leu.2016.275
   Nazha A, 2016, LEUKEMIA RES, V41, P43, DOI 10.1016/j.leukres.2015.12.007
   Oran B, 2012, HAEMATOL-HEMATOL J, V97, P1916, DOI 10.3324/haematol.2012.066100
   Paschka P, 2010, J CLIN ONCOL, V28, P3636, DOI 10.1200/JCO.2010.28.3762
   Roboz GJ, 2014, J CLIN ONCOL, V32, P1919, DOI 10.1200/JCO.2013.52.8562
   Rosenblat TL, 2010, CLIN CANCER RES, V16, P5303, DOI 10.1158/1078-0432.CCR-10-0382
   Sanz MA, 2014, BLOOD, V123, P2777, DOI 10.1182/blood-2013-10-512640
   Shih AH, 2014, BLOOD, V124, DOI 10.1182/blood.V124.21.437.437
   Tallman MS, 1997, NEW ENGL J MED, V337, P1021, DOI 10.1056/NEJM199710093371501
   Vardiman JW, 2009, BLOOD, V114, P937, DOI 10.1182/blood-2009-03-209262
   Walter RB, 2015, LEUKEMIA, V29, P770, DOI 10.1038/leu.2014.216
   Walter Roland B, 2013, Clin Adv Hematol Oncol, V11, P571
   Wang F, 2013, SCIENCE, V340, P622, DOI 10.1126/science.1234769
   Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020
   Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014
   Yen K, 2017, CANCER DISCOV, V7, P478, DOI 10.1158/2159-8290.CD-16-1034
   Zuckerman T, 2012, BLOOD, V120, P1993, DOI 10.1182/blood-2012-04-424440
NR 37
TC 677
Z9 692
U1 5
U2 60
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD AUG 10
PY 2017
VL 130
IS 6
BP 722
EP 731
DI 10.1182/blood-2017-04-779405
PG 10
WC Hematology
SC Hematology
GA FD2VQ
UT WOS:000407393300006
PM 28588020
OA Green Submitted, Bronze, Green Published
HC Y
HP N
DA 2021-10-30
ER

PT J
AU Delmonte, V
   Peixoto, EML
   Poggioli, R
   Enfield, G
   Luzi, L
   Ricordi, C
   Alejandro, R
AF Delmonte, V.
   Peixoto, E. M. L.
   Poggioli, R.
   Enfield, G.
   Luzi, L.
   Ricordi, C.
   Alejandro, R.
TI Ten Years' Evaluation of Diet, Anthropometry, and Physical Exercise
   Adherence After Islet Allotransplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT Berlin Symposium on Xenotransplantation / 24th International Congress of
   the Transplantation-Society (TTS)
CY JUL 13-19, 2012
CL Robert Koch Inst, Berlin, GERMANY
SP Transplantat Soc, Int Xenotransplantat Assoc
HO Robert Koch Inst
ID QUALITY-OF-LIFE; TRANSPLANTATION; IMMUNOSUPPRESSION; INFLAMMATION;
   DYSFUNCTION; EXENATIDE; OBESITY
AB Allogeneic islet transplantation (IT) provokes changes in metabolic responses and nutritional behaviors. The durability of these changes needs to be described as well as their impact on the recipients' lifestyle. The goal of this study was to investigate how islet transplantation influenced diet, exercise habits, and body composition during 10 years after IT. A retrospective study performed in 33 (14 males, 19 females) IT recipients used dietary, physical activity open- ended questionnaire and anthropometric measurements. Data were collected before transplantation, every 3 months up to the 18th and every 6 months thereafter. Data were grouped by gender and eras: pre-IT; 0-3 years; 4-6 years, and 7-10 years after IT. Reduction in body mass index (BMI) from pre-IT to 0-3 years was noted: 23.68 +/- 2,18 kg/m(2) to 22.07 +/- 2.94 kg/m(2) (P < .05). Increased values were observed from 0-3 years to 4-6 years in: waist circumference (WC) (76.68 +/- 7.22 to 79.44 +/- 7.58 cm), BMI (23,68 +/- 2,18 to 22,75 +/- 3,11 kg/m(2)) and weight (64.69 +/- 11.98 to 67.43 +/- 14 kg): (P < .03). WC increased continuously up to 7-10 years (86.33 +/- 9.45 cm; P < .05). There was an average of 5.3 +/- 5.6 h/wk of exercise during follow-up. From pre-IT to 0-3 years there was a 19% reduction in protein consumption (P < .05) and a 39% increase in calories from saturated fats (P < .05). A trend to reduce carbohydrates intake noted from pre-IT to 0-3 years was progressively inverted from then throughout 7-10 years (not significant). IT was associated with a significantly decreased BMI early on that it was not sustained. The subsequent weight gain and WC increase could be the result of chronic immunosuppressive therapy and/or voluntary change in eating habits. The increased consumption of carbohydrates could be related to an adaptation of a lifestyle or/and reintroduction of insulin after graft dysfunction. Active lifestyle might be result of the intensive clinical care after IT, concomitant awareness of the importance of routine physical exercise on blood glucose control, and diabetes management. Continuous follow-up of IT recipients is needed to better understand these changes and for comparison with subjects with type 1 diabetes mellitus.
C1 [Delmonte, V.; Peixoto, E. M. L.; Poggioli, R.; Enfield, G.; Luzi, L.; Ricordi, C.; Alejandro, R.] Univ Miami, Miller Sch Med, Diabet Res Inst, Miami, FL 33136 USA.
   [Delmonte, V.; Luzi, L.] Univ Milan, Dept Biomed Sci Hlth, Milan, Italy.
   [Delmonte, V.; Luzi, L.] IRCCS Policlin San Donato Milanese, Metab Res Ctr, Milan, Italy.
RP Delmonte, V (corresponding author), Univ Milan, Milan, Italy.
EM valentina.delmonte@unimi.it
RI RICORDI, CAMILLO/AAA-4740-2019; Luzi, Livio LL/M-2696-2016
OI Luzi, Livio LL/0000-0003-3183-0552; Ricordi, Camillo/0000-0001-8092-7153
FU NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000460] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH
   RESOURCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Research
   Resources (NCRR) [U42RR016603, M01RR016587] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Diabetes &
   Digestive & Kidney Diseases (NIDDK) [R01DK055347] Funding Source: NIH
   RePORTER; NCATS NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [1UL1TR000460] Funding Source:
   Medline; NCRR NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Research Resources (NCRR) [IU42 RR016603, MO1RR16587] Funding Source:
   Medline; NIDDK NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01-DK55347] Funding
   Source: Medline
CR Barton FB, 2012, DIABETES CARE, V35, P1436, DOI 10.2337/dc12-0063
   Bassi R, 2011, CURR DIABETES REP, V11, P355, DOI 10.1007/s11892-011-0211-1
   Chimen M, 2012, DIABETOLOGIA, V55, P542, DOI 10.1007/s00125-011-2403-2
   Cure P, 2008, TRANSPLANTATION, V85, P801, DOI 10.1097/TP.0b013e318166a27b
   Despres JP, 2012, CAN J CARDIOL, V28, P642, DOI 10.1016/j.cjca.2012.06.004
   Froud T, 2005, AM J TRANSPLANT, V5, P2037, DOI 10.1111/j.1600-6143.2005.00957.x
   Froud T, 2008, TRANSPLANTATION, V86, P36, DOI 10.1097/TP.0b013e31817c4ab3
   Froud T, 2008, TRANSPLANTATION, V86, P1695, DOI 10.1097/TP.0b013e31819025e5
   Garber CE, 2011, MED SCI SPORT EXER, V43, P1334, DOI 10.1249/MSS.0b013e318213fefb
   Johnston O, 2008, J AM SOC NEPHROL, V19, P1411, DOI 10.1681/ASN.2007111202
   Lee MJ, 2013, MOL ASPECTS MED, V34, P1, DOI 10.1016/j.mam.2012.10.001
   Leitao CB, 2008, DIABETES CARE, V31, P2113, DOI 10.2337/dc08-0741
   Lewis GF, 2002, ENDOCR REV, V23, P201, DOI 10.1210/er.23.2.201
   Souto DL, 2011, NUTR HOSP, V26, P425, DOI [10.1590/S0212-16112011000300001, 10.3305/nh.2011.26.3.4962]
   Luzi L, 2001, DIABETES, V50, P277, DOI 10.2337/diabetes.50.2.277
   Mineo D, 2008, AM J TRANSPLANT, V8, P1262, DOI 10.1111/j.1600-6143.2008.02230.x
   Peixoto EML, 2011, TRANSPL P, V43, P3231, DOI 10.1016/j.transproceed.2011.10.022
   Poggioli R, 2008, TRANSPLANTATION, V85, P501, DOI 10.1097/TP.0b013e3181629d7b
   Rickels MR, 2012, CURR DIABETES REP, V12, P587, DOI 10.1007/s11892-012-0294-3
   Senior PA, 2006, DIABETES, V55, pA448
   Skyler JS, 2011, DIABETES, V60, P1, DOI 10.2337/db10-1114
   Taube A, 2012, AM J PHYSIOL-HEART C, V302, pH2148, DOI 10.1152/ajpheart.00907.2011
   Tharavanij T, 2008, TRANSPLANTATION, V86, P1161, DOI 10.1097/TP.0b013e31818a7f45
NR 23
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0041-1345
EI 1873-2623
J9 TRANSPL P
JI Transplant. Proc.
PD JUN
PY 2013
VL 45
IS 5
BP 2025
EP 2028
DI 10.1016/j.transproceed.2013.01.031
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 176PL
UT WOS:000321316500079
PM 23769100
DA 2021-10-30
ER

PT J
AU Benci, JL
   Xu, BH
   Qiu, Y
   Wu, TJ
   Dada, H
   Twyman-Saint Victor, C
   Cucolo, L
   Lee, DSM
   Pauken, KE
   Huang, AC
   Gangadhar, TC
   Amaravadi, RK
   Schuchter, LM
   Feldman, MD
   Ishwaran, H
   Vonderheide, RH
   Maity, A
   Wherry, EJ
   Minn, AJ
AF Benci, Joseph L.
   Xu, Bihui
   Qiu, Yu
   Wu, Tony J.
   Dada, Hannah
   Twyman-Saint Victor, Christina
   Cucolo, Lisa
   Lee, David S. M.
   Pauken, Kristen E.
   Huang, Alexander C.
   Gangadhar, Tara C.
   Amaravadi, Ravi K.
   Schuchter, Lynn M.
   Feldman, Michael D.
   Ishwaran, Hemant
   Vonderheide, Robert H.
   Maity, Amit
   Wherry, E. John
   Minn, Andy J.
TI Tumor Interferon Signaling Regulates a Multigenic Resistance Program to
   Immune Checkpoint Blockade
SO CELL
LA English
DT Article
ID CD8(+) T-CELLS; CHRONIC VIRAL-INFECTION; PD-1 BLOCKADE; I INTERFERON;
   CANCER; THERAPY; EXHAUSTION; RADIATION; RECEPTORS; REJECTION
AB Therapeutic blocking of the PD1 pathway results in significant tumor responses, but resistance is common. We demonstrate that prolonged interferon signaling orchestrates PDL1-dependent and PDL1-independent resistance to immune checkpoint blockade (ICB) and to combinations such as radiation plus anti-CTLA4. Persistent type II interferon signaling allows tumors to acquire STAT1-related epigenomic changes and augments expression of interferon-stimulated genes and ligands for multiple T cell inhibitory receptors. Both type I and II interferons maintain this resistance program. Crippling the program genetically or pharmacologically interferes with multiple inhibitory pathways and expands distinct T cell populations with improved function despite expressing markers of severe exhaustion. Consequently, tumors resistant to multi-agent ICB are rendered responsive to ICB monotherapy. Finally, we observe that biomarkers for interferon-driven resistance associate with clinical progression after anti-PD1 therapy. Thus, the duration of tumor interferon signaling augments adaptive resistance and inhibition of the interferon response bypasses requirements for combinatorial ICB therapies.
C1 [Benci, Joseph L.; Xu, Bihui; Qiu, Yu; Wu, Tony J.; Dada, Hannah; Cucolo, Lisa; Lee, David S. M.; Maity, Amit; Minn, Andy J.] Univ Penn, Perelman Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA.
   [Twyman-Saint Victor, Christina; Huang, Alexander C.; Gangadhar, Tara C.; Amaravadi, Ravi K.; Schuchter, Lynn M.; Vonderheide, Robert H.] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA.
   [Pauken, Kristen E.; Wherry, E. John] Univ Penn, Perelman Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA.
   [Feldman, Michael D.] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
   [Pauken, Kristen E.; Huang, Alexander C.; Vonderheide, Robert H.; Wherry, E. John; Minn, Andy J.] Univ Penn, Perelman Sch Med, Inst Immunol, Philadelphia, PA 19104 USA.
   [Vonderheide, Robert H.; Wherry, E. John; Minn, Andy J.] Univ Penn, Perelman Sch Med, Parker Inst Canc Immunotherapy, Philadelphia, PA 19104 USA.
   [Benci, Joseph L.; Xu, Bihui; Qiu, Yu; Wu, Tony J.; Dada, Hannah; Twyman-Saint Victor, Christina; Cucolo, Lisa; Lee, David S. M.; Vonderheide, Robert H.; Minn, Andy J.] Univ Penn, Perelman Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.
   [Ishwaran, Hemant] Univ Miami, Dept Epidemiol & Publ Hlth, Div Biostat, Miami, FL 33136 USA.
RP Minn, AJ (corresponding author), Univ Penn, Perelman Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA.; Minn, AJ (corresponding author), Univ Penn, Perelman Sch Med, Inst Immunol, Philadelphia, PA 19104 USA.; Minn, AJ (corresponding author), Univ Penn, Perelman Sch Med, Parker Inst Canc Immunotherapy, Philadelphia, PA 19104 USA.; Minn, AJ (corresponding author), Univ Penn, Perelman Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.
EM andyminn@mail.med.upenn.edu
RI Wherry, John/ABI-1280-2020; Pauken, Kristen E./ABA-9363-2020
OI Lee, David/0000-0002-8821-9028; Wu, Tony James/0000-0002-5049-6986;
   Benci, Joseph/0000-0002-1759-4621; Twyman-Saint Victor,
   Christina/0000-0001-7253-6179; Maity, Amit/0000-0001-7151-2845
FU Melanoma Research Alliance; Parker Institute for Cancer Immunotherapy;
   Robertson Foundation/Cancer Research Institute Irvington Fellowship;
   NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [P50CA174523, R01CA163739, R01CA158186,
   P30CA016520, U19AI082630, R01AI105343, U01AI095608, P01AI112521]; Basser
   Research Center for BRCA; Abramson Cancer Center Translational Center of
   Excellence in Pancreatic Cancer; NIH/NCIUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Cancer Institute (NCI) [R01CA172651]; MerckMerck & Company;
   NATIONAL CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [R01CA172651, R01CA163739, P30CA016520, R01CA158186,
   P50CA174523] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [UL1TR000460] Funding Source:
   NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U19AI082630, R01AI105343, U01AI095608,
   P01AI112521] Funding Source: NIH RePORTER
FX A.J.M., R.H.V., and E.J.W. were supported by the Melanoma Research
   Alliance and the Parker Institute for Cancer Immunotherapy; K.E.P. was
   supported by a Robertson Foundation/Cancer Research Institute Irvington
   Fellowship; and M.D.F was supported by a grant from the NIH
   (P50CA174523). A.J.M. and R.H.V. were supported by the Basser Research
   Center for BRCA. H.I. and A.J.M. were supported by a grant from the NIH
   (R01CA163739). R.H.V. was supported by grants from the NIH (R01CA158186,
   P30CA016520) and by the Abramson Cancer Center Translational Center of
   Excellence in Pancreatic Cancer. E.J.W. was supported by funding from
   NIH (U19AI082630, R01AI105343, U01AI095608, and P01AI112521). A.J.M. is
   a Department of Defense Era of Hope Scholar (W81XWH-09-1-0339) and was
   supported by funding from the NIH/NCI (R01CA172651). This work was
   partly supported by a grant from Merck.
CR Blackburn SD, 2009, NAT IMMUNOL, V10, P29, DOI 10.1038/ni.1679
   Blackburn SD, 2008, P NATL ACAD SCI USA, V105, P15016, DOI 10.1073/pnas.0801497105
   Buenrostro JD, 2013, NAT METHODS, V10, P1213, DOI [10.1038/nmeth.2688, 10.1038/NMETH.2688]
   Chen X, 2012, GENOMICS, V99, P323, DOI 10.1016/j.ygeno.2012.04.003
   Cheon H, 2009, P NATL ACAD SCI USA, V106, P9373, DOI 10.1073/pnas.0903487106
   Diamond MS, 2011, J EXP MED, V208, P1989, DOI 10.1084/jem.20101158
   DIGHE AS, 1994, IMMUNITY, V1, P447, DOI 10.1016/1074-7613(94)90087-6
   Fu J, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4306
   Gajewski TF, 2011, CURR OPIN IMMUNOL, V23, P286, DOI 10.1016/j.coi.2010.11.013
   Galon J, 2013, IMMUNITY, V39, P11, DOI 10.1016/j.immuni.2013.07.008
   Gao JJ, 2016, CELL, V167, P397, DOI 10.1016/j.cell.2016.08.069
   He R, 2016, NATURE, V537, P412, DOI 10.1038/nature19317
   Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011
   Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065
   Im SJ, 2016, NATURE, V537, P417, DOI 10.1038/nature19330
   Ishwaran H, 2010, J AM STAT ASSOC, V105, P205, DOI 10.1198/jasa.2009.tm08622
   Johnson DB, 2016, NEW ENGL J MED, V375, P1749, DOI 10.1056/NEJMoa1609214
   McWilliams JA, 2006, J IMMUNOL, V177, P155, DOI 10.4049/jimmunol.177.1.155
   Minn AJ, 2016, CELL, V165, P272, DOI 10.1016/j.cell.2016.03.031
   Mittal D, 2014, CURR OPIN IMMUNOL, V27, P16, DOI 10.1016/j.coi.2014.01.004
   Ng CT, 2015, CELL HOST MICROBE, V17, P653, DOI 10.1016/j.chom.2015.04.005
   Paley MA, 2012, SCIENCE, V338, P1220, DOI 10.1126/science.1229620
   Pauken K. E., 2016, SCIENCE
   Pauken KE, 2015, TRENDS IMMUNOL, V36, P265, DOI 10.1016/j.it.2015.02.008
   Powles T, 2014, NATURE, V515, P558, DOI 10.1038/nature13904
   Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348
   Rooney MS, 2015, CELL, V160, P48, DOI 10.1016/j.cell.2014.12.033
   Sandler NG, 2014, NATURE, V511, P601, DOI 10.1038/nature13554
   Spranger S, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006504
   Taube JM, 2014, CLIN CANCER RES, V20, P5064, DOI 10.1158/1078-0432.CCR-13-3271
   Taube JM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003689
   Topalian SL, 2015, CANCER CELL, V27, P450, DOI 10.1016/j.ccell.2015.03.001
   Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954
   Twyman-Saint Victor C, 2015, NATURE, V520, P373, DOI 10.1038/nature14292
   Utzschneider DT, 2016, IMMUNITY, V45, P415, DOI 10.1016/j.immuni.2016.07.021
   Vanpouille-Box C, 2015, CANCER RES, V75, P2232, DOI 10.1158/0008-5472.CAN-14-3511
   Weichselbaum RR, 2008, P NATL ACAD SCI USA, V105, P18490, DOI 10.1073/pnas.0809242105
   Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862
   Wilson EB, 2013, SCIENCE, V340, P202, DOI 10.1126/science.1235208
   Zaretsky JM, 2016, NEW ENGL J MED, V375, P819, DOI 10.1056/NEJMoa1604958
NR 40
TC 435
Z9 448
U1 2
U2 123
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD DEC 1
PY 2016
VL 167
IS 6
BP 1540
EP +
DI 10.1016/j.cell.2016.11.022
PG 27
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA EE3EN
UT WOS:000389470500016
PM 27912061
OA Green Accepted, Bronze
HC Y
HP N
DA 2021-10-30
ER

PT J
AU Nearing, K
   Rainwater, J
   Neves, S
   Bhatti, P
   Conway, B
   Hafer, N
   Harter, K
   Kenyon, N
   McManus, MM
   McNeal, DM
   Morrato, EH
   Rajguru, SM
   Wasko, M
AF Nearing, Kathryn
   Rainwater, Julie
   Neves, Stacey
   Bhatti, Pamela
   Conway, Bruce
   Hafer, Nathaniel
   Harter, Kevin
   Kenyon, Nicholas
   McManus, Margaret M.
   McNeal, Demetria M.
   Morrato, Elaine H.
   Rajguru, Suhrud M.
   Wasko, Molly
TI I-Corps@NCATS trains clinical and translational science teams to
   accelerate translation of research innovations into practice
SO JOURNAL OF CLINICAL AND TRANSLATIONAL SCIENCE
LA English
DT Article
DE Innovation Corps (I-Corps); training; innovation; evaluation; research
   commercialization
ID COMMERCIALIZATION
AB Introduction: A key barrier to translation of biomedical research discoveries is a lack of understanding among scientists regarding the complexity and process of implementation. To address this challenge, the National Science Foundation's Innovation Corps (TM) (I-Corps (TM)) program trains researchers in entrepreneurship. We report results from the implementation of an I-Corps (TM) training program aimed at biomedical scientists from institutions funded by the National Center for Advancing Translational Sciences (NCATS).
   Methods: National/regional instructors delivered 5-week I-Corps@NCATS short courses to 62 teams (150 individuals) across six institutions. Content included customer discovery, value proposition, and validating needs. Teams interviewed real-life customers and presented the value of innovations for specific end-users weekly, culminating in a "Finale" featuring their refined business thesis and business model canvas. Methodology was developed to evaluate the newly adapted program. National mixed-methods evaluation assessed program implementation, reach, effectiveness using observations of training delivery and surveys at Finale (n = 55 teams), and 3-12 months post-training (n = 34 teams).
   Results: Innovations related to medical devices (33%), drugs/biologics (20%), software applications (16%), and diagnostics (8%). An average of 24 interviews was conducted. Teams reported increased readiness for commercialization over time (83%, 9 months; 14%, 3 months). Thirty-nine percent met with institutional technology transfer to pursue licensing/patents and 24% pursued venture capital/investor funding following the short courses.
   Conclusions: I-Corps@NCATS training provided the NCATS teams a rigorous and repeatable process to aid development of a business model based on customer needs. Outcomes of this pilot program support the expansion of I-Corps (TM) training to biomedical scientists for accelerating research translation.
C1 [Nearing, Kathryn] Univ Colorado, Sch Med, Div Geriatr Med, Anschutz Med Campus, Aurora, CO 80045 USA.
   [Rainwater, Julie; Neves, Stacey] Univ Calif Davis, Davis, CA 95616 USA.
   [Bhatti, Pamela] Georgia Inst Technol, Sch Elect & Comp Engn, Atlanta, GA USA.
   [Conway, Bruce] Rockefeller Univ, Robertson Therapeut Dev Fund, New York, NY USA.
   [Hafer, Nathaniel; McManus, Margaret M.] Univ Massachusetts, Ctr Clin & Translat Sci, Program Mol Med, Med Sch, Worcester, MA USA.
   [Harter, Kevin] Penn State Univ, Med Innovat, State Coll, PA USA.
   [Kenyon, Nicholas] Univ Calif Davis, Pulm Crit Care & Sleep Med, Davis, CA USA.
   [McNeal, Demetria M.] Univ Colorado, Sch Med, Div Gen Internal Med, Anschutz Med Campus, Aurora, CO 80045 USA.
   [Morrato, Elaine H.] Univ Colorado, Colorado Sch Publ Hlth, Colorado Clin & Translat Sci Inst, Innovat Ecosyst Program,Hlth Syst Management & Po, Anschutz Med Campus, Aurora, CO 80045 USA.
   [Morrato, Elaine H.] Loyola Univ, Parkinson Sch Hlth Sci & Publ Hlth, Chicago, IL USA.
   [Rajguru, Suhrud M.] Univ Miami, Dept Biomed Engn, Miami, FL USA.
   [Rajguru, Suhrud M.] Univ Miami, Dept Otolaryngol, Miami, FL USA.
   [Wasko, Molly] Univ Alabama Birmingham, Collat Sch Business, Res Innovat & Entrepreneurship & Fac Success, Birmingham, AL USA.
RP Nearing, K (corresponding author), Univ Colorado, Sch Med, Div Geriatr, Anschutz Med Campus,Acad Off One,12631E 17th Ave, Aurora, CO 80045 USA.
EM kathryn.nearing@cuanschutz.edu
OI Hafer, Nathaniel/0000-0002-0164-5092; McNeal,
   Demetria/0000-0002-7415-8631
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [UL1TR001417]; Colorado CTSA
   [UL1TR002535]; Georgia Clinical and Translational Science Alliance
   [UL1TR002378]; Miami CTSI [UL1TR002736]; Penn State University CTSA [UL1
   TR002014]; Rockefeller University CTSA [UL1TR001866]; University of
   Alabama, Birmingham CCTS [UL1TR003096]; UCDavis CTSC [UL1 TR001860];
   UMass CCTS [UL1TR001453]
FX The work to develop and implement the I-Corps@NCATS program and
   associated evaluation was made possible by a two-year supplement from
   the NIH (NIH GRANT UL1TR001417).; Additional funding support was
   provided by the CTSA awards of participating sites:; Colorado CTSA:
   UL1TR002535; Georgia Clinical and Translational Science Alliance:
   UL1TR002378; Miami CTSI: UL1TR002736; Penn State University CTSA: UL1
   TR002014; The Rockefeller University CTSA: UL1TR001866; University of
   Alabama, Birmingham CCTS: UL1TR003096; UCDavis CTSC: UL1 TR001860; UMass
   CCTS: UL1TR001453
CR Blank S.G., 2007, 4 STEPS EPIPHANY SUC
   Canaria CA, 2019, CTS-CLIN TRANSL SCI, V12, P324, DOI 10.1111/cts.12637
   Constable G., 2014, TALKING HUMANS SUCCE
   Dorf B., 2012, STARTUP OWNERS MANUA
   Huang-Saad A, 2017, J TECHNOL TRANSFER, V42, P1466, DOI 10.1007/s10961-016-9531-2
   Osterwalder A., 2015, VALUE PROPOSITION DE
   Pigneur, 2013, BUSINESS MODEL GENER
   Swamidass P, 2013, J TECHNOL TRANSFER, V38, P788, DOI 10.1007/s10961-012-9267-6
   VentureWell, 2019, IMP NSFS I CORPS NAT
NR 9
TC 4
Z9 4
U1 1
U2 1
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
EI 2059-8661
J9 J CLIN TRANSL SCI
JI J. Clin. Transl. Sci.
PY 2021
VL 5
IS 1
AR e66
DI 10.1017/cts.2020.561
PG 9
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA UF3GP
UT WOS:000688465400001
PM 33948285
OA Green Published, gold
DA 2021-10-30
ER

PT J
AU Goldberg, JM
   Fisher, DE
   Demetri, GD
   Neuberg, D
   Allsop, SA
   Fonseca, C
   Nakazaki, Y
   Nemer, D
   Raut, CP
   George, S
   Morgan, JA
   Wagner, AJ
   Freeman, GJ
   Ritz, J
   Lezcano, C
   Mihm, M
   Canning, C
   Hodi, FS
   Dranoff, G
AF Goldberg, John M.
   Fisher, David E.
   Demetri, George D.
   Neuberg, Donna
   Allsop, Stephen A.
   Fonseca, Catia
   Nakazaki, Yukoh
   Nemer, David
   Raut, Chandrajit P.
   George, Suzanne
   Morgan, Jeffrey A.
   Wagner, Andrew J.
   Freeman, Gordon J.
   Ritz, Jerome
   Lezcano, Cecilia
   Mihm, Martin
   Canning, Christine
   Hodi, F. Stephen
   Dranoff, Glenn
TI Biologic Activity of Autologous, Granulocyte-Macrophage
   Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear
   Cell Sarcoma Vaccines
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID MEDIATED TUMOR DESTRUCTION; PROTEIN ML-IAP; TRANSCRIPTION FACTOR;
   METASTATIC MELANOMA; CANCER-IMMUNOTHERAPY; MALIGNANT-MELANOMA; ANTITUMOR
   IMMUNITY; GROWTH-FACTOR; GENE; INHIBITOR
AB Purpose: Alveolar soft-part sarcoma (ASPS) and clear cell sarcoma (CCS) are rare mesenchymal malignancies driven by chromosomal translocations that activate members of the microphthalmia transcription factor (MITF) family. However, in contrast to malignant melanoma, little is known about their immunogenicity. To learn more about the host response to ASPS and CCS, we conducted a phase I clinical trial of vaccination with irradiated, autologous sarcoma cells engineered by adenoviral-mediated gene transfer to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF).
   Experimental Design: Metastatic tumors from ASPS and CCS patients were resected, processed to single-cell suspensions, transduced with a replication-defective adenoviral vector encoding GM-CSF, and irradiated. Immunizations were administered subcutaneously and intradermally weekly three times and then every other week.
   Results: Vaccines were successfully manufactured for 11 of the 12 enrolled patients. Eleven subjects received from three to 13 immunizations. Toxicities were restricted to grade 1-2 skin reactions at inoculation sites. Vaccination elicited local dendritic cell infiltrates and stimulated T cell-mediated delayed-type hypersensitivity reactions to irradiated, autologous tumor cells. Antibody responses to tissue-type plasminogen activator (tTPA) and angiopoietins-1/2 were detected. Tumor biopsies showed programmed death-1 (PD-1)-positive CD8(+) T cells in association with PD ligand-1 (PD-L1)-expressing sarcoma cells. No tumor regressions were observed.
   Conclusions: Vaccination with irradiated, GM-CSF-secreting autologous sarcoma cell vaccines is feasible, safe, and biologically active. Concurrent targeting of angiogenic cytokines and antagonism of the PD-1-negative regulatory pathway might intensify immune-mediated tumor destruction. (C) 2015 AACR.
C1 [Goldberg, John M.; Fisher, David E.; Wagner, Andrew J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
   [Goldberg, John M.; Fisher, David E.; Wagner, Andrew J.] Harvard Univ, Childrens Hosp, Sch Med, Dept Pediat, Boston, MA 02115 USA.
   [Goldberg, John M.] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Dept Pediat, Miami, FL 33136 USA.
   [Fisher, David E.] Harvard Univ, Sch Med, Dept Dermatol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
   [Demetri, George D.; Hodi, F. Stephen] Harvard Univ, Sch Med, Ludwig Ctr Harvard, Boston, MA USA.
   [Demetri, George D.; Allsop, Stephen A.; Fonseca, Catia; Nakazaki, Yukoh; Nemer, David; George, Suzanne; Morgan, Jeffrey A.; Freeman, Gordon J.; Ritz, Jerome; Canning, Christine; Hodi, F. Stephen; Dranoff, Glenn] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
   [Demetri, George D.; Allsop, Stephen A.; Fonseca, Catia; Nakazaki, Yukoh; Nemer, David; George, Suzanne; Morgan, Jeffrey A.; Freeman, Gordon J.; Ritz, Jerome; Canning, Christine; Hodi, F. Stephen; Dranoff, Glenn] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA.
   [Neuberg, Donna] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA.
   [Neuberg, Donna] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
   [Allsop, Stephen A.; Fonseca, Catia; Nakazaki, Yukoh; Nemer, David; Freeman, Gordon J.; Ritz, Jerome; Canning, Christine; Hodi, F. Stephen; Dranoff, Glenn] Dana Farber Canc Inst, Canc Vaccine Ctr, Ctr Immunooncol, Boston, MA 02215 USA.
   [Allsop, Stephen A.; Fonseca, Catia; Nakazaki, Yukoh; Nemer, David; Freeman, Gordon J.; Ritz, Jerome; Canning, Christine; Hodi, F. Stephen; Dranoff, Glenn] Dana Farber Canc Inst, Melanoma Dis Ctr, Boston, MA 02215 USA.
   [Raut, Chandrajit P.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Surg Oncol, Boston, MA 02115 USA.
   [Raut, Chandrajit P.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Surg, Boston, MA 02115 USA.
   [Lezcano, Cecilia] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA.
   [Mihm, Martin] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
RP Dranoff, G (corresponding author), Dana Farber Canc Inst, 44 Binney St,Dana 520C,450 Brookline Ave, Boston, MA 02215 USA.
EM glenn_dranoff@dfci.harvard.edu
RI Ritz, Jerome/C-7929-2009; Fisher, David/AAH-2878-2019; Freeman,
   Gordon/AAC-5380-2019
OI Ritz, Jerome/0000-0001-5526-4669; Freeman, Gordon/0000-0002-7210-5616
FU NCIUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [P01-CA163222, U54CA163125, R01 AR043369, R01 CA111506]; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [P01CA163222, U54CA163125, R01CA111506] Funding Source: NIH RePORTER;
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [KL2TR000461] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Arthritis & Musculoskeletal & Skin Diseases
   (NIAMS) [R01AR043369] Funding Source: NIH RePORTER
FX This work was supported by NCI grants P01-CA163222, U54CA163125, R01
   AR043369, R01 CA111506, and philanthropic support from the Dr. Miriam
   and Sheldon G. Adelson Medical Research Foundation (to D.E. Fisher and
   G.D. Demetri), iCureASPS (to G.D. Demetri and G. Dranoff), and the
   Knockin' Down ASPS Committee (to G.D. Demetri and G. Dranoff).
CR Azizi AA, 2006, LANCET ONCOL, V7, P521, DOI 10.1016/S1470-2045(06)70729-X
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   Castelli C, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-237
   Chen BJ, 2013, CLIN CANCER RES, V19, P3462, DOI 10.1158/1078-0432.CCR-13-0855
   CHRISTOPHERSON WM, 1952, CANCER, V5, P100, DOI 10.1002/1097-0142(195201)5:1<100::AID-CNCR2820050112>3.0.CO;2-K
   Collen D, 2009, ARTERIOSCL THROM VAS, V29, P1151, DOI 10.1161/ATVBAHA.108.179655
   Covell DG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048023
   Davis IJ, 2007, CELL CYCLE, V6, P1724, DOI 10.4161/cc.6.14.4484
   Davis IJ, 2006, CANCER CELL, V9, P473, DOI 10.1016/j.ccr.2006.04.021
   Davis IJ, 2010, CANCER RES, V70, P639, DOI 10.1158/0008-5472.CAN-09-1121
   Davis MB, 2011, CLIN CANCER RES, V17, P3984, DOI 10.1158/1078-0432.CCR-10-3262
   deVries TJ, 1996, MELANOMA RES, V6, P79, DOI 10.1097/00008390-199604000-00001
   Dynek JN, 2008, CANCER RES, V68, P3124, DOI 10.1158/0008-5472.CAN-07-6622
   Gasteiger G, 2014, NAT REV IMMUNOL, V14, P631, DOI 10.1038/nri3726
   Goldberg JM, 2014, J CLIN ONCOL, V32, pE114, DOI 10.1200/JCO.2013.48.7462
   Hodi FS, 2014, CANCER IMMUNOL RES, V2, P632, DOI 10.1158/2326-6066.CIR-14-0053
   Hodi FS, 2002, P NATL ACAD SCI USA, V99, P6919, DOI 10.1073/pnas.102025999
   Hung K, 1998, J EXP MED, V188, P2357, DOI 10.1084/jem.188.12.2357
   Jager E, 1998, J EXP MED, V187, P265, DOI 10.1084/jem.187.2.265
   Jinushi M, 2008, IMMUNOL REV, V222, P287, DOI 10.1111/j.1600-065X.2008.00618.x
   Jinushi M, 2007, J CLIN INVEST, V117, P1902, DOI 10.1172/JCI30966
   Jinushi M, 2006, P NATL ACAD SCI USA, V103, P9190, DOI 10.1073/pnas.0603503103
   Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331
   Kim JR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082870
   Kobos R, 2013, J PATHOL, V229, P743, DOI 10.1002/path.4158
   Kummar S, 2013, J CLIN ONCOL, V31, P2296, DOI 10.1200/JCO.2012.47.4288
   Ladanyi M, 2001, ONCOGENE, V20, P48, DOI 10.1038/sj.onc.1204074
   Lazar AJF, 2007, CLIN CANCER RES, V13, P7314, DOI 10.1158/1078-0432.CCR-07-0174
   LIEBERMAN PH, 1989, CANCER-AM CANCER SOC, V63, P1, DOI 10.1002/1097-0142(19890101)63:1<1::AID-CNCR2820630102>3.0.CO;2-E
   Malchau SS, 2007, J SURG ONCOL, V95, P519, DOI 10.1002/jso.20730
   Mellman I, 2011, NATURE, V480, P480, DOI 10.1038/nature10673
   Mollick Joseph A, 2003, Cancer Immun, V3, P3
   Orbach D, 2013, PEDIATR BLOOD CANCER, V60, P1826, DOI 10.1002/pbc.24683
   Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239
   Pennacchioli E, 2010, ANN SURG ONCOL, V17, P3229, DOI 10.1245/s10434-010-1186-x
   Portera CA, 2001, CANCER, V91, P585, DOI 10.1002/1097-0142(20010201)91:3<585::AID-CNCR1038>3.0.CO;2-0
   Rabinovich GA, 2007, ANNU REV IMMUNOL, V25, P267, DOI 10.1146/annurev.immunol.25.022106.141609
   Schmollinger JC, 2003, P NATL ACAD SCI USA, V100, P3398, DOI 10.1073/pnas.0530311100
   Schoenfeld J, 2010, CANCER RES, V70, P10150, DOI 10.1158/0008-5472.CAN-10-1852
   Segal NH, 2003, J CLIN ONCOL, V21, P1775, DOI 10.1200/JCO.2003.10.108
   Selvarajah S, 2014, CLIN CANCER RES, V20, P1521, DOI 10.1158/1078-0432.CCR-13-2090
   Soiffer R, 1998, P NATL ACAD SCI USA, V95, P13141, DOI 10.1073/pnas.95.22.13141
   Soiffer R, 2003, J CLIN ONCOL, V21, P3343, DOI 10.1200/JCO.2003.07.005
   Stacchiotti S, 2011, ANN ONCOL, V22, P1682, DOI 10.1093/annonc/mdq644
   Stacchiotti S, 2013, HEMATOL ONCOL CLIN N, V27, P1049, DOI 10.1016/j.hoc.2013.07.009
   Stacchiotti S, 2009, CLIN CANCER RES, V15, P1096, DOI 10.1158/1078-0432.CCR-08-2050
   Stockwin LH, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-22
   Tsuda M, 2007, CANCER RES, V67, P919, DOI 10.1158/0008-5472.CAN-06-2855
   Wagner AJ, 2012, CANCER-AM CANCER SOC, V118, P5894, DOI 10.1002/cncr.27582
   Yamada K, 2013, J CLIN INVEST, V123, P600, DOI 10.1172/JCI63572
   Zhou J, 2012, CANCER IMMUNOL IMMUN, V61, P655, DOI 10.1007/s00262-011-1124-1
   ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341
NR 52
TC 22
Z9 24
U1 0
U2 7
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JUL 15
PY 2015
VL 21
IS 14
BP 3178
EP 3186
DI 10.1158/1078-0432.CCR-14-2932
PG 9
WC Oncology
SC Oncology
GA CO7FC
UT WOS:000359324000012
PM 25805798
OA Green Accepted, Bronze
DA 2021-10-30
ER

PT J
AU Palmas, W
   Findley, SE
   Mejia, M
   Batista, M
   Teresi, J
   Kong, J
   Silver, S
   Fleck, EM
   Luchsinger, JA
   Carrasquillo, O
AF Palmas, Walter
   Findley, Sally E.
   Mejia, Miriam
   Batista, Milagros
   Teresi, Jeanne
   Kong, Jian
   Silver, Stephanie
   Fleck, Elaine M.
   Luchsinger, Jose A.
   Carrasquillo, Olveen
TI Results of the Northern Manhattan Diabetes Community Outreach Project: A
   Randomized Trial Studying a Community Health Worker Intervention to
   Improve Diabetes Care in Hispanic Adults
SO DIABETES CARE
LA English
DT Article
ID ETHNIC-DIFFERENCES; MEXICAN-AMERICANS; RISK; EDUCATION
AB OBJECTIVE
   The Northern Manhattan Diabetes Community Outreach Project evaluated whether a community health worker (CHW) intervention improved clinically relevant markers of diabetes care in adult Hispanics.
   RESEARCH DESIGN AND METHODS
   Participants were adult Hispanics, ages 35-70 years, with recent hemoglobin A(1c) (A1C) >= 8% (>= 64 mmol/mol), from a university-affiliated network of primary care practices in northern Manhattan (New York City, NY). They were randomized to a 12-month CHW intervention (n = 181), or enhanced usual care (educational materials mailed at 4-month intervals, preceded by phone calls, n = 179). The primary outcome was A1C at 12 months; the secondary outcomes were systolic blood pressure (SBP), diastolic blood pressure, and LDL-cholesterol levels.
   RESULTS
   There was a nonsignificant trend toward improvement in A1C levels in the intervention group (from unadjusted mean A1C of 8.77 to 8.40%), as compared with usual care (from 8.58 to 8.53%) (P = 0.131). There was also a nonsignificant trend toward an increase in SBP and LDL cholesterol in the intervention arm. Intervention fidelity, measured as the number of contacts in the intervention arm (visits, phone contacts, group support, and nutritional education), showed a borderline association with greater A1C reduction (P = 0.054). When assessed separately, phone contacts were associated with greater A1C reduction (P = 0.04).
   CONCLUSIONS
   The trend toward A1C reduction with the CHW intervention failed to achieve statistical significance. Greater intervention fidelity may achieve better glycemic control, and more accessible treatment models, such as phone-based interventions, may be more efficacious in socioeconomically disadvantaged populations.
C1 [Palmas, Walter] Columbia Univ, Med Ctr, New York, NY 10027 USA.
   [Findley, Sally E.] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA.
   [Mejia, Miriam; Batista, Milagros] Alianza, New York, NY USA.
   [Teresi, Jeanne; Kong, Jian; Silver, Stephanie] Hebrew Home Aged, Res Div, Bronx, NY USA.
   [Fleck, Elaine M.; Luchsinger, Jose A.] Columbia Univ, New York, NY USA.
   [Carrasquillo, Olveen] Univ Miami, Miller Sch Med, Div Gen Internal Med, Miami, FL 33136 USA.
RP Palmas, W (corresponding author), Columbia Univ, Med Ctr, New York, NY 10027 USA.
EM wp56@columbia.edu
OI Luchsinger, Jose/0000-0002-5886-3648
FU Centers of Excellence in Health Disparities, National Institute on
   Minority Health and Health Disparities [P60-MD-00206]; National Center
   for Advancing Translational Sciences, National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1-TR-000040]; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000460,
   UL1TR000040] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH
   RESOURCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Research
   Resources (NCRR) [UL1RR024156] Funding Source: NIH RePORTER; NATIONAL
   HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Heart Lung & Blood Institute (NHLBI) [R01HL083857] Funding Source: NIH
   RePORTER; National Institute on Minority Health and Health
   DisparitiesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Minority
   Health & Health Disparities (NIMHD) [P60MD000206] Funding Source: NIH
   RePORTER
FX Funding for this project was provided through the Centers of Excellence
   in Health Disparities, National Institute on Minority Health and Health
   Disparities (P60-MD-00206). This publication was also supported by the
   National Center for Advancing Translational Sciences, National
   Institutes of Health, through grant UL1-TR-000040, formerly the National
   Center for Research Resources (grant UL1-RR-024156).
CR Allen JK, 2011, CIRC-CARDIOVASC QUAL, V4, P595, DOI 10.1161/CIRCOUTCOMES.111.961573
   [Anonymous], 1999, Am J Public Health, V89, P428
   Babamoto KS, 2009, HEALTH EDUC BEHAV, V36, P113, DOI 10.1177/1090198108325911
   Bakken S, 2009, J AM BOARD FAM MED, V22, P436, DOI 10.3122/jabfm.2009.04.090017
   BLAIR SN, 1985, AM J EPIDEMIOL, V122, P794, DOI 10.1093/oxfordjournals.aje.a114163
   Brown SA, 2002, DIABETES CARE, V25, P259, DOI 10.2337/diacare.25.2.259
   Caballero A Enrique, 2007, Curr Opin Endocrinol Diabetes Obes, V14, P151, DOI 10.1097/MED.0b013e32809f9531
   Corkery E, 1997, DIABETES CARE, V20, P254, DOI 10.2337/diacare.20.3.254
   FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
   Gallivan Joanne, 2008, Prev Chronic Dis, V5, pA134
   Gary TL, 2009, ARCH INTERN MED, V169, P1788, DOI 10.1001/archinternmed.2009.338
   Harris MI, 1999, DIABETES CARE, V22, P403, DOI 10.2337/diacare.22.3.403
   Harris MI, 2001, DIABETES CARE, V24, P454, DOI 10.2337/diacare.24.3.454
   Klar N, 1997, STAT MED, V16, P1753, DOI 10.1002/(SICI)1097-0258(19970815)16:15<1753::AID-SIM597>3.3.CO;2-5
   Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x
   Little RJ, 2012, NEW ENGL J MED, V367, P1355, DOI 10.1056/NEJMsr1203730
   Lujan J, 2007, DIABETES EDUCATOR, V33, P660, DOI 10.1177/0145721707304080
   MacLaughlin EJ, 2005, DRUG AGING, V22, P231, DOI 10.2165/00002512-200522030-00005
   Mainous AG, 2007, DIABETOLOGIA, V50, P934, DOI 10.1007/s00125-006-0528-5
   Mieres JH, 2009, ARCH INTERN MED, V169, P1804, DOI 10.1001/archinternmed.2009.356
   Palmas W, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001051
   Perez LM, 2008, AM J PUBLIC HEALTH, V98, P11, DOI 10.2105/AJPH.2006.100842
   Spencer MS, 2011, AM J PUBLIC HEALTH, V101, P2253, DOI 10.2105/AJPH.2010.300106
   Thompson FE, 2000, AM J CLIN NUTR, V71, P1503
   United States Census Bureau, 2011, POP EST
   Wallerstein N, 2010, AM J PUBLIC HEALTH, V100, pS40, DOI 10.2105/AJPH.2009.184036
   White MJ, 2006, PATIENT EDUC COUNS, V61, P419, DOI 10.1016/j.pec.2005.05.008
   Winston GJ, 2009, DIABETES CARE, V32, P1467, DOI 10.2337/dc09-0260
NR 28
TC 25
Z9 26
U1 0
U2 12
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
EI 1935-5548
J9 DIABETES CARE
JI Diabetes Care
PD APR
PY 2014
VL 37
IS 4
BP 963
EP 969
DI 10.2337/dc13-2142
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AD7BB
UT WOS:000333414700025
PM 24496805
OA Green Published, hybrid
DA 2021-10-30
ER

PT J
AU Strbo, N
   Vaccari, M
   Pahwa, S
   Kolber, MA
   Doster, MN
   Fisher, E
   Gonzalez, L
   Stablein, D
   Franchini, G
   Podack, ER
AF Strbo, Natasa
   Vaccari, Monica
   Pahwa, Savita
   Kolber, Michael A.
   Doster, Melvin N.
   Fisher, Eva
   Gonzalez, Louis
   Stablein, Donald
   Franchini, Genoveffa
   Podack, Eckhard R.
TI Cutting Edge: Novel Vaccination Modality Provides Significant Protection
   against Mucosal Infection by Highly Pathogenic Simian Immunodeficiency
   Virus
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID SHOCK-PROTEIN GP96; RHESUS-MONKEYS; IMMUNE-RESPONSES; DENDRITIC CELLS;
   CHALLENGE; RECEPTOR; SIV; EFFICACY; VACCINES
AB Vaccine-induced protection against infection by HIV or highly pathogenic and virulent SIV strains has been limited. In a proof-of-concept study, we show that a novel vaccine approach significantly protects rhesus macaques from mucosal infection by the highly pathogenic strain SIVmac251. We vaccinated three cohorts of 12 macaques each with live, irradiated vaccine cells secreting the modified endoplasmic reticulum chaperone gp(96)-Ig. Cohort 1 was vaccinated with cells secreting gp96(SIV)Ig carrying SIV peptides. In addition, Cohort 2 received recombinant envelope protein SIV-gp120. Cohort 3 was injected with cells secreting gp(96)-Ig (no SIV Ags) vaccines. Cohort 2 was protected from infection. After seven rectal challenges with highly pathogenic SIVmac251, the hazard ratio was 0.27, corresponding to a highly significant, 73% reduced risk for viral acquisition. The apparent success of the novel vaccine modality recommends further study. The Journal of Immunology, 2013, 190: 2495-2499.
C1 [Strbo, Natasa; Pahwa, Savita; Fisher, Eva; Gonzalez, Louis; Podack, Eckhard R.] Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA.
   [Strbo, Natasa; Pahwa, Savita; Kolber, Michael A.; Gonzalez, Louis; Podack, Eckhard R.] Univ Miami, Miller Sch Med, Ctr AIDS Res, Miami, FL 33136 USA.
   [Vaccari, Monica; Doster, Melvin N.; Franchini, Genoveffa] NCI, Anim Models & Retroviral Vaccines Sect, NIH, Bethesda, MD 20817 USA.
   [Kolber, Michael A.; Podack, Eckhard R.] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA.
   [Stablein, Donald] EMMES Corp, Rockville, MD 20850 USA.
RP Podack, ER (corresponding author), Univ Miami, Miller Sch Med, 1600 NW 10th Ave,RMSB 3045, Miami, FL 33136 USA.
EM epodack@miami.edu
RI Pahwa, Savita/AAA-4900-2019
OI Pahwa, Savita/0000-0002-4470-4216
FU University of Miami; National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [NIAID R33 AI 073234]; Intramural Research Program of the National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA; National Cancer
   InstituteUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI);
   Center for Cancer ResearchUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI); Alliance for Cancer Gene Therapy, Stamford, CT;
   NATIONAL CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [ZIABC011126] Funding Source: NIH RePORTER; NATIONAL
   CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Advancing Translational Sciences (NCATS)
   [KL2TR000461] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [R01AI077501,
   R21AI073234, R21AI068515, P30AI073961, R33AI073234] Funding Source: NIH
   RePORTER
FX The work was supported by the National Institutes of Health (Grant NIAID
   R33 AI 073234 to E.R.P.), the Intramural Research Program of the
   National Institutes of Health (to G.F.), the National Cancer Institute,
   the Center for Cancer Research, and the Alliance for Cancer Gene
   Therapy, Stamford, CT (to E.R.P.). E.R.P. and the University of Miami
   have a financial interest in the commercial development of gp96-Ig-based
   vaccines. The other authors have no financial conflicts of interest.
CR ARNOLD D, 1995, J EXP MED, V182, P885, DOI 10.1084/jem.182.3.885
   Barouch DH, 2012, NATURE, V482, P89, DOI 10.1038/nature10766
   Barouch DH, 2010, NAT MED, V16, P319, DOI 10.1038/nm.2089
   Binder RJ, 2000, NAT IMMUNOL, V1, P151, DOI 10.1038/77835
   Brocca-Cofano E, 2011, VACCINE, V29, P3310, DOI 10.1016/j.vaccine.2011.02.066
   Fenizia C, 2011, J VIROL, V85, P12399, DOI 10.1128/JVI.05707-11
   Florese RH, 2009, J IMMUNOL, V182, P3718, DOI 10.4049/jimmunol.0803115
   Hansen SG, 2011, NATURE, V473, P523, DOI 10.1038/nature10003
   Hansen SG, 2009, NAT MED, V15, P293, DOI 10.1038/nm.1935
   Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425
   Letvin NL, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002351
   Liu JY, 2009, NATURE, V457, P87, DOI 10.1038/nature07469
   McMichael AJ, 2012, NAT IMMUNOL, V13, P423, DOI 10.1038/ni.2264
   Oizumi S, 2007, J IMMUNOL, V179, P2310, DOI 10.4049/jimmunol.179.4.2310
   Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492
   Singh-Jasuja H, 2000, EUR J IMMUNOL, V30, P2211, DOI 10.1002/1521-4141(2000)30:8<2211::AID-IMMU2211>3.0.CO;2-0
   Strbo N, 2010, MUCOSAL IMMUNOL, V3, P182, DOI 10.1038/mi.2009.127
   Strbo N, 2011, VACCINE, V29, P2619, DOI 10.1016/j.vaccine.2011.01.044
   Vabulas RM, 2002, J BIOL CHEM, V277, P20847, DOI 10.1074/jbc.M200425200
   Vaccari M, 2008, MUCOSAL IMMUNOL, V1, P497, DOI 10.1038/mi.2008.60
   Wrammert J, 2008, NATURE, V453, P667, DOI 10.1038/nature06890
   Yamazaki K, 1999, J IMMUNOL, V163, P5178
NR 22
TC 27
Z9 27
U1 1
U2 15
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAR 15
PY 2013
VL 190
IS 6
BP 2495
EP 2499
DI 10.4049/jimmunol.1202655
PG 5
WC Immunology
SC Immunology
GA 099XG
UT WOS:000315657200006
PM 23401588
OA Green Accepted, Bronze
DA 2021-10-30
ER

PT J
AU Marshall, GA
   Aghjayan, SL
   Dekhtyar, M
   Locascio, JJ
   Jethwani, K
   Amariglio, RE
   Czaja, SJ
   Loewenstein, DA
   Johnson, KA
   Sperling, RA
   Rentz, DM
AF Marshall, Gad A.
   Aghjayan, Sarah L.
   Dekhtyar, Maria
   Locascio, Joseph J.
   Jethwani, Kamal
   Amariglio, Rebecca E.
   Czaja, Sara J.
   Loewenstein, David A.
   Johnson, Keith A.
   Sperling, Reisa A.
   Rentz, Dorene M.
TI Measuring instrumental activities of daily living in non-demented
   elderly: a comparison of the new performance-based Harvard Automated
   Phone Task with other functional assessments
SO ALZHEIMERS RESEARCH & THERAPY
LA English
DT Article
DE Alzheimer's disease; Instrumental activities of daily living; Everyday
   functioning; Mild cognitive impairment; Performance-based; Validation
ID MILD COGNITIVE IMPAIRMENT; ALZHEIMERS ASSOCIATION WORKGROUPS; DIAGNOSTIC
   GUIDELINES; PREDICT PROGRESSION; NATIONAL INSTITUTE; OLDER-ADULTS;
   DEMENTIA; DISEASE; DISCRIMINATE; RECOMMENDATIONS
AB BackgroundImpairment in instrumental activities of daily living (IADL) may occur in the earliest stages of mild cognitive impairment (MCI). However, there are few reliable measures of IADL in MCI or that have a sufficient range of scores in clinically normal (CN) elderly. The objective of this pilot study was to examine the convergent validity of a phone performance-based IADL instrument, the Harvard Automated Phone Task (APT), designed to measure the earliest IADL changes in Alzheimer's disease (AD), with other sensitive performance-based and subjective measures of everyday functional capacity among CN and MCI participants.MethodsTwenty-nine CN and 17 MCI participants were administered the Harvard APT, the computer performance-based Czaja Functional Assessment Battery (CFAB), and the AD Cooperative Study ADL prevention instrument (ADCS ADL-PI) participant and study partner versions; in addition, 52 different CN and 7 MCI participants were administered the Harvard APT and the Subjective Study Partner and Participant-reported (SSPP) IADL scale. The Harvard APT was compared with the three other IADL assessments.ResultsIn both CN and MCI, better performance on the Harvard APT was associated with better performance on the CFAB. In CN, better performance on the Harvard APT was associated with better ADCS ADL-PI participant-reported IADL, while in MCI better performance on the Harvard APT was associated with better ADCS ADL-PI study partner-reported IADL. Furthermore, in CN better performance on the Harvard APT was associated with better SSPP-IADL participant and study partner-reported IADL.ConclusionsIn this small pilot study, the Harvard APT, a brief, self-administered, objective measure of IADL performance, appears to correlate well with other sensitive measures of everyday functioning, providing good preliminary convergent validity for this new measure. Moreover, it appears to perform well across both CN and MCI participants, which suggests that it is a promising measure of early, clinically meaningful functional change. This may not be the case as suggested in our small sample for subjective IADL scales that may perform differentially depending on the reporter (self vs. study partner) across the clinical spectrum possibly due to diminishing awareness of IADL difficulties in individuals who become cognitively impaired. Secondary prevention trials in AD have a great need for such ecologically valid and reliable measures of early IADL changes.
C1 [Marshall, Gad A.; Aghjayan, Sarah L.; Dekhtyar, Maria; Amariglio, Rebecca E.; Johnson, Keith A.; Sperling, Reisa A.; Rentz, Dorene M.] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurol, Ctr Alzheimer Res & Treatment, Boston, MA 02115 USA.
   [Marshall, Gad A.; Locascio, Joseph J.; Amariglio, Rebecca E.; Johnson, Keith A.; Sperling, Reisa A.; Rentz, Dorene M.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Massachusetts Alzheimers Dis Res Ctr, Boston, MA 02114 USA.
   [Jethwani, Kamal] Harvard Med Sch, Connected Hlth Innovat, Partners HealthCare, Boston, MA 02114 USA.
   [Czaja, Sara J.; Loewenstein, David A.] Univ Miami, Miller Sch Med, Dept Psychiat & Behav Sci, Ctr Aging, Miami, FL 33136 USA.
RP Marshall, GA (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Dept Neurol, Ctr Alzheimer Res & Treatment, Boston, MA 02115 USA.; Marshall, GA (corresponding author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Massachusetts Alzheimers Dis Res Ctr, Boston, MA 02114 USA.
EM gamarshall@partners.org
RI Aghjayan, Sarah/ABI-1456-2020
OI Marshall, Gad/0000-0002-9096-2355
FU Massachusetts Alzheimer's Disease Research Center [P50 AG005134];
   Harvard NeuroDiscovery; Alzheimer's AssociationAlzheimer's Association
   [SGCOG-13-282201];  [R01 AG027435]; NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [UL1TR002736] Funding Source:
   NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Aging (NIA) [R01AG027435, P50AG047266,
   P50AG005134] Funding Source: NIH RePORTER
FX This study was supported by the Massachusetts Alzheimer's Disease
   Research Center (P50 AG005134) and the Harvard NeuroDiscovery, which
   provided funding through a pilot grant awarded to GAM (Principal
   Investigator) and JJL (Co-Investigator), who designed the current study,
   performed the statistical analyses, interpreted the results, and drafted
   the manuscript; this pilot grant provided funding for data collection
   using the IADL tests. R01 AG027435 awarded to RAS (PI) and Alzheimer's
   Association SGCOG-13-282201 awarded to DMR (PI) provided funding for
   recruiting CN and MCI participants for the study.
CR Albert MS, 2011, ALZHEIMERS DEMENT, V7, P270, DOI 10.1016/j.jalz.2011.03.008
   Amariglio RE, 2015, JAMA NEUROL, V72, P446, DOI 10.1001/jamaneurol.2014.3375
   [Anonymous], 2018, EARLY ALZHEIMERS DIS
   Arguelles S, 2001, J GERIATR PSYCH NEUR, V14, P91, DOI 10.1177/089198870101400209
   Brown PJ, 2011, ARCH GEN PSYCHIAT, V68, P617, DOI 10.1001/archgenpsychiatry.2011.57
   Caselli RJ, 2014, ALZHEIMERS DEMENT, V10, P93, DOI 10.1016/j.jalz.2013.01.003
   Czaja SJ, 2017, SCHIZOPHR RES, V183, P130, DOI 10.1016/j.schres.2016.11.014
   Czaja SJ, 2017, J ALZHEIMERS DIS, V57, P1229, DOI 10.3233/JAD-161183
   Farias ST, 2008, NEUROPSYCHOLOGY, V22, P531, DOI 10.1037/0894-4105.22.4.531
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   Galasko D, 2006, ALZ DIS ASSOC DIS, V20, pS152, DOI 10.1097/01.wad.0000213873.25053.2b
   Goldberg TE, 2010, AM J PSYCHIAT, V167, P845, DOI 10.1176/appi.ajp.2010.09050692
   Grober E, 2010, ALZ DIS ASSOC DIS, V24, P284, DOI 10.1097/WAD.0b013e3181cfc78b
   Kozauer N, 2013, NEW ENGL J MED, V368, P1169, DOI 10.1056/NEJMp1302513
   Marshall GA, 2017, JPAD-J PREV ALZHEIM, V4, P81, DOI 10.14283/jpad.2017.10
   Marshall Gad A, 2015, J Prev Alzheimers Dis, V2, P242
   Marshall GA, 2015, CURR ALZHEIMER RES, V12, P493
   Marshall GA, 2014, CURR ALZHEIMER RES, V11, P853
   Marshall GA, 2012, NEURODEGENER DIS MAN, V2, P483, DOI 10.2217/NMT.12.55
   Marshall GA, 2011, ALZHEIMERS DEMENT, V7, P300, DOI 10.1016/j.jalz.2010.04.005
   Marson D, 2015, J Prev Alzheimers Dis, V2, P4
   McKhann GM, 2011, ALZHEIMERS DEMENT, V7, P263, DOI 10.1016/j.jalz.2011.03.005
   Miller D, 2013, J GERONTOL B-PSYCHOL, V68, P495, DOI 10.1093/geronb/gbs092
   Morris JC, 2012, ARCH NEUROL-CHICAGO, V69, P700, DOI 10.1001/archneurol.2011.3152
   Okereke OI, 2011, ARCH NEUROL-CHICAGO, V68, P343, DOI 10.1001/archneurol.2010.375
   PFEFFER RI, 1982, J GERONTOL, V37, P323, DOI 10.1093/geronj/37.3.323
   Sikkes SAM, 2009, J NEUROL NEUROSUR PS, V80, P7, DOI 10.1136/jnnp.2008.155838
   Wesson J, 2016, NEUROSCI BIOBEHAV R, V68, P335, DOI 10.1016/j.neubiorev.2016.05.024
   Zoller AS, 2014, CURR ALZHEIMER RES, V11, P785, DOI 10.2174/156720501108140910122220
NR 29
TC 4
Z9 4
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1758-9193
J9 ALZHEIMERS RES THER
JI Alzheimers Res. Ther.
PD JAN 10
PY 2019
VL 11
AR 4
DI 10.1186/s13195-018-0464-x
PG 12
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA HH0VV
UT WOS:000455438900001
PM 30630529
OA Green Published, gold
DA 2021-10-30
ER

PT J
AU Lippman, S
   Gardener, H
   Rundek, T
   Seixas, A
   Elkind, MSV
   Sacco, RL
   Wright, CB
   Ramos, AR
AF Lippman, Suzanne
   Gardener, Hannah
   Rundek, Tatjana
   Seixas, Azizi
   Elkind, Mitchell S. V.
   Sacco, Ralph L.
   Wright, Clinton B.
   Ramos, Alberto R.
TI Short sleep is associated with more depressive symptoms in a
   multi-ethnic cohort of older adults
SO SLEEP MEDICINE
LA English
DT Article
DE Depression; Sleep; Sleep duration; Short sleep; Race; Ethnic
ID US HISPANIC POPULATION; NORTHERN MANHATTAN; HEALTH-STATUS; DURATION;
   DISTURBANCES; INFLAMMATION; DISORDER
AB Objectives: To evaluate cross-sectional and prospective associations between short and long sleep duration and depressive symptoms in older adults (aged >65 years).
   Methods: The data from a subsample of the racially/ethnically diverse Northern Manhattan Study were analyzed. Depressive symptoms were assessed twice with the Center for Epidemiologic Studies Depression Scale (CES-D), approximately 5 years apart. The presence of depressive symptoms was defined as a CES-D score >= 16 or use of antidepressants. Self-reports of short (<6 h), intermediate (6-8 h) and long (>= 9 h) sleep were assessed prior to the initial CES-D. Logistic regression was used to evaluate the cross-sectional associations between short and long sleep durations with depressive symptoms, using intermediate sleep as the reference. The prospective association between sleep duration and depression in a sample of participants without depressive symptoms at first CES-D was also analyzed. All models were adjusted for demographic, behavioral, and vascular risk factors.
   Results: The initial sample consisted of 1110 participants: 62% women, 69% Hispanic, 17% black, 14% white. Short sleep was reported by 25%, intermediate sleep by 65%, and long sleep by 9%. Depressive symptoms were described in 25% of the initial sample. Short sleep, but not long sleep, was associated with depressive symptoms at baseline (adjusted OR 1.8, 95% CI 1.3-2.6), and at follow-up (adjusted OR 1.9, 95% CI 1.1-3.5; median follow-up = 5.1 years).
   Conclusion: Short sleep duration had a cross-sectional and prospective association with depressive symptoms in an urban multi-ethnic cohort of older adults. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Lippman, Suzanne; Gardener, Hannah; Rundek, Tatjana; Sacco, Ralph L.; Wright, Clinton B.; Ramos, Alberto R.] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA.
   [Lippman, Suzanne; Gardener, Hannah; Rundek, Tatjana; Sacco, Ralph L.; Wright, Clinton B.; Ramos, Alberto R.] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA.
   [Seixas, Azizi] NYU, Sch Med, Dept Populat Hlth, New York, NY USA.
   [Elkind, Mitchell S. V.] Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY USA.
   [Elkind, Mitchell S. V.] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY USA.
   [Wright, Clinton B.] NINDS, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.
RP Ramos, AR (corresponding author), Univ Miami, Miller Sch Med, Neurol, 1120 NW 14th St,Suite 1350, Miami, FL 33136 USA.
EM a.ramos1@med.miami.edu
RI Sacco, Ralph/Y-9278-2019; Ramos, Alberto/X-4249-2019
OI Seixas, Azizi/0000-0003-0843-2679
FU NIH/NINDSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Neurological
   Disorders & Stroke (NINDS) [R01 NS 29993, R01 NS 48134]; Miami Clinical
   and Translational Science Institute, from the National Center for
   Advancing Translational Sciences [1KL2TR000461]; National Institute on
   Minority Health and Health DisparitiesUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute on Minority Health & Health Disparities (NIMHD); NATIONAL
   CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Advancing Translational Sciences (NCATS)
   [KL2TR000461] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND
   BLOOD INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [K01HL135452, R01HL098297] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Neurological Disorders &
   Stroke (NINDS) [R01NS029993] Funding Source: NIH RePORTER
FX This work was supported by the NIH/NINDS (R01 NS 29993 and R01 NS
   48134). The project described herein was supported specifically by
   1KL2TR000461 (ARR), Miami Clinical and Translational Science Institute,
   from the National Center for Advancing Translational Sciences and the
   National Institute on Minority Health and Health Disparities. The
   sponsors did not have a role in the design, interpretation and draft of
   the manuscript.
CR Alcantara C, 2016, SLEEP, V39, P915, DOI 10.5665/sleep.5654
   Basner M, 2014, SLEEP, V37, P1889, DOI 10.5665/sleep.4238
   Benhayon D, 2013, J PEDIATR GASTR NUTR, V57, P335, DOI 10.1097/MPG.0b013e31829641df
   Berkman L F, 1982, Adv Cardiol, V29, P37
   Cheng P, 2013, J SLEEP RES, V22, P459, DOI 10.1111/jsr.12029
   Ertel KA, 2011, SLEEP, V34, P509, DOI 10.1093/sleep/34.4.509
   Mesas AE, 2011, AGE AGEING, V40, P318, DOI 10.1093/ageing/afr004
   Mesas AE, 2010, J AM GERIATR SOC, V58, P1870, DOI 10.1111/j.1532-5415.2010.03071.x
   Jeon SW, 2016, WORLD J PSYCHIATR, V6, P283, DOI 10.5498/wjp.v6.i3.283
   Kung PY, 2015, ARCH PSYCHIAT NURS, V29, P39, DOI 10.1016/j.apnu.2014.09.006
   Kuptniratsaikul Vilai, 2002, Journal of the Medical Association of Thailand, V85, P978
   Loredo JS, 2010, SLEEP, V33, P962, DOI 10.1093/sleep/33.7.962
   Mezick EJ, 2011, SLEEP MED REV, V15, P51, DOI 10.1016/j.smrv.2010.03.001
   Miller WC, 2008, SPINAL CORD, V46, P287, DOI 10.1038/sj.sc.3102127
   Murase K, 2014, SLEEP, V37, P1810, DOI 10.5665/sleep.4176
   Patel SR, 2007, SLEEP, V30, P1077, DOI 10.1093/sleep/30.9.1077
   Patel SR, 2015, SLEEP, V38, P1515, DOI 10.5665/sleep.5036
   Patel SR, 2009, SLEEP, V32, P200, DOI 10.1093/sleep/32.2.200
   RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306
   Ramos AR, 2014, J SLEEP RES, V23, P524, DOI 10.1111/jsr.12177
   Ramos AR, 2013, AM J CARDIOL, V112, P599, DOI 10.1016/j.amjcard.2013.04.029
   Ramos AR, 2013, J CLIN SLEEP MED, V9, P669, DOI 10.5664/jcsm.2834
   Ramos AR, 2011, NEUROEPIDEMIOLOGY, V37, P210, DOI 10.1159/000334315
   Ramos AR, 2016, NEUROLOGY
   Scheer FAJL, 2012, SLEEP, V35, P1395, DOI 10.5665/sleep.2122
   Willey JZ, 2009, NEUROLOGY, V73, P1774, DOI 10.1212/WNL.0b013e3181c34b58
   Yang DX, 2015, CEREBROVASC DIS, V40, P136, DOI 10.1159/000434761
   Zhai L, 2015, DEPRESS ANXIETY, V32, P664, DOI 10.1002/da.22386
NR 28
TC 16
Z9 16
U1 3
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1389-9457
EI 1878-5506
J9 SLEEP MED
JI Sleep Med.
PD DEC
PY 2017
VL 40
BP 58
EP 62
DI 10.1016/j.sleep.2017.09.019
PG 5
WC Clinical Neurology
SC Neurosciences & Neurology
GA FO8SK
UT WOS:000417157400009
PM 29221780
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Al Hazzouri, AZ
   Caunca, MR
   Nobrega, JC
   Elfassy, T
   Cheung, YK
   Alperin, N
   Dong, CH
   Elkind, MSV
   Sacco, RL
   DeCarli, C
   Wright, CB
AF Al Hazzouri, Adina Zeki
   Caunca, Michelle R.
   Nobrega, Juan Carlos
   Elfassy, Tali
   Cheung, Ying Kuen
   Alperin, Noam
   Dong, Chuanhui
   Elkind, Mitchell S. V.
   Sacco, Ralph L.
   DeCarli, Charles
   Wright, Clinton B.
TI Greater depressive symptoms, cognition, and markers of brain aging
   Northern Manhattan Study
SO NEUROLOGY
LA English
DT Article
ID WHITE-MATTER HYPERINTENSITIES; TEST-RETEST RELIABILITY; OLDER-ADULTS;
   LATE-LIFE; ISCHEMIC-STROKE; INFARCTION; RISK; SEGMENTATION;
   METAANALYSIS; PERFORMANCE
AB Objective
   We examined whether greater depressive symptoms were associated with domain-specific cognitive performance, change in cognition, and MRI markers of brain atrophy and subclinical cerebrovascular disease in a diverse sample of older adults from the Northern Manhattan Study.
   Methods
   Data were analyzed from the Northern Manhattan Study, a prospective cohort study of mostly Caribbean Hispanic, stroke-free, older adults. A total of 1,111 participants had baseline measures of depressive symptoms, measured as the Center of Epidemiological Studies-Depression Scale, MRI markers, and cognitive function. A Center of Epidemiological Studies-Depression score >= 16 was considered indicative of greater depressive symptoms. Multivariable linear and logistic regression models were used to examine the associations of interest.
   Results
   At baseline, 22% of participants had greater depressive symptoms. Greater depressive symptoms were significantly associated with worse baseline episodic memory in models adjusted for sociodemographic, vascular risk factor, behavioral, and antidepressive medication variables (beta [95% confidence interval] = -0.21 [-0.33 to -0.10], p = 0.0003). Greater depressive symptoms were also associated with smaller cerebral parenchymal fraction (beta [95% confidence interval] = -0.56 [-1.05 to -0.07], p = 0.02) and increased odds of subclinical brain infarcts (odds ratio [95% confidence interval] = 1.55 [1.00-2.42], p = 0.05), after adjustment for sociodemographic, behavioral, and vascular risk factor variables. Greater depressive symptoms were not significantly associated with white matter hyperintensity volume, hippocampal volume, or change in cognition over an average of 5 years. Results were unchanged when stabilized inverse probability weights were applied to address selective attrition during the study period.
   Conclusions
   In this sample of mostly Caribbean Hispanic, stroke-free, older adults, greater depressive symptoms were associated with worse episodic memory, smaller cerebral volume, and silent infarcts.
C1 [Al Hazzouri, Adina Zeki; Caunca, Michelle R.; Nobrega, Juan Carlos; Elfassy, Tali; Sacco, Ralph L.] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Div Epidemiol & Populat Hlth Sci, Coral Gables, FL 33124 USA.
   [Al Hazzouri, Adina Zeki; Caunca, Michelle R.; Alperin, Noam; Dong, Chuanhui; Sacco, Ralph L.] Univ Miami, Miller Sch Med, Evelyn F McKnight Brain Inst, Coral Gables, FL 33124 USA.
   [Dong, Chuanhui; Sacco, Ralph L.] Univ Miami, Miller Sch Med, Dept Neurol, Coral Gables, FL 33124 USA.
   [Alperin, Noam] Univ Miami, Miller Sch Med, Dept Radiol, Coral Gables, FL 33124 USA.
   [Cheung, Ying Kuen] Columbia Univ, Mailman Sch Publ Hlth, Dept Biostat, New York, NY USA.
   [Elkind, Mitchell S. V.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA.
   [Elkind, Mitchell S. V.] Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY USA.
   [DeCarli, Charles] Univ Calif Davis, Dept Neurol, Sacramento, CA 95817 USA.
   [DeCarli, Charles] Univ Calif Davis, Ctr Neurosci, Sacramento, CA 95817 USA.
   [Wright, Clinton B.] NINDS, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.
RP Al Hazzouri, AZ (corresponding author), Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Div Epidemiol & Populat Hlth Sci, Coral Gables, FL 33124 USA.; Al Hazzouri, AZ (corresponding author), Univ Miami, Miller Sch Med, Evelyn F McKnight Brain Inst, Coral Gables, FL 33124 USA.
EM axz122@miami.edu
RI Sacco, Ralph/Y-9278-2019; DeCarli, Charles/B-5541-2009
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01 NS29993, K01 AG047273, F30
   NS103462]; American Heart AssociationAmerican Heart Association [AHA
   17POST32490000]; Evelyn F. McKnight Brain Institute; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [KL2TR002737]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL
   DISORDERS AND STROKEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Neurological Disorders & Stroke (NINDS) [F30NS103462] Funding Source:
   NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Aging (NIA) [K01AG047273, P30AG010129] Funding
   Source: NIH RePORTER
FX This work was funded by grants from the NIH (R01 NS29993, K01 AG047273,
   F30 NS103462), the American Heart Association (AHA 17POST32490000), and
   the Evelyn F. McKnight Brain Institute.
CR Al Hazzouri AZ, 2014, J GERONTOL A-BIOL, V69, P595, DOI 10.1093/gerona/glt139
   Blazer DG, 2003, J GERONTOL A-BIOL, V58, P249
   Cole SR, 2008, AM J EPIDEMIOL, V168, P656, DOI 10.1093/aje/kwn164
   Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395
   Das RR, 2008, STROKE, V39, P2929, DOI 10.1161/STROKEAHA.108.516575
   DeCarli C, 2005, NEUROBIOL AGING, V26, P491, DOI 10.1016/j.neurobiolaging.2004.05.004
   DElia LF, 1996, COLOR TRAILS TEST PR
   Dong C, 2015, NEUROLOGY, V85, P441, DOI 10.1212/WNL.0000000000001716
   Dong JY, 2012, STROKE, V43, P32, DOI 10.1161/STROKEAHA.111.630871
   Eaton WW, 2004, USE PSYCHOL TESTING, V3, P363
   Elkind MSV, 2006, STROKE, V37, P13, DOI 10.1161/01.STR.0000195048.86810.5b
   Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X
   Flanagan JL, 1997, J COMMUN DISORD, V30, P33, DOI 10.1016/S0021-9924(96)00039-1
   FLOWERS KA, 1985, J NEUROL NEUROSUR PS, V48, P517, DOI 10.1136/jnnp.48.6.517
   Ganguli M, 2006, ARCH GEN PSYCHIAT, V63, P153, DOI 10.1001/archpsyc.63.2.153
   Harrison JE, 2000, BRIT J CLIN PSYCHOL, V39, P181, DOI 10.1348/014466500163202
   Herrmann LL, 2008, J NEUROL NEUROSUR PS, V79, P619, DOI 10.1136/jnnp.2007.124651
   Kaup AR, 2016, JAMA PSYCHIAT, V73, P525, DOI 10.1001/jamapsychiatry.2016.0004
   Koenig H G, 1992, Clin Geriatr Med, V8, P235
   Matthews C. G., 1964, INSTRUCTION MANUAL A
   Mayeda ER, 2016, ALZHEIMERS DEMENT, V12, P216, DOI 10.1016/j.jalz.2015.12.007
   McKenna MT, 2005, AM J PREV MED, V28, P415, DOI 10.1016/j.amepre.2005.02.009
   Parsons L.S, 2001, 26 ANN SAS US GROUP
   Prabhakaran S, 2008, NEUROLOGY, V70, P425, DOI 10.1212/01.wnl.0000277521.66947.e5
   RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306
   Sacco RL, 1998, STROKE, V29, P380, DOI 10.1161/01.STR.29.2.380
   Sacco RL, 1998, AM J EPIDEMIOL, V147, P259, DOI 10.1093/oxfordjournals.aje.a009445
   Siedlecki KL, 2012, J INT NEUROPSYCH SOC, V18, P223, DOI 10.1017/S135561771100155X
   Sierksma ASR, 2010, EUR J PHARMACOL, V626, P72, DOI 10.1016/j.ejphar.2009.10.021
   Videbech P, 2004, AM J PSYCHIAT, V161, P1957, DOI 10.1176/appi.ajp.161.11.1957
   Vinkers DJ, 2004, BRIT MED J, V329, P881, DOI 10.1136/bmj.38216.604664.DE
   Wardlaw JM, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.114.001140
   Wright CB, 2008, STROKE, V39, P800, DOI 10.1161/STROKEAHA.107.484147
   Zahodne LB, 2014, J AM GERIATR SOC, V62, P130, DOI 10.1111/jgs.12600
NR 34
TC 7
Z9 7
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD JUN 5
PY 2018
VL 90
IS 23
BP E2077
EP E2085
DI 10.1212/WNL.0000000000005639
PG 9
WC Clinical Neurology
SC Neurosciences & Neurology
GA GN6JL
UT WOS:000439187500008
PM 29743209
OA Green Published
DA 2021-10-30
ER

PT J
AU Coward, R
   Fornoni, A
AF Coward, Richard
   Fornoni, Alessia
TI Insulin signaling: implications for podocyte biology in diabetic kidney
   disease
SO CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
LA English
DT Review
DE Akt; GLUT4; insulin signaling; intracellular lipids; mammalian target of
   rapamycin
ID URINARY ALBUMIN EXCRETION; GLUCOSE-TRANSPORTER; GROWTH-FACTOR; GLUT4
   TRANSLOCATION; GLOMERULAR PODOCYTE; PROTECTS PODOCYTES; LIPID RAFTS;
   IN-VIVO; F-ACTIN; RESISTANCE
AB Purpose of review Several key elements of the insulin signaling cascade contribute to podocyte function and survival. While it was initially thought that the consequences of altered insulin signaling to podocyte function was strictly related to altered glucose uptake, it has become clear that upstream signaling events involved in cell survival, lipid metabolism or nutrient sensing and modulated by insulin are strong independent contributors to podocyte function.
   Recent findings Akt2, the major isoform of Akt activated following cellular insulin stimulation, protects against the progression of renal disease in nephron-deficient mice, and podocyte-specific deletion of Akt2 results in a more rapid progression of experimental glomerular disease. In diabetes, podocyte mammalian target of rapamycin activation clearly contributes to podocyte injury and regulated autophagy. Furthermore, podocyte-specific glucose transporter type 4 (GLUT4) deficiency protects podocytes by preventing mammalian target of rapamycin signaling independently of glucose uptake. Finally, intracellular lipids have been recently recognized as major modulators of podocyte insulin signaling and as a new therapeutic target.
   Summary The identification of new contributors to podocyte insulin signaling is of extreme translational value as it may lead to new drug development strategies for diabetic kidney disease, as well as for other proteinuric kidney diseases.
C1 [Coward, Richard] Univ Bristol, Bristol Royal Hosp Children, Childrens Renal Unit, Bristol, Avon, England.
   [Fornoni, Alessia] Univ Miami, Miller Sch Med, Katz Family Drug Discovery Ctr, Miami, FL 33136 USA.
   [Fornoni, Alessia] Univ Miami, Miller Sch Med, Div Nephrol & Hypertens, Miami, FL 33136 USA.
RP Fornoni, A (corresponding author), Univ Miami, Miller Sch Med, Katz Family Drug Discovery Ctr, 1580 NW 10th Ave, Miami, FL 33136 USA.
EM afornoni@med.miami.edu
OI Coward, Richard/0000-0001-6183-2546; fornoni,
   Alessia/0000-0002-1313-7773
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA; NIDDKUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)
   [DK090316, 5U24DX076169]; National Center for Advancing Translational
   SciencesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [1UL1TR000460]; Nephcure Foundation;
   Peggy and Harold Katz Family Foundation; MRC senior clinical
   fellowshipUK Research & Innovation (UKRI)Medical Research Council UK
   (MRC) [MR/K010492/1]; Kidney Research UKKidney Research UK (KRUK)
   [RP22/2012] Funding Source: researchfish; Medical Research CouncilUK
   Research & Innovation (UKRI)Medical Research Council UK (MRC)European
   Commission [MR/K010492/1] Funding Source: researchfish; NATIONAL CENTER
   FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000460]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND
   DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK090316,
   R01DK104753] Funding Source: NIH RePORTER
FX A.F. is supported by the NIH and NIDDK (grant numbers DK090316 and
   5U24DX076169), the National Center for Advancing Translational Sciences
   (grant number 1UL1TR000460), the Nephcure Foundation and the Peggy and
   Harold Katz Family Foundation. R.C. is supported by an MRC senior
   clinical fellowship (grant number MR/K010492/1).
CR Belfiore A, 2009, ENDOCR REV, V30, P586, DOI 10.1210/er.2008-0047
   Bentley AR, 2012, INT J NEPHROL, V2012, DOI 10.1155/2012/748984
   Berney T, 2001, TRANSPLANTATION, V71, P125, DOI 10.1097/00007890-200101150-00020
   Boute N, 2000, NAT GENET, V24, P349, DOI 10.1038/74166
   Buller CL, 2011, AM J PHYSIOL-RENAL, V301, pF588, DOI 10.1152/ajprenal.00472.2010
   Bussolati B, 2005, J AM SOC NEPHROL, V16, P1936, DOI 10.1681/ASN.2004080629
   Canaud G, 2013, NAT MED, V19, P1288, DOI 10.1038/nm.3313
   Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608
   Coward RJM, 2007, DIABETES, V56, P1127, DOI 10.2337/db06-0693
   Coward RJM, 2005, DIABETES, V54, P3095, DOI 10.2337/diabetes.54.11.3095
   de Boer IH, J AM MED ASS, V305, P2532
   Diez-Sampedro A, 2011, AM J KIDNEY DIS, V58, P637, DOI 10.1053/j.ajkd.2011.03.035
   Eid AA, 2010, J BIOL CHEM, V285, P37503, DOI 10.1074/jbc.M110.136796
   Ekstrand AV, 1998, NEPHROL DIAL TRANSPL, V13, P3079, DOI 10.1093/ndt/13.12.3079
   Faul C, 2007, TRENDS CELL BIOL, V17, P428, DOI 10.1016/j.tcb.2007.06.006
   Federation I., 2012, IDF DIABETES ATLAS
   Fornoni A, 2001, AM J PATHOL, V158, P275, DOI 10.1016/S0002-9440(10)63966-1
   Fornoni A, 2010, NEW ENGL J MED, V363, P2068, DOI 10.1056/NEJMcibr1008395
   FORSBLOM CM, 1995, DIABETOLOGIA, V38, P363, DOI 10.1007/s001250050294
   Gaede P, 2008, NEW ENGL J MED, V358, P580, DOI 10.1056/NEJMoa0706245
   Godel M, 2011, J CLIN INVEST, V121, P2197, DOI 10.1172/JCI44774
   GROOP L, 1993, DIABETOLOGIA, V36, P642, DOI 10.1007/BF00404074
   Gutwein P, 2009, AM J PATHOL, V174, P2061, DOI 10.2353/ajpath.2009.080960
   Guzman J, 2014, DIABETES, V63, P701, DOI 10.2337/db13-0752
   Hale LJ, 2013, AM J PHYSIOL-RENAL, V305, pF182, DOI 10.1152/ajprenal.00548.2012
   Hale LJ, 2013, J PATHOL, V230, P95, DOI 10.1002/path.4165
   Hansen CG, 2010, TRENDS CELL BIOL, V20, P177, DOI 10.1016/j.tcb.2010.01.005
   Hers I, 2011, CELL SIGNAL, V23, P1515, DOI 10.1016/j.cellsig.2011.05.004
   Hovind P, 2003, DIABETES CARE, V26, P1258, DOI 10.2337/diacare.26.4.1258
   Huber TB, 2007, NEPHRON EXP NEPHROL, V106, pE27, DOI 10.1159/000101789
   Hyvonen ME, 2010, MOL CELL ENDOCRINOL, V328, P70, DOI 10.1016/j.mce.2010.07.016
   Inoki K, 2011, J CLIN INVEST, V121, P2181, DOI 10.1172/JCI44771
   Kao AW, 1999, J BIOL CHEM, V274, P17742, DOI 10.1074/jbc.274.25.17742
   Kaplan JM, 2000, NAT GENET, V24, P251, DOI 10.1038/73456
   KATZ EB, 1995, NATURE, V377, P151, DOI 10.1038/377151a0
   Kestila M, 1998, MOL CELL, V1, P575, DOI 10.1016/S1097-2765(00)80057-X
   Kim EY, 2012, AM J PHYSIOL-RENAL, V302, pF298, DOI 10.1152/ajprenal.00423.2011
   Kim EY, 2011, J CELL PHYSIOL, V226, P2307, DOI 10.1002/jcp.22567
   Kume S, 2012, DIABETES, V61, P23, DOI 10.2337/db11-0555
   Lay A, 2014, NEPHROL DIAL TRANSPL, V29, P1127, DOI 10.1093/ndt/gft471
   Leibiger B, 2001, MOL CELL, V7, P559, DOI 10.1016/S1097-2765(01)00203-9
   Lennon R, 2009, NEPHROL DIAL TRANSPL, V24, P3288, DOI 10.1093/ndt/gfp302
   Lewko B, 2005, KIDNEY BLOOD PRESS R, V28, P1, DOI 10.1159/000080889
   Li C, 2000, AM J PHYSIOL-RENAL, V279, pF785, DOI 10.1152/ajprenal.2000.279.4.F785
   Liu P, 2004, AM J PHYSIOL-CELL PH, V286, pC317, DOI 10.1152/ajpcell.00073.2003
   Merscher-Gomez S, 2013, DIABETES, V62, P3817, DOI 10.2337/db13-0399
   Meyer TW, 1999, DIABETOLOGIA, V42, P1341, DOI 10.1007/s001250051447
   Mima A, 2011, KIDNEY INT, V79, P883, DOI 10.1038/ki.2010.526
   Miyauchi M, 2009, INTERNAL MED, V48, P1615, DOI 10.2169/internalmedicine.48.2137
   MOGENSEN CE, 1980, DIABETOLOGIA, V18, P453
   Morachevskaya E, 2007, CELL BIOL INT, V31, P374, DOI 10.1016/j.cellbi.2007.01.024
   Moutzouris DAD, 2007, RENAL FAILURE, V29, P353, DOI 10.1080/08860220601184126
   Musso C, 2006, CLIN J AM SOC NEPHRO, V1, P616, DOI 10.2215/CJN.01271005
   Mykkanen L, 1998, DIABETES, V47, P793, DOI 10.2337/diabetes.47.5.793
   Nathan DM, 2007, NEW ENGL J MED, V357, P64, DOI 10.1056/NEJMe078117
   Nissen SE, 2007, NEW ENGL J MED, V356, P2457, DOI 10.1056/NEJMoa072761
   Nystrom FH, 1999, MOL ENDOCRINOL, V13, P2013, DOI 10.1210/me.13.12.2013
   Ohno-Iwashita Y, 2010, GERIATR GERONTOL INT, V10, pS41, DOI 10.1111/j.1447-0594.2010.00600.x
   Pagtalunan ME, 1997, J CLIN INVEST, V99, P342, DOI 10.1172/JCI119163
   Parvanova AI, 2006, DIABETES, V55, P1456, DOI 10.2337/db05-1484
   Pavenstadt H, 2003, PHYSIOL REV, V83, P253, DOI 10.1152/physrev.00020.2002
   Pessin JE, 2000, J CLIN INVEST, V106, P165, DOI 10.1172/JCI10582
   Piwkowska A, 2013, BBA-MOL BASIS DIS, V1832, P791, DOI 10.1016/j.bbadis.2013.02.011
   Qi MS, 2009, J CELL BIOCHEM, V106, P1031, DOI 10.1002/jcb.22081
   Saltiel AR, 2003, TRAFFIC, V4, P711, DOI 10.1034/j.1600-0854.2003.00119.x
   Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a
   Sarafidis PA, 2006, KIDNEY INT, V70, P1223, DOI 10.1038/sj.ki.5001620
   Schermer B, 2009, J AM SOC NEPHROL, V20, P473, DOI 10.1681/ASN.2008070694
   Schiffer M, 2005, AM J PHYSIOL-RENAL, V289, pF186, DOI 10.1152/ajprenal.00234.2004
   Sieber J, 2013, AM J PATHOL, V183, P735, DOI 10.1016/j.ajpath.2013.05.023
   Sieber J, 2010, AM J PHYSIOL-RENAL, V299, pF821, DOI 10.1152/ajprenal.00196.2010
   Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052
   Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408
   Somlo S, 2000, NAT GENET, V24, P333, DOI 10.1038/74139
   Sorensson J, 2002, J AM SOC NEPHROL, V13, P2639, DOI 10.1097/01.ASN.0000033277.32822.23
   Steffes MW, 2001, KIDNEY INT, V59, P2104, DOI 10.1046/j.1523-1755.2001.0590062104.x
   Suarez MLG, 2013, WORLD J DIABETES, V4, P245, DOI 10.4239/wjd.v4.i6.245
   Susztak K, 2006, DIABETES, V55, P225, DOI 10.2337/diabetes.55.1.225
   System USRD, 2012, USRDS 2012 ANN DAT R
   Taniguchi CM, 2006, NAT REV MOL CELL BIO, V7, P85, DOI 10.1038/nrm1837
   Tejada T, 2008, KIDNEY INT, V73, P1385, DOI 10.1038/ki.2008.109
   Tomoiu A, 2007, ANN NY ACAD SCI, V1100, P98, DOI 10.1196/annals.1395.008
   Toyoda M, 2007, DIABETES, V56, P2155, DOI 10.2337/db07-0019
   Uhles S, 2003, J CELL BIOL, V163, P1327, DOI 10.1083/jcb.200306093
   Vainio S, 2005, BIOCHEM J, V391, P465, DOI 10.1042/BJ20050460
   Viberti G, 2005, J DIABETES COMPLICAT, V19, P168, DOI 10.1016/j.jdiacomp.2004.04.001
   Wang YL, 2010, AM J PHYSIOL-RENAL, V299, pF99, DOI 10.1152/ajprenal.00466.2009
   WARNER GJ, 1995, J BIOL CHEM, V270, P5772, DOI 10.1074/jbc.270.11.5772
   Wasik AA, 2012, MOL BIOL CELL, V23, P3370, DOI 10.1091/mbc.E11-12-1010
   Welsh GI, 2010, CELL METAB, V12, P329, DOI 10.1016/j.cmet.2010.08.015
   White KE, 2002, DIABETES, V51, P3083, DOI 10.2337/diabetes.51.10.3083
   Winn MP, 2005, SCIENCE, V308, P1801, DOI 10.1126/science.1106215
   Yamamoto M, 1998, J BIOL CHEM, V273, P26962, DOI 10.1074/jbc.273.41.26962
   YIP J, 1993, LANCET, V342, P883, DOI 10.1016/0140-6736(93)91943-G
   YIP J, 1993, LANCET, V341, P369, DOI 10.1016/0140-6736(93)90167-F
   Zhang HY, 2010, AM J PHYSIOL-RENAL, V299, pF91, DOI 10.1152/ajprenal.00021.2010
NR 96
TC 36
Z9 37
U1 0
U2 21
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1062-4821
EI 1473-6543
J9 CURR OPIN NEPHROL HY
JI Curr. Opin. Nephrol. Hypertens.
PD JAN
PY 2015
VL 24
IS 1
BP 104
EP 110
DI 10.1097/MNH.0000000000000078
PG 7
WC Urology & Nephrology; Peripheral Vascular Disease
SC Urology & Nephrology; Cardiovascular System & Cardiology
GA AU9SG
UT WOS:000345934400015
PM 25415617
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Wang, XY
   Strizich, G
   Hua, SM
   Sotres-Alvarez, D
   Buelna, C
   Gallo, LC
   Gellman, MD
   Mossavar-Rahmani, Y
   O'Brien, MJ
   Stoutenberg, M
   Wang, T
   Aviles-Santa, ML
   Kaplan, RC
   Qi, QB
AF Wang, Xueyin
   Strizich, Garrett
   Hua, Simin
   Sotres-Alvarez, Daniela
   Buelna, Christina
   Gallo, Linda C.
   Gellman, Marc D.
   Mossavar-Rahmani, Yasmin
   O'Brien, Matthew J.
   Stoutenberg, Mark
   Wang, Tao
   Aviles-Santa, M. Larissa
   Kaplan, Robert C.
   Qi, Qibin
TI Objectively Measured Sedentary Time and Cardiovascular Risk Factor
   Control in US Hispanics/Latinos With Diabetes Mellitus: Results From the
   Hispanic Community Health Study/Study of Latinos (HCHS/SOL)
SO JOURNAL OF THE AMERICAN HEART ASSOCIATION
LA English
DT Article
DE cardiovascular disease risk factors; diabetes mellitus; Hispanic/Latino;
   moderate-to; vigorous physical activity; sedentary behaviors
ID PHYSICAL-ACTIVITY; CARDIOMETABOLIC RISK; METABOLIC SYNDROME; ADULTS;
   ASSOCIATIONS; DISEASE; BIOMARKERS; MORTALITY; PEOPLE; INDIVIDUALS
AB Background--Cardiovascular disease (CVD) risk factor control is a cornerstone of diabetes mellitus management. Little is known about relationships of objectively measured sedentary time and physical activity with major CVD risk factor control in individuals with diabetes mellitus. We examined associations of objectively measured sedentary time and moderate-to-vigorous physical activity with reaching major CVD risk factor control goals among US Hispanic/Latino adults with diabetes mellitus.
   Methods and Results--This cross- sectional analysis included 1699 participants with diabetes mellitus from the Hispanic Community Health Study/Study of Latinos (2008-2011). Logistic regression models were used to estimate the odds ratios (ORs) of meeting the following 5 major CVD risk factor control goals: hemoglobin A(1c) < 7.0%; systolic/diastolic blood pressure < 140/80 mm Hg; triglycerides < 150 mg/ dL; low-density lipoprotein cholesterol < 100 mg/dL; and high-density lipoprotein cholesterol > 40/50 mg/dL for men/women. After adjustment for covariates including moderate-to-vigorous physical activity, less sedentary time was associated with increased odds of reaching hemoglobin A1c (OR= 1.76 [ 95% CI: 1.10, 2.82]) and triglyceride control goals (OR=2.16 [1.36, 3.46]), and reaching = 3 CVD risk factor control goals (OR=2.08 [1.34, 3.23]) (all ORs for comparisons of extreme tertiles of sedentary time). Moderate-to-vigorous physical activity was not associated with reaching any CVD risk factor control goals. Substituting 60-min/day of sedentary time with light-intensity physical activity was associated with increased odds of reaching hemoglobin A1c (OR= 1.18 [1.04, 1.35]), high-density lipoprotein cholesterol (OR=1.17 [ 1.04, 1.32]), and triglyceride (OR=1.20 [ 1.05, 1.36]) control goals.
   Conclusions--Among US Hispanic/Latino adults with diabetes mellitus, less sedentary time, but not moderate-to-vigorous physical activity, was associated with improved CVD risk factor control, specifically in reaching hemoglobin A(1c) and triglyceride control goals.
C1 [Wang, Xueyin] Peking Univ, Hosp 1, Dept Obstet & Gynecol, Beijing, Peoples R China.
   [Wang, Xueyin; Strizich, Garrett; Hua, Simin; Mossavar-Rahmani, Yasmin; Wang, Tao; Kaplan, Robert C.; Qi, Qibin] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, 1300 Morris Pk Ave, Bronx, NY 10461 USA.
   [Sotres-Alvarez, Daniela] Univ North Carolina Chapel Hill, Collaborat Studies Coordinating Ctr, Gillings Sch Global Publ Hlth, Dept Biostat, Chapel Hill, NC USA.
   [Buelna, Christina] San Diego State Univ, Grad Sch Publ Hlth, South Bay Latino Res Ctr, San Diego, CA 92182 USA.
   [Gallo, Linda C.] San Diego State Univ, Dept Psychol, San Diego, CA 92182 USA.
   [Gellman, Marc D.] Univ Miami, Miller Sch Med, Behav Med Res Ctr, Coral Gables, FL 33124 USA.
   [Stoutenberg, Mark] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Coral Gables, FL 33124 USA.
   [O'Brien, Matthew J.] Northwestern Univ, Div Gen Internal Med & Geriatr, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Aviles-Santa, M. Larissa] NHLBI, Div Cardiovasc Sci, NIH, Bldg 10, Bethesda, MD 20892 USA.
RP Qi, QB (corresponding author), Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, 1300 Morris Pk Ave, Bronx, NY 10461 USA.
EM qi@einstein.yu.edu
OI Mossavar-Rahmani, Yasmin/0000-0002-9214-6124; Aviles-Santa, M
   Larissa/0000-0002-8130-0026; Deloukas, Panos/0000-0001-9251-070X
FU National Heart, Lung, and Blood Institute (NHLBI)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [N01-HC65233];
   University of Miami [N01HC65234]; Albert Einstein College of Medicine
   [N01HC65235]; Northwestern University [N01-HC65236]; San Diego State
   University [N01-HC65237]; National Center on Minority Health and Health
   DisparitiesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Minority
   Health & Health Disparities (NIMHD); National Institute of Deafness and
   Other Communications DisordersUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Deafness & Other Communication Disorders (NIDCD); National Institute
   of Dental and Craniofacial ResearchUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Dental & Craniofacial Research (NIDCR); National Institute
   of Diabetes and Digestive and Kidney DiseasesUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK);
   National Institute of Neurological Disorders and StrokeUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Neurological Disorders & Stroke (NINDS);
   Office of Dietary SupplementsUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA; NHLBIUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [K01HL129892];
   China Scholarship CouncilChina Scholarship Council; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [P30CA013330] Funding Source: NIH RePORTER; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [KL2TR000461]
   Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [K01HL129892] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Diabetes & Digestive & Kidney Diseases
   (NIDDK) [P30DK020541] Funding Source: NIH RePORTER
FX This work was supported by contracts from the National Heart, Lung, and
   Blood Institute (NHLBI) to the University of North Carolina
   (N01-HC65233), University of Miami (N01HC65234), Albert Einstein College
   of Medicine (N01HC65235), Northwestern University (N01-HC65236), and San
   Diego State University (N01-HC65237). The following
   Institutes/Centers/Offices contribute to the HCHS/SOL through a transfer
   of funds to the NHLBI: National Center on Minority Health and Health
   Disparities, the National Institute of Deafness and Other Communications
   Disorders, the National Institute of Dental and Craniofacial Research,
   the National Institute of Diabetes and Digestive and Kidney Diseases,
   the National Institute of Neurological Disorders and Stroke, and the
   Office of Dietary Supplements. Dr Qi is supported by a Scientist
   Development Award (K01HL129892) from the NHLBI. Xueyin Wang was
   supported by the China Scholarship Council.
CR Amer Diabet Assoc, 2014, DIABETES CARE, V37, pS14, DOI 10.2337/dc14-S014
   Biswas A, 2015, ANN INTERN MED, V162, P123, DOI 10.7326/M14-1651
   Bittner V, 2015, J AM COLL CARDIOL, V66, P765, DOI 10.1016/j.jacc.2015.06.019
   BLAIR SN, 1995, JAMA-J AM MED ASSOC, V273, P1093, DOI 10.1001/jama.273.14.1093
   Buman MP, 2014, AM J EPIDEMIOL, V179, P323, DOI 10.1093/aje/kwt292
   Casagrande SS, 2013, DIABETES CARE, V36, P2271, DOI 10.2337/dc12-2258
   Center for Disease Control and Prevention, 2011, NAT DIAB FACT SHEET
   Chau JY, 2014, J SCI MED SPORT, V17, P78, DOI 10.1016/j.jsams.2013.03.004
   Chiuve SE, 2012, J NUTR, V142, P1009, DOI 10.3945/jn.111.157222
   Choi L, 2011, MED SCI SPORT EXER, V43, P357, DOI 10.1249/MSS.0b013e3181ed61a3
   Colberg SR, 2010, DIABETES CARE, V33, pe147, DOI DOI 10.2337/DC10-9990
   Colley Rachel C, 2011, Health Rep, V22, P7
   Cooper AR, 2012, DIABETOLOGIA, V55, P589, DOI 10.1007/s00125-011-2408-x
   Cooper AJM, 2014, DIABETOLOGIA, V57, P73, DOI 10.1007/s00125-013-3069-8
   Daviglus ML, 2012, JAMA-J AM MED ASSOC, V308, P1775, DOI 10.1001/jama.2012.14517
   Dunstan DW, 2005, DIABETES CARE, V28, P3, DOI 10.2337/diacare.28.1.3
   Esliger DW, 2007, MED SCI SPORT EXER, V39, P1200, DOI 10.1249/mss.0b013e3804ec4e9
   Esliger DW, 2006, MED SCI SPORT EXER, V38, P2173, DOI 10.1249/01.mss.0000239394.55461.08
   Evenson KR, 2015, MED SCI SPORT EXER, V47, P725, DOI 10.1249/MSS.0000000000000478
   Falconer CL, 2015, MED SCI SPORT EXER, V47, P2070, DOI 10.1249/MSS.0000000000000651
   Gibbs BB, 2015, DIABETES CARE, V38, P1835, DOI 10.2337/dc15-0226
   Green AN, 2014, EUR J APPL PHYSIOL, V114, P907, DOI 10.1007/s00421-014-2822-0
   Gregg EW, 2003, ARCH INTERN MED, V163, P1440, DOI 10.1001/archinte.163.12.1440
   Hamilton MT, 2007, DIABETES, V56, P2655, DOI 10.2337/db07-0882
   Healy GN, 2008, DIABETES CARE, V31, P369, DOI 10.2337/dc07-1795
   Healy GN, 2011, EUR HEART J, V32, P590, DOI 10.1093/eurheartj/ehq451
   Heiss G, 2014, DIABETES CARE, V37, P2391, DOI 10.2337/dc13-2505
   Henson J, 2013, DIABETOLOGIA, V56, P1012, DOI 10.1007/s00125-013-2845-9
   Kaplan RC, 2014, AM J PREV MED, V46, P496, DOI 10.1016/j.amepre.2014.01.014
   Lamb MJE, 2016, DIABETOLOGIA, V59, P110, DOI 10.1007/s00125-015-3756-8
   Lavange LM, 2010, ANN EPIDEMIOL, V20, P642, DOI 10.1016/j.annepidem.2010.05.006
   Leung MYM, 2015, DIABETES CARE, V38, P460, DOI 10.2337/dc14-1453
   Mekary RA, 2009, AM J EPIDEMIOL, V170, P519, DOI 10.1093/aje/kwp163
   Moe B, 2015, DIABETOLOGIA, V58, P59, DOI 10.1007/s00125-014-3388-4
   Morrato EH, 2007, DIABETES CARE, V30, P203, DOI 10.2337/dc06-1128
   Qi QB, 2015, CIRCULATION, V132, P1560, DOI 10.1161/CIRCULATIONAHA.115.016938
   Rodriguez CJ, 2014, CIRCULATION, V130, P593, DOI 10.1161/CIR.0000000000000071
   Seaman SR, 2013, STAT METHODS MED RES, V22, P278, DOI 10.1177/0962280210395740
   Siega-Riz AM, 2014, AM J CLIN NUTR, V99, P1487, DOI 10.3945/ajcn.113.082685
   Sorlie PD, 2010, ANN EPIDEMIOL, V20, P629, DOI 10.1016/j.annepidem.2010.03.015
   Vidot DC, 2016, METAB SYNDR RELAT D, V14, P354, DOI 10.1089/met.2015.0171
   Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003
   Wijndaele K, 2014, DIABETOLOGIA, V57, P305, DOI 10.1007/s00125-013-3102-y
   Zderic TW, 2006, J APPL PHYSIOL, V100, P249, DOI 10.1152/japplphysiol.00925.2005
NR 44
TC 7
Z9 7
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-9980
J9 J AM HEART ASSOC
JI J. Am. Heart Assoc.
PD JUN
PY 2017
VL 6
IS 6
AR e004324
DI 10.1161/JAHA.116.004324
PG 20
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA EY6MY
UT WOS:000404098700002
PM 28546455
OA Green Published, gold
DA 2021-10-30
ER

PT J
AU Swords, RT
   Azzam, D
   Al-Ali, H
   Lohse, I
   Volmar, CH
   Watts, JM
   Perez, A
   Rodriguez, A
   Vargas, F
   Elias, R
   Vega, F
   Zelent, A
   Brothers, SP
   Abbasi, T
   Trent, J
   Rangwala, S
   Deutsch, Y
   Conneally, E
   Drusbosky, L
   Cogle, CR
   Wahlestedt, C
AF Swords, Ronan T.
   Azzam, Diana
   Al-Ali, Hassan
   Lohse, Ines
   Volmar, Claude-Henry
   Watts, Justin M.
   Perez, Aymee
   Rodriguez, Ana
   Vargas, Fernando
   Elias, Roy
   Vega, Francisco
   Zelent, Arthur
   Brothers, Shaun P.
   Abbasi, Taher
   Trent, Jonathan
   Rangwala, Shaukat
   Deutsch, Yehuda
   Conneally, Eibhlin
   Drusbosky, Leylah
   Cogle, Christopher R.
   Wahlestedt, Claes
TI Ex-vivo sensitivity profiling to guide clinical decision making in acute
   myeloid leukemia: A pilot study
SO LEUKEMIA RESEARCH
LA English
DT Article
DE Acute myeloid leukemia; Ex-vivo sensitivity screening; Precision
   medicine
ID DRUG-SENSITIVITY; MEDICINE; AML
AB A precision medicine approach is appealing for use in AML due to ease of access to tumor samples and the significant variability in the patients' response to treatment. Attempts to establish a precision medicine platform for AML, however, have been unsuccessful, at least in part due to the use of small compound panels and having relatively slow turn over rates, which restricts the scope of treatment and delays its onset. For this pilot study, we evaluated a cohort of 12 patients with refractory AML using an ex vivo drug sensitivity testing (DST) platform. Purified AML blasts were screened with a panel of 215 FDA-approved compounds and treatment response was evaluated after 72 h of exposure. Drug sensitivity scoring was reported to the treating physician, and patients were then treated with either DST- or non-DST guided therapy. We observed survival benefit of DST-guided therapy as compared to the survival of patients treated according to physician recommendation. Three out of four DST-treated patients displayed treatment response, while all of the non-DST-guided patients progressed during treatment. DST rapidly and effectively provides personalized treatment recommendations for patients with refractory AML.
C1 [Swords, Ronan T.; Watts, Justin M.; Perez, Aymee; Rodriguez, Ana; Vargas, Fernando; Elias, Roy; Vega, Francisco; Zelent, Arthur; Trent, Jonathan] Univ Miami, Sylvester Comprehens Canc Ctr, Div Hematol Oncol, 1501 NW 10th Ave, Miami, FL 33136 USA.
   [Azzam, Diana; Lohse, Ines; Volmar, Claude-Henry; Brothers, Shaun P.; Wahlestedt, Claes] Univ Miami, Miller Sch Med, Ctr Therapeut Innovat, 1501 NW 10th Ave, Miami, FL 33136 USA.
   [Azzam, Diana; Lohse, Ines; Volmar, Claude-Henry; Brothers, Shaun P.; Wahlestedt, Claes] Dept Psychiat & Behav Sci, Miami, FL USA.
   [Azzam, Diana; Al-Ali, Hassan; Lohse, Ines; Volmar, Claude-Henry; Brothers, Shaun P.] Univ Miami, Sylvester Comprehens Canc Ctr, Mol Therapeut Shared Resource, 1501 NW 10th Ave, Miami, FL 33136 USA.
   [Al-Ali, Hassan] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, 1501 NW 10th Ave, Miami, FL 33136 USA.
   [Al-Ali, Hassan] Univ Miami, Miller Sch Med, Dept Neurol Surg, 1501 NW 10th Ave, Miami, FL 33136 USA.
   [Al-Ali, Hassan] Univ Miami, Miller Sch Med, Peggy & Harold Katz Family Drug Discovery Ctr, 1501 NW 10th Ave, Miami, FL 33136 USA.
   [Abbasi, Taher] Cellworks Grp Inc, San Jose, CA USA.
   [Rangwala, Shaukat] MOgene LC, St Louis, MO USA.
   [Deutsch, Yehuda] Mem Hlth Care Syst, Miami, FL USA.
   [Deutsch, Yehuda] St James Hosp, Dept Hematol, Dublin, Ireland.
   [Conneally, Eibhlin] Univ Florida, Coll Med, Dept Med, Div Hematol Oncol, Gainesville, FL USA.
RP Wahlestedt, C (corresponding author), Univ Miami, Miller Sch Med, 1501 NW 10th Ave, Miami, FL 33136 USA.
EM cwahlestedt@med.miami.edu
RI Conneally, Eibhlin/AAX-5804-2020; Azzam, Diana/ABB-8342-2021; Trent,
   Jonathan/AAR-7113-2021
OI Conneally, Eibhlin/0000-0002-7874-9359; Trent,
   Jonathan/0000-0001-6169-5238; Al-Ali, Hassan/0000-0002-8899-3443; Elias,
   Roy/0000-0002-8555-4322; Vega, Francisco/0000-0001-5956-452X; Volmar,
   Claude-Henry/0000-0001-9437-051X; Zelent, Arthur/0000-0002-7968-9888
FU Miami Clinical and Translational Science Institute; National Center for
   Advancing Translational SciencesUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [1KL2TR000461]; Paps
   Corps Champions for Cancer Research; National Institutes of HealthUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA [R21CA202488, R01NS092671, R01MH110441]; Broward
   Community Foundation (Fort Lauderdale, FL); Pap Corps Champions for
   Cancer Research (Deerfield Beach, FL); NIHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA
   [DA035592, DA035055, AA023781]; Florida Department of Health [6AZ08,
   7AZ26]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Advancing Translational
   Sciences (NCATS) [KL2TR000461] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Mental Health (NIMH) [R01MH110441] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Neurological Disorders & Stroke (NINDS)
   [R21NS056950, R01NS092671] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01AA023781]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European
   Commission [R01DA035055] Funding Source: NIH RePORTER
FX RS received support from the Miami Clinical and Translational Science
   Institute, from the National Center for Advancing Translational Sciences
   (1KL2TR000461), the Paps Corps Champions for Cancer Research and the
   National Institutes of Health (R21CA202488). JT received research
   support from the Broward Community Foundation (Fort Lauderdale, FL) and
   the Pap Corps Champions for Cancer Research (Deerfield Beach, FL). SB
   received support from the National Institutes of Health (R01NS092671 and
   R01MH110441). CW's laboratory is currently publically funded by NIH
   grants DA035592, DA035055 and AA023781, and Florida Department of Health
   grants 6AZ08 and 7AZ26. CRC is a Scholar in Clinical Research, Leukemia
   & Lymphoma Society.
CR Bosanquet Andrew G, 2004, J Exp Ther Oncol, V4, P145
   Brigulova K, 2010, TOXICOL IN VITRO, V24, P2108, DOI 10.1016/j.tiv.2010.08.010
   Cattaneo D, 2016, EXPERT OPIN DRUG MET, V12, P533, DOI 10.1517/17425255.2016.1166204
   Dohner H, 2011, HEMATOL-AM SOC HEMAT, P36, DOI 10.1182/asheducation-2011.1.36
   Ehemann V, 2008, INT J CANCER, V122, P2719, DOI 10.1002/ijc.23335
   Jeong E, 2017, ARCH PHARM RES
   KORTLEPEL K, 1993, LEUKEMIA, V7, P1174
   Kurtz S.E., 2017, P NATL ACAD SCI USA
   Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689
   Meijer TG, 2017, FUTUR SCI OA, V3, DOI 10.4155/fsoa-2017-0003
   Muraro MG, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1331798
   Pemovska T, 2013, CANCER DISCOV, V3, P1416, DOI 10.1158/2159-8290.CD-13-0350
   Perez F, 2016, EXPERT OPIN PHARMACO, V17, P761, DOI 10.1517/14656566.2016.1145658
   Sanguinetti M., 2017, CLIN MICROBIOL INFEC, P30195
   Smith FO, 2010, BLOOD, V116, P2622, DOI 10.1182/blood-2010-07-296418
   Villman K, 2005, ANTI-CANCER DRUG, V16, P609, DOI 10.1097/00001813-200507000-00003
   Welch JS, 2016, NEW ENGL J MED, V375, P2023, DOI 10.1056/NEJMoa1605949
   Welch JS, 2012, CELL, V150, P264, DOI 10.1016/j.cell.2012.06.023
   Yadav B, 2014, SCI REP-UK, V4, DOI 10.1038/srep05193
   Yamada S, 2001, LEUKEMIA, V15, P1892, DOI 10.1038/sj.leu.2402305
NR 20
TC 22
Z9 23
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0145-2126
EI 1873-5835
J9 LEUKEMIA RES
JI Leuk. Res.
PD JAN
PY 2018
VL 64
BP 34
EP 41
DI 10.1016/j.leukres.2017.11.008
PG 8
WC Oncology; Hematology
SC Oncology; Hematology
GA FR6ZI
UT WOS:000419215600006
PM 29175379
OA Green Accepted, hybrid
DA 2021-10-30
ER

PT J
AU Dazard, JE
   Ishwaran, H
   Mehlotra, R
   Weinberg, A
   Zimmerman, P
AF Dazard, Jean-Eudes
   Ishwaran, Hemant
   Mehlotra, Rajeev
   Weinberg, Aaron
   Zimmerman, Peter
TI Ensemble survival tree models to reveal pairwise interactions of
   variables with time-to-events outcomes in low-dimensional setting
SO STATISTICAL APPLICATIONS IN GENETICS AND MOLECULAR BIOLOGY
LA English
DT Article
DE epistasis; genetic variations interactions; interaction detection and
   modeling; random survival forest; time-to-event analysis
ID GENE-GENE INTERACTIONS; RANDOM FORESTS; REGRESSION TREES; EPISTASIS;
   SELECTION; TESTS
AB Unraveling interactions among variables such as genetic, clinical, demographic and environmental factors is essential to understand the development of common and complex diseases. To increase the power to detect such variables interactions associated with clinical time-to-events outcomes, we borrowed established concepts from random survival forest (RSF) models. We introduce a novel RSF-based pairwise interaction estimator and derive a randomization method with bootstrap confidence intervals for inferring interaction significance. Using various linear and nonlinear time-to-events survival models in simulation studies, we first show the efficiency of our approach: true pairwise interaction-effects between variables are uncovered, while they may not be accompanied with their corresponding main-effects, and may not be detected by standard semi-parametric regression modeling and test statistics used in survival analysis. Moreover, using a RSF-based cross-validation scheme for generating prediction estimators, we show that informative predictors may be inferred. We applied our approach to an HIV cohort study recording key host gene polymorphisms and their association with HIV change of tropism or AIDS progression. Altogether, this shows how linear or nonlinear pairwise statistical interactions of variables may be efficiently detected with a predictive value in observational studies with time-to-event outcomes.
C1 [Dazard, Jean-Eudes] Case Western Reserve Univ, Ctr Prote & Bioinformat, Sch Med, Cleveland, OH 44106 USA.
   [Ishwaran, Hemant] Univ Miami, Dept Epidemiol & Publ Hlth, Div Biostat, Miami, FL 33136 USA.
   [Mehlotra, Rajeev; Zimmerman, Peter] Case Western Reserve Univ, Ctr Global Hlth & Dis, Sch Med, Cleveland, OH 44106 USA.
   [Weinberg, Aaron] Case Western Reserve Univ, Sch Dent Med, Dept Biol Sci, Cleveland, OH 44106 USA.
RP Dazard, JE (corresponding author), Case Western Reserve Univ, Ctr Prote & Bioinformat, Sch Med, Cleveland, OH 44106 USA.
EM jean-eudes.dazard@case.edu; paz@case.edu
RI MEHLOTRA, RAJEEV/AAG-1026-2020
OI Dazard, Jean-Eudes/0000-0003-4720-3684
FU National Institute of Allergy and Infectious Diseases (NIAID)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID); National Cancer Institute (NCI)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI); National Heart, Lung, and
   Blood Institute (NHLBI)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI); National Institute on Deafness and
   Communication Disorders (NIDCD)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute on Deafness & Other Communication Disorders (NIDCD); Johns
   Hopkins University CTSA; National Institute of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [NIDCR P01DE019759, NCI R01CA163739]; National Science
   FoundationNational Science Foundation (NSF) [DMS 1148991]; Center for
   AIDS Research [P30AI036219]; NATIONAL CANCER INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI) [R01CA163739] Funding Source:
   NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Advancing Translational
   Sciences (NCATS) [UL1TR000460] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [P30AI036219] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL
   & CRANIOFACIAL RESEARCHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Dental & Craniofacial Research (NIDCR) [P01DE019759] Funding Source:
   NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of General Medical Sciences
   (NIGMS) [R01GM125072] Funding Source: NIH RePORTER
FX This work made use of the High Performance Computing Resource in the
   Core Facility for Advanced Research Computing at Case Western Reserve
   University. We are thankful to Ms. Janet Schollenberger, Senior Project
   Coordinator, CAMACS, as well as Dr. Jeremy J. Martinson, Sudhir
   Penugonda, Shehnaz K. Hussain, Jay H. Bream, and Priya Duggal, for
   providing us the data related to the samples analyzed in the present
   study. Data in this manuscript were collected by the Multicenter AIDS
   Cohort Study (MACS at http://www.statepi.jh-sph.edu/macs/macs.html) with
   centers at Baltimore, Chicago, Los Angeles, Pittsburgh, and the Data
   Coordinating Center: The Johns Hopkins University Bloomberg School of
   Public Health. The MACS is funded primarily by the National Institute of
   Allergy and Infectious Diseases (NIAID), with additional co-funding from
   the National Cancer Institute (NCI), the National Heart, Lung, and Blood
   Institute (NHLBI), and the National Institute on Deafness and
   Communication Disorders (NIDCD). MACS data collection is also supported
   by Johns Hopkins University CTSA. This study was supported by two grants
   from the National Institute of Health: NIDCR P01DE019759 (Aaron
   Weinberg, Peter Zimmerman, Richard J. Jurevic, Mark Chance) and NCI
   R01CA163739 (Hemant Ishwaran). The work was also partly supported by the
   National Science Foundation grant DMS 1148991 (Hemant Ishwaran) and the
   Center for AIDS Research grant P30AI036219 (Mark Chance). The contents
   of this publication are solely the responsibility of the authors and do
   not represent the official views of the granting agencies and
   institutions. The funders had also no role in the study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Bien J, 2013, ANN STAT, V41, P1111, DOI 10.1214/13-AOS1096
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Cantor RM, 2010, AM J HUM GENET, V86, P6, DOI 10.1016/j.ajhg.2009.11.017
   Chen W, 2012, STAT MED, V31, P3693, DOI 10.1002/sim.5429
   Chen X, 2012, GENOMICS, V99, P323, DOI 10.1016/j.ygeno.2012.04.003
   Chipman HA, 1998, J AM STAT ASSOC, V93, P935, DOI 10.2307/2669832
   Cordell HJ, 2009, NAT REV GENET, V10, P392, DOI 10.1038/nrg2579
   COX DR, 1972, J R STAT SOC B, V34, P187
   Cutler A., 2001, COMPUTING SCI STAT, V33, P490
   DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x
   Efron B., 1993, INTRO BOOTSTRAP CRC
   Ehrlinger J., 2014, COMPREHENSIVE R ARCH
   Friedman J. H., 1984, SLACPUB3477 STANF U
   GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515
   Gustafson P, 2000, J AM STAT ASSOC, V95, P795
   HARRELL FE, 1982, JAMA-J AM MED ASSOC, V247, P2543, DOI 10.1001/jama.247.18.2543
   Hastie T., 2009, ELEMENTS STAT LEARNI, V2
   Ishwaran H., 2013, COMPREHENSIVE R ARCH
   Ishwaran H., 2007, R NEWS, V7, P25
   Ishwaran H, 2008, ANN APPL STAT, V2, P841, DOI 10.1214/08-AOAS169
   Ishwaran H, 2007, ELECTRON J STAT, V1, P519, DOI 10.1214/07-EJS039
   Ishwaran H, 2014, BIOSTATISTICS, V15, P757, DOI 10.1093/biostatistics/kxu010
   Ishwaran H, 2010, J AM STAT ASSOC, V105, P205, DOI 10.1198/jasa.2009.tm08622
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   LEBLANC M, 1993, J AM STAT ASSOC, V88, P457, DOI 10.2307/2290325
   Li J, 2011, BIOINFORMATICS, V27, pI222, DOI 10.1093/bioinformatics/btr227
   Lin Y, 2006, J AM STAT ASSOC, V101, P578, DOI 10.1198/016214505000001230
   Lunetta KL, 2004, BMC GENET, V5, DOI 10.1186/1471-2156-5-32
   Marchini J, 2005, NAT GENET, V37, P413, DOI 10.1038/ng1537
   MCGILL R, 1978, AM STAT, V32, P12, DOI 10.2307/2683468
   Mehlotra R. K., 2012, AIDS CLIN RESJ AIDS, V3, P10
   Mogensen UB, 2012, J STAT SOFTW, V50, P1
   Phillips PC, 2008, NAT REV GENET, V9, P855, DOI 10.1038/nrg2452
   SEGAL MR, 1988, BIOMETRICS, V44, P35, DOI 10.2307/2531894
   Shepherd JC, 2008, J INFECT DIS, V198, P1104, DOI 10.1086/591623
   Simon N, 2015, J AM STAT ASSOC, V110, P1707, DOI 10.1080/01621459.2014.993079
   Tian L, 2014, J AM STAT ASSOC, V109, P1517, DOI 10.1080/01621459.2014.951443
   Ueki M, 2012, PLOS GENET, V8, P141, DOI 10.1371/journal.pgen.1002625
   Wang XF, 2010, HUM HERED, V70, P269, DOI 10.1159/000321967
   Yung LS, 2011, BIOINFORMATICS, V27, P1309, DOI 10.1093/bioinformatics/btr114
   Zhang X, 2011, SOURCE CODE BIOL MED, V6, DOI 10.1186/1751-0473-6-1
   Zhang XA, 2010, J COMPUT BIOL, V17, P401, DOI 10.1089/cmb.2009.0155
   Zhang X, 2010, BIOINFORMATICS, V26, pi217, DOI 10.1093/bioinformatics/btq186
   Zhang ZG, 2008, GENET EPIDEMIOL, V32, P285, DOI 10.1002/gepi.20304
   Zou H, 2005, J R STAT SOC B, V67, P301, DOI 10.1111/j.1467-9868.2005.00503.x
NR 45
TC 1
Z9 1
U1 2
U2 7
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
SN 2194-6302
EI 1544-6115
J9 STAT APPL GENET MOL
JI Stat. Appl. Genet. Mol. Biol.
PD FEB
PY 2018
VL 17
IS 1
AR 20170038
DI 10.1515/sagmb-2017-0038
PG 28
WC Biochemistry & Molecular Biology; Mathematical & Computational Biology;
   Statistics & Probability
SC Biochemistry & Molecular Biology; Mathematical & Computational Biology;
   Mathematics
GA FY1ZL
UT WOS:000426613000003
PM 29453930
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Jiang, JM
   Nguyen, T
   Rao, JS
AF Jiang, Jiming
   Thuan Nguyen
   Rao, J. Sunil
TI The E-MS Algorithm: Model Selection With Incomplete Data
SO JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION
LA English
DT Article
DE Backcross experiments; Conditional sampling; Consistency; Convergence;
   Missing data mechanism; Model selection; Regression
ID QUANTITATIVE TRAIT LOCI; MISSING-DATA; VARIABLE SELECTION; FENCE
   METHODS; SEMIPARAMETRIC REGRESSION; INFORMATION CRITERION;
   MAXIMUM-LIKELIHOOD; REPEATED OUTCOMES; IDENTIFICATION; STATISTICS
AB We propose a procedure associated with the idea of the E-M algorithm for model selection in the presence of missing data. The idea extends the concept of parameters to include both the model and the parameters under the model, and thus allows the model to be part of the E-M iterations. We develop the procedure, known as the E-MS algorithm, under the assumption that the class of candidate models is finite. Some special cases of the procedure are considered, including E-MS with the generalized information criteria (GIC), and E-MS with the adaptive fence (AF; Jiang et al.). We prove numerical convergence of the E-MS algorithm as well as consistency in model selection of the limiting model of the E-MS convergence, for E-MS with GIC and E-MS with AF. We study the impact on model selection of different missing data mechanisms. Furthermore, we carry out extensive simulation studies on the finite-sample performance of the E-MS with comparisons to other procedures. The methodology is also illustrated on a real data analysis involving QTL mapping for an agricultural study on barley grains. Supplementary materials for this article are available online.
C1 [Jiang, Jiming] Univ Calif Davis, Dept Stat, Davis, CA 95616 USA.
   [Thuan Nguyen] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97239 USA.
   [Rao, J. Sunil] Univ Miami, Sch Med, Div Biostat, Miami, FL 33136 USA.
RP Jiang, JM (corresponding author), Univ Calif Davis, Dept Stat, One Shield Ave, Davis, CA 95616 USA.
EM jiang@wald.ucdavis.edu; nguythua@ohsu.edu; JRao@biostat.med.miami.edu
FU NSFNational Science Foundation (NSF) [SES-1121794, SES-1118469,
   SES-1122399]; NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01-GM085205A1];
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000460] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   GENERAL MEDICAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of General Medical Sciences (NIGMS) [R01GM085205] Funding Source: NIH
   RePORTER; Direct For Mathematical & Physical ScienNational Science
   Foundation (NSF)NSF - Directorate for Mathematical & Physical Sciences
   (MPS) [1513266, 1509557] Funding Source: National Science Foundation
FX The research works of Jiming Jiang, Thuan Nguyen, and J. Sunil Rao were
   partially supported by the NSF grants SES-1121794, SES-1118469, and
   SES-1122399, respectively. The research works of all three authors were
   partially supported by the NIH grant R01-GM085205A1. The authors are
   grateful to a co-editor, an associate editor, and two referees for their
   valuable comments.
CR AFIFI AA, 1966, J AM STAT ASSOC, V61, P595, DOI 10.2307/2282773
   Bondell HD, 2010, BIOMETRICS, V66, P1069, DOI 10.1111/j.1541-0420.2010.01391.x
   Booth JG, 1999, J ROY STAT SOC B, V61, P265, DOI 10.1111/1467-9868.00176
   BOX GEP, 1979, J AM STAT ASSOC, V74, P1, DOI 10.2307/2286713
   Broman KW, 2002, J R STAT SOC B, V64, P641, DOI 10.1111/1467-9868.00354
   Bueso MC, 1999, J STAT PLAN INFER, V76, P273, DOI 10.1016/S0378-3758(98)00112-8
   Cavanaugh JE, 1998, J STAT PLAN INFER, V67, P45, DOI 10.1016/S0378-3758(97)00115-8
   Claeskens G, 2003, J AM STAT ASSOC, V98, P900, DOI 10.1198/016214503000000819
   Claeskens G, 2008, BIOMETRICS, V64, P1062, DOI 10.1111/j.1541-0420.2008.01003.x
   Copas J, 2005, J R STAT SOC B, V67, P459, DOI 10.1111/j.1467-9868.2005.00512.x
   DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x
   Fan JQ, 2001, J AM STAT ASSOC, V96, P1348, DOI 10.1198/016214501753382273
   FUCHS C, 1982, J AM STAT ASSOC, V77, P270, DOI 10.2307/2287230
   Garcia RI, 2010, STAT SINICA, V20, P149
   HARTLEY HO, 1971, BIOMETRICS, V27, P783, DOI 10.2307/2528820
   HAYES PM, 1993, THEOR APPL GENET, V87, P392, DOI 10.1007/BF01184929
   Hens N, 2006, STAT MED, V25, P2502, DOI 10.1002/sim.2559
   Ibrahim JG, 2011, BIOMETRICS, V67, P495, DOI 10.1111/j.1541-0420.2010.01463.x
   Ibrahim JG, 2008, J AM STAT ASSOC, V103, P1648, DOI 10.1198/016214508000001057
   JANSEN RC, 1993, GENETICS, V135, P205
   Jiang J, 2007, SPRINGER SER STAT, P1, DOI 10.1007/978-0-387-47946-0
   Jiang JM, 2008, ANN STAT, V36, P1669, DOI 10.1214/07-AOS517
   Jiang JM, 2011, STAT INTERFACE, V4, P403
   Jiang JM, 2011, J AM STAT ASSOC, V106, P732, DOI 10.1198/jasa.2011.tm10221
   Jiang JM, 2009, STAT PROBABIL LETT, V79, P625, DOI 10.1016/j.spl.2008.10.014
   Jiang JM, 2002, ANN STAT, V30, P1782, DOI 10.1214/aos/1043351257
   Jiang JM, 1997, ANN STAT, V25, P1781
   LANDER ES, 1989, GENETICS, V121, P185
   Little R. J., 2019, STAT ANAL MISSING DA, V793
   Liu J.S., 2004, MONTE CARLO STRATEGI
   Luo ZW, 2007, GENETICS, V176, P789, DOI 10.1534/genetics.106.067843
   Mou J., 2012, THESIS
   Muller S, 2013, STAT SCI, V28, P135, DOI 10.1214/12-STS410
   Muller S, 2010, INT STAT REV, V78, P240, DOI 10.1111/j.1751-5823.2010.00108.x
   Muller S, 2005, J AM STAT ASSOC, V100, P1297, DOI 10.1198/016214505000000529
   NISHII R, 1984, ANN STAT, V12, P758, DOI 10.1214/aos/1176346522
   Pang Z., 2014, J COMPUTATIONAL GRAP, V22, P341
   RISSANEN J, 1983, ANN STAT, V11, P416, DOI 10.1214/aos/1176346150
   ROBINS JM, 1995, J AM STAT ASSOC, V90, P106, DOI 10.2307/2291134
   Rotnitzky A, 1998, J AM STAT ASSOC, V93, P1321, DOI 10.2307/2670049
   RUBIN DB, 1976, BIOMETRIKA, V63, P581, DOI 10.1093/biomet/63.3.581
   Schomaker M, 2010, COMPUT STAT DATA AN, V54, P3336, DOI 10.1016/j.csda.2009.07.023
   Sebastiani P, 2001, J AM STAT ASSOC, V96, P1375, DOI 10.1198/016214501753382291
   Seghouane AK, 2005, SIGNAL PROCESS, V85, P1405, DOI 10.1016/j.sigpro.2005.02.004
   SHIBATA R, 1984, BIOMETRIKA, V71, P43, DOI 10.1093/biomet/71.1.43
   Shimodaira H., 1994, LECT NOTES STAT, V89, P21
   Nguyen T, 2014, J STAT COMPUT SIM, V84, P644, DOI 10.1080/00949655.2012.721885
   Tibshirani R. J., 1996, J R STAT SOC B, V16, P385
   Torok N.J., 2014, ADV HEPATOL, DOI [10.1155/2014/742931, DOI 10.1155/2014/742931]
   Van Buuren S, 2006, J STAT COMPUT SIM, V76, P1049, DOI 10.1080/10629360600810434
   Verbeke G, 2008, STAT SCI, V23, P201, DOI 10.1214/07-STS253
   ZENG ZB, 1993, P NATL ACAD SCI USA, V90, P10972, DOI 10.1073/pnas.90.23.10972
   Zhan HM, 2011, BIOINFORMATICS, V27, P63, DOI 10.1093/bioinformatics/btq558
NR 53
TC 10
Z9 10
U1 1
U2 20
PU AMER STATISTICAL ASSOC
PI ALEXANDRIA
PA 732 N WASHINGTON ST, ALEXANDRIA, VA 22314-1943 USA
SN 0162-1459
EI 1537-274X
J9 J AM STAT ASSOC
JI J. Am. Stat. Assoc.
PD SEP
PY 2015
VL 110
IS 511
BP 1136
EP 1147
DI 10.1080/01621459.2014.948545
PG 12
WC Statistics & Probability
SC Mathematics
GA CW6YO
UT WOS:000365144600023
PM 26783375
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Ricciardi, MJ
   Magnani, DM
   Grifoni, A
   Kwon, YC
   Gutman, MJ
   Grubaugh, ND
   Gangavarapu, K
   Sharkey, M
   Silveira, CGT
   Bailey, VK
   Pedreno-Lopez, N
   Gonzalez-Nieto, L
   Maxwell, HS
   Domingues, A
   Martins, MA
   Pham, J
   Weiskopf, D
   Altman, J
   Kallas, EG
   Andersen, KG
   Stevenson, M
   Lichtenberger, P
   Choe, H
   Whitehead, SS
   Sette, A
   Watkins, DI
AF Ricciardi, Michael J.
   Magnani, Diogo M.
   Grifoni, Alba
   Kwon, Young-Chan
   Gutman, Martin J.
   Grubaugh, Nathan D.
   Gangavarapu, Karthik
   Sharkey, Mark
   Silveira, Cassia G. T.
   Bailey, Varian K.
   Pedreno-Lopez, Nuria
   Gonzalez-Nieto, Lucas
   Maxwell, Helen S.
   Domingues, Aline
   Martins, Mauricio A.
   Pham, John
   Weiskopf, Daniela
   Altman, John
   Kallas, Esper G.
   Andersen, Kristian G.
   Stevenson, Mario
   Lichtenberger, Paola
   Choe, Hyeryun
   Whitehead, Stephen S.
   Sette, Alessandro
   Watkins, David I.
TI Ontogeny of the B- and T-cell response in a primary Zika virus infection
   of a dengue-naive individual during the 2016 outbreak in Miami, FL
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID CROSS-REACTIVITY; STRUCTURAL BASIS; ENHANCEMENT; TRANSMISSION;
   NEUTRALIZATION; RHESUS; REPLICATION; EMERGENCE; MODEL
AB Zika virus (ZIKV) is a mosquito-borne flavivirus of significant public health concern. In the summer of 2016, ZIKV was first detected in the contiguous United States. Here we present one of the first cases of a locally acquired ZIKV infection in a dengue-naive individual. We collected blood from a female with a maculopapular rash at day (D) 5 and D7 post onset of symptoms (POS) and we continued weekly blood draws out to D148 POS. To establish the ontogeny of the immune response against ZIKV, lymphocytes and plasma were analyzed in a longitudinal fashion. The plasmablast response peaked at D7 POS (19.6% of CD19(+) B-cells) and was undetectable by D15 POS. ZIKV-specific IgM was present at D5 POS, peaked between D15 and D21 POS, and subsequently decreased. The ZIKV-specific IgG response, however, was not detected until D15 POS and continued to increase after that. Interestingly, even though the patient had never been infected with dengue virus (DENV), cross-reactive IgM and IgG binding against each of the four DENV serotypes could be detected. The highest plasma neutralization activity against ZIKV peaked between D15 and D21 POS, and even though DENV binding antibodies were present in the plasma of the patient, there was neither neutralization nor antibody dependent enhancement (ADE) of DENV. Interestingly, ADE against ZIKV arose at D48 POS and continued until the end of the study. CD4(+) and CD8(+) T-cells recognized ZIKV-NS2A and ZIKV-E, respectively. The tetramer positive CD8(+) T-cell response peaked at D21 POS with elevated levels persisting for months. In summary, this is the first study to establish the timing of the ontogeny of the immune response against ZIKV.
C1 [Ricciardi, Michael J.; Magnani, Diogo M.; Gutman, Martin J.; Bailey, Varian K.; Pedreno-Lopez, Nuria; Gonzalez-Nieto, Lucas; Maxwell, Helen S.; Domingues, Aline; Martins, Mauricio A.; Watkins, David I.] Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL 33136 USA.
   [Grifoni, Alba; Pham, John; Weiskopf, Daniela; Sette, Alessandro] La Jolla Inst Allergy & Immunol, Div Vaccine Discovery, La Jolla, CA USA.
   [Kwon, Young-Chan; Choe, Hyeryun] Scripps Res Inst, Dept Immunol & Microbial Sci, Jupiter, FL USA.
   [Grubaugh, Nathan D.; Gangavarapu, Karthik; Andersen, Kristian G.] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA.
   [Sharkey, Mark; Stevenson, Mario; Lichtenberger, Paola] Univ Miami, Miller Sch Med, Div Infect Dis, Miami, FL 33136 USA.
   [Silveira, Cassia G. T.; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, SP, Brazil.
   [Altman, John] Emory Univ, Dept Microbiol & Immunol, Atlanta, GA 30322 USA.
   [Altman, John] Emory Univ, Emory Vaccine Res Ctr, Atlanta, GA 30322 USA.
   [Whitehead, Stephen S.] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
RP Ricciardi, MJ (corresponding author), Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL 33136 USA.
EM mricciardi@med.miami.edu
RI Whitehead, Stephen/AAG-2787-2019; Grifoni, Alba/AAS-7620-2021; Lopez,
   Nuria Pedreno/AAG-9496-2021; Martins, Mauricio/AAU-9226-2020
OI Lopez, Nuria Pedreno/0000-0001-6927-2301; Martins,
   Mauricio/0000-0001-8336-216X; , Alba/0000-0002-2209-5966; Grubaugh,
   Nathan/0000-0003-2031-1933; Weiskopf, Daniela/0000-0003-2968-7371;
   Magnani, Diogo/0000-0002-1773-2406; Kallas, Esper/0000-0003-2026-6925
FU U.S. National Institutes of HealthUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA
   [1P01AI094420-05]; University of Miami Clinical Translational Research
   Institute (CTSI); U.S, National Institutes for HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [HHSN27220140045C, 1P01AI106695-01A1, U19AI118626-01]; EUEuropean
   Commission [734584]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1TR000460] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [T32AI007244, U19AI118626, ZIAAI000987] Funding Source:
   NIH RePORTER
FX This work was supported by a grant from the U.S. National Institutes of
   Health supplement to 1P01AI094420-05 awarded to D.I.W., and an internal
   grant from the University of Miami Clinical Translational Research
   Institute (CTSI) [http://www.miamictsi.org]. Additional support was
   provided by the U.S, National Institutes for Health grants
   HHSN27220140045C, 1P01AI106695-01A1, U19AI118626-01, and the EU-grant
   734584 to A.S. The views expressed are those of the authors and not
   necessarily those of the funding bodies. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Akondy RS, 2009, J IMMUNOL, V183, P7919, DOI 10.4049/jimmunol.0803903
   [Anonymous], 2016, FLOR INV LINKS 4 REC
   Beltramello M, 2010, CELL HOST MICROBE, V8, P271, DOI 10.1016/j.chom.2010.08.007
   Bierlaire D, 2017, TRANSFUSION
   Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Brasil P, 2016, LANCET, V387, P1482, DOI 10.1016/S0140-6736(16)30058-7
   CALISHER CH, 1989, J GEN VIROL, V70, P37, DOI 10.1099/0022-1317-70-1-37
   Camacho E, 2016, EMERG INFECT DIS, V22, P927, DOI 10.3201/eid2205.160023
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Pro SC, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/763461
   Case Counts in the US, 2016, THE CENTERS FOR DISE
   Coffey LL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171148
   Cugola FR, 2016, NATURE, V534, P267, DOI 10.1038/nature18296
   de Alwis R, 2014, METHODS MOL BIOL, V1138, P27, DOI 10.1007/978-1-4939-0348-1_3
   de Alwis R, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001188
   Dejnirattisai W, 2016, NAT IMMUNOL, V17, P1102, DOI 10.1038/ni.3515
   Dejnirattisai W, 2010, SCIENCE, V328, P745, DOI 10.1126/science.1185181
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Dowd KA, 2011, VIROLOGY, V411, P306, DOI 10.1016/j.virol.2010.12.020
   Dudley DM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12204
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Durbin AP, 2001, AM J TROP MED HYG, V65, P405, DOI 10.4269/ajtmh.2001.65.405
   FIELDS BN, 1990, FIELDS VIROLOGY
   Friberg H, 2011, SCI REP-UK, V1, DOI 10.1038/srep00051
   Grifoni A, J VIROL IN PRESS
   Grubaugh ND, 2017, NATURE, V546, P401, DOI 10.1038/nature22400
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   HALSTEAD SB, 1976, P SOC EXP BIOL MED, V151, P136, DOI 10.3181/00379727-151-39160
   HALSTEAD SB, 1973, NATURE-NEW BIOL, V243, P24
   HALSTEAD SB, 1979, J INFECT DIS, V140, P527, DOI 10.1093/infdis/140.4.527
   HALSTEAD SB, 1977, J EXP MED, V146, P201, DOI 10.1084/jem.146.1.201
   Hayes EB, 2009, EMERG INFECT DIS, V15, P1347, DOI 10.3201/eid1509.090442
   Hirsch AJ, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006219
   Huerta-Cepas J, 2016, MOL BIOL EVOL, V33, P1635, DOI 10.1093/molbev/msw046
   Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010
   Kearse M, 2012, BIOINFORMATICS, V28, P1647, DOI 10.1093/bioinformatics/bts199
   Keasey SL, 2017, CLIN VACCINE IMMUNOL, V24, DOI 10.1128/CVI.00036-17
   Kraemer MUG, 2015, ELIFE, V4, DOI 10.7554/eLife.08347
   Kraus AA, 2007, J CLIN MICROBIOL, V45, P3777, DOI 10.1128/JCM.00827-07
   Krow-Lucal ER, 2017, EMERG INFECT DIS, V23
   Lazear HM, 2016, CELL HOST MICROBE, V19, P720, DOI 10.1016/j.chom.2016.03.010
   Lazear HM, 2016, J VIROL, V90, P4864, DOI 10.1128/JVI.00252-16
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Likos A, 2016, MMWR-MORBID MORTAL W, V65, P1032, DOI 10.15585/mmwr.mm6538e1
   Mansfield KL, 2011, J GEN VIROL, V92, P2821, DOI 10.1099/vir.0.031641-0
   Mansuy JM, 2017, EMERG INFECT DIS, V23, P863, DOI 10.3201/eid2305.161631
   MCCRAE AWR, 1982, T ROY SOC TROP MED H, V76, P552, DOI 10.1016/0035-9203(82)90161-4
   Metsky HC, 2017, NATURE, V546, P411, DOI 10.1038/nature22402
   Miner JJ, 2016, CELL, V165, P1080, DOI 10.1016/j.cell.2016.05.008
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Monaghan AJ, 2016, PLOS CURR, P8
   Mongkolsapaya J, 2003, NAT MED, V9, P921, DOI 10.1038/nm887
   MORLAN HB, 1965, AM J TROP MED HYG, V14, P892, DOI 10.4269/ajtmh.1965.14.892
   Musso D, 2014, CLIN MICROBIOL INFEC, V20, pO595, DOI 10.1111/1469-0691.12707
   Musso D, 2015, J CLIN VIROL, V68, P53, DOI 10.1016/j.jcv.2015.04.021
   Nguyen TPD, 2010, J IMMUNOL, V184, P7281, DOI 10.4049/jimmunol.0903262
   Nybakken GE, 2005, NATURE, V437, P764, DOI 10.1038/nature03956
   Osuna CE, 2016, NAT MED, V22, P1448, DOI 10.1038/nm.4206
   Parra B, 2016, NEW ENGL J MED, V375, P1513, DOI 10.1056/NEJMoa1605564
   Paz-Bailey G., 2017, N ENGL J MED
   Priyamvada L, 2016, P NATL ACAD SCI USA, V113, P7852, DOI 10.1073/pnas.1607931113
   Priyamvada L, 2016, J VIROL, V90, P5574, DOI 10.1128/JVI.03203-15
   Quick J, 2017, NAT PROTOC, V12, P1261, DOI 10.1038/nprot.2017.066
   Richard AS, 2017, P NATL ACAD SCI USA, V114, P2024, DOI 10.1073/pnas.1620558114
   Sapparapu G, 2016, NATURE, V540, P443, DOI 10.1038/nature20564
   Sarno M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004517
   Sikka V, 2016, J GLOB INFECT DIS, V8, P3, DOI 10.4103/0974-777X.176140
   SIMPSON D. I. H., 1964, TRANS ROY SOC TROP MED HYG, V58, P335, DOI 10.1016/0035-9203(64)90201-9
   Stettler K, 2016, SCIENCE, V353, P823, DOI 10.1126/science.aaf8505
   Tripathi S, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006258
   van der Eijk AA, 2016, NEW ENGL J MED, V375, P1002, DOI 10.1056/NEJMc1605898
   Vasilakis N, 2017, CURR OPIN VIROL, V22, P30, DOI 10.1016/j.coviro.2016.11.007
   Weiskopf D, 2015, J INFECT DIS, V212, P1743, DOI 10.1093/infdis/jiv289
   Weiskopf D, 2015, P NATL ACAD SCI USA, V112, pE4256, DOI 10.1073/pnas.1505956112
   Weiskopf D, 2013, P NATL ACAD SCI USA, V110, pE2046, DOI 10.1073/pnas.1305227110
   Wen JS, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.36
   Wrammert J, 2012, J VIROL, V86, P2911, DOI 10.1128/JVI.06075-11
   Xu MH, 2012, J IMMUNOL, V189, P5877, DOI 10.4049/jimmunol.1201688
   YANG ZH, 1994, J MOL EVOL, V39, P306, DOI 10.1007/BF00160154
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
   Zhao HY, 2016, CELL, V166, P1016, DOI 10.1016/j.cell.2016.07.020
NR 82
TC 27
Z9 27
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD DEC
PY 2017
VL 11
IS 12
AR e0006000
DI 10.1371/journal.pntd.0006000
PG 23
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA FR5LR
UT WOS:000419108500004
PM 29267278
OA gold, Green Published, Green Submitted
DA 2021-10-30
ER

PT J
AU Chopra, A
   Jung, M
   Kaplan, RC
   Appel, DW
   Dinces, EA
   Dhar, S
   Zee, PC
   Gonzalez, F
   Lee, DJ
   Ramos, AR
   Hoffman, HJ
   Redline, S
   Cruickshanks, KJ
   Shah, NA
AF Chopra, Amit
   Jung, Molly
   Kaplan, Robert C.
   Appel, David W.
   Dinces, Elizabeth A.
   Dhar, Sumitrajit
   Zee, Phyllis C.
   Gonzalez, Franklyn, II
   Lee, David J.
   Ramos, Alberto R.
   Hoffman, Howard J.
   Redline, Susan
   Cruickshanks, Karen J.
   Shah, Neomi A.
TI Sleep Apnea Is Associated with Hearing Impairment: The Hispanic
   Community Health Study/Study of Latinos
SO JOURNAL OF CLINICAL SLEEP MEDICINE
LA English
DT Article
DE sleep apnea; hearing impairment
ID NUTRITION EXAMINATION SURVEY; UNITED-STATES; OLDER-ADULTS; RISK-FACTORS;
   DISEASE; DEATH; PREVALENCE; PATHWAYS; DEMENTIA; EVENTS
AB Study Objective: Sleep apnea (SA) may promote hearing impairment (HI) through ischemia and inflammation of the cochlea. Our objective was to assess an independent association between SA and HI in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) participants.
   Methods: We used data from the HCHS/SOL, a multicenter population-based study of self-identifying Hispanic/Latinos 18-to 74-y-old adults from four US urban communities. We performed home SA testing and in-clinic audiometry testing in all participants. SA was defined as an apnea-hypopnea index (AHI) >= 15 events/h. HI was defined as a mean hearing threshold > 25 dB hearing level in either ear at the frequencies: 3,000 to 8,000 Hz for high-frequency HI (HF-HI) and 500 to 2,000 Hz for low-frequency HI (LF-HI). Combined-frequency HI (CF-HI) was defined as both conditions present, and Any-HI was considered as HI in either low or high frequencies.
   Results: Of 13,967 participants, 9.9% had SA and 32.3% had Any-HI. Adjusted for risk factors for HI, those with SA had a 30% higher odds of Any-HI (95% confidence interval [CI] = 8% to 57%), 26% higher odds of HF-HI (CI = 3% to 55%), 127% higher odds of LF-HI (CI = 21% to 326%), and 29% higher odds of CF-HI (CI = 0% to 65%). A dose-response association was observed between AHI severity and Any-HI (versus no SA, OR for AHI = 15 and < 30 = 1.22, CI = 0.96 to 1.54, and OR for AHI = 30 = 1.46, CI = 1.11 to 1.91, p = 0.002).
   Conclusion: SA is associated with HF-HI and LF-HI, independent of snoring and other confounders.
C1 [Chopra, Amit] Albany Med Ctr Hosp, Albany, NY 12208 USA.
   [Jung, Molly; Kaplan, Robert C.] Albert Einstein Coll Med, Bronx, NY 10467 USA.
   [Appel, David W.; Dinces, Elizabeth A.] Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA.
   [Dhar, Sumitrajit; Zee, Phyllis C.] Northwestern Univ, Evanston, IL USA.
   [Gonzalez, Franklyn, II] Univ N Carolina, Chapel Hill, NC USA.
   [Lee, David J.; Ramos, Alberto R.] Univ Miami, Miami, FL USA.
   [Hoffman, Howard J.] NIDCD, NIH, Bethesda, MD USA.
   [Redline, Susan] Harvard Univ, Sch Med, Boston, MA USA.
   [Cruickshanks, Karen J.] Univ Wisconsin, Madison, WI USA.
   [Shah, Neomi A.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
RP Chopra, A (corresponding author), Albany Med Coll, Dept Med, Div Pulm & Crit Care Med, Med, MC-91,47 New Scotland Ave, Albany, NY 12208 USA.
EM chopraa1@mail.amc.edu
RI Dhar, Sumit/B-6319-2009; Ramos, Alberto/X-4249-2019
OI Dhar, Sumitrajit/0000-0002-4496-6355
FU National Heart, Lung, and Blood Institute (NHLBI)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [N01-HC65233,
   N01-HC65234, N01-HC65235, N01-HC65236, N01-HC65237]; National Institute
   on Minority Health and Health DisparitiesUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Minority Health & Health Disparities (NIMHD);
   National Institute on Deafness and Other Communication DisordersUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute on Deafness & Other
   Communication Disorders (NIDCD); National Institute of Dental and
   Craniofacial ResearchUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Dental & Craniofacial Research (NIDCR); National Institute of
   Diabetes and Digestive and Kidney DiseasesUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK);
   National Institute of Neurological Disorders and StrokeUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Neurological Disorders & Stroke (NINDS);
   NIH Institution-Office of Dietary SupplementsUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA;
   JazzJazz Pharmaceuticals; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [KL2TR000461] Funding Source: NIH
   RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [T32HL007024,
   K23HL125923] Funding Source: NIH RePORTER
FX The Hispanic Community Health Study/Study of Latinos was carried out as
   a collaborative study supported by contracts from the National Heart,
   Lung, and Blood Institute (NHLBI) to the University of North Carolina
   (N01-HC65233), University of Miami (N01-HC65234), Albert Einstein
   College of Medicine (N01-HC65235), Northwestern University
   (N01-HC65236), and San Diego State University (N01-HC65237). The
   following Institutes/Centers/Offices contribute to the HCHS/SOL through
   a transfer of funds to the NHLBI: National Institute on Minority Health
   and Health Disparities, National Institute on Deafness and Other
   Communication Disorders, National Institute of Dental and Craniofacial
   Research, National Institute of Diabetes and Digestive and Kidney
   Diseases, National Institute of Neurological Disorders and Stroke, NIH
   Institution-Office of Dietary Supplements. Dr. Redline has received
   grant/research funds from Jazz. Dr. Ramos has consulted for MCMC, LLC,
   MRioA, Inc, and Comppartners. Dr. Zee has consulted for Merck, Vanda,
   Jazz, and Philips and is a stock holder of Teva. The other authors have
   indicated no financial conflicts of interest.
CR Agrawal Y, 2009, OTOL NEUROTOL, V30, P139, DOI 10.1097/MAO.0b013e318192483c
   American National Standards Institute, 2010, SPEC AUD
   American Speech and Language-Hearing Association, 1987, GUID MAN PUR TON AUD, V20, P287
   Ayappa I, 2008, J CLIN SLEEP MED, V4, P26
   Berry RB, 2012, J CLIN SLEEP MED, V8, P597, DOI 10.5664/jcsm.2172
   Cruickshanks KJ, 2015, JAMA OTOLARYNGOL, V141, P641, DOI 10.1001/jamaoto.2015.0889
   Dalton DS, 2003, GERONTOLOGIST, V43, P661, DOI 10.1093/geront/43.5.661
   Dyken ME, 2009, CHEST, V136, P1668, DOI 10.1378/chest.08-1512
   Gami AS, 2005, NEW ENGL J MED, V352, P1206, DOI 10.1056/NEJMoa041832
   Gottlieb DJ, 2010, CIRCULATION, V122, P352, DOI 10.1161/CIRCULATIONAHA.109.901801
   Grigg-Damberger MM, 2012, J CLIN SLEEP MED, V8, P323, DOI 10.5664/jcsm.1928
   Gurgel RK, 2014, OTOL NEUROTOL, V35, P775, DOI 10.1097/MAO.0000000000000313
   HERBST KG, 1980, BMJ-BRIT MED J, V281, P903, DOI 10.1136/bmj.281.6245.903
   Hoffstein V, 1999, AM J RESP CRIT CARE, V159, P1351, DOI 10.1164/ajrccm.159.4.9808147
   Hwang JH, 2011, OTOLARYNG HEAD NECK, V144, P114, DOI 10.1177/0194599810390859
   Kaplan RC, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.000923
   Kato M, 2000, CIRCULATION, V102, P2607
   Lavange LM, 2010, ANN EPIDEMIOL, V20, P642, DOI 10.1016/j.annepidem.2010.05.006
   LEE DJ, 1991, AM J PUBLIC HEALTH, V81, P1471, DOI 10.2105/AJPH.81.11.1471
   Lin FR, 2011, ARCH INTERN MED, V171, P1851, DOI 10.1001/archinternmed.2011.506
   Lopez-Jimenez F, 2008, CHEST, V133, P793, DOI 10.1378/chest.07-0800
   Louis J, 2012, OBSTET GYNECOL, V120, P1085, DOI 10.1097/AOG.0b013e31826eb9d8
   Mehra R, 2006, AM J RESP CRIT CARE, V173, P910, DOI 10.1164/rccm.200509-1442OC
   Mohr PE, 2000, INT J TECHNOL ASSESS, V16, P1120, DOI 10.1017/S0266462300103162
   Peker Y, 1999, EUR RESPIR J, V14, P179, DOI 10.1034/j.1399-3003.1999.14a30.x
   Peppard PE, 2000, NEW ENGL J MED, V342, P1378, DOI 10.1056/NEJM200005113421901
   PRAZIC M, 1973, ACTA OTO-LARYNGOL, V75, P216, DOI 10.3109/00016487309139698
   Redline S, 2014, AM J RESP CRIT CARE, V189, P335, DOI 10.1164/rccm.201309-1735OC
   Ryan S, 2005, CIRCULATION, V112, P2660, DOI 10.1161/CIRCULATIONAHA.105.556746
   Shah NA, 2010, SLEEP BREATH, V14, P131, DOI 10.1007/s11325-009-0298-7
   Shahar E, 2001, AM J RESP CRIT CARE, V163, P19, DOI 10.1164/ajrccm.163.1.2001008
   Sheu JJ, 2012, ARCH OTOLARYNGOL, V138, P55, DOI 10.1001/archoto.2011.227
   SIDMAN JD, 1988, ANN OTO RHINOL LARYN, V97, P9, DOI 10.1177/000348948809700102
   Sorlie PD, 2010, ANN EPIDEMIOL, V20, P629, DOI 10.1016/j.annepidem.2010.03.015
   UHLMANN RF, 1989, JAMA-J AM MED ASSOC, V261, P1916, DOI 10.1001/jama.261.13.1916
   Yaggi HK, 2005, NEW ENGL J MED, V353, P2034, DOI 10.1056/NEJMoa043104
   YAMASOBA T, 1993, ANN OTO RHINOL LARYN, V102, P873, DOI 10.1177/000348949310201110
   Yamauchi M, 2008, ANTIOXID REDOX SIGN, V10, P755, DOI 10.1089/ars.2007.1946
NR 38
TC 14
Z9 16
U1 0
U2 12
PU AMER ACAD SLEEP MEDICINE
PI WESTCHESTER
PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA
SN 1550-9389
EI 1550-9397
J9 J CLIN SLEEP MED
JI J. Clin. Sleep Med.
PY 2016
VL 12
IS 5
BP 719
EP 726
DI 10.5664/jcsm.5804
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA DP2QD
UT WOS:000378333300015
PM 26951413
OA Green Published, Bronze, Green Submitted
DA 2021-10-30
ER

PT J
AU Conner, GE
   Ivonnet, P
   Gelin, M
   Whitney, P
   Salathe, M
AF Conner, Gregory E.
   Ivonnet, Pedro
   Gelin, Murline
   Whitney, Philip
   Salathe, Matthias
TI H2O2 Stimulates Cystic Fibrosis Transmembrane Conductance Regulator
   through an Autocrine Prostaglandin Pathway, Using Multidrug-Resistant
   Protein-4
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Article
DE MRP4; H2O2; CFTR; EP4; EP1
ID HYDROGEN-PEROXIDE PRODUCTION; AIRWAY EPITHELIAL-CELLS; ANION SECRETION;
   OXIDANT STRESS; EP1 RECEPTOR; HOST-DEFENSE; K+ CHANNELS; EXPRESSION;
   TRANSPORT; POTENT
AB Cystic fibrosis transmembrane conductance regulator (CFTR) activity is essential for the maintenance of airway surface liquid depth, and therefore mucociliary clearance. Reactive oxygen species, increased during inflammatory airway diseases, alter CFTR activity. Here, H2O2 levels in the surface liquid of normal human bronchial epithelial cultures differentiated at the air-liquid interface were estimated, and H2O2-mediated changes in CFTR activity were examined. In Ussing chambers, H2O2-induced anion currents were sensitive to the CFTR inhibitors CFTR(inh)172 and GlyH-101. These currents were absent in cells from patients with cystic fibrosis. Responses to greater than 500 mM H2O2 were transient. Cyclooxygenase inhibitors blocked the H2O2 response, as did EP1 and EP4 receptor antagonists. Amultidrug-resistant protein (MRP) inhibitor and short hairpin RNA directed against MRP4 blocked H2O2 responses. EP1 and EP4 agonists mimicked H2O2 in both control and MRP4 knockdown cells. Thus, H2O2 activates the synthesis, export, and binding of prostanoids via EP4 and, interestingly, EP1 receptors in normal, differentiated human airway epithelial cells to activate cyclic adenosine monophosphate pathways that in turn activate CFTR channels in the apical membrane.
C1 [Conner, Gregory E.; Ivonnet, Pedro; Gelin, Murline; Whitney, Philip; Salathe, Matthias] Univ Miami, Miller Sch Med, Dept Med, Div Pulm Allergy Crit Care & Sleep Med, Miami, FL 33101 USA.
   [Conner, Gregory E.] Univ Miami, Miller Sch Med, Dept Cell Biol, Miami, FL 33101 USA.
RP Salathe, M (corresponding author), Univ Miami, Miller Sch Med, Dept Med, Div Pulm Allergy Crit Care & Sleep Med, POB 016960, Miami, FL 33101 USA.
EM msalathe@med.miami.edu
RI Conner, Gregory/AAI-1285-2021
OI Conner, Gregory/0000-0003-2217-2252; Salathe,
   Matthias/0000-0001-9092-4861
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [HL-66125, HL-60644,
   HL-89399]; Flight Attendant's Medical Research Institute [092061,
   103027]; James and Esther King Biomedical Research Program; NATIONAL
   CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000460] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND
   BLOOD INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [R01HL089399, R01HL066125, R01HL060644]
   Funding Source: NIH RePORTER
FX This work was supported by National Institutes of Health grants HL-66125
   (G. E. C.) and HL-60644 and HL-89399 (M. S.), Flight Attendant's Medical
   Research Institute grants 092061 (G. E. C.) and 103027 (M. S.), and the
   James and Esther King Biomedical Research Program (G.E.C.).
CR Abramovitz M, 2000, BBA-MOL CELL BIOL L, V1483, P285, DOI 10.1016/S1388-1981(99)00164-X
   Ameziane-El-Hassani R, 2005, J BIOL CHEM, V280, P30046, DOI 10.1074/jbc.M500516200
   Bernacki SH, 1999, AM J RESP CELL MOL, V20, P595, DOI 10.1165/ajrcmb.20.4.3442
   Billot X, 2003, BIOORG MED CHEM LETT, V13, P1129, DOI 10.1016/S0960-894X(03)00042-8
   Boots AW, 2009, J BIOL CHEM, V284, P17858, DOI 10.1074/jbc.M809761200
   Boucher RC, 2007, TRENDS MOL MED, V13, P231, DOI 10.1016/j.molmed.2007.05.001
   Boucher RC, 2007, ANNU REV MED, V58, P157, DOI 10.1146/annurev.med.58.071905.105316
   Brenneis C, 2006, FASEB J, V20, P1352, DOI 10.1096/fj.05-5346com
   Button B, 2007, J PHYSIOL-LONDON, V580, P577, DOI 10.1113/jphysiol.2006.126086
   Clarke DL, 2005, AM J PHYSIOL-LUNG C, V288, pL238, DOI 10.1152/ajplung.00313.2004
   Conner GE, 2007, FEBS LETT, V581, P271, DOI 10.1016/j.febslet.2006.12.025
   Cowley EA, 2002, J PHYSIOL-LONDON, V543, P201, DOI 10.1113/jphysiol.2002.022400
   Cowley EA, 2002, J PHYSIOL-LONDON, V538, P747, DOI 10.1113/jphysiol.2001.013300
   Dazy AC, 2003, TOXICOL IN VITRO, V17, P575, DOI 10.1016/S0887-2333(03)00092-4
   Fischer H, 2009, ANTIOXID REDOX SIGN, V11, P2453, DOI [10.1089/ars.2009.2558, 10.1089/ARS.2009.2558]
   Forteza R, 2005, AM J RESP CELL MOL, V32, P462, DOI 10.1165/rcmb.2004-0302OC
   Gattas MV, 2009, FREE RADICAL BIO MED, V47, P1450, DOI 10.1016/j.freeradbiomed.2009.08.017
   Gray T, 2004, AM J PHYSIOL-LUNG C, V286, pL320, DOI 10.1152/ajplung.00440.2002
   Harper RW, 2006, FEBS LETT, V580, P5150, DOI 10.1016/j.febslet.2006.08.048
   Harper RW, 2005, FEBS LETT, V579, P4911, DOI 10.1016/j.febslet.2005.08.002
   Harvey PR, 2011, AM J RESP CELL MOL, V45, P592, DOI 10.1165/rcmb.2010-0484OC
   HEMLER ME, 1979, ARCH BIOCHEM BIOPHYS, V193, P340, DOI 10.1016/0003-9861(79)90038-9
   Huang Pingbo, 2004, Proc Am Thorac Soc, V1, P33, DOI 10.1513/pats.2306012
   Jones CL, 2012, J PHARMACOL EXP THER, V341, P552, DOI 10.1124/jpet.111.187138
   Jones RL, 2009, BRIT J PHARMACOL, V158, P104, DOI 10.1111/j.1476-5381.2009.00317.x
   Joy AP, 2008, AM J RESP CELL MOL, V38, P143, DOI 10.1165/rcmb.2006-0295OC
   LAWRENCE RA, 1992, BRIT J PHARMACOL, V105, P271, DOI 10.1111/j.1476-5381.1992.tb14245.x
   Li CY, 2007, CELL, V131, P940, DOI 10.1016/j.cell.2007.09.037
   Li CY, 2011, METHODS MOL BIOL, V741, P255, DOI 10.1007/978-1-61779-117-8_17
   Li CY, 2010, INTEGR BIOL-UK, V2, P161, DOI [10.1039/b924455g, 10.1039/B924455G]
   Mall M, 2000, AM J RESP CELL MOL, V23, P283, DOI 10.1165/ajrcmb.23.3.4060
   Manzanares D, 2011, J BIOL CHEM, V286, P19830, DOI 10.1074/jbc.M110.185074
   Matlhagela K, 2006, PROSTAG OTH LIPID M, V79, P101, DOI 10.1016/j.prostaglandins.2005.12.002
   Matsui H, 1998, CELL, V95, P1005, DOI 10.1016/S0092-8674(00)81724-9
   Moskwa P, 2007, AM J RESP CRIT CARE, V175, P174, DOI 10.1164/rccm.200607-1029OC
   Nlend MC, 2002, AM J RESP CELL MOL, V27, P436, DOI 10.1165/rcmb.2002-0012OC
   Ohashi T, 2006, J PHARMACOL EXP THER, V318, P296, DOI 10.1124/jpet.106.102541
   Okada SF, 2011, AM J RESP CELL MOL, V45, P253, DOI 10.1165/rcmb.2010-0253OC
   Perreira M, 2005, J MED CHEM, V48, P4910, DOI 10.1021/jm050221l
   Pezzulo AA, 2011, AM J PHYSIOL-LUNG C, V300, pL25, DOI 10.1152/ajplung.00256.2010
   Rada B, 2010, FEBS LETT, V584, P917, DOI 10.1016/j.febslet.2010.01.025
   Rahman I, 2006, EUR J PHARMACOL, V533, P222, DOI 10.1016/j.ejphar.2005.12.087
   Reid G, 2003, MOL PHARMACOL, V63, P1094, DOI 10.1124/mol.63.5.1094
   Rutkai I, 2009, CARDIOVASC RES, V83, P148, DOI 10.1093/cvr/cvp098
   Salathe M, 2007, ANNU REV PHYSIOL, V69, P401, DOI 10.1146/annurev.physiol.69.040705.141253
   Schmid A, 2006, J CELL SCI, V119, P4176, DOI 10.1242/jcs.03181
   Seto V, 2008, AM J RESP CELL MOL, V38, P88, DOI 10.1165/rcmb.2007-0117OC
   Tang CH, 2005, J BIOL CHEM, V280, P22907, DOI 10.1074/jbc.M500130200
   Wijkstrom-Frei C, 2003, AM J RESP CELL MOL, V29, P206, DOI 10.1165/rcmb.2002-0152OC
NR 49
TC 18
Z9 18
U1 0
U2 5
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1044-1549
EI 1535-4989
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD OCT
PY 2013
VL 49
IS 4
BP 672
EP 679
DI 10.1165/rcmb.2013-0156OC
PG 8
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA 230OQ
UT WOS:000325351700020
PM 23742099
OA Green Published
DA 2021-10-30
ER

PT J
AU Murillo, R
   Reid, KJ
   Arredondo, E
   Cai, JW
   Gellman, MD
   Gotman, NM
   Marquez, DX
   Penedo, FJ
   Ramos, AR
   Zee, PC
   Daviglus, ML
AF Murillo, Rosenda
   Reid, Kathryn J.
   Arredondo, Elvam.
   Cai, Jianwen
   Gellman, Marc D.
   Gotman, Nathan M.
   Marquez, David X.
   Penedo, Frank J.
   Ramos, Alberto R.
   Zee, Phyllis C.
   Daviglus, Martha L.
TI Association of self-reported physical activity with obstructive sleep
   apnea: Results from the Hispanic Community Health Study/Study of Latinos
   (HCHS/SOL)
SO PREVENTIVE MEDICINE
LA English
DT Article
DE Motor activity; Sleep apnea syndromes; Hispanic Americans
ID RISK-FACTORS; EXERCISE; POPULATION; PREVALENCE; ADULTS; DESIGN
AB We examined associations of mild and moderate to severe obstructive sleep apnea (OSA; apnea-hypopnea index >= 5 and >= 15, respectively) with recommended amounts of moderate-vigorous physical activity (MVPA) or vigorous physical activity (VPA) and by type of activity (i.e., recreational, transportation, and work activity). The Hispanic Community Health Study/Study of Latinos (HCHS/SOL), a multicenter population-based study, enrolled individuals from 2008 to 2011 from four U.S. metropolitan areas (Bronx, New York; Chicago, Illinois; Miami, Florida; San Diego, California). Participants in this study included 14,087 self-identified Hispanic/Latino ages 18 to 74 years from the HCHS/SOL. Survey logistic regression analysis was used to compute odds ratios [OR] and 95% confidence intervals [CI], adjusting for sociodemographics, smoking status, and body mass index (BMI). Relative to being inactive, performing some MVPA (>0 to <150 min/week) or meeting the recommended MVPA (>= 150 min/week) were associated with lower odds of mild OSA (ORs and 95% CIs 0.70 [0.61-0.82] and 0.76 [0.63-0.91], respectively), as well as moderate to severe OSA (ORs and 95% CIs 0.76 [0.62-0.93] and 0.76 [0.59-0.98], respectively). Associations of VPA with OSA were not significant. Engaging in medium or high levels of transportation activity was associated with lower odds of mild OSA (OR: 0.84, 95% CI: 0.74-0.96; OR: 0.64, 95% CI: 0.43-0.95, respectively). Performing some recreational MVPA was associated with lower likelihood of mild and moderate to severe OSA (OR: 0.82, 95% CI: 0.71-0.93; OR: 0.79, 95% CI: 0.64-0.97, respectively). Health promotion and OSA prevention efforts should encourage individuals to engage in at least some MVPA. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Murillo, Rosenda] Univ Houston, Dept Psychol Hlth & Learning Sci, 3657 Cullen Blvd,Room 491, Houston, TX 77204 USA.
   [Reid, Kathryn J.] Northwestern Univ, Feinberg Sch Med, Dept Neurol, Abbott Hall 11th Floor,710 N Lake Shore Dr, Chicago, IL 60601 USA.
   [Arredondo, Elvam.] San Diego State Univ, Grad Sch Publ Hlth, Hardy Tower Room 119,5500 Campanile Dr, San Diego, CA 92182 USA.
   [Cai, Jianwen] Univ North Carolina Chapel Hill, Gillings Sch Global Publ Hlth, 3101-D McGavran Greenberg Hall,CB 7420, Chapel Hill, NC 27599 USA.
   [Gellman, Marc D.] Univ Miami, Miller Sch Med, Dept Psychol, Clinical Res Bldg,Room 1518,1120 NW 14th St, Miami, FL 33136 USA.
   [Gotman, Nathan M.] Univ North Carolina Chapel Hill, Gillings Sch Global Publ Hlth, 137 East Franklin St,Suite 200,CB 8030, Chapel Hill, NC 27514 USA.
   [Marquez, David X.] Univ Illinois, Dept Kinesiol & Nutr, 632 Appl Hlth Sci Bldg,1919 W Taylor St, Chicago, IL 60612 USA.
   [Penedo, Frank J.] Northwestern Univ, Feinberg Sch Med, Dept Med Social Sci, 633 N St Clair,Suite 19-000, Chicago, IL 60611 USA.
   [Ramos, Alberto R.] Univ Miami, Miller Sch Med, Dept Neurol, 1120 NW 14 St,Suite 1350, Miami, FL 33136 USA.
   [Zee, Phyllis C.] Northwestern Univ, Feinberg Sch Med, Dept Neurol, Abbott Hall 11th Floor,710 N Lake Shore Dr, Chicago, IL 60601 USA.
   [Daviglus, Martha L.] Univ Illinois, Inst Minor Hlth Res, 1819 W Polk St MC 764,Suite 246, Chicago, IL 60612 USA.
RP Murillo, R (corresponding author), 3657 Cullen Blvd,Room491, Houston, TX 77204 USA.
EM rmurillo3@uh.edu; k-reid@northwestern.edu; earredon@mail.sdsu.edu;
   cai@email.unc.edu; mgellman@miami.edu; nathan.gotman@unc.edu;
   marquezd@uic.edu; fpenedo@northwestern.edu; ramos1@med.miami.edu;
   zee@northwestern.edu; daviglus@uic.edu
RI Ramos, Alberto/X-4249-2019
FU National Heart, Lung, and Blood Institute (NHLBI)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [N01-HC65233,
   N01-HC65234, N01-HC65235, N01-HC65236, N01-HC65237]; National Center on
   Minority Health and Health DisparitiesUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute on Minority Health & Health Disparities (NIMHD); National
   Institute of Deafness and Other Communications DisordersUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Deafness & Other Communication Disorders
   (NIDCD); National Institute of Dental and Craniofacial ResearchUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Dental & Craniofacial
   Research (NIDCR); National Institute of Diabetes and Digestive and
   Kidney DiseasesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institute of
   Neurological Disorders and StrokeUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Neurological Disorders & Stroke (NINDS); Office of Dietary
   SupplementsUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA; DIVISION OF EPIDEMIOLOGY AND CLINICAL
   APPLICATIONSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Eye Institute (NEI)
   [N01HC065233] Funding Source: NIH RePORTER; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [KL2TR000461]
   Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [R01HL065234, U01HL065233] Funding Source: NIH
   RePORTER
FX The Hispanic Community Health Study/Study of Latinos was carried out as
   a collaborative study supported by contracts from the National Heart,
   Lung, and Blood Institute (NHLBI) to the University of North Carolina
   (N01-HC65233), University of Miami (N01-HC65234), Albert Einstein
   College of Medicine (N01-HC65235), Northwestern University
   (N01-HC65236), and San Diego State University (N01-HC65237). The
   following Institutes/Centers/Offices contribute to the HCHS/SOL through
   a transfer of funds to the NHLBI: National Center on Minority Health and
   Health Disparities, the National Institute of Deafness and Other
   Communications Disorders, the National Institute of Dental and
   Craniofacial Research, the National Institute of Diabetes and Digestive
   and Kidney Diseases, the National Institute of Neurological Disorders
   and Stroke, and the Office of Dietary Supplements.
CR Armstrong T, 2006, J PUBLIC HEALTH-HEID, V14, P66, DOI 10.1007/s10389-006-0024-x
   Arredondo EM, 2016, AM J PREV MED, V50, P500, DOI 10.1016/j.amepre.2015.08.029
   Awad KM, 2012, AM J MED, V125, P485, DOI 10.1016/j.amjmed.2011.11.025
   Billings ME, 2016, CHEST
   Carlson SA, 2010, AM J PREV MED, V39, P305, DOI 10.1016/j.amepre.2010.06.006
   Daviglus ML, 2012, JAMA-J AM MED ASSOC, V308, P1775, DOI 10.1001/jama.2012.14517
   Giebelhaus Valentina, 2000, Sleep Breath, V4, P173, DOI 10.1007/s11325-000-0173-z
   He XXZ, 2005, J GEN INTERN MED, V20, P259, DOI 10.1111/j.1525-1497.2005.40198.x
   Kline CE, 2011, SLEEP, V34, P1631, DOI 10.5665/sleep.1422
   Kripke DF, 1997, SLEEP, V20, P65, DOI 10.1093/sleep/20.1.65
   Lavange LM, 2010, ANN EPIDEMIOL, V20, P642, DOI 10.1016/j.annepidem.2010.05.006
   Loredo JS, 2010, SLEEP, V33, P962, DOI 10.1093/sleep/33.7.962
   Marquez DX, 2006, ANN BEHAV MED, V31, P138, DOI 10.1207/s15324796abm3102_5
   Murillo R, 2014, AM J HLTH PROMOT
   Norman J.F., 1999, SLEEP RES ONLINE, V3, P121
   OLSON LG, 1987, AM REV RESPIR DIS, V135, P356
   Peppard PE, 2004, SLEEP, V27, P480, DOI 10.1093/sleep/27.3.480
   Quan SF, 1997, SLEEP, V20, P1077
   Quan SF, 2007, SLEEP BREATH, V11, P149, DOI 10.1007/s11325-006-0095-5
   Redline S., 2014, AM J RESP CRIT CARE
   Robert RE, 2000, J NERV MENT DIS, V188, P222, DOI 10.1097/00005053-200004000-00005
   SCHMIDTNOWARA WW, 1990, ARCH INTERN MED, V150, P597, DOI 10.1001/archinte.150.3.597
   SCHWARTZ RS, 1988, METABOLISM, V37, P1128, DOI 10.1016/0026-0495(88)90188-6
   Sengul YS, 2011, SLEEP BREATH, V15, P49, DOI 10.1007/s11325-009-0311-1
   Shah N, 2009, CLIN CHEST MED, V30, P455, DOI 10.1016/j.ccm.2009.05.012
   Sorajja D, 2008, CHEST, V133, P927, DOI 10.1378/chest.07-2544
   Sorlie PD, 2010, ANN EPIDEMIOL, V20, P629, DOI 10.1016/j.annepidem.2010.03.015
   Tucker JM, 2011, AM J PREV MED, V40, P454, DOI 10.1016/j.amepre.2010.12.016
   USDHHS, 2008, 2008 PHYS ACT GUID A
   Westbrook PR, 2005, CHEST, V128, P2166, DOI 10.1378/chest.128.4.2166
   World Health Organization, 2012, GLOB PHYS ACT QUEST
   Yaggi HK, 2005, NEW ENGL J MED, V353, P2034, DOI 10.1056/NEJMoa043104
   Young T, 2008, SLEEP, V31, P1071
NR 33
TC 8
Z9 8
U1 0
U2 8
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0091-7435
EI 1096-0260
J9 PREV MED
JI Prev. Med.
PD DEC
PY 2016
VL 93
BP 183
EP 188
DI 10.1016/j.ypmed.2016.10.009
PG 6
WC Public, Environmental & Occupational Health; Medicine, General &
   Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA EC8IA
UT WOS:000388383700028
PM 27746338
OA Green Accepted, Green Submitted
DA 2021-10-30
ER

PT J
AU Patel, SR
   Weng, J
   Rueschman, M
   Dudley, KA
   Loredo, JS
   Mossavar-Rahmani, Y
   Ramirez, M
   Ramos, AR
   Reid, K
   Seiger, AN
   Sotres-Alvarez, D
   Zee, PC
   Wang, R
AF Patel, Sanjay R.
   Weng, Jia
   Rueschman, Michael
   Dudley, Katherine A.
   Loredo, Jose S.
   Mossavar-Rahmani, Yasmin
   Ramirez, Maricelle
   Ramos, Alberto R.
   Reid, Kathryn
   Seiger, Ashley N.
   Sotres-Alvarez, Daniela
   Zee, Phyllis C.
   Wang, Rui
TI Reproducibility of a Standardized Actigraphy Scoring Algorithm for Sleep
   in a US Hispanic/Latino Population
SO SLEEP
LA English
DT Article
DE actigraphy; reproducibility; Hispanic; sleep
ID RISK-FACTOR; DURATION; ASSOCIATION; OBESITY; ADULTS; FRAGMENTATION;
   RELIABILITY; VALIDATION; PARAMETERS; DESIGN
AB Study Objectives: While actigraphy is considered objective, the process of setting rest intervals to calculate sleep variables is subjective. We sought to evaluate the reproducibility of actigraphy-derived measures of sleep using a standardized algorithm for setting rest intervals.
   Design: Observational study.
   Setting: Community-based.
   Participants: A random sample of 50 adults aged 18-64 years free of severe sleep apnea participating in the Sueno sleep ancillary study to the Hispanic Community Health Study/Study of Latinos. Interventions: N/A.
   Measurements and Results: Participants underwent 7 days of continuous wrist actigraphy and completed daily sleep diaries. Studies were scored twice by each of two scorers. Rest intervals were set using a standardized hierarchical approach based on event marker, diary, light, and activity data. Sleep/wake status was then determined for each 30-sec epoch using a validated algorithm, and this was used to generate 11 variables: mean nightly sleep duration, nap duration, 24-h sleep duration, sleep latency, sleep maintenance efficiency, sleep fragmentation index, sleep onset time, sleep offset time, sleep midpoint time, standard deviation of sleep duration, and standard deviation of sleep midpoint. Intra-scorer intraclass correlation coefficients (ICCs) were high, ranging from 0.911 to 0.995 across all 11 variables. Similarly, inter-scorer ICCs were high, also ranging from 0.911 to 0.995, and mean inter-scorer differences were small. Bland-Altman plots did not reveal any systematic disagreement in scoring.
   Conclusions: With use of a standardized algorithm to set rest intervals, scoring of actigraphy for the purpose of generating a wide array of sleep variables is highly reproducible.
C1 [Patel, Sanjay R.; Weng, Jia; Rueschman, Michael; Dudley, Katherine A.; Seiger, Ashley N.; Wang, Rui] Brigham & Womens Hosp, Div Sleep & Circadian Disorders, Boston, MA 02115 USA.
   [Patel, Sanjay R.; Ramirez, Maricelle] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
   [Loredo, Jose S.] Univ Calif San Diego, San Diego, CA 92103 USA.
   [Mossavar-Rahmani, Yasmin] Albert Einstein Coll Med, Bronx, NY 10467 USA.
   [Ramos, Alberto R.] Univ Miami, Miami, FL USA.
   [Reid, Kathryn; Zee, Phyllis C.] Northwestern Univ, Chicago, IL 60611 USA.
   [Sotres-Alvarez, Daniela] Univ N Carolina, Dept Biostat, Collaborat Studies Coordinating Ctr, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA.
RP Patel, SR (corresponding author), Brigham & Womens Hosp, 221 Longwood Ave,Suite 225-C, Boston, MA 02115 USA.
EM spatel@partners.org
RI Wang, Rui/X-1699-2019; DeMarcus, Forrest/O-9190-2016; Sotres-Alvarez,
   Daniela/O-9085-2016; Ramos, Alberto/X-4249-2019
OI Sotres-Alvarez, Daniela/0000-0002-3226-6140; Mossavar-Rahmani,
   Yasmin/0000-0002-9214-6124; Patel, Sanjay/0000-0002-9142-5172
FU NHLBIUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [HL098297, N01-HC65233, N01-HC65234, N01-HC65235,
   N01-HC65236, N01-HC65237]; National Center on Minority Health and Health
   DisparitiesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Minority
   Health & Health Disparities (NIMHD); National Institute of Deafness and
   Other Communications DisordersUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Deafness & Other Communication Disorders (NIDCD); National Institute
   of Dental and Craniofacial ResearchUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Dental & Craniofacial Research (NIDCR); National Institute
   of Diabetes and Digestive and Kidney DiseasesUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK);
   National Institute of Neurological Disorders and StrokeUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Neurological Disorders & Stroke (NINDS);
   Office of Dietary SupplementsUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA; Philips Consumer
   Lifestyles; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Advancing Translational
   Sciences (NCATS) [UL1TR001073, KL2TR000461] Funding Source: NIH
   RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL098297]
   Funding Source: NIH RePORTER
FX This was not an industry supported study. This study was supported by
   NHLBI HL098297. In addition, the Hispanic Community Health Study/Study
   of Latinos was carried out as a collaborative study supported by
   contracts from NHLBI to the University of North Carolina (N01-HC65233),
   University of Miami (N01-HC65234), Albert Einstein College of Medicine
   (N01-HC65235), Northwestern University (N01-HC65236), and San Diego
   State University (N01-HC65237). The following Institutes/Center/Offices
   contribute to the HCHS/SOL through a transfer of funds to the NHLBI:
   National Center on Minority Health and Health Disparities, the National
   Institute of Deafness and Other Communications Disorders, the National
   Institute of Dental and Craniofacial Research, the National Institute of
   Diabetes and Digestive and Kidney Diseases, the National Institute of
   Neurological Disorders and Stroke, and the Office of Dietary
   Supplements. No off-label or investigational uses were evaluated in this
   study. Dr. Zee has consulted for Philips Respironics, Aptalis, Jazz,
   Vanda, and Merck and has stock in Teva. Dr. Reid has received research
   support from Philips Consumer Lifestyles. The other authors have
   indicated no financial conflicts of interest.
CR ANDRESEN EM, 1994, AM J PREV MED, V10, P77, DOI 10.1016/S0749-3797(18)30622-6
   Appelhans BM, 2013, OBESITY, V21, P77, DOI 10.1002/oby.20251
   Ayas NT, 2003, ARCH INTERN MED, V163, P205, DOI 10.1001/archinte.163.2.205
   Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4
   Blackwell T, 2005, SLEEP, V28, P1599, DOI 10.1093/sleep/28.12.1599
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Figueiro MG, 2013, LIGHTING RES TECHNOL, V45, P421, DOI 10.1177/1477153512450453
   Gangwisch JE, 2006, HYPERTENSION, V47, P833, DOI 10.1161/01.HYP.0000217362.34748.e0
   Jean-Louis G, 2001, J NEUROSCI METH, V105, P185, DOI 10.1016/S0165-0270(00)00364-2
   JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540
   Kripke DF, 2010, J SLEEP RES, V19, P612, DOI 10.1111/j.1365-2869.2010.00835.x
   Kripke DF, 2002, ARCH GEN PSYCHIAT, V59, P131, DOI 10.1001/archpsyc.59.2.131
   Kurina LM, 2011, SLEEP, V34, P1519, DOI 10.5665/sleep.1390
   Kushida CA, 2001, SLEEP MED, V2, P389, DOI 10.1016/S1389-9457(00)00098-8
   Lauderdale DS, 2008, EPIDEMIOLOGY, V19, P838, DOI 10.1097/EDE.0b013e318187a7b0
   Lauderdale DS, 2006, AM J EPIDEMIOL, V164, P5, DOI 10.1093/aje/kwj199
   Lavange LM, 2010, ANN EPIDEMIOL, V20, P642, DOI 10.1016/j.annepidem.2010.05.006
   Lemola S, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0071292, 10.1371/journal.pone.0082059]
   Lind Bonnie K, 2003, Sleep Breath, V7, P13, DOI 10.1007/s11325-003-0013-z
   Littner M, 2003, SLEEP, V26, P337, DOI 10.1093/sleep/26.3.337
   Marino M, 2013, SLEEP, V36, P1747, DOI 10.5665/sleep.3142
   Martin SK, 2002, CHRONOBIOL INT, V19, P695, DOI 10.1081/CBI-120006080
   McGraw KO, 1996, PSYCHOL METHODS, V1, P30, DOI 10.1037/1082-989X.1.1.30
   Oakley NR., 1997, VALIDATION POLYSOMNO
   Patel SR, 2014, INT J OBESITY, V38, P1159, DOI 10.1038/ijo.2014.13
   Patel SR, 2008, INT J OBESITY, V32, P1825, DOI 10.1038/ijo.2008.198
   Patel SR, 2006, AM J EPIDEMIOL, V164, P947, DOI 10.1093/aje/kwj280
   Patel SR, 2012, SLEEP, V35, P97, DOI 10.5665/sleep.1594
   Price LLA, 2012, LIGHTING RES TECHNOL, V44, P17, DOI 10.1177/1477153511433171
   RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306
   Redline S, 2014, AM J RESP CRIT CARE, V189, P335, DOI 10.1164/rccm.201309-1735OC
   Shrout P E, 1998, Stat Methods Med Res, V7, P301, DOI 10.1191/096228098672090967
   Sorlie PD, 2010, ANN EPIDEMIOL, V20, P629, DOI 10.1016/j.annepidem.2010.03.015
   Stone AA, 2003, CONTROL CLIN TRIALS, V24, P182, DOI 10.1016/S0197-2456(02)00320-3
   Ustinov Y, 2013, BEHAV SLEEP MED, V11, P313, DOI 10.1080/15402002.2012.688779
   van den Berg JF, 2008, INT J OBESITY, V32, P1083, DOI 10.1038/ijo.2008.57
   Westbrook PR, 2005, CHEST, V128, P2166, DOI 10.1378/chest.128.4.2166
   Yaggi HK, 2006, DIABETES CARE, V29, P657, DOI 10.2337/diacare.29.03.06.dc05-0879
NR 38
TC 59
Z9 59
U1 0
U2 8
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0161-8105
EI 1550-9109
J9 SLEEP
JI Sleep
PD SEP 1
PY 2015
VL 38
IS 9
BP 1497
EP 1503
DI 10.5665/sleep.4998
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA CT3CJ
UT WOS:000362683700021
PM 25845697
OA Green Published, Bronze, Green Submitted
DA 2021-10-30
ER

PT J
AU Patel, SR
   Sotres-Alvarez, D
   Castaneda, SF
   Dudley, KA
   Gallo, LC
   Hernandez, R
   Medeiros, EA
   Penedo, FJ
   Mossavar-Rahmani, Y
   Ramos, AR
   Redline, S
   Reid, KJ
   Zee, PC
AF Patel, Sanjay R.
   Sotres-Alvarez, Daniela
   Castaneda, Sheila F.
   Dudley, Katherine A.
   Gallo, Linda C.
   Hernandez, Rosalba
   Medeiros, Elizabeth A.
   Penedo, Frank J.
   Mossavar-Rahmani, Yasmin
   Ramos, Alberto R.
   Redline, Susan
   Reid, Kathryn J.
   Zee, Phyllis C.
TI Social and Health Correlates of Sleep Duration in a US Hispanic
   Population: Results from the Hispanic Community Health Study/Study of
   Latinos
SO SLEEP
LA English
DT Article
DE disparities; epidemiology; Hispanic; sleep
ID DIVERSE BACKGROUNDS; DAYTIME SLEEPINESS; WOMENS HEALTH; UNITED-STATES;
   RISK; PREVALENCE; ADULTS; RACE/ETHNICITY; ACCULTURATION; INDIVIDUALS
AB Study Objectives: To define the prevalence of poor sleep patterns in the US Hispanic/Latino population, identify sociodemographic and psychosocial predictors of short and long sleep duration, and the association between sleep and cardiometabolic outcomes.
   Design: Cross-sectional analysis.
   Setting: Community-based study.
   Participants: Adults age 18-74 y free of sleep disorders (n = 11,860) from the Hispanic Community Health Study/Study of Latinos baseline examination (2008-2011).
   Interventions: N/A.
   Measurements and Results: The mean self-reported sleep duration was 8.0 h per night with 18.6% sleeping less than 7 h and 20.1% sleeping more than 9 h in age-and sex-adjusted analyses. Short sleep was most common in individuals of Puerto Rican heritage (25.6%) and the Other Hispanic group (27.4%). Full-time employment, low level of education, and depressive symptoms were independent predictors of short sleep, whereas unemployment, low household income, low level of education, and being born in the mainland US were independent predictors of long sleep. After accounting for sociodemographic differences, short sleep remained significantly associated with obesity with an odds ratio of 1.29 [ 95% confidence interval 1.12-1.49] but not with diabetes, hypertension, or heart disease. In contrast, long sleep was not associated with any of these conditions.
   Conclusions: Sleep duration is highly variable among US Hispanic/Latinos, varying by Hispanic/Latino heritage as well as socioeconomic status. These differences may have health consequences given associations between sleep duration and cardiometabolic disease, particularly obesity.
C1 [Patel, Sanjay R.; Dudley, Katherine A.; Redline, Susan] Brigham & Womens Hosp, Div Sleep & Circadian Disorders, Boston, MA 02115 USA.
   [Sotres-Alvarez, Daniela] Univ N Carolina, Chapel Hill, NC USA.
   [Castaneda, Sheila F.; Gallo, Linda C.; Medeiros, Elizabeth A.] San Diego State Univ, San Diego, CA 92182 USA.
   [Hernandez, Rosalba] Univ Illinois, Urbana, IL USA.
   [Penedo, Frank J.; Reid, Kathryn J.; Zee, Phyllis C.] Northwestern Univ, Chicago, IL 60611 USA.
   [Mossavar-Rahmani, Yasmin] Albert Einstein Coll Med, Bronx, NY 10467 USA.
   [Ramos, Alberto R.] Univ Miami, Miami, FL USA.
RP Patel, SR (corresponding author), Brigham & Womens Hosp, 221 Longwood Ave,Suite 225-C, Boston, MA 02115 USA.
EM spatel@partners.org
RI Sotres-Alvarez, Daniela/O-9085-2016; DeMarcus, Forrest/O-9190-2016;
   Ramos, Alberto/X-4249-2019; Castaneda, Sheila F./AAK-3025-2020;
   Castaneda, Sheila/I-4132-2014
OI Sotres-Alvarez, Daniela/0000-0002-3226-6140; Gallo, Linda
   C./0000-0002-3678-5888; Castaneda, Sheila/0000-0002-1975-0544;
   Mossavar-Rahmani, Yasmin/0000-0002-9214-6124; Patel,
   Sanjay/0000-0002-9142-5172
FU NHLBIUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [N01-HC65233, N01-HC65234, N01-HC65235, N01-HC65236,
   N01-HC65237]; National Center on Minority Health and Health
   DisparitiesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Minority
   Health & Health Disparities (NIMHD); National Institute of Deafness and
   Other Communications DisordersUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Deafness & Other Communication Disorders (NIDCD); National Institute
   of Dental and Craniofacial ResearchUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Dental & Craniofacial Research (NIDCR); National Institute
   of Diabetes and Digestive and Kidney DiseasesUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK);
   National Institute of Neurological Disorders and StrokeUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Neurological Disorders & Stroke (NINDS);
   Office of Dietary SupplementsUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA; DIVISION OF
   EPIDEMIOLOGY AND CLINICAL APPLICATIONSUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Eye Institute (NEI) [N01HC065233] Funding Source: NIH RePORTER; NATIONAL
   CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Advancing Translational Sciences (NCATS)
   [UL1TR001073, KL2TR000461] Funding Source: NIH RePORTER; NATIONAL HEART,
   LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [R01HL098297] Funding Source: NIH RePORTER;
   National Institute on Minority Health and Health DisparitiesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute on Minority Health & Health
   Disparities (NIMHD) [R25MD006853] Funding Source: NIH RePORTER
FX This was not an industry supported study. Sources of financial support:
   This Hispanic Community Health Study/Study of Latinos (HCHS/SOL) was
   carried out as a collaborative study supported by contracts from NHLBI
   to the University of North Carolina (N01-HC65233), University of Miami
   (N01-HC65234), Albert Einstein College of Medicine (N01-HC65235),
   Northwestern University (N01-HC65236), and San Diego State University
   (N01-HC65237). The following Institutes/Center/Offices contribute to the
   HCHS/SOL through a transfer of funds to the NHLBI: National Center on
   Minority Health and Health Disparities, the National Institute of
   Deafness and Other Communications Disorders, the National Institute of
   Dental and Craniofacial Research, the National Institute of Diabetes and
   Digestive and Kidney Diseases, the National Institute of Neurological
   Disorders and Stroke, and the Office of Dietary Supplements. In
   addition, this publication was made possible by HL098297 from the
   National Heart, Lung, and Blood Institute (NHLBI). The authors have
   indicated no financial conflicts of interest.
CR Amer Diabet Assoc, 2010, DIABETES CARE, V33, pS62, DOI 10.2337/dc10-s062
   ANDRESEN EM, 1994, AM J PREV MED, V10, P77, DOI 10.1016/S0749-3797(18)30622-6
   Ayas NT, 2003, DIABETES CARE, V26, P380, DOI 10.2337/diacare.26.2.380
   Ayas NT, 2003, ARCH INTERN MED, V163, P205, DOI 10.1001/archinte.163.2.205
   Basner M, 2007, SLEEP, V30, P1085, DOI 10.1093/sleep/30.9.1085
   Chobanian AV, 2003, JAMA-J AM MED ASSOC, V289, P2560, DOI 10.1161/01.HYP.0000107251.49515.c2
   Daviglus ML, 2012, JAMA-J AM MED ASSOC, V308, P1775, DOI 10.1001/jama.2012.14517
   Ennis S. R., 2011, HISPANIC POPULATION
   Grandner MA, 2014, SLEEP MED, V15, P42, DOI 10.1016/j.sleep.2013.09.012
   Green R, 2010, CLIMACTERIC, V13, P534, DOI 10.3109/13697131003592713
   Gulley SP, 2014, MED CARE, V52, pS9, DOI 10.1097/MLR.0000000000000129
   Hackney JE, 2008, SLEEP MED REV, V12, P143, DOI 10.1016/j.smrv.2007.07.002
   Hale L, 2007, SLEEP, V30, P1096, DOI 10.1093/sleep/30.9.1096
   Hale L, 2014, SLEEP, V37, P309, DOI 10.5665/sleep.3404
   Hale L, 2011, J IMMIGR MINOR HEALT, V13, P402, DOI 10.1007/s10903-009-9284-1
   Hill TD, 2014, SLEEP MED
   Johns M, 1997, SLEEP, V20, P844, DOI 10.1093/sleep/20.10.844
   JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540
   Knutson KL, 2011, AM J HUM BIOL, V23, P138, DOI 10.1002/ajhb.21108
   Krueger PM, 2009, AM J EPIDEMIOL, V169, P1052, DOI 10.1093/aje/kwp023
   Lauderdale DS, 2006, AM J EPIDEMIOL, V164, P5, DOI 10.1093/aje/kwj199
   Lavange LM, 2010, ANN EPIDEMIOL, V20, P642, DOI 10.1016/j.annepidem.2010.05.006
   Lind Bonnie K, 2003, Sleep Breath, V7, P13, DOI 10.1007/s11325-003-0013-z
   MCCALL WV, 1995, SLEEP, V18, P646, DOI 10.1093/sleep/18.8.646
   Ogden CL, 2014, JAMA-J AM MED ASSOC, V311, P806, DOI 10.1001/jama.2014.732
   Patel SR, 2008, OBESITY, V16, P643, DOI 10.1038/oby.2007.118
   Patel SR, 2012, SLEEP, V35, P641, DOI 10.5665/sleep.1822
   Patel SR, 2004, SLEEP, V27, P440, DOI 10.1093/sleep/27.3.440
   Pi-Sunyer FX, 1998, OBES RES, V6, p51S
   RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306
   Redline S, 2014, AM J RESP CRIT CARE, V189, P335, DOI 10.1164/rccm.201309-1735OC
   Seicean S, 2011, SLEEP, V34, P1021, DOI 10.5665/SLEEP.1154
   Simonelli G, 2013, SLEEP, V36, P1669, DOI 10.5665/sleep.3124
   Slopen N, 2014, SLEEP, V37, P147, DOI 10.5665/sleep.3326
   Song YS, 2012, BEHAV SLEEP MED, V10, P54, DOI 10.1080/15402002.2012.636276
   Sorlie PD, 2010, ANN EPIDEMIOL, V20, P629, DOI 10.1016/j.annepidem.2010.03.015
   Spielberger CD, 1983, MANUAL STATE TRAIT A
   Stamatakis KA, 2007, ANN EPIDEMIOL, V17, P948, DOI 10.1016/j.annepidem.2007.07.096
   Westbrook PR, 2005, CHEST, V128, P2166, DOI 10.1378/chest.128.4.2166
   Youngstedt SD, 2004, SLEEP MED REV, V8, P159, DOI 10.1016/j.smrv.2003.10.002
NR 40
TC 56
Z9 57
U1 1
U2 12
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0161-8105
EI 1550-9109
J9 SLEEP
JI Sleep
PD OCT 1
PY 2015
VL 38
IS 10
BP 1515
EP 1522
DI 10.5665/sleep.5036
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA CT3CP
UT WOS:000362684500001
PM 26085298
OA Green Submitted, Green Published, Bronze
DA 2021-10-30
ER

PT J
AU Ramos, AR
   Tarraf, W
   Rundek, T
   Redline, S
   Wohlgemuth, WK
   Loredo, JS
   Sacco, RL
   Lee, DJ
   Arens, R
   Lazalde, P
   Choca, JP
   Mosley, T
   Gonzalez, HM
AF Ramos, Alberto R.
   Tarraf, Wassim
   Rundek, Tatjana
   Redline, Susan
   Wohlgemuth, William K.
   Loredo, Jose S.
   Sacco, Ralph L.
   Lee, David J.
   Arens, Raanan
   Lazalde, Patricia
   Choca, James P.
   Mosley, Thomas, Jr.
   Gonzalez, Hector M.
TI Obstructive sleep apnea and neurocognitive function in a Hispanic/Latino
   population
SO NEUROLOGY
LA English
DT Article
ID HEART HEALTH; COGNITIVE IMPAIRMENT; DIVERSE BACKGROUNDS;
   ENGLISH-SPEAKING; OLDER-PEOPLE; RISK-FACTORS; MEMORY TEST; ADULTS;
   HYPOPNEA; LATINOS
AB Objective:We evaluated the association between obstructive sleep apnea (OSA) and neurocognitive function among community-dwelling Hispanic/Latino individuals in the United States.Methods:Cross-sectional analysis of the Hispanic Community Health Study/Study of Latinos middle-aged and older adults, aged 45 to 74 years, with neurocognitive test scores at baseline measurements from 2008 to 2011. Neurocognitive scores were measured using the Word Fluency (WF) Test, the Brief-Spanish English Verbal Learning Test (SEVLT), and the Digit Symbol Substitution (DSS) Test. OSA was defined by the apnea-hypopnea index (AHI). Multivariable linear regression models were fit to evaluate relations between OSA and neurocognitive scores.Results:The analysis consisted of 8,059 participants, mean age of 56 years, 55% women, and 41% with less than high school education. The mean AHI was 9.0 (range 0-142; normal AHI <5/h). There was an association between the AHI and all 4 neurocognitive test scores: Brief-SEVLT-sum ( = -0.022) and -recall ( = -0.010), WF ( = -0.023), and DSS ( = -0.050) at p < 0.01 that was fully attenuated by age. In the fully adjusted regression model, female sex was a moderating factor between the AHI and WF ( = -0.027, p < 0.10), SVELT-sum ( = -0.37), SVELT-recall ( = -0.010), and DSS ( = -0.061) at p < 0.01.Conclusion:OSA was associated with worse neurocognitive function in a representative sample of Hispanic/Latino women in the United States.
C1 [Ramos, Alberto R.; Rundek, Tatjana; Sacco, Ralph L.] Univ Miami, Miller Sch Med, Dept Neurol, Coral Gables, FL 33124 USA.
   [Rundek, Tatjana; Sacco, Ralph L.; Lee, David J.] Univ Miami, Miller Sch Med, Dept Epidemiol & Publ Hlth, Coral Gables, FL 33124 USA.
   [Tarraf, Wassim] Wayne State Univ, Inst Gerontol, Detroit, MI 48202 USA.
   [Redline, Susan] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
   [Redline, Susan] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
   [Wohlgemuth, William K.] Bruce W Carter Dept Vet Affairs Med Ctr, Miami, FL USA.
   [Loredo, Jose S.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
   [Arens, Raanan] Childrens Hosp Montefiore, Albert Einstein Coll Med, Bronx, NY USA.
   [Lazalde, Patricia] San Diego State Univ, HCHS SOL Field Ctr, San Diego, CA 92182 USA.
   [Choca, James P.] Roosevelt Univ, Dept Psychol, Chicago, IL 60605 USA.
   [Mosley, Thomas, Jr.] Univ Mississippi, Dept Neurol, Jackson, MS USA.
   [Gonzalez, Hector M.] Michigan State Univ, Dept Epidemiol & Biostat, E Lansing, MI 48824 USA.
RP Gonzalez, HM (corresponding author), Michigan State Univ, Dept Epidemiol & Biostat, E Lansing, MI 48824 USA.
EM hmgonzalez@epi.msu.edu
RI Gonzalez, Hector/AAV-7576-2021; Sacco, Ralph/Y-9278-2019; Ramos,
   Alberto/X-4249-2019
FU National Heart, Lung, and Blood Institute (NHLBI)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [N01-HC65233,
   N01-HC65234, N01-HC65235, N01-HC65236, N01-HC65237]; National Institute
   on Minority Health and Health DisparitiesUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Minority Health & Health Disparities (NIMHD);
   National Institute on Deafness and Other Communication DisordersUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute on Deafness & Other
   Communication Disorders (NIDCD); National Institute of Dental and
   Craniofacial ResearchUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Dental & Craniofacial Research (NIDCR); National Institute of
   Diabetes and Digestive and Kidney DiseasesUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK);
   National Institute of Neurological Disorders and StrokeUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Neurological Disorders & Stroke (NINDS);
   NIH Office of Dietary SupplementsUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA; Miami Clinical
   and Translational Science Institute, from the National Center for
   Advancing Translational Sciences [1KL2TR000461]; DIVISION OF
   EPIDEMIOLOGY AND CLINICAL APPLICATIONSUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Eye Institute (NEI) [N01HC065233] Funding Source: NIH RePORTER; NATIONAL
   CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Advancing Translational Sciences (NCATS)
   [KL2TR000461] Funding Source: NIH RePORTER
FX The Hispanic Community Health Study/Study of Latinos was performed as a
   collaborative study supported by contracts from the National Heart,
   Lung, and Blood Institute (NHLBI) to the University of North Carolina
   (N01-HC65233), University of Miami (N01-HC65234), Albert Einstein
   College of Medicine (N01-HC65235), Northwestern University
   (N01-HC65236), and San Diego State University (N01-HC65237). The
   following institutes/centers/offices contribute to the HCHS/SOL through
   a transfer of funds to the NHLBI: National Institute on Minority Health
   and Health Disparities, National Institute on Deafness and Other
   Communication Disorders, National Institute of Dental and Craniofacial
   Research, National Institute of Diabetes and Digestive and Kidney
   Diseases, National Institute of Neurological Disorders and Stroke, and
   NIH Office of Dietary Supplements. The project described was also
   supported by grant 1KL2TR000461, Miami Clinical and Translational
   Science Institute, from the National Center for Advancing Translational
   Sciences and the National Institute on Minority Health and Health
   Disparities. Its contents are solely the responsibility of the authors
   and do not necessarily represent the official views of the NIH.
CR Al Hazzouri AZ, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.004978
   Alzheimer's A, 2014, ALZHEIMERS DEMENT, V2014, pe47, DOI [DOI 10.1016/J.JALZ.2010.01.009, 10.1016/j.jalz.2010.01.009, DOI 10.1016/J.JALZ.2014.02.001]
   Bennette C, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-21
   Benton AL., 1989, MULTILINGUAL APHASIA
   Boland LL, 2002, J SLEEP RES, V11, P265, DOI 10.1046/j.1365-2869.2002.00308.x
   Cohen-Zion M, 2001, J AM GERIATR SOC, V49, P1622, DOI 10.1111/j.1532-5415.2001.49270.x
   Daviglus ML, 2012, JAMA-J AM MED ASSOC, V308, P1775, DOI 10.1001/jama.2012.14517
   de la Torre Jack C, 2012, Cardiovasc Psychiatry Neurol, V2012, P367516, DOI 10.1155/2012/367516
   de la Torre JC, 2012, J ALZHEIMERS DIS, V32, P553, DOI 10.3233/JAD-2012-120793
   Flegal KM, 2012, JAMA-J AM MED ASSOC, V307, P491, DOI 10.1001/jama.2012.39
   Fox J., 2008, APPL REGRESSION ANAL, V2nd
   Goel N, 2009, SEMIN NEUROL, V29, P320, DOI 10.1055/s-0029-1237117
   Gonzalez HM, 2002, CLIN NEUROPSYCHOL, V16, P439, DOI 10.1076/clin.16.4.439.13908
   Gonzalez HM, 2001, J INT NEUROPSYCH SOC, V7, P544, DOI 10.1017/S1355617701755026
   Gorelick PB, 2013, STROKE, V44, P307, DOI 10.1161/STROKEAHA.111.000219
   GREENLAND S, 1995, EPIDEMIOLOGY, V6, P450, DOI 10.1097/00001648-199507000-00025
   Grigg-Damberger MM, 2012, J CLIN SLEEP MED, V8, P323, DOI 10.5664/jcsm.1928
   JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540
   Kielb SA, 2012, NEUROMOL MED, V14, P180, DOI 10.1007/s12017-012-8182-1
   Kushida CA, 2012, SLEEP, V35, P1593, DOI 10.5665/sleep.2226
   Lavange LM, 2010, ANN EPIDEMIOL, V20, P642, DOI 10.1016/j.annepidem.2010.05.006
   Lezak MD, 2004, NEUROPSYCHOLOGICAL A
   Macey PM, 2012, SLEEP, V35, P1603, DOI 10.5665/sleep.2228
   Mitchell M. N., 2012, INTERPRETING VISUALI
   Randby A, 2013, CHEST, V144, P915, DOI 10.1378/chest.12-2283
   Redline S, 2014, AM J RESP CRIT CARE, V189, P335, DOI 10.1164/rccm.201309-1735OC
   Redline S, 2010, AM J RESP CRIT CARE, V182, P269, DOI 10.1164/rccm.200911-1746OC
   Sorlie PD, 2010, ANN EPIDEMIOL, V20, P629, DOI 10.1016/j.annepidem.2010.03.015
   Wang G, 2011, TRENDS NEUROSCI, V34, P452, DOI 10.1016/j.tins.2011.07.005
   Wechsler D, 1981, WAIS R MANUAL
   Wen W, 2011, J NEUROSCI, V31, P1204, DOI 10.1523/JNEUROSCI.4085-10.2011
   Westbrook PR, 2005, CHEST, V128, P2166, DOI 10.1378/chest.128.4.2166
   Yaffe K, 2011, JAMA-J AM MED ASSOC, V306, P613, DOI 10.1001/jama.2011.1115
   Yaggi HK, 2005, NEW ENGL J MED, V353, P2034, DOI 10.1056/NEJMoa043104
   Yaouhi K, 2009, J SLEEP RES, V18, P36, DOI 10.1111/j.1365-2869.2008.00705.x
   Young T, 2002, AM J RESP CRIT CARE, V165, P1217, DOI 10.1164/rccm.2109080
   Young T, 1996, ARCH INTERN MED, V156, P2445, DOI 10.1001/archinte.156.21.2445
   Young T, 2002, ARCH INTERN MED, V162, P893, DOI 10.1001/archinte.162.8.893
   Zimmerman ME, 2012, CURR NEUROL NEUROSCI, V12, P537, DOI 10.1007/s11910-012-0298-z
NR 39
TC 23
Z9 25
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD JAN 27
PY 2015
VL 84
IS 4
BP 391
EP 398
DI 10.1212/WNL.0000000000001181
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA CA4VY
UT WOS:000348905800016
PM 25540308
OA Green Published
DA 2021-10-30
ER

PT J
AU Subbarayan, PR
   Sarkar, M
   Nathanson, L
   Doshi, N
   Lokeshwar, BL
   Ardalan, B
AF Subbarayan, Pochi R.
   Sarkar, Malancha
   Nathanson, Lubov
   Doshi, Nikesh
   Lokeshwar, Balakrishna L.
   Ardalan, Bach
TI In Vitro Global Gene Expression Analyses Support the
   Ethnopharmacological Use of Achyranthes aspera
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID CONDUCTANCE REGULATOR GENE; MUTATIONS; MANAGEMENT; MEDICINE; EXTRACT;
   CANCER; PLANTS
AB Achyranthes aspera (family Amaranthaceae) is known for its anticancer properties. We have systematically validated the in vitro and in vivo anticancer properties of this plant. However, we do not know its mode of action. Global gene expression analyses may help decipher its mode of action. In the absence of identified active molecules, we believe this is the best approach to discover the mode of action of natural products with known medicinal properties. We exposed human pancreatic cancer cell line MiaPaCa-2 (CRL-1420) to 34 mu g/mL of LE for 24, 48, and 72 hours. Gene expression analyses were performed using whole human genome microarrays (Agilent Technologies, USA). In our analyses, 82 (54/28) genes passed the quality control parameter, set at FDR <= 0.01 and FC of >=+/-2. LE predominantly affected pathways of immune response, metabolism, development, gene expression regulation, cell adhesion, cystic fibrosis transmembrane conductance regulation (CFTR), and chemotaxis (MetaCore tool (Thomson Reuters, NY)). Disease biomarker enrichment analysis identified LE regulated genes involved in Vasculitis-inflammation of blood vessels. Arthritis and pancreatitis are two of many etiologies for vasculitis. The outcome of disease network analysis supports the medicinal use of A. aspera, viz, to stop bleeding, as a cure for pancreatic cancer, as an antiarthritic medication, and so forth.
C1 [Subbarayan, Pochi R.] Univ Miami, Miller Sch Med, Dept Med, Div Hematol & Oncol, Miami, FL 33136 USA.
   [Sarkar, Malancha; Doshi, Nikesh] Univ Miami, Dept Biol, Miami, FL 33124 USA.
   [Nathanson, Lubov; Ardalan, Bach] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA.
   [Nathanson, Lubov] Nova SE Univ, Coll Osteopath Med, Inst Neuro Immune Med, Ft Lauderdale, FL 33328 USA.
   [Lokeshwar, Balakrishna L.] Univ Miami, Miller Sch Med, Dept Urol, Miami, FL 33136 USA.
   [Lokeshwar, Balakrishna L.] VA Med Ctr, Miami, FL 33136 USA.
RP Subbarayan, PR (corresponding author), Univ Miami, Miller Sch Med, Dept Med, Div Hematol & Oncol, 1550 NW 10th Ave,Fox 431A D8-4, Miami, FL 33136 USA.
EM spochi@med.miami.edu
OI Nathanson, Lubov/0000-0003-1038-9083
FU American Cancer Society Institutional Research Grant (IRG)American
   Cancer Society [98-277-07]; Interdisciplinary Research Development
   Initiative (IRDI) [102504]; Miami Clinical and Translational Science
   Institute (CTSI) Pilot Research Grant of the University of Miami
   [CTSI-2013-P03]; University of Miami CTSI, from the National Center for
   Advancing Translational Sciences; National Institute on Minority Health
   and Health DisparitiesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Minority Health & Health Disparities (NIMHD); Sheibar Foundation;
   NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [1R01AT003544, R01CA156776-01]; 
   [1UL1TR000460]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1TR000460] Funding Source: NIH
   RePORTER
FX Pochi R. Subbarayan thanks Dr. Ram Agarwal and Dr. Pradeep Kumar for the
   supply of A. aspera leaf powder. Undergraduate students Anthony
   Fernandez and Ravi Patel helped in real time PCR validation and proof
   reading the paper. Funding for this work was provided by the American
   Cancer Society Institutional Research Grant (IRG # 98-277-07),
   Interdisciplinary Research Development Initiative (IRDI # 102504) award,
   and the Miami Clinical and Translational Science Institute (CTSI) Pilot
   Research Grant (CTSI-2013-P03) of the University of Miami to PRS. The
   Pilot and Collaborative Translational and Clinical Studies component is
   supported by Grant no. 1UL1TR000460, the University of Miami CTSI, from
   the National Center for Advancing Translational Sciences and the
   National Institute on Minority Health and Health Disparities. Additional
   support was provided by Sheibar Foundation Grant to BA; NIH Grants:
   1R01AT003544 and R01CA156776-01 to BLL.
CR Ardalan B, 2010, CLIN CANCER RES, V16, P3019, DOI 10.1158/1078-0432.CCR-09-2590
   Audrezet MP, 2002, EUR J HUM GENET, V10, P100, DOI 10.1038/sj.ejhg.5200786
   Bagavan A, 2008, PARASITOL RES, V103, P223, DOI 10.1007/s00436-008-0962-z
   Balunas MJ, 2005, LIFE SCI, V78, P431, DOI 10.1016/j.lfs.2005.09.012
   Barrett T, 2011, NUCLEIC ACIDS RES, V39, pD1005, DOI 10.1093/nar/gkq1184
   Cragg GM, 2005, J ETHNOPHARMACOL, V100, P72, DOI 10.1016/j.jep.2005.05.011
   Deocaris CC, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-14
   Han ST, 2003, VET HUM TOXICOL, V45, P212
   HEDBERG I, 1982, J ETHNOPHARMACOL, V6, P29, DOI 10.1016/0378-8741(82)90070-8
   Lokeshwar VB, 2005, CANCER RES, V65, P7782, DOI 10.1158/0008-5472.CAN-05-1022
   McWilliams RR, 2010, CANCER, V116, P203, DOI [10.1002/cncr.24697, 10.1002/cncr.25465]
   Miller A, 2010, CLIN EXP IMMUNOL, V160, P143, DOI 10.1111/j.1365-2249.2009.04078.x
   Muller PY, 2002, BIOTECHNIQUES, V32, P1372
   Newman DJ, 2008, J MED CHEM, V51, P2589, DOI 10.1021/jm0704090
   Rittenhouse DW, 2011, J GASTROINTEST SURG, V15, P2284, DOI 10.1007/s11605-011-1639-y
   Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01
   Schroeder A, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-3
   Shan Jacqueline J, 2007, Proc West Pharmacol Soc, V50, P24
   Sharer N, 1998, NEW ENGL J MED, V339, P645, DOI 10.1056/NEJM199809033391001
   Sharma P, 2011, AM FAM PHYSICIAN, V83, P556
   Shibeshi Workineh, 2006, Afr Health Sci, V6, P108
   Souza V, 2005, J TRANSL MED, V3, DOI 10.1186/1479-5876-3-44
   Subbarayan PR, 2012, J ETHNOPHARMACOL, V142, P523, DOI 10.1016/j.jep.2012.05.030
   Subbarayan PR, 2010, J ETHNOPHARMACOL, V131, P78, DOI 10.1016/j.jep.2010.06.002
   Subbarayappa BV, 2001, J BIOSCIENCE, V26, P135, DOI 10.1007/BF02703637
   Yang NS, 2004, J BIOMED SCI, V11, P418, DOI 10.1007/BF02254447
NR 26
TC 2
Z9 2
U1 0
U2 7
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PY 2013
VL 2013
AR 471739
DI 10.1155/2013/471739
PG 13
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 279TY
UT WOS:000328983500001
PM 24454496
OA gold, Green Published, Green Submitted
DA 2021-10-30
ER

PT J
AU Arora, H
   Zuttion, MSSR
   Nahar, B
   Lamb, D
   Hare, JM
   Ramasamy, R
AF Arora, Himanshu
   Zuttion, Marilia Sanches Santos Rizzo
   Nahar, Bruno
   Lamb, Dolores
   Hare, Joshua M.
   Ramasamy, Ranjith
TI Subcutaneous Leydig Stem Cell Autograft: A Promising Strategy to
   Increase Serum Testosterone
SO STEM CELLS TRANSLATIONAL MEDICINE
LA English
DT Article
DE Leydig cell; Hypogonadism; Fertility; Sertoli cell; Myoid cell
ID DIFFERENTIATION; TRANSPLANTATION; SPERMATOGENESIS; IDENTIFICATION;
   PROLIFERATION; MICE
AB Exogenous testosterone therapy can be used to treat testosterone deficiency; however, it has several adverse effects including infertility due to negative feedback on the hypothalamic-pituitary-gonadal (HPG) axis. Leydig stem cell (LSC) transplantation could provide a new strategy for treating testosterone deficiency, but clinical translatability of injecting stem cells inside the testis is not feasible. Here, we explore the feasibility of subcutaneously autografting LSCs in combination with Sertoli and myoid cells to increase testosterone. We also studied whether the grafted LSCs can be regulated by the HPG axis and the molecular mechanism behind this regulation. LSCs were isolated from the testes of 12-week-old C57BL/6 mice, and subcutaneously autografted in combination with Sertoli cells and myoid cells. We found that LSCs alone were incapable of self-renewal and differentiation. However, in combination with Sertoli cells and myoid cells, LSCs underwent self-renewal as well as differentiation into mature Leydig cells. As a result, the recipient mice that received the LSC autograft showed testosterone production with preserved luteinizing hormone. We found that testosterone production from the autograft was regulated by hedgehog (HH) signaling. Gain of function and loss of function study confirmed that Desert HH (DHH) agonist increased and DHH antagonist decreased testosterone production from autograft. This study is the first to demonstrate that LSCs, when autografted subcutaneously in combination with Sertoli cells and myoid cells, can increase testosterone production. Therefore, LSC autograft may provide a new treatment for testosterone deficiency while simultaneously preserving the HPG axis. Stem Cells Translational Medicine 2019;8:58-65
C1 [Arora, Himanshu; Nahar, Bruno; Ramasamy, Ranjith] Univ Miami, Miller Sch Med, Dept Urol, Miami, FL 33136 USA.
   [Arora, Himanshu; Zuttion, Marilia Sanches Santos Rizzo; Hare, Joshua M.; Ramasamy, Ranjith] Univ Miami, Miller Sch Med, Interdisciplinary Stem Cell Inst, Miami, FL 33136 USA.
   [Lamb, Dolores] Weill Cornell Med, Dept Urol, New York, NY USA.
RP Ramasamy, R (corresponding author), 1120 NW 14th St,Suite 1563, Miami, FL 33136 USA.
EM ramasamy@miami.edu
RI Ramasamy, Ranjith/ABD-7373-2020; Nahar, Bruno/AAY-8599-2020
OI Ramasamy, Ranjith/0000-0003-1387-7904; 
FU American Urological Association Research Scholar Award; Stanley Glaser
   Award; NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [1R01 HL137355, 1R01 HL107110, 1R01
   HL134558, 5R01 CA136387, 5UM1 HL113460]; Soffer Family Foundation;
   NATIONAL CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [R01CA136387] Funding Source: NIH RePORTER; NATIONAL
   CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Advancing Translational Sciences (NCATS)
   [UL1TR002736] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND
   BLOOD INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [R01HL134558, R01HL137355, UM1HL113460,
   R01HL107110] Funding Source: NIH RePORTER
FX The authors thank Alexander Agoulnik, Florida International University,
   for mentorship and guidance. This work was supported by the American
   Urological Association Research Scholar Award and Stanley Glaser Award
   (to R.R.) as well as NIH grants 1R01 HL137355, 1R01 HL107110, 1R01
   HL134558, 5R01 CA136387, and 5UM1 HL113460 and Soffer Family Foundation
   (to J.M.H.).
CR Afiadata A, 2014, Hosp Pract (1995), V42, P69, DOI 10.3810/hp.2014.12.1160
   Ge RS, 2006, P NATL ACAD SCI USA, V103, P2719, DOI 10.1073/pnas.0507692103
   Hooper JE, 2005, NAT REV MOL CELL BIO, V6, P306, DOI 10.1038/nrm1622
   Jiang MH, 2014, CELL RES, V24, P1466, DOI 10.1038/cr.2014.149
   Li H, 2016, J UROLOGY, V195, P1065, DOI 10.1016/j.juro.2015.10.134
   Li XH, 2016, P NATL ACAD SCI USA, V113, P2666, DOI 10.1073/pnas.1519395113
   Lo KC, 2004, ENDOCRINOLOGY, V145, P4011, DOI 10.1210/en.2003-1729
   Machold R, 2003, NEURON, V39, P937, DOI 10.1016/S0896-6273(03)00561-0
   McLachlan RI, 2002, J ANDROL, V23, P149
   Mendis-Handagama SMLC, 2001, BIOL REPROD, V65, P660, DOI 10.1095/biolreprod65.3.660
   Nudleman E, 2014, RETINA-J RET VIT DIS, V34, P2128, DOI 10.1097/IAE.0000000000000198
   Pyczek J, 2016, SCI REP-UK, V6, DOI 10.1038/srep24928
   Shin K, 2011, NATURE, V472, P110, DOI 10.1038/nature09851
   Spaliviero JA, 2004, BIOL REPROD, V70, P32, DOI 10.1095/biolreprod.103.019398
   Stanley E, 2012, ENDOCRINOLOGY, V153, P5002, DOI 10.1210/en.2012-1417
   STARKA L, 1973, Casopis Lekaru Ceskych, V112, P166
   Tuttelmann F, 2014, ANDROLOGY-US, V2, P275, DOI 10.1111/j.2047-2927.2014.00190.x
   Zang ZJ, 2017, STEM CELLS, V35, P1222, DOI 10.1002/stem.2569
   Zhang M, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.531
NR 19
TC 14
Z9 15
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2157-6564
EI 2157-6580
J9 STEM CELL TRANSL MED
JI Stem Cells Transl. Med.
PD JAN
PY 2019
VL 8
IS 1
BP 58
EP 65
DI 10.1002/sctm.18-0069
PG 8
WC Cell & Tissue Engineering
SC Cell Biology
GA HF9YO
UT WOS:000454598900008
PM 30280521
OA Green Published, gold
DA 2021-10-30
ER

PT J
AU Sanders, AE
   Essick, GK
   Beck, JD
   Cai, JW
   Beaver, S
   Finlayson, TL
   Zee, PC
   Loredo, JS
   Ramos, AR
   Singer, RH
   Jimenez, MC
   Barnhart, JM
   Redline, S
AF Sanders, Anne E.
   Essick, Greg K.
   Beck, James D.
   Cai, Jianwen
   Beaver, Shirley
   Finlayson, Tracy L.
   Zee, Phyllis C.
   Loredo, Jose S.
   Ramos, Alberto R.
   Singer, Richard H.
   Jimenez, Monik C.
   Barnhart, Janice M.
   Redline, Susan
TI Periodontitis and Sleep Disordered Breathing in the Hispanic Community
   Health Study/Study of Latinos
SO SLEEP
LA English
DT Article
DE apnea-hypopnea index; periodontal disease; Hispanic; survey;
   epidemiology
ID C-REACTIVE PROTEIN; CARDIOVASCULAR-DISEASE; APNEA SYNDROME; US
   POPULATION; ASSOCIATION; PREVALENCE; MECHANISMS; GINGIVAL; HYPERTENSION;
   DESIGN
AB Study Objectives: To investigate the association between sleep disordered breathing (SDB) and severe chronic periodontitis.
   Design: Cross-sectional data analysis from the Hispanic Community Health Study/Study of Latinos.
   Setting: Community-based setting with probability sampling from four urban US communities.
   Participants: 12,469 adults aged 18-74 y.
   Interventions: None.
   Measurements and Results: Severe chronic periodontitis was defined using the Centers for Disease Control and Prevention/American Academy of Periodontology case classification based on full-mouth periodontal assessments performed by calibrated dentists. SDB was evaluated in standardized home sleep tests, and defined as the number of apnea plus hypopnea events associated with >= 3% desaturation, per hour of estimated sleep. SDB was quantified using categories of the apnea-hypopnea index (AHI): 0.0 events (nonapneic); 0.1-4.9 (subclinical); 5.0-14.9 (mild); and >= 15 (moderate/severe). Covariates were demographic characteristics and established periodontitis risk factors. C-reactive protein was a potential explanatory variable. Using survey estimation, multivariable binary logistic regression estimated odds ratios (OR) and 95% confidence limits (CL). Following adjustment for confounding, the SDB and periodontitis relationship remained statistically significant, but was attenuated in strength and no longer dose-response. Compared with the nonapneic referent, adjusted odds of severe periodontitis were 40% higher with subclinical SDB (OR = 1.4, 95% CL: 1.0, 1.9), 60% higher with mild SDB (OR = 1.6, 95% CL: 1.1, 2.2) and 50% higher with moderate/severe SDB (OR = 1.5, 95% CL: 1.0, 2.3) demonstrating an independent association between SDB and severe periodontitis.
   Conclusions: This study identifies a novel association between mild sleep disordered breathing and periodontitis that was most pronounced in young adults.
C1 [Sanders, Anne E.; Beck, James D.] Univ N Carolina, Dept Dent Ecol, Chapel Hill, NC 27599 USA.
   [Essick, Greg K.] Univ N Carolina, Ctr Pain Res & Innovat, Dept Prosthodont, Chapel Hill, NC 27599 USA.
   [Cai, Jianwen] Univ N Carolina, Dept Biostat, Chapel Hill, NC 27599 USA.
   [Beaver, Shirley] Sanford Brown Coll, Skokie, IL USA.
   [Finlayson, Tracy L.] San Diego State Univ, Grad Sch Publ Hlth, San Diego, CA 92182 USA.
   [Zee, Phyllis C.] Northwestern Univ, Ctr Sleep & Circadian Biol, Chicago, IL 60611 USA.
   [Loredo, Jose S.; Ramos, Alberto R.] Univ Calif San Diego, Sch Med, Sleep Med Ctr, San Diego, CA 92103 USA.
   [Loredo, Jose S.; Ramos, Alberto R.] Univ Calif San Diego, Sch Med, VA Pulm Sleep Disorders Lab, San Diego, CA 92103 USA.
   [Singer, Richard H.] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA.
   [Jimenez, Monik C.] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA.
   [Jimenez, Monik C.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
   [Barnhart, Janice M.] Yeshiva Univ, Albert Einstein Coll Med, Bronx, NY USA.
   [Redline, Susan] Brigham & Womens Hosp, Boston, MA 02115 USA.
   [Redline, Susan] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
RP Sanders, AE (corresponding author), Univ N Carolina, Koury Oral Hlth Sci Bldg,Room 4502,CB 7450, Chapel Hill, NC 27599 USA.
EM anne_sanders@unc.edu
RI Ramos, Alberto/X-4249-2019
FU National Heart, Lung, and Blood Institute (NHLBI)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [N01-HC65233];
   University of Miami [N01-HC65234]; Albert Einstein College of Medicine
   [N01-HC65235]; Northwestern University [N01-HC65236]; San Diego State
   University [N01-HC65237]; DIVISION OF EPIDEMIOLOGY AND CLINICAL
   APPLICATIONSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Eye Institute (NEI)
   [N01HC065233] Funding Source: NIH RePORTER; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [KL2TR000461]
   Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [R01HL065234, U01HL065233] Funding Source: NIH
   RePORTER
FX The Hispanic Community Health Study/Study of Latinos was carried out as
   a collaborative study supported by contracts from the National Heart,
   Lung, and Blood Institute (NHLBI) to the University of North Carolina
   (N01-HC65233), University of Miami (N01-HC65234), Albert Einstein
   College of Medicine (N01-HC65235), Northwestern University
   (N01-HC65236), and San Diego State University (N01-HC65237). The
   following Institutes/Centers/Offices contribute to the HCHS/SOL through
   a transfer of funds to the NHLBI: National Center on Minority Health and
   Health Disparities, the National Institute of Deafness and Other
   Communications Disorders, the National Institute of Dental and
   Craniofacial Research, the National Institute of Diabetes and Digestive
   and Kidney Diseases, the National Institute of Neurological Disorders
   and Stroke, and the Office of Dietary Supplements.
CR Ahmad Nuha Ejaz, 2013, J Dent Hyg, V87, P188
   Alani A, 2014, PERIODONTOL 2000, V64, P198, DOI 10.1111/j.1600-0757.2012.00454.x
   Barros SP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068592
   Beck JD, 2000, PERIODONTOL 2000, V23, P110, DOI 10.1034/j.1600-0757.2000.2230111.x
   Bixler EO, 1998, AM J RESP CRIT CARE, V157, P144, DOI 10.1164/ajrccm.157.1.9706079
   Chapple ILC, 2007, J NUTR, V137, P657, DOI 10.1093/jn/137.3.657
   Chin K, 2000, AM J MED, V109, P562, DOI 10.1016/S0002-9343(00)00580-5
   D'Aiuto F, 2008, J CLIN ENDOCR METAB, V93, P3989, DOI 10.1210/jc.2007-2522
   Dietrich T, 2013, J CLIN PERIODONTOL, V40, pS70, DOI [10.1902/jop.2013.134008, 10.1111/jcpe.12062]
   Eke PI, 2012, J DENT RES, V91, P914, DOI 10.1177/0022034512457373
   Fitzsimmons TR, 2010, J CLIN PERIODONTOL, V37, P30, DOI 10.1111/j.1600-051X.2009.01506.x
   Grandner MA, 2013, SLEEP, V36, P769, DOI 10.5665/sleep.2646
   Gunaratnam K, 2009, SLEEP BREATH, V13, P233, DOI 10.1007/s11325-008-0244-0
   Guner I, 2013, BIOL TRACE ELEM RES, V154, P262, DOI 10.1007/s12011-013-9722-8
   Humphrey LL, 2008, J GEN INTERN MED, V23, P2079, DOI 10.1007/s11606-008-0787-6
   Keller JJ, 2013, J CLIN PERIODONTOL, V40, P111, DOI 10.1111/jcpe.12036
   Konopka T, 2007, ARCH IMMUNOL THER EX, V55, P417, DOI 10.1007/s00005-007-0047-1
   Kumari M, 2014, ARCH ORAL BIOL, V59, P645, DOI 10.1016/j.archoralbio.2014.03.012
   Lavange LM, 2010, ANN EPIDEMIOL, V20, P642, DOI 10.1016/j.annepidem.2010.05.006
   Lavie L, 2009, EUR RESPIR J, V33, P1467, DOI 10.1183/09031936.00086608
   Loke W, 2015, J PERIODONTOL, V86, P232, DOI 10.1902/jop.2014.140229
   Louis J, 2012, OBSTET GYNECOL, V120, P1085, DOI 10.1097/AOG.0b013e31826eb9d8
   Maeder MT, 2015, CLIN BIOCHEM, V48, P340, DOI 10.1016/j.clinbiochem.2014.09.005
   Meurice JC, 1996, AM J RESP CRIT CARE, V153, P255, DOI 10.1164/ajrccm.153.1.8542125
   Mizutani S, 2015, J PERIODONTAL RES, V50, P74, DOI 10.1111/jre.12183
   Nibali L, 2013, CURR PHARM DESIGN, V19, P2687, DOI 10.2174/1381612811319150003
   Nizam N, 2014, J PERIODONTOL, V85, pE251, DOI 10.1902/jop.2014.130579
   Page RC, 2007, J PERIODONTOL, V78, P1387, DOI 10.1902/jop.2007.060264
   Paraskevas S, 2008, J CLIN PERIODONTOL, V35, P277, DOI 10.1111/j.1600-051X.2007.01173.x
   Peppard PE, 2000, NEW ENGL J MED, V342, P1378, DOI 10.1056/NEJM200005113421901
   PHIPPS KR, 1995, J PUBLIC HEALTH DENT, V55, P250, DOI 10.1111/j.1752-7325.1995.tb02377.x
   Redline S, 2014, AM J RESP CRIT CARE, V189, P335, DOI 10.1164/rccm.201309-1735OC
   Schenkein HA, 2013, J PERIODONTOL, V84, pS51, DOI [10.1902/jop.2013.134006, 10.1111/jcpe.12060]
   Schiller Jeannine S, 2012, Vital Health Stat 10, P1
   Seo WH, 2013, J PERIODONTAL RES, V48, P500, DOI 10.1111/jre.12032
   Seymour RA, 2006, PERIODONTOL 2000, V40, P120, DOI 10.1111/j.1600-0757.2005.00137.x
   Sforza E, 2013, SLEEP, V36, P1509, DOI 10.5665/sleep.3046
   Shepherd Simon, 2011, Evid Based Dent, V12, P76, DOI 10.1038/sj.ebd.6400808
   Slade GD, 2000, J DENT RES, V79, P49, DOI 10.1177/00220345000790010701
   Sorlie PD, 2010, ANN EPIDEMIOL, V20, P629, DOI 10.1016/j.annepidem.2010.03.015
   Southerland JH, 2012, ATHEROSCLEROSIS, V222, P196, DOI 10.1016/j.atherosclerosis.2012.01.026
   Taylor JJ, 2013, J CLIN PERIODONTOL, V40, pS113, DOI [10.1111/jcpe.12059, 10.1902/jop.2013.134005]
   Young T, 1997, ARCH INTERN MED, V157, P1746, DOI 10.1001/archinte.157.15.1746
NR 43
TC 13
Z9 13
U1 0
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
EI 1550-9109
J9 SLEEP
JI Sleep
PD AUG 1
PY 2015
VL 38
IS 8
BP 1195
EP 1203
AR PII sp-00427-14
DI 10.5665/sleep.4890
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA CO0JV
UT WOS:000358838100008
PM 25669183
OA Bronze, Green Published, Green Submitted
DA 2021-10-30
ER

PT J
AU Redline, S
   Sotres-Alvarez, D
   Loredo, J
   Hall, M
   Patel, SR
   Ramos, A
   Shah, N
   Ries, A
   Arens, R
   Barnhart, J
   Youngblood, M
   Zee, P
   Daviglus, ML
AF Redline, Susan
   Sotres-Alvarez, Daniela
   Loredo, Jose
   Hall, Martica
   Patel, Sanjay R.
   Ramos, Alberto
   Shah, Neomi
   Ries, Andrew
   Arens, Raanan
   Barnhart, Janice
   Youngblood, Marston
   Zee, Phyllis
   Daviglus, Martha L.
TI Sleep-disordered Breathing in Hispanic/Latino Individuals of Diverse
   Backgrounds The Hispanic Community Health Study/Study of Latinos
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article
DE sleep-disordered breathing; Hispanic; epidemiology; disparities
ID APNEA-HYPOPNEA; RISK-FACTOR; ASSOCIATION; PREVALENCE; PREDICTORS;
   SYMPTOMS; COHORT; RACE; HYPERTENSION; DISEASE
AB Rationale: Hispanic/Latino populations have a high prevalence of cardiovascular risk factors and may be at risk for sleep-disordered breathing (SDB). An understanding of SDB among these populations is needed given evidence that SDB increases cardiovascular risk.
   Objectives: To quantify SDB prevalence in the U. S. Hispanic/Latino population and its association with symptoms, risk factors, diabetes, and hypertension; and to explore variation by sex and Hispanic/Latino background.
   Methods: Cross-sectional analysis from the baseline examination of the Hispanic Community Health Study/Study of Latinos.
   Measurements and Main Results: The apnea-hypopnea index (AHI) was derived from standardized sleep tests; diabetes and hypertension were based on measurement and history. The sample of 14,440 individuals had an age-adjusted prevalence of minimal SDB (AHI >= 5), moderate SDB (AHI >= 15), and severe SDB (AHI >= 30) of 25.8, 9.8, and 3.9%, respectively. Only 1.3% of participants reported a sleep apnea diagnosis. Moderate SDB was associated with being male (adjusted odds ratio, 2.7; 95% confidence interval, 2.3-3.1), obese (16.8; 11.6-24.4), and older. SDB was associated with an increased adjusted odds of impaired glucose tolerance (1.7; 1.3-2.1), diabetes (2.3; 1.8-2.9), and hypertension. The association with hypertension varied across background groups with the strongest associations among individuals of Puerto Rican and Central American background.
   Conclusions: SDB is prevalent in U. S. Latinos but rarely associated with a clinical diagnosis. Associations with diabetes and hypertension suggest a large burden of disease may be attributed to untreated SDB, supporting the development and evaluation of culturally relevant detection and treatment approaches.
C1 [Redline, Susan; Patel, Sanjay R.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA.
   [Redline, Susan; Patel, Sanjay R.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA.
   [Sotres-Alvarez, Daniela; Youngblood, Marston] Univ N Carolina, Dept Biostat, Chapel Hill, NC USA.
   [Loredo, Jose] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA.
   [Hall, Martica] Univ Pittsburgh, Sch Med, Dept Psychiat, Western Psychiat Inst, Pittsburgh, PA USA.
   [Ramos, Alberto] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA.
   [Shah, Neomi] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA.
   [Arens, Raanan] Albert Einstein Coll Med, Childrens Hosp Montefiore, Bronx, NY 10467 USA.
   [Barnhart, Janice] Albert Einstein Coll Med, Dept Epidemiol & Publ Hlth, Bronx, NY 10467 USA.
   [Ries, Andrew] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA.
   [Ries, Andrew] Univ Calif San Diego, Dept Family & Prevent Med, San Diego, CA 92103 USA.
   [Zee, Phyllis] Northwestern Univ, Feinberg Sch Med, Dept Neurol, Chicago, IL 60611 USA.
   [Daviglus, Martha L.] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA.
   [Daviglus, Martha L.] Univ Illinois, Dept Med, Inst Minor Hlth Res, Chicago, IL USA.
RP Redline, S (corresponding author), Harvard Univ, Sch Med, BWH Sleep Reading Ctr, Brigham & Womens Hosp,Beth Israel Deaconess Med S, 221 Longwood Ave,Room 225, Boston, MA 02115 USA.
EM sredline@partners.org
RI Hall, Martica/D-2809-2012; Ramos, Alberto/X-4249-2019; DeMarcus,
   Forrest/O-9190-2016; Sotres-Alvarez, Daniela/O-9085-2016
OI Hall, Martica/0000-0003-0642-2098; Sotres-Alvarez,
   Daniela/0000-0002-3226-6140; Patel, Sanjay/0000-0002-9142-5172
FU NHLBIUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [N01-HC65233, N01-HC65234, N01-HC65235, N01-HC65236,
   N01-HC65237]; National Center on Minority Health and Health
   DisparitiesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Minority
   Health & Health Disparities (NIMHD); National Institute of Deafness and
   Other Communications DisordersUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Deafness & Other Communication Disorders (NIDCD); National Institute
   of Dental and Craniofacial ResearchUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Dental & Craniofacial Research (NIDCR); National Institute
   of Diabetes and Digestive and Kidney DiseasesUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK);
   National Institute of Neurological Disorders and StrokeUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Neurological Disorders & Stroke (NINDS);
   Office of Dietary SupplementsUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA; DIVISION OF
   EPIDEMIOLOGY AND CLINICAL APPLICATIONSUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Eye Institute (NEI) [N01HC065233] Funding Source: NIH RePORTER; NATIONAL
   CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Advancing Translational Sciences (NCATS)
   [KL2TR000461] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND
   BLOOD INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [U01HL065233, R01HL065234] Funding Source: NIH
   RePORTER
FX The Hispanic Community Health Study/Study of Latinos was performed as a
   collaborative study supported by contracts from the NHLBI to the
   University of North Carolina (N01-HC65233), University of Miami
   (N01-HC65234), Albert Einstein College of Medicine (N01-HC65235),
   Northwestern University (N01-HC65236), and San Diego State University
   (N01-HC65237). The following institutes, centers, or offices contribute
   to the Hispanic Community Health Study/Study of Latinos through a
   transfer of funds to the NHLBI: National Center on Minority Health and
   Health Disparities, the National Institute of Deafness and Other
   Communications Disorders, the National Institute of Dental and
   Craniofacial Research, the National Institute of Diabetes and Digestive
   and Kidney Diseases, the National Institute of Neurological Disorders
   and Stroke, and the Office of Dietary Supplements.
CR Ahmadi N, 2009, SLEEP BREATH, V13, P221, DOI 10.1007/s11325-008-0234-2
   Al-Delaimy WK, 2002, AM J EPIDEMIOL, V155, P387, DOI 10.1093/aje/155.5.387
   Billings ME, 2011, SLEEP, V34, P1653, DOI 10.5665/sleep.1428
   Bixler EO, 2000, ARCH INTERN MED, V160, P2289, DOI 10.1001/archinte.160.15.2289
   Butt M, 2010, INT J CARDIOL, V139, P7, DOI 10.1016/j.ijcard.2009.05.021
   Daviglus ML, 2012, JAMA-J AM MED ASSOC, V308, P1775, DOI 10.1001/jama.2012.14517
   FLEMONS WW, 1994, AM J RESP CRIT CARE, V150, P1279, DOI 10.1164/ajrccm.150.5.7952553
   Gottlieb DJ, 2010, CIRCULATION, V122, P352, DOI 10.1161/CIRCULATIONAHA.109.901801
   Hellevik O, 2009, QUAL QUANT, V43, P59, DOI 10.1007/s11135-007-9077-3
   Hong S, 2005, BRAIN BEHAV IMMUN, V19, P165, DOI 10.1016/j.bbi.2004.07.008
   James C, 2011, DIABETES CARE, V34, P387, DOI 10.2337/dc10-1314
   JOHNS MW, 1992, SLEEP, V15, P376, DOI 10.1093/sleep/15.4.376
   Kapur Vishesh, 2002, Sleep Breath, V6, P49, DOI 10.1055/s-2002-32318
   Kripke DF, 1997, SLEEP, V20, P65, DOI 10.1093/sleep/20.1.65
   KUMP K, 1994, AM J RESP CRIT CARE, V150, P735, DOI 10.1164/ajrccm.150.3.8087345
   Lavange LM, 2010, ANN EPIDEMIOL, V20, P642, DOI 10.1016/j.annepidem.2010.05.006
   Lavie L, 2003, SLEEP MED REV, V7, P35, DOI 10.1053/smrv.2002.0261
   Lind Bonnie K, 2003, Sleep Breath, V7, P13, DOI 10.1007/s11325-003-0013-z
   Louis J, 2012, OBSTET GYNECOL, V120, P1085, DOI 10.1097/AOG.0b013e31826eb9d8
   Marin JM, 2012, JAMA-J AM MED ASSOC, V307, P2169, DOI 10.1001/jama.2012.3418
   Mehra R, 2008, J ALLERGY CLIN IMMUN, V121, P1096, DOI 10.1016/j.jaci.2008.04.002
   Nieto FJ, 2000, JAMA-J AM MED ASSOC, V283, P1829, DOI 10.1001/jama.283.14.1829
   Norman D, 2006, HYPERTENSION, V47, P840, DOI 10.1161/01.HYP.0000217128.41284.78
   O'Connor GT, 2003, SLEEP, V26, P74
   Peppard PE, 2013, AM J EPIDEMIOL, V177, P1006, DOI 10.1093/aje/kws342
   Peppard PE, 2000, NEW ENGL J MED, V342, P1378, DOI 10.1056/NEJM200005113421901
   Punjabi NM, 2004, AM J EPIDEMIOL, V160, P521, DOI 10.1093/aje/kwh261
   Ram S, 2010, SLEEP BREATH, V14, P63, DOI 10.1007/s11325-009-0281-3
   Ramos AR, 2011, NEUROEPIDEMIOLOGY, V37, P210, DOI 10.1159/000334315
   Redline S, 2003, SLEEP, V26, P703, DOI 10.1093/sleep/26.6.703
   Redline S, 2012, SLEEP, V35, pA182
   Redline S, 2011, JOINT C NUTR PHYS AC
   Redline S, 2013, AM THOR SOC INT C MA
   Redline S, 2010, AM J RESP CRIT CARE, V182, P269, DOI 10.1164/rccm.200911-1746OC
   Savransky V, 2008, CIRC RES, V103, P1173, DOI 10.1161/CIRCRESAHA.108.178533
   Seicean S, 2008, DIABETES CARE, V31, P1001, DOI 10.2337/dc07-2003
   Shafazand S, 2012, J CLIN SLEEP MED, V8, P507, DOI 10.5664/jcsm.2142
   Shahar E, 2001, AM J RESP CRIT CARE, V163, P19, DOI 10.1164/ajrccm.163.1.2001008
   Skolarus LE, 2012, STROKE, V43, P1143, DOI 10.1161/STROKEAHA.111.638387
   Sorlie PD, 2010, ANN EPIDEMIOL, V20, P629, DOI 10.1016/j.annepidem.2010.03.015
   Spilsbury JC, 2006, J PEDIATR-US, V149, P342, DOI 10.1016/j.jpeds.2006.04.061
   Weinstock TG, 2012, SLEEP, V35, P617, DOI 10.5665/sleep.1816
   Westbrook PR, 2005, CHEST, V128, P2166, DOI 10.1378/chest.128.4.2166
   Young T, 2002, AM J RESP CRIT CARE, V165, P1217, DOI 10.1164/rccm.2109080
   Young T, 2005, J APPL PHYSIOL, V99, P1592, DOI 10.1152/japplphysiol.00587.2005
   YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704
   Young T, 2002, ARCH INTERN MED, V162, P893, DOI 10.1001/archinte.162.8.893
NR 47
TC 126
Z9 129
U1 0
U2 15
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD FEB 1
PY 2014
VL 189
IS 3
BP 335
EP 344
DI 10.1164/rccm.201309-1735OC
PG 10
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA AB4XN
UT WOS:000331793400016
PM 24392863
OA Green Published
DA 2021-10-30
ER

PT J
AU Frasca, D
   Blomberg, BB
AF Frasca, Daniela
   Blomberg, Bonnie B.
TI B Cell-Specific Biomarkers for Optimal Antibody Responses to Influenza
   Vaccination and Molecular Pathways That Reduce B Cell Function with
   Aging
SO CRITICAL REVIEWS IN IMMUNOLOGY
LA English
DT Article
DE aging; B cells; inflammation; vaccine responses
ID INDUCED CYTIDINE DEAMINASE; CLASS SWITCH RECOMBINATION; HUMORAL
   IMMUNE-RESPONSE; YELLOW-FEVER VACCINE; CD8(+) T-CELLS; SEASONAL
   INFLUENZA; LIFE-SPAN; CYTOMEGALOVIRUS-INFECTION; GRANZYME-B;
   PERIPHERAL-BLOOD
AB This review highlights recent findings on the effects of aging on influenza vaccine responses, with major emphasis on T and B cells, which are significantly impaired by aging. We discuss changes in T cell production and thymic output; T cell subsets; and TCR repertoire, function, and response to latent persistent infection. We also discuss changes in B cell subsets, repertoire, and function, and how function is impaired by increased intrinsic B cell inflammation and reduced signal transduction. This review presents age-related effects on antigen-presenting cells, summarizes recent studies, including our own, aimed at the identification of biomarkers of protective vaccine responses, and provides examples of recent technical advances and insights into human vaccine responses that are helping to define the features associated with successful vaccination and that may enable a more predictive vaccinology in the future.
C1 [Frasca, Daniela; Blomberg, Bonnie B.] Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, POB 016960 R-138, Miami, FL 33101 USA.
RP Frasca, D (corresponding author), Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, POB 016960 R-138, Miami, FL 33101 USA.
EM dfrasca@med.miami.edu
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [AG023717, R56 AG32576, AI096446,
   AG042826, AG032576]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1TR000460] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [R21AI096446] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE ON AGINGUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Aging (NIA) [R01AG032576, R56AG032576, R21AG042826, R01AG023717,
   R37AG023717] Funding Source: NIH RePORTER
FX This study was supported by NIH AG023717 (BBB), NIH R56 AG32576
   (DF/BBB), AI096446, AG042826, and AG032576 (BBB/DF).
CR Adlowitz DG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128269
   Agrawal S, 2011, J CLIN IMMUNOL, V31, P89, DOI [10.1007/s10875-010-9456-8, 10.1007/s10875-010-9507-1]
   Amanna IJ, 2007, NEW ENGL J MED, V357, P1903, DOI 10.1056/NEJMoa066092
   Andrews SF, 2015, J VIROL, V89, P3308, DOI 10.1128/JVI.02871-14
   Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767
   Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588
   Bernstein E, 1999, VACCINE, V17, P82, DOI 10.1016/S0264-410X(98)00117-0
   Bucasas KL, 2011, J INFECT DIS, V203, P921, DOI 10.1093/infdis/jiq156
   Bulati M, 2014, EXP GERONTOL, V54, P123, DOI 10.1016/j.exger.2013.12.011
   Caro-Maldonado A, 2014, J IMMUNOL, V192, P3626, DOI 10.4049/jimmunol.1302062
   Chang LY, 2017, J VIRAL HEPATITIS, V24, P389, DOI 10.1111/jvh.12659
   Claes N, 2016, J IMMUNOL, V197, P4576, DOI 10.4049/jimmunol.1502448
   Colonna-Romano G, 2009, MECH AGEING DEV, V130, P681, DOI 10.1016/j.mad.2009.08.003
   DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0
   de Bruijn IA, 1999, J INFECT DIS, V179, P31, DOI 10.1086/314540
   den Elzen WPJ, 2011, VACCINE, V29, P4869, DOI 10.1016/j.vaccine.2011.03.086
   Derhovanessian E, 2014, J IMMUNOL, V193, P3624, DOI 10.4049/jimmunol.1303361
   Derhovanessian E, 2013, AGE, V35, P1387, DOI 10.1007/s11357-012-9425-7
   Derhovanessian E, 2013, VACCINE, V31, P685, DOI 10.1016/j.vaccine.2012.11.041
   Dorsett Y, 2008, IMMUNITY, V28, P630, DOI 10.1016/j.immuni.2008.04.002
   Durandy A, 2002, BIOCHEM SOC T, V30, P815, DOI 10.1042/bst0300815
   Ferrucci L, 1997, JAMA-J AM MED ASSOC, V277, P728
   Franco LM, 2013, ELIFE, V2, DOI 10.7554/eLife.00299
   Frasca D, 2008, J IMMUNOL, V180, P5283, DOI 10.4049/jimmunol.180.8.5283
   Frasca D, 2017, EXP GERONTOL, V87, P113, DOI 10.1016/j.exger.2016.12.001
   Frasca D, 2016, VACCINE, V34, P2834, DOI 10.1016/j.vaccine.2016.04.023
   Frasca D, 2016, HUM VACC IMMUNOTHER, V12, P682, DOI 10.1080/21645515.2015.1105413
   Frasca D, 2016, OBESITY, V24, P615, DOI 10.1002/oby.21383
   Frasca D, 2015, J IMMUNOL, V195, P2134, DOI 10.4049/jimmunol.1500520
   Frasca D, 2015, VACCINE, V33, P1433, DOI 10.1016/j.vaccine.2015.01.071
   Frasca D, 2014, EXP GERONTOL, V54, P116, DOI 10.1016/j.exger.2014.01.004
   Frasca D, 2013, VACCINE, V31, P3603, DOI 10.1016/j.vaccine.2013.05.003
   Frasca D, 2013, IMMUN AGEING, V10, DOI 10.1186/1742-4933-10-14
   Frasca D, 2012, INT IMMUNOL, V24, P175, DOI 10.1093/intimm/dxr123
   Frasca D, 2010, VACCINE, V28, P8077, DOI 10.1016/j.vaccine.2010.10.023
   Furman D, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.15
   Gaucher D, 2008, J EXP MED, V205, P3119, DOI 10.1084/jem.20082292
   Goenka R, 2014, EXP GERONTOL, V54, P109, DOI 10.1016/j.exger.2013.12.013
   Goodwin K, 2006, VACCINE, V24, P1159, DOI 10.1016/j.vaccine.2005.08.105
   Goronzy JJ, 2001, J VIROL, V75, P12182, DOI 10.1128/JVI.75.24.12182-12187.2001
   GROSS PA, 1995, ANN INTERN MED, V123, P518, DOI 10.7326/0003-4819-123-7-199510010-00008
   Haralambieva IH, 2016, VACCINE, V34, P3993, DOI 10.1016/j.vaccine.2016.06.034
   Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221
   Heikamp EB, 2012, SEMIN IMMUNOL, V24, P414, DOI 10.1016/j.smim.2012.12.003
   Henson SM, 2014, J CLIN INVEST, V124, P4004, DOI 10.1172/JCI75051
   HIROKAWA K, 1975, J IMMUNOL, V114, P1659
   Hopping AM, 2016, VACCINE, V34, P540, DOI 10.1016/j.vaccine.2015.11.058
   Illingworth J, 2013, J IMMUNOL, V190, P1038, DOI 10.4049/jimmunol.1202438
   Jiang N, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004794
   Johnson BJ, 2003, P NATL ACAD SCI USA, V100, P2657, DOI 10.1073/pnas.0538056100
   Kaeberlein M, 2005, SCIENCE, V310, P1193, DOI 10.1126/science.1115535
   Kapahi P, 2004, CURR BIOL, V14, P885, DOI 10.1016/j.cub.2004.03.059
   Kennedy RB, 2016, IMMUNOLOGY, V148, P266, DOI 10.1111/imm.12599
   Khurana S, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002920
   Lanna A, 2014, NAT IMMUNOL, V15, P965, DOI 10.1038/ni.2981
   Lawrence CW, 2005, J IMMUNOL, V174, P5332, DOI 10.4049/jimmunol.174.9.5332
   Li S, 2014, NAT IMMUNOL, V15, P195, DOI 10.1038/ni.2789
   Mannick JB, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009892
   Martin V, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0237
   Martorana A, 2014, IMMUNOL LETT, V162, P303, DOI 10.1016/j.imlet.2014.06.003
   McElhaney JE, 2013, LANCET INFECT DIS, V13, P485, DOI 10.1016/S1473-3099(13)70046-X
   McElhaney JE, 2012, VACCINE, V30, P2060, DOI 10.1016/j.vaccine.2012.01.015
   McElhaney JE, 2011, AGEING RES REV, V10, P379, DOI 10.1016/j.arr.2010.10.008
   McElhaney JE, 2009, CURR OPIN IMMUNOL, V21, P418, DOI 10.1016/j.coi.2009.05.023
   McElhaney JE, 2009, VACCINE, V27, P2418, DOI 10.1016/j.vaccine.2009.01.136
   McElhaney JE, 2006, J IMMUNOL, V176, P6333, DOI 10.4049/jimmunol.176.10.6333
   Mohanty S, 2015, J INFECT DIS, V211, P1174, DOI 10.1093/infdis/jiu573
   Moir S, 2008, J EXP MED
   Muller-Durovic B, 2016, J IMMUNOL, V197, P2891, DOI 10.4049/jimmunol.1600590
   Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7
   Muramatsu Masamichi, 2007, Adv Immunol, V94, P1, DOI 10.1016/S0065-2776(06)94001-2
   Murasko DM, 2002, EXP GERONTOL, V37, P427, DOI 10.1016/S0531-5565(01)00210-8
   Nakaya HI, 2015, IMMUNITY, V43, P1186, DOI 10.1016/j.immuni.2015.11.012
   Nakaya HI, 2011, NAT IMMUNOL, V12, P786, DOI 10.1038/ni.2067
   Naylor K, 2005, J IMMUNOL, V174, P7446, DOI 10.4049/jimmunol.174.11.7446
   Obermoser G, 2013, IMMUNITY, V38, P831, DOI 10.1016/j.immuni.2012.12.008
   Panda A, 2010, J IMMUNOL, V184, P2518, DOI 10.4049/jimmunol.0901022
   Pawelec G, 2002, FRONT BIOSCI-LANDMRK, V7, pD1056
   Pawelec G, 2012, CURR OPIN IMMUNOL, V24, P507, DOI 10.1016/j.coi.2012.04.002
   Pera A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088538
   Precopio ML, 2007, J EXP MED, V204, P1405, DOI 10.1084/jem.20062363
   Pritz T, 2015, EUR J IMMUNOL, V45, P738, DOI 10.1002/eji.201444878
   Pulendran B, 2014, P NATL ACAD SCI USA, V111, P12300, DOI 10.1073/pnas.1400476111
   Pulendran B, 2010, IMMUNITY, V33, P516, DOI 10.1016/j.immuni.2010.10.006
   Pulko V, 2016, NAT IMMUNOL, V17, P966, DOI 10.1038/ni.3483
   Querec TD, 2009, NAT IMMUNOL, V10, P116, DOI 10.1038/ni.1688
   Recalcati S, 2012, SEMIN IMMUNOL, V24, P393, DOI 10.1016/j.smim.2013.01.001
   Rinaldi S, 2014, VACCINE, V32, P657, DOI 10.1016/j.vaccine.2013.12.008
   Rosengart MR, 2000, SHOCK, V13, P183, DOI 10.1097/00024382-200003000-00003
   Ruderman N, 2004, NAT REV DRUG DISCOV, V3, P340, DOI 10.1038/nrd1344
   Saadoun D, 2013, ARTHRITIS RHEUM-US, V65, P1085, DOI 10.1002/art.37828
   Sambhara S, 2009, CURR TOP MICROBIOL, V333, P413, DOI 10.1007/978-3-540-92165-3_20
   Sasaki S, 2011, J CLIN INVEST, V121, P3109, DOI 10.1172/JCI57834
   Sasaki S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002975
   Saurwein-Teissl M, 2002, J IMMUNOL, V168, P5893, DOI 10.4049/jimmunol.168.11.5893
   Shahid Z, 2010, VACCINE, V28, P6145, DOI 10.1016/j.vaccine.2010.07.036
   Simonsen L, 2007, LANCET INFECT DIS, V7, P658, DOI 10.1016/S1473-3099(07)70236-0
   Spazzafumo L, 2013, AGE, V35, P419, DOI 10.1007/s11357-011-9348-8
   Tangye SG, 2009, EUR J IMMUNOL, V39, P2065, DOI 10.1002/eji.200939531
   Targonski PV, 2007, VACCINE, V25, P3066, DOI 10.1016/j.vaccine.2007.01.025
   Teng G, 2008, IMMUNITY, V28, P621, DOI 10.1016/j.immuni.2008.03.015
   Thiery J, 2011, NAT IMMUNOL, V12, P770, DOI 10.1038/ni.2050
   Trzonkowski P, 2003, VACCINE, V21, P3826, DOI 10.1016/S0264-410X(03)00309-8
   Tsang JS, 2014, CELL, V157, P499, DOI 10.1016/j.cell.2014.03.031
   Vallejo AN, 2005, IMMUNOL REV, V205, P158, DOI 10.1111/j.0105-2896.2005.00256.x
   Vallejo AN, 2004, TRENDS MOL MED, V10, P119, DOI 10.1016/j.molmed.2004.01.002
   van Essen GA, 2014, INFLUENZA OTHER RESP, V8, P452, DOI 10.1111/irv.12245
   Vellai T, 2003, NATURE, V426, P620, DOI 10.1038/426620a
   Verbist KC, 2012, SEMIN IMMUNOL, V24, P399, DOI 10.1016/j.smim.2012.12.006
   Wehr C, 2004, CLIN IMMUNOL, V113, P161, DOI 10.1016/j.clim.2004.05.010
   Weill JC, 2009, ANNU REV IMMUNOL, V27, P267, DOI 10.1146/annurev.immunol.021908.132607
   Wertheimer AM, 2014, J IMMUNOL, V192, P2143, DOI 10.4049/jimmunol.1301721
   WHISLER RL, 1991, LYMPHOKINE CYTOK RES, V10, P463
   Wikby A, 2006, MECH AGEING DEV, V127, P695, DOI 10.1016/j.mad.2006.04.003
   Wilkinson TM, 2012, NAT MED, V18, P274, DOI 10.1038/nm.2612
   Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016
   Xu XJ, 2012, SEMIN IMMUNOL, V24, P429, DOI 10.1016/j.smim.2012.12.005
   Zhang XH, 2008, J IMMUNOL, V181, P5015, DOI 10.4049/jimmunol.181.7.5015
NR 118
TC 4
Z9 4
U1 0
U2 2
PU BEGELL HOUSE INC
PI DANBURY
PA 50 NORTH ST, DANBURY, CT 06810 USA
SN 1040-8401
EI 2162-6472
J9 CRIT REV IMMUNOL
JI Crit. Rev. Immunol.
PY 2016
VL 36
IS 6
BP 523
EP 537
DI 10.1615/CritRevImmunol.2017020113
PG 15
WC Immunology
SC Immunology
GA FE8XZ
UT WOS:000408490100005
PM 28845758
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Mitrofanova, A
   Mallela, SK
   Ducasa, GM
   Yoo, TH
   Rosenfeld-Gur, E
   Zelnik, ID
   Molina, J
   Santos, JV
   Ge, M
   Sloan, A
   Kim, JJ
   Pedigo, C
   Bryn, J
   Volosenco, I
   Faul, C
   Zeidan, YH
   Hernandez, CG
   Mendez, AJ
   Leibiger, I
   Burke, GW
   Futerman, AH
   Barisoni, L
   Ishimoto, Y
   Inagi, R
   Merscher, S
   Fornoni, A
AF Mitrofanova, A.
   Mallela, S. K.
   Ducasa, G. M.
   Yoo, T. H.
   Rosenfeld-Gur, E.
   Zelnik, I. D.
   Molina, J.
   Santos, J. Varona
   Ge, M.
   Sloan, A.
   Kim, J. J.
   Pedigo, C.
   Bryn, J.
   Volosenco, I.
   Faul, C.
   Zeidan, Y. H.
   Hernandez, C. Garcia
   Mendez, A. J.
   Leibiger, I.
   Burke, G. W.
   Futerman, A. H.
   Barisoni, L.
   Ishimoto, Y.
   Inagi, R.
   Merscher, S.
   Fornoni, A.
TI SMPDL3b modulates insulin receptor signaling in diabetic kidney disease
SO NATURE COMMUNICATIONS
LA English
DT Article
ID SPHINGOSINE KINASE 2; CERAMIDE 1-PHOSPHATE; CELL-MIGRATION;
   SPHINGOSINE-1-PHOSPHATE; EXPRESSION; RESISTANT; SPHINGOLIPIDS;
   DEFICIENCY; INHIBITION; CAVEOLIN
AB Sphingomyelin phosphodiesterase acid-like 3b (SMPDL3b) is a lipid raft enzyme that regulates plasma membrane (PM) fluidity. Here we report that SMPDL3b excess, as observed in podocytes in diabetic kidney disease (DKD), impairs insulin receptor isoform B-dependent pro-survival insulin signaling by interfering with insulin receptor isoforms binding to caveolin-1 in the PM. SMPDL3b excess affects the production of active sphingolipids resulting in decreased ceramide-1-phosphate (C1P) content as observed in human podocytes in vitro and in kidney cortexes of diabetic db/db mice in vivo. Podocyte-specific Smpdl3b deficiency in db/ db mice is sufficient to restore kidney cortex C1P content and to protect from DKD. Exogenous administration of C1P restores IR signaling in vitro and prevents established DKD progression in vivo. Taken together, we identify SMPDL3b as a modulator of insulin signaling and demonstrate that supplementation with exogenous C1P may represent a lipid therapeutic strategy to treat diabetic complications such as DKD.
C1 [Mitrofanova, A.; Mallela, S. K.; Ducasa, G. M.; Yoo, T. H.; Molina, J.; Santos, J. Varona; Ge, M.; Sloan, A.; Kim, J. J.; Pedigo, C.; Bryn, J.; Volosenco, I.; Faul, C.; Hernandez, C. Garcia; Merscher, S.; Fornoni, A.] Univ Miami, Miller Sch Med, Dept Med, Katz Family Div Nephrol & Hypertens, Miami, FL 33136 USA.
   [Mitrofanova, A.; Mallela, S. K.; Ducasa, G. M.; Yoo, T. H.; Molina, J.; Santos, J. Varona; Ge, M.; Sloan, A.; Kim, J. J.; Pedigo, C.; Bryn, J.; Volosenco, I.; Faul, C.; Zeidan, Y. H.; Hernandez, C. Garcia; Merscher, S.; Fornoni, A.] Univ Miami, Miller Sch Med, Peggy & Harold Katz Family Drug Discovery Ctr, Miami, FL 33136 USA.
   [Mitrofanova, A.; Burke, G. W.] Univ Miami, Miller Sch Med, Dept Surg, Miami, FL 33136 USA.
   [Ducasa, G. M.; Ge, M.] Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA.
   [Yoo, T. H.] Yonsei Univ, Coll Med, Dept Internal Med, Seoul 03722, South Korea.
   [Rosenfeld-Gur, E.; Zelnik, I. D.; Futerman, A. H.] Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.
   [Pedigo, C.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA.
   [Volosenco, I.] Lewis Gale Med Ctr, Salem, VI 24153 USA.
   [Faul, C.] Univ Alabama Birmingham, Dept Med, Div Nephrol, Birmingham, AL 35233 USA.
   [Zeidan, Y. H.; Hernandez, C. Garcia] Univ Miami, Miller Sch Med, Dept Radiat Oncol, Miami, FL 33136 USA.
   [Zeidan, Y. H.] Amer Univ Beirut, Dept Radiat Oncol, Beirut 11072020, Lebanon.
   [Mendez, A. J.; Burke, G. W.] Univ Miami, Miller Sch Med, Diabet Res Inst, Miami, FL 33136 USA.
   [Leibiger, I.] Karolinska Inst, Rolf Luft Res Ctr Diabet & Endocrinol, S-17176 Stockholm, Sweden.
   [Barisoni, L.] Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL 33136 USA.
   [Ishimoto, Y.; Inagi, R.] Univ Tokyo, Grad Sch Med, Div Nephrol & Endocrinol, Tokyo 1138654, Japan.
   [Ishimoto, Y.; Inagi, R.] Univ Tokyo, Grad Sch Med, Div CKD Pathophysiol, Tokyo 1138654, Japan.
RP Fornoni, A (corresponding author), Univ Miami, Miller Sch Med, Dept Med, Katz Family Div Nephrol & Hypertens, Miami, FL 33136 USA.; Fornoni, A (corresponding author), Univ Miami, Miller Sch Med, Peggy & Harold Katz Family Drug Discovery Ctr, Miami, FL 33136 USA.
EM afornoni@med.miami.edu
RI Mallela, Shamroop kumar/W-6982-2019
OI Mallela, Shamroop kumar/0000-0002-4553-8504; Yoo,
   Tae-Hyun/0000-0002-9183-4507; Futerman, Anthony/0000-0003-0013-0115;
   fornoni, Alessia/0000-0002-1313-7773; Volosenco,
   Ion/0000-0003-0580-1811; Merscher, Sandra/0000-0002-4757-7494; KIM,
   JINJU/0000-0001-8432-7956; Garcia, Claudia/0000-0003-2441-3638
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [DK090316, U24DK076169, U54DK083912,
   UM1DK100846, 1UL1TR000460, DK104753, DK11759, CA227493]; Hoffman-La
   Roche; American Heart AssociationAmerican Heart Association
   [16PRE30200010]; NRSA Post-doctoral fellowship from NIH/NIDDK
   [F32DK115109]; NATIONAL CANCER INSTITUTEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Cancer Institute (NCI) [R01CA227493] Funding Source: NIH
   RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Advancing Translational
   Sciences (NCATS) [UL1TR000460] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Diabetes & Digestive & Kidney Diseases
   (NIDDK) [P30DK079626, U24DK076169, U54DK083912, UM1DK100846,
   R01DK104753, F32DK115109] Funding Source: NIH RePORTER
FX A.F. and S.M. are supported by the NIH grants DK104753, DK11759 and
   CA227493. A.F. is supported by the NIH grants DK090316, U24DK076169,
   U54DK083912, UM1DK100846, and 1UL1TR000460. A.F., S.M., C.F. are
   supported by Hoffman-La Roche. G.M.D. is supported by a Predoctoral
   Fellowship of the American Heart Association (16PRE30200010). JJK is
   supported by NRSA Post-doctoral fellowship from NIH/NIDDK (F32DK115109).
   We thank Dr. Chalfant for his suggestions in the design of exogenous C1P
   experiments in vivo. We thank Dr. Heinz the CeMM Research Center for
   Molecular Medicine of the Austrian Academy of Sciences for a kind gift
   of HA-tagged human wildtype and mutant SMPDL3b constructs. We would like
   to acknowledge the skilled assistance of the Flow Cytometry Shared
   Resource and the Analytical Imaging Shared Resource of the Sylvester
   Comprehensive Cancer Center at the University of Miami, Miller School of
   Medicine, for the provision of the sophisticated fluorescence analysis.
CR Adams JM, 2004, DIABETES, V53, P25, DOI 10.2337/diabetes.53.1.25
   Ahmad A, 2017, FASEB J, V31, P771, DOI 10.1096/fj.201600618R
   Asanuma K, 2005, J CLIN INVEST, V115, P1188, DOI 10.1172/JCI200523371
   Bajwa A, 2017, J AM SOC NEPHROL, V28, P1145, DOI 10.1681/ASN.2016030306
   Baudiss K, 2016, J IMMUNOL, V196, P2319, DOI 10.4049/jimmunol.1402681
   Bielawski J, 2006, METHODS, V39, P82, DOI 10.1016/j.ymeth.2006.05.004
   BOUDKER O, 1993, J BIOL CHEM, V268, P22150
   Chalfant CE, 2005, J CELL SCI, V118, P4605, DOI 10.1242/jcs.02637
   Chaurasia B, 2016, CELL METAB, V24, P820, DOI 10.1016/j.cmet.2016.10.002
   Chavez JA, 2005, J BIOL CHEM, V280, P20148, DOI 10.1074/jbc.M412769200
   Chavez JA, 2003, J BIOL CHEM, V278, P10297, DOI 10.1074/jbc.M212307200
   Choudhary V, 2015, J CELL BIOL, V211, P261, DOI 10.1083/jcb.201505067
   Cohen AW, 2003, AM J PHYSIOL-ENDOC M, V285, pE1151, DOI 10.1152/ajpendo.00324.2003
   Crowley SD, 2009, J CLIN INVEST, V119, P943, DOI 10.1172/JCI34862
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Eduardsen K, 2011, CELL PHYSIOL BIOCHEM, V28, P1231, DOI 10.1159/000335855
   Farley FW, 2000, GENESIS, V28, P106, DOI 10.1002/1526-968X(200011/12)28:3/4<106::AID-GENE30>3.0.CO;2-T
   Fornoni A, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002231
   Gangoiti P, 2008, CELL SIGNAL, V20, P726, DOI 10.1016/j.cellsig.2007.12.008
   Gomez-Munoz A, 2000, SHINGOLIPIDS SIGNALI
   Gomez-Munoz A, 2006, BBA-BIOMEMBRANES, V1758, P2049, DOI 10.1016/j.bbamem.2006.05.011
   Gorelik A, 2016, J BIOL CHEM, V291, P24054, DOI 10.1074/jbc.M116.755801
   Graf C, 2008, J IMMUNOL, V180, P3457, DOI 10.4049/jimmunol.180.5.3457
   Granado MH, 2009, CELL SIGNAL, V21, P405, DOI 10.1016/j.cellsig.2008.11.003
   Guzman J, 2014, DIABETES, V63, P701, DOI 10.2337/db13-0752
   Hait NC, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/4806541
   Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329
   He XX, 2010, NEUROBIOL AGING, V31, P398, DOI 10.1016/j.neurobiolaging.2008.05.010
   Heinz LX, 2015, CELL REP, V11, P1919, DOI 10.1016/j.celrep.2015.05.006
   Holland WL, 2007, CELL METAB, V5, P167, DOI 10.1016/j.cmet.2007.01.002
   Janecke AR, 2017, HUM MUTAT, V38, P365, DOI 10.1002/humu.23192
   Kabayama K, 2007, P NATL ACAD SCI USA, V104, P13678, DOI 10.1073/pnas.0703650104
   Kim CH, 2012, LEUKEMIA, V26, P106, DOI 10.1038/leu.2011.185
   Kinoshita T, 2016, J LIPID RES, V57, P6, DOI 10.1194/jlr.R063313
   Lee JA, 2015, ONCOTARGET, V6, P1942, DOI 10.18632/oncotarget.3039
   Lee SY, 2017, DIABETES, V66, P2596, DOI 10.2337/db16-1232
   Lee YD, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2015.77
   Leibiger B, 2001, MOL CELL, V7, P559, DOI 10.1016/S1097-2765(01)00203-9
   Lovric S, 2017, J CLIN INVEST, V127, P912, DOI 10.1172/JCI89626
   Marfia G, 2014, GLIA, V62, P1968, DOI 10.1002/glia.22718
   McCloy RA, 2014, CELL CYCLE, V13, P1400, DOI 10.4161/cc.28401
   Meikle PJ, 2017, NAT REV ENDOCRINOL, V13, P79, DOI 10.1038/nrendo.2016.169
   Mima A, 2011, KIDNEY INT, V79, P883, DOI 10.1038/ki.2010.526
   Mitsutake S, 2004, J BIOL CHEM, V279, P17570, DOI 10.1074/jbc.M312885200
   Moeller MJ, 2003, GENESIS, V35, P39, DOI 10.1002/gene.10164
   Montes GS, 1996, CELL BIOL INT, V20, P15, DOI 10.1006/cbir.1996.0004
   Natarajan V, 2013, AM J RESP CELL MOL, V49, P6, DOI 10.1165/rcmb.2012-0411TR
   Ogretmen B, 2006, FEBS LETT, V580, P5467, DOI 10.1016/j.febslet.2006.08.052
   Ogretmen B, 2018, NAT REV CANCER, V18, P33, DOI 10.1038/nrc.2017.96
   Otsu K, 2010, AM J PHYSIOL-CELL PH, V298, pC450, DOI 10.1152/ajpcell.00077.2009
   Perreault L, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.96805
   Prasad R, 2017, J CLIN INVEST, V127, P942, DOI 10.1172/JCI90171
   Rao RP, 2013, J LIPIDS, V2013, DOI 10.1155/2013/178910
   Razani B, 2002, J BIOL CHEM, V277, P8635, DOI 10.1074/jbc.M110970200
   Rivera IG, 2016, BIOCHEM PHARMACOL, V102, P107, DOI 10.1016/j.bcp.2015.12.009
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Saleem MA, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133630
   Sedding DG, 2005, CIRC RES, V96, P635, DOI 10.1161/01.RES.0000160610.61306.0f
   Sivasubramanian M, 2015, NEUROSCIENCE, V290, P636, DOI 10.1016/j.neuroscience.2015.01.032
   Stratford S, 2004, J BIOL CHEM, V279, P36608, DOI 10.1074/jbc.M406499200
   Summers SA, 2010, CURR OPIN LIPIDOL, V21, P128, DOI 10.1097/MOL.0b013e3283373b66
   Takahashi N, 2007, KIDNEY INT, V71, P266, DOI 10.1038/sj.ki.5002033
   Tejada T, 2008, KIDNEY INT, V73, P1385, DOI 10.1038/ki.2008.109
   TURINSKY J, 1990, J BIOL CHEM, V265, P16880
   van den Berg JG, 2004, KIDNEY INT, V66, P1901, DOI 10.1111/j.1523-1755.2004.00964.x
   Van Krieken R, 2017, CURR DIABETES REP, V17, DOI 10.1007/s11892-017-0844-9
   Villarreal R, 2016, J AM SOC NEPHROL, V27, P1029, DOI 10.1681/ASN.2015020210
   Wei CL, 2011, NAT MED, V17, P952, DOI 10.1038/nm.2411
   Yamamoto M, 1998, J BIOL CHEM, V273, P26962, DOI 10.1074/jbc.273.41.26962
   Yoo TH, 2015, J AM SOC NEPHROL, V26, P133, DOI 10.1681/ASN.2013111213
NR 70
TC 36
Z9 36
U1 2
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JUN 19
PY 2019
VL 10
AR 2692
DI 10.1038/s41467-019-10584-4
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA ID9UJ
UT WOS:000472032300007
PM 31217420
OA Green Published, gold
DA 2021-10-30
ER

PT J
AU Mitrofanova, A
   Molina, J
   Santos, JV
   Guzman, J
   Morales, XA
   Ducasa, GM
   Bryn, J
   Sloan, A
   Volosenco, I
   Kim, JJ
   Ge, MY
   Mallela, SK
   Kretzler, M
   Eddy, S
   Martini, S
   Wahl, P
   Pastori, S
   Mendez, AJ
   Burke, GW
   Merscher, S
   Fornoni, A
AF Mitrofanova, Alla
   Molina, Judith
   Santos, Javier Varona
   Guzman, Johanna
   Morales, Ximena A.
   Ducasa, G. Michelle
   Bryn, Jonathan
   Sloan, Alexis
   Volosenco, Ion
   Kim, Jin-Ju
   Ge, Mengyuan
   Mallela, Shamroop K.
   Kretzler, Matthias
   Eddy, Sean
   Martini, Sebastian
   Wahl, Patricia
   Pastori, Santiago
   Mendez, Armando J.
   Burke, George W.
   Merscher, Sandra
   Fornoni, Alessia
TI Hydroxypropyl-beta-cyclodextrin protects from kidney disease in
   experimental Alport syndrome and focal segmental glomerulosclerosis
SO KIDNEY INTERNATIONAL
LA English
DT Article
DE Alport syndrome; cholesterol metabolism; FSGS; hydroxypropyl beta
   cyclodextrin; renal function
ID LECITHIN-CHOLESTEROL ACYLTRANSFERASE; RENAL LIPID-METABOLISM; ADRIAMYCIN
   NEPHROPATHY; ACCUMULATION; MICE; PATHOGENESIS; MACROPHAGE; DEPOSITION;
   MONOCYTES; KNOCKOUT
AB Studies suggest that altered renal lipid metabolism plays a role in the pathogenesis of diabetic kidney disease and that genetic or pharmacological induction of cholesterol efflux protects from the development of diabetic kidney disease and focal segmental glomerulosclerosis (FSGS). Here we tested whether altered lipid metabolism contributes to renal failure in the Col4a3 knockout mouse model for Alport Syndrome. There was an eight-fold increase in the cholesterol content in renal cortexes of mice with Alport Syndrome. This was associated with increased glomerular lipid droplets and cholesterol crystals. Treatment of mice with Alport Syndrome with hydroxypropyl-beta-cyclodextrin (HP beta CD) reduced cholesterol content in the kidneys of mice with Alport Syndrome and protected from the development of albuminuria, renal failure, inflammation and tubulointerstitial fibrosis. Cholesterol efflux and trafficking-related genes were primarily affected in mice with Alport Syndrome and were differentially regulated in the kidney cortex and isolated glomeruli. HP beta CD also protected from proteinuria and mesangial expansion in a second model of non-metabolic kidney disease, adriamycin-induced nephropathy. Consistent with our experimental findings, microarray analysis confirmed dysregulation of several lipid-related genes in glomeruli isolated from kidney biopsies of patients with primary FSGS enrolled in the NEPTUNE study. Thus, lipid dysmetabolism occurs in non-metabolic glomerular disorders such as Alport Syndrome and FSGS, and HP beta CD improves renal function in experimental Alport Syndrome and FSGS.
C1 [Mitrofanova, Alla; Molina, Judith; Santos, Javier Varona; Guzman, Johanna; Morales, Ximena A.; Ducasa, G. Michelle; Bryn, Jonathan; Sloan, Alexis; Volosenco, Ion; Kim, Jin-Ju; Ge, Mengyuan; Mallela, Shamroop K.; Wahl, Patricia; Pastori, Santiago; Merscher, Sandra; Fornoni, Alessia] Univ Miami, Miller Sch Med, Dept Med, Katz Family Div Nephrol & Hypertens, Miami, FL 33136 USA.
   [Mitrofanova, Alla; Molina, Judith; Santos, Javier Varona; Guzman, Johanna; Morales, Ximena A.; Ducasa, G. Michelle; Bryn, Jonathan; Sloan, Alexis; Volosenco, Ion; Kim, Jin-Ju; Ge, Mengyuan; Mallela, Shamroop K.; Wahl, Patricia; Pastori, Santiago; Merscher, Sandra; Fornoni, Alessia] Univ Miami, Miller Sch Med, Peggy & Harold Katz Family Drug Discovery Ctr, Miami, FL 33136 USA.
   [Mitrofanova, Alla; Burke, George W.] Univ Miami, Miller Sch Med, Dept Surg, Miami, FL 33136 USA.
   [Ducasa, G. Michelle; Ge, Mengyuan] Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA.
   [Kretzler, Matthias; Eddy, Sean; Martini, Sebastian] Univ Michigan, Sch Med, Dept Internal Med, Div Nephrol, Ann Arbor, MI 48109 USA.
   [Kretzler, Matthias; Eddy, Sean; Martini, Sebastian] Univ Michigan, Sch Med, Dept Computat Med & Bioinformat, Div Nephrol, Ann Arbor, MI 48109 USA.
   [Mendez, Armando J.; Burke, George W.] Univ Miami, Miller Sch Med, Diabet Res Inst, Miami, FL 33136 USA.
RP Fornoni, A (corresponding author), Univ Miami, Katz Family Div Nephrol & Hypertens, 1580 NW 10th Ave, Miami, FL 33136 USA.; Fornoni, A (corresponding author), Univ Miami, Peggy & Harold Katz Family Drug Discovery Ctr, 1580 NW 10th Ave, Miami, FL 33136 USA.
EM afornoni@med.miami.edu
RI Mitrofanova, Alla/L-1590-2019; Mallela, Shamroop kumar/W-6982-2019
OI Mitrofanova, Alla/0000-0001-5065-9522; Mallela, Shamroop
   kumar/0000-0002-4553-8504; Eddy, Sean/0000-0001-8578-3443; KIM,
   JINJU/0000-0001-8432-7956; fornoni, Alessia/0000-0002-1313-7773;
   Merscher, Sandra/0000-0002-4757-7494
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [DK090316, DK104753, U24DK076169,
   U54DK083912, UM1DK100846, 1UL1TR000460]; Hoffman-La Roche; Predoctoral
   Fellowship of the American Heart Association [16PRE30200010]; Office of
   Rare Diseases Research [U54-DK-083912]; NCATSUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Advancing Translational Sciences (NCATS)
   [U54-DK-083912]; National Institute of Diabetes, Digestive, and Kidney
   DiseasesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Diabetes &
   Digestive & Kidney Diseases (NIDDK) [U54-DK-083912]; University of
   MichiganUniversity of Michigan System; NephCure Kidney International;
   Halpin Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1TR000460] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Diabetes &
   Digestive & Kidney Diseases (NIDDK) [UM1DK100846, R01DK090316,
   R01DK104753, U24DK076169, U54DK083912] Funding Source: NIH RePORTER
FX AF is supported by NIH grants DK090316, DK104753, U24DK076169,
   U54DK083912, UM1DK100846, and 1UL1TR000460. AF, SM, and CF are supported
   by Hoffman-La Roche. GMD is supported by a Predoctoral Fellowship of the
   American Heart Association (16PRE30200010).; The Nephrotic Syndrome
   Study Network Consortium (NEPTUNE), U54-DK-083912, is a part of the
   National Institutes of Health Rare Disease Clinical Research Network,
   supported through a collaboration between the Office of Rare Diseases
   Research, NCATS, and the National Institute of Diabetes, Digestive, and
   Kidney Diseases. Additional funding and/or programmatic support for this
   project has also been provided by the University of Michigan, the
   NephCure Kidney International, and the Halpin Foundation.
CR Bi XN, 2010, SUBCELL BIOCHEM, V51, P319, DOI 10.1007/978-90-481-8622-8_11
   BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255
   Cosgrove D, 1996, GENE DEV, V10, P2981, DOI 10.1101/gad.10.23.2981
   Crumling MA, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00355
   Dai MH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni179
   Davidson CD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006951
   den Hartigh LJ, 2010, J IMMUNOL, V184, P3927, DOI 10.4049/jimmunol.0903475
   Franco M, 2003, MOL CELL BIOCHEM, V246, P51, DOI 10.1023/A:1023451811547
   Gadegbeku CA, 2013, KIDNEY INT, V83, P749, DOI 10.1038/ki.2012.428
   Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405
   Herman-Edelstein M, 2014, J LIPID RES, V55, P561, DOI 10.1194/jlr.P040501
   Ioannou GN, 2016, TRENDS ENDOCRIN MET, V27, P84, DOI 10.1016/j.tem.2015.11.008
   Janoudi A, 2016, EUR HEART J, V37, P1959, DOI 10.1093/eurheartj/ehv653
   Jiang T, 2005, KIDNEY INT, V68, P2608, DOI 10.1111/j.1523-1755.2005.00733.x
   Jimi S, 1999, ARTERIOSCL THROM VAS, V19, P794, DOI 10.1161/01.ATV.19.3.794
   Julve-Gil J, 1999, METABOLISM, V48, P415, DOI 10.1016/S0026-0495(99)90097-5
   Kang HM, 2015, NAT MED, V21, P37, DOI 10.1038/nm.3762
   KATZ SS, 1977, J CLIN INVEST, V59, P1045, DOI 10.1172/JCI108727
   Lee VWS, 2011, NEPHROLOGY, V16, P30, DOI 10.1111/j.1440-1797.2010.01383.x
   Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353
   Lopez-Hellin J, 2013, AM J TRANSPLANT, V13, P493, DOI 10.1111/j.1600-6143.2012.04338.x
   Ma KL, 2008, HEPATOLOGY, V48, P770, DOI 10.1002/hep.22423
   Mehlem A, 2013, NAT PROTOC, V8, P1149, DOI 10.1038/nprot.2013.055
   Merscher-Gomez S, 2013, DIABETES, V62, P3817, DOI 10.2337/db13-0399
   Mizoguchi T, 2004, J LIPID RES, V45, P396, DOI 10.1194/jlr.D300024-JLR200
   Montes GS, 1996, CELL BIOL INT, V20, P15, DOI 10.1006/cbir.1996.0004
   Pedigo CE, 2016, J CLIN INVEST, V126, P3336, DOI 10.1172/JCI85939
   Puri P, 2007, HEPATOLOGY, V46, P1081, DOI 10.1002/hep.21763
   Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01
   Saeed AI, 2006, METHOD ENZYMOL, V411, P134, DOI 10.1016/S0076-6879(06)11009-5
   Swirski FK, 2007, J CLIN INVEST, V117, P195, DOI 10.1172/JCI29950
   Takahashi N, 2007, KIDNEY INT, V71, P266, DOI 10.1038/sj.ki.5002033
   TANGIRALA RK, 1994, J LIPID RES, V35, P93
   Tomimoto S, 2001, ARTERIOSCL THROM VAS, V21, P394, DOI 10.1161/01.ATV.21.3.394
   Vaziri ND, 2010, NEPHROL DIAL TRANSPL, V25, P3525, DOI 10.1093/ndt/gfq274
   Wang Y, 2000, KIDNEY INT, V58, P1797, DOI 10.1046/j.1523-1755.2000.00342.x
   Wang ZW, 2005, DIABETES, V54, P2328, DOI 10.2337/diabetes.54.8.2328
   Wu HZ, 2009, CIRCULATION, V119, P2708, DOI 10.1161/CIRCULATIONAHA.108.823740
   Yao JQ, 2012, J EXP MED, V209, P2501, DOI 10.1084/jem.20121239
   Yoo TH, 2015, J AM SOC NEPHROL, V26, P133, DOI 10.1681/ASN.2013111213
   Zimmer S, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad6100
NR 41
TC 31
Z9 32
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0085-2538
EI 1523-1755
J9 KIDNEY INT
JI Kidney Int.
PD DEC
PY 2018
VL 94
IS 6
BP 1151
EP 1159
DI 10.1016/j.kint.2018.06.031
PG 9
WC Urology & Nephrology
SC Urology & Nephrology
GA HA7BE
UT WOS:000450435000016
PM 30301568
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Arredondo, EM
   Sotres-Alvarez, D
   Stoutenberg, M
   Davis, SM
   Crespo, NC
   Carnethon, MR
   Castaneda, SF
   Isasi, CR
   Espinoza, RA
   Daviglus, ML
   Perez, LG
   Evenson, KR
AF Arredondo, Elva M.
   Sotres-Alvarez, Daniela
   Stoutenberg, Mark
   Davis, Sonia M.
   Crespo, Noe C.
   Carnethon, Mercedes R.
   Castaneda, Sheila F.
   Isasi, Carmen R.
   Espinoza, Rebeca A.
   Daviglus, Martha L.
   Perez, Lilian G.
   Evenson, Kelly R.
TI Physical Activity Levels in US Latino/Hispanic Adults Results From the
   Hispanic Community Health Study/Study of Latinos
SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE
LA English
DT Article
ID ACTIVITY QUESTIONNAIRE GPAQ; SELF-REPORT; DESIGN
AB Introduction: Physical activity (PA) prevalence among U.S. Latino/Hispanic adults of diverse backgrounds is not well known. This study describes PA among a representative sample of U.S. Latino/Hispanic adults.
   Methods: A population-based cohort of Hispanic/Latino adults (aged 18-74 years) participating in the Hispanic Community Health Study/Study of Latinos from March 2008 to June 2011 (N=16,415) was recruited in four urban areas from Miami, the Bronx, Chicago, and San Diego. Participants wore an Actical hip accelerometer for 1 week (n=12,253) and completed the Global Physical Activity Questionnaire (n=15,741). Data were analyzed in 2015.
   Results: Based on accelerometry, Hispanics/Latinos engaged in 23.8 minutes/day (10.3 minutes/day when only considering minutes from sustained 10-minute bouts) of moderate to vigorous PA (MVPA). Individuals of Puerto Rican and Dominican background had the most minutes/day of MVPA (32.1 and 29.1, respectively), whereas those of Cuban background had the fewest (15.3). Based on the Global Physical Activity Questionnaire, 65% of Hispanic/Latinos met the aerobic component of 2008 Physical Activity Guidelines for Americans. Men and individuals of Puerto Rican background had the most minutes/day of leisure-time MVPA (30.3 and 30.2, respectively). Individuals of Puerto Rican and Dominican background had the most minutes/day of transportation-related PA (48.7 and 39.7, respectively). Individuals of Mexican and Central American background had the most minutes/day of work-related MVPA (90.7 and 93.2, respectively).
   Conclusions: Among Hispanics/Latinos, self-reported data provided information on the type of PA and helped explain variability identified from accelerometer-assessed PA. These findings highlight variability in PA among Hispanics from diverse ethnic backgrounds. (C) 2016 American Journal of Preventive Medicine. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
C1 [Arredondo, Elva M.; Castaneda, Sheila F.; Espinoza, Rebeca A.; Perez, Lilian G.] San Diego State Univ, Grad Sch Publ Hlth, Inst Behav & Community Hlth, San Diego, CA 92182 USA.
   [Sotres-Alvarez, Daniela; Davis, Sonia M.] Univ N Carolina, Dept Biostat, Gillings Sch Global Publ Hlth, Collaborat Studies Coordinating Ctr, Chapel Hill, NC USA.
   [Stoutenberg, Mark] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA.
   [Crespo, Noe C.] Arizona State Univ, Sch Nutr & Hlth Promot, Phoenix, AZ USA.
   [Carnethon, Mercedes R.] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA.
   [Isasi, Carmen R.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA.
   [Daviglus, Martha L.] Univ Illinois, Coll Med, Inst Minor Hlth Res, Chicago, IL USA.
   [Evenson, Kelly R.] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA.
RP Arredondo, EM (corresponding author), San Diego State Univ, Grad Sch Publ Hlth, Hardy Tower Room 119,5500 Campanile Dr, San Diego, CA 92182 USA.
EM earredon@mail.sdsu.edu
RI Castaneda, Sheila F./AAK-3025-2020; DeMarcus, Forrest/O-9190-2016;
   Sotres-Alvarez, Daniela/O-9085-2016; Castaneda, Sheila/I-4132-2014
OI Sotres-Alvarez, Daniela/0000-0002-3226-6140; Evenson,
   Kelly/0000-0002-3720-5830; Thomas, Sonia/0000-0003-1362-5627; Carnethon,
   Mercedes/0000-0001-7035-0848; Castaneda, Sheila/0000-0002-1975-0544
FU National Heart, Lung, and Blood Institute (NHLBI)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [N01-HC65233,
   N01-HC65234, N01-HC65235, N01-HC65236, N01-HC65237]; Coca-Cola Company;
   Technogym; Miami Clinical and Translational Science Institute - National
   Center for Advancing Translational Sciences [1KL2TR000461]; National
   Institute on Minority Health and Health DisparitiesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Minority Health & Health Disparities
   (NIMHD); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Eye Institute (NEI) [N01HC065233] Funding Source: NIH
   RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Advancing Translational
   Sciences (NCATS) [KL2TR000461] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Diabetes & Digestive & Kidney Diseases
   (NIDDK) [P30DK020541] Funding Source: NIH RePORTER
FX The HCHS/SOL was carried out as a collaborative study supported by
   contracts from the National Heart, Lung, and Blood Institute (NHLBI) to
   the University of North Carolina at Chapel Hill (N01-HC65233);
   University of Miami (N01-HC65234); Albert Einstein College of Medicine
   (N01-HC65235); Northwestern University (N01-HC65236); and San Diego
   State University (N01-HC65237). The following Institutes/Centers/Offices
   contributed to the HCHS/SOL through a transfer of funds to the NHLBI:
   National Institute on Minority Health and Health Disparities, National
   Institute on Deafness and Other Communication Disorders, National
   Institute of Dental and Craniofacial Research, National Institute of
   Diabetes and Digestive and Kidney Diseases, National Institute of
   Neurological Disorders and Stroke, and the NIH Office of Dietary
   Supplements. This paper's contents are solely the responsibility of the
   authors and do not represent the official views of the NIH.; Mark
   Stoutenberg is a consultant to Exercise is Medicine, a program of the
   American College of Sports Medicine, which receives funding from The
   Coca-Cola Company and Technogym. Dr. Stoutenberg is supported by Grant
   Number 1KL2TR000461 from the Miami Clinical and Translational Science
   Institute, which is funded by the National Center for Advancing
   Translational Sciences and the National Institute on Minority Health and
   Health Disparities.
CR Blair CK, 2014, MED SCI SPORT EXER, V46, P1375, DOI 10.1249/MSS.0000000000000241
   Bull FC, 2009, J PHYS ACT HEALTH, V6, P790, DOI 10.1123/jpah.6.6.790
   Buman MP, 2010, AM J EPIDEMIOL, V172, P1155, DOI 10.1093/aje/kwq249
   Carlson SA, 2010, AM J PREV MED, V39, P305, DOI 10.1016/j.amepre.2010.06.006
   Choi L, 2011, MED SCI SPORT EXER, V43, P357, DOI 10.1249/MSS.0b013e3181ed61a3
   Colley RC, 2011, J SPORT SCI, V29, P783, DOI 10.1080/02640414.2011.557744
   Colley Rachel C, 2011, Health Rep, V22, P7
   Dowd KP, 2014, MED SCI SPORT EXER, V46, P2295, DOI 10.1249/MSS.0000000000000357
   Evenson KR, 2015, MED SCI SPORT EXER, V47, P725, DOI 10.1249/MSS.0000000000000478
   Ham SA, 2010, AM J PUBLIC HEALTH, V100, pS263, DOI 10.2105/AJPH.2009.180075
   Harris CD, 2013, MMWR-MORBID MORTAL W, V62, P326
   Hoos T, 2012, J PHYS ACT HEALTH, V9, P698, DOI 10.1123/jpah.9.5.698
   Lavange LM, 2010, ANN EPIDEMIOL, V20, P642, DOI 10.1016/j.annepidem.2010.05.006
   Mathews CE, 2012, EXERC SPORT SCI REV, V40, P118, DOI 10.1097/JES.0b013e31825b34a0
   Nicaise V, 2011, J PHYS ACT HEALTH, V8, P881, DOI 10.1123/jpah.8.7.881
   Prince SA, 2008, INT J BEHAV NUTR PHY, V5, DOI 10.1186/1479-5868-5-56
   Sallis JF, 2000, RES Q EXERCISE SPORT, V71, pS1, DOI 10.1080/02701367.2000.11082780
   Samitz G, 2011, INT J EPIDEMIOL, V40, P1382, DOI 10.1093/ije/dyr112
   Schafer JL, 1998, MULTIVAR BEHAV RES, V33, P545, DOI 10.1207/s15327906mbr3304_5
   Seaman SR, 2013, STAT METHODS MED RES, V22, P278, DOI 10.1177/0962280210395740
   Sorlie PD, 2010, ANN EPIDEMIOL, V20, P629, DOI 10.1016/j.annepidem.2010.03.015
   Troiano RP, 2008, MED SCI SPORT EXER, V40, P181, DOI 10.1249/mss.0b013e31815a51b3
   Troiano RP, 2012, J PHYS ACT HEALTH, V9, pS68, DOI 10.1123/jpah.9.s1.s68
   Troiano Richard P., 2008, [The Korean Journal of Measurement and Evaluation in Physical Education and Sports Science, 한국체육측정평가학회지], V10, P31
   Tucker JM, 2011, AM J PREV MED, V40, P454, DOI 10.1016/j.amepre.2010.12.016
   USDHHS, 2008, 2008 PHYS ACT GUID A
   van Poppel MNM, 2010, SPORTS MED, V40, P565, DOI 10.2165/11531930-000000000-00000
   Wong SL, 2011, J PHYS ACT HEALTH, V8, P587, DOI 10.1123/jpah.8.4.587
NR 28
TC 67
Z9 67
U1 0
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0749-3797
EI 1873-2607
J9 AM J PREV MED
JI Am. J. Prev. Med.
PD APR
PY 2016
VL 50
IS 4
BP 500
EP 508
DI 10.1016/j.amepre.2015.08.029
PG 9
WC Public, Environmental & Occupational Health; Medicine, General &
   Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA DH1RP
UT WOS:000372562900009
PM 26597505
OA hybrid, Green Accepted, Green Submitted
DA 2021-10-30
ER

PT J
AU Vidot, DC
   Stoutenberg, M
   Gellman, M
   Arheart, KL
   Teng, YP
   Daviglus, ML
   Gonzalez, HM
   Talavera, G
   Isasi, CR
   Heiss, G
   Schneiderman, N
AF Vidot, Denise C.
   Stoutenberg, Mark
   Gellman, Marc
   Arheart, Kristopher L.
   Teng, Yanping
   Daviglus, Martha L.
   Gonzalez, Hector M.
   Talavera, Gregory
   Isasi, Carmen R.
   Heiss, Gerardo
   Schneiderman, Neil
TI Alcohol Consumption and Metabolic Syndrome Among Hispanics/Latinos: The
   Hispanic Community Health Study/Study of Latinos
SO METABOLIC SYNDROME AND RELATED DISORDERS
LA English
DT Article
ID CORONARY-HEART-DISEASE; NATIONAL-HEALTH; PREVALENCE; RISK; METAANALYSIS;
   HYPERTENSION; PATTERNS; DESIGN; ADULTS
AB Background: The association between alcohol consumption and metabolic syndrome (MetS) among Hispanic/Latino populations has not been studied in great detail. Our study examined the relationship between alcohol consumption and MetS among U.S. Hispanics/Latinos and explored whether this relationship varied by age, body mass index, gender, and Hispanic/Latino backgrounds.
   Methods: The Hispanic Community Health Study/Study of Latinos (HCHS/SOL) is a multisite, prospective, population-based, cohort study of Hispanics/Latinos, ages 18-74 years from four U.S. communities. Participants were categorized into never, former, occasional, low, moderate, and high alcohol consumption categories. A cross-sectional analysis of 15,905 participants with complete data was conducted. Survey design appropriate chi-squared and logistic regression models were run to detect significant associations between alcohol consumption categories and cases of MetS.
   Results: Almost half (47.4%) of the sample was classified as occasional, low, moderate, or heavy drinkers. Low and moderate alcohol consumers had lower odds of MetS than never drinkers. Low and heavy drinkers had higher odds of presenting with elevated central obesity, while occasional, low, moderate, and heavy drinkers had higher odds of having low high-density lipoprotein cholesterol levels compared to never drinkers. Low and moderate wine drinkers had lower odds of MetS compared to never drinkers. There were no significant findings among beer or liquor drinkers, or with binge drinking after model adjustments.
   Conclusions: Our findings suggest that low and moderate alcohol consumption may lower the odds of MetS in a sample of Hispanic/Latino adults, but that the relationship of alcohol consumption varies with the individual components of MetS.
C1 [Vidot, Denise C.; Gellman, Marc; Schneiderman, Neil] Univ Miami, Dept Psychol, POB 248185, Coral Gables, FL 33124 USA.
   [Vidot, Denise C.; Gellman, Marc; Schneiderman, Neil] Univ Miami, Behav Med Res Ctr, Coral Gables, FL 33124 USA.
   [Stoutenberg, Mark; Arheart, Kristopher L.] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, 1120 NW 14th St,Clin Res Bldg,Suite 1008, Miami, FL 33136 USA.
   [Teng, Yanping] Univ North Carolina Chapel Hill, Gillings Sch Publ Hlth, Dept Biostat, Chapel Hill, NC USA.
   [Daviglus, Martha L.] Univ Illinois, Inst Minor Hlth Res, Chicago, IL USA.
   [Gonzalez, Hector M.] Michigan State Univ, Dept Epidemiol & Biostat, E Lansing, MI 48824 USA.
   [Talavera, Gregory] San Diego State Univ, Grad Sch Publ Hlth, Inst Behav & Community Hlth, San Diego, CA 92182 USA.
   [Isasi, Carmen R.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA.
   [Heiss, Gerardo] Univ North Carolina Chapel Hill, Gillings Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA.
RP Stoutenberg, M (corresponding author), Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, 1120 NW 14th St,Clin Res Bldg,Suite 1008, Miami, FL 33136 USA.
EM mstoutenberg@med.miami.edu
RI Gonzalez, Hector/AAV-7576-2021
FU National Heart, Lung, and Blood Institute (NHLBI)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [N01-HC65233];
   University of Miami [N01-HC65234]; Albert Einstein College of Medicine
   [N01-HC65235]; Northwestern University [N01-HC65236]; San Diego State
   University [N01-HC65237]; DIVISION OF EPIDEMIOLOGY AND CLINICAL
   APPLICATIONSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Eye Institute (NEI)
   [N01HC065233] Funding Source: NIH RePORTER; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [KL2TR000461]
   Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [T32HL007426] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Diabetes & Digestive & Kidney Diseases
   (NIDDK) [P30DK020541] Funding Source: NIH RePORTER
FX The Hispanic Community Health Study/Study of Latinos was carried out as
   a collaborative study supported by contracts from the National Heart,
   Lung, and Blood Institute (NHLBI) to the University of North
   Carolina-Chapel Hill (N01-HC65233), University of Miami (N01-HC65234),
   Albert Einstein College of Medicine (N01-HC65235), Northwestern
   University (N01-HC65236), and San Diego State University (N01-HC65237).
   The following Institutes/Centers/Offices contributed to the HCHS/SOL
   through a transfer of funds to the NHLBI: National Institute on Minority
   Health and Health Disparities, National Institute on Deafness and Other
   Communication Disorders, National Institute of Dental and Craniofacial
   Research, National Institute of Diabetes and Digestive and Kidney
   Diseases, National Institute of Neurological Disorders and Stroke, and
   the NIH Institution-Office of Dietary Supplements.
CR Alberti KGMM, 2009, CIRCULATION, V120, P1640, DOI 10.1161/CIRCULATIONAHA.109.192644
   Alkerwi A, 2009, ATHEROSCLEROSIS, V204, P624, DOI 10.1016/j.atherosclerosis.2008.10.036
   Baliunas DO, 2009, DIABETES CARE, V32, P2123, DOI 10.2337/dc09-0227
   Beltran-Sanchez H, 2013, J AM COLL CARDIOL, V62, P697, DOI 10.1016/j.jacc.2013.05.064
   Brien SE, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d636
   Caetano Raul, 2014, Handb Clin Neurol, V125, P629, DOI 10.1016/B978-0-444-62619-6.00037-9
   Chartier K, 2010, ALCOHOL RES HEALTH, V33, P152
   Churilla JR, 2014, DIABETES METAB SYND, V8, P119, DOI 10.1016/j.dsx.2014.04.001
   Danaei G, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000058
   Di Castelnuovo A, 2006, ARCH INTERN MED, V166, P2437, DOI 10.1001/archinte.166.22.2437
   Djousse L, 2004, OBES RES, V12, P1375, DOI 10.1038/oby.2004.174
   Falkner B, 2014, CURR HYPERTENS REP, V16, DOI 10.1007/s11906-014-0449-5
   Flores YN, 2008, AM J GASTROENTEROL, V103, P2231, DOI 10.1111/j.1572-0241.2008.02022.x
   Freiberg MS, 2004, DIABETES CARE, V27, P2954, DOI 10.2337/diacare.27.12.2954
   Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143
   Heiss G, 2014, DIABETES CARE, V37, P2391, DOI 10.2337/dc13-2505
   Hvidtfeldt UA, 2010, CIRCULATION, V121, P1589, DOI 10.1161/CIRCULATIONAHA.109.887513
   Lavange LM, 2010, ANN EPIDEMIOL, V20, P642, DOI 10.1016/j.annepidem.2010.05.006
   Mukamal KJ, 2006, J AM GERIATR SOC, V54, P30, DOI 10.1111/j.1532-5415.2005.00561.x
   Rodriguez CJ, 2014, AM J MED, V127, P1186, DOI 10.1016/j.amjmed.2014.07.026
   Sacco RL, 1999, JAMA-J AM MED ASSOC, V281, P53, DOI 10.1001/jama.281.1.53
   Sorlie PD, 2010, ANN EPIDEMIOL, V20, P629, DOI 10.1016/j.annepidem.2010.03.015
   *SUBST AB MENT HLT, 2003, RES 2002 NAT SURV DR
   Substance Abuse and Mental Health Services Administration, 2013, RES 2012 NAT SURV DR
   Taylor B, 2009, ADDICTION, V104, P1981, DOI 10.1111/j.1360-0443.2009.02694.x
   U.S Department of Agriculture U.S Department of Health and Human Services, 2010, DIET GUID AM
   Vieira Edna Cunha, 2014, Rev. bras. epidemiol., V17, P805, DOI 10.1590/1809-4503201400040001
   Wannamethee SG, 2003, AM J CLIN NUTR, V77, P1312, DOI 10.1093/ajcn/77.5.1312
   WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184
   Yi H, 2008, SURVEILLANCE REPORT
   Yoon YS, 2004, AM J CLIN NUTR, V80, P217
NR 31
TC 9
Z9 10
U1 0
U2 7
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-4196
EI 1557-8518
J9 METAB SYNDR RELAT D
JI Metab. Syndr. Relat. Disord.
PY 2016
VL 14
IS 7
BP 354
EP 362
DI 10.1089/met.2015.0171
PG 9
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA DU5WD
UT WOS:000382283200005
PM 27304318
OA Green Published, Green Submitted
DA 2021-10-30
ER

PT J
AU Espay, AJ
   Bonato, P
   Nahab, FB
   Maetzler, W
   Dean, JM
   Klucken, J
   Eskofier, BM
   Merola, A
   Horak, F
   Lang, AE
   Reilmann, R
   Giuffrida, J
   Nieuwboer, A
   Horne, M
   Little, MA
   Litvan, I
   Simuni, T
   Dorsey, ER
   Burack, MA
   Kubota, K
   Kamondi, A
   Godinho, C
   Daneault, JF
   Mitsi, G
   Krinke, L
   Hausdorff, JM
   Bloem, BR
   Papapetropoulos, S
AF Espay, Alberto J.
   Bonato, Paolo
   Nahab, Fatta B.
   Maetzler, Walter
   Dean, John M.
   Klucken, Jochen
   Eskofier, Bjoern M.
   Merola, Aristide
   Horak, Fay
   Lang, Anthony E.
   Reilmann, Ralf
   Giuffrida, Joe
   Nieuwboer, Alice
   Horne, Malcolm
   Little, Max A.
   Litvan, Irene
   Simuni, Tanya
   Dorsey, E. Ray
   Burack, Michelle A.
   Kubota, Ken
   Kamondi, Anita
   Godinho, Catarina
   Daneault, Jean-Francois
   Mitsi, Georgia
   Krinke, Lothar
   Hausdorff, Jeffery M.
   Bloem, Bastiaan R.
   Papapetropoulos, Spyros
CA Movement Disorders Soc Task Force
TI Technology in Parkinson's disease: Challenges and opportunities
SO MOVEMENT DISORDERS
LA English
DT Review
DE digital health; digital biomarkers; eHealth; Parkinson's disease;
   precision medicine; remote monitoring; technology; wearable technology
ID BODY-WORN SENSORS; QUALITY-OF-LIFE; WEARABLE SENSORS; GAIT; MANAGEMENT;
   SYMPTOMS; MOVEMENT; BALANCE; FLUCTUATIONS; PROGRESSION
AB The miniaturization, sophistication, proliferation, and accessibility of technologies are enabling the capture of more and previously inaccessible phenomena in Parkinson's disease (PD). However, more information has not translated into a greater understanding of disease complexity to satisfy diagnostic and therapeutic needs. Challenges include noncompatible technology platforms, the need for wide-scale and long-term deployment of sensor technology (among vulnerable elderly patients in particular), and the gap between the big data acquired with sensitive measurement technologies and their limited clinical application. Major opportunities could be realized if new technologies are developed as part of open-source and/or open-hardware platforms that enable multichannel data capture sensitive to the broad range of motor and nonmotor problems that characterize PD and are adaptable into self-adjusting, individualized treatment delivery systems. The International Parkinson and Movement Disorders Society Task Force on Technology is entrusted to convene engineers, clinicians, researchers, and patients to promote the development of integrated measurement and closed-loop therapeutic systems with high patient adherence that also serve to (1) encourage the adoption of clinico-pathophysiologic phenotyping and early detection of critical disease milestones, (2) enhance the tailoring of symptomatic therapy, (3) improve subgroup targeting of patients for future testing of disease-modifying treatments, and (4) identify objective biomarkers to improve the longitudinal tracking of impairments in clinical care and research. This article summarizes the work carried out by the task force toward identifying challenges and opportunities in the development of technologies with potential for improving the clinical management and the quality of life of individuals with PD. (c) 2016 International Parkinson and Movement Disorder Society
C1 [Espay, Alberto J.] Univ Cincinnati, James J & Joan A Gardner Family Ctr Parkinsons Di, Cincinnati, OH 45267 USA.
   [Bonato, Paolo; Daneault, Jean-Francois] Harvard Med Sch, Dept Phys Med & Rehabil, Boston, MA USA.
   [Nahab, Fatta B.; Litvan, Irene] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.
   [Maetzler, Walter] Univ Tubingen, Hertie Inst Clin Brain Res HIH, Dept Neurodegenerat, Tubingen, Germany.
   [Maetzler, Walter] German Ctr Neurodegenerat Dis, DZNE, Tubingen, Germany.
   [Dean, John M.] Davis Phinney Fdn Parkinsons, Boulder, CO USA.
   [Klucken, Jochen] Univ Erlangen Nurnberg, Univ Hosp Erlangen, Dept Mol Neurol, Erlangen, Germany.
   [Eskofier, Bjoern M.] Univ Erlangen Nurnberg, Digital Sports Grp, Erlangen, Germany.
   [Merola, Aristide] Citta Salute & Sci Torino, Dept Neurosci Rita Levi Montalcini, Turin, Italy.
   [Horak, Fay] Oregon Hlth & Sci Univ, Dept Neurol, Portland VA Med Syst, Portland, OR 97201 USA.
   [Horak, Fay] APDM Inc, Portland, OR USA.
   [Lang, Anthony E.] Toronto Western Hosp, Morton & Gloria Movement Disorders Clin, Toronto, ON, Canada.
   [Lang, Anthony E.] Toronto Western Hosp, Edmond J Safra Program Parkinsons Dis, Toronto, ON, Canada.
   [Reilmann, Ralf] George Huntington Inst, Munster, Germany.
   [Reilmann, Ralf] Univ Munster, Dept Radiol, Munster, Germany.
   [Reilmann, Ralf] Univ Tubingen, Dept Neurodegenerat Dis, Tubingen, Germany.
   [Reilmann, Ralf] Univ Tubingen, Hertie Inst Clin Brain Res, Tubingen, Germany.
   [Giuffrida, Joe] Great Lakes NeuroTechnol, Cleveland, OH USA.
   [Nieuwboer, Alice] Katholieke Univ Leuven, Neuromotor Rehabil Res Grp, Dept Rehabil Sci, Leuven, Belgium.
   [Horne, Malcolm] Univ Melbourne, Global Kinet Corp, Parkville, Vic, Australia.
   [Horne, Malcolm] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Parkville, Vic, Australia.
   [Little, Max A.] Aston Univ, Dept Math, Birmingham, W Midlands, England.
   [Little, Max A.] MIT, Media Lab, Cambridge, MA 02139 USA.
   [Simuni, Tanya] Northwestern Univ, Dept Neurol, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Dorsey, E. Ray; Burack, Michelle A.] Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA.
   [Kubota, Ken] Michael J Fox Fdn Parkinsons Res, New York, NY USA.
   [Kamondi, Anita] Natl Inst Clin Neurosci, Dept Neurol, Budapest, Hungary.
   [Godinho, Catarina] Inst Super Ciencias Saude Egas Moniz, Ctr Interdisciplinary Res Egas Moniz CiiEM, Monte De Caparica, Portugal.
   [Mitsi, Georgia] Apptomics LLC, Wellesley, MA USA.
   [Krinke, Lothar] Medtron Neuromodulat, Minneapolis, MN USA.
   [Hausdorff, Jeffery M.] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel.
   [Hausdorff, Jeffery M.] Tel Aviv Sourasky Med Ctr, Ctr Study Movement Cognit & Mobil, Neurol Inst, Tel Aviv, Israel.
   [Bloem, Bastiaan R.] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Neurol, Nijmegen, Netherlands.
   [Papapetropoulos, Spyros] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Espay, AJ (corresponding author), Univ Cincinnati, Acad Hlth Ctr, 260 Stetson St,Suite 2300, Cincinnati, OH 45267 USA.
EM alberto.espay@uc.edu
RI Daneault, Jean-Francois/AAI-5413-2020; Godinho, Catarina/ABF-6650-2020;
   Maetzler, Walter/A-6796-2011; Espay, Alberto J./AAC-4255-2020; Horne,
   Malcolm/AAL-5214-2020; Bonato, Paolo/AAH-6111-2019; Maetzler,
   Walter/AAE-5831-2020; Bloem, B.R./H-8013-2014; Litvan,
   Irene/X-9319-2018; Nieuwboer, Alice/F-5643-2013
OI Daneault, Jean-Francois/0000-0002-8530-1827; Godinho,
   Catarina/0000-0003-2304-3129; Maetzler, Walter/0000-0002-5945-4694;
   Espay, Alberto J./0000-0002-3389-136X; Horne,
   Malcolm/0000-0001-9427-2100; Bonato, Paolo/0000-0002-1818-1714;
   Maetzler, Walter/0000-0002-5945-4694; Bloem, B.R./0000-0002-6371-3337;
   Litvan, Irene/0000-0002-3485-3445; Reilmann, Ralf/0000-0002-5904-9517;
   Krinke, Lothar/0000-0002-3359-113X; Nieuwboer,
   Alice/0000-0003-1193-6229; Merola, Aristide/0000-0002-5587-726X
FU Great Lakes Neurotechnologies; Michael J Fox Foundation; National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA; National Science
   FoundationNational Science Foundation (NSF); Office of Naval
   ResearchOffice of Naval Research; Medtronic Inc.Medtronic; European
   UnionEuropean Commission; Davis Phinney Foundation; Astrum IT; LicherMT;
   Bosch Sensortec; MedtronicMedtronic; GE MedicalGeneral Electric; Prana
   Biotechnology; Netherlands Organization for Scientific
   ResearchNetherlands Organization for Scientific Research (NWO); Prinses
   Beatrix Foundation; Stichting Parkinson Fonds; National Parkinson
   Foundation; Hersenstichting Nederland; Parkinson Vereniging; NATIONAL
   CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000460, KL2TR000095] Funding Source: NIH RePORTER; NATIONAL HEART,
   LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [T35HL007491] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Mental Health (NIMH) [K23MH092735] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Neurological Disorders &
   Stroke (NINDS) [R01NS073683, P20NS092529, U01NS086659, U54NS092089]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Aging (NIA) [R01AG006457, P50AG005131]
   Funding Source: NIH RePORTER; Parkinson&quot;s UKParkinson&apos;s UK
   [J-1403, J-0901] Funding Source: researchfish
FX The MDS Technology Task Force assembled a group of experts from the
   device and biopharmaceutical industry, clinical researchers, and
   engineers. The authors have taken every effort to minimize the influence
   of their home institutions and industries on the summarized outcome of
   the deliberations. A.J.E. has received grant support from Great Lakes
   Neurotechnologies. He serves as chair of the MDS Technology Task Force.
   P.B. is supported by the Michael J Fox Foundation, the National
   Institutes of Health, the National Science Foundation, and the Office of
   Naval Research. F.N. has received an educational grant from Medtronic
   Inc. W.M. has received grants from the European Union for FAIR-PARK-II,
   Moving beyond and SENSE-PARK. J.M.D. is supported by the Davis Phinney
   Foundation to direct their Healthcare Strategy and Technology division.
   J.K. has received grant support Astrum IT and LicherMT and is chair of
   the task force "sensor-based movement analysis" of the German Parkinson
   Society. B.M.E. has received grant support from Bosch Sensortec and
   Astrum IT and is co-chair of the task force "sensor-based movement
   analysis" of the German Parkinson Society. F.H. has research grants from
   Medtronic and has an equity/interest in APDM, a technology company.
   A.E.L. has served as an advisor for and received honoraria from
   Medtronic. R.R. is founding director and owner of the
   George-Huntington-Institute, a private research institute and
   QuantiMedis, a clinical research organization providing Q-Motor
   (quantitative motor) services in clinical trials and research. J.G. is a
   full-time employee of Great Lakes Neurotechnologies. M.H. has a
   financial interest in Global Kinetics Corporation, a company that
   manufactures and supplies the Parkinson's KinetiGraph (PKG), a wearable
   technology. M.A.L. has nothing to disclose. T.S. has received funding
   support for educational programming from GE Medical and Medtronic.
   E.R.D. has filed for a patent related to telemedicine and neurology and
   has received research funding from Great Lakes Neurotechnologies and
   Prana Biotechnology. K.K. directs data science and the partnership with
   Intel on wearable technologies and analytics enacted through the Michael
   J Fox Foundation for Parkinson's Research full time. G.M. is the founder
   and chief executive officer of Apptomics LLC. L.K. is a full-time
   employee of Medtronic and serves as Board Observer at Functional
   Neuromodulation, Ltd. J.M.H. submitted a patent application on the use
   of body-fixed sensors in Parkinson disease. The intellectual property
   rights for this patent application are held by the Tel Aviv Sourasky
   Medical Center. B.R.B. received research support from the Netherlands
   Organization for Scientific Research, the Michael J Fox Foundation, the
   Prinses Beatrix Foundation, the Stichting Parkinson Fonds, the National
   Parkinson Foundation, the Hersenstichting Nederland and the Parkinson
   Vereniging. S.P. is a full-time employee of TEVA Pharmaceuticals. He
   serves as co-chair of the MDS Technology Task Force. All other authors
   have no financial disclosure to report related to research covered in
   this article.
CR [Anonymous], CONS INT SER WEAR FU
   Arora S, 2015, PARKINSONISM RELAT D, V21, P650, DOI 10.1016/j.parkreldis.2015.02.026
   Bachlin M, 2010, IEEE T INF TECHNOL B, V14, P436, DOI 10.1109/TITB.2009.2036165
   Basu I, 2013, J NEURAL ENG, V10, DOI 10.1088/1741-2560/10/3/036019
   Bayestehtashk A, 2015, COMPUT SPEECH LANG, V29, P172, DOI 10.1016/j.csl.2013.12.001
   Berganzo K, 2016, NEUROLOGIA, V31, P585, DOI 10.1016/j.nrl.2014.10.010
   Bonato P, 2010, IEEE ENG MED BIOL, V29, P25, DOI 10.1109/MEMB.2010.936554
   Brun L, 2014, CLIN NEUROL NEUROSUR, V127, P93, DOI 10.1016/j.clineuro.2014.10.006
   Caldara M, 2016, SENSOR ACTUAT B-CHEM, V222, P213, DOI 10.1016/j.snb.2015.08.073
   Cavanaugh JT, 2012, J NEUROL PHYS THER, V36, P51, DOI 10.1097/NPT.0b013e318254ba7a
   Cazale A, 2016, SENSOR ACTUAT B-CHEM, V225, P1, DOI 10.1016/j.snb.2015.10.114
   Chen BR, 2011, IEEE T BIO-MED ENG, V58, P831, DOI 10.1109/TBME.2010.2090044
   Das S, 2011, IEEE ENG MED BIO, P6789, DOI 10.1109/IEMBS.2011.6091674
   Del Din S, 2015, IEEE J BIOMED HLTH I
   Dubey H, 2015, P C WIR HLTH
   Ellis T, 2011, PARKINSONISM RELAT D, V17, P693, DOI 10.1016/j.parkreldis.2011.07.004
   Espay AJ, 2011, MOVEMENT DISORD, V26, P2504, DOI 10.1002/mds.23893
   Fereshtehnejad SM, 2015, JAMA NEUROL, V72, P863, DOI 10.1001/jamaneurol.2015.0703
   Ferreira JJ, 2015, BMC NEUROL, V15, DOI 10.1186/s12883-015-0343-z
   FirstWord, 2015, PAT CTR MOB APPS KEY
   Fisher JM, 2016, TELEMED E-HEALTH, V22, P63, DOI 10.1089/tmj.2015.0026
   Goetz CG, 2009, MOVEMENT DISORD, V24, P551, DOI 10.1002/mds.22379
   Guo Y, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-447
   Hellman AM, 2015, PARKINSONISM RELAT D, V21, P723, DOI 10.1016/j.parkreldis.2015.04.016
   Horak F, 2015, PHYS THER, V95, P461, DOI 10.2522/ptj.20140253
   Horak FB, 2013, MOVEMENT DISORD, V28, P1544, DOI 10.1002/mds.25684
   Hubble RP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123705
   Hung SW, 2010, J NEUROL NEUROSUR PS, V81, P1112, DOI 10.1136/jnnp.2009.173286
   Jankovic J, 2005, MOVEMENT DISORD, V20, pS11, DOI 10.1002/mds.20458
   Klucken J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056956
   Ledger D, 2014, INSIDE WEARABLES SCI, P1
   Lee SI, 2015, IEEE ENG MED BIO, P8087, DOI 10.1109/EMBC.2015.7320270
   Lieber B, 2015, WORLD NEUROSURG, V84, P561, DOI 10.1016/j.wneu.2015.03.024
   Liu G, 2016, SENSOR ACTUAT B-CHEM, V227, P35, DOI 10.1016/j.snb.2015.12.034
   Maetzler W, 2013, MOVEMENT DISORD, V28, P1628, DOI 10.1002/mds.25628
   Maetzler W, 2009, LANCET NEUROL, V8, P1158, DOI 10.1016/S1474-4422(09)70291-1
   Mariani B, 2013, IEEE T BIO-MED ENG, V60, P155, DOI 10.1109/TBME.2012.2227317
   Mazilu S, 2015, IEEE J BIOMED HEALTH, V19, P1843, DOI 10.1109/JBHI.2015.2465134
   Mccall C, 2012, J SLEEP RES, V21, P122, DOI 10.1111/j.1365-2869.2011.00917.x
   Mendiola MF, 2015, JMIR MHEALTH UHEALTH, V3, DOI 10.2196/mhealth.4283
   Mera TO, 2012, IEEE ENG MED BIO, P154, DOI 10.1109/EMBC.2012.6345894
   Moore ST, 2013, J NEUROENG REHABIL, V10, DOI 10.1186/1743-0003-10-19
   Nieuwboer A, 1998, DISABIL REHABIL, V20, P142, DOI 10.3109/09638289809166074
   Ozinga SJ, 2015, MOVEMENT DISORD, V30, P1214, DOI 10.1002/mds.26214
   Papapetropoulos S, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00034
   Pasluosta CF, 2015, IEEE J BIOMED HEALTH, V19, P1873, DOI 10.1109/JBHI.2015.2461555
   Patel S, 2009, IEEE T INF TECHNOL B, V13, P864, DOI 10.1109/TITB.2009.2033471
   Quinn EJ, 2015, MOVEMENT DISORD, V30, P1750, DOI 10.1002/mds.26376
   Rahimi F, 2014, J PARKINSON DIS, V4, P617, DOI 10.3233/JPD-140370
   Rampp A, 2015, IEEE T BIO-MED ENG, V62, P1089, DOI 10.1109/TBME.2014.2368211
   Roy SH, 2013, MOVEMENT DISORD, V28, P1080, DOI 10.1002/mds.25391
   Shen X, 2015, NEUROREHAB NEURAL RE, V29, P103, DOI 10.1177/1545968314537559
   Shukla P, 2014, IEEE ENG MED BIO, P2605, DOI 10.1109/EMBC.2014.6944156
   Shull PB, 2014, GAIT POSTURE, V40, P11, DOI 10.1016/j.gaitpost.2014.03.189
   Solla P, 2015, J NEURAL TRANSM, P1
   Sommerauer M, 2015, MOVEMENT DISORD, V30, P866, DOI 10.1002/mds.26165
   Son D, 2014, NAT NANOTECHNOL, V9, P397, DOI [10.1038/nnano.2014.38, 10.1038/NNANO.2014.38]
   Stamford JA, 2015, IEEE J BIOMED HEALTH, V19, P1862, DOI 10.1109/JBHI.2015.2464354
   Thenganatt MA, 2014, JAMA NEUROL, V71, P499, DOI 10.1001/jamaneurol.2013.6233
   Valappil RA, 2010, MOVEMENT DISORD, V25, P2296, DOI 10.1002/mds.23348
   Wang HG, 2015, IEEE INTERNET THINGS, V2, P1, DOI 10.1109/JIOT.2015.2394696
   Weiss A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096675
   Zheng YL, 2014, IEEE T BIO-MED ENG, V61, P1538, DOI 10.1109/TBME.2014.2309951
NR 63
TC 237
Z9 237
U1 7
U2 102
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-3185
EI 1531-8257
J9 MOVEMENT DISORD
JI Mov. Disord.
PD SEP
PY 2016
VL 31
IS 9
BP 1272
EP 1282
DI 10.1002/mds.26642
PG 11
WC Clinical Neurology
SC Neurosciences & Neurology
GA DW6PO
UT WOS:000383773600046
PM 27125836
OA Green Accepted, Green Submitted
HC Y
HP N
DA 2021-10-30
ER

PT J
AU Chang, WG
   Fornoni, A
   Tietjen, G
   Mendez, JJ
   Niklason, LE
   Saltzman, WM
   Pober, JS
AF Chang, William Gee
   Fornoni, Alessia
   Tietjen, Gregory
   Mendez, Julio J.
   Niklason, Laura E.
   Saltzman, W. Mark
   Pober, Jordan S.
TI Tissue-Engineered Microvasculature to Reperfuse Isolated Renal Glomeruli
SO TISSUE ENGINEERING PART A
LA English
DT Article
ID ENDOTHELIAL-CELL TRANSPLANTATION; PERICYTES; DELIVERY; MOUSE; MICE
AB Kidney transplantation is often the most effective therapy for end-stage renal disease, but there are not enough donor organs to meet the rising demand. Tissue engineering of kidneys is a potential solution to this organ shortage. Achieving microvascular perfusion has been a major barrier to engineering tissues beyond thin muscularized sheets such as the bladder wall. Our laboratory has previously reported that human umbilical vein endothelial cells (ECs) transduced with the antiapoptotic protein Bcl-2 will spontaneously organize into perfused microvessels within type I collagen gels when implanted in immunodeficient mice. To test if this system can be used to perfuse more complex structures, we combined Bcl-2-transduced ECs (Bcl-2-ECs) with renal glomeruli, the specialized vascular filtration units of the kidney. Microdissected green fluorescent protein-expressing rat glomeruli suspended in type I collagen gels were implanted within immunodeficient mice with or without the inclusion of Bcl-2-ECs. Survival of rat glomeruli was enhanced by coimplantation with Bcl-2-ECs. Intravital rhodamine dextran injections demonstrated that surviving glomeruli were perfused through Bcl-2-EC-derived microvessels. Perfused glomeruli maintained podocin staining, but transmission electron microscopy revealed endothelial swelling and podocyte foot process effacement. Anastomosis of microvessels derived from Bcl-2-ECs with glomerular capillaries provides proof of concept that self-assembled microvessels can perfuse specialized organ structures such as glomeruli, but that perfusion alone may be insufficient to maintain normal structure.
C1 [Chang, William Gee] Yale Univ, Sch Med, Dept Med, New Haven, CT 06520 USA.
   [Chang, William Gee] Yale Univ, Sch Med, Nephrol Sect, New Haven, CT 06520 USA.
   [Fornoni, Alessia] Univ Miami, Miller Sch Med, Div Nephrol & Hypertens, Miami, FL 33136 USA.
   [Fornoni, Alessia] Univ Miami, Miller Sch Med, Diabet Res Inst, Miami, FL 33136 USA.
   [Tietjen, Gregory; Saltzman, W. Mark] Yale Univ, Dept Biomed Engn, New Haven, CT 06520 USA.
   [Mendez, Julio J.; Niklason, Laura E.] Yale Univ, Sch Med, Dept Anesthesiol, New Haven, CT 06510 USA.
   [Pober, Jordan S.] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA.
RP Chang, WG (corresponding author), Yale Univ, Sch Med, Dept Med, POB 208029, New Haven, CT 06520 USA.
EM w.chang@yale.edu
RI Tietjen, Gregory/U-1979-2019
OI Chang, William/0000-0002-7707-9242; fornoni, Alessia/0000-0002-1313-7773
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01-HL085416];
   Clinical and Translational Science Award from the National Center for
   Advancing Translational Science [KL2-RR024138]; NIH/NIDDKUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Diabetes & Digestive & Kidney Diseases
   (NIDDK) [R01-DK090316, DK104753, 5U24DX076169]; National Center for
   Advancing Translational SciencesUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [1UL1TR000460];
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000460] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH
   RESOURCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Research
   Resources (NCRR) [KL2RR024138] Funding Source: NIH RePORTER; NATIONAL
   HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Heart Lung & Blood Institute (NHLBI) [R01HL085416] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Diabetes &
   Digestive & Kidney Diseases (NIDDK) [R01DK104753, R01DK090316] Funding
   Source: NIH RePORTER
FX This work was supported by the National Institutes of Health Grants
   (R01-HL085416 to J.S.P. and W.M.S.) and a Clinical and Translational
   Science Award (KL2-RR024138 to W.G.C. from the National Center for
   Advancing Translational Science. A.F. is supported by the NIH/NIDDK
   (R01-DK090316, DK104753, and 5U24DX076169), and by the National Center
   for Advancing Translational Sciences (1UL1TR000460). Its contents are
   solely the responsibility of the authors and do not necessarily
   represent the official view of NIH. The authors thank Morven Graham
   (Yale University, New Haven, CT) for assistance with electron microscopy
   and David Gonzalez (Yale University) for assistance with multiphoton
   microscopy.
CR Auger FA, 2013, ANNU REV BIOMED ENG, V15, P177, DOI 10.1146/annurev-bioeng-071812-152428
   Chang WG, 2013, CARDIOVASC RES, V100, P492, DOI 10.1093/cvr/cvt215
   Chevalier RL, 2008, J AM SOC NEPHROL, V19, P197, DOI 10.1681/ASN.2007080862
   Devalliere J, 2014, FASEB J, V28, P908, DOI 10.1096/fj.13-238527
   Enis DR, 2005, P NATL ACAD SCI USA, V102, P425, DOI 10.1073/pnas.0408357102
   Gimbrone M A Jr, 1976, Prog Hemost Thromb, V3, P1
   Hama H, 2011, NAT NEUROSCI, V14, P1481, DOI 10.1038/nn.2928
   Harding MJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009987
   Jay SM, 2008, FASEB J, V22, P2949, DOI 10.1096/fj.08-108803
   Kistler AD, 2014, SCI REP-UK, V4, DOI 10.1038/srep03872
   Maier CL, 2010, MICROCIRCULATION, V17, P367, DOI 10.1111/j.1549-8719.2010.00038.x
   MARCUSSEN N, 1990, VIRCHOWS ARCH A, V417, P513, DOI 10.1007/BF01625732
   Nichol JW, 2009, SOFT MATTER, V5, P1312, DOI 10.1039/b814285h
   Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X
   Orlando G, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a015693
   Reidy K, 2011, PEDIATR NEPHROL, V26, P1407, DOI 10.1007/s00467-011-1769-1
   Schechner JS, 2000, P NATL ACAD SCI USA, V97, P9191, DOI 10.1073/pnas.150242297
   Schlondorff D, 2009, J AM SOC NEPHROL, V20, P1179, DOI 10.1681/ASN.2008050549
   Shepherd BR, 2009, TISSUE ENG PT A, V15, P165, DOI 10.1089/ten.tea.2008.0010
   U.S. Renal Data System. USRDS, 2013, ANN DAT REP ATL CHRO
   Zheng L, 2002, J IMMUNOL, V169, P6850, DOI 10.4049/jimmunol.169.12.6850
NR 21
TC 0
Z9 1
U1 0
U2 6
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937-3341
EI 1937-335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD NOV 1
PY 2015
VL 21
IS 21-22
BP 2673
EP 2679
DI 10.1089/ten.tea.2015.0060
PG 7
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
SC Cell Biology; Engineering; Materials Science
GA CV7UI
UT WOS:000364480600004
PM 26414101
OA Green Published
DA 2021-10-30
ER

PT J
AU Knutson, KL
   Wu, DW
   Patel, SR
   Loredo, JS
   Redline, S
   Cai, JW
   Gallo, LC
   Mossavar-Rahmani, Y
   Ramos, AR
   Teng, YP
   Daviglus, ML
   Zee, PC
AF Knutson, Kristen L.
   Wu, Donghong
   Patel, Sanjay R.
   Loredo, Jose S.
   Redline, Susan
   Cai, Jianwen
   Gallo, Linda C.
   Mossavar-Rahmani, Yasmin
   Ramos, Alberto R.
   Teng, Yanping
   Daviglus, Martha L.
   Zee, Phyllis C.
TI Association Between Sleep Timing, Obesity, Diabetes: The Hispanic
   Community Health Study/Study of Latinos (HCHS/SOL) Cohort Study
SO SLEEP
LA English
DT Article
DE sleep timing; diabetes; insulin resistance; circadian
ID IMPAIRED GLUCOSE-TOLERANCE; FOOD-INTAKE; SHIFT WORK; HEART-DISEASE;
   WEIGHT-GAIN; BODY-MASS; NIGHT; DURATION; LIGHT; TIME
AB Study Objectives: Recent studies implicate inadequate sleep duration and quality in metabolic disease. Fewer studies have examined the timing of sleep, which may be important because of its potential impact on circadian rhythms of metabolic function. We examined the association between sleep timing and metabolic risk among Hispanic/Latino adults.
   Methods: Cross-sectional data from community-based study of 13429 participants aged 18-74 years. People taking diabetic medications were excluded. Sleep timing was determined from self-reported bedtimes and wake times. Chronotype was defined as the midpoint of sleep on weekends adjusted for sleep duration on weekdays. Other measurements included body mass index (BMI), fasting glucose levels, estimated insulin resistance (HOMA-IR), glucose levels 2 hours post oral glucose ingestion, and hemoglobin A1c. Survey linear regression models tested associations between sleep timing and metabolic measures. Analyses were stratified by diabetes status and age-group when significant interactions were observed.
   Results: Among participants with diabetes, fasting glucose levels were positively associated with bedtime (approximately +3%/hour later, p <.01) and midpoint of sleep (approximately +2%/hour later, p <.05). In participants with and without diabetes combined, HOMA-IR was positively associated with midpoint of sleep (+1.5%/hr later, p <.05), and chronotype (+1.2%/hour later, p <.05). Associations differed by age-group. Among those < 36 years, later sleep timing was associated with lower BMI, lower fasting glucose, and lower HbA1c, but the opposite association was observed among older participants.
   Conclusions: Later sleep timing was associated with higher estimated insulin resistance across all groups. Some associations between sleep timing and metabolic measures may be age-dependent.
C1 [Knutson, Kristen L.; Zee, Phyllis C.] Northwestern Univ, Ctr Circadian & Sleep Med, Dept Neurol, Evanston, IL 60208 USA.
   [Wu, Donghong; Daviglus, Martha L.] Univ Illinois, Inst Minor Hlth Res, Chicago, IL USA.
   [Patel, Sanjay R.] Univ Pittsburgh, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA USA.
   [Loredo, Jose S.] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA.
   [Redline, Susan] Harvard Med Sch, Brigham & Womens Hosp, Div Sleep & Circadian Disorders, Boston, MA USA.
   [Redline, Susan] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Pulm Crit Care & Sleep, Boston, MA USA.
   [Cai, Jianwen; Teng, Yanping] Univ N Carolina, Collaborat Studies Coordinating Ctr, Dept Biostat, Chapel Hill, NC USA.
   [Gallo, Linda C.] San Diego State Univ, Dept Psychol, San Diego, CA 92182 USA.
   [Mossavar-Rahmani, Yasmin] Albert Einstein Coll Med, Dept Epidemiol Populat Hlth, Bronx, NY 10467 USA.
   [Ramos, Alberto R.] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL USA.
RP Knutson, KL (corresponding author), Northwestern Univ, Ctr Sleep & Circadian Med, Feinberg Sch Med, Dept Neurol, 710 N Lakeshore Dr,Room 523, Chicago, IL 60611 USA.
EM kristen.knutson@northwestern.edu
RI Ramos, Alberto/X-4249-2019
OI Patel, Sanjay/0000-0002-9142-5172; Gallo, Linda C./0000-0002-3678-5888;
   Knutson, Kristen/0000-0002-2751-6168; Mossavar-Rahmani,
   Yasmin/0000-0002-9214-6124
FU National Heart, Lung, and Blood Institute (NHLBI)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [N01-HC65233,
   N01-HC65234, N01-HC65235, N01-HC65236, HHSN268201300003I, N01-HC65237];
   National Center on Minority health and health Disparities; National
   Institute of Deafness and Other Communications DisordersUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Deafness & Other Communication Disorders
   (NIDCD); National Institute of Dental and Craniofacial ResearchUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Dental & Craniofacial
   Research (NIDCR); National Institute of Diabetes and Digestive and
   Kidney DiseasesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institute of
   Neurological Disorders and StrokeUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Neurological Disorders & Stroke (NINDS); Office of Dietary
   SupplementsUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA; NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [KL2TR000461] Funding Source:
   NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [U01HL065233,
   R01HL065234] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)
   [R01DK095207] Funding Source: NIH RePORTER
FX The Hispanic Community Health Study/Study of Latinos was carried out as
   a collaborative study supported by contracts from the National Heart,
   Lung, and Blood Institute (NHLBI) to the University of North Carolina
   (N01-HC65233), University of Miami (N01-HC65234), Albert Einstein
   College of Medicine (N01-HC65235), Northwestern University
   (N01-HC65236), University of Illinois at Chicago (HHSN268201300003I),
   and San Diego State University (N01-HC65237). The following
   Institutes/Centers/Offices contribute to the HCHS/SOL through a transfer
   of funds to the NHLBI: National Center on Minority health and health
   Disparities, the National Institute of Deafness and Other Communications
   Disorders, the National Institute of Dental and Craniofacial Research,
   the National Institute of Diabetes and Digestive and Kidney Diseases,
   the National Institute of Neurological Disorders and Stroke, and the
   Office of Dietary Supplements.
CR Arble DM, 2009, OBESITY, V17, P2100, DOI 10.1038/oby.2009.264
   Baron KG, 2011, OBESITY, V19, P1374, DOI 10.1038/oby.2011.100
   Bass J, 2012, NATURE, V491, P348, DOI 10.1038/nature11704
   Duffy JF, 1998, AM J PHYSIOL-REG I, V275, pR1478, DOI 10.1152/ajpregu.1998.275.5.R1478
   Duffy JF, 2002, AM J PHYSIOL-ENDOC M, V282, pE297, DOI 10.1152/ajpendo.00268.2001
   Fonken LK, 2013, ENDOCRINOLOGY, V154, P3817, DOI 10.1210/en.2013-1121
   Fonken LK, 2010, P NATL ACAD SCI USA, V107, P18664, DOI 10.1073/pnas.1008734107
   Fujino Y, 2006, AM J EPIDEMIOL, V164, P128, DOI 10.1093/aje/kwj185
   Garaulet M, 2013, INT J OBESITY, V37, P604, DOI 10.1038/ijo.2012.229
   Gerstein HC, 2006, LANCET, V368, P1096, DOI 10.1016/S0140-6736(06)69420-8
   Gottlieb DJ, 2005, ARCH INTERN MED, V165, P863, DOI 10.1001/archinte.165.8.863
   Hansen AB, 2016, OCCUP ENVIRON MED, V73, P262, DOI 10.1136/oemed-2015-103342
   Knutson KL, 2010, BEST PRACT RES CL EN, V24, P731, DOI 10.1016/j.beem.2010.07.001
   Lavange LM, 2010, ANN EPIDEMIOL, V20, P642, DOI 10.1016/j.annepidem.2010.05.006
   LEE A, 1992, DIABETES, V41, P750, DOI 10.2337/diab.41.6.750
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   McMullan CJ, 2013, JAMA-J AM MED ASSOC, V309, P1388, DOI 10.1001/jama.2013.2710
   Merikanto I, 2013, CHRONOBIOL INT, V30, P470, DOI 10.3109/07420528.2012.741171
   Mossavar-Rahmani Y, 2015, APPETITE, V95, P275, DOI 10.1016/j.appet.2015.07.014
   Mullington JM, 2009, PROG CARDIOVASC DIS, V51, P294, DOI 10.1016/j.pcad.2008.10.003
   Nakanishi-Minami T, 2012, DIABETOL METAB SYNDR, V4, DOI 10.1186/1758-5996-4-18
   Obayashi K, 2013, J CLIN ENDOCR METAB, V98, P337, DOI 10.1210/jc.2012-2874
   Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549
   Ong KL, 2008, ANN EPIDEMIOL, V18, P222, DOI 10.1016/j.annepidem.2007.10.007
   Qin LQ, 2003, LIFE SCI, V73, P2467, DOI 10.1016/S0024-3205(03)00628-3
   Redline S, 2014, AM J RESP CRIT CARE, V189, P335, DOI 10.1164/rccm.201309-1735OC
   Roenneberg T, 2012, CURR BIOL, V22, P939, DOI 10.1016/j.cub.2012.03.038
   Scheer FAJL, 2009, P NATL ACAD SCI USA, V106, P4453, DOI 10.1073/pnas.0808180106
   Schmid SM, 2015, LANCET DIABETES ENDO, V3, P52, DOI 10.1016/S2213-8587(14)70012-9
   Sorlie PD, 2010, ANN EPIDEMIOL, V20, P629, DOI 10.1016/j.annepidem.2010.03.015
   Tenkanen L, 1997, SCAND J WORK ENV HEA, V23, P257, DOI 10.5271/sjweh.218
   van Amelsvoort LGMP, 1999, INT J OBESITY, V23, P973, DOI 10.1038/sj.ijo.0801028
   Wallace TM, 2004, DIABETES CARE, V27, P1487, DOI 10.2337/diacare.27.6.1487
NR 33
TC 35
Z9 35
U1 3
U2 18
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
EI 1550-9109
J9 SLEEP
JI Sleep
PD APR 1
PY 2017
VL 40
IS 4
AR PII zsx014
DI 10.1093/sleep/zsx014
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA EU2MJ
UT WOS:000400863200019
PM 28329091
OA Green Published, Bronze
DA 2021-10-30
ER

PT J
AU Strbo, N
   Vaccari, M
   Pahwa, S
   Kolber, MA
   Fisher, E
   Gonzalez, L
   Doster, MN
   Hryniewicz, A
   Felber, BK
   Pavlakis, GN
   Franchini, G
   Podack, ER
AF Strbo, Natasa
   Vaccari, Monica
   Pahwa, Savita
   Kolber, Michael A.
   Fisher, Eva
   Gonzalez, Louis
   Doster, Melvin N.
   Hryniewicz, Anna
   Felber, Barbara K.
   Pavlakis, George N.
   Franchini, Genoveffa
   Podack, Eckhard R.
TI Gp96(SIV)Ig immunization induces potent polyepitope specific,
   multifunctional memory responses in rectal and vaginal mucosa
SO VACCINE
LA English
DT Article
DE gp96-chaperone; Mucosa; Non-human primate; Rectum; Vagina
ID HEAT-SHOCK PROTEINS; CYTOTOXIC T-LYMPHOCYTES; DENDRITIC CELLS; ANTIGEN
   PRESENTATION; PROTECTIVE IMMUNITY; CROSS-PRESENTATION; CUTTING EDGE;
   REJECTION; RECEPTOR; VACCINE
AB The ER-resident chaperone gp96, when released by cell lysis, induces an immunogenic chemokine signature and causes innate immune activation of DC and NK cells. Here we show that intraperitoneal immunization with a genetically engineered, secreted form of gp96, gp96-Ig chaperoning SIV antigens, induces high levels of antigen specific CD8 CTL in the rectal and vaginal mucosa of Rhesus macaques. The frequency of SIV Gag- and SIV Tat-tetramer positive CD8 CTL in the intestinal mucosa reached 30-50% after the third immunization. Tetramer positive CD8 CTL expressed appropriate functional (granzyme B) and migration markers (CD103). The polyepitope specificity of the mucosal CD8 and CD4 response is evident from a strong, multifunctional cytokine response upon stimulation with peptides covering the gag, tat and env proteins. Induction of powerful mucosal effector CD8 CTL, responses by cell-based gp96(SIV)-Ig immunization may provide a pathway to the development of safe and effective SIV/HIV vaccines. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Strbo, Natasa; Pahwa, Savita; Fisher, Eva; Gonzalez, Louis; Podack, Eckhard R.] Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA.
   [Strbo, Natasa; Pahwa, Savita; Kolber, Michael A.; Gonzalez, Louis; Podack, Eckhard R.] Univ Miami, Miller Sch Med, Ctr AIDS Res, Miami, FL 33136 USA.
   [Vaccari, Monica; Doster, Melvin N.; Hryniewicz, Anna; Franchini, Genoveffa] NCI, Anim Models & Retroviral Vaccines Sect, NIH, Bethesda, MD 20892 USA.
   [Kolber, Michael A.] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA.
   [Felber, Barbara K.] NCI, Human Retrovirus Pathogenesis Sect, Frederick, MD 21702 USA.
   [Pavlakis, George N.] NCI, Human Retrovirus Sect, Frederick, MD 21702 USA.
RP Podack, ER (corresponding author), 1600 NW 10th Ave,RMSB 3045, Miami, FL 33136 USA.
EM epodack@med.miami.edu
RI Pahwa, Savita/AAA-4900-2019; Hryniewicz, Anna/F-2497-2016
OI Pahwa, Savita/0000-0002-4470-4216; Hryniewicz, Anna/0000-0003-0351-5547
FU Public Health ServiceUnited States Department of Health & Human
   ServicesUnited States Public Health Service [R21 AIO68515, R21/R33
   AI073234, CA109094]; ACGT (Alliance for Cancer Gene Therapy),
   Developmental Center for AIDS Research (DCFAR) University of Miami; NIH,
   National Cancer Institute, Center for Cancer ResearchUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI); NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [ZIABC010350, ZIABC010749, P01CA109094] Funding Source: NIH RePORTER;
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [KL2TR000461] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [R21AI073234,
   R21AI068515, R33AI073234, P30AI073961, R01AI077501] Funding Source: NIH
   RePORTER
FX This research was supported by Public Health Service Grants R21
   AIO68515, R21/R33 AI073234, CA109094, by a Grant from ACGT (Alliance for
   Cancer Gene Therapy), Developmental Center for AIDS Research (DCFAR)
   University of Miami and by the Intramural Research Program of the NIH,
   National Cancer Institute, Center for Cancer Research.
CR Annunziato F, 2006, GUT, V55, P961, DOI 10.1136/gut.2005.077560
   Arnold-Schild D, 1999, J IMMUNOL, V162, P3757
   Bedoui S, 2009, NAT IMMUNOL, V10, P488, DOI 10.1038/ni.1724
   Belyakov IM, 2004, J CLIN INVEST, V113, P998, DOI 10.1172/JCI200420261
   Belyakov IM, 1998, P NATL ACAD SCI USA, V95, P1709, DOI 10.1073/pnas.95.4.1709
   Binder RJ, 2005, NAT IMMUNOL, V6, P593, DOI 10.1038/ni1201
   Binder RJ, 2000, NAT IMMUNOL, V1, P151, DOI 10.1038/77835
   Blachere NE, 1997, J EXP MED, V186, P1315, DOI 10.1084/jem.186.8.1315
   Carlow DA, 2009, J IMMUNOL, V183, P1155, DOI 10.4049/jimmunol.0900409
   Chandawarkar RY, 1999, J EXP MED, V189, P1437, DOI 10.1084/jem.189.9.1437
   Cicin-Sain L, 2007, P NATL ACAD SCI USA, V104, P19960, DOI 10.1073/pnas.0705905104
   Hel Z, 2002, VACCINE, V20, P3171, DOI 10.1016/S0264-410X(02)00258-X
   Jankovic V, 2003, BLOOD, V102, P3244, DOI 10.1182/blood-2003-03-0927
   Kaech SM, 2003, NAT IMMUNOL, V4, P1191, DOI 10.1038/ni1009
   Kunkel EJ, 2000, J EXP MED, V192, P761, DOI 10.1084/jem.192.5.761
   Li QS, 2009, SCIENCE, V323, P1726, DOI 10.1126/science.1168676
   LI ZH, 1993, EMBO J, V12, P3143, DOI 10.1002/j.1460-2075.1993.tb05983.x
   Masopust D, 2009, J INTERN MED, V265, P125, DOI 10.1111/j.1365-2796.2008.02054.x
   Matsutake Toyoshi, 2010, Cancer Immun, V10, P7
   Oizumi S, 2008, J IMMUNOTHER, V31, P394, DOI 10.1097/CJI.0b013e31816bc74d
   Oizumi S, 2007, J IMMUNOL, V179, P2310, DOI 10.4049/jimmunol.179.4.2310
   Oyama T, 2007, MICROCIRCULATION, V14, P753, DOI 10.1080/10739680701409993
   Pitcher CJ, 2002, J IMMUNOL, V168, P29, DOI 10.4049/jimmunol.168.1.29
   Raez LE, 2004, J CLIN ONCOL, V22, P2800, DOI 10.1200/JCO.2004.10.197
   Raez LE, 2003, CANCER GENE THER, V10, P850, DOI 10.1038/sj.cgt.7700641
   Rangel-Moreno J, 2009, IMMUNITY, V30, P731, DOI 10.1016/j.immuni.2009.03.014
   Schneider R, 1997, J VIROL, V71, P4892, DOI 10.1128/JVI.71.7.4892-4903.1997
   Schreiber TH, 2009, CANCER RES, V69, P2026, DOI 10.1158/0008-5472.CAN-08-3706
   Singh-Jasuja H, 2001, BIOL CHEM, V382, P629, DOI 10.1515/BC.2001.074
   SRIVASTAVA PK, 1988, IMMUNOGENETICS, V28, P205, DOI 10.1007/BF00375860
   SRIVASTAVA PK, 1986, P NATL ACAD SCI USA, V83, P3407, DOI 10.1073/pnas.83.10.3407
   SRIVASTAVA PK, 1993, ADV CANCER RES, V62, P153, DOI 10.1016/S0065-230X(08)60318-8
   Stenstad H, 2007, P NATL ACAD SCI USA, V104, P10122, DOI 10.1073/pnas.0700269104
   Strbo N, 2010, MUCOSAL IMMUNOL, V3, P182, DOI 10.1038/mi.2009.127
   Vaccari M, 2005, J IMMUNOL, V175, P3502, DOI 10.4049/jimmunol.175.6.3502
   vonGegerfelt A, 1997, VIROLOGY, V232, P291, DOI 10.1006/viro.1997.8567
   Yamazaki K, 1999, J IMMUNOL, V163, P5178
NR 37
TC 14
Z9 14
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD MAR 21
PY 2011
VL 29
IS 14
BP 2619
EP 2625
DI 10.1016/j.vaccine.2011.01.044
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 745CD
UT WOS:000289140600017
PM 21277409
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Delville, M
   Sigdel, TK
   Wei, CL
   Li, J
   Hsieh, SC
   Fornoni, A
   Burke, GW
   Bruneval, P
   Naesens, M
   Jackson, A
   Alachkar, N
   Canaud, G
   Legendre, C
   Anglicheau, D
   Reiser, J
   Sarwal, MM
AF Delville, Marianne
   Sigdel, Tara K.
   Wei, Changli
   Li, Jing
   Hsieh, Szu-Chuan
   Fornoni, Alessia
   Burke, George W.
   Bruneval, Patrick
   Naesens, Maarten
   Jackson, Annette
   Alachkar, Nada
   Canaud, Guillaume
   Legendre, Christophe
   Anglicheau, Dany
   Reiser, Jochen
   Sarwal, Minnie M.
TI A circulating antibody panel for pretransplant prediction of FSGS
   recurrence after kidney transplantation
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID FOCAL SEGMENTAL GLOMERULOSCLEROSIS; UROKINASE RECEPTOR LEVELS;
   MONOCLONAL-ANTIBODY; NEPHROTIC SYNDROME; RENAL-ALLOGRAFT; RISK-FACTORS;
   SUPAR; PROTEINURIA; LIGAND; PERMEABILITY
AB Recurrence of focal segmental glomerulosclerosis (rFSGS) after kidney transplantation is a cause of accelerated graft loss. To evaluate pathogenic antibodies (Abs) in rFSGS, we processed 141 serum samples from 64 patients with and without primary rFSGS and 34 non-FSGS control patients transplanted at four hospitals. We screened about 9000 antigens in pretransplant sera and selected 10 Abs targeting glomerular antigens for enzyme-linked immunosorbent assay (ELISA) validation. A panel of seven Abs (CD40, PTPRO, CGB5, FAS, P2RY11, SNRPB2, and APOL2) could predict posttransplant FSGS recurrence with 92% accuracy. Pretransplant elevation of anti-CD40 Ab alone had the best correlation (78% accuracy) with rFSGS risk after transplantation. Epitope mapping of CD40 with customized peptide arrays and rFSGS sera demonstrated altered immunogenicity of the extracellular CD40 domain in rFSGS. Immunohistochemistry of CD40 demonstrated a differential expression in FSGS compared to non-FSGS controls. Anti-CD40 Abs purified from rFSGS patients were particularly pathogenic in human podocyte cultures. Injection of anti-CD40/rFSGS Ab enhanced suPAR (soluble urokinase receptor)-mediated proteinuria in wild-type mice, yet no sensitizing effect was noted in mice deficient in CD40 or in wild-type mice that received blocking Ab to CD40. In conclusion, a panel of seven Abs can help identify primary FSGS patients at high risk of recurrence before transplantation. Intrarenal CD40 (and possibly other specific glomerular antigens) is an important contributor to FSGS disease pathogenesis. Human trials of anti-CD40 therapies are warranted to evaluate their efficacy for preventing rFSGS and improving graft survival.
C1 [Delville, Marianne; Canaud, Guillaume; Legendre, Christophe; Anglicheau, Dany] Univ Paris 05, Sorbonne Paris Cite, Necker Hosp, AP HP,INSERM U1171,Dept Kidney Transplantat, F-75015 Paris, France.
   [Sigdel, Tara K.; Hsieh, Szu-Chuan; Sarwal, Minnie M.] Univ Calif San Francisco, Div Transplant Surg, San Francisco, CA 94143 USA.
   [Wei, Changli; Li, Jing; Reiser, Jochen] Rush Univ, Med Ctr, Dept Med, Chicago, IL 60612 USA.
   [Fornoni, Alessia] Univ Miami, Sch Med, Peggy & Harold Katz Family Drug Discovery Ctr, Div Nephrol & Hypertens, Miami, FL 33146 USA.
   [Burke, George W.] Univ Miami, Sch Med, Div Transplant Surg, Miami, FL 33146 USA.
   [Bruneval, Patrick] Hop Europeen Georges Pompidou, Dept Pathol, F-75015 Paris, France.
   [Naesens, Maarten] Univ Hosp Leuven, B-3000 Louvain, Belgium.
   [Jackson, Annette; Alachkar, Nada] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21287 USA.
RP Sarwal, MM (corresponding author), Univ Calif San Francisco, Div Transplant Surg, San Francisco, CA 94143 USA.
EM jochen_reiser@rush.edu; minnie.sarwal@ucsf.edu
RI Naesens, Maarten/J-4766-2015; Delville, Marianne/H-2985-2017; Sigdel,
   Tara/AAV-5886-2020
OI Naesens, Maarten/0000-0002-5625-0792; Delville,
   Marianne/0000-0002-9585-2307; Sigdel, Tara/0000-0001-8448-0328; fornoni,
   Alessia/0000-0002-1313-7773; Alachkar, Nada/0000-0003-1249-2455
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA; National Institute of Diabetes and
   Digestive Kidney DiseasesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Diabetes & Digestive & Kidney Diseases (NIDDK) [DK090316,
   5U24DX076169, 1UL1TR000460, 12GHSU176]; Terumo BCT Plasma Exchange
   Innovation Award;  [DK083447];  [U01AI113362];  [DK089394];  [DK073495];
   [DK101350]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Advancing Translational
   Sciences (NCATS) [UL1TR000460] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [U01AI113362] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)
   [R01DK090316, R01DK089394, R01DK083447, R01DK073495, R56DK083447,
   R01DK101350] Funding Source: NIH RePORTER
FX M.M.S. was supported by R01 and U01 grants DK083447 and U01AI113362.
   M.D. received financial support for this study from Novartis. J.R. was
   supported by R01 grants DK089394, DK073495, and DK101350. A.F. was
   supported by the NIH and National Institute of Diabetes and Digestive
   Kidney Diseases grant nos. DK090316, 5U24DX076169, 1UL1TR000460, and
   12GHSU176. C.W. was supported by Terumo BCT Plasma Exchange Innovation
   Award.
CR Alachkar N, 2013, TRANSPLANTATION, V96, P649, DOI 10.1097/TP.0b013e31829eda4f
   Alachkar N, 2013, NEW ENGL J MED, V368, P971, DOI 10.1056/NEJMc1207233
   Assmann KJM, 2002, KIDNEY INT, V62, P116, DOI 10.1046/j.1523-1755.2002.00428.x
   Bensinger W, 2012, BRIT J HAEMATOL, V159, P58, DOI 10.1111/j.1365-2141.2012.09251.x
   Bitzan M, 2012, PEDIATR NEPHROL, V27, P2217, DOI 10.1007/s00467-012-2163-3
   Butte AJ, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.000497
   Canaud G, 2010, NEPHROL DIAL TRANSPL, V25, P1321, DOI 10.1093/ndt/gfp500
   Cathelin D, 2014, J AM SOC NEPHROL, V25, P1662, DOI 10.1681/ASN.2013040425
   Charba DS, 2009, AM J PHYSIOL-RENAL, V297, pF138, DOI 10.1152/ajprenal.00122.2008
   Chikamoto H, 2012, PEDIATR TRANSPLANT, V16, pE286, DOI 10.1111/j.1399-3046.2011.01610.x
   D'Agati VD, 2011, NEW ENGL J MED, V365, P2398, DOI 10.1056/NEJMra1106556
   Dantal J, 1998, J AM SOC NEPHROL, V9, P1709
   Fornoni A, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002231
   Gbadegesin R, 2011, PEDIATR NEPHROL, V26, P1001, DOI 10.1007/s00467-010-1692-x
   Grimbert P, 2003, J EXP MED, V198, P797, DOI 10.1084/jem.20030566
   Higgins JPT, 2004, MOL BIOL CELL, V15, P649, DOI 10.1091/mbc.E03-06-0432
   Huang J, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-81
   Huang J, 2013, KIDNEY INT, V84, P366, DOI 10.1038/ki.2013.55
   Kairaitis L, 2003, KIDNEY INT, V64, P1265, DOI 10.1046/j.1523-1755.2003.00223.x
   Law CL, 2009, ADV EXP MED BIOL, V647, P8, DOI 10.1007/978-0-387-89520-8_2
   Le Berre L, 2005, KIDNEY INT, V68, P2079
   Li L, 2009, P NATL ACAD SCI USA, V106, P4148, DOI 10.1073/pnas.0900563106
   Musante L, 2005, CLIN EXP IMMUNOL, V141, P491, DOI 10.1111/j.1365-2249.2005.02862.x
   Pardon A, 2006, NEPHROL DIAL TRANSPL, V21, P1053, DOI 10.1093/ndt/gfk005
   PEPPARD JV, 1980, IMMUNOLOGY, V40, P683
   Pescovitz MD, 2006, NEW ENGL J MED, V354, P1961, DOI 10.1056/NEJMc055495
   Saleem MA, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133630
   Savin VJ, 1996, NEW ENGL J MED, V334, P878, DOI 10.1056/NEJM199604043341402
   SENGGUTUVAN P, 1990, PEDIATR NEPHROL, V4, P21, DOI 10.1007/BF00858431
   Sigdel TK, 2012, J AM SOC NEPHROL, V23, P750, DOI 10.1681/ASN.2011060596
   Sutherland SM, 2009, KIDNEY INT, V76, P1277, DOI 10.1038/ki.2009.384
   Tanaka T, 2002, J AM SOC NEPHROL, V13, P2488, DOI 10.1097/01.ASN.0000029588.07166.20
   Topham PS, 1999, J CLIN INVEST, V104, P1559, DOI 10.1172/JCI7728
   Trachtman H, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-82
   Trachtman H, 2013, PEDIATR NEPHROL, V28, P1151, DOI 10.1007/s00467-013-2463-2
   VANKOOTEN C, 1994, EUR J IMMUNOL, V24, P787, DOI 10.1002/eji.1830240402
   Veron D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040589
   Vinai M, 2010, PEDIATR TRANSPLANT, V14, P314, DOI 10.1111/j.1399-3046.2009.01261.x
   Watanabe M, 2013, AM J TRANSPLANT, V13, P1976, DOI 10.1111/ajt.12330
   Wei C, 2008, NAT MED, V14, P55, DOI 10.1038/nm1696
   Wei CL, 2012, J AM SOC NEPHROL, V23, P2051, DOI 10.1681/ASN.2012030302
   Wei CL, 2011, NAT MED, V17, P952, DOI 10.1038/nm.2411
   Yu HY, 2013, MOL CELL BIOL, V33, P4755, DOI 10.1128/MCB.00730-13
NR 43
TC 114
Z9 118
U1 0
U2 13
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
EI 1946-6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD OCT 1
PY 2014
VL 6
IS 256
AR 256ra136
DI 10.1126/scitranslmed.3008538
PG 12
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA AR1CE
UT WOS:000343317700008
PM 25273097
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Arora, H
   Panara, K
   Kuchakulla, M
   Kulandavelu, S
   Burnstein, KL
   Schally, AV
   Hare, JM
   Ramasamy, R
AF Arora, Himanshu
   Panara, Kush
   Kuchakulla, Manish
   Kulandavelu, Shathiyah
   Burnstein, Kerry L.
   Schally, Andrew V.
   Hare, Joshua M.
   Ramasamy, Ranjith
TI Alterations of tumor microenvironment by nitric oxide impedes
   castration-resistant prostate cancer growth
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE nitric oxide; tumor microenvironment; CRPC; tumor-associated
   macrophages; immunotherapy
ID MEDIATED INHIBITION; CALCIUM LEAK; CELLS; MACROPHAGES; METASTASIS;
   AUTOPHAGY; INFILTRATION; ASSOCIATION; MECHANISMS; HEART
AB Immune targeted therapy of nitric oxide (NO) synthases are being considered as a potential frontline therapeutic to treat patients diagnosed with locally advanced and metastatic prostate cancer. However, the role of NO in castration-resistant prostate cancer (CRPC) is controversial because NO can increase in nitrosative stress while simultaneously possessing antiinflammatory properties. Accordingly, we tested the hypothesis that increased NO will lead to tumor suppression of CRPC through tumor microenvironment. S-nitrosoglutathione (GSNO), an NO donor, decreased the tumor burden in murine model of CRPC by targeting tumors in a cell nonautonomous manner. GSNO inhibited both the abundance of antiinflammatory (M2) macrophages and expression of pERK, indicating that tumor-associated macrophages activity is influenced by NO. Additionally, GSNO decreased IL-34, indicating suppression of tumor-associated macrophage differentiation. Cytokine profiling of CRPC tumor grafts exposed to GSNO revealed a significant decrease in expression of G-CSF and M-CSF compared with grafts not exposed to GSNO. We verified the durability of NO on CRPC tumor suppression by using secondary xenograft murine models. This study validates the significance of NO on inhibition of CRPC tumors through tumor microenvironment (TME). These findings may facilitate the development of previously unidentified NO-based therapy for CRPC.
C1 [Arora, Himanshu; Panara, Kush; Kuchakulla, Manish; Ramasamy, Ranjith] Univ Miami, Miller Sch Med, Dept Urol, Miami, FL 33136 USA.
   [Arora, Himanshu; Kulandavelu, Shathiyah; Hare, Joshua M.] Univ Miami, Interdisciplinary Stem Cell Inst, Miller Sch Med, Miami, FL 33136 USA.
   [Burnstein, Kerry L.] Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA.
   [Schally, Andrew V.] Vet Affairs Med Ctr, Endocrine Polypeptide & Canc Inst, Miami, FL 33125 USA.
   [Schally, Andrew V.] South Florida Vet Affairs Fdn Res & Educ, Miami, FL 33125 USA.
   [Schally, Andrew V.] Univ Miami, Miller Sch Med, Dept Med, Div Hematol Oncol, Miami, FL 33136 USA.
   [Schally, Andrew V.] Univ Miami, Miller Sch Med, Div Endocrinol, Dept Med, Miami, FL 33136 USA.
   [Schally, Andrew V.] Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL 33136 USA.
   [Schally, Andrew V.] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA.
   [Hare, Joshua M.] Univ Miami, Miller Sch Med, Div Cardiol, Dept Med, Miami, FL 33136 USA.
RP Arora, H; Ramasamy, R (corresponding author), Univ Miami, Miller Sch Med, Dept Urol, Miami, FL 33136 USA.; Arora, H (corresponding author), Univ Miami, Interdisciplinary Stem Cell Inst, Miller Sch Med, Miami, FL 33136 USA.; Schally, AV (corresponding author), Vet Affairs Med Ctr, Endocrine Polypeptide & Canc Inst, Miami, FL 33125 USA.; Schally, AV (corresponding author), South Florida Vet Affairs Fdn Res & Educ, Miami, FL 33125 USA.; Schally, AV (corresponding author), Univ Miami, Miller Sch Med, Dept Med, Div Hematol Oncol, Miami, FL 33136 USA.; Schally, AV (corresponding author), Univ Miami, Miller Sch Med, Div Endocrinol, Dept Med, Miami, FL 33136 USA.; Schally, AV (corresponding author), Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL 33136 USA.; Schally, AV (corresponding author), Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA.
EM andrew.schally@va.gov; hxa287@miami.edu; ramasamy@miami.edu
RI Ramasamy, Ranjith/ABD-7373-2020; Kulandavelu, Shathiyah/AAE-2472-2020
OI Ramasamy, Ranjith/0000-0003-1387-7904; Kulandavelu,
   Shathiyah/0000-0003-0966-7613
FU American Urological Association Research Scholar Award; Stanley Glaser
   Award; Sexual Medicine Society of North America (SMSNA); NIHUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA [1R01 HL137355, 1R01 HL107110, 1R01 HL134558, 5R01
   CA136387, 5UM1 HL113460]; Soffer Family Foundation; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [R01CA136387] Funding Source: NIH RePORTER; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR002736]
   Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [R01HL107110, UM1HL113460, R01HL137355, R01HL134558]
   Funding Source: NIH RePORTER
FX We thank all the mentors (Dr. Dipen J. Parekh), collaborators (Dr. Alan
   Pollack, Dr. Chad Ritch), and interns (Aysswarya Manoharan, Khushi Shah)
   for their insights, suggestions, and support during this study.
   Additionally, we thank the American Urological Association Research
   Scholar Award and Stanley Glaser Award (for R.R.) and the Sexual
   Medicine Society of North America (SMSNA) (for H.A.). J.M.H. is
   supported by NIH Grants 1R01 HL137355, 1R01 HL107110, 1R01 HL134558,
   5R01 CA136387, and 5UM1 HL113460, and the Soffer Family Foundation.
CR Gonano LA, 2014, CARDIOVASC RES, V104, P456, DOI 10.1093/cvr/cvu230
   Arsova-Sarafinovska Z, 2009, CLIN BIOCHEM, V42, P1228, DOI 10.1016/j.clinbiochem.2009.05.009
   Ashe HL, 2006, DEVELOPMENT, V133, P385, DOI 10.1242/dev.02238
   Balkwill FR, 2012, J CELL SCI, V125, P5591, DOI 10.1242/jcs.116392
   Baritaki S, 2010, CELL CYCLE, V9, P4931, DOI 10.4161/cc.9.24.14229
   Beigi F, 2012, P NATL ACAD SCI USA, V109, P4314, DOI 10.1073/pnas.1113319109
   Burke AJ, 2013, CARCINOGENESIS, V34, P503, DOI 10.1093/carcin/bgt034
   Carmona-Fontaine C, 2017, P NATL ACAD SCI USA, V114, P2934, DOI 10.1073/pnas.1700600114
   Chandrasekar T, 2015, TRANSL ANDROL UROL, V4, P365, DOI 10.3978/j.issn.2223-4683.2015.05.02
   Choudhari SK, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-118
   Corn Paul G, 2012, Cancer Manag Res, V4, P183, DOI 10.2147/CMAR.S32839
   Cronauer MV, 2007, ONCOGENE, V26, P1875, DOI 10.1038/sj.onc.1209984
   Culig Zoran, 2017, Curr Mol Biol Rep, V3, P230, DOI 10.1007/s40610-017-0079-1
   Decker NK, 2008, AM J PATHOL, V173, P1002, DOI 10.2353/ajpath.2008.080158
   Del Re M, 2017, EUR UROL, V71, P680, DOI 10.1016/j.eururo.2016.08.012
   DeNardo DG, 2011, CANCER DISCOV, V1, P54, DOI 10.1158/2159-8274.CD-10-0028
   DENICHILO MO, 1993, P NATL ACAD SCI USA, V90, P2517, DOI 10.1073/pnas.90.6.2517
   Donia M, 2009, EUR J PHARMACOL, V615, P228, DOI 10.1016/j.ejphar.2009.04.069
   Dulce RA, 2015, CIRC RES, V116, P46, DOI 10.1161/CIRCRESAHA.116.305172
   Enomoto M, 2015, CANCER SCI, V106, P1651, DOI 10.1111/cas.12816
   Gewirtz DA, 2018, BIOCHEM PHARMACOL, V153, P46, DOI 10.1016/j.bcp.2018.01.048
   Gewirtz DA, 2014, CANCER RES, V74, P647, DOI 10.1158/0008-5472.CAN-13-2966
   Gewirtz DA, 2013, AUTOPHAGY, V9, P1263, DOI 10.4161/auto.25233
   Gollapudi K, 2013, AM J CANCER RES, V3, P523
   Gonzalez DR, 2010, J BIOL CHEM, V285, P28938, DOI 10.1074/jbc.M110.154948
   Hare JM, 2005, J CLIN INVEST, V115, P509, DOI 10.1172/JCI200524459
   Hatzistergos KE, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.001974
   Hotte SJ, 2010, CURR ONCOL, V17, pS72
   Huh J, 2006, CANCER RES, V66, P3726, DOI 10.1158/0008-5472.CAN-05-4033
   Juang SH, 1998, HUM GENE THER, V9, P845, DOI 10.1089/hum.1998.9.6-845
   Kang HG, 2017, INT J ONCOL, V50, P545, DOI 10.3892/ijo.2017.3841
   Lanciotti M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/486798
   Laoui D, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00489
   Loges Sonja, 2010, Genes Cancer, V1, P12, DOI 10.1177/1947601909356574
   Mahon KL, 2015, BRIT J CANCER, V112, P1340, DOI 10.1038/bjc.2015.74
   Mantovani A, 2017, NAT REV CLIN ONCOL, V14, P399, DOI 10.1038/nrclinonc.2016.217
   Maolake A, 2017, ONCOTARGET, V8, P9739, DOI 10.18632/oncotarget.14185
   Masterson TA, 2018, J SEX MED, V15, P654, DOI 10.1016/j.jsxm.2018.03.002
   Miller MR, 2007, BRIT J PHARMACOL, V151, P305, DOI 10.1038/sj.bjp.0707224
   Paglin S, 2001, CANCER RES, V61, P439
   Qin Y, 2013, CANCER RES, V73, P6690, DOI 10.1158/0008-5472.CAN-13-1042
   Rizi BS, 2017, TRENDS CANCER, V3, P659, DOI 10.1016/j.trecan.2017.07.005
   Rogers KW, 2011, ANNU REV CELL DEV BI, V27, P377, DOI 10.1146/annurev-cellbio-092910-154148
   Sanina N, 2017, MOLECULES, V22, DOI 10.3390/molecules22091426
   Schleiffer R, 2000, NITRIC OXIDE-BIOL CH, V4, P583, DOI 10.1006/niox.2000.0310
   Shiao SL, 2016, CANCER LETT, V380, P340, DOI 10.1016/j.canlet.2015.12.022
   Shimura S, 2000, CANCER RES, V60, P5857
   Sun SH, 2010, J CLIN INVEST, V120, P2715, DOI 10.1172/JCI41824
   Tonry C, 2017, ONCOTARGET, V8, P14374, DOI 10.18632/oncotarget.14605
   Varghese P, 2000, J CLIN INVEST, V106, P697, DOI 10.1172/JCI9323
   Xu WM, 2002, CELL RES, V12, P311, DOI 10.1038/sj.cr.7290133
   Yang KR, 2014, J CELL BIOCHEM, V115, P1478, DOI 10.1002/jcb.24813
NR 52
TC 12
Z9 14
U1 1
U2 23
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 30
PY 2018
VL 115
IS 44
BP 11298
EP 11303
DI 10.1073/pnas.1812704115
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GY6PP
UT WOS:000448713200060
PM 30322928
OA Green Published, Bronze
DA 2021-10-30
ER

PT J
AU Rethorst, CD
   Moncrieft, AE
   Gellman, MD
   Arredondo, EM
   Buelna, C
   Castaneda, SF
   Daviglus, ML
   Khan, UI
   Perreira, KM
   Sotres-Alvarez, D
   Stoutenberg, M
AF Rethorst, Chad D.
   Moncrieft, Ashley E.
   Gellman, Marc D.
   Arredondo, Elva M.
   Buelna, Christina
   Castaneda, Shelia F.
   Daviglus, Martha L.
   Khan, Unab I.
   Perreira, Krista M.
   Sotres-Alvarez, Daniela
   Stoutenberg, Mark
TI Isotemporal Analysis of the Association of Objectively Measured Physical
   Activity With Depressive Symptoms: Results From Hispanic Community
   Health Study/Study of Latinos (HCHS/SOL)
SO JOURNAL OF PHYSICAL ACTIVITY & HEALTH
LA English
DT Article
DE exercise; depression
ID UNITED-STATES; MAJOR DEPRESSION; ANTIDEPRESSANT TREATMENT; SEDENTARY
   BEHAVIOR; ALAMEDA COUNTY; OLDER-ADULTS; PRIMARY-CARE; RISK-FACTORS;
   PREVALENCE; POPULATION
AB Background: The burden of depression among Hispanics/Latinos indicates the need to identify factors related to depressive symptoms. This paper examines the relationship of physical activity (PA) and sedentary behavior (SB) with depressive symptoms in Hispanic/Latinos. Methods: The Hispanic Community Health Study / Study of Latinos (HCHS/SOL) is a population-based, cohort study of Hispanic/Latinos in 4 United States metropolitan areas. Objectively measured PA was coded into: sedentary behavior (SB), light-intensity (LPA), moderate-intensity (MPA), and vigorous-intensity (VPA); and the Center for Epidemiological Studies Depression Scale-10 assessed depressive symptoms. Multiple regression analysis utilizing isotemporal substitution, adjusted for relevant covariates, examined PA as predictors of depressive symptoms. Results: Substitution of 1 hour of SB with VPA resulted in a significant decrease in depressive symptoms (beta = 1.215, P =.021). Similar decreases were observed when VPA replaced LPA(beta = 1.212, P =.021) and MPA (beta = -1.50 P =.034). MPA and LPA were not associated with lower depressive symptoms. Conclusions: Previous research has focused on the relationship of MVPA on depressive symptoms. Our results suggest these constructs should be examined separately as they may have unique relationships with depressive symptoms. The association of SB with greater depressive symptoms confirms previous reports.
C1 [Rethorst, Chad D.] Univ Texas Southwestern Med Ctr Dallas, Ctr Depress Res & Clin Care, Dept Psychiat, Dallas, TX 75390 USA.
   [Moncrieft, Ashley E.; Gellman, Marc D.] Univ Miami, Dept Psychol, POB 248185, Coral Gables, FL 33124 USA.
   [Arredondo, Elva M.; Buelna, Christina; Castaneda, Shelia F.] San Diego State Univ, Grad Sch Publ Hlth, Inst Behav & Community Hlth, San Diego, CA 92182 USA.
   [Daviglus, Martha L.] Univ Illinois, Inst Minor Hlth Res, Chicago, IL USA.
   [Khan, Unab I.] Albert Einstein Coll Med, Dept Pediat & Family & Social Med, Bronx, NY 10467 USA.
   [Perreira, Krista M.; Sotres-Alvarez, Daniela] Univ N Carolina, Gillings Sch Global Publ Hlth, Collaborat Studies Coordinating Ctr, Dept Biostat, Chapel Hill, NC USA.
   [Stoutenberg, Mark] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA.
RP Rethorst, CD (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Ctr Depress Res & Clin Care, Dept Psychiat, Dallas, TX 75390 USA.
EM chad.rethorst@utsouthwestern.edu
RI Castaneda, Sheila F./AAK-3025-2020; Castaneda, Sheila/I-4132-2014
OI Castaneda, Sheila/0000-0002-1975-0544
FU National Heart, Lung, and Blood Institute (NHLBI)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [N01-HC65233];
   University of Miami [N01-HC65234]; Albert Einstein College of Medicine
   [N01-HC65235]; Northwestern University [N01-HC65236]; San Diego State
   University [N01- HC65237];  [NI1V1H K01M11097847]; EUNICE KENNEDY
   SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child
   Health & Human Development (NICHD) [P2CHD050924] Funding Source: NIH
   RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Advancing Translational
   Sciences (NCATS) [KL2TR000461] Funding Source: NIH RePORTER; NATIONAL
   HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Heart Lung & Blood Institute (NHLBI) [R01HL065234, U01HL065233] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Mental Health (NIMH) [K01MH097847]
   Funding Source: NIH RePORTER
FX The authors thank the staff and participants of HCHS/SOL for their
   important contributions. (http://www.cscc.unc.edu.access.library.miami.edu/hchs/). Results of the
   study are presented clearly, honestly, and without fabrication
   falsification, or inappropriate data manipulation. Results do not
   constitute endorsement by ACSM. The Hispanic Community Health
   Study/Study of Latinos was carried out as a collaborative study
   supported by contracts from the National Heart, Lung, and Blood
   Institute (NHLBI) to the University of North Carolina (N01-HC65233),
   University of Miami (N01-HC65234), Albert Einstein College of Medicine
   (N01-HC65235), Northwestern University (N01-HC65236), and San Diego
   State University (N01- HC65237). The following Institutes/
   Centers/Offices contribute to the HCHS/SOL through a transfer of funds
   to the NHLBI: National Center on Minority Health and Health Disparities,
   the National Institute of Deafness and Other Communications Disorders,
   the National Institute of Dental and Craniofacial Research, the National
   Institute of Diabetes and Digestive and Kidney Diseases, the National
   Institute of Neurological Disorders and Stroke, and the Office of
   Dietary Supplements. Chad D. Rethorst is supported by NI1V1H
   K01M11097847.
CR Alegria M, 2008, AM J PSYCHIAT, V165, P359, DOI 10.1176/appi.ajp.2007.07040704
   Alegria M, 2007, AM J PUBLIC HEALTH, V97, P68, DOI 10.2105/AJPH.2006.087205
   Arredondo EM, 2013, MENT HEALTH PHYS ACT, V6, P3, DOI 10.1016/j.mhpa.2012.10.005
   Basavarajaiah S, 2008, J AM COLL CARDIOL, V51, P2256, DOI 10.1016/j.jacc.2007.12.061
   BERKMAN LF, 1979, AM J EPIDEMIOL, V109, P186, DOI 10.1093/oxfordjournals.aje.a112674
   BLAZER DG, 1994, AM J PSYCHIAT, V151, P979
   BROADHEAD WE, 1990, JAMA-J AM MED ASSOC, V264, P2524, DOI 10.1001/jama.264.19.2524
   Bromberger JT, 2004, AM J PUBLIC HEALTH, V94, P1378, DOI 10.2105/AJPH.94.8.1378
   Bustamante EE, 2013, MENT HEALTH PHYS ACT, V6, P69, DOI 10.1016/j.mhpa.2013.05.001
   CAMACHO TC, 1991, AM J EPIDEMIOL, V134, P220, DOI 10.1093/oxfordjournals.aje.a116074
   Chen LJ, 2012, INT J BEHAV NUTR PHY, V9, DOI 10.1186/1479-5868-9-28
   Choi L, 2011, MED SCI SPORT EXER, V43, P357, DOI 10.1249/MSS.0b013e3181ed61a3
   Colley Rachel C, 2011, Health Rep, V22, P7
   Daviglus ML, 2012, JAMA-J AM MED ASSOC, V308, P1775, DOI 10.1001/jama.2012.14517
   De Moor MHM, 2006, PREV MED, V42, P273, DOI 10.1016/j.ypmed.2005.12.002
   Enders CK, 2001, EDUC PSYCHOL MEAS, V61, P713, DOI 10.1177/0013164401615001
   Esliger DW, 2006, MED SCI SPORT EXER, V38, P2173, DOI 10.1249/01.mss.0000239394.55461.08
   Evenson KR, 2015, MED SCI SPORT EXER, V47, P725, DOI 10.1249/MSS.0000000000000478
   Faith MS, 2002, J PSYCHOSOM RES, V53, P935, DOI 10.1016/S0022-3999(02)00308-2
   Falcon LM, 2000, J GERONTOL B-PSYCHOL, V55, pS108, DOI 10.1093/geronb/55.2.S108
   FARMER ME, 1988, AM J EPIDEMIOL, V128, P1340, DOI 10.1093/oxfordjournals.aje.a115087
   Galper DI, 2006, MED SCI SPORT EXER, V38, P173, DOI 10.1249/01.mss.0000180883.32116.28
   Giffuni J, 2012, INT J EXERC SCI, V5, P9
   Gonzalez HM, 2010, J PSYCHIATR RES, V44, P1043, DOI 10.1016/j.jpsychires.2010.03.017
   Gonzalez P, 2017, PSYCHOL ASSESSMENT, V29, P372, DOI 10.1037/pas0000330
   Hallgren M, 2016, PREV MED, V88, P53, DOI 10.1016/j.ypmed.2016.03.021
   Harris MI, 1998, DIABETES CARE, V21, P518, DOI 10.2337/diacare.21.4.518
   Hooker SP, 2011, J PHYS ACT HEALTH, V8, P372, DOI 10.1123/jpah.8.3.372
   HORWATH E, 1992, ARCH GEN PSYCHIAT, V49, P817
   Irwin M, 1999, ARCH INTERN MED, V159, P1701, DOI 10.1001/archinte.159.15.1701
   Jenkinson C, 1997, J PUBLIC HEALTH MED, V19, P179, DOI 10.1093/oxfordjournals.pubmed.a024606
   Judd LL, 1996, AM J PSYCHIAT, V153, P1411
   JUDD LL, 1994, J CLIN PSYCHIAT, V55, P18
   KESSLER RC, 1992, PSYCHOL AGING, V7, P119, DOI 10.1037/0882-7974.7.1.119
   Kohout F J, 1993, J Aging Health, V5, P179, DOI 10.1177/089826439300500202
   Lavange LM, 2010, ANN EPIDEMIOL, V20, P642, DOI 10.1016/j.annepidem.2010.05.006
   Lyness JM, 2007, AM J GERIAT PSYCHIAT, V15, P214, DOI 10.1097/01.JGP.0000235763.50230.83
   MARIN G, 1987, HISPANIC J BEHAV SCI, V9, P183, DOI 10.1177/07399863870092005
   Mekary RA, 2009, AM J EPIDEMIOL, V170, P519, DOI 10.1093/aje/kwp163
   Mendelson T, 2008, J CONSULT CLIN PSYCH, V76, P355, DOI 10.1037/0022-006X.76.3.355
   Mikolajczyk RT, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-21
   Olfson M, 2006, AM J PSYCHIAT, V163, P101, DOI 10.1176/appi.ajp.163.1.101
   Olfson M, 2002, JAMA-J AM MED ASSOC, V287, P203, DOI 10.1001/jama.287.2.203
   Owen N, 2010, EXERC SPORT SCI REV, V38, P105, DOI 10.1097/JES.0b013e3181e373a2
   PAFFENBARGER RS, 1994, ACTA PSYCHIAT SCAND, V89, P16, DOI 10.1111/j.1600-0447.1994.tb05796.x
   Pinto-Meza A, 2008, PSYCHIAT SERV, V59, P78, DOI 10.1176/ps.2008.59.1.78
   Prince SA, 2008, INT J BEHAV NUTR PHY, V5, DOI 10.1186/1479-5868-5-56
   RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306
   Rethorst CD, 2009, SPORTS MED, V39, P491, DOI 10.2165/00007256-200939060-00004
   Simpson SM, 2007, PSYCHIAT QUART, V78, P3, DOI 10.1007/s11126-006-9022-y
   Sorlie PD, 2010, ANN EPIDEMIOL, V20, P629, DOI 10.1016/j.annepidem.2010.03.015
   Stamatakis E, 2015, INT J BEHAV NUTR PHY, V12, DOI 10.1186/s12966-015-0280-7
   Vallance JK, 2011, PREV MED, V53, P284, DOI 10.1016/j.ypmed.2011.07.013
   Welk GJ, 2004, MED SCI SPORT EXER, V36, P1637, DOI 10.1249/01.MSS.0000074670.03001.98
   Whelton SP, 2002, ANN INTERN MED, V136, P493, DOI 10.7326/0003-4819-136-7-200204020-00006
   Wong SL, 2011, J PHYS ACT HEALTH, V8, P587, DOI 10.1123/jpah.8.4.587
NR 56
TC 12
Z9 12
U1 2
U2 9
PU HUMAN KINETICS PUBL INC
PI CHAMPAIGN
PA 1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA
SN 1543-3080
EI 1543-5474
J9 J PHYS ACT HEALTH
JI J. Phys. Act. Health
PD SEP
PY 2017
VL 14
IS 9
BP 733
EP 739
DI 10.1123/jpah.2016-0648
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA FH4ZK
UT WOS:000411171100010
PM 28422609
OA Green Accepted, Green Submitted
DA 2021-10-30
ER

PT J
AU Ramos, AR
   Tarraf, W
   Daviglus, M
   Davis, S
   Gallo, LC
   Mossavar-Rahmani, Y
   Penedo, FJ
   Redline, S
   Rundek, T
   Sacco, RL
   Sotres-Alvarez, D
   Wright, CB
   Zee, PC
   Gonzalez, HM
AF Ramos, Alberto R.
   Tarraf, Wassim
   Daviglus, Martha
   Davis, Sonia
   Gallo, Linda C.
   Mossavar-Rahmani, Yasmin
   Penedo, Frank J.
   Redline, Susan
   Rundek, Tatjana
   Sacco, Ralph L.
   Sotres-Alvarez, Daniela
   Wright, Clinton B.
   Zee, Phyllis C.
   Gonzalez, Hector M.
TI Sleep Duration and Neurocognitive Function in the Hispanic Community
   Health Study/Study of Latinos
SO SLEEP
LA English
DT Article
DE sleep; Hispanic/Latino; epidemiology; neurocognitive
ID ENGLISH-SPEAKING; OLDER-ADULTS; MEMORY TEST; LONG-SLEEP; RISK;
   COGNITION; DEMENTIA; DESIGN; SAMPLE; SPEED
AB Study Objectives: To evaluate the association between sleep duration and neurocognitive function in a representative sample of middle-aged to older Hispanic/Latino adults in the US. We tested the hypothesis that sleep duration has a nonlinear, inverted U-shaped association with neurocognitive function.
   Methods: We performed a cross-sectional analysis from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) participants ages 45-74 years (n = 8,676). HCHS/SOL is a community-based cohort from four US urban areas sampled using a probability design from 2008-2011. Self-reported sleep duration was calculated as a weighted average of the difference between habitual wake and bedtimes assessed by separate questions for weekdays and weekends. Neurocognitive function was measured with standardized scores for Word (Phonemic) Fluency (WF), Brief-Spanish English Verbal learning test (B-SEVLT), and Digit Symbol Substitution (DSS) tests.
   Results: The mean age was 56.5 years; 55% were women; and 40.4% had less than high school education. Average sleep duration was 7.8 +/- 1.7 hours. There was an inverted U-shaped association with sleep duration and WF, B-SEVLT sum, and the DSS, with no association with B-SEVLT delayed-recall. Participants with intermediate sleep duration had the best neurocognitive function, while long sleepers had worse neurocognitive function adjusting for demographic, behavioral, and medical factors, daytime sleepiness, and use of sleep medications.
   Conclusions: Sleep duration had curvilinear inverted U-shaped associations with neurocognitive function, with worse scores among participants with longer sleep duration. These findings may provide a framework to further examine sleep duration in the prevention and treatment of neurocognitive disorders.
C1 [Ramos, Alberto R.; Rundek, Tatjana; Sacco, Ralph L.; Wright, Clinton B.] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA.
   [Tarraf, Wassim] Wayne State Univ, Detroit, MI USA.
   [Daviglus, Martha] Univ Illinois, Chicago, IL USA.
   [Daviglus, Martha; Penedo, Frank J.; Zee, Phyllis C.] Northwestern Univ, Chicago, IL 60611 USA.
   [Davis, Sonia; Sotres-Alvarez, Daniela] Univ N Carolina, Gillings Sch Global Publ Hlth, Collaborat Studies Coordinating Ctr Dept Biostat, Chapel Hill, NC USA.
   [Gallo, Linda C.] San Diego State Univ, San Diego, CA 92182 USA.
   [Mossavar-Rahmani, Yasmin] Albert Einstein Coll Med, Bronx, NY 10467 USA.
   [Redline, Susan] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
   [Gonzalez, Hector M.] Michigan State Univ, E Lansing, MI 48824 USA.
RP Gonzalez, HM (corresponding author), Michigan State Univ, Dept Epidemiol & Biostat, 909 Fee Rd,Room B601, E Lansing, MI 48824 USA.
EM hmgonzalez@epi.msu.edu
RI Ramos, Alberto/X-4249-2019; Sacco, Ralph/Y-9278-2019; Sotres-Alvarez,
   Daniela/O-9085-2016; Gonzalez, Hector/AAV-7576-2021
OI Sotres-Alvarez, Daniela/0000-0002-3226-6140; Mossavar-Rahmani,
   Yasmin/0000-0002-9214-6124; Thomas, Sonia/0000-0003-1362-5627; Gallo,
   Linda C./0000-0002-3678-5888
FU National Heart, Lung, and Blood Institute (NHLBI)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [N01-HC65233];
   University of Miami [N01-HC65234]; Albert Einstein College of Medicine
   [N01-HC65235]; Northwestern University [N01-HC65236]; San Diego State
   University [N01-HC65237]; National Institute on Minority Health and
   Health DisparitiesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Minority Health & Health Disparities (NIMHD); National Institute on
   Deafness and Other Communication DisordersUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Deafness & Other Communication Disorders (NIDCD);
   National Institute of Dental and Craniofacial ResearchUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Dental & Craniofacial Research (NIDCR);
   National Institute of Diabetes and Digestive and Kidney DiseasesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Diabetes & Digestive &
   Kidney Diseases (NIDDK); National Institute of Neurological Disorders
   and StrokeUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Neurological
   Disorders & Stroke (NINDS); NIH Institution-Office of Dietary
   SupplementsUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA; Miami Clinical and Translational
   Science Institute, from the National Center for Advancing Translational
   Sciences [1KL2TR000461]; JazzJazz Pharmaceuticals;  [AG48642]; NATIONAL
   CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Advancing Translational Sciences (NCATS)
   [KL2TR000461, UL1TR001073] Funding Source: NIH RePORTER; NATIONAL HEART,
   LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [R01HL065234, U01HL065233] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute on Aging (NIA) [R01AG048642] Funding Source: NIH RePORTER
FX This was not an industry supported study. The Hispanic Community Health
   Study/Study of Latinos was carried out as a collaborative study
   supported by contracts from the National Heart, Lung, and Blood
   Institute (NHLBI) to the University of North Carolina (N01-HC65233),
   University of Miami (N01-HC65234), Albert Einstein College of Medicine
   (N01-HC65235), Northwestern University (N01-HC65236), and San Diego
   State University (N01-HC65237). The following Institutes/Centers/Offices
   contribute to the HCHS/SOL through a transfer of funds to the NHLBI:
   National Institute on Minority Health and Health Disparities, National
   Institute on Deafness and Other Communication Disorders, National
   Institute of Dental and Craniofacial Research, National Institute of
   Diabetes and Digestive and Kidney Diseases, National Institute of
   Neurological Disorders and Stroke, NIH Institution-Office of Dietary
   Supplements. The project described was also supported by Grant Number
   1KL2TR000461 (Dr. Ramos), Miami Clinical and Translational Science
   Institute, from the National Center for Advancing Translational Sciences
   and the National Institute on Minority Health and Health Disparities.
   Its contents are solely the responsibility of the authors and do not
   necessarily represent the official views of the NIH. The project is also
   supported by grant number AG48642 (Dr. Gonzalez and Tarraf). Dr. Redline
   has received research support from Jazz. Dr. Zee has received research
   support from Jazz and has consulted for Merck, Philips, and Vanda. The
   other authors have indicated no financial conflicts of interest.
   Statistical Analysis was performed by Wassim Tarraf, PhD.
CR Alzheimer's A, 2014, ALZHEIMERS DEMENT, V2014, pe47, DOI [DOI 10.1016/J.JALZ.2010.01.009, 10.1016/j.jalz.2010.01.009, DOI 10.1016/J.JALZ.2014.02.001]
   ANDRESEN EM, 1994, AM J PREV MED, V10, P77, DOI 10.1016/S0749-3797(18)30622-6
   Benito-Leon J, 2009, EUR J NEUROL, V16, P990, DOI 10.1111/j.1468-1331.2009.02618.x
   Benito-Leon J, 2014, NEUROLOGY, V83, P1530, DOI 10.1212/WNL.0000000000000915
   Blackwell T, 2014, SLEEP, V37, P655, DOI 10.5665/sleep.3562
   Blackwell T, 2011, SLEEP, V34, P1347, DOI 10.5665/SLEEP.1276
   Cappuccio FP, 2011, EUR HEART J, V32, P1484, DOI 10.1093/eurheartj/ehr007
   Ferrie JE, 2011, SLEEP, V34, P565, DOI 10.1093/sleep/34.5.565
   Goel N, 2009, SEMIN NEUROL, V29, P320, DOI 10.1055/s-0029-1237117
   Gonzalez HM, 2015, ARCH CLIN NEUROPSYCH, V30, P68, DOI 10.1093/arclin/acu066
   Gonzalez HM, 2002, CLIN NEUROPSYCHOL, V16, P439, DOI 10.1076/clin.16.4.439.13908
   Gonzalez HM, 2001, J INT NEUROPSYCH SOC, V7, P544, DOI 10.1017/S1355617701755026
   Grandner MA, 2007, SLEEP MED REV, V11, P341, DOI 10.1016/j.smrv.2007.03.010
   Grandner MA, 2014, SLEEP MED, V15, P42, DOI 10.1016/j.sleep.2013.09.012
   Hale L, 2007, SLEEP, V30, P1096, DOI 10.1093/sleep/30.9.1096
   Hale L, 2014, SLEEP, V37, P309, DOI 10.5665/sleep.3404
   Hale L, 2011, J IMMIGR MINOR HEALT, V13, P402, DOI 10.1007/s10903-009-9284-1
   JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540
   Krueger PM, 2009, AM J EPIDEMIOL, V169, P1052, DOI 10.1093/aje/kwp023
   Lavange LM, 2010, ANN EPIDEMIOL, V20, P642, DOI 10.1016/j.annepidem.2010.05.006
   Leng Y, 2015, NEUROLOGY, V84, P1072, DOI 10.1212/WNL.0000000000001371
   Lind JT, 2010, OXFORD B ECON STAT, V72, P109, DOI 10.1111/j.1468-0084.2009.00569.x
   Lucey BP, 2015, NAT NEUROSCI, V18, P933, DOI 10.1038/nn.4048
   Patel SR, 2015, SLEEP, V38, P1515, DOI 10.5665/sleep.5036
   Potvin O, 2012, SLEEP, V35, P491, DOI 10.5665/sleep.1732
   Prins ND, 2005, BRAIN, V128, P2034, DOI 10.1093/brain/awh553
   Ramos AR, 2014, J SLEEP RES, V23, P524, DOI 10.1111/jsr.12177
   Ramos AR, 2013, AM J CARDIOL, V112, P599, DOI 10.1016/j.amjcard.2013.04.029
   Ramos AR, 2013, J CLIN SLEEP MED, V9, P669, DOI 10.5664/jcsm.2834
   Redline S, 2014, AM J RESP CRIT CARE, V189, P335, DOI 10.1164/rccm.201309-1735OC
   Scullin MK, 2015, PERSPECT PSYCHOL SCI, V10, P97, DOI 10.1177/1745691614556680
   Sorlie PD, 2010, ANN EPIDEMIOL, V20, P629, DOI 10.1016/j.annepidem.2010.03.015
   Spielberger CD, 1983, MANUAL STATE TRAIT A
   Spira AP, 2013, JAMA NEUROL, V70, P1537, DOI 10.1001/jamaneurol.2013.4258
   Stamatakis KA, 2007, ANN EPIDEMIOL, V17, P948, DOI 10.1016/j.annepidem.2007.07.096
   Suarez E, 2015, SLEEP HEALTH, V1, P90, DOI 10.1016/j.sleh.2015.02.003
   Watson NF, 2015, J CLIN SLEEP MED, V11, P591, DOI 10.5664/jcsm.4758
   Watson NF, 2015, SLEEP, V38, P843, DOI 10.5665/sleep.4716
   Wechsler D, 1981, WAIS R MANUAL
   Whinnery J, 2014, SLEEP, V37, P601, DOI 10.5665/sleep.3508
   Wright CB, 2008, STROKE, V39, P800, DOI 10.1161/STROKEAHA.107.484147
   Yaffe K, 2014, LANCET NEUROL, V13, P1017, DOI 10.1016/S1474-4422(14)70172-3
NR 42
TC 8
Z9 9
U1 0
U2 9
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
EI 1550-9109
J9 SLEEP
JI Sleep
PD OCT 1
PY 2016
VL 39
IS 10
BP 1843
EP 1851
DI 10.5665/sleep.6166
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA DX4ET
UT WOS:000384334700009
PM 27450689
OA Green Published, Green Submitted
DA 2021-10-30
ER

PT J
AU Messiah, SE
   Ludwig, DA
   Vidot, DC
   Accornero, VH
   Lipshultz, SE
   Miller, TL
   Xue, LH
   Bandstra, ES
AF Messiah, Sarah E.
   Ludwig, David A.
   Vidot, Denise C.
   Accornero, Veronica H.
   Lipshultz, Steven E.
   Miller, Tracie L.
   Xue, Lihua
   Bandstra, Emmalee S.
TI PRENATAL COCAINE EXPOSURE AND CARDIOMETABOLIC DISEASE RISK FACTORS IN
   18-TO 20-YEAR-OLD AFRICAN AMERICANS
SO ETHNICITY & DISEASE
LA English
DT Article
DE African American; Prenatal Cocaine Exposure; Cardiometabolic Risk
   Factors; Birth Weight; Metabolic Syndrome; Adolescents
ID 3RD NATIONAL-HEALTH; BODY-MASS INDEX; METABOLIC SYNDROME; FETAL ORIGINS;
   DEVELOPMENTAL ORIGINS; UNITED-STATES; CHILDREN; ADOLESCENTS; PREVALENCE;
   OBESITY
AB Objective: The long-term effects of prenatal cocaine exposure (PCE) on physical health are largely unknown. No human studies support or refute a relationship between PCE and the long-term risk for cardiovascular and/or metabolic disease. We investigated the association of PCE on primary cardiometabolic disease risk factors in African Americans (AA) aged 18 to 20 years.
   Design: Cohort, longitudinal, prospective.
   Setting: Miami-Dade County, Florida, and the University of Miami Miller School of Medicine/Jackson Memorial Medical Center.
   Participants: Healthy full-term inner-city AA adolescents (aged 18 to 20 years, N= 350) previously enrolled at birth from 1990-1993.
   Main Outcome Measures: Fasting serum insulin, glucose, lipids, and high-sensitivity C-reactive protein; systolic and diastolic blood pressures; and the components and prevalence of the metabolic syndrome.
   Results: There were no PCE-associated differences in cardiometabolic disease risk factors including the metabolic syndrome and its individual components in AAs aged 18 to 20 years.
   Conclusions: The results of our study do not support an association between PCE and increased cardiometabolic disease risk in AAs aged 18 to 20 years. Whether PCE is associated with cardiovascular or metabolic disease in adulthood would require further investigation.
C1 [Messiah, Sarah E.; Ludwig, David A.; Miller, Tracie L.] Univ Miami, Dept Pediat, Div Pediat Clin Res, Leonard M Miller Sch Medicine, Coral Gables, FL 33124 USA.
   [Vidot, Denise C.] Univ Miami, Dept Publ Hlth Sci, Div Epidemiol, Leonard M Miller Sch Medicine, Coral Gables, FL 33124 USA.
   [Accornero, Veronica H.; Xue, Lihua; Bandstra, Emmalee S.] Univ Miami, Dept Pediat, Div Neonatol, Leonard M Miller Sch Medicine, Coral Gables, FL 33124 USA.
   [Lipshultz, Steven E.] Wayne State Univ, Sch Med, Dept Pediat, Detroit, MI 48202 USA.
   [Lipshultz, Steven E.] Childrens Hosp Michigan, Detroit, MI USA.
RP Messiah, SE (corresponding author), Univ Miami, Miller Sch Med, Dept Pediat, Div Clin Res,Batchelor Childrens Res Inst, Room 541,1580 NW 10th Ave D820, Miami, FL 33101 USA.
EM smessiah@med.miami.edu
OI Messiah, Sarah/0000-0001-6685-2175
FU NIH/NIDAUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Drug Abuse
   (NIDA) [K01 DA 026993, R01 DA 006556, P50 DA 024584]; NIH/NIMHDUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA [1UL1TR000460]; NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [UL1TR000460] Funding Source:
   NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [T32HL007426]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European
   Commission [R01DA006556, K01DA026993, P50DA024584] Funding Source: NIH
   RePORTER
FX We would like to thank the Miami Prenatal Cocaine Study participants and
   their families for their continuing support of this longitudinal
   project. We are also grateful to Dr. Armando Mendez for his supervision
   of the laboratory analysis of the adolescents' blood samples for
   cardiometabolic disease risk factor biomarkers. This research was
   supported by NIH/NIDA grants K01 DA 026993, R01 DA 006556, P50 DA
   024584, and NIH/NIMHD grant 1UL1TR000460 (Miami Clinical and
   Translational Science Institute).
CR Ackerman JP, 2010, PEDIATRICS, V125, P554, DOI 10.1542/peds.2009-0637
   ALLAIN CC, 1974, CLIN CHEM, V20, P470
   [Anonymous], 2001, LANCET, V357, P405
   [Anonymous], 2001, NIH PUBLICATION, V01-3305
   Arendt RE, 2004, J DEV BEHAV PEDIATR, V25, P83, DOI 10.1097/00004703-200404000-00002
   Bandstra ES, 2010, J ADDICT DIS, V29, P245, DOI 10.1080/10550881003684871
   Bandstra ES, 2001, PEDIATRICS, V108, P1309, DOI 10.1542/peds.108.6.1309
   Barker DJP, 2007, J INTERN MED, V261, P412, DOI 10.1111/j.1365-2796.2007.01809.x
   BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171
   Barker DJP, 2002, INT J EPIDEMIOL, V31, P1235, DOI 10.1093/ije/31.6.1235
   Barker DJP, 1999, ANN MED, V31, P3, DOI 10.1080/07853890.1999.11904392
   Behnke M, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.5.e74
   Buckingham-Howes S, 2013, PEDIATRICS, V131, pE1917, DOI 10.1542/peds.2012-0945
   Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS), 2002, NAT HLTH NUTR EX ANT
   Chen W, 2000, DIABETES, V49, P1042, DOI 10.2337/diabetes.49.6.1042
   Cole TG, 2000, HDB LIPOPROTEIN TEST, P207
   Cook S, 2003, ARCH PEDIAT ADOL MED, V157, P821, DOI 10.1001/archpedi.157.8.821
   Crawford AG, 2010, POPUL HEALTH MANAG, V13, P151, DOI 10.1089/pop.2009.0039
   de Ferranti SD, 2004, CIRCULATION, V110, P2494, DOI 10.1161/01.CIR.0000145117.40114.C7
   Din-Dzietham R, 2007, CIRCULATION, V116, P1488, DOI 10.1161/CIRCULATIONAHA.106.683243
   DURNIN JVGA, 1974, BRIT J NUTR, V32, P77, DOI 10.1079/BJN19740060
   FRASSICA JJ, 1994, ARCH PEDIAT ADOL MED, V148, P1163, DOI 10.1001/archpedi.1994.02170110049008
   Gouin K, 2011, AM J OBSTET GYNECOL, V204, DOI 10.1016/j.ajog.2010.11.013
   Heyn H, 2012, P NATL ACAD SCI USA, V109, P10522, DOI 10.1073/pnas.1120658109
   HURT H, 1995, J DEV BEHAV PEDIATR, V16, P29, DOI 10.1097/00004703-199502000-00005
   Jarvelin MR, 2000, HEART, V84, P219, DOI 10.1136/heart.84.2.219
   Khuseyinova N, 2003, CLIN CHEM, V49, P1691, DOI 10.1373/49.10.1691
   Kristman VL, 2005, EUR J EPIDEMIOL, V20, P657, DOI 10.1007/s10654-005-7919-7
   Kuczmarski RJ, 2000, HEALTH, V11, P1
   Lambert BL, 2012, J PERINATOL, V32, P819, DOI 10.1038/jp.2012.90
   LIPSHULTZ SE, 1991, J PEDIATR-US, V118, P44, DOI 10.1016/S0022-3476(05)81842-6
   Messiah SE, 2008, J PEDIATR-US, V153, P215, DOI 10.1016/j.jpeds.2008.03.002
   Messiah SE, 2013, OBESITY, V21, P424, DOI 10.1002/oby.20343
   Messiah SE, 2012, INT J PEDIAT, V2012
   Mone SM, 2004, PEDIATRICS, V113, P1058
   MULE SJ, 1988, J ANAL TOXICOL, V12, P153, DOI 10.1093/jat/12.3.153
   NELDER JA, 1972, J R STAT SOC SER A-G, V135, P370, DOI 10.2307/2344614
   Ogden CL, 2014, JAMA-J AM MED ASSOC, V311, P806, DOI 10.1001/jama.2014.732
   Plessinger MA, 1998, OBSTET GYN CLIN N AM, V25, P99, DOI 10.1016/S0889-8545(05)70360-0
   Public Health Service Centers for Disease Control and Prevention, 1976, PROP METH DET GLUC U
   Rana JS, 2012, CURR ATHEROSCLER REP, V14, P130, DOI 10.1007/s11883-011-0224-x
   Richardson GA, 2007, PEDIATRICS, V120, pe1017, DOI 10.1542/peds.2006-3482
   Saltelli A., 2000, WILEY SERIES PROBABI
   Schempf AH, 2008, J URBAN HEALTH, V85, P858, DOI 10.1007/s11524-008-9315-6
   Shankaran S, 2010, J HYPERTENS, V28, P1166, DOI 10.1097/HJH.0b013e328337da75
   Swanson JM, 2009, SEMIN REPROD MED, V27, P391, DOI 10.1055/s-0029-1237427
   Urbina E, 2008, HYPERTENSION, V52, P433, DOI 10.1161/HYPERTENSIONAHA.108.190329
   Wilcox AJ, 2001, INT J EPIDEMIOL, V30, P1233, DOI 10.1093/ije/30.6.1233
   Zidek JV, 1996, ENVIRONMETRICS, V7, P441, DOI 10.1002/(SICI)1099-095X(199607)7:4<441::AID-ENV226>3.3.CO;2-M
NR 49
TC 3
Z9 3
U1 0
U2 4
PU INT SOC HYPERTENSION BLACKS-ISHIB
PI ATLANTA
PA 100 AUBURN AVE NE STE 401, ATLANTA, GA 30303-2527 USA
SN 1049-510X
EI 1945-0826
J9 ETHNIC DIS
JI Ethn. Dis.
PD FAL
PY 2015
VL 25
IS 4
BP 419
EP 426
DI 10.18865/ed.25.4.419
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DC9CA
UT WOS:000369517100007
PM 26672966
OA Bronze, Green Published
DA 2021-10-30
ER

PT J
AU Zoso, A
   Serafini, P
   Lanzoni, G
   Peixoto, E
   Messinger, S
   Mantero, A
   Padilla-Tellez, ND
   Baidal, DA
   Alejandro, R
   Ricordi, C
   Inverardi, L
AF Zoso, Alessia
   Serafini, Paolo
   Lanzoni, Giacomo
   Peixoto, Eduardo
   Messinger, Shari
   Mantero, Alejandro
   Padilla-Tellez, Nathalia D.
   Baidal, David A.
   Alejandro, Rodolfo
   Ricordi, Camillo
   Inverardi, Luca
TI G-CSF and Exenatide Might Be Associated with Increased Long-Term
   Survival of Allogeneic Pancreatic Islet Grafts
SO PLOS ONE
LA English
DT Article
ID TUMOR-NECROSIS-FACTOR; REGULATORY T-CELLS; INSULIN INDEPENDENCE; PRIMARY
   NONFUNCTION; DENDRITIC CELLS; IN-VIVO; TRANSPLANTATION; ATP;
   IMMUNOSUPPRESSION; INDUCTION
AB Background
   Allogeneic human islet transplantation is an effective therapy for the treatment of patients with Type 1 Diabetes (T1D). The low number of islet transplants performed worldwide and the different transplantation protocols used limit the identification of the most effective therapeutic options to improve the efficacy of this approach.
   Methods
   We present a retrospective analysis on the data collected from 44 patients with T1D who underwent islet transplantation at our institute between 2000 and 2007. Several variables were included: recipient demographics and immunological characteristics, donor and transplant characteristics, induction protocols, and additional medical treatment received. Immunosuppression was induced with anti-CD25 (Daclizumab), alone or in association with antitumor necrosis factor alpha (TNF-alpha) treatments (Etanercept or Infliximab), or with anti-CD52 (Alemtuzumab) in association with anti-TNF-alpha treatments (Etanercept or Infliximab). Subsets of patients were treated with Filgrastim for moderate/severe neutropenia and/or Exenatide for post prandial hyperglycemia.
   Results
   The analysis performed indicates a negative association between graft survival (c-peptide level >= 0.3 ng/ml) and islet infusion volume, with the caveat that, the progressive reduction of infusion volumes over the years has been paralleled by improved immunosuppressive protocols. A positive association is instead suggested between graft survival and administration of Exenatide and Filgrastim, alone or in combination.
   Conclusion
   This retrospective analysis may be of assistance to further improve long-term outcomes of protocols for transplant of islets and other organs.
C1 [Zoso, Alessia; Lanzoni, Giacomo; Peixoto, Eduardo; Padilla-Tellez, Nathalia D.; Baidal, David A.; Alejandro, Rodolfo; Ricordi, Camillo; Inverardi, Luca] Univ Miami, Diabet Res Inst, Miami, FL USA.
   [Serafini, Paolo] Univ Miami, Dept Microbiol Immunol, Miami, FL USA.
   [Messinger, Shari; Mantero, Alejandro] Univ Miami, Dept Publ Hlth Sci, Miami, FL USA.
   [Peixoto, Eduardo] Framingham Union Hosp, Internal Med, Framingham, MA USA.
RP Inverardi, L (corresponding author), Univ Miami, Diabet Res Inst, Miami, FL USA.
EM linverar@med.miami.edu
RI Lanzoni, Giacomo/K-7396-2019; Serafini, Paolo/C-8195-2012; RICORDI,
   CAMILLO/AAA-4740-2019; Mantero, Alejandro/AAS-6415-2021; Padilla,
   Nathalia/AAQ-9596-2020; Lanzoni, Giacomo/H-1695-2015
OI Serafini, Paolo/0000-0002-3651-9176; Padilla,
   Nathalia/0000-0002-7177-1107; Lanzoni, Giacomo/0000-0003-3996-4803
FU National Center for Research ResourcesUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Research Resources (NCRR) [U42-RR16603, GCRC-M01RR16587];
   National Institute of Diabetes and Digestive and Kidney DiseasesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Diabetes & Digestive &
   Kidney Diseases (NIDDK) [R01-DK55347, R01-DK25802]; National Center for
   Advancing Translational [1UL1TR000460]; Juvenile Diabetes Research
   FoundationJuvenile Diabetes Research Foundation [4-2000-946,
   4-2004-361]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Advancing Translational
   Sciences (NCATS) [UL1TR000460] Funding Source: NIH RePORTER
FX This work was supported by the National Center for Research Resources:
   U42-RR16603 (CR), GCRC-M01RR16587 (CR); the National Institute of
   Diabetes and Digestive and Kidney Diseases: R01-DK55347 (CR),
   R01-DK25802 (LI), R01-DK25802 (CR); National Center for Advancing
   Translational: 1UL1TR000460 (CR); and the Juvenile Diabetes Research
   Foundation: 4-2000-946 (CR), 4-2004-361 (CR).
CR Adeegbe D, 2011, CELL TRANSPLANT, V20, P941, DOI 10.3727/096368910X540621
   Balamurugan AN, 2014, AM J TRANSPLANT, V14, P2595, DOI 10.1111/ajt.12872
   Bassi R, 2011, CURR DIABETES REP, V11, P355, DOI 10.1007/s11892-011-0211-1
   Battaglia M, 2006, J IMMUNOL, V177, P8338, DOI 10.4049/jimmunol.177.12.8338
   Bellin MD, 2012, AM J TRANSPLANT, V12, P1576, DOI 10.1111/j.1600-6143.2011.03977.x
   Bruni A, 2014, DIABETES METAB SYNDR, V7, P211, DOI 10.2147/DMSO.S50789
   Bucher P, 2004, TRANSPL P, V36, P1119, DOI 10.1016/j.transproceed.2004.04.022
   Buss JL, 2012, J TRANSPLANT, V2012, DOI 10.1155/2012/382518
   Chaudhuri A, 2012, J CLIN ENDOCR METAB, V97, P198, DOI 10.1210/jc.2011-1508
   D'Addio F, 2014, DIABETES, V63, P3041, DOI 10.2337/db14-0295
   Deng S, 1997, TRANSPLANT P, V29, P2062, DOI 10.1016/S0041-1345(97)00232-7
   Emamaullee JA, 2009, DIABETES, V58, P1302, DOI 10.2337/db08-1113
   Faradji RN, 2008, TRANSPLANTATION, V86, P1658, DOI 10.1097/TP.0b013e31818fe448
   FARNEY AC, 1993, TRANSPL P, V25, P865
   Fiorina P, 2007, DIABETES, V56, P912, DOI 10.2337/db06-1445
   Fiorina P, 2011, J IMMUNOL, V186, P121, DOI 10.4049/jimmunol.1000799
   Froud T, 2005, AM J TRANSPLANT, V5, P2037, DOI 10.1111/j.1600-6143.2005.00957.x
   Froud T, 2008, TRANSPLANTATION, V86, P36, DOI 10.1097/TP.0b013e31817c4ab3
   Froud T, 2008, TRANSPLANTATION, V86, P1695, DOI 10.1097/TP.0b013e31819025e5
   Gangemi A, 2008, AM J TRANSPLANT, V8, P1250, DOI 10.1111/j.1600-6143.2008.02234.x
   Haag F, 2007, PURINERG SIGNAL, V3, P71, DOI 10.1007/s11302-006-9038-7
   Hering BJ, 2005, JAMA-J AM MED ASSOC, V293, P830, DOI 10.1001/jama.293.7.830
   Huss DJ, 2015, J IMMUNOL, V194, P84, DOI 10.4049/jimmunol.1402140
   Kared H, 2008, BLOOD, V112, P2575, DOI 10.1182/blood-2008-02-140681
   Kawahara T, 2012, J HEPATO-BIL-PAN SCI, V19, P281, DOI 10.1007/s00534-011-0441-2
   Khakh BS, 2006, NATURE, V442, P527, DOI 10.1038/nature04886
   Koh A, 2010, TRANSPLANTATION, V89, P361, DOI 10.1097/TP.0b013e3181bcdbe8
   Mineo D, 2008, AM J TRANSPLANT, V8, P1262, DOI 10.1111/j.1600-6143.2008.02230.x
   MITTAL VK, 1981, TRANSPLANTATION, V31, P302
   Niclauss N, 2014, TRANSPLANTATION, V98, P593, DOI 10.1097/TP.0000000000000288
   PATCHEN ML, 1986, J IMMUNOPHARMACOL, V8, P407
   Piemonti L, 2013, DIABETES, V62, P1656, DOI 10.2337/db12-1258
   Ricordi C, 2004, NAT REV IMMUNOL, V4, P258, DOI 10.1038/nri1332
   Rossetti M, 2010, EUR J IMMUNOL, V40, P3097, DOI 10.1002/eji.201040659
   Sade-Feldman M, 2013, IMMUNITY, V38, P541, DOI 10.1016/j.immuni.2013.02.007
   Serafini P, 2013, IMMUNOL RES, V57, P172, DOI 10.1007/s12026-013-8455-2
   Shapiro AMJ, 2006, NEW ENGL J MED, V355, P1318, DOI 10.1056/NEJMoa061267
   Steptoe RJ, 2005, DIABETES, V54, P434, DOI 10.2337/diabetes.54.2.434
   Toso C, 2009, TRANSPL INT, V22, P182, DOI 10.1111/j.1432-2277.2008.00746.x
   Van Belle T, 2008, J CLIN INVEST, V118, P1625, DOI 10.1172/JCI35639
   Vergani A, 2013, DIABETES, V62, P1665, DOI 10.2337/db12-0242
   VISTE A, 1990, TRANSPLANT P, V22, P808
   Wilhelm K, 2010, NAT MED, V16, P1434, DOI 10.1038/nm.2242
   Xue S, 2008, ANN NY ACAD SCI, V1150, P152, DOI 10.1196/annals.1447.049
NR 44
TC 6
Z9 6
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 10
PY 2016
VL 11
IS 6
AR e0157245
DI 10.1371/journal.pone.0157245
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DO1UG
UT WOS:000377564000048
PM 27285580
OA Green Submitted, Green Published, gold
DA 2021-10-30
ER

PT J
AU Pereira, LHM
   Reis, IM
   Reategui, EP
   Gordon, C
   Saint-Victor, S
   Duncan, R
   Gomez, C
   Bayers, S
   Fisher, P
   Perez, A
   Goodwin, WJ
   Hu, JJ
   Franzmann, EJ
AF Pereira, Lutecia H. Mateus
   Reis, Isildinha M.
   Reategui, Erika P.
   Gordon, Claudia
   Saint-Victor, Sandra
   Duncan, Robert
   Gomez, Carmen
   Bayers, Stephanie
   Fisher, Penelope
   Perez, Aymee
   Goodwin, W. Jarrard
   Hu, Jennifer J.
   Franzmann, Elizabeth J.
TI Risk Stratification System for Oral Cancer Screening
SO CANCER PREVENTION RESEARCH
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; HUMAN-PAPILLOMAVIRUS; SOLUBLE CD44;
   NECK-CANCER; TONSILLAR CARCINOMAS; OROPHARYNGEAL CANCER; HEAD;
   EXPRESSION; MARKER; PROTEIN
AB Oral cavity and oropharyngeal cancer (oral cancer) is a deadly disease that is increasing in incidence. Worldwide 5-year survival is only 50% due to delayed intervention with more than half of the diagnoses at stage III and IV, whereas earlier detection (stage I and II) yields survival rates up to 80% to 90%. Salivary soluble CD44 (CD44), a tumor-initiating marker, and total protein levels may facilitate oral cancer risk assessment and early intervention. This study used a hospital-based design with 150 cases and 150 frequency-matched controls to determine whether CD44 and total protein levels in oral rinses were associated with oral cancer independent of age, gender, race, ethnicity, tobacco and alcohol use, and socioeconomic status (SES). High-risk subjects receiving oral cancer prevention interventions as part of a community-based program (n = 150) were followed over 1 year to determine marker specificity and variation. CD44 >= 5.33 ng/mL was highly associated with case status [adjusted OR 14.489; 95% confidence interval (CI), 5.973-35.145; P < .0001, vs. reference group CD44 <2.22 ng/mL and protein <1.23 mg/mL]. Total protein aided prediction above CD44 alone. Sensitivity and specificity in the frequency-matched study was 80% and 48.7%, respectively. However, controls were not representative of the target screening population due, in part, to a high rate of prior cancer. In contrast, specificity in the high-risk community was 74% and reached 95% after annual retesting. Simple and inexpensive salivary CD44 and total protein measurements may help identify individuals at heightened risk for oral cancer from the millions who partake in risky behaviors.
C1 [Pereira, Lutecia H. Mateus] Miami Dade Coll, Miami, FL USA.
   [Reis, Isildinha M.; Gordon, Claudia; Perez, Aymee; Goodwin, W. Jarrard; Hu, Jennifer J.; Franzmann, Elizabeth J.] Univ Miami, Leonard Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL USA.
   [Reis, Isildinha M.; Duncan, Robert; Hu, Jennifer J.] Univ Miami, Leonard Miller Sch Med, Dept Publ Hlth Sci, Miami, FL USA.
   [Reategui, Erika P.; Saint-Victor, Sandra; Fisher, Penelope; Goodwin, W. Jarrard; Franzmann, Elizabeth J.] Univ Miami, Leonard Miller Sch Med, Dept Otolaryngol, Clin Res Bldg Room 1436,1120 NW14th St, Miami, FL 33136 USA.
   [Gomez, Carmen] Univ Miami, Leonard Miller Sch Med, Dept Pathol, Miami, FL USA.
   [Bayers, Stephanie] Macneal Mem Hosp, Berwyn, IL USA.
RP Franzmann, EJ (corresponding author), Univ Miami, Leonard Miller Sch Med, Dept Otolaryngol, Clin Res Bldg Room 1436,1120 NW14th St, Miami, FL 33136 USA.
EM efranzman@med.miami.edu
OI Stinnett, Sandra/0000-0002-6933-1233
FU Woman's Cancer Association;  [NCI R01CA118584];  [NCI RO3 CA107828]; 
   [4BB-20 Bankhead-Coley];  [10BG-02 Bankhead-Coley]; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [R01CA118584, R03CA107828] Funding Source: NIH RePORTER; NATIONAL CENTER
   FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000460]
   Funding Source: NIH RePORTER
FX The work was funded by Woman's Cancer Association, a gift from Vigilant
   Biosciences, Inc., Sylvester Comprehensive Cancer Center and University
   of Miami, Department of Otolaryngology. E.J. Franzmann was supported by
   grants NCI R01CA118584, NCI RO3 CA107828, 4BB-20 Bankhead-Coley, and
   10BG-02 Bankhead-Coley.
CR Allegra E, 2012, J CANC SCI THER, V4, P330
   American Cancer Society, 2012, CANC FACTS FIG 2012
   American Cancer Society, 2010, GLOB EC COST CANC
   Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217
   Balevi B, 2011, COMMUNITY DENT ORAL, V39, P171, DOI 10.1111/j.1600-0528.2010.00579.x
   BLOT WJ, 1988, CANCER RES, V48, P3282
   Bonita R., 2006, BASIC EPIDEMIOLOGY, Vsecond
   Breiman L., 1984, CLASSIFICATION REGRE
   Brocklehurst P, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004150.pub3
   Carvalho AL, 2008, CLIN CANCER RES, V14, P97, DOI 10.1158/1078-0432.CCR-07-0722
   Chen JQ, 2014, BMC CANCER, V14, DOI [10.1186/1471-2407-14-15, 10.1186/1471-2407-14-802]
   Cheng YSL, 2014, CLIN TRANSL MED, V3, DOI 10.1186/2001-1326-3-3
   D'Souza G, 2007, NEW ENGL J MED, V356, P1944, DOI 10.1056/NEJMoa065497
   Dasari S, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0139-9
   Dietz Noella A, 2011, J Carcinog, V10, P22, DOI 10.4103/1477-3163.85184
   Dikshit R, 2012, LANCET, V379, P1807, DOI 10.1016/S0140-6736(12)60358-4
   El-Naggar AK, 2012, HEAD NECK-J SCI SPEC, V34, P459, DOI 10.1002/hed.21974
   Elashoff D, 2012, CANCER EPIDEM BIOMAR, V21, P664, DOI 10.1158/1055-9965.EPI-11-1093
   Epstein JB, 2012, J AM DENT ASSOC, V143, P1332, DOI 10.14219/jada.archive.2012.0096
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Franzmann EJ, 2005, CANCER EPIDEM BIOMAR, V14, P735, DOI 10.1158/1055-9965.EPI-04-0546
   Franzmann EJ, 2007, CANCER EPIDEM BIOMAR, V16, P1348, DOI 10.1158/1055-9965.EPI-06-0011
   Franzmann EJ, 2012, HEAD NECK-J SCI SPEC, V34, P687, DOI 10.1002/hed.21810
   Gillison ML, 2012, JAMA-J AM MED ASSOC, V307, P693, DOI 10.1001/jama.2012.101
   Grizzle WE, 2011, CANCER BIOMARK, V9, P21, DOI 10.3233/CBM-2011-0172
   Hafkamp HC, 2008, INT J CANCER, V122, P2656, DOI 10.1002/ijc.23458
   Hirvikoski P, 1999, VIRCHOWS ARCH, V434, P37, DOI 10.1007/s004280050302
   Hu S, 2008, CLIN CANCER RES, V14, P6246, DOI 10.1158/1078-0432.CCR-07-5037
   Ioachim E, 1999, HISTOL HISTOPATHOL, V14, P1113, DOI 10.14670/HH-14.1113
   Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893
   Klussmann JP, 2003, AM J PATHOL, V162, P747, DOI 10.1016/S0002-9440(10)63871-0
   LARSSON A, 1991, J ORAL PATHOL MED, V20, P258, DOI 10.1111/j.1600-0714.1991.tb00924.x
   Lingen MW, 2008, ORAL ONCOL, V44, P10, DOI 10.1016/j.oraloncology.2007.06.011
   Pepe MS, 2001, J NATL CANCER I, V93, P1054, DOI 10.1093/jnci/93.14.1054
   Pereira LHM, 2011, CANCER BIOMARK, V10, P241, DOI 10.3233/CBM-2012-0252
   Perez A, 2013, ORAL ONCOL, V49, P306, DOI 10.1016/j.oraloncology.2012.11.009
   PINDBORG JJ, 1977, ORAL SURG ORAL MED O, V43, P383, DOI 10.1016/0030-4220(77)90325-5
   Poh CF, 2007, HEAD NECK-J SCI SPEC, V29, P71, DOI 10.1002/hed.20468
   Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004
   Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104
   Sankaranarayanan R, 2013, ORAL ONCOL, V49, P314, DOI 10.1016/j.oraloncology.2012.11.004
   SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160
   Srivastava S, 2015, J CELL PHYSL
   Therneau TM, 2014, MVPART PACKAGE RUNNI
NR 44
TC 15
Z9 15
U1 0
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1940-6207
EI 1940-6215
J9 CANCER PREV RES
JI Cancer Prev. Res.
PD JUN
PY 2016
VL 9
IS 6
BP 445
EP 455
DI 10.1158/1940-6207.CAPR-15-0200
PG 11
WC Oncology
SC Oncology
GA DQ8ZK
UT WOS:000379500000004
PM 27020654
OA Green Accepted, Bronze
DA 2021-10-30
ER

PT J
AU Shah, N
   Allison, M
   Teng, YP
   Wassertheil-Smoller, S
   Sotres-Alvarez, D
   Ramos, AR
   Zee, PC
   Criqui, MH
   Yaggi, HK
   Gallo, LC
   Redline, S
   Kaplan, RC
AF Shah, Neomi
   Allison, Matthew
   Teng, Yanping
   Wassertheil-Smoller, Sylvia
   Sotres-Alvarez, Daniela
   Ramos, Alberto R.
   Zee, Phyllis C.
   Criqui, Michael H.
   Yaggi, Henry K.
   Gallo, Linda C.
   Redline, Susan
   Kaplan, Robert C.
TI Sleep Apnea Is Independently Associated With Peripheral Arterial Disease
   in the Hispanic Community Health Study/Study of Latinos
SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
LA English
DT Article
DE ankle-brachial index; atherosclerosis; Hispanic Americans; peripheral
   arterial disease; sleep apnea syndromes
ID INTIMA-MEDIA THICKNESS; POSITIVE AIRWAY PRESSURE; C-REACTIVE PROTEIN;
   ANKLE-BRACHIAL INDEX; RISK-FACTOR; CARDIOVASCULAR-DISEASE; HEART HEALTH;
   EARLY SIGNS; CAROTID ATHEROSCLEROSIS; OXYGEN DESATURATION
AB Objective Sleep apnea (SA) has been linked with various forms of cardiovascular disease, but little is known about its association with peripheral artery disease (PAD) measured using the ankle-brachial index. This relationship was evaluated in the Hispanic Community Health Study/Study of Latinos.
   Approach and Results We studied 8367 Hispanic Community Health Study/Study of Latinos participants who were 45 to 74 years of age. Sleep symptoms were examined with the self-reported Sleep Health Questionnaire. SA was assessed using an in-home sleep study. Systolic blood pressure was measured in all extremities to compute the ankle-brachial index. PAD was defined as ankle-brachial index <0.90 in either leg. Multivariable logistic regression was used to investigate the association between moderate-to-severe SA, defined as apnea-hypopnea index 15, and the presence of PAD. Analyses were adjusted for covariates. The prevalence of PAD was 4.7% (n=390). The mean apnea-hypopnea index was significantly higher among adults with PAD compared with those without (11.1 versus 8.6 events/h; P=0.046). After adjusting for covariates, moderate-to-severe SA was associated with a 70% increase in the odds of PAD (odds ratio, 1.7; 95% confidence interval, 1.1-2.5; P=0.0152). This association was not modified by sex (P=0.8739). However, there was evidence that the association between moderate-to-severe SA and PAD varied by Hispanic/Latino background (P<0.01). Specifically, the odds were stronger in Mexican (adjusted odds ratio, 2.9; 95% confidence interval, 1.3-6.2) and in Puerto Rican Americans (adjusted odds ratio, 2.0; 95% confidence interval, 0.97-4.2) than in other backgrounds.
   Conclusions Moderate-to-severe SA is associated with higher odds of PAD in Hispanic/Latino adults.
C1 [Shah, Neomi] Montefiore Med Ctr, Dept Med, Bronx, NY 10467 USA.
   [Shah, Neomi; Wassertheil-Smoller, Sylvia; Kaplan, Robert C.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA.
   [Allison, Matthew; Criqui, Michael H.; Gallo, Linda C.] Univ Southern Calif San Diego, Dept Med, La Jolla, CA USA.
   [Teng, Yanping; Sotres-Alvarez, Daniela] Univ N Carolina, Dept Biostat, Collaborat Studies Coordinating Ctr, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA.
   [Ramos, Alberto R.] Univ Miami, Dept Med, Coral Gables, FL 33124 USA.
   [Zee, Phyllis C.] Northwestern Univ, Dept Neurol, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Yaggi, Henry K.] Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA.
   [Redline, Susan] Harvard Univ, Beth Israel Deaconess Med Ctr, Brigham & Womens Hosp, Dept Med,Med Sch, Boston, MA 02215 USA.
RP Shah, N (corresponding author), Montefiore Med Ctr, 3411 Wayne Ave,Suite 5H, Bronx, NY 10467 USA.
EM nshah@montefiore.org
RI Sotres-Alvarez, Daniela/O-9085-2016; Ramos, Alberto/X-4249-2019;
   DeMarcus, Forrest/O-9190-2016
OI Sotres-Alvarez, Daniela/0000-0002-3226-6140; Gallo, Linda
   C./0000-0002-3678-5888; Allison, Matthew/0000-0003-0777-8272
FU National Heart, Lung, and Blood Institute (NHLBI)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [N01-HC65233,
   N01-HC65234, N01-HC65235, N01-HC65236, N01-HC65237]; NHLBI: National
   Institute on Minority Health and Health Disparities; National Institute
   on Deafness and Other Communication DisordersUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Deafness & Other Communication Disorders (NIDCD);
   National Institute of Dental and Craniofacial ResearchUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Dental & Craniofacial Research (NIDCR);
   National Institute of Diabetes and Digestive and Kidney DiseasesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Diabetes & Digestive &
   Kidney Diseases (NIDDK); National Institute of Neurological Disorders
   and StrokeUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Neurological
   Disorders & Stroke (NINDS); National Institutes of Health
   Institution-Office of Dietary Supplements; Einstein-Montefiore ICTR's
   CTSA [KL2 TR001071]; DIVISION OF EPIDEMIOLOGY AND CLINICAL
   APPLICATIONSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Eye Institute (NEI)
   [N01HC065233] Funding Source: NIH RePORTER; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [KL2TR000461,
   UL1TR001073] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND
   BLOOD INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [R01HL065234, K24HL132093, U01HL065233]
   Funding Source: NIH RePORTER
FX The Hispanic Community Health Study/Study of Latinos (HCHS/SOL) was
   performed as a collaborative study supported by contracts from the
   National Heart, Lung, and Blood Institute (NHLBI) to the University of
   North Carolina (N01-HC65233), University of Miami (N01-HC65234), Albert
   Einstein College of Medicine (N01-HC65235), Northwestern University
   (N01-HC65236), and San Diego State University (N01-HC65237). The
   following Institutes/Centers/Offices contribute to the HCHS/SOL through
   a transfer of funds to the NHLBI: National Institute on Minority Health
   and Health Disparities, National Institute on Deafness and Other
   Communication Disorders, National Institute of Dental and Craniofacial
   Research, National Institute of Diabetes and Digestive and Kidney
   Diseases, National Institute of Neurological Disorders and Stroke,
   National Institutes of Health Institution-Office of Dietary Supplements.
   This research was supported in part by the Einstein-Montefiore ICTR's
   CTSA KL2 TR001071 grant to N.S.
CR Altin R, 2005, J CLIN ULTRASOUND, V33, P80, DOI 10.1002/jcu.20093
   Arik B, 2013, MULTIDISCIP RESP MED, V8, DOI 10.1186/2049-6958-8-9
   Arsenault BJ, 2011, NAT REV CARDIOL, V8, P197, DOI 10.1038/nrcardio.2010.223
   Baguet JP, 2005, CHEST, V128, P3407, DOI 10.1378/chest.128.5.3407
   Botros N, 2009, AM J MED, V122, P1122, DOI 10.1016/j.amjmed.2009.04.026
   Chami HA, 2009, VASC MED, V14, P351, DOI 10.1177/1358863X09105132
   Ciccone MM, 2012, RESP MED, V106, P740, DOI 10.1016/j.rmed.2011.12.016
   CRIQUI MH, 1985, CIRCULATION, V71, P510, DOI 10.1161/01.CIR.71.3.510
   Drager LF, 2005, AM J RESP CRIT CARE, V172, P613, DOI 10.1164/rccm.200503-340OC
   Drager LF, 2007, AM J RESP CRIT CARE, V176, P706, DOI 10.1164/rccm.200703-500OC
   Drager LF, 2011, CHEST, V140, P534, DOI 10.1378/chest.10-2223
   Drager LF, 2010, ATHEROSCLEROSIS, V208, P490, DOI 10.1016/j.atherosclerosis.2009.08.016
   Drager LF, 2009, HYPERTENSION, V53, P64, DOI 10.1161/HYPERTENSIONAHA.108.119420
   Faux MD, 2004, SLEEP, V27, P1113, DOI 10.1093/sleep/27.6.1113
   Friedlander AH, 1998, J ORAL MAXIL SURG, V56, P950, DOI 10.1016/S0278-2391(98)90657-7
   Gami AS, 2005, NEW ENGL J MED, V352, P1206, DOI 10.1056/NEJMoa041832
   Gottlieb DJ, 2010, CIRCULATION, V122, P352, DOI 10.1161/CIRCULATIONAHA.109.901801
   Hanssen NMJ, 2012, DIABETES CARE, V35, P1731, DOI 10.2337/dc12-0178
   Hayashi M, 2003, CHEST, V124, P936, DOI 10.1378/chest.124.3.936
   Heald CL, 2006, ATHEROSCLEROSIS, V189, P61, DOI 10.1016/j.atherosclerosis.2006.03.011
   Hirsch AT, 2006, CIRCULATION, V113, pE463, DOI 10.1161/CIRCULATIONAHA.106.174526
   Hui DS, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-22
   Kapsimalis F, 2008, LUNG, V186, P209, DOI 10.1007/s00408-008-9082-x
   Kent BD, 2013, EUR RESPIR J, V42, P1263, DOI 10.1183/09031936.00094812
   Kylintireas I, 2012, ATHEROSCLEROSIS, V222, P483, DOI 10.1016/j.atherosclerosis.2012.03.036
   Lavie L, 2003, SLEEP MED REV, V7, P35, DOI 10.1053/smrv.2002.0261
   Marin JM, 2005, LANCET, V365, P1046, DOI 10.1016/S0140-6736(05)71141-7
   Mehra R, 2006, AM J RESP CRIT CARE, V173, P910, DOI 10.1164/rccm.200509-1442OC
   Minoguchi K, 2005, AM J RESP CRIT CARE, V172, P625, DOI 10.1164/rccm.200412-1652OC
   Mohler E, 2008, CURR MED RES OPIN, V24, P2509, DOI 10.1185/03007990802274379 
   Nagahama H, 2004, INTERNAL MED, V43, P184, DOI 10.2169/internalmedicine.43.184
   Narkiewicz K, 2001, AUTON NEUROSCI-BASIC, V90, P89, DOI 10.1016/S1566-0702(01)00272-7
   Nieto FJ, 2004, AM J RESP CRIT CARE, V169, P354, DOI 10.1164/rccm.200306-756OC
   Peker Y, 1999, EUR RESPIR J, V14, P179, DOI 10.1034/j.1399-3003.1999.14a30.x
   Peppard PE, 2000, NEW ENGL J MED, V342, P1378, DOI 10.1056/NEJM200005113421901
   Punjabi NM, 2007, SLEEP, V30, P29, DOI 10.1093/sleep/30.1.29
   Punjabi NM, 2002, AM J RESP CRIT CARE, V165, P677, DOI 10.1164/ajrccm.165.5.2104087
   Redline S, 2014, AM J RESP CRIT CARE, V189, P335, DOI 10.1164/rccm.201309-1735OC
   Shah NA, 2010, SLEEP BREATH, V14, P131, DOI 10.1007/s11325-009-0298-7
   Shahar E, 2001, AM J RESP CRIT CARE, V163, P19, DOI 10.1164/ajrccm.163.1.2001008
   Sharma S, 2012, CLIN CARDIOL, V35, P641, DOI 10.1002/clc.22057
   Silvestrini M, 2002, STROKE, V33, P1782, DOI 10.1161/01.STR.0000019123.47840.2D
   Suzuki T, 2004, SLEEP, V27, P129, DOI 10.1093/sleep/27.1.129
   Szaboova E, 2007, RESP PHYSIOL NEUROBI, V155, P121, DOI 10.1016/j.resp.2006.05.004
   Tan A, 2014, CHEST, V145, P322, DOI 10.1378/chest.13-1163
   Tanriverdi H, 2006, RESPIRATION, V73, P741, DOI 10.1159/000093531
   Tian Jian-li, 2006, Zhonghua Jiehe He Huxi Zazhi, V29, P395
   Tsuda H, 2010, SLEEP BREATH, V14, P365, DOI 10.1007/s11325-009-0324-9
   Utriainen KT, 2013, EUR RESPIR J, V41, P616, DOI 10.1183/09031936.00227611
   Wattanakit K, 2008, ATHEROSCLEROSIS, V197, P125, DOI 10.1016/j.atherosclerosis.2007.02.029
   Yaggi H, 2004, STROKE, V316, P365
   Yaggi HK, 2005, NEW ENGL J MED, V353, P2034, DOI 10.1056/NEJMoa043104
   Yokoe T, 2003, CIRCULATION, V107, P1129, DOI 10.1161/01.CIR.0000052627.99976.18
   Young T, 1997, ARCH INTERN MED, V157, P1746, DOI 10.1001/archinte.157.15.1746
NR 54
TC 8
Z9 8
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1079-5642
EI 1524-4636
J9 ARTERIOSCL THROM VAS
JI Arterioscler. Thromb. Vasc. Biol.
PD MAR
PY 2015
VL 35
IS 3
BP 710
EP 715
DI 10.1161/ATVBAHA.114.304625
PG 6
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA CC5JV
UT WOS:000350395800030
PM 25657310
OA Green Accepted, Bronze
DA 2021-10-30
ER

PT J
AU Aliota, MT
   Bassit, L
   Bradrick, SS
   Cox, B
   Garcia-Blanco, MA
   Gavegnano, C
   Friedrich, TC
   Golos, TG
   Griffin, DE
   Haddow, AD
   Kallas, EG
   Kitron, U
   Lecuit, M
   Magnani, DM
   Marrs, C
   Mercer, N
   McSweegan, E
   Ng, LFP
   O'Connor, DH
   Osorio, JE
   Ribeiro, GS
   Ricciardi, M
   Rossi, SL
   Saade, G
   Schinazi, RF
   Schott-Lerner, GO
   Shan, C
   Shi, PY
   Watkins, DI
   Vasilakis, N
   Weaver, SC
AF Aliota, Matthew T.
   Bassit, Leda
   Bradrick, Shelton S.
   Cox, Bryan
   Garcia-Blanco, Mariano A.
   Gavegnano, Christina
   Friedrich, Thomas C.
   Golos, Thaddeus G.
   Griffin, Diane E.
   Haddow, Andrew D.
   Kallas, Esper G.
   Kitron, Uriel
   Lecuit, Marc
   Magnani, Diogo M.
   Marrs, Caroline
   Mercer, Natalia
   McSweegan, Edward
   Ng, Lisa F. P.
   O'Connor, David H.
   Osorio, Jorge E.
   Ribeiro, Guilherme S.
   Ricciardi, Michael
   Rossi, Shannan L.
   Saade, George
   Schinazi, Raymond F.
   Schott-Lerner, Geraldine O.
   Shan, Chao
   Shi, Pei-Yong
   Watkins, David I.
   Vasilakis, Nikos
   Weaver, Scott C.
TI Zika in the Americas, year 2: What have we learned? What gaps remain? A
   report from the Global Virus Network
SO ANTIVIRAL RESEARCH
LA English
DT Review
DE Zika virus; Arbovirus; Congenital manifestations; Maternal-fetal
   transmission; Antiviral therapy; Vaccines
ID GUILLAIN-BARRE-SYNDROME; MALE SEXUAL TRANSMISSION; UNITED-STATES; CELL
   TROPISM; PROLONGED DETECTION; NEURAL PROGENITORS; CEREBRAL ORGANOIDS;
   BORNE TRANSMISSION; INTERIM GUIDANCE; REPRODUCTIVE AGE
AB In response to the outbreak of Zika virus (ZIKV) infection in the Western Hemisphere and the recognition of a causal association with fetal malformations, the Global Virus Network (GVN) assembled an international taskforce of virologists to promote basic research, recommend public health measures and encourage the rapid development of vaccines, antiviral therapies and new diagnostic tests. In this article, taskforce members and other experts review what has been learned about ZIKV-induced disease in humans, its modes of transmission and the cause and nature of associated congenital manifestations. After describing the make-up of the taskforce, we summarize the emergence of ZIKV in the Americas, Africa and Asia, its spread by mosquitoes, and current control measures. We then review the spectrum of primary ZIKV-induced disease in adults and children, sites of persistent infection and sexual transmission, then examine what has been learned about maternal-fetal transmission and the congenital Zika syndrome, including knowledge obtained from studies in laboratory animals. Subsequent sections focus on vaccine development, antiviral therapeutics and new diagnostic tests. After reviewing current understanding of the mechanisms of emergence of Zika virus, we consider the likely future of the pandemic. (C) 2017 Published by Elsevier B.V.
C1 [Griffin, Diane E.; Haddow, Andrew D.; Kallas, Esper G.; Lecuit, Marc; Mercer, Natalia; McSweegan, Edward; Ng, Lisa F. P.; Osorio, Jorge E.; Schinazi, Raymond F.; Watkins, David I.; Weaver, Scott C.] Global Virus Network, 725 West Lombard St, Baltimore, MD 21201 USA.
   [Aliota, Matthew T.; Friedrich, Thomas C.; Osorio, Jorge E.] Univ Wisconsin Madison, Dept Pathobiol Sci, Madison, WI 53706 USA.
   [Bassit, Leda; Cox, Bryan; Gavegnano, Christina; Schinazi, Raymond F.] Emory Univ, Ctr AIDS Res, Sch Med, Dept Pediat, Atlanta, GA 30322 USA.
   [Bradrick, Shelton S.; Garcia-Blanco, Mariano A.; Schott-Lerner, Geraldine O.; Shan, Chao; Shi, Pei-Yong] Univ Texas Med Branch, Inst Human Infect & Immun, Dept Biochem & Mol Biol, Galveston, TX 77555 USA.
   [Friedrich, Thomas C.; Golos, Thaddeus G.; O'Connor, David H.] Univ Wisconsin Madison, Wisconsin Natl Primate Res Ctr, Madison, WI 53706 USA.
   [Golos, Thaddeus G.] Univ Wisconsin Madison, Dept Comparat Biosci, Madison, WI 53706 USA.
   [Golos, Thaddeus G.] Univ Wisconsin Madison, Dept Obstet & Gynecol, Madison, NJ 53706 USA.
   [Griffin, Diane E.] Johns Hopkins Bloomberg Sch Publ Hlth, Harry Feinstone Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA.
   [Haddow, Andrew D.] US Army, Med Res Inst Infect Dis, Div Virol, Ft Detrick, MD 21702 USA.
   [Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Kitron, Uriel] Emory Univ, Dept Environm Sci, Atlanta, GA 30322 USA.
   [Lecuit, Marc] Inst Pasteur, Biol Infect Unit, Paris, France.
   [Lecuit, Marc] INSERM, Unit 1117, Paris, France.
   [Lecuit, Marc] Paris Descartes Univ, Necker Enfants Malades Univ Hosp, Inst Imagine, Sorbonne Paris Cite,Div Infect Dis & Trop Med, Paris, France.
   [Magnani, Diogo M.; Ricciardi, Michael; Watkins, David I.] Univ Miami, Dept Pathol, Miami, FL 33101 USA.
   [Marrs, Caroline; Saade, George] Univ Texas Med Branch, Dept Obstet & Gynecol, Galveston, TX 77555 USA.
   [Ng, Lisa F. P.] ASTAR, Singapore Immunol Network, Singapore, Singapore.
   [O'Connor, David H.] Univ Wisconsin Madison, Dept Pathol & Lab Med, Madison, WI 53706 USA.
   [Ribeiro, Guilherme S.] Univ Fed Bahia, Fundacao Oswaldo Cruz, Inst Goncalo Moniz, Salvador, BA, Brazil.
   [Ribeiro, Guilherme S.] Univ Fed Bahia, Inst Sailde Colet, Salvador, BA, Brazil.
   [Rossi, Shannan L.; Weaver, Scott C.] Univ Texas Med Branch, Inst Human Infect & Immun, Dept Microbiol & Immunol, Galveston, TX 77555 USA.
   [Vasilakis, Nikos] Univ Texas Med Branch, Inst Human Infect & Immun, Dept Pathol, Galveston, TX 77555 USA.
RP Weaver, SC (corresponding author), Global Virus Network, 725 West Lombard St, Baltimore, MD 21201 USA.; Weaver, SC (corresponding author), Univ Texas Med Branch, Inst Human Infect & Immun, Dept Microbiol & Immunol, Galveston, TX 77555 USA.
EM sweaver@utmb.edu
RI Ribeiro, Guilherme/B-6624-2008; Haddow, Andrew D/C-5902-2008; Shan,
   Chao/AAN-8190-2021; Lecuit, Marc/J-4073-2013; Lecuit, Marc/M-4126-2019;
   Aliota, Matthew/AAS-6376-2021; Vasilakis, Nikos/ABE-7318-2020
OI Ribeiro, Guilherme/0000-0002-6798-2059; Haddow, Andrew
   D/0000-0002-8957-2608; Shan, Chao/0000-0002-3953-3782; Lecuit,
   Marc/0000-0002-4491-1063; Lecuit, Marc/0000-0002-4491-1063; Kallas,
   Esper/0000-0003-2026-6925; Aliota, Matthew/0000-0002-6902-9149;
   Garcia-Blanco, Mariano/0000-0001-8538-1997; Ng,
   Lisa/0000-0003-4071-5222; Magnani, Diogo/0000-0002-1773-2406
FU U.S. National Institutes of HealthUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [R01NS087539-S1,
   R21AI129607, R24AI120942, R01A1121452, R01 AI07157-01A1,
   R01AI116382-01A1S1, U01AI115577, P51 OD011106]; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000460]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [U01AI115577, R01AI121452,
   R01AI107157, R24AI120942, R21AI129607, R01AI116382] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Neurological Disorders &
   Stroke (NINDS) [R01NS087539] Funding Source: NIH RePORTER; OFFICE OF THE
   DIRECTOR, NATIONAL INSTITUTES OF HEALTHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA
   [P51OD011106] Funding Source: NIH RePORTER
FX Work from the authors' laboratories was funded by in part by U.S.
   National Institutes of Health grants: R01NS087539-S1 (to DEG),
   R21AI129607 (to RFS), and R24AI120942, R01A1121452 (to SCW) R01
   AI07157-01A1 (to TGG), R01AI116382-01A1S1 (to DHO), U01AI115577 (to NV)
   and P51 OD011106 (to the WNPRC).
CR Abbink P, 2016, SCIENCE, V353, P1129, DOI 10.1126/science.aah6157
   Aid M, 2017, CELL, V169, P610, DOI 10.1016/j.cell.2017.04.008
   Akoua-Koffi C, 2001, B SOC PATHOL EXOT, V94, P227
   Alera MT, 2015, EMERG INFECT DIS, V21, P722, DOI 10.3201/eid2104.141707
   Ali S, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005135
   Aliota MT, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005168
   Aliota MT, 2016, EMERG INFECT DIS, V22, P1857, DOI 10.3201/eid2210.161082
   Aliota MT, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004682
   Althouse BM, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005055
   Amraoui F, 2016, EUROSURVEILLANCE, V21, P2, DOI 10.2807/1560-7917.ES.2016.21.35.30333
   [Anonymous], 2015, Wkly Epidemiol Rec, V90, P609
   de Brito CAA, 2016, REV SOC BRAS MED TRO, V49, P537, DOI 10.1590/0037-8682-0328-2016
   de Brito CAA, 2016, REV SOC BRAS MED TRO, V49, P553, DOI 10.1590/0037-8682-0245-2016
   Azar SR, 2017, AM J TROP MED HYG, V97, P330, DOI 10.4269/ajtmh.16-0969
   Azmi SA, 2015, J VECTOR DIS, V52, P252
   Barba-Spaeth G, 2016, NATURE, V536, P48, DOI 10.1038/nature18938
   Barjas-Castro ML, 2016, TRANSFUSION, V56, P1684, DOI 10.1111/trf.13681
   Barouch DH, 2017, IMMUNITY, V46, P176, DOI 10.1016/j.immuni.2017.02.005
   Barrows NJ, 2016, CELL HOST MICROBE, V20, P259, DOI 10.1016/j.chom.2016.07.004
   Barzon L, 2016, EUROSURVEILLANCE, V21, P2, DOI 10.2807/1560-7917.ES.2016.21.32.30316
   Bayer A, 2016, CELL HOST MICROBE, V19, P705, DOI 10.1016/j.chom.2016.03.008
   BEARCROFT W. G. C., 1956, TRANS ROY SOC TROP MED AND HYG, V50, P442, DOI 10.1016/0035-9203(56)90090-6
   BEARCROFT WGC, 1957, J PATHOL BACTERIOL, V74, P295, DOI 10.1002/path.1700740207
   BELL TM, 1971, ARCH GES VIRUSFORSCH, V35, P183, DOI 10.1007/BF01249709
   Berthet N, 2014, VECTOR-BORNE ZOONOT, V14, P862, DOI 10.1089/vbz.2014.1607
   Besnard M, 2016, EUROSURVEILLANCE, V21, P22, DOI 10.2807/1560-7917.ES.2016.21.13.30181
   Besnard M, 2014, EUROSURVEILLANCE, P19, DOI DOI 10.2807/1560-7917.ES2014.19.13.20751
   Boccolini D, 2016, EUROSURVEILLANCE, V21, P6, DOI 10.2807/1560-7917.ES.2016.21.35.30328
   Bondarenko GI, 2007, J IMMUNOL, V179, P8042, DOI 10.4049/jimmunol.179.12.8042
   BOORMAN J. P. T., 1956, Transactions of the Royal Society of Tropical Medicine and Hygiene, V50, P238, DOI 10.1016/0035-9203(56)90029-3
   Bowen JR, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006164
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Brault JB, 2016, EBIOMEDICINE, V10, P71, DOI 10.1016/j.ebiom.2016.07.018
   Broutet N, 2016, NEW ENGL J MED, V374, P1506, DOI 10.1056/NEJMp1602708
   Buathong R, 2015, AM J TROP MED HYG, V93, P380, DOI 10.4269/ajtmh.15-0022
   Buck Louis Germaine M, 2015, Am J Obstet Gynecol, V213, DOI 10.1016/j.ajog.2015.08.032
   Buechler CR, 2017, MSPHERE, V2, DOI 10.1128/mSphere.00392-16
   BULMER JN, 1984, CLIN EXP IMMUNOL, V57, P393
   Calvet G, 2016, LANCET INFECT DIS, V16, P653, DOI 10.1016/S1473-3099(16)00095-5
   Cardoso CW, 2015, EMERG INFECT DIS, V21, P2274, DOI 10.3201/eid2112.151167
   Carter AM, 2011, BEST PRACT RES CL OB, V25, P249, DOI 10.1016/j.bpobgyn.2010.10.010
   Cauchemez S, 2016, LANCET, V387, P2125, DOI 10.1016/S0140-6736(16)00651-6
   Cavalcanti MG, 2017, INT J INFECT DIS, V57, P70, DOI 10.1016/j.ijid.2017.01.042
   Chen JC, 2016, INT J INFECT DIS, V51, P139, DOI 10.1016/j.ijid.2016.07.015
   Cheng FX, 2016, TRENDS MOL MED, V22, P919, DOI 10.1016/j.molmed.2016.09.006
   Chimelli L, 2017, ACTA NEUROPATHOL, V133, P983, DOI 10.1007/s00401-017-1699-5
   Chouin-Carneiro T, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004543
   Chua A, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005269
   Coffey LL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171148
   CORNET M, 1979, Cahiers O.R.S.T.O.M. (Office de la Recherche Scientifique et Technique Outre-Mer) Serie Entomologie Medicale et Parasitologie, V17, P47
   CORNET M, 1979, Cahiers O.R.S.T.O.M. (Office de la Recherche Scientifique et Technique Outre-Mer) Serie Entomologie Medicale et Parasitologie, V17, P149
   Costello A, 2016, B WORLD HEALTH ORGAN, V94, P406, DOI 10.2471/BLT.16.176990
   Cox Bryan D., 2015, Antiviral Chemistry & Chemotherapy, V24, P118, DOI 10.1177/2040206616653873
   Cugola FR, 2016, NATURE, V534, P267, DOI 10.1038/nature18296
   Culjat M, 2016, CLIN INFECT DIS, V63, P805, DOI 10.1093/cid/ciw324
   Cunha MS, 2016, MICROBIOL RESOUR ANN, V4, DOI 10.1128/genomeA.00032-16
   D'Ortenzio E, 2016, NEW ENGL J MED, V374, P2195, DOI 10.1056/NEJMc1604449
   Daffis S, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000607
   Dang J, 2016, CELL STEM CELL, V19, P258, DOI 10.1016/j.stem.2016.04.014
   Davidson A, 2016, MMWR-MORBID MORTAL W, V65, P716, DOI 10.15585/mmwr.mm6528e2
   de Araujo TVB, 2016, LANCET INFECT DIS, V16, P1356, DOI 10.1016/S1473-3099(16)30318-8
   de Carvalho GC, 2014, J VECTOR ECOL, V39, P146, DOI 10.1111/j.1948-7134.2014.12081.x
   de Noronha L, 2016, MEM I OSWALDO CRUZ, V111, P287, DOI 10.1590/0074-02760160085
   de Paula Freitas B, 2016, JAMA OPHTHALMOL BRAZ
   Deckard DT, 2016, MMWR-MORBID MORTAL W, V65, P372, DOI 10.15585/mmwr.mm6514a3
   Diallo D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109442
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P521, DOI 10.1016/0035-9203(52)90043-6
   do Rosario MS, 2016, AM J TROP MED HYG, V95, P1157, DOI 10.4269/ajtmh.16-0306
   dos Santos T, 2016, NEW ENGL J MED, V375, P1598, DOI 10.1056/NEJMc1609015
   Dowd KA, 2016, SCIENCE, V354, P237, DOI 10.1126/science.aai9137
   Dowd KA, 2016, CELL REP, V16, P1485, DOI 10.1016/j.celrep.2016.07.049
   Dowell SD, 2016, PLOS NEGLECT TROP D, V10, DOI [10.1371/8Durnal.pntd.0004658, DOI 10.1371/JOURNAL.PNTD.0004658]
   DRAPER C C, 1965, West Afr Med J, V14, P16
   Driggers RW, 2016, NEW ENGL J MED, V374, P2142, DOI 10.1056/NEJMoa1601824
   Dudley DM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12204
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Duggal NK, 2017, CELL REP, V18, P1751, DOI 10.1016/j.celrep.2017.01.056
   Duong V, 2017, EMERG INFECT DIS, V23, P296, DOI 10.3201/eid2302.161432
   El Costa H, 2016, SCI REP-UK, V6, DOI 10.1038/srep35296
   Enders AC, 2007, PLACENTA, V28, P794, DOI 10.1016/j.placenta.2006.11.001
   Enders AC, 2001, PLACENTA, V22, P284, DOI 10.1053/plac.2001.0626
   FAGBAMI AH, 1979, J HYG-CAMBRIDGE, V83, P213, DOI 10.1017/S0022172400025997
   Faria NR, 2016, SCIENCE, V352, P345, DOI 10.1126/science.aaf5036
   Fauci AS, 2016, NEW ENGL J MED, V374, P601, DOI 10.1056/NEJMp1600297
   Faye O, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002636
   FDA, 2017, ZIK VIR EM US AUTH
   Ferguson NM, 2016, SCIENCE, V353, P353, DOI 10.1126/science.aag0219
   Fernandes RS, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004993
   Fields B.N., 2007, FIELDS VIROLOGY
   Foy BD, 2011, EMERG INFECT DIS, V17, P880, DOI 10.3201/eid1705.101939
   Froeschl G, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-016-2123-9
   Gabriel E, 2017, CELL STEM CELL, V20, P397, DOI 10.1016/j.stem.2016.12.005
   Galel SA, 2017, TRANSFUSION, V57, P762, DOI 10.1111/trf.14029
   Garcez PP, 2016, SCIENCE, V352, P816, DOI 10.1126/science.aaf6116
   Gavegnano Christina, 2017, Pathog Immun, V2, P199, DOI 10.20411/pai.v2i2.190
   Godoy AS, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14764
   Goebel S, 2016, J VIROL METHODS, V238, P13, DOI 10.1016/j.jviromet.2016.09.015
   Golos TG, 2010, INT J DEV BIOL, V54, P431, DOI 10.1387/ijdb.082797tg
   Govero J, 2016, NATURE, V540, P438, DOI 10.1038/nature20556
   Grant A, 2016, CELL HOST MICROBE, V19, P882, DOI 10.1016/j.chom.2016.05.009
   Grard G, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002681
   Guerbois M, 2016, J INFECT DIS, V214, P1349, DOI 10.1093/infdis/jiw302
   Gulland A, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i4812
   Guo XX, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.102
   Guo XX, 2014, J AM MOSQUITO CONTR, V30, P309, DOI 10.2987/14-6439R.1
   HADDOW AJ, 1964, B WORLD HEALTH ORGAN, V31, P57
   Haddow AD, 2017, EMERG INFECT DIS, V23, P1274, DOI 10.3201/eid2308.170036
   Haddow AD, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005083
   Haddow AD, 2016, B WORLD HEALTH ORGAN, V94, P711, DOI 10.2471/BLT.16.181503
   Haddow AD, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001477
   Hall-Mendelin S, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004959
   Hamel R, 2015, J VIROL, V89, P8880, DOI 10.1128/JVI.00354-15
   Hamer DH, 2017, ANN INTERN MED, V166, P99, DOI 10.7326/M16-1842
   Hanley KA, 2013, INFECT GENET EVOL, V19, P292, DOI 10.1016/j.meegid.2013.03.008
   Hayes EB, 2009, EMERG INFECT DIS, V15, P1347, DOI 10.3201/eid1509.090442
   Heang V, 2012, EMERG INFECT DIS, V18, P349, DOI 10.3201/eid1802.111224
   Herrera B. B., 2017, J INFECT DIS
   Hills SL, 2016, MMWR-MORBID MORTAL W, V65, P215, DOI 10.15585/mmwr.mm6508e2
   Hirsch AJ, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006219
   Huang WC, 2016, SCI REP-UK, V6, DOI 10.1038/srep34793
   Huang YJS, 2016, VECTOR-BORNE ZOONOT, V16, P673, DOI 10.1089/vbz.2016.2058
   Huzly D, 2016, EUROSURVEILLANCE, V21, P9, DOI 10.2807/1560-7917.ES.2016.21.16.30203
   Johansson MA, 2016, NEW ENGL J MED, V375, P1, DOI 10.1056/NEJMp1605367
   Jurado KA, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.88461
   Katz LM, 2017, ARCH PATHOL LAB MED, V141, P85, DOI 10.5858/arpa.2016-0430-RA
   Kincaid E, 2016, NAT MED, V22, P824, DOI 10.1038/nm0816-824
   Koide F, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.02028
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Larocca RA, 2016, NATURE, V536, P474, DOI 10.1038/nature18952
   Lazear HM, 2016, CELL HOST MICROBE, V19, P720, DOI 10.1016/j.chom.2016.03.010
   Leal MC, 2016, MMWR-MORBID MORTAL W, V65, P917, DOI 10.15585/mmwr.mm6534e3
   Ledermann JP, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003188
   Li C, 2016, CELL STEM CELL, V19, P120, DOI 10.1016/j.stem.2016.04.017
   Li MI, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001792
   Li XF, 2016, EBIOMEDICINE, V12, P170, DOI 10.1016/j.ebiom.2016.09.022
   Li Y, 2017, CELL STEM CELL, V20, P385, DOI 10.1016/j.stem.2016.11.017
   Likos A, 2016, MMWR-MORBID MORTAL W, V65, P1032, DOI 10.15585/mmwr.mm6538e1
   Cuevas EL, 2016, MMWR-MORBID MORTAL W, V65, P1409, DOI 10.15585/mmwr.mm6549e1
   Liu Y, 2017, NATURE, V545, P482, DOI 10.1038/nature22365
   Lozier M, 2016, MMWR-MORBID MORTAL W, V65, P1219, DOI 10.15585/mmwr.mm6544a4
   Ma WQ, 2017, CELL, V168, P542, DOI 10.1016/j.cell.2017.01.009
   Ma WQ, 2016, CELL, V167, P1511, DOI 10.1016/j.cell.2016.11.016
   MACNAMARA FN, 1954, T ROY SOC TROP MED H, V48, P139, DOI 10.1016/0035-9203(54)90006-1
   Magnani D. M., 2017, PLOS NEGLEC IN PRESS
   Makhluf H, 2016, EXPERT OPIN DRUG DIS, V11, P921, DOI 10.1080/17460441.2016.1212013
   Mann A, 2011, NAT MED, V17, P394, DOI 10.1038/nm0411-394a
   Mansuy JM, 2017, EMERG INFECT DIS, V23, P863, DOI 10.3201/eid2305.161631
   Mansuy JM, 2016, LANCET INFECT DIS, V16, P894, DOI 10.1016/S1473-3099(16)30153-0
   Mansuy JM, 2016, LANCET INFECT DIS, V16, P405, DOI 10.1016/S1473-3099(16)00138-9
   MARCHETTE NJ, 1969, AM J TROP MED HYG, V18, P411, DOI 10.4269/ajtmh.1969.18.411
   Martines RB, 2016, MMWR-MORBID MORTAL W, V65, P159, DOI 10.15585/mmwr.mm6506e1
   Maurer-Stroh S, 2016, EUROSURVEILLANCE, V21, P7, DOI 10.2807/1560-7917.ES.2016.21.38.30347
   McCarthy M, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i212
   Meaney-Delman D, 2016, OBSTET GYNECOL, V128, P724, DOI 10.1097/AOG.0000000000001625
   Meaney-Delman D, 2016, MMWR-MORBID MORTAL W, V65, P211, DOI 10.15585/mmwr.mm6508e1
   Meertens L, 2017, CELL REP, V18, P324, DOI 10.1016/j.celrep.2016.12.045
   Melo ASO, 2016, ULTRASOUND OBST GYN, V47, P6, DOI 10.1002/uog.15831
   Miner JJ, 2017, CELL HOST MICROBE, V21, P134, DOI 10.1016/j.chom.2017.01.004
   Miner JJ, 2016, CELL REP, V16, P3208, DOI 10.1016/j.celrep.2016.08.079
   Miner JJ, 2016, CELL, V165, P1080, DOI 10.1016/j.cell.2016.05.008
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Molaei G, 2007, AM J TROP MED HYG, V77, P73
   Moreira J, 2017, CLIN MICROBIOL INFEC, V23, P296, DOI 10.1016/j.cmi.2016.12.027
   Morrison TE, 2017, J VIROL, V91, DOI 10.1128/JVI.00009-17
   Motta IJF, 2016, NEW ENGL J MED, V375, P1101, DOI 10.1056/NEJMc1607262
   Muller W.J., 2016, JAMA-J AM MED ASSOC
   Munoz-Jordan JL, 2010, VIRUSES-BASEL, V2, P676, DOI 10.3390/v2020676
   MURRAY KO, 2017, EMERG INFECT DIS, V23, P99, DOI DOI 10.3201/EID2301.161:394.EPUB
   Musso D, 2014, CLIN MICROBIOL INFEC, V20, pO595, DOI 10.1111/1469-0691.12707
   Musso D, 2014, EUROSURVEILLANCE, V19, P6, DOI 10.2807/1560-7917.ES2014.19.14.20761
   Musso D, 2016, CLIN MICROBIOL REV, V29, P487, DOI 10.1128/CMR.00072-15
   Musso D, 2015, EMERG INFECT DIS, V21, P359, DOI 10.3201/eid2102.141363
   Nguyen SM, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006378
   Nicastri E, 2016, EUROSURVEILLANCE, V21, P6, DOI 10.2807/1560-7917.ES.2016.21.32.30314
   Nowakowski A, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/4956063
   Oduyebo T, 2016, MMWR-MORBID MORTAL W, V65, P122, DOI 10.15585/mmwr.mm6505e2
   OLSON JG, 1981, T ROY SOC TROP MED H, V75, P389, DOI 10.1016/0035-9203(81)90100-0
   Olson KE, 2016, ARBOVIRUSES: MOLECULAR BIOLOGY, EVOLUTION AND CONTROL, P315
   Osuna CE, 2016, NAT MED, V22, P1448, DOI 10.1038/nm.4206
   Pacheco O, 2020, NEW ENGL J MED, V383, DOI 10.1056/NEJMoa1604037
   Pagani I, 2017, SCI REP-UK, V7, DOI 10.1038/srep44286
   PAHO, 2017, REG ZIK EP UPD AM 10
   Paploski IAD, 2016, EMERG INFECT DIS, V22, P1438, DOI 10.3201/eid2208.160496
   Pardi N, 2017, NATURE, V543, P248, DOI 10.1038/nature21428
   Parke DW, 2016, OPHTHALMOLOGY, V123, P2432, DOI 10.1016/j.ophtha.2016.06.039
   Paz-Bailey G, 2017, NEW ENGL J MED, DOI [10.1056/NEJMoa161310828195756, DOI 10.1056/NEJMOA1613108]
   Perkins TA, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.51
   Petersen EE, 2016, MMWR-MORBID MORTAL W, V65, P315, DOI 10.15585/mmwr.mm6512e2
   Petersen LR, 2016, NEW ENGL J MED, V374, P1552, DOI 10.1056/NEJMra1602113
   Plourde AR, 2016, EMERG INFECT DIS, V22, P1185, DOI 10.3201/eid2207.151990
   Qian XY, 2016, CELL, V165, P1238, DOI 10.1016/j.cell.2016.04.032
   Quicke KM, 2016, CELL HOST MICROBE, V20, P83, DOI 10.1016/j.chom.2016.05.015
   Rabe IB, 2016, MMWR-MORBID MORTAL W, V65, P543, DOI 10.15585/mmwr.mm6521e1
   Ragan IK, 2017, VECTOR-BORNE ZOONOT, V17, P161, DOI 10.1089/vbz.2016.2099
   Rasmussen SA, 2016, NEW ENGL J MED, V374, P1981, DOI 10.1056/NEJMsr1604338
   Retallack H, 2016, P NATL ACAD SCI USA, V113, P14408, DOI 10.1073/pnas.1618029113
   Reynolds MR, 2017, MMWR-MORBID MORTAL W, V66, P366, DOI 10.15585/mmwr.mm6613e1
   Richard AS, 2017, P NATL ACAD SCI USA, V114, P2024, DOI 10.1073/pnas.1620558114
   Richard V, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005024
   Richner JM, 2017, CELL, V168, P1114, DOI 10.1016/j.cell.2017.02.017
   Ritchie S, 2016, ARBOVIRUSES: MOLECULAR BIOLOGY, EVOLUTION AND CONTROL, P281
   Rossi SL, 2016, AM J TROP MED HYG, V94, P1362, DOI 10.4269/ajtmh.16-0111
   Roundy CM, 2017, EMERG INFECT DIS, V23, P625, DOI 10.3201/eid2304.161484
   Salchuddin AR, 2017, ASIAN PAC J TROP MED, V10, P201, DOI 10.1016/j.apjtm.2017.03.002
   Salje H, 2016, J INFECT DIS, V213, P604, DOI 10.1093/infdis/jiv470
   Sapparapu G, 2016, NATURE, V540, P443, DOI 10.1038/nature20564
   Sarno M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004517
   Schuler-Faccini L, 2016, MMWR-MORBID MORTAL W, V65, P59, DOI 10.15585/mmwr.mm6503e2
   Shan C, 2017, NAT MED, V23, P763, DOI 10.1038/nm.4322
   Shan C, 2017, EBIOMEDICINE, V17, P157, DOI 10.1016/j.ebiom.2017.03.006
   Shan C, 2016, CELL HOST MICROBE, V19, P891, DOI 10.1016/j.chom.2016.05.004
   Shan C, 2016, ACS INFECT DIS, V2, P170, DOI 10.1021/acsinfecdis.6b00030
   Sheridan MA, 2017, P NATL ACAD SCI USA, V114, pE1587, DOI 10.1073/pnas.1616097114
   Simoni MK, 2017, AM J REPROD IMMUNOL, V77, DOI 10.1111/aji.12613
   SIMPSON D. I. H., 1964, TRANS ROY SOC TROP MED HYG, V58, P335, DOI 10.1016/0035-9203(64)90201-9
   SMFM, 2015, AM J OBSTET GYNECOL
   SMITHBURN KC, 1954, AM J HYG, V59, P157, DOI 10.1093/oxfordjournals.aje.a119630
   Souza BSF, 2016, SCI REP-UK, V6, DOI 10.1038/srep39775
   Speer SD, 2016, SCIENCE, V353, P750, DOI 10.1126/science.aah6187
   Steinhagen K., 2015, EUROSURVEILLANCE, V2016, P21, DOI DOI 10.2807/1560-7917.ES.2016.21.50.30426
   Stettler K, 2016, SCIENCE, V353, P823, DOI 10.1126/science.aaf8505
   Strafela P, 2017, ARCH PATHOL LAB MED, V141, P73, DOI 10.5858/arpa.2016-0341-SA
   Tabata T, 2016, CELL HOST MICROBE, V20, P155, DOI 10.1016/j.chom.2016.07.002
   Tang HL, 2016, CELL STEM CELL, V18, P587, DOI 10.1016/j.stem.2016.02.016
   Tetro JA, 2016, MICROBES INFECT, V18, P167, DOI 10.1016/j.micinf.2015.12.010
   van der Eijk AA, 2016, NEW ENGL J MED, V375, P1002, DOI 10.1056/NEJMc1605898
   Vasilakis N, 2017, CURR OPIN VIROL, V22, P30, DOI 10.1016/j.coviro.2016.11.007
   Vasquez AM, 2016, MMWR-MORBID MORTAL W, V65, P375, DOI 10.15585/mmwr.mm6514e1
   Ventura CV, 2016, LANCET, V387, P2502, DOI 10.1016/S0140-6736(16)30776-0
   Venturi G, 2016, EUROSURVEILLANCE, V21, P2, DOI 10.2807/1560-7917.ES.2016.21.8.30148
   Vermillion MS, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14575
   Villar J, 2013, BJOG-INT J OBSTET GY, V120, P9, DOI 10.1111/1471-0528.12047
   Waldorf KMA, 2016, NAT MED, V22, P1256, DOI 10.1038/nm.4193
   Walker T, 2016, ARBOVIRUSES: MOLECULAR BIOLOGY, EVOLUTION AND CONTROL, P291
   Weaver SC, 2016, ANTIVIR RES, V130, P69, DOI 10.1016/j.antiviral.2016.03.010
   Weger-Lucarelli J, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005101
   Weisblum Y, 2017, J VIROL, V91, DOI [10.1128/JVI.01905-16, 10.1128/jvi.01905-16]
   Wells MF, 2016, CELL STEM CELL, V19, P703, DOI 10.1016/j.stem.2016.11.011
   WHO, 2016, INT GUID UPD PREGN M
   WHO, 2016, ZIK SIT REP 6 OCT 20
   WHO, 2017, GUID INF FEED AR ZIK
   Wikan N, 2016, ASIAN PAC J TROP MED, V9, P136, DOI 10.1016/j.apjtm.2016.01.017
   Wildman DE, 2006, P NATL ACAD SCI USA, V103, P3203, DOI 10.1073/pnas.0511344103
   Williamson PC, 2017, TRANSFUSION, V57, P770, DOI 10.1111/trf.14041
   Wolfe ND, 2001, AM J TROP MED HYG, V64, P310, DOI 10.4269/ajtmh.2001.64.310
   Wong PSJ, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002348
   Wong SJ, 2017, EBIOMEDICINE, V16, P136, DOI 10.1016/j.ebiom.2017.01.008
   Wu KY, 2016, CELL RES, V26, P645, DOI 10.1038/cr.2016.58
   Xie XP, 2017, MBIO, V8, DOI [10.1128/mBio.02134-16, 10.1128/mbio.02134-16]
   Xu M, 2016, NAT MED, V22, P1101, DOI 10.1038/nm.4184
   Yang YJ, 2017, EBIOMEDICINE, V17, P145, DOI 10.1016/j.ebiom.2017.02.003
   Yockey LJ, 2016, CELL, V166, P1247, DOI 10.1016/j.cell.2016.08.004
   Zambrano H, 2017, AM J REPROD IMMUNOL, V77, DOI 10.1111/aji.12630
   Zhang B, 2017, NAT MED, V23, P548, DOI 10.1038/nm.4302
   Zhang FR, 2016, NUCLEIC ACIDS RES, V44, P8610, DOI [10.1093/nar/gkw765, 10]
   Zhu Z, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.48
   Zmurko J, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004695
NR 258
TC 71
Z9 71
U1 0
U2 36
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0166-3542
EI 1872-9096
J9 ANTIVIR RES
JI Antiviral Res.
PD AUG
PY 2017
VL 144
BP 223
EP 246
DI 10.1016/j.antiviral.2017.06.001
PG 24
WC Pharmacology & Pharmacy; Virology
SC Pharmacology & Pharmacy; Virology
GA FD3DH
UT WOS:000407413200023
PM 28595824
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Mossavar-Rahmani, Y
   Weng, J
   Wang, R
   Shaw, PA
   Jung, M
   Sotres-Alvarez, D
   Castaneda, SF
   Gallo, LC
   Gellman, MD
   Qi, QB
   Ramos, AR
   Reid, KJ
   Van Horn, L
   Patel, SR
AF Mossavar-Rahmani, Yasmin
   Weng, Jia
   Wang, Rui
   Shaw, Pamela A.
   Jung, Molly
   Sotres-Alvarez, Daniela
   Castaneda, Sheila F.
   Gallo, Linda C.
   Gellman, Marc D.
   Qi, Qibin
   Ramos, Alberto R.
   Reid, Kathryn J.
   Van Horn, Linda
   Patel, Sanjay R.
TI Actigraphic sleep measures and diet quality in the Hispanic Community
   Health Study/ Study of Latinos Sueno ancillary study
SO JOURNAL OF SLEEP RESEARCH
LA English
DT Article
DE dietary patterns; diet quality assessment; sleep quantity; sleep
   quality; US minority populations
ID DIVERSE BACKGROUNDS; OLDER-ADULTS; DURATION; RISK; INDIVIDUALS;
   ASSOCIATION; PREVALENCE; WOMEN; CONSUMPTION; POPULATION
AB Using a cross-sectional probability sample with actigraphy data and two 24-h dietary recalls, we quantified the association between sleep duration, continuity, variability and timing with the Alternative Healthy Eating Index-2010 diet quality score and its components in 2140 Hispanic Community Health Study/Study of Latinos participants. The Alternative Healthy Eating Index diet quality-2010 score ranges from 0 to 110, with higher scores indicating greater adherence to the dietary guidelines and lower risk from major chronic disease. None of the sleep measures was associated with total caloric intake as assessed using dietary recalls. However, both an increase in sleep duration and sleep efficiency were associated with healthier diet quality. Each standard deviation increase in sleep duration (1.05 h) and sleep efficiency (4.99%) was associated with a 0.30 point increase and 0.28 point increase, respectively, in the total Alternative Healthy Eating Index-2010 score. The component of Alternative Healthy Eating Index-2010 most strongly associated with longer sleep duration was increased nuts and legumes intake. The components of Alternative Healthy Eating Index-2010 most strongly associated with higher sleep efficiency were increased whole fruit intake and decreased sodium intake. Both longer sleep duration and higher sleep efficiency were significantly associated with better diet quality among US Hispanic/Latino adults. The dietary components most strongly associated with sleep duration and sleep efficiency differed, suggesting potentially independent mechanisms by which each aspect of sleep impacts dietary choices. Longitudinal research is needed to understand the directionality of these identified relationships and the generalizability of these data across other ethnic groups.
C1 [Mossavar-Rahmani, Yasmin; Qi, Qibin] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA.
   [Weng, Jia; Wang, Rui] Brigham & Womens Hosp, Div Sleep & Circadian Disorders, 75 Francis St, Boston, MA 02115 USA.
   [Wang, Rui] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA.
   [Shaw, Pamela A.] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
   [Jung, Molly] Johns Hopkins Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   [Sotres-Alvarez, Daniela] Univ North Carolina Chapel Hill, Dept Biostat, Collaborat Studies Coordinating Ctr, Chapel Hill, NC USA.
   [Castaneda, Sheila F.] San Diego State Univ, Div Hlth Promot & Behav Sci, San Diego, CA 92182 USA.
   [Gallo, Linda C.] San Diego State Univ, Dept Psychol, San Diego, CA 92182 USA.
   [Gellman, Marc D.] Univ Miami, Dept Psychol, POB 248185, Coral Gables, FL 33124 USA.
   [Ramos, Alberto R.] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA.
   [Reid, Kathryn J.] Northwestern Univ, Feinberg Sch Med, Dept Neurol, Chicago, IL 60611 USA.
   [Van Horn, Linda] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA.
   [Patel, Sanjay R.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.
RP Mossavar-Rahmani, Y (corresponding author), Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Div Hlth Promot & Nutr Res, 1300 Morris Pk Ave,Belfer Bldg 1312, Bronx, NY 10461 USA.
EM yasmin.mossavar-rahmani@einstein.yu.edu
RI Castaneda, Sheila F./AAK-3025-2020; Ramos, Alberto/X-4249-2019; Wang,
   Rui/X-1699-2019; Castaneda, Sheila/I-4132-2014
OI Castaneda, Sheila/0000-0002-1975-0544; Patel,
   Sanjay/0000-0002-9142-5172; Mossavar-Rahmani,
   Yasmin/0000-0002-9214-6124; Gallo, Linda C./0000-0002-3678-5888
FU National Heart, Lung, and Blood InstituteUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [R01HL095856, R01HL098297,
   K01HL129892, N01-HC65233, N01-HC65234, N01-HC65235, N01-HC65236,
   N01-HC65237]; National Heart, Lung, and Blood Institute: the National
   Center on Minority Health and Health Disparities; National Institute of
   Deafness and Other Communications DisordersUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Deafness & Other Communication Disorders (NIDCD);
   National Institute of Dental and Craniofacial ResearchUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Dental & Craniofacial Research (NIDCR);
   National Heart, Lung, and Blood Institute: National Institute of
   Diabetes and Digestive and Kidney DiseasesUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)NIH
   National Heart Lung & Blood Institute (NHLBI); National Heart, Lung, and
   Blood Institute: National Institute of Neurological Disorders and
   StrokeUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI)NIH National Institute of Neurological Disorders &
   Stroke (NINDS); National Heart, Lung, and Blood Institute: Office of
   Dietary Supplements; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [KL2TR000461] Funding Source: NIH
   RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL098297,
   R01HL136266, U01HL065233, R01HL095856, K24HL127307, R01HL065234,
   K01HL129892] Funding Source: NIH RePORTER
FX This work was supported by grants R01HL095856 (Y.M.-R.), R01HL098297
   (S.R.P.), K01HL129892 (Q.Q.) from the National Heart, Lung, and Blood
   Institute. The Hispanic Community Health Study/Study of Latinos was
   carried out as a collaborative study supported by contracts from the
   National Heart, Lung, and Blood Institute to the University of North
   Carolina (N01-HC65233), University of Miami (N01-HC65234), Albert
   Einstein College of Medicine (N01-HC65235), Northwestern University
   (N01-HC65236), and San Diego State University (N01-HC65237). The
   following Institutes/Center/Offices contribute to the Hispanic Community
   Health Study/Study of Latinos through a transfer of funds to the
   National Heart, Lung, and Blood Institute: the National Center on
   Minority Health and Health Disparities, the National Institute of
   Deafness and Other Communications Disorders, the National Institute of
   Dental and Craniofacial Research, the National Institute of Diabetes and
   Digestive and Kidney Diseases, the National Institute of Neurological
   Disorders and Stroke, and the Office of Dietary Supplements.
CR Ancoli-Israel S, 2003, SLEEP, V26, P342, DOI 10.1093/sleep/26.3.342
   ANDRESEN EM, 1994, AM J PREV MED, V10, P77, DOI 10.1016/S0749-3797(18)30622-6
   Aune D, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0730-3
   Ayas NT, 2003, DIABETES CARE, V26, P380, DOI 10.2337/diacare.26.2.380
   Cespedes EM, 2016, AM J EPIDEMIOL, V183, P561, DOI 10.1093/aje/kwv251
   Chiuve SE, 2012, J NUTR, V142, P1009, DOI 10.3945/jn.111.157222
   Crispim CA, 2011, J CLIN SLEEP MED, V7, P659, DOI 10.5664/jcsm.1476
   Daviglus ML, 2012, JAMA-J AM MED ASSOC, V308, P1775, DOI 10.1001/jama.2012.14517
   Garrido M, 2013, J NUTR HEALTH AGING, V17, P553, DOI 10.1007/s12603-013-0029-4
   Hagan KA, 2016, J NUTR, V146, P1341, DOI 10.3945/jn.115.227900
   Kant AK, 2014, AM J CLIN NUTR, V100, P938, DOI 10.3945/ajcn.114.085191
   Kaplan RC, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.000923
   Kushida CA, 2001, SLEEP MED, V2, P389, DOI 10.1016/S1389-9457(00)00098-8
   Lavange LM, 2010, ANN EPIDEMIOL, V20, P642, DOI 10.1016/j.annepidem.2010.05.006
   Li YP, 2012, AM J EPIDEMIOL, V176, P279, DOI 10.1093/aje/kws016
   Lin HH, 2011, ASIA PAC J CLIN NUTR, V20, P169
   Liu K, 2012, CIRCULATION, V125, P996, DOI 10.1161/CIRCULATIONAHA.111.060681
   Marino M, 2013, SLEEP, V36, P1747, DOI 10.5665/sleep.3142
   Mattei J, 2016, J NUTR, V146, P2035, DOI 10.3945/jn.116.231209
   Mossavar-Rahmani Y, 2015, APPETITE, V95, P275, DOI 10.1016/j.appet.2015.07.014
   Mossavar-Rahmani Y, 2015, AM J EPIDEMIOL, V181, P996, DOI 10.1093/aje/kwu468
   Patel SR, 2014, INT J OBESITY, V38, P1159, DOI 10.1038/ijo.2014.13
   Patel SR, 2008, OBESITY, V16, P643, DOI 10.1038/oby.2007.118
   Patel SR, 2006, SLEEP, V29, P881, DOI 10.1093/sleep/29.7.881
   Patel SR, 2015, SLEEP, V38, P1497, DOI 10.5665/sleep.4998
   Peuhkuri K, 2012, NUTR RES, V32, P309, DOI 10.1016/j.nutres.2012.03.009
   Redline S, 2014, AM J RESP CRIT CARE, V189, P335, DOI 10.1164/rccm.201309-1735OC
   Schneiderman N, 2014, DIABETES CARE, V37, P2233, DOI 10.2337/dc13-2939
   Siega-Riz AM, 2014, AM J CLIN NUTR, V99, P1487, DOI 10.3945/ajcn.113.082685
   Sorlie PD, 2010, ANN EPIDEMIOL, V20, P629, DOI 10.1016/j.annepidem.2010.03.015
   Spaeth AM, 2015, OBESITY, V23, P2349, DOI 10.1002/oby.21198
   Spiegel K, 2004, ANN INTERN MED, V141, P846, DOI 10.7326/0003-4819-141-11-200412070-00008
   Stamatakis KA, 2007, ANN EPIDEMIOL, V17, P948, DOI 10.1016/j.annepidem.2007.07.096
   Stern JH, 2014, OBESITY, V22, pE55, DOI 10.1002/oby.20683
   Tooze JA, 2010, STAT MED, V29, P2857, DOI 10.1002/sim.4063
   van den Berg JF, 2008, INT J OBESITY, V32, P1083, DOI 10.1038/ijo.2008.57
   Watson NF, 2015, SLEEP, V38, P843, DOI 10.5665/sleep.4716
   Weiss A, 2010, SLEEP, V33, P1201, DOI 10.1093/sleep/33.9.1201
NR 38
TC 21
Z9 21
U1 1
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0962-1105
EI 1365-2869
J9 J SLEEP RES
JI J. Sleep Res.
PD DEC
PY 2017
VL 26
IS 6
BP 739
EP 746
DI 10.1111/jsr.12513
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA FO3AS
UT WOS:000416682000009
PM 28349622
OA Bronze, Green Accepted
DA 2021-10-30
ER

PT J
AU Ramos, AR
   Weng, J
   Wallace, DM
   Petrov, MR
   Wohlgemuth, WK
   Sotres-Alvarez, D
   Loredo, JS
   Reid, KJ
   Zee, PC
   Mossavar-Rahmani, Y
   Patel, SR
AF Ramos, Alberto R.
   Weng, Jia
   Wallace, Douglas M.
   Petrov, Megan R.
   Wohlgemuth, William K.
   Sotres-Alvarez, Daniela
   Loredo, Jose S.
   Reid, Kathryn J.
   Zee, Phyllis C.
   Mossavar-Rahmani, Yasmin
   Patel, Sanjay R.
TI Sleep Patterns and Hypertension Using Actigraphy in the Hispanic
   Community Health Study/ Study of Latinos
SO CHEST
LA English
DT Article
DE Hispanic; hypertension; insomnia; sleep duration; sleep quality
ID INSOMNIA SEVERITY INDEX; BLOOD-PRESSURE; CARDIOMETABOLIC HEALTH;
   INCIDENT HYPERTENSION; NIGHTTIME SLEEP; RISK-FACTORS; DURATION;
   METAANALYSIS; ASSOCIATION; POPULATION
AB BACKGROUND: The aim of this study was to evaluate the association between actigraphy-based measures of sleep and prevalent hypertension in a sample of US Latinos.
   METHODS: We analyzed data from 2,148 participants of the Sueno Sleep Ancillary Study of the Hispanic Community Health Study/Study of Latinos (HCHS/SOL), who underwent 1 week of wrist actigraphy to characterize sleep duration, sleep efficiency, sleep fragmentation index, and daytime naps. Insomnia was defined as an Insomnia Severity Index >= 15. Hypertension was defined based on self-reported physician diagnosis. Survey linear regression was used to evaluate the association of sleep measures with hypertension prevalence. Sensitivity analyses excluded participants with an apnea-hypopnea index (AHI) >= 15 events/h.
   RESULTS: The mean age was 46.3 +/- 11.6 years, and 65% of the sample consisted of women. The mean sleep duration was 6.7 +/- 1.1 hours. Thirty-two percent of the sample had hypertension. After adjusting for age, sex, ethnic background, site, and AHI, each 10% reduction in sleep efficiency was associated with a 7.5% (95% CI, -12.9 to -2.2; P = .0061) greater hypertension prevalence, each 10% increase in sleep fragmentation index was associated with a 5.2% (95% CI, 1.4-8.9; P = .0071) greater hypertension prevalence, and frequent napping was associated with a 11.6% greater hypertension prevalence (95% CI, 5.5-17.7; P = .0002). In contrast, actigraphy-defined sleep duration (P = .20) and insomnia (P = .17) were not associated with hypertension. These findings persisted after excluding participants with an AHI >= 15 events/h.
   CONCLUSIONS: Independent of sleep-disordered breathing, we observed associations between reduced sleep continuity and daytime napping, but not short sleep duration, and prevalent hypertension.
C1 [Ramos, Alberto R.; Wallace, Douglas M.] Univ Miami, Miller Sch Med, Dept Neurol, 1120 NW 14th St,Ste 1350, Miami, FL 33136 USA.
   [Wallace, Douglas M.; Wohlgemuth, William K.] Bruce W Carter Dept Vet Affairs Med Ctr, Neurol Serv, Miami, FL USA.
   [Wohlgemuth, William K.] Bruce W Carter Dept Vet Affairs Med Ctr, Psychol Serv, Miami, FL USA.
   [Weng, Jia] Brigham & Womens Hosp, Div Sleep & Circadian Disorders, Boston, MA 02115 USA.
   [Petrov, Megan R.] Arizona State Univ, Coll Nursing & Hlth Innovat, Phoenix, AZ USA.
   [Sotres-Alvarez, Daniela] Univ N Carolina, Gillings Sch Global Publ Hlth, Collaborat Studies Coordinating Ctr, Dept Biostat, Chapel Hill, NC USA.
   [Loredo, Jose S.] Univ Calif San Diego, Div Pulm & Crit Care Med, San Diego, CA 92103 USA.
   [Reid, Kathryn J.; Zee, Phyllis C.] Northwestern Univ, Dept Neurol, Chicago, IL 60611 USA.
   [Mossavar-Rahmani, Yasmin] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA.
   [Patel, Sanjay R.] Univ Pittsburgh, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA USA.
RP Ramos, AR (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol, 1120 NW 14th St,Ste 1350, Miami, FL 33136 USA.
EM aramos@med.miami.edu
RI Ramos, Alberto/X-4249-2019; Wallace, Douglas/AAL-3719-2020; Petrov,
   Megan/X-1648-2019
OI Petrov, Megan/0000-0001-5443-7548; Patel, Sanjay/0000-0002-9142-5172;
   Mossavar-Rahmani, Yasmin/0000-0002-9214-6124; Wallace,
   Douglas/0000-0002-8982-1088
FU NHLBIUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [HL098297, HL127307, N01-HC65233]; University of Miami
   [N01-HC65234]; Albert Einstein College of Medicine [N01-HC65235];
   Northwestern University [N01-HC65236]; San Diego State University
   [N01-HC65237]; National Center for Advancing Translational
   SciencesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [1KL2TR000461]; National Center for
   Advancing Translational SciencesUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS); National Institute
   on Minority Health and Health DisparitiesUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Minority Health & Health Disparities (NIMHD);
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [KL2TR000461] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND
   BLOOD INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [K24HL127307, R01HL065234, R01HL098297,
   U01HL065233] Funding Source: NIH RePORTER
FX This study was supported by NHLBI [Grants HL098297 and HL127307]. In
   addition, the Hispanic Community Health Study/Study of Latinos was
   carried out as a collaborative study supported by contracts from NHLBI
   to the University of North Carolina [Grant N01-HC65233], University of
   Miami [Grant N01-HC65234], Albert Einstein College of Medicine [Grant
   N01-HC65235], Northwestern University [Grant N01-HC65236], and San Diego
   State University [Grant N01-HC65237]. The project described herein was
   supported specifically by 1KL2TR000461 (ARR), Miami Clinical and
   Translational Science Institute, from the National Center for Advancing
   Translational Sciences and the National Institute on Minority Health and
   Health Disparities.
CR Altman NG, 2012, SLEEP MED, V13, P1261, DOI 10.1016/j.sleep.2012.08.005
   Appleton SL, 2016, CHEST, V150, P495, DOI 10.1016/j.chest.2016.03.010
   Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4
   Cao ZQ, 2014, J HYPERTENS, V32, P1993, DOI 10.1097/HJH.0000000000000291
   Cappuccio FP, 2007, HYPERTENSION, V50, P693, DOI 10.1161/HYPERTENSIONAHA.107.095471
   Cappuccio FP, 2011, EUR HEART J, V32, P1484, DOI 10.1093/eurheartj/ehr007
   Cespedes EM, 2016, AM J EPIDEMIOL, V183, P561, DOI 10.1093/aje/kwv251
   Cheungpasitporn Wisit, 2016, J Evid Based Med, V9, P205, DOI 10.1111/jebm.12211
   Daviglus ML, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.116.003929
   Daviglus ML, 2014, PROG CARDIOVASC DIS, V57, P230, DOI 10.1016/j.pcad.2014.07.006
   Dudley KA, ACTIGRAPHIC SLEEP PA
   Mesas AE, 2010, J AM GERIATR SOC, V58, P1870, DOI 10.1111/j.1532-5415.2010.03071.x
   Faraut B, 2017, SLEEP MED REV, V35, P85, DOI 10.1016/j.smrv.2016.09.002
   Fernandez-Mendoza J, 2012, HYPERTENSION, V60, P929, DOI 10.1161/HYPERTENSIONAHA.112.193268
   Fernandez-Mendoza J, 2012, SLEEP MED, V13, P207, DOI 10.1016/j.sleep.2011.06.019
   Gallicchio L, 2009, J SLEEP RES, V18, P148, DOI 10.1111/j.1365-2869.2008.00732.x
   Gonzalez HM, 2016, AM HEART J, V176, P134, DOI 10.1016/j.ahj.2016.02.008
   Gottlieb DJ, 2006, SLEEP, V29, P1009, DOI 10.1093/sleep/29.8.1009
   Knutson KL, 2009, ARCH INTERN MED, V169, P1055, DOI 10.1001/archinternmed.2009.119
   Lauderdale DS, 2008, EPIDEMIOLOGY, V19, P838, DOI 10.1097/EDE.0b013e318187a7b0
   Lauderdale DS, 2009, AM J EPIDEMIOL, V170, P805, DOI 10.1093/aje/kwp230
   Li Y, 2015, HYPERTENSION, V65, P644, DOI 10.1161/HYPERTENSIONAHA.114.04604
   Loredo JS, 2004, SLEEP, V27, P1097, DOI 10.1093/sleep/27.6.1097
   Loredo JS, 2001, AM J HYPERTENS, V14, P887, DOI 10.1016/S0895-7061(01)02143-4
   Meng L, 2013, HYPERTENS RES, V36, P985, DOI 10.1038/hr.2013.70
   Mossavar-Rahmani Y, J SLEEP RES
   Owens JF, 2010, J CLIN SLEEP MED, V6, P330
   Patel SR, 2015, SLEEP, V38, P1497, DOI 10.5665/sleep.4998
   Patel SR, 2004, SLEEP, V27, P440, DOI 10.1093/sleep/27.3.440
   Pepin JL, 2014, SLEEP MED REV, V18, P509, DOI 10.1016/j.smrv.2014.03.003
   Rasmussen-Torvik LJ, 2016, AM J HYPERTENS, V29, P1353, DOI 10.1093/ajh/hpw093
   Redline S, 2014, AM J RESP CRIT CARE, V189, P335, DOI 10.1164/rccm.201309-1735OC
   Simonelli G, SLEEP
   Sorlie PD, 2014, AM J HYPERTENS, V27, P793, DOI 10.1093/ajh/hpu003
   Sorlie PD, 2010, ANN EPIDEMIOL, V20, P629, DOI 10.1016/j.annepidem.2010.03.015
   St-Onge MP, 2016, CIRCULATION, V134, pE367, DOI 10.1161/CIR.0000000000000444
   Stergiou GS, 2008, HYPERTENS RES, V31, P1859, DOI 10.1291/hypres.31.1859
   Stergiou GS, 1997, J HUM HYPERTENS, V11, P125, DOI 10.1038/sj.jhh.1000383
   Stranges S, 2010, J HYPERTENS, V28, P896, DOI 10.1097/HJH.0b013e328335d076
   Thomas SJ, 2017, J AM SOC HYPERTENS, V11, P122, DOI 10.1016/j.jash.2016.11.008
   Vgontzas AN, 2013, SLEEP MED REV, V17, P241, DOI 10.1016/j.smrv.2012.09.005
   Vgontzas AN, 2009, SLEEP, V32, P491, DOI 10.1093/sleep/32.4.491
   Wang QJ, 2012, HYPERTENS RES, V35, P1012, DOI 10.1038/hr.2012.91
   Zizi F, 2010, CURR DIABETES REP, V10, P43, DOI 10.1007/s11892-009-0082-x
NR 44
TC 35
Z9 36
U1 2
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0012-3692
J9 CHEST
JI Chest
PD JAN
PY 2018
VL 153
IS 1
BP 87
EP 93
DI 10.1016/j.chest.2017.09.028
PG 7
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA FS9XC
UT WOS:000422771600020
PM 28970105
OA Green Published
DA 2021-10-30
ER

PT J
AU Mazumdar, M
   Messinger, S
   Finkelstein, DM
   Goldberg, JD
   Lindsell, CJ
   Morton, SC
   Pollock, BH
   Rahbar, MH
   Welty, LJ
   Parker, RA
AF Mazumdar, Madhu
   Messinger, Shari
   Finkelstein, Dianne M.
   Goldberg, Judith D.
   Lindsell, Christopher J.
   Morton, Sally C.
   Pollock, Brad H.
   Rahbar, Mohammad H.
   Welty, Leah J.
   Parker, Robert A.
CA Biostat Epidemiology Res Design BE
TI Evaluating Academic Scientists Collaborating in Team-Based Research: A
   Proposed Framework
SO ACADEMIC MEDICINE
LA English
DT Article
ID CRITERIA
AB Criteria for evaluating faculty are traditionally based on a triad of scholarship, teaching, and service. Research scholarship is often measured by first or senior authorship on peer-reviewed scientific publications and being principal investigator on extramural grants. Yet scientific innovation increasingly requires collective rather than individual creativity, which traditional measures of achievement were not designed to capture and, thus, devalue. The authors propose a simple, flexible framework for evaluating team scientists that includes both quantitative and qualitative assessments. An approach for documenting contributions of team scientists in team-based scholarship, nontraditional education, and specialized service activities is also outlined. Although biostatisticians are used for illustration, the approach is generalizable to team scientists in other disciplines. The authors offer three key recommendations to members of institutional promotion committees, department chairs, and others evaluating team scientists. First, contributions to team-based scholarship and specialized contributions to education and service need to be assessed and given appropriate and substantial weight. Second, evaluations must be founded on well-articulated criteria for assessing the stature and accomplishments of team scientists. Finally, mechanisms for collecting evaluative data must be developed and implemented at the institutional level. Without these three essentials, contributions of team scientists will continue to be undervalued in the academic environment.
C1 [Mazumdar, Madhu] Weill Cornell Med Coll, Div Biostat & Epidemiol, Dept Publ Hlth, New York, NY USA.
   [Mazumdar, Madhu] Clin & Translat Sci Ctr, Res Design & Biostat Core, New York, NY USA.
   [Messinger, Shari] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Div Biostat, Miami, FL 33136 USA.
   [Messinger, Shari] Miami Clin & Translat Sci Inst, Res Design & Biostat Core, Miami, FL USA.
   [Finkelstein, Dianne M.] Harvard Univ, Sch Med, Med Biostat, Boston, MA USA.
   [Finkelstein, Dianne M.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
   [Finkelstein, Dianne M.] Massachusetts Gen Hosp, Biostat Unit, Boston, MA 02114 USA.
   [Goldberg, Judith D.] NYU, Sch Med, Dept Populat Hlth, Biostat, New York, NY USA.
   [Goldberg, Judith D.] NYU, Sch Med, Dept Environm Med, Biostat, New York, NY USA.
   [Goldberg, Judith D.] NYU HHC Clin & Translat Sci Inst, Study Design Biostat & Clin Res Eth Program, New York, NY USA.
   [Lindsell, Christopher J.] Univ Cincinnati, Dept Emergency Med, Cincinnati, OH USA.
   [Lindsell, Christopher J.] Univ Cincinnati, Coll Med, Clin Res, Cincinnati, OH USA.
   [Lindsell, Christopher J.] Univ Cincinnati, Biostat Epidemiol & Res Design, Ctr Clin & Translat Sci & Training, Cincinnati, OH USA.
   [Morton, Sally C.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA.
   [Morton, Sally C.] Univ Pittsburgh, Comparat Effectiveness Res Core, Clin & Translat Sci Inst, Pittsburgh, PA USA.
   [Pollock, Brad H.] Univ Texas Hlth Sci Ctr San Antonio, Div Clin & Translat Sci, Dept Internal Med, San Antonio, TX 78229 USA.
   [Pollock, Brad H.] Univ Texas Hlth Sci Ctr San Antonio, Biostat Epidemiol & Res Design, San Antonio, TX 78229 USA.
   [Pollock, Brad H.] Univ Texas Hlth Sci Ctr San Antonio, Inst Integrat Med & Sci, San Antonio, TX 78229 USA.
   [Rahbar, Mohammad H.] Univ Texas Houston, Dept Internal Med, Div Clin & Translat Sci, Sch Publ Hlth, Houston, TX USA.
   [Rahbar, Mohammad H.] Univ Texas Houston, Div Epidemiol Human Genet & Environm Sci, Sch Publ Hlth, Houston, TX USA.
   [Rahbar, Mohammad H.] Univ Texas Hlth Sci Ctr Houston, Biostat Epidemiol & Res Design, Ctr Clin & Translat Sci, Houston, TX 77030 USA.
   [Welty, Leah J.] Northwestern Univ, Dept Prevent Med, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Parker, Robert A.] Univ Michigan, Dept Biostat, Biostat, Ann Arbor, MI 48109 USA.
   [Parker, Robert A.] Michigan Inst Clin & Hlth Res, Biostat Epidemiol & Res Design Core, Ann Arbor, MI USA.
RP Mazumdar, M (corresponding author), Icahn Sch Med Mt Sinai, Inst Healthcare Delivery Sci, Dept Populat Hlth Sci & Policy, 1425 Madison Ave,Room L2-70L, New York, NY 10029 USA.
EM madhu.mazumdar@mssm.edu
OI Kopras, Elizabeth/0000-0001-5429-2609; Goldberg, Judith
   D./0000-0003-3758-6976; Nietert, Paul/0000-0002-3933-4986; Oster,
   Robert/0000-0002-2247-8596
FU NATIONAL CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [P30CA016087] Funding Source: NIH RePORTER; NATIONAL
   CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000423, UL1TR000038, UL1TR000101, UL1TR000445, UL1TR000001,
   UL1TR001102, UL1TR000433, UL1TR001111, UL1TR002240, UL1TR000149,
   UL1TR001120, UL1TR001117, UL1TR000005, UL1TR000077, UL1TR000371,
   UL1TR000062, UL1TR000135, UL1TR000071, UL1TR000460, UL1TR000165,
   UL1TR002319, UL1TR001422, UL1TR000457, UL1TR001450, UL1TR001417] Funding
   Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Research Resources (NCRR)
   [UL1RR031982, UL1RR025767, UL1RR024153, UL1RR031975] Funding Source: NIH
   RePORTER; NCATS NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [UL1TR000062, UL1 TR000457, UL1
   TR000423, UL1TR000460, UL1 TR000005, UL1 TR000433, UL1 TR001102, UL1
   TR002240, UL1TR001117, UL1 TR000038, UL1 TR002319, UL1TR000371, UL1
   TR001111, UL1 TR000445, UL1 TR000371, UL1TR000071, UL1 TR000165, UL1
   TR000135, UL1TR000433, UL1 TR001422, UL1 TR000077, UL1 TR000001,
   UL1TR000038, UL1 TR000071, UL1 TR001417, UL1 TR000101, 2UL1 TR000457-06,
   UL1 TR000062, UL1 TR001120, UL1 TR001450, UL1 TR000149, UL1 TR000460,
   UL1TR000101] Funding Source: Medline; NCI NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI) [P30 CA016087] Funding Source:
   Medline; NCRR NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Research Resources (NCRR) [UL1RR031982, UL1 RR024153, UL1RR024153, UL1
   RR031975, UL1RR025767, UL1RR031975, UL1 RR025767, UL1 RR031982] Funding
   Source: Medline; PHS HHSUnited States Department of Health & Human
   ServicesUnited States Public Health Service [ULT1R000150] Funding
   Source: Medline
CR Benedyk M, 2009, J INVEST MED, V57, P477, DOI 10.2310/JIM.0b013e31819824be
   Bennett L. M, 2010, NIH PUBLICATION
   Bunton S, 2014, COMMUNICATION
   Deutsch R, 2007, STAT MED, V26, P709, DOI 10.1002/sim.2571
   [Gillings School of Global Public Health University of North Carolina Department of Biostatistics], 2013, GUID PROM TEN
   Gusic ME, 2014, ACAD MED, V89, P1006, DOI 10.1097/ACM.0000000000000233
   Jones M, 2013, MIDDLE AUTHOR PUBLIC
   King C, 2012, SCIENCEWATCH NEW JUL
   Mann S., 2013, AAMC REPORTER    JAN
   Parker RA, 1998, STAT MED, V17, P2289, DOI 10.1002/(SICI)1097-0258(19981030)17:20<2289::AID-SIM931>3.0.CO;2-L
   Pfirman SL, 2005, THRIVE PROSPER HIRIN
   Rikakis T., 2014, COMMUNICATION
   Rikakis T, 2009, 39 AM SOC ENG ED I E
   Simpson D, 2004, ACAD MED, V79, P783, DOI 10.1097/00001888-200408000-00014
NR 14
TC 21
Z9 21
U1 3
U2 16
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-2446
EI 1938-808X
J9 ACAD MED
JI Acad. Med.
PD OCT
PY 2015
VL 90
IS 10
BP 1302
EP 1308
DI 10.1097/ACM.0000000000000759
PG 7
WC Education, Scientific Disciplines; Health Care Sciences & Services
SC Education & Educational Research; Health Care Sciences & Services
GA DD0FI
UT WOS:000369595400014
PM 25993282
OA Green Accepted, Bronze
DA 2021-10-30
ER

PT J
AU Petrov, ME
   Weng, J
   Reid, KJ
   Wang, R
   Ramos, AR
   Wallace, DM
   Alcantara, C
   Cai, JW
   Perreira, K
   Giacinto, RAE
   Zee, PC
   Sotres-Alvarez, D
   Patel, SR
AF Petrov, Megan E.
   Weng, Jia
   Reid, Kathryn J.
   Wang, Rui
   Ramos, Alberto R.
   Wallace, Douglas M.
   Alcantara, Carmela
   Cai, Jianwen
   Perreira, Krista
   Giacinto, Rebeca A. Espinoza
   Zee, Phyllis C.
   Sotres-Alvarez, Daniela
   Patel, Sanjay R.
TI Commuting and Sleep: Results From the Hispanic Community Health
   Study/Study of Latinos Sueno Ancillary Study
SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE
LA English
DT Article
ID TIME USE SURVEY; WAKING ACTIVITIES; UNITED-STATES; OLDER-ADULTS;
   RISK-FACTORS; DURATION; ACTIGRAPHY; METAANALYSIS; PATTERNS; DISTANCE
AB Introduction: Commute time is associated with reduced sleep time, but previous studies have relied on self-reported sleep assessment. The present study investigated the relationships between commute time for employment and objective sleep patterns among non-shift working U.S. Hispanic/Latino adults.
   Methods: From 2010 to 2013, Hispanic/Latino employed, non-shift-working adults (n=760, aged 18-64 years) from the Sueno study, ancillary to the Hispanic Community Health Study/Study of Latinos, reported their total daily commute time to and from work, completed questionnaires on sleep and other health behaviors, and wore wrist actigraphs to record sleep duration, continuity, and variability for 1 week. Survey linear regression models of the actigraphic and self-reported sleep measures regressed on categorized commute time (short: 1-44 minutes; moderate: 45-89 minutes; long: >= 90 minutes) were built adjusting for relevant covariates. For associations that suggested a linear relationship, continuous commute time was modeled as the exposure. Moderation effects by age, sex, income, and depressive symptoms also were explored.
   Results: Commute time was linearly related to sleep duration on work days such that each additional hour of commute time conferred 15 minutes of sleep loss (p=0.01). Compared with short commutes, individuals with moderate commutes had greater sleep duration variability (p=0.04) and lower interdaily stability (p=0.046, a measure of sleep/wake schedule regularity). No significant associations were detected for self-reported sleep measures.
   Conclusions: Commute time is significantly associated with actigraphy-measured sleep duration and regularity among Hispanic/Latino adults. Interventions to shorten commute times should be evaluated to help improve sleep habits in this minority population. (C) 2017 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.
C1 [Petrov, Megan E.] Arizona State Univ, Coll Nursing & Hlth Innovat, 500 N 3rd St, Phoenix, AZ 85044 USA.
   [Weng, Jia; Wang, Rui] Brigham & Womens Hosp, Div Sleep & Circadian Disorders, 75 Francis St, Boston, MA 02115 USA.
   [Reid, Kathryn J.; Zee, Phyllis C.] Northwestern Univ, Dept Neurol, Chicago, IL 60611 USA.
   [Wang, Rui] Harvard Med Sch, Dept Populat Med, Boston, MA USA.
   [Wang, Rui] Harvard Pilgrim Hlth Care Inst, Boston, MA USA.
   [Ramos, Alberto R.; Wallace, Douglas M.] Univ Miami, Dept Neurol, Miami, FL USA.
   [Alcantara, Carmela] Columbia Univ, Sch Social Work, New York, NY USA.
   [Cai, Jianwen; Sotres-Alvarez, Daniela] Univ N Carolina, Dept Biostat, Collaborat Studies Coordinating Ctr, Chapel Hill, NC USA.
   [Perreira, Krista] Univ N Carolina, Dept Hlth Policy Management, Chapel Hill, NC USA.
   [Giacinto, Rebeca A. Espinoza] San Diego State Univ, Sch Publ Hlth, San Diego, CA 92182 USA.
   [Patel, Sanjay R.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.
RP Petrov, ME (corresponding author), Arizona State Univ, Coll Nursing & Hlth Innovat, 500 N 3rd St, Phoenix, AZ 85044 USA.
EM megan.petrov@asu.edu
RI Ramos, Alberto/X-4249-2019; Wang, Rui/X-1699-2019; Wallace,
   Douglas/AAL-3719-2020; Petrov, Megan/X-1648-2019
OI Petrov, Megan/0000-0001-5443-7548; Wallace, Douglas/0000-0002-8982-1088;
   Patel, Sanjay/0000-0002-9142-5172
FU National Heart, Lung, and Blood Institute (NHLBI)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [HL098297,
   HL127307]; NHLBIUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [N01-HC65233, N01-HC65234, N01-HC65235,
   N01-HC65236, N01-HC65237]; NHLBI: National Institute on Minority Health
   and Health Disparities; National Institute on Deafness and Other
   Communication DisordersUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Deafness & Other Communication Disorders (NIDCD); National Institute
   of Dental and Craniofacial ResearchUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Dental & Craniofacial Research (NIDCR); National Institute
   of Diabetes and Digestive and Kidney DiseasesUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK);
   National Institute of Neurological Disorders and StrokeUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Neurological Disorders & Stroke (NINDS);
   NIH Institution-Office of Dietary Supplements; National Institute on
   Minority Health and Health Disparities of the NIH [P20 MD002316]; EUNICE
   KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN
   DEVELOPMENTUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD) [P2CHD050924]
   Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [KL2TR000461] Funding Source:
   NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [K23HL125748,
   R01HL098297, K24HL127307] Funding Source: NIH RePORTER; National
   Institute on Minority Health and Health DisparitiesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Minority Health & Health Disparities
   (NIMHD) [P20MD002316] Funding Source: NIH RePORTER
FX This work was supported by HL098297 and HL127307 from the National
   Heart, Lung, and Blood Institute (NHLBI). In addition, the Hispanic
   Community Health Study/Study of Latinos was carried out as a
   collaborative study supported by contracts from the NHLBI to the
   University of North Carolina (N01-HC65233), University of Miami
   (N01-HC65234), Albert Einstein College of Medicine (N01-HC65235),
   Northwestern University (N01-HC65236), and San Diego State University
   (N01-HC65237). The following Institutes/Centers/Offices contribute to
   the Hispanic Community Health Study/Study of Latinos through a transfer
   of funds to the NHLBI: National Institute on Minority Health and Health
   Disparities, National Institute on Deafness and Other Communication
   Disorders, National Institute of Dental and Craniofacial Research,
   National Institute of Diabetes and Digestive and Kidney Diseases,
   National Institute of Neurological Disorders and Stroke, NIH
   Institution-Office of Dietary Supplements. Dr. Petrov would like to
   acknowledge that research assistance for data analysis and manuscript
   development was supported by training funds from the National Institute
   on Minority Health and Health Disparities of the NIH, award P20 MD002316
   (F. Marsiglia, PI). The content is solely the responsibility of the
   authors and does not necessarily represent the official views of the
   National Institute on Minority Health and Health Disparities or the NIH.
CR ANDRESEN EM, 1994, AM J PREV MED, V10, P77, DOI 10.1016/S0749-3797(18)30622-6
   Ari LL, 2013, BIOL RHYTHM RES, V44, P353, DOI 10.1080/09291016.2012.692251
   Baron KG, 2011, OBESITY, V19, P1374, DOI 10.1038/oby.2011.100
   Basner M, 2007, SLEEP, V30, P1085, DOI 10.1093/sleep/30.9.1085
   Basner M, 2014, SLEEP, V37, P1889, DOI 10.5665/sleep.4238
   Basner M, 2009, SLEEP, V32, P747, DOI 10.1093/sleep/32.6.747
   Bei B, 2016, SLEEP MED REV, V28, P108, DOI 10.1016/j.smrv.2015.06.003
   Biggs SN, 2007, J PSYCHOSOM RES, V63, P573, DOI 10.1016/j.jpsychores.2007.06.017
   Buman MP, 2015, CHEST, V147, P728, DOI 10.1378/chest.14-1187
   Buman MP, 2014, AM J EPIDEMIOL, V179, P323, DOI 10.1093/aje/kwt292
   Cappuccio FP, 2011, EUR HEART J, V32, P1484, DOI 10.1093/eurheartj/ehr007
   Cespedes EM, 2016, AM J EPIDEMIOL, V183, P561, DOI 10.1093/aje/kwv251
   Chatzitheochari S, 2009, WORK EMPLOY SOC, V23, P30, DOI 10.1177/0950017008099776
   Chiuve SE, 2006, CIRCULATION, V114, P160, DOI 10.1161/CIRCULATIONAHA.106.621417
   Christian TJ, 2012, J URBAN HEALTH, V89, P746, DOI 10.1007/s11524-012-9678-6
   Daviglus ML, 2012, JAMA-J AM MED ASSOC, V308, P1775, DOI 10.1001/jama.2012.14517
   Ding D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094602
   Dudley KA, 2017, SLEEP, V40, DOI 10.1093/sleep/zsw049
   Friswell R, 2008, ACCIDENT ANAL PREV, V40, P410, DOI 10.1016/j.aap.2007.07.009
   Grandner MA, 2010, SLEEP MED REV, V14, P191, DOI 10.1016/j.smrv.2009.07.006
   Hale L, 2007, SLEEP, V30, P1096, DOI 10.1093/sleep/30.9.1096
   Hale L, 2014, SLEEP, V37, P1879, DOI 10.5665/sleep.4228
   Hansson E, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-834
   Hirshkowitz M, 2015, SLEEP HEALTH, V1, P40, DOI 10.1016/j.sleh.2014.12.010
   Hoehner CM, 2012, AM J PREV MED, V42, P571, DOI 10.1016/j.amepre.2012.02.020
   Hu Y., 2017, PAP APPL GEOGR, DOI [10.1080/23754931.2016.1248577, DOI 10.1080/23754931.2016.1248577]
   JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540
   Kim M, 2015, J SLEEP RES, V24, P639, DOI [10.1111/jsr.12326, 10.7735/ksmte.2015.24.6.639]
   Knutson KL, 2010, SLEEP, V33, P37, DOI 10.1093/sleep/33.1.37
   Lauderdale DS, 2008, EPIDEMIOLOGY, V19, P838, DOI 10.1097/EDE.0b013e318187a7b0
   Lavange LM, 2010, ANN EPIDEMIOL, V20, P642, DOI 10.1016/j.annepidem.2010.05.006
   Loef M, 2012, PREV MED, V55, P163, DOI 10.1016/j.ypmed.2012.06.017
   Marino M, 2013, SLEEP, V36, P1747, DOI 10.5665/sleep.3142
   Marucci-Wellman HR, 2014, AM J PUBLIC HEALTH, V104, P1488, DOI 10.2105/AJPH.2014.301921
   McKenzie B, 2011, COMMUTING US 2009
   Morin C.M., 1993, INSOMNIA PSYCHOL ASS
   Niedzielski MA, 2014, ANN ASSOC AM GEOGR, V104, P1156, DOI 10.1080/00045608.2014.958398
   Ogilvie RP, 2016, SLEEP, V39, P1701, DOI 10.5665/sleep.6096
   Okun ML, 2011, PSYCHOSOM MED, V73, P142, DOI 10.1097/PSY.0b013e3182020d08
   Patel SR, 2014, INT J OBESITY, V38, P1159, DOI 10.1038/ijo.2014.13
   Patel SR, 2008, OBESITY, V16, P643, DOI 10.1038/oby.2007.118
   Patel SR, 2015, SLEEP, V38, P1497, DOI 10.5665/sleep.4998
   Philip P, 1999, SLEEP, V22, P475, DOI 10.1093/sleep/22.4.475
   Philip P, 2006, SLEEP MED REV, V10, P347, DOI 10.1016/j.smrv.2006.04.002
   Philip P, 2006, ANN INTERN MED, V144, P785, DOI 10.7326/0003-4819-144-11-200606060-00004
   Sadeh A, 2004, HEALTH PSYCHOL, V23, P542, DOI 10.1037/0278-6133.23.5.542
   Sadeh A, 2011, SLEEP MED REV, V15, P259, DOI 10.1016/j.smrv.2010.10.001
   Savard MH, 2005, PSYCHO-ONCOLOGY, V14, P429, DOI 10.1002/pon.860
   Sorlie PD, 2010, ANN EPIDEMIOL, V20, P629, DOI 10.1016/j.annepidem.2010.03.015
   Spielberger CD, 1983, MANUAL STATE TRAIT A
   Sultana S, 2007, PROF GEOGR, V59, P193, DOI 10.1111/j.1467-9272.2007.00607.x
   Van Someren EJW, 1999, CHRONOBIOL INT, V16, P505, DOI 10.3109/07420529908998724
   Walsleben JA, 1999, SLEEP, V22, P728, DOI 10.1093/sleep/22.6.728
   Wang FH, 2001, ENVIRON PLANN B, V28, P169, DOI 10.1068/b2710
   Watson NF, 2015, J CLIN SLEEP MED, V11, P591, DOI 10.5664/jcsm.4758
   Wu YL, 2014, SLEEP MED, V15, P1456, DOI 10.1016/j.sleep.2014.07.018
NR 56
TC 11
Z9 12
U1 0
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0749-3797
EI 1873-2607
J9 AM J PREV MED
JI Am. J. Prev. Med.
PD MAR
PY 2018
VL 54
IS 3
BP E49
EP E57
DI 10.1016/j.amepre.2017.11.006
PG 9
WC Public, Environmental & Occupational Health; Medicine, General &
   Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA FW4QC
UT WOS:000425297700002
PM 29338957
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Simonelli, G
   Dudley, KA
   Weng, J
   Gallo, LC
   Perreira, K
   Shah, NA
   Alcantara, C
   Zee, PC
   Ramos, AR
   Llabre, MM
   Sotres-Alvarez, D
   Wang, R
   Patel, SR
AF Simonelli, Guido
   Dudley, Katherine A.
   Weng, Jia
   Gallo, Linda C.
   Perreira, Krista
   Shah, Neomi A.
   Alcantara, Carmela
   Zee, Phyllis C.
   Ramos, Alberto R.
   Llabre, Maria M.
   Sotres-Alvarez, Daniela
   Wang, Rui
   Patel, Sanjay R.
TI Neighborhood Factors as Predictors of Poor Sleep in the Sueno Ancillary
   Study of the Hispanic Community Health Study/Study of Latinos
SO SLEEP
LA English
DT Article
DE sleep; insomnia; neighborhood; safety; noise; actigraphy
ID ROAD TRAFFIC NOISE; INSOMNIA SEVERITY INDEX; PSYCHOLOGICAL DISTRESS;
   DEPRESSIVE SYMPTOMS; DIVERSE BACKGROUNDS; ANXIETY DISORDERS;
   RISK-FACTORS; SHORT-FORM; DURATION; ADULTS
AB Study Objectives: To evaluate whether an adverse neighborhood environment has higher prevalence of poor sleep in a US Hispanic/Latino population.
   Methods: A cross-sectional analysis was performed in 2156 US Hispanic/Latino participants aged 18-64 years from the Sueno ancillary study of the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). Participants completed surveys of neighborhood environment including perceived safety, violence and noise, the Insomnia Severity Index (ISI), and 7 days of wrist actigraphy.
   Results: In age and sex-adjusted analyses, short sleep, low sleep efficiency, and late sleep midpoint were all more prevalent among those living in an unsafe neighborhood. After adjustment for background, site, nativity, income, employment, depressive symptoms, and sleep apnea, the absolute risk of sleeping < 6 hours was 7.7 (95% CI [0.9, 14.6]) percentage points greater in those living in an unsafe compared to a safe neighborhood. There were no differences in the prevalence of insomnia by level of safety or violence. Insomnia was more prevalent among those living in a noisy neighborhood. In adjusted analysis, the absolute risk of insomnia was 4.4 (95% CI [0.4, 8.4]) percentage points greater in those living in noisy compared to non-noisy neighborhoods.
   Conclusion: Using validated measures of sleep duration and insomnia, we have demonstrated the existence of a higher prevalence of short sleep and insomnia by adverse neighborhood factors. An adverse neighborhood environment is an established risk factor for a variety of poor health outcomes. Our findings suggest negative effects on sleep may represent one pathway by which neighborhood environment influences health.
C1 [Simonelli, Guido] Walter Reed Army Inst Res, Behav Biol Branch, Silver Spring, MD USA.
   [Dudley, Katherine A.] Beth Israel Deaconess Med Ctr, Div Pulm Crit Care & Sleep Med, Boston, MA 02215 USA.
   [Weng, Jia; Wang, Rui] Brigham & Womens Hosp, Div Sleep & Circadian Disorders, 75 Francis St, Boston, MA 02115 USA.
   [Gallo, Linda C.] San Diego State Univ, Dept Psychol, San Diego, CA 92182 USA.
   [Perreira, Krista] Univ N Carolina, Dept Publ Policy, Chapel Hill, NC USA.
   [Shah, Neomi A.] Icahn Sch Med Mt Sinai, Div Pulm Crit Care & Sleep, New York, NY 10029 USA.
   [Alcantara, Carmela] Columbia Univ, Sch Social Work, New York, NY USA.
   [Zee, Phyllis C.] Northwestern Univ, Feinberg Sch Med, Ctr Circadian & Sleep Med, Evanston, IL USA.
   [Ramos, Alberto R.] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA.
   [Llabre, Maria M.] Univ Miami, Dept Psychol, POB 248185, Coral Gables, FL 33124 USA.
   [Sotres-Alvarez, Daniela] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Biostat, Collaborat Studies Coordinating Ctr, Chapel Hill, NC USA.
   [Patel, Sanjay R.] Univ Pittsburgh, Div Pulm Allergy & Crit Care Med, NW MUH 628,3459 Fifth Ave, Pittsburgh, PA 15213 USA.
RP Patel, SR (corresponding author), Univ Pittsburgh, Div Pulm Allergy & Crit Care Med, NW MUH 628,3459 Fifth Ave, Pittsburgh, PA 15213 USA.
EM patelsr2@upmc.edu
RI Wang, Rui/X-1699-2019; Ramos, Alberto/X-4249-2019
OI Patel, Sanjay/0000-0002-9142-5172; Gallo, Linda C./0000-0002-3678-5888
FU National Heart, Lung, and Blood Institute (NHLBI)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [HL098297,
   HL127307]; NHLBIUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [N01-HC65233]; University of Miami
   [N01-HC65234]; Albert Einstein College of Medicine [N01-HC65235];
   Northwestern University [N01-HC65236]; San Diego State University
   [N01-HC65237]; NHLBI: National Center on Minority Health and Health
   DisparitiesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Minority
   Health & Health Disparities (NIMHD); National Institute of Deafness and
   Other Communications DisordersUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Deafness & Other Communication Disorders (NIDCD); National Institute
   of Dental and Craniofacial ResearchUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Dental & Craniofacial Research (NIDCR); National Institute
   of Diabetes and Digestive and Kidney DiseasesUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK);
   National Institute of Neurological Disorders and StrokeUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Neurological Disorders & Stroke (NINDS);
   Office of Dietary SupplementsUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA; EUNICE KENNEDY
   SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child
   Health & Human Development (NICHD) [P2CHD050924] Funding Source: NIH
   RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Advancing Translational
   Sciences (NCATS) [KL2TR000461] Funding Source: NIH RePORTER; NATIONAL
   HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Heart Lung & Blood Institute (NHLBI) [U01HL065233, K23HL125748,
   R01HL065234, K24HL127307, R01HL098297, K23HL125923] Funding Source: NIH
   RePORTER
FX This work was supported by National Heart, Lung, and Blood Institute
   (NHLBI) (HL098297) and (HL127307). In addition, HCHS/SOL was carried out
   as a collaborative study supported by contracts from NHLBI to the
   University of North Carolina (N01-HC65233), University of Miami
   (N01-HC65234), Albert Einstein College of Medicine (N01-HC65235),
   Northwestern University (N01-HC65236), and San Diego State University
   (N01-HC65237). The following Institutes/Centers/Offices contribute to
   the HCHS/SOL through a transfer of funds to the NHLBI: National Center
   on Minority Health and Health Disparities, the National Institute of
   Deafness and Other Communications Disorders, the National Institute of
   Dental and Craniofacial Research, the National Institute of Diabetes and
   Digestive and Kidney Diseases, the National Institute of Neurological
   Disorders and Stroke, and the Office of Dietary Supplements.
CR Agyemang C, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-118
   Akerstedt T, 2006, SCAND J WORK ENV HEA, V32, P493, DOI 10.5271/sjweh.1054
   Alegria M, 2014, DEPRESS ANXIETY, V31, P27, DOI 10.1002/da.22197
   ANDRESEN EM, 1994, AM J PREV MED, V10, P77, DOI 10.1016/S0749-3797(18)30622-6
   Astell-Burt T, 2015, SOC SCI MED, V138, P68, DOI 10.1016/j.socscimed.2015.05.014
   Barregard L, 2009, OCCUP ENVIRON MED, V66, P410, DOI 10.1136/oem.2008.042804
   Basner M, 2011, SLEEP, V34, P11, DOI 10.1093/sleep/34.1.11
   Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4
   Billings ME, 2016, CHEST, V150, P1042, DOI 10.1016/j.chest.2016.06.012
   Bishaw A, 2011, AREAS CONCENTRATED P
   Bluhm GL, 2007, OCCUP ENVIRON MED, V64, P122, DOI 10.1136/oem.2005.025866
   Bocquier A, 2014, EUR J PUBLIC HEALTH, V24, P298, DOI 10.1093/eurpub/ckt117
   Bodin T, 2009, ENVIRON HEALTH-GLOB, V8, DOI 10.1186/1476-069X-8-38
   Cappuccio FP, 2011, EUR HEART J, V32, P1484, DOI 10.1093/eurheartj/ehr007
   CARSKADON MA, 1976, AM J PSYCHIAT, V133, P1382
   Cespedes EM, 2016, AM J EPIDEMIOL, V183, P561, DOI 10.1093/aje/kwv251
   Chambers EC, 2016, BEHAV SLEEP MED, V14, P169, DOI 10.1080/15402002.2014.974180
   Chen XL, 2015, SLEEP, V38, P877, DOI 10.5665/sleep.4732
   Chen-Edinboro LP, 2015, INT PSYCHOGERIATR, V27, P289, DOI 10.1017/S1041610214001823
   Colten HR, 2006, NATL ACAD COLLECTION
   Daviglus ML, 2012, JAMA-J AM MED ASSOC, V308, P1775, DOI 10.1001/jama.2012.14517
   De Jesus M, 2010, HEALTH PLACE, V16, P1007, DOI 10.1016/j.healthplace.2010.06.005
   de Kluizenaar Y, 2009, J ACOUST SOC AM, V126, P626, DOI 10.1121/1.3158834
   DeSantis AS, 2013, SLEEP, V36, P1543, DOI 10.5665/sleep.3054
   Echeverria SE, 2004, J URBAN HEALTH, V81, P682, DOI 10.1093/jurban/jth151
   Ellaway A, 2005, BMJ-BRIT MED J, V331, P611, DOI 10.1136/bmj.38575.664549.F7
   Fernandez-Mendoza J, 2012, SLEEP MED, V13, P207, DOI 10.1016/j.sleep.2011.06.019
   Gangwisch JE, 2010, AM J HYPERTENS, V23, P62, DOI 10.1038/ajh.2009.202
   Glozier N, 2010, SLEEP, V33, P1139, DOI 10.1093/sleep/33.9.1139
   Grzywacz JG, 2006, HISPANIC J BEHAV SCI, V28, P404, DOI 10.1177/0739986306290645
   Hale L, 2013, SOC SCI MED, V79, P16, DOI 10.1016/j.socscimed.2012.07.021
   Hale L, 2010, PREV MED, V51, P275, DOI 10.1016/j.ypmed.2010.06.017
   Halonen JI, 2012, ENVIRON HEALTH PERSP, V120, P1391, DOI 10.1289/ehp.1205026
   Harris M, 2009, SLEEP MED REV, V13, P437, DOI 10.1016/j.smrv.2009.04.001
   Hellevik O, 2009, QUAL QUANT, V43, P59, DOI 10.1007/s11135-007-9077-3
   Hill TD, 2016, SLEEP MED, V18, P56, DOI 10.1016/j.sleep.2014.12.003
   Hill TD, 2009, HEALTH PLACE, V15, P1006, DOI 10.1016/j.healthplace.2009.04.001
   Jackson CL, 2014, SOC SCI MED, V118, P71, DOI 10.1016/j.socscimed.2014.07.059
   Johnson DA, 2015, SLEEP HEALTH, V1, P148, DOI 10.1016/j.sleh.2015.06.002
   Johnson SL, 2009, J URBAN HEALTH, V86, P538, DOI 10.1007/s11524-009-9345-8
   Kawachi I., 2003, NEIGHBOURHOODS HLTH
   Kim M, 2012, AM J PREV MED, V43, P353, DOI 10.1016/j.amepre.2012.06.014
   Kushida CA, 2001, SLEEP MED, V2, P389, DOI 10.1016/S1389-9457(00)00098-8
   Lauderdale DS, 2009, AM J EPIDEMIOL, V170, P805, DOI 10.1093/aje/kwp230
   Leal C, 2011, OBES REV, V12, P217, DOI 10.1111/j.1467-789X.2010.00726.x
   Li RHY, 2002, J PSYCHOSOM RES, V53, P601, DOI 10.1016/S0022-3999(02)00437-3
   Marino M, 2013, SLEEP, V36, P1747, DOI 10.5665/sleep.3142
   Matheson FI, 2006, SOC SCI MED, V63, P2604, DOI 10.1016/j.socscimed.2006.07.001
   McGinn AP, 2008, J PHYS ACT HEALTH, V5, P117, DOI 10.1123/jpah.5.1.117
   Michaud DS, 2016, SLEEP, V39, P97, DOI 10.5665/sleep.5326
   Morin CM, 2011, SLEEP, V34, P601, DOI 10.1093/sleep/34.5.601
   Morin CM, 1999, JAMA-J AM MED ASSOC, V281, P991, DOI 10.1001/jama.281.11.991
   Mujahid MS, 2008, EPIDEMIOLOGY, V19, P590, DOI 10.1097/EDE.0b013e3181772cb2
   Mujahid MS, 2008, AM J EPIDEMIOL, V167, P1349, DOI 10.1093/aje/kwn047
   Mujahid MS, 2007, AM J EPIDEMIOL, V165, P858, DOI 10.1093/aje/kwm040
   Ohayon MM, 2016, SLEEP, V39, P1311, DOI 10.5665/sleep.5860
   Orban E, 2016, ENVIRON HEALTH PERSP, V124, P578, DOI 10.1289/ehp.1409400
   Paquet J, 2007, SLEEP, V30, P1362, DOI 10.1093/sleep/30.10.1362
   Patel SR, 2008, OBESITY, V16, P643, DOI 10.1038/oby.2007.118
   Patel SR, 2015, SLEEP, V38, P1497, DOI 10.5665/sleep.4998
   Pirrera S, 2014, SCI TOTAL ENVIRON, V500, P84, DOI 10.1016/j.scitotenv.2014.08.061
   Pirrera S, 2010, ENVIRON INT, V36, P492, DOI 10.1016/j.envint.2010.03.007
   Putrik P, 2015, J COMMUN HEALTH, V40, P47, DOI 10.1007/s10900-014-9894-y
   Redline S, 2014, AM J RESP CRIT CARE, V189, P335, DOI 10.1164/rccm.201309-1735OC
   SCHACHTER FF, 1989, PEDIATRICS, V84, P522
   Schootman M, 2007, AM J EPIDEMIOL, V166, P379, DOI 10.1093/aje/kwm190
   Simonelli G, 2015, SLEEP HEALTH, V1, P98, DOI 10.1016/j.sleh.2015.02.006
   Simonelli G, 2013, SLEEP, V36, P1669, DOI 10.5665/sleep.3124
   Smith Sean M, 2006, Dialogues Clin Neurosci, V8, P383
   Soehner AM, 2012, SLEEP, V35, P1367, DOI 10.5665/sleep.2116
   Sofi F, 2014, EUR J PREV CARDIOL, V21, P57, DOI 10.1177/2047487312460020
   Sorlie PD, 2010, ANN EPIDEMIOL, V20, P629, DOI 10.1016/j.annepidem.2010.03.015
   Steptoe A, 2008, J PSYCHOSOM RES, V64, P409, DOI 10.1016/j.jpsychores.2007.11.008
   Tobias A, 2015, EUR J PREV CARDIOL, V22, P496, DOI 10.1177/2047487314528108
   Tobias A, 2015, ACTA DIABETOL, V52, P187, DOI 10.1007/s00592-014-0593-z
   Vgontzas AN, 2008, INT J OBESITY, V32, P801, DOI 10.1038/ijo.2008.4
   VOLLRATH M, 1989, EUR ARCH PSY CLIN N, V239, P113, DOI 10.1007/BF01759584
   Wu YN, 2013, RACE JUSTICE, V3, P339, DOI 10.1177/2153368713508191
   Zanobetti A, 2010, AM J RESP CRIT CARE, V182, P819, DOI 10.1164/rccm.200912-1797OC
   Zhai L, 2015, DEPRESS ANXIETY, V32, P664, DOI 10.1002/da.22386
NR 80
TC 20
Z9 20
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0161-8105
EI 1550-9109
J9 SLEEP
JI Sleep
PD JAN 1
PY 2017
VL 40
IS 1
AR zsw025
DI 10.1093/sleep/zsw025
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA EK7SO
UT WOS:000394125700025
PM 28364454
OA Green Published, Bronze, Green Submitted
DA 2021-10-30
ER

PT J
AU McCormack, RM
   de Armas, LR
   Shiratsuchi, M
   Fiorentino, DG
   Olsson, ML
   Lichtenheld, MG
   Morales, A
   Lyapichev, K
   Gonzalez, LE
   Strbo, N
   Sukumar, N
   Stojadinovic, O
   Plano, GV
   Munson, GP
   Tomic-Canic, M
   Kirsner, RS
   Russell, DG
   Podack, ER
AF McCormack, Ryan M.
   de Armas, Lesley R.
   Shiratsuchi, Motoaki
   Fiorentino, Desiree G.
   Olsson, Melissa L.
   Lichtenheld, Mathias G.
   Morales, Alejo
   Lyapichev, Kirill
   Gonzalez, Louis E.
   Strbo, Natasa
   Sukumar, Neelima
   Stojadinovic, Olivera
   Plano, Gregory V.
   Munson, George P.
   Tomic-Canic, Marjana
   Kirsner, Robert S.
   Russell, David G.
   Podack, Eckhard R.
TI Perforin-2 is essential for intracellular defense of parenchymal cells
   and phagocytes against pathogenic bacteria
SO ELIFE
LA English
DT Article
ID ENTERICA SEROVAR TYPHIMURIUM; NITRIC-OXIDE; STAPHYLOCOCCUS-AUREUS;
   MEMBRANE-ATTACK; SALMONELLA-TYPHIMURIUM; PROTECTS SALMONELLA; HUMAN
   KERATINOCYTES; MOLECULAR-CLONING; MUCOSAL BARRIER; NADPH-OXIDASE
AB Perforin-2 (MPEG1) is a pore-forming, antibacterial protein with broad-spectrum activity. Perforin-2 is expressed constitutively in phagocytes and inducibly in parenchymal, tissue-forming cells. In vitro, Perforin-2 prevents the intracellular replication and proliferation of bacterial pathogens in these cells. Perforin-2 knockout mice are unable to control the systemic dissemination of methicillin-resistant Staphylococcus aureus (MRSA) or Salmonella typhimurium and perish shortly after epicutaneous or orogastric infection respectively. In contrast, Perforin-2-sufficient littermates clear the infection. Perforin-2 is a transmembrane protein of cytosolic vesicles -derived from multiple organelles-that translocate to and fuse with bacterium containing vesicles. Subsequently, Perforin-2 polymerizes and forms large clusters of 100 angstrom pores in the bacterial surface with Perforin-2 cleavage products present in bacteria. Perforin-2 is also required for the bactericidal activity of reactive oxygen and nitrogen species and hydrolytic enzymes. Perforin-2 constitutes a novel and apparently essential bactericidal effector molecule of the innate immune system.
C1 [McCormack, Ryan M.; de Armas, Lesley R.; Shiratsuchi, Motoaki; Fiorentino, Desiree G.; Olsson, Melissa L.; Lichtenheld, Mathias G.; Morales, Alejo; Lyapichev, Kirill; Gonzalez, Louis E.; Strbo, Natasa; Plano, Gregory V.; Munson, George P.; Podack, Eckhard R.] Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA.
   [Sukumar, Neelima; Russell, David G.] Cornell Univ, Coll Vet Med, Dept Microbiol & Immunol, Ithaca, NY 14853 USA.
   [Stojadinovic, Olivera; Tomic-Canic, Marjana; Kirsner, Robert S.] Univ Miami, Miller Sch Med, Dept Dermatol & Cutaneous Surg, Wound Healing & Regenerat Med Res Program, Miami, FL 33136 USA.
RP Podack, ER (corresponding author), Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA.
EM epodack@miami.edu
RI Russell, David G/D-4533-2009; Russell, David G/N-5280-2019; Lyapichev,
   Kirill/AAO-9998-2021
OI Russell, David G/0000-0002-9748-750X; Russell, David
   G/0000-0002-9748-750X; Lyapichev, Kirill/0000-0001-9983-9735; Munson,
   George/0000-0002-3692-8199
FU National Institutes of Health (NIH)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [CA039201,
   AI0073234, AI096396, DK0942601, NR013881, AI106290, AI107062]; Lois Pope
   Life Foundation Developmental Fellowship; National Institute of Nursing
   Research (NINR)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Nursing Research (NINR) [NR015649]; NATIONAL CANCER INSTITUTEUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA039201,
   P01CA109094] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [KL2TR000461] Funding Source:
   NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R21AI073234, F31AI106290, R56AI107062,
   P01AI096396, R01AI110810, R33AI073234] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Nursing Research (NINR) [R01NR013881, R01NR015649] Funding
   Source: NIH RePORTER
FX Funder Grant reference Author; National Institutes of Health (NIH)
   CA039201 Eckhard R Podack; Lois Pope Life Foundation Developmental
   Fellowship Ryan M McCormack; National Institutes of Health (NIH)
   CA109094 Eckhard R Podack; National Institutes of Health (NIH) AI0073234
   Eckhard R Podack; National Institutes of Health (NIH) AI096396 Eckhard R
   Podack; National Institutes of Health (NIH) DK0942601 Robert S Kirsner;
   National Institutes of Health (NIH) NR013881 Marjana Tomic-Canic;
   National Institutes of Health (NIH) AI106290 Ryan M McCormack; National
   Institutes of Health (NIH) AI110810 George P Munson, Eckhard R Podack;
   National Institutes of Health (NIH) AI107062 Marjana Tomic-Canic, Robert
   S Kirsner, Eckhard R Podack; National Institute of Nursing Research
   (NINR) NR015649 Marjana Tomic-Canic, Eckhard R Podack; The funders had
   no role in study design, data collection and interpretation, or the
   decision to submit the work for publication.
CR Bang IS, 2006, J BIOL CHEM, V281, P28039, DOI 10.1074/jbc.M605174200
   Baran K, 2009, IMMUNITY, V30, P684, DOI 10.1016/j.immuni.2009.03.016
   Barthel M, 2003, INFECT IMMUN, V71, P2839, DOI 10.1128/IAI.71.5.2839-2858.2003
   Bartra SS, 2008, INFECT IMMUN, V76, P612, DOI 10.1128/IAI.01125-07
   Benard EL, 2015, J INNATE IMMUN, V7, P136, DOI 10.1159/000366103
   Bernard JJ, 2011, CELL MOL LIFE SCI, V68, P2189, DOI 10.1007/s00018-011-0712-8
   BHAKDI S, 1978, P NATL ACAD SCI USA, V75, P5655, DOI 10.1073/pnas.75.11.5655
   BLUMENTHAL R, 1984, P NATL ACAD SCI-BIOL, V81, P5551, DOI 10.1073/pnas.81.17.5551
   Cheng AG, 2009, FASEB J, V23, P3393, DOI 10.1096/fj.09-135467
   D'Angelo ME, 2012, BMC EVOL BIOL, V12, DOI 10.1186/1471-2148-12-59
   Daigneault M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008668
   Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297
   Dearman RJ, 2009, IMMUNOLOGY, V126, P475, DOI 10.1111/j.1365-2567.2008.02922.x
   DeGroote MA, 1997, P NATL ACAD SCI USA, V94, P13997, DOI 10.1073/pnas.94.25.13997
   DENNERT G, 1983, J EXP MED, V157, P1483, DOI 10.1084/jem.157.5.1483
   Fang FC, 1999, P NATL ACAD SCI USA, V96, P7502, DOI 10.1073/pnas.96.13.7502
   Fields KA, 2013, INFECT IMMUN, V81, P3045, DOI 10.1128/IAI.00497-13
   Green TJ, 2014, FISH SHELLFISH IMMUN, V36, P151, DOI 10.1016/j.fsi.2013.10.026
   Hadders MA, 2007, SCIENCE, V317, P1552, DOI 10.1126/science.1147103
   Hahn BL, 2009, MICROB PATHOGENESIS, V47, P16, DOI 10.1016/j.micpath.2009.04.007
   He XC, 2011, FISH SHELLFISH IMMUN, V30, P870, DOI 10.1016/j.fsi.2011.01.009
   Humphrey J H, 1969, Adv Immunol, V11, P75, DOI 10.1016/S0065-2776(08)60478-2
   JENNE DE, 1988, IMMUNOL REV, V103, P53, DOI 10.1111/j.1600-065X.1988.tb00749.x
   Kemp IK, 2011, FISH SHELLFISH IMMUN, V31, P754, DOI 10.1016/j.fsi.2011.07.010
   Kondos SC, 2010, TISSUE ANTIGENS, V76, P341, DOI 10.1111/j.1399-0039.2010.01566.x
   Krishnakumar R, 2004, J BACTERIOL, V186, P5230, DOI 10.1128/JB.186.16.5230-5238.2004
   Laroux FS, 2005, J IMMUNOL, V175, P5596, DOI 10.4049/jimmunol.175.9.5596
   Law RHP, 2010, NATURE, V468, P447, DOI 10.1038/nature09518
   Lee W, 2013, J BIOL CHEM, V288, P6788, DOI 10.1074/jbc.M112.445056
   LICHTENHELD MG, 1988, NATURE, V335, P448, DOI 10.1038/335448a0
   Linden SK, 2008, MUCOSAL IMMUNOL, V1, P183, DOI 10.1038/mi.2008.5
   Luo Y, 2001, Curr Protoc Immunol, VChapter 3, DOI 10.1002/0471142735.im0320s22
   Lutwyche P, 1998, ANTIMICROB AGENTS CH, V42, P2511, DOI 10.1128/AAC.42.10.2511
   Mah SA, 2004, BIOCHEM BIOPH RES CO, V316, P468, DOI 10.1016/j.bbrc.2004.02.073
   Mantena RKR, 2008, CELL MICROBIOL, V10, P1058, DOI 10.1111/j.1462-5822.2007.01105.x
   MASSON D, 1987, CELL, V49, P679, DOI 10.1016/0092-8674(87)90544-7
   Mastroeni P, 2000, J EXP MED, V192, P237, DOI 10.1084/jem.192.2.237
   MAYER MM, 1972, P NATL ACAD SCI USA, V69, P2954, DOI 10.1073/pnas.69.10.2954
   McCormack R, 2013, IMMUNOL RES, V57, P268, DOI 10.1007/s12026-013-8469-9
   McCormack R, 2013, J INNATE IMMUN, V5, P185, DOI 10.1159/000345249
   McCormack RM, 2015, ELIFE, V4, DOI 10.7554/eLife.06505
   Mempel M, 2003, J INVEST DERMATOL, V121, P1389, DOI 10.1111/j.1523-1747.2003.12630.x
   MEYER PA, 1990, ENVIRON HEALTH PERSP, V88, P179, DOI 10.2307/3431071
   MULLEREBERHARD HJ, 1975, ANNU REV BIOCHEM, V44, P697, DOI 10.1146/annurev.bi.44.070175.003405
   NODA Y, 1986, J BACTERIOL, V167, P1016, DOI 10.1128/jb.167.3.1016-1019.1986
   Oh Hana, 2008, J Vis Exp, DOI 10.3791/745
   Onunkwo CC, 2010, ARCH DERMATOL RES, V302, P375, DOI 10.1007/s00403-010-1030-y
   PODACK ER, 1984, J EXP MED, V160, P695, DOI 10.1084/jem.160.3.695
   PODACK ER, 1982, P NATL ACAD SCI-BIOL, V79, P574, DOI 10.1073/pnas.79.2.574
   PODACK ER, 1983, NATURE, V302, P442, DOI 10.1038/302442a0
   Prior K, 2009, ADV MICROB PHYSIOL, V56, P1, DOI 10.1016/S0065-2911(09)05601-X
   Rigby KM, 2012, SEMIN IMMUNOPATHOL, V34, P237, DOI 10.1007/s00281-011-0295-3
   Rosado CJ, 2007, SCIENCE, V317, P1548, DOI 10.1126/science.1144706
   Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9
   SCHREIBER RD, 1979, J EXP MED, V149, P870, DOI 10.1084/jem.149.4.870
   SHIVER JW, 1992, CELL, V71, P315, DOI 10.1016/0092-8674(92)90359-K
   Slade DJ, 2008, J MOL BIOL, V379, P331, DOI 10.1016/j.jmb.2008.03.061
   SMYTH MJ, 1994, CLIN EXP PHARMACOL P, V21, P67, DOI 10.1111/j.1440-1681.1994.tb02438.x
   Sohn H, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002435
   Song PI, 2002, J INVEST DERMATOL, V119, P424, DOI 10.1046/j.1523-1747.2002.01847.x
   SPILSBURY K, 1995, BLOOD, V85, P1620, DOI 10.1182/blood.V85.6.1620.bloodjournal8561620
   Stevanin TM, 2002, INFECT IMMUN, V70, P4399, DOI 10.1128/IAI.70.8.4399-4405.2002
   Stokes RW, 2004, INFECT IMMUN, V72, P5676, DOI 10.1128/IAI.72.10.5676-5686.2004
   TRAPANI JA, 1988, P NATL ACAD SCI USA, V85, P6924, DOI 10.1073/pnas.85.18.6924
   TSCHOPP J, 1982, NATURE, V298, P534, DOI 10.1038/298534a0
   Turner JR, 2009, NAT REV IMMUNOL, V9, P799, DOI 10.1038/nri2653
   Uzzau S, 2002, MOL MICROBIOL, V46, P147, DOI 10.1046/j.1365-2958.2002.03145.x
   Vanden Berghe T, 2015, IMMUNITY, V43, P200, DOI 10.1016/j.immuni.2015.06.011
   Vazquez-Torres A, 2000, SCIENCE, V287, P1655, DOI 10.1126/science.287.5458.1655
   Vijayan D, 2012, METHODS MOL BIOL, V844, P183, DOI 10.1007/978-1-61779-527-5_13
   Wang GD, 2008, FISH SHELLFISH IMMUN, V24, P346, DOI 10.1016/j.fsi.2007.12.008
   Wanke I, 2013, EXP DERMATOL, V22, P153, DOI 10.1111/exd.12083
   Wiens M, 2005, J BIOL CHEM, V280, P27949, DOI 10.1074/jbc.M504049200
   Zhang Xia, 2008, Curr Protoc Immunol, VChapter 14, DOI 10.1002/0471142735.im1401s83
NR 74
TC 36
Z9 36
U1 0
U2 3
PU ELIFE SCIENCES PUBLICATIONS LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050-084X
J9 ELIFE
JI eLife
PD SEP 24
PY 2015
VL 4
AR e06508
DI 10.7554/eLife.06508
PG 29
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA DJ0EI
UT WOS:000373874200001
PM 26402460
OA Green Published, gold
DA 2021-10-30
ER

PT J
AU Cespedes, EM
   Dudley, KA
   Sotres-Alvarez, D
   Zee, PC
   Daviglus, ML
   Shah, NA
   Talavera, GA
   Gallo, LC
   Mattei, J
   Qi, QB
   Ramos, AR
   Schneiderman, N
   Espinoza-Giacinto, RA
   Patel, SR
AF Cespedes, Elizabeth M.
   Dudley, Katherine A.
   Sotres-Alvarez, Daniela
   Zee, Phyllis C.
   Daviglus, Martha L.
   Shah, Neomi A.
   Talavera, Gregory A.
   Gallo, Linda C.
   Mattei, Josiemer
   Qi, Qibin
   Ramos, Alberto R.
   Schneiderman, Neil
   Espinoza-Giacinto, Rebeca A.
   Patel, Sanjay R.
TI Joint associations of insomnia and sleep duration with prevalent
   diabetes: The Hispanic Community Health Study/Study of Latinos
   (HCHS/SOL)
SO JOURNAL OF DIABETES
LA English
DT Article
DE acculturation; Hispanic Americans; insomnia; sleep; type 2 diabetes
   mellitus
ID WOMENS HEALTH; DIVERSE BACKGROUNDS; LONG-SLEEP; PHYSICAL-ACTIVITY;
   UNITED-STATES; RISK-FACTOR; ACCULTURATION; INDIVIDUALS; VALIDATION;
   MELLITUS
AB BackgroundInadequate sleep quantity and quality are associated with a higher risk of type 2 diabetes. This relationship is not well-examined in US Hispanics/Latinos, and prior analyses may be confounded by sleep apnea. This cross-sectional study examined joint associations of sleep duration and insomnia with diabetes among diverse US Hispanic/Latinos.
   MethodsBaseline data on sleep quantity and quality were obtained from 15227 participants (mean age 41; range 18-74 years) from the Hispanic Community Health Study/Study of Latinos. Complex survey multinomial logistic regression was used to examine associations between prevalent diabetes and six phenotypes defined by cross-classifying sleep duration (short 6h, average >6-9h, long >9h) and insomnia, adjusting for sex, age, site and Hispanic/Latino background interaction, education, physical activity, diet quality, and sleep apnea.
   ResultsIn the weighted population, 14% had diabetes, 28% had insomnia, 9% were short sleepers, and 19% were long sleepers. Compared with those with average sleep and no insomnia, those with short sleep and insomnia were more likely to have diabetes (odds ratio [OR] 1.46; 95% confidence interval [CI] 1.02, 2.11). Average sleepers with insomnia (1.28; 95% CI 1.02, 1.61) and long sleepers without insomnia (1.33; 95% CI 1.07, 1.65) also had elevated odds of diabetes. Further adjustment for body mass index attenuated associations, except with long sleep without insomnia.
   ConclusionsBoth decreased quantity and quality of sleep are associated with diabetes in Hispanic/Latinos, with the greatest odds among those with short sleep duration and insomnia. The association is largely explained by obesity.
C1 [Cespedes, Elizabeth M.; Mattei, Josiemer] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
   [Cespedes, Elizabeth M.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
   [Dudley, Katherine A.; Patel, Sanjay R.] Brigham & Womens Hosp, Div Sleep & Circadian Disorders, 75 Francis St, Boston, MA 02115 USA.
   [Sotres-Alvarez, Daniela] Univ N Carolina, Dept Biostat, Collaborat Studies Coordinating Ctr, Chapel Hill, NC USA.
   [Zee, Phyllis C.; Daviglus, Martha L.] Northwestern Univ, Dept Prevent Med, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Zee, Phyllis C.; Daviglus, Martha L.] Univ Illinois, Inst Minor Hlth Res, Chicago, IL USA.
   [Shah, Neomi A.] Yeshiva Univ, Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY USA.
   [Qi, Qibin] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA.
   [Talavera, Gregory A.] San Diego State Univ, Div Hlth Promot & Behav Sci, Grad Sch Publ Hlth, San Diego, CA 92182 USA.
   [Gallo, Linda C.] Univ Calif San Diego, Div Global Publ Hlth, Dept Psychol, San Diego, CA 92103 USA.
   [Espinoza-Giacinto, Rebeca A.] Univ Calif San Diego, Dept Med, Div Global Publ Hlth, San Diego, CA 92103 USA.
   [Ramos, Alberto R.] Univ Miami, Dept Neurol, Miller Sch Med, Miami, FL USA.
   [Schneiderman, Neil] Univ Miami, Dept Psychol, POB 248185, Coral Gables, FL 33124 USA.
RP Cespedes, EM (corresponding author), Harvard Univ, Dept Nutr, Sch Publ Hlth, 665 Huntington Ave,3rd Floor, Boston, MA 02115 USA.; Cespedes, EM (corresponding author), Harvard Univ, Dept Epidemiol, Sch Publ Hlth, 665 Huntington Ave,3rd Floor, Boston, MA 02115 USA.
EM emc611@mail.harvard.edu
RI Mattei, Josiemer/H-1800-2016; Sotres-Alvarez, Daniela/O-9085-2016;
   Feliciano, Elizabeth Cespedes/AAD-4459-2020; Ramos, Alberto/X-4249-2019;
   DeMarcus, Forrest/O-9190-2016
OI Mattei, Josiemer/0000-0001-5424-8245; Sotres-Alvarez,
   Daniela/0000-0002-3226-6140; Feliciano, Elizabeth
   Cespedes/0000-0003-1192-4017; Gallo, Linda C./0000-0002-3678-5888;
   Patel, Sanjay/0000-0002-9142-5172
FU National Heart, Lung, and Blood Institute (NHLBI)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [N01-HC65233];
   University of Miami [N01-HC65234]; Albert Einstein College of Medicine
   [N01-HC65235]; Northwestern University [N01-HC65236]; San Diego State
   University [N01-HC65237]; NIDDKUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)
   [T32-DK007703]; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONSUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Eye Institute (NEI) [N01HC065233] Funding
   Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [KL2TR000461] Funding Source: NIH
   RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [K23HL125923,
   R01HL065234, U01HL065233, K01HL120951] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Diabetes & Digestive &
   Kidney Diseases (NIDDK) [T32DK007703] Funding Source: NIH RePORTER
FX The authors thank the HCHS/SOL staff and participants for their
   contributions. The HCHS/SOL was supported by contracts from the National
   Heart, Lung, and Blood Institute (NHLBI) to the University of North
   Carolina (N01-HC65233), University of Miami (N01-HC65234), Albert
   Einstein College of Medicine (N01-HC65235), Northwestern University
   (N01-HC65236), and San Diego State University (N01-HC65237). The
   following fund NHLBI for HCHS/SOL: National Institute on Minority Health
   and Health Disparities, National Institute on Deafness and Other
   Communication Disorders, National Institute of Dental and Craniofacial
   Research, National Institute of Diabetes and Digestive and Kidney
   Diseases (NIDDK), National Institute of Neurological Disorders and
   Stroke, National Institutes of Health (NIH) Institution-Office of
   Dietary Supplements. EMC was supported by NIDDK T32-DK007703.
CR Amer Diabet Assoc, 2010, DIABETES CARE, V33, pS62, DOI 10.2337/dc10-s062
   Ayas NT, 2003, DIABETES CARE, V26, P380, DOI 10.2337/diacare.26.2.380
   Banna JC, 2012, PUBLIC HEALTH NUTR, V15, P198, DOI 10.1017/S1368980011001273
   Basner M, 2009, SLEEP, V32, P747, DOI 10.1093/sleep/32.6.747
   Beihl DA, 2009, ANN EPIDEMIOL, V19, P351, DOI 10.1016/j.annepidem.2008.12.001
   Cappuccio FP, 2010, DIABETES CARE, V33, P414, DOI 10.2337/dc09-1124
   Centers for Disease Control and Prevention USDoHaHS, 2011, NAT DIAB FACT SHEET
   Chiuve SE, 2012, J NUTR, V142, P1009, DOI 10.3945/jn.111.157222
   Daviglus ML, 2012, JAMA-J AM MED ASSOC, V308, P1775, DOI 10.1001/jama.2012.14517
   Ennis S. R., 2010, CENSUS BRIEFS HISPAN
   Gottlieb DJ, 2005, ARCH INTERN MED, V165, P863, DOI 10.1001/archinte.165.8.863
   Grandner MA, 2014, SLEEP MED, V15, P42, DOI 10.1016/j.sleep.2013.09.012
   Hale L, 2007, SLEEP, V30, P1096, DOI 10.1093/sleep/30.9.1096
   Hale L, 2014, SLEEP, V37, P309, DOI 10.5665/sleep.3404
   Hale L, 2011, J IMMIGR MINOR HEALT, V13, P402, DOI 10.1007/s10903-009-9284-1
   Hall MH, 2009, SLEEP, V32, P73
   Hayes AL, 2011, SLEEP, V34, P147, DOI 10.1093/sleep/34.2.147
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0053830, 10.1371/journal.pone.0082305]
   Hoos T, 2012, J PHYS ACT HEALTH, V9, P698, DOI 10.1123/jpah.9.5.698
   Jackson CL, 2014, SOC SCI MED, V118, P71, DOI 10.1016/j.socscimed.2014.07.059
   Jackson CL, 2013, DIABETES CARE, V36, P3557, DOI 10.2337/dc13-0777
   Kendzerska T, 2014, AM J RESP CRIT CARE, V190, P218, DOI 10.1164/rccm.201312-2209OC
   Knutson KL, 2011, DIABETES CARE, V34, P1171, DOI 10.2337/dc10-1962
   Knutson KL, 2011, AM J HUM BIOL, V23, P138, DOI 10.1002/ajhb.21108
   Kohout F J, 1993, J Aging Health, V5, P179, DOI 10.1177/089826439300500202
   Lauderdale DS, 2008, EPIDEMIOLOGY, V19, P838, DOI 10.1097/EDE.0b013e318187a7b0
   Lavange LM, 2010, ANN EPIDEMIOL, V20, P642, DOI 10.1016/j.annepidem.2010.05.006
   Levine DW, 2005, PSYCHOSOM MED, V67, P98, DOI 10.1097/01.psy.0000151743.58067.f0
   Liu Y, 2013, SLEEP, V36, P1421, DOI 10.5665/sleep.3028
   Loredo JS, 2010, SLEEP, V33, P962, DOI 10.1093/sleep/33.7.962
   Lucassen EA, 2012, ANN NY ACAD SCI, V1264, P110, DOI 10.1111/j.1749-6632.2012.06655.x
   Martins RC, 2008, BRAZ J MED BIOL RES, V41, P180, DOI 10.1590/S0100-879X2006005000194
   Muraki I, 2010, DIABETOLOGIA, V53, P481, DOI 10.1007/s00125-009-1616-0
   Pan A, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001141
   Patel SR, 2009, OBES REV, V10, P61, DOI 10.1111/j.1467-789X.2009.00664.x
   Patel SR, 2006, SLEEP, V29, P881, DOI 10.1093/sleep/29.7.881
   Plantinga L, 2012, PREV CHRONIC DIS, V9, DOI 10.5888/pcd9.110244
   Redline S, 2014, AM J RESP CRIT CARE, V189, P335, DOI 10.1164/rccm.201309-1735OC
   Sands-Lincoln M, 2013, J WOMENS HEALTH, V22, P477, DOI 10.1089/jwh.2012.3918
   Schmid SM, 2015, LANCET DIABETES ENDO, V3, P52, DOI 10.1016/S2213-8587(14)70012-9
   Schneiderman N, 2014, DIABETES CARE, V37, P2233, DOI 10.2337/dc13-2939
   Seicean S, 2011, SLEEP, V34, P1021, DOI 10.5665/SLEEP.1154
   Spiegel K, 1999, LANCET, V354, P1435, DOI 10.1016/S0140-6736(99)01376-8
   Spielberger C.D., 1970, STAI MANUAL
   Stranges S, 2008, AM J EPIDEMIOL, V168, P1353, DOI 10.1093/aje/kwn337
   Vgontzas AN, 2013, SLEEP MED REV, V17, P241, DOI 10.1016/j.smrv.2012.09.005
   Vgontzas AN, 2009, DIABETES CARE, V32, P1980, DOI 10.2337/dc09-0284
   Vishnu A, 2011, INT J ENDOCRINOL, V2011, DOI 10.1155/2011/789358
   Westbrook PR, 2005, CHEST, V128, P2166, DOI 10.1378/chest.128.4.2166
   Whinnery J, 2014, SLEEP, V37, P601, DOI 10.5665/sleep.3508
   Xiao Q, 2013, AM J EPIDEMIOL, V178, P1600, DOI 10.1093/aje/kwt180
   Yaggi HK, 2006, DIABETES CARE, V29, P657, DOI 10.2337/diacare.29.03.06.dc05-0879
   Youngstedt SD, 2011, J AM GERIATR SOC, V59, P957, DOI 10.1111/j.1532-5415.2011.03396.x
NR 53
TC 29
Z9 32
U1 1
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1753-0393
EI 1753-0407
J9 J DIABETES
JI J. Diabetes
PD MAY
PY 2016
VL 8
IS 3
BP 387
EP 397
DI 10.1111/1753-0407.12308
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DJ1FG
UT WOS:000373948100011
PM 25952169
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Merscher-Gomez, S
   Guzman, J
   Pedigo, CE
   Lehto, M
   Aguillon-Prada, R
   Mendez, A
   Lassenius, MI
   Forsblom, C
   Yoo, T
   Villarreal, R
   Maiguel, D
   Johnson, K
   Goldberg, R
   Nair, V
   Randolph, A
   Kretzler, M
   Nelson, RG
   Burke, GW
   Groop, PH
   Fornoni, A
AF Merscher-Gomez, Sandra
   Guzman, Johanna
   Pedigo, Christopher E.
   Lehto, Markku
   Aguillon-Prada, Robier
   Mendez, Armando
   Lassenius, Mariann I.
   Forsblom, Carol
   Yoo, TaeHyun
   Villarreal, Rodrigo
   Maiguel, Dony
   Johnson, Kevin
   Goldberg, Ronald
   Nair, Viji
   Randolph, Ann
   Kretzler, Matthias
   Nelson, Robert G.
   Burke, George W., III
   Groop, Per-Henrik
   Fornoni, Alessia
CA FinnDiane Study Grp
TI Cyclodextrin Protects Podocytes in Diabetic Kidney Disease
SO DIABETES
LA English
DT Article
ID CHOLESTEROL EFFLUX; EXPRESSION; MICE; ABCA1; ACCUMULATION; INFLAMMATION;
   METABOLISM; NUMBER; MOUSE; GLOMERULOSCLEROSIS
AB Diabetic kidney disease (DKD) remains the most common cause of end-stage kidney disease despite multifactorial intervention. We demonstrated that increased cholesterol in association with downregulation of ATP-binding cassette transporter ABCA1 occurs in normal human podocytes exposed to the sera of patients with type 1 diabetes and albuminuria (DKD+) when compared with diabetic patients with normoalbuminuria (DKD-) and similar duration of diabetes and lipid profile. Glomerular downregulation of ABCA1 was confirmed in biopsies from patients with early DKD (n = 70) when compared with normal living donors (n = 32). Induction of cholesterol efflux with cyclodextrin (CD) but not inhibition of cholesterol synthesis with simvastatin prevented podocyte injury observed in vitro after exposure to patient sera. Subcutaneous administration of CD to diabetic BTBR (black and tan, brachiuric) ob/ob mice was safe and reduced albuminuria, mesangial expansion, kidney weight, and cortical cholesterol content. This was followed by an improvement of fasting insulin, blood glucose, body weight, and glucose tolerance in vivo and improved glucose-stimulated insulin release in human islets in vitro. Our data suggest that impaired reverse cholesterol transport characterizes clinical and experimental DKD and negatively influences podocyte function. Treatment with CD is safe and effective in preserving podocyte function in vitro and in vivo and may improve the metabolic control of diabetes.
C1 [Merscher-Gomez, Sandra; Guzman, Johanna; Pedigo, Christopher E.; Aguillon-Prada, Robier; Yoo, TaeHyun; Villarreal, Rodrigo; Fornoni, Alessia] Univ Miami, Miller Sch Med, Dept Med, Div Nephrol & Hypertens, Miami, FL 33136 USA.
   [Guzman, Johanna; Aguillon-Prada, Robier; Mendez, Armando; Villarreal, Rodrigo; Maiguel, Dony; Johnson, Kevin; Goldberg, Ronald; Burke, George W., III; Fornoni, Alessia] Univ Miami, Miller Sch Med, Diabet Res Inst, Miami, FL 33136 USA.
   [Lehto, Markku; Lassenius, Mariann I.; Forsblom, Carol; Groop, Per-Henrik] Biomedicum Helsinki, Folkhalsan Res Ctr, Folkhalsan Inst Genet, Helsinki, Finland.
   [Lehto, Markku; Lassenius, Mariann I.; Forsblom, Carol; Groop, Per-Henrik] Univ Helsinki, Cent Hosp, Div Nephrol, Dept Med, Helsinki, Finland.
   [Nair, Viji; Randolph, Ann; Kretzler, Matthias] Univ Michigan, Ann Arbor, MI 48109 USA.
   [Nelson, Robert G.] NIDDK, Phoenix, AZ USA.
   [Burke, George W., III] Univ Miami, Dept Surg, Miami, FL USA.
RP Fornoni, A (corresponding author), Univ Miami, Miller Sch Med, Dept Med, Div Nephrol & Hypertens, Miami, FL 33136 USA.
EM afornoni@med.miami.edu
OI fornoni, Alessia/0000-0002-1313-7773
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [DK-090316]; Forest County Potawatomi
   Community Foundation; Max and Yetta Karasik Family Foundation; Diabetes
   Research Institute Foundation; Nephcure Foundation; Peggy and Harold
   Katz Family Foundation; University of Miami Clinical and Translational
   Science Institute [1UL1-TR-000460]; National Center for Advancing
   Translational SciencesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS); National Institute on Minority
   Health and Health DisparitiesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Minority Health & Health Disparities (NIMHD); University of
   MichiganUniversity of Michigan System; UAB-UCSD O'Brien Core Center [NIH
   1P30-DK-081943, 1P30-DK-079337]; National Institute of Diabetes and
   Digestive and Kidney DiseasesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Diabetes & Digestive & Kidney Diseases (NIDDK); Folkhalsan Research
   Foundation; Wilhelm and Else Stockmann Foundation; Waldemar von
   Frenckell Foundation; Liv och Halsa Foundation; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000460]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND
   DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Diabetes & Digestive & Kidney Diseases (NIDDK) [P30DK079337,
   R01DK090316, P30DK020572, P30DK081943, ZIADK069062] Funding Source: NIH
   RePORTER
FX A.F. is supported by the NIH (DK-090316), the Forest County Potawatomi
   Community Foundation, the Max and Yetta Karasik Family Foundation, the
   Diabetes Research Institute Foundation, the Nephcure Foundation, and the
   Peggy and Harold Katz Family Foundation. The project described was
   supported by Grant 1UL1-TR-000460, (University of Miami Clinical and
   Translational Science Institute), the National Center for Advancing
   Translational Sciences, and the National Institute on Minority Health
   and Health Disparities. The authors acknowledge support from the
   University of Michigan and UAB-UCSD O'Brien Core Center (NIH
   1P30-DK-081943 and -079337) for this project. This study was also
   supported by the Intramural Research Program of the National Institute
   of Diabetes and Digestive and Kidney Diseases, the Folkhalsan Research
   Foundation (P.-H.G.), the Wilhelm and Else Stockmann Foundation
   (P.-H.G., M.I.L., M.L., and C.F.), the Waldemar von Frenckell Foundation
   (M.I.L.), and the Liv och Halsa Foundation (M.I.L. and P.-H.G.). Gene
   expression data from nondiabetic glomerular disease were provided by the
   European Renal cDNA Bank-Kroener-Fresenius Biopsy Bank supported by the
   Else-Kroener Fresenius Foundation members (Supplementary Data 2). This
   research was conducted using the resources of the University of Miami
   Center for Computational Science.
CR Attie AD, 2007, TRENDS BIOCHEM SCI, V32, P172, DOI 10.1016/j.tibs.2007.02.001
   Basevi V, 2011, DIABETES CARE, V34, P1887, DOI 10.2337/dc11-s011
   Berthier CC, 2009, DIABETES, V58, P469, DOI 10.2337/db08-1328
   Christian AE, 1997, J LIPID RES, V38, P2264
   Cohen CD, 2002, KIDNEY INT, V61, P133, DOI 10.1046/j.1523-1755.2002.00113.x
   Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009
   Diez-Sampedro A, 2011, AM J KIDNEY DIS, V58, P637, DOI 10.1053/j.ajkd.2011.03.035
   DOI T, 1988, AM J PATHOL, V131, P398
   Fackler OT, 2008, J CELL BIOL, V181, P879, DOI 10.1083/jcb.200802081
   Fioretto P, 2008, DIABETOLOGIA, V51, P1347, DOI 10.1007/s00125-008-1051-7
   Fornoni A, 2008, DIABETOLOGIA, V51, P298, DOI 10.1007/s00125-007-0889-4
   Fornoni A, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002231
   Gaede P, 2008, NEW ENGL J MED, V358, P580, DOI 10.1056/NEJMoa0706245
   Grefhorst A, 2002, J BIOL CHEM, V277, P34182, DOI 10.1074/jbc.M204887200
   Helfand BT, 2011, MOL BIOL CELL, V22, P1274, DOI 10.1091/mbc.E10-08-0699
   Hovind P, 2003, DIABETES CARE, V26, P1258, DOI 10.2337/diacare.26.4.1258
   Hudkins KL, 2010, J AM SOC NEPHROL, V21, P1533, DOI 10.1681/ASN.2009121290
   Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037
   Katz A, 2009, J CLIN PHARMACOL, V49, P643, DOI 10.1177/0091270009335768
   Khera AV, 2011, NEW ENGL J MED, V364, P127, DOI 10.1056/NEJMoa1001689
   Kruit JK, 2012, DIABETES, V61, P659, DOI 10.2337/db11-1341
   KRUTH HS, 1984, ATHEROSCLEROSIS, V51, P281, DOI 10.1016/0021-9150(84)90175-8
   Lindenmeyer MT, 2007, J AM SOC NEPHROL, V18, P1765, DOI 10.1681/ASN.2006121304
   Lopez CA, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002020
   Maggio ABR, 2012, J PEDIATR GASTR NUTR, V54, P720, DOI 10.1097/MPG.0b013e318244a685
   MENDEZ AJ, 1995, J BIOL CHEM, V270, P5891, DOI 10.1074/jbc.270.11.5891
   Mendez AJ, 1997, J LIPID RES, V38, P1807
   Meyer TW, 1999, DIABETOLOGIA, V42, P1341, DOI 10.1007/s001250051447
   Pagtalunan ME, 1997, J CLIN INVEST, V99, P342, DOI 10.1172/JCI119163
   Proctor G, 2006, DIABETES, V55, P2502, DOI 10.2337/db05-0603
   Qi MS, 2009, J CELL BIOCHEM, V106, P1031, DOI 10.1002/jcb.22081
   Ramirez CM, 2010, PEDIATR RES, V68, P309, DOI 10.1203/00006450-201011001-00604
   Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01
   Saeed AI, 2006, METHOD ENZYMOL, V411, P134, DOI 10.1016/S0076-6879(06)11009-5
   Saleem MA, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133630
   Schaefer EJ, 2010, CURR OPIN LIPIDOL, V21, P289, DOI 10.1097/MOL.0b013e32833c1ef6
   Schwartz GG, 2012, NEW ENGL J MED, V367, P2089, DOI 10.1056/NEJMoa1206797
   Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019
   Somlo S, 2000, NAT GENET, V24, P333, DOI 10.1038/74139
   Steffes MW, 2001, KIDNEY INT, V59, P2104, DOI 10.1046/j.1523-1755.2001.0590062104.x
   Steinke Julia M, 2008, Pediatr Endocrinol Rev, V5 Suppl 4, P958
   Stella VJ, 2008, TOXICOL PATHOL, V36, P30, DOI 10.1177/0192623307310945
   Takahashi N, 2007, KIDNEY INT, V71, P266, DOI 10.1038/sj.ki.5002033
   Tam J, 2012, CELL METAB, V16, P167, DOI 10.1016/j.cmet.2012.07.002
   Tang CR, 2010, J LIPID RES, V51, P1719, DOI 10.1194/jlr.M003525
   Tejada T, 2008, KIDNEY INT, V73, P1385, DOI 10.1038/ki.2008.109
   US Renal Data System, 2011, USRDS 2011 ANN DAT R
   Van Rooyen DM, 2011, J GASTROEN HEPATOL, V26, P789, DOI 10.1111/j.1440-1746.2011.06704.x
   Verzola D, 2007, KIDNEY INT, V72, P1262, DOI 10.1038/sj.ki.5002531
   Wang ZW, 2005, DIABETES, V54, P2328, DOI 10.2337/diabetes.54.8.2328
   White KE, 2002, DIABETES, V51, P3083, DOI 10.2337/diabetes.51.10.3083
   Wijesekara N, 2012, DIABETES, V61, P653, DOI 10.2337/db11-0944
   Willer CJ, 2008, NAT GENET, V40, P161, DOI 10.1038/ng.76
   Xie XF, 2011, P NATL ACAD SCI USA, V108, P15330, DOI 10.1073/pnas.1112751108
   ZADOR IZ, 1993, J CLIN INVEST, V91, P797, DOI 10.1172/JCI116299
   Zhou HL, 2008, DIABETES-METAB RES, V24, P617, DOI 10.1002/dmrr.895
NR 56
TC 81
Z9 90
U1 0
U2 9
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
EI 1939-327X
J9 DIABETES
JI Diabetes
PD NOV
PY 2013
VL 62
IS 11
BP 3817
EP 3827
DI 10.2337/db13-0399
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 243BF
UT WOS:000326290700026
PM 23835338
OA Green Published, hybrid
DA 2021-10-30
ER

PT J
AU Kalangara, JP
   Galor, A
   Levitt, RC
   Felix, ER
   Alegret, R
   Sarantopoulos, CD
AF Kalangara, Jerry P.
   Galor, Anat
   Levitt, Roy C.
   Felix, Elizabeth R.
   Alegret, Ramon
   Sarantopoulos, Constantine D.
TI Burning Eye Syndrome: Do Neuropathic Pain Mechanisms Underlie Chronic
   Dry Eye?
SO PAIN MEDICINE
LA English
DT Review
DE Dry Eye; Cornea; Neuropathic Pain; Neuronal Dysfunction; Hyperalgesia;
   Sensitization
ID NERVE GROWTH-FACTOR; CORNEAL INNERVATION; CONFOCAL MICROSCOPY;
   POSTOPERATIVE PAIN; UTILITY-ASSESSMENT; CONTROLLED-TRIAL; TEAR
   SECRETION; DOUBLE-BLIND; DICLOFENAC; SENSITIVITY
AB Objective. Dry eye is a multi-factorial disorder that manifests with painful ocular symptoms and visual disturbances, which can only be partly attributed to tear dysfunction. This disorder may also involve neuroplasticity in response to neuronal injury. This review will emphasize the key characteristics of dry eye pain and its pathologic mechanisms, making the argument that a subset of dry eye represents a neuropathic pain disorder of the eye, more appropriately called "burning eye syndrome."
   Methods. A literature review was conducted using a PubMed search focusing on dry eye, corneal nociception, and neuropathic pain. Articles were reviewed and those discussing clinical course, pathophysiology, and neuronal regulation of chronic ocular pain as related to dry eye were summarized.
   Results. We found that there is a discordance between ocular pain and dryness on the ocular surface. Although tear dysfunction may be one of the initial insults, its persistence may be associated with repeated ocular sensory nerve injury leading to an acute-to-chronic pain transition associated with neuropathologic changes (peripheral and central sensitization), neuronal dysfunction, and spontaneous ocular pain.
   Conclusion. Dry eye is becoming a major health concern due to its increasing incidence, significant morbidity, and economic burden. Recent evidence suggests that a subset of dry eye may be better represented as a chronic neuropathic pain disorder due to its features of dysesthesia, spontaneous pain, allodynia, and hyperalgesia. Future therapies targeted at the underlying neuroplasticity may yield improved efficacy for patients with this subset of dry eye, which we term "burning eye syndrome.".
C1 [Kalangara, Jerry P.; Levitt, Roy C.; Alegret, Ramon; Sarantopoulos, Constantine D.] Univ Miami, Miller Sch Med, Dept Anesthesiol Perioperat Med & Pain Management, 1475 NW 12th Ave, Miami, FL 33136 USA.
   [Levitt, Roy C.] Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, Miami, FL 33136 USA.
   [Levitt, Roy C.] Univ Miami, Miller Sch Med, John T Macdonald Fdn Dept Human Genet, Miami, FL 33136 USA.
   [Felix, Elizabeth R.] Univ Miami, Miller Sch Med, Dept Phys Med & Rehabil, Miami, FL 33136 USA.
   [Galor, Anat; Levitt, Roy C.; Felix, Elizabeth R.; Sarantopoulos, Constantine D.] Miami Vet Affairs Med Ctr, Miami, FL USA.
   [Galor, Anat] Univ Miami, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL 33136 USA.
RP Kalangara, JP (corresponding author), Univ Miami, Miller Sch Med, Dept Anesthesiol Perioperat Med & Pain Management, 1475 NW 12th Ave, Miami, FL 33136 USA.
EM Jerry.kalangara@gmail.com
RI Felix, Elizabeth/AAD-6356-2021
OI Felix, Elizabeth/0000-0002-6239-715X
FU Department of Veterans Affairs, Veterans Health Administration, Office
   of Research and Development, Clinical Sciences Research and
   Development's Career Development Award [CDA-2-024-10S]; NIH Center Core
   GrantUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [P30EY014801]; Research to Prevent
   Blindness Unrestricted GrantResearch to Prevent Blindness (RPB);
   Department of Defense (DOD)United States Department of Defense
   [W81XWH-09-1-0675, W81XWH-13-1-0048 ONOVA]; NIH NIDCRUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Dental & Craniofacial Research (NIDCR)
   [R01 DE022903]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1TR000460] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTEUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National Eye
   Institute (NEI) [P30EY014801] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Dental & Craniofacial Research (NIDCR)
   [R01DE022903] Funding Source: NIH RePORTER; Veterans AffairsUS
   Department of Veterans Affairs [I01CX001089] Funding Source: NIH
   RePORTER
FX This article was supported by the Department of Veterans Affairs,
   Veterans Health Administration, Office of Research and Development,
   Clinical Sciences Research and Development's Career Development Award
   CDA-2-024-10S (Dr. Galor), NIH Center Core Grant P30EY014801, Research
   to Prevent Blindness Unrestricted Grant, Department of Defense (DOD-
   Grant#W81XWH-09-1-0675 and Grant#W81XWH-13-1-0048 ONOVA)
   (institutional), and NIH NIDCR R01 DE022903 (Dr. Levitt).
CR Abetz L, 2011, HEALTH QUAL LIFE OUT, V9, DOI 10.1186/1477-7525-9-111
   Acosta MC, 2004, INVEST OPHTH VIS SCI, V45, P2333, DOI 10.1167/iovs.03-1366
   Alfawaz AM, 2014, CURR EYE RES, V39, P257, DOI 10.3109/02713683.2013.841258
   Alhatem A, 2012, SEMIN OPHTHALMOL, V27, P138, DOI 10.3109/08820538.2012.711416
   Aloe L, 2008, PHARMACOL RES, V57, P253, DOI 10.1016/j.phrs.2008.01.010
   Alves M, 2013, OCUL SURF, V11, P181, DOI 10.1016/j.jtos.2013.02.002
   Barr MS, 2013, J NEUROIMMUNE PHARM, V8, P535, DOI 10.1007/s11481-012-9383-y
   Belmonte C, 2004, EXP EYE RES, V78, P513, DOI 10.1016/j.exer.2003.09.023
   BELMONTE C, 2007, ENCY PAIN, V3, P2515
   Belmonte C, 2007, J REFRACT SURG, V23, P598, DOI 10.3928/1081-597X-20070601-11
   Belmonte Carlos, 2004, Ocul Surf, V2, P248
   Benemei S, 2009, CURR OPIN PHARMACOL, V9, P9, DOI 10.1016/j.coph.2008.12.007
   Benitez-del-Castillo JM, 2007, INVEST OPHTH VIS SCI, V48, P173, DOI 10.1167/iovs.06-0127
   Bereiter DA, 1996, NEUROSCIENCE, V73, P249, DOI 10.1016/0306-4522(96)00038-3
   Beuerman RW, 2005, OCUL SURF, V3, pS203
   Bhargava R, 2013, INT J OPHTHALMOL-CHI, V6, P811, DOI 10.3980/j.issn.2222-3959.2013.06.13
   Borsook D, 2011, PAIN, V152, P2427, DOI 10.1016/j.pain.2011.06.006
   Brignole-Baudouin F, 2011, ACTA OPHTHALMOL, V89, pE591, DOI 10.1111/j.1755-3768.2011.02196.x
   Bron AJ, 2007, OCUL SURF, V5, P108
   Buchholz P, 2006, OCUL SURF, V4, P155, DOI 10.1016/S1542-0124(12)70043-5
   Chalmers RL, 2010, CONTACT LENS ANTERIO, V33, P55, DOI 10.1016/j.clae.2009.12.010
   Chao C, 2014, OCUL SURF, V12, P32, DOI 10.1016/j.jtos.2013.09.001
   COLLINS SM, 1992, ANN NY ACAD SCI, V664, P415, DOI 10.1111/j.1749-6632.1992.tb39780.x
   Costigan M, 2009, ANNU REV NEUROSCI, V32, P1, DOI 10.1146/annurev.neuro.051508.135531
   de Castro F, 1998, EUR J NEUROSCI, V10, P146, DOI 10.1046/j.1460-9568.1998.00037.x
   del Castillo JMB, 2004, INVEST OPHTH VIS SCI, V45, P3030, DOI 10.1167/iovs.04-0251
   Dimit R, 2013, CONTACT LENS ANTERIO, V36, P159, DOI 10.1016/j.clae.2013.02.004
   Eide PK, 2000, EUR J PAIN, V4, P5, DOI 10.1053/eujp.1999.0154
   Erdelyi B, 2007, GRAEF ARCH CLIN EXP, V245, P39, DOI 10.1007/s00417-006-0375-6
   Fahmy AM, 2011, CLIN OPHTHALMOL, V5, P465, DOI 10.2147/OPTH.S12291
   Finis D, 2014, OCUL SURF, V12, P146, DOI 10.1016/j.jtos.2013.12.001
   Fiscella Richard G, 2011, Am J Manag Care, V17 Suppl 16, pS432
   FRY LL, 1995, J CATARACT REFR SURG, V21, P187, DOI 10.1016/S0886-3350(13)80508-1
   Galor A, 2013, INVEST OPHTH VIS SCI, V54, P1426, DOI 10.1167/iovs.12-10819
   Galor A, 2012, CORNEA, V31, P1403, DOI 10.1097/ICO.0b013e31823cc0b7
   Guthoff RF, 2005, CORNEA, V24, P608, DOI 10.1097/01.ico.0000154384.05614.8f
   Hirata H, 2003, J NEUROPHYSIOL, V90, P2837, DOI 10.1152/jn.00544.2003
   Hudspith MJ, 1997, BRIT J ANAESTH, V78, P731, DOI 10.1093/bja/78.6.731
   Katz J, 2011, ANESTH ANALG, V113, P1242, DOI 10.1213/ANE.0b013e31822c9a59
   Kawano T, 2009, P NATL ACAD SCI USA, V106, P8725, DOI 10.1073/pnas.0901815106
   Labbe A, 2013, INVEST OPHTH VIS SCI, V54, P5144, DOI 10.1167/iovs.13-12370
   Labbe A, 2012, INVEST OPHTH VIS SCI, V53, P4926, DOI 10.1167/iovs.11-8708
   Lambiase A, 2011, ARCH OPHTHALMOL-CHIC, V129, P981, DOI 10.1001/archophthalmol.2011.200
   Lemp MA, 2007, OCUL SURF, V5, P75
   Lichtinger A, 2011, J REFRACT SURG, V27, P613, DOI 10.3928/1081597X-20110210-01
   Liu Q, 2009, EYE CONTACT LENS, V35, P232, DOI 10.1097/ICL.0b013e3181b3e87f
   Mantelli F, 2013, J CELL PHYSIOL, V228, P2253, DOI 10.1002/jcp.24398
   Maskin SL, 2010, CORNEA, V29, P1145, DOI 10.1097/ICO.0b013e3181d836f3
   Massingale ML, 2009, CORNEA, V28, P1023, DOI 10.1097/ICO.0b013e3181a16578
   McGreevy Kai, 2011, Eur J Pain Suppl, V5, P365
   Mertzanis P, 2005, INVEST OPHTH VIS SCI, V46, P46, DOI 10.1167/iovs.03-0915
   Mohammadpour M, 2011, J CATARACT REFR SURG, V37, P633, DOI 10.1016/j.jcrs.2010.10.040
   Moller AT, 2010, EUR J PAIN S, V4, P197
   Muller LJ, 2003, EXP EYE RES, V76, P521, DOI 10.1016/S0014-4835(03)00050-2
   Neumann S, 1996, NATURE, V384, P360, DOI 10.1038/384360a0
   Ortiz MI, 2012, PHARMACOL BIOCHEM BE, V102, P163, DOI 10.1016/j.pbb.2012.03.032
   Oswald DJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044574
   Pan Q, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009327.pub2
   Parra A, 2010, NAT MED, V16, P1396, DOI 10.1038/nm.2264
   Pflugfelder SC, 2007, OCUL SURF, V5, P163
   Ro Long-Sun, 2005, Chang Gung Med J, V28, P597
   Rosenthal P, 2012, OCUL SURF, V10, P2, DOI 10.1016/j.jtos.2012.01.002
   Rosenthal P, 2009, OCUL SURF, V7, P28, DOI 10.1016/S1542-0124(12)70290-2
   Sahai Anshu, 2005, Indian Journal of Ophthalmology, V53, P87
   Sarantopoulos C, 2013, REGION ANESTH PAIN M, V38, P378, DOI 10.1097/AAP.0b013e3182a3922b
   Schiffman RM, 2003, OPHTHALMOLOGY, V110, P1412, DOI 10.1016/S0161-6420(03)00462-7
   Scholz J, 2007, NAT NEUROSCI, V10, P1361, DOI 10.1038/nn1992
   Searle RD, 2012, BRIT J ANAESTH, V109, P240, DOI 10.1093/bja/aes147
   Smith JA, 2007, OCUL SURF, V5, P93
   Szucs PA, 2000, ANN EMERG MED, V35, P131, DOI 10.1016/S0196-0644(00)70132-6
   Tuisku IS, 2008, EXP EYE RES, V86, P879, DOI 10.1016/j.exer.2008.03.002
   Tuominen ISJ, 2003, INVEST OPHTH VIS SCI, V44, P2545, DOI 10.1167/iovs.02-1260
   Versura P, 1999, OPHTHALMOLOGICA, V213, P103, DOI 10.1159/000027401
   Villani E, 2007, INVEST OPHTH VIS SCI, V48, P2017, DOI 10.1167/iovs.06-1129
   von Hehn CA, 2012, NEURON, V73, P638, DOI 10.1016/j.neuron.2012.02.008
   Wenk HN, 2003, PAIN, V105, P455, DOI 10.1016/S0304-3959(03)00260-4
   Yu JH, 2011, CORNEA, V30, P379, DOI 10.1097/ICO.0b013e3181f7f363
   ZAIDMAN GW, 1995, ARCH OPHTHALMOL-CHIC, V113, P262, DOI 10.1001/archopht.1995.01100030016003
   Zhang M, 2005, CORNEA, V24, P818, DOI 10.1097/01.ico.0000154402.01710.95
   Zollner C, 2008, CLIN J PAIN, V24, P690, DOI 10.1097/AJP.0b013e318175929e
   Zoukhri D, 2006, EXP EYE RES, V82, P885, DOI 10.1016/j.exer.2005.10.018
NR 81
TC 26
Z9 26
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1526-2375
EI 1526-4637
J9 PAIN MED
JI Pain Med.
PD APR
PY 2016
VL 17
IS 4
BP 746
EP 755
DI 10.1093/pm/pnv070
PG 10
WC Anesthesiology; Medicine, General & Internal
SC Anesthesiology; General & Internal Medicine
GA DM5JB
UT WOS:000376383400016
PM 26814296
OA Bronze, Green Published
DA 2021-10-30
ER

PT J
AU Dudley, KA
   Weng, J
   Sotres-Alvarez, D
   Simonelli, G
   Feliciano, EC
   Ramirez, M
   Ramos, AR
   Loredo, JS
   Reid, KJ
   Mossavar-Rahmani, Y
   Zee, PC
   Chirinos, DA
   Gallo, LC
   Wang, R
   Patel, SR
AF Dudley, Katherine A.
   Weng, Jia
   Sotres-Alvarez, Daniela
   Simonelli, Guido
   Feliciano, Elizabeth Cespedes
   Ramirez, Maricelle
   Ramos, Alberto R.
   Loredo, Jose S.
   Reid, Kathryn J.
   Mossavar-Rahmani, Yasmin
   Zee, Phyllis C.
   Chirinos, Diana A.
   Gallo, Linda C.
   Wang, Rui
   Patel, Sanjay R.
TI Actigraphic Sleep Patterns of US Hispanics: The Hispanic Community
   Health Study/Study of Latinos
SO SLEEP
LA English
DT Article
DE Hispanic/Latino; sleep; actigraphy
ID CARDIOVASCULAR RISK-FACTORS; SELF-REPORTED SLEEP; PSYCHIATRIC-DISORDERS;
   DIVERSE BACKGROUNDS; NEUROBEHAVIORAL PERFORMANCE; MEXICAN-AMERICANS;
   CUBAN AMERICANS; PUERTO-RICANS; DURATION; PREVALENCE
AB Study objective: To assess the extent to which objective sleep patterns vary among U.S. Hispanics/Latinos.
   Methods: We assessed objective sleep patterns in 2087 participants of the Hispanic Community Health Study/Study of Latinos from 6 Hispanic/Latino subgroups aged 18-64 years who underwent 7 days of wrist actigraphy.
   Results: The age-and sex-standardized mean (SE) sleep duration was 6.82 (0.05), 6.72 (0.07), 6.61 (0.07), 6.59 (0.06), 6.57 (0.10), and 6.44 (0.09) hr among individuals of Mexican, Cuban, Dominican, Central American, Puerto Rican, and South American heritage, respectively. Sleep maintenance efficiency ranged from 89.2 (0.2)% in Mexicans to 86.5 (0.4)% in Puerto Ricans, while the sleep fragmentation index ranged from 19.7 (0.3)% in Mexicans to 24.2 (0.7)% in Puerto Ricans. In multivariable models adjusted for age, sex, season, socioeconomic status, lifestyle habits, and comorbidities, these differences persisted.
   Conclusions: There are important differences in actigraphically measured sleep across U.S. Hispanic/Latino heritages. Individuals of Mexican heritage have longer and more consolidated sleep, while those of Puerto Rican heritage have shorter and more fragmented sleep. These differences may have clinically important effects on health outcomes.
C1 [Dudley, Katherine A.; Patel, Sanjay R.] Beth Israel Deaconess Med Ctr, Div Pulm Crit Care & Sleep Med, Boston, MA 02215 USA.
   [Dudley, Katherine A.; Weng, Jia; Simonelli, Guido; Ramirez, Maricelle; Wang, Rui; Patel, Sanjay R.] Brigham & Womens Hosp, Div Sleep & Circadian Disorders, 75 Francis St, Boston, MA 02115 USA.
   [Sotres-Alvarez, Daniela] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Biostat, Collaborat Studies Coordinating Ctr, Chapel Hill, NC USA.
   [Simonelli, Guido] Ctr Mil Psychiat & Neurosci, Walter Reed Army Inst Res, Behav Biol Branch, Silver Spring, MD USA.
   [Feliciano, Elizabeth Cespedes] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA.
   [Feliciano, Elizabeth Cespedes] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
   [Feliciano, Elizabeth Cespedes] Kaiser Permanente, Div Res, Oakland, CA USA.
   [Ramos, Alberto R.] Univ Miami, Dept Neurol, Miami, FL USA.
   [Loredo, Jose S.] Univ Calif San Diego, Div Pulm & Crit Care Med, San Diego, CA 92103 USA.
   [Reid, Kathryn J.; Zee, Phyllis C.] Northwestern Univ, Dept Neurol, Chicago, IL 60611 USA.
   [Mossavar-Rahmani, Yasmin] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA.
   [Chirinos, Diana A.] Univ Miami, Dept Psychol, POB 248185, Coral Gables, FL 33124 USA.
   [Gallo, Linda C.] San Diego State Univ, Dept Psychol, San Diego, CA 92182 USA.
   [Wang, Rui] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA.
RP Dudley, KA (corresponding author), 330 Brookline Ave, Boston, MA 02215 USA.
EM kdudley@bidmc.harvard.edu
RI Feliciano, Elizabeth Cespedes/AAD-4459-2020; Wang, Rui/X-1699-2019;
   Ramos, Alberto/X-4249-2019
OI Feliciano, Elizabeth Cespedes/0000-0003-1192-4017; Patel,
   Sanjay/0000-0002-9142-5172; Mossavar-Rahmani,
   Yasmin/0000-0002-9214-6124; Gallo, Linda C./0000-0002-3678-5888
FU NHLBIUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [HL098297, HL007901, HL124767, N01-HC65233];
   University of Miami [N01-HC65234]; Albert Einstein College of Medicine
   [N01-HC65235]; Northwestern University [N01-HC65236]; San Diego State
   University [N01-HC65237]; National Center on Minority Health and Health
   DisparitiesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Minority
   Health & Health Disparities (NIMHD); National Institute of Deafness and
   Other Communications DisordersUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Deafness & Other Communication Disorders (NIDCD); National Institute
   of Dental and Craniofacial ResearchUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Dental & Craniofacial Research (NIDCR); National Institute
   of Diabetes and Digestive and Kidney DiseasesUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK);
   National Institute of Neurological Disorders and StrokeUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Neurological Disorders & Stroke (NINDS);
   Office of Dietary SupplementsUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [KL2TR000461]
   Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [K24HL127307, U01HL065233, R01HL098297, R01HL065234,
   F32HL124767, T32HL007901] Funding Source: NIH RePORTER
FX This study was supported by NHLBI HL098297, HL007901, and HL124767. In
   addition, the Hispanic Community Health Study/Study of Latinos was
   carried out as a collaborative study supported by contracts from NHLBI
   to the University of North Carolina (N01-HC65233), University of Miami
   (N01-HC65234), Albert Einstein College of Medicine (N01-HC65235),
   Northwestern University (N01-HC65236), and San Diego State University
   (N01-HC65237). The following Institutes/Center/Offices contribute to the
   HCHS/SOL through a transfer of funds to the NHLBI: National Center on
   Minority Health and Health Disparities, the National Institute of
   Deafness and Other Communications Disorders, the National Institute of
   Dental and Craniofacial Research, the National Institute of Diabetes and
   Digestive and Kidney Diseases, the National Institute of Neurological
   Disorders and Stroke, and the Office of Dietary Supplements.
CR Alegria M, 2006, J CLIN PSYCHIAT, V67, P56, DOI 10.4088/JCP.v67n0109
   Alegria M, 2008, AM J PSYCHIAT, V165, P359, DOI 10.1176/appi.ajp.2007.07040704
   Alegria M, 2007, AM J PUBLIC HEALTH, V97, P68, DOI 10.2105/AJPH.2006.087205
   ANDRESEN EM, 1994, AM J PREV MED, V10, P77, DOI 10.1016/S0749-3797(18)30622-6
   Anonymous, 2009, Morbidity and Mortality Weekly Report, V58, P1175
   Ayas NT, 2003, DIABETES CARE, V26, P380, DOI 10.2337/diacare.26.2.380
   Ayas NT, 2003, ARCH INTERN MED, V163, P205, DOI 10.1001/archinte.163.2.205
   Basner M, 2014, SLEEP, V37, P1889, DOI 10.5665/sleep.4238
   Blackwell T, 2008, SLEEP, V31, P283, DOI 10.1093/sleep/31.2.283
   BURNAM MA, 1987, J HEALTH SOC BEHAV, V28, P89, DOI 10.2307/2137143
   Buysse DJ, 2014, SLEEP, V37, P9, DOI 10.5665/sleep.3298
   Cappuccio FP, 2010, DIABETES CARE, V33, P414, DOI 10.2337/dc09-1124
   Center for Disease Control and Prevention, 2014, ALC US HLTH ALC US H
   Czeisler CA, 2015, SLEEP HEALTH, V1, P5, DOI 10.1016/j.sleh.2014.12.008
   Daviglus ML, 2012, JAMA-J AM MED ASSOC, V308, P1775, DOI 10.1001/jama.2012.14517
   Dawson DA, 2011, ALCOHOL RES HEALTH, V34, P144
   Epstein LJ, 2009, J CLIN SLEEP MED, V5, P263
   Gangwisch JE, 2005, SLEEP, V28, P1289, DOI 10.1093/sleep/28.10.1289
   Girschik J, 2012, J EPIDEMIOL, V22, P462, DOI 10.2188/jea.JE20120012
   Hale L, 2007, SLEEP, V30, P1096, DOI 10.1093/sleep/30.9.1096
   Heiss G, 2014, DIABETES CARE, V37, P2391, DOI 10.2337/dc13-2505
   Hjorth MF, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-808
   Ho GYF, 2006, REV PANAM SALUD PUBL, V19, P331, DOI 10.1590/S1020-49892006000500006
   IBER C., 2007, AASM MANUAL SCORING
   Jerant A, 2008, MED CARE, V46, P709, DOI 10.1097/MLR.0b013e3181789431
   Knutson KL, 2006, ARCH INTERN MED, V166, P1768, DOI 10.1001/archinte.166.16.1768
   Knutson KL, 2010, BEST PRACT RES CL EN, V24, P731, DOI 10.1016/j.beem.2010.07.001
   Knutson KL, 2009, ARCH INTERN MED, V169, P1055, DOI 10.1001/archinternmed.2009.119
   Kurina LM, 2011, SLEEP, V34, P1519, DOI 10.5665/sleep.1390
   Kushida CA, 2001, SLEEP MED, V2, P389, DOI 10.1016/S1389-9457(00)00098-8
   Lauderdale DS, 2008, EPIDEMIOLOGY, V19, P838, DOI 10.1097/EDE.0b013e318187a7b0
   Lauderdale DS, 2006, AM J EPIDEMIOL, V164, P5, DOI 10.1093/aje/kwj199
   Lauderdale DS, 2009, AM J EPIDEMIOL, V170, P805, DOI 10.1093/aje/kwp230
   Lavange LM, 2010, ANN EPIDEMIOL, V20, P642, DOI 10.1016/j.annepidem.2010.05.006
   Luik AI, 2013, CHRONOBIOL INT, V30, P1223, DOI 10.3109/07420528.2013.813528
   Marino M, 2013, SLEEP, V36, P1747, DOI 10.5665/sleep.3142
   Mollicone DJ, 2008, ACTA ASTRONAUT, V63, P833, DOI 10.1016/j.actaastro.2007.12.005
   Mollicone DJ, 2010, AVIAT SPACE ENVIR MD, V81, P735, DOI 10.3357/ASEM.2756.2010
   Morales LS, 2002, J HEALTH CARE POOR U, V13, P477, DOI 10.1177/104920802237532
   Oakley NR., 1997, VALIDATION POLYSOMNO
   Pabon-Nau LP, 2010, J GEN INTERN MED, V25, P847, DOI 10.1007/s11606-010-1335-8
   Patel SR, 2008, OBESITY, V16, P643, DOI 10.1038/oby.2007.118
   Patel SR, 2006, SLEEP, V29, P881, DOI 10.1093/sleep/29.7.881
   Patel SR, 2015, SLEEP, V38, P1515, DOI 10.5665/sleep.5036
   Patel SR, 2015, SLEEP, V38, P1497, DOI 10.5665/sleep.4998
   Perez CM, 2015, J IMMIGR MINOR HEALT, V17, P1002, DOI 10.1007/s10903-014-0025-8
   RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306
   Redline S, 2014, AM J RESP CRIT CARE, V189, P335, DOI 10.1164/rccm.201309-1735OC
   SCHACHTER FF, 1989, PEDIATRICS, V84, P522
   Schneiderman N, 2014, DIABETES CARE, V37, P2233, DOI 10.2337/dc13-2939
   Smith CAS, 2005, REV PANAM SALUD PUBL, V18, P381, DOI 10.1590/S1020-49892005001000001
   Sorlie PD, 2010, ANN EPIDEMIOL, V20, P629, DOI 10.1016/j.annepidem.2010.03.015
   Stamatakis KA, 2007, ANN EPIDEMIOL, V17, P948, DOI 10.1016/j.annepidem.2007.07.096
   Strine TW, 2005, SLEEP MED, V6, P23, DOI 10.1016/j.sleep.2004.06.003
   Thorleifsdottir B, 2002, J PSYCHOSOM RES, V53, P529, DOI 10.1016/S0022-3999(02)00444-0
   van den Berg JF, 2008, INT J OBESITY, V32, P1083, DOI 10.1038/ijo.2008.57
   Van Den Berg JF, 2008, J SLEEP RES, V17, P295, DOI 10.1111/j.1365-2869.2008.00638.x
   Van Someren EJW, 1999, CHRONOBIOL INT, V16, P505, DOI 10.3109/07420529908998724
   Watson NF, 2015, SLEEP, V38, P843, DOI 10.5665/sleep.4716
   WELLS KB, 1989, HEALTH SERV RES, V24, P237
   Westbrook PR, 2005, CHEST, V128, P2166, DOI 10.1378/chest.128.4.2166
NR 61
TC 15
Z9 15
U1 0
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0161-8105
EI 1550-9109
J9 SLEEP
JI Sleep
PD FEB 1
PY 2017
VL 40
IS 2
AR zsw049
DI 10.1093/sleep/zsw049
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA EK7UE
UT WOS:000394129900012
PM 28364514
OA Bronze, Green Published
DA 2021-10-30
ER

PT J
AU Wahl, P
   Ducasa, GM
   Fornoni, A
AF Wahl, Patricia
   Ducasa, Gloria Michelle
   Fornoni, Alessia
TI Systemic and renal lipids in kidney disease development and progression
SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY
LA English
DT Review
DE cholesterol; dyslipidemia; kidney disease; lipids; podocytes
ID HIGH-DENSITY-LIPOPROTEIN; CHOLESTEROL ACYLTRANSFERASE DEFICIENCY; TYPE-2
   DIABETES-MELLITUS; LOW HDL CHOLESTEROL; APOLIPOPROTEIN-A-I; TNF
   RECEPTORS 1; NEPHROTIC SYNDROME; FATTY-ACID; OXIDATIVE STRESS;
   TANGIER-DISEASE
AB Altered lipid metabolism characterizes proteinuria and chronic kidney diseases. While it is thought that dyslipidemia is a consequence of kidney disease, a large body of clinical and experimental studies support that altered lipid metabolism may contribute to the pathogenesis and progression of kidney disease. In fact, accumulation of renal lipids has been observed in several conditions of genetic and nongenetic origins, linking local fat to the pathogenesis of kidney disease. Statins, which target cholesterol synthesis, have not been proven beneficial to slow the progression of chronic kidney disease. Therefore, other therapeutic strategies to reduce cholesterol accumulation in peripheral organs, such as the kidney, warrant further investigation. Recent advances in the understanding of the biology of high-density lipoprotein (HDL) have revealed that functional HDL, rather than total HDL per se, may protect from both cardiovascular and kidney diseases, strongly supporting a role for altered cholesterol efflux in the pathogenesis of kidney disease. Although the underlying pathophysiological mechanisms responsible for lipid-induced renal damage have yet to be uncovered, several studies suggest novel mechanisms by which cholesterol, free fatty acids, and sphingolipids may affect glomerular and tubular cell function. This review will focus on the clinical and experimental evidence supporting a causative role of lipids in the pathogenesis of proteinuria and kidney disease, with a primary focus on podocytes.
C1 Univ Miami, Miller Sch Med, Peggy & Harold Katz Family Drug Discovery Ctr, Miami, FL 33136 USA.
   Univ Miami, Miller Sch Med, Div Nephrol & Hypertens, Miami, FL 33136 USA.
RP Fornoni, A (corresponding author), Univ Miami, Miller Sch Med, Peggy & Harold Katz Family Drug Discovery Ctr, Batchelor Childrens Res Inst, 1580 NW 10th Ave,633A, Miami, FL 33136 USA.
EM afornoni@med.miami.edu
OI Wahl, Patricia/0000-0001-7902-2373; fornoni, Alessia/0000-0002-1313-7773
FU National Institutes of Health (NIH) and National Institute of Diabetes
   and Digestive and Kidney Diseases (NIDDK) [DK-090316, DK-104753];
   National Center for Advancing Translational SciencesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [1UL1TR-000460]; Peggy and Harold Katz Family Foundation; NIHUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA; NIDDK Grant [DK-104753];  [U24DK-076169]; 
   [U54DK-083912];  [UL1TR-000460];  [UM1DK-100846]; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000460]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND
   DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK104753,
   R01DK090316, U54DK083912, U24DK076169, UM1DK100846] Funding Source: NIH
   RePORTER
FX A. Fornoni is supported by the National Institutes of Health (NIH) and
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
   (Grants DK-090316, DK-104753) and U24DK-076169, U54DK-083912,
   UL1TR-000460, UM1DK-100846, the National Center for Advancing
   Translational Sciences (Grant 1UL1TR-000460), and the Peggy and Harold
   Katz Family Foundation. G. M. Ducasa is also supported the NIH and NIDDK
   Grant DK-104753.
CR Agarwal R, 2006, AM J CARDIOL, V97, P748, DOI 10.1016/j.amjcard.2005.09.110
   [Anonymous], 2001, J Hypertens Suppl, V19, pS21
   Aron-Wisnewsky J, 2012, J HEPATOL, V56, P225, DOI 10.1016/j.jhep.2011.04.022
   Arora S, 2009, AM J PHYSIOL-RENAL, V297, pF653, DOI 10.1152/ajprenal.90668.2008
   ATTMAN PO, 1993, AM J KIDNEY DIS, V21, P573, DOI 10.1016/S0272-6386(12)80030-8
   ATTMAN PO, 1991, KIDNEY INT, V39, pS16
   Bagavant H, 2011, AM J PATHOL, V179, P651, DOI 10.1016/j.ajpath.2011.04.029
   Baragetti A, 2013, J INTERN MED, V274, P252, DOI 10.1111/joim.12081
   Barter PJ, 2007, NEW ENGL J MED, V357, P2109, DOI 10.1056/NEJMoa0706628
   Beltroy EP, 2007, J LIPID RES, V48, P869, DOI 10.1194/jlr.M600488-JLR200
   Bie JH, 2010, J BIOL CHEM, V285, P13630, DOI 10.1074/jbc.M109.069781
   BLUE ML, 1983, P NATL ACAD SCI-BIOL, V80, P283, DOI 10.1073/pnas.80.1.283
   Boden WE, 2011, NEW ENGL J MED, V365, P2255, DOI 10.1056/NEJMoa1107579
   Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914
   BORYSIEWICZ LK, 1982, Q J MED, V51, P411
   Bostrom P, 2006, ARTERIOSCL THROM VAS, V26, P1871, DOI 10.1161/01.ATV.0000229665.78997.0b
   Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905
   Bruneval P, 2002, NEPHROL DIAL TRANSPL, V17, P2099, DOI 10.1093/ndt/17.12.2099
   Brunzell JD, 2012, BBA-MOL CELL BIOL L, V1821, P365, DOI 10.1016/j.bbalip.2011.09.008
   Bruschi M, 2003, KIDNEY INT, V63, P686, DOI 10.1046/j.1523-1755.2003.00777.x
   Bussolati B, 2005, J AM SOC NEPHROL, V16, P1936, DOI 10.1681/ASN.2004080629
   Byrne CD, 2010, CLIN SCI, V118, P397, DOI 10.1042/CS20090565
   Calabresi L, 2005, ARTERIOSCL THROM VAS, V25, P1972, DOI 10.1161/01.ATV.0000175751.30616.13
   Calabresi L, 2015, J INTERN MED, V277, P552, DOI 10.1111/joim.12290
   Chapman MJ, 2011, EUR HEART J, V32, P1345, DOI 10.1093/eurheartj/ehr112
   Chen HM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045691
   Chen Y, 2007, AM J PHYSIOL-RENAL, V293, pF680, DOI 10.1152/ajprenal.00209.2007
   Cheng DM, 2015, J LIPID RES, V56, P1583, DOI 10.1194/jlr.M059733
   Clement LC, 2015, TRANSL RES, V165, P499, DOI 10.1016/j.trsl.2014.06.004
   Colhoun HM, 2009, AM J KIDNEY DIS, V54, P810, DOI 10.1053/j.ajkd.2009.03.022
   Cramer T, 2003, CELL, V112, P645, DOI 10.1016/S0092-8674(03)00154-5
   Crosby J, 2014, NEW ENGL J MED, V371, P22, DOI 10.1056/NEJMoa1307095
   D'Amico G, 2006, J AM SOC NEPHROL, V17, pS148, DOI 10.1681/ASN.2005121341
   de Boer IH, 2008, CLIN J AM SOC NEPHRO, V3, P125, DOI 10.2215/CJN.03390807
   Delville M, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008538
   Duchateau PN, 1997, J BIOL CHEM, V272, P25576, DOI 10.1074/jbc.272.41.25576
   Faber K, 2006, MOL ENDOCRINOL, V20, P212, DOI 10.1210/me.2005-0209
   Feng XB, 2007, J LIPID RES, V48, P794, DOI 10.1194/jlr.M600512-JLR200
   FERRANS VJ, 1975, AM J PATHOL, V78, P101
   Fornoni A, 2014, NAT REV NEPHROL, V10, P379, DOI 10.1038/nrneph.2014.87
   Fornoni A, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002231
   Freeburg PB, 2003, J AM SOC NEPHROL, V14, P927, DOI 10.1097/01.ASN.0000059308.82322.4F
   Garcia-Calvo M, 2005, P NATL ACAD SCI USA, V102, P8132, DOI 10.1073/pnas.0500269102
   Gaudet D, 2014, NEW ENGL J MED, V371, P2200, DOI 10.1056/NEJMoa1400284
   Gimm T, 2010, FASEB J, V24, P4443, DOI 10.1096/fj.10-159806
   Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0
   Gohda T, 2012, J AM SOC NEPHROL, V23, P516, DOI 10.1681/ASN.2011060628
   GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9
   Grafft CA, 2009, CLIN KIDNEY J, V2, P448, DOI 10.1093/ndtplus/sfp101
   Gregorini G, 2015, KIDNEY INT, V87, P1223, DOI 10.1038/ki.2014.389
   Greijer AE, 2005, J PATHOL, V206, P291, DOI 10.1002/path.1778
   Gutwein P, 2009, AM J PATHOL, V174, P2061, DOI 10.2353/ajpath.2009.080960
   Harper CR, 2008, J AM COLL CARDIOL, V51, P2375, DOI 10.1016/j.jacc.2008.03.025
   Haynes R, 2014, J AM SOC NEPHROL, V25, P1825, DOI 10.1681/ASN.2013090965
   Heinz LX, 2015, CELL REP, V11, P1919, DOI 10.1016/j.celrep.2015.05.006
   Heneghan JF, 2015, AM J PHYSIOL-CELL PH, V309, pC332, DOI 10.1152/ajpcell.00142.2015
   Herman-Edelstein M, 2014, J LIPID RES, V55, P561, DOI 10.1194/jlr.P040501
   Hu YW, 2010, BBA-MOL CELL BIOL L, V1801, P100, DOI 10.1016/j.bbalip.2009.10.013
   Huber TB, 2006, P NATL ACAD SCI USA, V103, P17079, DOI 10.1073/pnas.0607465103
   Ishigaki Y, 2000, J BIOL CHEM, V275, P31269, DOI 10.1074/jbc.M005906200
   Ishimura A, 2009, CLIN EXP NEPHROL, V13, P430, DOI 10.1007/s10157-009-0195-1
   Johnstone DB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051546
   JOVEN J, 1993, KIDNEY INT, V43, P410, DOI 10.1038/ki.1993.60
   Kang HM, 2015, NAT MED, V21, P37, DOI 10.1038/nm.3762
   KEANE WF, 1990, J AM SOC NEPHROL, V1, pS69
   Keith DS, 2004, ARCH INTERN MED, V164, P659, DOI 10.1001/archinte.164.6.659
   Kimmelstiel P, 1936, AM J PATHOL, V12, P83
   Kinouchi K, 2013, J ATHEROSCLER THROMB, V20, P245, DOI 10.5551/jat.14860
   Kojima I, 2007, J AM SOC NEPHROL, V18, P1218, DOI 10.1681/ASN.2006060639
   Lambert G, 2001, J BIOL CHEM, V276, P15090, DOI 10.1074/jbc.M008466200
   Lan XQ, 2014, AM J PHYSIOL-RENAL, V307, pF326, DOI 10.1152/ajprenal.00647.2013
   Lassila M, 2004, J AM SOC NEPHROL, V15, P2125, DOI 10.1097/01.ASN.0000133025.23732.46
   Lee HS, 2011, HISTOL HISTOPATHOL, V26, P1599, DOI 10.14670/HH-26.1599
   Lennon R, 2009, NEPHROL DIAL TRANSPL, V24, P3288, DOI 10.1093/ndt/gfp302
   Liao YJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077586
   Lin J, 2006, KIDNEY INT, V69, P336, DOI 10.1038/sj.ki.5000021
   Liu B, 2010, J LIPID RES, V51, P933, DOI 10.1194/jlr.M000257
   Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232
   Lopez-Hellin J, 2013, AM J TRANSPLANT, V13, P493, DOI 10.1111/j.1600-6143.2012.04338.x
   Ma KL, 2008, HEPATOLOGY, V48, P770, DOI 10.1002/hep.22423
   Mace C, 2014, J AM SOC NEPHROL, V25, P2393, DOI 10.1681/ASN.2014030267
   Madhavan SM, 2011, J AM SOC NEPHROL, V22, P2119, DOI 10.1681/ASN.2011010069
   Manalo DJ, 2005, BLOOD, V105, P659, DOI 10.1182/blood-2004-07-2958
   Matsumoto M, 2003, J AM SOC NEPHROL, V14, P1825, DOI 10.1097/01.ASN.0000074239.22357.06
   Maxwell P, 2003, J AM SOC NEPHROL, V14, P2712, DOI 10.1097/01.ASN.0000092792.97122.E0
   Mayrhofer C, 2009, AM J PATHOL, V174, P1191, DOI 10.2353/ajpath.2009.080654
   Mazzolai L, 2006, ATHEROSCLEROSIS, V186, P86, DOI 10.1016/j.atherosclerosis.2005.07.017
   Merscher S, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00127
   Merscher-Gomez S, 2013, DIABETES, V62, P3817, DOI 10.2337/db13-0399
   MOORHEAD JF, 1982, LANCET, V2, P1309
   Moriwaki Y, 2003, METABOLISM, V52, P605, DOI 10.1053/meta.2003.50096
   Morton J, 2012, DIABETES CARE, V35, P2201, DOI 10.2337/dc12-0306
   Mott S, 2000, ATHEROSCLEROSIS, V152, P457, DOI 10.1016/S0021-9150(99)00498-0
   Muntner P, 2000, KIDNEY INT, V58, P293, DOI 10.1046/j.1523-1755.2000.00165.x
   Muso E, 2014, CLIN EXP NEPHROL, V18, P286, DOI 10.1007/s10157-013-0930-5
   Musso G, 2013, PROG LIPID RES, V52, P175, DOI 10.1016/j.plipres.2012.11.002
   Nakamura T, 2005, AM J KIDNEY DIS, V45, P48, DOI 10.1053/j.ajkd.2004.09.013
   Nelson RH, 2013, PRIMARY CARE, V40, P195, DOI 10.1016/j.pop.2012.11.003
   NESTEL PJ, 1982, NEW ENGL J MED, V307, P329, DOI 10.1056/NEJM198208053070601
   Nichols B, 2015, KIDNEY INT, V87, P332, DOI 10.1038/ki.2014.270
   Niewczas MA, 2012, J AM SOC NEPHROL, V23, P507, DOI 10.1681/ASN.2011060627
   Niewczas MA, 2009, CLIN J AM SOC NEPHRO, V4, P62, DOI 10.2215/CJN.03010608
   Nishiwaki M, 2006, ARTERIOSCL THROM VAS, V26, P1370, DOI 10.1161/01.ATV.0000217910.90210.99
   Nosadini R, 2011, NUTR METAB CARDIOVAS, V21, P79, DOI 10.1016/j.numecd.2010.10.002
   Obermayr RP, 2008, NEPHROL DIAL TRANSPL, V23, P1265, DOI 10.1093/ndt/gfm790
   OHTA Y, 1986, AM J KIDNEY DIS, V7, P41, DOI 10.1016/S0272-6386(86)80055-5
   Ota T, 2003, DIABETOLOGIA, V46, P843, DOI 10.1007/s00125-003-1099-3
   Pagler TA, 2011, CIRC RES, V108, P194, DOI 10.1161/CIRCRESAHA.110.228619
   Pallottini V, 2008, J CELL BIOCHEM, V104, P701, DOI 10.1002/jcb.21757
   Panduru NM, 2013, DIABETES CARE, V36, P2077, DOI 10.2337/dc12-1868
   Patel A, 2008, NEW ENGL J MED, V358, P2560, DOI 10.1056/NEJMoa0802987
   Paykov ME, 2015, KIDNEY INT, V87, P812, DOI 10.1038/ki.2014.330
   Pentchev Peter G., 1994, Trends in Cell Biology, V4, P365, DOI 10.1016/0962-8924(94)90086-8
   PENTCHEV PG, 1985, P NATL ACAD SCI USA, V82, P8247, DOI 10.1073/pnas.82.23.8247
   Philit JB, 2002, NEPHROL DIAL TRANSPL, V17, P1829, DOI 10.1093/ndt/17.10.1829
   Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871
   Proctor G, 2006, DIABETES, V55, P2502, DOI 10.2337/db05-0603
   Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677
   RADER DJ, 1994, J CLIN INVEST, V93, P321, DOI 10.1172/JCI116962
   Rankin EB, 2009, MOL CELL BIOL, V29, P4527, DOI 10.1128/MCB.00200-09
   Ruan XZ, 2009, NAT REV NEPHROL, V5, P713, DOI 10.1038/nrneph.2009.184
   Ruan XZ, 2003, J AM SOC NEPHROL, V14, P593, DOI 10.1097/01.ASN.0000050414.52908.DA
   Ruan XZ, 2001, KIDNEY INT, V60, P1716, DOI 10.1046/j.1523-1755.2001.00025.x
   Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921
   Rye KA, 2014, J LIPID RES, V55, P168, DOI 10.1194/jlr.R039297
   Sacks FM, 2014, CIRCULATION, V129, P999, DOI 10.1161/CIRCULATIONAHA.113.002529
   SAITO T, 1989, AM J KIDNEY DIS, V13, P148, DOI 10.1016/S0272-6386(89)80134-9
   Saito T, 2006, AM J KIDNEY DIS, V47, P199, DOI 10.1053/j.ajkd.2005.10.017
   SAITO T, 1993, J PATHOL, V170, P179, DOI 10.1002/path.1711700214
   Sam R, 2006, AM J KIDNEY DIS, V47, P539, DOI 10.1053/j.ajkd.2005.12.031
   Schaeffner ES, 2003, J AM SOC NEPHROL, V14, P2084, DOI 10.1681/ASN.V1482084
   Sieber J, 2013, AM J PATHOL, V183, P735, DOI 10.1016/j.ajpath.2013.05.023
   Sieber J, 2010, AM J PHYSIOL-RENAL, V299, pF821, DOI 10.1152/ajprenal.00196.2010
   Simons M, 2001, AM J PATHOL, V159, P1069, DOI 10.1016/S0002-9440(10)61782-8
   Singh DK, 2008, NAT CLIN PRACT NEPHR, V4, P216, DOI 10.1038/ncpneph0757
   Sluimer JC, 2008, J AM COLL CARDIOL, V51, P1258, DOI 10.1016/j.jacc.2007.12.025
   Soetikno V, 2013, MOL NUTR FOOD RES, V57, P1649, DOI 10.1002/mnfr.201200540
   Sun LJ, 2002, J BIOL CHEM, V277, P18919, DOI 10.1074/jbc.M110650200
   SUZAKI K, 1990, ATHEROSCLEROSIS, V80, P181, DOI 10.1016/0021-9150(90)90025-E
   Tabet F, 2009, CLIN SCI, V116, P87, DOI 10.1042/CS20080106
   Takahashi S, 2013, J AM SOC NEPHROL, V24, P1305, DOI 10.1681/ASN.2012090913
   Tang CR, 2010, J LIPID RES, V51, P1719, DOI 10.1194/jlr.M003525
   Tsuruya K, 2015, AM J KIDNEY DIS, V66, P972, DOI 10.1053/j.ajkd.2015.05.011
   Usui H, 2003, NEPHROL DIAL TRANSPL, V18, P265, DOI 10.1093/ndt/18.2.265
   VANGOOR H, 1993, AM J PATHOL, V142, P1804
   Vaziri ND, 2006, AM J PHYSIOL-RENAL, V290, pF262, DOI 10.1152/ajprenal.00099.2005
   Vaziri Nosratola D, 2006, Hemodial Int, V10, P1, DOI 10.1111/j.1542-4758.2006.01168.x
   Vaziri ND, 2014, CLIN EXP NEPHROL, V18, P265, DOI 10.1007/s10157-013-0847-z
   Vaziri ND, 2010, NEPHROL DIAL TRANSPL, V25, P3525, DOI 10.1093/ndt/gfq274
   Vengellur A, 2003, GENE EXPRESSION, V11, P181, DOI 10.3727/000000003108749062
   Voight BF, 2012, LANCET, V380, P572, DOI 10.1016/S0140-6736(12)60312-2
   Wan GH, 2008, J BIOL CHEM, V283, P21540, DOI 10.1074/jbc.M800214200
   Weidemann A, 2008, J AM SOC NEPHROL, V19, P486, DOI 10.1681/ASN.2007040419
   Wen M, 2002, LAB INVEST, V82, P999, DOI 10.1097/01.LAB.0000022222.03120.D4
   Westerterp M, 2013, CIRC RES, V112, P1456, DOI 10.1161/CIRCRESAHA.113.301086
   Xu N, 1999, J BIOL CHEM, V274, P31286, DOI 10.1074/jbc.274.44.31286
   Xue C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083367
   Yamashita T, 2013, J ATHEROSCLER THROMB, V20, P790
   Yoo TH, 2015, J AM SOC NEPHROL, V26, P133, DOI 10.1681/ASN.2013111213
   Zhang GF, 2011, MOL CELL BIOCHEM, V346, P197, DOI 10.1007/s11010-010-0605-4
   Zhou HL, 2008, DIABETES-METAB RES, V24, P617, DOI 10.1002/dmrr.895
   Zuo PY, 2015, NUTR METAB CARDIOVAS, V25, P582, DOI 10.1016/j.numecd.2015.03.003
NR 162
TC 49
Z9 54
U1 1
U2 11
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1931-857X
EI 1522-1466
J9 AM J PHYSIOL-RENAL
JI Am. J. Physiol.-Renal Physiol.
PD MAR 15
PY 2016
VL 310
IS 6
BP F433
EP F445
DI 10.1152/ajprenal.00375.2015
PG 13
WC Physiology; Urology & Nephrology
SC Physiology; Urology & Nephrology
GA DG5BO
UT WOS:000372087700001
PM 26697982
OA Bronze, Green Published
DA 2021-10-30
ER

PT J
AU Cespedes, EM
   Hu, FB
   Redline, S
   Rosner, B
   Alcantara, C
   Cai, J
   Hall, MH
   Loredo, JS
   Mossavar-Rahmani, Y
   Ramos, AR
   Reid, KJ
   Shah, NA
   Sotres-Alvarez, D
   Zee, PC
   Wang, R
   Patel, SR
AF Cespedes, Elizabeth M.
   Hu, Frank B.
   Redline, Susan
   Rosner, Bernard
   Alcantara, Carmela
   Cai, Jianwen
   Hall, Martica H.
   Loredo, Jose S.
   Mossavar-Rahmani, Yasmin
   Ramos, Alberto R.
   Reid, Kathryn J.
   Shah, Neomi A.
   Sotres-Alvarez, Daniela
   Zee, Phyllis C.
   Wang, Rui
   Patel, Sanjay R.
TI Comparison of Self-Reported Sleep Duration With Actigraphy: Results From
   the Hispanic Community Health Study/Study of Latinos Sueno Ancillary
   Study
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE actigraphy; Hispanic Americans; Latinos; measurement error; sleep; sleep
   duration; validation studies
ID RECOVERY BIOMARKERS; ASSOCIATION; POPULATION; PROTEIN; ADULTS;
   VALIDATION; INSOMNIA; DESIGN; ENERGY; INDEX
AB Most studies of sleep and health outcomes rely on self-reported sleep duration, although correlation with objective measures is poor. In this study, we defined sociodemographic and sleep characteristics associated with misreporting and assessed whether accounting for these factors better explains variation in objective sleep duration among 2,086 participants in the Hispanic Community Health Study/Study of Latinos who completed more than 5 nights of wrist actigraphy and reported habitual bed/wake times from 2010 to 2013. Using linear regression, we examined self-report as a predictor of actigraphy-assessed sleep duration. Mean amount of time spent asleep was 7.85 (standard deviation, 1.12) hours by self-report and 6.74 (standard deviation, 1.02) hours by actigraphy; correlation between them was 0.43. For each additional hour of self-reported sleep, actigraphy time spent asleep increased by 20 minutes (95% confidence interval: 19, 22). Correlations between self-reported and actigraphy-assessed time spent asleep were lower with male sex, younger age, sleep efficiency < 85%, and night-to-night variability in sleep duration a parts per thousand yen1.5 hours. Adding sociodemographic and sleep factors to self-reports increased the proportion of variance explained in actigraphy-assessed sleep slightly (18%-32%). In this large validation study including Hispanics/Latinos, we demonstrated a moderate correlation between self-reported and actigraphy-assessed time spent asleep. The performance of self-reports varied by demographic and sleep measures but not by Hispanic subgroup.
C1 [Cespedes, Elizabeth M.; Hu, Frank B.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Nutr, 665 Huntington Ave,3rd Floor, Boston, MA 02115 USA.
   [Cespedes, Elizabeth M.; Hu, Frank B.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Epidemiol, 665 Huntington Ave,3rd Floor, Boston, MA 02115 USA.
   [Cespedes, Elizabeth M.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA.
   [Redline, Susan; Wang, Rui; Patel, Sanjay R.] Brigham & Womens Hosp, Dept Med, Div Sleep & Circadian Disorders, 75 Francis St, Boston, MA 02115 USA.
   [Redline, Susan; Wang, Rui; Patel, Sanjay R.] Brigham & Womens Hosp, Dept Neurol, Div Sleep & Circadian Disorders, 75 Francis St, Boston, MA 02115 USA.
   [Rosner, Bernard; Wang, Rui] Harvard Univ, Sch Med, Channing Div Network Med, Boston, MA USA.
   [Rosner, Bernard; Wang, Rui] Harvard Univ, Dept Biostat, TH Chan Sch Publ Hlth, Boston, MA 02115 USA.
   [Alcantara, Carmela] Columbia Univ, Dept Med, Med Ctr, New York, NY USA.
   [Alcantara, Carmela] Columbia Univ, Sch Social Work, New York, NY USA.
   [Cai, Jianwen; Sotres-Alvarez, Daniela] Univ N Carolina, Dept Biostat, Collaborat Studies Coordinating Ctr, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA.
   [Hall, Martica H.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA.
   [Loredo, Jose S.] Univ Calif San Diego, Sch Med, Div Pulm & Crit Care Med, Dept Med, San Diego, CA 92103 USA.
   [Loredo, Jose S.] VA San Diego Healthcare Syst, Sleep Med Sect, Med Serv, San Diego, CA USA.
   [Mossavar-Rahmani, Yasmin; Shah, Neomi A.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA.
   [Ramos, Alberto R.] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA.
   [Reid, Kathryn J.] Northwestern Univ, Dept Neurol, Feinberg Sch Med, Chicago, IL USA.
   [Shah, Neomi A.] Montefiore Med Ctr, Dept Med, New York, NY USA.
   [Zee, Phyllis C.] Northwestern Univ, Dept Prevent Med, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Zee, Phyllis C.] Univ Illinois, Inst Minor Hlth Res, Chicago, IL USA.
RP Cespedes, EM (corresponding author), Harvard Univ, TH Chan Sch Publ Hlth, Dept Nutr, 665 Huntington Ave,3rd Floor, Boston, MA 02115 USA.; Cespedes, EM (corresponding author), Harvard Univ, TH Chan Sch Publ Hlth, Dept Epidemiol, 665 Huntington Ave,3rd Floor, Boston, MA 02115 USA.
EM emc611@mail.harvard.edu
RI Hall, Martica/D-2809-2012; DeMarcus, Forrest/O-9190-2016; Feliciano,
   Elizabeth Cespedes/AAD-4459-2020; Sotres-Alvarez, Daniela/O-9085-2016;
   Ramos, Alberto/X-4249-2019; Wang, Rui/X-1699-2019
OI Hall, Martica/0000-0003-0642-2098; Feliciano, Elizabeth
   Cespedes/0000-0003-1192-4017; Sotres-Alvarez,
   Daniela/0000-0002-3226-6140; Patel, Sanjay/0000-0002-9142-5172;
   Mossavar-Rahmani, Yasmin/0000-0002-9214-6124
FU National Heart, Lung, and Blood Institute (NHLBI)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [HL098297];
   University of North Carolina [N01-HC65233]; University of Miami
   [N01-HC65234]; Albert Einstein College of Medicine [N01-HC65235];
   Northwestern University [N01-HC65236]; San Diego State University
   [N01-HC65237]; National Institute of Diabetes and Digestive and Kidney
   DiseasesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Diabetes &
   Digestive & Kidney Diseases (NIDDK) [T32 DK007703]; DIVISION OF
   EPIDEMIOLOGY AND CLINICAL APPLICATIONSUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Eye Institute (NEI) [N01HC065233] Funding Source: NIH RePORTER; NATIONAL
   CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Advancing Translational Sciences (NCATS)
   [UL1TR001073, KL2TR000461] Funding Source: NIH RePORTER; NATIONAL HEART,
   LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [U01HL065233, R01HL098297, R01HL065234,
   K23HL125748, K23HL125923] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Diabetes & Digestive & Kidney Diseases
   (NIDDK) [T32DK007703] Funding Source: NIH RePORTER
FX The Sueno ancillary sleep study was supported by a National Heart, Lung,
   and Blood Institute (NHLBI) grant (HL098297) to Brigham and Women's
   Hospital. The Hispanic Community Health Study/Study of Latinos was
   carried out as a collaborative study supported by contracts between the
   NHLBI and the University of North Carolina (N01-HC65233), the University
   of Miami (N01-HC65234), Albert Einstein College of Medicine
   (N01-HC65235), Northwestern University (N01-HC65236), and San Diego
   State University (N01-HC65237). The following institutes/centers/offices
   contributed to the Hispanic Community Health Study/Study of Latinos
   through a transfer of funds to the NHLBI: the National Institute on
   Minority Health and Health Disparities, the National Institute on
   Deafness and Other Communication Disorders, the National Institute of
   Dental and Craniofacial Research, the National Institute of Diabetes and
   Digestive and Kidney Diseases, the National Institute of Neurological
   Disorders and Stroke, and the National Institutes of Health Office of
   Dietary Supplements. E.M.C. was supported by grant T32 DK007703 from the
   National Institute of Diabetes and Digestive and Kidney Diseases.
CR Ancoli-Israel S, 2003, SLEEP, V26, P342, DOI 10.1093/sleep/26.3.342
   ANDRESEN EM, 1994, AM J PREV MED, V10, P77, DOI 10.1016/S0749-3797(18)30622-6
   Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4
   Curcio G, 2004, CLIN NEUROPHYSIOL, V115, P1178, DOI 10.1016/j.clinph.2003.12.018
   Girschik J, 2012, J EPIDEMIOL, V22, P462, DOI 10.2188/jea.JE20120012
   Gottlieb DJ, 2006, SLEEP, V29, P1009, DOI 10.1093/sleep/29.8.1009
   Grandner MA, 2014, SLEEP MED, V15, P42, DOI 10.1016/j.sleep.2013.09.012
   Grandner MA, 2013, SLEEP, V36, P769, DOI 10.5665/sleep.2646
   Hall MH, 2009, SLEEP, V32, P73
   Hasler G, 2004, SLEEP, V27, P661, DOI 10.1093/sleep/27.4.661
   Hoos T, 2012, J PHYS ACT HEALTH, V9, P698, DOI 10.1123/jpah.9.5.698
   Jackson CL, 2014, SOC SCI MED, V118, P71, DOI 10.1016/j.socscimed.2014.07.059
   Jackson CL, 2013, DIABETES CARE, V36, P3557, DOI 10.2337/dc13-0777
   JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540
   Knutson KL, 2011, AM J HUM BIOL, V23, P138, DOI 10.1002/ajhb.21108
   Kurina LM, 2013, ANN EPIDEMIOL, V23, P361, DOI 10.1016/j.annepidem.2013.03.015
   Kushida CA, 2001, SLEEP MED, V2, P389, DOI 10.1016/S1389-9457(00)00098-8
   Lauderdale DS, 2008, EPIDEMIOLOGY, V19, P838, DOI 10.1097/EDE.0b013e318187a7b0
   Lauderdale DS, 2009, AM J EPIDEMIOL, V170, P805, DOI 10.1093/aje/kwp230
   Lavange LM, 2010, ANN EPIDEMIOL, V20, P642, DOI 10.1016/j.annepidem.2010.05.006
   Lemola S, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0071292, 10.1371/journal.pone.0082059]
   Lind Bonnie K, 2003, Sleep Breath, V7, P13, DOI 10.1007/s11325-003-0013-z
   Loredo JS, 2010, SLEEP, V33, P962, DOI 10.1093/sleep/33.7.962
   Marino M, 2013, SLEEP, V36, P1747, DOI 10.5665/sleep.3142
   Miller CB, 2015, SLEEP HEALTH, V1, P133, DOI 10.1016/j.sleh.2015.02.007
   Mossavar-Rahmani Y, 2015, AM J EPIDEMIOL, V181, P996, DOI 10.1093/aje/kwu468
   Patel SR, 2015, SLEEP, V38, P1515, DOI 10.5665/sleep.5036
   Patel SR, 2015, SLEEP, V38, P1497, DOI 10.5665/sleep.4998
   Patel SR, 2012, SLEEP, V35, P641, DOI 10.5665/sleep.1822
   Prentice RL, 2011, AM J EPIDEMIOL, V174, P591, DOI 10.1093/aje/kwr140
   RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306
   Redline S, 2014, AM J RESP CRIT CARE, V189, P335, DOI 10.1164/rccm.201309-1735OC
   Sadeh A, 2002, SLEEP MED REV, V6, P113, DOI 10.1053/smrv.2001.0182
   Schmid SM, 2015, LANCET DIABETES ENDO, V3, P52, DOI 10.1016/S2213-8587(14)70012-9
   Silva GE, 2007, J CLIN SLEEP MED, V3, P622
   Sorlie PD, 2010, ANN EPIDEMIOL, V20, P629, DOI 10.1016/j.annepidem.2010.03.015
   St-Onge MP, 2010, INT J ENDOCRINOL, V2010, DOI 10.1155/2010/726071
   Van Den Berg JF, 2008, J SLEEP RES, V17, P295, DOI 10.1111/j.1365-2869.2008.00638.x
   Van Someren EJW, 2007, J SLEEP RES, V16, P269, DOI 10.1111/j.1365-2869.2007.00592.x
   Zhao H, 2013, ASIAN PAC J CANCER P, V14, P7509, DOI 10.7314/APJCP.2013.14.12.7509
NR 40
TC 116
Z9 116
U1 0
U2 27
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
EI 1476-6256
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD MAR 15
PY 2016
VL 183
IS 6
BP 561
EP 573
DI 10.1093/aje/kwv251
PG 13
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DH1XY
UT WOS:000372579500008
PM 26940117
OA Green Published, Bronze
HC Y
HP N
DA 2021-10-30
ER

PT J
AU Beasley, JM
   Jung, M
   Tasevska, N
   Wong, WW
   Siega-Riz, AM
   Sotres-Alvarez, D
   Gellman, MD
   Kizer, JR
   Shaw, PA
   Stamler, J
   Stoutenberg, M
   Van Horn, L
   Franke, AA
   Wylie-Rosett, J
   Mossavar-Rahmani, Y
AF Beasley, J. M.
   Jung, M.
   Tasevska, N.
   Wong, W. W.
   Siega-Riz, A. M.
   Sotres-Alvarez, D.
   Gellman, M. D.
   Kizer, J. R.
   Shaw, P. A.
   Stamler, J.
   Stoutenberg, M.
   Van Horn, L.
   Franke, A. A.
   Wylie-Rosett, J.
   Mossavar-Rahmani, Y.
TI Biomarker-predicted sugars intake compared with self-reported measures
   in US Hispanics/Latinos: results from the HCHS/SOL SOLNAS study
SO PUBLIC HEALTH NUTRITION
LA English
DT Article
DE Sugars; Doubly labelled water; Self-report; Urinary sucrose and fructose
   biomarkers; Hispanics/Latinos
ID DOUBLY-LABELED WATER; RECOVERY BIOMARKERS; SWEETENED BEVERAGES;
   ENERGY-EXPENDITURE; MEASUREMENT ERROR; URINARY SUCROSE; PROTEIN-INTAKE;
   CONSUMPTION; RISK; VALIDATION
AB Objective: Measurement error in self-reported total sugars intake may obscure associations between sugars consumption and health outcomes, and the sum of 24 h urinary sucrose and fructose may serve as a predictive biomarker of total sugars intake.
   Design: The Study of Latinos: Nutrition & Physical Activity Assessment Study (SOLNAS) was an ancillary study to the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) cohort. Doubly labelled water and 24 h urinary sucrose and fructose were used as biomarkers of energy and sugars intake, respectively. Participants' diets were assessed by up to three 24 h recalls (88% had two or more recalls). Procedures were repeated approximately 6 months after the initial visit among a subset of ninety-six participants.
   Setting: Four centres (Bronx, NY; Chicago, IL; Miami, FL; San Diego, CA) across the USA.
   Subjects: Men and women (n 477) aged 18-74 years.
   Results: The geometric mean of total sugars was 167.5 (95% CI 154.4, 181.7) g/d for the biomarker-predicted and 90.6 (95% CI 87.6, 93.6) g/d for the self-reported total sugars intake. Self-reported total sugars intake was not correlated with biomarker-predicted sugars intake (r=-0.06, P=0.20, n 450). Among the reliability sample (n 90), the reproducibility coefficient was 0 59 for biomarker-predicted and 0 20 for self-reported total sugars intake.
   Conclusions: Possible explanations for the lack of association between biomarker-predicted and self-reported sugars intake include measurement error in self-reported diet, high intra-individual variability in sugars intake, and/or urinary sucrose and fructose may not be a suitable proxy for total sugars intake in this study population.
C1 [Beasley, J. M.] NYU Sch Med, Dept Med, 550 First Ave,OBV CD 673, New York, NY 10016 USA.
   [Jung, M.] Johns Hopkins Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   [Tasevska, N.] Arizona State Univ, Sch Nutr & Hlth Promot, Phoenix, AZ USA.
   [Wong, W. W.] Baylor Coll Med, ARS, USDA, Childrens Nutr Res Ctr,Dept Pediat, Houston, TX 77030 USA.
   [Siega-Riz, A. M.] Univ North Carolina Chapel Hill, Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA.
   [Siega-Riz, A. M.] Univ North Carolina Chapel Hill, Gillings Sch Global Publ Hlth, Dept Nutr, Chapel Hill, NC USA.
   [Sotres-Alvarez, D.] Univ North Carolina Chapel Hill, Gillings Sch Global Publ Hlth, Dept Biostat, Collaborat Studies Coordinating Ctr, Chapel Hill, NC USA.
   [Gellman, M. D.] Univ Miami, Miller Sch Med, Behav Med Res Ctr, Dept Psychol, Miami, FL 33136 USA.
   [Kizer, J. R.; Wylie-Rosett, J.; Mossavar-Rahmani, Y.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA.
   [Shaw, P. A.] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
   [Stamler, J.; Van Horn, L.] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA.
   [Stoutenberg, M.] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA.
   [Franke, A. A.] Univ Hawaii, Ctr Canc, Honolulu, HI 96822 USA.
RP Beasley, JM (corresponding author), NYU Sch Med, Dept Med, 550 First Ave,OBV CD 673, New York, NY 10016 USA.
EM jeannette.beasley@nyumc.org
RI Beasley, Jeannette/Y-4065-2019
OI Beasley, Jeannette/0000-0002-9343-6895; Mossavar-Rahmani,
   Yasmin/0000-0002-9214-6124; Wong, William/0000-0002-7147-5850
FU Sackler Institute for Nutrition Sciences; National Heart, Lung, and
   Blood Institute (NHLBI)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [11414319-R01HL095856]; NHLBIUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [N01-HC65233];
   University of Miami [N01-HC65234]; Albert Einstein College of Medicine
   [N01-HC65235]; Northwestern University [N01-HC65236]; San Diego State
   University [N01-HC65237]; National Center for Advancing Translational
   Sciences at the National Institutes of Health [UL1 TR001073]; HCHS/SOL;
   EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN
   DEVELOPMENTUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD) [P2CHD050924]
   Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI) [P30CA071789] Funding Source:
   NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Advancing Translational
   Sciences (NCATS) [UL1TR001073, KL2TR000461] Funding Source: NIH
   RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL065234,
   R01HL095856, U01HL065233, T32HL007024] Funding Source: NIH RePORTER
FX The authors would like to acknowledge Laurie J. Custer at the University
   of Hawaii for her LCMS work. The authors also thank the staff and
   participants of the Hispanic Community Health Study/Study of Latinos
   (HCHS/SOL) for their important contributions (investigators' website:
   http://www.cscc.unc.edu.access.library.miami.edu/hchs/). Financial support: The Sackler Institute
   for Nutrition Sciences funded this study. The Study of Latinos Nutrition
   & Physical Activity Assessment Study (SOLNAS) was supported by the
   National Heart, Lung, and Blood Institute (NHLBI; grant
   #11414319-R01HL095856). The HCHS/SOL was carried out as a collaborative
   study supported by contracts from the NHLBI to the University of North
   Carolina (N01-HC65233), the University of Miami (N01-HC65234), Albert
   Einstein College of Medicine (N01-HC65235), Northwestern University
   (N01-HC65236) and San Diego State University (N01-HC65237). The
   following institutes/centres/offices contribute to the HCHS/SOL through
   a transfer of funds to the NHLBI: the National Center on Minority Health
   and Health Disparities; the National Institute of Deafness and Other
   Communications Disorders; the National Institute of Dental and
   Craniofacial Research; the National Institute of Diabetes and Digestive
   and Kidney Diseases; the National Institute of Neurological Disorders
   and Stroke; and the Office of Dietary Supplements. Additional support at
   the Albert Einstein College of Medicine was provided from the Clinical &
   Translational Science Award (grant number UL1 TR001073) from the
   National Center for Advancing Translational Sciences at the National
   Institutes of Health. The funders had no role in the design, analysis or
   writing of this article. Conflict of interest: The authors have no
   conflict of interest to disclose. Authorship: Y.M.-R. and J.M.B.
   designed the research; W.W.W., P.A.S., A.M.S.-R., D.S.-A., M.D.G., M.S.,
   L.V.H., A.A.F. and Y.M.-R. conducted the research and provided essential
   materials; M.J., P.A.S., N.T., D.S.-A. and J.M.B. developed the analytic
   approach and analysed the data; and J.M.B., J.R.K., J.S., J.W.-R. and
   Y.M.-R. wrote the paper. All authors read and approved the final
   manuscript. Ethics of human subject participation: This study was
   conducted according to the guidelines laid down in the Declaration of
   Helsinki and all procedures involving human subjects/patients were
   approved by the Albert Einstein College of Medicine Institutional Review
   Board. Written informed consent was obtained from all subjects.
CR Beasley JM, 2011, J NUTR, V141, P1502, DOI 10.3945/jn.110.135814
   Beasley JM, 2010, J AM GERIATR SOC, V58, P1063, DOI 10.1111/j.1532-5415.2010.02866.x
   Bingham SA, 2006, PUBLIC HEALTH NUTR, V5, P821
   Bingham S, 2007, CANCER EPIDEM BIOMAR, V16, P1651, DOI 10.1158/1055-9965.EPI-06-1050
   Blanc S, 2002, J APPL PHYSIOL, V92, P1036, DOI 10.1152/japplphysiol.00743.2001
   Bull FC, 2009, J PHYS ACT HEALTH, V6, P790, DOI 10.1123/jpah.6.6.790
   Dodd KW, 2006, J AM DIET ASSOC, V106, P1640, DOI 10.1016/j.jada.2006.07.011
   Freedman LS, 2014, AM J EPIDEMIOL, V180, P172, DOI 10.1093/aje/kwu116
   Freedman Laurence S, 2010, Epidemiol Perspect Innov, V7, P2, DOI 10.1186/1742-5573-7-2
   Han E, 2013, J ACAD NUTR DIET, V113, P43, DOI 10.1016/j.jand.2012.09.016
   Hu FB, 2010, PHYSIOL BEHAV, V100, P47, DOI 10.1016/j.physbeh.2010.01.036
   Jenab M, 2009, HUM GENET, V125, P507, DOI 10.1007/s00439-009-0662-5
   Johnson RK, 2009, CIRCULATION, V120, P1011, DOI 10.1161/CIRCULATIONAHA.109.192627
   Joosen AMCP, 2008, INT J OBESITY, V32, P1736, DOI 10.1038/ijo.2008.145
   Kipnis V, 2003, AM J EPIDEMIOL, V158, P14, DOI 10.1093/aje/kwg091
   KLEIN PD, 1984, HUM NUTR-CLIN NUTR, V38C, P95
   Kuhnle GGC, 2008, RAPID COMMUN MASS SP, V22, P279, DOI 10.1002/rcm.3355
   Kuhnle GGC, 2015, PUBLIC HEALTH NUTR, V18, P2815, DOI 10.1017/S1368980015000300
   Lissner L, 2007, INT J OBESITY, V31, P956, DOI 10.1038/sj.ijo.0803527
   Mossavar-Rahmani Y, 2015, AM J EPIDEMIOL, V181, P996, DOI 10.1093/aje/kwu468
   Neuhouser ML, 2008, AM J EPIDEMIOL, V167, P1247, DOI 10.1093/aje/kwn026
   Nielsen SJ, 2007, J AM DIET ASSOC, V107, P792, DOI 10.1016/j.jada.2007.02.003
   Prentice RL, 2002, PUBLIC HEALTH NUTR, V5, P977, DOI 10.1079/PHN2002382
   Prentice RL, 2011, AM J EPIDEMIOL, V174, P591, DOI 10.1093/aje/kwr140
   Prentice RL, 2009, STAT BIOSCI, V1, P112, DOI 10.1007/s12561-009-9003-4
   Prentice RL, 2011, EPIDEMIOLOGY, V22, P170, DOI 10.1097/EDE.0b013e31820839bc
   Prentice RL, 2009, AM J EPIDEMIOL, V169, P977, DOI 10.1093/aje/kwp008
   RAVUSSIN E, 1991, AM J PHYSIOL, V261, pE402, DOI 10.1152/ajpendo.1991.261.3.E402
   Schneiderman N, 2014, DIABETES CARE, V37, P2233, DOI 10.2337/dc13-2939
   Siega-Riz AM, 2014, AM J CLIN NUTR, V99, P1487, DOI 10.3945/ajcn.113.082685
   Sorlie PD, 2010, ANN EPIDEMIOL, V20, P629, DOI 10.1016/j.annepidem.2010.03.015
   Subar AF, 2003, AM J EPIDEMIOL, V158, P1, DOI 10.1093/aje/kwg092
   Tasevska N, 2005, CANCER EPIDEM BIOMAR, V14, P1287, DOI 10.1158/1055-9965.EPI-04-0827
   Tasevska N, 2011, CANCER EPIDEM BIOMAR, V20, P490, DOI 10.1158/1055-9965.EPI-10-0820
   Tasevska N, 2015, NUTRIENTS, V7, P5816, DOI 10.3390/nu7075255
   Tasevska N, 2014, CANCER EPIDEM BIOMAR, V23, P2874, DOI 10.1158/1055-9965.EPI-14-0594
   Tasevska N, 2014, AM J CLIN NUTR, V99, P1077, DOI 10.3945/ajcn.113.069369
   Tooze JA, 2010, STAT MED, V29, P2857, DOI 10.1002/sim.4063
   WONG WW, 1987, AM J CLIN NUTR, V45, P905, DOI 10.1093/ajcn/45.5.905
   Worldwide Health Organisation (WHO), 2013, GLOB PHYS ACT QUEST
NR 40
TC 7
Z9 7
U1 0
U2 1
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 1368-9800
EI 1475-2727
J9 PUBLIC HEALTH NUTR
JI Public Health Nutr.
PD DEC
PY 2016
VL 19
IS 18
BP 3256
EP 3264
DI 10.1017/S1368980016001580
PG 9
WC Public, Environmental & Occupational Health; Nutrition & Dietetics
SC Public, Environmental & Occupational Health; Nutrition & Dietetics
GA FH6CU
UT WOS:000411260700002
PM 27339078
OA Green Submitted, Bronze, Green Accepted
DA 2021-10-30
ER

PT J
AU Mossavar-Rahmani, Y
   Shaw, PA
   Wong, WW
   Sotres-Alvarez, D
   Gellman, MD
   Van Horn, L
   Stoutenberg, M
   Daviglus, ML
   Wylie-Rosett, J
   Siega-Riz, AM
   Ou, FS
   Prentice, RL
AF Mossavar-Rahmani, Yasmin
   Shaw, Pamela A.
   Wong, William W.
   Sotres-Alvarez, Daniela
   Gellman, Marc D.
   Van Horn, Linda
   Stoutenberg, Mark
   Daviglus, Martha L.
   Wylie-Rosett, Judith
   Siega-Riz, Anna Maria
   Ou, Fang-Shu
   Prentice, Ross L.
TI Applying Recovery Biomarkers to Calibrate Self-Report Measures of Energy
   and Protein in the Hispanic Community Health Study/Study of Latinos
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE biological markers; calibration equations; dietary measurement error;
   Hispanics/Latinos; 24-hour dietary recall; nutrition assessment
ID DOUBLY-LABELED WATER; URINE; RISK; ASSOCIATIONS; BACKGROUNDS;
   EXPENDITURE; CONSUMPTION; SAMPLES; DESIGN; DIET
AB We investigated measurement error in the self-reported diets of US Hispanics/Latinos, who are prone to obesity and related comorbidities, by background (Central American, Cuban, Dominican, Mexican, Puerto Rican, and South American) in 2010-2012. In 477 participants aged 18-74 years, doubly labeled water and urinary nitrogen were used as objective recovery biomarkers of energy and protein intakes. Self-report was captured from two 24-hour dietary recalls. All measures were repeated in a subsample of 98 individuals. We examined the bias of dietary recalls and their associations with participant characteristics using generalized estimating equations. Energy intake was underestimated by 25.3% (men, 21.8%; women, 27.3%), and protein intake was underestimated by 18.5% (men, 14.7%; women, 20.7%). Protein density was overestimated by 10.7% (men, 11.3%; women, 10.1%). Higher body mass index and Hispanic/Latino background were associated with underestimation of energy (P < 0.05). For protein intake, higher body mass index, older age, nonsmoking, Spanish speaking, and Hispanic/Latino back-ground were associated with underestimation (P < 0.05). Systematic underreporting of energy and protein intakes and overreporting of protein density were found to vary significantly by Hispanic/Latino background. We developed calibration equations that correct for subject-specific error in reporting that can be used to reduce bias in diet-disease association studies.
C1 [Mossavar-Rahmani, Yasmin; Wylie-Rosett, Judith] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10461 USA.
   [Shaw, Pamela A.] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
   [Wong, William W.] ARS, USDA, Houston, TX USA.
   [Wong, William W.] Baylor Coll Med, Dept Pediat, Childrens Nutr Res Ctr, Houston, TX 77030 USA.
   [Sotres-Alvarez, Daniela; Ou, Fang-Shu] Univ N Carolina, Dept Biostat, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA.
   [Gellman, Marc D.] Univ Miami, Dept Psychol, Coral Gables, FL 33124 USA.
   [Van Horn, Linda] Northwestern Univ, Dept Prevent Med, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Stoutenberg, Mark] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA.
   [Daviglus, Martha L.] Univ Illinois, Inst Minor Hlth Res, Chicago, IL USA.
   [Siega-Riz, Anna Maria] Univ N Carolina, Dept Nutr, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA.
   [Siega-Riz, Anna Maria] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA.
   [Prentice, Ross L.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA.
RP Mossavar-Rahmani, Y (corresponding author), Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Div Hlth Promot & Nutr Res, 1300 Morris Pk Ave,Block Bldg,Room 339, Bronx, NY 10461 USA.
EM yasmin.mossavar-rahmani@einstein.yu.edu
RI Sotres-Alvarez, Daniela/O-9085-2016; DeMarcus, Forrest/O-9190-2016
OI Sotres-Alvarez, Daniela/0000-0002-3226-6140; Mossavar-Rahmani,
   Yasmin/0000-0002-9214-6124; Wong, William/0000-0002-7147-5850
FU National Heart, Lung, and Blood InstituteUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [11414319-R01HL095856,
   NO1-HC65233, N01-HC65234, N01-HC65235, N01-HC65236, N01-HC65237];
   National Center for Advancing Translational Sciences at the National
   Institutes of Health [UL1 TR001073]; National Cancer InstituteUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Cancer Institute (NCI) [CA53996];
   National Heart, Lung, and Blood Institute: the National Center on
   Minority Health and Health Disparities; National Heart, Lung, and Blood
   Institute: National Institute of Deafness and Other Communications
   Disorders; National Heart, Lung, and Blood Institute: National Institute
   of Dental and Craniofacial Research; National Heart, Lung, and Blood
   Institute: National Institute of Diabetes and Digestive and Kidney
   DiseasesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Diabetes &
   Digestive & Kidney Diseases (NIDDK)NIH National Heart Lung & Blood
   Institute (NHLBI); National Heart, Lung, and Blood Institute: National
   Institute of Neurological Disorders and StrokeUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI)NIH National Institute of
   Neurological Disorders & Stroke (NINDS); National Heart, Lung, and Blood
   Institute: Office of Dietary Supplements; DIVISION OF EPIDEMIOLOGY AND
   CLINICAL APPLICATIONSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Eye
   Institute (NEI) [N01HC065233] Funding Source: NIH RePORTER; EUNICE
   KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN
   DEVELOPMENTUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD) [P2CHD050924]
   Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI) [P01CA053996, R01CA119171]
   Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [UL1TR001073, KL2TR000461]
   Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [U01HL065233, R01HL065234, R01HL095856] Funding
   Source: NIH RePORTER
FX This work was supported by grant 11414319-R01HL095856 from the National
   Heart, Lung, and Blood Institute. The Hispanic Community Health
   Study/Study of Latinos was carried out as a collaborative study
   supported by contracts from the National Heart, Lung, and Blood
   Institute to the University of North Carolina (NO1-HC65233), University
   of Miami (N01-HC65234), Albert Einstein College of Medicine
   (N01-HC65235), Northwestern University (N01-HC65236), and San Diego
   State University (N01-HC65237). The following contribute to the Hispanic
   Community Health Study/Study of Latinos through a transfer of funds to
   the National Heart, Lung, and Blood Institute: the National Center on
   Minority Health and Health Disparities, the National Institute of
   Deafness and Other Communications Disorders, the National Institute of
   Dental and Craniofacial Research, the National Institute of Diabetes and
   Digestive and Kidney Diseases, the National Institute of Neurological
   Disorders and Stroke, and the Office of Dietary Supplements. Additional
   support at the Albert Einstein College of Medicine was provided from the
   Clinical and Translational Science Award (UL1 TR001073) from the
   National Center for Advancing Translational Sciences at the National
   Institutes of Health, and support at the Fred Hutchinson Cancer Research
   Center was provided from National Cancer Institute grant CA53996.
CR BINGHAM SA, 1994, AM J CLIN NUTR, V59, p227S, DOI 10.1093/ajcn/59.1.227S
   BLACK AE, 1986, HUM NUTR-CLIN NUTR, V40C, P381
   Blanc S, 2002, J APPL PHYSIOL, V92, P1036, DOI 10.1152/japplphysiol.00743.2001
   Daviglus ML, 2012, JAMA-J AM MED ASSOC, V308, P1775, DOI 10.1001/jama.2012.14517
   Emond JA, 2014, INT J OBESITY, V38, P603, DOI 10.1038/ijo.2013.130
   Harrison GG, 2000, J NUTR, V130, P2049, DOI 10.1093/jn/130.8.2049
   Kay MC, 2014, J PHYS ACT HEALTH, V11, P693, DOI 10.1123/jpah.2012-0171
   Kipnis V, 2003, AM J EPIDEMIOL, V158, P14, DOI 10.1093/aje/kwg091
   Lavange LM, 2010, ANN EPIDEMIOL, V20, P642, DOI 10.1016/j.annepidem.2010.05.006
   Mossavar-Rahmani Y, 2013, NUTR J, V12, DOI 10.1186/1475-2891-12-63
   Neuhouser ML, 2008, AM J EPIDEMIOL, V167, P1247, DOI 10.1093/aje/kwn026
   PRENTICE RL, 1982, BIOMETRIKA, V69, P331, DOI 10.1093/biomet/69.2.331
   Prentice RL, 2002, PUBLIC HEALTH NUTR, V5, P977, DOI 10.1079/PHN2002382
   Prentice RL, 2011, AM J EPIDEMIOL, V174, P591, DOI 10.1093/aje/kwr140
   Prentice RL, 2011, EPIDEMIOLOGY, V22, P170, DOI 10.1097/EDE.0b013e31820839bc
   Prentice RL, 2009, AM J EPIDEMIOL, V169, P977, DOI 10.1093/aje/kwp008
   Schoeller DA, 1996, J NUTR, V126, pS348
   Siega-Riz AM, 2014, AM J CLIN NUTR, V99, P1487, DOI 10.3945/ajcn.113.082685
   Sorlie PD, 2010, ANN EPIDEMIOL, V20, P629, DOI 10.1016/j.annepidem.2010.03.015
   Subar AF, 2013, EUR J CLIN NUTR, V67, P863, DOI 10.1038/ejcn.2013.62
   Tinker LF, 2011, AM J CLIN NUTR, V94, P1600, DOI 10.3945/ajcn.111.018648
   Tooze JA, 2004, AM J CLIN NUTR, V79, P795
   WEIR JBD, 1949, J PHYSIOL-LONDON, V109, P1, DOI 10.1113/jphysiol.1949.sp004363
   WONG WW, 1992, EUR J CLIN NUTR, V46, P69
   WONG WW, 1987, AM J CLIN NUTR, V45, P905, DOI 10.1093/ajcn/45.5.905
NR 25
TC 30
Z9 30
U1 0
U2 7
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
EI 1476-6256
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD JUN 15
PY 2015
VL 181
IS 12
BP 996
EP 1007
DI 10.1093/aje/kwu468
PG 12
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA CK4GE
UT WOS:000356180600009
PM 25995289
OA Green Published, Green Submitted, hybrid
DA 2021-10-30
ER

PT J
AU Kahkoska, AR
   Abrahamsen, TJ
   Alexander, GC
   Bennett, TD
   Chute, CG
   Haendel, MA
   Klein, KR
   Mehta, H
   Miller, JD
   Moffitt, RA
   Sturmer, T
   Kvist, K
   Buse, JB
AF Kahkoska, Anna R.
   Abrahamsen, Trine Julie
   Alexander, G. Caleb
   Bennett, Tellen D.
   Chute, Christopher G.
   Haendel, Melissa A.
   Klein, Klara R.
   Mehta, Hemalkumar
   Miller, Joshua D.
   Moffitt, Richard A.
   Sturmer, Til
   Kvist, Kajsa
   Buse, John B.
CA N3C Consortium
TI Association Between Glucagon-Like Peptide 1 Receptor Agonist and
   Sodium-Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes
SO DIABETES CARE
LA English
DT Article
ID MAXIMUM-LIKELIHOOD-ESTIMATION; TYPE-2; DISEASE; IMPACT
AB OBJECTIVE To determine the respective associations of premorbid glucagon-like peptide-1 receptor agonist (GLP1-RA) and sodium-glucose cotransporter 2 inhibitor (SGLT2i) use, compared with premorbid dipeptidyl peptidase 4 inhibitor (DPP4i) use, with severity of outcomes in the setting of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. RESEARCH DESIGN AND METHODS We analyzed observational data from SARS-CoV-2-positive adults in the National COVID Cohort Collaborative (N3C), a multicenter, longitudinal U.S. cohort (January 2018-February 2021), with a prescription for GLP1-RA, SGLT2i, or DPP4i within 24 months of positive SARS-CoV-2 PCR test. The primary outcome was 60-day mortality, measured from positive SARS-CoV-2 test date. Secondary outcomes were total mortality during the observation period and emergency room visits, hospitalization, and mechanical ventilation within 14 days. Associations were quantified with odds ratios (ORs) estimated with targeted maximum likelihood estimation using a super learner approach, accounting for baseline characteristics. RESULTS The study included 12,446 individuals (53.4% female, 62.5% White, mean +/- SD age 58.6 +/- 13.1 years). The 60-day mortality was 3.11% (387 of 12,446), with 2.06% (138 of 6,692) for GLP1-RA use, 2.32% (85 of 3,665) for SGLT2i use, and 5.67% (199 of 3,511) for DPP4i use. Both GLP1-RA and SGLT2i use were associated with lower 60-day mortality compared with DPP4i use (OR 0.54 [95% CI 0.37-0.80] and 0.66 [0.50-0.86], respectively). Use of both medications was also associated with decreased total mortality, emergency room visits, and hospitalizations. CONCLUSIONS Among SARS-CoV-2-positive adults, premorbid GLP1-RA and SGLT2i use, compared with DPP4i use, was associated with lower odds of mortality and other adverse outcomes, although DPP4i users were older and generally sicker.
C1 [Kahkoska, Anna R.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Nutr, Chapel Hill, NC 27515 USA.
   [Abrahamsen, Trine Julie; Kvist, Kajsa] Novo Nordisk AS, Copenhagen, Denmark.
   [Alexander, G. Caleb; Mehta, Hemalkumar] Johns Hopkins Bloomberg, Sch Publ Hlth, Ctr Drug Safety & Effectiveness, Baltimore, MD USA.
   [Alexander, G. Caleb; Mehta, Hemalkumar] Johns Hopkins Bloomberg, Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   [Alexander, G. Caleb] Johns Hopkins Med, Div Gen Internal Med, Baltimore, MD USA.
   [Bennett, Tellen D.] Univ Colorado, Sch Med, Dept Pediat, Sect Informat & Data Sci, Aurora, CO USA.
   [Chute, Christopher G.] Johns Hopkins Univ, Sch Med Publ Hlth & Nursing, Baltimore, MD USA.
   [Haendel, Melissa A.] Univ Colorado, Sch Med, Ctr Hlth AI, Aurora, CO USA.
   [Klein, Klara R.; Buse, John B.] Univ N Carolina, Sch Med, Dept Med, Div Endocrinol & Metab, Chapel Hill, NC 27515 USA.
   [Miller, Joshua D.] SUNY Stony Brook, Renaissance Sch Med, Dept Med, Div Endocrinol & Metab, Stony Brook, NY 11794 USA.
   [Moffitt, Richard A.] SUNY Stony Brook, Dept Biomed Informat, Stony Brook, NY 11794 USA.
   [Sturmer, Til] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27515 USA.
   [Buse, John B.] Univ N Carolina, Sch Med, NC Translat & Clin Sci Inst, Chapel Hill, NC 27515 USA.
RP Buse, JB (corresponding author), Univ N Carolina, Sch Med, Dept Med, Div Endocrinol & Metab, Chapel Hill, NC 27515 USA.; Buse, JB (corresponding author), Univ N Carolina, Sch Med, NC Translat & Clin Sci Inst, Chapel Hill, NC 27515 USA.
EM jbuse@med.unc.edu
FU National Institute of Diabetes and Digestive and Kidney Diseases,
   National Institutes of Health (NIH)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)
   [F30DK113728]; NCATS, NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [UL1TR002489]; National
   Institute of Diabetes and Digestive and Kidney Diseases, NIHUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Diabetes & Digestive &
   Kidney Diseases (NIDDK) [P30DK124723]; National Institute on Aging,
   NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)
   [R01 AG056479, R01 HL118255, R01MD011680]; NIH/Eunice Kennedy Shriver
   National Institute of Child Health and Human DevelopmentUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH Eunice Kennedy Shriver National Institute of Child Health &
   Human Development (NICHD); UNC Clinical and Translational Science Award
   [UL1TR002489]; American Diabetes AssociationAmerican Diabetes
   Association; Patient-Centered Outcomes Research
   InstitutePatient-Centered Outcomes Research Institute - PCORI; National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA; Carilion Clinic
   [UL1TR003015-02S2]; George Washington Children's Research Institute
   [UL1TR001876]; Duke University [UL1TR002553]; Johns Hopkins
   UniversityJohns Hopkins University [UL1TR003098]; Mayo Clinic Rochester
   [UL1TR002377]; Medical University of South Carolina [UL1TR001450]; Penn
   State Health Milton S. Hershey Medical Center [UL1TR002014]; Rush
   University Medical Center [UL1TR002389]; Stony Brook University
   [U24TR002306-04S1]; Ohio State UniversityOhio State University
   [UL1TR002733]; Tufts University (Boston, MA) [UL1TR002544-03S4];
   University of Massachusetts Medical School (Worcester, MA)
   [UL1TR001453]; University of Alabama at Birmingham [UL1TR003096];
   University of Arkansas for Medical Sciences [UL1TR003107]; University of
   ChicagoUniversity of Chicago [UL1TR002389]; University of Colorado
   Denver [UL1TR002535-03S2]; University of Illinois at Chicago
   [UL1TR002003]; University of Iowa [UL1TR002537]; University of Kentucky
   [UL1TR001998-04S1]; Maine Medical Center [P20GM103423]; University of
   Miami [UL1TR002736]; University of Michigan at Ann ArborUniversity of
   Michigan System [UL1TR002240]; University of MinnesotaUniversity of
   Minnesota System [UL1TR002494]; University of Nebraska-Lincoln
   [U54GM115458]; University of North Carolina at Chapel Hill
   [UL1TR002489]; Northwestern University [UL1TR001422]; University of
   Southern California [UL1TR001855]; University of Texas Medical Branch at
   Galveston [UL1TR001439]; University of Utah [UL1TR002538-03S3];
   University of WashingtonUniversity of Washington [UL1TR002319];
   University of Wisconsin-Madison [UL1TR002373]; University of Virginia
   [UL1TR003015-02S2]; Virginia Commonwealth University [UL1TR002649-03S3];
   Wake Forest University Health Sciences [UL1TR001420]; Washington
   University in St. Louis [UL1TR002345]; West Virginia University
   [U54GM104942]; NIH/NCATSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS); NCATSUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Advancing Translational Sciences (NCATS) [UL1
   TR002535, UL1 TR002535 03S2, U24 TR002306]
FX A.R.K. is supported by National Institute of Diabetes and Digestive and
   Kidney Diseases, National Institutes of Health (NIH), under award
   F30DK113728. The content is solely the responsibility of the authors and
   does not necessarily represent the official views of the National
   Institutes of Health. J.B.B.'s effort was supported by grants from the
   NCATS (UL1TR002489) and National Institute of Diabetes and Digestive and
   Kidney Diseases (P30DK124723), NIH. T.S. receives investigator-initiated
   research funding and support from the National Institute on Aging, NIH,
   as Principal Investigator (R01 AG056479) and as Co-Investigator (R01
   HL118255, R01MD011680). T.D.B. receives research funding from NIH/Eunice
   Kennedy Shriver National Institute of Child Health and Human Development
   and NIH/NCATS. G.C.A. formerly served as Chair of the U.S. Food and Drug
   Administration's Peripheral and Central Nervous System Advisory
   Committee. T.S. receives salary support as Director of Comparative
   Effectiveness Research (CER), NC TraCS Institute, and from UNC Clinical
   and Translational Science Award UL1TR002489. J.B. B. is supported by
   grants from the National Institutes of Health, American Diabetes
   Association, and the Patient-Centered Outcomes Research Institute.
   M.A.H. is supported by grants from the National Institutes of Health and
   the Patient-Centered Outcomes Research Institute. This work was
   supported, in part, by NCATS UL1 TR002535 and NCATS UL1 TR002535 03S2.
   The analyses described here were conducted with data or tools accessed
   through the NCATS N3C Data Enclave (https://covid.cd2h.org) and
   supported by NCATS U24 TR002306. N3C is supported by the following grant
   sources: Carilion Clinic (UL1TR003015-02S2: Provision of Clinical Data
   to Support a Nationwide COVID-19 Cohort Collaborative), George
   Washington Children's Research Institute (UL1TR001876: Clinical and
   Translational Science Institute at Children's National), Duke University
   (UL1TR002553: Duke Clinical and Translational Science Award), Johns
   Hopkins University (UL1TR003098: Johns Hopkins Institute for Clinical
   and Translational Research), Mayo Clinic Rochester (UL1TR002377: Mayo
   Clinic Center for Clinical and Translational Science), Medical
   University of South Carolina (UL1TR001450: South Carolina Clinical &
   Translational Research Institute), Penn State Health Milton S. Hershey
   Medical Center (UL1TR002014: Penn State Clinical and Translational
   Science Institute), Rush University Medical Center (UL1TR002389:
   Institute for Translational Medicine), Stony Brook University
   (U24TR002306-04S1), The Ohio State University (UL1TR002733: The OSU
   Center for Clinical and Translational Science: Advancing Today's
   Discoveries to Improve Health), Tufts University (Boston, MA)
   (UL1TR002544-03S4: Tufts Clinical and Translational Science Institute
   N3C Supplement), University of Massachusetts Medical School (Worcester,
   MA) (UL1TR001453: University of Massachusetts Center for Clinical and
   Translational Science), University of Alabama at Birmingham
   (UL1TR003096: Center for Clinical and Translational Science), University
   of Arkansas for Medical Sciences (UL1TR003107: UAMS Translational
   Research Institute), The University of Chicago (UL1TR002389: ITM 2.; 0:
   Advancing Translational Science in Metropolitan Chicago), University of
   Colorado Denver (UL1TR002535-03S2: Colorado Clinical and Translational
   Sciences Institute Participation in the National COVID Cohort
   Collaborative N3C), University of Illinois at Chicago (UL1TR002003:
   Clinical and Translational Science Award), The University of Iowa
   (UL1TR002537: The University of Iowa Clinical and Translational Science
   Award), University of Kentucky (UL1TR001998-04S1: Kentucky Center for
   Clinical and Translational Science), Maine Medical Center (P20GM103423),
   University of Miami (UL1TR002736: Miami Clinical and Translational
   Science Institute), The University of Michigan at Ann Arbor
   (UL1TR002240: Michigan Institute for Clinical and Health Research),
   University of Minnesota (UL1TR002494: University of Minnesota Clinical
   and Translational Science Institute), University of Nebraska-Lincoln
   (U54GM115458: University of Nebraska Center for Clinical & Translational
   Research), University of North Carolina at Chapel Hill (UL1TR002489: NC
   Translational and Clinical Sciences Institute and the ICEES1 COVID-19
   Open Infrastructure to Democratize and Accelerate Cross-Institutional
   Clinical Data Sharing and Research), Northwestern University
   (UL1TR001422), University of Southern California (UL1TR001855: Southern
   California Clinical and Translational Institute), The University of
   Texas Medical Branch at Galveston (UL1TR001439: UTMB Clinical and
   Translational Science Award), The University of Utah (UL1TR002538-03S3:
   Infrastructure Support for Participation in the N3C Data Repository),
   University of Washington (UL1TR002319: Institute of Translational Health
   Sciences), University of Wisconsin-Madison (UL1TR002373: Institutional
   Clinical and Translational Science Award), University of Virginia
   (UL1TR003015-02S2: Provision of Clinical Data to Support a Nationwide
   COVID-19 Cohort Collaborative), Virginia Commonwealth University
   (UL1TR002649-03S3: N3C & All of Us Research Program Collaborative
   Project), Wake Forest University Health Sciences (UL1TR001420: Wake
   Forest Clinical and Translational Science Award), Washington University
   in St. Louis (UL1TR002345: Washington University Institute of Clinical
   Translational Sciences), and West Virginia University (U54GM104942: West
   Virginia Clinical and Translational Science Institute).
CR Bennett TD., 2021, DIABETES OBES METAB, V23, P1397
   Chen YC, 2020, DIABETES CARE, V43, P1399, DOI 10.2337/dc20-0660
   Chow N, 2020, MMWR-MORBID MORTAL W, V69, P382, DOI 10.15585/mmwr.mm6913e2
   Das L, 2020, EUR J CLIN INVEST, V50, DOI 10.1111/eci.13339
   Drucker DJ, 2020, ENDOCR REV, V41, P457, DOI 10.1210/endrev/bnaa011
   Franklin JM, 2021, CIRCULATION, V143, P1002, DOI 10.1161/CIRCULATIONAHA.120.051718
   Gregory JM, 2021, DIABETES CARE, V44, P526, DOI 10.2337/dc20-2260
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00547-2020
   Haendel MA, 2021, J AM MED INFORM ASSN, V28, P427, DOI 10.1093/jamia/ocaa196
   Hartmann-Boyce J, 2020, DIABETES CARE, V43, P1695, DOI 10.2337/dc20-1192
   Heerspink HJL, 2020, NEW ENGL J MED, V383, P1436, DOI 10.1056/NEJMoa2024816
   Israelsen SB, 2021, PHARMACOEPIDEM DR S, V30, P53, DOI 10.1111/dom.14329
   Kim MK, 2020, DIABETES METAB J, V44, P602, DOI 10.4093/dmj.2020.0146
   Marshall JC, 2020, LANCET INFECT DIS, V20, pE192, DOI 10.1016/S1473-3099(20)30483-7
   Marso SP, 2016, NEW ENGL J MED, V375, P1834, DOI 10.1056/NEJMoa1607141
   Marso SP, 2016, NEW ENGL J MED, V375, P311, DOI 10.1056/NEJMoa1603827
   McGurnaghan SJ, 2021, LANCET DIABETES ENDO, V9, P82, DOI 10.1016/S2213-8587(20)30405-8
   McMurray JJV, 2019, NEW ENGL J MED, V381, P1995, DOI 10.1056/NEJMoa1911303
   Mirani M, 2020, DIABETES CARE, V43, P3042, DOI 10.2337/dc20-1340
   Monda VM, 2020, DIABETES THER, V11, P1909, DOI 10.1007/s13300-020-00898-8
   Montvida O, 2018, DIABETES CARE, V41, P69, DOI 10.2337/dc17-1414
   Nauck MA, 2020, DIABETES CARE, V43, P2906, DOI 10.2337/dci20-0062
   Neal B, 2017, NEW ENGL J MED, V377, P644, DOI 10.1056/NEJMoa1611925
   Noh Y, 2021, DIABETES CARE, V44, pE64, DOI 10.2337/dc20-1824
   Packer M, 2020, NEW ENGL J MED, V383, P1413, DOI 10.1056/NEJMoa2022190
   Pang ML, 2016, EPIDEMIOLOGY, V27, P570, DOI 10.1097/EDE.0000000000000487
   Perez-Belmonte LM, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01832-2
   Perkovic V, 2019, NEW ENGL J MED, V380, P2295, DOI 10.1056/NEJMoa1811744
   Quan HD, 2011, AM J EPIDEMIOL, V173, P676, DOI 10.1093/aje/kwq433
   Rados DV, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-69738-w
   Ray WA, 2003, AM J EPIDEMIOL, V158, P915, DOI 10.1093/aje/kwg231
   Sarafidis PA, 2016, NEW ENGL J MED, V374, P1092, DOI 10.1056/NEJMc1600827
   Scheen AJ, 2020, DIABETES METAB, V46, P343, DOI 10.1016/j.diabet.2020.06.003
   Schuler MS, 2017, AM J EPIDEMIOL, V185, P65, DOI 10.1093/aje/kww165
   Solerte SB, 2020, DIABETES CARE, V43, P2999, DOI 10.2337/dc20-1521
   Stokes EK, 2020, MMWR-MORBID MORTAL W, V69, P759, DOI 10.15585/mmwr.mm6924e2
   Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4
   Zhu LH, 2020, CELL METAB, V31, P1068, DOI 10.1016/j.cmet.2020.04.021
NR 38
TC 3
Z9 3
U1 2
U2 2
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
EI 1935-5548
J9 DIABETES CARE
JI Diabetes Care
PD JUL
PY 2021
VL 44
IS 7
BP 1564
EP 1572
DI 10.2337/dc21-0065
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA TR2PT
UT WOS:000678813200020
PM 34135013
OA Bronze, Green Submitted, Green Published
DA 2021-10-30
ER

PT J
AU Portale, AA
   Wolf, MS
   Messinger, S
   Perwad, F
   Juppner, H
   Warady, BA
   Furth, SL
   Salusky, IB
AF Portale, Anthony A.
   Wolf, Myles S.
   Messinger, Shari
   Perwad, Farzana
   Juppner, Harald
   Warady, Bradley A.
   Furth, Susan L.
   Salusky, Isidro B.
TI Fibroblast Growth Factor 23 and Risk of CKD Progression in Children
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID CHRONIC KIDNEY-DISEASE; LEFT-VENTRICULAR HYPERTROPHY;
   GLOMERULAR-FILTRATION-RATE; VITAMIN-D METABOLISM; STAGE RENAL-DISEASE;
   CARDIOVASCULAR EVENTS; MINERAL METABOLISM; FGF23;
   FIBROBLAST-GROWTH-FACTOR-23; ASSOCIATION
AB Background and objectives Plasma fibroblast growth factor 23 (FGF23) concentrations increase early in the course of CKD in children. High FGF23 levels associate with progression of CKD in adults. Whether FGF23 predicts CKD progression in children is unknown.
   Design, setting, participants, & measurements We tested the hypothesis that high plasma FGF23 is an independent risk factor for CKD progression in 419 children, aged 1-16 years, enrolled in the Chronic Kidney Disease in Children (CKiD) cohort study. We measured plasma FGF23 concentrations at baseline and determined GFR annually using plasma disappearance of iohexol or the CKiD study estimating equation. We analyzed the association of baseline FGF23 with risk of progression to the composite end point, defined as start of dialysis or kidney transplantation or 50% decline from baseline GFR, adjusted for demographics, baseline GFR, proteinuria, other CKD-specific factors, and other mineral metabolites.
   Results At enrollment, median age was 11 years [interquartile range (IQR), 8-15], GFR was 44 ml/min per 1.73 m(2) (IQR, 33-57), and FGF23 was 132 RU/ml (IQR, 88-200). During a median follow-up of 5.5 years (IQR, 3.5-6.6), 32.5% of children reached the progression end point. Higher FGF23 concentrations were independently associated with higher risk of the composite outcome (fully adjusted hazard ratio, 2.52 in the highest versus lowest FGF23 tertile; 95% confidence interval, 1.44 to 4.39, P=0.002; fully adjusted hazard ratio, 1.33 per doubling of FGF23; 95% confidence interval, 1.13 to 1.56, P=0.001). The time to progression was 40% shorter for participants in the highest compared with the lowest FGF23 tertile. In contrast, serum phosphorus, vitamin D metabolites, and parathyroid hormone did not consistently associate with progression in adjusted analyses.
   Conclusions High plasma FGF23 is an independent risk factor for CKD progression in children.
C1 [Portale, Anthony A.; Perwad, Farzana] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA.
   [Wolf, Myles S.] Northwestern Univ, Dept Med, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Messinger, Shari] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA.
   [Juppner, Harald] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA USA.
   [Juppner, Harald] Harvard Med Sch, Boston, MA USA.
   [Warady, Bradley A.] Univ Missouri, Sch Med, Dept Pediat, Kansas City, MO 64108 USA.
   [Furth, Susan L.] Univ Penn, Dept Pediat, Philadelphia, PA USA.
   [Salusky, Isidro B.] Univ Calif Los Angeles, Dept Pediat, Los Angeles, CA 90024 USA.
RP Portale, AA (corresponding author), Univ Calif San Francisco, Dept Pediat, Div Pediat Nephrol, 550 16th St,Box 3214, San Francisco, CA 94143 USA.
EM anthony.portale@ucsf.edu
FU National Institute of Diabetes and Digestive and Kidney Diseases
   [NIDDK)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Diabetes &
   Digestive & Kidney Diseases (NIDDK) [R01-DK-084978, PO1-DK-11794];
   AbbVieAbbVie; Genzyme CorporationSanofi-AventisGenzyme Corporation;
   Pediatric Nephrology Innovative Research Fund; NIDDKUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Diabetes & Digestive & Kidney Diseases
   (NIDDK); Eunice Kenney Shriver National Institute of Child Health and
   Human Development; National Heart, Lung and Blood InstituteUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [UO1-DK-66143,
   UO1-DK-66174, U01-DK-082194, UO1-DK-66116]; EUNICE KENNEDY SHRIVER
   NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH Eunice Kennedy Shriver National Institute of Child Health &
   Human Development (NICHD) [U54HD079123] Funding Source: NIH RePORTER;
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000460] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)
   [U01DK066116, R01DK084978, U01DK066143, U01DK066174, U01DK082194]
   Funding Source: NIH RePORTER
FX This study was supported by grants from the National Institute of
   Diabetes and Digestive and Kidney Diseases [NIDDK; R01-DK-084978 to
   A.A.P., PO1-DK-11794 (subproject IV) to H.J.], grants from AbbVie and
   Genzyme Corporation (to A.A.P.), and the Pediatric Nephrology Innovative
   Research Fund (to A.A.P.). The CKiD study is funded by the NIDDK, Eunice
   Kenney Shriver National Institute of Child Health and Human Development,
   and National Heart, Lung and Blood Institute [UO1-DK-66143,
   UO1-DK-66174, U01-DK-082194, and UO1-DK-66116 (Principal Investigators:
   S.L.F. and B.A.W.)].
CR Agarwal R, 2005, KIDNEY INT, V68, P2823, DOI 10.1111/j.1523-1755.2005.00755.x
   Cheng ZQ, 2013, J BONE MINER RES, V28, P1087, DOI 10.1002/jbmr.1846
   Collins A, 2014, AM J KIDNEY DIS, V63, pE1
   de Zeeuw D, 2010, LANCET, V376, P1543, DOI 10.1016/S0140-6736(10)61032-X
   Di Marco GS, 2014, NEPHROL DIAL TRANSPL, V29, P2028, DOI 10.1093/ndt/gfu190
   Ersfeld DL, 2004, CLIN BIOCHEM, V37, P867, DOI 10.1016/j.clinbiochem.2004.06.006
   Fathallah-Shaykh SA, 2015, CLIN J AM SOC NEPHRO, V10, P571, DOI 10.2215/CJN.07480714
   Faul C, 2011, J CLIN INVEST, V121, P4393, DOI 10.1172/JCI46122
   Fliser D, 2007, J AM SOC NEPHROL, V18, P2600, DOI 10.1681/ASN.2006080936
   Freundlich M, 2008, KIDNEY INT, V74, P1394, DOI 10.1038/ki.2008.408
   Furth SL, 2006, CLIN J AM SOC NEPHRO, V1, P1006, DOI 10.2215/CJN.01941205
   Furth SL, 2011, CLIN J AM SOC NEPHRO, V6, P2132, DOI 10.2215/CJN.07100810
   Grabner A, 2015, CELL METAB, V22, P1020, DOI 10.1016/j.cmet.2015.09.002
   Gutierrez O, 2005, J AM SOC NEPHROL, V16, P2205, DOI 10.1681/ASN.2005010052
   Gutierrez OM, 2008, NEW ENGL J MED, V359, P584, DOI 10.1056/NEJMoa0706130
   Gutierrez OM, 2009, CIRCULATION, V119, P2545, DOI 10.1161/CIRCULATIONAHA.108.844506
   Hollis BW, 1996, CLIN CHEM, V42, P586
   Isakova T, 2011, JAMA-J AM MED ASSOC, V305, P2432, DOI 10.1001/jama.2011.826
   Isakova T, 2011, KIDNEY INT, V79, P1370, DOI 10.1038/ki.2011.47
   Kendrick J, 2011, J AM SOC NEPHROL, V22, P1913, DOI 10.1681/ASN.2010121224
   LOCKITCH G, 1988, CLIN CHEM, V34, P1625
   Lundberg S, 2012, CLIN J AM SOC NEPHRO, V7, P727, DOI 10.2215/CJN.10331011
   McDonald SP, 2004, NEW ENGL J MED, V350, P2654, DOI 10.1056/NEJMoa031643
   Mehrotra R, 2013, KIDNEY INT, V84, P989, DOI 10.1038/ki.2013.145
   Mitsnefes MM, 2013, JAMA-J AM MED ASSOC, V309, P1921, DOI 10.1001/jama.2013.4208
   Natl High Blood Pressure Educ Prog, 2004, PEDIATRICS, V114, P555
   Norris KC, 2006, J AM SOC NEPHROL, V17, P2928, DOI 10.1681/ASN.2005101101
   Perwad F, 2007, AM J PHYSIOL-RENAL, V293, pF1577, DOI 10.1152/ajprenal.00463.2006
   Portale AA, 2014, CLIN J AM SOC NEPHRO, V9, P344, DOI 10.2215/CJN.05840513
   Rebholz CM, 2015, J AM SOC NEPHROL, V26, P192, DOI 10.1681/ASN.2014020218
   Saito H, 2003, J BIOL CHEM, V278, P2206, DOI 10.1074/jbc.M207872200
   Schwartz GJ, 2006, KIDNEY INT, V69, P2070, DOI 10.1038/sj.ki.5000385
   Schwartz GJ, 2012, KIDNEY INT, V82, P445, DOI 10.1038/ki.2012.169
   SCHWARTZ GJ, 1976, PEDIATRICS, V58, P259
   Schwarz S, 2006, CLIN J AM SOC NEPHRO, V1, P825, DOI 10.2215/CJN.02101205
   Schwarz U, 1998, KIDNEY INT, V53, P1696, DOI 10.1046/j.1523-1755.1998.00951.x
   Scialla JJ, 2014, J AM SOC NEPHROL, V25, P349, DOI 10.1681/ASN.2013050465
   Scialla JJ, 2013, J AM SOC NEPHROL, V24, P125, DOI 10.1681/ASN.2012070713
   Seegmiller JC, 2016, AM J KIDNEY DIS, V67, P49, DOI 10.1053/j.ajkd.2015.08.020
   Shimada T, 2004, J BONE MINER RES, V19, P429, DOI 10.1359/JBMR.0301264
   Shroff R, 2016, J AM SOC NEPHROL, V27, P314, DOI 10.1681/ASN.2014090947
   Soveri I, 2014, AM J KIDNEY DIS, V64, P411, DOI 10.1053/j.ajkd.2014.04.010
   Staples AO, 2010, CLIN J AM SOC NEPHRO, V5, P2172, DOI 10.2215/CJN.07851109
   Titan SM, 2011, CLIN J AM SOC NEPHRO, V6, P241, DOI 10.2215/CJN.04250510
   Wagner D, 2009, CLIN BIOCHEM, V42, P1549, DOI 10.1016/j.clinbiochem.2009.07.013
   Warady BA, 2007, PEDIATR NEPHROL, V22, P1999, DOI 10.1007/s00467-006-0410-1
   Warady BA, 2015, AM J KIDNEY DIS, V65, P878, DOI 10.1053/j.ajkd.2015.01.008
   Wesseling-Perry K, 2011, NEPHROL DIAL TRANSPL, V26, P3779, DOI 10.1093/ndt/gfr126
   Wolf M, 2011, J AM SOC NEPHROL, V22, P956, DOI 10.1681/ASN.2010080894
NR 49
TC 35
Z9 35
U1 0
U2 5
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555-9041
EI 1555-905X
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD NOV
PY 2016
VL 11
IS 11
BP 1989
EP 1998
DI 10.2215/CJN.02110216
PG 10
WC Urology & Nephrology
SC Urology & Nephrology
GA EA8DA
UT WOS:000386864300012
PM 27561289
OA Green Published, Bronze
DA 2021-10-30
ER

PT J
AU Trivedi, MH
   Greer, TL
   Rethorst, CD
   Carmody, T
   Grannemann, BD
   Walker, R
   Warden, D
   Shores-Wilson, K
   Stoutenberg, M
   Oden, N
   Silverstein, M
   Hodgkins, C
   Love, L
   Seamans, C
   Stotts, A
   Causey, T
   Szucs-Reed, RP
   Rinaldi, P
   Myrick, H
   Straus, M
   Liu, D
   Lindblad, R
   Church, T
   Blair, SN
   Nunes, EV
AF Trivedi, Madhukar H.
   Greer, Tracy L.
   Rethorst, Chad D.
   Carmody, Thomas
   Grannemann, Bruce D.
   Walker, Robrina
   Warden, Diane
   Shores-Wilson, Kathy
   Stoutenberg, Mark
   Oden, Neal
   Silverstein, Meredith
   Hodgkins, Candace
   Love, Lee
   Seamans, Cindy
   Stotts, Angela
   Causey, Trey
   Szucs-Reed, Regina P.
   Rinaldi, Paul
   Myrick, Hugh
   Straus, Michele
   Liu, David
   Lindblad, Robert
   Church, Timothy
   Blair, Steven N.
   Nunes, Edward V.
TI Randomized Controlled Trial Comparing Exercise to Health Education for
   Stimulant Use Disorder: Results From the CTN-0037 STimulant Reduction
   Intervention Using Dosed Exercise (STRIDE) Study
SO JOURNAL OF CLINICAL PSYCHIATRY
LA English
DT Article
ID CONDITIONED PLACE PREFERENCE; DOUBLE-BLIND; SMOKING-CESSATION;
   DRUG-ADDICTION; SUBSTANCE USE; COCAINE; EFFICACY; FITNESS; WOMEN;
   METAANALYSIS
AB Objective: To evaluate exercise as a treatment for stimulant use disorders.
   Methods: The STimulant Reduction Intervention using Dosed Exercise (STRIDE) study was a randomized clinical trial conducted in 9 residential addiction treatment programs across the United States from July 2010 to February 2013. Of 497 adults referred to the study, 302 met all eligibility criteria, including DSM-IV criteria for stimulant abuse and/or dependence, and were randomized to either a dosed exercise intervention (Exercise) or a health education intervention (Health Education) control, both augmenting treatment as usual and conducted thrice weekly for 12 weeks. The primary outcome of percent stimulant abstinent days during study weeks 4 to 12 was estimated using a novel algorithm adjustment incorporating self-reported Timeline Followback (TLFB) stimulant use and urine drug screen (UDS) data.
   Results: Mean percent of abstinent days based on TLFB was 90.8% (SD = 16.4%) for Exercise and 91.6% (SD = 14.7%) for Health Education participants. Percent of abstinent days using the eliminate contradiction (ELCON) algorithm was 75.6% (SD = 27.4%) for Exercise and 77.3% (SD = 25.1%) for Health Education. The primary intent-to-treat analysis, using a mixed model controlling for site and the ELCON algorithm, produced no treatment effect (P = .60). In post hoc analyses controlling for treatment adherence and baseline stimulant use, Exercise participants had a 4.8% higher abstinence rate (78.7%) compared to Health Education participants (73.9%) (P = .03, number needed to treat = 7.2).
   Conclusions: The primary analysis indicated no significant difference between exercise and health education. Adjustment for intervention adherence showed modestly but significantly higher percent of abstinent days in the exercise group, suggesting that exercise may improve outcomes for stimulant users who have better adherence to an exercise dose. (C) Copyright 2017 Physicians Postgraduate Press, Inc.
C1 [Trivedi, Madhukar H.; Greer, Tracy L.; Rethorst, Chad D.; Carmody, Thomas; Grannemann, Bruce D.; Walker, Robrina; Warden, Diane; Shores-Wilson, Kathy] Univ Texas Southwestern Med Ctr Dallas, Dept Psychiat, Dallas, TX USA.
   [Stoutenberg, Mark] Univ Miami, Dept Publ Hlth Serv, Miami, FL USA.
   [Oden, Neal; Lindblad, Robert] EMMES Corp, Rockville, MD USA.
   [Silverstein, Meredith] Arapahoe House, Denver, CO USA.
   [Hodgkins, Candace] Gateway Community Serv, Jacksonville, FL USA.
   [Love, Lee] Gibson Recovery Ctr, Cape Girardeau, MO USA.
   [Seamans, Cindy] Nexus Recovery Ctr, Dallas, TX USA.
   [Stotts, Angela] Univ Texas Hlth Sci Ctr Houston, Dept Family & Community Med, Houston, TX 77030 USA.
   [Causey, Trey] Morris Village Alcohol & Drug Addict Treatment Ct, Columbia, SC USA.
   [Szucs-Reed, Regina P.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
   [Rinaldi, Paul] St Lukes Roosevelt Hosp, New York, NY USA.
   [Myrick, Hugh] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
   [Straus, Michele; Liu, David] NIDA, NIH, Bethesda, MD 20892 USA.
   [Church, Timothy] Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70803 USA.
   [Blair, Steven N.] Univ South Carolina, Arnold Sch Publ Hlth, Columbia, SC 29208 USA.
   [Nunes, Edward V.] Columbia Univ, Dept Psychiat, Med Ctr, New York, NY USA.
RP Trivedi, MH (corresponding author), UT Southwestern Med Ctr, Ctr Depress Res & Clin Care, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
EM Madhukar.Trivedi@utsouthwestern.edu
OI Trivedi, Madhukar/0000-0002-2983-1110
FU National Institute on Drug Abuse of the National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Drug Abuse
   (NIDA) [U10 DA020024, UG1DA020024, U10 DA013727, U10 DA013035, U10
   DA013720, U10 DA013732, HHSN271200900034C]; NIDAUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Drug Abuse (NIDA) [K24 DA022412]; NIMHUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K01
   MH097847]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Advancing Translational
   Sciences (NCATS) [KL2TR000461] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Mental Health (NIMH) [K01MH097847] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute on Drug Abuse (NIDA)European Commission [U10DA013727,
   K24DA022412, U10DA013720, UG1DA020024, U10DA013035, UG1DA013727,
   UG1DA013720, U10DA020024, U10DA013732] Funding Source: NIH RePORTER
FX This work was supported by the National Institute on Drug Abuse of the
   National Institutes of Health under Award Numbers U10 DA020024 and
   UG1DA020024 (PI: Trivedi), U10 DA013727 (PI: Brady), U10 DA013035 (PIs:
   Nunes and Rotrosen), U10 DA013720 (PIs: Szapocznik and Metsch), U10
   DA013732 (PI: Winhusen), and HHSN271200900034C and HHSN271200900034C
   (Emmes Corporation). Additional grant support was provided by NIDA K24
   DA022412 (PI: Nunes) and NIMH K01 MH097847 (PI: Rethorst).
CR American College of Sports Medicine, 2013, ACSMS GUIDELINES EXE
   Brown Richard A, 2010, Ment Health Phys Act, V3, P27
   Buchowski MS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017465
   Carroll KM, 2012, DRUG ALCOHOL DEPEN, V126, P224, DOI 10.1016/j.drugalcdep.2012.05.019
   Church TS, 2007, JAMA-J AM MED ASSOC, V297, P2081, DOI 10.1001/jama.297.19.2081
   Church TS, 2010, JAMA-J AM MED ASSOC, V304, P2253, DOI 10.1001/jama.2010.1710
   Cohen J., 2013, STAT POWER ANAL BEHA
   COLLINGWOOD TR, 1991, J DRUG EDUC, V21, P73, DOI 10.2190/HV5J-4EYN-GPP7-Y3QG
   Cooney GM, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004366.pub6
   de Lima MS, 2002, ADDICTION, V97, P931, DOI 10.1046/j.1360-0443.2002.00209.x
   Dunn AL, 2005, AM J PREV MED, V28, P1, DOI 10.1016/j.amepre.2004.09.003
   Fals-Stewart W, 2000, J CONSULT CLIN PSYCH, V68, P134, DOI 10.1037/0022-006X.68.1.134
   Greer T. L., 2012, J GLOB DRUG POLICY P, V6
   Haerian BS, 2013, PHARMACOGENOMICS, V14, P2055, DOI [10.2217/PGS.13.217, 10.2217/pgs.13.217]
   Hillman CH, 2008, NAT REV NEUROSCI, V9, P58, DOI 10.1038/nrn2298
   Knapp WP, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003023.pub2
   Koob GF, 2000, ANN NY ACAD SCI, V909, P170, DOI 10.1111/j.1749-6632.2000.tb06682.x
   Kraemer HC, 2006, BIOL PSYCHIAT, V59, P990, DOI 10.1016/j.biopsych.2005.09.014
   Kramer AF, 2006, J APPL PHYSIOL, V101, P1237, DOI 10.1152/japplphysiol.00500.2006
   Lynch WJ, 2013, NEUROSCI BIOBEHAV R, V37, P1622, DOI 10.1016/j.neubiorev.2013.06.011
   Lynch WJ, 2010, BIOL PSYCHIAT, V68, P774, DOI 10.1016/j.biopsych.2010.06.022
   Marcus BH, 1999, ARCH INTERN MED, V159, P1229, DOI 10.1001/archinte.159.11.1229
   MARCUS BH, 1995, ADDICT BEHAV, V20, P87, DOI 10.1016/0306-4603(94)00048-4
   Mustroph ML, 2011, EUR J NEUROSCI, V34, P1161, DOI 10.1111/j.1460-9568.2011.07828.x
   Oden NL, 2011, AM J DRUG ALCOHOL AB, V37, P350, DOI 10.3109/00952990.2011.601777
   Rethorst CD, 2014, MENT HEALTH PHYS ACT, V7, P37, DOI 10.1016/j.mhpa.2013.12.001
   Rethorst CD, 2009, SPORTS MED, V39, P491, DOI 10.2165/00007256-200939060-00004
   Rush AJ, 2003, BIOL PSYCHIAT, V54, P573, DOI 10.1016/S0006-3223(02)01866-8
   Sheehan DV, 1997, EUR PSYCHIAT, V12, P232, DOI 10.1016/S0924-9338(97)83297-X
   SINYOR D, 1982, J STUD ALCOHOL, V43, P380, DOI 10.15288/jsa.1982.43.380
   Sobell L. C., 1996, TIMELINE FOLLOWBACK
   Sobell LC, 1992, MEASURING ALCOHOL CO, P41, DOI [10.1007/978-1-4612-0357-5_3, DOI 10.1007/978-1-4612-0357-5_3]
   Somoza EC, 2013, JAMA PSYCHIAT, V70, P630, DOI 10.1001/jamapsychiatry.2013.872
   Stoutenberg Mark, 2012, Ment Health Phys Act, V5, P175
   Thanos PK, 2010, BEHAV BRAIN RES, V215, P77, DOI 10.1016/j.bbr.2010.06.033
   Thiel KJ, 2011, PHARMACOL BIOCHEM BE, V97, P595, DOI 10.1016/j.pbb.2010.09.014
   Trivedi MH, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-206
   Ussher MH, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002295.pub5
   Warden D, 2012, CONTEMP CLIN TRIALS, V33, P29, DOI 10.1016/j.cct.2011.08.011
   Weinstock J, 2008, ADDICT BEHAV, V33, P1072, DOI 10.1016/j.addbeh.2008.03.011
   *WHO, 1997, COMP INT DIAGN INT C
   Williams DM, 2011, ADDICT BEHAV, V36, P894, DOI 10.1016/j.addbeh.2011.04.001
   Winhusen T, 2007, DRUG ALCOHOL DEPEN, V91, P141, DOI 10.1016/j.drugalcdep.2007.05.028
   Winhusen T, 2007, DRUG ALCOHOL DEPEN, V91, P205, DOI 10.1016/j.drugalcdep.2007.05.021
   Wipfli BM, 2008, J SPORT EXERCISE PSY, V30, P392, DOI 10.1123/jsep.30.4.392
NR 45
TC 23
Z9 23
U1 0
U2 7
PU PHYSICIANS POSTGRADUATE PRESS
PI MEMPHIS
PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA
SN 0160-6689
EI 1555-2101
J9 J CLIN PSYCHIAT
JI J. Clin. Psychiatry
PD SEP-OCT
PY 2017
VL 78
IS 8
BP 1075
EP 1082
DI 10.4088/JCP.15m10591
PG 8
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA FK7VZ
UT WOS:000413716700025
PM 28199070
OA Green Accepted
DA 2021-10-30
ER

PT J
AU Yu, CC
   Fornoni, A
   Weins, A
   Hakroush, S
   Maiguel, D
   Sageshima, J
   Chen, L
   Ciancio, G
   Faridi, MH
   Behr, D
   Campbell, KN
   Chang, JM
   Chen, HC
   Oh, J
   Faul, C
   Arnaout, MA
   Fiorina, P
   Gupta, V
   Greka, A
   Burke, GW
   Mundel, P
AF Yu, Chih-Chuan
   Fornoni, Alessia
   Weins, Astrid
   Hakroush, Samy
   Maiguel, Dony
   Sageshima, Junichiro
   Chen, Linda
   Ciancio, Gaetano
   Faridi, Mohd Hafeez
   Behr, Daniel
   Campbell, Kirk N.
   Chang, Jer-Ming
   Chen, Hung-Chun
   Oh, Jun
   Faul, Christian
   Arnaout, M. Amin
   Fiorina, Paolo
   Gupta, Vineet
   Greka, Anna
   Burke, George W., III
   Mundel, Peter
TI Abatacept in B7-1-Positive Proteinuric Kidney Disease
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID RHEUMATOID-ARTHRITIS; INTEGRIN ACTIVATION; PODOCYTES; TALIN
AB Abatacept (cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion protein [CTLA-4-Ig]) is a costimulatory inhibitor that targets B7-1 (CD80). The present report describes five patients who had focal segmental glomerulosclerosis (FSGS) (four with recurrent FSGS after transplantation and one with primary FSGS) and proteinuria with B7-1 immunostaining of podocytes in kidney-biopsy specimens. Abatacept induced partial or complete remissions of proteinuria in these patients, suggesting that B7-1 may be a useful biomarker for the treatment of some glomerulopathies. Our data indicate that abatacept may stabilize 1-integrin activation in podocytes and reduce proteinuria in patients with B7-1-positive glomerular disease.
C1 [Yu, Chih-Chuan; Weins, Astrid; Hakroush, Samy; Maiguel, Dony; Arnaout, M. Amin; Greka, Anna; Mundel, Peter] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
   [Yu, Chih-Chuan; Weins, Astrid; Hakroush, Samy; Behr, Daniel; Arnaout, M. Amin; Greka, Anna; Mundel, Peter] Harvard Univ, Sch Med, Boston, MA USA.
   [Weins, Astrid] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
   [Fiorina, Paolo] Childrens Hosp, Div Nephrol, Boston, MA 02115 USA.
   [Yu, Chih-Chuan] Kaohsiung Med Univ, Coll Med, Grad Inst Med, Kaohsiung, Taiwan.
   [Chang, Jer-Ming; Chen, Hung-Chun] Kaohsiung Med Univ, Coll Med, Dept Internal Med, Kaohsiung, Taiwan.
   [Fornoni, Alessia; Maiguel, Dony; Faridi, Mohd Hafeez; Faul, Christian; Gupta, Vineet] Univ Miami, Miller Sch Med, Div Nephrol & Hypertens, Miami, FL 33136 USA.
   [Sageshima, Junichiro; Chen, Linda; Ciancio, Gaetano; Burke, George W., III] Univ Miami, Miller Sch Med, Lilian Jean Kaplan Div Kidney Pancreas Transplant, Miami Transplant Inst,Dept Surg, Miami, FL 33136 USA.
   [Campbell, Kirk N.] Mt Sinai Sch Med, Div Nephrol, New York, NY USA.
   [Oh, Jun] Univ Med Ctr Hamburg Eppendorf, Childrens Hosp, Hamburg, Germany.
RP Mundel, P (corresponding author), Massachusetts Gen Hosp, Div Nephrol, 149 13th St, Charlestown, MA 02129 USA.
EM mundel.peter@mgh.harvard.edu
RI Oh, Jun/K-4039-2013; Fiorina, Paolo/B-4532-2019
OI fornoni, Alessia/0000-0002-1313-7773; Fiorina,
   Paolo/0000-0002-1093-7724; Hakroush, Samy/0000-0002-2843-3567
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [DK57683, DK062472,
   DK093783, DK068253, HL109582, DK0903616, DK090316, DK083511, DK093746];
   Boston Area Diabetes Endocrinology Research Center; National Institute
   of Diabetes and Digestive and Kidney DiseasesUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)
   [P30DK057521]; Deutsche ForschungsgemeinschaftGerman Research Foundation
   (DFG) [HA 6334/1-1]; NephCure Foundation; Transplant Foundation of South
   Florida; American Society of Nephrology; NephCure Young Investigator
   Award; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000460] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND
   BLOOD INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [R01HL109582] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Diabetes & Digestive &
   Kidney Diseases (NIDDK) [R01DK062472, R01DK091218, R01DK057683,
   K08DK083511, R01DK048549, R56DK093746, K01DK068253, P30DK057521,
   K08DK093783, R01DK090316, R01DK084195, R01DK088327] Funding Source: NIH
   RePORTER
FX Supported by grants from the National Institutes of Health (DK57683 and
   DK062472, to Dr. Mundel; DK093783, to Dr. Weins; DK068253 and HL109582,
   to Dr. Gupta; DK0903616, to Drs. Fornoni and Burke; and DK090316,
   DK083511, and DK093746, to Dr. Greka), the Boston Area Diabetes
   Endocrinology Research Center and the National Institute of Diabetes and
   Digestive and Kidney Diseases (P30DK057521, to Dr. Greka), Deutsche
   Forschungsgemeinschaft (HA 6334/1-1, to Dr. Hakroush), and the NephCure
   Foundation and Transplant Foundation of South Florida (to Drs. Fornoni
   and Burke), and by an American Society of Nephrology Gottschalk Career
   Development Award and a NephCure Young Investigator Award (to Dr.
   Greka).
CR Beck LH, 2009, NEW ENGL J MED, V361, P11, DOI 10.1056/NEJMoa0810457
   Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071
   D'Agati VD, 2011, NEW ENGL J MED, V365, P2398, DOI 10.1056/NEJMra1106556
   Genovese MC, 2005, NEW ENGL J MED, V353, P1114, DOI 10.1056/NEJMoa050524
   Greenwald RJ, 2005, ANNU REV IMMUNOL, V23, P515, DOI 10.1146/annurev.immunol.23.021704.115611
   Greka A, 2012, ANNU REV PHYSIOL, V74, P299, DOI 10.1146/annurev-physiol-020911-153238
   Gupta V, 2007, BLOOD, V109, P3513, DOI 10.1182/blood-2005-11-056689
   Hoi AY, 2012, EXPERT OPIN BIOL TH, V12, P1399, DOI 10.1517/14712598.2012.713934
   Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331
   Reiser J, 2004, J CLIN INVEST, V113, P1390, DOI 10.1172/JCI200420402
   Scott DL, 2010, LANCET, V376, P1094, DOI 10.1016/S0140-6736(10)60826-4
   Shattil SJ, 2010, NAT REV MOL CELL BIO, V11, P288, DOI 10.1038/nrm2871
   Smolen JS, 2007, LANCET, V370, P1861, DOI 10.1016/S0140-6736(07)60784-3
   Wegener KL, 2007, CELL, V128, P171, DOI 10.1016/j.cell.2006.10.048
   Yanagida-Asanuma E, 2007, AM J PATHOL, V171, P415, DOI 10.2353/ajpath.2007.070075
NR 15
TC 228
Z9 244
U1 0
U2 17
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD DEC 19
PY 2013
VL 369
IS 25
BP 2416
EP 2423
DI 10.1056/NEJMoa1304572
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 274DQ
UT WOS:000328586000009
PM 24206430
OA Green Accepted
HC Y
HP N
DA 2021-10-30
ER

PT J
AU Bennett, TD
   Moffitt, RA
   Hajagos, JG
   Amor, B
   Anand, A
   Bissell, MM
   Bradwell, KR
   Bremer, C
   Byrd, JB
   Denham, A
   DeWitt, PE
   Gabriel, D
   Garibaldi, BT
   Girvin, AT
   Guinney, J
   Hill, EL
   Hong, SS
   Jimenez, H
   Kavuluru, R
   Kostka, K
   Lehmann, HP
   Levitt, E
   Mallipattu, SK
   Manna, A
   McMurry, JA
   Morris, M
   Muschelli, J
   Neumann, AJ
   Palchuk, MB
   Pfaff, ER
   Qian, ZL
   Qureshi, N
   Russell, S
   Spratt, H
   Walden, A
   Williams, AE
   Wooldridge, JT
   Yoo, YJ
   Zhang, XT
   Zhu, RL
   Austin, CP
   Saltz, JH
   Gersing, KR
   Haendel, MA
   Chute, CG
AF Bennett, Tellen D.
   Moffitt, Richard A.
   Hajagos, Janos G.
   Amor, Benjamin
   Anand, Adit
   Bissell, Mark M.
   Bradwell, Katie Rebecca
   Bremer, Carolyn
   Byrd, James Brian
   Denham, Alina
   DeWitt, Peter E.
   Gabriel, Davera
   Garibaldi, Brian T.
   Girvin, Andrew T.
   Guinney, Justin
   Hill, Elaine L.
   Hong, Stephanie S.
   Jimenez, Hunter
   Kavuluru, Ramakanth
   Kostka, Kristin
   Lehmann, Harold P.
   Levitt, Eli
   Mallipattu, Sandeep K.
   Manna, Amin
   McMurry, Julie A.
   Morris, Michele
   Muschelli, John
   Neumann, Andrew J.
   Palchuk, Matvey B.
   Pfaff, Emily R.
   Qian, Zhenglong
   Qureshi, Nabeel
   Russell, Seth
   Spratt, Heidi
   Walden, Anita
   Williams, Andrew E.
   Wooldridge, Jacob T.
   Yoo, Yun Jae
   Zhang, Xiaohan Tanner
   Zhu, Richard L.
   Austin, Christopher P.
   Saltz, Joel H.
   Gersing, Ken R.
   Haendel, Melissa A.
   Chute, Christopher G.
CA Natl COVID Cohor
TI Clinical Characterization and Prediction of Clinical Severity of
   SARS-CoV-2 Infection Among US Adults Using Data From the US National
   COVID Cohort Collaborative
SO JAMA NETWORK OPEN
LA English
DT Article
AB IMPORTANCE The National COVID Cohort Collaborative (N3C) is a centralized, harmonized, high-granularity electronic health record repository that is the largest, most representative COVID-19 cohort to date. This multicenter data set can support robust evidence-based development of predictive and diagnostic tools and inform clinical care and policy.
   OBJECTIVES To evaluate COVID-19 severity and risk factors over time and assess the use of machine learning to predict clinical severity.
   DESIGN, SETTING, AND PARTICIPANTS In a retrospective cohort study of 1 926 526 US adults with SARS-CoV-2 infection (polymerase chain reaction >99% or antigen <1%) and adult patients without SARS-CoV-2 infection who served as controls from 34 medical centers nationwide between January 1, 2020, and December 7, 2020, patients were stratified using a World Health Organization COVID-19 severity scale and demographic characteristics. Differences between groups over time were evaluated using multivariable logistic regression. Random forest and XGBoost models were used to predict severe clinical course (death, discharge to hospice, invasive ventilatory support, or extracorporeal membrane oxygenation).
   MAIN OUTCOMES AND MEASURES Patient demographic characteristics and COVID-19 severity using the World Health Organization COVID-19 severity scale and differences between groups over time using multivariable logistic regression.
   RESULTS The cohort included 174 568 adults who tested positive for SARS-CoV-2 (mean [SD] age, 44.4 [18.6] years; 53.2% female) and 1 133 848 adult controls who tested negative for SARS-CoV-2 (mean [SD] age, 49.5 [19.2] years; 57.1% female). Of the 174 568 adults with SARS-CoV-2, 32 472 (18.6%) were hospitalized, and 6565 (20.2%) of those had a severe clinical course (invasive ventilatory support, extracorporeal membrane oxygenation, death, or discharge to hospice). Of the hospitalized patients, mortality was 11.6% overall and decreased from 16.4% in March to April 2020 to 8.6% in September to October 2020 (P = .002 for monthly trend). Using 64 inputs available on the first hospital day, this study predicted a severe clinical course using random forest and XGBoost models (area under the receiver operating curve = 0.87 for both) that were stable over time. The factor most strongly associated with clinical severity was pH; this result was consistent across machine learning methods. In a separate multivariable logistic regression model built for inference, age (odds ratio [OR], 1.03 per year; 95% CI, 1.03-1.04), male sex (OR, 1.60; 95% CI, 1.51-1.69), liver disease (OR, 1.20; 95% CI, 1.08-1.34), dementia (OR, 1.26; 95% CI, 1.13-1.41), African American (OR, 1.12; 95% CI, 1.05-1.20) and Asian (OR, 1.33; 95% CI, 1.12-1.57) race, and obesity (OR, 1.36; 95% CI, 1.27-1.46) were independently associated with higher clinical severity.
   CONCLUSIONS AND RELEVANCE This cohort study found that COVID-19 mortality decreased over time during 2020 and that patient demographic characteristics and comorbidities were associated with higher clinical severity. The machine learning models accurately predicted ultimate clinical severity using commonly collected clinical data from the first 24 hours of a hospital admission.
C1 [Bennett, Tellen D.; DeWitt, Peter E.; Russell, Seth] Univ Colorado, Sect Informat & Data Sci, Dept Pediat, Sch Med, 13199 E Montview Blvd,Ste 300, Aurora, CO 80045 USA.
   [Moffitt, Richard A.; Qian, Zhenglong; Saltz, Joel H.] SUNY Stony Brook, Dept Biomed Informat, Stony Brook, NY USA.
   [Hajagos, Janos G.; Anand, Adit; Bremer, Carolyn; Jimenez, Hunter; Mallipattu, Sandeep K.; Wooldridge, Jacob T.; Yoo, Yun Jae] SUNY Stony Brook, Stony Brook, NY USA.
   [Amor, Benjamin; Bissell, Mark M.; Bradwell, Katie Rebecca; Girvin, Andrew T.; Manna, Amin; Qureshi, Nabeel] Palantir Technol, Denver, CO USA.
   [Byrd, James Brian] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA.
   [Denham, Alina; Hill, Elaine L.] Univ Rochester, Med Ctr, Dept Publ Hlth Sci, Rochester, NY 14642 USA.
   [Gabriel, Davera] Johns Hopkins Univ, Sch Med, Inst Clin & Translat Res, Baltimore, MD USA.
   [Garibaldi, Brian T.; Hong, Stephanie S.; Zhang, Xiaohan Tanner; Zhu, Richard L.; Chute, Christopher G.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
   [Guinney, Justin; Walden, Anita] Sage Bionetworks, Seattle, WA USA.
   [Kavuluru, Ramakanth] Univ Kentucky, Dept Internal Med, Div Biomed Informat, Lexington, KY USA.
   [Kostka, Kristin] RealWorld Solut, IQVIA, Cambridge, MA USA.
   [Kostka, Kristin] Observat Hlth Data Sci & Informat, New York, NY USA.
   [Lehmann, Harold P.] Johns Hopkins Univ, Sch Med, Dept Med, Div Hlth Sci Informat, Baltimore, MD 21205 USA.
   [Levitt, Eli] Univ Alabama Birmingham, Dept Orthopaed Surg, Birmingham, AL USA.
   [McMurry, Julie A.; Neumann, Andrew J.] Oregon State Univ, Translat & Integrat Sci Ctr, Corvallis, OR 97331 USA.
   [Morris, Michele] Univ Pittsburgh, Dept Biomed Informat, Pittsburgh, PA USA.
   [Muschelli, John] Johns Hopkins Univ, Dept Biostat, Sch Med, Baltimore, MD 21205 USA.
   [Palchuk, Matvey B.; Haendel, Melissa A.] TriNetX, Cambridge, MA USA.
   [Pfaff, Emily R.] Univ N Carolina, North Carolina Translat & Clin Sci Inst, Chapel Hill, NC 27515 USA.
   [Spratt, Heidi] Univ Texas Med Branch, Dept Prevent Med & Publ Hlth, Galveston, TX 77555 USA.
   [Walden, Anita] Oregon Hlth & Sci Univ, Oregon Clin & Translat Res Inst, Portland, OR 97201 USA.
   [Williams, Andrew E.] Tufts Med Ctr, Clin & Translat Sci Inst, Boston, MA 02111 USA.
   [Austin, Christopher P.; Gersing, Ken R.] NIH, Natl Ctr Adv Translat Sci, Bldg 10, Bethesda, MD 20892 USA.
   [Haendel, Melissa A.] Univ Colorado, Ctr Hlth AI, Aurora, CO USA.
   [Chute, Christopher G.] Johns Hopkins Univ, Dept Hlth Policy & Management, Sch Med, Baltimore, MD 21218 USA.
   [Chute, Christopher G.] Johns Hopkins Univ, Sch Med, Dept Nursing, Baltimore, MD USA.
RP Bennett, TD (corresponding author), Univ Colorado, Sect Informat & Data Sci, Dept Pediat, Sch Med, 13199 E Montview Blvd,Ste 300, Aurora, CO 80045 USA.; Chute, CG (corresponding author), Johns Hopkins Univ, 2024 E Monument St, Baltimore, MD 21287 USA.
EM tell.bennett@cuanschutz.edu; chute@jhu.edu
RI Levitt, Eli B/AAH-3231-2019; Harper, Diane/I-2180-2014; Kharrazi,
   Hadi/Q-1725-2015
OI Levitt, Eli B/0000-0002-3921-5653; Anzalone, Alfred/0000-0002-3212-7845;
   Harper, Diane/0000-0001-7648-883X; Kharrazi, Hadi/0000-0003-1481-4323
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA; NCATSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [U24 TR002306]; Stony Brook University [U24TR002306]; Oklahoma Clinical
   and Translational Science Institute, University of Oklahoma Health
   Sciences Center [U54GM104938]; West Virginia Clinical and Translational
   Science Institute, West Virginia University [U54GM104942]; Mississippi
   Center for Clinical and Translational Research, University of
   Mississippi Medical Center [U54GM115428]; Great Plains IDeA-Clinical &
   Translational Research, University of Nebraska Medical Center
   [U54GM115458]; Northern New England Clinical & Translational Research)
   Network, Maine Medical Center [U54GM115516]; Wake Forest Clinical and
   Translational Science Institute, Wake Forest University Health Sciences
   [UL1TR001420]; Northwestern University Clinical and Translational
   Science Institute, Northwestern University [UL1TR001422]; Center for
   Clinical and Translational Science and Training, University of
   Cincinnati [UL1TR001425]; Institute for Translational Sciences,
   University of Texas Medical Branch at Galveston [UL1TR001439]; South
   Carolina Clinical & Translational Research Institute, Medical University
   of South Carolina [UL1TR001450]; UMass Center for Clinical and
   Translational Science, University of Massachusetts Medical
   SchoolWorcester [UL1TR001453]; Southern California Clinical and
   Translational Science Institute, University of Southern California
   [UL1TR001855]; Irving Institute for Clinical and Translational Research,
   Columbia University Irving Medical Cente [UL1TR001873]; Clinical and
   Translational Science Institute at Children's National, GeorgeWashington
   Children's Research Institute [UL1TR001876]; Appalachian Translational
   Research Network, University of Kentucky [UL1TR001998]; University of
   Rochester Clinical & Translational Science Institute [UL1TR001998];
   University of Illinois at Chicago Center for Clinical and Translational
   Science [UL1TR002003]; Penn State Clinical and Translational Science
   Institute [UL1TR002014]; Michigan Institute for Clinical and Health
   Research, University of Michigan at Ann Arbor [UL1TR002240]; Vanderbilt
   Institute for Clinical and Translational Research, Vanderbilt University
   Medical Center [UL1TR002243]; Institute of Translational Health
   Sciences, University ofWashington [UL1TR002319]; Institute of Clinical
   and Translational Sciences, Washington University in St. Louis
   [UL1TR002345]; Oregon Clinical and Translational Research Institute,
   Oregon Health & Science University [UL1TR002369]; Wisconsin Network For
   Health Research, University of Wisconsin-Madison [UL1TR002373];
   Institute for Translational Medicine, Rush University Medical Center
   [UL1TR002389]; Institute for Translational Medicine, University of
   Chicago [UL1TR002389]; North Carolina Translational and Clinical Science
   Institute, University of North Carolina at Chapel Hill [UL1TR002489];
   Clinical and Translational Science Institute, University of Minnesota
   [UL1TR002494]; Colorado Clinical and Translational Sciences Institute
   and Children's Hospital Colorado [UL1TR002535]; Institute for Clinical
   and Translational Science, University of Iowa [UL1TR002537, UL1TR002535
   03S2]; Uhealth Center for Clinical and Translational Science, University
   of Utah [UL1TR002538]; Tufts Clinical and Translational Science
   Institute, Tufts Medical Center [UL1TR002544]; Duke Clinical and
   Translational Science Institute, Duke University [UL1TR002553]; C.
   Kenneth and DianneWright Center for Clinical and Translational Research,
   Virginia Commonwealth University [UL1TR002649]; Center for Clinical and
   Translational Science, Ohio State University [UL1TR002733]; University
   of Miami Clinical and Translational Science Institute [UL1TR002736];
   iTHRIVL Integrated Translational health Research Institute of Virginia,
   University of Virginia [UL1TR003015]; iTHRIVL Integrated Translational
   health Research Institute of Virginia, Carilion Clinic [UL1TR003015];
   Center for Clinical and Translational Science, University of Alabama at
   Birmingham [UL1TR003096]; Johns Hopkins Institute for Clinical and
   Translational Research, Johns Hopkins University [UL1TR003098];
   Consortium of Rural States, University of Arkansas for Medical Sciences
   [UL1TR003107]; Delaware CTR ACCEL Program, Nemours [U54GM104941];
   Colorado Clinical and Translational Sciences Institute, University of
   Colorado, Denver, Anschutz Medical Campus [UL1TR002535]; Mayo Clinic
   Center for Clinical and Translational Science, Mayo Clinic Rochester
   [UL1TR002377]; Institute for Translational Medicine, Loyola University
   Medical Center [UL1TR002389]; Institute for Translational Medicine,
   Advocate Health Care Network [UL1TR002389]; Center for Clinical and
   Translational Science, Rockefeller University [UL1TR001866]; Scripps
   Research Translational Institute, The Scripps Research Institute
   [UL1TR002550]; Institute for Integration of Medicine and Science,
   University of Texas Health Science Center at San Antonio [UL1TR002645];
   Center for Clinical and Translational Sciences, The University of Texas
   Health Science Center at Houston [UL1TR003167]; Institute for
   Translational Medicine, NorthShore University HealthSystem
   [UL1TR002389]; Yale Center for Clinical Investigation, Yale New Haven
   Hospital [UL1TR001863]; Georgia Clinical and Translational Science
   Alliance, Emory University [UL1TR002378]; Weill Cornell Medicine
   Clinical and Translational Science Center, Weill Medical College of
   Cornell University [UL1TR002384]; Institute for Clinical and
   Translational Research at Einstein and Montefiore, Montefiore Medical
   Center [UL1TR002556]; Clinical and Translational Science Institute of
   Southeast Wisconsin, Medical College of Wisconsin [UL1TR001436];
   University of New Mexico Clinical and Translational Science Center,
   University of New Mexico Health Sciences Center [UL1TR001449]; Clinical
   and Translational Science Institute at Children's National,
   GeorgeWashington University [UL1TR001876]; Spectrum: The Stanford Center
   for Clinical and Translational Research and Education, Stanford
   University [UL1TR003142]; Indiana Clinical and Translational Science
   Institute, Regenstrief Institute [UL1TR002529]; Center for Clinical and
   Translational Science and Training, Cincinnati Children's Hospital
   Medical Center [UL1TR001425]; Boston University Clinical and
   Translational Science Institute, Boston University Medical Campus
   [UL1TR001430]; Louisiana Clinical and Translational Science Center,
   University Medical Center New Orleans [U54GM104940]; Clinical and
   Translational Science Institute, The State University of New York at
   Buffalo [UL1TR001412]; Wisconsin Network For Health Research, Aurora
   Health Care [UL1TR002373]; Advance Clinical Translational Research,
   Brown University [U54GM115677]; New Jersey Alliance for Clinical and
   Translational Science, Rutgers, The State University of New Jersey
   [UL1TR003017]; Institute for Translational Medicine, Loyola University
   Chicago [UL1TR002389]; Langone Health's Clinical and Translational
   Science Institute, New York University Grossman School of Medicine
   [UL1TR001445]; Institute for Translational Medicine and Therapeutics,
   Children's Hospital of Philadelphia [UL1TR001878]; Frontiers: University
   of Kansas Clinical and Translational Science Institute, University of
   Kansas Medical Center [UL1TR002366]; Harvard Catalyst, Massachusetts
   General Brigham [UL1TR002541]; Bill and Melinda Gates FoundationBill &
   Melinda Gates Foundation [INV-018455]; ConduITS Institute for
   Translational Sciences, Icahn School of Medicine at Mount Sinai
   [UL1TR001433]; Louisiana Clinical and Translational Science Center,
   Ochsner Medical Center [U54GM104940]; University of California, Irvine
   Institute for Clinical and Translational Science [UL1TR001414]; Altman
   Clinical and Translational Research Institute, University of California,
   San DiegoUniversity of California System [UL1TR001442]; UCDavis Health
   Clinical and Translational Science Center, University of California,
   DavisUniversity of California System [UL1TR001860]; University of
   California, San Francisco Clinical and Translational Science
   InstituteUniversity of California System [UL1TR001872]; UCLA Clinical
   Translational Science Institute [UL1TR001881]
FX The primary study sponsors are multiple institutes of the National
   Institutes of Health. The NCATS is the primary steward of the N3C data,
   created the underlying architecture of the N3C Data Enclave, manages the
   Data Transfer Agreements and Data Use Agreements, houses the Data Access
   Committee, and supports contracts to vendors (see Conflicts of Interest
   Disclosures) to help build various aspects of the N3C Data Enclave. The
   analyses described in this publicationwere conducted with data or tools
   accessed through the NCATS N3C Data Enclave and supported by NCATS U24
   TR002306 (Drs Haendel, Guinney, Chute, Saltz, and Williams; also
   supporting Dr Pfaff, MsWalden, Ms McMurry, Mr Neumann, Ms Gabriel, and
   Dr Lehmann).This study was also supported by the following (institutions
   with release data): grants U24TR002306 (Stony Brook University),
   U54GM104938 (Oklahoma Clinical and Translational Science Institute,
   University of Oklahoma Health Sciences Center), U54GM104942 (West
   Virginia Clinical and Translational Science Institute, West Virginia
   University), U54GM115428 (Mississippi Center for Clinical and
   Translational Research, University of Mississippi Medical Center),
   U54GM115458 (Great Plains IDeA-Clinical & Translational Research,
   University of Nebraska Medical Center), U54GM115516 (Northern New
   England Clinical & Translational Research) Network, Maine Medical
   Center), UL1TR001420 (Wake Forest Clinical and Translational Science
   Institute, Wake Forest University Health Sciences), UL1TR001422
   (Northwestern University Clinical and Translational Science Institute,
   Northwestern University)), UL1TR001425 (Center for Clinical and
   Translational Science and Training, University of Cincinnati),
   UL1TR001439 (Institute for Translational Sciences, University of Texas
   Medical Branch at Galveston), UL1TR001450 (South Carolina Clinical &
   Translational Research Institute, Medical University of South Carolina),
   UL1TR001453 (UMass Center for Clinical and Translational Science,
   University of Massachusetts Medical SchoolWorcester), UL1TR001855
   (Southern California Clinical and Translational Science Institute,
   University of Southern California), UL1TR001873 (Irving Institute for
   Clinical and Translational Research, Columbia University Irving Medical
   Center), UL1TR001876 (Clinical and Translational Science Institute at
   Children's National, GeorgeWashington Children's Research Institute),
   UL1TR001998 (Appalachian Translational Research Network, University of
   Kentucky), (University of Rochester Clinical & Translational Science
   Institute), UL1TR002003 (University of Illinois at Chicago Center for
   Clinical and Translational Science), UL1TR002014 (Penn State Clinical
   and Translational Science Institute), UL1TR002240 (Michigan Institute
   for Clinical and Health Research, University of Michigan at Ann Arbor),
   UL1TR002243 (Vanderbilt Institute for Clinical and Translational
   Research, Vanderbilt University Medical Center), UL1TR002319 (Institute
   of Translational Health Sciences, University ofWashington), UL1TR002345
   (Institute of Clinical and Translational Sciences, Washington University
   in St.; Louis), UL1TR002369 (Oregon Clinical and Translational Research
   Institute, Oregon Health & Science University), UL1TR002373 (Wisconsin
   Network For Health Research, University of Wisconsin-Madison),
   UL1TR002389 (Institute for Translational Medicine, Rush University
   Medical Center), UL1TR002389 (Institute for Translational Medicine,
   University of Chicago), UL1TR002489 (North Carolina Translational and
   Clinical Science Institute, University of North Carolina at Chapel
   Hill), UL1TR002494 (Clinical and Translational Science Institute,
   University of Minnesota), UL1TR002535 (Colorado Clinical and
   Translational Sciences Institute and Children's Hospital Colorado),
   UL1TR002537 and UL1TR002535 03S2 (Institute for Clinical and
   Translational Science, University of Iowa), UL1TR002538 (Uhealth Center
   for Clinical and Translational Science, University of Utah), UL1TR002544
   (Tufts Clinical and Translational Science Institute, Tufts Medical
   Center), UL1TR002553 (Duke Clinical and Translational Science Institute,
   Duke University), UL1TR002649 (C. Kenneth and DianneWright Center for
   Clinical and Translational Research, Virginia Commonwealth University),
   UL1TR002733 (Center for Clinical and Translational Science, Ohio State
   University) UL1TR002736 (University of Miami Clinical and Translational
   Science Institute), UL1TR003015 (iTHRIVL Integrated Translational health
   Research Institute of Virginia, University of Virginia), UL1TR003015
   (iTHRIVL Integrated Translational health Research Institute of Virginia,
   Carilion Clinic), UL1TR003096 (Center for Clinical and Translational
   Science, University of Alabama at Birmingham), UL1TR003098 (Johns
   Hopkins Institute for Clinical and Translational Research, Johns Hopkins
   University), UL1TR003107 (Consortium of Rural States, University of
   Arkansas for Medical Sciences), U54GM104941 (Delaware CTR ACCEL Program,
   Nemours), UL1TR002535 (Colorado Clinical and Translational Sciences
   Institute, University of Colorado, Denver, Anschutz Medical Campus),
   UL1TR002377 (Mayo Clinic Center for Clinical and Translational Science,
   Mayo Clinic Rochester), UL1TR002389 (Institute for Translational
   Medicine, Loyola University Medical Center), and UL1TR002389 (Institute
   for Translational Medicine, Advocate Health Care Network).; Additional
   support (data release pending) as provided as follows: UL1TR001866
   (Center for Clinical and Translational Science, Rockefeller University),
   UL1TR002550 (Scripps Research Translational Institute, The Scripps
   Research Institute), UL1TR002645 (Institute for Integration of Medicine
   and Science, University of Texas Health Science Center at San Antonio),
   UL1TR003167 (Center for Clinical and Translational Sciences, The
   University of Texas Health Science Center at Houston), UL1TR002389
   (Institute for Translational Medicine, NorthShore University
   HealthSystem), UL1TR001863 (Yale Center for Clinical Investigation, Yale
   New Haven Hospital), UL1TR002378 (Georgia Clinical and Translational
   Science Alliance, Emory University), UL1TR002384 (Weill Cornell Medicine
   Clinical and Translational Science Center, Weill Medical College of
   Cornell University), UL1TR002556 (Institute for Clinical and
   Translational Research at Einstein and Montefiore, Montefiore Medical
   Center), UL1TR001436 (Clinical and Translational Science Institute of
   Southeast Wisconsin, Medical College of Wisconsin), UL1TR001449
   (University of New Mexico Clinical and Translational Science Center,
   University of New Mexico Health Sciences Center), UL1TR001876 (Clinical
   and Translational Science Institute at Children's National,
   GeorgeWashington University), UL1TR003142 (Spectrum: The Stanford Center
   for Clinical and Translational Research and Education, Stanford
   University), UL1TR002529 (Indiana Clinical and Translational Science
   Institute, Regenstrief Institute), UL1TR001425 (Center for Clinical and
   Translational Science and Training, Cincinnati Children's Hospital
   Medical Center), UL1TR001430 (Boston University Clinical and
   Translational Science Institute, Boston University Medical Campus),
   U54GM104940 (Louisiana Clinical and Translational Science Center,
   University Medical Center New Orleans), UL1TR001412 (Clinical and
   Translational Science Institute, The State University of New York at
   Buffalo), UL1TR002373 (Wisconsin Network For Health Research, Aurora
   Health Care), U54GM115677 (Advance Clinical Translational Research,
   Brown University), UL1TR003017 (New Jersey Alliance for Clinical and
   Translational Science, Rutgers, The State University of New Jersey),
   UL1TR002389 (Institute for Translational Medicine, Loyola University
   Chicago), UL1TR001445 (Langone Health's Clinical and Translational
   Science Institute, New York University Grossman School of Medicine),
   UL1TR001878 (Institute for Translational Medicine and Therapeutics,
   Children's Hospital of Philadelphia), UL1TR002366 (Frontiers: University
   of Kansas Clinical and Translational Science Institute, University of
   Kansas Medical Center), UL1TR002541 (Harvard Catalyst, Massachusetts
   General Brigham), INV-018455 (Bill and Melinda Gates Foundation grant to
   Sage Bionetworks, OCHIN), UL1TR001433 (ConduITS Institute for
   Translational Sciences, Icahn School of Medicine at Mount Sinai),
   U54GM104940 (Louisiana Clinical and Translational Science Center,
   Ochsner Medical Center), UL1TR001414 (University of California, Irvine
   Institute for Clinical and Translational Science), UL1TR001442 (Altman
   Clinical and Translational Research Institute, University of California,
   San Diego), UL1TR001860 (UCDavis Health Clinical and Translational
   Science Center, University of California, Davis), UL1TR001872
   (University of California, San Francisco Clinical and Translational
   Science Institute), and UL1TR001881 (UCLA Clinical Translational Science
   Institute).
CR Angus DC, 2020, JAMA-J AM MED ASSOC, V324, P1317, DOI 10.1001/jama.2020.17022
   [Anonymous], 2020, JAMA, V323, P2098, DOI 10.1001/jama.2020.7681
   [Anonymous], 2021, I DEV AWARD PROGRAM
   Auld SC, 2020, CRIT CARE MED, V48, pE799, DOI 10.1097/CCM.0000000000004457
   Azar KMJ, 2020, HEALTH AFFAIR, V39, P1253, DOI 10.1377/hlthaff.2020.00598
   Brat GA, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-00308-0
   Butt JH, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-044421
   Deng GT, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02902-w
   Dennis JM, 2021, CRIT CARE MED, V49, P209, DOI 10.1097/CCM.0000000000004747
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   FU WH, 2020, ECLINICALMEDICINE, V25
   Garibaldi BT, 2021, ANN INTERN MED, V174, P33, DOI 10.7326/M20-3905
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Gupta S, 2020, JAMA INTERN MED, V180, P1436, DOI [10.1001/jamainternmed.2020.3596, 10.1001/jamainternmed.2020.6252]
   Guzik TJ, 2020, CARDIOVASC RES, V116, P1666, DOI 10.1093/cvr/cvaa106
   Haendel MA, 2021, J AM MED INFORM ASSN, V28, P427, DOI 10.1093/jamia/ocaa196
   HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747
   Horby P, 2021, NEW ENGL J MED, V384, P693, DOI 10.1056/NEJMoa2021436
   Horwitz LI, 2021, J HOSP MED, V16, P90, DOI 10.12788/jhm.3552
   Hyrich KL, 2021, NAT REV RHEUMATOL, V17, P71, DOI 10.1038/s41584-020-00562-2
   Jarrett M, 2020, J MED INTERNET RES, V22, DOI 10.2196/23565
   Latz CA, 2020, ANN HEMATOL, V99, P2113, DOI 10.1007/s00277-020-04169-1
   Liu NY, 2020, J ALZHEIMERS DIS, V78, P1775, DOI 10.3233/JAD-201016
   Marshall JC, 2020, LANCET INFECT DIS, V20, pE192, DOI 10.1016/S1473-3099(20)30483-7
   Mehra MR, 2020, LANCET, V395, P1820, DOI [10.1016/S0140-6736(20)31324-6, 10.1016/S0140-6736(20)31180-6]
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
   Moon AM, 2020, J HEPATOL, V73, P705, DOI 10.1016/j.jhep.2020.05.013
   Peters SAE, 2021, DIABETES OBES METAB, V23, P258, DOI 10.1111/dom.14199
   Price-Haywood EG, 2020, NEW ENGL J MED, V382, P2534, DOI 10.1056/NEJMsa2011686
   Ray JG, 2021, ANN INTERN MED, V174, P308, DOI 10.7326/M20-4511
   Sottile Peter D, 2021, medRxiv, DOI 10.1101/2021.01.14.21249793
   Tartof SY, 2020, ANN INTERN MED, V173, P773, DOI 10.7326/M20-3742
   Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4
   Zietz Michael, 2020, medRxiv, DOI 10.1101/2020.04.08.20058073
NR 34
TC 3
Z9 3
U1 1
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2574-3805
J9 JAMA NETW OPEN
JI JAMA Netw. Open
PD JUL 13
PY 2021
VL 4
IS 7
AR e2116901
DI 10.1001/jamanetworkopen.2021.16915
PG 15
WC Medicine, General & Internal
SC General & Internal Medicine
GA TI7ET
UT WOS:000672963900008
PM 34255046
OA Green Published, gold
DA 2021-10-30
ER

PT J
AU Portale, AA
   Wolf, M
   Juppner, H
   Messinger, S
   Kumar, J
   Wesseling-Perry, K
   Schwartz, GJ
   Furth, SL
   Warady, BA
   Salusky, IB
AF Portale, Anthony A.
   Wolf, Myles
   Jueppner, Harald
   Messinger, Shari
   Kumar, Juhi
   Wesseling-Perry, Katherine
   Schwartz, George J.
   Furth, Susan L.
   Warady, Bradley A.
   Salusky, Isidro B.
TI Disordered FGF23 and Mineral Metabolism in Children with CKD
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID GROWTH-FACTOR 23; CHRONIC KIDNEY-DISEASE; GLOMERULAR-FILTRATION-RATE;
   VITAMIN-D METABOLISM; D DEFICIENCY; PHOSPHATE;
   FIBROBLAST-GROWTH-FACTOR-23; 1,25-DIHYDROXYVITAMIN-D;
   HYPERPARATHYROIDISM; PROGRESSION
AB Background and objectives In children with CKD, information is limited regarding the prevalence and determinants of fibroblast growth factor 23 excess and 1,25-dihyroxyvitamin D deficiency across the spectrum of predialysis CKD. This study characterized circulating concentrations of fibroblast growth factor 23 and 1,25-dihyroxyvitamin D, and investigated their interrelationships and associations with GFR and secondary hyperparathyroidism in children with CKD who were enrolled in the Chronic Kidney Disease in Children observational cohort study.
   Design, setting, participants, & measurements Plasma fibroblast growth factor 23 concentrations and determinants of mineral metabolism were measured in 464 children ages 1-16 years with predialysis CKD. GFR was measured by plasma disappearance of iohexol in 70% of participants and estimated by the Chronic Kidney Disease in Children estimating equation using serum creatinine and cystatin C concentrations in the remainder of the participants. Participants were grouped according to CKD stage and by 10-ml/min categories of GFR.
   Results Median GFR for the cohort was 45 ml/min per 1.73m(2) (interquartile range=33-57; range=15-109). Plasma fibroblast growth factor 23 concentration was above the normal range in 67% of participants (with higher levels observed among participants with lower GFR) before higher levels of serum parathyroid hormone and phosphorus were observed. Plasma fibroblast growth factor 23 levels were 34% higher in participants with glomerular disease than in participants with nonglomerular disease, despite similar GFR. Serum phosphorus levels, adjusted for age, were significantly lower at GFR of 60-69ml/min per 1.73m(2) than higher GFR, but thereafter they became higher in parallel with fibroblast growth factor 23 as GFR declined. Serum 1,25-dihyroxyvitamin D concentrations were lower in those participants with low GFR values, high fibroblast growth factor 23 levels, 25-hydroxyvitamin D deficiency, and proteinuria. Secondary hyperparathyroidism was present in 55% of participants with GFR<50 ml/min per 1.73 m(2).
   Conclusion In children with predialysis CKD, high plasma fibroblast growth factor 23 is the earliest detectable abnormality in mineral metabolism, and levels are highest in glomerular diseases.
C1 [Portale, Anthony A.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA.
   [Wolf, Myles] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA.
   [Messinger, Shari] Univ Miami, Miller Sch Med, Dept Epidemiol & Publ Hlth, Miami, FL 33136 USA.
   [Jueppner, Harald] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
   [Kumar, Juhi] Weill Cornell Med Coll, Dept Pediat, New York, NY USA.
   [Wesseling-Perry, Katherine; Salusky, Isidro B.] Univ Calif Los Angeles, Dept Pediat, Los Angeles, CA 90024 USA.
   [Schwartz, George J.] Univ Rochester, Sch Med, Dept Pediat, Rochester, NY 14642 USA.
   [Furth, Susan L.] Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA.
   [Warady, Bradley A.] Univ Missouri, Sch Med, Dept Pediat, Kansas City, MO 64108 USA.
RP Portale, AA (corresponding author), Univ Calif San Francisco, Div Pediat Nephrol, 533 Parnassus Ave,Box 0748, San Francisco, CA 94143 USA.
EM aportale@peds.ucsf.edu
FU National Institute of Diabetes and Digestive and Kidney DiseasesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Diabetes & Digestive &
   Kidney Diseases (NIDDK) [R01-DK-084978, R01-DK-35423, R01-DK-67563,
   UL1-TR-000122, P01-DK-11794]; Abbott LaboratoriesAbbott Laboratories;
   Pediatric Nephrology Innovative Research Fund; National Institute of
   Diabetes and Digestive and Kidney DiseasesUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK);
   National Institute of Neurological Disorders and StrokeUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Neurological Disorders & Stroke (NINDS);
   National Institute of Child Health and Human DevelopmentUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH Eunice Kennedy Shriver National Institute of Child Health &
   Human Development (NICHD); National Heart, Lung, and Blood
   InstituteUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [UO1-DK-66143, UO1-DK-66174, UO1-DK-66116]; Genzyme
   CorporationSanofi-AventisGenzyme Corporation; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000460,
   KL2TR000122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)
   [U01DK066174, R01DK067563, U01DK066116, R01DK084978, R01DK035423,
   U01DK066143, P01DK011794, U01DK082194] Funding Source: NIH RePORTER
FX This study was supported by National Institute of Diabetes and Digestive
   and Kidney Diseases Grants R01-DK-084978 (to A. A. P.), R01-DK-35423,
   R01-DK-67563, UL1-TR-000122 (to I. B. S.), and P01-DK-11794 (subproject
   IV; to H.J.), grants from Abbott Laboratories and Genzyme Corporation
   (to A. A. P.), and the Pediatric Nephrology Innovative Research Fund (to
   A. A. P.). The Chronic Kidney Disease in Children study is funded by the
   National Institute of Diabetes and Digestive and Kidney Diseases, the
   National Institute of Neurological Disorders and Stroke, the National
   Institute of Child Health and Human Development, and National Heart,
   Lung, and Blood Institute Grants UO1-DK-66143, UO1-DK-66174, and
   UO1-DK-66116.
CR Bacchetta J, 2010, J CLIN ENDOCR METAB, V95, P1741, DOI 10.1210/jc.2009-1576
   Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272-6386(03)00111-2
   Ersfeld DL, 2004, CLIN BIOCHEM, V37, P867, DOI 10.1016/j.clinbiochem.2004.06.006
   Faul C, 2011, J CLIN INVEST, V121, P4393, DOI 10.1172/JCI46122
   Fischer DC, 2012, ANN CLIN BIOCHEM, V49, P546, DOI 10.1258/acb.2012.011274
   Fliser D, 2007, J AM SOC NEPHROL, V18, P2600, DOI 10.1681/ASN.2006080936
   Furth SL, 2006, CLIN J AM SOC NEPHRO, V1, P1006, DOI 10.2215/CJN.01941205
   Furth SL, 2011, CLIN J AM SOC NEPHRO, V6, P2132, DOI 10.2215/CJN.07100810
   Gordon CM, 2008, ARCH PEDIAT ADOL MED, V162, P505, DOI 10.1001/archpedi.162.6.505
   Gutierrez O, 2005, J AM SOC NEPHROL, V16, P2205, DOI 10.1681/ASN.2005010052
   Gutierrez OM, 2008, NEW ENGL J MED, V359, P584, DOI 10.1056/NEJMoa0706130
   Gutierrez OM, 2009, CIRCULATION, V119, P2545, DOI 10.1161/CIRCULATIONAHA.108.844506
   Hari P, 2010, PEDIATR NEPHROL, V25, P2483, DOI 10.1007/s00467-010-1639-2
   Hasegawa H, 2010, KIDNEY INT, V78, P975, DOI 10.1038/ki.2010.313
   Hollis BW, 1996, CLIN CHEM, V42, P586
   Isakova T, 2011, JAMA-J AM MED ASSOC, V305, P2432, DOI 10.1001/jama.2011.826
   Isakova T, 2011, KIDNEY INT, V79, P1370, DOI 10.1038/ki.2011.47
   John GB, 2011, AM J KIDNEY DIS, V58, P127, DOI 10.1053/j.ajkd.2010.12.027
   Kalkwarf HJ, 2012, KIDNEY INT, V81, P690, DOI 10.1038/ki.2011.431
   Kumar J, 2009, PEDIATRICS, V124, pE362, DOI 10.1542/peds.2009-0051
   Levin A, 2007, KIDNEY INT, V71, P31, DOI 10.1038/sj.ki.5002009
   LOCKITCH G, 1988, CLIN CHEM, V34, P1625
   Lundberg S, 2012, CLIN J AM SOC NEPHRO, V7, P727, DOI 10.2215/CJN.10331011
   McDonald SP, 2004, NEW ENGL J MED, V350, P2654, DOI 10.1056/NEJMoa031643
   Menon S, 2008, PEDIATR NEPHROL, V23, P1831, DOI 10.1007/s00467-008-0842-x
   Pavik I, 2011, KIDNEY INT, V79, P234, DOI 10.1038/ki.2010.375
   Pereira RC, 2009, BONE, V45, P1161, DOI 10.1016/j.bone.2009.08.008
   Perwad F, 2007, AM J PHYSIOL-RENAL, V293, pF1577, DOI 10.1152/ajprenal.00463.2006
   PITTS TO, 1988, J CLIN ENDOCR METAB, V67, P876, DOI 10.1210/jcem-67-5-876
   PORTALE AA, 1982, KIDNEY INT, V21, P627, DOI 10.1038/ki.1982.70
   Saito H, 2003, J BIOL CHEM, V278, P2206, DOI 10.1074/jbc.M207872200
   Schwartz GJ, 2006, KIDNEY INT, V69, P2070, DOI 10.1038/sj.ki.5000385
   Schwartz GJ, 2012, KIDNEY INT, V82, P445, DOI 10.1038/ki.2012.169
   SCHWARTZ GJ, 1976, PEDIATRICS, V58, P259
   Scialla JJ, 2013, J AM SOC NEPHROL, V24, P125, DOI 10.1681/ASN.2012070713
   Shigematsu T, 2004, AM J KIDNEY DIS, V44, P250, DOI 10.1053/j.ajkd.2004.04.029
   Shimada T, 2004, J CLIN INVEST, V113, P561, DOI 10.1172/JCI200419081
   Shimada T, 2004, J BONE MINER RES, V19, P429, DOI 10.1359/JBMR.0301264
   Sinha MD, 2012, NEPHROL DIAL TRANSPL, V27, P4361, DOI 10.1093/ndt/gfs109
   Siomou E, 2011, PEDIATR NEPHROL, V26, P1105, DOI 10.1007/s00467-011-1870-5
   Tuchman S, 2010, PEDIATR NEPHROL, V25, P2509, DOI 10.1007/s00467-010-1612-0
   van Husen M, 2010, KIDNEY INT, V78, P200, DOI 10.1038/ki.2010.107
   Wagner D, 2009, CLIN BIOCHEM, V42, P1549, DOI 10.1016/j.clinbiochem.2009.07.013
   Wan M, 2013, NEPHROL DIAL TRANSPL, V28, P153, DOI 10.1093/ndt/gfs411
   Wesseling-Perry K, 2012, CLIN J AM SOC NEPHRO, V7, P146, DOI 10.2215/CJN.05940611
   WILSON L, 1985, KIDNEY INT, V27, P565, DOI 10.1038/ki.1985.48
NR 46
TC 74
Z9 76
U1 0
U2 6
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555-9041
EI 1555-905X
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD FEB 7
PY 2014
VL 9
IS 2
BP 344
EP 353
DI 10.2215/CJN.05840513
PG 10
WC Urology & Nephrology
SC Urology & Nephrology
GA AI9FY
UT WOS:000337238400019
PM 24311704
OA Bronze, Green Published
DA 2021-10-30
ER

PT J
AU Grubaugh, ND
   Ladner, JT
   Kraemer, MUG
   Dudas, G
   Tan, AL
   Gangavarapu, K
   Wiley, MR
   White, S
   Theze, J
   Magnani, DM
   Prieto, K
   Reyes, D
   Bingham, AM
   Paul, LM
   Robles-Sikisaka, R
   Oliveira, G
   Pronty, D
   Barcellona, CM
   Metsky, HC
   Baniecki, ML
   Barnes, KG
   Chak, B
   Freije, CA
   Gladden-Young, A
   Gnirke, A
   Luo, C
   MacInnis, B
   Matranga, CB
   Park, DJ
   Qu, J
   Schaffner, SF
   Tomkins-Tinch, C
   West, KL
   Winnicki, SM
   Wohl, S
   Yozwiak, NL
   Quick, J
   Fauver, JR
   Khan, K
   Brent, SE
   Reiner, RC
   Lichtenberger, PN
   Ricciardi, MJ
   Bailey, VK
   Watkins, DI
   Cone, MR
   Kopp, EW
   Hogan, KN
   Cannons, AC
   Jean, R
   Monaghan, AJ
   Garry, RF
   Loman, NJ
   Faria, NR
   Porcelli, MC
   Vasquez, C
   Agle, ERN
   Cummings, DAT
   Stanek, D
   Rambaut, A
   Sanchez-Lockhart, M
   Sabeti, PC
   Gillis, LD
   Michael, SF
   Bedford, T
   Pybus, OG
   Isern, S
   Palacios, G
   Andersen, KG
AF Grubaugh, Nathan D.
   Ladner, Jason T.
   Kraemer, Moritz U. G.
   Dudas, Gytis
   Tan, Amanda L.
   Gangavarapu, Karthik
   Wiley, Michael R.
   White, Stephen
   Theze, Julien
   Magnani, Diogo M.
   Prieto, Karla
   Reyes, Daniel
   Bingham, Andrea M.
   Paul, Lauren M.
   Robles-Sikisaka, Refugio
   Oliveira, Glenn
   Pronty, Darryl
   Barcellona, Carolyn M.
   Metsky, Hayden C.
   Baniecki, Mary Lynn
   Barnes, Kayla G.
   Chak, Bridget
   Freije, Catherine A.
   Gladden-Young, Adrianne
   Gnirke, Andreas
   Luo, Cynthia
   MacInnis, Bronwyn
   Matranga, Christian B.
   Park, Daniel J.
   Qu, James
   Schaffner, Stephen F.
   Tomkins-Tinch, Christopher
   West, Kendra L.
   Winnicki, Sarah M.
   Wohl, Shirlee
   Yozwiak, Nathan L.
   Quick, Joshua
   Fauver, Joseph R.
   Khan, Kamran
   Brent, Shannon E.
   Reiner, Robert C., Jr.
   Lichtenberger, Paola N.
   Ricciardi, Michael J.
   Bailey, Varian K.
   Watkins, David I.
   Cone, Marshall R.
   Kopp, Edgar W.
   Hogan, Kelly N.
   Cannons, Andrew C.
   Jean, Reynald
   Monaghan, Andrew J.
   Garry, Robert F.
   Loman, Nicholas J.
   Faria, Nuno R.
   Porcelli, Mario C.
   Vasquez, Chalmers
   Agle, Elyse R. N.
   Cummings, Derek A. T.
   Stanek, Danielle
   Rambaut, Andrew
   Sanchez-Lockhart, Mariano
   Sabeti, Pardis C.
   Gillis, Leah D.
   Michael, Scott F.
   Bedford, Trevor
   Pybus, Oliver G.
   Isern, Sharon
   Palacios, Gustavo
   Andersen, Kristian G.
TI Genomic epidemiology reveals multiple introductions of Zika virus into
   the United States
SO NATURE
LA English
DT Article
ID MAXIMUM-LIKELIHOOD; AEDES-AEGYPTI; SEQUENCE DATA; TRANSMISSION; AMERICA;
   DENGUE; INFECTION; OUTBREAK; FLORIDA; SPREAD
AB Zika virus (ZIKV) is causing an unprecedented epidemic linked to severe congenital abnormalities(1,2). In July 2016, mosquito-borne ZIKV transmission was reported in the continental United States; since then, hundreds of locally acquired infections have been reported in Florida(3,4). To gain insights into the timing, source, and likely route(s) of ZIKV introduction, we tracked the virus from its first detection in Florida by sequencing ZIKV genomes from infected patients and Aedes aegypti mosquitoes. We show that at least 4 introductions, but potentially as many as 40, contributed to the outbreak in Florida and that local transmission is likely to have started in the spring of 2016-several months before its initial detection. By analysing surveillance and genetic data, we show that ZIKV moved among transmission zones in Miami. Our analyses show that most introductions were linked to the Caribbean, a finding corroborated by the high incidence rates and traffic volumes from the region into the Miami area. Our study provides an understanding of how ZIKV initiates transmission in new regions.
C1 [Grubaugh, Nathan D.; Robles-Sikisaka, Refugio; Andersen, Kristian G.] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA.
   [Ladner, Jason T.; Wiley, Michael R.; Prieto, Karla; Reyes, Daniel; Sanchez-Lockhart, Mariano; Palacios, Gustavo] US Army Med Res Inst Infect Dis, Ctr Genome Sci, Ft Detrick, MD 21702 USA.
   [Kraemer, Moritz U. G.; Theze, Julien; Faria, Nuno R.; Pybus, Oliver G.] Univ Oxford, Dept Zool, Oxford OX1 3PS, England.
   [Kraemer, Moritz U. G.] Boston Childrens Hosp, Boston, MA 02115 USA.
   [Kraemer, Moritz U. G.] Harbor Med Sch, Boston, MA 02115 USA.
   [Dudas, Gytis; Bedford, Trevor] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98109 USA.
   [Tan, Amanda L.; Paul, Lauren M.; Michael, Scott F.; Isern, Sharon] Florida Gulf Coast Univ, Coll Arts & Sci, Dept Biol Sci, Ft Myers, FL 33965 USA.
   [Wiley, Michael R.; Prieto, Karla] Univ Nebraska Med Ctr, Coll Publ Hlth, Omaha, NE 68198 USA.
   [White, Stephen; Pronty, Darryl; Gillis, Leah D.] Florida Dept Hlth, Bur Publ Hlth Labs, Div Dis Control & Hlth Protect, Miami, FL 33125 USA.
   [Magnani, Diogo M.; Ricciardi, Michael J.; Bailey, Varian K.; Watkins, David I.] Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL 33136 USA.
   [Reyes, Daniel; Agle, Elyse R. N.; Sanchez-Lockhart, Mariano] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA.
   [Bingham, Andrea M.] Florida Dept Hlth, Bur Epidemiol, Div Dis Control & Hlth Protect, Tallahassee, FL 32399 USA.
   [Oliveira, Glenn; Andersen, Kristian G.] Scripps Translat Sci Inst, La Jolla, CA 92037 USA.
   [Metsky, Hayden C.; Baniecki, Mary Lynn; Barnes, Kayla G.; Chak, Bridget; Freije, Catherine A.; Gladden-Young, Adrianne; Gnirke, Andreas; Luo, Cynthia; MacInnis, Bronwyn; Matranga, Christian B.; Park, Daniel J.; Qu, James; Schaffner, Stephen F.; Tomkins-Tinch, Christopher; West, Kendra L.; Winnicki, Sarah M.; Wohl, Shirlee; Yozwiak, Nathan L.; Sabeti, Pardis C.] Broad Inst & Harvard, Cambridge, MA 02142 USA.
   [Quick, Joshua] Univ Birmingham, Inst Microbiol & Infect, Birmingham B15 2TT, W Midlands, England.
   [Fauver, Joseph R.] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA.
   [Khan, Kamran; Brent, Shannon E.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1T8, Canada.
   [Khan, Kamran] Univ Toronto, Dept Med, Div Infect Dis, Toronto, ON M5S 1A8, Canada.
   [Reiner, Robert C., Jr.] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98121 USA.
   [Lichtenberger, Paola N.] Univ Miami, Miller Sch Med, Div Infect Dis, Miami, FL 33136 USA.
   [Cone, Marshall R.; Kopp, Edgar W.; Hogan, Kelly N.; Cannons, Andrew C.] Florida Dept Hlth, Bur Publ Hlth Labs, Div Dis Control & Hlth Protect, Tampa, FL 33612 USA.
   [Jean, Reynald] Florida Dept Hlth Miami Dade Cty, Miami, FL 33125 USA.
   [Monaghan, Andrew J.] Natl Ctr Atmospher Res, Boulder, CO 80307 USA.
   [Garry, Robert F.] Tulane Univ, Sch Med, Dept Microbiol & Immunol, 1430 Tulane Ave, New Orleans, LA 70112 USA.
   [Porcelli, Mario C.; Vasquez, Chalmers] Miami Dade Cty Mosquito Control, Miami, FL 33178 USA.
   [Cummings, Derek A. T.] Univ Florida, Dept Biol, Gainesville, FL 32610 USA.
   [Cummings, Derek A. T.] Univ Florida, Emerging Pathogens Inst, Gainesville, FL USA.
   [Rambaut, Andrew] Univ Edinburgh, Inst Evolutionary Biol, Edinburgh EH9 3FL, Midlothian, Scotland.
   [Rambaut, Andrew] NIH, Fogarty Int Ctr, Bldg 10, Bethesda, MD 20892 USA.
   [Sabeti, Pardis C.] Harvard Univ, Dept Organism & Evolutionary Biol, Ctr Syst Biol, Cambridge, MA 02138 USA.
   [Sabeti, Pardis C.] Harvard Univ, Harvard TH Chan Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
   [Sabeti, Pardis C.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.
   [Andersen, Kristian G.] Scripps Res Inst, Dept Integrat Struct & Computat Biol, La Jolla, CA 92037 USA.
RP Andersen, KG (corresponding author), Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA.; Palacios, G (corresponding author), US Army Med Res Inst Infect Dis, Ctr Genome Sci, Ft Detrick, MD 21702 USA.; Andersen, KG (corresponding author), Scripps Translat Sci Inst, La Jolla, CA 92037 USA.; Andersen, KG (corresponding author), Scripps Res Inst, Dept Integrat Struct & Computat Biol, La Jolla, CA 92037 USA.
EM gustavo.f.palacios.ctr@mail.mil; andersen@scripps.edu
RI Faria, Nuno R/I-2975-2012; Sanchez-Lockhart, Mariano/H-1321-2019;
   Rambaut, Andrew/B-2481-2009; Palacios, Gustavo/I-7773-2015;
   Sanchez-Lockhart, Mariano/M-6446-2019; Pybus, Oliver G/B-2640-2012;
   Schaffner, Stephen F/D-1189-2011; Dudas, Gytis/H-5968-2019; Loman,
   Nicholas/Z-1573-2019
OI Faria, Nuno R/0000-0001-8839-2798; Sanchez-Lockhart,
   Mariano/0000-0001-8009-7540; Rambaut, Andrew/0000-0003-4337-3707;
   Palacios, Gustavo/0000-0001-5062-1938; Sanchez-Lockhart,
   Mariano/0000-0001-8009-7540; Pybus, Oliver G/0000-0002-8797-2667; Dudas,
   Gytis/0000-0002-0227-4158; White, Stephen/0000-0002-2112-1560; Wiley,
   Michael/0000-0001-6688-007X; Monaghan, Andrew/0000-0002-8170-2359;
   Rambaut FRSE, Professor Andrew/0000-0002-1278-598X; Theze,
   Julien/0000-0001-8188-9494; Garry, Robert/0000-0002-5683-3250; Loman,
   Nicholas/0000-0002-9843-8988; Grubaugh, Nathan/0000-0003-2031-1933;
   Paul, Lauren/0000-0001-5503-7570; Tomkins-Tinch,
   Christopher/0000-0002-9114-6421; Magnani, Diogo/0000-0002-1773-2406
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [5T32AI007244-33, R35 GM11977401];
   Mahan Postdoctoral Fellowship from the Computational Biology Program at
   Fred Hutch; ASTMH Shope Fellowship; Sir Henry Dale Fellowship
   [204311/Z/16/Z]; US NIH MIDAS programUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USA
   [U54-GM088491]; CDCUnited States Department of Health & Human
   ServicesCenters for Disease Control & Prevention - USA [U01CK000510];
   EUEuropean Commission [278433-PREDEMICS]; ERCEuropean Research Council
   (ERC)European Commission [260864]; Horizon grant [643476-COMPARE]; NIH
   NIAIDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U19AI110818, R01AI099210]; Howard Hughes
   Medical InstituteHoward Hughes Medical Institute; AWS Cloud Credits for
   Research; Broad Institute BroadNext10 program; EU ERCEuropean Research
   Council (ERC)European Commission [614725-PATHPHYLODYN]; USAID Emerging
   Pandemic Threats Program-2 PREDICT-2United States Agency for
   International Development (USAID) [AID-OAA-A-14-00102]; DARPAUnited
   States Department of DefenseDefense Advanced Research Projects Agency
   (DARPA); NIH NCATS CTSAUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [UL1TR001114]; NIAIDUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [HHSN272201400048C]; Ray Thomas Foundation; NATIONAL
   CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Advancing Translational Sciences (NCATS)
   [UL1TR001114, UL1TR000460] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [U19AI115589, T32AI007244, R01AI099210] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of General Medical Sciences (NIGMS) [U54GM088491,
   R35GM119774] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR,
   NATIONAL INSTITUTES OF HEALTHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [S10OD020069] Funding
   Source: NIH RePORTER; Medical Research CouncilUK Research & Innovation
   (UKRI)Medical Research Council UK (MRC)European Commission
   [MR/L015080/1, MC_PC_15100, MR/M501621/1] Funding Source: researchfish;
   ALLCDCUnited States Department of Health & Human ServicesCenters for
   Disease Control & Prevention - USA [6U01CK000510-01M001] Funding Source:
   Federal RePORTER
FX We thank J. Weger-Lucarelli, G. Ebel, C. Moore, B. Alto, G. Donatti, and
   S. Taylor for discussions; E. Spencer for IRB and logistics support; M.
   Pilcher for sequencing assistance; and G. Schroth and S. Gross for
   designing and providing enrichment probes. N.D.G. is supported by NIH
   training grant 5T32AI007244-33. G.D. is supported by the Mahan
   Postdoctoral Fellowship from the Computational Biology Program at Fred
   Hutch. K.G.B. is supported by the ASTMH Shope Fellowship. N.R.F. is
   funded by a Sir Henry Dale Fellowship (Wellcome Trust/Royal Society
   grant 204311/Z/16/Z). D.A.T.C. was supported by US NIH MIDAS program
   (U54-GM088491) and CDC Cooperative Agreement U01CK000510. A.R. is
   supported by EU Seventh Framework Programme (FP7/2007-2013) under grant
   278433-PREDEMICS, ERC grant 260864, Horizon 2020 grant 643476-COMPARE.
   P.C.S. is supported by Marc and Lynne Benioff; NIH NIAID U19AI110818;
   Howard Hughes Medical Institute; AWS Cloud Credits for Research; Broad
   Institute BroadNext10 program (also A. G.). T. B. is a Pew Biomedical
   Scholar and is supported by NIH R35 GM11977401. O.G.P. received funding
   from EU ERC Seventh Framework Programme (FP7/2007-2013)/ERC number
   614725-PATHPHYLODYN and the USAID Emerging Pandemic Threats Program-2
   PREDICT-2 (Cooperative Agreement No. AID-OAA-A-14-00102). S. I. and S.
   F. M. are supported by NIH NIAID R01AI099210. ZIKV sequencing at
   USAMRIID was supported by DARPA (PI: C. Kane). K. G. A. is a Pew
   Biomedical Scholar, and is supported by NIH NCATS CTSA UL1TR001114,
   NIAID contract HHSN272201400048C, and The Ray Thomas Foundation. The
   content of this publication does not necessarily reflect the views or
   policies of the US Army, the Department of Health and Human Services,
   the CDC, or the Florida Department of Health.
CR [Anonymous], 2016, MMWR-MORBID MORTAL W, V65, P474, DOI 10.15585/mmwr.mm6518e1
   [Anonymous], 2017, NAT DIR EP SURV VECT
   [Anonymous], 2017, ZIK VIR
   [Anonymous], 2017, DENG PUERT RIC
   [Anonymous], 2017, DAIL ZIK UPD
   [Anonymous], 2016, ZIK CUM CAS
   [Anonymous], 2017, FCCA RES STAT
   Baele G, 2012, MOL BIOL EVOL, V29, P2157, DOI 10.1093/molbev/mss084
   Biggerstaff BJ, 2009, POOLEDINFRATE VERSIO
   Bogoch II, 2016, LANCET INFECT DIS, V16, P1237, DOI 10.1016/S1473-3099(16)30270-5
   Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
   Bouri N, 2012, PUBLIC HEALTH REP, V127, P259, DOI 10.1177/003335491212700305
   Centers for Disease Control and Prevention, 2016, ZIK VIR CAS COUNTS U
   Chouin-Carneiro T, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004543
   Churcher TS, 2014, SCIENCE, V344, P1230, DOI 10.1126/science.1251449
   Corman V. M., 2016, B WHO
   Darriba D, 2012, NAT METHODS, V9, P772, DOI 10.1038/nmeth.2109
   Dinh L, 2016, THEOR BIOL MED MODEL, V13, DOI 10.1186/s12976-016-0046-1
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI [10.1093/molbev/msi103, 10.1093/molbev/mss075]
   Drummond AJ, 2012, MOL BIOL EVOL, V29, P1969, DOI 10.1093/molbev/mss075
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Dzul-Manzanilla F, 2016, T ROY SOC TROP MED H, V110, P141, DOI 10.1093/trstmh/trv106
   Faria N. R., 2017, NATURE
   Faria NR, 2016, SCIENCE, V352, P345, DOI 10.1126/science.aaf5036
   Fauver JR, 2016, J MED ENTOMOL, V53, P425, DOI 10.1093/jme/tjv234
   Ferguson NM, 2016, SCIENCE, V353, P353, DOI 10.1126/science.aag0219
   Ferreira MAR, 2008, CAN J STAT, V36, P355, DOI 10.1002/cjs.5550360302
   Ferreira-de-Brito A, 2016, MEM I OSWALDO CRUZ, V111, P655, DOI 10.1590/0074-02760160332
   Florida Department of Health, 2017, MOSQ BORN DIS SURV
   Gelman A, 1998, STAT SCI, V13, P163
   Graham AS, 2011, EMERG INFECT DIS, V17, P2074, DOI 10.3201/eid1711.110419
   Guerbois M, 2016, J INFECT DIS, V214, P1349, DOI 10.1093/infdis/jiw302
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   Hennessey M, 2016, MMWR-MORBID MORTAL W, V65, P55, DOI 10.15585/mmwr.mm6503e1
   Hunter JD, 2007, COMPUT SCI ENG, V9, P90, DOI 10.1109/MCSE.2007.55
   Hwang WH, 2011, METHODS ECOL EVOL, V2, P550, DOI 10.1111/j.2041-210X.2011.00105.x
   Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010
   Kearse M, 2012, BIOINFORMATICS, V28, P1647, DOI 10.1093/bioinformatics/bts199
   Kendrick K, 2014, MMWR-MORBID MORTAL W, V63, P1137
   Koster J., 2012, OASICS OPENACCESS SE, V26
   Kraemer MUG, 2015, J R SOC INTERFACE, V12, DOI 10.1098/rsif.2015.0468
   Kraemer MUG, 2017, LANCET INFECT DIS, V17, P330, DOI [10.1016/S1473-3099(16)30513-8, 10.1016/s1473-3099(16)30513-8]
   Kraemer MUG, 2015, ELIFE, V4, DOI 10.7554/eLife.08347
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Lazear HM, 2016, J VIROL, V90, P4864, DOI 10.1128/JVI.00252-16
   Lee S, 2013, TOURISM MANAGE, V34, P236, DOI 10.1016/j.tourman.2012.03.009
   Lessler J, 2016, B WORLD HEALTH ORGAN, V94, P841, DOI 10.2471/BLT.16.174540
   Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352
   Likos A, 2016, MMWR-MORBID MORTAL W, V65, P1032, DOI 10.15585/mmwr.mm6538e1
   Lloyd-Smith JO, 2005, NATURE, V438, P355, DOI 10.1038/nature04153
   Martin M., 2011, EMBNET J, V17, P10, DOI [10.14806/ej.17.1.200, DOI 10.14806/EJ.17.1.200]
   McCarthy M, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i212
   Metsky H. C., 2017, NATURE
   Monaghan A. J., 2016, PLOS CURR
   Murray KO, 2013, VECTOR-BORNE ZOONOT, V13, P835, DOI 10.1089/vbz.2013.1413
   Nelson B, 2016, PLOS CURR, DOI 10.1371/currents.outbreaks.ac6d0f8c9c35e88825c1a1147697531c
   Nishiura H, 2012, J THEOR BIOL, V294, P48, DOI 10.1016/j.jtbi.2011.10.039
   Nunes MRT, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002769
   Pan-American Health Organization, 2016, REG ZIK EP UPD AM
   Pan-American Health Organization, 2016, COUNTR TERR AUT TRAN
   Perkins TA, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2016.126, 10.1038/nmicrobiol.2016.126]
   Perkins TA, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003327
   Quick J., 2017, NAT PROTOCOLS
   Rabe IB, 2016, MMWR-MORBID MORTAL W, V65, P543, DOI 10.15585/mmwr.mm6521e1
   Rambaut A., 2016, VIRUS EVOL
   Ramos MM, 2008, AM J TROP MED HYG, V78, P364
   Robert MA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161365
   Rocklov J, 2016, EBIOMEDICINE, V9, P250, DOI 10.1016/j.ebiom.2016.06.009
   Schmieder R, 2011, BIOINFORMATICS, V27, P863, DOI 10.1093/bioinformatics/btr026
   Shapiro B, 2006, MOL BIOL EVOL, V23, P7, DOI 10.1093/molbev/msj021
   Struchiner CJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136286
   Teets Frank D, 2014, Virol Rep, V1-2, P2
   Waggoner JJ, 2016, J CLIN MICROBIOL, V54, P860, DOI 10.1128/JCM.00279-16
   Weger-Lucarelli J, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005101
   WHO, 2016, ZIK VIR COMPL
   Worobey M, 2016, NATURE, V539, P98, DOI 10.1038/nature19827
   Xie WG, 2011, SYST BIOL, V60, P150, DOI 10.1093/sysbio/syq085
   YANG ZH, 1994, J MOL EVOL, V39, P306, DOI 10.1007/BF00160154
NR 79
TC 185
Z9 188
U1 1
U2 63
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD JUN 15
PY 2017
VL 546
IS 7658
BP 401
EP +
DI 10.1038/nature22400
PG 20
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EX5BK
UT WOS:000403250900034
PM 28538723
OA Green Published, Green Submitted, Green Accepted
HC Y
HP N
DA 2021-10-30
ER

PT J
AU Morris, AP
   Le, TH
   Wu, HJ
   Akbarov, A
   van der Most, PJ
   Hemani, G
   Smith, GD
   Mahajan, A
   Gaulton, KJ
   Nadkarni, GN
   Valladares-Salgado, A
   Wacher-Rodarte, N
   Mychaleckyj, JC
   Dueker, ND
   Guo, XQ
   Hai, Y
   Haessler, J
   Kamatani, Y
   Stilp, AM
   Zhu, G
   Cook, JP
   Arnlov, J
   Blanton, SH
   de Borst, MH
   Bottinger, EP
   Buchanan, TA
   Cechova, S
   Charchar, FJ
   Chu, PL
   Damman, J
   Eales, J
   Gharavi, AG
   Giedraitis, V
   Heath, AC
   Ipp, E
   Kiryluk, K
   Kramer, HJ
   Kubo, M
   Larsson, A
   Lindgren, CM
   Lu, YC
   Madden, PAF
   Montgomery, GW
   Papanicolaou, GJ
   Raffel, LJ
   Sacco, RL
   Sanchez, E
   Stark, H
   Sundstrom, J
   Taylor, KD
   Xiang, AH
   Zivkovic, A
   Lind, L
   Ingelsson, E
   Martin, NG
   Whitfield, JB
   Cai, JW
   Laurie, CC
   Okada, Y
   Matsuda, K
   Kooperberg, C
   Chen, YDI
   Rundek, T
   Rich, SS
   Loos, RJF
   Parra, EJ
   Cruz, M
   Rotter, JI
   Snieder, H
   Tomaszewski, M
   Humphreys, BD
   Franceschini, N
AF Morris, Andrew P.
   Le, Thu H.
   Wu, Haojia
   Akbarov, Artur
   van der Most, Peter J.
   Hemani, Gibran
   Smith, George Davey
   Mahajan, Anubha
   Gaulton, Kyle J.
   Nadkarni, Girish N.
   Valladares-Salgado, Adan
   Wacher-Rodarte, Niels
   Mychaleckyj, Josyf C.
   Dueker, Nicole D.
   Guo, Xiuqing
   Hai, Yang
   Haessler, Jeffrey
   Kamatani, Yoichiro
   Stilp, Adrienne M.
   Zhu, Gu
   Cook, James P.
   Arnlov, Johan
   Blanton, Susan H.
   de Borst, Martin H.
   Bottinger, Erwin P.
   Buchanan, Thomas A.
   Cechova, Sylvia
   Charchar, Fadi J.
   Chu, Pei-Lun
   Damman, Jeffrey
   Eales, James
   Gharavi, Ali G.
   Giedraitis, Vilmantas
   Heath, Andrew C.
   Ipp, Eli
   Kiryluk, Krzysztof
   Kramer, Holly J.
   Kubo, Michiaki
   Larsson, Anders
   Lindgren, Cecilia M.
   Lu, Yingchang
   Madden, Pamela A. F.
   Montgomery, Grant W.
   Papanicolaou, George J.
   Raffel, Leslie J.
   Sacco, Ralph L.
   Sanchez, Elena
   Stark, Holger
   Sundstrom, Johan
   Taylor, Kent D.
   Xiang, Anny H.
   Zivkovic, Aleksandra
   Lind, Lars
   Ingelsson, Erik
   Martin, Nicholas G.
   Whitfield, John B.
   Cai, Jianwen
   Laurie, Cathy C.
   Okada, Yukinori
   Matsuda, Koichi
   Kooperberg, Charles
   Chen, Yii-Der Ida
   Rundek, Tatjana
   Rich, Stephen S.
   Loos, Ruth J. F.
   Parra, Esteban J.
   Cruz, Miguel
   Rotter, Jerome, I
   Snieder, Harold
   Tomaszewski, Maciej
   Humphreys, Benjamin D.
   Franceschini, Nora
TI Trans-ethnic kidney function association study reveals putative causal
   genes and effects on kidney-specific disease aetiologies
SO NATURE COMMUNICATIONS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; GLOMERULAR-FILTRATION-RATE; MENDELIAN
   RANDOMIZATION; GENOTYPE IMPUTATION; SERUM CREATININE; BLOOD-PRESSURE;
   CELL-TYPES; EXPRESSION; VARIANTS; LOCI
AB Chronic kidney disease (CKD) affects -10% of the global population, with considerable ethnic differences in prevalence and aetiology. We assemble genome-wide association studies of estimated glomerular filtration rate (eGFR), a measure of kidney function that defines CKD, in 312,468 individuals of diverse ancestry. We identify 127 distinct association signals with homogeneous effects on eGFR across ancestries and enrichment in genomic annotations including kidney-specific histone modifications. Fine-mapping reveals 40 high-confidence variants driving eGFR associations and highlights putative causal genes with cell-type specific expression in glomerulus, and in proximal and distal nephron. Mendelian randomisation supports causal effects of eGFR on overall and cause-specific CKD, kidney stone formation, diastolic blood pressure and hypertension. These results define novel molecular mechanisms and putative causal genes for eGFR, offering insight into clinical outcomes and routes to CKD treatment development.
C1 [Morris, Andrew P.; Cook, James P.] Univ Liverpool, Dept Biostat, Liverpool L69 3GL, Merseyside, England.
   [Morris, Andrew P.; Mahajan, Anubha; Lindgren, Cecilia M.] Univ Oxford, Wellcome Ctr Human Genet, Oxford OX3 7BN, England.
   [Le, Thu H.; Cechova, Sylvia] Univ Virginia, Dept Med, Div Nephrol, Charlottesville, VA 22908 USA.
   [Wu, Haojia; Humphreys, Benjamin D.] Washington Univ, Div Nephrol, Sch Med, St Louis, MO 63110 USA.
   [Akbarov, Artur; Eales, James; Tomaszewski, Maciej] Fac Med, Biol & Hlth, Div Cardiovasc Sci, Manchester M13 9PT, Lancs, England.
   [van der Most, Peter J.; Snieder, Harold] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, POB 30-001, NL-9700 RB Groningen, Netherlands.
   [Hemani, Gibran; Smith, George Davey] Univ Bristol, MRC Integrat Epidemiol Unit, Populat Hlth Sci, Bristol BS8 1TH, Avon, England.
   [Gaulton, Kyle J.] Univ Calif San Diego, Dept Pediat, San Diego, CA 92161 USA.
   [Nadkarni, Girish N.; Bottinger, Erwin P.; Lu, Yingchang; Loos, Ruth J. F.] Icahn Sch Med Mt Sinai, Charles Bronfman Inst Personalized Med, New York, NY 10029 USA.
   [Nadkarni, Girish N.] Icahn Sch Med Mt Sinai, Div Nephrol, New York, NY 10029 USA.
   [Nadkarni, Girish N.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA.
   [Valladares-Salgado, Adan; Cruz, Miguel] Inst Mexicano Seguro Social, Ctr Med Nacl Siglo XXI, Hosp Especialidades, Unidad Invest Med Bioquim, Mexico City 06720, DF, Mexico.
   [Wacher-Rodarte, Niels] Inst Mexicano Seguro Social, Ctr Med Nacl Siglo XXI, Hosp Especialidades, Unidad Invest Med Epidemiol Clin, Mexico City 06720, DF, Mexico.
   [Mychaleckyj, Josyf C.; Rich, Stephen S.] Univ Virginia, Ctr Publ Hlth Genom, Sch Med, Charlottesville, VA 22908 USA.
   [Dueker, Nicole D.; Blanton, Susan H.] Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, Miami, FL 33124 USA.
   [Guo, Xiuqing; Hai, Yang; Taylor, Kent D.; Chen, Yii-Der Ida; Rotter, Jerome, I] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Inst Translat Genom & Populat Sci, Dept Pediat, Torrance, CA 90502 USA.
   [Guo, Xiuqing; Hai, Yang; Taylor, Kent D.; Chen, Yii-Der Ida; Rotter, Jerome, I] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Inst Translat Genom & Populat Sci, Dept Med, Torrance, CA 90502 USA.
   [Haessler, Jeffrey; Kooperberg, Charles] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA.
   [Kamatani, Yoichiro; Okada, Yukinori] RIKEN, Lab Stat Anal, Ctr Integrat Med Sci, Yokohama, Kanagawa 2300045, Japan.
   [Stilp, Adrienne M.; Laurie, Cathy C.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
   [Zhu, Gu; Martin, Nicholas G.; Whitfield, John B.] QIMR Berghofer Med Res Inst, Genet Epidemiol Lab, Brisbane, Qld 4006, Australia.
   [Arnlov, Johan] Karolinska Inst, Div Family Med & Primary Care, Dept Neurobiol Care Sci & Soc, S-14183 Huddinge, Sweden.
   [Arnlov, Johan] Dalarna Univ, Sch Hlth & Social Studies, S-79188 Falun, Sweden.
   [Blanton, Susan H.] Univ Miami, Dr John T Macdonald Dept Human Genet, Miami, FL 33124 USA.
   [de Borst, Martin H.] Univ Groningen, Univ Med Ctr Groningen, Dept Internal Med, Div Nephrol, POB 30-001, NL-9700 RB Groningen, Netherlands.
   [Buchanan, Thomas A.] Keck Sch Med USC, Dept Med, Div Endocrinol & Diabet, Los Angeles, CA 90033 USA.
   [Charchar, Fadi J.] Federat Univ Australia, Sch Hlth & Life Sci, Ballarat, Vic 3350, Australia.
   [Charchar, Fadi J.] Univ Leicester, Dept Cardiovasc Sci, Leicester LE1 7RH, Leics, England.
   [Charchar, Fadi J.] Univ Melbourne, Dept Physiol, Parkville, Vic 3010, Australia.
   [Chu, Pei-Lun] Fu Jen Catholic Univ, Fu Jen Catholic Univ Hosp, Sch Med, Dept Internal Med, New Taipei 242, Taiwan.
   [Damman, Jeffrey] Erasmus MC, Dept Pathol, PO Box 2040, NL-3000 CA Rotterdam, Netherlands.
   [Gharavi, Ali G.; Kiryluk, Krzysztof; Sanchez, Elena] Columbia Univ, Coll Phys & Surg, Dept Med, Div Nephrol, New York, NY 10032 USA.
   [Giedraitis, Vilmantas] Uppsala Univ, Dept Publ Hlth & Caring Sci, Mol Geriatr, S-75185 Uppsala, Sweden.
   [Heath, Andrew C.; Madden, Pamela A. F.] Washington Univ, Dept Psychiat, St Louis, MO 63110 USA.
   [Ipp, Eli] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA.
   [Ipp, Eli] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA 90502 USA.
   [Kramer, Holly J.] Loyola Univ, Dept Med & Nephrol, Med Ctr, Maywood, IL 60153 USA.
   [Kubo, Michiaki] RIKEN, Lab Genotyping Dev, Ctr Integrat Med Sci, Yokohama, Kanagawa 2300045, Japan.
   [Larsson, Anders; Sundstrom, Johan; Lind, Lars] Uppsala Univ, Dept Med Sci, Clin Epidemiol, S-75185 Uppsala, Sweden.
   [Lindgren, Cecilia M.] Univ Oxford, Li Ka Shing Ctr Hlth Informat & Discovery, Big Data Inst, Nuffield Dept Med, Oxford OX3 7FZ, England.
   [Lindgren, Cecilia M.] Brd Inst Harvard & MIT, Boston, MA 02142 USA.
   [Montgomery, Grant W.] Univ Queensland, Brisbane Inst Mol Biosci, St Lucia, Qld 4072, Australia.
   [Papanicolaou, George J.] NHLBI, Epidemiol Branch, Div Cardiovasc Sci, Bethesda, MD 20892 USA.
   [Raffel, Leslie J.] Univ Calif Irvine, Div Genet & Genom Med, Dept Pediat, Orange, CA 92868 USA.
   [Sacco, Ralph L.; Rundek, Tatjana] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA.
   [Sacco, Ralph L.; Rundek, Tatjana] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA.
   [Sacco, Ralph L.; Rundek, Tatjana] Univ Miami, Miller Sch Med, Evelyn F McKnight Brain Inst, Miami, FL 33136 USA.
   [Sacco, Ralph L.] Univ Miami, Jackson Mem Hosp, Miami, FL 33136 USA.
   [Stark, Holger; Zivkovic, Aleksandra] Heinrich Heine Univ Dusseldorf, Inst Pharmaceut & Med Chem, D-40225 Dusseldorf, Germany.
   [Xiang, Anny H.] Kaiser Permanente Southern Calif, Dept Res & Educ, Pasadena, CA 91101 USA.
   [Ingelsson, Erik] Stanford Univ, Dept Med, Div Cardiovasc Med, Sch Med, Stanford, CA 94309 USA.
   [Ingelsson, Erik] Stanford Univ, Stanford Cardiovasc Inst, Stanford, CA 94309 USA.
   [Ingelsson, Erik] Stanford Univ, Stanford Diabet Res Ctr, Stanford, CA 94305 USA.
   [Ingelsson, Erik] Uppsala Univ, Dept Med Sci, Mol Epidemiol & Sci Life Lab, S-75185 Uppsala, Sweden.
   [Cai, Jianwen] Univ North Carolina Chapel Hill, Dept Biostat, Collaborat Studies Coordinating Ctr, Chapel Hill, NC 27599 USA.
   [Okada, Yukinori] Osaka Univ, Dept Stat Genet, Grad Sch Med, Suita, Osaka 5650871, Japan.
   [Matsuda, Koichi] Univ Tokyo, Human Genome Ctr, Inst Med Sci, Lab Mol Med, Tokyo 1088639, Japan.
   [Loos, Ruth J. F.] Icahn Sch Med Mt Sinai, Mindich Child Hlth & Dev Inst, New York, NY 10029 USA.
   [Parra, Esteban J.] Univ Toronto, Dept Anthropol, Mississauga, ON L5L 1C6, Canada.
   [Tomaszewski, Maciej] Manchester Univ NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Div Med, Manchester M13 9WL, Lancs, England.
   [Franceschini, Nora] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27516 USA.
RP Morris, AP (corresponding author), Univ Liverpool, Dept Biostat, Liverpool L69 3GL, Merseyside, England.; Morris, AP (corresponding author), Univ Oxford, Wellcome Ctr Human Genet, Oxford OX3 7BN, England.; Franceschini, N (corresponding author), Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27516 USA.
EM apmorris@liverpool.ac.uk; noraf@unc.edu
RI Arnlov, Johan/AAF-2746-2019; Montgomery, Grant W/B-7148-2008; Sundstrom,
   Johan/R-2139-2019; Sacco, Ralph/Y-9278-2019; Stark, Holger/A-4235-2009;
   Smith, George Davey/A-7407-2013; Wu, Haojia/AAL-1327-2020; Sundstrom,
   Johan/A-6286-2009; Loos, Ruth J F/Q-2862-2016; Lopez, Miguel
   Cruz/O-5493-2018; Rotter, Jerome/AAY-6598-2021; Charchar,
   Fadi/I-6656-2017
OI Arnlov, Johan/0000-0002-6933-4637; Montgomery, Grant
   W/0000-0002-4140-8139; Sundstrom, Johan/0000-0003-2247-8454; Stark,
   Holger/0000-0003-3336-1710; Smith, George Davey/0000-0002-1407-8314; Wu,
   Haojia/0000-0002-7866-2544; Sundstrom, Johan/0000-0003-2247-8454; Loos,
   Ruth J F/0000-0002-8532-5087; Lopez, Miguel Cruz/0000-0001-9985-6172;
   Hemani, Gibran/0000-0003-0920-1055; Charchar, Fadi/0000-0002-6164-9941;
   Morris, Andrew/0000-0002-6805-6014; van der Most,
   Peter/0000-0001-8450-3518; De Borst, Martin/0000-0002-4127-8733;
   Tomaszewski, Maciej/0000-0001-8215-6567; Mahajan,
   Anubha/0000-0001-5585-3420; Xiang, Anny/0000-0003-2786-1268; parra,
   esteban J/0000-0002-2057-8577; Lindgren, Cecilia/0000-0002-4903-9374;
   Eales, James/0000-0001-6238-5952
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01-DK-113632, 5P50-HD-028138-27,
   R37-NS-029993, U54-TR-002736, R01-MD-012765, R56-DK-104806,
   R01-DK-117445-01A1]; Wellcome TrustWellcome TrustEuropean Commission
   [208806/Z/17/Z]; Medical Research Council Integrative Epidemiology Unit
   at the University of BristolUK Research & Innovation (UKRI)Medical
   Research Council UK (MRC) [MC_UU_00011/1]; Li Ka Shing Foundation;
   WT-SSI/John Fell funds; Oxford NIHR Biomedical Research CentreNational
   Institute for Health Research (NIHR); Widenlife; Evelyn F McKnight Brain
   Institute; DFGGerman Research Foundation (DFG)European Commission [INST
   208/664-1]; British Heart FoundationBritish Heart Foundation
   [PG/17/35/33001]; Kidney Research UKKidney Research UK (KRUK)
   [RP_017_20180302]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD
   HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD)
   [P50HD028138] Funding Source: NIH RePORTER; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR002736]
   Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [R21HL140385] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Diabetes & Digestive & Kidney Diseases
   (NIDDK) [R01DK105124, R01DK113632, R01DK117445, R56DK104806,
   P30DK116074] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Environmental Health Sciences (NIEHS) [P30ES010126] Funding Source:
   NIH RePORTER; National Institute on Minority Health and Health
   DisparitiesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Minority
   Health & Health Disparities (NIMHD) [R01MD012765] Funding Source: NIH
   RePORTER
FX T.H.L. is supported by the NIH (R01-DK-113632). G.H. is supported by the
   Wellcome Trust (208806/Z/17/Z). G.H. and G.D.S. work in the Medical
   Research Council Integrative Epidemiology Unit at the University of
   Bristol (MC_UU_00011/1). C.M.L. is supported by the Li Ka Shing
   Foundation, WT-SSI/John Fell funds, the Oxford NIHR Biomedical Research
   Centre, Widenlife and the NIH (5P50-HD-028138-27). R.L.S. and T.R. are
   supported by the NIH (R37-NS-029993 and U54-TR-002736) and the Evelyn F
   McKnight Brain Institute. H.S. and A. Z. are supported by the DFG (INST
   208/664-1). M.T. is supported the British Heart Foundation
   (PG/17/35/33001) and Kidney Research UK (RP_017_20180302). N.F. is
   supported by the NIH (R01-MD-012765, R56-DK-104806, and
   R01-DK-117445-01A1). Additional funding and acknowledgements can be
   found in Supplementary Note 1.
CR Aguet F, 2017, NATURE, V550, P204, DOI 10.1038/nature24277
   Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393
   Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632
   Ardlie KG, 2015, SCIENCE, V348, P648, DOI 10.1126/science.1262110
   Bates JM, 2004, KIDNEY INT, V65, P791, DOI 10.1111/j.1523-1755.2004.00452.x
   Beam TA, 2017, PHYSIOL GENOMICS, V49, P81, DOI 10.1152/physiolgenomics.00126.2016
   Bowden J, 2018, INT J EPIDEMIOL, V47, P1264, DOI [10.1093/ije/dyy101, 10.1093/ije/dyy265]
   Bowden J, 2016, GENET EPIDEMIOL, V40, P304, DOI 10.1002/gepi.21965
   Bowden J, 2015, INT J EPIDEMIOL, V44, P512, DOI 10.1093/ije/dyv080
   Bray NL, 2016, NAT BIOTECHNOL, V34, P888, DOI 10.1038/nbt0816-888d
   Bulik-Sullivan BK, 2015, NAT GENET, V47, P291, DOI 10.1038/ng.3211
   Burge JA, 2012, CURR NEUROL NEUROSCI, V12, P62, DOI 10.1007/s11910-011-0238-3
   Burgess S, 2013, GENET EPIDEMIOL, V37, P658, DOI 10.1002/gepi.21758
   Cancilla B, 2001, KIDNEY INT, V60, P147, DOI 10.1046/j.1523-1755.2001.00781.x
   Cechova S, 2018, J AM SOC NEPHROL, V29, P155, DOI 10.1681/ASN.2015060707
   Chen SW, 2011, J BIOL CHEM, V286, P32775, DOI 10.1074/jbc.M111.248278
   Cho GS, 2011, DEVELOPMENT, V138, P465, DOI 10.1242/dev.061234
   Collins AJ, 2013, AM J KIDNEY DIS, V61, pE1, DOI 10.1053/j.ajkd.2012.11.031
   Damman J, 2015, TRANSPLANTATION, V99, P1293, DOI 10.1097/TP.0000000000000500
   Das S, 2016, NAT GENET, V48, P1284, DOI 10.1038/ng.3656
   Delaneau O, 2012, NAT METHODS, V9, P179, DOI [10.1038/NMETH.1785, 10.1038/nmeth.1785]
   Devlin B, 1999, BIOMETRICS, V55, P997, DOI 10.1111/j.0006-341X.1999.00997.x
   Dong CL, 2015, HUM MOL GENET, V24, P2125, DOI 10.1093/hmg/ddu733
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Dupuis J, 2010, NAT GENET, V42, P105, DOI 10.1038/ng.520
   Ehret GB, 2011, NATURE, V478, P103, DOI 10.1038/nature10405
   Fehrmann RSN, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002197
   Finucane HK, 2015, NAT GENET, V47, P1228, DOI 10.1038/ng.3404
   Fuchsberger C, 2015, BIOINFORMATICS, V31, P782, DOI 10.1093/bioinformatics/btu704
   Ghirotto S, 2016, J AM SOC NEPHROL, V27, P2983, DOI 10.1681/ASN.2015070830
   Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031
   Gorski M, 2017, SCI REP-UK, V7, DOI 10.1038/srep45040
   Gudbjartsson DF, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001039
   Haberle J, 2011, HUM MUTAT, V32, P579, DOI 10.1002/humu.21406
   Hanchard NA, 2013, CLIN GENET, V83, P457, DOI 10.1111/j.1399-0004.2012.01951.x
   Harrow J, 2012, GENOME RES, V22, P1760, DOI 10.1101/gr.135350.111
   Hayashi K, 1996, Hypertens Res, V19, P31, DOI 10.1291/hypres.19.31
   Hemani G, 2018, ELIFE, V7, DOI 10.7554/eLife.34408
   HESS B, 1989, AM J PHYSIOL, V257, pF99, DOI 10.1152/ajprenal.1989.257.1.F99
   Hnisz D, 2013, CELL, V155, P934, DOI 10.1016/j.cell.2013.09.053
   Horio M, 2010, AM J KIDNEY DIS, V56, P32, DOI 10.1053/j.ajkd.2010.02.344
   Howie B, 2012, NAT GENET, V44, P955, DOI 10.1038/ng.2354
   Howie BN, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000529
   Hunter JM, 2015, MOL GENET GENOM MED, V3, P283, DOI 10.1002/mgg3.142
   Imgrund S, 2009, J BIOL CHEM, V284, P33549, DOI 10.1074/jbc.M109.031971
   Kanai M, 2018, NAT GENET, V50, P390, DOI 10.1038/s41588-018-0047-6
   Keith DS, 2004, ARCH INTERN MED, V164, P659, DOI 10.1001/archinte.164.6.659
   Kottgen A, 2009, NAT GENET, V41, P712, DOI 10.1038/ng.377
   Levey AS, 2006, ANN INTERN MED, V145, P247, DOI 10.7326/0003-4819-145-4-200608150-00004
   Levey AS, 2010, AM J KIDNEY DIS, V55, P622, DOI 10.1053/j.ajkd.2010.02.337
   Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006
   Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002
   Li Y, 2010, GENET EPIDEMIOL, V34, P816, DOI 10.1002/gepi.20533
   Li YR, 2014, GENOME MED, V6, DOI 10.1186/s13073-014-0091-5
   Liu C.-T., 2012, PLOS GENET, V7
   Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653
   Magi R, 2017, HUM MOL GENET, V26, P3639, DOI 10.1093/hmg/ddx280
   Mahajan A, 2016, AM J HUM GENET, V99, P636, DOI 10.1016/j.ajhg.2016.07.012
   Malik R, 2016, NEUROLOGY, V86, P1217, DOI 10.1212/WNL.0000000000002528
   Maller JB, 2012, NAT GENET, V44, P1294, DOI 10.1038/ng.2435
   Marques FZ, 2015, MOL MED, V21, P739, DOI 10.2119/molmed.2015.00096
   Naghavi M, 2017, LANCET, V390, P1151, DOI 10.1016/S0140-6736(17)32152-9
   Nikpay M, 2015, NAT GENET, V47, P1121, DOI 10.1038/ng.3396
   Park J, 2018, SCIENCE, V360, P758, DOI 10.1126/science.aar2131
   Pattaro C, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10023
   Pierce BL, 2013, AM J EPIDEMIOL, V178, P1177, DOI 10.1093/aje/kwt084
   Rich SS, 2016, NAT GENET, V48, P702, DOI 10.1038/ng.3582
   Sarnak Mark J, 2003, Am J Kidney Dis, V41, P11, DOI 10.1016/S0272-6386(03)00372-X
   Schiffmann S, 2012, BIOCHIMIE, V94, P558, DOI 10.1016/j.biochi.2011.09.007
   SCHWARZ G, 1978, ANN STAT, V6, P461, DOI 10.1214/aos/1176344136
   Shiffman D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106631
   Shihab HA, 2013, HUM MUTAT, V34, P57, DOI 10.1002/humu.22225
   Sofi MH, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.91701
   Stegle O, 2012, NAT PROTOC, V7, P500, DOI 10.1038/nprot.2011.457
   't Hoen PAC, 2013, NAT BIOTECHNOL, V31, P1015, DOI 10.1038/nbt.2702
   Tedla FM, 2011, INT J HYPERTENS, V2011, DOI 10.4061/2011/132405
   Teumer A, 2016, DIABETES, V65, P803, DOI 10.2337/db15-1313
   Tomaszewski M, 2015, J AM SOC NEPHROL, V26, P3151, DOI 10.1681/ASN.2014121211
   Trudu M, 2013, NAT MED, V19, P1655, DOI 10.1038/nm.3384
   Trynka G, 2013, NAT GENET, V45, P124, DOI 10.1038/ng.2504
   Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419
   Vaaraniemi K, 2014, J CLIN HYPERTENS, V16, P722, DOI 10.1111/jch.12405
   Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Visarius TM, 1996, BIOCHEM PHARMACOL, V52, P259, DOI 10.1016/0006-2952(96)00203-1
   Vos T, 2017, LANCET, V390, P1211, DOI 10.1016/S0140-6736(17)32154-2
   Wain LV, 2017, HYPERTENSION, V70, pE4, DOI 10.1161/HYPERTENSIONAHA.117.09438
   Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764
   Willer CJ, 2010, BIOINFORMATICS, V26, P2190, DOI 10.1093/bioinformatics/btq340
   Wolf G, 2002, AM J KIDNEY DIS, V39, P1, DOI 10.1053/ajkd.2002.29865
   Wright FA, 2014, NAT GENET, V46, P430, DOI 10.1038/ng.2951
   Wu HJ, 2018, CELL STEM CELL, V23, P869, DOI 10.1016/j.stem.2018.10.010
   Yang J, 2012, NAT GENET, V44, P369, DOI 10.1038/ng.2213
NR 92
TC 40
Z9 44
U1 1
U2 9
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JAN 3
PY 2019
VL 10
AR 29
DI 10.1038/s41467-018-07867-7
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA HG1YE
UT WOS:000454756900006
PM 30604766
OA Green Published, gold, Green Submitted
DA 2021-10-30
ER

PT J
AU Perkins, SM
   Bacchetti, P
   Davey, CS
   Lindsell, CJ
   Mazumdar, M
   Oster, RA
   Peduzzi, PN
   Rocke, DM
   Rudser, KD
   Kim, M
AF Perkins, Susan M.
   Bacchetti, Peter
   Davey, Cynthia S.
   Lindsell, Christopher J.
   Mazumdar, Madhu
   Oster, Robert A.
   Peduzzi, Peter N.
   Rocke, David M.
   Rudser, Kyle D.
   Kim, Mimi
CA BERD Key Function
TI Best Practices for Biostatistical Consultation and Collaboration in
   Academic Health Centers
SO AMERICAN STATISTICIAN
LA English
DT Article
DE Biostatistics; Collaboration; Consultation; Funding; Prioritization
ID CLINICAL RESEARCH; STATISTICIANS; RESOURCES
AB Given the increasing level and scope of biostatistics expertise needed at academic health centers today, we developed best practices guidelines for biostatistics units to be more effective in providing biostatistical support to their institutions, and in fostering an environment in which unit members can thrive professionally. Our recommendations focus on the key areas of: (1) funding sources and mechanisms; (2) providing and prioritizing access to biostatistical resources; and (3) interacting with investigators. We recommend that the leadership of biostatistics units negotiate for sufficient long-term infrastructure support to ensure stability and continuity of funding for personnel, align project budgets closely with actual level of biostatistical effort, devise and consistently apply strategies for prioritizing and tracking effort on studies, and clearly stipulate with investigators prior to project initiation policies regarding funding, lead time, and authorship.
C1 [Perkins, Susan M.] Indiana Univ Sch Med, Dept Biostat, Indianapolis, IN 46202 USA.
   [Perkins, Susan M.] Sch Publ Hlth, Indianapolis, IN 46202 USA.
RP Perkins, SM (corresponding author), Indiana Univ Sch Med, Dept Biostat, Indianapolis, IN 46202 USA.; Perkins, SM (corresponding author), Sch Publ Hlth, Indianapolis, IN 46202 USA.
EM sperkin1@iu.edu
OI Oster, Robert/0000-0002-2247-8596; Nietert, Paul/0000-0002-3933-4986
FU National Center for Research Resources, National Institutes of Health
   (NIH), through the Clinical and Translational Science Awards Program
   (CTSA); National Center for Advancing Translational Sciences (NCATS),
   National Institutes of Health (NIH), through the Clinical and
   Translational Science Awards Program (CTSA)United States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Advancing Translational Sciences (NCATS); NCATS NIH
   CTSA [UL1 TR000006, UL1 TR000004, UL1TR000114, UL1 TR000077, UL1
   TR000457, UL1 TR000165, UL1 TR000142, UL1 TR000002, UL1 TR000086];
   NATIONAL CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [P30CA013148] Funding Source: NIH RePORTER; NATIONAL
   CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000101, UL1TR001108, UL1TR000114, UL1TR001425, UL1TR000457,
   UL1TR000038, UL1TR000062, UL1TR000006, UL1TR000075, UL1TR001120,
   UL1TR000165, UL1TR000142, UL1TR000001, UL1TR001863, UL1TR000150,
   UL1TR000135, UL1TR001417, UL1TR000149, UL1TR000460, UL1TR000002,
   UL1TR000077, UL1TR001422, UL1TR001409, UL1TR000086, UL1TR000371,
   UL1TR001073, UL1TR000004] Funding Source: NIH RePORTER
FX This project has been funded in whole or in part with Federal funds from
   the National Center for Research Resources and National Center for
   Advancing Translational Sciences (NCATS), National Institutes of Health
   (NIH), through the Clinical and Translational Science Awards Program
   (CTSA). The article was approved by the CTSA Consortium Publications
   Committee. Its contents are solely the responsibility of the authors and
   do not necessarily represent the official views of the NIH. The NCATS
   NIH CTSA funding for co-authors was awarded to Indiana University (UL1
   TR000006), the University of California, San Francisco (UL1 TR000004),
   the University of Minnesota (UL1TR000114), the University of Cincinnati
   (UL1 TR000077), Weill Cornell Medical College (UL1 TR000457), the
   University of Alabama at Birmingham (UL1 TR000165), Yale University (UL1
   TR000142), University of California, Davis (UL1 TR000002), and Yeshiva
   University (UL1 TR000086).
CR Ambrosius WT, 2002, STAT MED, V21, P2739, DOI 10.1002/sim.1212
   ARNDT S, 1991, AM STAT, V45, P22, DOI 10.2307/2685234
   Buderer NMF, 1999, AM J EMERG MED, V17, P692, DOI 10.1016/S0735-6757(99)90162-6
   Byrne DW, 2012, ACAD MED, V87, P1052, DOI 10.1097/ACM.0b013e31825d29d4
   Denne SC, 2013, TRANSL RES BIOMED, V3, P63, DOI 10.1159/000343154
   Deutsch R, 2007, STAT MED, V26, P709, DOI 10.1002/sim.2571
   Geller NL, 2011, J AM STAT ASSOC, V106, P1225, DOI 10.1198/jasa.2011.ap11592
   ITTENBACH RF, 2012, RES MANAGEMENT REV, V19, P1
   LESSER ML, 1995, STAT MED, V14, P1683, DOI 10.1002/sim.4780141508
   Mazumdar M, 2015, ACAD MED, V90, P1302, DOI 10.1097/ACM.0000000000000759
   MOSES L, 1984, STAT MED, V3, P1, DOI 10.1002/sim.4780030102
   Parker RA, 1998, STAT MED, V17, P2289, DOI 10.1002/(SICI)1097-0258(19981030)17:20<2289::AID-SIM931>3.0.CO;2-L
   Rubio DM, 2011, STAT MED, V30, P2767, DOI 10.1002/sim.4184
   Tobi H, 2001, STAT MED, V20, P3921, DOI 10.1002/sim.1082
   Welty LJ, 2013, ACAD MED, V88, P454, DOI 10.1097/ACM.0b013e31828578ed
NR 15
TC 8
Z9 8
U1 4
U2 21
PU AMER STATISTICAL ASSOC
PI ALEXANDRIA
PA 732 N WASHINGTON ST, ALEXANDRIA, VA 22314-1943 USA
SN 0003-1305
EI 1537-2731
J9 AM STAT
JI Am. Stat.
PD MAY
PY 2016
VL 70
IS 2
BP 187
EP 194
DI 10.1080/00031305.2015.1077727
PG 8
WC Statistics & Probability
SC Mathematics
GA DP4JN
UT WOS:000378462300011
PM 27777443
OA Green Accepted, Green Submitted
DA 2021-10-30
ER

PT J
AU Shirey-Rice, J
   Mapes, B
   Basford, M
   Zufelt, A
   Wehbe, F
   Harris, P
   Alcorn, M
   Allen, D
   Arnim, M
   Autry, S
   Briggs, MS
   Carnegie, A
   Chavis-Keeling, D
   De La Pena, C
   Dworschak, D
   Earnest, J
   Grieb, T
   Guess, M
   Hafer, N
   Johnson, T
   Kasper, A
   Kopp, J
   Lockie, T
   Lombardo, V
   McHale, L
   Minogue, A
   Nunnally, B
   O'Quinn, D
   Peck, K
   Pemberton, K
   Perry, C
   Petrie, G
   Pontello, A
   Posner, R
   Rehman, B
   Roth, D
   Sacksteder, P
   Scahill, S
   Schieri, L
   Simpson, R
   Skinner, A
   Toussant, K
   Turner, A
   Van der Put, E
   Wasser, J
   Webb, CD
   Williams, M
   Wiseman, L
   Yasko, L
   Pulley, J
AF Shirey-Rice, Jana
   Mapes, Brandy
   Basford, Melissa
   Zufelt, Anneliese
   Wehbe, Firas
   Harris, Paul
   Alcorn, Michael
   Allen, David
   Arnim, Margaret
   Autry, Susan
   Briggs, Michael S.
   Carnegie, Andrea
   Chavis-Keeling, Deborah
   De La Pena, Carlos
   Dworschak, Doris
   Earnest, Julie
   Grieb, Terri
   Guess, Marilyn
   Hafer, Nathaniel
   Johnson, Tesheia
   Kasper, Amanda
   Kopp, Janice
   Lockie, Timothy
   Lombardo, Vincetta
   McHale, Leslie
   Minogue, Andrea
   Nunnally, Beth
   O'Quinn, Deanna
   Peck, Kelly
   Pemberton, Kieran
   Perry, Cheryl
   Petrie, Ginny
   Pontello, Andria
   Posner, Rachel
   Rehman, Bushra
   Roth, Deborah
   Sacksteder, Paulette
   Scahill, Samantha
   Schieri, Lorri
   Simpson, Rosemary
   Skinner, Anne
   Toussant, Kim
   Turner, Alicia
   Van der Put, Elaine
   Wasser, June
   Webb, Chris D.
   Williams, Maija
   Wiseman, Lori
   Yasko, Laurel
   Pulley, Jill
TI The CTSA Consortium's Catalog of Assets for Translational and Clinical
   Health Research ( CATCHR)
SO CTS-CLINICAL AND TRANSLATIONAL SCIENCE
LA English
DT Article
DE CTSA; resource identification; translational discovery
ID SCIENCE; SUPPORT
AB The 61 CTSA Consortium sites are home to valuable programs and infrastructure supporting translational science and all are charged with ensuring that such investments translate quickly to improved clinical care. Catalog of Assets for Translational and Clinical Health Research (CATCHR) is the Consortium's effort to collect and make available information on programs and resources to maximize efficiency and facilitate collaborations. By capturing information on a broad range of assets supporting the entire clinical and translational research spectrum, CATCHR aims to provide the necessary infrastructure and processes to establish and maintain an open-access, searchable database of consortium resources to support multisite clinical and translational research studies. Data are collected using rigorous, defined methods, with the resulting information made visible through an integrated, searchable Web-based tool. Additional easy-to-use Web tools assist resource owners in validating and updating resource information over time. In this paper, we discuss the design and scope of the project, data collection methods, current results, and future plans for development and sustainability. With increasing pressure on research programs to avoid redundancy, CATCHR aims to make available information on programs and core facilities to maximize efficient use of resources.
C1 [Shirey-Rice, Jana; Mapes, Brandy; Basford, Melissa; Zufelt, Anneliese; Wehbe, Firas; Harris, Paul] CTSA Consortium Coordinating Ctr, Nashville, TN 37206 USA.
   [Alcorn, Michael] Scripps Translat Sci Inst, La Jolla, CA USA.
   [Allen, David] Virginia Commonwealth Univ, Richmond, VA USA.
   [Arnim, Margaret] Albert Einstein Coll Med, Bronx, NY 10467 USA.
   [Autry, Susan] Univ So Calif, Los Angeles, CA USA.
   [Briggs, Michael S.] Univ New Mexico, Hlth Sci Ctr, Albuquerque, NM 87131 USA.
   [Carnegie, Andrea] Univ Illinois, Chicago, IL USA.
   [Chavis-Keeling, Deborah] NYU, Sch Med, New York, NY USA.
   [De La Pena, Carlos] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
   [Dworschak, Doris] Univ Calif San Diego, San Diego, CA 92103 USA.
   [Earnest, Julie] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
   [Grieb, Terri] Univ Michigan, Ann Arbor, MI 48109 USA.
   [Guess, Marilyn] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
   [Hafer, Nathaniel] Univ Massachusetts, Sch Med, Worcester, MA USA.
   [Johnson, Tesheia] Yale Univ, New Haven, CT USA.
   [Kasper, Amanda] Childrens Natl Med Ctr, Washington, DC 20010 USA.
   [Kopp, Janice] Boston Univ, Boston, MA 02215 USA.
   [Lockie, Timothy] Univ Colorado, Denver, CO 80202 USA.
   [Lombardo, Vincetta] Univ Calif Davis, Davis, CA 95616 USA.
   [McHale, Leslie] Columbia Univ, New York, NY USA.
   [Minogue, Andrea] Northwestern Univ, Chicago, IL 60611 USA.
   [Nunnally, Beth] Univ Minnesota Twin Cities, Minneapolis, MN USA.
   [O'Quinn, Deanna] Univ Iowa, Iowa City, IA USA.
   [Peck, Kelly] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
   [Pemberton, Kieran] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA.
   [Perry, Cheryl] Univ Alabama Birmingham, Birmingham, AL USA.
   [Petrie, Ginny] Case Western Reserve Univ, Cleveland, OH 44106 USA.
   [Pontello, Andria] Univ Calif Irvine, Irvine, CA USA.
   [Posner, Rachel] Mt Sinai Sch Med, New York, NY USA.
   [Rehman, Bushra] Univ Chicago, Chicago, IL 60637 USA.
   [Roth, Deborah] Duke Univ, Durham, NC USA.
   [Sacksteder, Paulette] Univ Wisconsin, Madison, WI USA.
   [Scahill, Samantha] Indiana Univ, Sch Med, Indianapolis, IN USA.
   [Schieri, Lorri] Univ Penn, Philadelphia, PA 19104 USA.
   [Simpson, Rosemary] Univ N Carolina, Chapel Hill, NC USA.
   [Skinner, Anne] Univ Calif Los Angeles, Los Angeles, CA USA.
   [Toussant, Kim] Ohio State Univ, Columbus, OH 43210 USA.
   [Turner, Alicia] Univ Florida, Gainesville, FL USA.
   [Van der Put, Elaine] Univ Miami, Miami, FL USA.
   [Wasser, June] Tufts Univ, Sch Med, Boston, MA 02111 USA.
   [Webb, Chris D.] Stanford Univ, Palo Alto, CA 94304 USA.
   [Williams, Maija] Rockefeller Univ, New York, NY 10021 USA.
   [Wiseman, Lori] Univ Texas Med Branch, Galveston, TX 77555 USA.
   [Yasko, Laurel] Univ Pittsburgh, Pittsburgh, PA USA.
   [Pulley, Jill] Vanderbilt Univ, Nashville, TN 37235 USA.
RP Shirey-Rice, J (corresponding author), CTSA Consortium Coordinating Ctr, Nashville, TN 37206 USA.
EM jana.shirey@vanderbilt.edu
RI Wehbe, Firas/Q-6176-2019
OI Wehbe, Firas/0000-0002-3984-9584; Hafer, Nathaniel/0000-0002-0164-5092;
   Mapes, Brandy/0000-0001-6365-347X
FU National Center for Accelerating Translational Sciences (NCATS), NIH,
   through the CTSA Program [5U54TR000123, UL1TR000109, UL1TR000058,
   UL1TR000086, UL1TR000130, UL1TR000041, UL1TR000050, UL1TR000038,
   UL1TR000055, UL1TR000100, UL1TR000128, UL1TR000433, UL1TR000149,
   UL1TR000161, UL1TR000142, UL1TR000075, UL1TR000157, UL1TR000154,
   UL1TR000002]; NCATS, NIH, through the CTSA Program [UL1TR000040,
   UL1TR000150, UL1TR000114, UL1TR000442, UL1TR000451, UL1TR000001,
   UL1TR000165, UL1TR000439, UL1TR000153, UL1TR000067, UL1TR000430,
   UL1TR000436, UL1TR000427, UL1TR000006, UL1TR000003, UL1TR000083,
   UL1TR000124, UL1TR000090]; NCATS, NIH, CTSA [UL1TR000064, UL1TR000460,
   UL1TR000073, UL1TR000093, UL1TR000043, UL1TR000071, UL1TR000005,
   UL1TR000445]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Advancing Translational
   Sciences (NCATS) [UL1TR000100, UL1TR000064, UL1TR000050, UL1TR000149,
   UL1TR000128, UL1TR000451, UL1TR000073, UL1TR000433, UL1TR001082,
   UL1TR000005, UL1TR000083, UL1TR000130, UL1TR000165, UL1TR000142,
   UL1TR000445, UL1TR000124, UL1TR000153, UL1TR000071, UL1TR000041,
   UL1TR000043, UL1TR000093, UL1TR000058, UL1TR000001, UL1TR001070,
   UL1TR000040, UL1TR000038, UL1TR000442, UL1TR000075, UL1TR000003,
   UL1TR000086, UL1TR001085, UL1TR001073, UL1TR001105, UL1TR000427,
   UL1TR000439, UL1TR000114, UL1TR000161, UL1TR000436, UL1TR000109,
   UL1TR000002, UL1TR000460, U54TR000123, UL1TR000006, UL1TR000430,
   UL1TR000157, UL1TR000067, UL1TR000090, UL1TR000150, UL1TR000154,
   UL1TR000055] Funding Source: NIH RePORTER
FX Federal funds from National Center for Accelerating Translational
   Sciences (NCATS), NIH, through the CTSA Program, grants 15U54TR000123,
   2UL1TR000109, 3UL1TR000058, 4UL1TR000086, 5UL1TR000130, 6UL1TR000041,
   7UL1TR000050, 8UL1TR000038, 9UL1TR000055, 10UL1TR000100, 11UL1TR000128,
   12UL1TR000433, 13UL1TR000149, 14UL1TR000161, 15UL1TR000142,
   16UL1TR000075, 17UL1TR000157, 18UL1TR000154, 19UL1TR000002,
   20UL1TR000040, 21UL1TR000150, 22UL1TR000114, 23UL1TR000442,
   24UL1TR000451, 25UL1TR000001, 26UL1TR000165, 27UL1TR000439,
   28UL1TR000153, 29UL1TR000067, 30UL1TR000430, 31UL1TR000436,
   32UL1TR000427, 33UL1TR000006, 34UL1TR000003, 35UL1TR000083,
   36UL1TR000124, 37UL1TR000090, 38UL1TR000064, 39UL1TR000460,
   40UL1TR000073, 41UL1TR000093, 42UL1TR000043, 43UL1TR000071,
   44UL1TR000005, and 45UL1TR000445.
CR Berro M, 2011, ACAD MED, V86, P217, DOI 10.1097/ACM.0b013e3182045059
   Collins FS, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002747
   Dilts DM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002951
   DuBois JM, 2010, CTS-CLIN TRANSL SCI, V3, P109, DOI 10.1111/j.1752-8062.2010.00193.x
   Farber GK, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002421
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Kiriakis J, 2013, CTS-CLIN TRANSL SCI, V6, P279, DOI 10.1111/cts.12073
   National Research Council, 2013, CTSA PROGR NIH OPP A
   President and Fellows of Harvard College, 2013, EAGLE I EAGEL I
   Rosenblum D, 2012, CTS-CLIN TRANSL SCI, V5, P78, DOI 10.1111/j.1752-8062.2011.00385.x
   Shamoon H, 2012, CTS-CLIN TRANSL SCI, V5, P121, DOI 10.1111/j.1752-8062.2012.00401.x
   Vasilevsky N, 2012, DATABASE-OXFORD, V2012
   Zerhouni EA, 2007, CLIN PHARMACOL THER, V81, P126, DOI 10.1038/sj.clpt.6100029
   Zerhouni EA, 2005, NEW ENGL J MED, V353, P1621, DOI 10.1056/NEJMsb053723
   Zerhouni EA, 2006, TRANSL RES, V148, P4, DOI 10.1016/j.lab.2006.05.001
NR 15
TC 2
Z9 2
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1752-8054
EI 1752-8062
J9 CTS-CLIN TRANSL SCI
JI CTS-Clin. Transl. Sci.
PD APR
PY 2014
VL 7
IS 2
BP 100
EP 107
DI 10.1111/cts.12144
PG 8
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA AF9UJ
UT WOS:000335059900008
PM 24456567
OA Green Submitted, Bronze, Green Published, Green Accepted
DA 2021-10-30
ER

PT J
AU Grifoni, A
   Pham, J
   Sidney, J
   O'Rourke, PH
   Paul, S
   Peters, B
   Martini, SR
   de Silva, AD
   Ricciardi, MJ
   Magnani, DM
   Silveira, CGT
   Maestri, A
   Costa, PR
   de-Oliveira-Pinto, LM
   de Azeredo, EL
   Damasco, PV
   Phillips, E
   Mallal, S
   de Silva, AM
   Collins, M
   Durbin, A
   Diehl, SA
   Cerpas, C
   Balmaseda, A
   Kuan, G
   Coloma, J
   Harris, E
   Crowe, JE
   Stone, M
   Norris, PJ
   Busch, M
   Vivanco-Cid, H
   Cox, J
   Graham, BS
   Ledgerwood, JE
   Turtle, L
   Solomon, T
   Kallas, EG
   Watkins, DI
   Weiskopf, D
   Sette, A
AF Grifoni, Alba
   Pham, John
   Sidney, John
   O'Rourke, Patrick H.
   Paul, Sinu
   Peters, Bjoern
   Martini, Sheridan R.
   de Silva, Aruna D.
   Ricciardi, Michael J.
   Magnani, Diogo M.
   Silveira, Cassia G. T.
   Maestri, Alvino
   Costa, Priscilla R.
   de-Oliveira-Pinto, Luzia Maria
   de Azeredo, Elzinandes Leal
   Damasco, Paulo Vieira
   Phillips, Elizabeth
   Mallal, Simon
   de Silva, Aravinda M.
   Collins, Matthew
   Durbin, Anna
   Diehl, Sean A.
   Cerpas, Cristhiam
   Balmaseda, Angel
   Kuan, Guillermina
   Coloma, Josefina
   Harris, Eva
   Crowe, James E., Jr.
   Stone, Mars
   Norris, Phillip J.
   Busch, Michael
   Vivanco-Cid, Hector
   Cox, Josephine
   Graham, Barney S.
   Ledgerwood, Julie E.
   Turtle, Lance
   Solomon, Tom
   Kallas, Esper G.
   Watkins, David I.
   Weiskopf, Daniela
   Sette, Alessandro
TI Prior Dengue Virus Exposure Shapes T Cell Immunity to Zika Virus in
   Humans
SO JOURNAL OF VIROLOGY
LA English
DT Article
DE ZIKV; DENV; T cells; heterologous immunity; cross-reactivity;
   immunodominance
ID ORIGINAL ANTIGENIC SIN; COMPREHENSIVE ANALYSIS; HETEROLOGOUS IMMUNITY;
   CROSS-REACTIVITY; PROTECTIVE ROLE; RESPONSES; INFECTION; VACCINE;
   ANTIBODIES; CD4(+)
AB While progress has been made in characterizing humoral immunity to Zika virus (ZIKV) in humans, little is known regarding the corresponding T cell responses to ZIKV. Here, we investigate the kinetics and viral epitopes targeted by T cells responding to ZIKV and address the critical question of whether preexisting dengue virus (DENV) T cell immunity modulates these responses. We find that memory T cell responses elicited by prior infection with DENV or vaccination with tetravalent dengue attenuated vaccines (TDLAV) recognize ZIKV-derived peptides. This cross-reactivity is explained by the sequence similarity of the two viruses, as the ZIKV peptides recognized by DENV-elicited memory T cells are identical or highly conserved in DENV and ZIKV. DENV exposure prior to ZIKV infection also influences the timing and magnitude of the T cell response. ZIKV-reactive T cells in the acute phase of infection are detected earlier and in greater magnitude in DENV-immune patients. Conversely, the frequency of ZIKV-reactive T cells continues to rise in the convalescent phase in DENV-naive donors but declines in DENV-preexposed donors, compatible with more efficient control of ZIKV replication and/or clearance of ZIKV antigen. The quality of responses is also influenced by previous DENV exposure, and ZIKV-specific CD8 T cells from DENV-preexposed donors selectively upregulated granzyme B and PD1, unlike DENV-naive donors. Finally, we discovered that ZIKV structural proteins (E, prM, and C) are major targets of both the CD4 and CD8 T cell responses, whereas DENV T cell epitopes are found primarily in nonstructural proteins.
   IMPORTANCE The issue of potential ZIKV and DENV cross-reactivity and how preexisting DENV T cell immunity modulates Zika T cell responses is of great relevance, as the two viruses often cocirculate and Zika virus has been spreading in geographical regions where DENV is endemic or hyperendemic. Our data show that memory T cell responses elicited by prior infection with DENV recognize ZIKV-derived peptides and that DENV exposure prior to ZIKV infection influences the timing, magnitude, and quality of the T cell response. Additionally, we show that ZIKV-specific responses target different proteins than DENV-specific responses, pointing toward important implications for vaccine design against this global threat.
C1 [Grifoni, Alba; Pham, John; Sidney, John; O'Rourke, Patrick H.; Paul, Sinu; Peters, Bjoern; Martini, Sheridan R.; Weiskopf, Daniela; Sette, Alessandro] Jolla Inst Allergy & Immunol, Div Vaccine Discovery, La Jolla, CA 92037 USA.
   [de Silva, Aruna D.] Genetech Res Inst, Colombo, Sri Lanka.
   [Ricciardi, Michael J.; Magnani, Diogo M.; Watkins, David I.] Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL 33136 USA.
   [Silveira, Cassia G. T.; Maestri, Alvino; Costa, Priscilla R.; Kallas, Esper G.] Univ Sao Paulo, Div Clin Immunol & Allergy, Sch Med, Sao Paulo, Brazil.
   [de-Oliveira-Pinto, Luzia Maria; de Azeredo, Elzinandes Leal] Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Damasco, Paulo Vieira] Fed Univ State Rio Janeiro UNIRIO, Rio De Janeiro, Brazil.
   [Phillips, Elizabeth; Mallal, Simon] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA.
   [de Silva, Aravinda M.; Collins, Matthew] Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA.
   [Durbin, Anna] Johns Hopkins Univ Bloomberg, Sch Publ Hlth, Baltimore, MD USA.
   [Diehl, Sean A.] Univ Vermont, Sch Med, Burlington, VT 05405 USA.
   [Cerpas, Cristhiam; Balmaseda, Angel] Minist Hlth, Natl Ctr Diag & Reference, Natl Virol Lab, Managua, Nicaragua.
   [Kuan, Guillermina] Minist Hlth, Hlth Ctr Socrates Flores Vivas, Managua, Nicaragua.
   [Coloma, Josefina; Harris, Eva] Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis & Vaccinol, Berkeley, CA 94720 USA.
   [Crowe, James E., Jr.] Vanderbilt Univ, Med Ctr, Vanderbilt Vaccine Ctr, Nashville, TN USA.
   [Stone, Mars; Norris, Phillip J.] Blood Syst Res Inst, San Francisco, CA USA.
   [Vivanco-Cid, Hector] Univ Veracruzana, Inst Invest Med Biolog, Veracruz, Mexico.
   [Cox, Josephine; Graham, Barney S.; Ledgerwood, Julie E.] NIH, Vaccine Res Ctr, NIAID, Bldg 10, Bethesda, MD 20892 USA.
   [Turtle, Lance] Univ Liverpool, Inst Infect & Global Hlth, Ctr Global Vaccine Res, Liverpool, Merseyside, England.
   [Turtle, Lance; Solomon, Tom] Univ Liverpool, NIHR Hlth Protect Res Unit Emerging & Zoonot Infe, Liverpool, Merseyside, England.
   [Turtle, Lance] Royal Liverpool Univ Hosp, Trop & Infect Dis Unit, Liverpool, Merseyside, England.
   [Solomon, Tom] Univ Liverpool, Inst Infect & Global Hlth, Liverpool, Merseyside, England.
   [Solomon, Tom] Walton Ctr NHS Fdn Trust, Liverpool, Merseyside, England.
   [Phillips, Elizabeth; Mallal, Simon] Murdoch Univ, Inst Immunol & Infect Dis, Perth, WA, Australia.
RP Sette, A (corresponding author), Jolla Inst Allergy & Immunol, Div Vaccine Discovery, La Jolla, CA 92037 USA.
EM alex@lji.org
RI Graham, Barney S./AAC-5898-2019; de-Oliveira-Pinto, Luzia/AAX-6421-2021;
   /AAD-2097-2020; desilva, Aravinda/ABE-6260-2020; Grifoni,
   Alba/AAS-7620-2021; Crowe, James E./B-5549-2009; Diehl,
   Sean/AAE-2779-2020
OI Graham, Barney S./0000-0001-8112-0853; desilva,
   Aravinda/0000-0003-3317-5950; Crowe, James E./0000-0002-0049-1079;
   Diehl, Sean/0000-0001-9700-235X; De Silva, Aruna/0000-0001-5291-9543; ,
   Alba/0000-0002-2209-5966; Turtle, Lance/0000-0002-0778-1693; Magnani,
   Diogo/0000-0002-1773-2406; Solomon, Tom/0000-0001-7266-6547; Kallas,
   Esper/0000-0003-2026-6925; Cox, Josephine/0000-0003-1301-7373; Weiskopf,
   Daniela/0000-0003-2968-7371
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [HHSN272200900042C,
   HHSN27220140045C, U19 AI118626-01, HHSN268201100001I, 1P01AI106695-01A1,
   RO1 AI127828]; ZikaPLAN - European Union [734584]; BMGF [457
   OPP1104710]; University of Miami Clinical and Translational Research
   Institute; Consejo Nacional de Ciencia y Tecnologia (CONACyT) Fonteras
   de la CienciaConsejo Nacional de Ciencia y Tecnologia (CONACyT)
   [2015-02-1192]; Ciencia Basica SEP-CONACyT [256235]; Fosiss-CONACyT
   [233697]; Medical Research CouncilUK Research & Innovation (UKRI)Medical
   Research Council UK (MRC)European Commission [MC_PC_15096, G116/194]
   Funding Source: researchfish; National Institute for Health
   ResearchNational Institute for Health Research (NIHR)
   [IS-HPU-1112-10117, RP-PG-0108-10048, CL-2013-07-005, NF-SI-0514-10177,
   12/205/28] Funding Source: researchfish; Wellcome TrustWellcome
   TrustEuropean Commission [205228/Z/16/Z] Funding Source: researchfish;
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000460] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [P01AI106695,
   ZIAAI005037, U19AI118626, ZIAAI005047, R01AI127828] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of General Medical Sciences (NIGMS)
   [P50GM115305] Funding Source: NIH RePORTER
FX This work was supported by National Institutes of Health contracts and
   grants HHSN272200900042C, HHSN27220140045C, and U19 AI118626-01 to A.S.,
   HHSN268201100001I to BSRI, 1P01AI106695-01A1 to E.H., and RO1 AI127828
   to J.E.C. Further support was provided by ZikaPLAN, which has received
   funding from the European Union's Horizon 2020 research and innovation
   program under grant agreement no. 734584, to A.S., by BMGF grant 457
   OPP1104710 to A.P.D., an internal grant from the University of Miami
   Clinical and Translational Research Institute to D.I.W., and grants from
   Consejo Nacional de Ciencia y Tecnologia (CONACyT) Fonteras de la
   Ciencia 2015-02-1192, Ciencia Basica SEP-CONACyT 256235, and
   Fosiss-CONACyT 233697 to H.V.-C.
CR Ahmed R, 2011, IMMUNOL CELL BIOL, V89, P340, DOI 10.1038/icb.2010.155
   Akondy RS, 2009, J IMMUNOL, V183, P7919, DOI 10.4049/jimmunol.0803903
   Angelo MA, 2017, J VIROL, V91, DOI 10.1128/JVI.02147-16
   Balmaseda A, 2006, TROP MED INT HEALTH, V11, P935, DOI 10.1111/j.1365-3156.2006.01641.x
   Barba-Spaeth G, 2016, NATURE, V536, P48, DOI 10.1038/nature18938
   Chandele A, 2016, J VIROL, V90, P11259, DOI 10.1128/JVI.01424-16
   Collins MH, 2017, EMERG INFECT DIS, V23, P773, DOI 10.3201/eid2305.161630
   de Alwis R, 2016, J VIROL, V90, P4771, DOI 10.1128/JVI.02892-15
   Dejnirattisai W, 2016, NAT IMMUNOL, V17, P1102, DOI 10.1038/ni.3515
   Domingues RB, 2008, J NEUROL SCI, V267, P36, DOI 10.1016/j.jns.2007.09.040
   Durbin AP, 2013, J INFECT DIS, V207, P957, DOI 10.1093/infdis/jis936
   Fauci AS, 2016, NEW ENGL J MED, V374, P601, DOI 10.1056/NEJMp1600297
   FERNANDEZ RJ, 1990, MEM I OSWALDO CRUZ, V85, P347, DOI 10.1590/S0074-02761990000300012
   Heymann DL, 2016, LANCET, V387, P719, DOI 10.1016/S0140-6736(16)00320-2
   Kanakaratne N, 2009, EMERG INFECT DIS, V15, P192, DOI 10.3201/eid1502.080926
   Kirkpatrick BD, 2015, J INFECT DIS, V212, P702, DOI 10.1093/infdis/jiv082
   Kraus AA, 2007, J CLIN MICROBIOL, V45, P3777, DOI 10.1128/JCM.00827-07
   Kuan G, 2009, AM J EPIDEMIOL, V170, P120, DOI 10.1093/aje/kwp092
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lanteri MC, 2008, J INFECT DIS, V197, P1296, DOI 10.1086/586898
   Ledgerwood JE, 2010, VACCINE, V29, P304, DOI 10.1016/j.vaccine.2010.10.037
   Moutaftsi M, 2006, NAT BIOTECHNOL, V24, P817, DOI 10.1038/nbt1215
   Musso D, 2016, CLIN MICROBIOL REV, V29, P487, DOI 10.1128/CMR.00072-15
   Ngono AE, 2016, EBIOMEDICINE, V13, P284, DOI 10.1016/j.ebiom.2016.10.006
   Pantoja P, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15674
   Paul Sinu, 2016, Curr Protoc Immunol, V114, DOI 10.1002/cpim.12
   Pierson TC, 2016, CELL, V167, P625, DOI 10.1016/j.cell.2016.09.020
   Priyamvada L, 2016, P NATL ACAD SCI USA, V113, P7852, DOI 10.1073/pnas.1607931113
   Report S, 2017, ZIK VIR MICR GUILL B
   Rivino L, 2017, IMMUNOLOGY, V150, P146, DOI 10.1111/imm.12681
   Rothman AL, 2011, NAT REV IMMUNOL, V11, P532, DOI 10.1038/nri3014
   Rubin EJ, 2016, NEW ENGL J MED, V374, P984, DOI 10.1056/NEJMe1601862
   Sharma S, 2014, J LEUKOCYTE BIOL, V95, P405, DOI 10.1189/jlb.0713386
   Sikka V, 2016, J GLOB INFECT DIS, V8, P3, DOI 10.4103/0974-777X.176140
   Sips GJ, 2012, REV MED VIROL, V22, P69, DOI 10.1002/rmv.712
   Soares CN, 2010, INT J INFECT DIS, V14, pE150, DOI 10.1016/j.ijid.2009.03.016
   Speer SD, 2016, SCIENCE, V353, P750, DOI 10.1126/science.aah6187
   Stettler K, 2016, SCIENCE, V353, P823, DOI 10.1126/science.aaf8505
   Swanstrom JA, 2016, MBIO, V7, DOI 10.1128/mBio.01123-16
   Turtle L, 2016, J EXP MED, V213, P1331, DOI 10.1084/jem.20151517
   Waggoner JJ, 2016, EMERG INFECT DIS, V22, P1295, DOI 10.3201/eid2207.160326
   Waggoner JJ, 2016, J CLIN VIROL, V78, P57, DOI 10.1016/j.jcv.2016.01.007
   Waggoner JJ, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002116
   Weiskopf D, 2016, J INFECT DIS, V214, P1117, DOI 10.1093/infdis/jiw309
   Weiskopf D, 2015, J INFECT DIS, V212, P1743, DOI 10.1093/infdis/jiv289
   Weiskopf D, 2015, P NATL ACAD SCI USA, V112, pE4256, DOI 10.1073/pnas.1505956112
   Weiskopf D, 2015, J VIROL, V89, P120, DOI 10.1128/JVI.02129-14
   Weiskopf D, 2014, J VIROL, V88, P11383, DOI 10.1128/JVI.01108-14
   Weiskopf D, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00093
   Weiskopf D, 2013, P NATL ACAD SCI USA, V110, pE2046, DOI 10.1073/pnas.1305227110
   Welsh RM, 2010, IMMUNOL REV, V235, P244, DOI 10.1111/j.0105-2896.2010.00897.x
   Wen JS, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.36
   Xu X, 2016, PLOS CURR, V8
   Yun SI, 2017, J MICROBIOL, V55, P204, DOI 10.1007/s12275-017-7063-6
   Zehn D, 2010, J IMMUNOL, V184, P6320, DOI 10.4049/jimmunol.1000149
NR 55
TC 72
Z9 72
U1 1
U2 6
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD DEC
PY 2017
VL 91
IS 24
AR e01469-17
DI 10.1128/JVI.01469-17
PG 19
WC Virology
SC Virology
GA FO1TT
UT WOS:000416548700018
PM 28978707
OA Bronze, Green Published, Green Accepted
DA 2021-10-30
ER

PT J
AU Ricordi, C
   Goldstein, JS
   Balamurugan, AN
   Szot, GL
   Kin, T
   Liu, CY
   Czarniecki, CW
   Barbaro, B
   Bridges, ND
   Cano, J
   Clarke, WR
   Eggerman, TL
   Hunsicker, LG
   Kaufman, DB
   Khan, A
   Lafontant, DE
   Linetsky, E
   Luo, XR
   Markmann, JF
   Naji, A
   Korsgren, O
   Oberholzer, J
   Turgeon, NA
   Brandhorst, D
   Friberg, AS
   Lei, J
   Wang, LJ
   Wilhelm, JJ
   Willits, J
   Zhang, XM
   Hering, BJ
   Posselt, AM
   Stock, PG
   Shapiro, AMJ
AF Ricordi, Camillo
   Goldstein, Julia S.
   Balamurugan, A. N.
   Szot, Gregory L.
   Kin, Tatsuya
   Liu, Chengyang
   Czarniecki, Christine W.
   Barbaro, Barbara
   Bridges, Nancy D.
   Cano, Jose
   Clarke, William R.
   Eggerman, Thomas L.
   Hunsicker, Lawrence G.
   Kaufman, Dixon B.
   Khan, Aisha
   Lafontant, David-Erick
   Linetsky, Elina
   Luo, Xunrong
   Markmann, James F.
   Naji, Ali
   Korsgren, One
   Oberholzer, Jose
   Turgeon, Nicole A.
   Brandhorst, Daniel
   Friberg, Andrew S.
   Lei, Ji
   Wang, Ling-jia
   Wilhelm, Joshua J.
   Willits, Jamie
   Zhang, Xiaomin
   Hering, Bernhard J.
   Posselt, Andrew M.
   Stock, Peter G.
   Shapiro, A. M. James
TI National Institutes of Health-Sponsored Clinical Islet Transplantation
   Consortium Phase 3 Trial: Manufacture of a Complex Cellular Product at
   Eight Processing Facilities
SO DIABETES
LA English
DT Article
ID SINGLE-DONOR; EDMONTON PROTOCOL; CULTURED ISLETS; PANCREAS;
   PRESERVATION; LANGERHANS; PERFUSION; OUTCOMES; YIELD
AB Eight manufacturing facilities participating in the National Institutes of Health-sponsored Clinical Islet Transplantation (CIT) Consortium jointly developed and implemented a harmonized process for the manufacture of allogeneic purified human pancreatic islet (PHPI) product evaluated in a phase 3 trial in subjects with type 1 diabetes. Manufacturing was controlled by a common master production batch record, standard operating procedures that included acceptance criteria for deceased donor organ pancreata and critical raw materials, PHPI product specifications, certificate of analysis, and test methods. The process was compliant with Current Good Manufacturing Practices and Current Good Tissue Practices. This report describes the manufacturing process for 75 PHPI clinical lots and summarizes the results, including lot release. The results demonstrate the feasibility of implementing a harmonized process at multiple facilities for the manufacture of a complex cellular product. The quality systems and regulatory and operational strategies developed by the CIT Consortium yielded product lots that met the prespecified characteristics of safety, purity, potency, and identity and were successfully transplanted into 48 subjects. No adverse events attributable to the product and no cases of primary nonfunction were observed.
C1 [Ricordi, Camillo; Khan, Aisha; Linetsky, Elina] Univ Miami, Miller Sch Med, Diabet Res Inst, Miami, FL 33136 USA.
   [Goldstein, Julia S.; Czarniecki, Christine W.; Bridges, Nancy D.] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Balamurugan, A. N.; Wilhelm, Joshua J.; Hering, Bernhard J.] Univ Minnesota, Schulze Diabet Inst, Minneapolis, MN USA.
   [Balamurugan, A. N.; Wilhelm, Joshua J.; Hering, Bernhard J.] Univ Minnesota, Dept Surg, Box 242 UMHC, Minneapolis, MN 55455 USA.
   [Szot, Gregory L.; Posselt, Andrew M.; Stock, Peter G.] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA.
   [Kin, Tatsuya; Shapiro, A. M. James] Univ Alberta, Clin Islet Transplant Program, Edmonton, AB, Canada.
   [Kin, Tatsuya; Shapiro, A. M. James] Univ Alberta, Fac Med & Dent, Edmonton, AB, Canada.
   [Liu, Chengyang; Naji, Ali] Univ Penn, Perelman Sch Med, Inst Diabet Obes & Metab, Philadelphia, PA 19104 USA.
   [Liu, Chengyang; Naji, Ali] Univ Penn, Dept Surg, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Liu, Chengyang; Naji, Ali] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Barbaro, Barbara; Oberholzer, Jose] Univ Illinois Hosp & Hlth Sci Syst, Div Transplantat, Chicago, IL USA.
   [Cano, Jose; Turgeon, Nicole A.] Emory Univ, Dept Surg, Emory Transplant Ctr, Div Transplantat, Atlanta, GA 30322 USA.
   [Clarke, William R.; Hunsicker, Lawrence G.; Lafontant, David-Erick; Willits, Jamie] Univ Iowa, Clin Trials Stat & Data Management Ctr, Iowa City, IA USA.
   [Eggerman, Thomas L.] NIDDK, NIH, Bethesda, MD 20892 USA.
   [Kaufman, Dixon B.; Luo, Xunrong; Wang, Ling-jia; Zhang, Xiaomin] Northwestern Univ, Feinberg Sch Med, Comprehens Transplant Ctr, Chicago, IL 60611 USA.
   [Markmann, James F.; Lei, Ji] Harvard Med Sch, Massachusetts Gen Hosp, Div Transplant Surg, Boston, MA USA.
   [Korsgren, One; Friberg, Andrew S.] Uppsala Univ, Dept Immunol Genet & Pathol, Uppsala, Sweden.
   [Brandhorst, Daniel] Uppsala Univ, Dept Clin Immunol, Rudbeck Lab, Uppsala, Sweden.
   [Balamurugan, A. N.] Univ Louisville, Dept Surg, Islet Cell Lab, Cardiovasc Innovat Inst, Louisville, KY 40292 USA.
   [Kaufman, Dixon B.] Univ Wisconsin, Madison, WI USA.
RP Ricordi, C (corresponding author), Univ Miami, Miller Sch Med, Diabet Res Inst, Miami, FL 33136 USA.; Goldstein, JS (corresponding author), NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
EM ricordi@miami.edu; goldsteinj@niaid.nih.gov
RI Kin, Tatsuya/A-3776-2012; RICORDI, CAMILLO/AAA-4740-2019; Turgeon,
   Nicole/M-9969-2019; Kaufman, Dixon B/E-4524-2016; Wilhelm,
   Joshua/H-2314-2015
OI Kin, Tatsuya/0000-0002-5179-6067; Szot, Gregory/0000-0002-3921-049X;
   Wilhelm, Joshua/0000-0002-6187-4874; Korsgren, Olle/0000-0002-8524-9547
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID);
   National Institute for Diabetes and Digestive and Kidney DiseasesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Diabetes & Digestive &
   Kidney Diseases (NIDDK) [U01-AI-089317]; Northwestern University
   (Evanston, IL) [U01-AI-089316]; University of Alberta (Edmonton,
   Alberta, Canada)University of Alberta [U01-AI-065191]; University of
   California, San Francisco (San Francisco, CA)University of California
   System [U01-DK-085531]; University of Illinois at Chicago (Chicago, IL)
   [5U01-DK-070431-10]; University of Iowa (Iowa City, IA) [U01-DK-070431];
   University of Miami (Miami, FL) [U01-DK-070460]; University of Minnesota
   (Minneapolis, MN)University of Minnesota System [U01-AI-065193];
   University of Pennsylvania (Philadelphia, PA) [U01-DK-070430]; Uppsala
   University (Uppsala, Sweden) [U01-AI-065192]; General Clinical Research
   Center Awards and Clinical and Translational Science Awards: Emory
   University [UL1-TR-000454]; Northwestern University [5UL1-RR-025741,
   8UL1-TR-000150]; University of California, San FranciscoUniversity of
   California System [UL1-TR-000004]; University of Illinois at Chicago
   [UL1-TR-000050]; University of Miami [1UL1-TR-000460]; University of
   MinnesotaUniversity of Minnesota System [5M01-RR-000400, UL1-TR-000114];
   University of Pennsylvania [M01-RR-00040, UL1-TR-000003]; Novo Nordisk
   FondenNovo Nordisk Foundation [NNF14OC0010935] Funding Source:
   researchfish; Alberta Innovates [201201154] Funding Source:
   researchfish; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Advancing Translational
   Sciences (NCATS) [UL1TR000003, UL1TR000150, UL1TR000454, UL1TR001878,
   UL1TR000460, UL1TR000050, UL1TR000114, UL1TR000004, UL1TR001422] Funding
   Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Research Resources (NCRR)
   [M01RR000040, UL1RR025741, M01RR000400] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [U01AI065193, U01AI065191, U01AI089317, U01AI089316] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Diabetes &
   Digestive & Kidney Diseases (NIDDK) [U01DK070460, U01DK070431,
   U01DK070430, U01DK085531] Funding Source: NIH RePORTER
FX This research was supported by grants from the National Institute of
   Allergy and Infectious Diseases and the National Institute for Diabetes
   and Digestive and Kidney Diseases to the following institutions: Emory
   University (Atlanta, GA), U01-AI-089317; Northwestern University
   (Evanston, IL), U01-AI-089316; University of Alberta (Edmonton, Alberta,
   Canada), U01-AI-065191; University of California, San Francisco (San
   Francisco, CA), U01-DK-085531; University of Illinois at Chicago
   (Chicago, IL), 5U01-DK-070431-10; University of Iowa (Iowa City, IA),
   U01-DK-070431; University of Miami (Miami, FL), U01-DK-070460;
   University of Minnesota (Minneapolis, MN), U01-AI-065193; University of
   Pennsylvania (Philadelphia, PA), U01-DK-070430; and Uppsala University
   (Uppsala, Sweden), U01-AI-065192. In addition, the study was supported
   by the following General Clinical Research Center Awards and Clinical
   and Translational Science Awards: Emory University, UL1-TR-000454;
   Northwestern University, 5UL1-RR-025741 and 8UL1-TR-000150; University
   of California, San Francisco, UL1-TR-000004; University of Illinois at
   Chicago, UL1-TR-000050; University of Miami, 1UL1-TR-000460; University
   of Minnesota, 5M01-RR-000400 and UL1-TR-000114; and University of
   Pennsylvania, M01-RR-00040 and UL1-TR-000003.
CR Ansite J, 2014, CELLR4, V2, pe891
   Ansite J, 2015, CELLR4, V3, pe1342
   Ansite J, 2015, CELLR4, V3, pe1376
   Ansite J., 2014, CELLR4, V2, pe999
   Ansite J, 2014, CELLR4, V2, pe900
   Ansite J, 2015, CELLR4, V3, pe1437
   Ansite J, 2016, CELLR4, V4, pe1895
   Ansite J, 2014, CELLR4, V2, pe997
   Ansite J, 2015, CELLR4, V3, pe1360
   Ansite J, 2015, CELLR4, V3, pe1523
   Ansite J, 2015, CELLR4, V3, pe1350
   Ansite J, 2014, CELLR4, V2, pe993
   Ansite J, 2015, CELLR4, V3, pe1374
   Ansite J, 2014, CELLR4, V2, pe995
   Ansite J, 2015, CELLR4, V3, pe1446
   Ansite J, 2016, CELLR4, V4, pe1932
   Ansite J, 2014, CELLR4, V2, pe991
   Ansite J, 2015, CELLR4, V3, pe1448
   Ansite J., 2014, CELLR4, V2, pe981
   Ansite J, 2015, CELLR4, V3, pe1378
   Ansite J, 2014, CELLR4, V2, pe989
   Ansite J, 2014, CELLR4, V2, pe985
   Balamurugan AN, 2006, PANCREAS, V32, P231, DOI 10.1097/01.mpa.0000203961.16630.2f
   Balamurugan AN, 2012, TRANSPLANTATION, V93, P693, DOI 10.1097/TP.0b013e318247281b
   Barton FB, 2012, DIABETES CARE, V35, P1436, DOI 10.2337/dc12-0063
   Brandhorst H, 1995, TRANSPLANT P, V27, P3175
   BRANDHORST H, 1994, TRANSPLANT P, V26, P590
   Brennan DC, 2016, AM J TRANSPLANT, V16, P509, DOI 10.1111/ajt.13458
   Cross SE, 2008, TRANSPLANTATION, V86, P907, DOI 10.1097/TP.0b013e318186df87
   Froud T, 2005, AM J TRANSPLANT, V5, P2037, DOI 10.1111/j.1600-6143.2005.00957.x
   Hering BJ, 2016, DIABETES CARE, V39, P1230, DOI 10.2337/dc15-1988
   Hering BJ, 2005, JAMA-J AM MED ASSOC, V293, P830, DOI 10.1001/jama.293.7.830
   Hering BJ, 2004, AM J TRANSPLANT, V4, P390, DOI 10.1046/j.1600-6143.2003.00351.x
   Iwanaga Y, 2008, CURR OPIN ORGAN TRAN, V13, P135, DOI 10.1097/MOT.0b013e3282f63942
   Kin T, 2006, TRANSPLANTATION, V82, P1286, DOI 10.1097/01.tp.0000244347.61060.af
   Kin T, 2010, ADV EXP MED BIOL, V654, P683, DOI 10.1007/978-90-481-3271-3_30
   Kissler HJ, 2010, CLIN TRANSPLANT, V24, P236, DOI 10.1111/j.1399-0012.2009.01052.x
   Lakey JRT, 2003, TRANSPL INT, V16, P613, DOI 10.1007/s00147-003-0651-x
   Lakey JRT, 1996, TRANSPLANTATION, V61, P1047, DOI 10.1097/00007890-199604150-00010
   Lakey JRT, 1999, CELL TRANSPLANT, V8, P285, DOI 10.1177/096368979900800309
   Markmann JF, 2003, ANN SURG, V237, P741, DOI 10.1097/00000658-200306000-00001
   NIH CIT Consortium Chemistry Manufacturing Controls Monitoring Committee; NIH CIT Consortium, 2015, CELLR4 REPAIR REPLAC, V3, pE1369
   Noguchi H, 2015, CELL MED, V8, P25, DOI 10.3727/215517915X689047
   Papas KK, 2009, CURR OPIN ORGAN TRAN, V14, P674, DOI 10.1097/MOT.0b013e328332a489
   Piemonti L, 2013, CELLR4 REPAIR REPLAC, V1, P128
   Ricordi C, 2004, NAT REV IMMUNOL, V4, P258, DOI 10.1038/nri1332
   Ricordi C, 2003, DIABETES, V52, P1595, DOI 10.2337/diabetes.52.7.1595
   Shapiro AMJ, 2011, CURR OPIN ORGAN TRAN, V16, P627, DOI 10.1097/MOT.0b013e32834cfb84
   Shapiro AMJ, 2006, NEW ENGL J MED, V355, P1318, DOI 10.1056/NEJMoa061267
   Shapiro AMJ, 2004, AM J TRANSPLANT, V4, P295, DOI 10.1046/j.1600-6143.2003.00375.x
   Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401
   WARNOCK GL, 1994, TRANSPLANT P, V26, P3438
   Yamamoto T, 2009, J HEPATO-BILIARY-PAN, V16, P131, DOI 10.1007/s00534-009-0064-z
NR 53
TC 89
Z9 93
U1 1
U2 10
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
EI 1939-327X
J9 DIABETES
JI Diabetes
PD NOV
PY 2016
VL 65
IS 11
BP 3418
EP 3428
DI 10.2337/db16-0234
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA EA3VX
UT WOS:000386538500020
PM 27465220
OA Green Published, Bronze
DA 2021-10-30
ER

PT J
AU Foster, ED
   Bridges, ND
   Feurer, ID
   Eggerman, TL
   Hunsicker, LG
   Alejandro, R
AF Foster, Eric D.
   Bridges, Nancy D.
   Feurer, Irene D.
   Eggerman, Thomas L.
   Hunsicker, Lawrence G.
   Alejandro, Rodolfo
CA Clinical Islet Transplantation Con
TI Improved Health-Related Quality of Life in a Phase 3 Islet
   Transplantation Trial in Type 1 Diabetes Complicated by Severe
   Hypoglycemia
SO DIABETES CARE
LA English
DT Article
ID FALSE DISCOVERY RATE; PANCREAS TRANSPLANTATION; TOTAL PANCREATECTOMY;
   DISTRESS SCALE; FOLLOW-UP; FEAR; MELLITUS; IMPACT; ADULTS; OUTCOMES
AB OBJECTIVE
   Attaining glycemic targets without severe hypoglycemic events (SHEs) is a challenging treatment goal for patients with type 1 diabetes complicated by impaired awareness of hypoglycemia (IAH). The CIT Consortium Protocol 07 (CIT-07) trial showed islet transplantation to be an effective treatment for subjects with IAH and intractable SHEs. We evaluated health-related quality of life (HRQOL), functional health status, and health utility before and after pancreatic islet transplantation in CIT-07 trial participants.
   RESEARCH DESIGN AND METHODS
   Four surveys, the Diabetes Distress Scale (DDS), the Hypoglycemic Fear Survey (HFS), the Short Form 36 Health Survey (SF-36), and the EuroQoL 5 Dimensions (EQ-5D), were administered repeatedly before and after islet transplantation. Summary statistics and longitudinal modeling were used to describe changes in survey scores from baseline and to characterize change in relation to a minimally important difference (MID) threshold of half an SD.
   RESULTS
   Improvements in condition-specific HRQOL met the MID threshold. Reductions from baseline in the DDS total score and its four DDS subscales (all P <= 0.0013) and in the HFS total score and its two subscales (all P < 0.0001) were observed across all time points. Improvements were observed after both 1 and 2 years for the EQ-5D visual analog scale (both P < 0.0001).
   CONCLUSIONS
   In CIT-07, 87.5% of the subjects achieved the primary end point of freedom from SHE along with glycemic control (HbA(1c) < 7% [< 53 mmol/mol]) at 1 year post-initial islet transplantation. The same subjects reported consistent, statistically significant, and clinically meaningful improvements in condition-specific HRQOL as well as self-assessments of overall health.
C1 [Foster, Eric D.; Hunsicker, Lawrence G.] Univ Iowa, Dept Biostat, Clin Trials Stat & Data Management Ctr, Iowa City, IA 52242 USA.
   [Bridges, Nancy D.] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Feurer, Irene D.] Vanderbilt Univ, Dept Surg, Med Ctr, Nashville, TN 37240 USA.
   [Feurer, Irene D.] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN USA.
   [Feurer, Irene D.] Vanderbilt Transplant Ctr, Nashville, TN USA.
   [Eggerman, Thomas L.] NIDDK, NIH, Bethesda, MD USA.
   [Alejandro, Rodolfo] Univ Miami, Miller Sch Med, Diabet Res Inst, Miami, FL 33136 USA.
RP Foster, ED (corresponding author), Univ Iowa, Dept Biostat, Clin Trials Stat & Data Management Ctr, Iowa City, IA 52242 USA.
EM eric-foster@uiowa.edu
OI Korsgren, Olle/0000-0002-8524-9547
FU National Institute of Allergy and Infectious Diseases (NIAID)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID); National Institute of Diabetes and Digestive and
   Kidney Diseases (NIDDK)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Diabetes & Digestive & Kidney Diseases (NIDDK); NIDDK at Emory
   University [NIAID U01-AI-089317]; NIDDK at Northwestern University
   [NIAID U01-AI-089316]; NIDDK at the University of Alberta, Edmonton
   [NIAID U01-AI-065191]; NIDDK at the University of California, San
   Francisco [NIDDK U01-DK-085531]; NIDDK at the University of Illinois,
   Chicago [NIDDK 5U01-DK-070431-10]; NIDDK at the University of Iowa
   [NIDDK U01-DK-070431]; NIDDK at the University of Miami [NIDDK
   U01-DK-070460]; NIDDK at the University of Minnesota [NIAID
   U01-AI-065193]; NIDDK at the University of Pennsylvania [NIDDK
   U01-DK-070430]; NIDDK at Uppsala University [NIAID U01-AI-065192]; Emory
   University [UL1-TR-000454]; Northwestern University [5UL1-RR-025741,
   8UL1-TR-000150]; University of California, San FranciscoUniversity of
   California System [UL1-TR-000004]; University of Illinois, Chicago
   [UL1-TR-000050]; University of Miami [1UL1-TR-000460]; University of
   MinnesotaUniversity of Minnesota System [5M01-RR-000400, UL1-TR-000114];
   University of Pennsylvania [M01-RR00040, UL1-TR-000003]; NATIONAL CENTER
   FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000460,
   UL1TR000003, UL1TR002378, UL1TR001422, UL1TR000004, UL1TR000114,
   UL1TR000050] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH
   RESOURCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Research
   Resources (NCRR) [M01RR000400] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [U01AI089317, U01AI065191, U01AI065192, U01AI065193] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Diabetes &
   Digestive & Kidney Diseases (NIDDK) [U01DK085531, U01DK070460,
   U01DK070431, U01DK070430] Funding Source: NIH RePORTER
FX This research was funded by the National Institute of Allergy and
   Infectious Diseases (NIAID) and the National Institute of Diabetes and
   Digestive and Kidney Diseases (NIDDK), ClinicalTrials.gov no.
   NCT00434811. This research was supported by the following grants from
   the NIAID and the NIDDK: at Emory University, NIAID U01-AI-089317; at
   Northwestern University, NIAID U01-AI-089316; at the University of
   Alberta, Edmonton, NIAID U01-AI-065191; at the University of California,
   San Francisco, NIDDK U01-DK-085531; at the University of Illinois,
   Chicago, NIDDK 5U01-DK-070431-10; at the University of Iowa, NIDDK
   U01-DK-070431; at the University of Miami, NIDDK U01-DK-070460; at the
   University of Minnesota, NIAID U01-AI-065193; at the University of
   Pennsylvania, NIDDK U01-DK-070430; and at Uppsala University, NIAID
   U01-AI-065192. In addition, the study was supported by the following
   General Clinical Research Center grants and Clinical and Translational
   Science Awards: at Emory University, UL1-TR-000454; at Northwestern
   University, 5UL1-RR-025741 and 8UL1-TR-000150; at the University of
   California, San Francisco, UL1-TR-000004; at the University of Illinois,
   Chicago, UL1-TR-000050; at the University of Miami, 1UL1-TR-000460; at
   the University of Minnesota, 5M01-RR-000400 and UL1-TR-000114; and at
   the University of Pennsylvania, M01-RR00040 and UL1-TR-000003.
CR Ahroni JH, 2000, J DIABETES COMPLICAT, V14, P31, DOI 10.1016/S1056-8727(00)00066-0
   [Anonymous], 1997, DIABETES, V46, P271, DOI 10.2337/diab.46.2.271
   Barshes NR, 2005, TRANSPLANTATION, V79, P1727, DOI 10.1097/01.TP.0000160816.21799.F5
   Bellin MD, 2011, CLIN GASTROENTEROL H, V9, P793, DOI 10.1016/j.cgh.2011.04.024
   Benhamou PY, 2009, DIABETIC MED, V26, P617, DOI 10.1111/j.1464-5491.2009.02731.x
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bjorner JB, 2013, VALUE HEALTH, V16, P993, DOI 10.1016/j.jval.2013.06.022
   Bohme P, 2013, DIABETES METAB, V39, P63, DOI 10.1016/j.diabet.2012.10.006
   Chinnakotla S, 2014, J AM COLL SURGEONS, V218, P530, DOI 10.1016/j.jamcollsurg.2013.12.037
   COX DJ, 1987, DIABETES CARE, V10, P617, DOI 10.2337/diacare.10.5.617
   Cryer PE, 2014, DIABETES, V63, P2188, DOI 10.2337/db14-0059
   Cure P, 2008, TRANSPLANTATION, V85, P801, DOI 10.1097/TP.0b013e318166a27b
   DCCT Res Grp, 1988, DIABETES CARE, V11, P725
   Fisher L, 2012, DIABETES CARE, V35, P259, DOI 10.2337/dc11-1572
   Glickman ME, 2014, J CLIN EPIDEMIOL, V67, P850, DOI 10.1016/j.jclinepi.2014.03.012
   Hart HE, 2003, QUAL LIFE RES, V12, P1089, DOI 10.1023/A:1026197119569
   Hering BJ, 2016, DIABETES CARE, V39, P1230, DOI 10.2337/dc15-1988
   IRVINE AA, 1992, HEALTH PSYCHOL, V11, P135, DOI 10.1037/0278-6133.11.2.135
   JACOBSON AM, 1994, DIABETES CARE, V17, P267, DOI 10.2337/diacare.17.4.267
   Janssen MF, 2011, DIABETIC MED, V28, P395, DOI 10.1111/j.1464-5491.2010.03136.x
   Johnson JA, 2004, DIABETES CARE, V27, P624, DOI 10.2337/diacare.27.2.624
   Martyn-Nemeth P, 2016, J DIABETES COMPLICAT, V30, P167, DOI 10.1016/j.jdiacomp.2015.09.003
   Mehrabi A, 2014, PANCREAS, V43, P1190, DOI 10.1097/MPA.0000000000000181
   Norman GR, 2003, MED CARE, V41, P582, DOI 10.1097/00005650-200305000-00004
   Poggioli R, 2006, AM J TRANSPLANT, V6, P371, DOI 10.1111/j.1600-6143.2005.01174.x
   Polonsky WH, 2005, DIABETES CARE, V28, P626, DOI 10.2337/diacare.28.3.626
   Polonsky WH, 2017, DIABETES CARE, V40, P736, DOI 10.2337/dc17-0133
   Radosevich DM, 2013, CLIN TRANSPLANT, V27, pE715, DOI 10.1111/ctr.12265
   Reenen M., 2015, EQ 5D 3L USER GUIDE
   Ricordi C, 2016, DIABETES, V65, P3418, DOI 10.2337/db16-0234
   Rubin RR, 2012, DIABETES TECHNOL THE, V14, P143, DOI 10.1089/dia.2011.0162
   Ryan EA, 2005, DIABETES, V54, P2060, DOI 10.2337/diabetes.54.7.2060
   Scalea JR, 2018, CLIN TRANSPLANT, V32, DOI 10.1111/ctr.13177
   SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401
   Shaw JW, 2005, MED CARE, V43, P203, DOI 10.1097/00005650-200503000-00003
   Speight J, 2010, DIABETIC MED, V27, P812, DOI 10.1111/j.1464-5491.2010.03029.x
   Tharavanij T, 2008, TRANSPLANTATION, V86, P1161, DOI 10.1097/TP.0b013e31818a7f45
   Toso C, 2007, TRANSPLANTATION, V84, P664, DOI 10.1097/01.tp.0000280550.01028.89
   Vanstone Meredith, 2015, Ont Health Technol Assess Ser, V15, P1
   Ware Jr JE, 2000, SF 36 HLTH SURVEY MA, V10, P24
   WILLIAMS A, 1990, HEALTH POLICY, V16, P199
NR 41
TC 51
Z9 51
U1 0
U2 9
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
EI 1935-5548
J9 DIABETES CARE
JI Diabetes Care
PD MAY
PY 2018
VL 41
IS 5
BP 1001
EP 1008
DI 10.2337/dc17-1779
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA GD4EJ
UT WOS:000430456100020
PM 29563196
OA Bronze, Green Published
DA 2021-10-30
ER

PT J
AU Hering, BJ
   Clarke, WR
   Bridges, ND
   Eggerman, TL
   Alejandro, R
   Bellin, MD
   Chaloner, K
   Czarniecki, CW
   Goldstein, JS
   Hunsicker, LG
   Kaufman, DB
   Korsgren, O
   Larsen, CP
   Luo, XR
   Markmann, JF
   Naji, A
   Oberholzer, J
   Posselt, AM
   Rickels, MR
   Ricordi, C
   Robien, MA
   Senior, PA
   Shapiro, AMJ
   Stock, PG
   Turgeon, NA
AF Hering, Bernhard J.
   Clarke, William R.
   Bridges, Nancy D.
   Eggerman, Thomas L.
   Alejandro, Rodolfo
   Bellin, Melena D.
   Chaloner, Kathryn
   Czarniecki, Christine W.
   Goldstein, Julia S.
   Hunsicker, Lawrence G.
   Kaufman, Dixon B.
   Korsgren, Olle
   Larsen, Christian P.
   Luo, Xunrong
   Markmann, James F.
   Naji, Ali
   Oberholzer, Jose
   Posselt, Andrew M.
   Rickels, Michael R.
   Ricordi, Camillo
   Robien, Mark A.
   Senior, Peter A.
   Shapiro, A. M. James
   Stock, Peter G.
   Turgeon, Nicole A.
CA Clinical Islet Transplantation Con
TI Phase 3 Trial of Transplantation of Human Islets in Type 1 Diabetes
   Complicated by Severe Hypoglycemia
SO DIABETES CARE
LA English
DT Article
ID EXCHANGE CLINIC REGISTRY; INSULIN PUMP THERAPY; PANCREAS
   TRANSPLANTATION; GLYCEMIC CONTROL; CURRENT STATE; AWARENESS; ADULTS;
   MELLITUS; OUTCOMES; IDDM
AB OBJECTIVE
   Impaired awareness of hypoglycemia (IAH) and severe hypoglycemic events (SHEs) cause substantial morbidity and mortality in patients with type 1 diabetes (T1D). Current therapies are effective in preventing SHEs in 50-80% of patients with IAH and SHEs, leaving a substantial number of patients at risk. We evaluated the effectiveness and safety of a standardized human pancreatic islet product in subjects in whom IAH and SHEs persisted despite medical treatment.
   RESEARCH DESIGN AND METHODS
   This multicenter, single-arm, phase 3 study of the investigational product purified human pancreatic islets (PHPI) was conducted at eight centers in North America. Forty-eight adults with T1D for >5 years, absent stimulated C-peptide, and documented IAH and SHEs despite expert care were enrolled. Each received immunosuppression and one or more transplants of PHPI, manufactured on-site under good manufacturing practice conditions using a common batch record and standardized lot release criteria and test methods. The primary end point was the achievement of HbA(1c) <7.0% (53 mmol/mol) at day 365 and freedom from SHEs from day 28 to day 365 after the first transplant.
   RESULTS
   The primary end point was successfully met by 87.5% of subjects at 1 year and by 71% at 2 years. The median HbA(1c) level was 5.6% (38 mmol/mol) at both 1 and 2 years. Hypoglycemia awareness was restored, with highly significant improvements in Clarke and HYPO scores (P > 0.0001). No study-related deaths or disabilities occurred. Five of the enrollees (10.4%) experienced bleeds requiring transfusions (corresponding to 5 of 75 procedures), and two enrollees (4.1%) had infections attributed to immunosuppression. Glomerular filtration rate decreased significantly on immunosuppression, and donor-specific antibodies developed in two patients.
   CONCLUSIONS
   Transplanted PHPI provided glycemic control, restoration of hypoglycemia awareness, and protection from SHEs in subjects with intractable IAH and SHEs. Safety events occurred related to the infusion procedure and immunosuppression, including bleeding and decreased renal function. Islet transplantation should be considered for patients with T1D and IAH in whom other, less invasive current treatments have been ineffective in preventing SHEs.
C1 [Hering, Bernhard J.; Bellin, Melena D.] Univ Minnesota, Schulze Diabet Inst, Minneapolis, MN 55455 USA.
   [Hering, Bernhard J.] Univ Minnesota, Dept Surg, Box 242 UMHC, Minneapolis, MN 55455 USA.
   [Clarke, William R.; Chaloner, Kathryn; Hunsicker, Lawrence G.] Univ Iowa, Clin Trials Stat & Data Management Ctr, Iowa City, IA USA.
   [Bridges, Nancy D.; Czarniecki, Christine W.; Goldstein, Julia S.; Robien, Mark A.] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Eggerman, Thomas L.] NIDDK, NIH, Bethesda, MD 20892 USA.
   [Alejandro, Rodolfo; Ricordi, Camillo] Univ Miami, Miller Sch Med, Diabet Res Inst, Miami, FL 33136 USA.
   [Bellin, Melena D.] Univ Minnesota, Dept Pediat, Minneapolis, MN 55455 USA.
   [Kaufman, Dixon B.] Univ Wisconsin, Dept Surg, Div Transplantat, Madison, WI USA.
   [Korsgren, Olle] Uppsala Univ, Dept Immunol Genet & Pathol, Uppsala, Sweden.
   [Larsen, Christian P.; Turgeon, Nicole A.] Emory Univ, Emory Transplant Ctr, Atlanta, GA 30322 USA.
   [Luo, Xunrong] Northwestern Univ, Feinberg Sch Med, Comprehens Transplant Ctr, Chicago, IL 60611 USA.
   [Markmann, James F.] Harvard Med Sch, Massachusetts Gen Hosp, Div Transplant Surg, Boston, MA USA.
   [Naji, Ali; Rickels, Michael R.] Univ Penn, Perelman Sch Med, Inst Diabet Obes & Metab, Philadelphia, PA 19104 USA.
   [Naji, Ali; Rickels, Michael R.] Univ Penn, Perelman Sch Med, Dept Surg, Philadelphia, PA 19104 USA.
   [Naji, Ali; Rickels, Michael R.] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA.
   [Oberholzer, Jose] Univ Illinois Hosp & Hlth Sci Syst, Div Transplantat, Chicago, IL USA.
   [Posselt, Andrew M.; Stock, Peter G.] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA.
   [Senior, Peter A.; Shapiro, A. M. James] Univ Alberta, Clin Islet Transplant Program, Edmonton, AB, Canada.
   [Senior, Peter A.; Shapiro, A. M. James] Univ Alberta, Fac Med & Dent, Edmonton, AB, Canada.
RP Hering, BJ (corresponding author), Univ Minnesota, Schulze Diabet Inst, Minneapolis, MN 55455 USA.; Hering, BJ (corresponding author), Univ Minnesota, Dept Surg, Box 242 UMHC, Minneapolis, MN 55455 USA.
EM bhering@umn.edu
RI Kaufman, Dixon B/E-4524-2016; Senior, Peter/O-4934-2019; Senior, Peter
   A/E-3031-2013; Robien, Mark/AAA-9260-2021; Rickels, Michael/D-1380-2009;
   Turgeon, Nicole/M-9969-2019; RICORDI, CAMILLO/AAA-4740-2019
OI Senior, Peter/0000-0003-1033-8673; Senior, Peter A/0000-0003-1033-8673;
   Robien, Mark/0000-0003-0403-0955; Rickels, Michael/0000-0002-9253-838X;
   Korsgren, Olle/0000-0002-8524-9547; Ricordi, Camillo/0000-0001-8092-7153
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID);
   National Institute for Diabetes and Digestive and Kidney DiseasesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Diabetes & Digestive &
   Kidney Diseases (NIDDK) [U01-AI-089317, U01-AI-089316, U01-AI-065191,
   U01-DK-085531, 5U01-DK-070431-10, U01-DK-070431, U01-DK070460,
   U01-AI-065193, U01-DK-070430, U01-AI-065192]; General Clinical Research
   Center Awards and Clinical and Translational Science Awards
   [UL1-TR-000454, 5UL1-RR-025741, 8UL1-TR-000150, UL1-TR-000004,
   UL1-TR-000050, 1UL1-TR-000460, 5M01-RR-000400, UL1-TR-000114,
   M01-RR-00040, UL1-TR-000003]; National Institute of Allergy and
   Infectious Diseases of the National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [NO1-AI-15416, UM1-AI-109565]; Novo Nordisk FondenNovo Nordisk
   Foundation [NNF14OC0010935] Funding Source: researchfish; Alberta
   Innovates [201201154] Funding Source: researchfish; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000114,
   UL1TR000050, UL1TR000460, UL1TR000003, UL1TR000454, UL1TR000150,
   UL1TR000004] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH
   RESOURCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Research
   Resources (NCRR) [UL1RR025741, M01RR000040, M01RR000400] Funding Source:
   NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U01AI089317, UM1AI109565, U01AI065193,
   U01AI089316, U01AI065191, N01AI015416, U01AI065192] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Diabetes &
   Digestive & Kidney Diseases (NIDDK) [U01DK085531, U01DK070430,
   U01DK070460, U01DK070431] Funding Source: NIH RePORTER
FX This research was supported by grants from the National Institute of
   Allergy and Infectious Diseases and the National Institute for Diabetes
   and Digestive and Kidney Diseases to the following institutions: Emory
   University (Atlanta, GA), U01-AI-089317; Northwestern University
   (Evanston, IL), U01-AI-089316; University of Alberta(Edmonton, Alberta,
   Canada), U01-AI-065191; University of California, San Francisco (San
   Francisco, CA) U01-DK-085531; University of Illinois, Chicago(Chicago,
   IL), 5U01-DK-070431-10; University of Iowa (Iowa City, IA),
   U01-DK-070431; University of Miami (Miami, FL), U01-DK070460; University
   of Minnesota (Minneapolis, MN), U01-AI-065193; University of
   Pennsylvania (Philadelphia, PA), U01-DK-070430; and Uppsala University
   (Uppsala, Sweden), U01-AI-065192. In addition, the study was supported
   by the following General Clinical Research Center Awards and Clinical
   and Translational Science Awards: to Emory University, UL1-TR-000454;
   Northwestern University, 5UL1-RR-025741 and 8UL1-TR-000150; University
   of California, San Francisco, UL1-TR-000004; University of Illinois,
   Chicago, UL1-TR-000050; University of Miami, 1UL1-TR-000460; University
   of Minnesota, 5M01-RR-000400 and UL1-TR-000114; and University of
   Pennsylvania, M01-RR-00040 and UL1-TR-000003. TrialShare, a public
   database maintained by the Immune Tolerance Network, is supported by the
   National Institute of Allergy and Infectious Diseases of the National
   Institutes of Health under award numbers NO1-AI-15416 and UM1-AI-109565.
CR Amer Diabet Assoc, 2008, DIABETES CARE, V31, pS12, DOI 10.2337/dc08-S012
   [Anonymous], 2012, DIABETES CARE, V35, pS11, DOI [10.2337/dc12-s011, 10.2337/dc35-S011, 10.2337/dc12-s004]
   Bartlett ST, 2016, TRANSPLANTATION, V100, pS1, DOI 10.1097/TP.0000000000001055
   Beck RW, 2014, DIABETES CARE, V37, P1224, DOI 10.2337/dc13-2775
   Bergenstal RM, 2013, NEW ENGL J MED, V369, P224, DOI 10.1056/NEJMoa1303576
   Brooks AM, 2013, AM J TRANSPLANT, V13, P3236, DOI 10.1111/ajt.12469
   Byrne ML, 2015, HORM METAB RES, V47, P9, DOI 10.1055/s-0034-1394455
   Choudhary P, 2015, DIABETES CARE, V38, P1016, DOI 10.2337/dc15-0090
   CLARKE WL, 1995, DIABETES CARE, V18, P517, DOI 10.2337/diacare.18.4.517
   CRANSTON I, 1994, LANCET, V344, P283, DOI 10.1016/S0140-6736(94)91336-6
   Cryer PE, 2014, DIABETES, V63, P2188, DOI 10.2337/db14-0059
   DAGOGOJACK S, 1994, DIABETES, V43, P1426, DOI 10.2337/diabetes.43.12.1426
   de Zoysa N, 2014, DIABETES CARE, V37, P863, DOI 10.2337/dc13-1245
   DIEM P, 1990, J CLIN INVEST, V86, P2008, DOI 10.1172/JCI114936
   FANELLI CG, 1993, DIABETES, V42, P1683, DOI 10.2337/diabetes.42.11.1683
   Food and Drug Administration Center for Biologics Evaluation and Research, 2003, BIOL RESP MOD ADV CO
   Frier BM, 2014, NAT REV ENDOCRINOL, V10, P711, DOI 10.1038/nrendo.2014.170
   Geddes J, 2008, DIABETIC MED, V25, P501, DOI 10.1111/j.1464-5491.2008.02413.x
   Gruessner RWG, 2013, NAT REV ENDOCRINOL, V9, P555, DOI 10.1038/nrendo.2013.138
   Haidar A, 2015, LANCET DIABETES ENDO, V3, P17, DOI 10.1016/S2213-8587(14)70226-8
   Hering BJ, 2005, JAMA-J AM MED ASSOC, V293, P830, DOI 10.1001/jama.293.7.830
   Hopkins D, 2012, DIABETES CARE, V35, P1638, DOI 10.2337/dc11-1579
   Kaneku H., 2012, CLIN TRANSPL, V2012, P207
   Kendall DM, 1997, DIABETES, V46, P249, DOI 10.2337/diabetes.46.2.249
   Little SA, 2014, DIABETES CARE, V37, P2114, DOI 10.2337/dc14-0030
   Ly TT, 2013, JAMA-J AM MED ASSOC, V310, P1240, DOI 10.1001/jama.2013.277818
   McCoy RG, 2012, DIABETES CARE, V35, P1897, DOI 10.2337/dc11-2054
   Miller KM, 2015, DIABETES CARE, V38, P971, DOI 10.2337/dc15-0078
   Naziruddin B, 2012, CELL TRANSPLANT, V21, P901, DOI 10.3727/096368911X612468
   O'Connell PJ, 2013, AM J TRANSPLANT, V13, P1850, DOI 10.1111/ajt.12250
   Rodbard Helena W, 2007, Endocr Pract, V13 Suppl 1, P1
   Ryan EA, 2004, DIABETES, V53, P955, DOI 10.2337/diabetes.53.4.955
   Seaquist ER, 2013, DIABETES CARE, V36, P1384, DOI 10.2337/dc12-2480
   Shapiro AMJ, 2006, NEW ENGL J MED, V355, P1318, DOI 10.1056/NEJMoa061267
   Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401
   The NIH CIT Consortium Chemistry Manufacturing Controls Monitoring Committee, 2014, PUR HUM PANCR ISL PH
   U.S. Food and Drug Administration, 2009, GUID IND CONS ALL PA
   Weinstock RS, 2013, J CLIN ENDOCR METAB, V98, P3411, DOI 10.1210/jc.2013-1589
   Yeh HC, 2012, ANN INTERN MED, V157, P336, DOI 10.7326/0003-4819-157-5-201209040-00508
   Yeoh E, 2015, DIABETES CARE, V38, P1592, DOI 10.2337/dc15-0102
NR 40
TC 265
Z9 274
U1 2
U2 26
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
EI 1935-5548
J9 DIABETES CARE
JI Diabetes Care
PD JUL
PY 2016
VL 39
IS 7
BP 1230
EP 1240
DI 10.2337/dc15-1988
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DT3YG
UT WOS:000381416500032
PM 27208344
OA Green Published, Bronze
HC Y
HP N
DA 2021-10-30
ER

PT J
AU Cade, BE
   Chen, H
   Stilp, AM
   Gleason, KJ
   Sofer, T
   Ancoli-Israel, S
   Arens, R
   Bell, GI
   Below, JE
   Bjonnes, AC
   Chun, S
   Conomos, MP
   Evans, DS
   Johnson, WC
   Frazier-Wood, AC
   Lane, JM
   Larkin, EK
   Loredo, JS
   Post, WS
   Ramos, AR
   Rice, K
   Rotter, JI
   Shah, NA
   Stone, KL
   Taylor, KD
   Thornton, TA
   Tranah, GJ
   Wang, CL
   Zee, PC
   Hanis, CL
   Sunyaev, SR
   Patel, SR
   Laurie, CC
   Zhu, XF
   Saxena, R
   Lin, XH
   Redline, S
AF Cade, Brian E.
   Chen, Han
   Stilp, Adrienne M.
   Gleason, Kevin J.
   Sofer, Tamar
   Ancoli-Israel, Sonia
   Arens, Raanan
   Bell, Graeme I.
   Below, Jennifer E.
   Bjonnes, Andrew C.
   Chun, Sung
   Conomos, Matthew P.
   Evans, Daniel S.
   Johnson, W. Craig
   Frazier-Wood, Alexis C.
   Lane, Jacqueline M.
   Larkin, Emma K.
   Loredo, Jose S.
   Post, Wendy S.
   Ramos, Alberto R.
   Rice, Ken
   Rotter, Jerome I.
   Shah, Neomi A.
   Stone, Katie L.
   Taylor, Kent D.
   Thornton, Timothy A.
   Tranah, Gregory J.
   Wang, Chaolong
   Zee, Phyllis C.
   Hanis, Craig L.
   Sunyaev, Shamil R.
   Patel, Sanjay R.
   Laurie, Cathy C.
   Zhu, Xiaofeng
   Saxena, Richa
   Lin, Xihong
   Redline, Susan
TI Genetic Associations with Obstructive Sleep Apnea Traits in
   Hispanic/Latino Americans
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article
DE sleep apnea; hypoxia; genetics; GWAS; Prader-Willi syndrome
ID GENOME-WIDE ASSOCIATION; DIVERSE BACKGROUNDS; METABOLISM; EXPRESSION;
   GPR83; IDENTIFICATION; INFLAMMATION; INDIVIDUALS; PREVALENCE; RESOURCE
AB Rationale: Obstructive sleep apnea is a common disorder associated with increased risk for cardiovascular disease, diabetes, and premature mortality. Although there is strong clinical and epidemiologic evidence supporting the importance of genetic factors in influencing obstructive sleep apnea, its genetic basis is still largely unknown. Prior genetic studies focused on traits defined using the apnea-hypopnea index, which contains limited information on potentially important genetically determined physiologic factors, such as propensity for hypoxemia and respiratory arousability. Objectives: To define novel obstructive sleep apnea genetic risk loci for obstructive sleep apnea, we conducted genome-wide association studies of quantitative traits in Hispanic/Latino Americans from three cohorts.
   Methods: Genome-wide data from as many as 12,558 participants in the Hispanic Community Health Study/Study of Latinos, Multi Ethnic Study of Atherosclerosis, and Starr County Health Studies population-based cohorts were metaanalyzed for association with the apnea-hypopnea index, average oxygen saturation during sleep, and average respiratory event duration.
   Measurements and Main Results: Two novel loci were identified at genome-level significance (rs11691765, GPR83, P =1.90 X 10(-8) for the apnea-hypopnea index, and rs35424364; C6ORF183/CCDC162P, P = 4.88 X 10(-8) for respiratory event duration) and seven additional loci were identified with suggestive significance (P < 5 X 10(-7)). Secondary sex-stratified analyses also identified one significant and several suggestive associations. Multiple loci overlapped genes with biologic plausibility.
   Conclusions: These are the first genome-level significant findings reported for obstructive sleep apnea-related physiologic traits in any population. These findings identify novel associations in inflammatory, hypoxia signaling, and sleep pathways.
C1 [Cade, Brian E.; Gleason, Kevin J.; Lane, Jacqueline M.; Patel, Sanjay R.; Saxena, Richa; Redline, Susan] Brigham & Womens Hosp, Div Sleep & Circadian Disorders, 75 Francis St, Boston, MA 02115 USA.
   [Bjonnes, Andrew C.; Chun, Sung; Sunyaev, Shamil R.] Brigham & Womens Hosp, Div Genet, 75 Francis St, Boston, MA 02115 USA.
   [Cade, Brian E.; Lane, Jacqueline M.; Patel, Sanjay R.; Redline, Susan] Harvard Med Sch, Div Sleep Med, Boston, MA USA.
   [Chun, Sung; Sunyaev, Shamil R.] Harvard Med Sch, Div Med Sci, Boston, MA USA.
   [Chen, Han; Wang, Chaolong; Lin, Xihong] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA.
   [Stilp, Adrienne M.; Sofer, Tamar; Conomos, Matthew P.; Johnson, W. Craig; Rice, Ken; Thornton, Timothy A.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
   [Ancoli-Israel, Sonia] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA.
   [Ancoli-Israel, Sonia] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA.
   [Ancoli-Israel, Sonia] San Diego Ctr Excellence Stress & Mental Hlth, Dept Vet Affairs, San Diego, CA USA.
   [Arens, Raanan] Childrens Hosp Montefiore, Albert Einstein Coll Med, Div Resp & Sleep Med, Bronx, NY USA.
   [Bell, Graeme I.] Univ Chicago, Sect Adult & Pediat Endocrinol Diabet & Metab, Chicago, IL 60637 USA.
   [Below, Jennifer E.; Hanis, Craig L.] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Ctr Human Genet, Houston, TX 77030 USA.
   [Evans, Daniel S.; Stone, Katie L.; Tranah, Gregory J.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA.
   [Frazier-Wood, Alexis C.] Baylor Coll Med, Childrens Nutr Res Ctr, Houston, TX 77030 USA.
   [Lane, Jacqueline M.; Saxena, Richa] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
   [Lane, Jacqueline M.; Saxena, Richa] Massachusetts Gen Hosp, Dept Anesthesia Pain & Crit Care Med, Boston, MA 02114 USA.
   [Lane, Jacqueline M.; Sunyaev, Shamil R.; Saxena, Richa] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA.
   [Larkin, Emma K.] Vanderbilt Univ, Med Ctr, Dept Med, Div Allergy Pulm & Crit Care, 221 Kirkland Hall, Nashville, TN 37235 USA.
   [Loredo, Jose S.] Univ Calif San Diego, Sch Med, Dept Med, Div Pulm Crit Care & Sleep Med, La Jolla, CA USA.
   [Post, Wendy S.] Johns Hopkins Univ, Div Cardiol, Baltimore, MD USA.
   [Ramos, Alberto R.] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA.
   [Rotter, Jerome I.; Taylor, Kent D.] Harbor UCLA Med Ctr, Los Angeles BioMed Res Inst, Inst Translat Genom & Populat Sci, Torrance, CA 90509 USA.
   [Shah, Neomi A.] Montefiore Med Ctr, Dept Med, 111 E 210th St, Bronx, NY 10467 USA.
   [Wang, Chaolong] Genome Inst Singapore, Singapore, Singapore.
   [Zee, Phyllis C.] Northwestern Univ, Dept Neurol, Chicago, IL 60611 USA.
   [Zee, Phyllis C.] Northwestern Univ, Sleep Med Ctr, Chicago, IL 60611 USA.
   [Patel, Sanjay R.; Redline, Susan] Beth Israel Deaconess Med Ctr, Div Pulm Crit Care & Sleep Med, Boston, MA 02215 USA.
   [Zhu, Xiaofeng] Case Western Reserve Univ, Sch Med, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
RP Cade, BE (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Div Sleep & Circadian Disorders, 221 Longwood Ave, Boston, MA 02115 USA.
EM bcade@partners.org
RI Wood, Lekki/B-8053-2010; Rotter, Jerome/AAY-6598-2021; Chun,
   Sung/I-2212-2015; Below, Jennifer E/W-2179-2018; Conomos, Matthew
   P./A-8136-2019; Saxena, Richa/AAG-7279-2020; Cade, Brian/J-6770-2019;
   Zhu, Xiaofeng/O-6874-2019; Ramos, Alberto/X-4249-2019
OI Wood, Lekki/0000-0001-7616-2119; Chun, Sung/0000-0003-3440-1913; Below,
   Jennifer E/0000-0002-1346-1872; Conomos, Matthew P./0000-0001-9744-0851;
   Cade, Brian/0000-0003-1424-0673; Below, Jennifer/0000-0002-6372-6402;
   Saxena, Richa/0000-0003-2233-1065; Patel, Sanjay/0000-0002-9142-5172;
   Zhu, Xiaofeng/0000-0003-0037-411X; Chen, Han/0000-0002-9510-4923; Sofer,
   Tamar/0000-0001-8520-8860
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [T32-HL007901-16,
   R01-HL113338-04, 5-R01-HL046380-15, 5-KL2-RR024990-05, R01 DK073541, U01
   DK085501, R01 AI085014, R01 HL102830]; NHLBIUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [N01-HC65233,
   N02-HL-64278]; University of Miami [N01-HC65234]; Albert Einstein
   College of Medicine [N01-HC65235]; Northwestern University
   [N01-HC65236]; San Diego State University [N01-HC65237]; National
   Institute of Dental and Craniofacial ResearchUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Dental & Craniofacial Research (NIDCR)
   [HHSN268201300005C AM03, MOD03]; National Center for Advancing
   Translational Sciences (NCATS) CTSI [UL1TR000124]; National Institute of
   Diabetes and Digestive and Kidney Diseases (NIDDK) DRC grant [DK063491];
   NCATS CTSI [UL1TR000124]; NIDDK DRC [DK063491]; Kovler Family Foundation
   [P30 DK020595]; University of North Carolina [N01-HC-55015,
   N01-HC-55018]; Baylor College of Medicine [N01-HC-55016]; University of
   MinnesotaUniversity of Minnesota System [N01-HC-55019]; Johns Hopkins
   UniversityJohns Hopkins University [N01-HC-55020]; University of
   Mississippi Medical Center [N01-HC-55021];  [N01-HC-95159]; 
   [N01-HC-95160];  [N01-HC-95161];  [N01-HC-95162];  [N01-HC-95163]; 
   [N01-HC-95164];  [N01-HC-95165];  [N01-HC-95166];  [N01-HC-95167]; 
   [N01-HC-95168];  [N01-HC-95169];  [UL1-TR-001079];  [UL1-TR-000040]; 
   [HL56984]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &
   HUMAN DEVELOPMENTUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD)
   [U54HD083211] Funding Source: NIH RePORTER; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000040,
   UL1TR001079, UL1TR001073, KL2TR000461, UL1TR000124] Funding Source: NIH
   RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Research Resources (NCRR) [KL2RR024990] Funding
   Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)
   [T32HL007901, R01HL046380, U01HL065233, R44HL095169, R41HL055018,
   R01HL102830, R13HL095166, R43HL095169, R43HL095161, R42HL055018,
   R01HL064278, R41HL055019, P50HL056984, R43HL095160, K23HL125923,
   R43HL095167, R01HL065234, R21HL095165, R01HL095163, R01HL113338] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R01AI085014] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Diabetes & Digestive &
   Kidney Diseases (NIDDK) [R01DK073541, U01DK085501, P30DK020595,
   P30DK063491] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL
   MEDICAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of General Medical Sciences (NIGMS) [P01GM099568] Funding Source: NIH
   RePORTER
FX Supported by National Institutes of Health grants T32-HL007901-16 and
   R01-HL113338-04 (B.E.C.). The Sleep Reading Center of Brigham and
   Women's Hospital has been supported by National Institutes of Health
   grants 5-R01-HL046380-15 and 5-KL2-RR024990-05. Hispanic Community
   Health Study/Study of Latinos (HCHS/SOL): baseline examination of
   HCHS/SOL was performed as a collaborative study supported by contracts
   from the NHLBI to the University of North Carolina (N01-HC65233),
   University of Miami (N01-HC65234), Albert Einstein College of Medicine
   (N01-HC65235), Northwestern University (N01-HC65236), and San Diego
   State University (N01-HC65237). The following institutes/centers/offices
   contributed to the first phase of HCHS/SOL through a transfer of kinds
   to the NHLBI: National Institute on Minority Health and Health
   Disparities, National Institute on Deafness and Other Communication
   Disorders, National Institute of Dental and Craniofacial Research,
   National Institute of Diabetes and Digestive and Kidney Diseases,
   National Institute of Neurological Disorders and Stroke, and National
   Institutes of Heath Institution-Office of Dietary Supplements. The
   Genetic Analysis Center at the University of Washington was supported by
   NHLBI and National Institute of Dental and Craniofacial Research
   contracts (HHSN268201300005C AM03 and MOD03). Provision of genotyping
   services supported in part by National Center for Advancing
   Translational Sciences (NCATS) CTSI grant UL1TR000124 and National
   Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) DRC
   grant DK063491. Multi-Ethnic Study of Atherosclerosis (MESA): MESA is
   conducted and supported by the NHLBI in collaboration with MESA
   investigators. Support for MESA is provided by contracts N01-HC-95159,
   N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164,
   N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169,
   UL1-TR-001079, UL1-TR-000040, and DK063491. Funding for SHARe genotyping
   was provided by NHLBI contract N02-HL-64278. Genotyping was performed at
   Affymetrix (Santa Clara, CA) and the Broad Institute of Harvard and
   Massachusetts Institute of Technology (Boston, MA). Funding support for
   the Sleep Polysomnography dataset was provided by grant HL56984.
   Provision of genotyping services supported in part by NCATS CTSI grant
   UL1TR000124 and NIDDK DRC grant DK063491. Starr County Health Studies
   (Starr): Starr is supported in part by grants R01 DK073541, U01
   DK085501, R01 AI085014, and R01 HL102830 from the National Institutes of
   Health, and kinds from the University of Texas Health Science Center at
   Houston. G.I.B. supported in part by grant P30 DK020595 and a gift from
   the Kovler Family Foundation. The Atherosclerosis Risk in Communities
   Study is conducted and supported by the NHLBI in collaboration with the
   University of North Carolina (N01-HC-55015, N01-HC-55018), Baylor
   College of Medicine (N01-HC-55016), University of Minnesota
   (N01-HC-55019), Johns Hopkins University (N01-HC-55020), and University
   of Mississippi Medical Center (N01-HC-55021).
CR Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534
   Baik I, 2015, SLEEP, V38, P1137, DOI 10.5665/sleep.4830
   Ban HJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018455
   Berry RB, 1997, SLEEP, V20, P654, DOI 10.1093/sleep/20.8.654
   Bild DE, 2002, AM J EPIDEMIOL, V156, P871, DOI 10.1093/aje/kwf113
   Boyd JH, 2004, AM J RESP CRIT CARE, V170, P541, DOI 10.1164/rccm.200308-1100OC
   Chatterjee S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005197
   Clambey ET, 2012, P NATL ACAD SCI USA, V109, pE2784, DOI 10.1073/pnas.1202366109
   Claussnitzer M, 2015, NEW ENGL J MED, V373, P895, DOI 10.1056/NEJMoa1502214
   Conomos MP, 2014, THESIS
   Cronin RM, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00250
   Daviglus ML, 2012, JAMA-J AM MED ASSOC, V308, P1775, DOI 10.1001/jama.2012.14517
   Dubins JS, 2012, METABOLISM, V61, P1486, DOI 10.1016/j.metabol.2012.03.015
   Eckert DJ, 2013, AM J RESP CRIT CARE, V188, P996, DOI 10.1164/rccm.201303-0448OC
   Eisenstein EM, 2009, PEDIATR RES, V65, p26R, DOI 10.1203/PDR.0b013e31819e76c7
   Gottlieb DJ, 2010, CIRCULATION, V122, P352, DOI 10.1161/CIRCULATIONAHA.109.901801
   Grilo A, 2013, GENE, V521, P150, DOI 10.1016/j.gene.2013.03.024
   Guindalini C, 2010, EUR RESPIR J, V36, P834, DOI 10.1183/09031936.00146809
   HANIS CL, 1983, AM J EPIDEMIOL, V118, P659, DOI 10.1093/oxfordjournals.aje.a113677
   Hansen W, 2010, GENES IMMUN, V11, P357, DOI 10.1038/gene.2010.5
   Hirschhorn JN, 2005, NAT REV GENET, V6, P95, DOI 10.1038/nrg1521
   Holton M, 2010, CARDIOVASC RES, V87, P440, DOI 10.1093/cvr/cvq077
   Howie BN, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000529
   Ishihara H, 1999, BIOCHEM BIOPH RES CO, V254, P77, DOI 10.1006/bbrc.1998.9468
   Kendzerska T, 2014, AM J RESP CRIT CARE, V190, P218, DOI 10.1164/rccm.201312-2209OC
   Kim D, 1997, NATURE, V389, P290, DOI 10.1038/38508
   Kripke DF, 2015, SLEEP MED, V16, P217, DOI 10.1016/j.sleep.2014.11.003
   Larkin EK, 2010, AM J RESP CRIT CARE, V182, P947, DOI 10.1164/rccm.201002-0192OC
   Li JG, 2007, PHYSIOL GENOMICS, V31, P273, DOI 10.1152/physiolgenomics.00082.2007
   Liu X, 2009, AM J PHYSIOL-LUNG C, V296, pL158, DOI 10.1152/ajplung.90383.2008
   LIVINGSTON FR, 1995, CHEST, V108, P1627, DOI 10.1378/chest.108.6.1627
   Marin JM, 2005, LANCET, V365, P1046, DOI 10.1016/S0140-6736(05)71141-7
   Muller TD, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2968
   Patel SR, 2008, INT J OBESITY, V32, P795, DOI 10.1038/sj.ijo.0803803
   Patel SR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048836
   Pruim RJ, 2010, BIOINFORMATICS, V26, P2336, DOI 10.1093/bioinformatics/btq419
   Qin BD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095856
   Redline S, 2011, PRINCIPLES PRACTICE, P1183
   Redline S, 2014, AM J RESP CRIT CARE, V189, P335, DOI 10.1164/rccm.201309-1735OC
   Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516
   Sah R, 2005, NEUROSCIENCE, V133, P281, DOI 10.1016/j.neuroscience.2005.01.066
   Schneiderman N, 2014, DIABETES CARE, V37, P2233, DOI 10.2337/dc13-2939
   Schuh K, 2003, J BIOL CHEM, V278, P41246, DOI 10.1074/jbc.M307606200
   Sedky K, 2014, J CLIN SLEEP MED, V10, P403, DOI 10.5664/jcsm.3616
   Shin J, 2005, P NATL ACAD SCI USA, V102, P18165, DOI 10.1073/pnas.0505498102
   Skarnes WC, 2011, NATURE, V474, P337, DOI 10.1038/nature10163
   Sorlie PD, 2010, ANN EPIDEMIOL, V20, P629, DOI 10.1016/j.annepidem.2010.03.015
   STAUFFER TP, 1995, J BIOL CHEM, V270, P12184, DOI 10.1074/jbc.270.20.12184
   van der Harst P, 2012, NATURE, V492, P369, DOI 10.1038/nature11677
   Varvarigou V, 2011, SLEEP, V34, P1461, DOI 10.5665/sleep.1376
   Ward LD, 2012, NUCLEIC ACIDS RES, V40, pD930, DOI 10.1093/nar/gkr917
   Wellman A, 2011, J APPL PHYSIOL, V110, P1627, DOI 10.1152/japplphysiol.00972.2010
   Whitney CW, 1998, SLEEP, V21, P749, DOI 10.1093/sleep/21.7.749
   Willer CJ, 2010, BIOINFORMATICS, V26, P2190, DOI 10.1093/bioinformatics/btq340
   Wood AR, 2014, NAT GENET, V46, P1173, DOI 10.1038/ng.3097
   Xu HJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086460
   Yabe D, 2002, P NATL ACAD SCI USA, V99, P12753, DOI 10.1073/pnas.162488899
   Ye J, 2015, PEDIATR RES, V78, P165, DOI 10.1038/pr.2015.76
   Zecchini V, 2014, EMBO J, V33, P1365, DOI 10.15252/embj.201386874
   Zhou X, 2012, NAT GENET, V44, P821, DOI 10.1038/ng.2310
NR 60
TC 58
Z9 59
U1 1
U2 19
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD OCT 1
PY 2016
VL 194
IS 7
BP 886
EP 897
DI 10.1164/rccm.201512-2431OC
PG 12
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA DX4ZH
UT WOS:000384389100017
PM 26977737
OA Green Published
DA 2021-10-30
ER

PT J
AU Chen, H
   Cade, BE
   Gleason, KJ
   Bjonnes, AC
   Stilp, AM
   Sofer, T
   Conomos, MP
   Ancoli-Israel, S
   Arens, R
   Azarbarzin, A
   Bell, GI
   Below, JE
   Chun, S
   Evans, DS
   Ewert, R
   Frazier-Wood, AC
   Gharib, SA
   Haba-Rubio, J
   Hagen, EW
   Heinzer, R
   Hillman, DR
   Johnson, WC
   Kutalik, Z
   Lane, JM
   Larkin, EK
   Lee, SK
   Liang, JJ
   Loredo, JS
   Mukherjee, S
   Palmer, LJ
   Papanicolaou, GJ
   Penzel, T
   Peppard, PE
   Post, WS
   Ramos, AR
   Rice, K
   Rotter, JI
   Sands, SA
   Shah, NA
   Shin, C
   Stone, KL
   Stubbe, B
   Sul, JH
   Tafti, M
   Taylor, KD
   Teumer, A
   Thornton, TA
   Tranah, GJ
   Wang, CL
   Wang, HM
   Warby, SC
   Wellman, DA
   Zee, PC
   Hanis, CL
   Laurie, CC
   Gottlieb, DJ
   Patel, SR
   Zhu, XF
   Sunyaev, SR
   Saxena, R
   Lin, XH
   Redline, S
AF Chen, Han
   Cade, Brian E.
   Gleason, Kevin J.
   Bjonnes, Andrew C.
   Stilp, Adrienne M.
   Sofer, Tamar
   Conomos, Matthew P.
   Ancoli-Israel, Sonia
   Arens, Raanan
   Azarbarzin, Ali
   Bell, Graeme I.
   Below, Jennifer E.
   Chun, Sung
   Evans, Daniel S.
   Ewert, Ralf
   Frazier-Wood, Alexis C.
   Gharib, Sina A.
   Haba-Rubio, Jose
   Hagen, Erika W.
   Heinzer, Raphael
   Hillman, David R.
   Johnson, W. Craig
   Kutalik, Zoltan
   Lane, Jacqueline M.
   Larkin, Emma K.
   Lee, Seung Ku
   Liang, Jingjing
   Loredo, Jose S.
   Mukherjee, Sutapa
   Palmer, Lyle J.
   Papanicolaou, George J.
   Penzel, Thomas
   Peppard, Paul E.
   Post, Wendy S.
   Ramos, Alberto R.
   Rice, Ken
   Rotter, Jerome I.
   Sands, Scott A.
   Shah, Neomi A.
   Shin, Chol
   Stone, Katie L.
   Stubbe, Beate
   Sul, Jae Hoon
   Tafti, Mehdi
   Taylor, Kent D.
   Teumer, Alexander
   Thornton, Timothy A.
   Tranah, Gregory J.
   Wang, Chaolong
   Wang, Heming
   Warby, Simon C.
   Wellman, D. Andrew
   Zee, Phyllis C.
   Hanis, Craig L.
   Laurie, Cathy C.
   Gottlieb, Daniel J.
   Patel, Sanjay R.
   Zhu, Xiaofeng
   Sunyaev, Shamil R.
   Saxena, Richa
   Lin, Xihong
   Redline, Susan
TI Multiethnic Meta-Analysis Identifies RAI1 as a Possible Obstructive
   Sleep Apnea-related Quantitative Trait Locus in Men
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Article
DE obstructive sleep apnea; genetics; genome-wide association studies;
   multiethnic; sexual dimorphism
ID HIGH-DENSITY; GENE; DISTURBANCES; DUPLICATION; ASSOCIATION; SEVERITY;
   DISEASE; 17P11.2; OBESITY; GENDER
AB Obstructive sleep apnea (OSA) is a common heritable disorder displaying marked sexual dimorphism in disease prevalence and progression. Previous genetic association studies have identified a few genetic loci associated with OSA and related quantitative traits, but they have only focused on single ethnic groups, and a large proportion of the heritability remains unexplained. The apnea-hypopnea index (AHI) is a commonly used quantitative measure characterizing OSA severity. Because OSA differs by sex, and the pathophysiology of obstructive events differ in rapid eye movement (REM) and non-REM (NREM) sleep, we hypothesized that additional genetic association signals would be identified by analyzing the NREM/REM-specific AHI and by conducting sex-specific analyses in multiethnic samples. We performed genomewide association tests for up to 19,733 participants of African, Asian, European, and Hispanic/Latino American ancestry in 7 studies. We identified rs12936587 on chromosome 17 as a possible quantitative trait locus for NREM AHI in men (N = 6,737; P = 1.7310(-8)) but not in women (P = 0.77). The association with NREMAHI was replicated in a physiological research study (N = 67; P = 0.047). This locus overlapping the RAI1 gene and encompassing genes PEMT1, SREBF1, and RASD1 was previously reported to be associated with coronary artery disease, lipid metabolism, and implicated in Potocki-Lupski syndrome and Smith-Magenis syndrome, which are characterized by abnormal sleep phenotypes. We also identified gene-by-sex interactions in suggestive association regions, suggesting that genetic variants for AHI appear to vary by sex, consistent with the clinical observations of strong sexual dimorphism.
C1 [Chen, Han; Wang, Chaolong; Lin, Xihong] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA.
   [Chen, Han; Below, Jennifer E.; Hanis, Craig L.] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Human Genet Ctr, Dept Epidemiol Human Genet & Environm Sci, Houston, TX 77030 USA.
   [Chen, Han] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Ctr Precis Hlth, Houston, TX 77030 USA.
   [Chen, Han] Univ Texas Hlth Sci Ctr Houston, Sch Biomed Informat, Houston, TX 77030 USA.
   [Cade, Brian E.; Gleason, Kevin J.; Sofer, Tamar; Azarbarzin, Ali; Lane, Jacqueline M.; Sands, Scott A.; Wang, Heming; Wellman, D. Andrew; Gottlieb, Daniel J.; Saxena, Richa; Redline, Susan] Brigham & Womens Hosp, Div Sleep & Circadian Disorders, 75 Francis St, Boston, MA 02115 USA.
   [Cade, Brian E.; Sofer, Tamar; Azarbarzin, Ali; Lane, Jacqueline M.; Sands, Scott A.; Wang, Heming; Wellman, D. Andrew; Gottlieb, Daniel J.; Saxena, Richa; Redline, Susan] Harvard Med Sch, Div Sleep Med, Boston, MA USA.
   [Gleason, Kevin J.] Univ Chicago, Dept Publ Hlth Sci, Chicago, IL 60637 USA.
   [Bjonnes, Andrew C.; Chun, Sung; Sul, Jae Hoon; Sunyaev, Shamil R.] Brigham & Womens Hosp, Div Genet, 75 Francis St, Boston, MA 02115 USA.
   [Bjonnes, Andrew C.; Lane, Jacqueline M.; Saxena, Richa] Massachusetts Gen Hosp, Ctr Genom Med, Boston, MA 02114 USA.
   [Bjonnes, Andrew C.; Lane, Jacqueline M.; Saxena, Richa] Massachusetts Gen Hosp, Dept Anesthesia Pain & Crit Care Med, Boston, MA 02114 USA.
   [Stilp, Adrienne M.; Sofer, Tamar; Conomos, Matthew P.; Johnson, W. Craig; Rice, Ken; Thornton, Timothy A.; Laurie, Cathy C.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
   [Ancoli-Israel, Sonia] Univ Calif San Diego, Dept Med & Psychiat, San Diego, CA 92103 USA.
   [Arens, Raanan; Haba-Rubio, Jose] Albert Einstein Coll Med, Childrens Hosp Montefiore, Div Resp & Sleep Med, Bronx, NY 10467 USA.
   [Bell, Graeme I.] Univ Chicago, Sect Adult & Pediat Endocrinol, Diabet & Metab, Chicago, IL 60637 USA.
   [Below, Jennifer E.] Vanderbilt Univ, Med Ctr, Vanderbilt Genet Inst, 221 Kirkland Hall, Nashville, TN 37235 USA.
   [Chun, Sung; Sul, Jae Hoon; Sunyaev, Shamil R.] Harvard Med Sch, Div Med Sci, Boston, MA USA.
   [Evans, Daniel S.; Stone, Katie L.; Tranah, Gregory J.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA.
   [Ewert, Ralf; Stubbe, Beate] Univ Med Greifswald, Internal Med B, Greifswald, Germany.
   [Frazier-Wood, Alexis C.] Baylor Coll Med, Childrens Nutr Res Ctr, Houston, TX 77030 USA.
   [Gharib, Sina A.] Univ Washington, Med Sleep Ctr, Ctr Lung Biol, Computat Med Core,Div Pulm Crit Care & Sleep Med, Seattle, WA 98195 USA.
   [Haba-Rubio, Jose; Heinzer, Raphael; Tafti, Mehdi] Lausanne Univ Hosp, Ctr Invest & Res Sleep, Lausanne, Switzerland.
   [Hagen, Erika W.; Peppard, Paul E.] Univ Wisconsin, Dept Populat Hlth Sci, Madison, WI USA.
   [Hillman, David R.] Sir Charles Gairdner Hosp, Dept Pulm Physiol & Sleep Med, Perth, WA, Australia.
   [Kutalik, Zoltan] Univ Hosp Lausanne, Inst Social & Prevent Med, Lausanne, Switzerland.
   [Kutalik, Zoltan] Swiss Inst Bioinformat, Lausanne, Switzerland.
   [Lane, Jacqueline M.; Sunyaev, Shamil R.; Saxena, Richa] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA.
   [Larkin, Emma K.] Vanderbilt Univ, Med Ctr, Dept Med, Div Allergy Pulm & Crit Care, 221 Kirkland Hall, Nashville, TN 37235 USA.
   [Lee, Seung Ku] Korea Univ, Ansan Hosp, Coll Med, Inst Human Genom Study, Ansan, Gyeonggi Do, South Korea.
   [Liang, Jingjing; Wang, Heming; Zhu, Xiaofeng] Case Western Reserve Univ, Sch Med, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
   [Loredo, Jose S.] Univ Calif San Diego, Sch Med, Dept Med, Div Pulm Crit Care & Sleep Med, La Jolla, CA 92093 USA.
   [Mukherjee, Sutapa] Flinders Univ S Australia, Flinders Ctr Res Excellence, Adelaide Inst Sleep Hlth, Adelaide, SA, Australia.
   [Palmer, Lyle J.] Univ Adelaide, Sch Publ Hlth, Adelaide, SA, Australia.
   [Papanicolaou, George J.] NHLBI, Div Cardiovasc Sci, Bldg 10, Bethesda, MD 20892 USA.
   [Penzel, Thomas] Univ Hosp Charite Berlin, Sleep Ctr, Berlin, Germany.
   [Post, Wendy S.] Johns Hopkins Univ, Div Cardiol, Baltimore, MD USA.
   [Ramos, Alberto R.] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA.
   [Rotter, Jerome I.; Taylor, Kent D.] Univ Calif Los Angeles, Med Ctr, Los Angeles BioMed Res Inst, Inst Translat Genom & Populat Sci, Torrance, CA 90509 USA.
   [Rotter, Jerome I.; Taylor, Kent D.] Univ Calif Los Angeles, Med Ctr, Dept Pediat Harbor, Torrance, CA 90509 USA.
   [Shah, Neomi A.] Icahn Sch Med Mt Sinai, Div Pulm Crit Care & Sleep, New York, NY 10029 USA.
   [Shin, Chol] Korea Univ, Ansan Hosp, Coll Med, Dept Pulm Sleep & Crit Care Med, Ansan, Gyeonggi Do, South Korea.
   [Sul, Jae Hoon] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
   [Tafti, Mehdi] Univ Lausanne, Fac Biol & Med, Dept Physiol, Lausanne, Switzerland.
   [Teumer, Alexander] Univ Med Greifswald, Inst Community Med, Greifswald, Germany.
   [Wang, Chaolong] Genome Inst Singapore, Computat & Syst Biol, Singapore, Singapore.
   [Warby, Simon C.] Univ Montreal, Dept Psychiat, Montreal, PQ, Canada.
   [Zee, Phyllis C.] Northwestern Univ, Dept Neurol, Chicago, IL 60611 USA.
   [Zee, Phyllis C.] Northwestern Univ, Sleep Med Ctr, Chicago, IL 60611 USA.
   [Gottlieb, Daniel J.] Vet Affairs Boston Healthcare Syst, Boston, MA USA.
   [Patel, Sanjay R.] Univ Pittsburgh, Med Ctr, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA USA.
   [Sunyaev, Shamil R.] Harvard Med Sch, Dept Biomed Informat, Boston, MA USA.
   [Redline, Susan] Beth Israel Deaconess Med Ctr, Div Pulm Crit Care & Sleep Med, Boston, MA 02215 USA.
RP Chen, H (corresponding author), Univ Texas Hlth Sci Ctr Houston, Sch Biomed Informat, Dept Epidemiol Human Genet & Environm Sci, Ctr Precis Hlth,Sch Publ Hlth,Human Genet Ctr, 1200 Pressler St,RAS E-517, Houston, TX 77030 USA.
EM han.chen.2@uth.tmc.edu
RI Zhu, Xiaofeng/O-6874-2019; Ramos, Alberto/X-4249-2019; Palmer, Lyle
   John/K-3196-2014; Palmer, Lyle John/N-1948-2019; Below, Jennifer
   E/W-2179-2018; Penzel, Thomas/M-2344-2014; Rotter, Jerome/AAY-6598-2021;
   Conomos, Matthew P./A-8136-2019; Colaus, PsyColaus/K-6607-2013; Teumer,
   Alexander/S-7438-2019; Cade, Brian/J-6770-2019; Azarbarzin,
   Ali/AAH-8045-2021; Saxena, Richa/AAG-7279-2020; Wood, Lekki/B-8053-2010;
   Mukherjee, Sutapa/U-7262-2017
OI Palmer, Lyle John/0000-0002-1628-3055; Palmer, Lyle
   John/0000-0002-1628-3055; Below, Jennifer E/0000-0002-1346-1872; Penzel,
   Thomas/0000-0002-4304-0112; Conomos, Matthew P./0000-0001-9744-0851;
   Teumer, Alexander/0000-0002-8309-094X; Cade, Brian/0000-0003-1424-0673;
   Azarbarzin, Ali/0000-0002-4986-4753; Wood, Lekki/0000-0001-7616-2119;
   Zhu, Xiaofeng/0000-0003-0037-411X; Saxena, Richa/0000-0003-2233-1065;
   Sofer, Tamar/0000-0001-8520-8860; Patel, Sanjay/0000-0002-9142-5172;
   Sands, Scott/0000-0003-3752-0328; Hillman, David/0000-0001-9987-539X;
   Mukherjee, Sutapa/0000-0001-5021-1648; GHARIB, SINA
   A./0000-0002-2480-4367; Below, Jennifer/0000-0002-6372-6402; Chen,
   Han/0000-0002-9510-4923
FU National Institutes of Health (NIH)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [R01-HL113338,
   P01-CA134294, R35-CA197449, T32-HL007901, R35-HL135818]; NIHUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA [5-R01-HL046380-15, 5-KL2-RR024990-05, R01 DK073541,
   U01 DK085501, R01 AI085014, R01 HL102830, R01HL62252, 1UL1RR02501];
   National Heart, Lung, and Blood Institute (NHLBI)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI)
   [HHSN268201100005C, HHSN268201100006C, HHSN268201100007C,
   HHSN268201100008C, HHSN268201100009C, HHSN268201100010C,
   HHSN268201100011C, HHSN268201100012C]; NHLBIUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI); Boston University
   [N01-HC-25195]; NHLBIUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [N02-HL-64278, N01-HC65233, HHSN268201500003I,
   N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163,
   N01-HC-95164]; NIH/NHLBI grantUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [U01 HL 53941]; NIDCRUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Dental & Craniofacial Research (NIDCR)
   [HHSN268201300005C AM03, MOD03]; National Center for Advancing
   Translational Sciences (NCATS) Clinical and Translational Science
   Institute (CTSI) grant [UL1TR000124]; NIDDK Diabetes Research Center
   (DRC) [DK063491]; National Center for Research Resources (NCRR)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Research Resources (NCRR)
   [UL1-TR-000040, UL1-TR-001079]; NCATS CTSI grant [UL1TR000124]; NIDDK
   DRC grant [DK063491]; NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA; National Institute on
   Aging (NIA)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Aging (NIA);
   National Institute of Arthritis and Musculoskeletal and Skin Diseases
   (NIAMS)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Arthritis &
   Musculoskeletal & Skin Diseases (NIAMS); NCATSUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Advancing Translational Sciences (NCATS); NIH
   Roadmap for Medical ResearchUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [U01 AG027810, U01
   AG042124, U01 AG042139, U01 AG042140, U01 AG042143, U01 AG042145, U01
   AG042168, U01 AR066160, UL1 TR000128]; NIAMSUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Arthritis & Musculoskeletal & Skin Diseases
   (NIAMS) [R01 AR051124, RC2 AR058973]; University of Texas Health Science
   Center at Houston; Korea Centers for Disease Control AMP; Prevention,
   Republic of Korea [4845-301, 2009-E71002-00, 2010-E71001-00,
   2011-E71004-00, 2012-E71005-00, 2013-E71005-00, 2014-E71003-00,
   4851-307]; NINDSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Neurological Disorders & Stroke (NINDS); NIAUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Aging (NIA) [R01AG023629];
   GlaxoSmithKlineGlaxoSmithKline; Faculty of Biology and Medicine of
   Lausanne; Swiss National Science FoundationSwiss National Science
   Foundation (SNSF)European Commission [3200B0-105993, 3200B0-118308,
   33CSCO-122661, 33CS30-139468, 33CS30-148401]; Leenaards Foundation; Vaud
   Pulmonary League (Ligue Pulmonaire Vaudoise); Federal Ministry of
   Education and ResearchFederal Ministry of Education & Research (BMBF)
   [01ZZ9603, 01ZZ0103, 01ZZ0403, 03IS2061A]; Competence Network
   Asthma/COPD grant [FKZ 01GI0881-0888]; Ministry of Cultural Affairs;
   Social Ministry of the Federal State of Mecklenburg-West Pomerania;
   network "Greifswald Approach to Individualized Medicine"; German
   Restless Legs Association; Sir Charles Gairdner Foundation; Hollywood
   Private Hospital Research Foundation; Western Australian Sleep Disorders
   Research Institute; Centre for Genetic Epidemiology and Biostatistics at
   the University of Western Australia; Ontario Institute for Cancer
   Research; McLaughlin Centre Accelerator Grant from the University of
   Toronto;  [DK020595];  [N01-HC-95165];  [N01-HC-95166];  [N01-HC-95167];
   [N01-HC-95168];  [N01-HC-95169];  [HL56984];  [R01 HL071194];  [R01
   HL070848];  [R01 HL070847];  [R01 HL070842];  [R01 HL070841];  [R01
   HL070837];  [R01 HL070838];  [R01 HL070839];  [HHSN268201200036C]; 
   [HHSN268200800007C];  [N01HC55222];  [N01HC85079];  [N01HC85080]; 
   [N01HC85081];  [N01HC85082];  [N01HC85083];  [N01HC85086]; 
   [U01HL080295];  [R01HL087652];  [R01HL105756];  [R01HL103612]; 
   [R01HL120393];  [R01HL130114];  [HL085251];  [N01-HC65234]; 
   [N01-HC65235];  [N01-HC65236];  [N01-HC65237]; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [P01CA134294, R35CA197449] Funding Source: NIH RePORTER; NATIONAL CENTER
   FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [KL2TR000461,
   UL1TR000040, UL1TR001881, UL1TR000124, UL1TR000128, UL1TR000439,
   UL1TR001079] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH
   RESOURCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Research
   Resources (NCRR) [KL2RR024990] Funding Source: NIH RePORTER; NATIONAL
   HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Heart Lung & Blood Institute (NHLBI) [T32HL007901, U01HL065233,
   R01HL120393, R01HL087652, R01HL064278, R01HL103612, R01HL095163,
   R43HL095169, R01HL070839, R01HL046380, R44HL095169, R43HL095160,
   U01HL053941, R01HL071194, R13HL095166, U01HL130114, R35HL135818,
   R01HL113338, R01HL065234, R01HL070848, P50HL056984, R01HL062252,
   R01HL070847, R43HL095161, R01HL070837, R01HL102830, U01HL080295,
   R01HL085083, K01HL135405, R01HL070838, R21HL095165, R43HL095167,
   R01HL105756, R01HL085251, R01HL070841, R01HL070842] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [R01AI085014] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal
   & Skin Diseases (NIAMS) [U01AR066160, RC2AR058973, R01AR051124] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND
   KIDNEY DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Diabetes & Digestive & Kidney Diseases (NIDDK) [P30DK063491,
   R01DK105072, R01DK073541, P30DK020595, U01DK085501, R01DK107859] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Aging (NIA) [U01AG042140, U01AG027810,
   R21AG056952, U01AG042168, U01AG042124, U01AG042145, R01AG023629,
   U01AG042139, U01AG042143] Funding Source: NIH RePORTER
FX This work was supported by National Institutes of Health (NIH) grants
   R01-HL113338, P01-CA134294, and R35-CA197449 (H.C.), T32-HL007901 and
   R01-HL113338 (B.E.C.), and R01-HL113338 and R35-HL135818 (S.R.). The
   Sleep Reading Center of Brigham and Women's Hospital was supported by
   NIH grants 5-R01-HL046380-15 and 5-KL2-RR024990-05; the Atherosclerosis
   Risk in Communities Study is carried out as a collaborative study
   supported by National Heart, Lung, and Blood Institute (NHLBI) contracts
   HHSN268201100005C, HHSN268201100006C, HHSN268201100007C,
   HHSN268201100008C, HHSN268201100009C, HHSN268201100010C,
   HHSN268201100011C, and HHSN268201100012C; the Framingham Heart Study is
   conducted and supported by NHLBI in collaboration with Boston University
   contract N01-HC-25195; funding for SHARe Affymetrix genotyping was
   provided by NHLBI contract N02-HL-64278; SHARe Illumina genotyping was
   provided under an agreement between Illumina and Boston University;
   funding support for the Framingham Sleep Heart Health Study was provided
   by NIH/NHLBI grant U01 HL 53941; the baseline examination of the
   Hispanic Community Health Study/Study of Latinos (HCHS/SOL) was carried
   out as a collaborative study supported by contracts from the NHLBI to
   the University of North Carolina (N01-HC65233), University of Miami
   (N01-HC65234), Albert Einstein College of Medicine (N01-HC65235),
   Northwestern University (N01-HC65236), and San Diego State University
   (N01-HC65237). The following institutes/centers/offices contributed to
   the first phase of HCHS/SOL through a transfer of funds to the NHLBI:
   National Institute on Minority Health and Health Disparities, National
   Institute on Deafness and Other Communication Disorders, National
   Institute of Dental and Craniofacial Research (NIDCR), National
   Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),
   National Institute of Neurological Disorders and Stroke (NINDS), and NIH
   Institution-Office of Dietary Supplements. The Genetic Analysis Center
   at the University of Washington was supported by NHLBI and NIDCR
   contracts HHSN268201300005C AM03 and MOD03. Provision of genotyping
   services was supported in part by the National Center for Advancing
   Translational Sciences (NCATS) Clinical and Translational Science
   Institute (CTSI) grant UL1TR000124 and NIDDK Diabetes Research Center
   (DRC) grant DK063491. The Multi-Ethnic Study of Atherosclerosis (MESA)
   is conducted and supported by the NHLBI in collaboration with MESA
   investigators, and was supported by contracts HHSN268201500003I,
   N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163,
   N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168,
   and N01-HC-95169 from the NHLBI and by grants UL1-TR-000040 and
   UL1-TR-001079 from National Center for Research Resources (NCRR).
   Funding for SHARe genotyping was provided by NHLBI contract
   N02-HL-64278. Genotyping was performed at Affymetrix and the Broad
   Institute of Harvard and Massachusetts Institute of Technology. Funding
   support for the Sleep Polysomnography dataset was provided by NHLBI
   grant HL56984. Provision of genotyping services supported in part by
   NCATS CTSI grant UL1TR000124 and NIDDK DRC grant DK063491. The
   Osteoporotic Fractures in Men Study (MrOS) is supported by NIH funding.;
   r The following institutes provide support: the National Institute on
   Aging (NIA), the National Institute of Arthritis and Musculoskeletal and
   Skin Diseases (NIAMS), NCATS, and NIH Roadmap for Medical Research under
   grants U01 AG027810, U01 AG042124, U01 AG042139, U01 AG042140, U01
   AG042143, U01 AG042145, U01 AG042168, U01 AR066160, and UL1 TR000128.
   The NHLBI provides funding for the MrOS Sleep ancillary study "Outcomes
   of Sleep Disorders in Older Men" under grants R01 HL071194, R01
   HL070848, R01 HL070847, R01 HL070842, R01 HL070841, R01 HL070837, R01
   HL070838, and R01 HL070839. The NIAMS provides funding for the MrOS
   ancillary study "Replication of candidate gene associations and bone
   strength phenotype in MrOS" under grant R01 AR051124. The NIAMS provides
   funding for the MrOS ancillary study "GWAS in MrOS and SOF" under grant
   RC2 AR058973. The Starr County Health Studies are supported in part by
   NIH grants R01 DK073541, U01 DK085501, R01 AI085014, and R01 HL102830,
   and funds from The University of Texas Health Science Center at Houston.
   G.I.B. was supported in part by grant P30 DK020595 and a gift from the
   Kovler Family Foundation. The KoGES_Ansan study was provided with
   biospecimens and data from the Korean Genome Analysis Project
   (4845-301), the Korean Genome and Epidemiology Study (2009-E71002-00,
   2010-E71001-00, 2011-E71004-00, 2012-E71005-00, 2013-E71005-00, and
   2014-E71003-00), and Korea Biobank Project (4851-307) that were
   supported by the Korea Centers for Disease Control & Prevention,
   Republic of Korea. The Cardiovascular Health Study research was
   supported by NHLBI contracts HHSN268201200036C, HHSN268200800007C,
   N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083,
   N01HC85086, and NHLBI grants U01HL080295, R01HL087652, R01HL105756,
   R01HL103612, R01HL120393, and R01HL130114, with additional contribution
   from NINDS. Genotyping among the African American cohort was supported
   in part by HL085251 from NHLBI. Additional support was provided through
   NIA grant R01AG023629. The provision of genotyping data was supported in
   part by NCATS CTSI grant UL1TR000124 and NIDDK DRC grant DK063491 to the
   Southern California Diabetes Endocrinology Research Center. The
   HypnoLaus and CoLaus/HypnoLaus study was supported by research grants
   from GlaxoSmithKline, the Faculty of Biology and Medicine of Lausanne,
   the Swiss National Science Foundation grants 3200B0-105993,
   3200B0-118308, 33CSCO-122661, 33CS30-139468, and 33CS30-148401, the
   Leenaards Foundation, and the Vaud Pulmonary League (Ligue Pulmonaire
   Vaudoise). The Study of Health in Pomerania is part of the Community
   Medicine Research net of the University of Greifswald, Germany, which is
   funded by Federal Ministry of Education and Research grants 01ZZ9603,
   01ZZ0103, and 01ZZ0403, Competence Network Asthma/COPD grant FKZ
   01GI0881-0888, the Ministry of Cultural Affairs, as well as the Social
   Ministry of the Federal State of Mecklenburg-West Pomerania, and the
   network "Greifswald Approach to Individualized Medicine" funded by
   Federal Ministry of Education and Research grant 03IS2061A. The
   polysomnography was additionally funded by the German Restless Legs
   Association. Funding for the Western Australian Sleep Health Study was
   obtained from the Sir Charles Gairdner and Hollywood Private Hospital
   Research Foundations, the Western Australian Sleep Disorders Research
   Institute, and the Centre for Genetic Epidemiology and Biostatistics at
   the University of Western Australia.; r Funding for the genome-wide
   association studies (GWAS) genotyping was obtained from the Ontario
   Institute for Cancer Research and a McLaughlin Centre Accelerator Grant
   from the University of Toronto. The Wisconsin Sleep Cohort (WSC) Study
   phenotype data collection was supported by NIH grants R01HL62252 and
   1UL1RR02501. GWAS typing of the WSC was conducted thanks to private
   donations and NIH-23724 to Dr. Emmanuel Mignot, Psychiatry and
   Behavioral Sciences, Stanford Center for Sleep Sciences and Medicine.
CR Alkhazna Ammar, 2011, Hosp Pract (1995), V39, P82, DOI 10.3810/hp.2011.10.926
   Ardlie KG, 2015, SCIENCE, V348, P648, DOI 10.1126/science.1262110
   Boone PM, 2011, AM J MED GENET A, V155A, P2024, DOI 10.1002/ajmg.a.34098
   Brown A, 1996, AM J MED GENET, V63, P373, DOI 10.1002/(SICI)1096-8628(19960517)63:2<373::AID-AJMG9>3.0.CO;2-U
   Burns B, 2010, HUM MOL GENET, V19, P4026, DOI 10.1093/hmg/ddq317
   Cade BE, 2016, AM J RESP CRIT CARE, V194, P886, DOI 10.1164/rccm.201512-2431OC
   Cakirer B, 2001, AM J RESP CRIT CARE, V163, P947, DOI 10.1164/ajrccm.163.4.2005136
   Chen XL, 2015, SLEEP, V38, P877, DOI 10.5665/sleep.4732
   Cheng HYM, 2006, J NEUROSCI, V26, P12984, DOI 10.1523/JNEUROSCI.4253-06.2006
   Delaneau O, 2012, NAT METHODS, V9, P179, DOI [10.1038/NMETH.1785, 10.1038/nmeth.1785]
   Deloukas P, 2013, NAT GENET, V45, P25, DOI 10.1038/ng.2480
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Elsea SH, 2008, EUR J HUM GENET, V16, P412, DOI 10.1038/sj.ejhg.5202009
   Girirajan S, 2008, EUR J HUM GENET, V16, P941, DOI 10.1038/ejhg.2008.21
   Gottlieb DJ, 2010, CIRCULATION, V122, P352, DOI 10.1161/CIRCULATIONAHA.109.901801
   Gropman AL, 2006, PEDIATR NEUROL, V34, P337, DOI 10.1016/j.pediatrneurol.2005.08.018
   Hachul H, 2015, MATURITAS, V80, P170, DOI 10.1016/j.maturitas.2014.11.002
   Howie BN, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000529
   Keating BJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003583
   Kendzerska T, 2014, AM J RESP CRIT CARE, V190, P218, DOI 10.1164/rccm.201312-2209OC
   Koo BB, 2008, CHEST, V134, P1156, DOI 10.1378/chest.08-1311
   Kundaje A, 2015, NATURE, V518, P317, DOI 10.1038/nature14248
   Lappalainen T, 2013, NATURE, V501, P506, DOI 10.1038/nature12531
   Larkin EK, 2010, AM J RESP CRIT CARE, V182, P947, DOI 10.1164/rccm.201002-0192OC
   Li JG, 2007, PHYSIOL GENOMICS, V31, P273, DOI 10.1152/physiolgenomics.00082.2007
   Link JC, 2015, ARTERIOSCL THROM VAS, V35, P1778, DOI 10.1161/ATVBAHA.115.305460
   Lozo T, 2017, RESP PHYSIOL NEUROBI, V245, P65, DOI 10.1016/j.resp.2016.11.001
   Lupski JR, 2005, PLOS GENET, V1, P627, DOI 10.1371/journal.pgen.0010049
   Marin JM, 2005, LANCET, V365, P1046, DOI 10.1016/S0140-6736(05)71141-7
   McCaffery PJ, 2003, EUR J NEUROSCI, V18, P457, DOI 10.1046/j.1460-9568.2003.02765.x
   Mohsenin V, 2003, SLEEP MED, V4, P523, DOI 10.1016/S1389-9457(03)00168-0
   Noga AA, 2003, J BIOL CHEM, V278, P21851, DOI 10.1074/jbc.M301982200
   Patel SR, 2008, INT J OBESITY, V32, P795, DOI 10.1038/sj.ijo.0803803
   Patel SR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048836
   Pensuksan WC, 2014, AM J HYPERTENS, V27, P229, DOI 10.1093/ajh/hpt194
   Plantier L, 2012, J BIOL CHEM, V287, P10099, DOI 10.1074/jbc.M111.303669
   Potocki L, 2000, NAT GENET, V24, P84, DOI 10.1038/71743
   Potocki L, 2007, AM J HUM GENET, V80, P633, DOI 10.1086/512864
   Randall JC, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003500
   REDLINE S, 1995, AM J RESP CRIT CARE, V151, P682
   Redline S, 2000, AM J RESP CRIT CARE, V161, P369, DOI 10.1164/ajrccm.161.2.9904031
   Redline S, 2014, AM J RESP CRIT CARE, V189, P335, DOI 10.1164/rccm.201309-1735OC
   Shungin D, 2015, NATURE, V518, P187, DOI 10.1038/nature14132
   Siddiqui F, 2006, SLEEP MED, V7, P281, DOI 10.1016/j.sleep.2005.10.006
   Smith ACM, 1998, AM J MED GENET, V81, P186, DOI 10.1002/(SICI)1096-8628(19980328)81:2<186::AID-AJMG11>3.3.CO;2-A
   Thaker VV, 2015, J CLIN ENDOCR METAB, V100, P1723, DOI 10.1210/jc.2014-4215
   Vermunt MW, 2014, CELL REP, V9, P767, DOI 10.1016/j.celrep.2014.09.023
   Ward LD, 2012, NUCLEIC ACIDS RES, V40, pD930, DOI 10.1093/nar/gkr917
   Westra HJ, 2013, NAT GENET, V45, P1238, DOI 10.1038/ng.2756
   Willer CJ, 2010, BIOINFORMATICS, V26, P2190, DOI 10.1093/bioinformatics/btq340
   Williams SR, 2012, AM J HUM GENET, V90, P941, DOI 10.1016/j.ajhg.2012.04.013
   Wimms AJ, 2014, OBSTRUCTIVE SLEEP AP
   Winkler TW, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005378
   YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704
   Yue WH, 2008, SLEEP, V31, P1535, DOI 10.1093/sleep/31.11.1535
   Zeller T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010693
   Zhou X, 2012, NAT GENET, V44, P821, DOI 10.1038/ng.2310
NR 57
TC 29
Z9 30
U1 1
U2 15
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1044-1549
EI 1535-4989
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD MAR
PY 2018
VL 58
IS 3
BP 391
EP 401
DI 10.1165/rcmb.2017-0237OC
PG 11
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA FY7AJ
UT WOS:000427013700015
PM 29077507
OA Green Accepted, Green Published
DA 2021-10-30
ER

EF